



Federal Register

11-27-07

Vol. 72 No. 227

Book 1 of 2 Books

Pages 66041-66578

Tuesday

Nov. 27, 2007



The **FEDERAL REGISTER** (ISSN 0097-6326) is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. Periodicals postage is paid at Washington, DC.

The **FEDERAL REGISTER** provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see www.archives.gov.

The seal of the National Archives and Records Administration authenticates the **Federal Register** as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the **Federal Register** shall be judicially noticed.

The **Federal Register** is published in paper and on 24x microfiche. It is also available online at no charge as one of the databases on GPO Access, a service of the U.S. Government Printing Office.

The online edition of the **Federal Register** www.gpoaccess.gov/nara, available through GPO Access, is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the **Federal Register** is published and includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward.

For more information about GPO Access, contact the GPO Access User Support Team, call toll free 1-888-293-6498; DC area 202-512-1530; fax at 202-512-1262; or via e-mail at gpoaccess@gpo.gov. The Support Team is available between 7:00 a.m. and 9:00 p.m. Eastern Time, Monday–Friday, except official holidays.

The annual subscription price for the **Federal Register** paper edition is \$749 plus postage, or \$808, plus postage, for a combined **Federal Register**, **Federal Register** Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the **Federal Register** including the **Federal Register** Index and LSA is \$165, plus postage. Six month subscriptions are available for one-half the annual rate. The prevailing postal rates will be applied to orders according to the delivery method requested. The price of a single copy of the daily **Federal Register**, including postage, is based on the number of pages: \$11 for an issue containing less than 200 pages; \$22 for an issue containing 200 to 400 pages; and \$33 for an issue containing more than 400 pages. Single issues of the microfiche edition may be purchased for \$3 per copy, including postage. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard, American Express, or Discover. Mail to: U.S. Government Printing Office—New Orders, P.O. Box 979050, St. Louis, MO 63197-9000; or call toll free 1-866-512-1800, DC area 202-512-1800; or go to the U.S. Government Online Bookstore site, see bookstore.gpo.gov.

There are no restrictions on the republication of material appearing in the **Federal Register**.

How To Cite This Publication: Use the volume number and the page number. Example: 72 FR 12345.

Postmaster: Send address changes to the Superintendent of Documents, Federal Register, U.S. Government Printing Office, Washington, DC 20402, along with the entire mailing label from the last issue received.

SUBSCRIPTIONS AND COPIES

PUBLIC

Subscriptions:

Paper or fiche 202-512-1800
Assistance with public subscriptions 202-512-1806

General online information 202-512-1530; 1-888-293-6498

Single copies/back copies:

Paper or fiche 202-512-1800
Assistance with public single copies 1-866-512-1800
(Toll-Free)

FEDERAL AGENCIES

Subscriptions:

Paper or fiche 202-741-6005
Assistance with Federal agency subscriptions 202-741-6005

FEDERAL REGISTER WORKSHOP

THE FEDERAL REGISTER: WHAT IT IS AND HOW TO USE IT

FOR: Any person who uses the Federal Register and Code of Federal Regulations.

WHO: Sponsored by the Office of the Federal Register.

WHAT: Free public briefings (approximately 3 hours) to present:

1. The regulatory process, with a focus on the Federal Register system and the public's role in the development of regulations.
2. The relationship between the Federal Register and Code of Federal Regulations.
3. The important elements of typical Federal Register documents.
4. An introduction to the finding aids of the FR/CFR system.

WHY: To provide the public with access to information necessary to research Federal agency regulations which directly affect them. There will be no discussion of specific agency regulations.

WHEN: Tuesday, December 11, 2007
9:00 a.m.–Noon

WHERE: Office of the Federal Register
Conference Room, Suite 700
800 North Capitol Street, NW.
Washington, DC 20002

RESERVATIONS: (202) 741-6008



Contents

Federal Register

Vol. 72, No. 227

Tuesday, November 27, 2007

Agency for International Development

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 66129

Agriculture Department

See Forest Service

See Rural Business-Cooperative Service

RULES

Administrative regulations:

Official records, authentication, 66041–66042

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 66129

Antitrust Division

NOTICES

Competitive impact statements and proposed consent judgments:

Multiple Listing Service of Hilton Head Island, Inc., 66188–66198

Centers for Disease Control and Prevention

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 66176–66177

Centers for Medicare & Medicaid Services

RULES

Medicare:

Hospital Outpatient Prospective Payment System and CY 2008 payment rates, etc., 66580–67225

Physician fee schedule and other Part B payment policies for CY 2008; payment policy revisions, 66222–66578

Children and Families Administration

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 66177–66180

Coast Guard

RULES

Drawbridge operations:

Texas, 66046–66048

PROPOSED RULES

Ports and waterways safety; regulated navigation areas, safety zones, security zones, etc.:

Cape Cod, MA; North Atlantic right whales; port access route study of potential vessel routing measures to reduce vessel strikes

Correction, 66122

NOTICES

Committees; establishment, renewal, termination, etc.:

Delaware River and Bay Oil Spill Advisory Committee, 66182–66184

Commerce Department

See Industry and Security Bureau

See National Institute of Standards and Technology

See National Oceanic and Atmospheric Administration

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 66133–66134

Commodity Futures Trading Commission

PROPOSED RULES

Commodity Exchange Act:

Federal speculative position limits; risk management exemption, 66097–66103

Defense Department

See Navy Department

NOTICES

Federal Acquisition Regulation (FAR):

Agency information collection activities; proposals, submissions, and approvals, 66140

Delaware River Basin Commission

NOTICES

Meetings and hearings, 66140–66142

Drug Enforcement Administration

PROPOSED RULES

Schedules of controlled substances:

U.S. Official Order Form (DEA Form-222); new single-sheet format, 66118–66122

Education Department

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 66142–66143

Grants and cooperative agreements; availability, etc.:

Special education and rehabilitative services—

Children with disabilities; personnel development to improve services and results, 66143–66154

Meetings:

Historically Black Colleges and Universities President's Board of Advisors, 66154–66155

Privacy Act; systems of records, 66155–66162

Energy Department

See Federal Energy Regulatory Commission

Environmental Protection Agency

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 66165–66170

Environmental statements; notice of intent:

Apra Harbor, Guam; permanent ocean dredged material disposal site designation, 66170–66171

Reports and guidance documents; availability, etc.:

Clean Air Act—

Renewable fuel standard, 66171–66173

Superfund; response and remedial actions, proposed settlements, etc.:

Vermiculite Intermountain Site, UT, 66173

Executive Office of the President

See Privacy and Civil Liberties Oversight Board

Export-Import Bank

RULES

Technical amendments, 66042–66043

Federal Aviation Administration**RULES**

Aircraft:

Non fixed-wing aircraft; nationality and registration markings, 66045

Airworthiness directives:

Eclipse Aviation Corp., 66043–66045

PROPOSED RULES

Airworthiness directives:

Alpha Aviation Design Ltd., 66089–66091

British Aerospace Aircraft Group, 66087–66089

Airworthiness standards:

Special conditions—

Boeing Model 757 series airplanes, 66085–66087

Federal Election Commission**NOTICES**

Special elections; filing dates:

Louisiana, 66173–66175

Federal Energy Regulatory Commission**NOTICES**

Environmental statements; availability, etc.:

Alabama Power Co., 66164

Meetings:

Jordan Cove Energy Project, L.P.; technical conference, 66164

Midwest Independent Transmission System Operator, Inc.; technical conference, 66164–66165

Applications, hearings, determinations, etc.:

Alabama Intrastate, LLC, 66163

Chambersburg, PA, 66163

Discovery Gas Transmission LLC, 66163–66164

Enterprise Texas Pipeline LLC, 66164

Federal Maritime Commission**NOTICES**

Agreements filed, etc., 66175

Federal Reserve System**NOTICES**

Banks and bank holding companies:

Change in bank control, 66175–66176

Permissible nonbanking activities, 66176

Federal Trade Commission**PROPOSED RULES**

Industry guides:

Environmental marketing claims use—

Carbon offsets and renewable energy certificates; workshop, 66094–66097

Meetings, 66091–66093

Fish and Wildlife Service**PROPOSED RULES**

Endangered and threatened species:

Critical habitat designations—

San Diego thornmint, 66122–66128

Food and Drug Administration**RULES**

Animal drugs, feeds, and related products:

Fenbendazole, 66045–66046

PROPOSED RULES

Food for human consumption:

Food labeling—

Alpha-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid omega-3 fatty acids; nutrient content claims, 66103–66118

NOTICES

Meetings:

Behind-the-counter availability of drugs, 66180–66181

Forest Service**NOTICES**

Agency information collection activities; proposals, submissions, and approvals, 66130

Reports and guidance documents; availability, etc.:

Wind energy development on National Forest Service lands; proposed directives, 66130–66131

General Services Administration**NOTICES**

Federal Acquisition Regulation (FAR):

Agency information collection activities; proposals, submissions, and approvals, 66140, 66176

Health and Human Services Department

See Centers for Disease Control and Prevention

See Centers for Medicare & Medicaid Services

See Children and Families Administration

See Food and Drug Administration

See Health Resources and Services Administration

Health Resources and Services Administration**NOTICES**

National Vaccine Injury Compensation Program:

Health insurance policy; average cost update, 66181

Reports and guidance documents; availability, etc.:

Ryan White HIV/AIDS Program; core medical services waiver application requirements; uniform standards (2008 FY), 66181–66182

Homeland Security Department

See Coast Guard

See U.S. Customs and Border Protection

Housing and Urban Development Department**NOTICES**

Agency information collection activities; proposals, submissions, and approvals, 66185–66186

Industry and Security Bureau**NOTICES**

Agency information collection activities; proposals, submissions, and approvals, 66134–66135

Interior Department

See Fish and Wildlife Service

See National Park Service

International Trade Commission**NOTICES**

Import investigations:

Brake rotors from—

China, 66187–66188

Meetings; Sunshine Act, 66188

Justice Department

See Antitrust Division

See Drug Enforcement Administration

Labor Department**NOTICES**

Agency information collection activities; proposals, submissions, and approvals, 66198–66199

National Aeronautics and Space Administration**NOTICES**

Federal Acquisition Regulation (FAR):
Agency information collection activities; proposals, submissions, and approvals, 66140

National Highway Traffic Safety Administration**NOTICES**

Agency information collection activities; proposals, submissions, and approvals, 66218

National Institute of Standards and Technology**NOTICES**

Meetings:
Advanced Technology Visiting Committee, 66135–66136
Information Security and Privacy Advisory Board, 66136

National Oceanic and Atmospheric Administration**RULES**

Fishery conservation and management:
Alaska; fisheries of Exclusive Economic Zone—
Gulf of Alaska halibut, 66083–66084
Caribbean, Gulf, and South Atlantic fisheries—
Gulf of Mexico reef fish, 66080–66081
Northeastern United States fisheries—
Atlantic bluefish, 66082
Summer flounder, 66083

Marine mammals:

Commercial fishing authorizations—
Fisheries categorized according to frequency of incidental takes; 2008 list, 66048–66080

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 66136–66137

Endangered and threatened species:

Anadromous fish take—
Southwest Fisheries Science Center, CA; coho and chinook salmon, and steelhead, 66137–66138

Marine mammal permit applications, determinations, etc., 66138

Meetings:

Mid-Atlantic Fishery Management Council, 66138–66139
New England Fishery Management Council, 66139

National Park Service**NOTICES**

National Register of Historic Places; pending nominations, 66186–66187

National Science Foundation**NOTICES**

Meetings:

Proposal reviews, 66199–66200

Navy Department**NOTICES**

Meetings:

Naval Research Advisory Committee; correction, 66140

Nuclear Regulatory Commission**NOTICES**

Meetings; Sunshine Act, 66200

Applications, hearings, determinations, etc.:

Tennessee Valley Authority, 66200

Privacy and Civil Liberties Oversight Board**RULES**

Freedom of Information Act: CFR removal, 66041

Rural Business-Cooperative Service**NOTICES**

Grants and cooperative agreements; availability, etc.:
Rural Business Enterprise Program, 66131–66133

Securities and Exchange Commission**NOTICES**

Agency information collection activities; proposals, submissions, and approvals, 66200–66203

Self-regulatory organizations; proposed rule changes:

American Stock Exchange LLC, 66203–66205

Chicago Board Options Exchange, Inc., 66205–66213

Fixed Income Clearing Corp., 66213–66214

NYSE Arca, Inc., 66214–66216

Social Security Administration**NOTICES**

Agency information collection activities; proposals, submissions, and approvals, 66216

State Department**NOTICES**

Presidential permit applications:

Greater Yuma Port Authority, San Luis, AZ, at U.S.-

Mexico international boundary; livestock border crossing construction, operation, and maintenance, 66216–66217

Tennessee Valley Authority**NOTICES**

Meetings; Sunshine Act, 66217–66218

Transportation Department

See Federal Aviation Administration

See National Highway Traffic Safety Administration

U.S. Customs and Border Protection**NOTICES**

Commercial gauger and laboratory accreditations:

Approval—

Columbia Inspection, Inc., 66185

Intertek USA, Inc., 66184

Marine Technical Surveyors, Inc., 66184

SGS North America Inc., 66185

Veterans Affairs Department**NOTICES**

Reports and guidance documents; availability, etc.:

Adjudication Procedures Manual (M21-1); provisions related to exposure to herbicides based on receipt of Vietnam Service Medal, 66218–66219

Separate Parts In This Issue**Part II**

Health and Human Services Department, Centers for Medicare & Medicaid Services, 66222–66578

Part III

Health and Human Services Department, Centers for Medicare & Medicaid Services, 66580–67225

Reader Aids

Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.

To subscribe to the Federal Register Table of Contents
LISTSERV electronic mailing list, go to [http://
listserv.access.gpo.gov](http://listserv.access.gpo.gov) and select Online mailing list
archives, FEDREGTOC-L, Join or leave the list (or change
settings); then follow the instructions.

CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.

6 CFR

Ch. X.....66041

7 CFR

1.....66041

12 CFR

403.....66042

407.....66042

414.....66042

14 CFR

39.....66043

45.....66045

Proposed Rules:

25.....66085

39 (2 documents)66087,
66089

16 CFR**Proposed Rules:**

260 (2 documents)66091,
66094

17 CFR**Proposed Rules:**

150.....66097

21 CFR

558.....66045

Proposed Rules:

101.....66103

1305.....66118

33 CFR

117 (2 documents)66046,
66047

Proposed Rules:

167.....66122

42 CFR

409.....66222

410 (2 documents)66222,
66580

411 (2 documents)66222,
66580

412.....66222

413 (2 documents)66222,
66580

414 (2 documents)66222,
66580

415.....66222

416.....66580

418.....66222

419.....66580

423.....66222

424.....66222

482 (2 documents)66222,
66580

484.....66222

485 (2 documents)66222,
66580

50 CFR

229.....66048

622.....66080

648 (3 documents)66082,
66083

679.....66083

Proposed Rules:

17.....66122

Rules and Regulations

Federal Register

Vol. 72, No. 227

Tuesday, November 27, 2007

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

EXECUTIVE OFFICE OF THE PRESIDENT

Privacy and Civil Liberties Oversight Board

6 CFR Chapter X

[Docket No. 0311-AA00]

Removal of 6 CFR Chapter X

AGENCY: Privacy and Civil Liberties Oversight Board, the White House.

ACTION: Removal of Regulations.

SUMMARY: The Privacy and Civil Liberties Oversight Board (PCLOB), the White House, is removing its Freedom of Information Act regulations currently published at 6 CFR Chapter X. This action is being taken because, pursuant to provisions of the Implementing Recommendations of the 9/11 Commission Act of 2007 (Pub. L. 110-53), PCLOB as it is currently constituted will be abolished no later than January 30, 2008 and replaced with a new independent agency within the Executive Branch. This new independent agency will be responsible for promulgating its own regulations.

EFFECTIVE DATE: January 30, 2008.

ADDRESSES: Privacy and Civil Liberties Oversight Board, The White House, Washington, DC 20502, (202) 456-1240. Mail security procedures may delay the delivery of mail. The fax number is: (202) 456-1066.

FOR FURTHER INFORMATION CONTACT: Mark A. Robbins, (202) 456-1065.

SUPPLEMENTARY INFORMATION: The Intelligence Reform and Terrorism Prevention Act (IRTPA) of 2004, Pub. L. 108-458 (IRTPA), established the PCLOB, at the recommendation of the 9/11 Commission. PCLOB is presently part of the White House Office and operates within the Executive Office of the President. It has a general responsibility to ensure that privacy and

civil liberties are appropriately considered as part of the development and implementation of policies and programs designed to protect the Nation against terrorism. IRTPA subjected the Board to the Freedom of Information Act, 5 U.S.C. 552 (FOIA). IRTPA § 1061(i)(2). PCLOB promulgated regulations to implement FOIA which were published as interim final regulations in the **Federal Register** on April 10, 2007.

On August 3, 2007, the President signed into law the Implementing Recommendations of the 9/11 Commission Act of 2007 (Pub. L. 110-53). Among other things, this law abolishes the present Board no later than January 30, 2008 and replaces it with a new independent agency within the Executive Branch. This new entity will promulgate its own regulations consistent with its responsibilities.

Upon closure, the records of the present PCLOB will be transferred to the National Archives and Records Administration pursuant to the Federal Records Act (44 U.S.C. 3101) and will be available to interested members of the public consistent with the provisions of FOIA.

List of Subjects in 6 CFR Chapter X

Freedom of Information Act Procedures.

■ Accordingly, by the authority of the Intelligence Reform and Terrorism Prevention Act (IRTPA) of 2004, Pub. L. 108-458, the Privacy and Civil Liberties Oversight Board is removing 6 CFR Chapter X, in its entirety.

Mark A. Robbins,

Executive Director, Privacy and Civil Liberties Oversight Board.

[FR Doc. 07-5834 Filed 11-26-07; 8:45 am]

BILLING CODE 3195-W7-M

DEPARTMENT OF AGRICULTURE

Office of the Secretary

7 CFR Part 1

Official Records, Authentication

AGENCY: Office of the Secretary, USDA.

ACTION: Final rule.

SUMMARY: This final rule amends Department of Agriculture (USDA) regulations on the procedures that

USDA agencies follow upon receipt of a request for an authenticated copy of an agency document. Specifically, this rule authorizes the Inspector General to authenticate copies of documents in the records of the Office of Inspector General (OIG).

DATES: Effective November 27, 2007.

FOR FURTHER INFORMATION CONTACT: Mr. David R. Gray, Counsel to the Inspector General, Office of Inspector General, U.S. Department of Agriculture, 1400 Independence Avenue, SW., Room 441-E, Washington, DC 20250-2308, Telephone: (202) 720-9110, Facsimile: (202) 690-1528, e-mail: dry@oig.usda.gov.

SUPPLEMENTARY INFORMATION: 7 CFR 1.22 provides that when a USDA agency receives a request for an authenticated copy of an agency document, the agency will send a correct copy to the Office of the General Counsel (OGC). If appropriate, OGC will authenticate the document by certifying that the copy is correct and affixing the USDA seal on the document. The regulation makes an exception for two offices within USDA: (1) The Hearing Clerk in the Office of Administrative Law Judges (OALJ) may authenticate copies of documents in the records of the Hearing Clerk; and (2) the Director of the National Appeals Division (NAD) may authenticate copies of documents in the records of the NAD.

This amendment provides that the Inspector General may authenticate copies of documents in the records of OIG.

Pursuant to section 2 of the Inspector General Act of 1978 (5 U.S.C. App. 3), Congress established Offices of Inspectors General to serve as independent and objective units within Government departments and agencies that would promote economy, efficiency, and effectiveness in the administration of, and prevent and detect fraud and abuse in, the programs and operations of such departments and agencies. Toward that end, the USDA-OIG conducts investigations, audits, inspections, and reviews related to USDA programs and operations, and prepares reports and other documents setting forth the results of such investigations, audits, inspections, and reviews.

OIG controls the distribution and release of its documents in response to requests pursuant to the Freedom of Information Act (5 U.S.C. 552) and the

Privacy Act (5 U.S.C. 552a). This rule ensures that the authentication of OIG documents is conducted by the Inspector General, who may certify that a copy of a requested document is authentic, true, and correct.

This rule relates to internal agency management. Therefore, pursuant to 5 U.S.C. 553, notice of proposed rulemaking and opportunity for comment are not required. This rule may be made effective less than 30 days after publication in the **Federal Register**. Further, this rule is exempt from the provisions of Executive Order 12866 because it relates to internal agency management. In addition, the provisions of the Regulatory Flexibility Act relating to an initial and final regulatory flexibility analysis (5 U.S.C. 603, 604) are not applicable to this final rule because USDA was not required to publish a notice of proposed rulemaking under 5 U.S.C. 553 or any other law. Finally, this action does not require review by Congress because it is not a rule as defined in 5 U.S.C. 804.

List of Subjects in 7 CFR Part 1

Administrative practice and procedure, Freedom of information, Privacy.

■ For the reasons set forth in the preamble, USDA amends 7 CFR part 1 as follows:

PART 1—ADMINISTRATIVE REGULATIONS

■ 1. The authority citation for subpart A continues to read as follows:

Authority: 5 U.S.C. 301, 552; 7 U.S.C. 3125a; 31 U.S.C. 9701; and 7 CFR 2.28(b)(7)(viii).

■ 2. Revise § 1.22 to read as follows:

§ 1.22 Authentication.

When a request is received for an authenticated copy of a document that the agency determines to make available to the requesting party, the agency shall cause a correct copy to be prepared and sent to the Office of the General Counsel, which shall certify the same and cause the seal of the Department to be affixed, except that the Hearing Clerk in the Office of Administrative Law Judges may authenticate copies of documents in the records of the Hearing Clerk, the Director of the National Appeals Division may authenticate copies of documents in the records of the National Appeals Division, and the Inspector General may authenticate copies of documents in the records of the Office of Inspector General.

Dated: October 18, 2007.

Charles F. Conner,

Acting Secretary of Agriculture.

[FR Doc. 07-5826 Filed 11-26-07; 8:45 am]

BILLING CODE 3410-23-M

EXPORT-IMPORT BANK OF THE UNITED STATES

12 CFR Parts 403, 407 and 414

RIN 3048-ZA03

Technical Amendments

AGENCY: Export-Import Bank of the United States.

ACTION: Final rule.

SUMMARY: The Export-Import Bank of the United States (Ex-Im Bank) is amending a number of its regulations by making minor, non-substantive revisions. This rule makes the following changes: removing references to an internal committee that no longer exists, correcting the time of Board meetings, and updating contact information at the Department of Justice. The rule also establishes a new part that implements Ex-Im Bank's authority, found at 12 U.S.C. 635(a)(1), to collect reasonable fees to cover the cost of conferences, seminars and publications.

DATES: The effective date for this final is November 27, 2007.

FOR FURTHER INFORMATION CONTACT:

Brian J. Sonfield, Assistant General Counsel for Administration, (202) 565-3439, brian.sonfield@exim.gov.

SUPPLEMENTARY INFORMATION:

A. Background

Ex-Im Bank recently reviewed its existing regulations to ensure that they accurately reflect the Bank's current operating procedures. The review revealed that minor, nonsubstantive revisions are necessary to part 407 (governing the public observation of Ex-Im Bank meetings) and part 403 (governing the procedures for handling and safeguarding classified information). The review also indicated the need for a regulation implementing the Bank's statutory authority to collect conference and publication fees.

B. Regulatory Changes

Part 407

This Part contains Ex-Im Bank's regulations governing the public observation of its Board of Director meetings, promulgated in part under the Government in the Sunshine Act, 5 U.S.C. 552b(g). Several provisions within this part make reference to the "Executive Committee of the Board of

Directors," an entity that no longer exists. The amendment deletes these references. A couple of provisions also make reference to regularly scheduled Board meetings as being held on Thursdays at 9 a.m. The meetings are now held at 9:30 a.m., and the amendments reflect this change.

Section 403.11

This section concerns classification, declassification and safeguarding of national security information and details enforcement and investigation procedures. Subsection 403.11(b)(12) currently requires Ex-Im Bank to consult with the Department of Justice's Criminal Division prior to taking action against an employee in connection with an unauthorized disclosure of classified information. Disclosures of classified information are now handled by the Department of Justice's National Security Division, and the amendment reflects this change.

Section 414

This new section is created to implement Ex-Im Bank's authority, pursuant to 12 U.S.C. § 635(a)(1), to collect reasonable fees to cover the costs of conferences, seminars and publications.

List of Subjects

12 CFR Part 403

Classified information.

12 CFR Part 407

Sunshine Act.

12 CFR Part 414

Exports, Government publications.

■ Accordingly, for the reasons stated in the preamble, Ex-Im Bank amends the Code of Federal Regulations, Title 12, Chapter IV, parts 403 and 407 as follows and adds part 414 as described below:

PART 403—CLASSIFICATION, DECLASSIFICATION, AND SAFEGUARDING OF NATIONAL SECURITY INFORMATION

■ 1. The authority citation for part 403 continues to read as follows:

Authority: E.O. 12356, National Security Information, April 2, 1982 (3 CFR, 1982 Comp. p. 166) (hereafter referred to as the "Order"), Information Security Oversight Directive No. 1, June 25, 1982 (32 CFR Part 2001) (hereafter referred to as the "Directive"), and National Security Decision Directive 84, "Safeguarding National Security Information," signed by the President on March 11, 1983 (hereafter referred to as "NSDD 84").

§ 403.11 [Amended]

■ 2. Section 403.11(b)(12) is amended by replacing the word “Criminal” with the phrase “National Security”.

PART 407—REGULATIONS GOVERNING PUBLIC OBSERVATION OF EX-IM BANK MEETINGS

■ 3. The authority citation for part 407 continues to read as follows:

Authority: Sec. (g) Government in the Sunshine Act, 5 U.S.C. 552b(g); secs. (b) through (f), 5 U.S.C. 552b.

■ 4. Amend § 407.1 as follows:

- a. Revise paragraph (b) to read as set forth below.
- b. In paragraph (c), remove “9:00” and add in its place “9:30”.

§ 407.1 Purpose, scope and definitions.

* * * * *

(b) The term *meeting* means any meeting of the Board of Directors of Eximbank at which a quorum is present and where deliberations determine or result in the joint conduct or disposition of official Eximbank business.

* * * * *

§ 407.2 [Amended]

■ 5. Amend § 407.2(a) introductory text by removing the phrase “or the Executive Committee”.

§ 407.2 [Amended]

- 6. Amend § 407.3 as follows:
 - a. In paragraph (a), remove the phrase “or the Executive Committee”, and remove “9:00” and add in its place “9:30”.
 - b. In paragraph (b), remove the phrase “or the Executive Committee”.

§ 407.4 [Amended]

■ 5. Amend § 407.4 by removing the phrase “or the Executive Committee” wherever it appears.

§ 407.6 [Amended]

- 6. Amend § 407.6 by removing the phrase “or the Executive Committee”.
- 7. Part 414 is added to read as follows:

PART 414—CONFERENCE AND OTHER FEES

Authority: 12 U.S.C. 635(a)(1), 5 U.S.C. 553.

§ 414.1 Collection of conference and other fees.

Ex-Im Bank may impose and collect reasonable fees to cover the costs of conferences and seminars sponsored by, and publications provided by Ex-Im Bank. Amounts received under the preceding sentence shall be credited to the fund which initially paid for such

activities and shall be offset against the expenses of Ex-Im Bank for such activities.

Howard A. Schweitzer,
General Counsel.

[FR Doc. 07-5807 Filed 11-26-07; 8:45 am]

BILLING CODE 6690-01-M

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2007-0247; Directorate Identifier 2007-CE-083-AD; Amendment 39-15278; AD 2007-24-12]

RIN 2120-AA64

Airworthiness Directives; Eclipse Aviation Corporation Model EA500 Airplanes

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule; request for comments.

SUMMARY: The FAA is adopting a new airworthiness directive (AD) for certain Eclipse Aviation Corporation Model (Eclipse) EA500 airplanes. This AD requires you to inspect the fuel filler adapters for primer and/or paint in the surround and, if present, remove the primer and/or paint. This AD results from an observation during a factory walk-around that the fuel filler surround was primed instead of being bare metal. We are issuing this AD to inspect and, if necessary, remove any paint and/or primer to restore the fuel filler adapter lightning strike protection. A lightning strike on the filler cap with insulating primer on the surround could result in the strike not dissipating to the surround. This could lead to arcing and ignition of fuel vapor inside the fuel tank.

DATES: This AD becomes effective on November 27, 2007.

On November 27, 2007, the Director of the Federal Register approved the incorporation by reference of certain publications listed in this AD.

We must receive any comments on this AD by January 28, 2008.

ADDRESSES: Use one of the following addresses to comment on this AD.

- *Federal eRulemaking Portal:* Go to <http://www.regulations.gov>. Follow the instructions for submitting comments.
- *Fax:* (202) 493-2251.
- *Mail:* U.S. Department of Transportation, Docket Operations, M-30, West Building, Ground Floor, Room W12-140, 1200 New Jersey Avenue, SE., Washington, DC 20590.

- *Hand Delivery:* U.S. Department of Transportation, Docket Operations, M-30, West Building, Ground Floor, Room W12-140, 1200 New Jersey Avenue, SE., Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

To get the service information identified in this AD, contact Eclipse Aviation Corporation, 4100 Aerospace Parkway, Albuquerque, New Mexico 87121; phone (505) 245-7555; fax: (505) 241-8802; email: customercare@EclipseAviation.com.

To view the comments to this AD, go to <http://www.regulations.gov>. The docket number is FAA-2007-0247; Directorate Identifier 2007-CE-083-AD.

FOR FURTHER INFORMATION CONTACT: Mitchell Soth, Flight Test Engineer, 2601 Meacham Blvd., Fort Worth, Texas 76137; telephone: (817) 222-5104; fax: (817) 222-5960.

SUPPLEMENTARY INFORMATION:

Discussion

The aircraft type certification requires compliance to 14 CFR 23.954, Fuel system lightning protection. During the lightning protection testing of certain Eclipse Model EA500 airplanes, it was determined that the fuel filler surround required exposed bare metal to dissipate arc products when the fuel filler cap is struck by lightning. We were notified by Eclipse that, during a factory walk-around, they observed that the fuel filler surround was primed instead of being bare metal. The affected airplanes are only those with the extended tip tanks (ETT).

A lightning strike on the filler cap with insulating primer on the surround could result in the strike not dissipating to the surround. This could lead to arcing and ignition of fuel vapor inside the fuel tank.

Relevant Service Information

We reviewed Eclipse Aviation Corporation Alert Service Bulletin SB 500-57-007, Rev A, dated October 12, 2007, and Eclipse Aviation Corporation Alert Service Bulletin SB 500-57-007, Rev B, dated October 23, 2007. The service information describes procedures for inspecting the fuel filler fitting surround for primer and/or paint and removing the primer and/or paint if found.

FAA’s Determination and Requirements of This AD

We are issuing this AD because we evaluated all the information and determined the unsafe condition described previously is likely to exist or develop on other products of the same type design. This AD requires you to

inspect and if necessary restore the fuel filler adapter lightning strike protection by removing any primer and/or paint from the fuel filler adapter surround.

In preparing this rule, we contacted type clubs and aircraft operators to get technical information and information on operational and economic impacts. We did not receive any information through these contacts. If received, we would have included a discussion of any information that may have influenced this action in the rulemaking docket.

FAA’s Determination of the Effective Date

An unsafe condition exists that requires the immediate adoption of this AD. The FAA has found that the risk to the flying public justifies waiving notice and comment prior to adoption of this rule, because a lightning strike to the fuel filler cap might not properly dissipate to the surround and could cause arcing and ignition of fuel vapor inside the fuel tank. Therefore, we determined that notice and opportunity for public comment before issuing this AD are impracticable and that good cause exists for making this amendment effective in fewer than 30 days.

Comments Invited

This AD is a final rule that involves requirements affecting flight safety, and we did not precede it by notice and an opportunity for public comment. We invite you to send any written relevant data, views, or arguments regarding this AD. Send your comments to an address listed under the ADDRESSES section. Include the docket number “FAA–2007–0247; Directorate Identifier 2007–CE–083–AD” at the beginning of your comments. We specifically invite comments on the overall regulatory, economic, environmental, and energy aspects of the AD. We will consider all comments received by the closing date and may amend the AD in light of those comments.

We will post all comments we receive, without change, to <http://www.regulations.gov>, including any personal information you provide. We will also post a report summarizing each substantive verbal contact we receive concerning this AD.

Authority for This Rulemaking

Title 49 of the United States Code specifies the FAA’s authority to issue rules on aviation safety. Subtitle I, Section 106, describes the authority of the FAA Administrator. Subtitle VII, Aviation Programs, describes in more detail the scope of the Agency’s authority.

We are issuing this rulemaking under the authority described in Subtitle VII, Part A, Subpart III, Section 44701, “General requirements.” Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.

Regulatory Findings

We determined that this AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.

For the reasons discussed above, I certify that this AD:

- (1) Is not a “significant regulatory action” under Executive Order 12866;
- (2) Is not a “significant rule” under DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and
- (3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

We prepared a regulatory evaluation of the estimated costs to comply with this AD and placed it in the AD docket.

Examining the AD Docket

You may examine the AD docket that contains the AD, the regulatory evaluation, any comments received, and other information on the Internet at <http://www.regulations.gov>; or in person at the Docket Management Facility between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

The Docket Office (telephone (800) 647–5527) is located at the street address stated in the ADDRESSES section. Comments will be available in the AD docket shortly after receipt.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.

Adoption of the Amendment

■ Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:

PART 39—AIRWORTHINESS DIRECTIVES

■ 1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

■ 2. The FAA amends § 39.13 by adding the following new airworthiness directive (AD):

2007–24–12 Eclipse Aviation Corporation:
Amendment 39–15278; Docket No. FAA–2007–0247; Directorate Identifier 2007–CE–083–AD.

Effective Date

(a) This AD becomes effective on November 27, 2007.

Affected ADs

(b) None.

Applicability

(c) This AD applies to Model EA500 airplanes, serial numbers 000039 through 000062, that are certificated in any category.

Unsafe Condition

(d) This AD results from an observation during a factory walk-around that the fuel filler surround was primed instead of being bare metal. We are issuing this AD to inspect and, if necessary, remove any paint and/or primer to restore the fuel filler adapter lightning strike protection. A lightning strike on the filler cap with insulating primer on the surround could result in the strike not dissipating to the surround. This could lead to arcing and ignition of fuel vapor inside the fuel tank.

Compliance

(e) To address this problem, you must do the following, unless already done:

Actions	Compliance	Procedures
(1) Inspect the right and left fuel filler adapters for application of primer and/or paint.	At whichever of the following occurs first: (i) Within 10 hours time-in-service (TIS) after November 27, 2007 (the effective date of this AD). (ii) Within 30 days after November 27, 2007 (the effective date of this AD).	Follow the procedures in Eclipse Aviation Corporation Alert Service Bulletin SB 500–57–007, Rev A, dated October 12, 2007, or Eclipse Aviation Corporation Alert Service Bulletin SB 500–57–007, Rev B, dated October 23, 2007.

Actions	Compliance	Procedures
(2) Remove any primer and/or paint from the fuel filler adapter surround.	Before further flight after the inspection required by paragraph (e)(1) of this AD where primer and/or paint was found on the fuel filler adapter surround.	Follow the procedures in Eclipse Aviation Corporation Alert Service Bulletin SB 500-57-007, Rev B, dated October 23, 2007.

Special Flight Permit

(f) Under 14 CFR 39.23, we are limiting the special flight permits for this AD by allowing "Flight in Day Visual Flight Rules (VFR) Only."

Alternative Methods of Compliance (AMOCs)

(g) The Manager, Fort Worth Airplane Certification Office, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. Send information to ATTN: Mitchell Soth, Flight Test Engineer, 2601 Meacham Blvd., Fort Worth, Texas 76137; telephone: (817) 222-5104; fax: (817) 222-5960. Before using any approved AMOC on any airplane to which the AMOC applies, notify your appropriate principal inspector (PI) in the FAA Flight Standards District Office (FSDO), or lacking a PI, your local FSDO.

Material Incorporated by Reference

(h) You must use Eclipse Aviation Corporation Alert Service Bulletin SB 500-57-007, Rev A, dated October 12, 2007 or Eclipse Aviation Corporation Alert Service Bulletin SB 500-57-007, Rev B, dated October 23, 2007, to do the actions required by this AD, unless the AD specifies otherwise.

(1) The Director of the Federal Register approved the incorporation by reference of this service information under 5 U.S.C. 552(a) and 1 CFR part 51.

(2) For service information identified in this AD, contact Eclipse Aviation Corporation, 4100 Aerospace Parkway, Albuquerque, New Mexico 87121; phone (505) 245-7555; fax: (505) 241-8802; e-mail: customer-care@EclipseAviation.com.

(3) You may review copies at the FAA, Central Region, Office of the Regional Counsel, 901 Locust, Kansas City, Missouri 64106; or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.

Issued in Kansas City, Missouri, on November 20, 2007.

Kim Smith,

Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. E7-23024 Filed 11-26-07; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 45

[Docket No. FAA-2007-27173; Amendment No. 45-25]

RIN 2120-AJ02

Nationality and Registration Marks; Non Fixed-Wing Aircraft

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Direct final rule confirmation of effective date.

SUMMARY: This action confirms the direct final rule issued on September 14, 2007, which became effective on November 13, 2007. The rule changes certain display requirements for nationality and registration marks for powered parachutes and weight-shift-control aircraft. No comments were received on this direct final rule.

DATES: The direct final rule published at 72 FR 52467 is confirmed effective November 13, 2007.

ADDRESSES: The complete docket for the direct final rule on nationality and registration marks; non fixed-wing aircraft, Docket ID FAA-2007-27173 may be examined at <http://www.regulations.gov> at any time or go to Docket Operations in Room W12-140 of the West Building, Ground Floor, at 1200 New Jersey Avenue, SE., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Grant Schneemann, AIR-230, Airworthiness Branch, Production and Airworthiness Division, Aircraft Certification Service, Federal Aviation Administration, 800 Independence Avenue, SW., Washington, DC 20591; telephone (202) 267-8473.

SUPPLEMENTARY INFORMATION:

Background

On September 14, 2007, the FAA published a direct final rule (72 FR 52467) that permits operators of U.S. registered powered parachutes and weight-shift-control aircraft to display their nationality and registration marks in other than a horizontal orientation on the fuselage, a structural member, or a

component of the aircraft. The direct final rule also clarifies the size requirements for nationality and registration marks on U.S. registered powered parachutes and weight-shift-control aircraft.

Discussion of Comments

The FAA received no comments on the nationality and registration marks; non fixed-wing aircraft direct final rule.

Conclusion

In consideration that no comments were submitted in response to the direct final rule, the FAA has determined that no further rulemaking action is necessary. Amendment 45-25 remains in effect as adopted.

Issued in Washington, DC, on November 20, 2007.

John Hickey,

Director, Aircraft Certification Services.

[FR Doc. E7-23028 Filed 11-26-07; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558

New Animal Drugs For Use in Animal Feeds; Fenbendazole

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Intervet Inc. The supplemental NADA provides for a revised food safety warning on labeling for fenbendazole Type A medicated article and Type B and Type C medicated horse feeds.

DATES: This rule is effective November 27, 2007.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-7540, e-mail: melanie.berson@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Intervet Inc., P.O. Box 318, 29160 Intervet Lane,

Millsboro, DE 19966, filed a supplement to NADA 131-675 for use of SAFE-GUARD (fenbendazole) 20% Type A medicated article to formulate Type B and Type C medicated horse feeds. The supplemental NADA provides for a revised food safety warning on labeling. The supplemental NADA is approved as of November 5, 2007, and the regulations are amended in 21 CFR 558.258 to reflect the approval.

Approval of this supplemental NADA did not require review of additional safety or effectiveness data or information. Therefore, a freedom of information summary is not required.

FDA has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 558

Animal drugs, Animal feeds.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

■ 1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

§ 558.258 [Amended]

■ 2. In § 558.258, in the table in paragraph (e)(4)(i), in the "Limitations" column, remove "Do not use in horses intended for food." and add in its place "Do not use in horses intended for human consumption."

Dated: November 16, 2007.

Bernadette Dunham,

Deputy Director, Center for Veterinary Medicine.

[FR Doc. E7-22987 Filed 11-26-07; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 117

[CGD08-07-040]

RIN 1625-AA09

Drawbridge Operation Regulations; Sabine River (Old Channel) Behind Orange Harbor Island, Orange, TX

AGENCY: Coast Guard, DHS.

ACTION: Final rule.

SUMMARY: The Coast Guard is removing the existing drawbridge operation regulation for the drawbridge across the Sabine River (Old Channel) behind Orange Harbor Island, mile 9.5, at Orange, Texas. The regulation can be removed because the bridge no longer exists.

DATES: This rule is effective November 27, 2007.

ADDRESSES: Documents indicated in this preamble as being available in the docket are part of docket CGD08-07-040 and are available for inspection or copying at Eighth Coast Guard District, Bridge Administration Branch, Hale Boggs Federal Building, Room 1313, 500 Poydras Street, New Orleans, Louisiana 70130-3310 between 7 a.m. and 3 p.m., Monday through Friday, except Federal holidays. The telephone number is (504) 671-2128.

FOR FURTHER INFORMATION CONTACT: Bart Marcules, Bridge Administration Branch, telephone (504) 671-2128.

SUPPLEMENTARY INFORMATION: We did not publish a notice of proposed rulemaking (NPRM) for this regulation. Under 5 U.S.C. 553(b)(B), the Coast Guard finds that good cause exists for not publishing an NPRM. Public comment is not necessary since the bridge that the regulation governed no longer exists.

Under 5 U.S.C. 553(d)(3), the Coast Guard finds that good cause exists for making this rule effective in less than 30 days after publication in the **Federal Register**. There is no need to delay the implementation of this rule because the bridge it governs has been removed in its entirety.

Background and Purpose

The entire drawbridge across the Sabine River (Old Channel) behind Orange Harbor Island, mile 9.5, at Orange, Texas has been removed. Since the bridge has been removed, mariners are no longer required to go around the bridge. The regulation governing the

operation of the bridge is found in 33 CFR 117.983. The purpose of this rule is to remove 33 CFR 117.983 from the Code of Federal Regulations since it governs a bridge that is no longer across the waterway.

Discussion of Rule

The Coast Guard is changing the regulation in 33 CFR 117 without publishing an NPRM. The change removes the regulation governing the bridge since the bridge has been removed in its entirety. This change does not affect vessel operators using the waterway. Thus, it is not necessary to publish an NPRM.

Regulatory Evaluation

This rule is not a "significant regulatory action" under section 3(f) of Executive Order 12866, Regulatory Planning and Review, and does not require an assessment of potential costs and benefits under section 6(a)(3) of that Order. The Office of Management and Budget has not reviewed it under that Order.

The Coast Guard does not consider this rule to be "significant" under that Order because it does not affect the way vessels operate on the waterway.

Small Entities

Under the Regulatory Flexibility Act (5 U.S.C. 601-612), we have considered whether this rule would have a significant economic impact on a substantial number of small entities. The term "small entities" comprises small businesses, not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000.

The Coast Guard certifies under 5 U.S.C. 605(b) that this rule will not have a significant economic impact on a substantial number of small entities. This rule will have no impact on any small entities because the bridge has been removed in its entirety, and it will not adversely affect the owners and operators of vessels needing to transit the waterway.

Assistance for Small Entities

Under section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104-121), we want to assist small entities in understanding this rule so that they can better evaluate its effects on them and participate in the rulemaking process.

Small businesses may send comments on the actions of Federal employees who enforce, or otherwise determine compliance with, Federal regulations to

the Small Business and Agriculture Regulatory Enforcement Ombudsman and the Regional Small Business Regulatory Fairness Boards. The Ombudsman evaluates these actions annually and rates each agency's responsiveness to small business. If you wish to comment on actions by employees of the Coast Guard, call 1-888-REG-FAIR (1-888-734-3247). The Coast Guard will not retaliate against small entities that question or complain about this rule or any policy or action of the Coast Guard.

Collection of Information

This rule calls for no new collection of information under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520).

Federalism

A rule has implications for federalism under Executive Order 13132, Federalism, if it has a substantial direct effect on State or local governments and would either preempt State law or impose a substantial direct cost of compliance on them. We have analyzed this rule under that Order and have determined that it does not have implications for federalism.

Unfunded Mandates Reform Act

The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531-1538) requires Federal agencies to assess the effects of their discretionary regulatory actions. In particular, the Act addresses actions that may result in the expenditure by a State, local, or tribal government, in the aggregate, or by the private sector of \$100,000,000 or more in any one year. Though this rule will not result in such an expenditure, we do discuss the effects of this rule elsewhere in this preamble.

Taking of Private Property

This rule will not affect a taking of private property or otherwise have taking implications under Executive Order 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

Civil Justice Reform

This rule meets applicable standards in sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

Protection of Children

We have analyzed this rule under Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and

would not create an environmental risk to health or risk to safety that might disproportionately affect children.

Indian Tribal Governments

This rule does not have tribal implications under Executive Order 13175, Consultation and Coordination with Indian Tribal Governments, because it does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes.

Energy Effects

We have analyzed this rule under Executive Order 13211, Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use. We have determined that it is not a "significant energy action" under that order because it is not a "significant regulatory action" under Executive Order 12866 and is not likely to have a significant adverse effect on the supply, distribution, or use of energy. The Administrator of the Office of Information and Regulatory Affairs has not designated it as a significant energy action. Therefore, it does not require a Statement of Energy Effects under Executive Order 13211.

Technical Standards

The National Technology Transfer and Advancement Act (NTTAA) (15 U.S.C. 272 note) directs agencies to use voluntary consensus standards in their regulatory activities unless the agency provides Congress, through the Office of Management and Budget, with an explanation of why using these standards would be inconsistent with applicable law or otherwise impractical. Voluntary consensus standards are technical standards (e.g., specifications of materials, performance, design, or operation; test methods; sampling procedures; and related management systems practices) that are developed or adopted by voluntary consensus standards bodies.

This rule does not use technical standards. Therefore, we did not consider the use of voluntary consensus standards.

Environment

We have analyzed this rule under Commandant Instruction M16475.ID which guides the Coast Guard in complying with the National Environmental Policy Act of 1969 (NEPA) (42 U.S.C. 4321-4370f), and have concluded that there are no factors in this case that would limit the use of

a categorical exclusion under section 2.B.2 of the Instruction. Therefore, this rule is categorically excluded, under figure 2-1, paragraph (32)(e) of the Instruction, from further environmental documentation. Under figure 2-1, paragraph (32)(e), of the Instruction, an "Environmental Analysis Check List" and a "Categorical Exclusion Determination" are not required for this rule.

List of Subjects in 33 CFR Part 117

Bridges.

■ For the reasons discussed in the preamble, the Coast Guard amends 33 CFR part 117 as follows:

PART 117—DRAWBRIDGE OPERATION REGULATIONS

■ 1. The authority citation for part 117 continues to read as follows:

Authority: 33 U.S.C. 499; 33 CFR 1.05-1(g); Department of Homeland Security Delegation No. 0170.1.

§ 117.983 [Removed]

■ 2. Remove § 117.983.

Dated: November 7, 2007.

J.H. Korn,

Captain U.S. Coast Guard, Commander, 8th Coast Guard District, Acting.

[FR Doc. E7-23042 Filed 11-26-07; 8:45 am]

BILLING CODE 4910-15-P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 117

[CGD08-07-043]

Drawbridge Operating Regulations; Sabine Lake, near Sabine Pass, Port Arthur, TX

AGENCY: Coast Guard, DHS.

ACTION: Notice of temporary deviation from regulations.

SUMMARY: The Commander, Eighth Coast Guard District, has issued a temporary deviation from the regulation governing the operation of the State Route 82 (SR 82) swing span bridge across the Sabine Lake at mile 10.0, Port Arthur, Jefferson County, Texas. This deviation provides for the bridge to remain closed to navigation to repair sections of the steel truss members of the drawbridge.

DATES: This deviation is effective from 5 a.m. on Monday, December 3, 2007 until 12 p.m. on Friday, December 7, 2007 and from 5 a.m. on Monday,

December 10, 2007 until 9 p.m. on Friday, December 14, 2007.

ADDRESSES: Materials referred to in this document are available for inspection or copying at the office of the Eighth Coast Guard District, Bridge Administration Branch, Hale Boggs Federal Building, Room 1313, 500 Poydras Street, New Orleans, Louisiana 70130-3310 between 7 a.m. and 3 p.m., Monday through Friday, except Federal holidays. The telephone number is (504) 671-2128. The Bridge Administration Branch maintains the public docket for this temporary deviation.

FOR FURTHER INFORMATION CONTACT: Kay Wade, Bridge Administration Branch, telephone (504) 671-2128.

SUPPLEMENTARY INFORMATION: The Texas Department of Transportation has requested a temporary deviation in order to repair sections of the steel truss members of the SR 82 swing span bridge across the Sabine Lake at Port Arthur, Jefferson County, Texas. Repair of the steel truss members is necessary for continued operation of the swing span of the bridge. This temporary deviation will allow the bridge to remain in the closed-to-navigation position from 5 a.m. on Monday, December 3, 2007 until 12 p.m. on Friday, December 7, 2007 and from 5 a.m. on Monday, December 10, 2007 until 9 p.m. on Friday, December 14, 2007. During the closure period, the draw may be able to open during the scheduled maintenance period if at least 2 hours' advance notice is given. Currently, the draw opens on signal; except that, from 9 p.m. to 5 a.m., the draw shall open on signal, if at least 6 hours' notice is given to the Maintenance Supervisor at the Port Arthur Area Office. The draw opens on signal at any time for an emergency aboard a vessel.

The bridge is a swing span bridge with an available vertical navigational clearance of 9 feet above high water in the closed-to-navigation position. Navigation on the waterway consists primarily of recreational craft, although the bridge is occasionally transited by small tugs with tows transporting sand, gravel and marine shells. Due to prior experience, as well as coordination with waterway users, it has been determined that this closure will not have a significant effect on these vessels. An alternate route is available via the Sabine Neches Waterway, which is comprised of the Sabine Pass Channel, Port Arthur Channel and Sabine Neches Canal, thence passage into the lake from the north side.

In accordance with 33 CFR 117.35(e), the drawbridge must return to its regular operating schedule immediately at the

end of the designated time period. This deviation from the operating regulations is authorized under 33 CFR 117.35.

Dated: November 19, 2007.

David M. Frank,

Bridge Administrator.

[FR Doc. E7-23046 Filed 11-26-07; 8:45 am]

BILLING CODE 4910-15-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 229

[Docket No. 070417093-7582-02]

RIN 0648-AV54

List of Fisheries for 2008

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Department of Commerce.

ACTION: Final rule.

SUMMARY: The National Marine Fisheries Service (NMFS) is publishing its final List of Fisheries (LOF) for 2008, as required by the Marine Mammal Protection Act (MMPA). The final LOF for 2008 reflects new information on interactions between commercial fisheries and marine mammals. NMFS must categorize each commercial fishery on the LOF into one of three categories under the MMPA based upon the level of serious injury and mortality of marine mammals that occurs incidental to each fishery. The categorization of a fishery in the LOF determines whether participants in that fishery are subject to certain provisions of the MMPA, such as registration, observer coverage, and take reduction plan requirements.

DATES: This final rule is effective January 1, 2008.

ADDRESSES: See **SUPPLEMENTARY INFORMATION** for a listing of all Regional offices.

Written comments regarding the burden-hour estimates, or any other aspect of the collection of information requirements contained in this final rule, should be submitted in writing to Chief, Marine Mammal and Sea Turtle Conservation Division, Office of Protected Resources, NMFS, 1315 East-West Highway, Silver Spring, MD 20910, or to David Rostker, Office of Management and Budget (OMB), by fax to 202-395-7285 or by email to David_Rostker@omb.eop.gov.

FOR FURTHER INFORMATION CONTACT:

Melissa Andersen, Office of Protected Resources, 301-713-2322; David

Gouveia, Northeast Region, 978-281-9280; Nancy Young, Southeast Region, 727-551-5607; Elizabeth Petras, Southwest Region, 562-980-3238; Brent Norberg, Northwest Region, 206-526-6733; Bridget Mansfield, Alaska Region, 907-586-7642; Lisa Van Atta, Pacific Islands Region, 808-944-2257.

Individuals who use a telecommunications device for the hearing impaired may call the Federal Information Relay Service at 1-800-877-8339 between 8 a.m. and 4 p.m. Eastern time, Monday through Friday, excluding Federal holidays.

SUPPLEMENTARY INFORMATION:

Availability of Published Materials

Information regarding the LOF and the Marine Mammal Authorization Program, including registration procedures and forms, current and past LOFs, observer requirements, and marine mammal injury/mortality reporting forms and submittal procedures, may be obtained at: <http://www.nmfs.noaa.gov/pr/interactions/>, or from any NMFS Regional Office at the addresses listed below.

Regional Offices

NMFS, Northeast Region, One Blackburn Drive, Gloucester, MA 01930-2298, Attn: Marcia Hobbs;
 NMFS, Southeast Region, 263 13th Avenue South, St. Petersburg, FL 33701, Attn: Teletha Mincey;
 NMFS, Southwest Region, 501 W. Ocean Blvd., Suite 4200, Long Beach, CA 90802-4213, Attn: Lyle Enriquez;
 NMFS, Northwest Region, 7600 Sand Point Way NE, Seattle, WA 98115, Attn: Permits Office;
 NMFS, Alaska Region, Protected Resources, P.O. Box 22668, 709 West 9th Street, Juneau, AK 99802; or
 NMFS, Pacific Islands Region, Protected Resources, 1601 Kapiolani Boulevard, Suite 1100, Honolulu, HI 96814-4700.

What is the List of Fisheries?

Section 118 of the MMPA requires NMFS to place all U.S. commercial fisheries into one of three categories based on the level of incidental serious injury and mortality of marine mammals occurring in each fishery (16 U.S.C. 1387(c)(1)). The categorization of a fishery in the LOF determines whether participants in that fishery may be required to comply with certain provisions of the MMPA, such as registration, observer coverage, and take reduction plan requirements. NMFS must reexamine the LOF annually, considering new information in the Marine Mammal Stock Assessment Reports (SAR) and other relevant

sources, and publish in the **Federal Register** any necessary changes to the LOF after notice and opportunity for public comment (16 U.S.C. 1387 (c)(1)(C)).

How Does NMFS Determine in which Category a Fishery is Placed?

The definitions for the fishery classification criteria can be found in the implementing regulations for section 118 of the MMPA (50 CFR 229.2). The criteria are also summarized here.

Fishery Classification Criteria

The fishery classification criteria consist of a two-tiered, stock-specific approach that first addresses the total impact of all fisheries on each marine mammal stock, and then addresses the impact of individual fisheries on each stock. This approach is based on consideration of the rate, in numbers of animals per year, of incidental mortalities and serious injuries of marine mammals due to commercial fishing operations relative to the potential biological removal (PBR) level for each marine mammal stock. The MMPA (16 U.S.C. 1362 (20)) defines the PBR level as the maximum number of animals, not including natural mortalities, that may be removed from a marine mammal stock while allowing that stock to reach or maintain its optimum sustainable population. This definition can also be found in the implementing regulations for section 118 of the MMPA (50 CFR 229.2).

Tier 1: If the total annual mortality and serious injury of a marine mammal stock, across all fisheries, is less than or equal to 10 percent of the PBR level of the stock, all fisheries interacting with the stock would be placed in Category III (unless those fisheries interact with other stock(s) in which total annual mortality and serious injury is greater than 10 percent of PBR). Otherwise, these fisheries are subject to the next tier (Tier 2) of analysis to determine their classification.

Tier 2, Category I: Annual mortality and serious injury of a stock in a given fishery is greater than or equal to 50 percent of the PBR level.

Tier 2, Category II: Annual mortality and serious injury of a stock in a given fishery is greater than 1 percent and less than 50 percent of the PBR level.

Tier 2, Category III: Annual mortality and serious injury of a stock in a given fishery is less than or equal to 1 percent of the PBR level.

While Tier 1 considers the cumulative fishery mortality and serious injury for a particular stock, Tier 2 considers fishery-specific mortality and serious injury for a particular stock. Additional

details regarding how the categories were determined are provided in the preamble to the proposed rule implementing section 118 of the MMPA (60 FR 45086, August 30, 1995).

Since fisheries are categorized on a per-stock basis, a fishery may qualify as one Category for one marine mammal stock and another Category for a different marine mammal stock. A fishery is typically categorized on the LOF at its highest level of classification (e.g., a fishery qualifying for Category III for one marine mammal stock and for Category II for another marine mammal stock will be listed under Category II).

Other Criteria That May Be Considered

In the absence of reliable information indicating the frequency of incidental mortality and serious injury of marine mammals by a commercial fishery, NMFS will determine whether the fishery qualifies for Category II by evaluating other factors such as fishing techniques, gear used, methods used to deter marine mammals, target species, seasons and areas fished, qualitative data from logbooks or fisher reports, stranding data, and the species and distribution of marine mammals in the area, or at the discretion of the Assistant Administrator for Fisheries (50 CFR 229.2).

How Does NMFS Determine which Species or Stocks are Included as Incidentally Killed or Seriously Injured in a Fishery?

The LOF includes a list of marine mammal species or stocks incidentally killed or seriously injured in each commercial fishery, based on the level of mortality or serious injury in each fishery relative to the PBR level for each stock. To determine which species or stocks are included as incidentally killed or seriously injured in a fishery, NMFS annually reviews the information presented in the current SARs. The SARs are based upon the best available scientific information and provide the most current and inclusive information on each stock's PBR level and level of mortality or serious injury incidental to commercial fishing operations. NMFS also reviews other sources of new information, including observer data, stranding data, and fisher self-reports.

In the absence of reliable information on the level of mortality or serious injury of a marine mammal stock, or insufficient observer data, NMFS will determine whether a species or stock should be added to, or deleted from, the list by considering other factors such as: changes in gear used, increases or decreases in fishing effort, increases or decreases in the level of observer

coverage, and/or changes in fishery management that are expected to lead to decreases in interactions with a given marine mammal stock (such as a Fishery Management Plan or a Take Reduction Plan). NMFS will provide case-specific justification in the LOF for changes to the list of species or stocks incidentally killed or seriously injured.

How Does NMFS Determine the Level of Observer Coverage in a Fishery?

Data obtained from observers and the level of observer coverage are important tools in estimating the level of marine mammal mortality and serious injury in commercial fishing operations. The best available information on the level of observer coverage, and the spatial and temporal distribution of observed marine mammal interactions, is presented in the SARs. Starting with the 2005 SARs, each SAR includes an appendix with detailed descriptions of each Category I and II fishery in the LOF. The SARs generally do not provide detailed information on observer coverage in Category III fisheries because under the MMPA Category III fisheries are not required to accommodate observers aboard vessels due to the remote likelihood of mortality and serious injury of marine mammals. Information presented in the SARs' appendices include: level of observer coverage, target species, levels of fishing effort, spatial and temporal distribution of fishing effort, gear characteristics, management and regulations, and interactions with marine mammals. Copies of the SARs are available on the NMFS Office of Protected Resource's Web site at: <http://www.nmfs.noaa.gov/pr/sars/>. Additional information on observer coverage in commercial fisheries can be found on the NMFS National Observer Program's website: <http://www.st.nmfs.gov/st4/nop/>.

How Do I Find Out if a Specific Fishery is in Category I, II, or III?

This final rule includes two tables that list all U.S. commercial fisheries by LOF Category. Table 1 lists all of the fisheries in the Pacific Ocean (including Alaska). Table 2 lists all of the fisheries in the Atlantic Ocean, Gulf of Mexico, and Caribbean.

Are High Seas Fisheries Included in the LOF?

High seas fisheries in which U.S. persons or vessels participate are not included in the LOF. However, NMFS is considering the inclusion of U.S.-authorized high seas fisheries (fisheries operating beyond 200 nmi of U.S. coasts) in future LOFs. At this time,

NMFS is gathering available information on the number of vessels permitted and/or actively fishing in U.S.-authorized high seas fisheries, gear types used, and marine mammal-fishery interactions data included in documents published under the Magnuson-Stevens Fishery Conservation and Management Act (MSA), National Environmental Policy Act (NEPA), Endangered Species Act (ESA), and MMPA, and from relevant Regional Fishery Management Organizations (RFMO) and the International Whaling Commission (IWC).

Am I Required to Register Under the MMPA?

Owners of vessels or gear engaging in a Category I or II fishery are required under the MMPA (16 U.S.C. 1387(c)(2)), as described in 50 CFR 229.4, to register with NMFS and obtain a marine mammal authorization from NMFS in order to lawfully incidentally take a marine mammal in a commercial fishery. Owners of vessels or gear engaged in a Category III fishery are not required to register with NMFS or obtain a marine mammal authorization.

How Do I Register?

Vessel or gear owners must register with the Marine Mammal Authorization Program (MMAP) by contacting the relevant NMFS Regional Office (see **ADDRESSES**), unless they participate in a fishery that has an integrated registration program (described below). Upon receipt of a completed registration, NMFS will issue vessel or gear owners an authorization certificate. The authorization certificate, or a copy, must be on board the vessel while it is operating in a Category I or II fishery, or for non-vessel fisheries, in the possession of the person in charge of the fishing operation (50 CFR 229.4(e)).

What is the Process for Registering in an Integrated Fishery?

For some fisheries, NMFS has integrated the MMAP registration process with existing state and Federal fishery license, registration, or permit systems. Participants in these fisheries are automatically registered under the MMAP and are not required to submit registration or renewal materials or pay the \$25 registration fee. The following section indicates which fisheries are integrated fisheries and has a summary of the integration process for each Region. Although efforts are made to limit the issuance of authorization certificates to only those vessel or gear owners that participate in Category I or II fisheries, not all state and Federal permit systems distinguish between

fisheries as classified by the LOF. Therefore, some vessel or gear owners in Category III fisheries may receive authorization certificates even though they are not required for Category III fisheries. Individuals fishing in Category I and II fisheries for which no state or Federal permit is required must register with NMFS by contacting their appropriate Regional Office (see **ADDRESSES**).

Which Fisheries Have Integrated Registration Programs?

The following fisheries have integrated registration programs under the MMPA:

1. All Alaska Category II fisheries;
2. All Washington and Oregon Category II fisheries;
3. Northeast Regional fisheries for which a state or Federal permit is required;
4. All Southeast Regional fisheries for which a Federal permit is required, as well as fisheries permitted by the states of North Carolina, South Carolina, Georgia, Florida, Alabama, Mississippi, Louisiana, and Texas; and
5. The HI Swordfish, Tuna, Billfish, Mahi Mahi, Wahoo, Oceanic Sharks Longline/Set line Fishery.

How Do I Receive My Authorization Certificate and Injury/Mortality Reporting Forms?

All vessel or gear owners will receive their authorization certificates and/or injury/mortality reporting forms via U.S. mail upon registration, except those vessel owners participating in the Northeast and Southeast Regional Integrated Registration Program. Vessel or gear owners participating in the Northeast and Southeast Regional Integrated Registration Program will receive their authorization certificates as follows:

1. Northeast Region vessel or gear owners participating in Category I or II fisheries for which a state or Federal permit is required may receive their authorization certificate and/or injury/mortality reporting form by contacting the Northeast Regional Office at 978-281-9328 or by visiting the Northeast Regional Office Web site (http://www.nero.noaa.gov/prot_res/) and following instructions for printing the necessary documents.
2. Southeast Region vessel or gear owners participating in Category I or II fisheries for which a Federal permit is required, as well as fisheries permitted by the states of North Carolina, South Carolina, Georgia, Florida, Alabama, Mississippi, Louisiana, and Texas may receive their authorization certificate and/or injury/mortality reporting form

by contacting the Southeast Regional Office at 727-824-5312 or by visiting the Southeast Regional Office Web site (<http://sero.nmfs.noaa.gov/pr/pr.htm>) and following instructions for printing the necessary documents.

How Do I Renew My Registration Under the MMPA?

Vessel or gear owners that participate in Pacific Islands or Alaska regional fisheries are automatically renewed and should receive an authorization certificate by January 1 of each new year. Vessel or gear owners in Washington and Oregon fisheries receive authorization with each renewed state fishing license, the timing of which varies based on target species. Vessel or gear owners who participate in Pacific Islands, Alaska, Washington, or Oregon fisheries and have not received authorization certificates by January 1 or with renewed fishing licenses must contact the appropriate NMFS Regional Office (see **ADDRESSES**).

Vessel or gear owners in Southeast or Northeast regional fisheries may receive their authorization certificates by calling the relevant NMFS Regional Office or visiting the relevant NMFS Regional Office Web site (see How Do I Receive My Authorization Certificate and Injury/Mortality Reporting Forms).

Vessel or gear owners that participate in Southwest regional fisheries, which do not have an integrated registration program, and have previously registered in a Category I or II fishery will receive a renewal packet from the NMFS Southwest Regional Office at least 30 days prior to January 1 of each new year. It is the responsibility of the vessel or gear owner in these fisheries to complete their renewal form and return it to the NMFS Southwest Regional Office at least 30 days in advance of fishing. Individuals who have not received a renewal packet by January 1 must request a registration form from the NMFS Southwest Regional Office (see **ADDRESSES**).

Am I Required to Submit Reports When I Injure or Kill a Marine Mammal During the Course of Commercial Fishing Operations?

In accordance with the MMPA (16 U.S.C. 1387(e)) and 50 CFR 229.6, any vessel owner or operator, or gear owner or operator (in the case of non-vessel fisheries), participating in a Category I, II, or III fishery must report to NMFS all incidental injuries and mortalities of marine mammals that occur during commercial fishing operations. "Injury" is defined in 50 CFR 229.2 as a wound or other physical harm. In addition, any animal that ingests fishing gear or any animal that is released with fishing gear

entangling, trailing, or perforating any part of the body is considered injured, regardless of the presence of any wound or other evidence of injury, and must be reported. Injury/mortality reporting forms and instructions for submitting forms to NMFS can be downloaded from: http://www.nmfs.noaa.gov/pr/pdfs/interactions/mmap_reporting_form.pdf. Reporting requirements and procedures can be found in 50 CFR 229.6.

Am I Required to Take an Observer Aboard My Vessel?

Fishers participating in a Category I or II fishery are required to accommodate an observer aboard vessel(s) upon request. Observer requirements can be found in 50 CFR 229.7.

Am I Required to Comply With Any Take Reduction Plan Regulations?

Fishers participating in a Category I or II fishery are required to comply with any applicable take reduction plans. Take reduction plan regulations can be found at 50 CFR 229.30–35.

Sources of Information Reviewed for the Final 2008 LOF

NMFS reviewed the marine mammal incidental mortality and serious injury information presented in the SARs for all observed fisheries to determine whether changes in fishery classification were warranted. NMFS' SARs are based on the best scientific information available at the time of preparation, including the level of mortality and serious injury of marine mammals that occurs incidental to commercial fisheries and the PBR levels of marine mammal stocks. The information contained in the SARs is reviewed by regional Scientific Review Groups (SRGs) representing Alaska, the Pacific (including Hawaii), and the U.S. Atlantic, Gulf of Mexico, and Caribbean. The SRGs were created by the MMPA to review the science that informs the SARs, and to advise NMFS on population status and trends, stock structure, uncertainties in the science, research needs, and other issues.

NMFS also reviewed other sources of new information, including marine mammal stranding data, observer program data, fisher self-reports, and other information that may not be included in the SARs.

The final LOF for 2008 was based, among other things, on information provided in the final SARs for 1996 (63 FR 60, January 2, 1998), the final SARs for 2001 (67 FR 10671, March 8, 2002), the final SARs for 2002 (68 FR 17920, April 14, 2003), the final SARs for 2003 (69 FR 54262, September 8, 2004), the

final SARs for 2004 (70 FR 35397, June 20, 2005), the final SARs for 2005 (71 FR 26340, May 4, 2006), the final SARs for 2006 (72 FR 12774, March 19, 2007), and the draft SARs for 2007 (72 FR 35428, June 28, 2007). All the SARs are available at: <http://www.nmfs.noaa.gov/pr/sars/>.

Fishery Descriptions

Below, NMFS briefly describes each Category I and II fishery in the final LOF for 2008. While detailed information describing each fishery in the LOF is included in the SARs, within a Fishery Management Plan (FMP) or Take Reduction Plan (TRP), or by state agencies, general descriptive information is important to include in the LOF for improved clarity. Fisheries are defined based on the gear and fishing methods, target species, temporal and spatial distribution, and management and regulatory schemes. NMFS refers readers to the SARs for more additional information on Category I and II fisheries.

Abbreviations used in the following descriptions include: AK (Alaska), AL (Alabama), CA (California), DE (Delaware), FL (Florida), GA (Georgia), HI (Hawaii), LA (Louisiana), MA (Massachusetts), ME (Maine), MS (Mississippi), NC (North Carolina), NJ (New Jersey), NY (New York), OR (Oregon), RI (Rhode Island), SC (South Carolina), TX (Texas), VA (Virginia), and WA (Washington).

Category I and II Commercial Fisheries in the Pacific Ocean

HI Swordfish, Tuna, Billfish, Mahi Mahi, Wahoo, Oceanic Sharks Longline/Set Line Fishery

The Category I HI longline fishery targets swordfish, tuna, billfish, mahi mahi, wahoo, and oceanic sharks. The basic unit of gear is a 30–40 mi (48–64 km) long mainline made of 0.13–0.16 in (3.2–4.0 mm) diameter monofilament line, with 800–1,000 hooks attached to the mainline. Deployment and retrieval of gear must occur at night. Shallow swordfish sets are required to use size 18/0 circle hooks with a 10-degree offset and mackerel bait. Using squid bait is prohibited. For deep sets, all float lines must be at least 20 m (65.6 ft) long with a minimum of 15 branch lines attached to the mainline between any 2 floats, except for basket-style longline gear that may have as few as 10 branch lines. The use of any light emitting device is prohibited and vessels may not land or possess more than 10 swordfish at any time. The fishery operates over a huge geographic range extending north-south from 40° N. lat. to the equator and

east-west from Kure Atoll to as far as 135° W. long. Fishing for swordfish generally occurs north of Hawaii (as much as 2,000 mi (3,219 km) from Honolulu), whereas fishing for tunas occurs primarily around the main Hawaiian Islands and south of the Hawaiian Islands. The fishery operates year-round, with effort generally lower in the third quarter of the year.

The HI longline fishery is managed in part under the FMP for Pelagic Fisheries of the Western Pacific Region. The shallow-set swordfish component has annual fleetwide limits on interactions with leatherback and loggerhead sea turtles, an annual fleetwide limit of 2,120 shallow sets north of the equator per year, and a requirement for operators to annually participate in a protected species workshop and get a valid protected species certification. Also, regulations mandate 100 percent observer coverage in the shallow-set component of the fishery and at least 20 percent observer coverage in the deep-set component.

CA/OR Thresher Shark/Swordfish Drift Gillnet Fishery (≥14 in mesh)

The Category I CA/OR thresher shark/swordfish drift gillnet fishery primarily targets common thresher sharks and swordfish using a 1000-fathom (6,000 ft; 1,829 m) gillnet with stretched mesh size from 18–22 in (46–56 cm) with a 14-in (35.6 cm) minimum. Other species caught include: pelagic thresher, bigeye thresher, shortfin mako, blue shark, albacore, other tunas, and dorado. One end of the net is typically attached to the vessel and is set at dusk and allowed to drift during the night, typically for 12–14 hours. Fishing effort extends from the U.S.-Mexico border north to waters off of OR, with the majority of effort occurring from October to December. OR restricts landings to swordfish only.

This fishery is a limited entry fishery managed under the Pacific Highly Migratory Species (HMS) FMP and by regulations under the Pacific Offshore Cetacean Take Reduction Plan (POCTRP), including multiple area-season closures and gear restrictions, a requirement for pingers on drift gillnets, a requirement that extenders (buoy lines) be at least 36 ft (11 m) long, and a requirement for vessel captains to attend skipper education workshops, when notified by NMFS.

CA Angel Shark/Halibut and Other Species Set Gillnet Fishery (>3.5 in mesh)

The Category I CA angel shark/halibut and other species set gillnet fishery targets angel shark and halibut from the

U.S.-Mexico border north to Monterey Bay using 200 fathom (1,200 ft; 366 m) gillnet with a stretch mesh size of 8.5 in (31.6 cm). Net soak duration is typically 8–10, 19–24, or 44–49 hours at a depth ranging from 15–50 fathoms (90–300 ft; 27–91 m) with most sets from 15–35 fathoms (90–210 ft; 27–64 m). No more than 1500 fathoms (9,000 ft; 2,743 m) of gill or trammel net may be fished in combination for CA halibut and angel shark. Fishing occurs year-round, with effort generally increasing during summer months and declining during last the 3 months of the year. The central CA portion of the fishery from Point Arguello to Point Reyes has been closed since September, 2002, following a ban on gillnets inshore of 60 fathoms (360 ft; 110 m). Set gill nets have been prohibited in state waters south of Point Arguello and within 70 fathoms (420 ft; 128 m) or one mile (1.6 km), whichever is less, around the Channel Islands since 1990. The CA Department of Fish and Game (CDFG) manages the fishery as a limited entry fishery with gear restrictions and area closures.

CA Yellowtail, Barracuda, and White Seabass Drift Gillnet (mesh size \geq 3.5 in and $<$ 14 in) Fishery

The Category II CA yellowtail, barracuda, and white seabass drift gillnet fishery targets primarily yellowtail and white seabass, and secondarily barracuda, with target species typically determined by market demand on a short-term basis. Drift gillnets are up to 6,000 ft (1,829 m) long and are set at the surface. The mesh size depends on target species and is typically 6.0–6.5 in (15–16.5 cm). When targeting yellowtail and barracuda, the mesh size must be \geq 3.5 in (9 cm); when targeting white seabass, the mesh size must be \geq 6 in (15.2 cm). From June 16 to March 14 not more than 20 percent, by number, of a load of fish may be white seabass with a total length of 28 in (71 cm). A maximum of ten white seabass per load may be taken, if taken in gillnet or trammel nets with meshes from 3.5–6.0 in (9–15 cm) in length. The fishery operates year-round, primarily south of Point Conception with some effort around San Clemente Island and San Nicolas Island. This fishery is a limited entry fishery with various gear restrictions and area closures managed by the CDFG. Targeting tuna with this type of gear was effectively prohibited in April, 2004, under the Pacific HMS FMP.

CA Anchovy, Mackerel, Sardine Purse Seine Fishery

The Category II CA anchovy, mackerel, sardine purse seine fishery

targets wetfish (anchovy, mackerel, and sardine), with the target species primarily driven by availability and market demand. The fishery uses purse seines, drum seines, and lampara nets using standard seining techniques. A typical purse seine net is 185 fathoms (1,110 ft; 338 m) long, 22 fathoms (132 ft; 40 m) deep, and 1,600 meshes deep with each mesh measuring 1.25 in (3 cm). The fishery operates year-round predominantly in southern CA (including the Channel Islands) from San Diego, Oceanside, Dana Point, and San Pedro then north to San Francisco. This fishery is a limited entry fishery, and the mackerel and sardine fisheries are quota fisheries. The fishery is managed in accordance with the Coastal Pelagic Species (CPS) FMP.

CA Tuna Purse Seine Fishery

The Category II CA tuna purse seine fishery targets yellowfin, skipjack, and bluefin tuna using purse seine nets similar to those used to target Coastal Pelagic Species (see the description under “CA anchovy, mackerel, sardine purse seine fishery”). The fishery operates from May to October south of Point Conception to the U.S.-Mexico border and in the Southern California Bight. The fishery is managed under the Pacific HMS FMP. This fishery is considered an opportunistic fishery, meaning that fishers only target tuna when certain oceanographic and market conditions exist to make the fishery viable. Effort in the fishery is highly variable, ranging from zero to ten participants annually over the past several years.

CA Squid Purse Seine Fishery

The Category II CA squid purse seine fishery targets market squid using several gear types. From 1997–2001, 98 percent of fishermen used purse (77 percent) or drum (21 percent) seine nets. Other types used were lampara, dip, and brail nets. The fishery uses lights (shielded and oriented downward, with a maximum of 30,000 watts) to aggregate spawning squid. The fishery operates year-round with the effort focusing north of Point Conception from April to September and south of Point Conception from October to March. El Nino events cause northern landings to increase, while La Nina events cause southern landings to increase.

The fishery is managed by the CDFG and is monitored under the CPS FMP and the Market Squid FMP. Commercial squid purse seine fishing is prohibited year-round from noon on Friday until noon on Sunday to allow a 2-day consecutive uninterrupted period of spawning. All vessels must be permitted

and comply with a mandatory logbook program for fishing and lighting. Since 2001, a seasonal harvest guideline is set to limit further expansion of the fishery.

CA Pelagic Longline Fishery

The Category II CA pelagic longline fishery includes both shallow-set and deep-set gear targeting swordfish and bigeye, albacore, and yellowfin tuna. The fishery operates in waters outside of the U.S. Exclusive Economic Zone (EEZ) because the Pacific HMS FMP prohibits targeting swordfish with longlines within 200 nmi of shore. In 2004, the CA-based shallow-set longline fishery was closed due to anticipated levels of sea turtle interactions. The following is a general description of the shallow-set fishery as it operated prior to 2004 and the current deep-set longline fishery.

Prior to 2004, shallow-set longlines operated year-round primarily targeting swordfish with 15–45 mi (24–72 km) of mainline rigged with 72–ft (22–m) gangions at approximately 197 ft (60 m) intervals. A shallow-set typically has 800–1,300 hooks with large squid or mackerel for bait. Most shallow-set fishing takes place at night when swordfish are at the surface, using various colored lightsticks. A shallow-set mainline is deployed for 4–7 hours and left to drift unattached for 7–10 hours. At this time there is no CA-based shallow-set longline fishing due to anticipated levels of sea turtle interactions.

Deep-set longlines operate year-round primarily targeting tuna with 4–46.6 mi (7–75 km) mainline rigged with 25.6–36 ft (7.8–10.9 m) gangions with 15–16 branchlines set between floats. Deep-set longlines are set at dawn with an average 12 hour soak time. The deep-set sag of the mainline is between 328–1,050 ft (100–320 m) below the water's surface. A deep-set typically contains 270–1,900 hooks with double weighted leaders and sardine for bait. Deep-sets use a variety of hooks including size 38 tuna hooks, size 9 J-hooks, and size 16/0 circle hooks. A small scale deep-set longline fishery began in January 2005 and continues currently. One hundred percent observer coverage is required in the deep-set longline fishery.

WA Puget Sound Regional Salmon Drift Gillnet

The Category II WA Puget Sound regional salmon drift gillnet fishery targets coho, pink, sockeye, chinook, and chum salmon in inland marine waters (state waters) south of the U.S.-Canada border and east of the Bonilla-Tatoosh line at the entrance to the Strait of Juan de Fuca. Drift gillnet gear consists of single web construction, not

exceeding 300 fathoms (1,800; 549 m) in length, attached at one end of the vessel. The minimum mesh size varies from 5–7 in (13–18 cm) depending on the target species. While the depths fished vary, fishermen strive to keep the net off of the bottom. The drift times vary depending on the fishing area, tidal condition, and catch. This fishery is a limited entry fishery with seasonal openings, area closures, and gear restrictions. Regulations governing incidental take of marine mammals do not apply to tribal members exercising fishing treaty rights within this fishery.

AK Prince William Sound Salmon Drift Gillnet Fishery

The Category II AK Prince William Sound salmon drift gillnet fishery targets salmon using drift gillnet gear with soak times of 15 minutes to 3 hours. The gear is set both during the day and night, with 10–14 sets per day. The fishery operates from mid-May to the end of September in the Prince William Sound Fisheries Management Area, the Copper River, and the Bering Sea. The Prince William Sound Fisheries Management Area consists of 11 districts with six hatcheries contributing to the salmon fisheries. This drift gillnet fishery is managed by the AK Department of Fish and Game (ADFG) as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Peninsula/Aleutian Islands Salmon Drift Gillnet Fishery

The Category II AK Peninsula/Aleutian Islands salmon drift gillnet fishery targets salmon using drift gillnet gear with soak times of 2–5 hours. The gear is set during the day and night, with 3–8 sets per day. The fishery operates from mid-June to mid-September in two districts north of the AK Peninsula (Northern and Northwestern), and four districts south of the AK Peninsula (Unimake, Southwestern, Southcentral, and Southeastern). This drift gillnet fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Peninsula/Aleutian Islands Salmon Set Gillnet Fishery

The Category II AK Peninsula/Aleutian Islands salmon set gillnet fishery targets salmon using set gillnet with the gear set every 2 hours during the day and night. The gear is set with continuous soak times during the opener. Salmon may only be fished commercially during periods known as openers established by ADFG in-season.

During some periods of the season fishing may be continuous with openers lasting days or even many weeks at a time. The ADFG posts weekly notices of fishing openers and announces the openers on regular radio channels a few days or a few hours before each opener. Fishing periods are often extended by Emergency Order during the last 24 hours of the opener.

This fishery generally operates from June 18 to mid-August in two districts north of the AK Peninsula (Northern and Northwestern), and four districts south of the AK Peninsula (Unimake, Southwestern, Southcentral, and Southeastern). Set gillnet fishing effort also occurs off Atka and Amelia Islands. This set gillnet fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Southeast Salmon Drift Gillnet Fishery

The Category II AK Southeast salmon drift gillnet fishery targets salmon using drift gillnet gear with soak times of 20 minutes to 3 hours. The gear is set during the day and night, with 6–20 sets set per day. This fishery generally operates from June 18 to early October in five main fishing areas off Southeast AK, as well as at Annette Island, in Terminal Harvest Areas (THA) adjacent to hatchery facilities, and for hatchery cost recovery. The majority of salmon are caught by drift gillnets in the five main fishing areas (81 percent in 2003) and the THAs (13 percent in 2003), with small contributions from Annette Island (4 percent in 2003), and for hatchery cost recovery (1.8 percent in 2003). This drift gillnet fishery is managed by ADFG as a limited entry fishery, with gear restrictions (mesh and net size) and area closures.

AK Cook Inlet Salmon Drift Gillnet Fishery

The Category II AK Cook Inlet salmon drift gillnet fishery targets salmon using drift gillnet gear with soak times of 15 minutes to 3 hours, or continuously. The gear is set during the day, with 6–18 sets per day. This fishery generally operates from June 25 to end of August in the Central District of the Upper Cook Inlet. Drift gillnet fishing effort for sockeye salmon peaks in mid to late July. Currently, drift gillnet fishing for salmon in the Cook Inlet occurs in the Central District area only for the two regular 12-hour openers on Mondays and Thursdays. This drift gillnet fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Cook Inlet Salmon Set Gillnet Fishery

The Category II AK Cook Inlet salmon set gillnet fishery targets salmon using set gillnet gear with continuous soak times during the opener. Fishing effort occurs during the day and night in the Upper Cook Inlet; while fishing effort occurs only during the day in the Lower Cook Inlet, except during fishery extensions. In the Upper Cook Inlet, the catch is picked from the net (i.e., the net is tended) each day during a slack tide; while the catch is picked from the net every 2–6 hours in the Lower Cook Inlet. The net becomes dry with low tide. The fishery generally operates from June 2 to mid-September in Cook Inlet. This set gillnet fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Yakutat Salmon Set Gillnet Fishery

The Category II AK Yakutat salmon set gillnet fishery targets salmon using set gillnet gear with continuous soak times during the opener, during the day and night. The catch is picked from the net every 2–4 hours each day or continuously during peak fishing times. The fishery generally operates from June 4 to the end of August. The Yakutat salmon set gillnet fishery consists of multiple set gillnet fisheries occurring in two fishing districts, the Yakutat District and the Yakataga District. As many as 25 different areas in the Yakutat and Yakataga Districts are open to commercial fishing each year. The Yakutat District fisheries primarily target sockeye and coho salmon, although all species of salmon are harvested. The Yakataga District fisheries target coho salmon. With a few exceptions, set gillnetting is confined to the intertidal area inside the mouths of rivers and streams, and to the ocean waters immediately adjacent to each. Due to the terminal nature of these fisheries, ADFG has been able to develop salmon escapement goals for most of the major, and several of the minor, fisheries. This set gillnet fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Kodiak Salmon Set Gillnet Fishery

The Category II AK Kodiak salmon set gillnet fishery targets salmon using set gillnet gear with continuous soak times during the opener. Fishing effort occurs during the day, with the catch picked from the net 2 or more times each day. The majority of set gillnets are attached to a shore lead up to 80 fathoms (480 ft; 146 m) long in a straight line to a king

buoy offshore, with numerous anchor lines and buoys holding the net in place. The last 25 fathoms (150 ft; 46 m) of the gillnet is usually formed into a fish trap, also called a hook. The fishery generally operates from June 9 to the end of September or early October. Many areas are open until early October, but most fishermen remove the nets by early September. As the runs progress in late July and change from sockeye to pink salmon, the ADFG often reduces the length of openers if escapement goals have not been met. Fishing effort begins to reduce in mid to late August as salmon runs begin to decline.

This fishery consists of 2 Districts, the Northwest District from Spruce Island to the south side of Uyak Bay, and the Alitak Bay District located on the southwestern corner of Kodiak Island. In most years, the Northwest District is fished by approximately 100 permit holders and constitutes approximately 70 percent of the annual fishing effort, while the Alitak Bay District is fished by approximately 70 permit holders and constitutes approximately 30 percent of the annual fishing effort. Traditionally, the Northwest District is open for the majority of June and July, while effort in the Alitak Bay District typically occurs 5 to 7 days out of every 10 days during the fishing season. This set gillnet fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Bristol Bay Salmon Drift Gillnet Fishery

The Category II AK Bristol Bay salmon drift gillnet fishery targets salmon using drift gillnet gear with continuous soak times for part of the net, while other parts of the net are tended. Fishing effort occurs during the day and night, with a continuous number of sets per day. This fishery generally operates from June 17 to the end of August in Bristol Bay. Approximately 80 percent of the salmon catch in Bristol Bay is caught with drift gillnets. The Bristol Bay management area consists of five management districts including all coastal and inland waters from Cape Newenham to Cape Mensehikof. There are eight major river systems in the area, and these form the largest commercial sockeye salmon fishery in the world. Although sockeye salmon is the most abundant salmon species that returns to Bristol Bay each year, chinook, chum, coho, and pink salmon returns are also important to the fishery. This drift gillnet fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Bristol Bay Salmon Set Gillnet Fishery

The Category II AK Bristol Bay salmon set gillnet fishery targets salmon using set gillnet gear with continuous soak times during the opener, but the net is dry during low tide. Fishing effort occurs during the day and night, with 2 or more continuous sets per day. This fishery generally operates from June 17 to the end of August or mid-September in the same areas in Bristol Bay as the AK Bristol Bay salmon drift gillnet fishery discussed above. Approximately 20 percent of the salmon catch in Bristol Bay is caught with set gillnets. This set gillnet fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Metlakatla/Annette Island Salmon Drift Gillnet Fishery

The Category II AK Metlakatla/Annette Island salmon drift gillnet fishery targets salmon using drift gillnet gear off Annette Island in Southeast AK. This drift gillnet fishery is an exclusively tribal fishery. The fishery is a limited entry fishery with gear restrictions (mesh and net size) and area closures. This fishery, as a tribal fishery, is separate from the AK Southeast drift gillnet fishery only for regulation purposes. The fisheries are considered the same for LOF categorization purposes.

AK Southeast Salmon Purse Seine Fishery

The Category II AK Southeast salmon purse seine fishery targets salmon using purse seine gear with soak times of 20–45 minutes. Fishing effort occurs mostly in daylight hours, except at the peak of the season, with 6–20 sets per day. The fishery generally operates from the end of June to September. In 2003, purse seine fishing ran through November 12 in THAs. Regulations allow purse seine fishing to occur in certain fishing districts, and also in certain THAs, hatchery cost recovery areas, and the Annette Island Fishery Reserve. This purse seine fishery accounts for approximately 80 percent of the total salmon harvest in Southeast AK, and approximately 87 percent of the fish caught are pink salmon. This purse seine fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Cook Inlet Salmon Purse Seine Fishery

The Category II AK Cook Inlet salmon purse seine fishery targets salmon using purse seine gear in Cook Inlet from June

1 to October 31. Purse seines must be between 90 fathoms (540 ft; 165 m) and 250 fathoms (1,500 ft; 457 m) long, and 100 meshes and 325 meshes deep. Detachable or loose leads are not permitted. In Cook Inlet, purse seines may be used in the Southern District, Kamishak Bay District, Outer District, Eastern District, and Chinitna Bay Subdistrict east of a line from the crane on the south shore to the largest boulder on the landward end of Glacier Spit. This purse seine fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Kodiak Salmon Purse Seine Fishery

The Category II AK Kodiak salmon purse seine fishery targets salmon using purse seine gear from June 1 to October 31, with fishing periods open by regulation and emergency orders. Purse seine gear must have a mesh size of less than 7 in (18 cm). Purse seine gear must be between 100 fathoms (600 ft; 183 m) and 200 fathoms (1,200 ft; 366 m) long, and between 100 meshes and 325 meshes deep. At least 50 fathoms (300 ft; 91 m) of a purse seine must be 150 meshes in depth. One lead, no more than 100 fathoms (600 ft; 183 m) in length, may be used with each purse seine. The aggregate length of a seine and lead may not exceed 250 fathoms (1,500 ft; 457 m). Leads must be removed from the water within two hours after a season or fishing period closure. Overlapping panels of net web may not be used in seine leads.

This fishery occurs in the Kodiak Area, including all waters of AK south of Cape Douglas (58° 51.10' N. lat.), west of 150° W. long., north of 55° 30' N. lat., and north and east of the southern entrance of Imuya Bay. This purse seine fishery is managed by ADFG as a limited entry fishery with gear restrictions (mesh and net size) and area closures.

AK Bering Sea and Aleutian Islands (BSAI) Flatfish Trawl Fishery

The Category II AK BSAI flatfish trawl fishery targets flatfish using trawl gear in the U.S. EEZ of the eastern Bering Sea and the portion of the North Pacific Ocean adjacent to the Aleutian Islands, which is west of 170° W. long. up to the U.S.-Russian Convention Line of 1867. Management measures for the BSAI groundfish fisheries constrain fishing both temporally and spatially. This fishery is federally managed under the BSAI FMP. The authorized gear, fishing season, criteria for determining fishing seasons, and area restrictions by gear type are defined in the regulations

implementing the BSAI FMP (50 CFR part 679).

AK Bering Sea and Aleutian Islands (BSAI) Pollock Trawl Fishery

The Category II AK BSAI pollock trawl fishery targets flatfish using trawl gear in the same location as the AK BSAI flatfish trawl fishery described above. The use of non-pelagic trawl gear in the directed fishery for pollock is prohibited. This fishery is federally managed under the BSAI FMP. Management measures for the BSAI groundfish fisheries constrain fishing both temporally and spatially. The gear authorized, fishing year, criteria for determining fishing seasons, and area restrictions by gear type are defined in the regulations implementing the BSAI FMP (50 CFR part 679).

AK Bering Sea and Aleutian Islands (BSAI) Pacific Cod Longline Fishery

The Category II AK BSAI Pacific cod longline fishery targets Pacific cod using longline gear in the same location as the AK BSAI flatfish trawl fishery described above. This fishery is federally managed under the BSAI FMP. Management measures for the BSAI groundfish fisheries constrain fishing both temporally and spatially. The gear authorized, fishing year, criteria for determining fishing seasons, and area restrictions by gear type are defined in the regulations implementing the BSAI FMP (50 CFR part 679).

AK Bering Sea Sablefish Pot Fishery

The Category II AK Bering Sea sablefish pot fishery targets sablefish using pot gear in the same location as the AK BSAI flatfish trawl fishery described above. This fishery is Federally managed under the BSAI FMP and is operated under Individual Fishing Quotas. Management measures for the BSAI groundfish fisheries constrain fishing both temporally and spatially. The gear authorized, fishing year, criteria for determining fishing seasons, and area restrictions by gear type are defined in the regulations implementing the BSAI FMP (50 CFR part 679).

Category I and II Commercial Fisheries in the Atlantic Ocean, Gulf of Mexico, and Caribbean

Northeast Sink Gillnet Fishery

The Category I Northeast sink gillnet fishery targets Atlantic cod, haddock, pollock, yellowtail flounder, winter flounder, witch flounder, American plaice, windowpane flounder, spiny dogfish, monkfish, silver hake, red hake, white hake, ocean pout, skate spp, mackerel, redfish, and shad. This

fishery uses sink gillnet gear, which is anchored gillnet (bottom-tending net) fished in the lower one-third of the water column. The dominant material is monofilament twine with stretched mesh sizes from 6–12 in (15–30.5 cm) and string lengths from 600–10,500 ft (183–3,200 m), depending on the target species. The fishery operates from the U.S.-Canada border to Long Island, NY, at 72° 30' W. long. south to 36° 33.03' N. lat. (corresponding with the VA/NC border) and east to the eastern edge of the EEZ, including the Gulf of Maine, Georges Bank, and Southern New England, and excluding Long Island Sound or other waters where gillnet fisheries are listed as Category III. At this time, these Category II and II fisheries include: the Northeast anchored float gillnet; Northeast drift gillnet; Long Island Sound inshore gillnet; and RI, southern MA (to Monomoy Island), and NY Bight (Raritan and Lower NY Bays) inshore gillnet. Fishing effort occurs year-round, peaking from May to July primarily on continental shelf regions in depths from 30–750 ft (9–228.6 m), with some nets deeper than 800 ft (244 m).

This fishery is managed by the Northeast Multispecies (Groundfish) FMP and the Monkfish FMP. This fishery is also managed by the Atlantic Large Whale Take Reduction Plan (ALWTRP) and the Harbor Porpoise Take Reduction Plan (HPTRP) to reduce the risk of entanglement of right, humpback, and fin whales, and harbor porpoises, respectively. The fishery is primarily managed by Total Allowable Catch (TAC) limits; individual trip limits (quotas); effort caps (limited number of days at sea per vessel); time and area closures; and gear restrictions.

Mid-Atlantic Gillnet Fishery

The Category I Mid-Atlantic gillnet fishery targets monkfish, spiny dogfish, smooth dogfish, bluefish, weakfish, menhaden, spot, croaker, striped bass, large and small coastal sharks, Spanish mackerel, king mackerel, American shad, black drum, skate spp., yellow perch, white perch, herring, scup, kingfish, spotted seatrout, and butterfish. The fishery uses drift and sink gillnets, including nets set in a sink, stab, set, strike, or drift fashion, with some unanchored drift or sink nets used to target specific species. The dominant material is monofilament twine with stretched mesh sizes from 2.5–12 in (6.4–30.5 cm), and string lengths from 150–8,400 ft. (46–2,560 m). This fishery operates year-round west of a line drawn at 72° 30' W. long. south to 36° 33.03' N. lat. and east to the eastern edge of the EEZ and north of the

NC/SC border, not including waters where Category II and Category III inshore gillnet fisheries operate in bays, estuaries, and rivers. At this time, these Category II and Category III fisheries include: the Chesapeake Bay inshore gillnet; NC inshore gillnet; DE River inshore gillnet; Long Island Sound inshore gillnet; and RI, southern MA (to Monomoy Island), and NY Bight (Raritan and Lower NY Bays) inshore gillnet. This fishery includes any residual large pelagic driftnet effort in the mid-Atlantic and any shark and dogfish gillnet effort in the mid-Atlantic zone described. The fishing effort is prosecuted right off the beach (6 ft [1.8 m]) or in nearshore coastal waters to offshore waters (250 ft [76 m]).

Gear in this fishery is managed by several Federal FMPs and Inter-State FMPs managed by the Atlantic States Marine Fisheries Commission (ASMFC), the ALWTRP, the HPTRP, and the Bottlenose Dolphin Take Reduction Plan (BDTRP). Fisheries are primarily managed by TACs; individual trip limits (quotas); effort caps (limited number of days at sea per vessel); time and area closures; and gear restrictions and modifications.

Atlantic Ocean, Caribbean, Gulf of Mexico Large Pelagics Longline Fishery

The Category I Atlantic Ocean, Caribbean, Gulf of Mexico large pelagics longline fishery targets swordfish, yellowfin tuna, bigeye tuna, bluefin tuna, albacore tuna, dolphin fish, wahoo, shortfin mako shark, and a variety of other shark species. The fishery uses a mainline of >700 lb (317.5 kg) test monofilament typically ranging from 10–45 mi (16–72 km) long. Bullet-shaped floats are suspended at regular intervals along the mainline and long sections of gear are marked by radio beacons. Long gangion lines of 200–400 lb (91–181 kg) test monofilament of typically 100–200 ft (30.5–61 m) are suspended from the mainline. Only certain sized hooks and baits are allowed based on fishing location. Hooks are typically fished at depths between 40–120 ft (12–36.6 m). Longlines targeting tuna are typically set at dawn are hauled near dusk, while longlines targeting swordfish are typically set at night and hauled in the morning. Gear remains in the water typically for 10–14 hours. Fishermen generally modify only select sections of longline gear to target dolphin or wahoo, with the remaining gear configured to target swordfish, tuna, and/or sharks.

This fishery operates year-round and occurs within and outside the U.S. EEZ throughout Atlantic, Caribbean and Gulf

of Mexico waters. The fishery has historically been composed of five relatively distinct segments with different fishing practices and strategies, including: Gulf of Mexico yellowfin tuna fishery; South Atlantic-Florida east coast to Cape Hatteras swordfish fishery; Mid-Atlantic and New England swordfish and bigeye tuna fishery; U.S. distant water swordfish fishery; and Caribbean Islands tuna and swordfish fishery. In addition to geographical area, these segments have historically differed by percentage of various target and non-target species, gear characteristics, and deployment techniques.

This fishery is managed under the Consolidated Atlantic HMS FMP. The dolphin and wahoo portions of the fishery are managed under the South Atlantic FMP for Dolphin and Wahoo. Regulations under the MSA address the target fish species, as well as bycatch species protected under the ESA and/or the MMPA. A portion of this fishery is the subject of the Pelagic Longline Take Reduction Team (PLTRT), convened in 2005. NMFS is currently developing regulations to implement the Take Reduction Plan.

Northeast/Mid-Atlantic American Lobster Trap/Pot Fishery

The Category I Northeast/Mid-Atlantic American lobster trap/pot fishery targets American lobster primarily with traps, while 2–3 percent of the target species is taken by mobile gear (trawls and dredges). The fishery operates in inshore and offshore waters from ME to NJ and may extend as far south as Cape Hatteras. Approximately 80 percent of American lobster are harvested from state waters; therefore, the ASMFC has a primary regulatory role. The EEZ portion of the fishery operates under regulations from the Federal American Lobster FMP. Both the EEZ and state fishery are operating under Federal regulations from the ALWTRP.

Northeast Anchored Float Gillnet Fishery

The Category II Northeast anchored float gillnet fishery targets mackerel, herring (particularly for bait), shad, and menhaden using gillnet gear of any size anchored and fished in the upper two-thirds of the water column. The fishery operates from the U.S.-Canada border to Long Island, NY, at 72° 30' W. long south to 36° 33.03' N. lat. and east to the eastern edge of the EEZ, not including Long Island Sound or other waters where gillnet fisheries are listed as Category III. The fishery is managed under the Interstate FMPs for Atlantic

Menhaden and Shad and is subject to ALWTRP implementing regulations. A total closure of the American shad ocean intercept fishery was fully implemented in January, 2005.

Northeast Drift Gillnet Fishery

The Category II Northeast drift gillnet fishery targets species other than large pelagics, including shad, herring, mackerel, and menhaden. This fishery uses drift gillnet gear, which is gillnet gear not anchored to the bottom and is free-floating on both ends or free-floating at one end and attached to the vessel at the other end. Mesh sizes are likely less than those used to target large pelagics. The fishery includes any residual large pelagic driftnet effort in New England and occurs at any depth in the water column from the U.S.-Canada border to Long Island, NY, at 72° 30' W. long. south to 36° 33.03' N. lat. and east to the eastern edge of the EEZ. The fishery is managed under the Interstate FMPs for Atlantic Menhaden and Shad and is subject to ALWTRP implementing regulations. A total closure of the American shad ocean intercept fishery was fully implemented in January, 2005.

Chesapeake Bay Inshore Gillnet Fishery

The Category II Chesapeake Bay inshore gillnet fishery targets menhaden and croaker using gillnet gear with mesh sizes ranging from 2.75–5 in (7–12.7 cm), depending on the target species. The fishery operates between the Chesapeake Bay/Bridge Tunnel and the mainland. The fishery is managed under the Interstate FMPs for Atlantic Menhaden and Atlantic Croaker.

Northeast Mid-Water Trawl (Including Pair Trawl) Fishery

The Category II Northeast mid-water trawl fishery targets Atlantic herring with bycatch of several finfish species, predominantly mackerel, spiny dogfish, and silver hake. This fishery uses primarily mid-water (pelagic) trawls (single and paired), which is trawl gear designed, capable, or used to fish for pelagic species with no portion designed to be operated in contact with the bottom. The fishery occurs primarily in ME State waters, Jeffrey's Ledge, southern New England, and Georges Bank during the winter months when the target species continues its southerly migration from the Gulf of Maine/Georges Bank, into mid-Atlantic waters. The fishery is managed jointly by the Mid-Atlantic Fishery Management Council and the ASMFC as a migratory stock complex.

Mid-Atlantic Flynet Fishery

The Category II Mid-Atlantic flynet fishery is a multispecies fishery composed of nearshore and offshore components that operate along the eastern coast of the Mid-Atlantic United States. Flynets are high profile trawls similar to bottom otter trawls. These nets typically range from 80–120 ft (24–36.6 m) in headrope length, with wing mesh sizes of 16–64 in (41–163 cm), following a slow 3:1 taper to smaller mesh sizes in the body, extension, and codend sections of the net. The nearshore fishery operates from October to April inside of 30 fathoms (180 ft; 55 m) from NC to NJ. This nearshore fishery targets Atlantic croaker, weakfish, butterfish, harvestfish, bluefish, menhaden, striped bass, kingfishes, and other finfish species. Flynet fishing is no longer permitted south of Cape Hatteras in order to protect weakfish stocks. The offshore component operates from November to April outside of 30 fathoms (180 ft; 55 m) from the Hudson Canyon off NY, south to Hatteras Canyon off NC. These deeper water fisheries target bluefish, Atlantic mackerel, *Loligo* squid, black sea bass, and scup (72 FR 7382, February 15, 2007). *Illex* Squid are also targeted offshore (70–200 fathoms [420–1,200 ft; 128–366 m]) during summer months from May to September.

Northeast Bottom Trawl Fishery

The Category II Northeast bottom trawl fishery uses bottom trawl gear to target species included in the NE Multispecies FMP, Summer Flounder FMP, and Scup and Seabass FMP, including, but not limited to: Atlantic cod, haddock, pollock, yellowtail flounder, winter flounder, witch flounder, American plaice, Atlantic halibut, redfish, windowpane flounder, summer flounder, spiny dogfish, monkfish, silver hake, red hake, white hake, ocean pout, and skate spp. The fishery operates year-round, with a peak from May to July, from the U.S.-Canada border through waters east of 72° 30' W. long., primarily on the continental shelf and throughout the Gulf of Maine, Georges Bank, and Southern New England. The fishery is primarily managed by TACs, individual trip limits (quotas), effort caps (limited number of days at sea per vessel), time and area closures, and gear restrictions.

VA Pound Net Fishery

The Category II VA pound net fishery targets weakfish, spot, and croaker using stationary gear in nearshore coastal and estuarine waters off VA. Pound net gear includes a large mesh lead posted

perpendicular to the shoreline and extending outward to the corral, or "heart," where the catch accumulates. This fishery includes all pound net effort in VA State waters, including waters inside the Chesapeake Bay. The fishery is managed under Interstate FMPs for Atlantic Croaker and Spot, and is an affected fishery under the BDTRP.

Atlantic Mixed Species Trap/Pot Fishery

The Category II Atlantic mixed species trap/pot fishery's target species include, but are not limited to, hagfish, shrimp, conch/whelk, red crab, Jonah crab, rock crab, black sea bass, scup, tautog, cod, haddock, Pollock, redfish (ocean perch) white hake, spot, skate, catfish, stone crab, American eel, and cunner. The fishery includes all trap/pot operations from the U.S.-Canada border south through the waters east of the fishery management demarcation line between the Atlantic Ocean and the Gulf of Mexico (50 CFR 600.105), but does not include the following Category I, II, and III trap/pot fisheries: Northeast/Mid-Atlantic American lobster trap/pot; Atlantic blue crab trap/pot; Florida spiny lobster trap/pot; Southeastern U.S. Atlantic, Gulf of Mexico stone crab trap/pot; U.S. Mid-Atlantic eel trap/pot fisheries; and the Southeastern U.S. Atlantic, Gulf of Mexico golden crab fishery (68 FR 1421, January 10, 2003). The fishery is managed under various Interstate FMPs and is subject to ALWTRP implementing regulations.

Atlantic Blue Crab Trap/Pot Fishery

The Category II Atlantic blue crab trap/pot fishery targets blue crab using pots baited with fish or poultry typically set in rows in shallow water. The pot position is marked by either a floating or sinking buoy line attached to a surface buoy. The fishery occurs year-round from the south shore of Long Island at 72° 30' W. long. in the Atlantic and east of the fishery management demarcation line between the Atlantic Ocean and the Gulf of Mexico (50 CFR 600.105), including state waters. The fishery is managed under state FMPs, and is subject to ALWTRP implementing regulations. It is also an affected fishery under the BDTRP.

Mid-Atlantic Bottom Trawl Fishery

The Category II Mid-Atlantic bottom trawl fishery uses bottom trawl gear to target species including, but not limited to, bluefish, croaker, monkfish, summer flounder (fluke), winter flounder, silver hake (whiting), spiny dogfish, smooth dogfish, scup, and black sea bass. The fishery occurs year-round from Cape Cod, MA, to Cape Hatteras, NC, in

waters west of 72° 30' W. long. and north of a line extending due east from the NC/SC border. The gear is managed by several state and Federal FMPs that range from MA to NC.

Mid-Atlantic Mid-Water Trawl (Including Pair Trawl) Fishery

The Category II Mid-Atlantic mid-water trawl fishery targets Atlantic mackerel, *Loligo* squid, *Illex* squid, and Atlantic butterflyfish using mainly mid-trawl gear, with some bottom trawls. The fishery is dominated by small-mesh otter trawls, but *Loligo* squid are also taken by inshore pound nets and fish traps in spring and summer. The fishery for *Illex* occurs offshore, mainly in continental shelf and slope waters during summer months (June to September), from southern New England to Cape Hatteras, NC. The fishery for *Loligo* occurs mostly offshore near the edge of the continental shelf during fall and winter months (October to March), and inshore during spring and summer (April to September) in southern New England and mid-Atlantic waters. The fishery for Atlantic mackerel occurs primarily in southern New England and the mid-Atlantic from January to March, and in the Gulf of Maine during summer and fall (May to December). Atlantic butterflyfish are mainly caught as bycatch in the directed squid and mackerel fisheries due to their northerly inshore migration in summer months and southerly offshore migration in winter months. The fishery is managed by the Federal Squid, Mackerel, Butterflyfish FMP. The *Illex* and *Loligo* fisheries are managed by moratorium permits, gear and area restrictions, quotas, and trip limits. The Atlantic mackerel and Atlantic butterflyfish fisheries are managed by an annual quota system.

Mid-Atlantic Haul/Beach Seine Fishery

Due to pending rulemakings by the NC Division of Marine Fisheries (NCDMF), particularly pertaining to NC beach gear, NMFS is basing its description of the Category II Mid-Atlantic haul/beach seine fishery on the proposed 2001 LOF (66 FR 6545, January 22, 2001) and components of the proposed 2008 LOF (72 FR 35393, June 28, 2007). NMFS is including components of both definitions that more accurately reflect the current fishery. This includes the following description: The Category II Mid-Atlantic haul/beach seine fishery targets striped bass, mullet, spot, weakfish, sea trout, bluefish, kingfish, and harvestfish using seines with one end secured (e.g., swipe nets and long seines) and seines secured at both ends or those anchored

to the beach and hauled up on the beach. The beach seine system also uses a bunt and a wash net that are attached to the beach and extend into the surf. The fishery occurs in waters west of 72° 30' W. long. and north of a line extending due east from the NC/SC border. The fishery is managed under several state and Interstate FMPs and is an affected fishery under the BDTRP. Further revision to the description of this fishery will appear in a future LOF pending the NCDMF rulemakings.

Mid-Atlantic Menhaden Purse Seine Fishery

The Category II Mid-Atlantic menhaden purse seine fishery targets menhaden and thread herring using purse seine gear. Most sets occur within 3 mi (4.8 km) of shore with the majority of the effort occurring off NC from November to January, and moving northward during warmer months to southern New England. The fishery is managed under the Interstate FMP for Atlantic Menhaden.

Southeastern U.S. Atlantic Shark Gillnet Fishery

The Category II Southeastern U.S. Atlantic shark gillnet fishery targets large and small coastal sharks (blacktip, blacknose, finetooth, bonnethead, and sharpnose) using gillnets set in a sink, stab, set, strike, or drift fashion. Mesh size is typically greater than 5 in (13 cm), but may be as small as 2.87 in (7.3 cm) when targeting small coastal sharks. Drift gillnets most commonly use a mesh size of 5 in (13 cm) and average 10.2 hours from setting the gear through completion of haulback; sink gillnets most frequently use a mesh size of 7 in (18 cm) soaking for approximately 2.7 hours; and strike gillnets use the largest mesh size of 9 in (23 cm) soaking for approximately 0.8 hours. This fishery has traditionally operated in coastal waters off FL and GA.

This fishery is managed under the Consolidated Atlantic HMS FMP, the ALWTRP, and the BDTRP, and is subject to ESA biological opinion requirements. Regulations implemented under the MSA address managed target species, as well as bycatch species, including some protected under the ESA and MMPA (e.g., sea turtles, smalltooth sawfish, and right whales).

Southeast Atlantic Gillnet Fishery

The Category II Southeast Atlantic gillnet fishery targets finfish including, but not limited to, king mackerel, Spanish mackerel, whiting, bluefish, pompano, spot, croaker, little tunny, bonita, jack crevalle, cobia, and striped mullet. This fishery does not include

gillnet effort targeting sharks as part of the "Southeastern U.S. Atlantic shark gillnet" fishery. This fishery uses gillnets set in sink, stab, set, or strike fashion. The fishery operates in waters south of a line extending due east from the NC/SC border and south and east of the fishery management council demarcation line between the Atlantic Ocean and the Gulf of Mexico. The majority of fishing effort occurs in Federal waters since SC, GA, and FL prohibit the use of gillnets, with limited exceptions, in state waters.

Fishing for king mackerel, Spanish mackerel, cobia, cero, and little tunny in Federal waters is managed under the Coastal Migratory Pelagic Resources (CMPR) FMP. None of the other target species are Federally managed under the MSA. In state waters, state and ASMFC Interstate FMPs apply. The fishery is also subject to BDTRP and ALWTRP implementing regulations.

NC Inshore Gillnet Fishery

The Category II NC inshore gillnet fishery targets species including, but not limited to, southern flounder, weakfish, bluefish, Atlantic croaker, striped mullet, spotted seatrout, Spanish mackerel, striped bass, spot, red drum, black drum, and shad. This fishery includes any fishing effort using any type of gillnet gear, including set (float and sink), drift, and runaround gillnet for any target species inshore of the COLREGS lines in NC. This fishery is managed under state and ASMFC interstate FMPs, applying net and mesh size regulations, and seasonal area closures in the Pamlico Sound Gillnet Restricted Area (PSGNRA). It is also an affected fishery under the BDTRP.

Gulf of Mexico Gillnet Fishery

The Category II Gulf of Mexico gillnet fishery targets a wide variety of target species, including, but not limited to: black drum, sheepshead, weakfish, mullet, spot, croaker, king mackerel, Spanish mackerel, Florida pompano, flounder shark, menhaden, bluefish, blue runner, ladyfish, spotted seatrout, croaker, kingfish, and red drum. This fishery operates year-round using any type of gillnet, including strike and straight gillnets, in waters north of the U.S.-Mexico border and west of the fishery management council demarcation line between the Atlantic Ocean and the Gulf of Mexico. Gillnet gear is prohibited in TX and FL State waters, but fixed and runaround gillnets are currently used in LA, MS, and AL with highly variable fishing effort.

Fishing for king mackerel, Spanish mackerel, cobia, cero, little tunny, dolphin, and bluefish are managed

under the CMPR FMP. In the Gulf of Mexico, CMPR FMP species are the only Federally managed species for which gillnet gear is authorized, and only run-around gillnetting for these species is allowed. In state waters, state and Gulf States Marine Fisheries Commission (GSMFC) Interstate FMPs apply.

NC Long Haul Seine Fishery

The Category II NC long haul seine fishery targets species including, but not limited to, weakfish, spot, croaker, menhaden, bluefish, spotted seatrout, and hogfish using multi-filament seines consisting of a 3,000–6,000 ft (914–1,829 m) net pulled by two boats for 1–2 nmi (2–4 km). Fish are encircled and concentrated by pulling the net around a fixed stake. The fishery includes fishing with long haul seine gear to target any species in waters off NC, including estuarine waters in Pamlico and Core Sounds and their tributaries. The fishery occurs from February to November, with peak effort occurring from June to October. The fishery is managed under ASMFC interstate FMPs, and is an affected fishery under the BDTRP.

NC Roe Mullet Stop Net Fishery

The Category II NC roe mullet stop net fishery targets striped mullet from October to November using a stationary, multi-filament anchored net extended perpendicular to the beach. Once the catch accumulates near the end of the stop net, a beach haul seine is used to capture fish and bring them ashore. The stop net is traditionally left in the water for 1–5 days, but can be left as long as 15 days. This fishery is unique to Bogue Banks, NC. This fishery is managed under the NC Striped Mullet FMP, and is an affected fishery under the BDTRP.

Gulf of Mexico Menhaden Purse Seine Fishery

The Category II Gulf of Mexico menhaden purse seine fishery targets menhaden and thread herring using purse seine gear in bays, sounds, and nearshore coastal waters along the Gulf of Mexico coast. The majority of the fishing effort is concentrated off LS and MS, with lesser effort in AL and TX State waters. FL prohibits the use of purse seines in state waters. The fishery is managed under the GSMFC Interstate Gulf Menhaden FMP.

Comments and Responses

NMFS received 10 comment letters and 1 comment via phone on the proposed 2008 LOF (72 FR 35393, June 28, 2007) from the Marine Mammal Commission, Hawaii Longline Association, Western Pacific Regional

Fishery Management Council, Mid-Atlantic Fishery Management Council, Pacific Fishery Management Council's Groundfish Management Team, Gulf States Marine Fisheries Commission, Center for Biological Diversity, 2 representatives of the commercial fishing industry, and 2 representatives of Federal agencies. Comments on issues outside the scope of the LOF were noted, but are not responded to in this final rule.

General Comments

Comment 1: Two commenters commended NMFS for describing all Category I and II fisheries within the proposed 2008 LOF. While additional description materials are available elsewhere, one commenter believes these descriptions provide important context for readers attempting to evaluate the LOF. One commenter recommended NMFS describe all Category III fisheries in future LOFs.

Response: NMFS will consider describing Category III fisheries in future LOFs.

Comment 2: Two commenters commended NMFS for publishing the proposed 2008 LOF early enough to allow for ample time to review and comment on the rule, as well as to publish a final 2008 LOF before the beginning of the 2008 calendar year.

Response: NMFS will make every effort to publish future proposed LOFs by July of each year, to allow sufficient time for review and comment by organizations and individuals. This will also allow NMFS to publish the final LOF in time for the rule to become effective by January 1 of the respective calendar year.

Comment 3: One commenter commended NMFS for its support of depredation studies, as outlined in response to comments in the final 2007 LOF (72 FR 14466, March 28, 2007). The commenter encourages NMFS to continue and enhance its efforts to evaluate and address this developing issue.

Response: NMFS will continue to develop, conduct, and support research efforts on depredation-related interactions between marine mammals and fisheries as funding is available. See the response to Comment 1 in the final 2007 LOF (72 FR 14466, March 28, 2007) for details on research conducted in the past and research currently being conducted.

Comment 4: One commenter reiterated previous letters on the 2005, 2006, and 2007 LOFs calling for the inclusion of observer coverage on the LOF. The Service indicated in its response to comments on the final 2007

LOF that it would “present information associated with the level of observer coverage or lack of observer coverage, if available, as part of the justification for proposing changes in future [lists].” However, information on observer coverage is not provided in the justification for reclassifying the “CA yellowtail, barracuda, and white seabass drift gillnet” fishery in the proposed 2008 LOF. Further, the commenter also believes observer information is important for justifying the status quo. Without such information, it is not possible to determine whether a given fishery was adequately observed and no marine mammals were taken or the fishery was not adequately observed and mortality and serious injury may have occurred, but were not documented.

Response: Please see responses to Comment 6 in the final 2005 LOF (71 FR 250, January 4, 2006), Comment 4 in the final 2006 LOF (71 FR 48802, August 22, 2006), and Comment 8 in the final 2007 LOF (72 FR 14466, March 28, 2007). NMFS still feels that it will be of limited use to include observer coverage data or percentages in the LOF without also including the confidence associated with mortality/serious injury estimates generated from observer data. Presenting the level of observer coverage in the LOF without the associated confidence information will likely lead to misinterpretation of the information provided. Information including details of the interaction data and the Coefficient of Variance (CV) for stock-specific information is reported in the SARs. NMFS continues to refer readers to the SARs for the most current, peer-reviewed information on observer coverage. The SARs can be accessed through the NMFS Office of Protected Resource’s web site at: <http://www.nmfs.noaa.gov/pr.sars/>. Additional information can also be found on the National Observer Program web site at: <http://www.st.nmfs.gov/st4/nop/>.

NMFS acknowledges the lack of inclusion of observer information in the explanation for the proposed elevation of the “CA yellowtail, barracuda, and white seabass drift gillnet” fishery in the proposed 2008 LOF. This was an unintentional oversight. NMFS will ensure that information on observer coverage, if available, is included as part of the justification for proposing classification changes in future LOFs. NMFS has corrected this oversight here: In the draft 2007 Pacific Marine Mammal Stock Assessments, the level of observer coverage in the CA small mesh drift gillnet fishery for white seabass, yellowtail, and barracuda observer coverage was listed as 11 percent in

2002 and 2003. During the public comment of the draft 2007 SARs, errors were found in the listed levels of observer coverage in the CA small mesh drift gillnet for white seabass, yellowtail, and barracuda. The correct levels of observer coverage for 2002, 2003, and 2004, are 11.5 percent, 10.4 percent and 17.6 percent, respectively. There has been no observer coverage in this fishery since 2004. NMFS is seeking funding to observe this fishery in 2008.

Comment 5: One commenter reiterated previous comments made on the 2004 and 2007 LOFs for inclusion of high seas fisheries on the LOF. Multiple high sea fisheries, in which U.S.-flagged vessels operate, are known to interact or are likely to interact with marine mammals. Section 118 of the MMPA applies to “commercial fishing operations by persons using vessels of the United States.” Therefore, NMFS failure to include these high seas fisheries is unlawful. The commenter notes that NMFS responded in 2004 stating, “NMFS will consider this comment and whether the LOF applies to high seas fisheries during the development of future proposed LOFs (69 FR 48407, August 10, 2004). The commenter recognized that the proposed 2008 LOF provides a longer explanation of the issue of high seas fisheries, but NMFS has continued to fail to analyze these fisheries and include them on the LOF. Specific fisheries suggested as additions to the LOF are the Cobb Seamount fishery, Pacific pelagic squid jig fishery, South Pacific tuna purse seine fishery, and fisheries in the area of the Convention on the Conservation of Antarctic Marine Living Resources (CCAMLR) including the Patagonian toothfish longline fishery and a trawl fishery for krill.

Response: NMFS is continuing to consider the inclusion of U.S.-authorized high seas fisheries in future LOFs. Also, NMFS is gathering available information on the fishing effort, gear used, and marine mammal interaction levels specific to U.S. vessels operating in high seas fisheries. NMFS faces significant challenges in accurately categorizing high seas fisheries in the LOF. As discussed under in the preamble of this rule, fisheries are categorized in the LOF based on the level of mortality and serious injury of marine mammal stocks relevant to the stock’s PBR level. PBR levels are calculated based on the stock’s abundance using data presented in the SARs, required under section 117 of the MMPA (16 U.S.C. 1386). Section 117 requires NMFS to prepare SARs for marine mammal stocks occurring “in waters under the jurisdiction of the

United States.” NMFS does not develop SARs, or therefore calculate PBR levels, for marine mammal stocks on the high seas. NMFS will continue to explore options for categorizing high seas fisheries in a future LOF in the absence of marine mammal stock abundance and PBR level information. Please see response to Comment 9 in the final 2007 LOF (72 FR 14466, March 28, 2007) and the preamble of this rule for information on NMFS current efforts.

NMFS provides high seas fishing permits under the High Seas Fishing Compliance Act (HSFCA). NMFS issues permits only for high seas fisheries analyzed in accordance with the NEPA and the ESA. There are currently 7 U.S.-authorized high seas fisheries: Atlantic Highly Migratory Species Fisheries (50 CFR 635), Pacific Highly Migratory Species Fisheries (50 CFR 660, subpart K), Western Pacific Pelagic Fisheries (50 CFR 665, subpart C), South Pacific Albacore Troll Fishing, Pacific Tuna Fisheries (50 CFR 300, subpart C), South Pacific Tuna Fisheries (50 CFR 300, subpart D), and the Antarctic Marine Living Resources (50 CFR 300, subpart G). For more information please see the NMFS Office of International Affairs HSPCA information website: <http://www.nmfs.noaa.gov/ia/services/highseas.htm>.

The commenter suggested the addition of several specific high sea fisheries to the LOF, including the Cobb Seamount fishery, Pacific pelagic squid jig fishery, South Pacific tuna purse seine fishery, and fisheries in the CCAMLR area including the Patagonian toothfish longline fishery and a trawl fishery for krill. Currently, NMFS does not authorize U.S. vessels to participate in the Cobb Seamount fishery or the Pacific pelagic squid jig fishery. Therefore, these fisheries would not be considered for addition to the LOF. Also, the South Pacific tuna purse seine fishery is managed separately under section 301 of the MMPA (16 U.S.C. 1411); therefore, it would not be added to the LOF required under section 118 of the MMPA. Regarding the CCAMLR fisheries, in the past there has been a single U.S. vessel participating in the trawl fishery for krill. However, this vessel has not fished in the last 2 years. Also, in the past there have been 2 U.S. vessels (under 1 owner) participating in the Patagonian toothfish longline fishery. NMFS has not received any permit applications for U.S. vessels to participate in either of the CCAMLR fisheries in the coming year.

Comment 6: One commenter stated that all Category I and II fisheries not already subject to take reduction teams should promptly have such teams

convened for them. The Category I HI longline fishery should be the highest priority as takes continue to exceed PBR for false killer whales.

Response: At this time, NMFS' resources for TRTs are fully utilized and new TRTs will be initiated when additional resources become available. When additional TRTs are convened, they will follow priorities set out in section 118(f)(3) of the MMPA (16 U.S.C. 1387). When there is insufficient funding available to develop and implement a TRT for all stocks that interact with Category I and II fisheries, the highest priority for developing and implementing new TRTs will be given to species or stocks whose level of incidental mortality and serious injury exceeds PBR, those with a small population size, and those which are declining most rapidly.

Comments on Fishery Classification Methodology

Comment 7: One commenter reiterated previous recommendations that NMFS revise the dividing PBR thresholds for Category I and II fisheries. The current range for a Category II fishery is an interaction rate between 1 percent and 50 percent of a stock's PBR, which is too broad and unnecessarily lumps fisheries with rare interactions alongside fisheries with numerous interactions. NMFS uses catch as a proxy for fishing effort, unreasonably large expansion factors, and double counting of interactions, resulting in one rare event in a fishery being expanded into an unrealistic overestimation of takes. Given the precautionary methodology in the PBR formula, the minimum threshold for Category II should be increased from 1 percent to 10 percent of PBR. Interactions under 10 percent of PBR should be a Category III. In doing so, rare events (i.e., 1 take in 5 years) would result in a Category III instead of a Category II classification.

Response: NMFS implemented the classification criteria in the final regulations to implement the 1994 amendments to the MMPA (60 FR 45086, August 30, 1995) after ample consideration of comments and suggestions from the public. NMFS refers the reader to the response to comments 5 through 9 in that rule for a detailed explanation of the reasoning for setting the dividing thresholds between Category II and III as 1 percent of PBR. NMFS also finalized an Environmental Assessment (EA) in August, 1995, to analyze the impacts of the regulations implementing the 1994 amendments on the environment and the public. NMFS also finalized a

revised EA in December 2005 on the process of classifying U.S. commercial fisheries. A full copy of the updated 2005 EA can be found at http://www.nmfs.noaa.gov/pr/pdfs/interactions/lof_ea.pdf.

The fishery classification criteria consider the rate of incidental serious injury and mortality of marine mammals in commercial fisheries on a stock-specific basis. Therefore, the rate of interaction of a fishery with a marine mammal stock with a low PBR can be significant even if it appears to be a minimal problem based on the size of the fishery or frequency of the interactions. The chosen approach allows NMFS to focus management actions where fishery interactions have a significant negative effect on the population.

In addition to the 1-percent threshold, the definitions of Category II and III fisheries include qualitative criteria that allow the Assistant Administrator for Fisheries to place a fishery into Category II or III in the absence of reliable information. This qualitative criteria will allow the Assistant Administrator to take into consideration cases where the PBR level for a particular stock is very low and/or where the level of incidental interaction with commercial fisheries is low and not likely to delay the population's attainment of its Optimum Sustainable Population. See the general description of the two-tiered scheme and qualitative criteria that may be used to classify a fishery in the preamble in this rule under *Fishery Classification Criteria*.

Comment 8: One commenter questioned NMFS' inconsistent use of time periods in the LOF, instead of always including interaction data from the most recent 5-year period (e.g. 2002–2006 for the 2006 SAR). For some fisheries, including those with high levels of observer coverage, the time period used to calculate annual take rates to categorize fisheries is 2000–2004. For other fisheries the time period is 2001–2005. Given that the most recent final SAR is 2006, why isn't the time period used to calculate annual interaction rates and classify fisheries for all fisheries 2002–2006? Or consistent for those fisheries with observer coverage every year?

Response: Fishery classifications on the LOF are based on interaction data published in the most recent SARs, when available. SARs are revised on a rotating schedule, so not all SARs will include data from the same period of time. Section 117 of the MMPA requires NMFS to review SARs for strategic stocks and for stocks for which

significant new information is available at least annually, and at least once every 3 years for all other stocks, and make changes if necessary. Therefore, while the SARs for strategic stocks are reviewed annually and updated if new information is available, SARs for non-strategic stocks may be updated only once every 3 years.

Also, it takes approximately a full year to develop new, final SARs. The annual interaction rates presented in the SARs are based on the most current observer data available. The draft SARs for 2006 were prepared in the fall of 2005; at which time, observer data for 2004 were the most current data available. Observer data for 2005 became available in 2006 and were incorporated into the draft SARs for 2007, which was published in June, 2007.

Comment 9: One commenter questioned NMFS' continued use of a recovery factor of 0.1 in the PBR formula for most whale stocks instead of updating the recovery factor based on new information. The commenter cited various sections of the GAMMS Workshop Report (Wade and Angliss, 1996) discussing recovery factors, including text stating that recovery factors can be adjusted to accommodate additional information, when mortality estimates are known to be relatively unbiased based on high observer coverage, and to allow for management discretion as consistent with the goals of the ESA and MMPA. The commenter cites 3 examples in the report of recovery factors for ESA listed stocks being altered.

Response: This comment is not specifically relevant to the LOF. While fisheries on the LOF are categorized based on the incidental mortality and serious injury relevant to a marine mammal stock's PBR, the calculation of PBR levels are completed and peer-reviewed during the annual SARs process. NMFS urges the commenter to present these comments during the public comment period for the draft 2008 SARs, as the comment period for the draft 2007 SARs has closed.

Comment 10: One commenter stated that a take in which the marine mammal stock cannot be determined should not be counted as a take for 2 separate stocks, but should be apportioned across the 2 stocks in question using a weighted probability.

Response: See response to Comments 13 and 14 in the final 2005 LOF (71 FR 247, January 4, 2006) and Comment 10 in the final 2003 LOF (68 FR 41725, July 15, 2003) for detailed responses to the same comment. Where there is considerable uncertainty regarding to

which stock a serious injury or mortality should be assigned, NMFS exercises a conservative approach of assigning the serious injury or mortality to both stocks. Clearly, if information were available regarding the location of take, genetics of the taken animal, or other conclusive information linking the serious injury or mortality to a specific stock, NMFS would use it to assign the take to a specific stock. Also, NMFS continues to conduct research and review data to determine to which stock an incidental mortality or serious injury can be assigned. For example, in this final rule NMFS is removing the Gulf of Alaska, Aleutian Islands, and Bering Sea transient stock of killer whales from the list of species incidentally injured or killed in two AK fisheries based on genetic analyses of tissue samples collected by observers over the past few years, which revealed that the interaction occurred with the resident stock of killer whales (see below under Summary of Changes to the LOF for 2008).

Comment 11: One commenter stated that if NMFS persists in using observed catch as a proxy of effort and expands observed takes, then takes that occur outside of the observed sample should not be counted. The apparent point of expansion is to make an estimate for the “unobserved” takes; therefore, counting takes in the unobserved sample is double counting.

Response: See response to Comments 19 and 20 in the final 2005 LOF (71 FR 247, January 4, 2006) for a very detailed response to the same comment. Also see response to and Comment 47 in the Notice of Availability for the 2005 SARs (71 FR 26430, May 4, 2006). The analysis of bycatch is stratified into many different strata, and estimates of bycatch are calculated for each individual stratum using data from monitored hauls. If an observer reported an injury or mortality incidental to a non-monitored haul, and there were no injuries or mortalities from monitored hauls in that strata, the report in the non-monitored haul is used as the estimate of serious injury and mortality for that stratum. Data from non-monitored hauls are not extrapolated using the ratio estimation approach but are simply added to an extrapolation using observer data from monitored hauls.

Comments on Fisheries in the Pacific Ocean

Comment 12: Two commenters questions the SAR for false killer whales in HI. One commenter stated that the proposed 2008 LOF perpetuates serious errors and uncertainties found in NMFS’

SAR for false killer whales, errors which persist in the draft 2007 SAR. NMFS’ SAR conflates false killer whale stocks, underestimates false killer whale abundance, and overestimates the seriousness of the deep-set longline fishery’s (within the Category I HI longline fishery) interactions with false killer whales.

The second commenter stated that there is no scientifically recognized HI stock of false killer whales that the proposed LOF lists as incidentally killed or injured in the Category I HI longline fishery. There are large uncertainties in the available science for a “HI” stock, including the fact that NMFS’ population assessment is based on a single sighting. Available information indicates that the HI-based tuna longline fishery interacts with a larger Eastern North Pacific stock of false killer whales. This information needs to be presented and objectively discussed by NMFS and outside peers.

Response: This comment pertains to the SAR for false killer whales, HI stock, and has been recently addressed in the response to comments 46–67 in the Notice of Availability of the final 2006 SARs (72 FR 12774, March 19, 2007). NMFS stands by the analysis of the false killer whale stocks and recognizes that it is the best information currently available. NMFS will continue to work to reduce any uncertainties that may be associated with this stock assessment.

Comment 13: Two commenters recommended that NMFS distinguish between the shallow-set and the deep-set fisheries in the Category I HI longline fishery. The HI longline fishery should be split into 2 fisheries based on the fact that the shallow-set and deep-set fisheries have different target species, operating patterns, management regimes, and interaction rates. Splitting the HI longline fishery into two fisheries would result in a Category I deep-set fishery and a Category III shallow-set fishery. The shallow-set fishery began commercial fishing in late 2004 and is distinct from the deep-set fishery in that it targets swordfish while the deep-set fishery targets tuna; uses different gear (including the number of hooks, gangions and float intervals); uses different bait; and fishes in different areas of the Pacific Ocean (generally does not operate within the HI EEZ) at different times of day. The shallow-set fishery, which has 100 percent observer coverage, has significantly different interaction and mortality rates involving protected species. An interaction with a false killer whale has never been observed in the shallow-set fishery. Also, the shallow-set and deep-set fisheries are managed differently by the

Western Pacific Regional Fishery Management Council and NMFS and have entirely different regulatory requirements.

Response: The commenters requested that the HI longline fisheries be split and subsequently listed in the LOF as two separately managed commercial fisheries: (1) the deep-set (tuna target) fishery; and (2) the shallow-set (swordfish target) fishery. This is the first request to split the fishery in this manner that NMFS has received to date.

NMFS believes the request to split the HI longline fishery into two fisheries (the deep-set fishery and the shallow-set fishery) for purposes of the LOF has merit, and is therefore taking the commenters’ request under consideration. Indeed, NMFS has split other fisheries in prior year’s LOFs based upon factors such as different target species, operating patterns, regulations, marine mammal interaction rates, etc. However, if NMFS were to split the HI longline fishery into a deep-set and shallow-set fishery in the LOF, and then potentially re-categorize the shallow-set fishery as a Category III fishery, these changes would necessarily be presented in the 2009 Proposed LOF, and not in the 2008 Final LOF, as making such considerable changes between a “Proposed” and “Final” draft of the LOF would negate the important public comment and response period required for agency rulemaking.

Additionally, if NMFS were to make the changes articulated above, NMFS would need to consider whether the current system under which the HI longline fishery is permitted would also need to be changed. The HI longline fishery is managed, in part, under the Fishery Management Plan (FMP) for Pelagic Fisheries of the Western Pacific Region (Pelagics FMP), as amended. The Pelagics FMP and its amendments are developed by the Western Pacific Fishery Management Council under the authority of the MSA, 16 U.S.C. 1801 *et seq.* NMFS also promulgates regulations under the MSA to administer enforceable elements of the Pelagics FMP.

Currently, participants in the HI longline fishery are required to obtain a single HI Longline Limited Entry Permit whether they intend to engage in deep-set longline fishing, shallow-set longline fishing, or both. Integrated with the single Limited Entry Permit requirement is the MMAP Certificate. Any vessel engaging in a Category I or II fishery must obtain a MMAP certificate from NMFS in order to lawfully incidentally take a marine mammal in a commercial fishery. Unless the current fishery permitting system under the FMP is

likewise amended, the single Limited Entry Permit would still require a MMAP certificate even if the longline fishery was subsequently split into Category I deep-set and Category III shallow-set fisheries. NMFS will be soliciting comments on these and other issues in the 2009 Proposed LOF.

Comment 14: One commenter reiterated a comment from the 2007 LOF recommending NMFS elevate the Category III “CA lobster, prawn, shrimp, rock crab, fish pot” and the “WA/OR/CA crab pot” fisheries to Category II based on interactions with humpback and gray whales. At least 14 large whales were documented entangled in this gear type from 2000–2005.

Response: As described in responses to comment 18 in the final 2007 LOF (72 FR 38393, March 28, 2007), NMFS is aware of interactions between humpback and gray whales and pot and trap gear and is taking steps to address this issue. The NMFS Northwest Regional Office reviewed interactions between humpback and gray whales and all crab trap/pot gear in the waters off WA and OR and found that there have been no observed takes of humpback whales and that the level of take of gray whale was well below 10 percent of the stock’s PBR. Therefore, the available information did not support elevating the WA and OR crab fisheries to Category I or II on the 2007 LOF. The NMFS Southwest Regional Office recently completed a draft characterization of the CA pot and trap fisheries as a first step in helping to determine which fisheries are most likely to be interacting with large whales and whether recategorization of the “CA lobster, prawn, shrimp, rock crab, fish pot” fishery or the CA component of the “WA/OR/CA crab pot” fishery is appropriate. Before NMFS can recategorize these fisheries, a better understanding of the fisheries is necessary, since reports of interactions between large whales and pot and trap gear come primarily from stranding reports (including sighting of free-swimming whales). These reports may not provide reliable identification of the fishing gear types associated with an interaction because it is difficult to distinguish between various pot and trap gears from surface observations of line and floats. Currently, NMFS is working with the State of CA to develop the characterization of the state and Federal fisheries that utilize these gear types in the waters off of CA.

Furthermore, NMFS is reviewing observed marine mammal entanglements from stranding reports to assess the extent of injuries (i.e., whether or not the injuries were serious

injuries) and whether specific fisheries can be identified from the available data.

NMFS is also considering whether to change descriptions for the CA pot and trap fishery in the LOF. Currently, the CA lobster, prawn, shrimp, rock crab and fish pot fisheries are listed as one fishery on the LOF. NMFS is reviewing of the CA pot and trap fisheries to determine whether these fisheries should be listed separately on future LOFs to more accurately reflect spatial and temporal differences in the various fisheries, the regulatory authority for the fisheries, and the likelihood of interactions with marine mammals.

Comment 15: One commenter commended NMFS for its support of efforts to address concerns regarding trap and pot fisheries, such as support for research efforts and outreach efforts to encourage voluntary reductions in the amount of potentially entangling gear. The commenter encouraged NMFS to continue its work with Regional Fishery Management Councils to improve monitoring and mitigation of serious injury and mortality.

Response: NMFS acknowledges this comment. See the response to comment 14 above for more information related to these fisheries.

Comment 16: One commenter noted that the number of vessels listed in Table 1 of the proposed 2008 LOF for the Category III “WA/OR/CA groundfish trawl” fishery is incorrect. Table 1 indicates an estimated 585 vessels participating; however, the Pacific Fishery Management Council’s Groundfish Management Team estimates that 160–180 vessels will participate in 2007. The estimated range is based on recent participants, which varies depending on the choice of some skippers to participate in trawl fisheries on the West Coast or in AK.

Response: NMFS acknowledges this comment and will make the suggested change to the number of participants in the “WA/OR/CA groundfish trawl” fishery to 160–180.

Comment 17: Two commenters supported the elevation of the “CA yellowtail, barracuda, and white seabass drift gillnet” fishery to Category I because the estimated annual serious injury and mortality of long-beaked common dolphins incidental to the fishery exceeds 50 percent of the stock’s PBR. One commenter stated that a take reduction team must now be convened because this fishery interacts with strategic marine mammal stocks.

Response: Since the publication of the proposed 2008 LOF, new information has become available on the level of serious injury and mortality of the CA

stock of long-beaked common dolphin in the “CA yellowtail, barracuda, and white seabass drift gillnet” fishery which indicates that elevating this fishery to Category I is not appropriate at this time. The proposed 2008 LOF states that, based on observer documented interactions in 2003 and 2004, reported in the draft 2007 SAR for long-beaked common dolphin, the estimated annual serious injury and mortality of the CA stock of long-beaked common dolphins in the “CA yellowtail, barracuda, and white seabass drift gillnet” fishery is approximately 82 percent of the stock’s PBR. However, during the public comment on the draft 2007 SARs, errors were found in the reported levels of observer coverage in this fishery. The correct levels of observer coverage for 2002, 2003, and 2004, are 11.5 percent, 10.4 percent, and 17.6 percent, respectively. Based upon these observer coverage levels, NMFS recalculated the mean annual serious injury or mortality of the CA stock of long-beaked common dolphin. The revised mean annual serious injury or mortality in this fishery is 4.7 (0.98) (CV in parenthesis), which is 43 percent of the stock’s PBR of 11. Based upon these revisions to the draft 2007 SAR, the “CA yellowtail, barracuda, and white seabass drift gillnet” fishery will remain a Category II fishery, and will not be elevated to a Category I fishery as proposed in the proposed 2008 LOF. The strategic stock classification of the CA stock of long-beaked common dolphins remains supported by the updated information in the SAR. Please also see the response to Comment 4 in this rule for additional information.

In April 2007, the Pacific Offshore Cetacean Take Reduction Team (POCTRT) considered CA State gillnet fisheries at their team meeting, including the “CA yellowtail, barracuda, and white seabass drift gillnet” fishery, and the possible impacts on marine mammals. The POCTRT made a number of recommendations to NMFS related to these fisheries, including expanding observer coverage, encouraging research and information sharing on methods to reduce marine mammal bycatch, and adding representatives from these fisheries and an additional CDFG advisor to the POCTRT to address marine mammal bycatch in state gillnet fisheries. NMFS and the POCTRT are considering expanding the scope of the POCTRT to include CA gillnet fisheries, including the “CA yellowtail, barracuda, and white seabass drift gillnet” fishery. Please see response to

comment 6 in this rule for more information on Take Reduction Teams.

Comment 18: One commenter recommended NMFS remove short-finned pilot whales from the list of species incidentally killed or injured in the Category II "CA squid purse seine" fishery for two reasons. First, the information presented in the draft 2007 SAR for the CA squid purse seine fishery does not reflect the best available science. The SAR states that the fishery is "not currently monitored, and has expanded markedly since 1992." However, NMFS Southwest Region observer data from the CA Coastal Pelagic Purse Seine Observer Program indicates that 95 pilot whale interaction-free trips were observed from July 2004 to March 2007. Second, the draft 2007 SAR assigns each of the 14 incidents of "undetermined" strandings of short-finned pilot whales as "probably" the result of interactions with the "CA squid purse seine" fishery. However, the SAR does not provide clear evidence for this determination. Since NMFS does not typically assign fishery-specific mortality from fishery interaction stranding events in the absence of clear evidence (for example, several East Coast species covered under TRPs including harbor porpoise, bottlenose dolphins, and large whales), then it should not be done in this case.

Response: NMFS acknowledges the error in the draft 2007 SAR regarding the monitoring of the "CA squid purse seine" fishery and it will be corrected in the final 2007 SAR. NMFS has reviewed the report with records of the stranded short-finned pilot whales from 1975 through 1990 and has concluded that the strandings were most likely caused by interactions with the purse seine fishery for squid. This is based upon the location and time of the strandings and the operation of the squid fishery in the same area and time and other details from the stranding. NMFS notes that there have been no observed takes of short-finned pilot whales in this fishery since the observer program began in 2004. However, observer coverage in this fishery is quite low at less than 2 percent annually. The recommendation to remove short-finned pilot whales from the list of marine mammals incidentally killed in the squid purse seine fishery will be further reviewed by NMFS when more observer information becomes available. NMFS will continue to monitor this fishery and consider the recommendation to remove short-finned pilot whales, CA/OR/WA stock, from the list of species incidentally killed or injured in the "CA squid purse seine" fishery for the 2009 LOF.

Comment 19: One commenter requested a review of the Category II "CA squid purse seine" fishery interaction with a species listed as "common dolphin, unknown" and removal of this species from the list of species incidentally killed or injured in this fishery if supported by the data. The CA Coastal Pelagic Purse Seine Observer Program data contains an observed "1 dead unidentified common dolphin" off Santa Barbara on January 3, 2005. The observer data also indicated that a group of seven unidentified common dolphins were sighted near the vessel during this particular haul. The commenter requests that NMFS re-examine this interaction and determine whether the animals' location, group size, and time of capture might better match the survey distribution and group observations for short-beaked common dolphins than for long-beaked common dolphins. Given the recent increased abundance reported for short-beaked common dolphins and virtual disappearance of long-beaked common dolphins in CA waters, the commenter believes the animal interaction was likely with a short-beaked common dolphin.

Response: There is insufficient information available to identify the species of common dolphin observed taken in the "CA squid purse seine" fishery. Both species, long-beaked common dolphins and short-beaked common dolphins, utilize much of the same habitat and overlap in areas with this fishery. Therefore, it is possible that either species could have been taken.

Comment 20: One commenter recommended that the "strategic" designation for the long-beaked common dolphin be viewed with extreme caution in the 2008 LOF. The draft 2007 SAR and proposed 2008 LOF do not adequately reflect the stock's high interannual variability. Despite a slight increase in human interactions from 11 to 17 animals, the observed population plummeted causing the PBR to drop from 242 animals to 11 animals reported in the draft 2007 SAR. Clearly the reason for the strategic listing is not fishery interactions but likely environmental in nature, and the LOF should clearly reflect this.

Response: It is the purpose of the LOF to categorize fisheries based on their level of mortality and serious injury of a marine mammal stock relative to the stock's PBR level. It is not the purpose or intent of the LOF to determine a stock's PBR or status as strategic. The factors leading to a stock's designation as "strategic" are irrelevant for the purposes of categorization fisheries on the LOF. NMFS urges the commenter to

present these comments during the public comment period for the draft 2008 SARs, as the comment period for the 2007 SARs has closed.

One error was found in the draft 2007 SAR during public review related to long-beaked common dolphins and takes in the CA small mesh drift gillnet fishery for white seabass, yellowtail, and barracuda; the fishery was observed at 11.5 percent, 10.4 percent and 17.6 percent respectively in 2002, 2003, and 2004, and one serious injury or mortality was observed in 2003 and one in 2004, with none observed in 2002. The draft SAR does not list the 2004 observer coverage and assigned the observed takes of long-beaked common dolphins to the years 2002 and 2003. This error will be corrected in the final 2007 SARs and will lower the mean annual takes estimate for this stock to from 17 to 12.5, but this adjustment does not change the strategic designation of this stock.

Comment 21: One commenter stated that the Category II Bering Sea Aleutian Islands (BSAI) Pacific cod longline fishery has a high level of observer coverage and effort is known, yet catch is used as a proxy for estimating effort. A proxy is not needed in cases where observer coverage is high and effort is known. Also, the Science and Statistical Committee (SSC) of the North Pacific Fishery Management Council stated in minutes from its February 2005 meeting that NMFS should "explore the use of direct measures of fishing effort (instead of using catch as a proxy for effort) in future analyses at least when and where possible."

Response: The response to Comment 15 in the final LOF for 2005 states that catch is the only data that can be used to measure effort for all vessels, seasons, and areas, to measure relative levels of effort (71 FR 247, 4 January 2006). NMFS took note of the recommendation made by the North Pacific Fishery Management Council's SSC to consider other measures of fishing effort, and discussed this with the analyst. At this time, catch remains the best method of quantifying observed and total fishing effort. Should another measure of effort become available that can be used for all vessels, seasons, and areas, NMFS will consider modifying the analytical approach.

Comment 22: One commenter noted that, according to a study by Perez in 2004, 68 percent of longline hauls from 1998–2003 were sampled by observers. Also, NMFS stated in 2000 (in a Pacific cod paper) that 94 percent of the BSAI Pacific cod longline harvest came from observed vessels.

Response: The response to Comment 25 in the final LOF for 2005 (71 FR 247, 4 January 2006) describes why there is a difference between the percent of hauls observed (or the percent of hooks observed, or the percent of sets observed) and the percent of boats observed. Also, NMFS notes that the commenter did not provide citations for the literature referenced in the comment.

Comment 23: One commenter asked NMFS to explain certain observer percentages and associated expansions of takes in the 2006 SARs associated with the Category II BSAI Pacific cod longline fishery. The 2006 SAR for ribbon seal lists one take in 2001 (although the most recent 5-year period of 2002–2006 should make this interaction drop out), which is expanded to 3.0 takes with observer coverage of 29.5 percent; for Steller sea lion (Western stock) lists one take in 2002, expanded to 3.7 takes with observer coverage of 29.6 percent; and for killer whale (Eastern North Pacific Alaska resident) lists one take in 2003, expanded to 4.2 takes with observer coverage of 29.9 percent. Why does one take, at the same stated level of observer coverage (29 percent) expand to a range of 3 to 4.2 takes depending on the stock?

Response: To provide as precise an estimate of marine mammal bycatch as possible, fishery effort and observed marine mammal serious injury/mortality levels are stratified by fishery, geographic area and by 2-week period. The percent observer coverage reflected in the SARs is an average percent observer coverage, not the percent for each strata. Thus, users of the SARs cannot use the reported percent observer coverage in the SARs to directly calculate an estimated marine mammal serious injury/mortality from the observed serious injury/mortality level.

Comment 24: One commenter questioned why the observer coverage in these SARs listed as 29 percent when 94 percent of the BSAI Pacific cod longline catch comes from observed vessels (NMFS 2000 Pacific cod paper) and 68 percent of the catch comes from observed sets (Perez 2004)?

Response: Please see response to comment 22. Also, NMFS notes that the commenter did not provide citations for the literature referenced in the comment.

Comment 25: One commenter stated that the formula used to estimate PBR for the strategic Central North Pacific stock of humpback whales uses a population estimate from 1993, which causes several fisheries that interact with this stock to be classified as

Category II. However, all studies indicate that this stock is steadily increasing. A 2001 study calculates an annual growth rate increase of 7 percent (now used as r_{max}) and a 2004 study calculates an annual growth rate increase of 10 percent. A 2002 study of the Southeast humpback stock reports that estimates are substantially higher and that the abundance has increased in recent years. The commenter cites the GAMMS workshop report (Wade and Angliss, 1996) which states, “The SARs should be revised whenever new information becomes available on abundance, mortality, r_{max} , or stock structure “Why then is the 1993 estimate still used if growth population has been 7 percent–10 percent annually?”

Response: This is a comment that related to the Stock Assessment Reports, not the proposed List of Fisheries for 2008. In short, a change in the abundance estimate will be made when the results of a recent basin-wide study of North Pacific humpback whales is available in 2009 or 2010.

Comment 26: One commenter questioned the use of 16-year old data to categorize the Prince William Sound salmon drift gillnet fishery as Category II. The categorization is partly due to estimated takes of Stellar sea lions (Western stock) observed in 1990–1991, when 0 and 2 takes of Stellar sea lions were observed in 1990–1991, respectively. With 4–5 percent observer coverage the take expanded to 29, or 14.5 takes per year, comprising 50 percent of all fishing mortality of Stellar sea lions (Western stock).

Response: NMFS agrees that marine mammal interaction data used to classify commercial fisheries should be as current as is practicable to ensure that the estimated levels of serious injury and mortality reflect current fishing practices and conditions. In some cases, information on marine mammal serious injury and mortality is quite dated. Currently there are eleven Category II state-managed fisheries in Alaska on the LOF. Since 1990, seven Category II fisheries have been observed. Of those, two have been reclassified from Category II to Category III because the observer program documented very low levels of marine mammal serious injuries and mortalities that occurred incidental to these fisheries. Six state-managed Category II fisheries have never been observed. With currently available funds, only one fishery can be observed at a time due to the high cost of the observer programs. There have also been interim years with no Alaska state-managed fishery observed. Ideally, NMFS would observe each of these

fisheries every five years to ensure data quality and timeliness. However, without the availability of newer information, NMFS must rely on the best available information.

Comment 27: One commenter noted that the fishery description for the Category II AK Metlakatla/Annette Island salmon drift gillnet fishery is incorrect. The proposed 2008 LOF states that this fishery is managed by the ADFG with a tribal portion separate from the Category II “AK Southeast salmon drift gillnet” fishery only for regulation purposes. The commenter states that this fishery is an exclusively tribal fishery managed exclusively by the tribe. There is no relation or connection with any state fishery or management by any other state or Federal agency.

Response: NMFS agrees and the change has been made to the final 2008 LOF.

Comments on Fisheries in the Atlantic Ocean, Gulf of Mexico, and Caribbean

Comment 28: One commenter stated that all of the butterfish and *Illex* and *Loligo* squid fisheries on the East coast are bottom trawl fisheries, yet the proposed 2008 LOF defines them as Mid-Atlantic mid-water trawl fisheries. The mackerel fishery consists primarily of mid-water trawlers, but also includes bottom trawls. This information can be found in the most recent stock assessments for each fish and squid species at: <http://www.nefsc.noaa.gov/nefsc/publications/series/crdlist.htm>. In addition, butterfish were deemed overfished in 2005 and there is no longer a directed fishery. Trip limits and a very low bycatch quota will be in place for 2008.

Response: NMFS agrees that based on how some trawl gear is fished in the *Illex* and *Loligo* squid fisheries, the current “Mid-Atlantic mid-water trawl” designation for the *Illex* and *Loligo* squid fisheries may not be an appropriate description of the fishing gear used for these specific Mid-Atlantic fisheries. However, in the past NMFS has also received information that suggests that the *Illex* and *Loligo* squid fisheries utilize their trawl gear in a more traditional mid-water trawl fishing operation. Therefore, NMFS believes that it would be inappropriate to reclassify this fishery in this 2008 final LOF. NMFS will consult with the Atlantic Trawl Gear Take Reduction Team and the Northeast Fisheries Science Center to determine a more appropriate characterization. NMFS will then propose any necessary changes in the 2009 proposed LOF, allowing adequate time for public comment. The

inclusion of the butterfly fishery within the "Mid-Atlantic mid-water trawl" fishery will also be addressed and examined at that time.

Comment 29: One commenter reiterated their comment from the 2007 LOF raising concern over NMFS' failure to adequately classify certain Gulf of Mexico fisheries as Category I or II based on known or estimated mortality and serious injury of marine mammals in those fisheries. The commenter specifically recommended NMFS elevate the Gulf of Mexico blue crab trap/pot fishery to at least a Category II and perhaps a Category I, and the Gulf of Mexico menhaden purse seine fishery to a Category I, based on known or likely impacts to bottlenose dolphin stocks.

Response: NMFS does not believe elevation of the "Gulf of Mexico blue crab trap/pot" fishery or "Gulf of Mexico menhaden purse seine" fishery is warranted at this time. There is no observer program for either of these fisheries; therefore, NMFS relies on stranding data and fishermen self-reports to document fishery interactions with marine mammals. Available data from both of these sources do not justify a reclassification of either fishery at this time. However, NMFS will continue monitoring fishermen self-reports and stranding data, as well as enhance stranding response in the Gulf of Mexico, which has been low, particularly following Hurricanes Katrina and Rita. Observer coverage for both these fisheries also remains a priority when resources become available.

Available data indicate interactions with marine mammals occurred in both fisheries between 2002–2006. In the Gulf of Mexico blue crab trap/pot fishery, stranding data indicate there were two confirmed bottlenose dolphin interactions with crab pot fishing gear between 2002–2006, one alive and one dead. In the same period, four dead bottlenose dolphins stranded with rope or rope marks that may have been from trap/pot gear, but cause of death could not be determined. NMFS acknowledges these numbers may underestimate the number of interactions that are occurring. However, interpreting the data is difficult due to limitations of the stranding network to accurately document human interactions, and insufficient information on bottlenose dolphin abundance and stock structure in the Gulf of Mexico to calculate PBR or quantify the impacts of fishery interactions on bottlenose dolphin stocks.

The "Gulf of Mexico menhaden purse seine" fishery was observed by

researchers from Louisiana State University in 1992, 1994, and 1995. The observers documented nine bottlenose dolphin captures, three of which were mortalities. Using observed and total fishery effort data, the number of takes was linearly extrapolated to an estimate of 68 animals. On the basis of this information, the fishery was elevated from Category III to Category II on the 1999 LOF (64 FR 9067, February 24, 1999). Since that time, there has been no observer coverage in this fishery. Fishermen self-reports through the MMAP reveal five bottlenose dolphin mortalities from 2002–2006, with two mortalities in 2002, one in 2004, and two in 2005. One of these animals was believed to have been dead prior to capture. However, information gathered under the MMAP cannot be verified and it is not possible to extrapolate these numbers to obtain an estimate of total takes in this fishery.

The current lack of information on bottlenose dolphin abundance and stock structure in the Gulf of Mexico combined with a low level of stranding response, particularly following Hurricanes Katrina and Rita, make it difficult to assess the population-level impacts of either of these fisheries. For example, the percentage of stranded animals that are necropsied is low (FL, TX, and AL necropsied over 50 percent of all stranded marine mammals from 2002–2006, but MS and LA had much lower necropsy rates, 16 percent and 3 percent, respectively), making documentation of human interactions difficult. NMFS is focused on building capacity in the Gulf and increasing the level and quality of stranding response. NMFS held workshops in LA and MS in September 2007 to raise awareness of marine mammal management challenges in the Gulf of Mexico and to enhance marine mammal stranding response. NMFS staff met with representatives from state fishery and wildlife management agencies, marine mammal stranding networks, research institutions, universities, Sea Grant, and other Federal agencies to identify ways to better manage protected and endangered marine mammals in the Gulf of Mexico. Furthermore, NMFS intends to provide additional training workshops in 2008 to enhance the stranding network's capacity for identifying and documenting human interaction, and instruction on conducting necropsies. NMFS expects these efforts to increase the effectiveness of the stranding networks and better inform management decisions in the future.

Comment 30: One commenter reiterated concerns raised in their letters

on the 2003 through 2007 LOFs recommending that NMFS expedite its investigation of bottlenose dolphin stock structure and reevaluate the classification of Gulf of Mexico fisheries. The commenter further recommended that NMFS expand its efforts to collect reliable information on serious injury and mortality of marine mammals incidental to Gulf of Mexico fisheries, with priority given to instituting an observer program for the menhaden purse seine fishery and expanding efforts to evaluate bottlenose dolphin entanglement in the blue crab trap/pot fishery. NMFS has initiated efforts to address some of these issues and has indicated that it intends to reevaluate these fisheries as new information becomes available, particularly information regarding the stock structure of bottlenose dolphins in the Gulf of Mexico. Nonetheless, the commenter remains concerned about marine mammal interactions with Gulf of Mexico fisheries, believes that more active management is needed in this region, and therefore reiterates its previous recommendations.

Response: NMFS agrees that collection of reliable information on serious injury and mortality of marine mammals in the Gulf of Mexico is essential. NMFS is making efforts to more actively manage marine mammals and build capacity in this area to: (1) address significant data gaps regarding the distribution, abundance, stock structure, and health of marine mammals; (2) enhance stranding response capabilities to better understand threats to marine mammals in the Gulf of Mexico ecosystem, and (3) ensure constituents are informed regarding NMFS efforts, threats to the ecosystem, and mitigation strategies to further reduce impacts to marine mammals. See the response to Comment 29 regarding efforts to enhance stranding network coverage and response in the Gulf of Mexico.

Managing bottlenose dolphin stocks in the Gulf of Mexico is especially challenging due to lack of data, particularly regarding abundance and stock structure. There is currently no PBR calculated for coastal stocks or bay, sound, and estuarine stocks, so NMFS is unable to assess the population-level impacts of fishery-related serious injuries and mortalities. To address this, NMFS is working towards updating estimates of bottlenose dolphin abundance and refining our understanding of bottlenose dolphin stock structure in the Gulf of Mexico. Specifically, in July and August 2007, NMFS completed a ship-based survey of the Gulf of Mexico continental shelf

from 20 m (65.6 ft) depth to 500 m (1640 ft) depth from Cedar Key, FL, to Brownsville, TX, which included line-transect abundance surveys and the collection of over 200 bottlenose dolphin biopsies for stock structure analysis. In 2007, NMFS also completed winter and summer aerial line-transect abundance surveys of coastal bottlenose dolphin stocks (shore to 20 m [65.6 ft] depth) from Key West to the MS River delta. NMFS has also worked on bay, sound, and estuarine stocks, conducting a photo-ID mark-recapture study and biopsy sampling in Choctawhatchee Bay, FL in July and August 2007 and biopsy sampling in Mississippi Sound in 2005 and 2006. Data collected during these surveys are currently being analyzed, and updated information on population abundance and stock structure should be available in the 2008 SARs. Once this information is available and PBR is calculated for each stock, NMFS will be better able to assess the impacts of mortality and serious injury of marine mammals associated with commercial fisheries in the Gulf. Observer coverage remains a priority for Gulf of Mexico fisheries, when resources become available.

Comment 31: One commenter stated that the number of vessels listed in the proposed 2008 LOF for the Category II Gulf of Mexico menhaden purse seine fishery is incorrect. Table 2 lists 50 vessels as operating in this fishery; however, 1999 was the last year that the number of vessels in the fishery exceeded 50. Since 2000 there have been between 40 and 42 vessels annually participating in the fishery, 2 of which are typically run boats from the fishing grounds back to the reduction plants and do not actively fish.

Response: NMFS thanks the commenter for this information. The number of vessels in the Gulf of Mexico menhaden purse seine fishery has been updated from 50 to 40–42.

Summary of Changes to the LOF for 2008

The following summarizes changes to the LOF for 2008 in fishery classification, fisheries listed in the LOF, the number of participants in a particular fishery, and the species and/or stocks that are incidentally killed or seriously injured in a particular fishery. The classifications and definitions of U.S. commercial fisheries for 2008 are identical to those provided in the LOF for 2007 with the following exceptions.

Commercial Fisheries in the Pacific Ocean

Fishery Classification

The “CA yellowtail, barracuda, and white seabass drift gillnet (mesh size ≥ 3.5 inches and < 14 inches)” fishery is not elevated to a Category I fishery as proposed in the proposed 2008 LOF. The mean annual mortality and serious injury for the CA stock of long-beaked common dolphins was recalculated due to errors in the reporting of observer coverage for this fishery discovered during the public comment period for the draft 2007 SARs. Using the correct information, the data indicate that the annual mortality and serious injury of this stock in this fishery is 43 percent, not 82 percent, of the stock’s PBR as had been reported in the proposed 2008 LOF. For this reason, the “CA yellowtail, barracuda, and white seabass drift gillnet (mesh size ≥ 3.5 inches and < 14 inches)” fishery remains a Category II on the final 2008 LOF.

The superscript “2” is removed from Table 1 following the “CA yellowtail, barracuda, and white seabass drift gillnet (mesh size ≥ 3.5 inches and < 14 inches)” fishery because it is no longer classified by analogy to other gillnet fisheries. The current data shows that the mortality and serious injury of the CA stock of long-beaked common dolphin is 43 percent; therefore, it is driving the classification of this fishery. A superscript “1” is placed next to this stock in Table 1 to indicate its role as a driving stock.

Removal of Fisheries from the LOF

The Category II “OR blue shark floating longline” fishery is removed from the LOF.

The Category II “OR swordfish floating longline” fishery is removed from the LOF.

Fishery Name and Organizational Changes and Clarifications

The Category II “CA yellowtail, barracuda, and white seabass drift gillnet (mesh size > 3.5 inches and < 14 inches)” fishery is renamed the “CA yellowtail, barracuda, and white seabass drift gillnet (mesh size ≥ 3.5 inches and < 14 inches)” fishery.

The Category III “CA set and drift gillnet fisheries that use a stretched mesh size of 3.5 in or less” is renamed the “CA set gillnet fishery (mesh size < 3.5 inches).”

NMFS reviewed the various West Coast pot and trap fisheries for information on the takes of humpback and gray whales in Category III trap/pot fisheries on the Pacific Coast. NMFS anticipates that incidental serious injury

and mortality of gray and humpback whales in OR and WA crab fisheries is unlikely to increase; therefore, NMFS did not reclassify the crab pot fisheries at this time. NMFS will continue to analyze information from the remaining pot fisheries along the West Coast for potential recategorization of certain West Coast trap/pot fisheries in future LOFs.

The fishery description for the Category II “AK Metlakatla/Annette Island salmon drift gillnet” fishery is changed to reflect that the fishery is an exclusively tribal fishery managed exclusively by the tribe. There is no management by any state or Federal agency.

Number of Vessels/Persons

The estimated number of vessels or persons in the Category II “CA anchovy, mackerel, and sardine purse seine” fishery is updated to 63.

The estimated number of vessels or persons in the Category II “CA squid purse seine” fishery is updated to 71.

The estimated number of vessels or persons in the Category III “HI inshore gillnet” fishery is updated to 5.

The estimated number of vessels or persons in the Category III “WA/OR/CA groundfish trawl” fishery is updated to 160–180.

The estimated number of vessels or persons in the Category III “CA abalone” fishery is updated to zero.

The estimated number of vessels or persons in the Category III “CA set gillnet (mesh size < 3.5 inches)” fishery (renamed from the “CA set and drift gillnet fisheries that use a stretched mesh size of 3.5 in or less” fishery in this final rule) is updated to 304.

List of Species That are Incidentally Injured or Killed

The Hawaiian stocks of striped dolphin and Bryde’s whale are added to the list of marine mammal species and stocks incidentally injured or killed in the Category I “HI swordfish, tuna, billfish, mahi mahi, wahoo, oceanic sharks longline/set line” fishery.

The Gulf of Alaska, Aleutian Islands, and Bering Sea transient stock of killer whales is removed from the list of marine mammal species and stocks incidentally injured or killed in the Category II “AK Bering Sea and Aleutian Islands Pacific cod longline” fishery and the Category III “AK Bering Sea and Aleutian Islands Greenland turbot longline” fishery.

Commercial Fisheries in the Atlantic Ocean, Gulf of Mexico, and Caribbean

Addition of Fisheries to the LOF

The “GA cannonball jellyfish trawl” fishery is added to the LOF as a Category III fishery.

Removal of Fisheries from the LOF

The Category III “U.S. Mid-Atlantic hand seine” fishery is removed from the LOF.

Fishery Name and Organizational Changes and Clarifications

The estimated number of vessels or persons in the Category II “Gulf of Mexico menhaden purse seine” fishery is updated to 40–42.

The list of target fish species associated with the Category II “Atlantic mixed species trap/pot” fishery is expanded to include cunner.

The list of target species associated with the Category II “Southeast Atlantic gillnet” fishery is updated by removing shad.

The description of the Category II “Southeast Atlantic gillnet” fishery is corrected by clarifying that the fishery is also managed under ALWTRP implementing regulations. Management under the ALWTRP was inadvertently left out of the description in the proposed rule.

The boundaries and excluded fisheries associated with the Category I “Mid-Atlantic gillnet” fishery are updated through the addition of the following language, “ NC/SC border, but not including waters where gillnet fisheries are listed as Category II and Category III. At this time, these Category II and Category III fisheries include: the Chesapeake Bay inshore gillnet; NC inshore gillnet; DE River inshore gillnet; Long Island Sound inshore gillnet; and RI, southern MA (to Monomy Island), and NY Bight (Raritan and Lower NY Bays) inshore gillnet.”

The boundaries and excluded fisheries associated with the Category II “Atlantic mixed species trap/pot” fishery are updated through the addition of the following language, “The Atlantic mixed species trap/pot fishery (Category II) includes all trap/pot operations for species from the U.S.-Canada border down through the waters east of the fishery management demarcation line between the Atlantic Ocean and the Gulf of Mexico (50 CFR 600.105), but does not include the following Category I, II, and III trap/pot fisheries: Northeast/Mid-Atlantic American lobster trap/pot; Atlantic blue crab trap/pot; FL spiny lobster trap/ pot; Southeastern U.S. Atlantic, Gulf of Mexico stone crab trap/pot; U.S. Mid-Atlantic eel trap/pot

fisheries; and the Southeastern U.S. Atlantic, Gulf of Mexico golden crab fishery (68 FR 1421, January 10, 2003).”

The definition of the Category II “Mid-Atlantic flynet” fishery, provided in the final 2007 LOF (71 FR 70345, December 4, 2006), is replaced with the following language: “The flynet fishery is a multispecies fishery composed of nearshore and offshore components that operate along the eastern coast of the Mid-Atlantic United States. Flynets are high profile trawls similar to bottom otter trawls. These nets typically range from 80–120 ft (24–36.6 m) in headrope length, with wing mesh sizes of 16–64 in (41–163 cm), following a slow 3:1 taper to smaller mesh sizes in the body, extension, and codend sections of the net. The nearshore fishery operates from October to April inside of 30 fathoms (180 ft–55 m) from NC to NJ. This nearshore fishery targets Atlantic croaker, weakfish, butterfish, harvestfish, bluefish, menhaden, striped bass, kingfishes, and other finfish species. Flynet fishing is no longer permitted south of Cape Hatteras in order to protect weakfish stocks. The offshore component operates from November to April outside of 30 fathoms (180 ft; 55 m) from the Hudson Canyon off NY, south to Hatteras Canyon off NC. These deeper water fisheries target bluefish, Atlantic mackerel, *Loligo* squid, black sea bass, and scup (72 FR 7382, February 15, 2007). *Illex* squid are also targeted offshore (70–200 fathoms [420–1,200 ft; 128–366 m]) during summer months from May to September.” NMFS acknowledges that concerns have been raised over the possible colloquial nature of this fishery and will continue working to resolve these concerns.

The descriptions of the Category II “Northeast anchored float gillnet”, “Northeast drift gillnet”, “Atlantic blue crab trap/pot, and “Atlantic mixed species trap/pot” fisheries are updated to reflect that each is now also managed under ALWTRP implementing regulations under a recent rulemaking (72 FR 57104, October 5, 2007).

The description of the Category II “Mid-Atlantic haul/beach seine” fishery is undergoing change, particularly pertaining to NC beach gear, due to pending rulemakings by NCDMF. An updated description of this fishery will be provided in a future LOF.

List of Species That are Incidentally Seriously Injured or Killed

The Northern Gulf of Mexico continental shelf and Eastern Gulf of Mexico coastal stocks of bottlenose dolphins are added to the list of marine mammal species and stocks incidentally

injured or killed in the Category III “Southeastern U.S. Atlantic, Gulf of Mexico, shark bottom longline/hook-and-line” fishery.

The name of the bottlenose dolphin stocks incidentally seriously injured or killed in the Category I “Atlantic Ocean, Caribbean, Gulf of Mexico large pelagics longline” and Category III “Gulf of Mexico butterfly trawl” fisheries are changed from “Bottlenose dolphin, Northern Gulf of Mexico outer continental shelf” to “Bottlenose dolphin, Northern Gulf of Mexico oceanic”, and from “Bottlenose dolphin, Northern Gulf of Mexico continental shelf edge and slope” to “Bottlenose dolphin, Northern Gulf of Mexico continental shelf.”

The name the humpback whale stock incidentally killed/injured in the Category I “Northeast sink gillnet”, Category I “Northeast/Mid-Atlantic American lobster trap/pot”, Category II “Northeast anchored float gillnet”, and Category III “Gulf of Maine, U.S. Mid-Atlantic tuna, shark, swordfish hook-and-line/harpoon” fisheries is changed from “Western North Atlantic (WNA)” to “Gulf of Maine.”

List of Fisheries

The following two tables list U.S. commercial fisheries according to their assigned categories under section 118 of the MMPA. The estimated number of vessels/participants is expressed in terms of the number of active participants in the fishery, when possible. If this information is not available, the estimated number of vessels or persons licensed for a particular fishery is provided. If no recent information is available on the number of participants in a fishery, the number from the most recent LOF is used.

The tables also list the marine mammal species and stocks incidentally killed or injured in each fishery based on observer data, logbook data, stranding reports, and fisher reports. This list includes all species or stocks known to experience mortality or injury in a given fishery, but also includes species or stocks for which there are anecdotal records of interaction. Additionally, species identified by logbook entries may not be verified. Bycatch of species or stocks identified is not necessarily driving a fishery’s classification in a given Category. NMFS has designated those stocks driving a fishery’s classification (i.e., the fishery is classified based on serious injuries and mortalities of a marine mammal stock greater than 50 percent [Category I], or greater than 1 percent and less

than 50 percent [Category II], of a stock's PBR) by a "1" after the stock's name.
 There are several fisheries classified in Category II that have no recently documented interactions with marine mammals, or interactions that did not result in a serious injury or mortality. Justification for classifying these

fisheries as a Category II is by analogy to other gear types that are known to cause mortality or serious injury of marine mammals, as discussed in the final LOF for 1996 (60 FR 67063, December 28, 1995), and according to factors listed in the definition of a "Category II fishery" in 50 CFR 229.2.

NMFS has designated those fisheries originally listed by analogy in Tables 1 and 2 by a "2" after the fishery's name. Table 1 lists commercial fisheries in the Pacific Ocean (including Alaska); Table 2 lists commercial fisheries in the Atlantic Ocean, Gulf of Mexico, and Caribbean.

TABLE 1 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE PACIFIC OCEAN

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
CATEGORY I		
GILLNET FISHERIES:		
CA angel shark/halibut and other species set gillnet (>3.5 in. mesh)	58	California sea lion, U.S. Harbor seal, CA Harbor porpoise, Central CA ¹ Long-beaked common dolphin, CA Northern elephant seal, CA breeding Sea otter, CA Short-beaked common dolphin, CA/OR/WA
CA/OR thresher shark/swordfish drift gillnet (≥14 in. mesh)	85	California sea lion, U.S. Dall's porpoise, CA/OR/WA Fin whale, CA/OR/WA Gray whale, Eastern North Pacific Humpback whale, Eastern North Pacific Long-beaked common dolphin, CA Northern elephant seal, CA breeding Northern right-whale dolphin, CA/OR/WA Pacific white-sided dolphin, CA/OR/WA Risso's dolphin, CA/OR/WA Short-beaked common dolphin, CA/OR/WA Short-finned pilot whale, CA/OR/WA ¹ Sperm whale, CA/OR/WA
LONGLINE/SET LINE FISHERIES:		
HI swordfish, tuna, billfish, mahi mahi, wahoo, oceanic sharks longline/set line	140	Blainville's beaked whale, HI Bottlenose dolphin, HI Bryde's whale, HI False killer whale, HI ¹ Humpback whale, Central North Pacific Pantropical spotted dolphin, HI Risso's dolphin, HI Short-finned pilot whale, HI Spinner dolphin, HI Sperm whale, HI Striped dolphin, HI
CATEGORY II		
GILLNET FISHERIES:		
AK Bristol Bay salmon drift gillnet ²	1,903	Beluga whale, Bristol Bay Gray whale, Eastern North Pacific Harbor seal, Bering Sea Northern fur seal, Eastern Pacific Pacific white-sided dolphin, North Pacific Spotted seal, AK Steller sea lion, Western U.S. ¹
AK Bristol Bay salmon set gillnet ²	1,014	Beluga whale, Bristol Bay Gray whale, Eastern North Pacific Harbor seal, Bering Sea Northern fur seal, Eastern Pacific Spotted seal, AK

TABLE 1 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE PACIFIC OCEAN—Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
AK Cook Inlet salmon set gillnet	745	Beluga whale, Cook Inlet Dall's porpoise, AK Harbor porpoise, GOA Harbor seal, GOA Humpback whale, Central North Pacific ¹ Steller sea lion, Western U.S.
AK Cook Inlet salmon drift gillnet	576	Beluga whale, Cook Inlet Dall's porpoise, AK Harbor porpoise, GOA ¹ Harbor seal, GOA Steller sea lion, Western U.S.
AK Kodiak salmon set gillnet	188	Harbor porpoise, GOA ¹ Harbor seal, GOA Sea otter, Southwest AK Steller sea lion, Western U.S.
AK Metlakatla/Annette Island salmon drift gillnet ²	60	None documented
AK Peninsula/Aleutian Islands salmon drift gillnet ²	164	Dall's porpoise, AK Harbor porpoise, GOA Harbor seal, GOA Northern fur seal, Eastern Pacific
AK Peninsula/Aleutian Islands salmon set gillnet ²	116	Harbor porpoise, Bering Sea Steller sea lion, Western U.S.
AK Prince William Sound salmon drift gillnet	541	Dall's porpoise, AK Harbor porpoise, GOA ¹ Harbor seal, GOA Northern fur seal, Eastern Pacific Pacific white-sided dolphin, North Pacific Sea Otter, South Central AK Steller sea lion, Western U.S. ¹
AK Southeast salmon drift gillnet	481	Dall's porpoise, AK Harbor porpoise, Southeast AK Harbor seal, Southeast AK Humpback whale, Central North Pacific ¹ Pacific white-sided dolphin, North Pacific Steller sea lion, Eastern U.S.
AK Yakutat salmon set gillnet ²	170	Gray whale, Eastern North Pacific Harbor seal, Southeast AK Humpback whale, Central North Pacific (Southeast AK)
CA yellowtail, barracuda, and white seabass drift gillnet fishery (mesh size \geq 3.5 in and <14 in)	24	California sea lion, U.S. Long-beaked common dolphin, CA ¹ Short-beaked common dolphin, CA/OR/WA
WA Puget Sound Region salmon drift gillnet (includes all inland waters south of US-Canada border and eastward of the Bonilla-Tatoosh line-Treaty Indian fishing is excluded)	210	Dall's porpoise, CA/OR/WA Harbor porpoise, inland WA ¹ Harbor seal, WA inland
PURSE SEINE FISHERIES:		
AK Southeast salmon purse seine	416	Humpback whale, Central North Pacific ¹
AK Cook Inlet salmon purse seine	82	Humpback whale, Central North Pacific ¹
AK Kodiak salmon purse seine	370	Humpback whale, Central North Pacific ¹
CA anchovy, mackerel, sardine purse seine	63	Bottlenose dolphin, CA/OR/WA offshore ¹ California sea lion, U.S. Harbor seal, CA
CA squid purse seine	71	Common dolphin, unknown Short-finned pilot whale, CA/OR/WA ¹

TABLE 1 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE PACIFIC OCEAN—Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
CA tuna purse seine ²	10	None documented
TRAWL FISHERIES:		
AK Bering Sea, Aleutian Islands flatfish trawl	26	Bearded seal, AK Harbor porpoise, Bering Sea Harbor seal, Bering Sea Killer whale, AK resident ¹ Northern fur seal, Eastern North Pacific Spotted seal, AK Steller sea lion, Western U.S. ¹ Walrus, AK
AK Bering Sea, Aleutian Islands pollock trawl	120	Dall's porpoise, AK Harbor seal, AK Humpback whale, Central North Pacific ¹ Humpback whale, Western North Pacific ¹ Killer whale, Eastern North Pacific, GOA, Aleutian Islands, and Bering Sea transient ¹ Minke whale, AK Ribbon seal, AK Spotted seal, AK Steller sea lion, Western U.S. ¹
LONGLINE/SET LINE FISHERIES:		
AK Bering Sea, Aleutian Islands Pacific cod longline	114	Killer whale, AK resident ¹ Ribbon seal, AK Steller sea lion, Western U.S.
CA pelagic longline ²	6	California sea lion, U.S. Risso's dolphin, CA/OR/WA
POT, RING NET, AND TRAP FISHERIES:		
AK Bering Sea sablefish pot	6	Humpback whale, Central North Pacific ¹ Humpback whale, Western North Pacific ¹
CATEGORY III		
GILLNET FISHERIES:		
AK Kuskokwim, Yukon, Norton Sound, Kotzebue salmon gillnet	1,922	Harbor porpoise, Bering Sea
AK miscellaneous finfish set gillnet	3	Steller sea lion, Western U.S.
AK Prince William Sound salmon set gillnet	30	Harbor seal, GOA Steller sea lion, Western U.S.
AK roe herring and food/bait herring gillnet	2,034	None documented
CA set gillnet (mesh size <3.5 inches)	304	None documented
HI inshore gillnet	5	Bottlenose dolphin, HI Spinner dolphin, HI
WA Grays Harbor salmon drift gillnet (excluding treaty Tribal fishing)	24	Harbor seal, OR/WA coast
WA/OR herring, smelt, shad, sturgeon, bottom fish, mullet, perch, rockfish gillnet	913	None documented
WA/OR lower Columbia River (includes tributaries) drift gillnet	110	California sea lion, U.S. Harbor seal, OR/WA coast
WA Willapa Bay drift gillnet	82	Harbor seal, OR/WA coast Northern elephant seal, CA breeding
PURSE SEINE, BEACH SEINE, ROUND HAUL AND THROW NET FISHERIES:		

TABLE 1 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE PACIFIC OCEAN—Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
AK Metlakatla salmon purse seine	10	None documented
AK miscellaneous finfish beach seine	1	None documented
AK miscellaneous finfish purse seine	3	None documented
AK octopus/squid purse seine	2	None documented
AK roe herring and food/bait herring beach seine	8	None documented
AK roe herring and food/bait herring purse seine	624	None documented
AK salmon beach seine	34	None documented
AK salmon purse seine (except Southeast Alaska, which is in Category II)	953	Harbor seal, GOA
WA/OR sardine purse seine	42	None documented
HI Kona crab loop net	42	None documented
HI opelu/akule net	12	None documented
HI inshore purse seine	23	None documented
HI throw net, cast net	14	None documented
WA (all species) beach seine or drag seine	235	None documented
WA/OR herring, smelt, squid purse seine or lampara	130	None documented
WA salmon purse seine	440	None documented
WA salmon reef net	53	None documented
DIP NET FISHERIES:		
CA squid dip net	115	None documented
WA/OR smelt, herring dip net	119	None documented
MARINE AQUACULTURE FISHERIES:		
CA marine shellfish aquaculture	unknown	None documented
CA salmon enhancement rearing pen	>1	None documented
CA white seabass enhancement net pens	13	California sea lion, U.S.
HI offshore pen culture	2	None documented
OR salmon ranch	1	None documented
WA/OR salmon net pens	14	California sea lion, U.S. Harbor seal, WA inland waters
TROLL FISHERIES:		
AK North Pacific halibut, AK bottom fish, WA/OR/CA albacore, groundfish, bottom fish, CA halibut non-salmonid troll fisheries	1,530 (330 AK)	None documented
AK salmon troll	2,335	Steller sea lion, Eastern U.S. Steller sea lion, Western U.S.
American Samoa tuna troll	< 50	None documented
CA/OR/WA salmon troll	4,300	None documented
Commonwealth of the Northern Mariana Islands tuna troll	88	None documented

TABLE 1 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE PACIFIC OCEAN—Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
Guam tuna troll	401	None documented
HI trolling, rod and reel	1,321	None documented
LONGLINE/SET LINE FISHERIES:		
AK Bering Sea, Aleutian Islands Greenland turbot longline	12	Killer whale, AK resident
AK Bering Sea, Aleutian Islands rockfish longline	17	None documented
AK Bering Sea, Aleutian Islands sablefish longline	63	None documented
AK Gulf of Alaska halibut longline	1,302	None documented
AK Gulf of Alaska Pacific cod longline	440	None documented
AK Gulf of Alaska rockfish longline	421	None documented
AK Gulf of Alaska sablefish longline	412	Sperm whale, North Pacific Steller sea lion, Eastern U.S.
AK halibut longline/set line (State and Federal waters)	3,079	Steller sea lion, Western U.S.
AK octopus/squid longline	7	None documented
AK state-managed waters groundfish longline/setline (including sablefish, rockfish, and miscellaneous finfish)	731	None documented
American Samoa longline	60	None documented
WA/OR/CA groundfish, bottomfish longline/set line	367	None documented
WA/OR North Pacific halibut longline/set line	350	None documented
TRAWL FISHERIES:		
AK Bering Sea, Aleutian Islands Atka mackerel trawl	8	Steller sea lion, Western U.S.
AK Bering Sea, Aleutian Islands Pacific cod trawl	87	Harbor seal, Bering Sea Steller sea lion, Western U.S.
AK Bering Sea, Aleutian Islands rockfish trawl	9	None documented
AK Gulf of Alaska flatfish trawl	52	None documented
AK Gulf of Alaska Pacific cod trawl	101	Steller sea lion, Western U.S.
AK Gulf of Alaska pollock trawl	83	Fin whale, Northeast Pacific Northern elephant seal, North Pacific Steller sea lion, Western U.S.
AK Gulf of Alaska rockfish trawl	45	None documented
AK food/bait herring trawl	3	None documented
AK miscellaneous finfish otter or beam trawl	6	None documented
AK shrimp otter trawl and beam trawl (statewide and Cook Inlet)	58	None documented
AK state-managed waters of Cook Inlet, Kachemak Bay, Prince William Sound, Southeast AK groundfish trawl	2	None documented
CA halibut bottom trawl	53	None documented

TABLE 1 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE PACIFIC OCEAN—Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
WA/OR/CA groundfish trawl	160-180	California sea lion, U.S. Dall's porpoise, CA/OR/WA Harbor seal, OR/WA coast Northern fur seal, Eastern Pacific Pacific white-sided dolphin, CA/OR/WA Steller sea lion, Eastern U.S.
WA/OR/CA shrimp trawl	300	None documented
POT, RING NET, AND TRAP FISHERIES:		
AK Aleutian Islands sablefish pot	8	None documented
AK Bering Sea, Aleutian Islands Pacific cod pot	76	None documented
AK Bering Sea, Aleutian Islands crab pot	329	None documented
AK Gulf of Alaska crab pot	unknown	None documented
AK Gulf of Alaska Pacific cod pot	154	Harbor seal, GOA
AK Southeast Alaska crab pot	unknown	Humpback whale, Central North Pacific (Southeast AK)
AK Southeast Alaska shrimp pot	unknown	Humpback whale, Central North Pacific (Southeast AK)
AK octopus/squid pot	72	None documented
AK snail pot	2	None documented
CA lobster, prawn, shrimp, rock crab, fish pot	608	Gray whale, Eastern North Pacific Harbor seal, CA Humpback whale, Eastern North Pacific Sea otter, CA
OR/CA hagfish pot or trap	25	None documented
WA/OR/CA crab pot	1,478	Gray whale, Eastern North Pacific Humpback whale, Eastern North Pacific
WA/OR/CA sablefish pot	176	None documented
WA/OR shrimp pot/trap	254	None documented
HI crab trap	22	None documented
HI fish trap	19	None documented
HI lobster trap	0	Hawaiian monk seal
HI shrimp trap	5	None documented
HANDLINE AND JIG FISHERIES:		
AK miscellaneous finfish handline and mechanical jig	100	None documented
AK North Pacific halibut handline and mechanical jig	93	None documented
AK octopus/squid handline	2	None documented
American Samoa bottomfish	<50	None documented
Commonwealth of the Northern Mariana Islands bottomfish	<50	None documented
Guam bottomfish	200	None documented
HI aku boat, pole and line	4	None documented
HI Main Hawaiian Islands, Northwest Hawaiian Islands deep sea bottomfish	300	Hawaiian monk seal

TABLE 1 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE PACIFIC OCEAN—Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
HI inshore handline	307	None documented
HI tuna handline	298	Hawaiian monk seal
WA groundfish, bottomfish jig	679	None documented
Western Pacific squid jig	6	None documented
HARPOON FISHERIES:		
CA swordfish harpoon	30	None documented
POUND NET/WEIR FISHERIES:		
AK herring spawn on kelp pound net	452	None documented
AK Southeast herring roe/food/bait pound net	3	None documented
WA herring brush weir	1	None documented
BAIT PENS:		
WA/OR/CA bait pens	13	California sea lion, U.S.
DREDGE FISHERIES:		
Coastwide scallop dredge	108 (12 AK)	None documented
DIVE, HAND/MECHANICAL COLLECTION FISHERIES:		
AK abalone	0	None documented
AK clam	156	None documented
WA herring spawn on kelp	4	None documented
AK dungeness crab	3	None documented
AK herring spawn on kelp	363	None documented
AK urchin and other fish/shellfish	471	None documented
CA abalone	0	None documented
CA sea urchin	583	None documented
HI black coral diving	1	None documented
HI fish pond	N/A	None documented
HI handpick	37	None documented
HI lobster diving	19	None documented
HI squidding, spear	91	None documented
WA/CA kelp	4	None documented
WA/OR sea urchin, other clam, octopus, oyster, sea cucumber, scallop, ghost shrimp hand, dive, or mechanical collection	637	None documented
WA shellfish aquaculture	684	None documented
COMMERCIAL PASSENGER FISHING VESSEL (CHARTER BOAT) FISHERIES:		
AK/WA/OR/CA commercial passenger fishing vessel	>7,000 (1,107 AK)	Killer whale, stock unknown Steller sea lion, Eastern U.S. Steller sea lion, Western U.S.

TABLE 1 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE PACIFIC OCEAN—Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
HI charter vessel	114	None documented
LIVE FINFISH/SHELLFISH FISHERIES:		
CA finfish and shellfish live trap/hook-and-line	93	None documented

List of Abbreviations and Symbols Used in Table 1: AK - Alaska; CA - California; GOA - Gulf of Alaska; HI - Hawaii; OR - Oregon; WA - Washington

¹ Fishery classified based on serious injuries and mortalities of this stock, which are greater than 1 percent of the stock's PBR

² Fishery classified by analogy.

TABLE 2 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE ATLANTIC OCEAN, GULF OF MEXICO, AND CARIBBEAN

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
CATEGORY I		
GILLNET FISHERIES:		
Mid-Atlantic gillnet	>670	Bottlenose dolphin, WNA coastal ¹ Bottlenose dolphin, WNA offshore Common dolphin, WNA Gray seal, WNA Harbor porpoise, GME/BF ¹ Harbor seal, WNA Harp seal, WNA Humpback whale, Gulf of Maine ¹ Long-finned pilot whale, WNA Minke whale, Canadian east coast Short-finned pilot whale, WNA White-sided dolphin, WNA
Northeast sink gillnet	341	Bottlenose dolphin, WNA offshore Common dolphin, WNA Fin whale, WNA Gray seal, WNA Harbor porpoise, GME/BF ¹ Harbor seal, WNA Harp seal, WNA Hooded seal, WNA Humpback whale, Gulf of Maine ¹ Minke whale, Canadian east coast ¹ North Atlantic right whale, WNA ¹ Risso's dolphin, WNA White-sided dolphin, WNA
LONGLINE FISHERIES:		
Atlantic Ocean, Caribbean, Gulf of Mexico large pelagics longline	94	Atlantic spotted dolphin, Northern GMX Atlantic spotted dolphin, WNA Bottlenose dolphin, Northern GMX oceanic Bottlenose dolphin, Northern GMX continental shelf Bottlenose dolphin, WNA offshore Common dolphin, WNA Cuvier's beaked whale, WNA Long-finned pilot whale, WNA ¹ Mesoplodon beaked whale, WNA Northern bottlenose whale, WNA Pantropical spotted dolphin, Northern GMX Pantropical spotted dolphin, WNA Pygmy sperm whale, WNA ¹ Risso's dolphin, Northern GMX Risso's dolphin, WNA Short-finned pilot whale, Northern GMX Short-finned pilot whale, WNA ¹
TRAP/POT FISHERIES:		

TABLE 2 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE ATLANTIC OCEAN, GULF OF MEXICO, AND CARIBBEAN—
Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
Northeast/Mid-Atlantic American lobster trap/pot	13,000	Fin whale, WNA Harbor seal, WNA Humpback whale, Gulf of Maine ¹ Minke whale, Canadian east coast ¹ North Atlantic right whale, WNA ¹
CATEGORY II		
GILLNET FISHERIES:		
Chesapeake Bay inshore gillnet ²	45	None documented
Gulf of Mexico gillnet ²	724	Bottlenose dolphin, Eastern GMX coastal Bottlenose dolphin, GMX bay, sound, and estuarine Bottlenose dolphin, Northern GMX coastal Bottlenose dolphin, Western GMX coastal
NC inshore gillnet	94	Bottlenose dolphin, WNA coastal ¹
Northeast anchored float gillnet ²	133	Harbor seal, WNA Humpback whale, Gulf of Maine White-sided dolphin, WNA
Northeast drift gillnet ²	unknown	None documented
Southeast Atlantic gillnet ²	779	Bottlenose dolphin, WNA coastal
Southeastern U.S. Atlantic shark gillnet	30	Atlantic spotted dolphin, WNA Bottlenose dolphin, WNA coastal ¹ North Atlantic right whale, WNA
TRAWL FISHERIES:		
Mid-Atlantic mid-water trawl (including pair trawl)	620	Bottlenose dolphin, WNA offshore Common dolphin, WNA Long-finned pilot whale, WNA Risso's dolphin, WNA Short-finned pilot whale, WNA White-sided dolphin, WNA ¹
Mid-Atlantic bottom trawl	>1,000	Common dolphin, WNA ¹ Long-finned pilot whale, WNA ¹ Short-finned pilot whale, WNA ¹
Mid-Atlantic flynet ²	21	None documented
Northeast mid-water trawl (including pair trawl)	17	Harbor seal, WNA Long-finned pilot whale, WNA ¹ Short-finned pilot whale, WNA ¹ White-sided dolphin, WNA
Northeast bottom trawl	1,052	Common dolphin, WNA Harbor porpoise, GME/BF Harp seal, WNA Long-finned pilot whale, WNA Short-finned pilot whale, WNA White-sided dolphin, WNA ¹
TRAP/POT FISHERIES:		
Atlantic blue crab trap/pot	>16,000	Bottlenose dolphin, WNA coastal ¹ West Indian manatee, FL ¹
Atlantic mixed species trap/pot ²	unknown	Fin whale, WNA Humpback whale, Gulf of Maine
PURSE SEINE FISHERIES:		

TABLE 2 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE ATLANTIC OCEAN, GULF OF MEXICO, AND CARIBBEAN—
Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
Gulf of Mexico menhaden purse seine	40-42	Bottlenose dolphin, Eastern GMX coastal Bottlenose dolphin, GMX bay, sound, estuarine Bottlenose dolphin, Northern GMX coastal ¹ Bottlenose dolphin, Western GMX coastal
Mid-Atlantic menhaden purse seine ²	22	Bottlenose dolphin, WNA coastal
HAUL/BEACH SEINE FISHERIES:		
Mid-Atlantic haul/beach seine	25	Bottlenose dolphin, WNA coastal ¹
NC long haul seine	33	Bottlenose dolphin, WNA coastal ¹
STOP NET FISHERIES:		
NC roe mullet stop net	13	Bottlenose dolphin, WNA coastal ¹
POUND NET FISHERIES:		
VA pound net	187	Bottlenose dolphin, WNA coastal ¹
CATEGORY III		
GILLNET FISHERIES:		
Caribbean gillnet	>991	Dwarf sperm whale, WNA West Indian manatee, Antillean
DE River inshore gillnet	60	None documented
Long Island Sound inshore gillnet	20	None documented
RI, southern MA (to Monomoy Island), and NY Bight (Raritan and Lower NY Bays) inshore gillnet	32	None documented
Southeast Atlantic inshore gillnet	unknown	None documented
TRAWL FISHERIES:		
Atlantic shellfish bottom trawl	972	None documented
Gulf of Mexico butterflyfish trawl	2	Bottlenose dolphin, Northern GMX oceanic Bottlenose dolphin, Northern GMX continental shelf
Gulf of Mexico mixed species trawl	20	None documented
GA cannonball jellyfish trawl	1	None documented
Southeastern U.S. Atlantic, Gulf of Mexico shrimp trawl	>18,000	Bottlenose dolphin, WNA coastal Bottlenose dolphin, Eastern GMX coastal Bottlenose dolphin, Western GMX coastal Bottlenose dolphin, GMX bay, sound, estuarine West Indian Manatee, FL
MARINE AQUACULTURE FISHERIES:		
Finfish aquaculture	48	Harbor seal, WNA
Shellfish aquaculture	unknown	None documented
PURSE SEINE FISHERIES:		
Gulf of Maine Atlantic herring purse seine	30	Harbor seal, WNA Gray seal, WNA
Gulf of Maine menhaden purse seine	50	None documented
FL west coast sardine purse seine	10	Bottlenose dolphin, Eastern GMX coastal

TABLE 2 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE ATLANTIC OCEAN, GULF OF MEXICO, AND CARIBBEAN—
Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
U.S. Atlantic tuna purse seine	5	Long-finned pilot whale, WNA Short-finned pilot whale, WNA
LONGLINE/HOOK-AND-LINE FISHERIES:		
Northeast/Mid-Atlantic bottom longline/hook-and-line	46	None documented
Gulf of Maine, U.S. Mid-Atlantic tuna, shark swordfish hook-and-line/harpoon	26,223	Humpback whale, Gulf of Maine
Southeastern U.S. Atlantic, Gulf of Mexico, and Caribbean snapper-grouper and other reef fish bottom longline/hook-and-line	>5,000	None documented
Southeastern U.S. Atlantic, Gulf of Mexico shark bottom longline/hook-and-line	<125	Bottlenose dolphin, Eastern GMX coastal Bottlenose dolphin, Northern GMX continental shelf
Southeastern U.S. Atlantic, Gulf of Mexico, and Caribbean pelagic hook-and-line/harpoon	1,446	None documented
TRAP/POT FISHERIES:		
Caribbean mixed species trap/pot	>501	None documented
Caribbean spiny lobster trap/pot	>197	None documented
FL spiny lobster trap/pot	2,145	Bottlenose dolphin, Eastern GMX coastal
Gulf of Mexico blue crab trap/pot	4,113	Bottlenose dolphin, Western GMX coastal Bottlenose dolphin, Northern GMX coastal Bottlenose dolphin, Eastern GMX coastal Bottlenose dolphin, GMX Bay, Sound, & Estuarine West Indian manatee, FL
Gulf of Mexico mixed species trap/pot	unknown	None documented
Southeastern U.S. Atlantic, Gulf of Mexico golden crab trap/pot	10	None documented
Southeastern U.S. Atlantic, Gulf of Mexico stone crab trap/pot	4,453	None documented
U.S. Mid-Atlantic eel trap/pot	>700	None documented
STOP SEINE/WEIR/POUND NET FISHERIES:		
Gulf of Maine herring and Atlantic mackerel stop seine/weir	50	Gray seal, Northwest North Atlantic Harbor porpoise, GME/BF Harbor seal, WNA Minke whale, Canadian east coast White-sided dolphin, WNA
U.S. Mid-Atlantic crab stop seine/weir	2,600	None documented
U.S. Mid-Atlantic mixed species stop seine/weir/pound net (except the North Carolina roe mullet stop net)	751	None documented
DREDGE FISHERIES:		
Gulf of Maine mussel	>50	None documented
Gulf of Maine, U.S. Mid-Atlantic sea scallop dredge	233	None documented
U.S. Mid-Atlantic/Gulf of Mexico oyster	7,000	None documented
U.S. Mid-Atlantic offshore surf clam and quahog dredge	100	None documented
HAUL/BEACH SEINE FISHERIES:		

TABLE 2 - LIST OF FISHERIES COMMERCIAL FISHERIES IN THE ATLANTIC OCEAN, GULF OF MEXICO, AND CARIBBEAN—
Continued

Fishery Description	Estimated # of vessels/persons	Marine mammal species and stocks incidentally killed/injured
Caribbean haul/beach seine	15	West Indian manatee, Antillean
Gulf of Mexico haul/beach seine	unknown	None documented
Southeastern U.S. Atlantic, haul/beach seine	25	None documented
DIVE, HAND/MECHANICAL COLLECTION FISHERIES:		
Atlantic Ocean, Gulf of Mexico, Caribbean shellfish dive, hand/mechanical collection	20,000	None documented
Gulf of Maine urchin dive, hand/mechanical collection	>50	None documented
Gulf of Mexico, Southeast Atlantic, Mid-Atlantic, and Caribbean cast net	unknown	None documented
COMMERCIAL PASSENGER FISHING VESSEL (CHARTER BOAT) FISHERIES:		
Atlantic Ocean, Gulf of Mexico, Caribbean commercial passenger fishing vessel	4,000	Bottlenose dolphin, Eastern GMX coastal Bottlenose dolphin, Northern GMX coastal Bottlenose dolphin, Western GMX coastal Bottlenose dolphin, WNA coastal

List of Abbreviations and Symbols Used in Table 2: DE - Delaware; FL - Florida; GA - Georgia; GME/BF - Gulf of Maine/Bay of Fundy; GMX - Gulf of Mexico; MA - Massachusetts; NC - North Carolina; VA - Virginia; WNA - Western North Atlantic

¹ - Fishery classified based on serious injuries and mortalities of this stock, which are greater than 1 percent of the stock's PBR

² - Fishery classified by analogy.

Classification

During the proposed rulemaking stage for this rule, the Chief Counsel for Regulation of the Department of Commerce certified to the Chief Counsel for Advocacy of the Small Business Administration that this rule would not have a significant economic impact on a substantial number of small entities. The factual basis leading to the certification is repeated below.

Under existing regulations, all fishers participating in Category I or II fisheries must register under the MMPA, obtain an Authorization Certificate, and pay a fee of \$25 (with the exception of those in regions with a registration process integrated with existing state and Federal permitting processes). Additionally, fishers may be subject to a Take Reduction Plan (TRP) and requested to carry an observer. The Authorization Certificate authorizes the taking of marine mammals incidental to commercial fishing operations. NMFS has estimated that approximately 42,000 fishing vessels, most of which are small entities, operate in Category I or II fisheries, and therefore, are required to register. However, registration has been integrated with existing state or Federal registration programs for the majority of these fisheries so these fishers do not need to register separately under the

MMPA. Currently, approximately 350 fishers register directly with NMFS under the MMPA authorization program.

Though this final rule will affect approximately 350 small entities, the \$25 registration fee, with respect to anticipated revenues, is not considered a significant economic impact. If a vessel is requested to carry an observer, fishers will not incur any direct economic costs associated with carrying that observer. Potential indirect costs to individual fishers required to take observers may include: lost space on deck for catch, lost bunk space, and lost fishing time due to time needed to process bycatch data. However, effective monitoring will rotate observers among a limited number of vessels in a fishery at any given time and each vessel within an observed fishery has an equal probability of being requested to accommodate an observer. Therefore, the potential indirect costs to individual fishers are expected to be minimal since observer coverage would only be required for a small percentage of an individual's total annual fishing time. In addition, section 118 of the MMPA states that an observer will not be placed on a vessel if the facilities for quartering an observer or performing observer functions are inadequate or unsafe, thereby exempting vessels too

small to accommodate an observer from this requirement. As a result of this certification, an initial regulatory flexibility analysis is not required and was not prepared. In the event that reclassification of a fishery to Category I or II results in a TRP, economic analyses of the effects of that plan will be summarized in subsequent rulemaking actions.

This final rule contains collection-of-information requirements subject to the Paperwork Reduction Act. The collection of information for the registration of fishers under the MMPA has been approved by the Office of Management and Budget (OMB) under OMB control number 0648-0293 (0.15 hours per report for new registrants and 0.09 hours per report for renewals). The requirement for reporting marine mammal injuries or mortalities has been approved by OMB under OMB control number 0648-0292 (0.15 hours per report). These estimates include the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding these reporting burden estimates or any other aspect of the collections of information, including suggestions for reducing burden, to

NMFS and OMB (see **ADDRESSES** and **SUPPLEMENTARY INFORMATION**).

Notwithstanding any other provision of law, no person is required to respond to nor shall a person be subject to a penalty for failure to comply with a collection of information subject to the requirements of the Paperwork Reduction Act unless that collection of information displays a currently valid OMB control number.

This final rule has been determined to be not significant for the purposes of Executive Order 12866.

An environmental assessment (EA) was prepared under the National Environmental Policy Act (NEPA) for regulations to implement section 118 of the MMPA in June 1995. NMFS revised that EA relative to classifying U.S. commercial fisheries on the LOF in December 2005. Both the 1995 EA and the 2005 EA concluded that implementation of MMPA section 118 regulations would not have a significant impact on the human environment. This final rule does not make any significant change in the management of reclassified fisheries, and therefore, this final rule is not expected to change the analysis or conclusion of the 2005 EA. If NMFS takes a management action, for example, through the development of a TRP, NMFS will first prepare an environmental document, as required under NEPA, specific to that action.

This final rule will not affect species listed as threatened or endangered under the Endangered Species Act (ESA) or their associated critical habitat. The impacts of numerous fisheries have been analyzed in various biological opinions, and this final rule will not affect the conclusions of those opinions. The classification of fisheries on the LOF is not considered to be a management action that would adversely affect threatened or endangered species. If NMFS takes a management action, for example, through the development of a TRP, NMFS would conduct consultation under ESA section 7 for that action.

This final rule will have no adverse impacts on marine mammals and may have a positive impact on marine mammals by improving knowledge of marine mammals and the fisheries interacting with marine mammals through information collected from observer programs, stranding and sighting data, or take reduction teams.

This final rule will not affect the land or water uses or natural resources of the coastal zone, as specified under section 307 of the Coastal Zone Management Act.

Dated: November 19, 2007.

Samuel D. Rauch III,

Deputy Assistant Administrator for Regulatory Programs, National Marine Fisheries Service.

[FR Doc. E7-23076 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 622

[Docket No. 061121304-7053-02; I.D. 112006B]

RIN 0648-AT87

Fisheries of the Caribbean, Gulf of Mexico, and South Atlantic; Reef Fish Fishery of the Gulf of Mexico; Republication of Gulf Red Snapper Interim Management Measures

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Temporary rule; republication of interim measures.

SUMMARY: This temporary rule republishes interim measures to reduce overfishing of Gulf red snapper that were previously implemented via a temporary rule published by NMFS on April 2, 2007, and extended through March 28, 2008, by a temporary rule published by NMFS on September 24, 2007. The interim measures reduce the commercial and recreational quotas for red snapper, reduce the commercial minimum size limit for red snapper, reduce the recreational bag limit for Gulf red snapper, prohibit the retention of red snapper under the bag limit for captain and crew of a vessel operating as a charter vessel or headboat, and establish a target level of reduction of shrimp trawl bycatch mortality of red snapper. The intended effect of this temporary rule is to reinstate the text of the interim measures in the Code of Federal Regulations that was inadvertently removed.

DATES: This rule is effective November 27, 2007 through March 28, 2008.

ADDRESSES: Copies of the final environmental impact statement (FEIS) and Record of Decision (ROD) prepared for the April 2, 2007, temporary final rule (72 FR 15617) are available from Peter Hood, Southeast Regional Office, NMFS, 263 13th Avenue South, St. Petersburg, FL 33701.

SUPPLEMENTARY INFORMATION: The red snapper fishery of the Gulf of Mexico is

managed under the Fishery Management Plan (FMP) for the Reef Fish Fishery of the Gulf of Mexico, and the shrimp fishery is managed under the FMP for the Shrimp Fishery of the Gulf of Mexico. The FMPs were prepared by the Gulf of Mexico Fishery Management Council (Council) and are implemented under the authority of the Magnuson-Stevens Fishery Conservation and Management Act (Magnuson-Stevens Act) by regulations at 50 CFR part 622.

NMFS issued a temporary rule (72 FR 15617, April 2, 2007) under section 305(c) of the Magnuson-Stevens Act, to implement interim measures to reduce fishing mortality on red snapper by reducing harvest and bycatch levels. Specifically, that rule: (1) reduced red snapper total allowable catch (TAC) from 9.12 million lb (4.14 million kg) to 6.5 million lb (2.9 million kg), whole weight, resulting in a commercial quota of 3.315 million lb (1.504 million kg) and a recreational quota of 3.185 million lb (1.445 million kg); (2) reduced the commercial minimum size limit for red snapper from 15 inches (38 cm) to 13 inches (33 cm) total length (TL); (3) reduced the daily recreational bag limit from four fish to two fish per person and prohibits the captain and crew of for-hire vessels (charter vessels and headboats) from retaining the recreational bag limit; and (4) established a goal to reduce red snapper bycatch mortality in the shrimp fishery to 50 percent of the bycatch mortality that occurred during 2001-2003. These measures remain necessary to address overfishing of the red snapper resource.

Under section 305(c)(3)(B) of the Magnuson-Stevens Act, NMFS may extend the effectiveness of interim measures for one additional period of not more than 186 days, provided the public has had an opportunity to comment on the interim measures and the Council is actively preparing proposed regulations to address the overfishing on a permanent basis. NMFS solicited public comments on the interim measures in a temporary proposed rule (71 FR 75220, December 14, 2006) and received numerous comments. These comments were summarized and NMFS's responses were provided in the temporary final rule (72 FR 15617, April 2, 2007). The Council prepared joint Amendment 27/14 to the Reef Fish and Shrimp FMPs in the Gulf of Mexico (Amendment 27/14) to address overfishing of red snapper. NMFS partially approved Amendment 27/14 on October 19, 2007. The approved portions of the amendment include additional measures to end overfishing and to rebuild the red snapper stock.

To continue to address overfishing of red snapper pending implementation of more permanent measures recommended by the Council in Amendment 27/14, NMFS published a temporary rule (72 FR 54223, September 24, 2007) to extend the effective date of the interim measures contained in the April 2, 2007, temporary final rule (72 FR 15617). Although the extension of the interim measures was properly promulgated and those interim measures are still applicable, a technical error resulted in the extended interim measures not being incorporated into the Code of Federal Regulations as intended. To correct this inadvertent error, NMFS, via this temporary rule, is republishing the regulatory text of the interim measures contained in the April 2, 2007, temporary final rule (72 FR 15617), with an effective date from November 27, 2007 through March 28, 2008, which is consistent with the Magnuson-Stevens Act and with the intent of the September 24, 2007, temporary rule (72 FR 54223).

Additional details concerning the basis for these interim measures and discussion of the ongoing efforts of the Council and NMFS to evaluate and implement measures to rebuild the red snapper stock consistent with the requirements of the Magnuson-Stevens Act are contained in the preamble of the December 14, 2006, temporary proposed rule (71 FR 75220) and are not repeated here. Public comment and NMFS' responses are contained in the preamble of the April 2, 2007, temporary final rule (72 FR 15617) and are not repeated here.

Classification

The Administrator, Southeast Region, NMFS, (RA), has determined that this temporary rule is necessary to resolve an inadvertent error in the Code of Federal Regulations, and is consistent with the Magnuson-Stevens Act and other applicable laws.

This temporary rule has been determined to be not significant for purposes of Executive Order 12866.

This temporary rule is exempt from the procedures of the Regulatory Flexibility Act because the rule is issued without opportunity for prior notice and comment.

An FEIS was prepared for the interim measures contained in the April 2, 2007, temporary rule. The conditions that existed at the time the April 2, 2007, temporary rule was implemented have not changed, and the republication of those same interim measures has no additional impact beyond those already considered in the FEIS. Copies of the

FEIS are available from NMFS (see ADDRESSES).

The Assistant Administrator for Fisheries, NOAA (AA) finds good cause under 5 U.S.C. 553(b)(B) to waive prior notice and opportunity for public comment on this temporary rule. This rule would republish the same interim measures for which opportunity for public comment was solicited in a proposed interim rule published on December 14, 2006 (71 FR 75220). These same interim measures were implemented by the April 2, 2007, interim final rule (72 FR 15617) and extended by the September 24, 2007, interim rule (72 FR 54223). The conditions prompting the initial temporary rule still remain. Because the republishing of these interim measures is only necessary to resolve an inadvertent technical error that resulted in these extended interim measures not being incorporated into the Code of Federal Regulations as intended, there is no additional regulatory burden associated with this temporary rule. Therefore, the AA finds that it would be unnecessary to provide additional opportunity for public comment.

The AA also finds good cause under 5 U.S.C. 553(d)(3) to waive the delay of the effective date of this temporary rule. This republication of interim measures does not impose any additional regulatory burden on the public; it resolves a technical error that resulted in the already effective interim measures not being incorporated into the Code of Federal Regulations as intended. Therefore, NMFS finds good cause to waive the 30-day delay in effectiveness for this temporary rule.

List of Subjects in 50 CFR Part 622

Fisheries, Fishing, Puerto Rico, Reporting and recordkeeping requirements, Virgin Islands.

Dated: November 20, 2007.

Samuel D. Rauch III,

Deputy Assistant Administrator For Regulatory Programs, National Marine Fisheries Service.

■ For the reasons set out in the preamble, 50 CFR part 622 is amended as follows:

PART 622—FISHERIES OF THE CARIBBEAN, GULF, AND SOUTH ATLANTIC

1. The authority citation for part 622 continues to read as follows:

Authority: 16 U.S.C. 1801 *et seq.*

■ 2. In § 622.37, paragraph (d)(1)(iv) is suspended and paragraph (d)(1)(vi) is added to read as follows:

§ 622.37 Size limits.

* * * * *

(d) * * *

(1) * * *

(vi) Red snapper--16 inches (40.6 cm), TL, for a fish taken by a person subject to the bag limit specified in § 622.39(b)(1)(iii) and 13 inches (38.1 cm), TL, for a fish taken by a person not subject to the bag limit.

* * * * *

■ 3. In § 622.39, paragraphs (b)(1)(iii) and (b)(1)(v) are suspended and paragraphs (b)(1)(viii) and (b)(1)(ix) are added to read as follows:

§ 622.39 Bag and possession limits.

* * * * *

(b) * * *

(1) * * *

(viii) Red snapper -2. However, no red snapper may be retained by the captain or crew of a vessel operating as a charter vessel or headboat. The bag limit for such captain and crew is zero.

(ix) Gulf reef fish, combined, excluding those specified in paragraphs (b)(1)(i), (ii), (iv), (vi), (vii), and (viii) of this section and excluding dwarf sand perch and sand perch--20, but not to exceed 10 vermilion snapper.

* * * * *

■ 4. In § 622.42, paragraphs (a)(1)(i) and (a)(2) are suspended and paragraphs (a)(1)(v) and (a)(3) are added to read as follows:

§ 622.42 Quotas.

* * * * *

(a) * * *

(1) * * *

(v) Red snapper -3.315 million lb (1.504 million kg), round weight.

* * * * *

(3) *Recreational quota for red snapper.* The following quota applies to persons who harvest red snapper other than under commercial vessel permits for Gulf reef fish and the commercial quota specified in paragraph (a)(1)(v) of this section-- 3.185 million lb (1.445 million kg), round weight.

* * * * *

[FR Doc. E7-23049 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 648

[Docket No. 061109296-7009-02]

RIN 0648-XE07

Fisheries of the Northeastern United States; Atlantic Bluefish Fishery; Quota Transfer

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Temporary rule; inseason quota transfer.

SUMMARY: NMFS announces that the State of Delaware is transferring commercial bluefish quota to the State of Rhode Island from its 2007 quota. By this action, NMFS adjusts the quotas and announces the revised commercial quota for each state involved.

DATES: Effective November 21, 2007, through December 31, 2007.

FOR FURTHER INFORMATION CONTACT: Emily Bryant, Fishery Management Specialist, (978) 281-9244, fax (978) 281-9135.

SUPPLEMENTARY INFORMATION: Regulations governing the Atlantic bluefish fishery are found at 50 CFR part 648. The regulations require annual specification of a commercial quota that is apportioned among the coastal states from Florida through Maine. The process to set the annual commercial quota and the percent allocated to each state is described in § 648.160.

Two or more states, under mutual agreement and with the concurrence of the Administrator, Northeast Region, NMFS (Regional Administrator), can transfer or combine bluefish commercial quota under § 648.160(f). The Regional Administrator is required to consider the criteria set forth in § 648.160(f)(1) in the evaluation of requests for quota transfers or combinations.

Delaware has agreed to transfer 80,000 lb (36,287 kg) of its 2007 commercial quota to Rhode Island. The Regional Administrator has determined that the criteria set forth in § 648.160(f)(1) have been met. The revised bluefish quotas for calendar year 2007 are: Rhode Island, 663,790 lb (301,090 kg); and Delaware, 81,055 lb (36,766 kg).

Classification

This action is taken under 50 CFR part 648 and is exempt from review under Executive Order 12866.

Authority: 16 U.S.C. 1801 *et seq.*

Dated: November 21, 2007.

Emily Menashes,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 07-5848 Filed 11-21-07; 2:53 pm]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 648

[Docket No. 061109296-7009-02]

RIN 0648-XD64

Fisheries of the Northeastern United States; Atlantic Bluefish Fishery; Commercial Quota Harvested for New York

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Temporary rule; closure.

SUMMARY: NMFS announces that the 2007 Atlantic bluefish commercial quota allocated to the State of New York has been harvested. Vessels issued a commercial Federal fisheries permit for the Atlantic bluefish fishery may not land bluefish in New York for the remainder of calendar year 2007, unless additional quota becomes available through a transfer from another state. Regulations governing the Atlantic bluefish fishery require publication of this notification to advise New York that the quota has been harvested and to advise vessel permit holders and dealer permit holders that no commercial quota is available for landing bluefish in New York.

DATES: Effective 0001 hours, November 27, 2007, through 2400 hours, December 31, 2007.

FOR FURTHER INFORMATION CONTACT: Emily Bryant, Fishery Management Specialist, (978) 281-9244.

SUPPLEMENTARY INFORMATION: Regulations governing the Atlantic bluefish fishery are found at 50 CFR part 648. The regulations require annual specification of a commercial quota that is apportioned on a percentage basis among the coastal states from Florida through Maine. The process to set the annual commercial quota and the percent allocated to each state is described in § 648.160.

The initial total commercial quota for Atlantic bluefish for the 2007 calendar year was set equal to 8,688,760 lb (3,941 mt) (72 FR 4458, January 31, 2007). The percent allocated to vessels landing

bluefish in New York is 10.3851 percent, resulting in a commercial quota of 902,336 lb (409,927 kg). The 2007 allocation was reduced to 884,278 lb (401,106 kg) when research set-aside was deducted and after the 2006 overages had been applied.

Subsequently, during the 2007 fishing year, New York received two transfers of bluefish quota from Virginia in the amounts of 150,000 lb (68,039 kg) (72 FR 10934) and 200,000 lb (90,718 kg) (72 FR 62416). These transfers increased New York's bluefish quota allocation to 1,234,278 lb (559,859 kg).

Section 648.161(b) requires the Administrator, Northeast Region, NMFS (Regional Administrator) to monitor state commercial quotas and to determine when a state's commercial quota has been harvested. NMFS then publishes a notification in the **Federal Register** to advise the state and to notify Federal vessel and dealer permit holders that, effective upon a specific date, the state's commercial quota has been harvested and no commercial quota is available for landing bluefish in that state. The Regional Administrator has determined, based upon dealer reports and other available information, that New York has harvested its quota for 2007.

The regulations at § 648.4(b) provide that Federal permit holders agree, as a condition of the permit, not to land bluefish in any state that the Regional Administrator has determined no longer has commercial quota available. Therefore, effective 0001 hours, November 27, 2007, further landings of bluefish in New York by vessels holding bluefish commercial Federal fisheries permits are prohibited for the remainder of the 2007 calendar year, unless additional quota becomes available through a transfer and is announced in the **Federal Register**. Effective 0001 hours, November 27, 2007, federally permitted dealers are also notified that they may not purchase bluefish from federally permitted vessels that land in New York for the remainder of the calendar year, or until additional quota becomes available through a transfer from another state.

Classification

This action is required by 50 CFR part 648 and is exempt from review under Executive Order 12866.

Authority: 16 U.S.C. 1801 *et seq.*

Dated: November 21, 2007.

Emily H. Menashes,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. E7-23051 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE**National Oceanic and Atmospheric Administration****50 CFR Part 648**

[Docket No. 061020273-7001-03]

RIN 0648-XE00

Fisheries of the Northeastern United States; Summer Flounder Fishery; Commercial Quota Harvested for New Jersey

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Temporary rule; closure.

SUMMARY: NMFS announces that the 2007 summer flounder commercial quota allocated to the State of New Jersey has been harvested. Vessels issued a commercial Federal fisheries permit for the summer flounder fishery may not land summer flounder in New Jersey for the remainder of calendar year 2007, unless additional quota becomes available through a transfer from another state. Regulations governing the summer flounder fishery require publication of this notification to advise New Jersey that the quota has been harvested and to advise vessel permit holders and dealer permit holders that no commercial quota is available for landing summer flounder in New Jersey.

DATES: Effective 0001 hours, November 27, 2007, through 2400 hours, December 31, 2007.

FOR FURTHER INFORMATION CONTACT: Emily Bryant, Fishery Management Specialist, (978) 281-9244.

SUPPLEMENTARY INFORMATION:

Regulations governing the summer flounder fishery are found at 50 CFR part 648. The regulations require annual specification of a commercial quota that is apportioned on a percentage basis among the coastal states from North Carolina through Maine. The process to set the annual commercial quota and the percent allocated to each state is described in § 648.100.

The initial total commercial quota for summer flounder for the 2007 calendar year was set equal to 7,789,800 lb (3,533 mt) (71 FR 75134, December 14, 2006). This quota was increased through an emergency action to 10,267,098 lb (4,658 mt) (72 FR 2458, January 19, 2007). The percent allocated to vessels landing summer flounder in New Jersey is 16.72499 percent, resulting in a commercial quota of 1,302,843 lb (591 mt). The 2007 allocation was reduced to

1,263,758 lb (573 mt) when research set-aside was deducted.

Section 648.101(b) requires the Administrator, Northeast Region, NMFS (Regional Administrator) to monitor state commercial quotas and to determine when a state's commercial quota has been harvested. NMFS then publishes a notification in the **Federal Register** to advise the state and to notify Federal vessel and dealer permit holders that, effective upon a specific date, the state's commercial quota has been harvested and no commercial quota is available for landing summer flounder in that state. The Regional Administrator has determined, based upon dealer reports and other available information, that New Jersey has harvested its quota for 2007.

The regulations at § 648.4(b) provide that Federal permit holders agree, as a condition of the permit, not to land summer flounder in any state that the Regional Administrator has determined no longer has commercial quota available. Therefore, effective 0001 hours, November 27, 2007, further landings of summer flounder in New Jersey by vessels holding summer flounder commercial Federal fisheries permits are prohibited for the remainder of the 2007 calendar year, unless additional quota becomes available through a transfer and is announced in the **Federal Register**. Effective 0001 hours, November 27, 2007, federally permitted dealers are also notified that they may not purchase summer flounder from federally permitted vessels that land in New Jersey for the remainder of the calendar year, or until additional quota becomes available through a transfer from another state.

Classification

This action is required by 50 CFR part 648 and is exempt from review under Executive Order 12866.

Authority: 16 U.S.C. 1801 *et seq.*

Dated: November 21, 2007.

Emily H. Menashes,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. E7-23062 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE**National Oceanic and Atmospheric Administration****50 CFR Part 679**

[Docket No. 070213032-7032-01]

RIN 0648-XE05

Fisheries of the Exclusive Economic Zone Off Alaska; Reallocation of Halibut in the Gulf of Alaska

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Temporary rule; reallocation.

SUMMARY: NMFS is reallocating the projected unused amount of halibut prohibited species catch (PSC) from rockfish cooperatives in the Central Gulf of Alaska (GOA) Rockfish Pilot Program to vessels using trawl gear in the GOA. This action is necessary to provide the opportunity to vessels using trawl gear to harvest available GOA groundfish total allowable catch (TAC) under existing PSC limits.

DATES: Effective November 21, 2007, until 2400 hours, A.l.t., December 31, 2007.

FOR FURTHER INFORMATION CONTACT:

Jennifer Hogan, 907-586-7228.

SUPPLEMENTARY INFORMATION: NMFS manages the groundfish fishery in the GOA according to the Fishery Management Plan for Groundfish of the Gulf of Alaska Management Area (FMP) prepared by the North Pacific Fishery Management Council under authority of the Magnuson-Stevens Fishery Conservation and Management Act. Regulations governing fishing by U.S. vessels in accordance with the FMP appear at subpart H of 50 CFR part 600 and 50 CFR part 679.

The 2007 allocation of halibut PSC to vessels using trawl gear in the GOA is 2,000 metric tons (mt) as established by the 2007 and 2008 final harvest specifications (72 FR 9676, March 5, 2007, as corrected by 72 FR 13217, March 21, 2007) for groundfish in the GOA. Section 679.81(c) allocates 176 mt to catcher processor and catcher vessel rockfish cooperatives in the Central GOA. The website at <http://www.fakr.noaa.gov/sustainablefisheries/goarat/07rppallocations.xls> lists this amount. The remaining 1,824 mt is allocated to vessels using trawl gear not in a rockfish cooperative.

As of November 19, 2007, the Administrator, Alaska Region, NMFS (Regional Administrator), has

determined that rockfish cooperatives in the Central GOA have not used 128 mt of the allocation under § 679.21(d)(5)(iii)(B). Therefore, NMFS reallocates 128 mt of halibut PSC from rockfish cooperatives in the Central GOA to the last seasonal apportionment for vessels using trawl gear in the GOA.

The harvest specifications for halibut PSC included in the harvest specifications for groundfish in the GOA (72 FR 9676, March 5, 2007, as corrected by 72 FR 13217, March 21, 2007) are revised as follows: 48 mt to rockfish cooperatives in the Central GOA and 1,952 mt to vessels using trawl gear.

Classification

This action responds to the best available information recently obtained

from the fishery. The Assistant Administrator for Fisheries, NOAA, (AA) finds good cause to waive the requirement to provide prior notice and opportunity for public comment pursuant to the authority set forth at 5 U.S.C. 553(b)(B) as such a requirement is impracticable and contrary to the public interest. This requirement is impracticable and contrary to the public interest as it would prevent NMFS from responding to the most recent fisheries data in a timely fashion and would delay the reallocation of projected unused amounts of halibut PSC in the GOA. NMFS was unable to publish a notice providing time for public comment because the most recent, relevant data only became available as of November 19, 2007.

The AA also finds good cause to waive the 30-day delay in the effective date of this action under 5 U.S.C. 553(d)(3). This finding is based upon the reasons provided above for waiver of prior notice and opportunity for public comment.

This action is required by § 679.20 and is exempt from review under Executive Order 12866.

Authority: 16 U.S.C. 1801 *et seq.*

Dated: November 20, 2007.

Emily H. Menashes,
Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.
[FR Doc. 07-5844 Filed 11-21-07; 1:45 pm]

BILLING CODE 3510-22-S

Proposed Rules

Federal Register

Vol. 72, No. 227

Tuesday, November 27, 2007

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 25

[Docket No. NM385; Notice No. 25–07–17–SC]

Special Conditions: Boeing Model 757 Series Airplanes; Seats With Non-Traditional, Large, Non-Metallic Panels

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed special conditions.

SUMMARY: This action proposes special conditions for Boeing Model 757 series airplanes. These airplanes, as modified by Triad International Maintenance Company (TIMCO), will have a novel or unusual design feature(s) associated with seats that include non-traditional, large, non-metallic panels that would affect survivability during a post-crash fire event. The applicable airworthiness regulations do not contain adequate or appropriate safety standards for this design feature. These proposed special conditions contain the additional safety standards that the Administrator considers necessary to establish a level of safety equivalent to that established by the existing airworthiness standards.

DATES: We must receive your comments by December 12, 2007.

ADDRESSES: You must mail two copies of your comments to: Federal Aviation Administration, Transport Airplane Directorate, Attn: Rules Docket (ANM–113), Docket No. NM385, 1601 Lind Avenue, SW., Renton, Washington 98057–3356. You may deliver two copies to the Transport Airplane Directorate at the above address. You must mark your comments: Docket No. NM385. You can inspect comments in the Rules Docket weekdays, except Federal holidays, between 7:30 a.m. and 4 p.m.

FOR FURTHER INFORMATION CONTACT: Dan Jacquet, FAA, Airframe/Cabin Safety Branch, ANM–115, Transport Airplane

Directorate, Aircraft Certification Service, 1601 Lind Avenue, SW., Renton, Washington 98057–3356; telephone (425) 227–2676; facsimile (425) 227–1232; electronic mail daniel.jacquet@faa.gov.

SUPPLEMENTARY INFORMATION:

Comments Invited

We invite interested people to take part in this rulemaking by sending written comments, data, or views. The most helpful comments reference a specific portion of the special conditions, explain the reason for any recommended change, and include supporting data. We ask that you send us two copies of written comments.

We will file in the docket all comments we receive, as well as a report summarizing each substantive public contact with FAA personnel concerning these special conditions. You can inspect the docket before and after the comment closing date. If you wish to review the docket in person, go to the address in the **ADDRESSES** section of this preamble between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

We will consider all comments we receive on or before the closing date for comments. We will consider comments filed late if it is possible to do so without incurring expense or delay. We may change these special conditions based on the comments we receive.

If you want the FAA to acknowledge receipt of your comments on this proposal, include with your comments a pre-addressed, stamped postcard on which the docket number appears. We will stamp the date on the postcard and mail it back to you.

Background

On July 31, 2007, Triad International Maintenance Company (TIMCO), 623 Radar Road, Greensboro, North Carolina 27410, applied for a supplemental type certificate for installing seats that include non-traditional, large, non-metallic panels in a Boeing Model 757 series airplane. The Boeing Model 757 series airplanes, currently approved under Type Certificate No. A2NM, are swept-wing, conventional tail, twin-engine, turboprop-powered, single aisle, medium-sized transport category airplanes.

The applicable regulations to airplanes currently approved under

Type Certificate No. A2NM do not require seats to meet the more stringent flammability standards required of large, non-metallic panels in the cabin interior. At the time the applicable rules were written, seats were designed with a metal frame covered by fabric, not with large, non-metallic panels. Seats also met the then recently adopted standards for flammability of seat cushions. With the seat design being mostly fabric and metal, the contribution to a fire in the cabin had been minimized and was not considered a threat. For these reasons, seats did not need to be tested to heat release and smoke emission requirements.

Seat designs have now evolved to occasionally include non-traditional, large, non-metallic panels. Taken in total, the surface area of these panels is on the same order as the sidewall and overhead stowage bin interior panels. To provide the level of passenger protection intended by the airworthiness standards, these non-traditional, large, non-metallic panels in the cabin must meet the standards of Title 14 Code of Federal Regulations (CFR), part 25, Appendix F, parts IV and V, heat release and smoke emission requirements.

Type Certification Basis

Under the provisions of 14 CFR 21.101, TIMCO must show that the Boeing Model 757 series airplanes, as changed, continue to meet the applicable provisions of the regulations incorporated by reference in Type Certificate No. A2NM, or the applicable regulations in effect on the date of application for the change. The regulations incorporated by reference in the type certificate are commonly referred to as the “original type certification basis.” The regulations incorporated by reference in Type Certificate No. A2NM are as follows:

- For Model 757–200 airplanes—part 25, as amended by Amendment 25–1 through Amendment 25–45. In addition, an equivalent safety finding exists with respect to § 25.853(c), Compartment interiors.
- For Model 757–300 airplanes—part 25, as amended by Amendment 25–1 through Amendment 25–85 with the exception listed: Section 25.853(d)(3), Compartment interiors, at Amendment 25–72.

In addition, the certification basis includes certain special conditions,

exemptions, or later amended sections of the applicable part that are not relevant to these proposed special conditions.

If the Administrator finds that the applicable airworthiness regulations (i.e., part 25) do not contain adequate or appropriate safety standards for the Boeing Model 757 series airplanes because of a novel or unusual design feature, special conditions are prescribed under the provisions of § 21.16.

In addition to the applicable airworthiness regulations and special conditions, the Boeing Model 757 series airplanes must comply with the fuel vent and exhaust emission requirements of 14 CFR part 34 and the noise certification requirements of 14 CFR part 36.

The FAA issues special conditions, as defined in § 11.19, under § 11.38 and they become part of the type certification basis under § 21.101.

Special conditions are initially applicable to the model for which they are issued. Should the applicant apply for a supplemental type certificate to modify any other model included on the same type certificate to incorporate the same or similar novel or unusual design feature, the special conditions would also apply to the other model under § 21.101.

Novel or Unusual Design Features

The Boeing Model 757 series airplanes will incorporate the following novel or unusual design features: These models offer interior arrangements that include passenger seats that incorporate non-traditional, large, non-metallic panels in lieu of the traditional metal frame covered by fabric. The flammability properties of these panels have been shown to significantly affect the survivability of the cabin in the case of fire. These seats are considered a novel design for transport category airplanes that include Amendment 25–61 and Amendment 25–66 in the certification basis, and were not considered when those airworthiness standards were established.

The existing regulations do not provide adequate or appropriate safety standards for seat designs that incorporate non-traditional, large, non-metallic panels in their designs. In order to provide a level of safety that is equivalent to that afforded to the balance of the cabin, additional airworthiness standards, in the form of special conditions, are necessary. These special conditions supplement § 25.853. The requirements contained in these special conditions consist of applying the identical test conditions required of

all other large panels in the cabin, to seats with non-traditional, large, non-metallic panels.

Definition of “Non-Traditional, Large, Non-Metallic Panel”

A non-traditional, large, non-metallic panel, in this case, is defined as a panel with exposed-surface areas greater than 1.5 square feet installed per seat place. The panel may consist of either a single component or multiple components in a concentrated area. Examples of parts of the seat where these non-traditional panels are installed include, but are not limited to: Seat backs, bottoms and leg/foot rests, kick panels, back shells, credenzas and associated furniture. Examples of traditional exempted parts of the seat include: Arm caps, armrest close-outs such as end bays and armrest-styled center consoles, food trays, video monitors, and shrouds.

Clarification of “Exposed”

“Exposed” is considered to include panels that are directly exposed to the passenger cabin in the traditional sense, and panels that are enveloped, such as by a dress cover. Traditional fabrics or leathers currently used on seats are excluded from these special conditions. These materials must still comply with § 25.853(a) and § 25.853(c) if used as a covering for a seat cushion, or § 25.853(a) if installed elsewhere on the seat. Non-traditional, large, non-metallic panels covered with traditional fabrics or leathers will be tested without their coverings or covering attachments.

Discussion

In the early 1980s the FAA conducted extensive research on the effects of post-crash flammability in the passenger cabin. As a result of this research and service experience, we adopted new standards for interior surfaces associated with large surface area parts. Specifically, the rules require measurement of heat release and smoke emission (part 25, Appendix F, parts IV and V) for the affected parts. Heat release has been shown to have a direct correlation with post-crash fire survival time. Materials that comply with the standards (i.e., § 25.853 entitled “Compartment interiors” as amended by Amendment 25–61 and Amendment 25–66) extend survival time by approximately 2 minutes over materials that do not comply.

At the time these standards were written the potential application of the requirements of heat release and smoke emission to seats was explored. The seat frame itself was not a concern because it was primarily made of aluminum and there were only small amounts of non-

metallic materials. It was determined that the overall effect on survivability was negligible, whether or not the food trays met the heat release and smoke requirements. The requirements therefore did not address seats. The preambles to both the Notice of Proposed Rule Making (NPRM), Notice No. 85–10 (50 FR 15038, April 16, 1985) and the Final Rule at Amendment 25–61 (51 FR 26206, July 21, 1986), specifically note that seats were excluded “because the recently-adopted standards for flammability of seat cushions will greatly inhibit involvement of the seats.”

Subsequently, the Final Rule at Amendment 25–83 (60 FR 6615, March 6, 1995) clarified the definition of minimum panel size: “It is not possible to cite a specific size that will apply in all installations; however, as a general rule, components with exposed-surface areas of one square foot or less may be considered small enough that they do not have to meet the new standards. Components with exposed-surface areas greater than two square feet may be considered large enough that they do have to meet the new standards. Those with exposed-surface areas greater than one square foot, but less than two square feet, must be considered in conjunction with the areas of the cabin in which they are installed before a determination could be made.”

In the late 1990s, the FAA issued Policy Memorandum 97–112–39, *Guidance for Flammability Testing of Seat/Console Installations*, October 17, 1997 (<http://rgl.faa.gov>). That memo was issued when it became clear that seat designs were evolving to include large, non-metallic panels with surface areas that would impact survivability during a cabin fire event, comparable to partitions or galleys. The memo noted that large surface area panels must comply with heat release and smoke emission requirements, even if they were attached to a seat. If the FAA had not issued such policy, seat designs could have been viewed as a loophole to the airworthiness standards that would result in an unacceptable decrease in survivability during a cabin fire event.

In October of 2004, an issue was raised regarding the appropriate flammability standards for passenger seats that incorporated non-traditional, large, non-metallic panels in lieu of the traditional metal covered by fabric. The Seattle Aircraft Certification Office and Transport Standards Staff reviewed this design and determined that it represented the kind and quantity of material that should be required to pass the heat release and smoke emissions

requirements. We have determined that special conditions would be promulgated to apply the standards defined in § 25.853(d) to seats with large, non-metallic panels in their design.

Applicability

As discussed above, these special conditions are applicable to Boeing Model 757 series airplanes. It is not our intent, however, to require seats with large, non-metallic panels to meet § 25.853, Appendix F, parts IV and V, if they are installed in cabins of airplanes that otherwise are not required to meet these standards. Because the heat release and smoke testing requirements of § 25.853 per Appendix F, parts IV and V, are not part of the type certification basis of the Model 757, these special conditions are only applicable if the Model 757 series airplanes are in 14 CFR part 121 operations. Section 121.312 requires compliance with the heat release and smoke testing requirements of § 25.853, for certain airplanes, irrespective of the type certification bases of those airplanes. For Model 757 series airplanes, these are the airplanes that would be affected by these special conditions. Should TIMCO apply at a later date for a supplemental type certificate to modify any other model included on Type Certificate No. A2NM to incorporate the same novel or unusual design feature, the special conditions would apply to that model as well.

Conclusion

This action affects only certain novel or unusual design features on one model series of airplanes. It is not a rule of general applicability and it affects only the applicant who applied to the FAA for approval of these features on the airplane.

List of Subjects in 14 CFR Part 25

Aircraft, Aviation safety, Reporting and recordkeeping requirements.

The authority citation for these special conditions is as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701, 44702, 44704.

The Proposed Special Conditions

Accordingly, the Federal Aviation Administration (FAA) proposes the following special conditions as part of the type certification basis for Boeing Model 757 series airplanes modified by TIMCO.

1. Except as provided in paragraph 3 of these special conditions, compliance with Title 14 CFR part 25, Appendix F, parts IV and V, heat release and smoke emission, is required for seats that

incorporate non-traditional, large, non-metallic panels that may either be a single component or multiple components in a concentrated area in their design.

2. The applicant may designate up to and including 1.5 square feet of non-traditional, non-metallic panel material per seat place that does not have to comply with special condition Number 1, above. A triple seat assembly may have a total of 4.5 square feet excluded on any portion of the assembly (e.g., outboard seat place 1 square foot, middle 1 square foot, and inboard 2.5 square feet).

3. Seats do not have to meet the test requirements of Title 14 CFR part 25, Appendix F, parts IV and V, when installed in compartments that are not otherwise required to meet these requirements. Examples include:

- a. Airplanes with passenger capacities of 19 or less,
- b. Airplanes that do not have § 25.853, Amendment 25–61 or later, in their certification basis and do not need to comply with the requirements of 14 CFR § 121.312, and
- c. Airplanes exempted from § 25.853, Amendment 25–61 or later.

Issued in Renton, Washington, on November 19, 2007.

Ali Bahrami,

Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. E7–23079 Filed 11–26–07; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA–2007–0248; Directorate Identifier 2007–CE–084–AD]

RIN 2120–AA64

Airworthiness Directives; British Aerospace Aircraft Group, Scottish Division, Model Beagle B.121 Series 1, 2, 3 Airplanes

AGENCY: Federal Aviation Administration (FAA), Department of Transportation (DOT).

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: We propose to adopt a new airworthiness directive (AD) for the products listed above. This proposed AD results from mandatory continuing airworthiness information (MCAI) originated by an aviation authority of another country to identify and correct an unsafe condition on an aviation

product. The MCAI describes the unsafe condition as:

The Type Certificate Holder (TCH) has received several reports of failed Rudder torque tube assemblies. The torque tube assemblies are subject to repetitive inspection in accordance Airworthiness Directive 2060 PRE 80. The recent failures occurred in service after the inspections required by AD 2060 PRE 80 had been performed. In the event of such failures, loss of directional control through both the Rudder and Nosewheel Steering may occur. The TCH has also received reports of loose rivets attaching the inboard Anchor Assembly to the Starboard Torque Tube.

The proposed AD would require actions that are intended to address the unsafe condition described in the MCAI.

DATES: We must receive comments on this proposed AD by December 27, 2007.

ADDRESSES: You may send comments by any of the following methods:

- *Federal eRulemaking Portal:* Go to <http://www.regulations.gov>. Follow the instructions for submitting comments.

- *Fax:* (202) 493–2251.

- *Mail:* U.S. Department of Transportation, Docket Operations, M–30, West Building Ground Floor, Room W12–140, 1200 New Jersey Avenue, SE., Washington, DC 20590.

- *Hand Delivery:* U.S. Department of Transportation, Docket Operations, M–30, West Building Ground Floor, Room W12–140, 1200 New Jersey Avenue, SE., Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

Examining the AD Docket

You may examine the AD docket on the Internet at <http://www.regulations.gov>; or in person at the Docket Management Facility between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this proposed AD, the regulatory evaluation, any comments received, and other information. The street address for the Docket Office (telephone (800) 647–5527) is in the **ADDRESSES** section. Comments will be available in the AD docket shortly after receipt.

FOR FURTHER INFORMATION CONTACT: Taylor Martin, Aerospace Engineer, FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329–4138; fax: (816) 329–4090.

SUPPLEMENTARY INFORMATION:

Comments Invited

We invite you to send any written relevant data, views, or arguments about this proposed AD. Send your comments

to an address listed under the **ADDRESSES** section. Include "Docket No. FAA-2007-****; Directorate Identifier 2007-CE-084-AD" at the beginning of your comments. We specifically invite comments on the overall regulatory, economic, environmental, and energy aspects of this proposed AD. We will consider all comments received by the closing date and may amend this proposed AD because of those comments.

We will post all comments we receive, without change, to <http://www.regulations.gov>, including any personal information you provide. We will also post a report summarizing each substantive verbal contact we receive about this proposed AD.

Discussion

The United Kingdom Civil Aviation Authority, which is the aviation authority for United Kingdom, has issued AD No: G-2005-0030, dated October 12, 2005 (referred to after this as "the MCAI"), to correct an unsafe condition for the specified products. The MCAI states:

The Type Certificate Holder (TCH) has received several reports of failed Rudder torque tube assemblies. The torque tube assemblies are subject to repetitive inspection in accordance Airworthiness Directive 2060 PRE 80. The recent failures occurred in service after the inspections required by AD 2060 PRE 80 had been performed. In the event of such failures, loss of directional control through both the Rudder and Nosewheel Steering may occur. The TCH has also received reports of loose rivets attaching the inboard Anchor Assembly to the Starboard Torque Tube.

The MCAI requires the inspection of the rudder torque tube assemblies and hubs for cracking and loose rivets with conditional correction or replacement following de Havilland Support Limited Service Bulletin B121/65, Issue 2, dated August 10, 2005.

You may obtain further information by examining the MCAI in the AD docket.

Relevant Service Information

De Havilland Support Limited has issued Service Bulletin No. B121/65, Issue 2, dated August 10, 2005. The actions described in this service information are intended to correct the unsafe condition identified in the MCAI.

FAA's Determination and Requirements of the Proposed AD

This product has been approved by the aviation authority of another country, and is approved for operation in the United States. Pursuant to our bilateral agreement with this State of

Design Authority, they have notified us of the unsafe condition described in the MCAI and service information referenced above. We are proposing this AD because we evaluated all information and determined the unsafe condition exists and is likely to exist or develop on other products of the same type design.

Differences Between This Proposed AD and the MCAI or Service Information

We have reviewed the MCAI and related service information and, in general, agree with their substance. But we might have found it necessary to use different words from those in the MCAI to ensure the AD is clear for U.S. operators and is enforceable. In making these changes, we do not intend to differ substantively from the information provided in the MCAI and related service information.

We might also have proposed different actions in this AD from those in the MCAI in order to follow FAA policies. Any such differences are highlighted in a NOTE within the proposed AD.

Costs of Compliance

Based on the service information, we estimate that this proposed AD would affect about 1 product of U.S. registry. We also estimate that it would take about 1 work-hour per product to comply with the basic requirements of this proposed AD. The average labor rate is \$80 per work-hour.

Based on these figures, we estimate the cost of the proposed AD on U.S. operators to be \$80, or \$80 per product.

In addition, we estimate that any necessary follow-on actions would take about 12 work-hours and require parts costing \$10,000 for a cost of \$10,960 per product.

Authority for This Rulemaking

Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. "Subtitle VII: Aviation Programs," describes in more detail the scope of the Agency's authority.

We are issuing this rulemaking under the authority described in "Subtitle VII, Part A, Subpart III, Section 44701: General requirements." Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition

that is likely to exist or develop on products identified in this rulemaking action.

Regulatory Findings

We determined that this proposed AD would not have federalism implications under Executive Order 13132. This proposed AD would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government.

For the reasons discussed above, I certify this proposed regulation:

1. Is not a "significant regulatory action" under Executive Order 12866;
2. Is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and
3. Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

We prepared a regulatory evaluation of the estimated costs to comply with this proposed AD and placed it in the AD docket.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, under the authority delegated to me by the Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. The FAA amends § 39.13 by adding the following new AD:

British Aerospace (Scotland): Docket No. FAA-2007-0248; Directorate Identifier 2007-CE-084-AD.

Comments Due Date

- (a) We must receive comments by December 27, 2007.

Affected ADs

- (b) None.

Applicability

- (c) This AD applies to Beagle B.121 Series 1, 2, 3 airplanes, all serial numbers, certificated in any category.

Subject

- (d) Air Transport Association of America (ATA) Code 27: Flight Controls.

Reason

(e) The mandatory continuing airworthiness information (MCAI) states:

The Type Certificate Holder (TCH) has received several reports of failed Rudder torque tube assemblies. The torque tube assemblies are subject to repetitive inspection in accordance Airworthiness Directive 2060 PRE 80. The recent failures occurred in service after the inspections required by AD 2060 PRE 80 had been performed. In the event of such failures, loss of directional control through both the Rudder and Nosewheel Steering may occur. The TCH has also received reports of loose rivets attaching the inboard Anchor Assembly to the Starboard Torque Tube. The MCAI requires the inspection of the rudder torque tube assemblies and hubs for cracking and loose rivets with conditional correction or replacement in accordance with de Havilland Support Limited Service Bulletin B121/65, Issue 2, dated August 10, 2005.

Actions and Compliance

(f) Unless already done, do the following actions:

(1) Within 100 hours time-in-service (TIS) after the effective date of this AD and thereafter at intervals not to exceed 100 hours TIS, inspect the Rudder Torque Tube Assemblies following de Havilland Support Limited Service Bulletin B121/65, Issue 2, dated August 10, 2005.

(2) Before further flight, replace any cracked Rudder Torque Tube Assemblies and correct any loose rivets in the Rudder Torque Tube Assemblies that are found in the inspections required in paragraph (f)(1) of this AD, following de Havilland Support Limited Service Bulletin B121/65, Issue 2, dated August 10, 2005.

(3) After the effective date of this AD, used rudder torque assemblies held as spares for British Aerospace Aircraft Group, Scottish Division, Model Beagle B.121 Series 1, 2, 3 airplanes must be inspected following de Havilland Support Limited Service Bulletin B121/65, Issue 2, dated August 10, 2005, and found free of cracks prior to installation.

FAA AD Differences

Note: This AD differs from the MCAI and/or service information as follows: No differences.

Other FAA AD Provisions

(g) The following provisions also apply to this AD:

(1) *Alternative Methods of Compliance (AMOCs):* The Manager, Standards Office, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. Send information to ATTN: Taylor Martin, Aerospace Engineer, FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329-4138; fax: (816) 329-4090. Before using any approved AMOC on any airplane to which the AMOC applies, notify your appropriate principal inspector (PI) in the FAA Flight Standards District Office (FSDO), or lacking a PI, your local FSDO.

(2) *Airworthy Product:* For any requirement in this AD to obtain corrective actions from a manufacturer or other source, use these actions if they are FAA-approved. Corrective actions are considered FAA-approved if they are approved by the State of Design Authority (or their delegated agent). You are required to assure the product is airworthy before it is returned to service.

(3) *Reporting Requirements:* For any reporting requirement in this AD, under the provisions of the Paperwork Reduction Act (44 U.S.C. 3501 et seq.), the Office of Management and Budget (OMB) has approved the information collection requirements and has assigned OMB Control Number 2120-0056.

Related Information

(h) Refer to MCAI United Kingdom Civil Aviation Authority AD No: G-2005-0030, dated October 12, 2005; and de Havilland Support Limited Service Bulletin B121/65, Issue 2, dated August 10, 2005, for related information.

Issued in Kansas City, Missouri, on November 20, 2007.

Kim Smith,

Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. E7-23025 Filed 11-26-07; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF TRANSPORTATION**Federal Aviation Administration****14 CFR Part 39**

[Docket No. FAA-2007-0249; Directorate Identifier 2007-CE-088-AD]

RIN 2120-AA64

Airworthiness Directives; Alpha Aviation Design Limited Model R2160 Airplanes

AGENCY: Federal Aviation Administration (FAA), Department of Transportation (DOT).

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: We propose to adopt a new airworthiness directive (AD) for the products listed above that would supersede an existing AD. This proposed AD results from mandatory continuing airworthiness information (MCAI) originated by an aviation authority of another country to identify and correct an unsafe condition on an aviation product. The MCAI describes the unsafe condition as distortion of the rudder bars due to rudder control forces during aerobatic operation and nose wheel steering reaction forces. Rudder bar distortion could result in reduced control or loss of control. The proposed AD would require actions that are

intended to address the unsafe condition described in the MCAI.

DATES: We must receive comments on this proposed AD by December 27, 2007.

ADDRESSES: You may send comments by any of the following methods:

- *Federal eRulemaking Portal:* Go to <http://www.regulations.gov>. Follow the instructions for submitting comments.

- *Fax:* (202) 493-2251.

- *Mail:* U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue, SE., Washington, DC 20590.

- *Hand Delivery:* U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue, SE., Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

Examining the AD Docket

You may examine the AD docket on the Internet at <http://www.regulations.gov>; or in person at the Docket Management Facility, U.S. Department of Transportation, Docket Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue, SE., Washington, DC 20590.

Docket Management Facility between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The AD docket contains this proposed AD, the regulatory evaluation, any comments received, and other information. The street address for the Docket Office (telephone (800) 647-5527) is in the **ADDRESSES** section. Comments will be available in the AD docket shortly after receipt.

FOR FURTHER INFORMATION CONTACT: Karl Schletzbaum, Aerospace Engineer, FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329-4146; fax: (816) 329-4090.

SUPPLEMENTARY INFORMATION:**Comments Invited**

We invite you to send any written relevant data, views, or arguments about this proposed AD. Send your comments to an address listed under the **ADDRESSES** section. Include "Docket No. FAA-2007-0249; Directorate Identifier 2007-CE-088-AD" at the beginning of your comments. We specifically invite comments on the overall regulatory, economic, environmental, and energy aspects of this proposed AD. We will consider all comments received by the closing date and may amend this

proposed AD because of those comments.

We will post all comments we receive, without change, to <http://regulations.gov>, including any personal information you provide. We will also post a report summarizing each substantive verbal contact we receive about this proposed AD.

Discussion

In 1987, we issued AD 87-08-01, Amendment 39-5601, and in 1999, we issued AD 99-01-04, Amendment 39-10971. Those two ADs required actions intended to address an unsafe condition on the products listed above.

We since determined that it is necessary to expand the airplane applicability of AD 99-01-04 to require rudder bar replacement on Alpha Aviation Design Limited Model R2160 airplanes, serial numbers 1 through 378. The requirement to replace the rudder bars makes the inspection requirement of AD 87-08-01 no longer necessary.

The Civil Aviation Authority, which is the aviation authority for New Zealand, has issued AD DCA/R2000/23B, dated October 25, 2007 (referred to after this as "the MCAI"), to correct an unsafe condition for the specified products. The MCAI states that rudder control forces during aerobatic operation and nose wheel steering reaction forces may cause rudder bar distortion. Rudder bar distortion could result in reduced control or loss of control.

The MCAI requires you to replace the left and right rudder bars with reinforced rudder bars.

You may obtain further information by examining the MCAI in the AD docket.

Relevant Service Information

Alpha Aviation has issued Service Bulletin AA-SB-27-003, dated October 19, 2007. The actions described in this service information are intended to correct the unsafe condition identified in the MCAI.

FAA's Determination and Requirements of the Proposed AD

This product has been approved by the aviation authority of another country, and is approved for operation in the United States. Pursuant to our bilateral agreement with this State of Design Authority, they have notified us of the unsafe condition described in the MCAI and service information referenced above. We are proposing this AD because we evaluated all information and determined the unsafe condition exists and is likely to exist or

develop on other products of the same type design.

Differences Between This Proposed AD and the MCAI or Service Information

We have reviewed the MCAI and related service information and, in general, agree with their substance. But we might have found it necessary to use different words from those in the MCAI to ensure the AD is clear for U.S. operators and is enforceable. In making these changes, we do not intend to differ substantively from the information provided in the MCAI and related service information.

We might also have proposed different actions in this AD from those in the MCAI in order to follow FAA policies. Any such differences are highlighted in a NOTE within the proposed AD.

Costs of Compliance

Based on the service information, we estimate that this proposed AD would affect about 9 products of U.S. registry. We also estimate that it would take about 3 work-hours per product to comply with the basic requirements of this proposed AD. The average labor rate is \$80 per work-hour. Required parts would cost about \$657 per product.

Based on these figures, we estimate the cost of the proposed AD on U.S. operators to be \$8,073, or \$897 per product.

Authority for This Rulemaking

Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. "Subtitle VII: Aviation Programs," describes in more detail the scope of the Agency's authority.

We are issuing this rulemaking under the authority described in "Subtitle VII, Part A, Subpart III, Section 44701: General requirements." Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.

Regulatory Findings

We determined that this proposed AD would not have federalism implications under Executive Order 13132. This proposed AD would not have a

substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government.

For the reasons discussed above, I certify this proposed regulation:

1. Is not a "significant regulatory action" under Executive Order 12866;
2. Is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and
3. Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

We prepared a regulatory evaluation of the estimated costs to comply with this proposed AD and placed it in the AD docket.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, under the authority delegated to me by the Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. The FAA amends § 39.13 by removing Amendment 39-5601 and Amendment 39-10971, and adding the following new AD:

Alpha Aviation Design Limited: Docket No. FAA-2007-0249; Directorate Identifier 2007-CE-088-AD.

Comments Due Date

- (a) We must receive comments by December 27, 2007.

Affected ADs

- (b) This AD supersedes AD 87-08-01, Amendment 39-5601; and AD 99-01-04, Amendment 39-10971.

Applicability

- (c) This AD applies to Model R2160 airplanes, serial numbers 1 through 378, that:
 - (1) Are certificated in any category; and
 - (2) Have not installed the improved design rudder bars part number (P/N) 27.40.31.010 and P/N 27.40.31.020 following either Avions Pierre Robin Service Bulletin No. 143, dated September 8, 1995, or Alpha Aviation Service Bulletin AA-SB-27-003, dated October 19, 2007.

Subject

- (d) Air Transport Association of America (ATA) Code 27: Flight Controls.

Reason

(e) The mandatory continuing airworthiness information (MCAI) states that rudder control forces during aerobatic operation and nose wheel steering reaction forces may cause rudder bar distortion. Rudder bar distortion could result in reduced or loss of control. The MCAI requires you to replace the left and right rudder bars with reinforced rudder bars.

Restatement of Requirements of AD 99-01-04

(f) For airplanes with serial numbers 250 through 378: Unless already done, within the next 50 hours time-in-service (TIS) after March 12, 1999 (the effective date of AD 99-01-04) replace the left and right rudder bars, part number (P/N) 27.23.01.010 (left) and P/N 27.23.01.020 (right), with the reinforced rudder bars, P/N 27.40.31.010 (left) and P/N 27.40.31.020 (right) or FAA-equivalent part numbers, following Alpha Aviation Service Bulletin AA-SB-27-003, dated October 19, 2007.

New Requirements of This AD: Actions and Compliance

(g) For airplanes with serial numbers 1 through 249: Unless already done, within the next 50 hours TIS after the effective date of this AD or within the next 3 months after the effective date of this AD, whichever occurs first, replace the left and right rudder bars, P/N 27.23.05.010 (left) and P/N 27.23.05.020 (right), with the reinforced rudder bars, P/N 27.40.31.010 (left) and P/N 27.40.31.020 (right) or FAA-equivalent part numbers, following Alpha Aviation Service Bulletin AA-SB-27-003, dated October 19, 2007.

FAA AD Differences

Note: This AD differs from the MCAI and/or service information as follows: No differences.

Other FAA AD Provisions

(h) The following provisions also apply to this AD:

(1) *Alternative Methods of Compliance (AMOCs):* The Manager, Standards Office, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. Send information to ATTN: Karl Schletzbaum, Aerospace Engineer, FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City, Missouri 64106; telephone: (816) 329-4146; fax: (816) 329-4090. Before using any approved AMOC on any airplane to which the AMOC applies, notify your appropriate principal inspector (PI) in the FAA Flight Standards District Office (FSDO), or lacking a PI, your local FSDO.

(2) *Airworthy Product:* For any requirement in this AD to obtain corrective actions from a manufacturer or other source, use these actions if they are FAA-approved. Corrective actions are considered FAA-approved if they are approved by the State of Design Authority (or their delegated agent). You are required to assure the product is airworthy before it is returned to service.

(3) *Reporting Requirements:* For any reporting requirement in this AD, under the provisions of the Paperwork Reduction Act

(44 U.S.C. 3501 et seq.), the Office of Management and Budget (OMB) has approved the information collection requirements and has assigned OMB Control Number 2120-0056.

Related Information

(i) Refer to New Zealand Civil Aviation Authority AD DCA/R2000/23B, dated October 25, 2007; and Alpha Aviation Service Bulletin AA-SB-27-003, dated October 19, 2007, for related information.

Issued in Kansas City, Missouri, on November 20, 2007.

Kim Smith,

Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. E7-23017 Filed 11-26-07; 8:45 am]

BILLING CODE 4910-13-P

FEDERAL TRADE COMMISSION**16 CFR Part 260****Guides for the Use of Environmental Marketing Claims**

AGENCY: Federal Trade Commission.

ACTION: Request for public comment; announcement of public meetings.

SUMMARY: The Federal Trade Commission ("FTC" or "Commission") requests public comment on its Guides for the Use of Environmental Marketing Claims ("Green Guides" or "Guides"). The Commission is soliciting comment as part of its systematic review of all current FTC rules and guides. The Commission also is announcing plans to host public meetings to explore developments in environmental and "green energy-related" marketing.

DATES: Written comments relating to the Green Guides review must be received by February 11, 2008. The first public meeting, "Carbon Offsets and Renewable Energy Certificates," will be held on January 8, 2008 in Washington, DC. Details, including location and registration information, are set forth in a separate **Federal Register** notice published concurrently. The Commission plans to announce additional environmental marketing public meetings at later dates.

ADDRESSES: Interested parties are invited to submit written comments relating to the Green Guides review. Comments should refer to "Green Guides Regulatory Review, 16 CFR part 260, Comment, Project No. P954501" to facilitate organization of comments. A comment filed in paper form should include this reference both in the text and on the envelope, and should be mailed or delivered to the following address: Federal Trade Commission/Office of the Secretary, Room H-135

(Annex B), 600 Pennsylvania Avenue, NW., Washington, DC 20580. Comments containing confidential material must be filed in paper form, must be clearly labeled "Confidential", and must comply with Commission Rule 4.9(c).¹ The FTC is requesting that any comment filed in paper form be sent by courier or overnight service, if possible, because postal mail in the Washington area and at the Commission is subject to delay due to heightened security precautions.

Comments filed in electronic form should be submitted by following the instructions on the web-based form at <https://secure.commentworks.com/ftc-GreenGuidesReview>. To ensure that the Commission considers an electronic comment, you must file it on that web-based form. You may also visit <http://www.regulations.gov> to read this notice, and may file an electronic comment through that Web site. The Commission will consider all comments that www.regulations.gov forwards to it.

The FTC Act and other laws the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives, whether filed in paper or electronic form. Comments received will be available to the public on the FTC Web site, to the extent practicable, at <http://www.ftc.gov>. As a matter of discretion, the FTC makes every effort to remove home contact information for individuals from the public comments it receives before placing those comments on the FTC Web site. To read our policy on how we handle the information you submit—including routine uses permitted by the Privacy Act—please review the FTC's privacy policy, at <http://www.ftc.gov/ftc/privacy.shtm>.

FOR FURTHER INFORMATION CONTACT: Janice Podoll Frankle, Attorney, 202-326-3022, or Laura Koss, Attorney, 202-326-2890, Division of Enforcement, Bureau of Consumer Protection, Federal Trade Commission.

SUPPLEMENTARY INFORMATION:**I. Background**

The Commission issued the Green Guides, 16 CFR part 260, to help marketers avoid making environmental

¹ The comment must be accompanied by an explicit request for confidential treatment, including the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. The request will be granted or denied by the Commission's General Counsel, consistent with applicable law and the public interest. See Commission Rule 4.9(C), 16 CFR 4.9(c).

claims that are unfair or deceptive under Section 5 of the FTC Act, 15 U.S.C. 45.² Industry guides, such as these, are administrative interpretations of the law. Therefore, they do not have the force and effect of law and are not independently enforceable. The Commission can take action under the FTC Act, however, if a business makes environmental marketing claims inconsistent with the Guides. In any such enforcement action, the Commission must prove that the act or practice at issue is unfair or deceptive.

The Green Guides outline general principles that apply to all environmental marketing claims and then provide guidance regarding specific environmental claims. For all claims, the Guides advise: That qualifications and disclosures be sufficiently clear and prominent to prevent deception; that marketers make clear whether their claims apply to the product, the package, or a component of either; that claims not overstate an environmental attribute or benefit, expressly or by implication; and that marketers present comparative claims in a manner that makes the basis for the comparison sufficiently clear to avoid consumer deception.

The Guides then specifically address: general environmental benefit claims, such as “environmentally friendly”; degradable claims; compostable claims; recyclable claims; recycled content claims; source reduction claims; refillable claims; and ozone safe/ozone friendly claims. For each of these claims, the Green Guides explain how reasonable consumers are likely to interpret them. The Guides also describe the basic elements necessary to substantiate claims within each category and present options for qualifying specific claims to avoid deception.³ The illustrative qualifications provide “safe harbors” for marketers who want certainty about how to make environmental claims, but do not represent the only permissible approaches to qualifying a claim.

² The Commission issued the Green Guides in 1992, 57 FR 36363, and subsequently revised them in 1996 (61 FR 53311) and 1998 (63 FR 24240). The FTC also administers other rules and guides in the environmental and energy areas, pursuant to several federal statutes including the FTC Act. See Guide Concerning Fuel Economy Advertising for New Automobiles (16 CFR part 259), Appliance Labeling Rule (16 CFR part 305), Fuel Rating Rule (16 CFR part 306), Alternative Fuel Vehicles Rule (16 CFR part 309), Recycled Oil Rule (16 CFR part 311), and Labeling and Advertising of Home Insulation Rule (the “R-Value” Rule) (16 CFR part 460).

³ The Guides do not, however, establish standards for environmental performance or prescribe testing protocols.

II. Regulatory Review of the Green Guides

The Commission reviews all of its rules and guides periodically to examine their efficacy, costs, and benefits; and to determine whether to retain, modify, or rescind them. This notice commences the Commission’s review of the Green Guides.

A. General Areas of Interest for FTC Review

As part of its review, the Commission is seeking comment on a number of general issues, including the continuing need for the Guides and their economic impact, the effect of the Guides on the accuracy of various environmental claims, and the interaction of the Guides with other environmental marketing regulations. The Commission believes that this review is important to ensure that the Guides are appropriately responsive to any changes in the marketplace. Since the Commission’s last revisions in 1998, sellers and marketers increasingly have publicized the environmental attributes of certain products, packaging, services, and manufacturing processes. Moreover, sellers and marketers are making new green claims, including those regarding renewable energy, carbon offsets, and sustainability, among others, that are not currently covered by the Green Guides.

The Commission also seeks to ensure that the Guides are appropriately responsive to any changes in consumer perception of environmental claims. As the Commission recognized in originally issuing the Guides, science and technology in the environmental area are constantly changing and new developments might affect consumer perception. Thus, the Commission solicits specific consumer survey evidence and consumer perception data addressing environmental claims, including claims not currently covered by the Guides.

B. Specific Areas of Interest for FTC Review

Since the last revisions to the Guides in 1998, the Commission occasionally has received informal input regarding the efficacy of its guidance on specific claims as well as requests for clarification through additional examples. Some of the questions included in this notice, therefore, address claim-specific issues. By including these issues, the Commission intends to facilitate comment, and the inclusion or exclusion of any issue is no indication of the Commission’s intent to

make any specific modifications to the Guides.

III. Issues for Comment

The Commission requests written comment on any or all of the following questions. The Commission requests that responses to its questions be as specific as possible, including a reference to the question being answered, and reference to empirical data or other evidence wherever available and appropriate.

A. General Issues

(1) Is there a continuing need for the Guides? Why or why not?

(2) What benefits have the Guides provided to consumers? What evidence supports the asserted benefits?

(3) What modifications, if any, should be made to the Guides to increase their benefits to consumers?

(a) What evidence supports your proposed modifications?

(b) How would these modifications affect the costs the Guides impose on businesses, and in particular on small businesses?

(c) How would these modifications affect the benefits to consumers?

(4) What impact have the Guides had on the flow of truthful information to consumers and on the flow of deceptive information to consumers?

(5) What significant costs have the Guides imposed on consumers? What evidence supports the asserted costs?

(6) What modifications, if any, should be made to the Guides to reduce the costs imposed on consumers?

(a) What evidence supports your proposed modifications?

(b) How would these modifications affect the benefits provided by the Guides?

(7) Please provide any evidence that has become available since 1998 concerning consumer perception of environmental claims, including claims not currently covered by the Guides. Does this new information indicate that the Guides should be modified? If so, why, and how? If not, why not?

(8) Please provide any evidence that has become available since 1998 concerning consumer interest in particular environmental issues. Does this new information indicate that the Guides should be modified? If so, why, and how? If not, why not?

(9) What benefits, if any, have the Guides provided to businesses, and in particular to small businesses? What evidence supports the asserted benefits?

(10) What modifications, if any, should be made to the Guides to increase their benefits to businesses, and in particular to small businesses?

(a) What evidence supports your proposed modifications?

(b) How would these modifications affect the costs the Guides impose on businesses, and in particular on small businesses?

(c) How would these modifications affect the benefits to consumers?

(11) What significant costs, including costs of compliance, have the Guides imposed on businesses, and in particular on small businesses? What evidence supports the asserted costs?

(12) What modifications, if any, should be made to the Guides to reduce the costs imposed on businesses, and in particular on small businesses?

(a) What evidence supports your proposed modifications?

(b) How would these modifications affect the benefits provided by the Guides?

(13) What evidence is available concerning the degree of industry compliance with the Guides?

(a) To what extent has there been a reduction in deceptive environmental claims since the Guides were issued? Please provide any supporting evidence. Does this evidence indicate that the Guides should be modified? If so, why, and how? If not, why not?

(b) To what extent have the Guides reduced marketers' uncertainty about which claims might lead to FTC law enforcement actions? Please provide any supporting evidence. Does this evidence indicate that the Guides should be modified? If so, why, and how? If not, why not?

(14) Are there claims addressed in the Guides on which guidance is no longer needed? If so, explain. Please provide supporting evidence.

(15) What potentially unfair or deceptive environmental marketing claims, if any, are not covered by the Guides?

(a) What evidence demonstrates the existence of such claims?

(b) With reference to such claims, should the Guides be modified? If so, why, and how? If not, why not?

(16) What modifications, if any, should be made to the Guides to account for changes in relevant technology or economic conditions? What evidence supports the proposed modifications?

(17) Do the Guides overlap or conflict with other federal, state, or local laws or regulations? If so, how?

(a) What evidence supports the asserted conflicts?

(b) With reference to the asserted conflicts, should the Guides be modified? If so, why, and how? If not, why not?

(c) Is there evidence concerning whether the Guides have assisted in

promoting national consistency with respect to the regulation of environmental claims? If so, please provide that evidence.

(18) Are there international laws, regulations, or standards with respect to environmental marketing claims that the Commission should consider as it reviews the Guides, such as the International Organization for Standardization ("ISO") 14021, Environmental Labels and Declarations—Self-Declared Environmental Claims? If so, what are they? Should the Guides be modified in order to harmonize with these international laws, regulations, or standards? If so, why, and how? If not, why not?

B. Specific Issues

(1) Should the Guides be revised to include guidance regarding renewable energy or carbon offset claims? If so, why, and what guidance should be provided? If not, why not?

(a) What evidence supports making your proposed revision(s)?

(b) What evidence is available concerning consumer understanding of the terms "renewable energy" and "carbon offset"?

(c) What evidence constitutes a reasonable basis to support each such claim?

(2) Should the Guides be revised to include guidance regarding "sustainable" claims? If so, why, and what guidance should be provided? If not, why not?

(a) What evidence supports making your proposed revision(s)?

(b) What evidence is available concerning consumer understanding of the term "sustainable"?

(c) What evidence constitutes a reasonable basis to support a "sustainable" claim?

(3) Should the Guides be revised to include guidance regarding "renewable" claims? If so, why, and what guidance should be provided? If not, why not?

(a) What evidence supports making your proposed revision(s)?

(b) What evidence is available concerning consumer understanding of the term "renewable"?

(c) What evidence constitutes a reasonable basis to support a "renewable" claim?

(4) The Guides provide that a recycled content claim may be made only for materials that have been recovered or otherwise diverted from the solid waste stream, either during the manufacturing process or after consumer use. Do the current Guides provide sufficient guidance for recycled content claims for textile products? If so, why? If not, why

not, and what guidance should be provided? What evidence supports making your proposed revision(s)?

(5) The Guides suggest that recycled content be calculated on the annual weighted average of a product. Should the Guides be revised to include alternative method(s) of calculating recycled content, e.g., based on the average recycled content within a product line, or an average amount of recycled content used by a manufacturer across many or all of its product lines? If so, why, and what is the appropriate method(s) of calculation? If not, why not? What evidence supports making your proposed revision(s)?

(6) The Guides provide that an unqualified claim that a product or package is degradable, biodegradable or photodegradable should be substantiated by competent and reliable scientific evidence that the entire product or package will completely break down and return to nature within a "reasonably short period of time after customary disposal." Should the Guides be revised to provide more specificity with respect to the time frame for product decomposition? If so, why, and what should the time frame be? If not, why not? What evidence supports making your proposed revision(s)?

IV. Public Meetings

Because of the wide-reaching issues involved in environmental marketing, the Commission also believes it would be beneficial to facilitate public dialogue on select issues by hosting public meetings. Commission staff will review and consider information gathered at these meetings in addition to the public comments in formulating its final recommendation to the Commission concerning the Green Guides review. As noted above, the first public meeting, to be held on January 8, 2008, will address carbon offsets and renewable energy certificates. The Commission plans to announce additional public meetings addressing other green topics, such as green labeling and advertising developments and consumer perception of green marketing claims.

List of Subjects in 16 CFR Part 260

Advertising, Environmental claims, Labeling, Trade practices.

Authority: 15 U.S.C. 41–58.

By direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. E7–23007 Filed 11–26–07; 8:45 am]

BILLING CODE 6750-01-P

FEDERAL TRADE COMMISSION

16 CFR Part 260

Guides for the Use of Environmental Marketing Claims; Carbon Offsets and Renewable Energy Certificates; Public Workshop

AGENCY: Federal Trade Commission.

ACTION: Announcement of public workshop; request for public comment.

SUMMARY: The Federal Trade Commission (“FTC” or “Commission”) is planning to host a public workshop on January 8, 2008 to examine the emerging market for carbon offsets (*i.e.*, greenhouse gas emission reduction products) and renewable energy certificates, and related advertising claims. The workshop is a component of the Commission’s regulatory review of the Guides for the Use of Environmental Marketing Claims, which is being announced in a separate **Federal Register** notice published concurrently. **DATES:** The workshop will be held on Tuesday, January 8, 2008, from 9 a.m. to 5 p.m. at the FTC’s Satellite Building Conference Center, located at 601 New Jersey Avenue, NW., Washington, DC. Any written comments related to the workshop must be received by January 25, 2008.

ADDRESSES: Registration Information: The workshop is open to the public, and there is no fee for attendance. The FTC also plans to make this workshop available via a webcast (see <http://www.ftc.gov/bcp/workshops/carbonoffsets/index.shtml>). For admittance to the Conference Center, all attendees will be required to show a valid photo identification, such as a driver’s license. The FTC will accept pre-registration for this workshop. Pre-registration is not necessary to attend, but is encouraged so that we may better plan this event. To pre-register, please e-mail your name and affiliation to carbonworkshop@ftc.gov. When you pre-register, we will collect your name, affiliation, and your e-mail address. This information will be used to estimate how many people will attend. We may use your e-mail address to contact you with information about the workshop.

Under the Freedom of Information Act (“FOIA”) or other laws, we may be required to disclose to outside organizations the information you provide. For additional information, including routine uses permitted by the Privacy Act, see the Commission’s Privacy Policy at <http://www.ftc.gov/ftc/privacy.htm>. The FTC Act and other laws the Commission administers

permit the collection of this contact information to consider and use for the above purposes.

Written and Electronic Comments: The submission of comments is not required for attendance at the workshop. If you wish to submit written or electronic comments about the topics to be discussed at the workshop, such comments must be received by January 25, 2008. Such comments may be submitted before or after the workshop at the discretion of the commenter. Comments should refer to “Carbon Offset Workshop—Comment, Project No. P074207,” to facilitate organization of comments. A comment filed in paper form should include this reference both in the text and on the envelope, and should be mailed or delivered to the following address: Federal Trade Commission/Office of the Secretary, Room H-135 (Annex O), 600 Pennsylvania Avenue, NW., Washington, DC 20580. Comments containing confidential material must be filed in paper form; must be clearly labeled “Confidential;” and must comply with Commission Rule 4.9(c).¹ The FTC is requesting that any comment filed in paper form be sent by courier or overnight service, if possible, because postal mail in the Washington area and at the Commission is subject to delay due to heightened security precautions.

Comments filed in electronic form should be submitted by following the instructions on the web-based form at <http://secure.commentworks.com/ftc-carbonworkshop>. To ensure that the Commission considers an electronic comment, you must file it on that web-based form. You may also visit <http://www.regulations.gov> to read this notice, and may file an electronic comment through that Web site. The Commission will consider all comments that <http://www.regulations.gov> forwards to it.

The FTC Act and other laws the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives, whether filed in paper or electronic form. Comments received will be available to the public on the FTC Web site, to the extent practicable, at <http://www.ftc.gov>. As a matter of discretion,

¹ The comment must be accompanied by an explicit request for confidential treatment, including the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. The request will be granted or denied by the Commission’s General Counsel, consistent with applicable law and the public interest. See Commission Rule 4.9(c), 16 CFR 4.9(c).

the FTC makes every effort to remove home contact information for individuals from the public comments it receives before placing those comments on the FTC Web site. To read our policy on how we handle the information you submit—including routine uses permitted by the Privacy Act—please review the FTC’s privacy policy, at <http://www.ftc.gov/ftc/privacy.shtm>.

FOR FURTHER INFORMATION CONTACT: Hampton Newsome, Attorney, 202–326–2889, Division of Enforcement, Bureau of Consumer Protection, Federal Trade Commission.

SUPPLEMENTARY INFORMATION:

I. Introduction

The FTC staff is planning to conduct a one-day workshop on January 8, 2008 related to the marketing of greenhouse gas reduction credits (commonly referred to as “carbon offsets”) and renewable energy certificates (“RECs”). The workshop will focus on consumer protection issues in these markets, such as consumer perception of carbon offset and REC advertising claims and substantiation for such claims. This workshop is one component of the Commission’s regulatory review of the Guides for the Use of Environmental Marketing Claims (16 CFR Part 260), which the FTC is announcing in a separate, concurrent **Federal Register** notice.² The FTC is seeking comment on the issues that will be addressed at this workshop. Comments may be submitted before or after the workshop provided they are received by January 25, 2008 as explained in the “WRITTEN AND ELECTRONIC COMMENTS” section of this notice.

This notice addresses several issues related to the upcoming workshop. It provides background on carbon offsets and RECs. It briefly discusses the existing regulatory framework in this area, including the FTC’s consumer protection authority. In addition, the notice discusses consumer protection issues raised by the marketing of offsets and RECs, as well as marketing and advertising claims based on the purchase of these products. The notice concludes with a short description of possible issues for discussion at the workshop and questions for comment.

² The Commission reviews all of its rules and guides periodically. These reviews seek information about the costs and benefits of the Commission’s existing rules and guides and their regulatory and economic impact. The information obtained during these reviews assists the Commission in identifying rules and guides that warrant modification or rescission.

II. Background

A. Carbon Offsets and RECs

The market for the sale of carbon offsets in the United States has experienced significant growth in the last two years.³ The FTC's workshop, therefore, will focus primarily on consumer protection issues involving the newly-emerging carbon offset market. Because the REC market is closely associated with the sale of carbon offsets, the workshop also will address REC marketing.⁴ This notice briefly describes these products, as well as the current regulatory framework in which these activities take place.

Carbon Offsets: In general, carbon offsets are credits or certificates that represent the right to claim responsibility for greenhouse gas emission reductions. For example, a carbon offset provider might use offset proceeds to pay for landfill methane collection activities or tree planting in an effort to reduce greenhouse gasses. In some cases, carbon offset sellers use the proceeds to purchase RECs (discussed below). By acquiring these greenhouse gas reduction credits, purchasers, including individuals and businesses, seek to reduce their "carbon footprints" or to make themselves "carbon neutral." For example, a consumer who flies across the country is "responsible" for a percentage of the carbon emitted from the fossil fuel burned by the plane. That consumer can purchase a certificate that funds activities that purport to reduce carbon emissions elsewhere, in quantities equal to all, or a portion, of the carbon for which that consumer is "responsible." Additionally, some businesses purchase offsets to provide a basis for their advertising claims (e.g., "our coffee is carbon neutral").

Renewable Energy Certificates ("RECs"): Generally, retail electricity customers can support renewable energy⁵ through one of two methods: by purchasing renewable electricity or by purchasing renewable energy certificates.⁶ Under the first approach, consumers purchase renewable energy

through traditional electricity contracts with their local utility or power provider, in areas in which such energy is sold.⁷ This energy is often more expensive to produce than conventional energy; consequently, consumers usually pay a premium.⁸ Some generators who cannot sell all of their renewable energy at a sufficient premium in their "home" market, therefore, may find it advantageous to split their output into two products: The electricity itself and certificates (RECs) representing the renewable attributes of that electricity. Under this second approach, generators sell their electricity at market prices applicable to conventionally-produced power. Generators then charge for the electricity's renewable attribute separately by selling certificates to individuals and business purchasers across the country who use them to characterize the conventional electricity they buy as renewable.⁹ The REC market, therefore, helps renewable energy generators by significantly expanding the number of potential renewable energy purchasers, possibly avoiding transmission costs associated with traditional contracts, and helping to ameliorate supply and demand problems associated with the intermittent operation of some renewable energy facilities (e.g., solar power facilities).¹⁰

B. Regulatory Framework

Offset and REC sales can generally occur in two types of markets: (1) Markets that facilitate compliance with regulatory targets (so called "mandatory" or "compliance" markets),

and (2) markets unrelated to existing regulatory programs (so called "voluntary" markets).

RECs currently play a role in mandatory markets. For example, some states require certain electricity providers to purchase a minimum percentage of their electricity from renewable sources. Purchasing renewable energy directly, however, is not always practical. Thus, some states allow providers to meet their quotas, usually called "renewable portfolio standards," through the purchase of RECs. Although there are no current mandatory markets for carbon offsets in the United States, there are ongoing efforts at the state level to develop greenhouse gas reduction programs that may impact carbon offset sales in the future.¹¹ Because the sale of RECs to meet regulatory targets already involves ongoing state oversight, and there are no current, mandatory markets for carbon offsets, the workshop will concentrate on marketing in the voluntary market.

Where offsets and RECs are not generated to meet regulatory targets, they are bought and sold in a voluntary market to meet demand. In this voluntary market, no federal agency currently has a comprehensive environmental regulatory program.¹² In the absence of national regulation, voluntary third-party certification programs have arisen, and more are under development, to help reduce inappropriate practices and to provide guidance to marketers through the development of industry standards.

The FTC, however, has an important role to play in combating unfair and deceptive practices in this market. In carrying out this mission, the Commission enforces the FTC Act, which states that unfair or deceptive trade practices are unlawful.¹³ In interpreting the FTC Act, the Commission has determined that a representation, omission, or practice is deceptive if it is likely to mislead

⁷ Electricity generated from renewable sources is physically indistinguishable from conventional electricity once it is introduced into the power grid. Therefore, it is impossible for consumers to determine that the electricity that flows into their homes is generated by renewable energy. By purchasing a certain amount of renewable electricity through their utility, consumers simply buy the right to call the electricity they use "renewable" and ensure that an equivalent amount of renewable electricity is supplied to the power grid.

⁸ While some generators may be able to sell renewable energy at the same price as, or even lower prices than, conventional electricity, they nonetheless may be able to charge premium prices—either through direct sales or the marketing of certificates.

⁹ The certificate represents a property right in the technological and environmental attributes of renewable energy. The precise nature of the attributes represented by a REC, however, continues to be a matter of discussion. Generally, one REC represents the right to describe one megawatt of electricity as "renewable." Currently, there is no uniform or mandatory definition of a REC.

¹⁰ See Holt, Ed and Bird, Lori, "Emerging Markets for Renewable Energy Certificates: Opportunities and Challenges," National Renewable Energy Laboratory (Jan. 2005) at 8–9.

¹¹ See, e.g., Regional Greenhouse Gas Initiative, <http://www.rggi.org/>.

¹² The Environmental Protection Agency has established the Green Power Partnership, a voluntary program to encourage organizations in the United States to purchase renewable power through RECs and other renewable energy products (<http://www.epa.gov/grmpower/>).

¹³ 15 U.S.C. 45. An act or practice is unfair if the injury it causes, or is likely to cause, is substantial, not outweighed by other benefits, and not reasonably avoidable. See Section 5(n) of the FTC Act, 15 U.S.C. 5(n); see also FTC Policy Statement on Unfairness, appended to *International Harvester Co.*, 104 F.T.C. 949, 1070 (1984) (<http://www.ftc.gov/bcp/policystmt/ad-unfair.htm>).

³ See, e.g., Hamilton, Katherine, et al., "State of the Voluntary Carbon Market 2007: Picking Up Steam," New Carbon Finance and The Ecosystem Marketplace (July 17, 2007) (http://ecosystemmarketplace.com/documents/acrobat/StateoftheVoluntaryCarbonMarket-18July_Final.pdf).

⁴ RECs are known also as green certificates, green tags, or tradable renewable certificates.

⁵ Renewable energy, such as wind and solar power, is energy derived from sources that are constantly replenished. See, e.g., http://www.nrel.gov/learning/re_basics.html and <http://www.epa.gov/greenpower/whatis/renewableenergy.htm>.

⁶ Some consumers may also have the option of producing their own electricity.

consumers acting reasonably in the circumstances and is material.¹⁴

Under the FTC Act, all marketers making express or implied claims about the attributes of their product or service must have a reasonable basis for their claims at the time they make them. In the realm of environmental advertising, a reasonable basis often requires competent and reliable scientific evidence. Such evidence includes tests, research, studies, or other evidence, based on the expertise of professionals in the relevant area, that have been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results.

In exercising its authority under the FTC Act or other statutes, the FTC has developed a variety of rules and guides related to energy and environmental marketing practices.¹⁵ One of these, the Guides for the Use of Environmental Marketing Claims (“Green Guides”), addresses the application of Section 5 of the FTC Act to environmental advertising and marketing practices.¹⁶ The Green Guides provide information on consumer interpretation of certain environmental marketing claims so that marketers can avoid making false or misleading claims. The Guides focus on the way in which consumers understand environmental claims and not necessarily the technical or scientific definition of various terms.

While the FTC has often addressed consumer protection issues related to energy and environmental issues, the FTC does not have the authority or expertise to establish environmental performance standards. Accordingly, we do not plan to develop environmental standards for carbon offsets and RECs. Instead, the FTC’s efforts in this area will focus on our traditional consumer

protection role, addressing deceptive and unfair practices under the FTC Act.

C. Consumer Protection Issues

Carbon offset and REC marketing activities raise several consumer protection issues. These issues stem both from claims for offset and REC products themselves and from claims for other products based on offset and REC purchases (e.g., “our snacks are made with green electricity”). As discussed in more detail below, the nature of these products, consumer understanding of claims, and substantiation of claims all raise consumer protection challenges for offset and REC marketers.

The nature of offset and REC claims raises particular challenges because consumers cannot easily verify that they are receiving that for which they paid. For example, most consumers would have great difficulty confirming that their payments actually fund projects that may take place in a distant location. Moreover, even if a consumer could verify a project’s existence, it likely would be impossible for the average consumer to determine whether the scientifically complex project actually reduces atmospheric carbon in the amount claimed, or how much the consumer’s offset purchase actually contributes to the project.¹⁷ As a result, the potential for deception is greater than with more tangible products for which consumers more easily can confirm most advertising claims.

In addition, consumer interpretation of offset and REC-related claims is an essential factor in addressing consumer protection questions in these markets. We are not aware of any research that addresses consumer understanding of advertising claims related to carbon offsets and RECs. As a result, there appear to be many open questions. For example, when consumers buy these products, do they know what they are buying? How do consumers interpret express or implied claims about environmental benefits from offsets and RECs? Do consumers assume that their offset purchases are creating reductions in greenhouse gas emissions beyond what would have otherwise occurred without offset sales? How quickly do they believe reductions occur? Should marketers consider consumer understanding about the incidental benefits of renewable energy, such as air pollutant reductions or regional environmental improvements? Do

¹⁷ Similarly, it is difficult for consumers to determine for themselves whether the RECs they purchase actually represent the environmental attributes of renewable energy generation.

consumers interpret REC and offset claims to include implied claims of broader (or narrower) environmental benefit? Questions of consumer interpretation are important because marketers must ensure that all reasonable interpretations of their claims are truthful, not misleading, and substantiated.

Substantiation in particular can pose challenges in the REC and offset markets. For example, bringing RECs and offsets to market may involve multiple transactions and a large number of entities; consequently, the methods used to track RECs and offsets through the market are often complicated. In addition, efforts to verify the validity of these products can be difficult because the underlying activities may take place in remote locations or over an extended time period. Inadequate tracking and verification systems could lead to substantiation problems, even for marketers acting in good faith, and create opportunities for bad actors to deceive consumers. For example, marketers could inadvertently, or intentionally, sell multiple certificates based on the same carbon reduction or renewable energy activities (i.e., “double counting”).

One carbon offset issue, commonly referred to as “additionality,” has generated significant discussion.¹⁸ “Additionality” addresses whether carbon offset consumers are paying for a project that would have occurred without the offset market. In the view of many involved with this market,¹⁹ offset sellers have a duty to demonstrate that their underlying greenhouse gas reduction projects would not have occurred but for the sale of the offset; otherwise, they argue, sellers are not really reducing greenhouse gas

¹⁸ “Additionality” is a term generally associated with mandatory carbon reduction programs implemented pursuant to the Kyoto Protocol, an international agreement under the United Nations Framework Convention on Climate Change (<http://unfccc.int/resource/docs/convkp/kpeng.pdf>). While no such mandatory program exists in the United States, many offset marketers and other interested parties here have looked to the Kyoto framework in developing practices in the voluntary offset market in the United States.

¹⁹ See, e.g., “A Consumers’” Guide to Retail Carbon Offset Providers,” Clean Air-Cool Planet (2006) (<http://www.cleanair-coolplanet.org/ConsumersGuidetoCarbonOffsets.pdf>); Kollmus, A., “Voluntary Offsets For Air-Travel Carbon Emissions: Evaluations and Recommendations of Thirteen Offset Companies,” Tufts Climate Initiative (Dec. 2006) (http://www.tufts.edu/tie/tci/pdf/TCL_Carbon_Offsets_Paper_April-2-07.pdf); and “The Green-e Greenhouse Gas Emission Reduction Product Certification Program Standard,” Center for Resource Solutions (June 2007) (http://resourcesolutions.org/mv/docs/Ge_GHG_Product_Standard_V1.pdf).

¹⁴ See FTC Policy Statement on Deception, appended to *Cliffdale Associates, Inc.*, 103 F.T.C. 110, 174 (1984) (<http://www.ftc.gov/bcp/policystmt/ad-decept.htm>).

¹⁵ See Guide Concerning Fuel Economy Advertising for New Automobiles (16 CFR part 259), Guides for the Use of Environmental Marketing Claims (16 CFR part 260), Appliance Labeling Rule (16 CFR part 305), Fuel Rating Rule (16 CFR part 306), Alternative Fuel Vehicles Rule (16 CFR part 309), Recycled Oil Rule (16 CFR part 311), and Labeling and Advertising of Home Insulation Rule (the “R-Value” Rule) (16 CFR part 460).

¹⁶ FTC guides “are administrative interpretations of laws administered by the Commission for the guidance of the public in conducting its affairs in conformity with legal requirements.” 16 CFR part 17. Conduct that is inconsistent with the guides may result in corrective action by the Commission, if after investigation, the Commission has reason to believe that the conduct is unfair or deceptive to consumers.

emissions. Under this view, for example, it would not be appropriate to sell offsets based on a project (e.g., capturing methane from a landfill) implemented to comply with existing environmental regulations because any greenhouse gas reductions would have occurred without the sale of the offsets. The practical application of the "additionality" concept to specific fact scenarios has raised a large number of questions and produced a variety of opinions among industry members and other stakeholders.

III. Issues and Questions for Discussion at the Workshop

As discussed above, the Commission's public workshop will explore advertising claims for carbon offsets and RECs, as well as advertising claims based on the purchase of those products. We have identified several possible issues for discussion at the workshop: (1) Trends in marketing carbon offsets and RECs, (2) the nature of the commodities in question (i.e., the property rights transferred from seller to buyer through the sale of offsets and RECs), (3) product marketing based on offset or REC purchases, (4) consumer perception of carbon offset and REC claims, (5) potential market problems such as double-counting and other forms of fraud, (6) third-party certification and other standard-setting programs, (7) the issue of "additionality" for carbon offsets and its relationship to potential consumer deception, (8) the use of RECs as a basis for carbon offset claims, (9) the state of substantiation for offsets and REC claims, and (10) the need for additional FTC guidance in these areas.

In addition to considering these possible topics, the Commission invites written comments on any or all of the following questions regarding the consumer protection aspects of the carbon offset and REC market. The Commission requests that responses to these questions be as specific as possible, including a reference to the question being answered, and reference to empirical data or other evidence wherever available and appropriate.

(1) What express claims are sellers making for carbon offsets and RECs? What claims, if any, are implied by that advertising? How do consumers interpret these claims? Please provide any supporting evidence. What evidence constitutes a reasonable basis to support these claims? What challenges do offset and REC sellers face in substantiating their claims? Is there evidence that any claims in the current marketplace are unsubstantiated or otherwise deceptive?

(2) What express claims are companies making for their products and services based on their purchase of carbon offsets or RECs

(e.g., "our product is made with renewable energy")? What claims, if any, are implied by that advertising? How do consumers interpret these claims? Please provide any supporting evidence. What evidence constitutes a reasonable basis to support these claims? Is there evidence that any claims in the current marketplace are unsubstantiated or otherwise deceptive?

(3) When consumers purchase carbon offsets or RECs, what property rights do they acquire?

(4) When consumers purchase carbon offsets or RECs, what do they think they are buying? Please provide any supporting evidence.

(5) What impact do consumers believe their carbon offset purchases will have on the future quantities of greenhouse gasses in the atmosphere? Please provide any supporting evidence.

(6) Do consumers understand that some activities supported by carbon offset programs do not result in immediate carbon emission reductions? If so, when do consumers expect such offset programs will have an impact? Please provide any supporting evidence.

(7) What is the relationship between the concept of "additionality" in carbon offset markets and the FTC's standard for deception under the FTC Act?

(8) Please identify state laws that specifically address consumer protection issues in the carbon offset and REC markets. Please explain how the laws address these issues and whether they are effective.

(9) Please identify third-party and self-regulatory programs that address consumer protection issues in the carbon offset and REC markets. Please explain how the programs address these issues and whether they are effective.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. E7-23006 Filed 11-26-07; 8:45 am]

BILLING CODE 6750-01-P

COMMODITY FUTURES TRADING COMMISSION

17 CFR Part 150

RIN 3038-AC40

Risk Management Exemption From Federal Speculative Position Limits

AGENCY: Commodity Futures Trading Commission.

ACTION: Notice of proposed rulemaking.

SUMMARY: Section 150.2 of the Commodity Futures Trading Commission's ("Commission") regulations imposes limits on the size of speculative positions that traders may hold or control in futures and futures equivalent option contracts on certain designated agricultural commodities named therein. Section 150.3 lists

certain types of positions that may be exempted from these Federal speculative position limits. The Commission is proposing to provide an additional exemption for "risk management positions." A risk management position would be defined as a futures or futures equivalent position, held as part of a broadly diversified portfolio of long-only or short-only futures or futures equivalent positions, that is based upon either: A fiduciary obligation to match or track the results of a broadly diversified index that includes the same commodity markets in fundamentally the same proportions as the futures or futures equivalent position; or a portfolio diversification plan that has, among other substantial asset classes, an exposure to a broadly diversified index that includes the same commodity markets in fundamentally the same proportions as the futures or futures equivalent position. The exemption would be subject to conditions, including that the positions must be passively managed, must be unleveraged, and may not be carried into the spot month.

DATES: Comments must be received on or before January 28, 2008.

ADDRESSES: Comments should be submitted to David Stawick, Secretary, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street, NW., Washington, DC 20581. Comments also may be sent by facsimile to (202) 418-5521, or by electronic mail to secretary@cftc.gov. Reference should be made to "Proposed Risk Management Exemption from Federal Speculative Position Limits." Comments may also be submitted by connecting to the Federal eRulemaking Portal at <http://www.regulations.gov> and following comment submission instructions.

FOR FURTHER INFORMATION CONTACT: Donald Heitman, Senior Special Counsel, Division of Market Oversight, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street, NW., Washington, DC 20581, telephone (202) 418-5041, facsimile number (202) 418-5507, electronic mail dheitman@cftc.gov; or John Fenton, Director of Surveillance, Division of Market Oversight, telephone (202) 418-5298, facsimile number (202) 418-5507, electronic mail jfenton@cftc.gov.

SUPPLEMENTARY INFORMATION:

I. Background

A. Statutory Framework

Speculative position limits have been a tool for the regulation of the U.S. futures markets since the adoption of the Commodity Exchange Act of 1936. Section 4a(a) of the Commodity Exchange Act ("Act"), 7 U.S.C. 6a(a), states that:

Excessive speculation in any commodity under contracts of sale of such commodity for future delivery made on or subject to the rules of contract markets or derivatives transaction execution facilities causing sudden or unreasonable fluctuations or unwarranted changes in the price of such commodity, is an undue and unnecessary burden on interstate commerce in such commodity.

Accordingly, section 4a(a) of the Act provides the Commission with the authority to:

Fix such limits on the amounts of trading which may be done or positions which may be held by any person under contracts of sale of such commodity for future delivery on or subject to the rules of any contract market or derivatives transaction execution facility as the Commission finds are necessary to diminish, eliminate, or prevent such burden.

This longstanding statutory framework providing for Federal speculative position limits was supplemented with the passage of the Futures Trading Act of 1982, which acknowledged the role of exchanges in setting their own speculative position limits. The 1982 legislation also provided, under section 4a(e) of the Act, that limits set by exchanges and approved by the Commission were subject to Commission enforcement.

Finally, the Commodity Futures Modernization Act of 2000 ("CFMA") established designation criteria and core principles with which a designated contract market ("DCM") must comply to receive and maintain designation. Among these, Core Principle 5 in section 5(d) of the Act states:

Position Limitations or Accountability—To reduce the potential threat of market manipulation or congestion, especially during trading in the delivery month, the board of trade shall adopt position limitations or position accountability for speculators, where necessary and appropriate.

B. Regulatory Framework

The regulatory structure based upon these statutory provisions consists of three elements, the levels of the speculative position limits, certain exemptions from the limits (for hedging, spreading/arbitrage, and other positions), and the policy on aggregating commonly owned or controlled

accounts for purposes of applying the limits. This regulatory structure is administered under a two-pronged framework. Under the first prong, the Commission establishes and enforces speculative position limits for futures contracts on a limited group of agricultural commodities. These Federal limits are enumerated in Commission regulation 150.2, and apply to the following futures and option markets: Chicago Board of Trade ("CBOT") corn, oats, soybeans, wheat, soybean oil, and soybean meal; Minneapolis Grain Exchange ("MGE") hard red spring wheat and white wheat; ICE Futures U.S. (formerly the New York Board of Trade) cotton No. 2; and Kansas City Board of Trade ("KCBOT") hard winter wheat. Under the second prong, individual DCMs establish and enforce their own speculative position limits or position accountability provisions (including exemption and aggregation rules), subject to Commission oversight and separate authority to enforce exchange-set speculative position limits approved by the Commission. Thus, responsibility for enforcement of speculative position limits is shared by the Commission and the DCMs.¹

Commission regulation 150.3, "Exemptions," lists certain types of positions that may be exempted from (and thus may exceed) the Federal speculative position limits. For example, under § 150.3(a)(1), *bona fide* hedging transactions, as defined in § 1.3(z) of the Commission's regulations, may exceed the limits. The Commission has periodically amended the exemptive rules applicable to Federal speculative position limits in response to changing conditions and practices in futures markets. These amendments have included an exemption from speculative position limits for the positions of multi-advisor commodity pools and

¹ Provisions regarding the establishment of exchange-set speculative position limits were originally set forth in CFTC regulation 1.61. In 1999, the Commission simplified and reorganized its rules by relocating the substance of regulation 1.61's requirements to part 150 of the Commission's rules, thereby incorporating within part 150 provisions for both Federal speculative position limits and exchange-set speculative position limits (see 64 FR 24038, May 5, 1999). With the passage of the Commodity Futures Modernization Act in 2000 and the Commission's subsequent adoption of the Part 38 regulations covering DCMs in 2001 (66 FR 42256, August 10, 2001), Part 150's approach to exchange-set speculative position limits was incorporated as an acceptable practice under DCM Core Principle 5—Position Limitations and Accountability. Section 4a(e) provides that a violation of a speculative position limit set by a Commission-approved exchange rule is also a violation of the Act. Thus, the Commission can enforce directly violations of exchange-set speculative position limits as well as those provided under Commission rules.

other similar entities that use independent account controllers,² and an amendment to extend the exemption for positions that have a common owner but are independently controlled to include certain commodity trading advisors.³ In 1987, the Commission also issued an agency interpretation clarifying certain aspects of the hedging definition.⁴ The Commission has also issued guidance with respect to exchange speculative limits, including guidelines regarding the exemption of risk-management positions from exchange-set speculative position limits in financial futures contracts.⁵ However, the last significant amendment to the Commission's exemptive rules was implemented in 1991.

C. Changes in Trading Practices

The intervening 16 years have seen significant changes in trading patterns and practices in derivatives markets, thus prompting the Commission to reassess its policies regarding exemptions from the Federal speculative position limits. These changes primarily involve trading strategies and programs based on commodity indexes. In particular, pension funds and other investors (including individual investors participating in commodity index-based funds or trading programs) have become interested in taking on commodity price exposure as a way of diversifying portfolios that might otherwise be limited to stocks and interest rate instruments. Financial research has shown that the risk/return performance of a portfolio is improved by acquiring uncorrelated or negatively correlated assets, and commodities (including agricultural commodities) generally perform that role in a portfolio of other financial assets.⁶

The components of a commodity index-based investment might include energy commodities, metals (both precious metals and industrial metals), agricultural commodities that are subject to exchange limits (including coffee, sugar, cocoa, and orange juice, as well as livestock and meat), and those agricultural commodities named above that are subject to Federal speculative position limits (grains, the soybean complex and cotton). With respect to agricultural commodities subject to Federal limits, the Commission has responded to various instances where

² 53 FR 41563 (October 24, 1988).

³ 56 FR 14308 (April 9, 1991).

⁴ 52 FR 27195 (July 20, 1987).

⁵ 52 FR 34633 (September 14, 1987).

⁶ The argument has also been made that commodities act as a general hedge of liability obligations that are linked to inflation.

index-based positions in such commodities exceed (or might grow to exceed) the Federal speculative position limits. In certain cases, the Commission has granted exemptive or no-action relief from Federal speculative position limits. In granting such relief, the Commission has included conditions to protect the market from the potential for the sudden or unreasonable fluctuations or unwarranted changes in prices that speculative limits are designed to prevent.

For example, in 1991, the Commission received a request from a large commodity merchandising firm that engaged in commodity related swaps⁷ as a part of a commercial line of business. The firm, through an affiliate, wished to enter into an OTC swap transaction with a qualified counterparty (a large pension fund) involving an index based on the returns afforded by investments in exchange-traded futures contracts on certain non-financial commodities meeting specified criteria. The commodities making up the index included wheat, corn and soybeans, all of which were (and still are) subject to Federal speculative position limits. As a result of the swap, the swap dealing firm would, in effect, be going short the index. In other words, it would be required to make payments to the pension fund counterparty if the value of the index was higher at the end of the swap payment period than at the beginning. In order to hedge itself against this risk, the swap dealer planned to establish a portfolio of long futures positions in the commodities making up the index, in such amounts as would replicate its exposure under the swap transaction. By design, the index did not include contract months that had entered the delivery period and the swap dealer, in replicating the index, stated that it would not maintain futures positions based on index-related swap activity into the spot month (when physical commodity markets are most vulnerable to manipulation and attendant unreasonable price fluctuations). The result of the hedge was that the composite return on the futures portfolio would offset the net payments the swap dealer would be required to make to the pension fund counterparty.

Because the futures positions the swap dealer would have to establish to hedge its exposure on the swap transaction would be in excess of the speculative position limits on wheat,

corn and soybeans, it requested, and was granted, a hedge exemption for those positions. The swap transaction allowed the pension fund to add commodities exposure to its portfolio indirectly, through the OTC trade with the swap dealer—something it could have done directly, but only in a limited fashion.⁸

Similar hedge exemptions were subsequently granted in other cases where the futures positions clearly offset risks related to swaps or similar OTC positions involving both individual commodities and commodity indexes. These non-traditional hedges were all subject to specific limitations to protect the marketplace from potential ill effects. The limitations included: (1) The futures positions must offset specific price risk; (2) the dollar value of the futures positions would be no greater than the dollar value of the underlying risk; and (3) the futures positions would not be carried into the spot month.

The Commission's Division of Market Oversight ("Division" or "DMO") has also recently issued two no-action letters involving another type of index-based trading.⁹ Both cases involved trading that offered investors the opportunity to participate in a broadly diversified commodity index-based fund or program ("index fund"). The futures positions of these index funds differed from the futures positions taken by the swap dealers described above. The swap dealer positions were taken to offset OTC swaps exposure that was directly linked to the price of an index. For that reason, the Division granted hedge exemptions to these swap dealer positions. On the other hand, in the index fund positions described in the no-action letters, the price exposure results from a promise or obligation to track an index, rather than from holding an OTC swap position whose value is directly linked to the price of the index. The Division believed that this difference was significant enough that the index fund positions would not qualify for a hedge exemption. Nevertheless, because the index fund positions represented a legitimate and potentially useful investment strategy, the Division granted the index funds no-action relief, subject to certain

conditions, described below, that were intended to protect the futures markets from potential ill effects.

II. Proposed Amendment

A. Introduction

In light of the changing trading practices and conditions described above, the Commission is now considering whether to amend its Part 150 regulations to create a new exemption from Federal speculative position limits. In addition to the above-described policy of granting index-based hedge exemptions to swap dealers, which policy would remain in effect, the proposal would create an additional risk management exemption. That exemption would apply to positions held by: (1) Intermediaries, such as index funds, who pass price risks on to their customers; and (2) pension funds and other institutional investors seeking to diversify risks in portfolios by including an allocation to commodity exposure. As noted above, pension funds can already benefit from a hedge exemption indirectly, by entering into an OTC position with a swap dealer who, in turn, puts on an offsetting futures position in reliance on the existing hedge exemption policy. The proposed rules would allow a pension fund to receive an exemption directly, by putting on a futures position itself pursuant to the new risk management exemption provision.

In determining whether the new risk management exemption proposed herein is appropriate, it is important to recall that the purpose of position limits, as specified in Section 4a(a) of the Act, is to diminish, eliminate, or prevent sudden or unreasonable fluctuations or unwarranted changes in the prices of commodities. Within this constraint, it is appropriate that the Commission (and the exchanges) not unduly restrict trading activity. A position limit is a means to an end, not an end in itself. Accordingly, to the extent that a type of trading activity can be identified that is unlikely to cause sudden or unreasonable fluctuations or unwarranted changes in prices, it is a good candidate to qualify for an exemption from position limits. Commodity index-based trading has characteristics that recommend it on that score: (1) It is generally passively managed, so that positions tend not to be changed based on market news or short-term price volatility; (2) it is generally unleveraged, so that financial considerations should not cause rapid liquidation of positions; and (3) it is inherently diversified, in that futures positions are normally held in many

⁷ A swap is a privately negotiated exchange of one asset or cash flow for another asset or cash flow. In a commodity swap, at least one of the assets or cash flows is related to the price of one or more commodities.

⁸ The pension fund would have been limited in its ability to take on this commodities exposure directly, by putting on the long futures position itself, because the pension fund—having no offsetting price risk incidental to commercial cash or spot operations—would not have qualified for a hedge exemption with respect to the position. (See § 1.3(z) of the Commission's regulations.)

⁹ CFTC Letter 06-09 (April 19, 2006); CFTC Letter 06-19 (September 6, 2006).

different markets, and its purpose typically is to diversify a portfolio containing assets with different risk profiles.

B. Conditions for the Exemption

To be eligible for an exemption as a “risk management position” under the proposed amendments to Part 150, a futures position would need to comply with several conditions designed to protect the futures markets from sudden or unreasonable fluctuations or unwarranted changes in prices. First, § 150.3(a) would be amended to add a requirement that all positions subject to the exemptive provisions must be “established and liquidated in an orderly manner.” This requirement already applies to the positions referred to in § 150.3(a)(1), which exempts *bona fide* hedging transactions, by virtue of similar language appearing in the *bona fide* hedging definition (see § 1.3(z)(1)). However, the proposed amendment would clarify that the same requirement would apply not only to the risk management positions to be exempted under proposed new § 150.3(a)(2), but also to the spread or arbitrage positions already exempted under current § 150.3(a)(3) and the positions carried in the separate account of an independent account controller already exempted under current § 150.3(a)(4).

Second, the proposed rules would define a “risk management position” as a futures or futures equivalent position, held as part of a broadly diversified portfolio of long-only or short-only¹⁰ futures or futures equivalent¹¹ positions, that is based upon either: (1) A fiduciary obligation to match or track the results of a broadly diversified index that includes the same commodity markets in fundamentally the same proportions as the futures or futures equivalent position; or (2) a portfolio diversification plan that has, among other substantial asset classes, an exposure to a broadly diversified index that includes the same commodity markets in fundamentally the same

proportions as the futures or futures equivalent position. The first of these alternatives covers positions held by index funds, such as those that were the subject of the Commission No-action letters discussed above. The second alternative covers positions held directly by pension funds and other institutional investors.

A “broadly diversified index” would be defined to limit the weighting of certain agricultural commodities in the index so that commodities subject to Federal speculative position limits would not comprise a disproportionate share of the index. Thus, a “broadly diversified index” would mean an index based on physical commodities in which: (1) not more than 15% of the index is composed of any single agricultural commodity named in § 150.2 (for which purposes, wheat shall be regarded as a single commodity, so that positions in all varieties of wheat, on all exchanges, combined, may not exceed 15% of the index, and the soybean complex shall likewise be regarded as a single commodity, so that positions in soybeans, soybean oil and soybean meal, on all exchanges combined, may not exceed 15% of the index); and (2) not more than 50% of the index as a whole is composed of agricultural commodities named in § 150.2. The Commission believes that a narrowly based index could be used to evade speculative position limits. For example, the grains all tend to have similar risk profiles—*i.e.*, they tend to respond similarly to common market factors, such as weather. Therefore, the Commission is concerned that an index composed, for example, of 25% each of corn, wheat, oats and soybeans—rather than constituting a means of portfolio diversification—could operate as a mechanism for evading speculative position limits in one or more of those commodities.

Third, the positions subject to the exemption must be passively managed. The proposed rules would define a “passively managed position” as a futures or futures equivalent position that is part of a portfolio that tracks a broadly diversified index, which index is calculated, adjusted, and re-weighted pursuant to an objective, predetermined mathematical formula the application of which allows only limited discretion with respect to trading decisions. This definition contemplates a certain limited amount of discretion in the manner in which the futures position tracks the underlying index. For example, index funds generally provide rules or standards for periodically re-weighting the index to account for price changes in the commodities that make

up the index, or readjusting the composition of the index to account for changing economic or market factors. Such discretion would be permissible. However, the definition contemplates that the position holder’s discretion would not extend to frequently or arbitrarily changing the composition of the index or the weighting of the commodities in the index. Such actions would indicate that the position was being actively managed with a view to taking advantage of short-term market trends. The definition also contemplates that the position holder could exercise some discretion as to when to roll futures positions forward into the next delivery month without violating the “passively managed” requirement (provided no positions were carried into the spot month). The Commission believes that limited discretion as to when a position must be rolled forward can mitigate the market impact that might otherwise result from large positions being rolled forward on a pre-determined date and, consequently, help to avoid liquidity problems.

Fourth, the futures trading undertaken pursuant to the exemption must be unleveraged. An unleveraged position would be defined as a futures or futures equivalent position that is part of a portfolio of futures or futures equivalent positions directly relating to an underlying broadly diversified index, the notional value of which positions does not exceed the sum of the value of: (1) Cash set aside in an identifiable manner, or unencumbered short-term U.S. Treasury obligations so set aside, plus any funds deposited as margin on such position; and (2) accrued profits on such position held at the futures commission merchant. Because the futures positions would be fully offset by cash or profits on such positions, financial considerations (e.g., significant price changes) should not cause rapid liquidation of positions, which can cause sudden or unreasonable fluctuations or unwarranted changes in prices.

Finally, positions may not be carried into the spot month, a period during which physical commodity markets are particularly vulnerable to manipulations, squeezes and sudden or unreasonable fluctuations or unwarranted changes in prices.

Entities intending to hold risk management positions pursuant to the exemption in § 150.3(a)(2) would be required to apply to the Commission and receive Commission approval in order to receive an exemption. The applicant would be required to provide the following information:

¹⁰ The long-only or short-only qualification would limit risk management positions to positions offsetting either a long index or portfolio or a short index or portfolio, and thus would not allow for spread or straddle positions. With respect to short-only positions, it should be noted that all the applications for index-based trading relief received by the Commission to date, whether for hedge exemptions or no-action relief, have involved long-only futures positions. However, the proposed rules would also provide for an entity that might offer investors a “bear market index.” Such an index would require the offeror to be long opposite its customers. It would, therefore, need to offset that exposure with short futures positions.

¹¹ For example, a long call option combined with a short put option is equivalent to a long futures contract.

Application for a Risk Management Exemption as Defined in § 150.1(j)

1. Initial application materials:

A. For an exemption related to a “fiduciary obligation”:

- A description of the underlying index or group of commodities, including the commodities, the weightings, the method and timing of re-weightings, the selection of futures months, and the timing and criteria for rolling from one futures month to another;

- A description of the “fiduciary obligation;”

- The actual or anticipated value of the underlying funds to be invested in commodities within the next fiscal or calendar year and the method for calculating that value, as well as the equivalent numbers of futures contracts in each of the § 150.2 markets for which the exemption is sought;

- A description of the manner in which the funds to be invested in commodities will be set aside;

- A statement certifying that the requirements of this exemption are met and will be observed at all times going forward and that the Commission will be notified promptly of any material changes in this information; and

- Such other information as the Commission may request.

B. For an exemption based upon a “portfolio diversification plan”:

- A description of the investment index or group of commodities, including the commodities, the weightings, the method and timing of re-weightings, the selection of futures months, and the timing and criteria for rolling from one futures month to another;

- A description of the entire portfolio, including the total size of the assets, the asset classes making up the portfolio, and a description of the allocation among the asset classes;

- The actual or anticipated value of the underlying funds to be invested in commodities and the method for calculating that value, as well as the equivalent numbers of futures contracts in each of the § 150.2 markets for which the exemption is sought;

- A description of the manner in which the funds to be invested in commodities will be set aside;

- A statement certifying that the requirements of this exemption are met and will be observed at all times going forward and that the Commission will be notified promptly of any material changes in this information; and
- Such other information as the Commission may request.

2. Supplemental Material: Whenever the purchases or sales that a person

wishes to qualify under this risk management exemption shall exceed the amount provided in the person’s most recent filing pursuant to this section, or the amount previously specified by the Commission pursuant to this section, such person shall file with the Commission a statement that updates the information provided in the person’s most recent filing and provides the reasons for this change. Such statement shall be filed at least ten business days in advance of the date that such person wishes to exceed those amounts and if the notice filer is not notified otherwise by the Commission within the 10-day period, the exemption will continue to be effective. The Commission may, upon call, obtain such additional materials from the applicant or person availing themselves of this exemption as the Commission deems necessary to exercise due diligence with respect to granting and monitoring this exemption.

Entities holding risk management positions pursuant to the exemption in § 150.3(a)(2) would also be required to immediately report to the Commission in the event they know, or have reason to know,¹² that any person holds a greater than 25% interest in such position. The reason for this requirement is to alert the Commission to the possibility that an individual might be attempting to use the exemption as a means of avoiding otherwise applicable speculative position limits.

C. Questions

The Commission would welcome public comments on any aspect of the proposed risk management exemption from Federal speculative position limits. However, the Commission is particularly interested in the views of commenters on the following specific questions:

(1) Are any of the proposed conditions for receiving a risk management exemption unnecessary and, if so, why? Alternatively, should any of the proposed conditions be modified and, if so, why?

(2) Should any other conditions, in addition to those set out in these proposed rules, be imposed as a prerequisite for receiving a risk management exemption? If so, what is the rationale for such additional

¹² The Commission understands that not every entity that might qualify for this exemption would necessarily know the identities of all of the participants in the position. For example, a fund based on a commodity index may qualify for the exemption but the entity operating the fund may not know the identities of the owners of outstanding shares and, therefore, may not know when any given person had acquired a 25% or more interest in the position held by the fund.

conditions (*i.e.*, what potential harm would they address)?

(3) Is there any type of index-based trading that should be covered by the proposed rules, but is not? If so, how should the proposed rules be revised to apply to such trading?

(4) The proposed rules would allow for a risk management exemption in the case of short-only futures or futures equivalent positions used to manage risks in connection with a “bear market index.” Would any of the exemptive rules, as proposed, create potential problems as applied to such an index? For example, in applying the definition of “unleveraged position,” would problems be encountered in comparing the notional value of an unleveraged short futures position to the value of the cash, margins and accrued profits on such position?

(5) Should the proposed rules impose any restrictions or conditions regarding how broad- or narrow-based an index should be if a position based on the index is to qualify for an exemption? For example, with respect to narrow-based indices reflecting specific industry or commodity sectors, should the Commission be concerned that a narrow-based index composed entirely of agricultural commodities—for example, 25% each of corn, wheat, oats and soybeans—could operate as a mechanism for evading speculative position limits in one or more of those commodities?

(6) The proposed rules list the information that must be provided in an application for a risk management exemption. Are the requirements set out in the proposed rules appropriate? Should the requirements be revised and, if so, how?

III. Related Matters

A. Cost Benefit Analysis

Section 15(a) of the Act requires the Commission to consider the costs and benefits of its action before issuing a new regulation under the Act. By its terms, section 15(a) does not require the Commission to quantify the costs and benefits of a new regulation or to determine whether the benefits of the proposed regulation outweigh its costs. Rather, section 15(a) requires the Commission to “consider the costs and benefits” of the subject rule.

Section 15(a) further specifies that the costs and benefits of the proposed rule shall be evaluated in light of five broad areas of market and public concern: (1) Protection of market participants and the public; (2) efficiency, competitiveness, and financial integrity of futures markets; (3) price discovery;

(4) sound risk management practices; and (5) other public interest considerations. The Commission may, in its discretion, give greater weight to any one of the five enumerated areas of concern and may, in its discretion, determine that, notwithstanding its costs, a particular rule is necessary or appropriate to protect the public interest or to effectuate any of the provisions or to accomplish any of the purposes of the Act.

The proposed rules would provide for a risk management exemption from the Federal speculative position limits applicable to certain agricultural commodities, thus giving entities such as index funds and pension funds an opportunity to more effectively manage risks for their investors through greater diversification of their portfolios. The rules would seek to protect the futures markets from potential ill effects of such risk management positions by imposing conditions on the exemption and creating an application process (including a requirement to file updates as necessary) to assure those conditions are met. The Commission, in proposing these rules, has endeavored to impose the minimum requirements necessary consistent with its mandate to protect the markets and the public from ill effects.

The Commission specifically invites public comment on its application of the cost benefits criteria of the Act. Commenters are also invited to submit any quantifiable data that they may have concerning the costs and benefits of the proposed rules with their comment letter.

B. Regulatory Flexibility Act

The Regulatory Flexibility Act ("RFA"), 5 U.S.C. 601 *et seq.*, requires Federal agencies, in proposing rules, to consider the impact of those rules on small businesses. The Commission believes that the proposed rule amendments to implement a new exemption from Federal speculative position limits would only affect large traders. The Commission has previously determined that large traders are not small entities for the purposes of the RFA.¹³ Therefore, the Chairman, on behalf of the Commission, hereby certifies, pursuant to 5 U.S.C. 605(b), that the action taken herein will not have a significant economic impact on a substantial number of small entities.

C. Paperwork Reduction Act

When publishing proposed rules, the Paperwork Reduction Act of 1995 (44 U.S.C. 3507(d)) imposes certain

requirements on Federal agencies (including the Commission) in connection with their conducting or sponsoring any collection of information as defined by the Paperwork Reduction Act. In compliance with the Act, the Commission, through this rule proposal, solicits comment to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including the validity of the methodology and assumptions used; (2) evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (3) enhance the quality, utility and clarity of the information to be collected; and (4) minimize the burden of the collection of the information on those who are to respond through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

The Commission has submitted the proposed rule and its associated information collection requirements to the Office of Management and Budget ("OMB") for its review.

Collection of Information: Rules Establishing Risk Management Exemption From Federal Speculative Position Limits, OMB Control Number.

The estimated burden was calculated as follows:

Estimated number of respondents: 6.

Annual responses by each respondent: 1.

Total annual responses: 6.

Estimated average hours per response: 10.

Annual reporting burden: 60 hours.

List of Subjects in 17 CFR Part 150

Agricultural commodities, Bona fide hedge positions, Position limits, Spread exemptions.

In consideration of the foregoing, pursuant to the authority contained in the Commodity Exchange Act, the Commission hereby proposes to amend part 150 of chapter I of title 17 of the Code of Federal Regulations as follows:

PART 150—LIMITS ON POSITIONS

1. The authority citation for part 150 is revised to read as follows:

Authority: 7 U.S.C. 6a, 6c, and 12a(5), as amended by the Commodity Futures Modernization Act of 2000, Appendix E of Pub. L. 106-554, 114 Stat. 2763 (2000).

2. Section 150.1 is amended by adding new paragraphs (j) through (m) to read as follows:

§ 150.1 Definitions.

* * * * *

(j) *Risk management position*, for the purposes of an exemption under § 150.3(a)(2), means a futures or futures equivalent position, held as part of a broadly diversified portfolio of long-only or short-only futures or futures equivalent positions, that is based upon either:

(1) A fiduciary obligation to match or track the results of a broadly diversified index that includes the same commodity markets in fundamentally the same proportions as the futures or futures equivalent position; or

(2) A portfolio diversification plan that has, among other substantial asset classes, an exposure to a broadly diversified index that includes the same commodity markets in fundamentally the same proportions as the futures or futures equivalent position.

(k) *Broadly diversified index* means an index based on physical commodities in which:

(1) Not more than 15% of the index is composed of any single agricultural commodity named in § 150.2 (for which purposes, wheat shall be regarded as a single commodity, so that positions in all varieties of wheat, on all exchanges combined, may not exceed 15% of the index, and the soybean complex shall be regarded as a single commodity, so that positions in soybeans, soybean oil and soybean meal, on all exchanges combined, may not exceed 15% of the index); and

(2) Not more than 50% of the index as a whole is composed of agricultural commodities named in § 150.2.

(l) *Passively managed position* means a futures or futures equivalent position that is part of a portfolio that tracks a broadly diversified index, which index is calculated, adjusted, and re-weighted pursuant to an objective, predetermined mathematical formula the application of which allows only limited discretion with respect to trading decisions.

(m) *Unleveraged position* means:

(1) A futures or futures equivalent position that is part of a portfolio of futures or futures equivalent positions directly relating to an underlying broadly diversified index, the notional value of which positions does not exceed the sum of the value of:

(i) Cash set aside in an identifiable manner, or unencumbered short-term U.S. Treasury obligations so set aside, plus any funds deposited as margin on such position; and

¹³ 47 FR 18618 (April 30, 1982).

(ii) Accrued profits on such position held at the futures commission merchant.

(2) [Reserved]

3. Section 150.3 is amended by revising paragraph (a) introductory text, adding a new paragraph (a)(2), and adding a new paragraph (c) to read as follows:

§ 150.3 Exemptions.

(a) *Positions which may exceed limits.* The position limits set forth in § 150.2 of this part may be exceeded to the extent such positions are established and liquidated in an orderly manner and are:

* * * * *

(2) Risk management positions, as defined in § 150.1(j), that fulfill the following requirements:

(i) Such risk management positions must comply with the following conditions:

(A) The positions must be passively managed;

(B) The positions must be unleveraged; and

(C) The positions must not be carried into the spot month.

(ii) Entities intending to hold risk management positions pursuant to the exemption in § 150.3(a)(2) must apply to the Commission and receive Commission approval. Such applications must include the following information:

(A) In the case of an exemption based on a fiduciary obligation, as described in § 150.1(j)(1), an application must include:

(1) A description of the underlying index or group of commodities, including the commodities, the weightings, the method and timing of re-weightings, the selection of futures months, and the timing and criteria for rolling from one futures month to another;

(2) A description of the "fiduciary obligation;"

(3) The actual or anticipated value of the underlying funds to be invested in commodities within the next fiscal or calendar year and the method for calculating that value, as well as the equivalent numbers of futures contracts in each of the § 150.2 markets for which the exemption is sought;

(4) A description of the manner in which the funds to be invested in commodities will be set aside;

(5) A statement certifying that the requirements of this exemption are met and will be observed at all times going forward and that the Commission will be notified promptly of any material changes in this information; and

(6) Such other information as the Commission may request.

(B) In the case of an exemption based on a portfolio diversification plan, as described in § 150.1(j)(2), an application must include:

(1) A description of the investment index or group of commodities, including the commodities, the weightings, the method and timing of re-weightings, the selection of futures months, and the timing and criteria for rolling from one futures month to another;

(2) A description of the entire portfolio, including the total size of the assets, the asset classes making up the portfolio, and a description of the allocation among the asset classes;

(3) The actual or anticipated value of the underlying funds to be invested in commodities and the method for calculating that value, as well as the equivalent numbers of futures contracts in each of the § 150.2 markets for which the exemption is sought;

(4) A description of the manner in which the funds to be invested in commodities will be set aside;

(5) A statement certifying that the requirements of this exemption are met and will be observed at all times going forward and that the Commission will be notified promptly of any material changes in this information; and

(6) Such other information as the Commission may request.

(iii) Whenever the purchases or sales that a person wishes to qualify under this risk management exemption shall exceed the amount provided in the person's most recent filing pursuant to this section, or the amount previously specified by the Commission pursuant to this section, such person shall file with the Commission a statement that updates the information provided in the person's most recent filing and provides the reasons for this change. Such statement shall be filed at least ten business days in advance of the date that such person wishes to exceed those amounts and if the notice filer is not notified otherwise by the Commission within the 10-day period, the exemption will continue to be effective. The Commission may, upon call, obtain such additional materials from the applicant or person availing themselves of this exemption as the Commission deems necessary to exercise due diligence with respect to granting and monitoring this exemption.

(iv) Entities holding risk management positions pursuant to the exemption in § 150.3(a)(2) shall immediately report to the Commission in the event that they know, or have reason to know, that any person holds a greater than 25% interest in such position.

* * * * *

(c) The Commission hereby delegates, until such time as the Commission orders otherwise, to the Director of the Division of Market Oversight, or the Director's designee, the functions reserved to the Commission in § 150.3(a)(2) of this chapter.

Issued by the Commission this 20th day of November, 2007, in Washington, DC.

David Stawick,

Secretary of the Commission.

[FR Doc. E7-22992 Filed 11-26-07; 8:45 am]

BILLING CODE 6351-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 101

[Docket Nos. 2004N-0217, 2005P-0189, and 2006P-0137]

RIN No. 0910-ZA28

Food Labeling: Nutrient Content Claims; Alpha-Linolenic Acid, Eicosapentaenoic Acid, and Docosahexaenoic Acid Omega-3 Fatty Acids

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of proposed rulemaking.

SUMMARY: The Food and Drug Administration (FDA) proposes to issue this rule finding that certain nutrient content claims for foods, including conventional foods and dietary supplements, that contain omega-3 fatty acids, do not meet the requirements of the Federal Food, Drug, and Cosmetic Act (the act) and may not appear in food labeling. This rule is being proposed in response to three notifications submitted to FDA under the act. One notification concerning nutrient content claims for alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) was submitted collectively by Alaska General Seafoods, Ocean Beauty Seafoods, Inc., and Trans-Ocean Products, Inc. (the seafood processors notification); a second notification concerning nutrient content claims for ALA, DHA, and EPA was submitted by Martek Biosciences Corp. (the Martek notification); and a third notification concerning nutrient content claims for DHA and EPA was submitted by Ocean Nutrition Canada, Ltd. (the Ocean Nutrition notification).

FDA has reviewed the information included in the three notifications and is proposing to prohibit the nutrient content claims for DHA and EPA set

forth in the three notifications because they are not based on an authoritative statement that identifies a nutrient level to which the claims refer, as required by the controlling statutory authority. FDA is also proposing to prohibit the nutrient content claims for ALA set forth in the seafood processors notification because they are based on a daily value that was determined by a different method than daily values already established for other nutrients. Because of the different methodology used to set the daily value, the ALA claims set forth in the seafood processors notification do not enable the public to comprehend the information provided in the claims and to understand the relative significance of such information in the context of the daily diet, as required by the controlling statutory authority. FDA is proposing to take no regulatory action with respect to the nutrient content claims for ALA set forth in the Martek notification. Therefore, if this proposed rule is finalized without change, these claims will be allowed to remain on the market.

DATES: Submit written or electronic comments by February 11, 2008.

ADDRESSES: You may submit comments, identified by Docket Nos. 2004N-0217, 2005P-0189, and 2006P-0137 by any of the following methods:

Electronic Submissions

Submit electronic comments in the following ways:

- Federal eRulemaking Portal: <http://www.regulations.gov>. Follow the instructions for submitting comments.
- Agency Web site: <http://www.fda.gov/dockets/ecomments>.

Follow the instructions for submitting comments on the agency Web site.

Written Submissions

Submit written submissions in the following ways:

- FAX: 301-827-6870.
- Mail/Hand delivery/Courier [For paper, disk, or CD-ROM submissions]: Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

To ensure more timely processing of comments, FDA is no longer accepting comments submitted to the agency by e-mail. FDA encourages you to continue to submit electronic comments by using the Federal eRulemaking Portal or the agency Web site, as described in the *Electronic Submissions* portion of this paragraph.

Instructions: All submissions received must include the agency name and Docket No(s), and Regulatory Information Number (RIN) (if a RIN number has been assigned) for this rulemaking. All comments received may

be posted without change to <http://www.fda.gov/ohrms/dockets/default.htm>, including any personal information provided. For additional information on submitting comments, see the "Comments" heading of the **SUPPLEMENTARY INFORMATION** section of this document.

Docket: For access to the docket to read background documents or comments received, go to <http://www.fda.gov/ohrms/dockets/default.htm> and insert the docket number(s), found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Vincent de Jesus, Center for Food Safety and Applied Nutrition (HFS-830), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 301-436-1450.

SUPPLEMENTARY INFORMATION:

I. Background

A. Section 403(r) of the Act

On November 8, 1990, President George H.W. Bush signed into law the Nutrition Labeling and Education Act of 1990 (the 1990 amendments) (Public Law 101-535), which amended the act. Section 403(r)(1)(A) of the act (21 U.S.C. 343(r)(1)(A)), which was added by the 1990 amendments, states that a food for human consumption is misbranded if a claim is made in its label or labeling that expressly or implicitly characterizes the level of any nutrient of the type required to be declared in nutrition labeling, unless such claim uses terms defined in regulations by FDA under section 403(r)(2)(A) of the act.¹

In 1993, FDA established regulations that implemented the 1990 amendments (58 FR 2066 to 2941, January 6, 1993). Among these regulations, § 101.13 (21 CFR 101.13) sets forth general principles for nutrient content claims (see 58 FR 2302, January 6, 1993). Other sections in part 101, subpart D (21 CFR part 101, subpart D), define specific nutrient content claims, such as "high," "good source," and "more," and provide that claims such as these must be made in relation to reference values set out in regulations by FDA. For example, to bear the claim "high in fiber" in its label or labeling, a food must contain 20 percent or more of the reference value

for fiber set out in 21 CFR 101.9(c)(9). Other provisions set forth the procedures whereby a person who wishes to make a nutrient content claim not already defined by regulation may petition the agency to authorize that claim under section 403(r)(4) of the act (see 21 CFR 101.69). A petitioner bears the burden of establishing the scientific basis for a proposed nutrient content claim.

On November 21, 1997, President William J. Clinton signed the Food and Drug Administration Modernization Act (FDAMA) into law (Public Law 105-115), which, among other things, added new sections (r)(2)(G) and (r)(2)(H) to the act. These sections provide for the filing of notifications as an alternative to the petition process in section 403(r)(4) of the act. Under the notification process, the scientific basis for a nutrient content claim or health claim is established through reliance on an authoritative statement.

Section 403(r)(2)(G) of the act requires that a notification of the prospective nutrient content claim be submitted to FDA at least 120 days before a food bearing the claim may be introduced into interstate commerce. The notification must contain specific information including the following: (1) The exact wording of the prospective nutrient content claim; (2) a concise description of the basis upon which the notifier relied for determining that the requirements for an authoritative statement in section 403(r)(2)(G)(i) have been satisfied; (3) a copy of the authoritative statement that serves as the basis for the claim; and (4) a balanced representation of the scientific literature relating to the nutrient level for a prospective nutrient content claim. An authoritative statement must have been published by a scientific body of the U.S. Government that has official responsibility for public health protection or research directly relating to human nutrition or the National Academy of Sciences (NAS) or any of its subdivisions. In addition, an authoritative statement must identify the nutrient level to which the claim refers and must be currently in effect. Thus, the requirements of 403(r)(2)(G) of the act are not met by a statement that does not identify the nutrient level to which the claim refers.

FDA considers the term "nutrient level" as used in section 403(r)(2)(G) of the act to mean a reference value that is similar to a label reference value for use in nutrition labeling. To date, FDA has established by regulation two sets of label reference values: Reference Daily Intakes (RDIs) and Daily Reference Values (DRVs) (see 21 CFR

¹The requirements in section 403(r)(2) of the act for nutrient content claims, apply to foods and food labeling unless an exemption applies for the food or the claim under section 403(r)(2) of the act, another section of the act, or FDA regulations.

101.9(c)(8)(iv) and 101.9(c)(9), respectively). FDA based its RDIs on Recommended Daily Allowances (RDAs) and Estimated Safe and Adequate Daily Dietary Intakes (ESADDIs) established by NAS. FDA based its DRV's on recommendations in the NAS Diet and Health Report, the Surgeon General's Report on Nutrition and Health, and the 1990 Dietary Guidelines for Americans. FDA uses RDIs and DRV's as Daily Values (DV's) for purposes of nutrition labeling. Thus, FDA considers DV's to be a specific set of reference values established by regulation (58 FR 2079 at 2125, January 6, 1993).

A DV for a particular nutrient is used to calculate the percent DV that a serving of food provides for that nutrient, based on the assumption of a 2,000 calorie per day diet. The percent DV is listed in the Nutrition Facts and Supplement Facts boxes in nutrition labeling and provides consumers with an overall reference value for the nutrient. DV's are intended to help consumers understand the relative significance of information about the amount of certain nutrients in a food in the context of a total daily diet, and to help consumers compare the nutritional values of food products.

In the preamble to one of its regulations implementing the 1990 amendments (1990 preamble), FDA drew a distinction between the term "Daily Value," or "DV," used as a proper noun, and the term "daily value," used in a more generic sense. As noted above, DV's are established by regulation. By contrast, "daily values" are alternate values that are not established by regulation, such as those based on alternate daily caloric requirements (i.e., 2,500 calories per day) (58 FR 2079 at 2125, January 6, 1993). Notwithstanding this distinction between "Daily Values" or "DV's" and "daily values," FDA and industry have occasionally used the term "Daily Value" or "DV" to refer to alternate values that are not established by regulation, such as the quantity of a nutrient that has been proposed for use in nutrition labeling, or that is the basis for the use of a claim with respect to which FDA has taken no regulatory action under section 403(r)(2)(H) of the act (21 U.S.C. 343(r)(2)(H)).²

FDA intends to maintain the distinction between "Daily Values" or "DV's" and "daily values" that it articulated in its 1990 preamble. FDA

has not established by regulation any DV for ALA, DHA, or EPA. Therefore, this proposal uses the term "daily value" when referring to the quantity of ALA, DHA, and EPA on which the nutrient content claims at issue are based, unless the proposal is quoting a claim submitted by one of the notifiers.

Under section 403(r)(2)(H) of the act, a nutrient content claim authorized under section 403(r)(2)(G) may be made beginning 120 days after submission of the notification until the following occurs: (1) FDA issues an effective regulation that prohibits or modifies the claim; (2) the agency issues a regulation finding that the requirements under section 403(r)(2)(G) have not been met; or (3) a district court of the United States in an enforcement proceeding under chapter III of the act has determined that the requirements under section 403(r)(2)(G) have not been met.

B. The IOM Final Report

In 2005, the Food and Nutrition Board of the Institute of Medicine (IOM) of the National Academy of Sciences published a report titled "Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids" (IOM Final Report, Ref. 1). The report is one in a series that presents a comprehensive set of reference values for nutrient intakes for healthy U.S. and Canadian individuals and populations. Publication of the IOM Final Report was preceded by release in 2002 of a prepublication copy under the same title (IOM Prepublication Report, Ref. 2).

In relevant part, the IOM Final Report establishes Dietary Reference Intakes (DRIs) for a number of nutrients that are essential³ in the human diet (e.g., linoleic acid) or provide a beneficial role in human health (e.g., total fiber). According to the IOM Final Report, DRIs "comprise a set of reference values for specific nutrients, each category of which has special uses." These reference values "include the Estimated Average Requirement (EAR), Recommended Daily Allowance (RDA), AI, and Tolerable Upper Intake Level (UL)."⁴

³The criteria for essentiality of a nutrient are that absence of the nutrient from the diet results in characteristic signs of a deficiency disease and these signs are prevented only by the nutrient itself or a specific precursor of it. (Ref. 3 Carpenter and Harper, *Modern Nutrition in Health and Disease*).

⁴The IOM Final Report also establishes Acceptable Macronutrient Distribution Ranges (AMDRs) for some nutrients. AMDRs are ranges of macronutrient intakes that are associated with reduced risk of chronic disease, while providing recommended intakes of other essential nutrients. AMDRs are not considered to be a type of DRI.

An RDA is an estimate of the minimum daily average dietary intake level that meets the nutrient requirements of nearly all (97 to 98 percent) healthy individuals in a particular life stage and gender group. The setting of an RDA is contingent on there being sufficient scientific evidence to establish an EAR, which is the average daily nutrient intake level estimated to meet the requirement of half the healthy individuals in a particular life stage and gender group.

If there is insufficient scientific evidence to establish an EAR, then an AI is established instead of an RDA (assuming there is sufficient data to support establishment of an AI). An AI is the recommended average daily intake level that is assumed to be adequate based on observed or experimentally determined approximations or estimates of nutrient intake by a group (or groups) of apparently healthy people.

Among other nutrients, the IOM Final Report addresses omega-3 fatty acids, including ALA, EPA, and DHA. These fatty acids are also called *n*-3 fatty acids because the first double bond is located at the third carbon from the methyl end of the molecule (Ref. 4). For ALA, the IOM Final Report does not establish a DRI in the form of an RDA because there is insufficient scientific evidence to establish an EAR. As noted, if there is insufficient scientific evidence to establish an EAR, then no RDA is established. Instead, the IOM Final Report establishes AIs for different life stage groups (e.g., girls ages 9 through 13, boys ages 14 through 18). Those AIs are based on median intakes in the United States, where an omega-3 fatty acid deficiency is nonexistent in healthy individuals. The IOM Final Report does not establish a DRI in any form for either EPA or DHA.

II. The Three Notifications Submitted to FDA

A. The Seafood Processors Notification

On January 16, 2004, FDA received a nutrient content claim notification for foods, including conventional foods and dietary supplements, containing ALA, EPA, and DHA omega-3 fatty acids submitted jointly in the seafood processors notification under section 403(r)(2)(G) of the act (Ref. 5). The notification stated that the nutrient content claims it proposed were based upon authoritative statements made in the IOM Prepublication Report (Ref. 2). As of May 16, 2004, it has been permissible to make the nutrient content claims set forth in the notification.

²See, e.g., FDA's statement titled "Nutrient Content Claims Notification for Choline Containing Foods," August 30, 2001, and also the notifications addressed by this rulemaking.

The notification proposed “high,” “good source,” and “more” claims for ALA, and “high” claims for DHA and EPA. With respect to specific authoritative statements that identify a nutrient level for ALA, the seafood processors notification referenced the following age-gender group specific AIs identified in the IOM Prepublication Report: 0.9 grams/day (g/day) for males and females age 4 to 8 years; 1.2 g/day for males age 9 to 13 years; 1.0 g/day for females age 9 to 13 years; 1.6 g/day for males 14 and more years of age; and 1.1 g/day for females 14 and more years of age. Also, the notification quoted the following as authoritative statements that identify a nutrient level for ALA, EPA, and DHA: “Because of a lack of evidence for determining the requirement for *n-3* fatty acids, an AI [for ALA] is set based on the highest median intake of [ALA] by adults in the United States where a deficiency is basically nonexistent in free-living populations * * * and rounding. Small amounts of EPA and DHA can contribute towards reversing an *n-3* fatty acid deficiency * * * EPA and DHA can contribute up to 10 percent of the total *n-3* fatty acid intake and therefore up to this percent can contribute toward the AI for [ALA] * * *” (Ref. 2, p. 8 to 38).

In calculating a qualifying level for the basis of the “high,” “good source,” and “more” claims for ALA, the seafood processors notification set 1.3 g as a daily value for ALA and applied the specific percentages of this value as qualifying levels for the three ALA nutrient content claims as outlined in 21 CFR 101.54.⁵ The value of 1.3 g was a result of computing a population-weighted average of age and gender-specific AIs for ALA, using 2005 projected U.S. census data. The notification acknowledged that there is currently in effect a nutrient content claim for choline that is based on the highest age and gender-specific AI for that nutrient (Refs. 6 and 7). Nonetheless, the notification set a daily value for ALA using a population-weighted average because a recent report from the IOM, titled “Dietary Reference Intakes: Guiding Principles for Nutrition Labeling and Fortification” (IOM Guiding Principles Report, Ref. 8), recommended setting new DVs based on

this method, rather than on the highest age and gender-specific AI.

In setting a qualifying level for the “high” claim for EPA or DHA, the seafood processors notification set 130 milligrams (mg) as the daily value for EPA or DHA (i.e., 10 percent of the daily value for ALA) and set 130 mg (i.e., equal to the daily value) as the qualifying level for the “high” claim. The notification did not request “good source” or “more” claims for EPA or DHA.

Also, the seafood processors notification specified accompanying statements for the above claims. The “high” and “good source” claims would include one of the following statements:

(1) “Contains ___ mg of [DHA/EPA/ALA] per serving, which is ___ % of the Daily Value for [DHA/EPA (130 mg) or {ALA (1.3 g)}].”

(2) “Contains ___ % of the Daily Value for [DHA/EPA/ALA] per serving. The Daily Value for [{DHA/EPA is 130 mg} or [ALA is 1.3 g)].”

For “more” claims, the notification specified that the claims would be accompanied by statements such as: “___ % [10 % or greater] more of the Daily Value for ALA per serving than [reference food]. This product contains ___ mg ALA omega-3 per serving, which is ___ % of the Daily Value for ALA omega-3 (1.3 g). [Reference food] contains ___ mg ALA omega-3 per serving.”

To qualify for “high” claims for ALA, the product would need to contain at least 260 mg of ALA per reference amount customarily consumed (RACC). To qualify for “good source” claims for ALA, the product would need to contain at least 130 mg of ALA per RACC. To qualify for “more” claims for ALA, the product would need to contain at least 130 mg or more of ALA per RACC than the reference food. To qualify for “high” claims for EPA or DHA, the product would need to contain at least 130 mg of EPA or DHA per RACC.

B. The Martek Notification

On January 21, 2005, FDA received a notification of nutrient content claims for foods, including conventional foods and dietary supplements, containing ALA and DHA omega-3 fatty acids in the Martek Notification, under section 403(r)(2)(G) of the act (Ref. 9). The notification stated that the nutrient content claims were based upon authoritative statements made in the IOM Prepublication Report (Ref. 2). As of May 22, 2005, it has been permissible to make the nutrient content claims set forth in the notification.

The notification proposed “high,” “good source,” and “more” claims for

ALA, and “high” claims for DHA. With respect to specific authoritative statements that identify a nutrient level for ALA, the Martek notification cited AIs for ALA identified in the IOM Prepublication Report (i.e., 1.6 grams per (g)/ day for adult men and 1.1 g/day for adult women, specifically) and cited the following sentence: “While intake levels much lower than the AI occur in the United States without the presence of a deficiency, the AI can provide the beneficial health effects associated with the consumption of *n-3* fatty acids” (Ref. 2, p. 8–2). As authoritative statements that identify a nutrient level for DHA, the notification cited the following statements from the IOM Prepublication Report the following: (1) “EPA and DHA can contribute up to 10 percent of the total *n-3* fatty acid intake and therefore up to this percent can contribute towards the AI for alpha-linolenic acid;” (2) “The AMDR for [ALA] is set at 0.6 to 1.2 percent of energy. Up to 10 percent of this range can be consumed as [EPA] and/or [DHA];” and (3) “A growing body of literature suggests that higher intakes of [ALA], [EPA] and [DHA] may afford some degree of protection against CHD. Because the physiological potency of EPA and DHA is much greater than that for [ALA] acid, it is not possible to estimate one AMDR for all *n-3* fatty acids. Up to 10 percent of the AMDR can be consumed as EPA and/or DHA.”

In determining nutrient qualifying levels for the proposed “excellent,” “good source,” and “more” claims for ALA, the Martek notification set 1.6 g as the daily value for ALA and applied specific percentages of this value as qualifying levels for these claims as outlined in § 101.54. The Martek notification based the daily value for ALA on the AI of 1.6 g identified for adult males in the IOM Prepublication Report, making no adjustments for intakes based on population-weighted averages. The Martek notification took issue with the seafood processors notification because that notification set a daily value for ALA based on a population-weighted method rather than the historically used highest age and gender-specific reference value.

In determining a qualifying level of nutrient for the proposed “excellent” claim for DHA, the Martek notification set 160 mg as the daily value for DHA (i.e., 10 percent of the daily value for ALA) and applied 32 mg or more (i.e., 20 percent of the daily value for DHA) as a qualifying level for the claim. The Martek notification proposed the following exact words for the claims:

(1) “‘Excellent source of ALA.’ (‘High in ALA,’ ‘Rich in ALA’) Contains ___ mg

⁵For a “high” claim, the food must contain 20 percent or more of the reference value per reference amount customarily consumed. For a “good source” claim, the food must contain 10 to 19 percent of the reference value per reference amount customarily consumed. For a “more” claim, the food must contain at least 10 percent more of the reference value per reference amount customarily consumed than an appropriate reference food.

of ALA per serving, which is ___ % of the 1.6 g Daily Value for ALA.” [Products would need to contain at least 320 mg of ALA per RACC to qualify for the claim.]

(2) “ ‘Good source of ALA.’ (‘Contains ALA,’ ‘Provides ALA’) Contains ___ mg of ALA per serving, which is ___ % of the 1.6 g Daily Value for ALA” [Products would need to contain at least 160 mg of ALA per RACC to qualify for the claim.]

(3) “ ‘More ALA.’ (‘Fortified with ALA,’ ‘Enriched with ALA,’ ‘Added ALA,’ ‘Extra ALA,’ ‘Plus ALA’) Contains ___ % more of the Daily Value for ALA per serving than [reference food]. This product contains ___ mg of ALA which is ___ % of the Daily Value for ALA (1.6 g).” [Products would need to contain at least 160 mg or more ALA per RACC than an appropriate reference food and would comply with the requirements for relative claims found at 21 CFR 101.13(j).]

(4) “ ‘Excellent source of DHA.’ (‘High in DHA,’ ‘Rich in DHA’) Contains ___ mg of DHA per serving, which is ___ % of the 160 mg Daily Value for DHA.” [Products would need to contain at least 32 mg of DHA per RACC to qualify for the claim.]

C. The Ocean Nutrition Notification

On December 9, 2005, FDA received a notification of nutrient content claims for foods, including conventional foods and dietary supplements, containing both EPA and DHA omega-3 fatty acids in the Ocean Nutrition notification, under section 403(r)(2)(G) of the act (Ref. 10). The notification stated that the nutrient content claims were based upon authoritative statements made in the IOM prepublication report (Ref. 2). As of April 9, 2006, it has been permissible to make the nutrient content claims set forth in the notification.

The Ocean Nutrition notification proposed “high” claims for EPA and DHA combined. With respect to specific authoritative statements that identify the nutrient level for EPA and DHA combined, the Ocean Nutrition notification referenced the AI for adult males of 1.6 g per day of ALA identified in the IOM Prepublication Report (Ref. 2). In addition, the notification referenced the following statements from the IOM Prepublication Report (Ref. 2): (1) “EPA and DHA can contribute up to 10 percent of the total n-3 fatty acid intake and therefore up to this percent can contribute towards the AI for [ALA],” and (2) “The AMDR for [ALA] is set at 0.6 to 1.2 percent of energy. Up to 10 percent of this range can be consumed as [EPA] and/or [DHA].” The notification contended that

a combination of EPA and DHA is the most appropriate basis for establishing nutrient content claims derived from the IOM Prepublication Report.

In calculating a nutrient qualifying level for the proposed “excellent source” claim for the combination of EPA and DHA, the Ocean Nutrition notification set 1.6 g as a daily value for ALA and 160 mg as a daily value for the combination of EPA and DHA (i.e., 10 percent of the daily value for ALA), and used 32 mg or more (i.e., 20 percent of the daily value for the combination of EPA and DHA) as a qualifying level for the “excellent source” claim.

The Ocean Nutrition notification proposed the following exact words for the claims:

“ ‘Excellent source of Omega-3 EPA and DHA.’ (‘High in Omega-3 EPA and DHA,’ ‘Rich in Omega-3 EPA and DHA’). Contains ___ mg of EPA and DHA combined per serving, which is ___ % of the 160 mg EPA and DHA combined per serving, which is ___ % of the 160 mg Daily Value for a combination of EPA and DHA.”

III. Basis for the Proposed Action

FDA has reviewed the three notifications submitted in support of the claims for ALA, EPA, and DHA. With respect to the claims for ALA in the Martek notification, FDA proposes to take no regulatory action at this time. FDA expresses no opinion as to whether those claims are supported by a statement that satisfies the requirements of section 403(r)(2)(G) of the act for authoritative statements. In the November 2, 2007, **Federal Register** (72 FR 62149), we have published an Advance Notice of Proposed Rulemaking (ANPRM) soliciting comment on how daily values for nutrients should be calculated, including the appropriateness of using an AI to set a DV.⁶

With respect to the claims for ALA in the seafood processors notification, FDA proposes to prohibit those claims because they are based on a population-weighted average of the AIs for ALA. The population-weighted average approach to determining DVs for nutrients is different from the “population coverage” approach that FDA has used to date and continues to

⁶In one other instance, FDA has taken no regulatory action with respect to a notification that proposed a nutrient content claim based on an AI. The nutrient content claim for choline (Ref. 7) was based upon a reference value that the notifier set using the AIs established by the IOM in 1998 for that nutrient (Ref. 8). Choline is essential in the human diet and the AIs for that nutrient were established based upon experimental data demonstrating prevention of alanine aminotransferase abnormalities in healthy men.

use, pending any possible rulemaking based on the issuance of the agency’s ANPRM on DV issues.⁷ The concurrent use of two different methods to set daily values on which nutrient content claims in food labeling are based creates an inconsistency that could lead to consumer confusion about such claims, as discussed more fully below.

Therefore, FDA proposes to conclude that the ALA claims set forth in the seafood processors notification do not enable the public to comprehend the information provided and to understand the relative significance of such information in the context of the daily diet, as required by section 403(r)(2)(G)(iv) of the act. A claim that does not meet the requirements of section 403(r)(2)(G) of the act may not be made on the label or labeling of food.

With respect to claims for EPA and DHA, whether singly or in combination, FDA proposes to conclude that the IOM statements submitted as the basis of the claims do not meet the requirements of section 403(r)(2)(G) of the act in two respects. First, none of the statements identify the nutrient level to which the claims refer (i.e., daily values for EPA and DHA that can serve as the basis for the requested nutrient content claims) (see section 403(r)(2)(G)(i) of the act). Second, in the absence of a nutrient level for EPA and DHA derived from the authoritative statement of a scientific body defined in 403(r)(2)(G)(i) of the act, the requested claims do not convey meaningful information about EPA and DHA content because they lack an adequate scientific basis. Thus, the claims do not enable the public to comprehend the information provided and to understand the relative significance of such information in the context of the daily diet, as required by section 403(r)(2)(G)(iv) of the act.

In this regard, FDA notes that the setting of daily values and qualifying levels for claims in food labeling on the basis of statements that do not identify the nutrient level to which the claims refer can result in inconsistent and conflicting claims that confuse consumers. The requirement in section 403(r)(2)(G) of the act that an authoritative statement identify the nutrient level to which the claim refers helps to ensure consistency in the use of a particular nutrient content claim

⁷FDA seeks comment in the ANPRM on whether the agency should continue to use the population-coverage approach or switch to the population-weighted average approach to setting DVs. The agency’s reasons for adopting the population-coverage approach to set DVs in 1993 are discussed in the final rule entitled “Reference Daily Intakes and Daily Reference Values” (see 58 FR 2206 at 2211, January 6, 1993).

among different products from different manufacturers.

The notification process in section 403(r)(2)(G) of the act provides a mechanism for authorizing a new nutrient content claim based on an authoritative statement by a scientific body of the United States government with official responsibility for public health protection or research directly relating to human nutrition, or by the National Academy of Sciences or any of its subdivisions. Under this expedited process, the scientific basis for a nutrient content claim is established through reliance on an authoritative statement of one of the scientific bodies designated in section 403(r)(2)(G), which has already reviewed the relevant scientific evidence. Therefore, when FDA is reviewing a notification under section 403(r)(2)(G), the agency does not conduct an independent review of the body of scientific evidence associated with the proposed nutrient content claim. Rather, FDA's review is limited to considering whether the authoritative statement and the proposed nutrient content claim meet the requirements of section 403(r)(2)(G) of the act. (In contrast, the agency will conduct its own review of the scientific evidence for the proposed claim when a nutrient content claim petition is submitted under section 403(r)(4) of the act (see 21 CFR 101.69).)

FDA notes that all of the notifications at issue in this rulemaking relied on statements made in the IOM Prepublication Report. For purposes of this proposed rule, FDA has evaluated the claims in the notifications in light of relevant statements made in the IOM Final Report. Unless stated otherwise, those statements may be presumed to be identical to statements made in the IOM Prepublication Report.

A. ALA

The following statement in the IOM Final Report is pertinent to this proposed rule and is identical to a statement made in the IOM Prepublication Report that was cited by all three of the notifications: "The AI for [ALA] is 1.6 and 1.1 g/day for men and women, respectively." (Ref. 1, Summary, p. 9). ALA is essential in the human diet. The IOM established AIs for ALA based upon the median intake of ALA by different gender and life stage groups in the United States, where a deficiency is basically nonexistent in free-living populations (see pages 427, 469 to 472, 1051 to 1051) (Ref. 1).

At this time, FDA proposes to take no regulatory action with respect to the nutrient content claims for ALA in the Martek notification. FDA notes that

those claims are based on a daily value that the notifier set using the highest gender and life-stage AI (i.e., 1.6 g/day of ALA for men ages 19 years and older). Assuming, without deciding the issue, that it is appropriate to use an AI to set a DV, the population-coverage approach used by Martek in this notification ensures that the nutritional needs of almost all segments of the population are covered. This approach is consistent with the method that FDA has used in determining DVs to date (see 58 FR 2206 at 2211, January 6, 1993).

In contrast, FDA proposes to prohibit the claims for ALA in the seafood processors notification because those claims are based on a daily value that the notifier set using a population-weighted average of AI reference values (1.3 g/day).⁸ A daily intake level based on a population-weighted average of AI values may not be adequate for some segments of the population (e.g., men ages 19 and over). Use of the population-weighted average approach in the seafood processors notification also results in a daily value for ALA that is inconsistent with the daily value for ALA claims based on the population-coverage approach used in the Martek ALA notification. As discussed in the preceding paragraph, FDA is proposing no regulatory action concerning nutrient content claims for ALA based on the Martek ALA notification, which means that such claims will continue to be permitted on food labels if this rule is finalized as proposed.

The inconsistency between the population-weighted average method used to set the daily value for ALA in the seafood processors notification and the population coverage method used for that purpose in the Martek notification is likely to result in inconsistent and conflicting nutrient content claims on food labels. For example, a food labeled as a "good source" of ALA must contain at least 160 mg of ALA per RACC under the criteria in the Martek notification, while another food containing only 130 mg ALA per RACC would also be able to bear the same "good source" claim under the criteria in the seafood processors notification. Such inconsistencies make meaningful product-to-product comparisons of ALA content based on label claims impossible. To enable the public to comprehend the information provided

⁸FDA's proposal to prohibit the claims for ALA in the seafood processors notification should not be read as an endorsement of the use of an AI to set a DV. As previously noted, FDA has published an ANPRM to seek comment on the appropriateness of using an AI to set a DV, among other issues.

in nutrient content claims and understand the relative significance of that information in the context of the daily diet, as required by section 403(r)(2)(G)(iv) of the act, qualifying ALA levels for nutrient content claims in food labeling must be based on a single daily value determined using the same method as the DVs for other nutrients.

FDA recognizes that the IOM Guiding Principles Report recommends setting new DVs based on a population-weighted average of reference values. However, that report disclaims any intent to make regulatory recommendations; rather, the guiding principles it provides are recommendations that FDA may accept or reject as appropriate to its activities. As previously noted, in the November 2, 2007, **Federal Register** (72 FR 62149), we have published an ANPRM that seeks comment on the appropriateness of using a population-weighted average, as opposed to a population-coverage approach, to set a DV. In the interim, FDA's position continues to be that the population-coverage approach should be used, for the reasons discussed in the 1993 final rule on DVs (58 FR 2206 at 2211) and for consistency with the manner in which FDA has determined DVs for nutrients to date.

Therefore, FDA is proposing to find that the nutrient content claims for ALA set forth in the seafood processors notification do not meet the requirements of the act.

B. EPA and DHA

The following statements about EPA and DHA in the IOM Final Report are pertinent to this proposed rule and are essentially similar to statements made in the IOM Prepublication Report that were cited by one or more of the notifications:

"[EPA] and [DHA] contribute approximately 10 percent of the total *n*-3 fatty acid intake and therefore this percent contributes toward the AI for [ALA]."

"Small amounts of EPA and DHA can contribute towards reversing an *n*-3 fatty acid deficiency * * * and can therefore contribute toward the AI for [ALA]. EPA and DHA contribute approximately 10 percent of the total *n*-3 fatty acid intake and therefore this percent contributes toward the AI for [ALA]."

"The AMDR for [ALA] is set at 0.6 to 1.2 percent of energy. Ten percent of this range can be consumed as [EPA] and/or [DHA]."

"Approximately 10 percent of the AMDR for *n*-3 fatty acids ([ALA]) can be

consumed as EPA and/or DHA (0.06 to 0.12 percent of energy).⁹

FDA proposes to conclude that these statements do not identify a nutrient level, or reference value, for EPA and/or DHA that FDA could use to establish by regulation a label reference value for use in nutrition labeling. As noted, the IOM Final Report establishes reference values in the form of DRIs for a number of nutrients. DRIs include the EAR, RDA, AI, and UL. The IOM Final Report does not establish an EAR, RDA, AI, or UL for EPA or DHA. The “approximately 10 percent” statements in the IOM Final Report are not reference values. They do not reflect a recommended or defined intake level of EPA and/or DHA that could serve as a basis for setting a DV that could be used to characterize a given level of EPA and/or DHA for purposes of nutrition labeling.

In summary, FDA proposes to conclude that the statements cited by the three notifications and the essentially similar statements in the IOM Final Report do not identify a nutrient level to which the EPA and DHA claims refer, and therefore do not meet the requirements of section 403(r)(2)(G) of the act for authoritative statements. In the absence of an authoritative statement that identifies the nutrient level to which a claim refers, the requirements of section 403(r)(2)(G) of the act are not met. Therefore, FDA proposes to find that any nutrient content claim pertaining to EPA or DHA that is made on the label or labeling of a food renders that food misbranded under section 403(r) of the act.

FDA recognizes that consumption of EPA and/or DHA may provide health benefits and that industry may wish to alert consumers to those benefits. There are numerous lawful means of doing so. Under 21 CFR 101.13(i)(3), the label or labeling of a food may contain a statement about the amount or percentage of a nutrient if the statement does not in any way implicitly characterize the level of the nutrient in the food and is not false or misleading in any respect. For example, a conventional food or a dietary supplement may bear a statement such as “Contains x mg of EPA and DHA omega-3 fatty acids per serving.” Also, under 21 CFR 101.13(q)(3)(ii)(A), dietary supplements are permitted to bear simple percentage claims (e.g., 40 percent EPA and DHA omega-3 fatty

acids), and under 21 CFR 101.14(q)(3)(ii)(B), they are permitted to bear comparative percentage claims (e.g., “four times the EPA and DHA omega-3 fatty acids per capsule (80 mg) as in 100 mg of menhaden oil (20 mg)”). In addition, the potential health benefits of consuming EPA and DHA can be communicated to consumers by using the qualified health claim about the relationship between EPA and DHA and reduced risk of CHD (Refs. 11 and 12).

IV. Environmental Impact

We have carefully considered the potential environmental effects of this action. FDA has determined under 21 CFR 25.30(k) that this action is of a type that does not have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

V. Analysis of Impacts

FDA has examined the impacts of the proposed rule under Executive Order 12866 and the Regulatory Flexibility Act (5 U.S.C. 601–612), and the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). FDA has determined that this proposed rule is not a significant regulatory action as defined by the Executive order.

The Regulatory Flexibility Act requires agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Based on FDA’s review of the labels in the marketplace, FDA does not believe that a substantial number of small entities will be significantly affected. The agency requests comment on whether this rule will have a significant economic impact on a substantial number of small entities.

Section 202(a) of the Unfunded Mandates Reform Act of 1995 requires that agencies prepare a written statement, which includes an assessment of anticipated costs and benefits, before proposing “any rule that includes any Federal mandate that may result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of \$100,000,000 or more (adjusted annually for inflation) in any one year.” The current threshold after adjustment for inflation is \$127 million, using the most current (2006)

Implicit Price Deflator for the Gross Domestic Product. FDA does not expect this proposed rule to result in any 1-year expenditure that would meet or exceed this amount.

Benefit-Cost Analysis

1. The Need for This Regulation

We discussed the legal and regulatory need for this proposed rule in section III of this document.

2. Options

We analyzed two regulatory options: (1) Take no new regulatory action; and (2) prohibit the EPA and DHA claims and the ALA claims based on a daily value of 1.3 grams, but allow the ALA claims based on a daily value of 1.6 grams.

Option 1: Take No New Regulatory Action

This option would result in no change to the current situation, and so would result in no costs or benefits. This is not a viable option under FDA’s current statutory and regulatory framework, as we discussed earlier in this preamble. However, we use this option as the basis for comparing the costs and benefits of other regulatory options.

Option 2: Take the Regulatory Actions as Described in the Proposed Rule

FDA received the first notification from the seafood processors on January 16, 2004. Because FDA did not issue a regulation prohibiting the use of these nutrient content claims within 120 days, “high” claims for ALA, EPA, and DHA, as well as “good source” and “more” claims for ALA have been permissible since May 16, 2004. A second notification, from Martek, received on January 21, 2005, notified FDA of “high” claims for ALA and DHA, as well as “good source”, and “more” claims for ALA. A third notification, from Ocean Nutrition, received on December 9, 2005, notified FDA of a “high” claim and an “excellent source” claim for EPA and DHA combined. All of these claims became permissible 120 days after the FDA received the respective notifications because the agency did not issue a regulation prohibiting them. A cost of this rule will be label changes for products bearing claims that are prohibited. These costs may be lower if producers can schedule regulatory label changes to coincide with their scheduled label changes.

Number of Labels Affected

FDA does not have data on the number of products bearing an ALA, EPA, DHA, or EPA plus DHA nutrient content claim on the label. Therefore, we attempt to estimate a range for the number of products that may bear an affected nutrient content claim.

⁹Generally, in place of “approximately 10 percent” and “this percent,” the IOM Prepublication Report stated “up to 10 percent” and “up to this percent.”

Products whose eligibility will be affected by this rule:

- Have levels of DHA greater than 32 mg.;
- Have levels of EPA greater than 130 mg.;
- Have levels of EPA and DHA combined of greater than 32 mg.;
- Have levels of ALA greater than 130 mg and less than 160 mg for “good source” or “more” claim; and
- Have levels of ALA greater than 260 mg and less than 320 mg for “high” claim.

In this analysis, we distinguish between levels of DHA greater than 32 mg and less than 130 mg and levels greater than 130 mg, because FDA received the notification for “high” claims for foods with more than 32 mg of DHA in January of 2005 and the notification for “high” claims for foods with more than 130 mg of DHA in January of 2004. The longer a claim has been in effect, the more likely that it is in use by manufacturers. More time allows manufacturers to integrate the label change with other packaging changes. Also, if a food is reformulated to meet claim requirements, it may take more time to test the new formulation and put it into the marketplace. In addition to label changes due to loss of claims, products that refer to the ALA daily value of 1.3 g have to alter their packaging to refer to the revised daily value of 1.6 g. FDA was not able to undertake a comprehensive review of

labels in the marketplace to determine how many products currently have labels with an affected nutrient content claim. Instead, FDA went through a multi-step process to estimate the likely number of claims in the marketplace.

1. We determined which products are eligible to make a nutrient content claim.

2. We conducted an informal review of these products in local groceries and online groceries to determine if any were making an affected nutrient content claim.

3. We determined how many labels there were in the marketplace for each of the products eligible to make an affected nutrient content claim.

4. We estimated the number of products likely to make an affected claim based on the number of products in the marketplace, the results of the informal review, and the length of time the claim had been in effect.

EPA and DHA occur naturally in some fish, with higher levels in fattier fish. Many dietary supplements, particularly fish oils, contain EPA and DHA. ALA is present in some nuts and nut oils, flaxseeds and flaxseed oil, vegetable oils, and in many prepared foods that include flaxseeds, nuts, or oils as an ingredient. We searched an online grocer for all packaged fish and seafood products and expanded this list by a review of all canned, frozen, and refrigerated fish and seafood products in the 1999 Infoscan supermarket scanner

data collected by Information Resources, Inc. (IRI) (Ref. 13). The IRI Infoscan supermarket scanner data provide very specific information on individual food items. Infoscan store tracking is based primarily on all-store, census scanner data, which are collected weekly from more than 32,000 supermarket, drug, and mass merchandiser outlets across the United States. For these products, we determined the average serving size for each product type, for example, 2 ounces (oz) for canned tuna. We then used the United States Department of Agriculture (USDA) National Nutrient Database for Standard Reference (Ref. 14) to determine the levels of EPA and/or DHA in a serving size of that food. USDA updates this database frequently. We used the most current version available when we calculated these numbers. However, we have not recalculated the numbers with each subsequent update because we do not expect that doing so would affect our estimates to any significant degree. Therefore, the benefit of recalculating the numbers would probably not justify the time and cost of doing so. We classified all products whose levels of EPA and/or DHA exceeded the threshold for a nutrient content claim as potential claim losers. Tables 1 and 2 of this document show the products and their levels of EPA and/or DHA. Table 2 reflects a 3-oz serving size for cooked fish.

TABLE 1.—DHA AND/OR EPA LEVELS OF CANNED SEAFOOD AND FISH

Canned Foods	Serving Size	DHA (mg)	EPA (mg)	EPA or DHA Eligible \geq 130 mg	DHA Eligible \geq 32 mg	EPA plus DHA Eligible \geq 32 mg
Herring	2 oz	668	550	Yes	Yes	Yes
Mackerel	2 oz	452	246	Yes	Yes	Yes
Caviar	.5 oz	539	389	Yes	Yes	Yes
Salmon	2 oz	459	481	Yes	Yes	Yes
White Tuna in water	2 oz	358	133	Yes	Yes	Yes
Sardines	2 oz	288	268	Yes	Yes	Yes
Anchovies	.5 oz	123	73	No	Yes	Yes
Shrimp, mixed species	2 oz	126	146	Yes	Yes	Yes
Oyster	2 oz	130	120	Yes	Yes	Yes
Canned shrimp	3 oz	249	214	Yes	Yes	Yes
Light Tuna in water	2 oz	127	27	No	Yes	Yes
Crabmeat	2 oz	71	81	No	Yes	Yes
White Tuna in oil	2 oz	101	38	No	Yes	Yes
Light Tuna in oil	2 oz	58	15	No	Yes	Yes

TABLE 1.—DHA AND/OR EPA LEVELS OF CANNED SEAFOOD AND FISH—Continued

Canned Foods	Serving Size	DHA (mg)	EPA (mg)	EPA or DHA Eligible \geq 130 mg	DHA Eligible \geq 32 mg	EPA plus DHA Eligible \geq 32 mg
Gefiltefish	1.5 oz	19	32	No	No	Yes

TABLE 2.—DHA AND/OR EPA LEVELS OF FROZEN AND REFRIGERATED SEAFOOD AND FISH

Frozen and Refrigerated	Serving Size	DHA (mg)	EPA (mg)	EPA or DHA Eligible \geq 130 mg	DHA Eligible \geq 32 mg	EPA plus DHA Eligible \geq 32 mg
Salmon	3 oz	1099	525	Yes	Yes	Yes
Mackerel	3 oz	1016	555	Yes	Yes	Yes
Tuna	3 oz	757	241	Yes	Yes	Yes
Herring	3 oz	733	603	Yes	Yes	Yes
Albacore Tuna	3 oz	535	198	Yes	Yes	Yes
Trout	3 oz	449	172	Yes	Yes	Yes
Sardines	3 oz	433	402	Yes	Yes	Yes
Mussels	3 oz	430	235	Yes	Yes	Yes
Pollock	3 oz	383	77	Yes	Yes	Yes
Squid	3 oz	323	138	Yes	Yes	Yes
Other (fish sticks)	6 sticks	216	144	Yes	Yes	Yes
Halibut	3 oz	248	60	Yes	Yes	Yes
Oyster	3 oz	245	225	Yes	Yes	Yes
Sole/Flounder	3 oz	219	207	Yes	Yes	Yes
Whiting	3 oz	200	241	Yes	Yes	Yes
Shrimp	3 oz	189	219	Yes	Yes	Yes
Grouper	3 oz	187	23	Yes	Yes	Yes
Perch	3 oz	179	68	Yes	Yes	Yes
Yellowfin Tuna	3 oz	154	31	Yes	Yes	Yes
Haddock	3 oz	138	65	Yes	Yes	Yes
Cod	3 oz	131	3	Yes	Yes	Yes
Clams	3 oz	124	117	No	Yes	Yes
Lobster	3 oz	118	290	Yes	Yes	Yes
Catfish	3 oz	109	42	No	Yes	Yes
Crab	3 oz	96	239	Yes	Yes	Yes
Scallop	3 oz	92	76	No	Yes	Yes
Octopus	3 oz	69	65	No	Yes	Yes
Snapper	3 oz	43	3	No	Yes	Yes
Gefiltefish/Whitefish/Pike	3 oz	38	63	No	Yes	Yes
Crawfish	3 oz	23	99	No	No	Yes
Orange Roughy	3 oz	2	2	No	No	No

FDA was not able to carry out a similar systematic review of foods for ALA claims, because a much wider range of foods may meet the ALA claim. However, only a small proportion of foods have ALA levels between 130 and 160 mg (for “good source” and “more” claims) and ALA levels between 260 and 320 mg (for “high” claim), and therefore will lose their eligibility. In addition to foods that naturally contain these fatty acids, some manufacturers have been increasing the levels of ALA, EPA, or DHA in their products. Foods, such as eggs and milk, can be enriched with ALA, EPA, or DHA by manipulating the diet of chickens and cows, respectively. Also, manufacturers can add ALA to their products by including ingredients like flaxseed oil or ground flaxseed. To find ALA-, EPA-, or DHA-enriched foods, we searched the Internet using keyword searches and in local grocery stores.

FDA searched three local grocery stores for products bearing claims involving ALA, EPA, or DHA. FDA found one new line of products making an ALA claim: pasta with ground flaxseeds to increase the ALA content. This product meets the level of ALA needed to make a “good source” ALA claim under both the 130 and 160 mg levels. FDA did not find any products making a “high” claim. However, the labels refer to an ALA daily value of 1.3 g, so they will have to be changed to reflect the 1.6 g daily value. FDA also searched the Internet to find food products that are likely to include a nutrient content claim. FDA found several brands of eggs, one with added DHA and many with added ALA. FDA reviewed 12 Web sites for ALA- or DHA-enriched eggs. In many cases the Web sites provided a picture of the egg carton, but did not give the full label information. For the ALA eggs, nutrition information on the Web site always emphasized the omega-3 content (which is appropriate on the label or in the labeling of the product as long as the statement does not in any way implicitly characterize the level of the nutrient in the food and it is not false or misleading in any respect (e.g., “100 mg omega-3 fatty acids per serving”) (21 CFR 101.13(i)(3)), not the specific ALA content. However, the Web site for the DHA-enriched eggs emphasized the DHA content and the DHA daily value established under the seafood processors notification. Based on the Internet review, FDA thinks it unlikely that any of the ALA-enriched eggs would be making an affected claim and likely that the DHA-enriched egg would make an affected claim. The DHA-

enriched eggs included processed and shell eggs and were sold in six different packages. FDA also searched a major online drugstore that compiles dietary supplements sold by many other online retailers. This Web site also provided all the labeling information in the dietary supplement package. FDA searched for dietary supplements using the keywords EPA, DHA, fish oil, and ALA. The searches resulted in 53 hits for EPA, 49 hits for DHA, 55 hits for fish oil, and 48 hits for ALA. Many of the products in the searches overlapped. In reviewing these products, FDA found two dietary supplements making affected claims. Overall, these searches were limited and ad hoc and do not constitute a representative sample of the marketplace. Table 3 of this document presents the affected stock keeping units (SKUs). Every product and package size combination represents an SKU. Therefore, the number of SKUs corresponds to the number of product labels.

TABLE 3.—CLAIMS FOUND IN THE MARKETPLACE

Product	Number of Manufacturers	Number of SKUs
Dietary supplements	2	2
Eggs	1	6
Pasta	1	6

Because FDA is unsure about whether the egg product that we identified actually makes a claim, the actual number of SKUs may be slightly lower than FDA indicates in Table 3 of this document. However, because our searches were not representative and we did not perform a comprehensive review of food labels, there are likely to be more claims in the marketplace than we were able to identify using the ad-hoc search procedure we discussed above. For the categories of food FDA was able to identify as containing more than the qualifying levels of EPA and/or DHA, FDA counted the number of SKUs in the 1999 IRI database by downloading all canned, frozen, and refrigerated seafood and fish from the database, then further breaking down these categories into types of seafood and fish using the information provided in each record. FDA only counted branded products, because private label brands make claims infrequently. In the IRI data, the type of fish is usually represented by an abbreviation in the product name, like “abtn” for albacore tuna. So, we counted the number of each type of fish using the abbreviations

in the name provided by IRI. For some products, we were not able to identify the fish or we could not find data on the EPA and/or DHA contents. Most of the foods in the IRI data that did not specify the type of fish were breaded fish fillets or fish sticks. Therefore, for the “other” category of fish we assigned the usual serving size and EPA and DHA levels for fish sticks. Some fish and seafood had multiple levels of EPA and DHA in the USDA Nutrient Laboratory database, depending on the specific variety. If we were not able to determine the relevant type of fish or seafood, we used the median value in the database for the type of fish or seafood. Because 1999 is the most recent IRI data available to us, we needed to correct for changes in the marketplace since 1999. To do so, we used the USDA food disappearance data to estimate changes in the availability of seafood on the market between 1999 and 2003 (the most recent year for which data is available) (Ref. 15). FDA then adjusted the 1999 IRI data by the growth in the relevant seafood category. FDA made an additional adjustment to the count of potentially affected products based on the usual frequency of scheduled label changes. Table 4 of this document presents the proportion of branded SKUs that are typically redesigned within a given period of time. Therefore, FDA estimates that 67 percent of labels would have been redesigned in the timeframe since the seafood processors notification went into effect, 33 percent of the labels would have been redesigned since the Martek notification went into effect, and 5 percent of the labels would have been redesigned since the Ocean Nutrition notification went into effect. In tables 5 and 6 of this document, FDA presents an estimate of the number of labels (SKUs) in the market currently eligible to make an EPA and/or DHA claim. Because foods eligible to make ALA claims include nuts and nut oils and flaxseed and flaxseed oils, as well as foods that include one of these sources as an ingredient, FDA was not able to estimate the number of foods eligible to make an ALA claim. However, only foods with between 130 mg and 160 mg of ALA or foods with between 260 mg and 320 mg of ALA will have a change in their eligibility status, which should be a relatively small number of the total number of eligible foods. Also, we do not count the number of packages of enriched foods because we did not have a comprehensive, up-to-date database of foods enriched with ALA, EPA, or DHA.

TABLE 4.—FREQUENCY OF LABEL REDESIGNS

Time period	Proportion of SKUs
6-month	5 percent

TABLE 4.—FREQUENCY OF LABEL REDESIGNS—Continued

Time period	Proportion of SKUs
12-month	33 percent

TABLE 4.—FREQUENCY OF LABEL REDESIGNS—Continued

Time period	Proportion of SKUs
24-month	67 percent
36-month	100 percent

TABLE 5.—NUMBER OF CANNED FOODS ELIGIBLE TO MAKE AN EPA AND/OR DHA CLAIM

Canned Foods	EPA or DHA Eligible at 130 mg	DHA Eligible at 32 mg	EPA plus DHA Eligible at 32 mg	Adjusted SKUs
Salmon	Yes	Yes	Yes	335
Sardines	Yes	Yes	Yes	282
Gefiltefish	No	No	Yes	161
Light Tuna in water	No	Yes	Yes	130
Shrimp, mixed species	Yes	Yes	Yes	146
Anchovies	No	Yes	Yes	116
Oyster	Yes	Yes	Yes	111
Shrimp	Yes	Yes	Yes	104
Crabmeat	No	Yes	Yes	93
Herring	Yes	Yes	Yes	93
Light Tuna in oil	No	Yes	Yes	76
Mackerel	Yes	Yes	Yes	84
White Tuna in water	Yes	Yes	Yes	58
Caviar	Yes	Yes	Yes	33
White Tuna in oil	No	Yes	Yes	9
Number of SKUs eligible	1,246	1,540	1,701	
Adjusted for time since eligibility	835	508	85	

TABLE 6.—NUMBER OF FROZEN AND REFRIGERATED SEAFOOD AND FISH ELIGIBLE TO MAKE AN EPA AND/OR DHA CLAIM

Frozen and Refrigerated	EPA or DHA Eligible at 130 mg	DHA Eligible at 32 mg	EPA plus DHA Eligible at 32 mg	Adjusted SKUs
Shrimp	Yes	Yes	Yes	1,272
Salmon	Yes	Yes	Yes	329
Other	Yes	Yes	Yes	116
Tuna	Yes	Yes	Yes	249
Herring	Yes	Yes	Yes	242
Oyster	Yes	Yes	Yes	228
Crab	Yes	Yes	Yes	155
Octopus	No	Yes	Yes	160
Cod	Yes	Yes	Yes	95
Lobster	Yes	Yes	Yes	126
Scallop	No	Yes	Yes	101
Whiting	Yes	Yes	Yes	82

TABLE 6.—NUMBER OF FROZEN AND REFRIGERATED SEAFOOD AND FISH ELIGIBLE TO MAKE AN EPA AND/OR DHA CLAIM—Continued

Frozen and Refrigerated	EPA or DHA Eligible at 130 mg	DHA Eligible at 32 mg	EPA plus DHA Eligible at 32 mg	Adjusted SKUs
Clams	No	Yes	Yes	75
Crawfish	No	No	Yes	80
Albacore Tuna	Yes	Yes	Yes	78
Sole/Flounder	Yes	Yes	Yes	61
Catfish	No	Yes	Yes	55
Haddock	Yes	Yes	Yes	37
Squid	Yes	Yes	Yes	43
Pollock	Yes	Yes	Yes	31
Mussels	Yes	Yes	Yes	39
Orange Roughy	No	No	No	30
Gefiltefish/Whitefish/Pike	No	Yes	Yes	19
Halibut	Yes	Yes	Yes	17
Trout	Yes	Yes	Yes	19
Perch	Yes	Yes	Yes	18
Yellowfin Tuna	Yes	Yes	Yes	7
Mackerel	Yes	Yes	Yes	9
Snapper	No	Yes	Yes	7
Grouper	Yes	Yes	Yes	3
Sardines	Yes	Yes	Yes	4
Number of SKUs eligible	3,335	3,677	3,757	
Adjusted for time since eligibility	2,234	1,213	188	

Cost of Label Changes

Producers who will be affected by this rule are likely to go through several steps to modify their labels to come into compliance with the proposed requirements. The producers will do the following: (1) Conduct administrative activities, (2) alter the graphic design, (3) conduct prepress activities, engrave plates or cylinders, and (4) print and manufacture labels. Producers incur costs associated with each step of the process. The first step requires that producers read and develop a strategy to comply with the proposed requirements. Second, they will develop

a new graphic design for the label that complies with the proposed requirements. Third, a prepress operator will convert the new design into printing plates or cylinders. Fourth, the new labels will be printed. The costs associated with label changes will also vary depending on whether the label change can be coordinated with a scheduled label change. There may be an additional inventory cost to producers if they have to dispose of already printed labels.

FDA contracted with RTI International to estimate the costs of label changes to producers (Ref. 16). RTI

estimated the costs associated with each of these steps, as well as the cost of discarded inventory of unused labels. Manufacturers regularly redesign their labels, so RTI only estimated a cost associated with the label change if the regulatory label change could not be done with a regularly scheduled label change. The estimated schedule for label changes is presented in table 4 of this table. Tables 7 and 8 present estimates of per SKU cost of a label change.

TABLE 7.—COST OF LABEL CHANGE (PER SKU) FOR SEAFOOD AND PASTA (IN 2005 DOLLARS)

	Canned Seafood	Frozen Seafood	Refrigerated Seafood	Pasta
Administrative	\$200	\$200	\$400	\$500
Graphic	\$800	\$900	\$1,400	\$1,600

TABLE 7.—COST OF LABEL CHANGE (PER SKU) FOR SEAFOOD AND PASTA (IN 2005 DOLLARS)—Continued

	Canned Seafood	Frozen Seafood	Refrigerated Seafood	Pasta
Prepress	\$1,200	\$500	\$800	\$900
Engraving	\$2,900	\$700	\$1,100	\$1,300
Inventory	\$0	\$0	\$0	\$0
Total	\$5,100	\$2,300	\$3,700	\$4,300

TABLE 8.—COST OF LABEL CHANGE (PER SKU) FOR DIETARY SUPPLEMENTS AND EGGS (IN 2005 DOLLARS)

	Dietary Supplement Liquid	Dietary Supplement Pills	Processed Eggs	Shell Eggs
Administrative	\$900	\$900	\$500	\$500
Graphic	\$3,300	\$2,200	\$1,600	\$1,600
Prepress	\$2,100	\$2,100	\$1,100	\$1,100
Engraving	\$2,100	\$2,100	\$900	\$900
Inventory	\$0	\$100	\$0	\$500
Total	\$8,400	\$7,400	\$4,100	\$4,600

Based on our ad hoc searching, it is clear that not all products eligible to make an affected claim are making a claim. Overall, we estimate that at least 14 product labels will have to be changed as a result of this rule. Table 9

of this document presents an estimate of the cost associated with known label changes. This is probably an underestimate of the labeling cost because FDA has not conducted a comprehensive review of food labels to

identify the number of products bearing these claims and we have probably underestimated the number of such claims. However, we are uncertain about the true number of existing claims.

TABLE 9.—LOWER BOUND ESTIMATE OF TOTAL COSTS FROM LABELING CHANGES

Product	Number of SKUs	Cost of Label Change*
Dietary supplements	2	\$5,200
Eggs	6	\$8,600
Pasta	6	\$8,500
Total	14	\$22,300

*Assumes 67 percent of label changes can be made with regularly scheduled label changes.

To determine the number of dietary supplements that qualify for a nutrient content claim, FDA counted the number of dietary supplements that have fish oil, ALA, EPA, or DHA as an ingredient in the Dietary Supplement Sales Information database (Ref. 17). The Dietary Supplement Sales Information database is a survey of the ingredients in 3,000 dietary supplements. Based on a total count of 113 qualifying dietary supplements in the database, FDA estimates that the Internet review of dietary supplements covered

approximately half of the qualifying dietary supplements, and so a likely estimate is that four dietary supplements would have to change their labels. In the search of local grocery stores, we reviewed approximately 200 fish and seafood packages. None of the labels we reviewed included an affected claim. However, it seems likely that each of the five companies that participated in notifications to FDA may make some nutrient content claim. Therefore, FDA estimates that it is likely that a label change would be required

for six SKUs for each of the five manufacturers. FDA estimated 6 SKUs per manufacturer because the product lines identified for eggs and pasta that were making an affected nutrient content claim both included 6 SKUS. Finally, for the other two types of products we found that made a label claim, we estimate that, similar to dietary supplements, there are twice as many affected claims in the market. Table 10 of this document presents an estimate of the likely total cost of label changes.

TABLE 10.—LIKELY ESTIMATE OF TOTAL COSTS FROM LABELING CHANGES

Product	Number of SKUs	Cost of Label Change*
Dietary supplements	4	\$10,400

TABLE 10.—LIKELY ESTIMATE OF TOTAL COSTS FROM LABELING CHANGES—Continued

Product	Number of SKUs	Cost of Label Change*
Notifiers	30	\$39,200
Eggs	12	\$17,200
Pasta	12	\$17,000
Total	58	\$83,800

* Assumes 67 percent of label changes can be made with regularly scheduled label changes

Health Effects

Benefits from a labeling rule typically arise from changes in consumption of nutrients, either increases in consumption of beneficial nutrients or decreases in consumption of detrimental nutrients. Consumption changes because the behavior of producers or consumers changes. Product reformulation, in which producers alter the composition of their product to qualify for a positive label claim or avoid a negative label statement, may lead to substantial changes in the consumption of certain beneficial nutrients. There may also be direct changes in consumer choices, if consumers purchase healthier food based on information they see on the label. Several studies have linked label use to improved diet (Refs. 18 and 19).

The removal of nutrient content claims for EPA and/or DHA may result in reduced consumption of EPA and DHA under two scenarios. First, consumption of these nutrients may be reduced if consumers choose not to purchase and consume products because they do not have the prohibited nutrient content claims on the label. Second, producers might face reduced incentives to increase levels of EPA and DHA in products, which might lead some producers to a decision not to reformulate. A review of the literature on product reformulation in a report on modeling manufacturers' decision to reformulate finds evidence that increased provision of nutrition information on labels leads manufacturers to reformulate to make healthier products or to attempt to market new healthier products (Ref. 20). If the continued availability of nutrient content claims for EPA and/or DHA would have encouraged producers to increase levels of EPA and/or DHA, there may be additional reductions in consumption of EPA and/or DHA due to lower levels in the food supply. However, because the agency has yet to conduct a review of the scientific evidence concerning the health effects of consuming EPA and DHA at different levels, we cannot determine whether the

loss of these claims would have any impact on consumer health, either beneficial or detrimental.

Furthermore, FDA wishes to emphasize that this ruling does not affect the continuing availability of a qualified health claim that states, "Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of CHD. One serving of [Name of the food] provides [] gram of EPA and DHA omega-3 fatty acids. [See nutrition information for total fat, saturated fat, and cholesterol content]." To make the qualified health claim, the product must contain EPA and DHA, and meet limits for cholesterol, saturated fat, total fat, and sodium and meet the 10 percent nutrient content requirement for vitamin C, vitamin A, iron, calcium, protein, or fiber (Ref. 21). Producers may opt to reformulate their products to use the qualified health claim.

Therefore, FDA estimates the quantitative costs of this rule to be \$83,800 due entirely to projected labeling changes, and potential non-quantified costs associated with a potential forgone decrease in risk of CHD resulting from a possible decrease in the consumption of EPA and/or DHA.

Benefits

This option would prevent consumers from mistakenly interpreting "high," "good source," and "more" claims relating to the level of EPA and/or DHA in food to imply that an authoritative scientific body has determined that consumers should consume a particular level of EPA and/or DHA per day. This, in turn, might prevent some consumers from forming an incorrect assessment of the relationship of the levels of EPA and/or DHA in particular foods to such recommended levels. This could generate a health benefit because if consumers base their consumption patterns on an incorrect assessment of the significance of the amount of EPA and/or DHA in particular foods, then they might change their consumption patterns in ways that could be detrimental to their health. For example,

some consumers might believe they would not receive any additional benefit from consuming additional food containing EPA and/or DHA after eating a food that is labeled as being "high" in those nutrients even though they might actually benefit significantly from additional amounts of those nutrients. Alternatively, some consumers might believe that it is worthwhile to forgo a certain level of other nutrients in order to consume a food that is "high" level of EPA and/or DHA when, in fact, they could obtain nearly the same benefit from a food with less EPA and/or DHA. FDA does not have sufficient information to quantify this potential benefit.

VI. The Paperwork Reduction Act of 1995

FDA tentatively concludes that this proposed rule contains no collection of information. Therefore clearance by OMB under the Paperwork Reduction Act of 1995 is not required.

VII. Federalism Analysis

FDA has analyzed this proposed rule in accordance with the principles set forth in Executive Order 13132. FDA has determined that the proposed rule, if finalized as proposed, would have a preemptive effect on State law. Section 4(a) of the Executive order requires agencies to "construe * * * a Federal Statute to preempt State law only where the statute contains an express preemption provision, there is some other clear evidence that the Congress intended preemption of State law, or where the exercise of State authority conflicts with the exercise of Federal authority under the Federal statute." Section 403A of the act (21 U.S.C. 343-1) is an express preemption provision. In relevant part, section 403A(a)(5) of the act (21 U.S.C. 343-1(a)(5)) provides that: "* * * no State or political subdivision of a State may directly or indirectly establish under any authority or continue in effect as to any food in interstate commerce— * * * (5) any requirement respecting any claim of the type described in section 403(r)(1) made

in the label or labeling of food that is not identical to the requirement of section 403(r) * * *”.

Currently, this provision operates to preempt States from imposing nutrient content claim labeling requirements concerning ALA, EPA, DHA, and EPA and DHA combined because no such requirements have been imposed by FDA under section 403(r) of the act. Under FDA's authority under section 403(r)(2)(H) of the act, the agency proposes to find that the requirements of section 403(r)(2)(G) have not been met with respect to the nutrient content claims for EPA and DHA in the seafood processors notification, the nutrient content claim for DHA in the Martek notification, and the nutrient content claim for EPA and DHA in the Ocean Nutrition notification. FDA also proposes to prohibit the nutrient content claims for ALA in the seafood processors notification.

Although this proposed rule, if finalized as proposed, would have preemptive effect in that it would preclude States from promulgating any nutrient content claim labeling requirements for ALA, EPA, DHA, and EPA and DHA combined that are not identical to those required by this proposed rule, this preemptive effect would be consistent with what Congress set forth in section 403A of the act. Section 403A(a)(5) of the act displaces both state legislative requirements and state common law duties. *Medtronic v. Lohr*, 518 U.S. 470, 503 (1996) (Breyer, J., concurring in part and concurring in judgment); *id.* at 510 (O'Connor, J., joined by Rehnquist, C.J., Scalia, J., and Thomas, J., concurring in part and dissenting in part); *Cipollone v. Liggett Group, Inc.*, 505 U.S. 504, 521 (1992) (plurality opinion); *id.* at 548-49 (Scalia, J., joined by Thomas, J., concurring in judgment in part and dissenting in part).

FDA believes that the preemptive effect of the proposed rule, if finalized as a proposed, would be consistent with Executive Order 13132. Section 4(e) of the Executive order provides that “when an agency proposes to act through adjudication or rulemaking to preempt State law, the agency shall provide all affected State and local officials notice and an opportunity for appropriate participation in the proceedings.” FDA's Division of Federal and State Relations is inviting the States' participation in this rulemaking by providing notice via fax and e-mail transmission to State health commissioners, State agriculture commissioners, food program directors, and drug program directors as well as FDA field personnel of FDA's publication of the proposed rule prohibiting the nutrient content claims

for ALA, EPA, DHA, and EPA and DHA combined set forth in the three FDAMA notifications received by FDA. The notice provides the States with further opportunity for input on the rule. It advises the States of FDA's publication of the proposed rule and encourages the States and local governments to review the notice of proposed rulemaking and to provide any comments to the docket (Docket No. 2004N-0217, 2005P-0189, or 2006P-0137).

In conclusion, FDA has determined that the preemptive effects of this proposed rule, if finalized as proposed, are consistent with Executive Order 13132.

VIII. Effective Date

FDA is proposing to make this regulation effective on the uniform compliance date for food labeling regulations established by the agency that is applicable to the publication date of the final rule.

IX. Comments

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) written or electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Please note that in January 2008, the FDA Web site is expected to transition to the Federal Dockets Management System (FDMS). FDMS is a Government-wide, electronic docket management system. After the transition date, electronic submissions will be accepted by FDA through the FDMS only. When the exact date of the transition to FDMS is known, FDA will publish a **Federal Register** notice announcing that date.

X. References

The following references have been placed on display in the Division of Dockets Management (see **ADDRESSES**) and may be seen between 9 a.m. and 4 p.m., Monday through Friday, except on Federal Government holidays. (FDA has verified the Web site addresses, but is not responsible for any subsequent changes to the Web sites after this document publishes in the **Federal Register**.)

1. Institute of Medicine of the National Academies, “Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids,

Cholesterol, Protein, and Amino Acids,” Summary, Chapter 8, and Chapter 11, the National Academies Press, Washington, DC, 2005.

2. Institute of Medicine of the National Academies, Prepublication Copy, “Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids,” Summary, Chapter 8, and Chapter 11, the National Academies Press, Washington, DC, 2002.

3. Carpenter, K.J. and A.E. Harper, “Evolution of Knowledge of Essential Nutrients,” in *Modern Nutrition in Health and Disease*, Eds. M.E. Shils, M. Shike, A.C. Ross, B. Caballero, and R.J. Cousins, Philadelphia, P.A.: Lippincott Williams & Wilkins, p. 7, 2006.

4. Stryer, L., *Biochemistry*, Fourth Edition, New York: W.H. Freeman and Co., p. 604, 1995.

5. Alaska General Seafoods, Ocean Beauty Seafoods, Inc., and Trans-Ocean Products, Inc. “Notification for a Nutrient Content Claim Based on an Authoritative Statement,” Item CP1, Docket No. 2004N-0217, Division of Dockets Management, May 15, 2004.

6. U.S. Food and Drug Administration, “Nutrient Content Claims Notification for Choline Containing Foods,” (<http://www.cfsan.fda.gov/~dms/flcholin.html>) August 30, 2001.

7. Institute of Medicine of the National Academies, “Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline,” the National Academies Press, Washington, DC, pp. 390 to 422, 1998.

8. Institute of Medicine of the National Academies, “Dietary Reference Intakes: Guiding Principles for Nutrition Labeling and Fortification,” the National Academies Press, Washington, DC, pp. 82 to 95, 2003.

9. Martek Biosciences Corporation, “Notification for a Nutrient Content Claim Based on an Authoritative Statement,” Item CP1, Docket 2005P-0189, Division of Dockets Management, May 23, 2005.

10. Ocean Nutrition Canada, “Notification for a Nutrient Content Claim Based on an Authoritative Statement,” Item CP1, Docket No. 2006P-0137, Division of Dockets Management, December 9, 2005.

11. A letter from William K. Hubbard, FDA to Jonathan W. Emord, Esq., Emord & Associates, P.C., (<http://www.cfsan.fda.gov/~dms/ds-ltr38.html>), September 8, 2004.

12. A letter from William K. Hubbard, FDA to Martin J. Hahn, Esq., Hogan & Hartson, L.L.P., (<http://www.cfsan.fda.gov/~dms/ds-ltr37.html>), September 8, 2004.

13. Information Resources, Inc., (IRI), download, (<http://www.infocan.com/public/us/content/infocan/fooddrugmass.htm>), 1999.

14. U.S. Department of Agriculture, Agricultural Research Service, USDA National Nutrient Database for Standard Reference, Release 17, Nutrient Data Laboratory Home Page (<http://www.nal.usda.gov/fnic/foodcomp>), 2004.

15. U.S. Department of Agriculture Economic Research Service, Food Consumption Data System (<http://www.ers.usda.gov/data/foodconsumption/Index.htm>), 2005.

16. RTI International, "FDA Labeling Cost Model," Prepared for FDA, January, 2003.

17. RTI International, "Dietary Supplement Sales Information," Prepared for FDA, October 1999.

18. Neuhouser, M.L., A.R. Kristal, and R.E. Patterson, "Use of Food Nutrition Labels Associated with Lower Fat Intake," *Journal of the American Dietetic Association*, vol. 53, pp. 45 to 50, 53, 1999.

19. Kim, S., R.M. Nayga, Jr., and O. Capps, Jr., "The Effect of Food Label Use on Nutrient Intakes: An Endogenous Switching Regression Analysis," *Journal of Agricultural and Resource Economics*, vol. 25, pp. 215 to 231, 2000.

20. RTI International, "Modeling the Decision to Reformulate Food and Cosmetics," Prepared for FDA, October 2003.

21. U.S. Food and Drug Administration, "Summary of Qualified Health Claims Permitted," Accessed at <http://www.cfsan.fda.gov/~dms/qhc-sum.html#omega3> on September 26, 2005.

Dated: November 19, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. E7-22991 Filed 11-26-07; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR PART 1305

[Docket No. DEA-303P]

RIN 1117-AB15

New Single-Sheet Format for U.S. Official Order Form for Schedule I and II Controlled Substances (DEA Form 222)

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice of proposed rulemaking.

SUMMARY: The Drug Enforcement Administration (DEA) is proposing to amend its regulations to implement a new format for order forms (DEA Form 222) which are issued by DEA to DEA registrants to allow them to order schedule I and/or II controlled substances. The present format utilizes a three-part, carbon-copy form with Copies 2 and 3 replicating Copy 1. The proposed format will employ a single-sheet form. The new form will have enhanced security features and will be easier for DEA registrants to use.

DATES: Written comments must be postmarked, and electronic comments must be sent, on or before January 28, 2008.

ADDRESSES: To ensure proper handling of comments, please reference "Docket No. DEA-303P" on all written and

electronic correspondence. Written comments being sent via regular mail should be sent to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, *Attention:* DEA Federal Register Representative/ODL. Written comments sent via express mail should be sent to DEA Headquarters, *Attention:* DEA Federal Register Representative/ODL, 8701 Morrisette Drive, Springfield, VA 22152. Comments may be sent directly to DEA electronically by sending an electronic message to dea.diversion.policy@usdoj.gov. Comments may also be sent electronically through <http://www.regulations.gov> using the electronic comment form provided on that site. An electronic copy of this document is also available at the <http://www.regulations.gov> Web site. DEA will accept electronic comments containing MS Word, WordPerfect, Adobe PDF, or Excel files only. DEA will not accept any file format other than those specifically listed here.

Posting of Public Comments: Please note that all comments received are considered part of the public record and made available for public inspection online at <http://www.regulations.gov> and in the Drug Enforcement Administration's public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "PERSONAL IDENTIFYING INFORMATION" in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "CONFIDENTIAL BUSINESS INFORMATION" in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be posted online or made available in the public docket.

Personal identifying information and confidential business information identified and located as set forth above will be redacted and the comment, in redacted form, will be posted online and placed in the Drug Enforcement Administration's public docket file. If you wish to inspect the agency's public docket file in person by appointment, please see the **FOR FURTHER INFORMATION CONTACT** paragraph.

FOR FURTHER INFORMATION CONTACT: Mark W. Caverly, Chief, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Telephone (202) 307-7297.

SUPPLEMENTARY INFORMATION:

Background

Legal Authority

The Drug Enforcement Administration (DEA) administers the Controlled Substances Act (CSA) (21 U.S.C. 801 *et seq.*) as amended. DEA regulations implementing this statute are published in Title 21 of the Code of Federal Regulations (CFR), Parts 1300 to 1316. These regulations are designed to establish a framework for the legal distribution of controlled substances to ensure that there is a sufficient supply of these drugs for legitimate medical purposes while deterring their diversion to illegal purposes. Controlled substances are those substances listed in the schedules of the CSA and 21 CFR 1308.11-1308.15, and generally include narcotics, stimulants, depressants, hallucinogens, and anabolic steroids that have potential for abuse and physical and psychological dependence.

Controlled substances are divided into five schedules. Schedule I substances are drugs which have a high potential for abuse and no currently accepted medical use in treatment in the United States. They may be used only for research, chemical analysis, or manufacture of other drugs. Schedule II substances have legitimate medical uses, but a high potential for abuse and physical and psychological dependence, and are subject to more stringent controls than other legitimate controlled substances. Schedule III through V substances have legitimate medical uses; however, they have a lower potential for abuse and physical and psychological dependence than do schedule II controlled substances.

The CSA and DEA regulations require that persons involved in the manufacture, distribution, research, dispensing, import, and export of controlled substances register with DEA, keep track of all stocks of controlled substances, and maintain records to

account for all controlled substances received, distributed, or otherwise disposed of. The overall goal of the CSA and its implementing regulations is to provide a closed distribution system so that a controlled substance is at all times under the legal control of a person registered, or specifically exempted from registration, by the Drug Enforcement Administration until it reaches the ultimate user or is destroyed. DEA achieves this goal by registering manufacturers, distributors, reverse distributors, dispensers, researchers, importers and exporters of controlled substances. Thus, any movement of controlled substances between these registered persons is covered by DEA regulations.

Order Forms

The CSA requires that schedule I and II controlled substances be distributed only pursuant to a written order made by the purchaser on a form issued by the Attorney General, (21 U.S.C. 828). This responsibility has been delegated to the Administrator of DEA (28 CFR 0.100) and redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (28 CFR 0.104; Appendix to Subpart R, § 7). DEA uses these order forms to allow better tracking of all distributions of schedule I and II controlled substances. As stated previously, order forms are required for schedule I and II controlled substances because they have a higher potential for abuse and physical and psychological dependence than schedule III through V controlled substances. The order forms are issued to DEA registrants to allow them to purchase controlled substances. The order forms are designated as DEA Form 222. The law and regulations require that DEA preprint certain information on these order forms including the name, address, and DEA number of the registrant, the authorized activity, and the schedules of the registrant (21 U.S.C. 828, 21 CFR 1305.11). Order forms are triplicate forms, printed on interleaved carbon sheets.

Whenever a DEA registrant wishes to acquire a schedule I and/or II controlled substance, that registrant must annotate on the order form the name and address of the supplying DEA registrant, the date requested, the number of packages of controlled substance ordered, the size of the package of the controlled substance ordered, and the name of the controlled substance ordered. The purchaser retains one copy (Copy 3) of the form and sends two copies to the supplier so that the order for a controlled substance can be filled. The supplier annotates the form by entering

the actual number of packages of the controlled substance(s) shipped and the actual date shipped. The supplier retains one copy (Copy 1) of the order form sent to him/her by the purchaser, and sends the other copy (Copy 2) of the form to the DEA Special Agent in Charge in the area where the supplier is located. Upon receiving the controlled substances, the purchaser annotates on its copy of the order form the number of packages of the controlled substance(s) ordered which are actually received and the actual date received. Both the purchaser and the supplier are required to preserve their respective copy of the order form for two years and make it available to officials of the DEA for inspection, if requested.

Need for New Form

The proposed new format for DEA Form 222 will employ a single-sheet form. In executing a transaction of a schedule I and/or II controlled substance, a DEA registrant will process the new single-sheet form in a similar manner to the processing of the current three-part form. The change in processing will be that the single-sheet form will have to be copied rather than having the copies pre-printed. DEA will continue to preprint and issue the original form.

The new form is being initiated to improve security and to allow better ease in handling. The new form will have enhanced security features over the current three-part form. DEA will preprint the new form on sturdier paper with a special embedded watermark of the DEA emblem making it more difficult to copy for counterfeit purposes. If photocopied, the photocopy of the new form will display the DEA emblem and the statement "Copy" to hinder counterfeiting.

It is anticipated that the new form will be more convenient for DEA registrants to utilize. The old three-part form format was created more than thirty years ago and the processing of a transaction with carbon copies is an outdated concept. Today, new office technology exists such as laser printers and photocopiers which will allow DEA registrants greater ease in utilizing the single-sheet form.

The single-sheet form will be beneficial for DEA as well. The equipment used to print the interleaved carbon forms is old, and finding replacement parts and otherwise maintaining the equipment is costly, difficult, and time-consuming.

Transition From Old to New Format

If this regulation is finalized as proposed, once the new single-sheet

form is in use, the current three-part form will be phased out, and eventually will no longer be issued by DEA. DEA registrants will be allowed to exhaust their supply of the old three-part forms as part of the transition. To effect a smooth transition, DEA registrants will be allowed to continue to order the current three-part form for at least one year once the new single-sheet form is introduced. Approximately two years after the establishment of the new single-sheet format, the old three-part form will be totally discontinued. Thus, business firms will have time to shift their processes to accommodate the new form.

Revision of DEA Regulations to Accommodate Single Sheet DEA Form 222

DEA proposes to amend its regulations pertaining to orders for schedule I and II controlled substances to allow for the transition from the three-part form to the single-sheet form of DEA Form 222. Initially, the new procedures for the single-sheet format will exist alongside the existing procedures for the three-part form. Eventually, in a later rulemaking, the procedures detailing the use of the three-part form will be deleted from the regulations.

DEA is amending its regulations to reflect the fact that only one original DEA Form 222 will be provided to purchasing registrants by DEA. Registrants purchasing schedule I and II controlled substances will now be required to make a copy of the form and send the original to their supplier for filling. It is important to note that the process for handling the DEA Form 222 remains unchanged. The only difference made by these proposed amendments is to require registrants to make photocopies of the form, rather than having DEA provide an original and two carbon copies.

Other Minor Regulatory Changes

In addition to the changes discussed above, DEA is proposing several minor regulatory changes as part of this rulemaking, as discussed below.

Currently, interleaved triplicate order forms are produced in books, with each book containing 7 order forms. The new single-sheet form will not be produced in books, giving DEA and registrants greater flexibility regarding the number of order forms to be requisitioned. Therefore, in § 1305.11, DEA is proposing to modify the language regarding the new single-sheet DEA Form 222 to indicate that a predetermined number of order forms, based on the business activity of the

registrant, will be issued, rather than books of 7 order forms.

In § 1305.12, DEA is proposing to add to the list of acceptable methods for filling out a DEA Form 222 use of a computer printer, in addition to the existing typewriter, pen, or indelible pencil.

Regulatory Certifications

Regulatory Flexibility Act

The Deputy Assistant Administrator hereby certifies that this rulemaking has been drafted in accordance with the Regulatory Flexibility Act (5 U.S.C. 605(b)), and by approving it certifies that this regulation will not have a significant economic impact upon a substantial number of small entities. This rule proposes that DEA regulations be amended to implement a new format for order forms (DEA Form 222) which are issued by DEA to DEA registrants to allow them to order schedule I and/or II controlled substances. The present format utilizes a three-part, carbon-copy form with Copies 2 and 3 replicating Copy 1. The proposed format will employ a single-sheet form, which will incorporate additional security features and will be easier for DEA registrants to use.

Executive Order 12866

The Deputy Assistant Administrator further certifies that this rulemaking has been drafted in accordance with the principles of Executive Order 12866 Section 1(b). It has been determined that this is a significant regulatory action. Therefore, this action has been reviewed by the Office of Management and Budget.

Executive Order 12988

The Deputy Assistant Administrator further certifies that this regulation meets the applicable standards set forth in Sections 3(a) and 3(b)(2) of Executive Order 12988.

Executive Order 13132

This rulemaking does not preempt or modify any provision of State law; nor does it impose enforcement responsibilities on any State; nor does it diminish the power of any State to enforce its own laws. Accordingly, this rulemaking does not have federalism implications warranting the application of Executive Order 13132.

Unfunded Mandates Reform Act of 1995

This rule will not result in the expenditure by State, local and tribal governments, in the aggregate, or by the private sector, of \$120,000,000 or more (adjusted for inflation) in any one year,

and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

Paperwork Reduction Act

Although this rule establishes a new DEA Form 222, it does not affect the time necessary to complete the collection of information nor the persons required to use DEA Form 222 in the ordering of schedule I and II controlled substances. Nor does the revision of the design of the form—use of triplicate interleaved sheets versus single sheet—revise the fields contained on the form. The new form does not collect any new information or modify any existing information being collected. Accordingly, revisions to the DEA information collection entitled “U.S. Official Order Forms for Schedule I and II Controlled Substances (Accountable Forms), Order Form Requisition” (OMB approval number 1117–0010) are not necessary.

Congressional Review Act

This rule is not a major rule as defined by Section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act). This rule will not result in an annual effect on the economy of \$100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.

List of Subjects in 21 CFR Part 1305

Drug traffic control, Reporting requirements.

For the reasons set forth above, 21 CFR part 1305 is proposed to be amended as follows:

PART 1305—ORDERS FOR SCHEDULE I AND II CONTROLLED SUBSTANCES [AMENDED]

1. The authority citation for part 1305 continues to read as follows:

Authority: 21 U.S.C. 821, 828, and 871, unless otherwise noted.

2. Section 1305.11 is amended by revising paragraphs (a) and (b) to read as follows:

§ 1305.11 Procedure for obtaining DEA Forms 222.

(a)(1) Except as provided in paragraph (a)(2) of this section, DEA Forms 222 are issued in mailing envelopes containing seven forms, each form containing an

original, duplicate, and triplicate copy (respectively, Copy 1, Copy 2, and Copy 3) (hereafter referred to as the “triplicate” form). A limit, which is based on the business activity of the registrant, will be imposed on the number of DEA Forms 222 which will be furnished on any requisition, unless additional forms are specifically requested and a reasonable need for such additional forms is shown.

(2) DEA Forms 222 are issued in mailing envelopes containing a predetermined number of forms based on the business activity of the registrant, each form consisting of one single-sheet (hereafter referred to as the “single sheet” form). A limit, which is based on the business activity of the registrant, will be imposed on the number of DEA Forms 222 which will be furnished on any requisition unless additional forms are specifically requested and a reasonable need for such additional forms is shown.

(b) Any person applying for a registration that would entitle him or her to obtain a DEA Form 222 may requisition the forms by so indicating on the application or renewal form; a DEA Form 222 will be supplied upon the registration of the applicant. Any person holding a registration entitling him or her to obtain a DEA Form 222 may requisition the forms for the first time by contacting any Division Office or the Registration Section of the Administration. Any person already holding a DEA Form 222 may requisition additional forms by contacting any Division Office or the Registration Section of the Administration.

* * * * *

3. Section 1305.12 is amended by revising paragraph (a) to read as follows:

§ 1305.12 Procedure for executing DEA Forms 222.

(a)(1) A purchaser must prepare and execute a triplicate DEA Form 222 simultaneously in triplicate by means of interleaved carbon sheets that are part of the DEA Form 222. DEA Form 222 must be prepared by use of a typewriter, computer printer, pen, or indelible pencil.

(2) A purchaser must prepare a single sheet DEA Form 222 by use of a typewriter, computer printer, pen, or indelible pencil.

* * * * *

4. Section 1305.13 is amended by revising paragraphs (a), (b), (d), and (e) to read as follows:

§ 1305.13 Procedure for filling DEA Forms 222.

(a)(1) A purchaser must submit Copy 1 and Copy 2 of the triplicate DEA Form 222 to the supplier and retain Copy 3 in the purchaser's files.

(2) A purchaser must submit the original of the single sheet DEA Form 222 to the supplier and retain a copy in the purchaser's files.

(b)(1) For the triplicate DEA Form 222, a supplier may fill the order, if possible and if the supplier desires to do so, and must record on Copies 1 and 2 the number of commercial or bulk containers furnished on each item and the date on which the containers are shipped to the purchaser. If an order cannot be filled in its entirety, it may be filled in part and the balance supplied by additional shipments within 60 days following the date of the DEA Form 222. No DEA Form 222 is valid more than 60 days after its execution by the purchaser, except as specified in paragraph (f) of this section.

(2) For the single sheet DEA Form 222, a supplier may fill the order, if possible and if the supplier desires to do so, and must record on the original and a copy the number of commercial or bulk containers furnished on each item and the date on which the containers are shipped to the purchaser. If an order cannot be filled in its entirety, it may be filled in part and the balance supplied by additional shipments within 60 days following the date of the DEA Form 222. No DEA Form 222 is valid more than 60 days after its execution by the purchaser, except as specified in paragraph (f) of this section.

* * * * *

(d)(1) The supplier must retain Copy 1 of the triplicate DEA Form 222 for his or her files and forward Copy 2 to the Special Agent in Charge of the Drug Enforcement Administration in the area in which the supplier is located. Copy 2 must be forwarded at the close of the month during which the order is filled. If an order is filled by partial shipments, Copy 2 must be forwarded at the close of the month during which the final shipment is made or the 60-day validity period expires.

(2) The supplier must retain the original of the single sheet DEA Form 222 for his or her files and forward a copy to the Special Agent in Charge of the Drug Enforcement Administration in the area in which the supplier is located. The copy must be forwarded at the close of the month during which the order is filled. If an order is filled by partial shipments, the copy must be forwarded at the close of the month during which the final shipment is

made or the 60-day validity period expires.

(e)(1) The purchaser must record on Copy 3 of the triplicate DEA Form 222 the number of commercial or bulk containers furnished on each item and the dates on which the containers are received by the purchaser.

(2) The purchaser must record on its copy of the single sheet DEA Form 222 the number of commercial or bulk containers furnished on each item and the dates on which the containers are received by the purchaser.

* * * * *

5. Section 1305.14 is amended by revising paragraph (a) to read as follows:

§ 1305.14 Procedure for endorsing DEA Forms 222.

(a)(1) A triplicate DEA Form 222, made out to any supplier who cannot fill all or a part of the order within the time limitation set forth in § 1305.13, may be endorsed to another supplier for filling. The endorsement must be made only by the supplier to whom the DEA Form 222 was first made, must state (in the spaces provided on the reverse sides of Copies 1 and 2 of the triplicate DEA Form 222) the name and address of the second supplier, and must be signed by a person authorized to obtain and execute DEA Forms 222 on behalf of the first supplier. The first supplier may not fill any part of an order on an endorsed form. The second supplier may fill the order, if possible and if the supplier desires to do so, in accordance with § 1305.13(b), (c), and (d), including shipping all substances directly to the purchaser.

(2) A single-sheet DEA Form 222, made out to any supplier who cannot fill all or a part of the order within the time limitation set forth in § 1305.13, may be endorsed to another supplier for filling. The endorsement must be made only by the supplier to whom the DEA Form 222 was first made, must state (in the spaces provided in Part 2 on the original DEA Form 222 and on the copy to be sent to DEA) the name and address of the second supplier, and must be signed by a person authorized to obtain and execute DEA Forms 222 on behalf of the first supplier. The first supplier may not fill any part of an order on an endorsed form. The second supplier may fill the order, if possible and if the supplier desires to do so, in accordance with § 1305.13(b), (c), (d), including shipping all substances directly to the purchaser.

* * * * *

6. Section 1305.15 is amended by revising paragraphs (b) and (d) to read as follows:

§ 1305.15 Unaccepted and defective DEA Forms 222.

* * * * *

(b)(1) If a triplicate DEA Form 222 cannot be filled for any reason under this section, the supplier must return Copies 1 and 2 to the purchaser with a statement as to the reason (e.g. illegible or altered).

(2) If a single-sheet DEA Form 222 cannot be filled for any reason under this section, the supplier must return the original copy to the purchaser with a statement as to the reason (e.g. illegible or altered).

* * * * *

(d)(1) When a purchaser receives an unaccepted order, Copies 1 and 2 of the triplicate DEA Form 222 and the statement must be attached to Copy 3 and retained in the files of the purchaser in accordance with § 1305.17. A defective DEA Form 222 may not be corrected; it must be replaced by a new DEA Form 222 for the order to be filled.

(2) When a purchaser receives an unaccepted order, the original of the single-sheet DEA Form 222 and the statement must be retained in the files of the purchaser in accordance with § 1305.17. A defective DEA Form 222 may not be corrected; it must be replaced by a new DEA Form 222 for the order to be filled.

7. Section 1305.16 is amended by revising paragraph (a) to read as follows:

§ 1305.16 Lost and stolen DEA Forms 222.

(a)(1) If a purchaser ascertains that an unfilled triplicate DEA Form 222 has been lost, he or she must execute another in triplicate and attach a statement containing the serial number and date of the lost form, and stating that the goods covered by the first DEA Form 222 were not received through loss of that DEA Form 222. Copy 3 of the second form and a copy of the statement must be retained with Copy 3 of the DEA Form 222 first executed. A copy of the statement must be attached to Copies 1 and 2 of the second DEA Form 222 sent to the supplier. If the first DEA Form 222 is subsequently received by the supplier to whom it was directed, the supplier must mark upon the face "Not accepted" and return Copies 1 and 2 to the purchaser, who must attach it to Copy 3 and the statement.

(2) If a purchaser ascertains that an unfilled single-sheet DEA Form 222 has been lost, he or she must execute another and attach a statement containing the serial number and date of the lost form, and stating that the goods covered by the first DEA Form 222 were not received through loss of that DEA Form 222. A copy of the second form and a copy of the statement must be

retained with a copy of the DEA Form 222 first executed. A copy of the statement must be attached to a copy of the second DEA Form 222 sent to the supplier. If the first DEA Form 222 is subsequently received by the supplier to whom it was directed, the supplier must mark upon the face "Not accepted" and return it ("the original") to the purchaser, who must attach it to the statement.

* * * * *

8. Section 1305.17 is amended by revising paragraphs (a), (b), and (c) to read as follows:

§ 1305.17 Preservation of DEA Forms 222.

(a)(1) The purchaser must retain Copy 3 of each executed triplicate DEA Form 222 and all copies of unaccepted or defective forms with each statement attached.

(2) The purchaser must retain a copy of each executed single-sheet DEA Form 222 and all copies of unaccepted or defective forms with each statement attached.

(b)(1) The supplier must retain Copy 1 of each triplicate DEA Form 222 that it has filled.

(2) The supplier must retain the original of each single-sheet DEA Form 222 that it has filled.

(c)(1) Triplicate DEA Forms 222 must be maintained separately from all other records of the registrant. DEA Forms 222 are required to be kept available for inspection for a period of two years. If a purchaser has several registered locations, the purchaser must retain Copy 3 of the executed triplicate DEA Form 222 and any attached statements or other related documents (not including unexecuted DEA Forms 222, which may be kept elsewhere under § 1305.12 (e)), at the registered location printed on the DEA Form 222.

(2) Single-sheet DEA Forms 222 must be maintained separately from all other records of the registrant. DEA Forms 222 are required to be kept available for inspection for a period of two years. If a purchaser has several registered locations, the purchaser must retain a copy of the executed single-sheet DEA Form 222 and any attached statements or other related documents (not including unexecuted DEA Forms 222, which may be kept elsewhere under § 1305.12 (e)), at the registered location printed on the DEA Form 222.

* * * * *

9. Section 1305.19 is revised to read as follows:

§ 1305.19 Cancellation and voiding of DEA Forms 222.

(a)(1) A purchaser may cancel part or all of an order on a triplicate DEA Form

222 by notifying the supplier in writing of the cancellation. The supplier must indicate the cancellation on Copies 1 and 2 of the triplicate DEA Form 222 by drawing a line through the canceled items and printing "canceled" in the space provided for the number of items shipped.

(2) A purchaser may cancel part or all of an order on a single-sheet DEA Form 222 by notifying the supplier in writing of the cancellation. The supplier must indicate the cancellation on the original copy of the DEA Form 222 sent by the purchaser to the supplier by drawing a line through the canceled items and printing "canceled" in the space provided for the number of items shipped.

(b)(1) A supplier may void part or all of an order on a triplicate DEA Form 222 by notifying the purchaser in writing of the voiding. The supplier must indicate the voiding in the manner prescribed for cancellation in paragraph (a)(1) of this section.

(2) A supplier may void part or all of an order on a single-sheet DEA Form 222 by notifying the purchaser in writing of the voiding. The supplier must indicate the voiding in the manner prescribed for cancellation in paragraph (a)(2) of this section.

Dated: November 17, 2007.

Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control.
[FR Doc. E7-22984 Filed 11-26-07; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 167

[USCG-2007-0057]

Port Access Route Study of Potential Vessel Routing Measures To Reduce Vessel Strikes of North Atlantic Right Whales; Correction

AGENCY: Coast Guard, DHS.

ACTION: Notice of study; request for comments; correction.

SUMMARY: The Coast Guard is correcting a notice of study and request for comments that appeared in the **Federal Register** on November 19, 2007 (72 FR 64968). That notice informed the public the Coast Guard is conducting a Port Access Route Study (PARS) on the area east and south of Cape Cod, Massachusetts, to include the northern right whale critical habitat, mandatory

ship reporting system area, and the Great South Channel including Georges Bank out to the exclusive economic zone (EEZ) boundary. The purpose of the PARS is to analyze potential vessel routing measures that might help reduce ship strikes with the highly endangered North Atlantic right whale while minimizing any adverse effects on vessel operations. The recommendations of the study will inform the Coast Guard and may lead to appropriate international actions.

DATES: Comments and related material must reach the Docket Management Facility on or before January 18, 2008.

FOR FURTHER INFORMATION CONTACT: If you have questions on the notice of study, call Mr. George Detweiler, Coast Guard Division of Navigation Systems, 202-372-1566, or send e-mail to *George.H.Detweiler@uscg.mil*. If you have questions on viewing or submitting material to the docket, call Ms. Renee K. Wright, Program Manager, Docket Operations, telephone 202-366-9826.

SUPPLEMENTARY INFORMATION: In **Federal Register** Volume 72, Number 222, appearing on page 64969 on Monday, November 19, 2007, the following correction is made:

1. On page 64969, in the third column, under "What are the timeline, study area, and processes of this PARS?," remove the words "and must be completed by December 2007."

Dated: November 20, 2007.

Stefan G. Venckus,
Chief, Office of Regulations and Administrative Law, United States Coast Guard.
[FR Doc. E7-23050 Filed 11-26-07; 8:45 am]
BILLING CODE 4910-15-P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

50 CFR Part 17

RIN 1018-AU86

Endangered and Threatened Wildlife and Plants; Designation of Critical Habitat for *Acanthomintha ilicifolia* (San Diego Thornmint)

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Proposed rule; reopening of comment period, corrections to proposed critical habitat, notice of availability of draft economic analysis, and amended Required Determinations.

SUMMARY: We, the U.S. Fish and Wildlife Service (Service), announce the reopening of the comment period on the

proposed designation of critical habitat for *Acanthomintha ilicifolia* (San Diego thornmint) under the Endangered Species Act of 1973, as amended (Act). We also announce corrections to proposed critical habitat subunits 3C, 3D, 3F, 4A, 4B, and 4C as described in the preamble to the proposed rule published in the **Federal Register** on March 14, 2007 (72 FR 11946); announce the availability of the draft economic analysis for the proposed critical habitat designation; and announce amended Required Determinations for the proposal. The draft economic analysis provides information about the pre-designation costs and forecasts post-designation costs associated with conservation efforts for *Acanthomintha ilicifolia*. The draft economic analysis estimates potential future costs to be approximately \$0.6 to \$2.8 million in undiscounted dollars over a 20-year period in areas proposed as final critical habitat and approximately \$1.6 to \$5.1 million in undiscounted dollars over a 20-year period in areas proposed for exclusion from critical habitat under section 4(b)(2) of the Act. The amended Required Determinations section provides our determination concerning compliance with applicable statutes and Executive orders that we have deferred until the information from the draft economic analysis of the proposal was available.

We are reopening the comment period to allow all interested parties an opportunity to comment simultaneously on the proposed rule, corrections to the preamble of the proposed rule, the associated draft economic analysis, and the amended Required Determinations section. Comments previously submitted need not be resubmitted as they will be incorporated into the public record as part of this comment period and will be fully considered in preparation of the final rule.

DATES: We will accept public comments until December 27, 2007.

ADDRESSES: If you wish to comment, you may submit your comments and materials by any one of several methods:

(1) *By mail or hand-delivery to:* Jim Bartel, Field Supervisor, U.S. Fish and Wildlife Service, Carlsbad Fish and Wildlife Office, 6010 Hidden Valley Road, Carlsbad, CA 92011.

(2) *By electronic mail (e-mail) to:* fw8cfwocomments@fws.gov. Please see the Public Comments Solicited section below for other information about electronic filing.

(3) *By fax to:* the attention of Jim Bartel at 760-431-5901.

(4) *Via the Federal eRulemaking Portal:* at <http://www.regulations.gov>. Follow the instructions for submitting comments.

FOR FURTHER INFORMATION CONTACT: Jim Bartel, Field Supervisor, Carlsbad Fish and Wildlife Office, at the address listed in the **ADDRESSES** section (telephone 760-431-9440; facsimile 760-431-5901). If you use a telecommunications device for the deaf (TDD), call the Federal Information Relay Service (FIRS) at 800-877-8339.

SUPPLEMENTARY INFORMATION:

Public Comments Solicited

We will accept written comments and information during this reopened comment period on the proposed critical habitat designation for *Acanthomintha ilicifolia* published in the **Federal Register** on March 14, 2007 (72 FR 11946), the corrections to the proposed critical habitat described herein (see Corrections to Proposed Critical Habitat section), and our draft economic analysis of the proposed designation. We will consider information and recommendations from all interested parties. We are particularly interested in comments concerning:

(1) The reasons why we should or should not designate habitat as "critical habitat" under section 4 of the Act (16 U.S.C. 1531 *et seq.*), including whether the benefit of designation would outweigh threats to the species caused by the designation, such that the designation of critical habitat is prudent.

(2) Specific information on:

- The amount and distribution of *Acanthomintha ilicifolia* habitat,
- What areas occupied at the time of listing and that contain features essential to the conservation of the species we should include in the designation and why, and
- What areas not occupied at the time of listing are essential to the conservation of the species and why.

(3) Land use designations and current or planned activities in the subject areas and their possible impacts on proposed critical habitat.

(4) Our proposed exclusion of 1,134 acres (ac) (459 hectares (ha)) of lands already conserved or targeted for conservation within subarea plans under the San Diego Multiple Species Conservation Program (MSCP) and the San Diego Multiple Habitat Conservation Program (MHCP) from the final designation of critical habitat for *Acanthomintha ilicifolia* under section 4(b)(2) of the Act (see Exclusions Under Section 4(b)(2) of the Act in the

proposed critical habitat rule for details of these habitat conservation plans (HCPs)). Please note that in the March 14, 2007, proposed rule (72 FR 11946), we sought comments on our proposed exclusion of 1,302 ac (527 ha) of non-Federal lands from the final designation. In this notice, we have made several corrections that have resulted in reductions in the areas being proposed as critical habitat and the area being proposed for exclusion (see Corrections to the Proposed Rule below for a detailed discussion of these corrections).

We are specifically seeking public comment on our proposed exclusion of lands covered under the City of Encinitas subarea plan of the MHCP (see Exclusions Under Section 4(b)(2) of the Act in the proposed critical habitat rule for details of this HCP). It is our understanding that little progress has been made by the City of Encinitas to finalize their subarea plan since the 2001 release of the draft plan. Based on information received during the public comment period, the Secretary may determine that sufficient progress has not been made and that lands within the City of Encinitas' subarea plan should not be excluded from the final designation. Specifically, useful information would include: whether essential lands within Encinitas are being managed, or are reasonably assured of being managed, to conserve *Acanthomintha ilicifolia*, and the outlook for completion of the draft subarea plan.

Please provide information concerning whether the benefit of excluding any of these specific areas from the critical habitat designation outweighs the benefit of including these areas in the designation under section 4(b)(2). If the Secretary determines that the benefits of including these lands outweigh the benefits of excluding them, they will not be excluded from final critical habitat.

(5) Our corrections to proposed critical habitat subunits 3C, 3D, 3F, 4A, 4B, and 4C as described in this notice (see Corrections to Proposed Critical Habitat section below).

(6) Information on whether, and, if so, the extent to which any State and local environmental protection measures referenced in the draft economic analysis were adopted largely as a result of the listing of *Acanthomintha ilicifolia*, and which were either already in place at the time of listing or enacted for other reasons.

(7) Information on whether the draft economic analysis identifies all State and local costs and benefits attributable to the proposed critical habitat

designation, and information on any costs or benefits that have been inadvertently overlooked.

(8) Information on whether the draft economic analysis makes appropriate assumptions regarding current practices and likely regulatory changes imposed as a result of the designation of critical habitat.

(9) Information on whether the draft economic analysis correctly assesses the effect on regional costs associated with any land use controls that may derive from the designation of critical habitat.

(10) Information on areas that could potentially be disproportionately impacted by designation of critical habitat for *Acanthomintha ilicifolia*.

(11) Any foreseeable economic, national security, or other potential impacts resulting from the proposed designation, and in particular, any impacts on small entities, and the benefits of including or excluding areas that exhibit these impacts; the reasons why our conclusion that the proposed designation of critical habitat will not result in a disproportionate impact on small businesses should or should not warrant further consideration; and other information that would indicate that the designation of critical habitat would or would not have any impacts on small entities.

(12) Information on whether the draft economic analysis appropriately identifies all costs that could result from the designation.

(13) Information on whether there are any quantifiable economic benefits that could result from the designation of critical habitat.

(14) Whether the benefit of excluding any particular area from the critical habitat designation under section 4(b)(2) of the Act outweighs the benefit of including the area in the designation.

(15) Economic data on the incremental impacts that would result from designating any particular area as critical habitat, since it is our intent to include the incremental costs attributed to the critical habitat designation in the final economic analysis.

(16) Whether we could improve or modify our approach to designating critical habitat in any way to provide for greater public participation and understanding, or to better accommodate public concerns and comments.

The Secretary shall designate critical habitat on the basis of the best scientific data available and after taking into consideration the economic impact, the impact on national security, and any other relevant impact of specifying any particular area as critical habitat. Pursuant to section 4(b)(2) of the Act, an

area may be excluded from critical habitat if it is determined that the benefits of such exclusion outweigh the benefits of including the area as critical habitat, unless the failure to designate such area as critical habitat will result in the extinction of the species. We may exclude an area from designated critical habitat based on economic impacts, national security, or any other relevant impact.

Comments and information submitted during the initial comment period from March 14, 2007, to May 14, 2007, on the proposed rule (72 FR 11946) need not be resubmitted as they will be incorporated into the public record as part of this comment period and will be fully considered in preparation of the final rule. If you wish to comment, you may submit your comments and materials concerning the draft economic analysis and the proposed rule by any one of several methods (see **ADDRESSES**). Our final designation of critical habitat will take into consideration all comments and any additional information we have received during both comment periods. On the basis of public comment on the draft economic analysis, the critical habitat proposal, and the final economic analysis, we may, during the development of our final determination, find that areas proposed are not essential, are appropriate for exclusion under section 4(b)(2) of the Act, or are not appropriate for exclusion.

If you use e-mail to submit your comments, please include “*Attn: San Diego thornmint*” in your e-mail subject header, preferably with your name and return address in the body of your message. If you do not receive a confirmation from the system that we have received your e-mail, please contact the person listed under **FOR FURTHER INFORMATION CONTACT**.

Before including your address, phone number, e-mail address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

Comments and materials received, as well as supporting documentation used in preparation of the proposal to designate critical habitat, will be available for public inspection, by appointment during normal business hours, at the Carlsbad Fish and Wildlife Office (see **ADDRESSES**). You may obtain copies of the proposed critical habitat rule and the draft economic analysis by

mail from the Carlsbad Fish and Wildlife Office (see **ADDRESSES**) or by visiting our Web site at <http://www.fws.gov/carlsbad>.

Background

On August 10, 2004, the Center for Biological Diversity and California Native Plant Society challenged our failure to designate critical habitat for this species as well as four other plant species (*Center for Biological Diversity, et al. v. Norton*, C-04-3240 JL (N. D. Cal.)). In settlement of the lawsuit, the Service agreed to submit to the **Federal Register** a proposed rule to designate critical habitat, if prudent, on or before February 28, 2007, and a final designation by February 28, 2008. On March 14, 2007, we published a proposed rule to designate critical habitat for *Acanthomintha ilicifolia* (72 FR 11946), identifying a total of approximately 1,936 ac (783 ha) of land in San Diego County, California. Of the total area proposed, we proposed to exclude from the final critical habitat designation 1,302 ac (527 ha) of land under section 4(b)(2) of the Act.

Critical habitat is defined in section 3 of the Act as the specific areas within the geographical area occupied by a species, at the time it is listed in accordance with the Act, on which are found those physical or biological features essential to the conservation of the species and that may require special management considerations or protection, and specific areas outside the geographical area occupied by a species at the time it is listed, upon a determination that such areas are essential for the conservation of the species. If the proposed rule is made final, section 7 of the Act will prohibit destruction or adverse modification of critical habitat by any activity funded, authorized, or carried out by any Federal agency. Federal agencies proposing actions affecting areas designated as critical habitat must consult with us on the effects of their proposed actions, in accordance with section 7(a)(2) of the Act.

Corrections to Proposed Critical Habitat

By this notice, we are advising the public of corrections in area, land ownership, and San Diego MSCP boundary associations within six of the subunits described in the March 14, 2007, proposed rule (72 FR 11946): Subunit 3C (Viejas Mountain), Subunit 3D (Viejas Mountain), Subunit 3F (Poser Mountain), Subunit 4A (McGinty Mountain), Subunit 4B (McGinty Mountain), and Subunit 4C (McGinty Mountain).

In our March 14, 2007, proposed rule (72 FR 11946) we proposed to exclude a total of 95 ac (38 ha) of private lands in subunits 3C, 3D, and 3F from the final critical habitat designation under section 4(b)(2) of the Act. We believed that these lands were within the planning boundary for the San Diego MSCP (see "Relationship of Critical Habitat to Habitat Conservation Plan Lands—Exclusions Under Section 4(b)(2) of the Act" section of the proposed rule (72 FR 11946, March 14, 2007) for a detailed discussion of this proposed exclusion). However, the private lands in subunits 3C, 3D, and 3F are not within the planning boundary for the San Diego MSCP, and we are no longer proposing to exclude these lands from the final designation under section 4(b)(2) of the Act. The draft economic analysis reflects that we are no longer proposing to exclude these 95 ac (38 ha) of lands.

In this notice, we are also correcting errors within subunits 4A and 4B. The maps and boundary descriptions of subunits 4A and 4B were delineated correctly in the March 14, 2007, proposed rule (72 FR 11946); however, the area estimates in the preamble were incorrect. The correct area for subunit 4A is 20 ac (8 ha) rather than 18 ac (7 ha), and the correct area for subunit 4B is 148 ac (60 ha) rather than 220 ac (89 ha). The draft economic analysis reflects these corrections to area estimates.

Furthermore, the March 14, 2007, proposed rule (72 FR 11946), did not identify that subunit 4A contains 2 ac (1 ha) of federally owned land and subunit 4C contains 1 ac (less than 1/2 ha) of federally owned land. Both of these subunits overlap slightly with the Service's San Diego National Wildlife Refuge. We proposed to exclude all private and State/local lands in subunits 4A and 4C from the final designation based on the benefits provided to *Acanthomintha ilicifolia* by the MSCP (see "Relationship of Critical Habitat to Habitat Conservation Plan Lands—Exclusions Under Section 4(b)(2) of the Act" section of the proposed rule (72 FR 11946, March 14, 2007) for a detailed discussion of this proposed exclusion). While we are continuing to propose to exclude all private and State/local lands covered by the MSCP, we are clarifying that this proposed exclusion does not include Federal lands, and, therefore, we overestimated the proposed exclusion by 3 acres (1 ha). The draft economic analysis does not reflect this change; however, the final economic analysis will be revised to address the incorporation of 3 ac (1 ha) of the San Diego National Wildlife Refuge into the proposed designation.

As a result of these corrections, the total identified critical habitat area has been reduced from 1,936 ac (783 ha) to 1,867 ac (756 ha). The total area being proposed for exclusion from the final designation has been reduced from 1,302 ac (527 ha) to 1,134 ac (459 ha). The draft economic analysis states that we are proposing to exclude 1,137 ac (460 ha) of critical habitat; however, that figure erroneously includes 3 ac (1 ha) of federally owned lands in subunits 4A and 4C. Other than these corrections, the proposed rule of March 14, 2007, remains intact.

Draft Economic Analysis

Section 4(b)(2) of the Act requires that we designate or revise critical habitat based upon the best scientific and commercial data available, after taking into consideration the economic impact, impact on national security, or any other relevant impact of specifying any particular area as critical habitat. Based on the March 14, 2007, proposed rule to designate critical habitat for *Acanthomintha ilicifolia*, (72 FR 11946), we have prepared a draft economic analysis of the proposed critical habitat designation.

The draft economic analysis is intended to quantify the economic impacts of all potential conservation efforts for *Acanthomintha ilicifolia*; some of these costs will likely be incurred regardless of whether critical habitat is designated. The draft economic analysis provides estimated costs of the foreseeable potential economic impacts of the proposed critical habitat designation and other conservation-related actions for this species over the next 20 years. It also considers past costs associated with conservation of the species from the time it was listed (63 FR 54938, October 13, 1998), until the year the proposed critical habitat rule was published (72 FR 11946, March 14, 2007).

Activities associated with the conservation of *Acanthomintha ilicifolia* are likely to primarily impact future land development, recreation management, and exotic plant species management. Pre-designation (1998–2007) impacts associated with species conservation activities in areas proposed for final designation are estimated at \$53,000 in 2007 dollars. The draft economic analysis forecasts post-designation impacts in the areas proposed for final designation at \$0.6 to \$2.8 million (undiscounted dollars) over the next 20 years. The present value of these impacts, applying a 3 percent discount rate, is \$0.4 to \$2.1 million (\$25,000 to \$137,000 annualized); or \$0.3 to \$1.5 million (\$25,000 to

\$136,000 annualized) using a 7 percent discount rate. Total undiscounted future impacts in areas proposed for exclusion according to section 4(b)(2) of the Act are forecast at approximately \$1.6 to \$5.1 million over the next 20 years. The present value of these impacts applying a 3 percent discount rate is approximately \$1.2 to \$3.7 million or approximately \$0.8 to \$2.6 million applying a 7 percent discount rate. In annualized terms, potential impacts are expected to range from \$77,000 to \$253,000 (annualized at 3 percent) and \$72,000 to \$248,000 (annualized at 7 percent) in areas proposed for exclusion. The cost estimates are based on the proposed designation of critical habitat published in the **Federal Register** on March 14, 2007 (72 FR 11946) as well as the corrections we have identified above in subunits 3C, 3D, 3F, 4A, and 4B. The cost estimates assume that we are proposing to exclude 3 ac (1 ha) of federally owned lands in subunits 4A and 4C; we are not proposing to exclude any federally owned lands from this designation. We will address the costs associated with this last correction in more detail in the final economic analysis.

The draft economic analysis considers the potential economic effects of actions relating to the conservation of *Acanthomintha ilicifolia*, including costs associated with sections 4, 7, and 10 of the Act, and including those attributable to the designation of critical habitat. It further considers the economic effects of protective measures taken as a result of other Federal, State, and local laws that aid habitat conservation for *Acanthomintha ilicifolia* in areas containing features essential to the conservation of the species. The draft economic analysis considers both economic efficiency and distributional effects. In the case of habitat conservation, efficiency effects generally reflect the "opportunity costs" associated with the commitment of resources to comply with habitat protection measures (such as lost economic opportunities associated with restrictions on land use).

This analysis also addresses how potential economic impacts are likely to be distributed, including an assessment of any local or regional impacts of habitat conservation and the potential effects of conservation activities on small entities and the energy industry. This information can be used by decision-makers to assess whether the effects of the designation might unduly burden a particular group or economic sector. Finally, the draft analysis looks retrospectively at costs that have been incurred since the date *Acanthomintha*

ilicifolia was listed as threatened (63 FR 54938; October 13, 1998) and considers those costs that may occur in the 20 years following the designation of critical habitat. Forecasts of economic conditions and other factors beyond this point would be speculative.

As stated earlier, we solicit data and comments from the public on the draft economic analysis, as well as on all aspects of the proposal. We may revise the proposal or its supporting documents to incorporate or address new information received during the comment period. In particular, we may exclude an area from critical habitat if we determine that the benefits of excluding the area outweigh the benefits of including the area as critical habitat, provided such exclusion will not result in the extinction of the species.

Required Determinations—Amended

In our March 14, 2007 proposed rule (72 FR 11946), we indicated that we would be deferring our determination of compliance with several statutes and Executive Orders until the information concerning potential economic impacts of the designation and potential effects on landowners and stakeholders was available in the draft economic analysis. Those data are now available for our use in making these determinations. In this notice we are affirming the information contained in the proposed rule concerning Executive Order (E.O.) 13132; E.O. 12988; the Paperwork Reduction Act; and the President's memorandum of April 29, 1994, "Government-to-Government Relations with Native American Tribal Governments" (59 FR 22951). Based on the information made available to us in the draft economic analysis, we are amending our Required Determinations, as provided below, concerning E.O. 12866 and the Regulatory Flexibility Act, E.O. 13211, E.O. 12630, and the Unfunded Mandates Reform Act.

Regulatory Planning and Review

In accordance with E.O. 12866, this document is a significant rule because it may raise novel legal and policy issues. Based on our draft economic analysis of the proposed designation of critical habitat for *Acanthomintha ilicifolia*, post-designation impacts are estimated to be approximately \$0.6 to \$2.8 million (undiscounted dollars) over the next 20 years in the areas proposed as final critical habitat and approximately \$1.6 to \$5.1 million (undiscounted dollars) over the next 20 years in areas proposed for exclusion from the final critical habitat designation. These impacts would occur only if the area proposed for exclusion is instead designated as

critical habitat. The cost estimates are based on the proposed designation of critical habitat published in the **Federal Register** on March 14, 2007 (72 FR 11946), as well as the corrections we have identified above in subunits 3C, 3D, 3F, 4A, and 4B. The cost estimates assume that we are proposing to exclude 3 ac (1 ha) of federally owned lands in subunits 4A and 4C; we are not proposing to exclude any federally owned lands from this designation. We will address the costs associated with this last correction in more detail in the final economic analysis.

Discounted future costs in areas proposed as final critical habitat are estimated to be approximately \$0.4 to \$2.1 million (\$25,000 to \$137,000 annualized) at a 3 percent discount rate or approximately \$0.3 to \$1.5 million (\$25,000 to \$136,000 annualized) at a 7 percent discount rate. In areas proposed for exclusion from the final critical habitat designation, the discounted future costs are estimated to be approximately \$1.2 to \$3.7 million (\$77,000 to \$253,000 annualized) at a 3 percent discount rate or approximately \$0.8 to \$2.6 million (\$72,000 to \$248,000 annualized) over the next 20 years.

Therefore, based on our draft economic analysis, we have determined that the proposed designation of critical habitat for *Acanthomintha ilicifolia* would not result in an annual effect on the economy of \$100 million or more or affect the economy in a material way. Due to the timeline for publication in the **Federal Register**, the Office of Management and Budget (OMB) has not formally reviewed the proposed rule or accompanying draft economic analysis.

Further, E.O. 12866 directs Federal agencies promulgating regulations to evaluate regulatory alternatives (Office of Management and Budget, Circular A-4, September 17, 2003). Pursuant to Circular A-4, once it has determined that the Federal regulatory action is appropriate, the agency will then need to consider alternative regulatory approaches. Since the designation of critical habitat is a statutory requirement pursuant to the Act, we must then evaluate alternative regulatory approaches, where feasible, when promulgating a designation of critical habitat.

In developing our designations of critical habitat, we consider economic impacts, impacts to national security, and other relevant impacts pursuant to section 4(b)(2) of the Act. Based on the discretion allowable under this provision, we may exclude any particular area from the designation of critical habitat providing that the

benefits of such exclusion outweigh the benefits of specifying the area as critical habitat and that such exclusion would not result in the extinction of the species. As such, we believe that the evaluation of the inclusion or exclusion of particular areas, or combination thereof, in a designation constitutes our regulatory alternative analysis.

Regulatory Flexibility Act (5 U.S.C. 601 et seq.)

Under the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et seq.), as amended by the Small Business Regulatory Enforcement Fairness Act (5 U.S.C. 802(2)) (SBREFA), whenever an agency is required to publish a notice of rulemaking for any proposed or final rule, it must prepare and make available for public comment a regulatory flexibility analysis that describes the effect of the rule on small entities (i.e., small businesses, small organizations, and small government jurisdictions). However, no regulatory flexibility analysis is required if the head of an agency certifies the rule will not have a significant economic impact on a substantial number of small entities. Based upon our draft economic analysis of the proposed designation, we provide our analysis for determining whether the proposed rule would result in a significant economic impact on a substantial number of small entities. Based on comments received, this determination is subject to revision as part of the final rulemaking.

According to the Small Business Administration (SBA), small entities include small organizations, such as independent nonprofit organizations; small governmental jurisdictions, including school boards and city and town governments that serve fewer than 50,000 residents; and small businesses (13 CFR 121.201). Small businesses include manufacturing and mining concerns with fewer than 500 employees, wholesale trade entities with fewer than 100 employees, retail and service businesses with less than \$5 million in annual sales, general and heavy construction businesses with less than \$27.5 million in annual business, special trade contractors doing less than \$11.5 million in annual business, and agricultural businesses with annual sales less than \$750,000. To determine if potential economic impacts to these small entities are significant, we considered the types of activities that might trigger regulatory impacts under this designation as well as types of project modifications that may result. In general, the term "significant economic impact" is meant to apply to a typical

small business firm's business operations.

To determine if the proposed designation of critical habitat for *Acanthomintha ilicifolia* would affect a substantial number of small entities, we considered the number of small entities affected within particular types of economic activities (such as residential development and dispersed recreational activities). We considered each industry or category individually to determine if certification is appropriate. In estimating the numbers of small entities potentially affected, we also considered whether their activities have any Federal involvement; some kinds of activities are unlikely to have any Federal involvement and thus will not be affected by the designation of critical habitat. Designation of critical habitat affects only activities conducted, funded, permitted, or authorized by Federal agencies; non-Federal activities are not affected by the designation.

If this proposed critical habitat designation is made final, Federal agencies must consult with us under section 7 of the Act if their activities may affect designated critical habitat. Consultations to avoid the destruction or adverse modification of critical habitat would be incorporated into the existing consultation process.

In our draft economic analysis of the proposed critical habitat designation (including those areas proposed for exclusion), we evaluated the potential economic effects on small business entities resulting from conservation actions related to the listing of *Acanthomintha ilicifolia* and the proposed designation of critical habitat. The analysis is based on the estimated impacts associated with the proposed rulemaking as described in Chapters 2 through 4 and Appendices A, B, C, and F of the analysis and evaluates the potential for economic impacts related to three categories: development and HCP implementation; recreation management; and invasive, nonnative plant management.

The U.S. Forest Service (USFS), the California Department of Fish and Game (CDFG), and the U.S. Fish and Wildlife Service are not considered small entities by the Small Business Administration. Two nonprofit organizations, The Nature Conservancy (TNC) and the Center for Natural Lands Management (CNLM), are involved with conservation activities for *Acanthomintha ilicifolia*; however, the primary mission of both of these organizations is to preserve, restore, and protect natural resources. Therefore, impacts from species conservation on these organizations is

not considered in the small business impacts analysis.

Additionally, the boundaries of four city governments encompass portions of the proposed critical habitat—Carlsbad, Encinitas, San Diego, and Poway—with the remainder of the proposed critical habitat located within unincorporated San Diego County. All four cities and the County exceed the criteria to be considered a “small entity” under the RFA.

The draft analysis identified 18 privately owned, undeveloped parcels within areas proposed as critical habitat. The 18 parcels are owned by 9 individual landowners. For the nine individual landowners that may be affected by the proposed designation of critical habitat, the DEA could not determine if any of these landowners qualify as small businesses. However, for the purposes of estimating potential costs associated with the proposed designation of critical habitat, the DEA determine that two landowners own four parcels that are in proposed subunits 3D, 3E, and 3F, and the remaining seven landowners own parcels in subunits we are proposing to exclude from the final designation.

For the two landowners of proposed subunits 3D, 3E, and 3F, the DEA estimates annualized impacts associated with conservation activities for *Acanthomintha ilicifolia* could range from a low of \$700 to \$35,700, with an average range of annualized impact of \$5,300 to \$42,300 per landowner over the next 20 years. The remaining seven landowners of the 14 parcels in subunits we are proposing to exclude from the final designation, annualized impacts are estimated to range from a low of \$300 in subunit 4D up to \$18,700 in subunit 2C, with an average annualized impact ranging from \$17,000 to \$84,000.

With only nine private landowners, it is not considered a substantial number. However, even if the landowners were to represent small development businesses, any developer directly impacted by the proposed designation of critical habitat would not be expected to bear the additional cost of conservation measures for *Acanthomintha ilicifolia*. We anticipate that additional costs that could arise from the designation would be passed on to individual homebuyers if the parcels were to be developed. Please refer to our DEA of the proposed critical habitat designation for a more detailed discussion of potential economic impacts.

In summary, we have considered whether this proposed designation of critical habitat would result in a significant economic impact on a

substantial number of small entities. We have determined, and therefore, certify that, for the above reasons and based on currently available information, the proposed designation will not have a significant economic impact on a substantial number of small business entities.

Executive Order 13211—Energy Supply, Distribution, and Use

On May 18, 2001, the President issued E.O. 13211 on regulations that significantly affect energy supply, distribution, and use. E.O. 13211 requires agencies to prepare Statements of Energy Effects when undertaking certain actions. This proposed designation of critical habitat for *Acanthomintha ilicifolia* is considered a significant regulatory action under E.O. 12866 due to its potentially raising novel legal and policy issues. OMB has provided guidance for implementing E.O. 13211 that outlines nine outcomes that may constitute “a significant adverse effect” when compared without the regulatory action under consideration. The draft economic analysis finds that none of these criteria are relevant to this analysis. Thus, based on the information in the draft economic analysis, energy-related impacts associated with *Acanthomintha ilicifolia* conservation activities within proposed critical habitat are not expected. As such, the proposed designation of critical habitat is not expected to significantly affect energy supplies, distribution, or use and a Statement of Energy Effects is not required.

Unfunded Mandates Reform Act (2 U.S.C. 1501 et seq.)

In accordance with the Unfunded Mandates Reform Act (2 U.S.C. 1501), the Service makes the following findings:

(a) This rule will not produce a Federal mandate. In general, a Federal mandate is a provision in legislation, statute, or regulation that would impose an enforceable duty upon State, local, or Tribal governments, or the private sector, and includes both “Federal intergovernmental mandates” and “Federal private sector mandates.” These terms are defined in 2 U.S.C. 658(5)–(7). “Federal intergovernmental mandate” includes a regulation that “would impose an enforceable duty upon State, local, or tribal governments,” with two exceptions. It excludes “a condition of federal assistance.” It also excludes “a duty arising from participation in a voluntary Federal program,” unless the regulation “relates to a then-existing Federal

program under which \$500,000,000 or more is provided annually to State, local, and Tribal governments under entitlement authority," if the provision would "increase the stringency of conditions of assistance" or "place caps upon, or otherwise decrease, the Federal Government's responsibility to provide funding" and the State, local, or tribal governments "lack authority" to adjust accordingly. (At the time of enactment, these entitlement programs were: Medicaid; Aid to Families with Dependent Children work programs; Child Nutrition; Food Stamps; Social Services Block Grants; Vocational Rehabilitation State Grants; Foster Care, Adoption Assistance, and Independent Living; Family Support Welfare Services; and Child Support Enforcement.) "Federal private sector mandate" includes a regulation that "would impose an enforceable duty upon the private sector, except (i) a condition of Federal assistance; or (ii) a duty arising from participation in a voluntary Federal program."

The designation of critical habitat does not impose a legally binding duty on non-Federal government entities or private parties. Under the Act, the only regulatory effect is that Federal agencies must ensure that their actions do not

destroy or adversely modify critical habitat under section 7. Non-Federal entities that receive Federal funding, assistance, permits, or otherwise require approval or authorization from a Federal agency for an action may be indirectly impacted by the designation of critical habitat. However, the legally binding duty to avoid destruction or adverse modification of critical habitat rests squarely on the Federal agency. Furthermore, to the extent that non-Federal entities are indirectly impacted because they receive Federal assistance or participate in a voluntary Federal aid program, the Unfunded Mandates Reform Act would not apply, nor would critical habitat shift the costs of the large entitlement programs listed above on to State governments.

(b) We do not believe that this rule will significantly or uniquely affect small governments. As discussed in the DEA, approximately 59 percent of the lands proposed as critical habitat are owned or managed by Federal, State, or local governments, none of which qualify as a small government. Consequently, we do not believe that critical habitat designation would significantly or uniquely affect small government entities. As such, a Small

Government Agency Plan is not required.

Executive Order 12630—Takings

In accordance with E.O. 12630 ("Government Actions and Interference with Constitutionally Protected Private Property Rights"), we have analyzed the potential takings implications of proposing critical habitat for *Acanthomintha ilicifolia* in a takings implications assessment. The takings implications assessment concludes that this proposed designation of critical habitat for *Acanthomintha ilicifolia* does not pose significant takings implications.

Author

The primary author of this notice is staff of the Carlsbad Fish and Wildlife Office.

Authority

The authority for this action is the Endangered Species Act of 1973 (16 U.S.C. 1531 *et seq.*).

Dated: November 15, 2007.

Todd Willens,

Acting Assistant Secretary for Fish and Wildlife and Parks.

[FR Doc. E7-22971 Filed 11-26-07; 8:45 am]

BILLING CODE 4310-55-P

Notices

Federal Register

Vol. 72, No. 227

Tuesday, November 27, 2007

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

AGENCY FOR INTERNATIONAL DEVELOPMENT

Notice of Public Information Collections Being Reviewed by the U.S. Agency for International Development: Comments Requested

SUMMARY: U.S. Agency for International Development (USAID) is making efforts to reduce the paperwork burden. USAID invites the general public and other Federal agencies to take this opportunity to comment on the following proposed and/or continuing information collections, as required by the Paperwork Reduction Act for 1995. Comments are requested concerning: (a) Whether the proposed or continuing collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the burden estimates; (c) ways to enhance the quality, utility, an clarity of the information collected; and (d) ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology.

DATES: Submit comments on or before January 28, 2008.

FOR FURTHER INFORMATION CONTACT: Beverly Johnson, Bureau for Management, Office of Administrative Services, Information and Records Division, U.S. Agency for International Development, Room 2.07-106, RRB, Washington, DC, 20523, (202) 712-1365 or via e-mail bjohnson@usaid.gov.

SUPPLEMENTARY INFORMATION:

OMB No.: OMB 0412-0035.

Form No.: AID 1550-2.

Title: PVO Initial and Annual Registration Form.

Type of Review: Renewal of Information Collection.

Purpose: USAID is required to collect information regarding the financial

support of private and voluntary organizations registered with the Agency. The information is used to determine the eligibility of PVOs to receive USAID funding.

Annual Reporting Burden:

Respondents: 533.

Total annual responses: 533.

Total annual hours requested: 1,599 hours.

Dated: November 19, 2007.

Joanne Paskar,

*Chief, Information and Records Division,
Office of Administrative Services, Bureau for
Management.*

[FR Doc. 07-5840 Filed 11-26-07; 8:45 am]

BILLING CODE 6116-01-M

DEPARTMENT OF AGRICULTURE

Submission for OMB Review; Comment Request

November 21, 2007.

The Department of Agriculture has submitted the following information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104-13. Comments regarding (a) whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency's estimate of burden including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology should be addressed to: jDesk Officer for Agriculture, Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), OIRA_Submission@OMB.EOP.GOV or fax (202) 395-5806 and to Departmental Clearance Office, USDA, OCIO, Mail Stop 7602, Washington, DC 20250-7602. Comments regarding these information collections are best assured of having their full effect if received within 30 days of this notification.

Copies of the submission(s) may be obtained by calling (202) 720-8681.

An agency may not conduct or sponsor a collection of information unless the collection of information displays a currently valid OMB control number and the agency informs potential persons who are to respond to the collection of information that such persons are not required to respond to the collection of information unless it displays a currently valid OMB control number.

Rural Housing Service

Title: Rural Rental Housing Program, 7 CFR Part 3560.

OMB Control Number: 0575-0189.

Summary of Collection: The programs covered by 7 CFR Part 3560 provide financing to support the development of adequate, affordable housing and rental units for very low-, low-, and moderate-income households, and farm workers. Rural Housing Service (RHS) is authorized to collect the information needed to administer these various programs under Title V of the Housing Act of 1949, Section 515 Rural Rental Housing, Sections 514 and 516 Farm Labor Housing loans and grants, and Section 521 Rental Assistance.

Need and Use of the Information: The information collected by RHS is used to plan, manage, evaluate and account for Government resources. The reports are required to ensure the proper and judicious use of public funds. The purpose of the Multi-Family Housing programs is to provide adequate, affordable, decent, safe, and sanitary rental units for very low-, low-, and moderate-income households and farm workers in rural areas.

Description of Respondents: Business or other for profit: Individual or households; Farms; Not-for-profit institutions; State, Local, or Tribal Government.

Number of Respondents: 500,000.

Frequency of Responses: Recordkeeping; Reporting: Quarterly; Monthly, Annually.

Total Burden Hours: 1,138,607.

Charlene Parker,

*Departmental Information Collection
Clearance Officer.*

[FR Doc. E7-23035 Filed 11-26-07; 8:45 am]

BILLING CODE 3410-XT-P

DEPARTMENT OF AGRICULTURE**Forest Service****Information Collection; Federal Excess Personal Property (FEPP) Inventory****AGENCY:** Forest Service, USDA.**ACTION:** Request for comment; notice.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, the Forest Service is seeking comments from all interested individuals and organizations on the new information collection, Federal Excess Personal Property (FEPP) Inventory.

DATES: Comments must be received in writing on or before January 28, 2008 to be assured of consideration. Comments received after that date will be considered to the extent practicable.

ADDRESSES: Comments concerning this notice should be addressed to Melissa Frey, USDA Forest Service, F&AM, 1400 Independence Ave., SW., Mailstop Code: 1107, Washington, DC 20250-1107.

Comments also may be submitted via facsimile to (202) 205-1401; or by e-mail to mfrey@fs.fed.us.

The public may inspect comments received at USDA Forest Service, Fire and Aviation Management—Room 2SO, 201 14th St., SW., Washington, DC 20024 during normal business hours. Visitors are encouraged to call ahead to (202) 205-1483 to facilitate entry to the building.

FOR FURTHER INFORMATION CONTACT: Melissa Frey, Fire and Aviation Management, phone: (202) 205-0955, mfrey@fs.fed.us. Individuals who use TDD may call the Federal Relay Service (FRS) at 1-800-877-8339, 24 hours a day, every day of the year, including holidays.

SUPPLEMENTARY INFORMATION:

Title: Federal Excess Personal Property (FEPP) Inventory.

OMB Number: 0596-New.

Type of Request: New.

Abstract: The Forest Service acquires excess federally-owned property to loan to state cooperators for wildland fire fighting. Since the property belongs to the Forest Service, the proposed inventory system will facilitate reporting by state agencies to the Forest Service on the status and location of the property.

Program authorities include, the Federal Property and Administrative Services Act of 1949, as amended (40 U.S.C. 483), and the Cooperative Forestry Assistance Act of 1978 (16 U.S.C. 2101 (note)). Additional pertinent regulations include the USDA

Organic Act of 1944 (16 U.S.C. 508a) and Federal Property Management Regulations 101-43.309-1, 101-43-313, and 101-43-314 (40 U.S.C. 483).

State agencies will use the electronic database (Federal Excess Property Management Information System or FEPMIS) to submit information regarding property make, model, serial number, acquisition value, location, and acquisition date when an item is acquired or no longer needed. Forest Service property management technicians will collect the information from FEPMIS and enter it into a National Finance Center database (PROP), as required by Federal Property Management Regulations. Forest Service property management officers will analyze the data collected to ensure that the property accountability is accurate and no misuse of property is occurring.

Estimate of Annual Burden: 2 minutes.

Type of Respondents: State agency FEPP property managers.

Estimated Annual Number of Respondents: 55.

Estimated Annual Number of Responses per Respondent: 300.

Estimated Total Annual Burden on Respondents: 5,800 hours.

Comment is invited on: (1) Whether this collection of information is necessary for the stated purposes and the proper performance of the functions of the agency, including whether the information will have practical or scientific utility; (2) the accuracy of the agency's estimate of the burden of the collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including the use of automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

All comments received in response to this notice, including names and addresses when provided, will be a matter of public record. Comments will be summarized and included in the request for Office of Management and Budget approval.

Dated: November 20, 2007.

Kent P. Connaughton,

Associate Deputy Chief, State and Private Forestry.

[FR Doc. E7-23034 Filed 11-26-07; 8:45 am]

BILLING CODE 3410-11-P

DEPARTMENT OF AGRICULTURE**Forest Service****RIN 0596-AC61****Notice of Extension of Public Comment Period for the Forest Service Proposed Wind Energy Directives (FSM 2720, FSH 2609.13 and FSH 2709.11)****AGENCY:** Forest Service, USDA.**ACTION:** Notice of extension of public comment period.

SUMMARY: The Forest Service is extending the public comment period an additional 60 days, from November 23, 2007, to January 23, 2008, for the proposed directives for wind energy development on National Forest System (NFS) lands. As stated in the original Public Notice which was published on Monday, September 24, 2007, **Federal Register** Vol. 72, No. 184, the Forest Service is proposing to amend its internal directives for special use authorizations and wildlife monitoring. Reviewers may obtain a copy of the proposed amendments from the address cited in the addresses section below or from the Forest Service home page on the World Wide Web at: <http://www.fs.fed.us/recreation/permits/energy.htm>. Public comment is invited and will be considered in the development of final directives.

DATES: Comments must be received by January 23, 2008.

ADDRESSES: Send written comments to Wind Energy Proposed Directives, *Attention:* Director, Lands Staff, 4th Floor-South, USDA Forest Service, 1400 Independence Avenue, SW., Mailstop 1124, Washington, DC 20250, or by facsimile to (202) 205-1604. You may also submit comments by following the instructions at the Federal e-rulemaking portal at <http://www.regulations.gov>.

All comments, including names and addresses when provided, will be placed in the record and will be available for public inspection and copying. The public may inspect comments received on the proposed directives in the USDA Forest Service Headquarters located at 201 14th Street, SW., Washington, DC, during regular business hours between 8:30 a.m. and 4:30 p.m., Monday through Friday, except holidays. Those wishing to inspect comments are encouraged to call ahead to (202) 205-1248 or (202) 205-0895 to facilitate entry into the building.

FOR FURTHER INFORMATION CONTACT: Paul Johnson, Minerals and Geology Management, (703) 605-4793, or Julett Denton, Lands Staff, (202) 205-1256.

Individuals who use telecommunication devices for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1-800-877-8339 between 8 a.m. and 8 p.m., Eastern Standard Time, Monday through Friday.

Dated: November 20, 2007.

Corbin L. Newman, Jr.,

Acting Deputy Chief, National Forest System.

[FR Doc. E7-22977 Filed 11-26-07; 8:45 am]

BILLING CODE 3410-11-P

DEPARTMENT OF AGRICULTURE

Rural Business-Cooperative Service

Inviting Rural Business Enterprise Grant Program Preapplications for Technical Assistance for Rural Transportation Systems

AGENCY: Rural Business-Cooperative Service, USDA.

ACTION: Notice.

SUMMARY: The Rural Business-Cooperative Service (RBS), an Agency within the USDA Rural Development mission area, announces the availability of two individual grants: one grant from the passenger transportation funds appropriated for the Rural Business Enterprise Grant (RBEG) program and another grant for Federally Recognized Native American Tribes' (FRNAT) from funds appropriated for the RBEG program. USDA Rural Development will administer these awards under the RBEG program and 7 U.S.C. 1932(c)(2) for fiscal year (FY) 2008. Historically, Congress has appropriated funding for these specific programs. This notice is being issued prior to passage of a FY 2008 Appropriations Act, which may or may not provide an appropriation for these programs, to allow applicants sufficient time to leverage financing, submit applications, and give the Agency time to process applications within the current fiscal year. A subsequent notice identifying the amount received in the appropriations will be published, if any. Each grant is to be competitively awarded to a qualified national organization. One grant is for the provision of technical assistance to rural transportation projects. The other grant is for the provision of technical assistance to rural transportation projects operated by FRNAT's only. This notice will be amended to publish final funding levels, if any.

DATES: The deadline for receipt of preapplications in the USDA Rural Development State Office is January 31, 2008. Applications received at a USDA Rural Development State Office after

that date will not be considered for FY 2008 funding.

FOR FURTHER INFORMATION CONTACT:

Cindy Mason, Loan Specialist, USDA Rural Development, USDA, STOP 3225, Room 6866, 1400 Independence Avenue, SW., Washington, DC 20250-3225. Telephone: (202) 690-1433, Fax: (202) 720-2213.

ADDRESSES: For additional information, entities wishing to apply for assistance should contact a USDA Rural Development State Office to obtain copies of the application package. A list of USDA Rural Development State Offices follows:

District of Columbia, Rural Development Business Programs, USDA, Specialty Lenders Division, 1400 Independence Avenue, SW., STOP 3225, Room 6867, Washington, DC 20250-3225, (202) 720-1400.

Alabama, USDA Rural Development State Office, Sterling Centre, Suite 601, 4121 Carmichael Road, Montgomery, AL 36106-3683, (334) 279-3400/TDD (334) 279-3495.

Alaska, USDA Rural Development State Office, 800 West Evergreen, Suite 201, Palmer, AK 99645-6539, (907) 761-7705/TDD (907) 761-8905.

Arizona, USDA Rural Development State Office, 230 N. 1st Ave., Suite 206, Phoenix, AZ 85003, (602) 280-8701/TDD (602) 280-8705.

Arkansas, USDA Rural Development State Office, 700 West Capitol Avenue, Room 3416, Little Rock, AR 72201-3225, (501) 301-3200/TDD (501) 301-3279.

California, USDA Rural Development State Office, 430 G Street, # 4169, Davis, CA 95616-4169, (530) 792-5800/TDD (530) 792-5848.

Colorado, USDA Rural Development State Office, 655 Parfet Street, Room E-100, Lakewood, CO 80215, (720) 544-2903/TDD (720) 544-2976.

Delaware-Maryland, USDA Rural Development State Office, 1221 College Park Drive, Suite 200, Dover, DE 19904, (302) 857-3580/TDD (302) 857-3585.

Florida/Virgin Islands, USDA Rural Development State Office, 4440 NW 25th Place, P.O. Box 147010, Gainesville, FL 32614-7010, (352) 338-3400/TDD (352) 338-3499.

Georgia, USDA Rural Development State Office, Stephens Federal Building, 355 E. Hancock Avenue, Athens, GA 30601-2768, (706) 546-2162/TDD (706) 546-2034.

Hawaii, USDA Rural Development State Office, Federal Building, Room 311, 154 Waiuanue Avenue, Hilo, HI 96720, (808) 933-8380/TDD (808) 933-8321.

Idaho, USDA Rural Development State Office, 9173 West Barnes Dr., Suite

A1, Boise, ID 83709, (208) 378-5600/TDD (208) 378-5644.

Illinois, USDA Rural Development State Office, 2118 West Park Court, Suite A, Champaign, IL 61821, (217) 403-6200/TDD (217) 403-6240.

Indiana, USDA Rural Development State Office, 5975 Lakeside Boulevard, Indianapolis, IN 46278, (317) 290-3100/TDD (317) 290-3343.

Iowa, USDA Rural Development State Office, Federal Building, Room 873, 210 Walnut Street, Des Moines, IA 50309, (515) 284-4663/TDD (515) 284-4858.

Kansas, USDA Rural Development State Office, 1303 SW. First American Place, Suite 100, Topeka, KS 66604-4040, (785) 271-2700/TDD (785) 271-2767.

Kentucky, USDA Rural Development State Office, 771 Corporate Drive, Suite 200, Lexington, KY 40503, (859) 224-7300/TDD (859) 224-7422.

Louisiana, USDA Rural Development State Office, 3727 Government Street, Alexandria, LA 71302, (318) 473-7921/TDD (318) 473-7655.

Maine, USDA Rural Development State Office, 967 Illinois Avenue, Suite 4, P.O. Box 405, Bangor, ME 04402-0405, (207) 990-9160/TDD (207) 942-7331.

Massachusetts/Rhode Island/Connecticut, USDA Rural Development State Office, 451 West Street, Suite 2, Amherst, MA 01002-2999, (413) 253-4300/TDD (413) 253-4590.

Michigan, USDA Rural Development State Office, 3001 Coolidge Road, Suite 200, East Lansing, MI 48823, (517) 324-5190/TDD (517) 324-5169.

Minnesota, USDA Rural Development State Office, 375 Jackson Street, Suite 410, St. Paul, MN 55101-1853, (651) 602-7800/TDD (651) 602-3799.

Mississippi, USDA Rural Development State Office, Federal Building, Suite 831, 100 W. Capitol Street, Jackson, MS 39269, (601) 965-4316/TDD (601) 965-5850.

Missouri, USDA Rural Development State Office, 601 Business Loop 70 West, Parkade Center, Suite 235, Columbia, MO 65203, (573) 876-0976/TDD (573) 876-9480.

Montana, USDA Rural Development State Office, 900 Technology Boulevard, Suite B, P.O. Box 850, Bozeman, MT 59771, (406) 585-2580/TDD (406) 585-2562.

Nebraska, USDA Rural Development State Office Federal Building, Room 152, 100 Centennial Mall North Lincoln, NE 68508 (402) 437-5551/TDD (402) 437-5093.

Nevada, USDA Rural Development State Office, 1390 South Curry Street, Carson City, NV 89703-5146, (775) 887-1222/TDD (775) 885-0633.

New Jersey, USDA Rural Development State Office, 8000 Midlantic Drive, 5th Floor North, Suite 500, Mt. Laurel, NJ 08054, (856) 787-7700/TDD (856) 787-7784.

New Mexico, USDA Rural Development State Office, 6200 Jefferson Street, NE, Room 255, Albuquerque, NM 87109, (505) 761-4950/TDD (505) 761-4938.

New York, USDA Rural Development State Office, The Galleries of Syracuse, 441 South Salina Street, Suite 357, Syracuse, NY 13202-2541, (315) 477-6400/TDD (315) 477-6447.

North Carolina, USDA Rural Development State Office, 4405 Bland Road, Suite 260, Raleigh, NC 27609, (919) 873-2000/TDD (919) 873-2003.

North Dakota, USDA Rural Development State Office, Federal Building, Room 208, 220 East Rosser, P.O. Box 1737, Bismarck, ND 58502-1737, (701) 530-2037/TDD (701) 530-2113.

Ohio, USDA Rural Development State Office, Federal Building, Room 507, 200 North High Street, Columbus, OH 43215-2418, (614) 255-2400/TDD (614) 255-2554.

Oklahoma, USDA Rural Development State Office, 100 USDA, Suite 108, Stillwater, OK 74074-2654, (405) 742-1000/TDD (405) 742-1007.

Oregon, USDA Rural Development State Office, 1201 NE Lloyd Blvd., Suite 801, Portland, OR 97232, (503) 414-3300/TDD (503) 414-3387.

Pennsylvania, USDA Rural Development State Office, One Credit Union Place, Suite 330, Harrisburg, PA 17110-2996, (717) 237-2299/TDD (717) 237-2261.

Puerto Rico, USDA Rural Development State Office, IBM Building, Suite 601, 654 Munos Rivera Avenue, San Juan, PR 00918-6106, (787) 766-5095/TDD (787) 766-5332.

South Carolina, USDA Rural Development State Office, Strom Thurmond Federal Building, 1835 Assembly Street, Room 1007, Columbia, SC 29201, (803) 765-5163/TDD (803) 765-5697.

South Dakota, USDA Rural Development State Office, Federal Building, Room 210, 200 Fourth Street, SW., Huron, SD 57350, (605) 352-1100/TDD (605) 352-1147.

Tennessee, USDA Rural Development State Office, 3322 West End Avenue, Suite 300, Nashville, TN 37203-1084, (615) 783-1300.

Texas, USDA Rural Development State Office, Federal Building, Suite 102, 101 South Main, Temple, TX 76501, (254) 742-9700/TDD (254) 742-9712.

Utah, USDA Rural Development State Office, Wallace F. Bennett Federal Building, 125 South State Street, Room 4311, Salt Lake City, UT 84138, (801) 524-4320/TDD (801) 524-3309.

Vermont/New Hampshire, USDA Rural Development State Office, City Center, 3rd Floor, 89 Main Street, Montpelier, VT 05602, (802) 828-6000/TDD (802) 223-6365.

Virginia, USDA Rural Development State Office, 1606 Santa Rosa Road, Suite 238, Richmond, VA 23229-5014, (804) 287-1550/TDD (804) 287-1753.

Washington, USDA Rural Development State Office, 1835 Black Lake Boulevard SW., Suite B, Olympia, WA 98512-5715, (360) 704-7740/TDD (360) 704-7760.

West Virginia, USDA Rural Development State Office, 75 High Street, Room 320, Morgantown, WV 26505-7500, (304) 284-4860/TDD (304) 284-4836.

Wisconsin, USDA Rural Development State Office, 4949 Kirschling Court, Stevens Point, WI 54481, (715) 345-7600/TDD (715) 345-7614.

Wyoming, USDA Rural Development State Office, 100 East B, Federal Building, Room 1005, P.O. Box 11005, Casper, WY 82602-5006, (307) 233-6700/TDD (307) 233-6733.

SUPPLEMENTARY INFORMATION:

Overview

Federal Agency: Rural Business-Cooperative Service (Rural Development).

Funding Opportunity Title: Rural Business Enterprise Grants.

Announcement Type: Initial Announcement.

Catalog of Federal Domestic Assistance Number: 10.769.

Dates: Application Deadline: Completed applications must be received in the USDA Rural Development State Office no later than January 31, 2008, to be eligible for FY 2008 grant funding. Applications received after this date will not be eligible for FY 2008 grant funding.

I. Funding Opportunity Description
The RBEG program is authorized by section 310B(c)(2) of the Consolidated Farm and Rural Development Act (CONACT) (7 U.S.C. 1932(c)(2)). Regulations are contained in 7 CFR part 1942, subpart G. The primary objective of the program is to improve the economic conditions of rural areas. The program is administered on behalf of RBS at the State level by the USDA Rural Development State Offices. Assistance provided to rural areas under this program may include on-site technical assistance to local and regional governments, public transit

agencies, and related nonprofit and for-profit organizations in rural areas; the development of training materials; and the provision of necessary training assistance to local officials and agencies in rural areas.

Awards under the RBEG passenger transportation program will be made on a competitive basis using specific selection criteria contained in 7 CFR part 1942, subpart G, and in accordance with section 310B(c)(2) of the CONACT. Information required to be in the application package include Forms SF 424; "Application for Federal Assistance;" RD 1940-20, "Request for Environmental Information;" Scope of Work Narrative; Income Statement; Balance Sheet or Audit for previous 3 years; AD-1047, "Debarment/Suspension Certification;" AD-1048, "Certification Regarding Debarment, Suspension, Ineligibility and Voluntary Exclusion;" AD-1049, "Certification Regarding Drug-Free Workplace Requirements;" Restrictions on Lobbying, RD 400-1; "Equal Opportunity Agreement;" RD 400-4, "Assurance Agreement;" Letter stating Board authorization to obtain assistance; and Letter certifying citizenship, as referenced in 7 CFR 1942.307(b). For the FRNAT grant, which must benefit Federally Recognized Native American Tribes, at least 75 percent of the benefits of the project must be received by members of Federally Recognized Native American Tribes. The project that scores the greatest number of points based on the RBEG selection criteria and the discretionary points will be selected for each grant. Applications will be tentatively scored by the State Offices and submitted to the National Office for review, final scoring, and selection.

Applicants must be qualified national nonprofit organizations with experience in providing technical assistance and training to rural communities for the purpose of improving passenger transportation service or facilities. To be considered "national" RBS requires a qualified organization to provide evidence that it operates rural transportation assistance programming in multiple States. There is not a requirement to use the grant funds in a multi-State area. Under this notice, grants will be made to qualified, private, nonprofit organizations for the provision of technical assistance and training to rural communities for the purpose of improving passenger transportation services or facilities.

Definitions

The definitions are published at 7 CFR 1942.304.

II. Award Information

Type of Award: Grant.

Fiscal Year Funds: FY 2008.

Total Funding: To be determined by appropriations bill.

Approximate Number of Awards: Two.

Average Award: Will be determined by amount received in appropriations. This Notice will be amended to provide this information once an appropriation has been enacted.

Anticipated Award Date: April 30, 2008.

III. Eligibility Information

A. Eligible Applicants

To be considered eligible, an entity must be a public body or private non-profit corporation serving rural areas. Grants will be competitively awarded to one or more qualified national organizations.

B. Cost Sharing or Matching

Matching funds are not required.

C. Other Eligibility Requirements

Applications will only be accepted from qualified national organizations to provide technical assistance for rural transportation.

D. Completeness Eligibility

Applications will not be considered for funding if they do not provide sufficient information to determine eligibility or are missing required elements.

IV. Fiscal Year 2008 Application and Submission Information:

A. Address To Request Application Package

For further information, entities wishing to apply for assistance should contact the USDA Rural Development State Office identified in this NOFA to obtain copies of the application package.

B. Content and Form of Submission

An application must contain all of the required elements. Each application received in a USDA Rural Development State Office will be reviewed to determine if it is consistent with the eligible purposes contacted in section 310B(c) of the CONACT. Each selection priority criterion outlined in 7 CFR 1942.305 (b)(3), must be addressed in the application. Failure to address any of the criteria will result in a zero-point score for that criterion and will impact the overall evaluation of the application. Copies of 7 CFR part 1942, subpart G, will be provided by any interested applicant making a request to a USDA

Rural Development State Office listed in this notice.

All projects to receive technical assistance through these passenger transportation grant funds are to be identified when the applications are submitted to the USDA Rural Development State Office. Multiple project applications must identify each individual project, indicate the amount of funding requested for each individual project, and address the criteria as stated above for each individual project.

For multiple-project applications, the average of the individual project scores will be the score for that application.

C. Submission Dates and Times

Application Deadline Date: January 31, 2008.

Explanation of Deadlines: Applications must be in the USDA Rural Development State Office by the deadline date.

V. Application Review Information

The National Office will score applications based on the grant selection criteria and weights contained in 7 CFR part 1942, subpart G and will select a grantee subject to the grantee's satisfactory submission of the additional items required by 7 CFR part 1942, subpart G and the USDA Rural Development Letter of Conditions.

VI. Award Administration Information

A. Award Notices

Successful applicants will receive notification for funding from the USDA Rural Development State Office. Applicants must comply with all applicable statutes and regulations before the grant award will be approved. Unsuccessful applications will receive notification by mail.

B. Administrative and National Policy Requirements

Additional requirements that apply to grantees selected for this program can be found in the 7 CFR 1942, subpart G and 7 CFR chapter XXX.

VII. Agency Contacts

For general questions about this announcement, please contact your USDA Rural Development State Office identified in this NOFA.

Nondiscrimination Statement: "The U.S. Department of Agriculture (USDA) prohibits discrimination in all its programs and activities on the basis of race, color, national origin, age, disability, and where applicable, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an

individual's income is derived from any public assistance program. (Not all prohibited bases apply to all programs.) Persons with disabilities who require alternative means for communication of program information (Braille, large print, audiotape, etc.) should contact USDA's TARGET Center at (202) 720-2600 (voice and TDD). To file a complaint of discrimination write to USDA, Director, Office of Civil Rights, 1400 Independence Avenue, SW., Washington, DC 20250-9410 or call (800) 795-3272 (voice) or (202) 720-6382 (TDD). USDA is an equal opportunity provider, employer, and lender."

Dated: November 19, 2007.

Ben Anderson,

Administrator, Rural Business-Cooperative Service.

[FR Doc. E7-22986 Filed 11-26-07; 8:45 am]

BILLING CODE 3410-XY-P

DEPARTMENT OF COMMERCE

Submission for OMB Review; Comment Request

The Department of Commerce will submit to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Agency: Bureau of Industry and Security (BIS).

Title: Technology Letter of Explanation.

OMB Control Number: 0694-0047.

Form Number(s): None.

Type of Request: Regular submission.

Burden Hours: 10,964.

Number of Respondents: 6,313.

Average Hours Per Response: Letter of Assurance, 30 minutes; and Technology Letter of Explanation, 2 hours.

Needs and Uses: The information contained in the Technology Letter of Explanation, and the Letter of Assurance will assure BIS that no unauthorized technical data will be exported for unauthorized end-uses or to unauthorized destinations. This will also provide assurance of compliance to U.S. national security and foreign policy programs.

Affected Public: Businesses and other for-profit institutions.

Frequency: On occasion.

Respondent's Obligation: Required to obtain or retain benefits.

OMB Desk Officer: David Rostker, (202) 395-3897.

Copies of the above information collection proposal can be obtained by

calling or writing Diana Hynek, Departmental Paperwork Clearance Officer, (202) 482-0266, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, Fax number (202) 395-7285 or via the Internet at David_Rostker@omb.eop.gov.

Dated: November 20, 2007.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E7-22994 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-33-P

DEPARTMENT OF COMMERCE

Submission for OMB Review; Comment Request

The Department of Commerce will submit to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Agency: International Trade Administration (ITA).

Title: ITA Environmental Technologies Non-Tariff Barriers Survey.

OMB Control Number: 0625-0241.

Form Number(s): ITA-4150P.

Type of Request: Regular submission.

Burden Hours: 33.

Number of Respondents: 200.

Average Hours Per Response: 10 minutes.

Needs and Uses: The environmental technologies industry has cited the proliferation of non-tariff barriers as a factor that is making U.S. exporting more difficult. This factor has been cited across all sub-sectors of environmental technologies products and all global geographic regions. The collection of information related to the experience of U.S. exporters with regard to these non-tariff measures is essential to the mission of the U.S. Department of Commerce's ITA, Office of Energy and Environmental Industries.

Affected Public: Business or other for-profit organizations.

Frequency: On occasion.

Respondent's Obligation: Voluntary.

OMB Desk Officer: David Rostker, (202) 395-3897.

Copies of the above information collection proposal can be obtained by

calling or writing Diana Hynek, Departmental Paperwork Clearance Officer, (202) 482-0266, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, Fax number (202) 395-7285 or via the Internet at David_Rostker@omb.eop.gov.

Dated: November 20, 2007.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E7-22996 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-DR-P

DEPARTMENT OF COMMERCE

Submission for OMB Review; Comment Request

The Department of Commerce will submit to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Agency: International Trade Administration (ITA).

Title: Information on Articles for Physically or Mentally Handicapped Persons Imported Free of Duty.

OMB Control Number: 0625-0118.

Form Number(s): ITA-362P.

Type of Request: Regular submission.

Burden Hours: 188.

Number of Respondents: 180.

Average Hours Per Response: 4 minutes.

Needs and Uses: When Congress enacted legislation to implement the Nairobi Protocol to the Florence Agreement, it included a provision for the Departments of Commerce and Homeland Security to collect information on the import of articles for the handicapped.

The form ITA-362P, Information on Articles for Physically or Mentally Handicapped Persons Imported Free of Duty, is the instrument by which statistical information is obtained to assess whether the duty-free treatment of articles for the handicapped has had a significant adverse impact on a domestic industry (or portion thereof) manufacturing or producing a like or directly competitive article. Without the collection of this information, it would be impossible for ITA to make a sound determination of the adverse impact and

the President to appropriately redress the situation.

Affected Public: Businesses or other for-profit; not-for-profit institutions; state, local or tribal government; federal government; individuals or households.

Frequency: On occasion.

Respondent's Obligation: Required to obtain or retain a benefit.

OMB Desk Officer: David Rostker, (202) 395-3897.

Copies of the above information collection proposal can be obtained by calling or writing Diana Hynek, Departmental Paperwork Clearance Officer, (202) 482-0266, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, Fax number (202) 395-7285 or via the Internet at David_Rostker@omb.eop.gov.

Dated: November 20, 2007.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E7-22997 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE

Bureau of Industry and Security

Proposed Information Collection; Comment Request; Procedures for Acceptance or Rejection of a Rated Order

AGENCY: Bureau of Industry and Security, DOC.

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995.

DATES: Written comments must be submitted on or before January 28, 2008.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or

copies of the information collection instrument and instructions should be directed to Larry Hall, BIS ICB Liaison, (202)482-4896, lhall@bis.doc.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract

This collection is necessary for administration and enforcement of delegated authority under the Defense Production Act of 1950, as amended (50 U.S.C. App. 2061, et seq.) and the selective Service Act of 1948 (50 U.S.C. App. 468). Any person (supplier) who receives a priority rated order under Defense Priorities and Allocations System (DPAS) regulation (15 CFR 700) must notify the customer of acceptance or rejection of that order within a specified period of time. Also, if shipment against a priority rated order will be delayed, the supplier must immediately notify the customer. The purpose of this authority is to ensure the timely delivery of goods and services to meet current national defense and civil emergency preparedness program requirements.

II. Method of Collection

Paper form or electronically.

III. Data

OMB Control Number: 0694-0092.

Form Number(s): None.

Type of Review: Business or other for-profit organizations.

Estimated Number of Respondents: 18,000.

Estimated Time Per Response: 1 to 15 minutes.

Estimated Total Annual Burden Hours: 21,963.

Estimated Total Annual Cost to Public: \$0.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection;

they also will become a matter of public record.

Dated: November 20, 2007.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E7-22993 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-33-P

DEPARTMENT OF COMMERCE

Bureau of Industry and Security

Proposed Information Collection; Comment Request; Export and Reexport Controls for Iraq

AGENCY: Bureau of Industry and Security, DOC.

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995.

DATES: Written comments must be submitted on or before January 28, 2008.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument and instructions should be directed to Larry Hall, BIS ICB Liaison, (202)482-4896, lhall@bis.doc.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract

The primary purpose of this collection of information is to maintain an expedited export license type developed specifically for exports and reexports of controlled items destined to civil infrastructure rebuilding projects in Iraq. The name given this license type is the Special Iraq Reconstruction License or SIRL. The information covered under this collection is furnished by U.S. exporters when applying for an export license. The export license is authorized under OMB 0694-0088 "Multipurpose Application." This collection involves additional information and documentation about the project in Iraq which are necessary to properly evaluate the request.

II. Method of Collection

Information will be supplied electronically via the BIS SNAP-R system or in paper form.

III. Data

OMB Control Number: 0694-0129.

Form Number(s): None.

Type of Review: Business or other for-profit organizations.

Estimated Number of Respondents: 25.

Estimated Time Per Response: 3 to 3.5 hours.

Estimated Total Annual Burden Hours: 93.

Estimated Total Annual Cost to Public: \$0.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: November 20, 2007.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E7-22998 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-33-P

DEPARTMENT OF COMMERCE

National Institute of Standards and Technology

Visiting Committee on Advanced Technology

AGENCY: National Institute of Standards and Technology, Department of Commerce.

ACTION: Notice of partially closed meeting.

SUMMARY: Pursuant to the Federal Advisory Committee Act, 5 U.S.C. app. 2, notice is hereby given that the Visiting Committee on Advanced

Technology (VCAT), National Institute of Standards and Technology (NIST), will meet Tuesday, December 11, 2007, from 8:30 a.m. to 2:30 p.m. and Wednesday, December 12, 2007, from 8:30 a.m. to 12 p.m. The Visiting Committee on Advanced Technology is composed of fifteen members appointed by the Director of NIST who are eminent in such fields as business, research, new product development, engineering, labor, education, management consulting, environment, and international relations. The purpose of this meeting is to review and make recommendations regarding general policy for the Institute, its organization, its budget, and its programs within the framework of applicable national policies as set forth by the President and the Congress. The agenda will include an update on NIST and its R&D priorities, NIST's vision for 2017, and strategic plan; an overview presentation on the U.S. standards and conformity assessment system; break-out sessions of the Information Technology and Nanotechnology subcommittees to discuss NIST's programs and plans and how they fit into the national agenda with input back to the full committee. Discussions on NIST budget and planning information scheduled to begin at 8 a.m. and to end at 8:30 a.m. on December 11 will be closed. The agenda may change to accommodate Committee business. The final agenda will be posted on the NIST Web site at <http://www.nist.gov/director/vcat/agenda.htm>.

Anyone wishing to attend this meeting should submit name, e-mail address and phone number to Denise Herbert (denise.herbert@nist.gov or 301-975-5607) no later than December 7, 2007.

DATES: The meeting will convene on December 11, 2007 at 8:30 a.m. and will adjourn on December 12, 2007 at 12 p.m.

ADDRESSES: The meeting will be held at the Doubletree Guest Suites, Historic Charleston, 181 Church Street, Charleston, South Carolina, 29401.

FOR FURTHER INFORMATION CONTACT: Denise Herbert, Visiting Committee on Advanced Technology, National Institute of Standards and Technology, Gaithersburg, Maryland 20899-1000, telephone number (301) 975-5607.

SUPPLEMENTARY INFORMATION: The Assistant Secretary for Administration, with the concurrence of the General Counsel, formally determined on November 19, 2007, that portions of the meeting of the Visiting Committee on Advanced Technology which deal with

discussion of sensitive budget and planning information that would cause harm to third parties if publicly shared be closed in accordance with section 10 (d) of the Federal Advisory Committee Act, 5 U.S.C. app. 2.

Dated: November 20, 2007.

Richard F. Kayser,

Acting Deputy Director.

[FR Doc. E7-23032 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-13-P

DEPARTMENT OF COMMERCE

National Institute of Standards and Technology

Announcing a Meeting of the Information Security and Privacy Advisory Board

AGENCY: National Institute of Standards and Technology, DOC.

ACTION: Notice of meeting.

SUMMARY: Pursuant to the Federal Advisory Committee Act, 5 U.S.C. App., notice is hereby given that the Information Security and Privacy Advisory Board (ISPAB) will meet Thursday, December 6, 2007, from 8:30 a.m. until 5 p.m., and Friday, December 7, 2007, from 8 a.m. until 4:30 p.m. All sessions will be open to the public. The Advisory Board was established by the Computer Security Act of 1987 (Pub. L. 100-235) and amended by the Federal Information Security Management Act of 2002 (Pub. L. 107-347) to advise the Secretary of Commerce and the Director of NIST on security and privacy issues pertaining to federal computer systems. Details regarding the Board's activities are available at <http://csrc.nist.gov/ispab/>.

DATES: The meeting will be held on December 6, 2007 from 8:30 a.m. until 5 p.m. and December 7, 2007, from 8 a.m. until 4:30 p.m.

ADDRESSES: The meeting will take place at the George Washington University Cafritz Conference Center, 800 21st Street, NW., Room 405, Washington, DC.

Agenda

- Welcome and Overview.
- NIST Computer Security Division (CSD) Update.
- DHS National Communication Systems Update.
- Identify Management Briefing.
- System Assurance Activities Update.
- Privacy Technology White Paper Update.
- ISPAB Work Plan Discussion and Panel on Einstein Program.
- Federal IT Security Products.

—ISPAB Work Plan Discussion on SISA Alliance.

—Social Networking and Security Briefing.

Note that agenda items may change without notice because of possible unexpected schedule conflicts of presenters.

Public Participation: The Board agenda will include a period of time, not to exceed thirty minutes, for oral comments and questions from the public. Each speaker will be limited to five minutes. Members of the public who are interested in speaking are asked to contact the Board Secretariat at the telephone number indicated below. In addition, written statements are invited and may be submitted to the Board at any time. Written statements should be directed to the ISPAB Secretariat, Information Technology Laboratory, 100 Bureau Drive, Stop 8930, National Institute of Standards and Technology, Gaithersburg, MD 20899-8930. It would be appreciated if 25 copies of written material were submitted for distribution to the Board and attendees no later than November 20, 2007. Approximately 15 seats will be available for the public and media.

FOR FURTHER INFORMATION CONTACT: Ms. Pauline Bowen, Board Secretariat, Information Technology Laboratory, National Institute of Standards and Technology, 100 Bureau Drive, Stop 8930, Gaithersburg, MD 20899-8930, telephone: (301) 975-2938.

Dated: November 20, 2007.

Richard F. Kayser,

Acting Deputy Director.

[FR Doc. E7-23023 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-CN-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

Proposed Information Collection; Comment Request; Cooperative Charting Programs

AGENCY: National Oceanic and Atmospheric Administration (NOAA), DOC.

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995.

DATES: Written comments must be submitted on or before January 28, 2008.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument and instructions should be directed to Ken Forster, 301-713-2737 or ken.forster@noaa.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract

The U.S. Coast Guard Auxiliary members report observations of changes that require additions, corrections or revisions to Nautical Charts, on the NOAA Form 77-05. The U.S. Power Squadrons use a Web site to report the same information. The information provided is used by NOAA National Ocean Service to maintain and prepare new additions that are used nationwide by commercial and recreational navigators.

II. Method of Collection

Methods of submittal include Internet and facsimile transmission of paper forms.

III. Data

OMB Number: 0648-0022.

Form Number: NOAA 77-5.

Type of Review: Regular submission.

Affected Public: Individuals or households; not-for-profit institutions.
Estimated Number of Respondents: 1,025.

Estimated Time Per Response: 2½ hours.

Estimated Total Annual Burden

Hours: 4,400.

Estimated Total Annual Cost to Public: \$0.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: November 20, 2007.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E7-22995 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-JS-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

RIN 0648-XE08

Endangered and Threatened Species; Take of Anadromous Fish

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice.

SUMMARY: Notice is hereby given that NMFS has issued Permit 1044 Modification 4 to the NMFS Southwest Fisheries Science Center (SWFSC) Fisheries Ecology Division (FED) in Santa Cruz, California.

ADDRESSES: The application, permit, and related documents are available for review by appointment at: Protected Resources Division, NMFS, 777 Sonoma Avenue, Room 315, Santa Rosa, CA 95404 (ph: 707-575-6097, fax: 707-578-3435, e-mail at: Jeffrey.Jahn@noaa.gov).

FOR FURTHER INFORMATION CONTACT: Jeffrey Jahn at 707-575-6097, or e-mail: Jeffrey.Jahn@noaa.gov.

SUPPLEMENTARY INFORMATION:

Authority

The issuance of permits and permit modifications, as required by the Endangered Species Act of 1973 (16 U.S.C. 1531-1543) (ESA), is based on a finding that such permits/modifications: (1) are applied for in good faith; (2) would not operate to the disadvantage of the listed species which are the subject of the permits; and (3) are consistent with the purposes and policies set forth in section 2 of the ESA. Authority to take listed species is subject to conditions set forth in the permits. Permits and modifications are issued in accordance with and are subject to the ESA and NMFS regulations (50 CFR parts 222-226) governing listed fish and wildlife permits.

Species Covered in This Notice

This notice is relevant to federally threatened Southern Oregon/Northern California Coast coho salmon (*Oncorhynchus kisutch*), endangered Central California Coast coho salmon (*O. kisutch*), threatened California Coastal Chinook salmon (*O. tshawytscha*), endangered Sacramento River winter-run Chinook salmon (*O. tshawytscha*), threatened Central Valley spring-run Chinook salmon (*O. tshawytscha*), threatened Northern California steelhead (*O. mykiss*), threatened Central California Coast steelhead (*O. mykiss*), threatened California Central Valley steelhead (*O. mykiss*), threatened South-Central California Coast steelhead (*O. mykiss*), and endangered Southern California steelhead (*O. mykiss*).

Permit Issued

A notice of the receipt of an application for a scientific research permit (1044 Modification 4) was published in the **Federal Register** on August 16, 2006 (71 FR 47179). Permit 1044 Modification 4 was issued to SWFSC FED on July 26, 2007.

Permit 1044 Modification 4 authorizes SWFSC FED to capture (by backpack electrofishing, seine, rotary screw trap, fyke-net trap, pipe-trap, weir-trap, or hook-and-line), sample (by collection of scales, fin-clips, or stomach contents), mark (using fin-clips, passive integrated transponder (PIT) tags, visible implant elastomer (VIE) tags, or visible implant alpha (VI alpha) tags), and release juvenile Southern Oregon/Northern California Coast coho salmon, Central California Coast coho salmon, California Coastal Chinook salmon, Sacramento River winter-run Chinook salmon, Central Valley spring-run Chinook salmon, Northern California steelhead, Central California Coast steelhead, California Central Valley steelhead, South-Central California Coast steelhead, and Southern California steelhead. Permit 1044 Modification 4 also authorizes SWFSC FED to capture (by seine, weir-trap, or hook-and-line), sample (by collection of scales or fin-clips), mark (using fin-clips, PIT tags, or external anchor tags), and release adult Southern Oregon/Northern California Coast coho salmon and Northern California steelhead. In addition, Permit 1044 Modification 4 authorizes SWFSC FED to capture, handle, sample (by collection of scales, fin-clips, or other tissue), mark, and release adult carcasses of Southern Oregon/Northern California Coast coho salmon, Central California Coast coho salmon, California Coastal Chinook salmon, Sacramento

River winter-run Chinook salmon, Central Valley spring-run Chinook salmon, and Northern California steelhead.

Permit 1044 Modification 4 authorizes unintentional lethal take of juvenile Southern Oregon/Northern California Coast coho salmon, Central California Coast coho salmon, California Coastal Chinook salmon, Sacramento River winter-run Chinook salmon, Central Valley spring-run Chinook salmon, Northern California steelhead, Central California Coast steelhead, California Central Valley steelhead, South-Central California Coast steelhead, and Southern California steelhead not to exceed 2.5 percent of fish captured. Permit 1044 Modification 4 authorizes unintentional lethal take of adult Southern Oregon/Northern California Coast coho salmon and Northern California steelhead not to exceed 1 percent of fish captured. Permit 1044 Modification 4 authorizes intentional lethal take of 500 juvenile Northern California steelhead, 300 juvenile Central California Coast steelhead, 300 juvenile California Central Valley steelhead, and 200 juvenile South-Central California Coast steelhead.

Permit 1044 Modification 4 is for research to be conducted in streams and estuaries throughout the State of California. The purpose of the research is to support conservation and recovery planning of ESA-listed salmonids, address information needs identified by NMFS, and contribute to the general body of scientific knowledge pertaining to ESA-listed salmonids. Permit 1044 Modification 4 expires on December 31, 2012.

Dated: November 21, 2007.

Angela Somma,

Chief, Endangered Species Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. E7-23093 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

RIN 0648-XC38

Marine Mammals; File No. 1034-1854

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice; issuance of permit amendment.

SUMMARY: Notice is hereby given that Dr. Markus Horning, Department of

Fisheries & Wildlife, Oregon State University, Hatfield Marine Science Center, 2030 SE Marine Science Drive, Newport, OR 97365 has been issued an amendment to scientific research Permit No. 1034-1854.

ADDRESSES: The amendment and related documents are available for review upon written request or by appointment in the following office(s):

Permits, Conservation and Education Division, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13705, Silver Spring, MD 20910; phone (301)713-2289; fax (301)427-2521; and

Southwest Region, NMFS, 501 West Ocean Blvd., Suite 4200, Long Beach, CA 90802-4213; phone (562)980-4001; fax (562)980-4018.

FOR FURTHER INFORMATION CONTACT:

Amy Sloan or Tammy Adams, (301)713-2289.

SUPPLEMENTARY INFORMATION:

On September 10, 2007, notice was published in the **Federal Register** (72 FR 51621) that an amendment of Permit No. 1034-1854, had been requested by the above-named individual. The requested amendment has been granted under the authority of the Marine Mammal Protection Act of 1972, as amended (16 U.S.C. 1361 *et seq.*), and the regulations governing the taking and importing of marine mammals (50 CFR part 216).

The permit amendment authorizes the permit holder to (1) increase the number of blood samples taken from animals with Evans blue dye administered; (2) leave satellite data transmitters on adult females until they fall off during the annual molt, rather than removing them at the end of the field season; and (3) opportunistically attach satellite transmitters to selected adult females older than 21 years when first encountered, for subsequent recapture, sampling, and outfitting with remaining telemetry devices. The permit holder is also authorized to collect opportunistic fecal samples and import them into the U.S..

In compliance with the National Environmental Policy Act of 1969 (42 U.S.C. 4321 *et seq.*), a final determination has been made that the activity proposed is categorically excluded from the requirement to prepare an environmental assessment or environmental impact statement.

Dated: November 21, 2007.

P. Michael Payne,

Chief, Permits, Conservation and Education Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. E7-23063 Filed 11-26-07; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

RIN: 0648-XE10

Mid-Atlantic Fishery Management Council; Public Meetings

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public meetings.

SUMMARY: The Mid-Atlantic Fishery Management Council (Council), its Mid-Atlantic section of the Monkfish Committee, its Squid, Mackerel, and Butterfish Committee, its Bycatch/Limited Access Committee, and its Executive Committee will hold public meetings.

DATES: The meetings will be held on Monday, December 10, 2007 through Thursday, December 14, 2007. See **SUPPLEMENTARY INFORMATION** for specific dates and times

ADDRESSES: This meeting will be held at the Holiday Inn Harmon Meadow, 300 Plaza Drive, Secaucus, NJ 07094; telephone: (201) 348-2000.

Council address: Mid-Atlantic Fishery Management Council, 300 S. New Street, Dover, DE 19904; telephone: (302) 674-2331.

FOR FURTHER INFORMATION CONTACT:

Daniel T. Furlong, Executive Director, Mid-Atlantic Fishery Management Council; telephone: (302) 674-2331, ext. 19.

SUPPLEMENTARY INFORMATION:

On Monday, December 10, the Council will convene to conduct a workshop on the impact of the Reauthorized Magnuson-Stevens Act on its specification setting process. On Tuesday, December 11, the Council will convene jointly with the Atlantic States Marine Fisheries Commission's (ASMFC) Summer Flounder, Scup, and Black Sea Bass Board beginning at 8:30 a.m. through 4:30 p.m. From 4:30 p.m. until 5:30 p.m. the Mid-Atlantic section of the Monkfish Committee will meet. On Wednesday, December 12, the Council will convene at 8 a.m. until 1:15 p.m. From 1:15 p.m. until 3:30 p.m. the Squid, Mackerel, and Butterfish Committee will meet. From 3:30 p.m. until 5:30 p.m. the Bycatch / Limited Access Committee will meet. On Thursday, December 13, the Executive Committee will meet from 8 a.m. until 9 a.m. The Council will convene at 9 a.m. and remain in session until approximately 12 p.m.

Agenda items by day for the Council's committees and the Council itself are:

Monday, December 10 - The Council will convene to conduct a workshop on the impact of the Reauthorized Magnuson-Stevens Act on its specification setting process. Tuesday, December 11 - The Council will convene jointly with the Atlantic States Marine Fisheries Commission's (ASMFC) Summer Flounder, Scup, and Black Sea Bass Board. They will review and discuss the Monitoring Committee's and the Advisory Panel's recommendations on summer flounder, scup, and black sea bass recreational management measures, and develop and approve management measures for the 2008 summer flounder recreational fisheries. The Mid-Atlantic section of the Monkfish Committee will review and discuss action taken by the New England Council regarding Framework 5 and 6, and develop a Council position regarding Framework 5 and Framework 6. Wednesday, December 12 - The Council will conduct its regular business session to approve October Council minutes, approve actions from the October meeting, and receive various organizational reports. The Council will review and approve the final action on Framework 5 to the Monkfish FMP. There will be an awards presentation to recognize the 2007 Fisheries Achievement Award winner. The Squid, Mackerel, and Butterfish Committee will review management alternatives to address the mackerel limited entry program. The Bycatch/Limited Access Committee will receive an update on the National Bycatch Report. Thursday, December 13 - The Executive Committee will review the Scientific and Statistical Committee (SSC) membership process and SSC member stipends. The Council will then convene to receive a Marine Debris presentation and Committee reports, review and approve changes to the Statement of Organization, Practices, and Procedures (SOPP) related to the SSC role, address reappointment of existing members, fill two vacancies on the SSC, and discuss the concept of adjunct SSC members.

Although non-emergency issues not contained in this agenda may come before the Council for discussion, these issues may not be the subject of formal Council action during this meeting. Council action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the Magnuson-Stevens Act, provided the public has been notified of the Council's

intent to take final actions to address such emergencies.

Special Accommodations

This meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to M. Jan Bryan, (302) 674-2331 ext: 18, at least 5 days prior to the meeting date.

Dated: November 21, 2007.

Tracey L. Thompson,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.
[FR Doc. E7-23018 Filed 11-26-07; 8:45 am]
BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

RIN 0648-XE12

New England Fishery Management Council; Public Meeting

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of a public meeting.

SUMMARY: The New England Fishery Management Council's (Council) Multispecies (Groundfish) Committee will meet to consider actions affecting New England fisheries in the exclusive economic zone (EEZ).

DATES: The two-day meeting will be held on Wednesday, December 12, 2007, at 9 a.m. and Thursday, December 13, 2007, at 8:30 a.m.

ADDRESSES: The meeting will be held at the Holiday Inn, One Newbury Street, Peabody, MA 01960; telephone: (978) 535-4600.

Council address: New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950.

FOR FURTHER INFORMATION CONTACT: Paul J. Howard, Executive Director, New England Fishery Management Council; telephone: (978) 465-0492.

SUPPLEMENTARY INFORMATION: The Multispecies (Groundfish) Committee will meet for two days to consider additional issues for Amendment 16 to the Northeast Multispecies Fishery Management Plan. The items of discussion in the committee's agenda are as follows:

Wednesday, December 12, 2007

The Committee will continue to develop a process for allocation of groundfish species and a process to set the Annual Catch Limits (ACL's) and

Accountability Measures (AM's) for the recreational users. It also will continue to develop days-at-sea (DAS) measures to meet the mortality requirements set under Amendment 13, establishing a process to set ACL's and AM's for the common pool commercial users, and developing DAS transfer and leasing taxes. The Committee may also consider other DAS measures necessary to complete its work for Amendment 16.

Thursday, December 13, 2007

The Committee will finish any uncompleted issues from day one and work on the following items:

Measures for sector management to include baseline time-frame; allocation mechanisms, replacing the 20% species cap; monitoring mechanisms for sectors.

The Committee may also consider other sector issues and any measures necessary to complete its work for Amendment 16.

Although non-emergency issues not contained in this agenda may come before this group for discussion, those issues may not be the subject of formal action during this meeting. Action will be restricted to those issues specifically identified in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the Magnuson-Stevens Fishery Conservation and Management Act, provided the public has been notified of the Council's intent to take final action to address the emergency.

Special Accommodations

This meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Paul J. Howard (see **ADDRESSES**) at least 5 days prior to the meeting date.

Authority: 16 U.S.C. 1801 *et seq.*

Dated: November 21, 2007.

Tracey L. Thompson,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.
[FR Doc. E7-23019 Filed 11-26-07; 8:45 am]
BILLING CODE 3510-22-S

DEPARTMENT OF DEFENSE**GENERAL SERVICES
ADMINISTRATION****NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION**

[OMB Control No. 9000-0013]

**Federal Acquisition Regulation;
Information Collection; Cost or Pricing
Data Requirements and Information
Other Than Cost or Pricing Data**

AGENCIES: Department of Defense (DOD), General Services Administration (GSA), and National Aeronautics and Space Administration (NASA).

ACTION: Notice of request for public comments regarding an extension to an existing OMB clearance.

SUMMARY: Under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), the Federal Acquisition Regulation (FAR) Secretariat will be submitting to the Office of Management and Budget (OMB) a request to review and approve an extension of a currently approved information collection requirement concerning cost or pricing data requirements and information other than cost or pricing data. The clearance currently expires on May 31, 2008.

Public comments are particularly invited on: Whether this collection of information is necessary for the proper performance of functions of the FAR, and whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate, and based on valid assumptions and methodology; ways to enhance the quality, utility, and clarity of the information to be collected; and ways in which we can minimize the burden of the collection of information on those who are to respond, through the use of appropriate technological collection techniques or other forms of information technology.

DATES: Submit comments on or before January 28, 2008.

ADDRESSES: Submit comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to the General Services Administration, FAR Secretariat (VIR), 1800 F Street, NW., Room 4035, Washington, DC 20405.

FOR FURTHER INFORMATION CONTACT: Edward Chambers, Contract Policy Division, GSA (202) 501-3221.

SUPPLEMENTARY INFORMATION:**A. Purpose**

The Truth in Negotiations Act requires the Government to obtain certified cost or pricing data under certain circumstances. Contractors may request an exemption from this requirement under certain conditions and provide other information instead.

B. Annual Reporting Burden

Respondents: 33,332.

Responses Per Respondent: 6.

Total Responses: 199,992.

Hours Per Response: 50.51.

Total Burden Hours: 10,101,684.

OBTAINING COPIES OF

PROPOSALS: Requesters may obtain a copy of the information collection documents from the General Services Administration, FAR Secretariat (VIR), Room 4035, 1800 F Street, NW., Washington, DC 20405, telephone (202) 501-4755. Please cite OMB Control No. 9000-0013, Cost or Pricing Data Requirements and Information Other Than Cost or Pricing Data, in all correspondence.

Dated: November 8, 2007.

Al Matera,

Director, Office of Acquisition Policy.

[FR Doc. 07-5836 Filed 11-26-07; 8:45 am]

BILLING CODE 6820-EP-S

DEPARTMENT OF DEFENSE**Department of the Navy****Notice of Partially Closed Meeting of
the Naval Research Advisory
Committee; Correction**

AGENCY: Department of the Navy, DoD.

ACTION: Notice; correction.

SUMMARY: The Department of the Navy published a document in the **Federal Register** of November 14, 2007, announcing a partially closed meeting of the Naval Research Advisory Committee (NRAC). The dates of the meeting contained in the document have changed.

FOR FURTHER INFORMATION CONTACT: Mr. William H. Ellis, Jr., Program Director, Naval Research Advisory Committee, 875 North Randolph Street, Arlington, VA 22203-1995; *telephone:* 703-696-5775.

Correction

In the **Federal Register** of November 14, 2007, in FR Doc. E7-22200, make the following changes:

1. In the second column, on page 64060, correct the second sentence of the **SUMMARY** to read:

“With the exception of two unclassified sessions on December 19,

2007 from 2 p.m. to 3 p.m. and from 3 p.m. to 4 p.m., all other sessions on December 18, 2007 and December 19, 2007 will include discussions involving proprietary information regarding technology applications and systems under development in the private sector between competing companies and/or information classified at the SECRET level that is devoted to intelligence briefings; emerging threats posed by potential adversaries; the exploitation of physical vulnerabilities; the tactical applications of known and emerging technologies; an assessment of the emerging concepts in such areas as: Training, S&T funding allocation, technology monitoring, progress assessments, and probable timeframes for transformation and implementation; the challenges raised with the utilization and fielding of various technology applications; and a security briefing that will discuss security policies and procedures, and counterintelligence information classified at the SECRET level.”

2. In the third column, on page 64060, correct the **DATES** caption to read:

“**DATES:** The Winter Meetings will be held on Tuesday, December 18, 2007 and Wednesday, December 19, 2007. The open sessions of the meeting will be held on Wednesday, December 19, 2007, from 2 p.m. to 3 p.m. and from 3 p.m. to 4 p.m. The closed sessions will be held all day on Tuesday, December 18, 2007, and on Wednesday, December 19, 2007, from 8 a.m. to 2 p.m. and 4 p.m. to 4:15 p.m.”

Dated: November 20, 2007.

T. M. Cruz,

*Lieutenant, Judge Advocate General's Corps,
U.S. Navy, Federal Register Liaison Officer.*

[FR Doc. E7-22990 Filed 11-26-07; 8:45 am]

BILLING CODE 3810-FF-P

**DELAWARE RIVER BASIN
COMMISSION****Notice of Commission Meeting and
Public Hearing**

Notice is hereby given that the Delaware River Basin Commission will hold an informal conference followed by a public hearing on Wednesday, December 12, 2007. The hearing will be part of the Commission's regular business meeting. Both the conference session and business meeting are open to the public and will be held at the Commission's office building, located at 25 State Police Drive in West Trenton, New Jersey. The conference among the commissioners and staff will begin at 10 a.m. Topics of discussion will include:

a status report by staff of the U.S. Geological Survey on the flood analysis model under development in accordance with DRBC Resolution No. 2006-20 to evaluate the potential for reservoirs throughout the basin to be used to mitigate flooding along the Delaware River and its tributaries; status of a proposal to update the water quality standard for PCBs in the Delaware Estuary and provide for implementation of the new standard; a report on the status of three pending rulemakings—(a) amendments to the Water Code and Water Quality Regulations relating to water accountability and source metering, recording and reporting; (b) Water Code amendments to implement a Flexible Flow Management Program proposed by the parties to the Supreme Court Decree of 1954 for operation of the New York City Delaware Basin reservoirs; and (c) amendments to the Water Code and Water Quality Regulations regarding Special Protection Waters. In addition, there will be a discussion of the proposed DRBC FY 2008-2009 Water Resources Program and a presentation by Dr. Rebecca L. Schneider of Cornell University on how networks of roadside ditches across watersheds contribute significantly to flooding, droughts, and degraded water quality downstream.

The subjects of the public hearing to be held during the 1:30 p.m. business meeting include the dockets listed below:

1. *Deptford Township Municipal Utilities Authority D-94-68 CP-2*. An application for the renewal of a ground water withdrawal project to continue withdrawal of 123 mg/30 days to supply the applicant's public water supply distribution system from existing Wells Nos. 1, 2, 4, 6, 7, 8 and 9R in the Potomac-Raritan-Magothy Formation. The project is located in the Lower Delaware Watershed in Deptford Township, Gloucester County, New Jersey, in New Jersey Critical Water Supply Area 2.

2. *City of Vineland D-95-47 CP-2*. An application for the renewal of a ground water withdrawal project to continue the withdrawal of 494.5 mg/30 days to supply the applicant's public water supply distribution system from existing Wells Nos. 2 through 14 in the Cohansey Formation. The project is located in the Maurice River Watershed in the City of Vineland, Cumberland County, New Jersey.

3. *Merchantville-Pennsauken Water Commission D-97-5 CP-2*. An application for the renewal of a ground water withdrawal project to continue withdrawal of 335 mg/30 days to supply the applicant's public water supply

distribution system from fifteen (15) existing wells in the Potomac-Raritan-Magothy Formation. The project is located in the Pennsauken Creek Watershed in Merchantville Borough and Pennsauken Township, Camden County, New Jersey.

4. *Nestlé Waters North America, Inc. D-98-27-3*. An application for the renewal of a spring water withdrawal project to continue withdrawal of 9 mg/30 days to supply the applicant's bottled water operations from existing Hoffman Springs Nos. 1, 2 and 3 and new Mattos Catchment No. 1. The project is located in the Ontelaunee Creek Watershed in Lynn Township, Lehigh County, Pennsylvania.

5. *Sapa Extrusions, Inc. (formerly Alcoa Extrusions, Inc.) D-2005-1-3*. An application to continue to discharge up to 0.10 mgd from an existing outfall to the West Branch Schuylkill River. No expansion of the treatment facility is proposed and no alterations to the existing effluent limits are requested. The treatment facility is located in Cressona Borough, Schuylkill County, Pennsylvania.

6. *E. I. du Pont de Nemours and Company D-71-86-2*. An application for the renewal and update of the Edge Moor facility's IWTP and non-contact cooling water discharges and for approval of the installation of an effluent diffuser. The permitted discharges from the applicant's titanium dioxide production facility include a 5.2 mgd discharge of treated IWTP effluent from Outfall 001, a 2.89 mgd discharge of non-contact cooling water and storm water from Outfall 002, and a 5.9 mgd discharge of non-contact cooling water and stormwater from Outfall 003. The facility will continue to discharge to the Delaware River. The facility is located in Edgemoor, Delaware.

7. *Warren County (Pequest River) Municipal Authority D-71-96 CP-2*. An application to modify an existing docket by providing a Total Dissolved Solids (TDS) determination for the Warren County (Pequest River) Municipal Utilities Authority's Oxford Area Wastewater Treatment Plant (WWTP). The Oxford Area WWTP has a design flow of 0.5 million gallons per day (mgd) and treats primarily domestic sewage prior to discharge to the Pequest River at River Mile 197.8-7.2-0.9. The facility also accepts leachate from a landfill operated by the Pollution Control Financing Authority of Warren County and from Covanta Industry. Because these waste streams can result in a WWTP discharge that exceeds DRBC's basinwide effluent TDS limitation of 1000 mg/L, the applicant has requested a variance in the form of

an adjusted effluent TDS limitation of 9,864 pounds per day. DRBC criteria allow for a variance from a TDS effluent limit where the variance would not result in an instream TDS concentration in excess of 500 mg/L or an increase in the instream TDS concentrations of more than 33%. The Pequest is a tributary of the Lower Delaware River, which DRBC has designated on an interim basis as Special Protection Waters with a classification of Significant Resource Waters. The facility is located in Oxford Township, Warren County, New Jersey.

8. *County of Chester Department of Facilities Management D-83-15 CP-3*. An application for approval to expand a 0.105 mgd WWTP to treat an average flow of 0.13676 mgd. The WWTP will continue to serve only the Pocopson Home and Prison, located in Pocopson Township, Chester County, Pennsylvania. Following advanced treatment, the WWTP effluent will be applied to expanded adjacent spray fields, which are located in the Pocopson Creek Watershed. A new aerated lagoon will be constructed to provide sufficient supplemental effluent storage, so that a WWTP discharge to a stream will not be needed.

9. *The Premcor Refining Group, Inc. D-93-4-6*. An application to replace the withdrawal of water from Wells Nos. P-3A and P-4A in the applicant's water supply system that have become unreliable sources of supply and to increase the applicant's surface water withdrawal from the Delaware River and Red Lion Creek. Premcor requests that its combined withdrawal from replacement Wells Nos. P-3B and P-4B and seven existing wells remain limited to 180 million gallons per thirty days (mg/30 days); that its withdrawal from the Delaware River intake remain 13,560 mg/30 days; that the docket authorize withdrawals of 38.9 mg/30 days from the Red Lion Creek intake and up to 56.2 mg/30 days from the Dragon Run intake, and that Premcor's combined withdrawal from all sources be limited to 13,835.1 mg/30 days. The proposed allocation represents no increase in groundwater withdrawals and no increase from the Delaware River intake. The docket is proposed to include previously un-docketed pre-Compact DNREC allocations from Dragon Run and Red Lion Creek. The project is located in the Potomac Formation in the C&D Canal East, Dragon Run Creek, Red Lion Creek and Delaware River watersheds in Delaware City, New Castle County, Delaware.

10. *Valero Paulsboro Refinery D-2006-28-1*. An application for approval of a surface water withdrawal project to

supply up to 10.8 mgd (324 mg/30 days) of water to the applicant's petroleum refinery from an existing surface water intake. The project is located in the Delaware Watershed in Greenwich Township, Gloucester County, New Jersey, in New Jersey Critical Water Supply Area 2.

11. *Exelon Power D-2006-44-1*. An application for approval of an existing surface water withdrawal project to supply up to 9,975 mg/30 days of water to the applicant's Cromby Generating Station from the Schuylkill River and to limit the existing withdrawal from all intakes to 9,975 mg/30 days. No increase in withdrawals is requested. The project is located in the Schuylkill River Watershed in East Pikeland Township, Chester County, Pennsylvania and is located in the Southeastern Pennsylvania Ground Water Protected Area.

12. *To-Jo Mushrooms Inc. D-2007-3-1*. An application for approval of the rerate of the existing To-Jo Mushroom IWTP from 0.03 mgd to 0.049 mgd and for approval of the existing 0.035 mgd discharge of contact cooling water. The applicant's IWTP serves a mushroom canning facility. The IWTP and contact cooling water will continue to be discharged to Trout Run, a tributary of the White Clay Creek. The facility is located in New Garden Township, Chester County, Pennsylvania.

13. *The Asbury Graphite Mills, Inc. D-2007-26-1*. An application for approval of a ground water withdrawal project to supply up to 5.65 mg/30 days of water to the applicant's manufacturing facility from Intakes Nos. 1, 2A, 2B and 2C in the Musconetcong River and to supply up to 1.43 mg/30 days from Wells Nos. 1 and 2 completed in the Allentown Dolomite Formation in the Musconetcong River Watershed, for a total allocation of 7.08 mg/30 days. The project is located in Bethlehem Township, Hunterdon County, New Jersey, within the drainage area to the section of the non-tidal Delaware River known as the Lower Delaware, which is designated as Special Protection Waters.

14. *Woodbourne Correctional Facility D-2007-28 CP-1*. An application for approval of a ground water withdrawal project to supply up to 7.20 mg/30 days of water to the applicant's domestic water supply from Wells Nos. 1, 2, 3, 4, 5, 6 and 7 and to limit the existing withdrawal from all wells to 7.20 mg/30 days. The project is located in the Valley Fill Aquifer in the Middle Delaware Watershed in Woodbourne Township, Sullivan County, New York, within the drainage area to the section of the non-tidal Delaware River known

as the Upper Delaware, which is designated as Special Protection Waters.

In addition, the Commission's 1:30 p.m. business meeting will include a public hearing on the proposed Fiscal Year 2008-2009 Current Expense and Capital Budgets.

The business meeting also will include adoption of the Minutes of the Commission's September 26, 2007 business meeting; announcements of upcoming advisory committee meetings and other events; a report by the Executive Director; a report by the Commission's General Counsel; and an opportunity for public dialogue.

Draft dockets scheduled for public hearing on December 12, 2007 will be posted on the Commission's Web site, <http://www.drbc.net>, where they can be accessed through the Notice of Commission Meeting and Public Hearing. Additional documents relating to the dockets and other items may be examined at the Commission's offices. Please contact William Muszynski at 609-883-9500, extension 221, with any docket-related questions.

Individuals in need of an accommodation as provided for in the Americans with Disabilities Act who wish to attend the informational meeting, conference session or hearings should contact the Commission secretary directly at 609-883-9500 ext. 203 or through the Telecommunications Relay Services (TRS) at 711, to discuss how the Commission can accommodate your needs.

November 19, 2007.

Pamela M. Bush,

Commission Secretary.

[FR Doc. E7-23013 Filed 11-26-07; 8:45 am]

BILLING CODE 6360-01-P

DEPARTMENT OF EDUCATION

Submission for OMB Review; Comment Request

AGENCY: Department of Education.

SUMMARY: The IC Clearance Official, Regulatory Information Management Services, Office of Management invites comments on the submission for OMB review as required by the Paperwork Reduction Act of 1995.

DATES: Interested persons are invited to submit comments on or before December 27, 2007.

ADDRESSES: Written comments should be addressed to the Office of Information and Regulatory Affairs, Attention: Education Desk Officer, Office of Management and Budget, 725 17th Street, NW., Room 10222, Washington, DC 20503. Commenters are

encouraged to submit responses electronically by email to oir_submission@omb.eop.gov or via fax to (202) 395-6974. Commenters should include the following subject line in their response "Comment: [insert OMB number], [insert abbreviated collection name, e.g., "Upward Bound Evaluation"]". Persons submitting comments electronically should not submit paper copies.

SUPPLEMENTARY INFORMATION: Section 3506 of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) requires that the Office of Management and Budget (OMB) provide interested Federal agencies and the public an early opportunity to comment on information collection requests. OMB may amend or waive the requirement for public consultation to the extent that public participation in the approval process would defeat the purpose of the information collection, violate State or Federal law, or substantially interfere with any agency's ability to perform its statutory obligations. The IC Clearance Official, Regulatory Information Management Services, Office of Management, publishes that notice containing proposed information collection requests prior to submission of these requests to OMB. Each proposed information collection, grouped by office, contains the following: (1) Type of review requested, e.g. new, revision, extension, existing or reinstatement; (2) Title; (3) Summary of the collection; (4) Description of the need for, and proposed use of, the information; (5) Respondents and frequency of collection; and (6) Reporting and/or Recordkeeping burden. OMB invites public comment.

Dated: November 20, 2007.

Angela C. Arrington,

IC Clearance Official, Regulatory Information Management Services, Office of Management.

Office of Postsecondary Education

Type of Review: Revision.

Title: Targeted Teacher Shortage Areas.

Frequency: Annually.

Affected Public: State, Local, or Tribal Gov't, SEAs or LEAs.

Reporting and Recordkeeping Hour Burden:

Responses: 57.

Burden Hours: 4,560.

Abstract: This request is for approval of record-keeping and reporting requirements that are contained in the FFELP regulations which address the targeted teacher deferment provision of the Higher Education Act of 1965, as amended. The information collected is necessary for a state to support its

annual request for designation of teacher shortage areas within the state. The collection of certification documentation by the borrower/scholar is necessary to support his/her request for a deferment/reduction in teaching obligation or cancellation of their loan debt.

Requests for copies of the information collection submission for OMB review may be accessed from <http://edicsweb.ed.gov>, by selecting the "Browse Pending Collections" link and by clicking on link number 3460. When you access the information collection, click on "Download Attachments" to view. Written requests for information should be addressed to U.S. Department of Education, 400 Maryland Avenue, SW., Potomac Center, 9th Floor, Washington, DC 20202-4700. Requests may also be electronically mailed to ICDocketMgr@ed.gov or faxed to 202-245-6623. Please specify the complete title of the information collection when making your request.

Comments regarding burden and/or the collection activity requirements should be electronically mailed to ICDocketMgr@ed.gov. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1-800-877-8339.

[FR Doc. E7-23061 Filed 11-26-07; 8:45 am]
BILLING CODE 4000-01-P

DEPARTMENT OF EDUCATION

Office of Special Education and Rehabilitative Services; Overview Information; Personnel Development to Improve Services and Results for Children With Disabilities; Notice Inviting Applications for New Awards for Fiscal Year (FY) 2008

Catalog of Federal Domestic Assistance (CFDA) Numbers: 84.325D, 84.325K, 84.325R, and 84.325T.

Note: This notice invites applications for four separate competitions. For key dates, contact person information, and funding information regarding each of the four competitions, see the chart in the *Award Information* section of this notice.

Dates: Applications Available: See chart.

Deadline for Transmittal of Applications: See chart.

Deadline for Intergovernmental Review: See chart.

Full Text of Announcement

I. Funding Opportunity Description

Purpose of Program: The purposes of this program are to (1) help address

State-identified needs for highly qualified personnel—in special education, related services, early intervention, and regular education—to work with infants, toddlers and children with disabilities; and (2) ensure that those personnel have the necessary skills and knowledge, derived from practices that have been determined through scientifically based research and experience, to be successful in serving those children.

Priorities: In accordance with 34 CFR 75.105(b)(2)(iv), these priorities are from allowable activities specified in the statute (see sections 662 and 681 of the Individuals with Disabilities Education Act (IDEA)). Each of the absolute priorities announced in this notice corresponds to a separate competition as follows:

Absolute priority	Competition CFDA No.
Preparation of Leadership Personnel	84.325D
Combined Personnel Preparation	84.325K
National Outreach and Technical Assistance Center on Discretionary Awards for Minority Institutions	84.325R
Special Education Preservice Training Improvement Grants	84.325T

Absolute Priorities: For FY 2008 and any subsequent year in which we make awards based on the list of unfunded applications from these competitions, these priorities are absolute priorities. Under 34 CFR 75.105(c)(3), for each competition, we consider only applications that meet the absolute priority for that competition.

The priorities are:

Absolute Priority 1—Preparation of Leadership Personnel (84.325D)

Background

Training of special educators and related services personnel at the highest levels, including both the doctoral and post-doctoral levels, is critical to ensure the continued development and availability of quality services for children with disabilities. Over the last several decades, research has consistently suggested that there is a persistent need for additional special education and related services personnel who have been trained at the doctoral and post-doctoral levels. Such personnel play a critical role in ensuring the availability of, and improving the quality of, services for children with disabilities and their families.

Accordingly, the Department seeks to support programs that provide doctoral,

post-doctoral, and advanced graduate level training that is designed to prepare professionals to work in special education as researchers, teacher educators, administrators, and direct service providers.

Priority

The Preparation of Leadership Personnel priority supports and is limited to projects that train personnel at the preservice doctoral or post-doctoral level in early intervention, special education or related services, and at the advanced graduate level (masters and specialists) in special education administration/supervision. In order to be eligible under this priority, programs must provide training and support for scholars to complete their training within the project period of the grant. Therefore, only the following types of programs of study will meet the requirements of this priority:

1. A major in special education, related services or early intervention at the doctoral or post-doctoral level; and
2. Training at the advanced graduate level (masters and specialists programs) in special education administration/supervision.

Note: Training that leads to a Doctor of Audiology (DAud) degree is not included as part of this priority because training programs that lead to a DAud degree are eligible to apply for funding under the Combined Personnel Preparation priority (CFDA 84.325K) announced elsewhere in this notice.

To be considered for funding under the Preparation of Leadership Personnel absolute priority, applicants must meet the application requirements contained in the priority. All projects funded under the absolute priority also must meet the programmatic and administrative requirements specified in the priority. The application, programmatic, and administrative requirements are as follows:

(a) Demonstrate, in the narrative section of the application under "Quality of Project Services," how—

(1) The program prepares personnel to address the specialized needs of children with disabilities from diverse cultural and language backgrounds, including limited English proficient children with disabilities, by—

(i) Identifying the competencies needed by leadership personnel to understand and work with culturally and linguistically diverse populations (the competencies identified should reflect the current knowledge base); and

(ii) Preparing personnel to use those competencies through early

intervention, special education, and related services training programs;

(2) All relevant coursework for the proposed program reflects current research and pedagogy on—

(i) Participation and achievement in the general education curriculum and improved outcomes for all children with disabilities; and

(ii) The provision of coordinated services in natural environments to improve outcomes for infants and toddlers with disabilities and their families;

(3) The program is designed to offer integrated training and practice opportunities that will enhance the competencies of all personnel who share responsibility for providing effective services for children with disabilities;

(4) For programs that train personnel in early intervention, special education or related services, the program ensures that scholars are knowledgeable about:

(i) The provisions of the No Child Left Behind Act of 2001 (NCLB); (ii) the IDEA and NCLB requirement that teachers be highly qualified; and (iii) the need to foster collaboration between regular and special education teachers; and

(5) The proposed training program includes training on State academic achievement standards for children, if applicable.

(b) Submit electronically annual data on each scholar who receives grant support within 60 days after the end of each grant budget year. Applicants are encouraged to visit the Personnel Prep Data (PPD) Web site at www.osepppd.org for further information about this data collection requirement. This data collection is in addition to and does not supplant the annual grant performance report required of each grantee for continuation funding (see 34 CFR 75.590).

(c) Budget for attendance at a three-day Project Director's meeting in Washington, DC, during each year of the project.

(d) If the project maintains a Web site, include relevant information and documents in a format that meets a government or industry-recognized standard for accessibility.

(e) Include, in the application appendix, all course syllabi for the proposed training program. Course syllabi must clearly reflect the incorporation of research-based curriculum and pedagogy as required under paragraph (a) of this priority.

(f) Provide, in the application narrative, a detailed description of the program, including the sequence of the

courses offered in the program, that describes the comprehensive curriculum designed to meet program goals and obtain mastery of the following required professional domains:

(1) Research methodology.

(2) Personnel preparation.

(3) Policy/advocacy or professional practice.

(g) Include, in the application narrative under "Quality of Project Evaluation," a clear and effective plan for evaluating the extent to which graduates of the training program have the knowledge and competencies necessary to provide research-based instruction and services that result in improved outcomes for children with disabilities.

(h) Communicate the results of the evaluation conducted in accordance with paragraph (g) of this priority to the Office of Special Education Programs (OSEP) in required annual performance reports for continuation funding and the project final performance report.

(i) Certify that all scholars will be recruited into the program with the intention of graduating from the program during the performance period of the grant.

(j) Certify that the institution will not require scholars recruited into the program to work as a condition of receiving a scholarship, e.g., as graduate assistants, unless the work is required to complete their training program.

(k) If the program is addressing national or regional needs, demonstrate in the application narrative the existence of the needs through appropriate research data.

(l) Ensure that at least 65 percent of the total requested budget per year be used for student support or provide justification in the application narrative for any designation less than 65 percent. Examples of sufficient justification for proposing less than 65 percent of the budget for student support might include:

(1) A project servicing rural areas that provides long distance training, and that may require Web Masters, adjunct professors, or mentors to operate effectively.

(2) A project that is expanding or adding a new area of emphasis to the program, and as a result of this expansion, may need additional faculty or other resources such as expert consultants, additional training supplies, or equipment that would enhance the program.

Note: Applicants proposing projects to develop, expand, or add a new area of emphasis to special education or related services programs must provide, in their

applications, information on how these new areas will be sustained once Federal funding ends.

(m) Meet the statutory requirements contained in section 662(e) through 662(h) of IDEA.

Absolute Priority 2—Combined Personnel Preparation (84.325K)

Background

State agencies, university training programs, local schools, and community-based entities have indicated the importance and difficulty of improving training programs for personnel to serve infants, toddlers, and children with disabilities.

The national demand for fully credentialed early intervention, special education, and related services personnel to serve infants, toddlers, and children with disabilities exceeds available supply. Thus, Federal support is required to improve both the quality and supply of these personnel.

Priority

The purpose of the Combined Personnel Preparation priority is to improve the quality, and increase the number, of personnel who are fully credentialed to serve infants, toddlers, and children with disabilities—especially in areas of chronic personnel shortage—by supporting projects that prepare early intervention, special education, and related services personnel at the associate, baccalaureate, master's, and specialist levels. In order to be eligible under this priority, programs must provide training and support for students to complete, within the project period of the grant, a degree, State certification, professional license, or State endorsement in early intervention, special education or related services. Programs preparing students to be special education paraprofessionals, related services assistants or educational interpreters are also eligible under this priority.

To be considered for funding under the Combined Personnel Preparation absolute priority, applicants must meet the application requirements contained in the priority. All projects funded under the absolute priority also must meet the programmatic and administrative requirements specified in the priority. The application, programmatic, and administrative requirements are as follows:

(a) Demonstrate, in the narrative section of the application under "Quality of Project Services", how—

(1) Training requirements and required coursework for the proposed training program incorporate research-

based practices that improve outcomes for children with disabilities (including relevant research citations);

(2) The program is designed to offer integrated training and practice opportunities that will enhance the competencies of all personnel who share responsibility for providing effective services for children with disabilities;

(3) The program prepares personnel to address the specialized needs of children with disabilities from diverse cultural and language backgrounds, including limited English proficient children with disabilities, by—

(i) Identifying the competencies needed by personnel to understand and work with culturally and linguistically diverse populations (the competencies identified should reflect the current knowledge base); and

(ii) Preparing personnel to use those competencies through early intervention, special education, and related services training programs;

(4) If preparing beginning special educators, the program is designed to provide extended clinical learning opportunities, field experiences, or supervised practica (such as an additional year) and ongoing high quality mentoring and induction opportunities;

(5) The program includes field-based training opportunities for scholars (as defined in 34 CFR 304.3(g)) in diverse settings including schools and settings in high-poverty communities, rural areas, and urban areas;

(6) The proposed training program will enable scholars to be highly qualified, in accordance with section 602(10) of IDEA, in the State(s) to be served by the applicant;

(7) The training program equips scholars with the knowledge and skills necessary to assist children effectively in achieving State academic achievement standards; and

(8) The training program provides student support systems (including tutors, mentors, and other innovative practices) to enhance student retention and success in the program.

(b) Include, in the narrative section of the application under "Quality of Project Evaluation," a clear, effective plan for evaluating the extent to which graduates of the training program have the knowledge and skills necessary to provide scientifically based or evidence-based instruction and services that result in improved outcomes for children with disabilities. Applicants also must clearly describe, under "Quality of Project Evaluation," how the project will report these evaluation results to the Office of Special

Education Programs (OSEP) in the grantee's annual performance reports and final performance report.

(c) Meet the statutory requirements contained in section 662(e) through 662(h) of IDEA.

(d) Ensure that at least 65 percent of the total requested budget per year be used for student support.

(e) Budget for attendance at a three-day Project Director's meeting in Washington, DC, during each year of the project.

(f) If the project maintains a Web site, include relevant information and documents in a form that meets a government or industry-recognized standard for accessibility.

(g) Include, in the application appendix, all course syllabi for the proposed training program. Course syllabi must clearly reflect the incorporation of research-based curriculum and pedagogy as required under paragraph (a) of this priority.

(h) Submit electronically annual data on each scholar who receives grant support within 60 days after the end of each grant budget year. Applicants are encouraged to visit the Personnel Prep Data (PPD) Web site at www.osepppd.org for further information about this data collection requirement. This data collection is in addition to and does not supplant the annual grant performance report required of each grantee for continuation funding (see 34 CFR 75.590).

Focus Areas

Within this absolute priority, the Secretary intends to support projects under the following four focus areas: (a) Training Personnel to Serve Infants, Toddlers, and Pre-school Age Children with Disabilities, (b) Training Personnel to Serve School Age Children with Low Incidence Disabilities, (c) Training Personnel to Provide Related Services, Speech/Language Services, and Adapted Physical Education to Infants, Toddlers, and Children with Disabilities, and (d) Training Personnel in Minority Institutions to Serve Infants, Toddlers, and Children with Disabilities.

Note: Applicants must identify the specific focus area (i.e., (a), (b), (c), or (d)), under which they are applying as part of the competition title on the application cover sheet (SF form 424, line 4). Applicants may not submit the same proposal under more than one focus area.

Focus Area a: Training Personnel To Serve Infants, Toddlers, and Pre-School Age Children With Disabilities. For the purpose of this focus area, early intervention personnel are those who are trained to provide services to infants

and toddlers with disabilities ages birth through two, and early childhood personnel are those who are trained to provide services to children with disabilities ages three through five (in States where the age range is other than ages three through five, we will defer to the State's certification for early childhood). In States where certification in early intervention (EI) is combined with certification in early childhood (EC), applicants may propose a combined EI/EC training project under this focus area. Projects training related services, speech/language, or adapted physical education personnel are *not* eligible under this focus area (see Focus Area c).

Focus Area b: Training Personnel To Serve School Age Children with Low Incidence Disabilities. For the purpose of this focus area, low incidence personnel are special education personnel, including paraprofessionals, trained to serve school-age children with low incidence disabilities including visual impairments, hearing impairments, simultaneous vision and hearing impairments, significant cognitive impairments (severe mental retardation), orthopedic impairments, autism, and traumatic brain injury. Programs preparing special education personnel to provide services to visually impaired or blind children that can be appropriately provided in Braille must prepare those individuals to provide those services in Braille. Projects training educational interpreters are eligible under this focus area. Projects training other related services, speech/language or adapted physical education personnel are *not* eligible under this focus area (see Focus Area c). Projects training special education pre-school personnel are eligible under Focus Area a.

Focus Area c: Training Personnel to Provide Related Services, Speech/Language Services, and Adapted Physical Education to Infants, Toddlers, and Children with Disabilities. Programs training related services, speech/language or adapted physical education personnel to serve infants, toddlers, or children with disabilities are eligible within this focus area. For the purpose of this focus area, related services include, but are not limited to, psychological services, physical therapy (including therapy provided by personnel trained at the Doctor of Physical Therapy (DPT) level), occupational therapy, therapeutic recreation, social work services, counseling services, audiology services (including services provided by personnel trained at the Doctor of Audiology (DAud) level), and speech/

language services. Training programs in States where personnel trained to serve children with speech/language impairments are considered to be special educators are eligible under this focus area. Projects training educational interpreters are not eligible under this focus area, but may apply under Focus Area b.

Focus Area d: Training Personnel in Minority Institutions to Serve Infants, Toddlers, and Children with Disabilities. Programs in minority institutions are eligible under this focus area if they train: (a) Personnel to serve one or more of the following: Infants, toddlers, and pre-school age children with disabilities; (b) personnel to serve school age children with low incidence disabilities; or (c) personnel to provide related services, speech/language or adapted physical education to infants, toddlers, and children with disabilities. Minority institutions include institutions with a minority student enrollment of 25 percent or more, which may include Historically Black Colleges and Universities, Tribal Colleges, and Predominantly Hispanic Serving Colleges and Universities.

Within this focus area, institutions that are recommended for funding in FY 2008 and that have not received support under the IDEA Personnel Development Program in FY 2007 will receive 10 competitive preference points. (Programs in minority institutions training personnel in Focus Areas a, b and c are eligible within Focus Area d. Programs that are training high incidence special education personnel are *not* eligible within Focus Area d. However, programs that are training high incidence special education personnel are eligible under Absolute Priority 4 located elsewhere in this notice.)

Under Focus Area d, a project may budget for less than the required percentage (65 percent) for student support if the applicant can provide sufficient justification for any designation less than 65 percent. Sufficient justification for proposing less than 65 percent of the budget for student support would include support for activities such as program development, program expansion, or the addition of a new area of emphasis. Some examples include the following:

(1) A project that is starting a new program may request up to a year for program development and capacity building. In the initial project year, no student support would be required. Instead, a project could hire a new faculty member or a consultant to assist in program development.

(2) A project that is proposing to build capacity may hire a field supervisor so that additional students can be trained.

(3) A project that is expanding or adding a new area of emphasis to the program may hire additional faculty or obtain other resources such as expert consultants, additional training supplies, or equipment that would enhance the program.

Note: Applicants proposing projects to develop, expand, or to add a new area of emphasis to special education or related services programs must provide information, in their applications, on how these new areas will be sustained once Federal funding ends.

Within this absolute priority, we are particularly interested in applications that address the following invitational priorities.

Invitational Priorities: Under 34 CFR 75.105(c)(1) we do not give an application that meets these invitational priorities a competitive or absolute preference over other applications.

These priorities are:

(1) In Focus Areas b and d, the Secretary is particularly interested in programs that prepare special educators who provide instruction in core academic areas to children with disabilities.

(2) The Secretary is also particularly interested in programs that provide enhanced support for beginning special educators (see section 662(b)(3) of IDEA).

Absolute Priority 3—National Outreach and Technical Assistance Center on Discretionary Awards for Minority Institutions (84.325R)

Background

Section 681(c)(2) of IDEA requires the Secretary to set aside funds to support one or both of the following activities:

(1) The provision of outreach and technical assistance to Historically Black Colleges and Universities (HBCUs) and to institutions of higher education (IHEs) with minority enrollments of not less than 25 percent to promote their participation in certain activities under IDEA; or (2) the provision of support to enable the institutions to assist other institutions and agencies in improving educational and transitional results for children with disabilities. Consistent with this requirement, this priority is aimed at promoting the participation of HBCUs and IHEs with minority enrollments of not less than 25 percent in discretionary grant competitions conducted by the Department, pursuant to section 662 of IDEA (the Personnel Development to Improve Services and Results for Children with Disabilities program); and

building the capacity of such institutions to prepare personnel to work effectively with children with disabilities from diverse backgrounds.

The current technical assistance center funded by the Office of Special Education Programs (OSEP) under section 681(c)(2) of IDEA provides technical assistance to IHEs in grant writing and disseminates specific information to aid HBCUs and other minority IHEs in developing applications for grants, cooperative agreements, and contracts. This priority shifts the focus of the center that will be funded by OSEP under section 681(c)(2) of IDEA from that of grant-writing technical assistance to assistance that will help HBCUs and minority IHEs build their capacity to prepare personnel to work effectively with children with disabilities from linguistically and culturally diverse backgrounds.

Priority

The purpose of the National Outreach and Technical Assistance Center on Discretionary Awards for Minority Institutions (Center) is to increase: (a) The participation of HBCUs and other institutions with a minority student enrollment of at least 25 percent in the Personnel Development to Improve Services and Results for Children with Disabilities program competitions authorized under section 662 of IDEA; and (b) the capacity of these institutions to prepare personnel to work with children with disabilities from diverse backgrounds.

To be considered for funding under the National Outreach and Technical Assistance Center on Discretionary Awards for Minority Institutions absolute priority, each applicant must demonstrate, in its application, that it will—

(a) Maintain contacts with HBCUs and other minority institutions;

(b) Prepare and disseminate grant-writing technical assistance materials that will enable HBCUs and other minority IHEs to become competitive applicants in competitions authorized under section 662 of IDEA;

(c) Prepare and disseminate Web-based program development materials, such as: Modules on a variety of research-based pedagogy and practices that are effective in preparing personnel to provide quality service to children with disabilities; a State-by-State directory of resources organized by such topics as State, disability type, personnel supply and demand, etc.; other materials that include information on identifying competencies that personnel need to work effectively with

linguistically and culturally diverse populations and how to increase those competencies through personnel preparation programs;

(d) Analyze the results of each applicable discretionary grant competition conducted by the Department under IDEA to determine which HBCUs and minority IHEs applied and whether they were successful, and submit this analysis to the Department;

(e) Provide support and guidance to faculty at HBCUs and other minority IHEs to enhance the capacity of these institutions to design and implement professional education programs that graduate highly qualified special educators;

(f) Ensure that all program development and professional education program enhancements that the Center recommends to HBCUs and minority IHEs include research-based practices, and appropriate competencies that personnel need to work effectively with linguistically and culturally diverse populations to improve outcomes for infants, toddlers, and children with disabilities;

(g) Develop a plan in the first three months of the project period that outlines a comprehensive technical assistance approach based on effective strategies;

(h) Establish, maintain, and meet (at least once a year) with an Advisory Board that includes individuals with disabilities, members from underrepresented groups, technical assistance providers, and university personnel;

(i) Use a third party evaluator, approved by OSEP, that will conduct a rigorous evaluation of core Center activities, and determine the overall impact of its work;

(j) Budget for attendance at a three-day Project Directors' meeting in Washington, DC, the Technical Assistance and Dissemination Project Directors' meeting, and at least 2 one-day planning meetings with the OSEP Project Officer and other appropriate staff in Washington, DC;

(k) If the project maintains a Web site, include relevant information and documents in a form that meets a government or industry-recognized standard for accessibility; and

(l) Include a line item in the proposed budget for an annual set-aside of five percent of the grant amount to support emerging needs that are consistent with the proposed project's activities, as those needs are identified in consultation with OSEP.

Note: With approval from the OSEP Project Officer, the Center will reallocate any

remaining funds from this annual set-aside no later than the end of the third quarter of each budget period.

Fourth and Fifth Years of Project: Finally, in deciding whether to continue funding the Center for the fourth and fifth years, the Secretary will consider the requirements of 34 CFR 75.253(a), in addition to the following items:

(a) The recommendation of a review team consisting of experts selected by the Secretary. This review will be conducted in Washington, DC during the last half of the project's second year. Projects must budget for travel expenses associated with this one-day intensive review.

(b) The timeliness and effectiveness with which all requirements of the negotiated cooperative agreement have been or are being met by the Center.

(c) Evidence of changes in capacity at HBCUs and other participating institutions.

(d) Evidence of increased participation of HBCUs and IHEs with minority enrollments of not less than 25 percent in competitions conducted under section 662 of IDEA.

Absolute Priority 4—Special Education Preservice Training Improvement Grants (84.325T)

Background

State educational agencies, IHEs, and local educational agencies consistently report that it is necessary to restructure or redesign most preparation programs for kindergarten through grade 12 (K–12) special education teachers to ensure that graduates of these programs are able to meet the highly qualified teacher (HQT) requirements in the No Child Left Behind Act of 2001 (NCLB) and the Individuals with Disabilities Education Act, as amended by the Individuals with Disabilities Education Improvement Act of 2004 (IDEA). To accomplish this goal, preparation programs must ensure that their graduates who expect to be providing instruction in core academic subjects are not only able to meet State certification or licensure requirements, but that they also have the necessary content knowledge, consistent with the HQT requirements in NCLB and IDEA.

Children with disabilities are now expected to meet high standards for learning in core academic subjects, regardless of classroom setting. Because this is the case, K–12 special education teacher preparation programs must address content knowledge, standards, assessments, and evidence-based practices. Federal support can assist in improving the quality of IHE programs that prepare special education teachers, and help to ensure that these teachers

have the knowledge and skills needed to teach students with disabilities using evidence-based interventions.

Priority

The purpose of this priority is to improve the quality of K–12 special education teacher preparation programs to ensure that program graduates are able to meet the HQT requirements under sections 602(10) and 612(a)(14) of IDEA, and are well prepared to serve children with high incidence disabilities. For purposes of this priority, the term “high incidence disabilities” refers to learning disabilities, emotional disturbance, or mental retardation. In order to be eligible under this priority, applicants must currently prepare personnel (at the baccalaureate or master's level) to serve school-age children with high incidence disabilities.

Note: This priority only supports the improvement or expansion of existing programs for high incidence personnel, such as the expansion of an elementary program to include a secondary program in high incidence. This priority does not support the development of new programs for high incidence personnel.

To be considered for funding under the Special Education Preservice Training Improvement Grants priority, applicants must meet the application requirements contained in the priority. All projects funded under the absolute priority also must meet the programmatic and administrative requirements specified in the priority. The application, programmatic, and administrative requirements are as follows:

(a) Demonstrate, in the narrative section of the application under “Quality of Project Services,” how—

(1) The first year of the project period will be used for planning an improved or restructured K–12 teacher preparation program that includes induction and mentoring components; revising curriculum for, and integrating evidence-based interventions that improve outcomes for children with high incidence disabilities into, the improved or restructured program (including providing research citations for those evidence-based interventions); and coordinating with the National Center to Enhance the Professional Development of School Personnel on the use of its web-based training modules (see <http://www.iris.peabody.vanderbilt.edu>). Applicants must describe first year activities and include a five-year timeline and implementation plan in their applications. This plan must describe the proposed project activities

associated with implementation of the improved or restructured program that includes the induction and mentoring components, and may not be implemented without the approval of OSEP, if the proposed project is funded under this competition;

(2) The improved or restructured program is designed to offer integrated training and practice opportunities that will enhance the competencies of beginning special education teachers who share responsibility with general education teachers and other personnel for providing effective services and instruction in academic subjects to children with high incidence disabilities in K–12 classrooms;

(3) The improved or restructured program is designed to prepare special education teachers to address the specialized needs of children with high incidence disabilities from diverse cultural and language backgrounds, including limited English proficient children with disabilities, by identifying the competencies that special education teachers need to work effectively with culturally and linguistically diverse populations;

(4) The improved or restructured program is designed to provide extended clinical learning opportunities, field experiences, or supervised practica and ongoing high quality mentoring and induction opportunities in local schools. Applicants also must demonstrate how they will coordinate with the National Center on Policy and Practice in Special Education in designing the program to provide extended clinical learning opportunities, field experiences, or supervised practica;

(5) The improved or restructured program is designed to include field-based training opportunities in diverse settings including schools and settings in high-poverty communities and in schools not making adequate yearly progress (AYP) under NCLB;

(6) Upon completion of the improved or restructured program, graduates will be able to meet the HQT requirements in accordance with section 602(10) of IDEA and 34 CFR 300.18; and will be equipped with the knowledge and skills necessary to assist children in achieving State academic achievement standards;

(7) The improved or restructured program is designed to provide support systems (including tutors, mentors, and other innovative practices) to enhance retention and success in the program; and

(8) The improved or restructured program will be maintained once Federal funding ends.

(b) For programs that will be restructured or re-designed to produce graduates who will meet the standards of HQT upon program completion, particularly as those standards relate to certification in core academic subjects, applicants will establish partnerships with appropriate academic departments in schools of arts and sciences. To address this requirement, applications must also—

(i) Demonstrate how such partnerships will include representation by academic departments that have expertise in the core academic subjects being addressed in the application;

(ii) Demonstrate how such partnerships will include a permanent faculty member, from one or more of the corresponding academic departments, who will be involved in developing the overall project and designing the curriculum used to train scholars in core academic subjects;

(iii) Provide evidence of the extent of participation by permanent faculty members from the corresponding academic departments; and

(iv) Provide funding to the core academic subject departments appropriate to the significant involvement outlined in paragraph (4) of this priority;

(c) Include, in the narrative section of the application under “Quality of Project Evaluation,” a clear, effective plan for evaluating the extent to which graduates of the training program have the knowledge and skills necessary to provide scientifically based or evidence-based instruction and services that result in improved outcomes for children with disabilities. Applicants also must clearly describe, under “Quality of Project Evaluation,” how the project will report these evaluation results to the OSEP in the grantee’s annual performance reports and final performance report.

(d) Meet the statutory requirements in section 662(e) through 662(f) of IDEA.

(e) Budget for planning and improvement activities, including activities to be performed by consultants. This priority does not provide for financial support of scholars during any year of the project.

(f) Budget for attendance at a three-day Project Director’s meeting in Washington, DC, during each year of the project.

(g) If the project maintains a Web site, include relevant information and documents in a form that meets a government or industry-recognized standard for accessibility.

(h) Include, in the application appendix, all course syllabi for the existing teacher preparation program.

Revised syllabi for the improved or restructured program must be submitted at the end of the first year of the project period.

Within this absolute priority, we give competitive preference to applications that address the following priority.

Competitive Preference Priority:
Under 34 CFR 75.105(c)(2)(i) we award up to an additional 10 points to an application, depending on how well the application meets this priority.

This priority is:

Competitive Preference Points Based on Number of High Incidence Special Education Teacher Graduates From Program in a Recent Year

In order to earn competitive preference points under this priority, applicants must document the number of K–12 special education teachers who have graduated from a preparation program that prepares personnel (at the baccalaureate or master’s level) to serve school-age children with high incidence disabilities in any recent year, regardless of whether the graduates received support from a Federal grant. For purposes of this competitive preference priority, the term “recent year” is defined as any of the past three fiscal years (i.e., FY 2004, FY 2005, or FY 2006). For example, an applicant that documents 10 graduates (new K–12 high incidence special education teachers) during a recent year earns 2 competitive preference points. An applicant that documents 30 graduates (new K–12 high incidence special education teachers) during a recent year earns 6 competitive preference points. An applicant that documents 50 or more graduates (new K–12 high incidence special education teachers) during a recent year earns 10 competitive preference points.

Number of students graduating (new K–12 high incidence special education teachers) from program in a recent year (including non- OSEP funded graduates)	Number of competitive preference points awarded
8–19	2
20–29	4
30–39	6
40–49	8
50+	10

The number of students (i.e., new K–12 high incidence special education teachers) graduating from the program must be documented in the application. A letter from the Dean or Department Chair reporting the number of high incidence graduates in a recent fiscal year is adequate documentation for purposes of this competitive preference.

Waiver of Proposed Rulemaking: Under the Administrative Procedure Act (APA) (5 U.S.C. 553) the Department generally offers interested parties the opportunity to comment on proposed priorities and requirements. Section 681(d) of IDEA, however, makes the public comment requirements of the APA inapplicable to the priorities in this notice.

Program Authority: 20 U.S.C. 1462 and 1481.

Applicable Regulations: (a) The Education Department General Administrative Regulations (EDGAR) in 34 CFR parts 74, 75, 77, 79, 80, 81, 82, 84, 85, 86, 97, 98, and 99. (b) The regulations for this program in 34 CFR part 304.

II. Award Information

Type of Awards: Discretionary grants for competitions CFDA 84.325D, 84.325K, and 84.325R, and one cooperative agreement for competition CFDA 84.325T.

Estimated Available Funds: The Administration has requested \$89,719,000 for the Personnel Development to Improve Services and Results for Children with Disabilities program for FY 2008, of which we intend to use an estimated \$2,950,000 for the competitions announced in this notice. Please refer to the "Estimated Range of Awards" column of the chart in this section for the estimated dollar amounts for individual competitions. The actual level of funding, if any,

depends on final congressional action. However, we are inviting applications to allow enough time to complete the grant process if Congress appropriates funds for this program.

Contingent upon the availability of funds and the quality of applications for the competitions announced in this notice, we may make additional awards in FY 2009 from the lists of unfunded applicants from individual competitions.

Estimated Range of Awards: See chart.

Estimated Average Size of Awards: See chart.

Maximum Award: See chart.

Estimated Number of Awards: See chart.

Project Period: See chart.

PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES APPLICATION NOTICE FOR FISCAL YEAR 2008

CFDA number and name	Applications available	Deadline for transmittal of applications	Deadline for intergovernmental review	Estimated range of awards	Estimated average size of awards	Maximum award	Estimated number of awards	Project period	Contact person
84.325D Preparation of Leadership Personnel.	11/27/07	01/04/08	03/04/08	\$171,969–\$200,000.	\$196,200	\$200,000*	25	Up to 60 mos.	Bob Gilmore (202) 245–7354 Rm 4083.
84.325K Combined Personnel Preparation.	11/27/07	01/11/08	03/11/08	\$150,000–\$200,000.	\$175,000	\$200,000*	14	Up to 48 mos.	Maryann McDermott (202) 245–7439 Rm 4062.
Focus Area a: Training Personnel to Serve Infants, Toddlers, and Pre-school Age Children with Disabilities.	11/27/07	01/11/08	03/11/08	\$150,000–\$200,000.	\$175,000	\$200,000*	23	Up to 48 mos.	
Focus Area b: Training Personnel to Serve School Age Children with Low Incidence Disabilities.	11/27/07	01/11/08	03/11/08	\$150,000–\$200,000.	\$175,000	\$200,000*	14	Up to 48 mos.	
Focus Area c: Training Personnel to Provide Related Services, Speech/Language Services, and Adapted Physical Education to Infants, Toddlers, and Children with Disabilities.	11/27/07	01/11/08	03/11/08	\$150,000–\$200,000.	\$175,000	\$200,000*	14	Up to 48 mos.	
Focus Area d: Training Personnel in Minority Institutions to Serve Infants, Toddlers, and Children with Disabilities.	11/27/07	01/11/08	03/11/08	\$150,000–\$200,000.	\$175,000	\$200,000*	14	Up to 48 mos.	Ernest Hairston (202) 245–7366 Rm 4070.
84.325R National Outreach and Technical Assistance Center on Disability Awards for Minority Institutions.	11/27/07	01/11/08	03/11/08	\$100,000–\$150,000 (first year of project).	\$125,000 (first year of project).	\$150,000** (first year of project).	21	Up to 60 mos.	Bonnie Jones (202) 245–7395 Rm 4153.

* We will reject any application that proposes a budget exceeding the maximum award for a single budget period of 12 months. The Assistant Secretary for Special Education and Rehabilitation Services may change the maximum amount through a notice published in the *Federal Register*.

** For the *Special Education Preservice Training Improvement Grants*, 84.325T competition.

NOTE: We will reject any application that proposes a budget exceeding \$150,000 for a single budget period of 12 months for the first year of the project; we will reject any application that proposes a budget exceeding \$100,000 for a single budget period of 12 months over the last four years of the project; and we will reject any application that exceeds \$500,000 for the five years of the budget period.

NOTE: No more than one cooperative agreement will be awarded per IHE. Programs in minority institutions that are preparing special education teachers of children with high incidence disabilities are eligible to apply under this competition. For purposes of this competition, the term "minority institutions" include IHEs with a minority student enrollment of 25 percent or more, which may include Historically Black Colleges and Universities, Tribal Colleges, and Predominantly Hispanic Serving Colleges and Universities.

NOTE: The Department is not bound by any estimates in this notice.

III. Eligibility Information

1. *Eligible Applicants:* Institutions of higher education (IHEs).

Note: For Absolute Priority 4 (*Special Education Preservice Training Improvement Grants*, 84.325T), programs in IHEs that are preparing preschool teachers are not eligible to apply under that competition.

2. *Cost Sharing or Matching:* This program does not require cost sharing or matching.

3. *Other: General Requirements—(a)* The projects funded under this program must make positive efforts to employ and advance in employment qualified individuals with disabilities (see section 606 of IDEA).

(b) Each applicant and grant recipient funded under this program must involve individuals with disabilities or parents of individuals with disabilities ages birth through 26 in planning, implementing, and evaluating the project (see section 682(a)(1)(A) of IDEA).

IV. Application and Submission Information

1. *Address to Request Application Package:* Education Publications Center (ED Pubs), P.O. Box 1398, Jessup, MD 20794-1398. Telephone, toll free: 1-877-433-7827. FAX: (301) 470-1244. If you use a telecommunications device for the deaf (TDD), call, toll free: 1-877-576-7734.

You can contact ED Pubs at its Web site, also: <http://www.ed.gov/pubs/edpubs.html> or at its e-mail address: edpubs@inet.ed.gov.

If you request an application from ED Pubs, be sure to identify the competition to which you want to apply, as follows: CFDA number 84.325D, 84.325K, 84.325R, or 84.325T.

Individuals with disabilities may obtain a copy of the application package in an alternative format (e.g., Braille, large print, audiotape, or computer diskette) by contacting the person or team listed under *Alternative Format* in section VIII of this notice.

2. *Content and Form of Application Submission:* Requirements concerning the content of an application, together with the forms you must submit, are in the application package for each competition announced in this notice.

Page Limit: The application narrative (Part III of the application) is where you, the applicant, address the selection criteria that reviewers use to evaluate your application. You must limit Part III to the equivalent of no more than 50 pages for each absolute priority, using the following standards:

- A "page" is 8.5" x 11", on one side only, with 1" margins at the top, bottom, and both sides.

- Double space (no more than three lines per vertical inch) all text in the application narrative, including titles, headings, footnotes, quotations, references, and captions, as well as all text in charts, tables, figures, and graphs.

- Use a font that is either 12 point or larger or no smaller than 10 pitch (characters per inch).

The page limit does not apply to Part I, the cover sheet; Part II, the budget section, including the narrative budget justification; Part IV, the assurances and certifications; or the two-page abstract, the resumes, the bibliography, the references, or the letters of support. However, you must include all of the application narrative in Part III.

We will reject your application if—

- You apply these standards and exceed the page limit; or
- You apply other standards and exceed the equivalent of the page limit.

3. *Submission Dates and Times:*

Applications Available: See chart.

Deadline for Transmittal of

Applications: See chart.

Applications for grants under this program may be submitted electronically using the Grants.gov Apply site (Grants.gov), or in paper format by mail or hand delivery. For information (including dates and times) about how to submit your application electronically, or in paper format by mail or hand delivery, please refer to section IV. 6. *Other Submission Requirements* in this notice.

We do not consider an application that does not comply with the deadline requirements.

Individuals with disabilities who need an accommodation or auxiliary aid in connection with the application process should contact the person listed under **FOR FURTHER INFORMATION CONTACT** in section VII in this notice. If the Department provides an accommodation or auxiliary aid to an individual with a disability in connection with the application process, the individual's application remains subject to all other requirements and limitations in this notice.

Deadline for Intergovernmental Review: See chart.

4. *Intergovernmental Review:* This program is subject to Executive Order 12372 and the regulations in 34 CFR part 79. Information about Intergovernmental Review of Federal Programs under Executive Order 12372 is in the application package for each of the competitions announced in this notice.

5. *Funding Restrictions:* We reference regulations outlining funding

restrictions in the *Applicable Regulations* section in this notice.

6. *Other Submission Requirements:* Applications for grants under this program may be submitted electronically or in paper format by mail or hand delivery.

a. *Electronic Submission of Applications.*

To comply with the President's Management Agenda, we are participating as a partner in the Governmentwide Grants.gov Apply site. The Personnel Development to Improve Services and Results for Children with Disabilities competitions, CFDA numbers 84.325D, 84.325K, 84.325R, and 84.325T, announced in this notice are included in this project. We request your participation in Grants.gov.

If you choose to submit your application electronically, you must use the Governmentwide Grants.gov Apply site at <http://www.Grants.gov>. Through this site, you will be able to download a copy of the application package, complete it offline, and then upload and submit your application. You may not e-mail an electronic copy of a grant application to us.

You may access the electronic grant application for the Personnel Development to Improve Services and Results for Children with Disabilities program competitions—CFDA numbers 84.325D, 84.325K, 84.325R, and 84.325T at <http://www.Grants.gov>. You must search for the downloadable application package for this program by the CFDA number. Do not include the CFDA number's alpha suffix in your search (e.g., search for 84.325, not 84.325D).

Please note the following:

- Your participation in Grants.gov is voluntary.
- When you enter the Grants.gov site, you will find information about submitting an application electronically through the site, as well as the hours of operation.

- Applications received by Grants.gov are date and time stamped. Your application must be fully uploaded and submitted and must be date and time stamped by the Grants.gov system no later than 4:30 p.m., Washington, DC time, on the application deadline date. Except as otherwise noted in this section, we will not consider your application if it is date and time stamped by the Grants.gov system later than 4:30 p.m., Washington, DC time, on the application deadline date. When we retrieve your application from Grants.gov, we will notify you if we are rejecting your application because it was date and time stamped by the Grants.gov system after 4:30 p.m.,

Washington, DC time, on the application deadline date.

- The amount of time it can take to upload an application will vary depending on a variety of factors, including the size of the application and the speed of your Internet connection. Therefore, we strongly recommend that you do not wait until the application deadline date to begin the submission process through Grants.gov.

- You should review and follow the Education Submission Procedures for submitting an application through Grants.gov that are included in the application package for the competition to which you are applying to ensure that you submit your application in a timely manner to the Grants.gov system. You can also find the Education Submission Procedures pertaining to Grants.gov at <http://e-Grants.ed.gov/help/GrantsgovSubmissionProcedures.pdf>.

- To submit your application via Grants.gov, you must complete all steps in the Grants.gov registration process (see http://www.grants.gov/applicants/get_registered.jsp). These steps include (1) registering your organization, a multi-part process that includes registration with the Central Contractor Registry (CCR); (2) registering yourself as an Authorized Organization Representative (AOR); and (3) getting authorized as an AOR by your organization. Details on these steps are outlined in the Grants.gov 3-Step Registration Guide (see <http://www.grants.gov/section910/Grants.govRegistrationBrochure.pdf>). You also must provide on your application the same D-U-N-S Number used with this registration. Please note that the registration process may take five or more business days to complete, and you must have completed all registration steps to allow you to submit successfully an application via Grants.gov. In addition you will need to update your CCR registration on an annual basis. This may take three or more business days to complete.

- You will not receive additional point value because you submit your application in electronic format, nor will we penalize you if you submit your application in paper format.

- If you submit your application electronically, you must submit all documents electronically, including all information you typically provide on the following forms: Application for Federal Assistance (SF 424), the Department of Education Supplemental Information for SF 424, Budget Information—Non-Construction Programs (ED 524), and all necessary assurances and certifications. Please note that two of these forms—the SF 424

and the Department of Education Supplemental Information for SF 424—have replaced the ED 424 (Application for Federal Education Assistance).

- If you submit your application electronically, you must attach any narrative sections of your application as files in a .DOC (document), .RTF (rich text), or .PDF (Portable Document) format. If you upload a file type other than the three file types specified in this paragraph or submit a password-protected file, we will not review that material.

- Your electronic application must comply with any page-limit requirements described in this notice.

- After you electronically submit your application, you will receive from Grants.gov an automatic notification of receipt that contains a Grants.gov tracking number. (This notification indicates receipt by Grants.gov only, not receipt by the Department.) The Department then will retrieve your application from Grants.gov and send a second notification to you by e-mail. This second notification indicates that the Department has received your application and has assigned your application a PR/Award number (an ED-specified identifying number unique to your application).

- We may request that you provide us original signatures on forms at a later date.

Application Deadline Date Extension in Case of Technical Issues With the Grants.gov System: If you are experiencing problems submitting your application through Grants.gov, please contact the Grants.gov Support Desk, toll free, at 1-800-518-4726. You must obtain a Grants.gov Support Desk Case Number and must keep a record of it.

If you are prevented from electronically submitting your application on the application deadline date because of technical problems with the Grants.gov system, we will grant you an extension until 4:30 p.m., Washington, DC time, the following business day to enable you to transmit your application electronically or by hand delivery. You also may mail your application by following the mailing instructions described elsewhere in this notice.

If you submit an application after 4:30 p.m., Washington, DC time, on the application deadline date, please contact the person listed under **FOR FURTHER INFORMATION CONTACT** in section VII in this notice and provide an explanation of the technical problem you experienced with Grants.gov, along with the Grants.gov Support Desk Case Number. We will accept your application if we can confirm that a

technical problem occurred with the Grants.gov system and that that problem affected your ability to submit your application by 4:30 p.m., Washington, DC time, on the application deadline date. The Department will contact you after a determination is made on whether your application will be accepted.

Note: The extensions to which we refer in this section apply only to the unavailability of, or technical problems with, the Grants.gov system. We will not grant you an extension if you failed to fully register to submit your application to Grants.gov before the application deadline date and time or if the technical problem you experienced is unrelated to the Grants.gov system.

b. Submission of Paper Applications by Mail.

If you submit your application in paper format by mail (through the U.S. Postal Service or a commercial carrier), you must mail the original and two copies of your application, on or before the application deadline date, to the Department at the applicable following address:

By mail through the U.S. Postal Service: U.S. Department of Education, Application Control Center, Attention: (CFDA Number 84.325D, 84.325R, or 84.325T), 400 Maryland Avenue, SW., Washington, DC 20202-4260; or

By mail through a commercial carrier: U.S. Department of Education, Application Control Center—Stop 4260, Attention: (CFDA Number 84.325D, 84.325K, 84.325R, or 84.325T), 7100 Old Landover Road, Landover, MD 20785-1506.

Regardless of which address you use, you must show proof of mailing consisting of one of the following:

(1) A legibly dated U.S. Postal Service postmark.

(2) A legible mail receipt with the date of mailing stamped by the U.S. Postal Service.

(3) A dated shipping label, invoice, or receipt from a commercial carrier.

(4) Any other proof of mailing acceptable to the Secretary of the U.S. Department of Education.

If you mail your application through the U.S. Postal Service, we do not accept either of the following as proof of mailing:

(1) A private metered postmark.

(2) A mail receipt that is not dated by the U.S. Postal Service.

If your application is postmarked after the application deadline date, we will not consider your application.

Note: The U.S. Postal Service does not uniformly provide a dated postmark. Before relying on this method, you should check with your local post office.

c. Submission of Paper Applications by Hand Delivery.

If you submit your application in paper format by hand delivery, you (or a courier service) must deliver the original and two copies of your application by hand, on or before the application deadline date, to the Department at the following address: U.S. Department of Education, Application Control Center, Attention: (CFDA Number 84.325D, 84.325K, 84.325R, or 84.325T), 550 12th Street, SW., Room 7041, Potomac Center Plaza, Washington, DC 20202-4260.

The Application Control Center accepts hand deliveries daily between 8 a.m. and 4:30 p.m., Washington, DC time, except Saturdays, Sundays and Federal holidays. *Note for Mail or Hand Delivery of Paper Applications:* If you mail or hand deliver your application to the Department—

(1) You must indicate on the envelope and—if not provided by the Department—in Item 11 of the SF 424 the CFDA number, including suffix letter, if any, of the competition under which you are submitting your application; and

(2) The Application Control Center will mail to you a notification of receipt of your grant application. If you do not receive this notification within 15 business days from the application deadline date, you should call the U.S. Department of Education Application Control Center at (202) 245-6288.

V. Application Review Information

1. *Selection Criteria:* The selection criteria for this program are from 34 CFR 75.210 and are listed in the application

packages for each competition announced in this notice.

2. *Peer Review:* In the past, the Department has had difficulty finding peer reviewers for certain competitions, because so many individuals who are eligible to serve as peer reviewers have conflicts of interest. The Standing Panel requirements under IDEA also have placed additional constraints on the availability of reviewers. Therefore, the Department has determined that, for some discretionary grant competitions, applications may be separated into two or more groups and ranked and selected for funding within specific groups. This procedure will make it easier for the Department to find peer reviewers, by ensuring that greater numbers of individuals who are eligible to serve as reviewers for any particular group of applicants will not have conflicts of interest. It also will increase the quality, independence, and fairness of the review process, while permitting panel members to review applications under discretionary grant competitions for which they also have submitted applications. However, if the Department decides to select an equal number of applications in each group for funding, this may result in different cut-off points for fundable applications in each group.

VI. Award Administration Information

1. *Award Notices:* If your application is successful, we notify your U.S. Representative and U.S. Senators and send you a Grant Award Notice (GAN). We may notify you informally, also.

If your application is not evaluated or not selected for funding, we notify you.

2. *Administrative and National Policy Requirements:* We identify administrative and national policy requirements in the application package and reference these and other requirements in the *Applicable Regulations* section in this notice.

We reference the regulations outlining the terms and conditions of an award in the *Applicable Regulations* section in this notice and include these and other specific conditions in the GAN. The GAN also incorporates your approved application as part of your binding commitments under the grant.

3. *Reporting:* At the end of your project period, you must submit a final performance report, including financial information, as directed by the Secretary. If you receive a multi-year award, you must submit an annual performance report that provides the most current performance and financial expenditure information as directed by the Secretary under 34 CFR 75.118. The Secretary may also require more frequent performance reports under 34 CFR 75.720(c). For specific requirements on reporting, please go to <http://www.ed.gov/fund/grant/apply/appforms/appforms.html>.

4. *Performance Measures:* Under the Government Performance and Results Act of 1993 (GPRA), the Department has established a set of performance measures, including long-term measures, that are designed to yield information on various aspects of the effectiveness and quality of the Personnel Development to Improve Services and Results for Children with Disabilities program. These measures include:

For 84.325D, 84.325K and 84.325T

- (1) The percentage of projects that incorporate scientifically based or evidence-based practices;
- (2) The percentage of scholars who exit training programs prior to completion due to poor academic performance;
- (3) The percentage of degree or certification recipients who are working in the area(s) for which they were trained upon program completion;
- (4) The percentage of degree or certification recipients who are working in the area(s) for which they were trained upon program completion and are fully qualified under IDEA;
- (5) The percentage of scholars completing IDEA-funded training programs who are knowledgeable and skilled in scientifically based or evidence-based practices for infants, toddlers, and children with disabilities;
- (6) The percentage of low incidence positions that are filled by personnel who are fully qualified under IDEA; and
- (7) The percentage of program graduates who maintain employment for three or more years in the area(s) for which they were trained.

84.325R

- (1) The extent to which projects provide high quality products and services;
- (2) The relevance of project products and services to educational and early intervention policy and practice; and
- (3) The use of products and services to improve educational and early intervention policy and practice.

Grantees may be asked to participate in assessing and providing information on these aspects of program quality.

VII. Agency Contact

For Further Information Contact: See chart in the *Award Information* section in this notice for the name, room number and telephone number of the contact person for each competition. You can write to the contact person at the following address: U.S. Department of Education, 400 Maryland Avenue, SW., Potomac Center Plaza (PCP), Washington, DC 20202-2600.

If you use a TDD, call the FRS at 1-800-877-8339.

VIII. Other Information

Alternative Format: Individuals with disabilities can obtain this document and a copy of the application package in an alternative format (e.g., Braille, large print, audiotape, or computer diskette) by contacting the Grants and Contracts Services Team, U.S. Department of Education, 400 Maryland Avenue, SW., room 5075, PCP, Washington, DC 20202-2550. Telephone: (202) 245-7363. If you use a TDD, call the FRS, toll-free, at 1-800-877-8339.

Electronic Access to This Document: You can view this document, as well as all other documents of this Department published in the **Federal Register**, in text or Adobe Portable Document Format (PDF) on the Internet at the following site: www.ed.gov/news/fedregister.

To use PDF you must have Adobe Acrobat Reader, which is available free at this site. If you have questions about using PDF, call the U.S. Government Printing Office (GPO), toll free, at 1-888-293-6498; or in the Washington, DC, area at (202) 512-1530.

Note: The official version of this document is the document published in the **Federal Register**. Free Internet access to the official edition of the **Federal Register** and the Code of Federal Regulations is available on GPO Access at: www.gpoaccess.gov/nara/index.html.

Dated: November 21, 2007.

William W. Knudsen,

Deputy Assistant Secretary for Special Education and Rehabilitative Services.

[FR Doc. E7-23080 Filed 11-26-07; 8:45 am]

BILLING CODE 4000-01-P

DEPARTMENT OF EDUCATION

President's Board of Advisors on Historically Black Colleges and Universities

AGENCY: U.S. Department of Education, White House Initiative on Historically Black Colleges and Universities.

ACTION: Notice of an open meeting.

SUMMARY: This notice sets forth the schedule and agenda of the meeting of the President's Board of Advisors on Historically Black Colleges and Universities. This notice also describes the functions of the Board. Notice of this meeting is required by section 10(a)(2) of the Federal Advisory Committee Act and is intended to notify the public of its opportunity to attend.

DATES: Saturday, December 8, 2007.

TIME: 9 a.m.-3 p.m.

ADDRESSES: The Board will meet at the Xavier University of Louisiana, University Center Building, Suite 308, 1 Drexel Drive, New Orleans, LA 70125, Phone: 504-520-7904, Fax: 504-520-7904.

FOR FURTHER INFORMATION, CONTACT:

Leonard L. Haynes III, Executive Director, White House Initiative on Historically Black Colleges and Universities, 1990 K Street, NW., Washington, DC 20006; telephone: (202) 502-7549, fax: 202-502-7852.

SUPPLEMENTARY INFORMATION: The President's Board of Advisors on Historically Black Colleges and Universities is established under Executive Order 13256, dated February 12, 2002 and Executive Order 13316 dated September 17, 2003. The Board is established (a) to report to the President annually on the results of the participation of historically black colleges and universities (HBCUs) in federal programs, including recommendations on how to increase the private sector role in strengthening these institutions, with particular emphasis given to enhancing institutional planning and development; strengthening fiscal stability and financial management; and improving institutional infrastructure, including the use of technology, to ensure the long-term viability and enhancement of these institutions; (b) to advise the President and the Secretary of Education (Secretary) on the needs of HBCUs in the areas of infrastructure, academic programs, and faculty and institutional development; (c) to advise the Secretary in the preparation of an annual Federal plan for assistance to HBCUs in increasing their capacity to participate in Federal programs; (d) to

provide the President with an annual progress report on enhancing the capacity of HBCUs to serve their students; and (e) to develop, in consultation with the Department of Education and other Federal agencies, a private sector strategy to assist HBCUs.

Agenda: The purpose of the meeting is to receive and deliberate on policy issues pertinent to the Board and the nation's HBCUs and to discuss relevant issues to be addressed in the Board's annual report. This meeting will also provide the Board with a forum to vote and approve action items regarding implementation of Presidential Executive Order 13256.

Additional Information: Individuals who will need accommodations for a disability in order to attend the meeting (e.g., interpreting services, assistive listening devices, or material in alternative format) should notify ReShone Moore at (202) 502-7893, no later than Thursday, December 6, 2007. We will attempt to meet requests for accommodations after this date, but, cannot guarantee availability. The meeting site is accessible to individuals with disabilities.

An opportunity for public comment is available on Saturday, December 8, 2007, between 2:30 p.m.-3 p.m. Individuals who wish to provide comments will be allowed three to five minutes to speak. Those members of the public interested in submitting written comments may do so by submitting it to the attention of Leonard L. Haynes, 1990 K Street NW., Washington, DC., by Thursday, December 6, 2007.

Records are kept of all Board proceedings and are available for public inspection at the office of the White House Initiative on Historically Black Colleges and Universities, U.S. Department of Education, 1990 K Street, NW., Washington, DC 20006, Monday-Friday during the hours of 8 a.m. to 5 p.m.

Electronic Access to this Document: You may view this document, as well as all other documents of this Department published in the **Federal Register**, in text or Adobe Portable Document Format (PDF) on the internet at the following site: <http://www.ed.gov/news/fedregister/index.html>. To use PDF you must have Adobe Acrobat Reader, which is available free at this site. If you have questions about using PDF, call the U.S. Government Printing Office (GPO), toll free at 1-888-293-6498; or in the Washington, DC area at 202-512-1530.

Dated: November 16, 2007.

Diane Auer Jones,

Assistant Secretary, U.S. Department of Education, Office of Postsecondary Education.

[FR Doc. E7-22988 Filed 11-26-07; 8:45 am]

BILLING CODE 4000-01-P

DEPARTMENT OF EDUCATION

Privacy Act of 1974; System of Records—Department of Education Federal Docket Management System (EDFDMS)

AGENCY: Office of the General Counsel, Department of Education.

ACTION: Notice of a new system of records.

SUMMARY: In accordance with the Privacy Act of 1974, as amended (Privacy Act), the Department of Education (Department) publishes this notice of a new system of records entitled “Department of Education Federal Docket Management System” (EDFDMS) (18–09–05).

EDFDMS contains individually identifying information voluntarily provided by individuals who submit public comments on the Department’s rulemaking documents that are in the Federal Docket Management System (FDMS). FDMS is an interagency system that allows the public to search, view, download, and comment on Federal agency rulemaking documents through a single online system. The public accesses the FDMS Web portal at <http://www.regulations.gov>.

DATES: The Department seeks comment on the new system of records described in this notice, in accordance with the requirements of the Privacy Act. We must receive your comments on the proposed routine uses for the system of records referenced in this notice on or before December 27, 2007.

The Department filed a report describing the new system of records covered by this notice with the Chair of the Senate Committee on Homeland Security and Governmental Affairs, the Chair of the House Committee on Oversight and Government Reform, and the Administrator of the Office of Information and Regulatory Affairs, Office of Management and Budget (OMB) on November 21, 2007. This system of records will become effective at the later date of—(1) The expiration of the 40-day period for OMB review on December 31, 2007, unless OMB waives 10 days of the 40-day review period for compelling reasons shown by the Department, or (2) December 27, 2007, unless the system of records needs to be

changed as a result of public comment or OMB review.

ADDRESSES: Address all comments about the proposed routine uses to Elizabeth McFadden, Assistant General Counsel, Regulatory Services Division, Office of the General Counsel, U.S. Department of Education, 400 Maryland Avenue, SW., room 6E227, Washington, DC 20202–6110. *Telephone:* (202) 401–6307. If you prefer to send comments through the Internet, use the following address: comments@ed.gov.

You must include the term “EDFDMS” in the subject line of the electronic message.

During and after the comment period, you may inspect all comments about this notice in room 6E227, 400 Maryland Avenue, SW., Washington, DC, between the hours of 8 a.m. and 4:30 p.m., Eastern time, Monday through Friday of each week except Federal holidays.

Assistance to Individuals With Disabilities in Reviewing the Rulemaking Record

On request, we will supply an appropriate aid to an individual with a disability who needs assistance to review the comments or other documents in the public rulemaking record for this notice. If you want to schedule an appointment for this type of aid, please contact the person listed under **FOR FURTHER INFORMATION CONTACT**.

FOR FURTHER INFORMATION CONTACT: Elizabeth McFadden. *Telephone:* (202) 401–6307. If you use a telecommunications device for the deaf (TDD), call the Federal Relay Service (FRS) at 1–800–877–8339.

Individuals with disabilities can obtain this document in an alternative format (e.g., Braille, large print, audiotape, or computer diskette) on request to the contact person listed in this section.

SUPPLEMENTARY INFORMATION:

Introduction

FDMS serves as a central, electronic repository for Federal rulemaking dockets and includes **Federal Register** notices, supporting materials such as scientific or economic analyses, and public comments, as well as non-rulemaking dockets. Each agency that uses FDMS, including the Department, is responsible for managing its own dockets and rulemaking documents.

Through the Department’s portion of FDMS, members of the public may comment on the Department’s rulemaking documents contained in the system. In order to submit a comment

through the Department’s portion of FDMS, members of the public only need to complete two fields—the “Category” field and the “General Comments” field. To complete the “Category” field, commenters are prompted to select the most appropriate category from the following list: Parent/relative, teacher, student, individual, public elementary/secondary school, private elementary/secondary school, school administrator, institution of higher education, lender, guarantor, local educational agency, State educational agency, State agency, association/organization, Federal agency, child advocate, lobbyist, law firm, tribal organization, and other. The “General Comments” field in FDMS is a free text field in which individuals provide their actual comments. In addition to these two required fields, commenters may, but are not required to, provide the following information: First name, last name, city, country, State or province, e-mail address, organization name, submitter’s representative, government agency type, and government agency.

Generally, the Department makes all of the information provided by commenters, including commenters’ names and other individually identifying information provided within the comments, publicly viewable on the Federal government’s interagency FDMS Web portal at <http://www.regulations.gov>. FDMS has full text search capability, enabling any member of the public to search all public submissions on any Department rulemaking in FDMS by any term, including any name and contact information submitted in or as part of a comment.

On the <http://www.regulations.gov> Web site and in the Department’s notices of proposed rulemaking, the Department clearly notifies the public that, with few exceptions, comments received from members of the public (including those comments submitted by mail, commercial delivery, or hand delivery) are made publicly available on the Federal eRulemaking Portal (<http://www.regulations.gov>) without change. The Department makes efforts to ensure that comments containing material the disclosure of which is restricted by Federal law, such as the Children’s Online Privacy Protection Act of 1998 (COPPA), are not made publicly available. While not publicly posted, the Department will retain, evaluate, and consider these comments. EDFDMS is comprised of both these comments that are not publicly available, as well as the comments on the Department’s rulemakings that are available to the

public through <http://www.regulations.gov>.

The Privacy Act

The Department is publishing this new system of records notice, in accordance with the applicable requirements of the Privacy Act, to inform the public about how it will collect, maintain, use, and disclose the information that members of the public provide when commenting on a Department rulemaking that is part of FDMS.

The Privacy Act applies to information about individuals that contains individually identifying information and that is retrieved by a unique identifier associated with each individual, such as a name or social security number. The information about each individual is called a "record," and the system, whether manual or computer-based, is called a "system of records." The Privacy Act requires each agency to publish notices of systems of records in the **Federal Register** and to prepare reports to OMB and Congress whenever the agency publishes a new system of records.

The portion of the EDFDMS system that comes under the Privacy Act includes only the individually identifying information that commenters voluntarily submit to the Department when they comment on the Department's rulemaking documents in FDMS. The Privacy Act, 5 U.S.C. 552a(e)(4), requires the Department to publish in the **Federal Register** this notice of a new system of records maintained by the Department. The Department's regulations implementing the Privacy Act are contained in the Code of Federal Regulations (CFR) in 34 CFR part 5b.

Electronic Access to This Document

You may view this document, as well as all other documents of this Department published in the **Federal Register**, in text or Adobe Portable Document Format (PDF) on the Internet at the following site: <http://www.ed.gov/news/fedregister>.

To use PDF you must have Adobe Acrobat Reader, which is available free at this site. If you have questions about using PDF, call the U.S. Government Printing Office (GPO), toll free, at 1-888-293-6498; or in the Washington, DC area, at (202) 512-1530.

Note: The official version of this document is the document published in the **Federal Register**. Free Internet access to the official edition of the **Federal Register** and the Code of Federal Regulations is available on GPO Access at: <http://www.gpoaccess.gov/nara/index.html>.

Dated: November 21, 2007.

Kent D. Talbert,
General Counsel.

For the reasons discussed in the preamble, the General Counsel of the Department of Education publishes a notice of a new system of records to read as follows:

18-09-05

SYSTEM NAME:

Department of Education Federal Docket Management System (EDFDMS).

SECURITY CLASSIFICATION:

None.

SYSTEM LOCATION:

The central location is at the U.S. Environmental Protection Agency, Research Triangle Park, NC 27711-0001. Access is available through the Internet from other locations.

CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM:

Information on individuals who voluntarily provide individually identifying information when submitting a public comment or supporting materials in response to a Department rulemaking document or notice in the Federal Docket Management System (FDMS) are covered by this system. Although this system may also contain information on and public comments submitted by representatives of governmental or organizational entities, the purpose for which the Department is establishing this system of records is only to cover individuals protected under the Privacy Act of 1974 (5 U.S.C. 552a(a)(2)).

CATEGORIES OF RECORDS IN THE SYSTEM:

The categories of records in the system include: First name, last name, category (such as parent/relative, student, teacher, local educational agency, or lender), city, country, State or province, email address, organization name, submitter's representative, government agency type, government agency, additional information provided in the "General Comments" section, and other supporting documentation furnished by the submitter.

AUTHORITY FOR MAINTENANCE OF THE SYSTEM:

Section 206(d) of the E-Government Act of 2002 (Pub. L. 107-347, 44 U.S.C. 3501 note); 5 U.S.C. 301; and 5 U.S.C. 553.

PURPOSE:

The EDFDMS system of records permits the Department to identify individuals who have submitted comments, in response to the

Department's rulemaking documents or notices that are in FDMS, so that communications or other actions, as appropriate and necessary, can be effected. Examples of such communications are seeking clarification of a comment and responding directly to a comment.

ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSES OF SUCH USES:

The Department may disclose information contained in a record in this system of records without the consent of the individual if the disclosure is compatible with the purposes for which the record was collected. The Department may make these disclosures on a case-by-case basis, or, if the Department has complied with the computer matching requirements of the Computer Matching and Privacy Protection Act of 1988, as amended, under a computer matching agreement.

(1) *Disclosure to the Public.* With few exceptions, the Department may disclose information in EDFDMS to any member of the public. EDFDMS permits members of the public to search the public comments that are received by the Department and included in FDMS by the name of the individual submitting the comment. Unless the individual submits a comment anonymously, a full-text search, using the individual's name, will generally result in the comment and the commenter's information being displayed for view. With few exceptions, comments that are submitted using the FDMS system will include any information that the commenter provided when submitting the comment. In addition, with few exceptions, comments that are submitted in writing and then scanned and uploaded into the FDMS system will include any identifying information about the submitter that is provided in the written comment. If a commenter provides individually identifying information about a third party, a full-text search using the third party's name, with some exceptions, will result in the third party's information being displayed for view.

Note: Identification of an individual commenter or third party is possible only if the commenter voluntarily provides his or her name or contact information, or that of a third party. If this information is not furnished, the submitted comments or supporting documentation cannot be linked to the commenter or a third party.

(2) *Disclosure for Use by Other Law Enforcement Agencies.* The Department may disclose information to any

Federal, State, local, or foreign agency, or other public authority responsible for enforcing, investigating, or prosecuting violations of administrative, civil, or criminal law or regulation if that information is relevant to any enforcement, regulatory, investigative, or prosecutorial responsibility within the receiving entity's jurisdiction.

(3) *Enforcement Disclosure*. In the event that information in this system of records indicates, either on its face or in connection with other information, a violation or potential violation of any applicable statute, regulation, or order of a competent authority, the Department may disclose the relevant records to the appropriate agency, whether foreign, Federal, State, Tribal, or local, charged with the responsibility of investigating or prosecuting that violation or charged with enforcing or implementing the statute, Executive order, rule, regulation, or order issued pursuant thereto.

(4) *Litigation and Alternative Dispute Resolution (ADR) Disclosure*.

(a) *Introduction*. In the event that one of the parties listed below is involved in litigation or ADR, or has an interest in litigation or ADR, the Department may disclose certain records to the parties described in paragraphs (b), (c), and (d) of this routine use under the conditions specified in those paragraphs:

(i) The Department or any of its components.

(ii) Any Department employee in his or her official capacity.

(iii) Any Department employee in his or her individual capacity if the U.S. Department of Justice (DOJ) has been requested to or has agreed to provide or arrange for representation for the employee.

(iv) Any Department employee in his or her individual capacity where the Department has agreed to represent the employee.

(v) The United States where the Department determines that the litigation is likely to affect the Department or any of its components.

(b) *Disclosure to DOJ*. If the Department determines that disclosure of certain records to DOJ is relevant and necessary to litigation or ADR, the Department may disclose those records as a routine use to DOJ.

(c) *Adjudicative Disclosure*. If the Department determines that it is relevant and necessary to the litigation or ADR to disclose certain records to an adjudicative body before which the Department is authorized to appear, to an individual, or to an entity designated by the Department or otherwise empowered to resolve or mediate disputes, the Department may disclose

those records as a routine use to the adjudicative body, individual, or entity.

(d) *Disclosure to parties, counsels, representatives, or witnesses*. If the Department determines that disclosure of certain records to a party, counsel, representative, or witness is relevant and necessary to the litigation or ADR, the Department may disclose those records as a routine use to the party, counsel, representative, or witness.

(5) *Freedom of Information Act (FOIA) and Privacy Act Advice Disclosure*. The Department may disclose records to DOJ or OMB if the Department concludes that disclosure is desirable or necessary in determining whether particular records are required to be disclosed under the FOIA or the Privacy Act.

(6) *Disclosure to DOJ*. The Department may disclose records to DOJ to the extent necessary for obtaining DOJ advice on any matter relevant to an audit, inspection, or other inquiry related to the programs covered by this system.

(7) *Contract Disclosure*. If the Department contracts with an entity for the purposes of performing any function that requires disclosure of records in this system to employees of the contractor, the Department may disclose the records to those employees. Before entering into such a contract, the Department shall require the contractor to maintain Privacy Act safeguards as required under 5 U.S.C. 552a(m) with respect to the records in the system.

(8) *Congressional Member Disclosure*. The Department may disclose the records of an individual to a member of Congress or the member's staff in response to an inquiry from the member made at the written request of that individual. The member's right to the information is no greater than the right of the individual who requested the inquiry.

(9) *Disclosure in the Course of Responding to Breach of Data*. The Department may disclose records to appropriate agencies, entities, and persons when (1) it is suspected or confirmed that the security or confidentiality of information in this system has been compromised; (2) the Department has determined that as a result of the suspected or confirmed compromise, there is a risk of harm to economic or property interests, identity theft or fraud, or harm to the security or integrity of this system or other systems or programs (whether maintained by the Department or by another agency or entity) that rely upon the compromised information; and (3) the disclosure is made to such agencies, entities, and persons who are reasonably necessary to

assist the Department in responding to the suspected or confirmed compromise and in helping the Department prevent, minimize, or remedy such harm.

POLICIES AND PRACTICES FOR STORING, RETRIEVING, ACCESSING, RETAINING, AND DISPOSING OF RECORDS IN THE SYSTEM:

STORAGE:

Records are maintained on electronic storage media and in paper.

RETRIEVABILITY:

EDFDMS enables record retrieval by various data elements and key word searches. These data elements are: document identification number, comment tracking number, document title, Code of Federal Regulation (CFR) (search for a specific title within the CFR), CFR citation (search for the part or parts within the CFR title being searched), document type, document sub type, date posted, and comment period end date.

SAFEGUARDS:

As discussed above in routine use (1), *Disclosure to the Public*, any member of the public who accesses FDMS through <http://www.regulations.gov> and searches the comments associated with the Department's rulemakings can view EDFDMS records that are included in FDMS.

To the extent paper records from this system of records are maintained, they will be maintained in a controlled facility where physical entry is restricted by locks, guards, and administrative procedures.

Access to electronic and paper EDFDMS records that are not otherwise available to the public through FDMS is limited to those Department and contract staff who require the records to perform their official duties consistent with the purposes for which the information was collected. Personnel whose official duties require access to either electronic or written EDFDMS records that are not otherwise available to the public through FDMS are trained in the proper safeguarding and use of the information.

RETENTION AND DISPOSAL:

Until the National Archives and Records Administration (NARA) approves a retention and disposition schedule for EDFDMS, the Department will treat all EDFDMS records as permanent.

SYSTEM MANAGER AND ADDRESS:

Elizabeth McFadden, Assistant General Counsel, Regulatory Services Division, Office of the General Counsel, U.S. Department of Education, 400

Maryland Avenue, SW., room 6E227, Washington, DC 20202-6110.

NOTIFICATION PROCEDURE:

If you wish to determine whether a record exists regarding you in the system of records, contact the system manager. Your request must meet the requirements of regulations in 34 CFR 5b.5, including proof of identity.

RECORD ACCESS PROCEDURES:

If you wish to gain access to your record in the system of records, contact the system manager at the address listed under **SYSTEM MANAGER AND ADDRESS**. Requests should contain your full name, address, and telephone number. Your request must meet the requirements of regulations in 34 CFR 5b.5, including proof of identity.

CONTESTING RECORD PROCEDURES:

If you wish to contest the content of a record regarding you in the system of records, contact the system manager. Your request must meet the requirements of the regulations in 34 CFR 5b.7, including proof of identity.

RECORD SOURCE CATEGORIES:

Information maintained in this system of records is obtained from anyone who chooses to voluntarily submit a public comment or supporting materials in response to a Department rulemaking document or notice, including individuals and representatives of Federal, State or local governments, businesses, and other organizations.

EXEMPTIONS CLAIMED FOR THE SYSTEM:

None.

[FR Doc. E7-23058 Filed 11-26-07; 8:45 am]

BILLING CODE 4000-01-P

DEPARTMENT OF EDUCATION

Privacy Act of 1974; System of Records—Investigatory Material Compiled for Personnel Security, Suitability, Positive Identification Verification and Access Control for the Department of Education Security Tracking and Reporting System (EDSTAR)

AGENCY: Office of Management, Department of Education.

ACTION: Notice of altered and deleted systems of records.

SUMMARY: In accordance with the Privacy Act of 1974, as amended (Privacy Act), the Department of Education (Department), publishes this notice to amend and rename the system of records entitled “Investigatory Material Compiled for Personnel

Security and Suitability Purposes” (18-05-17) as “Investigatory Material Compiled for Personnel Security, Suitability, Positive Identification Verification and Access Control for the Department of Education Security Tracking and Reporting System (EDSTAR)” (18-05-17) and to delete the system of records entitled “Identification Media Records” (18-05-16). The Department is taking these actions because these systems of records have been merged into and consolidated with the EDSTAR system of records.

EDSTAR is designed to implement the requirements of Homeland Security Presidential Directive (HSPD)-12. HSPD-12 is a Presidential directive that requires the promulgation of a Federal standard to ensure a common, governmentwide standard for secure and reliable forms of Personal Identity Verification (PIV). On February 25, 2005, the National Institute of Standards and Technology’s (NIST’s) Computer Security Division issued Federal Information Processing Standard (FIPS) 201, entitled “Personal Identity Verification of Federal Employees and Contractors”, in order to satisfy the requirements of HSPD-12 to improve the identification and authentication of Federal employees and contractors for access to Federal facilities and information systems.

The Department maintains records in EDSTAR for the purpose of making individual positive identification verification, adjudication determinations concerning suitability for Federal employment and contract positions, decisions concerning access to the Department’s facilities and information systems, and information related to the issuance of PIV and FIPS compliant identification media and access to restricted areas. Because many of these records are currently covered by the systems of records entitled “Identification Media Records” (18-05-16) and “Investigatory Material Compiled for Personnel Security and Suitability Purposes” (18-05-17), the Department is merging and consolidating these systems of records by amending and renaming the “Investigatory Material Compiled for Personnel Security and Suitability Purposes” (18-05-17) system as EDSTAR and deleting the system of records for “Identification Media Records” (18-05-16).

DATES: We must receive your comments about the altered and deleted systems of records notice on or before December 27, 2007.

The Department filed a report describing the altered system of records

covered by this notice with the Chair of the Senate Committee on Homeland Security and Governmental Affairs, the Chair of the House Committee on Oversight and Government Reform, and the Administrator of the Office of Information and Regulatory Affairs, Office of Management and Budget (OMB) on November 21, 2007. The altered system of records will become effective at the later date of—(1) The expiration of the 40-day period for OMB review on December 31, 2007 or (2) December 27, 2007, unless the system of records needs to be changed as a result of public comment or OMB review.

ADDRESSES: Address all comments about the altered and deleted systems of records to Cecelia E. Briscoe, Senior Program Analyst, Security Services, Office of Management, Room 2W312, U.S. Department of Education, 400 Maryland Avenue, SW., Washington, DC 20202-5345. If you prefer to send comments through the Internet, use the following address:

Security.Services@Ed.gov.

You must include the term “EDSTAR Comments” in the subject line of your electronic message.

During and after the comment period, you may inspect all public comments about this notice at the U.S. Department of Education in room 2W330, 400 Maryland Avenue, SW., Washington, DC, between the hours of 8 a.m. and 4:30 p.m., Eastern time, Monday through Friday of each week except Federal holidays.

Assistance to Individuals With Disabilities in Reviewing the Rulemaking Record

On request, we will supply an appropriate aid, such as a reader or print magnifier, to an individual with a disability who needs assistance to review the comments or other documents in the public rulemaking record for this notice. If you want to schedule an appointment for this type of aid, please contact the person listed under **FOR FURTHER INFORMATION CONTACT**.

FOR FURTHER INFORMATION CONTACT: Colette Hawley, Security Services, Office of Management, room 2W312, U.S. Department of Education, 400 Maryland Avenue, SW., Washington, DC 20202-5345. Telephone number: (202) 401-2993. If you use a telecommunications device for the deaf (TDD), you may call the Federal Relay Service (FRS) at 1-800-877-8339.

Individuals with disabilities may obtain this document in an alternative format (e.g., Braille, large print, audiotope, or computer diskette) on

request to the contact person listed in the preceding paragraph.

SUPPLEMENTARY INFORMATION:

Introduction

The Privacy Act (5 U.S.C. 552a(e)(4)) requires the Department to publish in the **Federal Register** this notice of an altered system of records maintained by the Department. The Department's regulations implementing the Privacy Act are contained in part 5b of title 34 of the Code of Federal Regulations (CFR).

The Privacy Act applies to information about individuals that is maintained in a system of records from which individually identifying information is retrieved by a unique identifier associated with each individual, such as a name or social security number. The information about each individual is called a "record," and the system, whether manual or computer-based, is called a "system of records." The Privacy Act requires each agency to publish notices of new or altered systems of records in the **Federal Register** and to submit reports to the Administrator of the Office of Information and Regulatory Affairs, OMB, the Chair of the House Committee on Oversight and Government Reform, and the Chair of the Senate Committee on Homeland Security and Governmental Affairs, whenever the agency publishes a new or altered system of records.

Electronic Access to This Document

You can view this document, as well as all other documents of this Department published in the **Federal Register**, in text or Adobe Portable Document Format (PDF) on the Internet at the following site: www.ed.gov/news/fedregister.

To use PDF you must have Adobe Acrobat Reader, which is available free at this site. If you have questions about using PDF, call the U.S. Government Printing Office (GPO), toll free, at 1-888-293-6498; or in the Washington, DC, area at (202) 512-1530.

Note: The official version of this document is the document published in the **Federal Register**. Free Internet access to the official edition of the **Federal Register** and the Code of Federal Regulations is available on GPO Access at: www.gpoaccess.gov/nara/index.html.

Dated: November 21, 2007.

Michell C. Clark,

Assistant Secretary for Management.

For the reasons discussed in the preamble, the Assistant Secretary for Management of the Department

publishes a notice of altered and deleted systems of records to read as follows:

DELETED SYSTEM OF RECORDS

The Department identifies the system of records entitled Identification Media Records (18-05-16), as published in the **Federal Register** on December 26, 2002 (67 FR 78794-96), to be deleted because it has been merged into and consolidated with the following system of records:

ALTERED SYSTEM OF RECORDS

18-05-17

SYSTEM NAME:

Investigatory Material Compiled for Personnel Security, Suitability, Positive Identification Verification and Access Control for the Department of Education Security Tracking and Reporting System (EDSTAR).

SECURITY CLASSIFICATION:

None.

SYSTEM LOCATIONS:

- (1) Security Services, Office of Management, U.S. Department of Education, 400 Maryland Avenue, SW., Washington, DC 20202-5345.
- (2) U.S. Department of Education, Data Center, 6710 Oxon Hill Road, Oxon Hill, MD 20745-1117.
- (3) U.S. Office of Personnel Management (OPM), Federal Investigations Processing Center, P.O. Box 618, 1137 Branchton Road, Boyers, PA 16018-0618.
- (4) Verisign, 487 E. Middlefield Road, Mountain View, CA 94043-4047.
- (5) U.S. Department of Justice (DOJ), DOJ Rockville Data Center, 1151-D Seven Locks Road, Rockville, MD 20854-0001.

CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM:

This system contains information on applicants seeking Federal or contract employment with the Department, current Federal employees and contractors, and other persons or entities doing business with the Department, or persons either seeking unescorted access to the facilities, or access to the information systems of the Department, or both. The system does not cover term employees of less than 30 calendar days with monitored access to either the Department's facilities or information system, or both. Nor does it cover occasional visitors or short-term guests to the Department to the extent that they are issued non-Personal Identity Verification (PIV) temporary identification.

CATEGORIES OF RECORDS IN THE SYSTEM:

This system consists of records containing investigative information pertaining to current and former Department employees, current and former contractor personnel, and current employees of entities making offers to the Department for purposes of doing business. This information may include information pertaining to the individuals' character, conduct, and loyalty to the United States as relevant to determination of their suitability for employment in the Department. This system of records may include an individual's name, former names, birth date, birth place, Social Security number, home address, phone numbers, employment history, residential history, education and degrees earned, names of associates and references and their contact information, citizenship, names of relatives, birth dates and birth places of relatives, citizenship of relatives, names of relatives who work for the Federal government, mental health history, drug use, financial information, summary report of investigation, results of suitability decisions, level of security clearance, date of issuance of security clearance, requests for appeal, witness statements, investigator's notes, tax return information, credit reports, security violations, circumstances of violation, and agency action taken.

These records also may, as appropriate to the individual being investigated, include the following types of information:

- (1) Documentation as to his or her arrests and convictions for violations of the law.
- (2) Reporting as to interviews held with the individual, his or her present and former supervisors, co-workers, associates, neighbors, educators, etc.
- (3) Correspondence relating to adjudication matters involving the individual.
- (4) Reports of inquiries made of law enforcement agencies for information about the individual contained in the agencies' records.
- (5) Information provided by organizations having association with the individual, such as employers, educational institutions attended, professional or fraternal or social organizations to which the individual is or was a member, etc.
- (6) Reports of action following an OPM investigation or a Federal Bureau of Investigation Section 8(d) full field investigation.
- (7) Personal access logs of individuals entering access controlled space.
- (8) Public Key Infrastructure (PKI) Certificates issued under direct guidance from Homeland Security

Presidential Directive (HSPD)-12 and Federal Information Processing Standard (FIPS)-201.

(9) Personal fingerprint records for identification and criminal records checks.

(10) Other information developed from the previous sources.

In addition, this system contains records maintained on individuals issued PIV credentials by the Department. These records may include the following data fields: Full name; Social Security number; date of birth; signature; image (photograph); fingerprints; hair color; eye color; height; weight; organization or office of assignment; company name; copy of background investigation form; PIV card issuance and expiration dates; personal identification number (PIN); results of background investigation; PIV request form; PIV registrar approval signature; PIV card serial number; emergency responder designation (if applicable); copies of documents used to verify identification or information derived from those documents such as document title, document issuing authority, document number, document expiration date, document other information; level of national security clearance and expiration date; computer system user name; user access and permission rights, authentication certificates; and digital signature information. For those issued non-PIV identification these fields do not apply.

Note 1: OPM and DOJ issue the standard forms used to collect information in this system, i.e. Standard Form (SF) 85, SF-85P, SF-85PS, SF-86, SF-87, and Fingerprint card FD-258.

Note 2: To the extent that the Department has records of a personnel investigative nature that come from OPM or its contractors, these records are covered by OPM/CENTRAL-9, Personnel Investigations Records, and are not covered by this system notice.

AUTHORITY FOR MAINTENANCE OF THE SYSTEM:

HSPD-12, Policy for a Common Identification Standard for Federal Employees and Contractors (August 27, 2004); Executive Orders 10450, 18 FR 2489, 3 CFR 1949-1953 Comp., p. 936); 10577 (3 CFR 1954-1958 Comp., p. 218); and 12968 (Access to Classified Information); 5 U.S.C. 3301 and 7301; Federal Property and Administrative Act of 1949, as amended through Public Law 106-580; and 5 CFR parts 5, 731, 732, and 736.

PURPOSE(S):

Records in this system are maintained to assist in making determinations concerning suitability for Federal

employment, security clearances, access to classified information, unescorted access to Federal government owned and Federal government leased facilities or restricted areas, and evaluations as to acceptability for performance under Federal contracts or other agreements with the Federal government. Purposes of this system also include: Ensuring the safety and security of Federal facilities, systems, and information resources, as well as the safety and security of the occupants and users of these facilities, systems, and information resources; verifying that persons entering Federal facilities and using Federal systems and information resources, are authorized to do so; and tracking and controlling PIV cards issued to persons entering the Federal government's facilities and using its systems and information resources.

ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSES OF SUCH USES:

The Department may disclose information contained in a record in this system of records under the routine uses listed in this system of records without the consent of the individual if the disclosure is compatible with the purposes for which the record was collected. The Department may make these disclosures on a case-by-case basis or, if the Department has complied with the computer matching requirements of the Computer Matching and Privacy Protection Act of 1998, as amended, under a computer matching agreement.

(1) *Program Purpose.* The Department may disclose records from this system of records to any source or potential source from which information is requested in the course of an investigation concerning the suitability or retention of an employee or a contractor, or the retention of a security clearance, contract, grant, license, or other benefit, to the extent necessary to identify the individual being investigated, inform the source of the nature and purpose of the investigation, and to identify the type of information requested.

(2) *Enforcement Disclosure.* The Department may disclose relevant records to a Federal, State, local, foreign, or tribal entity or other public authority responsible for the investigation, prosecution, enforcement, or implementation of a statute, rule, regulation, or order, when a record on its face or in combination with any other information indicates a violation or potential violation of law (whether civil, criminal, or regulatory in nature) if that information is relevant to any enforcement, regulatory, investigative, or prosecutorial responsibility of the

receiving entity. It is Office of Management policy not to disclose records under this routine use that pertain to those questions for which the Office of Management has promised confidentiality under SF-85P, Questionnaire for Public Trust Positions.

(3) *Contract Disclosure.* If the Department contracts with an entity for the purpose of performing any function that requires disclosure of records in this system to employees of the contractor, the Department may disclose the records as a routine use to those employees. Before entering into such a contract, the Department shall require the contractor to maintain Privacy Act safeguards as required under 5 U.S.C. 552a(m) with respect to the records in the system.

(4) *Litigation or Alternative Dispute Resolution (ADR) Disclosure.* (a) *Introduction.* In the event that one of the following parties is involved in litigation or ADR, or has an interest in litigation or ADR, the Department may disclose certain records to the parties described in paragraphs (b), (c), and (d) of this routine use under the conditions specified in those paragraphs:

(i) The Department or any of its components.

(ii) Any Department employee in his or her official capacity.

(iii) Any employee of the Department in his or her individual capacity where the DOJ has agreed to or has been requested to provide or arrange for representation of the employee.

(iv) Any employee of the Department in his or her individual capacity where the Department has agreed to represent the employee.

(v) The United States where the Department determines that the litigation is likely to affect the Department or any of its components.

(b) *Disclosure to the DOJ.* If the Department determines that disclosure of certain records to the DOJ or attorneys engaged by DOJ is relevant and necessary to litigation or ADR and is compatible with the purpose for which the records were collected, the Department may disclose those records as a routine use to DOJ.

(c) *Adjudicative Disclosure.* If the Department determines that disclosure of certain records to an adjudicative body before which the Department is authorized to appear or to an individual or entity designated by the Department or otherwise empowered to resolve or mediate disputes is relevant and necessary to litigation or ADR and is compatible with the purpose for which the records were collected, the Department may disclose those records

as a routine use to the adjudicative body, individual, or entity.

(d) *Disclosure to Parties, Counsel, Representative, or Witnesses.* If the Department determines that disclosure of certain records to a party, an opposing counsel, representative, or witness is relevant and necessary to litigation or ADR and is compatible with the purpose for which the records were collected, the Department may disclose those records as a routine use to a party, counsel, representative, or witness.

(5) *Freedom of Information Act (FOIA) Advice Disclosure.* The Department may disclose information from this system of records to DOJ for the purpose of obtaining advice regarding the releasability of records maintained in this system of records under the FOIA and the Privacy Act of 1974.

(6) *Congressional Member Disclosure.* The Department may disclose information from this system of records to a Member of Congress or to a Congressional staff member in response to an inquiry of the Congressional office made at the written request of the constituent about whom the record is maintained.

(7) *Disclosure for Use by Other Law Enforcement Agencies.* The Department may disclose information from this system of records to any Federal, State, local or foreign agency or other public authority responsible for enforcing, investigating, or prosecuting violations of administrative, civil, or criminal law or regulation if that information is relevant to any enforcement, investigative, or prosecutorial responsibility within the receiving entity's jurisdiction.

(8) *Disclosure for Use for Intelligence Activities.* The Department may disclose information from this system of records to Federal, State, or local agencies, other appropriate entities or individuals, or, through established liaison channels, to selected foreign governments, in order to enable an intelligence agency to carry out its responsibilities as authorized by law, including the National Security Act of 1947 as amended, the CIA Act of 1949 as amended, Executive Order 12333 or any successor order, applicable national security directives, or classified implementing procedures approved by the Attorney General and promulgated pursuant to such statutes, orders or directives.

(9) *Employment, Benefits, and Contracting Disclosure.* (a) *For Decisions by the Department.* The Department may disclose information from this system of records to a Federal, State, or local agency or to another public authority or professional organization,

to obtain information relevant to the Department's conduct of a security or suitability investigation of an individual seeking employment, licensure, other benefits, or to perform contractual services for, or to otherwise associate with, the Department.

(b) *For Decisions by Other Public Agencies and Professional Organizations.* The Department may disclose information from this system of records to a Federal, State, local, or foreign agency, or other public authority or professional organization, so that the receiving entity may obtain information relevant to its conduct of a security or suitability investigation of an individual seeking employment, licensure, other benefits, or to perform contractual services for, or to otherwise associate with, the receiving entity.

(10) *Employee Grievance, Complaint, or Conduct Disclosure.* If a record is relevant and necessary to a grievance, complaint, or disciplinary proceeding regarding a present or former employee of the Department, the Department may disclose the record in the course of an investigation, fact-finding, or adjudication to another agency of the Federal government, or to any witness, designated fact-finder, mediator, or other person designated to resolve issues or decide the matter. The disclosure may only be made during the course of the investigation or the proceeding.

(11) *Disclosure in the Course of Responding to Breach of Data.* The Department may disclose records to appropriate agencies, entities, and persons when (a) it is suspected or confirmed that the security or confidentiality of information in this system has been compromised; (b) the Department has determined that as a result of the suspected or confirmed compromise there is a risk of harm to economic or property interests, identity theft or fraud, or harm to the security or integrity of this system or other systems or programs (whether maintained by the Department or by another agency or entity) that rely upon the compromised information; and (c) the disclosure is made to such agencies, entities, and persons who are reasonably necessary to assist the Department in responding to the suspected or confirmed compromise and in helping the Department prevent, minimize, or remedy such harm.

(12) *Disclosure to Protect Safety and Security of Department Employees, Customers, and Facilities.* The Department may disclose to Federal, State, and local law enforcement agencies and private security contractors, as appropriate, information that the Department deems necessary in

order to: (a) Assist with the protection of the safety of Department employees and customers, the security of the Department's workplace, or the operation of the Department's facilities or information systems; or (b) assist with investigations or prosecutions with respect to activities that affect such safety and security or activities that disrupt the operation of the Department.

Note 3: Disclosures within the Department of data pertaining to date and time of entry and exit of a Department employee working in the District of Columbia may not be made to supervisors, managers, or any other persons (other than the individual to whom the information applies) to verify employee time and attendance records for personnel actions because 5 U.S.C. 6106 prohibits Federal Executive agencies (other than the Bureau of Engraving and Printing) from using a recording clock within the District of Columbia, unless used as a part of a flexible schedule or compressed work schedule under 5 U.S.C. 6120, *et seq.*

POLICIES AND PRACTICES OF STORING, RETRIEVING, ACCESSING, RETAINING, AND DISPOSING OF RECORDS IN THE SYSTEM:

STORAGE:

Records are maintained on paper and in electronic form. Paper records are stored in fire resistant locked file cabinets in locked access-controlled rooms. Within the locked access-controlled room, electronic files are encrypted and stored in alarmed electronic retrieval file systems. The data servers, the laptops, and the desk computers where the data resides are in locked access-controlled rooms.

PIV identification card data on cardholders entering the Department's facilities is stored in an encrypted database.

RETRIEVABILITY:

Electronic and paper records are retrieved by a unique identifying number by the Department pursuant to the National Institute of Standards and Technology (NIST), Federal Information Processing Standard (FIPS) 201, Personal Identity Verification for Federal Employees and Contractors; this number is cross-referenced to the name of the individual.

SAFEGUARDS:

All physical access to the Department's sites, and the sites of the Department's contractors where this system of records is maintained, is controlled and monitored by security personnel who check each individual entering the building for his or her employee or visitor badge.

In accordance with the Department's Administrative Communications System (ACS) Directive OM: 5-101 entitled

“Contractor Employee Personnel Security Screenings,” all contract and Department personnel who have facility access and system access are required to undergo a security clearance investigation. Individuals requiring access to Privacy Act data are required to hold, at a minimum, a moderate-risk security clearance level. These individuals are required to undergo periodic screening at five-year intervals.

In addition to undergoing a security clearance investigation, contract and Department personnel are required to complete security awareness training on an annual basis. This training is required to ensure that contract and Department users are trained appropriately in safeguarding Privacy Act data in accordance with OMB Circular No. A-130, Appendix III.

Computer databases are kept on encrypted servers on an isolated virtual local area network (V-LAN) that is not connected to any outside network including the Internet. Database accessibility is restricted to hard wire network connection from within the Office Management, Security Services, and direct Integrated Services Digital Network (ISDN) line to the Department of Justice (DOJ), or via secure portal to the Office of Personnel Management (OPM). Authorized log-on codes and passwords prevent unauthorized users from gaining access to data and system resources. All users have unique log-on codes and passwords. The password scheme requires that users must change passwords every 60 days and may not repeat the old password.

Any individual attempting to log on who fails is locked out of the system after three attempts. Access after that time requires intervention by the system manager.

RETENTION AND DISPOSAL:

Most background investigative records are maintained in accordance with General Records Schedule (GRS) 18, Item 22—destroy not later than five years after separation or transfer of employee or no later than five years after contract relationship expires, whichever is later. Records are destroyed by deletion or shredding.

Reports of background investigations conducted by the Office of Inspector General under delegated authority of the OPM are retained in accordance with OPM retention standards for similar records, pending National Archives and Records Administration (NARA) approval. Records will be maintained for 15 years after the last investigative activity, except investigations involving potentially actionable issue(s) will be maintained for 25 years after the last

investigative activity and then destroyed by deletion or shredding.

Personal access logs of individuals entering controlled space are retained in accordance with GRS 18, Item 17. In the Department’s secured facilities, records are destroyed five years after final entry or five years after date of document, as appropriate. For all other facilities, records are destroyed two years after final entry or two years after date of document, as appropriate. Records are destroyed by deletion or shredding.

PKI certificates and PIV cards issued under guidance of HSPD-12 and FIPS-201 will be retained in accordance with the pending GRS disposition authority as issued by NARA, or in a NARA-approved, Departmental records retention schedule, as appropriate.

SYSTEM MANAGER(S) AND ADDRESS:

Security Services, Office of Management, U.S. Department of Education, 400 Maryland Avenue, SW., Room 2W314, Washington, DC 20202-5345.

NOTIFICATION PROCEDURE:

If an individual wishes to determine whether a record exists regarding him or her in this system of records, the individual must contact the system manager and provide his or her name, date of birth, social security number, signature, and the address to which the record information should be sent. This information is required to ensure the positive identification of the person’s record in the system. Requests for notification about an individual must meet the requirements of the regulations in 34 CFR 5b.5.

RECORD ACCESS PROCEDURE:

If an individual wishes to gain access to a record in this system, he or she must contact the system manager and provide information as described in the notification procedure.

CONTESTING RECORD PROCEDURE:

If an individual wishes to change the content of a record in the system of records, he or she must contact the system manager with the information described in the notification procedure, identify the specific item or items to be changed, and provide a written justification for the change, including any supporting documentation. Requests to amend a record must meet the requirements of the regulations in 34 CFR 5b.7.

RECORD SOURCE CATEGORIES:

Information contained in this system of records is obtained from—

(a) Investigative and other record material furnished by other Federal

entities, other departmental components, State, local, and foreign governments;

(b) Applications and other personnel and security forms;

(c) Personal investigation, written inquiry, interview, and the electronic accessing of computer databases of sources, such as the OPM system of records known as Personnel Investigations Records (OPM/Central-9), employers, educational institutions, references, neighbors, associates, police departments, courts, credit bureaus, medical records, probation officials, prison officials, DOJ, newspapers, magazines, periodicals, and other publications; and

(d) Confidential sources.

EXEMPTIONS CLAIMED FOR THE SYSTEM:

The Secretary has exempted by regulation—in 34 CFR 5b.11(d)—this system of records only to the extent that the information is investigatory material compiled solely for the purpose of determining suitability, eligibility, or qualifications for Federal civilian employment, Federal contracts, or access to classified information from the following provisions of the Privacy Act pursuant to 5 U.S.C. 552a(k)(5):

(1) 5 U.S.C. 552a(c)(3), regarding access to an accounting of disclosures of records.

(2) 5 U.S.C. 552a(d)(1) through (4) and (f), regarding notification of and access to records and correction or amendment of records.

(3) 5 U.S.C. 552a(e)(4)(G) and (H) regarding inclusion of information in the system notice about procedures for notification, access, and correction of records.

As indicated in 34 CFR 5b.11(f), individuals will be provided access to information in this system, except when, in accordance with the provisions of 5 U.S.C. 552a(k)(5):

(1) The disclosure of such information would reveal the identity of a source who furnished information to the Government under an express promise that the identity of the source would be held in confidence; or

(2) The information was obtained prior to September 28, 1975 and the disclosure of such information would reveal the identity of the source under an implied promise that the identity of the source would be held in confidence.

[FR Doc. E7-23059 Filed 11-26-07; 8:45 am]

BILLING CODE 4000-01-P

DEPARTMENT OF ENERGY**Federal Energy Regulatory
Commission**

[Docket No. PR07-13-002]

**Alabama Intrastate, LLC; Notice of
Compliance Filing**

November 19, 2007.

Take notice that on November 13, 2007, Enterprise Alabama Intrastate, LLC filed a Report of Refunds in compliance with the Commission's letter order issued on September 4, 2007, in Docket Nos. PR07-13-000 and PR07-13-001.

Any person desiring to protest this filing must file in accordance with Rule 211 of the Commission's Rules of Practice and Procedure (18 CFR 385.211). Protests to this filing will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Such protests must be filed on or before the date as indicated below. Anyone filing a protest must serve a copy of that document on all the parties to the proceeding.

The Commission encourages electronic submission of protests in lieu of paper using the "eFiling" link at <http://www.ferc.gov>. Persons unable to file electronically should submit an original and 14 copies of the protest to the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.

This filing is accessible on-line at <http://www.ferc.gov>, using the "eLibrary" link and is available for review in the Commission's Public Reference Room in Washington, DC. There is an "eSubscription" link on the Web site that enables subscribers to receive e-mail notification when a document is added to a subscribed docket(s). For assistance with any FERC Online service, please e-mail FERCOnlineSupport@ferc.gov, or call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.

Comment Date: 5 p.m. Eastern Time Monday, November 26, 2007.

Kimberly D. Bose,
Secretary.

[FR Doc. E7-23036 Filed 11-26-07; 8:45 am]
BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY**Federal Energy Regulatory
Commission**

[Docket No. EL08-7-000]

**The Borough of Chambersburg, PA;
Notice of Filing**

November 19, 2007.

Take notice that on November 11, 2007, The Borough of Chambersburg, Pennsylvania (Chambersburg), tendered for filing pursuant to Rule 207(a)(5) of the Commission's Rules of Practice and Procedure a petition for approval of Chambersburg's annual revenue requirement for its contribution to the supply of Reactive Power and Voltage Control from Generation Sources Service under Schedule 2 of the PJM Interconnection, L.L.C. open access transmission tariff.

Any person desiring to intervene or to protest this filing must file in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211, 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a notice of intervention or motion to intervene, as appropriate. Such notices, motions, or protests must be filed on or before the comment date. On or before the comment date, it is not necessary to serve motions to intervene or protests on persons other than the Applicant.

The Commission encourages electronic submission of protests and interventions in lieu of paper using the "eFiling" link at <http://www.ferc.gov>. Persons unable to file electronically should submit an original and 14 copies of the protest or intervention to the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.

This filing is accessible on-line at <http://www.ferc.gov>, using the "eLibrary" link and is available for review in the Commission's Public Reference Room in Washington, DC. There is an "eSubscription" link on the Web site that enables subscribers to receive e-mail notification when a document is added to a subscribed docket(s). For assistance with any FERC Online service, please e-mail FERCOnlineSupport@ferc.gov, or call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.

Comment Date: 5 p.m. Eastern Time on November 27, 2007.

Kimberly D. Bose,
Secretary.

[FR Doc. E7-23037 Filed 11-26-07; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY**Federal Energy Regulatory
Commission**

[Docket No. RP08-70-000]

**Discovery Gas Transmission LLC;
Notice of Petition for Approval of
Settlement**

November 20, 2007.

Take notice on November 16, 2007, Discovery Gas Transmission, LLC (Discovery) tendered for filing a "Petition for Approval of Settlement," including a proposed stipulation and settlement agreement (Settlement Agreement) and associated pro forma tariff sheets.

Discovery states that copies of its filing have been served upon all affected customers of Discovery and interested state commissions.

Any person desiring to intervene or to protest this filing must file in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a notice of intervention or motion to intervene, as appropriate. Such notices, motions, or protests must be filed on or before the date as indicated below. Anyone filing an intervention or protest must serve a copy of that document on the Applicant. Anyone filing an intervention or protest on or before the intervention or protest date need not serve motions to intervene or protests on persons other than the Applicant.

The Commission encourages electronic submission of protests and interventions in lieu of paper using the "eFiling" link at <http://www.ferc.gov>. Persons unable to file electronically should submit an original and 14 copies of the protest or intervention to the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.

This filing is accessible on-line at <http://www.ferc.gov>, using the "eLibrary" link and is available for review in the Commission's Public Reference Room in Washington, DC.

There is an "eSubscription" link on the Web site that enables subscribers to receive e-mail notification when a document is added to a subscribed docket(s). For assistance with any FERC Online service, please e-mail FERCOnlineSupport@ferc.gov, or call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.

Comment Date: 5 p.m. Eastern Time, Tuesday, November 27, 2007.

Kimberly D. Bose,

Secretary.

[FR Doc. E7-23065 Filed 11-26-07; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. PR07-12-002]

Enterprise Texas Pipeline LLC; Notice of Compliance Filing

November 19, 2007.

Take notice that on November 13, 2007, Enterprise Texas Pipeline LLC filed a Report of Refunds in compliance with the Commission's letter order issued on September 4, 2007 in Docket Nos. PR07-12-000 and PR07-12-001.

Any person desiring to protest this filing must file in accordance with Rule 211 of the Commission's Rules of Practice and Procedure (18 CFR 385.211). Protests to this filing will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Such protests must be filed on or before the date as indicated below. Anyone filing a protest must serve a copy of that document on all the parties to the proceeding.

The Commission encourages electronic submission of protests in lieu of paper using the "eFiling" link at <http://www.ferc.gov>. Persons unable to file electronically should submit an original and 14 copies of the protest to the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.

This filing is accessible on-line at <http://www.ferc.gov>, using the "eLibrary" link and is available for review in the Commission's Public Reference Room in Washington, DC. There is an "eSubscription" link on the Web site that enables subscribers to receive e-mail notification when a document is added to a subscribed docket(s). For assistance with any FERC Online service, please e-mail FERCOnlineSupport@ferc.gov, or call

(866) 208-3676 (toll free). For TTY, call (202) 502-8659.

Comment Date: 5 p.m. Eastern Time, Monday, November 26, 2007.

Kimberly D. Bose,

Secretary.

[FR Doc. E7-23040 Filed 11-26-07; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project Nos. 349-134 and 2407-121]

Alabama Power Company; Notice of Availability Of Environmental Assessment

November 19, 2007.

An environmental assessment (EA) is available for public review. The EA was prepared for an application filed by Alabama Power Company (licensee) on October 23, 2007, and supplemented on November 14, 2007, requesting Commission approval for a drought-based temporary variance to the Martin Project (FERC No. 349) rule curve and associated temporarily modified minimum flows from the Thurlow development of the Yates and Thurlow Project (FERC No. 2407). The projects are located on the Tallapoosa River in the counties of Coosa, Elmore and Tallapoosa, Alabama.

The EA evaluates the environmental impacts that would result from approving the licensee's temporary variance to the Martin Project rule curve and associated minimum flow modification from the Thurlow Development. The EA finds that approval of the application would not constitute a major federal action significantly affecting the quality of the human environment.

A copy of the EA is available for review in the Commission's Public Reference Room. A copy of the EA may also be viewed on the Commission's Web site at <http://www.ferc.gov> using the "eLibrary" link. Enter the docket number (P-349) in the docket number field to access the document. For assistance, contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at 1-866-208-3676, or for TTY, (202) 502-8659.

Kimberly D. Bose,

Secretary.

[FR Doc. E7-23039 Filed 11-26-07; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP07-444-000]

Jordan Cove Energy Project, L.P.; Notice of Technical Conference

November 19, 2007.

On Wednesday, December 12, 2007, at 9 a.m. (PST), staff of the Office of Energy Projects will convene an engineering design and technical conference regarding the proposed Jordan Cove LNG import terminal. The conference will be held at the Red Lion Hotel in Coos Bay, Oregon. The hotel is located at 1313 N Bayshore Dr. #1, Coos Bay, OR 97420. For hotel details call (541) 267-4141.

In view of the nature of critical energy infrastructure information and security issues to be explored, the cryogenic conference will not be open to the public. Attendance at this conference will be limited to existing parties to the proceeding (anyone who has specifically requested to intervene as a party) and to representatives of interested federal, state, and local agencies. Any person planning to attend the December 12th cryogenic conference *must register* by close of business on Monday, December 10, 2007.

Registrations may be submitted either online at <http://www.ferc.gov/whats-new/registration/cryo-conf-form.asp> or by faxing a copy of the form (found at the referenced online link) to 202-208-0353. All attendees must sign a non-disclosure statement prior to entering the conference. Upon arrival at the hotel, check the reader board in the hotel lobby for venue. For additional information regarding the cryogenic conference, please contact Steven Busch at 202-502-6353.

Kimberly D. Bose,

Secretary.

[FR Doc. E7-23041 Filed 11-26-07; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket Nos. ER07-1372-000, ER07-1372-001]

Midwest Independent Transmission System Operator, Inc.; Notice of Staff Technical Conference

November 19, 2007.

Take notice that on December 6, 2007, a staff technical conference will be held

at the Federal Energy Regulatory Commission to discuss the market power analysis and mitigation measures set forth in the Midwest Independent Transmission System Operator, Inc.'s (Midwest ISO) ancillary services market proposal. This technical conference was established in an Order Establishing Technical Conference in the above-captioned dockets, issued November 19, 2007. It will be held in the Commission Meeting Room at the headquarters of the Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC from 9 a.m.–4 p.m. (EST).

The technical conference will be divided into two sessions. The first session will address market power issues and the second session will address mitigation issues. The format of the conference and sessions will be as follows:

Staff and Midwest ISO Introduction To Conference: 9–9:15.

First Session: Market Power Issues:

Independent Market Monitor (IMM) Presentation Addressing Appendix Questions: 9:15–9:45.

(See attached Appendix to this Notice)

Questions and Issues From Parties: 9:45–11:30.

Staff Follow-up Questions: 11:30–12.

Lunch: 12–1.

Second Session: Mitigation Issues:

IMM Presentation Addressing Appendix Questions: 1–1:30.

Questions and Issues From Parties: 1:30–3:15.

Staff Follow-up Questions: 3:15–3:45.

Next Steps: 3:45–4.

The conference is open for the public to attend. The conference will not be transcribed and telephone participation will not be available.

The Commission will accept written comments on the discussion at this technical conference no later than 5 p.m. Eastern Time on December 20, 2007, and reply comments no later than 5 p.m. Eastern Time on January 7, 2008.

Commission conferences are accessible under section 508 of the Rehabilitation Act of 1973. For accessibility accommodations please send an e-mail to accessibility@ferc.gov or call toll free 1–866–208–3372 (voice) or 202–208–1659 (TTY), or send a FAX to 202–208–2106 with the required accommodations.

For more information about this conference, please contact: John Nail, Office of Energy Market Regulation,

Federal Energy Regulatory Commission, (202) 502–8209, john.nail@ferc.gov.

Kimberly D. Bose,
Secretary.

Appendix

The following questions pertain to aspects of the Midwest ISO proposal that require further clarification. The Midwest ISO is requested to provide materials at the conference addressing these questions and to be prepared to discuss them. The Midwest ISO should provide its full and complete answers to all questions for the record of this proceeding in its filing of comments.

Questions To Be Discussed in the First Session

- Provide a market power analysis for the spring and fall shoulder seasons. Present the results of the new analysis at the technical conference.

- The definition of ancillary services sub-markets:

- Provide the basis for how the sub-markets and reserve zones are defined and explain the differences between the two.

- Is the IMM market power analysis for only illustrative purposes or is it intended to be relied on in this proceeding?

- How will the potential for market power be evaluated as a result of any zonal reconfiguration?

- Either submit separate analyses for spinning and supplemental reserves or provide an analysis demonstrating that the two products are substitutes for each other. Present the results of the analysis at the technical conference.

- Provide historical data, separately for each ancillary services product (regulating reserves, spinning reserves and supplemental reserves), since the start of the Midwest ISO energy markets that indicates: (1) The capacity (in MWs) and number of generator resources that could provide ancillary services; and (2) the actual ancillary services provided, in MW and number of generator resources. Present the results of the analysis at the technical conference.

Questions To Be Discussed in the Second Session

- What is the basis for the IMM's conclusion that there will be sufficient competition to ensure just and reasonable prices in those hours and locations when mitigation thresholds are not triggered?

- Explain how reference levels are determined for suppliers in constrained areas, such as those identified in the IMM analysis. In his testimony, the IMM indicates reference levels are based on competitive offers. Please provide the basis for this assertion and explain whether all offers by suppliers in constrained areas are considered to be offers made under competitive conditions. If not, how does the IMM determine which offers are made under competitive conditions?

- Is a backstop reference price, such as is used in the New York Independent System Operator (NYISO), appropriate for sub-markets with only one or two suppliers? Explain the reasons underlying your response.

- Considering the market power characteristics of the Midwest ISO ancillary services market and its sub-markets, what are the pros and cons of conduct/impact mitigation compared to mitigating offers at a cost-based rate?

- What method and criteria will the IMM use to audit and identify any supplier that withholds power in either the energy or ancillary services markets, including during periods of scarcity pricing?

- The Midwest ISO states that variations of how it intends to mitigate its ancillary services market are being used by existing RTOs/ISOs. Explain the similarities and differences between the Midwest ISO mitigation proposal and the PJM Interconnection (PJM) and California Independent System Operator (CAISO) ancillary services markets mitigation programs.

- The Midwest ISO states that there are no unreasonable barriers to entry that would compromise the competitiveness of the Regulating Reserve market. Prospectively, what will the Midwest ISO do to ensure a lack of barriers to entry and encourage suppliers to bid into the congested submarket areas?

[FR Doc. E7–23038 Filed 11–26–07; 8:45 am]

BILLING CODE 6717–01–P

ENVIRONMENTAL PROTECTION AGENCY

[EPA–HQ–OA–2007–0933; FRL–8499–6]

Agency Information Collection Activities; Proposed Collection; Comment Request; Confidential Financial Disclosure Form for Special Government Employees Serving on Federal Advisory Committees at the U.S. Environmental Protection Agency; EPA ICR No. 2260.02, OMB Control No. 2090–0029

AGENCY: Environmental Protection Agency.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) (44 U.S.C. 3501, *et seq.*), this document announces that EPA is planning to submit a request to renew an existing approved Information Collection Request (ICR) to the Office of Management and Budget (OMB). This ICR is scheduled to expire on 2/29/2008. Before submitting the ICR to OMB for review and approval, EPA is soliciting comments on specific aspects of the proposed information collection as described below.

DATES: Comments must be submitted on or before January 28, 2008.

ADDRESSES: Submit your comments, identified by Docket ID No. EPA–HQ–OA–2007–0933 by one of the following methods:

• *www.regulations.gov*: Follow the on-line instructions for submitting comments.

• *E-mail*: oei.docket@epa.gov.

• *Fax*: 202-566-9744

• *Mail*: OEI Docket, USEPA, Mail

Code: 2822T, 1200 Pennsylvania Ave., NW., Washington, DC 20460. *Hand Delivery*: EPA Docket Center, EPA West Room 3334, 1301 Constitution Ave., NW., Washington, DC 20460. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information.

Instructions: Direct your comments to Docket ID No. EPA-HQ-OA-2007-0933. EPA's policy is that all comments received will be included in the public docket without change and may be made available online at

www.regulations.gov, including any personal information provided, unless the comment includes information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through *www.regulations.gov* or e-mail. The *www.regulations.gov* Web site is an "anonymous access" system, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through *www.regulations.gov* your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD-ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses. For additional information about EPA's public docket visit the EPA Docket Center homepage at <http://www.epa.gov/epahome/dockets.htm>.

FOR FURTHER INFORMATION CONTACT:

Vicki Ellis, Office of Cooperative Environmental Management, Mail Code 1601M, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: 202-564-1203; fax number: 202-564-8129; e-mail address: ellis.vicki@epa.gov.

SUPPLEMENTARY INFORMATION:

How Can I Access the Docket and/or Submit Comments?

EPA has established a public docket for this ICR under Docket ID No. EPA-HQ-OA-2007-0933, which is available for online viewing at *www.regulations.gov*, or in person viewing at the Environmental Information Docket in the EPA Docket Center (EPA/DC), EPA West Room 3334, 1301 Constitution Ave., NW., Washington, DC 20460. The EPA/DC Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Reading Room is 202-566-1744, and the telephone number for the Environmental Information Docket is 202-566-9744.

Use *www.regulations.gov* to obtain a copy of the draft collection of information, submit or view public comments, access the index listing of the contents of the docket, and to access those documents in the public docket that are available electronically. Once in the system, select "search," then key in the docket ID number identified in this document.

What Information Is EPA Particularly Interested In?

Pursuant to section 3506(c)(2)(A) of the PRA, EPA specifically solicits comments and information to enable it to:

(i) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility;

(ii) evaluate the accuracy of the Agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(iii) enhance the quality, utility, and clarity of the information to be collected; and

(iv) minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. In particular, EPA is requesting comments from very small businesses (those that employ less than 25) on examples of specific additional efforts that EPA could make to reduce the paperwork burden for very small businesses affected by this collection.

What Should I Consider When I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible and provide specific examples.
2. Describe any assumptions that you used.
3. Provide copies of any technical information and/or data you used that support your views.
4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.
5. Offer alternative ways to improve the collection activity.
6. Make sure to submit your comments by the deadline identified under **DATES**.
7. To ensure proper receipt by EPA, be sure to identify the docket ID number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and **Federal Register** citation.

What Information Collection Activity or ICR Does This Apply to?

Affected entities: Entities potentially affected by this action are approximately 300 candidates for membership as Special Government Employees (SGEs) on EPA Federal advisory committees. The Form 3110-48 is completed as part of the member selection process and before they are invited to serve as a member of a Federal advisory committee (FAC) at EPA.

Title: Confidential Financial Disclosure Form for Special Government Employees Serving on Federal Advisory Committees at the U.S. Environmental Protection Agency.

ICR numbers: EPA ICR No. 2260.02, OMB Control No. 2090-0029.

ICR status: This ICR is currently scheduled to expire on 02/29/2008. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information, unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations in title 40 of the CFR, after appearing in the **Federal Register** when approved, are listed in 40 CFR part 9, and are displayed either by publication in the **Federal Register** or by other appropriate means, such as on the related collection instrument or form, if applicable. The display of OMB control numbers in certain EPA regulations is consolidated in 40 CFR part 9.

Abstract: The purpose of this information collection request is to assist the United States Environmental

Protection Agency (EPA or the Agency) in selecting Federal advisory committee members who will be appointed as Special Government Employees (SGEs), mostly to EPA's scientific and technical committees. To select SGE members as efficiently and cost effectively as possible, the Agency needs to evaluate potential conflicts of interest before a candidate is hired as an SGE and appointed as a member to a committee by EPA's Administrator or Deputy Administrator.

Agency officials developed the "Confidential Financial Disclosure Form for Special Government Employees Serving on Federal Advisory Committees at the U.S. Environmental Protection Agency," also referred to as Form 3110-48, for a greater inclusion of information to discover any potential conflicts of interest as recommended by the Government Accountability Office.

Burden Statement: The annual public reporting and recordkeeping burden for this collection of information is estimated to average one hour per response. Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements which have subsequently changed; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

The ICR provides a detailed explanation of the Agency's estimate, which is only briefly summarized here:

- *Estimated total number of potential respondents:* 300.
- *Frequency of response:* Annual.
- *Estimated total average number of responses for each respondent:* 1.
- *Estimated total annual burden hours:* 300 hours/1 hour per respondent.
- *Estimated total annual costs:* \$33,000. There are no capital investment or maintenance and operational costs.

Are There Changes in the Estimates From the Last Approval?

The burden estimates have been changed to reflect an expected increase of the number of respondents (from 276 to 300), as well as an increase of

respondents' costs to complete the form, to cover the next 3 years.

What is the Next Step in the Process for This ICR?

EPA will consider the comments received and amend the ICR as appropriate. The final ICR package will then be submitted to OMB for review and approval pursuant to 5 CFR 1320.12. At that time, EPA will issue another **Federal Register** notice pursuant to 5 CFR 1320.5(a)(1)(iv) to announce the submission of the ICR to OMB and the opportunity to submit additional comments to OMB. If you have any questions about this ICR or the approval process, please contact Vicki Ellis, Office of Cooperative Environmental Management, Mail Code 1601M, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: 202-564-1203; fax number: 202-564-8129; e-mail address: ellis.vicki@epa.gov.

Dated: November 20, 2007.

Rafael DeLeon,

Director, Office of Cooperative Environmental Management, Office of the Administrator.

[FR Doc. E7-23052 Filed 11-26-07; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-RCRA-2007-0387; FRL-8499-1]

Agency Information Collection Activities; Submission to OMB for Review and Approval; Comment Request; Hazardous Waste Specific Unit Requirements, and Special Waste Processes and Types (Renewal), EPA ICR Number 1572.07, OMB Control Number 2050-0050

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA)(44 U.S.C. 3501, *et seq.*), this document announces that an Information Collection Request (ICR) has been forwarded to the Office of Management and Budget (OMB) for review and approval. This is a request to renew an existing approved collection. The ICR, which is abstracted below, describes the nature of the information collection and its estimated burden and cost.

DATES: Additional comments may be submitted on or before December 27, 2007.

ADDRESSES: Submit your comments, referencing Docket ID No. EPA-HQ-

RCRA-2007-0387, to (1) EPA, either online using www.regulations.gov (our preferred method), or by e-mail to rcradocket@epa.gov, or by mail to: RCRA Docket (2822T), U.S. Environmental Protection Agency, 1200 Pennsylvania Avenue, NW., Washington, DC 20460; and (2) OMB, by mail to: Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), Attention: Desk Officer for EPA, 725 17th Street, NW., Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT:

Norma Abdul-Malik, Office of Solid Waste (5303P), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: 703-308-8753; fax number: 703-308-8617; e-mail address: abdul-malik.norma@epa.gov.

SUPPLEMENTARY INFORMATION: EPA has submitted the following ICR to OMB for review and approval according to the procedures prescribed in 5 CFR 1320.12. On June 11, 2007 (72 FR 32093), EPA sought comments on this ICR pursuant to 5 CFR 1320.8(d). EPA received no comments. Any additional comments on this ICR should be submitted to EPA and OMB within 30 days of this notice.

EPA has established a public docket for this ICR under Docket ID No. EPA-HQ-RCRA-2007-0387, which is available for online viewing at www.regulations.gov, or in person viewing at the Resource Conservation and Recovery Act (RCRA) Docket in the EPA Docket Center (EPA/DC), EPA West, Room 3334, 1301 Constitution Ave., NW., Washington, DC. The EPA/DC Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Reading Room is (202) 566-1744, and the telephone number for the RCRA Docket is (202) 566-0270.

Use EPA's electronic docket and comment system at www.regulations.gov, to submit or view public comments, access the index listing of the contents of the docket, and to access those documents in the docket that are available electronically. Once in the system, select "docket search," then key in the docket ID number identified above. Please note that EPA's policy is that public comments, whether submitted electronically or in paper, will be made available for public viewing at www.regulations.gov as EPA receives them and without change, unless the comment contains copyrighted material, Confidential Business Information (CBI), or other information whose public disclosure is restricted by statute. For further

information about the electronic docket, go to www.regulations.gov.

Title: Hazardous Waste Specific Unit Requirements, and Special Waste Processes and Types (Renewal).

ICR numbers: EPA ICR No. 1572.07, OMB Control No. 2050-0050.

ICR Status: This ICR is scheduled to expire on November 30, 2007. Under OMB regulations, the Agency may continue to conduct or sponsor the collection of information while this submission is pending at OMB. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information, unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations in title 40 of the CFR, after appearing in the **Federal Register** when approved, are listed in 40 CFR part 9, are displayed either by publication in the **Federal Register** or by other appropriate means, such as on the related collection instrument or form, if applicable. The display of OMB control numbers in certain EPA regulations is consolidated in 40 CFR part 9.

Abstract: This ICR provides a discussion of all of the information collection requirements associated with specific unit standards applicable to owners and operators of facilities that treat, store, or dispose of hazardous wastes as defined by 40 CFR part 261. It includes a detailed description of the data items and respondent activities associated with each requirement and with each hazardous waste management unit at a facility. The specific units and processes included in this ICR are: Tank systems, Surface impoundments, Waste piles, Land treatment, Landfills, Incinerators, Thermal treatment, Chemical, physical, and biological treatment, Miscellaneous (subpart X), Drip pads, Process vents, Equipment leaks, Containment buildings, Recovery/recycling.

With each information collection covered in this ICR, EPA is aiding the goal of complying with its statutory mandate under RCRA to develop standards for hazardous waste treatment, storage, and disposal facilities, to protect human health and the environment. Without the information collection, the agency cannot assure that the facilities are designed and operated properly.

Burden Statement: The annual public reporting and recordkeeping burden for this collection of information is estimated to average as follows:

Unit type	Hours per response
Subpart I: Containers	73
Subpart J: Tank Systems	74
Subpart K: Surface Impoundments	78
Subpart L: Waste Piles	17
Subpart M: Land Treatment	0
Subpart N: Landfills	37
Subpart O: Incinerators	3
Subpart W: Drip Pads	0
Subpart X: Miscellaneous Units	0
Subpart AA: Process Vents	400
Subpart BB: Equipment Leaks	4
Subpart DD: Containment Buildings	27

Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements which have subsequently changed; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

Respondents/Affected Entities: Private sector and State, Local, or Tribal governments.

Estimated Number of Respondents: 3,326.

Frequency of Response: On occasion.

Estimated Total Annual Hour Burden: 626,476.

Estimated Total Annual Cost: \$27,289,816, which includes \$23,349,024 annualized labor and \$3,940,793 annualized capital and O&M costs.

Changes in the Estimates: There is a decrease of 42,098 hours in the total estimated burden currently identified in the OMB Inventory of Approved ICR Burdens. This decrease is due to the decrease in the number of respondents, which is based on more accurate, current data.

Dated: November 19, 2007.

Joseph A. Sierra,

Acting Director, Collection Strategies Division.

[FR Doc. E7-23057 Filed 11-26-07; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OAR-2007-0093; FRL-8499-4]

Agency Information Collection Activities; Submission to OMB for Review and Approval; Comment Request; Clean Air Act Tribal Authority (Renewal); EPA ICR No. 1676.05, OMB Control No. 2060-0306

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) (44 U.S.C. 3501, *et seq.*), this document announces that an Information Collection Request (ICR) has been forwarded to the Office of Management and Budget (OMB) for review and approval. This is a request to renew an existing approved collection. The ICR, which is abstracted below, describes the nature of the information collection and its estimated burden and cost.

DATES: Additional comments may be submitted on or before December 27, 2007.

ADDRESSES: Submit your comments, referencing Docket ID No. EPA-HQ-OAR-2007-0093, to (1) EPA online using www.regulations.gov (our preferred method), by e-mail to a-and-r-Docket@epa.gov or by mail to: EPA Docket Center, Environmental Protection Agency, Clean Air and Radiation Docket and Information Center (Mailcode 2822T), 1200 Pennsylvania Ave., NW., Washington, DC 20460, and (2) OMB by mail to: Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), Attention: Desk Officer for EPA, 725 17th Street, NW., Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Darrel Harmon, Office of Air and Radiation, Immediate Office, (6101A), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: 202-564-7416; fax number: 202-501-0394; e-mail address: harmon.darrel@epa.gov.

SUPPLEMENTARY INFORMATION: EPA has submitted the following ICR to OMB for review and approval according to the procedures prescribed in 5 CFR 1320.12. On July 6, 2007 (72 FR 37002), EPA sought comments on this ICR pursuant to 5 CFR 1320.8(d). EPA received no comments. Any additional comments on this ICR should be submitted to EPA and OMB within 30 days of this notice.

EPA has established a public docket for this ICR under Docket ID No. EPA-HQ-OAR-2007-0093, which is

available for online viewing at www.regulations.gov, or in person viewing at the Air Docket in the EPA Docket Center (EPA/DC), EPA West, Room 3334, 1301 Constitution Ave., NW., Washington, DC. The EPA/DC Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Reading Room is 202-566-1744, and the telephone number for the Air Docket is 202-566-1742.

Use EPA's electronic docket and comment system at www.regulations.gov, to submit or view public comments, access the index listing of the contents of the docket, and to access those documents in the docket that are available electronically. Once in the system, select "docket search," then key in the docket ID number identified above. Please note that EPA's policy is that public comments, whether submitted electronically or in paper, will be made available for public viewing at www.regulations.gov as EPA receives them and without change, unless the comment contains copyrighted material, Confidential Business Information (CBI), or other information whose public disclosure is restricted by statute. For further information about the electronic docket, go to www.regulations.gov.

Title: Clean Air Act Tribal Authority (Renewal).

ICR Numbers: EPA ICR No. 1676.05, OMB Control No. 2060-0306.

ICR Status: This ICR is scheduled to expire on 12/31/2007. Under OMB regulations, the Agency may continue to conduct or sponsor the collection of information while this submission is pending at OMB. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information, unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations in title 40 of the CFR, after appearing in the **Federal Register** when approved, are listed in 40 CFR part 9, are displayed either by publication in the **Federal Register** or by other appropriate means, such as on the related collection instrument or form, if applicable. The display of OMB control numbers in certain EPA regulations is consolidated in 40 CFR part 9.

Abstract: This Information Collection Request (ICR) seeks authorization for tribes to demonstrate their eligibility to be treated in the same manner as states under the Clean Air Act (CAA) and to submit applications to implement a CAA program. This ICR extends the collection period of information for

determining eligibility, which expires December 31, 2007.

The program regulation provides for Indian tribes, if they so choose, to assume responsibility for the development and implementation of CAA programs. The regulation, Indian Tribes: Air Quality Planning and Management (Tribal Authority Rule [TAR] 40 CFR parts 9, 35, 49, 50 and 81), sets forth how tribes may seek authority to implement their own air quality planning and management programs. The rule establishes: (1) Which CAA provisions Indian tribes may seek authority to implement, (2) what requirements the tribes must meet when seeking such authorization, and (3) what Federal financial assistance may be available to help tribes establish and manage their air quality programs. The TAR provides tribes the authority to administer air quality programs over all air resources, including non-Indian owned fee lands, within the exterior boundaries of a reservation and other areas over which the tribe can demonstrate jurisdiction. An Indian tribe that takes responsibility for a CAA program would essentially be treated in the same way as a state would be treated for that program.

Burden Statement: The annual public reporting and recordkeeping burden for this collection of information is estimated to average 40 hours per response. Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements which have subsequently changed; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

Respondents/Affected Entities: Indian tribes.

Estimated Number of Respondents: 27.

Frequency of Response: One-time application.

Estimated Total Annual Hour Burden: 360.

Estimated Total Annual Cost: \$18,838.20, includes \$0 annualized capital or O&M costs.

Changes in the Estimates: There is no change in hours in the total estimated burden currently identified in the OMB Inventory of Approved ICR Burdens.

Dated: November 20, 2007.

Sara Hisel-McCoy,

Director, Collections Strategies Division.

[FR Doc. E7-23073 Filed 11-26-07; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OAR-2007-0176; FRL-8499-3]

Agency Information Collection Activities; Submission to OMB for Review and Approval; Comment Request; Reformulated Gasoline and Conventional Gasoline: Requirements for Refiners, Oxygenated Blenders, and Importers of Gasoline, Requirements for Parties in the Gasoline Distribution Network (Renewal), EPA ICR No. 1591.24, OMB Control No. 2060-0277

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) (44 U.S.C. 3501, *et seq.*), this document announces that an Information Collection Request (ICR) has been forwarded to the Office of Management and Budget (OMB) for review and approval. This is a request to renew an existing approved collection. The ICR, which is abstracted below, describes the nature of the information collection and its estimated burden and cost.

DATES: Additional comments may be submitted on or before December 27, 2007.

ADDRESSES: Submit your comments, referencing Docket ID No. EPA-HQ-OAR-2007-0176, to (1) EPA online using www.regulations.gov (our preferred method), by e-mail to a-and-r-Docket@epa.gov or by mail to: EPA Docket Center, Environmental Protection Agency, EPA Docket Center (EPA/DC), Air and Radiation Docket, 1200 Pennsylvania Ave., NW., Washington, DC 20460, and (2) OMB by mail to: Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), Attention: Desk Officer for EPA, 725 17th Street, NW., Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Jose M. Solar, Office of Transportation and Air Quality, mail code 6406], Environmental Protection Agency, 1200

Pennsylvania Ave., NW., Washington, DC 20460; telephone number: 202-343-9027; fax number: 202-343-2801; e-mail address: Solar.jose@epa.gov.

SUPPLEMENTARY INFORMATION: EPA has submitted the following ICR to OMB for review and approval according to the procedures prescribed in 5 CFR 1320.12. On Tuesday, July 31, 2007 (72 FR 41747), EPA sought comments on this ICR pursuant to 5 CFR 1320.8(d). EPA received no comments. Any additional comments on this ICR should be submitted to EPA and OMB within 30 days of this notice.

EPA has established a public docket for this ICR under Docket ID No. EPA-HQ-OAR-2007-0176, which is available for online viewing at www.regulations.gov, or in person viewing at the Office of Air and Radiation Docket in the EPA Docket Center (EPA/DC), EPA West, Room 3334, 1301 Constitution Ave., NW., Washington, DC. The EPA/DC Public Reading Room is open from 8 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Reading Room is 202-566-1744, and the telephone number for the Office of Air and Radiation Docket is 202-566-1742.

Use EPA's electronic docket and comment system at www.regulations.gov, to submit or view public comments, access the index listing of the contents of the docket, and to access those documents in the docket that are available electronically. Once in the system, select "docket search," then key in the docket ID number identified above. Please note that EPA's policy is that public comments, whether submitted electronically or in paper, will be made available for public viewing at www.regulations.gov as EPA receives them and without change, unless the comment contains copyrighted material, confidential business information (CBI), or other information whose public disclosure is restricted by statute. For further information about the electronic docket, go to www.regulations.gov.

Title: Reformulated Gasoline and Conventional Gasoline: Requirements for Refiners, Oxygenated Blenders, and Importers of Gasoline and Requirements for Parties in the Gasoline Distribution Network (Renewal).

ICR numbers: EPA ICR No. 1591.24, OMB Control No. 2060-0277.

ICR Status: This ICR is scheduled to expire on November 30, 2007. Under OMB regulations, the Agency may continue to conduct or sponsor the collection of information while this submission is pending at OMB. An

Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information, unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations in title 40 of the CFR, after appearing in the **Federal Register** when approved, are listed in 40 CFR part 9, are displayed either by publication in the **Federal Register** or by other appropriate means, such as on the related collection instrument or form, if applicable. The display of OMB control numbers in certain EPA regulations is consolidated in 40 CFR part 9.

Abstract: Gasoline combustion is the major source of air pollution in most urban areas. In the 1990 Amendments to the Clean Air Act (Act), section 211(k), Congress required that gasoline dispensed in nine areas with severe air quality problems, and areas that opt-in, be reformulated to reduce toxic and ozone-forming emissions. (Ozone is also known as smog.) Congress also required that, in the process of producing reformulated gasoline (RFG), dirty components removed in the reformulation process not be "dumped" into the remainder of the country's gasoline, known as conventional gasoline (CG). The Environmental Protection Agency (EPA) promulgated regulations at 40 CFR part 80, Subpart D—Reformulated Gasoline, Subpart E—Anti-Dumping, and Subpart F—Attest Engagements, implementing the statutory requirements, which include standards for RFG (§ 80.41) and CG (§ 80.101). The regulations also contain reporting and recordkeeping requirements for the production, importation, transport and storage of gasoline, in order to demonstrate compliance and facilitate compliance and enforcement.

The program is run by the Transportation and Regional Programs Division, Office of Transportation and Air Quality, Office of Air and Radiation. Enforcement is done by the Air Enforcement Division, Office of Regulatory Enforcement, Office of Enforcement and Compliance Assurance. This program excludes California, which has separate requirements for gasoline.

Burden Statement: The annual public reporting and recordkeeping burden for this collection of information is estimated to average 2.4 hours per response. Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize

technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements which have subsequently changed; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

Respondents/Affected Entities: Refiners, Oxygenate Blenders, and Importers of Gasoline; Requirements for Parties in the Gasoline Distribution Network.

Estimated Number of Respondents: 4,068.

Frequency of Response: Once, Quarterly, Annually, On Occasion.

Estimated Total Annual Hour Burden: 127,041.

Estimated Total Annual Cost: \$35,255,669, which includes \$25,092,389 in annualized capital or O&M costs.

Changes in the Estimates: There is an increase of 5,351 hours in the total estimated burden currently identified in the OMB Inventory of Approved ICR Burdens. This increase is due to new requirements.

Dated: November 20, 2007.

Sara Hisel-McCoy,

Director, Collection Strategies Division.

[FR Doc. E7-23074 Filed 11-26-07; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[ER-FRL-6693-4]

Intent To Prepare an Environmental Impact Statement; Apra Harbor, GU

AGENCY: U.S. Environmental Protection Agency (EPA).

ACTION: Notice of Intent to prepare an Environmental Impact Statement (EIS) to designate a permanent ocean dredged material disposal site (ODMDS) off Apra Harbor, Guam.

Purpose: EPA has the authority to designate ODMDSs under section 102 of the Marine Protection, Research and Sanctuaries Act (MPRSA) of 1972 (33 USC 1401 *et. seq.*). It is EPA's policy to publish an EIS for all ODMDS designations (39 FR 37119, October 1974). Comments on the scope of the EIS evaluation will be accepted for 45 days from the date of this notice.

FOR FURTHER INFORMATION, TO SUBMIT COMMENTS, AND TO BE PLACED ON A

PROJECT MAILING LIST, CONTACT: Mr. Allan Ota, U.S. Environmental Protection Agency, Region 9, Dredging and Sediment Management Team (WTR-8), 75 Hawthorne Street, San Francisco, California 94105-3901, Telephone: (415) 972-3476 or Fax: (415) 947-3537 or E-mail: R9Guam_ODMDS_Scoping@epa.gov.

SUMMARY: EPA intends to conduct public meetings and collect public comments in advance of preparing an EIS to designate a permanent ODMDS off Apra Harbor, Guam. This EIS will be prepared in cooperation with the U.S. Department of the Navy (Navy). An EIS is needed to provide the environmental information necessary to evaluate the potential environmental impacts associated with ODMDS alternatives and select a preferred alternative that meets EPA's site selection criteria at 40 CFR 228.5 and 228.6.

Need for Action: Both the Navy and the Port Authority of Guam (PAG) have plans to expand their operations in Apra Harbor, Guam. Expansion of the Apra Harbor Naval Complex and Commercial Port is proposed to accommodate projected increases in vessel and cargo traffic, newer classes of vessels and dockside maintenance and support operations. Expansion plans would require dredging to increase water depths for the safe navigation of military and commercial vessels. In addition, ongoing navigation activities also require periodic maintenance dredging. It should be noted that designation of an ODMDS does not constitute approval of ocean disposal. The Corps, with EPA concurrence, must first determine on a case by case basis that the proposed dredged material is suitable and that all beneficial reuse or other alternatives to ocean disposal have been considered. However, not all of the anticipated dredged materials can be accommodated in existing landfills and these sediments may not all be suitable for beneficial reuse (e.g., construction fills, wetlands restoration). Therefore, it is necessary to establish a permanent ODMDS to accommodate dredged material generated from anticipated new work and maintenance dredging in Apra Harbor.

Alternatives: The following proposed alternatives have been tentatively defined.

—“No Action”—Do not designate a permanent ODMDS, and continue to manage dredged material generated from new work and maintenance dredging with existing landfill and construction fill options subject to disposal volume limits. Future expansion of the naval and

commercial port facilities will be limited significantly.

—“North Alternative ODMDS”—Designate a permanent ODMDS north of Apra Harbor, Guam, in a study area approximately 12–15 nautical miles offshore and in depths ranging from 6,000 to 6,600 feet.

—“Northwest Alternative ODMDS”—Designate a permanent ODMDS northwest of Apra Harbor, Guam, in a study area approximately 9–15 nautical miles offshore and in depths ranging from 6,600 to 8,400 feet.

The North and Northwest study areas were identified in the Zone of Siting Feasibility (ZSF) Study, Ocean Dredged Material Disposal Site, Apra Harbor, Guam, Final Report (September 2006). This ZSF study excluded areas from further consideration, such as: shipping lanes, navigational hazards, military operating areas (i.e., for submarines), marine protected areas (i.e., marine preserves), and important fishing areas (commercial and recreational).

Scoping: EPA is requesting written comments from federal, state, and local governments, industry, non-governmental organizations, and the general public on the range of alternatives considered, specific environmental issues to be evaluated in the EIS, and the potential impacts of the alternatives for an ODMDS designated offshore of Apra Harbor, Guam. Scoping comments will be accepted for 45 days, beginning with the date of this Notice. A public scoping meeting is scheduled on the following date: December 6, 2007, from 6–8 p.m., at The Weston Resort Guam, 105 Gun Beach Road, Tumon, Guam. The EPA presentation will be followed by public comments and questions.

Estimated Date of Draft EIS Release: March 2009.

Dated: November 9, 2007.

Laura Yoshii,
Deputy Regional Administrator,
Environmental Protection Agency, Region 9.

Dated: November 20, 2007.

Anne Norton-Miller,
Director, OFA.
[FR Doc. E7-23043 Filed 11-26-07; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OAR-2006-0340; FRL-8499-5]

Renewable Fuel Standard Under Section 211(o) of the Clean Air Act as Amended by the Energy Policy Act of 2005

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: Section 211(o) of the Clean Air Act (the Act), as amended by the Energy Policy Act of 2005, requires the Administrator of the Environmental Protection Agency (EPA) to annually determine a renewable fuel standard (RFS) which is applicable to refiners, importers and certain blenders of gasoline, and publish the standard in the **Federal Register** by November 30 of each year. On the basis of this standard, each obligated party determines the volume of renewable fuel that it must ensure is consumed as motor vehicle fuel. This standard is calculated as a percentage, by dividing the amount of renewable fuel that the Act requires to be blended into gasoline for a given year by the amount of gasoline expected to be used during that year, including certain adjustments specified by the Act. In this notice we are publishing an RFS of 4.66% for 2008.

FOR FURTHER INFORMATION CONTACT: Chris McKenna, Environmental Protection Agency, MC 6406J, 1200 Pennsylvania Ave., NW., Washington, DC 20460; *telephone number:* 202-343-9037; *fax number:* 202-343-2801; *e-mail address:* mckenna.chris@epa.gov.

SUPPLEMENTARY INFORMATION:

I. Calculation of the 2008 RFS

A. Background

The preamble to the final rulemaking for the Renewable Fuel Standard Program included a projected RFS for 2008 of 4.63%. 72 FR 23912 (May 1, 2007). In today's notice we are again using the calculational procedure from the final rulemaking to calculate the 2008 RFS. However, since some projections and assumptions used in the final rulemaking to calculate the projected 2008 RFS have changed, today's notice includes a recalculated and final 2008 RFS using the most recently available information. Since the RFS rule established clear legal criteria for deriving the standard (including specification of the formula used in today's notice, and all data sources), EPA is simply applying facts to pre-established law in issuing the final 2008 RFS standard. EPA is advising the

regulated community of the revised standard through a **Federal Register** Notice, without prior notice and comment, in accordance with the Clean Air Act and EPA regulations.

The 2008 RFS is calculated by dividing the volume of renewable fuels required by the Act to be blended into gasoline in 2008, by the volume of gasoline projected by the Energy Information Administration (EIA) to be

consumed in 2008 (including certain adjustments specified by the Act). The following equation from the final RFS Program regulations summarizes all of the variables that must be considered in the calculation.

$$\text{RFStd}_i = 100 \times \frac{\text{RFV}_i - \text{Cell}_i}{(\text{G}_i - \text{R}_i) + (\text{GS}_i - \text{RS}_i) - \text{GE}_i}$$

Where:

RFStd_i = Renewable Fuel Standard in year i, in percent

RFV_i = Annual volume of renewable fuels required by section 211(o)(2)(B) of the Act for year i, in gallons

G_i = Amount of gasoline projected to be used in the 48 contiguous states, in year i, in gallons

R_i = Amount of renewable fuel blended into gasoline that is projected to be consumed in the 48 contiguous states, in year i, in gallons

GS_i = Amount of gasoline projected to be used in Alaska, Hawaii, or a U.S. territory in year i if the state or territory opts-in, in gallons

RS_i = Amount of renewable fuel blended into gasoline that is projected to be consumed in Alaska, Hawaii, or a U.S. territory in year i if the state or territory opts-in, in gallons

GE_i = Amount of gasoline projected to be produced by exempt small refineries and small refiners in year i, in gallons (through 2010 only unless exemption extended under §§ 211(o)(9)(A)(ii) or (B)).

Cell_i = Beginning in 2013, the amount of renewable fuel that is required to come from cellulosic sources, in year i, in gallons (250,000,000 gallons minimum)

B. Data Sources for 2008 RFS Calculation

The following discussion describes the sources of data for the variables in the above equation. For ease of calculation, this discussion regroups the terms (G_i - R_i) + (GS_i - RS_i) in the denominator of the above equation into the terms (G_i + GS_i) - (R_i + RS_i).

Calculation of (RFV_i - Cell_i), Total Amount of Renewable Fuels From Non-cellulosic Sources That Must Be Blended Into Gasoline in 2008

The Act requires 5.4 billion gallons of renewable fuels to be blended into gasoline in 2008. Because there is no cellulosic volume requirement in the Act until 2013, the amount of renewable fuel that the Act requires to be produced from cellulosic sources in 2008 (Cell_i) is zero. Thus the total amount of renewable fuels from non-cellulosic sources that must be blended into gasoline in 2008 is 5.4 billion gallons.

Calculation of (G_i + GS_i), Total Amount of Gasoline Projected To Be Used in the 48 Contiguous States Plus Opt-in States/Territories, in Year i, in Gallons

The Act requires the Administrator of the EIA by October 31 of each year to provide EPA with an estimate of the volumes of gasoline projected to be sold or introduced into commerce in the United States for the following year. During the development of the RFS Program, EIA informed EPA that the projected gasoline consumption in "Table 4a: U.S. Petroleum Supply, Consumption, and Inventories" (formerly "Table 5a. U.S. Petroleum Supply and Demand: Base Case") of the October issue of the monthly *Short-Term Energy Outlook* (STEO) should be used to calculate the RFS for the coming year. The October 2007 STEO projects that an average of 9.42 million barrels/day of gasoline will be consumed in all of the United States in 2008. Multiplying this average consumption rate by 366 days (2008 is a leap year) produces a total consumption of 144.80 billion gallons of gasoline in 2008.

Only one non-contiguous state or territory has petitioned EPA to opt into the RFS Program beginning in 2008. Hawaii petitioned EPA on June 22, 2007 to opt into the RFS program, and EPA approved their request.¹ Thus, Alaska is the only one of the 50 states that is not included in the RFS Program.

In order to calculate gasoline consumption in the 48 contiguous states plus Hawaii, we subtracted Alaska's projected gasoline consumption from the projected nationwide gasoline consumption of 144.80 billion gallons. Alaska's projected gasoline consumption was calculated by multiplying the projected nationwide gasoline consumption in 2008 by the ratio of Alaska's gasoline consumption in 2006 to the total U.S. consumption in 2006, based on Table 48, "Prime Supplier Sales Volumes of Motor Gasoline by Grade Formulation, PAD District, and State" gasoline data from

EIA's *Petroleum Marketing Annual* 2006 (the final rulemaking used data from *Petroleum Marketing Annual* 2005). According to EIA, Prime Supplier data reflects where gasoline is used, rather than where it is produced.² Alaska's projected gasoline consumption in 2008 is 0.30 billion gallons. Subtracting this consumption from the projected nationwide consumption of 144.80 billion gallons in 2008 produces a total consumption of 144.50 billion gallons of gasoline in 2008 in the 48 contiguous states plus Hawaii.

Calculation of (R_i + RS_i), Total Amount of Renewable Fuel Blended Into Gasoline That Is Projected To Be Consumed in the 48 Contiguous States Plus Opt-in States/Territories, in Year i, in Gallons

The projected gasoline consumption in the October 2007 STEO includes renewable fuel that is blended into gasoline. This volume of renewable fuel must be subtracted from the total volume of gasoline in order to calculate the total consumption of non-renewable gasoline. In Table 8 of the October 2007 STEO, EIA estimates that 0.755 quadrillion Btu of ethanol will be used as transportation fuel in all of the United States in 2008. Dividing this energy usage by the high heating value of ethanol (3.539 million Btu/barrel), and multiplying by 42 gallons/barrel produces a total ethanol usage of 8.96 billion gallons nationwide in 2008.

Since Hawaii has opted in, but Alaska has not opted in, to the RFS program for 2008, Alaska's renewable fuels consumption must be subtracted from the nationwide renewable fuels consumption to calculate renewable consumption in the 48 contiguous states plus Hawaii. In Chapter 2 of the Regulatory Impact Analysis for the RFS program rulemaking, EPA estimated that ethanol consumption in Alaska would be negligible prior to 2012. Thus, we project renewable fuels consumption in

¹ Letter to the Honorable Laura Lingle, Governor of Hawaii, from Stephen Johnson of EPA dated July 30, 2007.

² Energy Information Administration, *Petroleum Marketing Annual* 2006, Explanatory Notes, Relationship of Refiner and Prime Supplier Sales Volumes (p. 382).

the 48 contiguous states plus Hawaii to be 8.96 billion gallons in 2008.³

Calculation of GE_i, Amount of Gasoline Projected To Be Produced by Exempt Small Refineries and Small Refiners in Year i, in Gallons⁴

In the final rulemaking, we stated that we would estimate the combined small refinery and small refiner gasoline

volume using a constant percentage of national consumption. Using information from gasoline batch reports submitted to EPA, EIA data and input from the California Air Resources Board regarding California small refiners, we estimated this percentage to be 13.5%.⁵ Multiplying the projected nationwide consumption of gasoline in 2008 (144.80 billion gallons) by 13.5% results in a

total projected production of 19.55 billion gallons of gasoline from small refiners and small refineries in 2008.

Calculation of RFStd_i, Renewable Fuel Standard in Year i, in Percent

Substituting all of the terms calculated above into the equation for RFStd_i results in the following RFS for 2008,

$$\text{RFStd}_i = 100 \times \frac{5.4}{144.50 - 8.96 - 19.55} = 4.66\%$$

Therefore, the RFS for 2008 is 4.66%. This is the standard referenced in 40 CFR 80.1105(b) through (d) and which obligated parties apply to determine their renewable volume obligation under 40 CFR 80.1107.

Dated: November 20, 2007.

Stephen L. Johnson,

Administrator.

[FR Doc. E7-23095 Filed 11-26-07; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[FRL-8499-2]

Proposed Cercla Administrative Agreement for the Recovery of Past and Future Response Costs Incurred at the Vermiculite Intermountain Site in Salt Lake City, UT

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice and request for public comment.

SUMMARY: In accordance with the requirements of Section 122(i) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended ("CERCLA"), 42 U.S.C. 9622(i), notice is hereby given of a proposed administrative settlement under section 122(h)(1) of CERCLA, 42 U.S.C. 9622(h)(1), concerning the Vermiculite Intermountain Site located at and around 333 West 100 South in Salt Lake City, Utah. This settlement, embodied in a CERCLA Section 104, 106(a), 107 and 122(h) Administrative Settlement Agreement and Order On Consent for Removal Action ("Agreement"), is designed to resolve the liability of Settling Respondents for past and future costs at the Site through

covenants under sections 106 and 107 of CERCLA, 42 U.S.C. 9606 and 9607, while requiring long-term institutional controls to protect remedies already in place at the Site. The proposed Agreement requires the Van Cott, Bagley, Cornwall & McCarthy 401(k) Profit Sharing Plan Supplemental Trust to pay a total of \$100,000, La Quinta Properties, Inc., to pay a total of \$441,000 and recognizes PacifiCorp's performance of approximately \$3.5 million in cleanup work at the Site. In addition, PacifiCorp and La Quinta Properties, Inc., will record EPA-approved Environmental Covenants to ensure the continued protection of remedial features at the Site.

Opportunity for Comment: For thirty (30) days following the date of publication of this notice, the Agency will consider all comments received, and may modify or withdraw its consent to the Agreement if comments received indicate that the Agreement is inappropriate, improper, or inadequate. The Agency's response to any comments received will be available for public inspection at EPA Region 8's Central Records Center, 1595 Wynkoop Street, 3rd Floor, in Denver, Colorado.

DATES: Comments must be submitted on or before December 27, 2007.

ADDRESSES: The proposed Agreement and additional background information relating to the settlement are available for public inspection at EPA Region 8's Central Records Center, 1595 Wynkoop Street, 3rd Floor, in Denver, Colorado. Comments and requests for a copy of the proposed Agreement should be addressed to Kelcey Land (8ENF-RC), Technical Enforcement Program, U.S. Environmental Protection Agency, 1595 Wynkoop Street, Denver, Colorado 80202-1129, and should reference the

Settlement for the Vermiculite Intermountain Site, in Salt Lake City, Utah.

FOR FURTHER INFORMATION CONTACT: Kelcey Land, Enforcement Specialist (8ENF-RC), Technical Enforcement Program, U.S. Environmental Protection Agency, 1595 Wynkoop Street, Denver, Colorado 80202-1129, (303) 312-6393.

SUPPLEMENTARY INFORMATION: Regarding the proposed administrative settlement under Sections 104, 106(a), 107 and 122(h)(1) of CERCLA, 42 U.S.C. 9604, 9606(a), 9607 and 9622(h)(1): In accordance with section 122(i) of CERCLA, 42 U.S.C. 9622(i), notice is hereby given that the terms of the Agreement have been agreed to by the Settling Respondents and EPA. By the terms of the proposed Agreement, the Van Cott, Bagley, Cornwall & McCarthy 401(k) Profit Sharing Plan Supplemental Trust will pay a total of \$100,000 and La Quinta Properties will pay \$441,000 to the Hazardous Substance Superfund. These payments, in addition to the cleanup already performed by PacifiCorp, amounts to more than half of the funds expended at the Site.

It is so agreed:

Dated: November 14, 2007.

Eddie A. Sierra,

Acting Assistant Regional Administrator, Office of Enforcement, Compliance, and Environmental Justice, Region 8.

[FR Doc. E7-23064 Filed 11-26-07; 8:45 am]

BILLING CODE 6560-50-P

FEDERAL ELECTION COMMISSION

[Notice 2007-24]

Filing Dates for the Louisiana Special Election in the 1st Congressional District

AGENCY: Federal Election Commission.

³ Table 2.2-21 "2012 Forecasted Ethanol Consumption by State," Regulatory Impact Analysis: Renewable Fuel Standard Program, April 2007.

⁴ Through 2010 only, unless the exemption is extended under 211(o)(9)(A)(ii) or (B) of the Act.

⁵ "Calculation of the Small Refiner/Small Refinery Fraction for the Renewable Fuel Program," memo to the docket from Christine Brunner, ASD, OIAQ, EPA, September 2006.

ACTION: Notice of filing dates for special election.

SUMMARY: Louisiana has scheduled special elections to fill the U.S. House of Representatives seat in the First Congressional District being vacated by Representative Bobby Jindal. There are three possible special elections, but only two may be necessary.

- *Primary Election:* March 8, 2008.
- *Possible Runoff Election:* April 5, 2008. In the event that one candidate does not achieve a majority vote in his/her party's Special Primary Election, the top two vote-getters will participate in a Special Runoff Election.
- *General Election:* May 3, 2008.

However, if a Special Runoff Election is not necessary, the Special General will instead be held on April 5, 2008.

FOR FURTHER INFORMATION CONTACT: Mr. Kevin R. Salley, Information Division, 999 E Street, NW., Washington, DC 20463; Telephone: (202) 694-1100; Toll Free (800) 424-9530.

SUPPLEMENTARY INFORMATION:

Principal Campaign Committees

Special Primary Only

All principal campaign committees of candidates *only* participating in the Louisiana Special Primary shall file a

12-day Pre-Primary Report on February 25, 2008. (See chart below for the closing date for the report.)

Special Primary and General Without Runoff

If only two elections are held, all principal campaign committees of candidates participating in the Louisiana Special Primary and Special General Elections shall file a 12-day Pre-Primary Report on February 25, 2008; a Pre-General Report on March 24, 2008; and a Post-General Report on May 5, 2008. (See chart below for the closing date for each report.)

Special Primary and Runoff Elections

If three elections are held, all principal campaign committees of candidates *only* participating in the Louisiana Special Primary and Special Runoff Elections shall file a 12-day Pre-Primary Report on February 25, 2008; and a Pre-Runoff Report on March 24, 2008. (See chart below for the closing date for each report.)

Special Primary, Runoff and General Elections

All principal campaign committees of candidates participating in the Louisiana Special Primary, Special Runoff and Special General Elections

shall file a 12-day Pre-Primary Report on February 25, 2008; a Pre-Runoff Report on March 24, 2008; a Pre-General Report on April 21, 2008; and a Post-General Report on June 2, 2008. (See chart below for the closing date for each report.)

Unauthorized Committees (PACs and Party Committees)

Political committees that file on a quarterly basis during 2008 are subject to special election reporting if they make previously undisclosed contributions or expenditures in connection with the Louisiana Special Primary, Runoff or General Elections by the close of books for the applicable report(s). Consult the chart below that corresponds to the committee's situation for close of books and filing date information.

Committees filing monthly that support candidates in the Louisiana Special Primary, Special Runoff or Special General Elections should continue to file according to the monthly reporting schedule.

Additional disclosure information in connection with the Louisiana Special Election may be found on the FEC Web site at http://www.fec.gov/info/report_dates.shtml.

CALENDAR OF REPORTING DATES FOR LOUISIANA SPECIAL ELECTIONS

Report	Close of books ¹	Reg./cert. & overnight mailing deadline	Filing deadline
Committees Involved in Only the Special Primary (03/08/08) Must File:			
Pre-Primary	02/17/08	02/22/08	02/25/08
April Quarterly	03/31/08	04/15/08	04/15/08
If Only Two Elections Are Held, Committees Involved in Both the Special Primary (03/08/08) and the Special General (04/05/08) ² Must File:			
Pre-Primary	02/17/08	02/22/08	02/25/08
Pre-General	03/16/08	03/21/08	03/24/08
April Quarterly	03/31/08	04/15/08	04/15/08
Post-General	04/25/08	05/05/08	05/05/08
July Quarterly	06/30/08	07/15/08	07/15/08
If Two Elections Are Held, Committees Involved in <i>Only</i> the Special General (04/05/08) ² Must File:			
Pre-General	03/16/08	03/21/08	03/24/08
April Quarterly	03/31/08	04/15/08	04/15/08
Post-General	04/25/08	05/05/08	05/05/08
July Quarterly	06/30/08	07/15/08	07/15/08
If Three Elections Are Held, Committees Involved in Only the Special Primary (03/08/08) and Special Runoff (04/05/08) Must File:			
Pre-Primary	02/17/08	02/22/08	02/25/08
Pre-Runoff	03/16/08	03/21/08	03/24/08
April Quarterly	03/31/08	04/15/08	04/15/08
Committees Involved in Only the Special Runoff (04/05/08) Must File:			
Pre-Runoff	03/16/08	03/21/08	03/24/08
April Quarterly	03/31/08	04/15/08	04/15/08

CALENDAR OF REPORTING DATES FOR LOUISIANA SPECIAL ELECTIONS—Continued

Report	Close of books ¹	Reg./cert. & overnight mailing deadline	Filing deadline
Committees Involved in the Special Primary (03/08/08), Special Runoff (04/05/08) and the Special General (05/03/08) Must File:			
Pre-Primary	02/17/08	02/22/08	02/25/08
Pre-Runoff	03/16/08	03/21/08	03/24/08
April Quarterly	—Waived—		
Pre-General	04/13/08	04/18/08	04/21/08
Post-General	05/23/08	06/02/08	06/02/08
July Quarterly	06/30/08	07/15/08	07/15/08

If Three Elections Are Held, Committees Involved in *Only* the Special General (05/03/08) Must File:

April Quarterly	—Waived—		
Pre-General	04/13/08	04/18/08	04/21/08
Post-General	05/23/08	06/02/08	06/02/08
July Quarterly	06/30/08	07/15/08	07/15/08

¹ The period begins with the close of books of the last report filed by the committee. If the committee has filed no previous reports, the period begins with the date of the committee's first activity.

² If a Special Runoff Election is necessary, it will be held April 5, 2008, and the Special General Election will be held on May 3, 2008.

Dated: November 21, 2007.

Robert D. Lenhard,

Chairman, Federal Election Commission.

[FR Doc. E7-23075 Filed 11-26-07; 8:45 am]

BILLING CODE 6715-01-P

FEDERAL MARITIME COMMISSION

Notice of Agreements Filed

The Commission hereby gives notice of the filing of the following agreements under the Shipping Act of 1984. Interested parties may submit comments on agreements to the Secretary, Federal Maritime Commission, Washington, DC 20573, within ten days of the date this notice appears in the **Federal Register**. Copies of agreements are available through the Commission's Office of Agreements (202-523-5793 or tradeanalysis@fmc.gov).

Agreement No.: 011602-011.

Title: Grand Alliance Agreement II.

Parties: Hapag-Lloyd AG; Hapag-Lloyd USA LLC; Nippon Yusen Kaisha; Orient Overseas Container Line, Inc.; Orient Overseas Container Line Limited; and Orient Overseas Container Line (Europe) Limited.

Filing Party: Wayne R. Rohde, Esq.; Sher & Blackwell; 1850 M Street, NW.; Suite 900; Washington, DC 20036.

Synopsis: The amendment extends the agreement for ten years. It would also increase the number and size of vessels the parties are authorized to deploy, clarify the parties' use of space, delete the minimum service duration, and reduce the notice required for

membership withdrawals. The parties request expedited review.

Agreement No.: 201048-002.

Title: Restated Lease and Operating Agreement between PRPA and DRS.

Parties: Philadelphia Regional Port Authority and Delaware River Stevedores, Inc.

Filing Party: Paul D. Coleman, Esq.; Hoppel, Mayer & Coleman; 1000 Connecticut Avenue, NW.; Washington, DC 20036.

Synopsis: The amendment changes the insurance language of the lease.

By Order of the Federal Maritime Commission.

Dated: November 21, 2007.

Karen V. Gregory,

Assistant Secretary.

[FR Doc. E7-23060 Filed 11-26-07; 8:45 am]

BILLING CODE 6730-01-P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices

also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than December 10, 2007.

A. Federal Reserve Bank of Dallas (W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Christopher T. Moser, and FFP Investments, Ltd. (its general partner, WAFCO, Inc., and William A. Freed, principal),* all of San Antonio, Texas; to acquire voting shares of Medina Community Bancshares, Inc., and thereby indirectly acquire voting shares of Community National Bank, both of Hondo, Texas.

Dated: November 20, 2007.

Board of Governors of the Federal Reserve System.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E7-22965 Filed 11-26-07; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are

considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than December 14, 2007.

A. Federal Reserve Bank of Kansas City (Todd Offenbacher, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. *Max T. Wake*, Lincoln, Nebraska and Elizabeth B. Wake, San Francisco, California; to acquire voting shares of Jones National Corporation, and thereby acquire shares of The Jones National Bank & Trust Company of Seward, both in Seward, Nebraska.

Board of Governors of the Federal Reserve System, November 21, 2007.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E7-23014 Filed 11-26-07; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be

obtained from the National Information Center Web site at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 20, 2007.

A. Federal Reserve Bank of New York (Anne MacEwen, Bank Applications Officer) 33 Liberty Street, New York, New York 10045-0001:

1. *Investors Bancorp, MHC, and Investors Bancorp, Inc.*, both of Short Hills, New Jersey; to acquire Summit Federal Bankshares, MHC, and thereby indirectly acquire Summit Federal Bankshares, Inc., and Summit Federal Savings Bank, all of Summit, New Jersey, and engage in operating a savings and loan association, pursuant to section 225.28(b)(4)(ii) of Regulation Y.

November 20, 2007.

Board of Governors of the Federal Reserve System.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E7-22964 Filed 11-26-07; 8:45 am]

BILLING CODE 6210-01-S

GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090-0200]

General Services Administration Acquisition Regulation; Information Collection; Sealed Bidding

AGENCY: Office of the Chief Acquisition Officer, GSA.

ACTION: Notice of request for comments regarding a renewal to an existing OMB clearance.

SUMMARY: Under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35), the General Services Administration will be submitting to the Office of Management and Budget (OMB) a request to review and approve an extension of a currently approved information collection requirement regarding sealed bidding. The clearance currently expires on April 30, 2008.

Public comments are particularly invited on: Whether this collection of information is necessary and whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate and based on valid assumptions and methodology; and ways to enhance the quality, utility, and clarity of the information to be collected.

DATES: Submit comments on or before January 28, 2008.

FOR FURTHER INFORMATION CONTACT: Michael Jackson, Procurement Analyst,

Contract Policy Division, at telephone (202) 208-4949 or via e-mail to michaelo.jackson@gsa.gov.

ADDRESSES: Submit comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to the Regulatory Secretariat (VIR), General Services Administration, Room 4035, 1800 F Street, NW., Washington, DC 20405. Please cite OMB Control No. 3090-0200, Sealed Bidding, in all correspondence.

SUPPLEMENTARY INFORMATION:

A. Purpose

The General Services Administration is requesting that the Office of Management and Budget (OMB) review and approve information collection, 3090-0200, Sealed Bidding. The information requested regarding an offeror's monthly production capability is needed to make progressive awards to ensure coverage of stock items.

B. Annual Reporting Burden

Respondents: 10.

Responses Per Respondent: 1.

Hours Per Response: .5.

Total Burden Hours: 5.

OBTAINING COPIES OF

PROPOSALS: Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat (VIR), 1800 F Street, NW., Room 4035, Washington, DC 20405, telephone (202) 208-7312. Please cite OMB Control No. 3090-0200, Sealed Bidding, in all correspondence.

Dated: November 8, 2007.

Al Matera,

Director, Acquisition Policy.

[FR Doc. 07-5837 Filed 11-26-07; 8:45 am]

BILLING CODE 6820-61-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-08-0591]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC/ATSDR Reports Clearance Officer at (404) 639-5960 or send an e-mail to omb@cdc.gov. Send

written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (303) 395-6974. Written comments should be received within 30 days of this notice.

Proposed Project

Select Agent Distribution Activity: Request for Select Agent (OMB Control No. 0920-0591)—Reinstatement without change—National Center for Preparedness, Detection, and Control of Infectious Diseases (NCPDCID), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The Centers for Disease Control and Prevention is requesting a three year extension to continue data collection

under the Select Agent Distribution Activity. The form used for this activity is currently approved under OMB Control No. 0920-0591. The purpose of this data collection is to provide a systematic and consistent mechanism to review requests that come to CDC for Select Agents. The term select agents is used to describe a limited group of viruses, bacteria, rickettsia, and toxins that have the potential for use as agents of bioterrorism, inflicting significant morbidity and mortality on susceptible populations. In light of current terrorism concerns and the significant NIH grant monies directed toward Select Agent research, CDC receives hundreds of requests for Select Agents from researchers. Applicants are required to complete an application form in which

they identify themselves and their institution, provide a Curriculum Vitae or biographical sketch, a summary of their research proposal, and sign indemnification and material transfer agreement statements. A user fee will be collected to recover costs for materials, handling and shipping (except for public health laboratories). The cost to the respondent will vary based on which agent is requested. CDC is updating the name of the National Center on the application form. The National Center for Preparedness, Detection, and Control of Infectious Diseases officially became a National Center in April, 2007. The total estimated annualized burden hours are 450.

ESTIMATED ANNUALIZED BURDEN

Respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Researcher	900	1	30/60

Dated: November 20, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and Prevention.
 [FR Doc. E7-23015 Filed 11-26-07; 8:45 am]
BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Assets for Independence Program Performance Management and Report to Congress Data Collection Form.
OMB No.: New Collection.

Description: The Assets for Independence (AFI) program is a program authorized by Section 403 of the Community Opportunities, Accountability, and Training and Educational Services Act of 1998 (the Act). The Office of Community Services (OCS) within the U.S. Department of Health and Human Services (HHS) administers the AFI program to support innovative asset-building projects that feature Individual Development Accounts (IDAs), financial education, and related services. The Act requires AFI program grantees to submit annual reports to OCS with detailed information about project operations and participant activities. The information collected is issued by OCS for performance management and to prepare mandated Reports to Congress.

The AFI Program Performance Management and Report to Congress Data Collection Form is used to collect eight categories of information, as required by the Act. Examples of the types of information collected include: Project features; the number and characteristics of project participants; amounts of participant savings and matching funds deposited in the IDAs; amounts withdrawn from the IDAs; the withdrawal purposes; and current balances in participant IDAs. The data collection form is an online form available on the OCS asset-building Web site. Grantees provided training and technical assistance in completing the form.

Respondents: Organizations receiving funding to implement an AFI program.

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Assets for Independence Program Performance Management and Report to Congress Data Collection Form	400	1	10	4,000

Estimated Total Annual Burden Hours:

Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington,

DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: infocollection@acf.hhs.gov.

OMB Comment

OMB is required to make a decision concerning the collection of information

between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed

information collection should be sent directly to the following:

Office of Management and Budget, Paperwork Reduction Project, Fax: 202-395-6974, Attn: Desk Officer for the Administration for Children and Families.

Dated: November 19, 2007.

Robert Sargis,

Reports Clearance Officer.

[FR Doc. 07-5831 Filed 11-26-07; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Administrative Subpoena.

OMB No.: 0970-0152.

Description: Section 452(a)(11) of the Social Security Act requires the Secretary of the Department of Health and Human Services to promulgate a form for administrative subpoenas to be used in State child support enforcement programs to collect information for use in the establishment, modification and

enforcement of child support orders in interstate cases. Section 454(9)(E) of the Social Security Act requires each State to cooperate with any other State in using the Federal form for issuance of administrative subpoenas in interstate child support cases. Tribal IV-D agencies are not required to use this form but may choose to do so. OMB approval of this form is expiring in January 2008 and the administration for Children and Families is requesting an extension of this form.

Respondents: State, local or Tribal agencies administering a child support enforcement program under title IV-D of the Social Security Act.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Administrative Subpoena	19,508	1	.5	9,754

Estimated Total Annual Burden Hours: 9,754.

Additional Information

Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: infocollection@acf.hhs.gov.

OMB Comment

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following:

Office of Management and Budget, Paperwork Reduction Project, Fax: 202-395-6974, Attn: Desk Officer for the Administration for Children and Families.

Dated: November 19, 2007.

Robert Sargis,

Reports Clearance Officer.

[FR Doc. 07-5832 Filed 11-26-07; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Voluntary Surveys of Program Partners to Implement Executive Order 12862.

OMB No.: 0980-0266.

Description: Under the provisions of the Federal Paperwork Reduction Act of 1995 (Pub. L. 104-13), the

Administration for Children and Families (ACFR) is requesting clearance for instruments to implement Executive Order 12862 within ACF. The purpose of the data collection is to obtain customer satisfaction information from those entities who are funded to be ACF's partners in the delivery of services to the American public. ACF partners are those entities that receive funding to deliver services or assistance from ACF programs. Examples of partners are State and local governments, Territories, service providers, Indian Tribes and Tribal organizations, grantees, researchers or other intermediaries serving target populations identified by and funded directly or indirectly by ACF. The surveys will obtain information about how well ACF is meeting the needs of its partners in operating the programs.

Respondents: State, local, Tribal governments or Not-for-profit organizations.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
State Governments, Territories and District of Columbia	54	10	1	540
Head Start grantees & Delegates	200	1	0.5	100
Other Discretionary grant Programs	200	10	0.5	1,000
Indian Tribes and Tribal Organizations	25	10	0.5	125

Estimated Total Annual Burden Hours: 1,765.

Additional Information

Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: infocollection@acf.hhs.gov.

OMB Comment

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect of OMB receives it within 30 days of publication. Written comments and recommendations for the proposed

information collection should be sent directly to the following:

Office of Management and Budget, Paperwork Reduction Project, Fax: 202-395-6974, Attn: Desk Officer for the Administration for Children and Families.

Dated: November 20, 2007.

Robert Sargis,

Reports Clearance Officer.

[FR Doc. 07-5835 Filed 11-26-07; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request

Proposed Projects

Title: Required Data Elements for Voluntary Establishment of Paternity Affidavits.

OMB No.: 0970-0171.

Description: Section 466(a)(5)(C)(iv) of the Social Security Act (the Act) requires States to develop and use an affidavit for the voluntary acknowledgement of paternity. The affidavit for the voluntary acknowledgement of paternity must include the minimum requirements specified by the Secretary under section 452(a)(7) of the Act. The affidavits will be used by hospitals, birth record agencies, and other entities participating in the voluntary paternity establishment program.

Respondents: State and Tribal IV-D agencies, hospitals, birth record agencies and other entities participating in the voluntary paternity establishment program.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
None	1,025,521	Variable	.166	170,236

Estimated Total Annual Burden Hours: 170,236.

In compliance with the requirements of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. E-mail address: infocollection@acf.hhs.gov. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d)

ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: November 20, 2007.

Robert Sargis,

Reports Clearance Officer.

[FR Doc. 07-5841 Filed 11-26-07; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request

Proposed Project

Title: Descriptive Study of Early Head Start (DSEHS).

OMB No.: New Collection.

Description: The Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), requests clearance to

recruit Early Head Start (EHS) programs for participation in the Descriptive Study of Early Head Start (DSEHS) and to conduct a pilot test of potential measures.

DSEHS is a longitudinal study of a representative sample of programs and children in three age cohorts, which will collect information about programs, families, and services. When completed, data will be collected on a sample of approximately 2,100 children and families from 60 EHS programs. Data will be collected in four waves: Fall 2008, Fall 2009, Fall 2010, and Fall 2011. Children and families will be followed until children are three years old and exit EHS programs.

Data collected under DSEHS will complement information gathered under the Survey of Early Head Start Programs (SEHSP), OMB Control No. 0992-0008. SEHSP gathered information on the management systems, services, and characteristics of children and families served by EHS programs. To complement this information, DSEHS will gather information on the needs and characteristics of children and families enrolled in EHS programs, including an assessment of children's and families' needs, how programs meet

the needs of children and families in EHS programs, and how children and families in EHS programs progress over time.

The activity proposed under this notice includes only the data collected during the selection and recruitment of programs to participate in DSEHS and a pilot study on the feasibility of proposed measures.

To select and recruit programs, ACF intends to send letters to program directors of selected EHS programs.

Directors will receive a summary of the study goals that will include an overview of the design and data collection, a brochure describing the study, and examples of the consent materials for enrolling study participants. Programs will not be asked to enroll participants during the initial selection and recruitment phase.

Selected programs may also receive a follow-up phone call to answer questions from EHS directors or staff. Program directors will be asked to

provide information on the numbers of families enrolled with children who will be within two months of the target ages at the time of each of the four fall data collections.

ACF intends to conduct a feasibility pilot study at two EHS programs in June 2008. In the pilot study, ACF will test the feasibility of administering various direct child assessment measures and parent interviews.

Respondents: EHS Program Directors, Parents, and Children.

ANNUAL BURDEN ESTIMATES

Instrument	Annual number of respondents	Number of responses per respondent	Average burden hours per response	Estimated annual burden hours
Recruitment materials sent to program sites	60	1	.25	15
Program roster of children in target ages	60	1	.50	30
Pilot Test—Child Assessment	40	1	1.0	40
Pilot Test—Parent Interview	40	1	1.0	40

Estimated Total Annual Burden Hours: 125.

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. E-mail address: infocollection@acf.hhs.gov. All requests should be identified by the title of the information collection.

The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: November 20, 2007.

Brendan C. Kelly,

OPRE Reports Clearance Officer.

[FR Doc. 07-5842 Filed 11-26-07; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2007N-0356]

Behind the Counter Availability of Certain Drugs; Public Meeting; Comment Period Clarification

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; comment period clarification.

SUMMARY: In the **Federal Register** of October 4, 2007 (72 FR 56769), the Food and Drug Administration (FDA) published a notice that announced a public meeting to obtain comments regarding behind-the-counter (BTC) availability of human drugs. An incorrect date was published in that notice. This document clarifies that Docket No. 2007N-0356 will close on December 17, 2007.

ADDRESSES: You may submit comments, identified by Docket No. 2007N-0356, by any of the following methods:
Electronic Submissions

Submit electronic comments in the following ways:

- Federal eRulemaking Portal: <http://www.regulations.gov>. Follow the instructions for submitting comments.
- Agency Web site: <http://www.fda.gov/dockets/ecomments>.

Follow the instructions for submitting comments on the agency Web site.

Written Submissions

Submit written registration and comments in the following ways:

- FAX: 301-827-6870.
- Mail/Hand delivery/Courier (for paper, disk, or CD-ROM submissions): Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

To ensure more timely processing of comments, FDA is no longer accepting comments submitted to the agency by e-mail. FDA encourages you to continue to submit electronic comments by using the Federal eRulemaking Portal or the agency Web site, as described previously, in the **ADDRESSES** portion of this document under *Electronic Submissions*.

Instructions: All submissions received must include the agency name and docket number for this notice. All comments received may be posted without change to <http://www.fda.gov/ohrms/dockets/default.htm>, including any personal information provided. For additional information on submitting comments, see the "Comments" heading of the **SUPPLEMENTARY INFORMATION** section of this document.

Docket: For access to the docket to read background documents or comments received, go to <http://www.fda.gov/ohrms/dockets/default.htm> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Transcripts of the meeting will be available for review at the Division of Dockets Management and on the Internet at <http://www.fda.gov/ohrms/dockets> approximately 30 days after the meeting.

FOR FURTHER INFORMATION CONTACT: Erik Mettler, Office of Policy (HF-11), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3360, FAX: 301-594-6777
Erik.Mettler@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

In the **Federal Register** of October 4, 2007 (72 FR 56769), FDA announced that it would hold a public meeting regarding BTC availability of certain human drugs. BTC availability could make certain drugs available behind the counter at the pharmacy without a prescription and require the intervention of a pharmacist before dispensing.

Some groups have asserted that pharmacist interaction with the consumer could ensure safe and effective use of a drug product that otherwise might require a prescription. Because pharmacists have the training and knowledge to provide certain interventions, they may be able to ensure that patients meet the conditions for use and educate patients on appropriate use of the drug product. These groups have suggested that the availability of certain drugs BTC could increase patient access to medications that may be underutilized, particularly by patients without health insurance, because these medications otherwise would be available only with a prescription.

The **Federal Register** notice stated that interested persons would be able to submit comments to the Division of Dockets Management and that the public docket would remain open for 30 days following the meeting. Our intent was to state that the docket would remain open until December 17, 2007 (30 days after the meeting, which occurred on November 14, 2007). However, the notice also instructed persons to register if they wished to attend or participate in the meeting; the instructions stated that registration would occur on a first-come, first-serve basis, but then mistakenly declared that written or electronic comments would be accepted "until November 28, 2007" (72 FR 56769).

II. Comments

This notice clarifies that we will accept comments to the public docket until December 17, 2007.

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) written or electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Please note that in January 2008, the FDA Web site is expected to transition to the Federal Dockets Management System (FDMS). FDMS is a Government-wide, electronic docket management system. After the transition date, electronic submissions will be accepted by FDA through the FDMS only. When the exact date of the transition to FDMS is known, FDA will publish a **Federal Register** notice announcing that date.

Dated: November 20, 2007.

Randall W. Lutter,

Deputy Commissioner for Policy.

[FR Doc. E7-23026 Filed 11-26-07; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

National Vaccine Injury Compensation Program: Revised Amount of the Average Cost of a Health Insurance Policy

The Health Resources and Services Administration is publishing an updated monetary amount of the average cost of a health insurance policy as it relates to the National Vaccine Injury Compensation Program (VICP).

Pursuant to section 100.2 of the VICP's implementing regulations (42 CFR Part 100), the Secretary announces that the revised average cost of a health insurance policy under the VICP is \$380.04 per month. In accordance with § 100.2, the revised amount was effective upon its delivery by the Secretary to the United States Court of Federal Claims. Such notice was delivered to the Court on October 17, 2007.

Dated: November 19, 2007.

Elizabeth M. Duke,

Administrator.

[FR Doc. E7-23090 Filed 11-26-07; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

HIV/AIDS Bureau; Ryan White HIV/AIDS Program Core Medical Services Waiver Application Requirements

AGENCY: Health Resources and Services Administration (HRSA), HHS.

ACTION: Notice of opportunity to provide written comments.

SUMMARY: This notice solicits comments on the HRSA proposed uniform waiver standards for Ryan White HIV/AIDS Program grantees requesting a core medical services waiver for Fiscal Year 2008 and beyond. Title XXVI of the Public Health Service Act (PHS) Act, as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2006 (Ryan White HIV/AIDS Program) requires that grantees expend 75 percent of Parts A, B, and C funds on core medical services, including antiretroviral drugs, for individuals with HIV/AIDS identified and eligible under the legislation, effective Fiscal Year (FY) 2007. HRSA has issued guidance for obtaining a waiver for FY 2007 and seeks to issue waiver requirements for grantees under Parts A, B, and C of Title XXVI of the PHS Act for FY 2008 and future years.

DATES: Written comments must be received no later than 30 days after date of publication in the **Federal Register**.

ADDRESSES: Written comments should be sent to HRSA, HAB, Division of Science and Policy, *Attention:* LCDR Gettie A. Butts, 5600 Fishers Lane, Room 7-18, Rockville, Maryland 20857.

FOR FURTHER INFORMATION CONTACT:

LCDR Gettie A. Butts, at:

GButts@hrsa.gov or by writing to the address above.

SUPPLEMENTARY INFORMATION: The statute, Title XXVI of the Public Health Service Act (PHS) Act, as amended by the Ryan White HIV/AIDS Treatment Modernization Act of 2006, imposes two criteria for waiver eligibility: (1) No waiting lists for AIDS Drug Assistance Program (ADAP) services; and (2) core medical services availability within the relevant service area to all individuals with HIV/AIDS identified and eligible under Title XXVI of the PHS Act. See sections 2604(c)(2), 2612(b)(2), and 2651(c)(2) of the PHS Act. The Health Resources and Services Administration (HRSA) HIV/AIDS Bureau has issued interim waiver eligibility guidance for FY 2007 to provide immediate implementation of these waiver provisions. The FY 2007 guidance

required that grantees provide written certification stating that all Ryan White-funded core medical services are available in the service area and that no ADAP waiting list exists. Given the need for immediate implementation, the guidance offered an expeditious process by which grantees could apply for a waiver for FY 2007. HRSA now provides notice of its proposal for a more permanent process by which such waivers will be granted beginning in FY 2008 and seeks public comment on its proposal.

Beginning in FY 2008, HRSA will utilize new standards for granting waivers of the core medical services requirement for Ryan White HIV/AIDS Programs. These standards meet the intent of the Ryan White HIV/AIDS Treatment Modernization Act of 2006 to increase access to core medical services, including antiretroviral drugs, for persons with HIV/AIDS and to ensure that grantees receiving waivers demonstrate the availability of such services for individuals with HIV/AIDS identified and eligible under Title XXVI of the PHS Act. The purposes of this notice are: (1) To establish requirements for core medical services waiver eligibility for grantees under Parts A, B, and C of Title XXVI of the PHS Act; and (2) to establish a process for waiver request submission, review and notification. The core medical services waiver uniform standard and waiver request process proposed in this notice will apply to Ryan White HIV/AIDS Program grant awards under Parts A, B, and C of Title XXVI of the PHS Act.

Proposed Uniform Standard for Waiver of Core Medical Services Requirements for Grantees Under Parts A, B, and C

Grantees must submit a waiver request with the annual grant application containing the following certifications and documentation which will be utilized by HRSA in determining whether to grant a waiver. The waiver must be signed by the chief elected official or the fiscally responsible agent, and include:

1. Certification from the Part B state grantee that there are no current or anticipated ADAP services waiting lists in the state for the year in which such waiver request is made. This certification must also specify that there are no waiting lists for a particular core class of antiretroviral therapeutics established by the Secretary, e.g., fusion inhibitors;

2. Certification that all core medical services listed in the statute (Part A section 2604(c)(3), Part B section 2612(b)(3), and Part C section 2651(c)(3)), regardless of whether such

services are funded by the Ryan White HIV/AIDS Program, are available within 30 days for all identified and eligible individuals with HIV/AIDS in the service area;

3. Evidence that a public process was conducted to seek public input on availability of core medical services;

4. Evidence that receipt of the core medical services waiver is consistent with the grantee's Ryan White HIV/AIDS Program application (e.g., "Description of Priority Setting and Resource Allocation Processes" and "Unmet Need Estimate and Assessment" sections of the application for Parts A, "Needs Assessment and Unmet Need" section of the application under Part B, and "Description of the Local HIV Service Delivery System," and "Current and Projected Sources of Funding" sections of the application under Part C).

Types of Documentation and Evidence

Grantees must provide evidence that all of the core medical services listed in the statute, regardless of whether such services are funded by the Ryan White HIV/AIDS Program, are available to all individuals with HIV/AIDS identified and eligible under Title XXVI of the PHS Act in the service area within 30 days. Such documentation may include one or more of the following types of information for the service area for the prior fiscal year: HIV/AIDS care and treatment services inventories including funding sources, HIV/AIDS met and unmet need assessments, HIV/AIDS client/patient service utilization data, planning council core medical services priority setting and funding allocations documents, and letters from Medicaid and other state and local HIV/AIDS entitlement and benefits programs including private insurers. Information provided by grantees must show specific verifiable evidence that all listed core medical services are available and are being utilized to meet the needs of persons with HIV/AIDS who are identified and eligible for Ryan White HIV/AIDS Program services without further infusion of Ryan White HIV/AIDS Program dollars. Such documentation must also describe which specific core medical services are available, from whom, and through what funding source.

Grantees must have evidence of a public process for the dissemination of information and must seek input from affected communities related to the availability of core medical services and the decision to request a waiver. This public process may be the same one utilized for obtaining input on community needs as part of the

comprehensive planning process. In addition, grantees must describe in narrative form the following:

1. Local/state underlying issues that influenced the grantee's decision to request a waiver and how the submitted documentation supports the assertion that such services are available and accessible to all individuals with HIV/AIDS identified and eligible under Title XXVI in the service area.

2. How the approval of a waiver will impact the grantee's ability to address unmet need for HIV/AIDS services and perform outreach to HIV-positive individuals not currently in care.

3. The consistency of the waiver request with the grantee's grant application, including proposed service priorities and funding allocations.

Waiver Review and Notification Process

As indicated, grantees must submit a waiver request with their annual grant application. No waiver requests will be accepted at any other time (other than with the annual grant application). Application guidance documents will be amended to include this requirement. HRSA/HAB will review requests for waiver of the core medical services requirement and will notify grantees of waiver approval no later than the date of issuance of Notice of Grant Award. Core medical services waivers will be effective for a one-year period consistent with the grant award period.

The Paperwork Reduction Act of 1995

This activity is subject to Office of Management and Budget review and approval under the Paperwork Reduction Act of 1995.

Dated: November 16, 2007.

Elizabeth M. Duke,
Administrator.

[FR Doc. E7-22982 Filed 11-26-07; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG-2007-29114]

Delaware River and Bay Oil Spill Advisory Committee; Vacancies

AGENCY: Coast Guard, DHS.

ACTION: Notice of committee establishment and request for applications.

SUMMARY: The Secretary of Homeland Security is establishing the Delaware River and Bay Oil Spill Advisory

Committee (DRBOSAC) under authority of the Coast Guard and Maritime Transportation Act of 2006, Public Law 109–241. Individuals interested in serving on this committee are invited to apply for membership.

DATES: Application forms for membership should reach the Coast Guard on or before January 28, 2008.

ADDRESSES: You may request a copy of the charter for the Delaware River and Bay Oil Spill Advisory Committee or a form to apply for membership by writing to Captain David L. Scott, Designated Federal Officer (DFO) of the Delaware River and Bay Oil Spill Advisory Committee, USCG Sector Delaware Bay, 1 Washington Avenue, Philadelphia, PA 19147. Send your application in written form to the above street address. A copy of this notice, the Committee Charter, and the application form are available in our online docket, USCG–2007–29114, at <http://www.regulations.gov>.

FOR FURTHER INFORMATION CONTACT: Mr. Gerald Conrad, Assistant to the DFO of the Delaware River and Bay Oil Spill Advisory Committee, at 215–271–4824.

SUPPLEMENTARY INFORMATION:

Establishment of the Delaware River and Bay Oil Spill Advisory Committee. The Federal Advisory Committee Act (FACA), 5 U.S.C. App. (Pub. L. 92–463), governs the establishment of committees by Federal agencies. Section 607 of the Coast Guard and Maritime Transportation Act of 2006 (Pub. L. 109–241) requires the Secretary of the Department in which the Coast Guard is operating to establish a Delaware River and Bay Oil Spill Advisory Committee. The Commandant of the Coast Guard will select the people to be on the advisory committee.

The DRBOSAC shall provide advice and recommendations and a ranking of priorities for measures to improve the prevention of, and response to, future oil spills in the Delaware River and Delaware Bay to the Commandant of the Coast Guard, the Governors of the States of New Jersey, Pennsylvania, and Delaware, the Committee on Commerce, Science and Transportation of the Senate, and the Committee on Transportation and Infrastructure of the House of Representatives.

FACA requires advisory committees to meet at least yearly. However, we anticipate that this Committee will meet more frequently. Subcommittees, if established, may also meet between meetings of the parent committee. Most meetings will be held at Coast Guard Sector Delaware Bay in Philadelphia, Pennsylvania, but some meetings may be held at nearby facilities.

Request for Applications

The Committee will be composed of 27 members who are appointed by the Commandant of the Coast Guard and who have a particular expertise, knowledge, and experience regarding the transportation, equipment, and techniques that are used to ship cargo and to navigate vessels in the Delaware River and Delaware Bay, as follows:

(A) Three members who are employed by port authorities that oversee operations on the Delaware River or have been selected to represent these port authorities, of whom—

(i) One member shall be an employee or representative of the Port of Wilmington;

(ii) One member shall be an employee or representative of the South Jersey Port Corporation;

(iii) One member shall be an employee or representative of the Philadelphia Regional Port Authority.

(B) Two members who represent organizations that operate tugs or barges that utilize the port facilities on the Delaware River and Delaware Bay.

(C) Two members who represent shipping companies that transport cargo by vessel from ports on the Delaware River and Delaware Bay, of whom at least one may not be a representative of a shipping company that transports oil or petroleum products.

(D) Two members who represent operators of oil refineries adjacent to the Delaware River and Delaware Bay.

(E) Two members who represent State-licensed pilots who work on the Delaware River and Delaware Bay.

(F) One member who represents labor organizations whose members load and unload cargo at ports on the Delaware River and Delaware Bay.

(G) One member who represents local commercial fishing interests or an aquaculture organization that depends on fisheries and resources of the Delaware River or Delaware Bay.

(H) Three members who represent environmental organizations active with respect to the Delaware River and Delaware Bay, including a watershed advocacy group and a wildlife conservation advocacy group.

(I) One member who represents an organization affiliated with recreational fishing interests in the vicinity of the Delaware River and Delaware Bay.

(J) Two members who are scientists or researchers associated with an academic institution, and who have professional credentials in fields of research relevant to oil spill safety, oil spill response, or wildlife and ecological recovery.

(K) Two members who are municipal or county officials from Delaware.

(L) Two members who are municipal or county officials from New Jersey.

(M) Two members who are municipal or county officials from Pennsylvania.

(N) One member who represents an oil spill response organization located on the lower Delaware River and Delaware Bay.

(O) One member who represents the general public.

The DRBOSAC may also consist of an appropriate number (as determined by the Commandant of the Coast Guard) of non-voting members who represent Federal agencies and the agencies of the states of New Jersey, Pennsylvania, and Delaware with an interest in oil spill prevention in the Delaware River and Delaware Bay.

The members outlined in (A) can be either Special Government Employees (SGEs) or representatives. Members who are merely employed by port authorities shall be designated as SGEs and members that represent these port authorities shall be designated as representative members.

The members in paragraphs (B), (C), (D), (E), (F), (G), (H), (I), (K), (L), (M) and (N) are representative members and not Special Government Employees as defined in section 202(a) of Title 18, United States Code.

The members in paragraphs (J), and (O) serve as Special Government Employees as defined in section 202(a) of Title 18, United States Code.

The terms of office for members initially appointed to the committee shall expire 18 months from the date of their appointment. Applicants may be required to pass an appropriate security background check prior to appointment to the committee.

Applicants should submit their application on Form DOT F 1120.1 to Captain David L. Scott at the address given in the **ADDRESSES** section at the beginning of this Notice. The application form is available from Mr. Gerald Conrad by calling him at 215–271–4824, or by going to the docket for this notice [USCG–2007–29114] at <http://www.regulations.gov>.

While attending meetings or otherwise engaged in Committee business, members will be reimbursed for travel expenses as permitted under applicable Federal travel regulations. However, members will not receive any salary or other compensation for their service on the Committee.

In support of the policy of the U.S.C.G. on gender and ethnic diversity, we encourage qualified women and members of minority groups to apply.

If you are selected as a Special Government Employee (SGE), including a member of the general public, we will

require you to complete a Confidential Financial Disclosure Report (OGE Form 450). We may not release the report or the information in it to the public, except under an order issued by a Federal court or as otherwise provided under the Privacy Act (5 U.S.C. 552a).

Dated: October 13, 2007.

David L. Scott,

Captain, U.S. Coast Guard, Commanding Officer, Sector Delaware Bay.

[FR Doc. E7-23044 Filed 11-26-07; 8:45 am]

BILLING CODE 4910-15-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

[CBP Dec. 07-87]

Re-Approval of Marine Technical Surveyors, Inc., as a Commercial Gauger

AGENCY: U.S. Customs and Border Protection, Department of Homeland Security.

ACTION: Notice of re-approval of Marine Technical Surveyors, Inc., of Donaldsonville, LA, as a commercial gauger.

SUMMARY: Notice is hereby given that, pursuant to 19 CFR 151.13, Marine Technical Surveyors, Inc., 2382 Highway 1 South, Donaldsonville, Louisiana 70346, has been re-approved to gauge petroleum and petroleum products, organic chemicals and vegetable oils for customs purposes, in accordance with the provisions of 19 CFR 151.13. Anyone wishing to employ this entity for gauger services should request and receive written assurances from the entity that it is approved by the U.S. Customs and Border Protection to conduct the specific gauger service requested. Alternatively, inquiries regarding the specific gauger services this entity is approved to perform may be directed to the U.S. Customs and Border Protection by calling (202) 344-1060. The inquiry may also be sent to http://www.cbp.gov/xp/cgov/import/operations_support/labs_scientific_svcs/org_and_operations.xml.

DATES: The re-approval of Marine Technical Surveyors, Inc., as a commercial gauger became effective on January 10, 2006. The next triennial inspection date will be scheduled for January 2009.

FOR FURTHER INFORMATION CONTACT: Eugene J. Bondoc, Ph.D, or Randall Breaux, Laboratories and Scientific Services, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue,

NW., Suite 1500N, Washington, DC 20229, 202-344-1060.

Dated: November 19, 2007.

Ira S. Reese,

Executive Director, Laboratories and Scientific Services.

[FR Doc. E7-23086 Filed 11-26-07; 8:45 am]

BILLING CODE 9111-14-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

[CBP Dec. 07-88]

Re-Approval of Intertek USA, Inc., as a Commercial Gauger

AGENCY: U.S. Customs and Border Protection, Department of Homeland Security.

ACTION: Notice of re-approval of Intertek USA, Inc., of Valdez, AK, as a commercial gauger.

SUMMARY: Notice is hereby given that, pursuant to 19 CFR 151.13, Intertek USA, Inc., 354 Fairbanks Street, Valdez, Alaska 99686, has been re-approved to gauge petroleum and petroleum products, organic chemicals and vegetable oils for customs purposes, in accordance with the provisions of 19 CFR 151.13. Anyone wishing to employ this entity for gauger services should request and receive written assurances from the entity that it is approved by the U.S. Customs and Border Protection to conduct the specific gauger service requested. Alternatively, inquiries regarding the specific gauger services this entity is approved to perform may be directed to the U.S. Customs and Border Protection by calling (202) 344-1060. The inquiry may also be sent to http://www.cbp.gov/xp/cgov/import/operations_support/labs_scientific_svcs/org_and_operations.xml.

DATES: The re-approval of Intertek USA, Inc., as a commercial gauger became effective on September 6, 2006. The next triennial inspection date will be scheduled for September 2009.

FOR FURTHER INFORMATION CONTACT: Eugene J. Bondoc, Ph.D, or Randall Breaux, Laboratories and Scientific Services, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue, NW., Suite 1500N, Washington, DC 20229, 202-344-1060.

Dated: November 19, 2007.

Ira S. Reese,

Executive Director, Laboratories and Scientific Services.

[FR Doc. E7-23087 Filed 11-26-07; 8:45 am]

BILLING CODE 9111-14-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

[CBP Dec. 07-89]

Re-Approval of Intertek USA, Inc., as a Commercial Gauger

AGENCY: U.S. Customs and Border Protection, Department of Homeland Security.

ACTION: Notice of re-approval of Intertek USA, Inc., of Kapolei, Hawaii, as a commercial gauger.

SUMMARY: Notice is hereby given that, pursuant to 19 CFR 151.13, Intertek USA, Inc., 91-110 Hanua Street, #204, Kapolei, Hawaii 96707, has been re-approved to gauge petroleum and petroleum products, organic chemicals and vegetable oils for customs purposes, in accordance with the provisions of 19 CFR 151.13. Anyone wishing to employ this entity for gauger services should request and receive written assurances from the entity that it is approved by the U. S. Customs and Border Protection to conduct the specific gauger service requested. Alternatively, inquiries regarding the specific gauger services this entity is approved to perform may be directed to the U. S. Customs and Border Protection by calling (202) 344-1060. The inquiry may also be sent to http://www.cbp.gov/xp/cgov/import/operations_support/labs_scientific_svcs/org_and_operations.xml.

DATES: The re-approval of Intertek USA, Inc., as a commercial gauger became effective on August 22, 2006. The next triennial inspection date will be scheduled for August 2009.

FOR FURTHER INFORMATION CONTACT: Eugene J. Bondoc, Ph.D, or Randall Breaux, Laboratories and Scientific Services, U. S. Customs and Border Protection, 1300 Pennsylvania Avenue, NW., Suite 1500N, Washington, DC 20229, 202-344-1060.

Dated: November 19, 2007.

Ira S. Reese,

Executive Director, Laboratories and Scientific Services.

[FR Doc. E7-23088 Filed 11-26-07; 8:45 am]

BILLING CODE 9111-14-P

DEPARTMENT OF HOMELAND SECURITY**U.S. Customs and Border Protection**

[CBP Dec. 07–90]

Re-Accreditation and Re-Approval of SGS North America Inc., as a Commercial Gauger and Laboratory

AGENCY: U. S. Customs and Border Protection, Department of Homeland Security.

ACTION: Notice of re-approval of SGS North America Inc., of Wilmington, North Carolina, as a commercial gauger and laboratory.

SUMMARY: Notice is hereby given that, pursuant to 19 CFR 151.12 and 151.13, SGS North America Inc., 111 Cowan Road, Wilmington, North Carolina 28401, has been re-approved to gauge petroleum and petroleum products, organic chemicals and vegetable oils, and to test petroleum and petroleum products for customs purposes, in accordance with the provisions of 19 CFR 151.12 and 151.13. Anyone wishing to employ this entity to conduct laboratory analysis or gauger services should request and receive written assurances from the entity that it is accredited or approved by the U. S. Customs and Border Protection to conduct the specific test or gauger service requested. Alternatively, inquiries regarding the specific tests or gauger services this entity is accredited or approved to perform may be directed to the U. S. Customs and Border Protection by calling (202) 344–1060. The inquiry may also be sent to http://www.cbp.gov/xp/cgov/import/operations_support/labs_scientific_svcs/org_and_operations.xml.

DATES: The re-approval of SGS North America Inc., as a commercial gauger and laboratory became effective on August 31, 2006. The next triennial inspection date will be scheduled for August 2009.

FOR FURTHER INFORMATION CONTACT: Eugene J. Bondoc, Ph.D, or Randall Breaux, Laboratories and Scientific Services, U. S. Customs and Border Protection, 1300 Pennsylvania Avenue, NW., Suite 1500N, Washington, DC 20229, 202–344–1060.

Dated: November 19, 2007.

Ira S. Reese,
Executive Director, Laboratories and Scientific Services.

[FR Doc. E7–23089 Filed 11–26–07; 8:45 am]

BILLING CODE 9111–14–P

DEPARTMENT OF HOMELAND SECURITY**U.S. Customs and Border Protection**

[CBP Dec. 07–91]

Re-Accreditation and Re-Approval of Columbia Inspection, Inc., as a Commercial Gauger and Laboratory

AGENCY: U.S. Customs and Border Protection, Department of Homeland Security.

ACTION: Notice of re-approval of Columbia Inspection, Inc., of Fife, Washington, as a commercial gauger and laboratory.

SUMMARY: Notice is hereby given that, pursuant to 19 CFR 151.12 and 151.13, Columbia Inspection, Inc., 5013 Pacific Highway East, Suite #2, Fife, Washington 98424, has been re-approved to gauge petroleum and petroleum products, organic chemicals and vegetable oils, and to test petroleum and petroleum products for customs purposes, in accordance with the provisions of 19 CFR 151.12 and 151.13. Anyone wishing to employ this entity to conduct laboratory analysis or gauger services should request and receive written assurances from the entity that it is accredited or approved by the U.S. Customs and Border Protection to conduct the specific test or gauger service requested. Alternatively, inquiries regarding the specific tests or gauger services this entity is accredited or approved to perform may be directed to the U. S. Customs and Border Protection by calling (202) 344–1060. The inquiry may also be sent to http://www.cbp.gov/xp/cgov/import/operations_support/labs_scientific_svcs/org_and_operations.xml.

DATES: The re-approval of Columbia Inspection, Inc., as a commercial gauger and laboratory became effective on March 13, 2007. The next triennial inspection date will be scheduled for March 2010.

FOR FURTHER INFORMATION CONTACT: Eugene J. Bondoc, Ph.D, or Randall Breaux, Laboratories and Scientific Services, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue, NW., Suite 1500N, Washington, DC 20229, 202–344–1060.

Dated: November 19, 2007.

Ira S. Reese,
Executive Director, Laboratories and Scientific Services.

[FR Doc. E7–23091 Filed 11–26–07; 8:45 am]

BILLING CODE 9111–14–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–5117–N–100]

Notice of Submission of Proposed Information Collection to OMB; Brownfields Economic Development Initiative (BEDI) Grant Application

AGENCY: Office of the Chief Information Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

This information collection is required to rate and rank applications submitted as part of a funding competition and to ensure funding eligibility of applicant activities. Respondents are units of general local government eligible for Section 108 Loan Guarantees.

DATES: *Comments Due Date:* December 27, 2007.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval Number (2506–0153) and should be sent to: HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; fax: 202–395–6974.

FOR FURTHER INFORMATION CONTACT: Lillian Deitzer, Departmental Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; e-mail Lillian_L_Deitzer@HUD.gov or telephone (202) 402–8048. This is not a toll-free number. Copies of available documents submitted to OMB may be obtained from Ms. Deitzer or from HUD's Web site at <http://www5.hud.gov:63001/po/i/icbts/collectionsearch.cfm>.

SUPPLEMENTARY INFORMATION: This notice informs the public that the Department of Housing and Urban Development has submitted to OMB a request for approval of the information collection described below. This notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have

practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology,

e.g., permitting electronic submission of responses.
 This notice also lists the following information:
Title of Proposal: Brownfields Economic Development Initiative (BEDI) Grant Application.
OMB Approval Number: 2506-0153.
Form Numbers: HUD 40122, HUD 40123, SF 424, SF 424S, SF LLL, HUD 424B, HUD 2880, HUD 96010 and HUD 2993.

Description of the Need for the Information and Its Proposed Use: This information collection is required to rate and rank applications submitted as part of a funding competition and to ensure funding eligibility of applicant activities. Respondents are units of general local government eligible for Section 108 Loan Guarantees.
Frequency of Submission: Quarterly, Annually.

	Number of respondents	x	Annual responses	x	Hours per response	=	Burden hours
Reporting Burden	50		1		40		2,000

Total Estimated Burden Hours: 2,000
Status: Extension of a currently approved collection.

Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended.

Dated: November 19, 2007.

Lillian L. Deitzer,

Departmental Paperwork Reduction Act Officer, Office of the Chief Information Officer.

[FR Doc. E7-23081 Filed 11-26-07; 8:45 am]

BILLING CODE 4210-67-P

DEPARTMENT OF THE INTERIOR

National Park Service

National Register of Historic Places; Notification of Pending Nominations and Related Actions

Nominations for the following properties being considered for listing or related actions in the National Register were received by the National Park Service before November 10, 2007. Pursuant to section 60.13 of 36 CFR part 60 written comments concerning the significance of these properties under the National Register criteria for evaluation may be forwarded by United States Postal Service, to the National Register of Historic Places, National Park Service, 1849 C St., NW., 2280, Washington, DC 20240; by all other carriers, National Register of Historic Places, National Park Service, 1201 Eye St., NW., 8th floor, Washington, DC 20005; or by fax, 202-371-6447. Written

or faxed comments should be submitted by December 12, 2007.

J. Paul Loether,

Chief, National Register of Historic Places/ National Historic Landmarks Program.

Colorado

Las Animas County

East Street School, 206 East St., Trinidad, 07001277

Indiana

Elkhart County

Conn, Charles Gerard, Mansion, 723 Strong Ave., Elkhart, 07001278

Hendricks County

Smith Farm, 2698 S Cty. Rd. 900 E., Plainfield, 07001279

Jackson County

Cavanaugh Bridge, .6 mi S of Cty. Rd. 700 S on Cty. Rd. 550 W over Muscatatuck R., Brownstown, 07001280

Porter County

Wolf, Josephus, House, 453 W 700 N., Valparaiso, 07001281

Pulaski County

Pulaski County Courthouse, 112 E Main St., Winamac, 07001282

Vermillion County

Vermillion County Courthouse, 255 S Main St., Newport, 07001283

Maryland

Baltimore County

Winters Lane Historic District, Winters Ln. between Frederick Rd. & Baltimore National Pike, Catonsville, 07001285

Baltimore Independent City

Grief, L. and Bro., Inc. Manufactory, 901 N Milton Ave., Baltimore (Independent City), 07001284

Carroll County

Keefer—Brubaker Farm, 2719 Roop Rd., Taneytown, 07001286

Kent County

Woodland Hall, 13111 Shallcross Wharf Rd., Kennedyville, 07001287

Prince George's County

Hilltop Manor, 4100-4112, 4200-4214 53rd Ave., 4100-4210 53rd Pl., & 5300-5304 Annapolis Rd., Bladensburg, 07001288

Missouri

Greene County

Gottfried Furniture Company Building, (Springfield MPS) 326 Boonville Ave., Springfield, 07001289

Jackson County

Smith and Sons Manufacturing Company Building, (Railroad Related Historic Commercial and Industrial Resources in Kansas City, Missouri MPS) 1400-26 Guinotte Ave., Kansas City, 07001290

St. Louis Independent City

Central Carondelet Historic District (Boundary Increase), Roughly bounded by Loughborough, Holly Hills, Idaho and S. Broadway, St. Louis (Independent City), 07001291

Wagoner Place Historic District, Bounded by Dick Gregory, Marcus, Dr. M.L. King & N. Market Sts., St. Louis (Independent City), 07001292

Montana

Golden Valley County

Lavina State Bank, 101 Main St., Lavina, 07001293

Ohio

Ashtabula County

Cleveland Hotel, The, 230-238 State St., Conneaut, 07001294

Hamilton County

Bullerdick, Frederick E. and Catherine, House, 4321 Hamilton Ave., Cincinnati, 07001295

Summit County

Rhodes and Watters Apartment Buildings, The, 614, 608, 610, 612 W. Market St. & 16 Rhodes Ave., Akron, 07001296

Rhode Island*Washington County*

Westerly Downtown Historic District
(Boundary Increase), 12 Canal St.,
Westerly, 07001297

Vermont*Franklin County*

Bridge 12, (Metal Truss, Masonry, and
Concrete Bridges in Vermont MPS) Boston
Post Rd., Enosburg, 07001299

Bridge 9,

(Metal Truss, Masonry, and Concrete Bridges
in Vermont MPS) Shawville Rd., Sheldon,
07001298

Lamoille County

Bridge 6, (Metal Truss, Masonry, and
Concrete Bridges in Vermont MPS)
Railroad St., Johnson, 07001300

A request for REMOVAL has been made for
the following resource:

Tennessee*Shelby County*

Douglass High School, 3200 Mount Olive
Rd., Memphis, 98000241

[FR Doc. E7-22989 Filed 11-26-07; 8:45 am]

BILLING CODE 4312-51-P

**INTERNATIONAL TRADE
COMMISSION**

[Investigation No. 731-TA-744 (Second
Review)]

Brake Rotors From China

AGENCY: United States International
Trade Commission.

ACTION: Scheduling of a full five-year
review concerning the antidumping
duty order on brake rotors from China.

SUMMARY: The Commission hereby gives
notice of the scheduling of a full review
pursuant to section 751(c)(5) of the
Tariff Act of 1930 (19 U.S.C. 1675(c)(5))
(the Act) to determine whether
revocation of the antidumping duty
order on brake rotors from China would
be likely to lead to continuation or
recurrence of material injury within a
reasonably foreseeable time. For further
information concerning the conduct of
this review and rules of general
application, consult the Commission's
Rules of Practice and Procedure, part
201, subparts A through E (19 CFR part
201), and part 207, subparts A, D, E, and
F (19 CFR part 207).

EFFECTIVE DATE: November 19, 2007.

FOR FURTHER INFORMATION CONTACT:

Mary Messer (202-205-3193), Office of
Investigations, U.S. International Trade
Commission, 500 E Street, SW.,
Washington, DC 20436. Hearing-impaired
persons can obtain

information on this matter by contacting
the Commission's TDD terminal on 202-
205-1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202-205-2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (<http://www.usitc.gov>). The public record for
this review may be viewed on the
Commission's electronic docket (EDIS)
at <http://edis.usitc.gov>.

SUPPLEMENTARY INFORMATION:

Background. On October 5, 2007, the
Commission determined that responses
to its notice of institution of the subject
five-year review were such that a full
review pursuant to section 751(c)(5) of
the Act should proceed (72 F.R. 59111,
October 18, 2007). A record of the
Commissioners' votes, the
Commission's statement on adequacy,
and any individual Commissioner's
statements are available from the Office
of the Secretary and at the
Commission's Web site.

**Participation in the review and public
service list.** Persons, including
industrial users of the subject
merchandise and, if the merchandise is
sold at the retail level, representative
consumer organizations, wishing to
participate in this review as parties
must file an entry of appearance with
the Secretary to the Commission, as
provided in section 201.11 of the
Commission's rules, by 45 days after
publication of this notice. A party that
filed a notice of appearance following
publication of the Commission's notice
of institution of the review need not file
an additional notice of appearance. The
Secretary will maintain a public service
list containing the names and addresses
of all persons, or their representatives,
who are parties to the review.

**Limited disclosure of business
proprietary information (BPI) under an
administrative protective order (APO)
and BPI service list.** Pursuant to section
207.7(a) of the Commission's rules, the
Secretary will make BPI gathered in this
review available to authorized
applicants under the APO issued in the
review, provided that the application is
made by 45 days after publication of
this notice. Authorized applicants must
represent interested parties, as defined
by 19 U.S.C. 1677(9), who are parties to
the review. A party granted access to
BPI following publication of the
Commission's notice of institution of
the review need not reapply for such
access. A separate service list will be
maintained by the Secretary for those

parties authorized to receive BPI under
the APO.

Staff report. The prehearing staff
report in the review will be placed in
the nonpublic record on March 25,
2008, and a public version will be
issued thereafter, pursuant to section
207.64 of the Commission's rules.

Hearing. The Commission will hold a
hearing in connection with the review
beginning at 9:30 a.m. on April 15,
2008, at the U.S. International Trade
Commission Building. Requests to
appear at the hearing should be filed in
writing with the Secretary to the
Commission on or before April 8, 2008.
A nonparty who has testimony that may
aid the Commission's deliberations may
request permission to present a short
statement at the hearing. All parties and
nonparties desiring to appear at the
hearing and make oral presentations
should attend a prehearing conference
to be held at 9:30 a.m. on April 10,
2008, at the U.S. International Trade
Commission Building. Oral testimony
and written materials to be submitted at
the public hearing are governed by
sections 201.6(b)(2), 201.13(f), 207.24,
and 207.66 of the Commission's rules.
Parties must submit any request to
present a portion of their hearing
testimony *in camera* no later than 7
business days prior to the date of the
hearing.

Written submissions. Each party to the
review may submit a prehearing brief to
the Commission. Prehearing briefs must
conform with the provisions of section
207.65 of the Commission's rules; the
deadline for filing is April 3, 2008.
Parties may also file written testimony
in connection with their presentation at
the hearing, as provided in section
207.24 of the Commission's rules, and
posthearing briefs, which must conform
with the provisions of section 207.67 of
the Commission's rules. The deadline
for filing posthearing briefs is April 24,
2008; witness testimony must be filed
no later than three days before the
hearing. In addition, any person who
has not entered an appearance as a party
to the review may submit a written
statement of information pertinent to
the subject of the review on or before
April 24, 2008. On May 19, 2008, the
Commission will make available to
parties all information on which they
have not had an opportunity to
comment. Parties may submit final
comments on this information on or
before May 21, 2008, but such final
comments must not contain new factual
information and must otherwise comply
with section 207.68 of the Commission's
rules. All written submissions must
conform with the provisions of section
201.8 of the Commission's rules; any

submissions that contain BPI must also conform with the requirements of sections 201.6, 207.3, and 207.7 of the Commission's rules. The Commission's rules do not authorize filing of submissions with the Secretary by facsimile or electronic means, except to the extent permitted by section 201.8 of the Commission's rules, as amended, 67 FR 68036 (November 8, 2002). Even where electronic filing of a document is permitted, certain documents must also be filed in paper form, as specified in II (C) of the Commission's Handbook on Electronic Filing Procedures, 67 FR 68168, 68173 (November 8, 2002).

Additional written submissions to the Commission, including requests pursuant to section 201.12 of the Commission's rules, shall not be accepted unless good cause is shown for accepting such submissions, or unless the submission is pursuant to a specific request by a Commissioner or Commission staff.

In accordance with sections 201.16(c) and 207.3 of the Commission's rules, each document filed by a party to the review must be served on all other parties to the review (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Authority: This review is being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.62 of the Commission's rules.

Issued: November 20, 2007.

By order of the Commission.

Marilyn R. Abbott,

Secretary to the Commission.

[FR Doc. E7-22975 Filed 11-26-07; 8:45 am]

BILLING CODE 7020-02-P

INTERNATIONAL TRADE COMMISSION

[USITC SE-07-026]

Government in the Sunshine Act Meeting Notice

Agency Holding the Meeting: United States International Trade Commission.

Time and Date: November 29, 2007 at 11 a.m.

Place: Room 101, 500 E Street SW., Washington, DC 20436, Telephone: (202) 205-2000.

Status: Open to the public.

Matters To Be Considered

1. *Agenda for future meetings:* None.
2. Minutes.
3. Ratification List.
4. *Inv. No. 731-TA-909 (Review)(Low Enriched Uranium from France)—*

briefing and vote. (The Commission is currently scheduled to transmit its determination and Commissioners' opinions to the Secretary of Commerce on or before December 13, 2007.)

5. *Outstanding action jackets:* None.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission.

Issued: November 21, 2007.

William R. Bishop,

Hearings and Meetings Coordinator.

[FR Doc. E7-23008 Filed 11-26-07; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Antitrust Division

United States v. Multiple Listing Service Of Hilton Head Island, Inc.; Proposed Final Judgment and Competitive Impact Statement

Notice is hereby given pursuant to the Antitrust Procedures and Penalties Act, 15 U.S.C. 16(b)-(h), that a proposed Final Judgment, Stipulation and Competitive Impact Statement have been filed with the United States District Court for the District of South Carolina in *United States of America v. Multiple Listing Service of Hilton Head Island, Inc.*, Civil Action No. 07-3435. On October 17, 2007, the United States filed a Complaint alleging that the Multiple Listing Service of Hilton Head Island, Inc. violated section 1 of the Sherman Act, 15 U.S.C. 1, by adopting and enforcing rules that restrict access to the Multiple Listing Service database and limit members' business behavior. The proposed Final Judgment, filed at the same time as the Complaint, requires the group to change its membership rules so that low-priced and innovative real estate brokers can compete in the Hilton Head area.

Copies of the Complaint, proposed Final Judgment and Competitive Impact Statement are available for inspection at the Department of Justice, Antitrust Division, Antitrust Documents Group, 325 7th Street, NW., Room 215, Washington, DC 20530 (telephone: 202-514-2481), on the Department of Justice's Web site at <http://www.usdoj.gov/atr>. and at the Office of the Clerk of the United States District Court for the District of South Carolina. Copies of these materials may be obtained from the Antitrust Division upon request and payment of the copying fee set by Department of Justice regulations.

Public comment is invited within 60 days of the date of this notice. Such comments, and responses thereto, will be published in the **Federal Register** and filed with the Court. Comments should be addressed to John R. Read, Chief, Litigation III Section, Antitrust Division, U.S. Department of Justice, 325 7th Street, NW., Suite 300, Washington, DC 20530, (202) 307-0468.

J. Robert Kramer II,

Director of Operations Antitrust Division.

United States District Court for the District of South Carolina Beaufort Division

United States of America, Department of Justice, Antitrust Division, 325 7th Street, NW., Suite 300, Washington, DC 20530, Plaintiff, v. Multiple Listing Service of Hilton Head Island, Inc., 18 Bow Circle, Hilton Head Island, SC 29928, Defendant

Civil Action No.9 :07-CV-3435-SB

Filed: 10/16/07

Complaint for Equitable Relief for Violation of 15 U.S.C. 1 Sherman Antitrust Act

Complaint

The United States of America, by its attorneys acting under the direction of the acting Attorney General, brings this civil antitrust action against Defendant Multiple Listing Service of Hilton Head Island, Inc. ("Hilton Head MLS") to obtain equitable and other relief for violation of Section 1 of the Sherman Act, 15 U.S.C. 1, as amended.

Introduction

1. The United States brings this action to enjoin the Defendant from enforcing certain of its rules that unreasonably restrain competition among real estate brokers in the Hilton Head, South Carolina area Defendant is a multiple listing service, which is controlled by its members who are real estate brokers competing to sell brokerage services to consumers in the Hilton Head area.

2. Defendant provides a variety of services to its members, including the maintenance of a database of past and current listings of properties for sale in the Hilton Head area. Access to the database is critical to being a successful broker. Therefore, brokers seeking to provide brokerage services in the Hilton Head area need to be members of the Hilton Head MLS.

3. By its rules, Defendant denies membership to brokers who would likely compete aggressively on price or would introduce Internet-based brokerage into the market, and imposes unreasonable membership costs on publicly-owned brokerage companies.

Defendant's rules also stabilize prices by forcing member brokers to provide a certain set of brokerage services, whether or not the consumer desires to purchase those services.

4. Additionally, Defendant has authorized its Board of Trustees to adopt rules that would regulate commissions and impose discriminatory requirements on Internet-based brokers. The mere prospect that the Board might adopt such rules likely inhibits price and service competition. Their actual adoption would stabilize prices and competitively disadvantage Internet-based brokers.

5. By adopting and enforcing rules that restrict access to its database and limit members' business behavior, Defendant has restrained competition, reduced consumers' choices, and stabilized prices on Hilton Head Island.

Defendant And Its Members

6. Defendant Hilton Head MLS is organized as a not-for-profit corporation under the laws of South Carolina with its principal place of business on Hilton Head Island, Beaufort County, South Carolina.

7. Hilton Head MLS is a joint venture of over one hundred competing licensed brokers and other licensed real estate professionals doing business in the Hilton Head area. Hilton Head MLS serves Hilton Head Island, South Carolina. Although Hilton Head MLS also serves several surrounding counties as well as Hilton Head Island, close to 85 percent of the properties listed—as measured by dollar volume of closed transactions—in the Hilton Head MLS are located on Hilton Head Island, which no other MLS serves.

8. Whenever this complaint refers to any act, deed, or transaction of the Hilton Head MLS, it means the Hilton Head MLS is engaged in the act, deed, or transaction by or through its members, officers, directors, trustees, employees, or other representatives while they were actively engaged in the management, direction, control, or transaction of its business or affairs.

9. Various others, not named as Defendants, have participated as conspirators with Hilton Head MLS in the violations alleged in this complaint, and have performed acts and made statements to further the conspiracy.

Jurisdiction and Venue

10. This Court has subject matter jurisdiction over this action under Section 4 of the Sherman Act, as amended, 15 U.S.C. 4, and 28 U.S.C. 1331, 1337(a), and 1345.

11. Because Hilton Head MLS maintains its principal place of business

on Hilton Head Island, South Carolina and transacts business and is found within this District, venue is proper in this District under 15 U.S.C. 22 and 28 U.S.C. 1391(b).

Trade and Commerce

12. Broker-members of the Hilton Head MLS provided residential real estate brokerage services to in-state and out-of-state clients seeking to buy or sell property in the Hilton Head area. In 2005, those brokers facilitated the exchange of property worth over \$2.5 billion, and they collected fees of approximately \$170 million for their services. Interstate mortgage financing is affected by this exchange of property.

13. The Hilton Head MLS's activities and the violations alleged in this Complaint affect brokers, home buyers, and home sellers located throughout the United States. The Hilton Head MLS's real estate activities are in the flow of, and have a substantial effect on, interstate commerce.

Concerted Action

14. The rules of the Hilton Head MLS are the product of agreements or concerted action among brokers who compete in the Hilton Head area. The broker-members of the Hilton Head MLS, as a group and through the Board they elect and the staff they indirectly employ, maintain and enforce MLS rules affecting a broker's participation in the MLS.

Relevant Markets

15. The provision of real estate brokerage services to sellers of residential real property and the provision of real estate brokerage services to buyers of residential real property are relevant service markets within the meaning of the antitrust laws. In the event of a small but significant increase in the price of brokerage services, the number of buyers and sellers that would switch to another way of selling or buying a home would not be sufficient to make such a price increase unprofitable.

16. The real estate brokerage business is local in nature. Most sellers prefer to work with a broker who is familiar with local market conditions. Likewise, most buyers seek to purchase property in a particular city, community, or neighborhood, and typically prefer to work with a broker who has knowledge of the area in which they have an interest. Both home buyers and home sellers desire a residential real estate broker who is a member of the MLS that serves the area in which they are purchasing or selling a home. Even though the Hilton Head MLS's service

area encompasses neighboring counties as well as Hilton Head Island, nearly 85 percent of the properties listed—as measured by dollar volume of closed transactions—in the database are located on Hilton Head Island. In the event of a small but significant increase in the price of brokerage services relating to properties located on Hilton Head Island, the number of buyers and sellers who would switch to brokerage services relating to properties located elsewhere would not be sufficient to make such a price increase unprofitable. Therefore, for purposes of this complaint, Hilton Head Island constitutes the relevant geographic market, within the meaning of the antitrust laws.

Background Of The Offense

Industry Background and MLS Market Power

17. Most prospective home sellers and buyers engage the services of a broker to purchase and sell homes. Real estate brokers formed the Hilton Head MLS to facilitate the provision of real estate brokerage services to such buyers and sellers.

18. The Hilton Head MLS pools and disseminates information on almost every property available for sale on Hilton Head Island. It combines its members' property listings information into an electronic database and makes this data available to all brokers who are members of the MLS. By listing information on a home in the MLS, a broker can market it to a large number of potential buyers. A broker representing a buyer likewise can search the MLS to provide a home buyer with information about nearly all the listed properties in the area that match the buyer's housing needs.

19. Members of the Hilton Head MLS utilize the database as a clearinghouse to, among other things: communicate the listings information of the properties that they have for sale to other members; offer to compensate other members as cooperating brokers if they locate purchasers for those listings; locate properties for prospective purchasers; distribute listings to other members for advertisement purposes; and compile and distribute market statistics.

20. The Hilton Head MLS also maintains records of sold homes. These "sold data" records are very important for brokers working with sellers to set an optimum sales price. Brokers representing a buyer likewise use the sold data to help buyers determine what price to offer for a home.

21. Access to the database provided by the Hilton Head MLS is critical for

brokers who wish to serve buyers or sellers successfully on Hilton Head Island. By virtue of marketwide participation and control over a critically important input, the Hilton Head MLS has market power.

Growth of Alternative Business Models

22. The prices consumers paid to brokers for the brokerage services associated with a typical home sales transaction have increased substantially since 2003 on Hilton Head Island and in many other parts of the country. This is because brokers who adhere to traditional methods of doing business typically charge a fee calculated as a percentage of the sales price of the home, and that percentage has tended to be relatively inflexible as housing prices on Hilton Head Island and in many other parts of the country have increased dramatically. As a result of these higher prices, brokers offering competitively significant alternatives to traditional methods have emerged in other areas of the country.

23. *Technology-Savvy Brokers.* Some brokers in other parts of the United States use technology to automate certain tasks and to communicate more efficiently with consumers. For example, technology enables brokers to contact, communicate with, and service consumers remotely or in-person without the need for a retail office location that consumers can visit. Such technology-savvy brokers can reduce brokerage costs by operating fewer or no physical offices, and may pass cost savings on to consumers through reduced brokerage fees.

24. *Fee-for-Service Brokers.* Other brokers around the country now contract with buyers and sellers to provide a subset of services for a flat fee rather than for a percentage of the home sale price. Fee-for-service brokers provide certain enumerated services such as marketing the house or attending closings, while the buyer or seller takes responsibility for other services associated with brokerages such as making offers and counteroffers or conducting open houses on their own. Through fee-for-service packages, buyers and sellers can save money by purchasing only the services that they wish for their broker to provide.

25. *Price Discounters and Publicly-owned Brokerages.* Brokers in other areas of the country have attracted customers by offering full-service, reduced commission brokerage services. Additionally, brokers in other areas of the country have sought competitive advantage by creating nationwide firms. These firms raise capital through public ownership, invest in nationwide brands

and provide brokerage services to consumers in multiple markets.

26. These types of brokerage models have not emerged on Hilton Head Island due to Defendant's rules. As a result, the prices that consumers pay for brokerage services are higher on Hilton Head Island than in other areas of the country.

Restraints on Competition

27. Defendant's rules and practices have harmed competition in a variety of ways. As a result of Defendant's rules, consumers of residential real estate brokerage services on Hilton Head Island have fewer choices among types of brokers and pay higher fees for those services than consumers in other areas of the country. Defendant's rules and practices are not reasonably necessary to achieve the procompetitive benefits of the MLS. Instead, the rules at issue here unreasonably: (1) Raise entry barriers for potential competitors by imposing burdensome prerequisites for membership; (2) provide a means of identifying potentially aggressive competitors so they can be excluded from membership; (3) stabilize the price of brokerage services through the prospect of price controls; (4) deter the emergence of Internet-based brokerages; (5) stabilize the price of, and reduce consumer options for, brokerage services by dictating the services that all brokers must provide; and (6) discourage entry of potential competitors who raise funds through public ownership.

28. Defendant's rules achieve these adverse effects by requiring that broker-members: (1) Maintain a physical office within the Hilton Head MLS service area; (2) reside within the area served by the Hilton Head MLS; (3) operate their offices during hours deemed reasonable by the Hilton Head MLS; and (4) hold a South Carolina real estate license as their primary license. (Bylaw Article II, Section II; Bylaw Article VII; & Rule II.) These rules allow Defendant to deny membership to brokers who operate business models that would increase competition. For example, these rules enable Defendant to exclude technology-savvy brokers who serve their clients without a physical office and who can pass along the cost savings to consumers through reduced commission rates. These rules also deprive consumers of the benefits of competition from brokers who work part-time or who are licensed under reciprocity provisions of South Carolina law.

29. Defendant's rules have enabled it to identify applicants who could be aggressive competitors and deny their application for membership. Broker-

applicants are required to disclose their business history and prior employment, undergo a credit check, and obtain letters of recommendation from three current broker-members, *i.e.*, those with whom the applicant would compete. (Bylaw Article VII, Section IV; Bylaw Article VII, Section IV(a); Rule II.A.2.) These rules have allowed unreasonable denials of membership and thus deprived consumers of the benefits of competition.

30. Defendant has authorized its Board of Trustees to adopt mandatory guidelines that would regulate the commission that listing brokers offer to selling brokers in exchange for their cooperation on the home sale. (Bylaw Article XI, Section I.) The mere prospect that the Board might adopt such controls likely inhibits price competition. Their actual adoption would directly fix and stabilize prices.

31. Defendant has a rule that requires its members to provide certain services to all brokerage customers, whether or not desired by the customer. (Bylaw Article X; MLS Listing Agreement.) Embodied in the terms of Defendant's mandatory form listing agreement, this rule prevents current and prospective members from operating a fee-for-service business model. This rule decreases competition and harms consumers because it insulates Defendant's members from the competitive pressures posed by brokers who would offer additional pricing and service choices to their customers.

32. Defendant has authorized its Board of Trustees to impose discriminatory requirements on Internet-based real estate brokers. (Bylaw Article II, Section II.) The mere prospect that the Board might adopt such controls likely deters Hilton Head brokers from developing that business model and thereby inhibits such service competition. Such requirements, if implemented, would competitively disadvantage Internet-based brokers and discourage them from joining the MLS and competing on Hilton Head Island, thereby limiting consumer choice.

33. Defendant has a "change in ownership" rule that requires publicly-held brokerages to make a significant payment to the Defendant every time a share of their stock changes hands. (Bylaw Article VII, Section X; Rules II.A.3; II.B & II.E.) This rule competitively disadvantages publicly-owned companies and discourages them from joining the MLS and competing on Hilton Head Island, thereby limiting consumer choice.

34. Taken together, Defendant's rules discourage competition on price and service, and inhibit competitive actions

that would alter the status quo. As a result of Defendant's anticompetitive rules, consumers of brokerage services on Hilton Head Island have fewer choices of service options and pay higher prices for real estate brokerage services than do consumers in other parts of the country.

Violations Alleged

35. Defendant's above-referenced rules and practices constitute a contract, combination, or conspiracy by competitors with market power that unreasonably restrains competition on Hilton Head Island in violation of section I of the Sherman Act, 15 U.S.C. 1. Defendant's rules and practices are not reasonably necessary to carry out the procompetitive purposes of a multiple listing service.

36. The aforesaid contract, combination, or conspiracy has had and will continue to have unreasonable anticompetitive effects in the relevant market, including:

- a. stabilizing and raising prices for real estate brokerage services;
- b. reducing competition on price and quality for real estate brokerage services;
- c. impeding innovation in the provision of real estate brokerage services;
- d. preventing consumers from choosing fee-for-service brokerage models; and
- e. creating barriers to entry into the provision of real estate brokerage services.

Request for Relief

Wherefore, the United States prays that final judgment be entered against Defendant declaring, ordering, and adjudging:

- a. That the aforesaid contract, combination, or conspiracy unreasonably restrains trade and is illegal under Section 1 of the Sherman Act, 15 U.S.C. 1;
- b. That the Defendant, its officers, directors, agents, employees, successors, and assigns and all other persons acting or claiming to act on their behalf, be permanently enjoined from engaging in, carrying out, renewing or attempting to engage in, carry out or renew the combination and conspiracy alleged herein, or any other combination or conspiracy having a similar purpose or effect in violation of section 1 of the Sherman Act, 15 U.S.C. 1; and
- c. That the Court grant such other relief as the United States may request and the Court deems just and proper.

Dated: October 16, 2007.

For Plaintiff United States of America.
Thomas O. Barnett,

Assistant Attorney General.

David L. Meyer,

Deputy Assistant Attorney General.

J. Robert Kramer II,
Director of Operations.

John Read,
Chief, Litigation III Section.

Nina Hale,
Assistant Chief, Litigation III Section.

Lisa A. Scanlon, Owen M. Kendler,
Christopher M. Ries,
*Attorneys for the United States of America,
U.S. Department of Justice, Antitrust
Division, 325 7th Street, N.W., Suite 300,
Washington, DC 20530, Telephone: (202)
616-5954, Facsimile: (202) 514-7308.*

Respectfully submitted,

Reginald I. Lloyd,
United States Attorney.

By:

Barbara M. Bowens (I.D. 4004),
*Assistant United States Attorney, 1441 Main
Street, Suit 500, Columbia, South Carolina
29201.*

United States District Court for the District of South Carolina;

*United States of America, Plaintiff, v.
Multiple Listing Service of Hilton Head
Island, Inc., Defendant*

Proposed Final Judgment

Whereas, Plaintiff, United States of America, filed its Complaint on October 16, 2007, and Plaintiff and Defendant, Multiple Listing Service of Hilton Head Island, Inc., by their respective attorneys, have consented to the entry of this Final Judgment (the "Final Judgment") without trial or adjudication of any issue of fact or law, and this Final Judgment shall not be evidence against or an admission by any party regarding any issue of fact or law;

And Whereas, Defendant is a multiple listing service among competing real estate brokerages, organized as a not-for-profit corporation under the laws of South Carolina, and maintains its principal place of business in Hilton Head Island, South Carolina;

And Whereas, Defendant agrees to be bound by the provisions of this Final Judgment pending its approval by the Court;

And Whereas, Defendant agrees to take certain actions for the purpose of remedying the loss of competition alleged in the Complaint;

And Whereas, Defendant has represented to the United States that the actions required below can and will be made and that Defendant will later raise no claim of hardship or difficulty as grounds for asking the Court to modify any of the provisions contained below;

Now Therefore, before any testimony is taken, without trial or adjudication of any issue of fact or law, and upon

consent of the parties, it is *Ordered, adjudged, and decreed:*

I. Jurisdiction

This Court has jurisdiction over the subject matter of and each of the parties to this action. The Complaint states a claim upon which relief may be granted against Defendant under section 1 of the Sherman Act, as amended, 15 U.S.C. 1.

II. Definitions

As used in this Final Judgment:

A "Defendant" means the Multiple Listing Service of Hilton Head Island, Inc., its successors and assigns, and its members, officers, managers, committees, and employees.

B. "Affiliate Member" means any member of the Defendant that is engaged in banking, mortgage lending, mortgage brokering, and similarly related fields.

C. "Associate Member" means: (1) A member of the Defendant who is an 'associated licensee' as the term is defined in S.C. Code Ann. § 40-57-30 (2005) or any recodification thereof; and (2) a Licensee who associates with a Full Member or a Broker-in-Charge of a Full Member.

D. "Applicant" means a person who applies for full, associate, or affiliate membership in the Multiple Listing Service of Hilton Head Island.

E. "Appraiser" means any person who is licensed under Title 40 Chapter 60 of the South Carolina Revised Statutes or any future recode fication thereof and legally can perform real estate appraisal.

F. "Appraisal Firm" means a firm owned by or employing an Appraiser.

G. "Broker-in-Charge" means: (1) A "broker-in-charge" as the term is defined in S.C. Code Ann. § 40-57-30 (2005) or any recodification thereof; or (2) any licensed broker who is designated as having responsibility over the actions of all its associated licensees and is affiliated with a Full Member.

H. "Buyer's Representation Agreement" means the contract between a Licensee and Client or any other person who is a prospective home buyer.

I. "Client" means a person with whom a Licensee has established an agency relationship.

J. "Compensation" means: (1) Any commission or fee charged by, or rebate offered by, a Licensee to a Client or any person who is a prospective home buyer or seller; (2) any commission or payment offered to other Licensees in exchange for cooperation on a property transaction; or (3) any commission, salary, or fee exchanged between a Full Member and its affiliated or employed Licensees.

K. "Full Member" means any member of the MLS that is a real estate brokerage firm having a Broker-in-Charge or an Appraisal firm.

L. "Licensee" means: (1) Any person who is licensed under Title 40 Chapter 57 of the South Carolina Code Annotated or any future recodification thereof; (2) any person who legally can perform acts of real estate brokerage; or (3) any person who legally can perform acts of real estate brokerage while acting under the supervision of a licensed broker.

M. "Listing Agreement" means the contract between a Licensee and Client or any other person who is a prospective home seller.

N. "Member MLS Database Access" means the security measures, such as a login-id and password or key token, needed to access the complete MLS database provided by Defendant to Full, Associate or Affiliate Members. Member MLS Database Access does not mean or encompass any login-id or password that a Full or Associate Member establishes for, or grants to, its customers or clients either to access the broker's website or to access listings content provided on the broker's website.

O. "Method of Service" means the time, place, or manner in which a Licensee provides brokerage services to Clients or any other person who is a prospective home buyer or seller, subject to state and federal law (e.g., office hours, the method by which the Licensee markets properties for sale, and the method by which the Licensee provides listings information to Clients or any other person who is a prospective home buyer or seller).

P. "MLS" means any multiple listing service owned or operated by Multiple Listing Service of Hilton Head Island, Inc.

Q. "MLS Listing" means any listing in which:

1. The Client or any other person who is a prospective home seller grants the Licensee the sole right to make an offer of compensation to cooperating brokers; and

2. The Licensee makes an offer of compensation to other cooperating Full or Associate Members.

R. "MLS Service Area" means the geographic area from which listings are placed in the MLS by Full or Associate Members.

S. "Office Exclusive" means a listing in which the owner refuses to grant permission for distribution of the listing to the MLS.

T. "Real Estate Brokerage Firm" means a firm owned by or employing a Broker-in-Charge.

U. "Scope of Service" means the set of specific brokerage services a Licensee has agreed it will provide to a Client or such other person who is a prospective home buyer or seller as well as the set of specific services that a Licensee will allow a Client or any other person who is prospective home buyer or seller to perform herself or himself (whether or not the licensee offers to provide such services). The Scope of Service may be set forth in a Listing Agreement, Buyers Representation Agreement, or other agreement between a Licensee and a Client or any other person who is a prospective home buyer or seller.

V. "Trustees" means the Trustees elected by the Full Members of Defendant.

III. Applicability

This Final Judgment applies to the Defendant and all other persons in active concert or participation with it who receive actual notice of this Final Judgment by personal service or otherwise.

IV. Prohibited Conduct

A. Subject to the provisions of paragraph VI, Defendant is enjoined and restrained from adopting or enforcing any bylaw, rule, regulation, policy, or practice that has the purpose or effect of excluding:

1. from full membership any Real Estate Brokerage Firm that has a broker-in-charge holding an active real estate broker license issued by the appropriate State of South Carolina governmental licensing authority or any Appraisal Firm owned by or employing at least one person with an active appraiser license issued by the appropriate State of South Carolina governmental licensing authority; or

2. from associate membership any Licensee who holds an active real estate broker, agent, or salesman license issued by the appropriate State of South Carolina governmental licensing authority.

B. Subject to the provisions of paragraph VI, Defendant is enjoined and restrained from adopting or enforcing any bylaw, rule, regulation, policy, or practice that has the purpose or effect of:

1. failing to make available or furnish on like terms to any Full Member any and all services that Defendant now or hereafter makes available or furnishes to any of its Full Members;

2. failing to make available or furnish on like terms to any Associate Member any and all services that Defendant now or hereafter makes available or furnishes to any of its Associate Members;

3. failing to make available or furnish on like terms to any member who is an Appraiser any and all services that Defendant now or hereafter makes available or furnishes to any of its members who are Appraisers;

4. discriminating against, disfavoring, disciplining, or expelling any Full or Associate Member based on its office location, corporate structure, level or type of Compensation, Scope of Service, or Method of Service;

5. requiring any Full or Associate Member to perform brokerage services in excess of those required by South Carolina law;

6. prescribing the terms of Listing Agreements, Buyer's Representation Agreements, or any other agreement between a Full or Associate Member and any Client or any other person who is a prospective home buyer or seller;

7. refusing to accept or place in the MLS any MLS Listing submitted by a Full or Associate Member;

8. prescribing, recommending, setting standards, or guidelines concerning Compensation;

9. requiring an Applicant or a Full Member to inform Defendant of the ownership interests that others have in such Applicant or Full Member or charging a fee for a change in ownership;

10. requiring any Full or Associate Member, Appraiser or Trustee to reside or have an office in the MLS Service Area or any particular area or location; or

11. changing its three classes of membership (Full, Associate, and Affiliate) without the prior approval of the Department of Justice.

V. Required Conduct

A. Defendant is required to accept all Applicants into the Applicant's corresponding membership class (Full, Associate, or Affiliate) as follows:

1. any Real Estate Brokerage Firm that has a Broker-in-Charge who holds an active real estate broker license issued by the appropriate State of South Carolina governmental licensing authority shall be granted Full Membership;

2. any Licensee who holds an active real estate broker, agent, or salesman license issued by the appropriate State of South Carolina governmental licensing authority shall be granted Associate Membership; and

3. any Appraisal Firm with an owner or employee holding an active appraiser license issued by the appropriate State of South Carolina governmental licensing authority shall be granted Full Membership.

B. Defendant is ordered to delete from its Bylaws and Rules and suspend enforcement of:

1. The language in Bylaw Article II, Section II stating:

"Any realty or appraisal firm whose Broker in Charge or Head Appraiser applies for membership and which is owned as a subsidiary or affiliate of a realty firm which has its headquarters a state other than South Carolina must comply with the following additional regulations: * * * (2) it must have an office located within the Multiple Listing Service area (Beaufort, Jasper, Allendale, Bamberg, Barnwell, Colleton, Hampton and Orangeburg counties); (3) the broker in charge or head appraiser of such realty or appraisal must be a resident of the Multiple

Listing Service area (Beaufort, Jasper, Allendale, Bamberg, Barnwell, Colleton, Hampton and Orangeburg counties); and (4) all licensees of the realty firm or appraisal firm must hold their South Carolina license as their primary license.”

2. The language in Bylaw Article V, Section I stating:

“The Board of Trustees of MLS shall consist of persons who are residents of the counties served by MLS, including Beaufort, Jasper, Allendale, Bamberg, Barnwell, Colleton, Hampton and Orangeburg, South Carolina.”

3. The language in Bylaw Article VII, Section II stating:

i. “and shall consist of the brokers-in-charge or Head appraiser of realty and appraisal firms who qualify for membership based upon the following criteria: (a) the firm has established and maintained a specific place of business in any of the following counties served by MLS: Beaufort, Jasper, Allendale, Bamberg, Barnwell, Colleton, Hampton and Orangeburg, which office is available to the public during reasonable business hours;” and

ii. “Membership of internet only members are subject to restrictions set by the Board of Trustees.”

4. The language in Bylaw Article VII, Section III stating:

“which: (a) Have established and maintained a specific place of business within the Multiple Listing Service Area (which includes Beaufort, Jasper, Allendale, Bamberg, Barnwell, Colleton, Hampton and Orangeburg counties) that is available to the public during reasonable business hours;”

5. The language in Bylaw Article VII, Section IV stating:

i. “to obtain or make credit checks or”; and
ii. “and applications may require that the applicant supply various information and recommendations, including but not limited to:

(a) Three (3) separate character references from three (3) presently qualified Full Members; and

(b) In the case of Full Members, a history of business experience and employment information concerning all persons, including all partners and shareholders, who have any ownership interest in the applicant. Any such party acquiring an ownership interest of any kind after acceptance of the realty firm as a Full Member must submit all information required by this Section within ten (10) days after acquisition of the ownership interest and must be approved by the Board of Trustees.”

6. The Bylaw Article VII, Section X stating:

“In the event of any change of ownership of a member firm as determined by the Board of Trustees in accordance with the provisions of the Rules and Regulations, the Board of Trustees, at its option, may terminate the membership of such firm and require the firm to reapply for membership and pay the then current initiations fees in MLS as if said firm had never been a member of MLS.”

7. The language in Bylaw Article XI, Section I stating:

“The listing Full Member shall specify a commission split or other compensation which would be reasonably expected to

encourage cooperation by other Full Members. It is to the advantage of the listing Full Member, and, consequently the owner, to establish compensation which will encourage other MLS Full Members to devote time and energy to the sale of the owner's listing with the expectation of reasonable compensation for the member's efforts. The Board of Trustees may adopt compensation guidelines that it deems sufficient to encourage such devotion of time and energy. Any Full Member which the Board of Trustees, in its sole discretion, believes is consistently establishing compensation which would discourage the intended cooperation by other Full Members may have its membership terminated by a majority vote of the Board of Trustees.”

8. The language in Rules and Regulations Section II, stating:

i. “A.1.c. Establish and maintain a specific place of business in Beaufort, Jasper, Allendale, Bamberg, Barnwell, Colleton, Hampton, Orangeburg Counties, which is available to the public.”;

ii. “A.2.c. Submit letters of recommendation from the Broker-In-Charge/Head Appraiser of three (3) firms who are members in good standing with the MLS of Hilton Head Island, Inc.”;

iii. “A.2.g. Submit statement of Residence of Owners and Broker-In-Charge/Head Appraiser”;

iv. “A.2.h. (2) address of the New Firm's office located within the Multiple Listing Service area (Beaufort, Jasper, Allendale, Bamberg, Barnwell, Colleton, Hampton, [and] Orangeburg Counties); (3) the address of the Broker-In-Charge/Head Appraiser to confirm that he/she is a resident of the Multiple Listing Service area; and (4) confirmation that all licensees of the New Firm hold their South Carolina licenses as their primary license and are residences of the aforementioned area”;

v. “B. Board of Trustees must be notified of any ownership changes within 10 days of said change and all changes of ownership fees paid. Notification must be in writing and signed by the BIC/Head Appraiser. A new Membership Agreement and Principals Audit must be fully executed and signed by the BIC/Head Appraiser and submitted to the MLS office along with notification. (Forms may be obtained on the MLS website www.hiltonheadmls.com and selecting Members Only.)”

9. The language in Rules and Regulations Section IT, Subsection E referring to principals.

10. The language in Rules and Regulations Section VI, Subsection 2 stating:

“Only MLS Exclusive Right to Sell Listing Agreements are accepted.”

C. Defendant is ordered to delete the term “Exclusive Agency” in Rules and Regulations Section VI, Subsection 7 and replace it with “Office Exclusive.”

VI. PERMITTED CONDUCT

Notwithstanding the above, nothing shall prohibit Defendant from:

A. Requiring Applicants or Full, Associate, or Affiliate Members to pay:

1. A fee equal to the reasonable set-up costs of preparing to make Defendant's services available to the Applicant, Full, Associate, or Affiliate Member;

2. A reasonable security deposit, to secure against any unpaid claims or charges that may be asserted by Defendant against the Applicant, Full, Associate, or Affiliate Member; and

3. Fees for use of Defendant's services that are non-discriminatory and reflect the reasonable expenses of Defendant's operations.

B. Adopting or enforcing any bylaw, rule, regulation, policy practice, or agreement that is required for the MLS not to violate South Carolina law.

C. Publishing or making available illustrative Listing Agreements, Buyer's Representation Agreements, and any other written agreements, or contracts that Full or Associate Members may choose to use or modify, provided any such agreements leave blank the Compensation terms.

D. Adopting or enforcing any bylaw, rule, regulation, policy, practice, or agreement that prohibits Full, Associate, or Affiliate Members from enabling a third party to make use of its Member MLS Database Access.

E. Requiring a Full Member to notify the MLS of a change in or departure of its Broker-in-Charge, or the departure of any Associate Member.

F. Requiring a Full Member to provide the MLS with the name of a designated contact person to whom the MLS may direct correspondence and inquiries.

VII. COMPLIANCE AND INSPECTION

A. Within sixty (60) days after the date of entry of this Final Judgment, Defendant shall: (1) provide each of its members, trustees, and employees with notice of the amendments to its bylaws, rules, regulations and policies to conform to the provisions of this Order; (2) provide each of its members, trustees, and employees with a copy of this Order via its member-only Internet page; (3) inform all persons who are known to have inquired about membership in the last two years but who are not members of the amendments to its bylaws, rules, regulations and policies to conform to the provisions of this Order; (4) inform all persons under subsection (3) that they may apply or reapply for membership and that Defendant will grant membership if the applicant meets the requirements of the bylaws, rules, regulations and policies as revised by this Order; and (5) place on its home page of its publicly accessible web site (currently <http://www.hiltonheadmls.com>) a notice of the Final Judgment with a link to the Final Judgment.

B. For the purposes of determining or securing compliance with this Final Judgment, or of determining whether the Final Judgment should be modified or vacated, and subject to any legally recognized privilege, from time to time duly authorized representatives of the United States Department of Justice, including consultants and other persons retained by the United States, shall, upon written request of a duly authorized representative of the Assistant Attorney General in charge of the Antitrust Division, and on reasonable notice to Defendant, be permitted:

1. access during Defendant's office hours to inspect and copy, or at Plaintiffs option, to require Defendant to provide copies of, all books, ledgers, accounts, records and documents in the Defendant's possession, custody, or control, relating to any matters contained in this Final Judgment; and

2. to interview, either informally or on the record, Defendant's trustees, officers, employees, or agents, who may have their individual counsel present, regarding such matters. The interviews shall be subject to the reasonable convenience of the interviewee and without restraint or interference by Defendant.

C. Upon the written request of a duly authorized representative of the Assistant Attorney General in charge of the Antitrust Division, for the purposes of determining or securing compliance with this Final Judgment, or of determining whether the Final Judgment should be modified or vacated, and subject to any legally recognized privilege, Defendant shall submit written reports or interrogatory responses, under oath if requested, relating to any of the matters contained in this Final Judgment as may be requested.

D. No information or documents obtained by the means provided in this section shall be divulged by the United States to any person other than an authorized representative of the executive branch of the United States, except in the course of legal proceedings to which the United States is a party (including grand jury proceedings), or for the purpose of securing compliance with this Final Judgment, or as required by law.

VIII. Retention Of Jurisdiction

This Court retains jurisdiction to enable any party to this Final Judgment to apply to this Court at any time for further orders and directions as may be necessary or appropriate to carry out or construe this Final Judgment, to modify any of its provisions, to extend the duration of the Final Judgment, to enforce compliance, and to punish violations of its provisions.

IX. Expiration Of Final Judgment

This Final Judgment will expire ten (10) years from the date of its entry.

X. Notice

For purposes of this Final Judgment, any notice or other communication shall be given to the person at the address set forth below (or such other addresses as the recipient may specify in writing): John R. Read, Chief, Litigation III Section, U.S. Department of Justice, Antitrust Division, 325 Seventh Street, NW., Suite 300, Washington, DC 20530.

XI. Public Interest Determination

Entry of this Final Judgment is in the public interest.

Date:

Court approval subject to procedures of Antitrust Procedures and Penalties Act, 15 U.S.C. 16

United States District Judge.

United States District Court for the District of South Carolina Beaufort Division;

United States of America, Plaintiff, v. Multiple Listing Service of Hilton Head Island, Inc, Defendant

Civil Action No. 9:07-CY-3435-SB
Filed: 10/16/2007

Competitive Impact Statement

Plaintiff United States of America ("United States"), pursuant to section 2(b) of the Antitrust Procedures and Penalties Act ("APPA" or "Tunney Act"), 15 U.S.C 16(b)-(h), files this Competitive Impact Statement relating to the proposed Final Judgment submitted for entry in this civil antitrust proceeding.

I. Nature and Purpose of the Proceedings

On October __, 2007, the United States filed a civil antitrust complaint alleging that Defendant Multiple Listing Service of Hilton Head Island, Inc. ("Hilton Head MLS") violated Section 1 of the Sherman Act, 15 U.S.C. 1, by enforcing certain rules that unreasonably restrain competition among real estate brokers in the Hilton Head, South Carolina area. Defendant is a multiple listing service, which is controlled by its members who are real estate brokers competing to sell brokerage services to consumers in the Hilton Head area. As explained more fully below, brokers seeking to provide brokerage services in the Hilton Head area need to be members of the Hilton Head MLS.

In its Complaint, the United States alleges that the Defendant, by its rules,

denies membership to brokers who would likely compete aggressively on price or would introduce Internet-based brokerage, and imposes unreasonable membership costs on publicly-owned brokerage companies. Defendant's rules also stabilize prices by forcing member brokers to provide a certain set of brokerage services, whether or not the consumer desires to purchase those services. The United States also alleges that the Defendant has authorized its Board of Trustees to adopt rules that would regulate commissions and impose discriminatory requirements on Internet-based brokers.

At the same time the Complaint was filed, the United States filed a Stipulation and proposed Final Judgment, which are designed to eliminate the anticompetitive effects of the acquisition. The proposed Final Judgment, which is explained more fully below, requires the Defendant to rescind certain of its rules. The proposed Final Judgment also prohibits Defendant from adopting new rules that have the effect of excluding real estate brokers from membership based on such criteria as their business model, price structure, or office location. The proposed Final Judgment further prohibits Defendant from adopting new rules that would dictate the services and prices that its members must offer to their clients.

The Stipulation and proposed Order require Hilton Head MLS to take the actions required under the proposed Final Judgment. The United States and Hilton Head MLS have also stipulated that the proposed Final Judgment may be entered after compliance with the APPA, unless the United States withdraws its consent. Entry of the proposed Final Judgment would terminate this action, except that this Court would retain jurisdiction to construe, modify, and enforce the proposed Final Judgment and to punish violations thereof.

II. Description of the Events Giving Rise to the Alleged Violation of the Antitrust Laws

A. Description of the Defendant and Its Activities

Hilton Head MLS is organized as a not-for-profit corporation under the laws of South Carolina with its principal place of business on Hilton Head Island, Beaufort County, South Carolina. Hilton Head MLS is a joint venture of over one hundred competing licensed brokers and other licensed real

estate professionals doing business in the Hilton Head area.¹

Most prospective home sellers and buyers engage the services of a broker to purchase and sell homes. Real estate brokers formed the Hilton Head MLS to facilitate the provision of real estate brokerage services to such buyers and sellers. The Hilton Head MLS pools and disseminates information on almost every property available for sale on Hilton Head Island. It combines its members' property listings information into an electronic database and makes this data available to all brokers who are members of the MLS. By listing information on a home in the MLS, a broker can market it to a large number of potential buyers. A broker representing a buyer likewise can search the MLS to provide a home buyer with information about nearly all the listed properties in the area that match the buyer's housing needs.

Members of the Hilton Head MLS utilize the database as a clearinghouse to, among other things: communicate the listings information of the properties that they have for sale to other members; offer to compensate other members as cooperating brokers if they locate purchasers for those listings; locate properties for prospective purchasers; distribute listings to other members for advertisement purposes; and compile and distribute market statistics. The Hilton Head MLS also maintains records of sold homes. These "sold data" records are very important for brokers working with sellers to set an optimum sales price. Brokers representing a buyer likewise use the sold data to help buyers determine what price to offer for a home.

Access to the database provided by the Hilton Head MLS is critical for brokers who wish to serve buyers or sellers successfully on Hilton Head Island. By virtue of market-wide participation and control over a critically important input, the Hilton Head MLS has market power.

Industry Background

The prices consumers paid to brokers for the brokerage services associated with a typical home sales transaction have increased substantially since 2003 on Hilton Head Island and in many other parts of the country. This is because brokers who adhere to traditional methods of doing business typically charge a fee calculated as a percentage of the sales price of the

home, and that percentage has tended to be relatively inflexible as housing prices on Hilton Head Island and in many other parts of the country have increased dramatically. As a result of these higher prices, brokers offering competitively significant alternatives to traditional methods have emerged in other areas of the country.

Some brokers in other parts of the United States use technology to automate certain tasks and to communicate more efficiently with consumers. For example, technology enables brokers to contact, communicate with, and service consumers remotely or in-person without the need for a retail office location that consumers can visit. Such technology-savvy brokers can reduce brokerage costs by operating fewer or no physical offices, and may pass cost savings on to consumers through reduced brokerage fees.

Other brokers around the country now contract with buyers and sellers to provide a subset of services for a flat fee rather than for a percentage of the home sale price. Fee-for-service brokers provide certain enumerated services such as marketing the house or attending closings, while the buyer or seller takes responsibility for other services associated with brokerages such as making offers and counteroffers or conducting open houses on their own. Through fee-for-service packages, buyers and sellers can save money by purchasing only the services that they wish their broker to provide. Brokers in other areas of the country have attracted customers by offering full-service, reduced commission brokerage. Additionally, still other brokers in other areas of the country have sought a competitive advantage by creating nationwide firms. These firms raise capital through public ownership, invest in nationwide brands, and provide brokerage services to consumers in multiple markets.

C. Description of the Alleged Violation

Defendant Hilton Head MLS, through the collective voting of its broker membership, has adopted and enforced rules and practices that exclude new entry and restrict member output. These rules are not reasonably necessary to carry out the procompetitive purposes of the multiple listing service. As such, these rules are agreements amongst competitors that restrain competition. Accordingly, in its Complaint, the United States alleges that Defendant's rules constitute a contract, combination, or conspiracy by competitors with market power that unreasonably restrains competition on Hilton Head

Island in violation of Section I of the Sherman Act, 15 U.S.C. 1.

Specifically, the Complaint alleges that Defendant has rules and practices that require broker-members to: (1) Maintain a physical office within the Hilton Head MLS service area; (2) reside within the area served by the Hilton Head MLS; (3) operate their offices during hours deemed reasonable by the Hilton Head MLS; and (4) hold a South Carolina real estate license as their primary license. (Bylaw Article II, Section II; Bylaw Article VII; & Rule II.) These rules allow Defendant to deny membership to brokers who operate business models that would increase competition. These rules enable Defendant to exclude technology-savvy brokers who serve their clients without a physical office and who can pass along the cost savings to consumers through reduced commission rates. These rules also deprive consumers of the benefits of competition from brokers who work part-time or who are licensed under reciprocity provisions of South Carolina Law.

Defendant's rules have also enabled it to identity applicants for MLS membership who could be aggressive competitors and deny their application for membership. Broker-applicants are required to disclose their business history and prior employment, undergo a credit check, and obtain letters of recommendation from three current broker-members, *i.e.*, those with whom the applicant would compete. (Bylaw Article VII, Section IV; Bylaw Article VII, Section IV(a); Rule II.A.2.) These rules have allowed unreasonable denials of membership and thus deprived consumers of the benefits of competition.

Defendant has authorized its Board of Trustees to adopt mandatory guidelines that would regulate the commission that listing brokers offer to selling brokers in exchange for their cooperation on the home sale. (Bylaw Article XI, Section I.) The mere prospect that the Board might adopt such controls likely inhibits price competition. Their actual adoption would directly fix and stabilize prices. Defendant also has a rule that requires its members to provide certain services to all brokerage customers, whether or not desired by the customer. (Bylaw Article X; MLS Listing Agreement.) Embodied in the terms of Defendant's mandatory form listing agreement, this rule prevents current and prospective members from operating a fee-for-service business model. This rule decreases competition and harms consumers because it insulates Defendant's members from the competitive pressures posed by brokers

¹ The Hilton Head MLS requires that brokerage firms, rather than individual brokers, be members of the MLS. For the purposes of this document, any reference to brokers includes also the brokerage firms with which the broker is associated.

who would offer additional pricing and service choices to their customers.

Defendant has also authorized its Board of Trustees to impose discriminatory requirements on Internet-based real estate brokers. (Bylaw Article II, Section II.) Such requirements, if implemented, would competitively disadvantage Internet-based brokers and discourage them from joining the MLS and competing on Hilton Head Island, thereby limiting consumer choice. The mere prospect that the Board might adopt such controls likely deters Hilton Head brokers from developing an Internet-based model and thereby inhibits such service competition.

In addition, Defendant has a "change in ownership" rule that requires publicly-held brokerages to make a significant payment to the Defendant every time a share of their stock changes hands. (Bylaw Article VII, Section X; Rules II.A.3; IIB & IIE.). This rule competitively disadvantages publicly-owned companies and discourages them from joining the MLS and competing on Hilton Head Island, thereby limiting consumer choice.

D. Harm From the Alleged Violation

Taken together, Defendant's rules discourage competition on price and service, and inhibit competitive actions that would alter the status quo. Furthermore, there are no plausible justifications that these rules are reasonably necessary to carry out the procompetitive purposes of the multiple listing service. As a result of Defendant's anticompetitive rules, consumers of brokerage services on Hilton Head Island have fewer choices of service options and pay higher prices for real estate brokerage services than do consumers in other parts of the country.

Data analyzed from a MLS in another area of the country support these allegations. Data have shown an inverse correlation between the share of homes listed by fee-for-service brokers in the area and the level of cooperating commission offered to buyer's brokers for homes in that area. Thus, controlling for other influences, where fee-for-service brokers account for a greater portion of listings in an area, traditional brokers in that area offer lower cooperating commissions, on average, to brokers representing buyers.

III. Explanation of the Proposed Amended Final Judgment

The proposed Final Judgment will restore the competition that the agreement among the Hilton Head MLS members has eliminated and will prevent Hilton Head MLS from engaging

in similar conduct in the future. The proposed Final Judgment will first require Hilton Head MLS to rescind all of the current MLS rules discussed above. Second, the proposed Final Judgment will enjoin Hilton Head MLS from adopting or enforcing any rules that will have a similar purpose or effect. More specifically, the proposed Final Judgment will prevent the Defendant from adopting rules or engaging in practices that (i) exclude active, licensed real estate professionals from their respective membership class in the MLS; (ii) fail to furnish under like terms to any member any services it furnishes to other members in its membership class; (iii) discriminate against any member based on its office location, corporate structure, level or type of compensation, scope of service, or method of service; (iv) require members to perform brokerage services in excess of those required by state law; (v) prescribe the terms of agreements between a member and its clients or any other person who is a prospective home buyer or seller; (vi) refuse to accept and place in the Multiple Listing Service any member's MLS listing; (vii) set standards or guidelines concerning compensation; (viii) charge members a fee for any change in ownership; (ix) require a member to maintain an office or reside in the MLS Service Area or any other particular location; or (x) alter any of its three classes of membership without the prior approval of the Department of Justice. The proposed Final Judgment will also require Hilton Head MLS to provide each of its members, trustees, employees, and agents with a copy of the proposed Final Judgment; inform all persons who inquired about membership in the last two years but who are not members of the MLS of the changes in the MLS rules caused by the proposed Final Judgment; and place on the home page of its publicly accessible website a notice of the proposed Final Judgment with a link to the proposed Final Judgment and the amended rules.

IV. Remedies Available to Potential Private Litigants

Section 4 of the Clayton Act (15 U.S.C. 15) provides that any person who has been injured as a result of conduct prohibited by the antitrust laws may bring suit in federal court to recover three times the damages the person has suffered, as well as costs and reasonable attorneys' fees. Entry of the proposed Final Judgment will neither impair nor assist the bringing of any private antitrust damage action. Under the provisions of section 5(a) of the Clayton Act (15 U.S.C. 16(a)), the proposed Final

Judgment has no *prima facie* effect in any subsequent private lawsuit that may be brought against the Defendant.

V. Procedures Available for Modification of the Proposed Final Judgment

The United States and the Defendant have stipulated that the proposed Final Judgment may be entered by the Court after compliance with the provisions of the APPA, provided that the United States has not withdrawn its consent. The APPA conditions entry upon the Court's determination that the proposed Final Judgment is in the public interest.

The APPA provides a period of at least sixty (60) days preceding the effective date of the proposed Final Judgment within which any person may submit to the United States written comments regarding the proposed Final Judgment. Any person who wishes to comment should do so within sixty (60) days of the date of publication of this Competitive Impact Statement in the **Federal Register**, or the last date of publication in a newspaper of the summary of this Competitive Impact Statement, whichever is later. All comments received during this period will be considered by the United States Department of Justice, which remains free to withdraw its consent to the proposed Final Judgment at any time prior to the Court's entry of judgment. The comments and the response of the United States will be filed with the Court and published in the **Federal Register**.

Written comments should be submitted to: John Read, Chief, Litigation III Section, Antitrust Division, United States Department of Justice, 325 Seventh Street, NW., Suite 300, Washington, DC 20530.

The proposed Final Judgment provides that the Court retains jurisdiction over this action, and the parties may apply to the Court for any order necessary or appropriate for the modification, interpretation, or enforcement of the Final Judgment.

VI. Alternatives to the Proposed Amended Final Judgment

The United States considered, as an alternative to the proposed Final Judgment, a full trial on the merits against the Defendant. Given the inherent delays of a full trial and the appeals process, the United States is satisfied that the relief contained in the proposed Final Judgment will quickly establish, preserve, and ensure competition for real estate brokerage services in the Hilton Head MLS Service Area.

VII. Standard of Review Under the APPA for Proposed Amended Final Judgment

The APPA requires that proposed consent judgments in antitrust cases brought by the United States be subject to a sixty-day comment period, after which the Court shall determine whether entry of the proposed Final Judgment “is in the public interest.” 15 U.S.C. 16(e)(1). In making that determination, the Court, in accordance with amendments to the APPA in 2004, is required to consider:

(A) the competitive impact of such judgment, including termination of alleged violations, provisions for enforcement and modification, duration of relief sought, anticipated effects of alternative remedies actually considered, whether its terms are ambiguous, and any other competitive considerations bearing upon the adequacy of such judgment that the court deems necessary to a determination of whether the consent judgment is in the public interest; and

(B) the impact of entry of such judgment upon competition in the relevant market or markets, upon the public generally and individuals alleging specific injury from the violations set forth in the complaint including consideration of the public benefit, if any, to be derived from a determination of the issues at trial.

15 U.S.C. 16(e)(1)(A) & (B); see generally *United States v. SBC Commc'ns, Inc.*, Nos. 05–2102 and 05–2103, 2007 WL 1020746, at *9–16 (D.D.C. Mar. 29, 2007) (assessing public interest standard under APPA and effect of 2004 amendments).² As courts have held—both before and after the 2004 amendments—the United States is entitled to deference in crafting its antitrust settlements, especially with respect to the scope of its complaint and the adequacy of its remedy, which are the “two most significant legal questions” relating to a public interest determination. *United States v. Microsoft Corp.*, 56 F.3d 1448, 1458–62 (D.C. Cir. 1995); *SBC Commc'ns*, 2007 WL 1020746, at *12–*16.3.

² Compare 15 U.S.C. 16(e) (2004), with 15 U.S.C. 16(e)(1) (2006) (substituting “shall” for “may” in directing relevant factors for court to consider and amending list of factors to focus on competitive considerations and to address potentially ambiguous judgment terms). The 2004 amendments do not affect the substantial precedent in this and other circuits analyzing the scope and standard of review for APPA proceedings. See *SBC Commc'ns*, 2007 WL 1020746, at *9 (“[A] close reading of the law demonstrates that the 2004 amendments effected minimal changes. * * *”).

³ The *Microsoft* court explained that a court making a public interest determination under the APPA should consider, among other things, the relationship between the remedy secured and the specific allegations set forth in the government’s complaint, whether the decree is sufficiently clear,

With respect to the adequacy of the relief secured by the decree, a court may not “engage in an unrestricted evaluation of what relief would best serve the public.” *United States v. BNS, Inc.*, 858 F.2d 456, 462 (9th Cir. 1988) (citing *United States v. Bechtel Corp.*, 648 F.2d 660, 666 (9th Cir. 1981)); see also *Microsoft*, 56 F.3d at 1460–62. Courts have held that:

[t]he balancing of competing social and political interests affected by a proposed antitrust consent decree must be left, in the first instance, to the discretion of the Attorney General. The court’s role in protecting the public interest is one of insuring that the government has not breached its duty to the public in consenting to the decree. The court is required to determine not whether a particular decree is the one that will best serve society, but whether the settlement is “within the reaches of the public interest.” More elaborate requirements might undermine the effectiveness of antitrust enforcement by consent decree.

Bechtel, 648 F.2d at 666 (emphasis added) (citations omitted).⁴ In making its public interest determination, a district court must accord due respect to the United States’ prediction as to the effect of proposed remedies, its perception of the market structure, and its views of the nature of the case. *SBC Commc'ns*, 2007 WL 1020746, at *16 (United States entitled to “deference” as to “predictions about the efficacy of its remedies”); *United States v. Archer-Daniels-Midland Co.*, 272 F. Supp. 2d 1, 6 (D.D.C. 2003).

Court approval of a final judgment requires a standard more flexible and less strict than the standard required for a finding of liability. “[A] proposed decree must be approved even if it falls short of the remedy the court would impose on its own, as long as it falls within the range of acceptability or is ‘within the reaches of public interest.’” *United States v. AT&T Co.*, 552 F. Supp. 131, 151 (D.D.C. 1982) (citations omitted) (quoting *Gillette*, 406 F. Supp. at 716); see also *United States v. Alcan Aluminum Ltd.*, 605 F. Supp. 619, 622 (W.O. Ky. 1985) (approving the consent

whether enforcement mechanisms are sufficient, and whether the decree may positively harm third parties. *Microsoft*, 56 F.3d at 1458–62.

⁴ Cf. *BNS*, 858 F.2d at 464 (holding that the court’s “ultimate authority under the [APPA] is limited to approving or disapproving the consent decree”); *United States v. Gillette Co.*, 406 F. Supp. 713, 716 (D. Mass. 1975) (noting that, in this way, the court is constrained to “look at the overall picture not hypercritically, nor with a microscope, but with an artist’s reducing glass”), *aff’d sub nom. Maryland v. United States*, 460 U.S. 1001 (1983). See generally *Microsoft*, 56 F.3d at 1461 (discussing whether “the remedies [obtained in the decree are] so inconsonant with the allegations charged as to fall outside of the ‘reaches of the public interest’”).

decree even though the court would have imposed a greater remedy). To meet this standard, the United States “need only provide a factual basis for concluding that the settlements are reasonably adequate remedies for the alleged harms;” *SBC Commc'ns*, 2007 WL 1020746, at *16.

Moreover, the Court’s role under the APPA is limited to reviewing the remedy in relationship to the violations that the United States has alleged in its Complaint, and does not authorize the Court to “construct [its] own hypothetical case and then evaluate the decree against that case.” *Microsoft*, 56 F.3d at 1459. Because the “court’s authority to review the decree depends entirely on the government’s exercising its prosecutorial discretion by bringing a case in the first place,” it follows that “the court is only authorized to review the decree itself,” and not to “effectively redraft the complaint” to inquire into other matters that the United States did not pursue. *Id.* at 1459–60. As the United States District Court for the District of Columbia recently confirmed in *SBC Communications*, courts “cannot look beyond the complaint in making the public interest determination unless the complaint is drafted so narrowly as to make a mockery of judicial power.” *SBC Commc'ns*, 2007 WL 1020746, at *14.

In its 2004 amendments to the Tunney Act, Congress made clear its intent to preserve the practical benefits of utilizing consent decrees in antitrust enforcement, adding the unambiguous instruction “[n]othing in this section shall be construed to require the court to conduct an evidentiary hearing or to require the court to permit anyone to intervene.” 15 U.S.C. 16(e)(2). This language codified the intent of the original 1974 statute, expressed by Senator Tunney in the legislative history: “[t]he court is nowhere compelled to go to trial or to engage in extended proceedings which might have the effect of vitiating the benefits of prompt and less costly settlement through the consent decree process.” 119 Cong. Rec. 24,598 (1973) (statement of Senator Tunney). Rather, the procedure for the public interest determination is left to the discretion of the court, with the recognition that the court’s “scope of review remains sharply proscribed by precedent and the nature of Tunney Act proceedings.” *SSC Commc'ns*, 2007 WL 1020746, at *9.⁵

⁵ *United States v. Mid-Am. Dairymen, Inc.*, 1977–1 Trade Cas. (CCH) ¶ 61,508, at 71,980 (W.D. Mo. 1977) (“[T]he Court, in making its public interest finding, should * * * carefully consider the explanations of the government in the competitive

VIII. Determinative Documents

There are no determinative materials or documents within the meaning of the APPA that were considered by the United States in formulating the proposed Amended Final Judgment.

Dated: October 16, 2007.

Respectfully submitted,

Lisa A. Scanlon,
Owen M. Kendler,
Christopher M. Ries,
*Attorneys for the United States of America,
U.S. Department of Justice, Antitrust
Division, 325 7th Street, NW., Suite 300,
Washington, DC 20530, Telephone: (202)
616-5954, Facsimile: (202) 514-7308.*

Certificate of Service

I hereby certify that on October 16, 2007, I caused a copy of the foregoing Competitive Impact Statement to be served on counsel for Defendant in this matter in the manner set forth below:

Jane W. Trinkley,
*McNair Law Firm, P.A. P.O. Box 11390,
Columbia, SC 29211, (via e-mail and first-
class mail).*

Respectfully submitted,

Reginald I. Lloyd,
United States Attorney.

By:

Barbara M. Bowens (I.D. 4004),
*Counsel for Defendant, Assistant United
States Attorney, 1441 Main Street, Suite
500, Columbia, South Carolina 29201.*

Christopher M. Ries,
*Attorney for the United States of America,
U.S. Department of Justice, Antitrust
Division, 325 7th Street, NW., Suite 300,
Washington, DC 20530, Telephone: (202)
616-5954, Facsimile: (202) 514-7308.*

[FR Doc. 07-5653 Filed 11-26-07; 8:45 am]

BILLING CODE 4410-11-M

DEPARTMENT OF LABOR

Office of the Secretary

Submission for OMB Review: Comment Request

November 20, 2007.

The Department of Labor (DOL) hereby announces the submission of the following public information collection requests (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. chapter 35). A copy of each ICR, with applicable supporting documentation; including among other things a description of the likely respondents, proposed frequency of response, and estimated total burden

impact statement and its responses to comments in order to determine whether those explanations are reasonable under the circumstances.”)

may be obtained from the RegInfo.gov Web site at <http://www.reginfo.gov/public/do/PRAMain> or by contacting Darrin King on 202-693-4129 (this is not a toll-free number)/e-mail: king.darrin@dol.gov.

Interested parties are encouraged to send comments to the Office of Information and Regulatory Affairs, Attn: Katherine Astrich, OMB Desk Officer for the Employment and Training Administration (ETA), Office of Management and Budget, Room 10235, Washington, DC 20503, Telephone: 202-395-7316/Fax: 202-395-6974 (these are not a toll-free numbers), e-mail: OIRA_submission@omb.eop.gov within 30 days from the date of this publication in the **Federal Register**. In order to ensure the appropriate consideration, comments should reference the OMB Control Number (see below).

The OMB is particularly interested in comments which:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Agency: Employment and Training Administration.

Type of Review: Extension without change of a currently approved collection.

Title: Application for Alien Employment Certification.

OMB Control Number: 1205-0015.

Form Number: ETA-750, Parts A and B.

Affected Public: Private Sector: Business or other for-profits; Farms; and Not-for-profit institutions.

Estimated Number of Respondents: 38,635.

Estimated Total Annual Burden Hours: 56,426.

Estimated Total Annual Costs Burden: \$1,318,838.

Description: The information collection is required by section

212(a)(5)(A), section 214(c) and section 218 of the Immigration and Nationality Act (INA) (8 U.S.C. 1182(a)(5)(A), 1184(c) and 1188). The INA mandates the Secretary of Labor to certify that any alien seeking to enter the United States for the purpose of performing skilled or unskilled labor is not adversely affecting wages and working conditions of U.S. workers similarly employed and that there are not sufficient U.S. workers able, willing, and qualified to perform such skilled or unskilled labor. Before any employer may request any skilled or unskilled alien labor, it must submit a request for certification to the Secretary of Labor containing the elements prescribed by the INA or meet one of the exceptions in the INA. Both the Department of Labor and the Department of Homeland Security have promulgated regulations to implement these sections of the INA. The relevant regulations are 20 CFR 655.1-4, 20 CFR 655.90-113, 20 CFR 655.200-215, 8 CFR 204.5(k)(4)(ii), and 8 CFR 214.2(h)(5) and (6).

In order to meet its statutory responsibilities under the INA, the Department needs to extend an existing collection of information pertaining to employers seeking to import foreign labor. The Form ETA-750 is the mechanism used to collect the necessary information which is utilized not only by the Department, but also by other Federal agencies to meet the requirements of the INA. The Department uses the information collected to implement several of its nonimmigrant worker programs, including the H-2A and H-2B temporary work programs, and for both permanent and temporary programs for the employment of alien professional athletes. The Department of Homeland Security, U.S. Citizenship and Immigration Services, utilizes the form for its National Interest Waiver program for employment-sponsored immigration.

Agency: Employment and Training Administration.

Type of Review: Revision and extension of a currently approved collection.

Title: Employment and Training Data Validation Requirement.

OMB Number: 1205-0448.

Form Numbers: ETA-DRVS Labor Exchange User's Guide Version 6.3; DRVS Workforce Investment Act Users Guide Version 6.3; NFJP Validation Form Version 2.0; and TAA Handbook Version 2.0.

Affected Public: State governments and not-for-profit institutions.

Estimated Number of Respondents: 318.

Estimated Total Annual Burden Hours: 69,332.

Estimated Total Annual Costs Burden: \$0.

Description: The accuracy and reliability of program reports submitted by states and grantees using Federal funds are fundamental elements of good public administration, and are necessary tools for maintaining and demonstrating system integrity. The President's Management Agenda to improve the management and performance of the Federal government has emphasized the importance of complete information for program monitoring and improving program results. States and grantees receiving funding under WIA Title IB, Wagner-Peyser Act, TAA, and the Older Americans Act (i.e., SCSEP) are required to maintain and report accurate program and financial information (WIA section 185 (29 U.S.C. 2935) and WIA Regulations 20 CFR 667.300(e)(2), Wagner-Peyser Act section 10 (29 U.S.C. 49i), Older Americans Act section 503(f)(3) and (4) (42 U.S.C. 3056a(f)(3) and (4)), and TAA regulations 20 CFR 617.57). Further, all states and grantees receiving funding from ETA and the Veterans' Employment and Training Service are required to submit reports or participant records and attest to the accuracy of these reports and records. For additional information, please refer to a related notice published on June 1, 2007 at 72 FR 30639.

Darrin A. King,

Acting Departmental Clearance Officer.

[FR Doc. E7-23005 Filed 11-26-07; 8:45 am]

BILLING CODE 4510-FW-P

DEPARTMENT OF LABOR

Office of the Secretary

Submission for OMB Review: Comment Request

November 21, 2007.

The Department of Labor (DOL) hereby announces the submission the following public information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. chapter 35). A copy of this ICR, with applicable supporting documentation; including among other things a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained from the RegInfo.gov Web site at <http://www.reginfo.gov/public/do/PRAMain> or by contacting Darrin King on 202-693-4129 (this is

not a toll-free number) / e-mail: king.darrin@dol.gov.

Interested parties are encouraged to send comments to the Office of Information and Regulatory Affairs, Attn: John Kraemer, OMB Desk Officer for the Occupational Safety and Health Administration (OSHA), Office of Management and Budget, Room 10235, Washington, DC 20503, Telephone: 202-395-7316 / Fax: 202-395-6974 (these are not a toll-free numbers), E-mail: OIRA_submission@omb.eop.gov within 30 days from the date of this publication in the **Federal Register**. In order to ensure the appropriate consideration, comments should reference the OMB Control Number (see below).

The OMB is particularly interested in comments which:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Agency: Occupational Safety and Health Administration.

Type of Review: Extension without change of a previously approved collection.

Title: Bloodborne Pathogens Standard (29 CFR § 1910.1030).

OMB Control Number: 1218-0180.

Affected Public: Private Sector: Business or other for-profits and Not-for-profit institutions.

Estimated Number of Respondents: 632,236.

Estimated Total Annual Burden Hours: 14,059,435.

Estimated Total Annual Costs Burden: \$23,774,874.

Description: The Bloodborne Pathogen Standard (29 CFR 1910.1030) is an occupational safety and health standard that prevents occupational exposure to bloodborne pathogens. The standard's information-collection requirements are essential components that protect employees from

occupational exposure. The information is used by employers and employees to implement the protection required by the Standard. OSHA compliance officers will use some of the information in their enforcement of the Standard. For additional information, please refer to a related notice published on July 27, 2007 at 72 FR 41357.

Darrin A. King,

Acting Departmental Clearance Officer.

[FR Doc. E7-23030 Filed 11-26-07; 8:45 am]

BILLING CODE 4510-26-P

NATIONAL SCIENCE FOUNDATION

Proposal Review; Notice of Meetings

In accordance with the Federal Advisory Committee Act (Pub. L. 92-463, as amended), the National Science Foundation (NSF) announces its intent to hold proposal review meetings throughout the year. The purpose of these meetings is to provide advice and recommendations concerning proposals submitted to the NSF for financial support. The agenda for each of these meetings is to review and evaluate proposals as part of the selection process for awards. The review and evaluation may also include assessment of the progress of awarded proposals. The majority of these meetings will take place at NSF, 4201 Wilson Blvd., Arlington, Virginia 22230.

These meetings will be closed to the public. The proposals being reviewed include information of a proprietary or confidential nature, including technical information; financial data, such as salaries; and personal information concerning individuals associated with the proposals. These matters are exempt under 5 U.S.C. 552(b)(c), (4) and (6) of the Government in the Sunshine Act. NSF will continue to review the agenda and merits of each meeting for overall compliance of the Federal Advisory Committee Act.

These closed proposal review meetings will no longer be announced on an individual basis in the **Federal Register**. NSF intends to publish a notice similar to this on a quarterly basis. For an advance listing of the closed proposal review meetings that include the names of the proposal review panel and the time, date, place, and any information on changes, corrections, or cancellations, please visit the NSF Web site: <http://www.nsf.gov/events/advisory.jsp>. This information may also be requested by telephoning 703/292-8182.

Dated: November 21, 2007.

Susanne Bolton,

Committee Management Officer.

[FR Doc. E7-23012 Filed 11-26-07; 8:45 am]

BILLING CODE 7555-01-P

NUCLEAR REGULATORY COMMISSION

Tennessee Valley Authority; Notice of Receipt and Availability of Application for a Combined License

On October 30, 2007, the Tennessee Valley Authority (TVA, or the applicant) filed with the Nuclear Regulatory Commission (NRC, the Commission) pursuant to section 103 of the Atomic Energy Act and 10 CFR Part 52, an application for a combined license (COL) for two AP1000 advanced passive pressurized water reactor nuclear power plants at the Bellefonte facility near the town of Scottsboro in Jackson County, Alabama. The reactors are to be identified as Bellefonte Units 3 and 4.

An applicant may seek a COL in accordance with Subpart C of 10 CFR part 52. The information submitted by the applicant includes certain administrative information such as financial qualifications submitted pursuant to 10 CFR 52.77, as well as technical information submitted pursuant to 10 CFR 52.79.

Subsequent **Federal Register** notices will address the acceptability of the tendered COL application for docketing and provisions for participation of the public in the COL review process.

A copy of the application is available for public inspection at the Commission's Public Document Room (PDR), located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland, and via the Agencywide Documents Access and Management System (ADAMS) Public Electronic Reading Room on the Internet at the NRC Web site, <http://www.nrc.gov/reading-rm/adams.html>. The accession number for the application is ML073110527. Future publicly available documents related to the application will also be posted in ADAMS. Persons who do not have access to ADAMS, or who encounter problems in accessing the documents located in ADAMS, should contact the NRC Public Document Room staff by telephone at 1-800-397-4209 or 301-415-4737, or by e-mail to pdr@nrc.gov. The application is also available at <http://www.nrc.gov/reactors/new-licensing/col.html>.

Dated at Rockville, Maryland, this 20th day of November, 2007.

For the Nuclear Regulatory Commission.

Thomas A. Bergman,

*Deputy Director for Licensing Operations,
Division of New Reactor Licensing, Office of
New Reactors.*

[FR Doc. E7-23010 Filed 11-26-07; 8:45 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

Notice of Sunshine Act Meetings

AGENCY HOLDING THE MEETINGS: Nuclear Regulatory Commission.

DATES: Weeks of November 26, December 3, 10, 17, 24, 31, 2007.

PLACE: Commissioners' Conference Room, 11555 Rockville Pike, Rockville, Maryland.

STATUS: Public and Closed.

Matters To Be Considered

Week of November 26, 2007

Tuesday, November 27, 2007.

9:30 a.m.

Discussion of Security Issues
(Closed—Ex. 1 & 3).

1:30 p.m.

Briefing on Equal Employment
Opportunity (EEO) Programs
(Public Meeting) (Contact: Sandra
Talley, 301-415-8059).

This meeting will be webcast live at the Web address—www.nrc.gov.

Week of December 3, 2007—Tentative

Friday, December 7, 2007.

10 a.m.

Discussion of Intragovernmental
Issues (Closed—Ex. 1 & 9).

2 p.m.

Briefing on Threat Environment
Assessment (Closed—Ex. 1).

Week of December 10, 2007—Tentative

Wednesday, December 12, 2007.

9:30 a.m.

Discussion of Management Issues
(Closed—Ex. 2).

Week of December 17, 2007—Tentative

There are no meetings scheduled for the Week of December 17, 2007.

Week of December 24, 2007—Tentative

There are no meetings scheduled for the Week of December 24, 2007.

Week of December 31, 2007—Tentative

There are no meetings scheduled for the Week of December 31, 2007.

* The schedule for Commission meetings is subject to change on short notice. To verify the status of meetings, call (recording)—(301) 415-1292.

Contact person for more information: Michelle Schroll, (301) 415-1662.

ADDITIONAL INFORMATION: Affirmation of "Pacific Gas and Electric Co. (Diablo Canyon ISFSI), Docket No. 72-26-ISFSI, San Luis Obispo Mothers for Peace's Contentions and Request for a Hearing Regarding Diablo Canyon Environmental Assessment Supplement (Tentative)" previously scheduled on Tuesday, November 20, 2007, at 9:05 a.m. was postponed.

The NRC Commission Meeting Schedule can be found on the Internet at: www.nrc.gov/about-nrc/policy-making/schedule.html.

The NRC provides reasonable accommodation to individuals with disabilities where appropriate. If you need a reasonable accommodation to participate in these public meetings, or need this meeting notice or the transcript or other information from the public meetings in another format (e.g. braille, large print), please notify the NRC's Disability Program Coordinator, Rohn Brown, at 301-492-2279, TDD: 301-415-2100, or by e-mail at REB3@nrc.gov. Determinations on requests for reasonable accommodation will be made on a case-by-case basis.

This notice is distributed by mail to several hundred subscribers; if you no longer wish to receive it, or would like to be added to the distribution, please contact the Office of the Secretary, Washington, DC 20555 (301-415-1969). In addition, distribution of this meeting notice over the Internet system is available. If you are interested in receiving this Commission meeting schedule electronically, please send an electronic message to dkw@nrc.gov.

Dated: November 21, 2007.

R. Michelle Schroll,

Office of the Secretary.

[FR Doc. 07-5856 Filed 11-23-07; 10:27 am]

BILLING CODE 7590-01-P

SECURITIES AND EXCHANGE COMMISSION

Submission for OMB Review; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of Investor Education and Advocacy, Washington, DC 20549

Extension:

Rule 17a-4(b)(11); SEC File No. 270-449; OMB Control No. 3235-0506

Notice is hereby given that pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. Sec. 3501 et seq.), the Securities and Exchange Commission

("Commission") has submitted to the Office of Management and Budget ("OMB") a request for extension of the previously approved collection of information discussed below.

Rule 17a-4(b)(11) (17 CFR 240.17a-4(b)(11)) under the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) describes the record preservation requirements for those records required to be kept pursuant to Rule 17a-3(a)(16), including how such records should be kept and for how long, to be used in monitoring compliance with the Commission's financial responsibility program and antifraud and antimanipulative rules as well as other rules and regulations of the Commission and the self-regulatory organizations. It is estimated that approximately 105 active broker-dealer respondents registered with the Commission incur an average burden of 315 hours per year (105 respondents multiplied by 3 burden hours per respondent equals 315 total burden hours) to comply with this rule.

Under Rule 17a-4(a)(11) broker-dealers are required to retain records for a period of not less than three years. Compliance with the rule is mandatory. The required records are available only to the examination staff of the Commission and the self-regulatory organization of which the broker-dealer is a member. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid control number.

Comments should be directed to (i) Desk Officer for the Securities and Exchange Commission, Office of Information and Regulatory Affairs, Office of Management and Budget, Room 10102, New Executive Office Building, Washington, DC 20503 or by sending an e-mail to: Alexander_T._Hunt@omb.eop.gov; and (ii) R. Corey Booth, Director/Chief Information Officer, Securities and Exchange Commission, c/o Shirley Martinson, 6432 General Green Way, Alexandria, VA 22312 or send an e-mail to: PRA_Mailbox@sec.gov. Comments must be submitted within 30 days of this notice.

Dated: November 19, 2007.

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-22978 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

Submission for OMB Review; Comment Request

Upon Written Request, Copy Available From: Securities and Exchange Commission, Office of Investor Education and Advocacy, Washington, DC 20549-0213.

Extension:

Form N-14; SEC File No. 270-297; OMB Control No. 3235-0336

Notice is hereby given that pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.), the Securities and Exchange Commission ("Commission") has submitted to the Office of Management and Budget requests for extension of the previously approved collection of information discussed below.

Form N-14 (17 CFR 239.23) is used by investment companies registered under the Investment Company Act of 1940 (15 U.S.C. 80a-1 et seq.) ("Investment Company Act") and business development companies as defined by Section 2(a)(48) of the Investment Company Act to register securities under the Securities Act of 1933 (15 U.S.C. 77a et seq.) to be issued in business combination transactions specified in rule 145(a) (17 CFR 230.145(a)) and exchange offers. The securities are registered under the Securities Act to ensure that investors receive the material information necessary to evaluate securities issued in business combination transactions. The Commission staff reviews registration statements on Form N-14 for the adequacy and accuracy of the disclosure contained therein. Without Form N-14, the Commission would be unable to verify compliance with securities law requirements. The respondents to the collection of information are investment companies or business development companies issuing securities in business combination transactions. The estimated number of responses is 375 and the collection occurs only when a merger or other business combination is planned. The estimated total annual reporting burden of the collection of information is approximately 620 hours per response for a new registration statement, and approximately 350 hours per response for an amended Form N-14, for a total of 196,050 annual burden hours. Providing the information on Form N-14 is mandatory. Responses will not be kept confidential. Estimates of the burden hours are made solely for the purposes of the Paperwork Reduction Act, and are not derived from a

comprehensive or even a representative survey or study of the costs of SEC rules and forms.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

Please direct general comments regarding the above information to the following persons: (i) Desk Officer for the Securities and Exchange Commission, Office of Management and Budget, Room 10102, New Executive Office Building, Washington, DC 20503 or e-mail to:

Alexander_T._Hunt@omb.eop.gov; and (ii) R. Corey Booth, Director/Chief Information Officer, Securities and Exchange Commission, C/O Shirley Martinson, 6432 General Green Way, Alexandria, VA 22312; or send an e-mail to: PRA_Mailbox@sec.gov. Comments must be submitted to OMB within 30 days of this notice.

Dated: November 19, 2007.

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-22980 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

Submission for OMB Review; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of Investor Education and Advocacy, Washington, DC 20549

Extension:

Rule 17a-3; SEC File No. 270-026; OMB Control No. 3235-0033

Notice is hereby given that pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.), the Securities and Exchange Commission ("Commission") has submitted to the Office of Management and Budget ("OMB") a request for extension of the previously approved collection of information discussed below. The Code of Federal Regulations citation to this collection of information is: 17 CFR 240.17a-3.

Rule 17a-3 under the Securities Exchange Act of 1934 (15 U.S.C. 78a et seq.) establishes minimum standards with respect to business records that broker-dealers registered with the Commission must make and keep current. These records are maintained by the broker-dealer (in accordance with a separate rule), so they can be used by the broker-dealer and reviewed by

Commission examiners, as well as other regulatory authority examiners, during inspections of the broker-dealer.

The collection of information included in Rule 17a-3 is necessary to provide Commission, self-regulatory organization, and State examiners to conduct effective and efficient examinations to determine whether broker-dealers are complying with relevant laws, rules, and regulations. If broker-dealers were not required to create these baseline, standardized records, Commission, self-regulatory organization, and State examiners could be unable to determine whether broker-dealers are in compliance with the Commission's antifraud and anti-manipulation rules, financial responsibility program, and other Commission, self-regulatory organization, and State laws, rules, and regulations.

As of July 30, 2007 there were 5,850 broker-dealers registered with the Commission. The Commission estimates that these broker-dealer respondents incur a total burden of 2,984,760 hours per year to comply with Rule 17a-3. Approximately 1,524,210 of those hours are attributable to Rule 17a-3(a)(17), and about 1,460,550 hours are attributable to the rest of Rule 17a-3. Rule 17a-3(a)(17) contains requirements to provide customers with account information (approximately 975,809 hours) and requirements to update customer account information (approximately 548,401 hours).

In addition, Rule 17a-3 contains ongoing operation and maintenance costs for broker-dealers including the cost of postage to provide customers with account information, and costs for equipment and systems development. The Commission estimates that under Rule 17a-3(a)(17), approximately 36,365,553 customers will need to be provided with information regarding their account on a yearly basis. The Commission estimates that the postage costs associated with providing those customers with copies of their account record information would be approximately \$8,176,435 per year ($28,390,400 \times \0.288).¹ Based on comments provided in response to the 2001 Amendments (as adjusted to account for inflation), the staff believes that the ongoing equipment and systems development costs relating to Rule 17a-3 for the industry would be about \$23,362,847 per year. Consequently, the total cost burden associated with Rule

17a-3 would be approximately \$31,539,282 per year.

Rule 17a-3 does not contain record retention requirements. Compliance with the rule is mandatory. The required records are available only to the staffs of the Commission, self-regulatory organizations of which the broker-dealer is a member, and the States during examinations, inspections and investigations. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid control number.

Comments should be directed to (i) Desk Officer for the Securities and Exchange Commission, Office of Information and Regulatory Affairs, Office of Management and Budget, Room 10102, New Executive Office Building, Washington, DC 20503 or by sending an e-mail to: Alexander_T._Hunt@omb.eop.gov; and (ii) R. Corey Booth, Director/Chief Information Officer, Securities and Exchange Commission, c/o Shirley Martinson, 6432 General Green Way, Alexandria, VA 22312 or send an e-mail to: PRA_Mailbox@sec.gov. Comments must be submitted within 30 days of this notice.

Dated: November 19, 2007.

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-22981 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

Proposed Collection; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of Investor Education and Advocacy, Washington, DC 20549-0213

Extension: Rule 203-3, Form ADV-H; SEC File No. 270-481; OMB Control No. 3235-0538

Notice is hereby given that pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*) the Securities and Exchange Commission ("Commission") is soliciting comments on the collection of information summarized below. The Commission plans to submit this existing collection of information to the Office of Management and Budget for extension and approval.

The title for the collection of information is "Rule 203-3 and Form ADV-H under the Investment Advisers Act of 1940." Rule 203-3 (17 CFR

275.203-3) under the Investment Advisers Act of 1940 (15 U.S.C. 80b) establishes procedures for an investment adviser to obtain a hardship exemption from the electronic filing requirements of the Investment Advisers Act. Rule 203-3 requires every person requesting a hardship exemption to file Form ADV-H (17 CFR 279.3) with the Commission. The purpose of this collection of information is to permit advisers to obtain a hardship exemption, on a continuing or temporary basis, to not complete an electronic filing. The temporary hardship exemption permits advisers to make late filings due to unforeseen computer or software problems, while the continuing hardship exemption permits advisers to submit all required electronic filings on hard copy for data entry by the operator of the IARD.

The respondents to the collection of information are all investment advisers that are registered with the Commission. The Commission has estimated that compliance with the requirement to complete Form ADV-H imposes a total burden of approximately 1 hour for an adviser. Based on our experience with hardship filings, we estimate that we will receive 11 Form ADV-H filings annually. Based on the 60 minute per respondent estimate, the Commission estimates a total annual burden of 11 hours for this collection of information.

Written comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency's estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted in writing within 60 days of this publication.

Please direct your written comments to R. Corey Booth, Director/Chief Information Officer, Securities and Exchange Commission, C/O Shirley Martinson, 6432 General Green Way, Alexandria, VA 22312; or send an e-mail to: PRA_Mailbox@sec.gov.

Dated: November 19, 2007.

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-23002 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

¹ Estimates of postage costs are derived from past conversations with industry representatives and have been adjusted to account for inflation.

SECURITIES AND EXCHANGE COMMISSION

Proposed Collection; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of Investor Education and Advocacy, Washington, DC 20549-0213.

Extension:

Rule 206(4)-4; SEC File No. 270-304; OMB Control No. 3235-0345

Notice is hereby given that, pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*), the Securities and Exchange Commission ("Commission") is soliciting comments on the collections of information summarized below. The Commission plans to submit these existing collections of information to the Office of Management and Budget for extension and approval.

The title for the collection of information is "Rule 206(4)-4" (17 CFR 275.206(4)-4) under the Investment Advisers Act of 1940 (15 U.S.C. 80b-1 *et seq.*). Rule 206(4)-4 requires advisers to disclose certain financial and disciplinary information to clients. The disclosure requirements in rule 206(4)-4 are designed so that a client will have information about an adviser's financial condition and disciplinary events that may be material to an evaluation of the adviser's integrity or ability to meet contractual commitments to clients. Respondents are registered investment advisers with certain disciplinary history or a financial condition that is reasonably likely to affect contractual commitments. We estimate that approximately 1,839 advisers are subject to this rule. The rule requires approximately 7.5 burden hours per year per adviser and amounts to approximately 13,793 total burden hours (7.5 × 1,839) for all advisers.

Written comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency's estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on respondents, including

through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted in writing within 60 days of this publication.

Please direct your written comments to R. Corey Booth, Director/Chief Information Officer, Securities and Exchange Commission, c/o Shirley Martinson, 6432 General Green Way, Alexandria, VA 22312; or send an e-mail to: PRA_Mailbox@sec.gov.

Dated: November 19, 2007.

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-23004 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56809; File No. SR-Amex-2007-116]

Self-Regulatory Organizations; American Stock Exchange LLC; Notice of Filing of Proposed Rule Change, as Modified by Amendment Nos. 1 and 2 Thereto, To Harmonize the Annual Listing Fees for All Exchange Traded Funds

November 16, 2007.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Act")¹ and Rule 19b-4 thereunder,² notice is hereby given that on October 29, 2007, the American Stock Exchange LLC ("Amex" or "Exchange") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I, II, and III below, which Items have been substantially prepared by Amex. On November 9, 2007, the Exchange filed Amendment No. 1 to the proposed rule change.³ On November 16, 2007, the Exchange filed Amendment No. 2 to the proposal.⁴ The

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ Amendment No. 1 made clarifying changes to the purpose section of the original filing and revised the proposed annual listing fee schedule.

⁴ Amendment No. 2 made an additional clarifying change to the proposed annual listing fee schedule. Specifically, all references to a "maximum" or "minimum" identified as a parenthetical in the "Stock Issues" and "Issues Listed Under Section 106 and Section 107; Rule 1000A (Index Fund Shares); Rule 1200 (Trust Issued Receipts); Rule 1200A (Commodity Based Trust Shares); Rule

Commission is publishing this notice to solicit comments on the proposed rule change, as modified by Amendment Nos. 1 and 2, from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The Exchange proposes to revise the annual listing fees for index fund shares, trust-issued receipts, commodity-based trust shares, currency trust shares, paired trust shares, partnership units, and closed-end funds (collectively, "Exchange Traded Funds" or "ETFs") set forth in section 141 of the *Amex Company Guide*. The text of the proposed rule change is available at <http://www.amex.com>, the Exchange's principal, and the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

Amex proposes to amend section 141 of the *Company Guide* to adopt a single annual fee schedule for all ETFs. The proposed annual listing fee schedule is largely based on the existing annual listing fee schedule for index and currency warrants, equity- and index-linked securities, trust-issued receipts, commodity-based trust shares, currency trust shares, paired trust shares, partnership units, and closed-end funds. The current annual listing fees are shown in the table below.

1200B (Currency Trust Shares); Rule 1400 (Paired Trust Shares); Rule 1500 (Partnership Units); and Closed-End Funds' Annual Fee Tables in the *Company Guide* are to be removed.

ISSUES LISTED UNDER SECTION 106 AND SECTION 107; RULES 1200 (TRUST ISSUED RECEIPTS) AND 1200A (COMMODITY-BASED TRUST SHARES); RULE 1200B (CURRENCY TRUST SHARES); RULE 1400 (PAIRED TRUST SHARES); RULE 1500 (PARTNERSHIP UNITS); AND CLOSED-END FUNDS

Shares or units outstanding	Fee
5,000,000 shares (units) or less	\$15,000 (minimum).
5,000,001 to 10,000,000 shares (units)	17,500.
10,000,001 to 25,000,000 shares (units)	20,000.
25,000,001 to 50,000,000 shares (units)	22,500.
In excess of 50,000,000 shares (units)	30,000 (maximum).

ISSUES LISTED UNDER RULE 1000A (INDEX FUND SHARES)

Shares outstanding	Fee
1,000,000 shares or less	\$6,500 (minimum).
1,000,001 to 2,000,000 shares	7,000.
2,000,001 to 3,000,000 shares	7,500.
3,000,001 to 4,000,000 shares	8,000.
4,000,001 to 5,000,000 shares	8,500.
5,000,001 to 6,000,000 shares	9,000.
6,000,001 to 7,000,000 shares	9,500.
7,000,001 to 8,000,000 shares	10,000.
8,000,001 to 9,000,000 shares	10,500.
9,000,001 to 10,000,000 shares	11,000.
10,000,001 to 11,000,000 shares	11,500.
11,000,001 to 12,000,000 shares	12,000.
12,000,001 to 13,000,000 shares	12,500.
13,000,001 to 14,000,000 shares	13,000.
14,000,001 to 15,000,000 shares	13,500.
15,000,001 to 16,000,000 shares	14,000.
In excess of 16,000,000 shares	14,500 (maximum).

The annual listing fees for index fund shares are based on a sliding schedule based on the number of outstanding shares, with a minimum fee of \$6,500 and a maximum of \$14,500. In comparison, the other ETFs have an annual listing fee schedule based on the

number of outstanding shares or units with a minimum fee of \$15,000 and a maximum fee of \$30,000. This proposal would conform the annual listing fees for index fund shares with those of other ETFs and add an additional demarcation for outstanding shares or

units of over 100 million, so that the maximum annual listing fee would increase to \$50,000.

Set forth below is the proposed annual listing fee schedule for all ETFs.

SECURITIES LISTED UNDER SECTION 106 AND SECTION 107 OF THE COMPANY GUIDE; RULE 1000A–AEMI (INDEX FUND SHARES); 1200–AEMI (TRUST ISSUED RECEIPTS); RULE 1200A–AEMI (COMMODITY-BASED TRUST SHARES); RULE 1200B–AEMI (CURRENCY TRUST SHARES); RULE 1400 (PAIRED TRUST SHARES); RULE 1500–AEMI (PARTNERSHIP UNITS); AND CLOSED-END FUNDS

Shares or units outstanding	Fee
5,000,000 shares (units) or less	\$15,000
5,000,001 to 10,000,000 shares (units)	17,500
10,000,001 to 25,000,000 shares (units)	20,000
25,000,001 to 50,000,000 shares (units)	22,500
50,000,001 to 100,000,000 shares (units)	30,000
100,000,001 shares (units) or greater	50,000

Each series of the securities listed as index fund shares, trust-issued receipts, commodity-based trust shares, currency trust shares, paired trust shares, partnership units, or closed-end funds would be separately aggregated. The annual listing fee would then be applied to all of the outstanding securities of a particular issuer for each appropriate product class. Securities listed under Sections 106 and 107 of the Company Guide would be charged listing fees

based on the shares outstanding of each individual issue.

The Exchange believes that the proposed revision to the annual listing fee schedule for ETFs would benefit the marketplace by providing uniformity to its annual fee structure for similarly situated products. In addition, the Exchange believes that slightly increasing the annual listing fees for index fund shares should provide

additional incremental revenue to fund Exchange operations.

The Exchange submits that the proposal to revise the annual listing fees for ETFs in section 141 of the Company Guide is consistent with section 6(b)(4) of the Act.⁵ The Exchange believes that the proposal provides an equitable allocation of annual listing fees among issuers of ETFs. The Exchange further

⁵ 15 U.S.C. 78f(b)(4).

submits that the proposal to simplify and slightly increase annual listing fees for similarly situated derivative products is appropriate for the purpose of uniformity and to generate revenue to fund Exchange operations.

2. Statutory Basis

The proposed rule change is consistent with section 6(b) of the Act⁶ in general, and furthers the objectives of sections 6(b)(4) of the Act⁷ in particular, in that the proposed rule change provides for the equitable allocation of reasonable dues, fees, and other charges among members and issuers and other persons using the Exchange's facilities.

B. Self-Regulatory Organization's Statement on Burden on Competition

The proposed rule change does not impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

No written comments were solicited nor received with respect to the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the **Federal Register** or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the Exchange consents, the Commission will:

(A) By order approve such proposed rule change, or

(B) Institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

Electronic Comments

- Use the Commission's Internet comment form (<http://www.sec.gov/rules/sro.shtml>); or
- Send an e-mail to rule-comments@sec.gov. Please include File

Number SR-Amex-2007-116 on the subject line.

Paper Comments

- Send paper comments in triplicate to Nancy M. Morris, Secretary, Securities and Exchange Commission, 100 F Street, NE., Washington, DC 20549-1090.

All submissions should refer to File Number SR-Amex-2007-116. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (<http://www.sec.gov/rules/sro.shtml>). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room, 100 F Street, NE., Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of such filings also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR-Amex-2007-116 and should be submitted on or before December 17, 2007.

For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.⁸

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-22974 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56818; File No. SR-CBOE-2007-65]

Self-Regulatory Organizations; Chicago Board Options Exchange, Incorporated; Notice of Filing of a Proposed Rule Change as Modified by Amendment No. 1 Thereto Regarding Nullification and Modification of Transactions Executed on CBOE Stock Exchange

November 19, 2007.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"),¹ and Rule 19b-4 thereunder,² notice is hereby given that on June 12, 2007, the Chicago Board Options Exchange, Incorporated ("CBOE" or "Exchange") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I, II, and III below, which Items have been substantially prepared by the Exchange. On November 8, 2007, the CBOE submitted Amendment No. 1 to the proposed rule change.³ The Commission is publishing this notice to solicit comments on the proposed rule change, as amended, from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The Exchange proposes various revisions to CBOE Stock Exchange ("CBSX") Rule 52.4, which governs the nullification and modification of transactions executed on CBSX. The text of the proposed rule change is available at the Exchange, the Commission's Public Reference Room, and <http://www.cboe.com>.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ Amendment No. 1 supersedes and replaces the original filing in its entirety. The substance of Amendment No. 1 is incorporated into this notice.

⁶ 15 U.S.C. 78f(b).

⁷ 15 U.S.C. 78f(b)(4).

⁸ 17 CFR 200.30-3(a)(12).

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The Exchange states that the purpose of this proposed rule change is to revise CBSX Rule 52.4, which governs the nullification and modification of transactions executed on CBSX. Specifically, the Exchange proposes to: (1) Require a request for review of a transaction to be made by only one of the following methods: Telephone; facsimile; or e-mail (in order to simplify the process for those making requests); (2) require such a request to be made within thirty minutes of the trade in question, or within forty-five minutes of the trade if that trade occurred within the first thirty minutes of trading in the product involved in the trade (in order to give more time for requests which, based on the Exchange's experience so far, is necessary); (3) give the individual(s) who reviews transactions under the Rule the label of "designated official," so that they need not be officers of the Exchange; and (4) eliminate the requirement that the notification to the parties to the trade of the official's determination be given in writing and by the official. The aforementioned changes labeled (1) and (4) are based on, and conform CBSX Rule 52.4 to NYSE Arca Equities Rules 7.10(b) and 7.10(c)(1), respectively.

2. Statutory Basis

The Exchange believes the proposed rule change is consistent with section 6(b) of the Act,⁴ in general, and furthers the objectives of section 6(b)(5) of the Act,⁵ in particular, in that it is designed to promote just and equitable principles of trade, serve to remove impediments to and perfect the mechanism of a free and open market and a national market system, and to protect investors and the public interest.

B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received from Members, Participants or Others

No written comments were solicited or received by the Exchange with respect to the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the **Federal Register** or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding, or (ii) as to which the Exchange consents, the Commission will:

A. By order approve the proposed rule change or

B. Institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

Electronic Comments

- Use the Commission's Internet comment form (<http://www.sec.gov/rules/sro.shtml>); or
- Send an e-mail to rule-comments@sec.gov. Please include File Number SR-CBOE-2007-65 on the subject line.

Paper Comments

- Send paper comments in triplicate to Nancy M. Morris, Secretary, Securities and Exchange Commission, 100 F Street, NE., Washington, DC 20549-1090.

All submissions should refer to File Number SR-CBOE-2007-65. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (<http://www.sec.gov/rules/sro.shtml>). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than

those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room, 100 F Street, NE., Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of such filing also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR-CBOE-2007-65 and should be submitted on or before December 18, 2007.

For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.⁶

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-22985 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56817; File No. SR-CBOE-2007-124]

Self-Regulatory Organizations; Chicago Board Options Exchange, Incorporated; Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Change, as Modified by Amendment No. 1 Thereto, To Trade Shares of 93 Funds of the ProShares Trust Pursuant to Unlisted Trading Privileges

November 19, 2007.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Act")¹ and Rule 19b-4 thereunder,² notice is hereby given that on October 30, 2007, the Chicago Board Options Exchange, Incorporated ("CBOE" or "Exchange") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I and II below, which Items have been substantially prepared by the Exchange. On November 15, 2008, the Exchange filed Amendment No. 1 to the proposed rule change. This order provides notice of, and approves, the proposed rule change, as modified by Amendment No. 1 thereto, on an accelerated basis.

⁶ 17 CFR 200.30-3(a)(12).

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

⁴ 15 U.S.C. 78f(b).

⁵ 15 U.S.C. 78f(b)(5).

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

CBOE is proposing to trade on its stock trading facility, the CBOE Stock Exchange ("CBSX"), shares ("Shares") of the 93 funds identified below (collectively, the "Funds") of the ProShares Trust ("Trust") pursuant to unlisted trading privileges ("UTP").

The text of the proposed rule change is available from the Exchange's Web site (<http://www.cboe.org/Legal>), at the principal office of the Exchange, and at the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item III below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The Exchange proposes to trade, pursuant to UTP, the Shares of 93 Funds, which are exchange-traded funds ("ETFs"). The Commission has approved exchange rules for the original listing and trading of the Shares on the American Stock Exchange ("Amex"). CBOE is submitting this filing because its current generic listing standards for ETFs do not extend to ETFs with the investment objective of corresponding to a specified multiple of the performance, or the inverse performance, of an index that underlies each Fund (each such index is referred to below as an "Underlying Index"), rather than merely mirroring the performance of the index. Some of the Shares were approved for listing and trading only recently, and actual trading has not yet commenced.

Ultra Funds

Certain Funds seek daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Underlying Indexes ("Ultra Funds"). If such Funds meet their objective, the net asset value (the

"NAV")³ of the Shares of each Fund should increase (on a percentage basis) approximately twice as much as the Fund's Underlying Index when the prices of the securities in such Index increase on a given day, and should lose approximately twice as much when such prices decline on a given day. This filing applies to the following Ultra Funds: Four Ultra Funds listed and traded on Amex pursuant to Commission order on May 10, 2006:⁴ (1) Ultra S&P 500, (2) Ultra Nasdaq-100, (3) Ultra Dow 30, and (4) Ultra S&P Mid-Cap 400; and 27 Ultra Funds listed and traded on Amex pursuant to Commission order on January 17, 2007:⁵ (1) Ultra Russell 2000, (2) Ultra S&P SmallCap 600, (3) Ultra S&P500/Citigroup Value, (4) Ultra S&P500/Citigroup Growth, (5) Ultra S&P MidCap 400/Citigroup Value, (6) Ultra S&P MidCap 400/Citigroup Growth, (7) Ultra S&P SmallCap 600/Citigroup Value, (8) Ultra S&P SmallCap 600/Citigroup Growth, (9) Ultra Basic Materials, (10) Ultra Consumer Goods, (11) Ultra Consumer Services, (12) Ultra Financials, (13) Ultra Health Care, (14) Ultra Industrials, (15) Ultra Oil & Gas, (16) Ultra Real Estate, (17) Ultra Semiconductors, (18) Ultra Technology, (19) Ultra Utilities, (20) Ultra Russell Midcap Index, (21) Ultra Russell Midcap Growth Index, (22) Ultra Russell Midcap Value Index, (23) Ultra Russell 1000 Index, (24) Ultra Russell 1000 Growth Index, (25) Ultra Russell 1000 Value Index, (26) Ultra Russell 2000 Growth Index, and (27) Ultra Russell 2000 Value Index.

Short Funds

CBOE also proposes to trade Shares of certain Funds that seek daily investment results, before fees and expenses, that correspond to the inverse or opposite of the daily performance (-100%) of the Underlying Indexes ("Short Funds"). If such a Fund is successful in meeting its

³ NAV per Share of each Fund is computed by dividing the value of the net assets of such Fund (i.e., the value of its total assets less total liabilities) by its total number of Shares outstanding. Expenses and fees are accrued daily and taken into account for purposes of determining NAV.

⁴ Securities Exchange Act Release No. 53784 (May 10, 2006), 71 FR 28721 (May 17, 2006). These Funds were subsequently approved for UTP trading on NYSE Arca, Inc. and The NASDAQ Stock Market LLC. See Securities Exchange Act Release Nos. 54026 (June 21, 2006), 71 FR 36850 (June 28, 2006) and 55353 (February 26, 2007), 72 FR 9802 (March 5, 2007).

⁵ Securities Exchange Act Release No. 55117 (January 17, 2007), 72 FR 3442 (January 25, 2007). These Funds were subsequently approved for UTP trading on NYSE Arca, Inc. and The NASDAQ Stock Market LLC. See Securities Exchange Act Release Nos. 55125 (January 18, 2007), 72 FR 3462 (January 25, 2007) and 55353 (February 26, 2007), 72 FR 9802 (March 5, 2007).

objective, the NAV of the corresponding Shares should increase approximately as much (on a percentage basis) as the respective Underlying Index loses when the prices of the securities in the Index decline on a given day, or should decrease approximately as much as the respective Index gains when prices in the Index rise on a given day.

This filing applies to the following Short Funds: Four Short Funds listed and traded on Amex pursuant to Commission order on May 10, 2006:⁶ (1) Short S&P 500, (2) Short Nasdaq-100, (3) Short Dow 30, and (4) Short S&P Mid-Cap 400; and 27 Short Funds listed and traded on Amex pursuant to Commission order on January 17, 2007:⁷ (1) Short Russell 2000, (2) Short S&P SmallCap 600, (3) Short S&P500/Citigroup Value, (4) Short S&P500/Citigroup Growth, (5) Short S&P MidCap 400/Citigroup Value, (6) Short S&P MidCap 400/Citigroup Growth, (7) Short S&P SmallCap 600/Citigroup Value, (8) Short S&P SmallCap 600/Citigroup Growth, (9) Short Basic Materials, (10) Short Consumer Goods, (11) Short Consumer Services, (12) Short Financials, (13) Short Health Care, (14) Short Industrials, (15) Short Oil & Gas, (16) Short Real Estate, (17) Short Semiconductors, (18) Short Technology, (19) Short Utilities, (20) Short Russell Midcap Index, (21) Short Russell Midcap Growth Index, (22) Short Russell Midcap Value Index, (23) Short Russell 1000 Index, (24) Short Russell 1000 Growth Index, (25) Short Russell 1000 Value Index, (26) Short Russell 2000 Growth Index, and (27) Short Russell 2000 Value Index.

UltraShort Funds

CBOE also proposes to trade Shares of certain Funds that seek daily investment results, before fees and expenses, that correspond to twice the inverse (-200%) of the daily performance of the Underlying Indexes ("UltraShort Funds"). If such a Fund is successful in meeting its objective, the NAV of the corresponding Shares should increase approximately twice as much (on a percentage basis) as the respective Underlying Index loses when the prices of the securities in the Index decline on a given day, or should decrease approximately twice as much as the respective Underlying Index gains when such prices rise on a given day.

This filing applies to the following UltraShort Funds: Four UltraShort Funds listed and traded on Amex pursuant to Commission order on June

⁶ See supra note 2.

⁷ See supra note 3.

23, 2006:⁸ (1) UltraShort S&P 500, (2) UltraShort Nasdaq-100, (3) UltraShort Dow 30, and (4) UltraShort S&P Mid-Cap 400; and 27 UltraShort funds listed and traded on Amex pursuant to Commission order on January 17, 2007:⁹ (1) UltraShort Russell 2000, (2) UltraShort S&P SmallCap 600, (3) UltraShort S&P500/Citigroup Value, (4) UltraShort S&P500/Citigroup Growth, (5) UltraShort S&P MidCap 400/Citigroup Value, (6) UltraShort S&P MidCap 400/Citigroup Growth, (7) UltraShort S&P SmallCap 600/Citigroup Value, (8) UltraShort S&P SmallCap 600/Citigroup Growth, (9) UltraShort Basic Materials, (10) UltraShort Consumer Goods, (11) UltraShort Consumer Services, (12) UltraShort Financials, (13) UltraShort Health Care, (14) UltraShort Industrials, (15) UltraShort Oil & Gas, (16) UltraShort Real Estate, (17) UltraShort Semiconductors, (18) UltraShort Technology, (19) UltraShort Utilities, (20) UltraShort Russell Midcap Index, (21) UltraShort Russell Midcap Growth Index, (22) UltraShort Russell Midcap Value Index, (23) UltraShort Russell 1000 Index, (24) UltraShort Russell 1000 Growth Index, (25) UltraShort Russell 1000 Value Index, (26) UltraShort Russell 2000 Growth Index, and (27) UltraShort Russell 2000 Value Index.

Access to the current portfolio composition of each Fund is currently available through the Trust's Web site (<http://www.proshares.com>).¹⁰ The Underlying Indexes are identified in Amex's proposed rule changes to list the Funds (the "Original Filings").¹¹ The Original Filings state that Amex would disseminate for each Fund on a daily basis by means of Consolidated Tape Association ("CTA") and CQ High Speed Lines information with respect to

an Indicative Intra-Day Value ("IIV"), the daily trading volume, closing price, NAV, and final dividend amounts, if any, to be paid for each Fund.¹²

The Original Filings state that the daily closing index value and the percentage change in the daily closing index value for each Underlying Index would be publicly available on various Web sites such as <http://www.bloomberg.com>. The Original Filings further state that data regarding each Underlying Index are also available from the respective index provider to subscribers. According to the Original Filings, several independent data vendors package and disseminate index data in various value-added formats (including vendors displaying both securities and index levels and vendors displaying index levels only).

The Original Filings state that the value of each Underlying Index is updated intra-day on a real-time basis as its individual component securities change in price, and the intra-day values of each Underlying Index are disseminated at least every 15 seconds throughout Amex's trading day by Amex or another organization authorized by the relevant Underlying Index provider.

To provide updated information relating to each Fund for use by investors, professionals, and persons wishing to create or redeem Shares, Amex disseminates through the facilities of the CTA: (1) Continuously throughout Amex's trading day, the market value of a Share; and (2) at least every 15 seconds throughout Amex's trading day, the IIV as calculated by Amex.

Shares would trade on CBOE from 8:15 a.m. until 3:15 p.m. Central Time. CBOE has appropriate rules to facilitate transactions in the Shares during that trading session.

With respect to trading halts, the Exchange may consider all relevant factors in exercising its discretion to halt or suspend trading in the Funds. Trading in the Funds may be halted because of market conditions or for reasons that, in the view of the Exchange, make trading in the Funds inadvisable. These may include: (1) The extent to which trading is not occurring in the securities comprising an underlying Index and/or the financial instruments of the Funds, or (2) whether other unusual conditions or circumstances detrimental to the maintenance of a fair and orderly

market are present. In addition, trading in the Funds would be subject to trading halts caused by extraordinary market volatility pursuant to the Exchange's "circuit breaker" rule.¹³

Moreover, the Exchange represents that it would cease trading a Fund if the listing market stopped trading that Fund because of a regulatory halt similar to a halt based on CBOE Rule 6.3. UTP trading in the Funds is also governed by the trading halts provisions of CBOE Rule 52.3 relating to temporary interruptions in the calculation or wide dissemination of IIVs or the values of underlying indexes. Finally, CBOE would stop trading the Shares of a Fund if the listing market delists them.

In connection with the trading of the Shares, CBOE will inform its members in an Information Circular of the special characteristics and risks associated with trading the Shares, as well as the requirements of CBOE Rule 53.6, which requires members of the Exchange to determine that a particular security is suitable for a customer before recommending a transaction in it. The Exchange also will require its members to deliver a prospectus or product description to investors purchasing the Shares prior to or concurrently with a transaction in the Shares.

CBOE deems the Shares to be equity securities, thus rendering trading in the Shares subject to the Exchange's existing rules applicable to UTP trading of equity securities. The Exchange intends to utilize its existing surveillance procedures applicable to equity securities to monitor trading in the Shares. The Exchange represents that these procedures are adequate to monitor Exchange trading of the Shares.

Finally, the Exchange is proposing to amend CBOE Rule 53.6, the CBSX suitability rule, so that each member organization's obligation under that rule is heightened. Specifically, the Exchange proposes to amend CBOE Rule 53.6 to provide that, in making a recommendation to a customer, a member organization must have reasonable grounds for the recommendation upon the basis of the information furnished by the customer after reasonable inquiry concerning the customer's investment objectives, tax status, financial situation and needs, and any other information known by such member organization. Other exchanges have adopted similar rule text.¹⁴ That enhanced obligation would apply to a member organization's recommendation of any security that is

⁸ Securities Exchange Act Release No. 54040 (June 23, 2006), 71 FR 37629 (June 30, 2006). These Funds were subsequently approved for UTP trading on NYSE Arca. See Securities Exchange Act Release No. 54045 (June 26, 2006), 71 FR 37971 (July 3, 2006).

⁹ See *supra* note 5.

¹⁰ The Trust's Web site is publicly accessible at no charge and contains the following information for each Fund's Shares: (1) The prior business day's closing NAV, the reported closing price, and a calculation of the premium or discount of such price in relation to the closing NAV; (2) data for a period covering at least the current and three immediately preceding calendar quarters (or the life of a Fund, if shorter) indicating how frequently each Fund's Shares traded at a premium or discount to NAV based on the daily closing price and the closing NAV, and the magnitude of such premiums and discounts; (3) its prospectus and product description; and (4) other quantitative information such as daily trading volume. The prospectus and/or product description for each Fund would inform investors that the Trust's Web site has information about the premiums and discounts at which the Fund's Shares have traded.

¹¹ See *supra* notes 4, 5, and 8.

¹² The Original Filings explain that, if the IIV is not disseminated as required, Amex would halt trading in the shares of the Funds. If Amex halts trading for this reason, then CBOE would do so as well.

¹³ See CBOE Rule 6.3B.

¹⁴ See, e.g., Amex Rule 411, Commentary .05; NYSE Arca Rule 9.2(a)(2).

subject to Chapters 50 through 54 of the Exchange's rules, including the Shares.

2. Statutory Basis

CBOE believes that the proposed rule change is consistent with the Act and the rules and regulations thereunder applicable to a national securities exchange and, in particular, section 6(b) of the Act.¹⁵ Specifically, CBOE believes that the proposed rule change is consistent with the section 6(b)(5)¹⁶ requirements that an exchange have rules designed to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and, in general, to protect investors and the public interest. In addition, CBOE believes that the proposal is consistent with Rule 12f-5 under the Act¹⁷ because it deems the Shares to be equity securities, thus rendering trading in the Shares subject to the Exchange's existing rules governing the trading of equity securities.

B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

The Exchange neither solicited nor received comments on the proposal.

III. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

Electronic Comments

- Use the Commission's Internet comment form (<http://www.sec.gov/rules/sro.shtml>); or
- Send an e-mail to rule-comments@sec.gov. Please include File Number SR-CBOE-2007-124 on the subject line.

Paper Comments

- Send paper comments in triplicate to Nancy M. Morris, Secretary, Securities and Exchange Commission,

100 F Street, NE., Washington, DC 20549-1090.

All submissions should refer to File Number SR-CBOE-2007-124. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (<http://www.sec.gov/rules/sro.shtml>). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room, 100 F Street NE., Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of such filing also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR-CBOE-2007-124 and should be submitted on or before December 18, 2007.

IV. Commission's Findings and Order Granting Accelerated Approval of the Proposed Rule Change

After careful review, the Commission finds that the proposed rule change is consistent with the requirements of the Act and the rules and regulations thereunder applicable to a national securities exchange.¹⁸ In particular, the Commission finds that the proposed rule change is consistent with section 6(b)(5) of the Act,¹⁹ which requires that an exchange have rules designed, among other things, to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism of a free and open market and a national market system, and in general to protect investors and the public interest. The Commission believes that this proposal should

benefit investors by increasing competition among markets that trade the Shares.

In addition, the Commission finds that the proposal is consistent with section 12(f) of the Act,²⁰ which permits an exchange to trade, pursuant to UTP, a security that is listed and registered on another exchange.²¹ The Commission notes that it previously approved the listing and trading of the Shares on Amex and the trading of the Shares on NYSE Arca and The NASDAQ Stock Market pursuant to UTP.²² The Commission also finds that the proposal is consistent with Rule 12f-5 under the Act,²³ which provides that an exchange shall not extend UTP to a security unless the exchange has in effect a rule or rules providing for transactions in the class or type of security to which the exchange extends UTP. The Exchange has represented that it meets this requirement because it deems the Shares to be equity securities, thus rendering trading in the Shares subject to the Exchange's existing rules governing the trading of equity securities.

The Commission further believes that the proposal is consistent with section 11A(a)(1)(C)(iii) of the Act,²⁴ which sets forth Congress' finding that it is in the public interest and appropriate for the protection of investors and the maintenance of fair and orderly markets to assure the availability to brokers, dealers, and investors of information with respect to quotations for and transactions in securities. Quotations for and last-sale information regarding the Shares are disseminated through the facilities of the CTA and the Consolidated Quotation System. Furthermore, the IIV, updated to reflect changes in currency exchange rates, is calculated by Amex and published via the facilities of the Consolidated Tape Association on a 15-second delayed basis throughout the trading hours for the Shares.

The Commission also believes that the proposal appears reasonably designed to preclude trading of the Shares when transparency is impaired. Trading in the

²⁰ 15 U.S.C. 78l(f).

²¹ Section 12(a) of the Act, 15 U.S.C. 78l(a), generally prohibits a broker-dealer from trading a security on a national securities exchange unless the security is registered on that exchange pursuant to Section 12 of the Act. Section 12(f) of the Act excludes from this restriction trading in any security to which an exchange "extends UTP." When an exchange extends UTP to a security, it allows its members to trade the security as if it were listed and registered on the exchange even though it is not so listed and registered.

²² See *supra* notes 4-9.

²³ 17 CFR 240.12f-5.

²⁴ 15 U.S.C. 78k-1(a)(1)(C)(iii).

¹⁸ In approving this rule change, the Commission notes that it has considered the proposal's impact on efficiency, competition, and capital formation. See 15 U.S.C. 78c(f).

¹⁹ 15 U.S.C. 78f(b)(5).

¹⁵ 15 U.S.C. 78f(b).

¹⁶ 15 U.S.C. 78f(b)(5).

¹⁷ 17 CFR 240.12f-5.

Shares will be subject to CBOE Rule 52.3, which provides that, if the listing market halts trading when the IIV or value of the underlying index is not being calculated or disseminated, the Exchange also would halt trading.

In support of this proposal, the Exchange has made the following additional representations:

1. The Exchange's surveillance procedures are adequate to properly monitor Exchange trading of the Shares in all trading sessions and to deter and detect violations of Exchange rules.

2. Prior to the commencement of trading, the Exchange would inform its members in an Information Bulletin of the special characteristics and risks associated with trading the Shares.

3. The Information Bulletin also would discuss the requirement that members deliver a prospectus to investors purchasing newly issued Shares prior to or concurrently with the confirmation of a transaction.

This approval order is based on the Exchange's representations.

The Commission notes that, if the Shares should be delisted by the listing exchange, the Exchange would no longer have authority to trade the Shares pursuant to this order.

The Commission finds good cause for approving this proposal before the thirtieth day after the publication of notice thereof in the **Federal Register**. As noted above, the Commission previously found that the listing and trading of the Shares on Amex and the trading of the Shares on NYSE Arca and The NASDAQ Stock Market pursuant to UTP are consistent with the Act. The Commission presently is not aware of any regulatory issue that should cause it to revisit those findings or would preclude the trading of the Shares on the Exchange pursuant to UTP. Therefore, accelerating approval of this proposal should benefit investors by creating, without undue delay, additional competition in the market for the Shares.

V. Conclusion

It is therefore ordered, pursuant to section 19(b)(2) of the Act,²⁵ that the proposed rule change (SR-CBOE-2007-124), as modified by Amendment No. 1 thereto, be, and it hereby is, approved on an accelerated basis.

For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.²⁶

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-23000 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56821; File No. SR-CBOE-2007-82]

Self-Regulatory Organizations; Chicago Board Options Exchange, Incorporated; Order Granting Approval of Proposed Rule Change as Modified by Amendment No. 1 Thereto To Allow the Exchange To List Up to Seven Expiration Months for Broad-Based Security Index Options Upon Which the Exchange Calculates a Constant Three-Month Volatility Index

November 20, 2007.

I. Introduction

On July 17, 2007, the Chicago Board Options Exchange, Incorporated ("CBOE" or "Exchange") filed with the Securities and Exchange Commission ("Commission") a proposed rule change, pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Act")¹ and Rule 19b-4 thereunder,² to permit the Exchange to: (i) Amend Rule 24.9(a)(2), *Terms of Index Option Contracts*, to allow the Exchange to list up to seven expiration months for broad-based security index options upon which the Exchange calculates a constant three-month volatility index; and (ii) remove outdated rule text from Rule 24.9(a)(2). On September 19, 2007, CBOE filed Amendment No. 1 to the proposed rule change. The proposed rule change, as modified by Amendment No. 1, was published for comment in the **Federal Register** on October 16, 2007.³ The Commission received no comments on the proposal. This order approves the proposed rule change, as amended.

II. Description of the Proposal

In its proposal, CBOE proposed to amend Rule 24.9(a)(2), *Terms of Index Options*, to allow the Exchange to list up to seven expiration months for broad-based security index options upon which the Exchange calculates a constant three-month volatility index. Currently, Rule 24.9(a)(2) permits the

Exchange to list only six expiration months in any index options at any one time.

In the filing, CBOE explained that it had plans to introduce new volatility products and new volatility indexes in the near future, including the CBOE S&P 500 Three-Month Volatility Index ("VXV").⁴ According to CBOE, VXV is a measure of S&P 500 implied volatility—the volatility implied by S&P option prices—but instead of reflecting a constant 1-month implied volatility period (like other volatility indexes such as the CBOE Volatility Index or "VIX"), VXV is designed to reflect the implied volatility of an option with a constant 3 months to expiration. Since there is only one day on which an option has exactly 3 months to expiration, VXV is calculated as a weighted average of options expiring immediately before and immediately after the three-month standard. Accordingly, the Exchange would need to use four consecutive expiration months in order to calculate a constant three-month volatility index.

CBOE stated in its filing that under the current application of CBOE Rule 24.9(a)(2), the Exchange generally lists three consecutive near term months and three months on a quarterly expiration cycle. One of the three consecutive near term months is always a quarterly month; however, that near term contract month (which is also a quarterly month) is not included as part of the three months listed on a quarterly expiration cycle. Therefore, in order to permit the addition of four consecutive near term months under current Rule 24.9(a)(2), the Exchange would only be able to list two months on a quarterly expiration cycle. Because of customer demand and other investment strategy reasons for having three months on a quarterly expiration cycle, the Exchange proposed to increase, from six to seven, the number of expiration months for broad-based security index options upon which the Exchange calculates a constant three-month volatility index.

CBOE explained that without this proposed rule change, if the Exchange calculated a three-month volatility using only three consecutive near term months, this would result in the VXV being calculated with options expiring three months apart about one-third of

⁴ The Exchange calculates volatility indexes on other broad-based security indexes, such as the Dow Jones Industrial Average index ("DJX"), the Nasdaq-100 index ("NDX"), and the Russell 2000 index ("RUT"). The Exchange may calculate a constant three-month volatility index on DJX, NDX or RUT in the future.

²⁶ 17 CFR 200.30-3(a)(12).

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ See Securities Exchange Act Release No. 56632 (October 9, 2007), 72 FR 58694 ("Notice").

²⁵ 15 U.S.C. 78s(b)(2).

the time.⁵ Another one-third of the time, VXV would be calculated with options expiring two months apart. And the final one-third of the time, VXV would be calculated with options expiring one month apart. As a result, the calculation of the three-month VXV under current Rule 24.9(a)(2) would render the VXV subject to inconsistencies that, according to CBOE, may make the index unattractive as an underlying for volatility products.

Under the proposed rule change, however, the Exchange will be permitted, eight times a year, to add an additional seventh month in order to maintain four consecutive near term contract months.

The Exchange also proposed to remove outdated rule text from Rule 24.9(a)(2). Specifically, the Exchange proposed to delete the provision that permitted the Exchange to list up to seven expiration months at any one time for the SPX, MNX and DJX index option contracts, provided that one of those expiration months is November 2004.⁶

Capacity

CBOE represented that it has analyzed its capacity and represents that it believes the Exchange and the Options Price Reporting Authority have the necessary systems capacity to handle the additional traffic associated with the additional listing of a seventh contract month in order to maintain four consecutive near term contract months for those broad-based security index options upon which the Exchange calculates a constant three-month volatility index.

III. Discussion

After careful review, the Commission finds that CBOE's proposal to amend Rule 24.9(a)(2), *Terms of Index Option Contracts*, to allow the Exchange to list up to seven expiration months for broad-based security index options upon which the Exchange calculates a constant three-month volatility index, and to remove certain outdated rule text from Rule 24.9(a)(2) is consistent with the requirements of the Act and the rules and regulations thereunder applicable to a national securities

⁵ See Notice, *supra* note 3, at 58695 (providing examples to illustrate the effect of the proposed rule change).

⁶ This provision was added in July 2004 in response to customer demand for index options expiring in November 2004 to hedge positions in stocks overlying particular index options or to hedge market exposure to the equity markets generally against the uncertainty presented by the elections. See Securities Exchange Act Release No. 50063 (July 22, 2004), 69 FR 45357 (July 29, 2004)(SR-CBOE-2004-49).

exchange⁷ and, in particular, the requirements of section 6 of the Act⁸ and the rules and regulations thereunder. The Commission believes that increasing, from six to seven, the number of expiration months for broad-based security indexes on which the Exchange calculates a constant three-month volatility index (to accommodate a fourth consecutive near-term month while maintaining the listing of three months on a quarterly expiration cycle) will result in a more consistent and predictable calculation in which the option series that bracket three months to expiration will always expire one month apart, thereby promoting just and equitable principles of trade while protecting investors and the public interest.

The Commission also notes CBOE's representations that it possesses the necessary systems capacity to handle the additional traffic associated with the additional listing of a seventh contract month in order to maintain four consecutive near term contract months for those broad-based security index options upon which the Exchange calculates a constant three-month volatility index.

IV. Conclusion

It is therefore ordered, pursuant to section 19(b)(2) of the Act,⁹ that the proposed rule change (SR-CBOE-2007-82), as amended, be, and hereby is, approved.

For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.¹⁰

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-23001 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

⁷ In approving this proposed rule change, the Commission has considered the proposed rule's impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).

⁸ 15 U.S.C. 78f.

⁹ 15 U.S.C. 78s(b)(2).

¹⁰ 17 CFR 200.30-3(a)(12).

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56813; File No. SR-CBOE-2007-52]

Self-Regulatory Organizations; Chicago Board Options Exchange, Incorporated; Order Granting Approval of Proposed Rule Change as Modified by Amendment No. 1 Thereto Relating to \$1 Strikes for VXD and VXN Options and \$1 Strikes for RVX, VIX, VXD and VXN LEAPs

November 19, 2007.

I. Introduction

On July 11, 2007, the Chicago Board Options Exchange, Incorporated ("CBOE" or "Exchange") filed with the Securities and Exchange Commission ("Commission") a proposed rule change, pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act")¹ and Rule 19b-4 thereunder,² to permit the Exchange to: (i) List and trade CBOE Dow Jones Industrial Average Volatility Index ("VXD") options and Nasdaq-100 Volatility Index ("VXN") options in \$1 strike price intervals; and (ii) list and trade CBOE Russell 2000 Volatility Index ("RVX"), VXD, VXN and CBOE Volatility Index ("VIX") LEAPs in \$1 strike price intervals. On August 20, 2007, CBOE filed Amendment No. 1 to the proposed rule change. The proposed rule change, as modified by Amendment No. 1, was published for comment in the **Federal Register** on September 24, 2007.³ The Commission received one comment letter regarding the proposal.⁴ This order approves the proposed rule change, as amended.

II. Description of the Proposal

In its proposal, CBOE proposed rules to permit the Exchange to list and trade options on the CBOE Dow Jones Industrial Average Volatility Index ("VXD") and the Nasdaq-100 Volatility Index ("VXN") in \$1 strike price intervals within certain parameters described below.⁵ Additionally, the rule change proposed to permit the Exchange

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ See Securities Exchange Act Release No. 56449 (September 17, 2007), 72 FR 54306 ("Notice").

⁴ See Letter from John C. Nagel, Director & Associate General Counsel, Citadel Investment Group, L.L.C. ("Citadel") to Nancy Morris, Secretary, Commission, dated November 2, 2007 ("Citadel Comment").

⁵ The Commission previously approved the listing and trading of VXD and VXN options, which the Exchange anticipates trading shortly. See Securities Exchange Act Release No. 49563 (April 14, 2004), 69 FR 21589 (April 21, 2004) (approving SR-CBOE-2003-40).

to list and trade CBOE Russell Volatility Index ("RVX"), CBOE Volatility Index ("VIX"), VXD, and VXN LEAPs in \$1 strike price intervals within certain parameters also described below.

\$1 Strikes for VXD and VXN Options

Similar to other volatility indexes, VXD and VXN are calculated using real-time quotes of out-of-the-money and at-the-money and second nearly index puts and calls on the Dow Jones Industrial Index ("DJIA") and the Nasdaq-100 Index ("NDX") respectively. VXD and VXN are quoted in absolute numbers that represent the volatility of the DJIA and the NDX respectively in percentage points per annum. For example, a VXD level of 11.63 (the closing value of the VXD on April 26, 2007) represents an annualized volatility of 11.63% in the DJIA Index and a VXN level of 15.97 (the closing value of the VXN on April 26, 2007) represents an annualized volatility of 15.97% in the NDX.⁶

According to CBOE, as with other proprietary CBOE volatility indexes, VXD and VXN levels fluctuate quite differently than individual equity securities or indexes of individual equity securities. Specifically, indexes such as VXD and VXN that track volatility are "mean-reverting," a statistical term used to describe a strong tendency for the volatility index to move toward its long-term historical average level. In other words, at historically low volatility index levels, there is a higher probability that the next big move will be up rather than down. Conversely, at historically high volatility index levels, the next big move is more likely to be down rather than up.

Thus, as represented by CBOE, volatility indexes such as VXD and VXN tend to move within set ranges, and even when a level moves outside that range, the tendency towards mean-reversion often results in the volatility index returning to a level within the range. In the case of VXD, the historical average index value since January 2, 2002 is 16.92. Since January 2002, VXD has fluctuated in a range between 9.28 and 41.85. Furthermore, VXD closed under 25 for 85% of the days on which the level was calculated since 2002 (1,171 days out of a total of 1,372 days) and has closed under 30 for 91% of the

days on which the level was calculated since 2002 (1,245 days out of a total of 1,372 days). VXD has closed between 10 and 25 for 82% of the days on which the level was calculated since 2002 (1,130 days out of a total of 1,372 days).

In the case of VXN, the historical average index value since January 2, 2002 is 26.14. Since January 2002, VXN has fluctuated in a range between 12.61 and 60.66. Furthermore, VXN closed under 25 for 61% of the days on which the level was calculated since 2002 (822 days out of a total of 1,355 days) and has closed under 30 for 73% of the days on which the level was calculated since 2002 (987 days out of a total of 1,355 days). VXN has closed between 15 and 30 for 66% of the days on which the level was calculated since 2002 (895 days out of a total of 1,355 days).

Because of the generally limited range in which VXD and VXN have fluctuated, CBOE proposed to list series at \$1 or greater strike price intervals for each expiration on up to 5 VXD and VXN option series above and 5 VXD and VXN option series below the current index level.⁷ As the current index level of VXD and VXN moves from the exercise price of those VXD and VXN option series that already have been opened for trading on the Exchange, the Exchange may open for trading additional series at \$1.00 or greater strike price intervals for each expiration on up to 5 VXD and VXN option series above and 5 VXD and VXN option series below the current index level.

Additionally, the Exchange proposed that it would not list series with \$1 intervals within \$0.50 of an existing \$2.50 strike price with the same expiration month (e.g., if there is an existing 12.50 strike, the Exchange would not list a 12 or 13 strike).

\$1 Strike LEAPs for RVX, VIX, VXN and VXD

Similarly, the Exchange proposed rules to permit \$1 strike intervals for RVX, VIX, VXD and VXN LEAPs. According to CBOE, typically LEAPs strike prices moves in increments of \$2.50 and \$5.00 and such incremental pricing is suited for long-term contracts on traditional equity and stock index products. However, as discussed above, the levels of volatility indexes fluctuate quite differently than equities and stock indexes. As a "mean-reverting" product,

volatility indexes gravitate towards their historical average levels; thus, limiting the range of movement.

Consequently, the Exchange proposed to list series at \$1 or greater strike price intervals for each expiration on up to 5 RVX, VIX, VXD and VXN LEAPs series above and 5 RVX, VIX, VXD and VXN LEAPs series below the current index level. As the current index level of RVX, VIX, VXD and VXN moves from the exercise price of those RVX, VIX, VXD and VXN LEAPs series that already have been opened for trading on the Exchange, the Exchange may open for trading additional series at \$1.00 or greater strike price intervals for each expiration on up to 5 RVX, VIX, VXD and VXN LEAPs series above and 5 RVX, VIX, VXD and VXN LEAPs series below the current index level.

For purposes of adding strike prices at \$1.00 or greater strike price intervals, as well as at \$2.50 or greater strike price intervals, the "current index level" would be defined as the "implied forward level" of RVX, VIX, VXN and VXD for each expiration.⁸

Capacity

CBOE represented that it has analyzed its capacity and represents that it believes the Exchange and the Options Price Reporting Authority have the necessary systems capacity to handle the additional traffic associated with the listing and trading of the \$1 strikes for VXD and VXN option and of the \$1 strikes for RVX, VIX, VXD and VXN LEAPs.

III. Summary of Comment Received

The Commission received one comment letter regarding the proposed rule change, from Citadel. Citadel supported the adoption of the proposal and, in general, the expansion of \$1 strike price intervals, stating that expansion of products available to exchanges and investors was "fundamentally pro-competitive" and that, moreover, "\$1 strike price intervals allow traders and investors to customize the risk profiles of their trading positions more precisely, and thus reduce the cost of trading."⁹ Citadel commented favorably about the Commission's prior pilot program to allow \$1 strike intervals,¹⁰ and advocated that the Commission "promote the expansion of \$1 strike programs even if doing so requires curtailing or slowing further expansion of penny quoting."¹¹ With regard to the

⁶ In its original filing, CBOE inadvertently reported annualized volatility percentages of 11.637% (rather than 11.63%) and 15.77% (rather than 15.97%). Telephone conversation between Jennifer Yeadon, Senior Attorney, CBOE and Geoffrey Pemble, Special Counsel, Division of Market Regulation, Commission, on November 15, 2007.

⁷ The Commission previously approved the listing of VIX and RVX options at \$1 strike intervals. See Securities Exchange Act Release No. 54192 (July 21, 2006), 71 FR 43251 (July 31, 2006) (approving SR-CBOE-2006-27); see also Securities Exchange Act Release No. 55425 (March 8, 2007), 72 FR 12238 (March 15, 2007) (approving SR-CBOE-2006-73).

⁸ See Notice, *supra* n. 3, for further discussion of this methodology.

⁹ See Citadel Comment at 1.

¹⁰ *Id.* at 2.

¹¹ *Id.* at 3.

proposal, Citadel noted that “permitting CBOE to list and trade options that are the subject of the Proposal in \$1 strike intervals would benefit the public, including retail investors,” for many of the same reasons \$1 strike options do, as well as for reasons specific to volatility options, such as the “mean-reverting” characteristics of volatility indexes.¹² Similarly, Citadel supported the listing and trading of LEAPs on certain volatility indexes, as proposed by CBOE, arguing that the “case for strike-intervals for LEAPs on volatility indexes is even stronger than the case for narrow-interval LEAPs on single stocks.”

IV. Discussion

After careful review, the Commission finds that CBOE’s proposal to (i) list and trade CBOE Dow Jones Industrial Average Volatility Index (“VXD”) options and Nasdaq-100 Volatility Index (“VXN”) options in \$1 strike price intervals; and (ii) list and trade CBOE Russell 2000 Volatility Index (“RVX”), VXD, VXN and CBOE Volatility Index (“VIX”) LEAPs in \$1 strike price intervals is consistent with the requirements of the Act and the rules and regulations thereunder applicable to a national securities exchange¹³ and, in particular, the requirements of section 6 of the Act¹⁴ and the rules and regulations thereunder. The Commission believes that CBOE’s proposal gives options investors the ability to make additional investment choices in a manner consistent with the requirements of section 6(b)(5) of the Act.¹⁵ The Commission further believes that trading options and LEAPs in \$1 strike price intervals on these volatility indexes provides investors with an important trading and hedging mechanism.

As explained by CBOE, volatility indexes such as the RVX, VIX, VXD and VXN fluctuate in a narrow range, and thus, the Commission believes that the implementation of \$1 strike price intervals on options and LEAPs based on these indexes, within the parameters detailed in CBOE’s proposal, is appropriate.

The Commission also notes CBOE’s representations that it possesses the necessary systems capacity to support new series that would result from the introduction of \$1 strikes for VXD and VXN options and of the \$1 strikes for

RVX, VIX, VXD and VXN LEAPs and that CBOE also has been informed that OPRA has the capacity to support such offerings.

V. Conclusion

It is therefore ordered, pursuant to section 19(b)(2) of the Act,¹⁶ that the proposed rule change (SR-CBOE-2007-52), as amended, be, and hereby is, approved.

For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.¹⁷

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-23003 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56820; File No. SR-FICC-2007-09]

Self-Regulatory Organizations; Fixed Income Clearing Corporation; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change Relating to the Correspondent Clearing Service

November 20, 2007.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),¹ notice is hereby given that on August 17, 2007, the Fixed Income Clearing Corporation (“FICC”) filed with the Securities and Exchange Commission (“Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared primarily by FICC. FICC filed the proposed rule change pursuant to section 19(b)(3)(A)(i) of the Act² and Rule 19b-4(f)(1)³ thereunder so that the proposal was effective upon filing with the Commission. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change

The proposed rule change enhances FICC’s Government Securities Division’s (“GSD”) correspondent clearing service for netting members submitting transaction data (“Submitting Members”) on behalf of non-member firms (“Executing Firms”).

II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, FICC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. FICC has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

Currently, GSD’s rules provide that a Submitting Member must submit transaction data to GSD when it acts on behalf of an Executing Firm for comparison-only processing or for both comparison and netting processing. The election made by the Submitting Member to submit Executing Firm transactions for comparison or comparison and netting is done on a firm level for each Executing Firm on whose behalf the Submitting Member acts. For example, when Submitting Member A elects to submit transactions for netting processing on behalf of Executing Firm B, all trades submitted on behalf of Executing Firm B will proceed to netting, and the Submitting Member will incur all resulting settlement and other obligations that arise under GSD’s rules with respect to trade data submitted on behalf of Executing Firm B. Conversely, when Submitting Member A elects to submit transactions for Executing Firm C for comparison-only processing, all transactions submitted on behalf of Executing Firm C will only enter the GSD’s comparison system with no settlement obligations arising for Submitting Member A with respect to these transactions.

Under the rule change, FICC will allow a Submitting Member to select for each Executing Firm for which it submits trades those trade types (*i.e.*, buy-sell or repurchase agreements) that will be comparison-only transactions and those trade types that will be netting transactions. For example, Submitting Member A may select to submit Executing Firm B’s repurchase agreement transactions for comparison-only processing and Executing Firm B’s buy-sell transactions for netting. Members will not be permitted to submit trades for either comparison-only or netting processing on a trade-by-

¹² *Id.*

¹³ In approving this proposed rule change, the Commission has considered the proposed rule’s impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).

¹⁴ 15 U.S.C. 78f.

¹⁵ 15 U.S.C. 78f(b)(5).

¹⁶ 15 U.S.C. 78s(b)(2).

¹⁷ 17 CFR 200.30-3(a)(12).

¹ 15 U.S.C. 78s(b)(1).

² 15 U.S.C. 78s(b)(3)(A)(i).

³ 17 CFR 240.19b-4(f)(1).

trade basis. Elections made with respect to how transaction types are processed through FICC must be effected through the applicable FICC Executing Firm Agreement. As noted above, settlement obligations will arise for Submitting Member A for each transaction that proceeds to netting.

Under the proposed changes, Submitting Members will be required to notify GSD with respect to each Executing Firm for which they submit data which transactions types that will be processed as comparison-only transactions and which will proceed to netting. Submitting members must notify GSD three business days prior to the commencement of the initial data submission on behalf of an Executing Firm. Any modifications made to an election will require three business days notice to GSD.

FICC will announce to its members by means of an Important Notice the effective date of this enhancement. GSD anticipates implementation to be during the fourth quarter of this year.

FICC believes that the proposed rule change is consistent with the requirements of section 17A of the Act⁴ and the rules thereunder. FICC states that this rule change enhances existing capabilities extended to netting members acting as Submitting Members under GSD's rules. FICC further states that the proposed changes will not affect FICC's ability to safeguard the funds and securities in FICC's control, or for which it is responsible.

B. Self-Regulatory Organization's Statement on Burden on Competition

FICC does not believe that the proposed rule change will have any impact or impose any burden on competition.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

Written comments relating to the proposed rule change have not yet been solicited or received. FICC will notify the Commission of any written comments received by FICC.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing rule change has become effective pursuant to section 19(b)(3)(A)(iii)⁵ of the Act and Rule 19b-4(f)(4)⁶ thereunder because it effects a change in an existing service of

FICC that does not adversely affect the safeguarding of securities or funds in FICC's control or for which FICC is responsible and does not significantly affect FICC's or its participants' respective rights or obligations. At any time within 60 days of the filing of the proposed rule change, the Commission could have summarily abrogated such rule change if it appeared to the Commission that such action was necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

Electronic Comments

- Use the Commission's Internet comment form (<http://www.sec.gov/rules/sro.shtml>); or
- Send an e-mail to rule-comments@sec.gov. Please include File No. SR-FICC-2007-09 on the subject line.

Paper Comments

- Send paper comments in triplicate to Nancy M. Morris, Secretary, Securities and Exchange Commission, Station Place, 100 F Street, NE., Washington, DC 20549-1090.

All submissions should refer to File No. FICC-2007-09. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (<http://www.sec.gov/rules/sro.shtml>). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room, 450 Fifth Street, NW., Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of such filing also will be available for inspection and copying at FICC's principal office and

on FICC's Web site at <http://ficc.com/gov/gov.docs.jsp?NS-query=#rf>. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submission should refer to File No. SR-FICC-2007-09 and should be submitted on or before December 18, 2007.

For the Commission by the Division of Trading and Markets pursuant to delegated authority.⁷

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-23021 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56819; File No. SR-NYSEArca-2007-115]

Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing of a Proposed Rule Change Relating to Rule 6.87—Obvious Error

November 19, 2007.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"),¹ and Rule 19b-4 thereunder,² notice is hereby given that on November 8, 2007, NYSE Arca, Inc. ("NYSE Arca" or "Exchange") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I, II, and III below, which Items have been substantially prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The Exchange proposes to amend NYSE Arca Rule 6.87 governing obvious errors. Specifically, the Exchange proposes a revised review procedure for contesting decisions made pursuant to the options obvious error rule. The text of the proposed rule change is available at the Exchange, the Commission's Public Reference Room, and <http://www.nyse.com>.

⁷ 17 CFR 200.30-3(a)(12).

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

⁴ 15 U.S.C. 78q-1.

⁵ 15 U.S.C. 78s(b)(3)(A)(iii).

⁶ 17 CFR 240.19b-4(f)(4).

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The Exchange proposes to amend NYSE Arca Rule 6.87 governing options obvious errors. Specifically, the Exchange proposes a revised review procedure for contesting decisions made pursuant to the obvious error rule. Currently, NYSE Arca Rule 6.87 provides that the Exchange will determine whether an "Obvious Error"³ has occurred after a market maker believes and notifies the Exchange that it participated in a transaction that was the result of an Obvious Error. If the Exchange believes that an Obvious Error has occurred, the Exchange will take one of the following actions depending on the parties to the trade: (1) Adjust the price with an adjustment; (2) bust the trade; or (3) adjust the trade without an adjustment penalty. Currently, if a party does not agree with the action taken by the Exchange, the party may appeal the decision to the Exchange's Board of Directors ("Board") pursuant to NYSE Arca Rule 10.14.

The Exchange proposes to amend Rule 6.87 by removing the Board appeal process pursuant to Rule 10.14 and replacing it with a revised appeal process. Proposed NYSE Arca Rule 6.87 would permit a party affected by the determination of an Obvious Error to request an appeal to the Obvious Error Panel ("OE Panel") to review the determination made by the Exchange's representative pursuant to Rule 6.87(a)(3). The OE Panel would be comprised of the NYSE Arca Chief Regulatory Officer ("CRO"), or a designee of the CRO,⁴ and

representatives from two options and trading permit firms ("OTP Firms").⁵ One representative on the OE Panel will be from an OTP Firm directly engaged in market making activities and one representative on the OE Panel will be from an OTP Firm directly engaged in the handling of options orders for public customers.

In addition, requests for an appeal would have to be made via facsimile or e-mail within thirty minutes after the party requesting the appeal is given notification of the initial determination. Thereafter, the OE Panel would review the information and may overturn or modify the action taken by the Officer. Such determination by the OE Panel would be considered a final action by the Exchange on the matter at issue. All final determinations made by the OE Panel would be rendered, without prejudice, as to the rights of the parties to the transaction to submit their dispute to arbitration. The Exchange states that the revised process is intended to provide a timely appeal for OTP Firms and options and trading permit holders ("OTP Holders") in place of the lengthy Board appeals process currently provided in Rule 10.14.

Finally, if the OE Panel upholds the Exchange's decision made pursuant to Rule 6.87(a)(4) to bust or adjust a trade, the Exchange would assess a \$500.00 fee against the OTP Holder or OTP Firm that initiated the request for appeal. The Exchange believes that assessing a \$500.00 fee would discourage frivolous and abusive practices of the appeal process.

The Exchange is also proposing amendments to Rule 10.14 to remove the Board appeals process for Rule 6.87, and remove the appeals process from Commentary .02 of Rule 6.87.

2. Statutory Basis

The Exchange believes the proposed rule change is consistent with section 6(b) of the Act,⁶ in general, and furthers the objectives of section 6(b)(5) of the Act,⁷ in particular, because it is designed to promote just and equitable

Regulation. The Exchange notes that the International Securities Exchange, LLC ("ISE") designates an obvious error panel to independently make appeals decisions and also to overturn or modify actions taken by the ISE. See ISE Rule 720.

⁵ The Exchange proposes to designate at least ten (10) OTP Firm representatives to be called upon to serve on the OE Panel. In no case would the OE Panel include a person related to a party to the trade in question. To the extent reasonably possible, the Exchange proposes to call upon the designated representatives to participate on an OE Panel on an equally frequent basis.

⁶ 15 U.S.C. 78f(b).

⁷ 15 U.S.C. 78f(b)(5).

principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, and to remove impediments and perfect the mechanisms of a free and open market and to protect investors and the public interest.

B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

No written comments were solicited or received by the Exchange with respect to the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the **Federal Register** or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding, or (ii) as to which the Exchange consents, the Commission will:

A. By order approve the proposed rule change; or

B. Institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

Electronic Comments

- Use the Commission's Internet comment form (<http://www.sec.gov/rules/sro.shtml>); or
- Send an e-mail to rule-comments@sec.gov. Please include File Number SR-NYSEArca-2007-115 on the subject line.

Paper Comments

- Send paper comments in triplicate to Nancy M. Morris, Secretary, Securities and Exchange Commission, 100 F Street, NE., Washington, DC 20549-1090.

All submissions should refer to File Number SR-NYSEArca-2007-115. This file number should be included on the

³ "Obvious Error" is defined in NYSE Arca Rule 6.87(a)(1).

⁴ The Exchange represents that a designee of the CRO would be an employee of the Exchange, working closely with and reporting directly to, the CRO, such as one of the Directors of Options

subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (<http://www.sec.gov/rules/sro.shtml>). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room, 100 F Street, NE., Washington, DC 20549, on official business days between the hours of 10 a.m. and 3 p.m. Copies of such filing also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR-NYSEArca-2007-115 and should be submitted on or before December 18, 2007.

For the Commission, by the Division of Trading and Markets, pursuant to delegated authority.⁸

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E7-22979 Filed 11-26-07; 8:45 am]

BILLING CODE 8011-01-P

SOCIAL SECURITY ADMINISTRATION

Agency Information Collection Activities: Comment Request

The Social Security Administration (SSA) publishes a list of information collection packages that will require clearance by the Office of Management and Budget (OMB) in compliance with Pub. L. 104-13, the Paperwork Reduction Act of 1995, effective October 1, 1995. The information collection packages that may be included in this notice are for new information collections, approval of existing information collections, revisions to OMB-approved information collections, and extensions (no change) of OMB-approved information collections.

SSA is soliciting comments on the accuracy of the agency's burden

estimate; the need for the information; its practical utility; ways to enhance its quality, utility, and clarity; and on ways to minimize burden on respondents, including the use of automated collection techniques or other forms of information technology. Written comments and recommendations regarding the information collection(s) should be submitted to the OMB Desk Officer and the SSA Reports Clearance Officer. The information can be mailed, faxed or e-mailed to the individuals at the addresses and fax numbers listed below:

(OMB)

Office of Management and Budget, Attn: Desk Officer for SSA, Fax: 202-395-6974, E-mail address: OIRA_Submission@omb.eop.gov.

(SSA)

Social Security Administration, DCBFM, Attn: Reports Clearance Officer, 1333 Annex Building, 6401 Security Blvd., Baltimore, MD 21235, Fax: 410-965-6400, E-mail address: OPLM.RCO@ssa.gov.

The information collections listed below have been submitted to OMB for clearance. Your comments on the information collections would be most useful if received by OMB and SSA within 30 days from the date of this publication. You can obtain a copy of the OMB clearance packages by calling the SSA Reports Clearance Officer at 410-965-0454, or by writing to the address listed above.

Letter to Custodian of Birth Records/ Letter to Custodian of School Records—20 CFR 404.704, 404.716, 416.802, and 422.107—0960-0693. SSA prepares the SSA-L106 and SSA-L706 for individuals who need help in obtaining evidence of their age in connection with Social Security number card applications and claims for benefits. SSA uses the SSA-L706 to determine the existence of primary evidence of age for Social Security Number (SSN) applicants. SSA also uses both letters to verify with the issuing entity, when necessary, the authenticity of the record submitted by the SSN applicant or claimant. The respondents are schools, state and local bureaus of vital statistics, and religious entities.

Type of Request: Revision of an OMB-approved information collection.

Number of Respondents: 7,200.

Frequency of Response: 1.

Average Burden Per Response: 10 minutes.

Estimated Annual Burden: 1,200 hours.

Dated: November 20, 2007.

Elizabeth A. Davidson,

Reports Clearance Officer, Social Security Administration.

[FR Doc. E7-23022 Filed 11-26-07; 8:45 am]

BILLING CODE 4191-02-P

DEPARTMENT OF STATE

[Public Notice 5996]

Issuance of a Presidential Permit Authorizing the Greater Yuma Port Authority To Construct, Operate, and Maintain a Livestock Border Crossing Near San Luis, Arizona, at the International Boundary Between the United States and Mexico

SUMMARY: The Department of State has issued a Presidential permit, effective November 16, 2007, authorizing the Greater Yuma Port Authority to construct, operate, and maintain a livestock border crossing near San Luis, Arizona, at the international boundary between the United States and Mexico. In making this determination, the Department consulted with other federal agencies, as required by Executive Order 11423, as amended.

FOR FURTHER INFORMATION CONTACT: Mr. Daniel Darrach, U.S.-Mexico Border Affairs Coordinator, via e-mail at WHA-BorderAffairs@state.gov; by phone at 202-647-9894 or by mail at WHA/MEX, Room 4258, Department of State, 2201 C St., NW., Washington, DC 20520.

SUPPLEMENTARY INFORMATION: Following is the text of the issued permit:

By virtue of the authority vested in me as Under Secretary of State for Economic, Energy and Agricultural Affairs, pursuant to Department of State Delegation number 118-2 from the Secretary of State dated January 26, 2006, to exercise, to the extent authorized by law, all authorities vested in the Secretary of State, including those authorities under Executive Order 11423, 33 FR 11741 (1968), as amended by Executive Order 12847 of May 17, 1993, 58 FR. 29511 (1993), Executive Order 13284 of January 23, 2003, 68 FR 4075 (2003), and Executive Order 13337 of April 30, 2004, 69 FR 25299 (2004); having considered the environmental effects of the proposed action in accordance with the National Environmental Policy Act of 1969 (83 Stat. 852; 42 U.S.C. § 4321, *et seq.*) and other statutes relating to environmental concerns; having considered the proposed action in accordance with the National Historic Preservation Act (80 Stat. 917, 16 U.S.C. § 470f, *et seq.*); and having requested and received the views of various of the federal departments

⁸ 17 CFR 200.30-3(a)(12).

and other interested persons; I hereby grant permission, subject to the conditions herein set forth, to the Greater Yuma Port Authority (GYPA, hereinafter referred to as the "permittee"), to construct, operate, and maintain a new livestock border crossing (hereinafter referred to as "San Luis Livestock Crossing"), 2,500 feet (approximately half a mile) east of the existing San Luis cattle crossing on the westerly border of the State of Arizona and the Mexican State of Sonora near the cities of San Luis, Arizona and San Luis Rio Colorado, Sonora, Mexico.

The term "facilities" as used in this permit means the lane or lanes leading to the livestock crossing, their approaches and any land, structure or installations appurtenant thereto. These facilities are the subject of a Finding of No Significant Impact, FONSI, approved by the Acting Director of the Office of Mexican Affairs in the Department of State on July 27, 2007, 72 FR 43314-43316 (August 3, 2007).

The term "United States facilities" as used in this permit means that part of the facilities in the United States.

This permit is subject to the following conditions:

Article 1. The United States facilities herein described, and all aspects of their operation, shall be subject to all the conditions, provisions, and requirements of this permit and any amendment thereof. This permit may be terminated at will by the Secretary of State or the Secretary's delegate or may be amended by the Secretary of State or the Secretary's delegate at will or upon proper application therefor. The permittee shall make no substantial change in the location of the livestock crossing facilities or in the operation authorized by this permit until such changes have been approved by the Secretary of State or the Secretary's delegate.

Article 2. The standards for, and the manner of, the construction, operation, and maintenance of the United States facilities shall be subject to inspection and approval by the representatives of appropriate federal, state and local agencies. The permittee shall allow duly authorized officers and employees of such agencies free and unrestricted access to said facilities in the performance of their official duties.

Article 3. The permittee shall comply with all applicable federal, state, and local laws and regulations regarding the construction, operation, and maintenance of the United States facilities, and with all applicable industrial codes. The permittee shall obtain the requisite permits from state

and local government entities and relevant federal agencies.

Article 4. Upon the termination, revocation, or surrender of this permit, and unless otherwise agreed by the Secretary of State or the Secretary's delegate, the United States facilities in the immediate vicinity of the international boundary shall be removed by and at the expense of the permittee within such time as the Secretary of State or the Secretary's delegate may specify, and upon failure of the permittee to remove this portion of the United States facilities as ordered, the Secretary of State or the Secretary's delegate may direct that possession of such facilities be taken and that they be removed at the expense of the permittee; and the permittee shall have no claim for damages by reason of such possession or removal.

Article 5. This permit and the operation of the United States facilities hereunder shall be subject to the limitations, terms, and conditions issued by any competent agency of the United States Government, including but not limited to the Department of Homeland Security (DHS), the Federal Highway Administration (FHWA), and the United States Section of the International Boundary and Water Commission (IBWC). This permit shall continue in force and effect only so long as the permittee shall continue the operations hereby authorized in accordance with such limitations, terms and conditions.

Article 6. Any transfer of ownership or control of the United States facilities or any part thereof shall be immediately notified in writing to the United States Department of State (the "Department") for approval, including identification of the transferee. In the event of such transfer of ownership or control, the permit shall remain in force and the United States facilities shall be subject to all the conditions, permissions, and requirements of this permit and any amendments thereof.

Article 7. (1) The permittee shall acquire such right-of-way grants or easements, permits, and other authorizations as may become necessary and appropriate.

(2) The permittee shall maintain the United States facilities and every part thereof in a condition of good repair for their safe operation.

Article 8. (1) The permittee shall take all appropriate measures to prevent or mitigate adverse environmental impacts or disruption of significant archeological resources in connection with the construction, operation and maintenance of the United States facilities, including those mitigation

measures set forth in the Finding of No Significant Impact (FONSI) approved by the Department on July 27, 2007, 72 Fed. Reg. 43314-43316 (August 3, 2007).

(2) Before beginning construction the permittee shall obtain the concurrence of the IBWC.

Article 9. The permittee shall file with the appropriate agencies of the United States Government such statements or reports under oath with respect to the United States facilities, and/or permittee's actions in connection therewith, as are now or may hereafter be required under any laws or regulations of the United States Government or its agencies.

Article 10. The permittee shall not begin construction until the Department has provided notification to the permittee that it has completed its exchange of diplomatic notes with the Government of Mexico regarding authorization of construction. The permittee shall provide written notice to the Department at such time as the construction authorized by this permit is begun, and again at such time as construction is completed, interrupted or discontinued.

In witness whereof, I, Reuben Jeffery III, Under Secretary of State for Economic, Energy and Agricultural Affairs of the United States, have hereunto set my hand this 31st day of October, 2007, in the City of Washington, District of Columbia.

End Permit text.

Dated: November 20, 2007.

Ian G. Brownlee,

*Acting Director, Office of Mexican Affairs,
Department of State.*

[FR Doc. E7-23085 Filed 11-26-07; 8:45 am]

BILLING CODE 4710-29-P

TENNESSEE VALLEY AUTHORITY

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Tennessee Valley Authority (Meeting No. 07-06).

TIME AND DATE: 9 a.m. EST, November 29, 2007, TVA West Tower Auditorium, 400 West Summit Hill Drive, Knoxville, Tennessee 37902.

Agenda

Old Business

Approval of minutes of September 27, 2007, Board Meeting.

New Business

1. President's Report
2. Report of the Finance, Strategy, and Rates Committee
 - A. Tax-equivalent payments for FY 07

- and estimated payments for FY 08
- B. Retention of Net Power Proceeds and Nonpower Proceeds and Payments to the U.S. Treasury
 - C. Customer issues
 - i. Rate adjustment to the Fuel Cost Adjustment baseline
 - ii. Market days option for 5-minute response interruptible product
 3. Report of the Operations, Environment, and Safety Committee
 - A. Gas capacity expansion
 - B. Contracts with BHP Billiton and Areva for uranium fuel
 4. Report of the Human Resources Committee
 - A. Executive compensation approvals for FY 08
 - B. Amendments to the TVA Retirement System plans
 5. Report of the Audit and Ethics Committee
 6. Report of the Community Relations Committee
 7. Report of the Corporate Governance Committee

FOR FURTHER INFORMATION: Please call Media Relations at (865) 632-6000, Knoxville, Tennessee. People who plan to attend the meeting and have special needs should call (865) 632-6000. Anyone who wishes to comment on any of the agenda in writing may send their comments to: TVA Board of Directors, Board Agenda Comments, 400 West Summit Hill Drive, Knoxville, Tennessee 37902.

Dated: November 21, 2007.

Maureen H. Dunn,

General Counsel and Secretary.

[FR Doc. 07-5855 Filed 11-23-07; 9:41 am]

BILLING CODE 8120-08-P

DEPARTMENT OF TRANSPORTATION

National Highway Traffic Safety Administration

Reports, Forms and Record Keeping Requirements Agency Information Collection Activity Under OMB Review

AGENCY: National Highway Traffic Safety Administration, DOT.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3501, *et seq.*), this notice announces that the Information Collection Request (ICR) abstracted regarding the Uniform Tire Quality Grading Standard (UTQGS) below has been forwarded to the Office of Management and Budget (OMB) for review and comment. The ICR describes the nature of the information collections

and their expected burden. The **Federal Register** Notice with a 60-day comment period was published on July 20, 2007 [72 FR 39889-39890].

DATES: Comments must be submitted on or before December 27, 2007.

FOR FURTHER INFORMATION CONTACT: Hisham Mohamed at the National Highway Traffic Safety Administration, Office of International Policy, Fuel Economy and Consumer Programs (NVS-131), 1200 New Jersey Ave, SE., W43-437, Washington, DC 20590. Mr. Mohamed's telephone number is (202) 366-0307.

SUPPLEMENTARY INFORMATION:

National Highway Traffic Safety Administration

Title: 49 CFR Part 575.104; Uniform Tire Quality Grading Standard.

OMB Number: 2127-0519.

Type of Request: Extension of a currently approved information collection.

Abstract: Part 575 requires tire manufacturers and tire brand owners to submit reports to NHTSA regarding the UTQGS grades of all passenger car tire lines they offer for sale in the United States. This information is used by consumers of passenger car tires to compare tire quality in making their purchase decisions. The information is provided in several different ways to insure that the consumer can readily see and understand the tire grades: (1) The grades are molded into the sidewall of the tire so that they can be reviewed on both the new and old tires; (2) a paper label is affixed to the tread face of the new tires that provides the grades of that particular tireline along with an explanation of the grading system; (3) the tire manufacturer or brand name owner provides prospective purchasers of tires the information for each tire offered for sale at the particular location; (4) vehicle manufacturers include in the owner's manual of each vehicle the grade information for the tires with which the vehicle is equipped; (5) NHTSA compiles the grading information of all manufacturers' tirelines into a booklet that is available to the public both in printed form and on NHTSA's Web site.

Affected Public: All passenger car tire manufacturers and brand name owners offering passenger car tires for sale in the United States.

Estimated Total Annual Burden: NHTSA estimates that a cost of approximately \$26 million to tire manufacturers is required to comply with this regulation.

ADDRESSES: Send comments, within 30 days, to the Office of Information and

Regulatory Affairs, Office of Management and Budget, 725-17th Street, NW., Washington, DC 20503, Attention NHTSA Desk Officer.

Comments are invited on: Whether the proposed collection of information is necessary for the proper performance of the functions of the Department, including whether the information will have practical utility; the accuracy of the Departments' estimate of the burden of the proposed information collection; ways to enhance the quality, utility and clarity of the information to be collected; and ways to minimize the burden of the collection of information on respondents, including the use of automated collection techniques or other forms of information technology. A comment to OMB is most effective if OMB receives it within 30 days of publication.

Issued on: November 21, 2007.

Stephen R. Kratzke,

Associate Administrator for Rulemaking.

[FR Doc. E7-23045 Filed 11-26-07; 8:45 am]

BILLING CODE 4910-59-P

DEPARTMENT OF VETERANS AFFAIRS

VA Adjudications Manual, M21-1; Rescission of Manual M21-1 Provisions Related To Exposure to Herbicides Based on Receipt of the Vietnam Service Medal

AGENCY: Department of Veterans Affairs.

ACTION: Notice, with request for comments.

SUMMARY: The Department of Veterans Affairs (VA) proposes to rescind provisions of its Adjudication Procedures Manual, M21-1 (M21-1) that were found by the U.S. Court of Appeals for Veterans Claims (CAVC) not to have been properly rescinded.

DATES: Comments must be received by VA on or before January 28, 2008.

ADDRESSES: Written comments may be submitted through www.Regulations.gov; by mail or hand-delivery to the Director, Regulations Management (OOREG), Department of Veterans Affairs, 810 Vermont Ave., NW., Room 1068, Washington, DC 20420; or by fax to (202) 273-9026. Comments should indicate that they are submitted in response to "Rescission of Manual M21-1 Provisions Related to Exposure to Herbicides Based On Receipt of the Vietnam Service Medal." Copies of comments received will be available for public inspection in the Office of Regulation Policy and Management, Room 1063B, between the

hours of 8 a.m. and 4:30 p.m. Monday through Friday (except holidays). Please call (202) 273-9515 for an appointment. In addition, during the comment period, comments may be viewed online through the Federal Docket Management System (FDMS) at www.Regulations.gov.

FOR FURTHER INFORMATION CONTACT:

Rhonda F. Ford, Chief, Regulations Staff (211D), Compensation and Pension Service, Veterans Benefits

Administration, Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273-7210.

SUPPLEMENTARY INFORMATION: This rulemaking is necessitated by the opinion rendered by the CAVC in *Haas v. Nicholson*, 20 Vet. App. 257 (2006), notice of appeal filed, No. 07-7037 (Oct. 26, 2006). In that opinion, the CAVC concluded that certain provisions of VA's Adjudication Procedures Manual M21-1 (M21-1) were substantive provisions that had not been properly rescinded. *Id.* at 276-78. We have appealed *Haas*, and if we are successful on appeal, this rulemaking will be withdrawn. However, in the event that we do not prevail on appeal, we now take action to properly rescind the provisions.

In *Haas*, the CAVC held that a 1991 M21-1 provision required VA to concede that Mr. Haas had served in Vietnam, and was presumed to have been exposed to herbicides during service, because he had received the Vietnam Service Medal (VSM). *Haas*, 20 Vet. App. at 270-72 (quoting in full and discussing M21-1, part III, para. 4.08(k)(1)-(2) (1991)). In 2002, VA had issued a new M21-1 provision that more clearly restated the 1991 provision, advising that receipt of the VSM could indicate service on land in Vietnam but, by itself, was not proof of such service. M21-1, pt. III, para. 4.24(e)(1)-(2), change 88 (Feb. 27, 2002). However, the CAVC held that VA's 2002 revision of the M21-1 was ineffective because VA had not followed the notice and comment procedures of the

Administrative Procedure Act, 5 U.S.C. § 553(a). *Haas*, 20 Vet. App. at 275-78.

As interpreted by the CAVC, the 1991 M21-1 provision requires VA, in at least some circumstances, to concede service in Vietnam, and thus herbicide exposure, based merely on the receipt of the VSM, even if all other evidence indicates that the veteran did not serve on land or on inland waterways in Vietnam and therefore was exceedingly unlikely to have been exposed to herbicides as a result of Vietnam service. VA revised the M21-1 in 2002 because, although receipt of the VSM is an indication of possible service in Vietnam, it is not definitive or conclusive evidence of such service. It is inappropriate to include receipt of the VSM as a sole criterion for the presumption of exposure to herbicide agents due to service in Vietnam because a veteran may have received this medal for service in locations other than Vietnam. (The VSM was awarded to all members of the Armed Forces who served between July 3, 1965, and March 28, 1973, either: (1) In Vietnam and contiguous waters and airspace thereover; or (2) in Thailand, Laos, or Cambodia, or airspace thereover, in direct support of operations in Vietnam. See Army Reg. 600-8-22, para. 2-13.) The 2002 revision was intended to clarify VA's view that receipt of the VSM does not require or permit VA to ignore other evidence indicating that a veteran did not serve in the Republic of Vietnam. Because the CAVC's interpretation of the 1991 M21-1 provision does not accord with VA's intent in issuing that provision, we propose to rescind it.

The M21-1 is an internal manual used to convey guidance to VA adjudicators. It is not intended to establish substantive rules beyond those contained in statute and regulation. Neither the 1991 nor the 2002 M21-1 provision, nor any intervening revision to such provisions, was intended to establish a substantive rule. Further, the

1991 provision was not intended to convey the rule the CAVC imputed to that provision, treating the VSM as conclusive evidence of service in Vietnam even if other evidence would support a finding that the veteran did not serve in Vietnam. However, because the CAVC held that the 1991 M21-1 provision established a substantive rule, and because that rule, as interpreted by the CAVC, is inconsistent with VA's intent, we are proposing to rescind the M21-1 provision.

We note as well that we will soon be revising § 3.307(a)(6)(iii) to clarify VA's interpretation of the statutory authority governing service in Vietnam for purposes of the presumption of herbicide exposure. In view of the confusion created by the M21-1 provisions in the *Haas* case, we believe it is preferable to rescind the M21-1 provisions relating to proof of service in Vietnam, including the 1991 provision at issue in *Haas*, the 2002 clarifying revision to that provision, and intervening revisions. This will enable VA to clarify and ensure that its interpretation of the governing statutory provisions set forth in its regulation and to minimize the possibility of a perceived or unintended inconsistency based on VA's internal manual.

Hence, VA proposes to rescind the following manual provisions describing service in Vietnam for the purposes of the presumption of exposure to herbicides: M21-1, pt. III, para. 4.08(k)(1)-(2) (November 8, 1991); M21-1, pt. III, para. 4.24(g)(1)-(2), change 23 (October 6, 1993); M21-1, pt. III, para. 4.24(g)(1)-(2), change 41 (July 12, 1995); M21-1, pt. III, para. 4.24(g)(1)-(2), change 76 (June 1, 1999); M21-1, pt. III, para. 4.24(e)(1)-(2), change 88 (February 27, 2002).

Approved: November 19, 2007.

Gordon H. Mansfield,

Acting Secretary of Veterans Affairs.

[FR Doc. E7-22983 Filed 11-26-07; 8:45 am]

BILLING CODE 8320-01-P



Federal Register

Tuesday,
November 27, 2007

Part II

Department of Health and Human Services

Centers for Medicare & Medicaid Services

42 CFR Parts 409, 410, et al.
Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule, and Other Part B Payment Policies for CY 2008; Revisions to the Payment Policies of Ambulance Services Under the Ambulance Fee Schedule for CY 2008; and the Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions; Final Rule

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Medicare & Medicaid Services**

42 CFR Parts 409, 410, 411, 413, 414, 415, 418, 423, 424, 482, 484, and 485

[CMS-1385-FC]

RIN 0938-AO65

Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule, and Other Part B Payment Policies for CY 2008; Revisions to the Payment Policies of Ambulance Services Under the Ambulance Fee Schedule for CY 2008; and the Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Final rule with comment period.

SUMMARY: This final rule with comment period addresses certain provisions of the Tax Relief and Health Care Act of 2006, as well as making other proposed changes to Medicare Part B payment policy. We are making these changes to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. This final rule with comment period also discusses refinements to resource-based practice expense (PE) relative value units (RVUs); geographic practice cost indices (GPCI) changes; malpractice RVUs; requests for additions to the list of telehealth services; several coding issues including additional codes from the 5-Year Review; payment for covered outpatient drugs and biologicals; the competitive acquisition program (CAP); clinical lab fee schedule issues; payment for renal dialysis services; performance standards for independent diagnostic testing facilities; expiration of the physician scarcity area (PSA) bonus payment; conforming and clarifying changes for comprehensive outpatient rehabilitation facilities (CORFs); a process for updating the drug compendia; physician self referral issues; beneficiary signature for ambulance transport services; durable medical equipment (DME) update; the chiropractic services demonstration; a Medicare economic index (MEI) data change; technical corrections; standards and requirements related to therapy services under Medicare Parts A and B; revisions to the ambulance fee schedule; the ambulance inflation factor for CY 2008; and amending the e-prescribing exemption

for computer-generated facsimile transmissions. We are also finalizing the calendar year (CY) 2007 interim RVUs and are issuing interim RVUs for new and revised procedure codes for CY 2008.

As required by the statute, we are announcing that the physician fee schedule update for CY 2008 is -10.1 percent, the initial estimate for the sustainable growth rate for CY 2008 is -0.1 percent, and the conversion factor (CF) for CY 2008 is \$34.0682.

DATES: Effective Date: The provisions of this final rule with comment period are effective January 1, 2008, except for the amendments to § 409.17 and § 409.23 which are effective July 1, 2008, and the amendments to § 423.160 which is effective January 1, 2009.

Comment Date: Comments will be considered if we receive them at one of the addresses provided below, no later than 5 p.m. e.s.t. on December 31, 2007.

ADDRESSES: In commenting, please refer to file code CMS-1385-FC. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission.

You may submit comments in one of three ways (no duplicates, please):

1. *Electronically.* You may submit electronic comments on specific issues in this regulation to <http://www.cms.hhs.gov/eRulemaking>. Click on the link "Submit electronic comments on CMS regulations with an open comment period." (Attachments should be in Microsoft Word, WordPerfect, or Excel; however, we prefer Microsoft Word.)

2. *By mail.* You may mail written comments (one original and two copies) to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1385-FC, P.O. Box 8020, Baltimore, MD 21244-8020.

Please allow sufficient time for mailed comments to be received before the close of the comment period.

3. *By express or overnight mail.* You may send written comments (one original and two copies) to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1385-FC, Mail Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.

4. *By hand or courier.* If you prefer, you may deliver (by hand or courier) your written comments (one original and two copies) before the close of the comment period to one of the following addresses. If you intend to deliver your comments to the Baltimore address, please call telephone number (410) 786-

7197 in advance to schedule your arrival with one of our staff members.

Room 445-G, Hubert H. Humphrey (HHH) Building, 200 Independence Avenue, SW., Washington, DC 20201; or 7500 Security Boulevard, Baltimore, MD 21244-1850.

(Because access to the interior of the HHH Building is not readily available to persons without Federal Government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of the building. A stamp-in clock is available for persons wishing to retain a proof of filing by stamping in and retaining an extra copy of the comments being filed.)

Comments mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received after the comment period.

Submission of comments on paperwork requirements. You may submit comments on this document's paperwork requirements by mailing your comments to the addresses provided at the end of the "Collection of Information Requirements" section in this document.

For information on viewing public comments, see the beginning of the **SUPPLEMENTARY INFORMATION** section.

FOR FURTHER INFORMATION CONTACT: Pam West, (410) 786-2302 for issues related to practice expense and comprehensive outpatient rehabilitation facilities.

Rick Ensor, (410) 786-5617 for issues related to practice expense methodology.

Stephanie Monroe, (410) 786-6864 for issues related to the geographic practice cost index and malpractice RVUs.

Craig Dobyski, (410) 786-4584 for issues related to list of telehealth services.

Ken Marsalek, (410) 786-4502 for issues related to the DRA imaging cap.

Catherine Jansto, (410) 786-7762 for issues related to payment for covered outpatient drugs and biologicals.

Edmund Kasaitis (410) 786-0477 for issues related to the Competitive Acquisition Program (CAP) for part B drugs.

Anita Greenberg (410) 786-4601 for issues related to the clinical laboratory fee schedule.

Henry Richter, (410) 786-4562 for issues related to payments for end-stage renal disease facilities.

August Nemec (410) 786-0612 for issues related to independent diagnostic testing facilities.

Kate Tillman (410) 786-9252 or Brijit Burton (410) 786-7364 for issues related to the drug compendia.

David Walczak (410) 786-4475 for issues related to reassignment and physician self-referral rules for diagnostic tests and beneficiary signature for ambulance transport.

Lisa Ohrin (410) 786-4565 or Joanne Sinsheimer (410) 786-4620 for issues related to physician self-referral rules.

Bob Kuhl (410) 786-4597 for issues related to the DME update.

Rachel Nelson (410) 786-1175 for issues related to the physician quality reporting system for CY 2008.

Maria Ciccanti (410) 786-3107 for issues related to the reporting of anemia quality indicators.

James Menas (410) 786-4507 for issues related to payment for physician pathology services.

Dorothy Shannon, (410) 786-3396 for issues related to the outpatient therapy caps.

Drew Morgan, (410) 786-2543 for issues related to the E-Prescribing Exemption for Computer Generated Facsimile Transmissions.

Rochel Kujawa (410) 786-9111 or Anne Tayloe (410) 786-4546 for issues related to the ambulance fee schedule.

Diane Milstead, (410) 786-3355 or Gaysha Brooks (410) 786-9649 for all other issues.

SUPPLEMENTARY INFORMATION:

Submitting Comments: We welcome comments from the public on the following issues: Interim Relative Value Units (RVUs) for selected codes identified in Addendum C and the physician self-referral designated health services (DHS) procedures listed in Addendum I. You can assist us by referencing the file code [CMS-1385-FC] and the specific "issue identifier" that precedes the section on which you choose to comment.

Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following Web site as soon as possible after they have been received: <http://www.cms.hhs.gov/eRulemaking>. Click on the link "Electronic Comments on CMS Regulations" on that Web site to view public comments.

Comments received timely will also be available for public inspection as they are received, generally beginning approximately 3 weeks after publication of a document, at the headquarters of the Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, Maryland 21244, Monday

through Friday of each week from 8:30 a.m. to 4 p.m. To schedule an appointment to view public comments, phone 1-800-743-3951.

This **Federal Register** document is also available from the **Federal Register** online database through Government Printing Office Access a service of the U.S. Government Printing Office. The Web site address is: <http://www.access.gpo.gov/nara/index.html>.

Information on the physician fee schedule can also be found on the CMS homepage. You can access this data by using the following directions:

1. Go to the following Web site: <http://www.cms.hhs.gov/PhysicianFeeSched/>.

2. Select "PFS Federal Regulation Notices."

To assist readers in referencing sections contained in this preamble, we are providing the following table of contents. Some of the issues discussed in this preamble affect the payment policies, but do not require changes to the regulations in the *Code of Federal Regulations*. Information on the regulation's impact appears throughout the preamble and is not exclusively in section VI.

Table of Contents

I. Background

A. Development of the Relative Value System

B. Components of the Fee Schedule Payment Amounts

C. Most Recent Changes to Fee Schedule

II. Provisions of the Final Rule Related to the Physician Fee Schedule

A. Resource Based Practice Expense (PE) Relative Value Units (RVUs)

1. Current Methodology

2. PE Proposals for CY 2008

B. Geographic Practice Cost Indices (GPCIs)

1. GPCI Update

2. Payment Localities

C. Malpractice (MP) RVUs (TC/PC issue)

D. Medicare Telehealth Services

E. Specific Coding Issues Related to PFS

1. Reduction in the Technical Component (TC) Payment for Imaging Services

Under the PFS to the Outpatient

Department (OPD) Payment Amount

2. Application of Multiple Procedure

Payment Reduction for Mohs Micrographic Surgery (CPT Codes 17311 Through 17315)

3. Payment for Intravenous Immune

Globulin (IVIG) Add On Code for

Preadmission Related Services

4. Reporting of Cardiac Rehabilitation

Services

F. Part B Drug Payment

1. Average Sales Price (ASP) Issues

2. Competitive Acquisition Program (CAP)

Issues

G. Issues Related to the Clinical Lab Fee

Schedule

1. Date of Service for the Technical

Component (TC) of Physician Pathology

Services (§ 414.510)

2. New Clinical Diagnostic Laboratory Test (§ 414.508)

H. Revisions Related to Payment for Renal Dialysis Services Furnished by End-Stage Renal Disease (ESRD) Facilities

1. Growth Update to the Drug Add-On

Adjustment to the Composite Rates

2. Update to the Geographic Adjustment to

the Composite Rates

I. Independent Diagnostic Testing Facility

(IDTF) Issues

1. Revisions of Existing IDTF Performance Standards

2. New IDTF Standards

J. Expiration of MMA Section 413

Provisions for Physician Scarcity Area

(PSA)

K. Comprehensive Outpatient

Rehabilitation Facility (CORF) Issues

1. Requirements for Coverage of CORF

Services Plan of Treatment (§ 410.105(c))

2. Included Services (§ 410.100)

3. Physician Services (§ 410.100(a))

4. Clarifications of CORF Respiratory

Therapy Services

5. Social and Psychological Services

6. Nursing Care Services

7. Drugs and Biologicals

8. Supplies and DME

9. Clarifications and Payment Updates for

Other CORF Services

10. Cost Based Payment (§ 413.1)

11. Payment for Comprehensive Outpatient

Rehabilitation Facility (CORF) Services

12. Vaccines

L. Compendia for Determination of

Medically Accepted Indications for Off

Label Uses of Drugs and Biologicals in an

Anti-Cancer Chemotherapeutic Regimen

(§ 414.930)

1. Background

2. Process for Determining Changes to the

Compendia List

M. Physician Self Referral Issues

1. General

2. Changes to Reassignment and Physician

Self Referral Rules Relating to Diagnostic

Tests (Anti Markup Provision)

N. Beneficiary Signature for Ambulance

Transport Services

O. Update to Fee Schedules for Class III

DME for CYs 2007 and 2008

1. Background

2. Update to Fee Schedule

P. Discussion of Chiropractic Services

Demonstration

Q. Technical Corrections

1. Particular Services Excluded From

Coverage (§ 411.15(a))

2. Medical Nutrition Therapy (§ 410.132(a))

3. Payment Exception: Pediatric Patient

Mix (§ 413.184)

4. Diagnostic X ray Tests, Diagnostic

Laboratory Tests, and Other Diagnostic

Tests: Conditions (§ 410.32(a)(1))

R. Other Issues

1. Recalls and Replacement Devices

2. Therapy Standards and Requirements

3. Amendment to the Exemption for

Computer Generated Facsimile

Transmission from the National Council

for Prescription Drug Programs (NCPDP)

SCRIPT Standard for Transmitting

Prescription and Certain Prescription

Related Information for Part D Eligible

Individuals

- S. Division B of the Tax Relief and Health Care Act of 2006—Medicare Improvements and Extension Act of 2006 (Pub. L. 109–432) (MIEA–TRHCA)
1. Section 101(b)—Physician Quality Reporting Initiative (PQRI)
 2. Section 110—Reporting of Hemoglobin or Hematocrit for Part B Cancer Anti-Anemia Drugs (§ 414.707(b))
 3. Section 104—Extension of Treatment of Certain Physician Pathology Services Under Medicare
 4. Section 201—Extension of Therapy Cap Exception Process
 5. Section 101(d)—Physician Assistance and Quality Initiative (PAQI) Fund
- III. Revisions to the Payment Policies of Ambulance Services Under the Fee Schedule for Ambulance Services; Ambulatory Inflation Factor Update for CY 2007
- A. History of Medicare Ambulance Services
 1. Statutory Coverage of Ambulance Services
 2. Medicare Regulations for Ambulance Services
 3. Transition to National Fee Schedule
 - B. Ambulance Inflation Factor (AIF) During the Transition Period
 - C. Ambulance Inflation Factor (AIF) for CY 2008
 - D. Revisions to the Publication of the Ambulance Fee Schedule (§ 414.620)
- IV. Refinement of Relative Value Units for Calendar Year 2008 and Response to Public Comments on Interim Relative Value Units for 2007
- A. Summary of Issues Discussed Related to the Adjustment of Relative Value Units
 - B. Process for Establishing Work Relative Value Units for the Physician Fee Schedule
 - C. 5 Year Review of Work RVUs
 1. Additional Codes from the 5-Year Review of Work RVUs
 2. Anesthesia Coding (Part of 5-Year Review)
 3. Budget Neutrality Adjustment
 - D. Work Relative Value Unit Refinements of Interim Relative Value Units (Interim 2007 Codes)
 - E. Establishment of Interim Work Relative Value Units for New and Revised Physician's Current Procedural Terminology (CPT) Codes and New Healthcare Common Procedure Coding System Codes (HCPCS) for 2008 (Includes Table Titled "American Medical Association Specialty Relative Value Update Committee and Health Care Professionals Advisory Committee Recommendations and CMS's Decisions for New and Revised 2008 CPT Codes")
 - F. Discussion of Codes and RUC/HCPAC Recommendations
 - G. Additional Coding Issues
 - H. Establishment of Interim PE RVUs for New and Revised Physician's Current Procedural Terminology (CPT) Codes and New Healthcare Common Procedure Coding System (HCPCS) Codes for 2008
- V. Physician Self-Referral Prohibition: Annual Update to the List of CPT/HCPCS Codes
- VI. Physician Fee Schedule Update for CY 2008
- A. Physician Fee Schedule Update
 - B. The Percentage Change in the Medicare Economic Index (MEI)
 - C. The Update Adjustment Factor (UAF)
- VII. Allowed Expenditures for Physicians' Services and the Sustainable Growth Rate
- A. Medicare Sustainable Growth Rate
 - B. Physicians' Services
 - C. Preliminary Estimate of the SGR for 2008
 - D. Revised Sustainable Growth Rate for 2007
 - E. Final Sustainable Growth Rate for 2006
 - F. Calculation of 2008, 2007, and 2006 Sustainable Growth Rates
- VIII. Anesthesia and Physician Fee Schedule Conversion Factors for CY 2008
- A. Physician Fee Schedule Conversion Factor
 - B. Anesthesia Fee Schedule Conversion Factor
- IX. Telehealth Originating Site Facility Fee Payment Amount Update
- X. Provisions of the Final Rule
- XI. Waiver of Proposed Rulemaking and Delay in Effective Date
- XII. Collection of Information Requirements
- XIII. Response to Comments
- XIV. Regulatory Impact Analysis
- Regulation Text
- Addendum A—Explanation and Use of Addendum B
- Addendum B—2008 Relative Value Units and Related Information Used in Determining Medicare Payments for 2007
- Addendum C—Codes With Interim RVUS
- Addendum D—2008 Geographic Adjustment Factors (GAFs)
- Addendum E—2008 Geographic Practice Cost Indices (GPCIs) by State and Medicare Locality
- Addendum F—CPT/HCPCS Imaging Codes Defined by Section 5102(b) of the DRA
- Addendum G—FY 2008 Wage Index for Urban Areas Based on CBSA Labor Market Areas
- Addendum H—FY 2008 Wage Index Based on CBSA Labor Market Areas for Rural Areas
- Addendum I—Updated List of CPT/HCPCS Codes Used To Describe Certain Designated Health Services Under the Physician Self-Referral Provision
- Acronyms**
- In addition, because of the many organizations and terms to which we refer by acronym in this final rule with comment period, we are listing these acronyms and their corresponding terms in alphabetical order below:
- AAA Abdominal aortic aneurysm
 AAP Average acquisition price
 ACOTE Accreditation Council for Occupational Therapy Education
 ACR American College of Radiology
 AFROC Association of Freestanding Radiation Oncology Centers
 AHFS—DI American Hospital Formulary Service—Drug Information
 AHRQ Agency for Healthcare Research and Quality (HHS)
 AIF Ambulance inflation factor
 AMA American Medical Association
 AMA—DE American Medical Association Drug Evaluations
 AMP Average manufacturer price
 AOTA American Occupational Therapy Association
 APC Ambulatory payment classification
 APTA American Physical Therapy Association
 ASA American Society of Anesthesiologists
 ASC Ambulatory surgical center
 ASP Average sales price
 ASTRO American Society for Therapeutic Radiology and Oncology
 ATA American Telemedicine Association
 AWP Average wholesale price
 BBA Balanced Budget Act of 1997 (Pub. L. 105–33)
 BBRA [Medicare, Medicaid and State Child Health Insurance Program] Balanced Budget Refinement Act of 1999 (Pub. L. 106–113)
 BIPA Medicare, Medicaid, and SCHIP Benefits Improvement Protection Act of 2000
 BLS Bureau of Labor Statistics
 BMD Bone mineral density
 BMI Body mass index
 BMM Bone mass measurement
 BN Budget neutrality
 BSA Body surface area
 CAD Computer aided detection
 CAH Critical access hospital
 CAP Competitive acquisition program
 CBSA Core-Based Statistical Area
 CEM Cardiac event monitoring
 CF Conversion factor
 CFR Code of Federal Regulations
 CMA California Medical Association
 CMS Centers for Medicare & Medicaid Services
 CNS Clinical nurse specialist
 CORF Comprehensive Outpatient Rehabilitation Facility
 COTA Certified Occupational Therapy Assistant
 CPEP Clinical Practice Expert Panel
 CPI Consumer Price Index
 CPI—U Consumer price index for urban customers
 CPT (Physicians') Current Procedural Terminology (4th Edition, 2002, copyrighted by the American Medical Association)
 CRT—D Cardiac resynchronization therapy defibrillator
 CT Computed tomography
 CTA Computed tomographic angiography
 CY Calendar year
 DEXA Dual energy x-ray absorptiometry
 DHS Designated health services
 DME Durable medical equipment
 DMEPOS Durable medical equipment, prosthetics, orthotics, and supplies
 DO Doctor of Osteopathy
 DRA Deficit Reduction Act of 2005 (Pub. L. 109–432)
 E/M Evaluation and management
 ECI Employment cost index
 EHR Electronic health record
 EPC [Duke] Evidence-based Practice Centers
 EPO Erythropoietin
 ESRD End stage renal disease
 F&C Facts and Comparisons
 FAW Furnish as written

FAX Facsimile
 FDA Food and Drug Administration (HHS)
 FMR Fair market rents
 FQHC Federally qualified health center
 FR **Federal Register**
 GAF Geographic adjustment factor
 GAO General Accounting Office
 GII Global Insight, Inc.
 GPO Group purchasing organization
 GPCI Geographic practice cost index
 HCPAC Health Care Professional Advisory Committee
 HCPCS Healthcare Common Procedure Coding System
 HCRIS Healthcare Cost Report Information System
 HIPAA Health Insurance Portability and Accountability Act of 1996 (Pub. L. 104–191)
 HHA Home health agency
 HHS [Department of] Health and Human Services
 HIT Health information technology
 HMO Health maintenance organization
 HPSA Health Professional Shortage Area
 HRSA Health Resources Services Administration (HHS)
 HUD [Department of] Housing and Urban Development
 ICD Implantable cardioverter-defibrillator
 ICF Intermediate care facilities
 IDTF Independent diagnostic testing facility
 IFC Interim final rule with comment period
 IOTED International Occupational Therapy Eligibility Determination
 IPPE Initial preventive physical examination
 IPPS Inpatient prospective payment system
 IV Intravenous
 IVIG Intravenous immune globulin
 IWPUT Intra-service work per unit of time
 JCAAI Joint Council of Allergy, Asthma, and Immunology
 LPN Licensed practical nurse
 MA Medicare Advantage
 MA–PD Medicare Advantage Prescription Drug Plans
 MD Medical doctor
 MedCAC Medicare Evidence Development and Coverage Advisory Committee (formerly the Medicare Coverage Advisory Committee (MCAC))
 MedPAC Medicare Payment Advisory Commission
 MEI Medicare Economic Index
 MIEA–TRHCA Medicare Improvements and Extension Act of 2006 (That is, Division B of the Tax Relief and Health Care Act of 2006 (TRHCA))
 MMA Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. 108–173)
 MNT Medical nutrition therapy
 MP Malpractice
 MRA Magnetic resonance angiography
 MRI Magnetic resonance imaging
 MSA Metropolitan statistical area
 MSP Medicare Secondary Payer
 MSVP Multi-specialty visit package
 NBCOT National Board for Certification in Occupational Therapy, Inc.
 NCCN National Comprehensive Cancer Network
 NCPDP National Council for Prescription Drug Programs
 NCQDIS National Coalition of Quality Diagnostic Imaging Services
 NDC National drug code
 NEMC New England Medical Center
 NISTA National Institute of Standards and Technology Act
 NLA National limitation amount
 NP Nurse practitioner
 NPP Nonphysician practitioners
 NQF National Quality Forum
 NTTAA National Technology Transfer and Advancement Act of 1995 (Pub. L. 104–113)
 OACT [CMS] Office of the Actuary
 OBRA Omnibus Budget Reconciliation Act
 OIG Office of Inspector General
 OMB Office of Management and Budget
 OPD Outpatient Department
 OPDS Outpatient prospective payment system
 OPT Outpatient physical therapy
 OSCAR Online Survey and Certification and Reporting
 PA Physician assistant
 PC Professional component
 PCF Patient compensation fund
 PDP Prescription Drug Plan
 PE Practice Expense
 PE/HR Practice expense per hour
 PEAC Practice Expense Advisory Committee
 PECOS Provider Enrollment, Chain, and Ownership System
 PERC Practice Expense Review Committee
 PET Positron emission tomography
 PFS Physician Fee Schedule
 PLI Professional liability insurance
 PPI Producer price index
 PPS Prospective payment system
 PQRI Physician Quality Reporting Initiative
 PRA Paperwork Reduction Act
 PSA Physician scarcity areas
 PT Physical therapy
 PT/INR Prothrombin time, international normalized ratio
 RFA Regulatory Flexibility Act
 RHC Rural health clinic
 RIA Regulatory impact analysis
 RN Registered nurse
 RT Respiratory therapist
 RUC [AMA's Specialty Society] Relative (Value) Update Committee
 RVU Relative value unit
 SBA Small Business Administration
 SGR Sustainable growth rate
 SLP Speech—language pathology
 SLPs Speech—language pathologists
 SMS [AMA's] Socioeconomic Monitoring System
 SNF Skilled nursing facility
 STS Society of Thoracic Surgeons
 TA Technology Assessment
 TC Technical Component
 TENS Transcutaneous electric nerve stimulator
 TRHCA Tax Relief and Health Care Act of 2006 (Pub. L. 109–432)
 USP–DI United States Pharmacopoeia-Drug Information
 WAC Wholesale acquisition cost
 WAMP Widely available market price
 Wet AMD Exudative age-related macular degeneration
 WFOT World Federation of Occupational Therapists

I. Background

Since January 1, 1992, Medicare has paid for physicians' services under

section 1848 of the Social Security Act (the Act), "Payment for Physicians' Services." The Act requires that payments under the physician fee schedule (PFS) be based on national uniform relative value units (RVUs) based on the resources used in furnishing a service. Section 1848(c) of the Act requires that national RVUs be established for physician work, practice expense (PE), and malpractice expense. Before the establishment of the resource-based relative value system, Medicare payment for physicians' services was based on reasonable charges.

A. Development of the Relative Value System

1. Work RVUs

The concepts and methodology underlying the PFS were enacted as part of the Omnibus Budget Reconciliation Act (OBRA) of 1989, Pub. L. 101–239, and OBRA 1990, (Pub. L. 101–508). The final rule, published November 25, 1991 (56 FR 59502), set forth the fee schedule for payment for physicians' services beginning January 1, 1992. Initially, only the physician work RVUs were resource-based, and the PE and malpractice RVUs were based on average allowable charges.

The physician work RVUs established for the implementation of the fee schedule in January 1992 were developed with extensive input from the physician community. A research team at the Harvard School of Public Health developed the original physician work RVUs for most codes in a cooperative agreement with the Department of Health and Human Services (HHS). In constructing the code-specific vignettes for the original physician work RVUs, Harvard worked with panels of experts, both inside and outside the Federal government, and obtained input from numerous physician specialty groups.

Section 1848(b)(2)(B) of the Act specifies that the RVUs for anesthesia services are based on RVUs from a uniform relative value guide. We established a separate conversion factor (CF) for anesthesia services, and we continue to utilize time units as a factor in determining payment for these services. As a result, there is a separate formula used to calculate payment for anesthesia services.

We establish physician work RVUs for new and revised codes based on recommendations received from the American Medical Association's (AMA) Specialty Society Relative Value Update Committee (RUC).

2. Practice Expense Relative Value Units (PE RVUs)

Section 121 of the Social Security Act Amendments of 1994 (Pub. L. 103-32), enacted on October 31, 1994, amended section 1848(c)(2)(C)(ii) of the Act and required us to develop resource-based PE RVUs for each physician's service beginning in 1998. We were to consider general categories of expenses (such as office rent and wages of personnel, but excluding malpractice expenses) comprising PEs.

Section 4505(a) of the Balanced Budget Act of 1997 (BBA) (Pub. L. 105-33), amended section 1848(c)(2)(C)(ii) of the Act to delay implementation of the resource-based PE RVU system until January 1, 1999. In addition, section 4505(b) of the BBA provided for a 4-year transition period from charge based PE RVUs to resource-based RVUs.

We established the resource based PE RVUs for each physician's service in a final rule, published November 2, 1998 (63 FR 58814), effective for services furnished in 1999. Based on the requirement to transition to a resource based system for PE over a 4-year period, resource-based PE RVUs did not become fully effective until 2002.

This resource-based system was based on two significant sources of actual PE data: The Clinical Practice Expert Panel (CPEP) data and the AMA's Socioeconomic Monitoring System (SMS) data. The CPEP data were collected from panels of physicians, practice administrators, and nonphysicians (for example, registered nurses (RNs)) nominated by physician specialty societies and other groups. The CPEP panels identified the direct inputs required for each physician's service in both the office setting and out-of-office setting. We have since refined and revised these inputs based on recommendations from the RUC. The AMA's SMS data provided aggregate specialty-specific information on hours worked and PEs.

Separate PE RVUs are established for procedures that can be performed in both a nonfacility setting, such as a physician's office, and a facility setting, such as a hospital outpatient department. The difference between the facility and nonfacility RVUs reflects the fact that a facility typically receives separate payment from Medicare for its costs of providing the service, apart from payment under the PFS. The nonfacility RVUs reflect all of the direct and indirect PEs of providing a particular service.

Section 212 of the Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106-113) directed the Secretary of

Health and Human Services (the Secretary) to establish a process under which we accept and use, to the maximum extent practicable and consistent with sound data practices, data collected or developed by entities and organizations to supplement the data we normally collect in determining the PE component. On May 3, 2000, we published the interim final rule (65 FR 25664) that set forth the criteria for the submission of these supplemental PE survey data. The criteria were modified in response to comments received, and published in the **Federal Register** (65 FR 65376) as part of a November 1, 2000 final rule. The PFS final rules published in 2001 and 2003, respectively, (66 FR 55246 and 68 FR 63196) extended the period during which we would accept these supplemental data through March 1, 2005.

In the CY 2007 PFS final rule with comment period (71 FR 69624), we revised the methodology for calculating PE RVUs beginning in CY 2007 and provided for a 4-year transition for the new PE RVUs under this new methodology. We will continue to reexamine this policy and proposed necessary revisions through future rulemaking.

3. Resource-Based Malpractice (MP) RVUs

Section 4505(f) of the BBA amended section 1848(c) of the Act to require us to implement resource-based malpractice (MP) RVUs for services furnished on or after 2000. The resource-based MP RVUs were implemented in the PFS final rule published November 2, 1999 (64 FR 59380). The MP RVUs were based on malpractice insurance premium data collected from commercial and physician-owned insurers from all the States, the District of Columbia, and Puerto Rico.

4. Refinements to the RVUs

Section 1848(c)(2)(B)(i) of the Act requires that we review RVUs no less often than every 5 years. The first 5-Year Review of the physician work RVUs was effective in 1997, published on November 22, 1996 (61 FR 59489). The second 5-Year Review went into effect in 2002, published in the CY 2002 PFS final rule (66 FR 55246). The third 5-Year Review of physician work RVUs went into effect on January 1, 2007 and was published in the CY 2007 PFS final rule with comment period (71 FR 69624) (although we note that certain additional proposals relating to the third 5-Year Review are addressed in the CY 2008 PFS proposed rule and in this final rule with comment period).

In 1999, the AMA's RUC established the Practice Expense Advisory Committee (PEAC) for the purpose of refining the direct PE inputs. Through March 2004, the PEAC provided recommendations to CMS for over 7,600 codes (all but a few hundred of the codes currently listed in the AMA's Current Procedural Terminology (CPT) codes). As part of the CY 2007 PFS final rule with comment period (71 FR 69624), we implemented a new methodology for determining resource-based PE RVUs and are transitioning this over a 4-year period.

In the CY 2005 PFS final rule with comment period (69 FR 66236), we implemented the first 5-Year Review of the malpractice RVUs (69 FR 66263).

5. Adjustments to RVUs are Budget Neutral

Section 1848(c)(2)(B)(ii)(II) of the Act provides that adjustments in RVUs for a year may not cause total PFS payments to differ by more than \$20 million from what they would have been if the adjustments were not made. In accordance with section 1848(c)(2)(B)(ii)(II) of the Act, if adjustments to RVUs cause expenditures to change by more than \$20 million, we make adjustments to ensure that expenditures do not increase or decrease by more than \$20 million.

As explained in the CY 2007 PFS final rule with comment period (71 FR 69624), due to the increase in work RVUs resulting from the third 5-Year Review of physician work RVUs, we are applying a separate budget neutrality (BN) adjustor to the work RVUs for services furnished during 2007. This approach is consistent with the method we use to make BN adjustments to the PE RVUs to reflect the changes in these PE RVUs.

B. Components of the Fee Schedule Payment Amounts

To calculate the payment for every physician service, the components of the fee schedule (physician work, PE, and MP RVUs) are adjusted by a geographic practice cost index (GPCI). The GPCIs reflect the relative costs of physician work, PE, and malpractice insurance in an area compared to the national average costs for each component.

Payments are converted to dollar amounts through the application of a CF, which is calculated by the Office of the Actuary (OACT) and is updated annually for inflation.

The formula for calculating the Medicare fee schedule amount for a given service and fee schedule area can be expressed as:

$$\text{Payment} = \frac{[(RVU \text{ work} \times \text{budget neutrality adjuster} \times \text{work GPCI}) + (RVU \text{ PE} \times \text{PE GPCI}) + (MP \text{ RVU} \times \text{MP GPCI})]}{\times CF}$$

C. Most Recent Changes to the Fee Schedule

The CY 2007 PFS final rule with comment period (71 FR 69624) addressed certain provisions of the Deficit Reduction Act of 2005 (Pub. L. 109-432) (DRA) and made other changes to Medicare Part B payment policy to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. This final rule with comment period also discussed GPCI changes; requests for additions to the list of telehealth services; payment for covered outpatient drugs and biologicals; payment for renal dialysis services; policies related to private contracts and opt-out; policies related to bone mass measurement (BMM) services, independent diagnostic testing facilities (IDTFs), the physician self-referral prohibition; laboratory billing for the technical component (TC) of physician pathology services; the clinical laboratory fee schedule; certification of advanced practice nurses; health information technology, the health care information transparency initiative; updated the list of certain services subject to the physician self-referral prohibitions, finalized ASP reporting requirements, and codified Medicare's longstanding policy that payment of bad debts associated with services paid under a fee schedule/charge-based system is not allowable.

We also finalized the CY 2006 interim RVUs and issued interim RVUs for new and revised procedure codes for CY 2007.

In addition, the CY 2007 PFS final rule with comment period included revisions to payment policies under the fee schedule for ambulance services and announced the ambulance inflation factor (AIF) update for CY 2007.

In accordance with section 1848(d)(1)(E)(i) of the Act, we also announced that the PFS update for CY 2007 is -5.0 percent, the initial estimate for the sustainable growth rate (SGR) for CY 2007 is 1.8 percent and the CF for CY 2007 is \$35.9848. However, subsequent to publication of the CY 2007 PFS final rule with comment period, section 101(a) of Division B, Title I of the Tax Relief and Health Care Act of 2006 (Pub. L. 109-432) (MIEA-TRHCA), which was enacted on December 20, 2006, amended section 1848(d) of the Act. [Division B of the Tax Relief and Health Care Act of 2006

is entitled Medicare and Other Health Provisions and its short title is the Medicare Improvements and Extension Act of 2006. Therefore, the law is hereinafter referred to as "MIEA-TRHCA".] As a result of this statutory change, the CF of \$37.8975 was maintained for CY 2007.

II. Provisions of the Final Rule Related to the Physician Fee Schedule

In response to the CY 2008 PFS proposed rule (72 FR 38122), we received approximately 27,000 comments. We received comments from individual physicians, health care workers, professional associations and societies, and beneficiaries. The majority of the comments addressed the proposals related to anesthesia coding and the 5-Year Review, the physician self-referral provisions and the technical correction to § 410.32(a)(1) concerning an exception to the requirement that diagnostic services (including x-rays) must be ordered by the treating physician. To the extent that comments were outside the scope of the proposed rule, they are not addressed in this final rule with comment period.

RVU changes implemented through this final rule with comment are subject to the \$20 million limitation on annual adjustments contained in section 1848(c)(2)(B)(ii)(II) of the Act. After reviewing the comments and determining the policies we would implement, we have estimated the costs and savings of these policies and discuss in detail the effects of these changes in the Regulatory Impact Analysis in section XIV. For the convenience of the reader, the headings for the policy issues correspond to the headings used in the CY 2008 PFS proposed rule (72 FR 38122). More detailed background information for each issue can be found in the CY 2008 PFS proposed rule.

A. Resource Based Practice Expense (PE) Relative Value Units (RVUs)

Practice expense (PE) is the portion of the resources used in furnishing the service that reflects the general categories of physician and practitioner expenses, such as office rent and personnel wages but excluding malpractice expenses, as specified in section 1848(c)(1)(B) of the Act.

Section 121 of the Social Security Amendments of 1994 (Pub. L. 103-432), enacted on October 31, 1994, required CMS to develop a methodology for a resource-based system for determining PE RVUs for each physician's service. Until that time, PE RVUs were based on historical allowed charges. This legislation required that the revised PE

methodology must consider the staff, equipment, and supplies used in the provision of various medical and surgical services in various settings beginning in 1998. The Secretary has interpreted this to mean that Medicare payments for each service would be based on the relative PE resources typically involved with furnishing the service.

The initial implementation of resource-based PE RVUs was delayed from January 1, 1998, until January 1, 1999, by section 4505(a) of the BBA. In addition, section 4505(b) of the BBA required that the new payment methodology be phased in over 4 years, effective for services furnished in CY 1999, and fully effective in CY 2002. The first step toward implementation of the statute was to adjust the PE values for certain services for CY 1998. Section 4505(d) of the BBA required that, in developing the resource-based PE RVUs, the Secretary must:

- Use, to the maximum extent possible, generally-accepted cost accounting principles that recognize all staff, equipment, supplies, and expenses, not solely those that can be linked to specific procedures and actual data on equipment utilization.
- Develop a refinement method to be used during the transition.
- Consider, in the course of notice and comment rulemaking, impact projections that compare new proposed payment amounts to data on actual physician PE.

In CY 1999, we began the 4-year transition to resource-based PE RVUs utilizing a "top-down" methodology whereby we allocated aggregate specialty-specific practice costs to individual procedures. The specialty-specific PEs were derived from the American Medical Association's (AMA's) Socioeconomic Monitoring Survey (SMS). In addition, under section 212 of the BBRA, we established a process extending through March 2005 to supplement the SMS data with data submitted by a specialty. The aggregate PEs for a given specialty were then allocated to the services furnished by that specialty on the basis of the direct input data (that is, the staff time, equipment, and supplies) and work RVUs assigned to each CPT code.

For CY 2007, we implemented a new methodology for calculating PE RVUs. Under this new methodology, we use the same data sources for calculating PE, but instead of using the "top-down" approach to calculate the direct PE RVUs, under which the aggregate direct and indirect costs for each specialty are allocated to each individual service, we now utilize a "bottom-up" approach to

calculate the direct costs. Under the "bottom-up" approach, we determine the direct PE by adding the costs of the resources (that is, the clinical staff, equipment, and supplies) typically required to furnish each service. The costs of the resources are calculated using the refined direct PE inputs assigned to each CPT code in our PE database, which are based on our review of recommendations received from the AMA's Relative Value Update Committee (RUC). For a more detailed explanation of the PE methodology see the Five-Year Review of Work RVUs Under the PFS and Proposed Changes to the PE Methodology proposed notice (71 FR 37242) and the CY 2007 PFS final rule with comment period (71 FR 69629).

1. Current Methodology

a. Data Sources for Calculating Practice Expense

The AMA's SMS survey data and supplemental survey data from the specialties of cardio-thoracic surgery, vascular surgery, physical and occupational therapy, independent laboratories, allergy/immunology, cardiology, dermatology, gastroenterology, radiology, independent diagnostic testing facilities (IDTFs), radiation oncology, and urology are used to develop the PE per hour (PE/HR) for each specialty. For those specialties for which we do not have PE/HR, the appropriate PE/HR is obtained from a crosswalk to a similar specialty.

The AMA developed the SMS survey in 1981 and discontinued it in 1999. Beginning in 2002, we incorporated the 1999 SMS survey data into our calculation of the PE RVUs, using a 5-year average of SMS survey data. (See the Revisions to Payment Policies and Five-Year Review of and Adjustments to the Relative Value Units Under the Physician Fee Schedule for CY 2002 final rule (66 FR 55246, November 1, 2002) (hereinafter referred to as CY 2002 PFS final rule).) The SMS PE survey data are adjusted to a common year, 2005. The SMS data provide the following six categories of PE costs:

- Clinical payroll expenses, which are payroll expenses (including fringe benefits) for nonphysician clinical personnel.
- Administrative payroll expenses, which are payroll expenses (including fringe benefits) for nonphysician personnel involved in administrative, secretarial or clerical activities.
- Office expenses, which include expenses for rent, mortgage interest,

depreciation on medical buildings, utilities and telephones.

- Medical material and supply expenses, which include expenses for drugs, x-ray films, and disposable medical products.
- Medical equipment expenses, which include expenses depreciation, leases, and rent of medical equipment used in the diagnosis or treatment of patients.
- All other expenses, which include expenses for legal services, accounting, office management, professional association memberships, and any professional expenses not previously mentioned in this section.

In accordance with section 212 of the BBRA, we established a process to supplement the SMS data for a specialty with data collected by entities and organizations other than the AMA (that is, the specialty itself). (See the Criteria for Submitting Supplemental Practice Expense Survey Data interim final rule with comment period, (65 FR 25664, May 3, 2000).) Originally, the deadline to submit supplementary survey data was through August 1, 2001. In the CY 2002 PFS final rule (66 FR 55246), the deadline was extended through August 1, 2003. To ensure maximum opportunity for specialties to submit supplementary survey data, we extended the deadline to submit surveys until March 1, 2005 in the Revisions to Payment Policies Under the Physician Fee Schedule for CY 2004 final rule, (November 7, 2003; 68 FR 63196) (hereinafter referred to as CY 2004 PFS final rule).

The direct cost data for individual services were originally developed by the Clinical Practice Expert Panels (CPEP). The CPEP data include the supplies, equipment, and staff times specific to each procedure. The CPEPs consisted of panels of physicians, practice administrators, and nonphysicians (for example, RNs) who were nominated by physician specialty societies and other groups. There were 15 CPEPs consisting of 180 members from more than 61 specialties and subspecialties. Approximately 50 percent of the panelists were physicians.

The CPEPs identified specific inputs involved in each physician's service provided in an office or facility setting. The inputs identified were the quantity and type of nonphysician labor, medical supplies, and medical equipment.

In 1999, the AMA's RUC established the Practice Expense Advisory Committee (PEAC). From 1999 to March 2004, the PEAC, a multi-specialty committee, reviewed the original CPEP inputs and provided us with

recommendations for refining these direct PE inputs for existing CPT codes. Through its last meeting in March 2004, the PEAC provided recommendations for over 7,600 codes which we have reviewed and accepted. As a result, the current PE inputs differ markedly from those originally recommended by the CPEPs. The PEAC has now been replaced by the Practice Expense Review Committee (PERC), which acts to assist the RUC in recommending PE inputs.

b. Allocation of PE to Services

The aggregate level specialty-specific PEs are derived from the AMA's SMS survey and supplementary survey data. To establish PE RVUs for specific services, it is necessary to establish the direct and indirect PE associated with each service.

(i) *Direct costs.* The direct costs are determined by adding the costs of the resources (that is, the clinical staff, equipment, and supplies) typically required to provide the service. The costs of these resources are calculated from the refined direct PE inputs in our PE database. These direct inputs are then scaled to the current aggregate pool of direct PE RVUs. The aggregate pool of direct PE RVUs can be derived using the following formula: (PE RVUs * physician CF) * (average direct percentage from SMS/(Supplemental PE/HR data)).

(ii) *Indirect costs.* The SMS and supplementary survey data are the source for the specialty-specific aggregate indirect costs used in our PE calculations. We then allocate the indirect costs to the code level on the basis of the direct costs specifically associated with a code and the maximum of either the clinical labor costs or the physician work RVUs. For calculation of the 2008 PE RVUs, we are using the 2006 procedure-specific utilization data crosswalked to 2007 services. To arrive at the indirect PE costs:

- We apply a specialty-specific indirect percentage factor to the direct expenses to recognize the varying proportion that indirect costs represent of total costs by specialty. For a given service, the specific indirect percentage factor to apply to the direct costs for the purpose of the indirect allocation is calculated as the weighted average of the ratio of the indirect to direct costs (based on the survey data) for the specialties that furnish the service. For example, if a service is furnished by a single specialty with indirect PEs that were 75 percent of total PEs, the indirect percentage factor to apply to the direct costs for the purposes of the indirect

allocation would be $(0.75/0.25) = 3.0$. The indirect percentage factor is then applied to the service level adjusted indirect PE allocators.

- We use the specialty-specific PE/HR from the SMS survey data, as well as the supplemental surveys for cardiothoracic surgery, vascular surgery, physical and occupational therapy, independent laboratories, allergy/immunology, cardiology, dermatology, radiology, gastroenterology, IDTFs, radiation oncology and urology. (**Note:** For radiation oncology, the data represent the combined survey data from the American Society for Therapeutic Radiology and Oncology (ASTRO) and the Association of Freestanding Radiation Oncology Centers (AFROC).) We incorporate this PE/HR into the calculation of indirect costs using an index which reflects the relationship between each specialty's indirect scaling factor and the overall indirect scaling factor for the entire PFS. For example, if a specialty had an indirect practice cost index of 2.00, this specialty would have an indirect scaling factor that was twice the overall average indirect scaling factor. If a specialty had an indirect practice cost index of 0.50, this specialty would have an indirect scaling factor that was half the overall average indirect scaling factor.

- When the clinical labor portion of the direct PE RVU is greater than the physician work RVU for a particular service, the indirect costs are allocated based upon the direct costs and the clinical labor costs. For example, if a service has no physician work and 1.10 direct PE RVUs, and the clinical labor portion of the direct PE RVUs is 0.65 RVUs, we would use the 1.10 direct PE RVUs and the 0.65 clinical labor portions of the direct PE RVUs to allocate the indirect PE for that service.

c. Facility/Nonfacility Costs

Procedures that can be furnished in a physician's office, as well as in a hospital or facility setting, have two PE RVUs: facility and nonfacility. The nonfacility setting includes physicians' offices, patients' homes, freestanding imaging centers, and independent pathology labs. Facility settings include hospitals, ambulatory surgical centers (ASCs), and skilled nursing facilities (SNFs). The methodology for calculating PE RVUs is the same for both, facility and nonfacility RVUs, but is applied independently to yield two separate PE RVUs. Because the PEs for services provided in a facility setting are generally included in the payment to the facility (rather than the payment to the physician under the PFS), the PE

RVUs are generally lower for services provided in the facility setting.

d. Services With Technical Components (TCs) and Professional Components (PCs)

Diagnostic services are generally comprised of two components: a professional component (PC) and a technical component (TC), which may be furnished independently or by different providers. When services have TC, PC, and global components that can be billed separately, the payment for the global component equals the sum of the payment for the TC and PCs. This is a result of using a weighted average of the ratio of indirect to direct costs across all the specialties that furnish the global components, TCs, and PCs; that is, we apply the same weighted average indirect percentage factor to allocate indirect expenses to the global components, PC, and TCs for a service. (The direct PE RVUs for the TC and PCs sum to the global under the bottom-up methodology.)

e. Transition Period

As discussed in the CY 2007 PFS final rule with comment period (71 FR 69674), we are implementing the change in the methodology for calculating PE RVUs over a 4-year period. During this transition period, the PE RVUs will be calculated on the basis of a blend of RVUs calculated using our methodology described previously in this section (weighted by 25 percent during CY 2007, 50 percent during CY 2008, 75 percent during CY 2009, and 100 percent thereafter), and the CY 2006 PE RVUs for each existing code. PE RVUs for codes that are new during this period will be calculated using only the current PE methodology, and will be paid at the fully transitioned rate.

f. PE RVU Methodology

The following is a description of the PE RVU methodology.

(i) Setup File

First, we create a setup file for the PE methodology. The setup file contains the direct cost inputs, the utilization for each procedure code at the specialty and facility/nonfacility place of service level, and the specialty-specific survey PE per physician hour data.

(ii) Calculate the Direct Cost PE RVUs

Sum the Costs of Each Direct Input

Step 1: Sum the direct costs of the inputs for each service. The direct costs consist of the costs of the direct inputs for clinical labor, medical supplies, and medical equipment. The clinical labor cost is the sum of the cost of all the staff

types associated with the service; it is the product of the time for each staff type and the wage rate for that staff type. The medical supplies cost is the sum of the supplies associated with the service; it is the product of the quantity of each supply and the cost of the supply. The medical equipment cost is the sum of the cost of the equipment associated with the service; it is the product of the number of minutes each piece of equipment is used in the service and the equipment cost per minute. The equipment cost per minute is calculated as described at the end of this section.

Apply a BN Adjustment to the Direct Inputs

Step 2: Calculate the current aggregate pool of direct PE costs. To do this, multiply the current aggregate pool of total direct and indirect PE costs (that is, the current aggregate PE RVUs multiplied by the CF) by the average direct PE percentage from the SMS and supplementary specialty survey data.

Step 3: Calculate the aggregate pool of direct costs. To do this, for all PFS services, sum the product of the direct costs for each service from Step 1 and the utilization data for that service.

Step 4: Using the results of Step 2 and Step 3 calculate a direct PE BN adjustment so that the proposed aggregate direct cost pool does not exceed the current aggregate direct cost pool and apply it to the direct costs from Step 1 for each service.

Step 5: Convert the results of Step 4 to an RVU scale for each service. To do this, divide the results of Step 4 by the Medicare PFS CF.

(iii) Create the Indirect PE RVUs

Create Indirect Allocators

Step 6: Based on the SMS and supplementary specialty survey data, calculate direct and indirect PE percentages for each physician specialty.

Step 7: Calculate direct and indirect PE percentages at the service level by taking a weighted average of the results of Step 6 for the specialties that furnish the service. Note that for services with a TC and PCs we are calculating the direct and indirect percentages across the global components, PCs and TCs. That is, the direct and indirect percentages for a given service (for example, echocardiogram) do not vary by the PC, TC and global component.

Step 8: Calculate the service level allocators for the indirect PEs based on the percentages calculated in Step 7. The indirect PEs are allocated based on the three components: the direct PE

RVU, the clinical PE RVU and the work RVU.

For most services the indirect allocator is: $\text{indirect percentage} * (\text{direct PE RVU} / \text{direct percentage}) + \text{work RVU}$.

There are two situations where this formula is modified:

- If the service is a global service (that is, a service with global, professional and technical components), then the indirect allocator is: $\text{indirect percentage} * (\text{direct PERVU} / \text{direct percentage}) + \text{clinical PE RVU} + \text{work RVU}$.

- If the clinical labor PE RVU exceeds the work RVU (and the service is not a global service), then the indirect allocator is: $\text{indirect percentage} * (\text{direct PERVU} / \text{direct percentage}) + \text{clinical PE RVU}$.

(Note that for global services the indirect allocator is based on both the work RVU and the clinical labor PE RVU. We do this to recognize that, for the professional service, indirect PEs will be allocated using the work RVUs, and for the TC service, indirect PEs will be allocated using the direct PE RVU and the clinical labor PE RVU. This also allows the global component RVUs to equal the sum of the PC and TC RVUs.)

For presentation purposes in the examples in Table 1, the formulas were divided into two parts for each service. The first part does not vary by service and is the $\text{indirect percentage} * (\text{direct PE RVU} / \text{direct percentage})$. The second part is either the work RVU, clinical PE RVU, or both depending on whether the service is a global service and whether the clinical PE RVU exceeds the work RVU (as described earlier in this step.)

Apply a BN Adjustment to the Indirect Allocators

Step 9: Calculate the current aggregate pool of indirect PE RVUs by multiplying the current aggregate pool of PE RVUs by the average indirect PE percentage from the physician specialty survey data. This is similar to the Step 2 calculation for the direct PE RVUs.

Step 10: Calculate an aggregate pool of proposed indirect PE RVUs for all PFS services by adding the product of the indirect PE allocators for a service from Step 8 and the utilization data for that service. This is similar to the Step 3 calculation for the direct PE RVUs.

Step 11: Using the results of Step 9 and Step 10, calculate an indirect PE adjustment so that the aggregate indirect allocation does not exceed the available aggregate indirect PE RVUs and apply it to indirect allocators calculated in Step 8. This is similar to the Step 4 calculation for the direct PE RVUs.

Calculate the Indirect Practice Cost Index

Step 12: Using the results of Step 11, calculate aggregate pools of specialty-specific adjusted indirect PE allocators for all PFS services for a specialty by adding the product of the adjusted indirect PE allocator for each service and the utilization data for that service.

Step 13: Using the specialty-specific indirect PE/HR data, calculate specialty-specific aggregate pools of indirect PE for all PFS services for that specialty by adding the product of the indirect PE/HR for the specialty, the physician time for the service, and the specialty's utilization for the service.

Step 14: Using the results of Step 12 and Step 13, calculate the specialty-specific indirect PE scaling factors as under the current methodology.

Step 15: Using the results of Step 14, calculate an indirect practice cost index at the specialty level by dividing each specialty-specific indirect scaling factor by the average indirect scaling factor for the entire PFS.

Step 16: Calculate the indirect practice cost index at the service level to ensure the capture of all indirect costs. Calculate a weighted average of the practice cost index values for the specialties that furnish the service. Note: For services with TC and PCs, we calculate the indirect practice cost index across the global components, PCs and TCs. Under this method, the indirect practice cost index for a given service (for example, echocardiogram) does not vary by the PC, TC and global components.

Step 17: Apply the service level indirect practice cost index calculated in Step 16 to the service level adjusted indirect allocators calculated in Step 11 to get the indirect PE RVU.

(iv) Calculate the Final PE RVUs

Step 18: Add the direct PE RVUs from Step 6 to the indirect PE RVUs from Step 17.

Step 19: Calculate and apply the final PE BN adjustment by comparing the results of Step 18 to the current pool of PE RVUs. This final BN adjustment is required primarily because certain specialties are excluded from the PE RVU calculation for rate-setting purposes, but all specialties are included for purposes of calculating the final BN adjustment. (See "Specialties excluded from rate-setting calculation" below in this section.)

(v) Setup File Information

- **Specialties excluded from rate-setting calculation:** For the purposes of calculating the PE RVUs, we exclude certain specialties such as midlevel practitioners paid at a percentage of the PFS, audiology, and low volume specialties from the calculation. These specialties are included for the purposes of calculating the BN adjustment.

- **Crosswalk certain low volume physician specialties:** Crosswalk the utilization of certain specialties with relatively low PFS utilization to the associated specialties.

- **Physical therapy utilization:** Crosswalk the utilization associated with all physical therapy services to the specialty of physical therapy.

- **Identify professional and technical services not identified under the usual TC and 26 modifier:** Flag the services that are PC and TC services, but do not use TC and 26 modifiers (for example, electrocardiograms). This flag associates the PC and TC with the associated global code for use in creating the indirect PE RVU. For example, the professional service code 93010 is associated with the global code 93000.

- **Payment modifiers:** Payment modifiers are accounted for in the creation of the file. For example, services billed with the assistant at surgery modifier are paid 16 percent of the PFS amount for that service; therefore, the utilization file is modified to only account for 16 percent of any service that contains the assistant at surgery modifier.

- **Work RVUs:** The setup file contains the work RVUs from this final rule with comment period.

(vi) Equipment Cost Per Minute =

The equipment cost per minute is calculated as:

$$\frac{1}{(\text{minutes per year} * \text{usage})} * \text{price} * \left(\frac{\text{interest rate}}{1 - (1 / ((1 + \text{interest rate}) * \text{life of equipment}))} \right) + \text{maintenance}$$

Where:

minutes per year = maximum minutes per year if usage were continuous (that is, usage = 1); 150,000 minutes.

usage = equipment utilization assumption; 0.5.

price = price of the particular piece of equipment.

interest rate = 0.11.

life of equipment = useful life of the particular piece of equipment.

maintenance = factor for maintenance; 0.05.

TABLE 1.—CALCULATION OF PE RVUS UNDER METHODOLOGY FOR SELECTED CODES

	Step	Source	Formula	99213 Office visit, est non- facility	33533 CABG, ar- terial, sin- gle facility	71020 Chest x- ray non- facility	71020TC Chest x- ray non- facility	7102026 Chest x- ray non- facility	93000 ECG, com- plete non- facility	93005 ECG, trac- ing non- facility	93010 ECG, re- port non- facility
(1) Labor cost (Lab)	Step 1	AMA	\$13.32	\$77.52	\$5.74	\$5.74	\$	\$6.12	\$6.12	\$
(2) Supply cost (Sup)	Step 1	AMA	\$2.98	\$7.34	\$3.39	\$3.39	\$	\$1.19	\$1.19	\$
(3) Equipment cost (Eqp)	Step 1	AMA	\$0.19	\$0.65	\$8.17	\$8.17	\$	\$0.12	\$0.12	\$
(4) Direct cost (Dir)	Step 1	\$16.50	\$85.51	\$17.31	\$17.31	\$	\$7.43	\$7.60	\$
(5) Direct adjustment (Dir Adj)	Steps 2-4	See footnote 1	0.592	0.592	0.592	0.592	0.592	0.592	0.592	0.592
(6) Adjusted labor	Steps 2-4	=Lab * Dir Adj	\$7.89	\$45.89	\$3.40	\$3.40	\$	\$3.62	\$3.62	\$
(7) Adjusted supplies	Steps 2-4	=Sup * Dir Adj	\$1.77	\$4.35	\$2.01	\$2.01	\$	\$0.71	\$0.71	\$
(8) Adjusted equipment	Steps 2-4	=Eqp * Dir Adj	\$0.12	\$0.39	\$4.84	\$4.84	\$	\$0.07	\$0.07	\$
(9) Adjusted direct	Steps 2-4	\$9.77	\$50.62	\$10.25	\$10.25	\$	\$4.40	\$4.40	\$
(10) Conversion Factor (CF)	Step 5	MFS	\$34.0682	\$34.0682	\$34.0682	\$34.0682	\$34.0682	\$34.0682	\$34.0682	\$34.0682
(11) Adj. labor cost converted.	Step 5	=(Lab * Dir Adj)/CF	0.23	1.35	0.10	0.10	0.11	0.11
(12) Adj. supply cost converted.	Step 5	=(Sup * Dir Adj)/CF	0.05	0.13	0.06	0.06	0.02	0.02
(13) Adj. equip cost converted.	Step 5	=(Eqp * Dir Adj)/CF	0.00	0.01	0.14	0.14	0.00	0.00
(14) Adj. direct cost converted.	Step 5	0.29	1.49	0.30	0.30	0.13	0.13
(15) Wrk RVU * Wrk Scaler.	Setup File	MFS	0.81	29.62	0.19	0.00-	0.19	0.15	0.00	0.15
(16) Dir. pct	Steps 6, 7	Surveys	33.8%	32.6%	40.7%	40.7%	40.7%	37.7%	37.7%	37.7%
(17) Ind. pct	Steps 6, 7	Surveys	66.2%	67.4%	59.3%	59.3%	59.3%	62.3%	62.3%	62.3%
(18) Ind. Alloc. formula (1st part).	Step 8	See Step 8	((14)/ (16)) * (17)	((14)/ (16)) * (17)	((14)/ (16)) * (17)	((14)/ (16)) * (17)	((14)/ (16)) * (17)	((14)/ (16)) * (17)	((14)/ (16)) * (17)	((14)/ (16)) * (17)
(19) Ind. Alloc. (1st part) (2nd part).	Step 8	See Step 8	0.56 (15)	3.07 (15)	0.44 (15)+(11)	0.44 (11)	0.44 (15)	0.21 (15)+(11)	0.21 (11)	0.21 (15)
(20) Ind. Alloc. formulas (2nd part).	Step 8	0.81	29.62	0.29	0.10	0.19	0.26	0.11	0.15
(21) Ind. Alloc. (2nd part)	Step 8	1.37	32.70	0.73	0.54	0.19	0.47	0.32	0.15
(22) Indirect Allocator (1st+2nd).	Steps 9-11	See footnote 2	0.362	0.362	0.362	0.362	0.362	0.362	0.362	0.362
(23) Indirect Adjustment (Ind Adj).	Steps 9-11	=Ind Alloc * Ind Adj	0.50	11.84	0.26	0.19	0.07	0.17	0.12	0.05
(24) Adjusted Indirect Allocator.	Steps 12-16	See Steps 12-16	0.968	0.942	1.054	1.054	1.054	1.280	1.280	1.280
(25) Ind. Practice Cost Index (PCI).	Step 17	= Adj. Ind Alloc * PCI	0.48	11.15	0.28	0.21	0.07	0.22	0.15	0.07
(26) Adjusted Indirect	Steps 18-19	=(Adj Dir+Adj Ind) * budn	0.77	12.64	0.58	0.51	0.07	0.35	0.28	0.07

¹The direct adj = [current pe rvus * CF * avg dir pct] / [sum direct inputs] = [Step 2] / [Step 3].
²The indirect adj = [current pe rvus * avg ind pct] / [sum of ind allocators] = [Step 9] / [Step 10].

Comments Related to PE Methodology

Comment: Several commenters recommend that the unadjusted work RVUs be used in the allocation of the indirect PE RVUs.

Response: The decision to use the budget neutralized work RVUs in the calculation of indirect PEs appropriately maintains the current relationships between the work, PE, and professional liability payments. We also believe it is important to apply the revised, budget neutralized work RVUs consistently within the PFS framework. It would not be consistent to apply one set of work RVUs for work payments, but a different set for purposes of calculating indirect PEs. Therefore, we will base the calculation of both the work payments and the indirect PE payments on the adjusted work RVUs, and maintain the current overall relationships between work, PE, and professional liability. The PE RVUs in Addendum B and throughout the rest of this rule reflect this policy.

Comment: Several commenters commended CMS on the bottom up approach to calculating resource based PE RVUs. Commenters expressed gratitude for the transparency and straight forward nature of the revised methodology.

Response: We appreciate the support for the revised bottom up practice methodology and agree that the bottom up methodology is a more straight forward methodology than its predecessor.

Comment: Some commenters contend that the approach of basing PE calculations on the weighted average of all specialties furnishing a service is flawed and should be replaced with an approach that bases the specialty weighted factors upon specialties that represent 95 percent of the total utilization of each respective service.

Response: This issue was fully addressed in the comment and response section of the CY 2007 PFS final rule with comment period (71 FR 69641), and we did not make any further proposals relating to this policy in the CY 2008 PFS proposed rule. Thus, these comments are outside the scope of the CY 2008 PFS proposed rule.

Comment: One commenter stated that the use of direct PEs in the allocation of indirect PEs unfairly penalizes PC only billers that do not have any direct costs. Additionally, this commenter contends that the use of only the work RVU in the allocation of indirect PEs for this situation underestimates the indirect PEs for PC only billers.

Response: The resource-based PE methodology uses both the work RVU

and the direct cost PE RVU in the allocation of indirect PEs. For PC only billers, which do not have any direct costs, indirect costs will only be allocated based upon the work RVUs. There is no provision within the current methodology to allocate the indirect PEs differently, and we made no proposals in the CY 2008 PFS proposed rule regarding this allocation. Additionally, we note that a review of comments on past regulations confirms that the physician community believes that the work RVUs "over allocate" the indirect PEs. Thus, there appear to be differing views regarding the effect of this allocation. We will continue to allocate the indirect PEs of PC only services on the work RVUs.

Comment: One commenter recommended that, for procedures that have supply costs in excess of 40 to 50 percent of total direct costs, all supply costs be passed through and exempt from the direct adjustment factor.

Response: The resource-based PE methodology converts the direct costs for a service, obtained from the direct cost database, into PE RVUs by comparing the service specific aggregate costs to the aggregate pool of costs available for expenditure on direct costs. Because the aggregate direct costs for all services contained in the direct cost database exceed the aggregate pool of available direct dollars, a direct cost adjustment must be applied to scale the database to the pool. Irrespective of the percentage of total direct costs for a specific service represented by supplies, this adjustment will still be applied. If this adjustment were not applied to certain services, the system would either not be budget neutral or RVUs for all other services would have to be reduced to offset these exemptions. We did not make any proposals relating to this adjustment. Moreover, we see no methodological reason to exempt any services regardless of the percentage of their direct costs represented by supplies from the adjustments that apply to all direct costs.

g. Discussion of Equipment Usage Percentage

In the CY 2008 PFS proposed rule (72 FR 38132), we included a discussion about our use of the equipment usage assumption of 50 percent, and stated that we continue to receive requests that we refine this usage percentage. Some groups and individuals state that this usage percentage should be in the range of 70 to 80 percent while others contend that the current utilization rate is too high at 50 percent and should be refined downward to a lower usage percentage.

If the equipment usage percentage is set too high, the result would be insufficient allowance at the service level for the practice costs associated with equipment. If the equipment usage percentage is set too low, the result would be an excessive allowance for the PE costs of equipment at the service level. Although we acknowledged the 50 percent across the board usage rate that we currently apply for all equipment does not capture the actual usage rates for all equipment, we indicated we do not believe that we have sufficient empirical evidence to justify an alternative proposal on this issue. Therefore, we requested that commenters submit information relating to alternative percentages and approaches that differentially classify equipment into mutually exclusive categories with category specific usage rate assumptions. In addition, we requested any empirical data that would assist us in these efforts.

h. Equipment Interest Rate

As part of our calculation of the PE equipment costs, we consider several factors, for example, the useful life of each piece of equipment and the typical interest that would be incurred in the purchase of the equipment. We updated the assigned useful life for all the equipment in our PE input database in the CY 2005 PFS final rule with comment period. However, we have used the same interest rate of 11 percent since the inception of the resource based PE methodology in 1999. There has been much discussion regarding whether this is still the appropriate interest rate to utilize in the calculation of the equipment costs. The majority of comments on the CY 2007 PFS final rule with comment period requested an interest rate of prime plus 2 percent while a small number of commenters requested an interest rate significantly lower than prime plus 2 percent.

In the CY 2008 PFS proposed rule (72 FR 38132), we discussed the basis for the current interest rate of 11 percent and indicated that, based on our analysis of the revised SBA interest rate data, we believe 11 percent continues to be an appropriate assumption; therefore, we stated we would retain the interest rate used in the calculation of equipment costs at 11 percent.

Comments Concerning Equipment Usage and Interest Rate

Comment: Several commenters, including several specialty societies, MedPAC, and the AMA RUC offered recommendations regarding the 11 percent interest rate and the 50 percent utilization rate used to calculate the

price per minute for each piece of equipment. The recommendations received regarding the proposed 11 percent interest rate were generally favorable with the majority of commenters recommending that we monitor the interest rate annually to ensure that the appropriate percentage is utilized in the calculation of the equipment costs.

The commenters' recommendations about making adjustments to the 50 percent utilization rate varied. Certain commenters recommended we do nothing until stronger empirical evidence is available, while other commenters recommended a decrease in the utilization assumptions, and some commenters recommended an increase in the utilization assumption. The particular changes recommended in the utilization assumptions were, in most cases, directly related to a specific code. Virtually all comments received support an on going process of obtaining reliable empirical data to utilize in the calculation of equipment costs in the future.

Response: As discussed in detail in the CY 2007 PFS final rule with comment period (71 FR 69650), we agree with commenters that both the equipment interest rate and the equipment utilization rate should continue to be examined for accuracy. We are committed to working with all interested parties to define the most accurate utilization and interest rate information for equipment used in the provision of physicians' services. Since we did not propose a specific change, we will maintain the assumptions of a 50-percent equipment utilization rate and an 11-percent equipment interest rate in the calculation of the PE RVUs published in Addendum B of this final rule with comment period. We will continue to monitor the appropriateness of these assumptions, and evaluate whether changes should be proposed in light of the data available.

Comment: A few commenters recommended that the equipment utilization rate associated with preventive services be reduced since much of the equipment associated with preventive services is procedure specific and thus not utilized at as high a rate as other medical equipment.

Response: Similar to our response regarding the equipment utilization rate associated with the entire universe of medical equipment, we do not believe that we have any strong empirical evidence to suggest a change in the current equipment utilization rate associated with preventive services. We are committed to continue working with all interested parties to identify the most

accurate utilization rate information for equipment used in the provision of physicians' services.

2. PE Proposals for CY 2008

a. Radiology Practice Expense Per Hour

The American College of Radiology (ACR) presented CMS with information regarding the PE/HR that was used in the PE methodology for radiology in the CY 2007 PFS final rule with comment period. ACR suggested that we change our methodology in a way that would weight the survey data to provide an alternative method of representing large and small practices. We agreed to take their approach to our contractor, the Lewin Group, for further analysis. (We note that the Lewin Group, in its initial analysis of the ACR survey data, had also raised concerns about the representation of small high cost entities in the ACR survey data.) The Lewin Group reviewed ACR's approach and concluded that weighting the ACR survey by practice size more appropriately accounts for the small high cost entities in the final PE/HR. After reviewing both the ACR inquiry and the Lewin response, we also agreed that ACR's approach more appropriately identifies the PE/HR for radiology.

For these reasons, we proposed to revise the PE/HR associated with radiology using the survey data weighted by practice size and included this revised PE/HR in Table 2 of the CY 2008 PFS proposed rule which identified the PE/HR for all specialties.

Comment: Several commenters, including the AMA's RUC, expressed concern over the proposed increase in the PE/HR for radiology whereby the PE/HR associated with this specialty would be developed based upon a revised practice size weighting methodology. Commenters believed that it is inappropriate to refine the current weighting methodology because: (1) This weighting methodology was not done for all specialties; and (2) some specialties requested to survey their memberships after the deadline to submit supplemental survey data and were denied this opportunity by CMS. Several other commenters commended CMS on their ability to review this potential problem and offer a timely resolution to the affected specialty.

Response: The American College of Radiology approached CMS with questions regarding the weighting methodology that were used in the development of their PE/HR. Specifically, ACR believed that small high cost practices that primarily furnish professional only services were severely underrepresented in the

published PE/HR. Therefore, we forwarded ACR's concerns to our contractor for further review. Upon review of ACR's concerns, our contractor concluded that their initial PE/HR recommendation to CMS was not fully representative of these smaller high cost practices. For this reason, our contractor recommended a revised weighting approach that would fairly represent these small high cost practices. We agree with both the ACR and our contractor and will finalize our proposal to use the revised PE/HR for radiology.

Additionally, we do not believe that these revisions to the PE/HR for radiology constitute a submission of data after the deadline. No new data were submitted. Rather, we view this as a revision to the weighting methodology in order to address a unique situation.

Comment: Several commenters recommended that all pain management services be crosswalked to the interventional pain management specialty as opposed to using the actual data which currently report the anesthesiology specialty furnishing a significant portion of the pain management services. According to the comments received, anesthesiology is listed as the primary specialty on many pain management services and since the PE/HR associated with anesthesiology is lower than interventional pain management, pain management services are being inappropriately valued.

Response: Physicians self-designate their respective specialty for purposes of Medicare enrollment. If commenters believe that physicians are incorrectly self-designating their specialty as anesthesiology when it would be more appropriate for them to designate interventional pain management, commenters should work with their respective specialty organizations to ensure physicians appropriately designate the correct specialty. If the specialty of a certain percentage of the physicians furnishing the pain management service is actually anesthesiology, we believe that weighting the various PE/HR for all specialties that furnish these services, as we currently do, is the appropriate methodology to establish the final PE/HR for pain management services.

Comment: One commenter recommends that only the PE/HR associated with ophthalmology be used in the establishment of RVUs for CPT code 66984, *Extracapsular cataract removal with insertion of intraocular lens prosthesis (one stage procedure), manual or mechanical technique (e.g., irrigation and aspiration or*

phacoemulsification). The commenter contends that the 14 percent of the utilization that is associated with optometry is in error as optometrist would only be involved in the post-operative care of these patients and not the surgical procedure.

Response: Although we did not make any proposals in the CY 2008 PFS proposed rule regarding this issue, we agree that, generally, optometrists will not be involved in the surgical procedure. As stated by the commenter, and supported by the utilization data, there are a significant number of services for which optometrists are involved in the post-operative care of CPT code 66984. The resource-based PE methodology appropriately adjusts for those services identified with modifier 55 (post-operative care only). Since there are PEs associated with the post-operative care of CPT code 66984, and since we adjust the utilization for those services that are identified as the post-operative care only of CPT code 66984, we believe the current methodology appropriately reflects the correct weighted specialty mix associated with this service.

Comment: One commenter recommended that the PE/HR for CPT codes 22862, *Revision including replacement of total disc arthroplasty (artificial disc) anterior approach, lumbar, single interspace*, and 22865, *Removal of total disc arthroplasty (artificial disc) anterior approach, lumbar, single interspace*, be crosswalked to orthopedic surgery as opposed to the all physician PE/HR. The commenter contended this is similar to the crosswalk change from all physicians to orthopedic surgery that was reflected in the PE methodology in the proposed rule for CPT code 22857, *Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), lumbar, single interspace*.

Response: CPT codes 22862 and 22865 were new for CY 2007 and absent specific information with respect to the specialty performing the services, we had crosswalked these codes to the all physician PE/HR. We agree with the commenter that these codes are of a similar nature to CPT code 22857. They are part of the same orthopedic family of codes and should be treated consistently when applying the PE methodology. Therefore, we will assign the orthopedic surgery PE/HR to CPT codes 22862 and 22865 as opposed to the all physician PE/HR.

Comment: Several commenters conveyed support for the Physician Practice Information Survey which is

currently being administered throughout the nation and encouraged CMS to use this practice cost information to update the current PE/HR data that is being utilized in the development of resourced-based PE RVUs.

Response: The Physician Practice Information Survey is a practice cost survey that is being conducted by the AMA with support from various specialty societies and CMS. We look forward to analyzing the results of the AMA data collection efforts for possible inclusion in the resource-based PE methodology in future rulemaking cycles.

b. RUC Recommendations for Direct PE Inputs and Other PE Input Issues

In the CY 2008 PFS proposed rule (72 FR 38133), we proposed the following concerning direct PE inputs.

(i) RUC Recommendations

In 2004, the AMA's Relative Value Update Committee (RUC) established a new committee, the Practice Expense Review Committee (PERC), to assist the RUC in recommending direct PE inputs (clinical staff, supplies, and equipment) for new and existing CPT codes, a process that was previously accomplished by the Practice Expense Advisory Committee (PEAC).

The PERC reviewed the PE inputs for nearly 300 existing codes at its meetings held in February 2007 and April 2007. (A list of these reviewed codes can be found in Addendum C of the CY 2008 PFS proposed rule.)

In the CY 2007 PFS final rule with comment period, we addressed several issues concerning direct PE inputs and encouraged specialty societies to pursue further review of these inputs through the RUC/PERC process. The following discussions summarize the PERC recommendations regarding these issues:

Cardiac Catheterization Procedures

As discussed in the CY 2008 PFS proposed rule, the PERC considered recommendations for new or updated PE inputs for the family of CPT codes 93501 through 93556 for cardiac catheterization. The American College of Cardiology (ACC), in cooperation with the Society of Cardiac Angiography and Interventions (SCA&I) and the Cardiovascular Outpatient Center Alliance (COCA), developed PE inputs for the nonfacility setting for 13 of the 28 CPT codes in this family.

We proposed to accept the PERC recommendations for the direct PE inputs for the nonfacility setting for the CPT codes 93501, 93505, 93508, 93510,

93526, 93539, 93540, 93542, 93543, 93544, 93545, 93555, and 93556.

In addition, we proposed that the PE for the following CPT codes will not be valued or applicable to the nonfacility setting: 93503, 93511, 93514, 93524, 93527, 93528, 93529, 93530, 93531, 93532, 93533, 93561, 93562, 93571, and 93572.

Comment: We received comments from the ACC and the SCA&I thanking us for our consideration of the PERC recommendations for 13 CPT codes for cardiac catheterization procedures performed in the nonfacility setting and for accepting their request not to establish nonfacility PE RVUs for the remaining 15 procedures in the cardiac catheterization family.

Response: We appreciate the commenters' support and have accepted the PERC recommendations for the 13 cardiac catheterization procedures and have changed our PE database to reflect the PE inputs. For the 15 remaining codes, we will finalize the proposal and attach the "NA" indicator to them.

Comment: We received comments from COCA, a national organization representing nonfacility medical cardiology practices that conducted a "Direct Cost Study" purporting to demonstrate that the major problem with the 2006 RUC estimates of direct PE costs for nonfacility outpatient cardiac catheterization was an inadequate list of direct patient care activities. In addition, COCA contends that the total RUC estimates of clinical labor time were so low as to lack credibility. The commenter contends that a significant amount of the data from its Direct Cost Study were not incorporated into the PE recommendations that were jointly prepared and presented at the April 2007 RUC meeting with ACC and SCA&I for the cardiac catheterization procedures. In addition to the inadequate clinical labor inputs, the commenter believes that the RUC process does not allow for the inclusion of safety devices, such as crash carts, as direct PE inputs because these are not used in the typical case; rather, these are considered indirect PE. COCA has requested that we review the data from the Direct Cost Study and revise the current proposed PE RVUs for these procedures to values that reflect more appropriately the direct and indirect costs of providing these services. As an alternative solution, COCA asks that we tie reimbursement for these services to a reasonable percentage of the hospital APC.

We also heard from many cardiology practices that provide cardiac catheterizations in the nonfacility

setting. They had similar comments and indicated their support for COCA's request that we review the cost study data and revise the PE RVUs to more appropriately value the cardiac catheterization procedures when performed in the nonfacility setting.

Response: While we understand COCA's and the other commenters' concerns about the decrease in the PE RVUs for the cardiac catheterization procedures, we want to clarify that the PE inputs for these procedures were fully considered by the RUC process. The RUC has identified standard descriptions of clinical staff activities that the specialty societies follow as they prepare their recommendations for direct PE inputs believed to be typical to a service and the RUC has established standard values for some of these clinical activities. The RUC does not deviate from accepted standard unless the specialty society presents compelling evidence to substantiate that the variance is typical to the practice for each procedure. In the past, the RUC has recommended, and we agreed, that the crash cart would be included as equipment necessary to perform the services of cardiopulmonary resuscitation, CPT 92950, but is not necessary to perform other services, even though many physicians have purchased and maintain crash carts as part of their medical practices. Since the crash cart is only specified as required for use in CPT 92950, it is considered as indirect PE for all other procedures. We note that COCA's request in the alternative to make payment for these procedures based on a percentage of the OPPI APC is not feasible. The PFS and the OPPI APC payment amounts are determined by different payment methodologies that are specified in the statute. We rely on the RUC process to assist us in establishing the typical PE inputs that are necessary to provide physician services. This is because the specialty-developed PE recommendations that are presented to the RUC are all subject to the same multi-specialty scrutiny. We agree with the PERC's direct PE recommendations for the 13 cardiac catheterization codes in the nonfacility setting and we will accept the RUC PE recommendations for these 13 procedures. However, we are sympathetic to the concerns raised by COCA and echoed by other commenters about the extent to which the data from the Direct Cost Study were considered in the RUC process and we ask that the RUC provide another opportunity for the review of the direct PE inputs for these cardiac catheterization procedures to ensure that the data from the COCA

Direct Cost Study is afforded appropriate and adequate consideration.

Obstetric/Gynecologic PE

As discussed in the CY 2008 PFS proposed rule, we agreed with the PERC recommendation to add a non-sterile sheet (drape) 40 in by 60 in (supply code SB006) priced at \$0.222 to the pelvic exam pack resulting in the new price of \$1.172. This change affected 236 CPT codes for obstetric/gynecologic services containing the pelvic exam pack. We also proposed to accept the PERC recommendations to standardize the equipment used in post-operative visits to include both a power table and fiberoptic light in the PE database for 70 obstetric/gynecologic codes.

Comment: We received a comment from the society representing gynecologic oncologists commending us for making the above changes to the pelvic exam pack and for standardizing the equipment used in follow-up visits. The society believes these changes enable gynecologic oncologists to account for the additional costs incurred in their practice specialty.

Response: We appreciate the specialty society's comments and we will adopt the PERC recommended inputs as proposed.

Dual Energy X-Ray Absorptiometry (DEXA)

The PERC recommended revisions to the direct PE inputs for CPT codes 77080, 77081, and 77082 to comply with established PERC standards, and more appropriately reflect the resources used to furnish these services. We agreed with these PERC recommendations.

Comment: We received several comments thanking us for accepting the RUC's PE recommendations for the DEXA codes. We also received comments from several device manufacturers and specialty societies representing gynecologists, endocrinologists, rheumatologists, and radiologists informing us that the PE recommendations passed by the RUC, which we had proposed to accept in the proposed rule, contained a mistake as to the correct DEXA equipment that is typically used to perform the procedure represented by CPT code 77080. The RUC's PE recommendations listed the DEXA equipment as that using a "pencil beam" technology, priced at \$41,000. However, the correct DEXA equipment used for CPT 77080 uses the "fan-beam" technology and is priced at \$85,000.

Response: We were sympathetic to the concerns expressed by the commenters about the listing of the incorrect DEXA equipment, and we worked with the

RUC staff to arrange for this equipment error to be reconsidered by the RUC at its September 2007 meeting. The RUC agreed to the specialty society's recommended change in the DXA equipment for CPT 77080. We agree with the recommendations from the specialty societies and the RUC and we have corrected our PE database to reflect that the fan-beam DEXA equipment is typically used for CPT 77080. In addition, a price of \$3,000, with documentation, was presented for the spinal phantom used in this procedure. We have also accepted this price and have changed the PE database accordingly.

Comment: We received many comments expressing concerns about the cuts to the PE RVUs for these DEXA services. These commenters believe the cuts are a result of the new PE methodology and may result in access problems for patients because physicians will no longer be able to afford to provide these services in the office setting. One commenter asked us to identify and make available to the public the inputs used to derive the indirect PE RVUs.

Response: We are aware that the PE RVUs for these DEXA services were negatively impacted by the change in the PE methodology, as were those for many other services in which the previous PE RVUs were not based on the PE resources used to furnish the service. Because the new PE methodology now utilizes these resources, it is important to make certain that the PE direct inputs actually reflect the typical resources that are used to provide each service. The methodology for determining the indirect PE RVUs, including a description of each step in the calculation, is detailed earlier in this section. We share the commenters' concerns about beneficiary access to DEXA services and will continue to monitor this issue.

Computer-Aided Detection (CAD) Codes

The specialty society for radiological services reviewed the direct inputs for CPT codes 77051 and 77052 and recommended that no changes to the PE inputs were needed. The PERC concurred with this decision and we are in agreement.

Comment: We received a comment from the society representing radiologists conveying their appreciation for accepting the unchanged direct PE inputs for CAD services.

Response: We appreciate the commenter's support and will maintain the PE inputs as proposed.

Nuclear Medicine Services

The specialty society representing nuclear medicine and the PERC recommended that the direct PE inputs for 2 CPT codes contained CPEP inputs and needed to be updated to agree with 2004 PEAC-approved inputs. However, in reviewing the PE database, we discovered that there were 4 other related codes which also had CPEP inputs which should be updated. We made the appropriate adjustments to substitute the PEAC inputs for the CPEP for CPT codes 78600, 78607, 78206, 78647, 78803 and 78807.

The specialty society also noted that for 7 CPT codes, revision of x-ray related supplies was required, including the number of x-ray films, developer solution, and film jackets. The PERC forwarded these recommendations and we made the appropriate changes to the PE database for the following CPT codes: 78600, 78601, 78605, 78606, 78607, 78610 and 78615.

Comment: The specialty society representing nuclear medicine expressed appreciation for acceptance of their recommended inputs and indicated it will continue to monitor the nuclear medicine codes and provide inputs and refinements as necessary and appropriate.

Response: We appreciate the specialty society's comments and we will adopt the PERC recommended inputs as proposed.

Transcatheter Placement of Stent(s)

At the request of the specialty societies representing radiology and interventional radiology, the PERC considered and approved direct PE inputs for the nonfacility setting for 3 CPT codes, 37205, 37206, and 75960, for transcatheter placement of stent(s). Among the supplies, a "vascular stent deployment system", valued at \$1,645, was noted by the society as the typical stent used for CPT codes 37205 and 37206 requiring 2 such stents for the placement in the initial vessel and 1 stent for each subsequent vessel, respectively. We reviewed a published clinical research study that was forwarded by the specialty society. The study indicated that 1 stent was typical for the procedure of CPT code 37205. As discussed in the CY 2008 PFS proposed rule (72 FR 38134), absent any further verification from the specialty, we included only 1 stent in the PE database for this code.

Comment: Commenters, representing specialty societies for radiology, interventional radiology and vascular surgery appreciated the proposal assigning direct PE inputs for the

nonfacility setting for these three CPT codes. However, these commenters expressed concern that the number of stents had been reduced. One commenter agreed that two stents may not be typical but requested guidance on how the cost of the additional stent could be billed; another of the commenters asked that we reconsider this decision or at a minimum include the "average" of 1.5 stents. One of the commenters also noted that several studies clearly establish that these peripheral stent services are safely performed in the nonfacility environment, with nearly all of the procedures in the studies resulting in short observation stays, typically of less than 4 hours.

Response: Based on a review of the literature and other information provided by the commenters we will revise the PE database for CPT code 37205 to reflect 1.5 stents.

Comment: Two commenters, representing manufacturers, expressly urged us to consider the safety issues surrounding the proposal to value these procedures in the nonfacility setting and believe that this conflicts with the decision to exclude these procedures from the ambulatory surgical center (ASC) list. One of these commenters acknowledged that, while we have no specific policy to identify which procedures can be safely performed in a physician's office, we do have some safety standards for ASCs. The commenter requested that the ASC standards be extended to the physician office. This commenter also referenced studies that demonstrate complications can be associated with these procedures, and suggested that these risks need to be addressed by appropriate safety or quality standards.

Response: We appreciate the commenters' viewpoint. However, as the commenters acknowledged, we have no established policy to designate procedures that can be "safely" performed in the physician office setting. The purpose of the PFS is to establish proper payment for procedures furnished by physicians and other health professionals. Several medical specialty societies recommended the valuation of these services in the nonfacility setting, which suggests to us that these procedures are being furnished in nonfacility settings on a regular basis. These societies provided the recommended PE inputs involved in furnishing the typical service in a nonfacility setting, and these inputs were reviewed, accepted and recommended by the RUC. We also note that, as indicated in the previous comment, one commenter provided

literature from studies to support that these services are safely performed in the nonfacility environment. Because it appears these procedures are being furnished regularly in nonfacility settings, we believe it is appropriate to value them for payment in those settings. Therefore, we will value these procedures in the nonfacility setting as proposed.

Comment: One commenter noted that payment for CPT code 75960, the supervision and interpretation service associated with the 2 CPT codes discussed above for the transcatheter placement of stent(s), is still shown as carrier-priced in the Addendum of the proposed rule.

Response: We regret the error. The Addendum and PFS database have been corrected to reflect the appropriate RVUs.

(ii) Remote Cardiac Event Monitoring

In the CY 2007 PFS final rule with comment period, direct PE inputs for remote cardiac event monitoring (CEM) services represented by CPT codes 93012, 93225, 93226, 93231, 93232, 93270, 93271, 93733, and 93736 were revised on an interim basis to reflect the unique circumstances surrounding the provision of these services. Unlike most physicians' services, CEM services are furnished primarily by specialized IDTFs that, due to the nature of CEM services, must operate on a 24/7 basis. The specialty group representing suppliers that furnish CEM services believes that these services require additional direct PE inputs, such as telephone line charges associated with trans-telephonic transmissions and fees associated with providing Web access for storage and transmission of clinical information to the patient's physician. We continue to work with the specialty group regarding the specific direct PE inputs, as well as the components for the indirect PE allocation, based on surveys conducted by the specialty group. To clarify and further the results of our discussions with and information provided by, the specialty group, we requested comments in the CY 2008 PFS proposed rule on the appropriateness of the above-mentioned direct PE inputs. In addition, we invited comments on any additional direct inputs and components of the indirect PE allocations which would be appropriate for these services, along with supporting documentation to justify their inclusion for PE purposes.

Comment: We received comments from medical societies, provider organizations and a device manufacturer thanking us for working with these organizations to develop direct PE for

these services that do not fit the typical physician service model. Several comments supported the specific PE proposals supplied by the specialty group representing providers that furnish CEM services, and urged us to adopt them. A medical society representing cardiologists requested to work with us and the remote CEM provider groups to gather and review any additional necessary data prior to adoption of additional direct PE inputs.

The CEM provider group specifically proposed that we add telephone transmission costs to the direct PE inputs for CPT codes for CEM, 93012 and 93271 and the CPT codes for pacemaker monitoring, 93733, and 93736. The group also identified expenses for Web-based storage, maintenance and access to clinical information to be allocated to the CEM and pacemaker monitoring CPT codes, as well as the holter monitoring CPT codes 93226 and 93232. In addition to these supply PE recommendations, the CEM provider group proposed equipment time-in-use increases for the holter monitors, cardiac event monitors and for INR monitors (which are discussed later in this section).

Response: We carefully reviewed the information supplied by all of the commenters and believe that it would be valuable for the commenters to work together, including the cardiology specialty society, before we establish further direct PE inputs for these cardiac monitoring services. In addition, we would like to make the CEM providers aware that it appears the assignment we made in CY 2007 of 43,200 time-in-use minutes for the looping CEM monitor used in CPT code 93271 (typically used for a 30-day period) pays back the cost of this CEM monitor, that is valued at \$995, in less than 5 months, even though the CEM monitor has an established 4-year useful life. As we discuss later in the Prothrombin Time, International Normalized Ratio (PT/INR) section, we believe that the time-in-use assigned to any one device should not exceed its useful life. We will review this time-in-use assignment for CEM monitors during our CY 2009 rulemaking.

(iii) Prothrombin Time, International Normalized Ratio (PTI/NR)

As discussed in the CY 2008 PFS proposed rule, based on comments received and subsequent discussions with entities that furnish these PT/INR services, we adjusted the time in use for the home monitor equipment for G0249 *Provision of test materials and equipment for home INR monitoring to patient with mechanical heart valve(s)*

who meets Medicare coverage criteria; includes provision of materials for use in the home and reporting pwiof [prothrombin] test results to physician; per four tests to 1440 minutes to reflect that the monitor is dedicated for use 24 hours a day and unavailable for others receiving this service. We invited comments on this change, as well as comments on any additional direct inputs which would be appropriate to this service, along with supporting documentation to justify their inclusion for PE purposes.

Comment: We received comments from specialty societies, provider groups, and individuals expressing their appreciation of our attempt to correct the problem concerning the application of PE methodology for the PT/INR service, but noted their concern that changing the INR home monitor time-in-use minutes from 32 to 1440 does not have a rational basis nor does it provide for an adequate recoupment of the cost of the device. These commenters requested that we assign a more realistic figure to capture the 28-day period that the patient is required to use the monitor. One commenter noted that using the current 1440 minutes, it would take 11.7 years to recoup the \$2000 price of the equipment which has an assigned life of 4 years. The commenters suggested several alternative methodologies to calculate the time-in-use for the INR monitor. One method suggests multiplying the 1-day time, 1440 minutes, by 4, which represents the number of tests conducted in the 28-day period, to equal 5,760 minutes. This method would take 3 years to get back the \$2000 value of the INR monitor. Another proposal suggests multiplying the 1-day 1440 minutes by 28 days which is the actual time the patient has the equipment. This method yields 40,300 minutes and the commenter admittedly states this method greatly overestimates the value of the INR monitor because it would take just 5 months to recoup the \$2000 price. One commenter suggested that we simply amortize the price of the equipment, \$2,000, over the useful life of 4 years. Another commenter's suggestion uses the annual minutes figure of 150,000 that we use in our formula for deriving per minute equipment costs, and divides it by 28 (days) to arrive at 5,753 minutes. This method recoups the INR monitor price in 3 years.

Other commenters voiced concerns about the valuation of the INR home monitor and offered alternatives to capture the cost of the device. One commenter suggested that we treat the cost of the INR home monitor as a one-

time upfront cost and include this price in HCPCS code G0248 that is used to report the demonstration of the INR monitor to the patient, at the initial use. Another commenter recommended that the INR home monitor be removed from the PE for both G0248 and G0249 and be considered under the DME benefit.

Response: We understand the concerns expressed by the commenters and appreciate their suggested alternatives that we could use to more appropriately cover the costs of the INR home monitor. Further, we agree that the 1440 minutes we assigned for CY 2007 seems too low considering that the patient uses the INR home monitor for 28 days, not just one. After reviewing all of the suggested alternatives, we eliminated the two proposals asking us to change the mechanism of payment for the INR home monitor. We, therefore, considered the various suggestions for establishing a more appropriate time-in-use value for the INR home monitor. We believe the proposal that best reflects the policy we use to determine the time-in-use for equipment items where the actual minutes-in-use exceed the assigned useful life is the commenter's suggestion to amortize the \$2000 INR monitor over its 4-year life. Using this method, 4,315 minutes is the necessary time-in-use figure to recover the purchase price of the equipment in 4 years. We will replace the 1440 minutes assigned for CY 2007 with 4,315 minutes as the time-in-use for the INR home monitor and will change the PE database accordingly.

(iv) Positron Emission Tomography (PET) Codes Clinical Labor Time

We received comments from the specialty society representing nuclear medicine regarding a discrepancy in the clinical labor time for CPT codes 78811, 78812, and 78813 which are PET codes for tumor imaging. The specialty noted that the clinical labor time indicated in the PE database differs by 7 minutes from the time that was previously recommended by the PERC in April 2004. We agreed with the specialty society that the PE database labor inputs for these 3 PET codes are incorrect and we made the appropriate adjustments to the PE database.

Comment: The specialty society representing nuclear medicine expressed appreciation for acceptance of its recommended inputs and indicated it will continue to monitor the nuclear medicine codes and provide inputs and refinements as necessary and appropriate.

Response: We thank the specialty society for reviewing the direct inputs for their related procedures in the PE

database that we post as a download with each proposed and final rule on our Web site (www.cms.hhs.gov/PhysicianFeeSchedule/PFSFRN). We will adopt the recommended inputs as proposed.

(v) Nuclear Medicine PE Supplies

The specialty society representing nuclear medicine commented that the PE database currently contains supply items that are inappropriate for certain procedures and provided the information to make the corrections. For respiratory imaging procedures represented by CPT codes 78587, 78591, 78593, 78594, 78630, 78660, 78291, and 78195, the specialty society noted specific IV supply items to be deleted from procedures where they are not required. For a thyroid imaging procedure represented by CPT code 78020, x-ray supply items were recommended for deletion. In addition, the society recommended adding supply items for respiratory imaging procedures, including nose clips, masks, and nebulizer kits, as appropriate, to CPT codes 78584, 78585, 78591, 78593, 78594, 78586, 78587, 78588, and 78596. For a kidney function study represented by CPT code 78725, injection supply items were noted as missing and the specialty society requested that these be added. We proposed to accept these direct PE input corrections and revised our PE database accordingly.

Comment: The specialty society voiced its gratitude for the acceptance of their recommended inputs.

Response: We thank the specialty society for its interest in assuring the accuracy of the PE inputs in the procedures provided by their members. We will adopt the PERC recommended inputs as proposed.

(vi) Arthroscopic Procedure Nonfacility Inputs

In the CY 2008 PFS proposed rule (72 FR 38135), we included a discussion about the establishment of nonfacility direct PE inputs for the arthroscopic procedures represented by CPT codes 29805, 29830, 29840, 29870, and 29900. Absent specific recommendations from the RUC and because some physicians are already performing these procedures in the office setting, we specifically requested comments regarding the appropriateness of establishing nonfacility PE inputs for these arthroscopic procedures when they are provided in the office setting. We also invited comments as to the specific direct PE inputs, following the RUC approved standardized format, that are typical in the provision of each above listed arthroscopic procedure furnished

in the physician's office. We indicated we will review these comments to determine whether or not it is appropriate to propose on an interim basis PE inputs for these codes in the nonfacility setting in our final rule.

Comment: We received comments from the specialty society representing orthopedic surgeons in opposition to the establishment of nonfacility PE for the arthroscopic procedures because they believe these procedures are not safely performed in the office setting. The specialty society indicated that one of these codes, CPT 29900, *Arthroscopy, metacarpophalangeal joint, diagnostic, includes synovial biopsy*, was surveyed by the RUC in April 2001 and, at that time, the RUC recommended this service only as a facility-based procedure. The RUC supported the AAOS concerns and recommended that the PE RVUs for the nonfacility setting remain designated as "NA." The specialty society believes that if the arthroscopic procedures were valued in the nonfacility setting, untrained physicians may begin to perform them and, as a result, patients will face significant risks. The specialty society believes that only credentialed physicians should perform these procedures and that this process can only be ensured in the facility-based setting. The specialty society also asserts the facility-based setting is the safest setting for these procedures because it affords the physician more clinical options for dealing with any complications that may arise. In addition, if the procedure is furnished in the nonfacility setting, there would be no way to address any treatable lesion that is found and a patient would need to be seen in the facility setting to undergo a second procedure.

Because the specialty society's position was established by an expert panel, the society states that it will reconsider its position if evidence is presented establishing the safety and efficacy of these procedures in the office setting and if a method is established to ensure that only qualified physicians perform these procedures in the office setting.

We also received comments from orthopedic practices and individual physicians—the majority of which indicated they are members of the orthopedic specialty society—all stating that they are currently performing these procedures in the nonfacility setting. These comments requested that we establish PE inputs for the arthroscopic procedures because this would allow patients greater access to these services in more convenient settings and, because it would establish payment that

would more fairly compensate them for the resources they use to provide these services in the office location. A product manufacturer supported the views of the physicians who requested the establishment of nonfacility PE for the nonfacility setting.

These physicians note that the safety of the in-office procedures is well documented in the literature, and provided us with citations of articles going back to the mid-1990s. We also received suggested PE inputs including clinical labor, supplies and equipment that are typically used when these procedures are provided in the nonfacility setting.

Response: We appreciate the concern expressed by the commenters opposing the establishment of PE for the office setting and are sympathetic to those supporting the assignment of PE for these codes. We are also dismayed that the parties involved on each side of this issue have not been able to resolve these issues to date. We have decided that the most prudent course of action is to defer proposing nonfacility inputs for these arthroscopic procedures in this final rule. We are hopeful that the specialty society and its physician colleagues who provide these services in the nonfacility setting will be able to discuss the issues of mutual concern regarding the safety of performing these procedures in the office setting. We are hopeful that this issue can be resolved and that the physicians performing these services in the nonfacility setting will be given the opportunity to have a multi-specialty review by the RUC. We are aware that this decision to refer this issue back to the specialty society and the RUC postpones the establishment of nonfacility PE values for these procedures until CY 2009, at the soonest, and that a review by the RUC process is not guaranteed. However, given the apparent level of dissension within the specialty, we believe that the specialty society, its physician colleagues, and the RUC should first be given an opportunity to resolve these important issues.

(vii) Nonfacility Inputs for CPT Code 52327

As discussed in the CY 2008 PFS proposed rule we indicated that the society representing urologists requested that we remove all of the nonfacility PE inputs for CPT code 52327, *Cystourethroscopy (including ureteral catheterization); with subureteric injection of implant material*. The specialty society reasoned that the nonfacility PE value is inappropriate since the procedure is never performed in the physician office;

it is specific to the pediatric population; and, as such, is always performed with general anesthesia. We agreed with the specialty society that this procedure is incorrectly valued for the nonfacility setting and proposed to accept its recommendation to remove the nonfacility direct PE inputs, revising the PE database accordingly.

Comment: The specialty society thanked us for accepting its recommendation to remove the nonfacility PE for this procedure. However, the society indicated that a review of the PE database on our Web site indicated that these inputs were still included and suggested that they be deleted.

Response: We appreciate the commenter's attention to detail and have removed the PE inputs from the PE database.

(viii) Maxillofacial Prosthetics

We have been working with the society representing maxillofacial prosthetists since 2005 to establish nonfacility direct inputs for the prosthetic services represented by the CPT code series, 21076 through 21087. The current PE database reflects the labor, supplies, and equipment needed to perform each procedure. However, we do not have pricing information and documentation for many supply items. The society provided information and documentation for equipment prices, but because specific time-in-use information was not provided, we developed time in use in 2006 for each equipment item in each procedure. For CY 2007, these equipment inputs were utilized under the new PE methodology to calculate the nonfacility PE RVUs for these procedures. Although we have asked the specialty society to provide the supply pricing information and time in use data for each equipment item for each procedure, we have not received the requested information to date. Consequently, unless such information is provided, the PE database will continue to have no prices associated with these supplies. Therefore, in the CY 2008 PFS proposed rule, we proposed to cap the time in use for each equipment item at 25 minutes until specific information is received regarding the actual time in use. Tables listing the needed information for were included in the proposed rule.

Comment: The specialty society representing the maxillofacial prosthetists supplied us with some of the requested information. The society provided us with the time-in-use data

for every piece of equipment for each of the procedures in the CPT code series 21076 through 21087. The specialty also provided prices for the supply items used in this code series; however, it did not provide any documentation to support these prices.

Response: We appreciate the information provided by the specialty, especially that in relation to the equipment time-in-use. The recommended equipment times were compared with the total clinical labor time for each procedure and times that were greater were reduced to equal the labor time, in accordance with our usual allocation policy. Capping the equipment time-in-use to match the labor time affected 4 pieces of equipment in every procedure including: the dental chair, ceiling light, air compressor, and delivery unit. For 3 of these codes, the time-in-use for a 5th piece of equipment, the washout and curing unit, was also capped. We will accept the specialty's equipment time-in-use information, with the aforementioned variances, and have changed the PE database accordingly.

We regret that documentation for the supply prices was not forwarded. We did, however, receive a catalog documented pricing for articulating paper/ribbon that was submitted by a different specialty in reference to another CPT code, and have entered this price in the PE database for 8 of the 10 codes in this family, as appropriate. The specialty is reminded that our policy for accepting prices for supplies or equipment in the PE database requires the submission of acceptable documentation, the definition of which is specified below the table that appeared in the proposed rule listing the outstanding prices for supply items needing documentation. We will continue to work with the specialty as it collects and forwards this important information.

(ix) Requests for Increases in Supply Prices

We received a request from the specialty society for obstetrics and gynecology to increase the price of supply item (kit, hysteroscopic tubal implant for sterilization) for CPT code 58565, *Hysteroscopy, surgical; with bilateral fallopian tube cannulation to induce occlusion by placement of permanent implants* for this code which was created for CY 2005. This hysteroscopic implant kit is priced at \$980 and the specialty is now

requesting a price of \$1,245, providing an invoice for documentation. The specialty reports that the higher price is attributed to a manufacturer change in design and materials, and submitted the manufacturer's documents supporting these changes that were used to secure FDA approval. Therefore, we proposed to accept the new price of \$1,245 for the hysteroscopic implant kit due to the changes made in the modified model.

Comment: We did not receive comments on this proposal.

Response: We will finalize our proposed price of \$1,245 for the hysteroscopic implant kit and will amend our PE database, as appropriate.

(x) Supply and Equipment Items Needing Specialty Input

We have identified certain supply and equipment items for which we were unable to verify the pricing information (see Table 2: Supply Items Needing Specialty Input for Pricing and Table 3: Equipment Items Needing Specialty Input for Pricing). In our CY 2008 PFS proposed rule, we listed both supply and equipment items for which pricing documentation was needed from the medical specialty societies and, for many of these items, we received sufficient documentation containing specific descriptors and pricing information in the form of catalog listings, vendor Web pages, invoices, and manufacturer quotes. We have accepted the documented prices for many of these items and these prices are reflected in the PE RVUs in Addendum B of this final rule with comment period. For the items listed in Tables 2 and 3, we are requesting that commenters provide pricing information on items in these tables along with acceptable documentation, as noted in the footnote to each table, to support recommended prices. For supplies or equipment that have previously appeared on this list, and for which we received no or inadequate documentation, we proposed to delete these items unless we receive adequate information to support current pricing by the conclusion of the comment period for this proposed rule.

In Tables 4 and 5, we have listed new supplies and equipment from the new CPT codes for CY 2008 that are discussed elsewhere in this final rule with comment period. These items have been added to the PE database and, where priced, are reflected in the PE RVUs in Addendum B.

TABLE 2.—SUPPLY ITEMS NEEDING SPECIALTY INPUT FOR PRICING

Code	2006/7 Description	Unit	Unit price	Primary associated specialties	Associated *CPT code(s)	Prior item status on table	Commenter response and CMS action	2008 item status refer to note(s)
SC088 ..	Fistula needle, dialysis, 17g.	Item	Dermatology	36522	Yes	Documentation received. Revised description per specialty's comments. Price accepted at \$1.62.	C
	Gas, argon, cryoablation.	Urology, Radiology, Interventional Radiology.	50395	No	New Item	A, E
	Gas, helium, cryoablation.	Urology, Radiology, Interventional Radiology.	50395	No	New Item	A, E
SD140 ..	Pressure bag	item	8.925	Cardiology	93501, 93508, 93510, 93526.	Yes	Documentation received. Price accepted at \$19.00.	C
SL119 ..	Sealant spray	oz	Radiation Oncology ...	77333	Yes	No comments received.	B
SD213 ..	Tubing, sterile, non-vented (fluid administration).	item	1.99	Cardiology	93501, 93508, 93510, 93526.	Yes	Documentation received. Price accepted at \$0.949.	C
	Stent, vascular, deployment system.	Kit	\$1,645	Radiology, Interventional Radiology.	37205, 37206	Yes	Documentation received. Price retained at \$1,645.	C
	Catheter, Kumpe	Item	Radiology, Interventional Radiology.	50385, 50386	No	New item	A, E
	Disposable aspirating syringe.	Oral and Maxillofacial Surgery.	21073	No	New item	A, E
	Guidewire, angle tip (Terumo), 180 cm ¹	Radiology, Interventional Radiology.	50385, 50386	No	New item	A, E
	Snare, Nitinol (Amplatz).	Item	Radiology, Interventional Radiology.	50385, 50386	No	New item	A, E

* CPT codes and descriptions only are copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

Note: Acceptable documentation includes—Detailed description (including system components), source, and current pricing information, such as copies of catalog pages, hard copy from specific Web pages, invoices, and quotes (letter format okay) from manufacturer, vendors or distributors. Unacceptable documentation includes—phone numbers and addresses of manufacturer, vendors or distributors, Web site links without pricing information, etc.

Note A: Additional documentation required. Need detailed description (including kit contents), source, and current pricing information (including pricing per specified unit of measure in database). Accept copies of catalog pages or hard copy from specific Web pages. Phone numbers or addresses of manufacturer, vendors or distributors are not acceptable documentation.

Note B: No/Insufficient received. Retained price in database on an interim basis. Forward acceptable documentation promptly.

Note C: Submitted price accepted.

Note D: Deleted per comment or CMS.

Note E: 2007/8 price retained on an interim basis. Forward acceptable documentation promptly.

TABLE 3.—EQUIPMENT ITEMS NEEDING SPECIALTY INPUT FOR PRICING AND PROPOSED DELETIONS

Code	2006/7 Description	2007/8 Price	Primary specialties associated with item	*CPT code(s) associated with item	Prior status on table	Commenter response and CMS action	2008 Item status refer to note(s)
EQ269 ...	Ambulatory blood pressure monitor.	3000	Cardiology	93784, 93786, 93788.	Yes	Documentation provided. Price accepted is \$1525 (Did not accept \$395 warranty cost.).	C
	Camera mount—floor	2300	Dermatology	96904	Yes	Specialty to submit, asap.	A, E
	Cross slide attachment.	500	Dermatology	96904	Yes	Specialty to submit, asap.	A, E
	Dermal imaging software.	4500	Dermatology	96904	Yes	Documentation provided. Price accepted at \$4500.	C
	Dermoscopy attachments.	650	Dermatology	96904	Yes	Documentation provided. Price accepted at \$650 (average of the cost of the two items provided).	C

TABLE 3.—EQUIPMENT ITEMS NEEDING SPECIALTY INPUT FOR PRICING AND PROPOSED DELETIONS—Continued

Code	2006/7 Description	2007/8 Price	Primary specialties associated with item	*CPT code(s) associated with item	Prior status on table	Commenter response and CMS action	2008 Item status refer to note(s)
EQ008 ...	ECG signal averaging system w-P waves and late potentials software.	8,250	Cardiology, IM	93278	Yes	Documentation provided. Revised description to better describe system. Price accepted at 17,900.	A, E
	Instrument, micro-dissection.	Pathology	88380	No	New Item	A, E
	Lens, macro, 35–70mm.	Dermatology	96904	Yes	Deleted item as price is less than \$500 per documentation received.	D
	Plasma pheresis machine.	37,900	Radiology, Dermatology.	36481, G0341	Yes	Revised description based on comments received that light source was not part of item. Documentation requested.	B
ED039 ...	Psychology Testing Equipment.	Psychology	96101, 96102	Yes	Specialty to submit, asap.	B
ER070 ...	Portal imaging system (w/PC work station and software).	377,319	Radiation oncology ...	77421	Yes	Documentation provided. Price accepted at \$489,940 (average of the cost of the two items provided).	C
	Strobe, 400 watts (Studio) (2).	1500	Dermatology	96904	Yes	Documentation requested.	B
	Cryosurgery system (for tumor ablation) ¹	Urology, Radiology, Interventional Radiology.	50593	No	New item	A, E

* CPT codes and descriptions only are copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

Note: Acceptable documentation includes—Detailed description (including system components), source, and current pricing information, such as copies of catalog pages, hard copy from specific Web pages, invoices, and quotes (letter format okay) from manufacturer, vendors or distributors. Unacceptable documentation includes—phone numbers and addresses of manufacturer, vendors or distributors, Web site links without pricing information, etc.

Note A: Additional documentation required. Need detailed description (including kit contents), source, and current pricing information (including pricing per specified unit of measure in database). Accept copies of catalog pages or hard copy from specific Web pages. Phone numbers or addresses of manufacturer, vendors or distributors are not acceptable documentation.

Note B: No/Insufficient received. Retained price in database on an interim basis. Forward acceptable documentation promptly.

Note C: Submitted price accepted.

Note D: Deleted per comment or CMS.

Note E: 2007/8 price, where specified, retained on an interim basis. Forward acceptable documentation promptly.

TABLE 4.—PRACTICE EXPENSE SUPPLY ITEM ADDITIONS FOR CY 2008

Equip code	Supply description	Unit	Unit price	*CPT code(s) associated with item	Supply category
NA	Blade, sharp pointed surgical	item	0.73	88381	Cutters, closures.
NA	Buffer, lysis	ml	0.46	88381	Lab.
NA	Caps, Capsure Macro LCM	ml	4.54	88380	Lab.
NA	Catheter, balloon, lacrimal	item	306	68816	Accessory.
NA	Catheter, Kumpe ¹	item	50385, 50386	Accessory.
NA	Disposable aspirating syringe ¹	21073
NA	Ethanol, 95%	ml	0.0033	88380, 88381	Lab.
NA	Fee, image analysis	item	18	99174	Office supply.
NA	Gas, argon, cryoablation	50593	Accessory.
NA	Gas, helium, cryoablation	50593	Accessory.
NA	Gastrostomy. Low profile replacement button (Mic-Key)	item	5	43760	Accessory.
NA	Gastrostomy. Stoma measuring device (Mic-Key)	item	10	43760	Accessory.
NA	Glycerol, 3%	ml	0.001	88380, 88381	Lab.
NA	Guidewire, angle tip (Terumo), 180 cm ¹	item	50385, 50386	Accessory.
NA	IV infusion set, Sof-set (Minimed)	item	11.50	90769, 90771	Hypodermic, IV.
NA	Methylene blue stain	ml	0.178	88380	Lab.
NA	Probe, cryoablation, renal	item	1175	50593	Accessory.
NA	Rnase-free water	ml	0.85	88381	Lab.
NA	Slide, microscope, sterile	item	1	88380, 88381	Lab.
NA	Snare, Nitinol (Amplatz) ¹	item	50385, 50386	Accessory.
NA	Swab, patient prep, 1.5 ml (chloraprep)	item	1.04	36592	Pharmacy, NonRx.

TABLE 4.—PRACTICE EXPENSE SUPPLY ITEM ADDITIONS FOR CY 2008—Continued

Equip code	Supply description	Unit	Unit price	*CPT code(s) associated with item	Supply category
NA	Tube, jejunostomy	item	195	49441, 49446, 49451 and 49452.	Accessory.

* CPT codes and descriptions only are copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
 1 Price verification needed. Item(s) added to table of supplies requiring specialty input.

TABLE 5.—PRACTICE EXPENSE EQUIPMENT ITEM ADDITIONS FOR CY 2008

Equip code	Equipment description	Life	Unit price	*CPT code(s) associated with item	Equipment category
NA	Cryosurgery system (for tumor ablation) ¹	10	50593	Other Equipment.
NA	Cardiac coil, 1.5T 8-channel (MR)	5	35400	7557, 7558 and 75559.	Imaging Equipment.
NA	Instrument, Microdissection	7	88381	Laboratory.
NA	Pressure sensor, wireless (for implanted AAA sac sensor)	5	25000	93982	Documentation.
NA	Camera, ocular photoscreening, w-laptop and software	5	7000	99174	Documentation.

* CPT codes and descriptions only are copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
 1 Price verification needed. Item(s) added to table of equipment requiring specialty input.

(xi) Additional PE Issues Raised By Commenters

Comment: One commenter recommends that the direct inputs associated with all fee schedule services be made available to the public.

Response: Since the inception of resource based PEs, all direct input data has been made available to the public on the CMS Web page. The direct inputs associated with this final rule with comment period are also available to the public at the following Web site under CMS-1385-IFC: <http://www.cms.hhs.gov/PhysicianFeeSched/PFSFRN/list.asp#TopOfPage>.

Comment: Several commenters recommend that we reprice supply items over \$200 in the PE direct input database annually. Additionally, commenters also requested that we establish individual J codes for these high cost supplies. Alternatively, several other commenters expressed concerns over this recommendation stating that utilization guidelines must be set up that would trigger repricing or an undue burden would be placed upon those specialties using these high cost supplies.

Response: Using an individual HCPCS code for each of these supplies would be difficult as there are multiple manufacturers, with multiple prices, associated with the majority of these codes. Having multiple manufacturers, and thus multiple prices, also makes it difficult to reprice these supplies within the PE methodology, which is why we continue to work with the AMA RUC to establish direct cost input data. Additionally, all direct inputs need to be budget neutralized within the PE methodology. Removing these high cost

supplies from the standard PE methodology would unfairly advantage procedures that contain these supplies as they would not be subject to the same budget neutrality adjustments as would other supplies. Finally, we agree with those commenters that state that any annual repricing of these supplies would place undue burden on specific physician groups. For these reasons, we will continue to price these high cost supplies within the standard PE methodology.

Comment: A few comments were received that recommended that desktop computers be included as a direct PE cost.

Response: The direct PE database includes desktop computers with monitor when this computer is identified as being dedicated to a specific procedure. The costs associated with computers that are used for non-clinical purposes assigned to a specific procedure, for example, used for administrative procedures, are more appropriately captured in the indirect cost category.

Comment: One commenter representing home care physicians requested that travel time and other inherent costs related to mobile medical services such as vehicle operation and mobile communication should be accounted for in the PE calculation.

Response: To the extent that travel time is necessary to furnish physician services outside of the office setting, these expenses are not considered direct costs under the PE methodology. Although the mobile communication devices are not specifically included as direct PE inputs, 12 minutes of clinical labor time is assigned for each of the home visit E/M services, 6 minutes in

the pre-time period and 6 minutes in the post time period. Phone calls are standardized at 3 minutes each for purposes of the direct PE inputs and would be included as part of this clinical labor time.

Comment: One commenter stated that adjustments need to be made to the PE database for certain dialysis codes and requested that for G0393 and G0392 an angioplasty balloon be added to the PE database and that for CPT code 36870 the PE database should be revised to include an angiographic room and a power table.

Response: The balloon catheters are reflected in the PE database, as supply number SD152, and the angiographic room and an exam table are included in the equipment for CPT code 36870.

Comment: Commenters expressed concern about the level of reimbursement for intrathecal pump management services for chronic pain patients and believe that the refill kit is not accounted for in the PE. In addition, commenters expressed concern that reimbursement did not cover the leasing costs for the equipment.

Response: We reviewed the PE database and have verified that a refill kit, priced at \$28, is included as a supply in CPT codes 95990 and 95991. In our PE database, equipment costs are assigned based on the purchase price for each piece of equipment, regardless of whether the equipment is owned, rented or leased.

Comment: A manufacturer expressed concern that the PE RVUs for intranasal administration of vaccines (CPT codes 90467/8 and 90473/4) are inappropriately low and should be equalized to the injectable immunization administration PE RVUs.

The commenter stated that when the codes were reevaluated in 2004 there was not enough experience in the office to fully understand the time associated with providing an intranasal vaccine. The commenter stated that specialty organizations have indicated that this issue is worth reexamining and indicated that they had been encouraged to communicate with the RUC in support of equalizing payment for the codes.

Response: We appreciate the commenter's concerns about the disparity in the PE RVUs for the intranasal and injectable immunization administration procedures. To the extent that these concerns relate to the direct PE inputs, we would encourage the commenter to work with the specialty organizations to determine if it is appropriate to bring these codes forward for further RUC review.

Comment: One commenter requested that we publish the RUC approved RVUs for all noncovered and carrier priced services, particularly for the positron emission tomography (PET) and PET/CT procedures.

Response: We have made it our policy to publish work and PE RVUs for services in instances where the information has been forwarded to us, with a few exceptions. One exception to this policy is for carrier priced codes. Our rationale for this policy is simply that any published values for carrier-priced codes would be in direct contradiction of our intentions with respect to this designation. As we state in Addendum A, a "C" status indicator means that carriers price this code establishing RVUs and payment amounts without direct guidance from CMS. Because the commenter did not provide us with information about specific noncovered services that do not have published RVUs, we are not able to address this particular aspect of the comment.

Comment: Commenters representing radiation oncologists expressed concern about the significant PE reductions in CPT code 77336 for continuing medical physics consults. The commenters noted this code was last reviewed by the PEAC in 2002 and the practice standard has changed significantly. Commenters recommended that the direct PE inputs for this code be reviewed and refined so that accurate PE data is reflected for this code.

Response: While we appreciate that the commenters expressed their concerns to us regarding a change in the practice standards for the services of CPT code 77336 which they believe results in the need to change the direct PE inputs, we believe that the

appropriate course of action for the commenters is to work together with the RUC affiliated specialty society in order to determine if these concerns can be appropriately addressed by the RUC.

Comment: We received comments from individuals and associations with concerns about the new bottom-up PE methodology and the resulting effect of decreases in the PE RVUs for various services including, but not limited to the following: chemotherapy administration, endovenous ablation procedures, brachytherapy treatments, 3-D imaging services, and procedures for photopheresis and plasma pheresis.

Response: As we noted earlier in this section, we are aware that the PE RVUs for some services were negatively impacted by the change in our PE methodology. However, we will reiterate here that it is our policy to make certain, to the maximum extent possible, that the direct PE inputs used in the PE RVU calculation actually reflect the typical resources used to provide each service. To the extent that the current PE RVUs are lower than those determined under our previous methodology, the difference is likely attributable to a previous PE RVU that was based on charges that overvalued the service. Because the current methodology uses the direct PE inputs that are inherent and typical to each procedure, the resulting PE RVUs more accurately reflect the resources that are used to provide the service.

Comment: One commenter explained that, in the CY 2004 PFS final rule, we decided to set the values for the monthly ESRD-related services for home dialysis patients (for example, G0323) at the same rate as the monthly ESRD related services with 2 or 3 visits per month (for example, HCPCS code G0318) to provide an incentive for the increase use of home dialysis (as authorized under 1881(b)(3)(B) of the Act). The commenter notes that the current payment rate for ESRD related services, with 2 or 3 face-to-face visits per month is higher than ESRD related services for home dialysis patients, (due to a difference in PE). As such, the commenter is concerned that the differential in payment rates mitigates the incentives that we previously attempted to establish. The commenter suggested that incentives for using home dialysis should be strengthened by using a consistent PE value for MCP codes G0323 and G0318. However, the commenter prefers that we establish a new payment rate for the monthly management of home dialysis patients based on the weighted average of the MCP for patients who dialyze in a

dialysis center or other outpatient facility.

Response: We appreciate the suggestions regarding our payment policy for the monthly management of home dialysis patients. We intend to consider the commenters suggestions as we continue to evaluate payment rates for the monthly management of patients on home dialysis.

Note: We received comments regarding certain items and services that are not germane to the PE RVUs or other components of the PFS. These issues include comments regarding: revisions to the definition of pre-service work and time for certain global services; inadequate pricing of HCPCS code A4562 for pessaries, requests for payment adjustments for certain services under PFS to approximate payment amounts for these services established under OPPS and ASCs, inadequate payment for pharmacy costs and nursing services for drug administration codes, and concerns about the reduction of PE RVUs in the nonfacility setting due to the changes in the PE methodology along with requests to freeze payment amounts at the level of the CY 2006 transitional PE RVUs. Because these comments are outside the scope of the issues raised in the CY 2008 PFS proposed rule, we will not respond to these issues in this final rule with comment period.

B. Geographic Practice Cost Indices (GPCIs)

We are required by section 1848(e)(1)(A) and (C) of the Act to develop separate Geographic Practice Cost Indices (GPCIs) to measure resource cost differences among localities; and to review and, if necessary, adjust the GPCIs at least every 3 years. In the CY 2008 PFS proposed rule, we published the proposed GPCIs for CY 2008 in Addendum E, noting that the proposed GPCIs do not reflect the 1,000 floor that was in place during CY 2006 and CY 2007. This floor expires as of January 1, 2008 in accordance with section 102 of the MIEA-TRHCA.

In developing a GPCI, section 1848(e)(1)(A)(i) and (ii) of the Act require that the PE and malpractice (MP) GPCIs reflect the full relative cost difference while section 1848(e)(1)(A)(iii) of the Act requires that the physician work GPCIs reflect only one quarter of the relative cost differences. Section 1848(e)(1)(C) of the Act also specifies that if more than 1 year has elapsed since the last GPCI revision, we must phase in the adjustment over 2 years, applying only one half of any adjustment in each year. All GPCIs are developed through a comparison to a national average for each component, and the RVUs for different services uniformly weight each component.

1. GPCI Update

A detailed description of the methodology used to develop and update the GPCIs can be found in the CY 2004 PFS proposed rule (68 FR 49039, August 15, 2003). There are three components of the GPCIs (physician work, PE, and MP) and each relies on its own data source.

a. Physician Work

The physician work GPCI is developed using the median hourly earnings from the 2000 Census of workers in six professional specialty occupation categories which we use as a proxy for physician wages and calculate to reflect one quarter of the relative cost differences. Physician wages are not included in the occupation categories because Medicare payments are a key determinant of physicians' earnings; therefore, including physician wages in the physician work GPCI would, in effect, make the index dependent upon Medicare payments. The physician work GPCI was updated in 2001, 2003, and 2005 using data from the 2000 Census; the proposed CY 2008 physician work GPCI is also based on the 2000 Census data. Because all updates since 2001 have relied on the 2000 Census data, the changes observed in the physician work GPCI in the update years are due to minor changes in utilization and budget neutrality factors; for CY 2008, Addendum E shows that there have been small changes in the physician work GPCI. Section 102 of the MIEA-TRHCA required application of a 1.000 floor on the work GPCI in payment localities where the work GPCI was less than 1.000. This provision expires on December 31, 2007. The CY 2008 proposed physician work GPCI reflects the removal of this floor.

b. Practice Expense

The PE GPCI is developed from three data sources:

(i) *Employee Wages*: We use 2000 Census median hourly earnings of four occupation categories. The physician work GPCI was updated in 2001, 2003, and 2005 using data from the 2000 Census.

(ii) *Office Rents*: We use residential apartment rental data produced annually by the Department of Housing and Urban Development (HUD) as a proxy for physician office rents. In 2001, 2003, and 2005, we used rents in the HUD 40th percentile. For CY 2008, we have calculated the GPCI using rents in the 50th percentile for the physician office rent proxy. We proposed to use

the 50th percentile because although HUD generally allows payment for subsidized housing up to the 40th percentile, in some areas it allows payment up to the 50th percentile. We made this change to reflect the trend toward higher rents across the country.

Fair Market Rents (FMRs) are gross rent estimates including rent and utilities. HUD calculates the FMRs annually using: (1) Decennial Census data; (2) American Housing Surveys conducted by the Census Bureau for HUD to enable HUD to develop revisions between Census years; and (3) random digit dial surveys to enable HUD to develop gross rent change factors. The American Housing Surveys cover 11 areas annually, rotating among the 44 largest metropolitan areas. The random digit dial component surveys 60 FMR areas annually.

The FMR is set as a percentile point in the distribution of rents for standard housing occupied by people who moved within the previous 15 months. The current FMR definition is the 40th percentile rent (the amount below which 40 percent of units are rented). Each year, the 50th percentile rent is also calculated by HUD and available through the HUDUSER Web site.

In 2000, HUD changed its FMR policy to increase access to housing for families receiving Section 8 rent subsidy vouchers (65 FR 58870). To do so, HUD increased FMRs from the 40th percentile to the 50th percentile in areas where subsidized families were highly concentrated in certain census tracts, given evidence that affordable housing was not well distributed. Only metropolitan areas with more than 100 census tracts are considered for possible increase to the 50th percentile rent. FMRs can be moved from 40th to 50th percentile or back from 50th to 40th percentile.

In the case of the office rent index for the PE GPCI, FMRs have been used to capture geographic differences in rental costs, in the absence of a consistent commercial rent index that covers all metropolitan and nonmetropolitan areas in the U.S. It has been used as a measure of the "average rent" in a market. However, since 2000, the FMRs have been a mixture of the 40th percentile and 50th percentile rents. FMR areas move between the two cutoffs. For example, in California, 9 counties had FMRs set at the 50th percentile in 2004. In 2007, only 2 of these 9 counties were still at the 50th percentile level for the FMR, out of 4 total counties at the 50th percentile level.

As described above in this section (and as detailed in 65 FR 58870), the criteria for setting the FMR at the 40th

or 50th percentile are based on concentrations of subsidized households. There is no reason to assume that commercial rents would follow the same patterns.

Therefore, we believe the 50th percentile, or median, rents calculated by HUD will be a more consistent, fair measure of geographic differences for the purpose of proxying for commercial rents.

Rent data produce the most significant changes because they are based on annual changes in HUD rents, and therefore, are more volatile than the wage (Census) data. While it has been suggested that we explore sources of commercial rental data for use in the GPCI, we do not believe there is a national data source better than the HUD data.

(iii) *Equipment and Supplies*: We assume that items such as medical equipment and supplies have a national market and that input prices do not vary among geographic areas. As mentioned in previous updates, some price differences may exist, but we believe these differences are more likely to be based on volume discounts rather than on geographic market differences. Equipment and supplies are factored into the GPCIs with a component index of 1.000.

c. Malpractice

The MP GPCI is calculated based on insurer rate filings of premium data for a \$1 million to \$3 million mature "claims made" policy along with premium or surcharge data for mandatory patient compensation funds (PCFs). The MP GPCI is the most volatile of the GPCIs. This GPCI was updated in 2001 and 2003 as scheduled with the physician work and PE GPCIs; but, there was an unscheduled update of the MP GPCI in 2004 (68 FR 49043) to reflect increases in MP premiums nationwide. The proposed CY 2008 MP update reflects the most recent premium data available. The physician work and PE GPCIs are being updated at the same time.

We received the following comments about our proposed GPCIs:

Comment: We received several comments expressing the concern that San Benito County in California was placed in the wrong payment locality.

Response: In 2003, the U.S. Census Bureau moved San Benito County from the Rest of State Census category and placed it in the San Jose MSA. Our data and methodology do not accommodate mid-decennial changes in Census data, and therefore, our 2008 update reflects that San Benito County remains in the Rest of California payment locality.

Comment: We received several comments about the PE GPCI for Santa Clara County, California. In the proposed rule, the PE GPCI was lower for Santa Clara than it has been in previous years and commenters were concerned about why this happened.

Response: We recognize that there was a decrease in the proposed Santa Clara County PE GPCI. We have studied this issue including examining both the source data and the methodology for obtaining the PE GPCI in case there was a mistake in the proposed values.

However, a close examination of the data showed that the GPCI is accurate and reflects a decrease in the value of HUD rentals in Santa Clara County.

Comment: One commenter suggested that a GPCI adjustment should not be applied to physician work, or that the physician work GPCI should be 1.000 for all localities.

Response: We are required to apply a GPCI adjustment to physician work in accordance with section 1848(e) of the Act. Therefore, we will continue to apply the physician work GPCI.

Comment: We received several comments suggesting that the PE GPCI is inaccurate due to our continued use of HUD rental data as a proxy for medical office space.

Response: Because Medicare is a national program, we believe it is important to use the best data that is available on a nationwide basis. We believe the HUD rental data is the most comprehensive and valid indicator of the national real estate rental market that is available. Additionally, as we stated most recently in the CY 2007 PFS final rule with comment period (71 FR 69656), we believe the HUD rental data remains the best data source to fulfill our requirements that the data be available for all areas, be updated annually, and retain consistency area-to-area and year-to-year. In the past, we have had both the GAO and the Research Triangle Institute examine available data sources for use in the PE GPCI, and both have found that available commercial data sets either have insufficient coverage nationally or are developed by suspect methodology. Therefore, we continue to believe the HUD rental data is the best nationally available data source to use as a proxy for physician office rents.

Comment: We received several comments suggesting that the GPCIs of Hawaii/Guam and Alaska need to be adjusted to accommodate the higher costs of transportation of supplies and equipment to these localities.

Response: The GPCIs are a proxy for costs associated with providing services to beneficiaries, not costs associated

with living in a particular place. However, we will consider these comments as we evaluate possible changes to our methodology.

Comment: We received comments from the Medicare Payment Advisory Commission (MedPAC) suggesting an alternative method for calculating the PE GPCI. This alternative PE GPCI method excludes cost measures for equipment and supplies.

Response: We appreciate MedPAC suggesting an alternative method. We intend to evaluate the suggested change to the PE GPCI methodology and will propose any changes in future rulemaking.

We will finalize the GPCIs shown in Addendum E. The GPCI values shown represent the first year of the two-year GPCI update transition and have been budget neutralized to ensure that nationwide total RVUs are not impacted by changes in locality GPCIs.

Specifically, this is done by applying a weight that is derived from the difference between payments using the "old" GPCIs and the "new" GPCIs to the proposed GPCIs that insures that total payments would not be different. As we indicated above in this section, there is no 1.000 floor on the physician work GPCI in 2008. The GAFs are shown in Addendum D.

2. Payment Localities

a. Background

The Medicare statute requires that PFS payments be adjusted for certain differences in the relative costs among areas. The statute requires an adjustment which reflects differences among areas for the relative costs of the mix of goods and services comprising PEs (other than Malpractice expenses) compared to the national average. The statute also requires adjustment for the relative costs of MP expenses among areas compared to the national average. Finally, the statute requires adjustment for one quarter of the difference between the relative value of physicians' work effort among areas and the national average of such work effort.

The physician work component represents 52.466 percent of the national average fee schedule payment amount. Thus, the statutory requirement for geographic adjustment of only one-quarter of the differences in the physician work component means that, on average, only 13.117 percentage points of physician work are geographically-adjusted, and, on average 39.349 percentage points of the physician work component are not adjusted and represent a national fee schedule amount.

In addition, the PE component represents 43.669 percent of the national average fee schedule payment amount. PEs are comprised of nonphysician employee compensation, office expenses (including rent), medical equipment, drugs and supplies, and other expenses. As explained above in this section, we do not make a geographic adjustment relating to medical equipment, drugs, and supplies because there is a national market for these items. Thus, only the categories of nonphysician employee compensation and rents are geographically adjusted. These categories represent, on average, 30.862 percentage points of the total PE, and 12.807 percentage points of PEs are not geographically-adjusted.

In total, more than half (52.156 percent) of the average PFS amount is a national payment that is the same in all areas of the country; that is, 52.156 percent of the average fee is not geographically-adjusted.

There are two additional points about the geographic indices that are important to note. First, as described above in this section, the data used to measure cost differences among localities are proxies for physician work, employee compensation and office rents. That is, wage data for various categories of employees are used to proxy the actual wages of physician employees. Second, the data used for such proxies are based on actual Census data only for a limited number of counties. The geographic adjustment factors (GAFs) for more than 90 percent of counties are developed using proxies based on larger geographic areas (for example, data for all rural areas in a State are combined and used to proxy the values for each rural county in a State). This aggregation is necessary for areas where country level data are not available. Thus, the underlying data are proxies for actual costs, and the resulting GPCIs do not measure perfectly the cost differences among localities.

Currently, there are 89 Medicare physician payment localities to which GPCIs are applied. The payment locality structure under the PFS was established in 1996 and took effect January 1, 1997. The development of this structure is described in detail in both the CY 1997 PFS proposed (61 FR 34615) and final rules (61 FR 59494).

b. Revision of Payment Localities

Over time, changing demographics and local economic conditions may lead to increased variations in practice costs within payment locality boundaries. We are concerned about the potential impact of these variations and have

been studying this issue and potential alternatives for a number of years. However, because changes to the GPCIs must be applied in a budget neutral manner (and under the current locality system, budget neutrality results in aggregate payments within each State remaining the same), there are significant redistributive effects to any change. Therefore, we are also concerned about the potential impact of locality revisions.

For the past several years, we have been involved in discussions with California physicians and their representatives about recent shifts in relative demographics and economic conditions among a number of counties within the current California payment locality structure.

The California Medical Association (CMA) suggested that we use our demonstration authority to adopt an alternative locality configuration and avoid certain redistributive effects, but such an approach was not feasible (as discussed in the CY 2005 PFS final rule with comment period (70 FR 70151)). In the CY 2006 PFS proposed rule (70 FR 45784), we proposed to remove two counties from the "Rest of California" payment locality and create a new payment locality for each county. These two counties were the ones with the largest difference between the county and locality GAFs. However, there was much more opposition than support for this proposal, in large part because of its negative effect on payments for the counties that would have remained in the "Rest of California" locality. For example, the CMA commented on this proposal stating, "a nationwide legislative solution that would provide additional funding * * * is the only solution we are supporting at this time." We did not finalize the proposal and described our reasons in the CY 2006 PFS final rule with comment period (70 FR 70151).

As indicated previously, we recognize that changing demographics and local economic conditions may lead to increased variations in practice costs within payment locality boundaries. We are concerned about the potential impact of these variations.

In considering potential changes in payment localities, we believe it is important to evaluate both the potential impact of intralocality practice cost variations and the redistributive impacts that would result from any revisions to the localities. We also indicated that we are concerned about the considerable administrative issues in making locality changes, particularly if such changes involve a transition, and if they occur when new GPCI data are being phased-

in. As we noted in the response to the June 2007 General Accountability Office report on localities (GAO-07-466), changing localities requires reprogramming systems and extensive provider education, both of which are expensive and burdensome administrative activities that can last for a significant period of time. We receive claims for payment that cross calendar years and carriers must maintain payment files for the 2 different years.

In the proposed rule we solicited comments on three possible locality reconfigurations. We indicated that because of the importance of striking an appropriate balance between intralocality variations and redistributive impacts with any such locality revisions, we wanted to be cautious and evaluate the impacts in California before considering applying the policy more broadly in the future.

The three options from the proposed rule are described as follows:

Option 1: Using the existing locality structure, apply a rule whereby if a county GAF is more than 5 percent greater than the GAF for the locality in which the county resides it would be removed from the current locality. A separate locality would be established for each county that is removed. Based on the new fully phased-in GPCI data (that is, for CY 2009), application of this approach in California would remove three counties (Santa Cruz, Monterey, and Sonoma) from the Rest of California payment locality and Marin county from the Marin/Napa/Solano payment locality and create separate payment localities for each of these four counties.

This approach focuses on counties for which there is the biggest difference between the county GAF and the locality GAF.

This proposal is similar to the policy we previously proposed in the CY 2006 PFS proposed rule (70 FR 45784) but did not adopt to address the counties with GAFs that are most different from their current locality designation. Implementation of this option would lead to an increase in payment of 7.6 percent for Santa Cruz County (and average increase of 5 percent for the other counties involved) and a decrease in payment of 4.3 percent for Napa and Solano Counties.

Option 2: This approach is similar to option 1, but the new localities would be structured differently. We would use the same 5 percent threshold methodology but instead of creating four new localities in which each county becomes its own new locality, the three counties that are removed from the Rest of California locality would become one new locality. Marin County would still

be removed from the Marin/Napa/Solano locality to become its own locality. Application of this approach would remove three counties (Santa Cruz, Sonoma, and Monterey) from the Rest of California payment locality, and Marin County from the existing Marin/Napa/Solano payment locality. This approach groups together counties from the Rest of California locality that have the greatest difference between the county and locality GAF. (This option would lead to an increase of 6 percent for the new 3-county payment locality.) These counties have similar cost structures and grouping them together into one new locality is consistent with our goal of homogeneous resource costs within a locality.

Option 3: Apply a methodology similar to that used in the 1997 locality revisions (61 FR 59495), but applied at the county level rather than the "existing locality" level. That is, we sorted the counties by descending GAFs and compared the highest county to the second highest. If the difference is less than 5 percent, the counties were included in the same locality. The third highest is then compared to the highest county GAF. This process continues until a county has a GAF difference that is more than 5 percent. When this occurs, that county becomes the highest county in a new payment locality and the process is repeated for all counties in the State. This approach would group counties within a State into localities based on similarity of GAFs even if the counties were not geographically contiguous.

This organizes payment localities based on costs, which would reduce the number of payment localities in California from 9 to 6 localities. This option alleviates the greatest variations in cost between counties in California. This proposal is unique in that the new localities are not contiguous. Currently, all localities encompass adjacent geographic areas.

The impacts associated with this option are significant. Depending on the tier, changes could reflect increases of as much as 7.6 percent or decreases of as much as 7.3 percent.

We received numerous comments on these options as discussed below:

We received similar comments from a number of individuals, State and local medical societies, and organizations, including the California Medical Association, on several significant issues and are addressing these together:

Comment: Santa Cruz County should be removed from the Rest of California payment locality due to its higher costs.

Response: We recognize that Santa Cruz County has higher costs than other

counties within the Rest of California locality, and the methodologies we presented in each of the options would result in Santa Cruz County being removed from the Rest of California payment locality.

Comment: Many commenters were concerned about the description of the methodology used for Options 1 and 2. Specifically, these comments directed us to adopt a methodology suggested by the California Medical Association. The methodology compares the highest GAF county to the weighted average (GAF) of the remaining counties of the locality.

Response: To clarify, the methodology we used identified counties where the county GAF was at least 5 percent higher than the GAF of the locality and then we either left that county as a payment locality itself or joined it with other counties into a payment locality. In Option 1, each of these counties became a separate locality; in Option 2, we combined several of these counties into a single payment locality. This approach is not the "iterative methodology" that some commenters suggested we should follow. We recognize that there are alternative methodologies that can be used to consider reconfigurations to locality structures. We will consider the suggestions of the commenters in the future.

Comment: There were concerns that combining several counties into a single payment locality in Option 2 was arbitrary and led to lower payments for these counties.

Response: As we stated in the proposed rule, there are trade-offs involved in making any changes to localities, and we recognize the importance of trying to achieve a reasonable balance among competing priorities. One of our goals was to keep the number of payment localities manageable. Although we recognize that there are effects on each of the individual counties, combining counties with very similar costs was a reasonable way to meet this goal.

Comment: Numerous commenters from California recommended that we implement Option 3 but suggested that we erred in describing the methodology used in the development of Table 9 of the proposed rule and recommended that if we implement it, we should use their suggested methodology. Commenters suggested that we really meant to insert a hierarchical approach and discussed how these are both acceptable ways to accomplish the restructuring of the counties. Other State societies expressed interest in this option as long as we use the alternative

methodology suggested by the California commenters.

Response: In Option 3 in the proposed rule, we ranked the counties by GAF from highest to lowest. We then combined into a new payment locality the county with the highest GAF and the other counties that have a GAF within 5 percent of the highest GAF county. Then, we found the county with the highest GAF among the remaining counties. We combined that county and all the counties that have a GAF within 5 percent of the new highest GAF county into a payment locality. We continued this method until all counties were included in a locality. As previously mentioned, there are multiple approaches to reconfiguring the localities that result in similar outcomes. We will further study the suggestions provided by the commenters.

Comment: We received a number of comments requesting that we provide a wide variety of data, at the county level, from numerous sources covering the years 1999 through 2006.

Response: We believe we provided commenters sufficient information to fairly evaluate our proposals. We note that many of these requests involved county level data. There is very little county level data available nationwide. Most of our data sources are collected at the MSA or Consolidated MSA, or Non-Metropolitan Area level, and our methodology was designed to be used to develop GPCIs within a payment locality analysis, not a county level analysis. We do our best to provide requestors with sources for publicly available data and to provide any other data that is requested of CMS. However, we often simply do not have data available at other than the locality level.

Comment: Several commenters are concerned that the data used to develop the latest GPCI update are out of date or inaccurate.

Response: We used the most up-to-date data available for the GPCIs used in the calculation of the proposed options. Descriptions of the data sources we use can be found in previous regulations (69 FR 66261) but we will reiterate them here. For the physician work GPCI, we use data files from the latest decennial census (currently 2000) supplied to CMS by the Census Bureau. These data are available to any individual or group interested in obtaining them from the Census Bureau. Data for the rental portion of the PE GPCI update come from HUD rental files, and these data are available online to anyone wishing to obtain them. Wage data for the PE GPCI come from the 2000 Census files which are available from the Census

Bureau. Data for the malpractice GPCI come from premium data that are filed by companies writing Professional Liability Insurance in each state. These filings are provided, upon request by our contractor, to CMS by each State Department of Insurance. Our latest update covers premium data for 2004, 2005 and 2006.

Comment: We received comments from certain physicians in Ohio requesting that we examine Ohio for a possible change in the current Statewide payment locality.

Response: We are currently examining alternatives to the current locality structure. As a part of our study we will revisit Statewide localities to determine if revisions are appropriate.

Comment: We received a number of comments from ambulance suppliers throughout the mid-West requesting that we make no changes that would have a negative impact on the GPCIs in rural areas. Other commenters expressed similar concerns about the impact of locality changes on rural physicians and beneficiaries.

Response: The vulnerability of rural areas to decreases in relative payments as a result of locality revisions is an issue that is of considerable concern to us and something we take very seriously. However, as previously noted we must find an acceptable balance between the multiple competing concerns when making changes in localities in order to best meet the needs of the entire program and this generally cannot be done without having any impact on rural areas.

Comment: MedPAC provided comments outlining two possible mechanisms for developing changes in the payment localities of the States. These methods are similar but differ in that one method begins at the locality level and the other starts with MSA level data. MedPAC also suggests that we determine whether those States that are currently single payment localities wish to remain single payment localities.

Response: As always, we value the input of MedPAC and we intend to analyze their suggested methods carefully as we discuss possible national policy changes.

Comment: Comments regarding changes in the payment localities in California were universally accompanied with a belief that we should implement these changes, without decreasing payments to any counties.

Response: We understand the desire to avoid the negative impact implementing any of these options might have on certain areas. However,

the statute requires that geographic adjustments be established based upon an index of costs that is tied to national averages. As a result, when the average increases in one locality because of the addition of a higher cost county, the average in the locality that previously contained the higher cost county will necessarily decrease. Any changes in localities will necessarily produce changes in the underlying GPCIs, and we have no authority to assign or retain GPCIs that do not represent the actual values for a locality.

Comment: Many commenters suggested that we consider a national solution to payment locality structure problems, not focus on a single state.

Response: Our proposals attempted to address locality issues in an area of the country where the incongruity of certain GAFs within localities is particularly evident. In addition, these issues have been brought to our attention regularly over the past several years, and the California Medical Association has demonstrated its desire and willingness to work with us to develop ideas for resolving them. We viewed these proposals relating only to California as a starting point and, as we indicated in the proposed rule, we would consider applying any changes to additional States in the future.

Decision: We appreciate the thoughtful comments we received in response to the three options we included in the proposed rule. As mentioned above, we recognize that changing the locality structure is a complex undertaking and there are competing concerns, including budget neutrality that results in payments in certain areas decreasing whenever payments in other areas are increased, that must be carefully balanced to achieve the most appropriate results. Historically, to help us find the best balance in a particular state, we have looked to State medical societies to work with us to provide leadership and support on preferred approaches to locality reconfiguration in that particular State.

The comments we received from California physicians, including the California Medical Association's indication that it does not support any of the options, and interested parties from other States have convinced us that this issue requires further study and analysis. Therefore, we will not be finalizing any of the three proposed options in this rule. Commenters have suggested some other methodologies that we find worthy of further exploration, including the use of Metropolitan Statistical Areas (MSAs). We do not necessarily believe that the

county is the appropriate geographic unit on which we should be focusing for locality revisions. Commenters also made strong arguments for why any locality reconfiguration should be done on a nationwide basis and not just one State at a time. Therefore, we intend to conduct a thorough analysis of approaches to reconfiguring localities and will address this issue again in future rulemaking.

C. Malpractice RVUs (TC/PC Issue)

In the CY 2008 PFS proposed rule (72 FR 38142), we included a discussion about the radiology codes for which the technical component malpractice RVUs are higher than the professional component malpractice RVUs. In the past, several organizations have requested that we examine these codes and make changes to this assignment of malpractice RVUs. We asked for information about how we could address this issue and obtain data on malpractice costs associated with these radiology codes.

We received the following comments on this issue.

Comment: The Professional Liability Insurance (PLI) workgroup of the AMA/Specialty Society RVU update committee (RUC) supported by several other organizations recommended that we reduce the PLI technical component for these codes to zero. They suggest that there are no identifiable separate costs for professional liability for technical components. They also recommend that the PLI RVUs be redistributed across all physicians' services. The RUC is concerned that the Deficit Reduction Act of 2005 (Pub. L. 109-171) (DRA) cap on the TC payment for imaging services will remove an estimated \$200 million from the Part B pool (as a result of the exemption of the reduced expenditures from the budget neutrality requirement at section 1848(c)(2)(B)(v)). The RUC believes that making the recommended changes will keep money that would be lost due to the DRA cap in the Part B pool. The RUC wants CMS to implement this change immediately and consider other changes to the PLI RVU assignment later.

Response: In the CY 2008 PFS proposed rule, we explained that these codes had not been reviewed due to a lack of suitable data on the cost of PLI for technical staff or imaging centers. The RUC believes that no such data are available because there are no identifiable separate costs. At this point in time, we are not able to evaluate whether sufficient data exists or to make a judgment on the RUC's assertion that such data are not available because

there are no identifiable costs. We will continue to explore possible sources of information about these costs. We made no proposal regarding malpractice RVU assignment and we are still considering possible changes. If we identify in the future what we believe is a more appropriate way to pay for these services, we will propose changes through notice and comment rulemaking.

Comment: Some commenters stated that the malpractice RVUs in the technical component should not be zero. These commenters suggested that we either "flip" the malpractice RVU assignment between the professional and technical components or make them equal.

Response: As we stated in the CY 2008 PFS proposed rule, we do not believe it would be appropriate to "flip" the PC and TC RVU values because the professional part of the MP RVUs has undergone a resource based review, is derived from actual data, and is consistent with the resource based methodology for PFS payments. Further, we will not simply equalize the PC and TC RVU values because at this time we have no data to demonstrate that the malpractice costs for the technical portion of these services are the same as the professional portion. We will continue to study this issue and will propose any changes in future rulemaking.

Comment: We received several comments recommending that we make the PLI RVUs resource based for all codes and that we should continue to collect and analyze appropriate malpractice premium data before making changes to the RVU assignment.

Response: We will continue to solicit, collect, and analyze appropriate data on this subject. Once we have sufficient information, we will be better able to make a determination as to what, if any, changes should be made, and we will propose any changes in future rulemaking.

D. Medicare Telehealth Services

1. Requests for Adding Services to the List of Medicare Telehealth Services

As discussed in the CY 2008 PFS proposed rule (72 FR 38143), section 1834(m)(4)(F) of the Act defines telehealth services as professional consultations, office visits, and office psychiatry services, and any additional service specified by the Secretary. In addition, the statute required us to establish a process for adding services to or deleting services from the list of telehealth services on an annual basis.

In the CY 2003 PFS final rule with comment period (67 FR 79988), we established a process for adding services to or deleting services from the list of Medicare telehealth services. This process provides the public an ongoing opportunity to submit requests for adding services. We assign any request to make additions to the list of Medicare telehealth services to one of the following categories:

- **Category #1:** Services that are similar to office and other outpatient visits, consultation, and office psychiatry services. In reviewing these requests, we look for similarities between the proposed and existing telehealth services for the roles of, and interactions among, the beneficiary, the physician (or other practitioner) at the distant site and, if necessary, the telepresenter. We also look for similarities in the telecommunications system used to deliver the proposed service, for example, the use of interactive audio and video equipment.

- **Category #2:** Services that are not similar to the current list of telehealth services. Our review of these requests includes an assessment of whether the use of a telecommunications system to deliver the service produces similar diagnostic findings or therapeutic interventions as compared with the face-to-face "hands on" delivery of the same service. Requestors should submit evidence showing that the use of a telecommunications system does not affect the diagnosis or treatment plan as compared to a face-to-face delivery of the requested service.

Since establishing the process, we have added the following to the list of Medicare telehealth services: psychiatric diagnostic interview examination; ESRD services furnished under the monthly capitation payment (MCP) with two to three visits per month and four or more visits per month (although we require at least one visit a month, in person "hands on", by a physician, Certified Nurse Specialist, NP, or PA to examine the vascular access site); and individual medical nutrition therapy.

Requests to add services to the list of Medicare telehealth services must be submitted and received no later than December 31 of each calendar year to be considered for the next rulemaking cycle. For example, requests submitted before the end of CY 2006 are considered for the CY 2008 proposed rule. For more information on submitting a request for an addition to the list of Medicare telehealth services, visit our Web site at www.cms.hhs.gov/telehealth/.

We received the following requests for additional approved services in CY 2006: (1) Subsequent hospital care (as represented by HCPCS codes 99231 through 99233); (2) neurobehavioral status exam (HCPCS code 96116); and (3) neuropsychological testing (HCPCS codes 96118 through 96120).

After reviewing the public requests, we proposed to add neurobehavioral status exam as described by HCPCS code 96116 to the list of Medicare telehealth services in the CY 2008 PFS proposed rule. We also proposed to revise § 410.78 and § 414.65 to include neurobehavioral status exam as a Medicare telehealth service. We did not propose to add subsequent hospital care or neuropsychological testing but requested comments as to how we could determine when subsequent hospital care is actually a follow-up inpatient consultation and specific information on neuropsychological testing. For further information on our proposals, see the CY 2008 PFS proposed rule (72 FR 38143).

Subsequent Hospital Care

The following is a summary of the comments we received regarding subsequent hospital care.

Comment: We received two comments regarding the conditions (or requirements) we could apply to subsequent hospital care so that subsequent hospital care reflects a follow-up inpatient consultation. One commenter suggested that follow-up inpatient consultation should be approved as a telehealth service only if the initial inpatient consultation was performed via telehealth. The commenter does not believe we should approve a follow-up inpatient consultation for telehealth if the initial inpatient consultation was furnished in-person (because it might lead to a reduction in follow-up consultations furnished face-to-face). The commenter also agreed with our proposal not to approve subsequent hospital care for telehealth. Another commenter noted that follow-up inpatient consultation was previously on the list of Medicare telehealth services and asserts that the AMA's deletion of follow-up inpatient consultation (as described by CPT codes 99261 through 99263) created the need to approve the addition of subsequent hospital care to the list of Medicare telehealth services when used for follow-up inpatient consultation care. The commenter suggested that we create a special modifier to report follow-up inpatient consultation via telehealth.

Response: We appreciate the comments on the conditions (or requirements) we could apply to

subsequent hospital care so that subsequent hospital care reflects a follow-up inpatient consultation. We intend to consider the suggestions raised by the commenters as we continue to evaluate whether subsequent hospital care should be approved for telehealth when it is used to furnish a follow-up inpatient consultation. With regard to the commenter who suggested the creation of a special modifier, we will assess whether it would be appropriate to use a modifier(s) to identify when a subsequent hospital care service is actually a follow-up inpatient consultation.

Comment: One commenter who supports approving subsequent hospital care for telehealth explained that recruiting specialists to North and South Dakota is difficult and that telehealth has helped hospital inpatients in these States to obtain access to various types of specialty care including pulmonology, endocrinology, pediatric gastroenterology, pediatric cardiology, and infectious disease specialties. The commenter also mentioned that inpatient consultations are frequently provided by infectious disease specialists for patients in the intensive care unit (ICU) and explained that once the patient has made progress and is moved from the ICU, the infectious disease specialist at the distant site continues to "follow" the patient until the patient is discharged from the hospital. The commenter recognized that access to on-going specialty care for outpatients is important but believes that obtaining access to specialty subsequent inpatient "follow-up" care is even more critical. Commenters submitted a comparative study between subsequent hospital care furnished as a telehealth service and furnished in-person.

Response: As discussed in the CY 2008 PFS proposed rule, given the potential acuity level of the patient in the hospital setting, we believe that many services furnished within the scope of the subsequent hospital service codes are not similar to the current telehealth services. As such, we indicated that subsequent hospital care is a category 2 service (which requires sufficient comparative analyses before approving it for telehealth). The commenters did submit one comparative analysis between subsequent hospital care furnished as a telehealth service and subsequent hospital care furnished in-person. However, the study submitted involved only continuing specialist care (for one specialty), not continuing inpatient care by the primary attending physician. In

addition, the sample size was extremely small. Thus, the study findings are not generalizable.

As such, we continue to have concerns about using a telecommunications system as a substitute for the on-going, day-to-day (in-person) evaluation and management of a hospital inpatient and believe further study is necessary. In the absence of sufficient, well-designed comparison studies showing that the use of a telecommunications system is an adequate substitute for the in-person delivery of subsequent hospital care, we are not adding subsequent hospital care to the list of Medicare telehealth services. As discussed above in this response, we will work with the industry organizations and groups to learn more about hospital care as a telehealth service when it is used for follow-up inpatient consultations.

Comment: One commenter (who submitted the request to approve subsequent hospital care for telehealth) stated that the original request to add subsequent hospital care to the list of Medicare telehealth services was a request to “re-establish” subsequent inpatient visits (as a Medicare telehealth service). The commenter described two scenarios in which subsequent hospital care could be furnished as a telehealth service. The first scenario would involve a specialty physician who furnishes an inpatient consultation as a telehealth service (as requested by the attending physician). The second scenario involves an attending or admitting physician who furnishes initial hospital care in-person (not as telehealth) and provides subsequent hospital care as a telehealth service. The commenter believes that access to telehealth care is better than not having access to any care and that studies have shown that telehealth care provides better clinical outcomes than no care at all. Additionally, the commenter asserts that tertiary care trauma surgeons, neurologists (for initial and follow-up stroke evaluation), psychiatrists (for initial assessment and prescriptive safety orders), infectious disease physicians, and cardiologists can be made available through telehealth when these specialties are not available on-site. The commenter believes that not approving subsequent hospital care for telehealth will severely hinder access to specialty care in the inpatient hospital setting and will lead to grave consequences for patients when no specialists are available on-site (at the hospital).

Response: We agree that telehealth services may help provide greater access to specialty care, and therefore, better

clinical outcomes where a shortage of medical professionals exist (or in situations when no care is available). As discussed in the CY 2008 PFS proposed rule, we are considering approving subsequent hospital care for telehealth when it is used for follow-up inpatient consultation. We believe that permitting follow-up inpatient consultations via telehealth will help provide greater access to specialty care in the inpatient hospital setting.

Additionally, we note that, contrary to the commenter’s assertion, subsequent inpatient hospital visits were not previously on the list of Medicare telehealth services. As mentioned by a previous commenter, the AMA deleted the codes for follow-up inpatient consultation (as described by CPT codes 99261 through 99263). Effective January 1, 2006, these CPT codes no longer exist and were removed from the PFS, and a conforming change was made to the list of Medicare telehealth services. Prior to January 1, 2006, the physician (or practitioner) at the distant site could have used these CPT codes to bill for follow-up inpatient consultations as a telehealth service. However, subsequent inpatient hospital visits were not on the list of Medicare telehealth services.

Comment: One commenter cited the concerns we raised in the proposed rule regarding the acuity level of a hospital inpatient and the use of a telecommunications system to furnish on going evaluation and management services in the inpatient hospital setting. The commenter believes that patients in the emergency department typically have a higher acuity level, are in a more precarious physical state (as compared to a hospital inpatient) and may not have a diagnosis. The commenter explains that hospitalized patients have already been seen and admitted by a physician on site and have at least a preliminary diagnosis. Despite the higher acuity level of a patient in the emergency department, the commenter asserts that we reimburse for telehealth care in the emergency department (but not for inpatients).

Additionally, the commenter discussed various scenarios involving the examination of acute stroke patients via telehealth in the emergency room and ICU. For example, the commenter provided a summary of a study that tested whether the use of an audio and video multimedia telecommunications system is a feasible and reliable means for delivering emergency stroke care (using the National Institute of Health Stroke Scale). This study concluded that “remote examination of acute stroke patients with a computer based telesupport system is feasible and

reliable when applied in the emergency room”. The commenter also explained how telehealth is being used to provide 24 hour access to acute stroke care expertise for a number of hospitals in Massachusetts and that similar programs are being established throughout the United States, Canada, the United Kingdom, Scandinavia, and other parts of the world. The commenter also provided a discussion of a study that examined the fiscal impact of providing telehealth consultation (for acutely ill and injured children in the ICU) on rural hospitals. The study found that as a result of greater access to pediatric consultations, savings are realized from a reduction in patient transfers (to larger hospitals) and increased revenue for rural hospitals.

Response: We appreciate the information the commenter has submitted on the remote evaluation of stroke patients and pediatric telehealth consultations in the emergency department or ICU. We intend to consider this information as we evaluate whether to approve subsequent hospital care for telehealth when it is used for follow up inpatient consultation. We would also mention that the nature of the comment indicates a misconception that we pay for emergency department services as a telehealth service. We note that only outpatient consultations (not visits) are approved as a Medicare telehealth service for a patient in the emergency department. If guidance or advice is needed in the emergency department (for example, for acute stroke care), an outpatient consultation may be requested from an appropriate source and may be furnished as a telehealth service. However, emergency department services (as described by CPT codes 99281 through 99285) are not on the list of Medicare telehealth services.

Comment: One commenter mentioned that we previously approved the psychiatric diagnostic interview examination and subsequent ESRD related visits furnished under the monthly capitation payment (MCP) for telehealth without comparative analyses and data showing patient satisfaction (which implies that subsequent hospital care could be approved for telehealth on the same basis). The commenter also cited the proposed regulatory impact analysis for telehealth stating that previous additions to the list of Medicare telehealth services have not resulted in a significant increase in Medicare program expenditures.

Response: In approving the psychiatric diagnostic interview examination for telehealth, we considered this service to be comparable

to an initial office visit, or consultation service, which are currently Medicare telehealth services. Likewise, we considered the outpatient dialysis visits furnished under the MCP (except for one visit to examine the vascular access site) to be comparable to office and other outpatient visits currently on the list of Medicare telehealth services. Therefore, we considered these services to be category 1, and therefore, we were able to review and approve them for telehealth without reviewing additional research studies to support their approval. However, as discussed above in this section, because of the potential acuity of a hospital inpatient, we were not able to conclude that the entire scope of services described by the subsequent hospital care codes is similar to the existing list of telehealth services (for example, an office visit, office psychology service, or consultation). Therefore, we considered subsequent hospital care to be a category 2 service (which requires sufficient comparative analyses before approving for telehealth).

For more information on the addition of the psychiatric diagnostic interview examination see the CY 2003 PFS proposed rule (67 FR 43863). For more information on the addition of ESRD-related visits furnished under the MCP, see the CY 2005 PFS proposed rule (69 FR 47511).

Neurobehavioral Status Exam

Comment: Several commenters expressed support for our proposal to add the neurobehavioral status exam to the list of Medicare telehealth services. Commenters agreed that because the neurobehavioral status exam is primarily a clinical interview (similar to the psychiatric diagnostic interview which is currently a Medicare telehealth service), it is logical and consistent to approve this service for telehealth.

Response: We agree with the commenters. As discussed in the proposed rule, the neurobehavioral status exam is furnished by a physician or psychologist and includes an initial assessment and evaluation of mental status for a psychiatric patient. In this regard, we believe the neurobehavioral status exam is similar to psychiatric diagnostic interview examination (which is currently approved as a Medicare telehealth service).

Comment: One commenter who supported our proposal to approve the neurobehavioral status exam for telehealth, stated that HCPCS code 96116 is a new code that replaced HCPCS code 96115 (the predecessor to HCPCS code 96116) in the 2006 CPT compendia. The commenter believes

that neurobehavioral status exam (as described by HCPCS code 96115) was previously on the list of Medicare telehealth services and considers our proposal to add neurobehavioral status exam (as described by CPT code 96116) to be a restoration of the neurobehavioral status exam as a telehealth service.

Response: The commenter's assertion that our proposal to add the neurobehavioral status exam to the list of Medicare telehealth services is a restoration of the neurobehavioral status exam as a telehealth service is not correct. The neurobehavioral status exam (as previously described by CPT code 96115) was not on the list of Medicare telehealth services. The proposed addition of neurobehavioral status exam is a new proposal.

Comment: One commenter stated that the neurobehavioral status exam appears to require that the service be provided face to face (in person). Therefore, the commenter requested us to clarify that face to face services may qualify as telehealth services.

Response: As discussed in the CY 2005 PFS final rule with comment period, only services that traditionally require a face-to-face (in-person) physician or practitioner encounter are candidates for the list of Medicare telehealth services. Services not requiring a face-to-face encounter with the patient that may be furnished through the use of a telecommunications system are already covered under Medicare. For more information see the CY 2005 PFS final rule (69 FR 66278).

Neuropsychological Testing

Comment: We received conflicting comments regarding neuropsychological testing. For example, one commenter agreed with the requestor that neuropsychological testing furnished via telehealth is not significantly different from being furnished in-person (especially when administered by a computer). Additionally, the commenter stated that existing telehealth services for psychiatric patients include office visits, consultation, and office psychiatry. The commenter believes that the patient-provider dynamics of these services would not appear to be so significantly different from those for neuropsychological testing as to justify not approving the services for telehealth. The commenter also believes that testing dynamics, such as the patient being blindfolded or having numbers assigned to his or her fingers, could be easily reproduced with the help of someone at the originating site.

The same commenter also provided a discussion of the importance of early detection of dementia through neuropsychological testing. The commenter included a letter from the Armed Forces Epidemiological Board about brain injury in military service members with recommendations on handling these injuries. The commenter stated that although the Epidemiological Board addressed military patients, the principles of its findings apply to civilian assessment and treatment of brain injuries; that is, appropriate testing at earlier stages of brain injury or disease is likely to elicit a more accurate patient profile, leading to more targeted interventions and better patient outcomes.

In addition, the commenter stated that the administration of neuropsychological testing may be more difficult for some patients than others; however, this is true in both the in-person and telehealth setting. The commenter believes that if the patient requires immediate in-person assistance, a telepresenter could be used to facilitate the testing and that the determination of patient suitability for testing should be up to the physician or practitioner at the distant site. Two commenters agreed that a telepresenter could assist the physician or psychologist at the distant site with the testing and that the physician or psychologist should determine which patients (and tests) are appropriate for telehealth.

Another commenter who provides neuropsychological testing via telehealth explained that many standardized neuropsychological tests are available (literally hundreds) to the physician or psychologist (or technician) and that tests vary widely in terms of administrative procedure and the level of interaction between the patient and practitioner responsible for administering the test. The commenter believes that many tests could be effectively administered via telehealth and that it is not appropriate for us to issue a "global denial" of neuropsychological testing. For example, the commenter believes that neuropsychological testing administered via a computer should be approved for telehealth and that testing administered by a physician, psychologist, or qualified technician should be re-evaluated. The commenter also explained that an RN is often used as a telepresenter to assist the neuropsychologist or technician with testing. When testing cannot be administered in a "standardized fashion" via telehealth, a qualified technician could be present on-site with the patient to assist a psychologist who

furnishes the test at the distant site. However, the commenter believes that some testing measures may not be appropriate for telehealth. The commenter estimated that "fewer than 35 percent of the hundreds of available measures do not lend themselves to standardized administration via telehealth". The commenter also cited the American Psychological Association's Ethical Principles of Psychologists and Code of Conduct and stated these guidelines would prohibit administration of certain individual tests via telehealth.

Other commenters believe that further study is necessary. The commenters urged us to seek additional information concerning the provision of neuropsychological testing before making a determination about these services for telehealth. One commenter believes that neuropsychological testing should be considered for telehealth approval stating, "however it is unclear whether the technology has advanced far enough to allow all neuropsychological testing to be provided via telehealth without compromising the quality of care". Additionally, the commenter stated that more time is needed to assess how neuropsychological testing could be provided via telehealth and listed the following issues that need further consideration:

- The variety of disorders and diagnoses appropriate via telehealth;
- The physical assistance that patients may need to complete tests; and
- The impact of face-to-face interactions with a psychologist or trained psychological technician during testing on the interpretation of test results.

Response: We appreciate the comments regarding the use of an interactive audio and video telecommunications system in furnishing neuropsychological testing services. Based on the comments received, we believe that further study is necessary before making a determination about neuropsychological testing for telehealth. As discussed above in this section, we received conflicting comments as to whether the administration of a neuropsychological test could be furnished adequately when the practitioner who is responsible for administering the test is not physically present with the patient.

For example, some commenters believe that neuropsychological testing furnished via telehealth is not significantly different than when furnished in-person and that a telepresenter could be used to assist the physician or psychologist at the distant

site if necessary. Other commenters believed that further study is necessary before approving neuropsychological testing for telehealth. One commenter believed that it is unclear whether the use of a telecommunications system for administering neuropsychological testing would compromise quality of care and listed specific issues that need greater exploration. Even a commenter who supports approving neuropsychological testing for telehealth indicated that many neuropsychological testing measures would not be appropriate for telehealth. As such, we continue to have concerns about using an interactive audio and video telecommunications system as a substitute for the face-to-face (in-person) requirements of neuropsychological testing.

Comment: Two commenters believe that sufficient empirical evidence exists to support the approval of neuropsychological testing for telehealth. The commenters submitted summaries of two comparative analyses between neuropsychological testing furnished via an interactive audio and video telecommunications system and neuropsychological testing furnished in-person.

Response: As discussed above in this section, we believe that further study is necessary before approving neuropsychological testing for telehealth. Although the commenters did submit comparative analyses, in one of the studies cited, the same psychologist furnished neuropsychological testing in both conditions (face-to-face and via telehealth). In another study cited, study participants without neuropsychological or psychiatric disturbance were tested. Additionally, the studies cited had extremely small samples. As such, we believe it would be difficult to generalize any findings to a broader population.

Comment: One commenter questioned whether the regulatory impact analysis for telehealth was intended to provide a rationale to make reductions in Medicare payment for telehealth services in the future. The commenter urged us to continue to fund a wide variety of telehealth services.

Response: The regulatory impact analysis was not intended to be used as a rationale for making reductions in Medicare payment for telehealth services. The intent of the regulatory impact analysis on telehealth was to illustrate that the proposed addition of neurobehavioral status exam to the list of Medicare telehealth services should not have a significant budgetary impact on the Medicare program. For more

information on our regulatory impact analysis for the proposed addition of neurobehavioral status exam to the list of Medicare telehealth services, see the CY 2008 PFS proposed rule (72 FR 38216).

Comment: One commenter stated that neuropsychological testing is ancillary to a neurobehavioral status exam and that neuropsychological testing would have little additional budgetary impact (beyond the impact of adding neurobehavioral status exam). To support this assertion, the commenter cited our proposed regulatory impact analysis on the addition of neurobehavioral status exam (as described by CPT code 96116).

Response: As discussed above in this section, we believe that further study is necessary before approving neuropsychological testing for telehealth.

Comment: A few commenters requested that we approve additional services for telehealth (for example, standardized performance testing as described by CPT code 96125).

Response: Requests for additions (including any supporting data analyses) should be submitted through our process for adding services and must be received by December 31 of each calendar year to be considered for the next proposed rule. For more information on how to submit a request for addition, please visit our Web site at <http://www.cms.hhs.gov/telehealth>.

Results of Evaluation of Comments

We are adding the neurobehavioral status exam as represented by HCPCS code 96116 to the list of Medicare telehealth services. Additionally, we are revising § 410.78 and § 414.65 to include neurobehavioral status exam as a Medicare telehealth service.

As discussed above, only services that traditionally require a face-to-face (in person) physician or practitioner encounter are candidates for the list of Medicare telehealth services. Services not requiring a face-to-face encounter with the patient that may be furnished through the use of a telecommunications system are already covered under Medicare. As discussed in chapter 15, section 30 of the Medicare Benefit Policy Manual, payment may be made for physicians' services delivered via a telecommunications system for services that do not require a face-to-face patient encounter. The interpretation of an x-ray, electrocardiogram, electroencephalogram and tissue samples are listed as examples of these services.

After further review of the requested services for addition, neuropsychological testing administered by a computer (as described by HCPCS code 96120) is not a candidate for the list of Medicare telehealth services. Neuropsychological testing administered by a computer (HCPCS code 96120) does not require a face-to-face (in person) encounter between the patient and the physician or psychologist (or qualified technician) responsible for the administration and interpretation of the test results (for example, the patient is interfacing with the computer, not a physician or psychologist). As such, a telecommunications system may be used to facilitate neuropsychological testing administered by a computer (as described by HCPCS code 96120); for example, Web-based computer neuropsychological testing, and/or transmission of neuropsychological test results to an interpreting physician or psychologist via telecommunications system.

E. Specific Coding Issues Related to the PFS

1. Reduction in the Technical Component (TC) for Imaging Services Under the PFS to the Outpatient Department (OPD)

Effective January 1, 2007, section 5102(b)(1) of the Deficit Reduction Act of 2005 (Pub. L. 109-171) (DRA) amended section 1848 of the Act to require that, for imaging services, if—“(i) The technical component (including the technical component portion of a global fee) of the service established for a year under the fee schedule* * * without application of the geographic adjustment factor * * *, exceeds (ii) The Medicare OPD fee schedule amount established under the prospective payment system for hospital outpatient department services* * * for such service for such year, determined without regard to geographic adjustment * * *, the Secretary shall substitute the amount described in clause (ii), adjusted by the geographic adjustment factor [under the PFS], for the fee schedule amount for such technical component for such year.”

As required by the statute, for imaging services (described in this section) furnished on or after January 1, 2007, we cap the TC of the PFS payment amount for the year (prior to geographic adjustment) by the Outpatient Prospective Payment System (OPPS) payment amount for the service (prior to geographic adjustment). We then apply the PFS geographic adjustment to the capped payment amount.

Section 5102(b)(1) of the DRA defines imaging services as “imaging and computer-assisted imaging services, including X-ray, ultrasound (including echocardiography), nuclear medicine (including PET), magnetic resonance imaging (MRI), computed tomography (CT), and fluoroscopy, but excluding diagnostic and screening mammography.”

To apply section 5102(b) of the DRA, we needed to determine the CPT and alpha-numeric HCPCS codes that fall within the scope of “imaging services” defined by the DRA provision. In the CY 2008 PFS proposed rule, we explain in detail the process we used for establishing the list of codes that fall within the scope of this DRA provision. We also stated that upon further review, we have determined that certain ophthalmologic procedures meet the DRA definition of imaging procedures, but were not included in the original list of imaging services subject to the OPPS cap. Therefore, we proposed to add the following procedures to the list of procedures subject to the OPPS cap, effective January 1, 2008:

- 92135, *Scanning computerized ophthalmic diagnostic imaging (e.g., scanning laser) with interpretation and report.*
- 92235, *Fluorescein angiography (includes multiframe imaging) with interpretation and report.*
- 92240, *Indocyanine-green angiography (includes multiframe imaging) with interpretation and report.*
- 92250, *Fundus photography with interpretation and report.*
- 92285, *External ocular photography with interpretation and report for documentation of medical progress (e.g., close-up photography, slit lamp photography, gonioscopy, stereophotography).*
- 92286, *Special anterior segment photography with interpretation and report; with specular endothelial microscopy and cell count.*

A complete list of CPT codes that identify imaging services as defined by the DRA OPPS cap provision, amended to include these ophthalmologic procedures, was also published in Addendum F of the CY 2008 PFS proposed rule (72 FR 38369 through 38372). Payment for an individual service on this list will only be capped if the PFS TC payment amount exceeds the OPPS payment amount.

Comment: Several commenters indicated that none of the six ophthalmologic CPT codes proposed for addition to the list of procedures subject to the OPPS cap meet the statutory definition of imaging under the DRA, that is, none of the procedures codes fall

under the categories of x-rays, ultrasound, MRI, PET, CT or fluoroscopy. Specifically, they noted that CPT code 92250 utilizes a wide angle camera used primarily for detecting retinopathy in diabetics. Likewise, CPT codes 92235, 92240, and 92285 are all photos, using photographic equipment, or an angioscope. The commenters concluded that the Congress did not intend for any service that uses a camera or microscope, takes photographs, and produces negatives to be included in the DRA definition of imaging services.

Another commenter indicated that CPT codes 92250 and 92285 do not meet our criterion for including a procedure under the DRA provision, that is, services that provide visual information regarding areas of the body that are not normally visible, thereby assisting in the diagnosis or treatment of injury. The commenter noted that the subject procedures take traditional pictures of parts of the eye that are normally visualized with the naked eye. One commenter noted that the six CPT codes have not experienced dramatic increases in utilization, but rather, utilization has remained stable or decreased.

Response: The DRA provision describes imaging services broadly as “imaging and computer-assisted imaging services,” and does not provide for the type of distinctions the commenters suggested. While it specifically includes certain imaging modalities (x-ray, ultrasound, MRI, PET, CT, and fluoroscopy), it does not exclude other imaging modalities. In fact, the DRA provision excludes only one imaging service, that is, diagnostic and screening mammography. Concerning CPT codes 92250 and 92285, we believe the images generated by these services may include information that requires the use of photographic or imaging equipment and is not normally visible by the unaided human eye. Finally, the description of imaging services to which the DRA provision applies is not limited to procedures that have experienced dramatic increases in utilization. We believe the six procedures meet the DRA definition of imaging services and are similar to other procedures already subject to the DRA provision. Therefore, we will include these CPT codes on the list of procedures subject to the OPPS cap. (**Note:** This list of procedures is published in Addendum F of this final rule with comment period.)

Comment: Many comments requested clarification of the application of the OPPS cap when there is no OPPS payment for comparison; where the code is bundled under OPPS; or where

the OPSS payment includes items (for example, contrast agents or radiopharmaceuticals) that are paid separately under the PFS.

Response: Where there is no OPSS payment for a procedure or where the OPSS for a procedure is bundled, there is no OPSS amount for the comparison with the PFS payment. Therefore, it is infeasible to apply an OPSS cap. The codes will remain on the list of codes subject to the OPSS cap, but will not be affected by the cap. Where the OPSS payment includes packaged services or items that are paid separately under the PFS, we can and do apply an OPSS cap. The physician can continue to bill separately for such services or items when furnished in a place of service, for example, a physician's office, where the item is paid separately.

2. Application of Multiple Procedure Reduction for Mohs Micrographic Surgery (CPT Codes 17311 Through 17315)

Under the multiple procedure payment reduction policy, reimbursement for subsequent surgical procedures performed during the same operative session by the same physician is reduced by 50 percent. The Mohs surgery codes have been exempt from the multiple procedure payment reduction rules since the inception of the PFS (56 FR 59602, November 25, 1991).

The CPT Editorial Panel reviewed all of the codes on the list of codes exempt from the multiple procedure payment reduction (the “–51 modifier exempt list”) to identify which codes should be exempt from the multiple procedure payment reduction rules. Based on the revisions to the code descriptors and a clearer understanding regarding the technical elements of the procedure, in CY 2007, the CPT Editorial Panel removed the Mohs procedure from the –51 modifier exempt list. The codes for Mohs surgery were revised to take into account the different level of physician work intensity involved based on anatomic site. The RVUs associated with the codes for each anatomic location were recommended by the RUC, as they are for other procedures, after a thorough discussion by the RUC of all aspects of the service. Work RVUs were developed for each Mohs surgery base code based on an assumption that each code is performed separately. Because the work RVUs for these services do not take into account the efficiencies that occur when multiple procedures are performed in one session, we do not believe that these codes should continue to be exempt from the multiple procedure payment

reduction. Therefore, we proposed to eliminate the modifier 51 exemption and apply the multiple procedure payment reduction rules to these codes.

Comment: We received comments supporting our proposal and expressing the belief that our proposal is fair and consistent with our multiple procedure payment policies already affecting a wide range of procedures with codes in the Surgery/Integumentary System of CPT. Many commenters opposed our proposal to eliminate the modifier –51 exemption and apply the multiple procedure payment reduction to these codes. These commenters believed that eliminating these codes from the modifier –51 exempt list would negatively impact Medicare beneficiaries’ access to timely and quality care, and could lead to increases in pathology charges and increase the amount spent on multiple facility fees, thereby raising the overall cost of treating an individual with skin cancer. In addition to these concerns, many of the commenters do not believe we have sufficient justification to make the change, and suggest that this is an arbitrary decision. Further, the commenters asserted that the AMA–RUC and CPT decisions were in error and should not be followed.

Response: We verified with the CPT Editorial Panel that the application of the modifier –51 exempt status indicator, and subsequently, the inclusion of this series of codes (CPT codes 17311 through 17315) in Appendix E, Summary of CPT Codes Exempt from Modifier –51, of the 2008 CPT codebook would not be carried forward with the new series of codes created in 2007. The CPT panel confirmed with us that the exclusion of these codes from Appendix E was not an error. The AMA RUC reviewed and valued the new and existing codes for Mohs surgery. Upon completion of a thorough review and discussion of the Mohs codes, the RUC valued these codes with the full understanding these codes were removed from the modifier –51 exempt list and would be subject to the multiple procedure payment reduction as well.

We believe the CPT Editorial Panel and the Mohs workgroup on the CPT Editorial Panel gave considerable time, effort and discussion in the creation of the new and existing codes for Mohs surgery. We also believe the AMA-RUC carefully reviewed the rationale and deliberations which lead to the creation of new Mohs surgery codes. In addition, we believe the specialty society had ample time and opportunity to express its point of view to both the CPT Panel and the AMA-RUC. As a result of the

revisions to these codes and their respective valuation, we do not believe they should continue to be treated differently from other codes in the Surgery/Integumentary System section of the CPT book and see no reason not to accept the recommendations provided by the CPT Panel and AMA-RUC. Therefore, we are finalizing our proposal to eliminate the modifier –51 exemption and apply the multiple surgery procedure payment reduction rules to these codes.

3. Payment for Intravenous Immune Globulin (IVIG) Add-On Code for Preadmission Related Services

Intravenous immune globulin (IVIG) is a unique product derived from blood plasma. This drug is paid for under the ASP methodology and the administration of this drug is reported using the first hour and second hour infusion codes for therapeutic, prophylactic and diagnostic services under CPT.

We recognize the importance of IVIG to patients who require it and are concerned about reports of problems with IVIG access and availability. We have initiated several actions in response to concerns about the supply of IVIG.

In July 2007, we implemented new codes for reporting IVIG for liquid non-lyophilized IVIG.

In CY 2006 and 2007, we established payment, through the creation of a special G-code, G0332, for preadministration services furnished in connection with the procurement of IVIG in the physician's office. This code is designed to compensate physicians for the extra resources required to be expended due to market conditions to locate and obtain the appropriate IVIG products and to schedule patient infusions.

Comment: We received several comments regarding our proposal to continue in CY 2008 the preadministration payment under the PFS for patients treated with IVIG in a physician's office.

The majority commenters supported our proposal and recommended that it be finalized, and recommended that this policy be made permanent. Commenters stated that if this code and payment are not made permanent, we would need to present a convincing evidence to terminate this payment. Commenters indicated that without continuation of the add on payment, access problems for Medicare beneficiaries in need of IVIG would be more severe.

Many commenters indicated problems with the ASP payment methodology for IVIG stating that IVIG is a unique

product for which market conditions are unlike all other drugs paid under ASP. Other commenters remarked that the addition of the four new billing codes for liquid IVIG adopted in July 2007 should improve market conditions and beneficiary access to IVIG. Some commenters asked that we consider making the liquid IVIG codes permanent J-codes. A few commenters asked that CMS consider establishing an add on payment for IVIG similar to the add on payment for clotting factor.

Two commenters indicated that Addendum B did not include the G-code for preadministration services and recommended that the code be included in Addendum B for the final rule.

Response: Comments regarding the ASP pricing methodology for IVIG, the adoption of new drug codes for liquid IVIG in CY 2007, and the consideration of an add-on payment for IVIG similar to the add-on payment for blood clotting factor are beyond the scope of our proposal which focuses on payment for a service under the PFS. We will consider these comments in context of any proposed policies for drug payments made as part of the CY 2009 PFS proposed rule.

In terms of the preadministration service for IVIG, we will continue the CY 2007 payment policy for code G0332 through CY 2008. We will carefully consider all relevant information including the conditions of the IVIG drug market during CY 2008 when we address whether it would be appropriate to continue the payment policy as part of the CY 2009 PFS.

We appreciate the commenters alerting us that G0332 was omitted from Addendum B in the proposed rule and we will ensure that this code is listed in Addendum B of this final rule with comment period.

Therefore, we are finalizing the proposal to continue to recognize payment for preadministration services for IVIG furnished to patients in a physician's office in CY 2008. Payment for this service will be made based on the PE RVUs previously established for this service in CY 2007. Payment for preadministration services for IVIG furnished to hospital outpatients is paid under the outpatient PPS (OPPS) and is addressed as part of that final rule.

4. Reporting of Cardiac Rehabilitation Services

For CY 2008, we proposed to assign a status indicator of "I" (invalid for Medicare purposes, Medicare recognizes another code for the billing of this service) to the current CPT codes for cardiac rehabilitation services, CPT codes 93797, *Physician services for*

outpatient cardiac rehabilitation; without continuous ECG monitoring (per session), and 93798, *Physician services for outpatient cardiac rehabilitation; with continuous ECG monitoring (per session)* and proposed to establish two new Level II HCPCS codes that we believe are more appropriate for specifically reporting cardiac rehabilitation services under the PFS. The proposed HCPCS codes are: GXXX1, *Physician services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per hour)*, and GXXX2, *Physician services for outpatient cardiac rehabilitation; with continuous ECG monitoring (per hour)*. We also proposed to crosswalk the current RVUs associated with CPT codes 93797 and 93798 to HCPCS Codes Gxxx1 and Gxxx1.

Comment: Many commenters, including physicians and providers of cardiac rehabilitation services, were generally supportive of the proposal for the specific G-codes. Commenters believed that this proposed coding change would allow for more appropriate coding and payment for cardiac rehabilitation services in those cases where intensive programs provide multiple sessions each day. In addition, commenters requested that we explicitly state that multiple sessions of cardiac rehabilitation can be paid for the same date of service when modifier 59 is reported. They also requested that we crosswalk the payments for both of the proposed G-codes to the higher cost CPT code 93798 to ensure that the full range of modalities provided in certain intensive cardiac rehabilitation programs are available.

Several of these commenters also requested that we provide additional guidance related to reporting of the cardiac rehabilitation G-codes, such as: (1) Explaining that it is likely to be reasonable and necessary to cover 72 cardiac rehab sessions when multiple sessions are provided in one day; (2) encouraging contractors to factor the "proven results" of a program into coverage decisions and that 72 sessions should be "presumptively covered" when they are furnished by a certain intensive cardiac rehabilitation program; and (3) providing further clarification and expansion of nutritional counseling by registered dietitians, indicating that they could independently bill for nutritional counseling within cardiac rehabilitation programs using the medical nutrition therapy codes because the NCD does not specifically mention these services.

Alternatively, a few commenters, including physician specialty groups, questioned the need for the proposed G-

codes, indicating that no new data would be gained by a coding shift that changes a unit from a session to an hour. Commenters also suggested that we work with the AMA to address the issue of whether it would be appropriate to modify the CPT definition for this code from a per session to per hour basis.

Many commenters also expressed concern that the use of the term "physician services" and "MD services" in the G-code descriptors could be misinterpreted by Medicare contractors as requiring a physician to directly deliver the care or be in attendance during each service episode and requested that the code descriptor be revised.

Response: We are aware of several intensive cardiac rehabilitation programs that provide multiple sessions in a day, lasting several hours total. The NCD for cardiac rehabilitation currently states that cardiac rehabilitation programs are covered for certain categories of patients and that the programs must be comprehensive. To be comprehensive the programs must include a medical evaluation, a program to modify cardiac risk factors (for example, nutritional counseling), prescribed exercise, education, and counseling. The NCD does not distinguish between different approaches to the delivery of cardiac rehabilitation services, whether the more common practice of two sessions per week or the more intensive programs of several sessions per day. In order to allow for flexibility and tailoring of cardiac rehabilitation programs based on patient needs, we have not been prescriptive regarding the precise amount of time that must be spent on each component of the program. Regarding intensity, we expect the intensity of cardiac rehabilitation programs to vary by patient and by program.

We believe it is important that our payment policy provides appropriate payment for cardiac rehabilitation services. In order to minimize the administrative burden to physicians and providers, but permit accurate reporting and payment for cardiac rehabilitation programs that provide more than one session per day, we believe that continuing the use of CPT codes 93797 and 93798 and allowing physicians and providers to bill more than one session per day under some circumstances would be the most appropriate course. Therefore, based upon the comments received and upon further review of this issue, for CY 2008, we will allow physicians and providers to report more than one unit for a date of service if

more than one cardiac rehabilitation session lasting at least 1 hour each is provided on the same day.

With respect to commenters' concerns about the use of the term "physician services" in the proposed G-code descriptors, we note that the descriptors for these codes were proposed to be parallel to the descriptors of the CPT codes for cardiac rehabilitation sessions which contain the term "physician services" in their descriptors. We are not aware that physicians and providers have problems with Medicare contractors' interpretation of the CPT code descriptors.

After consideration of all public comments received, we are not finalizing our proposal to establish two new G-codes for reporting cardiac rehabilitation services. Instead, we will continue to use the CPT codes 93797 and 93798 to report cardiac rehabilitation services under the CY 2008 PFS.

We will provide further guidance on coding and payment instructions for the cardiac rehabilitation services codes through program instructions.

We will not provide the additional coverage-related guidance requested by some commenters, such as the presumptive coverage and independent billing for registered dietitians. These recommendations effectively request changes to the NCD, and therefore, are outside of the scope of this final rule with comment period.

F. Part B Drug Payment

1. Average Sales Price (ASP) Issues

Medicare Part B covers a limited number of prescription drugs and biologicals. For the purposes of this proposed rule, the term "drugs" will hereafter refer to both drugs and biologicals, unless otherwise specified. Medicare Part B covered drugs not paid on a cost or prospective payment basis generally fall into the following three categories:

- Drugs furnished incident to a physician's service.
- DME drugs.
- Drugs specifically covered by statute (certain immunosuppressive drugs, for example).

Beginning in CY 2005, the vast majority of Medicare Part B drugs not paid on a cost or prospective payment basis are paid under the ASP methodology. The ASP methodology is based on data submitted to us quarterly by manufacturers. In addition to the payment for the drug, Medicare currently pays a furnishing fee for blood clotting factors, a dispensing fee for inhalation drugs, and a supplying fee to pharmacies for certain Part B drugs.

In January 2006, the drug coverage available to Medicare beneficiaries expanded with the implementation of Medicare Part D. The Medicare Part D program does not change Medicare Part B drug coverage.

In this section, we discuss changes and issues related to the determination of the payment amounts for covered Part B drugs and furnishing blood clotting factor. This section also discusses changes to how manufacturers calculate and report ASP data to us.

a. ASP Payment

Section 303(c) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. 108-173) (MMA) amended Title XVIII of the Act by adding section 1847A. This section revised the payment methodology for the vast majority of drugs and biologicals not paid on a cost or prospective payment basis furnished on or after January 1, 2005. The ASP reporting requirements are set forth in section 1927(b) of the Act. Manufacturers must submit ASP data by 11-digit National Drug Code (NDC) to us quarterly. The manufacturers' submissions are due to us not later than 30 days after the last day of each calendar quarter. The methodology for developing Medicare drug payment allowances based on the manufacturers' submitted ASP data is specified in 42 CFR, part 414, subpart K. We update the Part B drug payment amounts quarterly based on the data we receive. In this section of the preamble, we discuss certain aspects of the calculation of manufacturers' ASP data, issues related to bundled price concessions, and other Part B drug payment issues.

Further information on manufacturers' submission of ASP data for Medicare Part B drugs and biologicals is contained in prior rulemaking documents and other guidance accessible on the CMS Web page at (<http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/>). Specifically refer to the April 6, 2004 ASP interim final rule with comment period (IFC) (69 FR 17935) and the CY 2007 PFS final rule with comment period (71 FR 69624), which finalized the ASP calculation and reporting requirements of the April 6, 2004 IFC, and the Frequently Asked Questions available on the CMS Web page.

b. Bundled Price Concessions

In the CY 2007 PFS proposed rule and final rule with comment period, we solicited and responded to comments regarding the issue of how to allocate price concessions across drugs that are sold under bundling arrangements for

purposes of calculating the ASP. We did not establish a specific methodology that manufacturers must use for the treatment of bundled price concessions for purposes of the ASP calculation in the CY 2007 PFS final rule with comment period. In the absence of specific guidance, we maintained existing guidance that manufacturers may make reasonable assumptions in their calculation of ASP, consistent with the general requirements and the intent of the Act, Federal regulations, and their customary business practices. We also indicated that we would be closely monitoring this issue and may provide more specific guidance in the future if we determine it is warranted.

As stated in the CY 2008 PFS proposed rule (72 FR 38150), in its January 2007 Report to Congress, "Impact of Changes in Medicare Payments for Part B Drugs," the MedPAC discussed the issue of allocation of bundled price concessions for purposes of calculating the ASP, noting that "some manufacturers offer provider discounts for one of their products contingent on purchases of one or more other products." This report discusses two approaches for allocating bundled price concessions.

According to MedPAC, one option would be to require manufacturers to allocate bundled discounts in proportion to the sales of each drug sold under the bundled arrangement. For example, Drug A and Drug B are sold under a bundled arrangement and have a combined bundled discount equal to \$200,000 on total sales of \$1 million. If Drug A has sales of \$600,000, the manufacturer would allocate 60 percent of the bundled discount to that drug when calculating ASP. Forty percent of the bundled discount would be allocated to Drug B. MedPAC states that this approach would parallel bundling requirements under Medicaid and would be simpler to administer. However, MedPAC notes that this method might not capture contingent discounts.

The other approach discussed by MedPAC would be to require manufacturers to allocate bundled discounts to reflect the contingencies in the contract. That is, manufacturers would allocate any additional (or increased) discount to the sales of the drug (or drugs) that the discount is meant to increase. This approach would result in an ASP that more accurately reflects the transaction price of drugs when a discount for one drug or drugs is contingent in whole or in part on the purchase of another drug. For example, if a greater discount on the purchase price of Drug A is contingent on the

purchase (or purchases) of Drug B, this additional discount would be allocated to sales of Drug B in the calculation of ASP.

In its discussion of bundling, MedPAC states that the goal should be to ensure that ASP reflects the average transaction price for drugs. To that end, MedPAC recommends that the Secretary clarify the ASP reporting requirements for bundled products to ensure that ASP calculations allocate discounts to reflect the transaction price for each drug. Further, MedPAC states that we should ensure that the reporting requirements for allocating discounts are clear and that they can be implemented by manufacturers in a timely fashion.

In the CY 2008 PFS proposed rule (71 FR 77176), we also discussed the Medicaid Program: Prescription Drugs proposed rule published in the December 22, 2006 **Federal Register** (hereinafter referred to as the December 22, 2006 proposed rule) concerning the calculation of manufacturers' average manufacturer price (AMP). In the December 22, 2006 proposed rule, we proposed that discounts associated with a bundled sale would be allocated proportionately according to the dollar value of the units of each drug sold under the bundled arrangement. For bundled sales where multiple drugs are discounted, the aggregate value of all the discounts would be proportionately allocated across all of the drugs in the bundle. For AMP purposes, a bundled sale would mean an arrangement regardless of physical packaging under which the rebate, discount, or other price concession is conditioned upon the purchase of the same drug or drugs of different types (that is, at the nine-digit NDC level) or some other performance requirement (for example, the achievement of market share, inclusion or tier placement on a formulary), or where the resulting discounts or other price concessions are greater than those which would have been available had the bundled drugs been purchased separately or outside of the bundled arrangement. In the December 22, 2006 proposed rule, we further proposed that the AMP should be adjusted for bundled sales by determining the total value of all the discounts on all drugs in the bundle and allocating those discounts proportionately to the respective AMP calculations. The aggregate discount is allocated proportionately to the dollar value of the units of each drug sold under the bundled arrangement. Where discounts are offered on multiple products in a bundle, the aggregated value of all of the discounts should be proportionately allocated across all of

the drugs in the bundle. We received many comments on the many aspects of the December 22, 2006 proposed rule. However, the review of those comments and development of the final AMP calculation policies and rule were not complete at the time the CY 2008 PFS proposed rule was developed.

In light of MedPAC's recommendation that we clarify the ASP reporting requirements for bundled products and our discussion of bundled price concessions in the CY 2007 PFS rulemaking, we stated in the CY 2008 PFS proposed rule that we believe specific guidance in the ASP context is warranted to provide for greater consistency in ASP reporting across manufacturers and to enhance the accuracy of the ASP payment system. We stated that we found MedPAC's suggestion not to defer further guidance in this area compelling with respect to the potential that manufacturers may make differing assumptions in the absence of specific guidance on how to allocate bundled price concessions in the context of ASP. In addition, we stated that we believe it is appropriate at this time to establish a specified method for treating bundled price concessions in the calculation of ASP that is consistent with the treatment of such discounts for purposes of the AMP calculation, and that appropriate consistencies across the calculations of ASP and AMP will result in a lower potential for error and more accurate calculations of both prices.

As we noted in the CY 2008 PFS proposed rule, although ASP and AMP serve similar, but not identical, purposes, differences between these calculations provide a rationale for, and in some instances may require, minor differences between the final policies adopted in Medicaid and Medicare regulations. We believe any differences would be necessary to clarify certain aspects of a consistent approach for treatment of bundling, and would not result in significant policy differences on how bundling is addressed in the context of AMP and in the context of ASP.

Therefore, for purposes of calculating the ASP (beginning with the reporting period for the first calendar quarter of 2008 and thereafter), we proposed that the manufacturer must allocate the total value of all price concessions proportionately according to the dollar value of the units of each drug sold under a bundled arrangement to ensure that the ASP is adjusted for bundled arrangements as defined at proposed § 414.802. For a bundled arrangement, where multiple drugs are discounted, the aggregate value of all the discounts

would be proportionately allocated across all of the drugs sold under the bundled arrangement. We proposed that a bundled arrangement, for ASP purposes, would mean an arrangement, regardless of physical packaging under which the rebate, discount, or other price concession is conditioned upon the purchase of the same drug or biological or other drugs or biologicals or some other performance requirement (for example, the achievement of market share, inclusion or tier placement on a formulary, purchasing patterns, prior purchases), or where the resulting discounts or other price concessions are greater than those that would have been available had the drugs or biologicals sold under the bundled arrangement been purchased separately or outside of the bundled arrangement. We proposed to specify at proposed § 414.804(a)(2)(iii) that all price concessions on drugs sold under a bundled arrangement must be allocated proportionately to the dollar value of the units of each drug sold under the bundled arrangement.

In the CY 2008 PFS proposed rule, we also stated our intention to remain consistent, as appropriate, with the final policy adopted in the Medicaid Program: Prescription Drugs final rule with comment period published in the July 17, 2007 **Federal Register** (72 FR 39142) (hereinafter referred to as the July 17, 2007 final rule with comment period), which was still under development at that time. We stated that the Medicaid policies on bundled sales may ultimately differ from our discussion of the topic in the CY 2008 PFS proposed rule as a result of the final policy adopted in the July 17, 2007 final rule with comment period and that our policies for ASP in this final rule with comment period may reflect the final Medicaid policy on bundled sales, but only to the extent that it is appropriate for ASP and the public has had the opportunity to comment on how the final Medicaid policy for bundled sales, if appropriately adopted for ASP purposes, would effect the calculation of ASP. The final Medicaid policy on bundled sales adopted in the July 17, 2007 final rule with comment period was consistent with the discussion of this issue in the December 22, 2006 proposed rule with certain clarifications.

Comment: We received many comments on this issue. Most of these commenters noted that our proposal for the treatment of bundled price concessions in the ASP context was similar to the language finalized in the July 17, 2007 final rule with comment period. In general, most of the

commenters supported an appropriately consistent approach for the treatment of bundled price concessions within both the AMP and ASP calculations. However, several commenters indicated that they were still reviewing the July 17, 2007 final rule with comment period and believe additional time may be needed to better understand how the proposed Medicare bundled arrangement definition is to be applied. Several commenters had questions about how the proposed bundling policies may apply to certain contracting arrangements, and because of these questions, recommended that we cease or delay implementation of our proposed method for treatment of bundled price concessions for purposes of ASP.

Response: Based on comments recommending a delay and to better understand the concerns stated by the commenters, we are not finalizing the regulatory language changes we proposed in the CY 2008 PFS proposed rule at this time. Although we are not establishing a specific methodology that manufacturers must use for the treatment of bundled price concessions for purposes of calculating ASP at this time, we are clarifying that, in the absence of specific guidance, manufacturers may make reasonable assumptions in their calculation of ASP, consistent with the general requirements and the intent of the Act, Federal regulations, and their customary business practices. In making reasonable assumptions for purposes of calculating ASP, one method manufacturers could use is to reallocate price concessions that are conditioned upon other purchases or a performance requirement (for example, the achievement of market share, inclusion or tier placement on a formulary) so that the total value of all such price concessions are allocated proportionately according to the dollar value of the units of each drug sold. However, manufacturers may have other methods they could use to report bundled price concessions, so long as manufacturers apply reasonable assumptions consistent with the general requirements and the intent of the Act, Federal regulations, and their customary business practices. Manufacturers' reasonable assumptions consistent with our requirements, guidance and manufacturer's customary business practices remain an important aspect of ASP reporting. These assumptions should be submitted along with the ASP data and the signed certification form.

Recognizing that the treatment of bundled price concessions in the ASP calculation has implications for the integrity of the ASP payment

methodology, we will continue to monitor this issue, will consider the comments on this issue, and may provide more specific guidance in the future through rulemaking or through program instruction or other guidance (consistent with our authority under section 1847A(c)(5)(C) of the Act) if we determine it is warranted. As we continue to review these issues, we want to be sure we are aware of concerns from all stakeholders, and thus we encourage the public to provide additional information or concerns to us on this issue as they may arise.

c. Clotting Factor Furnishing Fee

Section 303(e)(1) of the MMA added section 1842(o)(5) of the Act which requires the Secretary, beginning in CY 2005, to pay a furnishing fee in an amount the Secretary determines to be appropriate to hemophilia treatment centers and homecare companies for the items and services associated with the furnishing of blood clotting factor. Section 1842(o)(5)(C) of the Act specifies that the furnishing fee for clotting factor for CY 2006 and subsequent years will be equal to the fee for the previous year increased by the percentage increase in the consumer price index (CPI) for medical care for the 12 month period ending with June of the previous year.

The furnishing fee for CY 2007 is \$0.152 per unit clotting factor. The percent increase in the CPI for medical care for the 12-month period ending in June 2007 is 4.0 percent. Consequently, the furnishing fee will be \$0.158 per unit of clotting factor for CY 2008. While the furnishing fee payment rate is calculated at 3 digits, the actual amount paid to providers and suppliers is rounded to 2 digits.

In the CY 2008 PFS proposed rule, we proposed to announce the annual update of the blood clotting factor furnishing fee, as specified in section 1842(o)(5)(C) of the Act, by issuing program instructions and postings on the CMS Web site in lieu of including a discussion of this issue in PFS rulemaking for CY 2009, and thereafter, until such time as the update methodology may be modified. We made our proposal because the update is statutorily determined, is based on an index not affected by administrative discretion or public comment, is based on the percentage increase in the CPI for medical care for the 12-month period ending with June of the previous year, and is not released by the Bureau of Labor Statistics until after our proposed rule is published.

As stated in the CY 2008 proposed rule, we believe that including a

discussion of the furnishing fee update in annual rulemaking does not provide an advantage over other means of announcing this information, so long as the current statutory update methodology continues in effect. We believe that the public's need for information and adequate notice regarding the updated furnishing fee can be better met by issuing program instructions which will eliminate the discussion of the furnishing fee update annually in rulemaking. In addition, by communicating the updated furnishing fee in program instruction, the actual figure for the percent change in the applicable CPI and the updated furnishing fee calculated based on that figure can be announced more timely than when included as part of the PFS final rulemaking process.

Comment: We received comments in support of our proposal to announce the update furnishing fee via program instructions beginning in CY 2009, and to continue updating the furnishing fee according to the consumer price index for medical care. Comments supported the continued use of our proposed approach until such time as the methodology is changed.

Response: After consideration of the public comments, beginning for CY 2009, we will announce the updated blood clotting factor furnishing fee via program instructions and via a Web posting. In addition, we may include the updated blood clotting factor furnishing fee in the annual PFS final rules to promote broader dissemination of the announcement.

d. Widely Available Market Prices (WAMP) and AMP Threshold

Section 1847A(d)(1) of the Act states that "the Inspector General of HHS shall conduct studies, which may include surveys to determine the widely available market prices (WAMP) of drugs and biologicals to which this section applies, as the Inspector General, in consultation with the Secretary, determines to be appropriate." Section 1847A(d)(2) of the Act states that, "Based upon such studies and other data for drugs and biologicals, the Inspector General shall compare the ASP under this section for drugs and biologicals with—

- The widely available market price (WAMP) for these drugs and biologicals (if any); and
- The AMP (as determined under section 1927(k)(1) of the Act for such drugs and biologicals."

Section 1847A(d)(3)(A) of the Act states that, "The Secretary may disregard the ASP for a drug or biological that exceeds the WAMP or

the AMP for such drug or biological by the applicable threshold percentage (as defined in subparagraph (B)).” The applicable threshold is specified in the statute as 5 percent for CY 2005. For CY 2006 and subsequent years, section 1847A(d)(3)(B) of the Act establishes that the applicable threshold is “the percentage applied under this subparagraph subject to such adjustment as the Secretary may specify for the WAMP or the AMP, or both.” In CY 2006 and CY 2007, we specified an applicable threshold percentage of 5 percent for both the WAMP and AMP. We based this decision on the limited data available to support a change in the current threshold percentage.

For CY 2008, we proposed to specify an applicable threshold percentage of 5 percent for the WAMP and the AMP. At present, the OIG is continuing its comparison of both the WAMP and the AMP. Furthermore, information on how recent changes to the calculation of the AMP may affect the comparison of AMP to ASP is not available at this time. Since we do not have data that suggest another level is more appropriate at this time, we believe that continuing the 5 percent applicable threshold percentage for both the WAMP and AMP is appropriate for CY 2008.

As we noted in the CY 2007 PFS final rule with comment period (71 FR 69680), we understand that there are complicated operational issues associated with potential payment substitutions and will continue to proceed cautiously in this area and provide stakeholders, particularly manufacturers of drugs impacted by potential price substitutions, with adequate notice of our intentions regarding such, including the opportunity to provide input with regard to the processes for substituting the WAMP or the AMP for the ASP. As part of our approach, we intend to develop a better understanding of the issues that may be related to certain drugs for which the WAMP and AMP may be lower than the ASP over time.

Comment: We received several comments regarding our proposal to maintain the threshold at 5 percent. Most commenters supported maintaining this threshold. One commenter suggested increasing the threshold but did not specify a percentage to which it should be increased. Another commenter suggested increasing the threshold for AMP to 10 percent while maintaining the 5 percent threshold for WAMP.

Response: We recognize the public’s concern regarding the establishment of an appropriate threshold for making price substitutions. We disagree with

the commenter who recommended different thresholds for WAMP comparisons and for AMP comparisons because of current operational difficulties associated with maintaining and communicating different thresholds. At the current time, we also believe that maintaining two thresholds lessens stakeholders’ ability to accurately predict the potential risk for price adjustments. After considering public comments on this issue, and as required by statute, we are finalizing our proposal to establish the WAMP/AMP threshold at 5 percent for CY 2008.

Comment: We received many comments suggesting that caution be exercised in the determination of price substitutions and that we develop a formal process and criteria to be used to determine when substitutions are necessary. Commenters also recommended that we assure adequate notice is provided prior to making a price substitution. Several commenters indicated recent policy changes made to the Medicaid AMP calculation could impact the accuracy of the comparisons between AMP and ASP and stated that these changes should be carefully studied and considered before implementing any pricing changes.

Additionally, several commenters opposed any price substitutions for certain classes of providers or for certain specific drugs. The commenters noted that certain classes of providers may be subject to different cost structures making wholesale substitution of prices impractical. Some commenters asserted that certain drugs experience unique market forces that may be adversely affected by pricing substitutions.

Response: We understand that complex operational issues, both within CMS and externally could impact potential payment rate substitutions. We acknowledge the recent changes to the AMP regulations and are studying such changes carefully. Furthermore, we recognize the variety of providers and the marketplace forces that impact drug pricing decisions under ASP. Therefore, we will proceed cautiously and provide stakeholders, particularly manufacturers of drugs impacted by potential price substitutions, with adequate notice of our intentions regarding such, including the opportunity to provide input with regard to the processes for substitution.

e. Other Issues

Comment: A few commenters noted that we did not discuss the payment for separately billable ESRD drugs in the CY 2008 PFS proposed rule. These commenters supported continuation of the current policy of basing the payment on the ASP+6 percent.

Response: We did not propose any policy changes to the approach that we currently use to pay for separately billed ESRD drugs. Therefore, for CY 2008 payment for separately billable drugs furnished by ESRD facilities will continue at ASP+6 percent in accordance with section 1847A of the Act.

Comment: Several commenters noted that the billing and payment codes recently established for liquid IVIG to implement separate payment under section 1847A(b)(4) of the Act should improve beneficiary access to these products.

Response: We thank the commenters for communicating their support.

Comment: We received a few comments expressing concern that, because ASP based payment limit updates lag time by at least 2 calendar quarters, increases in market prices may not be reflected in a drug’s payment limit for at least 6 months after a pricing adjustment. One commenter suggested that current technology should enable CMS to decrease the lag time from 6 months to 2 to 3 months.

Response: By statute, the ASP based payment allowances are determined on a quarterly basis and are based on ASPs reported by manufacturers quarterly. Manufacturers must report to us no later than 30 days after the close of the calendar quarter. There is a necessary time frame after the close of a calendar quarter for manufacturers to calculate and submit the ASP data to CMS, for CMS to prepare and issue the payment rates, and for the claims processing contractors to implement the updated payment files. We implement these new payment limits through program instructions or otherwise at the first opportunity after we received the data, which is the calendar quarter after receipt.

Comment: One commenter suggested that we modify the formula we use to calculate the payment amounts based on manufacturers’ ASP data so that the formula is volume weighted as suggested by the OIG.

Response: We discussed our formula for determining the payment amounts based on manufacturers’ ASP data in the CY 2006 PFS final rule (70 FR 70217). As we stated in the CY 2006 PFS final rule, in establishing the formula used to calculate the payment amounts based on manufacturers’ ASP data, we considered various approaches, including the alternative suggested by this commenter. If appropriate, we may consider revising the methodology in the future. We did not propose to change our current formula, and are not

implementing changes to our formula at this time.

Comment: We received a few requests to increase the pharmacy supplying fee for immunosuppressive, oral anticancer, and oral anti-emetic drugs for CY 2008 to reflect actual supplying costs. We also received comments expressing concerns that primarily because of the labor intensive Medicare Part B claims processing services provided by specialty transplant pharmacies, the current supplying fee payment for immunosuppressive drugs is substantially lower than reported actual supplying costs. One commenter requested that we eliminate the two-tiered pharmacy supplying fee for prescriptions filled within a 30-day period.

Response: We are committed to assuring that our claims systems process claims as timely and accurately as possible and that their payment methodologies result in the determination of accurate payment amounts. We recognize the operational complexities under which certain providers operate and strive to develop systems and processes to minimize such complexities. We appreciate the comments that were provided and may consider the issue in future rulemaking if appropriate. Since we did not propose a change to these rates for CY 2008, they will continue to be in effect in CY 2008. We received several other comments on the use and potential impacts of the ASP payment methodology and other issues related to Part B drugs that are also outside the scope of this rulemaking and will not be addressed in this final rule with comment. These topics include the following:

- Requests for billing codes for specific products;
- Whether alternative payment methodologies or exceptions to the ASP based payment should be considered;
- Variation in local coverage and payment policies, including use of least costly alternative policies and invoice pricing for compounded drugs;
- Excluding prompt pay discounts from the calculation of ASP; and
- Whether coverage under Part B should be expanded to include certain vaccines.

2. Competitive Acquisition Program (CAP) Issues

Section 303(d) of the MMA required the implementation of a CAP for certain Medicare Part B drugs and biologicals not paid on a cost or PPS basis. The provisions for acquiring and billing drugs under the CAP were described in the Competitive Acquisition of Outpatient Drugs and Biologicals Under

Part B proposed rule (published in the March 4, 2005 **Federal Register**; hereinafter referred to as the March 4, 2005 proposed rule) and interim final rule with comment period (published in the July 6, 2005 **Federal Register**; hereinafter referred to as the July 6, 2005 IFC) (70 FR 10746 and 70 FR 39022, respectively). Certain provisions were finalized in the CY 2006 PFS final rule with comment period (70 FR 70116). We specified a single CAP drug category to include a defined list of drugs furnished incident to a physician's service.

In this final rule with comment period, we discuss the impact of provisions in section 108 of the MIEA-TRHCA on administrative and operational aspects of the CAP. Topics include the implementation of a post-payment review process and the corresponding changes to claims processing procedures, and changes to other operational aspects of the CAP. This final rule with comment period implements conforming changes to the CAP regulations to reflect these provisions that made changes to the payment process of the CAP for Part B Drugs.

When the CAP program began on July 1, 2006, physicians were given a choice between obtaining these drugs from vendors selected through a competitive bidding process and approved by CMS, or directly purchasing these drugs and being paid under the ASP system. In this final rule with comment period, we discuss areas related to transporting CAP drugs and the administrative burden of the CAP submitted in response to the July 6, 2005 IFC. In addition, we are finalizing portions of the July 6, 2005 IFC that were not finalized in the CY 2006 PFS final rule with comment period and responding to the other timely comments we received on the July 6, 2005 IFC that we have not responded to previously.

a. MMA Operational Provisions

Prior to the enactment of the MIEA-TRHCA, section 1847B(a)(3)(A) of the Act set forth specific requirements that have a direct impact on the administrative and operational parameters for instituting a CAP. This section of the statute required the following:

(1) Approved CAP vendors bill the Medicare program for the drug or biological supplied, and collect any applicable deductibles and coinsurance from the Medicare beneficiary. (For purposes of the preamble, the term "approved CAP vendor" means the term "contractor" as referred to in the statute.)

(2) Any applicable deductible and coinsurance may not be collected unless the drug was administered to the beneficiary. (For purposes of the preamble, the term "drug" refers to drugs and biologicals furnished under the CAP, unless the context specifies otherwise.)

(3) Medicare can make payments only to the approved CAP vendor, and these payments are conditioned upon the administration of the drug.

Section 108 of the MIEA-TRHCA amended this third element.

b. MIEA-TRHCA

Section 108 of the MIEA-TRHCA made changes to the CAP payment methodology. Section 108(a)(1) of the MIEA-TRHCA amended section 1847B(a)(3)(A)(iii) of the Act by adding new language that requires that payment for drugs and biologicals be made upon receipt of a claim for a drug or biological supplied for administration to a beneficiary. This statutory change took effect on April 1, 2007.

Section 108(a)(2) of the MIEA-TRHCA requires the Secretary to establish (by program instruction or otherwise) a post-payment review process (which may include the use of statistical sampling) to assure that payment is made for a drug or biological only if the drug or biological has been administered to a beneficiary. The Secretary shall recoup, offset, or collect any overpayments determined by the Secretary under this process.

Section 108(b) of the MIEA-TRHCA states that nothing in this section shall be construed as requiring the conduct of any additional competition under section 1847B(b)(1) of the Act; or requiring an additional physician election process.

Section 108(c) of the MIEA-TRHCA states that the amendments of this section apply to payments for drugs and biologicals supplied: (1) On or after April 1, 2007; and (2) on or after July 1, 2006 and before April 1, 2007, for claims that are unpaid as of April 1, 2007.

Comment: Some commenters suggested that any changes to the CAP be made only after the expiration of the current vendor contract. The commenters stated that implementation of changes before the next vendor contract would be unfair to bidders who chose not to participate in the CAP because of previously issued guidance. The commenters cited the CAP statutory reference about waiving the FAR in order to promote competition. The commenters believe that such changes would inappropriately favor the single

existing vendor, and therefore, hurt competition.

Response: We do not have the authority to delay implementing the claims processing changes required by the MIEA–TRHCA, which were effective April 1, 2007. Although some of our changes were not expressly required by the statute, we believe these conforming changes are necessary to allow the program to function in a manner that is consistent with, and required by, the statutory changes. Further, because the CAP is a new payment program, change that is consistent with operational experience and improves efficiency for participants is to be expected. Finally, we disagree that the FAR affects our ability to make changes in the program while the current contract is in force. Because these changes do not modify an approved CAP vendor's responsibilities under its contract with us, we do not believe the FAR is implicated.

Further, as we have discussed in prior rulemaking, the CAP statute authorizes the waiver of provisions of the FAR (other than provisions relating to confidentiality of information and such other provisions as the Secretary determines appropriate) as necessary for the efficient implementation of Section 1847B of the Act, in order to promote competition.

We have discussed our approach to conforming to the confidentiality provisions in the July 6, 2005 IFC (70 FR 39077), and we intend to comply with this approach during future vendor bidding periods. In implementing the CAP, we have waived all of the FAR except for the confidentiality and the conflict of interest provisions to promote competition and the efficient implementation of the program. We made the decision to waive the FAR (other than the provisions on confidentiality and conflict of interest) in order to increase the pool of qualified vendors available to participate in the program. It is our understanding that compliance with the FAR is not normally required of the companies that make up the pool of potential CAP vendors. It is also not required of other Medicare suppliers. We waived these provisions in order to structure CAP bidding in a manner consistent with established vendor bidding practices.

The FAR's confidentiality provisions, as well as the conflict of interest standards and requirements found in FAR subsection 9.5, apply to approved CAP vendors and applicants. All other provisions of the FAR have been waived for purposes of the CAP. However, we have used certain provisions of the FAR for guidance in implementing the CAP, and we may from time to time used

other FAR provisions as a guide, even though they have been waived. For example, as we discussed in the July 6, 2005 IFC (70 FR 39063), we look to the provisions of the FAR to guide our assessment of bidder's financial solvency.

However, even if the FAR were implicated, we believe these changes promote competition because they make the program a more attractive option for physicians, which will provide physicians who compete among one another a more meaningful choice between the CAP and the ASP methodology. We further believe the changes we are implementing here are designed to improve the flexibility and administrative ease of the CAP. Therefore, we will proceed with implementing the provisions we are finalizing as indicated in this final rule with comment period.

c. CAP Claims Processing

In the July 6, 2005 IFC (70 FR 39042), we initially implemented a claims processing system that enables selected approved CAP vendors to bill the Medicare program directly, and to bill the Medicare beneficiary and his or her third party payer after verification that the physician has administered the drug. When a participating CAP physician elects to join the program, he or she must agree to obtain all drugs on the CAP drug list from the approved CAP vendor, with only a few exceptions. For example in furnish as written (FAW) situations (that is, where a beneficiary needs a particular formulation of a drug not available from the approved CAP vendor) the participating CAP physician would be allowed to obtain that drug outside of the CAP. In the case of Medicare Secondary Payer (MSP) (that is, where a Medicare beneficiary may have another payer primary to Medicare), the participating CAP physicians must obtain physician administered drugs from entities approved by the primary plan and bill the primary payer. Detailed MSP instructions have been issued by CMS that allow the physician to bill under the ASP methodology for the portion of the drug not covered by the primary payer in this situation.

Prior to the MIEA–TRHCA, the claims processing procedures for the approved CAP vendor and the participating CAP physician were as follows:

- Once a shipment is received from the approved CAP vendor, the participating CAP physician stores the drug until the date of drug administration.
- When the drug is administered to the beneficiary, the participating CAP

physician places the prescription order number for each drug administered on the claim form submitted to his or her regular Part B carrier.

Similarly, when the approved CAP vendor bills Medicare for the drug it shipped to the participating CAP physician, it places the relevant prescription order number on the claim form submitted to the designated carrier. The use of the prescription order number on both the participating CAP physician's claim and the approved CAP vendor's claim is intended to indicate drug administration to the beneficiary. The participating CAP physician's claim and the approved CAP vendor's claim are matched in the Medicare claims processing system so that drug administration can be verified and payment to the approved CAP vendor can be made.

d. Required Changes to CAP Claims Processing

As originally implemented, the claims matching process described above in this section was completed before payment was made. However, as of April 1, 2007, section 108 of the MIEA–TRHCA requires payment to be made to the CAP vendor for claims upon receipt. The statute also requires us to establish a post-payment review process to assure that payment is made for a drug only if the drug has been administered to a beneficiary. We are authorized under the statute to recoup, offset, or collect any overpayments by the Secretary. We are also authorized to conduct post-payment review using statistical sampling and to implement the post-payment review process by program instruction or otherwise. We implemented the necessary changes to our claims processing system and initiated the post-payment review process on April 1, 2007 via instructions to the CAP-designated claims processing contractor and Questions and Answers posted on the CMS competitive bidding Web site at http://www.cms.hhs.gov/CompetitiveAcquisforBios/15_Approved_Vendor.asp#TopOfPage.

Under the post-payment review process, the CAP-designated carrier will use the CMS claims processing system to look for a match between the CAP prescription order number on the participating CAP physician's claim and the same prescription order number on the approved CAP vendor's claim to track drug administration on a dose by dose basis. If the CAP-designated carrier is able to find a match between the two claims, the carrier makes a determination that the beneficiary did receive the drug being billed for by the CAP physician. The participating CAP

physician claim may also contain information on any determination of medical necessity and coverage made by the local carrier.

We will also use statistical sampling under the post-payment review process to determine whether drugs were medically necessary. All Medicare claims are subject to medical necessity determinations; however, under the changes required by the MIEA-TRHCA, CAP claims may not all have a chance to be reviewed for medical necessity before they are paid. Therefore, the post-payment review includes both verification of drug administration and a medical necessity review of a statistically valid sample of CAP claims. In conducting the post-payment review, we will continue to monitor for fraud, waste, and abuse. All CAP claims will remain eligible for review for medical necessity and verification of drug administration. We anticipate that the post-payment review process will provide us with additional opportunities to monitor for the appropriate payment of drugs furnished under this program.

To conduct post-payment review of claims, we may also ask for documentation of administration from the approved CAP vendor and for medical records from the participating CAP physician for any claim that is identified for review. While it is standard practice for CMS to require Medicare providers to submit medical records as part of claims review, we reserve the right to also specifically request any other records that verify the administration of a CAP drug. Furthermore, we want to make it very clear to the participating CAP physician that when electing to join the program that the physician may be asked to supply medical records for post-payment review. Therefore, in the CY 2008 PFS proposed rule (72 FR 38153), we proposed to revise § 414.908(a)(3)(xi) and the physician election agreement form to clarify that medical records and certain other information may be requested from the CAP physician during the post-payment review process.

The procedures used to verify valid claims and ensure proper payment for drugs supplied under the CAP are based on established post-payment review processes used in other parts of the Medicare program. The request for medical records as part of the claims payment process during CAP post-payment review is intended to work in conjunction with Item 12 on the Health Insurance Claim Form CMS-1500 which, when signed by a beneficiary, authorizes the release of "any medical

information necessary to process a claim."

When a claim is selected for review we notify the approved CAP vendor and request its records to verify administration. We also notify the approved CAP vendor that we will be requesting medical records from the participating CAP physician. If the medical record is not received within 30 days, the claim is denied because we will not have sufficient information to verify drug administration and medical necessity.

This review process is similar to those used elsewhere in the Medicare program such as clinical laboratory payment review or payment of radiology services.

As we specified in the July 6, 2005 IFC (70 FR 39038), the local carrier's medical review policies and coverage determinations will continue to apply in the CAP. Under our previous claims processing methodology, the local carrier made the coverage determination on the drug ordered by the participating CAP physician and furnished by the approved CAP vendor as part of the claim matching process prior to payment of the approved CAP vendor's claim. Under the new methodology, the drug claim will be paid upon receipt unless the local carrier has already made a coverage or medical necessity determination on the drug, and the match has already occurred showing that the drug claim should be denied.

As part of the post-payment review process, the CAP-designated carrier checks the CMS central claims processing system to determine whether the local carrier has made a coverage or medical necessity determination on the CAP drug indicated on the participating CAP physician's drug administration claim. If a coverage determination has been made, the CAP-designated carrier reflects the local carrier's decision in its post-payment review of the claim. If the local carrier has not reviewed the drug administration portion of the participating CAP physician's claim as of the date that the designated carrier processes the approved CAP vendor's drug claim, the CAP-designated carrier uses the local carrier's coverage determination policies when conducting medical review of the claim.

Comment: One commenter stated that we had exceeded the scope of the statute because we were planning to conduct a medical necessity review on CAP drug claims that were selected for review as part of the statistical sample.

Another commenter recommended that we make detailed description of the claims sampling process available for public comment and asked that we design the process consistent with the

Medicare Program Integrity Manual. The commenter also asked for more detail on the information necessary to include in the medical record to ensure that the participating CAP physician has appropriately documented the medical necessity of the drug administered.

One commenter questioned whether we needed to obtain additional information from the CAP participating physician on claims selected for post pay review based on the statistical sample and stated that the information contained on the claim form should be sufficient to verify administration.

Another commenter questioned why we were changing the CAP claims processing methodology to pay most claims upon receipt and to verify administration on a post pay basis. The commenter asked whether we would allow for extenuating circumstances if the medical record was not supplied by the participating CAP physician within the 30-day time period for situations such as bankruptcy, litigation, or closure of the practice.

Response: As stated in the CY 2008 PFS proposed rule (72 FR 38153), we were required to make changes to the CAP claims processing methodology because section 108 of the MIEA-TRHCA amended section 1847B(a)(3)(A)(iii) of the Act by adding new language that requires the payment for drugs and biologicals upon receipt of a claim for a drug or biological supplied for administration to a beneficiary. This change in the law was effective on April 1, 2007. Section 108(a)(2) of the MIEA-TRHCA requires the Secretary to establish (by program instruction or otherwise) a post-payment review process (which may include the use of statistical sampling) to assure that payment is made for a drug or biological only if the drug or biological has been administered to a beneficiary. The Secretary is required to recoup, offset, or collect any overpayment determined by the Secretary under this process. We implemented the necessary changes to our claims processing system and initiated the post-payment review process on April 1, 2007, via instructions to the CAP-designated claims processing contractor and Questions and Answers posted the CMS competitive bidding Web site at http://www.cmsm.hhs.gov/CompetitiveAcquisforBios/15_Approved_Vendor.asp#TopOfPage. In the CY 2008 PFS proposed rule, we described the changes we had made to our claims processing system and proposed conforming changes to our regulations for additional items not covered by the MIEA-TRHCA. Because the MIEA-TRHCA gave us authority to

implement its provisions by program instructions or otherwise by April 1, 2007, the necessary changes have already been made to our claims processing system and the post-pay review process had been implemented. The post-payment review process includes verification of drug administration and a medical necessity review of a statistically-valid sample of CAP claims. This process was designed in conformance with the Medicare Program Integrity Manual and in consultation with CMS statistical sampling experts, consistent with our authority to establish these procedures by program instruction or otherwise. For additional information on the requirements of the Program Integrity Manual see <http://www.cms.hhs.gov/manuals/downloads/pim83co2pdf>.

All Medicare claims are subject to medical necessity determinations; however, under the changes required by the MIEA-TRHCA, there may not be sufficient time for all CAP claims to be reviewed for medical necessity before they are paid. Prior to paying the approved CAP vendor's claim, the designated carrier will check the claims processing system to determine whether the participating CAP physician has submitted the claim for the administration of the drug. If the physician has submitted the claim and the local carrier has made a determination that the drug is not payable because of a coverage or medical necessity denial, the drug claim will be denied by the designated carrier. However, if no determination has been made on the physician's claim, the designated carrier will pay the approved CAP vendor's claims for the drug under the MIEA-TRHCA, and the claim will be subject to statistical sampling on a post-pay basis. If the claim is selected for review, verification of drug administration and a medical necessity review will be conducted. As part of this process, the designated carrier will check the system to see whether the local carrier had denied the claim as not medically necessary. If a denial has been made, the designated carrier will deny the approved CAP vendor's claim on medical necessity grounds. The designated carrier will use the local carrier's policies when conducting the review.

Medical necessity review is always conducted based on medical records obtained from the physician and will be conducted in an effort to look behind the information on the claim form. As specified in chapter 3 of the Medicare Program Integrity Manual, standard data elements for post-pay medical review include signature requirements,

diagnosis requirements, and documentation of orders for testing. The carrier may also specify additional information it will review to document that coverage and medical necessity requirements have been met. Under the current CAP post-pay review process, the designated carrier requests that all records be supplied by the physician within 30 days but allows for a limited amount of time beyond that period before the service will be considered not to have been administered. Participating CAP physicians are encouraged to send any information they can provide to the designated carrier within the timeframes provided. If the physician is unable to provide all of the requested information in a timely manner to the carrier, he or she may contact the carrier to determine if the contractor will grant an extension. There is also a provision in the Medicare Program Integrity Manual that allows contractors to grant additional time in the event of a natural disaster. As we indicated in the CY 2008 PFS proposed rule, it is standard practice for Medicare providers to be required to submit medical records to assist in claims review. Therefore, we are finalizing our proposal to revise § 414.908(a)(3)(xi) and the physician election agreement to make it very clear to the CAP participating physician that they may be asked to provide medical records for post-payment review in the CAP.

e. Provisions for Collection of Beneficiary Coinsurance

In the CY 2006 PFS final rule with comment period, we specified at § 414.914(h)(1) that subsequent to receipt of final payment by Medicare, or the verification of drug administration by the participating CAP physician, the approved CAP vendor must bill any applicable supplemental insurance policies. If a balance remains after the supplemental insurer pays its share of the bill, or if there is no supplemental insurance, the approved CAP vendor may bill the beneficiary for the balance. In prior practice, a match in the claims system between the participating CAP physician's drug administration claim and the approved CAP vendor's drug claim and the subsequent payment by Medicare was used to indicate that the beneficiary received the drug. We also allowed voluntary information exchanges between the approved CAP vendor and the participating CAP physician's office to verify CAP drug administration. Additionally, we note that under the CAP regulations, the participating CAP physician has a responsibility to notify the approved CAP vendor when a drug is not

administered or a smaller amount was administered than was originally ordered.

Because section 108 of the MIEA-TRHCA requires the payment of CAP claims upon receipt, payment of a claim by Medicare may occur before administration of the drug has been verified. However, section 1847B(a)(3)(A)(ii) of the Act, which states that deductible and coinsurance shall not be collected unless the drug or biological is administered, remains unchanged. Thus, because we have interpreted this provision as requiring verification of administration prior to the collection of applicable cost sharing amounts, the requirement for verification of administration similarly remains unchanged. However, because of the statutory change of section 108(a)(1) of the MIEA-TRHCA and its resulting impact on our claims processing methodology, the claims processing system no longer provides a way for CMS to verify administration on the approved CAP vendor's behalf before the approved CAP vendor collects coinsurance from the beneficiary or the supplemental insurer. Verification of CAP drug administration is also conducted in the post-payment review process. The approved CAP vendor is expected to make information available to verify administration for post-payment review as necessary.

We believe that an approved CAP vendor can verify whether a CAP drug was administered in a variety of ways. For example, an approved CAP vendor may enter into a voluntary agreement with a participating CAP physician to exchange such information as described in the CY 2006 PFS final rule with comment period (70 FR 70251). However, if a participating CAP physician is unwilling to enter into a voluntary agreement to verify administration, the approved CAP vendor may verify that the drug was administered by contacting the participating CAP physician's office to request verbal confirmation. In such an instance, the approved CAP vendor is expected to document the verbal confirmation of CAP drug administration, the identities of individuals who exchanged the information, and the date and time that the information was obtained. In addition to verifying administration through contact with the physician's office, we also suggest that the approved CAP vendor place a statement on beneficiaries' bills informing the individual of the statutory requirement and suggesting that the beneficiary contact the participating CAP physician to verify that he or she received the dose

of the drug for which he or she are being billed prior to paying any cost sharing amount.

For the reasons described above in this section, we believe that the verification of CAP drug administration remains a required element of the CAP; therefore, in the CY 2008 PFS proposed rule (72 FR 38155), we proposed to add § 414.906(a)(6) by specifying that all of the following elements are required to document the verification of CAP drug administration:

- Beneficiary's name.
- Health insurance number.
- Expected date of administration.
- Actual date of administration.
- Identity of the participating CAP physician.
- Prescription order number.
- Identity of the individuals who supply and receive the information.
- Dosage supplied.
- Dosage administered.

In the CY 2008 PFS proposed rule, these data elements were actually proposed in § 414.914 (72 FR 38226). We believe that the drug administration verification requirements best fit in § 414.914 since CAP vendors must collect this information as part of their terms of contract. Therefore, we are finalizing § 414.914 to include these provisions.

Also, as a result of changes mandated by section 108(a)(1) of the MIEA-TRHCA, we proposed to revise new § 414.914(i)(1) to remove the reference to "final payment by Medicare" and revise this language to state, "payment by Medicare." The original language was written to indicate that an approved CAP vendor could not bill a beneficiary's supplemental insurer for applicable amounts of cost sharing until the CAP drug claim had matched the corresponding physician's drug administration claim. Under the post-payment review process, the final payment would not occur until a statistical review of the claims was complete, a process that may take several months. Removing the word final from this section of the regulation will clarify that the approved CAP vendor may bill the supplemental insurer immediately after the designated CAP carrier makes the initial payment on a CAP drug claim. Under our current regulations, the approved CAP vendor may also bill the beneficiary if drug administration is verified by the participating CAP physician. This provision remains unchanged.

Under the revised CAP claims payment process, the approved CAP vendor will bill Medicare for the CAP drug that has been provided. In most cases Medicare will pay the claim upon

receipt. If the beneficiary has a supplemental insurance policy, and the supplemental insurer has a crossover agreement with Medicare, the claim automatically will cross over to the supplemental insurer for payment. The supplemental insurer will pay its share. Upon receipt of payment from the supplemental insurer, the approved CAP vendor may bill the beneficiary for any residual amount. For beneficiaries who do not have a supplemental insurance policy, the approved CAP vendor may bill the beneficiary after payment by Medicare.

However, in either case, the approved CAP vendor may not collect any coinsurance owed from the beneficiary or his or her supplemental insurer unless it has verified that the drug was administered. If the approved CAP vendor believes that the drug was administered but later learns that it was not, the approved CAP vendor must refund any coinsurance collected to the beneficiary and his or her supplemental insurer, as applicable. In addition, in § 414.914(i)(2), we proposed that the approved CAP vendor must promptly refund any payment made by CMS if the vendor has been paid for drugs that were not administered. We also proposed to interpret the word "promptly" to mean 2 weeks. Thus, the approved CAP vendor would have 2 weeks from the date it was notified that it had been paid for a drug that had not been administered to refund to the designated carrier any payment for the claim and refund any cost sharing collected to the beneficiary or his or her supplemental insurer.

Comment: We received few comments on our proposal for provisions for collection of beneficiary coinsurance. One commenter was concerned about the administrative burden placed on the participating CAP physician if the approved CAP vendor calls the physician's office to verify that a drug was administered. Another commenter agreed with our proposal to require that the approved CAP vendor refund any cost sharing collected in error promptly to the beneficiary and or his or her supplemental insurance provider. The commenter also suggested that we require the approved CAP vendor to pay a penalty above the amount owed if it does not refund the cost sharing amount within the 2 week time frame.

Response: Physicians and their staff are the best source of information for drug verification since they have direct contact with the beneficiary. We have structured the process for verification of CAP drug administration in the least burdensome way possible for the participating CAP physician that would

still provide us with information to comply with the statutory mandate to assure that payment is made for a CAP drug only if it has been administered to a beneficiary.

Physicians have flexibility in how verification for drug administration occurs. The physician is free to enter into a voluntary agreement with the approved CAP vendor to verify drug administration and to specify the manner in which he or she would like the verification to occur. Alternatively, if the physician chooses not to enter into such an agreement and does not notify the vendor that a dose of a CAP drug has been administered, the approved CAP vendor will contact the physician to verify administration before collecting coinsurance from the beneficiary.

We believe that the degree of flexibility built into this procedure for drug administration verification minimizes the burden for participating CAP physicians within the confines of our statutory obligation to assure that payment is made for a CAP drug only if it has been administered to a beneficiary. Therefore, we are finalizing our proposal to add new § 414.914(h)(1) as described above in this section.

We are also finalizing our proposal to revise new § 414.914(i)(1) to remove the reference to "final payment by Medicare" and revise this language to state, "payment by Medicare." Under the post-payment review process, the final payment will not occur until a statistical review of the claims was complete, a process that may take several months. Removing the word final from this section of the regulation will clarify that the approved CAP vendor may bill the supplemental insurer immediately after the designated CAP carrier makes the initial payment on a CAP drug claim. Under our current regulations, the approved CAP vendor may also bill the beneficiary if drug administration is verified by the participating CAP physician. This provision remains unchanged.

Under the revised CAP claims payment process, the approved CAP vendor will bill Medicare for the CAP drug that has been provided. In most cases Medicare will pay the claim upon receipt. If the beneficiary has a supplemental insurance policy, and the supplemental insurer has a crossover agreement with Medicare, the claim automatically will cross over to the supplemental insurer for payment. The supplemental insurer will pay its share. Upon receipt of payment from the supplemental insurer the approved CAP vendor may bill the beneficiary for any residual amount. For beneficiaries who

do not have a supplemental insurance policy, the approved CAP vendor may bill the beneficiary after payment by Medicare.

However, in either case, the approved CAP vendor may not collect any coinsurance owed from the beneficiary or his or her supplemental insurer unless it has verified that the drug was administered. If the approved CAP vendor believes that the drug was administered but later learns that it was not, the approved CAP vendor must refund any coinsurance collected to the beneficiary and his or her supplemental insurer, as applicable.

In addition, we are finalizing § 414.914(i)(2), so that the approved CAP vendor must promptly refund any payment made by CMS if the vendor has been paid for drugs that were not administered. We are implementing our proposal to interpret the term "promptly" to mean 2 weeks so that the approved CAP vendor would have 2 weeks from the date that they were notified that they had been paid for a drug that had not been administered to the beneficiary to refund any payment for the claim made to the designated carrier and refund any cost sharing collected to the beneficiary and his or her supplemental insurer. We are not implementing a penalty if the refund of any cost sharing collected in error exceeds the two week time frame because section 1847B of the Act does not provide for such a remedy.

f. Approved CAP Vendor Appeals for Denied Drug Claims

In the March 4, 2005 proposed rule (70 FR 10757 through 10758) and the July 6, 2005 IFC (70 FR 39054 through 39057), we discussed the development of the CAP dispute resolution process and the limited applicability of the traditional Medicare fee for service appeals process to an approved CAP vendor's dispute of CAP drugs claims that are denied by the CAP-designated carrier. We stated that the approved CAP vendor could file appeals as a Medicare supplier consistent with the rules at 42 CFR part 405, subpart I. For the purposes of the appeals regulations at Part 405, Subpart I, we indicated that a local carrier's initial determination of the participating CAP physician's drug administration claim was an initial determination regarding payment of the approved CAP vendor's drug claim. Thus, the approved CAP vendor was to be considered a party to any redetermination of the drug administration claim by the local carrier. In addition, the approved CAP vendor would be considered a party to an initial determination on the claim for

payment for the drug product that the approved CAP vendor filed with the CAP-designated carrier.

We also specified that appeals of either initial determination would be filed with the local carrier. We stated that the local carrier, rather than the designated carrier, possessed all information necessary to adjudicate an appeal in this situation. Such information included local coverage decisions, medical necessity determinations, and information regarding payment of drug administration claims. A dispute resolution process was set forth in § 414.916.

Under our initial implementation of the provision that authorized CAP, this alternative approach provided party status to the approved CAP vendor on the participating CAP physician's drug administration claim. This was necessary because an approved CAP vendor was not permitted to receive payment for a CAP drug until the corresponding drug administration claim was submitted by a participating CAP physician. Payment for the approved CAP vendor's claim was authorized when the participating CAP physician's claim and the approved CAP vendor's claim were matched in the system.

However, changes to the claims processing requirements and the addition of a post-payment review process required by section 108(a)(2) of the MIEA-TRHCA (discussed above in this section) eliminate the approved CAP vendor's dependency on a participating CAP physician's filing of a drug administration claim in order to receive payment for a CAP drug. Accordingly, the approved CAP vendor no longer needs party status on the drug administration claim submitted by the participating CAP physician. Instead, under the MIEA-TRHCA, the approved CAP vendor's drug claim may be paid by the CAP-designated carrier once it is received. This determination made on the claim constitutes an initial determination as defined in § 405.924. The approved CAP vendor is considered a party to this initial determination and may request a redetermination and subsequent appeals consistent with the process established under 42 CFR part 405, subpart I.

The changes to CAP claims processing in this final rule with comment period that conform to the MIEA-TRHCA result in two scenarios that create appeals rights for the approved CAP vendor with respect to their drug product claim: (1) Prepayment denials of the approved CAP vendor's claim made by the CAP-designated carrier

(based on information from the local carrier that the payment for the drug should be denied as excluded or non-covered); and (2) post-payment denials by the CAP-designated carrier based on the post-payment review process established under the MIEA-TRHCA.

Therefore, as proposed in the CY 2008 PFS proposed rule (72 FR 38156), we are making the following clarifications regarding the CAP appeals process for an approved CAP vendor's denied drug claims:

- For prepayment denials, the approved CAP vendor, as a supplier, has a direct right to appeal the initial determination made by the designated carrier on its drug product claim. The local carrier will conduct the redetermination on prepayment denials. It is the most appropriate entity to review prepayment denials since it is most familiar with the relevant coverage policies for that jurisdiction. We acknowledge that this process differs from a traditional fee-for-service appeal since the redetermination will not be conducted by the contractor that issued the initial determination.

- For the post-payment review process, an initial determination will be considered re-opened if the CAP-designated carrier selects the drug claim for review. If the CAP-designated carrier cannot verify administration or cannot determine that the drug is covered or medically reasonable and necessary, the CAP-designated carrier will issue a revised determination to deny coverage of the drug product claim. The CAP-designated carrier will then determine whether an overpayment exists, and if so, will recover the overpayment. As a supplier, the approved CAP vendor would then have the right to request a redetermination of the revised coverage determination, and the overpayment assessment. The CAP-designated carrier will process the redetermination.

We received no comments on this topic; therefore, we are finalizing the proposed conforming changes to the CAP appeals process as described herein.

g. Definition of Exigent Circumstances

Sections 1847B(a)(1)(A)(ii) and 1847B(a)(5)(A)(ii) of the Act require that each physician be given the opportunity annually to elect to obtain drugs and biologicals through the CAP and to select an approved CAP vendor. Section 1847B(a)(5)(A)(i) of the Act allows for selection of another approved CAP vendor more frequently than annually in exigent circumstances as defined by CMS.

In the CY 2005 PFS final rule with comment period (70 FR 70258), we

stated that participating CAP physicians would have the option of changing approved CAP vendors or opting out of the CAP program on an annual basis. We also provided the circumstances, as specified in § 414.908(a)(2), under which a participating CAP physician may choose a different approved CAP vendor mid-year or opt-out of the CAP. These circumstances are: (1) If the selected approved CAP vendor ceases to participate in the CAP; (2) if the participating CAP physician leaves the group practice that had selected the approved CAP vendor; (3) if the participating CAP physician relocates to another competitive acquisition area (if multiple CAP competitive areas are developed) or, (4) for other exigent circumstances defined by CMS.

We also identified a separate exigent circumstance relating to instances in which an approved CAP vendor declines to ship CAP drugs (when the conditions of new § 414.914(i) are met) in § 414.908(a)(5). We noted that in these cases, a physician may opt-out of his or her drug category, and because there is currently only one drug category for the CAP, then the participating CAP physician would be allowed to opt-out of the CAP altogether (70 FR 39081).

The CAP became operational on July 1, 2006. At that time, we believed that most issues raised by participating CAP physicians would relate to quality and service, which could be resolved through the approved CAP vendor's grievance process and the dispute resolution process conducted by the designated carrier. However, since then, we have been contacted by a few participating CAP physicians who have requested termination of their election agreement because they misunderstood the CAP program or determined that it was not a viable option for their practice.

These instances demonstrate that a practice might wish to leave the program for other business reasons that are unrelated to the approved CAP vendor's performance. However, we continue to believe that opportunities for leaving the CAP outside the annual election process should be limited because the CAP was designed as a program in which physicians would make an annual decision to participate, as consistent with sections 1847B(a)(1)(A)(ii) and 1847B(a)(5)(A) of the Act.

Therefore, in the CY 2008 PFS proposed rule (72 FR 38156), we proposed to define an additional exigent circumstance for opting out of the CAP. We proposed that within 30 days of the effective date of the election agreement, the participating CAP physician may

submit a written request to terminate his or her participation in the CAP. The request would be sent to the designated carrier under the dispute resolution process, and the designated carrier would determine within 1 business day whether the request was related to the service provided by the approved CAP vendor. If so, the designated carrier would refer the participating CAP physician to his or her approved CAP vendor's grievance process to further determine whether any appropriate and reasonable steps could be taken to resolve the identified issue.

We proposed that the approved CAP vendor would have 2 business days to respond to the participating CAP physician's concern, consistent with § 414.914(f)(5). If the approved CAP vendor is unable to identify a solution for resolving the issue that is consistent with the CAP statute, regulations, contracts and guidance, and that is acceptable to the physician, then the participating CAP physician would be referred back to the designated carrier for assistance under the dispute resolution process. We also proposed that the participating CAP physician's request would be handled under the dispute resolution process because protocols and defined time frames have already been developed for handling participating CAP physician and approved CAP vendor complaints in this set of procedures.

We proposed that if the designated carrier does not believe that the participating CAP physician's request is related to an issue that could be resolved by the approved CAP vendor, then the designated carrier would conduct an investigation and attempt to resolve any issues identified in the physician's request to terminate his or her CAP election agreement. If the designated carrier is unable to resolve the situation to the physician's satisfaction within 2 business days, then it can either make a recommendation to CMS that the physician be permitted to terminate his or her CAP election agreement, or request a 2-day extension to continue examining the issue. We stated that we believed that 4 business days would be sufficient to conclude this process because it would give the designated carrier time to gather information from other affected parties, such as the participating CAP physician's local carrier, but still prepare a speedy summary of the issues involved in the physician's request.

Under our proposal, after the 2-day or 4-day period, as applicable, the designated carrier would forward its recommendation and the physician's request to CMS. We would then review

the recommendation and make a final decision within 2 business days from the date that we received the request.

We proposed that if the participating CAP physician demonstrated that remaining in the CAP was a significant burden, then we would allow that physician to terminate his or her participation in the program. We would inform the designated carrier of our decision, which the designated carrier would then communicate to the participating CAP physician in writing. As part of this process, the physician's termination date for his or her CAP election agreement would be determined and communicated to all parties involved, including the physician's local carrier.

Conversely, if we did not believe that the physician demonstrated that CAP participation constituted a significant burden, then we would not allow the physician to terminate his or her CAP contract. Subsequently, we would inform the physician of our decision in writing via the designated carrier. We would also include a recommendation for corrective action.

In the CY 2008 PFS proposed rule, we also proposed that, even if we agreed to terminate the participating CAP physician's CAP election agreement, the physician would still be required to continue to cooperate in any post-payment review and appeal of claims for drugs that the approved CAP vendor had already provided and been paid for. The physician would also have to make arrangements with the approved CAP vendor for the return of any unused drugs that had not been administered to the beneficiary prior to the effective date of the physician's termination from the CAP. If the approved CAP vendor had billed CMS for drugs that had not yet been administered to a beneficiary, then the vendor would be required to correct the claim and return any overpayment.

Comment: We received several comments that supported defining an additional exigent circumstance for leaving the CAP because of a burden on the practice. Several commenters addressed the timeframe for leaving the CAP. Of these comments, all supported a 30-day timeframe, though several encouraged a longer window. Commenters who encouraged a longer time period believe that 30 days was insufficient time to determine the suitability of the CAP for their practice.

While most commenters agreed that a demonstration of burden should be required, one commenter stated that allowing physicians to opt-out for any reason would be desirable. One commenter suggested that physicians should be allowed to opt-out of the CAP

at any time for any reason. Several commenters asked that the opt-out process be simplified. Another commenter requested that the process for determining whether to grant a physician's request to leave the CAP be outlined.

Response: Based on the comments, we are revising our proposal to make it more flexible. While we recognize the concerns raised by commenters who recommended that we allow physicians to leave the CAP for any reason at any time, we continue to believe that there should be limits on a participating CAP physician's ability to leave the CAP. The CAP statute contemplates an annual election process. Our proposal to allow a 30-day period for opting out because of a burden is based on our authority to specify "exigent circumstances," and we do not believe it would be appropriate to allow physicians to opt-out under this process without some exigency that makes termination of CAP participation necessary. However, in recognition of these comments, and because we agree that participating CAP physicians should have a sufficient opportunity to assess the suitability of the CAP for their practice, we are making the following changes to the opt-out process.

First, we note that we intend to take a broad view of what would constitute a burden to the practice resulting in an "exigent circumstance." We believe that a broad view is appropriate because there may be many reasons why a participating CAP physician may find CAP participation more burdensome than he or she expected, and we do not wish at this time to place a limit on what those reasons may be. As we gain experience with this process, we may in a future rulemaking specify a list of "exigent circumstances" or prescribe more specific standards for what constitutes an "exigent circumstance" for purposes of the opt-out process; however, for now we will assess requests on a case-by-case basis under the process described in this preamble and set forth in the regulations at § 414.908.

In response to comments seeking greater flexibility in the process and a longer window in which to assess the CAP's suitability for the physician's practice, we are implementing a two-tiered process that would both expand the initial time frame for requesting to opt-out of the CAP and would allow for requests to opt-out at any time based on a change in circumstances that was not previously known to the participating CAP physician. We believe that such a process, which we outline below, strikes a balance between providing

participating CAP physicians with flexibility to opt-out of the CAP when participation is burdensome, while still placing appropriate limits on a physician's ability to leave the CAP outside the annual election process.

Thus, under the two-tiered process we are finalizing in this rule, we are changing to 60 days the initial period during which a physician can request termination of his or her CAP participation agreement as a result of exigent circumstances. We agree with commenters that allowing physicians more time to determine whether the CAP is suitable for their practices is advisable. We believe that an initial 60-day period will allow the participating CAP physician time to make a more complete assessment of the CAP's suitability. Although certain burdens will be likely to be apparent immediately, the first 30 days may be a period with a steep learning curve for the practice as it adapts to the CAP drug ordering process, and the first 30 days may involve working out any "start up" issues within the practice or with the approved CAP vendor. For this reason, the first 30 days may not be a fully representative time period during which to assess ongoing CAP participation. We believe an additional 30 days of CAP participation would be sufficient to identify, in the vast majority of cases, whether participation will constitute a burden to the practice.

Under this process, therefore, if a participating CAP physician's election agreement was effective on January 1, 2008, then he or she would have until March 1, 2008, to request to terminate participation in the program if CAP participation results in a burden to the practice. In addition, based on the concerns raised by commenters, we will allow physicians to leave the CAP at any time after the first 60 days if they can show that a change in circumstances that was not known to the practice *previously* results in a burden to the practice. As noted above, we believe that in the vast majority of cases participating CAP physicians will be able to identify a burden, if any, within the first 60 days. However, we also recognize that issues may arise during the course of the year that would result in an "exigent circumstance," but that were not known to the participating CAP physician during the first 60 days of CAP participation. In such instances, we agree with commenters that physicians should have a longer window to request an opt-out.

For purposes of the two-tiered process, then, examples of burdens that we would expect a practice could identify within the first 60 days may

include difficulties with CAP billing or drug ordering requirements, or documentation that the practice's initial understanding of these requirements was based on inaccurate information provided by a third party. Examples of burdens that might arise after the initial 60 days could include a change in practice personnel, patient population, computer systems, or vendor behavior that makes it harder to participate in the program. Where an opt-out request is submitted after the initial 60 days, we will require the participating CAP physician to demonstrate the request is based on information that he or she did not have within the first 60 days.

All requests to terminate participation, whether within the first 60 days or thereafter, would be submitted to the CAP-designated carrier and processed under the dispute resolution process. The request would need to document the physician's burden. Upon completion of the process outlined in proposed § 414.917, we would make the decision about whether the participating CAP physician's participation in the CAP will be terminated.

If the physician has not demonstrated that CAP participation represents a burden for his or her practice—either during the first 60 days or, if thereafter, as a result of a change in circumstances that was not known to the practice previously, then we would not allow the physician to terminate his or her participation in CAP because, as noted above, we continue to believe that a participating CAP physician's ability to opt-out of the CAP under this process should be limited to "exigent circumstances," as contemplated by the statute and our regulations.

We would inform the physician of our decision in writing via the designated carrier. We would also include a recommendation for corrective action, if appropriate. For example, if the reason that the CAP participating physician wanted to leave the program was that the approved CAP vendor was not delivering drugs timely, the designated carrier would investigate the situation. If it found that the approved CAP vendor was complying with our regulations on drug delivery at § 414.914(f) and § 414.902 but that the participating CAP physician was not ordering drugs consistent with the vendor's procedures, then the CAP-designated carrier could educate the physician about the proper drug ordering procedures and facilitate a discussion between the approved CAP vendor and the participating CAP physician about how the physician could order drugs in a way that met the

needs of his or her practice and the drug ordering requirements of the CAP vendor. The CAP-designated carrier would document the result of that discussion in writing. The participating CAP physician would have the right to request a reconsideration of our decision as specified in § 414.916(c). We are revising § 414.916(c) to clarify that the physician reconsideration process would apply to reconsiderations of our decision on whether the participating CAP physician may opt-out of the CAP.

Based on our experience with the program, we continue to believe that handling all requests to terminate CAP election under the dispute resolution process is reasonable and straightforward. We further believe the use of our pre-existing process will not create unnecessary delays in processing opt-out requests, particularly in light of the short time frames we have specified for responding to opt-out requests. Moreover, we believe the dispute resolution process is sufficiently detailed that it provides an ample description of how a physician's request to terminate CAP participation will be assessed.

Physicians will still be required to return unused CAP drugs and to complete any required CAP claims processing activities as described in proposed § 414.917. The notification to a physician will also include the end date of CAP participation in order to facilitate an orderly and efficient changeover between the CAP and ASP payment systems.

Therefore, we are finalizing § 414.908 and § 414.917 as proposed, subject to the changes described in this section. (We are making an additional technical change to § 414.908 to consolidate the "additional opt-out" provision, currently set forth at § 414.908(a)(5), with the other opt-out provisions at § 414.908(a)(2). We believe this nonsubstantive change will improve the clarity of the regulations.) Finally, we also are finalizing § 414.916(c) as amended as described in this section.

h. Transporting CAP Drugs

Although section 1847B(b)(4)(E) of the Act provides for the shipment of CAP drugs to settings other than a participating CAP physician's office under certain conditions, we did not propose to implement the CAP in alternative settings. In the July 6, 2005 IFC (70 FR 39047), we described both comments that supported the idea of allowing participating CAP physicians to transport drugs to multiple office locations, and comments that raised concerns about the risk of damaging a drug that has not been kept under

appropriate conditions while being transported.

As stated in § 414.906(a)(4), we implemented the CAP with a restriction that CAP drugs be shipped directly to the location where they will be administered. However, we were aware that physicians may desire to administer drugs in alternative settings, especially in a home. We sought comment on how this could be accommodated under the CAP in a way that addresses the concerns about product integrity and damage to the approved CAP vendors' property expressed by the potential vendors.

Several comments submitted in response to the July 6, 2005 IFC suggested either narrowing or removing the restriction on transporting drugs to other locations. Commenters believed that physicians, particularly those who specialize in oncology, and their staff are knowledgeable about drug stability and handling, and therefore, were capable of assuming this responsibility. Other commenters indicated that transporting the drug to another office location may allow for flexibility in scheduling patient visits. It would allow practices with satellite operations that are not open every business day to receive shipments of CAP drugs at another practice location and then to administer the drugs in the satellite office.

We also received several comments discussing the impact of CAP-delivery times on rural clinics and offices with satellite locations. Many of these responses discussed how easing the restriction on transporting CAP drugs between locations would be welcome in rural areas and for satellite offices with limited hours.

These comments and our experience with the CAP thus far have caused us to consider revising our policy. Therefore, in the CY 2008 PFS proposed rule (72 FR 38157), we requested comments on the potential feasibility of narrowing the restriction on transporting CAP drugs where this is permitted by State law and other applicable laws and regulations. We asked commenters to consider how such a policy could be constructed so that the approved CAP vendor could retain control over how the drugs that it owns are handled. We also requested comments on other issues that we should take into account concerning transportation of CAP drugs between practice locations listed on a physician's CAP election agreement form. Additionally, we also solicited comments on the following areas that we could use in the development of future proposals:

- How to structure requirements so that drugs are not subjected to conditions that will jeopardize their integrity, stability or sterility while being transported and steps to keep transportation activities consistent with all applicable laws and regulations;

- Whether any agreement allowing participating CAP physicians to transport CAP drugs to alternate practice locations should be voluntary. This means that approved CAP vendors would not be required to offer such an agreement and physicians who participate in the CAP would not be required to accept such an offer; and

- Whether the agreement should be documented in writing, and whether it is necessary to create any restrictions on which CAP drugs could be transported.

We stated that we were not making a specific proposal at this time but that we would use any information received to structure a future proposal in the event we made one.

Comment: Several commenters supported the concept of easing the restriction on transporting CAP drugs if this could be done safely, and if changes were consistent with applicable rules, regulations, and within the limitations of product stability and integrity. The restriction on transporting CAP drugs was perceived as a barrier to physician participation in the program. One commenter stated that elimination of the restriction would result in the same flexibility as the ASP (buy and bill) method of acquiring drugs. Another commenter expressed a strong desire to implement these changes promptly.

A few commenters also cautioned us to be certain that appropriate safeguards would be in place if we chose to ease the transportation restriction. One commenter asked that the safeguards be available for public scrutiny before they are implemented. Conversely, other commenters stated that a physician's certification or discretion were satisfactory.

Response: We are sympathetic to the concerns expressed by the commenters and expect to issue a proposal in the CY 2009 PFS proposed rule that would allow the transportation of CAP drugs from one physician practice location in certain circumstances. We further expect that our proposal would propose to permit transport of CAP subject to voluntary agreements between the approved CAP vendor and the participating CAP physician that complied with all applicable State and Federal laws and regulations and product liability requirements. We welcome comments on how to structure such a proposal.

i. Alternatives to the CAP Prescription Order Number

In the July 6, 2005 IFC (70 FR 39043 and 39049), we responded to several comments regarding the administrative burden that the CAP ordering and claims payment process imposes upon participating CAP physicians; specifically, activities associated with using and tracking the prescription order number were mentioned. We received additional comments on this issue in response to the IFC as well.

After the close of the comment period, we also received an inquiry from the current approved CAP vendor about the potential length of the CAP prescription order number and whether it could present a burden to participating CAP physicians. A 30-byte field is currently available on the electronic claim form for prescription numbers; however, it is not necessary for the prescription order number to be 30 bytes long. Typically, 15 or fewer total characters have been used by the approved CAP vendor.

The requirements for developing the CAP prescription order number are as follows: The first 9 characters are the approved CAP vendor's ID and the HCPCS code of the drug that is being billed; the approved CAP vendor sets the remaining characters. The assigned CAP prescription order number is captured in Loop 2410, REF02 (REF01=XZ) of the ANSI 4010A1 electronic claims transaction. This segment of the electronic claims transaction is part of a specific data format that Medicare claims must adhere to in order to meet national electronic standards for the automated transfer of certain health care data as mandated by the Health Insurance Portability and Accountability Act of 1996 (Pub. L. 104-191) (HIPAA).

Each prescription order number is unique to a dose of a CAP drug that is being shipped for administration to a particular beneficiary. The prescription order number is generated by the approved CAP vendor and, as stated in the July 6, 2005 IFC (70 FR 39042), each dose of a CAP drug is required to have a separate prescription order number. After the drug is administered, the participating CAP physician's drug administration claim is submitted with a no-pay line containing the prescription order number. The approved CAP vendor's claim for the CAP drug also contains the prescription order number.

When the CAP was implemented, the prescription order number was used in the claims matching process to facilitate accurate payment of the approved CAP vendor. Prior to payment, this system

paired an approved CAP vendor's drug claim to a participating CAP physician's drug administration claim using the prescription order number. A matching prescription order number between these two claims indicated that the drug had been administered.

Since the CAP began, the claims process has changed because of statutory changes. Section 108(a)(2) of the MIEA-TRHCA requires us to make payment upon receipt of an approved CAP vendor's drug claim and then to conduct a post-payment review of claims. As stated in the MIEA-TRHCA, the post-payment review process is intended to "assure that payment is made only for a drug or biological * * * if the drug or biological has been administered to a beneficiary."

Under this new process, the prescription order number still plays a pivotal role. Prior to the payment of the approved CAP vendor's drug claim, the CAP-designated carrier uses the prescription order number to check the claims processing system to ascertain whether the local carrier has adjudicated the drug administration claim. If the local carrier has done so, then the CAP-designated carrier will look to see whether the local carrier has determined that the CAP drug administered by the participating CAP physician is covered and is medically necessary. The local carrier's decision determines whether the CAP-designated carrier will pay the approved CAP vendor's drug claim. If the participating CAP physician's local carrier has not made a determination on the physician's claim and the CAP drug claim, then the designated carrier will pay the approved CAP vendor's claim upon receipt and use the CAP prescription order number to help verify drug administration on a post-payment basis.

The prescription order number is also still used in other CAP processes. Each dose of a CAP drug that is shipped by the approved CAP vendor is tracked using the prescription order number. Moreover, the prescription order number is particularly useful in certain situations such as those that involve recurring cyclic drug treatment regimens. In these cases, the prescription order number minimizes the possibility of confusion by serving as a unique differentiating factor between highly similar drug claims. Also, the prescription order number is valuable during instances in which the anticipated day of service submitted by the participating CAP physician differs from the actual date of drug administration. In these situations, the prescription order number would clarify

confusion stemming from discrepancies in dates. Overall, we believe that the prescription order number remains an appropriate and necessary tool to track the administration of a specific dose of a drug and for the accurate execution of the post-payment review process.

Although we believe that the use of the prescription order number is necessary to facilitate accurate review of CAP claims, we are aware that it may be considered an inconvenience by some potential participating CAP physicians and approved CAP vendors. Therefore, in the CY 2008 PFS proposed rule (72 FR 38158), we requested comments on alternative methods to accurately track the administration of specific doses of drugs in order to meet the requirements stated in section 108(a)(2) of the MIEA-TRHCA. These comments could then be used in the development of a proposal for future rulemaking.

Comment: We received a few comments on this issue. One commenter suggested that the CAP-designated carrier should simply match vendor and physician claims but did not provide any details about how that could be accomplished without the prescription order number. Another commenter stated that the CAP prescription order number was no longer needed to verify drug administration and should be eliminated. Instead they recommended that we should rely on the approved e-CAP vendor's verification of drug administration and the physician's records of drug administrations.

Response: While the records of participating CAP physicians and the CAP vendor are currently used in the post pay review process, the CAP prescription order number plays an important role in that it enables the designated carrier to identify the exact doses of a drug that was administered and provides a link between the approved CAP vendor's claim and the participating CAP physician's claim that is not available otherwise.

We do not believe the suggestions that we have received thus far would allow us to discontinue the use of the prescription order number. The prescription order number allows us to better "assure that payment is made only for a drug or biological * * * if the drug or biological has been administered to a beneficiary" since it tracks the administration of a specific dose of a drug, which allows CMS to match the vendor and the physician claim in the post pay review process. However, we would appreciate receiving other suggestions that would allow drug administration verification on a dose specific basis. Since we did not make a specific proposal about this

issue, we will not make any changes at this time to the requirement that the CAP prescription order number be supplied by the approved CAP vendor and included on claims from both the participating CAP physician and the approved CAP vendor.

j. Prefilled Syringes

In the July 6, 2005 IFC (70 FR 39061), we described public comments which stated that participating CAP physicians could not vouch for the quality of products that were opened by an approved CAP vendor for repackaging, for mixing the drug with other drugs or injectable fluids (admixture), or for removing a part of the contents to supply the exact dose for a beneficiary. Several commenters recommended that approved CAP vendors deliver their products in the same form in which they are received from the manufacturer, without opening packaging or containers, mixing or reconstituting vials, or repackaging. Specifically, the commenters were concerned about the capabilities of individuals who mix the drug, as well as shipping conditions, storage, and stability.

We responded by stating that the CAP is not intended to require approved CAP vendors to perform pharmacy admixture services (for example, to furnish reconstituted or otherwise mixed drugs repackaged in IV bags, syringes, or other containers that are ready to be administered to a patient) when furnishing CAP drugs. Admixture services for injectable drugs require specialized staff, training, and equipment, and these services are subject to standards such as United States Pharmacopoeia Chapter 797, Pharmaceutical Compounding—Sterile Preparations. These requirements have significant impact on drug shipping, storage, and stability requirements, as well as system cost and complexity. As stated in § 414.906(a)(4), the approved CAP vendor must deliver “CAP drugs directly to the participating CAP physician in unopened vials or other original containers as supplied by the manufacturer or from a distributor that has acquired the products directly from the manufacturer.”

Since issuing the July 6, 2005 IFC, we have become aware that bevacizumab (Avastin®) is being used for the treatment of exudative age-related macular degeneration (wet AMD) in very small doses. Although this is an off label use, it is gaining acceptance among ophthalmologists who treat wet AMD, and this use has been the subject of several carriers’ local coverage determinations. Bevacizumab is

considerably less expensive than certain other drugs used in the treatment of wet AMD.

The smallest commercially-available package of bevacizumab is a 100mg single use vial, while a dose used to treat wet AMD is approximately 1mg. Some local carriers who have issued coverage instructions for the use of bevacizumab in the treatment of wet AMD allow physicians to obtain these small doses of drug from a pharmacy that is capable of preparing sterile products. We expect to issue instructions that will allow participating CAP physicians to use the furnish as written option, as appropriate, and to obtain small doses of bevacizumab outside of the CAP in prefilled syringes if their local carrier’s coverage determinations allow such a practice and if it is consistent with applicable laws and regulations. We believe that this approach will minimize the waste associated with using a 100mg single use vial for the treatment of wet AMD and will increase the flexibility for participating CAP physicians by making an alternative quantity of this drug available to participating CAP physicians whose carriers have applicable policies.

However, this option is not available in all areas. Therefore, we stated that we are considering reassessing our policy on the use of prefilled syringes to determine whether it would be feasible to make the option of using prefilled syringes supplied by an approved CAP vendor available to all physicians who participate in the CAP, rather than requiring physicians to go outside the CAP in order to obtain CAP drugs in prefilled syringes. In the CY 2008 PFS proposed rule (72 FR 38159), we requested comments on whether allowing approved CAP vendors to repackage CAP drugs in certain situations may be beneficial to beneficiaries, the program, and to the physicians who participate in it.

In considering whether to propose a change to our regulations in the future, we also solicited comments on:

- Whether approved CAP vendors are likely to be pharmacies or have access to pharmacy services with trained personnel and facilities for the small scale preparation of sterile drug products in response to a specific prescription order for a specific patient;
- Whether an approved CAP vendor should be given an opportunity to supply bevacizumab under the CAP if it is repackaged in a patient-specific dose consistent with applicable state laws and regulations upon request from a participating CAP physician;

- Whether this sort of activity should be restricted to bevacizumab, or possibly phased-in for other CAP drugs. If we were to apply this sort of policy to other CAP drugs, we would also have to determine how phasing-in might occur, which drugs it should apply to and whether the preparation of admixtures (including the preparation of sterile syringes, minibags, and mixing of drugs and solutions intended for intravenous administration) should be allowed as well;

- How this sort of service could be limited to participating CAP physicians who voluntarily agree to use it, and whether such an agreement should be made in writing between the approved CAP vendor and the participating CAP physician;

- How such a program could be structured so that the service and staff engaged in providing the service would be required to meet all applicable laws (including Stark, Anti-kickback, and State pharmacy laws), as well as regulations for the preparation of sterile products, (including standards for product integrity and sterility);

- Whether the cost of preparing such product would be included in the CAP vendor’s bid price; and

- Whether any other important elements should be evaluated if we consider changing CAP policy on prefilled syringes in the future.

Comment: We received several comments on these issues. Overall, responses were generally equally divided among those who supported prefilled syringes, those who advocated a cautious approach, and those who opposed the practice.

Those who opposed making prefilled syringes available through the CAP cited stability and sterility concerns. Those commenters also raised concerns about whether the CAP vendor’s preparation of a particular drug product for an off-label use by participating CAP physicians would violate existing drug law because of the potential scale of an approved CAP vendor’s activities and because the drug was being prepared for use in a manner other than as described in its FDA-approved labeling. Several commenters urged that caution be used in developing changes to the aspects of the CAP that are discussed above in this section, but many of these commenters were not completely opposed to the preparation of prefilled syringes by approved CAP vendors.

Several commenters were quite supportive of using prefilled syringes. One commenter stated that pharmacy preparation of prefilled syringes was regarded as a “convenient and safe practice” and would avoid both waste

and some of the risk associated with transferring sterile products. Another commenter also recommended that a mechanism to pay for the preparation and waste associated with the process be established.

There was a general point of agreement between commenters who urged a cautious approach and those who agreed with the concept of prefilled syringes. These commenters agreed that that additional flexibility or enhancements to the CAP would be welcome provided that they did not affect beneficiary safety and were consistent with applicable laws, regulations, product stability, and product integrity requirements.

Response: We appreciate the comments on prefilled syringes and we will consider whether to develop a proposal that is consistent with applicable laws, regulations, product stability, and product integrity concerns in future rulemaking. Because we did not propose a change to our current regulations on the use of prefilled syringes in the CAP, they remain unchanged for the present time. We may make a proposal in the future.

k. Contractual Provisions

Section 1847B of the Act is generally silent on the subject of disputes surrounding the delivery of drugs and the denial of drug claims. However, section 1847B(b)(2)(A)(ii)(III) of the Act states that a grievance process is a quality and service requirement expected of approved CAP vendors. In the July 6, 2005 IFC (70 FR 39055 through 39058), we described the process for the resolution of approved CAP vendors' claims denials and the resolution of participating CAP physicians' drug quality and service complaints. We encouraged participating CAP physicians, beneficiaries, approved CAP vendors, and the designated carrier to use informal communication as a first step to resolve service-related administration issues. However, we recognized that certain disputes would require a more structured approach, and therefore, we established processes under § 414.916 and § 414.917.

Suspension and termination from the CAP were the only remedies described under the CAP dispute resolution processes. Having gained some experience with the CAP, we believe that having an intermediate level of remedy for less serious but persistent problems is desirable in order to bridge the gap between taking no action and suspension or termination of an approved CAP vendor.

We believe that additional contractual obligations, such as additional reporting requirements, could be useful, particularly if they provide an opportunity for the approved CAP vendor to come into compliance using objective goals and a set timeline. Therefore, in the CY 2008 PFS proposed rule (72 FR 38160), we requested comments on what types of potential contractual provisions could be used to encourage approved CAP vendors to comply with CAP requirements for less serious violations, such as missing reporting deadlines, or participation in inappropriate promotional strategies. We also requested comments on the following:

- The type of contractual provisions that would be suitable. For example, requests for specific or targeted reporting and monitoring activities in response to specific violations.
- Whether an approved CAP vendor's code of conduct could be used to address these types of less serious situations and how that could be accomplished; and
- Whether the CAP physician election agreement should be revised to include provisions to address participating CAP physicians' noncompliance with CAP rules or the CAP election agreement.

Comment: One commenter agreed with the use of contractual provisions, including additional reporting requirements, as an intermediate form of remedy in response to a CAP vendor's noncompliance with CAP requirements. The commenter also noted that a vendor code of conduct would be useful.

Response: We plan to develop a proposal for additional provisions that could be added to the CAP contract. These provisions would be used to encourage approved CAP vendors to comply with CAP requirements. We will propose such provisions in a future rulemaking period.

l. Finalizing Remaining Provisions of the July 6, 2005 Interim Final Rule with Comment Period

In this PFS final rule with comment, we are finalizing the portions of the July 6, 2005 IFC that were not finalized in previous rulemaking. We are also responding to other timely comments we received on the July 6, 2005 IFC that we have not responded to previously.

Comments that we will be addressing in this rule include the following:

- The use of e-prescribing in CAP.
- Updating CAP prices and data reporting.
- The application of Comprehensive Error Rate Testing (CERT) to CAP claims.

- The 14-day participating CAP physician billing requirement.
- The impact of CAP participation on clinical research.
- Licensure requirements for CAP pharmacies and distributors.
- Community mental health centers and participation in the CAP.
- Administrative and financial burden of CAP participation for physicians.

We have addressed drug transportation previously in this section of this final rule with comment period.

Basis and Scope (§ 414.900)

These provisions provide that the regulations in this subpart implement sections 1847A and 1847B of the Act. We received no comments on these provisions and we are finalizing the corresponding regulatory text at § 414.900 in its entirety.

Definitions (§ 414.902)

Section 414.902 lists the definitions used in 42 CFR Subpart K. We did not receive any comments about the revisions to this section that we made in the July 6, 2005 IFC (70 FR 39093). At this time, we are finalizing the regulatory text at § 414.902 as it currently reads.

Competitive Acquisition Program as the Basis for Payment (§ 414.906)

Section 414.906 specifies how payment for CAP drugs is determined, including vendor responsibilities for billing, shipment and delivery; computation of the payment amount; substitution of CAP drugs and resupply of a participating CAP physician's drug inventory.

i. 2005 Comments

In the July 6, 2005 IFC (70 FR 39074), we discussed the methodology used to update CAP drug prices during the bidding process. We responded to comments that suggested that single price updates for CAP drugs should be tied to changes in ASP prices. We stated that we did not believe that there had been enough experience with the ASP payment methodology to update the bids based on growth in the ASP. We also solicited comments on this method of updating single drug prices to the payment year in order to develop and refine the CAP in the future.

(a) Updating CAP Prices and Data Submission

Comment: We received comments about updating CAP drug prices more frequently than annually. One commenter suggested that we should consider quarterly data submissions and

pricing updates even during the phase in period in order to produce greater savings in instances where vendors' overall costs for CAP drugs were declining, while providing greater protection for vendors in instances where vendors were experiencing cost increases. Another commenter encouraged us to compare CAP prices to ASP prices using the most recent data available and to account for manufacturer price adjustments in a timely manner.

Response: In the July 6, 2005 IFC (70 FR 39076), we stated, "when the administrative mechanisms of the CAP are operational and vendors have more experience under the program, we will consider whether more frequent reporting (of reasonable net acquisition costs) would be appropriate." Section 414.914 requires that the CAP contract must provide for the disclosure of the approved CAP vendor's reasonable, net acquisition costs for a specified period of time, not to exceed quarterly and provide for appropriate adjustments as described in § 414.906(c)(1). This section describes the computation of an annual update to the payment amount and allows updates more often than annually but no more often than quarterly in any of the following cases: introduction of new drugs; expiration of a drug patent or availability of a generic drug; material shortages that result in a significant price increase for the drug; and withdrawal of a drug from the market. Also, the CAP payment amount is limited by the weighted payment amount established under section 1847A of the Act across all drugs for which a composite bid is required in the category, and limited by the payment amount established under section 1847A of the Act for each other drug for which the approved CAP vendor submits a bid. It is not clear how the commenter is proposing that we account for changes in manufacturer's price adjustments in a more timely manner. Because the CAP has been operational for 15 months, we are still gaining experience with the reporting and update mechanisms already in place. At present, we believe these processes are sufficient to address the needs of the CAP; however, as the program grows, we may consider other options, including more frequent price updates.

(b) Impact of CAP on Clinical Research

Comment: Some commenters stated that they were concerned that CAP participation would conflict with the Medicare National Coverage Decision (NCD) on Clinical Trials. Since the NCD enables Medicare to reimburse physicians for the current standard of

care drugs that are administered to beneficiaries in the control group of clinical trial protocols, commenters were concerned that physicians would not be able to enroll Medicare beneficiaries in clinical trials if drugs required in the protocol were not on the CAP drug list. In addition, some commenters expressed their concern that there was a lack of built in oversight in CAP to ensure that vendors would buy drugs directly from a manufacturer or wholesaler. The commenters were concerned that this could result in the acquisition of counterfeit product, and that as a result, such products could infiltrate clinical trials and compromise the results of cancer clinical research that a CAP physician might be participating in.

Response: As a result of an executive memorandum issued by the President of the United States in June 2000, we instituted the NCD in September 2000 as explained in our "September 2000 Program Memorandum" on clinical trials available at <http://www.cms.hhs.gov/ClinicalTrialPolicies/>. The NCD stipulates that Medicare will provide payment for routine costs associated with qualifying clinical trials and for items or services needed to treat complications arising from participation in such trials. The NCD was revised in July 2007 as outlined in CAG-00071R, the "Decision Memorandum for the Clinical Trial Policy," which may be found at <https://www.cms.hhs.gov/mcd>. More information about the National Coverage Decision on Clinical Trials can be found on the CMS Web site at <http://www.cms.hhs.gov/ClinicalTrialPolicies/> and through a Medicare Learning Network article at <http://www.cms.hhs.gov/MLNMattersArticles/>.

We are very aware of the importance of clinical trial research in the treatment of cancer, and we do not believe that CAP participation has imposed any undue hardships on participating CAP physicians or their Medicare patients who engage in such activities. Participating CAP physicians do not have to buy and bill for the medications they receive from the approved CAP vendor. The vendor is responsible for billing the designated carrier and the beneficiary. Thus, if the standard of care drug needed for the control group of a research protocol is on the CAP drug list, the participating CAP physician may order the medication from the approved CAP vendor. This should not affect the participating CAP physician's ability to enroll Medicare patients in clinical trials. Moreover, participating CAP physicians may still purchase and bill for medications that are not on the

CAP drug list through the ASP system, which would allow them to obtain the non-CAP drugs required in a research protocol. If a particular NDC for a drug is not on the CAP drug list but is part of the research protocol, a participating CAP physician may buy the medication on their own and bill for it via the "furnish as written" provision, which allows the physician to bill for the drug under the ASP methodology in that instance, even though it is on the CAP drug list.

Though we have had no reports that CAP physicians have been prevented from engaging in clinical trial research because of their CAP participation, we are mindful that this could be an issue because of the way some studies are structured. In the event that we receive comments that demonstrate that this has become a problem in the future, we will address the issues accordingly and possibly propose mechanisms to facilitate participation in clinical trial research and the CAP.

We would also like to reemphasize that CAP is a voluntary program. If physicians do not believe that the "furnish as written" option and the CAP drug list are sufficient to meet their clinical research needs, then they may decline to join the CAP and continue to purchase and bill for medication under the ASP system.

We also are cognizant of the importance of preserving drug quality and integrity in the CAP and have structured the program accordingly. The importance of drug quality and oversight are recognized in both the vendor bidding process and in the CAP dispute resolution process administered by the designated carrier. We have discussed our concern for maintaining CAP drug quality in the program as a whole on several occasions, most recently in the CY 2006 PFS final rule with comment period (70 FR 70244). Section 1847B of the Act and § 414.908(b) delineate several requirements that vendors must meet in order to be selected to participate in the CAP, including an ability to ensure product integrity, at least 3 years experience in furnishing Part B Injectable drugs, and acquisition of all CAP drugs directly from the manufacturer or from the distributor that has acquired the products directly from the manufacturers. After an entity has been awarded a contract, we work closely with the CAP-designated carrier and the approved CAP vendor to monitor and respond to any concerns that are raised by participating CAP physicians under the dispute resolution process.

We have not received any complaints regarding CAP drug quality and integrity. If such an event were to occur, it would be investigated and resolved promptly so that patient health and safety would not be jeopardized. In light of all of these requirements and protections, we do not believe that research and CAP participation are incompatible.

At this time, we are finalizing the remaining provisions of this section.

Competitive Acquisition Program (§ 414.908)

This section specifies the process for a physician to select an approved CAP vendor. It also details the responsibilities of a participating CAP physician, such as including the specific information required on the prescription order, notifying the CAP vendor about changes in drug administration, and adhering to the timeframe for submission of claims.

Moreover, § 414.908 delineates the process for selecting approved CAP vendors. It also outlines additional factors that are considered both during and after the vendor selection process such as exclusion of entities from participation in Medicare or other Federal health care programs under section 1128 of the Act.

i. 2005 Comments

(a) Physician Administrative and Financial Burden

Comment: We received several comments from individual physicians and physician groups expressing their concern that CAP could place a significant burden on physicians. Some commenters stated that the requirement to maintain a separate inventory of CAP drugs will increase physicians' administrative burden and costs. Others indicated that physicians would have no incentive to participate in the CAP unless these extra administrative costs could be reimbursed. One commenter indicated that the program was impractical and economically unfeasible.

Response: In the July 6, 2005 IFC (70 FR 39049), we discussed the issue of administrative burden. Although we agree that a physician may have to make some adjustments in his or her practice in order to comply with the requirements of the CAP, we believe that the relief from the financial burden of purchasing drugs and billing Medicare for them will be a substantial benefit for many physicians. We do not believe that the clerical and inventory resources associated with participation in the CAP exceed the clerical and

inventory resources associated with buying and billing drugs under the ASP system. A physician is free to design his or her practice in a way that minimizes the extent of changes necessary to comply with the CAP requirements. For example, an electronic inventory of CAP drugs is required, but separate drug storage is not; it is a suggested option if such a procedure makes it easier on the physician's practice to track the CAP drugs. We recognize that although a physician's staff or their software vendor may need to make system changes to bill using the CAP format and to accommodate the CAP modifiers and prescription numbers, these initial changes would be a one-time occurrence.

In the ASP system, the payment for clerical and inventory resources associated with buying and billing for drugs is bundled into the drug administration payment under the physician fee schedule. We have adopted this same logic in the CAP and believe that the drug administration payment is sufficient to cover any associated expenses of participating in the CAP.

If a physician perceives that CAP participation would be more burdensome than the ASP system, then he or she is under no obligation to join the CAP because it is a voluntary program. Additionally, as described in other parts of this rule, participating CAP physicians may also petition to terminate their CAP election due to exigent circumstances through the dispute resolution process in the event that they find the participation in the program becomes a burden.

Comment: One commenter expressed disappointment that community mental health centers (CMHCs) cannot elect to participate in the CAP.

Response: As noted in the July 6, 2005 IFC (70 FR 39030), CMHCs can not elect to participate in the CAP for provision of Part B drugs. The CAP statute is clear that only physicians may elect to have section 1847B of the Act apply in lieu of the ASP payment methodology.

(b) E-Prescribing

Comment: One commenter recommended that CAP vendors should be capable of accepting and submitting e-prescribing transactions in accordance with the final e-prescribing standards issued for Medicare Part D. The commenter reasoned that vendor compliance would not be an undue hardship because vendors already will have a fairly rigorous technical infrastructure in place.

Response: Section 101 of the MMA amended title XVIII of the Act to establish a voluntary prescription drug

benefit program. The MMA electronic prescription program provisions found in section 1860D-4(e) of the Act apply to the electronic transmission of prescription and certain prescription-related information for Medicare Part D drugs for Part D eligible individuals. The Part D e-prescribing requirements do not apply to the electronic transmission of prescriptions and prescription related information for Part B drugs unless those prescriptions are written for Part D eligible persons and the prescribed drug is a Part D drug. Prescription Drug Plan (PDP) sponsors Medicare Advantage (MA) organizations offering Medicare Advantage-Prescription Drug Plans (MA-PD) are required to establish electronic prescription drug programs to provide for electronic transmittal of certain information to the prescribing provider and dispensing pharmacy and pharmacist. Prescribers and dispensers of Part D drugs are not required to write prescriptions electronically, but those that do so would be required to comply with any applicable final e-prescribing standards that are in effect when they conduct electronic prescription transactions, or seek or transmit prescription information or certain other related information electronically.

We responded to a comment on whether participating physicians would be required to incorporate e-prescribing technologies into the CAP in the July 6, 2005 IFC (70 FR 39039). At that time, we stated that we would monitor the development of the program to see if some aspects of it could be adapted to the CAP. Since publication of the IFC, we have adopted three foundation standards (70 FR 67568), recognized six initial standards in a Request for Applications (RFA) (Available through <http://www.grants.nih.gov/grants/guide/rfa-files/FRA-HS-06-001.htm>), and conducted a pilot program in 2006 to test the six initial standards and their ability to interoperate with the foundation standards. More information about the MMA e-prescribing program and the outcome of the pilots can be found on the CMS Web site at <http://www.cms.hhs.gov/EPrescribing/>. The MMA requires the adoption of additional standards by the Secretary by April 1, 2008. We will continue to track the development of the e-prescribing program to see whether it would be appropriate to incorporate some of the program's elements into the CAP at a later date.

(c) The Comprehensive Error Rate Testing (CERT) Program and CAP Claims

The purpose of the CERT program is to monitor and report the accuracy of Medicare fee for service payments. In the July 6, 2005 IFC (70 FR 39038), we discussed CERT and how it would apply to CAP claims. While we anticipated that CERT would apply to CAP, the process had not been determined at that point. We received no additional comments on this issue and have implemented CERT review of CAP claims since publication of the July 6, 2005 IFC. CAP claims paid by the designated carrier may be selected for review in a manner consistent with other claims the carrier processes.

(d) 14-Day Billing Requirement

In the July 6, 2006 IFC (70 FR 39050), we summarized and responded to comments about the 14-day requirement for physicians to file claims for CAP drug administration. Although a number of commenters considered the time period to be too brief and were opposed to it, we decided to implement the 14-day requirement at § 414.908(a)(3)(x) because the approved CAP vendor's payment for drugs furnished under the CAP depended on a match between the vendor's drug claim and the physician's drug administration claim. Implementation of the post-payment review as mandated by section 108 of the MIEA-TRHCA has superseded our original implementation of CAP claims processing procedures, which had required a pre-payment claims matching process for CAP drug claims, and the 14-day billing requirement was not finalized in previous rules (70 FR 70260).

Comment: In 2006 several commenters asked us to allow at least 30 days or more for physicians to submit CAP drug administration claims. During this comment period, we also received several comments stating that the 14-day requirement be withdrawn because changes to the claims processing system made it unnecessary and such an action would encourage physician participation in the CAP.

Response: Our 14-day standard was based on a review of Medicare claims that showed approximately 75 percent of part B drug and drug administration claims were submitted within 14 days of the date of service. It was initially implemented as a means of facilitating the CAP claims matching process that was in effect prior to the implementation of the post-payment review process as mandated by section 108 of the MIEA TRHCA. As the

commenters indicated, a 14-day requirement is less than is allowed under claim submission requirements used in other parts of the program.

We agree that the claims processing changes required by Section 108 of MIEA-TRHCA have altered the role of the claims submission standard. However, we do not believe that it has eliminated the need for a claims-matching process under the CAP. Under the new payment process that resulted from the MIEA-TRHCA, the CAP-designated carrier also conducts a pre-payment review in which it checks for any local carrier decisions about medical necessity prior to paying for drug claims submitted by the approved CAP vendor. Retaining a claims submission requirement for participating CAP physician drug administration claims may prevent the agency from paying for drugs that have been denied on a medical necessity basis by the local carrier because when the local carrier reviews the physician's claim it makes a determination on whether the CAP drug that was administered was medically necessary. We are not eliminating the requirement for prompt billing altogether, as requested by commenters, because it will continue to facilitate a quicker determination that the drug can be administered.

However, we acknowledge that a somewhat longer claims submission standard would not adversely affect the post-payment review process because it still would allow for a relatively quick match between the claim for a particular dose of a CAP drug and the claim for its administration. Also, separate analyses of previous claims submission data and CAP drug claims lead us to conclude that the overwhelming majority of participating CAP drug administration claims are submitted within 30 days of the date of service. We further believe that, in light of the comments, increasing the 14-day claims submission requirement would make the CAP more appealing to physicians and provide them with greater claims submission flexibility.

Therefore, we are increasing the requirement for timely CAP drug administration claim submission from 14 days to 30 days. We are finalizing the requirements at § 414.908 to include this revision.

ii. Regulatory Text

At this time, we are finalizing § 414.908 as amended to reflect the changes discussed in this final rule with comment period.

The Bidding Process (§ 414.910)

This section outlines the specific criteria for the submission of a bidding price for a CAP drug, and specifies what costs should be included in the bid price. We received no comments on this provision and are now finalizing the regulatory text for § 414.910.

Conflicts of Interest (§ 414.912)

Section 414.912 states conflict of interest requirements and standards that vendor applicants and approved CAP vendors must meet in order to participate in CAP. We received no comments on this provision, and therefore, are finalizing § 414.912.

Terms of Contract (§ 414.914)

Section 414.914 outlines the contract provisions between CMS and the approved CAP vendor such as contract length and termination, and specific requirements that the approved CAP vendor must comply with.

i. 2005 Comments

(a) Licensure Requirements for Cap Pharmacies and Distributors

Comment: Some commenters requested clarification on the types of licenses that are required of CAP vendors. A few commenters also asked us to specify whether a CAP vendor will be operating as a pharmacy or as a wholesale distributor since licensing requirements and regulatory laws for these two types of entities can vary by state, and since pharmacies and distributors are two different models.

Response: As specified in § 414.914, approved CAP vendors and their subcontractors must meet applicable licensure requirements in each State in which it supplies drugs under the CAP. This includes appropriate licensure in States that the CAP vendor ships drug to even though the vendor does not maintain a physical establishment in these States. In the July 6, 2005 IFC (70 FR 39066), we stated that a vendor, its subcontractor, or both must be licensed appropriately by each State to conduct its operations under the CAP. Therefore, a vendor under the CAP would be required to be licensed as a pharmacy, as well as a distributor if a State requires it. It is the CAP vendor's responsibility to determine which State and national requirements it must adhere to. Based on our experience with the CAP, we are not persuaded by the comments that any changes to this policy are necessary at this time.

ii. Regulatory Text

We finalized portions of § 414.914 in the CY 2006 PFS final rule with

comment period (70 FR 70333) and are now finalizing the remainder of the regulatory text.

Dispute Resolution for Vendors and Beneficiaries (§ 414.916)

This section discusses the steps, timeframes, and requirements of the dispute resolution process that are available to an approved CAP vendor and beneficiaries to address the issue of denied CAP drug claims. It also describes the protocol that physicians would utilize to appeal the suspension of their CAP contract.

We did not receive any comment on this comments on this provision in response to the CY 2006 PFS proposed rule. However, a revision to this section will be made in light of the exigent circumstance discussion in section (g) of this section of the preamble. We are revising § 414.916(c) to clarify that the physician reconsideration process would apply to reconsiderations of our decision on whether the participating CAP physician may opt out of the CAP. We are finalizing § 414.916 at this time.

Dispute Resolution and Process for Suspension or Termination of Approved CAP Contract (§ 414.917)

This section discusses the steps and timeframes of the process available to participating CAP physicians for the resolution of quality or service issues concerning an approved CAP vendor.

We did not receive any comments on this section during the comment period for the July 6, 2005 IFC. Comments that we received on this section during the comment period for the CY 2008 PFS proposed rule are discussed above in this section. We are now finalizing the regulatory text for this section as described in this final rule with comment period.

Assignment (§ 414.918)

Section 414.918 specifies that payment for a competitively biddable drug may be made only on an assignment related basis. We received no comments on this provision and are now finalizing § 414.918.

Judicial Review (§ 414.920)

Section 414.920 outlines the areas under the CAP that are not subject to administrative or judicial review. We received no comments on this provision and are now finalizing this section.

m. Brief Summary of Comments We Are Not Addressing

In response to the FY 2007 IPPS final rule with comment period (71 FR 47870), we received a comment related to the payment rate for intravenous

immunoglobulin (IVIG) therapy in Medicare. We will not be addressing this comment since it is outside the scope of both the CY 2008 PFS proposed rule and the FY 2007 IPPS final rule with comment period. In addition, in response to the CY 2007 PFS proposed rule, one commenter recommended that we implement continuous open enrollment in the CAP and eliminate the requirement for annual physician election, and specify who are the appropriate people to sign the CAP election form. We are not addressing these comments because it is outside the scope of the proposed rule.

G. Issues Related to the Clinical Laboratory Fee Schedule

1. Date of Service for the Technical Component of Physician Pathology Services (§ 414.510)

In the CY 2007 PFS final rule with comment period (72 FR 69787), we added § 414.510 for the date of service of a clinical diagnostic laboratory test that uses a stored specimen.

When we added § 414.510, we indicated the provision applies to clinical diagnostic laboratory tests. For outpatients, clinical diagnostic laboratory tests are paid under the Medicare Part B clinical laboratory fee schedule. Upon further review, we believe the provision should also apply to the technical component (TC) of physician pathology services. In practice, the collection date for both clinical laboratory services and the TC of physician pathology services is similar. Therefore, we believe § 414.510 should apply to both types of services. This will improve claims processing and adjudication in relation to the clarity of dates of service, accuracy of payment, and detection of duplicate services. For outpatients, the TC of physician pathology services can be paid under the Physician Fee Schedule (PFS) or the hospital Outpatient prospective payment system (OPPS). As a result, for § 414.510, in the CY 2008 PFS proposed rule (72 FR 38160), we proposed to revise the section heading and introductory sentence to specify that the provision applies to both clinical laboratory and pathology specimens. We also proposed revising § 415.130(d) to include a reference to § 414.510.

Comment: Some commenters supported our proposal to revise the section heading and introductory sentence for § 414.510 to specify that the provision applies to both clinical laboratory and pathology specimens. (We also proposed revising § 415.130(d) to include a reference to § 414.510.) One

commenter asked that we clarify whether the provision applies to pathology tests where the technical component and the professional component (PC) are performed by the same lab and billed globally.

Response: Concerning one line global billing, we would like to point out that the TC and the PC of a laboratory test should be on separate line items on the same claim when two different dates of service are involved, even when both services are performed by the same independent laboratory. One line global billing is not appropriate in this instance. Program instructions on this issue will be forthcoming.

Comment: One commenter requested revisions to our regulations to specify that if the clinical laboratory test specimen is collected outside the hospital by nonhospital personnel, the beneficiary qualifies as a nonhospital patient.

Response: We do recognize that the determination of whether the beneficiary qualifies as an inpatient, outpatient, or nonpatient is important for payment purposes. However, we do not agree that the laboratory date of service regulation should be amended to address the employment arrangements of the personnel performing the specimen collection. Furthermore, this comment is outside the scope of our proposal to broaden the clinical laboratory date of service rules we adopted last year.

We continue to believe the date of service should relate to clear calendar dates for the specimen collection and day of discharge from the hospital if the specimen was collected while the patient was undergoing a hospital procedure.

We are implementing our proposed regulation at § 414.510 on the date of service of the TC of the physician pathology service.

2. New Clinical Diagnostic Laboratory Test (§ 414.508)

a. Background

In the CY 2007 PFS final rule with comment period (71 FR 69701), we adopted a new subpart G under part 414 that implemented section 942(b) of the MMA requiring that we establish procedures for determining the basis for, and amount of payment for any clinical diagnostic laboratory test for which a new or substantially revised HCPCS code is assigned on or after January 1, 2005 ("new tests").

Under § 414.508, we use one of two bases for payment to establish a payment amount for a new test. Under § 414.508(a), the first basis, called

“crosswalking,” is used if a new test is determined to be comparable to an existing test, multiple existing test codes, or a portion of an existing test code. If we use crosswalking, we assign to the new test code the local fee schedule amount and national limitation amount (NLA) of the existing test code or codes. If we crosswalk to multiple existing test codes, we determine the local fee schedule amount and NLA based on a blend of payment amounts for the existing test codes. The second basis for payment is “gapfilling.” Under § 414.508(b), we use gapfilling when no comparable existing test is available. We instruct each Medicare carrier or MAC to determine a carrier-specific amount for use in the 1st year that the new code is effective. The sources of information that these carriers or MACs examine in determining carrier-specific amounts include:

- Charges for the test and routine discounts to charges;
- Resources required to perform the test;
- Payment amounts determined by other payers; and
- Charges, payment amounts, and resources required for other tests that may be comparable (although not similar enough to justify crosswalking) or otherwise relevant.

After the first year, the carrier-specific amounts are used to calculate the NLA for subsequent years. Under § 414.508(b)(2), the test code is paid at the NLA, rather than the lesser of the NLA and the carrier-specific amounts.

We instruct our carriers or MACs to use the gapfill method through program instruction, which lists the specific new test code and the timeframes to establish carrier-specific amounts. During the first year a new test code is paid using the gapfill method, contractors are required to establish carrier-specific amounts on or before March 31. Contractors may revise their payment amounts, if necessary, on or before September 1. In this manner, a carrier or MAC may revise its carrier-specific amount based on additional information during the 1st year.

In the CY 2007 PFS final rule with comment period (71 FR 69702), we also described the timeframes for determining the amount of and basis for payment for new tests. The codes to be included in the upcoming year’s fee schedule (effective January 1) are available as early as May. We then list the new clinical laboratory test codes on our Web site, usually in June, along with registration information for the public meeting.

The public meeting is held no sooner than 30 days after we announce the meeting in the **Federal Register**. The public meeting is typically held in July. In September, we post our proposed determination of the basis for payment for each new code and seek public comment on these proposed determinations of the basis for payment. The updated clinical laboratory fee schedule is prepared in October for release to our contractors during the first week in November so that the updated clinical laboratory fee schedule is ready to pay claims effective January 1 of the following calendar year.

We received comments in response to the CY 2007 PFS proposed rule concerning information to be presented during the public meeting process. In responding to these comments in the CY 2007 PFS final rule, we stated that we did not believe that opportunities for information gathering on new tests have been fully utilized within the public meeting process. Payment recommendations from the public have sometimes lacked charge, cost, and clinically-detailed information for the new clinical laboratory tests. We also stated that when soliciting public input for the meeting we would recommend that all participants in the public meeting consultation process strive for transparency and try to provide as much supporting information as possible to assist us in evaluating their recommendations.

In addition, in the CY 2007 PFS final rule with comment period, in response to comments suggesting that the method used by contractors to determine their price for gapfilled tests should be more specific, we indicated that we would engage in discussions with our carrier contractors and laboratory industry representatives to explore their experiences with the gapfill process. We also agreed to host a forum to listen to suggestions from the public and said that we expected to solicit comments on a potential reconsideration process in a future rulemaking.

As explained in the CY 2008 PFS proposed rule, we discussed these issues with our contractors. We also solicited comments on the gapfill process in the July 16, 2007 clinical laboratory public meeting.

Discussions with our contractors and other interested parties revealed that the length of time we allow for a contractor to establish a carrier-specific amount may sometimes be insufficient for obtaining additional sources and data on a new test. However, our contractors and other interested parties were also concerned that if procedures and determinations were permitted to

extend over too long a time frame, the uncertainty of the final payment amount would be detrimental for laboratories, practitioners, and patients for incorporating new technology tests and improving patient care. In the CY 2008 PFS proposed rule, we also encouraged the public to submit written comments on gapfilling and said that we would respond to them to the extent they related to a proposal in the rule.

In the CY 2008 PFS proposed rule, we proposed a reconsideration process for determining the basis for and amount of payment for any new test for which a new or substantially revised HCPCS code is assigned on or after January 1, 2008. This proposed change attempted to balance additional opportunities for public input against the necessity for establishing final fees for new clinical laboratory test codes.

Section 1833(h)(8)(A) of the Act provides broad authority to develop through regulation procedures for the method for determining the basis for and amount of payment for new tests. We believe that we have authority under section 1833(h)(8)(A) of the Act to establish procedures under which we may reconsider the basis for and amount of payment for a new test. Furthermore, under section 1833(h)(8)(D) of the Act, the Secretary may convene such other public meetings to receive public comments on payment amounts for new tests as the Secretary deems appropriate.

We note that, under both section 1833(h)(8)(B)(v) of the Act and § 414.506(d)(2), the Secretary must make available to the public a list of “final determinations.” We do not believe that these provisions preclude us from reconsidering our final determinations. It is not unusual for us to provide for discretionary reopening or reconsideration of final agency action. It is not unusual for us to provide for discretionary reopening or reconsideration of final agency action. For example, under § 405.1885, we may reopen a final agency determination regarding payment to a provider of services.

Comment: Commenters were supportive of our proposal to add § 414.509 concerning a reconsideration process for new lab test payment determinations. Generally, commenters believed that in contrast to several other payment systems, which have been significantly revised in the last several years, the procedures for operating the clinical laboratory fee schedule have remained relatively static. They further commented that the implementation of a reconsideration process would be a significant step in helping assure reasonable pricing decisions for new

tests, and they commended us for our actions in this regard.

Response: We appreciate the support for our proposal for a reconsideration process for new lab test payment determinations. We believe this additional opportunity to revisit payment determinations for clinical laboratory test codes will foster accurate payment levels for new tests. We will discuss specific suggestions for revisions to § 414.509 below in this section.

b. Basis for Payment

Under our existing procedures for determining the basis for payment of a new test, either to crosswalk or gapfill, we receive comments on the appropriate basis for payment for a new test both at the public meeting in July and after we announce our proposed determinations in September. In November, we post our determination on the basis for payment for the new test on the CMS Web site. This determination of the basis for payment is final, except in the case of a gapfilled test for which we later determine that gapfilling is not appropriate under § 414.508(b)(3).

In the CY 2008 PFS proposed rule, we proposed to create a reconsideration process for determinations of the basis, either crosswalking or gapfilling, for payment of a new clinical diagnostic laboratory test. Consistent with our existing process, we would make a determination using the information gathered from the public meeting process and post a determination of the basis for payment, either to crosswalk or gapfill, on the CMS Web site, likely in September. We would accept written comments asking for a reconsideration on this basis determination for 30 days after we posted the determination on the CMS Web site. If a commenter recommended that we switch from gapfilling to crosswalking for a new code, the commenter would also have the opportunity to recommend the code or codes to which to crosswalk the new test code. Under § 414.508, claims would be paid using this basis to calculate fees beginning January 1.

After considering the comments received and the information from the public meeting, we would post our decision on our Web site as to whether we elect to reconsider our determination of the basis for payment. If we elect to reconsider the basis for payment (that is, whether to crosswalk or gapfill a test), we would post our determination as to whether we would change the basis for payment on the CMS Web site. Our decision regarding the basis for payment would be final and not subject to further reconsideration.

If we change our prior determination of the basis for payment, the new determination would be effective on January 1. We would not reopen or otherwise reprocess claims with dates of service prior to the effective date of the revised determination.

We note that, under our proposed reconsideration processes (for both the basis for payment and amount of payment) we would make two separate decisions. First, we would decide whether to reconsider our prior determination. If we elect to reconsider our prior determination, we would then determine whether we should change our prior determination.

Comment: One commenter suggested that the agenda for the public meeting should announce a list of requests received by CMS to reconsider the basis for and amount of payment for a new clinical laboratory test, and the agenda should invite comment, either written or orally, on the requests. The commenter stated that in this way, we will receive views on the validity of the requests for reconsideration. Another commenter indicated that more than one public meeting per year should be hosted by CMS to discuss comments under the reconsideration process, as well as the payment determination process.

Response: We are receptive to suggestions on providing information about the public meeting agenda. We do not believe a revision to the regulatory text at subpart of § 414.509(a) is required in order to disseminate information on our meetings. We publish a public meeting notice in the **Federal Register** to announce the meeting. The notice includes many details about the purpose and registration process for the meeting and also refers to additional Web site information for the meeting. If we receive a request to reconsider the basis of payment for a new test within the 60-day window after we post our basis of payment on the CMS Web site, the requestor could also request to present his or her comment orally at the next clinical laboratory public meeting. We can include this information in the meeting agenda that will be posted on the CMS Web site. Members of the public who are interested in addressing a particular reconsideration request at the laboratory public meeting can let us know of their interest in doing so after they review the reconsideration requests that will be addressed at the laboratory public meeting. In addition, we will accept written comments on the reconsideration request after the public meeting. We will accept written comments during the same time period

we set for accepting other comments after the clinical laboratory public meeting—usually 2 weeks. We note that, if the party that submitted the reconsideration request does not choose to present at the public meeting, members of the public may not comment on the reconsideration request and we will not accept written comments.

However, hosting more than one public meeting per year is a timing issue which is limited by the constraints of the process. Currently, there is a limited amount of time between the receipt of the new test codes for the upcoming year and the deadline to issue them via CMS instruction; therefore, we cannot accommodate two public meetings in a year. As a result, we are finalizing § 414.509(a) with revisions to specify that other commenters may speak about reconsideration requests on the laboratory public meeting agenda and that we will accept written comments on reconsideration requests addressed at the public meeting.

c. Amount of Payment

i. Crosswalking

Under our existing procedures, commenters recommend the code or codes to which to crosswalk a new clinical laboratory test both at the public meeting in July and during the comment period after we issue our proposed determination in September. We consider the appropriate basis for payment and the amount of payment at the same time. Therefore, commenters that recommend crosswalking as the basis for payment for a new test also make recommendations concerning the code or codes to which to crosswalk the new test. In November, we post the code or codes to which we will crosswalk the test and the payment amount for the test on the CMS Web site. This determination is final.

In the CY 2008 PFS proposed rule (72 FR 38162), we proposed to create a reconsideration process under which we may reevaluate the code or codes and their corresponding fees to which we crosswalk a new test's fees. We would accept reconsideration requests and written comments on the crosswalked code or codes and the resulting amount of payment for the new code for 60 days after we posted the determination on the CMS Web site, sometime in November. In addition, we proposed that a commenter who had submitted a written comment within the 60-day comment period would also be given the opportunity to present its comment at the public meeting. After considering the comments received and the

information of the public meeting, we would post our decision as to whether we had elected to reconsider our determination of the crosswalked code or codes and the resulting amount of payment on the CMS Web site. If we elect to reconsider the amount of payment and had determined that we should revise the amount of payment, we would post a new determination of the code or codes to which we would crosswalk the test on the CMS Web site. We proposed that, after we posted our determination of the code or codes to which the test would be crosswalked on the CMS Web site, we would pay claims on the basis of this determination beginning January 1. Our decision regarding the amount of payment would be final and not subject to further reconsideration.

If we change our prior determination of the amount of payment, the new determination would be effective January 1. We would not reopen or otherwise reprocess claims with dates of service prior to the effective date of the revised determination.

As discussed in section II.G.2.b., we may also change the basis for payment for a new test as the result of reconsideration. If we change the basis for payment from gapfilling to crosswalking, we would also determine the code or codes to which we would crosswalk the test. Because we believe it is important to establish final payment amounts within a reasonable amount of time, we also proposed that these determinations of crosswalked payment amounts would not be subject to reconsideration.

Comment: Some commenters indicated that § 414.509(b)(1) should establish payment amounts at the national limitation amount (NLA) of the tests to which the new tests are crosswalked. The NLA should replace carrier-specific amounts below the NLA for new tests. The commenters believe that if the amount of payment is lower than the NLA in a carrier's geographic area, patient access to a new test will be limited in the geographic area.

Response: In the CY 2008 PFS proposed rule, we did not make policy proposals regarding the level of payment for crosswalked tests. Rather, our policy proposals were limited to the reconsideration process. Accordingly, we believe that this comment is outside of the scope of this rulemaking.

Comment: One commenter suggested that a similar reconsideration process should also be available for existing laboratory tests. The commenter pointed out that the payment amounts determined for certain laboratory tests by one or another Medicare carrier or

MAC now differ from the payment amounts determined for these same tests by other Medicare contractors and from the corresponding NLA.

Response: Section 1833(h)(1) of the Act sets forth the calculation of the payment amounts for test codes included on the clinical laboratory fee schedule to be the lower of the charge submitted, the carrier-specific amount, or the NLA. We believe changes to payment amounts for tests that are not "new tests" under section 1833(h)(8)(A) of the Act would require a statutory change.

Comment: One commenter recommended that CMS clarify how fee schedule amounts below the NLA will be adjusted as carriers are phased out and their functions are moved to MACs.

Response: This comment is outside the scope of our proposal. If necessary we may address this comment in a future program memorandum.

We are finalizing § 414.509(b)(1). Consistent with the revisions we made to § 414.509(a), we are revising § 414.509(b)(1) to provide that other commenters may speak about reconsideration requests on the lab public meeting agenda and that we will accept written comments on reconsideration requests addressed at the public meeting.

ii. Gapfilling

As discussed in this preamble and in accordance with § 414.508(b), after we determine that gapfilling will be the basis for payment for a new clinical diagnostic laboratory test, we instruct our carriers or MACs to determine carrier-specific gapfill amounts by April 1 and finalize carrier-specific amounts by September 30. We include the determinations of carrier-specific amounts and the NLA for the new test code in the clinical laboratory fee schedule the following November when we post our payment determinations on the CMS Web site. Except in the case of a gapfilled test for which we determine that gapfilling was not appropriate under § 414.508(b)(3), these determinations are final.

We proposed to provide for a reconsideration process for gapfilled payment amounts. Under this process, by April 30, we would post the carrier-specific amounts on the CMS Web site at http://www.cms.hhs.gov/ClinicalLabFeeSched/02_clinlab.asp.

Interested parties would submit written comments to CMS (which we would provide to the carriers for their consideration) on the carrier-specific amounts within 60 days from the date of posting the carrier-specific amounts.

In the CY 2008 PFS proposed rule, we stated that carriers or MACs would finalize carrier-specific amounts by September 30 and that we would set the NLA at the median of the carrier-specific amounts, and we would post the carrier-specific amounts and the NLA on our Web site. In addition, we stated that the public would have 60 days to submit a reconsideration request.

We also proposed that if we elect to act on the reconsideration request to reconsider the carrier-specific amounts and decide to revise our prior determination, we would adjust the NLA based on comments received. We would post the revised NLA on the CMS Web site and payment for the test would be made at the NLA beginning January 1. This determination would be final and not subject to further reconsideration.

In addition we proposed that, if we change the basis of payment from crosswalking to gapfilling as the result of a reconsideration, the new gapfilled payment amount would be subject to reconsideration under proposed § 414.509(b)(2). Unlike a crosswalked test, the payment amount for a gapfilled test is not established when we determine the basis for payment because it takes approximately 9 months for our contractors to establish carrier-specific amounts. Thus providing for reconsideration of gapfilled payment amounts would not lengthen the period of time it would take to determine a final payment amount.

We proposed to amend § 414.508(b)(3) to provide that § 414.508(b)(3) applies to new tests for which a new or substantially revised HCPCS code assigned on or before December 31, 2007. We proposed that the more comprehensive reconsideration procedures would apply to new or substantially revised HCPCS codes assigned after December 31, 2007.

Comment: One commenter suggested that we should accept comments after the carrier-specific amounts become final, which is currently on September 30.

Response: We appreciate this commenter's input. We have decided to revise the reconsideration process that we proposed. Under the final policy we are adopting in this final rule with comment period, we will post interim determinations of carrier-specific amounts on the CMS Web site in April and, for 60 days, we will accept written comments that we will share with our carriers and MACs. However, we will not accept reconsideration requests on the interim carrier-specific amounts. In September, we will post final carrier-

specific amounts on the CMS Web site. Interested parties may request reconsideration of the final carrier-specific amounts within 30 days of when we post the final carrier-specific amounts on the CMS Web site. Based on the written reconsideration requests received, we would evaluate whether we should reconsider the carrier-specific amounts and NLA.

If we elect to reconsider the carrier-specific amounts and the NLA, we will process the request for reconsideration between the end of the 30-day comment period and the deadline for dissemination of the information to the Medicare carriers or MACs via CMS instruction so that we can finalize our determinations prior to January 1. A request for reconsideration can be denied or reconsidered for a different payment amount.

If we elect not to reconsider the carrier-specific amounts and the NLA, we will post the carrier-specific amounts and NLA on the CMS Web site on or before January 1. These amounts would be based on the carrier-specific amounts and NLA we had posted in September. Payment for the test would be made at the NLA on January 1. This determination would be final and not subject to further reconsideration.

In addition, after the final test codes and payment amounts are effective on January 1, there is no reconsideration process that occurs after that date.

Comment: One commenter suggested that CMS provide a rationale for either accepting or declining a reconsideration after it is received and for deciding whether to change a prior determination.

Response: We do not plan to post a rationale for our decision to accept or decline a reconsideration request. This is consistent with our policy in other areas of the Medicare program when we make a decision about whether to reopen a previous decision.

Comment: One commenter suggested that we should convene an expert advisory committee, broadly representative of the laboratory industry, to advise CMS on pricing along with standardizing the sources and quality of charge and cost data.

Response: The purpose of the Clinical Laboratory public meeting is to convene industry experts and entertain comments, both orally and in writing, as well as any charge and cost data that is available from the industry. In fact, we specifically asked, via public notice, those in the clinical laboratory industry to provide charge and cost data related to the agenda items at the annual public meeting. We welcome any related information that industry

representatives would like to provide via the public meeting forum and during the associated comment period.

Comment: There were specific concerns raised by commenters regarding varying payment amounts set by carriers when the gapfilling basis is utilized to determine payment amounts for a new test code. These commenters recommended that we establish formal procedures for carriers or MACs to apply when establishing payment amounts, including a formal appeals process. The commenters stated the payment amounts should be calculated using information on the following factors, resources needed to perform the test, staff expertise, time needed to perform the test and the test's potential value. In addition, the commenters suggested we should publish the gapfill payment amounts determined by carriers or MACs and an explanation of the payment amounts.

Response: Although we appreciate the comments on the establishment of payment amounts for new clinical laboratory test codes using the gapfill basis and the suggested improvements to the way we set rates, these comments are outside the scope of this rulemaking. In the CY 2008 PFS proposed rule, we proposed policies and requested comment regarding our proposed reconsideration process. We made no policy proposals with respect to the methodology our contractors use to establish gapfilled payment amounts. However, in the interest of transparency we will instruct carriers or MACs to provide a rationale for their final carrier-specific amounts, which we will post on our Web site.

Comment: One commenter suggested that we should establish a temporary NLA based on the carrier-specific amounts posted on April 30 within the first year of the gapfill process.

Response: We appreciate the commenter's suggestion; however, we are concerned that establishing a temporary NLA within a 3 month time period is not possible due to our substantial program requirements each year. Currently, clinical laboratory fee schedule payment rates are established on a calendar year basis. During the year preceding each January 1, an extensive multi-step process is in place in order to bring those payment rates to fruition. Currently, that process does not allow for additional ratesetting procedures.

d. Jurisdiction for Reconsideration Decisions

In the CY 2008 PFS proposed rule (72 FR 38163), we proposed that jurisdiction for reconsideration would rest exclusively with the Secretary. A

decision whether to reconsider a determination would be committed to the discretion of the Secretary. Accordingly, a refusal to reconsider an initial determination would not be subject to administrative or judicial review. We recognize that parties dissatisfied with an initial determination as to the amount of payment for a particular claim for laboratory services may appeal the initial determination under part 405, subpart I of our regulations. Under our proposal, a party could challenge under part 405, subpart I a determination regarding the amount of payment for a new test—regardless of whether the amount of payment was established as the result of a reconsideration—but a party could not challenge a decision not to reconsider.

Comment: One commenter stated that comments should be allowed on the final payment determination amounts.

Response: This comment appears to request an extension of the reconsideration process or a change in the jurisdiction as proposed in § 414.509. The commenter did not provide additional information on the circumstances that would warrant an extension of the reconsideration process. Also, the comment did not specify the length of time for an extension or procedures for an extension or change of jurisdiction. We believe § 414.506 through § 414.509 permit adequate opportunities for public participation in the process of establishing a payment amount and requesting a reconsideration. More than 2 years can elapse if all steps of these reconsideration procedures are necessary for the establishment of the basis and payment for a new test code. We do not agree that revisions to § 414.509(d) are warranted.

3. Technical Revisions

We also proposed technical revisions to § 414.502, § 414.506, and § 414.508. Under section 1833(h)(8)(A) of the Act, the term “new tests” is defined as any clinical diagnostic laboratory test for which a new or substantially revised HCPCS code is assigned on or after January 1, 2005. However, our regulations do not define the term “new test.” Therefore, we proposed to define the term “new test” under § 414.502 using the statutory definition. In addition, under § 414.506 and § 414.508, we proposed to replace references to “new clinical diagnostic laboratory test that is assigned a new or substantially revised code on or after January 1, 2005” with references to “new test.”

Response: We received one supportive comment on this subpart,

and we appreciate the positive input received on our technical revisions. Therefore, we are finalizing the technical revisions as proposed.

H. Revisions Related to Payment for Renal Dialysis Services Furnished by End-Stage Renal Disease (ESRD) Facilities

In the CY 2008 PFS proposed rule (72 FR 38163), we outlined the proposed updates to the case mix adjusted composite rate payment system established under section 1881(b)(12) of the Act, added by section 623 of the MMA. These included updates to the drug add-on component of the composite rate system, as well as the wage index values used to adjust the labor component of the composite rate.

Specifically, we proposed the following provisions which are described in more detail below in this section.

- A growth update to the drug add-on adjustment to the composite rates for 2008 required by section 1881(b)(12)(F) of the Act.
- An update to the wage index adjustments to reflect the latest hospital wage data, including a reduction to the wage index floor and a revised budget neutrality adjustment to the wage index for 2008.

We received approximately 7 comments on these proposed changes which are discussed in detail below in this section.

1. Growth Update to the Drug Add-On Adjustment to the Composite Rates

Section 623(d) of the MMA added section 1881(b)(12)(B)(ii) of the Act which required the establishment of an add-on to the composite rate to account for changes in the drug payment methodology stemming from enactment of the MMA. Section 1881(b)(12)(C) of the Act provides that the drug add-on must reflect the difference in aggregate payments between the revised drug payment methodology for separately billable ESRD drugs and the AWP payment methodology. In 2005, we generally paid for ESRD drugs based on average acquisition costs. Thus the difference from AWP pricing was calculated using acquisition costs. However, in 2006 when we moved to ASP pricing for ESRD drugs, we recalculated the difference from AWP pricing using ASP prices.

Comment: Two commenters supported our continued use of ASP+6 percent to pay for separately billable ESRD drugs.

Response: Although these comments are outside the scope of the proposed rule, we appreciate the support of our

previous decision to pay for separately billable ESRD drugs at ASP+6 percent.

In addition, section 1881(b)(12)(F) of the Act requires that beginning in CY 2006, we establish an annual update to the drug add-on to reflect the estimated growth in expenditures for separately billable drugs and biologicals furnished by ESRD facilities. This growth update applies only to the drug add-on portion of the case-mix adjusted payment system.

The CY 2007 drug add-on adjustment to the composite rate is 14.9 percent. The drug add-on adjustment for 2007 incorporates an inflation adjustment of 0.5 percent. This computation is explained in detail in the CY 2007 PFS final rule with comment period (71 FR 69682 through 69684). We note that the drug add-on adjustment of 15.1 percent that was published in the CY 2007 PFS final rule with comment period did not account for the 1.6 percent update to the composite rate portion of the basic case-mix adjustment payment system that was subsequently enacted by the MIEA-TRHCA, effective April 1, 2007. Since we compute the drug add-on adjustment as a percentage of the weighted average base composite rate, the drug add-on percentage was decreased to account for the higher composite payment rate resulting in a 14.9 percent add-on adjustment beginning April 1, 2007. This adjustment was necessary to ensure that the total drug add-on dollars remain constant.

(a) Estimating Growth in Expenditures for Drugs and Biologicals for CY 2008

In the CY 2007 PFS final rule with comment period (71 FR 69682), we established a methodology for annually estimating the growth in ESRD drugs and biological expenditures that uses the Producer Price Index (PPI) for pharmaceuticals as a proxy for pricing growth in conjunction with 2 years of ESRD drug data to estimate per patient utilization growth.

For CY 2008, we proposed to continue using this methodology to update the drug add-on adjustment, using expenditure data from CY 2005 and CY 2006 to estimate the growth in per patient utilization of drugs. However, we also proposed using only drug expenditure data from independent ESRD facilities because we were unable to determine utilization change in hospital-based dialysis facilities due to the changes in payment methodology for these types of dialysis facilities from CY 2005 to CY 2006. In 2005, payments to hospital-based facilities were based on cost (or a percentage of charges), whereas payments to those facilities in 2006 were based on ASP pricing.

Because of the cost payment methodology, the “drug unit” fields on the 2005 hospital-based ESRD facility bills were not used for payment purposes, and therefore, the data may not have been accurately reported on those bills. As such, we were unable to accurately isolate the per unit payment differential for hospital-based ESRD facility drug expenditures between 2005 (cost payments) and 2006 (ASP payments) for purposes of estimating the residual utilization change between years. We proposed imputing the same utilization growth for hospital-based ESRD facilities as estimated for independent ESRD facilities.

Comment: One comment urged us to reevaluate the data and methodology used to estimate utilization changes. The comment was specifically concerned about the timeliness of the data and that the exclusion of hospital-based drug data may significantly skew the accuracy of the utilization growth calculation. However, the comment did not suggest an alternative methodology.

Response: The data from CY 2005 and CY 2006 represent the most up to date and latest full years of data available. Contrary to the commenter’s suggestion, as we indicated in the CY 2008 PFS proposed rule, including hospital-based data in the computation would have resulted in a negative utilization growth. Therefore, we opted to exclude those data to avoid penalizing ESRD facilities because of the problems with the hospital-based ESRD facility drug data. We believe our approach provides the most reasonable result given the available data.

Comment: One comment suggested that we adopt an index that would account for both price and utilization such as the National Health Expenditures (NHE) index. This would avoid the data issues associated with estimating utilization growth.

Response: We do not believe that the NHE projections would be the best proxy for growth in ESRD drug expenditures. The NHE projections are based on the economic, demographic and Medicare spending projections contained in the Medicare Trustees Report as opposed to an independent forecast of economic assumptions, such as the Global Insights projections of the PPI for prescription drugs that are used in our Medicare market basket forecasts to update many of our payment systems. The NHE projection modeling approach is at an aggregate level and does not capture the nuances of both labor and economic markets as accurately as does the specific PPI forecast. We believe that, despite some of the limitations in the data, estimating utilization growth

from reported ESRD claims data provides the most accurate measure of actual ESRD facility drug utilization.

Comment: One comment suggested that the PPI may not result in an accurate assessment of prices for ESRD drugs and that there are other available indices that would provide more accurate data on ESRD drugs. In addition, they stated that should we choose to move forward with the PPI, the most up to date PPI forecast should be used.

Response: We do not know of any better price index than the PPI for measuring price growth for ESRD drugs. However, we welcome any suggestion the industry may have on an alternative price index suitable for measuring price growth of ESRD drugs. Global Insight, Inc. is a nationally recognized economic and financial forecasting firm that contracts with CMS to forecast the components of our market baskets. The current projection of the PPI for prescription drugs is based on the 2007 second quarter forecast using historical data through the first quarter of 2007, the most current data available at this time.

Comment: One comment recommended that a mechanism be established to provide for a forecasting error adjustment of prior estimates.

Response: While we appreciate the concern related to the accuracy of an update based on proxy measures for price and the proposed utilization computations, the very nature of estimating future expenditures under a prospective payment system requires that those estimates are based on the best historical data available. As such, we believe we have met our obligation under the statute in estimating growth in ESRD drug expenditures for CY 2008. Moreover, forecast error adjustments are rarely made in our prospective payment systems.

(b) Estimating Growth in Per Patient Drug Utilization

To isolate and project the growth in per patient utilization of ESRD drugs for CY 2008, we removed the enrollment and price growth components from the historical data and considered the residual to be utilization growth. As discussed previously, we proposed to use independent ESRD facility drug expenditure data from CY 2005 and CY 2006 to estimate per patient utilization growth for CY 2008.

We first estimated total drug expenditures. For the CY 2008 PFS proposed rule (72 FR 38165), we used the final CY 2005 ESRD facility claims data and the latest available CY 2006 ESRD facility claims data, updated

through December 31, 2006. That is, for CY 2006 we used claims that were received, processed, paid, and passed to the National Claims History File as of December 31, 2006. For this final rule with comment period, we are using more updated CY 2006 claims with dates of service for the same time period. This updated CY 2006 data file includes all claims that were received, processed, paid, and passed to the National Claims History File as of June 30, 2007 for CY 2006.

For the CY 2008 PFS proposed rule, we adjusted the December 2006 file to reflect our estimate of what total drug expenditures would be using the final June 30, 2007 bill file for CY 2006. The net adjustment we applied to the CY 2006 claims data was an increase of 12 percent to the December 2006 claims file. For this final rule with comment period, we are using the CY 2006 claims file as of June 30, 2007, which represents the final claims file for that year. To calculate the proposed per patient utilization growth, we removed the enrollment component by using the growth in enrollment data between 2005 and 2006. This was approximately 3 percent. To remove the price effect, we calculated the weighted difference between 2005 average acquisition price (AAP) and 2006 ASP pricing for the original top ten drugs for which we had average acquisition prices. We weighted the differences by the 2006 independent ESRD facility drug expenditure data. This process led to an overall 3 percent reduction in price between 2005 and 2006 (72 FR 38165 through 38166).

After removing the enrollment and price effects from the expenditure data, the residual growth would reflect the per patient utilization growth. To do this, we divided the product of the enrollment growth of 3 percent (1.03) and the price reduction of 3 percent ($1.00 - 0.03 = 0.97$) into the total drug expenditure change between 2005 and 2006 of -0.2 percent ($1.00 - 0.00 = 1.00$). The result is a proposed utilization growth factor equal to 1.00 ($1.00/1.03 * 0.97 = 1.00$).

Since we observed no growth in per patient utilization of drugs between 2005 and 2006, we proposed no projected growth in per patient utilization for all ESRD facilities for CY 2008.

c. Applying the Proposed Growth Update to the Drug Add-On Adjustment

In the CY 2007 PFS final rule with comment period (71 FR 69684), we revised our update methodology by applying the growth update to the per treatment drug add-on amount. That is, for CY 2007, we applied the growth

update factor of 4.03 percent to the \$18.88 per treatment drug add-on amount for an updated amount of \$19.64 per treatment.

For CY 2008, we proposed to update the per treatment drug add-on amount of \$19.64 established in CY 2007 by converting the update into an adjustment factor as specified in section 1881(b)(12)(F) of the Act.

(i) Update to the Drug Add-On Adjustment

In the CY 2008 PFS proposed rule (72 FR 38166), we estimated no growth in per patient utilization of ESRD drugs for CY 2008. Using the projected growth of the CY 2008 PPI for prescription drugs of 3.66 percent, we projected that the combined growth in per patient utilization and pricing for CY 2008 would result in an update equal to the PPI growth, or 3.66 percent ($1.0 * 1.0366 = 1.0366$). This proposed update factor was applied to the CY 2007 per treatment drug add-on amount of \$19.64 (reflecting a 14.9 percent adjustment in CY 2007), resulting in a proposed weighted average increase to the composite rate of \$0.72 for CY 2008 or a 0.5 percent increase in the drug add-on percentage. Thus, the total proposed drug add-on adjustment to the composite rate for CY 2008, including the growth update was 15.5 percent ($1.149 * 1.005 = 1.155$).

In addition, we proposed to continue to use this method to estimate the growth update to the drug add-on component of the case mix adjusted payment system until we have at least 3 years worth of ASP-based historical drug expenditure data that could be used to conduct a trend analysis to estimate the growth in drug expenditures. Given the time lag in the availability of ASP drug expenditure data, we expect that the earliest we could consider using trend analysis to update the drug add-on adjustment would be 2010. We intend to reevaluate our methodology for estimating the growth update at that time.

Comment: One comment suggested that we should work with the kidney care community as we consider a CY 2010 transition to trend analysis using ASP-based historical data. The comment expressed concern that using actual historical ESRD drug expenditure data reflecting ASP pricing could adversely affect ESRD facilities due to changes in ASP pricing for EPO and Procrit.

Response: Once we begin using trend analysis to update the drug add-on adjustment, we will provide details of that methodology in future rulemaking.

(ii) Final Growth Update to the Drug Add-On Adjustment for 2008

Similar to the proposed rule, we estimated no growth in per patient utilization of ESRD drugs for CY 2008. To remove the price effect, we used 2006 weights for each of the top ten ESRD drugs billed by independent ESRD facilities. These weights are shown in Table 6.

TABLE 6.—CY 2006 DRUG WEIGHTS FOR INDEPENDENT FACILITIES

Independent drugs	2006 weights (percent)
EPO	75.2
Paricalcitol	11.6
Sodium_ferric_glut	2.9
Iron_sucrose	5.7
Levocarnitine	0.3
Doxercalciferol	3.1
Calcitriol	0.1
Iron_dextran	0.0
Vancomycin	0.1
Alteplase	0.9

We removed the enrollment and price effects from the independent ESRD facility expenditure data to determine the per patient utilization growth. To do this we divided the product of the enrollment growth of 3 percent (1.03) and the price reduction of 3 percent (1.00 – 0.03 = 0.97) into the total drug expenditure change between 2005 and 2006 of – 0.1 percent (1.00 – 0.00 = 1.00). The result is a utilization growth factor equal to 1.00 (1.00/1.03 * 0.97) = 1.00.

Using the latest projected growth of the CY 2008 PPI for prescription drugs of 3.5 percent, we project that the combined growth in per patient utilization and pricing of ESRD drugs for CY 2008 would result in an update equal to the PPI growth or 3.5 percent (1.00 * 1.035 = 1.035). This update factor was applied to the CY 2007 average per treatment drug add-on amount of \$19.64 (reflecting a 14.9 percent adjustment for CY 2007), resulting in a weighted average increase to the composite rate of \$0.69 for CY 2008 or a 0.5 percent increase in the drug add-on percentage for CY 2008. Thus, the total drug add-on adjustment to the composite rate for CY 2008, including the growth update is 15.5 percent (1.149 * 1.005 = 1.155).

2. Update to the Geographic Adjustment to the Composite Rates

Section 1881(b)(12)(D) of the Act, as added by section 623(d) of the MMA, gives the Secretary the authority to revise the wage indexes previously applied to the ESRD composite rates.

The wage index values are calculated for each urban and rural area. The purpose of the wage index is to adjust the composite rates for differing wage levels covering the areas in which ESRD facilities are located.

(a) Updates to Core-Based Statistical Area (CBSA) Definitions

In the CY 2008 PFS proposed rule (72 FR 38166), we clarified that this and all subsequent ESRD rules and notices are considered to incorporate the CBSA changes published in the most recent OMB bulletin that applies to the hospital wage data used to determine the current ESRD wage index. The OMB bulletins may be accessed online at <http://www.whitehouse.gov/omb/bulletins/index.html>.

(b) Updated Wage Index Values

In the CY 2006 PFS final rule with comment period (70 FR 70167), we described that methodology for calculating the CY 2006 wage index values and stated that we intend to update the ESRD wage index values annually. Current wage index values for CY 2007 were developed from FY 2003 wage and employment data obtained from the Medicare hospital cost reports. The ESRD wage index values are calculated without regard to geographic reclassifications authorized under sections 1886(d)(8) and (d)(10) of the Act and utilize pre-floor hospital data that is unadjusted for occupational mix.

We proposed to use the same methodology for CY 2008 (72 FR 38167), with the exception that FY 2004 hospital data will be used to develop the CY 2008 ESRD wage index values. For a detailed description of the development of the CY 2008 wage index values based on FY 2004 hospital data, see the FY 2008 IPPS final rule entitled “Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2008 Rates” (72 FR 47320). Section G of the preamble to that final rule describes the cost report schedules, line items, data elements, adjustments, and wage index computations. The wage index data affecting ESRD composite rates for each urban and rural locale may also be accessed on the CMS Web site at <http://www.cms.hhs.gov/AcuteInpatientPPS/WIFN/list.asp>. The wage data are located in the section entitled “FY 2008 Final Rule Occupational Mix Adjusted and Unadjusted Average Hourly Wage and Pre-Reclassified Wage Index by CBSA.”

Comment: One commenter expressed concern in regard to our use of acute care hospital wage data in the calculation of the wage index stating that the cost for hospital based facilities

and ambulatory centers varies greatly. The commenter urged us to locate an alternative data source that reflects information directly tied to ESRD facilities.

Response: At the present time, data that is specific to independent dialysis facilities is not available upon which to base the wage index. As described in the CY 2007 PFS final rule with comment period (71 FR 69685), given the similarity of the labor market for professional, technical, and nursing staff between hospitals and ESRD facilities, we believe our use of hospital wage and employment data obtained from the Medicare cost reports to develop the ESRD wage index is appropriate. In addition, several of our major prospective payment systems (PPS) utilize the same wage index (for example, Skilled Nursing Home PPS, Inpatient Psychiatric Facility PPS, Inpatient Rehabilitation Facility PPS, Home Health PPS, and Hospice PPS.)

(i) Third Year of the Transition

In the CY 2006 PFS final rule with comment period (70 FR 70169), we indicated that we would apply a 4-year transition period to mitigate the impact on composite rates resulting from our adoption of CBSA-based geographic designations. Beginning January 1, 2006, during each year of the transition, an ESRD facility’s wage-adjusted composite rate (that is, without regard to any case-mix adjustments) will be a blend of its old MSA-based wage-adjusted payment rate and its new CBSA-based wage-adjusted payment rate for the transition year involved. In addition, beginning in CY 2006 we provided a gradual reduction in the wage index floor. We indicated that we would reassess the need for a wage index floor for CY 2008. In the CY 2008 PFS proposed rule (72 FR 38167), we proposed a further reduction in the wage index floor. For each transition year, the share of the blended wage-adjusted base payment rate that is derived from the MSA-based and CBSA-based wage index values and the applicable wage index floor is as follows:

- In CY 2006, the first year of the transition, we implemented a 75/25 blend. The wage index floor was reduced from 0.9000 to 0.8500.
- In CY 2007, the second year of the transition, we implemented a 50/50 blend. The wage index floor was reduced from 0.8500 to 0.8000.
- For CY 2008, consistent with the transition blends announced in the CY 2006 PFS final rule with comment period (70 FR 70170), we are implementing a 25/75 blend between an ESRD facility’s MSA based composite

rate, and its CY 2008 CBSA-based rate reflecting its revised wage index values. In addition, we proposed to continue the wage index floor, but to further reduce it from 0.8000 to 0.7500.

An example of how the wage-adjusted composite rates would be blended during CY 2008 and the additional subsequent transition year follows.

Example: An ESRD facility has a wage-adjusted composite rate (without regard to any case-mix adjustments) of \$135.00 per treatment in CY 2007. Using CBSA-based geographic area designations, the facility's CY 2008 wage-adjusted composite rate, reflecting its wage index value would be \$145.00. During the remaining 2 years of the 4-year transition period to the new CBSA-based wage index values, this facility's blended rate through 2009 would be calculated as follows:

$$\text{CY 2008} = 0.25 \times \$135.00 + 0.75 \times \$145.00 = \$142.50$$

$$\text{CY 2009} = 0 \times \$135.00 + 1.0 \times \$145.00 = \$145.00$$

We note that this hypothetical example assumes that the calculated wage-adjusted composite rate of \$145.00 for CY 2008 does not change in CY 2009. In actuality, the wage-adjusted composite rate for CY 2009 would change because of annual revisions to the wage index. However, the example serves only to demonstrate the effect on the composite rate of the CBSA-based wage index values which will be phased in during the remaining 2 years of the transition period. As noted above in this section, the 4-year transition period will expire and in CY 2009 and forward, we will be using CBSA-based wage index values.

Comment: Several commenters expressed concern in regard to our proposal to decrease the wage index floor from 0.80 to 0.75. In addition, one commenter indicated that a defunct licensing board in Puerto Rico has inhibited licensing of dialysis technicians for a long period of time. As a result, registered nurses are the only group of licensed professional qualified to furnish dialysis within this area.

In addition, a commenter believes that decreasing the floor will make it difficult to recruit and retain qualified personnel in areas affected by the removal of the floor. The commenter also identified the recent transition to the ASP drug pricing methodology and increases in operating expense as factors that have compounded the impact of any further drop in the wage index floor.

Response: As described in the CY 2007 PFS final rule with comment period (71 FR 69686 through 69687), the

proposed wage index floor was substantially higher than the actual wage index values for urban locales in Puerto Rico, without application of any floor and prior to the application of the BN adjustment. Specifically, the proposed wage index floor was 0.80 whereas the actual wage index values ranged from 0.3241 to 0.4893. Similarly, the proposed wage index floor for CY 2008 is 0.75 whereas the actual wage index values for urban locales in Puerto Rico range from 0.3064 to 0.4729. Therefore, we believe that the CY 2008 wage index floor of 0.75 compared to actual wage levels is an appropriate level and the new floor would not impede the ability of ESRD facilities to recruit and retain staff.

(ii) Wage Index Values for Areas With No Hospital Data

In CY 2006, while adopting the CBSA designations, we identified a small number of ESRD facilities in both urban and rural geographic areas where there is no hospital wage data from which to calculate ESRD wage index values. The affected areas were rural Massachusetts, rural Puerto Rico and the urban area of Hinesville, GA (CBSA 25980). For both CY 2006 and CY 2007, we calculated the ESRD wage index values for those areas as follows:

- For rural Massachusetts, because we had not determined a reasonable proxy for rural data in Massachusetts, we used the FY 2005 wage index value for rural Massachusetts.
- For rural Puerto Rico, the situation is similar to rural Massachusetts. However, since all geographic areas in Puerto Rico were subject to the wage index floor in CY 2006 and CY 2007, we applied the ESRD wage index floor to rural Puerto Rico as well.
- For the urban area of Hinesville, GA, we calculated the CY 2006 and CY 2007 wage index value for Hinesville, GA (CBSA 25980) based on the average wage index value for all urban areas within the State of Georgia.

In the CY 2008 PFS proposed rule (72 FR 38168), we proposed an alternative methodology for establishing a wage index value for rural Massachusetts. Since we have used the same wage index value for two years with no updates, we believed it was appropriate to establish a methodology that uses reasonable proxy data for rural areas (including rural Massachusetts) and also permits annual updates to the wage index value based on that proxy data. Therefore, in cases where there is a rural area without hospital wage data, we proposed to use the average wage index values from all contiguous CBSAs to

represent a reasonable proxy for that rural area.

In determining the imputed rural wage index, we interpret the term "contiguous" to mean sharing a border. In the case of Massachusetts, the entire rural area consists of Dukes and Nantucket Counties. We determined that the borders of Dukes and Nantucket counties are "contiguous" with Barnstable and Bristol counties. Under the proposed methodology, the wage index values for the counties of Barnstable (CBSA 12700, Barnstable Town, MA—(1.2539)) and Bristol (CBSA 39300, Providence-New Bedford-Fall River, RI-MA—(1.0783)) are averaged, resulting in a proposed imputed wage index value of 1.1665 for rural Massachusetts for CY 2008.

For rural Puerto Rico, we proposed to continue to apply the wage index floor in CY 2008. Since all areas in Puerto Rico that have a wage index are eligible for the proposed CY 2008 ESRD wage index floor of 0.7500, we proposed to also apply the floor to ESRD facilities located in rural Puerto Rico.

For Hinesville, GA (CBSA 25980) which is an urban area without specific hospital wage data, we proposed to continue using the same methodology used to impute a wage index value for that area as we used in CY 2006 and CY 2007. Specifically, we used the average wage index value for all urban areas within the State of Georgia for purposes of calculating the wage index value for Hinesville. Therefore, for CY 2008 we proposed that the wage index value for urban CBSA (25980) Hinesville-Fort Stewart, GA is calculated as the average of the wage index values of all urban areas in Georgia.

We solicited comments on these proposed approaches to calculate the wage index values for areas without hospital wage data for CY 2008 and subsequent years. We indicated that we would continue to evaluate existing hospital wage data and, possibly, wage data from other sources, such as the Bureau of Labor Statistics, to determine if other methodologies of imputing a wage index value for these areas may be feasible. We received one comment on this issue.

Comment: One commenter was supportive of our methodology used in calculating wage index values for areas with no hospital wage data including rural Massachusetts, Puerto Rico, and an urban area in Georgia. However, the commenter requested that we carefully evaluate the extent to which these methodologies would be appropriate in other situations nationwide.

Response: We agree with the commenter. As additional areas are

identified for which hospital wage data does not exist, we will reevaluate the extent to which the methodologies used for Massachusetts, Puerto Rico, and Georgia would be appropriate and consider alternative methodologies on an as needed basis.

We are finalizing the ESRD wage index and associated policies as proposed for CY 2008. In addition, we note that we plan to evaluate any policies adopted in the FY 2008 IPPS final rule (72 FR 47130, 47337 through 47338) that affect the wage index, including how we treat certain New England hospitals under section 601(g) of the Social Security Amendments of 1983 (Pub. L. 98–21).

(iii) Budget Neutrality (BN) Adjustment

Section 1881(b)(12)(E)(i) of the Act, as added by section 623(d) of the MMA, requires that any revisions to the ESRD composite rate payment system as a result of the MMA provision (including the geographic adjustment) be made in a budget neutral manner. This means that aggregate payments to ESRD facilities in CY 2007 should be the same as aggregate payments that would have been made if we had not made any changes to the geographic adjusters. We note that this BN adjustment only addresses the impact of changes in the geographic adjustments. A separate BN adjustment was developed for the case-mix adjustments, currently in effect. Since we are not proposing any changes to the case-mix measures for CY 2008, the current case-mix budget neutrality will remain in effect for CY 2008. For CY 2008, we again proposed to apply the BN adjustment directly to the ESRD wage index values, as we did in CY 2007. As we explained in the CY 2007 PFS final rule with comment period (71 FR 69687 through 69688), we believe this is the simplest approach because it allows us to maintain our base composite rates during the transition from the current wage adjustments to the revised wage adjustments described previously in this section. Because the ESRD wage index is only applied to the labor related portion of the composite rate, we computed the BN adjustment based on that proportion (53.711 percent).

To compute the proposed CY 2008 wage index BN adjustment, we used the proposed wage index values, 2006 outpatient claims (paid and processed as of December 31, 2006), and geographic location information for each facility.

Using the treatment counts from the 2006 claims and facility-specific CY 2007 composite rates, we computed the estimated total dollar amount each

ESRD provider would have received in CY 2007 (the 2nd year of the 4-year transition). The total of these payments became the target amount of expenditures for all ESRD facilities for CY 2008. Next, we computed the estimated dollar amount that would have been paid to the same ESRD facilities using the proposed ESRD wage index for CY 2008 (the 3rd year of the 4-year transition). The total of these payments became the third year amount of wage-adjusted composite rate expenditures for all ESRD facilities.

After comparing these two dollar amounts (target amount divided by 3rd year new amount), we calculated an adjustment factor that, when multiplied by the applicable CY 2008 ESRD proposed wage index value would result in payments to each facility that remain within the target amount of composite rate expenditures when totaled for all ESRD facilities. The proposed BN adjustment for the CY 2008 wage index was 1.054955.

We also must apply the BN adjustment to the proposed wage index floor of 0.7500 which resulted in a proposed adjusted wage index floor of 0.7912 (0.7500×1.054955) for CY 2008.

Comment: One commenter expressed concern in regard to the calculation of the BN adjustment for the geographic wage index stating that the methodology included in the proposed rule lacked transparency. The commenter urged us to provide the data and methodology used in calculating the BN adjustment.

Response: The commenter did not identify where transparency was lacking or any missing elements that would enable the community to assess the impact of the proposed changes. However, we received a similar request for clarification during last year's rulemaking process and provided an extensive description of the manner in which budget neutrality is applied to the wage index in the CY 2007 PFS final rule with comment period (71 FR 69687 through 69688). While claims data have been updated since publication of that final rule with comment period, the methodology has not changed.

During the CY 2008 PFS proposed rule comment period, we made available an ESRD Composite Rate Payment System File. This file contained select claims level data from the 2006 ESRD facility outpatient claims, updated through December 31, 2006. For more information on this file, see the following page on the CMS Web site at <http://www.cms.hhs.gov/LimitedDataSets/06.asp#TopOfPage>.

After publication of this final rule with comment period, we intend to provide the updated version of the CY

2006 outpatient claims (paid and processed as of June 30, 2007) that were used to compute the BN adjustment.

To compute the final CY 2008 ESRD wage index BN adjustment, we used FY 2004 pre-floor, pre-reclassified, non-occupational mix-adjusted hospital wage data to compute the wage index values, 2006 outpatient claims (paid and processed as of June 30, 2007), and geographic location information for each ESRD facility which may be found through Dialysis Facility Compare. The FY 2004 hospital wage index data for each urban and rural locale by CBSA may also be accessed on the CMS Web site at: <http://www.cms.hhs.gov/AcuteInpatientPPS/WIFN/list.asp>. The wage index data are located in the section entitled "FY 2008 Final Rule Occupational Mix Adjusted and Unadjusted Average Hourly Wage and Pre-Reclassified Wage Index by CBSA."

Dialysis Facility Compare Information can be found on the CMS Web site at <http://www.cms.hhs.gov/DialysisFacilityCompare/>.

Using treatment data from the latest 2006 claims file and facility-specific CY 2007 composite rates, we computed the estimated total dollar amount each ESRD provider would have received in CY 2007 (the 2nd year of the 4-year transition). The total of these payments became the target amount of expenditures for all ESRD facilities for CY 2008. Next, we computed the estimated dollar amount that would have been paid to the same ESRD facilities using the ESRD wage index for CY 2008 (the 3rd year of the 4-year transition). The total of these payments became the 3rd year new amount of wage adjusted composite rate expenditures for all ESRD facilities.

After comparing these dollar amounts (target amount divided by 3rd year new amount), we calculated an adjustment factor that when multiplied by the applicable CY 2008 wage index value, will result in aggregate payments to ESRD facilities that will remain within the target amount of composite rate expenditures. When making this calculation, the ESRD wage index floor value of 0.7500 is used whenever appropriate.

The final BN adjustment for the CY 2008 wage index is 1.055473.

To ensure budget neutrality, we also must apply the BN adjustment to all index values, including the wage index floor of 0.7500, which results in an adjusted wage index floor of 0.7916 for CY 2008.

(iv) ESRD Wage Index Tables

The final CY 2008 wage index tables applicable to ESRD facilities are located

in Addenda G and H of this final rule with comment period.

I. Independent Diagnostic Testing Facility (IDTF) Issues

In the CY 2008 PFS proposed rule (72 FR 38169 through 38171), we clarified our interpretation of several of the existing performance standards at § 410.33(b), and § 410.33(g), proposed a new IDTF performance standard at § 410.33(g)(15), and a new proposed IDTF provision at § 410.33(i).

We received numerous comments concerning the revisions to existing performance standards and new provisions affecting IDTFs and have revised our proposed changes, where applicable, to reflect the issues brought forth by the commenters. We are adopting the provisions contained in the proposed rule as final with the following changes.

1. Revisions of Existing IDTF Performance Standards

a. § 410.33(g)(6)

In § 410.33(g)(6), we had proposed to revise this existing performance standard to include the requirement that an IDTF must list our designated contractor as a Certificate Holder on the comprehensive liability insurance policy by revising § 410.33(g)(6) to state, "Has a comprehensive liability insurance policy in the amount of at least \$300,000 per location that covers both the supplier's place of business and all customers and employees of the supplier and ensures that this insurance policy must remain in force at all times. The policy must be carried by a nonrelative owned company. Failure to maintain required insurance at all times will result in revocation of the IDTF's billing privileges retroactive to the date the insurance lapsed. IDTF suppliers are responsible for providing the contact information for the issuing insurance agent and the underwriter. In addition, we proposed that the IDTF must: ensure that the insurance policy must remain in force at all times and provide coverage of at least \$300,000 per incident; notify the CMS-designated contractor in writing of any policy changes or cancellations; and list the CMS-designated contractor as a Certificate Holder on the policy."

Comment: One commenter suggested that we amend the § 410.33(g)(6) provision on the comprehensive liability insurance policy to state that IDTFs should have a comprehensive liability insurance policy of at least \$100,000 per incident, \$300,000 aggregate and that CMS should require the IDTF to list Medicare contractors as

certificate holders for notification purposes only.

Response: After receiving numerous comments supporting the proposed figures, we are adopting the proposed figure of \$300,000 per incident.

Comment: Several commenters recommended that we revise the proposed performance standard found at § 410.33(g)(6) to remove the requirement that our designated contractor be listed as a Certificate Holder on the liability insurance policy. One commenter supported the proposed changes to the performance standard at § 410.33(g)(6), but expressed concern about whether underwriters were willing to list the government as a certificate holder on an insurance policy.

Another commenter questioned whether insurance underwriters will be open to the idea of adding the government as a certificate holder on an insurance policy and suggested that CMS survey several insurance carriers which provide this type of coverage to determine if this performance standard is achievable. One commenter stated that the comprehensive liability insurance policy provision (§ 410.33(g)(6)) which requires the IDTF to list the Medicare contractor as the certificate holder on the policy is too burdensome and obtrusive on small business entities. They recommended using a comparable approach to the one required by DMEPOS supplier, and have the IDTF provide a copy of the annual renewal of the insurance coverage for the IDTF to the Medicare contractor (the renewal package would include information on the coverage levels, as well as the premiums paid).

One commenter suggested removing the contractor as the certificate holder for the comprehensive liability insurance policy, but if they are named as a certificate holder for the comprehensive liability insurance policy that it be only for notification purposes.

Response: Given the concerns raised about the increased administrative burden, we agree that our designated contractor should not be included as a Certificate Holder on the IDTF's comprehensive liability insurance policy. We have revised the performance standard found at § 410.33(g)(6) to remove the requirement that our designated contractor be listed as a Certificate Holder on the IDTF's comprehensive liability insurance policy. However, we believe that it is essential that a Medicare fee for service (FFS) contractor be allowed to verify information contained in the comprehensive liability insurance

policy. We believe that a Medicare contractor (that is, carrier or Part A/Part B Medicare Administrator Contractor) should be able to verify the issuance of a comprehensive liability insurance policy with an insurance agent or, as necessary, an underwriter. This approach will allow a Medicare FFS contractor to review and verify that a comprehensive liability insurance policy has been issued and is in effect at the time of enrollment and throughout the enrollment period. We have revised § 410.33(g)(6) to read, "Has a comprehensive liability insurance policy in the amount of at least \$300,000 per location that covers both the supplier's place of business and all customers and employees of the IDTF. The policy must be carried by a nonrelative-owned company. Failure to maintain required insurance at all times will result in revocation of the IDTF's billing privileges retroactive to the date the insurance lapsed. IDTF suppliers are responsible for providing the contact information for the issuing insurance agent and the underwriter. In addition, the IDTF must—

- Ensure that the insurance policy must remain in force at all times and provide coverage of at least \$300,000 per incident; and
- Notify the CMS designated contractor in writing of any policy changes or cancellations."

b. § 410.33(g)(2)

In § 410.33(g)(2), we proposed to establish a 30-day reporting period for certain reportable events and a 90-day reporting period for all other reportable events.

Comment: One commenter asked that we define the term "nonrelative owned" while another commenter asked that we remove this term altogether because we are not precluding self insurance.

Response: While we do not believe that it is necessary to define the term "nonrelative owned" in this rulemaking effort, a non-relative owned company applies to insurance policies obtained through a familial relationship, not a related organization or business partner. Therefore, we are not removing this term from the performance standard.

Comment: Several commenters supported our proposal to revise the reporting requirements found in the performance standard found at § 410.33(g)(2). One commenter supported the CMS proposal to revise the reporting requirements found in performance standard at § 410.33(g)(2) to establish separate reporting periods for different reportable events. The proposed changes will provide the information desired by CMS in a timely

manner while minimizing the administrative burdens on both IDTFs and the Medicare contractors caused by the current notification standard.

Response: We appreciate these comments and agree that revising this standard will reduce the administrative burden on both IDTFs and our contractors.

Comment: One commenter recommended that we revise the CMS-855B to list the specific changes that must be reported within 30 calendar days of the change. However, one commenter stated that requiring the reporting of changes depending on the type change in 30 or 90 days puts an unfair burden on IDTFs.

Response: We agree that the CMS-855B should be revised and should list the specific changes that must be reported within 30 calendar days of the change. Currently, IDTFs are required to report all changes in 30 days. Our proposal would limit the number of reportable events that would need to be reported within 30 days of the change. We intend to revise the CMS-855B to clarify which reportable events must be reported within 30 and 90 days. We will use the Paperwork Reduction Act process to seek specific comments in seeking revisions to the CMS-855B.

Comment: One commenter recommended that we allow IDTFs to make changes online.

Response: We are developing the Provider Enrollment, Chain, and Ownership System (PECOS) Web, which will allow all providers and suppliers, including IDTFs, to enroll or report enrollment changes via the Internet. We are hoping to implement PECOS Web in most parts of the country by March 2008.

Comment: One commenter suggested that all changes should be reported to CMS within 90 days or in the alternative. This commenter also recommended that IDTFs report any changes that have occurred in the preceding quarter on a quarterly basis.

Another commenter suggested that we should allow at least 90 days for reporting changes in contact information with the contractor. This commenter also suggested that we further define what the policy and coverage requirements for self insurance and the term "independent underwriter."

Response: Section 410.33(g)(2) requires IDTFs to report all changes in 30 days. By adopting our proposal, we limit the number of reportable events that would need to be reported within 30 days of the change. As stated above, we intend to revise the CMS-855B to clarify what items must be reported

within 30 and 90 days. Since many IDTFs operate on different schedules, it would not be practical to implement a quarterly reporting requirement.

As a result of the issues raised by the commenters, we are revising § 410.33(g)(2) to read, "Provides complete and accurate information on its enrollment application. Changes in ownership, changes of location, changes in general supervision, and adverse legal actions must be reported to the Medicare FFS contractor on the Medicare enrollment application within 30 calendar days of the change. All other changes to the enrollment application must be reported within 90 days."

c. § 410.33(g)(8)

We received the following comments in response to our proposal at § 410.33(g)(8).

Comment: Several commenters recommended that we consider limiting the types of beneficiary complaints that are subject to the performance standard found in § 410.33(g)(8). Another commenter recommended that the standard found in § 410.33(g)(8) apply only when a beneficiary formalizes their complaint in writing. Other commenters stated that the proposed change in § 410.33(g)(8) is unnecessary, not to mention ambiguous and labor intensive to implement.

One commenter recommended that we model the IDTF documentation requirement after standards established by the Food and Drug Administration. Specifically, this commenter recommends that IDTFs maintain a record for each serious complaint received by the facility for at least 3 years from the date the complaint was received.

Another commenter recommended that we clarify that IDTFs are required to monitor only those beneficiary complaints that relate to the quality of care the patient receives.

One commenter stated that the standard at § 410.33(g)(8) be clarified to eliminate the documentation of routine billing questions so there is no unnecessary burden on small business entities.

One commenter suggested that instead of adopting § 410.33(g)(8) as written for documenting a beneficiary's questions or complaints, IDTFs should be required to develop and adhere to a complaint policy that includes documentation of material medical or billing complaints, and that if CMS adopts the current provision, the word questions should be changed to complaints. The commenter also maintains that IDTFs should be allowed

to keep documents that are older than 30 days at a site other than the IDTF's physical location and CMS should clarify how long the IDTFs are required to keep each complaint and whether an IDTF will be required to record the insurance claim number for each complaint.

Other commenters recommended that we clarify § 410.33(g)(8) to specifically state that this standard relates to complaints regarding the provision of service, because as written, it will impose a sweeping new recordkeeping requirement that drastically affects small business entities.

Response: Based upon the comments received, we have revised this provision to clarify and limit the amount of documentation that is necessary when a clinical complaint is received in writing. We also are clarifying and limiting the amount of documentation that is necessary when a clinical complaint is received in writing. We believe that complaints should be readily available for examination and we will establish a time frame for maintaining this documentation. Therefore, we have revised § 410.33(g)(8) accordingly.

Comment: One commenter recommended that we develop a standardized complaint form and an electronic Web-based platform for submitting complaints regarding an IDTF.

Response: We believe that an IDTF can document any formal complaints it receives in the most convenient way possible for that IDTF.

After reviewing public comments regarding our proposed change to § 410.33(g)(8), we are adopting this proposed change with modifications. By revising this language, we believe that we are reducing the paperwork burden on IDTFs to maintain and respond to written clinical complaints, rather than all questions and complaints it receives from beneficiaries. Section 410.33(g)(8) is revised to read, "Answer, document, and maintain documentation of a beneficiary's written clinical complaint at the physical site of the IDTF (for mobile IDTFs, this documentation would be stored at their home office.) This includes, but is not limited to, the following:

- The name, address, telephone number, and health insurance claim number of the beneficiary.
- The date the complaint was received; the name of the person receiving the complaint; and a summary of actions taken to resolve the complaint.
- If an investigation was not conducted, the name of the person

making the decision and the reason for the decision.”

By making this change, we believe that we are reducing the paperwork burden on IDTFs by asking them to maintain and respond to written clinical complaints, rather than address all questions and complaints it receives from beneficiaries.

d. § 410.33(b)(1)

We received the following comments in response to our proposal at § 410.33(b)(1).

Comment: Several commenters agreed with our proposal to delete the requirement that the supervising physician is responsible for the overall operation and administration of an IDTF.

Response: We appreciate these comments and are adopting this change in the final regulation.

Comment: One commenter recommended that we delay the implementation of our clarification that a physician providing general supervision can oversee a maximum of three IDTF sites by noting that term, “sites” includes fixed, as well as mobile sites.

Response: We believe that a physician providing general supervision can oversee a maximum of three IDTF sites which includes fixed as well as mobile sites.

Comment: One commenter recommended that we clarify that the three site limitation only relates to the provision of general supervision. In addition, one commenter recommended that we clarify that while a physician may only provide general supervision to three IDTF sites, this provision does not apply to the number of interpreting physicians at an IDTF site.

Response: We agree with this comment and will clarify that the supervision limitation only applies to general supervision.

Comment: One commenter stated that our proposal to consider each mobile IDTF unit as one IDTF site was unreasonable.

Response: We disagree and we believe that a physician providing general supervision can oversee a maximum of three IDTF sites. We maintain that fixed and mobile IDTFs essentially are furnishing the same services. We note that the term, “sites” includes fixed as well as mobile sites because there are three concurrent locations where testing may occur at a given time.

Comment: One commenter stated individual locations should be counted only if they have separate Medicare PINs.

Response: With Medicare’s implementation of the National Provider Identifier (NPI) on or before May 23, 2008, Medicare contractors will no longer issue billing numbers to the public. Providers and suppliers will use their assigned NPI to submit claims to Medicare. As such, organizations may obtain one or many NPIs. Accordingly, we are not able to adopt this suggestion.

Comment: One commenter suggested that it would be inappropriate to require that a mobile IDTF have a different supervising physician for every three office locations that it visits, therefore this provision should apply only to those IDTFs in a fixed location.

Response: We believe that a physician providing general supervision can oversee a maximum of three IDTF sites and note that the term, “sites” includes fixed, as well as mobile sites, because there are three concurrent locations where testing may occur at a given time. A mobile IDTF may visit multiple locations and it would still be considered one mobile unit. The number of places a mobile IDTF visits does not change the fact that this is a single unit and up to three fixed base or mobile units may be under the general supervision of one physician.

Comment: One commenter stated that the mobile unit described at § 410.33(b)(1) should be consistent with the language used on the CMS-855B enrollment application.

Response: We will consider revising the CMS-855B to incorporate this recommendation.

Comment: One commenter recommended treating fixed base sites and portable units on a comparable basis in that a supervising physician not be limited to supervising three portable units, but also could supervise three sites from which portable units are dispatched.

Response: A mobile IDTF may visit multiple locations, and it would still be considered one mobile unit. The number of places a mobile IDTF visits does not change the fact that this is a single unit and up to three fixed base or mobile units may be under the general supervision of one physician. Under the commenter’s scenario, any number of mobile units could be in use and a physician would not be able to provide general supervision to an infinite number of mobile units.

Comment: One commenter recommended that we revise § 410.33(b) to move to a diagnostic equipment threshold limit instead of an IDTF site limit since, as proposed, the provision allowing fixed based IDTFs to run limitless testing procedures at the IDTF is equated with a mobile unit running

one test at a time. Therefore the number of supervising physicians should be determined through testing volume and not location.

Another commenter recommended that a maximum threshold of 15 units per supervising physician would be advisable and that it should be made clear that this section applies to general supervision and not direct or personal supervision.

Response: Due to the varied and ever changing equipment used by IDTFs, it would be impractical to establish such limits.

Comment: One commenter recommended that we conduct additional audits, monitoring, and enforcement actions, where warranted, to address existing compliance problems.

Response: We agree with the commenters that audits, monitoring, and enforcement efforts are effective ways to identify individual compliance issues. We already require that Medicare contractors conduct an onsite visit to verify the performance standards found in this section prior to initial enrollment. We will consider adding and/or redirecting existing resources to ensure that an IDTF remains in compliance with these standards.

Comment: One commenter requested clarification to differentiate between fixed and mobile IDTFs business models and the differences by which IDTFs using these models provide services.

Response: A fixed base IDTF performs all of its diagnostic testing at the practice location found on the Medicare enrollment application (CMS-855), whereas a mobile IDTF travels and performs its diagnostic tests at locations other than a single practice location.

Comment: One commenter requested that we clarify the definition of “site” versus “testing locations” distinction.

Response: We consider sites and testing locations to be a practice location for both fixed base and mobile IDTFs.

Comment: One commenter suggested that the language at § 410.33(i)(3) is in error and was meant to be a definition, because it explains the first two parts of the effective date provision. The commenter stated that they believe that the date which a signed enrollment application is submitted should be considered the date of filing and that any time lag in contractor decisions should be excluded when determining the date of filing.

Response: We agree with the commenter and are revising § 410.33(b)(1) accordingly.

After reviewing the public comments, we are amending the provision to

remove the following sentence from § 410.33(b)(1), "The IDTF supervising physician is responsible for the overall operation and administration of the IDTFs, including the employment of personnel who are competent to perform test procedures, record and report test results promptly, accurately and proficiently, and for assuring compliance with the applicable regulations".

We are adopting the provision at § 410.33(b)(1) which clarifies the meaning of what constitutes three IDTF sites to include both fixed sites and mobile units. This includes moving portable diagnostic equipment to another location and used it to provide IDTF services. Accordingly, we believe that a physician providing general supervision as defined in § 410.32(b)(3)(i) can oversee a maximum of three sites (that is, fixed or mobile) where concurrent operations can be performed. In addition, we are clarifying that that this provision applies only to general supervision within an IDTF setting. Section 410.33(b)(1) is revised to read, "Each supervising physician must be limited to providing general supervision to no more than three IDTF sites. This provision applies to both fixed sites and mobile units where three concurrent operations are capable of performing tests."

2. New IDTF Standards

a. § 410.33(i)

In § 410.33(i), we proposed to establish an initial enrollment date for IDTFs and to limit the retrospective period for which an IDTF can obtain payment for services after enrolling into the Medicare program.

Comment: One commenter recommended that we adopt an accelerated rollout plan of the PECOS Web to facilitate the enrollment process for IDTFs.

Response: We expect to implement PECOS Web in most parts of the country by March 2008.

Comment: One commenter recommended that we ensure that Medicare contractors process enrollment applications in a timely manner so that beneficiaries will have access to quality and convenient healthcare delivery at an IDTF.

Response: We will continue to work with all Medicare contractors to ensure that applications are processed in a timely and accurate manner. With the implementation of PECOS Web, we believe that many of the processing delays that have occurred within the last year will be corrected. Specifically, PECOS Web will facilitate the

submission of a complete application and allow applicants to make any necessary changes to their enrollment application in a timely manner.

Comment: Several commenters recommended that we revise our proposals to allow an IDTF to begin billing Medicare for claims with dates of service on or after the day on which the IDTF submits a "substantially correct" or "substantially complete" enrollment application or the date the IDTF first furnishes services at its location, whichever is later.

Response: We disagree with the recommendation to permit an IDTF to submit claims with dates of service on or after the day which the IDTF submits a "substantially correct" enrollment application or the date the IDTF first furnishes services at its location, whichever is later. We believe that it is essential that all providers and suppliers, including IDTFs, submit a complete application at the time of filing or perfect the submission of their enrollment application in response to a contractor's request for information. Accordingly, an applicant who submits a complete application or responds in a timely manner to a request for additional information is not disadvantaged by this proposal. However, it is important to note that if an application is rejected in accordance with the provisions found at § 424.525, the applicant will need to submit a new application to enroll in the Medicare program. In this case, the applicant only will be able to seek payments for those services furnished on or after the date of filing or when the Medicare contractor has approved the second application request.

Comment: One commenter recommended that retroactive billing (once approval has been determined) be allowed back to the time of the initial application (even if the first submission is rejected).

Response: As stated above in this section, we disagree with this recommendation. We believe that an IDTF should be allowed to bill for services furnished on or after the date of filing or the date the practice location became operational. However, we do not believe that it is appropriate to allow an IDTF to bill for services back to the filing date of the initial application if the initial application was rejected due to the nonsubmission of information or denied because the applicant did not meet the program requirements to enroll as an IDTF.

Comment: One commenter recommended that a 60-day period be allowed for retroactive billing before an IDTF is enrolled.

Response: While we believe that an IDTF should be allowed to bill for services furnished on or after the date of filing or the date the practice location became operational, we do not believe that it is appropriate to allow an IDTF to bill for services prior to the filing date associated with when the application was submitted.

Comment: One commenter recommended that Medicare contractors follow a protocol that outlines the items that will require a contractor to reject or deny an enrollment application.

Response: Medicare contractors are bound by applicable enrollment regulations and CMS manual instructions. Specifically, all Medicare contractors are required to follow regulations found at § 424.525 and manual instructions found in publication 100-8, Chapter 10 of the Program Integrity Manual (PIM) when rejecting an enrollment application for insufficient information. In addition, Medicare contractors are required to follow regulations found at § 424.530 and manual instructions found in publication 100-8, Chapter 10 of the PIM when denying an enrollment application.

Comment: One commenter recommended that we not implement our proposal to preclude an IDTF from being allowed to bill Medicare retroactively for services that are rendered prior to the provider being formally approved by the applicable Medicare contractor to participate in the Medicare program.

Response: Since our proposal specifically allows an IDTF to receive reimbursement for services furnished on or after the filing or the date the IDTF opened a new practice location, whichever was later, we believe that we are allowing IDTFs a limited amount for retroactive billing. As stated in the preamble to the proposed rule, the purpose of this rulemaking effort is to establish a date of enrollment for IDTFs where we believe that the enrolling IDTF meets all of the program requirements to participate in the Medicare program.

Comment: One commenter recommended that we clarify that our proposed change in billing be applied only to new or initial enrollment applications and would not affect existing operations when changes or additions are made to an enrollment application, such as the addition of a new physician or piece of equipment.

Response: In general, we agree with this commenter in that the proposed change only will apply to new or initial enrollment applications. Since the provision is designed to limit

retrospective billing prior to enrollment in the Medicare program, we do not believe this change will impact existing IDTFs who are making a change to an existing enrollment record for a fixed or mobile practice location. However, it is important to note that the limitations on retroactive billing will apply to existing IDTFs who are adding a new fixed or mobile practice location to their existing enrollment record. Moreover, a limitation on retroactive billing may apply when there is change of ownership.

Comment: One commenter stated that they had no issues with the effective date of the billing privileges provision. However, this commenter suggested that this provision be tied to a requirement that the CMS designated contractor process the application in a timely fashion.

Response: We are also concerned about delays associated with the enrollment process. However, we recognize that many of the delays are the result of IDTF suppliers not submitting a complete application at the time of filing or failing to submit complete and timely responses to a contractor's request for information.

In addition, we believe that it is appropriate to expect meaningful Medicare contractor processing timeliness standards. As necessary, the agency can update or revise processing standards found in Publication 100–8, Chapter 10 of the PIM. The PIM establishes processing standards for initial applications, changes of information, and reassignments that all Medicare contractors must adhere to. Specifically, we currently require Medicare contractors to process 80 percent of initial applications within 60 days, 90 percent of initial applications within 120 days, and 99 percent of initial applications within 180 days. We also require Medicare contractors to process 80 percent of changes of information and reassignments within 45 days, 90 percent of changes of information and reassignments within 60 days, and 99 percent within 90 days.

With the implementation of PECOS Web, an internet version of the Medicare enrollment process, in FY 2008, we expect to establish more stringent contractor processing timeliness standards for applications submitted via PECOS Web.

Comment: One commenter stated that the effective date of the billing

privileges provision may economically affect small and medium sized business in that the IDTF must list the credentialed employees on the application itself in order for the application to be processed, and that these businesses cannot use or bill for their services during the time periods that they are not enrolled. Further, the commenter states that it would be impractical to hire these technicians if they cannot use them to perform the tests for the time it takes to get approved.

Response: We disagree with the commenter because all IDTFs should have proper staffing, including credentialed technicians, at the time the IDTF practice location is applying to participate in the Medicare program or when the IDTF is operational.

Comment: One commenter suggested that an IDTF that is enrolled and in good standing in the Medicare program at one location be able to enroll new sites retroactively to the first date of service at the new location.

Response: We disagree with this recommendation because the approval of one practice location does not necessarily mean that a second practice location meets the requirements for approval.

Comment: One commenter recommended that we require that applicants be notified of their enrollment status within 60 days of submitting their applications.

Response: We believe that this comment is outside the scope of this final rule. However, given certain resource limitations, contractors are unable to respond to such status inquiries. With the implementation of PECOS Web, providers and suppliers, except DMEPOS suppliers, will be able to check the status of their applications via the Internet.

After reviewing the public comments we are finalizing the provision at § 410.33(i) to state that we will establish an initial enrollment date for an IDTF that would be the later of: (1) the date of filing of a Medicare enrollment application that was subsequently approved by Medicare FFS contractor; or (2) the date an IDTF first started furnishing services at its new practice location. We also adopted the “date of filing” as the date that the Medicare FFS contractor receives a signed provider enrollment application that the Medicare FFS contractor is able to process for approval. If the Medicare FFS contractor rejects or denies an enrollment application that is not later overturned during the appeals process, the new date of filing would be established when an IDTF submits a

new enrollment application that the contractor is able to process to approval.

With the implementation of an Internet enrollment process referred to as the PECOS Web in 2008, the date of filing for applications submitted through PECOS Web will be the date the Medicare contractor receives all of the following: (1) A signed Certification Statement; (2) an electronic version of the enrollment application; and (3) a signature page that the Medicare contractor processes to approval.

While this change limits the retrospective payments that an IDTF may obtain from the Medicare program, we believe that this approach will ensure that a Medicare contractor is able to verify that an IDTF meets all program requirements at the time of filing, including the performance standards outlined in § 410.33(g) before payment for service occurs.

b. § 410.33(g)(3)

We received the following comments regarding our proposal at § 410.33(g)(3) to expressly preclude hotels and motels from being considered an appropriate site for an IDTF setting.

Comment: One commenter stated that many IDTFs have contracts directly with a hotel or motel where they rent space for studies and that they disagreed with the rules' provision to ban such a situation.

Response: We disagree with this comment because we believe that space located within a hotel or motel can easily be transferred to other uses other than providing sleep studies.

Comment: Several commenters stated that a hotel or motel room is not appropriate places for diagnostic testing to take place.

Response: We agree with these comments and have revised § 410.33(g)(3) accordingly.

Comment: One commenter suggested that the provision at § 410.33(g)(3) be changed to state that the requirements for hand washing and patient privacy only apply to IDTFs that see patients and to clarify that being able to access records electronically fulfills the requirement of storing business and medical records.

Response: We have amended § 410.33(g)(3) to state that the requirements for hand washing and patient privacy only apply to IDTFs that see patients and to clarify that being able to access records electronically fulfills the requirement of storing business and medical records.

We are adopting a revision to § 410.33(g)(3) to expressly preclude hotels and motels from being considered an appropriate site for an IDTF setting.

Based on public comments, we believe that a hotel or motel is not an appropriate place for diagnostic testing to take occur. Accordingly, we have revised § 410.33(g)(3) to read, "Maintain a physical facility on an appropriate site. For the purposes of this standard, a post office box, commercial mailbox, motel, or hotel are not considered an appropriate site. The physical facility, including mobile units, must contain space for equipment appropriate to the services designated on the enrollment application, facilities for hand washing, adequate patient privacy accommodations, and the storage of both business records and current medical records within the office setting of the IDTF, or IDTF home office, not within the actual mobile unit."

Additionally, we have added an exception at § 410.33(g)(3)(ii), where IDTFs that do not see beneficiaries at their locations are exempt from providing hand washing and patient privacy accommodations.

c. § 410.33(g)(15)

At § 410.33(g)(15), we proposed a new performance standard which stated, "Does not share space, equipment, or staff or sublease its operations to another individual or organization."

Comment: One commenter stated that they were concerned about the emergence of arrangements in which a physician practice leases a block of time from an imaging provider (such as an IDTF) or agrees to pay the provider a per service fee to use its facility. The group practice then refers its patients to the imaging provider for imaging tests and bills the insurer for the services, usually profiting from the difference between the insurer's payment rates and the fees the practice pays to the imaging provider.

Response: We agree with the commenter and reiterate that our proposals are designed to prohibit such practices.

Comment: Several commenters supported our proposal to prohibit IDTFs from sharing space, equipment, or staff, or subleasing their operations to another individual or organization.

Response: We appreciate these comments and agree that there has been a proliferation of share use agreements between IDTFs and physicians and/or other organizations that have allowed the sharing of space and equipment.

Comment: One commenter stated that they applauded our efforts to address an alarming proliferation of referring physicians entering into "lease" or similar purchased test arrangements with imaging centers for the primary

purpose of enabling physicians to profit from their own referrals.

Response: We appreciate these comments as our proposals are designed to prohibit such practices.

Comment: Several commenters recommended that CMS not finalize § 410.33(g)(15) because it severely restricts the use of an IDTF's property and places unnecessary limitations on the entity.

Response: We disagree with this comment. With the revisions we are making to § 410.33(g)(15), we believe that an IDTF's property is fully available for use solely by the IDTF. The adopted provision at § 410.33(g)(15) will allow an IDTF to conduct all of its approved diagnostic testing procedures.

Comment: One commenter stated that the proposed rule would prohibit an IDTF from participating in any type of leasing arrangement.

Response: In this final rule with comment period, we are prohibiting the leasing or subleasing of an IDTF practice location, as well as diagnostic equipment that are used in taking the initial diagnostic test. In addition, we are prohibiting leasing and subleasing to a third party.

Comment: One commenter requested that we clarify whether the proposed performance standard found at § 433.10(g)(15) would permit a multi-specialty clinic and an IDTF to be enrolled as a clinic and an IDTF, and for portions of space and staff to be used for both clinic and IDTF activities.

Response: While we understand the commenter's concern, we do not believe that it is appropriate to co-locate a multi-specialty clinic in the same practice location as an IDTF. Specifically, while we are not prohibiting the sharing common of hallways, parking, or common areas, we believe that a multi-specialty clinic cannot occupy or be co-located within the same practice location. For example, a multi-specialty clinic and an IDTF could not enroll or remain enrolled using the same suite number within the same office building.

Comment: Some commenters recommended that we define the term, "individual or organization" to exclude hospitals and nonreferring radiologists, because hospitals and nonreferring radiologists are not in a position to self-refer.

Response: We disagree that the terms "individual and organization" needs to be defined. For the purposes of this rule, an individual is a person, and an organization is any entity other than an individual.

Comment: One commenter recommended that we permit an

adjoining physician practice or a radiology group that is the owner of an IDTF to share space, equipment, and staff.

Response: While we agree that it is common for IDTFs to share common areas (that is, waiting rooms) with the adjoining physician practice or radiology group that is an owner of the IDTF, we do not believe that it is appropriate for IDTFs to share common practice locations or diagnostic testing equipment.

Comment: Several commenters recommended that we not extend the prohibition of sharing space, equipment, and staff to the mobile IDTF setting.

Another commenter recommended that the proposed restriction on sharing space, equipment, and staff should not apply to mobile IDTFs, as this would add both physical and financial burdens that mobile units simply could not meet.

Response: We agree with these commenters that requiring mobile IDTFs to adhere to limitations regarding space, equipment, and staffing may limit beneficiary access to necessary mobile services and increase the costs of providing necessary diagnostic care. Accordingly, we are excluding mobile IDTFs from the provisions found at § 410.33(g)(15).

Comment: One commenter recommended that we revise our proposals to account for certain practical implications concerning the imaging industry, including common and legitimate sharing practices between multiple IDTFs, between IDTFs and hospitals, and between IDTFs and radiologist.

Response: While we agree that it is reasonable for IDTFs located within a hospital to share practice locations and diagnostic testing equipment, we continue to have significant concerns regarding the sharing of space by IDTFs in a nonhospital setting.

Comment: One commenter recommended that we revise the performance standard found at § 410.33(g)(15) to state, "Does not share space, equipment or staff or sublease its operations to another individual, organization, employee or contractor of such organizations, that refers Medicare patients to the IDTF for designated health services."

Response: We have considered this comment in revising the performance standard at § 410.33(g)(15).

Comment: One commenter believed that the performance standard found in § 410.33(g)(15) applies to hospitals.

Response: Upon review of the comments, we have revised § 410.33(g)(15) to exclude hospitals.

Comment: Several commenters recommended that we clarify that the proposed performance standard found in § 410.33(g)(15) would apply only to newly enrolling IDTFs and not IDTFs already enrolled in the Medicare program. Specifically, these commenters requested that we clarify that this new standard would allow an IDTF to continue to lease personnel and equipment from third parties provided that the IDTF uses the personnel, space, and equipment exclusively throughout the lease term.

Response: We maintain that the provision found in § 410.33(g)(15) applies to both newly enrolling IDTFs, as well as those IDTFs currently enrolled in the Medicare program. This provision does not prohibit an IDTF from leasing space or equipment that is used solely by that IDTF-party, such as a building management company or an equipment manufacturer. This does not preclude an IDTF from leasing any part of its practice location or equipment used in conducting the initial diagnostic procedure to another Medicare-enrolled individual or group to conduct diagnostic testing activities.

Comment: One commenter recommended that we clarify that employees of affiliated employers under the Fair Labor Standards Act are not considered "shared staff" under this new standard. In addition, several commenters recommended that the prohibition on sharing "staff" be limited to sharing nonphysician personnel.

Response: The new sharing provision has been modified to exclude the prohibition on the sharing of staff.

Comment: One commenter recommended that if we adopt the proposed performance standard found in § 410.33(g)(15) that the implementation date be delayed for at least 12 months to provide IDTFs and physician practices with sufficient time to find new office space, recruit additional staff, notify their patients and generally restructure their existing relationships. Another commenter recommended that we clarify our proposed performance standard found in § 410.33(g)(15).

Response: We agree with commenters and we are adopting a 1-year delay in implementation (effective January 1, 2009) of the space-sharing provision for IDTFs that are currently occupying a practice location with another Medicare-enrolled individual or organization that is found at § 410.33(g)(15)(i).

Comment: One commenter recommended that we clarify whether the proposed prohibition on sharing space, equipment, and staff is intended

to apply when the IDTF leases or subleases space from a hospital on a full-time, exclusive basis. Other commenters recommended that we exclude mobile IDTFs from the prohibition to share space because it is impractical in complying with this provision. One commenter stated that the sharing of staff standard is impractical to comply with and should not be extended to mobile IDTFs, because accredited and trained contracted personnel are sometimes necessary to contract with on a temporary basis.

Another commenter suggested that we not apply this provision to mobile IDTFs and instead, permit an IDTF to share space, equipment and staff with an entity that is related to the IDTF, such as through common control or ownership. Also, this commenter recommended that we should clarify in what situation an IDTF could not share staff, such as; supervising physician and nonphysician personnel.

Response: This provision is not intended to restrict an IDTF from entering into a rental agreement for space or equipment, excluding hospitals, as long as that IDTF, or the owner of the IDTF are exclusively using that space or equipment. We are excluding mobile IDTFs from the prohibition on sharing space and staff.

Comment: One commenter stated that the sharing of space provision should not apply to a Medicare-certified IDTF that leases or subleases space and/or qualified technical staff from a hospital on a full time, exclusive basis (they are not "shared" with the hospital).

Response: We agree with the comment and the standard has been revised to reflect this concern.

Comment: One commenter wanted clarification on whether we will permit an IDTF to utilize a common area in a building where an IDTF enters into a lease or sublease with a hospital for the full-time, exclusive use of the operation of the IDTF.

Response: We will permit an IDTF to utilize a common area in a building where an IDTF enters into a lease or sublease with a hospital for the full-time exclusive use of the operation of the IDTF. However, the IDTF must have its own practice location that is only used by that IDTF.

Comment: One commenter requested clarification on whether we intend to prohibit only new space, equipment, or staff sharing arrangements from the effective date of the rule or if it will apply to existing arrangements. If it applies to existing arrangements, then the commenter requests that the implementation be delayed by 1 year.

Response: While we intend to prohibit the sharing of space at a practice location from the effective date of the rule for newly-enrolling IDTFs (including those with applications that are still pending as of January 1, 2008), we are adopting a 1-year delay in implementation (effective January 1, 2009) of the space-sharing provision for IDTFs that are currently occupying a practice location with another Medicare-enrolled individual or organization that is found at § 410.33(g)(15)(i).

Comment: One commenter requested clarification as to whether we will permit an IDTF that leases or subleases space and/or staff from a hospital to purchase back-office services from the hospital. (These types of service may include, but are not limited to, transcription, billing, collection, recordkeeping, and computer access services, based upon a flat fee or at cost plus to the hospital).

Response: We will permit an IDTF to lease or sublease space from a hospital and to purchase services from the hospital which may include, but are not limited to, transcription, billing, collection, recordkeeping, and computer access services, based upon a flat fee or at cost plus to the hospital.

Comment: One commenter recommended that there should be an exception made at § 410.33(g)(15) for companies operating both an IDTF and portable x ray supplier, since both are surveyed and subject to multiple standards under the Medicare program.

Response: While we understand this concern, we believe that an IDTF must have a practice location where only one Medicare-enrolled IDTF is furnishing services. If another Medicare-enrolled entity is using the same practice location space as an IDTF, especially for shortened periods of time, our designated contractor is not able to determine which entity is responsible for meeting performance standards at a given time.

Comment: One commenter urged us to address the sharing of space, staff, and equipment provision by specifically excluding radiologists and radiology groups, who are not self-referring, from the sharing arrangements in IDTFs due to the increased costs and possible detriment to the beneficiary (numerous visits to different locations and increased stress) that may occur in this situation.

Response: We believe that the practice location and equipment that an IDTF uses for its initial diagnostic testing cannot be used by another Medicare provider or supplier, and therefore, we

are not excluding radiologists and radiology groups.

Comment: One commenter agreed that it would be inappropriate to commingle the clinical staff listed on the CMS-855 enrollment application during the times that the IDTF is open; however, the commenter maintains that non-clinical space and staff (such as waiting rooms, receptionists, and schedulers) should be shared with other entities.

Response: We agree with this comment and have amended the provision to reflect these concerns.

Comment: One commenter recommends that the sharing of nonclinical space, equipment and personnel be allowed between an IDTF and an adjacent facility, because it does not offer the same potential for abuse as situations where the clinical operations of the IDTF would be commingled.

Response: We have amended the provision found at § 410.33(g)(15) to address these concerns.

Comment: One commenter recommends that the sharing of space between a group or a physician practice and its own IDTF should not be prohibited. Another commenter recommends changing the proposed § 410.33(g)(15) because they believe it would prohibit wholly-owned corporate subsidiaries and affiliated under common control from sharing space, equipment, and staff in a cost efficient manner.

Response: We disagree with this recommendation since it is not feasible to distinguish between two different practices that are co-located at the same practice location. Also, this provision would not prohibit wholly-owned corporate subsidiaries and affiliated entities under common control from sharing equipment, as long as the change in equipment location is timely reported. In addition, the IDTF's practice location must be separately distinguishable and not commingled with another Medicare provider or supplier.

Comment: One commenter recommends changing the proposed § 410.33(g)(15) to read as follows: "Does not share space, equipment, or staff or sublease its operations to another individual or organization, except for a subsidiary or affiliated IDTF that is wholly owned by, and under the complete control of, the IDTF."

Response: We understand the commenter's recommendation and we have amended § 410.33(g)(15) to address the commenter's concern.

Comment: One commenter recommends that CMS specifically exempt IDTFs that have common ownership and common control from

the definition of "individual or organization," if CMS implements § 410.33(g)(15) as written.

Response: We disagree with the commenter's recommendation. While IDTFs may have common ownership, each practice location is enrolled separately.

Comment: One commenter offered support for our provision to prohibit fixed site IDTFs from sharing space, equipment, and staff or subleasing their operations to another individual or organization.

Response: We appreciate the commenters support on the proposed provisions.

Comment: One commenter suggested excluding radiologist and radiology groups from the definition of individual or organization in the regulatory language at § 410.33(g)(15) so that imaging IDTFs can share space, equipment, and staff with radiologists and radiology groups.

Response: We disagree with this recommendation because IDTFs enroll each practice location separately.

Comment: One commenter suggested that we clarify in the preamble that the prohibition does not preclude affiliated companies (which do not have any referring nonradiologist physicians as owners) that provide services integrally related to the operations of an imaging IDTF (such as interoperable information system, centralized credentialing, staff and billing) from sharing space, equipment and staff.

Response: We modified § 410.33(g)(15) to reflect concerns about the sharing of space and equipment. Since Medicare enrolls each IDTF at a separate location, we believe that it is not necessary to address how affiliated companies interact with an IDTF as long as each IDTF is in compliance with the provisions of this final rule with comment period.

Comment: One commenter suggested that CMS clarify that an ownership or investment interest held by radiologists and radiology groups in an imaging IDTF does not constitute sharing under § 410.33(g)(15).

Response: We agree that an ownership or investment interest held by radiologists and radiology groups in an imaging IDTF does not constitute sharing under § 410.33(g)(15).

Comment: One commenter suggested that we revise this provision to specify that an IDTF cannot share its space, equipment or staff with another individual or organization that has Medicare billing privileges, and that it is okay for another non-Medicare enrolled entity to use the IDTF's space, equipment, and staff.

Response: We agree with the commenter. The IDTF may not share clinical space or the diagnostic equipment involved in the original diagnostic test with a Medicare-enrolled provider or supplier.

Based on public comments, we have removed the sharing of staff aspect of this provision, and we are revising § 410.33(g)(15) to read, "With the exception of hospital-based and mobile IDTFs, a fixed-base IDTF does not—

- Share a practice location with another Medicare-enrolled individual or organization;
- Lease or sublease its operations or its practice location to another Medicare-enrolled individual or organization; or
- Share diagnostic testing equipment used in the initial diagnostic test with another Medicare-enrolled individual or organization."

We believe that it is inappropriate for a fixed-base (physical site) IDTF to commingle its practice location or the equipment used in conducting the initial diagnostic test with another individual or organization enrolled in the Medicare program. By sharing space and/or equipment, Medicare contractors are not able to determine if an IDTF meets all of enrollment requirements at § 424.500 through § 424.555 or whether each IDTF meets and maintains all performance standards and other requirements under § 410.33 and other applicable requirements.

After examining public comments, we believe that it is appropriate to establish two exceptions to the prohibition associated with sharing space and clinical equipment. These exceptions apply to mobile IDTFs or IDTFs that are co-located within a hospital.

A mobile IDTF, by its very nature, may share space with other Medicare-enrolled entities. As such, we believe that it would be detrimental to the IDTF industry to apply this new performance standard to mobile IDTFs, because this may limit beneficiary access to necessary mobile IDTF services and increase the costs of providing necessary diagnostic care. In addition, we believe that hospital-based IDTFs are inherently located within a larger facility type and based on the need of the hospital, may appropriately share space or clinical equipment to gain operating efficiencies with little additional risk to the Medicare program or its beneficiaries.

Finally, while all IDTF provisions are effective on the implementation date of this final rule with comment period, we believe that additional time may be needed for some IDTFs to change their business model if they are sharing a

practice location with another Medicare-enrolled individual or organization. Accordingly, we are adopting a 1-year transition period for IDTFs that are currently enrolled and are sharing a practice location with another Medicare individual or organization. While this 1-year transition period applies to the provision found at § 410.33(g)(15)(i) related to the sharing of space, it does not apply to the provisions found at § 410.33(g)(15)(ii) or § 410.33(g)(15)(iii). Accordingly, IDTFs are prohibited from maintaining or establishing leasing or subleasing agreements or the sharing of diagnostic testing equipment used in taking the initial diagnostic test, after the effective date of this rule.

3. Additional Comments and Responses

Comment: One commenter recommended that our proposal to prohibit the sharing of space, equipment, and staff be applied consistently in all imaging centers, whether enrolled as an IDTF or as a physician-directed clinic.

Another commenter recommended that any policy initiative intended to eliminate certain suspect leasing or space sharing arrangements should be applied to all imaging providers, not just IDTF providers.

One commenter supported the proposed prohibition on shared equipment but urged us to apply this prohibition to all entities (including physician practices, mobile units, and hospitals) that provide imaging services.

Some commenters believe an exception should be made to include cardiologists that are certified for the interpretation of nuclear cardiology studies in an IDTF as well as allow interpretation of nuclear cardiology studies for an IDTF.

One commenter stated that since self-insurance is permitted, the requirement that the insurance be purchased from a "non-relative owned company" should be removed, or replaced with a provision that permits an alternate method of meeting the requirement by maintaining insurance through a relative-owned company that has been approved by a state department of insurance or comparable state agency or that can be validated by a placing broker.

Another commenter recommended that CMS should end payments to independent contractor physicians who are not board-certified in Sleep Disorders Medicine.

One commenter recommended that CMS require interpreting physicians to have board certification in Sleep Medicine in metropolitan areas.

One commenter recommended that we edit the location of service language at § 410.33(e)(2) to redefine the location from which a service is billed.

Another commenter recommended requiring a hospital licensed entity and actual radiology group to be the owners of entities that do not have to register as IDTFs and allow related entities of the hospital and radiology group to also own the imaging center.

Response: We appreciate these comments and we will consider these recommendations in a future rulemaking effort.

J. Expiration of MMA Section 413 Provisions for Physician Scarcity Area (PSA)

Section 413(a) of the MMA added a new section 1833(u) to the Act. That section provided a 5 percent incentive payment to physicians furnishing services in physician scarcity areas (PSAs) for physicians' services furnished on or after January 1, 2005, and before January 1, 2008. Specifically, section 1833(u) of the Act provided for payment of an additional 5 percent of the payment amount for services furnished by primary care physicians in a primary care scarcity area and by non-primary care physicians in a specialist care scarcity area.

Because the provisions of section 1833(u) of the Act do not apply to services furnished after December 31, 2007, in the CY 2008 PFS proposed rule, we provided notification that these 5 percent incentive payments will no longer be made for services furnished on or after January 1, 2008.

The list of zip codes for both primary care and specialty PSAs can be found on the CMS Web site at http://www.cms.hhs.gov/hpsapsaphysicianbonuses/01_overview.asp.

Comment: We received comments expressing concern over the expiration of this provision. Commenters stated that the expiration of this provision may exacerbate the problems beneficiaries in rural areas experience in accessing medical services.

Response: We acknowledge the commenters' concerns regarding access to care, especially in rural areas. We provided notification of the pending expiration of this provision in the CY 2008 PFS proposed rule. We note that the Congress specifically established the PSA incentive program to apply only to claims for services furnished between January 1, 2005, and January 1, 2008. We do not have authority under the current statute to extend PSA bonus payments beyond this time frame.

K. Comprehensive Outpatient Rehabilitation Facility (CORF) Issues

In the CY 2008 PFS proposed rule (72 FR 38171), we discussed Medicare payment for comprehensive outpatient rehabilitation facility (CORF) services, including nursing services delivered within a CORF, which are defined by HCPCS code (G0128) for such services. We also explained that we use the payment amount established by an existing fee schedule other than the PFS when the PFS does not establish a payment amount for the CORF service. Specifically, we use the existing fee schedules for prosthetic and orthotic devices, DME and supplies, and drugs and biologicals for prosthetics and orthotics devices, durable medical equipment (DME) and supplies, and drugs and biologicals, respectively, provided by CORFs that are considered CORF services. Covered DME, orthotic and prosthetic devices, and supplies provided by a CORF are paid under the DMEPOS fee schedule.

Drugs and biologicals that are not considered to be self-administered are specified as CORF services at section 1861(cc)(1)(F) of the Act. However, as discussed in the proposed rule, we believe that drugs and biologicals provided to CORF patients are not appropriately provided as part of a rehabilitation plan of treatment and, as such, we proposed to remove drugs and biologicals from the scope of CORF services as defined at § 410.100. After reviewing comments, we have decided to retain within the definition of CORF services drugs and biologicals that are not self-administered, as discussed below in section II.K.7. However, as we are not aware of any non-self-administered drugs and biologicals that appropriately may be included as part of a rehabilitation plan of treatment, we intend to closely track the provision of drugs and biologicals in the CORF setting and do not expect CORFs to bill for such drugs and biologicals. In addition, because we believe it is appropriate for pneumococcal, influenza, and hepatitis B vaccines to be administered to CORF patients in the CORF setting, even though such vaccines fall outside the scope of CORF services, we also proposed to revise the conditions of participation at § 485.51(a) to permit CORFs to provide to their patients pneumococcal, influenza, and hepatitis B vaccines in addition to CORF services.

Because the regulations under 42 CFR parts 410 and 413 were never updated to reflect the change in CORF payment methodology from a "reasonable cost" basis to 80 percent of the lesser of a

payment amount under an existing fee schedule or the CORF's actual charge, we proposed to add a new subpart M to 42 CFR part 414 to reflect the change in CORF payment methodology.

In addition, we proposed revisions to the definitions of certain CORF services under § 410.100, in order to limit the scope of such services and items to those appropriately provided by qualified CORF personnel and related to the rehabilitation goals of the plan of treatment established under § 410.105(c). Specifically, we proposed to clarify the definition of physician services; respiratory therapy services; psychological and social services; nursing services; drugs and biologicals; supplies, appliances, and equipment; and the home environment evaluation. We also proposed to add clarifying language to § 410.105(b)(3) to make clear that physical therapy, occupational therapy, and speech-language pathology services can be provided offsite in the patient's home. In § 410.105(c), we proposed to clarify that CORF services, that are not skilled rehabilitation services, must directly relate to the physical therapy or other rehabilitation plan of treatment and its associated goals.

1. Requirements for Coverage of CORF Services Plan of Treatment (§ 410.105(c))

In accordance with section 1861(cc)(1) of the Act, requiring that CORF services be furnished "under a plan (for furnishing such items and services to such individual) established and periodically reviewed by a physician," § 410.105(c) provides that CORF services as defined under § 410.100 are covered only if furnished under a written plan of treatment. Specifically, the plan of treatment must: (1) Be established and signed by a physician prior to the commencement of treatment in the CORF setting; and (2) indicate the diagnosis and anticipated rehabilitation goals, and prescribe the type, amount, frequency, and duration of the services to be furnished. We interpret these provisions as requiring that the services furnished under the rehabilitation plan of treatment must relate directly to the rehabilitation of injured, disabled, or sick patients. Services provided in the CORF setting that do not relate directly to such rehabilitation goals and treatment plan are not covered as CORF services.

Therefore, we proposed to revise § 410.105(c) to clarify our policy that CORF services are covered only if they relate directly to the rehabilitation of injured, disabled, or sick patients. We believe our policy is consistent with the

statutory requirements under section 1861(cc) of the Act. Section 1861(cc)(1) of the Act specifies that CORF services must be furnished under a plan of treatment. Section 1861(cc)(1)(H) of the Act further states that "other items and services" are considered CORF services only if "medically necessary for the rehabilitation of the patient." We believe the implication of this limitation for "other items of services" is that all other CORF services (that is, those listed under sections 1861(cc)(1)(A) through (G) of the Act) also must be necessary for the rehabilitation of the patient. In addition, we noted that section 1861(cc)(2)(A) of the Act specifies that a CORF facility is a facility "primarily engaged in providing * * * diagnostic, therapeutic, and restorative services to outpatients for the rehabilitation of injured, disabled, or sick persons" (emphasis added). We believe this requirement further signals the Congress's intent that the services provided in a CORF setting be covered as CORF services only if such services relate directly to the rehabilitation of the patient.

Comment: One commenter supported the proposal to clarify that all services provided in a CORF must be directly related to the rehabilitation treatment plan. The commenter noted that this proposal is directly aligned with the goals and purpose of physical therapy.

Response: We appreciate the commenter's support of this clarification. Because the CORF is defined as a facility that is primarily engaged in providing diagnostic, therapeutic and restorative services to outpatients for the rehabilitation of injured, disabled or sick persons, we believe the intent of the statute is that all services rendered in a CORF must relate to the patient's rehabilitation needs which are stated in the patient's plan of treatment established by the physician. Section 1861(cc)(1) of the Act and § 410.100 clarify that physician services, and services of other qualified professionals, can be provided in a CORF; but, a physician must first certify that the patient requires skilled rehabilitation services, including physical therapy, occupational therapy, speech-language pathology, and respiratory therapy, and then establish the CORF patient's rehabilitation plan of treatment.

Therefore, we are finalizing § 410.105(c) as proposed with the exception that we have added language to clarify our policy that the rehabilitation plan of treatment, along with its goals, is specific to the skilled rehabilitation services for physical therapy, occupational therapy, speech-

language pathology, or respiratory therapy and that these services are distinct from all other CORF services which, when provided, must directly relate to the goals of the rehabilitation treatment plan.

2. Included Services (§ 410.100)

Section 410.100 establishes the services that are covered under the CORF services benefit, consistent with section 1861(cc)(1) of the Act. Because of the change in payment methodology from that based on cost to payment under the PFS and other existing fee schedules beginning in CY 1999, this section does not reflect our current payment policies. Therefore, we proposed to clarify our payment policy in the introductory paragraph of this section by including a cross reference to proposed § 414.1101, which sets forth the payment methodology for CORF services, including identifying the applicable fee schedule for each CORF service. In addition, we proposed to revise:

- The definition of physician services to reflect the change in payment methodology for CORF services;
- The definitions of physician services, respiratory therapy services, social and psychological services, and nursing services to ensure that these definitions include only those services appropriately provided by qualified nonphysician and physician personnel and related to the rehabilitation plan of treatment established under § 410.105(c); and
- The definition of supplies, equipment, and appliances to conform to the statutory provision at section 1861(cc)(1)(G) of the Act.

We also proposed to remove the provision for drugs and biologicals. Although vaccines are not included in the definition of CORF services at section 1861(cc)(1) and § 410.100, we proposed to make revisions to the CORF conditions of participation at § 485.51 to reflect current coverage and payment policy for vaccines provided in the CORF setting.

3. Physician Services (§ 410.100(a))

Section 410.100(a) defines the physician services included within the scope of CORF services. Specifically, those services of a CORF physician described as administrative in nature are considered CORF services, to the exclusion of diagnostic and therapeutic services, which are physician services under section 1861(q) of the Act and separately billable as physician services under 42 CFR part 414, subpart B. Section 1861(cc)(1) of the Act excludes from the definition of CORF services

any item or service that, if furnished to an inpatient of a hospital, would be excluded under section 1861(b) of the Act. Section 1861(b)(4) of the Act excludes from the definition of "inpatient hospital services" the "medical or surgical services provided by a physician," which would include the diagnostic and therapeutic services of a physician. Consequently, diagnostic and therapeutic services provided in the CORF setting by a physician are not considered CORF services. In contrast, because those services of a CORF physician that are of an administrative nature are not "medical" services, such services are included in the definition of CORF services.

In accordance with section 1861(cc)(2)(B)(i) of the Act and § 485.70(a)(1), the CORF physician must be either a medical doctor (MD) or a Doctor of Osteopathy (DO). The conditions of participation at § 485.70(a)(2) and (3) further require that the physician have training or experience in the medical management of patients requiring rehabilitation services. The conditions of participation at § 485.58(a)(1)(i) also require the CORF facility physician to provide, in accordance with accepted principles of medical practice, medical direction, medical supervision, medical care services and consultation. In the CY 2008 PFS proposed rule, we proposed to revise § 410.100(a) to clarify that only those physician services required and provided by the CORF facility physician that are administrative in nature are considered CORF services, whereas diagnostic and therapeutic services provided by a physician to CORF patients are considered physician services under section 1861(q) of that Act. Specifically, we proposed to define CORF physician services as those services provided by a CORF facility physician that are administrative in nature, such as consultation with and medical supervision of nonphysician staff, patient case review conferences, utilization review, and the review of the therapy plan of treatment, as appropriate.

Services provided to a CORF patient by the CORF facility physician or other physician that are not administrative in nature but that are diagnostic or therapeutic services are considered physician services under section 1861(q) of the Act. Where these services are covered, they are separately payable to the physician as physician services under the PFS at the nonfacility payment amount.

In addition, § 410.100(a) currently provides that physician services included within the definition of CORF

services are reimbursed on a reasonable cost basis under part 413, and that physician services to CORF patients not included within the definition of CORF services but billed as physician services are paid by the carrier on a reasonable charge basis subject to the provisions of subpart E of part 405 of this chapter. This description of the payment methodology for physician services provided in the CORF setting under § 410.100(a) is inconsistent with the payment methodology set forth under section 1834(k)(1) of the Act for CORF services and section 1848 of the Act for physician services, as well as the preamble discussion in the CY 1999 PFS final rule (63 FR 58860). In the CY 1999 PFS final rule, we stated that we would base payment for diagnostic and therapeutic physician services provided to individuals in the CORF setting on the PFS amount for the services. Therefore, we proposed to revise § 410.100(a) to remove the reference to reasonable cost based payments for CORF physician services and the reference to reasonable charge based payments for non CORF physician services. In place of these references, we proposed to revise § 410.100(a) to add a reference to 42 CFR part 414, subpart B, setting forth the payment methodology for non CORF physician services.

Comment: One commenter stated that the nonfacility fee schedule amounts for CORF services fail to fairly compensate the CORF for services provided by a CORF physician that are administrative in nature. The commenter stated that the PFS nonfacility amounts, containing higher PE RVUs (than those for the facility setting) for CORFs, are inappropriately low to cover these costs for the CORF setting. The commenter believes that the required level of physician activity in a CORF is greater than that in a physician office. Since there is no separate facility payment to the CORF, the commenter requests that we develop a new set of codes with associated fees to pay for the required CORF administrative physician services in a manner similar to that we employed to establish G0128 in the CY 1999 PFS final rule to pay for CORF nursing services.

Response: The 1997 BBA required CMS to establish prospectively determined payments for all outpatient physical therapy, occupational therapy and speech-language pathology services regardless of the site-of-service and additionally required that all other CORF services also be based on existing fee schedules. When we implemented these BBA requirements during the CY 1999 rulemaking process, we specifically addressed the issue of a site-

of-service differential payment to institutional providers of outpatient therapy services, including CORFs. In the CY 1999 PFS final rule, we reasoned that a site-of-service differential payment to a facility provider would create payment incentives that favor one setting over another. In addition, we believe that the law intended the creation of a "level playing field" for these services and that we accomplished this with the selection of the PFS nonfacility rate to pay for all rehabilitation and CORF services. Therefore, we will continue to make payment at the PFS nonfacility rate for CORF services and will not change this policy to allow a separate site-of-service differential payment to the CORF. Accordingly, we are finalizing § 410.100(a) as proposed.

4. Clarifications of CORF Respiratory Therapy Services

Section 1861(cc)(1)(B) of the Act states that CORF services include respiratory therapy services along with physical therapy, occupational therapy, and speech-language pathology services. Because respiratory therapists (RTs) are not recognized as independent practitioners in the Act or regulations, and respiratory therapy services are not specifically identified in a statutory benefit category except as specified in the CORF services benefit at section 1861(cc)(1)(B) of the Act, separate payment, except that made to the CORF provider, is not made for services provided by RTs.

The description of CORF respiratory therapy services currently includes some services that we believe are more appropriately provided by a physician rather than a RT. As discussed above in section II.K.3., diagnostic and other medical services provided in the CORF setting by a physician are not considered CORF services, and therefore may not be included in a respiratory therapy plan of treatment. In addition, the description of respiratory therapy services under § 410.100(e) currently includes services that in accordance with § 410.105(c) must be performed by a physician, and not a RT. For example, only the physician may indicate the clinical diagnosis and rehabilitation goals, and prescribe the type, amount, frequency, and duration of the services to be furnished under the rehabilitation plan of treatment.

Therefore, we proposed to amend § 410.100(e) to revise the definition of respiratory therapy services to include only those services that can be appropriately provided to CORF patients by RTs under a physician-established respiratory therapy plan of

treatment in accordance with current medical and clinical standards and the requirements of § 410.105(c). Specifically, we proposed to remove from the definition of CORF respiratory therapy services at § 410.100(e)(1) the terms “diagnostic evaluation”, “management”, and “assessment” because these services are performed by the physician to establish the medical and therapy-related diagnosis and the respiratory therapy plan of treatment. These services, referred to in the proposed rule as “evaluation and management (E/M)” services, may be provided by either the CORF facility physician, as CORF physician services or as non-CORF physician services, or by the patient’s referring physician, as appropriate. We also proposed to remove diagnostic tests and periodic assessment at § 410.100(e)(2)(v) and (vi), respectively, from the description of CORF respiratory therapy services. As discussed above, we believe that under current medical standards, diagnostic tests that are or become necessary for patients receiving rehabilitation services should be provided by physicians. In addition, we believe that under current medical standards, periodic assessment of chronically ill patients in order to determine their need for respiratory services should be within the purview of the physician. We note that these services are covered under the physician services benefit category at section 1861(s)(2)(C) of the Act when provided by the physician to a CORF patient, and therefore, may be separately billable by the physician under the PFS.

In addition to RTs, we noted that the conditions of participation also recognize respiratory therapy technicians as CORF personnel; however, during the CY 1999 PFS rulemaking to recognize the 1997 BBA payment requirements, we did not include services performed by respiratory therapy technicians because we believed that current medical standards for skilled respiratory therapy services provided to patients in the CORF setting required the educational requirements possessed by RTs. This determination to only recognize the services of RTs, and not those provided by respiratory therapy technicians in carrying out the therapy plan of treatment was further supported in the CY 2002 and CY 2003 rulemaking (66 FR 55311 and 67 FR 79999), when we developed and discussed G codes for certain CORF respiratory therapy services and specifically recognized the RT as the appropriate level of personnel to provide these CORF services. The three HCPCS codes G0237, G0238, and

G0239 are specific to services provided under the respiratory therapy treatment plan and, as such, are not designated as subject to the therapy caps. Therefore, in the CY 2008 PFS proposed rule, we proposed to revise the description of respiratory therapy services to include only those services that are appropriately provided under a respiratory therapy treatment plan. In so doing, we sought to clarify those services that we believe the physician should provide, such as E/M services, diagnostic tests, and establishing the rehabilitation plan of treatment. In addition, we stated that a condition of coverage for the respiratory therapy service is that it be provided by an individual meeting the educational and training level of the RT, rather than the RT technician. For these reasons, we indicated we would accept comments on the service description at § 410.100(e), and the personnel qualifications at § 485.70(j) and (k) for a respiratory therapist and a respiratory therapy technician, respectively.

Comment: One commenter opposed the proposed revisions to the definition of CORF respiratory therapy services which removes diagnostic E/M services from the list of services at § 410.100(e)(1) and diagnostic tests from § 410.100(e)(2)(v). The commenter suggested that respiratory therapists, by virtue of their training and competency testing, can and do provide such services as part of their scope of work and asks us to add at § 410.100(e)(2) certain tests, specifically “pulmonary function tests, spirometry and blood gas analyses”, as well as services for “assessment, evaluation and monitoring of the patient’s responses to the respiratory treatment plan.” The commenter also requested that we reinsert the term “assessment” in the definition of respiratory therapy services at § 410.100(e)(1) in order to bring consistency to the definitions of all other CORF therapy services, such as physical therapy, occupational therapy, and speech-language pathology. Lastly, the commenter objected to the CORF requirement that the respiratory therapy treatment plan be entirely established by the physician.

Response: Section 1861(cc)(1) of the Act states that respiratory therapy can be provided in a CORF, by qualified professional personnel, only under a treatment plan established and reviewed by a physician. In order to determine the need for and to construct an appropriate CORF respiratory therapy plan of treatment, a physician provides E/M services and often uses diagnostic tests, such as pulmonary function and spirometry tests, in order to establish

the patient’s medical and therapy related diagnoses. These findings are then detailed in the patient’s rehabilitation treatment plan which, in the CORF, the physician must wholly establish.

The plan of treatment is described at § 410.105(c) and must include services furnished under a written plan of treatment that: (1) Is established and signed by a physician before the treatment is begun; (2) prescribes the type, amount, frequency, and duration of the services to be furnished, and indicates the diagnosis and anticipated rehabilitation goals. The respiratory treatment plan must be reviewed at least every 60 days by the physician who must certify that the patient is making reasonable progress in attaining the treatment goals and that the treatment is having no harmful effects. Therefore, we believe that the E/M services and diagnostic services associated with establishing, periodically reviewing, and overseeing the respiratory therapy treatment plan are appropriately furnished by the physician. As discussed above, physician services, including E/M services and diagnostic services performed by the physician, are separate Medicare benefits, defined at sections 1861(q) and 1861(s)(3) of the Act, respectively. These therapeutic and diagnostic services are covered and separately paid to the physician, not the CORF, when they are furnished to a CORF patient in the CORF setting by the physician, as discussed previously in this section at II.K.3.

We agree with the commenter’s request to reinsert the word “assessment” in the definition of respiratory therapy services at § 410.100(e)(1). Because assessments are conducted as an integral part of any service, we agree that revising the definition more accurately describes the services provided by RTs, as well as other qualified and recognized CORF personnel. As illustrated below, assessments can be made by the RT using the physiologic data gathered from the monitoring services that are inherent to CORF respiratory therapy services.

Also, we would like to clarify the term “monitoring” as used in § 410.100(e)(1) specifically as it relates to the provision of CORF respiratory therapy services. As we stated in the CY 2003 PFS final rule with comment period (when we created 3 G-codes—G0237, G0238, and G0239—to better describe CORF respiratory therapy activities), we incorporated the term “monitoring” in to each of the 3 G-code descriptors. We further described this “monitoring” to include physiologic or

other data about the patient during the period before, during, and after the activities. It can represent, for example, pulse oximetry readings, electrocardiography data, pulmonary testing measurements of strength or endurance performed to assess the status of the patient before, during and after the activities. In order to further illustrate and clarify our intention, we provided an example in which pursed lip breathing, used to create positive pressure in the upper respiratory tract and to improve respiratory muscle action and described as G0237, was identified as an included service in the patient's respiratory therapy treatment plan.

Before providing this service, the RT assesses the patient to determine the appropriateness of providing this pursed lip breathing activity and may check the patient's oxygen saturation level (via pulse oximetry). If appropriate, the RT then provides the initial training and necessary retraining in order to ensure that the patient can accurately perform this activity. After this session, the RT may again check the patient's oxygen saturation level, or perform peak respiratory flow, or other respiratory parameters. These services are considered "monitoring" and are bundled into the payment for G0237 (as well as HCPCS codes G0238 and G0239).

Another example of monitoring includes the provision of a 6-minute walk test that is typically conducted before the start of the patient's respiratory therapy activities. When this "test" is conducted, the RT uses this information to form an assessment of the patient's condition and uses it to guide and monitor the activities that are furnished as specified in the treatment plan. This assessment, determined by data from monitoring activities is included as part of the activities inherent to G0237. The time spent by the RT, face-to-face and one-on-one, with the patient to conduct these respiratory measures is counted as part of each of the respiratory therapy 15-minute G-codes. When provided as part of a CORF respiratory therapy treatment plan, payment for these monitoring activities is bundled into the payment for other services provided by the RT, including the three respiratory therapy specific G-codes. The bundling of these monitoring activities into each CORF respiratory therapy service is to acknowledge that these activities are inherent to the services we envisioned RTs would provide in the CORF setting. Similarly, assessment, including the use of monitoring data, is included as part of services provided by other

rehabilitation therapists. The G-codes were specifically created to better describe the services provided as part of a respiratory therapy plan of care under the CORF benefit.

Comment: One commenter indicated that the personnel qualifications in the regulations for RTs and RT technicians are out of date and that for over a decade the term respiratory therapist has been used to describe both respiratory therapy care professional categories currently defined in the CORF regulations. Rather, the commenter states that the certified respiratory therapist (CRT) and the registered respiratory therapist (RRT) have replaced the older terms, RT techs and RTs, respectively. The commenter explained that the CRT designation is awarded after successfully passing the entry-level examination, while qualifications to sit for the RRT examination include graduation from advanced levels of respiratory therapy educational programs and obtaining the CRT credential. Based on the newer terminology for respiratory therapists, along with information provided regarding the CRT and RRT credentialing processes, the commenter requested that we change the CORF conditions of participation to reflect the newer qualifications. In addition, the commenter requested that we change the coverage provisions to recognize both the CRT and RRT as qualified personnel to provide CORF respiratory therapy services.

Response: Based on the information provided by the commenter, we will work within CMS to develop and update the personnel qualifications for RTs and RT technicians at § 485.70(j) and (k), respectively. This request involves changes to longstanding provisions for CORF personnel qualifications, and we believe that other organizations, individuals, and medical specialties should have the opportunity to comment on such changes. We will propose updated qualifications for the CRT and RRT in future rulemaking to seek and review comments from other interested parties, before finalizing any changes to these personnel qualifications. In that rulemaking, we will revisit the issue of the respiratory therapy professional(s) best qualified to provide services under the CORF respiratory therapy plan of treatment. Until such time, we expect that the RT, and not the RT technician, will provide the services of the respiratory therapy treatment plan as previously discussed in CY 2002 and CY 2003 rulemaking and, again, reinforced in this final rule.

We are finalizing our proposal to revise § 410.100(e)(1), with the

exception that we will not remove the term "assessment" for the reasons discussed above. We will also adopt the revisions to § 410.100(e)(2), as proposed.

5. Social and Psychological Services

In accordance with section 1861(cc)(1)(D) of the Act, social and psychological services are included within the definition of CORF services under § 410.100(h) and (i), respectively. In addition, § 485.58 specifies that the CORF must provide a coordinated rehabilitation program that includes, at a minimum, social or psychological services, along with physical therapy services and physician services, and that these services must be consistent with the therapy plan of treatment.

As discussed in the CY 2008 PFS proposed rule, the current description of social work services considered CORF services under § 410.100(h) includes: (1) Assessment of the social and emotional factors related to the individual's illness, need for care, response to treatment, and adjustment to care furnished by the facility; (2) casework services to assist in resolving social and emotional problems that may have an adverse effect on the beneficiary's ability to respond to treatment; and (3) assessment of the relationship of the individual's medical and nursing requirements to his or her home situation, financial resources, and the community resources available upon discharge from facility care. The current description of CORF psychological services under § 410.100(h) includes:

(1) Assessment diagnosis and treatment of an individual's mental and emotional functioning as it relates to the individual's rehabilitation; (2) psychological evaluations of the individual's response to and rate of progression under the treatment plan; and (3) assessment of those aspects of an individual's family and home situation that affect the individual's rehabilitation treatment. We believe these current definitions of CORF social and psychological services are too broad. As discussed above in this section, we proposed to revise § 410.105 to clarify our policy that CORF services are covered only if they are provided under the rehabilitation plan of treatment and relate directly to the rehabilitation of the patient. As such, we are concerned that the current descriptions of CORF social and psychological services may be misconstrued to include social and psychological services for the treatment of mental illness, which we believe is outside the scope of coverage for CORF social and psychological services because these services do not relate directly to a rehabilitation plan of

treatment and the associated rehabilitation goals.

In addition, we believe it unnecessary to distinguish between CORF social services and CORF psychological services given their similarities, and therefore, we proposed to merge the two definitions into a single definition of CORF social and psychological services. As noted at section 1861(cc)(2)(B) of the Act, we believe that CORFs are required to provide either social services or psychological services, and not both types of services. We believe that merging the § 410.100(h) and (i) into a single definition of CORF social and psychological services is warranted to clarify the similarities between them.

Therefore, we proposed to clarify the description of social and psychological services at § 410.100(h) to include only those services that address the patient's response and adjustment to the treatment plan; rate of improvement and progress towards the rehabilitation goals, or other services as they directly relate to the physical therapy, occupational therapy, speech-language pathology, or respiratory therapy plan of treatment. In addition, we proposed to change the heading at § 410.100(h) from "social services" to "social and psychological services," and to eliminate the separate definition for psychological services under § 410.100(i).

Because we proposed to revise the description of social and psychological services in § 410.100(h), we also solicited comments concerning the CORF personnel qualifications in the conditions of participation at § 485.70(g) and (l) for psychologists and social workers, respectively, and comments relating to the appropriate CPT codes to represent these CORF services.

Due to the specificity of the purpose of CORF social and psychological services requiring that these covered services directly relate to the patient's rehabilitation treatment plan, we also invited comments on which CPT codes would be appropriate for CORF social and psychological services. We believe that the procedure codes for health and behavior assessment and treatment, represented by CPT codes 96150 through 96154, specific to the patient's physical health problems, best describe the social and psychological services required in the CORF setting.

Comment: A commenter suggested that the proposed definition of social and psychological services is too restrictive. The commenter recommends including social work, biopsychosocial functioning, and discharge plans in the new proposed definition of social and psychological services.

One commenter is concerned that clarifying that CORFs are not intended to be used to treat mental illness may result in denial of the CORF benefit to persons who need CORF services, but who also suffer from a mental illness (for example, patient with schizophrenia suffers a stroke). A CORF patient's mental illness may need to be accounted for in developing a rehabilitation plan of treatment. The commenter urges us to avoid causing a "chilling effect" on those individuals providing social and psychological services in CORFs at the expense of allowing a patient to recover as fully as possible.

A CORF provider cautioned that by not treating social and psychological services as a stand-alone CORF service (like physical therapy or occupational therapy) may have an adverse effect on the patient's ability to make progress toward rehabilitation goals. They also state that social and psychological services may be needed even beyond the conclusion of other CORF services.

Response: We believe that our proposal to combine the descriptions of social services and psychological services into one definition best describes the services that CORFs are required to provide to their patients, as an adjunct to the rehabilitation plan of treatment. A broader definition of these services could be interpreted to include treatment of mental illness which the CORF statute and regulations do not permit, thereby causing Medicare to pay for services that fall outside the clearly defined scope of the CORF benefit.

We proposed to combine the definitions of social services and psychological services to clarify and simplify the associated regulatory provisions. We believe that our proposal does not result in any actual change to either the social or psychological services, or the rehabilitation services, provided to CORF patients that relate directly to their rehabilitation plan of treatment and the associated rehabilitation goals.

Therefore, we will finalize our proposal to combine the descriptions of social services at § 410.100(h) and psychological services at § 410.100(i) into one definition for social and psychological services at new § 410.100(h) to make clear that these CORF services are the same, regardless of whether provided by a qualified social worker or a psychologist.

Comment: One commenter stated that because there are several levels of social work education and licensure for social workers, a recommendation as to the qualifications for CORF social workers depends on whether we change our

proposal to include the treatment of mental illness. As proposed, the commenter supports the Bachelor of Social Work (BSW) as the appropriate qualification educational level. However, if the scope of services is expanded to include the treatment of mental illnesses, then the commenter believes that the educational level of the Masters of Social Work (MSW) would be the appropriate qualification.

A CORF provider stated that the personnel qualifications to perform CORF social and psychological services should be either a licensed psychologist at a Masters or PhD level, or a licensed social worker.

A medical society representing psychiatrists suggested we use an existing set of qualifications for CORF psychologists and social workers, such as those established by the Office of Personnel Management.

Response: We believe that the appropriate qualification for individuals providing social and psychological services in the CORF setting is a BSW for social workers and a Masters-level degree for psychologists. In response to the comment, the combination of social and psychological services into one definition was made for clarification and simplification, and does not result in any change to the scope of social and psychological services provided to CORF patients. Therefore, we believe it is appropriate to maintain the existing personnel qualifications for individuals providing these unique services in the CORF setting.

Comment: In terms of what CPT codes might best describe the proposed CORF social and psychological services, one commenter suggested that CPT code 96155 should be added to the suggested list of CPT codes 96150 through 96154 in order to allow CORFs to bill for social and psychological services provided to a patient's family without the patient presence.

Another commenter suggested that limiting the services to those described by CPT codes 96150 through 96154 is potentially too restrictive because it may not describe all of the services provided by CORFs. The commenter believes that this restriction would not permit CORFs to code the social or psychological services provided to the highest specificity, although no specific CPT codes were offered for consideration.

In addition, one commenter believes that using a full range of CPT codes to describe CORF social and psychological services is inappropriate because these codes were not intended to be used for providing non-clinical CORF services. This commenter specifically objects to the use of CPT codes 96150 through

96154 because these services are specifically used by PhD level psychologists to provide clinical services. The commenter notes that other CPT codes are inappropriate to CORF use, including the CPT code range 90801 through 90899 that is used to treat mental illnesses, and the E/M CPT code series (CPT codes 99XXX), because all of these CPT codes represent clinical services. Rather, they believe that the social and psychological services provided in CORFs have “strong case management and patient assessment components” as they relate to the rehabilitation treatment plan. Instead of using existing CPT code(s), the commenter suggested we develop HCPCS code(s) specifically for CORF social and psychological services in order to keep case management services clearly distinguished from patient treatment.

Response: In an effort to address the coding issues, at this time we believe that only CPT code 96152, *Health and behavior intervention, each 15 minutes, face to-face; individual*, best describes these unique CORF social and psychological services and should be used to bill for all social and psychological services provided in CORFs.

We are sensitive to the concerns expressed by the commenter that CPT codes 96150 through 96154 do not accurately represent the descriptions of CORF social and psychological services, and that there may be a need to develop a HCPCS code designed specifically for use in the CORF setting. However, in this final rule, we do not believe it is appropriate to create a HCPCS code to reflect the nonclinical nature of the CORF social and psychological services when we did not propose doing so in the proposed rule. However, we will consider the commenter’s views in making the determination regarding the necessity to create a new HCPCS code to describe CORF social and psychological services in the future.

6. Nursing Care Services

Because the PFS does not contain a CPT code for nursing services, we established in the CY 1999 PFS final rule a new HCPCS code (G0128) for direct face to face skilled nursing services delivered to a CORF patient by an RN as part of a rehabilitation therapy plan of treatment. In the CORF conditions of participation at § 485.70(b) and (h), qualified personnel for nursing services include an LPN or vocational nurse and an RN, respectively. However, when the HCPCS code G0128 was created for CORF nursing services we determined that a condition for

coverage is that the nursing service be provided by an individual meeting the qualifications of an RN, rather than the LPN, for CORF clinical nursing services as they relate, or are part of, the therapy plan of treatment. Because we established coverage for CORF nursing services only when provided by an RN, in the CY 2008 PFS proposed rule, we proposed to revise new § 410.100(i) (that is, the current § 410.100(j) is redesignated as § 410.100(i)) to specifically reflect this coverage decision. We also requested comments on the appropriateness of the personnel qualification standards at § 485.79(b) and (h) for the LPN and for the RN, respectively.

Comment: We received a comment that opposed the proposed revisions that would allow skilled nursing services to be performed only by registered nurses. The commenter suggested that the CORF nursing services provided by either a registered nurse or the licensed practice nurse should be determined by the legal scope of practice as outlined in State law by a State board of nursing.

Response: During the CY 1999 final rule, we defined HCPCS code G0128 as a face-to-face nursing service delivered to a CORF patient that is directly related to a rehabilitation plan of treatment. We believe that the level of skill needed to render clinical nursing services as they relate to, or are supportive of the rehabilitation plan of treatment is more appropriately performed by registered nurses.

Comment: One commenter asked us to provide an example of nursing services that would be appropriately furnished and separately payable as such in a CORF that also meets the criteria of directly relating to the rehabilitation treatment plan. This commenter also requests clarification as to whether an RN can provide services as part of the respiratory therapy treatment plan and if one of the HCPCS G-codes for respiratory therapy services, G0237, G0238, and G0239 can be used to bill for these services.

Response: In the CY 1999 PFS final rule, we established coverage for CORF nursing services only when provided by an RN. HCPCS code G0128 is used to bill for services that are not included in the work or PEs of other therapy or physician services. Because of the advances in medical science since the inception of the CORF benefit in 1982, the need for nursing services necessary to be provided as an adjunct to the rehabilitation treatment plan has decreased significantly. In the CY 1999 PFS final rule, we used the example of a RN who instructs a patient in the

proper procedure of “in and out” urethral catheterization to illustrate one such nursing service directly related to the rehabilitation treatment plan. At that time, nursing services might have been provided to patients receiving respiratory therapy services relating to tracheostomy tube suctioning. Another nursing service might be related to the cleaning instructions for ileostomy or colostomy bags for a patient receiving physical therapy services where the care is imminent to the start or completion of a therapy session.

Comment: Another commenter noted that CORFs are required to provide the 3 core services, including physician services, physical therapy services, and social or psychological services, and asked that we clarify the amount that these other non-core services—specifically nursing services and respiratory therapy services—can comprise of the total CORF services. The commenter cites examples of CORFs where non-core services comprise the majority of services, sometimes as much as 90 percent or more, including wound care services where RNs are used to provide the majority of these services and other CORFs specializing predominantly in respiratory therapy services. Specifically, the commenter requested that we unambiguously address our intent as it relates to the provision of non-core services.

Response: The CORF statutory provision at section 1861(cc)(2)(B) of the Act and § 485.58 require that the CORF, as a minimum condition of participation, provide three core services— physician services, physical therapy services, and social or psychological services. When a CORF provides only the three required core services, we expect that physical therapy services would comprise a clear majority of the total CORF services, since social and psychological services are provided only as an adjunct to the rehabilitation services and CORF physician services are administrative in nature and not easily identified. However, when a CORF provides physical therapy services and other skilled rehabilitation services, we expect that physical therapy services will be the predominant rehabilitation service provided. The case noted by the commenter where CORFs specialize in providing a preponderance of respiratory therapy services is counter to our expectations.

The example cited by the commenter where the CORF is using RNs to provide wound care services, which together with other non-core services constitute the majority of services provided to a

patient, exemplifies a situation in which the CORF is providing nursing services that are not in support of a rehabilitation plan of treatment. In this situation, the services provided by the RNs do not conform to the requirement that nursing services must directly relate to or further a rehabilitation treatment plan and its goals, and therefore, are noncovered. As we discussed previously in section II.K.6 of this final rule with comment period, we specifically define and require CORF nursing services to relate to the rehabilitation plan of treatment, with such nursing services necessary for the attainment of the rehabilitation goals of the physical therapy, occupational therapy, speech language pathology, or respiratory therapy plan of treatment. We believe only professional therapists/pathologists, such as PTs, OTs, SLPs, and RTs, may appropriately provide these rehabilitation services and that it is inappropriate for an RN to provide these services. Nursing services may not substitute for or supplant the services of these therapists/pathologists, but instead should lend support to or further the services provided by professional therapists/pathologists under the rehabilitation plan of treatment. Therefore, CORF nursing services are covered as CORF services only when provided by a RN and only to the extent that they support or are an adjunct to the rehabilitation services provided by professional therapists/pathologists under the rehabilitation plan of treatment.

In addition to above clarification regarding the coverage and provision of the listed CORF services, we would also like to clarify that CORFs cannot provide services that are not included in the definition of CORF services at § 410.100 (other than vaccines) and that those services included in the definition of CORF services are covered only to the extent that they support or further the rehabilitation plan of treatment. For example, we believe that CORF services do not include the provision of hyperbaric oxygen services, infusion therapy services, or diagnostic sleep studies because they do not meet the definition of CORF services at § 410.100 or they do not relate to the rehabilitation plan of treatment. We believe that these services and other services not specifically listed as CORF services may be covered under other categories of Medicare benefits, such as physician services and diagnostic services.

Comment: One commenter asked us to clarify if a RN could perform respiratory therapy services in a CORF.

Response: As we have discussed, we believe only professional therapists/

pathologists, such as PTs, OTs, SLPs, and RTs, may appropriately provide rehabilitation services, such as respiratory therapy services, and that it is inappropriate for an RN to provide these services. Therefore, respiratory therapy services provided by an RN are not considered CORF services under § 410.100. Services performed by an RN may not substitute for or supplant the services of these therapists, but instead are covered as CORF services only to the extent that they support or are an adjunct to the rehabilitation services provided by professional therapists/pathologists under the rehabilitation plan of treatment.

We would like to clarify that any CORF nursing service must be provided by a RN and coded as G0128 indicating that CORF “nursing services” were provided. Services provided by an RN may only be billed as CORF nursing services, provided they meet the definition of CORF nursing services at § 410.100(i). We are aware that some CORFs have billed RN services inappropriately as E/M services, such as CPT code 99211. In addition, we believe some physicians have inappropriately billed the services of CORF RNs as incident to physician services. Because CORF services are a distinct benefit category, and because any therapeutic and diagnostic services (as opposed to administrative and supervisory services) furnished by physicians are not CORF services, any service furnished by CORF personnel, including RNs, PTs, OTs, SLPs, and RTs, are not considered to be furnished incident to physicians’ services, and thus cannot be billed as services incident to physician services. Therefore, the CORF nursing services of RNs may only be billed using G0128, provided that such services meet the definition of CORF nursing services at § 410.100(i).

Therefore, we are finalizing § 410.100(i) as proposed.

7. Drugs and Biologicals

Section 410.100(k) currently provides that drugs and biologicals included within the definition of CORF services includes drugs and biologicals that are prescribed by a physician and administered by a physician or a CORF RN and not otherwise excluded from Medicare Part B payment under § 410.29 (relating to self-administered drugs). In addition, in accordance with § 410.105(c), drugs and biologicals administered to a CORF patient will be covered as CORF services only if included as part of the rehabilitation plan of treatment. However, we are unable to identify any physician prescribed drugs or biologicals that are

not self administered that would be appropriately provided under a patient’s rehabilitation plan of treatment. We also expressed our concerns about the potential for duplicative billing for drugs and biologicals provided in the CORF setting because they could be billed by the CORF or the physician furnishing such drugs and biologicals.

Therefore, we proposed to remove § 410.100(k) and invited comments on this proposed revision, particularly on the appropriateness of including drugs and biologicals under a CORF patient’s rehabilitation plan of treatment.

Comment: One commenter objected to the proposed removal of the provision for drugs and biologicals from the CORF benefit and believes there is an inherent risk that neither the CORF nor the physician would be paid for drugs and biologicals provided to CORF patients when they are purchased by the CORF. The commenter explained that, under our proposal, the CORF would no longer be permitted to submit claims for the drugs and biologicals they purchase, and further stated that, under this scenario, the physician also could not be compensated because the drug or biological provided in this manner would not satisfy the CMS incident to rules. The commenter questioned our concerns about the possibility of duplicative billing permitted under the current payment methodologies although they believe that we might be justified in our proposal should we have proof that both the CORF and physician are being paid for the same drug and biological. Until such time, the commenter requested we continue to permit both the CORF and the physician to submit claims for the drugs and biologicals provided to CORF patients.

Another commenter also disagreed with our proposal to remove drugs and biologicals as a CORF service claiming that when the Congress created the CORF benefit, it “intended to create a new type of facility that could provide all of the services required by a patient in a coordinated fashion.” They also challenged our authority to remove this provision and believe that duplicative billing possibilities by the CORF and the physician administering the drug or biological is not cause for us to rewrite the statute.

Response: The purpose of our proposal was not intended to deny patients access to or to avoid making payment for medically necessary drugs and biologicals. Because we proposed to make payment directly to physicians for the drugs and biologicals provided in the CORF setting, CORFs opting to continue purchasing these drugs and biologicals would not also be paid.

Nevertheless, we are persuaded by the commenter challenging our legal authority to remove drugs and biologicals from our regulatory definition of CORF services § 410.100 in light of their inclusion in the statutory definition of CORF services under section 1861(cc)(1) of the Act. As explained in the legislative history of the CORF statute, the intent of this benefit was to simplify coordination of, and access to, “a broad array of rehabilitation services” (H.R. Rep. No. 96–1167, 96th Cong., 2nd Sess., at 375 (1980). Although as discussed in the proposed rule, we have been unable to identify among currently available drugs or biologicals that are not self-administered any such drugs or biologicals that appropriately may be included in as part of a rehabilitation plan of treatment, we cannot rule out the possibility that others will alert us to such drugs or biologicals or that future non self-administered drugs or biologicals appropriately may be included under a rehabilitation plan of treatment. Therefore, in order to ensure that, should we learn of any non self-administered drugs or biologicals that appropriately may be included in a rehabilitation plan of treatment, we may give effect to Congressional intent that CORFs be able to provide any such drugs or biologicals in coordination with other CORF rehabilitation services, we will not remove the reference to drugs and biologicals from the definition of CORF services under § 410.100 as proposed.

Instead, we will retain the existing definition of CORF-covered drugs and biologicals provided at new § 410.100(j) (that is, the current § 410.100(k) is redesignated as § 410.100(j)) with the exception of adding the word “by” to the new § 410.100(j)(1) to clarify our policy that, in accordance with existing professional standards, the administration of the drug can be provided by a RN but not by others under the supervision of an RN. As we are not aware of any non-self-administered drugs and biologicals that appropriately may be included in a rehabilitation plan of treatment, we intend to closely track the provision of drugs in the CORF setting. If in the future we learn that the administration of drugs or biologicals in the CORF setting is an appropriate service to include in the rehabilitation treatment plan, the regulatory framework will allow for coverage of such drugs or biologicals. In the mean time, we do not expect to see CORFs submitting claims for drugs and biologicals for the reasons noted above.

8. Supplies and DME

Payment for supplies and DME as part of CORF services is specified at § 410.100(l) as “[s]upplies, appliances and equipment” and includes nonreusable supplies, medical equipment and appliances, and DME as defined in § 410.38 (except for renal dialysis systems). These are CORF covered services when provided for the patient’s use outside the CORF whether purchased or rented, and is paid under the DMEPOS fee schedule. We believe that the provision at § 410.100(l) is too broad, out of date, and inconsistent with current terminology used for covered services or items. The CORF provision at section 1861(cc)(1)(G) of the Act applies only to supplies and DME, yet the regulatory provision also encompasses medical equipment and appliances. Because we believe the requirements of § 410.100(l) are inconsistent with those of section 1861(cc)(1)(G) of the Act, we proposed to revise both the title and description at new § 410.100(k) (that is, the current § 410.100(l) is redesignated as § 410.100(k)) by deleting reference to medical equipment and appliances to reflect the CORF statutory provision by including only the items specified under section 1861(cc)(1)(G) of the Act. [Note: The preamble discussion incorrectly noted this new section as § 410.100(k) instead of § 410.100(j). Section 410.100(k) is correct in this final rule with comment period.] We also noted that DME, as well as prosthetics, orthotics, and supplies, provided in the CORF setting requires the CORF’s participation in the competitive bidding process, where applicable, in accordance with 42 CFR part 414 subpart F. In this final rule with comment period, we have added language at § 414.1105(c)(2) to clarify that payment for DME, prosthetics, orthotics, and supplies determined under the DMEPOS competitive bidding program is a single payment amount, rather than an amount determined under a fee schedule. While a payment amount determined under a competitive bidding program is not generally thought of as a “fee schedule” for purposes of section 1834(k)(3) of the Act we believe the term refers to a single payment amount determined through an existing prospective payment system. The Congress amended the Act to replace reasonable cost-based payment for CORF services with prospective payments. Therefore, we believe the reference to “fee schedule” at section 1834(k)(3) of the Act is meant to broadly refer to existing prospective payment systems for the CORF-covered services

or items, including amounts determined prospectively under a competitive bidding program, and should not be referring only to “fee schedules” in the narrow sense. We did not receive comments, in support of or in opposition to, our proposal to specify the new § 410.100(k) to include only supplies and durable medical equipment as specified at section 1861(cc)(G) of the Act in the CORF benefit provision.

Therefore, we are finalizing § 410.100(k) as proposed with the exception that we will add the revision, discussed above, regarding the single payment amount determined under the DMEPOS competitive bidding program.

9. Clarifications and Payment Updates for Other CORF Services

Section 4078 in the Omnibus Budget Reconciliation Act of 1987 (Pub. L. 100-203) (OBRA) amended section 1861(cc)(1) of the Act to provide that there is no requirement that any item or service furnished by a CORF in connection with physical therapy, occupational therapy, and speech pathology services under the plan of treatment be furnished at a single fixed location; however, such items and services are covered as CORF services only if payment is not otherwise made under Medicare. In the CY 2008 PFS proposed rule, we noted that such items and services may be covered under the Medicare home health benefit established under sections 1861(g), (m), and (p) of the Act. Accordingly, physical therapy, occupational therapy, and speech-language pathology services provided in the home are not covered as CORF services if such services and related items are covered under the Medicare home health benefit. Because the CORF regulations were not revised to reflect these changes in coverage and payment methodology, we proposed to clarify the regulations at new § 410.100(l) (that is, the current § 410.100(m) which is redesignated as § 410.100(l)) and § 410.105(b)(3) to reflect these requirements.

In § 410.105(b)(3), we proposed to clarify that physical therapy, occupational therapy, and speech-language pathology services can be furnished in the patient’s home when payment for these therapy services is not otherwise made under the Medicare home health benefit.

In addition, we proposed to revise § 410.100(l) to clarify that the patient must be present during the home environment evaluation that is performed by the PT, OT or SLP, as appropriate, because we believe that the patient’s presence is necessary to fully

evaluate the potential impact of the home situation on the patient's rehabilitation goals.

Comment: Some commenters supported our proposal to clarify the CORF therapy services that can be provided in the home and who can provide these services. One of these commenters expressed concern about the requirement that the patient be present for the home environment evaluation and requested that we further clarify this proposal.

Response: Section 1861(cc)(1)(H) of the Act states that there is no requirement for physical therapy, occupational therapy, or speech-language pathology services to be provided at a fixed location such as at the CORF's physical location. This provision was further clarified in section 4078 of OBRA 1987 to clearly permit that, so long as the physical therapy, occupational therapy, or speech language pathology services are not otherwise covered under the Medicare home health benefit, these therapy services can be provided in the patient's home. Section 410.105(b)(3) also provides that only physical therapy, occupational therapy, or speech-language pathology services can be provided offsite, in the patient's home, and that all other CORF services must be provided in the CORF facility. We also proposed to clarify the provision at the new § 410.100(l) (that is, the current § 410.100(m) is redesignated as § 410.100(l)) regarding the provision of a single home environment evaluation, to include the presence of the patient, which can be performed by a PT, OT, or SLP, as appropriate. [Note: The preamble discussion incorrectly noted this new section as § 410.100(l) instead of section § 410.100(k). Section 410.100(l) is correct in this final rule with comment period.]

Therefore, we are finalizing the new § 410.100(l) (that is, the current § 410.100(m) is redesignated as § 410.100(l)), as proposed.

10. Cost Based Payment (§ 413.1)

Section 413.1(a)(2)(iv) currently provides for cost-based payment for CORF services, which reflects the payment methodology provided for under section 1833(a) of the Act, requiring payment on the basis of the lesser of the provider's reasonable costs or customary charges. As discussed above, this payment methodology is inconsistent with section 1834(k) of the Act, requiring that the payment basis for outpatient physical therapy services (including outpatient speech-language pathology services), outpatient

occupational therapy services, and all other CORF services provided on or after January 1, 1999 be 80 percent of the lesser of: (1) The actual charge for the services; or (2) the applicable fee schedule amount. Therefore, we proposed to remove § 413.1(a)(2)(iv) to clarify that cost based payment is not applicable to CORF services. We also proposed to remove § 413.1(a)(2)(vi) for OPTs or rehabilitation agencies as referenced at section 1861(p) of the Act, because these providers were also affected by the same payment changes required by the 1997 BBA for physical therapy, occupational therapy, and speech-language pathology services effective for CY 1999.

We did not receive comments to these technical corrections regarding the change in payment methodology for CORFs and OPTs that was effective CY 1999. Therefore, we are finalizing the technical corrections to remove references to cost-based payment for CORFs and OPTs at § 413.1(a)(2)(iv) and (vi).

11. Payment for Comprehensive Outpatient Rehabilitation Facility (CORF) Services

In the CY 2008 PFS proposed rule, we proposed to establish a new regulatory subpart M at 42 CFR part 414 to specify the payment methodology for comprehensive outpatient rehabilitation services covered under Part B of Title XVIII of the Act that are described at section 1861(cc)(1) of the Act. Specifically, this proposed subpart would identify and describe how payment is determined for services included as CORF services under § 410.100.

Proposed § 414.1100 sets forth the basis and scope for payment for CORF services. Proposed § 414.1105 sets forth the payment methodology for CORF services, including identifying the applicable fee schedule for each type of CORF service identified in § 410.100.

Section 1834(k)(1)(B) of the Act provides that the payment basis for CORF services is 80 percent of the lesser of: (1) the actual charge for the services; or (2) the applicable fee schedule amount. The term "applicable fee schedule amount" is defined under section 1834(k)(3) of the Act to mean, for services furnished in a year, the payment amount determined under the PFS established under section 1848 of the Act for such services for the year "or, if there is no such fee schedule established for such services, the amount determined under the fee schedule established for such comparable services as the Secretary specifies." Accordingly, we proposed at

new § 414.1105(a) to base payment for a CORF service on 80 percent of the lesser of the actual charge or the PFS amount for the service when the PFS establishes a payment amount for such service. Payment for CORF services under the PFS is made for physical therapy, occupational therapy, speech-language pathology, and respiratory therapy services, as well as the related nursing and social and psychological services. In the CY 1999 PFS final rule (63 FR 58860), we explained that we interpret section 1834(k)(3) of the Act, defining the term "applicable fee schedule amount," as requiring us to use the payment amount established by an existing fee schedule other than the PFS when the PFS does not establish a payment amount for the CORF service. Therefore, in the CY 2008 PFS proposed rule we proposed at new § 414.1105(c) that payment for covered DME, orthotic and prosthetic devices and supplies provided by a CORF be based on the lesser of 80 percent of actual charges or the payment amount established under the DMEPOS fee schedule under sections 1834 and 1847 of the Act and in 42 CFR part 414, subparts D and F. Finally, we proposed at new § 414.1105(d) that if there is no fee schedule amount established for a CORF service, payment shall be based on the lesser of 80 percent of actual charges or the amount determined under the fee schedule established for a comparable service, as specified by the Secretary.

As discussed in section II.K.3., physician services included within the definition of CORF services under § 410.100(a) are limited to those services of a CORF physician described as administrative in nature, to the exclusion of diagnostic and therapeutic services which are considered separately billable physician services. Medicare generally does not permit providers to separately bill for their administrative costs; rather, such costs typically are subsumed in the payment amounts for covered medical services and items furnished to Medicare beneficiaries. Under the PFS these costs are included in the payment amount as part of the indirect PEs that are reflected in the PE RVUs for each service and also captured as part of the post-visit work RVU component. Similarly, we believe payment to CORFs for the administrative duties of a CORF physician, required as a condition of participation at § 485.58(a), such as participating in patient case review conferences is subsumed within PFS payments to CORFs for physical therapy, occupational therapy, speech-language pathology, and respiratory

therapy services, and the related nursing, and social and psychological services. Generally, administrative costs associated with the provision of such services is incorporated into payment amounts established under the PFS through the PE RVUs representing the resources necessary to perform each service in the physician office or nonfacility setting. Therefore, we believe it unnecessary to separately compensate CORFs for CORF physician services given that such services are administrative in nature, and proposed at § 414.1105(b) not to separately pay CORFs for CORF physician services.

To ensure that CORFs are not paid twice for CORF services, we proposed at new § 414.1105 to base payment for a CORF service on the applicable fee schedule amount only to the extent that payment for such service is not included in the payment amount for other CORF services. Accordingly, under proposed § 414.1105(c) a CORF could not bill separately for supplies included in the PE RVU component of the payment amount established for a service under the PFS. However, we noted that CORFs could bill separately for certain splint and cast supplies for the application of casts and strapping because these supplies have been removed from the payment amounts established under the PFS. We also noted that Medicare makes separate payment for surgical dressings, which are also referenced at section 1861(s)(5) of the Act, only when used by the beneficiary in his or her home. No separate payment is made when these surgical dressings are used in the CORF setting; rather the dressings' costs are bundled into the payment amount established under the PFS for the provided services.

For CORF services based on the payment amount determined under the PFS, we proposed at new § 414.1105(a)(2) to use the PFS amount applicable to services furnished in a nonfacility setting, with no separate payment made for facility costs. We proposed to use the PFS nonfacility amount for CORF services in order to offset any costs of providing such services in the CORF setting. [Note: in the proposed rule we incorrectly referenced the codification of the regulation text under proposed subpart M as § 414.1001 or § 414.1101 rather than § 414.1105. However, the proposed regulation text was presented accurately as § 414.1105 in the "List of Subjects" under the proposed subpart.]

Other than the objection discussed above in section II.K.7 regarding the proposed removal of the CORF provision for drugs and biologicals, we

did not receive other comments about our proposal to create a regulatory provision to specify the payment methodologies for the CORF services identified at section 1861(cc)(1) of the Act. Therefore, we are finalizing our proposal to add a new regulatory provision defining the payment methodologies used to pay for CORF services except that we also include a section for payment of drugs and biologicals included within the definition of CORF services under the new § 410.100(j), as explained in section II.K.7. We will implement this proposal, including the addition of the payment provision for drugs and biologicals included within the definition of CORF services under the new § 410.100(j), and revise, by adding a new subpart M to part 414. The basis and scope for payment for CORF services is set forth at § 414.1100 and § 414.1105 sets forth the payment methodology for CORF services, including identifying the applicable fee schedule for each type of CORF service identified in § 410.100.

12. Vaccines

Section 485.51(a) defines a CORF as a nonresidential facility that "is established and operated exclusively for the purpose of providing" rehabilitation services by or under the supervision of a physician. Because vaccines administered in the CORF setting are not rehabilitation services furnished under a plan of treatment relating directly to the rehabilitation of the patient (or, presumably, even medically necessary for the rehabilitation of the patient), in accordance with § 485.51(a), a CORF may not administer vaccines to its patients. However, in the CY 2008 PFS proposed rule we noted that nothing in the Medicare statute would prohibit a CORF from providing pneumococcal, influenza, and hepatitis B vaccines to its patients provided the facility is "primarily engaged in providing * * * diagnostic, therapeutic, and restorative services to outpatients for the rehabilitation of injured, disabled, or sick persons" (section 1861(cc)(2)(A) of the Act). Accordingly, under the statute, such vaccines may be covered separately from the CORF services benefit under section 1861(s)(10) of the Act—defining the term "medical and other health services" to include the pneumococcal, influenza, and hepatitis B vaccines—provided the applicable conditions of coverage under § 410.58 and § 410.63 are met. In order to include coverage and payment for these vaccines when provided to CORF patients in the CORF setting, we proposed to amend the CORF conditions of participation at

§ 485.51 to permit CORFs to provide vaccines to their patients in addition to rehabilitation services. Such vaccines would be covered in the CORF setting provided the conditions of coverage under § 410.58 and § 410.63 are met. In accordance with sections 1833(a)(1) and 1842(o)(1) of the Act, payment for covered pneumococcal, influenza, and hepatitis B vaccines provided in the CORF setting is based on 95 percent of the average wholesale price (AWP).

Comment: We received a few comments strongly supporting the proposal to permit vaccines to be provided in the CORF setting in addition to the CORF services. These commenters also strongly supported our proposal to clarify our policy regarding the administration of vaccines to CORF patients by revising the CORF conditions of participation to permit the provision of vaccines, in addition to CORF services. These commenters believe that increasing the number and types of providers where vaccinations can be furnished will not only help to ensure increased access to these vaccinations but will result in improved health outcomes and lower costs.

Response: We agree with the commenters and will implement our proposal to revise the CORF conditions of participation, accordingly.

L. Compendia for Determination of Medically-Accepted Indications for Off-Label Uses of Drugs and Biologicals in an Anti-Cancer Chemotherapeutic Regimen (§ 414.930)

1. Background

a. Statutory Requirements

Section 1861(t)(2)(B)(ii)(I) of the Act lists three drug compendia that may be used in determining the medically-accepted indications of drugs and biologicals used in an anti-cancer chemotherapeutic regimen. The three drug compendia listed are:

- American Hospital Formulary Service-Drug Information (AHFS—DI)
- American Medical Association Drug Evaluations (AMA—DE)
- United States Pharmacopoeia Drug Information (USP—DI)

Section 1861(t)(2) of the Act provides the Secretary the authority to revise the list of compendia for determining medically-accepted indications for drugs. Due to changes in the pharmaceutical reference industry, fewer of the statutorily named compendia are available for our reference. (That is, AMA—DE is no longer in publication; USP—DI has been purchased by Thomson Micromedex and it is our understanding that the

name “USP–DI” may not be used after 2007.)

Section 6001(f)(1) of the Deficit Reduction Act of 2005 (Pub. L. 109–171) (DRA) amends both “sections 1927(g)(1)(B)(i)(II) and 1861(t)(2)(B)(ii)(I) of the Act by inserting “(or its successor publications)” after ‘United States Pharmacopeia Drug Information’.” We interpret this DRA provision as explicitly authorizing the Secretary to continue recognition of the compendium currently known as USP–DI after its name change if the Secretary determines that it is in fact a successor publication rather than a substitute publication.

b. Requests To Amend the Compendia Listings

We received requests from the stakeholder community for recognition of additional compendia under the following authorities:

- Section 1861(t)(2)(B) of the Act which allows the Secretary to identify additional authoritative compendia; and
- Section 1873 of the Act which allows the Secretary to recognize a successor publication if one of the statutorily-named compendia changes its name.

In contrast, others suggested that the Secretary consider elimination of certain listed compendia. However, as we stated in the CY 2008 PFS proposed rule (72 FR 38177), there was no established regulatory process by which we could accept and act definitively on such requests. In addition, we saw the need to increase transparency of decision making criteria.

c. Technology Assessment of Drug Compendia Used To Determine Medically-Accepted Uses of Drugs and Biologicals in an Anti-Cancer Chemotherapeutic Regimen

We commissioned a technology assessment (TA) from the Agency for Healthcare Research and Quality (AHRQ) on the currently listed compendia (AHFS and USP–DI), as well as other compendia (that is, National Comprehensive Cancer Network (NCCN), ClinPharm, DrugDex, Facts & Comparisons (F&C)) which might provide comparable information. AHRQ contracted the TA to the New England Medical Center (NEMC) and Duke Evidence-based Practice Centers (EPCs) and found little agreement in the evidence cited among drug compendia. In addition, the TA found little agreement between the EPCs’ independent identification of evidence on 14 example off-label indications and evidence cited in the drug compendia. The TA can be found at [http://](http://www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=46)

www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=46.

d. Medicare Evidence Development and Coverage Advisory Committee (MedCAC)

On March 30, 2006, the MedCAC (formerly the Medicare Coverage Advisory Committee (MCAC)) met in public session to advise CMS on the evidence about the desirable characteristics of compendia to determine medically-accepted indications of drugs and biologicals in anti-cancer therapy and the degree to which the currently listed and other available compendia display those characteristics. All information on this MedCAC meeting can be found on the CMS Web site at <http://www.cms.hhs.gov/mcd/viewmccac.asp?where=index&mid=33>. The agenda included a presentation of the TA performed for AHRQ by staff of the NEMC and Duke EPCs, scheduled stakeholder presentations, as well as an opportunity to hear testimony from members of the audience. As is customary, the MedCAC panelists elicited additional information from the presenters and discussed the evidence in preparation for a formal vote.

The MedCAC identified the following desirable characteristics:

- Extensive breadth of listings.
- Quick processing from application for inclusion to listing.
- Detailed description of the evidence reviewed for every individual listing.
- Use of pre specified published criteria for weighing evidence.
- Use of prescribed published process for making recommendations.
- Publicly transparent process for evaluating therapies.
- Explicit “Not recommended” listing when validated evidence is appropriate.
- Explicit listing and recommendations regarding therapies, including sequential use or combination in relation to other therapies.
- Explicit “Equivocal” listing when validated evidence is equivocal.
- Process for public identification and notification of potential conflicts of interest of the compendia’s parent and sibling organizations, reviewers, and committee members, with an established procedure to manage recognized conflicts.

The MedCAC concluded that none of the compendia fully display the desirable characteristics. The voting results can be viewed at the same Web site provided previously for the MedCAC meeting. In addition the MedCAC noted significant variability among the compendia. There was no

agreement among the panel members that any particular predetermined number of compendia was desirable.

Participants in the meeting also discussed the clinical usefulness of drug compendia in the treatment of cancer. It was reported that oncologists do not rely on compendia when making treatment decisions, relying instead on published treatment guidelines, clinical trial protocols, or consultation with peers.

Prior to the CY 2008 PFS proposed rule, we received, and reviewed, unsolicited comments from professional societies regarding additions and deletions to the listing of compendia for purposes of section 1861(t) of the Act. We received 46 public comments regarding these provisions on the CY 2008 PFS proposed rule.

2. Process for Determining Changes to the Compendia List

A compendium for the purpose of this section is defined as a comprehensive listing of FDA-approved drugs and biologicals or a comprehensive listing of a specific subset of drugs and biologicals in a specialty compendium, for example, a compendium of anti-cancer treatment. A compendium: (1) Includes a summary of the pharmacologic characteristics of each drug or biological and may include information on dosage, as well as recommended or endorsed uses in specific diseases; (2) is indexed by drug or biological; (3) differs from a disease treatment guideline, which is indexed by disease. We believe that the use of compendia to determine medically-accepted indications of drugs and biologicals in the manner specified in section 1861(t)(2)(B)(ii)(I) of the Act is more efficiently accomplished if the information contained is organized by the drug or biological and if the listings are comprehensive.

We proposed an annual process, incorporating public notice and comment, to receive and make determinations regarding requests for changes to the list of compendia used to determine medically-accepted indications for drugs and biologicals used in anti-cancer treatment as described in section 1861(t)(2)(B)(ii)(I) of the Act. The specific details of the proposed process were outlined in PFS CY 2008 proposed rule (72 FR 38118). We received the following comments on our proposed process.

Comment: Several commenters remarked that we should correlate Part B and Part D compendia for consistency within the Medicare program.

Response: The Social Security Act separately determines the Agency’s use

of authoritative compendia for specific programs. The use of any compendium for Part D or for Medicaid is beyond the scope of this regulation.

Comment: Many commenters voiced concerns about the time line proposed by CMS to address requests for changes to the list of compendia.

Response: We are striving to achieve a more expedient and predictable time line that will better serve the needs of those who care for Medicare beneficiaries. We have carefully considered the comments and made the following revisions:

(1) In order to shorten the proposed timeline, CMS will not publish an annual notice for formal requests.

(2) We expect to receive requests annually during a 30-day window starting January 15th.

(3) We expect to post these complete requests received by March 15th for public notice and comment on the CMS Web site.

(4) We will accept public comments for a 30 day period beginning on the day that the request is posted by CMS on the Web site.

Comment: Some commenters suggested alternative review cycles including changing the annual review to: a rolling review process; an every 3-year review process; or an every 5-year review process.

Response: We appreciate the commenters' suggestions regarding alternative review cycles; however, at this time, we believe that an annual review cycle is the best balance of these suggestions to promote a publicly responsive review process. Due to the general stability of the compendium publishing market, an annual review process is sufficient. However, if we determine that the public interest would be served by an immediate compendia review, we reserve the right to internally generate a request at any time.

Comment: Several commenters suggested specific additions to the list of compendia.

Response: The addition or deletion of specific compendia is beyond the scope of this regulation. Formal requests for additions and deletions may be submitted during the annual open request period established in this final rule with comment period.

Comment: The comments received from several associations and manufacturers stated that the language used for the individual desirable characteristics was not clear and that we did not give the appropriate consideration to quality concerns and the potential conflicts of interest.

Response: We appreciate the commenters' concerns and strive to

provide clarity on the MedCAC desirable characteristics that we will utilize in the compendia review process. The characteristics presented here represent an evidence-based consensus from the MedCAC panel on the desirability and priority of those characteristics. We recognize that different compendia might attempt to achieve these characteristics in individualized ways. CMS plans to use the desirable characteristics as framework and guidance in the review process. However, we believe that the public interest is best served by CMS attention to the quality and the integrity of each compendium's evidence evaluation process.

Comment: A few commenters made the general suggestion for CMS to prioritize the desirable characteristics identified at the MedCAC meeting, March 2006.

Response: We wish to clarify that the desirable characteristics recommended by the MedCAC will serve as guidance and a framework which will aid in the CMS review process. As stated in the CY 2008 PFS proposed rule, we "may consider additional reasonable factors in making a determination" as deemed appropriate. While we have decided not to rank the MedCAC desirable characteristics, we do consider the characteristics referencing transparency and conflict of interest to be of high priority to preserve the integrity and minimize bias during the review process.

Comment: Some commenters stated that a deletion from the list of compendia could cause a beneficiary to lose coverage of an off-label treatment regimen already begun.

Response: We understand the concern expressed by the commenters on a beneficiary's loss of coverage during the continuance of off-label treatment in the absence of compendium support; however local contractors have additional authority to make determinations regarding medically accepted indications. While we require local contractors to use the compendia as a reference in the determination of "medically-accepted" off-label treatment regimens, the compendia are not the sole reference for these determinations. Section 1861(t)(2)(B)(ii)(II) of the Act provides that local contractors use "supportive clinical evidence in peer-reviewed medical literature" to aid in making determinations of "medically-accepted" off-label treatment regimens when appropriate.

Comment: Commenters asked that we recognize compendia indexed by disease.

Response: In order to meet our criteria, a compendium should: (1) Include a summary of the pharmacologic characteristics of each drug or biological and may include information on dosage, as well as recommended or endorsed uses in specific diseases; (2) be indexed by drug or biological; (3) differ from a disease treatment guideline, which is indexed by disease. We believe that the use of compendia to determine medically-accepted indications of drugs and biologicals in the manner specified in section 1861(t)(2)(B)(ii)(I) of the Act is more efficiently accomplished if the information contained is organized by the drug or biological and if the listings are comprehensive.

Comment: Several commenters suggested that we should regulate a time frame for compendia to update their recommendations.

Response: We believe that the public interest is served if compendia generally update their recommendations in a timely manner when new evidence regarding the use of drugs warrants an update. We also believe that this is consistent with spirit of the MedCAC's recommendations. However, medical evidence on a particular use of a specific drug may at times be complex and inconsistent, and thus, merit a prolonged rather than an expedited analysis. We do not believe that we should establish in regulation a specific broad time line requirement at this time. However, we will consider public input regarding a compendium's timely updating of its recommendations as an additional criterion in our compendium review process.

Comment: We received comments suggesting that a compendium's use of grades of evidence may add a confusing factor in determining whether a compendium citation supports a particular drug use. Commenters stated that it is desirable for a compendium to clarify in a summary recommendation whether it regards each drug use as medically-accepted.

Response: We recognize and support the desirability of an explicit summary recommendation for each drug or biological cited in each compendium. This will facilitate the consistent interpretation of off-label recommendations by Medicare contractors.

Comment: One commenter suggested that a recognized compendium should include and identify a well designed clinical trial that is pending FDA approval.

Response: We do not believe that we can specify how a compendium

references materials regarding clinical trials for a drug not yet FDA-approved.

Comment: Two commenters claimed that section 1861(t)(2) of the Act mandates separate processes for adding and removing compendia.

Response: While we appreciate the thoughtful interpretation of the language, we do not agree separate processes are required by the statute.

Comment: One commenter suggested that the identity of the members of the compendium's advisory board and scientific review committee should become public record. The commenter also requested that we to establish a formal process to facilitate stakeholder/compendia communication.

Response: Public identification of members of the compendium's advisory board and the scientific review committees and establishing a formal process for stakeholders/compendia communication is beyond our authority and scope of this regulation.

Based on the public comments received, we have made revisions to the proposed compendia review process. We appreciate the need for a more expedient process to provide a useful compendia list for Medicare providers and have made the necessary changes.

Requests may be submitted in two ways (no duplicates please). Electronic submissions are encouraged to facilitate administrative efficiency. We will identify the electronic address to be used for submissions. Hard copy requests can be sent to the Centers for Medicare & Medicaid Services, Coverage and Analysis Group, Mailstop C1-09-06, 7500 Security Boulevard, Baltimore, MD, 21244. Please allow sufficient time for hard copies to be received prior to the close of the receipt period.

We may consider additional reasonable factors in making a determination. (For example, we may consider factors that are likely to impact the compendium's suitability for this use, such as but not restricted to a change in ownership or affiliation, suspension of publication, the standards applicable to the evidence considered by the compendium, and any relevant conflicts of interest. We may consider that broad accessibility by the general public to the information contained in the compendium may assist beneficiaries, their treating physicians, or both, in choosing among treatment options.)

- We will also consider a compendium's grading of evidence used in making recommendations regarding off-label uses and the process by which the compendium grades the evidence.

- We may, at our discretion, combine and consider multiple requests that refer

to the same compendium, even if those requests are for different actions. This facilitates administrative efficiency in our review of requests.

- We will notify the public of additions or deletions to the list of compendia on the CMS Web site.
- In keeping with our desire to shorten the compendia review time line, we will publish our decision no later than 90 days following the close of the public comment period.

M. Physician Self-Referral Issues

1. General

In the CY 2008 PFS proposed rule (72 FR 38122), we proposed several revisions to the physician self-referral regulations. We also solicited comments regarding potential changes to or limitations on the use of the in-office ancillary services exception in § 411.355(b). We received approximately 1100 pieces of timely correspondence in response to these proposals.

We received the following comments regarding finalizing our proposals:

Comment: Many commenters were concerned about the perceived complexity and breadth of the physician self-referral proposals. Several commenters questioned our ability to analyze sufficiently, and give adequate consideration to, the public comments due to the brief time period between issuance of the CY 2008 PFS proposed rule (72 FR 38122) and the statutory deadline for publication of this final rule with comment period. Some commenters suggested that we not finalize any of the proposals at this time. Many of those commenters asserted that we should further contemplate the issues and propose revised regulatory provisions in the CY 2009 PFS proposed rule if we continue to believe that such revisions are necessary.

Response: We are not inclined to follow the commenters' suggestion regarding reproposal of the physician self-referral provisions in the CY 2009 PFS proposed rule. However, given the number of physician self-referral proposals, the significance of the provisions both individually and in concert with each other, and the volume of public comments, we do not believe it is prudent to finalize any of the proposals in this rule (except for the proposal for anti-markup provisions for diagnostic tests, as discussed below in this section). Although we are not finalizing the proposed revisions to the other physician self-referral regulations in this final rule with comment period, we are confident that we have sufficient

information, both from the commenters and our independent research, to finalize revisions to the physician self-referral regulations without the need for new proposals and additional public comment. We intend to publish a final rule that addresses the following proposals:

- Burden of proof;
- Obstetrical malpractice insurance subsidies;
- Unit-of-service (per-click) payments in lease arrangements;
- The period of disallowance for noncompliant financial relationships;
- Ownership or investment interests in retirement plans;
- "Set in advance" and percentage-based compensation arrangements;
- "Stand in the shoes" provisions;
- Alternative criteria for satisfying certain exceptions; and
- Services furnished "under arrangements." Because we did not make a specific proposal regarding the in-office ancillary services exception, but rather merely solicited comments regarding its scope and application, any revisions to the exception in § 411.355(b) will be accomplished through a future notice of proposed rulemaking with provisions for public comment.

A measured, thoughtful approach to the final physician self-referral rules is critical. We believe that the future rulemaking will address the public comments and present a coordinated, comprehensive approach to accomplishing the goals described in the proposed rule, namely, minimizing the threat of program and patient abuse while providing sufficient flexibility to enable those who are parties to financial arrangements to satisfy the requirements of, and remain in compliance with, the physician self-referral law and the exceptions thereto.

2. Changes to Reassignment and Physician Self-Referral Rules Relating to Diagnostic Tests (Anti-Markup Provisions)

Medicare regulations currently prohibit the markup of the technical component (TC) of certain diagnostic tests that are performed by outside suppliers and billed to Medicare by a different individual or entity (§ 414.50). In addition, Medicare program instructions restrict who may bill for the professional component (PC) (the interpretation) of diagnostic tests (Section 30.2.9.1 of the CMS Internet-Only Manual, Publication 100-04, Medicare Claims Processing Manual, Chapter 1, general billing requirements, as amended or replaced from time to time).

In the CY 2007 PFS proposed rule (71 FR 48982), we stated that recent changes to our rules on reassignment concerning the right to receive Medicare payment may have led to some confusion as to whether the anti-markup and purchased interpretation requirements apply in certain situations where a reassignment has occurred pursuant to a contractual arrangement. In addition, we expressed concern about the existence of certain arrangements that we believe are not within the intended purpose of the physician self-referral exception for in-office ancillary services, which permits physician group practices to bill for certain services referred by group physicians and furnished by a contractor physician in a "centralized building." We also expressed concern that allowing physician group practices or other suppliers to purchase or otherwise contract for the provision of diagnostic testing services and to then realize a profit when billing Medicare may: (1) Lead to program and patient abuse in the form of overutilization of services; and (2) result in higher costs to the Medicare program (71 FR 49054). In the CY 2007 PFS proposed rule, we proposed to amend § 424.80 to provide that, if the TC of a diagnostic test (other than a clinical diagnostic laboratory test paid under section 1833(a)(2)(D) of the Act, which is subject to the special rules set forth in section 1833(h)(5)(A) of the Act) is billed by a physician or medical group (the "billing entity") under a reassignment involving a contractual arrangement with a physician or other supplier who performs the service, the amount billed to Medicare by the billing entity would be limited. We also proposed that, to bill for the TC, the billing entity would be required to perform the interpretation. In addition, we considered imposing certain conditions on when a physician or medical group can bill for the reassigned PC of a diagnostic test. For our physician self-referral rules, we proposed to modify the definition of "centralized building" at § 411.351. Finally, we solicited comments on the specific application of our proposals. (See the CY 2007 and CY 2008 PFS proposed rules for more information on these proposals (71 FR 49054 through 49057 and 72 FR 38179 through 38180, respectively).)

We received numerous comments on the proposals in the CY 2007 PFS proposed rule. Because we decided to study the issues further, we did not finalize our proposals in the CY 2007 PFS final rule with comment period. Rather, based on the comments received and other information that we

considered, in the CY 2008 PFS proposed rule, we proposed to impose an anti-markup limitation on the TC and PC of diagnostic tests. We stated that we would apply the anti-markup provision irrespective of whether: (1) The billing entity outright purchases the TC or the PC; or (2) the physician or other supplier performing the TC or PC reassigns his or her right to bill the Medicare program to the billing entity (unless the performing supplier is a full-time employee of the billing entity). That is, we proposed to limit the payment to the billing entity to the lowest of: (1) The performing physician's or other supplier's net charge to the billing entity; (2) the billing entity's actual charge; or (3) the fee schedule amount for the service that would be allowed if the physician or other supplier performing the service billed directly. To prevent gaming, whereby the performing physician's or other supplier's net charge to the billing entity is inflated to cover the cost of equipment or space that is leased by the billing entity to the performing physician or other supplier, we stated that we would define "net charge" as exclusive of any amount that takes into consideration such charges.

We also stated that we were concerned that overutilization of diagnostic tests could continue despite our proposal to apply an anti-markup provision to TCs that are reassigned to, or outright purchased by, group practices. That is, we intended to address the situation in which the TC is performed by a part-time or leased employee of the group practice in a "centralized building," and the group neither receives a reassignment from the employee technician (if the technician is not able to bill for the TC in his or her own right), nor purchases the TC outright from the technician. Therefore, we proposed to apply an anti-markup provision to TCs that are performed in a centralized building, and sought comments on whether we should have such a provision and, if so, how we should effect such a provision (for example, by amending the definition of "centralized building" or through some other means). We stated that we would except from the anti-markup provision PCs performed by a physician pursuant to an arrangement with an independent laboratory as we do not believe that such PCs ordered by an independent laboratory pose a significant risk of program abuse because the independent laboratory does not order the diagnostic test. We proposed revisions to § 424.80 (reassignments) and § 414.50 (purchased diagnostic tests). (We did not propose

regulatory text revisions for our proposals to apply an anti-markup provision to TCs that are performed in a centralized building, and not apply the anti-markup provision to PCs billed by independent laboratories whose personnel do not order the diagnostic test.)

Many commenters supported our proposals to prohibit the markup of the TC and PC of diagnostic tests in order to prevent physicians, physician group practices, and medical groups from profiting through the ordering of such tests. Commenters that supported our proposals often cited a concern about overutilization. Many commenters were opposed to our proposals. These commenters stated that the Medicare program and its beneficiaries are better served by physicians who refer tests to specialists (such as pathologists who contract directly with group practices), instead of physicians who use large reference laboratories. These commenters asserted that, because physicians develop a working relationship with particular pathologists, and because the pathologists "specialize" in a particular type of biopsy (for example, prostate biopsies), results are obtained more quickly and quality is enhanced. Finally, most commenters who responded to our proposal to apply an anti-markup to reassignments from part-time employees, irrespective of whether they were in support generally of our proposals, opposed this specific proposal.

After careful consideration of all of the comments, we are adopting our proposals, with modification. We are imposing an anti-markup provision on TCs of diagnostic tests that are ordered by the billing physician or other supplier (or ordered by a party related by common ownership or control to such billing supplier), if the TC is outright purchased or if the TC is performed at a site other than the office of the billing physician or other supplier.¹ (For purposes of the anti-markup provisions, the "office of the billing physician or other supplier" has its common meaning. The term is defined at revised § 414.50(a)(2)(iii) as space where the physician or other supplier regularly furnishes patient care. With respect to a billing physician or other supplier that is a physician

¹ We note that, in our proposals, we used the term "billing entity" to refer to a billing physician or medical group. In this final rule with comment period, the anti-markup provisions potentially apply to TCs and PCs billed by any supplier; therefore, we use the terms "billing physician or other supplier" and "billing supplier." These terms are used interchangeably.

organization (as defined at § 411.351 of this chapter), the “office of the billing physician or other supplier” is space in which the physician organization provides substantially the full range of patient care services that the physician organization provides generally.) We are also imposing an anti-markup provision on PCs of diagnostic tests that are ordered by the billing physician or other supplier (or ordered by a party related by common ownership or control to such billing supplier), if the PC is outright purchased or if the PC is not performed in the office of the billing physician or other supplier. Also, part-time employees are treated no differently than full-time employees or contractors who reassign benefits.

We are primarily revising § 414.50, although we have also revised § 424.80 by adding (d)(3) to alert the reader that, in the case of the reassignment of the TC or PC of a diagnostic test, the reader should consult § 414.50 to investigate whether the anti-markup provisions apply to the TC or PC. We are also revising our definition of “entity” at § 411.351, which is relevant to our rules on physician self-referral. Currently, the definition of “entity” provides an exception for a physician’s practice when it bills Medicare for a diagnostic test in accordance with § 414.50. We are revising the definition of “entity” at § 411.351 to exclude a physician’s practice when it bills Medicare for the TC or PC of a diagnostic test in accordance with § 414.50.

Examples of the application of the final provisions to particular facts appear immediately below, followed by a discussion of the specific comments we received on our proposals. We note that the following examples are intended only to illustrate the application of the anti-markup provisions of this final rule with comment period; they are not intended to address whether the physician self-referral rules would prohibit payment due to financial relationships that may exist between the billing supplier and any physician ordering a test or performing the TC or PC of a test.

Example 1. A urology group practice contracts with a leasing company that supplies a technician and a pathologist to perform testing on prostate samples. The technician performs the tissue sampling and the pathologist reads the slides. All work is done outside of the office of the billing group practice, and instead is performed in space that is rented exclusively “24/7” by the group practice (thus meeting the definition of a “centralized building” at § 411.351) for the sole purpose of providing pathology services for the group’s patients. Because the centralized building does not qualify as “the office of the billing physician or other

supplier,” the anti-markup provisions apply to both the TC and the PC, and the group may bill Medicare the lowest of the following: (1) The leasing company’s net charge to the group; (2) the group’s actual charge; or (3) the fee schedule amounts for the TC and interpretation that would be allowed if the leasing company were enrolled in and billed Medicare directly.

Example 2. Same as Example 1, except that the TC and PC are performed by the group practice’s employee technician and a pathologist who is an independent contractor of the group practice, respectively. Here, the anti-markup provisions again apply to both the TC and the PC because the work was not done in the “office of the billing physician or other supplier” (that is, the office of the group practice). It does not matter that the technician is an employee and the pathologist is an independent contractor because the work was not performed in the office of the billing group practice.

Example 3. A physician in a group practice orders a diagnostic test and a technician who is a part-time employee of the group performs the test in the group’s office. A physician who is an independent contractor of the group performs the PC in the group’s office and reassigns his or her right to payment to the group. The anti-markup provisions do not apply to the group’s billing of the TC or the PC.

Example 4. Same as Example 3, except that the independent contractor physician performs the PC in his or her home and reassigns his or her right to payment to the group. The group’s billing of the TC is not subject to the anti-markup provision, but the group’s billing of the PC is subject to the anti-markup provision because the work was not performed in the office of the billing supplier.

Example 5. A group practice purchases both a diagnostic test and its interpretation from a laboratory and bills the TC and PC to Medicare. The anti-markup provisions apply to both the TC and the PC. Because the TC and the PC were purchased, the location(s) at which the TC and the PC were performed does not matter.

Example 6. A group practice orders a diagnostic test from an independent laboratory. The laboratory performs the test and contracts with a physician to perform the PC. The laboratory bills Medicare for both the TC and the PC. The laboratory is not subject to the anti-markup provision for the PC, because the laboratory did not order the test.

Example 7. Same as Example 6, except that a physician orders a diagnostic test from an independent diagnostic testing facility (IDTF). The IDTF bills Medicare for both the TC and the PC of the test. The anti-markup provisions do not apply because the IDTF did not order the test.

a. Authority

Comment: Several commenters questioned whether we have the authority pursuant to section 1842(n) of the Act to impose an anti-markup provision as described in the CY 2008 PFS proposed rule. The commenters specifically noted that, in section

1842(n) of the Act, the Congress directed the Secretary to impose an anti-markup on the TC of diagnostic tests, yet our proposal applied to the TC and the PC of diagnostic tests. Commenters stated that the interpretation of a diagnostic test is a physician service, and that section 1848 of the Act mandates that physician services be paid the lesser of the billing physician’s actual charge or the fee schedule amount, and therefore, we have no authority to extend the anti-markup rule to physician services.

Response: We believe that several provisions of the Medicare statute provide us with the requisite authority to impose anti-markup provisions on the TC and PC of certain diagnostic tests. Section 1842(n)(1)(A) of the Act, which was enacted as part of the Omnibus Budget Reconciliation Act of 1987, provides that, if the diagnostic test was not performed or supervised by the billing physician and also was not performed or supervised by a physician with whom the billing physician shares a practice, the Medicare payment is the lower of the costs (net of any discount) charged by the performing supplier to the billing physician, or the performing supplier’s reasonable charge (or other applicable limit). This is commonly known as the anti-markup provision. Although, to date, this statutory provision has been implemented through the regulation in § 414.50 that imposes an anti-markup provision on the TC only of a diagnostic test, nothing in this section limits our authority to apply this section to the PC of a diagnostic test.

Moreover, we believe that we can interpret the language “shares a practice” as giving us the authority to impose an anti-markup provision on the TC of tests that are outright purchased by a billing physician or group, as well as on the TC of tests for which payment is reassigned to the billing physician or group. Although we previously implemented this statutory provision through regulation in § 414.50 by enacting an anti-markup provision on the TC of “purchased” diagnostic tests from an outside supplier, the statutory provision does not speak in terms of “purchased” tests. In the intervening time since CMS promulgated the regulation in § 414.50, other changes to the Medicare program, in particular, the changes made by section 952 of the MMA to the reassignment exceptions authority, have created incentives for conduct that we believe increases the risk of overutilization and abuse of the Medicare program. We believe that the language “shares a practice” in section 1842(n)(1) of the Act can cover not just

tests that are outright purchased, but also tests for which payment is reassigned to the billing supplier. We are amending § 414.50 in this final rule to provide that TCs and PCs that are not performed in the office of the billing physician or other supplier are subject to the anti-markup provision. We believe that, if the TC or PC is not purchased and is performed in the office of the billing supplier by an employee (whether full-time or part-time) or an independent contractor who reassigns benefits, a sufficient nexus with the practice of the billing supplier (that is, the billing physician or group) is established such that the employee or independent contractor may be viewed as “sharing a practice” with the billing supplier for purposes of section 1842(n)(1) of the Act. In addition, we believe that we have authority under sections 1102(a) and 1871(a) of the Act (our general rulemaking authority) to impose anti-markup provisions on the TC and PC of diagnostic tests in order to fully effectuate the Congress’ intent in enacting section 1842(n)(1) of the Act.

We find additional authority in section 1842(b)(6) of the Act. This section generally prohibits Medicare payment to anyone other than the Medicare beneficiary or the physician or other person who furnished the item or service to the beneficiary. We allow a physician or other supplier to bill for tests and test interpretations that are purchased from an outside supplier because we have deemed the test or interpretation to be performed by the billing supplier; however, we are not *required* to deem the test or interpretation as having been performed by the billing supplier, nor are we required to do so without placing limits on the amount the purchasing supplier may bill. Likewise, whereas section 1842(b)(6) of the Act also provides exceptions (known as the reassignment exceptions) to the general rule that payment may be made only to the beneficiary or the physician or other person who furnished the item or service, such exceptions allow us (“payment may be made”), but do not require us, to make payment to an individual or an entity other than the beneficiary or the physician or other person who furnished the item or service to the beneficiary. (We note that the Congress specifically provided for CMS to implement safeguards in the context of reassignments pursuant to a contractual arrangement. Section 952 of the MMA permitted Medicare to pay a physician or entity billing for an item or service as a result of a reassignment created pursuant to a contractual

arrangement, regardless of the site of service. However, in section 952 of the MMA, the Congress specifically authorized the Secretary to subject such arrangements to “such program integrity and other safeguards as the Secretary may determine to be appropriate.”) Therefore, we believe that we have ample authority under section 1842(b)(6) of the Act to place restrictions on the billing of tests and interpretations when the tests or interpretations were performed by someone other than the billing supplier, particularly with respect to situations in which there is the potential for overutilization.

We do not view the application of the anti-markup provision to the PC of diagnostic tests as representing a conflict with section 1848 of the Act as stated by the commenters. Although section 1848 of the Act does outline how physician services will be paid in the typical situation, section 1848 of the Act does not preclude us from setting conditions on physician payment or from deviating from the payment methodology outlined in section 1848 of the Act where a physician or other supplier is seeking to take advantage of a special situation made available to physicians or other suppliers by CMS. Payment pursuant to the terms of section 1848 of the Act is available for all the diagnostic tests in question. Physicians and other suppliers are free not to take advantage of the purchased test option or the reassignment option, and bill and receive payment only for tests they have personally performed. Where physicians and other suppliers choose to take advantage of these options, for purposes of convenience or for other reasons, we have the authority under our general rulemaking authority in sections 1102(a) and 1871(a) of the Act, as well as under our authority to set conditions for the payment of purchased and reassigned tests in section 1842(b)(6) of the Act, to promulgate rules to ensure that these options do not increase the likelihood of Medicare program abuse.

b. Scope of Application of the Anti-Markup Provisions

Comment: One commenter offered alternatives to our proposals. The commenter stated that, at least initially, the anti-markup provisions should apply exclusively to gastroenterology, dermatology, and urology physician group practices because those specialties order a significant number of pathology tests. The commenter suggested that we could subsequently broaden application of the anti-markup provisions to the extent that “new

abusive” arrangements develop. Alternatively, according to the commenter, CMS could define the specialties to which the anti-markup provisions would apply on the basis of objective criteria. For example, the anti-markup provisions could apply to group practices billing for pathology services where at least 75 percent of the members are from a single nonpathology specialty and where at least 75 percent of the pathology services billed by the group practice were ordered by members of the group. The commenter asserted that such a definition should cover most of the abusive arrangements that have developed in recent years. The commenter urged us to impose a broad prohibition on profiting from pathology tests, which would apply without regard to whether the histotechnologists are full-time employees or independent contractors of the group practice. According to the commenter, a prohibition on profiting could be accomplished by prohibiting any markup over the direct costs incurred by the group practice in providing such services, and direct costs should be limited to the compensation paid to the persons providing the services and the cost of the equipment and supplies utilized in performing the services. Finally, the commenter suggested the alternative of amending the requirements for “group practices” in § 411.352 to prohibit gastroenterology, dermatology and urology group practices from profiting from Medicare payments for pathology services performed within the group practice.

Response: We decline to adopt any of the approaches suggested by the commenter. The anti-markup provisions in this final rule with comment period apply to group practices (as well as all other suppliers) regardless of specialty. We believe that making the rule applicable to all suppliers ensures fair and equitable treatment among types of suppliers and also ensures that the potential for overutilization is addressed regardless of the particular type of supplier involved. As we discuss in greater detail below, we agree with the commenter that it should not matter whether the person performing the TC is a full-time employee, part-time employee or independent contractor. If the TC (or PC) is purchased, or if it is performed in a place other than the office of the billing supplier, the anti-markup provision will apply, irrespective of the employment status of the person performing the TC (or PC). We are not revising the requirements for “group practices” at § 411.352 at this time. We did not propose to amend

these provisions and believe that such a change would be outside the scope of the proposed rulemaking.

Comment: A commenter suggested that we consider an anti-markup provision that would apply to any group practice where at least 90 percent of the practice is comprised of a single specialty other than pathology that orders the pathology tests billed by the group. The anti-markup rule should prohibit the markup of the direct costs incurred by the group (such as compensation paid to the histotechnologists and pathologists, and equipment and supplies utilized).

Response: We believe that the commenter's suggestion would be cumbersome and difficult to administer, and therefore, we are not persuaded to adopt it. We believe that the anti-markup rules that we have finalized are much more practical and will be an effective deterrent to the ordering of medically unnecessary tests.

Comment: One commenter stated that the anti-markup provisions should apply equally to all physicians, including pathologists. The commenter noted that, in some cases, a pathologist performing the PC purchases the TC from a hospital or another pathology laboratory and bills globally. In addition, the commenter asserted that it is a myth to say that pathologists do not order tests and, therefore, should be exempt from the proposed anti-markup provision applicable to the PC of a diagnostic test. Another commenter stated that there is no more likelihood of abuse in specialty physician-owned pathology laboratories than with pathology groups ordering expensive and unneeded special tests and stains on specimens that they then interpret in the pathology group-owned histology laboratory.

Response: The revisions to § 414.50 and § 424.80 concerning the anti-markup requirements apply equally to all physicians, including pathologists. We recognize that, in some situations, a pathologist may order additional tests to be performed by an outside pathologist. Where a pathologist orders and bills for a test that he or she did not personally perform, the anti-markup provisions may apply to the TC or PC, or both (depending on whether the TC or PC was purchased or, if not, whether the TC or PC was performed in the pathologist's office). If the pathologist did not order the test, the anti-markup rules do not apply.

Comment: One commenter requested clarification that § 414.50 applies only to physicians and medical groups, and not to suppliers, such as medical foundations, that, under State laws

governing the corporate practice of medicine, are required to enroll in Part B as a clinic or group practice. The commenter asserted that, in States prohibiting the corporate practice of medicine, many suppliers enrolled as a clinic or group practice are unable to directly employ the radiologist or other physician who performs a test interpretation.

Response: In this final rule with comment period, we are revising § 414.50 to apply to all suppliers. However, the anti-markup provisions do not apply to TCs and PCs that are not purchased and that are performed in the office of the billing physician or other supplier. Therefore, in the commenter's example, if clinic personnel order, for example, the TC and PC, and the TC and PC are performed in the clinic's office, neither the TC nor the PC will be subject to the anti-markup provisions.

Comment: Two commenters asserted that IDTFs operate similarly to independent laboratories in that the tests are ordered by a financially independent physician. The commenters also said that the physician performing the interpretation sees the patient. Therefore, the commenters recommended that we provide an exception to the proposed anti-markup rules for purchased interpretations for imaging suppliers, such as IDTFs, if the current purchased interpretation rules are met.

Response: We are not persuaded to provide an exception to the final anti-markup provisions for purchased interpretations for imaging suppliers if the current purchased interpretation rules are met. We note that, if the interpreting physician sees the patient, the purchased interpretation rules are not fully met. Therefore, the imaging supplier is not satisfying all of the purchased interpretation rules, and the imaging supplier should only bill for the TC portion of the test.

Comment: One commenter requested clarification that the anti-markup proposals do not apply to radiologists who have contractual arrangements with IDTFs. The commenter asserted that radiologists and IDTFs are not in a position to refer to each other or to themselves because both are dependent upon referrals from other physicians in the community. Another commenter asked us to clarify that the anti-markup for the PC will not apply to an IDTF that purchases the PC from the interpreting physician, particularly in States in which the corporate practice of medicine doctrine applies. Another commenter stated that the anti-markup provision for the PC should not be applied to physicians or group practices

that bill for the professional services performed by an independent contractor or part-time employee if those services were performed pursuant to the order of another practitioner who is independent of the group, and thus would not profit from his or her referral.

Response: As finalized, the anti-markup provisions are applicable to all types of suppliers. However, in the situation in which an IDTF, radiology practice, or other supplier does not order the diagnostic test, the anti-markup provisions do not apply.

Comment: A few commenters questioned whether the proposed anti-markup provision, for the PC of diagnostic tests, would apply to IDTFs that purchase the PC from an interpreting physician, particularly in States where the corporate practice of medicine prohibits an IDTF from hiring the physician as an employee.

Response: The anti-markup rules will not apply to entities that are enrolled as an IDTF where the IDTF does not order the test. If the IDTF orders the test, the anti-markup provisions will apply to the same extent that they apply to other suppliers.

Comment: A few commenters urged us to clarify in § 424.80 that the anti-markup provisions apply to reassignments under both the contractual arrangement exception as well as the employee reassignment exception. The commenters also suggested that § 424.80 and § 414.50 should state that the anti-markup provisions are limited to claims submitted by physicians and medical groups and do not apply to claims submitted by independent laboratories. The commenters were concerned that the preamble language on the applicability of the anti-markup provisions to independent laboratories was not carried over and included in the regulatory text in § 424.80 and § 414.50.

Response: We have determined to revise § 414.50, with a cross reference in new § 424.80(d)(3). As finalized, the anti-markup provisions apply to reassignments under both the employee exception and the contractual arrangements exception, to the extent that the services for which payment is reassigned are not performed in the office of the billing physician or other supplier. The anti-markup provisions apply to a billing supplier only if the billing supplier orders the TC. Therefore, if an independent laboratory does not order the TC, the anti-markup provisions will not apply to the laboratory billing of the TC or the PC.

Comment: Two commenters urged us to create an exception for entities that are located off-campus from a hospital

which are jointly owned by radiologists and the hospital and which have an exclusive contract for the provision of professional interpretations to the hospital. According to the commenters, it is important to allow such joint ventures to exist, because the profits generated by the ventures give financial stability to community hospitals that otherwise would be financially impaired as outpatient imaging continues to migrate away from the hospital. In States in which the corporate practice of medicine doctrine exists, the joint ventures do not directly employ the physicians, but rather typically contract with the professional radiology practice to provide the PC. The commenter stated that the radiologists providing the professional reads are neither full-time employees nor exclusively employed by the joint venture imaging center to which they reassign their right to Medicare payment.

Response: We do not believe that it is necessary to create such an exception. The comment is unclear as to which entity, the joint venture imaging center or the hospital, is billing for the service; however, if the imaging center is billing for the PC, the anti-markup provision will not apply if the physician performs the PC in the imaging center's office. If the imaging center, or an entity related to it by common ownership or control, orders the TC, and the physician does not perform the PC in the imaging center's office, the anti-markup provision will apply.

Comment: Some commenters believed that the anti markup provisions should not apply to imaging suppliers that meet the purchased test rules in CMS manuals.

Response: In the CY 2007 PFS proposed rule, we stated that we were considering placing restrictions on the ordering of PCs that would be similar to the purchased interpretation rules in our manuals. After giving the matter considerable thought, we believe that an anti-markup billing provision is necessary to guard against potential overutilization and that it would not be sufficient simply to require that billing entities meet the purchased interpretation rules in our manuals.

Comment: In the proposed rule, we proposed to add new § 424.80(d)(3) to require that, in order to bill for the TC, the billing entity must directly perform the PC of the service. Two commenters asked that we clarify what we meant by "directly perform." Other commenters recommended that we clarify in § 424.80 the requirement to bill for the TC of a diagnostic test, and clarify in § 414.50 the requirement that a billing

entity must directly perform the PC of the service.

Response: We are not finalizing the proposed change to § 424.80(d)(3). We note that the requirement continues to appear in our manuals at CMS Internet-Only Manual, Pub. 100-04, Chapter 1, section 30.2.9. Currently, we are considering whether to retain this requirement in the manuals or to withdraw it.

Comment: One commenter supported generally the establishment of an anti-markup provision on purchased interpretations, but voiced concerns that our proposal to incorporate the billing rules for purchased diagnostic testing services to all reassigned services (unless performed by a full-time employee of the group) could adversely affect the billing practices of pathologists and pathology groups who often depend upon the reassignment rules to bill for services performed by independent contractor and part-time pathologists. Therefore, the commenter requested an exception from our proposed rules for independent laboratories and single-specialty pathology physician groups.

The commenter also asserted that reassignment arrangements between pathology groups do not raise the same threat of abuse because the vast majority of pathology services are initiated by a request for a consultation from a referring physician of another specialty, and the pathologist is not in a position to influence the referrals from ordering physicians. The commenter further stated that a broader exception for single-specialty pathology physician groups and independent laboratories that covers both the TC and PC of a pathology service is supported by the existing physician self-referral law and regulations. The commenter stated that, the "Congress recognized that certain physicians, specifically pathologists, diagnostic radiologists and radiation oncologists, who order certain services pursuant to a consultation with another physician do not have the same risk of abuse and, consequently, will not be treated as having made a restricted referral to an entity with which they have a financial interest." The commenter urged us, for this same policy reason, to recognize an exception for single-specialty pathology physician groups and independent laboratories that bill for pathology services performed or supervised by another pathologist, whether an independent contractor or full-time or part-time employee.

Response: In order to be fair and to avoid the appearance of giving preferential treatment to one physician

specialty group over another, the anti-markup provisions on the TC and PC of diagnostic tests are potentially applicable to all physician specialty groups that order tests and wish to bill for the TC or PC, or both, performed by another person or group and billed as a purchased test or billed through a reassignment. (Whether the anti-markup provision for the TC or the anti-markup provision for the PC will, in fact, apply depends on whether the TC or the PC was purchased, or, if not purchased, whether the TC or the PC was performed in the office of the billing physician or other supplier.) Therefore, we are not recognizing an exception for single-specialty pathology physician groups that bill for pathology services performed or supervised by another pathologist, unless the single-specialty pathology physician group does not order the test. If a pathologist in the single-specialty pathology physician group orders and bills for the test performed by another supplier, the anti-markup rules apply. If the pathologist does not order the test and wishes to bill for the test, which is performed by another supplier, the anti-markup rules will not apply. Finally, we note that clinical diagnostic laboratory tests performed by independent laboratories and paid under section 1833(a)(2)(D) of the Act are not subject to the anti-markup provisions pertaining to diagnostic tests.

c. Overutilization

Comment: Many commenters in favor of the proposed rulemaking cited overutilization as a concern in the existing billing and payment environment. Commenters opposed to our proposals denied that contractual arrangements for pathology services lead to overutilization.

In support of their contention that current arrangements facilitate overutilization, some commenters cited various studies for the proposition that physician self-referral leads to increased utilization. For example, one commenter cited 1989 studies from the OIG and GAO that found that physicians who had an ownership or investment interest in a laboratory ordered more tests than those physicians who did not have such an interest. This commenter also noted that an analysis by the Florida Cost Containment Board in 1998 found that physician-owned clinical laboratories, diagnostic imaging centers, physical therapy centers, and rehabilitation centers performed more procedures on a per-patient basis than those facilities that were not physician-owned. The commenter also cited the 2007 study by

the McKinsey Global Institute that found that the United States spends more of its wealth on health care than any other developed country, and that one reason for the difference in spending is due to profit incentives in physician ownership of medical facilities. Other commenters mentioned the 2007 OIG studies of three urology practices, which the commenters described as finding that all three practices substantially increased the number of biopsies ordered per patient after entering into an arrangement for contracted pathology services, and that, after entering into such an arrangement, all three practices billed significantly more biopsies than what their respective carriers paid on average to other suppliers. One commenter cited a study by the Center for Health Policy Studies that examined the effects of State "direct billing" laws. Under such laws, the pathologist or entity performing the ordered pathology services is required to bill for the services. This study found that laboratory charges per enrollee under private health insurance programs were 41 percent higher in non-direct billing States than in direct billing States. Another commenter stated that a study in the American Journal of Roentgenology in 2002 confirmed that physician self-referral may be contributing to the uncontrolled growth in imaging services. According to the commenter, that study reported that, when a managed care organization prohibited certain non-radiologist specialties from billing for imaging services, total billings for imaging declined 20 to 25 percent from the amount of billings that were expected based on the previous trend in imaging growth.

One commenter stated that it is unaware of any evidence of overutilization by gastroenterologists who have entered into contractual arrangements for pathology services. Another commenter stated that its managed "pod labs" are vital to the accurate detection and treatment of prostate cancer and do not expose Medicare to an undue risk of program abuse. The commenter asserted that no data supports the accusation that its managed laboratories facilitate the generation of medically unnecessary biopsies, and in any event, clinical indications for prostate biopsy are not subject to manipulation.

Another commenter stated that urological pathology volume is based upon objectively demonstrated medical necessity, and is not affected by profit margin or who is billing for services. This commenter suggested that specific requirements could be placed on

contractual arrangements to address overutilization concerns, while preserving the benefits of these types of arrangements. The commenter stated that the best way to ensure that contractual arrangements are maximizing their potential for improving care and outcomes, while discouraging overutilization, is to prohibit arrangements that are merely passive investments of the treating physicians. The commenter asserted that physicians who own off-site pathology laboratories should be actively involved in their direction and supervision, and responsible for the services provided by the laboratory. The commenter offered several specific recommendations, including: (1) If a group practice intends to bill for the TC, it must also perform the PC; (2) consistent with CLIA regulations, a pathologist may not be the medical director of more than five laboratories; and (3) refined credentialing criteria for pathologists. In its comments to the CY 2008 PFS proposed rule, MedPAC stated that it agrees that allowing physicians to purchase or contract for the provision of diagnostic tests and to realize a profit when billing Medicare could lead to overuse of services and higher program costs.

One commenter discussed available types of diagnostic tests for prostate cancer and stated that there does not appear to be any added benefit to the patient from receiving a 12-part biopsy series instead of a smaller number. According to the commenter, this method of biopsy results only in increased diagnosis of minimal prostate disease or atypical small acinar proliferations, which leads only to further biopsies and increased medical costs. The commenter stated that the argument of urologists, that 12 biopsies is the standard of care, is shown to be fallacious by the fact that, when members of a particular urology group perform prostate biopsies in local hospitals, they are doing only two-part biopsies. However, another commenter stated that he knows of more than one urologist who routinely submitted two core biopsies for review, but after employing a pathologist, switched to 12 core biopsies. Another commenter stated that patient care improves with contractual arrangements because the test results are timelier and are of higher quality. Faster results, together with the opportunity to collaborate with pathologists, permit urologists to better manage their patients' care. According to the commenter, the number of cores taken for each prostate biopsy is a direct result of the evolving understanding of

the nature of prostate cancer, rather than, as some state, the formation of urology specialty laboratory arrangements between urologists and pathologists. One commenter stated that, whereas it understood our concern of overutilization, the current malpractice system creates far more incentive to perform unnecessary tests.

Two commenters stated that the incessant complaints of profits being made at the expense of the Medicare program do not serve any purpose. The commenters claimed that, unless a profit can be achieved, no one will perform services needed by Medicare or any other program. The commenters suggested that, regardless of who collects the fees for pathology and laboratory services and makes a profit, whether an individual pathologist, a commercial laboratory, or a physician specialty practice, this should not be a focus of CMS. Rather, CMS should review the standards of care and hold suppliers to those standards. The commenters pointed out that the National Comprehensive Cancer Network developed standards for a patient with early prostate cancer. At first, the standard was only two cores. In the mid 1990s, the standard was increased to six cores, then, with additional research, the standard was increased to ten cores, and, recently, the recommendation was further increased to 12 cores. The research has shown a dramatic increase in prostate cancer detection with increased core sampling. The commenters stated that it is hypocritical that pathologists are claiming overutilization of services by physician specialty groups, when these same pathologists accepted 12 core biopsies without a whisper of discontent. These commenters asserted that overutilization would cease to be an issue if CMS actively pursued those practitioners, including pathologists, who do not follow the accepted and published standards of care.

Response: It is difficult to determine whether and the extent to which overutilization is due to, or facilitated by, arrangements that allow the referring physician or group practice to bill for the TC and the PC of diagnostic tests. Our proposals were not predicated upon a belief that there was a correlation between the size of the group practice and the volume of diagnostic tests and the risk of program abuse. We appreciate that, for a particular practice specialty, an increase in biopsies ordered may be due to a change in business arrangements that produces profits for the referring physician or group practice, or it may be due to a change in the standard protocols (or in

the referring physician's or group's perception of the appropriate standard of care). Nevertheless, studies have shown that, in the aggregate, utilization of diagnostic tests increases in the case of physician self-referral. We believe it is appropriate to guard against the potential for overutilization through an anti-markup provision on the TC and PC of diagnostic tests. We decline to use a specific number of prostate biopsies as a trigger point for application of the anti-markup provisions, as we believe the appropriate number of biopsies is largely patient-specific.

Comment: Several commenters stated that contractual arrangements for anatomic pathology testing pose no risk of overutilization because Medicare patients would not be subjected to unnecessary testing due to the invasive nature of test procedures such as colon or prostate biopsies.

Response: We are skeptical that the risk of overutilization for biopsies is appreciably less than that of other types of diagnostic tests. In any event, in enacting the anti-markup provision in section 1842(n)(1) of the Act, the Congress made no exception for biopsies or other minimally invasive tests, and in order to effectuate Congressional intent we are not providing for such an exception.

d. Quality and Patient Access

Comment: Many commenters, both in favor of and against the proposed rulemaking, focused on the issue of the quality of the diagnostic testing, particularly pathology services.

Two commenters stated that the financial incentive inherent in some arrangements can result in physicians selecting laboratories not on the basis of quality but on the potential for profit from these arrangements. One commenter believes that "by reducing pathologists to the status of indentured servants of clinicians who 'own' the patients and their biopsies, the autonomy and quality of the pathology services provided is fatally eroded." According to one commenter, aspects of pathology practice, such as the adequacy of the biopsy, the sampling procedure, the need for deeper or additional sections, the severity of a process, the adequacy of margins, the need for re-excision, the appropriateness of special studies, and the need for outside expert consultation despite increased expense, ultimately are decided based on what provides the maximum economic benefit to the ordering and billing physician. The other commenter stated that a gastroenterology group practice that had been sending its pathology work to his

pathology practice ended the relationship because it entered into an arrangement with another pathology group under which the gastroenterology group practice could bill for the TC. The commenter stated that the gastroenterology group said that there was no dissatisfaction with quality or the service of the commenter's work, but rather it was purely a business decision that enabled the gastroenterology group practice to capture additional revenue in an environment of shrinking reimbursement. Another commenter stated that he received a biopsy for review that was performed on a urologist who routinely sent his (the urologist's) patients' biopsies to his (the urologist's) employed pathologist. The commenter stated that what was good enough for the urologist's patients was not good enough for the urologist.

One commenter stated that captive pathology arrangements are detrimental to patient care. The commenter stated that a local gastroenterology group was able to locate a pathologist who was desperate for work and who reads the biopsies only once a week. The commenter called the turn-around time of once per week "atrocious." The commenter claimed that pathologists who are not willing to work for less than fair market value are being put out of work by physicians who are ignorant of the value of quality pathology services and who hire anyone willing to read slides for any price under any condition. Another commenter asserted that, although gastroenterologists claim they get better service from pathologists who allow the gastroenterologists to bill for the pathology services, the "better service" is, in reality, more money for the gastroenterologists.

One commenter stated that surgeons and surgical pathologists need to work in close contact with each other, and that the pathologist in a "pod lab" has little or no interaction with surgeons and other clinicians. Hospital-based pathologists meet on a regular basis with surgeons and other clinicians to share insights and perspectives on cases, sometimes with immeasurable patient benefit. The "pod lab" arrangement impacts negatively upon the "pod" pathologist's professional growth. Another commenter suggested that we should be aware that the "current campaign" against so-called "pod labs" is led by a few self-interested private pathologists, some in leadership positions in their national organizations, who wish to monopolize the outpatient biopsy market. The commenter stated that these pathologists are using scare tactics to paint with the same brush any nontraditional pathology arrangement,

without regard to any real demonstration of quality problems. The commenter suggested that, instead of focusing on the "straw man" of "pod labs," we should require all suppliers of pathology services to demonstrate quality of service and appropriateness of utilization in order to end the ongoing abusive pathology practices that are occurring in traditional pathology groups, independent laboratories and academic medical centers.

One commenter asserted that the use of contractual arrangements allows specialization by pathologists that otherwise would be seen only in the largest medical centers or reference laboratories. Moreover, the commenter stated that pathologists who work together in contractual arrangements with various groups have the unique opportunity to consult with each other on a regular basis. An entity that manages "pod labs" stated that internal data generated by group practices that refer to their own managed laboratories show a higher positive incidence of prostate cancer now than before they contracted with the commenter. One commenter contended that most gastroenterologists who enter into contractual arrangements with pathology laboratories do so in order to achieve a higher quality of patient care through timely diagnoses and the use of pathology personnel who are experts in gastrointestinal and liver pathology. The commenter expressed certainty that our proposal would have an adverse effect on practice efficiency and the quality of patient care.

A commenter stated that large corporate laboratories do not always provide the highest level of care available. According to the commenter, large laboratories have an incentive to hire the cheapest physician labor in order to "churn out" a high volume of services. The commenter argued that the interaction between the urologists in a group practice and a dedicated pathologist in that practice will lead to better outcomes. Another commenter stated that some gastrointestinal group practices have opened their own pathology laboratories because they believed that the pathology reports they received from general laboratory companies were in some ways lacking. A commenter echoed that sentiment, and added that the fact that the pathologist was practicing in its office meant that the group can easily discuss the pathologist's findings with him and even review slides together.

One commenter contended that, based on her experience gained from working for large, national laboratories, sections are poorly processed there and, often,

much of the tissue is lost. According to the commenter, extra ribbons are not collected at these laboratories and immunostains often do not contain the area suspicious for carcinoma. There is no communication with the physician's office and usually no clinical information is exchanged. She further asserted that group practices that send tissue samples to large laboratories run the risk that an inexperienced pathologist could be performing the work. The commenter related a personal experience in which biopsies were read at a large national laboratory as showing HGPIN, a precursor to adenocarcinoma. The commenter stated that the slides she reviewed on re-biopsy showed no HGPIN, and, not only was the patient made to worry unnecessarily, but the mistaken biopsy review led to the expense of a re-biopsy and another reading. Another commenter stated that its clients say that it provides better quality services and in a timelier manner than do the national commercial laboratories. According to the commenter, this is because physician practices that send anatomic pathology specimens to large commercial laboratories do not choose the pathologists who interpret the slides and thus do not know the qualifications of the pathologist.

Response: We believe that, everything else being equal, there can be some advantages to a physician or group practice referring to the same pathologist, if the referring physician or group practice chooses the pathologist on the basis of his or her qualifications and experience, and the service that he or she provides. However, we also believe that, where there is a financial reward for choosing a pathologist or other diagnostic specialist based on financial self-interest, there is the potential to disregard, or at least subordinate, quality considerations. This final rule with comment period eliminates the profit incentive in choosing a pathologist or other specialist while preserving the referring physician or group practice's right to continue to use the pathologist or other specialist of its choosing. That is, if a billing group practice currently has a contractual arrangement with a particular histotechnologist and particular pathologist because it believes that the histotechnologist and the pathologist provide superior quality and service, it may continue to refer to them; it only will be prevented from marking up the TC and PC (unless the TC and PC are not purchased and are provided in the office of the group practice).

Comment: Many commenters asserted that there would be no adverse effect on patient access if the proposal was adopted. Other commenters stated that patient care would be significantly disrupted if the proposal was adopted. Specifically, commenters stated that the proposed changes would limit access to multiple urologic services in a local area, namely, radiation therapy, lithotripsy, and many in-office procedures such as thermal ablative procedures for prostate obstruction. These commenters contended that many in-office procedures are never performed in hospitals, and that, if the proposed changes to the reassignment and purchased diagnostic test rules become effective, it would be difficult, if not impossible, to provide these services to Medicare beneficiaries.

Response: We are skeptical that our proposal would cause any patient access problem. There appear to be adequate choices throughout the country for physicians and group practices to obtain timely access to diagnostic testing. No evidence was brought to our attention that a patient access problem previously existed and was somehow alleviated when physicians and group practices began entering into contractual arrangements for the provision of pathology and other diagnostic services. In any event, as noted above, our proposal as finalized does not prohibit physicians and group practices from continuing to use the same diagnostic services that they have been using to date.

e. Purchased Tests as They Relate to Reassigned Tests

Comment: We received comments stating that physician contractual arrangements with pathologists constitute an attempt to evade the restrictions of the physician self-referral law. Several commenters stated that there is no practical distinction between a purchased service and a reassigned service. One commenter stated that the proposal effectively eliminates the reassignment rules. The commenter argued that, although CMS states that, under section 952 of the Act, it is required to recognize contractual reassignments only to the extent they meet program integrity and other standards determined by the Secretary, the commenter asserts that the Congress surely did not mean that this statutory provision could be administratively repealed by merging it into the already existing purchased diagnostic test rules. Another commenter stated that our proposal appears to be mixing the purchased diagnostic test policies with contractual reassignments, which could

result in confusion for the imaging industry.

Response: We are concerned that some current arrangements are not in accord with the spirit or the letter of the anti-markup provision in section 1842(n)(1) of the Act. Section 1842(n)(1)(A) of the Act, which was enacted as part of the Omnibus Budget Reconciliation Act of 1987 (Pub. L. 100-203), provides that, if a diagnostic test described in section 1861(s)(3) of the Act (other than a clinical diagnostic laboratory test) was not performed or supervised by the billing physician and also was not performed or supervised by a physician with whom the billing physician "shares a practice," Medicare payment is the lower of the costs (net of any discount) charged by the performing supplier to the billing physician, or the performing supplier's reasonable charge (or other applicable limit). We implemented the anti-markup provision of section 1842(n)(1) of the Act by promulgating current § 414.50, "Physician billing for purchased diagnostic tests." The current version of § 414.50 applies to TCs performed by an "outside supplier," but that term is undefined. We acknowledge that some have understood § 414.50 as applying only to TCs that are outright purchased, instead of reassigned, but as we indicated in the CY 2007 PFS proposed rule (71 FR 49056), and as some commenters have noted, reassigned tests are functionally the equivalent of purchased tests. When section 1842(n)(1) of the Act was enacted, there was perhaps more of a difference between purchased tests and reassigned tests, but subsequent events have blurred the distinction between tests that are outright purchased and tests for which payment is reassigned.

At the time section 1842(n)(1) of the Act was enacted, reassignments under the contractual arrangement reassignment exception in section 1842(b)(6)(A)(ii) of the Act were permitted only to the extent the work was performed on the premises of the billing supplier. Therefore, at that time, a physician reassigning benefits to another physician was either an employee of the billing supplier or a contractor who was furnishing the services on the premises of the billing supplier. However, in our January 4, 2001 (Phase I) final rule with comment period, we provided that, for purposes of our rules on physician self-referral, an independent contractor physician is a "physician in the group practice," as defined at § 411.351, during the time the physician is providing care to the group practice's patients "in the group practice's facilities" (66 FR 885 through

886, 955). Further, in that same rulemaking, we provided that a group practice's facilities (again, for purposes of our rules on physician self-referral) can include a "centralized building" (66 FR 888 through 889). As defined at § 411.351, space qualifies as a group practice's "centralized building" if it is leased "24/7" by the group practice, irrespective of the amount of square footage of the space and irrespective of the proximity (or lack thereof) to the group's facilities. Following that rulemaking, a group practice could, in compliance with our rules on physician self-referral, refer patients for designated health services (DHS) (such as diagnostic testing) to an independent contractor physician, and such physician could perform or supervise the performance of diagnostic tests in a centralized building, provided that all requirements of an exception were satisfied. Further, the independent contractor physician arguably satisfied the "on the premises" requirement of section 1842(b)(6)(A)(ii) of the Act and, thus, was permitted to reassign benefits to the group practice for the work performed in the centralized building, because we considered a centralized building to be the group practice's facilities. In any event, in section 952 of the MMA of 2003, the Congress amended section 1842(b)(6)(A)(ii) of the Act to remove the requirement that the services must be performed on the premises of the billing supplier in order to utilize the contractual arrangement exception. Therefore, following the MMA amendment, it is clear that independent contractor physicians who perform or supervise the performance of diagnostic tests in a centralized building may reassign payment for such tests to the group practice that owns or leases the centralized building.

Being mindful of the Congress' intent to impose an anti-markup on the TC of diagnostic tests that are not performed or supervised by a physician who "shares a practice" with the billing physician, we are amending § 414.50 in this final rule with comment period to provide that TCs that are not performed in the office of the billing physician or other supplier are subject to the anti-markup provision. With respect to a physician organization (such as a group practice), we consider the "office of the billing physician or other supplier" to be medical office space in which the physician organization provides substantially the full range of patient care services that the physician organization provides generally. Therefore, with respect to group practices, we do not consider space to

be the "office of the physician or other supplier" if that space does not meet the requirement regarding patient care services in revised § 414.50(a)(2)(iii) (for example, space that is utilized as a "centralized building" for purposes of the exceptions for physician services and in-office ancillary services in § 411.355(a) and (b), respectively, but in which the group practice provides diagnostic testing services only).

We believe that, if the TC is performed by an employee (full-time or part-time), or by an independent contractor who reassigns benefits, in the office of the billing physician or other supplier, a sufficient nexus with the practice of the billing supplier is established. (In this regard, we note that, if the TC is performed by someone other than an employee or a contractor who reassigns benefits, that is, someone who sells the test to the billing physician or other supplier, the anti-markup provision will apply regardless of where the service is performed.) Further, we see no reason to distinguish between the TC and the PC of diagnostic tests for purposes of the anti-markup provisions. Although the Congress did not establish an anti-markup provision in section 1842(n)(1) of the Act or elsewhere for the PC of diagnostic tests, the omission may have been inadvertent. That is, it is not immediately clear why the Congress, if it wished to prevent overutilization of diagnostic testing, would not have desired an anti-markup on the PC, because without such a provision, the incentive to order unnecessary tests (and profit on the PC) remains. We believe that, in order to fully effectuate the Congress' intent to prevent or limit the ordering of unnecessary diagnostic tests, it is necessary to impose an anti-markup provision on the PC of diagnostic tests. Accordingly, our revisions to § 414.50 apply to PCs to the same extent as they apply to TCs.

We see no reason to distinguish between physicians and physician group practices on the one hand, and other types of suppliers on the other hand, that bill for diagnostic tests. In the proposed rule, we used the terminology "physician or medical group," which we borrowed from the existing manual provisions on purchased tests and purchased test interpretations. However, the term "medical group" is not defined and is not commonly used elsewhere. We are amending § 414.50 so that it applies to a billing "physician or other supplier." Any enrolled supplier that bills for a diagnostic test or its interpretation is potentially subject to the anti-markup provisions in § 414.50.

f. Definition of "Entity"

Comment: One commenter stated that, although we proposed to expand the purchased diagnostic test rule in § 414.50 to apply also to the purchased PC of a diagnostic test, it was not entirely clear whether we proposed to expand the scope of the exception in the definition of "entity" at § 411.351 for purposes of our rules on physician self-referral. The commenter noted that the definition of "entity" at § 411.351 provides that a physician's practice is not acting as an "entity" when it bills Medicare for "a diagnostic test in accordance with § 414.50." The commenter contended that the phrase "diagnostic test" is currently interpreted to mean only the TC, in part because § 414.50 currently applies only to the TC. The commenter also stated that if the scope of § 414.50 is expanded to cover both the TC and the PC, one could interpret the phrase in § 411.351, "diagnostic test in accordance with § 414.50," to mean that a physician practice is not an entity when it bills Medicare for either the TC or the PC in accordance with § 414.50. The commenter suggested that, if we finalize our proposal to apply an anti-markup provision to purchased TCs and PCs, we should revise the definition of "entity" at § 411.351 to clarify that the exception for purchased diagnostic tests applies to both the TC and the PC. Another commenter also supported changing the definition of "entity" at § 411.351 to except from that definition a supplier that is billing for the PC in accordance with the anti-markup provisions of § 414.50.

Response: Under our physician self-referral rules in part 411, subpart J of this chapter, a physician may not refer a patient for certain designated health services (DHS) to an entity with which the physician (or an immediate family member) has a financial relationship, and the entity may not bill Medicare for such DHS, unless an exception applies. The definition of "entity" at § 411.351 "does not include a physician's practice when it bills Medicare for a diagnostic test in accordance with § 414.50." The rationale for excluding from the definition of "entity," and hence from the application of our physician self-referral rules, a physician practice that is billing for a TC that is subject to the anti-markup provision, is that there is no risk of overutilization arising from a financial relationship between the referring physician and the physician's practice billing for the service. We believe the same rationale should apply to PCs made subject to an anti-markup provision under this final rule with

comment period. We are amending slightly the definition of “entity” at § 411.351 to make clear that the exclusion applies to both TCs and PCs. As amended, the pertinent language reads “does not include a physician’s practice when it bills Medicare for the TC or the PC of a diagnostic test for which the anti-markup provision is applicable in accordance with § 414.50.”

We note that, under our physician self-referral rules, an independent contractor physician is a “physician in the group” for purposes of the physician services exception in § 411.355(a) and the in-office ancillary services exception in § 411.355(b), only with respect to services performed on the group’s premises (including a “centralized building” as defined at § 411.351). Therefore, one practical effect of the change in the definition of “entity” is that a group practice that currently may not bill for a PC performed by an independent contractor physician, because the independent contractor physician is not performing the PC on the group’s premises, will be able to do so without running afoul of the physician self-referral rules if the PC is billed in accordance with the anti-markup provisions of this final rule with comment period.

g. Employment Status

Comment: A commenter that supported our proposed changes to the reassignment rules pertaining to diagnostic tests stated that it was appropriate for CMS to focus on the billing of diagnostic tests performed by someone other than a full-time employee. The vast majority of commenters that addressed the employment status issue, however, opposed applying the anti-markup provisions to part-time employees and independent contractors based simply on their employment status. Three commenters asserted that the proposed changes are unnecessary and would negatively impact the way physicians provide care to patients, possibly resulting in the termination of part-time physicians or a prohibition on part-time physicians furnishing diagnostic tests. Many commenters claimed that, if the proposed changes to the purchased diagnostic test rules are implemented, physicians and group practices would not be able to provide certain routine medical procedures if limited to using full-time employees. One commenter requested that we exempt part-time employees and independent contractors from the anti-markup rules provided that the billing supplier satisfies a physician self-referral exception and the

services are furnished in the billing supplier’s office. A few commenters proposed that CMS not apply the anti-markup requirements to technicians who work on-site at the medical group and who work at least half-time for that specific group.

One commenter stated that limiting reimbursement for the PC of diagnostic tests performed by outside suppliers would create an incentive to hire full-time staff and then overutilize pathology services in an attempt to recoup the costs of such personnel. The commenter urged us not to penalize physician groups by having the anti-markup rules apply when using part-time employees or independent contractors who furnish services on less than a full-time basis. Two commenters considered our proposal to be premised on the unsupported belief that group practices that perform a lower volume of diagnostic tests and, therefore, need only employ pathologists on a part-time basis, present more risk of program abuse. Another commenter stated that forcing suppliers and their staff into full-time relationships will impose needless costs and will require forgoing efficiencies that are available through more flexible supplier-staff relationships. Several commenters believed that applying an anti-markup provision based upon the employment status of the technician or physician would unfairly disadvantage individuals who want to work only part-time (for example, mothers of young children). One of these commenters stated that we essentially placed a hurdle in front of group practices that wish to accommodate the professional and personal needs of its employees, and that, given the shortage of qualified health professionals in many areas, we should be making it easier, and not more difficult, for professionals to provide care.

Response: We agree that it is not necessary or advisable to premise the application of the anti-markup provisions on the employment status of the person performing the TC or PC. We are revising the language in § 414.50 to clarify that an outside supplier is someone who is not an employee of the billing physician or other supplier and who does not furnish the test or interpretation to the billing supplier under a reassignment that meets the requirements of § 424.80. Therefore, diagnostic testing services furnished by part-time employees and independent contractors in the office of the billing supplier will not be subject to the anti-markup rules, unless the services of the independent contractor are billed as a purchased diagnostic test.

Comment: One commenter stated that the anti-markup provisions should apply only when the diagnostic service is provided in a centralized building outside of the physician’s primary office site where he or she provides his or her professional services, and should not apply based on the employment status of the individual performing the TC.

Response: We agree generally and have revised § 414.50 and § 424.80 to specify that the anti-markup rules apply to purchased tests and interpretations (regardless of site of service) and to TCs and PCs performed at a site other than the office of the billing supplier. With respect to physician group practices, the group’s “office” is the medical office space in which the physician organization provides substantially the full range of patient care services that the physician organization provides generally. The group’s office does not include space utilized by the group as a “centralized building” (or other space) where only (or primarily) diagnostic testing is performed by radiologists or pathologists.

Comment: One commenter found the proposed definition of an outside supplier as someone other than a full-time employee of the billing physician or medical group to be confusing and inconsistent with the definitions at § 411.351. Thus, the commenter recommended replacing the term “full-time employee of the billing physician or medical group” with the defined term “member of the group or member of a group practice.”

Response: In the CY 2007 PFS proposed rule (71 FR 49054), we proposed that TCs and PCs that are reassigned under the contractual arrangements exception in section 1842(b)(6)(A)(ii) of the Act would be subject to an anti-markup provision. We received comments expressing concern that our proposals would be ineffective to the extent that contractors who performed TCs and PCs for multiple group practices would now become part-time employees of the same group practices. In response, in the CY 2008 PFS proposed rule, we proposed that the anti-markup provisions would apply to reassigned TCs and PCs that are not performed by full-time employees. However, we believe we can guard adequately against potential overutilization by imposing an anti-markup provision on purchased PCs and TCs, and, with respect to non-purchased TCs and PCs, imposing an anti-markup provision on the TCs and PCs that are performed outside of the office of the billing physician or other supplier, without regard to the employment status of the person

performing the TC or PC, thus leaving intact the part-time employment arrangements that have traditionally existed. Therefore, we believe it is unnecessary and inadvisable to adopt the commenter's suggestion.

Comment: Several commenters requested that we clarify what is meant by a "full-time employee." They urged us to use the Department of Labor's Bureau of Labor Statistics standard, which is 35 hours per week.

Response: For the reasons stated above, we do not believe it is necessary to define "full-time employee."

Comment: Several commenters suggested that we exempt TCs and PCs furnished by part-time employees of the billing supplier from the anti-markup provisions, provided that the employees are working exclusively for one billing supplier, such as a single health care organization. Other commenters suggested that, instead of providing that the anti-markup provisions would apply to the TCs and PCs performed by part-time employees, we apply an anti-markup provision to work performed by employees who work for more than a certain number of physician practices.

Response: We considered creating an exception from the anti-markup provisions for services provided by part-time employees who work exclusively for one billing supplier. We also considered restricting the application of the anti-markup provision to work performed by employees who work for more than a certain number of physicians' practices. We rejected both approaches as unnecessary given our decision to base the application of the anti-markup primarily on the site of service, as well as because we believe that each approach would add undue complexity to the rule and would be difficult for both billing suppliers and for us to administer. We will monitor the effectiveness of our site-of-service approach in addressing our concerns regarding potential overutilization. If arrangements that currently are taking place at a site other than the office of the billing physician or other supplier simply migrate to the "office of the billing physician or other supplier" in order to escape the application of the anti-markup provisions, we may revisit the idea of imposing an anti-markup provision for services performed by a technician or physician who works for more than a certain number of physician practices.

h. Deductibles and Coinsurance

Comment: Several commenters observed that there appeared to be a drafting error regarding the application of deductibles and coinsurance to the

anti-markup limits in proposed § 414.50 and § 424.80. In both sections, the maximum payment is set as an amount that is net of deductibles and coinsurance, that is, "less the applicable deductibles and coinsurance." The commenters noted that the price limitation should represent the Medicare allowable amount, which should include any coinsurance or deductibles to be paid by the Medicare beneficiary. One of the commenters stated that the current language could be interpreted such that the combined Medicare and beneficiary payment to the physician could exceed the amount that a physician paid an outside supplier of a TC or PC by 20 percent, the applicable coinsurance for PFS services. The commenter recommended that the language be revised to read "the payment to the billing physician or medical group, *including applicable deductibles and coinsurance*, may not exceed the lowest of the following amounts."

Response: Proposed § 414.50 and proposed § 424.80 stated that, payment to the billing supplier, "less the applicable deductibles and coinsurance" may not exceed the lowest of the following amounts: (1) The supplier's net charge to the physician; (2) the physician's actual charge; or (3) the fee schedule amount for the test that would be allowed if the supplier billed directly. The quoted language referenced above is identical to that in current § 414.50 and is virtually identical to that in section 1842(n)(1) of the Act. We read the statute and regulations as saying that the contractor's payment to the billing supplier, in the situation in which the anti-markup provision applies, is the lowest of the performing supplier's net charge, or the billing supplier's actual charge, or the applicable fee schedule amount, *less* any applicable deductible and coinsurance amounts.

We agree with the commenters that the *total* payment (that is, by the contractor and the beneficiary or third party payor on behalf of the beneficiary) is limited to the lowest of the three amounts specified above. This interpretation represents historical Medicare policy, and we believe that this policy has been implemented correctly by the carriers. However, we are refining the language of the regulation as suggested by the commenter for greater clarity. We do not consider this a substantive change. We are revising § 414.50 to read "the payment to the billing physician or other supplier (*including applicable deductibles and coinsurance paid by the beneficiary or on behalf of the*

beneficiary) for the technical or professional component of the test may not exceed the lowest of the following amounts * * *"

i. Net Charge

Comment: Several commenters addressed the question of how to determine the net charge for purposes of applying the anti-markup provisions. Commenters asserted that most physicians are paid an aggregate monthly or annual amount for their services and therefore there is no "charge" to report on a claim. One commenter stated that independent contractors are frequently paid based on time spent furnishing the services, as opposed to a per-interpretation price. Alternatively, payment may be made at a fixed rate per month or year. Yet another model is a per-service price reflecting a blended rate of different payor pricing, not just the Medicare allowable amount. Employees, including part-time employees, are often salaried. Consequently, according to the commenter, there is no cost or charge per professional interpretation, and it would be impossible for a group practice to determine the unit price for purposes of the anti-markup provision. The commenter contended that all of the various types of employment relationships would have to be restructured, at great cost and administrative burden, to practices.

One commenter stated that it would not be administratively feasible to determine the net charge per test in order to apply the anti-markup provisions to part-time employees or independent contractors who are paid on an hourly basis or a per-diem rate. Other commenters complained that the proposed rules do not address how the billing entity is supposed to determine the net charge per service on the claim. According to these commenters, it causes confusion as well as the risk of false claims liability to require physician practices to include a charge for all diagnostic test services. Another commenter pointed to what it saw as difficulties in allocating charges between the TC and the PC when a billing supplier purchases both the TC and the PC.

A few commenters urged us to provide guidance on how to determine the "net charge" for a service. One commenter requested that we clearly state that the billing entity must calculate its net unit price, which may reflect payments divided by the number of slides referred; for example, if the billing entity pays a supplier a set amount per month or per year to prepare and read all the slides that were

referred. One commenter stated that it agreed with the proposed approach of not allowing the net charge to reflect the cost incurred by the performing supplier of leasing equipment or space from the billing supplier. The commenter expressed concern, however, that participants in some joint venture laboratories may inappropriately attempt to inflate the acquisition cost of the service, and suggested that we not permit other related costs, such as separately purchased or leased equipment, supplies, insurance, etc., to be included when determining the amount charged by the person performing the TC or PC. If these costs were included, it would have the effect of raising the net charge, and permit the billing suppliers to charge Medicare a higher price.

Response: We are leaving the responsibility for determining the net charge for a test with the billing supplier. The anti-markup provision imposed on the PC through this final rule with comment period is similar to the longstanding provision for prohibiting a markup on the TC. Thus, we do not believe most suppliers will experience significant difficulty in calculating the net charge, despite the fact that some physicians are paid an aggregate monthly or annual amount for their services. Suppliers that incur difficulty in calculating the net charge may structure arrangements so that the anti-markup provisions do not apply (for example, by ensuring that tests and interpretations are not purchased and are performed in the office of the billing physician or other supplier), may allow the performing supplier to bill for the TC or PC, or may use a payment method (such as per-procedure) that yields an easily ascertainable net charge. Suppliers must calculate the net charge in a reasonable manner. This final rule with comment period does not prevent suppliers from using any particular method that yields an accurate net charge. For example, in some situations, it may be appropriate to divide a technician's weekly compensation by the number of procedures performed to arrive at the net charge for each procedure performed during that week. Because suppliers would have the burden of establishing that the charge billed was the net charge, suppliers should retain contemporaneous documentation of the methodology and information used to calculate the net charge.

We are not adopting at this time the commenter's suggestion that, to guard against parties artificially inflating the cost of the TC or PC, we specifically prohibit the performing supplier to take

into account, when calculating its net charge, the costs of equipment or services (such as insurance), obtained from the billing supplier. However, we note that, to the extent that a billing supplier would sell goods or services at an inflated price so as to game the application of the anti-markup provisions, such excess compensation may constitute a violation of our rules on physician self-referral and may also be a violation of the anti-kickback statute (section 1128B(b) of the Act). We will monitor financial relationships between billing and performing suppliers and, if it appears that parties are attempting to evade application of the anti-markup provisions through the sale of goods and services, we may modify the provisions.

Comment: One commenter expressed concern about expanding the anti-markup provision to cover the PC, noting that, because a per-interpretation price is not the most efficient method of compensation for purchased PCs, practices would likely develop a system of compensation that would pay the reading physician differently depending on the patient's payor. For example, practices might pay the reading physician on a salary basis for reads for patients of private and non-Medicare payors and on a per-read basis for Medicare patients. According to the commenter, this could result in lower costs associated with non-Medicare patients than with Medicare patients, depending on the way in which the physician and the practice negotiate payment for the different groups of patients. The commenter questioned whether it is appropriate to charge Medicare more on a per-procedure basis than other payors.

Response: Nothing in this final rule with comment period requires practices to pay for professional services for Medicare patients on a per-procedure basis or using any particular payment method. What is important is that the practice calculates an accurate net charge for purposes of these regulations. In reviewing the accuracy of the net charges of a practice that pays differently for professional services based on the payor status of the patients, we would look to see whether the use of different payment structures results in inappropriate shifting of costs to Medicare (that is, by paying physicians more for Medicare reads than non-Medicare reads, the practice is able to collect more reimbursement under the anti-markup provisions). Moreover, we note that section 1128(b)(6)(A) of the Act provides for the permissive exclusion of providers or suppliers that submit bills or requests

for payment based on charges or costs to Medicare that are substantially in excess of the party's usual charges or costs, absent a finding of good cause for the differential. Responsibility for that statute is delegated to the OIG.

Comment: One commenter questioned whether the anti-markup provisions would apply to diagnostic tests performed through block lease arrangements. This commenter (and another commenter) also stated that it would be difficult to calculate the per-test charge on tests performed in block lease arrangements.

Response: The anti-markup rules do apply to diagnostic tests performed through block lease arrangements, and the burden is on the billing entity to determine how to calculate its net charge per test.

Comment: Several commenters urged us to ensure that the calculation of the payment level under the anti-markup rules will not impose new administrative burdens on the billing supplier. A few commenters stated that the billing supplier should be able to mark up the PC between 7 and 10 percent to cover the costs of billing. A few commenters asserted that the proposed anti-markup provisions will adversely affect group practices that wish to bill globally for interpretations performed by teleradiologists located outside of the billing group practice's office. The commenters were concerned that billing physicians or other suppliers would not be able to include administrative expenses in the price paid for the interpretation. One commenter stated that, by limiting reimbursement to a practice's actual acquisition cost, we are ignoring the role of the RBRVS system to appropriately establish a proper payment amount for services.

Response: Where the anti-markup provisions are applicable, the billing supplier will be responsible for calculating the net charge. Suppliers that do not wish to contend with calculating the net charge will have to structure arrangements so that the anti-markup provisions do not apply (for example, by requiring the suppliers performing the TC and PC to bill for them, or by ensuring that the TC and PC are performed in the office of the billing physician or other supplier), or utilize a per-procedure method of payment or other method that yields an easily ascertainable net charge. Similarly, suppliers that do not wish to incur the cost of billing without being able to mark up the TC or PC, should structure arrangements so that the anti-markup provisions do not apply.

Comment: One commenter contended that, in a medical foundation context, there is no way to determine the net charge to the foundation for the services of the interpreting physician. The commenter stated that the anti-markup proposal would result in the need to generate artificial invoices, greatly complicating and needlessly burdening medical foundations.

Response: A medical foundation, or any other medical group practice, billing for the TC or PC of a diagnostic test that it did not perform will need to calculate its own net charge per test. We perceive no need to generate artificial invoices. The purpose of this requirement is to address potential program abuse where physicians and other suppliers order tests and bill for tests that they did not perform at a markup from the price paid for the test.

Comment: Several commenters inquired how we would be able to verify the true cost of purchasing a TC or PC of a diagnostic test. The commenters questioned our rationale for this proposal and asserted that the proposal would be detrimental because it would have the effect of precluding suppliers from recouping overhead costs. The commenters voiced concerns that we are trying to eliminate purchased diagnostic tests entirely.

Response: We can verify the true cost of a purchased TC or PC by requesting supporting documentation from the provider or supplier. The burden of proof in substantiating the validity of a claim rests with the billing provider or supplier. The anti-markup provisions finalized in this rule are not designed to prevent the billing supplier from recovering overhead expenses or to eliminate purchased diagnostic tests entirely, but rather to minimize program and patient abuse. Where the TC or PC is performed in the office of the billing physician or other supplier, the billing supplier will be able to recoup some or all of the overhead it incurs in the performance of the TC or PC by billing at the fee schedule amount (or at the Medicare limiting charge amount). If, however, the billing supplier has incurred overhead expenses for a TC or PC that was performed at a site other than the office of the billing supplier (such as in space leased by a billing group practice and utilized by the group practice as a "centralized building" that does not meet the definition of "office of the billing physician or other supplier" at § 414.50(a)(2)(iii)), the billing supplier will not be able to recoup the overhead, but rather will be limited to the lowest of the performing supplier's net charge, the billing supplier's actual charge, or the

applicable fee schedule amount. (In the unlikely event that the lowest of the three amounts is either the billing supplier's actual charge or the applicable fee schedule amount, the billing supplier may be able to recoup its overhead but nevertheless would be receiving less payment than the performing supplier's net charge.) We believe that this result is appropriate. If billing suppliers were able to recoup overhead incurred for TCs and PCs that are performed at sites other than their offices, the effectiveness of the anti-markup provisions would be undermined, because there would be an incentive to overutilize to recover the overhead incurred for purchasing or leasing space.

Comment: One commenter recommended that we require, as a condition for reassignment of a purchased interpretation, that the parties to the arrangement calculate a net charge for the service. The commenter stated that, if this condition applied, per-diem or other time-based arrangements, which are more susceptible to markups, would not be permitted.

Response: We realize that, in most circumstances, a group practice would not want to pay an independent contractor more for a service than the payment it receives from an insurer for furnishing the service. However, we are under the impression that some physician group practices that have exclusive contracts with hospitals under which the group practice furnishes all PCs of inpatient and outpatient radiology services often hire independent contractors to provide PCs that are needed at night or on weekends. We have been informed that, in some of these cases, the group practice willingly pays its independent contractors more for their services than the group practice receives in reimbursement so that the group practice physicians do not have to provide services late at night. There may also be other reasons (for example, as an improper inducement for referrals) why parties could agree to an amount that does not accurately reflect the true net charge.

As explained above, we believe that a group practice may pay an independent contractor on a per-diem or hourly basis, and also arrive at an appropriate amount to bill Medicare for each service based on the number and differing work intensities of the services provided.

Comment: One commenter recommended that we prohibit any mark-up over the direct costs incurred by the group practice in providing diagnostic testing services. Direct costs would be defined as limited to the

compensation paid to the persons providing the services and the cost of equipment and supplies utilized in performing the services. One commenter asserted that the proposed restrictions would not allow a billing practice to be paid for its legitimate overhead costs. Two commenters requested that we permit employers to include in the calculation of a supplier's net charge the lower of the following: (1) A reasonable practice expense (PE) derived from its own relative value cost; or (2) the actual overhead costs attributable to the supplier. The commenters suggested that this would permit a group to utilize part-time diagnostic physicians without financially penalizing the employer, and at the same time safeguard against artificially inflated overhead costs.

Response: In effect, the commenters requested that we adopt a "net charge plus" approach. In order for the anti-markup provisions to have real effect, it is necessary that payment by Medicare be limited to the lowest of: (1) The physician's or other supplier's net charge to the billing supplier; (2) the billing supplier's actual charge; or (3) the fee schedule amount for the service that would be allowed if the physician or other supplier billed directly. If we were to allow billing suppliers to include costs in addition to the performing supplier's net charge, we would defeat the purpose of the anti-markup provisions.

Comment: A few commenters requested that we ensure consistency in the language in § 414.50 and § 424.80. For example, proposed § 414.50(a)(3)(i) states that net charge does not include "any charge that is intended to reflect the cost of equipment or space leased to the outside supplier," whereas § 424.80 states that it does not include "any charge that is intended to cover or address the cost of this equipment."

Response: As noted above, we have effectuated the anti-markup provisions by revising § 414.50, and by placing a cross reference to that section in new § 424.80(d)(3). The language of proposed § 414.50(a)(3)(i), "reflect the cost of equipment or space leased" survives.

Comment: One commenter recommended that we include in the net charge the costs incurred by the purchasing supplier to facilitate test interpretations, specifically, the cost of teleradiography to transmit images to the interpreting physician and the cost of producing a written report of the interpretation.

Response: To the extent that costs such as those noted by the commenter are incurred by the billing supplier, as opposed to the performing supplier, we are not persuaded to permit the inflation

of the net charge to include such costs. As discussed above with respect to the recoupment of overhead costs, we believe that allowing billing suppliers to recoup the costs suggested by the commenter would defeat the purpose of the anti-markup provisions.

i. Miscellaneous

Comment: One commenter suggested that, as an alternative to an anti-markup provision, we prescribe a fixed dollar amount (for example, based on a percentage of what Medicare would pay for the PC if billed directly), as a ceiling for Medicare payment. The ceiling would be adjusted for certain PEs such as *bona fide* collection costs and bad debt.

Response: We believe that setting a fixed dollar amount for diagnostic tests and interpretations performed under particular circumstances is problematic. There would be difficulties in determining what the fixed dollar amount should be, and what, if any, PEs should be taken into consideration to augment the fixed dollar amount. In addition, we did not propose such an approach, and believe it may be outside the logical outgrowth test for issuing final rules to adopt the commenter's approach in this final rule with comment period. Moreover, even if we were able to adopt such an approach without first specifically proposing one, it would take us considerable time to study the feasibility of prescribing a payment ceiling for TCs and PCs under particular circumstances, and we believe that it is important to issue a final rulemaking on this subject without further delay in order to address our current concerns with potential overutilization.

Comment: Two commenters stated that, in addition to restrictions contained in the proposed rule, we should also require that: (1) A pathologist not be allowed to work for more than one physician group practice; (2) a pathologist not be allowed to work for, or have any arrangement with, independent reference laboratories; and (3) medical liability insurance for the pathologist should be paid by the physician group practice billing for the pathologist's services. (The commenters explained that the purpose of the second proposed requirement is to eliminate the possibility that a reference laboratory could provide a pathologist to a physician group practice in return for receiving the right to bill for the TC.) One of the commenters was also concerned that, if a single pathologist is performing work for the billing physician practice, appropriate or optimal quality assurance will not take

place. The commenter stated that, in her pathology group practice, all malignancies are reviewed by at least two pathologists.

Response: With respect to the commenters' first suggested requirement, we proposed that an anti-markup provision would apply to PCs that are reassigned by someone who is not a full-time employee of the supplier billing for the PC, because we were concerned with the potential for overutilization where a single physician performs interpretations for more than one group practice in contiguous centralized buildings (such as in "pod" or "condo" laboratories). Specifically, we were concerned that a physician who formerly reassigned benefits under the contractual arrangements reassignment exception could simply be made a part-time employee of a number of group practices. As noted above, in response to public comments, we are not imposing an anti-markup on the PC of a diagnostic test simply because the PC was performed by someone other than a full-time employee of the billing supplier. Rather, we are addressing our concerns regarding potential overutilization by imposing an anti-markup on the PC of a diagnostic test if it is purchased or if it is not performed in the office of the billing physician or other supplier. We believe our decision to impose an anti-markup provision on PCs that are ordered by the billing supplier and performed at a site other than the office of the billing supplier (for example, in space that the billing supplier utilizes as a "centralized building" but that does not meet the definition of "office of the billing physician or other supplier" in revised § 414.50(a)(2)(iii)), regardless of the employment status of the physician, will adequately address our concerns with overutilization. As for the other two proposed requirements and the second commenter's implied proposed requirement, we do not believe it is within the scope of this rule to attempt to restrict a pathologist from working for more than one supplier, or to require a group practice to pay for a pathologist's malpractice premiums, or to impose quality standards for pathologist performed PCs.

Comment: A commenter recommended that we revise the definition of "centralized building" at § 411.351 to include the following language: "In the case of a space used for the performance of the [TC] of a diagnostic test, which is billed by a group practice, such space can qualify as a centralized building only if the group complies with the requirements of § 414.50 or § 424.80(d)(3) when

billing for the [TC]." The commenter also suggested that, by changing the definition of "centralized building," a physician or medical group would be prohibited from marking up what it paid for the TC of a test that was performed in a centralized building, unless it was performed by a full-time employee.

Response: We are not revising the definition of "centralized building" in this rule. Because the anti-markup provisions will apply to all TCs and PCs that are both: (1) Ordered by a group practice (or an entity related to the group practice by common ownership or control; see § 413.17 regarding "common ownership or control"); and (2) performed at a site other than the office of the physician or other supplier, it is not necessary at this time to narrow the definition of a "centralized building" in order to guard against potential overutilization.

Comment: One commenter expressed concern regarding physicians who have invested heavily in in-office equipment and have followed CMS guidelines established for the in-office ancillary services exception in § 411.355(b) for purposes of the physician self-referral rules. The commenter recommended that we regulate the usage of ancillary services through medical necessity guidelines and by requiring that the services be provided at fair market value, rather than by the proposed changes to the reassignment and purchased test rules.

Response: As finalized, the anti-markup provisions do not apply to non-purchased TCs and PCs performed in the office of the billing physician or other supplier. We note that in the CY 2008 PFS proposed rule, we sought comments as to whether we should narrow the in-office ancillary services exception, including whether we should exclude certain types of services from the protection of the exception. We received many comments on this issue, and if we are inclined to make any changes to the in-office ancillary services exception we will first propose such changes in a notice of proposed rulemaking.

Comment: One commenter urged us to require that imaging technology be provided only by physicians trained in modality-specific interpretation of imaging procedures who follow the guidelines of specialty organizations such as the American College of Cardiology and the American Society of Echocardiography. In addition, the commenter supported the accreditation of facilities that provide such imaging services, provided that we allow adequate time for practices to become accredited by relevant organizations that

are dedicated to improving the quality of imaging services.

Response: The comment is outside the scope of the proposed rule. Moreover, currently we do not have the statutory authority to restrict payment for these procedures to physicians who possess the training and accreditation recommended by the commenter.

Comment: One commenter urged us to enforce the anti-markup requirements on purchased diagnostic tests by auditing pathology practices and laboratories. The commenter contended that there is widespread ordering of unnecessary tests by pathologists with no regulatory oversight by CMS. The commenter suggested that effective enforcement and application of current anti-markup rules to the pathology community would obviate the need to add new regulations that would limit physician practices from providing quality pathology services to their Medicare patients. The commenter also suggested that we adopt reasonable protocols and standards for the review of Pap smears, among other tests, which, according to the commenter, would significantly reduce unnecessary testing by pathologists and result in tremendous cost savings to the Medicare program.

Response: Our contractors perform pre-pay and post-pay reviews of services, including reviews to determine if the services were reasonable and necessary. However, the extremely large number of claims that contractors must handle each year, as well as the difficulty in sometimes knowing whether services were reasonable and necessary, underscores the need to adopt rules to address the potential for overutilization in other ways, rather than relying solely on reviews for medical necessity. The proposed anti-markup provisions would apply equally to all physicians, including pathologists. However, section 1842(n)(1) of the Act does not authorize the anti-markup on diagnostic tests to apply to clinical laboratory tests, and we did not propose to extend the anti-markup provisions to such tests. We are concerned with preventing the billing supplier from ordering unnecessary tests for profit. Laboratories typically do not order tests, and therefore, there has not been a concern about abuse by laboratories in purchasing diagnostic tests. The comment that we should adopt protocols or standards for the review of Pap smears and other tests is outside the scope of the proposed rule.

Comment: One commenter urged us to prohibit any markup of the TC of surgical pathology specimens and let each physician decide where the TC is

performed in addition to where the PC is performed.

Response: Section 414.50 and section 30.2.9 of Pub. 100-04, Chapter 1, CMS Internet-Only Manual, currently prohibit markups of the TC of a diagnostic test if the TC is performed by an outside supplier. As finalized, our revisions to § 414.50 will prohibit the markup of a TC if the TC is ordered by the billing supplier and is either purchased or performed somewhere other than the office of the billing supplier. Physicians are permitted to determine where the TC and PC are performed, provided that the arrangement is in compliance with the purchased test rules and physician self-referral rules.

Comment: One commenter stated that the proposed anti-markup provisions are unfair and would interfere with existing business relationships. The commenter asserted that medical practices should have the freedom to hire in-house professionals or contract with other practices to perform services without fear of financial penalty.

Response: We are not persuaded that our anti-markup proposals, as finalized in this final rule with comment, are unfair. The proposals as finalized are designed to reduce overutilization of diagnostic tests, so that tests are ordered because they are medically necessary and are not ordered because a profit can be made on each test. Practices can maintain relationships with other professionals on a part-time or contractual basis. If the services are furnished in the office of the billing supplier, the anti-markup rules will not apply, unless the services of an independent contractor are billed as a purchased test.

N. Beneficiary Signature for Ambulance Transport Services

Section 424.36 requires that a beneficiary's signature must appear on all claims submitted for Medicare services, unless the beneficiary has died, or another exception applies. However, ambulance suppliers and providers have stated that, in emergency situations, it is often impossible or impractical for ambulance providers or suppliers to obtain a beneficiary's or other authorized person's signature on a claim to properly bill Medicare for ambulance transport services because: (1) Many beneficiaries are incapable of signing claims due to their medical condition at the time of transport; (2) another person authorized to sign the claim under § 424.36(b) is not available, or is unwilling to sign the claim at the time of transport; and (3) if an individual listed in § 424.36(b) is not

available or is unwilling to sign a claim on behalf of the beneficiary at the time of transport, it is impractical later to locate the beneficiary (or the beneficiary's authorized representative) to obtain a signature on the claim form before submitting it to Medicare for payment.

As stated in the CY 2008 PFS proposed rule (72 FR 38187), we are sympathetic to the concerns of ambulance providers and suppliers insofar as emergency transport services are involved. Therefore, we proposed to revise § 424.36 to provide that, for emergency ambulance transport services, where the ambulance provider or supplier documents that the beneficiary was physically or mentally incapable of signing a claim form at the time the service was provided and that none of the individuals listed in § 424.36(b)(1) through (b)(5)² was available or willing to sign a claim on behalf of the beneficiary, the ambulance provider or supplier could submit the claim without a beneficiary signature. Under our proposal, such claim submission would be permitted only if: (1) The beneficiary was physically or mentally incapable of signing the claim form at the time the service was provided; (2) none of the individuals listed in § 424.36(b)(1) through (b)(4) was available or willing to sign the claim form on behalf of the beneficiary at the time the service was provided; and (3) the ambulance provider or supplier maintains in its files for a period of at least 4 years from the date of service certain documentation. Required documentation would include:

(1) A signed contemporaneous statement, made by an ambulance employee present during the trip to the receiving facility, that the beneficiary was physically or mentally incapable of signing a claim form and that none of the individuals listed in § 424.36(b)(1) through (b)(4) was available or willing to sign the claim form on behalf of the beneficiary at the time the service was provided; (2) the date and time the beneficiary was transported, and the name and location of the facility where the beneficiary was received; and (3) a signed contemporaneous statement from a representative of the facility that received the beneficiary, which documents the name of the beneficiary and the time and date that the beneficiary was received by that facility.

For non-emergency ambulance transport services, the ambulance

² We are making a technical change in the final rule. The references in the proposed rule to § 424.36(b)(5) were in error, as individuals are specified only in § 424.36(b)(1) through (b)(4).

provider or supplier would continue to be required to obtain a beneficiary's signature on a claim form (or the signature of someone who is authorized to sign on behalf of the beneficiary under § 424.36(b)(1) through (b)(4)) prior to submitting claims to Medicare.

We received comments from two national associations that represent providers and suppliers of ambulance services and hospitals. The remainder of the comments came from ambulance owners and employees. The commenters generally agreed that we should eliminate the beneficiary signature requirement entirely when a beneficiary is mentally or physically incapable of signing a claim and no other person authorized to sign a claim on behalf of the beneficiary is available or willing to sign at the time of transport. In addition, the commenters argued that the proposed documentation requirements would be costly and burdensome to ambulance providers and suppliers.

We are adopting our proposal, with modification. Specifically, we are allowing a secondary form of verification to be used in lieu of the proposed signed contemporaneous statement from a representative of the facility that received the beneficiary (which remains an alternative). We are also amending § 424.32(a) to clarify that the beneficiary signature requirement is satisfied if one of the exceptions in § 424.36 is satisfied. Finally, we are making a technical change to our proposal. In the proposed rule, we stated that ambulance providers and suppliers could utilize proposed § 424.36(b)(6) if none of the individuals listed in § 424.36(b)(1) through (b)(5) were available or willing to sign the claim on behalf of the beneficiary at the time the service was provided. The references to § 424.36(b)(5) were in error, as individuals are specified only in § 424.36(b)(1) through (b)(4).

Comment: The majority of the commenters opposed our proposed changes to the beneficiary signature requirements in § 424.36. The commenters stated that the proposed changes would have the unintended effect of increasing the administrative and compliance burden on providers and suppliers of ambulance services and on the hospitals.

Response: The proposal would not have imposed any additional burdens on providers and suppliers of ambulance services. Rather, the proposal, which we are adopting with some modification, set forth an alternate method of satisfying the beneficiary signature requirement for claims submitted for emergency ambulance

services. Those ambulance providers and suppliers that believe that it is burdensome to comply with new § 424.36(b)(6), may avail themselves of the other means specified in § 424.36 for satisfying the beneficiary signature requirement.

Comment: Commenters asserted that when a beneficiary is physically or mentally incapable of signing a claim, the ambulance industry has already been signing claims on behalf of such beneficiaries in accordance with the requirements listed in the CMS Internet-Only Manual (IOM), Pub. 100-02, Medicare Benefit Policy Manual, Chapter 10, Section 20.1.2 and IOM, Pub. 100-04, Medicare Claims Processing Manual, Chapter 1, Section 50.1.6(A)(3)(c), without any objections from CMS contractors. The commenters stated that the ambulance industry has also been relying on § 424.36(b)(5) as further authority to sign claims on behalf of beneficiaries when beneficiaries are incapable of signing and the requirements of § 424.36(b)(1) through (b)(4) have not been met.

Response: Section 424.36(b)(5) applies only if the beneficiary is physically or mentally incapable of signing the claim and none of the persons listed in § 424.36(b)(1) through (b)(4) is available to sign the claim. Note that we interpret § 424.36(b), including § 424.36(b)(5), as meaning that neither the beneficiary nor any of the persons listed in § 424.36(b)(1) through (b)(4) is available at all, not just that none of them is available at the time the service is performed. Thus, even assuming that § 424.36(b)(5) applies to ambulance providers (and we believe that this subparagraph was intended to apply only to institutional providers such as a hospital), an ambulance provider would not be allowed to rely on § 424.36(b)(5) to sign a claim for ambulance services simply because the beneficiary was incapable of signing the claim at the time of delivery to the hospital or ESRD facility and none of the persons listed in § 424.36(b)(1) through (b)(4) was available and willing to sign the claim for ambulance services at the time of delivery. Instead, the provider would be required, in advance of submitting the claim, to make reasonable efforts to locate and obtain a signature from the beneficiary or, if the beneficiary is not capable of signing, one of the alternative individuals specified in § 424.36(b)(1) through (b)(4). It would make little sense to specify different categories of individuals in § 424.36(b)(1) through (b)(4) who could sign a claim on behalf of a beneficiary who is unable to sign, if a provider was allowed to file a claim without making an effort to obtain a

signature from one of the other authorized individuals. To the extent that ambulance *suppliers* have been relying on § 424.36(b)(5) under any circumstances, such suppliers have been failing to follow the regulations, as this subparagraph does not pertain to suppliers. We are clarifying § 424.36(b)(5) to provide that, before a provider may avail itself of the exception in § 424.36(b)(5), it must make reasonable efforts (including over a reasonable period of time) to have either the beneficiary or one of the individuals specified in § 424.36(b)(1) through (b)(4) to sign the claim. Similarly, the sections of the CMS IOM cited by the commenters, Pub. 100-02, Chapter 10, section 20.1.2 and Pub. 100-04, Chapter 1, section 50.1.6(A)(3)(c) imply that reasonable efforts must be made to locate other individuals prior to submitting the claim. We plan to issue clarifying instructions in the near future, to ensure that our regulations and manual instructions on the beneficiary signature requirement are fully consistent with each other.

In contrast, the proposal, as adopted with modification, allows ambulance providers and suppliers, in the case of emergency transport, to sign the claim, if certain documentation requirements are met, where the beneficiary is not capable of signing the claim *at the time of transport*.

Comment: Most of the commenters agreed that some of our proposed documentation requirements are already being followed by ambulance providers and suppliers. However, they strongly objected to proposed § 424.36(b)(6)(ii)(C), which would have required a signed contemporaneous statement from a representative of the facility that received the beneficiary, documenting the name of the beneficiary, and the date and time the beneficiary was received by that facility. The commenters asserted that it is not practical or feasible to obtain a signed contemporaneous statement from a representative of the receiving facility documenting the name of the beneficiary and the date and time the beneficiary was received by that facility. The commenters stated that hospital personnel in emergency departments often are either too busy or refuse to sign any forms when receiving a patient. In addition, the commenters contended that attempting to obtain a signature from a representative of the hospital would decrease the amount of time available for ambulances to serve their respective communities. Therefore, the commenters recommended that CMS modify the proposed beneficiary

signature requirements for ambulance services in § 424.36(b)(6) to include only proposed subsection § 424.36(b)(6)(i). One commenter stated that a signature from hospital staff does not add any more credibility to the ambulance provider or supplier's claim that the patient was unable to sign the claim than what is already present from the EMT's attestation that the patient was unable to sign.

Response: We are not persuaded to modify the proposed alternative to the beneficiary signature requirement in § 424.36(b)(6) to include only § 424.36(b)(6)(i). The purpose of the proposed requirement to secure a signed contemporaneous statement from a representative of the facility that received the beneficiary, as a means of satisfying the alternative, was to ensure that someone other than an ambulance employee verifies the transport and receipt of the beneficiary; the purpose was not to obtain verification that the beneficiary was unable to sign the claim. We continue to believe that in many, if not most, cases the ambulance transport personnel will have no difficulty in securing a signature from personnel at the hospital or other facility that acknowledges receipt of the patient. Indeed, it is our understanding that, as protection from liability or for other purposes, some ambulance providers and suppliers routinely secure a signature from the receiving facility in order to document that the patient was transported. We note that our proposal would not have required the hospital or other receiving facility to do anything more than acknowledge receipt through a signature. That is, the ambulance provider or supplier could add a signature block and an attestation clause, acknowledging receipt, to its trip ticket or other form that would already contain the necessary patient information (that is, the beneficiary's name and the date and time of delivery). However, after further consideration, we are revising § 424.36(b)(6)(ii)(C) to provide an alternative to the requirement under § 424.36(b)(6) that ambulance providers or suppliers must obtain a signed contemporaneous statement from a representative of the facility that received the beneficiary, which documents the name of the beneficiary and the date and time the beneficiary was received by that facility. The final rule allows the ambulance provider or supplier to meet the condition specified in § 424.36(b)(6) by obtaining a secondary form of verification, prior to submitting the claim for payment. Secondary methods of verification may include the patient

care or trip report, the patient medical record, the hospital registration/admissions sheet, the hospital log, or other internal hospital or facility records. Regardless of its specific form, the documentation must be from the receiving facility must indicate that the beneficiary in question was transported to the facility by the ambulance provider or supplier that is submitting the claim, and must be signed by a representative of the facility.

Comment: One commenter stated that the proposal was fair and correct, would not create a heavy burden on the service provider and can be accomplished in a timely manner. A signed contemporaneous statement used on a limited basis and tightly controlled so that it will not become a routine event should help compliance in this area. A clear and standardized format for the contemporaneous statement should be issued to allow for proper compliance with the new rule.

Response: We understand the commenter as supporting our proposal and as saying that ambulance providers and suppliers should not be entitled to routinely rely on proposed § 424.36(b)(6), but rather should be able to rely on this exception only when the beneficiary is, in fact, unable to sign the claim, and only when the proposed documentation requirements have been satisfied. We agree that in most cases an ambulance provider or supplier should not have difficulty in obtaining a signature from the hospital or other facility that acknowledges receipt of the beneficiary; however, we are modifying the proposal to provide for an alternate method of documenting that the beneficiary was transported to the facility. We do not believe that it is necessary to prescribe a specific form for ambulance providers and suppliers to use as a contemporaneous statement to document the transport of the beneficiary, but instead are allowing ambulance providers and suppliers to use existing forms of their own, or, where necessary, to modify their forms to comply with the requirements of the new § 424.36(b)(6)(ii). We again emphasize that ambulance providers and suppliers that do not wish to take advantage of the new exception in § 424.36(b)(6) to the beneficiary signature requirement, may instead obtain the beneficiary's signature prior to submitting the claim, satisfy one of the exceptions in § 424.36(b)(1) through (b)(5), or, where appropriate, bill the beneficiary.

Comment: Several commenters recommended that we eliminate the beneficiary signature requirement entirely. They believe that the

requirement is not necessary because, for every transport of a Medicare beneficiary, the ambulance crew completes a trip report that described the condition of the beneficiary, treatment, origin/destination, etc. Also, the origin and destination facilities complete their own records, which document that the beneficiary was sent or received. Commenters stated that if it becomes necessary to audit claims, CMS can obtain information from the transporting and receiving facilities in order to establish that the beneficiary was, in fact, transported as claimed by the ambulance provider or supplier.

Response: We proposed an alternative, optional method of fulfilling the beneficiary signature requirement for claims for emergency transport services. We did not propose to eliminate the signature requirement and are not prepared to do so at this time. The beneficiary signature requirements help ensure that services were in fact rendered and were rendered as billed. Although we agree that documentation obtained from the transporting and (particularly) from the receiving facility may help to alleviate any concern whether services were furnished or were furnished as claimed, we do not believe that it is our responsibility to attempt to locate such documentation should claims be called into question (and it is also uncertain whether we would have the right to compel the transporting or receiving facility to provide us with such documentation). Therefore, to the extent that an ambulance provider or supplier wishes to use third-party documentation to demonstrate that a beneficiary was transported as claimed, instead of having the beneficiary sign the claim or meeting one of the exceptions in § 424.36(b)(1) through (b)(4), it must follow the procedures in new § 424.36(b)(6).

Comment: Most of the commenters questioned the need for the beneficiary signature, because they asserted that the beneficiary signature is no longer necessary given that it is not required for the assignment of benefits or the authorization of records release to CMS or its contractors. In addition, the commenters stated that almost every covered ambulance transport is to or from a facility (that is, a hospital or skilled nursing facility) where a valid signature is already on file. These facilities typically obtain the beneficiary's signature at the time of admission, authorizing the release of medical records for their services, or any related services. The commenters believe that ambulance transport to a facility, for purposes of receiving treatment at that facility, constitutes a

“related service,” because the ambulance transports the patient to or from that facility for treatment or admission. Commenters also noted that, with respect to beneficiaries who are eligible both for Medicare and Medicaid, a signature is already on file with the State Medicaid office. Therefore, they argued that duplicating the requirement for a signature is costly and burdensome on ambulance service providers.

Response: The purpose of the assignment of benefits signature is different than the purpose of the beneficiary signature to file a claim. As stated above, the purpose of the beneficiary signature to file a claim is to ensure that services were furnished and were furnished as billed. Although the assignment of benefits signature is not required for services billed on mandatory assignment, the beneficiary signature is still required for submitting a claim to Medicare.

A beneficiary's signature on file at a hospital or a skilled nursing facility does not indicate that an ambulance provider or supplier was authorized to submit a claim for transport services on behalf of the beneficiary or that transport services in fact were furnished. Rather, the signature on file at a facility is used for claims filed by that facility for treatment the facility furnished to the beneficiary. Similarly, the fact that a beneficiary's signature may be on file with a State Medicaid office (or elsewhere) does not in any way speak to the issue of whether the ambulance provider or supplier was authorized to submit a claim for transport services on behalf of the beneficiary or that transport services in fact were furnished.

Comment: A commenter stated that when submitting claims electronically, a provider or supplier must answer “Y” or “N” for the question of whether the provider or supplier has obtained a beneficiary signature. The commenter suggested that we should add language to the regulations to indicate that the beneficiary signature requirement will be met if one of the exceptions to the requirement is met.

Response: We agree that it is proper and accurate to answer “Y” (for yes) to the question in the case where the beneficiary has not signed the claim but one of the alternatives in § 424.36(b) through § 424.36(e) has been satisfied. We are clarifying § 424.32(a)(3) (basic requirements of all claims) accordingly.

Comment: Many commenters stated that the proposal would encourage ambulance providers and suppliers to seek signatures from patients who are in need of medical care and under mental

duress. They stated that beneficiaries under duress should not be required to sign anything.

Response: We agree that beneficiaries under duress should not be required to sign claims; in fact, we consider a beneficiary signature obtained under duress to be invalid. We do not agree, however, that our proposal encouraged ambulance providers and suppliers to obtain beneficiary signatures under duress. As stated above, the proposal was intended to provide ambulance providers and suppliers with another alternative to obtaining the beneficiary's signature. It was not, and the final rule is not, a narrowing of the available alternatives to ambulance providers and suppliers. Moreover, the commenters appear to assume that if ambulance providers and suppliers are to obtain a beneficiary's signature, they must do so at the time of transport. However, ambulance providers and suppliers have always been able to obtain the beneficiary's signature (or the signature of one of the persons specified in § 424.36(b)(1) through (b)(4)) at any time prior to submitting the claim. In fact, as noted above, before providers may avail themselves of the exception in § 424.36(b)(5), they are required to make reasonable efforts to have the beneficiary or one of the persons specified in § 424.36(b)(1) through (b)(4) sign the claim. With this final rule, ambulance providers and suppliers, in the case of emergency transport services, may submit the claim without making such reasonable efforts if they satisfy the documentation requirements of new § 424.36(b)(6).

O. Update to Fee Schedules for Class III Durable Medical Equipment (DME) for CYs 2007 and 2008

1. Background

a. Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Classifications

Under § 414.210, for Medicare payment purposes, fee schedules are determined for the following classes of equipment and devices:

- Inexpensive or routinely purchased items as specified in § 414.220.
- Items requiring frequent and substantial servicing, as specified in § 414.222.
- Certain customized items, as specified in § 414.224.
- Oxygen and oxygen equipment, as specified in § 414.226.
- Prosthetic and orthotic devices, as specified in § 414.228.
- Other DME (capped rental items), as specified in § 414.229.

- Transcutaneous electric nerve stimulators (TENS), as specified in § 414.232.

We designate the items in each class of equipment or device through our program instructions.

Under section 513 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360c), the Food and Drug Administration (FDA) must classify devices into one of three regulatory classes: Class I, class II, or class III. FDA classification of a device is determined by the amount of regulation necessary to provide a reasonable assurance of safety and effectiveness; class III devices typically posing the greatest risk. See the CY 2008 PFS proposed rule (72 FR 38188) for a specific explanation of the three regulatory classifications of devices.

b. DMEPOS Payment

Section 302(b)(1) of the MMA amended section 1847 of the Act to require the Secretary to establish and implement competitive acquisition programs for the furnishing under Medicare Part B of certain types of DMEPOS. Section 1847(a)(2)(A) of the Act provides that devices determined by the FDA to be class III devices under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) cannot be included in the competitive acquisition programs. As part of the transition to competitive acquisition, the Congress mandated in sections 1834(a)(14)(G) through (I) of the Act that the fee schedule amounts for DME, other than class III devices, be frozen at 2003 levels through 2008.

For class III devices, section 1834(a)(14)(G)(i) of the Act mandates that an annual update factor based on the percentage change in the consumer price index for urban customers (CPI-U) be applied to the fee schedule amounts for CYs 2004 through 2006. Section 1834(a)(14)(H)(i) of the Act, as added by section 302 of the MMA, gives the Secretary discretion in determining the appropriate fee schedule update percentage for CY 2007 for DME which are class III medical devices described in section 513(a)(1)(C) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360c(a)(1)(C)).³ Specifically, for 2007, the 2006 fee schedule amounts for class III devices are to be updated by the percentage change determined to be appropriate by the Secretary, taking into account recommendations contained in

³ Section 513(a)(1)(C) of the Federal Food, Drug, and Cosmetic Act has been codified as 21 U.S.C. 360c(a)(1)(C). Accordingly, we believe that the references to 21 U.S.C. 360c(1)(C) in sections 1834(a)(14)(G)(i), (H)(i), and (I)(i) of the Act are scrivener's errors.

a report of the Comptroller General of the United States under section 302(c)(1)(B) of the MMA. Also mandated by section 1834(a)(14)(I)(i) of the Act, for 2008, the 2007 fee schedule amounts for class III devices are to be increased by an annual factor based on the percentage change in the CPI-U, as applied to the 2007 payment amount determined after application of the percentage change under section 1834(a)(14)(H)(i) of the Act.

As stated above in this section of this final rule with comment period, section 1834(a)(14)(H)(i) of the Act mandated that the Secretary take into account recommendations by the Comptroller General of the United States, who is the head of the Government Accountability Office (GAO), when determining the appropriate update percentage for class III devices for 2007. On March 1, 2006, the GAO published a report, "Class III Devices do not Warrant a Distinct Annual Payment Update" (GAO-06-62). The GAO concluded in that report, "because the initial payment rates for all classes of devices on the Medicare DME fee schedule are based on retail prices or an equivalent measure, they account for the costs of class III and similar class II devices in a consistent manner. Distinct updates for two different classes of devices are unwarranted." The GAO recommended that the Secretary establish a uniform payment update to the DME fee schedule for 2007 for class II and class III devices.

In the May 1, 2006 **Federal Register**, we published the Competitive Acquisition for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and Other Issues proposed rule (71 FR 25660). We solicited comments on how to determine the appropriate fee schedule percentage change for class III devices for 2007 and 2008. We stated that we would consider the comments received in conjunction with the recommendations in the GAO report in determining the appropriate update percentage for these devices for 2007 and 2008.

A majority of the submitted public comments indicated that the GAO report was flawed since it did not recommend a specific update factor or take into account changes over time in the costs of producing, supplying and servicing class III devices. Several commenters recommended that we continue to use the CPI-U to adjust fee schedule amounts for class III devices, but offered no substantive information that would otherwise support a distinct update factor for class III devices. Another commenter recommended that the class III proposal be included in a

separate rulemaking procedure because it is not related to competitive acquisition.

2. Update to Fee Schedule

We believe that the GAO has done a thorough job in reviewing Medicare payment rules and methods and issues associated with the costs of furnishing class III devices. Accordingly, we agree with the finding in the report that the costs of furnishing class II and class III DME devices have been factored into the fee schedule amounts calculated for these devices. We also agree with the GAO recommendation that a uniform payment update be established to the DME fee schedule for 2007 for class II and class III devices. For class II devices, the MMA provided for a zero percent payment update from 2004 through 2008. Accordingly, for 2007, in the CY 2008 PFS proposed rule we proposed a zero percent update for class III devices (72 FR 38188 through 38189). Also, in accordance with the MMA, we proposed to use the percent change in the CPI-U to update the class III device 2007 fee schedule amounts for 2008.

Comment: One commenter supported an update based on the CPI-U but did not provide any additional information. A second commenter indicated that class III devices are innovative, beneficial, cost-effective devices and supported a reasonable payment update but did not recommend a specific update and also did not provide any information explaining why class III devices should receive a different update for 2007 than other DME.

Response: We do not believe that the information submitted by the commenters provides any information that would indicate that class III devices warrant a different update than other DME. Accordingly, for 2007, we are adopting the proposed update methodology of applying a zero percent update for class III devices. Also, in accordance with the MMA, we are adopting the proposed methodology of applying the percent change in the CPI-U to update the class III device 2007 fee schedule amounts for 2008. The change in the CPI-U for the 12-month period ending with June 2007 was 2.7 percent. Therefore, a 2.7 percent increase will be applied to the 2007 fee schedule amounts for class III DME to determine the 2008 fee schedule amounts for these items.

P. Discussion of Chiropractic Services Demonstration

In the CY 2006 PFS final rule with comment period (70 FR 70266) and the CY 2007 PFS final rule with comment period (71 FR 69707), we included a

discussion of the 2-year chiropractic services demonstration that ended on March 31, 2007. This demonstration was authorized by section 651 of the MMA to evaluate the feasibility and advisability of covering chiropractic services under Medicare. These services extended beyond the current coverage for manipulation to care for neuromusculoskeletal conditions typical among eligible beneficiaries, and covered diagnostic and other services that a chiropractor was legally authorized to perform by the State or jurisdiction in which the treatment was provided. The demonstration was conducted in four sites, two rural and two urban. The demonstration was required to be budget neutral as the statute requires the Secretary to ensure that the aggregate payment made under the Medicare program does not exceed the amount which would be paid in the absence of the demonstration.

Ensuring budget neutrality requires that the Secretary develop a strategy for recouping funds should the demonstration result in costs higher than those that would occur in the absence of the demonstration. As we stated in the CY 2006 and CY 2007 PFS final rules with comment period, we would make adjustments to the chiropractor fees under the Medicare PFS to recover aggregate payments under the demonstration in excess of the amount estimated to yield budget neutrality. We will assess budget neutrality by determining the change in costs based on a pre- and post-comparison of aggregate payments and the rate of change for specific diagnoses that were treated by chiropractors and physicians in the demonstration sites and control sites. Because the aggregate payments under the expanded chiropractor services may have an impact on other Medicare expenditures, we will not limit our analysis to reviewing only chiropractor claims.

Any needed reduction to chiropractor fees under the PFS would be made in the CY 2010 and CY 2011 physician fee schedules as it will take approximately 2 years after the demonstration ends to complete the claims analysis. If we determine that the adjustment for BN is greater than 2 percent of spending for the chiropractor fee schedule codes (comprised of the 3 currently covered CPT codes 98940, 98941, and 98942), we would implement the adjustment over a 2-year period. However, if the adjustment is less than 2 percent of spending under the chiropractor fee schedule codes, we would implement the adjustment over a 1-year period. We will include the detailed analysis of budget neutrality and the proposed

offset during the CY 2009 PFS rulemaking process.

Comment: We received a number of comments on the methodology for determining budget neutrality. One commenter indicated that it continues to oppose our methodology for assuring budget neutrality under the demonstration. Instead of the application of an adjustment to the national chiropractor fee schedule, the commenter recommends that CMS make an adjustment to the totality of services payable under the Part B Trust Fund. This would be consistent with the requirements in section 651(f)(1)(A) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA).

Another commenter stated that CMS should apply budget neutrality only to the chiropractic codes used in the demonstration project. Because the demonstration did not require a physician referral, physicians should not be penalized for any utilization of chiropractic services. The commenter further noted that if budget neutrality is not limited to the chiropractic codes, CMS should incorporate estimates of the impact on other services into its SGR "law and regulation" factor estimates.

Response: Section 651(f)(1)(B) of the MMA requires that " * * * the Secretary shall ensure that the aggregate payment made by the Secretary under the Medicare program do not exceed the amount which the Secretary would have paid under the Medicare program if the demonstration projects under this section were not implemented." The statute does not specify a specific methodology for ensuring budget neutrality. Our methodology meets the statutory requirement for budget neutrality and appropriately impacts the chiropractic profession that is directly affected by the demonstration. The budget neutrality adjustment under the PFS will be limited to adjusting chiropractor fee schedule codes (comprised of the 3 currently covered CPT codes 98940, 98941, and 98942). No other codes would be affected.

Comment: One commenter noted that there are numerous dimensions to the analysis of effectiveness of treatment. By restricting our analysis only to Medicare expenditure, CMS would miss the important dimension of the effect of care on the beneficiary. Combining claims data with a measurement of functional status would permit a more useful examination of the impact of expanding chiropractor services. The commenter recommends that if CMS undertakes any further examination of the effectiveness of any intervention for

neuromuscular conditions, functional status be considered.

Response: The budget neutrality analysis is only one part of a broader evaluation of the chiropractic services demonstration. A survey was conducted of beneficiaries who received chiropractic services under the demonstration to determine the benefits of treatment and satisfaction with the chiropractic care provided under the demonstration. These results will be included in a Report to Congress on the demonstration.

Q. Technical Corrections

1. Particular Services Excluded From Coverage (§ 411.15)

Sections 612 and 613 of the MMA added coverage under Part B for cardiovascular disease screening tests and diabetes screening tests, effective for services furnished on or after January 1, 2005, subject to certain eligibility and other limitations. These provisions were implemented in the CY 2005 PFS final rule with comment period (69 FR 66236) and were codified in § 410.17 and § 410.18, respectively. However, at the time we neglected to make additional conforming changes to § 411.15, which discusses particular services excluded from coverage, to reflect this expansion in coverage.

To conform the regulations to the MMA provisions, we proposed a technical correction to the provisions in § 411.15 by specifying additional exceptions to provide payment for cardiovascular disease screening tests and diabetes screening tests that meet the eligibility limitation and the conditions for coverage that we specified under § 410.17, Cardiovascular Disease Screening Tests, and § 410.18, Diabetes Screening Tests.

Comment: One commenter suggested that the psychiatric screening examination should be included in the list of preventive health screenings and examinations exceptions from services that are excluded from Medicare coverage under proposed § 411.15. The commenter suggested the advantage for having Medicare cover psychiatric screening examination is that better patient outcomes and decreased use of services often occur as a result of early identification of psychiatric disorders.

Response: The purpose of the proposed technical correction in § 411.15 was to conform that provision to the cardiovascular disease screening test and the diabetes screening test benefits that were established in § 410.17 and § 410.18, respectively. These two part B screening benefits were specifically authorized by sections

612 and 613 of the MMA. The proposed rule did not address the possibility of coverage of a psychiatric screening examination under Medicare Part B. There is no statutory provision that authorizes a benefit for psychiatric screening. Therefore, the commenter's suggestion in this regard falls outside the scope of this final rule.

2. Medical Nutrition Therapy (§ 410.132(a))

In the CY 2006 PFS final rule with comment period (70 FR 70160), we added individual medical nutrition therapy, as represented by HCPCS/CPT codes G0270, G0271, 97802, 97803, and 97804 to the list of telehealth services. In the CY 2008 PFS proposed rule, we proposed a technical correction to § 410.132(a) to conform the regulations to include an exception for services provided at § 410.78. This revised paragraph reads as follows: "(a) *Conditions for coverage of MNT services.* Medicare Part B pays for MNT services provided by a registered dietitian or nutrition professional as defined in § 410.134 when the beneficiary is referred for the service by the treating physician. Except as provided at § 410.78, services covered consist of face to face nutritional assessments and interventions in accordance with nationally accepted dietary or nutritional protocols."

Comment: We received one comment concurring with the proposed technical correction.

Response: We are finalizing the technical correction to § 410.132(a) as proposed.

3. Payment Exception: Pediatric Patient Mix (§ 413.184)

In the CY 2006 PFS final rule with comment period (70 FR 70214), we revised § 413.180 through § 413.192 regarding criteria and the application procedures for requesting an exception to the ESRD composite rate payment. As part of the revisions we intended to amend the section heading of § 413.184 to reflect that, as specified in the statute, this exception only pertains to a pediatric ESRD facility. However, this change was not made. Therefore, we proposed to revise the section heading of § 413.184 to read as follows: "Payment exception: Pediatric patient mix."

We did not receive any comments regarding this proposal. Therefore, we are finalizing this provision as proposed.

4. Diagnostic X-Ray Tests, Diagnostic Laboratory Tests, and Other Diagnostic Tests: Conditions (§ 410.32(a)(1))

Section 1861(r)(5) of the Act was amended by section 4513(a) of the BBA to allow Medicare payment for a chiropractor's manual manipulation of the spine to correct subluxation, without requiring the subluxation to be demonstrated by an x-ray. The BBA provision was effective for services furnished on or after January 1, 2000. Prior to this statutory change, the subluxation was required to be demonstrated by an x-ray. Because chiropractors are limited by statute in the services they can provide under Medicare, it was necessary to create an exception to the requirement that diagnostic services (including x-rays) must be ordered by the treating physician as provided in § 410.32(a). This exception, which permits a physician who is not a treating physician to order and receive payment for an x-ray that is used by a chiropractor, is specified in § 410.32(a)(1).

Because of the BBA change, which removed the requirement that subluxation must be demonstrated by an x-ray, the so-called "chiropractic exception" at § 410.32(a)(1) is no longer warranted. We do not believe it is necessary or appropriate to continue to permit payment for an x-ray ordered by a nontreating physician when a chiropractor, not the ordering physician, will use that x-ray. Therefore, we proposed to revise § 410.32 by removing paragraph (a)(1) and redesignating paragraphs (a)(2) and (a)(3) as (a)(1) and (a)(2), respectively.

Comment: We received several comments on this proposal. Some commenters noted that x-rays are not necessary to identify spinal subluxations, but stated that the ability to obtain an x-ray for Medicare beneficiaries is critical to providing responsible, safe, and medically prudent care. They stated that without this ability they fear beneficiaries and the chiropractic profession as a whole will be at a higher risk for receiving and providing the wrong type of care. The majority of commenters expressed concern that without the chiropractic exception at § 410.32(a)(1), the beneficiary may incur greater out of pocket expenses to obtain a noncovered x-ray when needed by the chiropractor. Other commenters believed that the overall costs for medical services may increase because a beneficiary wanting to seek chiropractic care directly may elect to first seek care for their condition from a medical doctor (MD) or doctor of

osteopathy (DO) to obtain an order for a covered chiropractic x-ray, resulting in added costs for physician E/M services. Finally, many chiropractors commented that they are qualified to provide x-rays and other services that Medicare does not cover when furnished by a chiropractor and they believe that x-rays can be essential to rule out "red flags" and contraindications that may indicate the need for further diagnostic imaging or a referral to another health care professional.

Response: We believe that retaining the chiropractic exception would be inconsistent with the statutory provision at section 1861(r)(5) of the Act which defines a chiropractor as a physician only for the purposes of sections 1861(s)(1) and 1861(s)(2)(A) of the Act and only with respect to treatment by means of manual manipulation of the spine (that is, to correct a subluxation). This statutory provision does not include diagnostic services at section 1861(s)(3) of the Act, which is the benefit category under which x-rays are covered under Medicare. In addition, commenters noted that x-rays are not required to identify subluxations; rather, commenters stated that they use the x-rays to rule out other conditions where manual manipulation of the spine would be contraindicated or for which further imaging studies are indicated. While the use of x-rays for this purpose is outside the scope of covered chiropractic services, it is also not addressed by the chiropractic exception at § 410.32(a)(1). The chiropractic exception only permits a non treating physician to order an x-ray to identify a subluxation. Therefore, we are finalizing our proposal to revise § 410.32 by removing paragraph (a)(1) and redesignating paragraphs (a)(2) and (a)(3) as (a)(1) and (a)(2), respectively, so that it is consistent and conforms to the statutory revisions mandated by the BBA.

R. Other Issues

1. Recalls and Replacement Devices

In the CY 2008 PFS proposed rule (72 FR 38191), we included a discussion about recent recalls of implantable cardioverter-defibrillator (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). These recalls, as well as previous recalls of ICDs and pacemakers in CY 2004 and CY 2005, raise issues both with regard to the additional costs of replacement devices and with regard to the additional physicians' services and diagnostic tests that beneficiaries who have these devices often need.

The impact of the costs of replacement devices for Medicare payment of inpatient and outpatient hospital services is addressed in separate rulemaking for the respective inpatient and outpatient hospital payment systems. However, in the CY 2008 PFS proposed rule, we also acknowledged there are costs associated with physician monitoring of patients treated with recalled devices. This could involve extra visits to physicians' offices or hospital outpatient departments, as well as additional diagnostic tests which might be needed to care for the beneficiaries who have the recalled devices. Based on our concern of the potential costs to both Medicare and the beneficiary for these unforeseen extra services, we solicited comments on how to identify and address additional health care costs and Medicare expenditures associated with device recall actions.

Comment: We received several comments acknowledging the potential for additional costs that may result from recalled devices, particularly in light of the increases in technology. Commenters stated that such costs should be the responsibility of device manufacturers and not the Medicare program, private payers, or the general public. Some commenters expressed concern that we would impose a financial penalty on physicians who deal with the consequences of product recalls. Several of the commenters suggested alternatives that could be used to address this issue, such as development of a modifier or a specific "recall code" that could be used to track the additional time and work associated with these recalls, and urged us to ensure that these additional costs are accounted for in the SGR target. Commenters also stressed that any proposal should be "vetted" through the appropriate stakeholders.

Response: We appreciate the suggestions that the commenters provided. It is not our intention to "penalize" physicians who care for patients affected by implantable device recalls. Rather, it is our intention to ensure that costs of the additional physicians' services and diagnostic tests associated with recalled devices are recognized and appropriately addressed. We will consider the concerns and suggestions provided by the commenters as we develop a plan to address this issue.

2. Therapy Standards and Requirements

a. Revisions to Personnel Qualification Standards for Therapy Services

In the CY 2005 PFS final rule with comment period (69 FR 66354), we amended § 410.59, § 410.60, and § 410.62 to refer to the qualifications for physical therapists (PTs), occupational therapists (OTs) and speech-language pathologists (SLPs) at § 484.4, which sets the personnel qualifications required under the HHA Conditions of Participation.

Section 484.4 contains requirements for persons furnishing services in HHAs that include physical therapists (PTs), physical therapist assistants (PTAs), occupational therapists (OTs), occupational therapy assistants (OTAs) and SLPs. The CY 2005 PFS final rule with comment period clarified that the personnel qualifications in § 484.4 are applicable to all outpatient PT, OT, and SLP services "in order to create consistent requirements for therapists and therapy assistants" (69 FR 66345).

In the CY 2008 PFS proposed rule (72 FR 38191), we proposed to update the personnel qualifications in § 484.4 for PTs, PTAs, OTs, and OTAs. We also proposed to revise the qualifications for SLPs to remove a reference to audiologists in the definition for speech-language pathologists because a speech-language pathologist would not have a Certificate of Clinical Competence in audiology, as implied by the regulation, unless that person was dually qualified as an audiologist.

We proposed these changes for the following reasons.

- The current regulations at § 484.4 contain outdated terminology relating to several of the relevant professional organizations.
- The standards that now exist in the fields of physical therapy and occupational therapy have changed since a substantial portion of these qualification requirements were developed.
- Some of the current qualification requirements do not address individuals who have been trained outside of the United States, or refer to outdated requirements.
- These revisions would have the benefit of establishing consistent standards across provider/supplier lines.

Although all States license PTs, some States have no licensing provisions for PTAs, OTs, OTAs, and SLPs. We proposed to revise our requirements to recognize as qualified PTs, OTs, PTAs, or OTAs who meet their respective State qualifications (or have received State

recognition as PTs, OTs, PTAs or OTAs) before January 1, 2008.

We did not propose to allow those who, before January 1, 2008, meet only the State qualifications to practice physical therapy, and not the education requirements, to provide services under the Home Health PPS or the Hospice PPS. As we indicated in the CY 2008 PFS proposed rule, we did not expect that there are therapists furnishing services in a HHA or hospice that do not meet either the current or proposed revised qualifications.

Grandfathering Provision for Home Health

Comment: Commenters were concerned about the inconsistency in standards between settings, stating that there is no justification for the absence of a grandfathering provision for therapists and assistants practicing in Home Health settings. Many also indicated a concern that currently licensed or regulated professionals would not be allowed to continue to practice in a HHA or hospice, and recommended that sufficient time be allowed before implementation of the new standards for new professionals to meet their training.

Response: The commenters make a compelling case for the grandfathering provisions to be applied uniformly across payment systems. We agree that it is important to apply consistent standards and we will apply the grandfathering provision in all settings as specified in part 484 of our regulations. Since all of part 484 describes personnel qualifications, we refer to part 484 in this rule rather than specifically to § 484.4. The cross-reference has also been changed in the regulation text from § 484.4 to part 484 in all applicable sections. Although we proposed that these grandfathering provisions would be included in revisions to § 409.17, § 409.23, § 410.43, § 410.59, § 410.60, § 482.56, § 485.70, § 485.705, § 491.9, the application of the grandfathering provisions to home health in part 484 makes some sections of proposed regulation text unnecessary and necessitates changes in the language of others. The changes proposed to sections § 485.705 and § 491.9 have been omitted, as they are no longer necessary.

Delay in Implementation of New Personnel Qualifications

Comment: Some commenters requested that we delay implementation of consistent therapy standards and qualifications until we can apply them consistently to SNF services, and

provide education to providers and suppliers.

Response: We believe a 2-year delay in implementation of personnel qualifications will provide sufficient time for new personnel to come into compliance with the new standards. Therapists and assistants who met the qualifications of their State's practice act (in other words, who are licensed, certified or otherwise regulated by the State as a practitioner in the particular discipline) prior to December 31, 2009, will not be required to upgrade their qualifications. However, in States that have no regulations for practitioners in a particular discipline and for services furnished incident to the services of physicians where licensure does not apply, therapists and assistants must be qualified by education and examination as described in this final rule with comment period. Those who currently qualify to provide services without licensure by meeting the Medicare education or examination standards in effect at the time of the CY 2008 proposed rule will continue to qualify under those policies. On January 1, 2010, any individual who has not met the earlier requirements must meet the new requirements.

Consistent Policy Standards

Comment: Many commenters indicated we have not provided a justification for applying the personnel and policy standards that we have articulated for Part B services consistently to Part A services. Most of these comments came from commenters who also support the right of States to create Medicare standards, who represent interest groups other than Medicare beneficiary/therapy users, and who believe we favor professional organizations in setting policies.

Response: Under both Medicare Part A and B, we must ensure that all services are described within a statutory benefit category. In order to do so, we frequently establish qualifications for health care professionals who furnish, or are involved in furnishing, Medicare services. In many Part A settings, we have historically relied on Medicare contractors to review facility records, State laws and local policies to determine that services have been furnished by qualified therapists. As a result of information provided by new contractors, which has been confirmed by numerous comments to the proposed rule, we have concluded that therapy is not always being furnished by individuals trained as therapists—even in some Part A settings. Therefore, we believe it is critical that we establish in regulations consistent standards for

qualified therapists in the Medicare program.

Comment: Some commenters objected to the use of the terms therapy and rehabilitation to mean physical therapy (PT), occupational therapy (OT), and speech-language pathology (SLP) services. The commenters recommended allowing any State licensed or authorized health professional to provide rehabilitation services if the provider's medical staff and State law would permit them to do so. The commenters recommended convening a work group to discuss the creation of rational personnel qualifications and scope of services.

Response: The terms "therapy" and "rehabilitation", as used in this section of this final rule with comment period, apply only to the Medicare benefit for PT, OT, and SLP services and to the qualified professionals who provide them. The qualifications have been established to assure that all of the personnel who provide these services are suitably trained in the discipline they practice. We see no reason to believe the skills and training required to furnish therapy and rehabilitation in Part A settings are less than those required in Part B settings, and therefore, qualifications for personnel in the inpatient setting should not be less stringent than in the outpatient setting. Therefore, we will adopt the proposed qualifications (with minor modifications), and these qualifications will be made applicable in Part A and Part B settings.

Grandfathering Provision

Comment: Many commenters believe that a grandfathering provision is not necessary for physical therapists and speech-language pathologists since the changes to their qualifications are not substantial.

Response: We agree and have removed reference to physical therapists and speech-language pathologists from the relevant grandfather clauses in the final rule with comment period.

Comment: Several commenters believe that our proposal to require those who were grandfathered to continue to practice at least part time without an interruption of more than 2 years is not necessary, and that the language is confusing.

Response: We agree and have removed the requirement for continued practice from this final rule with comment period.

Comment: We received many comments concerning application of a requirement for State licensure, registration, certification or other regulation to physical therapist

assistants. The commenters indicate large numbers of PTAs in California and other States are licensed but do not meet the proposed education and examination requirements. The commenters report implementation of the proposed qualifications would cause severe access problems for beneficiaries and operational disruption for facilities. All commenters supported the adoption of a grandfather clause to allow currently practicing PTAs to continue furnishing services to Medicare patients, and many requested the grandfathering be implemented when the rule is finalized in November, rather than January 1, 2008.

Response: We will recognize as qualified to provide Medicare services those therapists and assistants who are licensed or otherwise regulated by their States before December 31, 2009. Individuals who are not licensed or otherwise regulated as PTs, OTs, PTAs, and OTAs in their States may furnish services incident to a physician's service if they meet the education and examination requirements in this final rule with comment period. These changes will be effective on the date this final rule with comment period is effective.

Personnel Qualifications—General

For therapists and assistants trained outside the United States or trained by the United States military, we proposed standards we considered comparable to those applied to therapists and assistants trained in the United States. However, we noted we would not recognize as qualified therapists or therapy assistants individuals trained in other disciplines for purposes of furnishing PT, OT, or SLP services to Medicare beneficiaries.

Comment: APTA recommends the use of the term "substantially equivalent" to replace "comparable" to avoid confusion in the language concerning those trained outside the United States.

Response: We have modified the language to substitute in regulations the term "substantially equivalent" for "comparable".

Comment: Several commenters believe that the qualifications for military trained OTs/OTAs (when applicable) and PTs/PTAs should be the same as for all OTs/OTAs and PTs/PTAs.

Response: We agree that separate qualifications for U.S. military-trained therapy personnel are not necessary for PTs, OTs, and OTAs, since the training programs available in the military already meet the same standards as other U.S.-trained OTs and PTs and OTAs. For PTAs who may, in the future,

be trained in the military, we will apply the standard of substantial equivalency consistent with those trained outside the United States, or the same standards as other United States trained PTAs, as appropriate.

Comment: Some commenters recommended that licensure be the only qualification for PTs and OTs. The commenters recommended we defer to individual States or to the medical staff of a hospital to determine the qualifications for physical therapists and occupational therapists.

Commenters agreed generally that we should rely on State licensure in those States where it exists and for those settings where licensure is applicable. The commenters note that there have been attempts to deregulate health professions in the name of regulatory reform and they recommend inclusion (for OT) and continuation (for PT) of education and exam requirements to assure there will be standards in place when licensure does not apply.

Response: We believe it is appropriate, as we proposed, to require qualifications related to education and examination to address those situations where licensure does not apply. We added language in regulations to indicate that when licensure or other regulation is not applicable for therapists and assistants, the education and examination requirements apply.

Comment: Several commenters support applying the proposed qualifications and therapy standards for staff providing services incident to the services of physicians. Some continue to object to the implementation of section 1862(a)(20) of the Act.

Response: Section 1862(a)(20) of the Act excludes from payment under Medicare Parts A and B any expenses for outpatient PT or OT services furnished incident to the services of a physician that do not meet the standards and conditions that apply to therapists, except "any licensing requirement specified by the Secretary." Therefore, as we described in the proposed rule, we will not apply the requirement that therapists and assistants be licensed or otherwise regulated by a State in the case of services furnished incident to the services of physicians. We will apply education and examination requirements.

In the proposed rule, we explained that when we referred to persons who are licensed, certified, and otherwise regulated by a State, we interpreted "otherwise regulated" to mean that, while a State may not regulate a profession by granting a license or certifying educational or training

credentials, it may nevertheless regulate the practice of a profession by application of certain other requirements.

We received no comments on the use of this term, and therefore, we intend to use it as proposed. Because we believe the term "certification" is redundant to "otherwise regulated", that term has been omitted.

Occupational Therapy

We proposed to require that OTs beginning their practice after January 1, 2010, must be licensed, certified, registered or otherwise regulated as an OT, and have graduated from an occupational therapist curriculum accredited by the Accreditation Council for Occupational Therapy Education (ACOTE) of the American Occupational Therapy Association (AOTA), and also have successfully completed the certification examination developed and administered by the National Board for Certification in Occupational Therapy (NBCOT). We established that "successfully completed" means the individual must perform sufficiently well on the exam to receive (or be eligible to receive) certification. For services incident to a physician's or nonphysician practitioner's service where the licensure requirement does not apply, we proposed the education and examination requirements continue to apply.

OT Comments

Comment: AOTA recommended qualifications based on licensure or education and examination.

Response: We require qualifications based both on licensure and on education and examination so that there are appropriate qualifications that apply where licensure is not applicable, for example, to therapy services furnished incident to the physician's service.

Comment: The NBCOT recommended that qualified OTs be credentialed by their examination and be members in good standing of their organization. The AOTA recommended that AOTA approve any new credentialing body that might develop in the future.

Response: We recognize that currently the ACOTE or the World Federation of Occupational Therapists (WFOT) credential education programs for OTs and/or OTAs and the NBCOT determines eligibility and furnishes examinations. We have modified the policy to approve those organizations and added "or successor organizations" to allow for changes in the ACOTE title. We do not agree membership in NBCOT should be a requirement. Since NBCOT is already approved by The American

National Standards Institute (ANSI), the National Commission for Certifying Agencies and the National Organization for Competency Assurance, CMS does not believe it is necessary to grant AOTA's request to permit it to approve any future credentialing body.

International OT/OTA

We also proposed that OTs who are educated outside the United States: (1) Be graduates of an occupational therapy curriculum accredited by the WFOT; (2) have successfully completed the NBCOT International Occupational Therapy Eligibility Determination (IOTED) review; and (3) have successfully completed the certification examination for Registered Occupational Therapist. We proposed to adopt similar standards for OTAs (but with an OTA curriculum) and requested comments on qualifications for internationally educated occupational therapy assistants.

Comment: The AOTA and NBCOT support the proposal that the internationally educated OT standards should be comparable to United States trained OTs and that the NBCOT conduct the credentialing process for these OTs. The AOTA requests that there be a way to allow a professionally recognized credentialing body other than NBCOT to develop or administer the examination.

NBCOT reports there are no internationally trained OTAs and recommends qualifications for such OTAs be stricken from the rules.

Response: This final rule with comment period recognizes the ACOTE, NBCOT or WFOT to contribute to credentialing internationally trained OTs and OTAs. Although NBCOT may not now recognize internationally trained OTAs, such OTAs do exist. In addition, we are adopting regulations in anticipation of any international programs that meet the qualifications in the future.

Comment: AOTA commented that the proposals for those who began practice between December 31, 1977, and January 1, 2008, are archaic and cannot be directly applied to many professionals qualified by their States.

Response: We agree that the current language is not applicable and we have updated this language for the new qualifications in this final rule with comment period, adding current credentialing bodies for United States trained and internationally trained OTs. To assure that no one covered under the existing qualifications is inadvertently disqualified, the prior language continues to apply for those who are not

licensed but were qualified under the previous policy.

Comment: Commenters note that many States allow graduate OTs and OTAs to furnish services under a temporary license or permit while eligible for examination. The commenters expressed concern that the qualifications in the proposed rule would limit new graduates from entering the workforce.

Response: We agree that it is not necessary to change the current requirement of eligibility for the examination for United States trained OTs and OTAs when they are licensed or otherwise regulated by their States. However, we will require foreign trained OTs and OTAs (when applicable) to have passed the examination, and not merely be eligible for it. We believe this requirement is appropriate in the case of foreign trained individuals in order to ensure that they have acquired sufficient knowledge through their education program to pass the examination and, thus, are adequately prepared to begin furnishing services to Medicare beneficiaries.

Physical Therapy

For PTs, we proposed the therapist must be licensed as a physical therapist by the State in which practicing and accredited by the CAPTE based on APTA guidelines. When the licensure requirement is not applicable (that is, for services furnished incident to the services of physicians and NPPs), we proposed to require that PTs must be accredited by the CAPTE. We requested comments on qualifications for PTs which include satisfactory completion of a curriculum and a national examination each approved by the APTA.

Comment: APTA recommended that we remove the requirement that a PT pass a National Examination approved by the APTA. Since all States require a national licensing exam, APTA does not believe it is necessary for APTA to approve the exam. State Boards supported State licensing requirements, which include examination.

Response: In cases where the licensing standards do not apply (for therapy services incident to a physician's service or in the event a State deregulates PT practice), we believe it is important to have standards in place to ensure that an individual is qualified to furnish physical therapy services. We will not finalize the requirement for APTA to approve the licensing exam. Instead, we will accept a national licensing exam used by State boards to qualify personnel who have

been trained in a physical therapy curriculum.

We proposed that licensure or certification, or other regulation by the State in which services are furnished would be required for PTAs under our regulations. We also proposed that PTAs be accredited by the CAPTE. We requested comments on appropriate qualifications for PTAs.

Comment: APTA believes it is critical that we require approval by APTA for foreign trained PTAs. The Commission on Accreditation of Physical Therapist Education (CAPTE) of the APTA has been nationally recognized since 1977 as the only organization that approves PT and PTA education programs; it has no financial interest in the credentialing bodies for PTs or PTAs.

Some commenters disagreed with our proposal to allow the APTA to approve the credentialing body that establishes qualifications for foreign trained PTs and/or PTAs. They suggest that the U.S. Citizenship and Immigration Services and the Department of Homeland Security approve credentialing bodies that set standards and credential individuals and the States decide whether to license that individual. The commenters note there are currently no approved foreign PTA programs.

Response: While commenters tell us there are no foreign PTA programs that meet their credentialing standards, there may be PTA programs in foreign countries that meet the standards in the future. Therefore, this final rule with comment period addresses this future need. The CAPTE of the APTA is approved by the U.S. Department of Education (USDE) and the Council for Higher Education Accreditation (CHEA). We find no reason to doubt that CAPTE/APTA will make fair determinations on the appropriateness of educational programs in the United States or credentials evaluation organizations for foreign trained PTs and PTAs. However, in response to comments, we have recognized both CAPTE and a credentials evaluation organization identified in 8 CFR 212.15(e) (the Homeland Security Act) as it relates to physical therapists and assistants to determine an education program to be substantially equivalent to PT and PTA entry level education in the United States. We believe the additional requirement for passing a national examination will mitigate any variations in credentialing.

Comment: Several commenters stated that adoption of the proposed qualifications for PTs would usurp the rights of State governments in licensing and determining the scope of practice

for healthcare professionals, creating “a monopoly for curriculum approval”.

Response: As we indicated in the proposed rule, we believe it is important to establish consistent and meaningful standards and conditions for the provision of Medicare covered services. Professional standards change periodically and these are often eventually adopted by State licensing boards, each of which has different language in its statutes. We believe the standards we proposed would not usurp or interfere with the adoption of standards by States. Rather, in most cases the standards incorporate the State standards. However, we believe it is necessary for CMS to address circumstances where State licensing or other regulation are not applicable. We are not creating a monopoly for curriculum approval by recognizing CAPTE. While it is the only existing credentialing body used by the States in their licensing process, we assess other credentialing qualifications if they are developed. Therefore, we are finalizing standards that include State standards (licensing or other regulation), as well as education and examination. We will assess other credentialing qualifications if they are developed.

b. Application of Consistent Therapy Standards

(1) Personnel Qualifications

We believe therapy services should be provided according to the same standards and policies in all settings, to the extent possible and consistent with statute. Therefore, we proposed to revise our regulations to cross-reference the personnel qualifications for therapists in § 484.4 to the personnel requirements for PTs, OTs, PTAs, OTAs, and SLPs in the following sections:

- § 409.10 and § 409.16 (Inpatient hospital services and inpatient critical access hospital services).
- § 409.23 (Posthospital SNF care).
- § 410.43 (Partial hospitalization services).
- § 410.59 (Outpatient occupational therapy services).
- § 410.60 (Outpatient physical therapy services).
- § 410.62 (Outpatient SLP services).
- § 418.92 (Hospice).
- § 482.56 (Optional hospital services, Rehabilitation services).
- § 485.70 (Specialized providers).
- § 485.705 (Clinics, Rehabilitation agencies, Public health agencies).
- § 491.9 (Rural health clinics and Federally qualified health centers (FQHCs)).

We also solicited comments on whether the personnel qualifications at

§ 484.4 should be made applicable in other settings.

Consistent Personnel Qualification Standards

Comment: Many commenters supported consistent personnel qualifications. Commenters indicated beneficiaries deserve to be treated by qualified professionals in both inpatient and outpatient settings.

We also heard from commenters who oppose the application of consistent qualifications for therapists in Part A settings. The commenters stated that if only qualified physical therapists provide physical therapy services in Part A settings, it will prevent hospitals from continuing to employ athletic trainers to provide physical medicine and rehabilitation services. The commenters suggest the medical staff should decide the qualifications for therapists at a hospital.

Response: The policies outlined in the proposed rule apply only to therapy services. The State Operations Manual Appendix A Survey Protocol, Regulations and Interpretive Guidelines for Hospitals (Rev. 1, 05–21–04) § 482.56 Condition of Participation: Rehabilitation Services indicates that therapy services, if provided, must be in accordance with acceptable standards of practice which include compliance with any applicable Federal or State laws, regulations or guidelines, as well as standards and recommendations promoted by APTA, ASHA, and AOTA. In States where there are no personnel qualifications for therapists or assistants, hospitals should currently be following the personnel qualification standards set by those professional organizations. Most States and all of the professional organizations require graduation from approved education programs and a passing grade on a national examination. Therefore, we do not anticipate that adherence to the personnel qualifications in this final rule will cause any changes in hospital personnel.

At the same time, we recognize that there may be athletic trainers (AT), lymphedema specialists, low vision specialists, nurses, physicians, and other staff employed in hospital settings who furnish other services for which they are qualified, and for which payment is included in the payment to the facility. Those services should be appropriately documented as, for example, athletic training or lymphedema services. Where the services of health care professionals who are not PTs, OTs, PTAs, OTAs, or SLPs are now being appropriately furnished, documented and reimbursed,

we anticipate the application of consistent personnel qualifications relating to PT, OT and SLP services will have no effect on the appropriate provision of these other services. In settings where therapy services are separately billable, there will only be an impact on current practice if services that are being documented as PT, OT, or SLP services are being furnished by personnel who do not meet the requirements to be considered qualified therapists. Personnel who do not meet the applicable professional standards to be considered qualified therapists cannot furnish or be paid for PT, OT, and SLP services.

Comment: Several commenters indicated that therapy services are not covered in rural health clinics.

Response: Rural Health Clinics (RHCs) provide a core set of primary health care services as defined in statute. RHC services include the services that would commonly be furnished in a physician's office, (such as PT, OT, and SLP services), but only when directly provided by a Medicare approved RHC provider, such as a physician, nurse practitioner, or physician assistant. A certified nurse midwife, clinical psychologist, and/or clinical social worker may provide RHC services, but not PT, OT, or SLP services, because PT, OT, and SLP services are not in their scope of practice. A face-to-face encounter with any other practitioner including, for example, a PT, OT, or SLP, athletic trainer, kinesiologist, or registered nurse is not covered as an RHC encounter, even if the service may be medically necessary, because these are not Medicare approved RHC providers (as defined in statute). Since therapists are not approved RHC providers, we will remove the reference in § 491.9 to personnel qualifications for therapists.

Consistent Policies

(2) Application of Consistent Therapy Standards

In tandem with cross-referencing Part A and Part B therapy personnel requirements in the regulations, we proposed to clarify our policies to improve consistency in the standards and conditions for Part A and Part B therapy services. Many, but not all, of the policies described for therapy services in Part B settings are also appropriate to Part A settings.

Specifically, in § 409.17, we proposed to clarify that hospital services include physical therapy, occupational therapy, and SLP. We also proposed to add regulations for inpatient hospital services to include a plan for therapy

services consistent with the plan required for outpatient therapy services. We invited comment on PT, OT, and SLP plan of treatment policies that are appropriately applied to all therapy services, whether provided under Medicare Part A or B.

While the concept of consistent policies was strongly supported, many commenters were concerned about the application of specific Part B policies to Part A settings.

Comment: Several commenters indicated concern that application of the Part B policies, especially plan and documentation policies, to the inpatient hospital setting would impact treatment and increase the paperwork burden to staff.

Response: We are aware that inpatient stays are short. If clinically appropriate documentation is now provided, the new policies are unlikely to increase the burden. We have not delineated which of the Part B policies would apply in Part A specifically to allow some flexibility in the application of the general treatment guidelines as appropriate to the setting. We anticipate addressing these issues in manual instructions.

We note that we continue to believe the general concept that therapy services should be provided in a similar manner by qualified personnel in all settings is an appropriate one.

Comment: The AOTA requests that any change to the therapy plan of care be incorporated "as soon as possible" rather than "immediately."

Response: We recognize that the term "immediately" could be relative. Therefore, we have substituted "as soon as possible" to refer to changes in the plan in § 424.24 and § 482.56.

Comment: Commenters indicated concern that the outpatient plan of care certification requirement would be transferred to inpatient policy and that an ordered service that is being provided under the care of a hospital physician would also require certification for every change in the provision of treatment.

Response: The policy at § 409.17 and § 482.56 is compatible with the concept of the therapy plan as part of the overall plan in a facility. Also, we defer to hospital policies and procedures for changes to the plan. Guidance will be provided in manuals concerning modifications in the provision of care that do not constitute changes to the plan. Requirements concerning orders for establishment of a therapy plan (development and implementation) in the hospital are not changed by this final rule with comment period. We anticipate clarifying further in manual

instructions documentation requirements that are consistent with the care of inpatients and will take into account comments received. We believe that, in general, good practice would call for documentation of significant changes to the patient's response to treatment in all settings, even if the Medicare program does not specifically require it.

Comment: AOTA asserts that in the inpatient setting, goal setting and treatment planning may not fit the mold of what is typically required by CMS in outpatient settings, that is, functional restoration. They indicate concern that therapy will not be provided consistent with their professional guidelines or scope of practice.

Response: We recognize that some of the services furnished by therapists in the acute inpatient hospital setting may not achieve functional changes expected in other settings. We have noted in § 482.56 that the provision of care and the personnel qualifications must be in accordance with national acceptable standards of practice. Although documentation is not relevant to billing in this setting, it is still critical that the services furnished be accurately documented. We anticipate issuing further guidance regarding documentation for therapy services in hospital settings in Medicare manuals.

Comment: AOTA requests removal of the reference to review of the plan prior to certification in § 409.17(e). APTA agrees that the review language is unnecessary.

Response: We agree that it is unnecessary in the regulation to remind physicians or nonphysician practitioners to read the plan before they certify it and we have removed the paragraph from § 410.61(e) and § 409.17(e), and § 482.56(e).

Comment: Several commenters agree with the proposal that in the hospital setting the physician's review and approval of a therapy plan should be implied in the physician's review and approval of a facility plan that includes therapy services. The commenters believe the same rationale applies to services furnished in skilled nursing facilities and urge CMS to state that, in the SNF Part A setting, review of the therapy plan is implied by the physician's review of the facility plan.

Response: We agree with the commenters regarding the implied physician review and approval of the therapy plan in the Part A SNF setting. We have recognized this issue previously in the preamble to the Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Update Notice (69 FR 45780),

where we stated that “ * * *. It is not necessary for a SNF to obtain a separate physician signature on the therapy treatment plan itself prior to billing Part A for therapy services * * * .”

Delay in Implementing Policies

Comment: Many commenters requested delays in the implementation of the policies for Part A therapy services, indicating they want time to have input into the manual guidelines and may need time to learn new procedures.

Response: We will delay the implementation of the policies pending the issuance of manual guidance which we anticipate that we will develop in mid 2008.

Students

Comment: Many commenters believe that it is imperative that we not inadvertently develop a policy that prevents students from receiving clinical training. APTA suggests we consider conforming the policies for students to the SNF policy for services provided by aides and students. The SNF policy allows services by aides and students in the “line of sight” of the therapist to count toward minutes accrued on the Minimum Data Set.

Response: We will consider conforming all policies for student supervision to the SNF policy for line of sight supervision, and will address this issue in manual guidance.

c. Outpatient Therapy Certification Requirements

In 1988, in an attempt to control the expanding utilization of therapy services, we added a 30-day recertification requirement for outpatient therapy services to our regulation at § 424.24. This requires that a physician certifies a plan of care for 30 days, regardless of the appropriate length of treatment. To continue treatment past 30 days, the physician is required to recertify the plan. As explained in the CY 2008 PFS proposed rule, after many years of experience with the current recertification requirements, we now believe that requiring recertification at 30-day intervals may not always provide sufficient flexibility to the physician to order the appropriate amount of therapy for the patient’s needs. Therefore, we proposed to change the plan recertification schedule in § 424.24 to an episode length based on the patient’s needs, not to exceed 90 days.

Comment: We received strong support for changing the recertification schedule to a date determined by the physician (not to exceed 90 days) from the therapy

associations, medical societies, facilities, and individuals. They emphasized that physician approval of a clinically appropriate length of treatment at the initial certification will improve the patients’ access to treatment, reduce administrative burden to physicians, therapists and office staff and reduce unnecessary visits for patients. Several indicated that a limit is not necessary since the physician should determine the episode length. MedPAC indicated a concern about reducing the number of physician reviews of the services in the context of the increasing utilization of therapy services

Response: We agree that a physician is qualified to certify the appropriate length of care in the initial certification; and that recertification should be required as often as the individual’s condition requires. However, we believe a 90-day limit is a reasonable modification of the policy at this time. We will continue to review the utilization of therapy services to assess any changes in the relative utilization patterns for beneficiaries or providers/suppliers that may suggest changes in practice related to this policy. As we proposed, after 2 years, if we determine that there are changes in relative utilization patterns that suggest inappropriate utilization of therapy services based on the certification timing, we will reconsider this policy.

Comment: One commenter stated that a physician generally does not have statistical data from which to make a decision regarding the appropriateness of initiation or continuation of therapy, and, therefore, recertification of therapy by physicians seems meaningless. The commenter urges the use of risk-adjusted data based on gains in functional status relative to number of visits to inform physician decision making for appropriate utilization.

Response: We agree that collection of data related to the patient’s functional condition and relative utilization of services may be useful in our ongoing development of recommendations for alternatives to therapy caps. On September 6, 2007, we released a Request for Task Order Proposals to the pool of contractors under the CMS MRAD (Master Research And Development) contract vehicle. The goal of this request for proposals is to develop recommendations for alternatives to therapy caps for CMS covered Outpatient Therapy services.

Comment: There was very strong support for extension of the 90 day recertification policy to CORF settings, consistent with the proposed policy for all other settings. There were no

comments opposed to consistent recertification policy in the CORF.

Response: We will apply this policy consistently across settings, including the CORF reference in § 410.105(c)(ii)(2) and 424.27(b).

Review of Plan

We proposed that review of the plan as required in § 424.24 would continue to be required at certification and recertification. Since the plan may be established by a nurse practitioner, a clinical nurse specialist, or a physician assistant (nonphysician practitioners), as well as a physician, we proposed to modify the language in § 410.61 to include those professionals among those who may review the plan. Since the certification and recertification of the plan for Part B services requires a signature, we proposed to remove the current redundant requirement at § 410.61(e) to date and sign a review at the same time the plan is certified. In addition, we proposed to revise § 424.24 to remove reference to a certification “statement.”

Comment: We received one comment supporting the changes to the review language and no dissenting comments.

Response: We are finalizing the proposed changes to the review of plan language in this final rule with comment period.

3. Amendment of the Exemption for Computer-Generated Facsimile Transmission From the National Council for Prescription Drug Programs (NCPDP) SCRIPT Standard for Electronically Transmitting Prescription and Certain Prescription-Related Information for Part D Eligible Individuals

a. Legislative History

Section 101 of the MMA amended title XVIII of the Act to establish a voluntary prescription drug benefit program. Prescription Drug Plan (PDP) sponsors and Medicare Advantage (MA) organizations offering Medicare Advantage—Prescription Drug Plans (MA—PD) are required to establish electronic prescription drug programs to provide for electronic transmittal of certain information to the prescribing provider and dispensing pharmacy and pharmacist. This would include information about eligibility, benefits (including drugs included in the applicable formulary, any tiered formulary structure and any requirements for prior authorization), the drug being prescribed or dispensed and other drugs listed in the medication history, as well as the availability of lower cost, therapeutically appropriate

alternatives (if any) for the drug prescribed. The MMA directed the Secretary to issue uniform standards for the electronic transmission of such data.

There is no requirement that prescribers or dispensers implement e-prescribing. However, prescribers and dispensers who electronically transmit prescription and certain other prescription-related information for covered drugs prescribed for Medicare Part D eligible beneficiaries, directly or through an intermediary, would be required to comply with any applicable final standards that are in effect.

b. Foundation Standards and Exemption for Computer Generated Facsimiles (Faxes)

In the E-Prescribing and the Prescription Drug Program final rule (70 FR 67568, November 7, 2005), we adopted the NCPDP SCRIPT standard, Implementation Guide, Version 5, Release 0 (Version 5.0), May 12, 2004, excluding the Prescription Fill Status Notification Transaction (and its three business cases; Prescription Fill Status Notification Transaction—Filled, Prescription Fill Status Notification Transaction—Not Filled, and Prescription Fill Status Notification Transaction—Partial Fill), hereafter referred to as NCPDP SCRIPT 5.0, as the standard for communicating prescriptions and prescription-related information between prescribers and dispensers. Subsequently, on June 23, 2006 (71 FR 36020), HHS published an interim final rule that maintained NCPDP SCRIPT 5.0 as the adopted standard, but allowed for the voluntary use of a subsequent backward compatible version of the standard, NCPDP SCRIPT 8.1. As use of either of these two named versions of the NCPDP SCRIPT standard is permitted, for ease of reference, we will simply refer to “NCPDP SCRIPT” in this rule.

The November 7, 2005 final rule also established an exemption to the requirement to utilize NCPDP SCRIPT for entities that transmit prescriptions or prescription-related information by means of computer generated facsimiles (faxes generated by one computer and electronically transmitted to another computer or fax machine which prints out or displays a image of the prescription or prescription-related information). Providers and dispensers who use this technology are not compliant with NCPDP SCRIPT. The exemption was intended to allow such providers and dispensers time to upgrade to software that utilizes the NCPDP SCRIPT standard, rather than forcing them to revert to paper prescribing.

c. Elimination of Exemption

In the CY 2008 PFS proposed rule (72 FR 38194), we proposed to revise § 423.160(a)(3)(i) to eliminate the computer generated fax exemption to the NCPDP SCRIPT Standard for the communication of prescription or certain prescription related information between prescribers and dispensers for the transactions listed at § 423.160(b)(1)(i) through (xii).

Since computer-generated faxing retains some of the disadvantages of paper prescribing (for example, the administrative cost of keying the prescription into the pharmacy system and the related potential for data entry errors that may impact patient safety), we believed it was important to take steps to encourage prescribers and dispensers to move toward use of NCPDP SCRIPT.

In our November 7, 2005 final rule discussion of computer-generated faxing, we distinguished between cases where the prescriber’s or dispenser’s software has the ability to generate transactions utilizing the NCPDP SCRIPT, but the prescriber has not activated the feature on their software, and other cases where software (such as a word processing program) is used to create a document that can be sent as a fax that results in print out or displays a image of a prescription or response at the receiving end, but does not have true e-prescribing (electronic data interchange using NCPDP SCRIPT) capabilities.

We believed the elimination of the computer-generated fax exemption would encourage prescribers and dispensers using this computer-generated fax technology to, where available, utilize true e-prescribing capabilities.

It might also encourage those without such capabilities to upgrade their current software products, or, where upgrades are not available, to switch to new products that would enable true e-prescribing.

Because the elimination of the computer-generated facsimile exception would encourage those prescribers that are already using e-prescribing software that is capable of true e-prescribing to utilize those capabilities, we believed that the elimination of the computer-generated fax exemption would increase the number of NCPDP SCRIPT transactions fairly significantly in a relatively short time period, and that this could, in turn, create a “tipping point” that could create economic incentives for independent pharmacies to adopt NCPDP SCRIPT capable software to begin to exchange true e-

prescribing transactions with their prescriber partners.

We proposed to eliminate the computer generated fax exemption effective 1 year after the effective date of the CY 2008 PFS final rule, on January 1, 2009. We believed that this would provide sufficient notice to prescribers and dispensers who would need to implement or upgrade e-prescribing software to look for products and upgrades that are capable of generating and receiving transactions that utilize NCPDP SCRIPT. It would also afford current e-prescribers time to work with their trading partners to eventually eliminate computer-to-fax transactions.

We believed the elimination of the exemption for computer-generated faxing would encourage e-prescribers and dispensers to move as quickly as possible to use of the NCPDP SCRIPT standard with what we perceived to be minimal impact.

We solicited comments on the impact of the proposed elimination of this exemption.

Comment: Several commenters concurred with our proposal to eliminate the exemption for computer-generated faxes. These commenters indicated that lifting the exemption for computer generated faxes would act as an incentive to move prescribers and dispensers toward true e-prescribing (electronic data interchange using the NCPDP SCRIPT standard) and that once the benefits of true e-prescribing are realized by a core group of prescribers and dispensers, word of mouth would help foster more extensive adoption.

Less than half of all commenters disagreed with our proposal to eliminate the exemptions for computer-generated faxes, citing concerns about increased hardware/software costs, transaction fees, certification and other activation costs. Some commenters agreed that many prescribers who are already e-prescribing likely already possess the ability to generate NCPDP SCRIPT compliant transactions using their software or can comply by obtaining a version upgrade under their maintenance agreements. Some commenters also questioned whether lifting the exemption would move the industry forward toward, or raise barriers to, greater use of true e-prescribing. We also received comments from some individuals who erroneously thought that we had proposed the elimination of all faxes, including paper-to-paper faxes.

Response: For new e-prescribers, the cost of implementing a product that can generate an NCPDP SCRIPT-compliant transaction would not differ from a

product that could not, and we expect that, over time, the market will move toward the exclusive use of NCPDP SCRIPT-compliant transactions. Moreover, the adoption of the PQRI structural measure discussed section II.S.1. of this final rule with comment period will provide an incentive to providers to implement e-prescribing. We recognize that pharmacies that are not now conducting transactions that utilize NCPDP SCRIPT will incur costs to implement this capability, and that pharmacies will likely experience an increase in e-prescribing transaction volumes and costs. However, those costs would be balanced by administrative savings. We refer to the November 7, 2005 final rule (70 FR 67568) for a further discussion of potential costs associated with e-prescribing.

As more prescribers and dispensers embrace interoperable health information technology in general, and the use of e-prescribing standards in particular, they will see real value and realize costs savings. Dispenser data entry time and transcription errors due to data re-entry or illegible paper prescriptions will be reduced. Prescribers and dispensers will spend less time on the phone requesting and responding to refill requests. Improved workflow will free up staff time for patient counseling and other services. Patient safety will improve as providers are linked with medication history, allergy information and/or drug contraindications that will result in a reduction of adverse drug events.

Comment: Many commenters agreed that the proposed compliance date of January 1, 2009 was a reasonable timeframe for those who needed to comply. Others urged us to extend the compliance date to April 1, 2009, to coincide with the projected effective date of the next set of e-prescribing standards, or to January 1, 2010, to give prospective e-prescribers more time to identify compliant products. Some commenters recommended that the requirement to use the adopted e-prescribing standards should only apply to those prescribers/dispensers who have software or applications that have the ability to generate transactions utilizing NCPDP SCRIPT. Others suggested that the use of computer-generated faxes continue to be permitted for those prescribers and dispensers who already have the functionality to engage in transactions utilizing NCPDP SCRIPT, and allow those who adopt software that generates transactions utilizing NCPDP SCRIPT after the compliance date of January 1, 2009, an additional 1 year to comply with the NCPDP SCRIPT requirement.

Response: The 2006 CMS e-prescribing pilot noted that the majority of e-prescribing software currently being used by prescribers is already able to transmit information using NCPDP SCRIPT. Moreover, commenters agreed that most current e-prescribers could become compliant by installing an NCPDP SCRIPT-enabled version upgrade. Therefore, we believe that the January 1, 2009 compliance date provides adequate time for current e-prescribers in the industry to comply with the NCPDP SCRIPT e-prescribing standard provisions while encouraging other prescribers and dispensers to move closer toward true e-prescribing. We do not see a purpose in affording new e-prescribers an additional year to comply, since it should not take more time to implement an NCPDP SCRIPT-compliant product than a noncompliant product.

Comment: Many commenters suggested that we continue to allow for the use of computer-generated faxes in the case of transmission failure and network outages.

Response: Computer-generated faxes may be needed for prescriptions which fail in electronic data interchange (EDI) transmission. Allowing computer-generated faxes as a fall back measure would allow the prescription to be expedited to the pharmacy, ensuring timely dispensing of the medication, thus enhancing patient safety. We agree that there should be a viable contingency plan in the event that an EDI-transmitted prescription fails due to network transmission failures or similar, temporary communication problems that are episodic and non-repetitive in nature. We find the use of computer-generated faxes, but only in instances of the aforementioned transmission failures or similar communication problems of a temporary/transient nature, to be an acceptable and viable solution. We do not, however, consider it to be a permanent substitute for ongoing EDI transmission problems. As we will continue to allow computer-generated faxes as a fallback in cases of temporary/transient transmission failures and communications problems, we will not totally eliminate but instead amend the exemption for computer-generated facsimile transmission from the NCPDP SCRIPT Standard to account for this contingency.

Comment: Approximately one-fourth of commenters from all sectors of the health care industry called for the delay of the elimination of the exemption for computer-generated faxes until such time as the Drug Enforcement Agency (DEA) changes its rules to allow the e-prescribing of controlled substances.

Commenters believe that the current DEA position on disallowing e-prescribing of controlled substances creates a barrier to adoption, and the proposed CMS compliance date of January 2009 will only exacerbate the issue.

Response: As we have no indication as to when the Drug Enforcement Agency will make a determination on the e-prescribing of controlled substances, it would be difficult for us to predicate eliminating the exemption for computer-generated faxes based upon such an unknown timetable. However, we concur with commenters who stated that the inability to prescribe these controlled substances electronically hampers e-prescribing adoption by providers. We continue to work with the DEA to help facilitate a solution that addresses both the enforcement requirements of the DEA with respect to prescribing of controlled substances, and the needs of the healthcare community for a solution that is scalable and commercially viable.

Comment: One commenter suggested that we exempt controlled substances from this requirement.

Response: The November 7, 2005 E-prescribing final rule (70 FR 67568) recognizes the DEA's role in the enforcement of the prescribing of controlled substances. As controlled substances cannot be legally e-prescribed, an exemption from the NCPDP SCRIPT standard for the e-prescribing of controlled substances would have no effect.

Comment: Some commenters were confused as to whether the computer generated fax exemption would affect the exemption in the long term care setting, and requested that we clarify that prescribers and dispensers in the long term care setting were exempt from the requirement to use NCPDP SCRIPT despite the amendment of the exemption of the computer generated faxes.

Response: Our amendment of the exemption for computer generated faxes does not apply at this time to the long term care industry as defined under Medicare Part D. At the time the CY 2008 PFS proposed rule (72 FR 38194) was published in the **Federal Register**, the long term care industry exemption for using adopted standards in e-prescribing (as contained in the November 7, 2005 final rule (70 FR 67568)) was, and remains, in place. Based on the comments we received, we are finalizing an amendment of the exemption for computer-generated faxes.

S. Division B of the Tax Relief and Health Care Act of 2006—Medicare Improvements and Extension Act of 2006 (Pub. L. 109–432) (MIEA–TRHCA)

In addition to the provisions of the MIEA–TRHCA discussed in sections II.B. (GPCIs) and II.F. (CAP), additional provisions of the MIEA–TRHCA are discussed in this section of the final rule with comment period.

1. Section 101(b)—Physician Quality Reporting Initiative (PQRI)

a. Background

(i) Program Background and Statutory Basis

Section 101(b) of the MIEA–TRHCA amended section 1848 of the Act by adding subsection (k). Section 1848(k)(1) of the Act requires the Secretary to implement a system for the reporting by eligible professionals of data on quality measures as described in section 1848(k)(2) of the Act. Section 1848(k)(3)(B) of the Act specifies that for the purpose of the quality reporting system, eligible professionals include physicians, other practitioners as described in section 1842(b)(18)(C) of the Act, physical and occupational therapists, and qualified speech-language pathologists. Section 101(c) of the MIEA–TRHCA authorizes “Transitional Bonus Incentive Payments for Quality Reporting” in 2007, specifically for satisfactory reporting of quality data, as defined by section 101(c)(2) of the MIEA–TRHCA. We have named this quality reporting system the “Physician Quality Reporting Initiative (PQRI)” for ease of reference.

For 2007, section 1848(k)(2)(A)(i) of the Act, as added by the MIEA–TRHCA, provides that the quality measures for the PQRI shall be the 66 physician quality measures published as 2007 Physician Voluntary Reporting Program (PVRP) quality measures on the CMS web site as of the date of enactment of this subsection, except for any changes based on the results of a consensus-based process in January 2007. Based on actions approved at the AQA Alliance (formerly the Ambulatory Care Quality Alliance) meeting on January 22, 2007, 8 measures were added to the 66 measures from the PVRP. Thus, the final “2007 PQRI Quality Measures” comprise 74 measures, which are applicable to specific combinations of patient conditions and Medicare Physician Fee Schedule (PFS) covered professional services. The measure titles, descriptions, and specifications are available for download from the PQRI Measures/Codes page of the PQRI section of the CMS Web site at <http://www.cms.hhs.gov/PQRI>.

Section 1848(k)(2)(A)(ii) of the Act does not allow for any further additions to or deletions from the 2007 PQRI Quality Measures after January 2007, and does not allow modifications or refinements (such as code additions, corrections, or revisions) to the detailed specifications for the 2007 PQRI quality measures after the July 1, 2007, beginning date of the reporting period. The final 2007 specifications for the 2007 PQRI quality measures are available as a download from the Measures/Codes page of the PQRI section of the CMS Web site at <http://www.cms.hhs.gov/pqri>. Additional information on the 2007 PQRI is also available from this section of the CMS Web site, including, but not limited to:

- Tools to help professionals select measures;
- Tools to help professionals capture data on 2007 PQRI quality measures;
- Explanations of the calculation of eligibility for and amount of bonus payment for satisfactory reporting; and
- A description of the methodology that we will use to validate whether professionals have satisfactorily reported the MIEA–TRHCA required minimum number of applicable measures.

Section 1848(k)(2)(B) of the Act further requires that the Secretary publish in the **Federal Register** not later than August 15, 2007, proposed quality measures that would be appropriate for eligible professionals to use to submit data to the Secretary in 2008. The final 2008 PQRI quality measures must be determined and published by November 15, 2007, as specified in section 1848(k)(2)(B) of the Act as amended by the MIEA–TRHCA.

(ii) Overview of the PQRI Section in the Final Rule With Comment Period

In the CY 2008 PFS proposed rule (72 FR 38196 through 38199), we provided a slightly longer summary of the MIEA–TRHCA requirements and the PQRI program than is provided immediately above in this section, and explained our interpretation of applicable statutory and government-wide policies relevant to defining a consensus organization and consensus-based measure development process, and our policy for determining which measures meet requirements for inclusion in PQRI. In satisfaction of the MIEA–TRHCA requirement to publish proposed 2008 PQRI measures by August 15th, we published 148 proposed 2008 PQRI quality measures in the CY 2008 PFS proposed rule (72 FR 38199 through 38202). We invited comments on the implications of including or not including any specific measure(s), and

on our plans to explore mechanisms for submission of electronic clinical performance measurement information and/or summary measure results information extracted from electronic health records (EHRs) and/or clinical data registries.

In this PQRI section of the final rule with comment period, we first address the general or overview public comments.

(iii) General/Program Comments and Responses

Comment: We received a number of comments commending CMS and the PQRI program for being responsive to stakeholder concerns, focusing on health care quality and performance improvement, and consistently using accurate and inclusive terminology (for example, where appropriate, “eligible professionals” rather than “physicians”) while implementing on an aggressive timeline a functional program with an extensive and well-received education and outreach component. A number of commenters also expressed a desire to continue to work with us in a spirit of partnership to advance and improve the program and its utility to beneficiaries, professionals, and the industry at large.

Response: We appreciate the constructive input of the wide variety of stakeholders who have provided insights, information, and partnered with us to disseminate informational materials about PQRI to the eligible professionals in the health care community. We plan to continue dialogue with stakeholder organizations and will consider their and PQRI participants’ input (including questions and comments submitted via informal, as well as formal, channels of inquiry) as we continue working to provide 2007 PQRI participants with reporting rate and clinical performance results feedback reports and (for those participants achieving satisfactory reporting per MIEA–TRHCA requirements) PQRI incentive payments in mid-2008, and as we develop and implement strategies for individual-clinician-level and related quality reporting and improvement initiatives for 2008 and beyond.

Comment: We received numerous comments identifying specific ways in which commenters recommended we enhance the PQRI in the future. One theme was that, although defined per MIEA–TRHCA as professionals eligible to participate in PQRI, some clinicians may be unable to participate due to lack of PQRI measures applicable to their practices. A closely related concern was that some clinicians with otherwise applicable PQRI measures may be

unable to participate due to data submission relying on the Part B PFS Fee-For-Service claims mechanism. These limitations include that some PQRI-eligible professionals (such as physical and occupational therapists) who cannot currently participate in PQRI because reimbursement for the MPFS covered professional services they furnish is claimed in a format (X12 837-I electronic transaction or the UB04 form) that does not allow for attribution of each service to the individual professional who furnished it.

Several commenters suggested that submission of electronic clinical information (ECI) from registries and/or electronic health records (EHRs) may potentially address the limitations of claims-based quality measures data submission. Other commenters simply urged us to find a mechanism, potentially a claims-based mechanism, to afford all eligible professionals the opportunity to participate prior to proceeding with PQRI subsequent to 2007.

Response: We agree with the goal of offering the opportunity to participate in PQRI to as many eligible professionals as feasible and practical, consistent with the MIEA-TRHCA statutory requirements. In support of this goal, especially where there are gaps in available consensus measures for specific practitioners, we have worked to encourage and contract for the development of quality measures and to fund consensus projects. For 2008, we have supported via contract with Quality Insights of Pennsylvania (QIP) the development of structural measures and measures applicable to a broad cross-section of PQRI eligible professionals, including some nonphysician practitioners (NPPs) who had few or no measures available in 2007. We prioritized development of these measures based on the existing gaps in measures available or otherwise in development and on a need to address as broad a cross section of eligible professions or specialties as possible within the limited volume of measures for which we could support development in time for inclusion in the 2008 PQRI.

We plan to continue working to fill gaps in available consensus-endorsed or adopted measures consistent with available time and resources. However, we largely depend on and encourage the development of measures by professional organizations and other measure developers. We note that MIEA-TRHCA includes a provision that requires the Secretary to include measures developed by specialty societies. Ideally, in the future CMS

would not need to be closely involved in the development of clinician-level quality measures, but would select from measures that meet the MIEA-TRHCA requirements.

In regard to the potential use of nonclaims mechanisms for submission of electronic clinical information, we agree with this goal; however it is not feasible to implement for 2008. In regard to claims-based alternatives to enable participation by professionals for whose covered professional services payment is made under or based on the MPFS but claimed via institutional formats (X12 837-I electronic transaction or UB04 form), we have analyzed the possibilities and determined that the MIEA-TRHCA requirement that satisfactory reporting and amount of any incentive payment be determined at the individual-professional level cannot be satisfied without extensive modifications to the claims processing systems of CMS and providers, which would represent a material administrative burden to us and providers, and/or modifications to the industry standard claims formats, which would require substantial time to effect via established processes and structures that we do not maintain or control.

Comment: Although most commenters acknowledged that we proposed and will finalize 2008 measures in response to MIEA-TRHCA statutory mandate, numerous commenters expressed concerns that we are proceeding with design and implementation of PQRI 2008 before we have been able to evaluate the 2007 PQRI. One such commenter specifically declined to comment on the 2007 PQRI in advance of public availability of 2007 PQRI evaluation information and requested that we solicit comments on the 2007 PQRI, and the 2007 PQRI evaluation information, in the CY 2009 PFS proposed rule. Specific examples of evaluation information that commenters requested CMS consider and publish include:

- Rates of participation by eligible professionals;
- Cost or administrative burden of the PQRI from the perspective of participating professionals and the Medicare program;
- The apparent impact of PQRI on professionals' clinical performance; and
- The impact on beneficiaries.

Some of these commenters, and several other commenters who did not specifically raise concerns about program-level evaluation, requested that we consider delaying the start of the 2008 reporting period until mid-2008 to give 2007 participants a chance to assess their 2008 results to identify process

changes to improve their 2008 reporting rate and clinical performance results.

Response: We are in the process of operationalizing, in a phased manner appropriate to data availability and analytic infrastructure implementation, a comprehensive ongoing program monitoring strategy that will provide interim indications, at the program level, of some of the same aspects of the program we will ultimately examine in our evaluation(s) of the impact of the 2007 program after the conclusion of the 2007 reporting period. To the extent feasible within the limits of available resources including, but not limited to, funding and sufficiently complete data, we anticipate conducting an evaluation of the 2007 PQRI. The aspects of PQRI impact we would expect to assess include participation rates by specialty/profession, associated trends in clinical performance and beneficiary outcomes, and other observable impacts on participants, the Medicare program, and beneficiaries. Although we have not yet finalized the operational details of our evaluation strategy, we do anticipate making the results of the evaluation, at the national level, available to the public. We may also make publicly available the results of such analyses aggregated at other meaningful levels (for example, State, specialty, or profession). We do not at this time plan to make results publicly available in a format or with content that would enable identification of individual professionals or specific practices' specific reporting or performance results. We have not made a determination as to the most appropriate venue(s) for making PQRI evaluation information available to the public.

This section of the final rule with comment period is specific to the establishment of measures appropriate for use by professionals to submit quality-of-care data in 2008, as we are directed to do by section 101(b) of the MIEA-TRHCA. The incentive bonus requirements and reporting period for PQRI in 2008 are addressed in section 101(d) of the MIEA-TRHCA, Physician Assistance and Quality Improvement (PAQI), section (II.S.5.) of this final rule with comment period. Such details of the 2008 bonus-incentive program are beyond the scope of this MIEA-TRHCA Section 101(b), PQRI section of this final rule with comment period.

Comment: A number of comments requested or recommended that we make readily available on an ongoing basis more detailed information on the measure development process and measures in development. Numerous commenters also requested final

measure specifications be published as far in advance of the beginning of the reporting period as possible, and that more detailed information about measures proposed or finalized for use in PQRI be published in, at the same time as, or in advance of future rulemaking.

Response: We agree that it could be useful to our stakeholder partners in health care quality measurement and improvement, including but not limited to potential measure developers, to make available in a prominent place (such as the CMS PQRI Web site) additional information on measure development in context of PQRI, potentially including guidance to other publicly available sources of general information on health care quality measurement and development of specific metrics. We will consider our options to accomplish this in a practical and sustainable way and use various appropriate communications channels to notify stakeholder organizations and the community at large of our strategy once we have developed it.

We agree with the commenters that it is desirable to provide final measure specifications sufficiently in advance of the reporting period to allow reasonable time for professionals to analyze new or revised measures and implement any needed changes in their office workflows to accurately capture and successfully submit data on a selection of measures applicable to their practice on which they can act to improve the quality of the services they furnish. We are aware that such "lead time" should also help the eligible professionals' specialty or professional societies be better prepared to support the professionals' selection of relevant, actionable measures. Having detailed information on measures available in advance of the reporting period also enhances the ability of vendors (such as practice-management software, billing services, and electronic health records vendors) to support professionals' successful implementation of revised data-capture processes for the measures.

The MIEA-TRHCA requires that we publish the final list of 2008 PQRI measures no later than November 15, 2007. We would expect to publish detailed specifications shortly after that date. Detailed measure specifications for measures new or revised for 2008 PQRI will be published on the Measures/ Codes page of the CMS PQRI Web site at <http://www.cms.hhs.gov/pqri>. These detailed specifications will include instructions for reporting and identify the circumstances in which each measure is applicable. The detailed technical specifications for measures in

the final listing for the 2008 PQRI remain potentially subject to corrections until the start of the 2008 reporting period, as we stated in the proposed rule.

Comment: Many commenters expressed concerns that recent legal rulings raise concerns about whether the individual participating professionals' reporting and clinical performance results may constitute administrative data potentially subject to disclosure requirements of the Freedom of Information Act (FOIA). Commenters urged that any clinician performance program or system should remain voluntary and its results confidential.

Response: Commenting on or otherwise addressing the legal standing of PQRI participants' reporting and performance results in context of FOIA, other applicable statutes, or case law is outside the scope of this rule. At this time, we have no plans to publish without participants' voluntary consent either 2007 or 2008 PQRI participants' reporting or performance results in a way that would be specifically identified or readily identifiable at the individual-professional, group practice-site, or billing unit (Taxpayer Identification Number) levels. As mentioned in response to comments urging us to share information resulting from its 2007 PQRI program-evaluation analyses, we do plan to make available information at various meaningful levels of aggregation other than the individual professional, practice, or billing unit.

Comment: Several commenters recommended specific enhancements to PQRI participant feedback reporting including displays of additional analyses (beyond the measure calculation as specified) for specific measure(s) and/or provision of interim reporting and performance results during the 2008 reporting period. Some commenters recommended we conduct additional analyses of measure data but did not specifically tie that recommendation to the participant feedback report content.

Response: Detailed design of the participant feedback reports and specific analyses of PQRI data for purposes other than calculating bonus payment eligibility or amount (for example, for future measure development or refinement) are outside the scope of this section of this final rule with comment period. However, we will consider these recommendations as part of the ongoing dialogue with the stakeholder and participant community in order to collaboratively identify ways to enhance the measures' and/or program's value to its participants and the Medicare program. We are currently

assessing the feasible options and timeframe within which we may be able to provide meaningful interim feedback reports to 2008 PQRI participants. As a matter of practical, operational reality, it is highly probable that we will not be able to make any 2008 interim feedback reports available until after we make available the 2007 final feedback reports. The 2007 PQRI was unable to offer during the reporting period any interim feedback reports of participants' reporting and performance rates to date because the aggressive statutory timeframe for implementing the program did not allow for the necessary data infrastructure (including analytic programming and report access mechanisms) to be implemented in time to provide accurate, meaningful results feedback for 2007 in an appropriately secure/confidential report access environment prior to mid 2008.

Comment: Some commenters requested specific or general clarifications or additional guidance on the PQRI program, and how to code its measures, in the implementation support tools (for example, a handbook, or worksheets) provided on the CMS PQRI Web site.

Response: Although not directly applicable to the proposed rule content on which we sought comment, these comments are appreciated and will be taken into consideration along with other input that these materials' users have provided via less formal avenues of communication.

Comment: Many commenters expressed concern that the burden of data collection and submission may be an obstacle to program participation for some practices. Some commenters further noted that the claims-based submission process may be particularly burdensome for those practices that are simultaneously implementing electronic health records or whose PQRI-eligible members already participate in a medical data registry.

Response: To implement a data submission mechanism that was technically feasible for CMS and providers, and that is broadly available to and already used by the vast majority of PQRI-eligible professionals, we determined that claims-based data submission is the only possible mechanism for 2007 and the only viable mechanism for full operationalization in 2008. Thus, measures appropriate for use by professionals to submit quality-of-care data to CMS in 2008 must be specified for claims-based submission and analysis. We are, however, committed to exploring and supporting practical, effective mechanisms for quality-of-care data submission that

promote efficiency by streamlining participants' and our data collection and handling. As discussed below in this section, in the registry- and EHR-based submission topics of this section of this final rule with comment period, we plan to test in 2008 registry- and EHR-based mechanisms for data submission, in order to develop the potential ability to fully implement such mechanisms in the future. Those professionals whose practices that have implemented the referenced HIT will have available EHR and e-prescribing structural measures for reporting in 2008, which would, if reported, count toward professionals' eligibility for the incentive payment discussed below in section II.S.5. of this final rule with comment period.

Comment: Several comments recommended or urged us to consider using the group practice as the unit of analysis, and to consider developing and implementing sampling methodologies at the group level as a means of reducing reporting burden in the future.

Response: The 2007 unit of analysis is established at the individual-professional level by MIEA-TRHCA, and we have not proposed to change that for 2008. As the 2007 PQRI evaluation results become available and further legislative action provides additional guidance, such alternatives may indeed prove important to explore or develop.

b. MIEA-TRHCA Requirements for Measures Included in the 2008 PQRI

(i) MIEA-TRHCA Requirements for 2008 Quality Measures

(A) Overview and Summary

As noted in the CY 2008 PFS proposed rule (72 FR 38196 through 38197), section 1848(k)(2)(B)(i) of the Act requires, "for purposes of reporting data on quality measures for covered professional services furnished during 2008, the quality measures specified under this paragraph for covered professional services shall be measures that have been adopted or endorsed by a consensus organization (such as the National Quality Forum or AQA), that include measures that have been submitted by a physician specialty, and that the Secretary identifies as having used a consensus-based process for developing such measures. Such measures shall include structural measures, such as the use of electronic health records and electronic prescribing technology."

Section 1848(k)(2)(B)(ii) of the Act requires that "[n]ot later than August 15, 2007, the Secretary shall publish in the **Federal Register** a proposed set of

quality measures that the Secretary determines are described in clause (i) and would be appropriate for eligible professionals to use to submit data to the Secretary in 2008. The Secretary shall provide for a period of public comment on such set of measures."

In the CY 2008 PFS proposed rule (72 FR 38197), we explained our interpretation of these statutory requirements and the policies used in selecting measures to propose as appropriate for professionals to use to submit data on the quality of covered professional services furnished to Medicare beneficiaries in 2008.

In examining the statutory requirements of section 1848(k)(2)(B)(i) of the Act, we believe that the requirement that measures be endorsed or adopted by a consensus organization applies to each measure that would be included in the measures set for submitting quality data on covered professional services furnished during 2008. Likewise, the requirement for measures to have been developed using a consensus based process applies to each measure. By contrast, we do not interpret the provision requiring inclusion of measures submitted by a specialty to apply to each measure. Rather, we believe this requirement means that in endorsing or adopting measures, a consensus organization must include in its consideration process at least some measures submitted by a physician or an organization representing a particular specialty. Similarly, we interpret the requirement that 2008 measures include structural measures, such as the use of EHRs and electronic prescribing technology, to mean that the 2008 measure set must include at least 2 structural measures.

In examining sections 1848(k)(2)(B) of the Act, we believe that the Secretary is given broad discretion to determine which quality measures meet the statutory requirements and are appropriate for inclusion in the final set of measures for 2008. We do not interpret the Act to require that all measures that meet the basic requirements of section 1848(k)(2)(B)(i) of the Act must be included in the 2008 set of quality measures. We next discuss the statutory requirements for consensus organizations and the use of a consensus-based process for developing quality measures as they relate to the requirements for the set of measures for 2008 in the context of other applicable Federal law and policy.

The MIEA-TRHCA requires that measures used for 2008 be identified by the Secretary as having been endorsed or adopted by a consensus organization

and have been developed through the use of a consensus-based process. As stated in the proposed rule (72 FR 38197 through 38199), we believe that these requirements should be interpreted in the context of the National Institute of Standards and Technology Act (NIST) (15 U.S.C. 271 et seq.) as amended by the National Technology Transfer and Advancement Act of 1995 (Pub. L. 104-113) (NTTAA) and implemented by Revised OMB Circular No. A-119 (OMB A-119) dated February 10, 1998.

Per the NTTAA, except when it is inconsistent with applicable law or otherwise impractical, all Federal agencies and departments shall use standards that are developed or approved by voluntary consensus standards bodies. OMB A-119 provides specific policy guidance to agencies on the appropriate interpretation of agency responsibilities under the NTTAA. As we discussed in the proposed rule (72 FR 38197 through 38199), OMB A-119 establishes as government-wide policy that agencies "must use voluntary consensus standards, both domestic and international, in its regulatory and procurement activities in lieu of government unique standards, unless use of such standards would be inconsistent with applicable law or otherwise impractical." OMB A-119 further explains that in determining whether use of existing voluntary consensus standards in its regulatory and procurement activities is otherwise impractical, "'Impractical' includes circumstances in which such use would fail to serve the agency's program needs; would be infeasible; would be inadequate, ineffectual, inefficient, or inconsistent with agency mission; or would impose more burdens, or be less useful, than the use of another standard." OMB A-119 also provides that "voluntary consensus standards" are standards developed or adopted by voluntary consensus standards bodies, and defines "voluntary consensus standards body" as an organization maintaining the following attributes: (1) Openness; (2) Balance of interest; (3) Due process; (4) An appeals process; (5) Consensus; which is defined as general agreement, but not necessarily unanimity, and also includes a process for attempting to resolve objections by interested parties. The process requires that, as long as all comments have been fairly considered, each objector is advised of the disposition of his or her objection(s) and the reasons for the disposition, and the consensus body members are given an opportunity to change their votes after reviewing the comments. Voluntary consensus

standards must include provisions requiring that owners of relevant intellectual property have agreed to make that intellectual property available to all interested parties on a nondiscriminatory, royalty-free, or reasonable royalty basis.

Other types of standards that are distinct from voluntary consensus standards but that may be used by federal agencies when voluntary consensus standards are not available and practical to address the government's programmatic needs, include government-unique standards, industry standards, company standards, nonconsensus standards, or de facto standards which are developed in the private sector but not in the full consensus process of a voluntary consensus standards body. For further discussion of the NTTAA, OMB A-119, and their relevance to quality measures for use of professionals to submit quality-of-care data to the Secretary, please review the 2008 MPFS Proposed Rule PQRI section at 72 FR 38197-38199.

Two consensus organizations are referenced in section 1848(k)(2)(B): the National Quality Forum (NQF) and the AQA Alliance. The NQF has a formal organizational structure and established processes that are intentionally designed to comply with the NTTAA and OMB A-119. Membership is open and includes a broad cross-section of stakeholder perspectives. In determining whether or not to endorse a standard, the NQF uses a formal process that consists of five principal steps that follow a project's conceptualization, prioritization, and planning. The steps are: (1) Consensus Standard Development; (2) Widespread Review; (3) Member Voting and Member Council Approval; (4) Board of Directors Action; and (5) Evaluation that includes an appeals process. The NQF meets the NTTAA requirements for a voluntary consensus standards body within the meaning of the NTTAA and its endorsed healthcare quality measures constitute voluntary consensus standards within the meaning of NTTAA.

The AQA is also referenced in section 1848(k)(2)(B) of the Act as a consensus organization for the purpose of identifying measures that have successfully completed review by a consensus organization, though it does not feature all of the structural characteristics or processes of a voluntary consensus standards body per NTTAA and the OMB A-119. By citing AQA as an example of an acceptable consensus organization, section 1848(k)(2)(B) of the Act establishes that AQA adoption satisfies the requirement

of section 1848(k)(2)(B) of the Act that PQRI quality measures be adopted or endorsed by a consensus organization. We believe it follows that the Congress did not intend to require all 2008 quality measures under section 1848(k)(2)(B) of the Act to meet the requirements to be considered voluntary consensus standards under the NTTAA. However, by giving NQF and AQA as examples of consensus organizations, we believe the Congress intended that consensus organizations should, in the context of section 1848(k)(2)(B) of the Act, have a breadth of stakeholder involvement and voting participation substantially comparable to that of the NQF or AQA.

Given the potential for apparent overlap of NQF and AQA as consensus organizations under the MIEA-TRHCA, it is important to distinguish their roles. As currently established, the principal purpose of AQA for physician quality measures is to select among NQF endorsed measures for coordinated implementation. However, during a time of rapid physician quality measures development and implementation, it is impractical to delay implementation of physician quality measures until the formal processes of NQF are completed. Therefore, AQA has been able to enable CMS to incorporate new measures into the quality reporting system by providing consensus review acceptable under MIEA-TRHCA for implementation of a measure prior to actual NQF endorsement. In the event of a determination by NQF to decline endorsement of a particular measure after it had been adopted by AQA, we anticipate that AQA would withdraw its adoption of such a measure.

Turning to the requirement of a consensus-based process for developing quality measures, we interpret this requirement in light of the NTTAA and the importance of broad consensus for health care quality measures used for regulatory purposes. In this context we have outlined in the proposed rule, and rather than cite the proposed rule, we will for readers' convenience reiterate below the process of health care quality measurement development and distinguish basic development steps from the completion of a consensus-based development process as required under MIEA-TRHCA.

Many organizations are involved in the development of health care quality measures. These organizations include physician organizations, health care providers, Federal agencies, accreditation organizations, disease-focused not-for-profit organizations, research organizations, and health

plans. The basic development processes of leading health care quality measure developers generally use standardized methods that include identification of a quality goal or gap, literature and evidence review, expert and technical evaluation, specification development, testing, organizational review, and that may include public comment.

In the framework of the NTTAA, upon completion of the basic development work, healthcare quality measures do not constitute voluntary consensus standards, even though they may have utilized consensus as a mechanism of achieving agreement among the developer's participants or within the developer's organizational structure. Rather, to achieve the status as a voluntary consensus standard under NTTAA, the measure must go through the additional development that occurs through the broader consensus process of consensus endorsement. During this process, based on the need to achieve agreement, quality measures are often modified in order to achieve the necessary broad consensus.

Consistent with this concept, we interpret "consensus-based process for developing measures" as used in MIEA-TRHCA to encompass not only the basic development work of the formal measure developer, but also to include the achievement of consensus among stakeholders in the health care system based on at least a level of openness, balance of interest, and consensus reflected in the structures and processes of the NQF or the AQA as of the date of enactment of MIEA-TRHCA.

Based on the considerations previously discussed, we apply the following policies in identifying measures that meet the MIEA-TRHCA requirements for having used a consensus-based process for development and the requirement for having been endorsed or adopted by a consensus organization such as the NQF or AQA, and that are appropriate for inclusion as 2008 measures:

(1) We interpret "a consensus-based development process" as meaning that in addition to the measure development, the measure has achieved adoption or endorsement by a consensus organization having at least the basic characteristics of the AQA as a consensus organization as of December 2006, when the MIEA-TRHCA incorporating reference to AQA was passed and signed into law. Those basic characteristics include a comparable level of openness, balance of interest, and consensus-based on voting participation. As discussed above in this section and further clarified in points (3) and (5) of this section, we do not

interpret “consensus-based development process” per section 1848(k)(2)(B) of the Act to require that the consensus organization or process meet all of the criteria of the NTTAA and OMB A–119 definition of a voluntary consensus standards body.

(2) “Voluntary consensus standard” is interpreted to mean a voluntary consensus standard that has been endorsed as such by a consensus organization that meets the requirements of the NTTAA, and the provisions of OMB A–119, for a voluntary consensus standards body.

(3) Where there are available quality measures, and some of these measures meet the definition of “voluntary consensus standards” while others do not, those measures that meet the definition of “voluntary consensus standards” are preferred to other measures not meeting the requirements of the NTTAA.

(4) In view of the preference for voluntary consensus standards, if, as of the earlier of November 15, 2007, or the date of publication of this final rule, a measure has been specifically considered by NQF for possible endorsement but NQF has declined to endorse it, we proposed not to include it in the final set of 2008 PQRI Quality Measures, even if previously adopted by AQA.

(5) Although the AQA does not meet the requirements of the NTTAA for a voluntary consensus standards body, it is a consensus organization per section 1848(k)(2)(B) of the Act. In circumstances where no voluntary consensus standard (NQF-endorsed) measure is available, and the measure has not been specifically declined for endorsement by NQF, a quality measure that has been adopted by the AQA (or another consensus organization with comparable consensus-organization characteristics), will meet the requirements of MIEA–TRHCA if we determine that it is appropriate for eligible professionals to use to submit data.

(6) We are unaware of other consensus organizations that are comparable to the NQF in terms of meeting the formal requirements of the NTTAA, or of organizations other than AQA that do not strictly meet the requirements of the NISTA, as amended by the NTTAA, but that feature the breadth of stakeholder involvement in the consensus process necessary to meet the intent of the MIEA–TRHCA. However, the MIEA–TRHCA does not limit consensus organizations to the NQF or the AQA, nor restrict the field of potential consensus organizations. The MIEA–TRHCA, thereby, maintains

flexibility in potential sources of measure consensus review, which is, like having multiple sources of measure development, key to maintaining a robust marketplace for development and review of quality measures.

(7) The basic steps for developing the physician level measures may be carried out by a variety of different organizations. We do not interpret the MIEA–TRHCA to place special restrictions on the type or make up of the organizations carrying out this basic development of physician measures, such as restricting the initial development to physician-controlled organizations. Any such restriction would unduly limit the basic development of physician quality measures and the scope and utility of measures that may be considered for endorsement as voluntary consensus standards.

(8) The policies we proposed were based on the preference as articulated in NTTAA and OMB A–119 for “voluntary consensus standards” to government-unique standards. However, the MIEA–TRHCA does not require that quality measures meet the NTTAA or OMB A–119 definition of “voluntary consensus standards” in order to be used for PQRI. Thus, though we prefer to use quality measures meeting the NTTAA and OMB A–119 criteria for voluntary consensus standards, neither this CMS preference nor the NTTAA or OMB A–119 preclude CMS from exercising our discretion under the MIEA–TRHCA to select measures for PQRI meeting the less stringent consensus requirements of the MIEA–TRHCA, when necessary to meet our program needs as determined by the Secretary.

(B) Summary of Comments and CMS’s Responses

Comment: Many commenters thanked us for clarifying the requirements for consensus-based development, consensus endorsement or adoption, and the basic, high level structure of the measure-development process. As discussed above in context of the PQRI program/overview content and comments topic, multiple commenters requested additional and more detailed information about measure development and related processes and organizations. In context of the consensus requirements, several commenters requested further explanation of the detailed definition or distinction between the stages of measure development.

Response: We are pleased that many commenters that found our description of the measurement development processes useful and were supportive of

our interpretation of the statutory requirements for consensus endorsement and adoption and consensus-based development process. In terms of providing additional clarification, the status for PQRI implementation of measures that have been approved by AQA but declined for endorsement by NQF is clarified in the final language. Measures approved by AQA are sufficient for inclusion in 2008 PQRI in terms of the statutory requirements for consensus-organization adoption or endorsement and consensus-based development requirements of MIEA–TRHCA. Measures, however, that have been specifically declined for endorsement by NQF, are not selected for use in 2008 PQRI, based on our preference for Voluntary Consensus Standards (72 FR 38198).

Comment: Many commenters requested or recommended that measure development processes employ robust mechanisms for incorporation of broadly inclusive consensus and/or public comment during the initial, as well as final phase of development. However, some commenters expressed the counterbalancing concern that we should more specifically clarify that appropriate quality measures for PQRI should in fact be based on evidence interpreted in processes which include consensus methods and organizations, as opposed to measures that are based primarily on stakeholder consensus about measure need and design without a firm foundation in scientifically sound clinical evidence.

Response: As described in the proposed rule (72 FR 38197 through 38198) the basic (initial) development processes of measure developers typically include various standardized processes that include both an evaluation of the evidence base for a measure and a public comment opportunity. We do not believe that we should delineate these processes via rulemaking, nor require a particular evidence base for a measure. Rather, the adequacy of measures from these and many other standpoints is subject to evaluation during the consensus process.

Comment: Several commenters suggested we consider establishing as policy that quality measures to be used by, and analyzed at the level of, individual PQRI-eligible professionals, must be developed by clinician-controlled organizations to assure relevance and promote uptake by the eligible professional community. Multiple commenters suggested explicit preference be given for measures developed or endorsed by physician

specialty societies, in context of consensus-organization review and CMS measure selection processes. Some commenters stated that the AMA-PCPI should be the sole source for physician-level measures. One commenter specifically presented an interpretation of the MIEA-TRHCA requirement for the 2008 PQRI measures to include measures submitted by a physician specialty as meaning that the 2008 PQRI should include only measures developed by physician organizations, to assure physician control of available measures applicable to assessing the clinical performance of individual physicians. Other commenters expressed differing viewpoints, commenting on the importance of an open process for initial measure development, and noting that no single organization stands ready to lead in the quality arena. Multiple commenters pointed to concerns about existing measure development and consensus organizations particularly in terms of structure and transparency, opposing any single organization controlling measurement development, opposing requiring PQRI measurement development to come solely from physician controlled organizations, and supporting alternatives to existing organizations.

Response: Physician involvement and leadership is standard in the work of both measure developers and consensus organizations. As a result, physicians are actively involved at all levels of measurement development and consensus adoption and endorsement. We are in agreement that physician expertise is an important ingredient in measurement development and in the consensus process. We further recognize the leadership of physician organizations, as is reflected in the large number of physician quality measures included in PQRI which were developed by the AMA-PCPI and its participating specialty societies.

However, we do not agree that physicians should be in complete control of the process of measure development, as would be the case if measures were required to be developed solely by physician-controlled organizations. Any such restriction would unduly limit the basic development of physician quality measures and the scope and utility of measures that may be considered for endorsement as voluntary consensus standards. Rather, as we described in the proposed rule, the basic steps for developing the physician level measures are appropriately carried out by a variety of different organizations. We do not interpret the MIEA-TRHCA to place

special restrictions on the type or make up of the organizations carrying out this basic development of physician measures, such as restricting the initial development to physician-controlled organizations. Similarly, we do not interpret MIEA-TRHCA to require that each measure included in the 2008 PQRI have been developed by a physician specialty.

Finally, we do not interpret MIEA-TRHCA to limit the field of potential consensus organizations to those it named as examples of acceptable organizations, so long as the requirements for broad consensus we articulated as required under MIEA-TRHCA is achieved. The MIEA-TRHCA, thereby, maintains flexibility in potential sources of measure consensus review, which is, like having multiple sources of measure development, key to maintaining a robust marketplace for development and review of quality measures.

Comment: Many commenters suggested we establish a centralized process or structure to prioritize measure development in specific ways. Some commenters recommended priority be given to meaningful, actionable gaps in care or specific high-impact disease conditions. Others recommended that the first priority be assuring measure availability for all PQRI-eligible professions and specialties. Commenters recommended a centralized establishment of national priorities for measure development and suggested that such prioritization would help to align clinician-focused quality measures with measures used in other governmental and private-sector initiatives focused on other provider types, and advance measurement and close gaps in care for high-prevalence and/or high-cost conditions.

Response: Health care quality measures are currently developed by a variety of organizations and used by a variety of governmental, nongovernmental, and public-private partnership initiatives which have various and at times differing programmatic needs for quality measures. Although a cooperative and voluntarily coordinated approach to agreeing upon quality goals which would guide development and selection of measures may be of value, the Secretary retains the authority to select from available measures meeting applicable statutory requirements those most appropriate for use in this program.

Comment: Many commenters illustrated, directly or indirectly, that the proposed rule language (72 FR 38198 through 38199) reads to a

material proportion of reviewers as meaning or implying that a measure must be both adopted by the AQA "and" endorsed by the NQF to be included in the PQRI for 2008. Several of these comments also specifically requested clarification of the status of measures that will, as of the date CMS finalizes the list of 2008 PQRI quality measures, be AQA-adopted but not yet reviewed by NQF.

Response: In general, the consensus requirement under the MIEA-TRHCA is met if a measure is either NQF-endorsed or AQA-adopted. However, where an AQA-adopted measure has been specifically considered by NQF but declined for endorsement, we have not selected such measures for 2008. This derives from our stated preference for standards of a voluntary consensus standards organization (such as NQF) over an organization which does not (such as AQA). Also, as stated in the proposed rule (72 FR 38198), in the event of a determination by NQF to decline endorsement of a particular measure after it had been adopted by AQA, we anticipate that AQA would withdraw its adoption of that measure. Thus, a measure that has been AQA adopted and then reviewed by NQF with a decision to decline endorsement we would expect would, soon after the NQF decision, be *neither* NQF-endorsed *nor* AQA-adopted and therefore it would be undesirable to include a measure imminently destined to not retain approval of either consensus organization simply because we may have been identifying final 2008 measures during the brief period of lag between the NQF's decision to decline endorsement and the AQA's opportunity to reconsider its adoption of the measure.

To further clarify this point, of the measures proposed for 2008 (72 FR 38199 through 38202), the only ones that might be removed as a result of having been AQA adopted but then subsequently declined NQF endorsement are certain measures that were included in the 2007 PQRI on the basis of AQA adoption and that have since been declined for endorsement by NQF after specifically being considered.

For newly-proposed measures (those not part of the 2007 PQRI set), either NQF or AQA consensus endorsement or adoption is sufficient for PQRI. Most of these measures will have been adopted by the AQA but not yet reviewed by NQF. Others may have been endorsed by the NQF, but not yet adopted by the AQA.

Comment: One commenter suggested that the entirety of the PQRI section of the proposed rule could potentially be

construed to imply that there may be, based on which specific entities develop or own a measure, different levels of consensus-standard status required for measures to qualify for our consideration for inclusion in PQRI.

Response: The measure developer was listed for identification purposes only. This was necessary for measures that when proposed were still under development. The remaining measures that had achieved consensus endorsement or adoption were sufficiently identified by consensus organization, without listing the developer. The statutory requirements for consensus-organization adoption or endorsement, consensus-based development and statutory and policy preferences for measures that have achieved the status of voluntary consensus standards apply equally to all potential PQRI quality measures regardless of the organization type or specific identity of any given measure's developer or owner.

Comment: We received a large number of comments on the interpretation of the requirement of per Section 1848(k)(2)(B)(i) of the Act, that 2008 PQRI measures "shall be measures that have been adopted or endorsed by a consensus organization (such as the National Quality Forum or AQA)". These comments reflected a diversity of opinion amongst various stakeholders on key conceptual points related to the balance between rigor and flexibility in measure review and approval, as well as on the suitability of specific organizations for their roles as we define them in the PFS rule.

Many commenters encouraged us to rely solely on highly structured, scientifically rigorous processes for measure approval to promote stability in measures over time. Many other comments advised against requiring a degree of formality or scientific rigor in the review process that would unduly slow the availability and implementation of new quality measures to fill current gaps in professionals or clinical foci for which applicable measures exist.

Several commenters closely related to the recommendation of reliance on more rigorous review processes further suggested we identify a single voluntary consensus standards body to be considered qualified to establish measures as PQRI measures. The rationales provided for this suggestion include enhanced probability of a cohesive or coordinated universe of endorsed measures and prevention of endorsement of duplicate or near duplicate ("competing" or "conflicting") measures.

The value of having multiple consensus organizations available to approve measures was noted by many comments that were closely related to, or that were elaborating upon, maintaining flexibility and adaptability of the universe of available measures. These commenters included observations that setting requirements that limit the total available capacity for measure review will slow the development not only of specific additional quality measures but likely also innovative advancement in the science of health care quality measurement. Some of these commenters urged us to remain alert for the development of additional organizations into potential consensus organizations on par with the NQF or with the AQA as of the date MIEA-TRHCA was signed into law, and two commenters named two specific potential candidates that might choose to develop to that degree in the near future.

Response: We believe the existence of multiple consensus organizations promotes availability of a broad array of measures from which we can select those most appropriate for use in PQRI based on program policy goals. The availability of the AQA as a consensus organization meeting the requirements of MIEA-TRHCA, though it does not meet the full NTTAA and OMB A-119 criteria for a voluntary consensus standards body (VCSB), has proven important to the consensus development of the 2008 PQRI measures. Specifically, the AQA's more flexible and expeditious processes have made measures available on a shorter timeline than would be possible within the more rigorous processes of a VCSB. At present, we are able to identify only the NQF and the AQA as satisfying the consensus organization requirements of MIEA-TRHCA. Should additional organizations develop to feature consensus characteristics at least comparable to the level of openness, balance of interest, and broadly representative voting membership demonstrated by the AQA as of the date MIEA-TRHCA became law, we would consider measures endorsed by those organizations eligible for consideration for inclusion in PQRI.

We concur with the commenters identifying the desirability of alignment or harmony of quality measures across settings to more effectively promote overall CMS quality goals. We strive to achieve synergy between measures used in various settings and quality related initiatives to the extent practical.

Comment: Many commenters concurred with our interpretation that

NQF is a VCSB per NTTAA and OMB A-119. Several commenters also commended NQF for the scientific rigor of its structure and review processes. Some commenters in favor of establishing a single consensus organization entity whose approval would qualify a measure for PQRI inclusion went on to name NQF as the leading or only named candidate for such an organization. Simultaneously, multiple concerns were raised about the uneven (project-driven) NQF funding stream and its resultant potentially long or uncertain review timeframes, and the potential for this to impede measure development. Several comments also raised concern that the NQF's processes for review of physician-applicable measures are not yet as developed and predictable as those measures applicable to other types of providers. A few commenters noted that the NQF determinations on physician-applicable measures apparently vary unpredictably between workgroups and that the appeals process is not clearly identifiable.

Some comments recommended that CMS or another agency should provide steady core funding to the NQF on an ongoing basis.

Response: The NQF is currently the only organization we identified that reviews health care quality measures while simultaneously meeting the NTTAA and OMB A-119 definition of a VCSB. NQF processes for review and endorsement of physician-applicable measures are expected to develop and stabilize as it gains more experience with such measures. We will continue to monitor the NQF and its processes and work with NQF and its members to promote the prompt achievement of that growth.

The funding stream of the NQF is outside the scope of this rulemaking. The concerns raised over the current NQF funding mechanism and internal operational structures does, however, highlight the desirability of having an alternative source or multiple alternative sources of consensus-organization review of quality measures to assure that the measure has been vetted in a process that offers at least a reasonable degree of openness, balance of interests, and broad voting participation.

Comment: Multiple comments expressed concerns about the AQA's structure and original intended purpose not being ideally suited to its current role in PQRI, and its role in the measure endorsement process being confusing or its role not clearly adding value to the process. Multiple other comments commended the AQA as currently

structured, including its responsiveness, openness, breadth of participation, and utility as a forum for building consensus among stakeholders in quality measurement. Several comments also noted that the AQA is currently re-evaluating its structure, and recommended either that the AQA be required to restructure itself to meet the NTTAA and OMB A-119 criteria for a VCSB or that we reassess the AQA after any restructure to assure that it retains at least the comparable level of consensus-organization characteristics that it featured at the time MIEA-TRHCA became law.

Response: As noted above in this section, we interpret that the AQA currently meets the MIEA-TRHCA intended definition of a consensus organization for purposes of measure approval, as its mention in MIEA-TRHCA as an example of a consensus organization confirms it did at the time the statute was enacted. Further, we have expressed what we understand its value to be for the purpose of making quality measures available for consideration for inclusion in the PQRI. We do not have direct control over the AQA; requiring the AQA to take any specific action or restructure in any specific way would be outside the scope of CMS authority. However, we are observing the AQA's re-evaluation of its structure and will consider altering its role in relation to approval of future PQRI measures based on its resultant structure.

Comment: Several commenters requested we specifically define the minimum criteria to be a non-VCSB consensus organization meeting the requirements of MIEA-TRHCA.

Response: We have defined the requirement as being that an organization must possess a level of consensus-organization characteristics at least comparable to those of the AQA as of the date MIEA-TRHCA became law. To attempt to quantify or score an organization's level of consensus characteristics would be difficult to do in a way that was not misleading or arbitrary. The key features, as stated in the proposed rule (at 72 FR 38198), include openness, balance of interest, and consensus based on voting participation.

c. The Final 2008 PQRI Quality Measures

In the proposed rule (72 FR 38199), we solicited comments on the implications of including or excluding 148 specific quality measures in 7 broad categories. We received numerous comments both general and measure-

specific, which are summarized and addressed as follows.

Comment: Many comments on measure inclusion were general or conceptual and, in fact, mirrored comments on prioritization of measure development or endorsement.

Specific to measure selection, some commenters supported our including or excluding measures based on a targeted focus on specific gaps in care, while other commenters supported maximum inclusivity of conditions, services, and professionals. Some of the comments specific to measure selection stated two main perspectives: (1) We should set the priorities and/or prioritization process in collaboration with a maximally inclusive and representative cohort of stakeholders (to specifically include pharmaceutical, device, and information technology manufacturers and trade associations, as well as clinicians and consumers); and (2) the prioritization or selection of quality measures should be accomplished by a VCSB in a formal consensus process.

Response: In selecting measures, we have sought to achieve a broad opportunity for eligible professionals to participate, and to promote the quality goals forming the basis for the measures themselves. The general quality goal underlying the measures as developed is a performance gap relating to important processes or outcomes of care. While we agree that prioritized themes for quality improvement can be useful in certain contexts, for PQRI the scope of practice of the various eligible professionals varies significantly. Therefore, it would be difficult to limit measures selected to a few specific prioritized quality goals without also limiting the opportunity to participate. With respect to the role of a VCSB under MIEA-TRHCA, it is to achieve consensus endorsement of particular measures, rather than to prioritize measures for PQRI. The responsibility for selection of measures for PQRI is directed to the Secretary, based on proposing measures, soliciting public comment, and then finalizing the measures. Public comment could include the views of a VCSB as to which measures are most appropriate for PQRI based on quality goals or other considerations. These could then be considered, in conjunction with the other public comments and the program needs as determined by the Secretary, in finalizing the measures.

Comment: Several comments in context of measure selection urged us to select or prioritize for PQRI inclusion measures aligned or harmonized with those used in other governmental initiatives that focus other provider

types in addition to or instead of individual PQRI-eligible professionals.

Response: We concur with comments identifying the desirability of alignment or harmony of quality measures across settings to more effectively promote overall CMS quality goals. We strive to achieve such synergy among settings and initiatives to the extent practical.

Comment: We received several comments specifically commending or recommending inclusion of specific quality measures, including, but not limited to: Specific eyecare measures; vaccination and preventive services measures; diabetic foot and ankle measures; and perioperative care measures including venous thromboembolism(VTE) prophylaxis.

Response: All of the proposed measures strongly supported by multiple comments are included in the final 2008 measures listed below in this section.

Comment: We received many comments expressing concern that the following 2007 PQRI measure that has achieved NQF endorsement was not included in measures proposed for 2008: "Age Related Macular Degeneration: Dilated Macular Examination".

Response: As noted in the proposed rule's correction notice (72 FR 43581), the omission of this measure was a technical/editorial error that was corrected via that notice. The measure titled "Age Related Macular Degeneration: Dilated Macular Examination" is included in the final list in Table 7.

Comment: Several commenters recommended changes to specific quality measures' titles, definitions, and detailed specifications or coding. Many of these recommendations were based on alternative interpretations of clinical evidence or concerns about the utility of the measures. Some requests were specifically concerned that measures be expanded or constrained to include or exclude specific professionals from those to whom the measure may be applicable.

Response: Quality measures that have completed the consensus processes of NQF or AQA have a designated party (generally the developer/owner) who has accepted responsibility for maintaining the measure. In general, it is the role of the measure owner, developer or maintainer to make any changes to the basic elements of a measure. Examples of such basic elements would be the particular process of care covered by the measure, professional services to which the measure applies, or the diagnosis (or diagnoses) defining the denominator

population. A request to modify any basic elements of a measure should be addressed to the measure's maintainer. In addition, NQF has for its endorsed measures an established maintenance process which may be accessed. Measure maintenance and modification activities are conducted by the developers/owners and/or maintainers of measures outside the CMS rule-making process. In implementing the measures for PQRI, CMS may, when necessary, make certain technical modifications to assure that reporting and performance rates can be calculated. These technical modifications do not modify the basic elements of the measure and are carried out in collaboration with the measure developer/owner or maintainer.

Comment: Many commenters requested the inclusion for 2008 of additional measures not proposed as PQRI measures in the proposed rule. Measures requested included additional structural measures, additional measures of medication use appropriateness and compliance, measures applicable to additional clinical topics, and the measures identified in the proposed rule as mandatory for erythropoietin stimulating agent reimbursement in 2008.

Response: The MIEA-TRHCA requires that measures proposed for use in the 2008 PQRI be published in the **Federal Register** prior to August 15, 2007. We are also required by other applicable statutes to provide opportunity for public comment on provisions of policy or regulation that are established via notice and comment rulemaking. Measures that were not included in the proposed rule for inclusion in the 2008 PQRI that were recommended to CMS via comments on

the proposed rule have not been placed before the public with opportunity for the public to comment on them within the rulemaking process. When measures have been published in the **Federal Register**, but in other contexts and not specifically proposed as PQRI measures, such publication does not provide true opportunity for public comment on those measures' potential inclusion in PQRI. Thus, such additional measures recommended via comments on the proposed rule cannot be included in the 2008 measures MIEA-TRHCA requires be finalized via publication in the **Federal Register** by November 15, 2007. However, we have captured these recommendations and will have them available for consideration in identifying measure sets for future years' PQRI and other initiatives to which those measures may be pertinent.

The measures we identify for 2008 in this final rule with comment period will be final as of the effective date of this final rule, and no changes (no additions or deletions of measures) will be made after that date. However, as was done for 2007, we may make modifications or refinements, such as code additions, corrections, or revisions, to the detailed specifications for the 2008 measures until the beginning of the reporting period. Such specification modifications may be made through the last day preceding the beginning of the reporting period. The 2008 measures specifications will be available on the PQRI section of the CMS Web site at <http://www.cms.hhs.gov/pqri> when they are sufficiently developed or finalized, but in no event later than December 31, 2007. No further changes to the specifications will be made after the start of the 2008 reporting period. The measures' detailed specifications will include instructions for reporting and

identify the circumstances in which each measure is applicable.

The final 2008 PQRI Quality Measures are listed in Tables 7 through 13, and fall into 7 broad categories. The final measures for 2008 were selected based upon the following:

- The achievement of NQF endorsement or AQA adoption by the earlier of November 15, 2007, or the date of publication of this final rule with comment period;
- Identification in the proposed rule for use in 2008 with opportunity for public comment via the rulemaking process;
- Development completion in a sufficiently timely manner that implementation for 2008 would be practical;
- Their importance in relation to quality goals;
- Their meaningfulness as measures of quality;
- Their utility in the PQRI program such as through augmenting the scope of services provided by eligible professionals to which PQRI measures apply;
- The degree to which they meet the needs of the Medicare program and their functionality in terms of ability to be collected and calculated in the PQRI program;
- Statutory requirement for inclusion in quality measures for 2008.

(i) Measures Selected From the 2007 PQRI Quality Measures

We include in the final 2008 PQRI measures the following 2007 PQRI measures in Table 7, proposed as 2008 PQRI measures (72 FR 38199 through 38200). The measures in Table 7 include measures submitted by specialties, in compliance with section 1848(k)(2)(B) of the Act.

TABLE 7.—2007 PQRI MEASURES

Hemoglobin A1c Poor Control in Type 1 or 2 Diabetes Mellitus.
Low Density Lipoprotein Control in Type 1 or 2 Diabetes Mellitus.
High Blood Pressure Control in Type 1 or 2 Diabetes Mellitus.
Screening for Future Fall Risk.
Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD).
Oral Antiplatelet Therapy Prescribed for Patients with Coronary Artery Disease.
Beta-blocker Therapy for Coronary Artery Disease Patients with Prior Myocardial Infarction (MI).
Heart Failure: Beta-blocker Therapy for Left Ventricular Systolic Dysfunction.
Antidepressant Medication During Acute Phase for Patients with New Episode of Major Depression.
Medication Reconciliation.
Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older.
Characterization of Urinary Incontinence in Women Aged 65 Years and Older.
Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older.
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation.
Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy.
Asthma: Pharmacologic Therapy.
Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports.
Stroke and Stroke Rehabilitation: Carotid Imaging Reports.
Primary Open Angle Glaucoma: Optic Nerve Evaluation.

TABLE 7.—2007 PQRI MEASURES—Continued

Age-Related Macular Degeneration: Dilated Macular Examination.
 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy.
 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care.
 Perioperative Care: Timing of Antibiotic Prophylaxis—Ordering Physician.
 Perioperative Care: Selection of Prophylactic Antibiotic—First OR Second Generation Cephalosporin.
 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures).
 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (when indicated in All patients).
 Osteoporosis: Management Following Fracture.
 Osteoporosis: Communication with the Physician Managing Ongoing Care Post-Fracture.
 Aspirin at Arrival for Acute Myocardial Infarction (AMI).
 Electrocardiogram Performed for Non-Traumatic Chest Pain.
 Electrocardiogram Performed for Syncope.
 Vital Signs for Community-Acquired Bacterial Pneumonia.
 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia.
 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia.
 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia.
 Asthma Assessment.
 Perioperative Care: Timing of Prophylactic Antibiotics—Administering Physician.
 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage.
 Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy.
 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge.
 Stroke and Stroke Rehabilitation: Tissue Plasminogen Activator (t-PA) Considered.
 Stroke and Stroke Rehabilitation: Screening for Dysphagia.
 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services.
 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older.
 Osteoporosis: Pharmacologic Therapy.
 Use of Internal Mammary Artery (IMA) in Coronary Artery Bypass Graft (CABG) Surgery.
 Preoperative Beta-blocker in Patients with Isolated Coronary Artery Bypass Graft (CABG) Surgery.
 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures).
 Appropriate Treatment for Children with Upper Respiratory Infection (URI).
 Appropriate Testing for Children with Pharyngitis.
 Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow.
 Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy.
 Multiple Myeloma: Treatment with Bisphosphonates.
 Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry.
 Hormonal Therapy for Stage IC–III ER/PR Positive Breast Cancer.
 Chemotherapy for Stage III Colon Cancer Patients.
 Plan for Chemotherapy Documented Before Chemotherapy Administered.
 Radiation Therapy Recommended for Invasive Breast Cancer Patients Who Have Undergone Breast Conserving Surgery.
 Advance Care Plan.

Please note that detailed specifications for some 2007 PQRI measures may have been updated or modified during the NQF endorsement process during 2007. The detailed 2008 PQRI measure specifications for any given measure may, therefore, be different from detailed specifications for the same measure used for 2007. All specifications for 2008 measures must be obtained from the specifications document for 2008 measures, which will be available on the CMS PQRI Web site on or before December 31, 2007.

The following measures proposed for 2008 (72 FR 38200) are not included in the final 2008 PQRI measures listed in Table 7 because they have been considered by NQF and did not achieve endorsement:

- Dialysis Dose in End Stage Renal Disease (ESRD) Patients.
- Hematocrit Level in ESRD Patients.

Comment: We did not receive any comments specifically suggesting that any of the 2007 PQRI measures proposed for 2008 be removed from the

2008 PQRI measures. Some commenters suggested alternative measures apparently in addition to the measures we had proposed.

Response: We have not included in final 2008 PQRI measures any measures that were not identified in the proposed rule as proposed 2008 measures for the reporting system as required by Section 1848(k)(1) and 1848(k)(2)(B) of the Act. As discussed above in this rule, we were obligated by MIEA–TRHCA and other applicable statutes to publish and provide opportunity for public comment on proposed PQRI quality measures. Measures recommended via comments on the proposed rule that were not included in the proposed rule have not been placed before the public with opportunity for the public to comment on their potential use in PQRI. Thus, such additional measures recommended via comments on the proposed rule cannot be included in the 2008 measures MIEA–TRHCA requires be finalized via publication in the **Federal Register** by November 15, 2007.

However, we have captured these recommendations and will have them available for consideration in identifying measure sets for future years' PQRI and other initiatives to which those measures may be pertinent.

(ii) AMA—PCPI Measures

The measures listed in Table 8, which were developed via the American Medical Association (AMA) Physicians Consortium for Performance Improvement (PCPI), are finalized as 2008 PQRI measures as of the date of publication of this final rule with comment period. All of these measures were proposed as 2008 PQRI measures (72 FR 38200 through 38201). The measures listed in Table 8 achieved AQA adoption or NQF endorsement on or before October 31, 2007.

We will publish the detailed specifications for all final PQRI measures on the CMS PQRI Web site at <http://www.cms.hhs.gov/pqri> on or before December 31, 2007.

TABLE 8.—AMA/PCPI MEASURES FINALIZED FOR 2008 WITH CONSENSUS-ORGANIZATION APPROVAL BY 10/31/2007

Prevention of Ventilator-Associated Pneumonia—Head elevation.
 Prevention of Catheter-Related Bloodstream Infections (CRBSI)—Central Venous Catheter Insertion Protocol.
 ACE Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy in patients with CKD.
 Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile).
 Influenza Vaccination in patients with End Stage Renal Disease (ESRD).
 Vascular Access for patients undergoing Hemodialysis.
 Plan of Care for ESRD patients with Anemia.
 Plan of Care for Inadequate Hemodialysis in ESRD patients.
 Plan of Care for Inadequate Peritoneal Dialysis.
 Assessment of GERD Symptoms in Patients Receiving Chronic Medication for GERD.
 Testing of patients with Chronic Hepatitis C (HCV) for Hepatitis C Viremia.
 Initial Hepatitis C RNA Testing.
 HCV Genotype Testing Prior to Therapy.
 Consideration for Antiviral Therapy in HCV Patients.
 HCV RNA Testing at Week 12 of Therapy.
 Hepatitis A and B Vaccination in patients with HCV.
 Counseling patients with HCV Regarding Use of Alcohol.
 Counseling of patients Regarding Use of Contraception Prior to Starting Antiviral Therapy.
 Patients who have Major Depression Disorder who meet DSM IV Criteria.
 Patients who have Major Depression Disorder who are assessed for suicide risks.
 Patients with Osteoarthritis who have an assessment of their pain and function.
 Acute Otitis Externa (AOE): Topical Therapy.
 Acute Otitis Externa (AOE): Pain Assessment.
 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy—Avoidance of Inappropriate Use.
 Otitis Media with Effusion (OME): Diagnostic Evaluation—Assessment of Tympanic Membrane Mobility.
 Otitis Media with Effusion (OME): Hearing Testing.
 Otitis Media with Effusion (OME): Antihistamines or Decongestants—Avoidance of Inappropriate Use.
 Otitis Media with Effusion (OME): Systemic Antimicrobials—Avoidance of Inappropriate Use.
 Otitis Media with Effusion (OME): Systemic Corticosteroids—Avoidance of Inappropriate Use.
 Breast cancer patients who have a pT and pN category and histologic grade for their cancer.
 Colorectal cancer patients who have a pT and pN category and histologic grade for their cancer.
 Appropriate initial evaluation of patients with Prostate Cancer.
 Inappropriate use of Bone Scan for staging Low-Risk Prostate Cancer patients.
 Review of treatment options in patients with clinically localized Prostate Cancer.
 Adjuvant Hormonal therapy for High-risk Prostate Cancer patients.
 Three-dimensional radiotherapy for patients with Prostate Cancer.
 Chronic Kidney Disease (CKD): Blood Pressure Management.
 Chronic Kidney Disease (CKD): Plan of Care: Elevated Hemoglobin for Patients Receiving Erythropoiesis—Stimulating Agents (ESA).

The AMA PCPI measures that were proposed in Table 17 of the proposed rule (72 FR 38200 through 38201) were under development at the time the proposed rule was published. Several of these measures did not complete development or did not complete development in a sufficiently timely manner to permit implementation in the 2008 PQRI program. We have not included in the final PQRI measures listed in Table 8 the following proposed 2008 measures (from Table 17 of the proposed rule, 72 FR 38200 through 38201) for which development was not completed or not completed in sufficient time for implementation for 2008:

- Stress Ulcer Disease (SUD) Prophylaxis in Ventilated Patients
- Perioperative Temperature Management for Surgical Procedures Under General Anesthesia
- Assessment of Thromboembolic Risk Factors in patients with Atrial Fibrillation
- Chronic Anticoagulation in patients with Atrial Fibrillation
- Monthly INR Measurements in patients with Atrial Fibrillation

- GFR Calculation in patients with Chronic Kidney Disease (CKD)
- Permanent Catheter Vascular Access for patients Receiving Hemodialysis
- Patients with Osteoarthritis who receive Anti inflammatory or Analgesia Medication
- Documentation of hydration status in Pediatric Patients with Acute Gastroenteritis (PAG)
- Weight measurement in patients with PAG
- Recommendation of appropriate oral rehydration solution in PAG patients
- Education parents of PAG patients
- Perioperative Cardiac risk assessment (history)
- Perioperative Cardiac risk assessment (current symptoms)
- Perioperative Cardiac risk assessment (physical examination)
- Perioperative Cardiac risk assessment (electrocardiogram)
- Perioperative Cardiac risk assessment (continuation of Beta Blockers).

During completion of the measure development process, the measure developer eliminated the restriction to ventilated patients of the proposed (72 FR 38201) measure titled, “Prevention

of Catheter-Related Bloodstream Infections in Ventilated Patients—Catheter Insertion Protocol”. This measure is, therefore, listed in the Final 2008 PQRI measures in Table 8 as “Prevention of Catheter-Related Bloodstream Infections (CRBSI)—Central Venous Catheter Insertion Protocol”.

During completion of the measure development process, several of the measures proposed for 2008 in Table 17 of the proposed rule (72 FR 38200 through 38201) were combined into one measure by the measure developer. The final, combined measures contain the substantive components of each of the measures. The following is reflected in the Final 2008 PQRI Measures listed in Table 8:

- Proposed measures (72 FR 38201) titled “Blood Pressure Measurement in patients with CKD” and “Plan of Care for patients with CKD and Elevated Blood Pressure” were combined into the measure entitled “Chronic Kidney Disease (CKD): Blood Pressure Management.”
- Proposed measures (72 FR 38201) “Calcium, Phosphorus and Intact

Parathyroid Hormone Measurement in patients with CKD” and “Lipid Profile in patients with CKD” were combined into the measure in Table 8 entitled “Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile).”

- Proposed measures (72 FR 38201) “Hemoglobin Monitoring in patients with CKD” and “Erythropoietin Overuse in patients with CKD and normal Hemoglobin” were combined into the measure in Table 8 entitled “Chronic Kidney Disease (CKD): Plan of Care: Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA).”

During the measure development process, several measures listed in the proposed rule (72 FR 38201) as pertaining to the medical conditions Acute Otitis Externa (AOE) and Otitis Media with Effusion (OME) were narrowed to apply to only one or the other. The measure developer made these refinements as a result of more in-depth consideration of the evidence for the clinical relevance of each specific measure to each or either condition. Modifications to the measures’ titles reflect these decisions. Otitis Media with Effusion (OME) was eliminated from the proposed 2008 measures below. The revised measure titles are listed in Table 8 for each proposed 2008 measures:

- Measure proposed (72 FR 38201) as “Patients with Acute Otitis Externa (AOE) or Otitis Media with Effusion (OME) who receive Topical Therapy” is now entitled “Acute Otitis Externa (AOE): Topical Therapy.”

- Measure proposed (72 FR 38201) as “Patients with AOE/OME who have a pain assessment” is now entitled “Acute Otitis Externa (AOE): Pain Assessment.”

- Measure proposed (72 FR 38201) as “Patients with AOE/OME who are inappropriately prescribed antimicrobials” is now entitled “Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy—Avoidance of Inappropriate Use”. Acute Otitis Externa (AOE) was eliminated from the proposed (72 FR 38201) measures below. The revised measure titles are listed in Table J2 for each proposed 2008 measures.

- Measure proposed (72 FR 38201) as “Patients with AOE/OME who have an assessment of tympanic membrane mobility” is now entitled “Otitis Media with Effusion (OME): Diagnostic Evaluation—Assessment of Tympanic Membrane Mobility.”

- Measure proposed (72 FR 38201) as “Patients with AOE/OME who undergo

hearing testing” is now entitled “Otitis Media with Effusion (OME): Hearing Testing.”

- Measure proposed (72 FR 38201) as “Patients with AOE/OME who inappropriately receive antihistamines/decongestants” is now entitled “Otitis Media with Effusion (OME): Antihistamines or Decongestants—Avoidance of Inappropriate Use.”

- Measure proposed (72 FR 38201) as “Patients with AOE/OME who inappropriately receive systemic antimicrobials” is now entitled “Otitis Media with Effusion (OME): Systemic Antimicrobials—Avoidance of Inappropriate Use.”

- Measure proposed (72 FR 38201) as “Patients with AOE/OME who inappropriately receive systemic steroids” is now entitled “Otitis Media with Effusion (OME): Systemic Corticosteroids—Avoidance of Inappropriate Use.”

Comment: We received several comments from organizations involved in the measure development process noting that the measure titles as proposed in Table 17 of the proposed rule (72 FR 38200 through 38201) were incorrect or obsolete based on progress in measure development between the time the proposed rule went on display (July 2, 2007) and the date the commenters submitted their comment letters (various specific dates at the end of August, 2007).

Response: As stated above, the measure titles in Table 8 reflect the correct titles as of the conclusion of the development process preparing these measures for consensus-organization review in the late summer and early fall of 2007.

Comment: We received comments in support of certain measures listed in Table 8, such as the Chronic Kidney Disease measures. Other commenters suggested including additional measures not proposed as 2008 PQRI measures. No commenters opposed inclusion of any of the measures listed on Table 8.

Response: The measures from Table 16 of the proposed rule (72 FR 38200 through 38201) that were sufficiently completed in time for use in the 2008 PQRI are included in Table 8. As discussed above, several of the CKD measures proposed in Table 16 of the proposed rule (72 FR 38201) have been combined into with one another as listed in Table 8.

As iterated above in response to comments on measures in Table 7, we cannot include in the 2008 PQRI measures that were not published as proposed 2008 PQRI measures in the **Federal Register** by August 15, 2007.

We have, however, made note of the measures suggested and may consider them for inclusion in future quality-reporting initiatives to which they may be relevant.

(iii) Nonphysician Measures

We include measures in the final 2008 PQRI quality measures listed in Table 9 developed by Quality Insights of Pennsylvania (under the Medicare Quality Improvement Organization (QIO) contract for the State of Pennsylvania) that were proposed as 2008 PQRI measures in Table 18 of the proposed rule (72 FR 38201 through 38202). These measures were developed primarily to afford expanded reporting opportunities for NPPs who had few or no measures available in 2007. Some may also be applicable to physicians. The clinicians who could report each measure are identified in the measure’s detailed specifications, which will be available on the Measures/Codes page of the CMS PQRI Web site at <http://www.cms.hhs.gov/pqri> as far in advance of the 2008 reporting period as practical. We have not included in the final PQRI measures listed in Table 9 the following measures proposed in Table 18 of the proposed rule (72 FR 38201 through 38202) whose development was not completed in a sufficiently timely manner for implementation in the 2008 PQRI program:

- Universal Hypertension Screening.
- Universal Hypertension Screening Follow-up.

During completion of the measure development process, several of the measures proposed for 2008 in Table 18 of the proposed rule (72 FR 38201 through 38202) were combined into one measure by the measure developer. The final, combined measures contain the substantive components of each of the measures. The following is reflected in the Final 2008 PQRI Measures listed in Table 8:

- Proposed (72 FR 38201) measures titled “Universal Weight Screening (BMI)” and “Universal Weight Screening Follow-up (BMI)” were combined into the measure entitled “Universal Weight Screening and Follow-up.”

- Proposed (72 FR 38201) measures “Patient Co-development of Treatment Plan” and “Patient Co-development of Plan of Care” were combined into the measure in Table 8 entitled “Patient Co-development of Treatment Plan/Plan of Care.”

Comment: We received numerous comments pertaining to the measures proposed in Table 18 of the proposed rule (72 FR 38201 through 38202), now listed in Table 9 of this final rule with

comment period. Most of these comments addressed the scope of applicability of these measures to particular non-physician specialties, such as speech language pathologists (SLPs) and occupational therapists.

Response: The applicability of the final 2008 PQRI measures is dependent on whether the given practitioner can bill for the services identified by the procedures or services represented by the Current Procedural Terminology (CPT) Category I codes in the measure's denominator per its detailed specifications. The inclusion of specific procedures or services in a measure's denominator is determined during the measure development and consensus process, based on the clinical relevance of the measure to particular services/procedures. The determination of services/procedures to which a specific measure is relevant and therefore applicable is not subject to change via the rulemaking process. The measures in Table 9 achieved AQA consensus adoption on or before October 19, 2007. These measures have not yet been reviewed by the NQF.

We will publish the detailed specifications for all final PQRI measures, including these QIP nonphysician measures, on the CMS PQRI Web site at <http://www.cms.hhs.gov/pqri> on or before December 31, 2007.

TABLE 9.—QUALITY INSIGHTS OF PENNSYLVANIA NONPHYSICIAN MEASURES

Universal Weight Screening (BMI) and Follow-up.
Universal Influenza Vaccine Screening and Counseling.
Universal Documentation and Verification of Current Medications in the Medical Record.
Screening for Clinical Depression.
Screening for Cognitive Impairment.
Patient Co-development of Treatment Plan/Plan of Care.
Pain Assessment Prior to Initiation of Patient Treatment.

(iv) Structural Measures Currently Under Development

We include structural measures in the final 2008 PQRI measures listed in Table 10 developed by Quality Insights of Pennsylvania (under the Medicare Quality Improvement Organization (QIO) contract for the State of Pennsylvania), that were proposed as 2008 measures in Table 19 of the proposed rule (72 FR 38202). These measures meet the requirement of section 1848(k)(2)(B)(i) of the Act.

Comment: Numerous comments expressed support of the measures listed in Table 10. Other commenters stated a belief that there is a lack of scientific evidence to support the benefits of e-prescribing.

Response: As required by MIEA-TRHCA, the final 2008 PQRI measures shall include structural measures such as the use of EHRs and electronic prescribing technology. The determination of the sufficiency of the scientific basis for quality measures is part of the review and evaluation during the measure development and consensus processes. The measures are included in Table 10. These measures were adopted by the AQA on or before October 31, 2007.

TABLE 10.—QUALITY INSIGHTS OF PENNSYLVANIA STRUCTURAL MEASURES

HIT—Adoption/Use of E-Prescribing.
HIT—Adoption/Use of Health Information Technology (Electronic Health Records).

(v) Additional AQA Starter-Set Measures

We include measures in the final 2008 PQRI measures from the AQA starter set that were not included in the 2007 PQRI quality measures but that are relevant to Medicare beneficiaries and which we proposed as 2008 measures in Table 20 of the proposed rule (72 FR 38202). We have not included in the final 2008 measures listed in Table 11 the

following measure that was listed in Table 20 of the proposed rule (72 FR 38202), because its adaptation to the claims-based provider-self-reported format was not found to be feasible:

- Beta Blocker Therapy (persistent for 6 months or more) Post MI.

We received several comments in support of the measures listed in Table 20 of the proposed rule (72 FR 38202) and now listed in Table 11, as preventive care measures and measures related to smoking cessation.

TABLE 11.—ADDITIONAL AQA STARTER-SET MEASURES

Dilated eye exam in diabetic patient.
Screening Mammography.
Colorectal Cancer Screening.
Inquiry regarding Tobacco Use.
Advising Smokers to Quit.

(vi) Other NQF-Endorsed Measures

We include in the final 2008 PQRI measures other measures endorsed by the NQF that were not included in the 2007 PQRI quality measures but that were proposed as 2008 measures (72 FR 38202) and that are relevant to Medicare beneficiaries, address overuse/misuse of pharmacologic therapy, and/or that expand the specialty applicability and patient population. We have not included in the final PQRI measures listed in Table 12 the following proposed measure (72 FR 38202), because its adaptation to the PQRI format was subsequently not found to be feasible:

- Annual Therapeutic monitoring for patients on the following persistent medications: Angiotensin Converting Enzyme Inhibitor (ACE)/Angiotensin Receptor Blocker (ARB), Digoxin, Diuretics, Anticonvulsants; and Statins.

We received several comments in support of including the measures listed in Table 12. We did not receive any comments opposing the inclusion of any of the measures listed in Table 12.

TABLE 12.—OTHER NQF-ENDORSED MEASURES

Inappropriate antibiotic treatment for adults with acute bronchitis.
Disease Modifying Anti-rheumatic Drug Therapy in Rheumatoid Arthritis.
Angiotensin Converting Enzyme Inhibitor (ACE) or Angiotensin Receptor Blocker (ARB) Therapy for patients with coronary artery disease and diabetes and/or left ventricular systolic dysfunction (LVSD).
Urine screening for microalbumin or medical attention for nephropathy in diabetic patients.
Influenza vaccination for patients ≥ 50 years old.
Pneumonia vaccination for patients 65 years and older.

(vii) Podiatric Measures

We include measures in the final 2008 PQRI quality measures listed in Table 13 developed by the American Podiatric

Medical Association (APMA). These two measures are finalized as 2008 PQRI measures as of the date of publication of this final rule with comment period.

These measures were proposed as 2008 PQRI measures in Table 21 of the proposed rule (72 FR 38202), and were

adopted by the AQA on or before October 31, 2007.

A third proposed measure (72 FR 38202), titled “Diabetic Foot and Ankle Care, Peripheral Arterial Disease: Ankle Brachial Index (ABI) Measurement” has not achieved AQA adoption or NQF endorsement in time to be included in this final rule with comment period, and is therefore not included in the final 2008 PQRI quality measures.

Comment: A number of comments expressed support of these measures. We received comments requesting correction of the title of this topic and the substantive title/heading for the table from “Podiatric Measures” to “Diabetic Foot and Ankle Measures” to reflect the potential applicability of these measures beyond podiatrist. At the same time, we received comments that these measures are not applicable to orthopedic surgeons.

Response: We have retained the original measure-category title to reflect the developer, and thus the origin of the measures, rather than the scope of applicability. This identification of nomenclature is aligned with the nomenclature used for other categories of measures, such as those in Table 11, which are identified as originating in the AQA Starter Set rather than by the type of services to which they pertain. MIEA–TRHCA makes no presumption as to applicability based solely on measure title or specifications, let alone the categorization that may be applied to various groups of measures for identification and ease of reference. Rather, measures are presumed applicable to a practitioner based on the scope and pattern of practice of the physician reporting the measure in combination with its specifications.

TABLE 13.—PODIATRIC MEASURES

Diabetic Foot and Ankle Care, Peripheral Neuropathy: Neurological Evaluation.
Diabetic Foot and Ankle Care, Ulcer Prevention: Evaluation of Footwear.

d. Addressing a Mechanism for Submission of Data on Quality Measures via a Medical Registry or Electronic Health Record

(i) Addressing a Mechanism for Submission of Data on Quality Measures via a Medical Registry—Background and Summary of Proposed Rule

As explained in the proposed rule (72 FR 38202), section 1848(k)(4) of the Act, as amended by the MIEA–TRHCA, requires that “as part of the publication of proposed and final quality measures for 2008 under clauses (i) and (iii) of paragraph (2)(B), the Secretary shall

address a mechanism whereby an eligible professional may provide data on quality measures through an appropriate medical registry”.

In the proposed rule, we discussed what constitutes a medical registry and the general desirability of registries serving as an alternative to claims based reporting. We proposed to address reporting from medical registries by testing one or more of five mechanisms for such reporting during 2008, and requested comment on five options for data submission by registries. These options vary as to whether individual beneficiary-level data is submitted by the registry, as well as the number and type of data elements needed from the registry. The five options were described in detail in the proposed rule (72 FR 38203 through 38204).

The 2008 registry reporting is only a test of the feasibility and accuracy for the two selected submission options (identified as Options 2 and 3 in the proposed rule (72 FR 38203 through 38204)) and described again, in summary, below in response to comments. In order to qualify for the incentive bonus for PQRI data submission, practitioners will need to continue their quality data codes through the claims process.

(ii) Addressing a Mechanism for Submission of Data on Quality Measures via a Medical Registry—Summary of Comments and CMS’s Responses

Comment: The majority of the comments advocated the use of option 2, 3, or 5. There was not significant support for option 1 or option 4; instead the preponderance of comments on options 1 and 4 were in opposition to their implementation.

Response: We have decided to test options 2 and 3 in 2008.

We agree that option 1 should not be tested. Under this option only the quality data codes for selected PQRI measures would be reported by the registry without submission of associated diagnosis or service rendered. Under this option, the denominator information would have to be obtained from the claims and linked to the quality data codes submitted via the registry. This option would create an added administrative burden for the CMS systems that would need to link data from the two sources at the beneficiary or episode/encounter/procedure level.

We also agree that option 4 should not be tested. Option 4 would place significant burden upon practitioners, by requiring practitioners not only to submit claims to Medicare for the services provided, but also enter data

obtained from the explanation of benefits into the registry.

Option 5, which calls for a “data dump” was supported by some commenters as this option would potentially provide the most complete and robust set of data for purposes of clinical improvement. It could also be beneficial in evaluating a physician’s practice, particularly since it would not necessarily need to be limited to Medicare Part B beneficiaries or solely PQRI measures. Thus, while we agree that data submission via registry-based mechanisms in models such as Option 5 has significant potential over time because of the comprehensiveness of the data, we do not believe that this option is currently practical for implementation even on a test basis. We intend to continue to explore ways to enhance our ability to capture registry data so that it may be suitable for future use.

Under Option 2, the registry would provide the quality data codes and diagnosis codes and beneficiary identification (HIC) numbers or other limited beneficiary information for identification. Using the beneficiary information to match registry information to a submitted claim for a particular service, CMS would have the data needed to calculate a practitioner’s reporting and performance rates.

Under Option 3 the registry will calculate and submit reporting and performance rates for various measures to CMS, rather than have CMS calculate the rates. While this is compatible with the role of a registry in providing feedback to the physician, for future PQRI implementation, a validation process for the registry calculations would need to be in place and provided to CMS.

Comment: Many commenters requested that registry-based mechanisms for 2008 be made a fully operational alternative through which participants could achieve satisfactory reporting and quality for a 2008 PQRI incentive payment. Several commenters suggested we find a way to let participants in testing activities “get credit” toward PQRI reporting for their participation in the test.

Response: We proposed a test of registry submission (72 FR 38203 through 38204). It is not feasible or practical to implement registry submission without such testing. Any registries and any of their subscribers participating in any testing activities in 2008 will be participating in this data-submission testing on a strictly voluntary basis. Any registry seeking to participate in the testing should notify their subscribers to continue submitting

quality data codes on their Part B professional services claims in order to pursue PQRI bonus payments.

Comment: We received several comments requesting that a specific organization's registry be deemed or "certified" to satisfy PQRI reporting. Additionally, it was suggested that we implement a mechanism to make those professionals submitting data to the registry potentially able to qualify for a 2008 PQRI bonus payment on the basis of participating in the registry. We received several related comments suggesting we consider deeming specialty boards' maintenance of certification (MOC) programs so that successful participation in a deemed MOC would qualify a professional for a 2008 PQRI bonus payment.

Response: We believe that, in the long run, registries having such deemed status may be a very suitable and desirable way for quality data submission and measures calculation to be conducted for physicians and other practitioners. However, at the present time we do not find it feasible or practical to implement such a suggestion.

Comment: Several commenters encouraged us to maintain for the foreseeable future multiple options for PQRI participants to submit data, including claims based, as well as registry or EHR-based submission mechanisms. Some of these comments noted that the state of the art for medical registries is embryonic to nascent. Commenters also noted that the percentage of eligible professionals who use EHRs capable of successful data extraction and transmission to a CMS data warehouse is relatively low. Related comments recommended we develop a long term strategy that will be sufficiently flexible to allow for innovative developments in the registry field as it begins to grow in sophistication and market penetration.

Response: For 2008, claims-based submission will remain the only mechanism of PQRI quality measure data submission. We hope in future years to make alternative ECI-based submission mechanisms available. However, we recognize that for the near future, claims-based submission is likely to be the only mechanism that will provide an avenue for virtually all eligible practitioners to participate within PQRI. As a result, we would anticipate that claims based submission would be maintained.

Comment: Several commenters expressed concern that many registries are proprietary and charge a fee for using the registry. Commenters expressed concern about using

proprietary registries, specifically that such use raises potential antitrust (barrier to competition) issues, as well as barriers to participation by professionals who would have to subscribe to a proprietary registry. Several commenters urged that any CMS registry-based mechanism be in the public domain and supported by a public domain registry available to individual professionals.

Response: In the proposed rule, we discussed registry-based reporting as an alternative, not a requirement. We agree that physicians should not be required to use any particular proprietary service. Rather, the purpose in addressing registries is to allow physicians who find it desirable to submit data to registries to be able to avoid duplicate data submission to CMS through the claims process.

Comment: A few commenters expressed concern that creating new registries or altering existing interfaces would be burdensome and costly.

Response: We are not recommending developing new registries and any decision to do so should be made independently of PQRI. Nevertheless, there are currently various registries in existence which may, ultimately, be capable of interfacing with the CMS data warehouse. As has been previously discussed, for 2008, we will only be testing registry-based data submission. As envisioned for the future, registry-based submission of quality-measures data would be an alternative, not a requirement.

Comment: Some comments expressed concerns about transmitting patient data through registries or EHRs in context of applicable statutes, regulations, and policies protecting patient privacy.

Response: Preserving the confidentiality of patients' individually identifiable and protected health information is a high priority at CMS. Generally, personally identifiable data on individuals and/or their health are protected by the Privacy Act of 1974 and/or the Health Insurance Portability and Accountability Act of 1996 (Pub. L. 104-191) (HIPAA). HIPAA establishes protections specific to certain individually identifiable health information, and the Privacy Act establishes the protections specific to certain information that the government maintains which is individually identifiable. HIPAA and its extensive implementing regulations have established privacy and security standards for health care plans, health care clearinghouses, and providers that conduct electronic transactions covered by HIPAA. These entities are termed "covered entities". All patient registries,

EHRs, data transmission, and data storage done by or on behalf of a covered entity must be HIPAA compliant. The claims-based method of reporting currently uses patient identifiers for submission of quality data along with data required to process the provider's claim for payment. The use of registries or EHRs would require, for purposes of validation, the same information as currently used by the claims-based method of submitting quality-measures data.

(iii) Addressing a Mechanism for Submission of Data on Quality Measures Via a Medical Registry—Final Plan

For 2008, we will test Options 2 and 3 on a voluntary basis, based on self-nomination by the registries. Each registry participating in the testing of each option must maintain compliance with all applicable statutory and regulatory requirements and any contractual obligations to the professionals/providers for processing, storing, and transmitting the data required by the option.

Functionally, the registry would act as a data submission vendor for the eligible professional. A "data submission vendor" is defined for purposes of this rule as an entity that has permission from the eligible professional to provide medical registry data to the Quality Reporting System developed per the MIEA-TRHCA. This definition parallels the definition of "data submission vendor" as used in other programs, such as the Hospital Compare data-submission process, where examples of such vendors include Joint Commission Oryx vendors.

In the testing process, again in parallel to similar mechanisms already implemented for other provider types by CMS, we anticipate the registry, acting as a data submission vendor, will submit data to the CMS clinical data warehouse, using a CMS-specified record layout based on the quality measures' specifications as published by CMS. For purposes of this rule, the term "CMS clinical data warehouse" is defined as a clinical data warehouse designated by CMS for use in this testing. The exact warehouse infrastructure may vary between the testing activity in 2008 and any full implementation of registry-based data submission that may in the future follow from that testing.

Options 1 and 4 as described in the proposed rule will not be tested in 2008, and we do not envision any future consideration. Thus, they are not described in this rule. Option 5, while of potential interest for future consideration, is also not described

below. As options 2 and 3 will be tested in 2008, they are described below.

Option 2: Registries provide the quality codes and diagnosis codes. In testing this option, we will use claims data extracted from the National Claims History to capture the payment information at the NPI/Tax ID level. All PQRI reporting and performance calculations will be performed using registry data. The registries will, therefore, be required to include specific data elements in their databases in order to include the codes needed to calculate performance measures and to match registry data to claims data. Although not identified in the proposed rule, we have upon further technical analysis concluded that along with data elements previously identified, patient identifiers will also be needed from the registry under this option. Patient identifier data are needed specifically in order to allow matching of registry data with Medicare claims. It is our understanding that for many, if not all, registries, inclusion of at least the patient identifier data elements will represent an addition to their databases.

While developing and through the implementation of the testing phase we may discover additional data elements are needed to support reliably valid analyses. The following is a list of examples of the minimum data elements we believe will be needed from a registry under Option 2:

- Beneficiary/procedure-level data (ICD 9 and CPT codes)
- HCPCS quality-data codes (G codes and CPT category II codes and modifiers)
- NPI and Tax ID
- Date of service
- Beneficiary Date of Birth
- HIC number

Option 3: Registries calculate the reporting and performance rates for Medicare beneficiaries only, and submit these rates to CMS (that is, aggregate information by NPI within a Tax ID). We assume no beneficiary level information will be shared. Registries will be required to include data elements in their databases to capture either quality-data codes or the clinical data needed to compute the quality-data codes. Registries will be required to perform the necessary calculations to be able to submit completed numerator/denominators for both reporting and performance rates. Additionally, the registries must have a validation strategy in place.

For any option, the registry must maintain compliance with all applicable statutory or regulatory requirements and any contractual obligations to the

providers for processing, storing, and transmitting the data required by the option. To be considered an appropriate registry from which we can accept and process data for the purposes of calculating PQRI measures, a registry must also comply with the interoperability standards recognized by the Secretary, and therefore, applicable to HHS initiatives. Examples of standards recognized by the Secretary include Consolidated Health Informatics Initiative (CHI) standards and standards subsequently recognized by the Secretary under Executive Order 13410 in place of CHI standards. A description of the specific health informatics standards adopted by the Federal government, as well as the specific interoperability standards recognized by the Secretary, is available on the HHS Office of the National Coordinator for Health Information Technology (ONC) Web site at <http://www.hhs.gov/healthit/chiinitiative.html>.

We will request that registries interested in participating in the testing of the registry based quality data submission project self nominate. A letter stating the registries interest should be received by CMS by 6 PM, Eastern time, on January 4, 2008. Self-nomination letters should be sent to: "PQRI IT Testing Nomination", Centers for Medicare and Medicaid Services Office of Clinical Standards and Quality, Quality Measurement and Health Assessment Group, 7500 Security Boulevard, Mail Stop S3-02-01, Baltimore, MD 21244-8532.

We plan to select for testing, from the self nominees, a group of registries that comply with all applicable statutory and/or regulatory requirements, and any contractual obligations to the professionals/providers for processing, storing, and transmitting the data required by the option(s) tested. Registries selected must also comply with applicable system interoperability standards recognized by the Secretary and be technically capable of interfacing with the CMS clinical warehouse electronic data exchange interface. The number of registries selected for testing may be limited to those that are technically capable or those that already contain key minimum data elements for testing purposes. Additionally, the actual level of complexity and effort required for testing from the CMS data infrastructure may also limit registry participation in the testing phase. (Experience with other initiatives has suggested that some data submission vendors and their software are more easily interfaced and tested with the CMS data warehouse electronic data exchange interface than others.)

In addition to the requirements listed above in this section, any registry that self-nominates for 2008 testing must, at a minimum, have the following characteristics:

(1) Be able to separate and report information for Medicare beneficiaries only.

(2) Use at least 1 PQRI measure that is selected for 2008 inclusion. We will consider other measures recommended by specialty registries for possible future use in quality reporting and performance.

(3) Provide the data as outlined in the rule for the particular available option under which they are submitting data (that is, being able to report using option 2 and/or option 3).

(4) Have a validation process for their data.

(5) Have or have applied for a QualityNet Exchange account.

We expect that information on the results of the testing in 2008 will be posted on the CMS PQRI Web site at <http://www.cms.hhs.gov/pqri>.

(iv) Electronic Health Records (EHRs)

The proposed rule noted (72 FR 38204) that we would explore the operational feasibility of accepting clinical quality data for a limited number of PQRI measures from EHRs, and solicited comments on this concept. The summaries of, and our responses to, the numerous comments we received on this topic are presented at the end of this PQRI-specific section.

Having conducted further technical analyses and reviewed public comments received on the proposed rule, we have determined that we will, in 2008, partner with several self nominated EHR vendors/groups that we select to develop and test EHR clinical quality data submission. Since mechanisms for submission of electronic clinical data extracted from an EHR will only be for testing purposes in 2008, vendors should notify their clients that the practitioners will need to submit their quality data codes through the claims process to be eligible for a 2008 bonus payment.

EHR vendors/groups who wish to participate in the development and testing process may self-nominate by sending a letter to CMS expressing their interest. Self-nomination letters should be sent to: "PQRI IT Testing Nomination", Centers for Medicare and Medicaid Services Office of Clinical Standards and Quality, Quality Measurement and Health Assessment Group, 7500 Security Boulevard, Mail Stop S3-02-01, Baltimore, MD 21244-8532.

The letter must be received by CMS by 6 p.m., e.s.t., on January 4, 2008. Vendors who are selected for this process must:

(1) Be able to submit data according to the HL7 technical specifications for submission of data to the Outpatient Clinical Warehouse, as defined for the Doctor's Office Quality—Information Technology (DOQ-IT) Project; and

(2) Have or have applied for a QualityNet Exchange account.

As with registry-based mechanisms, vendors and their customers (eligible professionals) who choose to participate in the testing in 2008 will be doing so on a strictly voluntary basis. We will continue to express this, and will urge EHR vendors to explain this to their customers when seeking volunteers to participate in the testing with them.

For more information on required capability (1), above, please see the QualityNet Exchange User's Guide, and the DOQ-IT measures' technical specifications (as implemented in the DOQ-IT project), both available for download free of charge from <http://qualitynet.org>. Additionally, 5 overlapping DOQ-IT and PQRI quality measures have been updated for potential use in the 2008 testing. The updated detailed technical specifications for these five DOQ-IT/PQRI overlapping measures are available for download from the 2008 PQRI Information page of the CMS PQRI Web site at <http://www.cms.hhs.gov/pqri>.

Comment: Numerous comments were received regarding accepting clinical quality data from EHRs for use in PQRI. While some commenters opposed the idea of using EHR-derived data in PQRI, the majority of responses were in favor of accepting clinical quality data from an EHR.

Response: Although we will be unable to offer EHR-based data submission mechanism on other than a test basis, we are encouraged by the generally positive response to the pursuit of this option due to its substantial potential to enhance data quality and reduce data collection burden on providers.

Comment: Numerous comments expressed concerns about data security, especially as it pertains to patient privacy, and patient privacy as it relates to CMS use of the quality data, in the context of EHR-based data submission mechanisms.

Response: Preservation of patient confidentiality is imperative. It is the inescapable responsibility of every party that collects, stores, handles, or uses patients' personally identifiable health information for any purpose. In order to participate in the 2008 testing, all

participating parties must be able to ensure that uses and disclosures of protected health information EHRs, data transmission mechanisms, and data receipt and storage systems will be in compliance with all applicable statutes and regulations and any contractual obligations to the professionals/providers for processing, storing, and transmitting the data required by each option tested. Moreover, although EHR submission may involve identifiable personal health information, that information is limited to what is minimally necessary to be able to audit the data accuracy and completeness in addition to the particular clinical information (lab values, vital sign values, documentation of a procedure or test ordered or performed) necessary to calculate the performance measure. It does not involve submitting the entire patient medical record, and it is possible that the information as transmitted can have the patient's actual identifying information (for example, name, and HIC number) "masked" by using a practice-internal chart ID # or other method that still allows for accurate audit.

Comment: Multiple comments urged us to develop and implement EHR-based data submission mechanisms in a way that minimizes the burden such submission might impose.

Response: We agree that data submission burden is an important factor to consider in PQRI data submission.

Comment: We received several comments expressing concern over professionals losing "control" of patient records as a result of EHR-based PQRI quality data submission. The comments appeared to assume that our plan was either to import and maintain within our data warehouse entire patient medical records or to implement an interface that would allow our warehouse to access and mine the data from patients' medical records.

Response: The patient's health record is populated and maintained in a practitioner's office, regardless of whether its content is stored on paper or electronic format or media. Nothing in this rule affects the rights of patients or practitioners with respect to the information contained in a patient's health record.

We plan to accept clinical data that is extracted from medical records and then submitted to us by a professional (or a data-submission vendor acting on a professional's behalf).

We would not attempt to upload entire medical records into the data warehouse, only the data elements minimally necessary to accomplish the

purposes of PQRI. We do not plan to enable our system to directly mine data from the practice's medical records database; that will need to be accomplished by the professional or a data vendor acting on the professional's behalf. The data submission requires an affirmative action on the part of the professional to submit the data or to instruct his or her data submission vendor to submit the data to our warehouse.

2. Section 110—Reporting of Hemoglobin or Hematocrit for Part B Cancer Anti-Anemia Drugs (§ 414.707(b))

Medicare Part B provides payment for certain drugs used to treat anemia. Anemia is common in cancer patients and may be caused by either the cancer itself or by various anti-cancer treatments, including chemotherapy, radiation therapy, and surgical therapy. Anemia occurs when the number of red blood cells is reduced by an anti-cancer treatment. This happens due to the effect of chemotherapy or radiation therapy on the bone marrow, wherein red blood cells are produced by dividing precursor cells. This chemotherapy effect is commonly referred to as "bone marrow suppression." Anemia may also result from blood loss in association with surgical therapy for the cancer.

Anemia adversely impacts the quality of life for beneficiaries being treated for cancer. Fatigue and reduced performance capacity are the side effects of anemia that cancer patients report as the most disabling and contributing to poor quality of life. The treatment of anemia in cancer patients commonly includes the use of drugs, specifically erythropoiesis stimulating agents (ESAs) such as recombinant erythropoietin and darbepoietin. Although other pharmacologic interventions are available, ESAs are the most commonly used drugs to treat anemia in this setting. Notably, recent research has prompted a Black Boxed warnings in the labels for ESAs, noting significant adverse effects including a higher risk of mortality and tumor progression in some populations.

In 2006, we implemented a revised ESA claims monitoring policy based on the last hemoglobin or hematocrit value from the preceding month on Medicare claims for payment of ESAs administered to beneficiaries with anemia due to end-stage renal disease (ESRD) receiving dialysis treatments in facilities. For many years prior, we have required the reporting of these red blood cell indicators on the Medicare claims by ESRD facilities to ensure that the beneficiaries' anemia was addressed.

Section 110 of the MIEA-TRHCA amends section 1842 of the Act by adding a new subsection (u) that reads as follows: "Each request for payment, or bill submitted, for a drug furnished to an individual for the treatment of anemia in connection with the treatment of cancer shall include (in a form and manner specified by the Secretary) information on the hemoglobin or hematocrit levels for the individual." Section 110 of the MIEA-TRHCA requires such reporting for drugs furnished on or after January 1, 2008. In addition, subsection (b) directs the Secretary to use the rulemaking process under section 1848 of the Act to address the implementation of this requirement.

By requiring the reporting of anemia quality indicators for Medicare Part B anti-anemia drugs that are used in the context of cancer treatment, we will facilitate assessment of the quality of care for this condition. We will use the information reported to help determine the prevalence and severity of anemia associated with cancer therapy, the clinical and hematologic responses to the institution of anti-anemia therapy, and the outcomes associated with various doses of anti-anemia therapy.

While not specifically addressing other indications, the recent research on the adverse effects of ESAs in patients with cancer does raise concerns as to whether patients receiving ESAs for other conditions, such as in the treatment of HIV-AIDS and for some surgical patients, are also at higher risk. We solicited public comment on the potential of expanding this regulation to include all uses of ESAs.

Comments and Responses

In general, commenters responded favorably to requiring the reporting of the most recent hemoglobin or hematocrit level on claims seeking payment for the administration of ESAs for all uses. One commenter supported broadening the requirement for reporting hemoglobin and hematocrit levels for all ESA claims and stated that such requirements would provide valuable data concerning reasonable care. The commenter stated that any new information on the use of ESAs for other, non-cancer diseases gained by the data collection would be helpful in understanding the effects of ESA use in different diseases. Another commenter supported the broad goal of gathering the information to improve the quality of care. Thus, in light of the potential adverse events from ESA use and in accordance with our reading of Congressional intent, we believe it is appropriate to require reporting of the

hemoglobin or hematocrit with respect to all ESA claims, and therefore, we have revised the regulations text to reflect this policy in this final rule with comment period.

Most commenters' concerns were limited to the implementation of the requirement and possible subsequent undue administrative burden placed on providers. A few commenters addressed a recently published National Coverage Determination on the use of ESAs for certain patients and others included comments related to our ESAs claims monitoring policy (EMP). We are not addressing those comments in this final rule with comment period as the issues are outside the scope of this regulation.

Comment: A commenter recommended that we exercise caution in implementing the anemia quality indicator secondary to a recent Food and Drug Association (FDA) Black Boxed Warning (BBW) on the use of ESAs. The commenter noted that anemia measures were removed from the Physician Consortium for Performance and Improvement ESRD measurement set pending further clarification by either the FDA or the National Kidney Foundation.

Response: This final rule with comment period does not establish new or additional standards related to anemia or the administration of ESAs. It simply mandates the reporting of the most recent hemoglobin or hematocrit level on claims for payment of the administration of ESAs to treat anemia. Similar to claims for ESAs administered in renal dialysis facilities, the requirement to report a recent hemoglobin or hematocrit on claims for the administration of ESAs for any use is not a development of a clinical standard. Thus, we believe that collecting this information will not impact nor be impacted by any consensus standard organizations' development of practice standards, quality measures or new scientific evidence.

Comment: A commenter asked that we clarify if the reporting requirement applies to all anemia treatment, which includes, but is not limited to, the use of ESAs.

Response: The statutory requirement does not limit the scope to ESAs. We recognize that other drugs and vitamin and mineral supplements such as Vitamin B12, folic acid, and iron may also be used in the treatment of anemia. ESAs are only FDA approved for the treatment of anemia while the other agents are commonly used to treat a variety of conditions other than anemia. Vitamin and mineral supplements are commonly self administered and we

expect that most uses of these agents would not result in claims for Medicare payment in the context of the treatment of anemia related to anti cancer therapy. However, if payment is requested for these anti-anemia drugs furnished to an individual for the treatment of anemia in connection with the treatment of cancer, we believe that they are within the scope of the statute.

We believe that the reporting of hemoglobin or hematocrit levels on claims for ESAs is consistent with Congressional intent that quality indicator data be submitted for patients receiving anti-anemia drugs and to ensure that anemia is addressed.

Comment: Several commenters recommended that we provide clear instruction on the scope and reporting of the hemoglobin or hematocrit levels.

Response: We will use the change request process to issue implementing instructions to Medicare contractors. Instructions to Medicare contractors include requirements for provider education.

Comment: Several commenters expressed concern that the requirement will be burdensome for providers. One commenter asked that we delay the implementation of this requirement until the administrative burden to practitioners is understood.

Response: We do not have the authority to delay the effective date of the statutory requirement. In addition, we believe that reporting the most recent hemoglobin or hematocrit level on a claim for ESA will not result in undue administrative burdens on providers. Many local Medicare contractors already require such reporting for claims submitting within their jurisdictions. ESRD providers have been reporting hemoglobin or hematocrit levels on claims for ESAs for several years.

Comment: A commenter recommended that should we broaden the reporting requirement to all ESA use and that we should assess minimal data sets for understanding how beneficiaries with various underlying conditions respond to a particular course of anemia management.

Response: We appreciate the recommendation and shall review available data sets when assessing responses to anemia management.

Comment: A commenter recommended that we include anemia quality indicators in the Physician Quality Reporting Initiative (PQRI) data reporting.

Response: This comment is addressed above in the section of this final rule specific to 2008 PQRI measures. The identification or establishment of PQRI

measures is not within the scope of this section of this final rule with comment period.

Comment: A commenter asked that retail pharmacies be exempt from this requirement.

Response: The MIEA TRHCA does not provide for any exemption for retail pharmacies.

Comment: One commenter asked that we clarify whether a provider may report a hematocrit or hemoglobin level.

Response: A provider seeking payment for ESAs may report the patient's most recent hematocrit or hemoglobin level on the claim.

Comment: Several commenters asked that we clarify the requirement to report "the most recent" hemoglobin or hematocrit level. They expressed concern that we may require a patient to have a hemoglobin or hematocrit level drawn each time an ESA is administered.

Response: We are not determining in this regulation when a hematocrit or hemoglobin level should be drawn to inform a provider's decision to administer ESA therapy. The requirement is that "the most recent" hemoglobin or hematocrit level be reported on the claim. Thus, the provider should report the most recent level preceding the ESA administration. We recognize that in some instances the same hemoglobin or hematocrit value might be reported on more than one claim.

Comment: Several commenters stated that we should permit providers to report hematocrit or hemoglobin levels in either box 19 or 24A of the CMS 1500 form. The CMS 1500 form was recently modified to allow reporting in box 24A; however, many providers utilize billing vendors that provide software and are unable to modify their product in time for the January 1, 2008 implementation.

Response: We will consider this information when developing claims processing systems instructions.

Comment: One commenter suggested that we employ Q codes for reporting the most recent hemoglobin or hematocrit levels. The commenter stated that permitting a provider to report the level in box 19 would not allow an automated extraction of the data element (the hemoglobin or hematocrit level) for data analysis.

Response: We are working with claims processing systems to ensure appropriate retrieval of data sets.

3. Section 104—Extension of Treatment of Certain Physician Pathology Services Under Medicare

The technical component (TC) of physician pathology services refers to

the preparation of the slide involving tissue or cells that a pathologist will interpret. (In contrast, the pathologist's interpretation of the slide is the professional component (PC) service. If this service is furnished by the hospital pathologist for a hospital patient, it is separately billable. If the independent laboratory's pathologist furnishes the PC service, it is usually billed with the TC service as a combined service.)

In the CY 2000 PFS final rule with comment period (64 FR 59408 through 59409), we stated that we would implement a policy to pay only the hospital for the TC of physician pathology services furnished to hospital patients. Before that provision, any independent laboratory could bill the carrier under the PFS for the TC of physician pathology services for hospital patients. As stated in the CY 2000 PFS final rule with comment period (64 FR 59408 through 59409), this policy has contributed to the Medicare program paying twice for the TC service, first through the inpatient prospective payment rate to the hospital where the patient is an inpatient and again to the independent laboratory that bills the carrier, instead of the hospital, for the TC service.

Therefore, in the CY 2000 PFS final rule with comment period (64 FR 59408 through 59409), in § 415.130, we specified that for services furnished on or after January 1, 2001, the carriers would no longer pay claims to the independent laboratory under the PFS for the TC of physician pathology services for hospital patients.

Ordinarily, the provisions in the PFS final rule with comment period are implemented in the following year. However, in this case, the change to § 415.130 was delayed 1 year (until January 1, 2001), at the request of the industry, to allow independent laboratories and hospitals sufficient time to negotiate arrangements. Moreover, our full implementation of § 415.130 was further delayed by section 542 of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (Pub. L. 106-554) (BIPA) and section 732 of the MMA, which directed us to continue payment to independent laboratories for the TC of physician pathology services for hospital patients through CY 2006.

In the CY 2007 PFS final rule with comment period (71 FR 69700), we announced that beginning January 1, 2007, we would no longer allow the carriers to pay the independent laboratory for the TC of physician pathology services to hospital patients. In effect, we would be: (1) Implementing the provisions of the CY 2000 PFS final

rule with comment period whose implementation had been delayed by section 542 of the BIPA and section 732 of the MMA; and (2) ensuring that the Medicare program does not make duplicate payments for the same service.

Subsequent to publication of the CY 2007 PFS final rule with comment period, the MIEA-TRHCA was enacted. Section 104 of the MIEA-TRHCA provided for an additional 1 year extension to allow carriers to continue to pay independent laboratories under the PFS for the TC portion of physician pathology services furnished to patients of a covered hospital.

Consistent with this legislative change, we are amending § 415.130(d) to specify that for services furnished after December 31, 2007, an independent laboratory may not bill the carrier for the TC of physician pathology services furnished to a hospital inpatient or outpatient.

Comment: Many commenters asked us to implement the grandfather provision on a permanent basis, and if this cannot be accomplished administratively, the commenter requested that we implement this provision no earlier than July 1, 2008. The commenter indicated that this delay would allow the grandfathered independent laboratories the opportunity to implement new billing requirements and inform customers of this change.

Response: We will delay implementation of this provision only if legislation is enacted requiring a further delay. Otherwise, we will, as explained in the CY 2008 PFS proposed rule, implement this provision effective for TC services furnished on or after January 1, 2008.

Comment: A commenter indicated a potential problem in the preamble language of the CY 2008 PFS proposed rule that explains the implementation of the TC physician pathology provision effective January 1, 2008. In the CY 2008 PFS proposed rule, the preamble reads, "Consistent with this legislative change, we are amending § 415.130(d) to reflect that for services furnished after December 31, 2007, an independent laboratory may not bill the carrier for physician pathology services furnished to a hospital inpatient or outpatient" (72 FR 38205). As currently written, this language would mean that the independent laboratory cannot bill the carrier for the PC of physician pathology services for hospital patients, an unintended result.

Response: The preamble inadvertently omitted the term "technical component" and should read, "For

services furnished after December 31, 2007, an independent laboratory may not bill the carrier for the *technical component* of physician pathology services furnished to a hospital inpatient or outpatient." We proposed this language in the regulations text of the proposed rule and are finalizing this language in this final rule with comment period.

4. Section 201—Extension of Therapy Cap Exception Process

Section 1833(g)(1) of the Act applies an annual per beneficiary combined cap beginning January 1, 1999, on outpatient physical therapy and speech-language pathology services, and a similar separate cap on outpatient occupational therapy services. These caps apply to expenses incurred for the respective therapy services under Medicare Part B, with the exception of services furnished as outpatient hospital services. Section 1833(g)(2) of the Act provides that, for CY 1999 through CY 2001, the caps were \$1500, and for the calendar years after 2001, the caps are equal to the preceding year's cap increased by the percentage increase in the Medicare Economic Index (MEI) (except that if an increase for a year is not a multiple of \$10, it is rounded to the nearest multiple of \$10).

The cap for CY 2008 will be \$1810 per beneficiary for PT and SLP services combined, and \$1810 for OT services. Therapy caps apply to expenses incurred for therapy services in all outpatient settings except the outpatient hospital department. As explained below in this section, the statute requires that we implement the therapy caps without providing for an exceptions process beginning on January 1, 2008.

Section 5107(a) of the DRA required the Secretary to develop an exceptions process for the therapy caps effective for expenses incurred during CY 2006. Details of the CY 2006 exceptions process were published in a manual change on February 13, 2006 (CR4364, which consists of Transmittal 855, Transmittal 47, and Transmittal 140). Section 201 of the MIEA-TRHCA extended the exceptions process to apply for expenses incurred through December 31, 2007. Therapy cap exception policies for 2007 were specified in Change Request 5478 which consists of three transmittals with current numbers of—

- Transmittal 1145CP, Pub. 100-04;
- Transmittal 63BP, Pub. 100-02; and
- Transmittal 181PI, Pub. 100-08.

The transmittals are incorporated into the Internet Only Manuals available at <http://www.cms.hhs.gov/Manuals> and

are also available on our Web site at <http://www.cms.hhs.gov/Transmittals/>.

In accordance with the statute as amended by the MIEA-TRHCA, we will continue to implement therapy caps, but the exceptions process will no longer be applicable for expenses incurred for services furnished beginning on January 1, 2008. As noted previously in this section, under current law, therapy caps will continue to apply to expenses incurred for therapy services after December 31, 2007, with one exception. That is, in accordance with section 1833(g) of the Act, the therapy caps will remain inapplicable to expenses incurred for therapy services furnished in the outpatient hospital setting.

We received several comments on this proposal.

Comment: Most commenters understood that we have no authority to change therapy caps, but still commented in favor of repealing them. Some commenters supported the continuation of the exceptions process as a well-conceived method of eliminating unnecessary treatment. Some commenters objected to the inapplicability of the caps for therapy expenses incurred in the outpatient hospital setting. One commenter supported the repeal of therapy caps and stated it is not an effective cost control when a steady source of replacement patients is available.

Another commenter opposed the policy underlying the statutory provision to apply a financial cap on therapy services. The commenter cited other means of ensuring appropriate utilization of therapy services including CCI edits, edits required by the Deficit Reduction Act, local coverage determination policies, and Transmittal 63, which required greater documentation. The commenter indicated that we are effectively achieving the objective to assure appropriate utilization of therapy services without the financial caps.

Response: We do not have the authority to repeal therapy caps, to change the exception to applicability of the caps for services provided in the outpatient hospital setting, or to extend the therapy cap exceptions process beyond the period for which was made applicable by statute (CYs 2006 and 2007).

Comment: Several commenters urged CMS to implement the recommendations contained in the Computer Science Corporation (CSC) Outpatient Therapy Service Pilot Report of 2006 to collect patient-specific data using available measurement tools. Although they acknowledged that we may have concerns about the use of

proprietary tools, the commenter urged the use of therapy-specific tools already on the market that were recommended by both CSC and MedPAC, including the National Outcomes Measurement System.

Response: In evaluating alternative payment systems, we will consider all methods of obtaining the required patient-related information including reports of past and future contract deliverables.

Comment: Many commenters are deeply concerned about the negative impact the caps would have, in the absence of the exceptions process, on an estimated 14.5 percent of the physical therapy (PT) users who would exceed the cap. The commenters commended CMS for progress made toward alternatives to the financial caps in recent years and urged a high priority in resources and funding to continuing research to identify alternatives that would also ensure access to medically necessary therapy services. The commenters support the collection of patient outcome data with patient assessment tools and use of risk adjustment to account for individual differences. They support the ongoing study for which CMS recently issued a Request for Task Order (RTOP-CMS-07-033) and look forward to participating in the study.

Many commenters reported that they will be collecting and reporting outcome data before January 1, 2008. They urged CMS to use clinical outcome data to determine the amount of care needed by individuals and offered assistance in data collection.

Response: We recently issued a request for proposals (RTOP-CMS-07-033) to continue our study of therapy services. The study will: (1) Identify, collect and use therapy-related information that is tied to beneficiary needs and treatment effectiveness; and (2) develop payment method alternatives to the current cap on outpatient therapy services.

We welcome any information concerning clinical outcome data studies from providers or suppliers. If the information is applicable to our deliberations on payment alternatives, we will consider it along with the results of past and future contract deliverables.

Comment: One commenter recommended that we continue to collect outpatient therapy utilization information for 2006 and 2007.

Response: We contracted with the CSC (HHSM-500-2007-00322G) to extract 2006 therapy utilization data and provide a high level analysis. To the extent possible, we intend to further

study the impact of therapy caps including the 2006 exceptions process.

5. Section 101(d)—Physician Assistance and Quality Initiative (PAQI) Fund

Section 1848(l) of the Act, as added by section 101(d) of the MIEA—TRHCA requires the Secretary to establish a Physician Assistance and Quality Initiative (PAQI) Fund (the Fund) which shall be available for physician payment and quality improvement initiatives, and which may include application of an adjustment to the update of the PFS conversion factor (CF). The provision makes available \$1.35 billion to the Fund for services furnished during CY 2008. Specifically, the provision directs the Secretary to provide for expenditures from the Fund in a manner designed to provide (to the maximum extent feasible) for the obligation of the entire \$1.35 billion for payment for physicians' services furnished during CY 2008. The provision also requires that if expenditures from the Fund are applied to, or otherwise affect, a CF for a year, the CF for a subsequent year shall be computed as if the adjustment to the CF had never occurred. We note that the Transitional Medical Assistance, Abstinence Education, and Qualifying Individual Programs Extension Act of 2007 (Pub. L. 110–90) recently was signed into law and it provides an additional \$325 million to be used as a part of the PAQI Fund for payment with regard to services furnished in 2009 and \$60 million for payment for physicians' services furnished on or after January 1, 2013. The legislation does not make any other changes to the program, and therefore, remains as discussed in the proposed rule.

As the MIEA—TRHCA legislation indicates, this Fund can be used for physician payment and quality improvement, including application of an adjustment to the update of the conversion factor. In the CY 2007 PFS proposed rule, we proposed to use the \$1.35 billion to fund bonus payments to be made during CY 2009 for physician reporting of measures during CY 2008. Specifically, we proposed that the physician quality initiative for CY 2008 be structured and implemented in the same manner as the 2007 PQRI with regard to the professionals eligible to participate in the program, reporting quality measures via claims submission, and the standards for satisfactory reporting.

The differences between CY 2007 and CY 2008 that we currently anticipate are noted below in this section. As we monitor the implementation of the 2007 PQRI and possibly make refinements to

the 2007 program, we anticipate that such refinements would also apply under the 2008 program. Such refinements, should they be needed, will be noted with guidance linked from the CMS quality reporting Web site at <http://www.cms.hhs.gov/PQRI>.

As with the 2007 PQRI, we proposed that eligible professionals who successfully report a designated set of quality measures in 2008 may earn a bonus payment of a percentage of total allowed charges for covered Medicare services, subject to a cap based on the volume of quality reporting. In contrast to 2007, we proposed that eligible professionals could report applicable measures for services furnished from January 1, 2008 through December 31, 2008, and allowed charges during such period would be the basis for calculating the bonus payments. We proposed that the CY 2008 measures that we finalize in this final rule with comment period would apply for CY 2008. We also proposed to estimate all of the bonus payments that would be payable to physicians using the same method as the one used for reporting during 2007 and to calculate the amount of the bonus payment, after the close of CY 2008 reporting period. Given that we proposed to use the PAQI Fund for the 2008 PQRI program, we also proposed that the bonus payments to individual physicians be subject to an aggregate cap of \$1.35 billion. Because we proposed to scale aggregate payments to physicians in a manner such that Medicare would pay \$1.35 billion during CY 2009 for measures reported for services furnished during CY 2008, we were unable to provide an exact percentage for the bonus payment. However, we anticipated that the bonus payments would be approximately 1.5 percent of allowed charges for participating professionals (and we did not expect that the ultimate percentage amount would exceed 2 percent).

Comment: Comments received on the proposed rule were generally opposed to using the PAQI Fund for CY 2008 PQRI bonus payments. Almost all comments on this issue requested that we use the entire \$1.35 billion to help offset the estimated negative 9.9 percent physician update for CY 2008.

Response: In the CY 2007 PFS proposed rule, we acknowledged this alternative approach of using the \$1.35 billion in some manner to reduce the update to the PFS of negative 9.9 percent that is projected for CY 2008. However, we noted that there are fundamental operational problems with this approach that make it not feasible. The \$1.35 billion is a fixed dollar amount. Once the amount is reached,

there is no authority to pay any more than that amount. Medicare is an entitlement program that covers medically necessary services for eligible beneficiaries, but such coverage is not limited to a fixed dollar amount for a year. While we estimate that the \$1.35 billion would reduce the negative update by approximately 2 percentage points, actual spending could be above or below the estimate. To insure that we do not exceed the Fund amount, we would have to estimate an amount to reduce the update by that is low enough to ensure the \$1.35 billion funding cap is not exceeded. While this approach might reduce the CY 2008 negative update, it could still leave money in the Fund. We are concerned that there may be potential oversight or other legal consequences in the event that we significantly exceed the Fund or do not apply the entire Fund. Therefore, we believe the best use of the Fund is to apply it to extend PQRI into CY 2008.

Comment: Commenters asserted that use of the PAQI Fund for anything other than the physician update was inconsistent with Congressional intent. Commenters cited TRHCA language that the Fund “may include application of an adjustment to the update of the conversion factor.” Commenters further noted that this use must have been Congressional intent, since the legislation includes explicit language of how to deal with the update in subsequent years when the Fund is used towards the update: “[I]n the case that expenditures from the Fund are applied to, or otherwise affect, a conversion factor * * * the conversion factor under such subsection shall be computed for a subsequent year as if such application or effect had never occurred.”

Many commenters cited the Congressional Budget Office's cost estimate for the TRHCA legislation, which anticipated CMS developing a plan to use approximately 90 percent of the Fund in CY 2008 and the remaining funds in CY 2009. These comments cited section 101(d) of the MIEA—TRHCA, where the Congress stated that the Fund should be used “to the maximum extent feasible” for physicians' services during CY 2008, interpreting Congressional intent to be that CMS do its best to distribute most of the money in CY 2008, and any remaining monies in CY 2009.

Commenters rejected the rationale that there were serious legal and operational barriers to applying the PAQI Fund to the physician update; they expressed confidence that we could find some way to use the Fund to offset the reduction.

Further, commenters noted that it was within our discretion to apply the PAQI Fund to the physician update, and they were highly critical of our unwillingness to take administrative steps to mitigate the negative 9.9 percent physician update.

Response: Section 101(d) of the MIEA–TRHCA directs the Secretary to establish a PAQI Fund to be available to the Secretary for physician payment and quality improvement initiatives, which may include application of an adjustment to the update of the CF under that subsection. The legislation clearly indicates that the Secretary has the discretion to use the Fund for physician payment and quality improvement initiatives, including application of an adjustment to the update of the conversion factor. However, we are not required to use the funds for the update.

As noted above, there are fundamental operational problems with applying the PAQI Fund to the conversion factor update. We are concerned that there may be potential oversight or other legal consequences in the event the Agency significantly exceeds the Fund or does not apply the entire Fund. For the reasons previously discussed, we believe it is in the best interests of the program to apply this Fund to the extension of PQRI.

Comment: Commenters rejected the notion that use of the \$1.35 billion to fund the CY 2008 PQRI is the best way to insure physicians get the greatest benefit from the PAQI Fund's resources. Commenters stated that the PQRI does not provide all physicians with an opportunity to participate and that many specialties treat patients with conditions for which PQRI measures do not apply. In contrast, using the Fund to offset the negative update for CY 2008 would benefit all physicians.

Response: Medicare payment systems need to encourage reliable, high quality and efficient care, rather than making payment simply based on the quantity of services provided and resources consumed. Applying the \$1.35 billion to PQRI bonuses allows CMS to further the goal of improving quality and efficiency by utilizing the infrastructure that both physicians and Medicare have invested in for the CY 2007 PQRI. We believe implementing this Fund through an extension of the PQRI program is the best way to ensure that the Fund is being used to increase quality and efficiency of care for Medicare beneficiaries.

Comment: Commenters rejected the notion that using the PAQI Fund for bonuses would improve quality. For most physicians, the proposed

estimated 1.5 percent bonus payment is insufficient to cover the costs to institute such quality reporting measures. Commenters noted that if CMS truly wished to encourage more providers to participate in the PQRI, "new money" must be found to fund the initiative. Commenters suggested bonuses between 5 and 10 percent of allowed charges would more reasonably cover the costs of improving their infrastructure to appropriately report quality measures.

Response: Funding the PQRI is consistent with the goal of improving quality and efficiency in Medicare. Eligible professional can participate in the PQRI by reporting the appropriate quality measure data on claims submitted to their Medicare claims processing contractor. We provide educational resources on the PQRI Web site that allow eligible professionals to integrate PQRI reporting into their care delivery process without significant changes in their infrastructures.

We appreciate the desire of eligible professionals to improve their infrastructure to better track quality of care. For many eligible professionals, such infrastructure is already in place for PQRI and will not require additional investment. However, we note that PQRI bonuses are financial incentives to participate in a voluntary quality reporting program and were not intended to cover the costs of significantly improving the infrastructure of eligible professionals.

Comment: Many commenters noted that the PQRI has not been proven to have any positive effect on patient care or health outcomes. Rather than utilizing the \$1.35 billion to support an unproven program, it would be better to directly improve physician reimbursement and better cover the costs of the necessary care they are currently providing to beneficiaries.

Response: The PAQI Fund was made available to the Secretary for physician payment and quality improvement initiatives. We are actively engaged with the physician community in identifying ways to align Medicare's physician payment system with the goals of health professionals for high-quality care. Using the PAQI Fund to pay for the PQRI aligns reimbursement with quality and efficiency. We have worked collaboratively with the physician community to develop measures that capture the quality of care being provided to our Medicare beneficiaries. The PQRI encourages physicians to provide the type of care that is best suited for our beneficiaries: Care focused on prevention and treating complications; and care focused on the

most effective, proven treatments available.

We acknowledge the relative newness of the PQRI. To that end, we are committed to continue working with the physician community in an open and transparent way to insure that the PQRI supports the best approaches to provide high quality health care services.

Comment: Commenters noted that Congressional intent was to provide some relief and stability to the physician payment system during CY 2008. However, under the terms of the proposed rule, CMS cannot let physicians know the amount of the reporting bonus until well after the close of the CY 2008 reporting period, and physicians would not receive bonuses until some time in CY 2009.

Response: Section 101(d) of the MIEA–TRHCA charges the Secretary with a timely obligation of all available funds for services furnished during CY 2008, directing the Secretary to provide for expenditures from the Fund in a manner designed to provide (to the maximum extent feasible) for the obligation of the entire \$1.35 billion for physicians' services furnished during CY 2008. Although the legislation is clear that payment of the Fund is based on services furnished during CY 2008, the legislation does not limit the Secretary to paying from the PAQI Fund during CY 2008.

Comment: One commenter stated that quality payments should not be geographically adjusted. The commenter suggested that PQRI payments should be based on RVUs, not allowed charges.

Response: Section 101(c) of MIEA–TRHCA authorizes a financial incentive for eligible professionals to participate in a voluntary quality reporting program. Eligible professionals, who choose to participate and successfully report on a designated set of quality measures for services paid under the Medicare Physician Fee Schedule and provided between July 1 and December 31, 2007, may earn a bonus payment of 1.5 percent of their allowed charges during that period, subject to a cap. In the CY 2008 PFS proposed rule (72 FR 38206), we proposed that the physician quality initiative for CY 2008 be structured and implemented in the same manner as the 2007 PQRI, as described above. This includes calculating the amounts of the 2008 bonus payments based upon a percentage of allowed charges, as was statutorily required for 2007 bonus payments. By definition, allowed charges include the geographical adjustments in payments, as determined by the geographic practice cost indices (GPCIs), which

reflect the variation in practice costs from area to area.

III. Revisions to the Payment Policies of Ambulance Services Under the Fee Schedule for Ambulance Services; Ambulatory Inflation Factor Update for CY 2007

As discussed in the CY 2008 PFS proposed rule (72 FR 38207), under the ambulance fee schedule, the Medicare program pays for transportation services for Medicare beneficiaries when other means of transportation are contraindicated. Ambulance services are classified into different levels of ground (including water) and air ambulance services based on the medically necessary treatment provided during transport. These services include the following levels of service:

For Ground—

- Basic Life Support (BLS).
- Advanced Life Support, Level 1 (ALS1).
- Advanced Life Support, Level 2 (ALS2).

• Specialty Care Transport (SCT).

• Paramedic ALS Intercept (PI).

For Air—

- Fixed Wing Air Ambulance (FW).
- Rotary Wing Air Ambulance (RW).

A. History of Medicare Ambulance Services

1. Statutory Coverage of Ambulance Services

Under sections 1834(l) and 1861(s)(7) of the Act, Medicare Part B covers and pays for ambulance services, to the extent prescribed in regulations, when the use of other methods of transportation would be contraindicated by the beneficiary's medical condition. The House Ways and Means Committee and Senate Finance Committee Reports that accompanied the 1965 Social Security Amendments suggest that the Congress intended that—

- The ambulance benefit cover transportation services only if other means of transportation are contraindicated by the beneficiary's medical condition; and
- Only ambulance service to local facilities be covered unless necessary services are not available locally, in which case, transportation to the nearest facility furnishing those services is covered (H.R. Rep. No. 213, 89th Cong., 1st Sess. 37 and Rep. No. 404, 89th Cong., 1st Sess. Pt 1, 43 (1965)).

The reports indicate that transportation may also be provided from one hospital to another, to the beneficiary's home, or to an extended care facility.

2. Medicare Regulations for Ambulance Services

Our regulations relating to ambulance services are set forth at 42 CFR part 410, subpart B and 42 CFR part 414, subpart H. Section 410.10(i) lists ambulance services as one of the covered medical and other health services under Medicare Part B. Therefore, ambulance services are subject to basic conditions and limitations set forth at § 410.12 and to specific conditions and limitations as specified in § 410.40. Part 414, subpart H, describes how payment is made for ambulance services covered by Medicare.

3. Transition to National Fee Schedule

The national fee schedule for ambulance services was phased in over a 5-year transitional period beginning April 1, 2002, as specified in § 414.615. As of January 1, 2006, the total payment amount for air ambulance providers and suppliers is based on 100 percent of the national ambulance fee schedule. In accordance with section 414 of the MMA, we added § 414.617 which specifies that for ambulance services furnished during the period July 1, 2004, through December 31, 2009, the ground ambulance base rate is subject to a floor amount, which is determined by establishing nine fee schedules based on each of the nine census divisions, and using the same methodology as was used to establish the national fee schedule. If the regional fee schedule methodology for a given census division results in an amount that is lower than or equal to the national ground base rate, then it is not used, and the national fee schedule amount applies for all providers and suppliers in the census division. If the regional fee schedule methodology for a given census division results in an amount that is greater than the national ground base rate, then the fee schedule portion of the base rate for that census division is equal to a blend of the national rate and the regional rate through CY 2009. Thus, as of January 1, 2007, the total payment amount for ground ambulance providers and suppliers is based on either 100 percent of the national ambulance fee schedule amount, or a combination of 80 percent of the national ambulance fee schedule and 20 percent of the regional ambulance fee schedule.

B. Ambulance Inflation Factor (AIF) During the Transition Period

As we noted in the previous section, the national fee schedule for ambulance services was phased in over a 5 year transition period beginning April 1, 2002, as specified in § 414.615. During

the transition period, the ambulance inflation factor (AIF) was applied separately to both the fee schedule portion of the blended payment amount (regardless of whether a national or regional fee schedule applied) and to the supplier's reasonable charge or provider's reasonable cost portion of the blended payment amount, respectively, for each ambulance provider or supplier. Then, the two amounts were added together to determine the total payment amount for each provider or supplier.

C. Ambulance Inflation Factor (AIF) for CY 2008

Section 1834(l)(3)(B) of the Act provides the basis for updating payment amounts for ambulance services. Section 414.610(f) specifies that certain components of the ambulance fee schedule are updated by the AIF annually, based on the consumer price index for all urban consumers (CPI-U) (U.S. city average) for the 12-month period ending with June of the previous year. In the CY 2008 PFS proposed rule, we stated the AIF for CY 2008 would be announced as part of this final rule with comment period. For CY 2008, the percentage is 2.7 percent. In addition, as set forth in Section III.D., we also proposed to announce the AIF for CY 2009 and subsequent years via CMS instruction and on the CMS Web site.

D. Revisions to the Publication of the Ambulance Fee Schedule (§ 414.620)

Currently, § 414.620 specifies that changes in payment rates resulting from incorporation of the AIF will be announced by notice in the **Federal Register** without opportunity for prior comment. As explained in the CY 2008 PFS proposed rule, we believe it is unnecessary to undertake notice and comment rulemaking to update the AIF because the statute and regulations specify the methods of computation of annual inflation updates, and we have no discretion in that matter. Thus, the annual AIF notice does not change or establish policy, but merely applies the update methods specified in the statute and regulations.

As discussed in the proposed rule, by mid-July of each year, we have the CPI-U for the 12-month period ending with June of such year. Therefore, we know what the AIF for the upcoming calendar year will be by mid-July of each year. However, § 414.620 currently states that the AIF will be announced in the **Federal Register**. Each document published in the **Federal Register** requires scheduling and a thorough review by CMS, HHS, and OMB prior to publication. Therefore, even though we

know the AIF by mid-July of each year, the final rule announcing the AIF is not published until November. This publication timeframe does not allow Medicare contractors the optimal amount of time to update their systems to implement the proper payment for Medicare ambulance claims by January 1 of the coming year. In addition, it does not provide an optimal amount of time for either the Medicare contractors or the ambulance industry to take advantage of testing systems to make sure that the update is working properly as implemented. We believe that announcing the AIF via CMS instructions and on the CMS Web site would enable the AIF to be released earlier in the calendar year, allowing the Medicare contractors to test their data systems, and to timely effectuate and provide accurate payments on Medicare ambulance claims.

Therefore, we proposed to revise § 414.620 to state that we will announce the AIF via CMS instruction and on the CMS Web site and to remove the language that states that we will announce the AIF by notice in the **Federal Register**.

Comment: Comments received regarding the issue of announcing the AIF via CMS instruction and on the CMS Web site were very supportive of this proposal.

Response: As we proposed, we are revising § 414.620 to state that CMS will announce the AIF via CMS instruction and on the CMS Web site, and to remove the language that states that we will announce the AIF by notice in the **Federal Register**.

IV. Refinement of RVUs for CY 2008 and Response to Public Comments on Interim RVUs for 2007

[If you choose to comment on issues in this section, please include the caption "Interim Relative Value Units" at the beginning of your comments.]

A. Summary of Issues Discussed Related to the Adjustment of Relative Value Units

Section IV.B. and IV.C. of this final rule with comment describes the methodology used to review the comments received on the RVUs for physician work, including the additional codes from the 5-Year Review of work RVUs, and the process used to establish RVUs for new and revised CPT codes. Changes to the RVUs and billing status codes reflected in Addendum B are effective for services furnished beginning January 1, 2008.

B. Process for Establishing Work Relative Value Units for the Physician Fee Schedule

The CY 2007 PFS final rule with comment period (71 FR 69624) contained the work RVUs for Medicare payment for existing procedure codes under the PFS and interim RVUs for new and revised codes beginning January 1, 2007. We considered the RVUs for the interim codes to be subject to public comment under the annual refinement process. In the CY 2008 PFS proposed rule we also proposed work RVUs for additional codes from the 5-Year Review of work RVUs. In this section, we address comments and summarize the refinements to the additional codes from the 5-Year Review of work RVUs, the interim work RVUs published in the CY 2007 PFS final rule with comment period, and our establishment of the work RVUs for new and revised codes for the CY 2008 PFS.

C. 5-Year Review of Work RVUs

1. Additional Codes From the 5-Year Review of Work RVUs

The CY 2008 PFS proposed rule (72 FR 38146) discussed the RUC recommendations on work RVUs for a number of codes from the 5-Year Review that were deferred from the CY 2007 PFS rulemaking and listed the specific codes in Table 10. We proposed to accept all of the RUC recommendations, with the exception of CPT code 93325, *Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)*, which we proposed to bundle. We also noted that CPT codes 92557, 92567, 92568, 92569, 92579, 92601, 92602, 92603 and 92604 previously had no work RVUs assigned to them.

Many commenters expressed support for our proposed valuations of many of the services. However, other commenters expressed specific concern or disagreement with the proposed valuation of approximately 17 codes.

To evaluate these comments, we used a process similar to the process used since 1997. (See the CY 1998 PFS final rule published in the October 31, 1997 **Federal Register** (62 FR 59084) for the discussion of refinement of CPT codes with interim work RVUs.) We convened a multi specialty panel of physicians to assist us in the review of the comments. The comments that we did not submit to panel review are discussed at the end of this section, as well as those that were reviewed by the panel, which are contained in Table 14: Work RVU Revisions for Additional 5-Year Review Codes. We invited representatives from

the organizations from which we received substantive comments to attend a panel for discussion of the code on which they had commented. The panel was moderated by our medical staff, and consisted of the following voting members:

- Clinicians representing the commenting specialty(ies), based on our determination of those specialties which are most identified with the services in question. Although commenting specialties were welcomed to observe the entire refinement process, they were only involved in the discussion of those services for which they were invited to participate.
- Primary care clinicians nominated by the AAFP and the American College of Physicians.
- Carrier Medical Directors.
- Clinicians who practice in related specialties and have knowledge of the services under review.

The panel discussed the work involved in the procedure under review in comparison to the work associated with other services under the PFS. We assembled a set of reference services and asked the panel members to compare the clinical aspects of the work for the service a commenter believed was incorrectly valued to one or more of the reference services. In compiling the reference set, we attempted to include: (1) Services that are commonly furnished for which work RVUs are not controversial; (2) services that span the entire spectrum of work intensity from the easiest to the most difficult; and (3) at least three services furnished by each of the major specialties so that each specialty would be represented. The intent of the panel process was to capture each participant's independent judgment based on the discussion and his or her clinical experience. Following the discussion for each service, each participant rated the work for that procedure. Ratings were individual and confidential; there was no attempt to achieve consensus among the panel members.

We then analyzed the ratings based on a presumption that the interim RVUs were correct. To overcome that presumption, the inaccuracy of the interim RVUs had to be apparent to the broad range of physicians participating in each panel.

Ratings of work were analyzed for consistency among the groups represented on each panel. In general terms, we used statistical tests to determine whether there was enough agreement among the groups on the panel and, if so, whether the agreed-upon work RVUs were significantly different from the proposed work RVUs

in the CY 2008 PFS proposed rule to demonstrate that the proposed work RVUs should be modified. We did not modify the work RVUs unless there was a clear indication for a change. If there was agreement across groups for change, but the groups did not agree on what the new work RVUs should be, we eliminated the outlier group, and looked for agreement among the remaining groups as to the basis for new work RVUs. We used the same methodology in analyzing the ratings that we first used in the refinement process for the CY 1993 PFS final rule published in the November 25, 1992 **Federal Register** which described the statistical tests in detail (57 FR 55938). Our decision to convene a multi-specialty panel of physicians and to apply the statistical tests described above in this section was

based on our need to balance the interests of those who commented on the work RVUs against the redistributive effects that would occur in other specialties.

Table 14 lists the additional codes for the 5-Year Review on which we received comments. This table includes the following information:

- *CPT/HCPCS Code.* This is the CPT or alphanumeric HCPCS code for a service.
- *Modifier.* A modifier 26 is shown if the work RVUs represent the professional component (PC) of the service.
- *Description.* This is an abbreviated version of the narrative description of the code.
- *Proposed Work RVUs.* This column includes the work RVUs proposed in the

CY 2008 PFS proposed rule for each reviewed code.

- *Requested Work RVUs.* This column identifies the work RVUs requested by the commenters. If the commenters requested different RVUs, the table lists the highest requested RVUs.

- *RUC Recommendation.* This column identifies the work RVUs recommended by the RUC that appeared in the CY 2008 PFS proposed rule.

- *2008 Work RVUs.* This column contains the work RVUs for the CY 2008 PFS.

- *Basis for Decision.* This column indicates whether the CY 2008 work RVUs resulted from comments received or the refinement panel process.

TABLE 14.—WORK RVU REVISIONS FOR ADDITIONAL 5-YEAR REVIEW CODES

CPT/HCPCS code ¹	Mod	Descriptor	Proposed work RVU	Work RVUs requested by commenters	RUC rec	2008 work RVU	Basis for decision
92557	Comprehensive hearing test	0.60	1.40	0.60	0.60	Refinement.
92579	Visual audiometry (vra)	0.70	1.70	0.70	0.70	Refinement.
99326	Domicil/r-home visit new pat	2.27	2.85	2.27	2.63	Refinement.
99327	Domicil/r-home visit new pat	3.03	3.75	3.03	3.46	Refinement.
99328	Domicil/r-home visit new pat	3.78	4.26	3.78	4.09	Refinement.
99334	Domicil/r-home visit est pat ..	0.76	1.25	0.76	1.07	Refinement.
99335	Domicil/r-home visit est pat ..	1.26	2.00	1.26	1.72	Refinement.
99336	Domicil/r-home visit est pat ..	2.02	2.75	2.02	2.46	Refinement.
99337	Domicil/r-home visit est pat ..	3.03	4.05	3.03	3.58	Refinement.
99343	Home visit, new patient	2.27	2.65	2.27	2.53	Refinement.
99344	Home visit, new patient	3.03	3.60	3.03	3.38	Refinement.
99345	Home visit, new patient	3.78	4.26	3.78	4.09	Refinement.
99347	Home visit, est patient	0.76	1.10	0.76	1.00	Refinement.
99348	Home visit, est patient	1.26	1.70	1.26	1.56	Refinement.
99349	Home visit, est patient	2.02	2.50	2.02	2.33	Refinement.
99350	Home visit, est patient	3.03	3.45	3.03	3.28	Refinement.
93325	Doppler color flow add-on	0.07	0.30	CPT	0.07	Comments.

¹ All CPT codes and descriptors copyright 2007 American Medical Association.

Discussion of Comments by Clinical Area

For CPT code 92557, *Comprehensive audiometry threshold evaluation and speech recognition*, and CPT code 92579, *Visual reinforcement audiometry (VRA)*, the RUC recommended 0.60 work RVUs for CPT 92557 and 0.70 work RVUs for CPT code 92579, which we accepted.

Comment: Commenters disagreed with the RUC-recommended work values for these services, which we had accepted. The commenters believed that the recommended values were not appropriate considering the time and intensity involved in performing these services. Based on these comments, we referred these codes to the multi-specialty validation panel for review.

Response: As a result of the statistical analysis of the 2007 multi-specialty

validation panel ratings, we have assigned 0.60 work RVUs to CPT code 92557 and 0.70 work RVUs to CPT code 92579.

For CPT code 99326, *Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components: A detailed history; a detailed examination; and medical decision making of moderate complexity*; CPT code 99327, *Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components: A comprehensive history; a comprehensive examination; and medical decision making of moderate complexity*; CPT code 99328, *Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components: A comprehensive history; a comprehensive examination; and*

medical decision making of high complexity; CPT code 99334, *Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components: A problem focused interval history; a problem focused examination; straightforward medical decision making*; CPT code 99335, *Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components: An expanded problem focused interval history; an expanded problem focused examination; medical decision making of low complexity*; CPT code 99336, *Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:*

A detailed interval history; a detailed examination; medical decision making of moderate complexity; CPT code 99337, Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components: A comprehensive interval history; a comprehensive examination; and medical decision making of moderate to high complexity; CPT code 99343, Home visit for the evaluation and management of a new patient, which requires these three key components: A detailed history; a detailed examination; and medical decision making of moderate complexity; CPT code 99344, Home visit for the evaluation and management of a new patient, which requires these three components: A comprehensive history; a comprehensive examination; and a medical decision making of moderate complexity; CPT code 99345, Home visit for the evaluation and management of a new patient, which requires these three key components: A comprehensive history; a comprehensive examination; and medical decision making of high complexity; CPT code 99347, Home visit for the evaluation and management of an established patient, which requires at least two of these three key components: A problem focused interval history; a problem focused examination; straightforward medical decision making; CPT code 99348, Home visit for the evaluation and management of an established patient, which requires at least two of these three key components: A problem focused interval history; a problem focused examination; straightforward medical decision making; CPT code 99349, Home visit for the evaluation and management of an established patient, which requires at least two of these three key components: A detailed interval history; a detailed examination; medical decision making of moderate complexity; and CPT code 99350, Home visit for the evaluation and management of an established patient, which requires at least two of these three key components: A comprehensive interval history; a comprehensive examination; medical decision making of moderate to high complexity, the RUC recommended that the work RVUs for these codes be maintained at their current values: 2.27 work RVUs for CPT code 99326; 3.03 work RVUs for CPT code 99327; 3.78 work RVUs for CPT code 99328; 0.76 work RVUs for CPT code 99334; 1.26 work RVUs for CPT code 99335; 2.02 work RVUs for CPT code 99336; 3.03 work RVUs for CPT code 99337; 2.27 work RVUs for CPT code 99343; 3.03 for

CPT code 99344; 3.78 work RVUs for CPT code 99345; 0.76 work RVUs for CPT code 99347; 1.26 work RVUs for CPT code 99348; 2.02 work RVUs for CPT code 99349; and 3.03 work RVUs for CPT code 99350, which we accepted.

Comment: Commenters disagreed with the RUC-recommended work values for these services, which we had accepted. The commenters disagreed with the RUC-recommended work RVUs and believed the services were undervalued. The commenters also believed that the home visit work RVUs should remain “relatively” the same with respect to office visit codes as they did prior to the five-year review and requested that CMS reject the RUC recommended work RVUs and follow their survey values. Based on these comments, we referred these codes to the multi-specialty validation panel for review.

Response: As a result of the statistical analysis of the 2007 multi-specialty validation panel ratings, we have assigned 2.63 work RVUs to CPT code 99326; 3.46 work RVUs to CPT code 99327; 4.09 work RVUs to CPT code 99328; 1.07 work RVUs to CPT code 99334; 1.72 work RVUs to CPT code 99335; 2.46 work RVUs to CPT code 99336; 3.58 work RVUs to CPT code 99337; 2.53 work RVUs to CPT code 99343; 3.38 work RVUs to CPT code 99344; 4.09 work RVUs to CPT code 99345; 1.00 work RVUs to CPT code 99347; 1.56 work RVUs to CPT code 99348; 2.33 work RVUs to CPT code 99349; and 3.28 work RVUs to CPT code 99350.

For CPT code 93325, *Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)*, the RUC 5-Year Review workgroup recommended sending the code to the CPT Editorial Panel so that it could bundle CPT code 93325 into doppler echo code 93307. However, we believe that the technology of doppler imaging has evolved over the past 2 decades to enable color flow velocity and spectral analysis, both important components of doppler imaging, to be furnished concurrently or in concert to obtain more accurate interpretation and documentation of the anatomy and physiologic function of the structure(s) and organ being evaluated. Since the services described in 93325 have become intrinsic to the performance of other echocardiography services, we proposed to bundle 93325 into CPT codes 76825, 76826, 76827, 76828, 93303, 93304, 93307, 93308, 93312, 93314, 93315, 93317, 93320, 93321, 93350 and assign CPT code 93325 a status indicator of “B” (Bundled).

Comment: Commenters uniformly opposed this proposal. They did not support the bundling of CPT codes 93325 into all of the codes we proposed. The commenters would prefer for CMS to adopt the new CPT code and not bundle CPT code 93325 with any other codes with CPT code 93325. The commenters believed we are circumventing the existing process to address bundling of these services and we should follow that process. Alternatively, the commenters believed that if we must bundle the codes, then we should increase the RVUs for the codes in which CPT code 93325 is being bundled to recognize the work, PE, and malpractice components that are unique to CPT code 93325.

Response: Based on comments received, we have decided to accept the RUC recommendation and allow the RUC to value the new CPT code for CY 2009 for bundling CPT code 93325 with CPT codes 93320 and 93307. As a result of this decision, the work RVUs for CPT code 93325 will be maintained for CY 2008 at the 2007 work value of 0.07. The cardiology community has indicated to the RUC and CMS that the newly bundled CPT code represents the first of a series of coding changes they intend to propose over the course of the next year. These changes would result in the bundling of CPT code 93325 and other echocardiography codes to reflect the utilization of ultrasound services that are routinely performed together when providing care to a patient. We appreciate the initiative the cardiology community is taking on this issue, and we will reassess the echocardiography codes once this process is complete.

2. Anesthesia Coding (Part of 5-Year Review)

Although anesthesia services are paid under the PFS, under section 1848(b)(2)(B) of the Act, they are paid on the basis of an anesthesia code specific base unit and time units that vary based on the actual anesthesia time of the case. Since anesthesia services do not have a work RVU per code as do other medical and surgical services, a work value must be imputed for each anesthesia code. The imputed value is determined by multiplying the national average allowed charge for each anesthesia service by its anesthesia work share and dividing this amount by the general PFS conversion factor (CF). This places the work of the anesthesia service on the same relative value scale as all other physicians' services.

As discussed in the CY 2008 PFS proposed rule, in the second 5-Year Review of anesthesia work implemented in 2002, the AMA RUC and the

American Society of Anesthesiologists (ASA) used a building block approach to estimate the value of anesthesia work and compared this value to the imputed work value to determine whether the work of anesthesia services is properly valued. Under the building block approach, each anesthesia code was uniformly divided into five components: pre anesthesia, equipment and supply preparation, induction, post induction anesthesia, and post anesthesia. Work is determined for each of the five components and summed to calculate total anesthesia work for the anesthesia code. The imputed value for the anesthesia code is compared to the building block estimate of work in order to assess whether, and if so, to what extent, the anesthesia code is not properly valued.

The most significant component of work for the anesthesia service is the intensity for the post-induction anesthesia time. The ASA thought that the RUC significantly misvalued this component in the second 5-Year Review. In addition, the ASA was dissatisfied that the RUC did not extend the analysis from the 19 high volume anesthesia codes reviewed by the RUC to all anesthesia codes.

In the CY 2007 PFS final rule with comment period, we addressed the issue of the work of anesthesia services under the third 5-Year Review of work. As explained in that rule, we made very modest adjustments to the work of the 19 anesthesia codes surveyed and analyzed by the RUC in the second 5-Year Review of work. These adjustments were made recognizing that the work of the pre- and post-anesthesia service components was linked to certain E/M services. Since we accepted the AMA RUC's recommendations for increased work values for certain E/M codes for the third 5-Year Review of work, we recalculated the work of the 19 anesthesia services to incorporate these higher work values. The adjustment in work was reflected by increasing the anesthesia CF by less than 1 percent.

However, on the more significant issue of the valuation of work in the post induction anesthesia period, we took no action. Rather, in the CY 2007 PFS final rule with comment period, we asked the RUC to review and consider this issue as part of the third 5-Year Review of work. We also asked the RUC to consider how increases in the work of pre- and post-anesthesia services could cause adjustments to the anesthesia services not specifically reviewed by the ASA and the RUC.

In January 2007, the ASA requested the AMA RUC to review the undervaluation of the work of the post-

induction anesthesia period and to consider also an analytic approach, based on linear regression analysis, which could be used to evaluate the work of the entire anesthesia service. The linear regression model relates the work of the post-induction period time and the work of the entire anesthesia service to the base unit value for the anesthesia code. Under this model, the work of anesthesia services is undervalued by approximately 34 percent.

The RUC established an anesthesia workgroup to examine this proposal. The workgroup discussed this proposal extensively at its two teleconferences, prior to the April RUC meeting, and at the April RUC meeting itself. In May 2007, the AMA RUC, based on the analyses and recommendations of its workgroup, submitted a recommendation to CMS for a 32 percent increase in the work of anesthesia services.

The workgroup approved the ASA's use of the linear regression model to value only the work of the post-induction period time. In contrast to the ASA proposal, the workgroup considered an analytic approach different from the regression model developed by the ASA. This approach is based on a building block approach that could be used to evaluate the work of all anesthesia service components other than the post induction period time. For example, for pre-anesthesia time, the methodology is as shown in Table 15.

TABLE 15.—PRE-ANESTHESIA TIME

All Anesthesia codes with 3 base units—linked to the work of 99201.
All Anesthesia codes with 4 base units—linked to the blend of work for 99201 and 99202.
All Anesthesia codes with 5 to 15 base units—linked to the work of 99202.
All Anesthesia codes with 16 to 30 base units—linked to the work of 99252.

Note: The source of the link for work is the pre anesthesia valuation from the 19 surveyed anesthesia codes whose base units varied from 3 units to 25 units.

Similar approaches are used for each anesthesia component: Preparation time, induction period time, and post-anesthesia time. Systematically, codes with lower anesthesia base unit values have lower work values for each component of the building block approach than do codes with higher anesthesia base unit values. For the given building block component, the work value of that component is the same for all anesthesia services that have the same base unit value.

According to the workgroup's revised methodology which is extended from the 19 surveyed codes to all CPT anesthesia codes, the work of anesthesia services is undervalued by approximately 32 percent. Thus, based on the acceptance of the workgroup and the RUC's recommendation, an adjustment of approximately 25 percent would be applied to the anesthesia CF.

Increases in the work of anesthesia services would have to be offset by additional adjustments to the PFS BN adjuster for work. We estimated that the increase in the anesthesia CF would result in an additional 1.0 percent increase in the BN adjuster for work.

Other adjustments also affect the anesthesia CF. For example, an increase in anesthesia work may have implications for PE because indirect PEs are allocated based on the sum of work and direct PEs. When we ran the PE RVU program, there was a 1 percent decrease in the aggregate anesthesia PEs for CY 2008. Thus, an adjustment was made to the PE share of the anesthesia service of the CY 2008 anesthesia CF for this component.

We proposed to accept the RUC's recommendation and increase the work of anesthesia services by 32 percent.

Comment: Organizations and individual commenters supported our proposal and urged us to take action to implement this proposal in CY 2008. They commented that this proposal improves the valuation of the work of anesthesia services and will help ensure that Medicare beneficiaries have access to quality anesthesia care. One commenter indicated that three additional anesthesia codes, 00142, 00210 and 00562, have been identified as misvalued during the AMA RUC's evaluation of the work of anesthesia services. Both CMS and the AMA RUC agreed that the RUC would review the base units for 00142 at the September 2007 RUC meeting and that the other codes, as agreed by the ASA, would be referred to the CPT so that the codes descriptors could be clarified. The RUC reviewed and approved the ASA's request to support the current base unit value of four units for anesthesia code 00142.

Response: We have decided to accept the RUC's recommendation and increase the work of anesthesia services by 32 percent. We have also accepted the RUC's recommendation to maintain the value of four base units for anesthesia code 00142.

3. Budget Neutrality Adjustment

Due to the proposed work RVU changes for the additional codes from the 5-Year Review of Work RVUs and

the proposed increases in the work of anesthesia services, in the CY 2008 PFS proposed rule, we proposed to revise the work adjustor to maintain budget neutrality. Based upon the increases, the proposed revised work adjustor was estimated to be 0.8816. Further discussion of this work adjustor was included in the impact section of the CY 2008 PFS proposed rule (72 FR 38211 through 38220).

Comment: Several commenters recommended that we reconsider applying the BN adjustment associated with the 5-Year Review of work RVUs to the CF rather than the work RVUs.

Response: We appreciate the commenters' interest in this topic. However, this issue was fully addressed in the CY 2007 PFS final rule with comment period (71 FR 69735), and we made no further proposals regarding this issue in the CY 2008 PFS proposed rule. We continue to believe that it is most appropriate to apply the BN adjustment to work RVUs and refer the commenters to the CY 2007 PFS final rule for an explanation of our decision.

We note that as a result of the changes made in response to comments received and the work of the refinement panel, the separate work adjustor has changed from the proposed 0.8816. The separate work adjustor for CY 2008 will be 0.8806.

D. Work Relative Value Unit Refinements of Interim Relative Value Units

1. Interim 2007 Codes

Although the RVUs in the CY 2007 PFS final rule with comment period were used to calculate 2007 payment amounts, we considered the RVUs for the new or revised codes to be interim. We accepted comments for a period of 60 days. We received comments on the following CPT codes.

Anticoagulation Management Codes

The CPT Editorial Panel created two anticoagulation management codes in February 2006: CPT code 99363, *Anticoagulant management for an outpatient taking warfarin, physician review and interpretation of International Normalized Ratio (INR) testing, patient instructions, dosage adjustment (as needed), and ordering of additional tests; initial 90 days of therapy (must include a minimum of 8 INR measurements)*, and CPT code 99364, *Anticoagulant management for an outpatient taking warfarin, physician review and interpretation of International Normalized Ratio (INR) testing, patient instructions, dosage adjustment (as needed), and ordering of*

additional tests; each subsequent 90 days of therapy (must include a minimum of 3 INR measurements). The RUC reviewed the codes and recommended 1.65 work RVUs for code 99363 and 0.63 work RVUs for 99364. In the CY 2007 PFS final rule with comment period, we decided not to accept the RUC recommendation and decided that the services provided by 99363 and 99364 are bundled into existing E/M services. Hence, there is no separate payment under the PFS. Currently clinicians managing anticoagulation therapy may bill, if appropriate, the CPT code that best represents the level of outpatient E/M service provided on that day, including CPT code 99211.

Comment: We received comments from commenters who strongly disagree with our decision to continue to consider anticoagulation management codes to be bundled into the work of E/M codes and noted that these CPT codes recognize the important work of managing serious disease. The commenters also requested that we not finalize our decision to consider these services bundled but instead change their status to separately payable, covered services.

Response: We generally do not pay separately for disease-specific management services. We believe the services represented by CPT codes 99363 and 99364 are inherent in the services captured by the existing E/M codes. We will continue to recognize codes 99363 and 99364 as bundled services and continue to pay for E/M services as appropriate.

Medical Genetics and Genetic Counseling

CPT code 96040, *Medical genetics and genetic counseling services, each 30 minutes face-to-face with patient/family*, was reviewed in the CY 2007 PFS final rule with comment period and assigned status B (bundled service).

Comment: Commenters disagree with the assigned status indicator of B (bundled service) for this service and urge CMS to reconsider its decision to make this a bundled service because they believe it is a separate and distinct procedure.

Response: The procedure does not contain any physician work and is a code that is designed to capture clinical labor time and PE. To the extent that this service is covered, we believe this service like other counseling services, is incorporated into existing E/M services, and therefore, will maintain the status assignment of B.

Home Ventilator Management

For CPT code 94005, *Home ventilator management care plan oversight of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living) requiring review of status, review of laboratories and other studies and revision of orders and respiratory care plan (as appropriate), within a calendar month, 30 minutes or more*, the RUC recommended 1.50 work RVUs. We assigned a status indicator of B (bundled service) to this service in the CY 2007 PFS final rule with comment period because: (1) The patient is not present when this service is rendered; and (2) we believe this service is captured in E/M services.

Comment: Commenters believe this service should not be bundled and recommend that this code be separately payable.

Response: We continue to believe this service should be assigned a status indicator of B (Bundled) for the reasons previously stated in the CY 2007 PFS final rule with comment period: (1) The patient is not present when the service is rendered; and (2) we believe this service is captured in the E/M services. (**Note:** The RUC-recommended RVUs for this code will be reflected in Addendum B.)

In the CY 2007 PFS final rule with comment period (70 FR 66370), we also responded to the RUC recommendations on the PE inputs for the new and revised CPT codes for 2007. In addition to PE comments discussed in section II.A.2. of this final rule with comment period, concerning PE inputs:

Comment: One commenter, representing a network of providers, requested that the PE inputs for CPT codes 35475 and 35476 be reviewed. These codes are used as the basis for the PE inputs for HCPCS codes G0392 and G0393 that were included in Addendum C. The commenter believes that the PE inputs have changed since the service was reviewed in 2004. The commenters also believed that items were missing from the PE database and included a list of these items.

Response: We suggest that the commenter work with the specialty group to determine if the PE inputs for CPT codes 35475 and 35476 should be reviewed by the RUC PE subcommittee. We have also reviewed the PE database regarding the missing PE items noted by the commenter and have verified that all PE inputs from CPT 35475 and 35476 have been crosswalked to G0392 and G0393, respectively.

Comment: One commenter, representing the specialty of dermatology, requested that the Unna

boot be removed from the PE database as a supply item and be assigned a HCPCS Q code so that it could be billed separately.

Response: This issue was specifically addressed in the CY 2007 PFS final rule with comment period (71 FR 69644 through 69645). We clarified that the policy we finalized relating to splint and cast supplies did not change the HCPCS Q-code descriptors or their pairing with certain CPT codes for payment purposes.

Comment: One commenter, representing the ophthalmology association, disagreed with our assessment that the specific topography equipment priced at \$44,000 is not typically used with CPT code 92025, *Computerized corneal topography, unilateral or bilateral, with interpretation and report*, and questioned our substitution of the topography equipment priced at \$13,495. The commenter pointed out that the \$44,000 topography equipment is the only equipment that will provide the services of this procedure.

Response: We have reviewed the request from the commenter and agree that the \$13,495 topography unit we assigned for CY 2007 should be replaced with the \$44,000 equipment that is specifically designed for the procedure inherent to CPT code 92025.

Comment: One commenter, representing therapeutic radiology, requested that for CPT code 77371, *Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cerebral lesion(s) consisting of 1 session; multi-source Cobalt 60 based*, we treat the radiation source (Cobalt 60), as a direct PE rather than an indirect one. Since Cobalt 60 is: (1) Purchased by the physician; (2) exceeds the \$500 threshold (price is \$15,000); and, (3) is clearly attributable to the procedure; it meets the established criteria for treatment as a direct expense. The commenter indicated that this radiation source must be replaced monthly, requiring a useful life assignment of 0.08 years.

Response: Based on this comment, we have re-examined our assignment of the Cobalt 60 radiation source used in CPT code 77371 as indirect PE. While the radiation source may meet some of the criteria to be considered as a direct PE input for equipment (for example, that it is an expense to the physician and its price is above the \$500 threshold), the commenter did not present information that is needed to verify the 1-month useful life that was requested. We lack the required evidence needed to determine the amount of viable radiation contained in the \$15,000 source that is consumed through the provision of the radiation treatments versus the amount that was not utilized but could have been used, during the 1-month time period. This unused amount would be considered a wasted resource and cannot be accounted for as a direct PE input. Consequently, we will not include the Cobalt-60 radiation source as a direct PE input as the commenter requested.

E. Establishment of Interim Work Relative Value Units for New and Revised Physician's Current Procedural Terminology (CPT) Codes and New Healthcare Common Procedure Coding System Codes (HCPCS) for 2008 (Includes Table titled "American Medical Association Specialty Relative Value Update Committee and Health Care Professionals Advisory Committee Recommendations and CMS's Decisions for New and Revised 2008 CPT Codes")

One aspect of establishing RVUs for 2008 was to assign interim work RVUs for all new and revised CPT codes. As described in our November 25, 1992 notice on the 1993 PFS (57 FR 55951) and in section III.B. of the CY 1997 PFS final rule (61 FR 59505), we established a process, based on recommendations received from the AMA's RUC, for establishing interim work RVUs for new and revised codes.

This year we received work RVU recommendations for 169 new and revised CPT codes from the RUC. Our staff and medical officers reviewed the RUC recommendations by comparing them to our reference set or to other

comparable services for which work RVUs had previously been established. We also considered the relationships among the new and revised codes for which we received RUC recommendations and agreed with the majority of the relative relationships reflected in the RUC values. In some instances, although we agreed with the relationships, we nonetheless revised the work RVUs to achieve work neutrality within families of codes. That is, the work RVUs were adjusted so that the sum of the new or revised work RVUs (weighted by projected frequency of use) for a family will be the same as the sum of the current work RVUs (weighted by projected frequency of use) for the family of codes.

We received approximately 7 recommendations from the Health Care Professional Advisory Committee (HCPAC).

Table 16: AMA RUC and HCPAC Recommendations and CMS Decisions for New and Revised 2008 CPT Codes lists the new or revised CPT codes, and their associated work RVUs, that will be interim in 2008. Table 16 includes the following information:

- A “#” identifies a new code for CY 2008.
- CPT code. This is the CPT code for a service.
- Modifier. A “26” in this column indicates that the work RVUs are for the PC of the code.
- Description. This is an abbreviated version of the narrative description of the code.
- RUC recommendations. This column identifies the work RVUs recommended by the RUC.
- HCPAC recommendations. This column identifies the work RVUs recommended by the HCPAC.
- CMS decision. This column indicates whether we agreed or we disagreed with the RUC recommendation. Codes for which we did not accept the RUC recommendation are discussed in greater detail following this table.
- 2008 Work RVUs. This column establishes the interim 2008 work RVUs for physician work.

TABLE 16.—AMA RUC AND HCPAC RECOMMENDATIONS AND CMS' DECISIONS FOR NEW AND REVISED 2008 CPT CODES

CPT ¹ code	Mod	Descriptor	RUC recommendation	HCPAC recommendation	CMS decision	2008 work RVU
# 20555	PLACE NDL MUSC/TIS FOR RT	6.00	Agree	6.00
20660	APPLY, REM FIXATION DEVICE	4.00	Agree	4.00
20690	APPLY BONE FIXATION DEVICE	8.65	Agree	8.65
20692	APPLY BONE FIXATION DEVICE	16.00	Agree	16.00
# 20985*	CPTR-ASST DIR MS PX	2.50	Agree	2.50

TABLE 16.—AMA RUC AND HCPAC RECOMMENDATIONS AND CMS' DECISIONS FOR NEW AND REVISED 2008 CPT CODES—Continued

CPT ¹ code	Mod	Descriptor	RUC recommendation	HCPAC recommendation	CMS decision	2008 work RVU
# 20986 *	..	CPTR-ASST DIR MS PX IO IMG	Carrier Priced	Agree	Carrier Priced.
# 20987 *	..	CPTR-ASST DIR MS PX PRE IMG	Carrier Priced	Agree	Carrier Priced.
# 21073	MNPJ OF TMJ W/ANESTH	3.33	Agree	3.33
# 22206	CUT SPINE 3 COL, THOR	37.00	Agree	37.00
# 22207	CUT SPINE 3 COL, LUMB	36.50	Agree	36.50
# 22208	CUT SPINE 3 COL, ADDL SEG	9.66	Agree	9.66
23515	TREAT CLAVICLE FRACTURE	11.00	Disagree	9.53
23585	TREAT SCAPULA FRACTURE	16.25	Disagree	14.07
23615	TREAT HUMERUS FRACTURE	14.00	Disagree	12.12
23616	TREAT HUMERUS FRACTURE	21.00	Disagree	18.19
23630	TREAT HUMERUS FRACTURE	12.00	Disagree	10.39
23670	TREAT DISLOCATION/FRACTURE	14.00	Disagree	12.12
23680	TREAT DISLOCATION/FRACTURE	15.00	Disagree	12.99
# 24357	REPAIR ELBOW, PERC	5.32	Agree	5.32
# 24358	REPAIR ELBOW W/DEB, OPEN	6.54	Agree	6.54
# 24359	REPAIR ELBOW DEB/ATTCH OPEN	8.86	Agree	8.86
24545	TREAT HUMERUS FRACTURE	15.00	Disagree	12.99
24546	TREAT HUMERUS FRACTURE	17.01	Disagree	14.73
24575	TREAT HUMERUS FRACTURE	11.00	Disagree	9.53
24579	TREAT HUMERUS FRACTURE	13.00	Disagree	11.26
24635	TREAT ELBOW FRACTURE	10.00	Disagree	8.64
24665	TREAT RADIUS FRACTURE	Referred to CPT	CPT	8.22
24666	TREAT RADIUS FRACTURE	Referred to CPT	CPT	9.74
24685	TREAT ULNAR FRACTURE	9.50	Disagree	8.21
25515	TREAT FRACTURE OF RADIUS	10.00	Disagree	8.64
25525	TREAT FRACTURE OF RADIUS	12.00	Disagree	10.37
25526	TREAT FRACTURE OF RADIUS	15.00	Disagree	12.96
25545	TREAT FRACTURE OF ULNA	9.00	Disagree	7.78
25574	TREAT FRACTURE RADIUS & ULNA	10.00	Disagree	8.64
25575	TREAT FRACTURE RADIUS/ULNA	14.00	Disagree	12.10
25628	TREAT WRIST BONE FRACTURE	11.00	Disagree	9.51
26615	TREAT METACARPAL FRACTURE	8.00	Disagree	6.91
26650	TREAT THUMB FRACTURE	6.00	Disagree	5.19
26665	TREAT THUMB FRACTURE	9.00	Disagree	7.78
26685	TREAT HAND DISLOCATION	8.00	Disagree	6.91
26715	TREAT KNUCKLE DISLOCATION	7.95	Disagree	6.87
26735	TREAT FINGER FRACTURE, EACH	8.40	Disagree	7.26
26746	TREAT FINGER FRACTURE, EACH	11.10	Disagree	9.59
26765	TREAT FINGER FRACTURE, EACH	6.60	Disagree	5.70
26785	TREAT FINGER DISLOCATION	7.45	Disagree	6.44
27248	TREAT THIGH FRACTURE	12.83	Disagree	10.64
# 27267	CLTX THIGH FX	5.38	Agree	5.38
# 27268	CLTX THIGH FX W/MNPJ	7.00	Agree	7.00
# 27269	OPTX THIGH FX	18.75	Agree	18.75
# 27416	OSTEOCHONDRAL KNEE AUTOGRAFT	14.00	Agree	14.00
27511	TREATMENT OF THIGH FRACTURE	18.05	Disagree	14.97
27513	TREATMENT OF THIGH FRACTURE	23.04	Disagree	19.11
27514	TREATMENT OF THIGH FRACTURE	17.43	Disagree	14.46
27519	TREAT THIGH FX GROWTH PLATE	15.80	Disagree	13.11
27535	TREAT KNEE FRACTURE	16.00	Disagree	13.27
27540	TREAT KNEE FRACTURE	13.45	Disagree	11.16
27556	TREAT KNEE DISLOCATION	15.50	Disagree	12.86
27557	TREAT KNEE DISLOCATION	19.00	Disagree	15.76
27558	TREAT KNEE DISLOCATION	22.00	Disagree	18.25
# 27726	REPAIR FIBULA NONUNION	14.20	Agree	14.20
27766	OPTX MEDIAL ANKLE FX	8.50	Disagree	7.73
# 27767	CLTX POST ANKLE FX	2.50	Agree	2.50
# 27768	CLTX POST ANKLE FX W/MNPJ	5.00	Agree	5.00
# 27769	OPTX POST ANKLE FX	10.00	Agree	10.00
27784	TREATMENT OF FIBULA FRACTURE	10.45	Disagree	9.51
27792	TREATMENT OF ANKLE FRACTURE	10.50	Disagree	9.55
27814	TREATMENT OF ANKLE FRACTURE	11.50	Disagree	10.46
27822	TREATMENT OF ANKLE FRACTURE	12.12	Disagree	11.03
27823	TREATMENT OF ANKLE FRACTURE	14.26	Disagree	12.98
27826	TREAT LOWER LEG FRACTURE	12.00	Disagree	10.92
27827	TREAT LOWER LEG FRACTURE	16.00	Disagree	14.56
27828	TREAT LOWER LEG FRACTURE	20.00	Disagree	18.20
27829	TREAT LOWER LEG JOINT	9.50	Disagree	8.64
27832	TREAT LOWER LEG DISLOCATION	11.00	Disagree	10.01

TABLE 16.—AMA RUC AND HCPAC RECOMMENDATIONS AND CMS' DECISIONS FOR NEW AND REVISED 2008 CPT CODES—Continued

CPT ¹ code	Mod	Descriptor	RUC recommendation	HCPAC recommendation	CMS decision	2008 work RVU
28415		TREAT HEEL FRACTURE	17.54		Disagree	15.96
28420		TREAT/GRAFT HEEL FRACTURE	19.00		Disagree	17.29
28445		TREAT ANKLE FRACTURE	17.07		Disagree	15.53
# 28446		OSTEOCHONDRAL TALUS AUTOGRFT	17.50		Agree	17.50
28465		TREAT MIDFOOT FRACTURE, EACH	9.50		Disagree	8.64
28485		TREAT METATARSAL FRACTURE	8.00		Disagree	7.28
28505		TREAT BIG TOE FRACTURE	8.00		Disagree	7.28
28525		TREAT TOE FRACTURE	6.00		Disagree	5.46
28555		REPAIR FOOT DISLOCATION	10.43		Disagree	9.49
28585		REPAIR FOOT DISLOCATION	12.00		Disagree	10.92
28615		REPAIR FOOT DISLOCATION	11.50		Disagree	10.46
28645		REPAIR TOE DISLOCATION	8.00		Disagree	7.28
28675		REPAIR OF TOE DISLOCATION	6.00		Disagree	5.46
# 29828*		ARTHROSCOPY BICEPS TENODESIS	13.00		Agree	13.00
# 29904		SUBTALAR ARTHRO W/FB RMVL	8.50		Agree	8.50
# 29905		SUBTALAR ARTHRO W/EXC	9.00		Agree	9.00
# 29906		SUBTALAR ARTHRO W/DEB	9.47		Agree	9.47
# 29907		SUBTALAR ARTHRO W/FUSION	12.00		Agree	12.00
31500		INSERT EMERGENCY AIRWAY	2.33		Agree	2.33
# 33257*		ABLATE ATRIA, LMTD, ADD-ON	9.63		Agree	9.63
# 33258*		ABLATE ATRIA, X10SV, ADD-ON	11.00		Agree	11.00
# 33259*		ABLATE ATRIA W/BYPASS ADD-ON	14.14		Agree	14.14
# 33864*		ASCENDING AORTIC GRAFT	60.00		Agree	60.00
# 34806*		ANEURYSM PRESS SENSOR ADD-ON	2.06		Agree	2.06
# 35523		ARTERY BYPASS GRAFT	24.00		Agree	24.00
36620		INSERTION CATHETER, ARTERY	1.15		Agree	1.15
# 41019		PLACE NEEDLES H&N FOR RT	8.84		Agree	8.84
43760		CHANGE GASTROSTOMY TUBE	0.90		Agree	0.90
# 49203		EXC ABD TUM 5 CM OR LESS	20.00		Agree	20.00
# 49204		EXC ABD TUM OVER 5 CM	26.00		Agree	26.00
# 49205		EXC ABD TUM OVER 10 CM	30.00		Agree	30.00
# 49440		PLACE GASTROSTOMY TUBE PERC	4.18		Agree	4.18
# 49441		PLACE DUOD/JEJ TUBE PERC	4.77		Agree	4.77
# 49442		PLACE CECOSTOMY TUBE PERC	4.00		Agree	4.00
# 49446		CHANGE G-TUBE TO G-J PERC	3.31		Agree	3.31
# 49450		REPLACE G/C TUBE PERC	1.36		Agree	1.36
# 49451		REPLACE DUOD/JEJ TUBE PERC	1.84		Agree	1.84
# 49452		REPLACE G-J TUBE PERC	2.86		Agree	2.86
# 49460		FIX G/COLON TUBE W/DEVICE	0.96		Agree	0.96
# 49465		FLUORO EXAM OF G/COLON TUBE	0.62		Agree	0.62
# 50385		CHANGE STENT VIA TRANSURETH	4.44		Agree	4.44
# 50386		REMOVE STENT VIA TRANSURETH	3.30		Agree	3.30
# 50593*		PERC CRYO ABLATE RENAL TUM	9.08		Agree	9.08
51797		INTRAABDOMINAL PRESSURE TEST	0.80		Agree	0.80
# 52649		PROSTATE LASER ENUCLEATION	17.16		Agree	17.16
# 55920		PLACE NEEDLES PELVIC FOR RT	8.31		Agree	8.31
57284		REPAIR PARAVAG DEFECT, OPEN	14.25		Agree	14.25
# 57285		REPAIR PARAVAG DEFECT, VAG	11.52		Agree	11.52
# 57423*		REPAIR PARAVAG DEFECT, LAP	16.00		Agree	16.00
# 58570*		TLH, UTERUS 250 G OR LESS	15.75		Agree	15.75
# 58571*		TLH W/T/O 250 G OR LESS	17.56		Agree	17.56
# 58572*		TLH, UTERUS OVER 250 G	19.96		Agree	19.96
# 58573*		TLH W/T/O UTERUS OVER 250 G	22.98		Agree	22.98
# 67041		VIT FOR MACULAR PUCKER	19.00		Agree	19.00
# 67042		VIT FOR MACULAR HOLE	22.13		Agree	22.13
# 67043		VIT FOR MEMBRANE DISSECT	22.94		Agree	22.94
# 67113		REPAIR RETINAL DETACH, CPLX	25.00		Agree	25.00
# 67229		TR RETINAL LES PRETERM INF	16.00		Agree	16.00
# 68816*		PROBE NL DUCT W/BALLOON	3.00		Agree	3.00
# 75557*	26	CARDIAC MRI FOR MORPH	2.35		Agree	2.35
# 75558*	26	CARDIAC MRI FLOW/VELOCITY	2.60		Agree (c)	2.60
# 75559*	26	CARDIAC MRI W/STRESS IMG	2.95		Agree	2.95
# 75560*	26	CARDIAC MRI FLOW/VEL/STRESS	3.00		Agree (c)	3.00
# 75561*	26	CARDIAC MRI FOR MORPH W/DYE	2.60		Agree	2.60
# 75562*	26	CARD MRI FLOW/VEL W/DYE	2.86		Agree (c)	2.86
# 75563*	26	CARD MRI W/STRESS IMG & DYE	3.00		Agree	3.00
# 75564*	26	HT MRI W/FLO/VEL/STRS & DYE	3.35		Agree (c)	3.35
78811*	26	PET IMAGE, LTD AREA	1.54		Agree	1.54
78812*	26	PET IMAGE, SKULL-THIGH	1.93		Agree	1.93

TABLE 16.—AMA RUC AND HCPAC RECOMMENDATIONS AND CMS' DECISIONS FOR NEW AND REVISED 2008 CPT CODES—Continued

CPT ¹ code	Mod	Descriptor	RUC recommendation	HCPAC recommendation	CMS decision	2008 work RVU
78813*	26	PET IMAGE, FULL BODY	2.00		Agree	2.00
78814*	26	PET IMAGE W/CT, LMTD	2.20		Agree	2.20
78815*	26	PET IMAGE W/CT, SKULL-THIGH	2.44		Agree	2.44
78816*	26	PET IMAGE W/CT, FULL BODY	2.50		Agree	2.50
86486		SKIN TEST, NOS ANTIGEN	(a)		(a)*	0.00
88380*		MICRODISSECTION, LASER	1.56		Agree	1.56
# 88381*		MICRODISSECTION, MANUAL	1.18		Agree	1.18
# 90769*		SC THER INFUSION, UP TO 1 HR	0.21		Agree	0.21
# 90770*		SC THER INFUSION, ADDL HR	0.18		Agree	0.18
93503	26	INSERT/PLACE HEART CATHETER	2.91		Agree	2.91
# 93982***		ANEURYSM PRESSURE SENS STUDY	0.30		Agree	0.30
95004		PERCUT ALLERGY SKIN TESTS	0.01		Agree	0.01
95024		ID ALLERGY TEST, DRUG/BUG	0.01		Agree	0.01
95027		ID ALLERGY TITRATE-AIRBORNE	0.01		Agree	0.01
# 95980*		IO ANAL GAST N-STIM INIT	0.80		Agree	0.80
# 95981*		IO ANAL GAST N-STIM SUBSQ	0.30		Agree	0.30
# 95982*		IO GA N-STIM SUBSQ W/REPROG	0.65		Agree	0.65
# 96125		COGNITIVE TEST BY HC PRO		1.70	Agree	1.70
# 98966*		HC PRO PHONE CALL 5-10 MIN		0.25	Agree (c)	0.25
# 98967*		HC PRO PHONE CALL 11-20 MIN		0.50	Agree (c)	0.50
# 98968*		HC PRO PHONE CALL 21-30 MIN		0.75	Agree (c)	0.75
# 98969		ONLINE SERVICE BY HC PRO		Carrier Priced	Agree (c)	Carrier Priced.
# 99174		OCULAR PHOTOSCREENING	(a)		(a)*	0.00
# 99366		TEAM CONF W/PAT BY HC PRO		0.82	Agree (b)	0.82
# 99367		TEAM CONF W/O PAT BY PHYS	1.10		Agree (b)	1.10
# 99368		TEAM CONF W/O PAT BY HC PRO		0.72	Agree (b)	0.72
# 99406		BEHAV CHNG SMOKING 3-10 MIN	0.24		Agree	0.24
# 99407		BEHAV CHNG SMOKING < 10 MIN	0.50		Agree	0.50
# 99408		AUDIT/DAST, 15-30 MIN	0.65		Agree (c)	0.65
# 99409		AUDIT/DAST, OVER 30 MIN	1.30		Agree (c)	1.30
# 99441*		PHONE E/M BY PHYS 5-10 MIN	0.25		Agree (c)	0.25
# 99442*		PHONE E/M BY PHYS 11-20 MIN	0.50		Agree (c)	0.50
# 99443*		PHONE E/M BY PHYS 21-30 MIN	0.75		Agree (c)	0.75
# 99444		ONLINE E/M BY PHYS	Carrier Priced		Agree (c)	Carrier Priced.
# 99477		INIT DAY HOSP NEONATE CARE	7.00		Agree	7.00

New CPT code.

¹ All CPT codes copyright 2007 AMA.

* New Code for Re-Examination at the next 5-Year Review.

** Denotes restricted coverage of code.

(a) No RUC work RVU recommendation.

(a)* See code discussion in Section F, Discussion of Codes and RUC/HCPAC Recommendations.

(b) RUC-recommended work RVU accepted but coverage status of code is Bundled.

(c) RUC-recommended work RVU accepted but coverage status of code is Noncovered.

Table 17: AMA RUC Anesthesia Recommendations and CMS Decisions for New and Revised 2008 CPT Codes lists the new or revised CPT codes for anesthesia and their base units that will be interim in CY 2008. Table 17 includes the following information:

- CPT code. This is the CPT code for a service.

- Description. This is an abbreviated version of the narrative description of the code.
- RUC recommendations. This column identifies the base units recommended by the RUC.
- CMS decision. This column indicates whether we agreed or we disagreed with the RUC

recommendation. Codes for which we did not accept the RUC recommendation are discussed in greater detail following this table.

- 2008 Base Units. This column establishes the CY 2007 base units for these services.

TABLE 17.—AMA RUC ANESTHESIA RECOMMENDATIONS AND CMS DECISIONS FOR NEW AND REVISED/REVIEWED CPT CODES

*CPT ¹ code	Description	RUC recommendation	CMS decision	2008 base units
## 00142	ANESTH, LENS SURGERY	4.00	Agree	4.00
# 01935	ANESTH, PERC IMG DX SP PROC	5.00	Agree	5.00
# 01936	ANESTH, PERC IMG TX SP PROC	5.00	Agree	5.00

¹ All CPT codes copyright 2007 AMA.

New CPT code.

Note: CPT code 00142 is neither a new nor revised code for 2008. However, the RUC reviewed the base unit values for this code for 2008 and recommended that the value be maintained.

F. Discussion of Codes and RUC/HCPAC Recommendations

The following is a summary of our rationale for not accepting particular RUC work RVUs. It is arranged by type of service in CPT order. This summary refers only to work RVUs.

1. Internal Fixation Codes—Shoulder/Elbow (CPT codes 23515, 23585, 23615, 23616, 23680, 23670, 23680, 24545, 24546, 24575 and 24579), Elbow/Hand (CPT codes 24635, 24685, 25515, 25525, 25526, 25545, 25574, 25575, 25628, 26615, 26650, 26665, 26685, 26715, 26735, 26746, 26765, 26785), Hip and Knee (CPT codes 27248, 27511, 27513, 27514, 27519, 27535, 27540, 27556, 27557 and 27558) and Foot and Ankle (CPT codes 27766, 27784, 27792, 27814, 27822, 27823, 27826, 27827, 27828, 27829, 27832, 28415, 28420, 28445, 28465, 28485, 28505, 28525, 28555, 28585, 28615, 28645 and 28675)

These codes were originally part of the 5-Year Review of work RVUs and were referred to the CPT Editorial Panel by the RUC for further clarification because it was unclear whether the previous valuation for these codes included the situation when internal and external fixation is applied to the fracture site. The CPT Editorial Panel agreed that these codes needed to be clarified and removed reference to external fixation from these codes. As a result of this editorial change, the RUC reexamined these families of codes and recommended increased work RVUs.

The RUC recommended 11.00 work RVUs for CPT code 23515; 16.25 work RVUs for CPT code 25385; 14.00 work RVUs for CPT code 23615; 21.00 work RVUs for CPT code 23616; 12.00 work RVUs for CPT code 23680; 14.00 work RVUs for CPT code 23670; 15.00 work RVUs for CPT code 23680; 15.00 work RVUs for CPT code 24545; 17.01 work RVUs for CPT code 24546; 11.00 work RVUs for CPT code 24575; 13.00 work RVUs for CPT code 24579; 10.00 work RVUs for CPT code 24635; 9.50 work RVUs for CPT code 24685; 10.00 work RVUs for CPT code 25515; 12.00 work RVUs for CPT code 25525; 15.00 work RVUs for CPT code 25526; 9.00 work RVUs for CPT code 25545; 10.00 work RVUs for CPT code 25574; 14.00 work RVUs for CPT code 25575; 11.00 work RVUs for CPT code 25628; 8.00 work RVUs for CPT code 26615; 6.00 work RVUs for CPT code 26650; 9.00 work RVUs for CPT code 26665; 8.00 work RVUs for CPT code 26685; 7.95 work RVUs for CPT code 26715; 8.40 work

RVUs for CPT code 26735; 11.10 work RVUs for CPT code 26746; 6.60 work RVUs for CPT code 26765; 7.45 work RVUs for CPT code 26785; 12.83 work RVUs for CPT code 27248; 18.05 work RVUs for CPT code 27511; 23.04 work RVUs for CPT code 27513; 17.43 work RVUs for CPT code 27514; 15.80 work RVUs for CPT code 27519; 16.00 work RVUs for CPT code 27535; 13.45 work RVUs for CPT code 27540; 15.50 work RVUs for CPT code 27556; 19.00 work RVUs for CPT code 27557; 22.00 work RVUs for CPT code 27558; 8.50 work RVUs for CPT code 27766; 10.45 work RVUs for CPT code 27784; 10.50 work RVUs for CPT code 27792; 11.50 work RVUs for CPT code 27814; 12.12 work RVUs for CPT code 27822; 14.26 work RVUs for CPT code 27823; 12.00 work RVUs for CPT code 27826; 16.00 work RVUs for CPT code 27827; 20.00 work RVUs for CPT code 27828; 9.50 work RVUs for CPT code 27829; 11.00 work RVUs for CPT code 27832; 17.54 work RVUs for CPT code 28415; 19.00 work RVUs for CPT code 28420; 17.07 work RVUs for CPT code 28445; 9.50 work RVUs for CPT code 28465; 8.00 work RVUs for CPT code 28485; 8.00 work RVUs for CPT code 28505; 6.00 work RVUs for CPT code 28525; 10.43 work RVUs for CPT code 28555; 12.00 work RVUs for CPT code 28585; 11.50 work RVUs for CPT code 28615; 8.00 work RVUs for CPT code 28645; and 6.00 work RVUs for CPT code 28675.

Although we agree with the relationships, the increases in work RVUs reestablish the relativity of the services in these families and in doing so created BN issues. In order to retain BN within these families of codes, the work RVUs associated with each code had to be adjusted. That is, the work RVUs were adjusted so that the sum of the new or revised work RVUs (weighted by projected frequency of use) for each family will be the same as the sum of the current work RVUs (weighted by projected frequency of use) for each family of codes. The adjusted work RVUs are as follows: 9.53 work RVUs for CPT code 23515; 14.07 work RVUs for CPT code 25385; 12.12 work RVUs for CPT code 23615; 18.19 work RVUs for CPT code 23616; 10.39 work RVUs for CPT code 23680; 12.12 work RVUs for CPT code 23670; 12.99 work RVUs for CPT code 23680; 12.99 work RVUs for CPT code 24545; 14.73 work RVUs for CPT code 24546; 9.53 work RVUs for CPT code 24575; 11.26 work RVUs for CPT code 24579; 8.64 work

RVUs for CPT code 24635; 8.21 work RVUs for CPT code 24685; 8.64 work RVUs for CPT code 25515; 10.37 work RVUs for CPT code 25525; 12.96 work RVUs for CPT code 25526; 7.78 work RVUs for CPT code 25545; 8.64 work RVUs for CPT code 25574; 12.10 work RVUs for CPT code 25575; 9.51 work RVUs for CPT code 25628; 6.91 work RVUs for CPT code 26615; 5.19 work RVUs for CPT code 26650; 7.78 work RVUs for CPT code 26665; 6.91 work RVUs for CPT code 26685; 6.87 work RVUs for CPT code 26715; 7.26 work RVUs for CPT code 26735; 9.59 work RVUs for CPT code 26746; 5.70 work RVUs for CPT code 26765; 6.44 work RVUs for CPT code 26785; 10.64 work RVUs for CPT code 27248; 14.97 work RVUs for CPT code 27511; 19.11 work RVUs for CPT code 27513; 14.46 work RVUs for CPT code 27514; 13.11 work RVUs for CPT code 27519; 13.27 work RVUs for CPT code 27535; 11.16 work RVUs for CPT code 27540; 12.86 work RVUs for CPT code 27556; 15.76 work RVUs for CPT code 27557; 18.25 work RVUs for CPT code 27558; 7.73 work RVUs for CPT code 27766; 9.51 work RVUs for CPT code 27784; 9.55 work RVUs for CPT code 27792; 10.46 work RVUs for CPT code 27814; 11.03 work RVUs for CPT code 27822; 12.98 work RVUs for CPT code 27823; 10.92 work RVUs for CPT code 27826; 14.56 work RVUs for CPT code 27827; 18.20 work RVUs for CPT code 27828; 8.64 work RVUs for CPT code 27829; 10.01 work RVUs for CPT code 27832; 15.96 work RVUs for CPT code 28415; 17.29 work RVUs for CPT code 28420; 15.53 work RVUs for CPT code 28445; 8.64 work RVUs for CPT code 28465; 7.28 work RVUs for CPT code 28485; 7.28 work RVUs for CPT code 28505; 5.46 work RVUs for CPT code 28525; 9.49 work RVUs for CPT code 28555; 10.92 work RVUs for CPT code 28585; 10.46 work RVUs for CPT code 28615; 7.28 work RVUs for CPT code 28645; and 5.46 work RVUs for CPT code 28675.

2. Cardiac MRI Codes

Cardiac MRI services have evolved over the past decade from providing primarily anatomic information to providing both anatomic and physiologic information. We have had a national noncoverage determination in place for Magnetic Resonance Imaging (MRI) that provides blood flow measurement since March 1994. This NCD provides that CPT code 75556,

Cardiac magnetic resonance imaging for velocity flow, is not covered.

As a result of the technological changes in MRI scanning, the CPT Editorial Panel created eight new Cardiac MRI codes and deleted five existing Cardiac MRI codes. The new codes are: CPT code 75557, *Cardiac magnetic resonance imaging for morphology and function without contrast material*; CPT code 75558, *Cardiac magnetic resonance imaging for morphology and function without contrast material; with flow/velocity quantification*; CPT code 75559, *Cardiac magnetic resonance imaging for morphology and function without contrast material; with stress imaging*; CPT code 75560, *Cardiac magnetic resonance imaging for morphology and function without contrast material; with flow/velocity quantification and stress*; CPT code 75561, *Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences*; CPT code 75562, *Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with flow/velocity quantification*; CPT code 75563, *Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with stress imaging*; and CPT code 75564, *Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with flow/velocity quantification and stress*. The RUC recommended 2.35 work RVUs for CPT code 75557; 2.60 work RVUs for CPT code 75558; 2.95 work RVUs for CPT code 75559; 3.00 work RVUs for CPT code 75560; 2.60 work RVUs for CPT code 75561; 2.86 work RVUs for CPT code 75562; 3.00 work RVUs for CPT code 75563; and 3.35 work RVUs for CPT code 75564.

The deleted codes are: CPT code 75552, *Cardiac magnetic resonance imaging for function, without contrast material*; CPT code 75553, *Cardiac magnetic resonance imaging for function, without contrast material with contrast material*; CPT code 75554, *Cardiac magnetic resonance imaging for function, with or without morphology; complete study*; CPT code 75555, *Cardiac magnetic resonance imaging for function, with or without morphology; limited study*; and CPT code 75556, *Cardiac magnetic resonance imaging for velocity flow mapping*.

Upon review of the new cardiac MRI codes, we recognize that four of the new codes incorporate blood flow measurement, which remains one of the nationally noncovered indications for MRI in the Medicare program. Due to a national non-coverage determination for MRI that provides blood flow measurement, CPT codes 75558, 75560, 75562 and 75564 will not be recognized by the Medicare program and have been assigned a status indicator of "N" (Noncovered) on the Medicare physician fee schedule. (Note: The RUC-recommended RVUs for these codes will be reflected in Addendum B.)

The remaining codes in this family (CPT codes 75557, 75559, 75561 and 75563) will be recognized as active on the Medicare PFS.

3. Skin Test, Unlisted Antigen

For CPT code 86486, *Skin test; unlisted antigen*, the RUC did not make a work RVU recommendation. During our 2007 public meeting for new clinical laboratory tests held in accordance with § 414.506, we received approximately four comments. The commenters indicated the code belongs in the skin test code series included in the PFS with a payment crosswalk to CPT code 86490 *Skin test; coccidioidomycosis*. We agree with the recommendations. We are assigning the code a status indicator of A (Active code). The status indicator does not mean that Medicare has made a national coverage determination regarding this service. Contractors may develop local coverage determinations. CPT also deleted predecessor CPT code 86586 effective January 1, 2008; thus, CPT code 86586 will be deleted from the 2008 clinical laboratory fee schedule.

4. Wireless Pressure Sensor Implantation and Study

For CPT code 93982, *Noninvasive physiologic study of implanted wireless pressure sensor in aneurysmal sac following endovascular repair, complete study including recording, analysis of pressure and waveform tracings, interpretation and report*, the RUC recommended 0.30 work RVUs. We have assigned a status indicator of R (Restricted) to this service because the sensor used in this procedure is FDA approved for pressure interpretation at the time of an endovascular aneurysm repair only and is currently not FDA approved for the follow-up evaluation of pressure analysis in the office or outpatient setting once the patient is discharged from the hospital.

5. Non-Face-to-Face Physician and Qualified Healthcare Professional Services

For CPT code 98966, *Telephone assessment and management service provided by a qualified non-physician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 5–10 minutes of medical discussion*; CPT code 98967, *Telephone assessment and management service provided by a qualified non-physician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 11–20 minutes of medical discussion*; CPT code 98968, *Telephone assessment and management service provided by a qualified non-physician health care professional to an established patient, parent, or guardian not originating from a related assessment and management service provided within the previous seven days nor leading to an assessment and management service or procedure within the next 24 hours or soonest available appointment; 21–30 minutes of medical discussion*; CPT code 98969, *Online evaluation and management service provided by a qualified non-physician health care professional to an established patient, guardian or health care provider not originating from a related assessment and management service provided within the previous 7 days, using the Internet or similar electronic communications network*; CPT code 99441, *Telephone evaluation and management service provided by a physician to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5–10 minutes of medical discussion*; CPT code 99442, *Telephone evaluation and management service provided by a physician to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11–20 minutes of medical discussion*;

CPT code 99443, *Telephone evaluation and management service provided by a physician to an established patient, parent, or guardian not originating from a related E/M service provided within the previous seven days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21–30 minutes of medical discussion; and CPT code 99444, Online evaluation and management service provided by a physician to an established patient, guardian or health care provider not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network*, the HCPAC recommended 0.25 work RVUs for CPT code 98966; 0.50 work RVUs for CPT code 98967; 0.75 work RVUs for CPT code 98968; carrier pricing for CPT code 98969; and the RUC recommended 0.25 work RVUs for CPT code 99441; 0.50 work RVUs for CPT code 99442; 0.75 work RVUs for CPT code 99443; and carrier pricing for CPT code 99444. We are assigning a status indicator of “N” (Non-covered service) to these services because: (1) These services are non-face-to-face; and (2) the code descriptor includes language that recognizes the provision of services to parties other than the beneficiary and for whom Medicare does not provide coverage (for example, guardian). (**Note:** The RUC or HCPAC recommended RVUs for these codes will be reflected in Addendum B.)

6. Team Conference

For CPT code 99366, *Medical team conference with interdisciplinary team of health care professionals, face-to-face with patient and/or family, 30 minutes or more; participation by non-physician qualified health care professional; CPT code 99367, Medical team conference with interdisciplinary team of health care professionals, patient and/or family not present, 30 minutes or more; participation by physician; and CPT code 99368, Medical team conference with interdisciplinary team of health care professionals, patient and/or family not present, 30 minutes or more; participation by non-physician qualified health care professional*, the HCPAC recommended 0.82 work RVUs for CPT code 99366; the RUC recommended 1.10 work RVUs for CPT code 99367; and the HCPAC recommended 0.72 work RVUs for CPT code 99368. We are assigning a status indicator of “B” (Bundled) to these services because to the extent that these services are covered, we believe these services like other counseling services are incorporated into existing E/M services. (**Note:** The RUC or HCPAC

recommended RVUs for these codes will be reflected in Addendum B.)

7. Reporting of Alcohol and/or Substance Abuse Assessment and Intervention Services

For CY 2008, the CPT Editorial Panel has created two new Category I CPT codes for reporting alcohol and/or substance abuse screening. They are CPT code 99408, *Alcohol and/or substance (other than tobacco) abuse structured screening (e.g., AUDIT, DAST), and brief intervention (SBI) services; 15 to 30 minutes*, and CPT code 99409, *Alcohol and/or substance (other than tobacco) abuse structured screening (e.g., AUDIT, DAST), and brief intervention (SBI) services; greater than 30 minutes*.

The code descriptions for these CPT codes suggest that these CPT codes may describe services that include screening services. In general, screening services under Medicare are considered to be those services provided to beneficiaries in the absence of signs or symptoms of illness or injury; therefore, to the extent that the services described by these two CPT codes have a screening element, the screening component would not meet the statutory requirements for coverage under section 1862(a)(1)(A) of the Act. Screening services are not covered by Medicare without specific statutory authority, such as has been provided for mammography, diabetes, and colorectal cancer screening. Accordingly, we will not recognize these CPT codes that incorporate screening for payment under the PFS.

Instead, we have created two parallel G-codes to allow for appropriate Medicare reporting and payment for alcohol and substance abuse assessment and intervention services that are not provided as screening services, but that are performed in the context of the diagnosis or treatment of illness or injury. The codes are HCPCS code G0396, *Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST) and brief intervention, 15 to 30 minutes* and HCPCS code G0397, *Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST) and intervention greater than 30 minutes*. We will instruct Medicare contractors to pay for these codes only when considered reasonable and necessary. We will also provide coding and payment instructions for these assessment and intervention services in the program instructions implementing the CY 2008 PFS.

We are assigning a status indicator of “N” (Noncovered) to CPT codes 99408 and 99409. However, the work RVUs

and PE inputs for 99408 will be crosswalked to G0396 and the work RVUs and PE inputs for 99409 will be crosswalked to G0397.

8. Ocular Photoscreening

For CPT code 99174, *Ocular photoscreening with interpretation and report, bilateral*, the RUC did not provide a recommendation. We are assigning a status indicator of “N” (Noncovered) to this service because it is a screening service that is not covered under the Medicare statute.

G. Additional Coding Issues

1. Modifier – 51 Exempt List

The CPT Editorial Panel reviewed all of the codes on the modifier – 51 exempt list to identify which codes should be exempt from the multiple procedure payment reduction rules and which codes should be removed from the exemption list. We have reviewed all codes recommended for removal from the exemption list and agree with the CPT Editorial Panel’s recommendations. We have updated payment modifiers where applicable.

2. New Codes for Re-Examination at the Next 5-Year Review

As part of its annual recommendations, the RUC includes a list identifying new CPT codes for reexamination at the next 5-Year Review of Work RVUs. New CPT codes that have been added to this list are identified with an asterisk (*) on Table 16: AMA RUC and HCPAC Recommendations and CMS’ Decisions for New and Revised 2008 CPT Codes.

H. Establishment of Interim PE RVUs for New and Revised Physician’s Current Procedural Terminology (CPT) Codes and New Healthcare Common Procedure Coding System (HCPCS) Codes for 2008

We have developed a process for establishing interim PE RVUs for new and revised codes that is similar to that used for work RVUs. Under this process, the RUC recommends the PE direct inputs (the staff time, supplies and equipment) associated with each new code. We then review the recommendations in a manner similar to our evaluation of the recommended work RVUs. The RUC recommendations on the PE inputs for the new and revised CY 2008 codes were submitted to us as interim recommendations. We have accepted, in the interim, the PE recommendations submitted by the RUC for the codes listed in Table 16: AMA RUC and HCPAC Recommendations and CMS’ Decisions for New and Revised

2008 CPT Codes except as noted below in this section.

CPT Code Series 49450 Through 49465

In this series of nine G-, J-, and G-J Tubes CPT codes, 49440, 49441, 49442, 49446, 49450, 49451, 49452, 49460 and 49465, we made revisions to the clinical labor time to conform to the RUC-established standard under which the time assigned to any one labor type for the “intra” time, based on the physician’s time to perform the procedure, can not exceed 100 percent of the physician time. These revisions affected the service period times for the angio-tech/RT for each code. For each CPT code, the angio-tech/RT time to assist the physician in performing the procedure was allocated at 67 percent of the physician time and the angio-tech/RT time to assist the physician with image acquisition during the procedure was allocated the remaining 33 percent of the physician time.

We also made minor revisions to the supply list for this family of codes in order to match the number of requested needles with the number of syringes. We allocated one needle for each saline flush syringe and 1 additional needle to administer the lidocaine. Each needle was assigned the supply category “SC029, needle, 18–27g” to encompass both the 18g and 25g needles requested. In addition, we added a 10–12 ml syringe that could be used to administer the lidocaine.

CPT Code 50593

We disagreed with the RUC recommended number of renal cryoablation probes typically needed to perform this procedure. Instead of 4 probes, we believe that an average of 2.5 probes is typical to this procedure based on 2005 clinical data (collected at Karmonos Cancer Institute) that was included as an attachment to information provided by the manufacturer. Therefore, we have assigned 2.5 probes for renal cryoablation, at \$1,175 each, for CPT 50593.

V. Physician Self-Referral Prohibition: Annual Update to List of CPT/HCPCS Codes

A. General

Section 1877 of the Act prohibits a physician from referring a Medicare beneficiary for certain designated health services (DHS) to a health care entity with which the physician (or a member of the physician’s immediate family) has a financial relationship, unless an exception applies. Section 1877 of the Act also prohibits the DHS entity from

submitting claims to Medicare or billing the beneficiary or any other entity for Medicare DHS that are furnished as a result of a prohibited referral.

As specified in our regulations at § 411.351, the following services are DHS:

- Clinical laboratory services.
- Physical therapy, occupational therapy, and speech-language pathology services.
- Radiology and certain other imaging services.
- Radiation therapy services and supplies.
- Durable medical equipment and supplies.
- Parenteral and enteral nutrients, equipment, and supplies.
- Prosthetics, orthotics, and prosthetic devices and supplies.
- Home health services.
- Outpatient prescription drugs.
- Inpatient and outpatient hospital services.

B. Annual Update to the Code List

1. Background

In § 411.351, we specify that the entire scope of four DHS categories is defined in a list of CPT/HCPCS codes (the Code List), which is updated annually to account for changes in the most recent CPT and HCPCS publications. The DHS categories defined and updated in this manner are:

- Clinical laboratory services.
- Physical therapy, occupational therapy, and speech-language pathology services.
- Radiology and certain other imaging services.
- Radiation therapy services and supplies.

The Code List also identifies those items and services that may qualify for either of the following two exceptions to the physician self-referral prohibition:

- EPO and other dialysis-related drugs furnished in or by an ESRD facility (§ 411.355(g)).
- Preventive screening tests, immunizations or vaccines (§ 411.355(h)).

The Code List was last updated in the CY 2007 PFS final rule with comment period (71 FR 69624) and in a subsequent correction notice (72 FR 18909).

2. Response to Comments

We received only one public comment relating to the Code List that became effective January 1, 2007. The commenter was supportive of our additions and deletions.

3. Revisions Effective for 2008

The updated, comprehensive Code List effective January 1, 2008, appears as

Addendum x in this final rule with comment period and is available on our Web site at http://www.cms.hhs.gov/PhysicianSelfReferral/11_List_of_Codes.asp#TopOfPage.

Tables 19 and 20 identify the additions and deletions, respectively, to the comprehensive Code List that was published in Addendum J of the CY 2007 PFS final rule (71 FR 70247 through 70251) and revised in a subsequent correction notice (72 FR 18909). Tables 19 and 20 also identify the additions and deletions to the lists of codes used to identify the items and services that may qualify for the exceptions in § 411.355(g) (regarding EPO and other dialysis-related outpatient prescription drugs furnished in or by an ESRD facility) and § 411.355(h) (regarding preventive screening tests, immunizations and vaccines).

The additions and deletions specified in Tables 19 and 20 are necessary to conform the Code List to the most recent publications of CPT and HCPCS and to changes in Medicare payment policies.

We will consider comments regarding the codes listed in Tables 19 and 20. Comments will be considered if we receive them by the date specified in the DATES section of this final rule with comment period. We will not consider any comment that advocates a substantive change to any of the DHS defined in § 411.351.

TABLE 19.—ADDITIONS TO THE PHYSICIAN SELF-REFERRAL LIST OF CPT¹ HCPCS CODES

CLINICAL LABORATORY SERVICES	
[no additions]	
PHYSICAL THERAPY, OCCUPATIONAL THERAPY, AND SPEECH-LANGUAGE PATHOLOGY SERVICES	
96125	Cognitive test by HC pro.
RADIOLOGY AND CERTAIN OTHER IMAGING SERVICES	
75557	Cardiac mri for morph.
75558	Cardiac mri flow/velocity.
75559	Cardiac mri w/stress img.
75560	Cardiac mri flow/vel/stress.
75561	Cardiac mri for morph w/dye.
75562	Card mri flow/vel w/dye.
75563	Card mri w/stress img & dye.
75564	Ht mri w/flo/vel/strs & dye.
A9501	Technetium TC-99m teboroxime.
A9509	Iodine I-123 sod iodide mil.
A9569	Technetium TC-99m auto WBC.
A9570	Indium In-111 auto WBC.
A9571	Indium In-111 auto platelet.

TABLE 19.—ADDITIONS TO THE PHYSICIAN SELF-REFERRAL LIST OF CPT¹/HCPCS CODES—Continued

A9572	Indium In-111 pentetretotide.
A9576	Inj prohance multipack.
A9577	Inj multihance.
A9578	Inj multihance multipack.
A9579	Gad-base MR contrast NOS, 1ml.
Q9965	LOCM 100–199mg/ml iodine, 1ml.
Q9966	LOCM 200–299mg/ml iodine, 1ml.
Q9967	LOCM 300–399mg/ml iodine, 1ml.
RADIATION THERAPY SERVICES AND SUPPLIES	
0182T	HDR elect brachytherapy.
20555	Place ndl musc/tis for rt.
41019	Place needles h&n for rt.
55920	Place needles pelvic for rt.
C1716	Brachytx source, Gold 198.
C1717	Brachytx source, HDR Ir-192.
C1719	Brachytx source, Non-HDR Ir-192.
C2616	Brachytx source, Yttrium-9.
C2634	Brachytx source, HA, I-125.
C2635	Brachytx source, HA, P-13.
C2636	Brachytx linear source, P-13.
C2637	Brachytx, Ytterbium-169.
C2638	Brachytx, stranded, I-125.
C2639	Brachytx, non-stranded, I-125.
C2640	Brachytx, stranded, P-13.
C2641	Brachytx, non-stranded, P-13.
C2642	Brachytx, stranded, C-131.
C2643	Brachytx, non-stranded, C-131.
C2698	Brachytx, stranded, NOS.
C2699	Brachytx, non-stranded, NOS.

DRUGS USED BY PATIENTS UNDERGOING DIALYSIS

[no additions]

PREVENTIVE SCREENING TESTS, IMMUNIZATIONS AND VACCINES

90669	Pneumococcal vacc, ped <5.
-------	----------------------------

¹ CPT codes and descriptions only are copyright 2007 AMA. All rights are reserved and applicable FARS/DFARS clauses apply.

TABLE 20.—DELETIONS TO THE PHYSICIAN SELF-REFERRAL LIST OF CPT¹/HCPCS CODES

CLINICAL LABORATORY SERVICES

[no deletions]

TABLE 20.—DELETIONS TO THE PHYSICIAN SELF-REFERRAL LIST OF CPT¹/HCPCS CODES—Continued

PHYSICAL THERAPY, OCCUPATIONAL THERAPY, AND SPEECH-LANGUAGE PATHOLOGY SERVICES

[no deletions]

RADIOLOGY AND CERTAIN OTHER IMAGING SERVICES

75552	Heart mri for morph w/o dye.
75553	Heart mri for morph w/dye.
75554	Cardiac MRI/function.
75555	Cardiac MRI/limited study.
78609	Brain imaging (PET).
78615	Cerebral vascular flow image.
A9565	In111 pentetretotide.
Q9945	LOCM≤149mg/ml iodine, 1ml.
Q9946	LOCM 150–199mg/ml iodine, 1ml.
Q9947	LOCM 200–249mg/ml iodine, 1ml.
Q9948	LOCM 250–299mg/ml iodine, 1ml.
Q9949	LOCM 300–349mg/ml iodine, 1ml.
Q9950	LOCM 350–399mg/ml iodine, 1ml.
Q9952	Inj Gad-base MR contrast, 1ml.

RADIATION THERAPY SERVICES AND SUPPLIES

[no deletions]

DRUGS USED BY PATIENTS UNDERGOING DIALYSIS

[no deletions]

PREVENTIVE SCREENING TESTS, IMMUNIZATIONS AND VACCINES

[no deletions]

¹ CPT codes and descriptions only are copyright 2007 AMA. All rights are reserved and applicable FARS/DFARS clauses apply.

VI. Physician Fee Schedule Update for CY 2008

A. Physician Fee Schedule Update

The PFS update is set under a formula specified in section 1848(d)(4) of the Act, as amended by the MIEA–TRHCA. Section 101 of the MIEA–TRHCA provided a 1 year increase in the CY 2007 conversion factor and specified that the conversion factor for CY 2008 must be computed as if the 1-year increase had never applied. Consistent with this requirement, the update for CY 2008 is equal to the product of 1 plus the CY 2007 update (as published in the CY 2007 PFS final rule with comment period (71 FR 69751)), 1 plus the percentage increase in the MEI (divided by 100), and 1 plus the UAF. As stated in the CY 2007 PFS final rule with comment period, if section 101 of the

MIEA–TRHCA had not subsequently been enacted, the CY 2007 update would have been – 5.0 percent (0.94953). For CY 2008, the MEI is equal to 1.8 percent (1.018). The UAF is – 7.0 percent (0.930). The product of the published CY 2007 update (0.94953), MEI (1.018), and the UAF (0.930) equals the CY 2008 update of – 10.1 percent (0.89896).

Our calculations of these figures are explained in this section.

B. The Percentage Change in the Medicare Economic Index (MEI)

The Medicare Economic Index (MEI) is authorized by section 1842(b)(3) of the Act, which states that prevailing charge levels beginning after June 30, 1973 may not exceed the level from the previous year except to the extent that the Secretary finds, on the basis of appropriate economic index data, that the higher level is justified by year-to-year economic changes.

The MEI measures the weighted-average annual price change for various inputs needed to produce physicians' services. The MEI is a fixed-weight input price index, with an adjustment for the change in economy-wide multifactor productivity. This index, which has CY 2000 base year weights, is comprised of two broad categories: (1) Physician's own time; and (2) physician's PE.

The physician's own time component represents the net income portion of business receipts and primarily reflects the input of the physician's own time into the production of physicians' services in physicians' offices. This category consists of two subcomponents: (1) Wages and salaries; and (2) fringe benefits.

The physician's PE category represents nonphysician inputs used in the production of services in physicians' offices. This category consists of wages and salaries and fringe benefits for nonphysician staff and other nonlabor inputs. The physician's PE component also includes the following categories of nonlabor inputs: Office expense; medical materials and supplies; professional liability insurance; medical equipment; prescription drugs; and other expenses. The components are adjusted to reflect productivity growth in physicians' offices by the 10-year moving average of productivity in the private nonfarm business sector.

In the CY 2008 PFS proposed rule (72 FR 38190), we presented a listing of the cost categories with the associated cost weights. We also explained that the Bureau of Labor Statistics (BLS) has discontinued production and publication of the white collar

occupation employment cost index (ECI) series which was used as the price proxy for nonphysician benefits in the MEI. There was no other comparable published series that was a suitable replacement for the white collar benefit ECI. Therefore, a nationally recognized economic and financial forecasting firm, Global Insight, Inc. (GII), and CMS jointly developed a composite series which is composed of four published ECI series and weighted by November 2004 National Industry Specific

Occupational Employment and Wage Estimates for NAICS 6211, Office of Physicians. We proposed to replace the ECI white collar benefit series with this composite benefit index effective for the CY 2008 MEI update (See the CY 2008 PFS proposed rule (72 FR 38190) for a more detailed explanation of the specific proposal). In addition, we also published a preliminary estimate of the expected MEI update.

Table 21 presents a listing of the MEI cost categories with associated weights and percent changes for price proxies

for the 2008 update. For CY 2008, the increase in the MEI is 1.8 percent, which includes a 1.4 percent productivity offset based on the 10-year moving average of multifactor productivity. This is the result of a 3.7 percent increase in physician's own time and a 2.7 percent increase in physician's PE. Within the physician's PE, the largest increase occurred in prescription drugs, which increased 4.2 percent, and professional and technical wages, which increased 4.0 percent.

TABLE 21.—INCREASE IN THE MEDICARE ECONOMIC INDEX UPDATE FOR CY 2008¹

Cost categories and price measures	CY 2000 weights ²	CY 2008 percent changes
Medicare Economic Index Total, productivity adjusted ³	N/A	1.8
Productivity: 10-year moving average of multifactor productivity, private nonfarm business sector ^{3,4}	N/A	1.4
Medicare Economic Index Total, without productivity adjustment ⁴	100.000	3.2
1. Physician's Own Time ⁵	52.466	3.7
a. Wages and Salaries: Average Hourly Earnings, private Nonfarm	42.730	4.0
b. Fringe Benefits: Employment Cost Index, benefits, private nonfarm	9.735	2.7
2. Physician's Practice Expense ⁵	47.534	2.7
a. Nonphysician Employee Compensation	18.653	3.6
(1) Wages and Salaries: Employment Cost Index, wages and salaries, weighted by occupation	13.808	3.6
(2) Fringe Benefits: Employment Cost Index, fringe benefits, weighted by occupation ⁷	4.845	3.7
b. Office Expense: Consumer Price Index for Urban Areas (CPI-U), housing	12.209	3.5
c. Drugs and Medical Materials and Supplies	4.319	2.9
(1) Medical Materials and Supplies: Producer Price Index (PPI), surgical appliances and supplies/CPI-U, medical equipment and supplies (equally weighted)	2.011	1.0
(2) Pharmaceuticals: Producer Price Index (PPI ethical prescription drugs)	2.308	4.2
d. Professional Liability Insurance: Professional liability insurance Premiums ⁶	3.865	-0.8
e. Medical Equipment: PPI, medical instruments and equipment	2.055	-0.4
f. Other Expenses	6.433	2.6

¹ The rates of historical change are estimated for the 12-month period ending June 30, 2007, which is the period used for computing the CY 2008 update. The price proxy values are based upon the latest available Bureau of Labor Statistics data as of August 31, 2007.

² The weights shown for the MEI components are the 2000 base year weights, which may not sum to subtotals or totals because of rounding. The MEI is a fixed weight, Laspeyres-type input price index whose category weights indicate the distribution of expenditures among the inputs to physicians' services for CY 2000. To determine the MEI level for a given year, the price proxy level for each component is multiplied by its 2000 weight. The sum of these products (weights multiplied by the price index levels) over all cost categories yields the composite MEI level for a given year. The annual percent change in the MEI levels is an estimate of price change over time for a fixed market basket of inputs to physicians' services.

³ These numbers may not sum due to rounding and the multiplicative nature of their relationship.

⁴ On March 23, 2006, Bureau of Labor Statistics introduced a new Multi Factor Productivity (MFP) series based on the 1997 NAICS classification system to replace its SIC based series published until 2005 (the last historical value was for 2002). The new series differs historically from the old MFP series and adds two new historical values through 2004. Therefore, we used the most recently available information (thru CY 2006) to develop the productivity adjustment for the CY 2008 update.

⁵ The measures of productivity, average hourly earnings, Employment Cost Indexes, as well as the various Producer and CPIs can be found on the BLS Web site at <http://stats.bls.gov>.

⁶ Derived from data collected from several major insurers (the latest available historical percent change data are for the period ending second quarter of 2007).

⁷ In April 2007, with their March 2007 publication, Bureau of Labor Statistics (BLS) discontinued production and publication of the white collar occupation employment cost index (ECI) series. CMS replaced this proxy with a composite benefit series. The historical percent changes for the non physician employee benefits match the BLS white collar benefit series through 2006Q4, and from 2007Q1 forward, the percent changes reflect those of the composite benefit series. For more detail on the composite benefit series see the CY 2008 PFS proposed rule (72 FR 38190).

Comment: Many commenters proposed that we should reduce the productivity adjustment to the MEI to 0.65 percentage points from the proposed productivity adjustment of 1.5 percentage points. They believe the MEI should be subject to the same productivity adjustment as the recommended productivity adjustment for hospital, hospice, and ambulance care providers, which they state was recommended in the President's Budget

proposal. The commenters also note that it is not logical for CMS to believe that physician's productivity is increasing at twice the rate of other health care providers.

Response: We disagree that the productivity adjustment to the MEI should be changed based on the proposals made in the FY 2008

President's Budget.⁴ The MEI has contained a productivity adjustment since its inception in 1973. The rationale for, and technical appropriateness of the current MEI productivity adjustment has been well documented in the **Federal Register** (for example, 67 FR 80020 through 80023). Moreover, we recently partnered with

⁴ <http://www.whitehouse.gov/omb/budget/fy2008/hhs.html>.

the Assistant Secretary of Planning and Evaluation of the Department of Health and Human Services to sponsor an analysis of physician-specific productivity. The results of this effort were presented at a conference of stakeholders in October 2006. A highly respected panel of experts concluded that the use of the 10-year moving average for private, nonfarm business sector multifactor productivity was not an unreasonable proxy for physician-specific productivity. Papers from this research effort are expected to be published in the forthcoming Winter 2007/2008 edition of the *Health Care Financing Review*. We will continue to monitor, on an ongoing basis, the appropriateness of the use of this economy-wide measure of multifactor productivity for purposes of adjusting the MEI.

With respect to historical productivity achievement in other health care sectors, there is comparatively little on this topic in the literature. We intend to continue to research various health-related productivity measures and would welcome the provision of data or completed studies on this topic.

Comment: One commenter questioned why other providers receive a 0.65 percent adjustment while physicians face an adjustment of more than twice that amount.

Response: To date, there are no laws in place requiring productivity adjustments for other PPS-reimbursed providers such as hospitals, and skilled nursing facilities. However, the MEI has contained an explicit productivity adjustment since its inception in 1973. The rationale and technical appropriateness of the current MEI productivity adjustment was addressed in the CY 2003 PFS final rule with comment period (67 FR 80019).

Comment: Several commenters requested that we address the broader issue that the MEI only measures changes in the specific types of practice costs that existed in 1973. They note that inputs to the MEI are vastly different now than when the MEI was first developed in the 1970s, and suggest additional inputs may be needed to ensure that the current MEI adequately measures the costs of practicing medicine.

Response: We disagree with the commenters' claim that the MEI only measures changes in specific types of practice costs that existed in 1973. The current MEI is based on costs reported by physicians for the year 2000. The 2000-based cost weights are derived from the *2003 AMA Physician Socioeconomic Characteristics* publication (2003 Patient Care

Physician Survey data), which measures physicians' earnings and overall PEs for 2000. This is the latest available data on the breakdown of physician expenses.

Although cost weights in the various market baskets do not tend to change dramatically over short periods of time, we do recognize that they can change over long periods of time. We are presently researching alternative data sources for a forthcoming rebasing of the MEI, including the potential use of an AMA-sponsored Physician Practice Information Survey that was fielded in 2007. We have also considered data from the Census Bureau's Business Expenditure Survey (BES). This survey is the most comprehensive source of periodic national industry statistics on major economic inputs by type. Data are published every 5 years for years ending in "2" and "7". Currently the most recent data is reported for 2002. We compared the cost weights we derived from the 2002 BES data for NAICS 6211, Offices of Physicians and found that the overall cost weights for compensation and all other costs are quite similar to the cost weights for the current MEI market basket as shown in Table 22. We are optimistic that the new data from AMA or the Census Bureau will be sufficiently robust for the purpose of updating the MEI's input cost weights.

TABLE 22.—A COMPARISON OF MAJOR COST CATEGORY MEI MARKET BASKET WEIGHTS USING AMA AND BES DATA

	MB 2000 weights (percent)	2002 BES (excluding capital) (percent)
Compensation ...	71.2	73.5
Other	28.8	26.5

Comment: Several commenters believe that the MEI does not adequately account for the costs related to the multitude of regulations and requirements that physicians must comply with in their practices. For example, they note that the physician quality reporting initiative (PQRI) has reduced productivity in physician's offices. Similarly, a commenter had concerns that employee wages used in the MEI formula do not capture the wages of highly skilled professionals such as nurse practitioners, physician assistants, certified nurse specialists, nurse midwives, therapists, computer professional, and other types of professional occupations.

Response: The current MEI cost weights are based on input costs reported by physicians for 2000, which

would reflect changes in the distributions of the cost weights associated with new government-imposed regulatory requirements up to that point. These cost weights are derived from the *2003 AMA Physician Socioeconomic Characteristics* publication (2003 Patient Care Physician Survey data), which measures physicians' earnings and overall PEs for CY 2000. While we understand that more recent data would better measure relative input costs, we presently lack a viable alternative data source with which to compute new cost weights. The data used as the basis for the current MEI market basket cost weights represent the latest available data on physician expenses. As stated previously, we are awaiting the data from the 2007 AMA Physician Practice Information Survey and are hopeful that this source will be sufficiently robust for use in rebasing the cost weights found in the MEI. We would expect that any relative cost changes related to regulatory changes would be reflected in this new data.

Comment: One commenter suggested we should discontinue use of the MEI to measure physician input price pressures and switch to the same market basket update used by the hospital outpatient prospective payment system (OPPS).

Response: We disagree with the commenter that physicians and outpatient hospital departments face the same input costs.

The MEI reflects the cost structure and price changes associated with the inputs used in furnishing physicians' services while the hospital market basket reflects the cost structure and price changes associated with the inputs used in providing hospital services.

Comment: One commenter noted that input expenses for recruiting and employing trained personnel and other PEs in the physician's office are identical to those in a hospital.

Response: The expenses for trained personnel are captured in the PE portion of the MEI. These PE cost weights are derived from the *2003 AMA Physician Socioeconomic Characteristics* publication (2003 Patient Care Physician Survey data), which measures physicians' earnings and overall PEs for CY 2000. As indicated above in this section, while we understand that more recent data would better measure relative input costs, we presently lack a viable alternative data source with which to compute new cost weights. The data used as the basis for the current MEI market basket cost weights represent the latest available data on physician expenses. We are awaiting the

data from the 2007 AMA Physician Practice Information Survey and are hopeful that this source will be sufficiently robust for use in rebasing the cost weights found in the MEI. We would expect that any relative cost changes related to PE costs would be reflected in this new data.

Comment: One commenter disagreed with the price proxy used for office expenses in the MEI noting that the growth in office rents differ from apartment rents. The commenter also suggested that we get data from a contractor comparing the cost of building medical office space to that of residential living space.

Response: We agree that the construction costs of a physician's office differ from the construction costs of a residential dwelling; however, the cost category for office expenses is not designed to measure the changes in initial construction costs. Instead, we attempt to measure the rate of price changes related to a monthly office

expense payment. The majority of monthly office expenses are related to rent or mortgage for commercial space. As we are not aware of a publicly-available proxy that measures the price changes in rental costs of commercial space, we use what we believe to be the best, technically appropriate alternative; the consumer price index (CPI) for housing. Other major office expenses, such as medical equipment, are broken out in greater detail. Once data is available for the next rebasing of the MEI, we will explore the feasibility of breaking office expenses into more comprehensive cost categories.

Comment: One commenter has concerns that the forecasts of the MEI have been and continue to be declining (from over 3 percent to below 2 percent) for the foreseeable future. The commenter would like for CMS to examine in more detail the assumptions of the price proxy forecasts produced by Global Insight Inc. (GII).

Response: It is important to note that the MEI update is based on historical data rather than on forecasted data. For example, the CY 2008 update is based on the actual measured price inflation through the second quarter of 2007. Since the MEI update is based on historical data, not on a forecast, the concern that GII's work does not involve forecasting the price proxies for compensation and PEs accurately is not relevant. Table 23 shows the MEI updates for the past 5 years and the current CY 2008 update. While the MEI update for CY 2003 through CY 2006 was closer to 3.0 percent, the MEI update for CY 2007 and CY 2008 is closer to 2.0 percent. These lower updates are not, however, a function of an incorrect forecast. The recent lower overall MEI updates are a function of both a deceleration in input price pressures and relatively higher gains in multifactor productivity.

TABLE 23.—MEI UPDATES FOR THE PAST 5 YEARS AND THE CURRENT CY 2008 UPDATE *

MEI final updates	Adjusted	Unadjusted	Productivity
CY 2003	3.0	3.8	0.8
CY 2004	2.9	3.8	0.9
CY 2005	3.1	4.0	0.9
CY 2006	2.8	3.8	1.0
CY 2007	2.1	3.5	1.3
CY 2008	1.8	3.2	1.4

* Prior to the update for CY 2003 the MEI was adjusted for Labor productivity rather than by private non-farm multifactor productivity.

Comment: One commenter stated that the only solution the commenter would support at this time would be a nationwide legislative solution that would provide additional funding for fair and equitable payment to Medicare participating physicians in every State.

Response: We do not have the administrative authority to make such a legislative change. More so, this comment is beyond the scope of the MEI proposals of the CY 2008 PFS proposed rule.

C. The Update Adjustment Factor (UAF)

Section 1848(d) of the Act provides that the PFS update is equal to the product of the MEI and the UAF. The UAF is applied to make actual and target expenditures (referred to in the statute as "allowed expenditures") equal. Allowed expenditures are equal to actual expenditures in a base period updated each year by the sustainable growth rate (SGR). The SGR sets the annual rate of growth in allowed expenditures and is determined by a formula specified in section 1848(f) of the Act.

Section 101 of the MIEA TRHCA provided a 1 year increase in the CY 2007 conversion factor. The provision specified that the CF for CY 2008 must be computed as if the 1 year increase for CY 2007 had never applied.

1. Calculation Under Current Law

Under section 1848(d)(4)(B) of the Act, the UAF for a year beginning with CY 2001 is equal to the sum of the following—

- *Prior Year Adjustment Component.* An amount determined by—
 - + Computing the difference (which may be positive or negative) between the amount of the allowed expenditures for physicians' services for the prior year (the year prior to the year for which the update is being determined) and the amount of the actual expenditures for those services for that year;
 - + Dividing that difference by the amount of the actual expenditures for those services for that year; and
 - + Multiplying that quotient by 0.75.
 - *Cumulative Adjustment Component.* An amount determined by—

- + Computing the difference (which may be positive or negative) between the amount of the allowed expenditures for physicians' services from April 1, 1996, through the end of the prior year and the amount of the actual expenditures for those services during that period;

- + Dividing that difference by actual expenditures for those services for the prior year as increased by the SGR for the year for which the UAF is to be determined; and
- + Multiplying that quotient by 0.33.

Section 1848(d)(4)(E) of the Act requires the Secretary to recalculate allowed expenditures consistent with section 1848(f)(3) of the Act. Section 1848(f)(3) specifies that the SGR (and, in turn, allowed expenditures) for the upcoming CY (CY 2008 in this case), the current CY (that is, CY 2007) and the preceding CY (that is, CY 2006) are to be determined on the basis of the best data available as of September 1 of the current year. Allowed expenditures for a year are initially estimated and subsequently revised twice. The second revision occurs after the CY has ended

(that is, we are making the final revision to 2006 allowed expenditures in this final rule with comment). Once the SGR and allowed expenditures for a year have been revised twice, they are final.

Table 24 shows annual and cumulative allowed and actual expenditures for physicians' services from April 1, 1996 through the end of the current CY, including the short

periods in 1999 when we transitioned to a CY system. Also shown is the SGR corresponding with each period. The calculation of the SGR is discussed in detail below in this section.

TABLE 24.—ANNUAL AND CUMULATIVE ALLOWED AND ACTUAL EXPENDITURES FOR PHYSICIANS' SERVICES FROM APRIL 1, 1996 THROUGH THE END OF THE CURRENT CALENDAR YEAR

Period	Annual allowed expenditures (\$ in billions)	Annual actual expenditures (\$ in billions)	Cumulative allowed expenditures (\$ in billions)	Cumulative actual expenditures (\$ in billions)	FY/CY SGR
4/1/96–3/31/97	¹ \$48.9	\$48.9	\$48.9	\$48.9	N/A
4/1/97–3/31/98	50.5	49.4	99.4	98.4	FY 1998=3.2%
4/1/98–3/31/99	52.6	50.5	152.0	148.9	FY 1999=4.2%
1/1/99–3/31/99	13.3	13.1	(²)	148.9	FY 1999=4.2%
4/1/99–12/31/99	42.1	39.5	(³)	188.4	FY 2000=6.9%
1/1/99–12/31/99	55.3	52.6	194.0	188.4	FY 1999/2000
1/1/00–12/31/00	59.3	58.1	253.4	246.5	CY 2000=7.3%
1/1/01–12/31/01	62.0	66.3	315.4	312.8	CY 2001=4.5%
1/1/02–12/31/02	67.2	70.9	382.6	383.7	CY 2002=8.3%
1/1/03–12/31/03	72.1	78.2	454.6	461.9	CY 2003=7.3%
1/1/04–12/31/04	76.8	87.1	531.5	549.0	CY 2004=6.6%
1/1/05–12/31/05	80.1	91.8	611.5	640.8	CY 2005=4.2%
1/1/06–12/31/06	81.3	93.4	692.8	734.2	CY 2006=1.5%
1/1/07–12/31/07	83.9	94.6	776.6	828.8	CY 2007=3.2%
1/1/08–12/31/08	83.8	NA	860.4	NA	CY 2008= 0.1%

¹ Allowed expenditures in the first year (April 1, 1996–March 31, 1997) are equal to actual expenditures. All subsequent figures are equal to quarterly allowed expenditure figures increased by the applicable SGR. Cumulative allowed expenditures are equal to the sum of annual allowed expenditures. We provide more detailed quarterly allowed and actual expenditure data on our Web site at the following address: <http://www.cms.hhs.gov/SustainableGRatesConFact/>. We expect to update the Web site with the most current information later this month.

² Allowed expenditures for the first quarter of 1999 are based on the FY 1999 SGR.

³ Allowed expenditures for the last three quarters of 1999 are based on the FY 2000 SGR.

Consistent with section 1848(d)(4)(E) of the Act, Table 24 includes our final revision of allowed expenditures for CY 2006, a recalculation of allowed expenditures for CY 2007, and our initial estimate of allowed expenditures for CY 2008. To determine the UAF for CY 2008, the statute requires that we

use allowed and actual expenditures from April 1, 1996 through December 31, 2007 and the CY 2008 SGR. Consistent with section 1848(d)(4)(E) of the Act, we will be making revisions to the CY 2007 and CY 2008 SGRs and CY 2007 and CY 2008 allowed expenditures. Because we have

incomplete actual expenditure data for CY 2007, we are using an estimate for this period. Any difference between current estimates and final figures will be taken into account in determining the UAF for future years.

We are using figures from Table 24 in the following statutory formula:

$$UAF_{08} = \frac{Target_{07} - Actual_{07}}{Actual_{07}} \times .75 + \frac{Target_{4/96-12/07} - Actual_{4/96-12/07}}{Actual_{07} \times SGR_{08}} \times .33$$

UAF₀₈ = Update Adjustment Factor for CY 2008 = -26.7 percent
 Target₀₇ = Allowed Expenditures for CY 2007 = \$83.9 billion

Actual₀₇ = Estimated Actual Expenditures for CY 2007 = \$94.6 billion
 Target_{4/96-12/07} = Allowed Expenditures from 4/1/1996–12/31/2007 = \$776.6 billion

Actual_{4/96-12/07} = Estimated Actual Expenditures from 4/1/1996–12/31/2007 = \$828.8 billion
 SGR₀₈ = -0.1 percent (0.999)

$$\frac{\$83.9 - \$94.6}{\$94.6} \times .75 + \frac{\$776.6 - \$828.8}{\$94.6 \times 0.999} \times .33 = -0.267$$

Section 1848(d)(4)(D) of the Act indicates that the UAF determined under section 1848(d)(4)(B) of the Act for a year may not be less than -0.070 or greater than 0.03. Since -0.267 is less than -0.070, the UAF for CY 2008 will be -0.070.

Section 1848(d)(4)(A)(ii) of the Act indicates that 1.0 should be added to the UAF determined under section

1848(d)(4)(B) of the Act. Thus, adding 1.0 to -0.070 makes the UAF equal to 0.930.

VII. Allowed Expenditures for Physicians' Services and the Sustainable Growth Rate

A. Medicare Sustainable Growth Rate

The SGR is an annual growth rate that applies to physicians' services paid by Medicare. The use of the SGR is intended to control growth in aggregate Medicare expenditures for physicians'

services. Payments for services are not withheld if the percentage increase in actual expenditures exceeds the SGR. Rather, the PFS update, as specified in section 1848(d)(4) of the Act, is adjusted based on a comparison of allowed expenditures (determined using the SGR) and actual expenditures. If actual expenditures exceed allowed expenditures, the update is reduced. If actual expenditures are less than allowed expenditures, the update is increased.

Section 1848(f)(2) of the Act specifies that the SGR for a year (beginning with CY 2001) is equal to the product of the following four factors:

- (1) The estimated change in fees for physicians' services;
- (2) The estimated change in the average number of Medicare fee-for-service beneficiaries;
- (3) The estimated projected growth in real GDP per capita; and
- (4) The estimated change in expenditures due to changes in statute or regulations.

In general, section 1848(f)(3) of the Act requires us to publish SGRs for 3 different time periods, no later than November 1 of each year, using the best data available as of September 1 of each year. Under section 1848(f)(3)(C)(i) of the Act, the SGR is estimated and subsequently revised twice (beginning with the FY and CY 2000 SGRs) based on later data. (The Act also provides for adjustments to be made to the SGRs for FY 1998 and FY 1999. See the February 28, 2003 **Federal Register** (68 FR 9567) for a discussion of these SGRs). Under section 1848(f)(3)(C)(ii) of the Act, there are no further revisions to the SGR once it has been estimated and subsequently revised in each of the 2 years following the preliminary estimate. In this final rule with comment, we are making our preliminary estimate of the CY 2008 SGR, a revision to the CY 2007 SGR, and our final revision to the CY 2006 SGR.

B. Physicians' Services

Section 1848(f)(4)(A) of the Act defines the scope of physicians' services covered by the SGR. The statute indicates that "the term physicians' services includes other items and services (such as clinical diagnostic laboratory tests and radiology services), specified by the Secretary, that are commonly performed or furnished by a physician or in a physician's office, but does not include services furnished to a Medicare+Choice plan enrollee." We published a definition of physicians' services for use in the SGR in the November 1, 2001 **Federal Register** (66 FR 55316). We defined physicians' services to include many of the medical

and other health services listed in section 1861(s) of the Act. For purposes of determining allowed expenditures, actual expenditures, and SGRs, we have specified that physicians' services include the following medical and other health services if bills for the items and services are processed and paid by Medicare carriers (and those paid through intermediaries where specified):

- Physicians' services.
- Services and supplies furnished incident to physicians' services.
- Outpatient physical therapy services and outpatient occupational therapy services.
- Antigens prepared by, or under the direct supervision of, a physician.
- Services of PAs, certified registered nurse anesthetists, certified nurse midwives, clinical psychologists, clinical social workers, NPs, and certified nurse specialists.
- Screening tests for prostate cancer, colorectal cancer, and glaucoma.
- Screening mammography, screening pap smears, and screening pelvic exams.
- Diabetes outpatient self-management training (DSMT) services.
- MNT services.
- Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests (including outpatient diagnostic laboratory tests paid through intermediaries).
- X-ray, radium, and radioactive isotope therapy.
- Surgical dressings, splints, casts, and other devices used for the reduction of fractures and dislocations.
- Bone mass measurements.
- An initial preventive physical exam.
- Cardiovascular screening blood tests.
- Diabetes screening tests.
- Telehealth services.
- Physician work and resources to establish and document the need for a power mobility device (70 FR 50940).

Telehealth services and the power mobility device related services were added because they meet the statutory criteria for services to be included in the SGR (that is, these services are commonly performed or furnished by a physician or in a physician's office) (70 FR 70305).

Summary of Comments on the Physician Update and the SGR

We appreciate the comments we received expressing concern about the negative update for CY 2008 and the SGR formula. These comments and our responses are summarized here.

Comment: The 2007 Medicare Trustees Report projected an

approximate 10 percent reduction in payment for physicians' services in CY 2008 and about a 5 percent reduction in each subsequent year through CY 2016. The cumulative impact of the projected reductions from CY 2008 to CY 2016 is estimated to be about -40 percent. In contrast, the MEI increase over this same period is projected to be about 15 percent.

Commenters noted that Medicare reimbursement does not reflect the actual costs of delivering services to Medicare beneficiaries. The commenters stated the reimbursement system has been unstable, and physicians cannot plan for the future in an unpredictable reimbursement environment that fails to keep pace with the costs of labor and supplies. Commenters also stated that practitioners unable to absorb the sustained losses will refuse or limit Medicare patients, resulting in reduced access to care. Commenters believe that beneficiaries will be forced to seek care in inpatient settings, which will be more costly for Medicare, less efficient in delivering care, and yield worse health outcomes for beneficiaries.

Commenters recommended that the SGR be replaced with a more equitable and sustainable formula, such as an appropriate inflation rate linked to changes in the actual costs of medical practice. Many commenters suggested the MEI as an appropriate measure. Commenters requested that we assume the leadership in pushing the Congress to enact legislation preventing a negative update for CY 2008, and to replace the SGR with a more sustainable system.

Response: We understand the potential implications of more than 9 years of negative physician updates. We remain concerned regarding these trends, and we are closely monitoring physicians' participation in the Medicare program, as well as beneficiaries' access to care.

It is a top priority at CMS to transform Medicare from a passive payor to an active purchaser of high quality, efficient health care services. We are studying and implementing value based purchasing initiatives for Medicare payment systems, including physicians' services. In addition, the FY 2008 President's Budget supports budget neutral physician payment reform and states that "an important component of improving quality is encouraging more efficient and high-quality physician services." (For further discussion of the President's FY 2008 Budget initiatives to improve the quality, efficiency and transparency of health care, see <http://www.whitehouse.gov/omb/budget/fy2008/hhs.html>.)

Ultimately, the formula for the SGR and the physician update are dictated by statute. We are required to follow this methodology when calculating the payment rates under the PFS. We look forward to working with the Congress, the physician community, and other interested parties as we continue to analyze appropriate alternatives to the current system that could ensure appropriate payments while promoting high quality care, without increasing Medicare costs.

Comment: Commenters noted that only physicians and other practitioners under the PFS face steep cuts under the SGR formula. The commenters also noted that other health care providers have payment updates that reflect the cost of inflation. Further, the commenters stated the approximately 10 percent cut in payment rates is in stark contrast to providers enrolled in Medicare Advantage (MA) plans, who are paid on average 112 percent above the cost of traditional Medicare.

Response: As noted previously, the formula for the SGR and the physician update are dictated by statute. We are required to follow this methodology when calculating the payment rates under the PFS. Other Medicare payment systems have their own update formulas.

Comment: Many commenters requested that we use our administrative authority to reduce the negative physician update for CY 2008. Many commenters stated that we are authorized to remove the cost of Medicare-covered physician-administered drugs from the SGR on a retrospective basis. They stated that we must also adjust the SGR target to reflect the impact of National and Local Coverage Decisions on physician spending. Commenters noted that the current formula does not account for costs and savings associated with new technologies. The commenters stated that if we make such administrative changes now, then the cost of legislation

revising the payment methodology for physicians' services will drop, and the likelihood of Congressional action to fix the SGR permanently will increase. Commenters expressed frustration that these administrative adjustments have been requested numerous times, yet we have never implemented the changes.

Response: We indicated in the past (most recently in the CY 2007 PFS final rule with comment period (71 FR 69756)) that many of these administrative changes are statutorily difficult, and according to our current estimates, making such changes would not provide relief from the projected negative updates for the next several years. As indicated above in this section, we are working with the Congress and health professional organizations on potential reforms that would improve the effectiveness of the payment methodology for physicians without increasing overall Medicare costs.

Comment: Commenters noted that payment updates under the SGR are tied to the gross domestic product (GDP), which bears little relationship to Medicare beneficiaries' health care needs or physician practice costs. Commenters noted that medical needs of individual patients are not related to the growth of the overall economy, and beneficiaries' medical needs do not decline during economic downturns. Commenters stated that MEI is a better reflection than GDP of the growth in health care costs.

Response: As discussed in the CY 2007 PFS final rule with comment period (71 FR 69756), the percentage change in the MEI is one of the key components used to update the PFS CF. GDP is a general measure of economic growth. It is not intended to reflect factors specific to operating a medical practice because these factors are captured in the MEI. The statute requires that GDP be used as a component of the SGR, which is then used to calculate the target level of

expenditures. Although both MEI and GDP are factors that affect the calculation of the CF, the MEI has a more direct and greater impact on the physician update than GDP.

Comment: Commenters stated that additional funds need to be added to the SGR allowed expenditures for all the ancillary costs associated with new benefits. New benefits adjust the target, but they generate other services whose costs are not added to the targeted allowed expenditures.

Response: As discussed in the CY 2007 PFS final rule with comment period (71 FR 69756 through 69757), our estimate of changes in expenditures arising from changes in laws and regulations includes induced spending impacts, when applicable and material. Our estimate of the additional expenditures associated with any new benefit, like all of the figures used to determine a particular year's SGR, is an estimate that will be revised based on subsequent data. A 2-year look back window allows adjustments to the estimates to reflect actual impacts. Any differences between these estimates and the actual measurement of these figures will be included in future revisions of the SGR and allowed expenditures and incorporated into subsequent PFS updates. (See below in this section for a discussion of all the new benefits that were considered in estimating the change in expenditures due to changes in law and regulation in 2006, 2007, and 2008.)

C. Preliminary Estimate of the SGR for 2008

Our preliminary estimate of the CY 2008 SGR is -0.1 percent. We first estimated the CY 2008 SGR in March 2007, and made the estimate available to the MedPAC and on our Web site. Table 25 shows the March 2007 estimate and our current estimates of the factors included in the CY 2008 SGR.

TABLE 25.—2008 SGR CALCULATION

Statutory factors	March estimate	Current estimate
Fees	2.0 percent (1.020)	1.9 percent (1.019).
Enrollment	-0.2 percent (0.998)	-0.7 percent (0.993).
Real Per Capita GDP	1.9 percent (1.019)	1.7 percent (1.017).
Law and Regulation	-1.5 percent (0.985)	-2.9 percent (0.971).
Total	2.2 percent (1.022)	-0.1 percent (0.999).

Note: Consistent with section 1848(f)(2) of the Act, the statutory factors are multiplied, not added, to produce the total (that is, $1.019 \times 0.993 \times 1.017 \times 0.971 = 0.999$). A more detailed explanation of each figure is provided in section VII.F.1 of this preamble.

D. Revised Sustainable Growth Rate for 2007

Our current estimate of the CY 2007 SGR is 3.2 percent. Table 26 shows our

preliminary estimate of the CY 2007 SGR that was published in the CY 2007 PFS final rule with comment period (71 FR 69757) and our current estimate.

TABLE 26.—2007 SGR CALCULATION

Statutory factors	Estimate from CY 2006 final rule	Current estimate
Fees	2.2 percent (1.022)	1.9 percent (1.019).
Enrollment	– 0.9 percent (0.991)	– 2.6 percent (0.974).
Real Per Capita GDP	2.0 percent (1.020)	1.9 percent (1.019).
Law and Regulation	– 1.5 percent (0.985)	2.0 percent (1.020).
Total	1.8 percent (1.018)	3.2 percent (1.032).

A more detailed explanation of each figure is provided in section VIII.F.2 of this preamble.

E. Final Sustainable Growth Rate for 2006

The SGR for 2006 is 1.5 percent. Table 27 shows our preliminary estimate of the 2006 SGR from the CY 2006 PFS

final rule with comment period (70 FR 70309), our revised estimate from the CY 2007 PFS final rule with comment period (71 FR 69757) and the final figures determined using the best available data as of September 1, 2007.

TABLE 27.—2006 SGR CALCULATION

Statutory factors	Estimate from CY 2006 final rule	Estimate from CY 2007 final rule	Final
Fees	2.7 percent (1.027)	2.2 percent (1.022)	2.1 percent (1.021).
Enrollment	– 3.1 percent (0.969)	– 2.2 percent (0.978)	– 2.6 percent (0.974).
Real Per Capita GDP	2.2 percent (1.022)	2.1 percent (1.021)	2.1 percent (1.021).
Law and Reg	0.0 percent (1.000)	0.0 percent (1.000)	0.0 percent (1.000).
Total	1.7 percent (1.017)	2.1 percent (1.021)	1.5 percent (1.015).

A more detailed explanation of each figure is provided in section VIII.F.3.

F. Calculation of CY 2008, CY 2007, and CY 2006 Sustainable Growth Rates

1. Detail on the CY 2008 SGR

All of the figures used to determine the CY 2008 SGR are estimates that will be revised based on subsequent data. Any differences between these estimates and the actual measurement of these figures will be included in future revisions of the SGR and allowed expenditures and incorporated into subsequent PFS updates.

- Factor 1—Changes in Fees for Physicians’ Services (Before Applying Legislative Adjustments) for CY 2008

This factor is calculated as a weighted-average of the CY 2008 changes in fees for the different types of services included in the definition of physicians’ services for the SGR. Medical and other health services paid using the PFS are estimated to account for approximately 80.4 percent of total allowed charges included in the SGR in CY 2008 and are updated using the MEI. The MEI for CY 2008 is 1.8 percent. Diagnostic laboratory tests are estimated

to represent approximately 7.6 percent of Medicare allowed charges included in the SGR for CY 2008. Medicare payments for these tests are updated by the Consumer Price Index for Urban Areas (CPI-U). However, section 629 of the MMA specifies that diagnostic laboratory services will receive an update of 0.0 percent from CY 2004 through CY 2008.

Drugs are estimated to represent 12.0 percent of Medicare allowed charges included in the SGR in CY 2008. We estimated a weighted average change in fees for drugs included in the SGR (using the ASP + 6 percent pricing methodology) of 4.0 percent for CY 2008.

Table 28 shows the weighted average of the MEI, laboratory, and drug price changes for CY 2008.

TABLE 28.—WEIGHTED AVERAGE OF THE MEI, LABORATORY, AND DRUG PRICE CHANGES FOR CY 2008

	Weight	Update
Physician	0.804	1.8
Laboratory	0.076	0.0
Drugs	0.120	4.0

TABLE 28.—WEIGHTED AVERAGE OF THE MEI, LABORATORY, AND DRUG PRICE CHANGES FOR CY 2008—Continued

	Weight	Update
Weighted-average	1.000	1.9

We estimate that the weighted average increase in fees for physicians’ services in CY 2008 under the SGR (before applying any legislative adjustments) will be 1.9 percent.

- Factor 2—The Percentage Change in the Average Number of Part B Enrollees From CY 2007 to CY 2008

This factor is our estimate of the percent change in the average number of fee-for-service enrollees from CY 2007 to CY 2008. Services provided to Medicare Advantage (MA) plan enrollees are outside the scope of the SGR and are excluded from this estimate. OACT estimates that the average number of Medicare Part B fee-for-service enrollees will decrease by 0.7 percent from CY 2007 to CY 2008. Table 29 illustrates how this figure was determined.

TABLE 29.—AVERAGE NUMBER OF MEDICARE PART B FEE-FOR-SERVICE ENROLLEES
 [(Excluding beneficiaries enrolled in MA plans) from CY 2007 to CY 2008]

	2007	2008
Overall	40.726 million	41.480 million.
Medicare Advantage (MA)	7.890 million	8.888 million.
Net	32.836 million	32.592 million.
Percent Increase	– 0.7 percent.

An important factor affecting fee-for-service enrollment is beneficiary enrollment in Medicare Advantage (MA) plans. Because it is difficult to estimate the size of the MA enrollee population before the start of a CY, at this time we do not know how actual enrollment in MA plans will compare to current estimates. For this reason, the estimate may change substantially as actual Medicare fee-for-service enrollment for CY 2008 becomes known.

- Factor 3—Estimated Real Gross Domestic Product Per Capita Growth in 2008

We estimate that the growth in real GDP per capita from CY 2007 to CY 2008 will be 1.7 percent (based on the 10-year average GDP over the 10-years of 1999–2008). Our past experience indicates that there have also been changes in estimates of real per capita GDP growth made before the year begins and the actual change in GDP computed after the year is complete. Thus, it is possible that this figure will change as actual information on economic performance becomes available to us in 2008.

- Factor 4—Percentage Change in Expenditures for Physicians’ Services Resulting From Changes in Statute or Regulations in CY 2008 Compared With CY 2007

The statutory and regulatory provisions that will affect expenditures in CY 2008 relative to CY 2007 are estimated to have an impact on expenditures of – 2.9 percent. These

provisions include the expiration of the MMA provisions for the work GPCI floor and HPSA bonuses, the DRA provision reducing payments for imaging services, and the MIEA–TRHCA provisions regarding the conversion factor and the 2007 PQRI reporting bonuses payable in 2008. The details of these provisions are discussed elsewhere in this final rule with comment.

2. Detail on the 2007 SGR

A more detailed discussion of our revised estimates of the four elements of the 2007 SGR follows.

- Factor 1—Changes in Fees for Physicians’ Services (Before Applying Legislative Adjustments) for 2007

This factor was calculated as a weighted-average of the 2007 changes in fees that apply for the different types of services included in the definition of physicians’ services for the SGR.

We estimate that services paid using the PFS account for approximately 82.5 percent of total allowed charges included in the SGR in CY 2007. These services were updated using the CY 2007 MEI of 2.1 percent. We estimate that diagnostic laboratory tests represent approximately 7.3 percent of total allowed charges included in the SGR in CY 2007. Medicare payments for these tests are updated by the CPI–U. However, section 629 of the MMA specifies that diagnostic laboratory services will receive an update of 0.0 percent from CY 2004 through CY 2008. We estimate that drugs represent 10.2 percent of Medicare-allowed charges

included in the SGR in CY 2007. We estimate a weighted-average change in fees for drugs included in the SGR of 1.3 percent for CY 2007.

Table 30 shows the weighted-average of the MEI, laboratory, and drug price changes for CY 2007.

TABLE 30.—WEIGHTED AVERAGE OF THE MEI, LABORATORY, AND DRUG PRICE CHANGES FOR CY 2007

	Weight	Update
Physician	0.825	2.1
Laboratory	0.073	0.0
Drugs	0.102	1.3
Weighted-average	1.000	1.9

After taking into account the elements described in Table 30, we estimate that the weighted-average increase in fees for physicians’ services in 2007 under the SGR (before applying any legislative adjustments) will be 1.9 percent. Our estimate of this factor in the CY 2007 PFS final rule with comment period was 2.2 percent. The decrease in the estimate is due to the availability of some actual data.

- Factor 2—The Percentage Change in the Average Number of Part B Enrollees from CY 2006 to CY 2007

OACT estimates that the average number of Medicare Part B fee-for-service enrollees (excluding beneficiaries enrolled in Medicare Advantage plans) decreased by 2.6 percent in CY 2007. Table 31 illustrates how we determined this figure.

TABLE 31.—AVERAGE NUMBER OF MEDICARE PART B FEE-FOR-SERVICE ENROLLEES
 [(Excluding beneficiaries enrolled in MA plans) from CY 2006 to CY 2007]

	2006	2007
Overall	40.271 million	40.726 million.
Medicare Advantage (MA)	6.550 million	7.890 million.
Net	33.721 million	32.836 million.
Percent Increase	– 2.6 percent.

OACT’s estimate of the – 2.6 percentage change in the number of fee-for-service enrollees, net of Medicare Advantage enrollment for CY 2007

compared to CY 2006, is lower than our original estimate of – 0.9 percent in the CY 2007 PFS final rule with comment period (71 FR 69758). While our current

projection based on data from 8 months of 2007 is lower than our original estimate of – 0.9 percent when we had no actual data, it is still possible that

our final estimate of this figure will be different once we have complete information on CY 2007 fee-for-service enrollment.

• Factor 3—Estimated Real Gross Domestic Product Per Capita Growth in CY 2007

We estimate that the growth in real GDP per capita will be 1.9 percent for CY 2007 (based on the 10-year average GDP over the 10 years of CY 1998 through CY 2007). Our past experience indicates that there have also been differences between our estimates of real per capita GDP growth made prior to the year's end and the actual change in this factor. Thus, it is possible that this figure will change further as complete actual information on CY 2007 economic performance becomes available to us in 2008.

• Factor 4—Percentage Change in Expenditures for Physicians' Services Resulting From Changes in Statute or Regulations in CY 2007 Compared With CY 2006

The statutory and regulatory provisions that will affect expenditures in CY 2007 relative to CY 2006 are estimated to have an impact on expenditures of 2.0 percent. These provisions include the DRA provisions adding the AAA ultrasound test to the Welcome to Medicare visit as a preventive benefit and reducing payments for imaging services. Also

included is the MIEA-TRHCA 1-year adjustment to the conversion factor. The details of these provisions are discussed elsewhere in this final rule with comment.

3. Detail on the CY 2006 SGR

A more detailed discussion of our final revised estimates of the four elements of the CY 2006 SGR follows.

• Factor 1—Changes in Fees for Physicians' Services (Before Applying Legislative Adjustments) for 2006

This factor was calculated as a weighted average of the CY 2006 changes in fees that apply for the different types of services included in the definition of physicians' services for the SGR.

Services paid using the PFS accounted for approximately 83.8 percent of total Medicare-allowed charges included in the SGR for CY 2006 and are updated using the MEI. The MEI for CY 2006 was 2.8 percent. Diagnostic laboratory tests represented approximately 7.2 percent of total CY 2006 Medicare allowed charges included in the SGR and are updated by the CPI-U. However, section 629 of the MMA specifies that diagnostic laboratory services will receive an update of 0.0 percent from CY 2004 through CY 2008. Drugs represented approximately 9.1 percent of total Medicare-allowed charges included in the SGR for CY 2006. We estimate a

weighted-average change in fees for drugs included in the SGR of -2.8 percent for 2006. Table 32 shows the weighted average of the MEI, laboratory, and drug price changes for CY 2006.

TABLE 32.—WEIGHTED AVERAGE OF THE MEI, LABORATORY, AND DRUG PRICE CHANGES FOR CY 2006

	Weight	Update
Physician	0.838	2.8
Laboratory	0.072	0.0
Drugs	0.091	-2.8
Weighted-average	1.000	2.1

After taking into account the elements described in Table 32, we estimate that the weighted-average increase in fees for physicians' services in CY 2006 under the SGR (before applying any legislative adjustments) was 2.1 percent. This figure is a final one based on complete data for CY 2006.

• Factor 2—The Percentage Change in the Average Number of Part B Enrollees from CY 2005 to CY 2006

We estimate the decrease in the number of fee-for-service enrollees (excluding beneficiaries enrolled in MA plans) from CY 2005 to CY 2006 was 2.6 percent. Our calculation of this factor is based on complete data from CY 2006. Table 33 illustrates the calculation of this factor.

TABLE 33.—AVERAGE NUMBER OF MEDICARE PART B FEE-FOR-SERVICE ENROLLEES [(Excluding beneficiaries enrolled in MA plans) from CY 2005 to CY 2006]

	2005	2006
Overall	39.698 million	40.271 million.
Medicare Advantage (MA)	5.084 million	6.550 million.
Net	34.615 million	33.721 million.
Percent Increase		-2.6 percent.

• Factor 3—Estimated Real Gross Domestic Product Per Capita Growth in 2006

We estimate that the growth in real per capita GDP was 2.1 percent in 2006 (based on the 10-year average GDP over the 10 years of CY 1997 through CY 2006). This figure is a final one based on complete data for CY 2006.

• Factor 4—Percentage Change in Expenditures for Physicians' Services Resulting From Changes in Statute or Regulations in CY 2006 Compared With CY 2005

Our final estimate for the net impact on expenditures from the statutory and regulatory provisions that affect expenditures in CY 2006 relative to CY

2005 is less than 0.05 percent. These provisions include the expiration of the temporary higher payments to physicians in Alaska, the new power wheelchair code for physicians, and the IVIG pre-administration fee.

VIII. Anesthesia and Physician Fee Schedule Conversion Factors for CY 2008

The CY 2008 PFS CF will be \$34.0682. The CY 2008 national average anesthesia CF is \$16.3176. Both CFs will be subject to a separate, independent BN adjustor, as described below.

A. Physician Fee Schedule Conversion Factor

Under section 1848(d)(1)(A) of the Act, the PFS CF is equal to the CF for the previous year timesplified by the update determined under section 1848(d)(4) of the Act, as amended by the MIEA-TRHCA. Section 101 of the MIEA-TRHCA provided a 1-year increase in the CY 2007 CF and specified that the CF for CY 2008 must be computed as if the 1-year increase had never applied.

The PFS update for CY 2008 is determined by timesplying the CY 2007 conversion factor update that would have occurred in the absence of the MIEA-TRHCA (as published in 71 FR 69760), the estimated MEI, and the

estimated update adjustment factor, as shown in Table 34 (0.89896 = 0.94953 × 1.018 × 0.930). To determine the estimated CY 2008 CF, the Pre-MIEA-TRHCA CY 2007 CF update is applied

to the CY 2006 CF of \$37.8975 to produce the Pre-MIEA-TRHCA CY 2007 CF of \$35.9848. Then applying the estimated MEI for CY 2008 and the estimated UAF for CY 2008 to the Pre-

MIEA-TRHCA CY 2007 a CF produces an estimated CF for CY 2008 of \$34.0682. We illustrate the calculation for the 2008 PFS CF in Table 34.

TABLE 34.—CALCULATION OF THE CY 2008 CONVERSION FACTOR

CY 2006 Conversion Factor	\$37.8975.
Pre-MIEA-TRHCA CY 2007 CF Update	– 5.0 percent (0.94953).
CY 2007 Pre-MIEA-TRHCA Conversion Factor	\$35.9848.
2008 MEI	1.8 percent (1.018).
2008 Update adjustment factor	– 7.0 percent (0.930).
CY 2008 Update	– 5.3 percent (0.94674).
CY 2008 Conversion Factor Update	– 10.1 percent (0.89896).
CY 2008 Conversion Factor	\$34.0682.

Section 1848(c)(2)(B)(ii)(II) of the Act requires that increases or decreases in RVUs for a year may not cause the amount of expenditures for the year to differ by more than \$20 million from what expenditures would have been in the absence of these changes. If this threshold is exceeded, we must make adjustments to preserve BN.

The 5-Year Review of work RVUs, including the refinement to the work RVU changes for the additional codes and the increases in the work of anesthesia services, would result in a change in expenditures that would exceed \$20 million if we made no offsetting adjustments to either the CF or RVUs. As discussed in section IV.C.3 of this final rule with comment period, we are applying the following BN adjustor to the work RVUs in order to calculate payment for a service:

2008 Work Adjustor: 11.94 percent (0.8806)

Payment for services under the PFS will be calculated as follows:

$$\text{Payment} = [(\text{RVU work} \times \text{BN adjustor (round product to two decimal places)} \times \text{GPCI work}) + (\text{RVU PE} \times \text{GPCI PE}) + (\text{RVU malpractice} \times \text{GPCI malpractice})] \times \text{CF}$$

B. Anesthesia Fee Schedule Conversion Factor

We calculate the physician anesthesia CF similar to the general PFS CF in Table 34. As noted, section 101 of the TRCHA provided for a 1-year increase in the CY 2007 conversion factor and specified the conversion factor for 2008 must be computed as if the 1-year increase had never applied. The PFS update for CY 2008 is determined by timesplying the CY 2007 conversion

factor that would have occurred in the absence of TRCHA by the estimated MEI and the estimated update adjustment factor for 2008.

Anesthesia services do not have RVUs like other PFS services. Therefore, we account for any necessary RVU adjustments through an adjustment to the anesthesia fee schedule CF to simulate changes to RVUs. We modeled the resource based PE methodology using imputed anesthesia RVUs that were made comparable to other PFS services. The 2008 adjustment factor in Table 35 includes the combined effect of the PE adjustment, the increase in work of anesthesia services under the recent five year review and the BN adjustment.

We illustrate the calculation for the 2008 anesthesia CF in Table 35.

TABLE 35.—CALCULATION FOR THE 2008 ANESTHESIA CONVERSION FACTOR

CY 2006 Anesthesia Conversion Factor	\$17.7663.
Pre-TRHCA CY 2007 CF Update	– 5.0 percent (0.94953).
2007 Combined Adjustment for PE and BN	0.9089.
CY 2007 Pre-TRHCA Anesthesia Conversion Factor	\$15.3328.
2008 MEI	1.8 percent (1.018).
2008 Update adjustment factor	– 7.0 percent (0.930).
CY 2008 Anesthesia CF after MEI and 2008 Adjustment Factor	\$14.5162.
2008 Combined Adjustment for PE and BN	1.1250.
CY 2008 Anesthesia Conversion Factor	\$16.3307.

IX. Telehealth Originating Site Facility Fee Payment Amount Update

Section 1834(m) of the Act establishes the payment amount for the Medicare telehealth originating site facility fee for telehealth services provided from October 1, 2001 through December 31

2002, at \$20. For telehealth services provided on or after January 1 of each subsequent calendar year, the telehealth originating site facility fee is increased by the percentage increase in the MEI as defined in section 1842(i)(3) of the Act. The MEI increase for 2008 is 1.8 percent.

Therefore, for CY 2007, the payment amount for HCPCS code Q3014, Telehealth originating site facility fee, is 80 percent of the lesser of the actual charge or \$23.35. The Medicare telehealth originating site facility fee and MEI increase by the applicable time period is shown in Table 36.

TABLE 36.—THE MEDICARE TELEHEALTH ORIGINATING SITE FACILITY FEE AND MEI INCREASE BY THE APPLICABLE TIME PERIOD

Facility fee	MEI increase (percent)	Period
\$20.00	N/A	10/01/2001–12/31/2002
\$20.60	3.0	01/01/2003–12/31/2003
\$21.20	2.9	01/01/2004–12/31/2004
\$21.86	3.1	01/01/2005–12/31/2005
\$22.47	2.8	01/01/2006–12/31/2006
\$22.94	2.1	01/01/2007–12/31/2007
\$23.35	1.8	01/01/2008–12/31/2008

X. Provisions of the Final Rule

The provisions of this final rule with comment restate the provisions of the CY 2008 PFS proposed rule, except as noted elsewhere in the preamble.

XI. Waiver of Proposed Rulemaking and Delay in Effective Date

We ordinarily publish a notice of proposed rulemaking in the **Federal Register** and invite public comment on the proposed rule. The notice of proposed rulemaking includes a reference to the legal authority under which the rule is proposed, and the terms and substances of the proposed rule or a description of the subjects and issues involved. This procedure can be waived, however, if an agency finds good cause that a notice-and-comment procedure is impracticable, unnecessary, or contrary to the public interest and incorporates a statement of the finding and its reasons in the rule issued.

We utilize HCPCS codes for Medicare payment purposes. The HCPCS is a national drug coding system comprised of Level I (CPT) codes and Level II (HCPCS National Codes) that are intended to provide uniformity to coding procedures, services, and supplies across all types of medical providers and suppliers. Level I (CPT) codes are copyrighted by the AMA and consist of several categories, including Category I codes which are 5-digit numeric codes, and Category III codes which are temporary codes to track emerging technology, services and procedures.

The AMA issues an annual update of the CPT code set each Fall, with January 1 as the effective date for implementing the updated CPT codes. The HCPCS, including both Level I and Level II codes, is similarly updated annually on a CY basis. Annual coding changes are not available to the public until the Fall immediately preceding the annual January update of the PFS. Because of the timing of the release of these new codes, it is impracticable for CMS to provide prior notice and solicit

comment on these codes and the RVUs assigned to them in advance of publication of the final rule that implements the PFS. Yet, it is imperative that these coding changes be accounted for and recognized timely under the PFS for payment because services represented by these codes will be provided to Medicare beneficiaries by physicians during the CY in which they become effective. Moreover, regulations implementing HIPAA (42 CFR parts 160 and 162) require that the HCPCS be used to report health care services, including services paid under the PFS. We also assign interim RVUs to any new codes based on a review of the RUC recommendations for valuing these services. By reviewing these RUC recommendations for the new codes, we are able to assign RVUs to services based on input from the medical community and to establish payment for them, on an interim basis, that corresponds to the relative resources associated with providing the services. If we did not assign RVUs to new codes on an interim basis, the alternative would be to either not pay for these services during the initial CY or have each carrier establish a payment rate for these new codes. We believe both of these alternatives are contrary to the public interest, particularly since the RUC process allows for an assessment of the valuation of these services by the medical community prior to our establishing payment for these codes on an interim basis. Therefore, we believe it would be contrary to the public interest to delay establishment of fee schedule payment amounts for these codes.

For the reasons outlined above in this section, we find good cause to waive the notice of proposed rulemaking for the interim RVUs for selected procedure codes identified in Addendum C and to establish RVUs for these codes on an interim final basis. We are providing a 60-day public comment period.

In addition, we ordinarily publish a notice of proposed rulemaking in the **Federal Register** and provide a period

for public comment before we make final the provisions of the notice. We can waive this procedure, however, if we find good cause that notice-and-comment procedure is impracticable, unnecessary, or contrary to the public interest and we incorporate a statement of finding and its reasons in the notice issued. We find it unnecessary to undertake notice and comment rulemaking in this instance for the ambulance inflation factor because the law specifies the method of computation of annual updates, and we have no discretion in this matter. Further, we are merely applying the update method specified in statute and regulation. Therefore, under 5 U.S.C. 553(b)(B), for good cause, we waive notice and comment procedures for this ambulance inflation factor update.

XII. Collection of Information Requirements

Under the Paperwork Reduction Act of 1995, we are required to provide 60-day notice in the **Federal Register** and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

This final rule with comment period does not contain any new information collection requirements. However, we are republishing the discussion of the information collection requirements as it appeared in the CY 2008 PFS

proposed rule (72 FR 38122). We are soliciting public comment on each of these issues for the following sections of this document that contain information collection requirements.

Independent Diagnostic Testing Facility (§ 410.33)

Section 410.33(g)(2) states that an independent diagnostic testing facility (IDTF) should provide complete and accurate information on its Medicare enrollment application. In addition, an IDTF is required to notify its designated fee-for-service contractor within 30-days of any changes in ownership, changes of location, changes in general supervision, and any adverse legal actions. The notification must be made on the Medicare enrollment application. All of the changes to the enrollment application must be reported within 90 days.

The aforementioned requirements are not new. The burden associated with completing the Medicare enrollment application is currently approved under OMB control number 0938-0685. The collection has an expiration date of April 30, 2009.

Section 410.33(g)(6) states the comprehensive liability insurance requirements for IDTFs. Specifically, § 410.33(g)(6)(1) states they must have a comprehensive insurance policy to notify the CMS designated contractor, in writing, of any policy changes or cancellations. The burden associated with this requirement is the time and effort necessary to draft and submit the written notification to the CMS designated contractor. While this requirement is subject to the PRA, we believe it is exempt from the PRA as stipulated under 5 CFR 1320.3(h)(6). This information will be collected on case by case basis.

Section 410.33(g)(8) requires an IDTF to answer, document, maintain documentation of beneficiaries questions and responses to beneficiary complaints at the physical site of the IDTF. Sections 410.33(g)(8) (i through iii) list the minimum amount of documentation needed to comply with this requirement. The burden associated with these requirements is the time and effort associated with responding to beneficiary questions and complaints, documenting the actions taken in response to the questions and complaints, and maintaining the documentation. While this requirement is subject to the PRA, we believe the associated burden is exempt under 5 CFR 1320.3(b)(2). The burden associated with documenting and maintaining the documentation of the corrective actions is a usual and customary business

practice. The time, effort, and financial resources necessary to comply this information collection requirement would be incurred by persons in the normal course of their activities (for example, in compiling and maintaining business records) and is not subject to the PRA.

Basis of Payment (§ 414.707)

Section 414.707(c) states that effective January 1, 2008, each request for payment for anti-anemia drugs furnished to treat anemia resulting from the treatment of cancer must report the beneficiary's most recent hemoglobin or hematocrit level. The burden associated with this requirement is the time and effort associated with obtaining the most recent hemoglobin or hematocrit levels and documenting it on the request for payment. The requirement and its associated burden are not subject to the PRA under 5 CFR 1320.3(h)(5). The interpretation of biological analyses of body fluids, tissues, or other specimens, or the identification or classification of such specimens is not subject to the PRA.

Term of Contract (§ 414.914)

Section 414.914(h) states that the approved CAP vendor must verify drug administration prior to the collection of any applicable cost sharing amount. As part of the verification process, § 414.914(h)(1) through (2) states lists the documentation that is required as part of the verification process. Section 414.914(h)(3) states that the approved CAP vendor must provide this information to CMS or the beneficiary upon request.

The burden associated with the requirements in § 414.914(1) through (3) is the time and effort needed to verify the drug administration. When obtaining written verification, the CAP vendor must document the elements listed in § 414.914(h)(1)(i) through (vi). When obtaining verbal verification, the CAP vendor must document the elements listed in § 414.914(h)(2)(i) through (ii). We believe the requirements and their associated burden are not subject to the PRA; they are part of the CAP vendor's usual and customary business practices as stipulated under 5 CFR 1320.3(h)(5).

In addition, § 414.914(h)(3) imposes both recordkeeping and reporting requirements. We believe that the burden associated with the recordkeeping requirement imposed by § 414.914(h)(3) is not subject to the PRA under 5 CFR 1320.3(c)(4) because it would affect less than 10 persons.

The reporting requirement places burden on the CAP vendor to provide

the information listed in § 414.914(h) (1–2) to a beneficiary upon request. We estimate that the CAP vendor will receive 72 requests per year from beneficiaries. We believe it will take 15 minutes per request for the vendor to provide this information to the beneficiary. The total annual burden associated with this requirement is 1080 minutes or 18 burden hours. However, we believe this information collection requirement and the associated burden is not subject to the PRA as defined in 5 CFR 1320.3(c)(4) because it would affect less than 10 persons.

Compendia for Determination of Medically-Accepted Indications for Off-Label Uses of Drugs and Biologicals in an Anti-Cancer Chemotherapeutic Regimen (§ 414.930)

Section 414.930(b) states the process for listing compendia for determining medically-accepted uses of drugs and biologicals in anti-cancer treatment. We will annually provide an annual opportunity to request changes to the list of compendia. As stated in § 414.930(c)(1), CMS will review a complete written request that is submitted in writing, electronically or via hard copy. A complete written request must contain the following information as stated in § 414.930(c)(1)(i) through (vi): Full name and contact information for the requestor; full identification of the compendium in question; a complete written copy of the compendium in question; the specific action requested of CMS; supporting documentation for the requested action; address a single compendium per request.

The burden associated with the requirements contained in § 414.930(b) through (c) is the time and effort required to draft and submit to CMS a complete written request for changes to the list of compendia. While these requirements are subject to the PRA, we believe the burden is exempt under 5 CFR 1320.3(c)(4) because it would affect less than 10 persons or entities. There are only 6 compendia that could reasonably be expected to be the subject of a request, so 6 requests is a likely maximum.

Signature Requirements (§ 424.36)

Section 424.36(a) requires the beneficiary's signature on a claim for payment of services unless the beneficiary has died or the provisions of § 424.36(b), (c), or (d) apply. Section 424.36(b) states that if the beneficiary is physically or mentally incapable of signing the claim, the claim may be signed by one of the parties specified in § 424.36(b)(1) through (5). Proposed

§ 424.36(b)(6) states that, for emergency ambulance transport services, if certain conditions and documentation requirements are met, an ambulance provider or supplier would be permitted to sign the claim on behalf of the beneficiary. Specifically, § 424.36(b)(6)(ii)(A) through (C) lists the documentation that would be required, all of which would have to be maintained by the ambulance provider or supplier in its files for a period of at least 4 years from the date of service. An ambulance provider or supplier would be required to obtain a signed, contemporaneous statement from an ambulance employee present during transport of the patient that, at the time the service was provided, the beneficiary was physically or mentally incapable of signing the claim and that none of the other qualified parties listed in § 424.36(b)(1) through (5) were available or willing to sign the claim on behalf of the beneficiary.

The ambulance provider or supplier would also be required to maintain documentation of the date and time that the beneficiary was transported and the name and location of the facility that received the beneficiary. In addition, the ambulance provider or supplier would be required to obtain and maintain a signed contemporaneous statement from a representative of the facility that received the beneficiary. The statement would have to contain the name of the beneficiary and the date and time the beneficiary was received at the facility.

The burden associated with the recordkeeping requirements contained in § 424.36(b)(6) is the time and effort associated with drafting, obtaining, and maintaining written statements from both employees of the ambulance provider or supplier transporting the beneficiary and employees of the facility receiving the beneficiary. We estimate that 9,000 ambulance providers or suppliers will comply with these requirements. We estimate that it will take no more than five minutes for each provider or supplier to comply with the recordkeeping requirements. Based on the best available data at this time, we estimate the total annual burden associated with the requirements in § 424.36(b)(6) to be 541,667 hours nationwide. The annual total number of burden hours was arrived at by multiplying five minutes by the total estimated number of emergency ambulance transports of 6,500,000. We note that the total number of burden hours may be overstated, because not every beneficiary who receives emergency ambulance transport services is unable to sign the claim. However, we also note that the 6.5 million figure for

emergency transports is the estimated number of ALS1-emergency and BLS-emergency ambulance claims processed by Part B carriers, incurred in 2006 and processed through April of 2007, and thus does not include the number of emergency ambulance transport services billed to fiscal intermediaries by ambulance providers (which number is not available to us). In any event, we believe our proposal will benefit ambulance providers and suppliers by allowing them an alternative procedure for submitting claims to Medicare. In the absence of the proposed procedure for signing claims on behalf of beneficiaries for emergency ambulance transport services, ambulance suppliers and providers would be required to track down beneficiaries after the emergency transport services have been rendered, in an attempt to have the beneficiary sign the claim. Moreover, such attempts may prove fruitless, thereby preventing the ambulance suppliers and providers from submitting the claim to Medicare.

Additional Information Collection Requirements

This final rule with comment period imposes collection of information requirements as outlined in the regulation text and specified above. However, this final rule with comment period also makes reference to several associated information collections that are not discussed in the regulation text. The following is a discussion of these collections, which have already received OMB approval.

Part B Drug Payment

Section II.F.1 of the preamble discusses payment for Medicare Part B drugs and biologicals under the ASP methodology. Drug manufacturers are required to submit ASP data to us on a quarterly basis. As stated in section II.F.1.a of the preamble, the ASP reporting requirements are set forth in section 1927(b) of the Act.

The collection of ASP data imposes a reporting requirement on the public. The burden associated with this requirement is the time and effort required by manufacturers of Medicare Part B drugs and biologicals to calculate, record, and submit the required data to CMS. While the burden associated with this requirement is subject to the PRA, it is currently approved under OMB control number 0938-0921, with an expiration date of May 31, 2009.

Competitive Acquisition Program (CAP)

In section II.F.2.d of the preamble, we propose to revise the CAP physician election agreement. In conjunction with

post-payment review process, we are revising the CAP physician election agreement to reflect the physician's obligation to provide medical records to assist with claims review. The CAP physician election agreement is currently approved under 0938-0955 with an expiration date of August 31, 2009. Under a separate notice, we will make the revised instrument available for public comment prior to submitting the revised information collection request to OMB for approval.

Section II.F.2.f of the preamble discusses details of the competitive acquisition program. Each year, physicians are given the option to elect to obtain Medicare Part B drugs and biologicals through the CAP. In addition, physicians are also given an opportunity to select an approved CAP vendor. The burden associated with these election requirements is the time and effort necessary for a physician to make an election and notify CMS. The burden associated with election requirements for participating in the CAP and selecting an approved CAP vendor is subject to the PRA. However, it is currently approved under OMB control numbers 0938-0955 and 0938-0987 with expiration dates of August 31, 2009 and April 30, 2009, respectively.

Section II.F.2.g. of the preamble also discusses the exigent circumstances exception for leaving the CAP outside of the annual election process. A physician may request a release from the CAP within the first 60 days of his or her participation if he or she can show that CAP participation imposes a burden on the practice, or later if he or she can show that a change in circumstances that was not known to the practice previously results in a burden to the practice. Specifically, the physician must submit a release request to the CAP-designated carrier.

While this burden is subject to the PRA, we believe it is exempt under 5 CFR 1320.3(h)(6). Facts or opinions collected from a single person or entity are not subject to the PRA. The aforementioned information collection request will be reviewed individually on a case by cases basis.

If the designated carrier receives an exigent circumstance removal request related to the approved CAP vendor's service, it is required to refer the physician to his or her approved CAP vendor within 1 business day of its receipt of the request. As part of the grievance process, the CAP vendor will try to work with the physician to address their concerns with respect to participation in the program. The designated carrier can alternatively continue to investigate, and within 2

business days of its receipt of the request, can request a single 2-business day extension (after which it must submit findings and a recommendation to CMS), submit findings and a recommendation to CMS that the physician be permitted to terminate his or her CAP participation, or submit findings and a recommendation to CMS that the physician not be permitted to terminate his or her CAP participation.

Requests from physicians will be reviewed by CAP vendors on an individual, case by case basis. We will continue to monitor the process. If we believe that we will receive 10 or more requests, we will submit an information collection request to OMB.

Physician Quality Reporting Initiative (PQRI)

Section II.U.1.a of the preamble discusses the background of the reporting initiative and provides information about the measures available to eligible professionals who choose to participate in PQRI. Section 1848(k)(1) of the Act requires the Secretary to implement a system for eligible professionals to submit data pertaining to certain quality measures. As stated in section II.U.1.a, eligible professionals, for the purpose of the quality reporting system, include physicians, other practitioners as described in section 1842(b)(18)(c) of the Act, physical and occupational therapists, and qualified speech-language pathologists. As also stated in

section II.U.1.a, this is a voluntary initiative. Eligible professionals may choose whether to participate and, to the extent they satisfactorily submit data on quality measures for covered professional services, they can qualify to receive a bonus incentive payment.

Specifically, to qualify to receive a bonus incentive payment for satisfactory reporting of quality data on covered professional services furnished in 2007, an eligible professional must submit data on 1, 2, or 3 measures selected from the 74 PQRI 2007 quality measures. The minimum number of measures each professional must report in order to qualify for the bonus payment is determined by how many available measures are applicable to the services that professional furnishes to Medicare beneficiaries. For a majority of the eligible professionals, the requirement, per 1848(k) of the Act, will be that they satisfactorily report on at least three measures. An eligible professional could meet the satisfactory reporting requirement, and thus be eligible for the bonus incentive payment, by reporting fewer than three measures only if his or her practice has fewer than three applicable measures. The quality measures are posted and available for download on the CMS Web site at <http://www.cms.hhs.gov/pqri>.

The burden associated with this requirement is the time and effort associated with eligible professionals identifying applicable PQRI quality measures for which they can report the

necessary information. In addition, they must gather the required information, select the appropriate quality data codes, and include the appropriate quality-data codes on the claims they submit for payment.

In 2007, the PQRI will collect quality-data codes exclusively as additional (optional) line items on the existing HIPAA transaction 837-P and/or CMS Form 1500. There will be no new forms and no modifications to the existing transaction or form in support of 2007 PQRI. CMS also does not anticipate changes to the 837-P or CMS Form 1500 for 2008.

Because this is a voluntary program, it is impossible to estimate with any degree of accuracy how many eligible professionals will opt to participate in the PQRI in 2008. Moreover, the time needed for an eligible professional to review the quality measures and other information, select measures applicable to his or her patients and the services he or she furnishes to them, and incorporate the use of quality data codes into the office work flows is expected to vary along with the number of measures that are potentially applicable to a given professional's practice. We estimate that the additional time required to put quality data codes on each claim is not a material increment to the time required to code the claim for payment. The total estimated annual burden for this requirement will also vary along with the volume of claims on which quality data is reported.

TABLE 37.—ESTIMATED ANNUAL REPORTING AND RECORDKEEPING BURDEN

Regulation section(s)	OMB control No.	Respondents	Responses	Total annual burden (hours)
Preamble section II.F.1	0938-0921	120	480	17,760
Preamble section II.F.2.f	0938-0955	12	12	480
§ 410.33	0938-0685	400,000	400,000	1,000,000
§ 424.36	0938-New	9,000	6,500,000	541,667
Total				1,579,907

If you comment on these information collection and recordkeeping requirements, please mail copies directly to the following: Centers for Medicare & Medicaid Services, Office of Strategic Operations and Regulatory Affairs, Regulations Development Group, Attn: William N. Parham, III, CMS-1385-FC, Room C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850; and Office of Information and Regulatory Affairs, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503, Attn: Carolyn

Lovett, CMS Desk Officer, [CMS-1385-P], carolyn_lovett@omb.eop.gov. Fax (202) 395 6974.

XIII. Response to Comments

Because of the large number of public comments we normally receive on **Federal Register** documents, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the **DATES** section of this preamble, and, when we proceed with a subsequent document, we will

respond to the comments in the preamble to that document.

XIV. Regulatory Impact Analysis

We have examined the impact of this rule as required by Executive Order 12866 (September 1993, Regulatory Planning and Review), the Regulatory Flexibility Act (RFA) (September 19, 1980 Pub. L. 96-354), section 1102(b) of the Social Security Act, the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4), and Executive Order 13132.

Executive Order 12866 (as amended by Executive Order 13258, which

merely reassigns responsibilities of duties) directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). A regulatory impact analysis must be prepared for final rules with economically significant effects (that is, a final rule that would have an annual effect on the economy of \$100 million or more in any one year, or would adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities). As indicated in more detail below in this regulatory impact analysis, we estimate that the PFS provisions included in this final rule with comment period rule will redistribute more than \$100 million in 1 year. We are considering this final rule with comment period rule to be economically significant because its provisions are estimated to result in an increase, decrease or aggregate redistribution of Medicare spending that will exceed \$100 million. Therefore, this final rule with comment period is a major rule and we have prepared a regulatory impact analysis.

The RFA requires agencies to analyze options for regulatory relief of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small governmental jurisdictions. Most hospitals and most other providers and suppliers are small entities, either by nonprofit status or by having revenues of \$6.5 million to \$31.5 million in any 1 year (For further information, see the Small Business Administration's regulation at 70 FR 72577, December 6, 2003.) Individuals and States are not included in the definition of a small entity. The RFA requires that we analyze regulatory options for small businesses and other entities. We prepare a regulatory flexibility analysis unless we certify that a rule would not have a significant economic impact on a substantial number of small entities. The analysis must include a justification concerning the reason action is being taken, the kinds and number of small entities the rule affects, and an explanation of any meaningful options that achieve the objectives with less significant adverse economic impact on the small entities.

For purposes of the RFA, physicians, NPPs, and suppliers, including IDTFs, are considered small businesses if they

generate revenues of \$6.5 million or less. Approximately 95 percent of physicians are considered to be small entities. There are about 980,000 physicians, other practitioners and medical suppliers that receive Medicare payment under the PFS.

The CAP provides alternatives to physicians who do not wish to purchase drugs directly or collect coinsurance. The impact of the CAP provisions on an individual physician is dependent on whether the drugs they furnish to Medicare beneficiaries are included in the list of CAP drugs, whether the physician chooses to obtain drugs administered to Medicare beneficiaries through the CAP. The CAP provisions in this final rule with comment period will also have a potential impact on entities that are involved in the dispensing or distribution of drugs, plan to become approved CAP vendors, or are approved CAP vendors.

For purposes of the RFA, approximately 80 percent of clinical diagnostic laboratories are considered small businesses according to the Small Business Administration's size standards. Ambulance providers and suppliers for purposes of the RFA are also considered to be small entities.

In addition, most ESRD facilities are considered small entities, either based on nonprofit status or by having revenues of \$31.5 million or less in any year. We consider a substantial number of entities to be affected if the rule is estimated to impact more than 5 percent of the total number of small entities. Based on our analysis of the 915 nonprofit ESRD facilities considered small entities in accordance with the above definitions, we estimate that the combined impact of the changes to payment for renal dialysis services included in this final rule with comment period will have a 0.9 percent increase in overall payments to nonprofit ESRD facilities relative to current overall payments. The analysis and discussion provided in this section, as well as elsewhere in this final rule with comment period, complies with the RFA requirements.

For the e-prescribing provisions, physician practices and independent pharmacies are considered small entities.

Because we acknowledge that many of the affected entities are small entities, the analysis discussed throughout the preamble of this final rule with comment period constitutes our regulatory flexibility analysis for the remaining provisions.

Section 1102(b) of the Act requires us to prepare a regulatory impact analysis for any final rule with comment period

that may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 604 of the RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside a Metropolitan Statistical Area and has fewer than 100 beds. We have determined that this final rule with comment period would have minimal impact on small hospitals located in rural areas. Of the 202 hospital based ESRD facilities located in rural areas, only 40 are affiliated with hospitals with fewer than 100 beds.

Section 202 of the Unfunded Mandates Reform Act of 1995 also requires that agencies assess anticipated costs and benefits before issuing any rule that may result in expenditures in any year by State, local, or tribal governments, in the aggregate, or by the private sector, of \$127 million. This final rule with comment period will not mandate any requirements for State, local, or tribal governments. Medicare beneficiaries are considered to be part of the private sector for this purpose. A discussion concerning the impact of this rule on beneficiaries is found later in this section.

We have examined this final rule with comment period in accordance with Executive Order 13132 and have determined that this regulation would not have any significant impact on the rights, roles, or responsibilities of State, local, or tribal governments.

We have prepared the following analysis, which, together with the information provided in the rest of this preamble, meets all assessment requirements. The analysis explains the rationale for and purposes of this final rule with comment period rule; details the costs and benefits of the rule; analyzes alternatives; and presents the measures we use to minimize the burden on small entities. As indicated elsewhere in this final rule with comment period, we are making a variety of changes to our regulations, payments, or payment policies to ensure that our payment systems reflect changes in medical practice and the relative value of services. We provide information for each of the policy changes in the relevant sections of this final rule with comment period. We are unaware of any relevant Federal rules that duplicate, overlap or conflict with this final rule with comment period. The relevant sections of this final rule with comment period contain a description of significant alternatives if applicable.

A. RVU Impacts

1. Resource-Based Work and PE RVUs

Section 1848(c)(2)(B)(ii) of the Act requires that increases or decreases in RVUs may not cause the amount of expenditures for the year to differ by more than \$20 million from what expenditures would have been in the absence of these changes. If this threshold is exceeded, we make adjustments to preserve BN. In the CY 2007 PFS final rule with comment period, the \$4 billion impact of changes in work RVUs resulting from the 5-Year Review required that a BN adjustment be made.

As discussed in section IV.D.3 of the CY 2007 PFS final rule with comment period (71 FR 69735), we carefully reviewed the comments received concerning the BN adjustment needed to offset the \$4 billion impact of changes in work RVUs resulting from the 5-Year Review. To meet the requirements set forth in section 1848(c)(2)(B)(ii)(II) of the Act, we implemented a BN adjustor of 0.8994 or 10.1 percent to be applied to the work RVUs.

Subsequent to the publication of the CY 2007 PFS final rule with comment period and the announcement of the 0.8994 BN adjustment to the work RVUs, the AMA RUC supplied work RVU recommendations on additional CPT codes from the 5-Year Review and recommendations for an increase in the

work of anesthesia services. As stated in the CY 2007 PFS final rule with comment period, these additional codes are still considered part of the 5-Year Review. The impact of these additional recommendations and increases in the work of anesthesia services on the BN adjustment must be accounted for by revising the current work adjustor of 0.8994. The work adjustor for CY 2008, based upon the final work RVUs for these additional CPT codes and increases in the work of anesthesia services, is approximately 0.8806. Table 38 shows the specialty-level impact of the work and PE RVU changes.

Our estimates of changes in Medicare revenues for PFS services compare payment rates for CY 2007 with payment rates for CY 2008 using CY 2006 Medicare utilization for all years. To the extent that there are year to year changes in the volume and mix of services provided by physicians, the actual impact on total Medicare revenues will be different than those shown in Table 38. The payment impacts reflect averages for each specialty based on Medicare utilization. The payment impact for an individual physician would be different from the average, based on the mix of services the physician provides. The average change in total revenues would be less than the impact displayed here because physicians furnish services to both Medicare and non Medicare patients

and specialties may receive substantial Medicare revenues for services that are not paid under the PFS. For instance, independent laboratories receive approximately 80 percent of their Medicare revenues from clinical laboratory services that are not paid under the PFS.

Table 38 shows only the payment impact on PFS services. The following is an explanation of the information represented in Table 38.

- Specialty: The physician specialty or type of practitioner/supplier.
- Allowed charges: Allowed charges are the Medicare Fee Schedule amounts for covered services and include copayments and deductibles (which are the financial responsibility of the beneficiary.) These amounts have been summed across all services furnished by physicians, practitioners, or suppliers within a specialty to arrive at the total allowed charges for the specialty.
- Impact of Work RVU Changes for additional changes in work RVUs from the 5-Year Review.
- Impact of PE RVU changes. The impact is shown for both 2008 which is the second year of the 4-year transition using the new methodology and the fully implemented 2010 PE RVUs.
- Combined impact of the finalized work RVUs and PE RVUs for both 2008 and the fully implemented 2010 PE RVUs.

TABLE 38.—COMBINED TOTAL ALLOWED CHARGE IMPACT FOR WORK AND PRACTICE EXPENSE RVU CHANGES

Specialty	Allowed charges (mil)	Impact of work RVU changes (percent)	Impact of PE RVU changes (percent)		Combined impact of PE and work changes*	
			2008 (PE trans. year 2) (percent)	2010 (PE full implement.) (percent)	2008 (PE trans. year 2) (percent)	2010 (PE full implement.) (percent)
TOTAL	\$76,551	0	0	0	0	0
ALLERGY/IMMUNOLOGY	173	1	1	3	2	4
ANESTHESIOLOGY	1,579	15	-1	-3	14	12
CARDIAC SURGERY	396	-1	-1	-2	-2	-3
CARDIOLOGY	7,519	-1	-1	-3	-2	-4
COLON AND RECTAL SURGERY	122	-1	1	2	0	2
CRITICAL CARE	199	-1	0	0	-1	-2
DERMATOLOGY	2,248	-1	2	7	2	7
EMERGENCY MEDICINE	2,203	-2	0	-1	-2	-2
ENDOCRINOLOGY	350	-1	0	0	-1	-1
FAMILY PRACTICE	5,060	0	0	1	0	1
GASTROENTEROLOGY	1,750	-1	1	4	0	3
GENERAL PRACTICE	974	0	0	0	0	0
GENERAL SURGERY	2,309	-1	0	0	-1	0
GERIATRICS	147	3	0	1	3	4
HAND SURGERY	80	-1	-1	-3	-2	-4
HEMATOLOGY/ONCOLOGY	1,917	-1	0	0	-1	-1
INFECTIOUS DISEASE	504	-1	0	1	-1	0
INTERNAL MEDICINE	9,981	1	0	0	0	0
INTERVENTIONAL RADIOLOGY	244	-1	-1	-3	-2	-4
NEPHROLOGY	1,664	-1	-1	-4	-3	-5
NEUROLOGY	1,398	-1	0	-1	-1	-2
NEUROSURGERY	576	-1	-1	-2	-2	-3
NUCLEAR MEDICINE	78	-1	5	14	4	14

TABLE 38.—COMBINED TOTAL ALLOWED CHARGE IMPACT FOR WORK AND PRACTICE EXPENSE RVU CHANGES—
Continued

Specialty	Allowed charges (mil)	Impact of work RVU changes (percent)	Impact of PE RVU changes (percent)		Combined impact of PE and work changes*	
			2008 (PE trans. year 2) (percent)	2010 (PE full implement.) (percent)	2008 (PE trans. year 2) (percent)	2010 (PE full implement.) (percent)
OBSTETRICS/GYNECOLOGY	628	-1	0	-1	-1	-1
OPHTHALMOLOGY	4,664	2	-1	-3	1	-1
ORTHOPEDIC SURGERY	3,248	-1	0	-1	-1	-2
OTOLARNGOLOGY	913	2	-1	-3	1	-1
PATHOLOGY	948	-1	-1	-3	-2	-4
PEDIATRICS	74	0	0	0	0	0
PHYSICAL MEDICINE	784	1	-1	-2	-1	-2
PLASTIC SURGERY	272	-1	0	1	-1	0
PSYCHIATRY	1,099	-1	1	2	0	1
PULMONARY DISEASE	1,691	-1	0	1	-1	0
RADIATION ONCOLOGY	1,612	-1	1	2	0	1
RADIOLOGY	5,245	-1	1	2	0	1
RHEUMATOLOGY	494	-1	0	-1	-1	-2
THORACIC SURGERY	436	-1	-1	-2	-2	-3
UROLOGY	2,033	-1	0	0	-1	-1
VASCULAR SURGERY	641	-1	0	0	-1	-1
AUDIOLOGIST	31	26	-14	-43	12	-17
CHIROPRACTOR	725	-1	-1	-2	-2	-3
CLINICAL PSYCHOLOGIST	531	-1	-2	-6	-3	-7
CLINICAL SOCIAL WORKER	354	-1	-2	-5	-3	-6
NURSE ANESTHETIST	608	22	0	0	22	21
NURSE PRACTITIONER	796	2	0	1	2	3
OPTOMETRY	790	4	0	-1	4	3
ORAL/MAXILLOFACIAL SURGERY	37	-1	1	3	1	3
PHYSICAL/OCCUPATIONAL THERAPY	1,391	-1	1	4	1	4
PHYSICIAN ASSISTANT	600	0	0	1	0	0
PODIATRY	1,575	0	2	5	2	5
DIAGNOSTIC TESTING FACILITY	1,191	0	0	1	0	1
INDEPENDENT LABORATORY	1,087	0	3	10	3	10
PORTABLE X-RAY SUPPLIER	81	0	2	7	2	7

* Components may not sum to total due to rounding.

2. Adjustments for Payments for Imaging Services

Section 1848(c)(2)(B)(iv)(II) of the Act as added by section 5102 of the Deficit Reduction Act of 2005 (Pub. L. 109-171) (DRA) exempts the estimated savings from the application of the OPSS based payment limitation on PFS imaging services from the PFS BN requirement. We estimate that the combined impact of the current BN exemptions instituted by such section, the addition of 6 codes to the list of services subject to the DRA OPSS cap (discussed in section II.E.1.), and the payment revisions to OPSS cap amounts would result in no measurable changes in the specialty specific impacts of the DRA provisions with the exception of vascular surgery in CY 2008.

3. Combined Impact

Table 39 shows the specialty-level impact of the work and PE RVU changes, section 5102 of the DRA (including the additional 6 services that were added to the list of services subject

to the DRA OPSS cap and the revision to OPSS payment amounts), and our most recent estimate (-10.1 percent) of the CY 2008 Medicare PFS update. Additionally, the impacts in this final rule with comment period rule reflect the use of updated physician time data from the AMA-RUC.

As indicated in Table 39, our estimates of changes in Medicare revenues for PFS services compare payment rates for CY 2007 with payment rates for CY 2008 using CY 2006 Medicare utilization crosswalked to 2008 services. To the extent that there are year-to-year changes in the volume and mix of services furnished by physicians, the actual impact on total Medicare revenues will be different than those shown in Table 39. The payment impacts reflect averages for each specialty based on Medicare utilization. The payment impact for an individual physician would be different from the average, based on the mix of services the physician furnishes.

Table 39 shows only the payment impact on PFS services. The following is an explanation of the information represented in Table 39.

- Specialty: The physician specialty or type of practitioner/supplier.
- Allowed Charges: Allowed charges are the Medicare Fee Schedule amounts for covered services and include copayments and deductibles (which are the financial responsibility of the beneficiary.) These amounts have been summed across all services furnished by physicians, practitioners, or suppliers within a specialty to arrive at the total allowed charges for the specialty.
- Impact of the CY 2008 Work and PE RVU changes using the methodology finalized in the CY 2007 PFS final rule with comment period and the revised data sources discussed in this final rule with comment period.
- Impact of section 5102 of the DRA: The CY 2008 percentage decrease in allowed charges attributed to section 5102 of the DRA with the addition of six codes to the OPSS cap list and revisions to the OPSS payment amounts.

• Combined impact of the finalized work and PE RVUs, section 5102 of the DRA and the addition of six codes to the OPPS cap list, and the revisions to OPPS payment amounts.

• CY 2008 Update: The percentage decrease in allowed charges attributed

to the estimated CY 2008 PFS conversion factor update of -10.1 percent.

• Combined impact with CY 2008 update: The CY 2008 percentage decrease in allowed charges attributed to the impact of the work and PE RVU

changes, section 5102 of the DRA (plus six additions to OPPS cap list), revisions to OPPS payment amounts, and the CY 2008 update.

TABLE 39.—COMBINED CY 2008 TOTAL ALLOWED CHARGE IMPACT FOR THE REMAINING 5-YEAR REVIEW OF WORK RVUS AND PRACTICE EXPENSE CHANGES, OPPS IMAGING CAP, AND THE CY 2008 UPDATE

Specialty	Allowed charges (mil)	Impact of work and PE RVU changes* (percent)	Impact of DRA 5102 (percent)	Combined impact RVU and DRA 5102** (percent)	CY 2008 update (percent)	Combined impact with CY 2008 update** (percent)
TOTAL	\$76,551	0	0	0	-10	-10
ALLERGY/IMMUNOLOGY	173	2	0	2	-10	-8
ANESTHESIOLOGY	1,579	14	0	14	-10	4
CARDIAC SURGERY	396	-2	0	-2	-10	-12
CARDIOLOGY	7,519	-2	0	-2	-10	-12
COLON AND RECTAL SURGERY	122	0	0	0	-10	-10
CRITICAL CARE	199	-1	0	-1	-10	-11
DERMATOLOGY	2,248	2	0	2	-10	-8
EMERGENCY MEDICINE	2,203	-2	0	-2	-10	-12
ENDOCRINOLOGY	350	-1	0	-1	-10	-11
FAMILY PRACTICE	5,060	0	0	0	-10	-10
GASTROENTEROLOGY	1,750	0	0	0	-10	-10
GENERAL PRACTICE	974	0	0	0	-10	-10
GENERAL SURGERY	2,309	-1	0	-1	-10	-11
GERIATRICS	147	3	0	3	-10	-7
HAND SURGERY	80	-2	0	-2	-10	-12
HEMATOLOGY/ONCOLOGY	1,917	-1	0	-1	-10	-11
INFECTIOUS DISEASE	504	-1	0	-1	-10	-11
INTERNAL MEDICINE	9,981	0	0	0	-10	-10
INTERVENTIONAL RADIOLOGY	244	-2	0	-2	-10	-12
NEPHROLOGY	1,664	-3	0	-3	-10	-13
NEUROLOGY	1,398	-1	0	-1	-10	-11
NEUROSURGERY	576	-2	0	-2	-10	-12
NUCLEAR MEDICINE	78	4	0	5	-10	-5
OBSTETRICS/GYNECOLOGY	628	-1	0	-1	-10	-11
OPHTHALMOLOGY	4,664	1	0	1	-10	-9
ORTHOPEDIC SURGERY	3,248	-1	0	-1	-10	-11
OTOLARNGOLOGY	913	1	0	1	-10	-9
PATHOLOGY	948	-2	0	-2	-10	-12
PEDIATRICS	74	0	0	0	-10	-10
PHYSICAL MEDICINE	784	-1	0	-1	-10	-11
PLASTIC SURGERY	272	-1	0	-1	-10	-11
PSYCHIATRY	1,099	0	0	0	-10	-10
PULMONARY DISEASE	1,691	-1	0	-1	-10	-11
RADIATION ONCOLOGY	1,612	0	0	0	-10	-10
RADIOLOGY	5,245	0	0	0	-10	-10
RHEUMATOLOGY	494	-1	0	-1	-10	-11
THORACIC SURGERY	436	-2	0	-2	-10	-12
UROLOGY	2,033	-1	0	-1	-10	-11
VASCULAR SURGERY	641	-1	-1	-1	-10	-11
AUDIOLOGIST	31	12	0	12	-10	2
CHIROPRACTOR	725	-2	0	-2	-10	-12
CLINICAL PSYCHOLOGIST	531	-3	0	-3	-10	-13
CLINICAL SOCIAL WORKER	354	-3	0	-3	-10	-13
NURSE ANESTHETIST	608	22	0	22	-10	12
NURSE PRACTITIONER	796	2	0	2	-10	-8
OPTOMETRY	790	4	0	4	-10	-6
ORAL/MAXILLOFACIAL SURGERY	37	1	0	1	-10	-9
PHYSICAL/OCCUPATIONAL THERAPY	1,391	1	0	1	-10	-9
PHYSICIAN ASSISTANT	600	0	0	0	-10	-10
PODIATRY	1,575	2	0	2	-10	-8
DIAGNOSTIC TESTING FACILITY	1,191	0	0	0	-10	-10
INDEPENDENT LABORATORY	1,087	3	0	3	-10	-7
PORTABLE X-RAY SUPPLIER	81	2	0	2	-10	-8

* PE changes are CY 2008 second year transition changes. For fully implemented CY 2010 PE changes see Table 1.

** Components may not sum to total due to rounding.

Table 40 shows the estimated impact on total payments for selected high volume procedures of all of the changes discussed previously. We selected these procedures because they are the most

commonly furnished by a broad spectrum of physician specialties. There are separate columns that show the change in the facility rates and the nonfacility rates. For an explanation of

facility and nonfacility PE refer to Addendum A of this final rule with comment period rule.

TABLE 40.—IMPACT OF FINAL RULE WITH COMMENT PERIOD AND ESTIMATED PHYSICIAN UPDATE ON 2008 PAYMENT FOR SELECTED PROCEDURES

CPT/HCPCS	MOD	Description	Facility			Non-facility		
			2007	2008	Percent change	2007	2008	Percent change
11721		Debride nail, 6 or more	\$28.80	\$24.53	-15	\$39.03	\$35.43	-9
17000		Destruct premalg lesion	44.72	41.56	-7	63.29	60.30	-5
27130		Total hip arthroplasty	1,360.52	1,194.77	-12	na	na	na
27244		Treat thigh fracture	1,100.92	963.11	-13	na	na	na
27447		Total knee arthroplasty	1,464.74	1,283.35	-12	na	na	na
33533		CABG, arterial, single	1,908.52	1,658.44	-13	na	na	na
35301		Rechannelling of artery	1,071.74	934.49	-13	na	na	na
43239		Upper GI endoscopy, biopsy	155.00	140.36	-9	325.16	294.01	-10
66821		After cataract laser surgery	253.53	222.81	-12	270.97	237.80	-12
66984		Cataract surg w/iol, 1 stage	641.98	560.08	-13	na	na	na
67210		Treatment of retinal lesion	556.34	487.86	-12	580.59	507.96	-13
71010		Chest x-ray	na	na	na	26.15	22.83	-13
71010	26	Chest x-ray	8.72	7.84	-10	8.72	7.84	-10
77056		Mammogram, both breasts	na	na	na	97.40	93.35	-4
77056	26	Mammogram, both breasts	41.31	37.48	-9	41.31	37.48	-9
77057		Mammogram, screening	na	na	na	81.86	73.93	-10
77057	26	Mammogram, screening	33.35	30.32	-9	33.35	30.32	-9
77427		Radiation tx management, x5	176.22	158.42	-10	176.22	158.42	-10
78465	26	Heart image (3d), multiple	73.14	66.43	-9	73.14	66.43	-9
88305	26	Tissue exam by pathologist	37.90	32.36	-15	37.90	32.36	-15
90801		Psy dx interview	129.99	112.08	-14	145.15	131.50	-9
90862		Medication management	44.72	39.18	-12	50.40	46.67	-7
90935		Hemodialysis, one evaluation	67.46	58.26	-14	na	na	na
92012		Eye exam established pat	34.11	38.50	13	61.77	62.69	1
92014		Eye exam & treatment	55.71	59.28	6	91.33	90.96	0
92980		Insert intracoronary stent	795.85	720.88	-9	na	na	na
93000		Electrocardiogram, complete	24.63	20.78	-16	24.63	20.78	-16
93010		Electrocardiogram report	8.34	7.50	-10	8.34	7.50	-10
93015		Cardiovascular stress test	104.22	93.01	-11	104.22	93.01	-11
93307	26	Echo exam of heart	46.99	42.24	-10	46.99	42.24	-10
93510	26	Left heart catheterization	242.92	215.31	-11	242.92	215.31	-11
98941		Chiropractic manipulation	28.80	25.55	-11	33.35	29.64	-11
99203		Office/outpatient visit, new	67.08	58.60	-13	91.71	81.42	-11
99213		Office/outpatient visit, est	42.07	37.48	-11	59.50	53.15	-11
99214		Office/outpatient visit, est	66.32	58.60	-12	90.20	80.40	-11
99222		Initial hospital care	119.00	104.59	-12	na	na	na
99223		Initial hospital care	173.57	153.65	-11	na	na	na
99231		Subsequent hospital care	35.62	31.68	-11	na	na	na
99232		Subsequent hospital care	63.67	56.55	-11	na	na	na
99233		Subsequent hospital care	90.95	81.08	-11	na	na	na
99236		Observ/hosp same date	205.40	179.20	-13	na	na	na
99239		Hospital discharge day	94.74	83.13	-12	na	na	na
99243		Office consultation	93.23	83.13	-11	122.41	109.36	-11
99244		Office consultation	145.91	130.14	-11	179.26	160.12	-11
99253		Inpatient consultation	108.77	97.09	-11	na	na	na
99254		Inpatient consultation	156.52	140.02	-11	na	na	na
99283		Emergency dept visit	60.64	52.81	-13	na	na	na
99284		Emergency dept visit	110.28	97.44	-12	na	na	na
99291		Critical care, first hour	208.82	182.61	-13	256.19	224.17	-12
99292		Critical care, addtl 30 min	104.60	91.64	-12	114.45	100.16	-12
99348		Home visit, est patient	na	na	na	66.32	68.14	2
99350		Home visit, est patient	na	na	na	150.83	139.34	-8
G0008		Admin influenza virus vac	na	na	na	18.95	18.40	-3
G0317		ESRD related svcs 4+mo 20+yrs	283.09	245.29	-13	283.09	245.29	-13

B. Geographic Practice Cost Index Changes

Section 1848(e)(1)(A) of the Act requires that payments under the Medicare physician fee schedule vary among payment areas only to the extent that area costs vary as reflected by the area GPCIs. The GPCIs measure area cost differences in the three components of the physician fee schedule: Physician work, PEs (employee wages, rent, medical supplies, and equipment), and malpractice insurance. Section 1848(e)(1)(C) of the Act requires that the GPCIs be reviewed and, if necessary, revised at least every 3 years. The first GPCI revision occurred in 1993. The second revision was implemented in 1998, the next in 2001, and the last in 2005. We are implementing the next GPCI update in this rule and the 2008 updated, budget neutralized values are shown in Addendum E. These values reflect the removal of the 1,000 floor on physician work as mandated by the MIEA-TRHCA law of December 2006. As required by law, the GPCIs are phased in over a two year period; therefore the 2008 GPCI values are calculated as one-half the difference between the fully implemented 2007 GPCIs and the fully implemented 2009 (updated) GPCIs.

An estimate of the overall effects of GPCI changes on fee schedule area payments can be demonstrated by a comparison of area geographic adjustment factors (GAFs). The GAFs are a weighted composite of each area's work, PE, and malpractice expense GPCIs using the national GPCI cost share weights. While we do not actually use the GAFs in computing the fee schedule payment for a specific service, they are useful in comparing overall area costs and payments. The actual effect on payment for any actual service will deviate from the GAF to the extent that the services proportions of work, PE, and malpractice expense RVUs differ from those of the GAF. The GAFs reflect the removal of the 1,000 floor on physician work as mandated by the MIEA-TRHCA law of December 2006.

The most significant positive changes occur in seven payment localities where the GAF moves up between 5.91 percent (Rest of Maine) and 2.05 percent (Ventura, Calif.). Nineteen payment localities show an increase in GAF of between 1.99 percent (Rest of Texas) to 1.05 percent (New Hampshire). Twenty-two payment localities have increases of less than 1 percent.

The Detroit, Michigan payment locality shows a drop in the GAF value of 4.32 percent, the largest, and eight other payment localities (including

Santa Clara, California, Atlanta, Georgia, Fort Worth, Texas, and Chicago, Illinois) decrease between 3.8 percent and 2.16 percent in the GAF value. Fourteen payment localities show decreases between 1.10 percent (Rest of Michigan) and 1.92 percent (Miami, Florida). Twenty-two payment localities show decreases between 0.01 percent (Anaheim, California) and 0.90 percent (Seattle, Washington).

Increases or decreases in GPCI values do not necessarily reflect increases or decreases in the actual costs associated with a specific locality, but rather reflect the relative costs compared to a national average. As an example, when rents go up in Wisconsin or Ohio, the index for California or New York goes down, even if actual costs for California or New York stay the same or even increase. Other factors also play a part in the overall GPCI picture. We do not have sufficient data to undertake a sensitivity analysis of exact elements of the change but we can make some generalized assumptions. For example, the changes in GAF values for several areas of California reflect significant changes in the malpractice GPCIs; and, a lowering of the PE GPCI in many urban settings is offset by increases in the PE GPCI of more rural settings.

The 2008 GPCIs are budget neutralized so the update does not result in an increase in spending as a result of the changes.

C. Telehealth

In section II.D of this rule, we are adding neurobehavioral status exam as represented by HCPCS code 96116 to the list of telehealth services. To date, Medicare expenditures for telehealth services have been extremely low. For instance, in CY 2006, the total Medicare payment amount for telehealth services (including the originating site facility fee) was approximately \$2 million. Moreover, previous additions to the list of Medicare telehealth services have not resulted in a significant increase in Medicare program expenditures. For example, the psychiatric diagnostic interview examination (as described by CPT code 90801) was added to the list of Medicare telehealth services in CY 2003. The addition of CPT code 90801 resulted in an increase in Medicare payment amounts of approximately \$100,000 in CY 2006.

The neurobehavioral status exam (CPT code 96116) includes an initial assessment and evaluation of the mental status for a psychiatric patient. In this regard, the neurobehavioral status exam is similar to the psychiatric diagnostic interview examination (CPT code 90801). However, the utilization rate of

psychiatric diagnostic interview examination is much greater than the neurobehavioral status exam. For instance, in CY 2006, the total allowed services for CPT code 90801 was approximately 1.3 million while total allowed services for neurobehavioral status exam in CY 2006 was approximately 105,000. Because utilization of neurobehavioral status exam is substantially less than the psychiatric diagnostic interview examination, we believe the budgetary impact of adding neurobehavioral status exam to the list of Medicare telehealth services will be even less than the previously added psychiatric diagnostic interview examination.

While we believe that addition of this service to the telehealth service list will enable more beneficiaries to access to these services, we do not anticipate that this change will have a significant budgetary impact on the Medicare program.

D. Payment for Covered Outpatient Drugs and Biologicals

1. ASP Issues

The issues discussed in section II.F.1. with respect to payment for covered outpatient drugs and biologicals, are estimated to have no impact on Medicare expenditures. However, we believe the policies we are adopting will assist in clarifying existing policy with respect to ASP payment.

2. CAP issues

This final rule describes a significant change in how CAP drug claims are paid due to the implementation of section 108(a)(2) of the MIEA-TRHCA. This rule also addresses comments and finalizes regulations on certain approaches to refining the CAP that seek to improve service by improving compliance, increasing flexibility, and increasing choices available to participating CAP physicians. The finalized CAP provisions will also have a potential impact on entities that are involved in the dispensing or distribution of drugs, that plan to become approved CAP vendors, or are approved CAP vendors. Changes associated with section 108(a)(2) of the MIEA-TRHCA, especially the provision for payment to vendors upon receipt of a claim, will almost certainly be perceived as a positive step. Other finalized changes seek to improve service by improving compliance and increasing flexibility under the CAP. At this time, we anticipate that these changes will result in no significant additional cost savings or increases

associated with the CAP, relative to the ASP payment system.

E. Clinical Laboratory Fee Schedule Issues

As discussed in section II.G of this final rule, we are adopting § 414.509 for establishing payment for a new clinical diagnostic laboratory paid under the Medicare Part B clinical laboratory fee schedule. Also, we are clarifying dates in § 414.502 and § 414.508. These changes will not increase or decrease payments for current clinical diagnostic laboratory tests. For newly developed tests, we will permit an opportunity for the public to request a reconsideration of a payment amount. Because any new laboratory tests to undergo a reconsideration request of a payment amount are unknown to us at the current time, we do not have any data to estimate the impact. However, we anticipate that the reconsideration process will apply to fewer than five new tests per year so that no significant additional costs to the clinical laboratory payment system will occur.

F. Provisions Related to Payment for Renal Dialysis Services Furnished by End State Renal Disease (ESRD) Facilities

The ESRD-related provisions in this final rule are discussed in section II.H. To understand the impact of the changes affecting payments to different categories of ESRD facilities, it is necessary to compare estimated payments under the current year (CY 2007 payments) to estimated payments under the revisions to the composite rate payment system as discussed in II.H. of this final rule with comment period (2008 payments). To estimate the impact among various classes of ESRD facilities, it is imperative that the estimates of current payments and projected payments contain similar inputs. Therefore, we simulated payments only for those ESRD facilities that we are able to calculate both current 2007 payments and projected 2008 payments.

ESRD providers were grouped into the categories based on characteristics

furnished in the Online Survey and Certification and Reporting (OSCAR) file and the most recent cost report data from the Healthcare Cost Report Information System (HCRIS). We also used the June 2007 update of CY 2006 National Claims History file as a basis for Medicare dialysis treatments and separately billable drugs and biologicals. Due to data limitations, we are unable to estimate current 2007 payments and projected 2008 payments for 153 of the 4,813 ESRD facilities that billed for ESRD dialysis treatments in CY 2006.

Table 41 shows the impact of this year's changes to CY 2008 payments to hospital-based and independent ESRD facilities. The first column of Table 41 identifies the type of ESRD provider, the second column indicates the number of ESRD facilities for each type, and the third column indicates the number of dialysis treatments.

The fourth column shows the effect of the change to the wage index floor as it affects the composite rate payments to ESRD facilities for CY 2008. The fourth column compares aggregate ESRD wage adjusted composite rate payments in the third year of the transition (CY 2008) using the CY 2008 wage index with a 0.80 floor compared to aggregate ESRD wage adjusted composite rate payments in the third year of the transition (CY 2008) using the CY 2008 wage index with a 0.75 floor. Note that the fourth column only includes the effect of the change to the wage index floor and does not include the effects of other wage index changes, such as, moving from the second to third year of the transition and updated wage index values from CY 2007 to CY 2008.

The fifth column shows the effect of all changes to the ESRD wage index for CY 2008 as it affects the composite rate payments to ESRD facilities. It is inclusive of the changes in the fourth column. The fifth column compares aggregate ESRD wage adjusted composite rate payments in the third year of the transition (CY 2008) to aggregate ESRD wage adjusted composite rate payments in the second year of the transition (CY 2007). In the

third year of the transition (CY 2008), ESRD facilities receive 75 percent of the CBSA wage adjusted composite rate and 25 percent of the MSA wage adjusted composite rate. In the second year of the transition, ESRD facilities receive 50 percent of the CBSA wage adjusted composite rate and 50 percent of the MSA wage adjusted composite rate. The overall effect to all ESRD providers in aggregate is zero because the CY 2008 ESRD wage index has been multiplied by a BN adjustment factor to comply with the statutory requirement that any wage index revisions be done in a manner that results in the same aggregate amount of expenditures as would have been made without any changes in the wage index. The decreases shown among census regions is primarily due to reducing the wage index floor, as there were areas in these areas with wage index values below the reduced floor.

The sixth column shows the overall effect of the changes in composite rate payments to ESRD providers. The overall effect is measured as the difference between the projected CY 2008 payment with all changes in this final rule and CY 2007 payment. This payment amount is computed by multiplying the wage adjusted composite rate with the drug add-on for each provider times the number of dialysis treatments from the CY 2006 claims. The projected CY 2008 payment is the transition year 3 wage-adjusted composite rate for each provider (with the 15.5 percent drug add-on) times dialysis treatments from CY 2006 claims. The CY 2007 current payment is the transition year 2 wage-adjusted composite rate for each provider (with the current 14.9 percent drug add-on) times dialysis treatments from CY 2006 claims.

The overall impact to ESRD providers in aggregate is 0.5 percent. This increase corresponds to the 0.5 percent increase to the drug add-on. The variation shown in column 6 is due to variation in changes in the wage index (column 5). All provider types receive the same 0.5 percent increase to the drug add-on.

TABLE 41.—IMPACT OF CY 2008 CHANGES IN PAYMENTS TO HOSPITAL BASED AND INDEPENDENT ESRD FACILITIES
[Percent change in composite rate payments to ESRD facilities (both program and beneficiaries)]

	Number of facilities	Number of dialysis treatments (in millions)	Effect of changes in floor only ¹	Effect of changes in wage index ²	Overall effect ³
All Providers	4,660	35.5	0.0	0.0	0.5
Independent	4,101	31.8	0.0	-0.1	0.5
Hospital Based	559	3.7	0.0	0.5	1.0
By Facility Size					
Less than 5000 treatments	1,650	4.7	-0.1	-0.3	0.3

TABLE 41.—IMPACT OF CY 2008 CHANGES IN PAYMENTS TO HOSPITAL BASED AND INDEPENDENT ESRD FACILITIES—
Continued

[Percent change in composite rate payments to ESRD facilities (both program and beneficiaries)]

	Number of facilities	Number of dialysis treatments (in millions)	Effect of changes in floor only ¹	Effect of changes in wage index ²	Overall effect ³
5000 to 9999 treatments	1,800	13.0	0.0	0.0	0.5
Greater than 9999 treatments	1,210	17.7	0.0	0.1	0.6
Type of Ownership					
Profit	3,745	28.9	0.0	-0.1	0.4
Nonprofit	915	6.5	0.0	0.3	0.9
By Geographic Location					
Rural	1,261	7.3	-0.4	-0.6	0.0
Urban	3,399	28.1	0.1	0.1	0.7
By Region					
New England	141	1.1	0.1	1.4	2.0
Middle Atlantic	553	4.5	0.1	0.5	1.0
East North Central	727	5.7	0.1	-0.6	-0.1
West North Central	358	1.9	0.1	-0.3	0.3
South Atlantic	1,063	8.1	0.0	0.0	0.6
East South Central	365	2.6	-0.5	-1.4	-0.8
West South Central	646	5.0	-0.1	-0.7	-0.2
Mountain	254	1.6	0.1	0.3	0.8
Pacific	523	4.4	0.1	1.4	2.0
Puerto Rico	30	0.4	-2.1	-3.0	-2.5

¹ This column shows the effect of the wage index floor changes on ESRD providers. Composite rate payments computed using the CY 2008 wage index with a 0.80 floor are compared to composite rate payments using the CY 2008 wage index with a 0.75 floor.

² This column shows the overall effect of wage index changes on ESRD providers. Composite rate payments computed using the current wage index are compared to composite rate payments using the CY 2008 wage index changes.

³ This column shows the percent change between CY 2008 and CY 2007 composite rate payments to ESRD facilities. The CY 2008 payments include the CY 2008 wage adjusted composite rate, and the 15.5% drug add-on times treatments. The CY 2007 payments to ESRD facilities includes the CY 2007 wage adjusted composite rate and the 14.9% drug add-on times treatments.

G. IDTF Changes

We believe that our provisions regarding IDTFs as discussed in section II.I. of this final rule with comment period would have no budgetary impact. However, we believe that these changes are necessary to ensure that only legitimate IDTFs are enrolled into the program. In addition, we believe that the IDTF provisions contained in this final rule will help ensure that beneficiaries receive quality care. Therefore, we expect to have an impact on an unknown number of persons and entities who will be denied enrollment into the Medicare program.

H. CORF Issues

The revisions to the CORF regulations discussed in section II.K. update the regulations for consistency with the PFS payment rules. These revisions will help to clarify payment for CORF services and are expected to have minimal impact on Medicare expenditures.

I. Compendia for Determination of Medically-Accepted Indications for Off-Label Use of Drugs and Biologicals in an Anti-Cancer Chemotherapeutic Regimen.

We anticipate that the changes related to the compendia discussed in section

II.L. of this final rule with comment period will have a negligible cost to the Medicare program. The changes will enable CMS to respond quickly should changes in the number and quality of the compendia indicate a need to amend the list.

J. Physician Self-Referral Provisions

We anticipate that our provisions in section II.M. of this final rule with comment period for the reassignment and anti-markup provisions, and the physician self-referral provisions will result in savings to the program by reducing overutilization and anti-competitive business arrangements. We cannot gauge with any certainty the extent of these savings to the Medicare program.

K. Beneficiary Signature for Ambulance Transport Services

We believe that our provision in section II.N. of this final rule with comment period for allowing the ambulance provider or supplier to sign the claim on behalf of the beneficiary with respect to emergency transport services, provided that certain conditions are satisfied, will have no budget impact.

L. Update to Fee Schedules for Class III DME for CYs 2007 and 2008

In section II.O. of this final rule with comment period, we discuss the update to the fee schedules for class III DME for CYs 2007 and 2008. Total allowed charges for class III devices in 2005 were \$71 million. Accordingly, with a zero percent increase for DME, other than class III devices, for 2005 and 2006 and with the establishment of an update for 2007 of zero percent for class III devices, rather than 4.3 percent based on the CPI-U, this results in a savings to the Medicare program of approximately \$2 million in FY 2007, \$4 million in FY 2008, \$4 million in FY 2009, \$5 million in FY 2010, \$5 million in FY 2011, and \$5 million in FY 2012.

M. Therapy Services

In section II.R.2., we are changing the certification requirement for the plan of care, for outpatient physical therapy, occupational therapy and speech-language pathology services from every 30 days to an appropriate length, based on the patient's needs, limited to 90 days. As we stated in the proposed rule, analysis of Medicare claims data shows negative or no impact for this change and this was also supported by commenters. In most cases, the appropriate length of treatment will be

less than 30 days. Certification of the appropriate length of treatment will discourage the practice of billing for re-evaluations prior to recertification regardless of need.

The 30-day recertification allows treatment under a plan of care for 30 days after initial certification, regardless of the appropriate length of treatment. The initial certification cannot assure that a physician reviews the plan or follows the patient's progress.

We will review the utilization of therapy services after a 2-year trial to assess any changes that might be related to certification of a plan of care for an appropriate length of treatment. At that time, if we determine that this change has caused an increase in inappropriate utilization, we will reconsider the 30-day certification requirement.

N. TRHCA 101(b) Physician Quality Reporting Initiative

As discussed section II.S.1. of this rule, the final 2008 PQRI measures satisfy the requirement of section 1848(k)(2)(B)(ii) of the Act that the Secretary publish in the **Federal Register** by August 15, 2007, measures that the Secretary proposes as appropriate for eligible professionals to use to submit data to the Secretary in 2008. We also expect to address registry- and EHR-based data submission on a test basis in 2008, as discussed in section II.T.1. of this rule. Although there may be some cost incurred for maintaining the measures and their associated code sets, and for enhancing an existing clinical data warehouse to accommodate the registry- and EHR-based data submission, we do not anticipate a significant cost impact on the Medicare program.

O. TRHCA 101(d) Physician Assistance and Quality Initiative Fund

As discussed in section II.S.5. of this final rule with comment period, section 101(d) of the MIEA-TRHCA created the Physician Assistance and Quality Initiative Fund (PAQI) which provides \$1.35 billion for physician payment and quality improvement initiatives. The legislation directs the Secretary to provide for expenditures from the Fund in a manner designed to provide (to the maximum extent feasible) for the obligation of the entire \$1.35 billion for payment for physicians' services furnished during 2008. As discussed in section II.S.5. of this final rule with comment period, we will scale aggregate payments to physicians in a manner such that Medicare would pay \$1.35 billion during CY 2009 for measures reported for services furnished during CY 2008. We are unable to provide an

exact percentage for the bonus payment, but we anticipate that the bonus payments will be approximately 1.5 percent of allowed charges for participating professionals (and we do not expect that the ultimate percentage amount would exceed 2 percent). We also note that the Transitional Medical Assistance, Abstinence Education, and Qualifying Individual Programs Extension Act of 2007 (Pub. L. 110-90) provided an additional \$325 million to be used as a part of the PAQI Fund for payment with regard to services furnished in 2009 and \$60,000,000 for payment with respect to physicians' services furnished on or after January 1, 2013.

P. TRHCA 110 Reporting of Anemia Quality Indicators

As discussed in section II.S.2. of this final rule with comment period, there are no program cost savings or increased expenditures associated with this change; however, we expect that the regulation will have a positive impact on patient care.

Q. Amendment of the Exemption From NCPDP SCRIPT Standard for Computer-Generated Facsimile Transmissions Under Medicare Part D

The amendment of the exemption for computer-generated fax transactions under Medicare Part D is discussed in section II.R.3. of this rule. E-prescribing is voluntary for providers and pharmacies. This amendment only affects providers and pharmacies that already conduct e-prescribing using products that generate faxes rather than SCRIPT transactions.

We believe that providers and pharmacies that are now e-prescribing using products that generate faxes generally already possess the hardware necessary to e-prescribe. Many would need to obtain software upgrades to send and receive the SCRIPT transaction. This software will generally be available to providers through automatic version upgrades built into annual software vendor maintenance fees. However, providers currently using software that cannot be upgraded to generate SCRIPT transactions would need to purchase and install new e-prescribing software or revert to sending paper fax transactions to pharmacies.

Dispensers that currently e-prescribe but have not established the connectivity necessary to receive and send SCRIPT transactions would need to connect to a network, and may need to install software upgrades, which will generally be covered under annual fees. Because pharmacies customarily bear the cost of transaction fees for the

SCRIPT transactions they receive and send, these costs would increase as the rate of e-prescribing increases.

The amendment of this exemption will have indirect benefits in that it will help to encourage e-prescribing using electronic data interchange, which will ultimately result in improved patient safety. We also will continue to allow computer-generated faxes as a fallback in cases of temporary/transient transmission failures and communications problems.

Because of the voluntary nature of e-prescribing for physicians and pharmacies, the relatively small number of entities currently e-prescribing, and the minimal nature of the anticipated costs, we believe this provision does not constitute a major rule for purposes of this analysis.

R. Revisions to Payment Policies Under the Ambulance Fee Schedule and the Ambulance Inflation Factor Update for CY 2008

For the purposes of the RFA, ambulance providers and suppliers are considered to be small entities. Removing the requirement that the AIF be published annually via **Federal Register** notice has no monetary impact on small entities or small businesses. It merely allows for the earlier dissemination of necessary information to the ambulance industry, the Medicare contractors, and the general public.

We estimate that the total program expenditure for CY 2007 for ambulance services covered by the Medicare program is approximately \$5.2 billion. Application of an AIF of 2.7 percent will result in an additional total program expenditure for CY 2008 of approximately \$140 million over CY 2007 expenditures.

S. Alternatives Considered

This final rule with comment period contains a range of policies, including some provisions related to specific MMA provisions. The preamble provides descriptions of the statutory provisions that are addressed, identifies those policies when discretion has been exercised, presents rationale for our decisions and, where relevant, alternatives that were considered.

T. Impact on Beneficiaries

There are a number of changes made in this final rule with comment period that would have an effect on beneficiaries. In general, we believe these changes, particularly the implementation of the PQRI with its continuing focus on measuring, submitting, and analyzing quality data, will have a positive impact and improve

the quality and value of care furnished to Medicare beneficiaries.

We do not believe that beneficiaries will experience drug access issues as a result of the changes with respect to Part B drugs and CAP.

As explained in more detail subsequently in this section, the regulatory provisions may affect beneficiary liability in some cases. Most changes in aggregate beneficiary liability from a particular provision would be a function of the coinsurance (20 percent if applicable for the particular provision after the beneficiary has met the deductible) and the effect of the aggregate cost (savings) of the provision on the calculation of the Medicare Part B premium rate (generally 25 percent of the provision's cost or savings). In 2008, total cost sharing (coinsurance and deductible) per Part B enrollee

associated with physician fee schedule services is estimated to be \$590. In addition, the portion of the 2008 standard monthly Part B premium attributable to PFS services is estimated to be \$38.60.

To illustrate this point, as shown in Table 40, the 2007 national payment amount in the nonfacility setting for CPT code 99203 (Office/outpatient visit, new), is \$91.71 which means that currently a beneficiary is responsible for 20 percent of this amount, or \$18.34. Based on this final rule with comment period, the 2008 national payment amount in the nonfacility setting for CPT code 99203, as shown in Table 40, is \$81.42 which means that, in 2008, the beneficiary coinsurance for this service would be \$16.28.

Policies discussed in this rule that do affect overall spending, such as the

additions to the list of codes that are subject to section 5102 of the DRA imaging provisions, would similarly impact beneficiaries' coinsurance.

U. Accounting Statement

As required by OMB Circular A-4 (available at <http://www.whitehouse.gov/omb/circulars/a004/a-4.pdf>), in Table 42, we have prepared an accounting statement showing the classification of the expenditures associated with this final rule with comment period. This estimate includes the incurred benefit impact associated with the estimated CY 2008 PFS update, shown in this final rule with comment period, based on the 2007 Trustees Report baseline. All estimated impacts are classified as transfers.

TABLE 42.—ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED EXPENDITURES FOR CY 2008
[In billions]

Category	Transfers
Annualized Monetized Transfers.	-\$6.0.
From Whom To Whom?	Federal Government to physicians, other practitioners and suppliers who receive payment under the Medicare Physician Fee Schedule; ESRD Medicare Providers; ambulance suppliers, DME suppliers, and Medicare suppliers billing for Part B drugs.

In accordance with the provisions of Executive Order 12866, this final rule with comment period was reviewed by the Office of Management and Budget.

List of Subjects

42 CFR Part 409

Health facilities, Medicare.

42 CFR Part 410

Health facilities, Health professions, Kidney diseases, Laboratories, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays.

42 CFR Part 411

Kidney diseases, Medicare, Physician Referral, Reporting and recordkeeping requirements.

42 CFR Part 413

Health facilities, Kidney diseases, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 414

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare, Reporting and recordkeeping.

42 CFR Part 415

Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 418

Health facilities, Hospice care, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 423

Administrative practice and procedure, Emergency medical services, Health facilities, Health maintenance organizations (HMO), Health Professionals, Medicare, Penalties, Privacy, Reporting and recordkeeping requirements.

42 CFR Part 424

Emergency medical services, Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 482

Grant programs—health, Hospitals, Medicaid, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 484

Grant programs—health, Health facilities, Health professions, Health records, Medicaid, Medicare, Nursing

homes, Nutrition, Reporting and recordkeeping requirements, Safety.

42 CFR Part 485

Grant programs—health, Health facilities, Medicaid, Medicare, Reporting and recordkeeping requirements.

■ For the reasons set forth in the preamble, the Centers for Medicare & Medicaid Services amends 42 CFR chapter IV as set forth below:

PART 409—HOSPITAL INSURANCE BENEFITS

■ 1. The authority citation for part 409 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

Subpart B—Inpatient Hospital Services and Inpatient Critical Access Hospital Services

■ 2. Section 409.17 is added to read as follows:

§ 409.17 Physical therapy, occupational therapy, and speech-language pathology services.

(a) *General rules.* (1) Except as specified in paragraph (a)(1)(ii) of this section, physical therapy, occupational

therapy or speech-language pathology services must be furnished by qualified physical therapists, physical therapist assistants, occupational therapists, occupational therapy assistants or speech-language pathologists who meet the requirements specified part 484 of this chapter.

(2) Physical therapy, occupational therapy or speech-language pathology services must be furnished under a plan that meets the requirements of paragraphs (b) through (d) of this section, or plan requirements specific to the payment policy under which the services are rendered, if applicable.

(b) *Establishment of the plan.* The plan must be established before treatment begins by one of the following:

- (1) A physician.
- (2) A nurse practitioner, a clinical nurse specialist or a physician assistant.
- (3) The physical therapist furnishing the physical therapy services.

(4) A speech-language pathologist furnishing the speech-language pathology services.

(5) An occupational therapist furnishing the occupational therapy services.

(c) *Content of the plan.* The plan:
(1) Prescribes the type, amount, frequency, and duration of the physical therapy, occupational therapy, or speech-language pathology services to be furnished to the individual; and

(2) Indicates the diagnosis and anticipated goals.

(d) *Changes in the plan.* Any changes in the plan are implemented in accordance with hospital policies and procedures.

Subpart C—Posthospital SNF Care

■ 3. Section 409.23 is amended by adding paragraph (c) to read as follows:

§ 409.23 Physical, occupational, and speech therapy.

* * * * *

(c) Except as specified in paragraph (c)(1)(ii) of this section, physical therapy, occupational therapy or speech-language pathology services must be furnished—

(1) By qualified physical therapists, physical therapist assistants, occupational therapists, occupational therapy assistants or speech-language pathologists as defined in part 484 of this chapter

(2) In accordance with a plan that meets the requirements of § 409.17(b) through (d) of this part.

PART 410—SUPPLEMENTARY MEDICAL INSURANCE (SMI) BENEFITS

■ 4. The authority citation for part 410 continues to read as follows:

Authority: Secs. 1102, 1834, 1871, and 1893 of the Social Security Act (42 U.S.C. 1302, 1395m, 1395hh, and 1395ddd).

Subpart B—Medical and Other Health Services

§ 410.32 [Amended]

■ 5. Section 410.32 is amended by—
■ A. Removing paragraph (a)(1).

■ B. Redesignating paragraphs (a)(2) and (a)(3) as paragraphs (a)(1) and (a)(2).

■ 6. Section 410.33 is amended by—
■ A. Revising paragraphs (b)(1), (g)(2), (g)(3), (g)(6), and (g)(8).

■ B. Adding paragraphs (g)(15) and (i).
The revisions and addition read as follows:

§ 410.33 Independent diagnostic testing facility.

* * * * *

(b) * * *

(1) Each supervising physician must be limited to providing general supervision to no more than three IDTF sites. This applies to both fixed sites and mobile units where three concurrent operations are capable of performing tests.

* * * * *

(g) * * *

(2) Provides complete and accurate information on its enrollment application. Changes in ownership, changes of location, changes in general supervision, and adverse legal actions must be reported to the Medicare fee-for-service contractor on the Medicare enrollment application within 30 calendar days of the change. All other changes to the enrollment application must be reported within 90 days.

(3) Maintain a physical facility on an appropriate site. For the purposes of this standard, a post office box, commercial mailbox, hotel, or motel is not considered an appropriate site.

(i) The physical facility, including mobile units, must contain space for equipment appropriate to the services designated on the enrollment application, facilities for hand washing, adequate patient privacy accommodations, and the storage of both business records and current medical records within the office setting of the IDTF, or IDTF home office, not within the actual mobile unit.

(ii) IDTF suppliers that provide services remotely and do not see beneficiaries at their practice location are exempt from providing hand

washing and adequate patient privacy accommodations.

* * * * *

(6) Have a comprehensive liability insurance policy of at least \$300,000 per location that covers both the place of business and all customers and employees of the IDTF. The policy must be carried by a nonrelative-owned company. Failure to maintain required insurance at all times will result in revocation of the IDTF's billing privileges retroactive to the date the insurance lapsed. IDTF suppliers are responsible for providing the contact information for the issuing insurance agent and the underwriter. In addition, the IDTF must—

(i) Ensure that the insurance policy must remain in force at all times and provide coverage of at least \$300,000 per incident; and

(ii) Notify the CMS designated contractor in writing of any policy changes or cancellations.

* * * * *

(8) Answer, document, and maintain documentation of a beneficiary's written clinical complaint at the physical site of the IDTF (For mobile IDTFs, this documentation would be stored at their home office.) This includes, but is not limited to, the following:

(i) The name, address, telephone number, and health insurance claim number of the beneficiary.

(ii) The date the complaint was received; the name of the person receiving the complaint; and a summary of actions taken to resolve the complaint.

(iii) If an investigation was not conducted, the name of the person making the decision and the reason for the decision.

* * * * *

(15) With the exception of hospital-based and mobile IDTFs, a fixed-base IDTF does not include the following:

(i) Sharing a practice location with another Medicare-enrolled individual or organization;

(ii) Leasing or subleasing its operations or its practice location to another Medicare-enrolled individual or organization; or

(iii) Sharing diagnostic testing equipment used in the initial diagnostic test with another Medicare-enrolled individual or organization.

* * * * *

(i) *Effective date of billing privileges.* The filing date of the Medicare enrollment application is the date that the Medicare contractor receives a signed provider enrollment application that it is able to process to approval. The effective date of billing privileges for a

newly enrolled IDTF is the later of the following:

(1) The filing date of the Medicare enrollment application that was subsequently approved by a Medicare fee-for-service contractor; or

(2) The date the IDTF first started furnishing services at its new practice location.

■ 7. Section 410.43 is amended by revising paragraph (a)(3)(ii) to read as follows:

§ 410.43 Partial hospitalization services: Conditions and exclusions.

- (a) * * *
- (3) * * *

(ii) Occupational therapy requiring the skills of a qualified occupational therapist, provided by an occupational therapist, or under appropriate supervision of a qualified occupational therapist by an occupational therapy assistant as specified in part 484 of this chapter.

■ 8. Section 410.59 is amended by revising the introductory text to paragraph (a) to read as follows:

§ 410.59 Outpatient occupational therapy services: Conditions.

(a) *Basic rule.* Except as specified in paragraph (a)(3)(iii) of this section, Medicare Part B pays for outpatient occupational therapy services only if they are furnished by an individual meeting the qualifications in part 484 of this chapter for an occupational therapist or an appropriately supervised occupational therapy assistant but only under the following conditions:

* * * * *

■ 9. Section 410.60 is amended by revising the introductory text of paragraph (a) to read as follows:

§ 410.60 Outpatient physical therapy services: Conditions.

* * * * *

(a) *Basic rule.* Except as specified in paragraph (a)(3)(iii) of this section, Medicare Part B pays for outpatient physical therapy services only if they are furnished by an individual meeting the qualifications in part 484 of this chapter for a physical therapist or an appropriately supervised physical therapist assistant but only under the following conditions:

* * * * *

§ 410.61 [Amended]

■ 10. Section 410.61 is amended by removing paragraph (e).

■ 11. Section 410.78 is amended by revising the introductory text of paragraph (b) to read as follows:

§ 410.78 Telehealth services.

* * * * *

(b) *General rule.* Medicare Part B pays for office and other outpatient visits, professional consultation, psychiatric diagnostic interview examination, individual psychotherapy, pharmacologic management, end stage renal disease related services included in the monthly capitation payment (except for one visit per month to examine the access site), individual medical nutrition therapy, and neurobehavioral status exam furnished by an interactive telecommunications system if the following conditions are met:

* * * * *

Subpart D—Comprehensive Outpatient Rehabilitation Facility (CORF) Services

- 12. Section 410.100 is amended by—
- A. Revising the introductory text and paragraphs (a), (e), and (h).
- B. Removing paragraph (i).
- C. Redesignating paragraphs (j), (k), (l), and (m) to (i), (j), (k), and (l) respectively.
- D. Revising new paragraphs (i), (j), (k), and (l).

The revisions read as follows:

§ 410.100 Included services.

Subject to the conditions and limitations set forth in § 410.102 and § 410.105, CORF services means the following services furnished to an outpatient of the CORF by personnel that meet the qualifications set forth in § 485.70 of this chapter. Payment for CORF services are made in accordance with § 414.1105.

(a) *Physician's services.* CORF facility physician services are administrative in nature and include consultation with and medical supervision of nonphysician staff, participation in plan of treatment reviews and patient care review conferences, and other medical and facility administration activities. Diagnostic and therapeutic services furnished to an individual CORF patient by a physician in a CORF facility are not CORF physician services. These services, if covered, are physician services under § 410.20 with payment for these services made to the physician in accordance with part 414 subpart B.

* * * * *

(e) *Respiratory therapy services.* (1) Respiratory therapy services are for the assessment, treatment, and monitoring of patients with deficiencies or abnormalities of cardiopulmonary function.

(2) Respiratory therapy services include the following:

(i) Application of techniques for support of oxygenation and ventilation of the patient.

(ii) Therapeutic use and monitoring of gases, mists, and aerosols and related equipment.

(iii) Bronchial hygiene therapy.

(iv) Pulmonary rehabilitation techniques to develop strength and endurance of respiratory muscles and other techniques to increase respiratory function, such as graded activity services; these services include physiologic monitoring and patient education.

* * * * *

(h) *Social and psychological services.* Social and psychological services include the assessment and treatment of an individual's mental and emotional functioning and the response to and rate of progress as it relates to the individual's rehabilitation plan of treatment, including physical therapy services, occupational therapy services, speech-language pathology services and respiratory therapy services.

(i) *Nursing care services.* Nursing care services include nursing services provided by a registered nurse that are prescribed by a physician and are specified in or directly related to the rehabilitation treatment plan and necessary for the attainment of the rehabilitation goals of the physical therapy, occupational therapy, speech-language pathology, or respiratory therapy plan of treatment.

(j) *Drugs and biologicals.* These are drugs and biologicals that are the following:

(1) Prescribed by a physician and administered by or under the supervision of a physician or by a registered professional nurse; and

(2) Not excluded from Medicare Part B payment for reasons specified in § 410.29.

(k) *Supplies and durable medical equipment.* Supplies and durable medical equipment include the following:

(1) Disposable supplies.

(2) Durable medical equipment of the type specified in § 410.38 (except for renal dialysis systems) for a patient's use outside the CORF, whether purchased or rented.

(l) *Home environment evaluation.* A home environment evaluation—

(1) Is a single home visit to evaluate the potential impact of the home situation on the patient's rehabilitation goals.

(2) Requires the presence of the patient and the physical therapist, occupational therapist, or speech-language pathologist, as appropriate.

■ 13. Section 410.105 is amended by revising paragraphs (b)(3)(i), (b)(3)(ii), (c)(1) introductory text, and (c)(2) to read as follows:

§ 410.105 Requirements for coverage of CORF services.

* * * * *

(b) * * *

(3) * * *

(i) Physical therapy, occupational therapy, and speech-language pathology services may be furnished away from the premises of the CORF including the individual's home when payment is not otherwise made under Title XVIII of the Act.

(ii) The single home environment evaluation visit specified in § 410.100(m) is also covered.

(c) * * *

(1) The service must be furnished under a written plan of treatment that—
(i) * * *

(ii) Indicates the diagnosis and rehabilitation goals, and prescribes the type, amount, frequency, and duration of the skilled rehabilitation services, including physical therapy, occupational therapy, speech-language pathology and respiratory therapy services, and indicates the other CORF services to be furnished that relate directly to such rehabilitation goals.

(2) The plan must be reviewed at least every 60 days for respiratory therapy services and every 90 days for physical therapy, occupational therapy and speech-language pathology services by a facility physician or the referring physician who, when appropriate, consults with the professional personnel providing the services.

* * * * *

Subpart G—Medical Nutrition Therapy

■ 14. Section 410.132 is amended by revising paragraph (a) to read as follows:

§ 410.132 Medical nutrition therapy.

(a) Conditions for coverage of MNT services. Medicare Part B pays for MNT services provided by a registered dietitian or nutrition professional as defined in § 410.134 when the beneficiary is referred for the service by the treating physician. Except as provided at § 410.78, services covered consist of face-to-face nutritional assessments and interventions in accordance with nationally-accepted dietary or nutritional protocols.

* * * * *

PART 411—EXCLUSIONS FROM MEDICARE AND LIMITATIONS ON MEDICARE PAYMENT

■ 15. The authority citation for part 411 continues to read as follows:

Authority: Secs. 1102, 1860D–1 through 1860D–42, 1871, and 1877 of the Social Security Act (42 U.S.C. 1302, 1395w–101 through 1395w–152, 1395hh, and 1395nn).

Subpart A—General Exclusions and Exclusion of Particular Services

■ 16. Section 411.15 is amended by—

■ A. Revising paragraph (a)(1).

■ B. Adding paragraphs (k)(13) and (k)(14).

The revision and additions read as follows:

§ 411.15 Particular services excluded from coverage.

* * * * *

(a) * * *

(1) Examinations performed for a purpose other than treatment or diagnosis of a specific illness, symptoms, complaint, or injury, except for screening mammography, colorectal cancer screening tests, screening pelvic exams, prostate cancer screening tests, glaucoma screening exams, initial preventive physical exams, ultrasound screening for abdominal aortic aneurysms (AAA), cardiovascular disease screening tests, or diabetes screening tests that meet the criteria specified in paragraphs (k)(6) through (k)(14) of this section.

* * * * *

(k) * * *

(13) In the case of cardiovascular disease screening tests for the early detection of cardiovascular disease or abnormalities associated with an elevated risk for that disease, subject to the conditions specified in § 410.17 of this chapter.

(14) In the case of diabetes screening tests furnished to an individual at risk for diabetes for the purpose of the early detection of that disease, subject to the conditions specified in § 410.18 of this chapter.

* * * * *

Subpart J—Financial Relationships Between Physicians and Entities Furnishing Designated Health Services

■ 17. Section 411.351 is amended by revising the definition of “entity” to read as follows:

§ 411.351 Definitions.

* * * * *

Entity means—

* * * * *

(3) For purposes of this subpart, “entity” does not include a physician’s practice when it bills Medicare for the technical component or professional component of a diagnostic test for which the anti-markup provision is applicable in accordance with § 414.50 of this chapter and section 30.2.9 of the CMS Internet-only Manual, publication 100–04, Claims Processing Manual, Chapter 1 (general billing requirements).

PART 413—PRINCIPLES OF REASONABLE COST REIMBURSEMENT; PAYMENT FOR END-STAGE RENAL DISEASE SERVICES; PROSPECTIVELY DETERMINED PAYMENT RATES FOR SKILLED NURSING FACILITIES

■ 18. The authority citation for part 413 continues to read as follows:

Authority: Secs. 1102, 1812(d), 1814(b), 1815, 1833(a), (i), and (n), 1861(v), 1871, 1881, 1883, and 1886 of the Social Security Act (42 U.S.C. 1302, 1395d(d), 1395f(b), 1395g, 1395l(a), (i), and (n), 1395x(v), 1395hh, 1395rr, 1395tt, and 1395ww); and sec. 124 of Pub. L. 106–133 (113 Stat. 1501A–332).

Subpart A—Introduction and General Rules

§ 413.1 [Amended]

■ 19. Section 413.1 is amended by—

■ A. Removing paragraphs (a)(2)(iv) and (vi).

■ B. Redesignating paragraphs (a)(2)(v) and (vii) as paragraphs (a)(2)(iv) and (v), respectively.

Subpart H—Payment for End-Stage Renal Disease (ESRD) Services and Organ Procurement Costs

■ 20. Section 413.184 is amended by revising the section heading as set forth below:

§ 413.184 Payment exception: Pediatric patient mix.

* * * * *

PART 414—PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES

■ 21. The authority citation for part 414 continues to read as follows:

Authority: Secs. 1102, 1871, and 1881(b)(l) of the Social Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(l)).

Subpart B—Physicians and Other Practitioners

■ 22. Section 414.50 is revised to read as follows:

§ 414.50 Physician or other supplier billing for diagnostic tests performed or interpreted by an outside supplier or at a site other than the office of the billing physician or other supplier.

(a) *General rules.* (1) The services covered under section 1861(s)(3) of the Act and paid for under part 414 of this chapter (other than clinical diagnostic laboratory tests paid under section 1833(a)(2)(D) of the Act, which are subject to the special billing rules set forth in section 1833(h)(5)(A) of the Act), if a physician or other supplier bills for the technical component or professional component of a diagnostic test that was ordered by the physician or other supplier (or ordered by a party related to such physician or other supplier through common ownership or control as described in § 413.17 of this chapter) and the diagnostic test is either purchased from an outside supplier or performed at a site other than the office of the billing physician or other supplier, the payment to the billing physician or other supplier (less the applicable deductibles and coinsurance paid by the beneficiary or on behalf of the beneficiary) for the technical component or professional component of the diagnostic test may not exceed the lowest of the following amounts:

(i) The performing supplier's net charge to the billing physician or other supplier.

(ii) The billing physician or other supplier's actual charge.

(iii) The fee schedule amount for the test that would be allowed if the performing supplier billed directly.

(2) The following requirements are applicable for purposes of paragraph (a) of this section:

(i) The net charge must be determined without regard to any charge that is intended to reflect the cost of equipment or space leased to the performing supplier by or through the billing physician or other supplier.

(ii) An "outside supplier" is someone who is not an employee of the billing physician or other supplier and who does not furnish the test or interpretation to the billing physician or other supplier under a reassignment that meets the requirements of § 424.80.

(iii) The "office of the billing physician or other supplier" is medical office space where the physician or other supplier regularly furnishes patient care. With respect to a billing physician or other supplier that is a physician organization (as defined at § 411.351 of this chapter), the "office of the billing physician or other supplier" is space in which the physician organization provides substantially the full range of patient care services that

the physician organization provides generally.

(b) *Restriction on payment.* (1) The billing physician or other supplier must identify the performing supplier and indicate the performing supplier's net charge for the test. If the billing physician or other supplier fails to provide this information, CMS makes no payment to the billing physician or other supplier and the billing physician or other supplier may not bill the beneficiary.

(2) Physicians and other suppliers that accept Medicare assignment may bill beneficiaries for only the applicable deductibles and coinsurance.

(3) Physicians and other suppliers that do not accept Medicare assignment may not bill the beneficiary more than the payment amount described in paragraph (a) of this section.

■ 23. Section 414.65 is amended by revising paragraph (a)(1) to read as follows:

§ 414.65 Payment for telehealth services.

(a) * * *

(1) The Medicare payment amount for office or other outpatient visits, consultation, individual psychotherapy, psychiatric diagnostic interview examination, pharmacologic management, end stage renal disease related services included in the monthly capitation payment (except for one visit per month to examine the access site), individual medical nutrition therapy, and neurobehavioral status exam furnished via an interactive telecommunications system is equal to the current fee schedule amount applicable for the service of the physician or practitioner.

* * * * *

Subpart G—Payment for New Clinical Diagnostic Laboratory Tests

■ 24. Section § 414.502 is amended by adding the definition, "New test" in alphabetical order to read as follows:

§ 414.502 Definitions.

* * * * *

New test means any clinical diagnostic laboratory test for which a new or substantially revised Healthcare Common Procedure Coding System Code is assigned on or after January 1, 2005.

■ 25. Section 414.506 is amended by revising the introductory text to read as follows:

§ 414.506 Procedures for public consultation for payment for a new clinical diagnostic laboratory test.

For a new test, CMS determines the basis for and amount of payment after performance of the following:

* * * * *

■ 26. Section 414.508 is amended by revising paragraph (b)(3) to read as follows:

§ 414.508 Payment for a new clinical diagnostic laboratory test.

* * * * *

(b) * * *

(3) For a new test for which a new or substantially revised HCPCS code was assigned on or before December 31, 2007, after the first year of gapfilling, CMS determines whether the carrier-specific amounts will pay for the test appropriately. If CMS determines that the carrier-specific amounts will not pay for the test appropriately, CMS may crosswalk the test.

■ 27. Section 414.509 is added to read as follows:

§ 414.509 Reconsideration of basis for and amount of payment for a new clinical diagnostic laboratory test.

For a new test for which a new or substantially revised HCPCS code was assigned on or after January 1, 2008, the following reconsideration procedures apply:

(a) *Reconsideration of basis for payment.* (1) CMS will receive reconsideration requests in written format for 60 days after making a determination of the basis for payment under § 414.506(d)(2) regarding whether CMS should reconsider the basis for payment and why a different basis for payment would be more appropriate. If a requestor recommends that the basis for payment should be changed from gapfilling to crosswalking, the requestor may also recommend the code or codes to which to crosswalk the new test.

(2)(i) A requestor that submitted a request under paragraph (a)(1) of this section may also present its reconsideration request at the public meeting convened under § 414.506(c), provided that the requestor requests an opportunity to present at the public meeting as part of its written submission under paragraph (a)(1) of this section.

(ii) If the requestor presents its reconsideration request at the public meeting convened under § 414.506(c), members of public may comment on the reconsideration request verbally at the public meeting and may submit written comments after the public meeting (within the timeframe for public comments established by CMS).

(3) Considering reconsideration requests and other comments received, CMS may reconsider its determination of the basis for payment. As the result of such a reconsideration, CMS may change the basis for payment from crosswalking to gapfilling or from gapfilling to crosswalking.

(4) If the basis for payment is revised as the result of a reconsideration, the new basis for payment is final and is not subject to further reconsideration.

(b) *Reconsideration of amount of payment*—(1) *Crosswalking*. (i) For 60 days after making a determination under § 414.506(d)(2) of the code or codes to which a new test will be crosswalked, CMS receives reconsideration requests in written format regarding whether CMS should reconsider its determination and the recommended code or codes to which to crosswalk the new test.

(ii)(A) A requestor that submitted a request under paragraph (b)(1)(i) of this section may also present its reconsideration request at the public meeting convened under § 414.506(c), provided that the requestor requests an opportunity to present at the public meeting as part of its written submission under paragraph (b)(1)(i) of this section.

(B) If a requestor presents its reconsideration request at the public meeting convened under § 414.506(c), members of public may comment on the reconsideration request verbally at the public meeting and may submit written comments after the public meeting (within the timeframe for public comments established by CMS).

(iii) Considering comments received, CMS may reconsider its determination of the amount of payment. As the result of such a reconsideration, CMS may change the code or codes to which the new test is crosswalked.

(iv) If CMS changes the basis for payment from gapfilling to crosswalking as a result of a reconsideration, the crosswalked amount of payment is not subject to reconsideration.

(2) *Gapfilling*. (i) By April 30 of the year after CMS makes a determination under § 414.506(d)(2) or § 414.509(a)(3) that the basis for payment for a new test will be gapfilling, CMS posts interim carrier-specific amounts on the CMS Web site.

(ii) For 60 days after CMS posts interim carrier-specific amounts on the CMS Web site, CMS will receive public comments in written format regarding the interim carrier-specific amounts.

(iii) After considering the public comments, CMS will post final carrier-specific amounts on the CMS Web site.

(iv) For 30 days after CMS posts final carrier-specific amounts on the CMS

Web site, CMS will receive reconsideration requests in written format regarding whether CMS should reconsider the final payment amounts and the appropriate national limitation amount for the new test.

(v) Considering reconsideration requests received, CMS may reconsider its determination of the amount of payment. As the result of a reconsideration, CMS may revise the national limitation amount for the new test.

(3) For both gapfilled and crosswalked new tests, if CMS revises the amount of payment as the result of a reconsideration, the new amount of payment is final and is not subject to further reconsideration.

(c) *Effective date*. If CMS changes a determination as the result of a reconsideration, the new determination regarding the basis for or amount of payment is effective January 1 of the year following reconsideration. Claims for services with dates of service prior to the effective date will not be reopened or otherwise reprocessed.

(d) *Jurisdiction for Reconsideration Decisions*. Jurisdiction for reconsidering a determination rests exclusively with the Secretary. A decision whether to reconsider a determination is committed to the discretion of the Secretary. A decision not to reconsider an initial determination is not subject to administrative or judicial review.

■ 28. Section 414.510 is amended by—

■ A. Revising the section heading to read as set forth below.

■ B. Revising the introductory text.

The revisions read as follows:

§ 414.510 Laboratory date of service for clinical laboratory and pathology specimens.

The date of service for either a clinical laboratory test or the technical component of physician pathology service is as follows:

* * * * *

Subpart H—Fee Schedule for Ambulance Services

§ 414.620 [Amended]

■ 29. In § 414.620, the phrase “notice in the *Federal Register* without opportunity for prior comment” is removed and the phrase “CMS by instruction and on the CMS Web site” is added in its place.

Subpart I—Payment for Drugs and Biologicals

■ 30. Section 414.707 is amended by adding paragraph (c) to read as follows:

§ 414.707 Basis of payment

* * * * *

(c) *Mandatory reporting of anemia quality indicators*. The following provisions are effective January 1, 2008:

(1) Each request for payment for anti-anemia drugs furnished to treat anemia resulting from the treatment of cancer must report the beneficiary’s most recent hemoglobin or hematocrit level;

(2) Each request for payment for use of erythropoiesis stimulating agents must report the beneficiary’s most recent hemoglobin or hematocrit level.

Subpart K—Payment for Drugs and Biologicals Under Part B

■ 31. Section 414.904 is amended by revising paragraph (d)(3) to read as follows:

§ 414.904 Average sales price as the basis for payment.

* * * * *

(d) * * *

(3) *Widely available market price and average manufacturer price*. If the Inspector General finds that the average sales price exceeds the widely available market price or the average manufacturer price by 5 percent or more in CY 2005, 2006, 2007 or 2008, the payment limit in the quarter following the transmittal of this information to the Secretary is the lesser of the widely available market price or 103 percent of the average manufacturer price.

* * * * *

■ 32. Section 414.908 is amended by—

■ A. Revising paragraphs (a)(2)(iv), (a)(3)(x), and (a)(3)(xi).

■ B. Adding paragraph (a)(2)(v).

■ C. Removing paragraph (a)(5).

The revisions and addition read as follows:

§ 414.908 Competitive acquisition program.

(a) * * *

(2) * * *

(iv) The approved CAP vendor refuses to ship to the participating CAP physician because the conditions of § 414.914(i) have been met (if this subparagraph (a)(2)(iv) applies, the physician can withdraw from the CAP category for the remainder of the year immediately upon notice to CMS and the approved CAP vendor); or

(v) Other exigent circumstances defined by CMS are present, including—

(A) If, up to and including 60 days after the effective date of the physician’s CAP election agreement, the participating CAP physician submits a written request to the designated carrier to terminate the CAP election agreement

because CAP participation imposes a burden on the physician's practice. The written request must document the burden. The designated carrier will process the participating CAP physician's request and CMS will approve or deny the request under the dispute resolution process as specified under § 414.917 of this subpart.

(B) If, more than 60 days after the effective date of the physician's CAP election agreement, the participating CAP physician submits a written request to the designated carrier to terminate the CAP election agreement because, based on a change in circumstances of which the participating CAP physician was not previously aware, CAP participation imposes a burden on the physician's practice. The written request must document the burden. The designated carrier will process the participating CAP physician's request and CMS will approve or deny the request under the dispute resolution process as specified under § 414.917 of this subpart.

(3) * * *

(x) Agrees to file the Medicare claim within 30 calendar days of the date of drug administration.

(xi) Agrees to submit documentation such as medical records or certification, as necessary, to support payment for a CAP drug;

* * * * *

- 33. Section 414.914 is amended by—
 - A. Redesignating paragraph (h) as (i)
 - B. Adding new paragraph (h).
 - C. Revising new paragraphs (i)(1) and (2).
 - D. Removing the reference “§ 414.914(h)” in paragraph (f)(12) and adding in its place the reference “§ 414.914(i)”.
 - E. Revising new paragraph (i)(5).
- The addition and revision read as follows:

§ 414.914 Terms of contract.

* * * * *

(h) The approved CAP vendor must verify drug administration prior to collection of any applicable cost sharing amount.

(1) The approved CAP vendor documents, in writing, the following information necessary to verify drug administration:

- (i) Beneficiary name.
- (ii) Health insurance number.
- (iii) Expected date of administration.
- (iv) Actual date of administration.
- (v) Identity of the participating CAP physician.
- (vi) Prescription order number.
- (vii) Identity of the individuals who supply and receive the information.

- (viii) Dosage supplied.
- (ix) Dosage administered.

* * * * *

(2) If the information is obtained verbally, the approved CAP vendor must also maintain the following information:

- (i) The identities of individuals who exchanged the information.
- (ii) The date and time that the information was obtained.
- (3) The approved CAP vendor must provide this information to CMS or the beneficiary upon request.

(i) * * *

(1) Subsequent to receipt of payment by Medicare, or the verification of drug administration by the participating CAP physician, the approved CAP vendor must bill any applicable supplemental insurance policies.

(2) An approved CAP vendor that has received payment from the designated carrier for CAP drugs that have not been administered must promptly refund payment for such drugs to the designated carrier and must refund any coinsurance and deductible collected from the beneficiary and his or her supplemental insurer.

* * * * *

(5) For purposes of paragraph (i) of this section delivery means postmark date, or the date the coinsurance bill or notice was presented to the beneficiary by the participating CAP physician on behalf of the approved CAP vendor.

(i) Except as specified in paragraph (i)(5)(ii) of this section, if after 45 days from delivery of the approved CAP vendor's bill to the beneficiary, the beneficiary's cost-sharing obligation remains unpaid, the approved CAP vendor may refuse further shipments to the participating CAP physician for that beneficiary.

(ii) If the beneficiary has requested cost-sharing assistance within 45 days of receiving delivery of the approved CAP vendor's bill, provisions of paragraphs (i)(6), (i)(7), or (i)(8) of this section, apply.

■ 34. Section 414.916 is amended by revising paragraph (c)(1) to read as follows:

§ 414.916 Dispute resolution for vendors and beneficiaries.

* * * * *

(c) * * *

(1) *Right to a reconsideration.* A participating CAP physician dissatisfied with a determination that his or her CAP election agreement has been suspended by CMS or a determination under § 414.917(d) denying the participating CAP physician's request to terminate participation in the CAP

under § 414.908(a)(v) is entitled to a reconsideration as provided in this subpart.

* * * * *

■ 35. Section 414.917 is amended by—

- A. Revising the section heading as set forth below.

- B. Adding paragraph (d).

The revision and addition read as follows:

§ 414.917 Dispute resolution and process for suspension or termination of approved CAP contract and termination of physician participation under exigent circumstances.

* * * * *

(d) *CAP participating physicians' exigent circumstances provision.* The following process must be completed for participating CAP physicians' requests to terminate their participation in the program under exigent circumstances provisions described in § 414.908(a)(2)(v):

(1) The designated carrier must—

- (i) Determine whether a request to terminate CAP participation was related to approved CAP vendor service, and if so, forward the issue to the approved CAP vendor's grievance process within 1 business day of the receipt of the request; or

- (ii) Continue to investigate, consistent with § 414.916(b)(2) of this chapter, and within 2 business days of receipt, do any of the following:

- (A) Request a single, 2-business day extension. No later than the end of any 2-business day extension, the designated carrier must make findings and a recommendation as provided in subparagraph (B) or (C).

- (B) Submit a recommendation and relevant findings to CMS that the requesting participating CAP physician be permitted to terminate his or her participation in the CAP.

- (C) Submit a recommendation and relevant findings to CMS that the requesting participating CAP physician not be permitted to terminate his or her participation in the CAP.

- (ii) In the case of a request made under § 414.908(a)(2)(v)(B), the designated carrier also shall include in its recommendation its finding with respect to whether the request is based on a change in circumstances of which the participating CAP physician was previously unaware.

(2) CMS will consider the carrier's findings and recommendation and may also make its own findings. As a result, CMS will—

- (i) Approve or deny the request to terminate participation in the CAP within 2 business days of receipt of the recommendation.

(ii) Communicate the decision to the appropriate Medicare contractors and the participating CAP physician.

(3) A denial of the participating CAP physician's request to terminate participation in the CAP must include written notification of the right to request reconsideration under § 414.916(c).

(4) Upon termination of participation in the CAP a physician must—

(i) Continue to submit claims for drugs supplied and administered under the CAP prior to the effective date of the physician's termination from the CAP consistent with § 414.908(a) until all such claims are timely submitted.

(ii) Return any unused CAP drugs that had not been administered to the beneficiary prior to the effective date of the physician's termination from the CAP to the approved CAP vendor consistent with applicable law and regulation and any agreement with the approved CAP vendor.

(iii) Cooperate in any post-payment review activities on claims submitted under the CAP, as required under section 1847B(a)(3) of the Act.

(5) An approved CAP vendor that has billed and been paid for CAP drugs that have not been administered must refund any payments made by CMS or the beneficiary and his or her supplemental insurer in accordance with § 414.914(h)(3)(i)(2) of this chapter.

■ 36. Section 414.930 is added to subpart K to read as follows:

§ 414.930 Compendia for determination of medically-accepted indications for off-label uses of drugs and biologicals in an anti-cancer chemotherapeutic regimen.

(a) *Definition.* For purposes of this section, *compendium* means a comprehensive listing of FDA-approved drugs and biologicals or a comprehensive listing of a specific subset of drugs and biologicals in a specialty compendium, for example a compendium of anti-cancer treatment. A compendium includes a summary of the pharmacologic characteristics of each drug or biological and may include information on dosage, as well as recommended or endorsed uses in specific diseases. A compendium is indexed by drug or biological.

(b) *Process for listing compendia for determining medically-accepted uses of drugs and biologicals in anti-cancer treatment.* (1) The CMS process—

(i) Receives formal written requests for changes to the list of compendia during a 30 day window beginning January 15 each year.

(ii) Publishes a listing of the timely, complete requests by March 15th and solicits public comment on the requests

for 30 days. The listing identifies the requestor and the requested action.

(iii) Considers a compendium's attainment of the MedCAC (Medicare Evidence Development and Coverage Advisory Committee, previously known as the MCAC—Medicare Coverage Advisory Committee) recommended desirable characteristics of compendia (including explicit listing and recommendations) in reviewing requests. CMS may consider additional reasonable factors.

(iv) Considers a compendium's grading of evidence used in making recommendations regarding off-label uses and the process by which the compendium grades the evidence.

(v) Publishes its decision no later than 90 days after the close of the public comment period.

(2) *Exception.* In addition to the annual process outlined in paragraph (b)(1) of this section, CMS may internally generate a request for changes to the list of compendia at any time.

(c) *Written request for review.* (1) CMS will review a complete, written request that is submitted in writing, electronically or via hard copy (no duplicate submissions) and includes the following:

(i) The full name and contact information of the requestor.

(ii) The full identification of the compendium that is the subject of the request, including name, publisher, edition if applicable, date of publication, and any other information needed for the accurate and precise identification of the specific compendium.

(iii) A complete written copy of the compendium that is the subject of the request.

(iv) The specific action that is requested of CMS.

(v) Materials that the requestor must submit for CMS review in support of the requested action.

(vi) A single compendium as its subject.

(d) CMS may at its discretion combine and consider multiple requests that refer to the same compendium.

(e) For the purposes of this section, publication by CMS may be accomplished by posting on the CMS Web site.

■ 37. Subpart M is added to read as follows:

Subpart M—Payment for Comprehensive Outpatient Rehabilitation Facility (CORF) Services

§ 414.1100 Basis and Scope.

This subpart implements sections 1834(k)(1) and (k)(3) of the Act by

specifying the payment methodology for comprehensive outpatient rehabilitation facility services covered under Part B of Title XVIII of the Act that are described at section 1861(cc)(1) of the Act.

§ 414.1105 Payment for Comprehensive Outpatient Rehabilitation Facility (CORF) Services.

(a) *Payment under the physician fee schedule.* Except as otherwise specified under paragraphs (b), (c), (d), and (e) of this section payment for CORF services, as defined under § 410.100 of this chapter, is paid the lesser of 80 percent of the following:

(1) The actual charge for the item or service; or

(2) The nonfacility amount determined under the physician fee schedule established under section 1848(b) of the Act for the item or service.

(b) *Payment for physician services.* No separate payment for physician services that are CORF services under § 410.100(a) of this chapter will be made.

(c) *Payment for supplies and durable medical equipment, prosthetic and orthotic devices, and drugs and biologicals.* Supplies and durable medical equipment that are CORF services under § 410.100(l) of this chapter, prosthetic device services that are CORF services under § 410.100(f), orthotic devices that are CORF services under § 410.100(g) of this chapter and drugs and biologicals that are CORF services under § 410.100(k) of this chapter are paid the lesser of 80 percent of the following:

(1) The actual charge for the service provided that payment for such item is not included in the payment amount for other CORF services paid under paragraphs (a) or (d); or

(2) The amount determined under the DMEPOS fee schedule established under part 414 subparts D and F for the item or the single payment amount established under the DMEPOS competitive bidding program provided that payment for such item is not included in the payment amount for other CORF services paid under paragraphs (a) or (d).

(d) *Payment for drugs and biologicals.* Drugs and biologicals that are CORF services under § 410.100(j) of this chapter, are paid the lesser of 80 percent of the following:

(1) The actual charge for the service provided that payment for such item is not included in the payment amount for other CORF services paid under paragraphs (a) or (c); or

(2) The amount determined using the same methodology for drugs (as defined

in § 414.704 of this chapter) described in section 1842(o)(1) of the Act provided that payment for such drug is not included in the payment amount for other CORF services paid under paragraphs (a) or (c).

(e) *Payment for CORF services when no fee schedule amount for the service.* If there is no fee schedule amount established for a CORF service, payment for the item or service will be the lesser of 80 percent of:

(i) The actual charge for the service provided that payment for such item or service is not included in the payment amount for other CORF services paid under paragraphs (a), (c), or (d) of this section.

(ii) The amount determined under the fee schedule established for a comparable service as specified by the Secretary provided that payment for such item or service is not included in the payment amount for other CORF services paid under paragraphs (a), (c), or (d) of this section.

PART 415—SERVICES FURNISHED BY PHYSICIANS IN PROVIDERS, SUPERVISING PHYSICIANS IN TEACHING SETTINGS, AND RESIDENTS IN CERTAIN SETTINGS

■ 38. The authority citation for part 415 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

Subpart C—Part B Carrier Payments for Physician Services to Beneficiaries in Providers

■ 39. Section 415.130 is amended by revising paragraph (d) to read as follows:

§ 415.130 Conditions for payment: Physician pathology services.

* * * * *

(d) *Physician pathology services furnished by an independent laboratory.* The technical component of physician pathology services furnished by an independent laboratory to a hospital inpatient or outpatient on or before December 31, 2007, may be paid to the laboratory by the carrier under the physician fee schedule if the Medicare beneficiary is a patient of a covered hospital as defined in paragraph (a)(1) of this section. For services furnished after December 31, 2007, an independent laboratory may not bill the carrier for the technical component of physician pathology services furnished to a hospital inpatient or outpatient. For services furnished on or after January 1, 2008, the date of service policy in § 414.510 of this chapter applies for the

technical component of specimens for physician pathology services.

PART 418—HOSPICE CARE

■ 40. The authority citation for part 418 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

Subpart E—Condition of Participation: Other Services

■ 41. Section 418.92 is amended by revising paragraph (a) to read as follows:

§ 418.92 Condition of participation—Physical therapy, occupational therapy, and speech-language pathology.

(a) Physical therapy, occupational therapy, and speech-language pathology services must be—

- (1) Available, and when provided, offered in a manner consistent with accepted standards of practice; and
- (2) Furnished by personnel who meet the qualifications specified in part 484 of this chapter.

* * * * *

PART 423—VOLUNTARY MEDICARE PRESCRIPTION DRUG BENEFIT

■ 42. The authority citation for part 423 continues to read as follows:

Authority: Secs 1102, 1860D–1 through 1860D–42, and 1871 of the Social Security Act (42 U.S.C. 1302, 1395w–101 through 1395w–152, and 1395hh).

Subpart D—Cost Control and Quality Improvement Requirements

■ 43. Section 423.160 is amended by—
■ A. Revising paragraph (a)(3)(i).
■ B. Redesignating paragraphs (a)(3)(ii) and (iii) to (a)(3)(iii) and (iv), respectively.

■ C. Adding new paragraph (a)(3)(ii). The revision and addition reads as follows:

§ 423.160 Standards for electronic prescribing.

- (a) * * *
- (3) * * *

(i) Entities transmitting prescriptions or prescription-related information by means of computer-generated facsimile are exempt from the requirement to use the NCPDP SCRIPT Standard adopted by this section in transmitting such prescriptions or prescription-related information until January 1, 2009;

(ii) After January 1, 2009, electronic transmission of prescriptions or prescription-related information by means of computer-generated facsimile is only permitted in instances of temporary/transient transmission failure

and communication problems that would preclude the use of the NCPDP SCRIPT Standard adopted by this section.

* * * * *

PART 424—CONDITIONS FOR MEDICARE PAYMENT

■ 44. The authority citation for part 424 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

■ 45. The heading for subpart B is revised to read as set forth below.

Subpart B—Certification and Plan Requirements

■ 46. Section 424.24 is amended by revising paragraphs (c)(2) and (c)(4) to read as follows:

§ 424.24 Requirements for medical and other health services furnished by providers under Medicare Part B.

* * * * *

(c) * * *

(2) *Timing.* The initial certification must be obtained as soon as possible after the plan is established.

(4) *Recertification.* (i) *Timing.* Recertification is required at least every 90 days.

(ii) *Content.* When it is recertified, the plan or other documentation in the patient's record must indicate the continuing need for physical therapy, occupational therapy or speech-language pathology services.

(iii) *Signature.* The physician, nurse practitioner, clinical nurse specialist, or physician assistant who reviews the plan must recertify the plan by signing the medical record.

* * * * *

■ 47. Section 424.27 is amended by revising paragraph (b)(1) to read as follows:

§ 424.27 Requirements for comprehensive outpatient rehabilitation facility (CORF) services

* * * * *

(b) * * *

(1) *Timing.* Recertification is required at least every 60 days for respiratory therapy services and every 90 days for physical therapy, occupational therapy, and speech-language pathology services based on review by a facility physician or the referring physician who, when appropriate, consults with the professional personnel who furnish the services.

* * * * *

■ 48. In § 424.32, paragraph (a)(3) is revised to read as follows:

§ 424.32 Basic requirements for all claims.

(a) * * *
(3) A claim must be signed by the beneficiary or on behalf of the beneficiary (in accordance with § 424.36).

* * * * *

Subpart C—Claims for Payment

- 49. Section 424.36 is amended by—
■ A. Revising paragraph (b)(5).
■ B. Adding paragraph (b)(6).

The revision and addition read as follows:

§ 424.36 Signature requirements.

* * * * *

(b) * * *
(5) A representative of the provider or of the nonparticipating hospital claiming payment for services it has furnished if the provider or nonparticipating hospital is unable to have the claim signed in accordance with paragraph (b)(1), (2), (3), or (4) of this section after making reasonable efforts to locate and obtain the signature of one of the individuals specified in paragraph (b)(1), (2), (3), or (4) of this section.

(6) An ambulance provider or supplier with respect to emergency ambulance transport services, if the following conditions and documentation requirements are met.

(i) None of the individuals listed in paragraph (b)(1), (2), (3), or (4) of this section was available or willing to sign the claim on behalf of the beneficiary at the time the service was provided;

(ii) The ambulance provider or supplier maintains in its files the following information and documentation for a period of at least four years from the date of service:

(A) A contemporaneous statement, signed by an ambulance employee present during the trip to the receiving facility, that, at the time the service was provided, the beneficiary was physically or mentally incapable of signing the claim and that none of the individuals listed in paragraph (b)(1), (2), (3), or (4) of this section were available or willing to sign the claim on behalf of the beneficiary, and

(B) Documentation with the date and time the beneficiary was transported, and the name and location of the facility that received the beneficiary, and

(C) Either of the following:

(1) A signed contemporaneous statement from a representative of the facility that received the beneficiary, which documents the name of the beneficiary and the date and time the beneficiary was received by that facility; or

(2) The requested information from a representative of the facility using a secondary form of verification obtained at a later date, but prior to submitting the claim to Medicare for payment. Secondary forms of verification include a copy of any of the following—

- (i) The signed patient care/trip report;
(ii) The hospital registration/admissions sheet;
(iii) The patient medical record;
(iv) The hospital log; or
(v) Other internal hospital records.

* * * * *

Subpart F—Limitations on Assignment and Reassignment of Claims

- 50. Section 424.80 is amended by adding paragraph (d)(3) to read as follows:

§ 424.80 Prohibition of reassignment of claims by suppliers.

* * * * *

(d) * * *
(3) Reassignment of the technical or professional component of a diagnostic test. If a physician or other supplier bills for the technical or professional component of a diagnostic test covered under section 1861(s)(3) of the Act and paid for under part 414 of this chapter (other than clinical diagnostic laboratory tests paid under section 1833(a)(2)(D) of the Act, which are subject to the special rules set forth in section 1833(h)(5)(A) of the Act) following a reassignment from a physician or other supplier who performed the technical or professional component, the amount payable to the billing physician or other supplier may be subject to the limits specified in § 414.50 of this chapter.

PART 482—CONDITIONS OF PARTICIPATION FOR HOSPITALS

- 51. The authority citation for part 482 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

- 52. Section 482.56 is amended by revising paragraphs (a)(2) and (b) to read as follows:

§ 482.56 Condition of participation: Rehabilitation services.

(a) * * *

(2) Physical therapy, occupational therapy, speech-language pathology or audiology services, if provided, must be provided by qualified physical therapists, physical therapist assistants, occupational therapists, occupational therapy assistants, speech-language pathologists, or audiologists as defined in part 484 of this chapter.

(b) Standard: Delivery of services. Services must be given in accordance with orders of practitioners who are authorized by the medical staff to order the services, and the orders must be incorporated in the patient's record. The provision of care and the personnel qualifications must be in accordance with national acceptable standards of practice and must also meet the requirements of § 409.17

PART 484—HOME HEALTH SERVICES

- 53. The authority citation for part 484 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395(hh)) unless otherwise indicated.

Subpart A—General Provisions

- 54. Section 484.4 is amended by revising the definitions of "Occupational therapist," "Occupational therapy assistant," "Physical therapist," "Physical therapist assistant" and "Speech language pathologist" to read as follows:

§ 484.4 Personnel Qualifications.

* * * * *

Occupational therapist. A person who—

(a)(1) Is licensed or otherwise regulated, if applicable, as an occupational therapist by the State in which practicing, unless licensure does not apply;

(2) Graduated after successful completion of an occupational therapist education program accredited by the Accreditation Council for Occupational Therapy Education (ACOTE) of the American Occupational Therapy Association, Inc. (AOTA), or successor organizations of ACOTE; and

(3) Is eligible to take, or has successfully completed the entry-level certification examination for occupational therapists developed and administered by the National Board for Certification in Occupational Therapy, Inc. (NBCOT).

(b) On or before December 31, 2009—

(1) Is licensed or otherwise regulated, if applicable, as an occupational therapist by the State in which practicing; or

(2) When licensure or other regulation does not apply—

(i) Graduated after successful completion of an occupational therapist education program accredited by the Accreditation Council for Occupational Therapy Education (ACOTE) of the American Occupational Therapy Association, Inc. (AOTA) or successor organizations of ACOTE; and

(ii) Is eligible to take, or has successfully completed the entry-level certification examination for occupational therapists developed and administered by the National Board for Certification in Occupational Therapy, Inc., (NBCOT).

(c) On or before January 1, 2008—

(1) Graduated after successful completion of an occupational therapy program accredited jointly by the committee on Allied Health Education and Accreditation of the American Medical Association and the American Occupational Therapy Association; or

(2) Is eligible for the National Registration Examination of the American Occupational Therapy Association or the National Board for Certification in Occupational Therapy.

(d) On or before December 31, 1977—

(1) Had 2 years of appropriate experience as an occupational therapist; and

(2) Had achieved a satisfactory grade on an occupational therapist proficiency examination conducted, approved, or sponsored by the U.S. Public Health Service.

(e) If educated outside the United States—

(1) Must meet both of the following:

(i) Graduated after successful completion of an occupational therapist education program accredited as substantially equivalent to occupational therapist assistant entry level education in the United States by one of the following:

(A) The Accreditation Council for Occupational Therapy Education (ACOTE).

(B) Successor organizations of ACOTE.

(C) The World Federation of Occupational Therapists.

(D) A credentialing body approved by the American Occupational Therapy Association.

(ii) Successfully completed the entry-level certification examination for occupational therapists developed and administered by the National Board for Certification in Occupational Therapy, Inc. (NBCOT).

(2) On or before December 31, 2009, is licensed or otherwise regulated, if applicable, as an occupational therapist by the State in which practicing.

Occupational therapy assistant. A person who—

(a) Meets all of the following:

(1) Is licensed or otherwise regulated, if applicable, as an occupational therapy assistant by the State in which practicing, unless licensure does apply.

(2) Graduated after successful completion of an occupational therapy assistant education program accredited

by the Accreditation Council for Occupational Therapy Education, (ACOTE) of the American Occupational Therapy Association, Inc. (AOTA) or its successor organizations.

(3) Is eligible to take or successfully completed the entry-level certification examination for occupational therapy assistants developed and administered by the National Board for Certification in Occupational Therapy, Inc. (NBCOT).

(b) On or before December 31, 2009—

(1) Is licensed or otherwise regulated as an occupational therapy assistant, if applicable, by the State in which practicing; or any qualifications defined by the State in which practicing, unless licensure does not apply; or

(2) Must meet both of the following:

(i) Completed certification requirements to practice as an occupational therapy assistant established by a credentialing organization approved by the American Occupational Therapy Association.

(ii) After January 1, 2010, meets the requirements in paragraph (a) of this section.

(c) After December 31, 1977 and on or before December 31, 2007—

(1) Completed certification requirements to practice as an occupational therapy assistant established by a credentialing organization approved by the American Occupational Therapy Association; or

(2) Completed the requirements to practice as an occupational therapy assistant applicable in the State in which practicing.

(d) On or before December 31, 1977—

(1) Had 2 years of appropriate experience as an occupational therapy assistant; and

(2) Had achieved a satisfactory grade on an occupational therapy assistant proficiency examination conducted, approved, or sponsored by the U.S. Public Health Service.

(e) If educated outside the United States, on or after January 1, 2008—

(1) Graduated after successful completion of an occupational therapy assistant education program that is accredited as substantially equivalent to occupational therapist assistant entry level education in the United States by—

(i) The Accreditation Council for Occupational Therapy Education (ACOTE).

(ii) Its successor organizations.

(iii) The World Federation of Occupational Therapists.

(iv) By a credentialing body approved by the American Occupational Therapy Association; and

(2) Successfully completed the entry-level certification examination for

occupational therapy assistants developed and administered by the National Board for Certification in Occupational Therapy, Inc. (NBCOT).

Physical therapist. A person who is licensed, if applicable, by the State in which practicing, unless licensure does not apply and meets one of the following requirements:

(a)(1) Graduated after successful completion of one of a physical therapist education program approved by one of the following:

(i) The Commission on Accreditation in Physical Therapy Education (CAPTE).

(ii) Successor organizations of CAPTE.

(iii) An education program outside the United States determined to be substantially equivalent to physical therapist entry level education in the United States by a credentials evaluation organization approved by the American Physical Therapy Association or an organization identified in 8 CFR 212.15(e) as it relates to physical therapists.

(2) Passed an examination for physical therapists approved by the State in which physical therapy services are provided.

(b) On or before December 31, 2009—

(1) Graduated after successful completion of a physical therapy curriculum approved by the Commission on Accreditation in Physical Therapy Education (CAPTE); or

(2) Meets both of the following:

(i) Graduated after successful completion of an education program determined to be substantially equivalent to physical therapist entry level education in the United States by a credentials evaluation organization approved by the American Physical Therapy Association or identified in 8 CFR 212.15(e) as it relates to physical therapists.

(ii) Passed an examination for physical therapists approved by the State in which physical therapy services are provided.

(c) Before January 1, 2008—

(1) Graduated from a physical therapy curriculum approved by one of the following:

(i) The American Physical Therapy Association.

(ii) The Committee on Allied Health Education and Accreditation of the American Medical Association.

(iii) The Council on Medical Education of the American Medical Association and the American Physical Therapy Association.

(d) On or before December 31, 1977 was licensed or qualified as a physical therapist and meets both of the following:

(1) Has 2 years of appropriate experience as a physical therapist.

(2) Has achieved a satisfactory grade on a proficiency examination conducted, approved, or sponsored by the U.S. Public Health Service.

(e) Before January 1, 1966—

(1) Was admitted to membership by the American Physical Therapy Association;

(2) Was admitted to registration by the American Registry of Physical Therapists; and

(3) Graduated from a physical therapy curriculum in a 4-year college or university approved by a State department of education.

(f) Before January 1, 1966 was licensed or registered, and before January 1, 1970, had 15 years of full-time experience in the treatment of illness or injury through the practice of physical therapy in which services were rendered under the order and direction of attending and referring doctors of medicine or osteopathy.

(g) If trained outside the United States before January 1, 2008, meets the following requirements:

(1) Was graduated since 1928 from a physical therapy curriculum approved in the country in which the curriculum was located and in which there is a member organization of the World Confederation for Physical Therapy.

(2) Meets the requirements for membership in a member organization of the World Confederation for Physical Therapy.

Physical therapist assistant. A person who is licensed, registered or certified as a physical therapist assistant, if applicable, by the State in which practicing, unless licensure does not apply and meets one of the following requirements:

(a)(1)(i) Graduated from a physical therapist assistant curriculum approved by the Commission on Accreditation in Physical Therapy Education of the American Physical Therapy Association; or if educated outside the United States or trained in the United States military, graduated from an education program determined to be substantially equivalent to physical therapist assistant entry level education in the United States by a credentials evaluation organization approved by the American Physical Therapy Association or identified at 8 CFR 212.15(e); and

(ii) Passed a national examination for physical therapist assistants.

(b) On or before December 31, 2009, meets one of the following:

(1) Is licensed, or otherwise regulated in the State in which practicing.

(2) In States where licensure or other regulations do not apply, graduated

before December 31, 2009, from a 2-year college-level program approved by the American Physical Therapy Association and after January 1, 2010, meets the requirements of paragraph (a) of this definition.

(c) Before January 1, 2008, where licensure or other regulation does not apply, graduated from a 2-year college-level program approved by the American Physical Therapy Association.

(d) On or before December 31, 1977, was licensed or qualified as a physical therapist assistant and has achieved a satisfactory grade on a proficiency examination conducted, approved, or sponsored by the U.S. Public Health Service.

Speech-language pathologist. A person who meets either of the following requirements:

(a) The education and experience requirements for a Certificate of Clinical Competence in speech-language pathology granted by the American Speech-Language-Hearing Association.

(b) The educational requirements for certification and is in the process of accumulating the supervised experience required for certification.

PART 485—CONDITIONS OF PARTICIPATION: SPECIALIZED PROVIDERS

■ 55. The authority citation for part 485 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395(hh)).

Subpart B—Conditions of Participation: Comprehensive Outpatient Rehabilitation Facilities

■ 56. Section 485.51 is amended by—
■ A. Revising paragraph (a).
■ B. Adding paragraph (c).

The revision and addition read as follows:

§ 485.51 Definition.

(a) Is established and operated exclusively for the purpose of providing diagnostic, therapeutic, and restorative services to outpatients for the rehabilitation of injured, disabled, or sick persons, at a single fixed location, by or under the supervision of a physician except as provided in paragraph (c) of this section;

(c) *Exception.* May provide influenza, pneumococcal and Hepatitis B vaccines provided the applicable conditions of coverage under § 410.58 and § 410.63 of this chapter are met.

■ 57. Section 485.70 is amended by revising paragraphs (c), (e), and (m) to read as follows:

§ 485.70 Personnel qualifications.

(c) An occupational therapist and an occupational therapy assistant must meet the qualifications in part 484 of this chapter.

(e) A physical therapist and a physical therapist assistant must meet the qualifications in part 484 of this chapter.

(m) A speech-language pathologist must meet the qualifications set forth in part 484 of this chapter.

Subpart F—Conditions of Participation: Critical Access Hospitals (CAHs)

■ 58. Section 485.635 is amended by adding paragraph (e) to read as follows:

§ 485.635 Condition of participation: Provision of services.

(e) Standard: Rehabilitation Therapy Services. Physical therapy, occupational therapy, and speech-language pathology services furnished at the CAH, if provided, are provided as direct services by staff qualified under State law, and consistent with the requirements for therapy services in 409.17.

(Catalog of Federal Domestic Assistance Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: October 23, 2007.

Kerry Weems,

Acting Administrator, Centers for Medicare & Medicaid Services.

Approved: October 31, 2007.

Michael O. Leavitt,
Secretary.

Addendum A:

Note: These addenda will not appear in the Code of Federal Regulations. Addendum A: Explanation and Use of Addendum B.

The addenda on the following pages provide various data pertaining to the Medicare fee schedule for physicians' services furnished in 2008. Addendum B contains the RVUs for work, non-facility PE, facility PE, and malpractice expense, and other information for all services included in the PFS.

In previous years, we have listed many services in Addendum B that are not paid under the PFS. To avoid publishing as many pages of codes for these services, we are not including clinical laboratory codes or the alphanumeric codes (Healthcare Common Procedure Coding System (HCPCS) codes not included in CPT) not paid under the PFS in Addendum B.

Addendum B—2008 Relative Value Units and Related Information Used in Determining Medicare Payments for 2008

This addendum contains the following information for each CPT code and alphanumeric HCPCS code, except for: Alphanumeric codes beginning with B (enteral and parenteral therapy), E (durable medical equipment), K (temporary codes for nonphysicians' services or items), or L (orthotics); and codes for anesthesiology. Please also note the following:

- An "NA" in the "Non-facility PE RVUs" column of Addendum B means that CMS has not developed a PE RVU in the non-facility setting for the service because it is typically performed in the hospital (for example, an open heart surgery is generally performed in the hospital setting and not a physician's office). If there is an "NA" in the non-facility PE RVU column, and the contractor determines that this service can be performed in the non-facility setting, the service will be paid at the facility PE RVU rate.

- Services that have an "NA" in the "Facility PE RVUs" column of Addendum B are typically not paid using the PFS when provided in a facility setting. These services (which include "incident to" services and the technical portion of diagnostic tests) are generally paid under either the outpatient hospital prospective payment system or bundled into the hospital inpatient prospective payment system payment.

- CPT/HCPCS code.** This is the CPT or alphanumeric HCPCS number for the service. Alphanumeric HCPCS codes are included at the end of this addendum.

- Modifier.** A modifier is shown if there is a technical component (modifier TC) and a professional component (PC) (modifier-26) for the service. If there is a PC and a TC for the service, Addendum B contains three entries for the code. A code for: the global values (both professional and technical); modifier-26 (PC); and, modifier TC. The global service is not designated by a modifier, and physicians must bill using the code without a modifier if the physician furnishes both the PC and the TC of the service.

Modifier-53 is shown for a discontinued procedure, for example, a colonoscopy that is not completed. There will be RVUs for a code with this modifier.

- Status indicator.** This indicator shows whether the CPT/HCPCS code is in the PFS and whether it is separately payable if the service is covered.

A = Active code. These codes are separately payable under the PFS if covered. There will be RVUs for codes with this status. The presence of an "A" indicator does not mean that Medicare has made a national coverage determination regarding the service. Carriers remain responsible for coverage

decisions in the absence of a national Medicare policy.

B = Bundled code. Payments for covered services are always bundled into payment for other services not specified. If RVUs are shown, they are not used for Medicare payment. If these services are covered, payment for them is subsumed by the payment for the services to which they are incident (an example is a telephone call from a hospital nurse regarding care of a patient).

C = Carriers price the code. Carriers will establish RVUs and payment amounts for these services, generally on an individual case basis following review of documentation, such as an operative report.

D* = Deleted/discontinued code.

E = Excluded from the PFS by regulation. These codes are for items and services that CMS chose to exclude from the fee schedule payment by regulation. No RVUs are shown, and no payment may be made under the PFS for these codes. Payment for them, when covered, continues under reasonable charge procedures.

F = Deleted/discontinued codes. (Code not subject to a 90-day grace period.) These codes are deleted effective with the beginning of the year and are never subject to a grace period. This indicator is no longer effective beginning with the 2005 fee schedule as of January 1, 2005.

G = Code not valid for Medicare purposes. Medicare uses another code for reporting of, and payment for, these services. (Codes subject to a 90-day grace period.) This indicator is no longer effective with the 2005 PFS as of January 1, 2005.

H* = Deleted modifier. For 2000 and later years, either the TC or PC component shown for the code has been deleted and the deleted component is shown in the database with the H status indicator.

I = Not valid for Medicare purposes. Medicare uses another code for the reporting of, and the payment for these services. (Codes not subject to a 90-day grace period.)

L = Local codes. Carriers will apply this status to all local codes in effect on January 1, 1998 or subsequently approved by central office for use. Carriers will complete the RVUs and payment amounts for these codes.

M = Measurement codes, used for reporting purposes only. There are no RVUs and no payment amounts for these codes. Medicare uses them to aid with performance measurement. No separate payment is made. These codes should be billed with a zero ((\$0.00) charge and are denied) on the MPFSDB.

N = Non-covered service. These codes are noncovered services. Medicare payment may not be made for these codes. If RVUs are shown, they are not used for Medicare payment.

R = Restricted coverage. Special coverage instructions apply. If the service is covered and no RVUs are shown, it is carrier-priced.

T = There are RVUs for these services, but they are only paid if there are no other services payable under the PFS billed on the same date by the same provider. If any other services payable under the PFS are billed on the same date by the same provider, these services are bundled into the service(s) for which payment is made.

X = Statutory exclusion. These codes represent an item or service that is not within the statutory definition of "physicians' services" for PFS payment purposes. No RVUs are shown for these codes, and no payment may be made under the PFS. (Examples are ambulance services and clinical diagnostic laboratory services.)

4. *Description of code.* This is an abbreviated version of the narrative description of the code.

5. *Physician work RVUs.* These are the RVUs for the physician work for this service in 2008.

Note: The separate budget neutrality adjustor is *not* reflected in these physician work RVUs.

6. *Fully implemented non-facility practice expense RVUs.* These are the fully implemented resource-based PE RVUs for non-facility settings.

7. *Year 2008 Transitional Non-facility practice expense RVUs.* These are the 2008 resource-based PE RVUs for non-facility settings.

8. *Fully implemented facility practice expense RVUs.* These are the fully implemented resource-based PE RVUs for facility settings.

9. *Year 2008 Transitional facility practice expense RVUs.* These are the 2008 resource-based PE RVUs for facility settings.

10. *Malpractice expense RVUs.* These are the RVUs for the malpractice expense for the service for 2008.

11. *Global period.* This indicator shows the number of days in the global period for the code (0, 10, or 90 days).

An explanation of the alpha codes follows:
MMM = Code describes a service furnished in uncomplicated maternity cases including antepartum care, delivery, and postpartum care. The usual global surgical concept does not apply. See the 1999 Physicians' Current Procedural Terminology for specific definitions.

XXX = The global concept does not apply.

YYY = The global period is to be set by the carrier (for example, unlisted surgery codes).

ZZZ = Code related to another service that is always included in the global period of the other service. (Note: Physician work and PE are associated with intra service time and in some instances in the post service time.)

*Codes with these indicators had a 90 day grace period before January 1, 2005.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
0016T		C	Thermotx choroid vasc lesion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0017T		C	Photocoagulat macular drusen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0019T		C	Extracorp shock wv tx,ms nos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0026T		C	Measure remnant lipoproteins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0027T		C	Endoscopic epidural lysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0028T		C	Dexa body composition study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0029T		C	Magnetic tx for incontinence	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0030T		C	Antiprothrombin antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0031T		C	Speculoscopy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0032T		C	Speculoscopy w/direct sample	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0041T		C	Detect ur infect agnt w/cpas	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0042T		C	Ct perfusion w/contrast, cbf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0043T		C	Co expired gas analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0046T		C	Cath lavage, mammary duct(s)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0047T		C	Cath lavage, mammary duct(s)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0048T		C	Implant ventricular device	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0049T		C	External circulation assist	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0050T		C	Removal circulation assist	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0051T		C	Implant total heart system	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0052T		C	Replace component heart syst	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0053T		C	Replace component heart syst	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0058T		C	Cryopreservation, ovary tiss	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0059T		C	Cryopreservation, oocyte	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0060T		C	Electrical impedance scan	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0061T		C	Destruction of tumor, breast	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0062T		C	Rep intradisc annulus;1 lev	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0063T		C	Rep intradisc annulus;>1lev	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0064T		C	Spectroscop eval expired gas	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0066T		N	Ct colonography;screen	0.00	0.00	0.00	NA	NA	0.00	XXX
0066T	TC	N	Ct colonography;screen	0.00	0.00	0.00	NA	NA	0.00	XXX
0066T	26	N	Ct colonography;screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0067T		C	Ct colonography;dx	0.00	0.00	0.00	NA	NA	0.00	XXX
0067T	TC	C	Ct colonography;dx	0.00	0.00	0.00	NA	NA	0.00	XXX
0067T	26	C	Ct colonography;dx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0068T		C	Interp/rept heart sound	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0069T		C	Analysis only heart sound	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0070T		C	Interp only heart sound	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0071T		C	U/s leiomyomata ablate <200	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0072T		C	U/s leiomyomata ablate >200	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0073T		A	Delivery, comp imrt	0.00	13.15	15.58	NA	NA	0.13	XXX
0075T		C	Perq stent/chest vert art	0.00	0.00	0.00	NA	NA	0.00	XXX
0075T	TC	C	Perq stent/chest vert art	0.00	0.00	0.00	NA	NA	0.00	XXX
0075T	26	C	Perq stent/chest vert art	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0076T		C	S&i stent/chest vert art	0.00	0.00	0.00	NA	NA	0.00	XXX
0076T	TC	C	S&i stent/chest vert art	0.00	0.00	0.00	NA	NA	0.00	XXX
0076T	26	C	S&i stent/chest vert art	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0077T		C	Cereb therm perfusion probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0078T		C	Endovasc aort repr w/device	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0079T		C	Endovasc visc extnsn repr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0080T		C	Endovasc aort repr rad s&i	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0081T		C	Endovasc visc extnsn s&i	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0084T		C	Temp prostate urethral stent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0085T		C	Breath test heart reject	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0086T		C	L ventricle fill pressure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0087T		C	Sperm eval hyaluronan	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0088T		C	Rf tongue base vol reduxn	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0089T		C	Actigraphy testing, 3-day	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0090T		C	Cervical artific disc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0092T		C	Artific disc addl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0093T		C	Cervical artific disectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0095T		C	Artific disectomy addl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0096T		C	Rev cervical artific disc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0098T		C	Rev artific disc addl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0099T		C	Implant corneal ring	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0100T		C	Prosth retina receive&gen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0101T		C	Extracorp shockwv tx,hi enrg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0102T		C	Extracorp shockwv tx,anesth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0103T		C	Holotranscobalamin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0104T		C	At rest cardio gas rebreathe	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional faci- lity PE RVUs ²	Mal- practice RVUs ²	Global
0105T		C	Exerc cardio gas rebreath	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0106T		C	Touch quant sensory test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0107T		C	Vibrate quant sensory test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0108T		C	Cool quant sensory test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0109T		C	Heat quant sensory test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0110T		C	Nos quant sensory test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0111T		C	Rbc membranes fatty acids	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0123T		C	Scleral fistulization	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0124T		C	Conjunctival drug placement	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0126T		C	Chd risk imt study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0130T		C	Chron care drug investigatn	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0137T		C	Prostate saturation sampling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0140T		C	Exhaled breath condensate ph	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0141T		I	Perq islet transplant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0142T		I	Open islet transplant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0143T		I	Laparoscopic islet transplnt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0144T		C	CT heart wo dye; qual calc	0.00	0.00	0.00	NA	NA	0.00	XXX
0144T	TC	C	CT heart wo dye; qual calc	0.00	0.00	0.00	NA	NA	0.00	XXX
0144T	26	C	CT heart wo dye; qual calc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0145T		C	CT heart w/wo dye funct	0.00	0.00	0.00	NA	NA	0.00	XXX
0145T	TC	C	CT heart w/wo dye funct	0.00	0.00	0.00	NA	NA	0.00	XXX
0145T	26	C	CT heart w/wo dye funct	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0146T		C	CCTA w/wo dye	0.00	0.00	0.00	NA	NA	0.00	XXX
0146T	TC	C	CCTA w/wo dye	0.00	0.00	0.00	NA	NA	0.00	XXX
0146T	26	C	CCTA w/wo dye	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0147T		C	CCTA w/wo, quan calcium	0.00	0.00	0.00	NA	NA	0.00	XXX
0147T	TC	C	CCTA w/wo, quan calcium	0.00	0.00	0.00	NA	NA	0.00	XXX
0147T	26	C	CCTA w/wo, quan calcium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0148T		C	CCTA w/wo, strxr	0.00	0.00	0.00	NA	NA	0.00	XXX
0148T	TC	C	CCTA w/wo, strxr	0.00	0.00	0.00	NA	NA	0.00	XXX
0148T	26	C	CCTA w/wo, strxr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0149T		C	CCTA w/wo, strxr quan calc	0.00	0.00	0.00	NA	NA	0.00	XXX
0149T	TC	C	CCTA w/wo, strxr quan calc	0.00	0.00	0.00	NA	NA	0.00	XXX
0149T	26	C	CCTA w/wo, strxr quan calc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0150T		C	CCTA w/wo, disease strxr	0.00	0.00	0.00	NA	NA	0.00	XXX
0150T	TC	C	CCTA w/wo, disease strxr	0.00	0.00	0.00	NA	NA	0.00	XXX
0150T	26	C	CCTA w/wo, disease strxr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0151T		C	CT heart funct add-on	0.00	0.00	0.00	NA	NA	0.00	XXX
0151T	TC	C	CT heart funct add-on	0.00	0.00	0.00	NA	NA	0.00	XXX
0151T	26	C	CT heart funct add-on	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0155T		C	Lap impl gast curve electrd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0156T		C	Lap remv gast curve electrd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0157T		C	Open impl gast curve electrd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0158T		C	Open remv gast curve electrd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0159T		C	Cad breast mri	0.00	0.00	0.00	NA	NA	0.00	ZZZ
0159T	TC	C	Cad breast mri	0.00	0.00	0.00	NA	NA	0.00	ZZZ
0159T	26	C	Cad breast mri	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
0160T		C	Tcranial magn stim tx plan	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0161T		C	Tcranial magn stim tx deliv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0162T		C	Anal program gast neurostim	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0163T		C	Lumb artif disectomy addl	0.00	0.00	0.00	0.00	0.00	0.00	YYY
0164T		C	Remove lumb artif disc addl	0.00	0.00	0.00	0.00	0.00	0.00	YYY
0165T		C	Revise lumb artif disc addl	0.00	0.00	0.00	0.00	0.00	0.00	YYY
0166T		C	Tcath vsd close w/o bypass	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0167T		C	Tcath vsd close w bypass	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0168T		C	Rhinophototx light app bilat	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0169T		C	Place stereo cath brain	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0170T		C	Anorectal fistula plug rpr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0171T		C	Lumbar spine proces distract	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0172T		C	Lumbar spine process addl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0173T		C	Iop monit io pressure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0174T		C	Cad cxr with interp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0175T		C	Cad cxr remote	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0176T		C	Aqu canal dilat w/o retent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0177T		C	Aqu canal dilat w retent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0178T		C	64 lead ecg w i&r	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0179T		C	64 lead ecg w tracing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0180T		C	64 lead ecg w i&r only	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0181T		C	Corneal hysteresis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0182T		C	Hdr elect brachytherapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0183T		C	Wound ultrasound	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0184T		C	Exc rectal tumor endoscopic	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
0185T	C	Comptr probability analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0186T	C	Suprachoroidal drug delivery	0.00	0.00	0.00	0.00	0.00	0.00	XXX
0187T	C	Ophthalmic dx image anterior	0.00	0.00	0.00	0.00	0.00	0.00	XXX
10021	A	Fna w/o image	1.27	2.18	2.17	0.37	0.46	0.10	XXX
10022	A	Fna w/image	1.27	2.15	2.35	0.41	0.41	0.08	XXX
10040	A	Acne surgery	1.19	1.33	1.17	0.98	0.88	0.05	010
10060	A	Drainage of skin abscess	1.19	1.50	1.35	1.08	1.01	0.12	010
10061	A	Drainage of skin abscess	2.42	2.06	1.94	1.51	1.50	0.26	010
10080	A	Drainage of pilonidal cyst	1.19	2.68	2.89	1.10	1.10	0.11	010
10081	A	Drainage of pilonidal cyst	2.47	3.48	3.77	1.45	1.47	0.24	010
10120	A	Remove foreign body	1.23	1.95	2.06	0.94	0.95	0.12	010
10121	A	Remove foreign body	2.71	3.51	3.51	1.65	1.72	0.33	010
10140	A	Drainage of hematoma/fluid	1.55	2.26	2.01	1.29	1.29	0.19	010
10160	A	Puncture drainage of lesion	1.22	1.85	1.72	1.07	1.08	0.14	010
10180	A	Complex drainage, wound	2.27	3.25	3.11	1.80	1.89	0.35	010
11000	A	Debride infected skin	0.60	0.72	0.65	0.16	0.19	0.07	000
11001	A	Debride infected skin add-on	0.30	0.23	0.23	0.08	0.10	0.04	ZZZ
11004	A	Debride genitalia & perineum	10.80	NA	NA	3.20	3.55	0.67	000
11005	A	Debride abdom wall	14.24	NA	NA	3.78	4.67	0.96	000
11006	A	Debride genit/per/abdom wall	13.10	NA	NA	3.95	4.40	1.28	000
11008	A	Remove mesh from abd wall	5.00	NA	NA	1.29	1.66	0.61	ZZZ
11010	A	Debride skin, fx	4.19	6.80	6.83	2.34	2.48	0.66	010
11011	A	Debride skin/muscle, fx	4.94	7.03	7.59	2.01	2.18	0.74	000
11012	A	Debride skin/muscle/bone, fx	6.87	9.00	10.55	3.10	3.47	1.16	000
11040	A	Debride skin, partial	0.50	0.68	0.60	0.16	0.18	0.06	000
11041	A	Debride skin, full	0.60	0.72	0.69	0.19	0.26	0.10	000
11042	A	Debride skin/tissue	0.80	0.95	0.96	0.24	0.34	0.13	000
11043	A	Debride tissue/muscle	3.04	3.50	3.44	2.60	2.59	0.32	010
11044	A	Debride tissue/muscle/bone	4.11	4.84	4.64	3.58	3.66	0.43	010
11055	R	Trim skin lesion	0.43	0.81	0.68	0.11	0.14	0.05	000
11056	R	Trim skin lesions, 2 to 4	0.61	0.88	0.76	0.16	0.19	0.07	000
11057	R	Trim skin lesions, over 4	0.79	0.99	0.86	0.20	0.25	0.10	000
11100	A	Biopsy, skin lesion	0.81	1.88	1.56	0.38	0.38	0.03	000
11101	A	Biopsy, skin add-on	0.41	0.41	0.37	0.20	0.19	0.02	ZZZ
11200	A	Removal of skin tags	0.79	1.23	1.13	0.90	0.83	0.04	010
11201	A	Remove skin tags add-on	0.29	0.16	0.16	0.11	0.12	0.02	ZZZ
11300	A	Shave skin lesion	0.51	1.19	1.09	0.21	0.21	0.03	000
11301	A	Shave skin lesion	0.85	1.51	1.31	0.38	0.38	0.04	000
11302	A	Shave skin lesion	1.05	1.76	1.53	0.48	0.47	0.05	000
11303	A	Shave skin lesion	1.24	2.03	1.80	0.55	0.53	0.07	000
11305	A	Shave skin lesion	0.67	1.06	0.96	0.20	0.24	0.07	000
11306	A	Shave skin lesion	0.99	1.42	1.26	0.38	0.40	0.07	000
11307	A	Shave skin lesion	1.14	1.70	1.49	0.47	0.48	0.07	000
11308	A	Shave skin lesion	1.41	1.70	1.57	0.49	0.54	0.13	000
11310	A	Shave skin lesion	0.73	1.38	1.24	0.31	0.32	0.04	000
11311	A	Shave skin lesion	1.05	1.64	1.43	0.48	0.48	0.05	000
11312	A	Shave skin lesion	1.20	1.92	1.67	0.56	0.55	0.06	000
11313	A	Shave skin lesion	1.62	2.18	1.99	0.73	0.72	0.10	000
11400	A	Exc tr-ext b9+marg 0.5 < cm	0.87	1.88	1.94	0.93	0.91	0.06	010
11401	A	Exc tr-ext b9+marg 0.6-1 cm	1.25	2.19	2.12	1.15	1.08	0.10	010
11402	A	Exc tr-ext b9+marg 1.1-2 cm	1.42	2.40	2.31	1.21	1.14	0.13	010
11403	A	Exc tr-ext b9+marg 2.1-3 cm	1.81	2.55	2.47	1.56	1.44	0.17	010
11404	A	Exc tr-ext b9+marg 3.1-4 cm	2.08	2.85	2.78	1.63	1.51	0.21	010
11406	A	Exc tr-ext b9+marg > 4.0 cm	3.47	3.53	3.30	2.10	1.87	0.32	010
11420	A	Exc h-f-nk-sp b9+marg 0.5 <	1.00	1.83	1.79	0.93	0.93	0.09	010
11421	A	Exc h-f-nk-sp b9+marg 0.6-1	1.44	2.21	2.14	1.16	1.13	0.13	010
11422	A	Exc h-f-nk-sp b9+marg 1.1-2	1.65	2.43	2.34	1.53	1.43	0.16	010
11423	A	Exc h-f-nk-sp b9+marg 2.1-3	2.03	2.67	2.62	1.66	1.55	0.20	010
11424	A	Exc h-f-nk-sp b9+marg 3.1-4	2.45	2.97	2.89	1.77	1.68	0.25	010
11426	A	Exc h-f-nk-sp b9+marg > 4 cm	4.04	3.59	3.53	2.31	2.20	0.44	010
11440	A	Exc face-mm b9+marg 0.5 < cm	1.02	2.00	2.10	1.31	1.31	0.08	010
11441	A	Exc face-mm b9+marg 0.6-1 cm	1.50	2.38	2.35	1.55	1.52	0.13	010
11442	A	Exc face-mm b9+marg 1.1-2 cm	1.74	2.64	2.59	1.66	1.61	0.16	010
11443	A	Exc face-mm b9+marg 2.1-3 cm	2.31	2.88	2.90	1.84	1.83	0.22	010
11444	A	Exc face-mm b9+marg 3.1-4 cm	3.16	3.31	3.39	2.10	2.14	0.30	010
11446	A	Exc face-mm b9+marg > 4 cm	4.75	4.09	4.06	2.68	2.73	0.43	010
11450	A	Removal, sweat gland lesion	3.14	5.12	5.07	2.41	2.22	0.34	090
11451	A	Removal, sweat gland lesion	4.35	6.37	6.49	2.91	2.73	0.53	090
11462	A	Removal, sweat gland lesion	2.92	5.32	5.21	2.47	2.24	0.32	090
11463	A	Removal, sweat gland lesion	4.35	6.52	6.67	2.94	2.81	0.54	090
11470	A	Removal, sweat gland lesion	3.66	5.47	5.26	2.62	2.44	0.40	090
11471	A	Removal, sweat gland lesion	4.81	6.50	6.60	3.01	2.88	0.58	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
11600	A	Exc tr-ext mlg+marg 0.5 < cm	1.58	2.74	2.69	1.14	1.05	0.10	010
11601	A	Exc tr-ext mlg+marg 0.6–1 cm	2.02	3.44	3.07	1.51	1.36	0.12	010
11602	A	Exc tr-ext mlg+marg 1.1–2 cm	2.22	3.84	3.33	1.69	1.47	0.12	010
11603	A	Exc tr-ext mlg+marg 2.1–3 cm	2.77	4.05	3.56	1.87	1.60	0.16	010
11604	A	Exc tr-ext mlg+marg 3.1–4 cm	3.12	4.33	3.85	1.93	1.66	0.20	010
11606	A	Exc tr-ext mlg+marg > 4 cm	4.97	5.49	4.77	2.46	2.10	0.36	010
11620	A	Exc h-f-nk-sp mlg+marg 0.5 <	1.59	2.85	2.72	1.19	1.07	0.09	010
11621	A	Exc h-f-nk-sp mlg+marg 0.6–1	2.03	3.50	3.10	1.54	1.39	0.12	010
11622	A	Exc h-f-nk-sp mlg+marg 1.1–2	2.36	3.90	3.43	1.75	1.57	0.14	010
11623	A	Exc h-f-nk-sp mlg+marg 2.1–3	3.06	4.11	3.72	1.95	1.76	0.20	010
11624	A	Exc h-f-nk-sp mlg+marg 3.1–4	3.57	4.43	4.08	2.08	1.93	0.27	010
11626	A	Exc h-f-nk-sp mlg+mar > 4 cm	4.56	4.96	4.79	2.32	2.36	0.45	010
11640	A	Exc face-mm malig+marg 0.5 <	1.62	3.05	2.85	1.29	1.20	0.11	010
11641	A	Exc face-mm malig+marg 0.6–1	2.12	3.63	3.33	1.61	1.57	0.16	010
11642	A	Exc face-mm malig+marg 1.1–2	2.57	4.04	3.72	1.84	1.77	0.19	010
11643	A	Exc face-mm malig+marg 2.1–3	3.37	4.28	4.04	2.11	2.04	0.26	010
11644	A	Exc face-mm malig+marg 3.1–4	4.29	5.07	4.87	2.46	2.46	0.37	010
11646	A	Exc face-mm mlg+marg > 4 cm	6.21	5.90	5.83	3.13	3.30	0.61	010
11719	R	Trim nail(s)	0.17	0.38	0.31	0.04	0.06	0.02	000
11720	A	Debride nail, 1–5	0.32	0.47	0.40	0.08	0.10	0.04	000
11721	A	Debride nail, 6 or more	0.54	0.55	0.49	0.14	0.17	0.07	000
11730	A	Removal of nail plate	1.10	1.33	1.18	0.28	0.36	0.14	000
11732	A	Remove nail plate, add-on	0.57	0.54	0.49	0.15	0.18	0.07	ZZZ
11740	A	Drain blood from under nail	0.37	0.80	0.67	0.43	0.39	0.04	000
11750	A	Removal of nail bed	2.40	2.95	2.56	1.88	1.82	0.22	010
11752	A	Remove nail bed/finger tip	3.48	4.06	3.52	2.77	2.88	0.35	010
11755	A	Biopsy, nail unit	1.31	2.02	1.79	0.76	0.76	0.14	000
11760	A	Repair of nail bed	1.60	3.40	3.01	1.43	1.61	0.21	010
11762	A	Reconstruction of nail bed	2.91	3.70	3.29	1.68	2.01	0.36	010
11765	A	Excision of nail fold, toe	0.71	2.67	2.23	1.01	0.88	0.08	010
11770	A	Removal of pilonidal lesion	2.63	3.45	3.47	1.52	1.51	0.33	010
11771	A	Removal of pilonidal lesion	5.98	6.63	6.14	3.69	3.50	0.74	090
11772	A	Removal of pilonidal lesion	7.23	8.03	7.76	5.55	5.31	0.89	090
11900	A	Injection into skin lesions	0.52	0.92	0.78	0.25	0.23	0.02	000
11901	A	Added skin lesions injection	0.80	1.01	0.83	0.39	0.37	0.03	000
11920	R	Correct skin color defects	1.61	2.34	3.02	1.09	1.09	0.24	000
11921	R	Correct skin color defects	1.93	2.66	3.31	1.25	1.26	0.29	000
11922	R	Correct skin color defects	0.49	0.92	1.03	0.22	0.24	0.07	ZZZ
11950	R	Therapy for contour defects	0.84	0.88	1.01	0.36	0.37	0.06	000
11951	R	Therapy for contour defects	1.19	0.90	1.19	0.36	0.43	0.11	000
11952	R	Therapy for contour defects	1.69	1.63	1.74	0.77	0.72	0.16	000
11954	R	Therapy for contour defects	1.85	1.79	2.11	0.77	0.83	0.25	000
11960	A	Insert tissue expander(s)	11.01	NA	NA	10.56	10.47	1.31	090
11970	A	Replace tissue expander	7.86	NA	NA	6.16	6.15	1.05	090
11971	A	Remove tissue expander(s)	3.21	7.39	8.25	4.01	3.90	0.32	090
11975	N	Insert contraceptive cap	1.48	1.53	1.47	0.34	0.45	0.17	XXX
11976	R	Removal of contraceptive cap	1.78	1.72	1.72	0.47	0.58	0.21	000
11977	N	Removal/reinsert contra cap	3.30	1.98	2.13	0.76	1.01	0.37	XXX
11980	A	Implant hormone pellet(s)	1.48	1.07	1.07	0.49	0.51	0.13	000
11981	A	Insert drug implant device	1.48	1.89	1.79	0.58	0.63	0.12	XXX
11982	A	Remove drug implant device	1.78	2.02	1.98	0.70	0.76	0.17	XXX
11983	A	Remove/insert drug implant	3.30	2.63	2.46	1.32	1.39	0.23	XXX
12001	A	Repair superficial wound(s)	1.72	1.73	1.86	0.73	0.75	0.15	010
12002	A	Repair superficial wound(s)	1.88	1.80	1.92	0.84	0.87	0.17	010
12004	A	Repair superficial wound(s)	2.26	2.08	2.20	0.92	0.96	0.21	010
12005	A	Repair superficial wound(s)	2.88	2.52	2.67	1.06	1.13	0.27	010
12006	A	Repair superficial wound(s)	3.68	3.06	3.22	1.30	1.40	0.35	010
12007	A	Repair superficial wound(s)	4.13	3.35	3.58	1.46	1.64	0.45	010
12011	A	Repair superficial wound(s)	1.78	1.91	2.02	0.76	0.77	0.16	010
12013	A	Repair superficial wound(s)	2.01	2.06	2.17	0.89	0.91	0.18	010
12014	A	Repair superficial wound(s)	2.48	2.29	2.43	0.98	1.02	0.23	010
12015	A	Repair superficial wound(s)	3.21	2.79	2.96	1.12	1.18	0.29	010
12016	A	Repair superficial wound(s)	3.94	3.17	3.36	1.28	1.40	0.37	010
12017	A	Repair superficial wound(s)	4.72	NA	NA	1.52	1.71	0.47	010
12018	A	Repair superficial wound(s)	5.54	NA	NA	1.92	2.09	0.64	010
12020	A	Closure of split wound	2.64	3.69	3.75	1.75	1.84	0.30	010
12021	A	Closure of split wound	1.86	1.85	1.83	1.33	1.37	0.24	010
12031	A	Layer closure of wound(s)	2.17	3.89	3.09	1.77	1.36	0.17	010
12032	A	Layer closure of wound(s)	2.49	5.21	4.52	2.28	2.04	0.16	010
12034	A	Layer closure of wound(s)	2.94	4.61	3.90	1.99	1.72	0.25	010
12035	A	Layer closure of wound(s)	3.44	5.29	5.24	2.11	2.13	0.39	010
12036	A	Layer closure of wound(s)	4.06	5.40	5.48	2.23	2.39	0.55	010

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
12037	A	Layer closure of wound(s)	4.68	5.98	6.04	2.63	2.80	0.66	010
12041	A	Layer closure of wound(s)	2.39	3.87	3.20	1.77	1.45	0.19	010
12042	A	Layer closure of wound(s)	2.76	4.49	3.88	2.12	1.79	0.17	010
12044	A	Layer closure of wound(s)	3.16	5.40	4.31	1.95	1.77	0.27	010
12045	A	Layer closure of wound(s)	3.65	5.03	5.14	2.06	2.17	0.41	010
12046	A	Layer closure of wound(s)	4.26	5.65	6.08	2.29	2.52	0.54	010
12047	A	Layer closure of wound(s)	4.66	6.49	6.41	2.66	2.87	0.58	010
12051	A	Layer closure of wound(s)	2.49	4.11	3.69	1.92	1.68	0.20	010
12052	A	Layer closure of wound(s)	2.81	4.86	4.04	2.56	1.99	0.17	010
12053	A	Layer closure of wound(s)	3.14	5.38	4.31	2.12	1.82	0.23	010
12054	A	Layer closure of wound(s)	3.47	5.42	4.49	2.05	1.84	0.30	010
12055	A	Layer closure of wound(s)	4.44	6.01	5.24	2.09	2.11	0.45	010
12056	A	Layer closure of wound(s)	5.25	6.56	6.65	2.58	2.81	0.59	010
12057	A	Layer closure of wound(s)	5.97	7.75	6.94	2.93	3.34	0.56	010
13100	A	Repair of wound or lesion	3.14	4.42	4.23	2.46	2.38	0.26	010
13101	A	Repair of wound or lesion	3.93	5.94	5.30	2.97	2.83	0.26	010
13102	A	Repair wound/lesion add-on	1.24	1.35	1.26	0.53	0.55	0.13	ZZZ
13120	A	Repair of wound or lesion	3.32	4.58	4.36	2.57	2.46	0.26	010
13121	A	Repair of wound or lesion	4.36	6.71	5.78	3.64	3.21	0.25	010
13122	A	Repair wound/lesion add-on	1.44	1.37	1.44	0.58	0.60	0.15	ZZZ
13131	A	Repair of wound or lesion	3.80	5.01	4.68	2.88	2.78	0.26	010
13132	A	Repair of wound or lesion	6.48	7.88	6.89	4.95	4.55	0.32	010
13133	A	Repair wound/lesion add-on	2.19	1.87	1.76	0.98	1.00	0.18	ZZZ
13150	A	Repair of wound or lesion	3.82	4.72	4.79	2.72	2.74	0.34	010
13151	A	Repair of wound or lesion	4.46	5.51	5.15	3.22	3.18	0.31	010
13152	A	Repair of wound or lesion	6.34	7.53	6.78	3.91	3.97	0.40	010
13153	A	Repair wound/lesion add-on	2.38	2.05	1.99	1.03	1.08	0.24	ZZZ
13160	A	Late closure of wound	11.84	NA	NA	7.02	7.09	1.54	090
14000	A	Skin tissue rearrangement	6.83	8.94	8.39	6.04	5.75	0.59	090
14001	A	Skin tissue rearrangement	9.60	11.01	10.21	7.48	7.27	0.82	090
14020	A	Skin tissue rearrangement	7.66	10.02	9.31	6.88	6.70	0.64	090
14021	A	Skin tissue rearrangement	11.18	12.45	11.21	8.65	8.46	0.81	090
14040	A	Skin tissue rearrangement	8.44	10.19	9.49	6.98	7.09	0.62	090
14041	A	Skin tissue rearrangement	12.67	13.56	12.07	9.34	9.00	0.73	090
14060	A	Skin tissue rearrangement	9.07	9.68	9.23	7.17	7.30	0.68	090
14061	A	Skin tissue rearrangement	13.67	14.82	13.21	10.17	9.83	0.76	090
14300	A	Skin tissue rearrangement	13.26	13.51	12.32	9.44	9.30	1.16	090
14350	A	Skin tissue rearrangement	10.82	NA	NA	6.89	7.01	1.34	090
15002	A	Wnd prep, ch/inf, trk/arm/leg	3.65	4.21	4.21	1.68	1.68	0.49	000
15003	A	Wnd prep, ch/inf addl 100 cm	0.80	0.90	0.90	0.26	0.26	0.11	ZZZ
15004	A	Wnd prep ch/inf, f/n/hf/g	4.58	4.87	4.87	2.01	2.01	0.62	000
15005	A	Wnd prep, f/n/hf/g, addl cm	1.60	1.24	1.24	0.52	0.52	0.22	ZZZ
15040	A	Harvest cultured skin graft	2.00	3.93	4.24	1.05	1.09	0.24	000
15050	A	Skin pinch graft	5.37	7.62	7.26	5.00	5.05	0.57	090
15100	A	Skin splnt grft, trnk/arm/leg	9.74	9.76	11.17	6.67	7.24	1.28	090
15101	A	Skin splnt grft t/a/l, add-on	1.72	2.47	3.10	0.85	1.01	0.24	ZZZ
15110	A	Epidrm autogrft trnk/arm/leg	10.88	8.74	9.70	6.36	6.68	1.31	090
15111	A	Epidrm autogrft t/a/l add-on	1.85	0.87	1.08	0.62	0.70	0.26	ZZZ
15115	A	Epidrm a-grft face/nck/hf/g	11.19	9.22	9.22	6.73	7.04	1.15	090
15116	A	Epidrm a-grft f/n/hf/g addl	2.50	1.19	1.38	0.86	0.99	0.33	ZZZ
15120	A	Skn splnt a-grft fac/nck/hf/g	10.96	11.34	11.03	7.45	7.61	1.16	090
15121	A	Skn splnt a-grft f/n/hf/g add	2.67	3.43	3.96	1.29	1.57	0.36	ZZZ
15130	A	Derm autogrft, trnk/arm/leg	7.41	7.95	8.90	5.57	5.95	0.97	090
15131	A	Derm autogrft t/a/l add-on	1.50	0.65	0.86	0.48	0.56	0.21	ZZZ
15135	A	Derm autogrft face/nck/hf/g	10.91	9.48	9.67	7.04	7.58	1.23	090
15136	A	Derm autogrft, f/n/hf/g add	1.50	0.66	0.77	0.51	0.59	0.20	ZZZ
15150	A	Cult epiderm grft t/arm/leg	9.30	7.04	7.74	5.75	6.10	1.14	090
15151	A	Cult epiderm grft t/a/l addl	2.00	0.88	1.09	0.67	0.76	0.28	ZZZ
15152	A	Cult epiderm grft t/a/l +%	2.50	1.05	1.30	0.84	0.95	0.35	ZZZ
15155	A	Cult epiderm grft, f/n/hf/g	10.05	7.65	7.73	6.30	6.63	1.05	090
15156	A	Cult epiderm grft f/n/hf/g add	2.75	1.15	1.35	0.94	1.09	0.36	ZZZ
15157	A	Cult epiderm grft f/n/hf/g +%	3.00	1.33	1.55	1.03	1.19	0.39	ZZZ
15170	A	Acell grft trnk/arms/legs	5.99	4.01	3.92	2.60	2.48	0.55	090
15171	A	Acell grft t/arm/leg add-on	1.55	0.60	0.64	0.46	0.54	0.19	ZZZ
15175	A	Acellular grft, f/n/hf/g	7.99	4.46	4.94	3.14	3.57	0.82	090
15176	A	Acell grft, f/n/hf/g add-on	2.45	1.04	1.07	0.79	0.89	0.29	ZZZ
15200	A	Skin full graft, trunk	8.97	9.90	9.65	6.34	6.27	0.98	090
15201	A	Skin full graft trunk add-on	1.32	2.02	2.29	0.47	0.54	0.19	ZZZ
15220	A	Skin full graft sclp/arm/leg	7.95	10.45	9.82	6.69	6.68	0.84	090
15221	A	Skin full graft add-on	1.19	2.00	2.16	0.50	0.53	0.16	ZZZ
15240	A	Skin full grft face/genit/hf	10.15	12.03	11.11	8.89	8.42	0.92	090
15241	A	Skin full graft add-on	1.86	2.54	2.49	0.81	0.86	0.23	ZZZ

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
15260	A	Skin full graft een & lips	11.39	13.00	11.60	9.33	8.95	0.69	090
15261	A	Skin full graft add-on	2.23	2.97	2.83	1.15	1.28	0.21	ZZZ
15300	A	Apply skinallogrft, t/arm/leg	4.65	3.44	3.32	2.15	2.19	0.49	090
15301	A	Apply sknallogrft t/a/l addl	1.00	0.46	0.46	0.32	0.36	0.14	ZZZ
15320	A	Apply skin allogrft f/n/hf/g	5.36	3.78	3.70	2.35	2.44	0.58	090
15321	A	Aply sknallogrft f/n/hfg add	1.50	0.69	0.69	0.51	0.55	0.21	ZZZ
15330	A	Aply acell allogrft t/arm/leg	3.99	3.49	3.34	2.14	2.18	0.49	090
15331	A	Aply acell grft t/a/l add-on	1.00	0.49	0.47	0.36	0.38	0.14	ZZZ
15335	A	Apply acell graft, f/n/hf/g	4.50	3.32	3.39	2.01	2.22	0.55	090
15336	A	Apply acell grft f/n/hf/g add	1.43	0.74	0.71	0.51	0.54	0.20	ZZZ
15340	A	Apply cult skin substitute	3.76	3.68	3.84	2.64	2.69	0.41	010
15341	A	Apply cult skin sub add-on	0.50	0.64	0.62	0.13	0.17	0.06	ZZZ
15360	A	Apply cult derm sub, t/a/l	3.93	4.85	4.66	3.53	3.31	0.43	090
15361	A	Aply cult derm sub t/a/l add	1.15	0.50	0.54	0.32	0.39	0.14	ZZZ
15365	A	Apply cult derm sub f/n/hf/g	4.21	4.21	4.38	3.09	3.14	0.46	090
15366	A	Apply cult derm f/hf/g add	1.45	0.67	0.68	0.47	0.53	0.17	ZZZ
15400	A	Apply skin xenograft, t/a/l	4.38	4.99	4.50	3.76	3.88	0.47	090
15401	A	Apply skn xenogrft t/a/l add	1.00	1.01	1.45	0.33	0.39	0.14	ZZZ
15420	A	Apply skin xgraft, f/n/hf/g	4.89	5.43	5.10	4.17	3.98	0.52	090
15421	A	Apply skn xgrft f/n/hf/g add	1.50	1.16	1.24	0.48	0.55	0.21	ZZZ
15430	A	Apply acellular xenograft	5.93	6.60	6.75	6.05	6.33	0.66	090
15431	C	Apply acellular xgraft add	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
15570	A	Form skin pedicle flap	10.00	10.08	10.69	6.27	6.51	1.34	090
15572	A	Form skin pedicle flap	9.94	9.78	9.63	6.66	6.55	1.20	090
15574	A	Form skin pedicle flap	10.52	10.54	10.61	7.03	7.41	1.20	090
15576	A	Form skin pedicle flap	9.24	9.66	9.70	6.51	6.70	0.87	090
15600	A	Skin graft	1.95	5.31	6.45	2.75	2.90	0.27	090
15610	A	Skin graft	2.46	5.56	5.12	3.04	3.23	0.35	090
15620	A	Skin graft	3.62	6.47	7.12	3.90	3.89	0.35	090
15630	A	Skin graft	3.95	7.07	7.05	4.31	4.23	0.34	090
15650	A	Transfer skin pedicle flap	4.64	7.27	7.20	4.38	4.29	0.42	090
15731	A	Forehead flap w/vasc pedicle	14.12	11.89	11.89	9.33	9.33	1.28	090
15732	A	Muscle-skin graft, head/neck	19.70	14.64	16.34	11.09	11.65	2.00	090
15734	A	Muscle-skin graft, trunk	19.62	15.68	16.89	11.84	12.10	2.62	090
15736	A	Muscle-skin graft, arm	16.92	13.39	15.80	9.59	10.40	2.46	090
15738	A	Muscle-skin graft, leg	18.92	13.76	15.86	10.18	10.95	2.66	090
15740	A	Island pedicle flap graft	11.57	13.56	11.84	9.41	8.83	0.63	090
15750	A	Neurovascular pedicle graft	12.73	NA	NA	8.85	8.94	1.42	090
15756	A	Free myo/skin flap microvasc	36.74	NA	NA	18.55	19.55	4.62	090
15757	A	Free skin flap, microvasc	36.95	NA	NA	17.85	19.71	3.90	090
15758	A	Free fascial flap, microvasc	36.70	NA	NA	17.56	19.56	4.24	090
15760	A	Composite skin graft	9.68	10.41	10.21	7.05	7.15	0.85	090
15770	A	Derma-fat-fascia graft	8.73	NA	NA	6.63	6.66	1.05	090
15775	R	Hair transplant punch grafts	3.95	2.88	3.55	1.23	1.26	0.52	000
15776	R	Hair transplant punch grafts	5.53	4.85	5.10	2.14	2.47	0.72	000
15780	A	Abrasion treatment of skin	8.50	11.23	11.37	6.52	7.38	0.67	090
15781	A	Abrasion treatment of skin	4.91	8.67	7.79	5.64	5.50	0.34	090
15782	A	Abrasion treatment of skin	4.36	8.70	9.28	4.96	5.75	0.34	090
15783	A	Abrasion treatment of skin	4.33	7.91	7.39	4.96	4.57	0.28	090
15786	A	Abrasion, lesion, single	2.05	3.89	3.62	1.24	1.28	0.11	010
15787	A	Abrasion, lesions, add-on	0.33	0.83	0.96	0.08	0.12	0.04	ZZZ
15788	R	Chemical peel, face, epiderm	2.09	9.45	8.08	4.12	3.60	0.11	090
15789	R	Chemical peel, face, dermal	4.91	9.42	8.75	5.83	5.31	0.20	090
15792	R	Chemical peel, nonfacial	1.86	8.97	8.03	4.58	4.51	0.13	090
15793	A	Chemical peel, nonfacial	3.82	8.09	7.19	4.90	4.64	0.19	090
15819	A	Plastic surgery, neck	10.45	NA	NA	6.68	6.93	0.97	090
15820	A	Revision of lower eyelid	6.09	6.39	6.68	5.19	5.38	0.40	090
15821	A	Revision of lower eyelid	6.66	6.56	6.95	5.28	5.49	0.45	090
15822	A	Revision of upper eyelid	4.51	5.23	5.53	4.09	4.29	0.37	090
15823	A	Revision of upper eyelid	8.12	7.38	7.61	6.10	6.27	0.50	090
15824	R	Removal of forehead wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	000
15825	R	Removal of neck wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	000
15826	R	Removal of brow wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	000
15828	R	Removal of face wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	000
15829	R	Removal of skin wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	000
15830	R	Exc skin abd	16.90	NA	NA	9.81	9.81	2.93	090
15832	A	Excise excessive skin tissue	12.65	NA	NA	8.27	8.30	1.66	090
15833	A	Excise excessive skin tissue	11.70	NA	NA	7.50	7.85	1.49	090
15834	A	Excise excessive skin tissue	11.97	NA	NA	8.15	7.92	1.61	090
15835	A	Excise excessive skin tissue	12.79	NA	NA	7.85	7.69	1.60	090
15836	A	Excise excessive skin tissue	10.41	NA	NA	6.82	6.80	1.34	090
15837	A	Excise excessive skin tissue	9.37	8.67	8.61	5.78	6.57	1.18	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
15838	A	Excise excessive skin tissue	8.07	NA	NA	5.44	5.75	0.58	090
15839	A	Excise excessive skin tissue	10.32	9.75	9.29	6.46	6.42	1.22	090
15840	A	Graft for face nerve palsy	14.76	NA	NA	8.91	9.44	1.32	090
15841	A	Graft for face nerve palsy	25.69	NA	NA	13.52	14.25	2.55	090
15842	A	Flap for face nerve palsy	40.68	NA	NA	20.86	21.88	4.94	090
15845	A	Skin and muscle repair, face	14.04	NA	NA	8.35	8.83	0.81	090
15847	C	Exc skin abd add-on	0.00	0.00	0.00	0.00	0.00	0.00	YYY
15850	B	Removal of sutures	0.78	1.20	1.38	0.18	0.24	0.05	XXX
15851	A	Removal of sutures	0.86	1.33	1.50	0.24	0.27	0.06	000
15852	A	Dressing change not for burn	0.86	NA	NA	0.25	0.29	0.09	000
15860	A	Test for blood flow in graft	1.95	NA	NA	0.64	0.71	0.27	000
15876	R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	000
15877	R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	000
15878	R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	000
15879	R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	000
15920	A	Removal of tail bone ulcer	8.15	NA	NA	5.34	5.45	1.04	090
15922	A	Removal of tail bone ulcer	10.23	NA	NA	7.16	7.18	1.42	090
15931	A	Remove sacrum pressure sore	9.96	NA	NA	5.56	5.62	1.25	090
15933	A	Remove sacrum pressure sore	11.60	NA	NA	7.30	7.57	1.52	090
15934	A	Remove sacrum pressure sore	13.54	NA	NA	7.72	7.87	1.79	090
15935	A	Remove sacrum pressure sore	15.58	NA	NA	9.17	9.74	2.10	090
15936	A	Remove sacrum pressure sore	13.04	NA	NA	7.41	7.81	1.77	090
15937	A	Remove sacrum pressure sore	15.00	NA	NA	8.93	9.37	2.07	090
15940	A	Remove hip pressure sore	10.11	NA	NA	5.80	5.99	1.31	090
15941	A	Remove hip pressure sore	12.24	NA	NA	8.42	8.93	1.66	090
15944	A	Remove hip pressure sore	12.27	NA	NA	8.13	8.36	1.65	090
15945	A	Remove hip pressure sore	13.57	NA	NA	8.80	9.22	1.85	090
15946	A	Remove hip pressure sore	23.80	NA	NA	13.69	14.03	3.17	090
15950	A	Remove thigh pressure sore	7.91	NA	NA	5.40	5.40	1.04	090
15951	A	Remove thigh pressure sore	11.41	NA	NA	7.33	7.59	1.49	090
15952	A	Remove thigh pressure sore	12.14	NA	NA	7.45	7.60	1.60	090
15953	A	Remove thigh pressure sore	13.39	NA	NA	8.22	8.61	1.80	090
15956	A	Remove thigh pressure sore	16.59	NA	NA	9.54	10.15	2.22	090
15958	A	Remove thigh pressure sore	16.55	NA	NA	10.42	10.72	2.26	090
15999	C	Removal of pressure sore	0.00	0.00	0.00	0.00	0.00	0.00	YYY
16000	A	Initial treatment of burn(s)	0.89	0.72	0.79	0.23	0.25	0.08	000
16020	A	Dress/debrid p-thick burn, s	0.80	1.11	1.20	0.56	0.57	0.08	000
16025	A	Dress/debrid p-thick burn, m	1.85	1.57	1.67	0.86	0.91	0.19	000
16030	A	Dress/debrid p-thick burn, l	2.08	2.08	2.13	1.02	1.07	0.24	000
16035	A	Incision of burn scab, initi	3.74	NA	NA	1.22	1.40	0.46	000
16036	A	Escharotomy; add'l incision	1.50	NA	NA	0.46	0.53	0.20	ZZZ
17000	A	Destruct premalg lesion	0.62	1.41	1.19	0.74	0.64	0.03	010
17003	A	Destruct premalg les, 2-14	0.07	0.10	0.11	0.03	0.05	0.01	ZZZ
17004	A	Destroy premalg lesions 15+	1.82	2.44	2.37	1.38	1.48	0.11	010
17106	A	Destruction of skin lesions	4.62	4.69	4.64	3.28	3.30	0.35	090
17107	A	Destruction of skin lesions	9.19	6.97	7.08	4.94	5.20	0.63	090
17108	A	Destruction of skin lesions	13.22	8.86	9.06	6.38	7.02	0.54	090
17110	A	Destruct b9 lesion, 1-14	0.67	1.79	1.70	0.88	0.79	0.05	010
17111	A	Destruct lesion, 15 or more	0.94	2.25	1.96	1.11	0.96	0.05	010
17250	A	Chemical cautery, tissue	0.50	1.32	1.27	0.38	0.36	0.06	000
17260	A	Destruction of skin lesions	0.93	1.41	1.34	0.71	0.69	0.04	010
17261	A	Destruction of skin lesions	1.19	2.49	2.05	1.07	0.95	0.05	010
17262	A	Destruction of skin lesions	1.60	2.83	2.36	1.27	1.14	0.06	010
17263	A	Destruction of skin lesions	1.81	3.06	2.56	1.37	1.23	0.07	010
17264	A	Destruction of skin lesions	1.96	3.27	2.74	1.43	1.28	0.08	010
17266	A	Destruction of skin lesions	2.36	3.50	3.00	1.59	1.40	0.09	010
17270	A	Destruction of skin lesions	1.34	2.43	2.06	1.10	0.98	0.05	010
17271	A	Destruction of skin lesions	1.51	2.66	2.22	1.22	1.10	0.06	010
17272	A	Destruction of skin lesions	1.79	2.97	2.48	1.36	1.24	0.07	010
17273	A	Destruction of skin lesions	2.07	3.21	2.71	1.49	1.35	0.08	010
17274	A	Destruction of skin lesions	2.61	3.60	3.08	1.74	1.59	0.10	010
17276	A	Destruction of skin lesions	3.22	3.88	3.41	1.97	1.82	0.16	010
17280	A	Destruction of skin lesions	1.19	2.36	1.98	1.03	0.92	0.05	010
17281	A	Destruction of skin lesions	1.74	2.73	2.32	1.33	1.21	0.07	010
17282	A	Destruction of skin lesions	2.06	3.14	2.64	1.49	1.36	0.08	010
17283	A	Destruction of skin lesions	2.66	3.55	3.05	1.76	1.62	0.11	010
17284	A	Destruction of skin lesions	3.23	3.97	3.44	2.02	1.89	0.13	010
17286	A	Destruction of skin lesions	4.45	4.44	4.06	2.49	2.46	0.23	010
17311	A	Mohs, 1 stage, h/n/hf/g	6.20	10.70	10.70	3.05	3.05	0.24	000
17312	A	Mohs addl stage	3.30	6.88	6.88	1.62	1.62	0.13	ZZZ
17313	A	Mohs, 1 stage, t/a/l	5.56	9.87	9.87	2.73	2.73	0.22	000
17314	A	Mohs, addl stage, t/a/l	3.06	6.37	6.37	1.50	1.50	0.12	ZZZ

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
17315	A	Mohs surg, addl block	0.87	1.14	1.14	0.43	0.43	0.03	ZZZ
17340	A	Cryotherapy of skin	0.76	0.35	0.36	0.38	0.37	0.05	010
17360	A	Skin peel therapy	1.44	1.86	1.65	1.01	0.94	0.06	010
17380	R	Hair removal by electrolysis	0.00	0.00	0.00	0.00	0.00	0.00	000
17999	C	Skin tissue procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
19000	A	Drainage of breast lesion	0.84	1.91	1.95	0.26	0.29	0.08	000
19001	A	Drain breast lesion add-on	0.42	0.25	0.25	0.14	0.14	0.04	ZZZ
19020	A	Incision of breast lesion	3.74	6.62	6.48	3.03	2.85	0.45	090
19030	A	Injection for breast x-ray	1.53	2.66	2.76	0.54	0.52	0.09	000
19100	A	Bx breast percut w/o image	1.27	2.08	2.08	0.33	0.37	0.16	000
19101	A	Biopsy of breast, open	3.20	4.37	4.43	1.78	1.85	0.39	010
19102	A	Bx breast percut w/image	2.00	3.46	3.64	0.68	0.67	0.14	000
19103	A	Bx breast percut w/device	3.69	10.09	10.79	1.19	1.21	0.30	000
19105	A	Cryosurg ablate fa, each	3.69	46.46	46.46	0.99	0.99	0.30	000
19110	A	Nipple exploration	4.35	6.06	5.93	3.09	2.98	0.57	090
19112	A	Excise breast duct fistula	3.72	6.22	6.14	3.12	2.90	0.48	090
19120	A	Removal of breast lesion	5.84	5.08	4.81	3.36	3.21	0.73	090
19125	A	Excision, breast lesion	6.59	5.55	5.16	3.64	3.46	0.80	090
19126	A	Excision, addl breast lesion	2.93	NA	NA	0.75	0.87	0.38	ZZZ
19260	A	Removal of chest wall lesion	17.60	NA	NA	10.14	10.64	2.14	090
19271	A	Revision of chest wall	21.86	NA	NA	15.81	16.87	2.63	090
19272	A	Extensive chest wall surgery	24.82	NA	NA	16.95	17.93	3.00	090
19290	A	Place needle wire, breast	1.27	2.89	2.87	0.45	0.43	0.07	000
19291	A	Place needle wire, breast	0.63	1.14	1.17	0.22	0.21	0.04	ZZZ
19295	A	Place breast clip, percut	0.00	2.28	2.48	NA	NA	0.01	ZZZ
19296	A	Place po breast cath for rad	3.63	85.92	105.62	1.19	1.36	0.36	000
19297	A	Place breast cath for rad	1.72	NA	NA	0.44	0.54	0.17	ZZZ
19298	A	Place breast rad tube/caths	6.00	21.99	32.06	2.10	2.26	0.43	000
19300	A	Removal of breast tissue	5.20	8.05	7.59	3.85	3.62	0.69	090
19301	A	Partical mastectomy	10.00	NA	NA	4.62	4.02	0.79	090
19302	A	P-mastectomy w/ln removal	13.88	NA	NA	6.14	6.23	1.80	090
19303	A	Mast, simple, complete	15.67	NA	NA	6.99	6.00	1.18	090
19304	A	Mast, subq	7.81	NA	NA	4.93	4.84	1.04	090
19305	A	Mast, radical	17.23	NA	NA	8.11	8.03	1.93	090
19306	A	Mast, rad, urban type	17.85	NA	NA	8.71	8.47	2.08	090
19307	A	Mast, mod rad	17.95	NA	NA	8.76	8.48	2.13	090
19316	A	Suspension of breast	10.98	NA	NA	6.94	7.22	1.64	090
19318	A	Reduction of large breast	15.91	NA	NA	9.90	10.53	2.93	090
19324	A	Enlarge breast	6.65	NA	NA	4.46	4.67	0.84	090
19325	A	Enlarge breast with implant	8.52	NA	NA	6.40	6.46	1.33	090
19328	A	Removal of breast implant	6.35	NA	NA	4.99	5.00	0.91	090
19330	A	Removal of implant material	8.39	NA	NA	5.95	5.99	1.26	090
19340	A	Immediate breast prosthesis	6.32	NA	NA	2.81	2.96	1.06	ZZZ
19342	A	Delayed breast prosthesis	12.40	NA	NA	8.92	8.92	1.84	090
19350	A	Breast reconstruction	8.99	9.88	11.86	6.58	6.87	1.41	090
19355	A	Correct inverted nipple(s)	8.37	7.40	8.82	4.67	4.68	0.92	090
19357	A	Breast reconstruction	20.57	NA	NA	15.37	15.49	2.94	090
19361	A	Breast reconstr w/lat flap	23.17	NA	NA	16.78	14.60	2.93	090
19364	A	Breast reconstruction	42.40	NA	NA	22.15	22.84	6.24	090
19366	A	Breast reconstruction	21.70	NA	NA	9.90	10.73	3.25	090
19367	A	Breast reconstruction	26.59	NA	NA	15.17	15.93	4.04	090
19368	A	Breast reconstruction	33.61	NA	NA	18.01	18.46	5.54	090
19369	A	Breast reconstruction	31.02	NA	NA	16.31	17.35	4.51	090
19370	A	Surgery of breast capsule	8.99	NA	NA	6.78	6.84	1.29	090
19371	A	Removal of breast capsule	10.42	NA	NA	7.68	7.75	1.62	090
19380	A	Revise breast reconstruction	10.21	NA	NA	7.60	7.65	1.44	090
19396	A	Design custom breast implant	2.17	4.53	2.80	1.28	1.13	0.30	000
19499	C	Breast surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
20000	A	Incision of abscess	2.14	2.78	2.74	1.52	1.63	0.25	010
20005	A	Incision of deep abscess	3.55	3.66	3.58	2.01	2.13	0.46	010
20100	A	Explore wound, neck	10.33	NA	NA	3.58	4.02	1.21	010
20101	A	Explore wound, chest	3.22	6.59	6.26	1.53	1.57	0.44	010
20102	A	Explore wound, abdomen	3.95	6.94	7.20	1.84	1.87	0.49	010
20103	A	Explore wound, extremity	5.31	7.80	8.19	2.78	3.09	0.75	010
20150	A	Excise epiphyseal bar	14.60	NA	NA	7.64	7.33	2.04	090
20200	A	Muscle biopsy	1.46	3.09	3.06	0.69	0.72	0.23	000
20205	A	Deep muscle biopsy	2.35	3.82	3.85	1.10	1.14	0.33	000
20206	A	Needle biopsy, muscle	0.99	5.22	5.86	0.57	0.60	0.07	000
20220	A	Bone biopsy, trocar/needle	1.27	2.71	3.63	0.68	0.73	0.08	000
20225	A	Bone biopsy, trocar/needle	1.87	11.99	18.21	1.02	1.07	0.22	000
20240	A	Bone biopsy, excisional	3.25	NA	NA	2.02	2.29	0.44	010
20245	A	Bone biopsy, excisional	8.77	NA	NA	5.74	6.15	1.31	010

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
20250	A	Open bone biopsy	5.16	NA	NA	3.63	3.56	1.02	010
20251	A	Open bone biopsy	5.69	NA	NA	3.84	4.00	1.15	010
20500	A	Injection of sinus tract	1.25	1.34	1.80	0.88	1.20	0.12	010
20501	A	Inject sinus tract for x-ray	0.76	2.36	2.64	0.27	0.26	0.04	000
20520	A	Removal of foreign body	1.87	2.60	2.76	1.45	1.61	0.21	010
20525	A	Removal of foreign body	3.51	7.11	8.12	2.21	2.41	0.51	010
20526	A	Ther injection, carp tunnel	0.94	0.81	0.89	0.41	0.46	0.13	000
20550	A	Inj tendon sheath/ligament	0.75	0.63	0.67	0.28	0.25	0.09	000
20551	A	Inj tendon origin/insertion	0.75	0.64	0.66	0.29	0.31	0.08	000
20552	A	Inj trigger point, 1/2 muscl	0.66	0.58	0.65	0.24	0.22	0.05	000
20553	A	Inject trigger points, => 3	0.75	0.64	0.73	0.26	0.24	0.04	000
20555	A	Place ndl musc/tis for rt	6.00	NA	NA	2.18	2.18	0.43	000
20600	A	Drain/inject, joint/bursa	0.66	0.66	0.66	0.31	0.33	0.08	000
20605	A	Drain/inject, joint/bursa	0.68	0.74	0.75	0.32	0.34	0.08	000
20610	A	Drain/inject, joint/bursa	0.79	1.06	1.01	0.40	0.41	0.11	000
20612	A	Aspirate/inj ganglion cyst	0.70	0.70	0.70	0.32	0.34	0.10	000
20615	A	Treatment of bone cyst	2.30	2.71	3.11	1.41	1.63	0.20	010
20650	A	Insert and remove bone pin	2.25	2.46	2.41	1.45	1.50	0.31	010
20660	A	Apply, rem fixation device	4.00	1.50	2.27	1.50	1.55	0.59	000
20661	A	Application of head brace	5.14	NA	NA	6.04	5.47	1.14	090
20662	A	Application of pelvis brace	6.26	NA	NA	4.80	5.16	0.56	090
20663	A	Application of thigh brace	5.62	NA	NA	4.85	4.84	0.94	090
20664	A	Halo brace application	9.86	NA	NA	7.80	7.42	1.75	090
20665	A	Removal of fixation device	1.33	1.37	1.76	0.98	1.16	0.19	010
20670	A	Removal of support implant	1.76	6.62	9.07	1.67	1.88	0.28	010
20680	A	Removal of support implant	5.90	8.13	8.46	4.06	3.89	0.56	090
20690	A	Apply bone fixation device	8.65	NA	NA	4.91	3.71	0.59	090
20692	A	Apply bone fixation device	16.00	NA	NA	9.79	6.78	1.05	090
20693	A	Adjust bone fixation device	5.97	NA	NA	4.49	4.96	0.98	090
20694	A	Remove bone fixation device	4.20	5.31	6.22	3.52	3.78	0.71	090
20802	A	Replantation, arm, complete	42.30	NA	NA	13.22	17.08	3.82	090
20805	A	Replant forearm, complete	51.14	NA	NA	17.97	26.13	4.85	090
20808	A	Replantation hand, complete	62.77	NA	NA	30.31	36.25	6.88	090
20816	A	Replantation digit, complete	31.74	NA	NA	16.35	27.06	4.53	090
20822	A	Replantation digit, complete	26.42	NA	NA	15.05	24.81	4.19	090
20824	A	Replantation thumb, complete	31.74	NA	NA	16.19	26.36	4.62	090
20827	A	Replantation thumb, complete	27.24	NA	NA	14.73	25.59	3.67	090
20838	A	Replantation foot, complete	42.56	NA	NA	14.01	18.14	1.12	090
20900	A	Removal of bone for graft	5.77	9.22	8.82	4.90	5.28	0.94	090
20902	A	Removal of bone for graft	7.98	NA	NA	5.98	6.43	1.30	090
20910	A	Remove cartilage for graft	5.41	NA	NA	4.56	4.87	0.71	090
20912	A	Remove cartilage for graft	6.42	NA	NA	4.94	5.37	0.69	090
20920	A	Removal of fascia for graft	5.42	NA	NA	4.33	4.28	0.66	090
20922	A	Removal of fascia for graft	6.84	7.56	7.54	4.99	4.93	0.70	090
20924	A	Removal of tendon for graft	6.59	NA	NA	4.97	5.42	1.04	090
20926	A	Removal of tissue for graft	5.70	NA	NA	4.49	4.62	0.87	090
20930	B	Sp bone algrft morsel add-on	0.00	0.00	0.00	0.00	0.00	0.00	XXX
20931	A	Sp bone algrft struct add-on	1.81	NA	NA	0.68	0.80	0.43	ZZZ
20936	B	Sp bone agrft local add-on	0.00	0.00	0.00	0.00	0.00	0.00	XXX
20937	A	Sp bone agrft morsel add-on	2.79	NA	NA	1.08	1.26	0.54	ZZZ
20938	A	Sp bone agrft struct add-on	3.02	NA	NA	1.15	1.35	0.64	ZZZ
20950	A	Fluid pressure, muscle	1.26	4.23	5.53	0.88	0.93	0.20	000
20955	A	Fibula bone graft, microvasc	40.02	NA	NA	18.53	21.39	4.90	090
20956	A	Iliac bone graft, microvasc	40.93	NA	NA	20.31	22.52	7.03	090
20957	A	Mt bone graft, microvasc	42.33	NA	NA	15.87	17.40	7.07	090
20962	A	Other bone graft, microvasc	39.21	NA	NA	21.29	23.90	6.57	090
20969	A	Bone/skin graft, microvasc	45.11	NA	NA	21.09	23.85	4.80	090
20970	A	Bone/skin graft, iliac crest	44.26	NA	NA	20.89	23.13	6.62	090
20972	A	Bone/skin graft, metatarsal	44.19	NA	NA	14.92	17.74	5.32	090
20973	A	Bone/skin graft, great toe	46.95	NA	NA	14.15	19.64	5.56	090
20974	A	Electrical bone stimulation	0.62	0.98	0.83	0.48	0.51	0.11	000
20975	A	Electrical bone stimulation	2.60	NA	NA	1.46	1.58	0.51	000
20979	A	Us bone stimulation	0.62	0.61	0.71	0.20	0.27	0.09	000
20982	A	Ablate, bone tumor(s) perq	7.27	79.99	94.74	2.68	2.83	0.69	000
20985	A	Cptr-asst dir ms px	2.50	0.99	0.99	0.99	0.99	0.48	ZZZ
20986	C	Cptr-asst dir ms px io img	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
20987	C	Cptr-asst dir ms px pre img	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
20999	C	Musculoskeletal surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21010	A	Incision of jaw joint	10.90	NA	NA	6.29	6.69	1.11	090
21015	A	Resection of facial tumor	5.59	NA	NA	4.30	4.65	0.70	090
21025	A	Excision of bone, lower jaw	11.07	12.54	12.39	8.74	9.04	1.32	090
21026	A	Excision of facial bone(s)	5.54	8.82	8.34	5.93	6.12	0.60	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
21029	A	Contour of face bone lesion	8.26	9.55	9.46	6.52	6.76	0.94	090
21030	A	Excise max/zygoma b9 tumor	4.80	7.19	6.76	4.68	4.85	0.54	090
21031	A	Remove exostosis, mandible	3.26	5.91	5.54	3.47	3.54	0.48	090
21032	A	Remove exostosis, maxilla	3.28	6.04	5.69	3.36	3.43	0.47	090
21034	A	Excise max/zygoma mlg tumor	17.17	13.92	14.92	10.11	11.38	1.72	090
21040	A	Excise mandible lesion	4.80	7.19	6.79	4.64	4.68	0.54	090
21044	A	Removal of jaw bone lesion	12.61	NA	NA	8.10	8.73	1.12	090
21045	A	Extensive jaw surgery	18.13	NA	NA	10.78	11.56	1.52	090
21046	A	Remove mandible cyst complex	13.97	NA	NA	11.48	11.69	1.86	090
21047	A	Excise lwr jaw cyst w/repair	19.83	NA	NA	10.21	11.82	2.13	090
21048	A	Remove maxilla cyst complex	14.47	NA	NA	11.38	11.75	1.77	090
21049	A	Excis uppr jaw cyst w/repair	19.08	NA	NA	10.28	11.65	1.59	090
21050	A	Removal of jaw joint	11.54	NA	NA	8.20	8.82	1.47	090
21060	A	Remove jaw joint cartilage	10.91	NA	NA	7.19	7.89	1.38	090
21070	A	Remove coronoid process	8.50	NA	NA	6.26	6.68	1.27	090
21073	A	Mnpj of tmj w/anesth	3.33	5.50	5.50	2.31	2.31	0.43	090
21076	A	Prepare face/oral prosthesis	13.40	8.01	10.18	4.68	7.34	2.00	010
21077	A	Prepare face/oral prosthesis	33.70	18.42	24.86	11.82	18.90	4.56	090
21079	A	Prepare face/oral prosthesis	22.31	13.95	17.72	8.09	12.62	3.16	090
21080	A	Prepare face/oral prosthesis	25.06	16.14	20.31	9.01	14.18	3.75	090
21081	A	Prepare face/oral prosthesis	22.85	15.01	18.65	8.40	12.94	3.21	090
21082	A	Prepare face/oral prosthesis	20.84	14.89	17.11	8.26	11.99	3.12	090
21083	A	Prepare face/oral prosthesis	19.27	14.89	16.83	7.77	11.10	2.89	090
21084	A	Prepare face/oral prosthesis	22.48	16.83	19.63	8.94	13.31	2.19	090
21085	A	Prepare face/oral prosthesis	8.99	6.92	7.60	3.51	5.14	1.27	010
21086	A	Prepare face/oral prosthesis	24.88	12.90	18.31	8.44	13.93	3.72	090
21087	A	Prepare face/oral prosthesis	24.88	13.03	18.15	8.54	13.86	3.45	090
21088	C	Prepare face/oral prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	090
21089	C	Prepare face/oral prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	090
21100	A	Maxillofacial fixation	4.56	14.86	13.19	5.53	5.13	0.34	090
21110	A	Interdental fixation	5.80	13.04	11.30	9.73	9.04	0.72	090
21116	A	Injection, jaw joint x-ray	0.81	2.52	3.42	0.23	0.28	0.06	000
21120	A	Reconstruction of chin	4.99	9.64	10.11	6.64	7.06	0.60	090
21121	A	Reconstruction of chin	7.70	10.63	10.18	7.58	7.70	0.90	090
21122	A	Reconstruction of chin	8.59	NA	NA	8.45	8.53	1.07	090
21123	A	Reconstruction of chin	11.22	NA	NA	7.03	8.91	1.40	090
21125	A	Augmentation, lower jaw bone	10.68	63.93	59.56	6.42	7.37	0.79	090
21127	A	Augmentation, lower jaw bone	12.24	84.93	63.85	7.49	8.47	1.52	090
21137	A	Reduction of forehead	10.12	NA	NA	7.43	7.58	1.32	090
21138	A	Reduction of forehead	12.73	NA	NA	7.78	8.65	1.75	090
21139	A	Reduction of forehead	14.90	NA	NA	6.98	9.02	1.18	090
21141	A	Reconstruct midface, lefort	19.27	NA	NA	11.85	12.75	2.36	090
21142	A	Reconstruct midface, lefort	19.98	NA	NA	10.07	11.44	2.39	090
21143	A	Reconstruct midface, lefort	20.75	NA	NA	11.80	13.05	1.66	090
21145	A	Reconstruct midface, lefort	23.64	NA	NA	12.96	13.43	2.85	090
21146	A	Reconstruct midface, lefort	24.54	NA	NA	9.17	12.25	3.10	090
21147	A	Reconstruct midface, lefort	26.14	NA	NA	14.29	14.67	1.85	090
21150	A	Reconstruct midface, lefort	25.78	NA	NA	16.90	16.83	2.56	090
21151	A	Reconstruct midface, lefort	28.84	NA	NA	11.60	17.27	2.31	090
21154	A	Reconstruct midface, lefort	31.05	NA	NA	17.87	20.49	2.49	090
21155	A	Reconstruct midface, lefort	34.98	NA	NA	18.15	21.02	6.66	090
21159	A	Reconstruct midface, lefort	42.90	NA	NA	15.12	22.09	8.20	090
21160	A	Reconstruct midface, lefort	46.95	NA	NA	23.21	25.33	4.14	090
21172	A	Reconstruct orbit/forehead	28.07	NA	NA	13.73	13.74	3.56	090
21175	A	Reconstruct orbit/forehead	33.43	NA	NA	13.51	15.65	4.84	090
21179	A	Reconstruct entire forehead	22.53	NA	NA	11.21	12.66	2.81	090
21180	A	Reconstruct entire forehead	25.46	NA	NA	12.98	14.18	3.49	090
21181	A	Contour cranial bone lesion	10.18	NA	NA	6.82	7.14	1.32	090
21182	A	Reconstruct cranial bone	32.45	NA	NA	15.26	17.18	2.81	090
21183	A	Reconstruct cranial bone	35.57	NA	NA	19.20	20.01	4.48	090
21184	A	Reconstruct cranial bone	38.49	NA	NA	15.61	18.77	5.72	090
21188	A	Reconstruction of midface	22.97	NA	NA	15.63	17.24	1.70	090
21193	A	Reconst lwr jaw w/o graft	18.65	NA	NA	9.80	11.23	2.24	090
21194	A	Reconst lwr jaw w/graft	21.54	NA	NA	12.12	12.93	2.03	090
21195	A	Reconst lwr jaw w/o fixation	18.88	NA	NA	13.06	13.94	1.64	090
21196	A	Reconst lwr jaw w/fixation	20.55	NA	NA	13.93	14.81	2.08	090
21198	A	Reconstr lwr jaw segment	15.48	NA	NA	11.88	12.29	1.44	090
21199	A	Reconstr lwr jaw w/advance	16.62	NA	NA	7.56	8.34	1.39	090
21206	A	Reconstruct upper jaw bone	15.36	NA	NA	10.88	11.75	1.33	090
21208	A	Augmentation of facial bones	11.15	33.14	27.73	8.00	8.79	1.09	090
21209	A	Reduction of facial bones	7.58	12.19	11.49	7.39	7.72	0.90	090
21210	A	Face bone graft	11.40	43.44	34.15	7.63	8.49	1.30	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
21215	A	Lower jaw bone graft	11.94	86.03	63.95	7.96	8.66	1.53	090
21230	A	Rib cartilage graft	11.06	NA	NA	7.01	7.52	1.29	090
21235	A	Ear cartilage graft	7.31	10.10	9.97	6.18	6.29	0.61	090
21240	A	Reconstruction of jaw joint	15.77	NA	NA	9.43	10.73	2.25	090
21242	A	Reconstruction of jaw joint	14.32	NA	NA	9.01	10.25	1.79	090
21243	A	Reconstruction of jaw joint	24.03	NA	NA	14.14	15.78	3.26	090
21244	A	Reconstruction of lower jaw	13.35	NA	NA	11.51	11.80	1.25	090
21245	A	Reconstruction of jaw	12.88	14.20	14.30	8.61	9.23	1.19	090
21246	A	Reconstruction of jaw	12.78	NA	NA	7.42	8.23	1.35	090
21247	A	Reconstruct lower jaw bone	24.05	NA	NA	12.69	15.01	2.84	090
21248	A	Reconstruction of jaw	12.54	12.60	12.36	7.51	8.45	1.55	090
21249	A	Reconstruction of jaw	18.57	15.72	16.22	9.61	11.15	2.49	090
21255	A	Reconstruct lower jaw bone	18.14	NA	NA	14.03	15.08	2.39	090
21256	A	Reconstruction of orbit	17.42	NA	NA	9.57	10.69	1.50	090
21260	A	Revise eye sockets	17.74	NA	NA	12.95	12.85	0.97	090
21261	A	Revise eye sockets	33.78	NA	NA	14.74	19.48	3.43	090
21263	A	Revise eye sockets	30.72	NA	NA	14.03	16.55	2.63	090
21267	A	Revise eye sockets	20.45	NA	NA	16.03	17.90	1.71	090
21268	A	Revise eye sockets	26.78	NA	NA	13.13	16.66	3.66	090
21270	A	Augmentation, cheek bone	10.52	11.15	11.39	5.90	6.57	0.72	090
21275	A	Revision, orbitofacial bones	11.65	NA	NA	7.15	7.65	1.29	090
21280	A	Revision of eyelid	6.92	NA	NA	5.66	5.79	0.42	090
21282	A	Revision of eyelid	4.11	NA	NA	4.16	4.32	0.26	090
21295	A	Revision of jaw muscle/bone	1.82	NA	NA	2.23	2.38	0.16	090
21296	A	Revision of jaw muscle/bone	4.67	NA	NA	5.43	5.16	0.34	090
21299	C	Cranio/maxillofacial surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21310	A	Treatment of nose fracture	0.58	1.99	2.14	0.11	0.13	0.05	000
21315	A	Treatment of nose fracture	1.78	4.71	4.47	1.78	1.83	0.14	010
21320	A	Treatment of nose fracture	1.86	4.29	4.10	1.36	1.49	0.18	010
21325	A	Treatment of nose fracture	4.07	NA	NA	6.97	7.79	0.31	090
21330	A	Treatment of nose fracture	5.68	NA	NA	7.62	8.66	0.56	090
21335	A	Treatment of nose fracture	8.91	NA	NA	8.47	9.04	0.74	090
21336	A	Treat nasal septal fracture	6.56	NA	NA	8.66	9.13	0.55	090
21337	A	Treat nasal septal fracture	3.26	6.14	6.13	3.56	3.56	0.28	090
21338	A	Treat nasoethmoid fracture	6.76	NA	NA	9.92	11.97	0.82	090
21339	A	Treat nasoethmoid fracture	8.39	NA	NA	9.82	11.86	0.96	090
21340	A	Treatment of nose fracture	11.33	NA	NA	7.24	7.82	1.15	090
21343	A	Treatment of sinus fracture	14.11	NA	NA	12.79	14.12	1.47	090
21344	A	Treatment of sinus fracture	21.36	NA	NA	13.05	14.77	2.44	090
21345	A	Treat nose/jaw fracture	8.87	10.48	10.16	6.55	6.86	0.92	090
21346	A	Treat nose/jaw fracture	11.29	NA	NA	10.82	11.51	1.21	090
21347	A	Treat nose/jaw fracture	13.37	NA	NA	11.73	13.96	1.47	090
21348	A	Treat nose/jaw fracture	17.36	NA	NA	10.99	11.05	2.49	090
21355	A	Treat cheek bone fracture	4.32	5.90	6.07	3.25	3.36	0.34	010
21356	A	Treat cheek bone fracture	4.70	6.97	7.04	4.05	4.30	0.46	010
21360	A	Treat cheek bone fracture	7.03	NA	NA	5.39	5.66	0.74	090
21365	A	Treat cheek bone fracture	16.52	NA	NA	9.09	9.95	1.70	090
21366	A	Treat cheek bone fracture	18.44	NA	NA	10.50	10.91	2.50	090
21385	A	Treat eye socket fracture	9.46	NA	NA	7.13	7.70	0.97	090
21386	A	Treat eye socket fracture	9.46	NA	NA	6.00	6.53	0.97	090
21387	A	Treat eye socket fracture	10.00	NA	NA	7.44	8.20	1.08	090
21390	A	Treat eye socket fracture	11.07	NA	NA	7.01	7.40	0.90	090
21395	A	Treat eye socket fracture	14.62	NA	NA	8.33	8.68	1.44	090
21400	A	Treat eye socket fracture	1.44	2.70	2.66	1.96	1.92	0.15	090
21401	A	Treat eye socket fracture	3.57	7.03	7.51	3.04	3.27	0.38	090
21406	A	Treat eye socket fracture	7.31	NA	NA	5.29	5.68	0.73	090
21407	A	Treat eye socket fracture	8.91	NA	NA	5.92	6.39	0.94	090
21408	A	Treat eye socket fracture	12.67	NA	NA	7.44	8.16	1.44	090
21421	A	Treat mouth roof fracture	5.80	12.45	10.89	9.20	8.75	0.73	090
21422	A	Treat mouth roof fracture	8.62	NA	NA	7.04	7.56	0.99	090
21423	A	Treat mouth roof fracture	10.71	NA	NA	7.39	8.36	1.27	090
21431	A	Treat craniofacial fracture	7.74	NA	NA	10.83	10.18	0.70	090
21432	A	Treat craniofacial fracture	8.76	NA	NA	6.81	7.43	0.81	090
21433	A	Treat craniofacial fracture	26.13	NA	NA	12.13	14.26	2.79	090
21435	A	Treat craniofacial fracture	20.02	NA	NA	11.07	11.88	1.99	090
21436	A	Treat craniofacial fracture	30.01	NA	NA	13.13	15.67	3.10	090
21440	A	Treat dental ridge fracture	3.28	10.06	8.58	7.45	6.80	0.38	090
21445	A	Treat dental ridge fracture	6.04	12.27	11.01	8.46	8.41	0.78	090
21450	A	Treat lower jaw fracture	3.55	10.50	8.94	7.71	7.29	0.33	090
21451	A	Treat lower jaw fracture	5.46	12.97	11.16	9.67	9.03	0.63	090
21452	A	Treat lower jaw fracture	2.29	12.02	12.52	6.05	5.33	0.27	090
21453	A	Treat lower jaw fracture	6.40	14.80	12.76	11.64	11.18	0.74	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
21454	A	Treat lower jaw fracture	7.17	NA	NA	5.72	5.99	0.82	090
21461	A	Treat lower jaw fracture	9.07	41.68	33.06	12.80	12.73	0.98	090
21462	A	Treat lower jaw fracture	10.77	42.97	35.28	13.40	13.05	1.27	090
21465	A	Treat lower jaw fracture	12.88	NA	NA	8.11	8.96	1.50	090
21470	A	Treat lower jaw fracture	17.24	NA	NA	10.17	11.09	1.97	090
21480	A	Reset dislocated jaw	0.61	1.52	1.64	0.18	0.18	0.06	000
21485	A	Reset dislocated jaw	4.58	12.09	10.15	9.10	8.38	0.51	090
21490	A	Repair dislocated jaw	12.71	NA	NA	8.12	8.90	1.97	090
21495	A	Treat hyoid bone fracture	6.55	NA	NA	10.47	9.44	0.46	090
21497	A	Interdental wiring	4.45	12.21	10.33	9.34	8.49	0.50	090
21499	C	Head surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21501	A	Drain neck/chest lesion	3.87	6.55	6.49	3.52	3.67	0.43	090
21502	A	Drain chest lesion	7.43	NA	NA	4.56	5.09	0.97	090
21510	A	Drainage of bone lesion	6.06	NA	NA	4.80	5.23	0.80	090
21550	A	Biopsy of neck/chest	2.08	4.35	3.97	1.78	1.75	0.16	010
21555	A	Remove lesion, neck/chest	4.40	5.78	5.65	3.43	3.31	0.56	090
21556	A	Remove lesion, neck/chest	5.63	NA	NA	4.14	4.12	0.65	090
21557	A	Remove tumor, neck/chest	8.91	NA	NA	4.51	4.93	1.08	090
21600	A	Partial removal of rib	7.14	NA	NA	5.96	5.85	0.99	090
21610	A	Partial removal of rib	15.76	NA	NA	8.89	8.88	3.08	090
21615	A	Removal of rib	10.31	NA	NA	5.16	5.92	1.45	090
21616	A	Removal of rib and nerves	12.54	NA	NA	6.51	7.26	1.87	090
21620	A	Partial removal of sternum	7.16	NA	NA	4.76	5.36	0.98	090
21627	A	Sternal debridement	7.18	NA	NA	5.54	5.92	1.02	090
21630	A	Extensive sternum surgery	19.01	NA	NA	10.34	11.09	2.59	090
21632	A	Extensive sternum surgery	19.51	NA	NA	9.42	10.26	2.66	090
21685	A	Hyoid myotomy & suspension	14.89	NA	NA	8.76	9.36	1.06	090
21700	A	Revision of neck muscle	6.23	NA	NA	4.39	4.41	0.32	090
21705	A	Revision of neck muscle/rib	9.83	NA	NA	4.35	4.97	1.43	090
21720	A	Revision of neck muscle	5.72	NA	NA	4.10	3.28	0.91	090
21725	A	Revision of neck muscle	7.10	NA	NA	5.14	5.29	1.21	090
21740	A	Reconstruction of sternum	17.47	NA	NA	8.20	8.35	2.37	090
21742	C	Repair stern/nuss w/o scope	0.00	0.00	0.00	0.00	0.00	0.00	090
21743	C	Repair sternum/nuss w/scope	0.00	0.00	0.00	0.00	0.00	0.00	090
21750	A	Repair of sternum separation	11.35	NA	NA	5.31	5.71	1.63	090
21800	A	Treatment of rib fracture	0.98	1.36	1.35	1.43	1.38	0.09	090
21805	A	Treatment of rib fracture	2.80	NA	NA	3.27	3.23	0.38	090
21810	A	Treatment of rib fracture(s)	6.92	NA	NA	5.37	5.17	0.94	090
21820	A	Treat sternum fracture	1.31	1.82	1.82	1.89	1.83	0.16	090
21825	A	Treat sternum fracture	7.65	NA	NA	5.37	5.88	1.11	090
21899	C	Neck/chest surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21920	A	Biopsy soft tissue of back	2.08	4.43	3.86	1.88	1.67	0.14	010
21925	A	Biopsy soft tissue of back	4.54	5.34	5.25	3.36	3.30	0.60	090
21930	A	Remove lesion, back or flank	5.06	6.04	5.88	3.77	3.58	0.66	090
21935	A	Remove tumor, back	18.38	NA	NA	8.44	9.03	2.48	090
22010	A	I&d, p-spine, c/t/cerv-thor	12.57	NA	NA	8.35	8.61	1.74	090
22015	A	I&d, p-spine, l/s/l	12.46	NA	NA	8.33	8.58	1.72	090
22100	A	Remove part of neck vertebra	10.80	NA	NA	8.19	7.86	2.14	090
22101	A	Remove part, thorax vertebra	10.88	NA	NA	8.11	7.93	1.91	090
22102	A	Remove part, lumbar vertebra	10.88	NA	NA	7.92	8.01	1.88	090
22103	A	Remove extra spine segment	2.34	NA	NA	0.90	1.05	0.44	ZZZ
22110	A	Remove part of neck vertebra	13.80	NA	NA	9.11	9.14	2.77	090
22112	A	Remove part, thorax vertebra	13.87	NA	NA	9.02	9.15	2.53	090
22114	A	Remove part, lumbar vertebra	13.87	NA	NA	9.00	9.13	2.64	090
22116	A	Remove extra spine segment	2.32	NA	NA	0.89	1.03	0.50	ZZZ
22206	A	Cut spine 3 col, thor	37.00	NA	NA	17.71	17.71	6.23	090
22207	A	Cut spine 3 col, lumb	36.50	NA	NA	17.59	17.59	6.07	090
22208	A	Cut spine 3 col, addl seg	9.66	3.72	3.72	3.72	3.72	2.07	ZZZ
22210	A	Revision of neck spine	25.13	NA	NA	14.54	14.97	5.46	090
22212	A	Revision of thorax spine	20.74	NA	NA	12.44	12.85	3.91	090
22214	A	Revision of lumbar spine	20.77	NA	NA	12.53	13.17	3.92	090
22216	A	Revise, extra spine segment	6.03	NA	NA	2.32	2.73	1.29	ZZZ
22220	A	Revision of neck spine	22.69	NA	NA	13.35	13.48	5.08	090
22222	A	Revision of thorax spine	22.84	NA	NA	10.46	10.79	4.13	090
22224	A	Revision of lumbar spine	22.84	NA	NA	12.89	13.55	4.19	090
22226	A	Revise, extra spine segment	6.03	NA	NA	2.28	2.68	1.29	ZZZ
22305	A	Treat spine process fracture	2.08	2.15	2.23	1.80	1.86	0.39	090
22310	A	Treat spine fracture	3.69	2.98	2.89	2.50	2.42	0.50	090
22315	A	Treat spine fracture	9.91	9.88	9.78	7.43	7.38	1.86	090
22318	A	Treat odontoid fx w/o graft	22.54	NA	NA	13.25	13.31	5.30	090
22319	A	Treat odontoid fx w/graft	25.15	NA	NA	13.45	14.07	6.05	090
22325	A	Treat spine fracture	19.62	NA	NA	12.13	12.10	3.88	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
22326	A	Treat neck spine fracture	20.64	NA	NA	12.02	12.36	4.43	090
22327	A	Treat thorax spine fracture	20.52	NA	NA	12.32	12.34	3.99	090
22328	A	Treat each add spine fx	4.60	NA	NA	1.76	2.01	0.94	ZZZ
22505	A	Manipulation of spine	1.87	NA	NA	1.10	1.02	0.36	010
22520	A	Percut vertebroplasty thor	9.17	43.78	52.71	4.58	4.84	1.72	010
22521	A	Percut vertebroplasty lumb	8.60	44.96	50.45	4.36	4.65	1.60	010
22522	A	Percut vertebroplasty add'l	4.30	NA	NA	1.51	1.59	0.82	ZZZ
22523	A	Percut kyphoplasty, thor	9.21	NA	NA	4.67	5.28	1.72	010
22524	A	Percut kyphoplasty, lumbar	8.81	NA	NA	4.52	5.11	1.60	010
22525	A	Percut kyphoplasty, add-on	4.47	NA	NA	1.69	1.98	0.82	ZZZ
22526	A	Idet, single level	6.07	46.67	46.67	2.04	2.04	1.16	010
22527	A	Idet, 1 or more levels	3.03	40.35	40.35	0.70	0.70	0.58	ZZZ
22532	A	Lat thorax spine fusion	25.81	NA	NA	13.77	14.29	4.35	090
22533	A	Lat lumbar spine fusion	24.61	NA	NA	13.56	13.57	3.16	090
22534	A	Lat thor/lumb, add'l seg	5.99	NA	NA	2.28	2.65	1.25	ZZZ
22548	A	Neck spine fusion	26.86	NA	NA	14.92	15.36	5.61	090
22554	A	Neck spine fusion	17.54	NA	NA	10.64	11.49	4.46	090
22556	A	Thorax spine fusion	24.50	NA	NA	12.95	13.83	4.35	090
22558	A	Lumbar spine fusion	23.33	NA	NA	11.42	12.35	3.16	090
22585	A	Additional spinal fusion	5.52	NA	NA	2.05	2.42	1.25	ZZZ
22590	A	Spine & skull spinal fusion	21.56	NA	NA	13.07	13.19	4.79	090
22595	A	Neck spinal fusion	20.44	NA	NA	12.63	12.73	4.41	090
22600	A	Neck spine fusion	17.20	NA	NA	11.19	11.19	3.73	090
22610	A	Thorax spine fusion	17.08	NA	NA	10.81	11.11	3.53	090
22612	A	Lumbar spine fusion	23.38	NA	NA	12.49	13.34	4.47	090
22614	A	Spine fusion, extra segment	6.43	NA	NA	2.45	2.90	1.38	ZZZ
22630	A	Lumbar spine fusion	21.89	NA	NA	12.53	13.06	4.73	090
22632	A	Spine fusion, extra segment	5.22	NA	NA	1.99	2.32	1.16	ZZZ
22800	A	Fusion of spine	19.30	NA	NA	11.15	11.96	3.76	090
22802	A	Fusion of spine	31.91	NA	NA	15.98	17.78	6.17	090
22804	A	Fusion of spine	37.30	NA	NA	18.11	20.40	7.00	090
22808	A	Fusion of spine	27.31	NA	NA	14.05	15.17	4.93	090
22810	A	Fusion of spine	31.30	NA	NA	14.90	16.62	5.15	090
22812	A	Fusion of spine	34.00	NA	NA	17.37	18.71	5.30	090
22818	A	Kyphectomy, 1-2 segments	34.18	NA	NA	16.61	17.73	6.47	090
22819	A	Kyphectomy, 3 or more	39.18	NA	NA	18.86	19.45	7.67	090
22830	A	Exploration of spinal fusion	11.13	NA	NA	7.05	7.50	2.30	090
22840	A	Insert spine fixation device	12.52	NA	NA	4.77	5.63	2.79	ZZZ
22841	B	Insert spine fixation device	0.00	0.00	0.00	0.00	0.00	0.00	XXX
22842	A	Insert spine fixation device	12.56	NA	NA	4.79	5.64	2.75	ZZZ
22843	A	Insert spine fixation device	13.44	NA	NA	5.15	5.88	2.86	ZZZ
22844	A	Insert spine fixation device	16.42	NA	NA	6.40	7.57	3.19	ZZZ
22845	A	Insert spine fixation device	11.94	NA	NA	4.48	5.27	2.86	ZZZ
22846	A	Insert spine fixation device	12.40	NA	NA	4.66	5.49	2.96	ZZZ
22847	A	Insert spine fixation device	13.78	NA	NA	5.19	6.10	3.00	ZZZ
22848	A	Insert pelv fixation device	5.99	NA	NA	2.33	2.76	1.15	ZZZ
22849	A	Reinsert spinal fixation	19.08	NA	NA	10.16	10.94	3.90	090
22850	A	Remove spine fixation device	9.74	NA	NA	6.40	6.69	2.05	090
22851	A	Apply spine prosth device	6.70	NA	NA	2.54	2.95	1.49	ZZZ
22852	A	Remove spine fixation device	9.29	NA	NA	6.17	6.48	1.90	090
22855	A	Remove spine fixation device	15.77	NA	NA	9.17	9.41	3.52	090
22857	R	Lumbar artif diskectomy	26.93	NA	NA	14.80	14.80	3.56	090
22862	R	Revise lumbar artif disc	32.43	NA	NA	10.06	10.06	5.36	090
22865	R	Remove lumb artif disc	31.55	NA	NA	9.86	9.86	5.18	090
22899	C	Spine surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
22900	A	Remove abdominal wall lesion	6.14	NA	NA	3.53	3.38	0.76	090
22999	C	Abdomen surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
23000	A	Removal of calcium deposits	4.40	7.88	8.20	3.73	4.07	0.68	090
23020	A	Release shoulder joint	9.24	NA	NA	6.48	7.02	1.54	090
23030	A	Drain shoulder lesion	3.44	6.28	6.83	2.40	2.65	0.57	010
23031	A	Drain shoulder bursa	2.76	6.51	7.18	2.21	2.47	0.46	010
23035	A	Drain shoulder bone lesion	9.04	NA	NA	6.45	7.35	1.47	090
23040	A	Exploratory shoulder surgery	9.63	NA	NA	6.74	7.30	1.60	090
23044	A	Exploratory shoulder surgery	7.48	NA	NA	5.51	5.97	1.24	090
23065	A	Biopsy shoulder tissues	2.28	2.95	2.72	1.74	1.68	0.20	010
23066	A	Biopsy shoulder tissues	4.21	7.75	7.71	3.61	3.79	0.63	090
23075	A	Removal of shoulder lesion	2.41	3.70	3.68	1.72	1.75	0.34	010
23076	A	Removal of shoulder lesion	7.77	NA	NA	5.32	5.43	1.13	090
23077	A	Remove tumor of shoulder	18.08	NA	NA	9.60	9.90	2.34	090
23100	A	Biopsy of shoulder joint	6.09	NA	NA	4.99	5.32	1.04	090
23101	A	Shoulder joint surgery	5.63	NA	NA	4.53	4.93	0.96	090
23105	A	Remove shoulder joint lining	8.36	NA	NA	6.09	6.60	1.42	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
23106	A	Incision of collarbone joint	6.02	NA	NA	4.78	5.24	0.99	090
23107	A	Explore treat shoulder joint	8.75	NA	NA	6.25	6.82	1.49	090
23120	A	Partial removal, collar bone	7.23	NA	NA	5.47	5.96	1.23	090
23125	A	Removal of collar bone	9.52	NA	NA	6.39	6.97	1.62	090
23130	A	Remove shoulder bone, part	7.63	NA	NA	6.07	6.60	1.30	090
23140	A	Removal of bone lesion	7.01	NA	NA	4.90	5.06	1.08	090
23145	A	Removal of bone lesion	9.28	NA	NA	6.49	6.96	1.49	090
23146	A	Removal of bone lesion	7.96	NA	NA	5.91	6.51	1.35	090
23150	A	Removal of humerus lesion	8.79	NA	NA	6.25	6.58	1.32	090
23155	A	Removal of humerus lesion	10.72	NA	NA	7.25	7.78	1.81	090
23156	A	Removal of humerus lesion	8.99	NA	NA	6.28	6.83	1.50	090
23170	A	Remove collar bone lesion	7.10	NA	NA	5.00	5.51	1.12	090
23172	A	Remove shoulder blade lesion	7.20	NA	NA	5.51	5.90	1.01	090
23174	A	Remove humerus lesion	9.90	NA	NA	7.17	7.76	1.65	090
23180	A	Remove collar bone lesion	8.85	NA	NA	6.41	7.70	1.47	090
23182	A	Remove shoulder blade lesion	8.47	NA	NA	6.42	7.48	1.37	090
23184	A	Remove humerus lesion	9.76	NA	NA	6.92	8.12	1.63	090
23190	A	Partial removal of scapula	7.36	NA	NA	5.31	5.74	1.17	090
23195	A	Removal of head of humerus	10.24	NA	NA	6.91	7.32	1.71	090
23200	A	Removal of collar bone	12.69	NA	NA	7.11	7.92	1.94	090
23210	A	Removal of shoulder blade	13.16	NA	NA	7.80	8.40	2.03	090
23220	A	Partial removal of humerus	15.36	NA	NA	9.14	9.98	2.49	090
23221	A	Partial removal of humerus	18.41	NA	NA	10.61	11.16	3.06	090
23222	A	Partial removal of humerus	25.44	NA	NA	13.33	14.55	3.95	090
23330	A	Remove shoulder foreign body	1.87	3.35	3.52	1.51	1.70	0.24	010
23331	A	Remove shoulder foreign body	7.51	NA	NA	5.83	6.31	1.27	090
23332	A	Remove shoulder foreign body	12.23	NA	NA	7.96	8.64	2.03	090
23350	A	Injection for shoulder x-ray	1.00	2.73	3.09	0.35	0.34	0.06	000
23395	A	Muscle transfer, shoulder/arm	18.29	NA	NA	11.20	12.03	2.94	090
23397	A	Muscle transfers	16.62	NA	NA	9.54	10.45	2.74	090
23400	A	Fixation of shoulder blade	13.73	NA	NA	8.54	9.30	2.30	090
23405	A	Incision of tendon & muscle	8.43	NA	NA	5.92	6.42	1.45	090
23406	A	Incise tendon(s) & muscle(s)	10.90	NA	NA	6.90	7.62	1.88	090
23410	A	Repair rotator cuff, acute	12.63	NA	NA	7.77	8.59	2.17	090
23412	A	Repair rotator cuff, chronic	13.55	NA	NA	8.15	9.02	2.32	090
23415	A	Release of shoulder ligament	10.09	NA	NA	6.58	7.28	1.74	090
23420	A	Repair of shoulder	14.75	NA	NA	9.70	10.27	2.32	090
23430	A	Repair biceps tendon	10.05	NA	NA	6.77	7.43	1.74	090
23440	A	Remove/transplant tendon	10.53	NA	NA	6.77	7.51	1.83	090
23450	A	Repair shoulder capsule	13.58	NA	NA	8.17	9.00	2.33	090
23455	A	Repair shoulder capsule	14.55	NA	NA	8.55	9.49	2.50	090
23460	A	Repair shoulder capsule	15.68	NA	NA	9.36	10.36	2.67	090
23462	A	Repair shoulder capsule	15.60	NA	NA	9.07	9.91	2.60	090
23465	A	Repair shoulder capsule	16.16	NA	NA	9.49	10.33	2.77	090
23466	A	Repair shoulder capsule	15.55	NA	NA	9.99	10.67	2.47	090
23470	A	Reconstruct shoulder joint	17.75	NA	NA	10.11	11.18	2.99	090
23472	A	Reconstruct shoulder joint	22.47	NA	NA	12.14	13.27	3.67	090
23480	A	Revision of collar bone	11.42	NA	NA	7.29	8.03	1.95	090
23485	A	Revision of collar bone	13.79	NA	NA	8.20	9.04	2.34	090
23490	A	Reinforce clavicle	12.04	NA	NA	6.74	7.72	1.47	090
23491	A	Reinforce shoulder bones	14.40	NA	NA	8.71	9.71	2.47	090
23500	A	Treat clavicle fracture	2.13	2.64	2.76	2.71	2.62	0.30	090
23505	A	Treat clavicle fracture	3.74	4.01	4.21	3.61	3.73	0.61	090
23515	A	Treat clavicle fracture	9.53	NA	NA	7.00	6.77	1.28	090
23520	A	Treat clavicle dislocation	2.21	2.77	2.81	2.84	2.79	0.34	090
23525	A	Treat clavicle dislocation	3.67	4.16	4.35	3.64	3.79	0.46	090
23530	A	Treat clavicle dislocation	7.37	NA	NA	5.30	5.62	1.20	090
23532	A	Treat clavicle dislocation	8.08	NA	NA	6.01	6.49	1.38	090
23540	A	Treat clavicle dislocation	2.28	2.66	2.76	2.73	2.55	0.29	090
23545	A	Treat clavicle dislocation	3.32	3.74	3.96	3.26	3.31	0.35	090
23550	A	Treat clavicle dislocation	7.48	NA	NA	5.54	5.95	1.25	090
23552	A	Treat clavicle dislocation	8.70	NA	NA	6.25	6.78	1.46	090
23570	A	Treat shoulder blade fx	2.28	2.78	2.89	2.92	2.91	0.36	090
23575	A	Treat shoulder blade fx	4.12	4.59	4.73	4.08	4.19	0.59	090
23585	A	Treat scapula fracture	14.07	NA	NA	8.50	8.07	1.54	090
23600	A	Treat humerus fracture	3.00	4.07	4.31	3.65	3.60	0.48	090
23605	A	Treat humerus fracture	4.94	5.38	5.76	4.59	4.85	0.84	090
23615	A	Treat humerus fracture	12.12	NA	NA	8.05	8.44	1.62	090
23616	A	Treat humerus fracture	18.19	NA	NA	10.45	12.29	3.70	090
23620	A	Treat humerus fracture	2.46	3.41	3.51	3.14	3.06	0.40	090
23625	A	Treat humerus fracture	3.99	4.44	4.69	3.91	4.09	0.67	090
23630	A	Treat humerus fracture	10.39	NA	NA	7.36	7.00	1.27	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
23650	A	Treat shoulder dislocation	3.44	3.29	3.53	2.82	2.79	0.30	090
23655	A	Treat shoulder dislocation	4.64	NA	NA	4.15	4.16	0.69	090
23660	A	Treat shoulder dislocation	7.55	NA	NA	5.68	6.03	1.29	090
23665	A	Treat dislocation/fracture	4.54	4.85	5.09	4.26	4.49	0.71	090
23670	A	Treat dislocation/fracture	12.12	NA	NA	7.92	7.37	1.36	090
23675	A	Treat dislocation/fracture	6.13	6.12	6.47	5.13	5.48	1.01	090
23680	A	Treat dislocation/fracture	12.99	NA	NA	8.23	8.16	1.76	090
23700	A	Fixation of shoulder	2.54	NA	NA	1.90	2.04	0.44	010
23800	A	Fusion of shoulder joint	14.59	NA	NA	8.86	9.63	2.36	090
23802	A	Fusion of shoulder joint	18.17	NA	NA	11.20	10.68	2.71	090
23900	A	Amputation of arm & girdle	20.57	NA	NA	10.41	11.06	3.19	090
23920	A	Amputation at shoulder joint	16.03	NA	NA	9.21	9.56	2.47	090
23921	A	Amputation follow-up surgery	5.61	NA	NA	4.85	4.96	0.78	090
23929	C	Shoulder surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
23930	A	Drainage of arm lesion	2.96	4.98	5.65	1.98	2.14	0.43	010
23931	A	Drainage of arm bursa	1.81	4.35	5.13	1.75	1.96	0.28	010
23935	A	Drain arm/elbow bone lesion	6.27	NA	NA	5.09	5.50	1.05	090
24000	A	Exploratory elbow surgery	5.99	NA	NA	4.75	5.08	0.97	090
24006	A	Release elbow joint	9.62	NA	NA	6.59	7.17	1.50	090
24065	A	Biopsy arm/elbow soft tissue	2.10	4.15	3.68	1.92	1.83	0.17	010
24066	A	Biopsy arm/elbow soft tissue	5.26	8.26	8.60	3.92	4.02	0.80	090
24075	A	Remove arm/elbow lesion	3.96	7.18	7.26	3.26	3.33	0.56	090
24076	A	Remove arm/elbow lesion	6.36	NA	NA	4.59	4.72	0.95	090
24077	A	Remove tumor of arm/elbow	11.95	NA	NA	6.85	7.29	1.73	090
24100	A	Biopsy elbow joint lining	4.98	NA	NA	4.09	4.30	0.85	090
24101	A	Explore/treat elbow joint	6.19	NA	NA	5.04	5.49	1.03	090
24102	A	Remove elbow joint lining	8.15	NA	NA	5.80	6.33	1.33	090
24105	A	Removal of elbow bursa	3.67	NA	NA	4.02	4.20	0.61	090
24110	A	Remove humerus lesion	7.46	NA	NA	5.65	6.15	1.28	090
24115	A	Remove/graft bone lesion	10.00	NA	NA	4.32	5.76	1.68	090
24116	A	Remove/graft bone lesion	12.11	NA	NA	7.67	8.37	2.06	090
24120	A	Remove elbow lesion	6.71	NA	NA	5.17	5.55	1.10	090
24125	A	Remove/graft bone lesion	8.02	NA	NA	5.99	6.07	1.06	090
24126	A	Remove/graft bone lesion	8.50	NA	NA	6.00	6.51	1.16	090
24130	A	Removal of head of radius	6.31	NA	NA	5.12	5.57	1.04	090
24134	A	Removal of arm bone lesion	10.10	NA	NA	6.90	7.87	1.64	090
24136	A	Remove radius bone lesion	8.29	NA	NA	5.76	6.49	1.38	090
24138	A	Remove elbow bone lesion	8.33	NA	NA	6.48	7.13	1.34	090
24140	A	Partial removal of arm bone	9.43	NA	NA	6.57	7.83	1.51	090
24145	A	Partial removal of radius	7.70	NA	NA	5.64	6.84	1.25	090
24147	A	Partial removal of elbow	7.69	NA	NA	6.28	7.43	1.30	090
24149	A	Radical resection of elbow	15.92	NA	NA	10.76	11.19	2.35	090
24150	A	Extensive humerus surgery	13.70	NA	NA	8.49	9.24	2.33	090
24151	A	Extensive humerus surgery	16.08	NA	NA	9.68	10.59	2.60	090
24152	A	Extensive radius surgery	10.24	NA	NA	6.16	6.94	1.48	090
24153	A	Extensive radius surgery	11.73	NA	NA	4.87	5.22	0.74	090
24155	A	Removal of elbow joint	11.97	NA	NA	7.41	7.90	1.93	090
24160	A	Remove elbow joint implant	7.89	NA	NA	5.82	6.35	1.30	090
24164	A	Remove radius head implant	6.34	NA	NA	4.89	5.33	1.03	090
24200	A	Removal of arm foreign body	1.78	2.74	3.07	1.36	1.49	0.20	010
24201	A	Removal of arm foreign body	4.61	7.79	8.80	3.66	3.94	0.72	090
24220	A	Injection for elbow x-ray	1.31	2.66	3.14	0.46	0.45	0.08	000
24300	A	Manipulate elbow w/anesth	3.86	NA	NA	5.16	5.43	0.65	090
24301	A	Muscle/tendon transfer	10.26	NA	NA	6.83	7.50	1.66	090
24305	A	Arm tendon lengthening	7.51	NA	NA	5.65	6.18	1.15	090
24310	A	Revision of arm tendon	6.03	NA	NA	4.73	5.15	0.96	090
24320	A	Repair of arm tendon	10.74	NA	NA	7.02	7.27	1.74	090
24330	A	Revision of arm muscles	9.67	NA	NA	6.63	7.25	1.60	090
24331	A	Revision of arm muscles	10.83	NA	NA	6.94	7.81	1.78	090
24332	A	Tenolysis, triceps	7.77	NA	NA	5.91	6.34	1.23	090
24340	A	Repair of biceps tendon	7.96	NA	NA	5.96	6.47	1.36	090
24341	A	Repair arm tendon/muscle	9.24	NA	NA	7.52	7.71	1.36	090
24342	A	Repair of ruptured tendon	10.74	NA	NA	7.06	7.79	1.86	090
24343	A	Repr elbow lat ligmnt w/tiss	8.99	NA	NA	6.98	7.56	1.43	090
24344	A	Reconstruct elbow lat ligmnt	14.97	NA	NA	9.95	10.73	2.37	090
24345	A	Repr elbw med ligmnt w/tissu	8.99	NA	NA	6.93	7.47	1.44	090
24346	A	Reconstruct elbow med ligmnt	14.97	NA	NA	10.03	10.68	2.34	090
24357	A	Repair elbow, perc	5.32	NA	NA	4.72	5.15	0.87	090
24358	A	Repair elbow w/deb, open	6.54	NA	NA	5.27	5.73	1.07	090
24359	A	Repair elbow deb/attch open	8.86	NA	NA	6.19	6.19	1.41	090
24360	A	Reconstruct elbow joint	12.53	NA	NA	7.84	8.65	2.06	090
24361	A	Reconstruct elbow joint	14.27	NA	NA	8.75	9.66	2.19	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
24362	A	Reconstruct elbow joint	15.18	NA	NA	5.73	7.88	2.61	090
24363	A	Replace elbow joint	22.47	NA	NA	12.16	12.93	3.02	090
24365	A	Reconstruct head of radius	8.51	NA	NA	5.96	6.58	1.41	090
24366	A	Reconstruct head of radius	9.25	NA	NA	6.30	6.92	1.52	090
24400	A	Revision of humerus	11.19	NA	NA	7.49	8.17	1.93	090
24410	A	Revision of humerus	14.96	NA	NA	9.24	9.77	2.58	090
24420	A	Revision of humerus	13.58	NA	NA	8.50	9.52	2.18	090
24430	A	Repair of humerus	15.07	NA	NA	9.22	9.48	2.22	090
24435	A	Repair humerus with graft	14.74	NA	NA	9.80	10.34	2.28	090
24470	A	Revision of elbow joint	8.81	NA	NA	5.65	6.68	1.48	090
24495	A	Decompression of forearm	8.30	NA	NA	6.41	7.57	1.18	090
24498	A	Reinforce humerus	12.16	NA	NA	7.66	8.46	2.07	090
24500	A	Treat humerus fracture	3.29	4.45	4.64	3.80	3.74	0.50	090
24505	A	Treat humerus fracture	5.25	5.83	6.21	4.87	5.13	0.89	090
24515	A	Treat humerus fracture	11.97	NA	NA	8.03	8.71	2.03	090
24516	A	Treat humerus fracture	12.07	NA	NA	7.64	8.37	2.03	090
24530	A	Treat humerus fracture	3.57	4.73	4.97	4.00	4.02	0.57	090
24535	A	Treat humerus fracture	6.96	6.81	7.32	5.86	6.24	1.18	090
24538	A	Treat humerus fracture	9.63	NA	NA	7.18	7.94	1.64	090
24545	A	Treat humerus fracture	12.99	NA	NA	8.27	8.36	1.83	090
24546	A	Treat humerus fracture	14.73	NA	NA	9.10	10.20	2.74	090
24560	A	Treat humerus fracture	2.87	4.11	4.29	3.43	3.31	0.44	090
24565	A	Treat humerus fracture	5.64	5.93	6.27	5.04	5.28	0.93	090
24566	A	Treat humerus fracture	8.86	NA	NA	6.79	7.47	1.30	090
24575	A	Treat humerus fracture	9.53	NA	NA	6.96	7.68	1.87	090
24576	A	Treat humerus fracture	2.94	4.41	4.58	3.71	3.71	0.46	090
24577	A	Treat humerus fracture	5.87	6.03	6.48	5.08	5.46	0.95	090
24579	A	Treat humerus fracture	11.26	NA	NA	7.74	8.28	2.03	090
24582	A	Treat humerus fracture	9.89	NA	NA	8.17	8.64	1.48	090
24586	A	Treat elbow fracture	15.64	NA	NA	9.31	10.27	2.65	090
24587	A	Treat elbow fracture	15.65	NA	NA	9.31	10.16	2.53	090
24600	A	Treat elbow dislocation	4.28	3.86	4.36	3.28	3.39	0.50	090
24605	A	Treat elbow dislocation	5.50	NA	NA	4.91	5.13	0.89	090
24615	A	Treat elbow dislocation	9.72	NA	NA	6.55	7.18	1.60	090
24620	A	Treat elbow fracture	7.07	NA	NA	5.48	5.87	1.07	090
24635	A	Treat elbow fracture	8.64	NA	NA	6.55	10.29	2.29	090
24640	A	Treat elbow dislocation	1.22	1.52	1.68	0.83	0.81	0.12	010
24650	A	Treat radius fracture	2.22	3.42	3.60	2.99	2.87	0.35	090
24655	A	Treat radius fracture	4.48	5.18	5.56	4.40	4.59	0.70	090
24665	A	Treat radius fracture	8.22	NA	NA	6.51	7.01	1.41	090
24666	A	Treat radius fracture	9.74	NA	NA	6.95	7.50	1.62	090
24670	A	Treat ulnar fracture	2.60	3.72	3.91	3.15	3.11	0.41	090
24675	A	Treat ulnar fracture	4.79	5.37	5.68	4.57	4.77	0.81	090
24685	A	Treat ulnar fracture	8.21	NA	NA	6.51	7.01	1.52	090
24800	A	Fusion of elbow joint	11.27	NA	NA	6.88	7.81	1.63	090
24802	A	Fusion/graft of elbow joint	14.18	NA	NA	8.02	9.20	2.38	090
24900	A	Amputation of upper arm	10.04	NA	NA	6.41	6.73	1.53	090
24920	A	Amputation of upper arm	10.02	NA	NA	6.03	6.48	1.61	090
24925	A	Amputation follow-up surgery	7.19	NA	NA	4.94	5.51	1.14	090
24930	A	Amputation follow-up surgery	10.72	NA	NA	6.19	6.71	1.68	090
24931	A	Amputate upper arm & implant	13.32	NA	NA	5.07	5.40	1.90	090
24935	A	Revision of amputation	16.30	NA	NA	10.46	9.24	2.14	090
24940	C	Revision of upper arm	0.00	0.00	0.00	0.00	0.00	0.00	090
24999	C	Upper arm/elbow surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
25000	A	Incision of tendon sheath	3.44	NA	NA	3.98	5.42	0.55	090
25001	A	Incise flexor carpi radialis	3.68	NA	NA	3.94	4.08	0.55	090
25020	A	Decompress forearm 1 space	5.97	NA	NA	6.94	8.25	0.93	090
25023	A	Decompress forearm 1 space	13.69	NA	NA	11.32	13.12	2.04	090
25024	A	Decompress forearm 2 spaces	10.62	NA	NA	7.08	7.27	1.36	090
25025	A	Decompress forearm 2 spaces	17.77	NA	NA	9.69	9.83	1.83	090
25028	A	Drainage of forearm lesion	5.30	NA	NA	6.19	7.17	0.81	090
25031	A	Drainage of forearm bursa	4.18	NA	NA	3.49	5.70	0.63	090
25035	A	Treat forearm bone lesion	7.54	NA	NA	5.62	9.60	1.24	090
25040	A	Explore/treat wrist joint	7.41	NA	NA	5.39	6.34	1.15	090
25065	A	Biopsy forearm soft tissues	2.01	4.33	3.77	1.98	1.94	0.15	010
25066	A	Biopsy forearm soft tissues	4.18	NA	NA	3.83	5.45	0.64	090
25075	A	Removal forearm lesion subcu	3.78	NA	NA	3.31	4.60	0.55	090
25076	A	Removal forearm lesion deep	4.97	NA	NA	4.11	6.82	0.74	090
25077	A	Remove tumor, forearm/wrist	9.90	NA	NA	6.17	9.13	1.42	090
25085	A	Incision of wrist capsule	5.55	NA	NA	4.61	5.86	0.85	090
25100	A	Biopsy of wrist joint	3.94	NA	NA	3.77	4.52	0.59	090
25101	A	Explore/treat wrist joint	4.74	NA	NA	4.35	5.12	0.75	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
25105	A	Remove wrist joint lining	5.91	NA	NA	4.97	6.13	0.92	090
25107	A	Remove wrist joint cartilage	7.50	NA	NA	6.24	7.28	0.99	090
25109	A	Excise tendon forearm/wrist	6.81	NA	NA	5.23	5.23	0.96	090
25110	A	Remove wrist tendon lesion	3.96	NA	NA	3.62	5.33	0.62	090
25111	A	Remove wrist tendon lesion	3.44	NA	NA	3.61	4.15	0.53	090
25112	A	Reremove wrist tendon lesion	4.58	NA	NA	4.07	4.66	0.70	090
25115	A	Remove wrist/forearm lesion	9.89	NA	NA	7.33	10.68	1.31	090
25116	A	Remove wrist/forearm lesion	7.38	NA	NA	6.18	9.66	1.11	090
25118	A	Excise wrist tendon sheath	4.42	NA	NA	4.14	4.94	0.68	090
25119	A	Partial removal of ulna	6.10	NA	NA	5.06	6.33	0.96	090
25120	A	Removal of forearm lesion	6.16	NA	NA	5.09	8.58	1.00	090
25125	A	Remove/graft forearm lesion	7.55	NA	NA	5.68	9.26	1.06	090
25126	A	Remove/graft forearm lesion	7.62	NA	NA	5.86	9.43	1.27	090
25130	A	Removal of wrist lesion	5.32	NA	NA	4.72	5.57	0.80	090
25135	A	Remove & graft wrist lesion	6.96	NA	NA	5.62	6.56	1.02	090
25136	A	Remove & graft wrist lesion	6.03	NA	NA	5.09	5.84	1.03	090
25145	A	Remove forearm bone lesion	6.43	NA	NA	5.21	8.63	1.01	090
25150	A	Partial removal of ulna	7.27	NA	NA	5.53	6.86	1.14	090
25151	A	Partial removal of radius	7.57	NA	NA	5.64	9.18	1.18	090
25170	A	Extensive forearm surgery	11.34	NA	NA	7.36	11.25	1.78	090
25210	A	Removal of wrist bone	6.01	NA	NA	5.04	5.91	0.88	090
25215	A	Removal of wrist bones	8.02	NA	NA	6.02	7.39	1.19	090
25230	A	Partial removal of radius	5.28	NA	NA	4.49	5.32	0.79	090
25240	A	Partial removal of ulna	5.22	NA	NA	4.46	5.70	0.81	090
25246	A	Injection for wrist x-ray	1.45	2.73	3.08	0.53	0.50	0.09	000
25248	A	Remove forearm foreign body	5.20	NA	NA	4.04	6.28	0.72	090
25250	A	Removal of wrist prosthesis	6.66	NA	NA	5.27	5.68	1.01	090
25251	A	Removal of wrist prosthesis	9.70	NA	NA	6.74	7.33	1.26	090
25259	A	Manipulate wrist w/anesthes	3.86	NA	NA	5.15	5.43	0.62	090
25260	A	Repair forearm tendon/muscle	7.89	NA	NA	6.37	9.84	1.19	090
25263	A	Repair forearm tendon/muscle	7.90	NA	NA	6.09	9.67	1.18	090
25265	A	Repair forearm tendon/muscle	9.96	NA	NA	7.10	10.70	1.47	090
25270	A	Repair forearm tendon/muscle	6.06	NA	NA	4.97	8.49	0.95	090
25272	A	Repair forearm tendon/muscle	7.10	NA	NA	5.48	9.13	1.11	090
25274	A	Repair forearm tendon/muscle	8.82	NA	NA	6.37	9.99	1.36	090
25275	A	Repair forearm tendon sheath	8.82	NA	NA	6.48	7.02	1.31	090
25280	A	Revise wrist/forearm tendon	7.28	NA	NA	5.55	9.09	1.08	090
25290	A	Incise wrist/forearm tendon	5.34	NA	NA	4.50	9.74	0.82	090
25295	A	Release wrist/forearm tendon	6.61	NA	NA	5.29	8.72	1.00	090
25300	A	Fusion of tendons at wrist	8.88	NA	NA	6.65	7.55	1.26	090
25301	A	Fusion of tendons at wrist	8.47	NA	NA	6.18	7.12	1.29	090
25310	A	Transplant forearm tendon	8.26	NA	NA	5.93	9.48	1.21	090
25312	A	Transplant forearm tendon	9.70	NA	NA	6.70	10.32	1.41	090
25315	A	Revise palsy hand tendon(s)	10.56	NA	NA	7.10	10.74	1.58	090
25316	A	Revise palsy hand tendon(s)	12.76	NA	NA	7.81	12.01	1.75	090
25320	A	Repair/revise wrist joint	12.38	NA	NA	9.86	10.62	1.61	090
25332	A	Revise wrist joint	11.60	NA	NA	7.60	8.39	1.84	090
25335	A	Realignment of hand	13.25	NA	NA	8.30	9.94	1.93	090
25337	A	Reconstruct ulna/radioulnar	11.44	NA	NA	8.62	9.85	1.61	090
25350	A	Revision of radius	8.97	NA	NA	6.34	10.15	1.46	090
25355	A	Revision of radius	10.41	NA	NA	6.74	10.67	1.74	090
25360	A	Revision of ulna	8.62	NA	NA	6.23	10.05	1.41	090
25365	A	Revise radius & ulna	12.77	NA	NA	8.17	11.90	2.16	090
25370	A	Revise radius or ulna	13.93	NA	NA	9.00	12.53	2.29	090
25375	A	Revise radius & ulna	13.41	NA	NA	8.36	12.39	2.27	090
25390	A	Shorten radius or ulna	10.58	NA	NA	7.06	10.82	1.65	090
25391	A	Lengthen radius or ulna	14.14	NA	NA	8.66	12.60	2.22	090
25392	A	Shorten radius & ulna	14.44	NA	NA	8.90	12.43	2.11	090
25393	A	Lengthen radius & ulna	16.42	NA	NA	9.55	13.56	2.77	090
25394	A	Repair carpal bone, shorten	10.71	NA	NA	6.94	7.50	1.59	090
25400	A	Repair radius or ulna	11.16	NA	NA	7.26	11.22	1.83	090
25405	A	Repair/graft radius or ulna	14.87	NA	NA	8.92	13.09	2.33	090
25415	A	Repair radius & ulna	13.66	NA	NA	8.79	12.64	2.18	090
25420	A	Repair/graft radius & ulna	16.89	NA	NA	9.92	14.09	2.62	090
25425	A	Repair/graft radius or ulna	13.58	NA	NA	8.48	14.93	2.09	090
25426	A	Repair/graft radius & ulna	16.31	NA	NA	9.19	12.86	2.55	090
25430	A	Vasc graft into carpal bone	9.57	NA	NA	7.03	7.18	1.27	090
25431	A	Repair nonunion carpal bone	10.75	NA	NA	7.15	7.77	1.91	090
25440	A	Repair/graft wrist bone	10.56	NA	NA	6.89	8.14	1.63	090
25441	A	Reconstruct wrist joint	13.15	NA	NA	8.10	9.05	2.08	090
25442	A	Reconstruct wrist joint	10.98	NA	NA	7.50	8.19	1.53	090
25443	A	Reconstruct wrist joint	10.52	NA	NA	7.21	7.99	1.37	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
25444	A	Reconstruct wrist joint	11.28	NA	NA	7.43	8.23	1.72	090
25445	A	Reconstruct wrist joint	9.76	NA	NA	6.69	7.34	1.55	090
25446	A	Wrist replacement	17.16	NA	NA	9.98	10.94	2.48	090
25447	A	Repair wrist joint(s)	10.95	NA	NA	7.86	8.26	1.61	090
25449	A	Remove wrist joint implant	14.80	NA	NA	8.95	9.81	2.22	090
25450	A	Revision of wrist joint	7.94	NA	NA	3.84	7.01	1.36	090
25455	A	Revision of wrist joint	9.57	NA	NA	6.84	8.85	0.96	090
25490	A	Reinforce radius	9.61	NA	NA	6.57	10.15	1.43	090
25491	A	Reinforce ulna	10.03	NA	NA	6.78	10.62	1.60	090
25492	A	Reinforce radius and ulna	12.52	NA	NA	8.33	11.81	2.15	090
25500	A	Treat fracture of radius	2.51	3.30	3.44	2.86	2.79	0.35	090
25505	A	Treat fracture of radius	5.30	5.82	6.18	4.98	5.20	0.90	090
25515	A	Treat fracture of radius	8.64	NA	NA	6.46	6.96	1.59	090
25520	A	Treat fracture of radius	6.35	5.69	6.27	5.14	5.60	1.08	090
25525	A	Treat fracture of radius	10.37	NA	NA	7.41	8.70	2.13	090
25526	A	Treat fracture of radius	12.96	NA	NA	8.68	11.09	2.20	090
25530	A	Treat fracture of ulna	2.15	3.48	3.62	2.97	2.92	0.34	090
25535	A	Treat fracture of ulna	5.22	5.57	5.79	4.83	5.06	0.89	090
25545	A	Treat fracture of ulna	7.78	NA	NA	6.23	6.94	1.53	090
25560	A	Treat fracture radius & ulna	2.50	3.36	3.53	2.85	2.73	0.35	090
25565	A	Treat fracture radius & ulna	5.71	5.90	6.30	4.92	5.17	0.93	090
25574	A	Treat fracture radius & ulna	8.64	NA	NA	6.55	6.87	1.21	090
25575	A	Treat fracture radius/ulna	12.10	NA	NA	8.36	8.93	1.82	090
25600	A	Treat fracture radius/ulna	2.69	3.68	3.88	3.17	3.07	0.42	090
25605	A	Treat fracture radius/ulna	7.02	6.86	7.04	6.13	6.17	1.00	090
25606	A	Treat fx distal radial	8.10	NA	NA	6.69	7.82	1.26	090
25607	A	Treat fx rad extra-articul	9.35	NA	NA	7.19	7.19	1.36	090
25608	A	Treat fx rad intra-articul	10.86	NA	NA	7.79	7.79	1.84	090
25609	A	Treat fx radial 3+ frag	14.12	NA	NA	9.65	9.65	2.38	090
25622	A	Treat wrist bone fracture	2.68	3.90	4.08	3.35	3.23	0.41	090
25624	A	Treat wrist bone fracture	4.62	5.63	5.96	4.77	4.92	0.76	090
25628	A	Treat wrist bone fracture	9.51	NA	NA	6.84	7.33	1.37	090
25630	A	Treat wrist bone fracture	2.94	3.75	3.96	3.25	3.09	0.45	090
25635	A	Treat wrist bone fracture	4.47	5.11	5.53	4.34	4.12	0.74	090
25645	A	Treat wrist bone fracture	7.31	NA	NA	5.55	6.09	1.20	090
25650	A	Treat wrist bone fracture	3.12	3.84	4.07	3.44	3.31	0.45	090
25651	A	Pin ulnar styloid fracture	5.68	NA	NA	5.15	5.31	0.86	090
25652	A	Treat fracture ulnar styloid	7.92	NA	NA	6.16	6.58	1.21	090
25660	A	Treat wrist dislocation	4.84	NA	NA	4.32	4.51	0.58	090
25670	A	Treat wrist dislocation	7.98	NA	NA	5.81	6.40	1.28	090
25671	A	Pin radioulnar dislocation	6.32	NA	NA	5.53	5.84	1.00	090
25675	A	Treat wrist dislocation	4.75	4.71	5.18	3.99	4.32	0.62	090
25676	A	Treat wrist dislocation	8.17	NA	NA	6.13	6.71	1.34	090
25680	A	Treat wrist fracture	6.08	NA	NA	4.38	4.56	0.78	090
25685	A	Treat wrist fracture	9.97	NA	NA	6.62	7.21	1.60	090
25690	A	Treat wrist dislocation	5.58	NA	NA	4.85	5.17	0.88	090
25695	A	Treat wrist dislocation	8.40	NA	NA	6.00	6.54	1.32	090
25800	A	Fusion of wrist joint	9.95	NA	NA	6.79	7.94	1.57	090
25805	A	Fusion/graft of wrist joint	11.59	NA	NA	7.67	8.96	1.81	090
25810	A	Fusion/graft of wrist joint	11.75	NA	NA	8.03	8.97	1.68	090
25820	A	Fusion of hand bones	7.52	NA	NA	6.41	7.12	1.22	090
25825	A	Fuse hand bones with graft	9.54	NA	NA	7.65	8.44	1.41	090
25830	A	Fusion, radioulnar jnt/ulna	10.69	NA	NA	10.57	12.49	1.55	090
25900	A	Amputation of forearm	9.46	NA	NA	6.73	9.64	1.30	090
25905	A	Amputation of forearm	9.48	NA	NA	6.06	9.17	1.40	090
25907	A	Amputation follow-up surgery	7.98	NA	NA	5.77	8.76	1.10	090
25909	A	Amputation follow-up surgery	9.20	NA	NA	6.32	9.30	1.44	090
25915	A	Amputation of forearm	17.38	NA	NA	5.97	12.42	2.94	090
25920	A	Amputate hand at wrist	8.92	NA	NA	6.59	7.21	1.35	090
25922	A	Amputate hand at wrist	7.54	NA	NA	6.27	6.66	1.12	090
25924	A	Amputation follow-up surgery	8.70	NA	NA	6.12	7.10	1.32	090
25927	A	Amputation of hand	8.98	NA	NA	8.65	10.16	1.27	090
25929	A	Amputation follow-up surgery	7.71	NA	NA	5.66	5.77	1.14	090
25931	A	Amputation follow-up surgery	7.93	NA	NA	8.32	9.89	1.15	090
25999	C	Forearm or wrist surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
26010	A	Drainage of finger abscess	1.56	4.06	4.81	1.52	1.57	0.18	010
26011	A	Drainage of finger abscess	2.21	6.24	7.53	1.96	2.14	0.33	010
26020	A	Drain hand tendon sheath	4.97	NA	NA	4.74	5.05	0.73	090
26025	A	Drainage of palm bursa	4.99	NA	NA	4.46	4.78	0.76	090
26030	A	Drainage of palm bursa(s)	6.16	NA	NA	5.00	5.36	0.92	090
26034	A	Treat hand bone lesion	6.49	NA	NA	5.57	5.96	1.01	090
26035	A	Decompress fingers/hand	11.14	NA	NA	8.12	7.99	1.47	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
26037	A	Decompress fingers/hand	7.48	NA	NA	5.49	5.91	1.13	090
26040	A	Release palm contracture	3.38	NA	NA	3.60	3.82	0.53	090
26045	A	Release palm contracture	5.62	NA	NA	4.88	5.26	0.93	090
26055	A	Incise finger tendon sheath	3.00	9.04	11.69	3.82	3.88	0.43	090
26060	A	Incision of finger tendon	2.85	NA	NA	3.05	3.28	0.45	090
26070	A	Explore/treat hand joint	3.73	NA	NA	3.05	3.21	0.48	090
26075	A	Explore/treat finger joint	3.83	NA	NA	3.37	3.57	0.53	090
26080	A	Explore/treat finger joint	4.36	NA	NA	4.32	4.58	0.66	090
26100	A	Biopsy hand joint lining	3.71	NA	NA	3.66	3.89	0.54	090
26105	A	Biopsy finger joint lining	3.75	NA	NA	3.68	3.95	0.59	090
26110	A	Biopsy finger joint lining	3.57	NA	NA	3.60	3.82	0.53	090
26115	A	Removal hand lesion subcut	3.92	9.83	11.46	4.23	4.49	0.59	090
26116	A	Removal hand lesion, deep	5.61	NA	NA	5.30	5.65	0.84	090
26117	A	Remove tumor, hand/finger	8.62	NA	NA	6.18	6.62	1.26	090
26121	A	Release palm contracture	7.61	NA	NA	5.92	6.44	1.17	090
26123	A	Release palm contracture	10.63	NA	NA	8.21	8.53	1.43	090
26125	A	Release palm contracture	4.60	NA	NA	1.87	2.15	0.70	ZZZ
26130	A	Remove wrist joint lining	5.48	NA	NA	4.88	5.11	0.94	090
26135	A	Revise finger joint, each	7.02	NA	NA	5.47	5.96	1.07	090
26140	A	Revise finger joint, each	6.23	NA	NA	5.16	5.60	0.92	090
26145	A	Tendon excision, palm/finger	6.38	NA	NA	5.18	5.62	0.97	090
26160	A	Remove tendon sheath lesion	3.46	9.03	10.70	3.94	4.03	0.49	090
26170	A	Removal of palm tendon, each	4.82	NA	NA	4.37	4.65	0.69	090
26180	A	Removal of finger tendon	5.24	NA	NA	4.71	5.06	0.78	090
26185	A	Remove finger bone	6.32	NA	NA	5.73	5.88	0.81	090
26200	A	Remove hand bone lesion	5.56	NA	NA	4.55	4.95	0.88	090
26205	A	Remove/graft bone lesion	7.82	NA	NA	5.85	6.37	1.20	090
26210	A	Removal of finger lesion	5.21	NA	NA	4.73	5.08	0.79	090
26215	A	Remove/graft finger lesion	7.16	NA	NA	5.54	5.92	0.98	090
26230	A	Partial removal of hand bone	6.38	NA	NA	4.95	5.43	1.01	090
26235	A	Partial removal, finger bone	6.24	NA	NA	4.94	5.38	0.95	090
26236	A	Partial removal, finger bone	5.37	NA	NA	4.57	4.95	0.81	090
26250	A	Extensive hand surgery	7.61	NA	NA	5.71	6.07	1.07	090
26255	A	Extensive hand surgery	12.80	NA	NA	8.28	8.82	1.69	090
26260	A	Extensive finger surgery	7.09	NA	NA	5.46	5.82	1.01	090
26261	A	Extensive finger surgery	9.28	NA	NA	6.72	6.44	1.14	090
26262	A	Partial removal of finger	5.72	NA	NA	4.74	5.04	0.88	090
26320	A	Removal of implant from hand	4.02	NA	NA	3.79	4.05	0.59	090
26340	A	Manipulate finger w/anesth	2.62	NA	NA	4.60	4.74	0.39	090
26350	A	Repair finger/hand tendon	6.07	NA	NA	9.52	12.06	0.93	090
26352	A	Repair/graft hand tendon	7.75	NA	NA	10.06	12.70	1.13	090
26356	A	Repair finger/hand tendon	10.22	NA	NA	13.70	16.03	1.21	090
26357	A	Repair finger/hand tendon	8.65	NA	NA	10.35	12.99	1.33	090
26358	A	Repair/graft hand tendon	9.22	NA	NA	10.94	13.79	1.38	090
26370	A	Repair finger/hand tendon	7.17	NA	NA	9.50	12.30	1.12	090
26372	A	Repair/graft hand tendon	8.89	NA	NA	10.53	13.52	1.40	090
26373	A	Repair finger/hand tendon	8.29	NA	NA	10.16	13.10	1.23	090
26390	A	Revise hand/finger tendon	9.31	NA	NA	9.20	11.24	1.40	090
26392	A	Repair/graft hand tendon	10.38	NA	NA	11.16	13.94	1.57	090
26410	A	Repair hand tendon	4.68	NA	NA	7.63	9.78	0.73	090
26412	A	Repair/graft hand tendon	6.37	NA	NA	8.62	10.94	0.97	090
26415	A	Excision, hand/finger tendon	8.40	NA	NA	7.46	9.62	0.98	090
26416	A	Graft hand or finger tendon	9.44	NA	NA	9.04	11.81	0.79	090
26418	A	Repair finger tendon	4.33	NA	NA	8.14	10.23	0.67	090
26420	A	Repair/graft finger tendon	6.83	NA	NA	8.80	11.21	1.07	090
26426	A	Repair finger/hand tendon	6.21	NA	NA	5.11	9.13	0.95	090
26428	A	Repair/graft finger tendon	7.28	NA	NA	9.25	11.55	1.09	090
26432	A	Repair finger tendon	4.07	NA	NA	6.78	8.52	0.64	090
26433	A	Repair finger tendon	4.61	NA	NA	7.01	8.90	0.72	090
26434	A	Repair/graft finger tendon	6.15	NA	NA	7.93	9.73	0.93	090
26437	A	Realignment of tendons	5.88	NA	NA	7.81	9.68	0.89	090
26440	A	Release palm/finger tendon	5.07	NA	NA	8.48	10.95	0.75	090
26442	A	Release palm & finger tendon	9.50	NA	NA	11.81	13.87	1.20	090
26445	A	Release hand/finger tendon	4.36	NA	NA	8.23	10.68	0.65	090
26449	A	Release forearm/hand tendon	8.34	NA	NA	7.27	11.52	1.06	090
26450	A	Incision of palm tendon	3.71	NA	NA	5.19	6.26	0.59	090
26455	A	Incision of finger tendon	3.68	NA	NA	5.15	6.21	0.58	090
26460	A	Incise hand/finger tendon	3.50	NA	NA	5.11	6.12	0.55	090
26471	A	Fusion of finger tendons	5.79	NA	NA	7.79	9.51	0.88	090
26474	A	Fusion of finger tendons	5.38	NA	NA	7.60	9.49	0.76	090
26476	A	Tendon lengthening	5.24	NA	NA	7.35	9.14	0.79	090
26477	A	Tendon shortening	5.21	NA	NA	7.57	9.31	0.81	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
26478	A	Lengthening of hand tendon	5.86	NA	NA	7.78	9.80	0.90	090
26479	A	Shortening of hand tendon	5.80	NA	NA	7.73	9.64	0.92	090
26480	A	Transplant hand tendon	6.76	NA	NA	9.65	12.34	1.02	090
26483	A	Transplant/graft hand tendon	8.36	NA	NA	10.22	12.85	1.26	090
26485	A	Transplant palm tendon	7.77	NA	NA	10.07	12.71	1.15	090
26489	A	Transplant/graft palm tendon	9.74	NA	NA	10.82	11.43	1.26	090
26490	A	Revise thumb tendon	8.48	NA	NA	8.87	10.84	1.21	090
26492	A	Tendon transfer with graft	9.70	NA	NA	9.82	11.71	1.40	090
26494	A	Hand tendon/muscle transfer	8.54	NA	NA	9.23	11.10	1.28	090
26496	A	Revise thumb tendon	9.66	NA	NA	9.57	11.40	1.45	090
26497	A	Finger tendon transfer	9.64	NA	NA	9.52	11.54	1.41	090
26498	A	Finger tendon transfer	14.07	NA	NA	11.65	13.90	2.11	090
26499	A	Revision of finger	9.05	NA	NA	8.84	10.94	1.35	090
26500	A	Hand tendon reconstruction	6.02	NA	NA	7.74	9.59	0.90	090
26502	A	Hand tendon reconstruction	7.20	NA	NA	8.32	10.17	1.13	090
26508	A	Release thumb contracture	6.07	NA	NA	7.80	9.73	0.98	090
26510	A	Thumb tendon transfer	5.49	NA	NA	7.63	9.48	0.79	090
26516	A	Fusion of knuckle joint	7.21	NA	NA	8.30	10.26	1.10	090
26517	A	Fusion of knuckle joints	8.96	NA	NA	8.99	11.24	1.41	090
26518	A	Fusion of knuckle joints	9.15	NA	NA	8.96	11.17	1.35	090
26520	A	Release knuckle contracture	5.36	NA	NA	8.86	11.37	0.80	090
26525	A	Release finger contracture	5.39	NA	NA	8.88	11.42	0.81	090
26530	A	Revise knuckle joint	6.76	NA	NA	5.41	5.77	1.04	090
26531	A	Revise knuckle with implant	7.99	NA	NA	6.16	6.64	1.17	090
26535	A	Revise finger joint	5.30	NA	NA	4.09	3.91	0.71	090
26536	A	Revise/implant finger joint	6.44	NA	NA	9.24	9.44	0.96	090
26540	A	Repair hand joint	6.49	NA	NA	8.05	9.96	0.99	090
26541	A	Repair hand joint with graft	8.69	NA	NA	9.11	11.25	1.28	090
26542	A	Repair hand joint with graft	6.84	NA	NA	8.19	10.11	1.02	090
26545	A	Reconstruct finger joint	6.99	NA	NA	8.45	10.29	1.05	090
26546	A	Repair nonunion hand	10.53	NA	NA	11.42	13.22	1.44	090
26548	A	Reconstruct finger joint	8.10	NA	NA	8.80	10.82	1.20	090
26550	A	Construct thumb replacement	21.54	NA	NA	14.53	16.05	2.46	090
26551	A	Great toe-hand transfer	48.23	NA	NA	17.15	24.79	7.98	090
26553	A	Single transfer, toe-hand	47.92	NA	NA	27.34	25.01	2.42	090
26554	A	Double transfer, toe-hand	56.73	NA	NA	35.78	36.65	9.44	090
26555	A	Positional change of finger	16.94	NA	NA	13.99	16.08	2.49	090
26556	A	Toe joint transfer	49.43	NA	NA	18.03	25.67	2.58	090
26560	A	Repair of web finger	5.43	NA	NA	6.65	8.22	0.85	090
26561	A	Repair of web finger	10.98	NA	NA	9.50	10.92	1.45	090
26562	A	Repair of web finger	16.40	NA	NA	8.76	12.95	2.24	090
26565	A	Correct metacarpal flaw	6.80	NA	NA	8.15	10.07	1.00	090
26567	A	Correct finger deformity	6.88	NA	NA	8.11	10.03	1.04	090
26568	A	Lengthen metacarpal/finger	9.15	NA	NA	10.69	13.05	1.49	090
26580	A	Repair hand deformity	19.50	NA	NA	9.73	11.68	2.29	090
26587	A	Reconstruct extra finger	14.36	NA	NA	8.01	8.61	1.53	090
26590	A	Repair finger deformity	18.51	NA	NA	12.41	13.17	2.78	090
26591	A	Repair muscles of hand	3.30	NA	NA	6.21	7.91	0.48	090
26593	A	Release muscles of hand	5.38	NA	NA	7.79	9.46	0.78	090
26596	A	Excision constricting tissue	9.02	NA	NA	7.48	8.15	1.43	090
26600	A	Treat metacarpal fracture	2.48	3.83	3.72	3.49	3.07	0.30	090
26605	A	Treat metacarpal fracture	2.92	4.08	4.32	3.50	3.58	0.49	090
26607	A	Treat metacarpal fracture	5.40	NA	NA	4.88	5.58	0.87	090
26608	A	Treat metacarpal fracture	5.43	NA	NA	5.22	5.74	0.88	090
26615	A	Treat metacarpal fracture	6.91	NA	NA	6.01	5.66	0.86	090
26641	A	Treat thumb dislocation	4.01	4.03	4.30	3.40	3.46	0.39	090
26645	A	Treat thumb fracture	4.47	4.60	4.88	3.92	4.05	0.67	090
26650	A	Treat thumb fracture	5.19	NA	NA	4.88	5.78	0.94	090
26665	A	Treat thumb fracture	7.78	NA	NA	6.31	6.46	0.90	090
26670	A	Treat hand dislocation	3.74	3.62	3.94	3.03	2.99	0.39	090
26675	A	Treat hand dislocation	4.71	5.25	5.36	4.51	4.49	0.77	090
26676	A	Pin hand dislocation	5.60	NA	NA	5.56	6.12	0.91	090
26685	A	Treat hand dislocation	6.91	NA	NA	5.97	6.05	1.09	090
26686	A	Treat hand dislocation	8.06	NA	NA	6.07	6.48	1.24	090
26700	A	Treat knuckle dislocation	3.74	3.30	3.53	2.93	2.89	0.35	090
26705	A	Treat knuckle dislocation	4.26	4.74	5.04	4.04	4.17	0.66	090
26706	A	Pin knuckle dislocation	5.19	NA	NA	4.70	4.89	0.81	090
26715	A	Treat knuckle dislocation	6.87	NA	NA	5.99	5.75	0.91	090
26720	A	Treat finger fracture, each	1.70	2.58	2.68	2.30	2.18	0.24	090
26725	A	Treat finger fracture, each	3.39	4.08	4.42	3.41	3.45	0.53	090
26727	A	Treat finger fracture, each	5.30	NA	NA	5.18	5.70	0.84	090
26735	A	Treat finger fracture, each	7.26	NA	NA	6.12	5.84	0.95	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
26740	A	Treat finger fracture, each	1.99	3.01	3.07	2.71	2.71	0.31	090
26742	A	Treat finger fracture, each	3.90	4.26	4.62	3.56	3.72	0.58	090
26746	A	Treat finger fracture, each	9.59	NA	NA	7.19	6.38	0.91	090
26750	A	Treat finger fracture, each	1.74	2.25	2.36	2.26	2.14	0.22	090
26755	A	Treat finger fracture, each	3.15	3.74	4.08	2.94	2.97	0.42	090
26756	A	Pin finger fracture, each	4.46	NA	NA	4.86	5.29	0.71	090
26765	A	Treat finger fracture, each	5.70	NA	NA	5.47	4.93	0.66	090
26770	A	Treat finger dislocation	3.07	2.92	3.17	2.54	2.48	0.27	090
26775	A	Treat finger dislocation	3.78	4.62	4.90	3.88	3.84	0.54	090
26776	A	Pin finger dislocation	4.87	NA	NA	4.98	5.49	0.77	090
26785	A	Treat finger dislocation	6.44	NA	NA	5.77	5.15	0.68	090
26820	A	Thumb fusion with graft	8.33	NA	NA	8.96	11.10	1.30	090
26841	A	Fusion of thumb	7.21	NA	NA	8.76	10.99	1.18	090
26842	A	Thumb fusion with graft	8.37	NA	NA	9.01	11.19	1.32	090
26843	A	Fusion of hand joint	7.67	NA	NA	8.56	10.45	1.15	090
26844	A	Fusion/graft of hand joint	8.86	NA	NA	9.15	11.25	1.33	090
26850	A	Fusion of knuckle	7.03	NA	NA	8.26	10.23	1.06	090
26852	A	Fusion of knuckle with graft	8.59	NA	NA	9.13	11.01	1.22	090
26860	A	Fusion of finger joint	4.76	NA	NA	7.53	9.35	0.73	090
26861	A	Fusion of finger jnt, add-on	1.74	NA	NA	0.70	0.81	0.27	ZZZ
26862	A	Fusion/graft of finger joint	7.44	NA	NA	8.66	10.50	1.10	090
26863	A	Fuse/graft added joint	3.89	NA	NA	1.58	1.85	0.56	ZZZ
26910	A	Amputate metacarpal bone	7.67	NA	NA	8.27	9.74	1.16	090
26951	A	Amputation of finger/thumb	5.85	NA	NA	8.39	9.27	0.71	090
26952	A	Amputation of finger/thumb	6.37	NA	NA	7.90	9.78	0.95	090
26989	C	Hand/finger surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
26990	A	Drainage of pelvis lesion	7.84	NA	NA	6.20	6.70	1.22	090
26991	A	Drainage of pelvis bursa	6.97	8.61	9.88	4.88	5.15	1.11	090
26992	A	Drainage of bone lesion	13.37	NA	NA	8.41	9.39	2.17	090
27000	A	Incision of hip tendon	5.66	NA	NA	4.51	4.90	0.98	090
27001	A	Incision of hip tendon	7.05	NA	NA	5.22	5.66	1.24	090
27003	A	Incision of hip tendon	7.70	NA	NA	5.72	6.10	1.12	090
27005	A	Incision of hip tendon	9.96	NA	NA	6.48	7.15	1.73	090
27006	A	Incision of hip tendons	9.99	NA	NA	6.75	7.36	1.70	090
27025	A	Incision of hip/thigh fascia	12.66	NA	NA	8.20	8.37	1.85	090
27030	A	Drainage of hip joint	13.54	NA	NA	8.03	8.83	2.27	090
27033	A	Exploration of hip joint	13.99	NA	NA	8.39	9.15	2.33	090
27035	A	Denervation of hip joint	17.23	NA	NA	8.52	9.87	2.16	090
27036	A	Excision of hip joint/muscle	14.18	NA	NA	8.91	9.45	2.27	090
27040	A	Biopsy of soft tissues	2.89	5.19	5.21	1.87	1.94	0.27	010
27041	A	Biopsy of soft tissues	10.07	NA	NA	5.73	6.18	1.35	090
27047	A	Remove hip/pelvis lesion	7.51	7.02	7.06	4.49	4.63	1.03	090
27048	A	Remove hip/pelvis lesion	6.44	NA	NA	4.60	4.70	0.92	090
27049	A	Remove tumor, hip/pelvis	15.20	NA	NA	8.16	8.28	2.07	090
27050	A	Biopsy of sacroiliac joint	4.65	NA	NA	3.01	3.71	0.60	090
27052	A	Biopsy of hip joint	7.27	NA	NA	5.64	5.76	1.08	090
27054	A	Removal of hip joint lining	9.09	NA	NA	6.49	6.91	1.47	090
27060	A	Removal of ischial bursa	5.78	NA	NA	4.36	4.37	0.80	090
27062	A	Remove femur lesion/bursa	5.66	NA	NA	4.60	4.89	0.93	090
27065	A	Removal of hip bone lesion	6.44	NA	NA	4.99	5.21	1.01	090
27066	A	Removal of hip bone lesion	11.06	NA	NA	7.43	7.93	1.80	090
27067	A	Remove/graft hip bone lesion	14.57	NA	NA	8.83	9.74	1.85	090
27070	A	Partial removal of hip bone	11.44	NA	NA	8.02	8.58	1.75	090
27071	A	Partial removal of hip bone	12.25	NA	NA	8.47	9.29	1.93	090
27075	A	Extensive hip surgery	36.77	NA	NA	16.13	17.66	5.66	090
27076	A	Extensive hip surgery	24.25	NA	NA	12.82	13.66	3.71	090
27077	A	Extensive hip surgery	42.54	NA	NA	19.92	21.29	6.14	090
27078	A	Extensive hip surgery	14.54	NA	NA	8.81	9.37	2.23	090
27079	A	Extensive hip surgery	14.91	NA	NA	8.00	8.77	1.95	090
27080	A	Removal of tail bone	6.80	NA	NA	4.58	4.70	0.93	090
27086	A	Remove hip foreign body	1.89	3.66	4.10	1.48	1.65	0.25	010
27087	A	Remove hip foreign body	8.72	NA	NA	5.65	6.15	1.35	090
27090	A	Removal of hip prosthesis	11.57	NA	NA	7.40	8.09	1.95	090
27091	A	Removal of hip prosthesis	24.15	NA	NA	12.90	13.44	3.85	090
27093	A	Injection for hip x-ray	1.30	3.15	3.80	0.47	0.48	0.13	000
27095	A	Injection for hip x-ray	1.50	3.71	4.71	0.51	0.51	0.14	000
27096	A	Inject sacroiliac joint	1.40	2.52	3.43	0.33	0.33	0.08	000
27097	A	Revision of hip tendon	9.16	NA	NA	6.33	6.37	1.57	090
27098	A	Transfer tendon to pelvis	9.20	NA	NA	4.91	5.96	0.95	090
27100	A	Transfer of abdominal muscle	11.21	NA	NA	7.39	8.03	1.86	090
27105	A	Transfer of spinal muscle	11.90	NA	NA	7.35	8.25	1.73	090
27110	A	Transfer of iliopsoas muscle	13.63	NA	NA	8.27	8.69	2.19	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
27111	A	Transfer of iliopsoas muscle	12.46	NA	NA	8.06	8.60	1.95	090
27120	A	Reconstruction of hip socket	19.10	NA	NA	10.81	11.32	3.09	090
27122	A	Reconstruction of hip socket	15.95	NA	NA	9.43	10.23	2.62	090
27125	A	Partial hip replacement	16.46	NA	NA	9.59	10.10	2.55	090
27130	A	Total hip arthroplasty	21.61	NA	NA	11.76	12.53	3.51	090
27132	A	Total hip arthroplasty	25.49	NA	NA	13.42	14.52	4.05	090
27134	A	Revise hip joint replacement	30.13	NA	NA	14.67	16.23	4.95	090
27137	A	Revise hip joint replacement	22.55	NA	NA	11.72	12.82	3.68	090
27138	A	Revise hip joint replacement	23.55	NA	NA	12.10	13.24	3.85	090
27140	A	Transplant femur ridge	12.66	NA	NA	7.87	8.64	2.12	090
27146	A	Incision of hip bone	18.72	NA	NA	10.68	11.40	2.97	090
27147	A	Revision of hip bone	21.87	NA	NA	12.00	12.62	3.58	090
27151	A	Incision of hip bones	23.92	NA	NA	12.87	10.41	3.92	090
27156	A	Revision of hip bones	26.03	NA	NA	13.71	14.88	4.22	090
27158	A	Revision of pelvis	20.89	NA	NA	11.51	11.23	3.17	090
27161	A	Incision of neck of femur	17.74	NA	NA	10.35	11.22	2.95	090
27165	A	Incision/fixation of femur	20.06	NA	NA	11.56	12.23	3.11	090
27170	A	Repair/graft femur head/neck	17.46	NA	NA	9.75	10.52	2.82	090
27175	A	Treat slipped epiphysis	9.29	NA	NA	5.16	5.91	1.46	090
27176	A	Treat slipped epiphysis	12.78	NA	NA	8.17	8.59	2.23	090
27177	A	Treat slipped epiphysis	15.94	NA	NA	9.63	10.26	2.62	090
27178	A	Treat slipped epiphysis	12.78	NA	NA	7.97	8.19	2.09	090
27179	A	Revise head/neck of femur	13.83	NA	NA	8.56	9.27	2.26	090
27181	A	Treat slipped epiphysis	15.98	NA	NA	9.73	9.96	1.57	090
27185	A	Revision of femur epiphysis	9.67	NA	NA	6.64	7.08	2.40	090
27187	A	Reinforce hip bones	14.09	NA	NA	8.68	9.50	2.38	090
27193	A	Treat pelvic ring fracture	5.98	4.62	4.85	4.75	4.92	0.96	090
27194	A	Treat pelvic ring fracture	10.08	NA	NA	6.60	7.12	1.65	090
27200	A	Treat tail bone fracture	1.87	2.07	2.15	2.22	2.19	0.28	090
27202	A	Treat tail bone fracture	7.25	NA	NA	4.90	10.88	1.06	090
27215	A	Treat pelvic fracture(s)	10.45	NA	NA	6.54	6.81	1.98	090
27216	A	Treat pelvic ring fracture	15.73	NA	NA	9.13	9.36	2.64	090
27217	A	Treat pelvic ring fracture	14.65	NA	NA	8.62	9.38	2.42	090
27218	A	Treat pelvic ring fracture	20.93	NA	NA	11.32	11.35	3.49	090
27220	A	Treat hip socket fracture	6.72	5.24	5.48	5.14	5.39	1.07	090
27222	A	Treat hip socket fracture	13.97	NA	NA	8.51	9.24	2.20	090
27226	A	Treat hip wall fracture	15.45	NA	NA	8.92	8.36	2.49	090
27227	A	Treat hip fracture(s)	25.21	NA	NA	13.37	14.38	4.06	090
27228	A	Treat hip fracture(s)	29.13	NA	NA	14.83	16.22	4.67	090
27230	A	Treat thigh fracture	5.69	4.93	5.22	4.86	4.98	0.95	090
27232	A	Treat thigh fracture	11.66	NA	NA	6.09	6.63	1.86	090
27235	A	Treat thigh fracture	12.88	NA	NA	7.97	8.71	2.12	090
27236	A	Treat thigh fracture	17.43	NA	NA	10.13	10.58	2.72	090
27238	A	Treat thigh fracture	5.64	NA	NA	4.65	4.89	0.89	090
27240	A	Treat thigh fracture	13.66	NA	NA	8.20	8.83	2.17	090
27244	A	Treat thigh fracture	17.08	NA	NA	9.61	10.45	2.78	090
27245	A	Treat thigh fracture	21.09	NA	NA	11.33	12.53	3.53	090
27246	A	Treat thigh fracture	4.75	3.91	4.18	3.94	4.18	0.81	090
27248	A	Treat thigh fracture	10.64	NA	NA	6.37	7.29	1.82	090
27250	A	Treat hip dislocation	7.21	NA	NA	4.29	4.45	0.62	090
27252	A	Treat hip dislocation	10.92	NA	NA	6.48	6.95	1.66	090
27253	A	Treat hip dislocation	13.46	NA	NA	8.16	8.97	2.25	090
27254	A	Treat hip dislocation	18.80	NA	NA	10.53	11.27	3.18	090
27256	A	Treat hip dislocation	4.25	2.52	3.02	1.41	1.74	0.46	010
27257	A	Treat hip dislocation	5.35	NA	NA	2.54	2.67	0.69	010
27258	A	Treat hip dislocation	16.04	NA	NA	9.47	10.17	2.65	090
27259	A	Treat hip dislocation	23.03	NA	NA	12.77	13.44	3.75	090
27265	A	Treat hip dislocation	5.12	NA	NA	3.94	4.36	0.63	090
27266	A	Treat hip dislocation	7.67	NA	NA	5.50	5.92	1.29	090
27267	A	Cltx thigh fx	5.38	NA	NA	4.39	4.39	0.89	090
27268	A	Cltx thigh fx w/mnpj	7.00	NA	NA	5.02	5.02	1.16	090
27269	A	Optx thigh fx	18.75	NA	NA	9.88	9.88	2.93	090
27275	A	Manipulation of hip joint	2.29	NA	NA	1.85	1.97	0.39	010
27280	A	Fusion of sacroiliac joint	14.49	NA	NA	8.87	9.56	2.54	090
27282	A	Fusion of pubic bones	11.71	NA	NA	7.77	7.88	1.87	090
27284	A	Fusion of hip joint	24.91	NA	NA	12.00	13.37	3.93	090
27286	A	Fusion of hip joint	24.97	NA	NA	12.60	14.19	3.13	090
27290	A	Amputation of leg at hip	24.38	NA	NA	12.10	13.07	3.44	090
27295	A	Amputation of leg at hip	19.54	NA	NA	9.57	10.44	2.96	090
27299	C	Pelvis/hip joint surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
27301	A	Drain thigh/knee lesion	6.67	8.19	9.13	4.64	4.89	1.04	090
27303	A	Drainage of bone lesion	8.52	NA	NA	5.99	6.48	1.43	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
27305	A	Incise thigh tendon & fascia	6.09	NA	NA	4.68	4.93	1.01	090
27306	A	Incision of thigh tendon	4.66	NA	NA	4.07	4.39	0.85	090
27307	A	Incision of thigh tendons	5.97	NA	NA	4.74	5.06	1.04	090
27310	A	Exploration of knee joint	9.88	NA	NA	6.77	7.17	1.61	090
27323	A	Biopsy, thigh soft tissues	2.30	4.19	3.85	1.93	1.90	0.24	010
27324	A	Biopsy, thigh soft tissues	4.95	NA	NA	3.82	4.00	0.75	090
27325	A	Neurectomy, hamstring	7.09	NA	NA	4.99	4.96	1.09	090
27326	A	Neurectomy, popliteal	6.36	NA	NA	5.12	5.17	1.06	090
27327	A	Removal of thigh lesion	4.52	6.03	6.01	3.57	3.65	0.64	090
27328	A	Removal of thigh lesion	5.62	NA	NA	4.06	4.21	0.84	090
27329	A	Remove tumor, thigh/knee	15.68	NA	NA	8.46	8.74	2.15	090
27330	A	Biopsy, knee joint lining	5.02	NA	NA	4.26	4.41	0.86	090
27331	A	Explore/treat knee joint	5.93	NA	NA	4.79	5.16	1.02	090
27332	A	Removal of knee cartilage	8.34	NA	NA	6.12	6.62	1.43	090
27333	A	Removal of knee cartilage	7.43	NA	NA	5.68	6.17	1.26	090
27334	A	Remove knee joint lining	9.07	NA	NA	6.43	6.92	1.51	090
27335	A	Remove knee joint lining	10.43	NA	NA	7.01	7.61	1.75	090
27340	A	Removal of kneecap bursa	4.23	NA	NA	4.03	4.29	0.72	090
27345	A	Removal of knee cyst	5.98	NA	NA	4.88	5.25	1.00	090
27347	A	Remove knee cyst	6.58	NA	NA	5.25	5.34	0.98	090
27350	A	Removal of kneecap	8.54	NA	NA	6.24	6.74	1.41	090
27355	A	Remove femur lesion	7.89	NA	NA	5.80	6.29	1.32	090
27356	A	Remove femur lesion/graft	9.97	NA	NA	6.83	7.34	1.65	090
27357	A	Remove femur lesion/graft	11.02	NA	NA	7.47	8.08	1.96	090
27358	A	Remove femur lesion/fixation	4.73	NA	NA	1.81	2.16	0.82	ZZZ
27360	A	Partial removal, leg bone(s)	11.34	NA	NA	8.04	8.79	1.84	090
27365	A	Extensive leg surgery	17.93	NA	NA	10.40	11.04	2.80	090
27370	A	Injection for knee x-ray	0.96	2.99	3.36	0.36	0.34	0.08	000
27372	A	Removal of foreign body	5.12	8.30	9.17	4.04	4.36	0.84	090
27380	A	Repair of kneecap tendon	7.34	NA	NA	6.05	6.66	1.24	090
27381	A	Repair/graft kneecap tendon	10.64	NA	NA	7.56	8.32	1.80	090
27385	A	Repair of thigh muscle	8.00	NA	NA	6.30	6.96	1.36	090
27386	A	Repair/graft of thigh muscle	10.99	NA	NA	7.92	8.71	1.86	090
27390	A	Incision of thigh tendon	5.44	NA	NA	4.46	4.78	0.92	090
27391	A	Incision of thigh tendons	7.38	NA	NA	5.54	6.05	1.23	090
27392	A	Incision of thigh tendons	9.51	NA	NA	6.66	7.12	1.57	090
27393	A	Lengthening of thigh tendon	6.50	NA	NA	4.95	5.39	1.10	090
27394	A	Lengthening of thigh tendons	8.68	NA	NA	6.14	6.68	1.47	090
27395	A	Lengthening of thigh tendons	12.10	NA	NA	7.92	8.62	2.05	090
27396	A	Transplant of thigh tendon	8.04	NA	NA	5.82	6.41	1.34	090
27397	A	Transplants of thigh tendons	12.46	NA	NA	8.34	8.69	1.83	090
27400	A	Revise thigh muscles/tendons	9.21	NA	NA	6.51	6.88	1.31	090
27403	A	Repair of knee cartilage	8.51	NA	NA	6.02	6.60	1.44	090
27405	A	Repair of knee ligament	8.96	NA	NA	6.38	6.93	1.51	090
27407	A	Repair of knee ligament	10.71	NA	NA	6.82	7.57	1.79	090
27409	A	Repair of knee ligaments	13.57	NA	NA	8.25	9.10	2.25	090
27412	A	Autochondrocyte implant knee	24.53	NA	NA	13.64	14.22	4.36	090
27415	A	Osteochondral knee allograft	19.79	NA	NA	11.77	12.16	4.36	090
27416	A	Osteochondral knee autograft	14.00	NA	NA	8.38	8.38	2.32	090
27418	A	Repair degenerated kneecap	11.46	NA	NA	7.57	8.23	1.89	090
27420	A	Revision of unstable kneecap	10.14	NA	NA	6.90	7.50	1.72	090
27422	A	Revision of unstable kneecap	10.09	NA	NA	6.87	7.49	1.71	090
27424	A	Revision/removal of kneecap	10.12	NA	NA	6.89	7.49	1.71	090
27425	A	Lat retinacular release open	5.28	NA	NA	4.70	5.11	0.90	090
27427	A	Reconstruction, knee	9.67	NA	NA	6.69	7.24	1.63	090
27428	A	Reconstruction, knee	15.33	NA	NA	10.03	10.63	2.43	090
27429	A	Reconstruction, knee	17.24	NA	NA	11.25	11.83	2.71	090
27430	A	Revision of thigh muscles	10.04	NA	NA	6.84	7.41	1.70	090
27435	A	Incision of knee joint	10.68	NA	NA	7.58	8.03	1.70	090
27437	A	Revise kneecap	8.82	NA	NA	6.18	6.71	1.49	090
27438	A	Revise kneecap with implant	11.77	NA	NA	7.49	8.01	1.96	090
27440	A	Revision of knee joint	10.97	NA	NA	6.99	6.49	1.82	090
27441	A	Revision of knee joint	11.42	NA	NA	7.35	7.03	1.89	090
27442	A	Revision of knee joint	12.25	NA	NA	7.64	8.27	2.10	090
27443	A	Revision of knee joint	11.29	NA	NA	7.34	8.03	1.91	090
27445	A	Revision of knee joint	18.52	NA	NA	10.40	11.38	3.09	090
27446	A	Revision of knee joint	16.26	NA	NA	9.28	10.27	2.81	090
27447	A	Total knee arthroplasty	23.04	NA	NA	12.56	13.58	3.80	090
27448	A	Incision of thigh	11.48	NA	NA	7.31	7.95	1.95	090
27450	A	Incision of thigh	14.47	NA	NA	8.83	9.70	2.43	090
27454	A	Realignment of thigh bone	18.97	NA	NA	10.72	11.61	3.13	090
27455	A	Realignment of knee	13.24	NA	NA	8.30	9.09	2.25	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
27457	A	Realignment of knee	13.92	NA	NA	8.22	9.07	2.35	090
27465	A	Shortening of thigh bone	18.44	NA	NA	10.28	10.25	2.48	090
27466	A	Lengthening of thigh bone	17.13	NA	NA	10.05	10.94	2.78	090
27468	A	Shorten/lengthen thighs	19.82	NA	NA	11.16	11.75	3.31	090
27470	A	Repair of thigh	16.97	NA	NA	10.15	10.96	2.80	090
27472	A	Repair/graft of thigh	18.57	NA	NA	10.63	11.65	3.08	090
27475	A	Surgery to stop leg growth	8.82	NA	NA	6.19	6.70	1.36	090
27477	A	Surgery to stop leg growth	10.03	NA	NA	6.59	7.16	1.74	090
27479	A	Surgery to stop leg growth	13.04	NA	NA	8.84	9.24	2.79	090
27485	A	Surgery to stop leg growth	9.02	NA	NA	6.21	6.80	1.53	090
27486	A	Revise/replace knee joint	20.92	NA	NA	11.62	12.55	3.37	090
27487	A	Revise/replace knee joint	26.91	NA	NA	13.97	15.25	4.40	090
27488	A	Removal of knee prosthesis	17.40	NA	NA	10.24	10.96	2.75	090
27495	A	Reinforce thigh	16.40	NA	NA	9.59	10.49	2.72	090
27496	A	Decompression of thigh/knee	6.66	NA	NA	4.97	5.29	0.99	090
27497	A	Decompression of thigh/knee	7.70	NA	NA	4.98	5.21	1.15	090
27498	A	Decompression of thigh/knee	8.54	NA	NA	5.18	5.57	1.24	090
27499	A	Decompression of thigh/knee	9.31	NA	NA	5.98	6.40	1.47	090
27500	A	Treatment of thigh fracture	6.21	5.36	5.74	4.58	4.78	1.02	090
27501	A	Treatment of thigh fracture	6.34	5.00	5.40	4.91	5.15	1.03	090
27502	A	Treatment of thigh fracture	11.24	NA	NA	6.85	7.48	1.79	090
27503	A	Treatment of thigh fracture	11.13	NA	NA	7.21	7.74	1.85	090
27506	A	Treatment of thigh fracture	19.42	NA	NA	11.35	12.07	3.04	090
27507	A	Treatment of thigh fracture	14.39	NA	NA	8.12	8.98	2.43	090
27508	A	Treatment of thigh fracture	6.08	5.68	6.07	5.05	5.26	0.97	090
27509	A	Treatment of thigh fracture	8.02	NA	NA	6.53	7.24	1.34	090
27510	A	Treatment of thigh fracture	9.68	NA	NA	6.26	6.79	1.53	090
27511	A	Treatment of thigh fracture	14.97	NA	NA	8.10	9.65	2.38	090
27513	A	Treatment of thigh fracture	19.11	NA	NA	9.74	11.81	3.13	090
27514	A	Treatment of thigh fracture	14.46	NA	NA	7.88	10.61	3.01	090
27516	A	Treat thigh fx growth plate	5.45	5.71	6.03	5.07	5.29	0.81	090
27517	A	Treat thigh fx growth plate	8.98	NA	NA	6.41	6.93	1.22	090
27519	A	Treat thigh fx growth plate	13.11	NA	NA	7.38	9.48	2.56	090
27520	A	Treat kneecap fracture	2.93	4.10	4.31	3.52	3.48	0.47	090
27524	A	Treat kneecap fracture	10.25	NA	NA	6.93	7.58	1.75	090
27530	A	Treat knee fracture	3.97	4.82	5.06	4.26	4.34	0.65	090
27532	A	Treat knee fracture	7.43	6.39	6.87	5.62	6.03	1.26	090
27535	A	Treat knee fracture	13.27	NA	NA	7.44	8.77	2.01	090
27536	A	Treat knee fracture	17.19	NA	NA	10.19	10.89	2.74	090
27538	A	Treat knee fracture(s)	4.95	5.51	5.82	4.89	5.04	0.84	090
27540	A	Treat knee fracture	11.16	NA	NA	7.38	8.44	2.28	090
27550	A	Treat knee dislocation	5.84	5.21	5.61	4.50	4.71	0.76	090
27552	A	Treat knee dislocation	8.04	NA	NA	6.08	6.51	1.36	090
27556	A	Treat knee dislocation	12.86	NA	NA	7.25	9.45	2.51	090
27557	A	Treat knee dislocation	15.76	NA	NA	8.44	10.78	2.98	090
27558	A	Treat knee dislocation	18.25	NA	NA	9.28	11.16	3.09	090
27560	A	Treat kneecap dislocation	3.88	4.24	4.54	3.71	3.45	0.40	090
27562	A	Treat kneecap dislocation	5.86	NA	NA	4.61	4.69	0.94	090
27566	A	Treat kneecap dislocation	12.59	NA	NA	7.88	8.60	2.13	090
27570	A	Fixation of knee joint	1.76	NA	NA	1.61	1.69	0.30	010
27580	A	Fusion of knee	20.90	NA	NA	12.17	13.48	3.38	090
27590	A	Amputate leg at thigh	13.35	NA	NA	6.01	6.34	1.75	090
27591	A	Amputate leg at thigh	13.82	NA	NA	7.34	7.99	2.03	090
27592	A	Amputate leg at thigh	10.86	NA	NA	5.45	5.81	1.45	090
27594	A	Amputation follow-up surgery	7.17	NA	NA	4.72	4.94	1.02	090
27596	A	Amputation follow-up surgery	11.15	NA	NA	5.97	6.39	1.57	090
27598	A	Amputate lower leg at knee	11.08	NA	NA	6.19	6.60	1.65	090
27599	C	Leg surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
27600	A	Decompression of lower leg	5.94	NA	NA	3.79	4.16	0.86	090
27601	A	Decompression of lower leg	5.94	NA	NA	4.17	4.51	0.80	090
27602	A	Decompression of lower leg	7.71	NA	NA	4.29	4.71	1.10	090
27603	A	Drain lower leg lesion	5.12	7.04	7.26	3.90	4.03	0.74	090
27604	A	Drain lower leg bursa	4.51	6.48	6.28	3.42	3.69	0.69	090
27605	A	Incision of achilles tendon	2.89	5.15	6.41	1.74	2.03	0.41	010
27606	A	Incision of achilles tendon	4.15	NA	NA	2.62	2.99	0.69	010
27607	A	Treat lower leg bone lesion	8.51	NA	NA	5.70	5.93	1.31	090
27610	A	Explore/treat ankle joint	9.01	NA	NA	6.10	6.55	1.40	090
27612	A	Exploration of ankle joint	8.01	NA	NA	5.17	5.63	1.13	090
27613	A	Biopsy lower leg soft tissue	2.19	3.91	3.57	1.77	1.79	0.20	010
27614	A	Biopsy lower leg soft tissue	5.71	7.75	7.44	3.93	4.18	0.78	090
27615	A	Remove tumor, lower leg	12.93	NA	NA	7.27	8.33	1.84	090
27618	A	Remove lower leg lesion	5.14	6.43	6.22	3.80	3.89	0.72	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
27619	A	Remove lower leg lesion	8.47	9.99	9.75	5.27	5.61	1.25	090
27620	A	Explore/treat ankle joint	6.04	NA	NA	4.56	5.01	0.97	090
27625	A	Remove ankle joint lining	8.37	NA	NA	5.49	5.98	1.28	090
27626	A	Remove ankle joint lining	8.98	NA	NA	5.77	6.34	1.48	090
27630	A	Removal of tendon lesion	4.85	7.98	7.76	3.80	4.09	0.74	090
27635	A	Remove lower leg bone lesion	7.91	NA	NA	5.63	6.18	1.31	090
27637	A	Remove/graft leg bone lesion	10.17	NA	NA	6.90	7.59	1.66	090
27638	A	Remove/graft leg bone lesion	10.87	NA	NA	7.04	7.66	1.85	090
27640	A	Partial removal of tibia	12.10	NA	NA	7.46	8.88	1.89	090
27641	A	Partial removal of fibula	9.73	NA	NA	6.09	7.21	1.46	090
27645	A	Extensive lower leg surgery	14.78	NA	NA	8.73	10.38	2.42	090
27646	A	Extensive lower leg surgery	13.21	NA	NA	7.64	9.33	2.06	090
27647	A	Extensive ankle/heel surgery	12.85	NA	NA	6.54	7.07	1.76	090
27648	A	Injection for ankle x-ray	0.96	2.88	3.20	0.34	0.34	0.08	000
27650	A	Repair achilles tendon	9.94	NA	NA	6.15	6.83	1.59	090
27652	A	Repair/graft achilles tendon	10.64	NA	NA	6.44	7.23	1.72	090
27654	A	Repair of achilles tendon	10.32	NA	NA	5.98	6.56	1.58	090
27656	A	Repair leg fascia defect	4.62	7.95	8.24	3.58	3.67	0.69	090
27658	A	Repair of leg tendon, each	5.03	NA	NA	3.88	4.22	0.79	090
27659	A	Repair of leg tendon, each	6.99	NA	NA	4.67	5.16	1.09	090
27664	A	Repair of leg tendon, each	4.64	NA	NA	3.88	4.21	0.76	090
27665	A	Repair of leg tendon, each	5.46	NA	NA	4.32	4.64	0.89	090
27675	A	Repair lower leg tendons	7.24	NA	NA	4.67	5.20	1.11	090
27676	A	Repair lower leg tendons	8.61	NA	NA	5.72	6.23	1.37	090
27680	A	Release of lower leg tendon	5.79	NA	NA	4.16	4.63	0.93	090
27681	A	Release of lower leg tendons	6.94	NA	NA	5.09	5.50	1.15	090
27685	A	Revision of lower leg tendon	6.57	8.77	8.03	4.57	5.02	0.97	090
27686	A	Revise lower leg tendons	7.64	NA	NA	5.28	5.89	1.24	090
27687	A	Revision of calf tendon	6.30	NA	NA	4.47	4.89	1.00	090
27690	A	Revise lower leg tendon	8.96	NA	NA	5.37	5.86	1.33	090
27691	A	Revise lower leg tendon	10.28	NA	NA	6.65	7.20	1.64	090
27692	A	Revise additional leg tendon	1.87	NA	NA	0.71	0.82	0.32	ZZZ
27695	A	Repair of ankle ligament	6.58	NA	NA	4.87	5.37	1.05	090
27696	A	Repair of ankle ligaments	8.46	NA	NA	5.25	5.84	1.28	090
27698	A	Repair of ankle ligament	9.49	NA	NA	5.87	6.40	1.47	090
27700	A	Revision of ankle joint	9.54	NA	NA	5.20	5.44	1.30	090
27702	A	Reconstruct ankle joint	14.28	NA	NA	8.64	9.55	2.38	090
27703	A	Reconstruction, ankle joint	16.79	NA	NA	9.77	10.50	2.77	090
27704	A	Removal of ankle implant	7.69	NA	NA	5.61	5.60	1.27	090
27705	A	Incision of tibia	10.74	NA	NA	6.95	7.56	1.81	090
27707	A	Incision of fibula	4.67	NA	NA	4.48	4.71	0.76	090
27709	A	Incision of tibia & fibula	17.32	NA	NA	9.95	9.04	1.74	090
27712	A	Realignment of lower leg	15.67	NA	NA	9.44	10.09	2.48	090
27715	A	Revision of lower leg	15.36	NA	NA	9.03	9.89	2.50	090
27720	A	Repair of tibia	12.22	NA	NA	7.92	8.66	2.05	090
27722	A	Repair/graft of tibia	12.31	NA	NA	7.88	8.50	2.06	090
27724	A	Repair/graft of tibia	19.18	NA	NA	10.28	11.32	3.17	090
27725	A	Repair of lower leg	17.15	NA	NA	10.58	11.24	2.72	090
27726	A	Repair fibula nonunion	14.20	NA	NA	7.67	7.67	1.43	090
27727	A	Repair of lower leg	14.69	NA	NA	9.06	9.70	2.44	090
27730	A	Repair of tibia epiphysis	7.59	NA	NA	5.30	5.86	1.73	090
27732	A	Repair of fibula epiphysis	5.37	NA	NA	4.16	4.54	0.77	090
27734	A	Repair lower leg epiphyses	8.72	NA	NA	6.16	6.22	1.35	090
27740	A	Repair of leg epiphyses	9.49	NA	NA	6.60	7.29	1.62	090
27742	A	Repair of leg epiphyses	10.49	NA	NA	4.60	5.08	1.80	090
27745	A	Reinforce tibia	10.37	NA	NA	6.99	7.58	1.76	090
27750	A	Treatment of tibia fracture	3.26	4.32	4.54	3.73	3.79	0.55	090
27752	A	Treatment of tibia fracture	6.15	5.94	6.29	5.10	5.39	1.01	090
27756	A	Treatment of tibia fracture	7.33	NA	NA	5.75	6.10	1.17	090
27758	A	Treatment of tibia fracture	12.40	NA	NA	8.02	8.60	2.04	090
27759	A	Treatment of tibia fracture	14.31	NA	NA	8.66	9.48	2.39	090
27760	A	Cltx medial ankle fx	3.09	4.28	4.47	3.67	3.63	0.48	090
27762	A	Cltx med ankle fx w/mnpj	5.33	5.47	5.90	4.65	4.96	0.85	090
27766	A	Optx medial ankle fx	7.73	NA	NA	6.12	6.67	1.44	090
27767	A	Cltx post ankle fx	2.50	3.62	3.62	3.65	3.65	0.30	090
27768	A	Cltx post ankle fx w/mnpj	5.00	NA	NA	4.29	4.29	0.79	090
27769	A	Optx post ankle fx	10.00	NA	NA	6.07	6.07	1.45	090
27780	A	Treatment of fibula fracture	2.72	3.86	4.02	3.31	3.26	0.41	090
27781	A	Treatment of fibula fracture	4.47	4.87	5.18	4.26	4.45	0.73	090
27784	A	Treatment of fibula fracture	9.51	NA	NA	6.84	6.65	1.23	090
27786	A	Treatment of ankle fracture	2.91	4.05	4.25	3.43	3.38	0.46	090
27788	A	Treatment of ankle fracture	4.52	4.96	5.30	4.23	4.44	0.74	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
27792	A	Treatment of ankle fracture	9.55	NA	NA	6.80	6.88	1.32	090
27808	A	Treatment of ankle fracture	2.91	4.39	4.59	3.70	3.70	0.46	090
27810	A	Treatment of ankle fracture	5.20	5.40	5.82	4.55	4.85	0.82	090
27814	A	Treatment of ankle fracture	10.46	NA	NA	7.23	7.89	1.86	090
27816	A	Treatment of ankle fracture	2.96	3.99	4.18	3.33	3.37	0.43	090
27818	A	Treatment of ankle fracture	5.57	5.41	5.89	4.44	4.80	0.82	090
27822	A	Treatment of ankle fracture	11.03	NA	NA	8.20	9.42	1.92	090
27823	A	Treatment of ankle fracture	12.98	NA	NA	8.93	10.19	2.26	090
27824	A	Treat lower leg fracture	3.20	3.65	3.85	3.47	3.51	0.45	090
27825	A	Treat lower leg fracture	6.60	5.78	6.19	4.75	5.07	1.02	090
27826	A	Treat lower leg fracture	10.92	NA	NA	8.20	8.51	1.47	090
27827	A	Treat lower leg fracture	14.56	NA	NA	10.17	11.47	2.44	090
27828	A	Treat lower leg fracture	18.20	NA	NA	11.56	12.74	2.82	090
27829	A	Treat lower leg joint	8.64	NA	NA	6.97	6.87	0.95	090
27830	A	Treat lower leg dislocation	3.85	4.09	4.24	3.56	3.70	0.54	090
27831	A	Treat lower leg dislocation	4.62	NA	NA	4.05	4.25	0.73	090
27832	A	Treat lower leg dislocation	10.01	NA	NA	6.83	6.50	1.03	090
27840	A	Treat ankle dislocation	4.65	NA	NA	3.65	3.70	0.46	090
27842	A	Treat ankle dislocation	6.34	NA	NA	4.85	4.98	1.00	090
27846	A	Treat ankle dislocation	10.16	NA	NA	6.76	7.34	1.71	090
27848	A	Treat ankle dislocation	11.56	NA	NA	7.31	8.51	1.95	090
27860	A	Fixation of ankle joint	2.36	NA	NA	1.68	1.83	0.39	010
27870	A	Fusion of ankle joint, open	15.21	NA	NA	9.07	9.79	2.37	090
27871	A	Fusion of tibiofibular joint	9.42	NA	NA	6.53	7.05	1.59	090
27880	A	Amputation of lower leg	15.24	NA	NA	6.64	6.88	1.76	090
27881	A	Amputation of lower leg	13.32	NA	NA	7.37	8.11	1.99	090
27882	A	Amputation of lower leg	9.67	NA	NA	4.90	5.69	1.29	090
27884	A	Amputation follow-up surgery	8.64	NA	NA	5.10	5.43	1.22	090
27886	A	Amputation follow-up surgery	9.88	NA	NA	5.65	6.08	1.40	090
27888	A	Amputation of foot at ankle	10.23	NA	NA	6.00	6.75	1.51	090
27889	A	Amputation of foot at ankle	10.72	NA	NA	5.43	5.95	1.46	090
27892	A	Decompression of leg	7.82	NA	NA	5.09	5.34	1.10	090
27893	A	Decompression of leg	7.78	NA	NA	5.12	5.29	1.10	090
27894	A	Decompression of leg	12.42	NA	NA	7.33	7.55	1.65	090
27899	C	Leg/ankle surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
28001	A	Drainage of bursa of foot	2.75	4.00	3.49	1.61	1.78	0.33	010
28002	A	Treatment of foot infection	5.78	6.67	5.83	3.57	3.67	0.61	010
28003	A	Treatment of foot infection	8.95	7.77	7.00	4.55	4.89	1.12	090
28005	A	Treat foot bone lesion	9.30	NA	NA	5.52	5.78	1.16	090
28008	A	Incision of foot fascia	4.50	6.17	5.36	3.00	3.10	0.57	090
28010	A	Incision of toe tendon	2.89	2.86	2.62	2.35	2.36	0.36	090
28011	A	Incision of toe tendons	4.19	3.79	3.55	3.03	3.16	0.59	090
28020	A	Exploration of foot joint	5.06	7.36	6.68	3.58	3.85	0.72	090
28022	A	Exploration of foot joint	4.72	6.92	6.06	3.33	3.59	0.62	090
28024	A	Exploration of toe joint	4.43	6.55	5.88	3.11	3.52	0.58	090
28035	A	Decompression of tibia nerve	5.14	7.27	6.56	3.54	3.81	0.70	090
28043	A	Excision of foot lesion	3.58	4.78	4.29	2.73	2.95	0.46	090
28045	A	Excision of foot lesion	4.77	7.02	6.20	3.24	3.42	0.63	090
28046	A	Resection of tumor, foot	10.55	10.36	9.56	5.76	6.11	1.36	090
28050	A	Biopsy of foot joint lining	4.30	6.94	5.91	3.29	3.44	0.60	090
28052	A	Biopsy of foot joint lining	3.98	6.30	5.60	2.87	3.15	0.53	090
28054	A	Biopsy of toe joint lining	3.49	6.25	5.48	2.79	3.01	0.46	090
28055	A	Neurectomy, foot	6.20	NA	NA	3.44	3.54	0.74	090
28060	A	Partial removal, foot fascia	5.29	7.07	6.27	3.54	3.70	0.70	090
28062	A	Removal of foot fascia	6.58	7.82	7.17	3.82	3.91	0.83	090
28070	A	Removal of foot joint lining	5.15	7.36	6.29	3.54	3.67	0.73	090
28072	A	Removal of foot joint lining	4.63	7.56	6.54	3.60	3.95	0.68	090
28080	A	Removal of foot lesion	4.65	7.66	6.38	4.19	3.93	0.47	090
28086	A	Excise foot tendon sheath	4.83	7.86	7.92	3.81	4.24	0.76	090
28088	A	Excise foot tendon sheath	3.90	7.00	6.37	3.19	3.54	0.61	090
28090	A	Removal of foot lesion	4.46	6.77	5.95	3.18	3.31	0.59	090
28092	A	Removal of toe lesions	3.69	6.46	5.84	2.98	3.25	0.49	090
28100	A	Removal of ankle/heel lesion	5.72	8.09	8.02	3.99	4.34	0.82	090
28102	A	Remove/graft foot lesion	7.80	NA	NA	4.84	5.39	1.14	090
28103	A	Remove/graft foot lesion	6.56	NA	NA	4.02	4.31	0.91	090
28104	A	Removal of foot lesion	5.17	7.23	6.35	3.46	3.69	0.70	090
28106	A	Remove/graft foot lesion	7.23	NA	NA	4.22	4.32	0.97	090
28107	A	Remove/graft foot lesion	5.62	7.69	7.11	3.66	3.93	0.74	090
28108	A	Removal of toe lesions	4.21	6.35	5.46	2.98	3.12	0.53	090
28110	A	Part removal of metatarsal	4.13	6.92	6.07	3.06	3.14	0.54	090
28111	A	Part removal of metatarsal	5.06	7.09	6.68	3.20	3.42	0.67	090
28112	A	Part removal of metatarsal	4.54	7.18	6.49	3.24	3.40	0.61	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
28113	A	Part removal of metatarsal	5.88	8.36	7.20	4.61	4.46	0.63	090
28114	A	Removal of metatarsal heads	11.61	13.38	12.49	8.29	8.33	1.42	090
28116	A	Revision of foot	8.94	9.44	8.11	5.34	5.25	1.03	090
28118	A	Removal of heel bone	6.02	7.92	7.08	4.02	4.18	0.84	090
28119	A	Removal of heel spur	5.45	7.21	6.31	3.57	3.65	0.70	090
28120	A	Part removal of ankle/heel	5.64	8.08	7.68	3.96	4.18	0.77	090
28122	A	Partial removal of foot bone	7.56	8.46	7.64	4.77	5.02	0.98	090
28124	A	Partial removal of toe	4.88	6.77	5.88	3.46	3.55	0.60	090
28126	A	Partial removal of toe	3.56	5.96	5.08	2.66	2.82	0.45	090
28130	A	Removal of ankle bone	9.30	NA	NA	6.15	6.43	1.26	090
28140	A	Removal of metatarsal	7.03	7.81	7.51	4.11	4.43	0.92	090
28150	A	Removal of toe	4.14	6.35	5.59	2.97	3.13	0.53	090
28153	A	Partial removal of toe	3.71	6.21	5.26	2.89	2.78	0.47	090
28160	A	Partial removal of toe	3.79	6.31	5.43	2.92	3.13	0.49	090
28171	A	Extensive foot surgery	9.85	NA	NA	5.25	5.34	1.33	090
28173	A	Extensive foot surgery	9.05	8.72	8.15	4.61	4.90	1.12	090
28175	A	Extensive foot surgery	6.17	7.14	6.42	3.62	3.66	0.73	090
28190	A	Removal of foot foreign body	1.98	4.01	3.70	1.34	1.41	0.22	010
28192	A	Removal of foot foreign body	4.69	6.71	6.09	3.19	3.41	0.61	090
28193	A	Removal of foot foreign body	5.79	7.33	6.47	3.63	3.77	0.73	090
28200	A	Repair of foot tendon	4.65	6.87	5.98	3.23	3.39	0.61	090
28202	A	Repair/graft of foot tendon	6.96	7.76	7.48	3.93	4.21	0.91	090
28208	A	Repair of foot tendon	4.42	6.69	5.75	3.18	3.24	0.58	090
28210	A	Repair/graft of foot tendon	6.41	7.62	6.91	3.93	3.97	0.81	090
28220	A	Release of foot tendon	4.58	6.41	5.54	3.07	3.25	0.57	090
28222	A	Release of foot tendons	5.67	6.92	6.08	3.34	3.73	0.69	090
28225	A	Release of foot tendon	3.70	6.01	5.14	2.71	2.81	0.46	090
28226	A	Release of foot tendons	4.58	6.88	5.83	3.25	3.49	0.58	090
28230	A	Incision of foot tendon(s)	4.28	6.26	5.46	2.87	3.27	0.55	090
28232	A	Incision of toe tendon	3.43	5.93	5.22	2.67	2.99	0.44	090
28234	A	Incision of foot tendon	3.43	6.29	5.48	3.05	3.20	0.44	090
28238	A	Revision of foot tendon	7.85	8.38	7.81	4.37	4.64	1.06	090
28240	A	Release of big toe	4.40	6.35	5.49	2.95	3.21	0.58	090
28250	A	Revision of foot fascia	5.97	7.55	6.58	3.82	3.97	0.82	090
28260	A	Release of midfoot joint	8.08	8.44	7.38	4.61	4.80	1.14	090
28261	A	Revision of foot tendon	12.91	10.66	9.63	6.33	6.81	1.57	090
28262	A	Revision of foot and ankle	17.01	15.52	14.53	9.72	10.31	2.60	090
28264	A	Release of midfoot joint	10.53	10.31	9.02	5.95	6.61	1.54	090
28270	A	Release of foot contracture	4.82	6.91	5.90	3.44	3.58	0.62	090
28272	A	Release of toe joint, each	3.84	5.83	5.00	2.65	2.75	0.46	090
28280	A	Fusion of toes	5.24	7.28	6.76	3.54	4.01	0.73	090
28285	A	Repair of hammertoe	4.65	6.70	5.78	3.34	3.38	0.59	090
28286	A	Repair of hammertoe	4.61	6.52	5.65	3.06	3.15	0.57	090
28288	A	Partial removal of foot bone	5.81	8.59	7.26	4.69	4.78	0.65	090
28289	A	Repair hallux rigidus	8.11	9.42	8.70	5.33	5.55	1.02	090
28290	A	Correction of bunion	5.72	8.18	7.21	3.96	4.34	0.82	090
28292	A	Correction of bunion	8.72	10.33	8.89	6.15	5.84	0.91	090
28293	A	Correction of bunion	11.10	14.46	12.60	6.91	6.50	1.13	090
28294	A	Correction of bunion	8.63	9.45	8.44	4.77	4.74	1.09	090
28296	A	Correction of bunion	9.31	9.57	8.86	4.79	5.10	1.19	090
28297	A	Correction of bunion	9.31	10.46	9.70	5.33	5.79	1.32	090
28298	A	Correction of bunion	8.01	9.29	8.25	4.59	4.79	1.05	090
28299	A	Correction of bunion	11.39	10.54	9.65	5.72	5.89	1.37	090
28300	A	Incision of heel bone	9.61	NA	NA	6.03	6.53	1.54	090
28302	A	Incision of ankle bone	9.62	NA	NA	6.21	6.54	1.42	090
28304	A	Incision of midfoot bones	9.29	9.55	8.74	5.08	5.40	1.27	090
28305	A	Incise/graft midfoot bones	10.63	NA	NA	5.78	6.25	1.27	090
28306	A	Incision of metatarsal	5.91	8.41	7.62	3.89	4.03	0.84	090
28307	A	Incision of metatarsal	6.39	9.27	10.14	4.33	4.81	0.90	090
28308	A	Incision of metatarsal	5.36	7.91	6.83	3.82	3.75	0.70	090
28309	A	Incision of metatarsals	13.96	NA	NA	7.68	7.81	2.05	090
28310	A	Revision of big toe	5.48	7.54	6.64	3.42	3.48	0.70	090
28312	A	Revision of toe	4.60	7.37	6.40	3.23	3.43	0.63	090
28313	A	Repair deformity of toe	5.06	7.26	6.27	3.60	4.21	0.73	090
28315	A	Removal of sesamoid bone	4.91	6.67	5.78	3.22	3.27	0.63	090
28320	A	Repair of foot bones	9.25	NA	NA	5.68	6.19	1.43	090
28322	A	Repair of metatarsals	8.41	9.74	9.45	5.31	5.82	1.27	090
28340	A	Resect enlarged toe tissue	7.04	8.09	7.26	4.07	4.15	0.84	090
28341	A	Resect enlarged toe	8.60	8.59	7.76	4.42	4.61	1.01	090
28344	A	Repair extra toe(s)	4.31	6.41	6.07	2.93	3.28	0.51	090
28345	A	Repair webbed toe(s)	5.98	7.61	6.90	3.78	4.23	0.80	090
28360	A	Reconstruct cleft foot	14.67	NA	NA	6.34	8.41	2.29	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
28400	A	Treatment of heel fracture	2.22	3.36	3.49	2.91	2.98	0.35	090
28405	A	Treatment of heel fracture	4.63	4.42	4.62	3.67	4.14	0.73	090
28406	A	Treatment of heel fracture	6.44	NA	NA	5.55	6.17	1.11	090
28415	A	Treat heel fracture	15.96	NA	NA	10.23	11.75	2.67	090
28420	A	Treat/graft heel fracture	17.29	NA	NA	10.27	11.59	2.81	090
28430	A	Treatment of ankle fracture	2.14	3.12	3.25	2.57	2.57	0.31	090
28435	A	Treatment of ankle fracture	3.45	3.98	3.93	3.26	3.50	0.55	090
28436	A	Treatment of ankle fracture	4.78	NA	NA	4.74	5.32	0.81	090
28445	A	Treat ankle fracture	15.53	NA	NA	9.48	10.25	2.59	090
28446	A	Osteochondral talus autogrft	17.50	NA	NA	10.34	10.34	2.45	090
28450	A	Treat midfoot fracture, each	1.95	2.91	3.01	2.41	2.44	0.28	090
28455	A	Treat midfoot fracture, each	3.15	3.74	3.58	3.10	3.26	0.44	090
28456	A	Treat midfoot fracture	2.75	NA	NA	3.72	3.94	0.44	090
28465	A	Treat midfoot fracture, each	8.64	NA	NA	6.06	6.18	1.10	090
28470	A	Treat metatarsal fracture	1.99	2.80	2.96	2.36	2.40	0.30	090
28475	A	Treat metatarsal fracture	2.97	3.13	3.23	2.51	2.86	0.44	090
28476	A	Treat metatarsal fracture	3.46	NA	NA	4.32	4.65	0.54	090
28485	A	Treat metatarsal fracture	7.28	NA	NA	5.56	5.50	0.83	090
28490	A	Treat big toe fracture	1.12	2.09	2.05	1.67	1.65	0.14	090
28495	A	Treat big toe fracture	1.62	2.46	2.32	1.86	1.96	0.20	090
28496	A	Treat big toe fracture	2.39	7.41	7.83	2.99	3.09	0.36	090
28505	A	Treat big toe fracture	7.28	8.45	8.27	4.81	4.36	0.56	090
28510	A	Treatment of toe fracture	1.12	1.68	1.60	1.61	1.57	0.14	090
28515	A	Treatment of toe fracture	1.50	2.22	2.06	1.82	1.86	0.18	090
28525	A	Treat toe fracture	5.46	8.11	7.81	4.31	3.87	0.49	090
28530	A	Treat sesamoid bone fracture	1.08	1.62	1.53	1.34	1.39	0.14	090
28531	A	Treat sesamoid bone fracture	2.51	6.54	6.90	2.42	2.24	0.34	090
28540	A	Treat foot dislocation	2.10	2.74	2.57	2.30	2.35	0.26	090
28545	A	Treat foot dislocation	2.51	3.43	2.88	2.81	2.57	0.37	090
28546	A	Treat foot dislocation	3.28	8.05	7.48	3.64	4.01	0.52	090
28555	A	Repair foot dislocation	9.49	10.80	10.35	6.29	5.98	1.04	090
28570	A	Treat foot dislocation	1.70	2.49	2.45	1.91	2.12	0.23	090
28575	A	Treat foot dislocation	3.38	4.41	4.06	3.71	3.71	0.56	090
28576	A	Treat foot dislocation	4.48	NA	NA	4.06	4.11	0.69	090
28585	A	Repair foot dislocation	10.92	11.56	9.44	6.96	6.40	1.25	090
28600	A	Treat foot dislocation	1.94	3.02	2.92	2.37	2.53	0.27	090
28605	A	Treat foot dislocation	2.78	3.89	3.50	3.27	3.19	0.40	090
28606	A	Treat foot dislocation	4.97	NA	NA	4.11	4.40	0.82	090
28615	A	Repair foot dislocation	10.46	NA	NA	8.13	8.08	1.30	090
28630	A	Treat toe dislocation	1.72	1.84	1.70	0.91	0.95	0.20	010
28635	A	Treat toe dislocation	1.93	2.27	2.15	1.33	1.43	0.26	010
28636	A	Treat toe dislocation	2.77	4.38	4.12	2.05	2.34	0.43	010
28645	A	Repair toe dislocation	7.28	8.33	6.64	4.61	3.94	0.57	090
28660	A	Treat toe dislocation	1.25	1.30	1.28	0.78	0.78	0.13	010
28665	A	Treat toe dislocation	1.94	1.82	1.62	1.32	1.37	0.26	010
28666	A	Treat toe dislocation	2.66	NA	NA	1.82	2.20	0.43	010
28675	A	Repair of toe dislocation	5.46	8.23	7.68	4.44	3.90	0.45	090
28705	A	Fusion of foot bones	20.12	NA	NA	10.64	11.54	3.09	090
28715	A	Fusion of foot bones	14.40	NA	NA	8.48	9.11	2.17	090
28725	A	Fusion of foot bones	11.97	NA	NA	6.82	7.52	1.87	090
28730	A	Fusion of foot bones	12.21	NA	NA	7.75	8.11	1.71	090
28735	A	Fusion of foot bones	12.03	NA	NA	6.96	7.39	1.69	090
28737	A	Revision of foot bones	10.83	NA	NA	6.06	6.43	1.47	090
28740	A	Fusion of foot bones	9.09	10.86	10.86	5.98	6.22	1.22	090
28750	A	Fusion of big toe joint	8.37	10.76	11.33	5.88	6.27	1.13	090
28755	A	Fusion of big toe joint	4.79	7.25	6.67	3.35	3.55	0.65	090
28760	A	Fusion of big toe joint	8.94	9.86	8.91	5.26	5.39	1.05	090
28800	A	Amputation of midfoot	8.65	NA	NA	5.00	5.40	1.15	090
28805	A	Amputation thru metatarsal	12.55	NA	NA	5.89	5.77	1.18	090
28810	A	Amputation toe & metatarsal	6.52	NA	NA	4.06	4.26	0.86	090
28820	A	Amputation of toe	4.89	7.64	7.59	3.55	3.66	0.61	090
28825	A	Partial amputation of toe	3.71	7.13	7.06	3.12	3.30	0.50	090
28890	A	High energy eswt, plantar f	3.36	4.56	5.14	2.20	2.14	0.41	090
28899	C	Foot/toes surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
29000	A	Application of body cast	2.25	4.00	3.48	1.64	1.69	0.41	000
29010	A	Application of body cast	2.06	4.38	3.83	1.62	1.70	0.45	000
29015	A	Application of body cast	2.41	3.61	3.29	1.56	1.58	0.28	000
29020	A	Application of body cast	2.11	3.81	3.49	1.41	1.41	0.28	000
29025	A	Application of body cast	2.40	4.04	3.59	1.76	1.81	0.44	000
29035	A	Application of body cast	1.77	3.70	3.65	1.48	1.53	0.28	000
29040	A	Application of body cast	2.22	3.28	2.87	1.34	1.42	0.36	000
29044	A	Application of body cast	2.12	3.57	3.77	1.47	1.69	0.35	000

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
29046	A	Application of body cast	2.41	4.49	3.86	1.91	2.00	0.42	000
29049	A	Application of figure eight	0.89	1.11	1.21	0.59	0.56	0.13	000
29055	A	Application of shoulder cast	1.78	2.82	2.90	1.23	1.35	0.30	000
29058	A	Application of shoulder cast	1.31	1.26	1.41	0.67	0.70	0.17	000
29065	A	Application of long arm cast	0.87	1.28	1.30	0.70	0.73	0.15	000
29075	A	Application of forearm cast	0.77	1.23	1.24	0.66	0.67	0.13	000
29085	A	Apply hand/wrist cast	0.87	1.26	1.27	0.68	0.66	0.14	000
29086	A	Apply finger cast	0.62	1.07	1.02	0.55	0.52	0.07	000
29105	A	Apply long arm splint	0.87	1.09	1.16	0.53	0.52	0.12	000
29125	A	Apply forearm splint	0.59	0.97	0.99	0.42	0.41	0.07	000
29126	A	Apply forearm splint	0.77	1.01	1.11	0.48	0.47	0.07	000
29130	A	Application of finger splint	0.50	0.43	0.45	0.18	0.18	0.06	000
29131	A	Application of finger splint	0.55	0.59	0.66	0.24	0.24	0.03	000
29200	A	Strapping of chest	0.65	0.60	0.66	0.34	0.34	0.04	000
29220	A	Strapping of low back	0.64	0.65	0.68	0.38	0.38	0.04	000
29240	A	Strapping of shoulder	0.71	0.68	0.76	0.40	0.38	0.06	000
29260	A	Strapping of elbow or wrist	0.55	0.67	0.70	0.37	0.35	0.05	000
29280	A	Strapping of hand or finger	0.51	0.67	0.73	0.37	0.35	0.03	000
29305	A	Application of hip cast	2.03	3.28	3.31	1.56	1.66	0.35	000
29325	A	Application of hip casts	2.32	3.33	3.43	1.58	1.77	0.40	000
29345	A	Application of long leg cast	1.40	1.66	1.71	0.94	1.00	0.24	000
29355	A	Application of long leg cast	1.53	1.62	1.66	0.93	1.03	0.26	000
29358	A	Apply long leg cast brace	1.43	2.01	2.03	0.91	1.00	0.25	000
29365	A	Application of long leg cast	1.18	1.58	1.62	0.85	0.90	0.20	000
29405	A	Apply short leg cast	0.86	1.19	1.20	0.65	0.68	0.14	000
29425	A	Apply short leg cast	1.01	1.22	1.22	0.65	0.70	0.15	000
29435	A	Apply short leg cast	1.18	1.52	1.54	0.81	0.87	0.20	000
29440	A	Addition of walker to cast	0.57	0.64	0.67	0.26	0.26	0.08	000
29445	A	Apply rigid leg cast	1.78	1.56	1.68	0.89	0.92	0.27	000
29450	A	Application of leg cast	2.08	1.59	1.53	0.90	0.99	0.27	000
29505	A	Application, long leg splint	0.69	1.07	1.12	0.45	0.45	0.08	000
29515	A	Application lower leg splint	0.73	0.96	0.91	0.46	0.46	0.09	000
29520	A	Strapping of hip	0.54	0.66	0.75	0.37	0.42	0.03	000
29530	A	Strapping of knee	0.57	0.65	0.72	0.36	0.35	0.05	000
29540	A	Strapping of ankle and/or ft	0.51	0.55	0.48	0.31	0.31	0.06	000
29550	A	Strapping of toes	0.47	0.56	0.49	0.30	0.29	0.06	000
29580	A	Application of paste boot	0.55	0.71	0.68	0.33	0.34	0.07	000
29590	A	Application of foot splint	0.76	0.59	0.55	0.26	0.27	0.09	000
29700	A	Removal/revision of cast	0.57	0.95	0.92	0.25	0.26	0.08	000
29705	A	Removal/revision of cast	0.76	0.76	0.79	0.36	0.37	0.13	000
29710	A	Removal/revision of cast	1.34	1.32	1.42	0.55	0.62	0.20	000
29715	A	Removal/revision of cast	0.94	1.20	1.18	0.43	0.42	0.09	000
29720	A	Repair of body cast	0.68	1.17	1.16	0.35	0.37	0.12	000
29730	A	Windowing of cast	0.75	0.74	0.77	0.34	0.34	0.12	000
29740	A	Wedging of cast	1.12	1.03	1.09	0.47	0.48	0.18	000
29750	A	Wedging of clubfoot cast	1.26	1.06	1.06	0.52	0.55	0.21	000
29799	C	Casting/strapping procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
29800	A	Jaw arthroscopy/surgery	6.73	NA	NA	4.62	5.79	0.99	090
29804	A	Jaw arthroscopy/surgery	8.71	NA	NA	5.69	6.65	1.38	090
29805	A	Shoulder arthroscopy, dx	5.94	NA	NA	4.71	5.19	1.02	090
29806	A	Shoulder arthroscopy/surgery	14.95	NA	NA	9.35	10.25	2.50	090
29807	A	Shoulder arthroscopy/surgery	14.48	NA	NA	9.19	10.09	2.42	090
29819	A	Shoulder arthroscopy/surgery	7.68	NA	NA	5.62	6.20	1.32	090
29820	A	Shoulder arthroscopy/surgery	7.12	NA	NA	5.17	5.70	1.22	090
29821	A	Shoulder arthroscopy/surgery	7.78	NA	NA	5.65	6.22	1.33	090
29822	A	Shoulder arthroscopy/surgery	7.49	NA	NA	5.57	6.13	1.28	090
29823	A	Shoulder arthroscopy/surgery	8.24	NA	NA	6.04	6.63	1.41	090
29824	A	Shoulder arthroscopy/surgery	8.82	NA	NA	6.53	7.03	1.42	090
29825	A	Shoulder arthroscopy/surgery	7.68	NA	NA	5.63	6.19	1.32	090
29826	A	Shoulder arthroscopy/surgery	9.05	NA	NA	6.18	6.85	1.55	090
29827	A	Arthroscop rotator cuff repr	15.44	NA	NA	9.31	10.41	2.67	090
29828	A	Arthroscopy biceps tenodesis	13.00	NA	NA	8.17	8.17	2.17	090
29830	A	Elbow arthroscopy	5.80	NA	NA	4.48	4.91	0.99	090
29834	A	Elbow arthroscopy/surgery	6.33	NA	NA	4.85	5.34	1.08	090
29835	A	Elbow arthroscopy/surgery	6.53	NA	NA	4.96	5.42	1.13	090
29836	A	Elbow arthroscopy/surgery	7.61	NA	NA	5.54	6.16	1.22	090
29837	A	Elbow arthroscopy/surgery	6.92	NA	NA	5.06	5.59	1.19	090
29838	A	Elbow arthroscopy/surgery	7.77	NA	NA	5.65	6.27	1.30	090
29840	A	Wrist arthroscopy	5.59	NA	NA	4.62	4.97	0.84	090
29843	A	Wrist arthroscopy/surgery	6.06	NA	NA	4.80	5.21	0.92	090
29844	A	Wrist arthroscopy/surgery	6.42	NA	NA	4.87	5.35	1.04	090
29845	A	Wrist arthroscopy/surgery	7.58	NA	NA	5.59	6.03	0.99	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
29846	A	Wrist arthroscopy/surgery	6.80	NA	NA	5.11	5.58	1.07	090
29847	A	Wrist arthroscopy/surgery	7.13	NA	NA	5.27	5.73	1.08	090
29848	A	Wrist endoscopy/surgery	6.24	NA	NA	5.27	5.44	0.86	090
29850	A	Knee arthroscopy/surgery	8.18	NA	NA	4.72	4.88	1.25	090
29851	A	Knee arthroscopy/surgery	13.08	NA	NA	8.21	9.00	2.35	090
29855	A	Tibial arthroscopy/surgery	10.60	NA	NA	7.27	8.02	1.85	090
29856	A	Tibial arthroscopy/surgery	14.12	NA	NA	8.69	9.67	2.40	090
29860	A	Hip arthroscopy, dx	8.85	NA	NA	6.24	6.60	1.36	090
29861	A	Hip arthroscopy/surgery	9.95	NA	NA	6.39	6.86	1.59	090
29862	A	Hip arthroscopy/surgery	10.97	NA	NA	7.57	8.06	1.62	090
29863	A	Hip arthroscopy/surgery	10.97	NA	NA	7.48	7.99	1.42	090
29866	A	Autgrft implnt, knee w/scope	14.48	NA	NA	9.46	10.40	2.40	090
29867	A	Allgrft implnt, knee w/scope	18.18	NA	NA	11.03	12.12	2.79	090
29868	A	Meniscal trnspl, knee w/scope	24.89	NA	NA	13.79	15.29	4.36	090
29870	A	Knee arthroscopy, dx	5.11	NA	NA	4.18	4.53	0.85	090
29871	A	Knee arthroscopy/drainage	6.60	NA	NA	5.05	5.46	1.14	090
29873	A	Knee arthroscopy/surgery	6.09	NA	NA	5.59	6.08	1.04	090
29874	A	Knee arthroscopy/surgery	7.10	NA	NA	5.08	5.58	1.11	090
29875	A	Knee arthroscopy/surgery	6.36	NA	NA	4.88	5.37	1.09	090
29876	A	Knee arthroscopy/surgery	8.72	NA	NA	6.18	6.60	1.37	090
29877	A	Knee arthroscopy/surgery	8.15	NA	NA	5.97	6.36	1.28	090
29879	A	Knee arthroscopy/surgery	8.84	NA	NA	6.23	6.67	1.39	090
29880	A	Knee arthroscopy/surgery	9.30	NA	NA	6.42	6.89	1.47	090
29881	A	Knee arthroscopy/surgery	8.56	NA	NA	6.13	6.55	1.34	090
29882	A	Knee arthroscopy/surgery	9.45	NA	NA	6.45	6.84	1.50	090
29883	A	Knee arthroscopy/surgery	11.61	NA	NA	7.58	8.32	1.93	090
29884	A	Knee arthroscopy/surgery	8.13	NA	NA	5.96	6.33	1.27	090
29885	A	Knee arthroscopy/surgery	10.03	NA	NA	7.03	7.49	1.58	090
29886	A	Knee arthroscopy/surgery	8.34	NA	NA	6.03	6.44	1.30	090
29887	A	Knee arthroscopy/surgery	9.98	NA	NA	6.96	7.44	1.57	090
29888	A	Knee arthroscopy/surgery	14.14	NA	NA	8.26	9.23	2.42	090
29889	A	Knee arthroscopy/surgery	17.15	NA	NA	10.61	11.52	2.79	090
29891	A	Ankle arthroscopy/surgery	9.47	NA	NA	6.64	7.07	1.39	090
29892	A	Ankle arthroscopy/surgery	10.07	NA	NA	6.38	7.06	1.41	090
29893	A	Scope, plantar fasciotomy	6.08	8.83	7.56	4.66	4.32	0.63	090
29894	A	Ankle arthroscopy/surgery	7.26	NA	NA	4.72	5.09	1.15	090
29895	A	Ankle arthroscopy/surgery	7.04	NA	NA	4.51	4.99	1.11	090
29897	A	Ankle arthroscopy/surgery	7.23	NA	NA	4.81	5.35	1.17	090
29898	A	Ankle arthroscopy/surgery	8.38	NA	NA	5.24	5.71	1.28	090
29899	A	Ankle arthroscopy/surgery	15.21	NA	NA	9.20	9.87	2.41	090
29900	A	Mcp joint arthroscopy, dx	5.74	NA	NA	4.66	5.26	0.94	090
29901	A	Mcp joint arthroscopy, surg	6.45	NA	NA	5.09	5.68	1.06	090
29902	A	Mcp joint arthroscopy, surg	7.02	NA	NA	4.70	5.62	1.12	090
29904	A	Subtalar arthro w/fb rml	8.50	NA	NA	5.89	5.89	1.25	090
29905	A	Subtalar arthro w/exc	9.00	NA	NA	6.51	6.51	1.32	090
29906	A	Subtalar arthro w/deb	9.47	NA	NA	6.87	6.87	1.39	090
29907	A	Subtalar arthro w/fusion	12.00	NA	NA	7.86	7.86	1.90	090
29999	C	Arthroscopy of joint	0.00	0.00	0.00	0.00	0.00	0.00	YYY
30000	A	Drainage of nose lesion	1.45	4.01	4.04	1.34	1.36	0.12	010
30020	A	Drainage of nose lesion	1.45	4.16	3.72	1.39	1.43	0.12	010
30100	A	Intranasal biopsy	0.94	2.58	2.28	0.75	0.78	0.07	000
30110	A	Removal of nose polyp(s)	1.65	3.90	3.57	1.45	1.51	0.14	010
30115	A	Removal of nose polyp(s)	4.38	NA	NA	5.99	5.87	0.41	090
30117	A	Removal of intranasal lesion	3.20	18.15	15.64	4.91	4.77	0.26	090
30118	A	Removal of intranasal lesion	9.81	NA	NA	8.55	8.87	0.78	090
30120	A	Revision of nose	5.31	7.07	6.78	5.09	5.54	0.52	090
30124	A	Removal of nose lesion	3.14	NA	NA	3.68	3.64	0.25	090
30125	A	Removal of nose lesion	7.21	NA	NA	7.40	7.86	0.63	090
30130	A	Excise inferior turbinate	3.41	NA	NA	5.63	5.61	0.31	090
30140	A	Resect inferior turbinate	3.48	NA	NA	7.10	6.64	0.35	090
30150	A	Partial removal of nose	9.44	NA	NA	9.02	10.01	0.93	090
30160	A	Removal of nose	9.88	NA	NA	8.87	9.54	0.88	090
30200	A	Injection treatment of nose	0.78	2.02	1.82	0.67	0.70	0.06	000
30210	A	Nasal sinus therapy	1.10	2.51	2.30	1.27	1.29	0.09	010
30220	A	Insert nasal septal button	1.56	5.81	5.02	1.42	1.47	0.12	010
30300	A	Remove nasal foreign body	1.06	4.29	4.46	1.87	1.89	0.08	010
30310	A	Remove nasal foreign body	1.98	NA	NA	2.91	3.00	0.16	010
30320	A	Remove nasal foreign body	4.56	NA	NA	6.35	6.69	0.39	090
30400	R	Reconstruction of nose	10.58	NA	NA	13.90	14.69	1.04	090
30410	R	Reconstruction of nose	13.72	NA	NA	15.32	16.84	1.42	090
30420	R	Reconstruction of nose	16.62	NA	NA	15.82	16.86	1.46	090
30430	R	Revision of nose	7.96	NA	NA	13.24	14.62	0.77	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
30435	R	Revision of nose	12.45	NA	NA	15.42	17.38	1.22	090
30450	R	Revision of nose	19.38	NA	NA	16.88	19.38	1.97	090
30460	A	Revision of nose	10.24	NA	NA	7.48	8.71	1.03	090
30462	A	Revision of nose	20.12	NA	NA	14.64	17.44	2.54	090
30465	A	Repair nasal stenosis	12.20	NA	NA	11.07	11.52	1.06	090
30520	A	Repair of nasal septum	6.85	NA	NA	8.04	7.35	0.46	090
30540	A	Repair nasal defect	7.81	NA	NA	8.54	8.91	0.67	090
30545	A	Repair nasal defect	11.50	NA	NA	11.08	11.48	1.71	090
30560	A	Release of nasal adhesions	1.28	5.28	5.02	2.02	2.08	0.10	010
30580	A	Repair upper jaw fistula	6.76	8.13	7.95	4.69	5.24	0.89	090
30600	A	Repair mouth/nose fistula	6.07	7.67	7.59	4.18	4.60	0.70	090
30620	A	Intranasal reconstruction	6.04	NA	NA	8.66	8.75	0.57	090
30630	A	Repair nasal septum defect	7.18	NA	NA	7.73	7.83	0.61	090
30801	A	Ablate inf turbinate, superf	1.11	4.30	4.21	2.12	2.02	0.09	010
30802	A	Cauterization, inner nose	2.05	4.97	4.79	2.51	2.44	0.16	010
30901	A	Control of nosebleed	1.21	1.27	1.31	0.30	0.31	0.11	000
30903	A	Control of nosebleed	1.54	3.27	2.99	0.43	0.46	0.13	000
30905	A	Control of nosebleed	1.97	3.93	3.72	0.51	0.63	0.17	000
30906	A	Repeat control of nosebleed	2.45	4.28	4.08	0.76	0.98	0.20	000
30915	A	Ligation, nasal sinus artery	7.36	NA	NA	6.46	6.57	0.58	090
30920	A	Ligation, upper jaw artery	11.03	NA	NA	8.96	8.96	0.80	090
30930	A	Ther fx, nasal inf turbinate	1.28	NA	NA	1.64	1.63	0.12	010
30999	C	Nasal surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
31000	A	Irrigation, maxillary sinus	1.17	3.22	3.03	1.34	1.37	0.09	010
31002	A	Irrigation, sphenoid sinus	1.93	NA	NA	2.69	2.96	0.15	010
31020	A	Exploration, maxillary sinus	2.99	8.60	8.56	5.54	5.36	0.29	090
31030	A	Exploration, maxillary sinus	5.95	10.40	10.94	6.44	6.55	0.60	090
31032	A	Explore sinus, remove polyps	6.61	NA	NA	7.00	7.11	0.59	090
31040	A	Exploration behind upper jaw	9.66	NA	NA	7.37	8.59	0.87	090
31050	A	Exploration, sphenoid sinus	5.31	NA	NA	6.50	6.43	0.49	090
31051	A	Sphenoid sinus surgery	7.16	NA	NA	8.36	8.30	0.62	090
31070	A	Exploration of frontal sinus	4.32	NA	NA	6.18	6.06	0.38	090
31075	A	Exploration of frontal sinus	9.40	NA	NA	9.32	9.52	0.75	090
31080	A	Removal of frontal sinus	12.54	NA	NA	10.61	12.07	1.23	090
31081	A	Removal of frontal sinus	13.99	NA	NA	15.36	14.67	2.47	090
31084	A	Removal of frontal sinus	14.75	NA	NA	12.87	13.18	1.19	090
31085	A	Removal of frontal sinus	15.44	NA	NA	14.42	14.19	1.73	090
31086	A	Removal of frontal sinus	14.16	NA	NA	12.77	13.02	1.07	090
31087	A	Removal of frontal sinus	14.39	NA	NA	11.64	12.08	1.44	090
31090	A	Exploration of sinuses	10.88	NA	NA	13.40	12.97	0.94	090
31200	A	Removal of ethmoid sinus	5.03	NA	NA	7.43	8.32	0.29	090
31201	A	Removal of ethmoid sinus	8.49	NA	NA	8.99	9.08	0.82	090
31205	A	Removal of ethmoid sinus	10.47	NA	NA	9.51	10.69	0.67	090
31225	A	Removal of upper jaw	26.44	NA	NA	17.88	17.85	1.59	090
31230	A	Removal of upper jaw	30.56	NA	NA	19.48	19.41	1.78	090
31231	A	Nasal endoscopy, dx	1.10	3.59	3.49	0.77	0.82	0.09	000
31233	A	Nasal/sinus endoscopy, dx	2.18	4.26	4.28	1.12	1.30	0.20	000
31235	A	Nasal/sinus endoscopy, dx	2.64	4.64	4.77	1.26	1.49	0.26	000
31237	A	Nasal/sinus endoscopy, surg	2.98	4.90	5.05	1.39	1.63	0.28	000
31238	A	Nasal/sinus endoscopy, surg	3.26	4.82	5.03	1.48	1.79	0.27	000
31239	A	Nasal/sinus endoscopy, surg	9.23	NA	NA	6.42	7.21	0.62	010
31240	A	Nasal/sinus endoscopy, surg	2.61	NA	NA	1.27	1.50	0.24	000
31254	A	Revision of ethmoid sinus	4.64	NA	NA	1.93	2.39	0.45	000
31255	A	Removal of ethmoid sinus	6.95	NA	NA	2.69	3.40	0.73	000
31256	A	Exploration maxillary sinus	3.29	NA	NA	1.49	1.80	0.33	000
31267	A	Endoscopy, maxillary sinus	5.45	NA	NA	2.20	2.74	0.55	000
31276	A	Sinus endoscopy, surgical	8.84	NA	NA	3.31	4.21	0.92	000
31287	A	Nasal/sinus endoscopy, surg	3.91	NA	NA	1.69	2.07	0.39	000
31288	A	Nasal/sinus endoscopy, surg	4.57	NA	NA	1.91	2.36	0.46	000
31290	A	Nasal/sinus endoscopy, surg	18.50	NA	NA	9.04	10.54	1.40	010
31291	A	Nasal/sinus endoscopy, surg	19.45	NA	NA	9.53	11.00	1.69	010
31292	A	Nasal/sinus endoscopy, surg	15.79	NA	NA	8.05	9.33	1.21	010
31293	A	Nasal/sinus endoscopy, surg	17.36	NA	NA	8.68	10.02	1.28	010
31294	A	Nasal/sinus endoscopy, surg	20.20	NA	NA	9.66	11.26	1.53	010
31299	C	Sinus surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
31300	A	Removal of larynx lesion	15.71	NA	NA	14.57	14.77	1.17	090
31320	A	Diagnostic incision, larynx	5.62	NA	NA	10.14	10.22	0.46	090
31360	A	Removal of larynx	29.57	NA	NA	20.06	18.39	1.38	090
31365	A	Removal of larynx	38.47	NA	NA	22.97	21.66	1.98	090
31367	A	Partial removal of larynx	30.23	NA	NA	22.50	22.19	1.79	090
31368	A	Partial removal of larynx	33.85	NA	NA	24.58	25.03	2.21	090
31370	A	Partial removal of larynx	27.23	NA	NA	22.13	22.19	1.75	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
31375	A	Partial removal of larynx	25.73	NA	NA	21.14	20.75	1.63	090
31380	A	Partial removal of larynx	25.23	NA	NA	20.78	20.69	1.71	090
31382	A	Partial removal of larynx	28.23	NA	NA	22.68	22.14	1.68	090
31390	A	Removal of larynx & pharynx	42.17	NA	NA	25.96	25.16	2.24	090
31395	A	Reconstruct larynx & pharynx	43.46	NA	NA	28.50	28.39	2.49	090
31400	A	Revision of larynx	11.48	NA	NA	12.49	13.12	0.83	090
31420	A	Removal of epiglottis	11.32	NA	NA	8.58	9.06	0.83	090
31500	A	Insert emergency airway	2.33	NA	NA	0.42	0.48	0.17	000
31502	A	Change of windpipe airway	0.65	NA	NA	0.21	0.25	0.05	000
31505	A	Diagnostic laryngoscopy	0.61	1.42	1.43	0.59	0.60	0.05	000
31510	A	Laryngoscopy with biopsy	1.92	3.22	3.26	1.00	1.12	0.16	000
31511	A	Remove foreign body, larynx	2.16	2.94	3.03	1.03	1.04	0.19	000
31512	A	Removal of larynx lesion	2.07	2.97	3.08	1.06	1.21	0.18	000
31513	A	Injection into vocal cord	2.10	NA	NA	1.08	1.27	0.17	000
31515	A	Laryngoscopy for aspiration	1.80	3.19	3.37	0.88	0.97	0.14	000
31520	A	Dx laryngoscopy, newborn	2.56	NA	NA	1.21	1.38	0.20	000
31525	A	Dx laryngoscopy excl nb	2.63	3.45	3.54	1.23	1.44	0.21	000
31526	A	Dx laryngoscopy w/oper scope	2.57	NA	NA	1.25	1.48	0.21	000
31527	A	Laryngoscopy for treatment	3.27	NA	NA	1.40	1.63	0.26	000
31528	A	Laryngoscopy and dilation	2.37	NA	NA	1.09	1.27	0.19	000
31529	A	Laryngoscopy and dilation	2.68	NA	NA	1.25	1.48	0.22	000
31530	A	Laryngoscopy w/fb removal	3.38	NA	NA	1.45	1.70	0.29	000
31531	A	Laryngoscopy w/fb & op scope	3.58	NA	NA	1.58	1.93	0.29	000
31535	A	Laryngoscopy w/biopsy	3.16	NA	NA	1.44	1.72	0.26	000
31536	A	Laryngoscopy w/bx & op scope	3.55	NA	NA	1.57	1.91	0.29	000
31540	A	Laryngoscopy w/exc of tumor	4.12	NA	NA	1.76	2.15	0.33	000
31541	A	Laryngosc w/tumr exc + scope	4.52	NA	NA	1.89	2.34	0.37	000
31545	A	Remove vc lesion w/scope	6.30	NA	NA	2.51	2.99	0.37	000
31546	A	Remove vc lesion scope/graft	9.73	NA	NA	3.43	4.20	0.78	000
31560	A	Laryngosc w/arytenoidectom	5.45	NA	NA	2.15	2.65	0.43	000
31561	A	Laryngosc, remove cart + scop	5.99	NA	NA	2.32	2.84	0.49	000
31570	A	Laryngoscope w/vc inj	3.86	4.26	4.96	1.64	2.01	0.31	000
31571	A	Laryngosc w/vc inj + scope	4.26	NA	NA	1.81	2.20	0.35	000
31575	A	Diagnostic laryngoscopy	1.10	1.69	1.80	0.76	0.82	0.09	000
31576	A	Laryngoscopy with biopsy	1.97	3.52	3.59	1.04	1.16	0.14	000
31577	A	Remove foreign body, larynx	2.47	3.37	3.56	1.17	1.35	0.21	000
31578	A	Removal of larynx lesion	2.84	3.99	4.13	1.34	1.43	0.23	000
31579	A	Diagnostic laryngoscopy	2.26	2.86	3.32	1.15	1.31	0.18	000
31580	A	Revision of larynx	14.46	NA	NA	13.82	14.86	1.00	090
31582	A	Revision of larynx	22.87	NA	NA	22.55	24.16	1.76	090
31584	A	Treat larynx fracture	20.35	NA	NA	15.26	16.70	1.72	090
31587	A	Revision of larynx	15.12	NA	NA	8.63	8.95	0.97	090
31588	A	Revision of larynx	14.62	NA	NA	12.50	13.05	1.06	090
31590	A	Reinnervate larynx	7.63	NA	NA	12.78	14.15	0.84	090
31595	A	Larynx nerve surgery	8.75	NA	NA	9.64	10.09	0.68	090
31599	C	Larynx surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
31600	A	Incision of windpipe	7.17	NA	NA	2.28	2.73	0.80	000
31601	A	Incision of windpipe	4.44	NA	NA	1.74	2.07	0.40	000
31603	A	Incision of windpipe	4.14	NA	NA	1.19	1.45	0.44	000
31605	A	Incision of windpipe	3.57	NA	NA	0.82	1.00	0.40	000
31610	A	Incision of windpipe	9.29	NA	NA	7.72	7.99	0.79	090
31611	A	Surgery/speech prosthesis	5.92	NA	NA	7.07	7.06	0.46	090
31612	A	Puncture/clear windpipe	0.91	1.09	1.09	0.26	0.30	0.08	000
31613	A	Repair windpipe opening	4.63	NA	NA	6.13	6.06	0.42	090
31614	A	Repair windpipe opening	8.47	NA	NA	9.57	9.14	0.58	090
31615	A	Visualization of windpipe	2.09	2.37	2.48	1.04	1.12	0.16	000
31620	A	Endobronchial us add-on	1.40	6.01	5.83	0.33	0.44	0.11	ZZZ
31622	A	Dx bronchoscope/wash	2.78	5.23	5.44	0.90	0.98	0.18	000
31623	A	Dx bronchoscope/brush	2.88	5.97	6.20	0.89	0.97	0.13	000
31624	A	Dx bronchoscope/lavage	2.88	5.33	5.55	0.89	0.97	0.13	000
31625	A	Bronchoscopy w/biopsy(s)	3.36	5.48	5.64	1.01	1.11	0.18	000
31628	A	Bronchoscopy/lung bx, each	3.80	6.95	6.98	1.10	1.20	0.18	000
31629	A	Bronchoscopy/needle bx, each	4.09	12.00	13.12	1.17	1.28	0.16	000
31630	A	Bronchoscopy dilate/fx repr	3.81	NA	NA	1.27	1.49	0.32	000
31631	A	Bronchoscopy, dilate w/stent	4.36	NA	NA	1.42	1.59	0.34	000
31632	A	Bronchoscopy/lung bx, add'l	1.03	0.85	0.83	0.24	0.27	0.18	ZZZ
31633	A	Bronchoscopy/needle bx add'l	1.32	0.99	0.95	0.31	0.35	0.16	ZZZ
31635	A	Bronchoscopy w/fb removal	3.67	5.19	5.65	1.13	1.28	0.24	000
31636	A	Bronchoscopy, bronch stents	4.30	NA	NA	1.34	1.55	0.31	000
31637	A	Bronchoscopy, stent add-on	1.58	NA	NA	0.41	0.48	0.13	ZZZ
31638	A	Bronchoscopy, revise stent	4.88	NA	NA	1.54	1.76	0.22	000
31640	A	Bronchoscopy w/tumor excise	4.93	NA	NA	1.53	1.80	0.46	000

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fac- ility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
31641	A	Bronchoscopy, treat blockage	5.02	NA	NA	1.49	1.68	0.35	000
31643	A	Diag bronchoscope/catheter	3.49	NA	NA	1.04	1.13	0.20	000
31645	A	Bronchoscopy, clear airways	3.16	4.72	4.93	0.96	1.04	0.16	000
31646	A	Bronchoscopy, reclear airway	2.72	4.41	4.63	0.85	0.92	0.14	000
31656	A	Bronchoscopy, inj for x-ray	2.17	5.68	6.48	0.68	0.76	0.15	000
31715	A	Injection for bronchus x-ray	1.11	NA	NA	0.25	0.29	0.07	000
31717	A	Bronchial brush biopsy	2.12	5.84	7.04	0.72	0.75	0.14	000
31720	A	Clearance of airways	1.06	NA	NA	0.27	0.30	0.07	000
31725	A	Clearance of airways	1.96	NA	NA	0.41	0.49	0.14	000
31730	A	Intro, windpipe wire/tube	2.85	25.71	13.95	0.74	0.87	0.21	000
31750	A	Repair of windpipe	15.19	NA	NA	17.44	17.49	1.05	090
31755	A	Repair of windpipe	17.19	NA	NA	23.97	24.24	1.29	090
31760	A	Repair of windpipe	23.36	NA	NA	9.77	10.24	2.95	090
31766	A	Reconstruction of windpipe	31.58	NA	NA	11.68	12.66	4.53	090
31770	A	Repair/graft of bronchus	23.48	NA	NA	8.53	9.38	2.84	090
31775	A	Reconstruct bronchus	24.51	NA	NA	9.50	10.64	3.02	090
31780	A	Reconstruct windpipe	19.70	NA	NA	8.79	9.92	1.65	090
31781	A	Reconstruct windpipe	24.77	NA	NA	9.66	10.89	2.25	090
31785	A	Remove windpipe lesion	18.29	NA	NA	7.67	8.92	1.59	090
31786	A	Remove windpipe lesion	25.34	NA	NA	9.61	11.35	3.30	090
31800	A	Repair of windpipe injury	8.10	NA	NA	8.67	8.95	0.79	090
31805	A	Repair of windpipe injury	13.34	NA	NA	6.21	6.71	1.83	090
31820	A	Closure of windpipe lesion	4.58	5.85	5.76	3.26	3.45	0.38	090
31825	A	Repair of windpipe defect	6.98	7.44	7.55	4.47	4.92	0.53	090
31830	A	Revise windpipe scar	4.54	5.93	5.84	3.56	3.77	0.44	090
31899	C	Airways surgical procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
32035	A	Exploration of chest	11.20	NA	NA	6.08	5.96	1.26	090
32036	A	Exploration of chest	12.21	NA	NA	6.29	6.36	1.43	090
32095	A	Biopsy through chest wall	10.06	NA	NA	5.10	5.23	1.22	090
32100	A	Exploration/biopsy of chest	16.08	NA	NA	7.00	7.41	2.24	090
32110	A	Explore/repair chest	25.15	NA	NA	9.87	10.29	3.22	090
32120	A	Re-exploration of chest	14.27	NA	NA	6.78	6.92	1.63	090
32124	A	Explore chest free adhesions	15.33	NA	NA	6.95	7.08	1.90	090
32140	A	Removal of lung lesion(s)	16.54	NA	NA	7.39	7.53	1.97	090
32141	A	Remove/treat lung lesions	27.10	NA	NA	10.17	8.86	2.01	090
32150	A	Removal of lung lesion(s)	16.70	NA	NA	7.50	7.55	2.01	090
32151	A	Remove lung foreign body	16.82	NA	NA	7.91	7.95	2.04	090
32160	A	Open chest heart massage	13.02	NA	NA	5.84	5.55	1.31	090
32200	A	Drain, open, lung lesion	18.48	NA	NA	8.76	8.68	2.14	090
32201	A	Drain, percut, lung lesion	3.99	19.84	20.27	1.42	1.36	0.24	000
32215	A	Treat chest lining	12.93	NA	NA	6.23	6.56	1.69	090
32220	A	Release of lung	26.41	NA	NA	11.90	12.42	3.57	090
32225	A	Partial release of lung	16.63	NA	NA	7.45	7.55	2.07	090
32310	A	Removal of chest lining	15.16	NA	NA	6.92	7.15	2.00	090
32320	A	Free/remove chest lining	27.04	NA	NA	11.44	11.79	3.52	090
32400	A	Needle biopsy chest lining	1.76	2.15	2.14	0.57	0.56	0.10	000
32402	A	Open biopsy chest lining	8.89	NA	NA	4.68	4.89	1.07	090
32405	A	Biopsy, lung or mediastinum	1.93	0.69	0.68	0.69	0.66	0.11	000
32420	A	Puncture/clear lung	2.18	NA	NA	0.71	0.69	0.12	000
32421	A	Thoracentesis for aspiration	1.54	2.40	2.73	0.47	0.47	0.08	000
32422	A	Thoracentesis w/tube insert	2.19	2.87	3.04	1.03	1.04	0.12	000
32440	A	Removal of lung	27.17	NA	NA	10.91	11.90	3.69	090
32442	A	Sleeve pneumonectomy	56.37	NA	NA	18.71	16.73	3.85	090
32445	A	Removal of lung	63.60	NA	NA	22.77	18.41	3.72	090
32480	A	Partial removal of lung	25.71	NA	NA	10.18	11.12	3.50	090
32482	A	Bilobectomy	27.28	NA	NA	11.08	11.99	3.67	090
32484	A	Segmentectomy	25.30	NA	NA	9.56	10.47	3.04	090
32486	A	Sleeve lobectomy	42.80	NA	NA	14.60	13.92	3.52	090
32488	A	Completion pneumonectomy	42.83	NA	NA	15.56	14.67	3.81	090
32491	R	Lung volume reduction	25.09	NA	NA	10.42	11.52	2.99	090
32500	A	Partial removal of lung	24.48	NA	NA	10.26	11.30	3.26	090
32501	A	Repair bronchus add-on	4.68	NA	NA	1.33	1.43	0.65	ZZZ
32503	A	Resect apical lung tumor	31.61	NA	NA	12.08	13.57	4.38	090
32504	A	Resect apical lung tum/chest	36.41	NA	NA	13.46	15.06	5.09	090
32540	A	Removal of lung lesion	30.22	NA	NA	11.48	10.55	2.08	090
32550	A	Insert pleural cath	4.17	14.95	17.45	1.51	1.58	0.42	000
32551	A	Insertion of chest tube	3.29	NA	NA	0.97	1.16	0.43	000
32560	A	Treat lung lining chemically	2.19	5.05	5.75	0.58	0.64	0.23	000
32601	A	Thoracoscopy, diagnostic	5.45	NA	NA	2.06	2.21	0.80	000
32602	A	Thoracoscopy, diagnostic	5.95	NA	NA	2.22	2.37	0.87	000
32603	A	Thoracoscopy, diagnostic	7.80	NA	NA	2.74	2.88	1.14	000
32604	A	Thoracoscopy, diagnostic	8.77	NA	NA	3.05	3.25	1.25	000

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
32605	A	Thoracoscopy, diagnostic	6.92	NA	NA	2.57	2.74	1.00	000
32606	A	Thoracoscopy, diagnostic	8.39	NA	NA	2.97	3.15	1.22	000
32650	A	Thoracoscopy, surgical	10.77	NA	NA	5.24	6.00	1.58	090
32651	A	Thoracoscopy, surgical	18.70	NA	NA	7.69	7.46	1.87	090
32652	A	Thoracoscopy, surgical	29.00	NA	NA	11.13	10.63	2.73	090
32653	A	Thoracoscopy, surgical	18.09	NA	NA	7.45	7.21	1.89	090
32654	A	Thoracoscopy, surgical	20.44	NA	NA	7.95	7.74	1.63	090
32655	A	Thoracoscopy, surgical	16.09	NA	NA	6.88	7.06	1.90	090
32656	A	Thoracoscopy, surgical	13.18	NA	NA	5.95	6.94	1.90	090
32657	A	Thoracoscopy, surgical	12.85	NA	NA	5.97	6.82	2.00	090
32658	A	Thoracoscopy, surgical	11.65	NA	NA	5.50	6.42	1.70	090
32659	A	Thoracoscopy, surgical	11.86	NA	NA	5.79	6.62	1.62	090
32660	A	Thoracoscopy, surgical	17.69	NA	NA	7.58	8.53	2.09	090
32661	A	Thoracoscopy, surgical	13.27	NA	NA	6.05	6.91	1.93	090
32662	A	Thoracoscopy, surgical	14.91	NA	NA	6.63	7.73	2.18	090
32663	A	Thoracoscopy, surgical	24.56	NA	NA	9.39	10.07	2.73	090
32664	A	Thoracoscopy, surgical	14.22	NA	NA	5.61	6.62	2.33	090
32665	A	Thoracoscopy, surgical	21.45	NA	NA	8.56	8.34	2.16	090
32800	A	Repair lung hernia	15.59	NA	NA	6.92	7.16	1.99	090
32810	A	Close chest after drainage	14.83	NA	NA	6.97	7.24	1.94	090
32815	A	Close bronchial fistula	49.79	NA	NA	18.57	14.77	3.28	090
32820	A	Reconstruct injured chest	22.33	NA	NA	10.56	11.36	2.53	090
32850	X	Donor pneumonectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
32851	A	Lung transplant, single	40.94	NA	NA	20.17	23.91	5.58	090
32852	A	Lung transplant with bypass	44.65	NA	NA	22.56	27.85	6.02	090
32853	A	Lung transplant, double	50.11	NA	NA	22.77	27.25	7.07	090
32854	A	Lung transplant with bypass	53.88	NA	NA	25.76	30.24	7.22	090
32855	C	Prepare donor lung, single	0.00	0.00	0.00	0.00	0.00	0.00	XXX
32856	C	Prepare donor lung, double	0.00	0.00	0.00	0.00	0.00	0.00	XXX
32900	A	Removal of rib(s)	23.69	NA	NA	9.56	9.72	2.94	090
32905	A	Revise & repair chest wall	23.17	NA	NA	9.52	9.82	3.16	090
32906	A	Revise & repair chest wall	29.18	NA	NA	11.03	11.54	3.98	090
32940	A	Revision of lung	21.22	NA	NA	8.48	8.98	2.89	090
32960	A	Therapeutic pneumothorax	1.84	1.61	1.67	0.68	0.62	0.16	000
32997	A	Total lung lavage	7.31	NA	NA	1.83	1.87	0.55	000
32998	A	Perq rf ablate tx, pul tumor	5.68	70.18	70.18	1.98	1.98	0.36	000
32999	C	Chest surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
33010	A	Drainage of heart sac	2.24	NA	NA	1.04	0.91	0.14	000
33011	A	Repeat drainage of heart sac	2.24	NA	NA	1.12	0.97	0.15	000
33015	A	Incision of heart sac	8.44	NA	NA	5.15	5.05	0.65	090
33020	A	Incision of heart sac	14.87	NA	NA	6.37	6.57	1.80	090
33025	A	Incision of heart sac	13.65	NA	NA	5.84	6.09	1.81	090
33030	A	Partial removal of heart sac	22.27	NA	NA	9.11	9.31	2.84	090
33031	A	Partial removal of heart sac	25.30	NA	NA	9.57	9.80	3.14	090
33050	A	Removal of heart sac lesion	16.85	NA	NA	7.36	7.60	2.15	090
33120	A	Removal of heart lesion	27.33	NA	NA	10.55	11.06	3.70	090
33130	A	Removal of heart lesion	24.05	NA	NA	9.36	9.73	3.01	090
33140	A	Heart revascularize (tmr)	28.26	NA	NA	10.29	10.58	2.86	090
33141	A	Heart tmr w/other procedure	2.54	NA	NA	0.78	1.18	0.69	ZZZ
33202	A	Insert epicard eltrd, open	13.15	NA	NA	6.07	6.07	1.71	090
33203	A	Insert epicard eltrd, endo	13.92	NA	NA	6.13	6.13	1.39	090
33206	A	Insertion of heart pacemaker	7.31	NA	NA	5.12	4.79	0.52	090
33207	A	Insertion of heart pacemaker	8.00	NA	NA	5.22	4.94	0.59	090
33208	A	Insertion of heart pacemaker	8.72	NA	NA	5.65	5.21	0.56	090
33210	A	Insertion of heart electrode	3.30	NA	NA	1.66	1.45	0.18	000
33211	A	Insertion of heart electrode	3.39	NA	NA	1.59	1.45	0.21	000
33212	A	Insertion of pulse generator	5.51	NA	NA	3.70	3.53	0.43	090
33213	A	Insertion of pulse generator	6.36	NA	NA	4.21	3.96	0.45	090
33214	A	Upgrade of pacemaker system	7.78	NA	NA	5.36	5.12	0.58	090
33215	A	Reposition pacing-defib lead	4.89	NA	NA	3.48	3.33	0.37	090
33216	A	Insert lead pace-defib, one	5.81	NA	NA	4.54	4.37	0.36	090
33217	A	Insert lead pace-defib, dual	5.78	NA	NA	4.43	4.33	0.39	090
33218	A	Repair lead pace-defib, one	5.97	NA	NA	4.82	4.56	0.37	090
33220	A	Repair lead pace-defib, dual	6.05	NA	NA	4.78	4.52	0.37	090
33222	A	Revise pocket, pacemaker	5.01	NA	NA	4.30	4.29	0.42	090
33223	A	Revise pocket, pacing-defib	6.49	NA	NA	4.87	4.73	0.45	090
33224	A	Insert pacing lead & connect	9.04	NA	NA	4.90	4.45	0.54	000
33225	A	L ventric pacing lead add-on	8.33	NA	NA	4.35	3.80	0.45	ZZZ
33226	A	Reposition I ventric lead	8.68	NA	NA	4.73	4.28	0.59	000
33233	A	Removal of pacemaker system	3.33	NA	NA	3.26	3.27	0.22	090
33234	A	Removal of pacemaker system	7.85	NA	NA	5.48	5.19	0.56	090
33235	A	Removal pacemaker electrode	9.93	NA	NA	7.23	7.02	0.73	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
33236	A	Remove electrode/thoracotomy	12.64	NA	NA	6.37	6.90	1.69	090
33237	A	Remove electrode/thoracotomy	13.75	NA	NA	8.01	7.89	1.59	090
33238	A	Remove electrode/thoracotomy	15.28	NA	NA	8.04	8.12	2.03	090
33240	A	Insert pulse generator	7.61	NA	NA	5.25	4.91	0.41	090
33241	A	Remove pulse generator	3.26	NA	NA	3.00	2.98	0.18	090
33243	A	Remove eltrd/thoracotomy	23.42	NA	NA	10.93	11.19	2.10	090
33244	A	Remove eltrd, transven	13.84	NA	NA	9.43	9.16	0.99	090
33249	A	Eltrd/insert pace-defib	15.02	NA	NA	10.15	9.25	0.77	090
33250	A	Ablate heart dysrhythm focus	25.78	NA	NA	10.88	10.94	3.19	090
33251	A	Ablate heart dysrhythm focus	28.80	NA	NA	10.95	11.30	3.60	090
33254	A	Ablate atria, lmtd	23.58	NA	NA	9.76	9.76	3.35	090
33255	A	Ablate atria w/o bypass, ext	28.91	NA	NA	11.36	11.36	3.94	090
33256	A	Ablate atria w/bypass, exten	34.77	NA	NA	13.11	13.11	4.95	090
33257	A	Ablate atria, lmtd, add-on	9.63	NA	NA	5.46	5.46	0.89	ZZZ
33258	A	Ablate atria, x10sv, add-on	11.00	NA	NA	5.98	5.98	1.09	ZZZ
33259	A	Ablate atria w/bypass add-on	14.14	NA	NA	7.79	7.79	1.78	ZZZ
33261	A	Ablate heart dysrhythm focus	28.80	NA	NA	11.68	11.72	3.46	090
33265	A	Ablate atria, lmtd, endo	23.58	NA	NA	9.76	9.76	3.35	090
33266	A	Ablate atria, x10sv, endo	32.91	NA	NA	12.55	12.55	4.80	090
33282	A	Implant pat-active ht record	4.70	NA	NA	4.23	4.12	0.23	090
33284	A	Remove pat-active ht record	3.04	NA	NA	3.37	3.45	0.14	090
33300	A	Repair of heart wound	44.89	NA	NA	15.05	12.14	2.66	090
33305	A	Repair of heart wound	76.85	NA	NA	25.11	17.85	3.13	090
33310	A	Exploratory heart surgery	20.22	NA	NA	8.35	8.96	2.59	090
33315	A	Exploratory heart surgery	26.05	NA	NA	10.34	10.61	3.28	090
33320	A	Repair major blood vessel(s)	18.46	NA	NA	8.00	8.11	2.08	090
33321	A	Repair major vessel	20.71	NA	NA	8.37	9.07	2.91	090
33322	A	Repair major blood vessel(s)	24.30	NA	NA	9.54	9.95	2.86	090
33330	A	Insert major vessel graft	25.17	NA	NA	9.49	9.87	2.82	090
33332	A	Insert major vessel graft	24.46	NA	NA	9.45	9.98	3.03	090
33335	A	Insert major vessel graft	33.79	NA	NA	12.48	12.90	4.28	090
33400	A	Repair of aortic valve	41.37	NA	NA	14.56	15.11	4.11	090
33401	A	Valvuloplasty, open	24.41	NA	NA	10.27	11.88	3.57	090
33403	A	Valvuloplasty, w/cp bypass	25.39	NA	NA	12.52	13.41	3.55	090
33404	A	Prepare heart-aorta conduit	31.25	NA	NA	12.00	13.27	4.33	090
33405	A	Replacement of aortic valve	41.19	NA	NA	15.10	16.69	5.33	090
33406	A	Replacement of aortic valve	52.55	NA	NA	18.36	18.74	5.45	090
33410	A	Replacement of aortic valve	46.28	NA	NA	16.51	16.54	4.69	090
33411	A	Replacement of aortic valve	61.94	NA	NA	21.08	19.90	5.48	090
33412	A	Replacement of aortic valve	43.77	NA	NA	16.20	18.30	6.39	090
33413	A	Replacement of aortic valve	59.74	NA	NA	23.52	22.16	6.53	090
33414	A	Repair of aortic valve	39.29	NA	NA	14.27	14.20	4.57	090
33415	A	Revision, subvalvular tissue	37.19	NA	NA	13.14	12.57	4.14	090
33416	A	Revise ventricle muscle	36.43	NA	NA	13.23	13.36	4.57	090
33417	A	Repair of aortic valve	29.17	NA	NA	11.69	12.65	4.10	090
33420	A	Revision of mitral valve	25.67	NA	NA	9.49	9.52	1.82	090
33422	A	Revision of mitral valve	29.61	NA	NA	11.35	12.50	3.94	090
33425	A	Repair of mitral valve	49.83	NA	NA	17.59	15.32	4.07	090
33426	A	Repair of mitral valve	43.15	NA	NA	15.74	16.43	5.03	090
33427	A	Repair of mitral valve	44.70	NA	NA	15.69	17.52	6.09	090
33430	A	Replacement of mitral valve	50.75	NA	NA	18.55	17.91	5.10	090
33460	A	Revision of tricuspid valve	44.62	NA	NA	14.70	13.00	3.45	090
33463	A	Valvuloplasty, tricuspid	56.95	NA	NA	19.71	16.31	3.87	090
33463	A	Valvuloplasty, tricuspid	56.95	NA	NA	19.71	16.31	3.87	090
33464	A	Valvuloplasty, tricuspid	44.49	NA	NA	15.83	14.67	4.15	090
33465	A	Replace tricuspid valve	50.59	NA	NA	17.63	15.29	4.39	090
33468	A	Revision of tricuspid valve	32.82	NA	NA	15.23	14.44	4.07	090
33470	A	Revision of pulmonary valve	21.32	NA	NA	7.92	9.30	1.03	090
33471	A	Valvotomy, pulmonary valve	22.83	NA	NA	11.58	10.67	3.39	090
33472	A	Revision of pulmonary valve	22.90	NA	NA	8.78	10.31	3.55	090
33474	A	Revision of pulmonary valve	39.27	NA	NA	12.93	11.90	3.22	090
33475	A	Replacement, pulmonary valve	42.27	NA	NA	15.05	15.21	4.93	090
33476	A	Revision of heart chamber	26.41	NA	NA	10.36	11.15	2.42	090
33478	A	Revision of heart chamber	27.38	NA	NA	11.01	12.03	3.89	090
33496	A	Repair, prosth valve clot	29.71	NA	NA	11.08	11.91	4.13	090
33500	A	Repair heart vessel fistula	27.82	NA	NA	11.02	11.24	3.87	090
33501	A	Repair heart vessel fistula	19.43	NA	NA	7.99	8.13	1.91	090
33502	A	Coronary artery correction	21.69	NA	NA	9.33	10.19	3.00	090
33503	A	Coronary artery graft	22.29	NA	NA	12.31	11.02	1.78	090
33504	A	Coronary artery graft	25.30	NA	NA	10.58	11.19	3.36	090
33505	A	Repair artery w/tunnel	38.35	NA	NA	15.12	14.01	2.19	090
33506	A	Repair artery, translocation	37.80	NA	NA	12.69	13.62	4.66	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
33507	A	Repair art, intramural	31.35	NA	NA	11.08	12.36	4.06	090
33508	A	Endoscopic vein harvest	0.31	NA	NA	0.09	0.10	0.04	ZZZ
33510	A	CABG, vein, single	34.87	NA	NA	12.90	14.61	4.41	090
33511	A	CABG, vein, two	38.34	NA	NA	14.15	15.60	4.56	090
33512	A	CABG, vein, three	43.87	NA	NA	15.93	16.76	4.67	090
33513	A	CABG, vein, four	45.26	NA	NA	16.36	17.07	4.88	090
33514	A	CABG, vein, five	47.97	NA	NA	17.33	17.69	4.77	090
33516	A	Cabg, vein, six or more	49.65	NA	NA	17.95	18.37	5.13	090
33517	A	CABG, artery-vein, single	3.61	NA	NA	1.08	0.96	0.39	ZZZ
33518	A	CABG, artery-vein, two	7.93	NA	NA	2.36	1.97	0.73	ZZZ
33519	A	CABG, artery-vein, three	10.49	NA	NA	3.14	2.73	1.04	ZZZ
33521	A	CABG, artery-vein, four	12.59	NA	NA	3.77	3.42	1.37	ZZZ
33522	A	CABG, artery-vein, five	14.14	NA	NA	4.23	4.02	1.78	ZZZ
33523	A	Cabg, art-vein, six or more	16.08	NA	NA	4.78	4.65	2.13	ZZZ
33530	A	Coronary artery, bypass/reop	10.13	NA	NA	2.95	2.43	0.88	ZZZ
33533	A	CABG, arterial, single	33.64	NA	NA	12.55	14.50	4.56	090
33534	A	CABG, arterial, two	39.77	NA	NA	14.73	16.22	4.70	090
33535	A	CABG, arterial, three	44.64	NA	NA	16.29	17.20	5.03	090
33536	A	Cabg, arterial, four or more	48.32	NA	NA	17.31	17.80	5.44	090
33542	A	Removal of heart lesion	48.08	NA	NA	16.88	14.93	4.38	090
33545	A	Repair of heart damage	56.93	NA	NA	20.13	17.87	5.21	090
33548	A	Restore/remodel, ventricle	53.96	NA	NA	19.32	19.30	5.53	090
33572	A	Open coronary endarterectomy	4.44	NA	NA	1.31	1.38	0.65	ZZZ
33600	A	Closure of valve	30.15	NA	NA	12.14	12.32	4.42	090
33602	A	Closure of valve	29.18	NA	NA	11.16	11.80	3.82	090
33606	A	Anastomosis/artery-aorta	31.37	NA	NA	11.90	12.78	4.41	090
33608	A	Repair anomaly w/conduit	31.72	NA	NA	12.85	13.47	4.74	090
33610	A	Repair by enlargement	31.24	NA	NA	13.54	13.57	4.56	090
33611	A	Repair double ventricle	35.49	NA	NA	12.36	13.24	4.37	090
33612	A	Repair double ventricle	36.49	NA	NA	14.30	14.72	5.30	090
33615	A	Repair, modified fontan	35.76	NA	NA	13.78	13.46	4.32	090
33617	A	Repair single ventricle	38.96	NA	NA	13.94	14.96	5.66	090
33619	A	Repair single ventricle	48.60	NA	NA	17.97	19.38	6.46	090
33641	A	Repair heart septum defect	29.50	NA	NA	10.88	10.22	3.23	090
33645	A	Revision of heart veins	27.98	NA	NA	10.66	11.21	3.79	090
33647	A	Repair heart septum defects	29.37	NA	NA	12.70	13.23	3.32	090
33660	A	Repair of heart defects	31.75	NA	NA	11.82	12.65	4.49	090
33665	A	Repair of heart defects	34.77	NA	NA	12.16	12.99	4.00	090
33670	A	Repair of heart chambers	36.58	NA	NA	15.62	14.39	4.65	090
33675	A	Close mult vsd	35.87	NA	NA	15.74	15.74	4.95	090
33676	A	Close mult vsd w/resection	36.87	NA	NA	16.04	16.04	5.44	090
33677	A	CI mult vsd w/rem pul band	38.37	NA	NA	16.61	16.61	5.68	090
33681	A	Repair heart septum defect	32.16	NA	NA	12.87	13.77	4.45	090
33684	A	Repair heart septum defect	34.29	NA	NA	13.28	13.45	3.39	090
33688	A	Repair heart septum defect	34.67	NA	NA	11.61	11.04	4.73	090
33690	A	Reinforce pulmonary artery	20.20	NA	NA	8.63	9.39	1.97	090
33692	A	Repair of heart defects	31.38	NA	NA	19.57	16.74	4.58	090
33694	A	Repair of heart defects	35.49	NA	NA	10.04	12.12	5.28	090
33697	A	Repair of heart defects	37.49	NA	NA	16.93	15.90	4.09	090
33702	A	Repair of heart defects	27.11	NA	NA	10.52	11.54	3.68	090
33710	A	Repair of heart defects	30.28	NA	NA	11.25	12.60	4.43	090
33720	A	Repair of heart defect	27.13	NA	NA	10.68	11.48	3.84	090
33722	A	Repair of heart defect	29.05	NA	NA	10.60	12.22	1.30	090
33724	A	Repair venous anomaly	27.55	NA	NA	10.37	10.37	4.00	090
33726	A	Repair pul venous stenosis	37.04	NA	NA	13.21	13.21	5.03	090
33730	A	Repair heart-vein defect(s)	36.01	NA	NA	12.85	13.48	5.03	090
33732	A	Repair heart-vein defect	28.80	NA	NA	12.65	13.01	3.68	090
33735	A	Revision of heart chamber	22.04	NA	NA	11.03	9.99	1.92	090
33736	A	Revision of heart chamber	24.16	NA	NA	12.06	11.95	3.09	090
33737	A	Revision of heart chamber	22.34	NA	NA	9.12	10.02	3.25	090
33750	A	Major vessel shunt	22.06	NA	NA	9.42	9.81	1.16	090
33755	A	Major vessel shunt	22.44	NA	NA	7.79	8.29	3.26	090
33762	A	Major vessel shunt	22.44	NA	NA	8.68	9.41	3.14	090
33764	A	Major vessel shunt & graft	22.44	NA	NA	8.94	9.58	3.01	090
33766	A	Major vessel shunt	23.41	NA	NA	8.47	10.06	3.70	090
33767	A	Major vessel shunt	25.14	NA	NA	8.50	10.11	3.82	090
33768	A	Cavopulmonary shunting	8.00	NA	NA	1.84	2.25	1.19	ZZZ
33770	A	Repair great vessels defect	39.02	NA	NA	11.91	13.29	5.74	090
33771	A	Repair great vessels defect	40.58	NA	NA	13.07	12.73	5.68	090
33774	A	Repair great vessels defect	31.54	NA	NA	12.19	13.42	4.81	090
33775	A	Repair great vessels defect	32.83	NA	NA	10.09	12.54	4.99	090
33776	A	Repair great vessels defect	34.53	NA	NA	10.24	13.02	5.09	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
33777	A	Repair great vessels defect	33.95	NA	NA	9.91	12.76	5.49	090
33778	A	Repair great vessels defect	42.62	NA	NA	14.91	15.90	6.20	090
33779	A	Repair great vessels defect	43.15	NA	NA	12.44	13.90	2.92	090
33780	A	Repair great vessels defect	43.85	NA	NA	13.13	16.10	3.68	090
33781	A	Repair great vessels defect	43.16	NA	NA	11.11	12.22	5.97	090
33786	A	Repair arterial trunk	41.74	NA	NA	14.09	15.40	5.71	090
33788	A	Revision of pulmonary artery	27.26	NA	NA	8.24	10.09	4.03	090
33800	A	Aortic suspension	17.23	NA	NA	6.82	7.46	2.46	090
33802	A	Repair vessel defect	18.24	NA	NA	7.94	8.58	2.27	090
33803	A	Repair vessel defect	20.18	NA	NA	6.38	8.07	3.20	090
33813	A	Repair septal defect	21.23	NA	NA	8.80	9.85	3.13	090
33814	A	Repair septal defect	26.41	NA	NA	10.39	11.52	3.85	090
33820	A	Revise major vessel	16.61	NA	NA	6.95	7.65	2.35	090
33822	A	Revise major vessel	17.63	NA	NA	5.93	7.44	2.68	090
33824	A	Revise major vessel	20.10	NA	NA	8.45	9.21	2.89	090
33840	A	Remove aorta constriction	21.21	NA	NA	9.33	9.81	2.16	090
33845	A	Remove aorta constriction	22.77	NA	NA	9.37	10.36	3.22	090
33851	A	Remove aorta constriction	21.85	NA	NA	8.87	9.77	3.18	090
33852	A	Repair septal defect	24.28	NA	NA	14.75	13.05	2.16	090
33853	A	Repair septal defect	32.35	NA	NA	12.24	13.53	4.48	090
33860	A	Ascending aortic graft	59.33	NA	NA	20.20	18.32	5.76	090
33861	A	Ascending aortic graft	43.94	NA	NA	15.69	16.69	6.37	090
33863	A	Ascending aortic graft	58.71	NA	NA	19.58	19.13	6.59	090
33864	A	Ascending aortic graft	60.00	NA	NA	20.09	20.09	6.73	090
33870	A	Transverse aortic arch graft	45.93	NA	NA	16.27	17.32	6.62	090
33875	A	Thoracic aortic graft	35.68	NA	NA	12.90	13.49	4.89	090
33877	A	Thoracoabdominal graft	68.85	NA	NA	21.00	18.65	5.94	090
33880	A	Endovasc taa repr incl subcl	34.48	NA	NA	10.91	12.19	2.75	090
33881	A	Endovasc taa repr w/o subcl	29.48	NA	NA	9.66	10.80	2.33	090
33883	A	Insert endovasc prosth, taa	20.99	NA	NA	7.23	8.20	2.11	090
33884	A	Endovasc prosth, taa, add-on	8.20	NA	NA	2.08	2.33	0.86	ZZZ
33886	A	Endovasc prosth, delayed	17.99	NA	NA	6.33	7.28	1.80	090
33889	A	Artery transpose/endovas taa	15.92	NA	NA	3.98	4.58	2.18	000
33891	A	Car-car bp grft/endovas taa	20.00	NA	NA	5.81	6.38	2.73	000
33910	A	Remove lung artery emboli	29.59	NA	NA	11.34	11.38	3.70	090
33915	A	Remove lung artery emboli	24.83	NA	NA	9.11	9.37	1.44	090
33916	A	Surgery of great vessel	28.30	NA	NA	10.82	11.07	3.67	090
33917	A	Repair pulmonary artery	25.14	NA	NA	10.02	11.10	3.70	090
33920	A	Repair pulmonary atresia	32.58	NA	NA	9.46	11.64	4.38	090
33922	A	Transect pulmonary artery	24.09	NA	NA	10.24	10.57	3.10	090
33924	A	Remove pulmonary shunt	5.49	NA	NA	1.59	1.72	0.82	ZZZ
33925	A	Rpr pul art unifocal w/o cpb	31.25	NA	NA	16.42	15.54	4.61	090
33926	A	Repr pul art, unifocal w/cpb	44.68	NA	NA	14.79	16.23	6.22	090
33930	X	Removal of donor heart/lung	0.00	0.00	0.00	0.00	0.00	0.00	XXX
33933	C	Prepare donor heart/lung	0.00	0.00	0.00	0.00	0.00	0.00	XXX
33935	R	Transplantation, heart/lung	61.68	NA	NA	22.94	25.84	9.06	090
33940	X	Removal of donor heart	0.00	0.00	0.00	0.00	0.00	0.00	XXX
33944	C	Prepare donor heart	0.00	0.00	0.00	0.00	0.00	0.00	XXX
33945	R	Transplantation of heart	89.08	NA	NA	30.37	25.87	6.26	090
33960	A	External circulation assist	19.33	NA	NA	5.25	5.08	2.67	000
33961	A	External circulation assist	10.91	NA	NA	2.98	3.30	0.88	ZZZ
33967	A	Insert ia percut device	4.84	NA	NA	2.40	2.12	0.35	000
33968	A	Remove aortic assist device	0.64	NA	NA	0.26	0.24	0.07	000
33970	A	Aortic circulation assist	6.74	NA	NA	2.53	2.41	0.82	000
33971	A	Aortic circulation assist	11.91	NA	NA	6.00	6.00	1.25	090
33973	A	Insert balloon device	9.75	NA	NA	3.94	3.62	1.26	000
33974	A	Remove intra-aortic balloon	14.93	NA	NA	7.73	7.80	1.74	090
33975	A	Implant ventricular device	20.97	NA	NA	6.29	6.29	3.07	XXX
33976	A	Implant ventricular device	22.97	NA	NA	7.66	7.60	3.26	XXX
33977	A	Remove ventricular device	20.07	NA	NA	9.41	10.23	2.81	090
33978	A	Remove ventricular device	22.51	NA	NA	10.42	11.08	3.31	090
33979	A	Insert intracorporeal device	45.93	NA	NA	13.28	14.09	6.97	XXX
33980	A	Remove intracorporeal device	64.86	NA	NA	23.06	24.14	8.59	090
33999	C	Cardiac surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
34001	A	Removal of artery clot	17.78	NA	NA	6.36	6.53	1.85	090
34051	A	Removal of artery clot	16.91	NA	NA	7.43	7.60	2.21	090
34101	A	Removal of artery clot	10.85	NA	NA	4.30	4.82	1.41	090
34111	A	Removal of arm artery clot	10.85	NA	NA	4.28	4.82	1.40	090
34151	A	Removal of artery clot	26.41	NA	NA	8.65	9.52	3.56	090
34201	A	Removal of artery clot	19.38	NA	NA	6.54	5.98	1.45	090
34203	A	Removal of leg artery clot	17.73	NA	NA	6.38	7.21	2.36	090
34401	A	Removal of vein clot	26.41	NA	NA	9.26	9.96	3.10	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
34421	A	Removal of vein clot	13.29	NA	NA	5.19	5.74	1.55	090
34451	A	Removal of vein clot	28.41	NA	NA	9.38	10.40	3.84	090
34471	A	Removal of vein clot	21.00	NA	NA	7.86	6.58	1.18	090
34490	A	Removal of vein clot	10.83	NA	NA	4.34	4.88	1.41	090
34501	A	Repair valve, femoral vein	16.74	NA	NA	6.42	7.45	2.35	090
34502	A	Reconstruct vena cava	27.86	NA	NA	10.47	11.38	3.63	090
34510	A	Transposition of vein valve	19.80	NA	NA	7.52	8.46	2.33	090
34520	A	Cross-over vein graft	19.05	NA	NA	7.01	7.73	2.29	090
34530	A	Leg vein fusion	17.77	NA	NA	6.76	7.68	1.74	090
34800	A	Endovas aaa repr w/sm tube	21.46	NA	NA	7.25	8.20	2.46	090
34802	A	Endovas aaa repr w/2-p part	23.71	NA	NA	8.17	8.97	2.33	090
34803	A	Endovas aaa repr w/3-p part	24.74	NA	NA	8.01	9.11	2.01	090
34804	A	Endovas aaa repr w/1-p part	23.71	NA	NA	8.06	8.93	2.30	090
34805	A	Endovas aaa repr w/long tube	22.59	NA	NA	7.26	8.45	2.01	090
34806	A	Aneurysm press sensor add-on	2.06	0.51	0.51	0.51	0.51	0.30	ZZZ
34808	A	Endovas iliac a device addon	4.12	NA	NA	1.05	1.21	0.59	ZZZ
34812	A	Xpose for endoprosth, femorl	6.74	NA	NA	1.66	1.95	1.18	000
34813	A	Femoral endovas graft add-on	4.79	NA	NA	1.16	1.36	0.67	ZZZ
34820	A	Xpose for endoprosth, iliac	9.74	NA	NA	2.45	2.84	1.50	000
34825	A	Endovasc extend prosth, init	12.72	NA	NA	5.14	5.64	1.28	090
34826	A	Endovasc exten prosth, add'l	4.12	NA	NA	1.14	1.25	0.44	ZZZ
34830	A	Open aortic tube prosth repr	35.10	NA	NA	10.33	12.01	4.55	090
34831	A	Open aortoiliac prosth repr	37.85	NA	NA	11.27	11.49	4.89	090
34832	A	Open aortofemor prosth repr	37.85	NA	NA	11.80	13.21	4.85	090
34833	A	Xpose for endoprosth, iliac	11.98	NA	NA	3.29	3.86	1.70	000
34834	A	Xpose, endoprosth, brachial	5.34	NA	NA	1.57	1.88	0.76	000
34900	A	Endovasc iliac repr w/graft	16.77	NA	NA	6.05	6.81	2.00	090
35001	A	Repair defect of artery	20.70	NA	NA	7.70	8.62	2.81	090
35002	A	Repair artery rupture, neck	22.12	NA	NA	7.51	8.60	3.00	090
35005	A	Repair defect of artery	19.18	NA	NA	8.52	8.68	1.77	090
35011	A	Repair defect of artery	18.50	NA	NA	6.29	7.13	2.55	090
35013	A	Repair artery rupture, arm	23.10	NA	NA	7.76	8.71	3.10	090
35021	A	Repair defect of artery	22.09	NA	NA	8.46	8.93	2.87	090
35022	A	Repair artery rupture, chest	25.62	NA	NA	10.57	10.21	3.17	090
35045	A	Repair defect of arm artery	17.94	NA	NA	6.27	6.88	2.45	090
35081	A	Repair defect of artery	33.37	NA	NA	10.70	11.08	4.01	090
35082	A	Repair artery rupture, aorta	41.93	NA	NA	12.76	14.02	5.44	090
35091	A	Repair defect of artery	35.35	NA	NA	9.99	11.77	5.14	090
35092	A	Repair artery rupture, aorta	50.81	NA	NA	14.50	16.06	6.40	090
35102	A	Repair defect of artery	36.37	NA	NA	11.28	11.82	4.48	090
35103	A	Repair artery rupture, groin	43.49	NA	NA	12.63	14.23	5.76	090
35111	A	Repair defect of artery	26.17	NA	NA	8.50	9.48	3.47	090
35112	A	Repair artery rupture, spleen	32.44	NA	NA	10.07	11.01	4.08	090
35121	A	Repair defect of artery	31.41	NA	NA	9.96	11.16	4.30	090
35122	A	Repair artery rupture, belly	37.76	NA	NA	11.51	12.65	4.75	090
35131	A	Repair defect of artery	26.29	NA	NA	8.63	9.68	3.80	090
35132	A	Repair artery rupture, groin	32.44	NA	NA	10.28	11.32	4.30	090
35141	A	Repair defect of artery	20.83	NA	NA	6.93	7.92	2.90	090
35142	A	Repair artery rupture, thigh	25.03	NA	NA	8.24	9.30	3.36	090
35151	A	Repair defect of artery	23.61	NA	NA	7.64	8.81	3.24	090
35152	A	Repair artery rupture, knee	27.53	NA	NA	9.11	10.24	3.61	090
35180	A	Repair blood vessel lesion	15.01	NA	NA	6.25	6.60	1.00	090
35182	A	Repair blood vessel lesion	31.58	NA	NA	10.82	11.81	4.36	090
35184	A	Repair blood vessel lesion	18.72	NA	NA	6.50	7.39	2.53	090
35188	A	Repair blood vessel lesion	15.05	NA	NA	6.28	6.95	2.16	090
35189	A	Repair blood vessel lesion	29.85	NA	NA	10.67	11.30	4.01	090
35190	A	Repair blood vessel lesion	13.33	NA	NA	5.23	5.85	1.80	090
35201	A	Repair blood vessel lesion	16.84	NA	NA	6.31	7.15	2.34	090
35206	A	Repair blood vessel lesion	13.76	NA	NA	5.30	5.92	1.87	090
35207	A	Repair blood vessel lesion	10.85	NA	NA	6.63	6.99	1.48	090
35211	A	Repair blood vessel lesion	24.50	NA	NA	9.70	10.15	3.20	090
35216	A	Repair blood vessel lesion	36.47	NA	NA	13.56	11.26	2.65	090
35221	A	Repair blood vessel lesion	26.54	NA	NA	8.33	9.13	3.37	090
35226	A	Repair blood vessel lesion	15.22	NA	NA	5.79	6.61	2.02	090
35231	A	Repair blood vessel lesion	21.08	NA	NA	7.72	8.74	2.89	090
35236	A	Repair blood vessel lesion	17.94	NA	NA	6.29	7.08	2.43	090
35241	A	Repair blood vessel lesion	25.50	NA	NA	10.02	10.56	3.53	090
35246	A	Repair blood vessel lesion	28.15	NA	NA	10.10	10.76	3.86	090
35251	A	Repair blood vessel lesion	31.83	NA	NA	9.45	10.61	4.13	090
35256	A	Repair blood vessel lesion	18.98	NA	NA	6.37	7.35	2.63	090
35261	A	Repair blood vessel lesion	18.88	NA	NA	6.97	7.49	2.61	090
35266	A	Repair blood vessel lesion	15.75	NA	NA	5.47	6.23	2.10	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
35271	A	Repair blood vessel lesion	24.50	NA	NA	9.68	10.09	3.16	090
35276	A	Repair blood vessel lesion	25.72	NA	NA	9.78	10.48	3.49	090
35281	A	Repair blood vessel lesion	29.93	NA	NA	9.28	10.48	3.97	090
35286	A	Repair blood vessel lesion	17.06	NA	NA	6.31	7.17	2.35	090
35301	A	Rechanneling of artery	19.53	NA	NA	6.68	7.55	2.68	090
35302	A	Rechanneling of artery	21.27	NA	NA	6.90	6.90	2.98	090
35303	A	Rechanneling of artery	23.52	NA	NA	7.45	7.45	3.26	090
35304	A	Rechanneling of artery	24.52	NA	NA	7.70	7.70	3.41	090
35305	A	Rechanneling of artery	23.52	NA	NA	7.45	7.45	3.26	090
35306	A	Rechanneling of artery	9.25	NA	NA	2.28	2.28	1.34	ZZZ
35311	A	Rechanneling of artery	28.52	NA	NA	9.63	10.68	3.42	090
35321	A	Rechanneling of artery	16.51	NA	NA	5.77	6.57	2.25	090
35331	A	Rechanneling of artery	27.61	NA	NA	8.81	10.01	3.83	090
35341	A	Rechanneling of artery	26.10	NA	NA	8.24	9.55	3.78	090
35351	A	Rechanneling of artery	24.53	NA	NA	7.64	8.61	3.35	090
35355	A	Rechanneling of artery	19.78	NA	NA	6.35	7.21	2.67	090
35361	A	Rechanneling of artery	30.11	NA	NA	9.59	10.64	4.15	090
35363	A	Rechanneling of artery	32.22	NA	NA	10.43	11.50	4.33	090
35371	A	Rechanneling of artery	15.23	NA	NA	5.33	6.14	2.14	090
35372	A	Rechanneling of artery	18.50	NA	NA	6.12	7.08	2.63	090
35390	A	Reoperation, carotid add-on	3.19	NA	NA	0.82	0.94	0.46	ZZZ
35400	A	Angioscopy	3.00	NA	NA	0.72	0.91	0.43	ZZZ
35450	A	Repair arterial blockage	10.05	NA	NA	2.97	3.26	1.25	000
35452	A	Repair arterial blockage	6.90	NA	NA	2.06	2.33	0.94	000
35454	A	Repair arterial blockage	6.03	NA	NA	1.76	2.04	0.87	000
35456	A	Repair arterial blockage	7.34	NA	NA	2.12	2.44	1.04	000
35458	A	Repair arterial blockage	9.48	NA	NA	2.80	3.13	1.26	000
35459	A	Repair arterial blockage	8.62	NA	NA	2.65	2.91	1.21	000
35460	A	Repair venous blockage	6.03	NA	NA	1.74	2.01	0.83	000
35470	A	Repair arterial blockage	8.62	61.12	74.97	3.44	3.39	0.69	000
35471	A	Repair arterial blockage	10.05	65.97	83.09	4.68	4.31	0.67	000
35472	A	Repair arterial blockage	6.90	47.48	55.90	2.81	2.78	0.58	000
35473	A	Repair arterial blockage	6.03	46.50	53.15	2.49	2.46	0.51	000
35474	A	Repair arterial blockage	7.35	60.37	74.03	2.98	2.93	0.57	000
35475	R	Repair arterial blockage	9.48	48.63	52.35	3.38	3.47	0.62	000
35476	A	Repair venous blockage	6.03	37.11	40.91	2.23	2.29	0.34	000
35480	A	Atherectomy, open	11.06	NA	NA	4.04	4.04	1.28	000
35481	A	Atherectomy, open	7.60	NA	NA	2.57	2.72	1.13	000
35482	A	Atherectomy, open	6.64	NA	NA	2.01	2.28	0.89	000
35483	A	Atherectomy, open	8.09	NA	NA	2.56	2.79	1.15	000
35484	A	Atherectomy, open	10.42	NA	NA	2.90	3.33	1.27	000
35485	A	Atherectomy, open	9.48	NA	NA	2.87	3.20	1.35	000
35490	A	Atherectomy, percutaneous	11.06	NA	NA	5.17	4.93	0.71	000
35491	A	Atherectomy, percutaneous	7.60	NA	NA	3.85	3.57	0.74	000
35492	A	Atherectomy, percutaneous	6.64	NA	NA	3.48	3.34	0.43	000
35493	A	Atherectomy, percutaneous	8.09	NA	NA	3.96	3.88	0.56	000
35494	A	Atherectomy, percutaneous	10.42	NA	NA	5.15	4.80	0.59	000
35495	A	Atherectomy, percutaneous	9.48	NA	NA	4.45	4.42	0.69	000
35500	A	Harvest vein for bypass	6.44	NA	NA	1.59	1.81	0.93	ZZZ
35501	A	Artery bypass graft	28.99	NA	NA	11.06	9.75	4.10	090
35506	A	Artery bypass graft	25.23	NA	NA	8.31	8.88	2.87	090
35508	A	Artery bypass graft	25.99	NA	NA	8.76	9.10	2.78	090
35509	A	Artery bypass graft	27.99	NA	NA	10.77	9.77	3.92	090
35510	A	Artery bypass graft	24.29	NA	NA	7.69	8.93	2.12	090
35511	A	Artery bypass graft	22.12	NA	NA	7.65	8.50	2.91	090
35512	A	Artery bypass graft	23.79	NA	NA	7.47	8.73	2.12	090
35515	A	Artery bypass graft	25.99	NA	NA	9.08	9.18	2.78	090
35516	A	Artery bypass graft	24.11	NA	NA	7.45	7.12	2.34	090
35518	A	Artery bypass graft	22.57	NA	NA	7.32	8.14	3.03	090
35521	A	Artery bypass graft	24.00	NA	NA	7.94	8.88	3.13	090
35522	A	Artery bypass graft	23.05	NA	NA	7.39	8.57	2.12	090
35523	A	Artery bypass graft	24.00	NA	NA	9.20	9.20	2.14	090
35525	A	Artery bypass graft	21.59	NA	NA	7.03	8.20	2.12	090
35526	A	Artery bypass graft	31.47	NA	NA	14.03	13.26	3.63	090
35531	A	Artery bypass graft	38.98	NA	NA	11.46	12.96	5.18	090
35533	A	Artery bypass graft	29.79	NA	NA	9.49	10.60	3.85	090
35536	A	Artery bypass graft	33.60	NA	NA	9.50	11.22	4.62	090
35537	A	Artery bypass graft	41.75	NA	NA	13.08	13.08	5.72	090
35538	A	Artery bypass graft	46.82	NA	NA	14.43	14.43	6.39	090
35539	A	Artery bypass graft	43.98	NA	NA	13.46	13.46	6.02	090
35540	A	Artery bypass graft	49.20	NA	NA	14.80	14.80	6.76	090
35548	A	Artery bypass graft	22.57	NA	NA	7.73	8.57	2.98	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
35549	A	Artery bypass graft	24.34	NA	NA	8.73	9.55	3.30	090
35551	A	Artery bypass graft	27.72	NA	NA	9.37	10.42	3.75	090
35556	A	Artery bypass graft	26.62	NA	NA	8.63	9.17	3.10	090
35558	A	Artery bypass graft	23.00	NA	NA	7.86	8.70	3.00	090
35560	A	Artery bypass graft	33.90	NA	NA	10.61	11.96	4.75	090
35563	A	Artery bypass graft	25.99	NA	NA	8.87	9.69	3.52	090
35565	A	Artery bypass graft	25.00	NA	NA	8.16	9.14	3.30	090
35566	A	Artery bypass graft	32.22	NA	NA	9.84	10.61	3.83	090
35571	A	Artery bypass graft	25.39	NA	NA	8.08	9.46	3.43	090
35572	A	Harvest femoropopliteal vein	6.81	NA	NA	1.92	2.08	0.99	ZZZ
35583	A	Vein bypass graft	27.62	NA	NA	8.63	9.39	3.17	090
35585	A	Vein bypass graft	32.22	NA	NA	10.10	11.15	4.02	090
35587	A	Vein bypass graft	26.08	NA	NA	8.50	9.97	3.52	090
35600	A	Harvest art for cabg add-on	4.94	NA	NA	1.52	1.57	0.73	ZZZ
35601	A	Artery bypass graft	26.99	NA	NA	10.42	9.52	3.72	090
35606	A	Artery bypass graft	22.36	NA	NA	7.30	8.15	2.70	090
35612	A	Artery bypass graft	16.71	NA	NA	6.31	7.09	2.09	090
35616	A	Artery bypass graft	21.74	NA	NA	7.12	7.61	2.20	090
35621	A	Artery bypass graft	20.95	NA	NA	6.77	7.72	2.92	090
35623	A	Bypass graft, not vein	25.79	NA	NA	8.43	9.46	3.46	090
35626	A	Artery bypass graft	29.06	NA	NA	10.27	11.12	4.08	090
35631	A	Artery bypass graft	35.90	NA	NA	10.55	12.18	4.96	090
35636	A	Artery bypass graft	31.62	NA	NA	9.71	11.00	4.10	090
35637	A	Artery bypass graft	32.92	NA	NA	10.64	10.64	4.44	090
35638	A	Artery bypass graft	33.47	NA	NA	10.78	10.78	4.52	090
35642	A	Artery bypass graft	18.85	NA	NA	6.21	7.45	2.28	090
35645	A	Artery bypass graft	18.34	NA	NA	7.97	8.12	2.50	090
35646	A	Artery bypass graft	32.84	NA	NA	10.44	11.77	4.44	090
35647	A	Artery bypass graft	29.62	NA	NA	9.65	10.70	3.99	090
35650	A	Artery bypass graft	20.08	NA	NA	6.92	7.64	2.72	090
35651	A	Artery bypass graft	25.97	NA	NA	8.70	9.71	3.36	090
35654	A	Artery bypass graft	26.17	NA	NA	8.35	9.50	3.53	090
35656	A	Artery bypass graft	20.39	NA	NA	6.83	7.71	2.80	090
35661	A	Artery bypass graft	20.22	NA	NA	7.04	7.98	2.72	090
35663	A	Artery bypass graft	23.80	NA	NA	7.89	8.93	3.11	090
35665	A	Artery bypass graft	22.22	NA	NA	7.35	8.40	3.01	090
35666	A	Artery bypass graft	23.53	NA	NA	8.50	9.56	3.16	090
35671	A	Artery bypass graft	20.64	NA	NA	7.62	8.49	2.78	090
35681	A	Composite bypass graft	1.60	NA	NA	0.40	0.47	0.23	ZZZ
35682	A	Composite bypass graft	7.19	NA	NA	1.69	2.04	1.03	ZZZ
35683	A	Composite bypass graft	8.49	NA	NA	1.96	2.39	1.20	ZZZ
35685	A	Bypass graft patency/patch	4.04	NA	NA	0.96	1.15	0.58	ZZZ
35686	A	Bypass graft/av fist patency	3.34	NA	NA	0.85	0.99	0.47	ZZZ
35691	A	Arterial transposition	18.32	NA	NA	5.94	7.17	2.59	090
35693	A	Arterial transposition	15.64	NA	NA	6.11	6.91	2.22	090
35694	A	Arterial transposition	19.19	NA	NA	6.31	7.45	2.70	090
35695	A	Arterial transposition	19.97	NA	NA	6.70	7.62	2.74	090
35697	A	Reimplant artery each	3.00	NA	NA	0.74	0.88	0.41	ZZZ
35700	A	Reoperation, bypass graft	3.08	NA	NA	0.76	0.89	0.44	ZZZ
35701	A	Exploration, carotid artery	9.11	NA	NA	4.31	4.73	1.12	090
35721	A	Exploration, femoral artery	7.66	NA	NA	3.83	4.13	1.03	090
35741	A	Exploration popliteal artery	8.61	NA	NA	3.86	4.26	1.12	090
35761	A	Exploration of artery/vein	5.84	NA	NA	3.43	3.72	0.75	090
35800	A	Explore neck vessels	7.99	NA	NA	3.95	4.30	0.95	090
35820	A	Explore chest vessels	36.81	NA	NA	12.90	10.05	1.95	090
35840	A	Explore abdominal vessels	10.87	NA	NA	4.81	5.04	1.34	090
35860	A	Explore limb vessels	6.72	NA	NA	3.38	3.70	0.78	090
35870	A	Repair vessel graft defect	24.39	NA	NA	7.91	8.84	3.01	090
35875	A	Removal of clot in graft	10.64	NA	NA	4.28	4.73	1.41	090
35876	A	Removal of clot in graft	17.74	NA	NA	5.94	6.72	2.40	090
35879	A	Revise graft w/vein	17.28	NA	NA	5.97	6.83	2.28	090
35881	A	Revise graft w/vein	19.22	NA	NA	6.46	7.56	2.56	090
35883	A	Revise graft w/nonauto graft	23.07	NA	NA	8.49	8.49	3.19	090
35884	A	Revise graft w/vein	24.57	NA	NA	8.93	8.93	3.41	090
35901	A	Excision, graft, neck	8.26	NA	NA	4.24	4.77	1.15	090
35903	A	Excision, graft, extremity	9.44	NA	NA	4.60	5.37	1.30	090
35905	A	Excision, graft, thorax	33.39	NA	NA	10.65	11.91	4.44	090
35907	A	Excision, graft, abdomen	37.14	NA	NA	10.87	12.51	4.92	090
36000	A	Place needle in vein	0.18	0.46	0.51	0.06	0.06	0.01	XXX
36002	A	Pseudoaneurysm injection trt	1.96	2.24	2.55	0.85	0.91	0.17	000
36005	A	Injection ext venography	0.95	8.46	8.05	0.39	0.35	0.05	000
36010	A	Place catheter in vein	2.43	11.09	15.19	0.78	0.79	0.20	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
36011	A	Place catheter in vein	3.14	19.61	23.71	1.01	1.03	0.27	XXX
36012	A	Place catheter in vein	3.51	20.23	19.58	1.28	1.23	0.23	XXX
36013	A	Place catheter in artery	2.52	18.76	20.06	0.93	0.81	0.25	XXX
36014	A	Place catheter in artery	3.02	18.94	19.52	1.11	1.07	0.19	XXX
36015	A	Place catheter in artery	3.51	18.54	21.09	1.05	1.12	0.21	XXX
36100	A	Establish access to artery	3.02	11.23	11.65	1.21	1.16	0.26	XXX
36120	A	Establish access to artery	2.01	9.20	9.95	0.59	0.62	0.14	XXX
36140	A	Establish access to artery	2.01	10.47	11.62	0.71	0.67	0.16	XXX
36145	A	Artery to vein shunt	2.01	10.28	11.41	0.66	0.66	0.11	XXX
36160	A	Establish access to aorta	2.52	11.54	12.51	1.05	0.94	0.26	XXX
36200	A	Place catheter in aorta	3.02	13.65	15.08	1.02	1.01	0.24	XXX
36215	A	Place catheter in artery	4.67	25.94	26.48	1.89	1.75	0.27	XXX
36216	A	Place catheter in artery	5.27	28.03	28.54	2.09	1.94	0.31	XXX
36217	A	Place catheter in artery	6.29	45.85	50.63	2.43	2.30	0.44	XXX
36218	A	Place catheter in artery	1.01	3.76	4.42	0.39	0.36	0.07	ZZZ
36245	A	Place catheter in artery	4.67	28.77	30.42	2.11	1.89	0.31	XXX
36246	A	Place catheter in artery	5.27	27.41	28.68	1.99	1.91	0.38	XXX
36247	A	Place catheter in artery	6.29	45.15	47.31	2.36	2.25	0.47	XXX
36248	A	Place catheter in artery	1.01	3.17	3.61	0.38	0.36	0.07	ZZZ
36260	A	Insertion of infusion pump	9.82	NA	NA	4.64	4.76	1.29	090
36261	A	Revision of infusion pump	5.55	NA	NA	3.06	3.36	0.70	090
36262	A	Removal of infusion pump	4.05	NA	NA	2.71	2.73	0.54	090
36299	C	Vessel injection procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
36400	A	Bl draw < 3 yrs fem/jugular	0.38	0.28	0.28	0.09	0.09	0.03	XXX
36405	A	Bl draw < 3 yrs scalp vein	0.31	0.27	0.27	0.08	0.08	0.03	XXX
36406	A	Bl draw < 3 yrs other vein	0.18	0.25	0.26	0.04	0.05	0.01	XXX
36410	A	Non-routine bl draw > 3 yrs	0.18	0.32	0.30	0.05	0.05	0.01	XXX
36415	X	Routine venipuncture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
36416	B	Capillary blood draw	0.00	0.00	0.00	0.00	0.00	0.00	XXX
36420	A	Vein access cutdown < 1 yr	1.01	NA	NA	0.21	0.24	0.07	XXX
36425	A	Vein access cutdown > 1 yr	0.76	NA	NA	0.21	0.21	0.06	XXX
36430	A	Blood transfusion service	0.00	0.93	0.97	NA	NA	0.06	XXX
36440	A	Bl push transfuse, 2 yr or <	1.03	NA	NA	0.25	0.27	0.10	XXX
36450	A	Bl exchange/transfuse, nb	2.23	NA	NA	0.77	0.74	0.21	XXX
36455	A	Bl exchange/transfuse non-nb	2.43	NA	NA	0.66	0.84	0.15	XXX
36460	A	Transfusion service, fetal	6.58	NA	NA	1.81	2.03	0.79	XXX
36468	R	Injection(s), spider veins	0.00	0.00	0.00	0.00	0.00	0.00	000
36469	R	Injection(s), spider veins	0.00	0.00	0.00	0.00	0.00	0.00	000
36470	A	Injection therapy of vein	1.09	2.41	2.54	0.64	0.68	0.12	010
36471	A	Injection therapy of veins	1.60	2.56	2.82	0.79	0.87	0.19	010
36475	A	Endovenous rf, 1st vein	6.72	35.74	43.55	1.88	2.20	0.37	000
36476	A	Endovenous rf, vein add-on	3.38	6.14	7.00	0.83	0.98	0.18	ZZZ
36478	A	Endovenous laser, 1st vein	6.72	26.95	36.85	2.04	2.29	0.37	000
36479	A	Endovenous laser vein addon	3.38	6.35	7.17	0.95	1.04	0.18	ZZZ
36481	A	Insertion of catheter, vein	6.98	NA	NA	2.35	2.47	0.55	000
36500	A	Insertion of catheter, vein	3.51	NA	NA	1.25	1.31	0.20	000
36510	A	Insertion of catheter, vein	1.09	1.08	2.48	0.30	0.45	0.10	000
36511	A	Apheresis wbc	1.74	NA	NA	0.57	0.65	0.08	000
36512	A	Apheresis rbc	1.74	NA	NA	0.60	0.67	0.08	000
36513	A	Apheresis platelets	1.74	NA	NA	0.55	0.64	0.17	000
36514	A	Apheresis plasma	1.74	10.49	13.73	0.53	0.62	0.08	000
36515	A	Apheresis, adsorp/reinfuse	1.74	45.46	55.86	0.48	0.57	0.08	000
36516	A	Apheresis, selective	1.22	49.53	66.77	0.39	0.43	0.08	000
36522	A	Photopheresis	1.67	37.40	34.87	0.94	0.95	0.13	000
36555	A	Insert non-tunnel cv cath	2.68	3.81	4.78	0.59	0.69	0.11	000
36556	A	Insert non-tunnel cv cath	2.50	2.85	4.24	0.55	0.65	0.19	000
36557	A	Insert tunneled cv cath	5.11	15.09	18.11	2.29	2.47	0.57	010
36558	A	Insert tunneled cv cath	4.81	14.84	17.93	2.35	2.45	0.57	010
36560	A	Insert tunneled cv cath	6.26	21.31	25.48	2.72	2.87	0.57	010
36561	A	Insert tunneled cv cath	6.01	22.24	25.90	2.64	2.79	0.57	010
36563	A	Insert tunneled cv cath	6.21	23.09	24.91	2.60	2.79	0.84	010
36565	A	Insert tunneled cv cath	6.01	17.51	21.10	2.47	2.71	0.57	010
36566	A	Insert tunneled cv cath	6.51	111.82	68.65	2.60	2.85	0.57	010
36568	A	Insert picc cath	1.92	5.87	6.70	0.59	0.59	0.11	000
36569	A	Insert picc cath	1.82	4.47	5.90	0.67	0.62	0.19	000
36570	A	Insert picvad cath	5.33	21.23	27.19	2.10	2.41	0.57	010
36571	A	Insert picvad cath	5.31	24.50	28.86	2.44	2.58	0.57	010
36575	A	Repair tunneled cv cath	0.67	3.30	3.67	0.23	0.25	0.20	000
36576	A	Repair tunneled cv cath	3.21	5.90	6.42	1.56	1.70	0.19	010
36578	A	Replace tunneled cv cath	3.51	9.16	10.14	2.00	2.15	0.19	010
36580	A	Replace cvad cath	1.31	3.96	5.45	0.43	0.42	0.19	000
36581	A	Replace tunneled cv cath	3.45	15.49	17.49	1.73	1.83	0.19	010

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
36582	A	Replace tunneled cv cath	5.21	21.53	23.76	2.45	2.66	0.19	010
36583	A	Replace tunneled cv cath	5.26	21.57	23.80	2.48	2.68	0.19	010
36584	A	Replace picc cath	1.20	3.96	5.47	0.61	0.58	0.19	000
36585	A	Replace picvad cath	4.81	22.54	25.17	2.42	2.58	0.19	010
36589	A	Removal tunneled cv cath	2.27	1.86	2.05	1.23	1.31	0.24	010
36590	A	Removal tunneled cv cath	3.32	3.62	3.49	1.59	1.65	0.44	010
36591	T	Draw blood off venous device	0.00	0.54	0.54	NA	NA	0.01	XXX
36592	T	Collect blood from picc	0.00	0.67	0.67	NA	NA	0.01	XXX
36593	A	Declot vascular device	0.00	0.82	0.60	NA	NA	0.37	XXX
36595	A	Mech remov tunneled cv cath	3.59	10.83	14.04	1.38	1.41	0.21	000
36596	A	Mech remov tunneled cv cath	0.75	2.57	3.13	0.43	0.47	0.05	000
36597	A	Reposition venous catheter	1.21	2.04	2.22	0.46	0.45	0.07	000
36598	T	Inj w/fluor, eval cv device	0.74	2.22	2.43	0.27	1.45	0.05	000
36600	A	Withdrawal of arterial blood	0.32	0.50	0.49	0.07	0.08	0.02	XXX
36620	A	Insertion catheter, artery	1.15	NA	NA	0.15	0.19	0.07	000
36625	A	Insertion catheter, artery	2.11	NA	NA	0.50	0.52	0.26	000
36640	A	Insertion catheter, artery	2.10	NA	NA	0.91	0.97	0.21	000
36660	A	Insertion catheter, artery	1.40	NA	NA	0.41	0.42	0.14	000
36680	A	Insert needle, bone cavity	1.20	NA	NA	0.28	0.38	0.11	000
36800	A	Insertion of cannula	2.43	NA	NA	1.53	1.67	0.25	000
36810	A	Insertion of cannula	3.96	NA	NA	1.32	1.50	0.45	000
36815	A	Insertion of cannula	2.62	NA	NA	1.04	1.10	0.35	000
36818	A	Av fuse, uppr arm, cephalic	11.81	NA	NA	4.49	5.26	1.90	090
36819	A	Av fuse, uppr arm, basilic	14.39	NA	NA	5.11	5.74	1.96	090
36820	A	Av fusion/forearm vein	14.39	NA	NA	5.24	5.81	1.95	090
36821	A	Av fusion direct any site	9.15	NA	NA	3.94	4.29	1.23	090
36822	A	Insertion of cannula(s)	5.51	NA	NA	3.74	4.06	0.79	090
36823	A	Insertion of cannula(s)	22.82	NA	NA	8.63	9.00	2.89	090
36825	A	Artery-vein autograft	10.00	NA	NA	4.22	4.63	1.35	090
36830	A	Artery-vein nonautograft	12.00	NA	NA	4.13	4.68	1.66	090
36831	A	Open thrombect av fistula	8.01	NA	NA	3.18	3.56	1.09	090
36832	A	Av fistula revision, open	10.50	NA	NA	3.74	4.23	1.44	090
36833	A	Av fistula revision	11.95	NA	NA	4.12	4.66	1.65	090
36834	A	Repair A-V aneurysm	11.11	NA	NA	4.21	4.50	1.37	090
36835	A	Artery to vein shunt	7.43	NA	NA	3.74	4.03	0.98	090
36838	A	Dist revas ligation, hemo	21.59	NA	NA	7.04	8.21	3.02	090
36860	A	External cannula declotting	2.01	3.36	2.57	0.63	0.65	0.11	000
36861	A	Cannula declotting	2.52	NA	NA	1.22	1.35	0.27	000
36870	A	Percut thrombect av fistula	5.17	40.78	46.89	2.76	2.95	0.29	090
37140	A	Revision of circulation	25.12	NA	NA	8.92	9.70	2.02	090
37145	A	Revision of circulation	26.13	NA	NA	10.45	10.65	3.26	090
37160	A	Revision of circulation	23.13	NA	NA	7.92	8.59	2.82	090
37180	A	Revision of circulation	26.13	NA	NA	9.27	9.78	3.35	090
37181	A	Splice spleen/kidney veins	28.26	NA	NA	8.83	9.91	3.41	090
37182	A	Insert hepatic shunt (tips)	16.97	NA	NA	6.33	6.19	1.00	000
37183	A	Remove hepatic shunt (tips)	7.99	NA	NA	3.09	3.05	0.47	000
37184	A	Prim art mech thrombectomy	8.66	49.91	60.78	3.23	3.29	0.55	000
37185	A	Prim art m-thrombect add-on	3.28	16.38	19.62	1.12	1.11	0.21	ZZZ
37186	A	Sec art m-thrombect add-on	4.92	34.90	42.13	1.79	1.72	0.32	ZZZ
37187	A	Venous mech thrombectomy	8.03	48.21	59.18	2.99	3.06	0.51	000
37188	A	Venous m-thrombectomy add-on	5.71	42.22	52.08	2.18	2.27	0.37	000
37195	C	Thrombolytic therapy, stroke	0.00	0.00	0.00	0.00	0.00	0.00	XXX
37200	A	Transcatheter biopsy	4.55	NA	NA	1.65	1.57	0.27	000
37201	A	Transcatheter therapy infuse	4.99	NA	NA	2.33	2.44	0.33	000
37202	A	Transcatheter therapy infuse	5.67	NA	NA	3.34	3.18	0.43	000
37203	A	Transcatheter retrieval	5.02	30.10	31.48	2.07	2.05	0.29	000
37204	A	Transcatheter occlusion	18.11	NA	NA	6.23	6.07	1.48	000
37205	A	Transcath iv stent, percut	8.27	108.64	56.20	3.25	3.50	0.60	000
37206	A	Transcath iv stent/perc addl	4.12	66.45	33.94	1.58	1.50	0.31	ZZZ
37207	A	Transcath iv stent, open	8.27	NA	NA	2.37	2.77	1.17	000
37208	A	Transcath iv stent/open addl	4.12	NA	NA	1.01	1.19	0.59	ZZZ
37209	A	Change iv cath at thromb tx	2.27	NA	NA	0.77	0.75	0.15	000
37210	A	Embolization uterine fibroid	10.60	83.21	83.21	3.68	3.68	0.60	000
37215	R	Transcath stent, cca w/eps	19.58	NA	NA	9.93	9.51	1.09	090
37216	N	Transcath stent, cca w/o eps	18.85	NA	NA	5.75	7.28	1.04	090
37250	A	Iv us first vessel add-on	2.10	NA	NA	0.77	0.76	0.21	ZZZ
37251	A	Iv us each add vessel add-on	1.60	NA	NA	0.50	0.52	0.19	ZZZ
37500	A	Endoscopy ligate perf veins	11.54	NA	NA	5.35	6.10	1.54	090
37501	C	Vascular endoscopy procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
37565	A	Ligation of neck vein	11.97	NA	NA	5.13	5.38	1.33	090
37600	A	Ligation of neck artery	12.34	NA	NA	4.91	5.77	1.41	090
37605	A	Ligation of neck artery	14.20	NA	NA	5.44	6.17	1.99	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
37606	A	Ligation of neck artery	8.72	NA	NA	4.86	4.71	1.23	090
37607	A	Ligation of a-v fistula	6.19	NA	NA	3.02	3.29	0.85	090
37609	A	Temporal artery procedure	3.02	4.19	4.34	1.82	1.89	0.36	010
37615	A	Ligation of neck artery	7.72	NA	NA	4.09	4.10	0.68	090
37616	A	Ligation of chest artery	18.89	NA	NA	7.92	8.00	2.33	090
37617	A	Ligation of abdomen artery	23.71	NA	NA	7.88	8.52	2.98	090
37618	A	Ligation of extremity artery	5.95	NA	NA	3.36	3.48	0.67	090
37620	A	Revision of major vein	11.49	NA	NA	5.45	5.58	0.91	090
37650	A	Revision of major vein	8.41	NA	NA	4.23	4.45	1.01	090
37660	A	Revision of major vein	22.20	NA	NA	7.58	8.32	2.49	090
37700	A	Revise leg vein	3.76	NA	NA	2.38	2.59	0.53	090
37718	A	Ligate/strip short leg vein	7.05	NA	NA	3.47	3.76	0.14	090
37722	A	Ligate/strip long leg vein	8.08	NA	NA	3.68	4.04	0.86	090
37735	A	Removal of leg veins/lesion	10.81	NA	NA	4.68	5.09	1.48	090
37760	A	Ligation, leg veins, open	10.69	NA	NA	4.48	4.91	1.44	090
37765	A	Phleb veins extrem 10-20	7.63	NA	NA	3.57	4.09	0.48	090
37766	A	Phleb veins extrem 20+	9.58	NA	NA	4.13	4.72	0.48	090
37780	A	Revision of leg vein	3.87	NA	NA	2.39	2.62	0.53	090
37785	A	Ligate/divide/excise vein	3.87	4.91	5.05	2.57	2.65	0.54	090
37788	A	Revascularization, penis	23.21	NA	NA	12.03	10.56	2.26	090
37790	A	Penile venous occlusion	8.37	NA	NA	5.15	4.76	0.59	090
37799	C	Vascular surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
38100	A	Removal of spleen, total	19.47	NA	NA	6.84	6.50	1.92	090
38101	A	Removal of spleen, partial	19.47	NA	NA	6.91	6.71	2.05	090
38102	A	Removal of spleen, total	4.79	NA	NA	1.23	1.43	0.63	ZZZ
38115	A	Repair of ruptured spleen	21.80	NA	NA	7.43	7.04	2.09	090
38120	A	Laparoscopy, splenectomy	16.97	NA	NA	6.92	7.15	2.25	090
38129	C	Laparoscope proc, spleen	0.00	0.00	0.00	0.00	0.00	0.00	YYY
38200	A	Injection for spleen x-ray	2.64	NA	NA	1.09	0.99	0.14	000
38204	B	BI donor search management	2.00	0.46	0.46	0.46	0.46	0.06	XXX
38205	R	Harvest allogenic stem cells	1.50	NA	NA	0.53	0.60	0.07	000
38206	R	Harvest auto stem cells	1.50	NA	NA	0.55	0.61	0.07	000
38207	I	Cryopreserve stem cells	0.89	0.40	0.40	0.40	0.40	0.01	XXX
38208	I	Thaw preserved stem cells	0.56	0.25	0.25	0.25	0.25	0.02	XXX
38209	I	Wash harvest stem cells	0.24	0.11	0.11	0.11	0.11	0.01	XXX
38210	I	T-cell depletion of harvest	1.57	0.71	0.71	0.71	0.71	0.03	XXX
38211	I	Tumor cell deplete of harvst	1.42	0.64	0.64	0.64	0.64	0.02	XXX
38212	I	Rbc depletion of harvest	0.94	0.42	0.42	0.42	0.42	0.02	XXX
38213	I	Platelet deplete of harvest	0.24	0.11	0.11	0.11	0.11	0.01	XXX
38214	I	Volume deplete of harvest	0.81	0.36	0.36	0.36	0.36	0.01	XXX
38215	I	Harvest stem cell concentrtr	0.94	0.42	0.42	0.42	0.42	0.02	XXX
38220	A	Bone marrow aspiration	1.08	2.67	3.20	0.45	0.48	0.05	XXX
38221	A	Bone marrow biopsy	1.37	2.78	3.36	0.57	0.61	0.07	XXX
38230	R	Bone marrow collection	4.80	NA	NA	3.13	3.17	0.48	010
38240	R	Bone marrow/stem transplant	2.24	NA	NA	0.93	0.98	0.11	XXX
38241	R	Bone marrow/stem transplant	2.24	NA	NA	0.94	0.99	0.11	XXX
38242	A	Lymphocyte infuse transplant	1.71	NA	NA	0.67	0.72	0.08	000
38300	A	Drainage, lymph node lesion	2.28	4.22	4.26	2.03	2.04	0.25	010
38305	A	Drainage, lymph node lesion	6.55	NA	NA	4.20	4.32	0.88	090
38308	A	Incision of lymph channels	6.73	NA	NA	3.54	3.64	0.85	090
38380	A	Thoracic duct procedure	8.34	NA	NA	5.05	5.37	0.74	090
38381	A	Thoracic duct procedure	13.32	NA	NA	6.07	6.47	1.85	090
38382	A	Thoracic duct procedure	10.51	NA	NA	5.43	5.59	1.37	090
38500	A	Biopsy/removal, lymph nodes	3.76	3.75	3.72	2.02	2.05	0.49	010
38505	A	Needle biopsy, lymph nodes	1.14	2.11	2.08	0.73	0.76	0.09	000
38510	A	Biopsy/removal, lymph nodes	6.69	5.38	5.46	3.08	3.28	0.72	010
38520	A	Biopsy/removal, lymph nodes	6.95	NA	NA	3.75	3.90	0.84	090
38525	A	Biopsy/removal, lymph nodes	6.35	NA	NA	3.47	3.38	0.80	090
38530	A	Biopsy/removal, lymph nodes	8.26	NA	NA	4.12	4.25	1.12	090
38542	A	Explore deep node(s), neck	6.08	NA	NA	3.96	4.22	0.60	090
38550	A	Removal, neck/armpit lesion	6.99	NA	NA	4.28	4.09	0.88	090
38555	A	Removal, neck/armpit lesion	15.42	NA	NA	7.45	7.98	1.76	090
38562	A	Removal, pelvic lymph nodes	10.92	NA	NA	5.76	5.76	1.20	090
38564	A	Removal, abdomen lymph nodes	11.29	NA	NA	5.20	5.22	1.32	090
38570	A	Laparoscopy, lymph node biop	9.28	NA	NA	4.03	4.00	1.13	010
38571	A	Laparoscopy, lymphadenectomy	14.70	NA	NA	6.79	6.22	1.15	010
38572	A	Laparoscopy, lymphadenectomy	16.86	NA	NA	5.93	6.50	1.91	010
38589	C	Laparoscope proc, lymphatic	0.00	0.00	0.00	0.00	0.00	0.00	YYY
38700	A	Removal of lymph nodes, neck	12.68	NA	NA	6.51	6.37	0.72	090
38720	A	Removal of lymph nodes, neck	21.72	NA	NA	10.16	9.76	1.20	090
38724	A	Removal of lymph nodes, neck	23.72	NA	NA	10.92	10.37	1.28	090
38740	A	Remove armpit lymph nodes	10.57	NA	NA	5.00	4.96	1.32	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
38745	A	Remove armpit lymph nodes	13.71	NA	NA	6.04	6.06	1.74	090
38746	A	Remove thoracic lymph nodes	4.88	NA	NA	1.42	1.51	0.72	ZZZ
38747	A	Remove abdominal lymph nodes	4.88	NA	NA	1.26	1.46	0.64	ZZZ
38760	A	Remove groin lymph nodes	13.49	NA	NA	5.91	6.02	1.72	090
38765	A	Remove groin lymph nodes	21.78	NA	NA	8.34	8.57	2.48	090
38770	A	Remove pelvis lymph nodes	13.98	NA	NA	6.71	6.22	1.40	090
38780	A	Remove abdomen lymph nodes	17.56	NA	NA	7.98	8.08	1.89	090
38790	A	Inject for lymphatic x-ray	1.29	NA	NA	0.75	0.75	0.13	000
38792	A	Identify sentinel node	0.52	NA	NA	0.49	0.46	0.06	000
38794	A	Access thoracic lymph duct	4.51	NA	NA	3.17	3.31	0.32	090
38999	C	Blood/lymph system procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
39000	A	Exploration of chest	7.49	NA	NA	4.27	4.46	0.89	090
39010	A	Exploration of chest	13.11	NA	NA	6.33	6.93	1.76	090
39200	A	Removal chest lesion	15.04	NA	NA	6.19	6.86	2.03	090
39220	A	Removal chest lesion	19.47	NA	NA	7.99	8.67	2.46	090
39400	A	Visualization of chest	8.00	NA	NA	4.15	4.50	0.82	010
39499	C	Chest procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
39501	A	Repair diaphragm laceration	13.89	NA	NA	5.81	6.13	1.78	090
39502	A	Repair paraesophageal hernia	17.09	NA	NA	6.58	6.86	2.17	090
39503	A	Repair of diaphragm hernia	108.67	NA	NA	27.38	30.37	10.98	090
39520	A	Repair of diaphragm hernia	16.63	NA	NA	6.79	7.41	2.24	090
39530	A	Repair of diaphragm hernia	16.22	NA	NA	6.23	6.68	2.11	090
39531	A	Repair of diaphragm hernia	17.23	NA	NA	6.58	6.98	2.22	090
39540	A	Repair of diaphragm hernia	14.51	NA	NA	5.70	5.96	1.80	090
39541	A	Repair of diaphragm hernia	15.67	NA	NA	6.06	6.32	1.93	090
39545	A	Revision of diaphragm	14.58	NA	NA	6.92	7.23	1.84	090
39560	A	Resect diaphragm, simple	12.97	NA	NA	5.52	5.90	1.59	090
39561	A	Resect diaphragm, complex	19.75	NA	NA	9.31	9.32	2.45	090
39599	C	Diaphragm surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
40490	A	Biopsy of lip	1.22	2.08	1.85	0.57	0.59	0.05	000
40500	A	Partial excision of lip	4.35	7.90	7.40	4.36	4.34	0.38	090
40510	A	Partial excision of lip	4.74	6.73	6.67	3.62	3.81	0.49	090
40520	A	Partial excision of lip	4.71	6.99	7.26	3.81	3.96	0.52	090
40525	A	Reconstruct lip with flap	7.61	NA	NA	5.33	5.81	0.85	090
40527	A	Reconstruct lip with flap	9.20	NA	NA	6.13	6.74	0.97	090
40530	A	Partial removal of lip	5.45	7.58	7.69	4.26	4.42	0.55	090
40650	A	Repair lip	3.69	5.98	6.38	3.16	3.23	0.38	090
40652	A	Repair lip	4.32	7.25	7.49	4.11	4.18	0.52	090
40654	A	Repair lip	5.37	8.08	8.34	4.68	4.80	0.60	090
40700	A	Repair cleft lip/nasal	13.97	NA	NA	8.65	8.86	0.95	090
40701	A	Repair cleft lip/nasal	17.03	NA	NA	7.81	9.56	1.65	090
40702	A	Repair cleft lip/nasal	14.09	NA	NA	5.81	7.03	1.23	090
40720	A	Repair cleft lip/nasal	14.54	NA	NA	9.52	9.70	1.80	090
40761	A	Repair cleft lip/nasal	15.69	NA	NA	9.28	9.77	1.94	090
40799	C	Lip surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
40800	A	Drainage of mouth lesion	1.19	3.84	3.40	1.88	1.83	0.13	010
40801	A	Drainage of mouth lesion	2.57	4.88	4.45	2.58	2.66	0.31	010
40804	A	Removal, foreign body, mouth	1.26	3.78	3.59	1.83	1.84	0.11	010
40805	A	Removal, foreign body, mouth	2.73	5.13	4.80	2.65	2.73	0.32	010
40806	A	Incision of lip fold	0.31	2.43	2.13	0.51	0.50	0.04	000
40808	A	Biopsy of mouth lesion	0.98	3.60	3.13	1.62	1.55	0.10	010
40810	A	Excision of mouth lesion	1.33	3.68	3.28	1.72	1.69	0.13	010
40812	A	Excise/repair mouth lesion	2.33	4.54	4.13	2.28	2.34	0.28	010
40814	A	Excise/repair mouth lesion	3.45	5.69	5.31	3.69	3.79	0.41	090
40816	A	Excision of mouth lesion	3.70	5.90	5.53	3.77	3.88	0.40	090
40818	A	Excise oral mucosa for graft	2.72	5.82	5.49	3.74	3.85	0.21	090
40819	A	Excise lip or cheek fold	2.45	4.93	4.50	3.10	3.10	0.29	090
40820	A	Treatment of mouth lesion	1.30	5.30	4.61	2.94	2.69	0.11	010
40830	A	Repair mouth laceration	1.78	4.04	3.88	2.00	2.05	0.19	010
40831	A	Repair mouth laceration	2.50	5.24	4.94	2.70	2.87	0.30	010
40840	R	Reconstruction of mouth	9.03	10.01	9.90	5.58	6.27	1.08	090
40842	R	Reconstruction of mouth	9.03	10.20	10.13	5.72	6.25	1.08	090
40843	R	Reconstruction of mouth	12.62	11.33	11.63	5.74	6.77	1.39	090
40844	R	Reconstruction of mouth	16.57	15.21	15.48	9.11	10.33	2.00	090
40845	R	Reconstruction of mouth	19.13	16.02	16.54	10.21	11.71	2.01	090
40899	C	Mouth surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
41000	A	Drainage of mouth lesion	1.32	2.55	2.43	1.33	1.37	0.12	010
41005	A	Drainage of mouth lesion	1.28	4.32	3.83	1.77	1.74	0.12	010
41006	A	Drainage of mouth lesion	3.28	5.43	5.11	2.82	2.99	0.35	090
41007	A	Drainage of mouth lesion	3.14	5.34	5.24	2.72	2.87	0.31	090
41008	A	Drainage of mouth lesion	3.40	5.51	5.09	2.84	3.02	0.42	090
41009	A	Drainage of mouth lesion	3.63	5.83	5.40	3.14	3.35	0.47	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
41010	A	Incision of tongue fold	1.08	3.90	3.66	1.56	1.58	0.07	010
41015	A	Drainage of mouth lesion	4.00	6.29	5.84	3.98	4.06	0.46	090
41016	A	Drainage of mouth lesion	4.11	6.22	5.92	4.07	4.14	0.53	090
41017	A	Drainage of mouth lesion	4.11	6.37	6.00	4.12	4.21	0.53	090
41018	A	Drainage of mouth lesion	5.14	6.75	6.44	4.48	4.52	0.68	090
41019	A	Place needles h&n for rt	8.84	NA	NA	3.28	3.28	0.59	000
41100	A	Biopsy of tongue	1.39	2.68	2.55	1.17	1.29	0.15	010
41105	A	Biopsy of tongue	1.44	2.67	2.49	1.20	1.26	0.13	010
41108	A	Biopsy of floor of mouth	1.07	2.52	2.30	1.08	1.10	0.10	010
41110	A	Excision of tongue lesion	1.53	3.65	3.32	1.64	1.64	0.13	010
41112	A	Excision of tongue lesion	2.77	5.26	4.86	3.24	3.23	0.28	090
41113	A	Excision of tongue lesion	3.23	5.51	5.12	3.39	3.43	0.34	090
41114	A	Excision of tongue lesion	8.71	NA	NA	6.30	6.74	0.83	090
41115	A	Excision of tongue fold	1.76	4.18	3.74	1.72	1.79	0.18	010
41116	A	Excision of mouth lesion	2.47	5.56	4.95	2.80	2.80	0.23	090
41120	A	Partial removal of tongue	10.91	NA	NA	14.32	14.81	0.79	090
41130	A	Partial removal of tongue	15.51	NA	NA	15.88	16.03	0.93	090
41135	A	Tongue and neck surgery	29.83	NA	NA	21.84	22.53	1.89	090
41140	A	Removal of tongue	28.81	NA	NA	23.56	25.11	2.27	090
41145	A	Tongue removal, neck surgery	37.59	NA	NA	28.79	29.66	2.55	090
41150	A	Tongue, mouth, jaw surgery	29.52	NA	NA	23.02	23.86	1.95	090
41153	A	Tongue, mouth, neck surgery	33.28	NA	NA	23.92	24.46	2.01	090
41155	A	Tongue, jaw, & neck surgery	43.96	NA	NA	27.59	27.19	2.34	090
41250	A	Repair tongue laceration	1.93	3.86	3.30	1.61	1.39	0.18	010
41251	A	Repair tongue laceration	2.29	3.48	3.38	1.78	1.66	0.22	010
41252	A	Repair tongue laceration	2.99	4.59	4.24	2.12	2.19	0.29	010
41500	A	Fixation of tongue	3.74	NA	NA	7.52	7.48	0.30	090
41510	A	Tongue to lip surgery	3.45	NA	NA	6.47	7.20	0.20	090
41520	A	Reconstruction, tongue fold	2.77	5.80	5.21	3.26	3.44	0.27	090
41599	C	Tongue and mouth surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
41800	A	Drainage of gum lesion	1.21	4.80	3.69	2.12	1.70	0.12	010
41805	A	Removal foreign body, gum	1.28	4.64	3.65	2.70	2.46	0.13	010
41806	A	Removal foreign body,jawbone	2.73	5.82	4.70	3.34	3.19	0.37	010
41820	R	Excision, gum, each quadrant	0.00	0.00	0.00	0.00	0.00	0.00	000
41821	R	Excision of gum flap	0.00	0.00	0.00	0.00	0.00	0.00	000
41822	R	Excision of gum lesion	2.35	4.80	4.34	1.85	1.86	0.31	010
41823	R	Excision of gum lesion	3.63	6.45	6.01	3.73	3.87	0.47	090
41825	A	Excision of gum lesion	1.35	3.69	3.37	1.46	1.85	0.15	010
41826	A	Excision of gum lesion	2.35	5.09	3.76	2.57	2.34	0.30	010
41827	A	Excision of gum lesion	3.72	6.64	6.08	3.38	3.52	0.35	090
41828	R	Excision of gum lesion	3.11	4.09	3.94	1.64	2.30	0.44	010
41830	R	Removal of gum tissue	3.38	5.98	5.47	3.11	3.37	0.44	010
41850	R	Treatment of gum lesion	0.00	0.00	0.00	0.00	0.00	0.00	000
41870	R	Gum graft	0.00	0.00	0.00	0.00	0.00	0.00	000
41872	R	Repair gum	2.90	6.04	5.53	3.30	3.38	0.30	090
41874	R	Repair tooth socket	3.13	5.66	5.25	2.72	2.94	0.45	090
41899	C	Dental surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
42000	A	Drainage mouth roof lesion	1.25	2.48	2.52	1.20	1.22	0.12	010
42100	A	Biopsy roof of mouth	1.33	2.27	2.18	1.26	1.31	0.13	010
42104	A	Excision lesion, mouth roof	1.66	3.57	3.06	1.67	1.60	0.16	010
42106	A	Excision lesion, mouth roof	2.12	4.45	3.83	2.07	2.25	0.25	010
42107	A	Excision lesion, mouth roof	4.48	6.53	6.12	3.69	3.82	0.44	090
42120	A	Remove palate/lesion	11.70	NA	NA	12.28	12.02	0.52	090
42140	A	Excision of uvula	1.65	4.58	4.15	2.11	2.10	0.13	090
42145	A	Repair palate, pharynx/uvula	9.63	NA	NA	7.48	7.48	0.65	090
42160	A	Treatment mouth roof lesion	1.82	3.77	4.01	1.69	1.99	0.17	010
42180	A	Repair palate	2.52	3.37	3.22	1.86	1.98	0.21	010
42182	A	Repair palate	3.84	3.99	3.93	2.39	2.71	0.40	010
42200	A	Reconstruct cleft palate	12.41	NA	NA	8.62	9.41	1.27	090
42205	A	Reconstruct cleft palate	13.57	NA	NA	7.36	8.71	1.58	090
42210	A	Reconstruct cleft palate	14.91	NA	NA	10.24	10.84	2.17	090
42215	A	Reconstruct cleft palate	8.88	NA	NA	7.41	8.24	1.31	090
42220	A	Reconstruct cleft palate	7.07	NA	NA	7.21	6.99	0.73	090
42225	A	Reconstruct cleft palate	9.66	NA	NA	12.23	14.64	0.86	090
42226	A	Lengthening of palate	10.24	NA	NA	11.89	13.29	1.01	090
42227	A	Lengthening of palate	9.81	NA	NA	11.20	13.37	0.98	090
42235	A	Repair palate	7.92	NA	NA	10.34	11.09	0.72	090
42260	A	Repair nose to lip fistula	10.10	9.73	9.96	6.02	6.54	1.26	090
42280	A	Preparation, palate mold	1.56	2.23	2.10	0.83	0.98	0.19	010
42281	A	Insertion, palate prosthesis	1.95	3.03	2.83	1.69	1.78	0.17	010
42299	C	Palate/uvula surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
42300	A	Drainage of salivary gland	1.95	3.13	2.98	1.74	1.77	0.16	010

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
42305	A	Drainage of salivary gland	6.23	NA	NA	3.99	4.35	0.51	090
42310	A	Drainage of salivary gland	1.58	2.29	2.28	1.39	1.46	0.13	010
42320	A	Drainage of salivary gland	2.37	3.74	3.50	1.88	1.99	0.21	010
42330	A	Removal of salivary stone	2.23	3.41	3.27	1.73	1.79	0.19	010
42335	A	Removal of salivary stone	3.35	5.77	5.33	2.85	2.99	0.29	090
42340	A	Removal of salivary stone	4.64	6.70	6.37	3.48	3.70	0.42	090
42400	A	Biopsy of salivary gland	0.78	2.00	1.82	0.65	0.68	0.06	000
42405	A	Biopsy of salivary gland	3.31	3.96	3.98	2.15	2.30	0.28	010
42408	A	Excision of salivary cyst	4.58	6.41	6.16	3.27	3.44	0.45	090
42409	A	Drainage of salivary cyst	2.85	5.31	4.91	2.53	2.65	0.27	090
42410	A	Excise parotid gland/lesion	9.46	NA	NA	5.36	5.79	0.91	090
42415	A	Excise parotid gland/lesion	17.99	NA	NA	8.62	9.74	1.43	090
42420	A	Excise parotid gland/lesion	20.87	NA	NA	9.56	10.97	1.65	090
42425	A	Excise parotid gland/lesion	13.31	NA	NA	6.83	7.72	1.05	090
42426	A	Excise parotid gland/lesion	22.54	NA	NA	10.00	11.50	1.81	090
42440	A	Excise submaxillary gland	7.05	NA	NA	3.86	4.32	0.59	090
42450	A	Excise sublingual gland	4.66	6.38	6.14	4.02	4.14	0.42	090
42500	A	Repair salivary duct	4.34	6.11	5.90	3.86	4.02	0.41	090
42505	A	Repair salivary duct	6.23	7.27	7.19	4.71	5.04	0.55	090
42507	A	Parotid duct diversion	6.16	NA	NA	6.33	6.43	0.49	090
42508	A	Parotid duct diversion	9.22	NA	NA	8.07	8.20	1.04	090
42509	A	Parotid duct diversion	11.65	NA	NA	8.91	9.55	0.93	090
42510	A	Parotid duct diversion	8.26	NA	NA	6.89	7.34	0.66	090
42550	A	Injection for salivary x-ray	1.25	2.28	2.74	0.44	0.43	0.07	000
42600	A	Closure of salivary fistula	4.86	6.57	6.57	3.42	3.77	0.43	090
42650	A	Dilation of salivary duct	0.77	1.28	1.19	0.66	0.68	0.07	000
42660	A	Dilation of salivary duct	1.13	1.46	1.40	0.75	0.80	0.09	000
42665	A	Ligation of salivary duct	2.57	5.00	4.58	2.40	2.49	0.23	090
42699	C	Salivary surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
42700	A	Drainage of tonsil abscess	1.64	2.97	2.81	1.65	1.67	0.13	010
42720	A	Drainage of throat abscess	6.31	4.69	4.76	3.17	3.48	0.44	010
42725	A	Drainage of throat abscess	12.28	NA	NA	7.08	7.65	0.91	090
42800	A	Biopsy of throat	1.41	2.46	2.32	1.30	1.35	0.11	010
42802	A	Biopsy of throat	1.56	4.13	4.44	1.67	1.87	0.12	010
42804	A	Biopsy of upper nose/throat	1.26	3.58	3.66	1.50	1.62	0.10	010
42806	A	Biopsy of upper nose/throat	1.60	3.83	3.95	1.61	1.77	0.13	010
42808	A	Excise pharynx lesion	2.32	3.22	3.15	1.60	1.77	0.19	010
42809	A	Remove pharynx foreign body	1.83	2.23	2.28	1.32	1.32	0.16	010
42810	A	Excision of neck cyst	3.30	6.22	5.96	3.73	3.63	0.29	090
42815	A	Excision of neck cyst	7.23	NA	NA	6.25	6.33	0.61	090
42820	A	Remove tonsils and adenoids	4.17	NA	NA	2.85	3.07	0.31	090
42821	A	Remove tonsils and adenoids	4.31	NA	NA	2.99	3.24	0.35	090
42825	A	Removal of tonsils	3.45	NA	NA	2.90	3.03	0.25	090
42826	A	Removal of tonsils	3.40	NA	NA	2.68	2.86	0.27	090
42830	A	Removal of adenoids	2.60	NA	NA	2.43	2.49	0.20	090
42831	A	Removal of adenoids	2.75	NA	NA	2.66	2.75	0.22	090
42835	A	Removal of adenoids	2.33	NA	NA	1.78	2.12	0.21	090
42836	A	Removal of adenoids	3.21	NA	NA	2.64	2.80	0.26	090
42842	A	Extensive surgery of throat	12.02	NA	NA	12.03	11.51	0.71	090
42844	A	Extensive surgery of throat	17.57	NA	NA	15.46	15.84	1.16	090
42845	A	Extensive surgery of throat	32.35	NA	NA	21.14	22.16	1.99	090
42860	A	Excision of tonsil tags	2.25	NA	NA	2.30	2.35	0.18	090
42870	A	Excision of lingual tonsil	5.44	NA	NA	8.70	8.63	0.44	090
42890	A	Partial removal of pharynx	18.92	NA	NA	15.24	14.69	1.05	090
42892	A	Revision of pharyngeal walls	25.77	NA	NA	19.20	18.18	1.28	090
42894	A	Revision of pharyngeal walls	33.61	NA	NA	23.53	22.77	1.87	090
42900	A	Repair throat wound	5.26	NA	NA	2.95	3.30	0.50	010
42950	A	Reconstruction of throat	8.16	NA	NA	11.06	11.46	0.72	090
42953	A	Repair throat, esophagus	9.33	NA	NA	13.77	15.54	0.88	090
42955	A	Surgical opening of throat	7.92	NA	NA	10.10	10.38	0.80	090
42960	A	Control throat bleeding	2.35	NA	NA	1.71	1.84	0.19	010
42961	A	Control throat bleeding	5.69	NA	NA	4.48	4.72	0.45	090
42962	A	Control throat bleeding	7.31	NA	NA	5.18	5.54	0.58	090
42970	A	Control nose/throat bleeding	5.76	NA	NA	3.58	3.88	0.39	090
42971	A	Control nose/throat bleeding	6.54	NA	NA	4.50	4.81	0.51	090
42972	A	Control nose/throat bleeding	7.53	NA	NA	4.98	5.34	0.62	090
42999	C	Throat surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43020	A	Incision of esophagus	8.14	NA	NA	4.57	4.99	0.87	090
43030	A	Throat muscle surgery	7.91	NA	NA	4.51	5.00	0.70	090
43045	A	Incision of esophagus	21.70	NA	NA	9.30	9.99	2.59	090
43100	A	Excision of esophagus lesion	9.55	NA	NA	5.20	5.71	0.93	090
43101	A	Excision of esophagus lesion	16.99	NA	NA	7.16	7.52	2.32	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
43107	A	Removal of esophagus	43.97	NA	NA	16.25	17.25	5.24	090
43108	A	Removal of esophagus	82.66	NA	NA	24.46	19.33	4.08	090
43112	A	Removal of esophagus	47.27	NA	NA	17.00	18.18	5.81	090
43113	A	Removal of esophagus	79.85	NA	NA	25.34	20.22	4.43	090
43116	A	Partial removal of esophagus	92.78	NA	NA	30.30	23.49	3.06	090
43117	A	Partial removal of esophagus	43.52	NA	NA	15.14	16.20	5.19	090
43118	A	Partial removal of esophagus	66.86	NA	NA	21.50	17.64	4.11	090
43121	A	Partial removal of esophagus	51.22	NA	NA	18.26	15.96	3.91	090
43122	A	Partial removal of esophagus	43.97	NA	NA	15.60	16.49	5.42	090
43123	A	Partial removal of esophagus	82.91	NA	NA	25.75	19.92	4.16	090
43124	A	Removal of esophagus	68.83	NA	NA	24.34	18.71	3.74	090
43130	A	Removal of esophagus pouch	12.41	NA	NA	6.37	6.96	1.16	090
43135	A	Removal of esophagus pouch	26.09	NA	NA	9.92	9.00	2.34	090
43200	A	Esophagus endoscopy	1.59	3.72	3.92	0.98	1.02	0.13	000
43201	A	Esoph scope w/submucous inj	2.09	5.62	5.12	1.19	1.14	0.15	000
43202	A	Esophagus endoscopy, biopsy	1.89	5.16	5.35	0.98	0.96	0.15	000
43204	A	Esoph scope w/sclerosis inj	3.76	NA	NA	2.01	1.76	0.30	000
43205	A	Esophagus endoscopy/ligation	3.78	NA	NA	2.06	1.79	0.28	000
43215	A	Esophagus endoscopy	2.60	NA	NA	1.29	1.24	0.22	000
43216	A	Esophagus endoscopy/lesion	2.40	3.08	2.07	1.26	1.16	0.20	000
43217	A	Esophagus endoscopy	2.90	6.57	6.76	1.38	1.28	0.26	000
43219	A	Esophagus endoscopy	2.80	NA	NA	1.55	1.45	0.24	000
43220	A	Esoph endoscopy, dilation	2.10	NA	NA	1.13	1.05	0.17	000
43226	A	Esoph endoscopy, dilation	2.34	NA	NA	1.29	1.16	0.19	000
43227	A	Esoph endoscopy, repair	3.59	NA	NA	1.77	1.61	0.28	000
43228	A	Esoph endoscopy, ablation	3.76	NA	NA	1.89	1.72	0.34	000
43231	A	Esoph endoscopy w/us exam	3.19	NA	NA	1.76	1.53	0.23	000
43232	A	Esoph endoscopy w/us fn bx	4.47	NA	NA	2.39	2.10	0.34	000
43234	A	Upper GI endoscopy, exam	2.01	4.98	5.15	1.02	0.94	0.17	000
43235	A	Uppr gi endoscopy, diagnosis	2.39	5.29	5.22	1.35	1.18	0.19	000
43236	A	Uppr gi scope w/submuc inj	2.92	6.71	6.55	1.65	1.43	0.21	000
43237	A	Endoscopic us exam, esoph	3.98	NA	NA	2.16	1.87	0.43	000
43238	A	Uppr gi endoscopy w/us fn bx	5.02	NA	NA	2.56	2.26	0.43	000
43239	A	Upper GI endoscopy, biopsy	2.87	6.05	5.88	1.56	1.37	0.22	000
43240	A	Esoph endoscopy w/drain cyst	6.85	NA	NA	3.28	2.94	0.56	000
43241	A	Upper GI endoscopy with tube	2.59	NA	NA	1.40	1.25	0.21	000
43242	A	Uppr gi endoscopy w/us fn bx	7.30	NA	NA	3.67	3.20	0.53	000
43243	A	Uppr gi endoscopy & inject	4.56	NA	NA	2.35	2.07	0.33	000
43244	A	Upper GI endoscopy/ligation	5.04	NA	NA	2.64	2.30	0.37	000
43245	A	Uppr gi scope dilate strictr	3.18	NA	NA	1.63	1.46	0.26	000
43246	A	Place gastrostomy tube	4.32	NA	NA	2.11	1.90	0.34	000
43247	A	Operative upper GI endoscopy	3.38	NA	NA	1.78	1.57	0.27	000
43248	A	Uppr gi endoscopy/guide wire	3.15	NA	NA	1.77	1.54	0.23	000
43249	A	Esoph endoscopy, dilation	2.90	NA	NA	1.62	1.41	0.22	000
43250	A	Upper GI endoscopy/tumor	3.20	NA	NA	1.61	1.46	0.26	000
43251	A	Operative upper GI endoscopy	3.69	NA	NA	1.92	1.70	0.29	000
43255	A	Operative upper GI endoscopy	4.81	NA	NA	2.52	2.20	0.35	000
43256	A	Uppr gi endoscopy w/stent	4.34	NA	NA	2.25	1.98	0.32	000
43257	A	Uppr gi scope w/thrml txmnt	5.50	NA	NA	2.14	2.17	0.36	000
43258	A	Operative upper GI endoscopy	4.54	NA	NA	2.37	2.07	0.33	000
43259	A	Endoscopic ultrasound exam	5.19	NA	NA	2.69	2.34	0.35	000
43260	A	Endo cholangiopancreatograph	5.95	NA	NA	3.06	2.67	0.43	000
43261	A	Endo cholangiopancreatograph	6.26	NA	NA	3.20	2.80	0.46	000
43262	A	Endo cholangiopancreatograph	7.38	NA	NA	3.73	3.25	0.54	000
43263	A	Endo cholangiopancreatograph	7.28	NA	NA	3.63	3.20	0.54	000
43264	A	Endo cholangiopancreatograph	8.89	NA	NA	4.44	3.87	0.65	000
43265	A	Endo cholangiopancreatograph	10.00	NA	NA	4.98	4.34	0.73	000
43267	A	Endo cholangiopancreatograph	7.38	NA	NA	3.39	3.09	0.54	000
43268	A	Endo cholangiopancreatograph	7.38	NA	NA	3.88	3.38	0.54	000
43269	A	Endo cholangiopancreatograph	8.20	NA	NA	4.10	3.58	0.60	000
43271	A	Endo cholangiopancreatograph	7.38	NA	NA	3.70	3.24	0.54	000
43272	A	Endo cholangiopancreatograph	7.38	NA	NA	3.77	3.28	0.54	000
43280	A	Laparoscopy, fundoplasty	18.00	NA	NA	6.65	6.96	2.28	090
43289	C	Laparoscope proc, esoph	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43300	A	Repair of esophagus	9.21	NA	NA	5.41	5.89	1.12	090
43305	A	Repair esophagus and fistula	17.98	NA	NA	8.33	9.51	1.54	090
43310	A	Repair of esophagus	26.18	NA	NA	9.81	10.43	3.61	090
43312	A	Repair esophagus and fistula	29.23	NA	NA	10.27	11.07	4.01	090
43313	A	Esophagoplasty congenital	48.17	NA	NA	17.46	18.13	5.47	090
43314	A	Tracheo-esophagoplasty cong	53.15	NA	NA	15.09	17.13	6.65	090
43320	A	Fuse esophagus & stomach	23.18	NA	NA	8.60	8.90	2.74	090
43324	A	Revise esophagus & stomach	22.86	NA	NA	8.34	8.55	2.76	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
43325	A	Revise esophagus & stomach	22.47	NA	NA	8.38	8.58	2.60	090
43326	A	Revise esophagus & stomach	22.15	NA	NA	9.20	9.24	2.85	090
43330	A	Repair of esophagus	22.06	NA	NA	8.09	8.31	2.63	090
43331	A	Repair of esophagus	22.93	NA	NA	9.82	9.80	2.94	090
43340	A	Fuse esophagus & intestine	22.86	NA	NA	9.27	9.12	2.46	090
43341	A	Fuse esophagus & intestine	24.10	NA	NA	9.65	9.83	2.92	090
43350	A	Surgical opening, esophagus	19.31	NA	NA	8.75	8.59	1.42	090
43351	A	Surgical opening, esophagus	21.87	NA	NA	10.86	10.32	2.47	090
43352	A	Surgical opening, esophagus	17.68	NA	NA	7.94	8.16	2.06	090
43360	A	Gastrointestinal repair	39.90	NA	NA	14.88	14.97	4.97	090
43361	A	Gastrointestinal repair	45.50	NA	NA	18.13	17.50	4.50	090
43400	A	Ligate esophagus veins	25.47	NA	NA	13.58	11.51	1.96	090
43401	A	Esophagus surgery for veins	26.36	NA	NA	9.54	9.51	3.05	090
43405	A	Ligate/staple esophagus	24.55	NA	NA	10.66	10.12	2.84	090
43410	A	Repair esophagus wound	16.28	NA	NA	7.66	7.64	1.72	090
43415	A	Repair esophagus wound	28.70	NA	NA	11.83	11.78	3.53	090
43420	A	Repair esophagus opening	16.65	NA	NA	7.47	7.43	1.43	090
43425	A	Repair esophagus opening	24.91	NA	NA	10.45	10.21	3.03	090
43450	A	Dilate esophagus	1.38	2.67	2.65	0.93	0.81	0.11	000
43453	A	Dilate esophagus	1.51	6.31	6.18	1.01	0.87	0.11	000
43456	A	Dilate esophagus	2.57	13.01	13.37	1.45	1.27	0.20	000
43458	A	Dilate esophagus	3.06	6.92	6.78	1.59	1.43	0.24	000
43460	A	Pressure treatment esophagus	3.79	NA	NA	1.76	1.62	0.31	000
43496	C	Free jejunum flap, microvasc	0.00	0.00	0.00	0.00	0.00	0.00	090
43499	C	Esophagus surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43500	A	Surgical opening of stomach	12.71	NA	NA	5.29	5.12	1.45	090
43501	A	Surgical repair of stomach	22.47	NA	NA	8.09	8.19	2.65	090
43502	A	Surgical repair of stomach	25.56	NA	NA	8.96	9.21	3.10	090
43510	A	Surgical opening of stomach	15.01	NA	NA	9.13	7.85	1.48	090
43520	A	Incision of pyloric muscle	11.21	NA	NA	4.81	5.03	1.36	090
43600	A	Biopsy of stomach	1.91	NA	NA	0.77	0.71	0.14	000
43605	A	Biopsy of stomach	13.64	NA	NA	5.36	5.32	1.58	090
43610	A	Excision of stomach lesion	16.26	NA	NA	6.03	6.08	1.94	090
43611	A	Excision of stomach lesion	20.25	NA	NA	7.48	7.52	2.36	090
43620	A	Removal of stomach	33.91	NA	NA	11.09	11.44	3.96	090
43621	A	Removal of stomach	39.40	NA	NA	12.39	12.17	4.04	090
43622	A	Removal of stomach	39.90	NA	NA	12.49	12.53	4.30	090
43631	A	Removal of stomach, partial	24.38	NA	NA	8.58	8.87	2.99	090
43632	A	Removal of stomach, partial	35.01	NA	NA	11.26	10.21	2.99	090
43633	A	Removal of stomach, partial	33.01	NA	NA	10.75	10.03	3.06	090
43634	A	Removal of stomach, partial	36.51	NA	NA	11.78	10.93	3.33	090
43635	A	Removal of stomach, partial	2.06	NA	NA	0.52	0.61	0.27	ZZZ
43640	A	Vagotomy & pylorus repair	19.43	NA	NA	7.34	7.29	2.26	090
43641	A	Vagotomy & pylorus repair	19.68	NA	NA	7.62	7.49	2.25	090
43644	A	Lap gastric bypass/roux-en-y	29.24	NA	NA	10.10	10.65	3.16	090
43645	A	Lap gastr bypass incl smll i	31.37	NA	NA	10.48	11.24	3.54	090
43647	C	Lap impl electrode, antrum	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43648	C	Lap revise/remv eltrd antrum	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43651	A	Laparoscopy, vagus nerve	10.13	NA	NA	4.61	4.68	1.33	090
43652	A	Laparoscopy, vagus nerve	12.13	NA	NA	5.22	5.49	1.55	090
43653	A	Laparoscopy, gastrostomy	8.38	NA	NA	4.46	4.32	1.01	090
43659	C	Laparoscope proc, stom	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43752	A	Nasal/orogastric w/stent	0.81	NA	NA	0.26	0.26	0.02	000
43760	A	Change gastrostomy tube	0.90	5.98	4.03	0.33	0.39	0.09	000
43761	A	Reposition gastrostomy tube	2.01	1.04	1.10	0.70	0.68	0.13	000
43770	A	Lap place gastr adj device	17.85	NA	NA	7.40	7.55	2.19	090
43771	A	Lap revise gastr adj device	20.64	NA	NA	8.12	8.35	2.55	090
43772	A	Lap rmvl gastr adj device	15.62	NA	NA	5.99	6.21	1.93	090
43773	A	Lap replace gastr adj device	20.64	NA	NA	8.10	8.34	2.56	090
43774	A	Lap rmvl gastr adj all parts	15.66	NA	NA	6.18	6.37	1.85	090
43800	A	Reconstruction of pylorus	15.35	NA	NA	5.81	5.85	1.82	090
43810	A	Fusion of stomach and bowel	16.80	NA	NA	6.13	6.15	1.94	090
43820	A	Fusion of stomach and bowel	22.40	NA	NA	8.07	7.23	2.04	090
43825	A	Fusion of stomach and bowel	21.63	NA	NA	7.89	7.95	2.54	090
43830	A	Place gastrostomy tube	10.75	NA	NA	5.17	5.00	1.25	090
43831	A	Place gastrostomy tube	8.38	NA	NA	4.92	4.71	1.03	090
43832	A	Place gastrostomy tube	17.26	NA	NA	7.06	6.95	1.98	090
43840	A	Repair of stomach lesion	22.70	NA	NA	8.14	7.45	2.06	090
43842	N	V-band gastroplasty	20.90	NA	NA	6.75	7.26	2.45	090
43843	A	Gastroplasty w/o v-band	21.08	NA	NA	7.84	7.79	2.46	090
43845	A	Gastroplasty duodenal switch	33.12	NA	NA	12.88	11.82	4.06	090
43846	A	Gastric bypass for obesity	27.23	NA	NA	9.97	9.99	3.19	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
43847	A	Gastric bypass incl small i	30.10	NA	NA	10.51	10.70	3.56	090
43848	A	Revision gastroplasty	32.57	NA	NA	11.29	11.55	3.88	090
43850	A	Revise stomach-bowel fusion	27.45	NA	NA	9.49	9.65	3.28	090
43855	A	Revise stomach-bowel fusion	28.56	NA	NA	9.70	10.01	3.47	090
43860	A	Revise stomach-bowel fusion	27.76	NA	NA	9.47	9.71	3.31	090
43865	A	Revise stomach-bowel fusion	28.92	NA	NA	9.73	10.11	3.51	090
43870	A	Repair stomach opening	11.36	NA	NA	4.95	4.73	1.27	090
43880	A	Repair stomach-bowel fistula	27.05	NA	NA	9.27	9.58	3.27	090
43881	C	Impl/redo electrd, antrum	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43882	C	Revise/remove electrd antrum	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43886	A	Revise gastric port, open	4.54	NA	NA	3.44	3.29	0.25	090
43887	A	Remove gastric port, open	4.24	NA	NA	3.05	2.91	0.51	090
43888	A	Change gastric port, open	6.34	NA	NA	4.01	3.88	0.70	090
43999	C	Stomach surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44005	A	Freeing of bowel adhesion	18.38	NA	NA	6.58	6.64	2.15	090
44010	A	Incision of small bowel	14.18	NA	NA	5.53	5.48	1.64	090
44015	A	Insert needle cath bowel	2.62	NA	NA	0.68	0.78	0.35	ZZZ
44020	A	Explore small intestine	16.14	NA	NA	6.00	5.96	1.86	090
44021	A	Decompress small bowel	16.23	NA	NA	6.15	6.05	1.87	090
44025	A	Incision of large bowel	16.43	NA	NA	6.05	6.03	1.90	090
44050	A	Reduce bowel obstruction	15.44	NA	NA	5.82	5.88	1.86	090
44055	A	Correct malrotation of bowel	25.53	NA	NA	8.48	8.60	2.91	090
44100	A	Biopsy of bowel	2.01	NA	NA	0.91	0.81	0.17	000
44110	A	Excise intestine lesion(s)	13.96	NA	NA	5.50	5.36	1.55	090
44111	A	Excision of bowel lesion(s)	16.44	NA	NA	6.09	6.10	1.87	090
44120	A	Removal of small intestine	20.74	NA	NA	7.14	7.11	2.25	090
44121	A	Removal of small intestine	4.44	NA	NA	1.12	1.32	0.58	ZZZ
44125	A	Removal of small intestine	19.93	NA	NA	7.03	7.14	2.27	090
44126	A	Enterectomy w/o taper, cong	42.02	NA	NA	13.59	13.85	4.69	090
44127	A	Enterectomy w/taper, cong	49.09	NA	NA	15.63	15.67	5.77	090
44128	A	Enterectomy cong, add-on	4.44	NA	NA	1.21	1.37	0.61	ZZZ
44130	A	Bowel to bowel fusion	21.98	NA	NA	7.97	7.09	1.88	090
44132	R	Enterectomy, cadaver donor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44133	R	Enterectomy, live donor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44135	R	Intestine transplnt, cadaver	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44136	R	Intestine transplant, live	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44137	C	Remove intestinal allograft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44139	A	Mobilization of colon	2.23	NA	NA	0.56	0.66	0.28	ZZZ
44140	A	Partial removal of colon	22.46	NA	NA	8.06	8.35	2.71	090
44141	A	Partial removal of colon	29.75	NA	NA	11.83	10.93	2.53	090
44143	A	Partial removal of colon	27.63	NA	NA	10.28	10.48	3.05	090
44144	A	Partial removal of colon	29.75	NA	NA	10.62	10.11	2.86	090
44145	A	Partial removal of colon	28.45	NA	NA	9.48	10.13	3.29	090
44146	A	Partial removal of colon	35.14	NA	NA	13.36	13.10	3.41	090
44147	A	Partial removal of colon	33.56	NA	NA	10.77	9.73	2.56	090
44150	A	Removal of colon	29.99	NA	NA	12.60	12.30	3.04	090
44151	A	Removal of colon/ileostomy	34.73	NA	NA	13.91	13.65	3.49	090
44155	A	Removal of colon/ileostomy	34.23	NA	NA	13.44	13.37	3.28	090
44156	A	Removal of colon/ileostomy	37.23	NA	NA	14.48	14.75	3.95	090
44157	A	Colectomy w/ileoanal anast	35.49	NA	NA	17.08	17.08	3.93	090
44158	A	Colectomy w/neo-rectum pouch	36.49	NA	NA	17.42	17.42	4.06	090
44160	A	Removal of colon	20.78	NA	NA	7.51	7.62	2.37	090
44180	A	Lap, enterolysis	15.19	NA	NA	5.80	6.01	1.86	090
44186	A	Lap, jejunostomy	10.30	NA	NA	4.58	4.68	1.27	090
44187	A	Lap, ileo/jejuno-stomy	17.27	NA	NA	8.12	8.19	1.96	090
44188	A	Lap, colostomy	19.20	NA	NA	8.67	8.75	2.24	090
44202	A	Lap, enterectomy	23.26	NA	NA	8.31	8.61	2.85	090
44203	A	Lap resect s/intestine, addl	4.44	NA	NA	1.12	1.31	0.57	ZZZ
44204	A	Laparo partial colectomy	26.29	NA	NA	8.88	9.41	3.11	090
44205	A	Lap colectomy part w/ileum	22.86	NA	NA	7.80	8.32	2.75	090
44206	A	Lap part colectomy w/stoma	29.63	NA	NA	10.46	10.85	3.46	090
44207	A	L colectomy/coloproctostomy	31.79	NA	NA	10.10	10.78	3.67	090
44208	A	L colectomy/coloproctostomy	33.86	NA	NA	12.01	12.57	3.88	090
44210	A	Laparo total proctocolectomy	29.88	NA	NA	11.17	11.52	3.42	090
44211	A	Lap colectomy w/proctectomy	36.87	NA	NA	13.58	14.12	4.17	090
44212	A	Laparo total proctocolectomy	34.37	NA	NA	13.03	13.35	3.78	090
44213	A	Lap, mobil splenic fl add-on	3.50	NA	NA	0.86	1.04	0.44	ZZZ
44227	A	Lap, close enterostomy	28.49	NA	NA	9.48	10.05	3.38	090
44238	C	Laparoscope proc, intestine	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44300	A	Open bowel to skin	13.65	NA	NA	5.55	5.52	1.60	090
44310	A	Ileostomy/jejunostomy	17.49	NA	NA	6.40	6.54	1.99	090
44312	A	Revision of ileostomy	9.33	NA	NA	4.65	4.32	0.92	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fac- ility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
44314	A	Revision of ileostomy	16.61	NA	NA	6.77	6.66	1.75	090
44316	A	Devise bowel pouch	23.46	NA	NA	8.87	8.70	2.38	090
44320	A	Colostomy	19.75	NA	NA	7.59	7.62	2.26	090
44322	A	Colostomy with biopsies	13.15	NA	NA	9.10	8.83	1.54	090
44340	A	Revision of colostomy	9.12	NA	NA	4.93	4.60	0.99	090
44345	A	Revision of colostomy	17.06	NA	NA	6.92	6.90	1.97	090
44346	A	Revision of colostomy	19.47	NA	NA	7.52	7.45	2.13	090
44360	A	Small bowel endoscopy	2.59	NA	NA	1.50	1.30	0.19	000
44361	A	Small bowel endoscopy/biopsy	2.87	NA	NA	1.63	1.41	0.21	000
44363	A	Small bowel endoscopy	3.49	NA	NA	1.85	1.61	0.27	000
44364	A	Small bowel endoscopy	3.73	NA	NA	1.97	1.73	0.27	000
44365	A	Small bowel endoscopy	3.31	NA	NA	1.74	1.55	0.24	000
44366	A	Small bowel endoscopy	4.40	NA	NA	2.37	2.05	0.32	000
44369	A	Small bowel endoscopy	4.51	NA	NA	2.36	2.05	0.33	000
44370	A	Small bowel endoscopy/stent	4.79	NA	NA	2.56	2.26	0.37	000
44372	A	Small bowel endoscopy	4.40	NA	NA	2.12	1.93	0.35	000
44373	A	Small bowel endoscopy	3.49	NA	NA	1.76	1.59	0.27	000
44376	A	Small bowel endoscopy	5.25	NA	NA	2.47	2.25	0.42	000
44377	A	Small bowel endoscopy/biopsy	5.52	NA	NA	2.76	2.45	0.40	000
44378	A	Small bowel endoscopy	7.12	NA	NA	3.57	3.13	0.52	000
44379	A	S bowel endoscope w/stent	7.46	NA	NA	3.92	3.42	0.62	000
44380	A	Small bowel endoscopy	1.05	NA	NA	0.74	0.65	0.08	000
44382	A	Small bowel endoscopy	1.27	NA	NA	0.84	0.73	0.12	000
44383	A	Ileoscopy w/stent	2.94	NA	NA	1.61	1.44	0.21	000
44385	A	Endoscopy of bowel pouch	1.82	4.90	4.12	0.89	0.82	0.15	000
44386	A	Endoscopy, bowel pouch/biop	2.12	6.65	6.64	1.02	0.95	0.20	000
44388	A	Colonoscopy	2.82	6.12	5.60	1.35	1.25	0.26	000
44389	A	Colonoscopy with biopsy	3.13	7.11	6.86	1.57	1.42	0.27	000
44390	A	Colonoscopy for foreign body	3.82	8.33	7.72	1.92	1.70	0.32	000
44391	A	Colonoscopy for bleeding	4.31	8.93	8.83	2.21	1.95	0.34	000
44392	A	Colonoscopy & polypectomy	3.81	7.36	6.97	1.72	1.60	0.34	000
44393	A	Colonoscopy, lesion removal	4.83	8.03	7.46	2.13	2.00	0.42	000
44394	A	Colonoscopy w/snare	4.42	8.50	8.15	2.07	1.89	0.38	000
44397	A	Colonoscopy w/stent	4.70	NA	NA	2.16	1.97	0.39	000
44500	A	Intro, gastrointestinal tube	0.49	NA	NA	0.17	0.17	0.03	000
44602	A	Suture, small intestine	24.64	NA	NA	7.61	7.00	2.12	090
44603	A	Suture, small intestine	28.03	NA	NA	8.96	8.11	2.42	090
44604	A	Suture, large intestine	18.06	NA	NA	6.06	6.25	2.12	090
44605	A	Repair of bowel lesion	22.00	NA	NA	7.82	8.10	2.52	090
44615	A	Intestinal stricturoplasty	18.08	NA	NA	6.53	6.60	2.07	090
44620	A	Repair bowel opening	14.35	NA	NA	5.50	5.41	1.51	090
44625	A	Repair bowel opening	17.20	NA	NA	6.14	6.22	1.86	090
44626	A	Repair bowel opening	27.82	NA	NA	8.88	9.34	3.27	090
44640	A	Repair bowel-skin fistula	24.12	NA	NA	8.01	8.29	2.78	090
44650	A	Repair bowel fistula	25.04	NA	NA	8.30	8.59	2.93	090
44660	A	Repair bowel-bladder fistula	23.83	NA	NA	9.75	9.04	2.14	090
44661	A	Repair bowel-bladder fistula	27.27	NA	NA	9.39	9.47	2.81	090
44680	A	Surgical revision, intestine	17.88	NA	NA	6.68	6.56	2.00	090
44700	A	Suspend bowel w/prosthesis	17.40	NA	NA	6.15	6.40	1.84	090
44701	A	Intraop colon lavage add-on	3.10	NA	NA	0.76	0.91	0.37	ZZZ
44715	C	Prepare donor intestine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44720	A	Prep donor intestine/venous	5.00	NA	NA	1.27	1.48	0.37	XXX
44721	A	Prep donor intestine/artery	7.00	NA	NA	1.78	2.08	0.97	XXX
44799	C	Unlisted procedure intestine	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44800	A	Excision of bowel pouch	11.94	NA	NA	5.49	5.43	1.47	090
44820	A	Excision of mesentery lesion	13.63	NA	NA	5.56	5.52	1.59	090
44850	A	Repair of mesentery	12.03	NA	NA	5.01	5.00	1.39	090
44899	C	Bowel surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44900	A	Drain app abscess, open	12.44	NA	NA	5.02	4.85	1.33	090
44901	A	Drain app abscess, percut	3.37	19.79	23.83	1.20	1.15	0.22	000
44950	A	Appendectomy	10.52	NA	NA	4.04	4.17	1.31	090
44955	A	Appendectomy add-on	1.53	NA	NA	0.40	0.47	0.20	ZZZ
44960	A	Appendectomy	14.39	NA	NA	5.40	5.37	1.63	090
44970	A	Laparoscopy, appendectomy	9.35	NA	NA	4.19	4.13	1.14	090
44979	C	Laparoscope proc, app	0.00	0.00	0.00	0.00	0.00	0.00	YYY
45000	A	Drainage of pelvic abscess	6.20	NA	NA	3.57	3.26	0.52	090
45005	A	Drainage of rectal abscess	2.00	3.98	4.01	1.59	1.58	0.25	010
45020	A	Drainage of rectal abscess	8.43	NA	NA	4.54	3.91	0.55	090
45100	A	Biopsy of rectum	3.96	NA	NA	2.81	2.59	0.44	090
45108	A	Removal of anorectal lesion	5.04	NA	NA	3.09	2.93	0.59	090
45110	A	Removal of rectum	30.57	NA	NA	11.84	12.12	3.36	090
45111	A	Partial removal of rectum	17.89	NA	NA	6.99	7.07	2.07	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
45112		A	Removal of rectum	33.05	NA	NA	10.30	11.02	3.43	090
45113		A	Partial proctectomy	33.09	NA	NA	11.57	12.08	3.49	090
45114		A	Partial removal of rectum	30.63	NA	NA	10.28	10.57	3.36	090
45116		A	Partial removal of rectum	27.56	NA	NA	9.64	9.83	2.88	090
45119		A	Remove rectum w/reservoir	33.35	NA	NA	11.53	11.99	3.36	090
45120		A	Removal of rectum	26.25	NA	NA	9.26	9.69	2.90	090
45121		A	Removal of rectum and colon	28.93	NA	NA	10.03	10.56	3.25	090
45123		A	Partial proctectomy	18.70	NA	NA	6.94	6.89	1.86	090
45126		A	Pelvic exenteration	48.89	NA	NA	17.87	18.53	4.33	090
45130		A	Excision of rectal prolapse	18.37	NA	NA	6.66	6.71	1.80	090
45135		A	Excision of rectal prolapse	22.15	NA	NA	8.60	8.50	2.36	090
45136		A	Excise ileoanal reservoir	30.63	NA	NA	11.94	12.23	2.82	090
45150		A	Excision of rectal stricture	5.77	NA	NA	3.34	3.15	0.61	090
45160		A	Excision of rectal lesion	16.17	NA	NA	6.43	6.54	1.68	090
45170		A	Excision of rectal lesion	12.48	NA	NA	5.36	5.29	1.35	090
45190		A	Destruction, rectal tumor	10.29	NA	NA	5.52	5.07	1.13	090
45300		A	Proctosigmoidoscopy dx	0.80	1.96	1.74	0.45	0.37	0.04	000
45303		A	Proctosigmoidoscopy dilate	1.50	19.91	19.29	0.66	0.49	0.05	000
45305		A	Proctosigmoidoscopy w/bx	1.25	3.19	2.91	0.59	0.55	0.11	000
45307		A	Proctosigmoidoscopy fb	1.70	3.25	3.14	0.70	0.59	0.11	000
45308		A	Proctosigmoidoscopy removal	1.40	3.40	2.70	0.63	0.53	0.09	000
45309		A	Proctosigmoidoscopy removal	1.50	3.53	3.17	0.67	0.75	0.22	000
45315		A	Proctosigmoidoscopy removal	1.80	3.82	3.34	0.87	0.75	0.15	000
45317		A	Proctosigmoidoscopy bleed	2.00	3.36	2.90	0.76	0.71	0.15	000
45320		A	Proctosigmoidoscopy ablate	1.78	3.40	3.15	0.80	0.75	0.16	000
45321		A	Proctosigmoidoscopy volvul	1.75	NA	NA	0.86	0.71	0.13	000
45327		A	Proctosigmoidoscopy w/stent	2.00	NA	NA	0.91	0.80	0.16	000
45330		A	Diagnostic sigmoidoscopy	0.96	2.52	2.40	0.62	0.56	0.08	000
45331		A	Sigmoidoscopy and biopsy	1.15	3.28	3.17	0.79	0.69	0.09	000
45332		A	Sigmoidoscopy w/fb removal	1.79	5.53	5.26	0.99	0.90	0.16	000
45333		A	Sigmoidoscopy & polypectomy	1.79	5.66	5.26	0.99	0.89	0.15	000
45334		A	Sigmoidoscopy for bleeding	2.73	NA	NA	1.53	1.34	0.20	000
45335		A	Sigmoidoscopy w/submuc inj	1.46	5.34	4.27	0.90	0.79	0.11	000
45337		A	Sigmoidoscopy & decompress	2.36	NA	NA	1.25	1.12	0.21	000
45338		A	Sigmoidoscopy w/tumr remove	2.34	5.90	5.56	1.28	1.14	0.19	000
45339		A	Sigmoidoscopy w/ablate tumr	3.14	5.73	4.59	1.66	1.47	0.26	000
45340		A	Sig w/balloon dilation	1.89	10.25	8.21	1.03	0.93	0.15	000
45341		A	Sigmoidoscopy w/ultrasound	2.60	NA	NA	1.47	1.27	0.19	000
45342		A	Sigmoidoscopy w/us guide bx	4.05	NA	NA	2.17	1.85	0.30	000
45345		A	Sigmoidoscopy w/stent	2.92	NA	NA	1.50	1.33	0.23	000
45355		A	Surgical colonoscopy	3.51	NA	NA	1.58	1.48	0.36	000
45378		A	Diagnostic colonoscopy	3.69	6.38	6.26	1.82	1.64	0.30	000
45378	53	A	Diagnostic colonoscopy	0.96	2.52	2.40	0.62	0.56	0.08	000
45379		A	Colonoscopy w/fb removal	4.68	8.07	7.86	2.17	1.99	0.39	000
45380		A	Colonoscopy and biopsy	4.43	7.75	7.47	2.23	1.98	0.35	000
45381		A	Colonoscopy, submucous inj	4.19	7.72	7.41	2.16	1.90	0.30	000
45382		A	Colonoscopy/control bleeding	5.68	10.35	10.14	2.88	2.53	0.41	000
45383		A	Lesion removal colonoscopy	5.86	8.55	8.23	2.63	2.43	0.48	000
45384		A	Lesion remove colonoscopy	4.69	7.19	6.99	2.18	2.00	0.38	000
45385		A	Lesion removal colonoscopy	5.30	8.37	8.08	2.59	2.31	0.42	000
45386		A	Colonoscopy dilate stricture	4.57	12.35	12.38	2.17	1.98	0.39	000
45387		A	Colonoscopy w/stent	5.90	NA	NA	2.80	2.57	0.48	000
45391		A	Colonoscopy w/endscope us	5.09	NA	NA	2.60	2.29	0.42	000
45392		A	Colonoscopy w/endoscopic fnb	6.54	NA	NA	3.21	2.85	0.42	000
45395		A	Lap, removal of rectum	32.79	NA	NA	12.94	13.30	3.63	090
45397		A	Lap, remove rectum w/pouch	36.29	NA	NA	13.38	13.82	3.67	090
45400		A	Laparoscopic proc	19.31	NA	NA	7.07	7.45	2.03	090
45402		A	Lap proctopexy w/sig resect	26.38	NA	NA	8.73	9.35	2.82	090
45499		C	Laparoscope proc, rectum	0.00	0.00	0.00	0.00	0.00	0.00	YYY
45500		A	Repair of rectum	7.64	NA	NA	4.46	3.99	0.75	090
45505		A	Repair of rectum	8.20	NA	NA	5.04	4.44	0.86	090
45520		A	Treatment of rectal prolapse	0.55	2.86	2.25	0.38	0.38	0.05	000
45540		A	Correct rectal prolapse	18.02	NA	NA	5.83	6.31	1.85	090
45541		A	Correct rectal prolapse	14.72	NA	NA	6.59	6.26	1.55	090
45550		A	Repair rectum/remove sigmoid	24.67	NA	NA	8.95	9.08	2.62	090
45560		A	Repair of rectocele	11.42	NA	NA	5.52	5.28	1.13	090
45562		A	Exploration/repair of rectum	17.82	NA	NA	8.10	7.54	1.84	090
45563		A	Exploration/repair of rectum	26.22	NA	NA	10.75	10.62	3.11	090
45800		A	Repair rect/bladder fistula	20.18	NA	NA	9.14	8.28	1.86	090
45805		A	Repair fistula w/colostomy	23.19	NA	NA	9.92	9.71	2.03	090
45820		A	Repair rectourethral fistula	20.24	NA	NA	9.09	8.35	1.58	090
45825		A	Repair fistula w/colostomy	24.01	NA	NA	9.46	9.63	2.32	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
45900	A	Reduction of rectal prolapse	2.96	NA	NA	1.65	1.57	0.30	010
45905	A	Dilation of anal sphincter	2.32	NA	NA	1.60	1.51	0.27	010
45910	A	Dilation of rectal narrowing	2.82	NA	NA	1.84	1.75	0.30	010
45915	A	Remove rectal obstruction	3.16	4.20	4.26	2.01	2.05	0.30	010
45990	A	Surg dx exam, anorectal	1.80	NA	NA	0.72	0.76	0.17	000
45999	C	Rectum surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
46020	A	Placement of seton	2.94	3.26	2.80	2.35	2.10	0.31	010
46030	A	Removal of rectal marker	1.24	1.88	1.61	0.81	0.76	0.14	010
46040	A	Incision of rectal abscess	5.26	6.53	6.01	3.98	3.78	0.62	090
46045	A	Incision of rectal abscess	5.79	NA	NA	3.94	3.41	0.54	090
46050	A	Incision of anal abscess	1.21	3.19	2.87	0.98	0.91	0.14	010
46060	A	Incision of rectal abscess	6.24	NA	NA	4.41	3.83	0.67	090
46070	A	Incision of anal septum	2.74	NA	NA	2.35	2.09	0.36	090
46080	A	Incision of anal sphincter	2.50	3.06	2.71	1.12	1.12	0.30	010
46083	A	Incise external hemorrhoid	1.42	2.36	2.44	0.96	0.94	0.15	010
46200	A	Removal of anal fissure	3.48	6.29	5.07	3.73	3.29	0.39	090
46210	A	Removal of anal crypt	2.73	5.82	5.46	3.30	2.96	0.31	090
46211	A	Removal of anal crypts	4.31	7.84	6.62	4.66	4.08	0.48	090
46220	A	Removal of anal tag	1.58	3.02	2.66	1.10	1.02	0.17	010
46221	A	Ligation of hemorrhoid(s)	2.31	3.73	3.19	2.00	1.87	0.23	010
46230	A	Removal of anal tags	2.59	3.50	3.29	1.33	1.31	0.30	010
46250	A	Hemorrhoidectomy	4.17	5.95	5.63	2.83	2.72	0.48	090
46255	A	Hemorrhoidectomy	4.88	6.34	6.08	3.06	2.95	0.58	090
46257	A	Remove hemorrhoids & fissure	5.68	NA	NA	3.84	3.36	0.64	090
46258	A	Remove hemorrhoids & fistula	6.28	NA	NA	3.95	3.61	0.68	090
46260	A	Hemorrhoidectomy	6.65	NA	NA	4.06	3.62	0.76	090
46261	A	Remove hemorrhoids & fissure	7.63	NA	NA	4.29	3.94	0.79	090
46262	A	Remove hemorrhoids & fistula	7.80	NA	NA	4.65	4.19	0.83	090
46270	A	Removal of anal fistula	4.81	6.38	5.68	3.91	3.37	0.46	090
46275	A	Removal of anal fistula	5.31	6.62	5.62	3.97	3.47	0.52	090
46280	A	Removal of anal fistula	6.28	NA	NA	4.27	3.76	0.66	090
46285	A	Removal of anal fistula	5.31	6.53	5.14	3.95	3.35	0.44	090
46288	A	Repair anal fistula	7.68	NA	NA	4.67	4.17	0.79	090
46320	A	Removal of hemorrhoid clot	1.62	2.41	2.26	0.88	0.86	0.18	010
46500	A	Injection into hemorrhoid(s)	1.64	3.60	2.86	1.25	1.20	0.16	010
46505	A	Chemodenervation anal musc	3.13	3.28	3.16	2.28	2.12	0.14	010
46600	A	Diagnostic anoscopy	0.55	1.37	1.46	0.38	0.36	0.05	000
46604	A	Anoscopy and dilation	1.03	12.51	10.81	0.51	0.56	0.12	000
46606	A	Anoscopy and biopsy	1.20	3.87	3.82	0.58	0.50	0.09	000
46608	A	Anoscopy, remove for body	1.30	3.76	4.08	0.58	0.61	0.16	000
46610	A	Anoscopy, remove lesion	1.28	3.79	3.91	0.59	0.60	0.15	000
46611	A	Anoscopy	1.30	2.53	2.93	0.57	0.67	0.19	000
46612	A	Anoscopy, remove lesions	1.50	4.70	4.94	0.72	0.85	0.28	000
46614	A	Anoscopy, control bleeding	1.00	1.93	2.13	0.52	0.68	0.20	000
46615	A	Anoscopy	1.50	1.74	2.11	0.64	0.85	0.33	000
46700	A	Repair of anal stricture	9.68	NA	NA	5.15	4.67	0.94	090
46705	A	Repair of anal stricture	7.32	NA	NA	4.06	3.87	0.91	090
46706	A	Repr of anal fistula w/glue	2.41	NA	NA	1.49	1.37	0.28	010
46710	A	Repr per/vag pouch snl proc	17.01	NA	NA	7.54	7.64	1.38	090
46712	A	Repr per/vag pouch dbl proc	36.32	NA	NA	14.00	14.52	3.67	090
46715	A	Rep perf anoper fistu	7.54	NA	NA	3.75	3.66	0.92	090
46716	A	Rep perf anoper/vestib fistu	17.14	NA	NA	9.59	8.77	1.58	090
46730	A	Construction of absent anus	30.17	NA	NA	12.49	12.25	2.47	090
46735	A	Construction of absent anus	35.66	NA	NA	15.00	14.27	3.21	090
46740	A	Construction of absent anus	33.42	NA	NA	15.28	14.25	2.42	090
46742	A	Repair of imperforated anus	39.66	NA	NA	13.75	15.56	3.20	090
46744	A	Repair of cloacal anomaly	58.46	NA	NA	18.13	19.61	6.40	090
46746	A	Repair of cloacal anomaly	64.93	NA	NA	19.66	22.39	7.70	090
46748	A	Repair of cloacal anomaly	70.91	NA	NA	21.04	22.33	3.37	090
46750	A	Repair of anal sphincter	12.02	NA	NA	5.76	5.40	1.10	090
46751	A	Repair of anal sphincter	9.19	NA	NA	5.02	5.22	0.94	090
46753	A	Reconstruction of anus	8.81	NA	NA	4.59	4.21	0.94	090
46754	A	Removal of suture from anus	2.88	3.63	3.61	2.21	1.94	0.19	010
46760	A	Repair of anal sphincter	17.21	NA	NA	8.05	7.56	1.59	090
46761	A	Repair of anal sphincter	15.16	NA	NA	6.47	6.23	1.43	090
46762	A	Implant artificial sphincter	14.66	NA	NA	7.07	6.29	1.24	090
46900	A	Destruction, anal lesion(s)	1.91	3.65	3.12	1.31	1.29	0.17	010
46910	A	Destruction, anal lesion(s)	1.88	3.88	3.39	1.20	1.13	0.19	010
46916	A	Cryosurgery, anal lesion(s)	1.88	3.77	3.46	1.58	1.48	0.11	010
46917	A	Laser surgery, anal lesions	1.88	8.78	8.95	1.22	1.17	0.21	010
46922	A	Excision of anal lesion(s)	1.88	4.14	3.70	1.20	1.13	0.22	010
46924	A	Destruction, anal lesion(s)	2.78	9.57	9.13	1.51	1.43	0.26	010

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
46934	A	Destruction of hemorrhoids	3.79	5.56	5.31	2.87	2.91	0.32	090
46935	A	Destruction of hemorrhoids	2.44	3.86	3.66	1.11	1.16	0.23	010
46936	A	Destruction of hemorrhoids	3.70	6.23	5.55	2.65	2.57	0.34	090
46937	A	Cryotherapy of rectal lesion	2.70	3.40	3.09	1.43	1.32	0.14	010
46938	A	Cryotherapy of rectal lesion	4.70	5.62	4.80	3.55	3.30	0.58	090
46940	A	Treatment of anal fissure	2.33	2.84	2.42	1.04	1.06	0.23	010
46942	A	Treatment of anal fissure	2.05	2.80	2.32	0.96	0.99	0.19	010
46945	A	Ligation of hemorrhoids	2.13	4.79	4.03	2.98	2.72	0.19	090
46946	A	Ligation of hemorrhoids	2.60	4.63	4.17	2.64	2.52	0.27	090
46947	A	Hemorrhoidopexy by stapling	5.49	NA	NA	3.10	2.91	0.75	090
46999	C	Anus surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47000	A	Needle biopsy of liver	1.90	7.66	5.36	0.70	0.66	0.12	000
47001	A	Needle biopsy, liver add-on	1.90	NA	NA	0.48	0.57	0.25	ZZZ
47010	A	Open drainage, liver lesion	19.27	NA	NA	8.31	8.35	1.81	090
47011	A	Percut drain, liver lesion	3.69	NA	NA	1.32	1.26	0.22	000
47015	A	Inject/aspirate liver cyst	18.37	NA	NA	8.16	7.82	1.84	090
47100	A	Wedge biopsy of liver	12.78	NA	NA	6.31	6.17	1.53	090
47120	A	Partial removal of liver	38.82	NA	NA	14.07	14.60	4.66	090
47122	A	Extensive removal of liver	59.35	NA	NA	18.74	20.08	7.21	090
47125	A	Partial removal of liver	52.91	NA	NA	17.16	18.33	6.47	090
47130	A	Partial removal of liver	57.06	NA	NA	18.10	19.53	6.96	090
47133	X	Removal of donor liver	0.00	0.00	0.00	0.00	0.00	0.00	XXX
47135	R	Transplantation of liver	83.29	NA	NA	27.72	29.60	9.96	090
47136	R	Transplantation of liver	70.39	NA	NA	24.53	25.76	8.44	090
47140	A	Partial removal, donor liver	59.22	NA	NA	21.60	21.93	5.19	090
47141	A	Partial removal, donor liver	71.27	NA	NA	25.33	26.11	5.19	090
47142	A	Partial removal, donor liver	79.21	NA	NA	27.34	28.39	5.19	090
47143	C	Prep donor liver, whole	0.00	0.00	0.00	0.00	0.00	0.00	XXX
47144	C	Prep donor liver, 3-segment	0.00	0.00	0.00	0.00	0.00	0.00	090
47145	C	Prep donor liver, lobe split	0.00	0.00	0.00	0.00	0.00	0.00	XXX
47146	A	Prep donor liver/venous	6.00	NA	NA	1.52	1.78	0.83	XXX
47147	A	Prep donor liver/arterial	7.00	NA	NA	1.77	2.08	0.97	XXX
47300	A	Surgery for liver lesion	18.01	NA	NA	7.74	7.48	1.99	090
47350	A	Repair liver wound	22.36	NA	NA	8.77	8.81	2.59	090
47360	A	Repair liver wound	31.18	NA	NA	11.24	11.40	3.38	090
47361	A	Repair liver wound	52.47	NA	NA	17.38	17.94	5.87	090
47362	A	Repair liver wound	23.41	NA	NA	9.30	9.00	2.51	090
47370	A	Laparo ablate liver tumor rf	20.67	NA	NA	7.69	7.90	2.56	090
47371	A	Laparo ablate liver cryosurg	20.67	NA	NA	7.89	8.01	2.61	090
47379	C	Laparoscope procedure, liver	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47380	A	Open ablate liver tumor rf	24.43	NA	NA	8.60	8.97	2.87	090
47381	A	Open ablate liver tumor cryo	24.72	NA	NA	9.31	9.44	2.85	090
47382	A	Percut ablate liver rf	15.19	NA	NA	6.20	6.14	0.96	010
47399	C	Liver surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47400	A	Incision of liver duct	36.23	NA	NA	13.01	13.21	3.08	090
47420	A	Incision of bile duct	21.92	NA	NA	8.54	8.65	2.63	090
47425	A	Incision of bile duct	22.20	NA	NA	8.64	8.72	2.62	090
47460	A	Incise bile duct sphincter	20.41	NA	NA	9.13	8.74	2.21	090
47480	A	Incision of gallbladder	13.12	NA	NA	6.64	6.27	1.42	090
47490	A	Incision of gallbladder	8.05	NA	NA	5.29	5.43	0.43	090
47500	A	Injection for liver x-rays	1.96	NA	NA	0.71	0.67	0.12	000
47505	A	Injection for liver x-rays	0.76	NA	NA	0.27	0.26	0.04	000
47510	A	Insert catheter, bile duct	7.94	NA	NA	4.63	4.82	0.46	090
47511	A	Insert bile duct drain	10.74	NA	NA	5.04	5.06	0.62	090
47525	A	Change bile duct catheter	5.55	14.85	14.96	2.69	2.74	0.33	010
47530	A	Revise/reinsert bile tube	5.96	30.56	32.16	3.44	3.58	0.37	090
47550	A	Bile duct endoscopy add-on	3.02	NA	NA	0.78	0.90	0.40	ZZZ
47552	A	Biliary endoscopy thru skin	6.03	NA	NA	2.48	2.43	0.42	000
47553	A	Biliary endoscopy thru skin	6.34	NA	NA	2.25	2.16	0.37	000
47554	A	Biliary endoscopy thru skin	9.05	NA	NA	3.29	3.32	0.96	000
47555	A	Biliary endoscopy thru skin	7.55	NA	NA	2.74	2.60	0.45	000
47556	A	Biliary endoscopy thru skin	8.55	NA	NA	3.09	2.93	0.50	000
47560	A	Laparoscopy w/cholangio	4.88	NA	NA	1.24	1.45	0.65	000
47561	A	Laparo w/cholangio/biopsy	5.17	NA	NA	1.58	1.75	0.66	000
47562	A	Laparoscopic cholecystectomy	11.63	NA	NA	5.26	5.12	1.46	090
47563	A	Laparo cholecystectomy/graph	12.03	NA	NA	5.06	5.18	1.58	090
47564	A	Laparo cholecystectomy/expl	14.21	NA	NA	5.41	5.68	1.89	090
47570	A	Laparo cholecystoenterostomy	12.56	NA	NA	4.96	5.16	1.65	090
47579	C	Laparoscope proc, biliary	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47600	A	Removal of gallbladder	17.35	NA	NA	7.22	6.67	1.80	090
47605	A	Removal of gallbladder	15.90	NA	NA	6.38	6.43	1.95	090
47610	A	Removal of gallbladder	20.84	NA	NA	7.65	7.78	2.49	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
47612	A	Removal of gallbladder	21.13	NA	NA	7.67	7.77	2.48	090
47620	A	Removal of gallbladder	22.99	NA	NA	8.15	8.33	2.74	090
47630	A	Remove bile duct stone	9.57	NA	NA	4.73	4.80	0.65	090
47700	A	Exploration of bile ducts	16.39	NA	NA	7.30	7.35	2.07	090
47701	A	Bile duct revision	28.62	NA	NA	10.64	11.05	3.68	090
47711	A	Excision of bile duct tumor	25.77	NA	NA	9.64	9.77	3.05	090
47712	A	Excision of bile duct tumor	33.59	NA	NA	11.65	12.02	3.93	090
47715	A	Excision of bile duct cyst	21.42	NA	NA	8.60	8.51	2.49	090
47720	A	Fuse gallbladder & bowel	18.21	NA	NA	7.70	7.58	2.11	090
47721	A	Fuse upper gi structures	21.86	NA	NA	8.54	8.54	2.53	090
47740	A	Fuse gallbladder & bowel	21.10	NA	NA	8.33	8.34	2.42	090
47741	A	Fuse gallbladder & bowel	24.08	NA	NA	9.24	9.26	2.83	090
47760	A	Fuse bile ducts and bowel	38.14	NA	NA	13.03	11.93	3.42	090
47765	A	Fuse liver ducts & bowel	52.01	NA	NA	16.94	13.86	3.30	090
47780	A	Fuse bile ducts and bowel	42.14	NA	NA	14.11	12.65	3.50	090
47785	A	Fuse bile ducts and bowel	56.01	NA	NA	17.84	15.36	4.10	090
47800	A	Reconstruction of bile ducts	26.04	NA	NA	9.77	9.90	3.08	090
47801	A	Placement, bile duct support	17.47	NA	NA	8.43	8.28	1.16	090
47802	A	Fuse liver duct & intestine	24.80	NA	NA	9.68	9.66	2.86	090
47900	A	Suture bile duct injury	22.31	NA	NA	8.85	8.85	2.65	090
47999	C	Bile tract surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
48000	A	Drainage of abdomen	31.82	NA	NA	10.86	11.17	3.48	090
48001	A	Placement of drain, pancreas	39.56	NA	NA	12.76	13.30	4.69	090
48020	A	Removal of pancreatic stone	18.96	NA	NA	7.59	7.44	2.13	090
48100	A	Biopsy of pancreas, open	14.38	NA	NA	5.95	5.77	1.62	090
48102	A	Needle biopsy, pancreas	4.68	9.60	8.77	1.91	1.93	0.28	010
48105	A	Resect/debride pancreas	49.05	NA	NA	15.76	16.15	5.56	090
48120	A	Removal of pancreas lesion	18.33	NA	NA	6.85	6.84	2.10	090
48140	A	Partial removal of pancreas	26.19	NA	NA	9.37	9.45	3.03	090
48145	A	Partial removal of pancreas	27.26	NA	NA	9.55	9.68	3.18	090
48146	A	Pancreatectomy	30.42	NA	NA	11.93	11.94	3.50	090
48148	A	Removal of pancreatic duct	20.26	NA	NA	8.20	7.89	2.30	090
48150	A	Partial removal of pancreas	52.63	NA	NA	18.01	18.74	6.32	090
48152	A	Pancreatectomy	48.47	NA	NA	16.82	17.50	5.80	090
48153	A	Pancreatectomy	52.61	NA	NA	17.89	18.70	6.31	090
48154	A	Pancreatectomy	48.70	NA	NA	17.05	17.62	5.84	090
48155	A	Removal of pancreas	29.27	NA	NA	11.96	11.80	3.27	090
48160	N	Pancreas removal/transplant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
48400	A	Injection, intraop add-on	1.95	NA	NA	0.66	0.65	0.15	ZZZ
48500	A	Surgery of pancreatic cyst	18.03	NA	NA	7.66	7.49	2.03	090
48510	A	Drain pancreatic pseudocyst	17.06	NA	NA	7.60	7.51	1.83	090
48511	A	Drain pancreatic pseudocyst	3.99	20.17	20.53	1.43	1.37	0.24	000
48520	A	Fuse pancreas cyst and bowel	18.07	NA	NA	6.82	6.76	2.06	090
48540	A	Fuse pancreas cyst and bowel	21.86	NA	NA	7.80	7.94	2.61	090
48545	A	Pancreatorrhaphy	22.10	NA	NA	8.41	8.19	2.38	090
48547	A	Duodenal exclusion	30.25	NA	NA	10.28	10.37	3.42	090
48548	A	Fuse pancreas and bowel	27.96	NA	NA	9.88	10.01	3.28	090
48550	X	Donor pancreatectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
48551	C	Prep donor pancreas	0.00	0.00	0.00	0.00	0.00	0.00	XXX
48552	A	Prep donor pancreas/venous	4.30	NA	NA	1.14	1.30	0.31	XXX
48554	R	Transpl allograft pancreas	37.03	NA	NA	20.51	19.37	4.19	090
48556	A	Removal, allograft pancreas	19.24	NA	NA	9.22	8.64	2.08	090
48999	C	Pancreas surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
49000	A	Exploration of abdomen	12.44	NA	NA	5.20	5.29	1.52	090
49002	A	Reopening of abdomen	17.55	NA	NA	6.38	5.69	1.37	090
49010	A	Exploration behind abdomen	15.98	NA	NA	6.19	6.04	1.51	090
49020	A	Drain abdominal abscess	26.46	NA	NA	9.88	10.03	2.85	090
49021	A	Drain abdominal abscess	3.37	19.63	20.33	1.21	1.16	0.20	000
49040	A	Drain, open, abdom abscess	16.41	NA	NA	6.51	6.46	1.70	090
49041	A	Drain, percut, abdom abscess	3.99	19.91	19.71	1.43	1.37	0.24	000
49060	A	Drain, open, retroper abscess	18.42	NA	NA	7.24	7.33	1.75	090
49061	A	Drain, percut, retroper abscess	3.69	19.74	19.68	1.33	1.27	0.22	000
49062	A	Drain to peritoneal cavity	12.12	NA	NA	5.11	5.27	1.39	090
49080	A	Puncture, peritoneal cavity	1.35	2.73	3.35	0.48	0.47	0.08	000
49081	A	Removal of abdominal fluid	1.26	2.93	2.76	0.47	0.45	0.09	000
49180	A	Biopsy, abdominal mass	1.73	2.47	2.79	0.62	0.59	0.10	000
49203	A	Exc abd tum 5 cm or less	20.00	NA	NA	7.65	7.65	2.27	090
49204	A	Exc abd tum over 5 cm	26.00	NA	NA	9.26	9.26	2.94	090
49205	A	Exc abd tum over 10 cm	30.00	NA	NA	10.34	10.34	3.40	090
49215	A	Excise sacral spine tumor	37.66	NA	NA	12.67	13.35	4.38	090
49220	A	Multiple surgery, abdomen	15.70	NA	NA	6.45	6.54	1.89	090
49250	A	Excision of umbilicus	8.93	NA	NA	4.34	4.30	1.08	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional-facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
49255	A	Removal of omentum	12.41	NA	NA	5.62	5.61	1.43	090
49320	A	Diag laparo separate proc	5.09	NA	NA	2.44	2.53	0.65	010
49321	A	Laparoscopy, biopsy	5.39	NA	NA	2.56	2.60	0.70	010
49322	A	Laparoscopy, aspiration	5.96	NA	NA	2.63	2.81	0.71	010
49323	A	Laparo drain lymphocele	10.13	NA	NA	4.68	4.58	1.20	090
49324	A	Lap insertion perm ip cath	6.27	NA	NA	2.78	2.78	0.73	010
49325	A	Lap revision perm ip cath	6.77	NA	NA	2.91	2.91	0.86	010
49326	A	Lap w/omentopexy add-on	3.50	NA	NA	0.92	0.92	0.44	ZZZ
49329	C	Laparo proc, abdm/per/oment	0.00	0.00	0.00	0.00	0.00	0.00	YYY
49400	A	Air injection into abdomen	1.88	2.47	2.77	0.62	0.62	0.15	000
49402	A	Remove foreign body, adbomen	14.01	NA	NA	5.51	5.50	1.62	090
49419	A	Insrt abdom cath for chemotx	7.03	NA	NA	3.43	3.49	0.81	090
49420	A	Insert abdom drain, temp	2.22	NA	NA	1.18	1.13	0.21	000
49421	A	Insert abdom drain, perm	5.87	NA	NA	3.12	3.13	0.74	090
49422	A	Remove perm cannula/catheter	6.26	NA	NA	2.61	2.75	0.83	010
49423	A	Exchange drainage catheter	1.46	13.08	13.57	0.56	0.54	0.09	000
49424	A	Assess cyst, contrast inject	0.76	3.08	3.39	0.30	0.30	0.04	000
49425	A	Insert abdomen-venous drain	12.13	NA	NA	5.29	5.44	1.54	090
49426	A	Revise abdomen-venous shunt	10.33	NA	NA	4.56	4.66	1.28	090
49427	A	Injection, abdominal shunt	0.89	NA	NA	0.32	0.31	0.07	000
49428	A	Ligation of shunt	6.79	NA	NA	2.99	3.45	0.80	010
49429	A	Removal of shunt	7.41	NA	NA	2.99	3.20	1.02	010
49435	A	Insert subq exten to ip cath	2.25	NA	NA	0.61	0.61	0.28	ZZZ
49436	A	Embedded ip cath exit-site	2.69	NA	NA	1.66	1.66	0.28	010
49440	A	Place gastrostomy tube perc	4.18	25.03	25.03	1.81	1.81	0.49	010
49441	A	Place duod/jej tube perc	4.77	30.10	30.10	2.00	2.00	0.29	010
49442	A	Place cecostomy tube perc	4.00	24.43	24.43	1.63	1.63	0.24	010
49446	A	Change g-tube to g-j perc	3.31	25.74	25.74	1.15	1.15	0.18	000
49450	A	Replace g/c tube perc	1.36	18.94	18.94	0.44	0.44	0.08	000
49451	A	Replace duod/jej tube perc	1.84	19.69	19.69	0.64	0.64	0.11	000
49452	A	Replace g-j tube perc	2.86	23.48	23.48	1.00	1.00	0.18	000
49460	A	Fix g/colon tube w/device	0.96	20.56	20.56	0.31	0.31	0.05	000
49465	A	Fluoro exam of g/colon tube	0.62	3.88	3.88	0.22	0.22	0.03	000
49491	A	Rpr hern preemie reduc	12.42	NA	NA	4.61	4.83	1.40	090
49492	A	Rpr ing hern premie, blocked	15.32	NA	NA	6.22	6.16	1.81	090
49495	A	Rpr ing hernia baby, reduc	6.15	NA	NA	3.06	3.01	0.74	090
49496	A	Rpr ing hernia baby, blocked	9.32	NA	NA	4.44	4.35	1.07	090
49500	A	Rpr ing hernia, init, reduce	5.76	NA	NA	3.64	3.38	0.71	090
49501	A	Rpr ing hernia, init blocked	9.28	NA	NA	4.26	4.23	1.12	090
49505	A	Prp i/hern init reduc >5 yr	7.88	NA	NA	3.88	3.81	1.03	090
49507	A	Prp i/hern init block >5 yr	9.97	NA	NA	4.45	4.45	1.27	090
49520	A	Rerepair ing hernia, reduce	9.91	NA	NA	4.37	4.40	1.28	090
49521	A	Rerepair ing hernia, blocked	12.36	NA	NA	4.98	5.11	1.59	090
49525	A	Repair ing hernia, sliding	8.85	NA	NA	4.12	4.09	1.13	090
49540	A	Repair lumbar hernia	10.66	NA	NA	4.57	4.65	1.37	090
49550	A	Rpr rem hernia, init, reduce	8.91	NA	NA	4.11	4.11	1.14	090
49553	A	Rpr fem hernia, init blocked	9.84	NA	NA	4.41	4.41	1.24	090
49555	A	Rerepair fem hernia, reduce	9.31	NA	NA	4.20	4.23	1.20	090
49557	A	Rerepair fem hernia, blocked	11.54	NA	NA	4.83	4.90	1.47	090
49560	A	Rpr ventral hern init, reduc	11.84	NA	NA	4.87	5.00	1.52	090
49561	A	Rpr ventral hern init, block	15.30	NA	NA	5.79	5.92	1.89	090
49565	A	Rerepair ventrl hern, reduce	12.29	NA	NA	5.08	5.15	1.52	090
49566	A	Rerepair ventrl hern, block	15.45	NA	NA	5.85	5.98	1.91	090
49568	A	Hernia repair w/mesh	4.88	NA	NA	1.24	1.45	0.64	ZZZ
49570	A	Rpr epigastric hern, reduce	5.97	NA	NA	3.38	3.27	0.75	090
49572	A	Rpr epigastric hern, blocked	7.79	NA	NA	3.82	3.64	0.88	090
49580	A	Rpr umbil hern, reduc < 5 yr	4.39	NA	NA	2.94	2.77	0.54	090
49582	A	Rpr umbil hern, block < 5 yr	7.05	NA	NA	3.69	3.57	0.88	090
49585	A	Rpr umbil hern, reduc > 5 yr	6.51	NA	NA	3.51	3.40	0.82	090
49587	A	Rpr umbil hern, block > 5 yr	7.96	NA	NA	3.86	3.79	0.99	090
49590	A	Repair spigelian hernia	8.82	NA	NA	4.08	4.08	1.13	090
49600	A	Repair umbilical lesion	11.47	NA	NA	5.38	5.35	1.32	090
49605	A	Repair umbilical lesion	86.85	NA	NA	27.56	28.02	9.39	090
49606	A	Repair umbilical lesion	18.92	NA	NA	6.77	7.22	2.46	090
49610	A	Repair umbilical lesion	10.83	NA	NA	5.28	5.24	1.07	090
49611	A	Repair umbilical lesion	9.26	NA	NA	4.21	5.59	0.78	090
49650	A	Laparo hernia repair initial	6.30	NA	NA	3.34	3.27	0.93	090
49651	A	Laparo hernia repair recur	8.29	NA	NA	4.22	4.13	1.14	090
49659	C	Laparo proc, hernia repair	0.00	0.00	0.00	0.00	0.00	0.00	YYY
49900	A	Repair of abdominal wall	12.26	NA	NA	6.28	6.25	1.62	090
49904	A	Omental flap, extra-abdom	22.16	NA	NA	11.88	13.54	2.70	090
49905	A	Omental flap, intra-abdom	6.54	NA	NA	1.69	1.99	0.75	ZZZ

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
49906	C	Free omental flap, microvasc	0.00	0.00	0.00	0.00	0.00	0.00	090
49999	C	Abdomen surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
50010	A	Exploration of kidney	12.13	NA	NA	6.73	5.97	0.93	090
50020	A	Renal abscess, open drain	17.88	NA	NA	8.48	8.11	1.34	090
50021	A	Renal abscess, percut drain	3.37	21.09	21.36	1.22	1.16	0.20	000
50040	A	Drainage of kidney	16.48	NA	NA	8.82	7.81	1.03	090
50045	A	Exploration of kidney	16.67	NA	NA	8.14	7.36	1.24	090
50060	A	Removal of kidney stone	20.80	NA	NA	10.81	9.31	1.36	090
50065	A	Incision of kidney	22.17	NA	NA	11.51	8.79	1.59	090
50070	A	Incision of kidney	21.70	NA	NA	11.32	9.76	1.44	090
50075	A	Removal of kidney stone	26.91	NA	NA	13.49	11.69	1.81	090
50080	A	Removal of kidney stone	15.61	NA	NA	8.55	7.41	1.04	090
50081	A	Removal of kidney stone	23.32	NA	NA	12.17	10.46	1.54	090
50100	A	Revise kidney blood vessels	17.30	NA	NA	6.51	7.14	2.07	090
50120	A	Exploration of kidney	17.06	NA	NA	9.11	7.93	1.21	090
50125	A	Explore and drain kidney	17.67	NA	NA	9.71	8.33	1.43	090
50130	A	Removal of kidney stone	18.67	NA	NA	10.05	8.60	1.22	090
50135	A	Exploration of kidney	20.44	NA	NA	10.69	9.23	1.33	090
50200	A	Biopsy of kidney	2.63	NA	NA	1.19	1.24	0.16	000
50205	A	Biopsy of kidney	12.19	NA	NA	5.51	5.25	1.30	090
50220	A	Remove kidney, open	18.53	NA	NA	9.51	8.37	1.35	090
50225	A	Removal kidney open, complex	21.73	NA	NA	11.01	9.57	1.50	090
50230	A	Removal kidney open, radical	23.68	NA	NA	11.64	10.10	1.55	090
50234	A	Removal of kidney & ureter	23.90	NA	NA	12.03	10.42	1.59	090
50236	A	Removal of kidney & ureter	26.74	NA	NA	13.90	12.07	1.77	090
50240	A	Partial removal of kidney	24.01	NA	NA	12.60	10.80	1.55	090
50250	A	Cryoablate renal mass open	22.06	NA	NA	11.48	10.31	1.39	090
50280	A	Removal of kidney lesion	16.94	NA	NA	9.06	7.87	1.19	090
50290	A	Removal of kidney lesion	16.00	NA	NA	7.73	7.09	1.41	090
50300	X	Remove cadaver donor kidney	0.00	0.00	0.00	0.00	0.00	0.00	XXX
50320	A	Remove kidney, living donor	22.28	NA	NA	12.30	11.47	2.36	090
50323	C	Prep cadaver renal allograft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
50325	C	Prep donor renal graft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
50327	A	Prep renal graft/venous	4.00	NA	NA	1.09	1.22	0.29	XXX
50328	A	Prep renal graft/arterial	3.50	NA	NA	0.98	1.08	0.26	XXX
50329	A	Prep renal graft/ureteral	3.34	NA	NA	1.05	1.09	0.25	XXX
50340	A	Removal of kidney	13.86	NA	NA	7.80	7.14	1.65	090
50360	A	Transplantation of kidney	40.45	NA	NA	18.66	17.06	3.82	090
50365	A	Transplantation of kidney	45.68	NA	NA	19.40	18.79	4.43	090
50370	A	Remove transplanted kidney	18.68	NA	NA	9.18	8.16	1.68	090
50380	A	Reimplantation of kidney	29.66	NA	NA	16.19	14.10	2.51	090
50382	A	Change ureter stent, percut	5.50	26.34	31.22	2.05	1.96	0.34	000
50384	A	Remove ureter stent, percut	5.00	20.66	27.93	1.86	1.78	0.31	000
50385	A	Change stent via transureth	4.44	30.61	30.61	2.05	2.05	0.27	000
50386	A	Remove stent via transureth	3.30	19.36	19.36	1.60	1.60	0.20	000
50387	A	Change ext/int ureter stent	2.00	12.60	15.40	0.73	0.70	0.12	000
50389	A	Remove renal tube w/fluoro	1.10	6.67	9.71	0.40	0.38	0.07	000
50390	A	Drainage of kidney lesion	1.96	NA	NA	0.71	0.67	0.12	000
50391	A	Instll rx agnt into mal tub	1.96	1.38	1.48	0.72	0.67	0.14	000
50392	A	Insert kidney drain	3.37	NA	NA	1.52	1.52	0.20	000
50393	A	Insert ureteral tube	4.15	NA	NA	1.80	1.79	0.25	000
50394	A	Injection for kidney x-ray	0.76	1.87	2.28	0.58	0.62	0.05	000
50395	A	Create passage to kidney	3.37	NA	NA	1.56	1.53	0.21	000
50396	A	Measure kidney pressure	2.09	NA	NA	1.08	1.08	0.13	000
50398	A	Change kidney tube	1.46	11.83	14.07	0.56	0.54	0.09	000
50400	A	Revision of kidney/ureter	21.12	NA	NA	10.94	9.40	1.38	090
50405	A	Revision of kidney/ureter	25.68	NA	NA	12.90	10.96	1.79	090
50500	A	Repair of kidney wound	21.07	NA	NA	8.69	8.53	2.02	090
50520	A	Close kidney-skin fistula	18.73	NA	NA	9.24	8.33	1.49	090
50525	A	Repair renal-abdomen fistula	24.21	NA	NA	11.79	10.39	1.84	090
50526	A	Repair renal-abdomen fistula	26.13	NA	NA	8.15	9.00	1.97	090
50540	A	Revision of horseshoe kidney	20.95	NA	NA	10.61	9.46	1.36	090
50541	A	Laparo ablate renal cyst	16.76	NA	NA	8.69	7.58	1.13	090
50542	A	Laparo ablate renal mass	21.18	NA	NA	11.17	9.65	1.39	090
50543	A	Laparo partial nephrectomy	27.18	NA	NA	14.08	12.13	1.81	090
50544	A	Laparoscopy, pyeloplasty	23.27	NA	NA	11.43	9.97	1.58	090
50545	A	Laparo radical nephrectomy	24.93	NA	NA	12.14	10.66	1.71	090
50546	A	Laparoscopic nephrectomy	21.69	NA	NA	11.28	9.81	1.57	090
50547	A	Laparo removal donor kidney	26.24	NA	NA	12.47	11.78	2.77	090
50548	A	Laparo remove w/ureter	25.26	NA	NA	12.10	10.64	1.73	090
50549	C	Laparoscope proc, renal	0.00	0.00	0.00	0.00	0.00	0.00	YYY
50551	A	Kidney endoscopy	5.59	4.59	4.36	2.64	2.31	0.40	000

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
50553	A	Kidney endoscopy	5.98	4.49	4.42	2.63	2.40	0.39	000
50555	A	Kidney endoscopy & biopsy	6.52	5.09	4.95	3.02	2.68	0.45	000
50557	A	Kidney endoscopy & treatment	6.61	5.26	4.92	3.07	2.68	0.47	000
50561	A	Kidney endoscopy & treatment	7.58	5.80	5.44	3.40	3.02	0.54	000
50562	A	Renal scope w/tumor resect	10.90	NA	NA	5.36	4.83	0.73	090
50570	A	Kidney endoscopy	9.53	NA	NA	4.14	3.68	0.68	000
50572	A	Kidney endoscopy	10.33	NA	NA	4.31	3.90	0.85	000
50574	A	Kidney endoscopy & biopsy	11.00	NA	NA	4.79	4.26	0.77	000
50575	A	Kidney endoscopy	13.96	NA	NA	5.95	5.29	0.99	000
50576	A	Kidney endoscopy & treatment	10.97	NA	NA	4.77	4.22	0.78	000
50580	A	Kidney endoscopy & treatment	11.84	NA	NA	5.09	4.52	0.83	000
50590	A	Fragmenting of kidney stone	9.64	17.08	14.73	6.12	5.11	0.65	090
50592	A	Perc rf ablate renal tumor	6.77	75.40	112.17	3.00	2.99	0.43	010
50593	A	Perc cryo ablate renal tum	9.08	114.48	114.48	3.44	3.44	0.58	010
50600	A	Exploration of ureter	17.04	NA	NA	8.50	7.58	1.13	090
50605	A	Insert ureteral support	16.66	NA	NA	7.88	7.31	1.45	090
50610	A	Removal of ureter stone	17.12	NA	NA	8.97	7.96	1.43	090
50620	A	Removal of ureter stone	16.30	NA	NA	8.87	7.60	1.07	090
50630	A	Removal of ureter stone	16.08	NA	NA	8.19	7.23	1.09	090
50650	A	Removal of ureter	18.67	NA	NA	9.95	8.58	1.23	090
50660	A	Removal of ureter	20.87	NA	NA	10.72	9.33	1.38	090
50684	A	Injection for ureter x-ray	0.76	3.96	4.46	0.63	0.55	0.05	000
50686	A	Measure ureter pressure	1.51	2.29	2.87	0.81	0.82	0.11	000
50688	A	Change of ureter tube/stent	1.18	NA	NA	0.95	1.00	0.07	010
50690	A	Injection for ureter x-ray	1.16	1.45	1.64	0.75	0.73	0.07	000
50700	A	Revision of ureter	16.54	NA	NA	8.75	7.93	1.27	090
50715	A	Release of ureter	20.49	NA	NA	8.53	8.63	2.14	090
50722	A	Release of ureter	17.80	NA	NA	7.26	7.53	1.91	090
50725	A	Release/revise ureter	20.05	NA	NA	8.81	8.42	1.52	090
50727	A	Revise ureter	8.17	NA	NA	5.72	5.00	0.61	090
50728	A	Revise ureter	12.00	NA	NA	6.74	6.15	1.00	090
50740	A	Fusion of ureter & kidney	19.92	NA	NA	8.96	8.34	1.97	090
50750	A	Fusion of ureter & kidney	21.07	NA	NA	11.07	9.52	1.38	090
50760	A	Fusion of ureters	19.92	NA	NA	9.88	8.77	1.55	090
50770	A	Splicing of ureters	21.07	NA	NA	10.87	9.41	1.45	090
50780	A	Reimplant ureter in bladder	19.80	NA	NA	10.10	8.84	1.51	090
50782	A	Reimplant ureter in bladder	19.51	NA	NA	9.88	9.32	1.61	090
50783	A	Reimplant ureter in bladder	20.52	NA	NA	10.11	9.15	1.99	090
50785	A	Reimplant ureter in bladder	22.08	NA	NA	11.18	9.73	1.45	090
50800	A	Implant ureter in bowel	16.23	NA	NA	9.16	7.81	1.19	090
50810	A	Fusion of ureter & bowel	22.38	NA	NA	10.56	9.82	2.32	090
50815	A	Urine shunt to intestine	22.06	NA	NA	11.45	9.94	1.54	090
50820	A	Construct bowel bladder	23.89	NA	NA	11.84	10.24	1.90	090
50825	A	Construct bowel bladder	30.48	NA	NA	14.89	13.00	2.08	090
50830	A	Revise urine flow	33.57	NA	NA	15.60	13.88	2.38	090
50840	A	Replace ureter by bowel	22.19	NA	NA	11.92	10.16	1.47	090
50845	A	Appendico-vesicostomy	22.21	NA	NA	12.05	10.47	1.57	090
50860	A	Transplant ureter to skin	16.93	NA	NA	9.21	7.91	1.29	090
50900	A	Repair of ureter	14.89	NA	NA	7.98	7.06	1.14	090
50920	A	Closure ureter/skin fistula	15.66	NA	NA	8.51	7.54	1.01	090
50930	A	Closure ureter/bowel fistula	20.04	NA	NA	9.48	8.72	1.28	090
50940	A	Release of ureter	15.78	NA	NA	7.78	7.08	1.26	090
50945	A	Laparoscopy ureterolithotomy	17.87	NA	NA	9.28	8.15	1.36	090
50947	A	Laparo new ureter/bladder	25.63	NA	NA	12.28	10.98	2.17	090
50948	A	Laparo new ureter/bladder	23.69	NA	NA	11.17	9.93	1.71	090
50949	C	Laparoscope proc, ureter	0.00	0.00	0.00	0.00	0.00	0.00	YYY
50951	A	Endoscopy of ureter	5.83	4.82	4.55	2.76	2.40	0.41	000
50953	A	Endoscopy of ureter	6.23	4.92	4.66	3.21	2.79	0.43	000
50955	A	Ureter endoscopy & biopsy	6.74	5.14	5.77	3.45	3.06	0.48	000
50957	A	Ureter endoscopy & treatment	6.78	5.37	4.96	3.14	2.75	0.48	000
50961	A	Ureter endoscopy & treatment	6.04	4.74	4.55	2.79	2.48	0.41	000
50970	A	Ureter endoscopy	7.13	NA	NA	3.24	2.85	0.52	000
50972	A	Ureter endoscopy & catheter	6.88	NA	NA	3.05	2.76	0.49	000
50974	A	Ureter endoscopy & biopsy	9.16	NA	NA	3.76	3.43	0.64	000
50976	A	Ureter endoscopy & treatment	9.03	NA	NA	3.85	3.45	0.66	000
50980	A	Ureter endoscopy & treatment	6.84	NA	NA	3.12	2.75	0.48	000
51020	A	Incise & treat bladder	7.56	NA	NA	5.38	4.62	0.47	090
51030	A	Incise & treat bladder	7.68	NA	NA	4.89	4.43	0.58	090
51040	A	Incise & drain bladder	4.43	NA	NA	3.68	3.22	0.31	090
51045	A	Incise bladder/drain ureter	7.68	NA	NA	5.14	4.53	0.52	090
51050	A	Removal of bladder stone	7.87	NA	NA	5.32	4.48	0.49	090
51060	A	Removal of ureter stone	9.82	NA	NA	6.42	5.45	0.62	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
51065		A	Remove ureter calculus	9.82	NA	NA	6.24	5.29	0.63	090
51080		A	Drainage of bladder abscess	6.61	NA	NA	4.60	4.07	0.43	090
51100		A	Drain bladder by needle	0.78	0.92	0.92	0.27	0.27	0.05	000
51101		A	Drain bladder by trocar/cath	1.02	2.40	2.40	0.34	0.34	0.10	000
51102		A	Drain bl w/cath insertion	4.27	4.74	4.74	2.36	2.36	0.28	010
51500		A	Removal of bladder cyst	10.92	NA	NA	5.75	5.37	1.03	090
51520		A	Removal of bladder lesion	10.08	NA	NA	6.31	5.48	0.69	090
51525		A	Removal of bladder lesion	15.29	NA	NA	8.46	7.29	0.99	090
51530		A	Removal of bladder lesion	13.58	NA	NA	7.38	6.56	1.05	090
51535		A	Repair of ureter lesion	13.77	NA	NA	7.37	6.74	1.23	090
51550		A	Partial removal of bladder	17.10	NA	NA	8.70	7.71	1.31	090
51555		A	Partial removal of bladder	23.03	NA	NA	11.34	10.00	1.70	090
51565		A	Revise bladder & ureter(s)	23.50	NA	NA	12.11	10.53	1.63	090
51570		A	Removal of bladder	27.31	NA	NA	13.48	11.60	1.72	090
51575		A	Removal of bladder & nodes	34.00	NA	NA	16.43	14.22	2.17	090
51580		A	Remove bladder/revise tract	35.14	NA	NA	17.57	15.02	2.25	090
51585		A	Removal of bladder & nodes	39.41	NA	NA	19.24	16.46	2.49	090
51590		A	Remove bladder/revise tract	36.15	NA	NA	17.22	14.91	2.28	090
51595		A	Remove bladder/revise tract	41.12	NA	NA	19.56	16.83	2.60	090
51596		A	Remove bladder/create pouch	44.01	NA	NA	21.18	18.19	2.78	090
51597		A	Removal of pelvic structures	42.61	NA	NA	20.17	17.49	2.82	090
51600		A	Injection for bladder x-ray	0.88	4.23	4.64	0.32	0.31	0.06	000
51605		A	Preparation for bladder xray	0.64	NA	NA	0.43	0.39	0.04	000
51610		A	Injection for bladder x-ray	1.05	1.91	2.10	0.70	0.65	0.07	000
51700		A	Irrigation of bladder	0.88	1.50	1.55	0.34	0.31	0.06	000
51701		A	Insert bladder catheter	0.50	1.04	1.31	0.24	0.22	0.04	000
51702		A	Insert temp bladder cath	0.50	1.53	1.80	0.33	0.29	0.04	000
51703		A	Insert bladder cath, complex	1.47	2.26	2.49	0.80	0.68	0.10	000
51705		A	Change of bladder tube	1.03	2.02	2.15	0.84	0.73	0.07	010
51710		A	Change of bladder tube	1.50	2.72	3.03	1.17	0.97	0.11	010
51715		A	Endoscopic injection/implant	3.73	4.41	4.15	1.72	1.54	0.29	000
51720		A	Treatment of bladder lesion	1.50	1.61	1.68	0.74	0.71	0.14	000
51725		A	Simple cystometrogram	1.51	4.22	4.90	NA	NA	0.16	000
51725	TC	A	Simple cystometrogram	0.00	3.67	4.38	NA	NA	0.04	000
51725	26	A	Simple cystometrogram	1.51	0.55	0.52	0.55	0.52	0.12	000
51726		A	Complex cystometrogram	1.71	7.11	7.30	NA	NA	0.18	000
51726	TC	A	Complex cystometrogram	0.00	6.47	6.70	NA	NA	0.05	000
51726	26	A	Complex cystometrogram	1.71	0.64	0.60	0.64	0.60	0.13	000
51736		A	Urine flow measurement	0.61	0.94	0.76	NA	NA	0.06	000
51736	TC	A	Urine flow measurement	0.00	0.70	0.54	NA	NA	0.01	000
51736	26	A	Urine flow measurement	0.61	0.24	0.22	0.24	0.22	0.05	000
51741		A	Electro-uroflowmetry, first	1.14	1.27	1.02	NA	NA	0.11	000
51741	TC	A	Electro-uroflowmetry, first	0.00	0.83	0.62	NA	NA	0.02	000
51741	26	A	Electro-uroflowmetry, first	1.14	0.44	0.40	0.44	0.40	0.09	000
51772		A	Urethra pressure profile	1.61	5.06	5.31	NA	NA	0.20	000
51772	TC	A	Urethra pressure profile	0.00	4.51	4.76	NA	NA	0.05	000
51772	26	A	Urethra pressure profile	1.61	0.55	0.55	0.55	0.55	0.15	000
51784		A	Anal/urinary muscle study	1.53	4.12	4.05	NA	NA	0.16	000
51784	TC	A	Anal/urinary muscle study	0.00	3.56	3.52	NA	NA	0.04	000
51784	26	A	Anal/urinary muscle study	1.53	0.56	0.53	0.56	0.53	0.12	000
51785		A	Anal/urinary muscle study	1.53	4.55	4.49	NA	NA	0.15	000
51785	TC	A	Anal/urinary muscle study	0.00	3.99	3.96	NA	NA	0.04	000
51785	26	A	Anal/urinary muscle study	1.53	0.56	0.53	0.56	0.53	0.11	000
51792		A	Urinary reflex study	1.10	5.05	5.52	NA	NA	0.20	000
51792	TC	A	Urinary reflex study	0.00	4.66	5.12	NA	NA	0.13	000
51792	26	A	Urinary reflex study	1.10	0.39	0.40	0.39	0.40	0.07	000
51795		A	Urine voiding pressure study	1.53	6.72	7.00	NA	NA	0.22	000
51795	TC	A	Urine voiding pressure study	0.00	6.15	6.47	NA	NA	0.10	000
51795	26	A	Urine voiding pressure study	1.53	0.57	0.53	0.57	0.53	0.12	000
51797		A	Intraabdominal pressure test	0.80	2.43	4.11	NA	NA	0.17	ZZZ
51797	TC	A	Intraabdominal pressure test	0.00	2.14	3.70	NA	NA	0.05	ZZZ
51797	26	A	Intraabdominal pressure test	0.80	0.29	0.41	0.29	0.41	0.12	ZZZ
51798		A	Us urine capacity measure	0.00	0.59	0.47	NA	NA	0.08	XXX
51800		A	Revision of bladder/urethra	18.74	NA	NA	9.71	8.63	1.32	090
51820		A	Revision of urinary tract	19.41	NA	NA	9.74	9.01	1.75	090
51840		A	Attach bladder/urethra	11.28	NA	NA	5.75	5.66	1.06	090
51841		A	Attach bladder/urethra	13.60	NA	NA	6.85	6.61	1.24	090
51845		A	Repair bladder neck	10.07	NA	NA	5.88	5.31	0.79	090
51860		A	Repair of bladder wound	12.49	NA	NA	6.73	6.24	1.16	090
51865		A	Repair of bladder wound	15.69	NA	NA	8.32	7.49	1.23	090
51880		A	Repair of bladder opening	7.81	NA	NA	4.72	4.34	0.72	090
51900		A	Repair bladder/vagina lesion	14.48	NA	NA	7.97	7.01	1.21	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
51920	A	Close bladder-uterus fistula	13.26	NA	NA	8.03	6.83	1.18	090
51925	A	Hysterectomy/bladder repair	17.35	NA	NA	12.40	10.50	2.04	090
51940	A	Correction of bladder defect	30.48	NA	NA	11.72	11.89	2.15	090
51960	A	Revision of bladder & bowel	25.20	NA	NA	12.88	11.25	1.63	090
51980	A	Construct bladder opening	12.44	NA	NA	7.06	6.21	0.86	090
51990	A	Laparo urethral suspension	13.26	NA	NA	5.92	6.03	1.39	090
51992	A	Laparo sling operation	14.77	NA	NA	6.51	6.35	1.41	090
51999	C	Laparoscope proc, bla	0.00	0.00	0.00	0.00	0.00	0.00	YYY
52000	A	Cystoscopy	2.23	3.66	3.48	1.31	1.03	0.14	000
52001	A	Cystoscopy, removal of clots	5.44	5.04	5.05	2.56	2.21	0.39	000
52005	A	Cystoscopy & ureter catheter	2.37	5.73	5.64	1.37	1.13	0.17	000
52007	A	Cystoscopy and biopsy	3.02	10.70	13.57	1.61	1.38	0.22	000
52010	A	Cystoscopy & duct catheter	3.02	8.07	9.41	1.62	1.38	0.21	000
52204	A	Cystoscopy w/biopsy(s)	2.59	8.30	11.40	1.37	1.14	0.17	000
52214	A	Cystoscopy and treatment	3.70	19.87	28.97	1.83	1.58	0.26	000
52224	A	Cystoscopy and treatment	3.14	19.05	27.74	1.60	1.37	0.22	000
52234	A	Cystoscopy and treatment	4.62	NA	NA	2.27	1.96	0.33	000
52235	A	Cystoscopy and treatment	5.44	NA	NA	2.63	2.28	0.39	000
52240	A	Cystoscopy and treatment	9.71	NA	NA	4.34	3.82	0.69	000
52250	A	Cystoscopy and radiotracer	4.49	NA	NA	2.29	1.97	0.32	000
52260	A	Cystoscopy and treatment	3.91	NA	NA	1.93	1.67	0.28	000
52265	A	Cystoscopy and treatment	2.94	7.48	10.41	1.46	1.28	0.22	000
52270	A	Cystoscopy & revise urethra	3.36	7.02	9.02	1.74	1.49	0.24	000
52275	A	Cystoscopy & revise urethra	4.69	9.29	12.42	2.27	1.96	0.33	000
52276	A	Cystoscopy and treatment	4.99	NA	NA	2.44	2.11	0.35	000
52277	A	Cystoscopy and treatment	6.16	NA	NA	2.90	2.56	0.44	000
52281	A	Cystoscopy and treatment	2.80	5.28	6.18	1.54	1.31	0.20	000
52282	A	Cystoscopy, implant stent	6.39	NA	NA	2.95	2.59	0.45	000
52283	A	Cystoscopy and treatment	3.73	4.06	4.00	1.86	1.62	0.26	000
52285	A	Cystoscopy and treatment	3.60	4.32	4.16	1.83	1.58	0.26	000
52290	A	Cystoscopy and treatment	4.58	NA	NA	2.26	1.95	0.32	000
52300	A	Cystoscopy and treatment	5.30	NA	NA	2.55	2.23	0.38	000
52301	A	Cystoscopy and treatment	5.50	NA	NA	2.68	2.33	0.46	000
52305	A	Cystoscopy and treatment	5.30	NA	NA	2.48	2.17	0.38	000
52310	A	Cystoscopy and treatment	2.81	4.00	4.34	1.42	1.23	0.20	000
52315	A	Cystoscopy and treatment	5.20	6.62	7.64	2.47	2.15	0.37	000
52317	A	Remove bladder stone	6.71	17.04	22.98	2.99	2.63	0.48	000
52318	A	Remove bladder stone	9.18	NA	NA	4.03	3.56	0.65	000
52320	A	Cystoscopy and treatment	4.69	NA	NA	2.20	1.91	0.33	000
52325	A	Cystoscopy, stone removal	6.15	NA	NA	2.78	2.44	0.44	000
52327	A	Cystoscopy, inject material	5.18	2.04	16.92	2.04	1.93	0.37	000
52330	A	Cystoscopy and treatment	5.03	20.39	29.59	2.34	2.05	0.36	000
52332	A	Cystoscopy and treatment	2.83	12.41	9.07	1.55	1.30	0.21	000
52334	A	Create passage to kidney	4.82	NA	NA	2.33	2.03	0.35	000
52341	A	Cysto w/ureter stricture tx	6.11	NA	NA	3.03	2.62	0.43	000
52342	A	Cysto w/up stricture tx	6.61	NA	NA	3.25	2.80	0.46	000
52343	A	Cysto w/renal stricture tx	7.31	NA	NA	3.48	3.03	0.51	000
52344	A	Cysto/uretero, stricture tx	7.81	NA	NA	3.90	3.34	0.55	000
52345	A	Cysto/uretero w/up stricture	8.31	NA	NA	4.10	3.53	0.58	000
52346	A	Cystouretero w/renal strict	9.34	NA	NA	4.50	3.89	0.65	000
52351	A	Cystouretero & or pyeloscope	5.85	NA	NA	2.95	2.55	0.41	000
52352	A	Cystouretero w/stone remove	6.87	NA	NA	3.46	2.98	0.49	000
52353	A	Cystouretero w/lithotripsy	7.96	NA	NA	3.90	3.37	0.57	000
52354	A	Cystouretero w/biopsy	7.33	NA	NA	3.64	3.15	0.52	000
52355	A	Cystouretero w/excise tumor	8.81	NA	NA	4.24	3.69	0.63	000
52400	A	Cystouretero w/congen repr	10.06	NA	NA	5.39	4.56	0.68	090
52402	A	Cystourethro cut ejacul duct	5.27	NA	NA	2.15	1.92	0.40	000
52450	A	Incision of prostate	7.63	NA	NA	5.47	4.57	0.54	090
52500	A	Revision of bladder neck	9.39	NA	NA	6.17	5.04	0.60	090
52601	A	Prostatectomy (TURP)	15.13	NA	NA	8.42	6.75	0.87	090
52606	A	Control postop bleeding	8.84	NA	NA	5.47	4.51	0.57	090
52612	A	Prostatectomy, first stage	9.07	NA	NA	5.87	4.80	0.56	090
52614	A	Prostatectomy, second stage	7.81	NA	NA	5.37	4.35	0.48	090
52620	A	Remove residual prostate	7.19	NA	NA	4.61	3.79	0.47	090
52630	A	Remove prostate regrowth	7.65	NA	NA	4.79	3.99	0.51	090
52640	A	Relieve bladder contracture	6.89	NA	NA	4.41	3.68	0.47	090
52647	A	Laser surgery of prostate	11.15	41.90	57.90	6.88	5.70	0.73	090
52648	A	Laser surgery of prostate	12.00	42.44	58.17	7.21	6.00	0.79	090
52649	A	2Prostate laser enucleation	17.16	NA	NA	9.31	9.31	1.11	090
52700	A	Drainage of prostate abscess	7.39	NA	NA	4.89	4.04	0.48	090
53000	A	Incision of urethra	2.30	NA	NA	1.78	1.66	0.16	010
53010	A	Incision of urethra	4.35	NA	NA	3.83	3.37	0.24	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
53020	A	Incision of urethra	1.77	NA	NA	0.95	0.81	0.13	000
53025	A	Incision of urethra	1.13	NA	NA	0.82	0.66	0.08	000
53040	A	Drainage of urethra abscess	6.49	NA	NA	4.40	3.91	0.45	090
53060	A	Drainage of urethra abscess	2.65	2.09	2.09	1.54	1.45	0.28	010
53080	A	Drainage of urinary leakage	6.82	NA	NA	4.96	5.46	0.52	090
53085	A	Drainage of urinary leakage	11.05	NA	NA	4.41	5.90	0.92	090
53200	A	Biopsy of urethra	2.59	1.70	1.51	1.29	1.13	0.20	000
53210	A	Removal of urethra	13.59	NA	NA	7.75	6.79	0.89	090
53215	A	Removal of urethra	16.72	NA	NA	9.11	7.87	1.10	090
53220	A	Treatment of urethra lesion	7.53	NA	NA	4.97	4.34	0.49	090
53230	A	Removal of urethra lesion	10.31	NA	NA	6.36	5.53	0.73	090
53235	A	Removal of urethra lesion	10.86	NA	NA	6.92	5.90	0.72	090
53240	A	Surgery for urethra pouch	6.98	NA	NA	4.86	4.19	0.52	090
53250	A	Removal of urethra gland	6.42	NA	NA	4.38	3.83	0.49	090
53260	A	Treatment of urethra lesion	3.00	2.45	2.35	1.83	1.62	0.25	010
53265	A	Treatment of urethra lesion	3.14	2.93	2.82	1.98	1.70	0.24	010
53270	A	Removal of urethra gland	3.11	2.46	2.33	1.84	1.69	0.30	010
53275	A	Repair of urethra defect	4.54	NA	NA	2.76	2.51	0.32	010
53400	A	Revise urethra, stage 1	13.98	NA	NA	8.16	7.09	0.98	090
53405	A	Revise urethra, stage 2	15.51	NA	NA	8.68	7.49	1.10	090
53410	A	Reconstruction of urethra	17.53	NA	NA	9.66	8.35	1.16	090
53415	A	Reconstruction of urethra	20.55	NA	NA	10.68	9.00	1.37	090
53420	A	Reconstruct urethra, stage 1	15.04	NA	NA	7.11	6.69	0.96	090
53425	A	Reconstruct urethra, stage 2	16.94	NA	NA	8.99	7.93	1.13	090
53430	A	Reconstruction of urethra	17.30	NA	NA	8.80	7.89	1.15	090
53431	A	Reconstruct urethra/bladder	21.03	NA	NA	10.97	9.50	1.41	090
53440	A	Male sling procedure	15.34	NA	NA	9.18	7.57	0.96	090
53442	A	Remove/revise male sling	13.29	NA	NA	8.35	6.89	0.82	090
53444	A	Insert tandem cuff	14.06	NA	NA	8.01	6.94	0.94	090
53445	A	Insert uro/ves nck sphincter	15.21	NA	NA	8.74	7.91	0.99	090
53446	A	Remove uro sphincter	10.89	NA	NA	6.99	6.10	0.72	090
53447	A	Remove/replace ur sphincter	14.15	NA	NA	8.37	7.39	0.95	090
53448	A	Remov/replic ur sphinctr comp	23.26	NA	NA	12.31	10.67	1.50	090
53449	A	Repair uro sphincter	10.43	NA	NA	6.60	5.66	0.68	090
53450	A	Revision of urethra	6.67	NA	NA	4.75	4.02	0.43	090
53460	A	Revision of urethra	7.65	NA	NA	5.04	4.36	0.50	090
53500	A	Urethrllys, transvag w/ scope	12.87	NA	NA	7.40	6.80	0.90	090
53502	A	Repair of urethra injury	8.16	NA	NA	5.10	4.54	0.62	090
53505	A	Repair of urethra injury	8.16	NA	NA	5.37	4.62	0.54	090
53510	A	Repair of urethra injury	10.83	NA	NA	6.82	5.99	0.74	090
53515	A	Repair of urethra injury	14.09	NA	NA	7.95	6.94	1.05	090
53520	A	Repair of urethra defect	9.35	NA	NA	6.20	5.33	0.61	090
53600	A	Dilate urethra stricture	1.21	1.15	1.14	0.57	0.50	0.09	000
53601	A	Dilate urethra stricture	0.98	1.36	1.31	0.52	0.44	0.07	000
53605	A	Dilate urethra stricture	1.28	NA	NA	0.51	0.46	0.09	000
53620	A	Dilate urethra stricture	1.62	1.70	1.84	0.83	0.71	0.11	000
53621	A	Dilate urethra stricture	1.35	1.81	1.94	0.67	0.58	0.10	000
53660	A	Dilation of urethra	0.71	1.32	1.31	0.45	0.38	0.05	000
53661	A	Dilation of urethra	0.72	1.29	1.29	0.41	0.35	0.05	000
53665	A	Dilation of urethra	0.76	NA	NA	0.27	0.26	0.06	000
53850	A	Prostatic microwave thermotx	9.98	49.19	71.60	5.86	4.90	0.67	090
53852	A	Prostatic rf thermotx	10.68	46.31	67.52	6.65	5.51	0.70	090
53853	A	Prostatic water thermother	5.54	29.06	42.19	4.34	3.60	0.37	090
53899	C	Urology surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
54000	A	Slitting of prepuce	1.56	2.69	2.80	1.48	1.20	0.11	010
54001	A	Slitting of prepuce	2.21	3.05	3.12	1.67	1.39	0.15	010
54015	A	Drain penis lesion	5.33	NA	NA	3.21	2.88	0.38	010
54050	A	Destruction, penis lesion(s)	1.26	2.10	1.87	1.39	1.21	0.08	010
54055	A	Destruction, penis lesion(s)	1.23	1.97	1.77	1.23	1.01	0.08	010
54056	A	Cryosurgery, penis lesion(s)	1.26	2.37	2.03	1.53	1.33	0.06	010
54057	A	Laser surg, penis lesion(s)	1.26	2.63	2.42	1.36	1.10	0.09	010
54060	A	Excision of penis lesion(s)	1.95	3.08	3.09	1.63	1.34	0.13	010
54065	A	Destruction, penis lesion(s)	2.44	3.29	2.96	1.99	1.61	0.13	010
54100	A	Biopsy of penis	1.90	3.34	3.07	1.36	1.09	0.10	000
54105	A	Biopsy of penis	3.51	3.97	4.12	2.43	2.18	0.25	010
54110	A	Treatment of penis lesion	10.79	NA	NA	6.71	5.73	0.72	090
54111	A	Treat penis lesion, graft	14.29	NA	NA	8.02	6.89	0.96	090
54112	A	Treat penis lesion, graft	16.83	NA	NA	9.30	8.04	1.11	090
54115	A	Treatment of penis lesion	6.82	5.75	5.06	4.94	4.19	0.43	090
54120	A	Partial removal of penis	10.88	NA	NA	6.72	5.69	0.68	090
54125	A	Removal of penis	14.43	NA	NA	8.06	6.94	0.95	090
54130	A	Remove penis & nodes	21.66	NA	NA	11.56	9.86	1.52	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
54135		A	Remove penis & nodes	27.99	NA	NA	14.10	12.13	1.88	090
54150		A	Circumcision w/regional block	1.90	2.39	3.13	0.73	0.72	0.16	000
54160		A	Circumcision, neonate	2.50	3.80	3.97	1.48	1.28	0.19	010
54161		A	Circum 28 days or older	3.29	NA	NA	2.20	1.88	0.23	010
54162		A	Lysis penil circumic lesion	3.27	4.00	4.32	2.26	1.85	0.21	010
54163		A	Repair of circumcision	3.27	NA	NA	2.85	2.43	0.21	010
54164		A	Frenulotomy of penis	2.77	NA	NA	2.65	2.24	0.18	010
54200		A	Treatment of penis lesion	1.08	2.01	1.90	1.30	1.13	0.08	010
54205		A	Treatment of penis lesion	8.84	NA	NA	6.05	5.36	0.56	090
54220		A	Treatment of penis lesion	2.42	3.31	3.58	1.35	1.15	0.17	000
54230		A	Prepare penis study	1.34	1.40	1.24	0.90	0.77	0.09	000
54231		A	Dynamic cavernosometry	2.04	1.97	1.67	1.24	1.06	0.16	000
54235		A	Penile injection	1.19	1.39	1.17	0.89	0.73	0.08	000
54240		A	Penis study	1.31	1.51	1.26	NA	NA	0.17	000
54240	TC	A	Penis study	0.00	1.03	0.81	NA	NA	0.06	000
54240	26	A	Penis study	1.31	0.48	0.45	0.48	0.45	0.11	000
54250		A	Penis study	2.22	1.22	1.06	NA	NA	0.18	000
54250	TC	A	Penis study	0.00	0.37	0.28	NA	NA	0.02	000
54250	26	A	Penis study	2.22	0.85	0.78	0.85	0.78	0.16	000
54300		A	Revision of penis	11.07	NA	NA	6.70	6.13	0.76	090
54304		A	Revision of penis	13.15	NA	NA	7.79	7.05	0.88	090
54308		A	Reconstruction of urethra	12.49	NA	NA	4.75	5.35	0.84	090
54312		A	Reconstruction of urethra	14.36	NA	NA	8.86	7.92	1.24	090
54316		A	Reconstruction of urethra	17.90	NA	NA	9.93	8.93	1.21	090
54318		A	Reconstruction of urethra	12.28	NA	NA	4.83	5.30	1.39	090
54322		A	Reconstruction of urethra	13.85	NA	NA	7.93	7.19	0.92	090
54324		A	Reconstruction of urethra	17.40	NA	NA	9.74	8.84	1.14	090
54326		A	Reconstruction of urethra	16.87	NA	NA	9.15	8.46	1.11	090
54328		A	Revise penis/urethra	16.74	NA	NA	9.47	8.35	0.98	090
54332		A	Revise penis/urethra	18.22	NA	NA	10.06	8.88	1.21	090
54336		A	Revise penis/urethra	21.44	NA	NA	7.31	8.79	2.21	090
54340		A	Secondary urethral surgery	9.58	NA	NA	6.35	5.69	0.63	090
54344		A	Secondary urethral surgery	16.91	NA	NA	9.53	8.63	1.54	090
54348		A	Secondary urethral surgery	18.17	NA	NA	10.12	9.22	1.23	090
54352		A	Reconstruct urethra/penis	25.95	NA	NA	13.98	12.57	2.25	090
54360		A	Penis plastic surgery	12.65	NA	NA	7.44	6.73	0.84	090
54380		A	Repair penis	14.03	NA	NA	8.03	7.32	0.93	090
54385		A	Repair penis	16.38	NA	NA	11.29	9.77	0.86	090
54390		A	Repair penis and bladder	22.59	NA	NA	7.41	8.41	1.54	090
54400		A	Insert semi-rigid prosthesis	9.09	NA	NA	5.74	5.04	0.64	090
54401		A	Insert self-contd prosthesis	10.26	NA	NA	8.14	6.93	0.73	090
54405		A	Insert multi-comp penis pros	14.39	NA	NA	8.11	7.01	0.95	090
54406		A	Remove multi-comp penis pros	12.76	NA	NA	7.59	6.50	0.86	090
54408		A	Repair multi-comp penis pros	13.73	NA	NA	8.24	6.98	0.90	090
54410		A	Remove/replace penis prosth	16.48	NA	NA	9.34	7.97	1.10	090
54411		A	Remov/replc penis pros, comp	18.14	NA	NA	10.39	8.71	1.13	090
54415		A	Remove self-contd penis pros	8.75	NA	NA	6.00	5.09	0.58	090
54416		A	Remv/repl penis contain pros	11.87	NA	NA	7.89	6.63	0.77	090
54417		A	Remv/replc penis pros, compl	15.94	NA	NA	9.09	7.63	1.00	090
54420		A	Revision of penis	12.26	NA	NA	7.38	6.47	0.81	090
54430		A	Revision of penis	10.93	NA	NA	6.96	6.03	0.72	090
54435		A	Revision of penis	6.71	NA	NA	4.99	4.30	0.43	090
54440		C	Repair of penis	0.00	0.00	0.00	0.00	0.00	0.00	090
54450		A	Preputial stretching	1.12	0.85	0.90	0.48	0.46	0.08	000
54500		A	Biopsy of testis	1.31	NA	NA	0.76	0.66	0.10	000
54505		A	Biopsy of testis	3.47	NA	NA	2.44	2.18	0.27	010
54512		A	Excise lesion testis	9.23	NA	NA	5.66	4.89	0.67	090
54520		A	Removal of testis	5.25	NA	NA	3.71	3.25	0.50	090
54522		A	Orchiectomy, partial	10.15	NA	NA	5.58	5.22	0.89	090
54530		A	Removal of testis	9.31	NA	NA	6.05	5.14	0.66	090
54535		A	Extensive testis surgery	13.06	NA	NA	6.90	6.22	0.95	090
54550		A	Exploration for testis	8.31	NA	NA	5.20	4.50	0.59	090
54560		A	Exploration for testis	11.97	NA	NA	6.87	6.00	0.90	090
54600		A	Reduce testis torsion	7.54	NA	NA	5.11	4.32	0.51	090
54620		A	Suspension of testis	5.16	NA	NA	3.22	2.82	0.37	010
54640		A	Suspension of testis	7.57	NA	NA	5.34	4.53	0.62	090
54650		A	Orchiopexy (Fowler-Stephens)	12.24	NA	NA	5.65	5.52	1.16	090
54660		A	Revision of testis	5.64	NA	NA	4.34	3.67	0.44	090
54670		A	Repair testis injury	6.57	NA	NA	4.79	4.16	0.47	090
54680		A	Relocation of testis(es)	13.91	NA	NA	7.69	6.92	1.16	090
54690		A	Laparoscopy, orchiectomy	11.60	NA	NA	5.58	5.25	1.02	090
54692		A	Laparoscopy, orchiopexy	13.64	NA	NA	7.55	6.49	1.30	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
54699	C	Laparoscope proc, testis	0.00	0.00	0.00	0.00	0.00	0.00	YYY
54700	A	Drainage of scrotum	3.44	NA	NA	2.37	2.15	0.28	010
54800	A	Biopsy of epididymis	2.33	NA	NA	1.22	1.06	0.23	000
54830	A	Remove epididymis lesion	5.91	NA	NA	4.43	3.72	0.41	090
54840	A	Remove epididymis lesion	5.22	NA	NA	3.79	3.28	0.37	090
54860	A	Removal of epididymis	6.85	NA	NA	4.86	4.08	0.45	090
54861	A	Removal of epididymis	9.57	NA	NA	6.24	5.27	0.63	090
54865	A	Explore epididymis	5.67	NA	NA	4.26	3.59	0.40	090
54900	A	Fusion of spermatic ducts	14.05	NA	NA	5.24	5.51	0.93	090
54901	A	Fusion of spermatic ducts	18.92	NA	NA	10.50	9.00	1.83	090
55000	A	Drainage of hydrocele	1.43	1.85	1.96	0.91	0.78	0.11	000
55040	A	Removal of hydrocele	5.39	NA	NA	3.95	3.42	0.43	090
55041	A	Removal of hydroceles	8.41	NA	NA	5.68	4.82	0.60	090
55060	A	Repair of hydrocele	6.05	NA	NA	4.45	3.76	0.46	090
55100	A	Drainage of scrotum abscess	2.40	3.49	3.58	2.10	1.83	0.17	010
55110	A	Explore scrotum	6.23	NA	NA	4.48	3.80	0.43	090
55120	A	Removal of scrotum lesion	5.62	NA	NA	4.20	3.57	0.39	090
55150	A	Removal of scrotum	8.01	NA	NA	5.44	4.63	0.56	090
55175	A	Revision of scrotum	5.77	NA	NA	4.33	3.66	0.37	090
55180	A	Revision of scrotum	11.63	NA	NA	7.26	6.31	0.90	090
55200	A	Incision of sperm duct	4.50	8.00	10.15	3.30	2.84	0.33	090
55250	A	Removal of sperm duct(s)	3.32	7.82	9.64	3.06	2.64	0.25	090
55300	A	Prepare, sperm duct x-ray	3.50	NA	NA	1.75	1.53	0.25	000
55400	A	Repair of sperm duct	8.53	NA	NA	5.40	4.73	0.64	090
55450	A	Ligation of sperm duct	4.38	5.46	6.22	2.56	2.21	0.29	010
55500	A	Removal of hydrocele	6.12	NA	NA	4.19	3.64	0.55	090
55520	A	Removal of sperm cord lesion	6.56	NA	NA	3.81	3.53	0.75	090
55530	A	Revise spermatic cord veins	5.69	NA	NA	4.08	3.54	0.45	090
55535	A	Revise spermatic cord veins	7.09	NA	NA	4.83	4.11	0.47	090
55540	A	Revise hernia & sperm veins	8.20	NA	NA	4.24	4.02	0.94	090
55550	A	Laparo ligate spermatic vein	7.10	NA	NA	4.54	3.92	0.57	090
55559	C	Laparo proc, spermatic cord	0.00	0.00	0.00	0.00	0.00	0.00	YYY
55600	A	Incise sperm duct pouch	6.91	NA	NA	4.90	4.11	0.62	090
55605	A	Incise sperm duct pouch	8.63	NA	NA	4.62	4.45	0.64	090
55650	A	Remove sperm duct pouch	12.52	NA	NA	7.39	6.33	0.92	090
55680	A	Remove sperm pouch lesion	5.59	NA	NA	3.92	3.44	0.47	090
55700	A	Biopsy of prostate	2.58	3.71	3.95	1.32	0.98	0.11	000
55705	A	Biopsy of prostate	4.58	NA	NA	2.85	2.57	0.32	010
55720	A	Drainage of prostate abscess	7.67	NA	NA	4.88	4.34	0.95	090
55725	A	Drainage of prostate abscess	9.90	NA	NA	6.27	5.37	0.70	090
55801	A	Removal of prostate	19.62	NA	NA	10.33	8.96	1.34	090
55810	A	Extensive prostate surgery	24.14	NA	NA	12.33	10.62	1.60	090
55812	A	Extensive prostate surgery	29.69	NA	NA	14.19	12.57	2.05	090
55815	A	Extensive prostate surgery	32.75	NA	NA	16.18	14.02	2.17	090
55821	A	Removal of prostate	15.63	NA	NA	8.66	7.43	1.01	090
55831	A	Removal of prostate	17.06	NA	NA	9.23	7.93	1.10	090
55840	A	Extensive prostate surgery	24.45	NA	NA	12.67	10.97	1.61	090
55842	A	Extensive prostate surgery	26.31	NA	NA	13.46	11.64	1.73	090
55845	A	Extensive prostate surgery	30.52	NA	NA	14.85	12.87	2.03	090
55860	A	Surgical exposure, prostate	15.71	NA	NA	8.53	7.46	1.02	090
55862	A	Extensive prostate surgery	19.89	NA	NA	10.69	9.26	1.49	090
55865	A	Extensive prostate surgery	24.39	NA	NA	12.40	10.82	1.63	090
55866	A	Laparo radical prostatectomy	32.25	NA	NA	15.94	13.82	2.17	090
55870	A	Electroejaculation	2.58	2.49	2.01	1.45	1.26	0.16	000
55873	A	Cryoblate prostate	20.25	NA	NA	11.27	10.10	1.38	090
55875	A	Transperi needle place, pros	13.31	NA	NA	7.83	6.83	0.89	090
55876	A	Place rt device/marker, pros	1.73	2.07	2.07	1.05	1.05	0.28	000
55899	C	Genital surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
55920	A	Place needles pelvic for rt	8.31	NA	NA	3.13	3.13	0.58	000
55970	N	Sex transformation, M to F	0.00	0.00	0.00	0.00	0.00	0.00	XXX
55980	N	Sex transformation, F to M	0.00	0.00	0.00	0.00	0.00	0.00	XXX
56405	A	I & D of vulva/perineum	1.46	1.18	1.25	1.16	1.15	0.17	010
56420	A	Drainage of gland abscess	1.41	1.52	1.90	0.78	0.91	0.16	010
56440	A	Surgery for vulva lesion	2.86	NA	NA	1.56	1.63	0.34	010
56441	A	Lysis of labial lesion(s)	1.99	1.71	1.76	1.56	1.48	0.20	010
56442	A	Hymenotomy	0.68	NA	NA	0.52	0.51	0.08	000
56501	A	Destroy, vulva lesions, sim	1.55	1.63	1.71	1.21	1.22	0.18	010
56515	A	Destroy vulva lesion/s compl	3.03	2.39	2.47	1.74	1.78	0.33	010
56605	A	Biopsy of vulva/perineum	1.10	0.92	1.00	0.34	0.40	0.13	000
56606	A	Biopsy of vulva/perineum	0.55	0.36	0.42	0.15	0.19	0.07	ZZZ
56620	A	Partial removal of vulva	8.44	NA	NA	4.39	4.59	0.90	090
56625	A	Complete removal of vulva	9.55	NA	NA	4.81	5.06	1.02	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
56630	A	Extensive vulva surgery	14.67	NA	NA	6.28	6.55	1.49	090
56631	A	Extensive vulva surgery	18.81	NA	NA	7.78	8.29	1.96	090
56632	A	Extensive vulva surgery	21.61	NA	NA	9.29	9.40	2.39	090
56633	A	Extensive vulva surgery	19.47	NA	NA	7.80	8.19	1.98	090
56634	A	Extensive vulva surgery	20.48	NA	NA	8.18	8.80	2.17	090
56637	A	Extensive vulva surgery	24.57	NA	NA	9.30	10.18	2.61	090
56640	A	Extensive vulva surgery	24.65	NA	NA	8.83	9.72	2.89	090
56700	A	Partial removal of hymen	2.79	NA	NA	1.77	1.80	0.30	010
56740	A	Remove vagina gland lesion	4.83	NA	NA	2.33	2.45	0.56	010
56800	A	Repair of vagina	3.90	NA	NA	1.96	2.08	0.44	010
56805	A	Repair clitoris	19.75	NA	NA	7.68	8.54	2.15	090
56810	A	Repair of perineum	4.26	NA	NA	2.04	2.16	0.49	010
56820	A	Exam of vulva w/scope	1.50	1.19	1.25	0.53	0.59	0.18	000
56821	A	Exam/biopsy of vulva w/scope	2.05	1.53	1.64	0.68	0.79	0.25	000
57000	A	Exploration of vagina	2.99	NA	NA	1.75	1.73	0.31	010
57010	A	Drainage of pelvic abscess	6.74	NA	NA	3.80	3.80	0.71	090
57020	A	Drainage of pelvic fluid	1.50	0.77	0.85	0.45	0.52	0.18	000
57022	A	I & d vaginal hematoma, pp	2.70	NA	NA	1.42	1.45	0.26	010
57023	A	I & d vag hematoma, non-ob	5.13	NA	NA	2.37	2.47	0.58	010
57061	A	Destroy vag lesions, simple	1.27	1.52	1.58	1.11	1.12	0.15	010
57065	A	Destroy vag lesions, complex	2.63	2.02	2.16	1.49	1.58	0.31	010
57100	A	Biopsy of vagina	1.20	0.95	1.01	0.37	0.42	0.14	000
57105	A	Biopsy of vagina	1.71	1.59	1.69	1.33	1.37	0.20	010
57106	A	Remove vagina wall, partial	7.35	NA	NA	4.27	4.22	0.73	090
57107	A	Remove vagina tissue, part	24.43	NA	NA	9.05	9.75	2.72	090
57109	A	Vaginectomy partial w/nodes	28.25	NA	NA	10.25	10.74	3.22	090
57110	A	Remove vagina wall, complete	15.38	NA	NA	6.19	6.73	1.74	090
57111	A	Remove vagina tissue, compl	28.25	NA	NA	10.42	11.51	3.18	090
57112	A	Vaginectomy w/nodes, compl	30.37	NA	NA	10.61	11.35	3.08	090
57120	A	Closure of vagina	8.18	NA	NA	4.19	4.39	0.89	090
57130	A	Remove vagina lesion	2.44	1.96	2.06	1.47	1.50	0.29	010
57135	A	Remove vagina lesion	2.68	2.03	2.15	1.53	1.59	0.31	010
57150	A	Treat vagina infection	0.55	0.58	0.84	0.15	0.18	0.07	000
57155	A	Insert uteri tandems/ovoids	6.79	NA	NA	3.49	4.02	0.43	090
57160	A	Insert pessary/other device	0.89	1.04	1.03	0.25	0.30	0.10	000
57170	A	Fitting of diaphragm/cap	0.91	0.57	1.02	0.25	0.29	0.11	000
57180	A	Treat vaginal bleeding	1.60	1.86	2.01	0.93	1.09	0.19	010
57200	A	Repair of vagina	4.34	NA	NA	2.99	2.94	0.46	090
57210	A	Repair vagina/perineum	5.63	NA	NA	3.27	3.35	0.62	090
57220	A	Revision of urethra	4.77	NA	NA	3.00	3.05	0.51	090
57230	A	Repair of urethral lesion	6.22	NA	NA	3.64	3.52	0.54	090
57240	A	Repair bladder & vagina	11.42	NA	NA	5.48	4.65	0.62	090
57250	A	Repair rectum & vagina	11.42	NA	NA	5.03	4.30	0.65	090
57260	A	Repair of vagina	14.36	NA	NA	5.85	5.34	0.97	090
57265	A	Extensive repair of vagina	15.86	NA	NA	6.32	6.17	1.32	090
57267	A	Insert mesh/pelvic flr addon	4.88	NA	NA	1.49	1.73	0.64	ZZZ
57268	A	Repair of bowel bulge	7.47	NA	NA	4.33	4.26	0.79	090
57270	A	Repair of bowel pouch	13.57	NA	NA	5.83	6.04	1.42	090
57280	A	Suspension of vagina	16.62	NA	NA	6.96	7.16	1.68	090
57282	A	Colpopexy, extraperitoneal	7.84	NA	NA	4.49	4.49	1.02	090
57283	A	Colpopexy, intraperitoneal	11.58	NA	NA	5.11	5.51	1.02	090
57284	A	Repair paravag defect, open	14.25	NA	NA	5.98	6.56	1.41	090
57285	A	Repair paravag defect, vag	11.52	NA	NA	5.16	5.16	0.63	090
57287	A	Revise/remove sling repair	11.49	NA	NA	6.35	5.91	0.90	090
57288	A	Repair bladder defect	14.01	NA	NA	7.01	6.46	1.12	090
57289	A	Repair bladder & vagina	12.69	NA	NA	6.70	6.37	1.21	090
57291	A	Construction of vagina	8.54	NA	NA	4.89	4.90	0.93	090
57292	A	Construct vagina with graft	13.91	NA	NA	5.90	6.41	1.58	090
57295	A	Revise vag graft via vagina	7.74	NA	NA	4.08	4.25	0.91	090
57296	A	Revise vag graft, open abd	16.46	NA	NA	6.66	6.66	1.68	090
57300	A	Repair rectum-vagina fistula	8.58	NA	NA	4.43	4.35	0.87	090
57305	A	Repair rectum-vagina fistula	15.24	NA	NA	6.19	6.23	1.73	090
57307	A	Fistula repair & colostomy	17.02	NA	NA	6.90	6.95	2.02	090
57308	A	Fistula repair, transperine	10.48	NA	NA	4.96	5.02	1.14	090
57310	A	Repair urethrovaginal lesion	7.55	NA	NA	5.01	4.42	0.54	090
57311	A	Repair urethrovaginal lesion	8.81	NA	NA	5.51	4.81	0.65	090
57320	A	Repair bladder-vagina lesion	8.78	NA	NA	5.28	4.82	0.69	090
57330	A	Repair bladder-vagina lesion	13.11	NA	NA	7.20	6.45	1.06	090
57335	A	Repair vagina	19.87	NA	NA	7.82	8.42	1.92	090
57400	A	Dilation of vagina	2.27	NA	NA	1.00	1.05	0.26	000
57410	A	Pelvic examination	1.75	NA	NA	0.91	0.90	0.18	000
57415	A	Remove vaginal foreign body	2.44	NA	NA	1.49	1.45	0.24	010

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
57420	A	Exam of vagina w/scope	1.60	1.23	1.29	0.56	0.61	0.19	000
57421	A	Exam/biopsy of vag w/scope	2.20	1.59	1.72	0.72	0.84	0.27	000
57423	A	Repair paravag defect, lap	16.00	NA	NA	6.51	6.51	1.65	090
57425	A	Laparoscopy, surg, colpopexy	16.93	NA	NA	6.90	6.77	1.76	090
57452	A	Exam of cervix w/scope	1.50	1.18	1.23	0.74	0.75	0.18	000
57454	A	Bx/curett of cervix w/scope	2.33	1.39	1.51	0.95	1.05	0.28	000
57455	A	Biopsy of cervix w/scope	1.99	1.50	1.61	0.66	0.76	0.24	000
57456	A	Endocerv curettage w/scope	1.85	1.45	1.55	0.62	0.72	0.22	000
57460	A	Bx of cervix w/scope, leep	2.83	4.28	5.06	1.09	1.23	0.34	000
57461	A	Conz of cervix w/scope, leep	3.43	4.56	5.33	1.05	1.26	0.41	000
57500	A	Biopsy of cervix	1.20	2.01	2.28	0.64	0.64	0.12	000
57505	A	Endocervical curettage	1.16	1.32	1.39	1.07	1.08	0.14	010
57510	A	Cauterization of cervix	1.90	1.30	1.43	0.89	0.97	0.23	010
57511	A	Cryocautery of cervix	1.92	1.60	1.71	1.26	1.31	0.23	010
57513	A	Laser surgery of cervix	1.92	1.57	1.64	1.28	1.34	0.23	010
57520	A	Conization of cervix	4.06	3.38	3.65	2.51	2.69	0.49	090
57522	A	Conization of cervix	3.62	2.77	2.96	2.25	2.35	0.41	090
57530	A	Removal of cervix	5.19	NA	NA	3.10	3.24	0.58	090
57531	A	Removal of cervix, radical	29.77	NA	NA	10.85	12.00	3.35	090
57540	A	Removal of residual cervix	13.19	NA	NA	5.44	5.83	1.49	090
57545	A	Remove cervix/repair pelvis	14.00	NA	NA	5.72	6.19	1.52	090
57550	A	Removal of residual cervix	6.24	NA	NA	3.61	3.71	0.67	090
57555	A	Remove cervix/repair vagina	9.84	NA	NA	4.75	4.91	1.09	090
57556	A	Remove cervix, repair bowel	9.26	NA	NA	4.60	4.72	0.92	090
57558	A	D&c of cervical stump	1.69	1.34	1.40	1.05	1.09	0.20	010
57700	A	Revision of cervix	4.22	NA	NA	3.28	3.19	0.41	090
57720	A	Revision of cervix	4.53	NA	NA	2.93	3.02	0.49	090
57800	A	Dilation of cervical canal	0.77	0.72	0.74	0.41	0.44	0.09	000
58100	A	Biopsy of uterus lining	1.53	1.14	1.23	0.58	0.65	0.18	000
58110	A	Bx done w/colposcopy add-on	0.77	0.39	0.47	0.21	0.26	0.09	ZZZ
58120	A	Dilation and curettage	3.54	2.70	2.50	1.65	1.76	0.39	010
58140	A	Myomectomy abdom method	15.69	NA	NA	6.17	6.64	1.82	090
58145	A	Myomectomy vag method	8.81	NA	NA	4.23	4.50	0.97	090
58146	A	Myomectomy abdom complex	20.24	NA	NA	7.34	8.17	2.33	090
58150	A	Total hysterectomy	17.21	NA	NA	6.55	7.01	1.85	090
58152	A	Total hysterectomy	21.73	NA	NA	8.02	8.93	2.48	090
58180	A	Partial hysterectomy	16.50	NA	NA	6.33	6.89	1.64	090
58200	A	Extensive hysterectomy	23.00	NA	NA	8.14	9.06	2.55	090
58210	A	Extensive hysterectomy	30.76	NA	NA	10.71	11.95	3.38	090
58240	A	Removal of pelvis contents	49.02	NA	NA	17.62	17.61	4.23	090
58260	A	Vaginal hysterectomy	14.02	NA	NA	5.78	6.23	1.57	090
58262	A	Vag hyst including t/o	15.81	NA	NA	6.23	6.80	1.80	090
58263	A	Vag hyst w/t/o & vag repair	17.10	NA	NA	6.63	7.25	1.95	090
58267	A	Vag hyst w/urinary repair	18.23	NA	NA	6.96	7.66	2.07	090
58270	A	Vag hyst w/enterocele repair	15.20	NA	NA	5.93	6.49	1.74	090
58275	A	Hysterectomy/revise vagina	16.90	NA	NA	6.60	7.18	1.92	090
58280	A	Hysterectomy/revise vagina	18.20	NA	NA	6.95	7.60	2.07	090
58285	A	Extensive hysterectomy	23.30	NA	NA	7.93	8.93	2.71	090
58290	A	Vag hyst complex	20.17	NA	NA	7.34	8.23	2.30	090
58291	A	Vag hyst incl t/o, complex	21.96	NA	NA	7.81	8.84	2.53	090
58292	A	Vag hyst t/o & repair, compl	23.25	NA	NA	8.20	9.28	2.68	090
58293	A	Vag hyst w/uro repair, compl	24.23	NA	NA	8.50	9.57	2.79	090
58294	A	Vag hyst w/enterocele, compl	21.45	NA	NA	7.50	8.52	2.40	090
58300	N	Insert intrauterine device	1.01	0.63	1.02	0.23	0.31	0.12	XXX
58301	A	Remove intrauterine device	1.27	1.04	1.18	0.34	0.41	0.15	000
58321	A	Artificial insemination	0.92	0.94	1.04	0.23	0.30	0.10	000
58322	A	Artificial insemination	1.10	1.03	1.11	0.31	0.36	0.13	000
58323	A	Sperm washing	0.23	0.16	0.34	0.07	0.08	0.03	000
58340	A	Catheter for hystero-graphy	0.88	2.15	2.66	0.56	0.61	0.09	000
58345	A	Reopen fallopian tube	4.67	NA	NA	2.11	2.27	0.41	010
58346	A	Insert heyman uteri capsule	7.48	NA	NA	3.73	3.83	0.56	090
58350	A	Reopen fallopian tube	1.03	1.35	1.42	0.88	0.90	0.12	010
58353	A	Endometr ablate, thermal	3.57	22.81	29.23	1.71	1.88	0.43	010
58356	A	Endometrial cryoablation	6.36	43.33	52.36	1.85	2.27	0.82	010
58400	A	Suspension of uterus	7.06	NA	NA	3.86	3.89	0.75	090
58410	A	Suspension of uterus	13.70	NA	NA	5.55	5.99	1.45	090
58520	A	Repair of ruptured uterus	13.38	NA	NA	5.48	5.76	1.47	090
58540	A	Revision of uterus	15.61	NA	NA	6.14	6.54	1.79	090
58541	A	Lsh, uterus 250 g or less	14.57	NA	NA	6.12	6.12	1.68	090
58542	A	Lsh w/t/o ut 250 g or less	16.43	NA	NA	6.63	6.63	1.69	090
58543	A	Lsh uterus above 250 g	16.74	NA	NA	6.71	6.71	1.73	090
58544	A	Lsh w/t/o uterus above 250 g	18.24	NA	NA	7.11	7.11	1.89	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional-facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
58545		A	Laparoscopic myomectomy	15.45	NA	NA	5.86	6.52	1.78	090
58546		A	Laparo-myomectomy, complex	19.84	NA	NA	7.04	7.98	2.31	090
58548		A	Lap radical hyst	31.45	NA	NA	12.45	12.45	3.52	090
58550		A	Laparo-asst vag hysterectomy	14.97	NA	NA	6.12	6.70	1.73	090
58552		A	Laparo-vag hyst incl t/o	16.78	NA	NA	6.55	7.28	1.73	090
58553		A	Laparo-vag hyst, complex	19.96	NA	NA	7.08	8.00	2.31	090
58554		A	Laparo-vag hyst w/t/o, compl	22.98	NA	NA	8.23	9.31	2.28	090
58555		A	Hysteroscopy, dx, sep proc	3.33	2.75	2.47	1.23	1.39	0.40	000
58558		A	Hysteroscopy, biopsy	4.74	3.62	2.90	1.65	1.91	0.57	000
58559		A	Hysteroscopy, lysis	6.16	NA	NA	2.04	2.38	0.74	000
58560		A	Hysteroscopy, resect septum	6.99	NA	NA	2.31	2.70	0.84	000
58561		A	Hysteroscopy, remove myoma	9.99	NA	NA	3.11	3.69	1.21	000
58562		A	Hysteroscopy, remove fb	5.20	3.52	2.94	1.75	2.05	0.63	000
58563		A	Hysteroscopy, ablation	6.16	37.22	46.69	2.04	2.40	0.74	000
58565		A	Hysteroscopy, sterilization	7.06	41.94	45.74	3.37	3.63	1.19	090
58570		A	Tlh, uterus 250 g or less	15.75	NA	NA	6.45	6.45	1.82	090
58571		A	Tlh w/t/o 250 g or less	17.56	NA	NA	6.94	6.94	1.81	090
58572		A	Tlh, uterus over 250 g	19.96	NA	NA	7.59	7.59	2.31	090
58573		A	Tlh w/t/o uterus over 250 g	22.98	NA	NA	8.41	8.41	2.28	090
58578		C	Laparo proc, uterus	0.00	0.00	0.00	0.00	0.00	0.00	YYY
58579		C	Hysteroscope procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
58600		A	Division of fallopian tube	5.86	NA	NA	2.92	3.12	0.66	090
58605		A	Division of fallopian tube	5.25	NA	NA	2.71	2.91	0.59	090
58611		A	Ligate oviduct(s) add-on	1.45	NA	NA	0.40	0.48	0.18	ZZZ
58615		A	Occlude fallopian tube(s)	3.91	NA	NA	2.03	2.37	0.47	010
58660		A	Laparoscopy, lysis	11.54	NA	NA	4.49	4.87	1.40	090
58661		A	Laparoscopy, remove adnexa	11.30	NA	NA	3.98	4.55	1.34	010
58662		A	Laparoscopy, excise lesions	12.08	NA	NA	4.75	5.27	1.43	090
58670		A	Laparoscopy, tubal cautery	5.86	NA	NA	2.94	3.11	0.67	090
58671		A	Laparoscopy, tubal block	5.86	NA	NA	2.93	3.10	0.68	090
58672		A	Laparoscopy, fimbrioplasty	12.88	NA	NA	4.77	5.47	1.60	090
58673		A	Laparoscopy, salpingostomy	13.99	NA	NA	5.12	5.84	1.70	090
58679		C	Laparo proc, oviduct-ovary	0.00	0.00	0.00	0.00	0.00	0.00	YYY
58700		A	Removal of fallopian tube	12.84	NA	NA	5.48	5.73	1.51	090
58720		A	Removal of ovary/tube(s)	12.08	NA	NA	5.08	5.43	1.39	090
58740		A	Revise fallopian tube(s)	14.79	NA	NA	6.05	6.59	1.72	090
58750		A	Repair oviduct	15.56	NA	NA	6.04	6.70	1.85	090
58752		A	Revise ovarian tube(s)	15.56	NA	NA	5.98	6.46	1.81	090
58760		A	Remove tubal obstruction	13.85	NA	NA	5.58	6.14	1.80	090
58770		A	Create new tubal opening	14.69	NA	NA	5.74	6.32	1.74	090
58800		A	Drainage of ovarian cyst(s)	4.54	3.21	3.42	2.69	2.79	0.43	090
58805		A	Drainage of ovarian cyst(s)	6.34	NA	NA	3.50	3.50	0.69	090
58820		A	Drain ovary abscess, open	4.62	NA	NA	2.90	3.09	0.52	090
58822		A	Drain ovary abscess, percut	11.71	NA	NA	5.15	5.18	1.16	090
58823		A	Drain pelvic abscess, percut	3.37	19.98	20.64	1.16	1.14	0.24	000
58825		A	Transposition, ovary(s)	11.70	NA	NA	4.83	5.31	1.32	090
58900		A	Biopsy of ovary(s)	6.51	NA	NA	3.55	3.56	0.69	090
58920		A	Partial removal of ovary(s)	11.87	NA	NA	5.05	5.31	1.43	090
58925		A	Removal of ovarian cyst(s)	12.33	NA	NA	5.24	5.46	1.41	090
58940		A	Removal of ovary(s)	8.12	NA	NA	4.03	4.06	0.91	090
58943		A	Removal of ovary(s)	19.42	NA	NA	7.17	7.90	2.23	090
58950		A	Resect ovarian malignancy	18.24	NA	NA	7.24	7.82	2.05	090
58951		A	Resect ovarian malignancy	24.15	NA	NA	8.59	9.51	2.64	090
58952		A	Resect ovarian malignancy	27.15	NA	NA	9.81	10.77	3.03	090
58953		A	Tah, rad dissect for debulk	33.97	NA	NA	11.62	13.08	3.84	090
58954		A	Tah rad debulk/lymph remove	36.97	NA	NA	12.51	14.10	4.18	090
58956		A	Bso, omentectomy w/tah	22.65	NA	NA	8.58	9.44	4.01	090
58957		A	Resect recurrent gyn mal	26.06	NA	NA	9.55	9.55	2.95	090
58958		A	Resect recur gyn mal w/lym	29.06	NA	NA	10.35	10.35	3.29	090
58960		A	Exploration of abdomen	15.68	NA	NA	6.24	6.79	1.80	090
58970		A	Retrieval of oocyte	3.52	1.85	2.08	1.28	1.38	0.43	000
58974		C	Transfer of embryo	0.00	0.00	0.00	0.00	0.00	0.00	000
58976		A	Transfer of embryo	3.82	1.94	2.31	1.20	1.51	0.47	000
58999		C	Genital surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
59000		A	Amniocentesis, diagnostic	1.30	1.75	1.91	0.55	0.61	0.31	000
59001		A	Amniocentesis, therapeutic	3.00	NA	NA	1.07	1.24	0.71	000
59012		A	Fetal cord puncture, prenatal	3.44	NA	NA	1.13	1.33	0.82	000
59015		A	Chorion biopsy	2.20	1.42	1.48	0.79	0.91	0.52	000
59020		A	Fetal contract stress test	0.66	1.07	0.92	NA	NA	0.26	000
59020	TC	A	Fetal contract stress test	0.00	0.89	0.70	NA	NA	0.10	000
59020	26	A	Fetal contract stress test	0.66	0.18	0.22	0.18	0.22	0.16	000
59025		A	Fetal non-stress test	0.53	0.63	0.54	NA	NA	0.15	000

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
59025	TC	A	Fetal non-stress test	0.00	0.48	0.36	NA	NA	0.02	000
59025	26	A	Fetal non-stress test	0.53	0.15	0.18	0.15	0.18	0.13	000
59030		A	Fetal scalp blood sample	1.99	NA	NA	0.46	0.61	0.47	000
59050		A	Fetal monitor w/report	0.89	NA	NA	0.27	0.31	0.21	XXX
59051		A	Fetal monitor/interpret only	0.74	NA	NA	0.20	0.25	0.17	XXX
59070		A	Transabdom amnioinfus w/us	5.24	4.39	4.77	1.76	2.04	0.28	000
59072		A	Umbilical cord occlud w/us	8.99	NA	NA	2.39	2.75	0.16	000
59074		A	Fetal fluid drainage w/us	5.24	3.60	4.08	1.53	1.92	0.28	000
59076		A	Fetal shunt placement, w/us	8.99	NA	NA	2.39	2.75	0.16	000
59100		A	Remove uterus lesion	13.26	NA	NA	5.55	6.00	2.95	090
59120		A	Treat ectopic pregnancy	12.56	NA	NA	5.39	5.82	2.73	090
59121		A	Treat ectopic pregnancy	12.64	NA	NA	5.34	5.83	2.79	090
59130		A	Treat ectopic pregnancy	14.98	NA	NA	6.73	5.76	3.39	090
59135		A	Treat ectopic pregnancy	14.82	NA	NA	5.08	6.15	3.31	090
59136		A	Treat ectopic pregnancy	14.15	NA	NA	4.93	5.76	3.14	090
59140		A	Treat ectopic pregnancy	5.86	NA	NA	3.30	2.76	1.29	090
59150		A	Treat ectopic pregnancy	12.19	NA	NA	5.23	5.61	2.79	090
59151		A	Treat ectopic pregnancy	12.01	NA	NA	4.86	5.45	2.74	090
59160		A	D & c after delivery	2.73	1.98	2.64	1.17	1.65	0.64	010
59200		A	Insert cervical dilator	0.22	0.94	1.06	0.22	0.26	0.19	000
59300		A	Episiotomy or vaginal repair	2.41	2.19	2.18	1.00	0.98	0.57	000
59320		A	Revision of cervix	2.48	NA	NA	1.00	1.12	0.59	000
59325		A	Revision of cervix	4.06	NA	NA	1.44	1.66	0.88	000
59350		A	Repair of uterus	4.94	NA	NA	1.21	1.54	1.17	000
59400		A	Obstetrical care	26.80	NA	NA	14.08	14.69	5.50	MMM
59409		A	Obstetrical care	13.48	NA	NA	3.70	4.50	3.22	MMM
59410		A	Obstetrical care	15.29	NA	NA	4.91	5.60	3.52	MMM
59412		A	Antepartum manipulation	1.71	NA	NA	0.64	0.72	0.40	MMM
59414		A	Deliver placenta	1.61	NA	NA	0.44	0.54	0.38	MMM
59425		A	Antepartum care only	6.22	4.24	4.22	1.68	1.77	1.14	MMM
59426		A	Antepartum care only	11.04	7.78	7.66	2.99	3.10	1.98	MMM
59430		A	Care after delivery	2.13	1.08	1.15	0.71	0.82	0.50	MMM
59510		A	Cesarean delivery	30.34	NA	NA	15.96	16.61	6.25	MMM
59514		A	Cesarean delivery only	15.95	NA	NA	4.42	5.32	3.80	MMM
59515		A	Cesarean delivery	18.26	NA	NA	6.13	6.98	4.13	MMM
59525		A	Remove uterus after cesarean	8.53	NA	NA	2.25	2.77	1.95	ZZZ
59610		A	Vbac delivery	28.21	NA	NA	14.93	15.39	5.87	MMM
59612		A	Vbac delivery only	15.04	NA	NA	4.19	5.12	3.59	MMM
59614		A	Vbac care after delivery	16.59	NA	NA	5.11	6.02	3.89	MMM
59618		A	Attempted vbac delivery	31.78	NA	NA	16.35	17.28	6.61	MMM
59620		A	Attempted vbac delivery only	17.50	NA	NA	4.66	5.71	4.17	MMM
59622		A	Attempted vbac after care	19.70	NA	NA	6.70	7.66	4.50	MMM
59812		A	Treatment of miscarriage	4.39	3.10	2.82	2.35	2.45	0.95	090
59820		A	Care of miscarriage	4.68	4.07	4.24	3.46	3.51	0.95	090
59821		A	Treatment of miscarriage	4.97	3.91	4.09	3.23	3.32	1.06	090
59830		A	Treat uterus infection	6.51	NA	NA	3.44	3.71	1.44	090
59840		R	Abortion	3.01	2.00	2.06	1.77	1.95	0.71	010
59841		R	Abortion	5.57	3.11	3.30	2.54	2.76	1.24	010
59850		R	Abortion	5.90	NA	NA	2.45	2.85	1.28	090
59851		R	Abortion	5.92	NA	NA	3.28	3.51	1.28	090
59852		R	Abortion	8.23	NA	NA	3.82	4.43	1.81	090
59855		R	Abortion	6.38	NA	NA	3.07	3.31	1.45	090
59856		R	Abortion	7.74	NA	NA	3.31	3.68	1.79	090
59857		R	Abortion	9.30	NA	NA	3.64	4.17	2.02	090
59866		R	Abortion (mpr)	3.99	NA	NA	1.36	1.63	0.87	000
59870		A	Evacuate mole of uterus	6.40	NA	NA	4.38	4.43	1.42	090
59871		A	Remove cerclage suture	2.13	NA	NA	0.90	1.02	0.50	000
59897		C	Fetal invas px w/us	0.00	0.00	0.00	0.00	0.00	0.00	YYY
59898		C	Laparo proc, ob care/deliver	0.00	0.00	0.00	0.00	0.00	0.00	YYY
59899		C	Maternity care procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
60000		A	Drain thyroid/tongue cyst	1.78	2.08	2.00	1.70	1.70	0.15	010
60100		A	Biopsy of thyroid	1.56	1.31	1.35	0.52	0.52	0.10	000
60200		A	Remove thyroid lesion	9.91	NA	NA	5.50	5.74	1.01	090
60210		A	Partial thyroid excision	11.15	NA	NA	5.22	5.43	1.23	090
60212		A	Partial thyroid excision	16.32	NA	NA	6.94	7.30	1.95	090
60220		A	Partial removal of thyroid	12.29	NA	NA	5.66	5.90	1.32	090
60225		A	Partial removal of thyroid	14.67	NA	NA	6.91	7.15	1.64	090
60240		A	Removal of thyroid	16.18	NA	NA	6.40	6.99	1.86	090
60252		A	Removal of thyroid	21.88	NA	NA	8.82	9.45	2.30	090
60254		A	Extensive thyroid surgery	28.29	NA	NA	11.21	12.67	2.61	090
60260		A	Repeat thyroid surgery	18.18	NA	NA	7.40	8.02	1.94	090
60270		A	Removal of thyroid	23.07	NA	NA	9.31	9.88	2.33	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fac- ility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
60271	A	Removal of thyroid	17.54	NA	NA	7.14	7.86	1.75	090
60280	A	Remove thyroid duct lesion	6.05	NA	NA	4.47	4.56	0.54	090
60281	A	Remove thyroid duct lesion	8.71	NA	NA	5.31	5.57	0.73	090
60300	A	Aspir/inj thyroid cyst	0.97	1.94	1.67	0.30	0.31	0.07	000
60500	A	Explore parathyroid glands	16.69	NA	NA	6.85	7.12	2.01	090
60502	A	Re-explore parathyroids	21.01	NA	NA	8.60	8.97	2.54	090
60505	A	Explore parathyroid glands	22.91	NA	NA	9.38	10.15	2.65	090
60512	A	Autotransplant parathyroid	4.44	NA	NA	1.21	1.41	0.53	ZZZ
60520	A	Removal of thymus gland	17.07	NA	NA	7.01	7.64	2.20	090
60521	A	Removal of thymus gland	19.11	NA	NA	8.12	8.83	2.82	090
60522	A	Removal of thymus gland	23.37	NA	NA	9.60	10.43	3.27	090
60540	A	Explore adrenal gland	17.91	NA	NA	8.24	7.91	1.75	090
60545	A	Explore adrenal gland	20.82	NA	NA	8.94	8.73	2.08	090
60600	A	Remove carotid body lesion	24.99	NA	NA	8.82	9.89	2.20	090
60605	A	Remove carotid body lesion	31.86	NA	NA	12.13	12.19	2.50	090
60650	A	Laparoscopy adrenalectomy	20.63	NA	NA	8.08	8.03	2.29	090
60659	C	Laparo proc, endocrine	0.00	0.00	0.00	0.00	0.00	0.00	YYY
60699	C	Endocrine surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
61000	A	Remove cranial cavity fluid	1.58	NA	NA	1.24	1.09	0.13	000
61001	A	Remove cranial cavity fluid	1.49	NA	NA	1.08	1.07	0.16	000
61020	A	Remove brain cavity fluid	1.51	NA	NA	1.63	1.48	0.34	000
61026	A	Injection into brain canal	1.69	NA	NA	1.30	1.34	0.33	000
61050	A	Remove brain canal fluid	1.51	NA	NA	1.15	1.21	0.11	000
61055	A	Injection into brain canal	2.10	NA	NA	1.33	1.37	0.17	000
61070	A	Brain canal shunt procedure	0.89	NA	NA	1.16	1.08	0.17	000
61105	A	Twist drill hole	5.40	NA	NA	4.90	4.41	1.32	090
61107	A	Drill skull for implantation	4.99	NA	NA	1.83	2.18	1.29	000
61108	A	Drill skull for drainage	11.51	NA	NA	8.34	7.74	2.64	090
61120	A	Burr hole for puncture	9.52	NA	NA	6.77	6.38	2.10	090
61140	A	Pierce skull for biopsy	17.10	NA	NA	10.40	10.14	4.12	090
61150	A	Pierce skull for drainage	18.80	NA	NA	10.67	10.52	4.32	090
61151	A	Pierce skull for drainage	13.41	NA	NA	8.43	8.12	3.01	090
61154	A	Pierce skull & remove clot	16.92	NA	NA	10.82	10.15	4.21	090
61156	A	Pierce skull for drainage	17.37	NA	NA	9.71	9.77	4.23	090
61210	A	Pierce skull, implant device	5.83	NA	NA	2.15	2.53	1.50	000
61215	A	Insert brain-fluid device	5.77	NA	NA	5.44	4.72	1.26	090
61250	A	Pierce skull & explore	11.41	NA	NA	7.37	7.11	2.77	090
61253	A	Pierce skull & explore	13.41	NA	NA	7.48	7.60	2.62	090
61304	A	Open skull for exploration	23.31	NA	NA	12.53	12.68	5.63	090
61305	A	Open skull for exploration	28.51	NA	NA	14.95	15.13	6.09	090
61312	A	Open skull for drainage	30.07	NA	NA	15.22	15.12	6.36	090
61313	A	Open skull for drainage	27.94	NA	NA	15.35	15.07	6.45	090
61314	A	Open skull for drainage	25.77	NA	NA	14.14	13.58	6.28	090
61315	A	Open skull for drainage	29.52	NA	NA	15.49	15.75	7.16	090
61316	A	Implt cran bone flap to abdo	1.39	NA	NA	0.51	0.55	0.35	ZZZ
61320	A	Open skull for drainage	27.32	NA	NA	14.23	14.48	6.62	090
61321	A	Open skull for drainage	30.40	NA	NA	16.05	16.08	7.14	090
61322	A	Decompressive craniotomy	34.08	NA	NA	17.46	16.56	7.63	090
61323	A	Decompressive lobectomy	34.93	NA	NA	17.29	16.68	8.03	090
61330	A	Decompress eye socket	25.17	NA	NA	11.52	12.62	2.32	090
61332	A	Explore/biopsy eye socket	28.50	NA	NA	12.95	14.27	4.83	090
61333	A	Explore orbit/remove lesion	29.17	NA	NA	12.87	14.22	3.92	090
61334	A	Explore orbit/remove object	19.50	NA	NA	9.01	9.81	1.75	090
61340	A	Subtemporal decompression	20.01	NA	NA	11.67	11.39	4.84	090
61343	A	Incise skull (press relief)	31.73	NA	NA	15.92	16.36	7.64	090
61345	A	Relieve cranial pressure	29.10	NA	NA	14.84	15.11	7.04	090
61440	A	Incise skull for surgery	28.53	NA	NA	15.22	14.70	6.90	090
61450	A	Incise skull for surgery	27.59	NA	NA	14.05	14.16	5.79	090
61458	A	Incise skull for brain wound	28.71	NA	NA	14.87	15.18	7.03	090
61460	A	Incise skull for surgery	30.11	NA	NA	14.56	15.48	6.04	090
61470	A	Incise skull for surgery	27.52	NA	NA	14.04	13.94	5.90	090
61480	A	Incise skull for surgery	27.95	NA	NA	8.13	11.70	6.73	090
61490	A	Incise skull for surgery	27.12	NA	NA	14.21	14.26	6.92	090
61500	A	Removal of skull lesion	19.05	NA	NA	10.68	10.74	4.11	090
61501	A	Remove infected skull bone	16.22	NA	NA	9.44	9.32	3.22	090
61510	A	Removal of brain lesion	30.63	NA	NA	16.93	16.81	7.35	090
61512	A	Remove brain lining lesion	36.99	NA	NA	18.44	19.05	9.08	090
61514	A	Removal of brain abscess	27.10	NA	NA	14.40	14.41	6.54	090
61516	A	Removal of brain lesion	26.45	NA	NA	14.04	14.15	6.35	090
61517	A	Implt brain chemotx add-on	1.38	NA	NA	0.51	0.57	0.35	ZZZ
61518	A	Removal of brain lesion	39.69	NA	NA	20.29	20.68	9.65	090
61519	A	Remove brain lining lesion	43.28	NA	NA	20.63	21.63	10.63	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
61520	A	Removal of brain lesion	56.89	NA	NA	25.93	28.12	11.21	090
61521	A	Removal of brain lesion	46.84	NA	NA	22.14	23.17	11.39	090
61522	A	Removal of brain abscess	31.41	NA	NA	15.75	16.08	7.62	090
61524	A	Removal of brain lesion	29.76	NA	NA	15.68	15.67	7.16	090
61526	A	Removal of brain lesion	53.90	NA	NA	22.50	25.98	7.07	090
61530	A	Removal of brain lesion	45.43	NA	NA	19.47	22.25	6.15	090
61531	A	Implant brain electrodes	16.28	NA	NA	10.45	9.79	3.79	090
61533	A	Implant brain electrodes	21.36	NA	NA	11.78	11.65	5.12	090
61534	A	Removal of brain lesion	22.88	NA	NA	13.11	12.59	5.44	090
61535	A	Remove brain electrodes	13.05	NA	NA	8.83	8.12	3.02	090
61536	A	Removal of brain lesion	37.59	NA	NA	18.51	19.14	9.21	090
61537	A	Removal of brain tissue	36.35	NA	NA	17.02	15.87	6.94	090
61538	A	Removal of brain tissue	39.35	NA	NA	18.35	16.82	6.94	090
61539	A	Removal of brain tissue	34.15	NA	NA	16.81	17.28	8.32	090
61540	A	Removal of brain tissue	31.30	NA	NA	16.28	16.76	8.32	090
61541	A	Incision of brain tissue	30.81	NA	NA	16.07	16.13	6.60	090
61542	A	Removal of brain tissue	33.03	NA	NA	16.76	17.29	8.03	090
61543	A	Removal of brain tissue	31.18	NA	NA	13.84	15.11	7.56	090
61544	A	Remove & treat brain lesion	27.26	NA	NA	14.26	14.04	5.97	090
61545	A	Excision of brain tumor	46.23	NA	NA	22.80	23.50	10.63	090
61546	A	Removal of pituitary gland	33.31	NA	NA	16.72	17.10	7.67	090
61548	A	Removal of pituitary gland	23.27	NA	NA	11.60	12.19	3.43	090
61550	A	Release of skull seams	15.44	NA	NA	5.65	6.29	0.98	090
61552	A	Release of skull seams	20.27	NA	NA	12.14	10.62	1.06	090
61556	A	Incise skull/sutures	24.00	NA	NA	13.27	12.31	4.65	090
61557	A	Incise skull/sutures	23.16	NA	NA	13.62	13.62	5.80	090
61558	A	Excision of skull/sutures	26.35	NA	NA	14.68	14.43	1.36	090
61559	A	Excision of skull/sutures	33.82	NA	NA	18.36	18.83	8.51	090
61563	A	Excision of skull tumor	28.35	NA	NA	13.07	14.15	5.17	090
61564	A	Excision of skull tumor	34.59	NA	NA	17.89	18.08	8.78	090
61566	A	Removal of brain tissue	32.32	NA	NA	16.63	17.19	6.94	090
61567	A	Incision of brain tissue	36.84	NA	NA	19.05	19.85	6.54	090
61570	A	Remove foreign body, brain	26.38	NA	NA	14.00	13.95	5.88	090
61571	A	Incise skull for brain wound	28.29	NA	NA	14.62	14.88	6.79	090
61575	A	Skull base/brainstem surgery	36.43	NA	NA	16.08	17.85	5.34	090
61576	A	Skull base/brainstem surgery	55.11	NA	NA	28.06	31.39	5.58	090
61580	A	Craniofacial approach, skull	34.34	NA	NA	22.82	24.19	3.37	090
61581	A	Craniofacial approach, skull	38.88	NA	NA	27.80	25.62	3.92	090
61582	A	Craniofacial approach, skull	34.93	NA	NA	30.44	28.86	7.21	090
61583	A	Craniofacial approach, skull	38.41	NA	NA	25.86	25.48	9.21	090
61584	A	Orbitocranial approach/skull	37.61	NA	NA	26.01	25.26	8.18	090
61585	A	Orbitocranial approach/skull	42.46	NA	NA	25.10	25.79	7.03	090
61586	A	Resect nasopharynx, skull	27.28	NA	NA	22.61	22.59	4.37	090
61590	A	Infratemporal approach/skull	46.87	NA	NA	24.78	26.69	5.31	090
61591	A	Infratemporal approach/skull	46.87	NA	NA	24.57	27.04	5.66	090
61592	A	Orbitocranial approach/skull	42.98	NA	NA	26.77	26.63	10.07	090
61595	A	Transtemporal approach/skull	33.57	NA	NA	21.12	21.73	3.98	090
61596	A	Transcochlear approach/skull	39.31	NA	NA	20.92	22.67	3.40	090
61597	A	Transcondylar approach/skull	40.73	NA	NA	23.25	23.11	8.84	090
61598	A	Transpetrosal approach/skull	36.41	NA	NA	22.13	22.68	5.70	090
61600	A	Resect/excise cranial lesion	29.84	NA	NA	19.74	19.75	3.79	090
61601	A	Resect/excise cranial lesion	31.04	NA	NA	22.35	21.42	6.63	090
61605	A	Resect/excise cranial lesion	32.40	NA	NA	19.44	20.69	2.86	090
61606	A	Resect/excise cranial lesion	41.94	NA	NA	23.74	24.44	8.97	090
61607	A	Resect/excise cranial lesion	40.82	NA	NA	20.98	22.37	6.90	090
61608	A	Resect/excise cranial lesion	45.45	NA	NA	26.29	26.43	10.75	090
61609	A	Transect artery, sinus	9.88	NA	NA	3.25	4.05	2.56	ZZZ
61610	A	Transect artery, sinus	29.63	NA	NA	11.05	12.09	7.68	ZZZ
61611	A	Transect artery, sinus	7.41	NA	NA	1.70	2.76	1.89	ZZZ
61612	A	Transect artery, sinus	27.84	NA	NA	6.40	9.85	4.31	ZZZ
61613	A	Remove aneurysm, sinus	44.94	NA	NA	27.32	26.78	8.45	090
61615	A	Resect/excise lesion, skull	35.63	NA	NA	21.27	21.99	4.73	090
61616	A	Resect/excise lesion, skull	46.60	NA	NA	27.21	27.92	8.26	090
61618	A	Repair dura	18.58	NA	NA	10.42	10.43	3.72	090
61619	A	Repair dura	22.01	NA	NA	11.66	11.95	3.95	090
61623	A	Endovasc temporary vessel occl	9.95	NA	NA	3.72	3.90	1.05	000
61624	A	Transcath occlusion, cns	20.12	NA	NA	7.29	7.09	1.96	000
61626	A	Transcath occlusion, non-cns	16.60	NA	NA	5.97	5.74	1.24	000
61630	N	Intracranial angioplasty	22.07	NA	NA	6.43	9.46	2.02	090
61635	N	Intracran angioplasty w/stent	24.28	NA	NA	6.94	10.24	2.21	090
61640	N	Dilate ic vasospasm, init	12.32	NA	NA	2.83	2.83	0.71	000
61641	N	Dilate ic vasospasm add-on	4.33	NA	NA	0.99	0.99	0.25	ZZZ

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
61642	N	Dilate ic vasospasm add-on	8.66	NA	NA	1.99	1.99	0.50	ZZZ
61680	A	Intracranial vessel surgery	32.40	NA	NA	16.73	17.07	7.95	090
61682	A	Intracranial vessel surgery	63.31	NA	NA	27.51	29.85	15.90	090
61684	A	Intracranial vessel surgery	41.49	NA	NA	20.35	21.17	10.31	090
61686	A	Intracranial vessel surgery	67.32	NA	NA	30.44	32.57	16.71	090
61690	A	Intracranial vessel surgery	31.18	NA	NA	16.50	16.61	6.94	090
61692	A	Intracranial vessel surgery	54.43	NA	NA	24.32	25.89	13.43	090
61697	A	Brain aneurysm repr, complx	63.22	NA	NA	28.60	28.30	12.85	090
61698	A	Brain aneurysm repr, complx	69.45	NA	NA	30.55	28.62	12.54	090
61700	A	Brain aneurysm repr, simple	50.44	NA	NA	24.00	25.89	13.02	090
61702	A	Inner skull vessel surgery	59.86	NA	NA	27.47	26.74	10.79	090
61703	A	Clamp neck artery	18.70	NA	NA	10.05	10.25	4.06	090
61705	A	Revise circulation to head	37.97	NA	NA	18.30	18.77	8.87	090
61708	A	Revise circulation to head	37.07	NA	NA	14.86	15.00	2.51	090
61710	A	Revise circulation to head	31.19	NA	NA	13.77	13.70	4.52	090
61711	A	Fusion of skull arteries	38.10	NA	NA	18.59	19.19	9.42	090
61720	A	Incise skull/brain surgery	17.52	NA	NA	7.88	8.92	2.79	090
61735	A	Incise skull/brain surgery	22.22	NA	NA	9.16	10.66	2.73	090
61750	A	Incise skull/brain biopsy	19.73	NA	NA	10.94	10.77	4.72	090
61751	A	Brain biopsy w/ct/mr guide	18.64	NA	NA	11.35	11.08	4.56	090
61760	A	Implant brain electrodes	22.24	NA	NA	12.05	10.38	5.42	090
61770	A	Incise skull for treatment	23.09	NA	NA	9.88	11.06	3.55	090
61790	A	Treat trigeminal nerve	11.50	NA	NA	7.69	6.80	2.82	090
61791	A	Treat trigeminal tract	15.31	NA	NA	8.20	8.56	3.40	090
61793	A	Focus radiation beam	17.75	NA	NA	9.54	9.83	4.46	090
61795	A	Brain surgery using computer	4.03	NA	NA	1.43	1.73	0.79	ZZZ
61850	A	Implant neuroelectrodes	13.26	NA	NA	7.88	7.77	3.22	090
61860	A	Implant neuroelectrodes	22.16	NA	NA	11.59	11.82	4.95	090
61863	A	Implant neuroelectrode	20.56	NA	NA	12.40	12.08	5.43	090
61864	A	Implant neuroelectrde, addl	4.49	NA	NA	1.67	1.98	5.43	ZZZ
61867	A	Implant neuroelectrode	32.88	NA	NA	16.35	17.18	5.43	090
61868	A	Implant neuroelectrde, add'l	7.91	NA	NA	2.94	3.47	5.43	ZZZ
61870	A	Implant neuroelectrodes	16.24	NA	NA	9.68	9.69	3.87	090
61875	A	Implant neuroelectrodes	16.36	NA	NA	5.33	6.94	2.95	090
61880	A	Revise/remove neuroelectrode	6.87	NA	NA	5.17	4.87	1.66	090
61885	A	Insrt/redo neurostim 1 array	7.37	NA	NA	7.05	6.18	1.59	090
61886	A	Implant neurostim arrays	9.73	NA	NA	8.51	7.43	1.97	090
61888	A	Revise/remove neuroreceiver	5.20	NA	NA	3.46	3.57	1.33	010
62000	A	Treat skull fracture	13.83	NA	NA	7.61	6.56	1.06	090
62005	A	Treat skull fracture	17.53	NA	NA	9.58	9.19	3.87	090
62010	A	Treatment of head injury	21.30	NA	NA	11.80	11.75	5.14	090
62100	A	Repair brain fluid leakage	23.40	NA	NA	12.08	12.43	4.84	090
62115	A	Reduction of skull defect	22.71	NA	NA	13.87	12.75	5.51	090
62116	A	Reduction of skull defect	24.90	NA	NA	13.33	13.34	6.11	090
62117	A	Reduction of skull defect	28.26	NA	NA	12.73	14.04	4.53	090
62120	A	Repair skull cavity lesion	24.39	NA	NA	17.31	17.89	3.00	090
62121	A	Incise skull repair	22.93	NA	NA	14.23	14.83	4.17	090
62140	A	Repair of skull defect	14.45	NA	NA	8.63	8.47	3.47	090
62141	A	Repair of skull defect	15.97	NA	NA	9.33	9.18	3.76	090
62142	A	Remove skull plate/flap	11.73	NA	NA	7.78	7.38	2.73	090
62143	A	Replace skull plate/flap	14.05	NA	NA	8.72	8.38	3.37	090
62145	A	Repair of skull & brain	19.99	NA	NA	10.25	10.56	4.50	090
62146	A	Repair of skull with graft	17.18	NA	NA	9.51	9.57	3.62	090
62147	A	Repair of skull with graft	20.57	NA	NA	10.98	11.14	4.32	090
62148	A	Retr bone flap to fix skull	2.00	NA	NA	0.74	0.80	0.48	ZZZ
62160	A	Neuroendoscopy add-on	3.00	NA	NA	1.11	1.32	0.77	ZZZ
62161	A	Dissect brain w/scope	21.10	NA	NA	12.14	12.11	5.19	090
62162	A	Remove colloid cyst w/scope	26.67	NA	NA	14.63	14.73	5.91	090
62163	A	Neuroendoscopy w/fb removal	16.40	NA	NA	9.24	9.58	4.01	090
62164	A	Remove brain tumor w/scope	29.27	NA	NA	15.91	15.42	5.38	090
62165	A	Remove pituit tumor w/scope	23.10	NA	NA	11.76	12.57	3.01	090
62180	A	Establish brain cavity shunt	22.45	NA	NA	12.36	12.32	4.98	090
62190	A	Establish brain cavity shunt	12.07	NA	NA	7.36	7.22	2.80	090
62192	A	Establish brain cavity shunt	13.25	NA	NA	8.01	7.81	3.02	090
62194	A	Replace/irrigate catheter	5.68	NA	NA	3.14	2.79	0.92	010
62200	A	Establish brain cavity shunt	19.19	NA	NA	10.69	10.76	4.65	090
62201	A	Brain cavity shunt w/scope	15.89	NA	NA	10.34	9.89	3.68	090
62220	A	Establish brain cavity shunt	14.00	NA	NA	8.61	8.29	3.35	090
62223	A	Establish brain cavity shunt	13.90	NA	NA	9.35	8.79	3.14	090
62225	A	Replace/irrigate catheter	6.11	NA	NA	5.48	4.78	1.39	090
62230	A	Replace/revise brain shunt	11.35	NA	NA	7.20	6.84	2.71	090
62252	A	Csf shunt reprogram	0.74	1.77	1.62	NA	NA	0.21	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional-facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
62252	TC	A	Csf shunt reprogram	0.00	1.50	1.30	NA	NA	0.02	XXX
62252	26	A	Csf shunt reprogram	0.74	0.27	0.32	0.27	0.32	0.19	XXX
62256		A	Remove brain cavity shunt	7.30	NA	NA	5.90	5.29	1.72	090
62258		A	Replace brain cavity shunt	15.54	NA	NA	9.29	9.00	3.74	090
62263		A	Epidural lysis mult sessions	6.41	9.45	11.07	2.97	3.08	0.41	010
62264		A	Epidural lysis on single day	4.42	5.62	6.67	1.24	1.33	0.27	010
62268		A	Drain spinal cord cyst	4.73	6.69	9.11	1.80	1.97	0.43	000
62269		A	Needle biopsy, spinal cord	5.01	6.25	10.46	1.48	1.73	0.37	000
62270		A	Spinal fluid tap, diagnostic	1.37	2.39	2.69	0.57	0.57	0.08	000
62272		A	Drain cerebro spinal fluid	1.35	3.13	3.37	0.62	0.66	0.18	000
62273		A	Inject epidural patch	2.15	1.67	2.19	0.57	0.64	0.13	000
62280		A	Treat spinal cord lesion	2.63	4.62	5.77	1.15	1.08	0.30	010
62281		A	Treat spinal cord lesion	2.66	4.07	4.86	1.02	0.96	0.19	010
62282		A	Treat spinal canal lesion	2.33	4.08	6.22	1.11	1.01	0.17	010
62284		A	Injection for myelogram	1.54	3.79	4.37	0.71	0.70	0.13	000
62287		A	Percutaneous discectomy	8.88	NA	NA	4.30	4.92	0.58	090
62290		A	Inject for spine disk x-ray	3.00	4.50	5.81	1.15	1.26	0.23	000
62291		A	Inject for spine disk x-ray	2.91	4.23	5.08	1.08	1.15	0.26	000
62292		A	Injection into disk lesion	9.14	NA	NA	2.87	3.67	0.82	090
62294		A	Injection into spinal artery	12.77	NA	NA	6.49	6.03	1.24	090
62310		A	Inject spine c/t	1.91	3.00	3.90	0.56	0.60	0.12	000
62311		A	Inject spine l/s (cd)	1.54	2.66	3.79	0.52	0.56	0.09	000
62318		A	Inject spine w/cath, c/t	2.04	3.09	4.40	0.43	0.54	0.12	000
62319		A	Inject spine w/cath l/s (cd)	1.87	2.79	3.88	0.44	0.52	0.11	000
62350		A	Implant spinal canal cath	8.04	NA	NA	3.98	3.96	1.02	090
62351		A	Implant spinal canal cath	11.54	NA	NA	7.64	7.38	2.25	090
62355		A	Remove spinal canal catheter	6.60	NA	NA	3.52	3.34	0.71	090
62360		A	Insert spine infusion device	3.68	NA	NA	3.17	2.92	0.34	090
62361		A	Implant spine infusion pump	6.59	NA	NA	4.06	3.99	0.80	090
62362		A	Implant spine infusion pump	8.58	NA	NA	4.65	4.50	1.18	090
62365		A	Remove spine infusion device	6.57	NA	NA	3.71	3.64	0.86	090
62367		A	Analyze spine infusion pump	0.48	0.42	0.52	0.11	0.11	0.03	XXX
62368		A	Analyze spine infusion pump	0.75	0.58	0.63	0.17	0.17	0.06	XXX
63001		A	Removal of spinal lamina	17.51	NA	NA	9.76	9.63	3.77	090
63003		A	Removal of spinal lamina	17.64	NA	NA	9.72	9.79	3.73	090
63005		A	Removal of spinal lamina	16.28	NA	NA	9.73	9.85	3.35	090
63011		A	Removal of spinal lamina	15.78	NA	NA	9.00	8.63	3.38	090
63012		A	Removal of spinal lamina	16.72	NA	NA	9.75	9.93	3.49	090
63015		A	Removal of spinal lamina	20.70	NA	NA	11.83	11.85	4.76	090
63016		A	Removal of spinal lamina	21.90	NA	NA	11.64	11.71	4.59	090
63017		A	Removal of spinal lamina	17.18	NA	NA	10.34	10.36	3.64	090
63020		A	Neck spine disk surgery	16.05	NA	NA	9.87	9.77	3.72	090
63030		A	Low back disk surgery	13.03	NA	NA	8.59	8.50	3.01	090
63035		A	Spinal disk surgery add-on	3.15	NA	NA	1.19	1.39	0.79	ZZZ
63040		A	Laminotomy, single cervical	20.18	NA	NA	11.01	11.25	4.68	090
63042		A	Laminotomy, single lumbar	18.61	NA	NA	10.57	10.95	4.26	090
63043		C	Laminotomy, add'l cervical	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
63044		C	Laminotomy, add'l lumbar	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
63045		A	Removal of spinal lamina	17.82	NA	NA	10.33	10.34	3.99	090
63046		A	Removal of spinal lamina	17.12	NA	NA	9.78	9.98	3.56	090
63047		A	Removal of spinal lamina	15.22	NA	NA	9.32	9.61	3.24	090
63048		A	Remove spinal lamina add-on	3.47	NA	NA	1.32	1.49	0.72	ZZZ
63050		A	Cervical laminoplasty	21.88	NA	NA	11.81	11.82	4.67	090
63051		A	C-laminoplasty w/graft/plate	25.38	NA	NA	13.07	13.26	4.67	090
63055		A	Decompress spinal cord	23.42	NA	NA	12.44	12.78	5.29	090
63056		A	Decompress spinal cord	21.73	NA	NA	11.37	11.96	4.76	090
63057		A	Decompress spine cord add-on	5.25	NA	NA	1.98	2.30	1.22	ZZZ
63064		A	Decompress spinal cord	26.09	NA	NA	13.20	13.81	5.71	090
63066		A	Decompress spine cord add-on	3.26	NA	NA	1.21	1.43	0.69	ZZZ
63075		A	Neck spine disk surgery	19.47	NA	NA	11.00	11.54	4.63	090
63076		A	Neck spine disk surgery	4.04	NA	NA	1.51	1.78	0.96	ZZZ
63077		A	Spine disk surgery, thorax	22.75	NA	NA	11.06	11.92	3.99	090
63078		A	Spine disk surgery, thorax	3.28	NA	NA	1.21	1.42	0.66	ZZZ
63081		A	Removal of vertebral body	25.97	NA	NA	13.48	13.89	5.56	090
63082		A	Remove vertebral body add-on	4.36	NA	NA	1.64	1.93	1.02	ZZZ
63085		A	Removal of vertebral body	29.34	NA	NA	13.52	14.49	4.49	090
63086		A	Remove vertebral body add-on	3.19	NA	NA	1.17	1.38	0.59	ZZZ
63087		A	Removal of vertebral body	37.38	NA	NA	16.63	18.03	6.22	090
63088		A	Remove vertebral body add-on	4.32	NA	NA	1.59	1.88	0.82	ZZZ
63090		A	Removal of vertebral body	30.78	NA	NA	14.38	15.20	4.22	090
63091		A	Remove vertebral body add-on	3.03	NA	NA	1.14	1.30	0.48	ZZZ
63101		A	Removal of vertebral body	33.92	NA	NA	17.02	18.14	5.71	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
63102	A	Removal of vertebral body	33.92	NA	NA	16.81	18.04	5.71	090
63103	A	Remove vertebral body add-on	4.82	NA	NA	1.74	2.12	0.69	ZZZ
63170	A	Incise spinal cord tract(s)	22.08	NA	NA	10.43	11.14	4.87	090
63172	A	Drainage of spinal cyst	19.66	NA	NA	11.06	10.85	4.49	090
63173	A	Drainage of spinal cyst	24.18	NA	NA	13.55	13.17	5.70	090
63180	A	Revise spinal cord ligaments	20.40	NA	NA	10.93	10.95	3.96	090
63182	A	Revise spinal cord ligaments	22.69	NA	NA	7.17	9.06	5.32	090
63185	A	Incise spinal column/nerves	16.36	NA	NA	9.79	8.94	2.80	090
63190	A	Incise spinal column/nerves	18.76	NA	NA	9.59	9.86	3.25	090
63191	A	Incise spinal column/nerves	18.79	NA	NA	4.10	7.28	6.36	090
63194	A	Incise spinal column & cord	21.97	NA	NA	11.18	11.44	3.27	090
63195	A	Incise spinal column & cord	21.54	NA	NA	12.09	11.56	4.88	090
63196	A	Incise spinal column & cord	25.14	NA	NA	13.77	13.57	5.78	090
63197	A	Incise spinal column & cord	23.95	NA	NA	7.46	9.83	5.38	090
63198	A	Incise spinal column & cord	29.75	NA	NA	8.92	8.67	6.45	090
63199	A	Incise spinal column & cord	31.32	NA	NA	9.28	12.15	1.40	090
63200	A	Release of spinal cord	21.31	NA	NA	12.09	11.68	4.97	090
63250	A	Revise spinal cord vessels	43.73	NA	NA	20.89	20.40	9.04	090
63251	A	Revise spinal cord vessels	44.49	NA	NA	21.51	22.04	10.44	090
63252	A	Revise spinal cord vessels	44.48	NA	NA	20.85	21.53	10.67	090
63265	A	Excise intraspinal lesion	23.69	NA	NA	12.98	12.87	5.45	090
63266	A	Excise intraspinal lesion	24.55	NA	NA	13.16	13.16	5.56	090
63267	A	Excise intraspinal lesion	19.32	NA	NA	11.12	11.09	4.38	090
63268	A	Excise intraspinal lesion	19.89	NA	NA	11.24	10.80	3.70	090
63270	A	Excise intraspinal lesion	29.67	NA	NA	15.34	15.39	6.84	090
63271	A	Excise intraspinal lesion	29.79	NA	NA	15.30	15.43	6.92	090
63272	A	Excise intraspinal lesion	27.37	NA	NA	14.28	14.47	6.20	090
63273	A	Excise intraspinal lesion	26.34	NA	NA	14.06	14.19	5.76	090
63275	A	Biopsy/excise spinal tumor	25.73	NA	NA	13.73	13.74	5.82	090
63276	A	Biopsy/excise spinal tumor	25.56	NA	NA	13.50	13.58	5.85	090
63277	A	Biopsy/excise spinal tumor	22.26	NA	NA	12.11	12.31	5.03	090
63278	A	Biopsy/excise spinal tumor	21.99	NA	NA	11.91	12.14	4.56	090
63280	A	Biopsy/excise spinal tumor	30.14	NA	NA	15.86	16.08	7.29	090
63281	A	Biopsy/excise spinal tumor	29.84	NA	NA	15.85	16.00	7.19	090
63282	A	Biopsy/excise spinal tumor	28.00	NA	NA	14.99	15.15	6.78	090
63283	A	Biopsy/excise spinal tumor	26.61	NA	NA	14.67	14.65	6.28	090
63285	A	Biopsy/excise spinal tumor	37.90	NA	NA	18.07	19.00	9.21	090
63286	A	Biopsy/excise spinal tumor	37.47	NA	NA	18.69	19.28	9.24	090
63287	A	Biopsy/excise spinal tumor	39.93	NA	NA	19.59	20.00	9.42	090
63290	A	Biopsy/excise spinal tumor	40.67	NA	NA	19.26	19.92	9.05	090
63295	A	Repair of laminectomy defect	5.25	NA	NA	1.95	2.05	1.03	ZZZ
63300	A	Removal of vertebral body	26.67	NA	NA	13.78	14.03	5.99	090
63301	A	Removal of vertebral body	31.42	NA	NA	14.19	14.87	5.41	090
63302	A	Removal of vertebral body	31.00	NA	NA	13.77	14.80	5.55	090
63303	A	Removal of vertebral body	33.42	NA	NA	14.98	15.94	4.69	090
63304	A	Removal of vertebral body	33.70	NA	NA	17.56	17.40	6.43	090
63305	A	Removal of vertebral body	36.09	NA	NA	16.97	17.50	5.73	090
63306	A	Removal of vertebral body	35.40	NA	NA	16.63	17.20	8.35	090
63307	A	Removal of vertebral body	34.81	NA	NA	14.81	15.80	4.47	090
63308	A	Remove vertebral body add-on	5.24	NA	NA	1.95	2.27	1.29	ZZZ
63600	A	Remove spinal cord lesion	15.02	NA	NA	4.03	4.71	1.52	090
63610	A	Stimulation of spinal cord	8.72	13.93	36.79	1.49	1.87	0.86	000
63615	A	Remove lesion of spinal cord	17.22	NA	NA	8.51	8.89	2.85	090
63650	A	Implant neuroelectrodes	7.57	NA	NA	2.92	3.04	0.53	090
63655	A	Implant neuroelectrodes	11.43	NA	NA	7.62	7.25	2.44	090
63660	A	Revise/remove neuroelectrode	6.87	NA	NA	3.42	3.51	0.78	090
63685	A	Insrt/reduce spine n generator	7.87	NA	NA	3.65	3.89	1.05	090
63688	A	Revise/remove neuroreceiver	6.10	NA	NA	3.53	3.54	0.89	090
63700	A	Repair of spinal herniation	17.32	NA	NA	9.94	10.12	3.53	090
63702	A	Repair of spinal herniation	19.26	NA	NA	9.97	10.49	4.13	090
63704	A	Repair of spinal herniation	22.23	NA	NA	11.65	12.28	4.58	090
63706	A	Repair of spinal herniation	25.15	NA	NA	14.29	13.93	6.25	090
63707	A	Repair spinal fluid leakage	12.52	NA	NA	7.82	7.76	2.52	090
63709	A	Repair spinal fluid leakage	15.52	NA	NA	8.96	9.17	3.10	090
63710	A	Graft repair of spine defect	15.27	NA	NA	9.18	9.10	3.41	090
63740	A	Install spinal shunt	12.50	NA	NA	8.27	7.80	2.94	090
63741	A	Install spinal shunt	9.02	NA	NA	4.93	4.84	1.66	090
63744	A	Revision of spinal shunt	8.86	NA	NA	5.75	5.50	1.90	090
63746	A	Removal of spinal shunt	7.25	NA	NA	5.68	4.72	1.53	090
64400	A	N block inj, trigeminal	1.11	1.41	1.65	0.44	0.44	0.07	000
64402	A	N block inj, facial	1.25	1.41	1.51	0.49	0.55	0.09	000
64405	A	N block inj, occipital	1.32	1.16	1.31	0.49	0.48	0.08	000

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
64408	A	N block inj, vagus	1.41	1.45	1.51	0.71	0.78	0.10	000
64410	A	N block inj, phrenic	1.43	1.92	2.21	0.56	0.51	0.09	000
64412	A	N block inj, spinal accessor	1.18	2.13	2.39	0.58	0.51	0.08	000
64413	A	N block inj, cervical plexus	1.40	1.31	1.57	0.48	0.49	0.08	000
64415	A	N block inj, brachial plexus	1.48	1.41	2.11	0.30	0.38	0.09	000
64416	A	N block cont infuse, b plex	3.85	NA	NA	0.46	0.63	0.31	010
64417	A	N block inj, axillary	1.44	1.43	2.23	0.32	0.40	0.11	000
64418	A	N block inj, suprascapular	1.32	1.89	2.26	0.52	0.48	0.07	000
64420	A	N block inj, intercost, sng	1.18	2.40	3.14	0.44	0.43	0.08	000
64421	A	N block inj, intercost, mlt	1.68	3.55	4.81	0.53	0.52	0.11	000
64425	A	N block inj, ilio-ing/hypogi	1.75	1.29	1.47	0.53	0.53	0.13	000
64430	A	N block inj, pudendal	1.46	2.39	2.45	0.77	0.66	0.10	000
64435	A	N block inj, paracervical	1.45	1.99	2.26	0.55	0.62	0.16	000
64445	A	N block inj, sciatic, sng	1.48	1.62	2.15	0.50	0.50	0.10	000
64446	A	N blk inj, sciatic, cont inf	3.61	NA	NA	0.48	0.74	0.20	010
64447	A	N block inj fem, single	1.50	NA	NA	0.17	0.30	0.09	000
64448	A	N block inj fem, cont inf	3.36	NA	NA	0.39	0.60	0.18	010
64449	A	N block inj, lumbar plexus	3.24	NA	NA	0.42	0.69	0.15	010
64450	A	N block, other peripheral	1.27	1.27	1.25	0.49	0.48	0.13	000
64470	A	Inj paravertebral c/t	1.85	3.82	5.52	0.70	0.70	0.11	000
64472	A	Inj paravertebral c/t add-on	1.29	1.22	1.78	0.33	0.33	0.08	ZZZ
64475	A	Inj paravertebral l/s	1.41	3.64	5.26	0.58	0.60	0.10	000
64476	A	Inj paravertebral l/s add-on	0.98	1.10	1.61	0.22	0.23	0.07	ZZZ
64479	A	Inj foramen epidural c/t	2.20	3.75	5.62	0.81	0.85	0.12	000
64480	A	Inj foramen epidural add-on	1.54	1.55	2.19	0.39	0.43	0.10	ZZZ
64483	A	Inj foramen epidural l/s	1.90	3.81	5.85	0.75	0.79	0.11	000
64484	A	Inj foramen epidural add-on	1.33	1.62	2.45	0.32	0.35	0.08	ZZZ
64505	A	N block, sphenopalatine gangl	1.36	1.13	1.18	0.74	0.70	0.10	000
64508	A	N block, carotid sinus s/p	1.12	2.03	2.68	0.56	0.65	0.07	000
64510	A	N block, stellate ganglion	1.22	1.90	2.67	0.43	0.47	0.07	000
64517	A	N block inj, hypogas plxs	2.20	1.72	2.22	0.68	0.77	0.11	000
64520	A	N block, lumbar/thoracic	1.35	2.57	3.85	0.51	0.53	0.08	000
64530	A	N block inj, celiac pelus	1.58	2.79	3.62	0.65	0.65	0.10	000
64550	A	Apply neurostimulator	0.18	0.20	0.24	0.05	0.05	0.01	000
64553	A	Implant neuroelectrodes	2.33	2.64	2.74	1.44	1.65	0.18	010
64555	A	Implant neuroelectrodes	2.29	2.78	2.94	1.49	1.34	0.19	010
64560	A	Implant neuroelectrodes	2.38	2.41	2.52	1.26	1.27	0.22	010
64561	A	Implant neuroelectrodes	7.07	19.59	24.81	3.76	3.26	0.51	010
64565	A	Implant neuroelectrodes	1.78	2.47	2.87	1.29	1.27	0.13	010
64573	A	Implant neuroelectrodes	8.15	NA	NA	5.16	5.20	1.60	090
64575	A	Implant neuroelectrodes	4.37	NA	NA	2.05	2.36	0.61	090
64577	A	Implant neuroelectrodes	4.64	NA	NA	4.78	4.03	1.04	090
64580	A	Implant neuroelectrodes	4.14	NA	NA	2.70	3.13	0.36	090
64581	A	Implant neuroelectrodes	14.15	NA	NA	6.60	5.98	1.05	090
64585	A	Revise/remove neuroelectrode	2.08	5.91	8.59	2.28	2.21	0.20	010
64590	A	Insrt/redo pn/gastr stimul	2.42	6.40	6.77	2.45	2.37	0.19	010
64595	A	Revise/rmv pn/gastr stimul	1.75	6.44	8.41	2.17	2.05	0.19	010
64600	A	Injection treatment of nerve	3.46	5.42	7.38	1.63	1.64	0.34	010
64605	A	Injection treatment of nerve	5.62	7.21	8.38	2.26	2.22	0.79	010
64610	A	Injection treatment of nerve	7.17	9.17	9.01	3.43	3.57	1.58	010
64612	A	Destroy nerve, face muscle	1.98	1.58	2.03	1.33	1.32	0.11	010
64613	A	Destroy nerve, neck muscle	1.98	1.37	2.15	1.14	1.18	0.11	010
64614	A	Destroy nerve, extrem musc	2.20	1.61	2.42	1.30	1.31	0.10	010
64620	A	Injection treatment of nerve	2.86	3.30	4.18	1.11	1.22	0.20	010
64622	A	Destr paravertebr nerve l/s	3.02	4.05	5.90	1.25	1.31	0.18	010
64623	A	Destr paravertebral n add-on	0.99	1.68	2.32	0.22	0.22	0.06	ZZZ
64626	A	Destr paravertebr nerve c/t	3.82	4.74	6.25	1.87	1.92	0.20	010
64627	A	Destr paravertebral n add-on	1.16	2.37	3.45	0.25	0.26	0.07	ZZZ
64630	A	Injection treatment of nerve	3.02	2.76	2.75	1.84	1.62	0.22	010
64640	A	Injection treatment of nerve	2.78	2.42	3.30	1.42	1.63	0.29	010
64650	A	Chemodenerv eccrine glands	0.70	0.72	0.79	0.16	0.23	0.06	000
64653	A	Chemodenerv eccrine glands	0.88	0.75	0.83	0.19	0.28	0.08	000
64680	A	Injection treatment of nerve	2.64	4.25	5.48	1.20	1.31	0.18	010
64681	A	Injection treatment of nerve	3.78	4.81	7.05	1.27	1.67	0.28	010
64702	A	Revise finger/toe nerve	6.10	NA	NA	5.19	4.52	0.61	090
64704	A	Revise hand/foot nerve	4.61	NA	NA	3.28	3.29	0.61	090
64708	A	Revise arm/leg nerve	6.22	NA	NA	4.20	4.53	0.96	090
64712	A	Revision of sciatic nerve	7.98	NA	NA	4.37	4.66	0.95	090
64713	A	Revision of arm nerve(s)	11.29	NA	NA	6.04	5.96	1.83	090
64714	A	Revise low back nerve(s)	10.44	NA	NA	4.36	4.28	1.19	090
64716	A	Revision of cranial nerve	6.86	NA	NA	5.45	5.71	0.63	090
64718	A	Revise ulnar nerve at elbow	7.06	NA	NA	6.20	6.09	1.05	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fa- cility PE RVUs ²	Mal- practice RVUs ²	Global
64719	A	Revise ulnar nerve at wrist	4.89	NA	NA	4.14	4.33	0.77	090
64721	A	Carpal tunnel surgery	4.84	4.70	5.03	4.65	5.00	0.73	090
64722	A	Relieve pressure on nerve(s)	4.74	NA	NA	2.99	3.02	0.48	090
64726	A	Release foot/toe nerve	4.21	NA	NA	2.80	2.79	0.54	090
64727	A	Internal nerve revision	3.10	NA	NA	1.19	1.34	0.48	ZZZ
64732	A	Incision of brow nerve	4.81	NA	NA	3.66	3.58	0.98	090
64734	A	Incision of cheek nerve	5.45	NA	NA	4.43	4.24	0.89	090
64736	A	Incision of chin nerve	5.13	NA	NA	3.72	3.87	0.52	090
64738	A	Incision of jaw nerve	6.26	NA	NA	4.64	4.62	1.08	090
64740	A	Incision of tongue nerve	6.12	NA	NA	4.98	5.05	0.69	090
64742	A	Incision of facial nerve	6.75	NA	NA	4.28	4.49	0.73	090
64744	A	Incise nerve, back of head	5.64	NA	NA	4.04	3.90	1.16	090
64746	A	Incise diaphragm nerve	6.46	NA	NA	3.86	4.18	0.82	090
64752	A	Incision of vagus nerve	7.59	NA	NA	3.79	4.03	0.93	090
64755	A	Incision of stomach nerves	14.97	NA	NA	5.50	5.56	1.84	090
64760	A	Incision of vagus nerve	7.49	NA	NA	3.78	3.61	0.81	090
64761	A	Incision of pelvis nerve	6.94	NA	NA	4.32	3.92	0.53	090
64763	A	Incise hip/thigh nerve	7.46	NA	NA	3.91	4.55	0.94	090
64766	A	Incise hip/thigh nerve	9.34	NA	NA	4.73	4.99	1.06	090
64771	A	Sever cranial nerve	8.02	NA	NA	5.63	5.59	1.23	090
64772	A	Incision of spinal nerve	7.74	NA	NA	5.12	5.01	1.40	090
64774	A	Remove skin nerve lesion	5.70	NA	NA	4.03	3.93	0.74	090
64776	A	Remove digit nerve lesion	5.52	NA	NA	3.72	3.70	0.76	090
64778	A	Digit nerve surgery add-on	3.11	NA	NA	1.21	1.35	0.46	ZZZ
64782	A	Remove limb nerve lesion	6.76	NA	NA	4.22	3.99	0.86	090
64783	A	Limb nerve surgery add-on	3.71	NA	NA	1.36	1.60	0.51	ZZZ
64784	A	Remove nerve lesion	10.49	NA	NA	6.40	6.49	1.38	090
64786	A	Remove sciatic nerve lesion	16.12	NA	NA	8.43	9.13	2.61	090
64787	A	Implant nerve end	4.29	NA	NA	1.64	1.88	0.58	ZZZ
64788	A	Remove skin nerve lesion	5.14	NA	NA	4.05	3.76	0.73	090
64790	A	Removal of nerve lesion	11.97	NA	NA	6.97	7.08	2.11	090
64792	A	Removal of nerve lesion	15.71	NA	NA	8.29	8.56	2.49	090
64795	A	Biopsy of nerve	3.01	NA	NA	1.43	1.49	0.52	000
64802	A	Remove sympathetic nerves	10.24	NA	NA	3.50	4.31	1.29	090
64804	A	Remove sympathetic nerves	15.78	NA	NA	5.96	6.56	2.15	090
64809	A	Remove sympathetic nerves	14.61	NA	NA	7.03	6.39	1.50	090
64818	A	Remove sympathetic nerves	11.24	NA	NA	4.32	4.80	1.33	090
64820	A	Remove sympathetic nerves	10.64	NA	NA	6.93	7.02	1.49	090
64821	A	Remove sympathetic nerves	9.19	NA	NA	6.53	6.93	1.24	090
64822	A	Remove sympathetic nerves	9.19	NA	NA	6.42	6.82	1.30	090
64823	A	Remove sympathetic nerves	10.80	NA	NA	6.46	7.29	1.57	090
64831	A	Repair of digit nerve	10.23	NA	NA	6.61	6.84	1.41	090
64832	A	Repair nerve add-on	5.65	NA	NA	2.31	2.62	0.85	ZZZ
64834	A	Repair of hand or foot nerve	10.71	NA	NA	6.44	6.76	1.54	090
64835	A	Repair of hand or foot nerve	11.60	NA	NA	6.90	7.29	1.74	090
64836	A	Repair of hand or foot nerve	11.60	NA	NA	7.06	7.36	1.68	090
64837	A	Repair nerve add-on	6.25	NA	NA	2.57	2.90	0.97	ZZZ
64840	A	Repair of leg nerve	13.87	NA	NA	7.51	7.88	1.37	090
64856	A	Repair/transpose nerve	14.94	NA	NA	8.47	8.83	2.13	090
64857	A	Repair arm/leg nerve	15.69	NA	NA	8.75	9.19	2.22	090
64858	A	Repair sciatic nerve	17.69	NA	NA	9.55	10.16	3.34	090
64859	A	Nerve surgery	4.25	NA	NA	1.75	1.97	0.67	ZZZ
64861	A	Repair of arm nerves	20.74	NA	NA	10.00	10.88	4.09	090
64862	A	Repair of low back nerves	20.94	NA	NA	10.12	11.02	4.32	090
64864	A	Repair of facial nerve	13.31	NA	NA	7.46	8.11	1.26	090
64865	A	Repair of facial nerve	15.96	NA	NA	11.52	12.52	1.50	090
64866	A	Fusion of facial/other nerve	16.70	NA	NA	11.09	12.13	2.05	090
64868	A	Fusion of facial/other nerve	14.80	NA	NA	9.78	10.60	1.43	090
64870	A	Fusion of facial/other nerve	16.95	NA	NA	8.05	8.39	1.30	090
64872	A	Subsequent repair of nerve	1.99	NA	NA	0.78	0.93	0.29	ZZZ
64874	A	Repair & revise nerve add-on	2.98	NA	NA	1.26	1.39	0.42	ZZZ
64876	A	Repair nerve/shorten bone	3.37	NA	NA	1.42	1.58	0.47	ZZZ
64885	A	Nerve graft, head or neck	17.50	NA	NA	8.94	10.26	1.63	090
64886	A	Nerve graft, head or neck	20.72	NA	NA	10.36	11.95	2.09	090
64890	A	Nerve graft, hand or foot	16.11	NA	NA	8.97	9.48	2.30	090
64891	A	Nerve graft, hand or foot	17.22	NA	NA	9.65	8.61	1.63	090
64892	A	Nerve graft, arm or leg	15.61	NA	NA	9.12	8.99	2.48	090
64893	A	Nerve graft, arm or leg	16.74	NA	NA	9.62	9.74	2.62	090
64895	A	Nerve graft, hand or foot	20.26	NA	NA	11.03	10.34	2.58	090
64896	A	Nerve graft, hand or foot	21.81	NA	NA	11.65	11.31	3.17	090
64897	A	Nerve graft, arm or leg	19.25	NA	NA	10.49	10.58	2.55	090
64898	A	Nerve graft, arm or leg	20.82	NA	NA	11.45	11.61	2.78	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
64901	A	Nerve graft add-on	10.20	NA	NA	3.62	4.44	1.37	ZZZ
64902	A	Nerve graft add-on	11.81	NA	NA	4.65	5.31	1.55	ZZZ
64905	A	Nerve pedicle transfer	14.98	NA	NA	6.99	7.74	2.01	090
64907	A	Nerve pedicle transfer	19.90	NA	NA	6.35	9.43	3.17	090
64910	A	Nerve repair w/allograft	11.21	NA	NA	4.66	4.66	1.74	090
64911	A	Neurography w/vein autograft	14.21	NA	NA	5.31	5.31	1.91	090
64999	C	Nervous system surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
65091	A	Revise eye	7.13	NA	NA	6.72	7.53	0.32	090
65093	A	Revise eye with implant	6.93	NA	NA	6.78	7.75	0.34	090
65101	A	Removal of eye	8.10	NA	NA	7.95	8.74	0.35	090
65103	A	Remove eye/insert implant	8.64	NA	NA	8.11	8.92	0.37	090
65105	A	Remove eye/attach implant	9.70	NA	NA	8.76	9.61	0.42	090
65110	A	Removal of eye	15.42	NA	NA	11.41	12.54	0.81	090
65112	A	Remove eye/revise socket	18.18	NA	NA	13.29	14.71	1.30	090
65114	A	Remove eye/revise socket	19.32	NA	NA	13.55	14.94	1.02	090
65125	A	Revise ocular implant	3.18	6.70	7.75	3.16	3.38	0.19	090
65130	A	Insert ocular implant	8.22	NA	NA	7.67	8.41	0.35	090
65135	A	Insert ocular implant	8.40	NA	NA	7.73	8.52	0.36	090
65140	A	Attach ocular implant	9.23	NA	NA	8.37	9.12	0.40	090
65150	A	Revise ocular implant	6.32	NA	NA	6.29	7.12	0.31	090
65155	A	Reinsert ocular implant	9.87	NA	NA	8.76	9.62	0.50	090
65175	A	Removal of ocular implant	7.22	NA	NA	7.04	7.75	0.31	090
65205	A	Remove foreign body from eye	0.71	0.57	0.60	0.32	0.30	0.03	000
65210	A	Remove foreign body from eye	0.84	0.71	0.76	0.39	0.38	0.04	000
65220	A	Remove foreign body from eye	0.71	0.59	0.62	0.28	0.28	0.05	000
65222	A	Remove foreign body from eye	0.93	0.78	0.83	0.41	0.39	0.04	000
65235	A	Remove foreign body from eye	8.78	NA	NA	6.77	6.76	0.37	090
65260	A	Remove foreign body from eye	12.29	NA	NA	8.73	9.19	0.57	090
65265	A	Remove foreign body from eye	14.06	NA	NA	9.58	10.10	0.62	090
65270	A	Repair of eye wound	1.92	3.82	4.52	1.20	1.29	0.09	010
65272	A	Repair of eye wound	4.49	6.29	7.00	3.15	3.22	0.19	090
65273	A	Repair of eye wound	5.03	NA	NA	3.36	3.47	0.22	090
65275	A	Repair of eye wound	6.14	6.29	6.30	3.89	3.92	0.26	090
65280	A	Repair of eye wound	8.87	NA	NA	5.83	6.03	0.38	090
65285	A	Repair of eye wound	14.43	NA	NA	8.38	8.79	0.64	090
65286	A	Repair of eye wound	6.45	8.69	9.91	4.38	4.49	0.27	090
65290	A	Repair of eye socket wound	6.35	NA	NA	4.43	4.58	0.31	090
65400	A	Removal of eye lesion	7.27	7.43	7.88	5.83	5.98	0.30	090
65410	A	Biopsy of cornea	1.47	1.66	1.89	0.86	0.91	0.07	000
65420	A	Removal of eye lesion	4.24	6.84	7.85	3.95	4.19	0.21	090
65426	A	Removal of eye lesion	5.93	8.08	9.12	4.49	4.70	0.25	090
65430	A	Corneal smear	1.47	1.08	1.18	0.86	0.92	0.07	000
65435	A	Curette/treat cornea	0.92	0.85	0.93	0.64	0.68	0.04	000
65436	A	Curette/treat cornea	4.72	3.75	3.92	3.43	3.55	0.21	090
65450	A	Treatment of corneal lesion	3.35	3.67	3.87	3.59	3.76	0.16	090
65600	A	Revision of cornea	4.07	4.42	4.71	3.38	3.36	0.17	090
65710	A	Corneal transplant	14.09	NA	NA	10.13	10.66	0.61	090
65730	A	Corneal transplant	15.99	NA	NA	10.94	11.48	0.70	090
65750	A	Corneal transplant	16.60	NA	NA	10.60	11.28	0.74	090
65755	A	Corneal transplant	16.49	NA	NA	10.56	11.22	0.73	090
65760	N	Revision of cornea	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65765	N	Revision of cornea	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65767	N	Corneal tissue transplant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65770	A	Revise cornea with implant	19.41	NA	NA	11.64	12.42	0.87	090
65771	N	Radial keratotomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65772	A	Correction of astigmatism	4.96	4.84	5.18	3.91	4.02	0.21	090
65775	A	Correction of astigmatism	6.73	NA	NA	5.29	5.62	0.28	090
65780	A	Ocular reconst, transplant	10.43	NA	NA	8.91	9.60	0.44	090
65781	A	Ocular reconst, transplant	17.84	NA	NA	11.56	12.61	0.44	090
65782	A	Ocular reconst, transplant	15.16	NA	NA	10.17	11.08	0.44	090
65800	A	Drainage of eye	1.91	1.39	1.59	1.02	1.10	0.09	000
65805	A	Drainage of eye	1.91	1.69	1.93	1.02	1.10	0.09	000
65810	A	Drainage of eye	5.67	NA	NA	4.66	4.68	0.24	090
65815	A	Drainage of eye	5.85	7.90	8.95	4.57	4.69	0.25	090
65820	A	Relieve inner eye pressure	8.72	NA	NA	7.49	8.27	0.40	090
65850	A	Incision of eye	11.24	NA	NA	7.31	7.87	0.52	090
65855	A	Laser surgery of eye	3.90	3.48	3.89	2.62	2.86	0.19	010
65860	A	Incise inner eye adhesions	3.56	3.25	3.64	2.07	2.29	0.18	090
65865	A	Incise inner eye adhesions	5.66	NA	NA	4.68	5.15	0.28	090
65870	A	Incise inner eye adhesions	7.21	NA	NA	5.69	6.05	0.31	090
65875	A	Incise inner eye adhesions	7.61	NA	NA	6.12	6.45	0.32	090
65880	A	Incise inner eye adhesions	8.16	NA	NA	6.29	6.66	0.35	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
65900	A	Remove eye lesion	12.26	NA	NA	8.88	9.56	0.54	090
65920	A	Remove implant of eye	9.74	NA	NA	7.45	7.81	0.41	090
65930	A	Remove blood clot from eye	8.24	NA	NA	5.76	6.30	0.37	090
66020	A	Injection treatment of eye	1.61	2.42	2.77	1.27	1.35	0.08	010
66030	A	Injection treatment of eye	1.27	2.29	2.63	1.15	1.21	0.06	010
66130	A	Remove eye lesion	7.74	7.50	8.56	4.86	5.23	0.38	090
66150	A	Glaucoma surgery	10.18	NA	NA	8.80	9.10	0.46	090
66155	A	Glaucoma surgery	10.17	NA	NA	8.80	9.07	0.41	090
66160	A	Glaucoma surgery	12.04	NA	NA	9.46	9.82	0.50	090
66165	A	Glaucoma surgery	9.89	NA	NA	8.76	9.00	0.40	090
66170	A	Glaucoma surgery	14.57	NA	NA	11.52	11.87	0.60	090
66172	A	Incision of eye	18.26	NA	NA	14.61	14.90	0.74	090
66180	A	Implant eye shunt	16.02	NA	NA	9.68	10.21	0.71	090
66185	A	Revise eye shunt	9.35	NA	NA	7.03	7.20	0.40	090
66220	A	Repair eye lesion	8.98	NA	NA	7.16	7.13	0.40	090
66225	A	Repair/graft eye lesion	12.38	NA	NA	8.10	8.42	0.55	090
66250	A	Follow-up surgery of eye	6.92	9.22	10.45	5.24	5.36	0.30	090
66500	A	Incision of iris	3.75	NA	NA	3.94	4.29	0.18	090
66505	A	Incision of iris	4.13	NA	NA	4.30	4.64	0.20	090
66600	A	Remove iris and lesion	9.89	NA	NA	8.24	8.23	0.43	090
66605	A	Removal of iris	13.99	NA	NA	9.44	9.73	0.77	090
66625	A	Removal of iris	5.19	NA	NA	4.20	4.46	0.26	090
66630	A	Removal of iris	7.10	NA	NA	5.33	5.52	0.31	090
66635	A	Removal of iris	7.19	NA	NA	5.36	5.55	0.31	090
66680	A	Repair iris & ciliary body	6.24	NA	NA	5.05	5.16	0.27	090
66682	A	Repair iris & ciliary body	7.15	NA	NA	6.70	6.65	0.31	090
66700	A	Destruction, ciliary body	5.06	4.77	5.01	3.58	3.76	0.24	090
66710	A	Ciliary transsleral therapy	5.06	4.59	4.88	3.59	3.72	0.23	090
66711	A	Ciliary endoscopic ablation	7.70	NA	NA	6.28	6.37	0.30	090
66720	A	Destruction, ciliary body	4.86	5.36	5.58	4.31	4.51	0.26	090
66740	A	Destruction, ciliary body	5.06	4.52	4.80	3.60	3.78	0.23	090
66761	A	Revision of iris	4.87	5.01	5.30	4.18	4.24	0.20	090
66762	A	Revision of iris	5.25	5.09	5.37	4.06	4.17	0.23	090
66770	A	Removal of inner eye lesion	5.98	5.52	5.80	4.58	4.69	0.26	090
66820	A	Incision, secondary cataract	3.93	NA	NA	4.61	5.21	0.19	090
66821	A	After cataract laser surgery	3.32	3.82	3.95	3.41	3.51	0.11	090
66825	A	Reposition intraocular lens	8.82	NA	NA	7.76	8.41	0.40	090
66830	A	Removal of lens lesion	9.27	NA	NA	6.36	6.65	0.36	090
66840	A	Removal of lens material	8.98	NA	NA	6.28	6.57	0.39	090
66850	A	Removal of lens material	10.32	NA	NA	7.06	7.35	0.45	090
66852	A	Removal of lens material	11.18	NA	NA	7.38	7.73	0.49	090
66920	A	Extraction of lens	9.93	NA	NA	6.63	6.96	0.44	090
66930	A	Extraction of lens	11.38	NA	NA	7.44	7.79	0.49	090
66940	A	Extraction of lens	10.14	NA	NA	6.99	7.29	0.43	090
66982	A	Cataract surgery, complex	14.83	NA	NA	8.94	9.40	0.63	090
66983	A	Cataract surg w/iol, 1 stage	10.20	NA	NA	6.50	6.31	0.14	090
66984	A	Cataract surg w/iol, 1 stage	10.36	NA	NA	6.44	6.93	0.39	090
66985	A	Insert lens prosthesis	9.73	NA	NA	7.12	7.28	0.36	090
66986	A	Exchange lens prosthesis	12.26	NA	NA	8.04	8.61	0.60	090
66990	A	Ophthalmic endoscope add-on	1.51	NA	NA	0.54	0.61	0.07	ZZZ
66999	C	Eye surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67005	A	Partial removal of eye fluid	5.77	NA	NA	4.57	4.71	0.28	090
67010	A	Partial removal of eye fluid	6.94	NA	NA	4.99	5.20	0.34	090
67015	A	Release of eye fluid	7.00	NA	NA	5.69	6.07	0.34	090
67025	A	Replace eye fluid	7.91	7.85	8.53	5.91	6.06	0.34	090
67027	A	Implant eye drug system	11.43	NA	NA	7.36	7.67	0.54	090
67028	A	Injection eye drug	2.52	2.15	2.42	1.24	1.35	0.12	000
67030	A	Incise inner eye strands	5.91	NA	NA	5.59	5.72	0.24	090
67031	A	Laser surgery, eye strands	4.34	4.09	4.34	3.42	3.53	0.18	090
67036	A	Removal of inner eye fluid	13.09	NA	NA	8.05	8.58	0.58	090
67039	A	Laser treatment of retina	16.39	NA	NA	10.68	11.43	0.71	090
67040	A	Laser treatment of retina	19.23	NA	NA	11.98	12.83	0.85	090
67041	A	Vit for macular pucker	19.00	NA	NA	10.36	10.36	0.86	090
67042	A	Vit for macular hole	22.13	NA	NA	11.48	11.48	1.00	090
67043	A	Vit for membrane dissect	22.94	NA	NA	12.34	12.34	1.04	090
67101	A	Repair detached retina	8.60	8.48	8.80	6.16	6.34	0.37	090
67105	A	Repair detached retina	8.35	7.40	7.74	5.78	5.96	0.37	090
67107	A	Repair detached retina	16.35	NA	NA	10.33	10.81	0.73	090
67108	A	Repair detached retina	22.49	NA	NA	12.92	13.66	1.02	090
67110	A	Repair detached retina	10.02	8.91	9.57	6.95	7.17	0.44	090
67112	A	Rerepair detached retina	18.45	NA	NA	10.84	11.32	0.83	090
67113	A	Repair retinal detach, cplx	22.49	NA	NA	12.75	12.75	1.13	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
67115	A	Release encircling material	5.93	NA	NA	4.92	5.00	0.25	090
67120	A	Remove eye implant material	6.92	7.34	7.96	5.27	5.40	0.29	090
67121	A	Remove eye implant material	12.00	NA	NA	7.94	8.23	0.53	090
67141	A	Treatment of retina	6.00	5.40	5.63	4.65	4.75	0.26	090
67145	A	Treatment of retina	6.17	5.33	5.53	4.70	4.81	0.27	090
67208	A	Treatment of retinal lesion	7.50	5.64	5.88	5.19	5.35	0.33	090
67210	A	Treatment of retinal lesion	9.35	5.91	6.24	5.43	5.65	0.44	090
67218	A	Treatment of retinal lesion	20.22	NA	NA	10.60	11.37	0.92	090
67220	A	Treatment of choroid lesion	14.19	9.20	9.81	8.15	8.58	0.65	090
67221	R	Ocular photodynamic ther	3.45	2.91	3.62	1.38	1.59	0.20	000
67225	A	Eye photodynamic ther add-on	0.47	0.22	0.24	0.17	0.19	0.02	ZZZ
67227	A	Treatment of retinal lesion	7.38	5.99	6.28	5.15	5.34	0.33	090
67228	A	Treatment of retinal lesion	13.67	13.58	12.52	10.18	9.36	0.63	090
67229	A	Tr retinal les preterm inf	16.00	NA	NA	9.51	9.51	0.71	090
67250	A	Reinforce eye wall	9.46	NA	NA	7.66	8.41	0.47	090
67255	A	Reinforce/graft eye wall	9.97	NA	NA	8.42	9.15	0.44	090
67299	C	Eye surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67311	A	Revise eye muscle	7.59	NA	NA	5.49	5.76	0.37	090
67312	A	Revise two eye muscles	9.48	NA	NA	6.19	6.47	0.43	090
67314	A	Revise eye muscle	8.59	NA	NA	6.15	6.35	0.39	090
67316	A	Revise two eye muscles	10.73	NA	NA	6.91	7.20	0.49	090
67318	A	Revise eye muscle(s)	8.92	NA	NA	6.50	6.71	0.41	090
67320	A	Revise eye muscle(s) add-on	5.40	NA	NA	1.92	1.94	0.22	ZZZ
67331	A	Eye surgery follow-up add-on	5.13	NA	NA	1.81	1.82	0.21	ZZZ
67332	A	Rerevise eye muscles add-on	5.56	NA	NA	1.97	2.00	0.23	ZZZ
67334	A	Revise eye muscle w/suture	5.05	NA	NA	1.80	1.80	0.20	ZZZ
67335	A	Eye suture during surgery	2.49	NA	NA	0.88	1.00	0.13	ZZZ
67340	A	Revise eye muscle add-on	6.00	NA	NA	2.13	2.17	0.25	ZZZ
67343	A	Release eye tissue	8.29	NA	NA	6.06	6.28	0.37	090
67345	A	Destroy nerve of eye muscle	2.98	2.17	2.38	1.69	1.85	0.17	010
67346	A	Biopsy, eye muscle	2.87	NA	NA	1.62	1.75	0.15	000
67399	C	Eye muscle surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67400	A	Explore/biopsy eye socket	10.97	NA	NA	9.41	10.33	0.56	090
67405	A	Explore/drain eye socket	9.00	NA	NA	8.33	9.05	0.44	090
67412	A	Explore/treat eye socket	10.17	NA	NA	8.52	9.72	0.48	090
67413	A	Explore/treat eye socket	10.09	NA	NA	8.69	9.73	0.50	090
67414	A	Explr/decompress eye socket	17.78	NA	NA	11.62	11.83	0.65	090
67415	A	Aspiration, orbital contents	1.76	NA	NA	0.62	0.69	0.09	000
67420	A	Explore/treat eye socket	21.62	NA	NA	14.22	15.80	1.15	090
67430	A	Explore/treat eye socket	14.99	NA	NA	11.86	13.37	0.86	090
67440	A	Explore/drain eye socket	14.56	NA	NA	11.86	13.06	0.70	090
67445	A	Explr/decompress eye socket	18.96	NA	NA	12.13	13.02	0.90	090
67450	A	Explore/biopsy eye socket	15.11	NA	NA	12.29	13.48	0.68	090
67500	A	Inject/treat eye socket	1.44	0.57	0.62	0.44	0.37	0.05	000
67505	A	Inject/treat eye socket	1.27	0.65	0.67	0.50	0.41	0.05	000
67515	A	Inject/treat eye socket	1.40	0.77	0.68	0.61	0.49	0.03	000
67550	A	Insert eye socket implant	11.52	NA	NA	9.81	10.55	0.72	090
67560	A	Revise eye socket implant	11.93	NA	NA	9.77	10.57	0.60	090
67570	A	Decompress optic nerve	14.21	NA	NA	11.00	12.28	0.68	090
67599	C	Orbit surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67700	A	Drainage of eyelid abscess	1.37	4.30	5.16	1.17	1.22	0.07	010
67710	A	Incision of eyelid	1.04	3.70	4.53	1.07	1.14	0.05	010
67715	A	Incision of eyelid fold	1.24	3.83	4.60	1.15	1.22	0.06	010
67800	A	Remove eyelid lesion	1.39	1.39	1.50	0.90	0.97	0.07	010
67801	A	Remove eyelid lesions	1.89	1.67	1.82	1.07	1.17	0.09	010
67805	A	Remove eyelid lesions	2.24	2.18	2.35	1.40	1.52	0.11	010
67808	A	Remove eyelid lesion(s)	4.47	NA	NA	3.60	3.69	0.19	090
67810	A	Biopsy of eyelid	1.48	3.93	3.63	0.68	0.68	0.06	000
67820	A	Revise eyelashes	0.71	0.43	0.52	0.50	0.53	0.04	000
67825	A	Revise eyelashes	1.40	1.40	1.57	1.26	1.33	0.07	010
67830	A	Revise eyelashes	1.72	3.99	4.76	1.32	1.41	0.08	010
67835	A	Revise eyelashes	5.61	NA	NA	4.12	4.37	0.28	090
67840	A	Remove eyelid lesion	2.06	3.90	4.69	1.45	1.55	0.10	010
67850	A	Treat eyelid lesion	1.71	3.28	3.33	1.44	1.45	0.07	010
67875	A	Closure of eyelid by suture	1.35	2.38	2.84	0.83	0.88	0.07	000
67880	A	Revision of eyelid	4.47	5.43	6.02	3.56	3.68	0.19	090
67882	A	Revision of eyelid	5.87	6.35	6.99	4.45	4.63	0.25	090
67900	A	Repair brow defect	6.69	7.36	8.21	4.60	4.93	0.38	090
67901	A	Repair eyelid defect	7.47	8.98	7.19	5.28	5.34	0.54	090
67902	A	Repair eyelid defect	9.68	NA	NA	6.33	5.90	0.60	090
67903	A	Repair eyelid defect	6.42	6.62	8.09	4.33	4.92	0.47	090
67904	A	Repair eyelid defect	7.83	8.16	8.89	5.37	5.30	0.41	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
67906	A	Repair eyelid defect	6.84	NA	NA	4.46	4.74	0.46	090
67908	A	Repair eyelid defect	5.19	5.55	6.09	4.12	4.73	0.28	090
67909	A	Revise eyelid defect	5.46	6.17	7.10	4.16	4.55	0.31	090
67911	A	Revise eyelid defect	7.38	NA	NA	5.04	4.91	0.31	090
67912	A	Correction eyelid w/implant	6.23	13.12	16.02	4.73	5.13	0.28	090
67914	A	Repair eyelid defect	3.70	4.74	5.54	2.67	2.86	0.19	090
67915	A	Repair eyelid defect	3.21	4.31	5.15	2.43	2.61	0.16	090
67916	A	Repair eyelid defect	5.37	6.36	7.20	4.14	4.45	0.28	090
67917	A	Repair eyelid defect	6.08	6.72	7.58	4.40	4.73	0.36	090
67921	A	Repair eyelid defect	3.42	4.61	5.40	2.55	2.72	0.17	090
67922	A	Repair eyelid defect	3.09	4.15	5.03	2.33	2.54	0.15	090
67923	A	Repair eyelid defect	5.94	6.43	7.27	4.32	4.64	0.30	090
67924	A	Repair eyelid defect	5.84	6.90	7.91	4.05	4.36	0.30	090
67930	A	Repair eyelid wound	3.62	4.36	5.04	1.78	1.97	0.19	010
67935	A	Repair eyelid wound	6.27	6.76	7.63	3.58	3.99	0.39	090
67938	A	Remove eyelid foreign body	1.35	3.83	4.60	1.22	1.24	0.06	010
67950	A	Revision of eyelid	5.88	6.65	7.64	4.37	4.79	0.36	090
67961	A	Revision of eyelid	5.75	6.81	7.74	4.30	4.66	0.33	090
67966	A	Revision of eyelid	8.83	8.04	8.58	5.74	5.65	0.37	090
67971	A	Reconstruction of eyelid	9.87	NA	NA	6.17	6.72	0.53	090
67973	A	Reconstruction of eyelid	12.96	NA	NA	7.70	8.51	0.75	090
67974	A	Reconstruction of eyelid	12.93	NA	NA	7.68	8.45	0.75	090
67975	A	Reconstruction of eyelid	9.21	NA	NA	5.94	6.44	0.50	090
67999	C	Revision of eyelid	0.00	0.00	0.00	0.00	0.00	0.00	YYY
68020	A	Incise/drain eyelid lining	1.39	1.23	1.32	1.05	1.13	0.06	010
68040	A	Treatment of eyelid lesions	0.85	0.60	0.65	0.35	0.39	0.04	000
68100	A	Biopsy of eyelid lining	1.35	2.36	2.80	0.86	0.90	0.07	000
68110	A	Remove eyelid lining lesion	1.79	3.07	3.58	1.48	1.56	0.09	010
68115	A	Remove eyelid lining lesion	2.38	4.32	5.14	1.69	1.80	0.12	010
68130	A	Remove eyelid lining lesion	4.99	6.63	7.67	4.02	4.31	0.24	090
68135	A	Remove eyelid lining lesion	1.86	1.58	1.70	1.47	1.56	0.09	010
68200	A	Treat eyelid by injection	0.49	0.45	0.49	0.29	0.31	0.02	000
68320	A	Revise/graft eyelid lining	6.44	9.15	10.21	5.30	5.41	0.27	090
68325	A	Revise/graft eyelid lining	8.43	NA	NA	6.09	6.32	0.44	090
68326	A	Revise/graft eyelid lining	8.22	NA	NA	5.91	6.16	0.35	090
68328	A	Revise/graft eyelid lining	9.25	NA	NA	6.37	6.83	0.54	090
68330	A	Revise eyelid lining	5.63	7.40	8.41	4.44	4.58	0.24	090
68335	A	Revise/graft eyelid lining	8.26	NA	NA	5.91	6.14	0.36	090
68340	A	Separate eyelid adhesions	4.84	6.87	7.87	3.86	3.98	0.21	090
68360	A	Revise eyelid lining	5.04	6.43	7.23	3.95	4.06	0.22	090
68362	A	Revise eyelid lining	8.41	NA	NA	5.97	6.18	0.36	090
68371	A	Harvest eye tissue, alograft	4.97	NA	NA	4.05	4.39	0.44	010
68399	C	Eyelid lining surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
68400	A	Incise/drain tear gland	1.71	4.42	5.16	1.21	1.52	0.08	010
68420	A	Incise/drain tear sac	2.32	4.58	5.39	1.41	1.76	0.11	010
68440	A	Incise tear duct opening	0.96	1.25	1.67	1.18	1.22	0.05	010
68500	A	Removal of tear gland	12.49	NA	NA	9.51	9.62	0.55	090
68505	A	Partial removal, tear gland	12.41	NA	NA	8.90	9.77	0.55	090
68510	A	Biopsy of tear gland	4.60	5.21	6.27	2.02	2.06	0.23	000
68520	A	Removal of tear sac	8.58	NA	NA	6.49	6.95	0.37	090
68525	A	Biopsy of tear sac	4.42	NA	NA	1.56	1.79	0.22	000
68530	A	Clearance of tear duct	3.67	5.59	6.88	2.07	2.36	0.18	010
68540	A	Remove tear gland lesion	11.93	NA	NA	8.48	8.93	0.52	090
68550	A	Remove tear gland lesion	14.86	NA	NA	9.66	10.50	0.80	090
68700	A	Repair tear ducts	7.67	NA	NA	5.55	5.77	0.32	090
68705	A	Revise tear duct opening	2.08	3.03	3.60	1.58	1.69	0.10	010
68720	A	Create tear sac drain	9.78	NA	NA	6.87	7.36	0.44	090
68745	A	Create tear duct drain	9.70	NA	NA	6.97	7.41	0.52	090
68750	A	Create tear duct drain	9.87	NA	NA	7.42	7.84	0.43	090
68760	A	Close tear duct opening	1.75	2.58	3.06	1.45	1.54	0.09	010
68761	A	Close tear duct opening	1.38	1.83	2.05	1.25	1.28	0.06	010
68770	A	Close tear system fistula	8.09	NA	NA	5.74	4.46	0.35	090
68801	A	Dilate tear duct opening	0.96	1.77	1.86	1.41	1.44	0.05	010
68810	A	Probe nasolacrimal duct	2.63	3.39	3.52	2.68	2.67	0.10	010
68811	A	Probe nasolacrimal duct	2.39	NA	NA	2.12	2.27	0.13	010
68815	A	Probe nasolacrimal duct	3.24	6.41	7.32	2.43	2.62	0.17	010
68816	A	Probe nl duct w/balloon	3.00	12.73	12.73	2.51	2.51	0.16	010
68840	A	Explore/irrigate tear ducts	1.27	1.51	1.55	1.28	1.20	0.06	010
68850	A	Injection for tear sac x-ray	0.80	0.72	0.80	0.60	0.64	0.04	000
68899	C	Tear duct system surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69000	A	Drain external ear lesion	1.47	2.88	2.88	1.34	1.35	0.12	010
69005	A	Drain external ear lesion	2.13	2.99	2.96	1.61	1.72	0.17	010

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
69020	A	Drain outer ear canal lesion	1.50	4.09	4.04	1.90	1.98	0.12	010
69090	N	Pierce earlobes	0.00	0.00	0.00	0.00	0.00	0.00	XXX
69100	A	Biopsy of external ear	0.81	1.85	1.78	0.39	0.39	0.03	000
69105	A	Biopsy of external ear canal	0.85	2.64	2.49	0.71	0.74	0.07	000
69110	A	Remove external ear, partial	3.47	7.83	7.29	4.44	4.45	0.30	090
69120	A	Removal of external ear	4.08	NA	NA	5.36	5.77	0.38	090
69140	A	Remove ear canal lesion(s)	8.03	NA	NA	13.21	13.24	0.65	090
69145	A	Remove ear canal lesion(s)	2.65	7.03	6.40	3.37	3.33	0.21	090
69150	A	Extensive ear canal surgery	13.49	NA	NA	11.45	12.42	1.22	090
69155	A	Extensive ear/neck surgery	23.06	NA	NA	16.98	18.25	1.93	090
69200	A	Clear outer ear canal	0.77	2.15	2.27	0.61	0.58	0.06	000
69205	A	Clear outer ear canal	1.20	NA	NA	1.24	1.30	0.10	010
69210	A	Remove impacted ear wax	0.61	0.58	0.60	0.17	0.20	0.05	000
69220	A	Clean out mastoid cavity	0.83	2.56	2.46	0.68	0.70	0.07	000
69222	A	Clean out mastoid cavity	1.42	3.97	3.91	1.90	1.98	0.12	010
69300	R	Revise external ear	6.69	10.71	7.46	5.18	4.70	0.72	YYY
69310	A	Rebuild outer ear canal	10.85	NA	NA	15.48	15.88	0.85	090
69320	A	Rebuild outer ear canal	17.03	NA	NA	20.05	20.94	1.37	090
69399	C	Outer ear surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69400	A	Inflate middle ear canal	0.83	2.81	2.49	0.68	0.67	0.07	000
69401	A	Inflate middle ear canal	0.63	1.53	1.38	0.59	0.62	0.05	000
69405	A	Catheterize middle ear canal	2.65	3.65	3.58	1.96	2.14	0.21	010
69420	A	Incision of eardrum	1.35	3.32	3.23	1.56	1.57	0.11	010
69421	A	Incision of eardrum	1.75	NA	NA	1.85	2.01	0.15	010
69424	A	Remove ventilating tube	0.85	2.34	2.26	0.68	0.68	0.07	000
69433	A	Create eardrum opening	1.54	3.32	3.20	1.59	1.61	0.13	010
69436	A	Create eardrum opening	1.98	NA	NA	1.90	2.09	0.19	010
69440	A	Exploration of middle ear	7.62	NA	NA	9.11	8.94	0.61	090
69450	A	Eardrum revision	5.61	NA	NA	7.61	7.32	0.45	090
69501	A	Mastoidectomy	9.12	NA	NA	8.65	8.82	0.73	090
69502	A	Mastoidectomy	12.44	NA	NA	11.04	11.31	1.00	090
69505	A	Remove mastoid structures	13.05	NA	NA	16.14	16.66	1.05	090
69511	A	Extensive mastoid surgery	13.58	NA	NA	16.32	16.89	1.09	090
69530	A	Extensive mastoid surgery	20.24	NA	NA	19.65	20.63	1.54	090
69535	A	Remove part of temporal bone	37.27	NA	NA	26.75	29.34	2.93	090
69540	A	Remove ear lesion	1.22	3.90	3.82	1.85	1.91	0.10	010
69550	A	Remove ear lesion	11.04	NA	NA	14.27	14.56	0.89	090
69552	A	Remove ear lesion	19.69	NA	NA	18.18	19.42	1.59	090
69554	A	Remove ear lesion	35.71	NA	NA	23.98	27.15	2.92	090
69601	A	Mastoid surgery revision	13.31	NA	NA	11.91	12.29	1.07	090
69602	A	Mastoid surgery revision	13.64	NA	NA	12.80	13.01	1.10	090
69603	A	Mastoid surgery revision	14.08	NA	NA	16.43	17.39	1.14	090
69604	A	Mastoid surgery revision	14.08	NA	NA	12.77	13.23	1.14	090
69605	A	Mastoid surgery revision	18.55	NA	NA	19.28	20.11	1.50	090
69610	A	Repair of eardrum	4.44	4.91	5.23	2.58	2.93	0.36	010
69620	A	Repair of eardrum	5.94	10.90	11.01	5.83	6.06	0.48	090
69631	A	Repair eardrum structures	9.93	NA	NA	11.52	11.36	0.80	090
69632	A	Rebuild eardrum structures	12.82	NA	NA	13.30	13.38	1.03	090
69633	A	Rebuild eardrum structures	12.17	NA	NA	13.08	13.06	0.98	090
69635	A	Repair eardrum structures	13.39	NA	NA	16.28	16.51	1.08	090
69636	A	Rebuild eardrum structures	15.29	NA	NA	18.19	18.74	1.23	090
69637	A	Rebuild eardrum structures	15.18	NA	NA	18.10	18.66	1.22	090
69641	A	Revise middle ear & mastoid	12.77	NA	NA	12.47	12.62	1.03	090
69642	A	Revise middle ear & mastoid	16.91	NA	NA	15.52	15.90	1.36	090
69643	A	Revise middle ear & mastoid	15.45	NA	NA	14.15	14.48	1.24	090
69644	A	Revise middle ear & mastoid	17.09	NA	NA	18.72	19.56	1.37	090
69645	A	Revise middle ear & mastoid	16.57	NA	NA	18.58	19.30	1.33	090
69646	A	Revise middle ear & mastoid	18.23	NA	NA	19.10	19.92	1.46	090
69650	A	Release middle ear bone	9.71	NA	NA	9.53	9.72	0.78	090
69660	A	Revise middle ear bone	11.94	NA	NA	10.49	10.83	0.96	090
69661	A	Revise middle ear bone	15.80	NA	NA	13.46	14.07	1.27	090
69662	A	Revise middle ear bone	15.49	NA	NA	12.50	13.12	1.25	090
69666	A	Repair middle ear structures	9.80	NA	NA	9.80	9.88	0.79	090
69667	A	Repair middle ear structures	9.81	NA	NA	9.83	9.90	0.79	090
69670	A	Remove mastoid air cells	11.62	NA	NA	11.24	11.47	0.93	090
69676	A	Remove middle ear nerve	9.58	NA	NA	10.60	10.67	0.81	090
69700	A	Close mastoid fistula	8.28	NA	NA	8.67	8.96	0.67	090
69710	N	Implant/replace hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
69711	A	Remove/repair hearing aid	10.50	NA	NA	10.40	10.59	0.83	090
69714	A	Implant temple bone w/stimul	14.31	NA	NA	11.78	12.22	1.13	090
69715	A	Temple bone implnt w/stimulat	18.80	NA	NA	13.32	14.17	1.48	090
69717	A	Temple bone implant revision	15.29	NA	NA	11.95	13.21	0.90	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
69718	A	Revise temple bone implant	19.05	NA	NA	13.40	14.35	3.22	090
69720	A	Release facial nerve	14.57	NA	NA	14.01	14.26	1.16	090
69725	A	Release facial nerve	27.44	NA	NA	18.01	19.07	2.45	090
69740	A	Repair facial nerve	16.18	NA	NA	11.58	12.49	1.27	090
69745	A	Repair facial nerve	16.91	NA	NA	9.93	12.44	1.14	090
69799	C	Middle ear surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69801	A	Incise inner ear	8.61	NA	NA	9.61	9.54	0.69	090
69802	A	Incise inner ear	13.39	NA	NA	11.86	12.09	1.06	090
69805	A	Explore inner ear	14.55	NA	NA	10.89	11.38	1.12	090
69806	A	Explore inner ear	12.52	NA	NA	10.39	10.71	1.00	090
69820	A	Establish inner ear window	10.40	NA	NA	10.24	10.73	0.90	090
69840	A	Revise inner ear window	10.32	NA	NA	11.37	12.27	0.79	090
69905	A	Remove inner ear	11.15	NA	NA	11.03	11.19	0.90	090
69910	A	Remove inner ear & mastoid	13.80	NA	NA	10.88	11.39	1.07	090
69915	A	Incise inner ear nerve	22.65	NA	NA	14.81	15.63	1.70	090
69930	A	Implant cochlear device	17.60	NA	NA	13.10	13.92	1.36	090
69949	C	Inner ear surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69950	A	Incise inner ear nerve	27.44	NA	NA	16.84	17.86	2.29	090
69955	A	Release facial nerve	29.22	NA	NA	19.38	20.37	2.49	090
69960	A	Release inner ear canal	29.22	NA	NA	17.90	18.97	2.18	090
69970	A	Remove inner ear lesion	32.21	NA	NA	19.51	21.39	2.42	090
69979	C	Temporal bone surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69990	R	Microsurgery add-on	3.46	NA	NA	1.27	1.53	0.89	ZZZ
70010	A	Contrast x-ray of brain	1.19	2.82	3.76	NA	NA	0.27	XXX
70010	TC	A	Contrast x-ray of brain	0.00	2.40	3.36	NA	NA	0.22	XXX
70010	26	A	Contrast x-ray of brain	1.19	0.42	0.40	0.42	0.40	0.05	XXX
70015	A	Contrast x-ray of brain	1.19	2.92	2.33	NA	NA	0.16	XXX
70015	TC	A	Contrast x-ray of brain	0.00	2.49	1.92	NA	NA	0.08	XXX
70015	26	A	Contrast x-ray of brain	1.19	0.43	0.41	0.43	0.41	0.08	XXX
70030	A	X-ray eye for foreign body	0.17	0.61	0.54	NA	NA	0.03	XXX
70030	TC	A	X-ray eye for foreign body	0.00	0.55	0.48	NA	NA	0.02	XXX
70030	26	A	X-ray eye for foreign body	0.17	0.06	0.06	0.06	0.06	0.01	XXX
70100	A	X-ray exam of jaw	0.18	0.63	0.61	NA	NA	0.03	XXX
70100	TC	A	X-ray exam of jaw	0.00	0.58	0.55	NA	NA	0.02	XXX
70100	26	A	X-ray exam of jaw	0.18	0.05	0.06	0.05	0.06	0.01	XXX
70110	A	X-ray exam of jaw	0.25	0.81	0.75	NA	NA	0.05	XXX
70110	TC	A	X-ray exam of jaw	0.00	0.72	0.67	NA	NA	0.04	XXX
70110	26	A	X-ray exam of jaw	0.25	0.09	0.08	0.09	0.08	0.01	XXX
70120	A	X-ray exam of mastoids	0.18	0.69	0.69	NA	NA	0.05	XXX
70120	TC	A	X-ray exam of mastoids	0.00	0.64	0.63	NA	NA	0.04	XXX
70120	26	A	X-ray exam of mastoids	0.18	0.05	0.06	0.05	0.06	0.01	XXX
70130	A	X-ray exam of mastoids	0.34	1.15	1.02	NA	NA	0.07	XXX
70130	TC	A	X-ray exam of mastoids	0.00	1.04	0.91	NA	NA	0.05	XXX
70130	26	A	X-ray exam of mastoids	0.34	0.11	0.11	0.11	0.11	0.02	XXX
70134	A	X-ray exam of middle ear	0.34	0.92	0.87	NA	NA	0.07	XXX
70134	TC	A	X-ray exam of middle ear	0.00	0.80	0.76	NA	NA	0.05	XXX
70134	26	A	X-ray exam of middle ear	0.34	0.12	0.11	0.12	0.11	0.02	XXX
70140	A	X-ray exam of facial bones	0.19	0.54	0.62	NA	NA	0.05	XXX
70140	TC	A	X-ray exam of facial bones	0.00	0.49	0.56	NA	NA	0.04	XXX
70140	26	A	X-ray exam of facial bones	0.19	0.05	0.06	0.05	0.06	0.01	XXX
70150	A	X-ray exam of facial bones	0.26	0.85	0.85	NA	NA	0.06	XXX
70150	TC	A	X-ray exam of facial bones	0.00	0.77	0.77	NA	NA	0.05	XXX
70150	26	A	X-ray exam of facial bones	0.26	0.08	0.08	0.08	0.08	0.01	XXX
70160	A	X-ray exam of nasal bones	0.17	0.71	0.64	NA	NA	0.03	XXX
70160	TC	A	X-ray exam of nasal bones	0.00	0.65	0.58	NA	NA	0.02	XXX
70160	26	A	X-ray exam of nasal bones	0.17	0.06	0.06	0.06	0.06	0.01	XXX
70170	C	X-ray exam of tear duct	0.00	0.00	0.00	NA	NA	0.00	XXX
70170	TC	C	X-ray exam of tear duct	0.00	0.00	0.00	NA	NA	0.00	XXX
70170	26	A	X-ray exam of tear duct	0.30	0.10	0.10	0.10	0.10	0.01	XXX
70190	A	X-ray exam of eye sockets	0.21	0.72	0.70	NA	NA	0.05	XXX
70190	TC	A	X-ray exam of eye sockets	0.00	0.65	0.63	NA	NA	0.04	XXX
70190	26	A	X-ray exam of eye sockets	0.21	0.07	0.07	0.07	0.07	0.01	XXX
70200	A	X-ray exam of eye sockets	0.28	0.87	0.87	NA	NA	0.06	XXX
70200	TC	A	X-ray exam of eye sockets	0.00	0.78	0.78	NA	NA	0.05	XXX
70200	26	A	X-ray exam of eye sockets	0.28	0.09	0.09	0.09	0.09	0.01	XXX
70210	A	X-ray exam of sinuses	0.17	0.58	0.62	NA	NA	0.05	XXX
70210	TC	A	X-ray exam of sinuses	0.00	0.53	0.57	NA	NA	0.04	XXX
70210	26	A	X-ray exam of sinuses	0.17	0.05	0.05	0.05	0.05	0.01	XXX
70220	A	X-ray exam of sinuses	0.25	0.73	0.80	NA	NA	0.06	XXX
70220	TC	A	X-ray exam of sinuses	0.00	0.65	0.72	NA	NA	0.05	XXX
70220	26	A	X-ray exam of sinuses	0.25	0.08	0.08	0.08	0.08	0.01	XXX
70240	A	X-ray exam, pituitary saddle	0.19	0.61	0.54	NA	NA	0.03	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
70240	TC	A	X-ray exam, pituitary saddle	0.00	0.55	0.48	NA	NA	0.02	XXX
70240	26	A	X-ray exam, pituitary saddle	0.19	0.06	0.06	0.06	0.06	0.01	XXX
70250		A	X-ray exam of skull	0.24	0.70	0.69	NA	NA	0.05	XXX
70250	TC	A	X-ray exam of skull	0.00	0.63	0.62	NA	NA	0.04	XXX
70250	26	A	X-ray exam of skull	0.24	0.07	0.07	0.07	0.07	0.01	XXX
70260		A	X-ray exam of skull	0.34	0.88	0.94	NA	NA	0.08	XXX
70260	TC	A	X-ray exam of skull	0.00	0.78	0.83	NA	NA	0.06	XXX
70260	26	A	X-ray exam of skull	0.34	0.10	0.11	0.10	0.11	0.02	XXX
70300		A	X-ray exam of teeth	0.10	0.24	0.27	NA	NA	0.03	XXX
70300	TC	A	X-ray exam of teeth	0.00	0.21	0.23	NA	NA	0.02	XXX
70300	26	A	X-ray exam of teeth	0.10	0.03	0.04	0.03	0.04	0.01	XXX
70310		A	X-ray exam of teeth	0.16	0.82	0.65	NA	NA	0.03	XXX
70310	TC	A	X-ray exam of teeth	0.00	0.77	0.59	NA	NA	0.02	XXX
70310	26	A	X-ray exam of teeth	0.16	0.05	0.06	0.05	0.06	0.01	XXX
70320		A	Full mouth x-ray of teeth	0.22	1.06	0.96	NA	NA	0.06	XXX
70320	TC	A	Full mouth x-ray of teeth	0.00	0.99	0.89	NA	NA	0.05	XXX
70320	26	A	Full mouth x-ray of teeth	0.22	0.07	0.07	0.07	0.07	0.01	XXX
70328		A	X-ray exam of jaw joint	0.18	0.63	0.59	NA	NA	0.03	XXX
70328	TC	A	X-ray exam of jaw joint	0.00	0.57	0.53	NA	NA	0.02	XXX
70328	26	A	X-ray exam of jaw joint	0.18	0.06	0.06	0.06	0.06	0.01	XXX
70330		A	X-ray exam of jaw joints	0.24	1.01	0.96	NA	NA	0.06	XXX
70330	TC	A	X-ray exam of jaw joints	0.00	0.93	0.88	NA	NA	0.05	XXX
70330	26	A	X-ray exam of jaw joints	0.24	0.08	0.08	0.08	0.08	0.01	XXX
70332		A	X-ray exam of jaw joint	0.54	1.45	1.88	NA	NA	0.14	XXX
70332	TC	A	X-ray exam of jaw joint	0.00	1.29	1.70	NA	NA	0.12	XXX
70332	26	A	X-ray exam of jaw joint	0.54	0.16	0.16	0.16	0.18	0.02	XXX
70336		A	Magnetic image, jaw joint	1.48	12.15	11.91	NA	NA	0.66	XXX
70336	TC	A	Magnetic image, jaw joint	0.00	11.65	11.42	NA	NA	0.59	XXX
70336	26	A	Magnetic image, jaw joint	1.48	0.50	0.49	0.50	0.49	0.07	XXX
70350		A	X-ray head for orthodontia	0.17	0.32	0.39	NA	NA	0.03	XXX
70350	TC	A	X-ray head for orthodontia	0.00	0.27	0.33	NA	NA	0.02	XXX
70350	26	A	X-ray head for orthodontia	0.17	0.05	0.06	0.05	0.06	0.01	XXX
70355		A	Panoramic x-ray of jaws	0.20	0.30	0.47	NA	NA	0.05	XXX
70355	TC	A	Panoramic x-ray of jaws	0.00	0.23	0.40	NA	NA	0.04	XXX
70355	26	A	Panoramic x-ray of jaws	0.20	0.07	0.07	0.07	0.07	0.01	XXX
70360		A	X-ray exam of neck	0.17	0.56	0.52	NA	NA	0.03	XXX
70360	TC	A	X-ray exam of neck	0.00	0.51	0.46	NA	NA	0.02	XXX
70360	26	A	X-ray exam of neck	0.17	0.05	0.06	0.05	0.06	0.01	XXX
70370		A	Throat x-ray & fluoroscopy	0.32	1.65	1.53	NA	NA	0.08	XXX
70370	TC	A	Throat x-ray & fluoroscopy	0.00	1.55	1.43	NA	NA	0.07	XXX
70370	26	A	Throat x-ray & fluoroscopy	0.32	0.10	0.10	0.10	0.10	0.01	XXX
70371		A	Speech evaluation, complex	0.84	1.47	1.93	NA	NA	0.16	XXX
70371	TC	A	Speech evaluation, complex	0.00	1.21	1.66	NA	NA	0.12	XXX
70371	26	A	Speech evaluation, complex	0.84	0.26	0.27	0.26	0.27	0.04	XXX
70373		A	Contrast x-ray of larynx	0.44	1.58	1.75	NA	NA	0.13	XXX
70373	TC	A	Contrast x-ray of larynx	0.00	1.47	1.62	NA	NA	0.11	XXX
70373	26	A	Contrast x-ray of larynx	0.44	0.11	0.13	0.11	0.13	0.02	XXX
70380		A	X-ray exam of salivary gland	0.17	0.82	0.78	NA	NA	0.05	XXX
70380	TC	A	X-ray exam of salivary gland	0.00	0.76	0.72	NA	NA	0.04	XXX
70380	26	A	X-ray exam of salivary gland	0.17	0.06	0.06	0.06	0.06	0.01	XXX
70390		A	X-ray exam of salivary duct	0.38	2.33	2.12	NA	NA	0.13	XXX
70390	TC	A	X-ray exam of salivary duct	0.00	2.20	1.99	NA	NA	0.11	XXX
70390	26	A	X-ray exam of salivary duct	0.38	0.13	0.13	0.13	0.13	0.02	XXX
70450		A	Ct head/brain w/o dye	0.85	4.91	4.95	NA	NA	0.29	XXX
70450	TC	A	Ct head/brain w/o dye	0.00	4.61	4.66	NA	NA	0.25	XXX
70450	26	A	Ct head/brain w/o dye	0.85	0.30	0.29	0.30	0.29	0.04	XXX
70460		A	Ct head/brain w/dye	1.13	6.51	6.27	NA	NA	0.35	XXX
70460	TC	A	Ct head/brain w/dye	0.00	6.11	5.88	NA	NA	0.30	XXX
70460	26	A	Ct head/brain w/dye	1.13	0.40	0.39	0.40	0.39	0.05	XXX
70470		A	Ct head/brain w/o & w/dye	1.27	7.93	7.70	NA	NA	0.43	XXX
70470	TC	A	Ct head/brain w/o & w/dye	0.00	7.48	7.27	NA	NA	0.37	XXX
70470	26	A	Ct head/brain w/o & w/dye	1.27	0.45	0.43	0.45	0.43	0.06	XXX
70480		A	Ct orbit/ear/fossa w/o dye	1.28	8.48	6.80	NA	NA	0.31	XXX
70480	TC	A	Ct orbit/ear/fossa w/o dye	0.00	8.03	6.37	NA	NA	0.25	XXX
70480	26	A	Ct orbit/ear/fossa w/o dye	1.28	0.45	0.43	0.45	0.43	0.06	XXX
70481		A	Ct orbit/ear/fossa w/dye	1.38	9.97	8.04	NA	NA	0.36	XXX
70481	TC	A	Ct orbit/ear/fossa w/dye	0.00	9.48	7.57	NA	NA	0.30	XXX
70481	26	A	Ct orbit/ear/fossa w/dye	1.38	0.49	0.47	0.49	0.47	0.06	XXX
70482		A	Ct orbit/ear/fossa w/o&w/dye	1.45	11.40	9.47	NA	NA	0.43	XXX
70482	TC	A	Ct orbit/ear/fossa w/o&w/dye	0.00	10.89	8.98	NA	NA	0.37	XXX
70482	26	A	Ct orbit/ear/fossa w/o&w/dye	1.45	0.51	0.49	0.51	0.49	0.06	XXX
70486		A	Ct maxillofacial w/o dye	1.14	6.78	5.93	NA	NA	0.30	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
70486	TC	A	Ct maxillofacial w/o dye	0.00	6.39	5.55	NA	NA	0.25	XXX
70486	26	A	Ct maxillofacial w/o dye	1.14	0.39	0.38	0.39	0.38	0.05	XXX
70487		A	Ct maxillofacial w/dye	1.30	8.34	7.21	NA	NA	0.36	XXX
70487	TC	A	Ct maxillofacial w/dye	0.00	7.88	6.77	NA	NA	0.30	XXX
70487	26	A	Ct maxillofacial w/dye	1.30	0.46	0.44	0.46	0.44	0.06	XXX
70488		A	Ct maxillofacial w/o & w/dye	1.42	10.39	8.96	NA	NA	0.43	XXX
70488	TC	A	Ct maxillofacial w/o & w/dye	0.00	9.90	8.48	NA	NA	0.37	XXX
70488	26	A	Ct maxillofacial w/o & w/dye	1.42	0.49	0.48	0.49	0.48	0.06	XXX
70490		A	Ct soft tissue neck w/o dye	1.28	6.48	5.81	NA	NA	0.31	XXX
70490	TC	A	Ct soft tissue neck w/o dye	0.00	6.03	5.37	NA	NA	0.25	XXX
70490	26	A	Ct soft tissue neck w/o dye	1.28	0.45	0.44	0.45	0.44	0.06	XXX
70491		A	Ct soft tissue neck w/dye	1.38	8.03	7.07	NA	NA	0.36	XXX
70491	TC	A	Ct soft tissue neck w/dye	0.00	7.54	6.60	NA	NA	0.30	XXX
70491	26	A	Ct soft tissue neck w/dye	1.38	0.49	0.47	0.49	0.47	0.06	XXX
70492		A	Ct sft tsue nck w/o & w/dye	1.45	10.03	8.78	NA	NA	0.43	XXX
70492	TC	A	Ct sft tsue nck w/o & w/dye	0.00	9.52	8.29	NA	NA	0.37	XXX
70492	26	A	Ct sft tsue nck w/o & w/dye	1.45	0.51	0.49	0.51	0.49	0.06	XXX
70496		A	Ct angiography, head	1.75	17.08	14.12	NA	NA	0.66	XXX
70496	TC	A	Ct angiography, head	0.00	16.45	13.52	NA	NA	0.58	XXX
70496	26	A	Ct angiography, head	1.75	0.63	0.60	0.63	0.60	0.08	XXX
70498		A	Ct angiography, neck	1.75	17.22	14.19	NA	NA	0.66	XXX
70498	TC	A	Ct angiography, neck	0.00	16.57	13.58	NA	NA	0.58	XXX
70498	26	A	Ct angiography, neck	1.75	0.65	0.61	0.65	0.61	0.08	XXX
70540		A	Mri orbit/face/neck w/o dye	1.35	14.16	12.90	NA	NA	0.45	XXX
70540	TC	A	Mri orbit/face/neck w/o dye	0.00	13.70	12.45	NA	NA	0.39	XXX
70540	26	A	Mri orbit/face/neck w/o dye	1.35	0.46	0.45	0.46	0.45	0.06	XXX
70542		A	Mri orbit/face/neck w/dye	1.62	15.28	14.61	NA	NA	0.54	XXX
70542	TC	A	Mri orbit/face/neck w/dye	0.00	14.72	14.07	NA	NA	0.47	XXX
70542	26	A	Mri orbit/face/neck w/dye	1.62	0.56	0.54	0.56	0.54	0.07	XXX
70543		A	Mri orb/fac/nck w/o & w/dye	2.15	18.75	22.16	NA	NA	0.94	XXX
70543	TC	A	Mri orb/fac/nck w/o & w/dye	0.00	18.01	21.44	NA	NA	0.84	XXX
70543	26	A	Mri orb/fac/nck w/o & w/dye	2.15	0.74	0.72	0.74	0.72	0.10	XXX
70544		A	Mr angiography head w/o dye	1.20	15.84	13.72	NA	NA	0.64	XXX
70544	TC	A	Mr angiography head w/o dye	0.00	15.42	13.31	NA	NA	0.59	XXX
70544	26	A	Mr angiography head w/o dye	1.20	0.42	0.41	0.42	0.41	0.05	XXX
70545		A	Mr angiography head w/dye	1.20	15.73	13.65	NA	NA	0.64	XXX
70545	TC	A	Mr angiography head w/dye	0.00	15.31	13.25	NA	NA	0.59	XXX
70545	26	A	Mr angiography head w/dye	1.20	0.42	0.40	0.42	0.40	0.05	XXX
70546		A	Mr angiograph head w/o&w/dye	1.80	24.00	23.50	NA	NA	0.67	XXX
70546	TC	A	Mr angiograph head w/o&w/dye	0.00	23.38	22.89	NA	NA	0.59	XXX
70546	26	A	Mr angiograph head w/o&w/dye	1.80	0.62	0.61	0.62	0.61	0.08	XXX
70547		A	Mr angiography neck w/o dye	1.20	15.77	13.68	NA	NA	0.64	XXX
70547	TC	A	Mr angiography neck w/o dye	0.00	15.36	13.28	NA	NA	0.59	XXX
70547	26	A	Mr angiography neck w/o dye	1.20	0.41	0.40	0.41	0.40	0.05	XXX
70548		A	Mr angiography neck w/dye	1.20	16.63	14.11	NA	NA	0.64	XXX
70548	TC	A	Mr angiography neck w/dye	0.00	16.21	13.70	NA	NA	0.59	XXX
70548	26	A	Mr angiography neck w/dye	1.20	0.42	0.41	0.42	0.41	0.05	XXX
70549		A	Mr angiograph neck w/o&w/dye	1.80	24.02	23.50	NA	NA	0.67	XXX
70549	TC	A	Mr angiograph neck w/o&w/dye	0.00	23.39	22.89	NA	NA	0.59	XXX
70549	26	A	Mr angiograph neck w/o&w/dye	1.80	0.63	0.61	0.63	0.61	0.08	XXX
70551		A	Mri brain w/o dye	1.48	14.42	13.05	NA	NA	0.66	XXX
70551	TC	A	Mri brain w/o dye	0.00	13.91	12.55	NA	NA	0.59	XXX
70551	26	A	Mri brain w/o dye	1.48	0.51	0.50	0.51	0.50	0.07	XXX
70552		A	Mri brain w/dye	1.78	15.58	14.79	NA	NA	0.78	XXX
70552	TC	A	Mri brain w/dye	0.00	14.96	14.19	NA	NA	0.70	XXX
70552	26	A	Mri brain w/dye	1.78	0.62	0.60	0.62	0.60	0.08	XXX
70553		A	Mri brain w/o & w/dye	2.36	18.06	21.86	NA	NA	1.41	XXX
70553	TC	A	Mri brain w/o & w/dye	0.00	17.24	21.06	NA	NA	1.31	XXX
70553	26	A	Mri brain w/o & w/dye	2.36	0.82	0.80	0.82	0.80	0.10	XXX
70554		A	Fmri brain by tech	2.11	15.40	15.40	NA	NA	0.92	XXX
70554	TC	A	Fmri brain by tech	0.00	14.71	14.71	NA	NA	0.82	XXX
70554	26	A	Fmri brain by tech	2.11	0.69	0.69	0.69	0.69	0.10	XXX
70555		C	Fmri brain by phys/psych	0.00	0.00	0.00	NA	NA	0.00	XXX
70555	TC	C	Fmri brain by phys/psych	0.00	0.00	0.00	NA	NA	0.00	XXX
70555	26	A	Fmri brain by phys/psych	2.54	0.90	0.90	0.90	0.90	0.11	XXX
70557		C	Mri brain w/o dye	0.00	0.00	0.00	NA	NA	0.00	XXX
70557	TC	C	Mri brain w/o dye	0.00	0.00	0.00	NA	NA	0.00	XXX
70557	26	A	Mri brain w/o dye	2.90	1.03	1.08	1.03	1.08	0.08	XXX
70558		C	Mri brain w/dye	0.00	0.00	0.00	NA	NA	0.00	XXX
70558	TC	C	Mri brain w/dye	0.00	0.00	0.00	NA	NA	0.00	XXX
70558	26	A	Mri brain w/dye	3.20	1.09	1.16	1.09	1.16	0.10	XXX
70559		C	Mri brain w/o & w/dye	0.00	0.00	0.00	NA	NA	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
70559	TC	C	Mri brain w/o & w/dye	0.00	0.00	0.00	NA	NA	0.00	XXX
70559	26	A	Mri brain w/o & w/dye	3.20	1.14	1.19	1.14	1.19	0.12	XXX
71010		A	Chest x-ray	0.18	0.43	0.48	NA	NA	0.03	XXX
71010	TC	A	Chest x-ray	0.00	0.37	0.42	NA	NA	0.02	XXX
71010	26	A	Chest x-ray	0.18	0.06	0.06	0.06	0.06	0.01	XXX
71015		A	Chest x-ray	0.21	0.58	0.58	NA	NA	0.03	XXX
71015	TC	A	Chest x-ray	0.00	0.51	0.51	NA	NA	0.02	XXX
71015	26	A	Chest x-ray	0.21	0.07	0.07	0.07	0.07	0.01	XXX
71020		A	Chest x-ray	0.22	0.57	0.63	NA	NA	0.05	XXX
71020	TC	A	Chest x-ray	0.00	0.50	0.56	NA	NA	0.04	XXX
71020	26	A	Chest x-ray	0.22	0.07	0.07	0.07	0.07	0.01	XXX
71021		A	Chest x-ray	0.27	0.71	0.76	NA	NA	0.06	XXX
71021	TC	A	Chest x-ray	0.00	0.62	0.67	NA	NA	0.05	XXX
71021	26	A	Chest x-ray	0.27	0.09	0.09	0.09	0.09	0.01	XXX
71022		A	Chest x-ray	0.31	0.90	0.86	NA	NA	0.06	XXX
71022	TC	A	Chest x-ray	0.00	0.80	0.76	NA	NA	0.05	XXX
71022	26	A	Chest x-ray	0.31	0.10	0.10	0.10	0.10	0.01	XXX
71023		A	Chest x-ray and fluoroscopy	0.38	1.54	1.23	NA	NA	0.06	XXX
71023	TC	A	Chest x-ray and fluoroscopy	0.00	1.40	1.09	NA	NA	0.05	XXX
71023	26	A	Chest x-ray and fluoroscopy	0.38	0.14	0.14	0.14	0.14	0.01	XXX
71030		A	Chest x-ray	0.31	0.92	0.90	NA	NA	0.06	XXX
71030	TC	A	Chest x-ray	0.00	0.82	0.80	NA	NA	0.05	XXX
71030	26	A	Chest x-ray	0.31	0.10	0.10	0.10	0.10	0.01	XXX
71034		A	Chest x-ray and fluoroscopy	0.46	2.11	1.85	NA	NA	0.10	XXX
71034	TC	A	Chest x-ray and fluoroscopy	0.00	1.90	1.67	NA	NA	0.08	XXX
71034	26	A	Chest x-ray and fluoroscopy	0.46	0.21	0.18	0.21	0.18	0.02	XXX
71035		A	Chest x-ray	0.18	0.78	0.68	NA	NA	0.03	XXX
71035	TC	A	Chest x-ray	0.00	0.72	0.62	NA	NA	0.02	XXX
71035	26	A	Chest x-ray	0.18	0.06	0.06	0.06	0.06	0.01	XXX
71040		A	Contrast x-ray of bronchi	0.58	2.06	1.85	NA	NA	0.11	XXX
71040	TC	A	Contrast x-ray of bronchi	0.00	1.88	1.67	NA	NA	0.08	XXX
71040	26	A	Contrast x-ray of bronchi	0.58	0.18	0.18	0.18	0.18	0.03	XXX
71060		A	Contrast x-ray of bronchi	0.74	3.11	2.77	NA	NA	0.16	XXX
71060	TC	A	Contrast x-ray of bronchi	0.00	2.85	2.52	NA	NA	0.13	XXX
71060	26	A	Contrast x-ray of bronchi	0.74	0.26	0.25	0.26	0.25	0.03	XXX
71090		C	X-ray & pacemaker insertion	0.00	0.00	0.00	NA	NA	0.00	XXX
71090	TC	C	X-ray & pacemaker insertion	0.00	0.00	0.00	NA	NA	0.00	XXX
71090	26	A	X-ray & pacemaker insertion	0.54	0.28	0.24	0.28	0.24	0.02	XXX
71100		A	X-ray exam of ribs	0.22	0.62	0.63	NA	NA	0.05	XXX
71100	TC	A	X-ray exam of ribs	0.00	0.55	0.56	NA	NA	0.04	XXX
71100	26	A	X-ray exam of ribs	0.22	0.07	0.07	0.07	0.07	0.01	XXX
71101		A	X-ray exam of ribs/chest	0.27	0.77	0.76	NA	NA	0.05	XXX
71101	TC	A	X-ray exam of ribs/chest	0.00	0.68	0.67	NA	NA	0.04	XXX
71101	26	A	X-ray exam of ribs/chest	0.27	0.09	0.09	0.09	0.09	0.01	XXX
71110		A	X-ray exam of ribs	0.27	0.77	0.82	NA	NA	0.06	XXX
71110	TC	A	X-ray exam of ribs	0.00	0.69	0.73	NA	NA	0.05	XXX
71110	26	A	X-ray exam of ribs	0.27	0.08	0.09	0.08	0.09	0.01	XXX
71111		A	X-ray exam of ribs/chest	0.32	1.06	1.02	NA	NA	0.07	XXX
71111	TC	A	X-ray exam of ribs/chest	0.00	0.96	0.92	NA	NA	0.06	XXX
71111	26	A	X-ray exam of ribs/chest	0.32	0.10	0.10	0.10	0.10	0.01	XXX
71120		A	X-ray exam of breastbone	0.20	0.63	0.67	NA	NA	0.05	XXX
71120	TC	A	X-ray exam of breastbone	0.00	0.56	0.60	NA	NA	0.04	XXX
71120	26	A	X-ray exam of breastbone	0.20	0.07	0.07	0.07	0.07	0.01	XXX
71130		A	X-ray exam of breastbone	0.22	0.76	0.76	NA	NA	0.05	XXX
71130	TC	A	X-ray exam of breastbone	0.00	0.68	0.69	NA	NA	0.04	XXX
71130	26	A	X-ray exam of breastbone	0.22	0.08	0.07	0.08	0.07	0.01	XXX
71250		A	Ct thorax w/o dye	1.16	6.45	6.36	NA	NA	0.36	XXX
71250	TC	A	Ct thorax w/o dye	0.00	6.04	5.97	NA	NA	0.31	XXX
71250	26	A	Ct thorax w/o dye	1.16	0.41	0.39	0.41	0.39	0.05	XXX
71260		A	Ct thorax w/dye	1.24	7.99	7.73	NA	NA	0.42	XXX
71260	TC	A	Ct thorax w/dye	0.00	7.55	7.31	NA	NA	0.37	XXX
71260	26	A	Ct thorax w/dye	1.24	0.44	0.42	0.44	0.42	0.05	XXX
71270		A	Ct thorax w/o & w/dye	1.38	10.03	9.67	NA	NA	0.52	XXX
71270	TC	A	Ct thorax w/o & w/dye	0.00	9.55	9.20	NA	NA	0.46	XXX
71270	26	A	Ct thorax w/o & w/dye	1.38	0.48	0.47	0.48	0.47	0.06	XXX
71275		A	Ct angiography, chest	1.92	11.75	12.38	NA	NA	0.48	XXX
71275	TC	A	Ct angiography, chest	0.00	11.06	11.72	NA	NA	0.39	XXX
71275	26	A	Ct angiography, chest	1.92	0.69	0.66	0.69	0.66	0.09	XXX
71550		A	Mri chest w/o dye	1.46	16.35	14.01	NA	NA	0.51	XXX
71550	TC	A	Mri chest w/o dye	0.00	15.85	13.52	NA	NA	0.45	XXX
71550	26	A	Mri chest w/o dye	1.46	0.50	0.49	0.50	0.49	0.06	XXX
71551		A	Mri chest w/dye	1.73	17.92	15.96	NA	NA	0.60	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
71551	TC	A	Mri chest w/dye	0.00	17.32	15.38	NA	NA	0.52	XXX
71551	26	A	Mri chest w/dye	1.73	0.60	0.58	0.60	0.58	0.08	XXX
71552		A	Mri chest w/o & w/dye	2.26	22.55	24.08	NA	NA	0.78	XXX
71552	TC	A	Mri chest w/o & w/dye	0.00	21.75	23.31	NA	NA	0.68	XXX
71552	26	A	Mri chest w/o & w/dye	2.26	0.80	0.77	0.80	0.77	0.10	XXX
71555		R	Mri angio chest w or w/o dye	1.81	15.30	13.54	NA	NA	0.67	XXX
71555	TC	R	Mri angio chest w or w/o dye	0.00	14.64	12.91	NA	NA	0.59	XXX
71555	26	R	Mri angio chest w or w/o dye	1.81	0.66	0.63	0.66	0.63	0.08	XXX
72010		A	X-ray exam of spine	0.45	1.43	1.30	NA	NA	0.08	XXX
72010	TC	A	X-ray exam of spine	0.00	1.30	1.16	NA	NA	0.06	XXX
72010	26	A	X-ray exam of spine	0.45	0.13	0.14	0.13	0.14	0.02	XXX
72020		A	X-ray exam of spine	0.15	0.47	0.47	NA	NA	0.03	XXX
72020	TC	A	X-ray exam of spine	0.00	0.42	0.42	NA	NA	0.02	XXX
72020	26	A	X-ray exam of spine	0.15	0.05	0.05	0.05	0.05	0.01	XXX
72040		A	X-ray exam of neck spine	0.22	0.76	0.72	NA	NA	0.05	XXX
72040	TC	A	X-ray exam of neck spine	0.00	0.69	0.65	NA	NA	0.04	XXX
72040	26	A	X-ray exam of neck spine	0.22	0.07	0.07	0.07	0.07	0.01	XXX
72050		A	X-ray exam of neck spine	0.31	1.08	1.03	NA	NA	0.07	XXX
72050	TC	A	X-ray exam of neck spine	0.00	0.97	0.93	NA	NA	0.06	XXX
72050	26	A	X-ray exam of neck spine	0.31	0.11	0.10	0.11	0.10	0.01	XXX
72052		A	X-ray exam of neck spine	0.36	1.39	1.32	NA	NA	0.08	XXX
72052	TC	A	X-ray exam of neck spine	0.00	1.27	1.20	NA	NA	0.06	XXX
72052	26	A	X-ray exam of neck spine	0.36	0.12	0.12	0.12	0.12	0.02	XXX
72069		A	X-ray exam of trunk spine	0.22	0.76	0.66	NA	NA	0.03	XXX
72069	TC	A	X-ray exam of trunk spine	0.00	0.68	0.58	NA	NA	0.02	XXX
72069	26	A	X-ray exam of trunk spine	0.22	0.08	0.08	0.08	0.08	0.01	XXX
72070		A	X-ray exam of thoracic spine	0.22	0.64	0.68	NA	NA	0.05	XXX
72070	TC	A	X-ray exam of thoracic spine	0.00	0.57	0.61	NA	NA	0.04	XXX
72070	26	A	X-ray exam of thoracic spine	0.22	0.07	0.07	0.07	0.07	0.01	XXX
72072		A	X-ray exam of thoracic spine	0.22	0.77	0.78	NA	NA	0.06	XXX
72072	TC	A	X-ray exam of thoracic spine	0.00	0.70	0.71	NA	NA	0.05	XXX
72072	26	A	X-ray exam of thoracic spine	0.22	0.07	0.07	0.07	0.07	0.01	XXX
72074		A	X-ray exam of thoracic spine	0.22	0.94	0.96	NA	NA	0.07	XXX
72074	TC	A	X-ray exam of thoracic spine	0.00	0.87	0.89	NA	NA	0.06	XXX
72074	26	A	X-ray exam of thoracic spine	0.22	0.07	0.07	0.07	0.07	0.01	XXX
72080		A	X-ray exam of trunk spine	0.22	0.70	0.71	NA	NA	0.05	XXX
72080	TC	A	X-ray exam of trunk spine	0.00	0.62	0.64	NA	NA	0.04	XXX
72080	26	A	X-ray exam of trunk spine	0.22	0.08	0.07	0.08	0.07	0.01	XXX
72090		A	X-ray exam of trunk spine	0.28	1.00	0.88	NA	NA	0.05	XXX
72090	TC	A	X-ray exam of trunk spine	0.00	0.90	0.78	NA	NA	0.04	XXX
72090	26	A	X-ray exam of trunk spine	0.28	0.10	0.10	0.10	0.10	0.01	XXX
72100		A	X-ray exam of lower spine	0.22	0.81	0.77	NA	NA	0.05	XXX
72100	TC	A	X-ray exam of lower spine	0.00	0.74	0.70	NA	NA	0.04	XXX
72100	26	A	X-ray exam of lower spine	0.22	0.07	0.07	0.07	0.07	0.01	XXX
72110		A	X-ray exam of lower spine	0.31	1.15	1.07	NA	NA	0.07	XXX
72110	TC	A	X-ray exam of lower spine	0.00	1.04	0.97	NA	NA	0.06	XXX
72110	26	A	X-ray exam of lower spine	0.31	0.11	0.10	0.11	0.10	0.01	XXX
72114		A	X-ray exam of lower spine	0.36	1.57	1.43	NA	NA	0.08	XXX
72114	TC	A	X-ray exam of lower spine	0.00	1.44	1.31	NA	NA	0.06	XXX
72114	26	A	X-ray exam of lower spine	0.36	0.13	0.12	0.13	0.12	0.02	XXX
72120		A	X-ray exam of lower spine	0.22	1.08	1.01	NA	NA	0.07	XXX
72120	TC	A	X-ray exam of lower spine	0.00	1.00	0.94	NA	NA	0.06	XXX
72120	26	A	X-ray exam of lower spine	0.22	0.08	0.07	0.08	0.07	0.01	XXX
72125		A	Ct neck spine w/o dye	1.16	6.46	6.37	NA	NA	0.36	XXX
72125	TC	A	Ct neck spine w/o dye	0.00	6.05	5.98	NA	NA	0.31	XXX
72125	26	A	Ct neck spine w/o dye	1.16	0.41	0.39	0.41	0.39	0.05	XXX
72126		A	Ct neck spine w/dye	1.22	7.99	7.72	NA	NA	0.42	XXX
72126	TC	A	Ct neck spine w/dye	0.00	7.56	7.31	NA	NA	0.37	XXX
72126	26	A	Ct neck spine w/dye	1.22	0.43	0.41	0.43	0.41	0.05	XXX
72127		A	Ct neck spine w/o & w/dye	1.27	10.03	9.65	NA	NA	0.52	XXX
72127	TC	A	Ct neck spine w/o & w/dye	0.00	9.59	9.22	NA	NA	0.46	XXX
72127	26	A	Ct neck spine w/o & w/dye	1.27	0.44	0.43	0.44	0.43	0.06	XXX
72128		A	Ct chest spine w/o dye	1.16	6.45	6.36	NA	NA	0.36	XXX
72128	TC	A	Ct chest spine w/o dye	0.00	6.04	5.97	NA	NA	0.31	XXX
72128	26	A	Ct chest spine w/o dye	1.16	0.41	0.39	0.41	0.39	0.05	XXX
72129		A	Ct chest spine w/dye	1.22	7.99	7.72	NA	NA	0.42	XXX
72129	TC	A	Ct chest spine w/dye	0.00	7.56	7.31	NA	NA	0.37	XXX
72129	26	A	Ct chest spine w/dye	1.22	0.43	0.41	0.43	0.41	0.05	XXX
72130		A	Ct chest spine w/o & w/dye	1.27	9.97	9.62	NA	NA	0.52	XXX
72130	TC	A	Ct chest spine w/o & w/dye	0.00	9.53	9.19	NA	NA	0.46	XXX
72130	26	A	Ct chest spine w/o & w/dye	1.27	0.44	0.43	0.44	0.43	0.06	XXX
72131		A	Ct lumbar spine w/o dye	1.16	6.42	6.36	NA	NA	0.36	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
72131	TC	A	Ct lumbar spine w/o dye	0.00	6.02	5.97	NA	NA	0.31	XXX
72131	26	A	Ct lumbar spine w/o dye	1.16	0.40	0.39	0.40	0.39	0.05	XXX
72132		A	Ct lumbar spine w/dye	1.22	7.97	7.71	NA	NA	0.42	XXX
72132	TC	A	Ct lumbar spine w/dye	0.00	7.54	7.30	NA	NA	0.37	XXX
72132	26	A	Ct lumbar spine w/dye	1.22	0.43	0.41	0.43	0.41	0.05	XXX
72133		A	Ct lumbar spine w/o & w/dye	1.27	10.01	9.64	NA	NA	0.52	XXX
72133	TC	A	Ct lumbar spine w/o & w/dye	0.00	9.57	9.21	NA	NA	0.46	XXX
72133	26	A	Ct lumbar spine w/o & w/dye	1.27	0.44	0.43	0.44	0.43	0.06	XXX
72141		A	Mri neck spine w/o dye	1.60	12.45	12.09	NA	NA	0.66	XXX
72141	TC	A	Mri neck spine w/o dye	0.00	11.90	11.55	NA	NA	0.59	XXX
72141	26	A	Mri neck spine w/o dye	1.60	0.55	0.54	0.55	0.54	0.07	XXX
72142		A	Mri neck spine w/dye	1.92	15.60	14.84	NA	NA	0.79	XXX
72142	TC	A	Mri neck spine w/dye	0.00	14.94	14.19	NA	NA	0.70	XXX
72142	26	A	Mri neck spine w/dye	1.92	0.66	0.65	0.66	0.65	0.09	XXX
72146		A	Mri chest spine w/o dye	1.60	12.47	12.72	NA	NA	0.71	XXX
72146	TC	A	Mri chest spine w/o dye	0.00	11.92	12.18	NA	NA	0.64	XXX
72146	26	A	Mri chest spine w/o dye	1.60	0.55	0.54	0.55	0.54	0.07	XXX
72147		A	Mri chest spine w/dye	1.92	13.56	13.81	NA	NA	0.79	XXX
72147	TC	A	Mri chest spine w/dye	0.00	12.89	13.16	NA	NA	0.70	XXX
72147	26	A	Mri chest spine w/dye	1.92	0.67	0.65	0.67	0.65	0.09	XXX
72148		A	Mri lumbar spine w/o dye	1.48	12.41	12.67	NA	NA	0.71	XXX
72148	TC	A	Mri lumbar spine w/o dye	0.00	11.90	12.17	NA	NA	0.64	XXX
72148	26	A	Mri lumbar spine w/o dye	1.48	0.51	0.50	0.51	0.50	0.07	XXX
72149		A	Mri lumbar spine w/dye	1.78	15.51	14.77	NA	NA	0.78	XXX
72149	TC	A	Mri lumbar spine w/dye	0.00	14.89	14.16	NA	NA	0.70	XXX
72149	26	A	Mri lumbar spine w/dye	1.78	0.62	0.61	0.62	0.61	0.08	XXX
72156		A	Mri neck spine w/o & w/dye	2.57	17.76	21.74	NA	NA	1.42	XXX
72156	TC	A	Mri neck spine w/o & w/dye	0.00	16.88	20.87	NA	NA	1.31	XXX
72156	26	A	Mri neck spine w/o & w/dye	2.57	0.88	0.87	0.88	0.87	0.11	XXX
72157		A	Mri chest spine w/o & w/dye	2.57	16.20	20.95	NA	NA	1.42	XXX
72157	TC	A	Mri chest spine w/o & w/dye	0.00	15.30	20.08	NA	NA	1.31	XXX
72157	26	A	Mri chest spine w/o & w/dye	2.57	0.90	0.87	0.90	0.87	0.11	XXX
72158		A	Mri lumbar spine w/o & w/dye	2.36	17.68	21.66	NA	NA	1.41	XXX
72158	TC	A	Mri lumbar spine w/o & w/dye	0.00	16.86	20.86	NA	NA	1.31	XXX
72158	26	A	Mri lumbar spine w/o & w/dye	2.36	0.82	0.80	0.82	0.80	0.10	XXX
72159		N	Mr angio spine w/o&w/dye	1.80	14.65	13.78	NA	NA	0.74	XXX
72159	TC	N	Mr angio spine w/o&w/dye	0.00	14.24	13.23	NA	NA	0.64	XXX
72159	26	N	Mr angio spine w/o&w/dye	1.80	0.41	0.55	0.41	0.55	0.10	XXX
72170		A	X-ray exam of pelvis	0.17	0.50	0.54	NA	NA	0.03	XXX
72170	TC	A	X-ray exam of pelvis	0.00	0.44	0.48	NA	NA	0.02	XXX
72170	26	A	X-ray exam of pelvis	0.17	0.06	0.06	0.06	0.06	0.01	XXX
72190		A	X-ray exam of pelvis	0.21	0.84	0.79	NA	NA	0.05	XXX
72190	TC	A	X-ray exam of pelvis	0.00	0.77	0.72	NA	NA	0.04	XXX
72190	26	A	X-ray exam of pelvis	0.21	0.07	0.07	0.07	0.07	0.01	XXX
72191		A	Ct angiograph pelv w/o&w/dye	1.81	11.32	11.97	NA	NA	0.47	XXX
72191	TC	A	Ct angiograph pelv w/o&w/dye	0.00	10.67	11.35	NA	NA	0.39	XXX
72191	26	A	Ct angiograph pelv w/o&w/dye	1.81	0.65	0.62	0.65	0.62	0.08	XXX
72192		A	Ct pelvis w/o dye	1.09	6.03	6.15	NA	NA	0.36	XXX
72192	TC	A	Ct pelvis w/o dye	0.00	5.64	5.78	NA	NA	0.31	XXX
72192	26	A	Ct pelvis w/o dye	1.09	0.39	0.37	0.39	0.37	0.05	XXX
72193		A	Ct pelvis w/dye	1.16	7.54	7.37	NA	NA	0.41	XXX
72193	TC	A	Ct pelvis w/dye	0.00	7.13	6.98	NA	NA	0.36	XXX
72193	26	A	Ct pelvis w/dye	1.16	0.41	0.39	0.41	0.39	0.05	XXX
72194		A	Ct pelvis w/o & w/dye	1.22	10.12	9.49	NA	NA	0.48	XXX
72194	TC	A	Ct pelvis w/o & w/dye	0.00	9.69	9.08	NA	NA	0.43	XXX
72194	26	A	Ct pelvis w/o & w/dye	1.22	0.43	0.41	0.43	0.41	0.05	XXX
72195		A	Mri pelvis w/o dye	1.46	14.43	13.04	NA	NA	0.51	XXX
72195	TC	A	Mri pelvis w/o dye	0.00	13.92	12.55	NA	NA	0.45	XXX
72195	26	A	Mri pelvis w/o dye	1.46	0.51	0.49	0.51	0.49	0.06	XXX
72196		A	Mri pelvis w/dye	1.73	15.52	14.76	NA	NA	0.60	XXX
72196	TC	A	Mri pelvis w/dye	0.00	14.91	14.17	NA	NA	0.52	XXX
72196	26	A	Mri pelvis w/dye	1.73	0.61	0.59	0.61	0.59	0.08	XXX
72197		A	Mri pelvis w/o & w/dye	2.26	18.95	22.27	NA	NA	1.02	XXX
72197	TC	A	Mri pelvis w/o & w/dye	0.00	18.16	21.51	NA	NA	0.92	XXX
72197	26	A	Mri pelvis w/o & w/dye	2.26	0.79	0.76	0.79	0.76	0.10	XXX
72198		A	Mr angio pelvis w/o & w/dye	1.80	15.08	13.42	NA	NA	0.67	XXX
72198	TC	A	Mr angio pelvis w/o & w/dye	0.00	14.44	12.81	NA	NA	0.59	XXX
72198	26	A	Mr angio pelvis w/o & w/dye	1.80	0.64	0.61	0.64	0.61	0.08	XXX
72200		A	X-ray exam sacroiliac joints	0.17	0.59	0.59	NA	NA	0.03	XXX
72200	TC	A	X-ray exam sacroiliac joints	0.00	0.54	0.53	NA	NA	0.02	XXX
72200	26	A	X-ray exam sacroiliac joints	0.17	0.05	0.06	0.05	0.06	0.01	XXX
72202		A	X-ray exam sacroiliac joints	0.19	0.74	0.71	NA	NA	0.05	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
72202	TC	A	X-ray exam sacroiliac joints	0.00	0.67	0.65	NA	NA	0.04	XXX
72202	26	A	X-ray exam sacroiliac joints	0.19	0.07	0.06	0.07	0.06	0.01	XXX
72220		A	X-ray exam of tailbone	0.17	0.57	0.61	NA	NA	0.05	XXX
72220	TC	A	X-ray exam of tailbone	0.00	0.52	0.55	NA	NA	0.04	XXX
72220	26	A	X-ray exam of tailbone	0.17	0.05	0.06	0.05	0.06	0.01	XXX
72240		A	Contrast x-ray of neck spine	0.91	2.58	3.80	NA	NA	0.29	XXX
72240	TC	A	Contrast x-ray of neck spine	0.00	2.26	3.50	NA	NA	0.25	XXX
72240	26	A	Contrast x-ray of neck spine	0.91	0.32	0.30	0.32	0.30	0.04	XXX
72255		A	Contrast x-ray, thorax spine	0.91	2.24	3.42	NA	NA	0.26	XXX
72255	TC	A	Contrast x-ray, thorax spine	0.00	1.96	3.14	NA	NA	0.22	XXX
72255	26	A	Contrast x-ray, thorax spine	0.91	0.28	0.28	0.28	0.28	0.04	XXX
72265		A	Contrast x-ray, lower spine	0.83	2.53	3.43	NA	NA	0.26	XXX
72265	TC	A	Contrast x-ray, lower spine	0.00	2.24	3.16	NA	NA	0.22	XXX
72265	26	A	Contrast x-ray, lower spine	0.83	0.29	0.27	0.29	0.27	0.04	XXX
72270		A	Contrast x-ray, spine	1.33	3.99	5.26	NA	NA	0.39	XXX
72270	TC	A	Contrast x-ray, spine	0.00	3.52	4.81	NA	NA	0.33	XXX
72270	26	A	Contrast x-ray, spine	1.33	0.47	0.45	0.47	0.45	0.06	XXX
72275		A	Epidurography	0.76	1.73	2.02	NA	NA	0.26	XXX
72275	TC	A	Epidurography	0.00	1.53	1.82	NA	NA	0.22	XXX
72275	26	A	Epidurography	0.76	0.20	0.20	0.20	0.20	0.04	XXX
72285		A	X-ray c/t spine disk	1.16	1.44	5.08	NA	NA	0.50	XXX
72285	TC	A	X-ray c/t spine disk	0.00	1.14	4.75	NA	NA	0.43	XXX
72285	26	A	X-ray c/t spine disk	1.16	0.30	0.33	0.30	0.33	0.07	XXX
72291		C	Perq vertebroplasty, fluor	0.00	0.00	0.00	NA	NA	0.00	XXX
72291	TC	C	Perq vertebroplasty, fluor	0.00	0.00	0.00	NA	NA	0.00	XXX
72291	26	A	Perq vertebroplasty, fluor	1.31	0.47	0.47	0.47	0.47	0.10	XXX
72292		C	Perq vertebroplasty, ct	0.00	0.00	0.00	NA	NA	0.00	XXX
72292	TC	C	Perq vertebroplasty, ct	0.00	0.00	0.00	NA	NA	0.00	XXX
72292	26	A	Perq vertebroplasty, ct	1.38	0.50	0.49	0.50	0.49	0.07	XXX
72295		A	X-ray of lower spine disk	0.83	1.45	4.79	NA	NA	0.46	XXX
72295	TC	A	X-ray of lower spine disk	0.00	1.21	4.53	NA	NA	0.40	XXX
72295	26	A	X-ray of lower spine disk	0.83	0.24	0.26	0.24	0.26	0.06	XXX
73000		A	X-ray exam of collar bone	0.16	0.55	0.56	NA	NA	0.03	XXX
73000	TC	A	X-ray exam of collar bone	0.00	0.50	0.51	NA	NA	0.02	XXX
73000	26	A	X-ray exam of collar bone	0.16	0.05	0.05	0.05	0.05	0.01	XXX
73010		A	X-ray exam of shoulder blade	0.17	0.58	0.58	NA	NA	0.03	XXX
73010	TC	A	X-ray exam of shoulder blade	0.00	0.52	0.52	NA	NA	0.02	XXX
73010	26	A	X-ray exam of shoulder blade	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73020		A	X-ray exam of shoulder	0.15	0.44	0.48	NA	NA	0.03	XXX
73020	TC	A	X-ray exam of shoulder	0.00	0.39	0.43	NA	NA	0.02	XXX
73020	26	A	X-ray exam of shoulder	0.15	0.05	0.05	0.05	0.05	0.01	XXX
73030		A	X-ray exam of shoulder	0.18	0.57	0.60	NA	NA	0.05	XXX
73030	TC	A	X-ray exam of shoulder	0.00	0.51	0.54	NA	NA	0.04	XXX
73030	26	A	X-ray exam of shoulder	0.18	0.06	0.06	0.06	0.06	0.01	XXX
73040		A	Contrast x-ray of shoulder	0.54	2.24	2.26	NA	NA	0.14	XXX
73040	TC	A	Contrast x-ray of shoulder	0.00	2.05	2.08	NA	NA	0.12	XXX
73040	26	A	Contrast x-ray of shoulder	0.54	0.19	0.18	0.19	0.18	0.02	XXX
73050		A	X-ray exam of shoulders	0.20	0.74	0.73	NA	NA	0.05	XXX
73050	TC	A	X-ray exam of shoulders	0.00	0.66	0.66	NA	NA	0.04	XXX
73050	26	A	X-ray exam of shoulders	0.20	0.08	0.07	0.08	0.07	0.01	XXX
73060		A	X-ray exam of humerus	0.17	0.58	0.60	NA	NA	0.05	XXX
73060	TC	A	X-ray exam of humerus	0.00	0.52	0.54	NA	NA	0.04	XXX
73060	26	A	X-ray exam of humerus	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73070		A	X-ray exam of elbow	0.15	0.55	0.56	NA	NA	0.03	XXX
73070	TC	A	X-ray exam of elbow	0.00	0.50	0.51	NA	NA	0.02	XXX
73070	26	A	X-ray exam of elbow	0.15	0.05	0.05	0.05	0.05	0.01	XXX
73080		A	X-ray exam of elbow	0.17	0.76	0.69	NA	NA	0.05	XXX
73080	TC	A	X-ray exam of elbow	0.00	0.70	0.63	NA	NA	0.04	XXX
73080	26	A	X-ray exam of elbow	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73085		A	Contrast x-ray of elbow	0.54	1.83	2.07	NA	NA	0.14	XXX
73085	TC	A	Contrast x-ray of elbow	0.00	1.65	1.88	NA	NA	0.12	XXX
73085	26	A	Contrast x-ray of elbow	0.54	0.18	0.19	0.18	0.19	0.02	XXX
73090		A	X-ray exam of forearm	0.16	0.55	0.56	NA	NA	0.03	XXX
73090	TC	A	X-ray exam of forearm	0.00	0.50	0.51	NA	NA	0.02	XXX
73090	26	A	X-ray exam of forearm	0.16	0.05	0.05	0.05	0.05	0.01	XXX
73092		A	X-ray exam of arm, infant	0.16	0.58	0.56	NA	NA	0.03	XXX
73092	TC	A	X-ray exam of arm, infant	0.00	0.53	0.51	NA	NA	0.02	XXX
73092	26	A	X-ray exam of arm, infant	0.16	0.05	0.05	0.05	0.05	0.01	XXX
73100		A	X-ray exam of wrist	0.16	0.61	0.57	NA	NA	0.03	XXX
73100	TC	A	X-ray exam of wrist	0.00	0.55	0.52	NA	NA	0.02	XXX
73100	26	A	X-ray exam of wrist	0.16	0.06	0.05	0.06	0.05	0.01	XXX
73110		A	X-ray exam of wrist	0.17	0.78	0.68	NA	NA	0.03	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
73110	TC	A	X-ray exam of wrist	0.00	0.72	0.62	NA	NA	0.02	XXX
73110	26	A	X-ray exam of wrist	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73115		A	Contrast x-ray of wrist	0.54	2.33	2.04	NA	NA	0.12	XXX
73115	TC	A	Contrast x-ray of wrist	0.00	2.14	1.86	NA	NA	0.10	XXX
73115	26	A	Contrast x-ray of wrist	0.54	0.19	0.18	0.19	0.18	0.02	XXX
73120		A	X-ray exam of hand	0.16	0.56	0.55	NA	NA	0.03	XXX
73120	TC	A	X-ray exam of hand	0.00	0.51	0.50	NA	NA	0.02	XXX
73120	26	A	X-ray exam of hand	0.16	0.05	0.05	0.05	0.05	0.01	XXX
73130		A	X-ray exam of hand	0.17	0.66	0.62	NA	NA	0.03	XXX
73130	TC	A	X-ray exam of hand	0.00	0.60	0.56	NA	NA	0.02	XXX
73130	26	A	X-ray exam of hand	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73140		A	X-ray exam of finger(s)	0.13	0.67	0.57	NA	NA	0.03	XXX
73140	TC	A	X-ray exam of finger(s)	0.00	0.63	0.53	NA	NA	0.02	XXX
73140	26	A	X-ray exam of finger(s)	0.13	0.04	0.04	0.04	0.04	0.01	XXX
73200		A	Ct upper extremity w/o dye	1.09	6.39	5.85	NA	NA	0.30	XXX
73200	TC	A	Ct upper extremity w/o dye	0.00	6.01	5.48	NA	NA	0.25	XXX
73200	26	A	Ct upper extremity w/o dye	1.09	0.38	0.37	0.38	0.37	0.05	XXX
73201		A	Ct upper extremity w/dye	1.16	7.91	7.09	NA	NA	0.36	XXX
73201	TC	A	Ct upper extremity w/dye	0.00	7.50	6.70	NA	NA	0.31	XXX
73201	26	A	Ct upper extremity w/dye	1.16	0.41	0.39	0.41	0.39	0.05	XXX
73202		A	Ct uppr extremity w/o&w/dye	1.22	10.54	9.18	NA	NA	0.44	XXX
73202	TC	A	Ct uppr extremity w/o&w/dye	0.00	10.12	8.77	NA	NA	0.39	XXX
73202	26	A	Ct uppr extremity w/o&w/dye	1.22	0.42	0.41	0.42	0.41	0.05	XXX
73206		A	Ct angio upr extrm w/o&w/dye	1.81	10.91	11.23	NA	NA	0.47	XXX
73206	TC	A	Ct angio upr extrm w/o&w/dye	0.00	10.24	10.60	NA	NA	0.39	XXX
73206	26	A	Ct angio upr extrm w/o&w/dye	1.81	0.67	0.63	0.67	0.63	0.08	XXX
73218		A	Mri upper extremity w/o dye	1.35	14.63	13.13	NA	NA	0.45	XXX
73218	TC	A	Mri upper extremity w/o dye	0.00	14.17	12.68	NA	NA	0.39	XXX
73218	26	A	Mri upper extremity w/o dye	1.35	0.46	0.45	0.46	0.45	0.06	XXX
73219		A	Mri upper extremity w/dye	1.62	15.39	14.68	NA	NA	0.54	XXX
73219	TC	A	Mri upper extremity w/dye	0.00	14.83	14.13	NA	NA	0.47	XXX
73219	26	A	Mri upper extremity w/dye	1.62	0.56	0.55	0.56	0.55	0.07	XXX
73220		A	Mri uppr extremity w/o&w/dye	2.15	19.03	22.31	NA	NA	0.94	XXX
73220	TC	A	Mri uppr extremity w/o&w/dye	0.00	18.29	21.58	NA	NA	0.84	XXX
73220	26	A	Mri uppr extremity w/o&w/dye	2.15	0.74	0.73	0.74	0.73	0.10	XXX
73221		A	Mri joint upr extrem w/o dye	1.35	13.55	12.59	NA	NA	0.45	XXX
73221	TC	A	Mri joint upr extrem w/o dye	0.00	13.08	12.14	NA	NA	0.39	XXX
73221	26	A	Mri joint upr extrem w/o dye	1.35	0.47	0.45	0.47	0.45	0.06	XXX
73222		A	Mri joint upr extrem w/dye	1.62	14.29	14.12	NA	NA	0.54	XXX
73222	TC	A	Mri joint upr extrem w/dye	0.00	13.73	13.58	NA	NA	0.47	XXX
73222	26	A	Mri joint upr extrem w/dye	1.62	0.56	0.54	0.56	0.54	0.07	XXX
73223		A	Mri joint upr extr w/o&w/dye	2.15	17.56	21.56	NA	NA	0.94	XXX
73223	TC	A	Mri joint upr extr w/o&w/dye	0.00	16.82	20.84	NA	NA	0.84	XXX
73223	26	A	Mri joint upr extr w/o&w/dye	2.15	0.74	0.72	0.74	0.72	0.10	XXX
73225		N	Mr angio upr extr w/o&w/dye	1.73	14.64	13.15	NA	NA	0.69	XXX
73225	TC	N	Mr angio upr extr w/o&w/dye	0.00	14.24	12.62	NA	NA	0.59	XXX
73225	26	N	Mr angio upr extr w/o&w/dye	1.73	0.40	0.53	0.40	0.53	0.10	XXX
73500		A	X-ray exam of hip	0.17	0.49	0.51	NA	NA	0.03	XXX
73500	TC	A	X-ray exam of hip	0.00	0.43	0.45	NA	NA	0.02	XXX
73500	26	A	X-ray exam of hip	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73510		A	X-ray exam of hip	0.21	0.77	0.71	NA	NA	0.05	XXX
73510	TC	A	X-ray exam of hip	0.00	0.70	0.64	NA	NA	0.04	XXX
73510	26	A	X-ray exam of hip	0.21	0.07	0.07	0.07	0.07	0.01	XXX
73520		A	X-ray exam of hips	0.26	0.79	0.77	NA	NA	0.05	XXX
73520	TC	A	X-ray exam of hips	0.00	0.70	0.68	NA	NA	0.04	XXX
73520	26	A	X-ray exam of hips	0.26	0.09	0.09	0.09	0.09	0.01	XXX
73525		A	Contrast x-ray of hip	0.54	1.82	2.05	NA	NA	0.15	XXX
73525	TC	A	Contrast x-ray of hip	0.00	1.64	1.87	NA	NA	0.12	XXX
73525	26	A	Contrast x-ray of hip	0.54	0.18	0.18	0.18	0.18	0.03	XXX
73530		C	X-ray exam of hip	0.00	0.00	0.00	NA	NA	0.00	XXX
73530	TC	C	X-ray exam of hip	0.00	0.00	0.00	NA	NA	0.00	XXX
73530	26	A	X-ray exam of hip	0.29	0.11	0.10	0.11	0.10	0.01	XXX
73540		A	X-ray exam of pelvis & hips	0.20	0.81	0.72	NA	NA	0.05	XXX
73540	TC	A	X-ray exam of pelvis & hips	0.00	0.74	0.65	NA	NA	0.04	XXX
73540	26	A	X-ray exam of pelvis & hips	0.20	0.07	0.07	0.07	0.07	0.01	XXX
73542		A	X-ray exam, sacroiliac joint	0.59	1.12	1.69	NA	NA	0.15	XXX
73542	TC	A	X-ray exam, sacroiliac joint	0.00	0.98	1.54	NA	NA	0.12	XXX
73542	26	A	X-ray exam, sacroiliac joint	0.59	0.14	0.15	0.14	0.15	0.03	XXX
73550		A	X-ray exam of thigh	0.17	0.55	0.59	NA	NA	0.05	XXX
73550	TC	A	X-ray exam of thigh	0.00	0.49	0.53	NA	NA	0.04	XXX
73550	26	A	X-ray exam of thigh	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73560		A	X-ray exam of knee, 1 or 2	0.17	0.58	0.58	NA	NA	0.03	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
73560	TC	A	X-ray exam of knee, 1 or 2	0.00	0.52	0.52	NA	NA	0.02	XXX
73560	26	A	X-ray exam of knee, 1 or 2	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73562		A	X-ray exam of knee, 3	0.18	0.73	0.68	NA	NA	0.05	XXX
73562	TC	A	X-ray exam of knee, 3	0.00	0.66	0.62	NA	NA	0.04	XXX
73562	26	A	X-ray exam of knee, 3	0.18	0.07	0.06	0.07	0.06	0.01	XXX
73564		A	X-ray exam, knee, 4 or more	0.22	0.86	0.77	NA	NA	0.05	XXX
73564	TC	A	X-ray exam, knee, 4 or more	0.00	0.78	0.70	NA	NA	0.04	XXX
73564	26	A	X-ray exam, knee, 4 or more	0.22	0.08	0.07	0.08	0.07	0.01	XXX
73565		A	X-ray exam of knees	0.17	0.65	0.60	NA	NA	0.03	XXX
73565	TC	A	X-ray exam of knees	0.00	0.59	0.54	NA	NA	0.02	XXX
73565	26	A	X-ray exam of knees	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73580		A	Contrast x-ray of knee joint	0.54	2.55	2.67	NA	NA	0.17	XXX
73580	TC	A	Contrast x-ray of knee joint	0.00	2.36	2.49	NA	NA	0.14	XXX
73580	26	A	Contrast x-ray of knee joint	0.54	0.19	0.18	0.19	0.18	0.03	XXX
73590		A	X-ray exam of lower leg	0.17	0.54	0.56	NA	NA	0.03	XXX
73590	TC	A	X-ray exam of lower leg	0.00	0.48	0.50	NA	NA	0.02	XXX
73590	26	A	X-ray exam of lower leg	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73592		A	X-ray exam of leg, infant	0.16	0.58	0.56	NA	NA	0.03	XXX
73592	TC	A	X-ray exam of leg, infant	0.00	0.53	0.51	NA	NA	0.02	XXX
73592	26	A	X-ray exam of leg, infant	0.16	0.05	0.05	0.05	0.05	0.01	XXX
73600		A	X-ray exam of ankle	0.16	0.56	0.55	NA	NA	0.03	XXX
73600	TC	A	X-ray exam of ankle	0.00	0.51	0.50	NA	NA	0.02	XXX
73600	26	A	X-ray exam of ankle	0.16	0.05	0.05	0.05	0.05	0.01	XXX
73610		A	X-ray exam of ankle	0.17	0.68	0.63	NA	NA	0.03	XXX
73610	TC	A	X-ray exam of ankle	0.00	0.62	0.57	NA	NA	0.02	XXX
73610	26	A	X-ray exam of ankle	0.17	0.06	0.06	0.06	0.06	0.01	XXX
73615		A	Contrast x-ray of ankle	0.54	2.00	2.14	NA	NA	0.15	XXX
73615	TC	A	Contrast x-ray of ankle	0.00	1.82	1.96	NA	NA	0.12	XXX
73615	26	A	Contrast x-ray of ankle	0.54	0.18	0.18	0.18	0.18	0.03	XXX
73620		A	X-ray exam of foot	0.16	0.52	0.54	NA	NA	0.03	XXX
73620	TC	A	X-ray exam of foot	0.00	0.48	0.49	NA	NA	0.02	XXX
73620	26	A	X-ray exam of foot	0.16	0.04	0.05	0.04	0.05	0.01	XXX
73630		A	X-ray exam of foot	0.17	0.65	0.62	NA	NA	0.03	XXX
73630	TC	A	X-ray exam of foot	0.00	0.60	0.56	NA	NA	0.02	XXX
73630	26	A	X-ray exam of foot	0.17	0.05	0.06	0.05	0.06	0.01	XXX
73650		A	X-ray exam of heel	0.16	0.55	0.53	NA	NA	0.03	XXX
73650	TC	A	X-ray exam of heel	0.00	0.50	0.48	NA	NA	0.02	XXX
73650	26	A	X-ray exam of heel	0.16	0.05	0.05	0.05	0.05	0.01	XXX
73660		A	X-ray exam of toe(s)	0.13	0.64	0.55	NA	NA	0.03	XXX
73660	TC	A	X-ray exam of toe(s)	0.00	0.60	0.51	NA	NA	0.02	XXX
73660	26	A	X-ray exam of toe(s)	0.13	0.04	0.04	0.04	0.04	0.01	XXX
73700		A	Ct lower extremity w/o dye	1.09	6.40	5.86	NA	NA	0.30	XXX
73700	TC	A	Ct lower extremity w/o dye	0.00	6.02	5.49	NA	NA	0.25	XXX
73700	26	A	Ct lower extremity w/o dye	1.09	0.38	0.37	0.38	0.37	0.05	XXX
73701		A	Ct lower extremity w/dye	1.16	7.97	7.13	NA	NA	0.36	XXX
73701	TC	A	Ct lower extremity w/dye	0.00	7.56	6.73	NA	NA	0.31	XXX
73701	26	A	Ct lower extremity w/dye	1.16	0.41	0.40	0.41	0.40	0.05	XXX
73702		A	Ct lwr extremity w/o&w/dye	1.22	10.72	9.27	NA	NA	0.44	XXX
73702	TC	A	Ct lwr extremity w/o&w/dye	0.00	10.28	8.85	NA	NA	0.39	XXX
73702	26	A	Ct lwr extremity w/o&w/dye	1.22	0.44	0.42	0.44	0.42	0.05	XXX
73706		A	Ct angio lwr extr w/o&w/dye	1.90	12.34	11.96	NA	NA	0.47	XXX
73706	TC	A	Ct angio lwr extr w/o&w/dye	0.00	11.62	11.29	NA	NA	0.39	XXX
73706	26	A	Ct angio lwr extr w/o&w/dye	1.90	0.72	0.67	0.72	0.67	0.08	XXX
73718		A	Mri lower extremity w/o dye	1.35	14.25	12.94	NA	NA	0.45	XXX
73718	TC	A	Mri lower extremity w/o dye	0.00	13.79	12.49	NA	NA	0.39	XXX
73718	26	A	Mri lower extremity w/o dye	1.35	0.46	0.45	0.46	0.45	0.06	XXX
73719		A	Mri lower extremity w/dye	1.62	15.39	14.68	NA	NA	0.54	XXX
73719	TC	A	Mri lower extremity w/dye	0.00	14.82	14.13	NA	NA	0.47	XXX
73719	26	A	Mri lower extremity w/dye	1.62	0.57	0.55	0.57	0.55	0.07	XXX
73720		A	Mri lwr extremity w/o&w/dye	2.15	18.98	22.27	NA	NA	0.94	XXX
73720	TC	A	Mri lwr extremity w/o&w/dye	0.00	18.23	21.55	NA	NA	0.84	XXX
73720	26	A	Mri lwr extremity w/o&w/dye	2.15	0.75	0.72	0.75	0.72	0.10	XXX
73721		A	Mri jnt of lwr extre w/o dye	1.35	13.86	12.74	NA	NA	0.45	XXX
73721	TC	A	Mri jnt of lwr extre w/o dye	0.00	13.39	12.29	NA	NA	0.39	XXX
73721	26	A	Mri jnt of lwr extre w/o dye	1.35	0.47	0.45	0.47	0.45	0.06	XXX
73722		A	Mri joint of lwr extr w/dye	1.62	14.48	14.22	NA	NA	0.54	XXX
73722	TC	A	Mri joint of lwr extr w/dye	0.00	13.91	13.67	NA	NA	0.47	XXX
73722	26	A	Mri joint of lwr extr w/dye	1.62	0.57	0.55	0.57	0.55	0.07	XXX
73723		A	Mri joint lwr extr w/o&w/dye	2.15	17.54	21.55	NA	NA	0.94	XXX
73723	TC	A	Mri joint lwr extr w/o&w/dye	0.00	16.80	20.83	NA	NA	0.84	XXX
73723	26	A	Mri joint lwr extr w/o&w/dye	2.15	0.74	0.72	0.74	0.72	0.10	XXX
73725		R	Mr ang lwr ext w or w/o dye	1.82	15.11	13.45	NA	NA	0.67	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
73725	TC	R	Mr ang lwr ext w or w/o dye	0.00	14.47	12.83	NA	NA	0.59	XXX
73725	26	R	Mr ang lwr ext w or w/o dye	1.82	0.64	0.62	0.64	0.62	0.08	XXX
74000		A	X-ray exam of abdomen	0.18	0.46	0.52	NA	NA	0.03	XXX
74000	TC	A	X-ray exam of abdomen	0.00	0.40	0.46	NA	NA	0.02	XXX
74000	26	A	X-ray exam of abdomen	0.18	0.06	0.06	0.06	0.06	0.01	XXX
74010		A	X-ray exam of abdomen	0.23	0.79	0.72	NA	NA	0.05	XXX
74010	TC	A	X-ray exam of abdomen	0.00	0.71	0.64	NA	NA	0.04	XXX
74010	26	A	X-ray exam of abdomen	0.23	0.08	0.08	0.08	0.08	0.01	XXX
74020		A	X-ray exam of abdomen	0.27	0.81	0.76	NA	NA	0.05	XXX
74020	TC	A	X-ray exam of abdomen	0.00	0.72	0.67	NA	NA	0.04	XXX
74020	26	A	X-ray exam of abdomen	0.27	0.09	0.09	0.09	0.09	0.01	XXX
74022		A	X-ray exam series, abdomen	0.32	0.98	0.91	NA	NA	0.06	XXX
74022	TC	A	X-ray exam series, abdomen	0.00	0.87	0.80	NA	NA	0.05	XXX
74022	26	A	X-ray exam series, abdomen	0.32	0.11	0.11	0.11	0.11	0.01	XXX
74150		A	Ct abdomen w/o dye	1.19	6.06	6.06	NA	NA	0.35	XXX
74150	TC	A	Ct abdomen w/o dye	0.00	5.64	5.65	NA	NA	0.30	XXX
74150	26	A	Ct abdomen w/o dye	1.19	0.42	0.41	0.42	0.41	0.05	XXX
74160		A	Ct abdomen w/dye	1.27	8.81	8.03	NA	NA	0.42	XXX
74160	TC	A	Ct abdomen w/dye	0.00	8.36	7.60	NA	NA	0.36	XXX
74160	26	A	Ct abdomen w/dye	1.27	0.45	0.43	0.45	0.43	0.06	XXX
74170		A	Ct abdomen w/o & w/dye	1.40	12.17	10.56	NA	NA	0.49	XXX
74170	TC	A	Ct abdomen w/o & w/dye	0.00	11.68	10.08	NA	NA	0.43	XXX
74170	26	A	Ct abdomen w/o & w/dye	1.40	0.49	0.48	0.49	0.48	0.06	XXX
74175		A	Ct angio abdom w/o & w/dye	1.90	12.27	12.45	NA	NA	0.47	XXX
74175	TC	A	Ct angio abdom w/o & w/dye	0.00	11.58	11.80	NA	NA	0.39	XXX
74175	26	A	Ct angio abdom w/o & w/dye	1.90	0.69	0.65	0.69	0.65	0.08	XXX
74181		A	Mri abdomen w/o dye	1.46	12.44	12.06	NA	NA	0.51	XXX
74181	TC	A	Mri abdomen w/o dye	0.00	11.93	11.56	NA	NA	0.45	XXX
74181	26	A	Mri abdomen w/o dye	1.46	0.51	0.50	0.51	0.50	0.06	XXX
74182		A	Mri abdomen w/dye	1.73	17.42	15.72	NA	NA	0.60	XXX
74182	TC	A	Mri abdomen w/dye	0.00	16.82	15.13	NA	NA	0.52	XXX
74182	26	A	Mri abdomen w/dye	1.73	0.60	0.59	0.60	0.59	0.08	XXX
74183		A	Mri abdomen w/o & w/dye	2.26	18.98	22.29	NA	NA	1.02	XXX
74183	TC	A	Mri abdomen w/o & w/dye	0.00	18.19	21.53	NA	NA	0.92	XXX
74183	26	A	Mri abdomen w/o & w/dye	2.26	0.79	0.76	0.79	0.76	0.10	XXX
74185		R	Mri angio, abdom w orw/o dye	1.80	15.07	13.42	NA	NA	0.67	XXX
74185	TC	R	Mri angio, abdom w orw/o dye	0.00	14.43	12.81	NA	NA	0.59	XXX
74185	26	R	Mri angio, abdom w orw/o dye	1.80	0.64	0.61	0.64	0.61	0.08	XXX
74190		C	X-ray exam of peritoneum	0.00	0.00	0.00	NA	NA	0.00	XXX
74190	TC	C	X-ray exam of peritoneum	0.00	0.00	0.00	NA	NA	0.00	XXX
74190	26	A	X-ray exam of peritoneum	0.48	0.17	0.16	0.17	0.16	0.02	XXX
74210		A	Contrst x-ray exam of throat	0.36	1.77	1.53	NA	NA	0.08	XXX
74210	TC	A	Contrst x-ray exam of throat	0.00	1.64	1.41	NA	NA	0.06	XXX
74210	26	A	Contrst x-ray exam of throat	0.36	0.13	0.12	0.13	0.12	0.02	XXX
74220		A	Contrast x-ray, esophagus	0.46	2.01	1.68	NA	NA	0.08	XXX
74220	TC	A	Contrast x-ray, esophagus	0.00	1.85	1.52	NA	NA	0.06	XXX
74220	26	A	Contrast x-ray, esophagus	0.46	0.16	0.16	0.16	0.16	0.02	XXX
74230		A	Cine/vid x-ray, throat/esoph	0.53	1.95	1.71	NA	NA	0.09	XXX
74230	TC	A	Cine/vid x-ray, throat/esoph	0.00	1.76	1.53	NA	NA	0.07	XXX
74230	26	A	Cine/vid x-ray, throat/esoph	0.53	0.19	0.18	0.19	0.18	0.02	XXX
74235		C	Remove esophagus obstruction	0.00	0.00	0.00	NA	NA	0.00	XXX
74235	TC	C	Remove esophagus obstruction	0.00	0.00	0.00	NA	NA	0.00	XXX
74235	26	A	Remove esophagus obstruction	1.19	0.47	0.43	0.47	0.43	0.05	XXX
74240		A	X-ray exam, upper gi tract	0.69	2.30	2.00	NA	NA	0.11	XXX
74240	TC	A	X-ray exam, upper gi tract	0.00	2.06	1.76	NA	NA	0.08	XXX
74240	26	A	X-ray exam, upper gi tract	0.69	0.24	0.24	0.24	0.24	0.03	XXX
74241		A	X-ray exam, upper gi tract	0.69	2.56	2.13	NA	NA	0.11	XXX
74241	TC	A	X-ray exam, upper gi tract	0.00	2.32	1.90	NA	NA	0.08	XXX
74241	26	A	X-ray exam, upper gi tract	0.69	0.24	0.23	0.24	0.23	0.03	XXX
74245		A	X-ray exam, upper gi tract	0.91	3.96	3.32	NA	NA	0.17	XXX
74245	TC	A	X-ray exam, upper gi tract	0.00	3.64	3.01	NA	NA	0.13	XXX
74245	26	A	X-ray exam, upper gi tract	0.91	0.32	0.31	0.32	0.31	0.04	XXX
74246		A	Contrst x-ray uppr gi tract	0.69	2.80	2.33	NA	NA	0.13	XXX
74246	TC	A	Contrst x-ray uppr gi tract	0.00	2.55	2.09	NA	NA	0.10	XXX
74246	26	A	Contrst x-ray uppr gi tract	0.69	0.25	0.24	0.25	0.24	0.03	XXX
74247		A	Contrst x-ray uppr gi tract	0.69	3.21	2.56	NA	NA	0.14	XXX
74247	TC	A	Contrst x-ray uppr gi tract	0.00	2.97	2.32	NA	NA	0.11	XXX
74247	26	A	Contrst x-ray uppr gi tract	0.69	0.24	0.24	0.24	0.24	0.03	XXX
74249		A	Contrst x-ray uppr gi tract	0.91	4.35	3.61	NA	NA	0.18	XXX
74249	TC	A	Contrst x-ray uppr gi tract	0.00	4.03	3.30	NA	NA	0.14	XXX
74249	26	A	Contrst x-ray uppr gi tract	0.91	0.32	0.31	0.32	0.31	0.04	XXX
74250		A	X-ray exam of small bowel	0.47	2.48	1.97	NA	NA	0.09	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
74250	TC	A	X-ray exam of small bowel	0.00	2.32	1.81	NA	NA	0.07	XXX
74250	26	A	X-ray exam of small bowel	0.47	0.16	0.16	0.16	0.16	0.02	XXX
74251		A	X-ray exam of small bowel	0.69	10.01	5.77	NA	NA	0.10	XXX
74251	TC	A	X-ray exam of small bowel	0.00	9.76	5.53	NA	NA	0.07	XXX
74251	26	A	X-ray exam of small bowel	0.69	0.25	0.24	0.25	0.24	0.03	XXX
74260		A	X-ray exam of small bowel	0.50	8.30	4.97	NA	NA	0.10	XXX
74260	TC	A	X-ray exam of small bowel	0.00	8.12	4.80	NA	NA	0.08	XXX
74260	26	A	X-ray exam of small bowel	0.50	0.18	0.17	0.18	0.17	0.02	XXX
74270		A	Contrast x-ray exam of colon	0.69	3.59	2.76	NA	NA	0.14	XXX
74270	TC	A	Contrast x-ray exam of colon	0.00	3.34	2.52	NA	NA	0.11	XXX
74270	26	A	Contrast x-ray exam of colon	0.69	0.25	0.24	0.25	0.24	0.03	XXX
74280		A	Contrast x-ray exam of colon	0.99	4.94	3.74	NA	NA	0.17	XXX
74280	TC	A	Contrast x-ray exam of colon	0.00	4.59	3.41	NA	NA	0.13	XXX
74280	26	A	Contrast x-ray exam of colon	0.99	0.35	0.33	0.35	0.33	0.04	XXX
74283		A	Contrast x-ray exam of colon	2.02	3.49	3.35	NA	NA	0.23	XXX
74283	TC	A	Contrast x-ray exam of colon	0.00	2.80	2.68	NA	NA	0.14	XXX
74283	26	A	Contrast x-ray exam of colon	2.02	0.69	0.67	0.69	0.67	0.09	XXX
74290		A	Contrast x-ray, gallbladder	0.32	1.58	1.21	NA	NA	0.06	XXX
74290	TC	A	Contrast x-ray, gallbladder	0.00	1.47	1.10	NA	NA	0.05	XXX
74290	26	A	Contrast x-ray, gallbladder	0.32	0.11	0.11	0.11	0.11	0.01	XXX
74291		A	Contrast x-rays, gallbladder	0.20	1.55	1.02	NA	NA	0.03	XXX
74291	TC	A	Contrast x-rays, gallbladder	0.00	1.48	0.95	NA	NA	0.02	XXX
74291	26	A	Contrast x-rays, gallbladder	0.20	0.07	0.07	0.07	0.07	0.01	XXX
74300		C	X-ray bile ducts/pancreas	0.00	0.00	0.00	NA	NA	0.00	XXX
74300	TC	C	X-ray bile ducts/pancreas	0.00	0.00	0.00	NA	NA	0.00	XXX
74300	26	A	X-ray bile ducts/pancreas	0.36	0.13	0.12	0.13	0.12	0.02	XXX
74301		C	X-rays at surgery add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
74301	TC	C	X-rays at surgery add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
74301	26	A	X-rays at surgery add-on	0.21	0.07	0.07	0.07	0.07	0.01	ZZZ
74305		C	X-ray bile ducts/pancreas	0.00	0.00	0.00	NA	NA	0.00	XXX
74305	TC	C	X-ray bile ducts/pancreas	0.00	0.00	0.00	NA	NA	0.00	XXX
74305	26	A	X-ray bile ducts/pancreas	0.42	0.15	0.15	0.15	0.15	0.02	XXX
74320		A	Contrast x-ray of bile ducts	0.54	2.13	2.73	NA	NA	0.19	XXX
74320	TC	A	Contrast x-ray of bile ducts	0.00	1.93	2.54	NA	NA	0.17	XXX
74320	26	A	Contrast x-ray of bile ducts	0.54	0.20	0.19	0.20	0.19	0.02	XXX
74327		A	X-ray bile stone removal	0.70	2.97	2.48	NA	NA	0.14	XXX
74327	TC	A	X-ray bile stone removal	0.00	2.72	2.24	NA	NA	0.11	XXX
74327	26	A	X-ray bile stone removal	0.70	0.25	0.24	0.25	0.24	0.03	XXX
74328		C	X-ray bile duct endoscopy	0.00	0.00	0.00	NA	NA	0.00	XXX
74328	TC	C	X-ray bile duct endoscopy	0.00	0.00	0.00	NA	NA	0.00	XXX
74328	26	A	X-ray bile duct endoscopy	0.70	0.26	0.25	0.26	0.25	0.03	XXX
74329		C	X-ray for pancreas endoscopy	0.00	0.00	0.00	NA	NA	0.00	XXX
74329	TC	C	X-ray for pancreas endoscopy	0.00	0.00	0.00	NA	NA	0.00	XXX
74329	26	A	X-ray for pancreas endoscopy	0.70	0.27	0.25	0.27	0.25	0.03	XXX
74330		C	X-ray bile/panc endoscopy	0.00	0.00	0.00	NA	NA	0.00	XXX
74330	TC	C	X-ray bile/panc endoscopy	0.00	0.00	0.00	NA	NA	0.00	XXX
74330	26	A	X-ray bile/panc endoscopy	0.90	0.33	0.31	0.33	0.31	0.04	XXX
74340		C	X-ray guide for GI tube	0.00	0.00	0.00	NA	NA	0.00	XXX
74340	TC	C	X-ray guide for GI tube	0.00	0.00	0.00	NA	NA	0.00	XXX
74340	26	A	X-ray guide for GI tube	0.54	0.19	0.19	0.19	0.19	0.02	XXX
74355		C	X-ray guide, intestinal tube	0.00	0.00	0.00	NA	NA	0.00	XXX
74355	TC	C	X-ray guide, intestinal tube	0.00	0.00	0.00	NA	NA	0.00	XXX
74355	26	A	X-ray guide, intestinal tube	0.76	0.28	0.26	0.28	0.26	0.03	XXX
74360		C	X-ray guide, GI dilation	0.00	0.00	0.00	NA	NA	0.00	XXX
74360	TC	C	X-ray guide, GI dilation	0.00	0.00	0.00	NA	NA	0.00	XXX
74360	26	A	X-ray guide, GI dilation	0.54	0.24	0.21	0.24	0.21	0.02	XXX
74363		C	X-ray, bile duct dilation	0.00	0.00	0.00	NA	NA	0.00	XXX
74363	TC	C	X-ray, bile duct dilation	0.00	0.00	0.00	NA	NA	0.00	XXX
74363	26	A	X-ray, bile duct dilation	0.88	0.32	0.30	0.32	0.30	0.04	XXX
74400		A	Contrst x-ray, urinary tract	0.49	2.60	2.22	NA	NA	0.13	XXX
74400	TC	A	Contrst x-ray, urinary tract	0.00	2.43	2.05	NA	NA	0.11	XXX
74400	26	A	Contrst x-ray, urinary tract	0.49	0.17	0.17	0.17	0.17	0.02	XXX
74410		A	Contrst x-ray, urinary tract	0.49	2.69	2.40	NA	NA	0.13	XXX
74410	TC	A	Contrst x-ray, urinary tract	0.00	2.51	2.23	NA	NA	0.11	XXX
74410	26	A	Contrst x-ray, urinary tract	0.49	0.18	0.17	0.18	0.17	0.02	XXX
74415		A	Contrst x-ray, urinary tract	0.49	3.27	2.78	NA	NA	0.14	XXX
74415	TC	A	Contrst x-ray, urinary tract	0.00	3.10	2.61	NA	NA	0.12	XXX
74415	26	A	Contrst x-ray, urinary tract	0.49	0.17	0.17	0.17	0.17	0.02	XXX
74420		C	Contrst x-ray, urinary tract	0.00	0.00	0.00	NA	NA	0.00	XXX
74420	TC	C	Contrst x-ray, urinary tract	0.00	0.00	0.00	NA	NA	0.00	XXX
74420	26	A	Contrst x-ray, urinary tract	0.36	0.14	0.13	0.14	0.13	0.02	XXX
74425		C	Contrst x-ray, urinary tract	0.00	0.00	0.00	NA	NA	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
74425	TC	C	Contrst x-ray, urinary tract	0.00	0.00	0.00	NA	NA	0.00	XXX
74425	26	A	Contrst x-ray, urinary tract	0.36	0.13	0.13	0.13	0.13	0.02	XXX
74430		A	Contrast x-ray, bladder	0.32	1.96	1.55	NA	NA	0.08	XXX
74430	TC	A	Contrast x-ray, bladder	0.00	1.84	1.44	NA	NA	0.06	XXX
74430	26	A	Contrast x-ray, bladder	0.32	0.12	0.11	0.12	0.11	0.02	XXX
74440		A	X-ray, male genital tract	0.38	2.11	1.68	NA	NA	0.08	XXX
74440	TC	A	X-ray, male genital tract	0.00	1.97	1.55	NA	NA	0.06	XXX
74440	26	A	X-ray, male genital tract	0.38	0.14	0.13	0.14	0.13	0.02	XXX
74445		C	X-ray exam of penis	0.00	0.00	0.00	NA	NA	0.00	XXX
74445	TC	C	X-ray exam of penis	0.00	0.00	0.00	NA	NA	0.00	XXX
74445	26	A	X-ray exam of penis	1.14	0.45	0.41	0.45	0.41	0.07	XXX
74450		C	X-ray, urethra/bladder	0.00	0.00	0.00	NA	NA	0.00	XXX
74450	TC	C	X-ray, urethra/bladder	0.00	0.00	0.00	NA	NA	0.00	XXX
74450	26	A	X-ray, urethra/bladder	0.33	0.12	0.12	0.12	0.12	0.02	XXX
74455		A	X-ray, urethra/bladder	0.33	2.18	1.94	NA	NA	0.12	XXX
74455	TC	A	X-ray, urethra/bladder	0.00	2.06	1.82	NA	NA	0.10	XXX
74455	26	A	X-ray, urethra/bladder	0.33	0.12	0.12	0.12	0.12	0.02	XXX
74470		C	X-ray exam of kidney lesion	0.00	0.00	0.00	NA	NA	0.00	XXX
74470	TC	C	X-ray exam of kidney lesion	0.00	0.00	0.00	NA	NA	0.00	XXX
74470	26	A	X-ray exam of kidney lesion	0.54	0.17	0.18	0.17	0.18	0.02	XXX
74475		A	X-ray control, cath insert	0.54	2.12	3.18	NA	NA	0.24	XXX
74475	TC	A	X-ray control, cath insert	0.00	1.92	2.99	NA	NA	0.22	XXX
74475	26	A	X-ray control, cath insert	0.54	0.20	0.19	0.20	0.19	0.02	XXX
74480		A	X-ray control, cath insert	0.54	2.13	3.19	NA	NA	0.24	XXX
74480	TC	A	X-ray control, cath insert	0.00	1.93	3.00	NA	NA	0.22	XXX
74480	26	A	X-ray control, cath insert	0.54	0.20	0.19	0.20	0.19	0.02	XXX
74485		A	X-ray guide, GU dilation	0.54	2.27	2.80	NA	NA	0.20	XXX
74485	TC	A	X-ray guide, GU dilation	0.00	2.07	2.61	NA	NA	0.17	XXX
74485	26	A	X-ray guide, GU dilation	0.54	0.20	0.19	0.20	0.19	0.03	XXX
74710		A	X-ray measurement of pelvis	0.34	0.64	0.90	NA	NA	0.08	XXX
74710	TC	A	X-ray measurement of pelvis	0.00	0.53	0.79	NA	NA	0.06	XXX
74710	26	A	X-ray measurement of pelvis	0.34	0.11	0.11	0.11	0.11	0.02	XXX
74740		A	X-ray, female genital tract	0.38	1.76	1.60	NA	NA	0.09	XXX
74740	TC	A	X-ray, female genital tract	0.00	1.63	1.47	NA	NA	0.07	XXX
74740	26	A	X-ray, female genital tract	0.38	0.13	0.13	0.13	0.13	0.02	XXX
74742		C	X-ray, fallopian tube	0.00	0.00	0.00	NA	NA	0.00	XXX
74742	TC	C	X-ray, fallopian tube	0.00	0.00	0.00	NA	NA	0.00	XXX
74742	26	A	X-ray, fallopian tube	0.61	0.19	0.20	0.19	0.20	0.03	XXX
74775		C	X-ray exam of perineum	0.00	0.00	0.00	NA	NA	0.00	XXX
74775	TC	C	X-ray exam of perineum	0.00	0.00	0.00	NA	NA	0.00	XXX
74775	26	A	X-ray exam of perineum	0.62	0.22	0.21	0.22	0.21	0.03	XXX
75557		A	Cardiac mri for morph	2.35	11.25	11.25	NA	NA	0.97	XXX
75557	TC	A	Cardiac mri for morph	0.00	10.31	10.31	NA	NA	0.87	XXX
75557	26	A	Cardiac mri for morph	2.35	0.94	0.94	0.94	0.94	0.10	XXX
75558		N	Cardiac mri flow/velocity	2.60	12.38	12.38	NA	NA	1.07	XXX
75558	TC	N	Cardiac mri flow/velocity	0.00	11.78	11.78	NA	NA	0.96	XXX
75558	26	N	Cardiac mri flow/velocity	2.60	0.60	0.60	0.60	0.60	0.11	XXX
75559		A	Cardiac mri w/stress img	2.95	17.24	17.24	NA	NA	0.97	XXX
75559	TC	A	Cardiac mri w/stress img	0.00	15.97	15.97	NA	NA	0.87	XXX
75559	26	A	Cardiac mri w/stress img	2.95	1.27	1.27	1.27	1.27	0.10	XXX
75560		N	Cardiac mri flow/vel/stress	3.00	16.82	16.82	NA	NA	1.00	XXX
75560	TC	N	Cardiac mri flow/vel/stress	0.00	16.13	16.13	NA	NA	0.89	XXX
75560	26	N	Cardiac mri flow/vel/stress	3.00	0.69	0.69	0.69	0.69	0.11	XXX
75561		A	Cardiac mri for morph w/dye	2.60	15.95	15.95	NA	NA	1.07	XXX
75561	TC	A	Cardiac mri for morph w/dye	0.00	14.92	14.92	NA	NA	0.96	XXX
75561	26	A	Cardiac mri for morph w/dye	2.60	1.03	1.03	1.03	1.03	0.11	XXX
75562		N	Card mri flow/vel w/dye	2.86	16.75	16.75	NA	NA	1.03	XXX
75562	TC	N	Card mri flow/vel w/dye	0.00	16.09	16.09	NA	NA	0.92	XXX
75562	26	N	Card mri flow/vel w/dye	2.86	0.66	0.66	0.66	0.66	0.11	XXX
75563		A	Card mri w/stress img & dye	3.00	20.20	20.20	NA	NA	1.08	XXX
75563	TC	A	Card mri w/stress img & dye	0.00	18.82	18.82	NA	NA	0.97	XXX
75563	26	A	Card mri w/stress img & dye	3.00	1.38	1.38	1.38	1.38	0.11	XXX
75564		N	Ht mri w/flo/vel/strs & dye	3.35	19.71	19.71	NA	NA	1.21	XXX
75564	TC	N	Ht mri w/flo/vel/strs & dye	0.00	18.94	18.94	NA	NA	1.08	XXX
75564	26	N	Ht mri w/flo/vel/strs & dye	3.35	0.77	0.77	0.77	0.77	0.13	XXX
75600		A	Contrast x-ray exam of aorta	0.49	6.42	9.61	NA	NA	0.67	XXX
75600	TC	A	Contrast x-ray exam of aorta	0.00	6.18	9.39	NA	NA	0.65	XXX
75600	26	A	Contrast x-ray exam of aorta	0.49	0.24	0.22	0.24	0.22	0.02	XXX
75605		A	Contrast x-ray exam of aorta	1.14	3.55	8.27	NA	NA	0.70	XXX
75605	TC	A	Contrast x-ray exam of aorta	0.00	3.06	7.83	NA	NA	0.65	XXX
75605	26	A	Contrast x-ray exam of aorta	1.14	0.49	0.44	0.49	0.44	0.05	XXX
75625		A	Contrast x-ray exam of aorta	1.14	3.35	8.16	NA	NA	0.71	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
75625	TC	A	Contrast x-ray exam of aorta	0.00	2.93	7.76	NA	NA	0.65	XXX
75625	26	A	Contrast x-ray exam of aorta	1.14	0.42	0.40	0.42	0.40	0.06	XXX
75630		A	X-ray aorta, leg arteries	1.79	3.76	8.75	NA	NA	0.80	XXX
75630	TC	A	X-ray aorta, leg arteries	0.00	3.05	8.09	NA	NA	0.69	XXX
75630	26	A	X-ray aorta, leg arteries	1.79	0.71	0.66	0.71	0.66	0.11	XXX
75635		A	Ct angio abdominal arteries	2.40	12.92	14.80	NA	NA	0.50	XXX
75635	TC	A	Ct angio abdominal arteries	0.00	12.00	13.95	NA	NA	0.39	XXX
75635	26	A	Ct angio abdominal arteries	2.40	0.92	0.85	0.92	0.85	0.11	XXX
75650		A	Artery x-rays, head & neck	1.49	3.52	8.30	NA	NA	0.72	XXX
75650	TC	A	Artery x-rays, head & neck	0.00	2.95	7.77	NA	NA	0.65	XXX
75650	26	A	Artery x-rays, head & neck	1.49	0.57	0.53	0.57	0.53	0.07	XXX
75658		A	Artery x-rays, arm	1.31	3.72	8.40	NA	NA	0.72	XXX
75658	TC	A	Artery x-rays, arm	0.00	3.28	7.94	NA	NA	0.65	XXX
75658	26	A	Artery x-rays, arm	1.31	0.44	0.46	0.44	0.46	0.07	XXX
75660		A	Artery x-rays, head & neck	1.31	3.88	8.46	NA	NA	0.71	XXX
75660	TC	A	Artery x-rays, head & neck	0.00	3.39	7.99	NA	NA	0.65	XXX
75660	26	A	Artery x-rays, head & neck	1.31	0.49	0.47	0.49	0.47	0.06	XXX
75662		A	Artery x-rays, head & neck	1.66	5.01	9.09	NA	NA	0.71	XXX
75662	TC	A	Artery x-rays, head & neck	0.00	4.31	8.45	NA	NA	0.65	XXX
75662	26	A	Artery x-rays, head & neck	1.66	0.70	0.64	0.70	0.64	0.06	XXX
75665		A	Artery x-rays, head & neck	1.31	4.09	8.57	NA	NA	0.74	XXX
75665	TC	A	Artery x-rays, head & neck	0.00	3.61	8.11	NA	NA	0.65	XXX
75665	26	A	Artery x-rays, head & neck	1.31	0.48	0.46	0.48	0.46	0.09	XXX
75671		A	Artery x-rays, head & neck	1.66	5.10	9.12	NA	NA	0.72	XXX
75671	TC	A	Artery x-rays, head & neck	0.00	4.46	8.53	NA	NA	0.65	XXX
75671	26	A	Artery x-rays, head & neck	1.66	0.64	0.59	0.64	0.59	0.07	XXX
75676		A	Artery x-rays, neck	1.31	3.86	8.45	NA	NA	0.72	XXX
75676	TC	A	Artery x-rays, neck	0.00	3.38	7.99	NA	NA	0.65	XXX
75676	26	A	Artery x-rays, neck	1.31	0.48	0.46	0.48	0.46	0.07	XXX
75680		A	Artery x-rays, neck	1.66	4.61	8.87	NA	NA	0.72	XXX
75680	TC	A	Artery x-rays, neck	0.00	3.95	8.27	NA	NA	0.65	XXX
75680	26	A	Artery x-rays, neck	1.66	0.66	0.60	0.66	0.60	0.07	XXX
75685		A	Artery x-rays, spine	1.31	3.88	8.46	NA	NA	0.71	XXX
75685	TC	A	Artery x-rays, spine	0.00	3.38	7.99	NA	NA	0.65	XXX
75685	26	A	Artery x-rays, spine	1.31	0.50	0.47	0.50	0.47	0.06	XXX
75705		A	Artery x-rays, spine	2.18	4.17	8.74	NA	NA	0.78	XXX
75705	TC	A	Artery x-rays, spine	0.00	3.37	7.98	NA	NA	0.65	XXX
75705	26	A	Artery x-rays, spine	2.18	0.80	0.76	0.80	0.76	0.13	XXX
75710		A	Artery x-rays, arm/leg	1.14	3.94	8.47	NA	NA	0.72	XXX
75710	TC	A	Artery x-rays, arm/leg	0.00	3.52	8.06	NA	NA	0.65	XXX
75710	26	A	Artery x-rays, arm/leg	1.14	0.42	0.41	0.42	0.41	0.07	XXX
75716		A	Artery x-rays, arms/legs	1.31	4.92	8.97	NA	NA	0.72	XXX
75716	TC	A	Artery x-rays, arms/legs	0.00	4.42	8.51	NA	NA	0.65	XXX
75716	26	A	Artery x-rays, arms/legs	1.31	0.50	0.46	0.50	0.46	0.07	XXX
75722		A	Artery x-rays, kidney	1.14	3.84	8.42	NA	NA	0.70	XXX
75722	TC	A	Artery x-rays, kidney	0.00	3.37	7.98	NA	NA	0.65	XXX
75722	26	A	Artery x-rays, kidney	1.14	0.47	0.44	0.47	0.44	0.05	XXX
75724		A	Artery x-rays, kidneys	1.49	5.12	9.14	NA	NA	0.70	XXX
75724	TC	A	Artery x-rays, kidneys	0.00	4.38	8.49	NA	NA	0.65	XXX
75724	26	A	Artery x-rays, kidneys	1.49	0.74	0.65	0.74	0.65	0.05	XXX
75726		A	Artery x-rays, abdomen	1.14	3.76	8.36	NA	NA	0.70	XXX
75726	TC	A	Artery x-rays, abdomen	0.00	3.34	7.97	NA	NA	0.65	XXX
75726	26	A	Artery x-rays, abdomen	1.14	0.42	0.39	0.42	0.39	0.05	XXX
75731		A	Artery x-rays, adrenal gland	1.14	4.09	8.54	NA	NA	0.71	XXX
75731	TC	A	Artery x-rays, adrenal gland	0.00	3.59	8.10	NA	NA	0.65	XXX
75731	26	A	Artery x-rays, adrenal gland	1.14	0.50	0.44	0.50	0.44	0.06	XXX
75733		A	Artery x-rays, adrenals	1.31	5.45	9.25	NA	NA	0.71	XXX
75733	TC	A	Artery x-rays, adrenals	0.00	4.80	8.70	NA	NA	0.65	XXX
75733	26	A	Artery x-rays, adrenals	1.31	0.65	0.55	0.65	0.55	0.06	XXX
75736		A	Artery x-rays, pelvis	1.14	3.87	8.42	NA	NA	0.71	XXX
75736	TC	A	Artery x-rays, pelvis	0.00	3.44	8.02	NA	NA	0.65	XXX
75736	26	A	Artery x-rays, pelvis	1.14	0.43	0.40	0.43	0.40	0.06	XXX
75741		A	Artery x-rays, lung	1.31	3.18	8.10	NA	NA	0.71	XXX
75741	TC	A	Artery x-rays, lung	0.00	2.69	7.64	NA	NA	0.65	XXX
75741	26	A	Artery x-rays, lung	1.31	0.49	0.46	0.49	0.46	0.06	XXX
75743		A	Artery x-rays, lungs	1.66	3.56	8.35	NA	NA	0.72	XXX
75743	TC	A	Artery x-rays, lungs	0.00	2.94	7.77	NA	NA	0.65	XXX
75743	26	A	Artery x-rays, lungs	1.66	0.62	0.58	0.62	0.58	0.07	XXX
75746		A	Artery x-rays, lung	1.14	3.52	8.25	NA	NA	0.70	XXX
75746	TC	A	Artery x-rays, lung	0.00	3.12	7.86	NA	NA	0.65	XXX
75746	26	A	Artery x-rays, lung	1.14	0.40	0.39	0.40	0.39	0.05	XXX
75756		A	Artery x-rays, chest	1.14	4.34	8.69	NA	NA	0.69	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
75756	TC	A	Artery x-rays, chest	0.00	3.76	8.18	NA	NA	0.65	XXX
75756	26	A	Artery x-rays, chest	1.14	0.58	0.51	0.58	0.51	0.04	XXX
75774		A	Artery x-ray, each vessel	0.36	2.50	7.61	NA	NA	0.67	ZZZ
75774	TC	A	Artery x-ray, each vessel	0.00	2.36	7.48	NA	NA	0.65	ZZZ
75774	26	A	Artery x-ray, each vessel	0.36	0.14	0.13	0.14	0.13	0.02	ZZZ
75790		A	Visualize A-V shunt	1.84	3.12	2.53	NA	NA	0.17	XXX
75790	TC	A	Visualize A-V shunt	0.00	2.52	1.93	NA	NA	0.08	XXX
75790	26	A	Visualize A-V shunt	1.84	0.60	0.60	0.60	0.60	0.09	XXX
75801		C	Lymph vessel x-ray, arm/leg	0.00	0.00	0.00	NA	NA	0.00	XXX
75801	TC	C	Lymph vessel x-ray, arm/leg	0.00	0.00	0.00	NA	NA	0.00	XXX
75801	26	A	Lymph vessel x-ray, arm/leg	0.81	0.22	0.25	0.22	0.25	0.08	XXX
75803		C	Lymph vessel x-ray, arms/legs	0.00	0.00	0.00	NA	NA	0.00	XXX
75803	TC	C	Lymph vessel x-ray, arms/legs	0.00	0.00	0.00	NA	NA	0.00	XXX
75803	26	A	Lymph vessel x-ray, arms/legs	1.17	0.40	0.39	0.40	0.39	0.05	XXX
75805		C	Lymph vessel x-ray, trunk	0.00	0.00	0.00	NA	NA	0.00	XXX
75805	TC	C	Lymph vessel x-ray, trunk	0.00	0.00	0.00	NA	NA	0.00	XXX
75805	26	A	Lymph vessel x-ray, trunk	0.81	0.27	0.27	0.27	0.27	0.05	XXX
75807		C	Lymph vessel x-ray, trunk	0.00	0.00	0.00	NA	NA	0.00	XXX
75807	TC	C	Lymph vessel x-ray, trunk	0.00	0.00	0.00	NA	NA	0.00	XXX
75807	26	A	Lymph vessel x-ray, trunk	1.17	0.39	0.39	0.39	0.39	0.05	XXX
75809		A	Nonvascular shunt, x-ray	0.47	2.17	1.54	NA	NA	0.07	XXX
75809	TC	A	Nonvascular shunt, x-ray	0.00	2.01	1.39	NA	NA	0.05	XXX
75809	26	A	Nonvascular shunt, x-ray	0.47	0.16	0.15	0.16	0.15	0.02	XXX
75810		C	Vein x-ray, spleen/liver	0.00	0.00	0.00	NA	NA	0.00	XXX
75810	TC	C	Vein x-ray, spleen/liver	0.00	0.00	0.00	NA	NA	0.00	XXX
75810	26	A	Vein x-ray, spleen/liver	1.14	0.39	0.38	0.39	0.38	0.05	XXX
75820		A	Vein x-ray, arm/leg	0.70	3.01	2.09	NA	NA	0.09	XXX
75820	TC	A	Vein x-ray, arm/leg	0.00	2.72	1.83	NA	NA	0.06	XXX
75820	26	A	Vein x-ray, arm/leg	0.70	0.29	0.26	0.29	0.26	0.03	XXX
75822		A	Vein x-ray, arms/legs	1.06	3.17	2.50	NA	NA	0.13	XXX
75822	TC	A	Vein x-ray, arms/legs	0.00	2.80	2.14	NA	NA	0.08	XXX
75822	26	A	Vein x-ray, arms/legs	1.06	0.37	0.36	0.37	0.36	0.05	XXX
75825		A	Vein x-ray, trunk	1.14	2.92	7.95	NA	NA	0.72	XXX
75825	TC	A	Vein x-ray, trunk	0.00	2.54	7.57	NA	NA	0.65	XXX
75825	26	A	Vein x-ray, trunk	1.14	0.38	0.38	0.38	0.38	0.07	XXX
75827		A	Vein x-ray, chest	1.14	2.95	7.96	NA	NA	0.70	XXX
75827	TC	A	Vein x-ray, chest	0.00	2.58	7.59	NA	NA	0.65	XXX
75827	26	A	Vein x-ray, chest	1.14	0.37	0.37	0.37	0.37	0.05	XXX
75831		A	Vein x-ray, kidney	1.14	3.05	8.00	NA	NA	0.71	XXX
75831	TC	A	Vein x-ray, kidney	0.00	2.67	7.63	NA	NA	0.65	XXX
75831	26	A	Vein x-ray, kidney	1.14	0.38	0.37	0.38	0.37	0.06	XXX
75833		A	Vein x-ray, kidneys	1.49	3.67	8.38	NA	NA	0.74	XXX
75833	TC	A	Vein x-ray, kidneys	0.00	3.17	7.88	NA	NA	0.65	XXX
75833	26	A	Vein x-ray, kidneys	1.49	0.50	0.50	0.50	0.50	0.09	XXX
75840		A	Vein x-ray, adrenal gland	1.14	2.96	7.97	NA	NA	0.72	XXX
75840	TC	A	Vein x-ray, adrenal gland	0.00	2.60	7.60	NA	NA	0.65	XXX
75840	26	A	Vein x-ray, adrenal gland	1.14	0.36	0.37	0.36	0.37	0.07	XXX
75842		A	Vein x-ray, adrenal glands	1.49	3.75	8.41	NA	NA	0.72	XXX
75842	TC	A	Vein x-ray, adrenal glands	0.00	3.20	7.90	NA	NA	0.65	XXX
75842	26	A	Vein x-ray, adrenal glands	1.49	0.55	0.51	0.55	0.51	0.07	XXX
75860		A	Vein x-ray, neck	1.14	3.39	8.19	NA	NA	0.69	XXX
75860	TC	A	Vein x-ray, neck	0.00	2.90	7.75	NA	NA	0.65	XXX
75860	26	A	Vein x-ray, neck	1.14	0.49	0.44	0.49	0.44	0.04	XXX
75870		A	Vein x-ray, skull	1.14	3.29	8.14	NA	NA	0.70	XXX
75870	TC	A	Vein x-ray, skull	0.00	2.89	7.74	NA	NA	0.65	XXX
75870	26	A	Vein x-ray, skull	1.14	0.40	0.40	0.40	0.40	0.05	XXX
75872		A	Vein x-ray, skull	1.14	4.04	8.51	NA	NA	0.79	XXX
75872	TC	A	Vein x-ray, skull	0.00	3.60	8.10	NA	NA	0.65	XXX
75872	26	A	Vein x-ray, skull	1.14	0.44	0.41	0.44	0.41	0.14	XXX
75880		A	Vein x-ray, eye socket	0.70	3.21	2.19	NA	NA	0.09	XXX
75880	TC	A	Vein x-ray, eye socket	0.00	2.94	1.94	NA	NA	0.06	XXX
75880	26	A	Vein x-ray, eye socket	0.70	0.27	0.25	0.27	0.25	0.03	XXX
75885		A	Vein x-ray, liver	1.44	3.18	8.12	NA	NA	0.71	XXX
75885	TC	A	Vein x-ray, liver	0.00	2.66	7.63	NA	NA	0.65	XXX
75885	26	A	Vein x-ray, liver	1.44	0.52	0.49	0.52	0.49	0.06	XXX
75887		A	Vein x-ray, liver	1.44	3.42	8.24	NA	NA	0.71	XXX
75887	TC	A	Vein x-ray, liver	0.00	2.85	7.72	NA	NA	0.65	XXX
75887	26	A	Vein x-ray, liver	1.44	0.57	0.52	0.57	0.52	0.06	XXX
75889		A	Vein x-ray, liver	1.14	3.07	8.02	NA	NA	0.70	XXX
75889	TC	A	Vein x-ray, liver	0.00	2.66	7.63	NA	NA	0.65	XXX
75889	26	A	Vein x-ray, liver	1.14	0.41	0.39	0.41	0.39	0.05	XXX
75891		A	Vein x-ray, liver	1.14	3.06	8.01	NA	NA	0.70	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fa- cility PE RVUs ²	Mal- practice RVUs ²	Global
75891	TC	A	Vein x-ray, liver	0.00	2.65	7.62	NA	NA	0.65	XXX
75891	26	A	Vein x-ray, liver	1.14	0.41	0.39	0.41	0.39	0.05	XXX
75893		A	Venous sampling by catheter	0.54	2.86	7.82	NA	NA	0.67	XXX
75893	TC	A	Venous sampling by catheter	0.00	2.66	7.63	NA	NA	0.65	XXX
75893	26	A	Venous sampling by catheter	0.54	0.20	0.19	0.20	0.19	0.02	XXX
75894		C	X-rays, transcath therapy	0.00	0.00	0.00	NA	NA	0.00	XXX
75894	TC	C	X-rays, transcath therapy	0.00	0.00	0.00	NA	NA	0.00	XXX
75894	26	A	X-rays, transcath therapy	1.31	0.46	0.44	0.46	0.44	0.08	XXX
75896		C	X-rays, transcath therapy	0.00	0.00	0.00	NA	NA	0.00	XXX
75896	TC	C	X-rays, transcath therapy	0.00	0.00	0.00	NA	NA	0.00	XXX
75896	26	A	X-rays, transcath therapy	1.31	0.52	0.48	0.52	0.48	0.05	XXX
75898		C	Follow-up angiography	0.00	0.00	0.00	NA	NA	0.00	XXX
75898	TC	C	Follow-up angiography	0.00	0.00	0.00	NA	NA	0.00	XXX
75898	26	A	Follow-up angiography	1.65	0.63	0.59	0.63	0.59	0.07	XXX
75900		C	Intravascular cath exchange	0.00	0.00	0.00	NA	NA	0.00	XXX
75900	TC	C	Intravascular cath exchange	0.00	0.00	0.00	NA	NA	0.00	XXX
75900	26	A	Intravascular cath exchange	0.49	0.17	0.16	0.17	0.16	0.03	XXX
75901		A	Remove cva device obstruct	0.49	4.15	2.80	NA	NA	0.85	XXX
75901	TC	A	Remove cva device obstruct	0.00	3.98	2.64	NA	NA	0.83	XXX
75901	26	A	Remove cva device obstruct	0.49	0.17	0.16	0.17	0.16	0.02	XXX
75902		A	Remove cva lumen obstruct	0.39	1.63	1.53	NA	NA	0.85	XXX
75902	TC	A	Remove cva lumen obstruct	0.00	1.50	1.40	NA	NA	0.83	XXX
75902	26	A	Remove cva lumen obstruct	0.39	0.13	0.13	0.13	0.13	0.02	XXX
75940		C	X-ray placement, vein filter	0.00	0.00	0.00	NA	NA	0.00	XXX
75940	TC	C	X-ray placement, vein filter	0.00	0.00	0.00	NA	NA	0.00	XXX
75940	26	A	X-ray placement, vein filter	0.54	0.18	0.18	0.18	0.18	0.04	XXX
75945		C	Intravascular us	0.00	0.00	0.00	NA	NA	0.00	XXX
75945	TC	C	Intravascular us	0.00	0.00	0.00	NA	NA	0.00	XXX
75945	26	A	Intravascular us	0.40	0.14	0.14	0.14	0.14	0.04	XXX
75946		C	Intravascular us add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
75946	TC	C	Intravascular us add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
75946	26	A	Intravascular us add-on	0.40	0.12	0.13	0.12	0.13	0.05	ZZZ
75952		C	Endovasc repair abdom aorta	0.00	0.00	0.00	NA	NA	0.00	XXX
75952	TC	C	Endovasc repair abdom aorta	0.00	0.00	0.00	NA	NA	0.00	XXX
75952	26	A	Endovasc repair abdom aorta	4.49	1.30	1.39	1.30	1.39	0.43	XXX
75953		C	Abdom aneurysm endovas rpr	0.00	0.00	0.00	NA	NA	0.00	XXX
75953	TC	C	Abdom aneurysm endovas rpr	0.00	0.00	0.00	NA	NA	0.00	XXX
75953	26	A	Abdom aneurysm endovas rpr	1.36	0.40	0.42	0.40	0.42	0.13	XXX
75954		C	Iliac aneurysm endovas rpr	0.00	0.00	0.00	NA	NA	0.00	XXX
75954	TC	C	Iliac aneurysm endovas rpr	0.00	0.00	0.00	NA	NA	0.00	XXX
75954	26	A	Iliac aneurysm endovas rpr	2.25	0.63	0.70	0.63	0.70	0.15	XXX
75956		C	Xray, endovasc thor ao repr	0.00	0.00	0.00	NA	NA	0.00	XXX
75956	TC	C	Xray, endovasc thor ao repr	0.00	0.00	0.00	NA	NA	0.00	XXX
75956	26	A	Xray, endovasc thor ao repr	7.00	1.88	2.29	1.88	2.29	0.69	XXX
75957		C	Xray, endovasc thor ao repr	0.00	0.00	0.00	NA	NA	0.00	XXX
75957	TC	C	Xray, endovasc thor ao repr	0.00	0.00	0.00	NA	NA	0.00	XXX
75957	26	A	Xray, endovasc thor ao repr	6.00	1.63	1.97	1.63	1.97	0.59	XXX
75958		C	Xray, place prox ext thor ao	0.00	0.00	0.00	NA	NA	0.00	XXX
75958	TC	C	Xray, place prox ext thor ao	0.00	0.00	0.00	NA	NA	0.00	XXX
75958	26	A	Xray, place prox ext thor ao	4.00	1.04	1.29	1.04	1.29	0.39	XXX
75959		C	Xray, place dist ext thor ao	0.00	0.00	0.00	NA	NA	0.00	XXX
75959	TC	C	Xray, place dist ext thor ao	0.00	0.00	0.00	NA	NA	0.00	XXX
75959	26	A	Xray, place dist ext thor ao	3.50	0.92	1.14	0.92	1.14	0.34	XXX
75960		A	Transcath iv stent rs&i	0.82	2.71	8.94	NA	NA	0.82	XXX
75960	TC	A	Transcath iv stent rs&i	0.00	2.39	8.64	NA	NA	0.77	XXX
75960	26	A	Transcath iv stent rs&i	0.82	0.32	0.30	0.32	0.30	0.05	XXX
75961		A	Retrieval, broken catheter	4.24	4.66	8.28	NA	NA	0.73	XXX
75961	TC	A	Retrieval, broken catheter	0.00	3.18	6.84	NA	NA	0.55	XXX
75961	26	A	Retrieval, broken catheter	4.24	1.48	1.44	1.48	1.44	0.18	XXX
75962		A	Repair arterial blockage	0.54	3.50	9.71	NA	NA	0.86	XXX
75962	TC	A	Repair arterial blockage	0.00	3.30	9.52	NA	NA	0.83	XXX
75962	26	A	Repair arterial blockage	0.54	0.20	0.19	0.20	0.19	0.03	XXX
75964		A	Repair artery blockage, each	0.36	2.35	5.42	NA	NA	0.46	ZZZ
75964	TC	A	Repair artery blockage, each	0.00	2.22	5.30	NA	NA	0.43	ZZZ
75964	26	A	Repair artery blockage, each	0.36	0.13	0.12	0.13	0.12	0.03	ZZZ
75966		A	Repair arterial blockage	1.31	4.16	10.17	NA	NA	0.89	XXX
75966	TC	A	Repair arterial blockage	0.00	3.59	9.66	NA	NA	0.83	XXX
75966	26	A	Repair arterial blockage	1.31	0.57	0.51	0.57	0.51	0.06	XXX
75968		A	Repair artery blockage, each	0.36	2.41	5.46	NA	NA	0.45	ZZZ
75968	TC	A	Repair artery blockage, each	0.00	2.25	5.32	NA	NA	0.43	ZZZ
75968	26	A	Repair artery blockage, each	0.36	0.16	0.14	0.16	0.14	0.02	ZZZ
75970		C	Vascular biopsy	0.00	0.00	0.00	NA	NA	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
75970	TC	C	Vascular biopsy	0.00	0.00	0.00	NA	NA	0.00	XXX
75970	26	A	Vascular biopsy	0.83	0.31	0.29	0.31	0.29	0.04	XXX
75978		A	Repair venous blockage	0.54	3.26	9.59	NA	NA	0.85	XXX
75978	TC	A	Repair venous blockage	0.00	3.08	9.41	NA	NA	0.83	XXX
75978	26	A	Repair venous blockage	0.54	0.18	0.18	0.18	0.18	0.02	XXX
75980		C	Contrast xray exam bile duct	0.00	0.00	0.00	NA	NA	0.00	XXX
75980	TC	C	Contrast xray exam bile duct	0.00	0.00	0.00	NA	NA	0.00	XXX
75980	26	A	Contrast xray exam bile duct	1.44	0.52	0.49	0.52	0.49	0.06	XXX
75982		C	Contrast xray exam bile duct	0.00	0.00	0.00	NA	NA	0.00	XXX
75982	TC	C	Contrast xray exam bile duct	0.00	0.00	0.00	NA	NA	0.00	XXX
75982	26	A	Contrast xray exam bile duct	1.44	0.52	0.50	0.52	0.50	0.06	XXX
75984		A	Xray control catheter change	0.72	2.31	2.24	NA	NA	0.14	XXX
75984	TC	A	Xray control catheter change	0.00	2.05	2.00	NA	NA	0.11	XXX
75984	26	A	Xray control catheter change	0.72	0.26	0.24	0.26	0.24	0.03	XXX
75989		A	Abscess drainage under x-ray	1.19	2.24	2.89	NA	NA	0.22	XXX
75989	TC	A	Abscess drainage under x-ray	0.00	1.82	2.48	NA	NA	0.17	XXX
75989	26	A	Abscess drainage under x-ray	1.19	0.42	0.41	0.42	0.41	0.05	XXX
75992		C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	XXX
75992	TC	C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	XXX
75992	26	A	Atherectomy, x-ray exam	0.54	0.22	0.21	0.22	0.21	0.03	XXX
75993		C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	ZZZ
75993	TC	C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	ZZZ
75993	26	A	Atherectomy, x-ray exam	0.36	0.14	0.13	0.14	0.13	0.02	ZZZ
75994		C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	XXX
75994	TC	C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	XXX
75994	26	A	Atherectomy, x-ray exam	1.31	0.54	0.50	0.54	0.50	0.07	XXX
75995		C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	XXX
75995	TC	C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	XXX
75995	26	A	Atherectomy, x-ray exam	1.31	0.48	0.47	0.48	0.47	0.05	XXX
75996		C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	ZZZ
75996	TC	C	Atherectomy, x-ray exam	0.00	0.00	0.00	NA	NA	0.00	ZZZ
75996	26	A	Atherectomy, x-ray exam	0.36	0.12	0.12	0.12	0.12	0.02	ZZZ
76000		A	Fluoroscope examination	0.17	2.77	2.06	NA	NA	0.08	XXX
76000	TC	A	Fluoroscope examination	0.00	2.71	2.01	NA	NA	0.07	XXX
76000	26	A	Fluoroscope examination	0.17	0.06	0.05	0.06	0.05	0.01	XXX
76001		C	Fluoroscope exam, extensive	0.00	0.00	0.00	NA	NA	0.00	XXX
76001	TC	C	Fluoroscope exam, extensive	0.00	0.00	0.00	NA	NA	0.00	XXX
76001	26	A	Fluoroscope exam, extensive	0.67	0.24	0.23	0.24	0.23	0.05	XXX
76010		A	X-ray, nose to rectum	0.18	0.54	0.56	NA	NA	0.03	XXX
76010	TC	A	X-ray, nose to rectum	0.00	0.48	0.50	NA	NA	0.02	XXX
76010	26	A	X-ray, nose to rectum	0.18	0.06	0.06	0.06	0.06	0.01	XXX
76080		A	X-ray exam of fistula	0.54	1.10	1.16	NA	NA	0.08	XXX
76080	TC	A	X-ray exam of fistula	0.00	0.90	0.97	NA	NA	0.06	XXX
76080	26	A	X-ray exam of fistula	0.54	0.20	0.19	0.20	0.19	0.02	XXX
76098		A	X-ray exam, breast specimen	0.16	0.32	0.39	NA	NA	0.03	XXX
76098	TC	A	X-ray exam, breast specimen	0.00	0.27	0.34	NA	NA	0.02	XXX
76098	26	A	X-ray exam, breast specimen	0.16	0.05	0.05	0.05	0.05	0.01	XXX
76100		A	X-ray exam of body section	0.58	3.55	2.50	NA	NA	0.10	XXX
76100	TC	A	X-ray exam of body section	0.00	3.35	2.30	NA	NA	0.07	XXX
76100	26	A	X-ray exam of body section	0.58	0.20	0.20	0.20	0.20	0.03	XXX
76101		A	Complex body section x-ray	0.58	5.45	3.53	NA	NA	0.11	XXX
76101	TC	A	Complex body section x-ray	0.00	5.27	3.34	NA	NA	0.08	XXX
76101	26	A	Complex body section x-ray	0.58	0.18	0.19	0.18	0.19	0.03	XXX
76102		A	Complex body section x-rays	0.58	7.64	4.78	NA	NA	0.14	XXX
76102	TC	A	Complex body section x-rays	0.00	7.46	4.60	NA	NA	0.11	XXX
76102	26	A	Complex body section x-rays	0.58	0.18	0.18	0.18	0.18	0.03	XXX
76120		A	Cine/video x-rays	0.38	1.87	1.52	NA	NA	0.08	XXX
76120	TC	A	Cine/video x-rays	0.00	1.74	1.39	NA	NA	0.06	XXX
76120	26	A	Cine/video x-rays	0.38	0.13	0.13	0.13	0.13	0.02	XXX
76125		C	Cine/video x-rays add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
76125	TC	C	Cine/video x-rays add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
76125	26	A	Cine/video x-rays add-on	0.27	0.12	0.11	0.12	0.11	0.01	ZZZ
76140		I	X-ray consultation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76150		A	X-ray exam, dry process	0.00	0.68	0.55	NA	NA	0.02	XXX
76350		C	Special x-ray contrast study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76376		A	3d render w/o postprocess	0.20	1.40	2.45	NA	NA	0.10	XXX
76376	TC	A	3d render w/o postprocess	0.00	1.33	2.38	NA	NA	0.08	XXX
76376	26	A	3d render w/o postprocess	0.20	0.07	0.07	0.07	0.07	0.02	XXX
76377		A	3d rendering w/postprocess	0.79	1.40	2.54	NA	NA	0.39	XXX
76377	TC	A	3d rendering w/postprocess	0.00	1.12	2.27	NA	NA	0.31	XXX
76377	26	A	3d rendering w/postprocess	0.79	0.28	0.27	0.28	0.27	0.08	XXX
76380		A	CAT scan follow-up study	0.98	4.71	4.26	NA	NA	0.22	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
76380	TC	A	CAT scan follow-up study	0.00	4.37	3.93	NA	NA	0.18	XXX
76380	26	A	CAT scan follow-up study	0.98	0.34	0.33	0.34	0.33	0.04	XXX
76390		N	Mr spectroscopy	1.40	9.42	10.44	NA	NA	0.66	XXX
76390	TC	N	Mr spectroscopy	0.00	9.10	10.05	NA	NA	0.59	XXX
76390	26	N	Mr spectroscopy	1.40	0.32	0.39	0.32	0.39	0.07	XXX
76496		C	Fluoroscopic procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76496	TC	C	Fluoroscopic procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76496	26	C	Fluoroscopic procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76497		C	Ct procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76497	TC	C	Ct procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76497	26	C	Ct procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76498		C	Mri procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76498	TC	C	Mri procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76498	26	C	Mri procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76499		C	Radiographic procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76499	TC	C	Radiographic procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76499	26	C	Radiographic procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76506		A	Echo exam of head	0.63	2.76	2.21	NA	NA	0.14	XXX
76506	TC	A	Echo exam of head	0.00	2.56	1.99	NA	NA	0.08	XXX
76506	26	A	Echo exam of head	0.63	0.20	0.22	0.20	0.22	0.06	XXX
76510		A	Ophth us, b & quant a	1.55	2.25	2.55	NA	NA	0.10	XXX
76510	TC	A	Ophth us, b & quant a	0.00	1.70	1.94	NA	NA	0.07	XXX
76510	26	A	Ophth us, b & quant a	1.55	0.55	0.61	0.55	0.61	0.03	XXX
76511		A	Ophth us, quant a only	0.94	1.35	1.88	NA	NA	0.10	XXX
76511	TC	A	Ophth us, quant a only	0.00	1.02	1.52	NA	NA	0.07	XXX
76511	26	A	Ophth us, quant a only	0.94	0.33	0.36	0.33	0.36	0.03	XXX
76512		A	Ophth us, b w/non-quant a	0.94	1.16	1.69	NA	NA	0.12	XXX
76512	TC	A	Ophth us, b w/non-quant a	0.00	0.83	1.32	NA	NA	0.10	XXX
76512	26	A	Ophth us, b w/non-quant a	0.94	0.33	0.37	0.33	0.37	0.02	XXX
76513		A	Echo exam of eye, water bath	0.66	1.52	1.66	NA	NA	0.12	XXX
76513	TC	A	Echo exam of eye, water bath	0.00	1.29	1.40	NA	NA	0.10	XXX
76513	26	A	Echo exam of eye, water bath	0.66	0.23	0.26	0.23	0.26	0.02	XXX
76514		A	Echo exam of eye, thickness	0.17	0.16	0.15	NA	NA	0.02	XXX
76514	TC	A	Echo exam of eye, thickness	0.00	0.10	0.08	NA	NA	0.01	XXX
76514	26	A	Echo exam of eye, thickness	0.17	0.06	0.07	0.06	0.07	0.01	XXX
76516		A	Echo exam of eye	0.54	1.15	1.30	NA	NA	0.08	XXX
76516	TC	A	Echo exam of eye	0.00	0.97	1.09	NA	NA	0.07	XXX
76516	26	A	Echo exam of eye	0.54	0.18	0.21	0.18	0.21	0.01	XXX
76519		A	Echo exam of eye	0.54	1.28	1.42	NA	NA	0.08	XXX
76519	TC	A	Echo exam of eye	0.00	1.09	1.20	NA	NA	0.07	XXX
76519	26	A	Echo exam of eye	0.54	0.19	0.22	0.19	0.22	0.01	XXX
76529		A	Echo exam of eye	0.57	1.15	1.26	NA	NA	0.10	XXX
76529	TC	A	Echo exam of eye	0.00	0.95	1.04	NA	NA	0.08	XXX
76529	26	A	Echo exam of eye	0.57	0.20	0.22	0.20	0.22	0.02	XXX
76536		A	Us exam of head and neck	0.56	2.67	2.13	NA	NA	0.10	XXX
76536	TC	A	Us exam of head and neck	0.00	2.49	1.95	NA	NA	0.08	XXX
76536	26	A	Us exam of head and neck	0.56	0.18	0.18	0.18	0.18	0.02	XXX
76604		A	Us exam, chest	0.55	1.83	1.66	NA	NA	0.09	XXX
76604	TC	A	Us exam, chest	0.00	1.64	1.47	NA	NA	0.07	XXX
76604	26	A	Us exam, chest	0.55	0.19	0.19	0.19	0.19	0.02	XXX
76645		A	Us exam, breast(s)	0.54	2.12	1.67	NA	NA	0.08	XXX
76645	TC	A	Us exam, breast(s)	0.00	1.93	1.49	NA	NA	0.06	XXX
76645	26	A	Us exam, breast(s)	0.54	0.19	0.18	0.19	0.18	0.02	XXX
76700		A	Us exam, abdom, complete	0.81	3.02	2.63	NA	NA	0.15	XXX
76700	TC	A	Us exam, abdom, complete	0.00	2.75	2.36	NA	NA	0.11	XXX
76700	26	A	Us exam, abdom, complete	0.81	0.27	0.27	0.27	0.27	0.04	XXX
76705		A	Echo exam of abdomen	0.59	2.35	1.98	NA	NA	0.11	XXX
76705	TC	A	Echo exam of abdomen	0.00	2.14	1.78	NA	NA	0.08	XXX
76705	26	A	Echo exam of abdomen	0.59	0.21	0.20	0.21	0.20	0.03	XXX
76770		A	Us exam abdo back wall, comp	0.74	2.93	2.57	NA	NA	0.14	XXX
76770	TC	A	Us exam abdo back wall, comp	0.00	2.67	2.32	NA	NA	0.11	XXX
76770	26	A	Us exam abdo back wall, comp	0.74	0.26	0.25	0.26	0.25	0.03	XXX
76775		A	Us exam abdo back wall, lim	0.58	2.42	2.01	NA	NA	0.11	XXX
76775	TC	A	Us exam abdo back wall, lim	0.00	2.21	1.81	NA	NA	0.08	XXX
76775	26	A	Us exam abdo back wall, lim	0.58	0.21	0.20	0.21	0.20	0.03	XXX
76776		A	Us exam k transpl w/doppler	0.76	3.43	2.82	NA	NA	0.14	XXX
76776	TC	A	Us exam k transpl w/doppler	0.00	3.16	2.57	NA	NA	0.11	XXX
76776	26	A	Us exam k transpl w/doppler	0.76	0.27	0.25	0.27	0.25	0.03	XXX
76800		A	Us exam, spinal canal	1.13	2.31	2.03	NA	NA	0.13	XXX
76800	TC	A	Us exam, spinal canal	0.00	2.03	1.72	NA	NA	0.08	XXX
76800	26	A	Us exam, spinal canal	1.13	0.28	0.31	0.28	0.31	0.05	XXX
76801		A	Ob us < 14 wks, single fetus	0.99	2.46	2.45	NA	NA	0.16	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
76801	TC	A	Ob us < 14 wks, single fetus	0.00	2.16	2.13	NA	NA	0.12	XXX
76801	26	A	Ob us < 14 wks, single fetus	0.99	0.30	0.32	0.30	0.32	0.04	XXX
76802		A	Ob us < 14 wks, add'l fetus	0.83	0.97	1.16	NA	NA	0.16	ZZZ
76802	TC	A	Ob us < 14 wks, add'l fetus	0.00	0.71	0.88	NA	NA	0.12	ZZZ
76802	26	A	Ob us < 14 wks, add'l fetus	0.83	0.26	0.28	0.26	0.28	0.04	ZZZ
76805		A	Ob us >= 14 wks, snl fetus	0.99	3.04	2.74	NA	NA	0.16	XXX
76805	TC	A	Ob us >= 14 wks, snl fetus	0.00	2.73	2.42	NA	NA	0.12	XXX
76805	26	A	Ob us >= 14 wks, snl fetus	0.99	0.31	0.32	0.31	0.32	0.04	XXX
76810		A	Ob us >= 14 wks, addl fetus	0.98	1.65	1.52	NA	NA	0.26	ZZZ
76810	TC	A	Ob us >= 14 wks, addl fetus	0.00	1.35	1.20	NA	NA	0.22	ZZZ
76810	26	A	Ob us >= 14 wks, addl fetus	0.98	0.30	0.32	0.30	0.32	0.04	ZZZ
76811		A	Ob us, detailed, snl fetus	1.90	3.05	3.64	NA	NA	0.52	XXX
76811	TC	A	Ob us, detailed, snl fetus	0.00	2.51	3.02	NA	NA	0.43	XXX
76811	26	A	Ob us, detailed, snl fetus	1.90	0.54	0.62	0.54	0.62	0.09	XXX
76812		A	Ob us, detailed, addl fetus	1.78	3.98	2.84	NA	NA	0.49	ZZZ
76812	TC	A	Ob us, detailed, addl fetus	0.00	3.48	2.26	NA	NA	0.41	ZZZ
76812	26	A	Ob us, detailed, addl fetus	1.78	0.50	0.58	0.50	0.58	0.08	ZZZ
76813		A	Ob us nuchal meas, 1 gest	1.18	2.21	2.21	NA	NA	0.19	XXX
76813	TC	A	Ob us nuchal meas, 1 gest	0.00	1.81	1.81	NA	NA	0.14	XXX
76813	26	A	Ob us nuchal meas, 1 gest	1.18	0.40	0.40	0.40	0.40	0.05	XXX
76814		A	Ob us nuchal meas, add-on	0.99	1.15	1.15	NA	NA	0.19	XXX
76814	TC	A	Ob us nuchal meas, add-on	0.00	0.86	0.86	NA	NA	0.14	XXX
76814	26	A	Ob us nuchal meas, add-on	0.99	0.29	0.29	0.29	0.29	0.05	XXX
76815		A	Ob us, limited, fetus(s)	0.65	1.80	1.72	NA	NA	0.11	XXX
76815	TC	A	Ob us, limited, fetus(s)	0.00	1.60	1.51	NA	NA	0.08	XXX
76815	26	A	Ob us, limited, fetus(s)	0.65	0.20	0.21	0.20	0.21	0.03	XXX
76816		A	Ob us, follow-up, per fetus	0.85	2.38	1.90	NA	NA	0.10	XXX
76816	TC	A	Ob us, follow-up, per fetus	0.00	2.13	1.62	NA	NA	0.06	XXX
76816	26	A	Ob us, follow-up, per fetus	0.85	0.25	0.28	0.25	0.28	0.04	XXX
76817		A	Transvaginal us, obstetric	0.75	2.02	1.89	NA	NA	0.09	XXX
76817	TC	A	Transvaginal us, obstetric	0.00	1.79	1.65	NA	NA	0.06	XXX
76817	26	A	Transvaginal us, obstetric	0.75	0.23	0.24	0.23	0.24	0.03	XXX
76818		A	Fetal biophys profile w/nst	1.05	2.21	2.11	NA	NA	0.15	XXX
76818	TC	A	Fetal biophys profile w/nst	0.00	1.91	1.76	NA	NA	0.10	XXX
76818	26	A	Fetal biophys profile w/nst	1.05	0.30	0.35	0.30	0.35	0.05	XXX
76819		A	Fetal biophys profil w/o nst	0.77	1.63	1.75	NA	NA	0.13	XXX
76819	TC	A	Fetal biophys profil w/o nst	0.00	1.40	1.50	NA	NA	0.10	XXX
76819	26	A	Fetal biophys profil w/o nst	0.77	0.23	0.25	0.23	0.25	0.03	XXX
76820		A	Umbilical artery echo	0.50	0.56	1.18	NA	NA	0.15	XXX
76820	TC	A	Umbilical artery echo	0.00	0.42	1.01	NA	NA	0.12	XXX
76820	26	A	Umbilical artery echo	0.50	0.14	0.17	0.14	0.17	0.03	XXX
76821		A	Middle cerebral artery echo	0.70	1.86	1.87	NA	NA	0.15	XXX
76821	TC	A	Middle cerebral artery echo	0.00	1.66	1.63	NA	NA	0.12	XXX
76821	26	A	Middle cerebral artery echo	0.70	0.20	0.24	0.20	0.24	0.03	XXX
76825		A	Echo exam of fetal heart	1.67	4.37	3.47	NA	NA	0.18	XXX
76825	TC	A	Echo exam of fetal heart	0.00	3.87	2.92	NA	NA	0.11	XXX
76825	26	A	Echo exam of fetal heart	1.67	0.50	0.55	0.50	0.55	0.07	XXX
76826		A	Echo exam of fetal heart	0.83	2.76	1.88	NA	NA	0.08	XXX
76826	TC	A	Echo exam of fetal heart	0.00	2.52	1.61	NA	NA	0.05	XXX
76826	26	A	Echo exam of fetal heart	0.83	0.24	0.27	0.24	0.27	0.03	XXX
76827		A	Echo exam of fetal heart	0.58	1.07	1.50	NA	NA	0.14	XXX
76827	TC	A	Echo exam of fetal heart	0.00	0.90	1.31	NA	NA	0.12	XXX
76827	26	A	Echo exam of fetal heart	0.58	0.17	0.19	0.17	0.19	0.02	XXX
76828		A	Echo exam of fetal heart	0.56	0.63	0.98	NA	NA	0.11	XXX
76828	TC	A	Echo exam of fetal heart	0.00	0.48	0.79	NA	NA	0.08	XXX
76828	26	A	Echo exam of fetal heart	0.56	0.15	0.19	0.15	0.19	0.03	XXX
76830		A	Transvaginal us, non-ob	0.69	2.76	2.26	NA	NA	0.13	XXX
76830	TC	A	Transvaginal us, non-ob	0.00	2.54	2.03	NA	NA	0.10	XXX
76830	26	A	Transvaginal us, non-ob	0.69	0.22	0.23	0.22	0.23	0.03	XXX
76831		A	Echo exam, uterus	0.72	2.73	2.25	NA	NA	0.13	XXX
76831	TC	A	Echo exam, uterus	0.00	2.52	2.02	NA	NA	0.10	XXX
76831	26	A	Echo exam, uterus	0.72	0.21	0.23	0.21	0.23	0.03	XXX
76856		A	Us exam, pelvic, complete	0.69	2.79	2.26	NA	NA	0.13	XXX
76856	TC	A	Us exam, pelvic, complete	0.00	2.55	2.03	NA	NA	0.10	XXX
76856	26	A	Us exam, pelvic, complete	0.69	0.24	0.23	0.24	0.23	0.03	XXX
76857		A	Us exam, pelvic, limited	0.38	2.48	2.15	NA	NA	0.08	XXX
76857	TC	A	Us exam, pelvic, limited	0.00	2.34	2.02	NA	NA	0.06	XXX
76857	26	A	Us exam, pelvic, limited	0.38	0.14	0.13	0.14	0.13	0.02	XXX
76870		A	Us exam, scrotum	0.64	2.83	2.28	NA	NA	0.13	XXX
76870	TC	A	Us exam, scrotum	0.00	2.60	2.06	NA	NA	0.10	XXX
76870	26	A	Us exam, scrotum	0.64	0.23	0.22	0.23	0.22	0.03	XXX
76872		A	Us, transrectal	0.69	3.40	2.82	NA	NA	0.14	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
76872	TC	A	Us, transrectal	0.00	3.13	2.58	NA	NA	0.10	XXX
76872	26	A	Us, transrectal	0.69	0.27	0.24	0.27	0.24	0.04	XXX
76873		A	Echograp trans r, pros study	1.55	3.40	2.99	NA	NA	0.25	XXX
76873	TC	A	Echograp trans r, pros study	0.00	2.85	2.47	NA	NA	0.16	XXX
76873	26	A	Echograp trans r, pros study	1.55	0.55	0.52	0.55	0.52	0.09	XXX
76880		A	Us exam, extremity	0.59	3.18	2.40	NA	NA	0.11	XXX
76880	TC	A	Us exam, extremity	0.00	3.00	2.21	NA	NA	0.08	XXX
76880	26	A	Us exam, extremity	0.59	0.18	0.19	0.18	0.19	0.03	XXX
76885		A	Us exam infant hips, dynamic	0.74	3.26	2.50	NA	NA	0.13	XXX
76885	TC	A	Us exam infant hips, dynamic	0.00	3.01	2.26	NA	NA	0.10	XXX
76885	26	A	Us exam infant hips, dynamic	0.74	0.25	0.24	0.25	0.24	0.03	XXX
76886		A	Us exam infant hips, static	0.62	2.27	1.94	NA	NA	0.11	XXX
76886	TC	A	Us exam infant hips, static	0.00	2.05	1.73	NA	NA	0.08	XXX
76886	26	A	Us exam infant hips, static	0.62	0.22	0.21	0.22	0.21	0.03	XXX
76930		A	Echo guide, cardiocentesis	0.67	2.08	1.92	NA	NA	0.12	XXX
76930	TC	A	Echo guide, cardiocentesis	0.00	1.74	1.63	NA	NA	0.10	XXX
76930	26	A	Echo guide, cardiocentesis	0.67	0.34	0.29	0.34	0.29	0.02	XXX
76932		C	Echo guide for heart biopsy	0.00	0.00	0.00	NA	NA	0.00	XXX
76932	TC	C	Echo guide for heart biopsy	0.00	0.00	0.00	NA	NA	0.00	XXX
76932	26	A	Echo guide for heart biopsy	0.67	0.35	0.30	0.35	0.30	0.02	XXX
76936		A	Echo guide for artery repair	1.99	6.12	6.54	NA	NA	0.47	XXX
76936	TC	A	Echo guide for artery repair	0.00	5.41	5.85	NA	NA	0.34	XXX
76936	26	A	Echo guide for artery repair	1.99	0.71	0.69	0.71	0.69	0.13	XXX
76937		A	Us guide, vascular access	0.30	0.62	0.55	NA	NA	0.13	ZZZ
76937	TC	A	Us guide, vascular access	0.00	0.52	0.45	NA	NA	0.10	ZZZ
76937	26	A	Us guide, vascular access	0.30	0.10	0.10	0.10	0.10	0.03	ZZZ
76940		C	Us guide, tissue ablation	0.00	0.00	0.00	NA	NA	0.00	XXX
76940	TC	C	Us guide, tissue ablation	0.00	0.00	0.00	NA	NA	0.00	XXX
76940	26	A	Us guide, tissue ablation	2.00	0.65	0.65	0.65	0.65	0.31	XXX
76941		C	Echo guide for transfusion	0.00	0.00	0.00	NA	NA	0.00	XXX
76941	TC	C	Echo guide for transfusion	0.00	0.00	0.00	NA	NA	0.00	XXX
76941	26	A	Echo guide for transfusion	1.34	0.38	0.42	0.38	0.42	0.07	XXX
76942		A	Echo guide for biopsy	0.67	4.79	3.91	NA	NA	0.13	XXX
76942	TC	A	Echo guide for biopsy	0.00	4.55	3.68	NA	NA	0.10	XXX
76942	26	A	Echo guide for biopsy	0.67	0.24	0.23	0.24	0.23	0.03	XXX
76945		C	Echo guide, villus sampling	0.00	0.00	0.00	NA	NA	0.00	XXX
76945	TC	C	Echo guide, villus sampling	0.00	0.00	0.00	NA	NA	0.00	XXX
76945	26	A	Echo guide, villus sampling	0.67	0.21	0.21	0.21	0.21	0.03	XXX
76946		A	Echo guide for amniocentesis	0.38	0.45	1.05	NA	NA	0.12	XXX
76946	TC	A	Echo guide for amniocentesis	0.00	0.34	0.93	NA	NA	0.10	XXX
76946	26	A	Echo guide for amniocentesis	0.38	0.11	0.12	0.11	0.12	0.02	XXX
76948		A	Echo guide, ova aspiration	0.38	0.45	1.04	NA	NA	0.12	XXX
76948	TC	A	Echo guide, ova aspiration	0.00	0.35	0.93	NA	NA	0.10	XXX
76948	26	A	Echo guide, ova aspiration	0.38	0.10	0.11	0.10	0.11	0.02	XXX
76950		A	Echo guidance radiotherapy	0.58	1.21	1.35	NA	NA	0.10	XXX
76950	TC	A	Echo guidance radiotherapy	0.00	1.02	1.16	NA	NA	0.07	XXX
76950	26	A	Echo guidance radiotherapy	0.58	0.19	0.19	0.19	0.19	0.03	XXX
76965		A	Echo guidance radiotherapy	1.34	1.20	3.60	NA	NA	0.37	XXX
76965	TC	A	Echo guidance radiotherapy	0.00	0.70	3.14	NA	NA	0.29	XXX
76965	26	A	Echo guidance radiotherapy	1.34	0.50	0.46	0.50	0.46	0.08	XXX
76970		A	Ultrasound exam follow-up	0.40	1.98	1.58	NA	NA	0.08	XXX
76970	TC	A	Ultrasound exam follow-up	0.00	1.87	1.46	NA	NA	0.06	XXX
76970	26	A	Ultrasound exam follow-up	0.40	0.11	0.12	0.11	0.12	0.02	XXX
76975		C	GI endoscopic ultrasound	0.00	0.00	0.00	NA	NA	0.00	XXX
76975	TC	C	GI endoscopic ultrasound	0.00	0.00	0.00	NA	NA	0.00	XXX
76975	26	A	GI endoscopic ultrasound	0.81	0.30	0.29	0.30	0.29	0.04	XXX
76977		A	Us bone density measure	0.05	0.10	0.48	NA	NA	0.06	XXX
76977	TC	A	Us bone density measure	0.00	0.09	0.46	NA	NA	0.05	XXX
76977	26	A	Us bone density measure	0.05	0.01	0.02	0.01	0.02	0.01	XXX
76998		C	Us guide, intraop	0.00	0.00	0.00	NA	NA	0.00	XXX
76998	TC	C	Us guide, intraop	0.00	0.00	0.00	NA	NA	0.00	XXX
76998	26	A	Us guide, intraop	1.20	0.35	0.37	0.35	0.37	0.13	XXX
76999		C	Echo examination procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76999	TC	C	Echo examination procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
76999	26	C	Echo examination procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77001		A	Fluoroguide for vein device	0.38	2.72	2.08	NA	NA	0.11	ZZZ
77001	TC	A	Fluoroguide for vein device	0.00	2.59	1.95	NA	NA	0.10	ZZZ
77001	26	A	Fluoroguide for vein device	0.38	0.13	0.13	0.13	0.13	0.01	ZZZ
77002		A	Needle localization by xray	0.54	1.23	1.35	NA	NA	0.09	XXX
77002	TC	A	Needle localization by xray	0.00	1.07	1.19	NA	NA	0.07	XXX
77002	26	A	Needle localization by xray	0.54	0.16	0.16	0.16	0.16	0.02	XXX
77003		A	Fluoroguide for spine inject	0.60	0.76	1.11	NA	NA	0.10	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
77003	TC	A	Fluoroguide for spine inject	0.00	0.62	0.96	NA	NA	0.07	XXX
77003	26	A	Fluoroguide for spine inject	0.60	0.14	0.15	0.14	0.15	0.03	XXX
77011		A	Ct scan for localization	1.21	20.26	14.45	NA	NA	0.47	XXX
77011	TC	A	Ct scan for localization	0.00	19.86	14.05	NA	NA	0.42	XXX
77011	26	A	Ct scan for localization	1.21	0.40	0.40	0.40	0.40	0.05	XXX
77012		A	Ct scan for needle biopsy	1.16	2.33	5.47	NA	NA	0.47	XXX
77012	TC	A	Ct scan for needle biopsy	0.00	1.92	5.08	NA	NA	0.42	XXX
77012	26	A	Ct scan for needle biopsy	1.16	0.41	0.39	0.41	0.39	0.05	XXX
77013		C	Ct guide for tissue ablation	0.00	0.00	0.00	NA	NA	0.00	XXX
77013	TC	C	Ct guide for tissue ablation	0.00	0.00	0.00	NA	NA	0.00	XXX
77013	26	A	Ct guide for tissue ablation	3.99	1.43	1.36	1.43	1.36	0.18	XXX
77014		A	Ct scan for therapy guide	0.85	4.47	3.85	NA	NA	0.20	XXX
77014	TC	A	Ct scan for therapy guide	0.00	4.19	3.57	NA	NA	0.16	XXX
77014	26	A	Ct scan for therapy guide	0.85	0.28	0.28	0.28	0.28	0.04	XXX
77021		A	Mr guidance for needle place	1.50	9.70	10.70	NA	NA	0.64	XXX
77021	TC	A	Mr guidance for needle place	0.00	9.18	10.19	NA	NA	0.55	XXX
77021	26	A	Mr guidance for needle place	1.50	0.52	0.51	0.52	0.51	0.09	XXX
77022		C	Mri for tissue ablation	0.00	0.00	0.00	NA	NA	0.00	XXX
77022	TC	C	Mri for tissue ablation	0.00	0.00	0.00	NA	NA	0.00	XXX
77022	26	A	Mri for tissue ablation	4.24	1.52	1.45	1.52	1.45	0.24	XXX
77031		A	Stereotact guide for brst bx	1.59	1.87	4.77	NA	NA	0.46	XXX
77031	TC	A	Stereotact guide for brst bx	0.00	1.34	4.25	NA	NA	0.37	XXX
77031	26	A	Stereotact guide for brst bx	1.59	0.53	0.52	0.53	0.52	0.09	XXX
77032		A	Guidance for needle, breast	0.56	0.84	1.16	NA	NA	0.09	XXX
77032	TC	A	Guidance for needle, breast	0.00	0.64	0.97	NA	NA	0.07	XXX
77032	26	A	Guidance for needle, breast	0.56	0.20	0.19	0.20	0.19	0.02	XXX
77051		A	Computer dx mammogram add-on	0.06	0.20	0.32	NA	NA	0.02	ZZZ
77051	TC	A	Computer dx mammogram add-on	0.00	0.18	0.30	NA	NA	0.01	ZZZ
77051	26	A	Computer dx mammogram add-on	0.06	0.02	0.02	0.02	0.02	0.01	ZZZ
77052		A	Comp screen mammogram add-on	0.06	0.20	0.32	NA	NA	0.02	ZZZ
77052	TC	A	Comp screen mammogram add-on	0.00	0.18	0.30	NA	NA	0.01	ZZZ
77052	26	A	Comp screen mammogram add-on	0.06	0.02	0.02	0.02	0.02	0.01	ZZZ
77053		A	X-ray of mammary duct	0.36	1.24	1.98	NA	NA	0.16	XXX
77053	TC	A	X-ray of mammary duct	0.00	1.11	1.86	NA	NA	0.14	XXX
77053	26	A	X-ray of mammary duct	0.36	0.13	0.12	0.13	0.12	0.02	XXX
77054		A	X-ray of mammary ducts	0.45	1.68	2.74	NA	NA	0.21	XXX
77054	TC	A	X-ray of mammary ducts	0.00	1.52	2.59	NA	NA	0.19	XXX
77054	26	A	X-ray of mammary ducts	0.45	0.16	0.15	0.16	0.15	0.02	XXX
77055		A	Mammogram, one breast	0.70	1.65	1.46	NA	NA	0.09	XXX
77055	TC	A	Mammogram, one breast	0.00	1.40	1.22	NA	NA	0.06	XXX
77055	26	A	Mammogram, one breast	0.70	0.25	0.24	0.25	0.24	0.03	XXX
77056		A	Mammogram, both breasts	0.87	2.15	1.86	NA	NA	0.11	XXX
77056	TC	A	Mammogram, both breasts	0.00	1.84	1.57	NA	NA	0.07	XXX
77056	26	A	Mammogram, both breasts	0.87	0.31	0.29	0.31	0.29	0.04	XXX
77057		A	Mammogram, screening	0.70	1.44	1.45	NA	NA	0.10	XXX
77057	TC	A	Mammogram, screening	0.00	1.20	1.21	NA	NA	0.07	XXX
77057	26	A	Mammogram, screening	0.70	0.24	0.24	0.24	0.24	0.03	XXX
77058		A	Mri, one breast	1.63	21.62	19.89	NA	NA	0.99	XXX
77058	TC	A	Mri, one breast	0.00	21.06	19.34	NA	NA	0.92	XXX
77058	26	A	Mri, one breast	1.63	0.56	0.55	0.56	0.55	0.07	XXX
77059		A	Mri, both breasts	1.63	21.56	22.99	NA	NA	1.31	XXX
77059	TC	A	Mri, both breasts	0.00	20.99	22.44	NA	NA	1.24	XXX
77059	26	A	Mri, both breasts	1.63	0.57	0.55	0.57	0.55	0.07	XXX
77071		A	X-ray stress view	0.41	0.77	0.47	0.77	0.47	0.06	XXX
77072		A	X-rays for bone age	0.19	0.42	0.42	NA	NA	0.03	XXX
77072	TC	A	X-rays for bone age	0.00	0.36	0.36	NA	NA	0.02	XXX
77072	26	A	X-rays for bone age	0.19	0.06	0.06	0.06	0.06	0.01	XXX
77073		A	X-rays, bone length studies	0.27	0.67	0.77	NA	NA	0.06	XXX
77073	TC	A	X-rays, bone length studies	0.00	0.57	0.67	NA	NA	0.05	XXX
77073	26	A	X-rays, bone length studies	0.27	0.10	0.10	0.10	0.10	0.01	XXX
77074		A	X-rays, bone survey, limited	0.45	1.44	1.30	NA	NA	0.08	XXX
77074	TC	A	X-rays, bone survey, limited	0.00	1.28	1.14	NA	NA	0.06	XXX
77074	26	A	X-rays, bone survey, limited	0.45	0.16	0.16	0.16	0.16	0.02	XXX
77075		A	X-rays, bone survey complete	0.54	2.29	1.96	NA	NA	0.10	XXX
77075	TC	A	X-rays, bone survey complete	0.00	2.10	1.77	NA	NA	0.08	XXX
77075	26	A	X-rays, bone survey complete	0.54	0.19	0.19	0.19	0.19	0.02	XXX
77076		A	X-rays, bone survey, infant	0.70	2.13	1.54	NA	NA	0.08	XXX
77076	TC	A	X-rays, bone survey, infant	0.00	1.90	1.31	NA	NA	0.05	XXX
77076	26	A	X-rays, bone survey, infant	0.70	0.23	0.23	0.23	0.23	0.03	XXX
77077		A	Joint survey, single view	0.31	0.66	0.93	NA	NA	0.08	XXX
77077	TC	A	Joint survey, single view	0.00	0.55	0.83	NA	NA	0.06	XXX
77077	26	A	Joint survey, single view	0.31	0.11	0.10	0.11	0.10	0.02	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
77078	A	Ct bone density, axial	0.25	4.74	3.88	NA	NA	0.17	XXX
77078	TC	A	Ct bone density, axial	0.00	4.65	3.80	NA	NA	0.16	XXX
77078	26	A	Ct bone density, axial	0.25	0.09	0.08	0.09	0.08	0.01	XXX
77079	A	Ct bone density, peripheral	0.22	0.83	1.92	NA	NA	0.06	XXX
77079	TC	A	Ct bone density, peripheral	0.00	0.75	1.85	NA	NA	0.05	XXX
77079	26	A	Ct bone density, peripheral	0.22	0.08	0.07	0.08	0.07	0.01	XXX
77080	A	Dxa bone density, axial	0.20	1.10	2.15	NA	NA	0.18	XXX
77080	TC	A	Dxa bone density, axial	0.00	1.04	2.07	NA	NA	0.17	XXX
77080	26	A	Dxa bone density, axial	0.20	0.06	0.08	0.06	0.08	0.01	XXX
77081	A	Dxa bone density/peripheral	0.22	0.47	0.65	NA	NA	0.06	XXX
77081	TC	A	Dxa bone density/peripheral	0.00	0.41	0.58	NA	NA	0.05	XXX
77081	26	A	Dxa bone density/peripheral	0.22	0.06	0.07	0.06	0.07	0.01	XXX
77082	A	Dxa bone density, vert fx	0.17	0.53	0.66	NA	NA	0.06	XXX
77082	TC	A	Dxa bone density, vert fx	0.00	0.48	0.61	NA	NA	0.05	XXX
77082	26	A	Dxa bone density, vert fx	0.17	0.05	0.05	0.05	0.05	0.01	XXX
77083	A	Radiographic absorptiometry	0.20	0.37	0.59	NA	NA	0.06	XXX
77083	TC	A	Radiographic absorptiometry	0.00	0.32	0.53	NA	NA	0.05	XXX
77083	26	A	Radiographic absorptiometry	0.20	0.05	0.06	0.05	0.06	0.01	XXX
77084	A	Magnetic image, bone marrow	1.60	13.55	12.63	NA	NA	0.66	XXX
77084	TC	A	Magnetic image, bone marrow	0.00	13.03	12.11	NA	NA	0.59	XXX
77084	26	A	Magnetic image, bone marrow	1.60	0.52	0.52	0.52	0.52	0.07	XXX
77261	A	Radiation therapy planning	1.39	0.48	0.49	0.48	0.49	0.07	XXX
77262	A	Radiation therapy planning	2.11	0.69	0.72	0.69	0.72	0.11	XXX
77263	A	Radiation therapy planning	3.14	1.03	1.07	1.03	1.07	0.16	XXX
77280	A	Set radiation therapy field	0.70	4.43	4.05	NA	NA	0.22	XXX
77280	TC	A	Set radiation therapy field	0.00	4.20	3.83	NA	NA	0.18	XXX
77280	26	A	Set radiation therapy field	0.70	0.23	0.22	0.23	0.22	0.04	XXX
77285	A	Set radiation therapy field	1.05	8.01	6.96	NA	NA	0.35	XXX
77285	TC	A	Set radiation therapy field	0.00	7.67	6.62	NA	NA	0.30	XXX
77285	26	A	Set radiation therapy field	1.05	0.34	0.34	0.34	0.34	0.05	XXX
77290	A	Set radiation therapy field	1.56	13.41	10.21	NA	NA	0.43	XXX
77290	TC	A	Set radiation therapy field	0.00	12.90	9.71	NA	NA	0.35	XXX
77290	26	A	Set radiation therapy field	1.56	0.51	0.50	0.51	0.50	0.08	XXX
77295	A	Set radiation therapy field	4.56	7.45	18.41	NA	NA	1.71	XXX
77295	TC	A	Set radiation therapy field	0.00	5.95	16.93	NA	NA	1.48	XXX
77295	26	A	Set radiation therapy field	4.56	1.50	1.48	1.50	1.48	0.23	XXX
77299	C	Radiation therapy planning	0.00	0.00	0.00	NA	NA	0.00	XXX
77299	TC	C	Radiation therapy planning	0.00	0.00	0.00	NA	NA	0.00	XXX
77299	26	C	Radiation therapy planning	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77300	A	Radiation therapy dose plan	0.62	1.18	1.36	NA	NA	0.10	XXX
77300	TC	A	Radiation therapy dose plan	0.00	0.98	1.16	NA	NA	0.07	XXX
77300	26	A	Radiation therapy dose plan	0.62	0.20	0.20	0.20	0.20	0.03	XXX
77301	A	Radiotherapy dose plan, imrt	7.99	57.41	43.94	NA	NA	1.88	XXX
77301	TC	A	Radiotherapy dose plan, imrt	0.00	54.79	41.35	NA	NA	1.48	XXX
77301	26	A	Radiotherapy dose plan, imrt	7.99	2.62	2.59	2.62	2.59	0.40	XXX
77305	A	Teletx isodose plan simple	0.70	0.90	1.50	NA	NA	0.15	XXX
77305	TC	A	Teletx isodose plan simple	0.00	0.67	1.27	NA	NA	0.11	XXX
77305	26	A	Teletx isodose plan simple	0.70	0.23	0.23	0.23	0.23	0.04	XXX
77310	A	Teletx isodose plan intermed	1.05	1.24	1.96	NA	NA	0.18	XXX
77310	TC	A	Teletx isodose plan intermed	0.00	0.90	1.62	NA	NA	0.13	XXX
77310	26	A	Teletx isodose plan intermed	1.05	0.34	0.34	0.34	0.34	0.05	XXX
77315	A	Teletx isodose plan complex	1.56	2.08	2.62	NA	NA	0.22	XXX
77315	TC	A	Teletx isodose plan complex	0.00	1.57	2.12	NA	NA	0.14	XXX
77315	26	A	Teletx isodose plan complex	1.56	0.51	0.50	0.51	0.50	0.08	XXX
77321	A	Special teletx port plan	0.95	1.51	2.93	NA	NA	0.26	XXX
77321	TC	A	Special teletx port plan	0.00	1.20	2.62	NA	NA	0.21	XXX
77321	26	A	Special teletx port plan	0.95	0.31	0.31	0.31	0.31	0.05	XXX
77326	A	Brachytx isodose calc simp	0.93	2.98	2.82	NA	NA	0.18	XXX
77326	TC	A	Brachytx isodose calc simp	0.00	2.68	2.52	NA	NA	0.13	XXX
77326	26	A	Brachytx isodose calc simp	0.93	0.30	0.30	0.30	0.30	0.05	XXX
77327	A	Brachytx isodose calc interm	1.39	4.09	4.00	NA	NA	0.25	XXX
77327	TC	A	Brachytx isodose calc interm	0.00	3.64	3.55	NA	NA	0.18	XXX
77327	26	A	Brachytx isodose calc interm	1.39	0.45	0.45	0.45	0.45	0.07	XXX
77328	A	Brachytx isodose plan compl	2.09	5.25	5.44	NA	NA	0.36	XXX
77328	TC	A	Brachytx isodose plan compl	0.00	4.56	4.76	NA	NA	0.25	XXX
77328	26	A	Brachytx isodose plan compl	2.09	0.69	0.68	0.69	0.68	0.11	XXX
77331	A	Special radiation dosimetry	0.87	0.81	0.79	NA	NA	0.06	XXX
77331	TC	A	Special radiation dosimetry	0.00	0.52	0.51	NA	NA	0.02	XXX
77331	26	A	Special radiation dosimetry	0.87	0.29	0.28	0.29	0.28	0.04	XXX
77332	A	Radiation treatment aid(s)	0.54	1.55	1.52	NA	NA	0.10	XXX
77332	TC	A	Radiation treatment aid(s)	0.00	1.37	1.35	NA	NA	0.07	XXX
77332	26	A	Radiation treatment aid(s)	0.54	0.18	0.17	0.18	0.17	0.03	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
77333		A	Radiation treatment aid(s)	0.84	0.52	1.34	NA	NA	0.15	XXX
77333	TC	A	Radiation treatment aid(s)	0.00	0.24	1.07	NA	NA	0.11	XXX
77333	26	A	Radiation treatment aid(s)	0.84	0.28	0.27	0.28	0.27	0.04	XXX
77334		A	Radiation treatment aid(s)	1.24	2.71	3.18	NA	NA	0.23	XXX
77334	TC	A	Radiation treatment aid(s)	0.00	2.31	2.78	NA	NA	0.17	XXX
77334	26	A	Radiation treatment aid(s)	1.24	0.40	0.40	0.40	0.40	0.06	XXX
77336		A	Radiation physics consult	0.00	1.14	2.06	NA	NA	0.16	XXX
77370		A	Radiation physics consult	0.00	3.04	3.27	NA	NA	0.18	XXX
77371		A	Srs, multisource	0.00	30.07	30.07	NA	NA	0.13	XXX
77372		A	Srs, linear based	0.00	22.80	22.80	NA	NA	0.13	XXX
77373		A	Sbrt delivery	0.00	42.62	42.62	NA	NA	0.13	XXX
77399		C	External radiation dosimetry	0.00	0.00	0.00	NA	NA	0.00	XXX
77399	TC	C	External radiation dosimetry	0.00	0.00	0.00	NA	NA	0.00	XXX
77399	26	C	External radiation dosimetry	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77401		A	Radiation treatment delivery	0.00	0.47	1.12	NA	NA	0.11	XXX
77402		A	Radiation treatment delivery	0.00	4.34	3.06	NA	NA	0.11	XXX
77403		A	Radiation treatment delivery	0.00	3.75	2.76	NA	NA	0.11	XXX
77404		A	Radiation treatment delivery	0.00	4.20	2.99	NA	NA	0.11	XXX
77406		A	Radiation treatment delivery	0.00	4.23	3.00	NA	NA	0.11	XXX
77407		A	Radiation treatment delivery	0.00	5.78	3.93	NA	NA	0.12	XXX
77408		A	Radiation treatment delivery	0.00	5.19	3.64	NA	NA	0.12	XXX
77409		A	Radiation treatment delivery	0.00	5.76	3.93	NA	NA	0.12	XXX
77411		A	Radiation treatment delivery	0.00	5.73	3.91	NA	NA	0.12	XXX
77412		A	Radiation treatment delivery	0.00	6.78	4.56	NA	NA	0.13	XXX
77413		A	Radiation treatment delivery	0.00	6.85	4.59	NA	NA	0.13	XXX
77414		A	Radiation treatment delivery	0.00	7.71	5.02	NA	NA	0.13	XXX
77416		A	Radiation treatment delivery	0.00	7.72	5.02	NA	NA	0.13	XXX
77417		A	Radiology port film(s)	0.00	0.36	0.48	NA	NA	0.04	XXX
77418		A	Radiation tx delivery, imrt	0.00	13.15	15.58	NA	NA	0.13	XXX
77421		A	Stereoscopic x-ray guidance	0.39	2.38	2.93	NA	NA	0.12	XXX
77421	TC	A	Stereoscopic x-ray guidance	0.00	2.25	2.80	NA	NA	0.10	XXX
77421	26	A	Stereoscopic x-ray guidance	0.39	0.13	0.13	0.13	0.13	0.02	XXX
77422		A	Neutron beam tx, simple	0.00	5.35	3.53	NA	NA	0.13	XXX
77423		A	Neutron beam tx, complex	0.00	7.46	4.86	NA	NA	0.13	XXX
77427		A	Radiation tx management, x5	3.70	1.39	1.22	1.39	1.22	0.17	XXX
77431		A	Radiation therapy management	1.81	0.77	0.73	0.77	0.73	0.09	XXX
77432		A	Stereotactic radiation trmt	7.92	2.59	2.75	2.59	2.75	0.41	XXX
77435		A	Sbrt management	13.00	4.75	4.75	NA	NA	0.67	XXX
77470		A	Special radiation treatment	2.09	1.92	6.87	NA	NA	0.70	XXX
77470	TC	A	Special radiation treatment	0.00	1.24	6.19	NA	NA	0.59	XXX
77470	26	A	Special radiation treatment	2.09	0.68	0.68	0.68	0.68	0.11	XXX
77499		C	Radiation therapy management	0.00	0.00	0.00	NA	NA	0.00	XXX
77499	TC	C	Radiation therapy management	0.00	0.00	0.00	NA	NA	0.00	XXX
77499	26	C	Radiation therapy management	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77520		C	Proton trmt, simple w/o comp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77522		C	Proton trmt, simple w/comp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77523		C	Proton trmt, intermediate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77525		C	Proton treatment, complex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77600		R	Hyperthermia treatment	1.56	10.23	6.89	NA	NA	0.24	XXX
77600	TC	R	Hyperthermia treatment	0.00	9.73	6.39	NA	NA	0.16	XXX
77600	26	R	Hyperthermia treatment	1.56	0.50	0.50	0.50	0.50	0.08	XXX
77605		R	Hyperthermia treatment	2.09	18.46	11.58	NA	NA	0.38	XXX
77605	TC	R	Hyperthermia treatment	0.00	17.91	10.98	NA	NA	0.22	XXX
77605	26	R	Hyperthermia treatment	2.09	0.55	0.60	0.55	0.60	0.16	XXX
77610		R	Hyperthermia treatment	1.56	17.92	10.74	NA	NA	0.24	XXX
77610	TC	R	Hyperthermia treatment	0.00	17.56	10.31	NA	NA	0.16	XXX
77610	26	R	Hyperthermia treatment	1.56	0.36	0.43	0.36	0.43	0.08	XXX
77615		R	Hyperthermia treatment	2.09	25.90	15.31	NA	NA	0.33	XXX
77615	TC	R	Hyperthermia treatment	0.00	25.26	14.66	NA	NA	0.22	XXX
77615	26	R	Hyperthermia treatment	2.09	0.64	0.65	0.64	0.65	0.11	XXX
77620		R	Hyperthermia treatment	1.56	10.49	7.03	NA	NA	0.36	XXX
77620	TC	R	Hyperthermia treatment	0.00	10.09	6.57	NA	NA	0.16	XXX
77620	26	R	Hyperthermia treatment	1.56	0.40	0.46	0.40	0.46	0.20	XXX
77750		A	Infuse radioactive materials	4.94	4.55	3.73	NA	NA	0.32	090
77750	TC	A	Infuse radioactive materials	0.00	2.93	2.13	NA	NA	0.07	090
77750	26	A	Infuse radioactive materials	4.94	1.62	1.60	1.62	1.60	0.25	090
77761		A	Apply intrcav radiat simple	3.82	6.34	4.96	NA	NA	0.33	090
77761	TC	A	Apply intrcav radiat simple	0.00	5.10	3.80	NA	NA	0.14	090
77761	26	A	Apply intrcav radiat simple	3.82	1.24	1.16	1.24	1.16	0.19	090
77762		A	Apply intrcav radiat interm	5.73	7.62	6.53	NA	NA	0.48	090
77762	TC	A	Apply intrcav radiat interm	0.00	5.75	4.68	NA	NA	0.19	090
77762	26	A	Apply intrcav radiat interm	5.73	1.87	1.85	1.87	1.85	0.29	090

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
77763		A	Apply intrcav radiat compl	8.60	10.33	8.78	NA	NA	0.66	090
77763	TC	A	Apply intrcav radiat compl	0.00	7.52	6.00	NA	NA	0.23	090
77763	26	A	Apply intrcav radiat compl	8.60	2.81	2.78	2.81	2.78	0.43	090
77776		A	Apply interstit radiat simpl	4.67	7.46	5.29	NA	NA	0.57	090
77776	TC	A	Apply interstit radiat simpl	0.00	5.79	3.98	NA	NA	0.13	090
77776	26	A	Apply interstit radiat simpl	4.67	1.67	1.31	1.67	1.31	0.44	090
77777		A	Apply interstit radiat inter	7.49	7.92	7.26	NA	NA	0.61	090
77777	TC	A	Apply interstit radiat inter	0.00	5.47	4.85	NA	NA	0.22	090
77777	26	A	Apply interstit radiat inter	7.49	2.45	2.41	2.45	2.41	0.39	090
77778		A	Apply interstit radiat compl	11.23	11.31	10.00	NA	NA	0.84	090
77778	TC	A	Apply interstit radiat compl	0.00	7.62	6.37	NA	NA	0.27	090
77778	26	A	Apply interstit radiat compl	11.23	3.69	3.63	3.69	3.63	0.57	090
77781		A	High intensity brachytherapy	1.21	4.41	12.61	NA	NA	1.14	XXX
77781	TC	A	High intensity brachytherapy	0.00	4.01	12.15	NA	NA	1.06	XXX
77781	26	A	High intensity brachytherapy	1.21	0.40	0.46	0.40	0.46	0.08	XXX
77782		A	High intensity brachytherapy	2.04	12.41	16.74	NA	NA	1.19	XXX
77782	TC	A	High intensity brachytherapy	0.00	11.74	16.01	NA	NA	1.06	XXX
77782	26	A	High intensity brachytherapy	2.04	0.67	0.73	0.67	0.73	0.13	XXX
77783		A	High intensity brachytherapy	3.27	24.19	22.83	NA	NA	1.25	XXX
77783	TC	A	High intensity brachytherapy	0.00	23.12	21.70	NA	NA	1.06	XXX
77783	26	A	High intensity brachytherapy	3.27	1.07	1.13	1.07	1.13	0.19	XXX
77784		A	High intensity brachytherapy	5.15	45.65	33.87	NA	NA	1.35	XXX
77784	TC	A	High intensity brachytherapy	0.00	43.97	32.13	NA	NA	1.06	XXX
77784	26	A	High intensity brachytherapy	5.15	1.68	1.74	1.68	1.74	0.29	XXX
77789		A	Apply surface radiation	1.14	2.02	1.42	NA	NA	0.08	000
77789	TC	A	Apply surface radiation	0.00	1.64	1.04	NA	NA	0.02	000
77789	26	A	Apply surface radiation	1.14	0.38	0.38	0.38	0.38	0.06	000
77790		A	Radiation handling	1.05	1.46	1.15	NA	NA	0.07	XXX
77790	TC	A	Radiation handling	0.00	1.12	0.81	NA	NA	0.02	XXX
77790	26	A	Radiation handling	1.05	0.34	0.34	0.34	0.34	0.05	XXX
77799		C	Radium/radioisotope therapy	0.00	0.00	0.00	NA	NA	0.00	XXX
77799	TC	C	Radium/radioisotope therapy	0.00	0.00	0.00	NA	NA	0.00	XXX
77799	26	C	Radium/radioisotope therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78000		A	Thyroid, single uptake	0.19	1.85	1.44	NA	NA	0.07	XXX
78000	TC	A	Thyroid, single uptake	0.00	1.79	1.38	NA	NA	0.06	XXX
78000	26	A	Thyroid, single uptake	0.19	0.06	0.06	0.06	0.06	0.01	XXX
78001		A	Thyroid, multiple uptakes	0.26	2.30	1.85	NA	NA	0.08	XXX
78001	TC	A	Thyroid, multiple uptakes	0.00	2.21	1.76	NA	NA	0.07	XXX
78001	26	A	Thyroid, multiple uptakes	0.26	0.09	0.09	0.09	0.09	0.01	XXX
78003		A	Thyroid suppress/stimul	0.33	1.94	1.50	NA	NA	0.07	XXX
78003	TC	A	Thyroid suppress/stimul	0.00	1.82	1.39	NA	NA	0.06	XXX
78003	26	A	Thyroid suppress/stimul	0.33	0.12	0.11	0.12	0.11	0.01	XXX
78006		A	Thyroid imaging with uptake	0.49	6.22	4.38	NA	NA	0.15	XXX
78006	TC	A	Thyroid imaging with uptake	0.00	6.05	4.22	NA	NA	0.13	XXX
78006	26	A	Thyroid imaging with uptake	0.49	0.17	0.16	0.17	0.16	0.02	XXX
78007		A	Thyroid image, mult uptakes	0.50	3.05	2.90	NA	NA	0.16	XXX
78007	TC	A	Thyroid image, mult uptakes	0.00	2.88	2.73	NA	NA	0.14	XXX
78007	26	A	Thyroid image, mult uptakes	0.50	0.17	0.17	0.17	0.17	0.02	XXX
78010		A	Thyroid imaging	0.39	4.18	3.07	NA	NA	0.13	XXX
78010	TC	A	Thyroid imaging	0.00	4.05	2.94	NA	NA	0.11	XXX
78010	26	A	Thyroid imaging	0.39	0.13	0.13	0.13	0.13	0.02	XXX
78011		A	Thyroid imaging with flow	0.45	4.54	3.55	NA	NA	0.15	XXX
78011	TC	A	Thyroid imaging with flow	0.00	4.38	3.40	NA	NA	0.13	XXX
78011	26	A	Thyroid imaging with flow	0.45	0.16	0.15	0.16	0.15	0.02	XXX
78015		A	Thyroid met imaging	0.67	5.34	4.07	NA	NA	0.17	XXX
78015	TC	A	Thyroid met imaging	0.00	5.12	3.84	NA	NA	0.14	XXX
78015	26	A	Thyroid met imaging	0.67	0.22	0.23	0.22	0.23	0.03	XXX
78016		A	Thyroid met imaging/studies	0.82	8.52	6.14	NA	NA	0.21	XXX
78016	TC	A	Thyroid met imaging/studies	0.00	8.25	5.86	NA	NA	0.18	XXX
78016	26	A	Thyroid met imaging/studies	0.82	0.27	0.28	0.27	0.28	0.03	XXX
78018		A	Thyroid met imaging, body	0.86	7.93	6.82	NA	NA	0.33	XXX
78018	TC	A	Thyroid met imaging, body	0.00	7.63	6.52	NA	NA	0.29	XXX
78018	26	A	Thyroid met imaging, body	0.86	0.30	0.30	0.30	0.30	0.04	XXX
78020		A	Thyroid met uptake	0.60	1.80	1.66	NA	NA	0.16	ZZZ
78020	TC	A	Thyroid met uptake	0.00	1.60	1.45	NA	NA	0.14	ZZZ
78020	26	A	Thyroid met uptake	0.60	0.20	0.21	0.20	0.21	0.02	ZZZ
78070		A	Parathyroid nuclear imaging	0.82	3.48	4.01	NA	NA	0.15	XXX
78070	TC	A	Parathyroid nuclear imaging	0.00	3.20	3.73	NA	NA	0.11	XXX
78070	26	A	Parathyroid nuclear imaging	0.82	0.28	0.28	0.28	0.28	0.04	XXX
78075		A	Adrenal nuclear imaging	0.74	11.61	8.64	NA	NA	0.32	XXX
78075	TC	A	Adrenal nuclear imaging	0.00	11.36	8.39	NA	NA	0.29	XXX
78075	26	A	Adrenal nuclear imaging	0.74	0.25	0.25	0.25	0.25	0.03	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional-fa- cility PE RVUs ²	Mal- practice RVUs ²	Global
78099	C	Endocrine nuclear procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
78099	TC	C	Endocrine nuclear procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
78099	26	C	Endocrine nuclear procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78102	A	Bone marrow imaging, ltd	0.55	4.18	3.20	NA	NA	0.14	XXX
78102	TC	A	Bone marrow imaging, ltd	0.00	3.99	3.01	NA	NA	0.12	XXX
78102	26	A	Bone marrow imaging, ltd	0.55	0.19	0.19	0.19	0.19	0.02	XXX
78103	A	Bone marrow imaging, mult	0.75	5.43	4.43	NA	NA	0.20	XXX
78103	TC	A	Bone marrow imaging, mult	0.00	5.17	4.17	NA	NA	0.17	XXX
78103	26	A	Bone marrow imaging, mult	0.75	0.26	0.26	0.26	0.26	0.03	XXX
78104	A	Bone marrow imaging, body	0.80	6.23	5.28	NA	NA	0.25	XXX
78104	TC	A	Bone marrow imaging, body	0.00	5.94	5.00	NA	NA	0.22	XXX
78104	26	A	Bone marrow imaging, body	0.80	0.29	0.28	0.29	0.28	0.03	XXX
78110	A	Plasma volume, single	0.19	2.13	1.57	NA	NA	0.07	XXX
78110	TC	A	Plasma volume, single	0.00	2.06	1.50	NA	NA	0.06	XXX
78110	26	A	Plasma volume, single	0.19	0.07	0.07	0.07	0.07	0.01	XXX
78111	A	Plasma volume, multiple	0.22	2.14	2.40	NA	NA	0.15	XXX
78111	TC	A	Plasma volume, multiple	0.00	2.07	2.32	NA	NA	0.14	XXX
78111	26	A	Plasma volume, multiple	0.22	0.07	0.08	0.07	0.08	0.01	XXX
78120	A	Red cell mass, single	0.23	2.10	1.96	NA	NA	0.12	XXX
78120	TC	A	Red cell mass, single	0.00	2.02	1.88	NA	NA	0.11	XXX
78120	26	A	Red cell mass, single	0.23	0.08	0.08	0.08	0.08	0.01	XXX
78121	A	Red cell mass, multiple	0.32	2.20	2.61	NA	NA	0.15	XXX
78121	TC	A	Red cell mass, multiple	0.00	2.10	2.50	NA	NA	0.14	XXX
78121	26	A	Red cell mass, multiple	0.32	0.10	0.11	0.10	0.11	0.01	XXX
78122	A	Blood volume	0.45	2.25	3.51	NA	NA	0.26	XXX
78122	TC	A	Blood volume	0.00	2.10	3.35	NA	NA	0.24	XXX
78122	26	A	Blood volume	0.45	0.15	0.16	0.15	0.16	0.02	XXX
78130	A	Red cell survival study	0.61	3.50	3.28	NA	NA	0.17	XXX
78130	TC	A	Red cell survival study	0.00	3.29	3.07	NA	NA	0.14	XXX
78130	26	A	Red cell survival study	0.61	0.21	0.21	0.21	0.21	0.03	XXX
78135	A	Red cell survival kinetics	0.64	8.67	6.88	NA	NA	0.28	XXX
78135	TC	A	Red cell survival kinetics	0.00	8.45	6.66	NA	NA	0.25	XXX
78135	26	A	Red cell survival kinetics	0.64	0.22	0.22	0.22	0.22	0.03	XXX
78140	A	Red cell sequestration	0.61	2.94	3.53	NA	NA	0.24	XXX
78140	TC	A	Red cell sequestration	0.00	2.72	3.32	NA	NA	0.21	XXX
78140	26	A	Red cell sequestration	0.61	0.22	0.21	0.22	0.21	0.03	XXX
78185	A	Spleen imaging	0.40	5.19	3.85	NA	NA	0.15	XXX
78185	TC	A	Spleen imaging	0.00	5.05	3.71	NA	NA	0.13	XXX
78185	26	A	Spleen imaging	0.40	0.14	0.14	0.14	0.14	0.02	XXX
78190	A	Platelet survival, kinetics	1.09	8.37	7.24	NA	NA	0.38	XXX
78190	TC	A	Platelet survival, kinetics	0.00	8.12	6.92	NA	NA	0.30	XXX
78190	26	A	Platelet survival, kinetics	1.09	0.25	0.32	0.25	0.32	0.08	XXX
78191	A	Platelet survival	0.61	3.51	5.53	NA	NA	0.40	XXX
78191	TC	A	Platelet survival	0.00	3.30	5.32	NA	NA	0.37	XXX
78191	26	A	Platelet survival	0.61	0.21	0.21	0.21	0.21	0.03	XXX
78195	A	Lymph system imaging	1.20	8.68	6.58	NA	NA	0.28	XXX
78195	TC	A	Lymph system imaging	0.00	8.27	6.17	NA	NA	0.22	XXX
78195	26	A	Lymph system imaging	1.20	0.41	0.41	0.41	0.41	0.06	XXX
78199	C	Blood/lymph nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78199	TC	C	Blood/lymph nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78199	26	C	Blood/lymph nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78201	A	Liver imaging	0.44	4.59	3.55	NA	NA	0.15	XXX
78201	TC	A	Liver imaging	0.00	4.46	3.41	NA	NA	0.13	XXX
78201	26	A	Liver imaging	0.44	0.13	0.14	0.13	0.14	0.02	XXX
78202	A	Liver imaging with flow	0.51	5.34	4.20	NA	NA	0.16	XXX
78202	TC	A	Liver imaging with flow	0.00	5.17	4.03	NA	NA	0.14	XXX
78202	26	A	Liver imaging with flow	0.51	0.17	0.17	0.17	0.17	0.02	XXX
78205	A	Liver imaging (3D)	0.71	5.27	5.70	NA	NA	0.34	XXX
78205	TC	A	Liver imaging (3D)	0.00	5.02	5.46	NA	NA	0.31	XXX
78205	26	A	Liver imaging (3D)	0.71	0.25	0.24	0.25	0.24	0.03	XXX
78206	A	Liver image (3d) with flow	0.96	8.60	7.41	NA	NA	0.15	XXX
78206	TC	A	Liver image (3d) with flow	0.00	8.26	7.08	NA	NA	0.11	XXX
78206	26	A	Liver image (3d) with flow	0.96	0.34	0.33	0.34	0.33	0.04	XXX
78215	A	Liver and spleen imaging	0.49	4.82	3.96	NA	NA	0.16	XXX
78215	TC	A	Liver and spleen imaging	0.00	4.65	3.79	NA	NA	0.14	XXX
78215	26	A	Liver and spleen imaging	0.49	0.17	0.17	0.17	0.17	0.02	XXX
78216	A	Liver & spleen image/flow	0.57	2.84	3.26	NA	NA	0.20	XXX
78216	TC	A	Liver & spleen image/flow	0.00	2.65	3.07	NA	NA	0.18	XXX
78216	26	A	Liver & spleen image/flow	0.57	0.19	0.19	0.19	0.19	0.02	XXX
78220	A	Liver function study	0.49	3.08	3.47	NA	NA	0.21	XXX
78220	TC	A	Liver function study	0.00	2.91	3.31	NA	NA	0.19	XXX
78220	26	A	Liver function study	0.49	0.17	0.16	0.17	0.16	0.02	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
78223	A	Hepatobiliary imaging	0.84	8.50	6.22	NA	NA	0.23	XXX
78223	TC	A	Hepatobiliary imaging	0.00	8.21	5.93	NA	NA	0.19	XXX
78223	26	A	Hepatobiliary imaging	0.84	0.29	0.29	0.29	0.29	0.04	XXX
78230	A	Salivary gland imaging	0.45	4.17	3.25	NA	NA	0.15	XXX
78230	TC	A	Salivary gland imaging	0.00	4.01	3.10	NA	NA	0.13	XXX
78230	26	A	Salivary gland imaging	0.45	0.16	0.15	0.16	0.15	0.02	XXX
78231	A	Serial salivary imaging	0.52	2.80	3.07	NA	NA	0.19	XXX
78231	TC	A	Serial salivary imaging	0.00	2.63	2.90	NA	NA	0.17	XXX
78231	26	A	Serial salivary imaging	0.52	0.17	0.17	0.17	0.17	0.02	XXX
78232	A	Salivary gland function exam	0.47	2.77	3.24	NA	NA	0.20	XXX
78232	TC	A	Salivary gland function exam	0.00	2.62	3.08	NA	NA	0.18	XXX
78232	26	A	Salivary gland function exam	0.47	0.15	0.16	0.15	0.16	0.02	XXX
78258	A	Esophageal motility study	0.74	5.52	4.32	NA	NA	0.17	XXX
78258	TC	A	Esophageal motility study	0.00	5.25	4.06	NA	NA	0.14	XXX
78258	26	A	Esophageal motility study	0.74	0.27	0.26	0.27	0.26	0.03	XXX
78261	A	Gastric mucosa imaging	0.69	6.00	5.17	NA	NA	0.25	XXX
78261	TC	A	Gastric mucosa imaging	0.00	5.76	4.93	NA	NA	0.22	XXX
78261	26	A	Gastric mucosa imaging	0.69	0.24	0.24	0.24	0.24	0.03	XXX
78262	A	Gastroesophageal reflux exam	0.68	5.95	5.21	NA	NA	0.25	XXX
78262	TC	A	Gastroesophageal reflux exam	0.00	5.73	4.99	NA	NA	0.22	XXX
78262	26	A	Gastroesophageal reflux exam	0.68	0.22	0.22	0.22	0.22	0.03	XXX
78264	A	Gastric emptying study	0.78	7.16	5.78	NA	NA	0.25	XXX
78264	TC	A	Gastric emptying study	0.00	6.89	5.51	NA	NA	0.22	XXX
78264	26	A	Gastric emptying study	0.78	0.27	0.27	0.27	0.27	0.03	XXX
78267	X	Breath tst attain/anal c-14	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78268	X	Breath test analysis, c-14	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78270	A	Vit B-12 absorption exam	0.20	1.95	1.78	NA	NA	0.11	XXX
78270	TC	A	Vit B-12 absorption exam	0.00	1.88	1.71	NA	NA	0.10	XXX
78270	26	A	Vit B-12 absorption exam	0.20	0.07	0.07	0.07	0.07	0.01	XXX
78271	A	Vit b-12 absrsp exam, int fac	0.20	1.88	1.79	NA	NA	0.11	XXX
78271	TC	A	Vit b-12 absrsp exam, int fac	0.00	1.83	1.73	NA	NA	0.10	XXX
78271	26	A	Vit b-12 absrsp exam, int fac	0.20	0.05	0.06	0.05	0.06	0.01	XXX
78272	A	Vit B-12 absorp, combined	0.27	2.06	2.23	NA	NA	0.14	XXX
78272	TC	A	Vit B-12 absorp, combined	0.00	1.99	2.15	NA	NA	0.13	XXX
78272	26	A	Vit B-12 absorp, combined	0.27	0.07	0.08	0.07	0.08	0.01	XXX
78278	A	Acute GI blood loss imaging	0.99	8.60	6.90	NA	NA	0.29	XXX
78278	TC	A	Acute GI blood loss imaging	0.00	8.25	6.56	NA	NA	0.25	XXX
78278	26	A	Acute GI blood loss imaging	0.99	0.35	0.34	0.35	0.34	0.04	XXX
78282	C	GI protein loss exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78282	TC	C	GI protein loss exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78282	26	A	GI protein loss exam	0.38	0.13	0.13	0.13	0.13	0.02	XXX
78290	A	Meckel's divert exam	0.68	8.51	5.89	NA	NA	0.19	XXX
78290	TC	A	Meckel's divert exam	0.00	8.27	5.66	NA	NA	0.16	XXX
78290	26	A	Meckel's divert exam	0.68	0.24	0.23	0.24	0.23	0.03	XXX
78291	A	Leveen/shunt patency exam	0.88	6.14	4.75	NA	NA	0.20	XXX
78291	TC	A	Leveen/shunt patency exam	0.00	5.84	4.45	NA	NA	0.16	XXX
78291	26	A	Leveen/shunt patency exam	0.88	0.30	0.30	0.30	0.30	0.04	XXX
78299	C	GI nuclear procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
78299	TC	C	GI nuclear procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
78299	26	C	GI nuclear procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78300	A	Bone imaging, limited area	0.62	4.23	3.46	NA	NA	0.17	XXX
78300	TC	A	Bone imaging, limited area	0.00	4.01	3.25	NA	NA	0.14	XXX
78300	26	A	Bone imaging, limited area	0.62	0.22	0.21	0.22	0.21	0.03	XXX
78305	A	Bone imaging, multiple areas	0.83	5.47	4.70	NA	NA	0.23	XXX
78305	TC	A	Bone imaging, multiple areas	0.00	5.19	4.42	NA	NA	0.19	XXX
78305	26	A	Bone imaging, multiple areas	0.83	0.28	0.28	0.28	0.28	0.04	XXX
78306	A	Bone imaging, whole body	0.86	6.06	5.31	NA	NA	0.26	XXX
78306	TC	A	Bone imaging, whole body	0.00	5.76	5.01	NA	NA	0.22	XXX
78306	26	A	Bone imaging, whole body	0.86	0.30	0.30	0.30	0.30	0.04	XXX
78315	A	Bone imaging, 3 phase	1.02	8.59	6.85	NA	NA	0.29	XXX
78315	TC	A	Bone imaging, 3 phase	0.00	8.23	6.50	NA	NA	0.25	XXX
78315	26	A	Bone imaging, 3 phase	1.02	0.36	0.35	0.36	0.35	0.04	XXX
78320	A	Bone imaging (3D)	1.04	5.35	5.81	NA	NA	0.35	XXX
78320	TC	A	Bone imaging (3D)	0.00	4.99	5.45	NA	NA	0.31	XXX
78320	26	A	Bone imaging (3D)	1.04	0.36	0.36	0.36	0.36	0.04	XXX
78350	N	Bone mineral, single photon	0.22	0.51	0.67	NA	NA	0.06	XXX
78350	TC	N	Bone mineral, single photon	0.00	0.46	0.61	NA	NA	0.05	XXX
78350	26	N	Bone mineral, single photon	0.22	0.05	0.06	0.05	0.06	0.01	XXX
78351	N	Bone mineral, dual photon	0.30	NA	NA	0.07	0.09	0.01	XXX
78399	C	Musculoskeletal nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78399	TC	C	Musculoskeletal nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78399	26	C	Musculoskeletal nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
78414	C	Non-imaging heart function	0.00	0.00	0.00	NA	NA	0.00	XXX
78414	TC	C	Non-imaging heart function	0.00	0.00	0.00	NA	NA	0.00	XXX
78414	26	A	Non-imaging heart function	0.45	0.17	0.17	0.17	0.17	0.02	XXX
78428	A	Cardiac shunt imaging	0.78	5.26	3.90	NA	NA	0.16	XXX
78428	TC	A	Cardiac shunt imaging	0.00	4.90	3.58	NA	NA	0.13	XXX
78428	26	A	Cardiac shunt imaging	0.78	0.36	0.32	0.36	0.32	0.03	XXX
78445	A	Vascular flow imaging	0.49	4.48	3.26	NA	NA	0.13	XXX
78445	TC	A	Vascular flow imaging	0.00	4.31	3.09	NA	NA	0.11	XXX
78445	26	A	Vascular flow imaging	0.49	0.17	0.17	0.17	0.17	0.02	XXX
78456	A	Acute venous thrombus image	1.00	8.80	6.56	NA	NA	0.33	XXX
78456	TC	A	Acute venous thrombus image	0.00	8.43	6.20	NA	NA	0.29	XXX
78456	26	A	Acute venous thrombus image	1.00	0.37	0.36	0.37	0.36	0.04	XXX
78457	A	Venous thrombosis imaging	0.77	4.65	3.78	NA	NA	0.17	XXX
78457	TC	A	Venous thrombosis imaging	0.00	4.41	3.53	NA	NA	0.14	XXX
78457	26	A	Venous thrombosis imaging	0.77	0.24	0.25	0.24	0.25	0.03	XXX
78458	A	Ven thrombosis images, bilat	0.90	4.51	4.43	NA	NA	0.25	XXX
78458	TC	A	Ven thrombosis images, bilat	0.00	4.22	4.12	NA	NA	0.21	XXX
78458	26	A	Ven thrombosis images, bilat	0.90	0.29	0.31	0.29	0.31	0.04	XXX
78459	C	Heart muscle imaging (PET)	0.00	0.00	0.00	NA	NA	0.00	XXX
78459	TC	C	Heart muscle imaging (PET)	0.00	0.00	0.00	NA	NA	0.00	XXX
78459	26	A	Heart muscle imaging (PET)	1.50	0.60	0.59	0.60	0.59	0.05	XXX
78460	A	Heart muscle blood, single	0.86	4.66	3.65	NA	NA	0.17	XXX
78460	TC	A	Heart muscle blood, single	0.00	4.34	3.35	NA	NA	0.13	XXX
78460	26	A	Heart muscle blood, single	0.86	0.32	0.30	0.32	0.30	0.04	XXX
78461	A	Heart muscle blood, multiple	1.23	4.07	4.60	NA	NA	0.30	XXX
78461	TC	A	Heart muscle blood, multiple	0.00	3.61	4.16	NA	NA	0.25	XXX
78461	26	A	Heart muscle blood, multiple	1.23	0.46	0.44	0.46	0.44	0.05	XXX
78464	A	Heart image (3d), single	1.09	5.86	6.65	NA	NA	0.41	XXX
78464	TC	A	Heart image (3d), single	0.00	5.36	6.21	NA	NA	0.37	XXX
78464	26	A	Heart image (3d), single	1.09	0.50	0.44	0.50	0.44	0.04	XXX
78465	A	Heart image (3d), multiple	1.46	11.44	11.87	NA	NA	0.67	XXX
78465	TC	A	Heart image (3d), multiple	0.00	10.73	11.26	NA	NA	0.62	XXX
78465	26	A	Heart image (3d), multiple	1.46	0.71	0.61	0.71	0.61	0.05	XXX
78466	A	Heart infarct image	0.69	4.57	3.71	NA	NA	0.17	XXX
78466	TC	A	Heart infarct image	0.00	4.28	3.45	NA	NA	0.14	XXX
78466	26	A	Heart infarct image	0.69	0.29	0.26	0.29	0.26	0.03	XXX
78468	A	Heart infarct image (ef)	0.80	5.86	4.89	NA	NA	0.22	XXX
78468	TC	A	Heart infarct image (ef)	0.00	5.47	4.56	NA	NA	0.19	XXX
78468	26	A	Heart infarct image (ef)	0.80	0.39	0.33	0.39	0.33	0.03	XXX
78469	A	Heart infarct image (3D)	0.92	6.28	5.90	NA	NA	0.31	XXX
78469	TC	A	Heart infarct image (3D)	0.00	5.84	5.53	NA	NA	0.28	XXX
78469	26	A	Heart infarct image (3D)	0.92	0.44	0.37	0.44	0.37	0.03	XXX
78472	A	Gated heart, planar, single	0.98	6.03	5.93	NA	NA	0.34	XXX
78472	TC	A	Gated heart, planar, single	0.00	5.62	5.56	NA	NA	0.30	XXX
78472	26	A	Gated heart, planar, single	0.98	0.41	0.37	0.41	0.37	0.04	XXX
78473	A	Gated heart, multiple	1.47	7.76	8.25	NA	NA	0.48	XXX
78473	TC	A	Gated heart, multiple	0.00	7.12	7.68	NA	NA	0.42	XXX
78473	26	A	Gated heart, multiple	1.47	0.64	0.57	0.64	0.57	0.06	XXX
78478	A	Heart wall motion add-on	0.50	0.80	1.30	NA	NA	0.12	XXX
78478	TC	A	Heart wall motion add-on	0.00	0.56	1.06	NA	NA	0.10	XXX
78478	26	A	Heart wall motion add-on	0.50	0.24	0.24	0.24	0.24	0.02	XXX
78480	A	Heart function add-on	0.30	0.70	1.24	NA	NA	0.12	XXX
78480	TC	A	Heart function add-on	0.00	0.56	1.06	NA	NA	0.10	XXX
78480	26	A	Heart function add-on	0.30	0.14	0.18	0.14	0.18	0.02	XXX
78481	A	Heart first pass, single	0.98	5.07	5.33	NA	NA	0.31	XXX
78481	TC	A	Heart first pass, single	0.00	4.58	4.90	NA	NA	0.28	XXX
78481	26	A	Heart first pass, single	0.98	0.49	0.43	0.49	0.43	0.03	XXX
78483	A	Heart first pass, multiple	1.47	6.87	7.63	NA	NA	0.46	XXX
78483	TC	A	Heart first pass, multiple	0.00	6.09	6.97	NA	NA	0.41	XXX
78483	26	A	Heart first pass, multiple	1.47	0.78	0.66	0.78	0.66	0.05	XXX
78491	C	Heart image (pet), single	0.00	0.00	0.00	NA	NA	0.00	XXX
78491	TC	C	Heart image (pet), single	0.00	0.00	0.00	NA	NA	0.00	XXX
78491	26	A	Heart image (pet), single	1.50	0.63	0.61	0.63	0.61	0.06	XXX
78492	C	Heart image (pet), multiple	0.00	0.00	0.00	NA	NA	0.00	XXX
78492	TC	C	Heart image (pet), multiple	0.00	0.00	0.00	NA	NA	0.00	XXX
78492	26	A	Heart image (pet), multiple	1.87	0.91	0.82	0.91	0.82	0.07	XXX
78494	A	Heart image, spect	1.19	6.22	6.85	NA	NA	0.35	XXX
78494	TC	A	Heart image, spect	0.00	5.68	6.37	NA	NA	0.30	XXX
78494	26	A	Heart image, spect	1.19	0.54	0.48	0.54	0.48	0.05	XXX
78496	A	Heart first pass add-on	0.50	0.88	4.06	NA	NA	0.32	ZZZ
78496	TC	A	Heart first pass add-on	0.00	0.65	3.86	NA	NA	0.30	ZZZ
78496	26	A	Heart first pass add-on	0.50	0.23	0.20	0.23	0.20	0.02	ZZZ

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fa- cility PE RVUs ²	Mal- practice RVUs ²	Global
78499	C	Cardiovascular nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78499	TC	C	Cardiovascular nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78499	26	C	Cardiovascular nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78580	A	Lung perfusion imaging	0.74	5.13	4.41	NA	NA	0.21	XXX
78580	TC	A	Lung perfusion imaging	0.00	4.87	4.15	NA	NA	0.18	XXX
78580	26	A	Lung perfusion imaging	0.74	0.26	0.26	0.26	0.26	0.03	XXX
78584	A	Lung V/Q image single breath	0.99	3.02	3.27	NA	NA	0.21	XXX
78584	TC	A	Lung V/Q image single breath	0.00	2.67	2.93	NA	NA	0.17	XXX
78584	26	A	Lung V/Q image single breath	0.99	0.35	0.34	0.35	0.34	0.04	XXX
78585	A	Lung V/Q imaging	1.09	8.62	7.31	NA	NA	0.35	XXX
78585	TC	A	Lung V/Q imaging	0.00	8.24	6.94	NA	NA	0.30	XXX
78585	26	A	Lung V/Q imaging	1.09	0.38	0.37	0.38	0.37	0.05	XXX
78586	A	Aerosol lung image, single	0.40	4.17	3.44	NA	NA	0.16	XXX
78586	TC	A	Aerosol lung image, single	0.00	4.03	3.31	NA	NA	0.14	XXX
78586	26	A	Aerosol lung image, single	0.40	0.14	0.13	0.14	0.13	0.02	XXX
78587	A	Aerosol lung image, multiple	0.49	5.43	4.20	NA	NA	0.16	XXX
78587	TC	A	Aerosol lung image, multiple	0.00	5.26	4.03	NA	NA	0.14	XXX
78587	26	A	Aerosol lung image, multiple	0.49	0.17	0.17	0.17	0.17	0.02	XXX
78588	A	Perfusion lung image	1.09	8.65	6.11	NA	NA	0.23	XXX
78588	TC	A	Perfusion lung image	0.00	8.27	5.74	NA	NA	0.18	XXX
78588	26	A	Perfusion lung image	1.09	0.38	0.37	0.38	0.37	0.05	XXX
78591	A	Vent image, 1 breath, 1 proj	0.40	4.17	3.57	NA	NA	0.16	XXX
78591	TC	A	Vent image, 1 breath, 1 proj	0.00	4.03	3.44	NA	NA	0.14	XXX
78591	26	A	Vent image, 1 breath, 1 proj	0.40	0.14	0.13	0.14	0.13	0.02	XXX
78593	A	Vent image, 1 proj, gas	0.49	4.82	4.21	NA	NA	0.20	XXX
78593	TC	A	Vent image, 1 proj, gas	0.00	4.65	4.05	NA	NA	0.18	XXX
78593	26	A	Vent image, 1 proj, gas	0.49	0.17	0.16	0.17	0.16	0.02	XXX
78594	A	Vent image, mult proj, gas	0.53	5.29	5.22	NA	NA	0.27	XXX
78594	TC	A	Vent image, mult proj, gas	0.00	5.11	5.04	NA	NA	0.25	XXX
78594	26	A	Vent image, mult proj, gas	0.53	0.18	0.18	0.18	0.18	0.02	XXX
78596	A	Lung differential function	1.27	8.67	8.08	NA	NA	0.42	XXX
78596	TC	A	Lung differential function	0.00	8.28	7.67	NA	NA	0.37	XXX
78596	26	A	Lung differential function	1.27	0.39	0.41	0.39	0.41	0.05	XXX
78599	C	Respiratory nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78599	TC	C	Respiratory nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78599	26	C	Respiratory nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78600	A	Brain image < 4 views	0.44	4.39	3.71	NA	NA	0.16	XXX
78600	TC	A	Brain image < 4 views	0.00	4.24	3.56	NA	NA	0.14	XXX
78600	26	A	Brain image < 4 views	0.44	0.15	0.15	0.15	0.15	0.02	XXX
78601	A	Brain image w/flow < 4 views	0.51	5.38	4.47	NA	NA	0.20	XXX
78601	TC	A	Brain image w/flow < 4 views	0.00	5.20	4.30	NA	NA	0.18	XXX
78601	26	A	Brain image w/flow < 4 views	0.51	0.18	0.17	0.18	0.17	0.02	XXX
78605	A	Brain image 4+ views	0.53	4.84	4.22	NA	NA	0.20	XXX
78605	TC	A	Brain image 4+ views	0.00	4.65	4.03	NA	NA	0.18	XXX
78605	26	A	Brain image 4+ views	0.53	0.19	0.19	0.19	0.19	0.02	XXX
78606	A	Brain image w/flow 4 + views	0.64	8.53	6.30	NA	NA	0.24	XXX
78606	TC	A	Brain image w/flow 4 + views	0.00	8.31	6.09	NA	NA	0.21	XXX
78606	26	A	Brain image w/flow 4 + views	0.64	0.22	0.21	0.22	0.21	0.03	XXX
78607	A	Brain imaging (3D)	1.23	8.63	7.80	NA	NA	0.40	XXX
78607	TC	A	Brain imaging (3D)	0.00	8.22	7.38	NA	NA	0.35	XXX
78607	26	A	Brain imaging (3D)	1.23	0.41	0.42	0.41	0.42	0.05	XXX
78608	C	Brain imaging (PET)	0.00	0.00	0.00	NA	NA	0.00	XXX
78608	TC	C	Brain imaging (PET)	0.00	0.00	0.00	NA	NA	0.00	XXX
78608	26	A	Brain imaging (PET)	1.50	0.49	0.50	0.49	0.50	0.06	XXX
78609	N	Brain imaging (PET)	1.50	0.00	0.49	NA	NA	0.06	XXX
78609	TC	N	Brain imaging (PET)	0.00	0.00	0.00	NA	NA	0.00	XXX
78609	26	N	Brain imaging (PET)	1.50	0.00	0.49	0.00	0.49	0.06	XXX
78610	A	Brain flow imaging only	0.30	4.45	4.23	NA	NA	0.11	XXX
78610	TC	A	Brain flow imaging only	0.00	4.35	4.10	NA	NA	0.10	XXX
78610	26	A	Brain flow imaging only	0.30	0.10	0.13	0.10	0.13	0.01	XXX
78630	A	Cerebrospinal fluid scan	0.68	8.65	6.95	NA	NA	0.30	XXX
78630	TC	A	Cerebrospinal fluid scan	0.00	8.41	6.72	NA	NA	0.27	XXX
78630	26	A	Cerebrospinal fluid scan	0.68	0.24	0.23	0.24	0.23	0.03	XXX
78635	A	CSF ventriculography	0.61	8.79	5.78	NA	NA	0.16	XXX
78635	TC	A	CSF ventriculography	0.00	8.58	5.56	NA	NA	0.14	XXX
78635	26	A	CSF ventriculography	0.61	0.21	0.22	0.21	0.22	0.02	XXX
78645	A	CSF shunt evaluation	0.57	8.48	6.04	NA	NA	0.20	XXX
78645	TC	A	CSF shunt evaluation	0.00	8.28	5.85	NA	NA	0.18	XXX
78645	26	A	CSF shunt evaluation	0.57	0.20	0.19	0.20	0.19	0.02	XXX
78647	A	Cerebrospinal fluid scan	0.90	8.52	7.37	NA	NA	0.35	XXX
78647	TC	A	Cerebrospinal fluid scan	0.00	8.23	7.07	NA	NA	0.31	XXX
78647	26	A	Cerebrospinal fluid scan	0.90	0.29	0.30	0.29	0.30	0.04	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
78650	A	CSF leakage imaging	0.61	8.56	6.70	NA	NA	0.27	XXX
78650	TC	A	CSF leakage imaging	0.00	8.35	6.49	NA	NA	0.24	XXX
78650	26	A	CSF leakage imaging	0.61	0.21	0.21	0.21	0.21	0.03	XXX
78660	A	Nuclear exam of tear flow	0.53	4.26	3.28	NA	NA	0.14	XXX
78660	TC	A	Nuclear exam of tear flow	0.00	4.07	3.10	NA	NA	0.12	XXX
78660	26	A	Nuclear exam of tear flow	0.53	0.19	0.18	0.19	0.18	0.02	XXX
78699	C	Nervous system nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78699	TC	C	Nervous system nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78699	26	C	Nervous system nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78700	A	Kidney imaging, morphol	0.45	4.38	3.80	NA	NA	0.18	XXX
78700	TC	A	Kidney imaging, morphol	0.00	4.22	3.64	NA	NA	0.16	XXX
78700	26	A	Kidney imaging, morphol	0.45	0.16	0.16	0.16	0.16	0.02	XXX
78701	A	Kidney imaging with flow	0.49	5.38	4.55	NA	NA	0.20	XXX
78701	TC	A	Kidney imaging with flow	0.00	5.21	4.38	NA	NA	0.18	XXX
78701	26	A	Kidney imaging with flow	0.49	0.17	0.17	0.17	0.17	0.02	XXX
78707	A	K flow/funct image w/o drug	0.96	5.49	5.14	NA	NA	0.27	XXX
78707	TC	A	K flow/funct image w/o drug	0.00	5.15	4.81	NA	NA	0.23	XXX
78707	26	A	K flow/funct image w/o drug	0.96	0.34	0.33	0.34	0.33	0.04	XXX
78708	A	K flow/funct image w/drug	1.21	3.48	4.18	NA	NA	0.28	XXX
78708	TC	A	K flow/funct image w/drug	0.00	3.05	3.76	NA	NA	0.23	XXX
78708	26	A	K flow/funct image w/drug	1.21	0.43	0.42	0.43	0.42	0.05	XXX
78709	A	K flow/funct image, multiple	1.41	8.88	6.91	NA	NA	0.29	XXX
78709	TC	A	K flow/funct image, multiple	0.00	8.39	6.43	NA	NA	0.23	XXX
78709	26	A	K flow/funct image, multiple	1.41	0.49	0.48	0.49	0.48	0.06	XXX
78710	A	Kidney imaging (3D)	0.66	5.28	5.70	NA	NA	0.34	XXX
78710	TC	A	Kidney imaging (3D)	0.00	5.06	5.48	NA	NA	0.31	XXX
78710	26	A	Kidney imaging (3D)	0.66	0.22	0.22	0.22	0.22	0.03	XXX
78725	A	Kidney function study	0.38	2.35	2.14	NA	NA	0.13	XXX
78725	TC	A	Kidney function study	0.00	2.23	2.01	NA	NA	0.11	XXX
78725	26	A	Kidney function study	0.38	0.12	0.13	0.12	0.13	0.02	XXX
78730	A	Urinary bladder retention	0.15	1.98	1.78	NA	NA	0.10	ZZZ
78730	TC	A	Urinary bladder retention	0.00	1.92	1.69	NA	NA	0.08	ZZZ
78730	26	A	Urinary bladder retention	0.15	0.06	0.09	0.06	0.09	0.02	ZZZ
78740	A	Ureteral reflux study	0.57	5.65	3.98	NA	NA	0.15	XXX
78740	TC	A	Ureteral reflux study	0.00	5.46	3.79	NA	NA	0.12	XXX
78740	26	A	Ureteral reflux study	0.57	0.19	0.19	0.19	0.19	0.03	XXX
78761	A	Testicular imaging w/flow	0.71	5.05	4.24	NA	NA	0.20	XXX
78761	TC	A	Testicular imaging w/flow	0.00	4.80	4.00	NA	NA	0.17	XXX
78761	26	A	Testicular imaging w/flow	0.71	0.25	0.24	0.25	0.24	0.03	XXX
78799	C	Genitourinary nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78799	TC	C	Genitourinary nuclear exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78799	26	C	Genitourinary nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78800	A	Tumor imaging, limited area	0.66	4.33	3.98	NA	NA	0.22	XXX
78800	TC	A	Tumor imaging, limited area	0.00	4.12	3.76	NA	NA	0.18	XXX
78800	26	A	Tumor imaging, limited area	0.66	0.21	0.22	0.21	0.22	0.04	XXX
78801	A	Tumor imaging, mult areas	0.79	6.04	5.27	NA	NA	0.27	XXX
78801	TC	A	Tumor imaging, mult areas	0.00	5.78	5.00	NA	NA	0.22	XXX
78801	26	A	Tumor imaging, mult areas	0.79	0.26	0.27	0.26	0.27	0.05	XXX
78802	A	Tumor imaging, whole body	0.86	8.14	6.98	NA	NA	0.34	XXX
78802	TC	A	Tumor imaging, whole body	0.00	7.84	6.69	NA	NA	0.30	XXX
78802	26	A	Tumor imaging, whole body	0.86	0.30	0.29	0.30	0.29	0.04	XXX
78803	A	Tumor imaging (3D)	1.09	8.53	7.74	NA	NA	0.40	XXX
78803	TC	A	Tumor imaging (3D)	0.00	8.16	7.36	NA	NA	0.35	XXX
78803	26	A	Tumor imaging (3D)	1.09	0.37	0.38	0.37	0.38	0.05	XXX
78804	A	Tumor imaging, whole body	1.07	14.83	13.13	NA	NA	0.34	XXX
78804	TC	A	Tumor imaging, whole body	0.00	14.46	12.76	NA	NA	0.30	XXX
78804	26	A	Tumor imaging, whole body	1.07	0.37	0.37	0.37	0.37	0.04	XXX
78805	A	Abscess imaging, ltd area	0.73	4.22	3.94	NA	NA	0.21	XXX
78805	TC	A	Abscess imaging, ltd area	0.00	3.97	3.69	NA	NA	0.18	XXX
78805	26	A	Abscess imaging, ltd area	0.73	0.25	0.25	0.25	0.25	0.03	XXX
78806	A	Abscess imaging, whole body	0.86	8.35	7.53	NA	NA	0.39	XXX
78806	TC	A	Abscess imaging, whole body	0.00	8.05	7.24	NA	NA	0.35	XXX
78806	26	A	Abscess imaging, whole body	0.86	0.30	0.29	0.30	0.29	0.04	XXX
78807	A	Nuclear localization/abscess	1.09	8.51	7.73	NA	NA	0.39	XXX
78807	TC	A	Nuclear localization/abscess	0.00	8.14	7.35	NA	NA	0.35	XXX
78807	26	A	Nuclear localization/abscess	1.09	0.37	0.38	0.37	0.38	0.04	XXX
78811	C	Pet image, ltd area	0.00	0.00	0.00	NA	NA	0.00	XXX
78811	TC	C	Pet image, ltd area	0.00	0.00	0.00	NA	NA	0.00	XXX
78811	26	A	Pet image, ltd area	1.54	0.54	0.53	0.54	0.53	0.11	XXX
78812	C	Pet image, skull-thigh	0.00	0.00	0.00	NA	NA	0.00	XXX
78812	TC	C	Pet image, skull-thigh	0.00	0.00	0.00	NA	NA	0.00	XXX
78812	26	A	Pet image, skull-thigh	1.93	0.67	0.66	0.67	0.66	0.11	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
78813	C	Pet image, full body	0.00	0.00	0.00	NA	NA	0.00	XXX
78813	TC	C	Pet image, full body	0.00	0.00	0.00	NA	NA	0.00	XXX
78813	26	A	Pet image, full body	2.00	0.68	0.68	0.68	0.68	0.11	XXX
78814	C	Pet image w/ct, lmted	0.00	0.00	0.00	NA	NA	0.00	XXX
78814	TC	C	Pet image w/ct, lmted	0.00	0.00	0.00	NA	NA	0.00	XXX
78814	26	A	Pet image w/ct, lmted	2.20	0.74	0.75	0.74	0.75	0.11	XXX
78815	C	Pet image w/ct, skull-thigh	0.00	0.00	0.00	NA	NA	0.00	XXX
78815	TC	C	Pet image w/ct, skull-thigh	0.00	0.00	0.00	NA	NA	0.00	XXX
78815	26	A	Pet image w/ct, skull-thigh	2.44	0.84	0.84	0.84	0.84	0.11	XXX
78816	C	Pet image w/ct, full body	0.00	0.00	0.00	NA	NA	0.00	XXX
78816	TC	C	Pet image w/ct, full body	0.00	0.00	0.00	NA	NA	0.00	XXX
78816	26	A	Pet image w/ct, full body	2.50	0.85	0.85	0.85	0.85	0.11	XXX
78890	B	Nuclear medicine data proc	0.05	0.39	0.86	NA	NA	0.07	XXX
78890	TC	B	Nuclear medicine data proc	0.00	0.38	0.84	NA	NA	0.06	XXX
78890	26	B	Nuclear medicine data proc	0.05	0.01	0.02	0.01	0.02	0.01	XXX
78891	B	Nuclear med data proc	0.10	0.88	1.77	NA	NA	0.14	XXX
78891	TC	B	Nuclear med data proc	0.00	0.86	1.74	NA	NA	0.13	XXX
78891	26	B	Nuclear med data proc	0.10	0.02	0.03	0.02	0.03	0.01	XXX
78999	C	Nuclear diagnostic exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78999	TC	C	Nuclear diagnostic exam	0.00	0.00	0.00	NA	NA	0.00	XXX
78999	26	C	Nuclear diagnostic exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
79005	A	Nuclear rx, oral admin	1.80	1.85	2.53	NA	NA	0.22	XXX
79005	TC	A	Nuclear rx, oral admin	0.00	1.27	1.94	NA	NA	0.14	XXX
79005	26	A	Nuclear rx, oral admin	1.80	0.58	0.59	0.58	0.59	0.08	XXX
79101	A	Nuclear rx, iv admin	1.96	2.17	2.72	NA	NA	0.22	XXX
79101	TC	A	Nuclear rx, iv admin	0.00	1.43	2.02	NA	NA	0.14	XXX
79101	26	A	Nuclear rx, iv admin	1.96	0.74	0.70	0.74	0.70	0.08	XXX
79200	A	Nuclear rx, intracav admin	1.99	2.22	2.77	NA	NA	0.23	XXX
79200	TC	A	Nuclear rx, intracav admin	0.00	1.57	2.10	NA	NA	0.14	XXX
79200	26	A	Nuclear rx, intracav admin	1.99	0.65	0.67	0.65	0.67	0.09	XXX
79300	C	Nuclr rx, interstit colloid	0.00	0.00	0.00	NA	NA	0.00	XXX
79300	TC	C	Nuclr rx, interstit colloid	0.00	0.00	0.00	NA	NA	0.00	XXX
79300	26	A	Nuclr rx, interstit colloid	1.60	0.54	0.55	0.54	0.55	0.13	XXX
79403	A	Hematopoietic nuclear tx	2.25	2.92	4.04	NA	NA	0.24	XXX
79403	TC	A	Hematopoietic nuclear tx	0.00	2.17	3.22	NA	NA	0.14	XXX
79403	26	A	Hematopoietic nuclear tx	2.25	0.75	0.82	0.75	0.82	0.10	XXX
79440	A	Nuclear rx, intra-articular	1.99	1.84	2.59	NA	NA	0.22	XXX
79440	TC	A	Nuclear rx, intra-articular	0.00	1.16	1.89	NA	NA	0.14	XXX
79440	26	A	Nuclear rx, intra-articular	1.99	0.68	0.70	0.68	0.70	0.08	XXX
79445	C	Nuclear rx, intra-arterial	0.00	0.00	0.00	NA	NA	0.00	XXX
79445	TC	C	Nuclear rx, intra-arterial	0.00	0.00	0.00	NA	NA	0.00	XXX
79445	26	A	Nuclear rx, intra-arterial	2.40	0.85	0.83	0.85	0.83	0.12	XXX
79999	C	Nuclear medicine therapy	0.00	0.00	0.00	NA	NA	0.00	XXX
79999	TC	C	Nuclear medicine therapy	0.00	0.00	0.00	NA	NA	0.00	XXX
79999	26	C	Nuclear medicine therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80500	A	Lab pathology consultation	0.37	0.20	0.20	0.11	0.14	0.01	XXX
80502	A	Lab pathology consultation	1.33	0.31	0.43	0.25	0.40	0.04	XXX
83020	26	A	Hemoglobin electrophoresis	0.37	0.12	0.13	0.12	0.13	0.01	XXX
83912	26	A	Genetic examination	0.37	0.11	0.12	0.11	0.12	0.01	XXX
84165	26	A	Protein e-phoresis, serum	0.37	0.12	0.13	0.12	0.13	0.01	XXX
84166	26	A	Protein e-phoresis/urine/csf	0.37	0.12	0.13	0.12	0.13	0.01	XXX
84181	26	A	Western blot test	0.37	0.12	0.13	0.12	0.13	0.01	XXX
84182	26	A	Protein, western blot test	0.37	0.12	0.14	0.12	0.14	0.02	XXX
85060	A	Blood smear interpretation	0.45	0.14	0.16	0.14	0.16	0.02	XXX
85097	A	Bone marrow interpretation	0.94	1.25	1.58	0.27	0.34	0.04	XXX
85390	26	A	Fibrinolysins screen	0.37	0.13	0.13	0.13	0.13	0.01	XXX
85396	A	Clotting assay, whole blood	0.37	NA	NA	0.10	0.13	0.04	XXX
85576	26	A	Blood platelet aggregation	0.37	0.12	0.14	0.12	0.14	0.01	XXX
86077	A	Physician blood bank service	0.94	0.38	0.39	0.30	0.34	0.03	XXX
86078	A	Physician blood bank service	0.94	0.38	0.42	0.30	0.35	0.03	XXX
86079	A	Physician blood bank service	0.94	0.39	0.42	0.30	0.36	0.03	XXX
86255	26	A	Fluorescent antibody, screen	0.37	0.12	0.13	0.12	0.13	0.01	XXX
86256	26	A	Fluorescent antibody, titer	0.37	0.12	0.13	0.12	0.13	0.01	XXX
86320	26	A	Serum immunoelectrophoresis	0.37	0.12	0.14	0.12	0.14	0.01	XXX
86325	26	A	Other immunoelectrophoresis	0.37	0.12	0.13	0.12	0.13	0.01	XXX
86327	26	A	Immunoelectrophoresis assay	0.42	0.12	0.15	0.12	0.15	0.02	XXX
86334	26	A	Immunofix e-phoresis, serum	0.37	0.12	0.13	0.12	0.13	0.01	XXX
86335	26	A	Immunifix e-phorsis/urine/csf	0.37	0.12	0.13	0.12	0.13	0.01	XXX
86485	C	Skin test, candida	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86486	A	Skin test, nos antigen	0.00	0.13	0.13	NA	NA	0.02	XXX
86490	A	Coccidioidomycosis skin test	0.00	0.13	0.21	NA	NA	0.02	XXX
86510	A	Histoplasmosis skin test	0.00	0.13	0.22	NA	NA	0.02	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
86580		A	TB intradermal test	0.00	0.16	0.20	NA	NA	0.02	XXX
87164	26	A	Dark field examination	0.37	0.12	0.12	0.12	0.12	0.01	XXX
87207	26	A	Smear, special stain	0.37	0.12	0.14	0.12	0.14	0.01	XXX
88104		A	Cytopath fl nongyn, smears	0.56	1.19	1.02	NA	NA	0.04	XXX
88104	TC	A	Cytopath fl nongyn, smears	0.00	1.03	0.82	NA	NA	0.02	XXX
88104	26	A	Cytopath fl nongyn, smears	0.56	0.16	0.20	0.16	0.20	0.02	XXX
88106		A	Cytopath fl nongyn, filter	0.56	1.52	1.44	NA	NA	0.04	XXX
88106	TC	A	Cytopath fl nongyn, filter	0.00	1.37	1.24	NA	NA	0.02	XXX
88106	26	A	Cytopath fl nongyn, filter	0.56	0.15	0.20	0.15	0.20	0.02	XXX
88107		A	Cytopath fl nongyn, sm/fltr	0.76	2.00	1.77	NA	NA	0.05	XXX
88107	TC	A	Cytopath fl nongyn, sm/fltr	0.00	1.77	1.49	NA	NA	0.02	XXX
88107	26	A	Cytopath fl nongyn, sm/fltr	0.76	0.23	0.28	0.23	0.28	0.03	XXX
88108		A	Cytopath, concentrate tech	0.56	1.47	1.34	NA	NA	0.04	XXX
88108	TC	A	Cytopath, concentrate tech	0.00	1.32	1.14	NA	NA	0.02	XXX
88108	26	A	Cytopath, concentrate tech	0.56	0.15	0.20	0.15	0.20	0.02	XXX
88112		A	Cytopath, cell enhance tech	1.18	1.47	1.72	NA	NA	0.04	XXX
88112	TC	A	Cytopath, cell enhance tech	0.00	1.18	1.32	NA	NA	0.02	XXX
88112	26	A	Cytopath, cell enhance tech	1.18	0.29	0.40	0.29	0.40	0.02	XXX
88125		A	Forensic cytopathology	0.26	0.21	0.24	NA	NA	0.02	XXX
88125	TC	A	Forensic cytopathology	0.00	0.16	0.16	NA	NA	0.01	XXX
88125	26	A	Forensic cytopathology	0.26	0.05	0.08	0.05	0.08	0.01	XXX
88141		A	Cytopath, c/v, interpret	0.42	0.38	0.26	0.38	0.26	0.02	XXX
88160		A	Cytopath smear, other source	0.50	0.91	0.87	NA	NA	0.04	XXX
88160	TC	A	Cytopath smear, other source	0.00	0.78	0.70	NA	NA	0.02	XXX
88160	26	A	Cytopath smear, other source	0.50	0.13	0.17	0.13	0.17	0.02	XXX
88161		A	Cytopath smear, other source	0.50	1.06	1.00	NA	NA	0.04	XXX
88161	TC	A	Cytopath smear, other source	0.00	0.92	0.82	NA	NA	0.02	XXX
88161	26	A	Cytopath smear, other source	0.50	0.14	0.18	0.14	0.18	0.02	XXX
88162		A	Cytopath smear, other source	0.76	1.58	1.30	NA	NA	0.05	XXX
88162	TC	A	Cytopath smear, other source	0.00	1.35	1.02	NA	NA	0.02	XXX
88162	26	A	Cytopath smear, other source	0.76	0.23	0.28	0.23	0.28	0.03	XXX
88172		A	Cytopathology eval of fna	0.60	0.81	0.77	NA	NA	0.04	XXX
88172	TC	A	Cytopathology eval of fna	0.00	0.64	0.55	NA	NA	0.02	XXX
88172	26	A	Cytopathology eval of fna	0.60	0.17	0.22	0.17	0.22	0.02	XXX
88173		A	Cytopath eval, fna, report	1.39	2.20	2.16	NA	NA	0.07	XXX
88173	TC	A	Cytopath eval, fna, report	0.00	1.82	1.68	NA	NA	0.02	XXX
88173	26	A	Cytopath eval, fna, report	1.39	0.38	0.48	0.38	0.48	0.05	XXX
88182		A	Cell marker study	0.77	2.02	1.99	NA	NA	0.07	XXX
88182	TC	A	Cell marker study	0.00	1.88	1.76	NA	NA	0.04	XXX
88182	26	A	Cell marker study	0.77	0.14	0.23	0.14	0.23	0.03	XXX
88184		A	Flowcytometry/ tc, 1 marker	0.00	2.46	1.89	NA	NA	0.02	XXX
88185		A	Flowcytometry/tc, add-on	0.00	1.50	1.07	NA	NA	0.02	ZZZ
88187		A	Flowcytometry/read, 2-8	1.36	0.39	0.42	0.39	0.42	0.01	XXX
88188		A	Flowcytometry/read, 9-15	1.69	0.44	0.50	0.44	0.50	0.01	XXX
88189		A	Flowcytometry/read, 16 & >	2.23	0.47	0.61	0.47	0.61	0.01	XXX
88199		C	Cytopathology procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
88199	TC	C	Cytopathology procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
88199	26	C	Cytopathology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88291		A	Cyto/molecular report	0.52	0.27	0.22	0.27	0.22	0.02	XXX
88299		C	Cytogenetic study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88300		A	Surgical path, gross	0.08	0.56	0.51	NA	NA	0.02	XXX
88300	TC	A	Surgical path, gross	0.00	0.54	0.48	NA	NA	0.01	XXX
88300	26	A	Surgical path, gross	0.08	0.02	0.03	0.02	0.03	0.01	XXX
88302		A	Tissue exam by pathologist	0.13	1.29	1.16	NA	NA	0.03	XXX
88302	TC	A	Tissue exam by pathologist	0.00	1.25	1.11	NA	NA	0.02	XXX
88302	26	A	Tissue exam by pathologist	0.13	0.04	0.05	0.04	0.05	0.01	XXX
88304		A	Tissue exam by pathologist	0.22	1.47	1.39	NA	NA	0.03	XXX
88304	TC	A	Tissue exam by pathologist	0.00	1.41	1.32	NA	NA	0.02	XXX
88304	26	A	Tissue exam by pathologist	0.22	0.06	0.07	0.06	0.07	0.01	XXX
88305		A	Tissue exam by pathologist	0.75	2.04	1.97	NA	NA	0.07	XXX
88305	TC	A	Tissue exam by pathologist	0.00	1.84	1.71	NA	NA	0.04	XXX
88305	26	A	Tissue exam by pathologist	0.75	0.20	0.26	0.20	0.26	0.03	XXX
88307		A	Tissue exam by pathologist	1.59	4.41	3.78	NA	NA	0.12	XXX
88307	TC	A	Tissue exam by pathologist	0.00	3.94	3.20	NA	NA	0.06	XXX
88307	26	A	Tissue exam by pathologist	1.59	0.47	0.58	0.47	0.58	0.06	XXX
88309		A	Tissue exam by pathologist	2.80	6.16	5.28	NA	NA	0.14	XXX
88309	TC	A	Tissue exam by pathologist	0.00	5.34	4.38	NA	NA	0.06	XXX
88309	26	A	Tissue exam by pathologist	2.80	0.82	0.90	0.82	0.90	0.08	XXX
88311		A	Decalcify tissue	0.24	0.24	0.23	NA	NA	0.02	XXX
88311	TC	A	Decalcify tissue	0.00	0.17	0.15	NA	NA	0.01	XXX
88311	26	A	Decalcify tissue	0.24	0.07	0.08	0.07	0.08	0.01	XXX
88312		A	Special stains	0.54	2.29	1.90	NA	NA	0.03	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
88312	TC	A	Special stains	0.00	2.15	1.72	NA	NA	0.01	XXX
88312	26	A	Special stains	0.54	0.14	0.18	0.14	0.18	0.02	XXX
88313		A	Special stains	0.24	1.94	1.59	NA	NA	0.02	XXX
88313	TC	A	Special stains	0.00	1.88	1.51	NA	NA	0.01	XXX
88313	26	A	Special stains	0.24	0.06	0.08	0.06	0.08	0.01	XXX
88314		A	Histochemical stain	0.45	1.96	2.00	NA	NA	0.04	XXX
88314	TC	A	Histochemical stain	0.00	1.82	1.84	NA	NA	0.02	XXX
88314	26	A	Histochemical stain	0.45	0.14	0.16	0.14	0.16	0.02	XXX
88318		A	Chemical histochemistry	0.42	2.94	2.29	NA	NA	0.03	XXX
88318	TC	A	Chemical histochemistry	0.00	2.82	2.14	NA	NA	0.01	XXX
88318	26	A	Chemical histochemistry	0.42	0.12	0.15	0.12	0.15	0.02	XXX
88319		A	Enzyme histochemistry	0.53	3.22	3.32	NA	NA	0.04	XXX
88319	TC	A	Enzyme histochemistry	0.00	3.07	3.13	NA	NA	0.02	XXX
88319	26	A	Enzyme histochemistry	0.53	0.15	0.19	0.15	0.19	0.02	XXX
88321		A	Microslide consultation	1.63	0.71	0.75	0.46	0.51	0.05	XXX
88323		A	Microslide consultation	1.83	2.21	1.99	NA	NA	0.07	XXX
88323	TC	A	Microslide consultation	0.00	1.75	1.48	NA	NA	0.02	XXX
88323	26	A	Microslide consultation	1.83	0.46	0.51	0.46	0.51	0.05	XXX
88325		A	Comprehensive review of data	2.50	2.40	2.66	0.69	0.82	0.07	XXX
88329		A	Path consult introp	0.67	0.66	0.66	0.20	0.24	0.02	XXX
88331		A	Path consult intraop, 1 bloc	1.19	1.21	1.15	NA	NA	0.08	XXX
88331	TC	A	Path consult intraop, 1 bloc	0.00	0.84	0.71	NA	NA	0.04	XXX
88331	26	A	Path consult intraop, 1 bloc	1.19	0.37	0.44	0.37	0.44	0.04	XXX
88332		A	Path consult intraop, add'l	0.59	0.48	0.46	NA	NA	0.04	XXX
88332	TC	A	Path consult intraop, add'l	0.00	0.30	0.25	NA	NA	0.02	XXX
88332	26	A	Path consult intraop, add'l	0.59	0.18	0.21	0.18	0.21	0.02	XXX
88333		A	Intraop cyto path consult, 1	1.20	1.32	1.20	NA	NA	0.08	XXX
88333	TC	A	Intraop cyto path consult, 1	0.00	0.95	0.75	NA	NA	0.04	XXX
88333	26	A	Intraop cyto path consult, 1	1.20	0.37	0.45	0.37	0.45	0.04	XXX
88334		A	Intraop cyto path consult, 2	0.73	0.78	0.69	NA	NA	0.04	XXX
88334	TC	A	Intraop cyto path consult, 2	0.00	0.56	0.45	NA	NA	0.02	XXX
88334	26	A	Intraop cyto path consult, 2	0.73	0.22	0.24	0.22	0.24	0.02	XXX
88342		A	Immunohistochemistry	0.85	1.99	1.72	NA	NA	0.05	XXX
88342	TC	A	Immunohistochemistry	0.00	1.77	1.43	NA	NA	0.02	XXX
88342	26	A	Immunohistochemistry	0.85	0.22	0.29	0.22	0.29	0.03	XXX
88346		A	Immunofluorescent study	0.86	1.91	1.73	NA	NA	0.05	XXX
88346	TC	A	Immunofluorescent study	0.00	1.68	1.44	NA	NA	0.02	XXX
88346	26	A	Immunofluorescent study	0.86	0.23	0.29	0.23	0.29	0.03	XXX
88347		A	Immunofluorescent study	0.86	1.31	1.29	NA	NA	0.05	XXX
88347	TC	A	Immunofluorescent study	0.00	1.13	1.02	NA	NA	0.02	XXX
88347	26	A	Immunofluorescent study	0.86	0.18	0.27	0.18	0.27	0.03	XXX
88348		A	Electron microscopy	1.51	18.24	13.79	NA	NA	0.13	XXX
88348	TC	A	Electron microscopy	0.00	17.82	13.26	NA	NA	0.07	XXX
88348	26	A	Electron microscopy	1.51	0.42	0.53	0.42	0.53	0.06	XXX
88349		A	Scanning electron microscopy	0.76	9.39	6.47	NA	NA	0.09	XXX
88349	TC	A	Scanning electron microscopy	0.00	9.16	6.19	NA	NA	0.06	XXX
88349	26	A	Scanning electron microscopy	0.76	0.23	0.28	0.23	0.28	0.03	XXX
88355		A	Analysis, skeletal muscle	1.85	3.22	5.99	NA	NA	0.13	XXX
88355	TC	A	Analysis, skeletal muscle	0.00	2.85	5.41	NA	NA	0.06	XXX
88355	26	A	Analysis, skeletal muscle	1.85	0.37	0.58	0.37	0.58	0.07	XXX
88356		A	Analysis, nerve	3.02	5.35	4.77	NA	NA	0.19	XXX
88356	TC	A	Analysis, nerve	0.00	4.77	3.85	NA	NA	0.07	XXX
88356	26	A	Analysis, nerve	3.02	0.58	0.92	0.58	0.92	0.12	XXX
88358		A	Analysis, tumor	0.95	1.10	0.97	NA	NA	0.17	XXX
88358	TC	A	Analysis, tumor	0.00	0.94	0.69	NA	NA	0.07	XXX
88358	26	A	Analysis, tumor	0.95	0.16	0.28	0.16	0.28	0.10	XXX
88360		A	Tumor immunohistochem/manual	1.10	2.22	1.97	NA	NA	0.08	XXX
88360	TC	A	Tumor immunohistochem/manual	0.00	1.95	1.60	NA	NA	0.02	XXX
88360	26	A	Tumor immunohistochem/manual	1.10	0.27	0.37	0.27	0.37	0.06	XXX
88361		A	Tumor immunohistochem/comput	1.18	2.79	2.91	NA	NA	0.17	XXX
88361	TC	A	Tumor immunohistochem/comput	0.00	2.52	2.53	NA	NA	0.07	XXX
88361	26	A	Tumor immunohistochem/comput	1.18	0.27	0.38	0.27	0.38	0.10	XXX
88362		A	Nerve teasing preparations	2.17	4.99	4.84	NA	NA	0.15	XXX
88362	TC	A	Nerve teasing preparations	0.00	4.42	4.09	NA	NA	0.06	XXX
88362	26	A	Nerve teasing preparations	2.17	0.57	0.75	0.57	0.75	0.09	XXX
88365		A	Insitu hybridization (fish)	1.20	3.34	2.73	NA	NA	0.05	XXX
88365	TC	A	Insitu hybridization (fish)	0.00	3.04	2.33	NA	NA	0.02	XXX
88365	26	A	Insitu hybridization (fish)	1.20	0.30	0.40	0.30	0.40	0.03	XXX
88367		A	Insitu hybridization, auto	1.30	5.15	4.59	NA	NA	0.12	XXX
88367	TC	A	Insitu hybridization, auto	0.00	4.93	4.21	NA	NA	0.06	XXX
88367	26	A	Insitu hybridization, auto	1.30	0.22	0.38	0.22	0.38	0.06	XXX
88368		A	Insitu hybridization, manual	1.40	4.97	3.69	NA	NA	0.12	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
88368	TC	A	Insitu hybridization, manual	0.00	4.72	3.26	NA	NA	0.06	XXX
88368	26	A	Insitu hybridization, manual	1.40	0.25	0.43	0.25	0.43	0.06	XXX
88371	26	A	Protein, western blot tissue	0.37	0.10	0.12	0.10	0.12	0.01	XXX
88372	26	A	Protein analysis w/probe	0.37	0.12	0.14	0.12	0.14	0.01	XXX
88380		A	Microdissection, laser	1.56	2.65	2.65	NA	NA	0.14	XXX
88380	TC	A	Microdissection, laser	0.00	2.22	2.22	NA	NA	0.07	XXX
88380	26	A	Microdissection, laser	1.56	0.43	0.43	0.43	0.43	0.07	XXX
88381		A	Microdissection, manual	1.18	4.47	4.47	NA	NA	0.08	XXX
88381	TC	A	Microdissection, manual	0.00	4.15	4.15	NA	NA	0.02	XXX
88381	26	A	Microdissection, manual	1.18	0.32	0.32	0.32	0.32	0.06	XXX
88384		C	Eval molecular probes, 11-50	0.00	0.00	0.00	NA	NA	0.00	XXX
88384	TC	C	Eval molecular probes, 11-50	0.00	0.00	0.00	NA	NA	0.00	XXX
88384	26	C	Eval molecular probes, 11-50	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88385		A	Eval molecu probes, 51-250	1.50	15.53	11.31	NA	NA	0.12	XXX
88385	TC	A	Eval molecu probes, 51-250	0.00	15.26	10.85	NA	NA	0.06	XXX
88385	26	A	Eval molecu probes, 51-250	1.50	0.27	0.46	0.27	0.46	0.06	XXX
88386		A	Eval molecu probes, 251-500	1.88	15.44	11.24	NA	NA	0.16	XXX
88386	TC	A	Eval molecu probes, 251-500	0.00	15.10	10.66	NA	NA	0.08	XXX
88386	26	A	Eval molecu probes, 251-500	1.88	0.34	0.58	0.34	0.58	0.08	XXX
88399		C	Surgical pathology procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
88399	TC	C	Surgical pathology procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
88399	26	C	Surgical pathology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89049		A	Chct for mal hyperthermia	1.40	3.56	3.55	0.19	0.23	0.06	XXX
89060	26	A	Exam,synovial fluid crystals	0.37	0.12	0.14	0.12	0.14	0.01	XXX
89100		A	Sample intestinal contents	0.60	7.89	4.86	0.54	0.37	0.03	XXX
89105		A	Sample intestinal contents	0.50	7.84	5.03	0.46	0.31	0.02	XXX
89130		A	Sample stomach contents	0.45	6.54	4.14	0.38	0.25	0.02	XXX
89132		A	Sample stomach contents	0.19	8.38	4.96	0.39	0.22	0.01	XXX
89135		A	Sample stomach contents	0.79	8.82	5.36	0.67	0.46	0.04	XXX
89136		A	Sample stomach contents	0.21	5.94	3.84	0.26	0.18	0.01	XXX
89140		A	Sample stomach contents	0.94	6.22	4.15	0.43	0.35	0.04	XXX
89141		A	Sample stomach contents	0.85	6.36	4.57	0.49	0.41	0.03	XXX
89220		A	Sputum specimen collection	0.00	0.37	0.40	NA	NA	0.02	XXX
89230		A	Collect sweat for test	0.00	0.07	0.09	NA	NA	0.02	XXX
89240		C	Pathology lab procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90281		I	Human ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90283		I	Human ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90284		X	Human ig, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90287		I	Botulinum antitoxin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90288		I	Botulism ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90291		I	Cmv ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90296		E	Diphtheria antitoxin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90371		E	Hep b ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90375		E	Rabies ig, im/sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90376		E	Rabies ig, heat treated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90378		X	Rsv ig, im, 50mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90379		I	Rsv ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90384		I	Rh ig, full-dose, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90385		E	Rh ig, minidose, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90386		I	Rh ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90389		I	Tetanus ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90393		E	Vaccina ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90396		E	Varicella-zoster ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90399		I	Immune globulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90465		A	Immune admin 1 inj, < 8 yrs	0.17	0.44	0.38	NA	NA	0.01	XXX
90466		A	Immune admin addl inj, < 8 y	0.15	0.12	0.12	0.04	0.08	0.01	ZZZ
90467		R	Immune admin o or n, < 8 yrs	0.17	0.17	0.17	0.07	0.08	0.01	XXX
90468		R	Immune admin o/n, addl < 8 y	0.15	0.11	0.11	0.04	0.05	0.01	ZZZ
90471		A	Immunization admin	0.17	0.44	0.38	NA	NA	0.01	XXX
90472		A	Immunization admin, each add	0.15	0.12	0.13	0.04	0.08	0.01	ZZZ
90473		R	Immune admin oral/nasal	0.17	0.17	0.18	0.04	0.06	0.01	XXX
90474		R	Immune admin oral/nasal addl	0.15	0.08	0.09	0.04	0.05	0.01	ZZZ
90476		E	Adenovirus vaccine, type 4	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90477		E	Adenovirus vaccine, type 7	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90581		E	Anthrax vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90585		E	Bcg vaccine, percut	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90586		E	Bcg vaccine, intravesical	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90632		E	Hep a vaccine, adult im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90633		E	Hep a vacc, ped/adol, 2 dose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90634		E	Hep a vacc, ped/adol, 3 dose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90636		E	Hep a/hep b vacc, adult im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90645		E	Hib vaccine, hboc, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
90646		E	Hib vaccine, prp-d, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90647		E	Hib vaccine, prp-omp, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90648		E	Hib vaccine, prp-t, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90649		E	H papilloma vacc 3 dose im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90655		X	Flu vaccine no preserv 6-35m	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90656		X	Flu vaccine no preserv 3 & >	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90657		X	Flu vaccine, 3 yrs, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90658		X	Flu vaccine, 3 yrs & >, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90660		X	Flu vaccine, nasal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90661		X	Flu vacc cell cult prsv free	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90662		X	Flu vacc prsv free inc antig	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90663		X	Flu vacc pandemic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90665		E	Lyme disease vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90669		X	Pneumococcal vacc, ped <5	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90675		E	Rabies vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90676		E	Rabies vaccine, id	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90680		E	Rotovirus vacc 3 dose, oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90690		E	Typhoid vaccine, oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90691		E	Typhoid vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90692		E	Typhoid vaccine, h-p, sc/id	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90693		E	Typhoid vaccine, akd, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90698		E	Dtap-hib-ip vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90700		E	Dtap vaccine, < 7 yrs, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90701		E	Dtp vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90702		E	Dt vaccine < 7, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90703		E	Tetanus vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90704		E	Mumps vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90705		E	Measles vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90706		E	Rubella vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90707		E	Mmr vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90708		E	Measles-rubella vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90710		E	Mmr vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90712		E	Oral poliovirus vaccine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90713		E	Poliovirus, ipv, sc/im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90714		E	Td vaccine no prsv >= 7 im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90715		E	Tdap vaccine >7 im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90716		E	Chicken pox vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90717		E	Yellow fever vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90718		E	Td vaccine > 7, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90719		E	Diphtheria vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90720		E	Dtp/hib vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90721		E	Dtap/hib vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90723		I	Dtap-hep b-ipv vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90725		E	Cholera vaccine, injectable	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90727		E	Plague vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90732		X	Pneumococcal vaccine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90733		E	Meningococcal vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90734		E	Meningococcal vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90735		E	Encephalitis vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90736		E	Zoster vacc, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90740		X	Hepb vacc, ill pat 3 dose im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90743		X	Hep b vacc, adol, 2 dose, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90744		X	Hepb vacc ped/adol 3 dose im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90746		X	Hep b vaccine, adult, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90747		X	Hepb vacc, ill pat 4 dose im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90748		I	Hep b/hib vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90749		E	Vaccine toxoid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90760		A	Hydration iv infusion, init	0.17	1.32	1.37	NA	NA	0.07	XXX
90761		A	Hydrate iv infusion, add-on	0.09	0.32	0.36	NA	NA	0.04	ZZZ
90765		A	Ther/proph/diag iv inf, init	0.21	1.62	1.69	NA	NA	0.07	XXX
90766		A	Ther/proph/dg iv inf, add-on	0.18	0.37	0.42	NA	NA	0.04	ZZZ
90767		A	Tx/proph/dg addl seq iv inf	0.19	0.69	0.79	NA	NA	0.04	ZZZ
90768		A	Ther/diag concurrent inf	0.17	0.33	0.39	NA	NA	0.04	ZZZ
90769		A	Sc ther infusion, up to 1 hr	0.21	3.92	3.92	NA	NA	0.06	XXX
90770		A	Sc ther infusion, addl hr	0.18	0.22	0.22	NA	NA	0.04	ZZZ
90771		A	Sc ther infusion, reset pump	0.00	1.86	1.86	NA	NA	0.01	ZZZ
90772		A	Ther/proph/diag inj, sc/im	0.17	0.44	0.38	NA	NA	0.01	XXX
90773		A	Ther/proph/diag inj, ia	0.17	0.30	0.31	NA	NA	0.02	XXX
90774		A	Ther/proph/diag inj, iv push	0.18	1.33	1.31	NA	NA	0.04	XXX
90775		A	Tx/pro/dx inj new drug addon	0.10	0.51	0.54	NA	NA	0.04	ZZZ
90776		X	Tx/pro/dx inj same drug adon	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
90779		C	Ther/prop/diag inj/inf proc	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
90801		A	Psy dx interview	2.80	1.49	1.33	0.60	0.76	0.06	XXX
90802		A	Intac psy dx interview	3.01	1.54	1.37	0.68	0.83	0.07	XXX
90804		A	Psytx, office, 20–30 min	1.21	0.56	0.52	0.21	0.30	0.03	XXX
90805		A	Psytx, off, 20–30 min w/e&m	1.37	0.60	0.55	0.24	0.33	0.03	XXX
90806		A	Psytx, off, 45–50 min	1.86	0.53	0.61	0.33	0.46	0.04	XXX
90807		A	Psytx, off, 45–50 min w/e&m	2.02	0.70	0.70	0.35	0.49	0.05	XXX
90808		A	Psytx, office, 75–80 min	2.79	0.69	0.86	0.49	0.69	0.06	XXX
90809		A	Psytx, off, 75–80, w/e&m	2.95	0.86	0.93	0.52	0.72	0.07	XXX
90810		A	Intac psytx, off, 20–30 min	1.32	0.54	0.52	0.23	0.33	0.04	XXX
90811		A	Intac psytx, 20–30, w/e&m	1.48	0.72	0.64	0.26	0.36	0.04	XXX
90812		A	Intac psytx, off, 45–50 min	1.97	0.65	0.72	0.34	0.49	0.04	XXX
90813		A	Intac psytx, 45–50 min w/e&m	2.13	0.83	0.80	0.37	0.52	0.05	XXX
90814		A	Intac psytx, off, 75–80 min	2.90	0.81	0.95	0.53	0.75	0.06	XXX
90815		A	Intac psytx, 75–80 w/e&m	3.06	0.99	1.02	0.53	0.74	0.07	XXX
90816		A	Psytx, hosp, 20–30 min	1.25	NA	NA	0.32	0.39	0.03	XXX
90817		A	Psytx, hosp, 20–30 min w/e&m	1.41	NA	NA	0.35	0.40	0.03	XXX
90818		A	Psytx, hosp, 45–50 min	1.89	NA	NA	0.44	0.56	0.04	XXX
90819		A	Psytx, hosp, 45–50 min w/e&m	2.05	NA	NA	0.46	0.55	0.05	XXX
90821		A	Psytx, hosp, 75–80 min	2.83	NA	NA	0.60	0.80	0.06	XXX
90822		A	Psytx, hosp, 75–80 min w/e&m	2.99	NA	NA	0.62	0.79	0.08	XXX
90823		A	Intac psytx, hosp, 20–30 min	1.36	NA	NA	0.35	0.41	0.03	XXX
90824		A	Intac psytx, hsp 20–30 w/e&m	1.52	NA	NA	0.37	0.43	0.04	XXX
90826		A	Intac psytx, hosp, 45–50 min	2.01	NA	NA	0.46	0.59	0.05	XXX
90827		A	Intac psytx, hsp 45–50 w/e&m	2.16	NA	NA	0.48	0.58	0.05	XXX
90828		A	Intac psytx, hosp, 75–80 min	2.94	NA	NA	0.62	0.84	0.06	XXX
90829		A	Intac psytx, hsp 75–80 w/e&m	3.10	NA	NA	0.64	0.81	0.07	XXX
90845		A	Psychoanalysis	1.79	0.39	0.48	0.32	0.43	0.04	XXX
90846		R	Family psytx w/o patient	1.83	0.51	0.58	0.42	0.54	0.04	XXX
90847		R	Family psytx w/patient	2.21	0.74	0.78	0.49	0.63	0.05	XXX
90849		R	Multiple family group psytx	0.59	0.33	0.30	0.21	0.22	0.02	XXX
90853		A	Group psychotherapy	0.59	0.26	0.26	0.20	0.21	0.01	XXX
90857		A	Intac group psytx	0.63	0.38	0.33	0.21	0.23	0.01	XXX
90862		A	Medication management	0.95	0.62	0.51	0.27	0.29	0.02	XXX
90865		A	Narcosynthesis	2.84	1.16	1.26	0.63	0.77	0.12	XXX
90870		A	Electroconvulsive therapy	1.88	1.92	1.93	0.38	0.48	0.04	000
90875		N	Psychophysiological therapy	1.20	0.53	0.71	0.28	0.37	0.04	XXX
90876		N	Psychophysiological therapy	1.90	0.67	0.91	0.44	0.58	0.05	XXX
90880		A	Hypnotherapy	2.19	0.57	0.81	0.39	0.54	0.05	XXX
90882		N	Environmental manipulation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90885		B	Psy evaluation of records	0.97	0.22	0.30	0.22	0.30	0.02	XXX
90887		B	Consultation with family	1.48	0.61	0.71	0.34	0.45	0.04	XXX
90889		B	Preparation of report	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90899		C	Psychiatric service/therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90901		A	Biofeedback train, any meth	0.41	0.46	0.56	0.10	0.12	0.02	000
90911		A	Biofeedback peri/uro/rectal	0.89	1.37	1.46	0.30	0.30	0.06	000
90918		I	ESRD related services, month	11.16	4.70	5.40	3.74	4.92	0.36	XXX
90919		I	ESRD related services, month	8.53	3.03	3.51	2.55	3.27	0.29	XXX
90920		I	ESRD related services, month	7.26	2.73	3.24	2.26	3.01	0.23	XXX
90921		I	ESRD related services, month	4.46	1.71	2.07	1.61	2.03	0.14	XXX
90922		I	ESRD related services, day	0.37	0.16	0.18	0.13	0.17	0.01	XXX
90923		I	Esrd related services, day	0.28	0.10	0.11	0.08	0.11	0.01	XXX
90924		I	Esrd related services, day	0.24	0.09	0.10	0.07	0.10	0.01	XXX
90925		I	Esrd related services, day	0.15	0.05	0.07	0.05	0.07	0.01	XXX
90935		A	Hemodialysis, one evaluation	1.22	NA	NA	0.53	0.60	0.04	000
90937		A	Hemodialysis, repeated eval	2.11	NA	NA	0.77	0.87	0.07	000
90940		X	Hemodialysis access study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90945		A	Dialysis, one evaluation	1.28	NA	NA	0.55	0.62	0.04	000
90947		A	Dialysis, repeated eval	2.16	NA	NA	0.79	0.89	0.07	000
90989		X	Dialysis training, complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90993		X	Dialysis training, incompl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90997		A	Hemoperfusion	1.84	NA	NA	0.50	0.58	0.06	000
90999		C	Dialysis procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
91000		A	Esophageal intubation	0.73	2.13	1.23	NA	NA	0.04	000
91000	TC	A	Esophageal intubation	0.00	1.91	0.99	NA	NA	0.01	000
91000	26	A	Esophageal intubation	0.73	0.22	0.24	0.22	0.24	0.03	000
91010		A	Esophagus motility study	1.25	3.67	4.03	NA	NA	0.12	000
91010	TC	A	Esophagus motility study	0.00	3.12	3.54	NA	NA	0.06	000
91010	26	A	Esophagus motility study	1.25	0.55	0.49	0.55	0.49	0.06	000
91011		A	Esophagus motility study	1.50	5.37	5.29	NA	NA	0.13	000
91011	TC	A	Esophagus motility study	0.00	4.65	4.67	NA	NA	0.06	000
91011	26	A	Esophagus motility study	1.50	0.72	0.62	0.72	0.62	0.07	000
91012		A	Esophagus motility study	1.46	5.44	5.60	NA	NA	0.13	000

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
91012	TC	A	Esophagus motility study	0.00	4.76	5.00	NA	NA	0.07	000
91012	26	A	Esophagus motility study	1.46	0.68	0.60	0.68	0.60	0.06	000
91020		A	Gastric motility studies	1.44	4.81	4.66	NA	NA	0.13	000
91020	TC	A	Gastric motility studies	0.00	4.20	4.11	NA	NA	0.06	000
91020	26	A	Gastric motility studies	1.44	0.61	0.55	0.61	0.55	0.07	000
91022		A	Duodenal motility study	1.44	3.13	3.76	NA	NA	0.13	000
91022	TC	A	Duodenal motility study	0.00	2.51	3.20	NA	NA	0.06	000
91022	26	A	Duodenal motility study	1.44	0.62	0.56	0.62	0.56	0.07	000
91030		A	Acid perfusion of esophagus	0.91	2.90	2.66	NA	NA	0.06	000
91030	TC	A	Acid perfusion of esophagus	0.00	2.48	2.29	NA	NA	0.02	000
91030	26	A	Acid perfusion of esophagus	0.91	0.42	0.37	0.42	0.37	0.04	000
91034		A	Gastroesophageal reflux test	0.97	4.15	4.69	NA	NA	0.12	000
91034	TC	A	Gastroesophageal reflux test	0.00	3.73	4.31	NA	NA	0.06	000
91034	26	A	Gastroesophageal reflux test	0.97	0.42	0.38	0.42	0.38	0.06	000
91035		A	G-esoph reflux tst w/electrod	1.59	11.37	11.08	NA	NA	0.12	000
91035	TC	A	G-esoph reflux tst w/electrod	0.00	10.67	10.45	NA	NA	0.06	000
91035	26	A	G-esoph reflux tst w/electrod	1.59	0.70	0.63	0.70	0.63	0.06	000
91037		A	Esoph impeded function test	0.97	3.47	3.20	NA	NA	0.12	000
91037	TC	A	Esoph impeded function test	0.00	3.03	2.81	NA	NA	0.06	000
91037	26	A	Esoph impeded function test	0.97	0.44	0.39	0.44	0.39	0.06	000
91038		A	Esoph impeded funct test > 1h	1.10	2.80	2.52	NA	NA	0.12	000
91038	TC	A	Esoph impeded funct test > 1h	0.00	2.30	2.07	NA	NA	0.06	000
91038	26	A	Esoph impeded funct test > 1h	1.10	0.50	0.45	0.50	0.45	0.06	000
91040		A	Esoph balloon distension tst	0.97	7.72	9.42	NA	NA	0.12	000
91040	TC	A	Esoph balloon distension tst	0.00	7.44	9.11	NA	NA	0.06	000
91040	26	A	Esoph balloon distension tst	0.97	0.28	0.31	0.28	0.31	0.06	000
91052		A	Gastric analysis test	0.79	2.92	2.68	NA	NA	0.05	000
91052	TC	A	Gastric analysis test	0.00	2.55	2.36	NA	NA	0.02	000
91052	26	A	Gastric analysis test	0.79	0.37	0.32	0.37	0.32	0.03	000
91055		A	Gastric intubation for smear	0.94	2.57	2.76	NA	NA	0.07	000
91055	TC	A	Gastric intubation for smear	0.00	2.28	2.48	NA	NA	0.02	000
91055	26	A	Gastric intubation for smear	0.94	0.29	0.28	0.29	0.28	0.05	000
91065		A	Breath hydrogen test	0.20	1.33	1.40	NA	NA	0.03	000
91065	TC	A	Breath hydrogen test	0.00	1.27	1.33	NA	NA	0.02	000
91065	26	A	Breath hydrogen test	0.20	0.06	0.07	0.06	0.07	0.01	000
91100		A	Pass intestine bleeding tube	1.08	2.14	2.46	0.32	0.30	0.07	000
91105		A	Gastric intubation treatment	0.37	1.67	1.89	0.07	0.08	0.03	000
91110		A	Gi tract capsule endoscopy	3.64	20.63	21.40	NA	NA	0.16	XXX
91110	TC	A	Gi tract capsule endoscopy	0.00	18.97	19.93	NA	NA	0.07	XXX
91110	26	A	Gi tract capsule endoscopy	3.64	1.66	1.47	1.66	1.47	0.09	XXX
91111		A	Esophageal capsule endoscopy	1.00	18.82	18.82	NA	NA	0.05	XXX
91111	TC	A	Esophageal capsule endoscopy	0.00	18.37	18.37	NA	NA	0.02	XXX
91111	26	A	Esophageal capsule endoscopy	1.00	0.45	0.45	0.45	0.45	0.03	XXX
91120		A	Rectal sensation test	0.97	8.88	9.92	NA	NA	0.11	XXX
91120	TC	A	Rectal sensation test	0.00	8.61	9.62	NA	NA	0.04	XXX
91120	26	A	Rectal sensation test	0.97	0.27	0.30	0.27	0.30	0.07	XXX
91122		A	Anal pressure record	1.77	4.30	4.70	NA	NA	0.21	000
91122	TC	A	Anal pressure record	0.00	3.68	4.09	NA	NA	0.08	000
91122	26	A	Anal pressure record	1.77	0.62	0.61	0.62	0.61	0.13	000
91123		B	Irrigate fecal impaction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
91132		C	Electrogastrography	0.00	0.00	0.00	NA	NA	0.00	XXX
91132	TC	C	Electrogastrography	0.00	0.00	0.00	NA	NA	0.00	XXX
91132	26	A	Electrogastrography	0.52	0.25	0.22	0.25	0.22	0.02	XXX
91133		C	Electrogastrography w/test	0.00	0.00	0.00	NA	NA	0.00	XXX
91133	TC	C	Electrogastrography w/test	0.00	0.00	0.00	NA	NA	0.00	XXX
91133	26	A	Electrogastrography w/test	0.66	0.32	0.28	0.32	0.28	0.03	XXX
91299		C	Gastroenterology procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
91299	TC	C	Gastroenterology procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
91299	26	C	Gastroenterology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92002		A	Eye exam, new patient	0.88	0.93	0.95	0.25	0.30	0.02	XXX
92004		A	Eye exam, new patient	1.82	1.57	1.63	0.55	0.62	0.04	XXX
92012		A	Eye exam established pat	0.92	0.99	1.01	0.31	0.30	0.02	XXX
92014		A	Eye exam & treatment	1.42	1.37	1.39	0.46	0.46	0.03	XXX
92015		N	Refraction	0.38	0.10	0.79	0.09	0.12	0.01	XXX
92018		A	New eye exam & treatment	2.50	NA	NA	0.86	0.96	0.07	XXX
92019		A	Eye exam & treatment	1.31	NA	NA	0.35	0.46	0.03	XXX
92020		A	Special eye evaluation	0.37	0.25	0.29	0.13	0.14	0.01	XXX
92025		A	Corneal topography	0.35	0.49	0.49	NA	NA	0.02	XXX
92025	TC	A	Corneal topography	0.00	0.37	0.37	NA	NA	0.01	XXX
92025	26	A	Corneal topography	0.35	0.12	0.12	0.12	0.12	0.01	XXX
92060		A	Special eye evaluation	0.69	0.76	0.75	NA	NA	0.03	XXX
92060	TC	A	Special eye evaluation	0.00	0.54	0.49	NA	NA	0.01	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
92060	26	A	Special eye evaluation	0.69	0.22	0.26	0.22	0.26	0.02	XXX
92065		A	Orthoptic/pleoptic training	0.37	0.86	0.69	NA	NA	0.02	XXX
92065	TC	A	Orthoptic/pleoptic training	0.00	0.77	0.57	NA	NA	0.01	XXX
92065	26	A	Orthoptic/pleoptic training	0.37	0.09	0.12	0.09	0.12	0.01	XXX
92070		A	Fitting of contact lens	0.70	0.90	0.98	0.22	0.27	0.02	XXX
92081		A	Visual field examination(s)	0.36	0.95	0.94	NA	NA	0.02	XXX
92081	TC	A	Visual field examination(s)	0.00	0.84	0.81	NA	NA	0.01	XXX
92081	26	A	Visual field examination(s)	0.36	0.11	0.13	0.11	0.13	0.01	XXX
92082		A	Visual field examination(s)	0.44	1.32	1.27	NA	NA	0.02	XXX
92082	TC	A	Visual field examination(s)	0.00	1.18	1.11	NA	NA	0.01	XXX
92082	26	A	Visual field examination(s)	0.44	0.14	0.16	0.14	0.16	0.01	XXX
92083		A	Visual field examination(s)	0.50	1.51	1.47	NA	NA	0.02	XXX
92083	TC	A	Visual field examination(s)	0.00	1.35	1.28	NA	NA	0.01	XXX
92083	26	A	Visual field examination(s)	0.50	0.16	0.19	0.16	0.19	0.01	XXX
92100		A	Serial tonometry exam(s)	0.92	1.24	1.29	0.27	0.32	0.02	XXX
92120		A	Tonography & eye evaluation	0.81	0.97	1.02	0.25	0.28	0.02	XXX
92130		A	Water provocation tonography	0.81	1.18	1.23	0.27	0.32	0.02	XXX
92135		A	Ophth dx imaging post seg	0.35	0.79	0.78	NA	NA	0.02	XXX
92135	TC	A	Ophth dx imaging post seg	0.00	0.67	0.65	NA	NA	0.01	XXX
92135	26	A	Ophth dx imaging post seg	0.35	0.12	0.13	0.12	0.13	0.01	XXX
92136		A	Ophthalmic biometry	0.54	1.42	1.54	NA	NA	0.08	XXX
92136	TC	A	Ophthalmic biometry	0.00	1.23	1.32	NA	NA	0.07	XXX
92136	26	A	Ophthalmic biometry	0.54	0.19	0.22	0.19	0.22	0.01	XXX
92140		A	Glaucoma provocative tests	0.50	0.89	0.94	0.14	0.18	0.01	XXX
92225		A	Special eye exam, initial	0.38	0.24	0.23	0.12	0.14	0.01	XXX
92226		A	Special eye exam, subsequent	0.33	0.23	0.22	0.11	0.13	0.01	XXX
92230		A	Eye exam with photos	0.60	0.68	1.10	0.19	0.19	0.02	XXX
92235		A	Eye exam with photos	0.81	2.26	2.44	NA	NA	0.08	XXX
92235	TC	A	Eye exam with photos	0.00	1.97	2.11	NA	NA	0.06	XXX
92235	26	A	Eye exam with photos	0.81	0.29	0.33	0.29	0.33	0.02	XXX
92240		A	lcg angiography	1.10	4.38	5.23	NA	NA	0.09	XXX
92240	TC	A	lcg angiography	0.00	3.99	4.79	NA	NA	0.06	XXX
92240	26	A	lcg angiography	1.10	0.39	0.44	0.39	0.44	0.03	XXX
92250		A	Eye exam with photos	0.44	1.30	1.41	NA	NA	0.02	XXX
92250	TC	A	Eye exam with photos	0.00	1.16	1.25	NA	NA	0.01	XXX
92250	26	A	Eye exam with photos	0.44	0.14	0.16	0.14	0.16	0.01	XXX
92260		A	Ophthalmoscopy/dynamometry	0.20	0.23	0.24	0.07	0.08	0.01	XXX
92265		A	Eye muscle evaluation	0.81	1.00	1.24	NA	NA	0.06	XXX
92265	TC	A	Eye muscle evaluation	0.00	0.76	0.98	NA	NA	0.02	XXX
92265	26	A	Eye muscle evaluation	0.81	0.24	0.26	0.24	0.26	0.04	XXX
92270		A	Electro-oculography	0.81	1.32	1.42	NA	NA	0.05	XXX
92270	TC	A	Electro-oculography	0.00	1.09	1.14	NA	NA	0.02	XXX
92270	26	A	Electro-oculography	0.81	0.23	0.28	0.23	0.28	0.03	XXX
92275		A	Electroretinography	1.01	2.42	2.18	NA	NA	0.05	XXX
92275	TC	A	Electroretinography	0.00	2.07	1.79	NA	NA	0.02	XXX
92275	26	A	Electroretinography	1.01	0.35	0.39	0.35	0.39	0.03	XXX
92283		A	Color vision examination	0.17	0.99	0.91	NA	NA	0.02	XXX
92283	TC	A	Color vision examination	0.00	0.94	0.85	NA	NA	0.01	XXX
92283	26	A	Color vision examination	0.17	0.05	0.06	0.05	0.06	0.01	XXX
92284		A	Dark adaptation eye exam	0.24	1.13	1.50	NA	NA	0.02	XXX
92284	TC	A	Dark adaptation eye exam	0.00	1.06	1.43	NA	NA	0.01	XXX
92284	26	A	Dark adaptation eye exam	0.24	0.07	0.07	0.07	0.07	0.01	XXX
92285		A	Eye photography	0.20	0.80	0.89	NA	NA	0.02	XXX
92285	TC	A	Eye photography	0.00	0.73	0.81	NA	NA	0.01	XXX
92285	26	A	Eye photography	0.20	0.07	0.08	0.07	0.08	0.01	XXX
92286		A	Internal eye photography	0.66	2.08	2.56	NA	NA	0.04	XXX
92286	TC	A	Internal eye photography	0.00	1.86	2.31	NA	NA	0.02	XXX
92286	26	A	Internal eye photography	0.66	0.22	0.25	0.22	0.25	0.02	XXX
92287		A	Internal eye photography	0.81	1.90	2.14	0.27	0.29	0.02	XXX
92310		N	Contact lens fitting	1.17	1.06	1.09	0.27	0.36	0.04	XXX
92311		A	Contact lens fitting	1.08	1.27	1.18	0.30	0.33	0.03	XXX
92312		A	Contact lens fitting	1.26	1.45	1.26	0.33	0.41	0.03	XXX
92313		A	Contact lens fitting	0.92	1.42	1.24	0.31	0.30	0.02	XXX
92314		N	Prescription of contact lens	0.69	1.14	1.04	0.16	0.21	0.01	XXX
92315		A	Prescription of contact lens	0.45	1.31	1.08	0.13	0.14	0.01	XXX
92316		A	Prescription of contact lens	0.68	1.63	1.27	0.22	0.26	0.02	XXX
92317		A	Prescription of contact lens	0.45	1.31	1.12	0.11	0.13	0.01	XXX
92325		A	Modification of contact lens	0.00	0.83	0.62	NA	NA	0.01	XXX
92326		A	Replacement of contact lens	0.00	0.73	1.18	NA	NA	0.06	XXX
92340		N	Fitting of spectacles	0.37	0.44	0.57	0.09	0.11	0.01	XXX
92341		N	Fitting of spectacles	0.47	0.46	0.60	0.11	0.14	0.01	XXX
92342		N	Fitting of spectacles	0.53	0.48	0.62	0.12	0.17	0.01	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fa- cility PE RVUs ²	Mal- practice RVUs ²	Global
92352		B	Special spectacles fitting	0.37	0.56	0.62	0.09	0.11	0.01	XXX
92353		B	Special spectacles fitting	0.50	0.59	0.66	0.11	0.15	0.02	XXX
92354		B	Special spectacles fitting	0.00	0.28	4.57	NA	NA	0.10	XXX
92355		B	Special spectacles fitting	0.00	0.44	2.38	NA	NA	0.01	XXX
92358		B	Eye prosthesis service	0.00	0.24	0.60	NA	NA	0.05	XXX
92370		N	Repair & adjust spectacles	0.32	0.39	0.47	0.07	0.10	0.02	XXX
92371		B	Repair & adjust spectacles	0.00	0.24	0.43	NA	NA	0.02	XXX
92499		C	Eye service or procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
92499	TC	C	Eye service or procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
92499	26	C	Eye service or procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92502		A	Ear and throat examination	1.51	NA	NA	0.90	1.00	0.05	000
92504		A	Ear microscopy examination	0.18	0.60	0.55	0.06	0.07	0.01	XXX
92506		A	Speech/hearing evaluation	0.86	3.49	3.04	0.28	0.34	0.03	XXX
92507		A	Speech/hearing therapy	0.52	1.23	1.17	0.16	0.19	0.02	XXX
92508		A	Speech/hearing therapy	0.26	0.55	0.53	0.09	0.11	0.01	XXX
92511		A	Nasopharyngoscopy	0.84	3.12	3.21	0.67	0.72	0.03	000
92512		A	Nasal function studies	0.55	1.00	1.07	0.17	0.18	0.02	XXX
92516		A	Facial nerve function test	0.43	1.23	1.21	0.14	0.18	0.01	XXX
92520		A	Laryngeal function studies	0.75	0.93	0.72	0.24	0.31	0.03	XXX
92526		A	Oral function therapy	0.55	1.70	1.67	0.16	0.18	0.02	XXX
92531		B	Spontaneous nystagmus study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92532		B	Positional nystagmus test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92533		B	Caloric vestibular test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92534		B	Optokinetic nystagmus test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92541		A	Spontaneous nystagmus test	0.40	1.14	1.09	NA	NA	0.04	XXX
92541	TC	A	Spontaneous nystagmus test	0.00	1.03	0.94	NA	NA	0.02	XXX
92541	26	A	Spontaneous nystagmus test	0.40	0.11	0.15	0.11	0.15	0.02	XXX
92542		A	Positional nystagmus test	0.33	1.29	1.22	NA	NA	0.03	XXX
92542	TC	A	Positional nystagmus test	0.00	1.20	1.09	NA	NA	0.02	XXX
92542	26	A	Positional nystagmus test	0.33	0.09	0.13	0.09	0.13	0.01	XXX
92543		A	Caloric vestibular test	0.10	0.65	0.61	NA	NA	0.02	XXX
92543	TC	A	Caloric vestibular test	0.00	0.62	0.57	NA	NA	0.01	XXX
92543	26	A	Caloric vestibular test	0.10	0.03	0.04	0.03	0.04	0.01	XXX
92544		A	Optokinetic nystagmus test	0.26	1.03	0.97	NA	NA	0.03	XXX
92544	TC	A	Optokinetic nystagmus test	0.00	0.96	0.87	NA	NA	0.02	XXX
92544	26	A	Optokinetic nystagmus test	0.26	0.07	0.10	0.07	0.10	0.01	XXX
92545		A	Oscillating tracking test	0.23	1.00	0.90	NA	NA	0.03	XXX
92545	TC	A	Oscillating tracking test	0.00	0.94	0.81	NA	NA	0.02	XXX
92545	26	A	Oscillating tracking test	0.23	0.06	0.09	0.06	0.09	0.01	XXX
92546		A	Sinusoidal rotational test	0.29	1.81	1.89	NA	NA	0.03	XXX
92546	TC	A	Sinusoidal rotational test	0.00	1.73	1.79	NA	NA	0.02	XXX
92546	26	A	Sinusoidal rotational test	0.29	0.08	0.10	0.08	0.10	0.01	XXX
92547		A	Supplemental electrical test	0.00	0.11	0.09	0.11	0.09	0.06	ZZZ
92548		A	Posturography	0.50	1.70	1.98	NA	NA	0.15	XXX
92548	TC	A	Posturography	0.00	1.56	1.78	NA	NA	0.13	XXX
92548	26	A	Posturography	0.50	0.14	0.20	0.14	0.20	0.02	XXX
92551		N	Pure tone hearing test, air	0.00	0.25	0.25	NA	NA	0.01	XXX
92552		A	Pure tone audiometry, air	0.00	0.61	0.52	NA	NA	0.04	XXX
92553		A	Audiometry, air & bone	0.00	0.77	0.71	NA	NA	0.06	XXX
92555		A	Speech threshold audiometry	0.00	0.41	0.40	NA	NA	0.04	XXX
92556		A	Speech audiometry, complete	0.00	0.51	0.54	NA	NA	0.06	XXX
92557		A	Comprehensive hearing test	0.60	0.29	0.74	0.20	0.69	0.12	XXX
92559		N	Group audiometric testing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92560		N	Bekesy audiometry, screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92561		A	Bekesy audiometry, diagnosis	0.00	0.70	0.71	NA	NA	0.06	XXX
92562		A	Loudness balance test	0.00	0.62	0.51	NA	NA	0.04	XXX
92563		A	Tone decay hearing test	0.00	0.55	0.46	NA	NA	0.04	XXX
92564		A	Sisi hearing test	0.00	0.48	0.47	NA	NA	0.05	XXX
92565		A	Stenger test, pure tone	0.00	0.25	0.33	NA	NA	0.04	XXX
92567		A	Tympanometry	0.20	0.13	0.33	0.07	0.29	0.06	XXX
92568		A	Acoustic refl threshold tst	0.29	0.10	0.24	0.09	0.24	0.04	XXX
92569		A	Acoustic reflex decay test	0.20	0.07	0.24	0.07	0.24	0.04	XXX
92571		A	Filtered speech hearing test	0.00	0.44	0.41	NA	NA	0.04	XXX
92572		A	Staggered spondaic word test	0.00	0.59	0.34	NA	NA	0.01	XXX
92575		A	Sensorineural acuity test	0.00	1.15	0.72	NA	NA	0.02	XXX
92576		A	Synthetic sentence test	0.00	0.58	0.51	NA	NA	0.05	XXX
92577		A	Stenger test, speech	0.00	0.26	0.49	NA	NA	0.07	XXX
92579		A	Visual audiometry (vra)	0.70	0.35	0.54	0.23	0.48	0.06	XXX
92582		A	Conditioning play audiometry	0.00	1.17	0.95	NA	NA	0.06	XXX
92583		A	Select picture audiometry	0.00	0.73	0.81	NA	NA	0.08	XXX
92584		A	Electrocochleography	0.00	1.36	1.91	NA	NA	0.21	XXX
92585		A	Auditor evoke potent, compre	0.50	2.10	2.08	NA	NA	0.17	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
92585	TC	A	Auditor evoke potent, compre	0.00	1.95	1.90	NA	NA	0.14	XXX
92585	26	A	Auditor evoke potent, compre	0.50	0.15	0.18	0.15	0.18	0.03	XXX
92586		A	Auditor evoke potent, limit	0.00	1.41	1.63	NA	NA	0.14	XXX
92587		A	Evoked auditory test	0.13	0.65	1.01	NA	NA	0.12	XXX
92587	TC	A	Evoked auditory test	0.00	0.61	0.96	NA	NA	0.11	XXX
92587	26	A	Evoked auditory test	0.13	0.04	0.05	0.04	0.05	0.01	XXX
92588		A	Evoked auditory test	0.36	1.11	1.37	NA	NA	0.14	XXX
92588	TC	A	Evoked auditory test	0.00	1.00	1.23	NA	NA	0.13	XXX
92588	26	A	Evoked auditory test	0.36	0.11	0.14	0.11	0.14	0.01	XXX
92590		N	Hearing aid exam, one ear	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92591		N	Hearing aid exam, both ears	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92592		N	Hearing aid check, one ear	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92593		N	Hearing aid check, both ears	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92594		N	Electro hearing aid test, one	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92595		N	Electro hearing aid test, both	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92596		A	Ear protector evaluation	0.00	1.02	0.80	NA	NA	0.06	XXX
92597		A	Oral speech device eval	0.86	1.99	1.84	0.28	0.37	0.03	XXX
92601		A	Cochlear implt f/up exam < 7	2.30	1.08	2.29	0.64	2.07	0.07	XXX
92602		A	Reprogram cochlear implt < 7	1.30	0.84	1.61	0.40	1.39	0.07	XXX
92603		A	Cochlear implt f/up exam 7 >	2.25	1.19	1.66	0.73	1.44	0.07	XXX
92604		A	Reprogram cochlear implt 7 >	1.25	0.78	1.06	0.41	0.88	0.07	XXX
92605		B	Eval for nonspeech device rx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92606		B	Non-speech device service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92607		A	Ex for speech device rx, 1hr	0.00	4.63	3.85	NA	NA	0.05	XXX
92608		A	Ex for speech device rx addl	0.00	0.88	0.72	NA	NA	0.05	XXX
92609		A	Use of speech device service	0.00	2.45	2.02	NA	NA	0.04	XXX
92610		A	Evaluate swallowing function	0.00	1.70	2.56	NA	NA	0.08	XXX
92611		A	Motion fluoroscopy/swallow	0.00	1.95	2.69	NA	NA	0.08	XXX
92612		A	Endoscopy swallow tst (fees)	1.27	2.97	2.85	0.42	0.54	0.04	XXX
92613		A	Endoscopy swallow tst (fees)	0.71	0.24	0.32	0.23	0.31	0.05	XXX
92614		A	Laryngoscopic sensory test	1.27	2.42	2.46	0.42	0.54	0.04	XXX
92615		A	Eval laryngoscopy sense tst	0.63	0.21	0.28	0.20	0.28	0.05	XXX
92616		A	Fees w/laryngeal sense test	1.88	3.16	3.27	0.60	0.80	0.06	XXX
92617		A	Interprt fees/laryngeal test	0.79	0.26	0.35	0.26	0.35	0.05	XXX
92620		A	Auditory function, 60 min	0.00	1.93	1.53	NA	NA	0.06	XXX
92621		A	Auditory function, + 15 min	0.00	0.44	0.34	NA	NA	0.06	ZZZ
92625		A	Tinnitus assessment	0.00	1.94	1.53	1.94	1.53	0.06	XXX
92626		A	Eval aud rehab status	0.00	2.00	2.10	NA	NA	0.06	XXX
92627		A	Eval aud status rehab add-on	0.00	0.46	0.50	0.46	0.50	0.02	ZZZ
92630		I	Aud rehab pre-ling hear loss	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92633		I	Aud rehab postling hear loss	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92640		A	Aud brainstem implt program	0.00	1.34	1.34	1.34	1.34	0.01	XXX
92700		C	Ent procedure/service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92950		A	Heart/lung resuscitation cpr	3.79	3.24	3.72	0.77	0.87	0.28	000
92953		A	Temporary external pacing	0.23	NA	NA	0.07	0.07	0.02	000
92960		A	Cardioversion electric, ext	2.25	4.37	5.34	1.45	1.31	0.07	000
92961		A	Cardioversion, electric, int	4.59	NA	NA	2.43	2.26	0.29	000
92970		A	Cardioassist, internal	3.51	NA	NA	1.46	1.26	0.16	000
92971		A	Cardioassist, external	1.77	NA	NA	1.09	0.97	0.06	000
92973		A	Percut coronary thrombectomy	3.28	NA	NA	1.76	1.52	0.23	ZZZ
92974		A	Cath place, cardio brachytx	3.00	NA	NA	1.62	1.40	0.21	ZZZ
92975		A	Dissolve clot, heart vessel	7.24	NA	NA	3.83	3.32	0.50	000
92977		A	Dissolve clot, heart vessel	0.00	1.73	4.88	NA	NA	0.46	XXX
92978		C	Intravasc us, heart add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
92978	TC	C	Intravasc us, heart add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
92978	26	A	Intravasc us, heart add-on	1.80	0.96	0.83	0.96	0.83	0.06	ZZZ
92979		C	Intravasc us, heart add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
92979	TC	C	Intravasc us, heart add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
92979	26	A	Intravasc us, heart add-on	1.44	0.77	0.67	0.77	0.67	0.06	ZZZ
92980		A	Insert intracoronary stent	14.82	NA	NA	8.12	7.08	1.03	000
92981		A	Insert intracoronary stent	4.16	NA	NA	2.22	1.92	0.29	ZZZ
92982		A	Coronary artery dilation	10.96	NA	NA	6.05	5.29	0.76	000
92984		A	Coronary artery dilation	2.97	NA	NA	1.58	1.37	0.21	ZZZ
92986		A	Revision of aortic valve	22.70	NA	NA	15.32	13.57	1.51	090
92987		A	Revision of mitral valve	23.48	NA	NA	15.94	14.07	1.59	090
92990		A	Revision of pulmonary valve	18.12	NA	NA	11.33	10.56	1.20	090
92992		C	Revision of heart chamber	0.00	0.00	0.00	0.00	0.00	0.00	090
92993		C	Revision of heart chamber	0.00	0.00	0.00	0.00	0.00	0.00	090
92995		A	Coronary atherectomy	12.07	NA	NA	6.64	5.80	0.84	000
92996		A	Coronary atherectomy add-on	3.26	NA	NA	1.76	1.51	0.10	ZZZ
92997		A	Pul art balloon repr, percut	11.98	NA	NA	5.61	5.21	0.40	000
92998		A	Pul art balloon repr, percut	5.99	NA	NA	3.00	2.60	0.28	ZZZ

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
93000		A	Electrocardiogram, complete	0.17	0.35	0.42	NA	NA	0.03	XXX
93005		A	Electrocardiogram, tracing	0.00	0.28	0.36	NA	NA	0.02	XXX
93010		A	Electrocardiogram report	0.17	0.07	0.06	0.07	0.06	0.01	XXX
93012		A	Transmission of ecg	0.00	4.16	5.09	NA	NA	0.18	XXX
93014		A	Report on transmitted ecg	0.52	0.22	0.21	0.22	0.21	0.02	XXX
93015		A	Cardiovascular stress test	0.75	1.90	1.93	NA	NA	0.14	XXX
93016		A	Cardiovascular stress test	0.45	0.22	0.20	0.22	0.20	0.02	XXX
93017		A	Cardiovascular stress test	0.00	1.53	1.60	NA	NA	0.11	XXX
93018		A	Cardiovascular stress test	0.30	0.15	0.13	0.15	0.13	0.01	XXX
93024		A	Cardiac drug stress test	1.17	2.40	1.98	NA	NA	0.12	XXX
93024	TC	A	Cardiac drug stress test	0.00	1.82	1.47	NA	NA	0.08	XXX
93024	26	A	Cardiac drug stress test	1.17	0.58	0.51	0.58	0.51	0.04	XXX
93025		A	Microvolt t-wave assess	0.75	3.93	5.76	NA	NA	0.14	XXX
93025	TC	A	Microvolt t-wave assess	0.00	3.55	5.42	NA	NA	0.11	XXX
93025	26	A	Microvolt t-wave assess	0.75	0.38	0.34	0.38	0.34	0.03	XXX
93040		A	Rhythm ECG with report	0.16	0.19	0.20	NA	NA	0.02	XXX
93041		A	Rhythm ECG, tracing	0.00	0.14	0.15	NA	NA	0.01	XXX
93042		A	Rhythm ECG, report	0.16	0.05	0.05	0.05	0.05	0.01	XXX
93224		A	ECG monitor/report, 24 hrs	0.52	2.31	2.96	NA	NA	0.24	XXX
93225		A	ECG monitor/record, 24 hrs	0.00	0.85	1.04	NA	NA	0.08	XXX
93226		A	ECG monitor/report, 24 hrs	0.00	1.19	1.69	NA	NA	0.14	XXX
93227		A	ECG monitor/review, 24 hrs	0.52	0.27	0.23	0.27	0.23	0.02	XXX
93230		A	ECG monitor/report, 24 hrs	0.52	2.30	3.09	NA	NA	0.26	XXX
93231		A	Ecg monitor/record, 24 hrs	0.00	0.72	1.12	NA	NA	0.11	XXX
93232		A	ECG monitor/report, 24 hrs	0.00	1.35	1.76	NA	NA	0.13	XXX
93233		A	ECG monitor/review, 24 hrs	0.52	0.23	0.21	0.23	0.21	0.02	XXX
93235		C	ECG monitor/report, 24 hrs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93236		C	ECG monitor/report, 24 hrs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93237		A	ECG monitor/review, 24 hrs	0.45	0.22	0.19	0.22	0.19	0.02	XXX
93268		A	ECG record/review	0.52	5.78	6.60	NA	NA	0.28	XXX
93270		A	ECG recording	0.00	0.29	0.76	NA	NA	0.08	XXX
93271		A	Ecg/monitoring and analysis	0.00	5.27	5.64	NA	NA	0.18	XXX
93272		A	Ecg/review, interpret only	0.52	0.22	0.20	0.22	0.20	0.02	XXX
93278		A	ECG/signal-averaged	0.25	0.62	0.93	NA	NA	0.12	XXX
93278	TC	A	ECG/signal-averaged	0.00	0.52	0.83	NA	NA	0.11	XXX
93278	26	A	ECG/signal-averaged	0.25	0.10	0.10	0.10	0.10	0.01	XXX
93303		A	Echo transthoracic	1.30	4.49	4.41	NA	NA	0.27	XXX
93303	TC	A	Echo transthoracic	0.00	3.96	3.91	NA	NA	0.23	XXX
93303	26	A	Echo transthoracic	1.30	0.53	0.50	0.53	0.50	0.04	XXX
93304		A	Echo transthoracic	0.75	3.10	2.66	NA	NA	0.15	XXX
93304	TC	A	Echo transthoracic	0.00	2.80	2.37	NA	NA	0.13	XXX
93304	26	A	Echo transthoracic	0.75	0.30	0.29	0.30	0.29	0.02	XXX
93307		A	Echo exam of heart	0.92	3.73	3.97	NA	NA	0.26	XXX
93307	TC	A	Echo exam of heart	0.00	3.28	3.57	NA	NA	0.23	XXX
93307	26	A	Echo exam of heart	0.92	0.45	0.40	0.45	0.40	0.03	XXX
93308		A	Echo exam of heart	0.53	2.62	2.38	NA	NA	0.15	XXX
93308	TC	A	Echo exam of heart	0.00	2.35	2.15	NA	NA	0.13	XXX
93308	26	A	Echo exam of heart	0.53	0.27	0.23	0.27	0.23	0.02	XXX
93312		A	Echo transesophageal	2.20	7.39	5.98	NA	NA	0.37	XXX
93312	TC	A	Echo transesophageal	0.00	6.42	5.10	NA	NA	0.29	XXX
93312	26	A	Echo transesophageal	2.20	0.97	0.88	0.97	0.88	0.08	XXX
93313		A	Echo transesophageal	0.95	NA	NA	0.12	0.17	0.06	XXX
93314		A	Echo transesophageal	1.25	7.21	5.73	NA	NA	0.33	XXX
93314	TC	A	Echo transesophageal	0.00	6.65	5.22	NA	NA	0.29	XXX
93314	26	A	Echo transesophageal	1.25	0.56	0.51	0.56	0.51	0.04	XXX
93315		C	Echo transesophageal	0.00	0.00	0.00	NA	NA	0.00	XXX
93315	TC	C	Echo transesophageal	0.00	0.00	0.00	NA	NA	0.00	XXX
93315	26	A	Echo transesophageal	2.78	1.30	1.16	1.30	1.16	0.09	XXX
93316		A	Echo transesophageal	0.95	NA	NA	0.26	0.25	0.05	XXX
93317		C	Echo transesophageal	0.00	0.00	0.00	NA	NA	0.00	XXX
93317	TC	C	Echo transesophageal	0.00	0.00	0.00	NA	NA	0.00	XXX
93317	26	A	Echo transesophageal	1.83	0.55	0.61	0.55	0.61	0.08	XXX
93318		C	Echo transesophageal intraop	0.00	0.00	0.00	NA	NA	0.00	XXX
93318	TC	C	Echo transesophageal intraop	0.00	0.00	0.00	NA	NA	0.00	XXX
93318	26	A	Echo transesophageal intraop	2.20	0.85	0.67	0.85	0.67	0.14	XXX
93320		A	Doppler echo exam, heart	0.38	1.67	1.77	NA	NA	0.13	ZZZ
93320	TC	A	Doppler echo exam, heart	0.00	1.49	1.60	NA	NA	0.12	ZZZ
93320	26	A	Doppler echo exam, heart	0.38	0.18	0.17	0.18	0.17	0.01	ZZZ
93321		A	Doppler echo exam, heart	0.15	0.61	0.89	NA	NA	0.09	ZZZ
93321	TC	A	Doppler echo exam, heart	0.00	0.54	0.82	NA	NA	0.08	ZZZ
93321	26	A	Doppler echo exam, heart	0.15	0.07	0.07	0.07	0.07	0.01	ZZZ
93325		A	Doppler color flow add-on	0.07	0.66	1.80	NA	NA	0.22	ZZZ

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
93325	TC	A	Doppler color flow add-on	0.00	0.63	1.77	NA	NA	0.21	ZZZ
93325	26	A	Doppler color flow add-on	0.07	0.03	0.03	0.03	0.03	0.01	ZZZ
93350		A	Echo transthoracic	1.48	5.09	3.71	NA	NA	0.18	XXX
93350	TC	A	Echo transthoracic	0.00	4.33	3.05	NA	NA	0.13	XXX
93350	26	A	Echo transthoracic	1.48	0.76	0.66	0.76	0.66	0.05	XXX
93501		A	Right heart catheterization	3.02	18.69	18.37	NA	NA	1.27	000
93501	TC	A	Right heart catheterization	0.00	17.12	17.01	NA	NA	1.06	000
93501	26	A	Right heart catheterization	3.02	1.57	1.36	1.57	1.36	0.21	000
93503		C	Insert/place heart catheter	0.00	NA	NA	NA	NA	0.00	000
93505		A	Biopsy of heart lining	4.37	20.90	12.28	NA	NA	0.46	000
93505	TC	A	Biopsy of heart lining	0.00	18.62	10.30	NA	NA	0.16	000
93505	26	A	Biopsy of heart lining	4.37	2.28	1.98	2.28	1.98	0.30	000
93508		A	Cath placement, angiography	4.09	28.82	21.75	NA	NA	0.93	000
93508	TC	A	Cath placement, angiography	0.00	26.65	19.62	NA	NA	0.65	000
93508	26	A	Cath placement, angiography	4.09	2.17	2.13	2.17	2.13	0.28	000
93510		A	Left heart catheterization	4.32	28.12	33.61	NA	NA	2.61	000
93510	TC	A	Left heart catheterization	0.00	25.84	31.39	NA	NA	2.31	000
93510	26	A	Left heart catheterization	4.32	2.28	2.22	2.28	2.22	0.30	000
93511		C	Left heart catheterization	0.00	NA	NA	NA	NA	0.00	000
93511	TC	C	Left heart catheterization	0.00	NA	NA	NA	NA	0.00	000
93511	26	A	Left heart catheterization	5.02	2.65	2.54	2.65	2.54	0.35	000
93514		C	Left heart catheterization	0.00	NA	NA	NA	NA	0.00	000
93514	TC	C	Left heart catheterization	0.00	NA	NA	NA	NA	0.00	000
93514	26	A	Left heart catheterization	7.04	2.95	3.03	2.95	3.03	0.49	000
93524		C	Left heart catheterization	0.00	NA	NA	NA	NA	0.00	000
93524	TC	C	Left heart catheterization	0.00	NA	NA	NA	NA	0.00	000
93524	26	A	Left heart catheterization	6.94	3.77	3.47	3.77	3.47	0.48	000
93526		A	Rt & Lt heart catheters	5.98	35.09	42.99	NA	NA	3.46	000
93526	TC	A	Rt & Lt heart catheters	0.00	31.93	40.00	NA	NA	3.04	000
93526	26	A	Rt & Lt heart catheters	5.98	3.16	2.99	3.16	2.99	0.42	000
93527		C	Rt & Lt heart catheters	0.00	NA	NA	NA	NA	0.00	000
93527	TC	C	Rt & Lt heart catheters	0.00	NA	NA	NA	NA	0.00	000
93527	26	A	Rt & Lt heart catheters	7.27	3.85	3.58	3.85	3.58	0.51	000
93528		C	Rt & Lt heart catheters	0.00	NA	NA	NA	NA	0.00	000
93528	TC	C	Rt & Lt heart catheters	0.00	NA	NA	NA	NA	0.00	000
93528	26	A	Rt & Lt heart catheters	8.99	4.43	4.23	4.43	4.23	0.62	000
93529		C	Rt, lt heart catheterization	0.00	NA	NA	NA	NA	0.00	000
93529	TC	C	Rt, lt heart catheterization	0.00	NA	NA	NA	NA	0.00	000
93529	26	A	Rt, lt heart catheterization	4.79	2.58	2.43	2.58	2.43	0.33	000
93530		C	Rt heart cath, congenital	0.00	NA	NA	NA	NA	0.00	000
93530	TC	C	Rt heart cath, congenital	0.00	NA	NA	NA	NA	0.00	000
93530	26	A	Rt heart cath, congenital	4.22	1.84	1.89	1.84	1.89	0.29	000
93531		C	R & l heart cath, congenital	0.00	NA	NA	NA	NA	0.00	000
93531	TC	C	R & l heart cath, congenital	0.00	NA	NA	NA	NA	0.00	000
93531	26	A	R & l heart cath, congenital	8.34	3.57	3.57	3.57	3.57	0.58	000
93532		C	R & l heart cath, congenital	0.00	NA	NA	NA	NA	0.00	000
93532	TC	C	R & l heart cath, congenital	0.00	NA	NA	NA	NA	0.00	000
93532	26	A	R & l heart cath, congenital	9.99	3.65	3.95	3.65	3.95	0.69	000
93533		C	R & l heart cath, congenital	0.00	NA	NA	NA	NA	0.00	000
93533	TC	C	R & l heart cath, congenital	0.00	NA	NA	NA	NA	0.00	000
93533	26	A	R & l heart cath, congenital	6.69	3.15	2.97	3.15	2.97	0.47	000
93539		A	Injection, cardiac cath	0.40	2.46	11.72	0.21	0.19	0.01	000
93540		A	Injection, cardiac cath	0.43	8.61	15.53	0.23	0.20	0.01	000
93541		A	Injection for lung angiogram	0.29	0.15	7.60	0.15	0.13	0.01	000
93542		A	Injection for heart x-rays	0.29	5.18	10.07	0.15	0.13	0.01	000
93543		A	Injection for heart x-rays	0.29	2.62	8.86	0.16	0.13	0.01	000
93544		A	Injection for aortography	0.25	1.84	7.41	0.13	0.12	0.01	000
93545		A	Injct for coronary x-rays	0.40	5.86	13.42	0.21	0.19	0.01	000
93555		A	Imaging, cardiac cath	0.81	0.59	3.59	NA	NA	0.37	XXX
93555	TC	A	Imaging, cardiac cath	0.00	0.17	3.22	NA	NA	0.34	XXX
93555	26	A	Imaging, cardiac cath	0.81	0.42	0.37	0.42	0.37	0.03	XXX
93556		A	Imaging, cardiac cath	0.83	0.88	5.54	NA	NA	0.54	XXX
93556	TC	A	Imaging, cardiac cath	0.00	0.44	5.16	NA	NA	0.51	XXX
93556	26	A	Imaging, cardiac cath	0.83	0.44	0.38	0.44	0.38	0.03	XXX
93561		C	Cardiac output measurement	0.00	NA	NA	NA	NA	0.00	000
93561	TC	C	Cardiac output measurement	0.00	NA	NA	NA	NA	0.00	000
93561	26	A	Cardiac output measurement	0.50	0.14	0.15	0.14	0.15	0.02	000
93562		C	Cardiac output measurement	0.00	NA	NA	NA	NA	0.00	000
93562	TC	C	Cardiac output measurement	0.00	NA	NA	NA	NA	0.00	000
93562	26	A	Cardiac output measurement	0.16	0.03	0.04	0.03	0.04	0.01	000
93571		C	Heart flow reserve measure	0.00	NA	NA	NA	NA	0.00	ZZZ
93571	TC	C	Heart flow reserve measure	0.00	NA	NA	NA	NA	0.00	ZZZ

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional faci- lity PE RVUs ²	Mal- practice RVUs ²	Global
93571	26	A	Heart flow reserve measure	1.80	0.95	0.82	0.95	0.82	0.06	ZZZ
93572		C	Heart flow reserve measure	0.00	NA	NA	NA	NA	0.00	ZZZ
93572	TC	C	Heart flow reserve measure	0.00	NA	NA	NA	NA	0.00	ZZZ
93572	26	A	Heart flow reserve measure	1.44	0.74	0.62	0.74	0.62	0.04	ZZZ
93580		A	Transcath closure of asd	17.97	NA	NA	9.40	8.39	1.25	000
93581		A	Transcath closure of vsd	24.39	NA	NA	11.55	10.47	1.72	000
93600		C	Bundle of His recording	0.00	0.00	0.00	NA	NA	0.00	000
93600	TC	C	Bundle of His recording	0.00	0.00	0.00	NA	NA	0.00	000
93600	26	A	Bundle of His recording	2.12	1.09	0.96	1.09	0.96	0.16	000
93602		C	Intra-atrial recording	0.00	0.00	0.00	NA	NA	0.00	000
93602	TC	C	Intra-atrial recording	0.00	0.00	0.00	NA	NA	0.00	000
93602	26	A	Intra-atrial recording	2.12	1.04	0.93	1.04	0.93	0.17	000
93603		C	Right ventricular recording	0.00	0.00	0.00	NA	NA	0.00	000
93603	TC	C	Right ventricular recording	0.00	0.00	0.00	NA	NA	0.00	000
93603	26	A	Right ventricular recording	2.12	1.04	0.92	1.04	0.92	0.18	000
93609		C	Map tachycardia, add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
93609	TC	C	Map tachycardia, add-on	0.00	0.00	0.00	NA	NA	0.00	ZZZ
93609	26	A	Map tachycardia, add-on	4.99	2.61	2.28	2.61	2.28	0.35	ZZZ
93610		C	Intra-atrial pacing	0.00	0.00	0.00	NA	NA	0.00	000
93610	TC	C	Intra-atrial pacing	0.00	0.00	0.00	NA	NA	0.00	000
93610	26	A	Intra-atrial pacing	3.02	1.47	1.31	1.47	1.31	0.24	000
93612		C	Intraventricular pacing	0.00	0.00	0.00	NA	NA	0.00	000
93612	TC	C	Intraventricular pacing	0.00	0.00	0.00	NA	NA	0.00	000
93612	26	A	Intraventricular pacing	3.02	1.42	1.29	1.42	1.29	0.25	000
93613		A	Electrophys map 3d, add-on	6.99	NA	NA	3.69	3.22	0.49	ZZZ
93615		C	Esophageal recording	0.00	0.00	0.00	NA	NA	0.00	000
93615	TC	C	Esophageal recording	0.00	0.00	0.00	NA	NA	0.00	000
93615	26	A	Esophageal recording	0.99	0.54	0.40	0.54	0.40	0.03	000
93616		C	Esophageal recording	0.00	0.00	0.00	NA	NA	0.00	000
93616	TC	C	Esophageal recording	0.00	0.00	0.00	NA	NA	0.00	000
93616	26	A	Esophageal recording	1.49	0.26	0.35	0.26	0.35	0.09	000
93618		C	Heart rhythm pacing	0.00	0.00	0.00	NA	NA	0.00	000
93618	TC	C	Heart rhythm pacing	0.00	0.00	0.00	NA	NA	0.00	000
93618	26	A	Heart rhythm pacing	4.25	2.28	1.97	2.28	1.97	0.30	000
93619		C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	000
93619	TC	C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	000
93619	26	A	Electrophysiology evaluation	7.31	3.87	3.52	3.87	3.52	0.51	000
93620		C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	000
93620	TC	C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	000
93620	26	A	Electrophysiology evaluation	11.57	6.08	5.46	6.08	5.46	0.80	000
93621		C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	ZZZ
93621	TC	C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	ZZZ
93621	26	A	Electrophysiology evaluation	2.10	1.10	0.96	1.10	0.96	0.15	ZZZ
93622		C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	ZZZ
93622	TC	C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	ZZZ
93622	26	A	Electrophysiology evaluation	3.10	1.56	1.39	1.56	1.39	0.22	ZZZ
93623		C	Stimulation, pacing heart	0.00	0.00	0.00	NA	NA	0.00	ZZZ
93623	TC	C	Stimulation, pacing heart	0.00	0.00	0.00	NA	NA	0.00	ZZZ
93623	26	A	Stimulation, pacing heart	2.85	1.49	1.30	1.49	1.30	0.20	ZZZ
93624		C	Electrophysiologic study	0.00	0.00	0.00	NA	NA	0.00	000
93624	TC	C	Electrophysiologic study	0.00	0.00	0.00	NA	NA	0.00	000
93624	26	A	Electrophysiologic study	4.80	2.60	2.39	2.60	2.39	0.33	000
93631		C	Heart pacing, mapping	0.00	0.00	0.00	NA	NA	0.00	000
93631	TC	C	Heart pacing, mapping	0.00	0.00	0.00	NA	NA	0.00	000
93631	26	A	Heart pacing, mapping	7.59	2.75	2.76	2.75	2.76	0.97	000
93640		C	Evaluation heart device	0.00	0.00	0.00	NA	NA	0.00	000
93640	TC	C	Evaluation heart device	0.00	0.00	0.00	NA	NA	0.00	000
93640	26	A	Evaluation heart device	3.51	1.81	1.58	1.81	1.58	0.24	000
93641		C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	000
93641	TC	C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	000
93641	26	A	Electrophysiology evaluation	5.92	3.10	2.71	3.10	2.71	0.41	000
93642		C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	000
93642	TC	A	Electrophysiology evaluation	0.00	4.76	5.97	NA	NA	0.42	000
93642	26	A	Electrophysiology evaluation	4.88	2.60	2.40	2.60	2.40	0.15	000
93650		A	Ablate heart dysrhythm focus	10.49	NA	NA	5.80	5.11	0.73	000
93651		A	Ablate heart dysrhythm focus	16.23	NA	NA	8.52	7.42	1.13	000
93652		A	Ablate heart dysrhythm focus	17.65	NA	NA	9.34	8.11	1.23	000
93660		A	Tilt table evaluation	1.89	3.01	2.71	NA	NA	0.08	000
93660	TC	A	Tilt table evaluation	0.00	2.04	1.86	NA	NA	0.02	000
93660	26	A	Tilt table evaluation	1.89	0.97	0.85	0.97	0.85	0.06	000
93662		C	Intracardiac eeg (ice)	0.00	0.00	0.00	NA	NA	0.00	ZZZ
93662	TC	C	Intracardiac eeg (ice)	0.00	0.00	0.00	NA	NA	0.00	ZZZ

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
93662	26	A	Intracardiac ecg (ice)	2.80	1.47	1.29	1.47	1.29	0.09	ZZZ
93668		N	Peripheral vascular rehab	0.00	0.41	0.41	NA	NA	0.01	XXX
93701		A	Bioimpedance, thoracic	0.17	0.70	0.84	NA	NA	0.02	XXX
93701	TC	A	Bioimpedance, thoracic	0.00	0.64	0.77	NA	NA	0.01	XXX
93701	26	A	Bioimpedance, thoracic	0.17	0.06	0.07	0.06	0.07	0.01	XXX
93720		A	Total body plethysmography	0.17	1.17	0.97	NA	NA	0.07	XXX
93721		A	Plethysmography tracing	0.00	1.13	0.92	NA	NA	0.06	XXX
93722		A	Plethysmography report	0.17	0.04	0.05	0.04	0.05	0.01	XXX
93724		A	Analyze pacemaker system	4.88	3.22	4.55	NA	NA	0.39	000
93724	TC	A	Analyze pacemaker system	0.00	0.87	2.42	NA	NA	0.24	000
93724	26	A	Analyze pacemaker system	4.88	2.35	2.13	2.35	2.13	0.15	000
93727		A	Analyze ilr system	0.52	0.63	0.42	0.63	0.42	0.02	XXX
93731		A	Analyze pacemaker system	0.45	0.79	0.72	NA	NA	0.05	XXX
93731	TC	A	Analyze pacemaker system	0.00	0.55	0.52	NA	NA	0.04	XXX
93731	26	A	Analyze pacemaker system	0.45	0.24	0.20	0.24	0.20	0.01	XXX
93732		A	Analyze pacemaker system	0.92	1.15	1.00	NA	NA	0.07	XXX
93732	TC	A	Analyze pacemaker system	0.00	0.67	0.59	NA	NA	0.04	XXX
93732	26	A	Analyze pacemaker system	0.92	0.48	0.41	0.48	0.41	0.03	XXX
93733		A	Telephone analy, pacemaker	0.17	0.93	0.86	NA	NA	0.07	XXX
93733	TC	A	Telephone analy, pacemaker	0.00	0.85	0.79	NA	NA	0.06	XXX
93733	26	A	Telephone analy, pacemaker	0.17	0.08	0.07	0.08	0.07	0.01	XXX
93734		A	Analyze pacemaker system	0.38	0.69	0.59	NA	NA	0.03	XXX
93734	TC	A	Analyze pacemaker system	0.00	0.50	0.42	NA	NA	0.02	XXX
93734	26	A	Analyze pacemaker system	0.38	0.19	0.17	0.19	0.17	0.01	XXX
93735		A	Analyze pacemaker system	0.74	0.96	0.84	NA	NA	0.06	XXX
93735	TC	A	Analyze pacemaker system	0.00	0.57	0.51	NA	NA	0.04	XXX
93735	26	A	Analyze pacemaker system	0.74	0.39	0.33	0.39	0.33	0.02	XXX
93736		A	Telephonic analy, pacemaker	0.15	0.91	0.79	NA	NA	0.07	XXX
93736	TC	A	Telephonic analy, pacemaker	0.00	0.84	0.73	NA	NA	0.06	XXX
93736	26	A	Telephonic analy, pacemaker	0.15	0.07	0.06	0.07	0.06	0.01	XXX
93740		B	Temperature gradient studies	0.16	0.04	0.11	NA	NA	0.02	XXX
93740	TC	B	Temperature gradient studies	0.00	0.00	0.07	NA	NA	0.01	XXX
93740	26	B	Temperature gradient studies	0.16	0.04	0.04	0.04	0.04	0.01	XXX
93741		A	Analyze ht pace device sngl	0.80	1.01	0.99	NA	NA	0.07	XXX
93741	TC	A	Analyze ht pace device sngl	0.00	0.59	0.63	NA	NA	0.04	XXX
93741	26	A	Analyze ht pace device sngl	0.80	0.42	0.36	0.42	0.36	0.03	XXX
93742		A	Analyze ht pace device sngl	0.91	1.15	1.09	NA	NA	0.07	XXX
93742	TC	A	Analyze ht pace device sngl	0.00	0.67	0.67	NA	NA	0.04	XXX
93742	26	A	Analyze ht pace device sngl	0.91	0.48	0.42	0.48	0.42	0.03	XXX
93743		A	Analyze ht pace device dual	1.03	1.19	1.16	NA	NA	0.07	XXX
93743	TC	A	Analyze ht pace device dual	0.00	0.64	0.69	NA	NA	0.04	XXX
93743	26	A	Analyze ht pace device dual	1.03	0.55	0.47	0.55	0.47	0.03	XXX
93744		A	Analyze ht pace device dual	1.18	1.35	1.23	NA	NA	0.08	XXX
93744	TC	A	Analyze ht pace device dual	0.00	0.72	0.69	NA	NA	0.04	XXX
93744	26	A	Analyze ht pace device dual	1.18	0.63	0.54	0.63	0.54	0.04	XXX
93745		C	Set-up cardiovert-defibrill	0.00	0.00	0.00	NA	NA	0.00	XXX
93745	TC	C	Set-up cardiovert-defibrill	0.00	0.00	0.00	NA	NA	0.00	XXX
93745	26	C	Set-up cardiovert-defibrill	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93760		N	Cephalic thermogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93762		N	Peripheral thermogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93770		B	Measure venous pressure	0.16	0.04	0.05	NA	NA	0.02	XXX
93770	TC	B	Measure venous pressure	0.00	0.00	0.01	NA	NA	0.01	XXX
93770	26	B	Measure venous pressure	0.16	0.04	0.04	0.04	0.04	0.01	XXX
93784		A	Ambulatory BP monitoring	0.38	1.39	1.47	NA	NA	0.03	XXX
93786		A	Ambulatory BP recording	0.00	0.81	0.86	NA	NA	0.01	XXX
93788		A	Ambulatory BP analysis	0.00	0.45	0.48	NA	NA	0.01	XXX
93790		A	Review/report BP recording	0.38	0.13	0.13	0.13	0.13	0.01	XXX
93797		A	Cardiac rehab	0.18	0.32	0.31	0.09	0.08	0.01	000
93798		A	Cardiac rehab/monitor	0.28	0.44	0.45	0.13	0.12	0.01	000
93799		C	Cardiovascular procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
93799	TC	C	Cardiovascular procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
93799	26	C	Cardiovascular procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93875		A	Extracranial study	0.22	2.54	2.43	NA	NA	0.12	XXX
93875	TC	A	Extracranial study	0.00	2.47	2.36	NA	NA	0.11	XXX
93875	26	A	Extracranial study	0.22	0.07	0.07	0.07	0.07	0.01	XXX
93880		A	Extracranial study	0.60	6.15	5.85	NA	NA	0.39	XXX
93880	TC	A	Extracranial study	0.00	5.94	5.65	NA	NA	0.35	XXX
93880	26	A	Extracranial study	0.60	0.21	0.20	0.21	0.20	0.04	XXX
93882		A	Extracranial study	0.40	4.11	3.81	NA	NA	0.26	XXX
93882	TC	A	Extracranial study	0.00	4.00	3.68	NA	NA	0.22	XXX
93882	26	A	Extracranial study	0.40	0.11	0.13	0.11	0.13	0.04	XXX
93886		A	Intracranial study	0.94	7.02	6.87	NA	NA	0.45	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
93886	TC	A	Intracranial study	0.00	6.74	6.55	NA	NA	0.39	XXX
93886	26	A	Intracranial study	0.94	0.28	0.32	0.28	0.32	0.06	XXX
93888		A	Intracranial study	0.62	4.91	4.57	NA	NA	0.32	XXX
93888	TC	A	Intracranial study	0.00	4.71	4.36	NA	NA	0.27	XXX
93888	26	A	Intracranial study	0.62	0.20	0.21	0.20	0.21	0.05	XXX
93890		A	Tcd, vasoreactivity study	1.00	6.44	5.67	NA	NA	0.45	XXX
93890	TC	A	Tcd, vasoreactivity study	0.00	6.13	5.31	NA	NA	0.39	XXX
93890	26	A	Tcd, vasoreactivity study	1.00	0.31	0.36	0.31	0.36	0.06	XXX
93892		A	Tcd, emboli detect w/o inj	1.15	6.84	6.00	NA	NA	0.45	XXX
93892	TC	A	Tcd, emboli detect w/o inj	0.00	6.52	5.61	NA	NA	0.39	XXX
93892	26	A	Tcd, emboli detect w/o inj	1.15	0.32	0.39	0.32	0.39	0.06	XXX
93893		A	Tcd, emboli detect w/inj	1.15	6.99	6.00	NA	NA	0.45	XXX
93893	TC	A	Tcd, emboli detect w/inj	0.00	6.66	5.61	NA	NA	0.39	XXX
93893	26	A	Tcd, emboli detect w/inj	1.15	0.33	0.39	0.33	0.39	0.06	XXX
93922		A	Extremity study	0.25	3.10	2.89	NA	NA	0.15	XXX
93922	TC	A	Extremity study	0.00	3.02	2.81	NA	NA	0.13	XXX
93922	26	A	Extremity study	0.25	0.08	0.08	0.08	0.08	0.02	XXX
93923		A	Extremity study	0.45	4.68	4.35	NA	NA	0.26	XXX
93923	TC	A	Extremity study	0.00	4.54	4.21	NA	NA	0.22	XXX
93923	26	A	Extremity study	0.45	0.14	0.14	0.14	0.14	0.04	XXX
93924		A	Extremity study	0.50	5.93	5.36	NA	NA	0.30	XXX
93924	TC	A	Extremity study	0.00	5.76	5.19	NA	NA	0.25	XXX
93924	26	A	Extremity study	0.50	0.17	0.17	0.17	0.17	0.05	XXX
93925		A	Lower extremity study	0.58	8.01	7.39	NA	NA	0.39	XXX
93925	TC	A	Lower extremity study	0.00	7.82	7.20	NA	NA	0.35	XXX
93925	26	A	Lower extremity study	0.58	0.19	0.19	0.19	0.19	0.04	XXX
93926		A	Lower extremity study	0.39	5.14	4.59	NA	NA	0.27	XXX
93926	TC	A	Lower extremity study	0.00	5.03	4.47	NA	NA	0.23	XXX
93926	26	A	Lower extremity study	0.39	0.11	0.12	0.11	0.12	0.04	XXX
93930		A	Upper extremity study	0.46	6.24	5.79	NA	NA	0.41	XXX
93930	TC	A	Upper extremity study	0.00	6.09	5.64	NA	NA	0.37	XXX
93930	26	A	Upper extremity study	0.46	0.15	0.15	0.15	0.15	0.04	XXX
93931		A	Upper extremity study	0.31	4.18	3.83	NA	NA	0.27	XXX
93931	TC	A	Upper extremity study	0.00	4.08	3.73	NA	NA	0.24	XXX
93931	26	A	Upper extremity study	0.31	0.10	0.10	0.10	0.10	0.03	XXX
93965		A	Extremity study	0.35	3.00	2.89	NA	NA	0.14	XXX
93965	TC	A	Extremity study	0.00	2.89	2.78	NA	NA	0.12	XXX
93965	26	A	Extremity study	0.35	0.11	0.11	0.11	0.11	0.02	XXX
93970		A	Extremity study	0.68	6.20	5.72	NA	NA	0.46	XXX
93970	TC	A	Extremity study	0.00	5.99	5.50	NA	NA	0.40	XXX
93970	26	A	Extremity study	0.68	0.21	0.22	0.21	0.22	0.06	XXX
93971		A	Extremity study	0.45	4.07	3.83	NA	NA	0.30	XXX
93971	TC	A	Extremity study	0.00	3.92	3.68	NA	NA	0.27	XXX
93971	26	A	Extremity study	0.45	0.15	0.15	0.15	0.15	0.03	XXX
93975		A	Vascular study	1.80	8.45	8.03	NA	NA	0.56	XXX
93975	TC	A	Vascular study	0.00	7.82	7.42	NA	NA	0.43	XXX
93975	26	A	Vascular study	1.80	0.63	0.61	0.63	0.61	0.13	XXX
93976		A	Vascular study	1.21	4.57	4.45	NA	NA	0.35	XXX
93976	TC	A	Vascular study	0.00	4.15	4.04	NA	NA	0.30	XXX
93976	26	A	Vascular study	1.21	0.42	0.41	0.42	0.41	0.05	XXX
93978		A	Vascular study	0.65	6.02	5.27	NA	NA	0.43	XXX
93978	TC	A	Vascular study	0.00	5.81	5.05	NA	NA	0.37	XXX
93978	26	A	Vascular study	0.65	0.21	0.22	0.21	0.22	0.06	XXX
93979		A	Vascular study	0.44	4.16	3.69	NA	NA	0.27	XXX
93979	TC	A	Vascular study	0.00	4.02	3.54	NA	NA	0.24	XXX
93979	26	A	Vascular study	0.44	0.14	0.15	0.14	0.15	0.03	XXX
93980		A	Penile vascular study	1.25	3.48	3.16	NA	NA	0.42	XXX
93980	TC	A	Penile vascular study	0.00	3.02	2.73	NA	NA	0.34	XXX
93980	26	A	Penile vascular study	1.25	0.46	0.43	0.46	0.43	0.08	XXX
93981		A	Penile vascular study	0.44	2.84	2.85	NA	NA	0.33	XXX
93981	TC	A	Penile vascular study	0.00	2.68	2.70	NA	NA	0.31	XXX
93981	26	A	Penile vascular study	0.44	0.16	0.15	0.16	0.15	0.02	XXX
93982		R	Aneurysm pressure sens study	0.30	0.80	0.80	NA	NA	0.01	XXX
93990		A	Doppler flow testing	0.25	5.21	4.61	NA	NA	0.26	XXX
93990	TC	A	Doppler flow testing	0.00	5.15	4.53	NA	NA	0.23	XXX
93990	26	A	Doppler flow testing	0.25	0.06	0.08	0.06	0.08	0.03	XXX
94002		A	Vent mgmt inpat, init day	1.99	NA	NA	0.35	0.34	0.09	XXX
94003		A	Vent mgmt inpat, subq day	1.37	NA	NA	0.32	0.32	0.06	XXX
94004		A	Vent mgmt nf per day	1.00	NA	NA	0.23	0.23	0.04	XXX
94005		B	Home vent mgmt supervision	1.50	0.70	0.70	NA	NA	0.06	XXX
94010		A	Breathing capacity test	0.17	0.74	0.71	NA	NA	0.03	XXX
94010	TC	A	Breathing capacity test	0.00	0.70	0.66	NA	NA	0.02	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional-fa- cility PE RVUs ²	Mal- practice RVUs ²	Global
94010	26	A	Breathing capacity test	0.17	0.04	0.05	0.04	0.05	0.01	XXX
94014		A	Patient recorded spirometry	0.52	0.81	0.78	NA	NA	0.03	XXX
94015		A	Patient recorded spirometry	0.00	0.67	0.63	NA	NA	0.01	XXX
94016		A	Review patient spirometry	0.52	0.14	0.15	0.14	0.15	0.02	XXX
94060		A	Evaluation of wheezing	0.31	1.32	1.19	NA	NA	0.07	XXX
94060	TC	A	Evaluation of wheezing	0.00	1.24	1.11	NA	NA	0.06	XXX
94060	26	A	Evaluation of wheezing	0.31	0.08	0.08	0.08	0.08	0.01	XXX
94070		A	Evaluation of wheezing	0.60	1.00	0.90	NA	NA	0.13	XXX
94070	TC	A	Evaluation of wheezing	0.00	0.85	0.74	NA	NA	0.10	XXX
94070	26	A	Evaluation of wheezing	0.60	0.15	0.16	0.15	0.16	0.03	XXX
94150		B	Vital capacity test	0.07	0.48	0.47	NA	NA	0.02	XXX
94150	TC	B	Vital capacity test	0.00	0.46	0.45	NA	NA	0.01	XXX
94150	26	B	Vital capacity test	0.07	0.02	0.02	0.02	0.02	0.01	XXX
94200		A	Lung function test (MBC/MVV)	0.11	0.50	0.47	NA	NA	0.03	XXX
94200	TC	A	Lung function test (MBC/MVV)	0.00	0.47	0.44	NA	NA	0.02	XXX
94200	26	A	Lung function test (MBC/MVV)	0.11	0.03	0.03	0.03	0.03	0.01	XXX
94240		A	Residual lung capacity	0.26	0.81	0.74	NA	NA	0.06	XXX
94240	TC	A	Residual lung capacity	0.00	0.75	0.67	NA	NA	0.05	XXX
94240	26	A	Residual lung capacity	0.26	0.06	0.07	0.06	0.07	0.01	XXX
94250		A	Expired gas collection	0.11	0.51	0.58	NA	NA	0.02	XXX
94250	TC	A	Expired gas collection	0.00	0.48	0.55	NA	NA	0.01	XXX
94250	26	A	Expired gas collection	0.11	0.03	0.03	0.03	0.03	0.01	XXX
94260		A	Thoracic gas volume	0.13	0.75	0.66	NA	NA	0.05	XXX
94260	TC	A	Thoracic gas volume	0.00	0.72	0.63	NA	NA	0.04	XXX
94260	26	A	Thoracic gas volume	0.13	0.03	0.03	0.03	0.03	0.01	XXX
94350		A	Lung nitrogen washout curve	0.26	0.61	0.69	NA	NA	0.05	XXX
94350	TC	A	Lung nitrogen washout curve	0.00	0.55	0.62	NA	NA	0.04	XXX
94350	26	A	Lung nitrogen washout curve	0.26	0.06	0.07	0.06	0.07	0.01	XXX
94360		A	Measure airflow resistance	0.26	0.95	0.82	NA	NA	0.07	XXX
94360	TC	A	Measure airflow resistance	0.00	0.89	0.75	NA	NA	0.06	XXX
94360	26	A	Measure airflow resistance	0.26	0.06	0.07	0.06	0.07	0.01	XXX
94370		A	Breath airway closing volume	0.26	0.60	0.66	NA	NA	0.03	XXX
94370	TC	A	Breath airway closing volume	0.00	0.53	0.59	NA	NA	0.02	XXX
94370	26	A	Breath airway closing volume	0.26	0.07	0.07	0.07	0.07	0.01	XXX
94375		A	Respiratory flow volume loop	0.31	0.73	0.66	NA	NA	0.03	XXX
94375	TC	A	Respiratory flow volume loop	0.00	0.65	0.58	NA	NA	0.02	XXX
94375	26	A	Respiratory flow volume loop	0.31	0.08	0.08	0.08	0.08	0.01	XXX
94400		A	CO2 breathing response curve	0.40	1.03	0.93	NA	NA	0.09	XXX
94400	TC	A	CO2 breathing response curve	0.00	0.93	0.82	NA	NA	0.06	XXX
94400	26	A	CO2 breathing response curve	0.40	0.10	0.11	0.10	0.11	0.03	XXX
94450		A	Hypoxia response curve	0.40	1.01	0.92	NA	NA	0.04	XXX
94450	TC	A	Hypoxia response curve	0.00	0.92	0.82	NA	NA	0.02	XXX
94450	26	A	Hypoxia response curve	0.40	0.09	0.10	0.09	0.10	0.02	XXX
94452		A	Hast w/report	0.31	1.27	1.14	NA	NA	0.04	XXX
94452	TC	A	Hast w/report	0.00	1.20	1.06	NA	NA	0.02	XXX
94452	26	A	Hast w/report	0.31	0.07	0.08	0.07	0.08	0.02	XXX
94453		A	Hast w/oxygen titrate	0.40	1.69	1.60	NA	NA	0.04	XXX
94453	TC	A	Hast w/oxygen titrate	0.00	1.59	1.49	NA	NA	0.02	XXX
94453	26	A	Hast w/oxygen titrate	0.40	0.10	0.11	0.10	0.11	0.02	XXX
94610		A	Surfactant admin thru tube	1.16	0.34	0.34	0.34	0.34	0.26	XXX
94620		A	Pulmonary stress test/simple	0.64	0.79	1.64	NA	NA	0.13	XXX
94620	TC	A	Pulmonary stress test/simple	0.00	0.63	1.46	NA	NA	0.10	XXX
94620	26	A	Pulmonary stress test/simple	0.64	0.16	0.18	0.16	0.18	0.03	XXX
94621		A	Pulm stress test/complex	1.42	3.18	2.69	NA	NA	0.16	XXX
94621	TC	A	Pulm stress test/complex	0.00	2.73	2.25	NA	NA	0.10	XXX
94621	26	A	Pulm stress test/complex	1.42	0.45	0.44	0.45	0.44	0.06	XXX
94640		A	Airway inhalation treatment	0.00	0.38	0.34	NA	NA	0.02	XXX
94642		C	Aerosol inhalation treatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
94644		A	Cbt, 1st hour	0.00	0.96	0.96	NA	NA	0.02	XXX
94645		A	Cbt, each addl hour	0.00	0.35	0.35	NA	NA	0.02	XXX
94660		A	Pos airway pressure, CPAP	0.76	0.81	0.73	0.19	0.21	0.04	XXX
94662		A	Neg press ventilation, cnp	0.76	NA	NA	0.20	0.21	0.03	XXX
94664		A	Evaluate pt use of inhaler	0.00	0.40	0.35	NA	NA	0.04	XXX
94667		A	Chest wall manipulation	0.00	0.53	0.53	NA	NA	0.05	XXX
94668		A	Chest wall manipulation	0.00	0.50	0.48	NA	NA	0.02	XXX
94680		A	Exhaled air analysis, o2	0.26	1.06	1.46	NA	NA	0.07	XXX
94680	TC	A	Exhaled air analysis, o2	0.00	1.00	1.39	NA	NA	0.06	XXX
94680	26	A	Exhaled air analysis, o2	0.26	0.06	0.07	0.06	0.07	0.01	XXX
94681		A	Exhaled air analysis, o2/co2	0.20	1.07	1.79	NA	NA	0.13	XXX
94681	TC	A	Exhaled air analysis, o2/co2	0.00	1.02	1.74	NA	NA	0.12	XXX
94681	26	A	Exhaled air analysis, o2/co2	0.20	0.05	0.05	0.05	0.05	0.01	XXX
94690		A	Exhaled air analysis	0.07	1.04	1.52	NA	NA	0.05	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
94690	TC	A	Exhaled air analysis	0.00	1.02	1.50	NA	NA	0.04	XXX
94690	26	A	Exhaled air analysis	0.07	0.02	0.02	0.02	0.02	0.01	XXX
94720		A	Monoxide diffusing capacity	0.26	1.15	1.08	NA	NA	0.07	XXX
94720	TC	A	Monoxide diffusing capacity	0.00	1.09	1.01	NA	NA	0.06	XXX
94720	26	A	Monoxide diffusing capacity	0.26	0.06	0.07	0.06	0.07	0.01	XXX
94725		A	Membrane diffusion capacity	0.26	0.98	1.94	NA	NA	0.13	XXX
94725	TC	A	Membrane diffusion capacity	0.00	0.91	1.87	NA	NA	0.12	XXX
94725	26	A	Membrane diffusion capacity	0.26	0.07	0.07	0.07	0.07	0.01	XXX
94750		A	Pulmonary compliance study	0.23	1.77	1.55	NA	NA	0.05	XXX
94750	TC	A	Pulmonary compliance study	0.00	1.71	1.49	NA	NA	0.04	XXX
94750	26	A	Pulmonary compliance study	0.23	0.06	0.06	0.06	0.06	0.01	XXX
94760		T	Measure blood oxygen level	0.00	0.06	0.05	NA	NA	0.02	XXX
94761		T	Measure blood oxygen level	0.00	0.11	0.09	NA	NA	0.06	XXX
94762		A	Measure blood oxygen level	0.00	0.84	0.66	NA	NA	0.10	XXX
94770		A	Exhaled carbon dioxide test	0.15	0.81	0.78	NA	NA	0.08	XXX
94770	TC	A	Exhaled carbon dioxide test	0.00	0.77	0.74	NA	NA	0.07	XXX
94770	26	A	Exhaled carbon dioxide test	0.15	0.04	0.04	0.04	0.04	0.01	XXX
94772		C	Breath recording, infant	0.00	0.00	0.00	NA	NA	0.00	XXX
94772	TC	C	Breath recording, infant	0.00	0.00	0.00	NA	NA	0.00	XXX
94772	26	C	Breath recording, infant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
94774		C	Ped home apnea rec, compl	0.00	0.00	0.00	0.00	0.00	0.00	YYY
94775		C	Ped home apnea rec, hk-up	0.00	0.00	0.00	0.00	0.00	0.00	YYY
94776		C	Ped home apnea rec, downld	0.00	0.00	0.00	0.00	0.00	0.00	YYY
94777		C	Ped home apnea rec, report	0.00	0.00	0.00	0.00	0.00	0.00	YYY
94799		C	Pulmonary service/procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
94799	TC	C	Pulmonary service/procedure	0.00	0.00	0.00	NA	NA	0.00	XXX
94799	26	C	Pulmonary service/procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95004		A	Percut allergy skin tests	0.01	0.15	0.13	NA	NA	0.01	XXX
95010		A	Percut allergy titrate test	0.15	0.31	0.31	NA	NA	0.01	XXX
95012		A	Exhaled nitric oxide meas	0.00	0.49	0.49	NA	NA	0.01	XXX
95015		A	Id allergy titrate-drug/bug	0.15	0.21	0.18	NA	NA	0.01	XXX
95024		A	Id allergy test, drug/bug	0.01	0.17	0.16	NA	NA	0.01	XXX
95027		A	Id allergy titrate-airborne	0.01	0.10	0.12	NA	NA	0.01	XXX
95028		A	Id allergy test-delayed type	0.00	0.31	0.27	NA	NA	0.01	XXX
95044		A	Allergy patch tests	0.00	0.15	0.18	NA	NA	0.01	XXX
95052		A	Photo patch test	0.00	0.16	0.20	NA	NA	0.01	XXX
95056		A	Photosensitivity tests	0.00	1.25	0.71	NA	NA	0.01	XXX
95060		A	Eye allergy tests	0.00	0.73	0.54	0.73	0.54	0.02	XXX
95065		A	Nose allergy test	0.00	0.70	0.45	0.70	0.45	0.01	XXX
95070		A	Bronchial allergy tests	0.00	0.81	1.55	NA	NA	0.02	XXX
95071		A	Bronchial allergy tests	0.00	0.98	1.95	NA	NA	0.02	XXX
95075		A	Ingestion challenge test	0.95	0.68	0.75	0.26	0.32	0.03	XXX
95115		A	Immunotherapy, one injection	0.00	0.23	0.31	NA	NA	0.02	XXX
95117		A	Immunotherapy injections	0.00	0.28	0.39	NA	NA	0.02	XXX
95120		I	Immunotherapy, one injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95125		I	Immunotherapy, many antigens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95130		I	Immunotherapy, insect venom	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95131		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95132		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95133		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95134		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95144		A	Antigen therapy services	0.06	0.27	0.23	0.02	0.02	0.01	XXX
95145		A	Antigen therapy services	0.06	0.36	0.34	0.02	0.02	0.01	XXX
95146		A	Antigen therapy services	0.06	0.68	0.56	0.02	0.02	0.01	XXX
95147		A	Antigen therapy services	0.06	0.66	0.54	0.02	0.02	0.01	XXX
95148		A	Antigen therapy services	0.06	0.98	0.78	0.02	0.02	0.01	XXX
95149		A	Antigen therapy services	0.06	1.30	1.05	0.02	0.02	0.01	XXX
95165		A	Antigen therapy services	0.06	0.26	0.23	0.02	0.02	0.01	XXX
95170		A	Antigen therapy services	0.06	0.20	0.17	0.02	0.02	0.01	XXX
95180		A	Rapid desensitization	2.01	1.66	1.85	0.77	0.85	0.04	XXX
95199		C	Allergy immunology services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95250		A	Glucose monitoring, cont	0.00	3.49	3.80	NA	NA	0.01	XXX
95251		A	Gluc monitor, cont, phys i&r	0.85	0.26	0.22	0.26	0.22	0.02	XXX
95805		A	Multiple sleep latency test	1.88	7.01	12.13	NA	NA	0.43	XXX
95805	TC	A	Multiple sleep latency test	0.00	6.50	11.55	NA	NA	0.34	XXX
95805	26	A	Multiple sleep latency test	1.88	0.51	0.58	0.51	0.58	0.09	XXX
95806		A	Sleep study, unattended	1.66	3.92	3.62	NA	NA	0.39	XXX
95806	TC	A	Sleep study, unattended	0.00	3.45	3.12	NA	NA	0.31	XXX
95806	26	A	Sleep study, unattended	1.66	0.47	0.50	0.47	0.50	0.08	XXX
95807		A	Sleep study, attended	1.66	12.29	12.07	NA	NA	0.50	XXX
95807	TC	A	Sleep study, attended	0.00	11.88	11.60	NA	NA	0.42	XXX
95807	26	A	Sleep study, attended	1.66	0.41	0.47	0.41	0.47	0.08	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
95808	A	Polysomnography, 1–3	2.65	15.74	14.46	NA	NA	0.55	XXX
95808	TC	A	Polysomnography, 1–3	0.00	15.04	13.65	NA	NA	0.42	XXX
95808	26	A	Polysomnography, 1–3	2.65	0.70	0.81	0.70	0.81	0.13	XXX
95810	A	Polysomnography, 4 or more	3.52	17.68	17.58	NA	NA	0.59	XXX
95810	TC	A	Polysomnography, 4 or more	0.00	16.78	16.54	NA	NA	0.42	XXX
95810	26	A	Polysomnography, 4 or more	3.52	0.90	1.04	0.90	1.04	0.17	XXX
95811	A	Polysomnography w/cpap	3.79	19.68	19.42	NA	NA	0.61	XXX
95811	TC	A	Polysomnography w/cpap	0.00	18.72	18.31	NA	NA	0.43	XXX
95811	26	A	Polysomnography w/cpap	3.79	0.96	1.11	0.96	1.11	0.18	XXX
95812	A	Eeg, 41–60 minutes	1.08	5.89	4.96	NA	NA	0.17	XXX
95812	TC	A	Eeg, 41–60 minutes	0.00	5.59	4.58	NA	NA	0.11	XXX
95812	26	A	Eeg, 41–60 minutes	1.08	0.30	0.38	0.30	0.38	0.06	XXX
95813	A	Eeg, over 1 hour	1.73	6.51	5.76	NA	NA	0.20	XXX
95813	TC	A	Eeg, over 1 hour	0.00	6.03	5.17	NA	NA	0.11	XXX
95813	26	A	Eeg, over 1 hour	1.73	0.48	0.59	0.48	0.59	0.09	XXX
95816	A	Eeg, awake and drowsy	1.08	5.27	4.49	NA	NA	0.16	XXX
95816	TC	A	Eeg, awake and drowsy	0.00	4.97	4.11	NA	NA	0.10	XXX
95816	26	A	Eeg, awake and drowsy	1.08	0.30	0.38	0.30	0.38	0.06	XXX
95819	A	Eeg, awake and asleep	1.08	6.13	4.55	NA	NA	0.16	XXX
95819	TC	A	Eeg, awake and asleep	0.00	5.83	4.17	NA	NA	0.10	XXX
95819	26	A	Eeg, awake and asleep	1.08	0.30	0.38	0.30	0.38	0.06	XXX
95822	A	Eeg, coma or sleep only	1.08	5.51	5.05	NA	NA	0.19	XXX
95822	TC	A	Eeg, coma or sleep only	0.00	5.21	4.67	NA	NA	0.13	XXX
95822	26	A	Eeg, coma or sleep only	1.08	0.30	0.38	0.30	0.38	0.06	XXX
95824	C	Eeg, cerebral death only	0.00	0.00	0.00	NA	NA	0.00	XXX
95824	TC	C	Eeg, cerebral death only	0.00	0.00	0.00	NA	NA	0.00	XXX
95824	26	A	Eeg, cerebral death only	0.74	0.21	0.26	0.21	0.26	0.04	XXX
95827	A	Eeg, all night recording	1.08	11.52	7.11	NA	NA	0.19	XXX
95827	TC	A	Eeg, all night recording	0.00	11.22	6.76	NA	NA	0.14	XXX
95827	26	A	Eeg, all night recording	1.08	0.30	0.35	0.30	0.35	0.05	XXX
95829	A	Surgery electrocorticogram	6.20	24.75	27.87	NA	NA	0.50	XXX
95829	TC	A	Surgery electrocorticogram	0.00	22.99	25.83	NA	NA	0.02	XXX
95829	26	A	Surgery electrocorticogram	6.20	1.76	2.04	1.76	2.04	0.48	XXX
95830	A	Insert electrodes for EEG	1.70	2.96	3.13	0.41	0.57	0.11	XXX
95831	A	Limb muscle testing, manual	0.28	0.40	0.43	0.09	0.11	0.01	XXX
95832	A	Hand muscle testing, manual	0.29	0.37	0.35	0.10	0.11	0.02	XXX
95833	A	Body muscle testing, manual	0.47	0.49	0.54	0.14	0.18	0.02	XXX
95834	A	Body muscle testing, manual	0.60	0.54	0.58	0.17	0.23	0.03	XXX
95851	A	Range of motion measurements	0.16	0.26	0.31	0.04	0.06	0.01	XXX
95852	A	Range of motion measurements	0.11	0.24	0.25	0.04	0.04	0.01	XXX
95857	A	Tensilon test	0.53	0.58	0.59	0.16	0.19	0.02	XXX
95860	A	Muscle test, one limb	0.96	1.16	1.29	NA	NA	0.07	XXX
95860	TC	A	Muscle test, one limb	0.00	0.84	0.92	NA	NA	0.02	XXX
95860	26	A	Muscle test, one limb	0.96	0.32	0.37	0.32	0.37	0.05	XXX
95861	A	Muscle test, 2 limbs	1.54	1.66	1.53	NA	NA	0.13	XXX
95861	TC	A	Muscle test, 2 limbs	0.00	1.15	0.94	NA	NA	0.06	XXX
95861	26	A	Muscle test, 2 limbs	1.54	0.51	0.59	0.51	0.59	0.07	XXX
95863	A	Muscle test, 3 limbs	1.87	1.92	1.82	NA	NA	0.15	XXX
95863	TC	A	Muscle test, 3 limbs	0.00	1.35	1.14	NA	NA	0.06	XXX
95863	26	A	Muscle test, 3 limbs	1.87	0.57	0.68	0.57	0.68	0.09	XXX
95864	A	Muscle test, 4 limbs	1.99	2.14	2.40	NA	NA	0.21	XXX
95864	TC	A	Muscle test, 4 limbs	0.00	1.53	1.66	NA	NA	0.12	XXX
95864	26	A	Muscle test, 4 limbs	1.99	0.61	0.74	0.61	0.74	0.09	XXX
95865	A	Muscle test, larynx	1.57	1.39	1.42	NA	NA	0.11	XXX
95865	TC	A	Muscle test, larynx	0.00	0.90	0.79	NA	NA	0.03	XXX
95865	26	A	Muscle test, larynx	1.57	0.49	0.63	0.49	0.63	0.08	XXX
95866	A	Muscle test, hemidiaphragm	1.25	1.32	1.03	NA	NA	0.10	XXX
95866	TC	A	Muscle test, hemidiaphragm	0.00	0.93	0.56	NA	NA	0.03	XXX
95866	26	A	Muscle test, hemidiaphragm	1.25	0.39	0.47	0.39	0.47	0.07	XXX
95867	A	Muscle test cran nerv unilat	0.79	1.15	1.03	NA	NA	0.07	XXX
95867	TC	A	Muscle test cran nerv unilat	0.00	0.91	0.74	NA	NA	0.04	XXX
95867	26	A	Muscle test cran nerv unilat	0.79	0.24	0.29	0.24	0.29	0.03	XXX
95868	A	Muscle test cran nerve bilat	1.18	1.47	1.34	NA	NA	0.10	XXX
95868	TC	A	Muscle test cran nerve bilat	0.00	1.11	0.90	NA	NA	0.05	XXX
95868	26	A	Muscle test cran nerve bilat	1.18	0.36	0.44	0.36	0.44	0.05	XXX
95869	A	Muscle test, thor paraspinal	0.37	1.03	0.70	NA	NA	0.04	XXX
95869	TC	A	Muscle test, thor paraspinal	0.00	0.91	0.56	NA	NA	0.02	XXX
95869	26	A	Muscle test, thor paraspinal	0.37	0.12	0.14	0.12	0.14	0.02	XXX
95870	A	Muscle test, nonparaspinal	0.37	0.99	0.68	NA	NA	0.04	XXX
95870	TC	A	Muscle test, nonparaspinal	0.00	0.87	0.54	NA	NA	0.02	XXX
95870	26	A	Muscle test, nonparaspinal	0.37	0.12	0.14	0.12	0.14	0.02	XXX
95872	A	Muscle test, one fiber	2.88	1.63	1.43	NA	NA	0.13	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
95872	TC	A	Muscle test, one fiber	0.00	0.76	0.68	NA	NA	0.05	XXX
95872	26	A	Muscle test, one fiber	2.88	0.87	0.75	0.87	0.75	0.08	XXX
95873		A	Guide nerv destr, elec stim	0.37	1.02	0.69	NA	NA	0.04	ZZZ
95873	TC	A	Guide nerv destr, elec stim	0.00	0.88	0.54	NA	NA	0.02	ZZZ
95873	26	A	Guide nerv destr, elec stim	0.37	0.14	0.15	0.14	0.15	0.02	ZZZ
95874		A	Guide nerv destr, needle emg	0.37	0.95	0.67	NA	NA	0.04	ZZZ
95874	TC	A	Guide nerv destr, needle emg	0.00	0.83	0.52	NA	NA	0.02	ZZZ
95874	26	A	Guide nerv destr, needle emg	0.37	0.12	0.15	0.12	0.15	0.02	ZZZ
95875		A	Limb exercise test	1.10	1.46	1.46	NA	NA	0.11	XXX
95875	TC	A	Limb exercise test	0.00	1.08	1.03	NA	NA	0.06	XXX
95875	26	A	Limb exercise test	1.10	0.38	0.43	0.38	0.43	0.05	XXX
95900		A	Motor nerve conduction test	0.42	0.92	1.09	NA	NA	0.04	XXX
95900	TC	A	Motor nerve conduction test	0.00	0.78	0.93	NA	NA	0.02	XXX
95900	26	A	Motor nerve conduction test	0.42	0.14	0.16	0.14	0.16	0.02	XXX
95903		A	Motor nerve conduction test	0.60	0.99	1.09	NA	NA	0.05	XXX
95903	TC	A	Motor nerve conduction test	0.00	0.82	0.88	NA	NA	0.02	XXX
95903	26	A	Motor nerve conduction test	0.60	0.17	0.21	0.17	0.21	0.03	XXX
95904		A	Sense nerve conduction test	0.34	0.84	0.97	NA	NA	0.04	XXX
95904	TC	A	Sense nerve conduction test	0.00	0.74	0.84	NA	NA	0.02	XXX
95904	26	A	Sense nerve conduction test	0.34	0.10	0.13	0.10	0.13	0.02	XXX
95920		A	Intraop nerve test add-on	2.11	1.72	1.97	NA	NA	0.23	ZZZ
95920	TC	A	Intraop nerve test add-on	0.00	1.10	1.20	NA	NA	0.07	ZZZ
95920	26	A	Intraop nerve test add-on	2.11	0.62	0.77	0.62	0.77	0.16	ZZZ
95921		A	Autonomic nerv function test	0.90	1.16	0.93	NA	NA	0.06	XXX
95921	TC	A	Autonomic nerv function test	0.00	0.91	0.64	NA	NA	0.02	XXX
95921	26	A	Autonomic nerv function test	0.90	0.25	0.29	0.25	0.29	0.04	XXX
95922		A	Autonomic nerv function test	0.96	1.61	1.19	NA	NA	0.07	XXX
95922	TC	A	Autonomic nerv function test	0.00	1.35	0.86	NA	NA	0.02	XXX
95922	26	A	Autonomic nerv function test	0.96	0.26	0.33	0.26	0.33	0.05	XXX
95923		A	Autonomic nerv function test	0.90	2.33	2.14	NA	NA	0.07	XXX
95923	TC	A	Autonomic nerv function test	0.00	2.08	1.82	NA	NA	0.02	XXX
95923	26	A	Autonomic nerv function test	0.90	0.25	0.32	0.25	0.32	0.05	XXX
95925		A	Somatosensory testing	0.54	3.07	2.10	NA	NA	0.10	XXX
95925	TC	A	Somatosensory testing	0.00	2.92	1.91	NA	NA	0.06	XXX
95925	26	A	Somatosensory testing	0.54	0.15	0.19	0.15	0.19	0.04	XXX
95926		A	Somatosensory testing	0.54	3.00	2.07	NA	NA	0.09	XXX
95926	TC	A	Somatosensory testing	0.00	2.85	1.88	NA	NA	0.06	XXX
95926	26	A	Somatosensory testing	0.54	0.15	0.19	0.15	0.19	0.03	XXX
95927		A	Somatosensory testing	0.54	3.12	2.14	NA	NA	0.10	XXX
95927	TC	A	Somatosensory testing	0.00	2.96	1.93	NA	NA	0.06	XXX
95927	26	A	Somatosensory testing	0.54	0.16	0.21	0.16	0.21	0.04	XXX
95928		A	C motor evoked, uppr limbs	1.50	3.94	3.47	NA	NA	0.09	XXX
95928	TC	A	C motor evoked, uppr limbs	0.00	3.50	2.93	NA	NA	0.03	XXX
95928	26	A	C motor evoked, uppr limbs	1.50	0.44	0.54	0.44	0.54	0.06	XXX
95929		A	C motor evoked, lwr limbs	1.50	4.25	3.74	NA	NA	0.09	XXX
95929	TC	A	C motor evoked, lwr limbs	0.00	3.81	3.19	NA	NA	0.03	XXX
95929	26	A	C motor evoked, lwr limbs	1.50	0.44	0.55	0.44	0.55	0.06	XXX
95930		A	Visual evoked potential test	0.35	2.63	2.44	NA	NA	0.03	XXX
95930	TC	A	Visual evoked potential test	0.00	2.53	2.31	NA	NA	0.01	XXX
95930	26	A	Visual evoked potential test	0.35	0.10	0.13	0.10	0.13	0.02	XXX
95933		A	Blink reflex test	0.59	1.11	1.07	NA	NA	0.10	XXX
95933	TC	A	Blink reflex test	0.00	0.94	0.86	NA	NA	0.06	XXX
95933	26	A	Blink reflex test	0.59	0.17	0.21	0.17	0.21	0.04	XXX
95934		A	H-reflex test	0.51	0.85	0.64	NA	NA	0.04	XXX
95934	TC	A	H-reflex test	0.00	0.70	0.45	NA	NA	0.02	XXX
95934	26	A	H-reflex test	0.51	0.15	0.19	0.15	0.19	0.02	XXX
95936		A	H-reflex test	0.55	0.59	0.52	NA	NA	0.05	XXX
95936	TC	A	H-reflex test	0.00	0.43	0.32	NA	NA	0.02	XXX
95936	26	A	H-reflex test	0.55	0.16	0.20	0.16	0.20	0.03	XXX
95937		A	Neuromuscular junction test	0.65	0.92	0.76	NA	NA	0.10	XXX
95937	TC	A	Neuromuscular junction test	0.00	0.72	0.53	NA	NA	0.02	XXX
95937	26	A	Neuromuscular junction test	0.65	0.20	0.23	0.20	0.23	0.08	XXX
95950		A	Ambulatory eeg monitoring	1.51	4.92	4.42	NA	NA	0.51	XXX
95950	TC	A	Ambulatory eeg monitoring	0.00	4.50	3.89	NA	NA	0.43	XXX
95950	26	A	Ambulatory eeg monitoring	1.51	0.42	0.53	0.42	0.53	0.08	XXX
95951		C	EEG monitoring/videorecord	0.00	0.00	0.00	NA	NA	0.00	XXX
95951	TC	C	EEG monitoring/videorecord	0.00	0.00	0.00	NA	NA	0.00	XXX
95951	26	A	EEG monitoring/videorecord	5.99	1.68	2.12	1.68	2.12	0.32	XXX
95953		A	EEG monitoring/computer	3.30	7.21	7.42	NA	NA	0.60	XXX
95953	TC	A	EEG monitoring/computer	0.00	6.29	6.31	NA	NA	0.43	XXX
95953	26	A	EEG monitoring/computer	3.30	0.92	1.11	0.92	1.11	0.17	XXX
95954		A	EEG monitoring/giving drugs	2.45	4.37	4.30	NA	NA	0.19	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
95954	TC	A	EEG monitoring/giving drugs	0.00	3.95	3.57	NA	NA	0.06	XXX
95954	26	A	EEG monitoring/giving drugs	2.45	0.42	0.73	0.42	0.73	0.13	XXX
95955		A	EEG during surgery	1.01	2.75	2.54	NA	NA	0.22	XXX
95955	TC	A	EEG during surgery	0.00	2.47	2.22	NA	NA	0.17	XXX
95955	26	A	EEG during surgery	1.01	0.28	0.32	0.28	0.32	0.05	XXX
95956		A	Eeg monitoring, cable/radio	3.08	16.28	15.84	NA	NA	0.59	XXX
95956	TC	A	Eeg monitoring, cable/radio	0.00	15.42	14.76	NA	NA	0.43	XXX
95956	26	A	Eeg monitoring, cable/radio	3.08	0.86	1.08	0.86	1.08	0.16	XXX
95957		A	EEG digital analysis	1.98	5.84	4.19	NA	NA	0.23	XXX
95957	TC	A	EEG digital analysis	0.00	5.29	3.49	NA	NA	0.12	XXX
95957	26	A	EEG digital analysis	1.98	0.55	0.70	0.55	0.70	0.11	XXX
95958		A	EEG monitoring/function test	4.24	6.70	5.09	NA	NA	0.34	XXX
95958	TC	A	EEG monitoring/function test	0.00	5.47	3.60	NA	NA	0.13	XXX
95958	26	A	EEG monitoring/function test	4.24	1.23	1.49	1.23	1.49	0.21	XXX
95961		A	Electrode stimulation, brain	2.97	3.05	2.83	NA	NA	0.55	XXX
95961	TC	A	Electrode stimulation, brain	0.00	2.18	1.74	NA	NA	0.07	XXX
95961	26	A	Electrode stimulation, brain	2.97	0.87	1.09	0.87	1.09	0.48	XXX
95962		A	Electrode stim, brain add-on	3.21	2.21	2.45	NA	NA	0.39	ZZZ
95962	TC	A	Electrode stim, brain add-on	0.00	1.30	1.30	NA	NA	0.07	ZZZ
95962	26	A	Electrode stim, brain add-on	3.21	0.91	1.15	0.91	1.15	0.32	ZZZ
95965		C	Meg, spontaneous	0.00	0.00	0.00	NA	NA	0.00	XXX
95965	TC	C	Meg, spontaneous	0.00	0.00	0.00	NA	NA	0.00	XXX
95965	26	A	Meg, spontaneous	7.99	2.39	2.90	2.39	2.90	0.46	XXX
95966		C	Meg, evoked, single	0.00	0.00	0.00	NA	NA	0.00	XXX
95966	TC	C	Meg, evoked, single	0.00	0.00	0.00	NA	NA	0.00	XXX
95966	26	A	Meg, evoked, single	3.99	1.19	1.45	1.19	1.45	0.19	XXX
95967		C	Meg, evoked, each add'l	0.00	0.00	0.00	NA	NA	0.00	ZZZ
95967	TC	C	Meg, evoked, each add'l	0.00	0.00	0.00	NA	NA	0.00	ZZZ
95967	26	A	Meg, evoked, each add'l	3.49	1.01	1.09	1.01	1.09	0.16	ZZZ
95970		A	Analyze neurostim, no prog	0.45	0.90	0.87	0.13	0.13	0.03	XXX
95971		A	Analyze neurostim, simple	0.78	0.58	0.63	0.18	0.20	0.07	XXX
95972		A	Analyze neurostim, complex	1.50	1.14	1.18	0.44	0.46	0.14	XXX
95973		A	Analyze neurostim, complex	0.92	0.49	0.55	0.21	0.28	0.07	ZZZ
95974		A	Cranial neurostim, complex	3.00	1.44	1.57	0.78	1.04	0.16	XXX
95975		A	Cranial neurostim, complex	1.70	0.73	0.81	0.47	0.60	0.12	ZZZ
95978		A	Analyze neurostim brain/1h	3.50	1.85	1.89	1.02	1.16	0.18	XXX
95979		A	Analyz neurostim brain addon	1.64	0.72	0.79	0.46	0.57	0.08	ZZZ
95980		A	lo anal gast n-stim init	0.80	NA	NA	0.25	0.25	0.07	XXX
95981		A	lo anal gast n-stim subsq	0.30	0.44	0.44	0.12	0.12	0.02	XXX
95982		A	lo ga n-stim subsq w/reprog	0.65	0.47	0.47	0.18	0.18	0.05	XXX
95990		A	Spin/brain pump refill & main	0.00	1.62	1.56	NA	NA	0.06	XXX
95991		A	Spin/brain pump refill & main	0.77	1.61	1.55	0.17	0.17	0.06	XXX
95999		C	Neurological procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
96000		A	Motion analysis, video/3d	1.80	NA	NA	0.44	0.48	0.11	XXX
96001		A	Motion test w/ft press meas	2.15	NA	NA	0.56	0.61	0.10	XXX
96002		A	Dynamic surface emg	0.41	NA	NA	0.10	0.13	0.02	XXX
96003		A	Dynamic fine wire emg	0.37	NA	NA	0.09	0.10	0.02	XXX
96004		A	Phys review of motion tests	2.14	0.65	0.79	0.65	0.79	0.11	XXX
96020		C	Functional brain mapping	0.00	0.00	0.00	NA	NA	0.00	XXX
96020	TC	C	Functional brain mapping	0.00	0.00	0.00	NA	NA	0.00	XXX
96020	26	A	Functional brain mapping	3.43	1.07	1.07	1.07	1.07	0.17	XXX
96040		B	Genetic counseling, 30 min	0.00	0.98	0.98	NA	NA	0.01	XXX
96101		A	Psycho testing by psych/phys	1.86	0.35	0.50	0.33	0.48	0.05	XXX
96102		A	Psycho testing by technician	0.50	1.10	0.88	0.09	0.13	0.01	XXX
96103		A	Psycho testing admin by comp	0.51	0.92	0.56	0.10	0.14	0.02	XXX
96105		A	Assessment of aphasia	0.00	1.66	1.71	NA	NA	0.18	XXX
96110		A	Developmental test, lim	0.00	0.19	0.18	NA	NA	0.18	XXX
96111		A	Developmental test, extend	2.60	0.69	0.87	0.58	0.81	0.18	XXX
96116		A	Neurobehavioral status exam	1.86	0.52	0.68	0.40	0.52	0.18	XXX
96118		A	Neuropsych tst by psych/phys	1.86	0.84	1.11	0.33	0.48	0.18	XXX
96119		A	Neuropsych testing by tec	0.55	1.53	1.27	0.10	0.14	0.18	XXX
96120		A	Neuropsych tst admin w/comp	0.51	1.69	1.21	0.10	0.13	0.02	XXX
96125		A	Cognitive test by hc pro	1.70	0.76	0.76	0.37	0.37	0.16	XXX
96150		A	Assess hlth/behave, init	0.50	0.10	0.14	0.09	0.13	0.01	XXX
96151		A	Assess hlth/behave, subseq	0.48	0.10	0.14	0.09	0.13	0.01	XXX
96152		A	Intervene hlth/behave, indiv	0.46	0.09	0.13	0.08	0.12	0.01	XXX
96153		A	Intervene hlth/behave, group	0.10	0.02	0.03	0.02	0.02	0.01	XXX
96154		A	Interv hlth/behav, fam w/pt	0.45	0.09	0.13	0.08	0.12	0.01	XXX
96155		N	Interv hlth/behav fam no pt	0.44	0.10	0.14	0.10	0.14	0.02	XXX
96401		A	Chemo, anti-neopl, sq/im	0.21	1.86	1.51	NA	NA	0.01	XXX
96402		A	Chemo hormon antineopl sq/im	0.19	0.77	0.89	NA	NA	0.01	XXX
96405		A	Chemo intralesional, up to 7	0.52	3.69	3.06	0.24	0.24	0.03	000

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
96406	A	Chemo intralesional over 7	0.80	3.61	3.31	0.32	0.31	0.03	000
96409	A	Chemo, iv push, singl drug	0.24	2.79	2.86	NA	NA	0.06	XXX
96411	A	Chemo, iv push, addl drug	0.20	1.50	1.55	NA	NA	0.06	ZZZ
96413	A	Chemo, iv infusion, 1 hr	0.28	3.63	3.91	NA	NA	0.08	XXX
96415	A	Chemo, iv infusion, addl hr	0.19	0.66	0.71	NA	NA	0.07	ZZZ
96416	A	Chemo prolong infuse w/pump	0.21	4.08	4.34	NA	NA	0.08	XXX
96417	A	Chemo iv infus each addl seq	0.21	1.73	1.83	NA	NA	0.07	ZZZ
96420	A	Chemo, ia, push technique	0.17	2.78	2.72	NA	NA	0.08	XXX
96422	A	Chemo ia infusion up to 1 hr	0.17	4.49	4.66	NA	NA	0.08	XXX
96423	A	Chemo ia infuse each addl hr	0.17	1.99	1.94	NA	NA	0.02	ZZZ
96425	A	Chemotherapy,infusion method	0.17	4.67	4.57	NA	NA	0.08	XXX
96440	A	Chemotherapy, intracavitary	2.37	5.55	6.84	0.98	1.10	0.17	000
96445	A	Chemotherapy, intracavitary	2.20	5.41	6.72	0.96	1.07	0.14	000
96450	A	Chemotherapy, into CNS	1.53	4.99	5.97	0.83	1.06	0.09	000
96521	A	Refill/maint, portable pump	0.21	3.15	3.45	NA	NA	0.06	XXX
96522	A	Refill/maint pump/resvr syst	0.21	2.78	2.71	NA	NA	0.06	XXX
96523	T	Irrig drug delivery device	0.04	0.64	0.66	NA	NA	0.01	XXX
96542	A	Chemotherapy injection	0.75	3.55	3.90	0.32	0.49	0.07	XXX
96549	C	Chemotherapy, unspecified	0.00	0.00	0.00	0.00	0.00	0.00	XXX
96567	A	Photodynamic tx, skin	0.00	3.74	2.84	NA	NA	0.04	XXX
96570	A	Photodynamic tx, 30 min	1.10	0.40	0.38	0.40	0.38	0.11	ZZZ
96571	A	Photodynamic tx, addl 15 min	0.55	0.19	0.19	0.19	0.19	0.03	ZZZ
96900	A	Ultraviolet light therapy	0.00	0.57	0.50	NA	NA	0.02	XXX
96902	B	Trichogram	0.41	0.11	0.15	0.09	0.13	0.01	XXX
96904	R	Whole body photography	0.00	1.90	1.90	NA	NA	0.01	XXX
96910	A	Photochemotherapy with UV-B	0.00	2.01	1.50	NA	NA	0.04	XXX
96912	A	Photochemotherapy with UV-A	0.00	2.58	1.92	NA	NA	0.05	XXX
96913	A	Photochemotherapy, UV-A or B	0.00	3.47	2.57	NA	NA	0.10	XXX
96920	A	Laser tx, skin < 250 sq cm	1.15	3.58	3.05	0.56	0.56	0.02	000
96921	A	Laser tx, skin 250-500 sq cm	1.17	3.32	2.96	0.51	0.54	0.03	000
96922	A	Laser tx, skin > 500 sq cm	2.10	4.63	4.06	1.04	0.83	0.04	000
96999	C	Dermatological procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97001	A	Pt evaluation	1.20	0.65	0.70	NA	NA	0.05	XXX
97002	A	Pt re-evaluation	0.60	0.41	0.42	NA	NA	0.02	XXX
97003	A	Ot evaluation	1.20	0.76	0.82	NA	NA	0.06	XXX
97004	A	Ot re-evaluation	0.60	0.54	0.60	NA	NA	0.02	XXX
97005	I	Athletic train eval	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97006	I	Athletic train reeval	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97010	B	Hot or cold packs therapy	0.06	0.07	0.06	NA	NA	0.01	XXX
97012	A	Mechanical traction therapy	0.25	0.14	0.13	NA	NA	0.01	XXX
97014	I	Electric stimulation therapy	0.18	0.18	0.18	NA	NA	0.01	XXX
97016	A	Vasopneumatic device therapy	0.18	0.24	0.21	NA	NA	0.01	XXX
97018	A	Paraffin bath therapy	0.06	0.17	0.13	NA	NA	0.01	XXX
97022	A	Whirlpool therapy	0.17	0.33	0.27	NA	NA	0.01	XXX
97024	A	Diathermy eg, microwave	0.06	0.08	0.07	NA	NA	0.01	XXX
97026	A	Infrared therapy	0.06	0.07	0.06	NA	NA	0.01	XXX
97028	A	Ultraviolet therapy	0.08	0.08	0.08	NA	NA	0.01	XXX
97032	A	Electrical stimulation	0.25	0.20	0.18	NA	NA	0.01	XXX
97033	A	Electric current therapy	0.26	0.44	0.36	NA	NA	0.01	XXX
97034	A	Contrast bath therapy	0.21	0.20	0.17	NA	NA	0.01	XXX
97035	A	Ultrasound therapy	0.21	0.10	0.10	NA	NA	0.01	XXX
97036	A	Hydrotherapy	0.28	0.44	0.38	NA	NA	0.01	XXX
97039	C	Physical therapy treatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97110	A	Therapeutic exercises	0.45	0.32	0.29	NA	NA	0.02	XXX
97112	A	Neuromuscular reeducation	0.45	0.34	0.33	NA	NA	0.01	XXX
97113	A	Aquatic therapy/exercises	0.44	0.53	0.46	NA	NA	0.01	XXX
97116	A	Gait training therapy	0.40	0.27	0.26	NA	NA	0.01	XXX
97124	A	Massage therapy	0.35	0.27	0.25	NA	NA	0.01	XXX
97139	C	Physical medicine procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97140	A	Manual therapy	0.43	0.29	0.27	NA	NA	0.01	XXX
97150	A	Group therapeutic procedures	0.27	0.22	0.20	NA	NA	0.01	XXX
97530	A	Therapeutic activities	0.44	0.38	0.35	NA	NA	0.01	XXX
97532	A	Cognitive skills development	0.44	0.22	0.21	NA	NA	0.01	XXX
97533	A	Sensory integration	0.44	0.27	0.25	NA	NA	0.01	XXX
97535	A	Self care mngmt training	0.45	0.37	0.35	NA	NA	0.01	XXX
97537	A	Community/work reintegration	0.45	0.28	0.27	NA	NA	0.01	XXX
97542	A	Wheelchair mngmt training	0.45	0.29	0.28	NA	NA	0.01	XXX
97545	R	Work hardening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97546	R	Work hardening add-on	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
97597	A	Active wound care/20 cm or <	0.58	1.09	0.88	0.12	0.39	0.05	XXX
97598	A	Active wound care > 20 cm	0.80	1.27	1.03	0.17	0.48	0.05	XXX
97602	B	Wound(s) care non-selective	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
97605	A	Neg press wound tx, < 50 cm	0.55	0.40	0.37	0.11	0.17	0.02	XXX
97606	A	Neg press wound tx, > 50 cm	0.60	0.41	0.38	0.13	0.18	0.03	XXX
97750	A	Physical performance test	0.45	0.33	0.32	NA	NA	0.02	XXX
97755	A	Assistive technology assess	0.62	0.27	0.28	NA	NA	0.02	XXX
97760	A	Orthotic mgmt and training	0.45	0.42	0.38	NA	NA	0.03	XXX
97761	A	Prosthetic training	0.45	0.33	0.30	NA	NA	0.02	XXX
97762	A	C/o for orthotic/prosth use	0.25	0.73	0.57	NA	NA	0.02	XXX
97799	C	Physical medicine procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97802	A	Medical nutrition, indiv, in	0.45	0.14	0.30	0.11	0.29	0.01	XXX
97803	A	Med nutrition, indiv, subseq	0.37	0.12	0.29	0.09	0.28	0.01	XXX
97804	A	Medical nutrition, group	0.25	0.08	0.13	0.07	0.12	0.01	XXX
97810	N	Acupunct w/o stimul 15 min	0.60	0.26	0.32	0.14	0.18	0.03	XXX
97811	N	Acupunct w/o stimul addl 15m	0.50	0.15	0.20	0.11	0.15	0.03	ZZZ
97813	N	Acupunct w/stimul 15 min	0.65	0.27	0.33	0.15	0.20	0.03	XXX
97814	N	Acupunct w/stimul addl 15m	0.55	0.19	0.24	0.13	0.17	0.03	ZZZ
98925	A	Osteopathic manipulation	0.45	0.29	0.30	0.12	0.13	0.02	000
98926	A	Osteopathic manipulation	0.65	0.37	0.39	0.17	0.21	0.03	000
98927	A	Osteopathic manipulation	0.87	0.45	0.47	0.22	0.26	0.03	000
98928	A	Osteopathic manipulation	1.03	0.51	0.55	0.26	0.30	0.04	000
98929	A	Osteopathic manipulation	1.19	0.57	0.62	0.30	0.33	0.05	000
98940	A	Chiropractic manipulation	0.45	0.21	0.22	0.12	0.12	0.01	000
98941	A	Chiropractic manipulation	0.65	0.27	0.29	0.17	0.17	0.01	000
98942	A	Chiropractic manipulation	0.87	0.33	0.35	0.24	0.23	0.02	000
98943	N	Chiropractic manipulation	0.40	0.17	0.21	0.09	0.13	0.01	XXX
98960	B	Self-mgmt educ & train, 1 pt	0.00	0.58	0.58	NA	NA	0.01	XXX
98961	B	Self-mgmt educ/train, 2-4 pt	0.00	0.28	0.28	NA	NA	0.01	XXX
98962	B	Self-mgmt educ/train, 5-8 pt	0.00	0.20	0.20	NA	NA	0.01	XXX
98966	N	Hc pro phone call 5-10 min	0.25	0.09	0.09	0.06	0.06	0.01	XXX
98967	N	Hc pro phone call 11-20 min	0.50	0.14	0.14	0.11	0.11	0.02	XXX
98968	N	Hc pro phone call 21-30 min	0.75	0.20	0.20	0.17	0.17	0.03	XXX
98969	N	Online service by hc pro	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99000	B	Specimen handling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99001	B	Specimen handling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99002	B	Device handling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99024	B	Postop follow-up visit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99026	N	In-hospital on call service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99027	N	Out-of-hosp on call service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99050	B	Medical services after hrs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99051	B	Med serv, eve/wkend/holiday	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99053	B	Med serv 10pm-8am, 24 hr fac	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99056	B	Med service out of office	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99058	B	Office emergency care	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99060	B	Out of office emerg med serv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99070	B	Special supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99071	B	Patient education materials	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99075	N	Medical testimony	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99078	B	Group health education	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99080	B	Special reports or forms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99082	C	Unusual physician travel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99090	B	Computer data analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99091	B	Collect/review data from pt	1.10	0.25	0.25	NA	NA	0.04	XXX
99100	B	Special anesthesia service	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99116	B	Anesthesia with hypothermia	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99135	B	Special anesthesia procedure	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99140	B	Emergency anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99143	C	Mod cs by same phys, < 5 yrs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99144	C	Mod cs by same phys, 5 yrs +	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99145	C	Mod cs by same phys add-on	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99148	C	Mod cs diff phys < 5 yrs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99149	C	Mod cs diff phys 5 yrs +	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99150	C	Mod cs diff phys add-on	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99170	A	Anogenital exam, child	1.75	1.83	1.80	0.61	0.58	0.08	000
99172	N	Ocular function screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99173	N	Visual acuity screen	0.00	0.06	0.06	NA	NA	0.01	XXX
99174	N	Ocular photoscreening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99175	A	Induction of vomiting	0.00	0.36	0.87	NA	NA	0.10	XXX
99183	A	Hyperbaric oxygen therapy	2.34	2.60	2.92	0.57	0.65	0.16	XXX
99185	A	Regional hypothermia	0.00	1.67	1.15	NA	NA	0.04	XXX
99186	A	Total body hypothermia	0.00	1.63	1.70	NA	NA	0.45	XXX
99190	X	Special pump services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99191	X	Special pump services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99192	X	Special pump services	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
99195	A	Phlebotomy	0.00	2.56	1.50	NA	NA	0.02	XXX
99199	C	Special service/proc/report	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99201	A	Office/outpatient visit, new	0.45	0.55	0.52	0.16	0.15	0.03	XXX
99202	A	Office/outpatient visit, new	0.88	0.84	0.81	0.29	0.30	0.05	XXX
99203	A	Office/outpatient visit, new	1.34	1.11	1.12	0.43	0.45	0.09	XXX
99204	A	Office/outpatient visit, new	2.30	1.49	1.49	0.71	0.71	0.12	XXX
99205	A	Office/outpatient visit, new	3.00	1.78	1.78	0.91	0.93	0.15	XXX
99211	A	Office/outpatient visit, est	0.17	0.32	0.36	0.06	0.06	0.01	XXX
99212	A	Office/outpatient visit, est	0.45	0.55	0.55	0.15	0.15	0.03	XXX
99213	A	Office/outpatient visit, est	0.92	0.76	0.72	0.28	0.26	0.03	XXX
99214	A	Office/outpatient visit, est	1.42	1.10	1.06	0.44	0.42	0.05	XXX
99215	A	Office/outpatient visit, est	2.00	1.38	1.35	0.61	0.63	0.08	XXX
99217	A	Observation care discharge	1.28	NA	NA	0.50	0.51	0.06	XXX
99218	A	Observation care	1.28	NA	NA	0.38	0.41	0.06	XXX
99219	A	Observation care	2.14	NA	NA	0.59	0.65	0.10	XXX
99220	A	Observation care	2.99	NA	NA	0.84	0.93	0.14	XXX
99221	A	Initial hospital care	1.88	NA	NA	0.54	0.50	0.07	XXX
99222	A	Initial hospital care	2.56	NA	NA	0.71	0.72	0.10	XXX
99223	A	Initial hospital care	3.78	NA	NA	1.07	1.05	0.13	XXX
99231	A	Subsequent hospital care	0.76	NA	NA	0.24	0.23	0.03	XXX
99232	A	Subsequent hospital care	1.39	NA	NA	0.42	0.40	0.04	XXX
99233	A	Subsequent hospital care	2.00	NA	NA	0.59	0.56	0.06	XXX
99234	A	Observ/hosp same date	2.56	NA	NA	0.78	0.83	0.13	XXX
99235	A	Observ/hosp same date	3.41	NA	NA	0.98	1.06	0.16	XXX
99236	A	Observ/hosp same date	4.26	NA	NA	1.21	1.32	0.19	XXX
99238	A	Hospital discharge day	1.28	NA	NA	0.49	0.52	0.05	XXX
99239	A	Hospital discharge day	1.90	NA	NA	0.67	0.70	0.07	XXX
99241	A	Office consultation	0.64	0.66	0.65	0.22	0.22	0.05	XXX
99242	A	Office consultation	1.34	1.08	1.06	0.48	0.47	0.10	XXX
99243	A	Office consultation	1.88	1.45	1.42	0.67	0.65	0.13	XXX
99244	A	Office consultation	3.02	1.93	1.88	1.08	1.00	0.16	XXX
99245	A	Office consultation	3.77	2.26	2.27	1.31	1.27	0.21	XXX
99251	A	Inpatient consultation	1.00	NA	NA	0.31	0.27	0.05	XXX
99252	A	Inpatient consultation	1.50	NA	NA	0.49	0.49	0.09	XXX
99253	A	Inpatient consultation	2.27	NA	NA	0.80	0.74	0.11	XXX
99254	A	Inpatient consultation	3.29	NA	NA	1.18	1.08	0.13	XXX
99255	A	Inpatient consultation	4.00	NA	NA	1.38	1.36	0.18	XXX
99281	A	Emergency dept visit	0.45	NA	NA	0.09	0.09	0.02	XXX
99282	A	Emergency dept visit	0.88	NA	NA	0.17	0.15	0.04	XXX
99283	A	Emergency dept visit	1.34	NA	NA	0.25	0.28	0.09	XXX
99284	A	Emergency dept visit	2.56	NA	NA	0.46	0.47	0.14	XXX
99285	A	Emergency dept visit	3.80	NA	NA	0.67	0.69	0.23	XXX
99288	B	Direct advanced life support	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99289	A	Ped crit care transport	4.79	NA	NA	1.08	1.26	0.24	XXX
99290	A	Ped crit care transport addl	2.40	NA	NA	0.89	0.85	0.12	ZZZ
99291	A	Critical care, first hour	4.50	2.26	2.41	1.10	1.19	0.21	XXX
99292	A	Critical care, add'l 30 min	2.25	0.80	0.85	0.56	0.60	0.11	ZZZ
99293	A	Ped critical care, initial	15.98	NA	NA	3.78	4.26	1.12	XXX
99294	A	Ped critical care, subseq	7.99	NA	NA	1.65	2.03	0.45	XXX
99295	A	Neonate crit care, initial	18.46	NA	NA	4.56	4.97	1.16	XXX
99296	A	Neonate critical care subseq	7.99	NA	NA	2.06	2.30	0.32	XXX
99298	A	lc for lbw infant < 1500 gm	2.75	NA	NA	0.68	0.80	0.17	XXX
99299	A	lc, lbw infant 1500–2500 gm	2.50	NA	NA	0.58	0.72	0.16	XXX
99300	A	lc, infant pbw 2501–5000 gm	2.40	NA	NA	0.71	0.77	0.15	XXX
99304	A	Nursing facility care, init	1.61	0.57	0.53	0.57	0.53	0.05	XXX
99305	A	Nursing facility care, init	2.30	0.74	0.68	0.74	0.68	0.07	XXX
99306	A	Nursing facility care, init	3.00	0.90	0.83	0.90	0.83	0.09	XXX
99307	A	Nursing fac care, subseq	0.76	0.31	0.29	0.31	0.29	0.03	XXX
99308	A	Nursing fac care, subseq	1.16	0.47	0.46	0.47	0.46	0.04	XXX
99309	A	Nursing fac care, subseq	1.55	0.61	0.61	0.61	0.61	0.06	XXX
99310	A	Nursing fac care, subseq	2.35	0.87	0.82	0.87	0.82	0.08	XXX
99315	A	Nursing fac discharge day	1.13	0.41	0.43	0.41	0.43	0.05	XXX
99316	A	Nursing fac discharge day	1.50	0.50	0.55	0.50	0.55	0.06	XXX
99318	A	Annual nursing fac assessmnt	1.71	0.56	0.53	0.56	0.53	0.05	XXX
99324	A	Domicil/r-home visit new pat	1.01	0.43	0.46	NA	NA	0.05	XXX
99325	A	Domicil/r-home visit new pat	1.52	0.55	0.62	NA	NA	0.07	XXX
99326	A	Domicil/r-home visit new pat	2.63	0.82	0.87	NA	NA	0.10	XXX
99327	A	Domicil/r-home visit new pat	3.46	1.02	1.09	NA	NA	0.13	XXX
99328	A	Domicil/r-home visit new pat	4.09	1.16	1.29	NA	NA	0.16	XXX
99334	A	Domicil/r-home visit est pat	1.07	0.43	0.41	NA	NA	0.04	XXX
99335	A	Domicil/r-home visit est pat	1.72	0.59	0.58	NA	NA	0.06	XXX
99336	A	Domicil/r-home visit est pat	2.46	0.77	0.79	NA	NA	0.09	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
99337	A	Domicil/r-home visit est pat	3.58	1.03	1.09	NA	NA	0.13	XXX
99339	B	Domicil/r-home care supervis	1.25	0.58	0.58	NA	NA	0.06	XXX
99340	B	Domicil/r-home care supervis	1.80	0.77	0.77	NA	NA	0.07	XXX
99341	A	Home visit, new patient	1.01	0.43	0.45	NA	NA	0.05	XXX
99342	A	Home visit, new patient	1.52	0.56	0.62	NA	NA	0.07	XXX
99343	A	Home visit, new patient	2.53	0.82	0.88	NA	NA	0.10	XXX
99344	A	Home visit, new patient	3.38	1.00	1.09	NA	NA	0.13	XXX
99345	A	Home visit, new patient	4.09	1.15	1.29	NA	NA	0.16	XXX
99347	A	Home visit, est patient	1.00	0.42	0.41	NA	NA	0.04	XXX
99348	A	Home visit, est patient	1.56	0.56	0.57	NA	NA	0.06	XXX
99349	A	Home visit, est patient	2.33	0.73	0.78	NA	NA	0.09	XXX
99350	A	Home visit, est patient	3.28	0.96	1.07	NA	NA	0.13	XXX
99354	A	Prolonged service, office	1.77	0.65	0.71	0.50	0.58	0.08	ZZZ
99355	A	Prolonged service, office	1.77	0.62	0.68	0.47	0.54	0.07	ZZZ
99356	A	Prolonged service, inpatient	1.71	NA	NA	0.50	0.56	0.07	ZZZ
99357	A	Prolonged service, inpatient	1.71	NA	NA	0.50	0.56	0.08	ZZZ
99358	B	Prolonged serv, w/o contact	2.10	0.51	0.51	0.51	0.51	0.09	ZZZ
99359	B	Prolonged serv, w/o contact	1.00	0.26	0.26	0.26	0.26	0.04	ZZZ
99360	X	Physician standby services	1.20	0.28	0.28	0.28	0.28	0.05	XXX
99363	B	Anticoag mgmt, init	1.65	1.30	1.30	0.38	0.38	0.07	XXX
99364	B	Anticoag mgmt, subseq	0.63	0.38	0.38	0.14	0.14	0.04	XXX
99366	B	Team conf w/pat by hc pro	0.82	0.20	0.20	0.19	0.19	0.06	XXX
99367	B	Team conf w/o pat by phys	1.10	0.25	0.25	0.25	0.25	0.05	XXX
99368	B	Team conf w/o pat by hc pro	0.72	0.16	0.16	0.16	0.16	0.03	XXX
99374	B	Home health care supervision	1.10	0.55	0.62	0.25	0.34	0.05	XXX
99375	I	Home health care supervision	1.73	0.75	1.15	0.40	0.97	0.07	XXX
99377	B	Hospice care supervision	1.10	0.55	0.62	0.25	0.34	0.05	XXX
99378	I	Hospice care supervision	1.73	0.75	1.35	0.40	1.17	0.07	XXX
99379	B	Nursing fac care supervision	1.10	0.55	0.62	0.25	0.34	0.04	XXX
99380	B	Nursing fac care supervision	1.73	0.75	0.87	0.40	0.53	0.06	XXX
99381	N	Init pm e/m, new pat, inf	1.19	1.00	1.25	0.27	0.36	0.05	XXX
99382	N	Init pm e/m, new pat 1-4 yrs	1.36	1.04	1.29	0.31	0.42	0.05	XXX
99383	N	Prev visit, new, age 5-11	1.36	1.03	1.25	0.31	0.42	0.05	XXX
99384	N	Prev visit, new, age 12-17	1.53	1.07	1.31	0.35	0.47	0.06	XXX
99385	N	Prev visit, new, age 18-39	1.53	1.07	1.31	0.35	0.47	0.06	XXX
99386	N	Prev visit, new, age 40-64	1.88	1.15	1.45	0.43	0.58	0.07	XXX
99387	N	Init pm e/m, new pat 65+ yrs	2.06	1.28	1.58	0.47	0.63	0.07	XXX
99391	N	Per pm reeval, est pat, inf	1.02	0.86	0.94	0.23	0.31	0.04	XXX
99392	N	Prev visit, est, age 1-4	1.19	0.90	0.99	0.27	0.36	0.05	XXX
99393	N	Prev visit, est, age 5-11	1.19	0.89	0.98	0.27	0.36	0.05	XXX
99394	N	Prev visit, est, age 12-17	1.36	0.93	1.03	0.31	0.42	0.05	XXX
99395	N	Prev visit, est, age 18-39	1.36	0.94	1.05	0.31	0.42	0.05	XXX
99396	N	Prev visit, est, age 40-64	1.53	0.98	1.11	0.35	0.47	0.06	XXX
99397	N	Per pm reeval est pat 65+ yr	1.71	1.12	1.24	0.39	0.53	0.06	XXX
99401	N	Preventive counseling, indiv	0.48	0.36	0.49	0.11	0.15	0.01	XXX
99402	N	Preventive counseling, indiv	0.98	0.48	0.67	0.22	0.30	0.02	XXX
99403	N	Preventive counseling, indiv	1.46	0.59	0.84	0.34	0.45	0.04	XXX
99404	N	Preventive counseling, indiv	1.95	0.70	1.01	0.45	0.60	0.05	XXX
99406	A	Behav chng smoking 3-10 min	0.24	0.11	0.10	0.07	0.08	0.01	XXX
99407	A	Behav chng smoking < 10 min	0.50	0.18	0.18	0.13	0.15	0.01	XXX
99408	N	Audit/dast, 15-30 min	0.65	0.19	0.19	0.15	0.15	0.01	XXX
99409	N	Audit/dast, over 30 min	1.30	0.34	0.34	0.30	0.30	0.03	XXX
99411	N	Preventive counseling, group	0.15	0.22	0.20	0.03	0.05	0.01	XXX
99412	N	Preventive counseling, group	0.25	0.24	0.25	0.06	0.08	0.01	XXX
99420	N	Health risk assessment test	0.00	0.22	0.22	NA	NA	0.01	XXX
99429	N	Unlisted preventive service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99431	A	Initial care, normal newborn	1.17	NA	NA	0.27	0.32	0.05	XXX
99432	A	Newborn care, not in hosp	1.26	1.01	0.97	0.29	0.34	0.07	XXX
99433	A	Normal newborn care/hospital	0.62	NA	NA	0.17	0.19	0.02	XXX
99435	A	Newborn discharge day hosp	1.50	NA	NA	0.50	0.54	0.06	XXX
99436	A	Attendance, birth	1.50	NA	NA	0.33	0.40	0.06	XXX
99440	A	Newborn resuscitation	2.93	NA	NA	0.67	0.80	0.12	XXX
99441	N	Phone e/m by phys 5-10 min	0.25	0.09	0.09	0.06	0.06	0.02	XXX
99442	N	Phone e/m by phys 11-20 min	0.50	0.14	0.14	0.11	0.11	0.02	XXX
99443	N	Phone e/m by phys 21-30 min	0.75	0.20	0.20	0.17	0.17	0.03	XXX
99444	N	Online e/m by phys	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99450	N	Basic life disability exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99455	R	Work related disability exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99456	R	Disability examination	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99477	A	Init day hosp neonate care	7.00	1.98	1.98	1.98	1.98	0.32	XXX
99499	C	Unlisted e&m service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99500	I	Home visit, prenatal	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented-fa- cility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
99501		I	Home visit, postnatal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99502		I	Home visit, nb care	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99503		I	Home visit, resp therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99504		I	Home visit mech ventilator	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99505		I	Home visit, stoma care	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99506		I	Home visit, im injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99507		I	Home visit, cath maintain	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99509		I	Home visit day life activity	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99510		I	Home visit, sing/m/fam couns	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99511		I	Home visit, fecal/enema mgmt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99512		I	Home visit for hemodialysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99600		I	Home visit nos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99601		I	Home infusion/visit, 2 hrs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99602		I	Home infusion, each addtl hr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99605		X	Mtms by pharm, np, 15 min	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99606		X	Mtms by pharm, est, 15 min	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99607		X	Mtms by pharm, addl 15 min	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4890		R	Repair/maint cont hemo equip	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0008		X	Admin influenza virus vac	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0009		X	Admin pneumococcal vaccine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0010		X	Admin hepatitis b vaccine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0027		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0101		A	CA screen;pelvic/breast exam	0.45	0.48	0.50	NA	NA	0.02	XXX
G0102		A	Prostate ca screening; dre	0.17	0.32	0.36	0.06	0.06	0.01	XXX
G0103		X	PSA screening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0104		A	CA screen;flexi sigmoidoscope	0.96	2.52	2.40	0.62	0.56	0.08	000
G0105		A	Colorectal scrn; hi risk ind	3.69	6.38	6.26	1.82	1.64	0.30	000
G0105	53	A	Colorectal scrn; hi risk ind	0.96	2.52	2.40	0.62	0.56	0.08	000
G0106		A	Colon CA screen;barium enema	0.99	4.94	3.74	NA	NA	0.17	XXX
G0106	TC	A	Colon CA screen;barium enema	0.00	4.59	3.41	NA	NA	0.13	XXX
G0106	26	A	Colon CA screen;barium enema	0.99	0.35	0.33	0.35	0.33	0.04	XXX
G0108		A	Diab manage trn per indiv	0.00	0.59	0.71	NA	NA	0.01	XXX
G0109		A	Diab manage trn ind/group	0.00	0.31	0.40	NA	NA	0.01	XXX
G0117		T	Glaucoma scrn high risk direc	0.45	0.76	0.74	NA	NA	0.01	XXX
G0118		T	Glaucoma scrn high risk direc	0.17	0.71	0.62	NA	NA	0.01	XXX
G0120		A	Colon ca scrn; barium enema	0.99	4.94	3.74	NA	NA	0.17	XXX
G0120	TC	A	Colon ca scrn; barium enema	0.00	4.59	3.41	NA	NA	0.13	XXX
G0120	26	A	Colon ca scrn; barium enema	0.99	0.35	0.33	0.35	0.33	0.04	XXX
G0121		A	Colon ca scrn not hi rsk ind	3.69	6.38	6.26	1.82	1.64	0.30	000
G0121	53	A	Colon ca scrn not hi rsk ind	0.96	2.52	2.40	0.62	0.56	0.08	000
G0122		N	Colon ca scrn; barium enema	0.99	5.64	4.10	NA	NA	0.18	XXX
G0122	TC	N	Colon ca scrn; barium enema	0.00	5.41	3.80	NA	NA	0.13	XXX
G0122	26	N	Colon ca scrn; barium enema	0.99	0.23	0.30	0.23	0.30	0.05	XXX
G0123		X	Screen cerv/vag thin layer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0124		A	Screen c/v thin layer by MD	0.42	0.38	0.26	0.38	0.26	0.02	XXX
G0127		R	Trim nail(s)	0.17	0.38	0.32	0.04	0.06	0.01	000
G0128		R	CORF skilled nursing service	0.08	0.02	0.02	0.02	0.02	0.01	XXX
G0130		A	Single energy x-ray study	0.22	0.55	0.71	NA	NA	0.06	XXX
G0130	TC	A	Single energy x-ray study	0.00	0.49	0.64	NA	NA	0.05	XXX
G0130	26	A	Single energy x-ray study	0.22	0.06	0.07	0.06	0.07	0.01	XXX
G0141		A	Scr c/v cyto,autosys and md	0.42	0.38	0.26	0.38	0.26	0.02	XXX
G0143		X	Scr c/v cyto,thinlayer,rescr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0144		X	Scr c/v cyto,thinlayer,rescr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0145		X	Scr c/v cyto,thinlayer,rescr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0147		X	Scr c/v cyto, automated sys	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0148		X	Scr c/v cyto, autosys, rescr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0166		A	Extrnl counterpulse, per tx	0.07	4.50	4.03	NA	NA	0.01	XXX
G0168		A	Wound closure by adhesive	0.45	1.58	1.76	0.21	0.21	0.03	000
G0173		X	Linear acc stereo radsur com	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0175		X	OPPS Service,sched team conf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0176		X	OPPS/PHP;activity therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0177		X	OPPS/PHP; train & educ serv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0179		A	MD recertification HHA PT	0.45	0.48	0.75	NA	NA	0.02	XXX
G0180		A	MD certification HHA patient	0.67	0.56	0.91	NA	NA	0.03	XXX
G0181		A	Home health care supervision	1.73	0.80	1.14	NA	NA	0.07	XXX
G0182		A	Hospice care supervision	1.73	0.82	1.24	NA	NA	0.07	XXX
G0186		C	Dstry eye lesn,fdr vsssl tech	0.00	0.00	0.00	0.00	0.00	0.00	YYY
G0202		A	Screeningmammographydigital	0.70	2.80	2.78	NA	NA	0.10	XXX
G0202	TC	A	Screeningmammographydigital	0.00	2.56	2.55	NA	NA	0.07	XXX
G0202	26	A	Screeningmammographydigital	0.70	0.24	0.23	0.24	0.23	0.03	XXX
G0204		A	Diagnosticmammographydigital	0.87	3.40	3.09	NA	NA	0.11	XXX
G0204	TC	A	Diagnosticmammographydigital	0.00	3.10	2.80	NA	NA	0.07	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
G0204	26	A	Diagnostic mammography digital	0.87	0.30	0.29	0.30	0.29	0.04	XXX
G0206		A	Diagnostic mammography digital	0.70	2.66	2.45	NA	NA	0.09	XXX
G0206	TC	A	Diagnostic mammography digital	0.00	2.42	2.22	NA	NA	0.06	XXX
G0206	26	A	Diagnostic mammography digital	0.70	0.24	0.23	0.24	0.23	0.03	XXX
G0219		N	PET img wholbod melano nonco	0.00	0.00	0.00	NA	NA	0.00	XXX
G0219	TC	N	PET img wholbod melano nonco	0.00	0.00	0.00	NA	NA	0.00	XXX
G0219	26	N	PET img wholbod melano nonco	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0235		N	PET not otherwise specified	0.00	0.00	0.00	NA	NA	0.00	XXX
G0235	TC	N	PET not otherwise specified	0.00	0.00	0.00	NA	NA	0.00	XXX
G0235	26	N	PET not otherwise specified	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0237		A	Therapeutic proced strg endur	0.00	0.21	0.34	NA	NA	0.02	XXX
G0238		A	Oth resp proc, indiv	0.00	0.23	0.36	NA	NA	0.02	XXX
G0239		A	Oth resp proc, group	0.00	0.31	0.32	NA	NA	0.02	XXX
G0245		R	Initial foot exam pt lops	0.88	0.84	0.81	0.29	0.30	0.04	XXX
G0246		R	Followup eval of foot pt lop	0.45	0.55	0.55	0.15	0.15	0.02	XXX
G0247		R	Routine footcare pt w lops	0.50	0.68	0.60	0.16	0.18	0.02	ZZZ
G0248		R	Demonstrate use home inr mon	0.00	3.40	5.00	NA	NA	0.01	XXX
G0249		R	Provide test material, equipm	0.00	3.40	3.68	NA	NA	0.01	XXX
G0250		R	MD review interpret of test	0.18	0.08	0.07	NA	NA	0.01	XXX
G0251		E	Linear acc based stero radio	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0252		N	PET imaging initial dx	0.00	0.00	0.00	NA	NA	0.00	XXX
G0252	TC	N	PET imaging initial dx	0.00	0.00	0.00	NA	NA	0.00	XXX
G0252	26	N	PET imaging initial dx	1.50	0.00	0.60	0.00	0.60	0.04	XXX
G0255		N	Current percep threshold tst	0.00	0.00	0.00	NA	NA	0.00	XXX
G0255	TC	N	Current percep threshold tst	0.00	0.00	0.00	NA	NA	0.00	XXX
G0255	26	N	Current percep threshold tst	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0257		E	Unsched dialysis ESRD pt hos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0259		E	Injct for sacroiliac joint	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0260		E	Inj for sacroiliac jt anesth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0268		A	Removal of impacted wax md	0.61	0.66	0.65	0.20	0.22	0.02	000
G0269		B	Occlusive device in vein art	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0270		A	MNT subs tx for change dx	0.37	0.12	0.29	0.09	0.28	0.01	XXX
G0271		A	Group MNT 2 or more 30 mins	0.25	0.08	0.13	0.07	0.12	0.01	XXX
G0275		A	Renal angio, cardiac cath	0.25	NA	NA	0.13	0.12	0.01	ZZZ
G0278		A	Iliac art angio, cardiac cath	0.25	NA	NA	0.13	0.12	0.01	ZZZ
G0281		A	Elec stim unattend for press	0.18	0.14	0.12	NA	NA	0.01	XXX
G0282		N	Elect stim wound care not pd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0283		A	Elec stim other than wound	0.18	0.14	0.12	NA	NA	0.01	XXX
G0288		A	Recon, CTA for surg plan	0.00	1.03	5.82	NA	NA	0.18	XXX
G0289		A	Arthro, loose body + chondro	1.48	NA	NA	0.58	0.69	0.26	ZZZ
G0290		E	Drug-eluting stents, single	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0291		E	Drug-eluting stents, each add	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0293		E	Non-cov surg proc, clin trial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0294		E	Non-cov proc, clinical trial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0295		N	Electromagnetic therapy onc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0297		X	Insert single chamber/cd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0300		X	Insert reposit lead dual+gen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0302		X	Pre-op service LVRS complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0303		X	Pre-op service LVRS 10-15dos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0304		X	Pre-op service LVRS 1-9 dos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0305		X	Post op service LVRS min 6	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0306		X	CBC/diffwbc w/o platelet	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0307		X	CBC without platelet	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0308		A	ESRD related svc 4+mo < 2yrs	12.74	5.57	7.05	5.57	7.05	0.42	XXX
G0309		A	ESRD related svc 2-3mo < 2yrs	10.61	4.16	5.63	4.16	5.63	0.36	XXX
G0310		A	ESRD related svc 1 vst < 2yrs	8.49	2.78	4.23	2.78	4.23	0.28	XXX
G0311		A	ESRD related svcs 4+mo 2-11yr	9.73	3.54	4.13	3.54	4.13	0.34	XXX
G0312		A	ESRD relate svcs 2-3 mo 2-11y	8.11	2.70	3.31	2.70	3.31	0.29	XXX
G0313		A	ESRD related svcs 1 mon 2-11y	6.49	1.83	2.49	1.83	2.49	0.22	XXX
G0314		A	ESRD related svcs 4+ mo 12-19	8.28	3.39	3.90	3.39	3.90	0.27	XXX
G0315		A	ESRD related svcs 2-3mo/12-19	6.90	2.56	3.11	2.56	3.11	0.23	XXX
G0316		A	ESRD related svcs 1vis/12-19y	5.52	1.66	2.30	1.66	2.30	0.17	XXX
G0317		A	ESRD related svcs 4+mo 20+yrs	5.09	2.25	2.55	2.25	2.55	0.17	XXX
G0318		A	ESRD related svcs 2-3 mo 20+y	4.24	1.69	2.04	1.69	2.04	0.14	XXX
G0319		A	ESRD related svcs 1visit 20+y	3.39	1.13	1.52	1.13	1.52	0.11	XXX
G0320		A	ESD related svcs home undr 2	10.61	2.68	4.89	2.68	4.89	0.36	XXX
G0321		A	ESRD related svcs home mo 2-11y	8.11	1.99	2.95	1.99	2.95	0.29	XXX
G0322		A	ESRD related svcs hom mo 12-19	6.90	1.71	2.69	1.71	2.69	0.23	XXX
G0323		A	ESRD related svcs home mo 20+	4.24	1.14	1.76	1.14	1.76	0.14	XXX
G0324		A	ESRD relate svcs home/dy < 2yr	0.35	0.16	0.20	0.16	0.20	0.01	XXX
G0325		A	ESRD relate home/day/ 2-11yr	0.23	0.09	0.10	0.09	0.10	0.01	XXX
G0326		A	ESRD relate home/day 12-19yr	0.27	0.10	0.11	0.10	0.11	0.01	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facil- ity PE RVUs ²	Mal- practice RVUs ²	Global
G0327		A	ESRD relate home/dy 20+yrs	0.14	0.06	0.07	0.06	0.07	0.01	XXX
G0328		X	Fecal blood scrn immunoassay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0329		A	Electromagnetic tx for ulcers	0.06	0.15	0.14	NA	NA	0.01	XXX
G0332		A	Preadmin IV immunoglobulin	0.00	0.00	1.97	NA	NA	0.00	XXX
G0333		X	Dispense fee initial 30 day	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0337		X	Hospice evaluation preelect	1.34	0.31	0.41	0.31	0.41	0.09	XXX
G0339		C	Robot lin-radsurg com, first	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0340		C	Robt lin-radsurg fractx 2-5	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0341		A	Percutaneous islet celltrans	6.98	NA	NA	2.35	2.47	0.48	000
G0342		A	Laparoscopy islet cell trans	11.92	NA	NA	5.06	5.18	1.46	090
G0343		A	Laparotomy islet cell transp	19.85	NA	NA	8.54	8.65	2.07	090
G0344		A	Initial preventive exam	1.34	1.11	1.12	0.43	0.45	0.10	XXX
G0364		A	Bone marrow aspirate & biopsy	0.16	0.16	0.15	0.07	0.06	0.04	ZZZ
G0365		A	Vessel mapping hemo access	0.25	5.21	4.61	NA	NA	0.25	XXX
G0365	TC	A	Vessel mapping hemo access	0.00	5.15	4.53	NA	NA	0.23	XXX
G0365	26	A	Vessel mapping hemo access	0.25	0.06	0.08	0.06	0.08	0.02	XXX
G0366		A	EKG for initial prevent exam	0.17	0.35	0.42	NA	NA	0.03	XXX
G0367		A	EKG tracing for initial prev	0.00	0.28	0.36	NA	NA	0.02	XXX
G0368		A	EKG interpret & report preve	0.17	0.07	0.06	0.07	0.06	0.01	XXX
G0372		A	MD service required for PMD	0.17	0.04	0.22	0.04	0.05	0.01	XXX
G0377		X	Administra Part D vaccine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0378		X	Hospital observation per hr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0379		X	Direct admit hospital observ	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0389		A	Ultrasound exam AAA screen	0.58	2.41	2.41	NA	NA	0.11	XXX
G0389	TC	A	Ultrasound exam AAA screen	0.00	2.21	2.21	NA	NA	0.08	XXX
G0389	26	A	Ultrasound exam AAA screen	0.58	0.20	0.20	0.20	0.20	0.03	XXX
G0392		A	AV fistula or graft arterial	9.48	48.63	48.63	NA	NA	0.62	000
G0393		A	AV fistula or graft venous	6.03	37.11	37.11	NA	NA	0.34	000
G0394		X	Blood occult test,colorectal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0396		A	Alcohol/subs interv 15-30mn	0.65	0.19	0.19	0.15	0.15	0.01	XXX
G0397		A	Alcohol/subs interv >30 min	1.30	0.34	0.34	0.29	0.29	0.03	XXX
G3001		X	Admin + supply, tositumomab	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9001		X	MCCD, initial rate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9002		X	MCCD,maintenance rate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9003		X	MCCD, risk adj hi, initial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9004		X	MCCD, risk adj lo, initial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9005		X	MCCD, risk adj, maintenance	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9006		X	MCCD, Home monitoring	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9007		X	MCCD, sch team conf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9008		X	Mccd,phys coor-care ovrsght	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9009		X	MCCD, risk adj, level 3	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9010		X	MCCD, risk adj, level 4	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9011		X	MCCD, risk adj, level 5	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9012		X	Other Specified Case Mgmt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9013		N	ESRD demo bundle level I	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9014		N	ESRD demo bundle-level II	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9016		N	Demo-smoking cessation coun	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9017		X	Amantadine HCL 100mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9018		X	Zanamivir,inhalation pwd 10m	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9019		X	Oseltamivir phosphate 75mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9020		X	Rimantadine HCL 100mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9033		X	Amantadine HCL oral brand	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9034		X	Zanamivir, inh pwdr, brand	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9035		X	Oseltamivir phosp, brand	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9036		X	Rimantadine HCL, brand	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9041		A	Low vision rehab occupationa	0.44	0.10	0.20	0.10	0.20	0.01	XXX
G9042		A	Low vision rehab orient/mobi	0.10	0.02	0.16	0.02	0.16	0.01	XXX
G9043		A	Low vision lowvision therapi	0.10	0.02	0.16	0.02	0.16	0.01	XXX
G9044		A	Low vision rehabilitate teache	0.10	0.02	0.13	0.02	0.13	0.01	XXX
G9140		X	Frontier extended stay demo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0064		A	Visit for drug monitoring	0.37	0.91	0.62	0.07	0.09	0.01	XXX
P3001		A	Screening pap smear by phys	0.42	0.38	0.26	0.38	0.26	0.02	XXX
Q0035		A	Cardiokymography	0.17	0.30	0.37	NA	NA	0.03	XXX
Q0035	TC	A	Cardiokymography	0.00	0.25	0.32	NA	NA	0.02	XXX
Q0035	26	A	Cardiokymography	0.17	0.05	0.05	0.05	0.05	0.01	XXX
Q0091		A	Obtaining screen pap smear	0.37	0.75	0.71	0.10	0.12	0.02	XXX
Q0092		A	Set up port xray equipment	0.00	0.47	0.40	0.47	0.40	0.01	XXX
Q3001		C	Brachytherapy Radioelements	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3014		X	Telehealth facility fee	0.00	0.00	0.00	0.00	0.00	0.00	XXX
R0070		C	Transport portable x-ray	0.00	0.00	0.00	0.00	0.00	0.00	XXX
R0075		C	Transport port x-ray multipl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
R0076		B	Transport portable EKG	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM B.—RELATIVE VALUE UNITS AND RELATED INFORMATION USED IN DETERMINING MEDICARE PAYMENTS FOR 2008—Continued

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
V5299	R	Hearing service	0.00	0.00	0.00	0.00	0.00	0.00	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM C.—CODES WITH INTERIM RVUS

CPT 1/ HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented fa- cility PE RVUs ²	Year 2008 transi- tional fac- ility PE RVUs ²	Mal- practice RVUs ²	Global
20555	A	Place ndl musc/tis for rt	6.00	NA	NA	2.18	2.18	0.43	000
20660	A	Apply, rem fixation device	4.00	2.27	2.27	1.55	1.55	0.59	000
20690	A	Apply bone fixation device	8.65	NA	NA	3.71	3.71	0.59	090
20692	A	Apply bone fixation device	16.00	NA	NA	6.78	6.78	1.05	090
20985	A	Cptr-asst dir ms px	2.50	0.99	0.99	0.99	0.99	0.48	ZZZ
20986	C	Cptr-asst dir ms px io img	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
20987	C	Cptr-asst dir ms px pre img	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
21073	A	Mnpj of tmj w/anesth	3.33	5.50	5.50	2.31	2.31	0.43	090
22206	A	Cut spine 3 col, thor	37.00	NA	NA	17.71	17.71	6.23	090
22207	A	Cut spine 3 col, lumb	36.50	NA	NA	17.59	17.59	6.07	090
22208	A	Cut spine 3 col, addl seg	9.66	3.72	3.72	3.72	3.72	2.07	ZZZ
23515	A	Treat clavicle fracture	9.53	NA	NA	6.77	6.77	1.28	090
23585	A	Treat scapula fracture	14.07	NA	NA	8.07	8.07	1.54	090
23615	A	Treat humerus fracture	12.12	NA	NA	8.44	8.44	1.62	090
23616	A	Treat humerus fracture	18.19	NA	NA	12.29	12.29	3.70	090
23630	A	Treat humerus fracture	10.39	NA	NA	7.00	7.00	1.27	090
23670	A	Treat dislocation/fracture	12.12	NA	NA	7.37	7.37	1.36	090
23680	A	Treat dislocation/fracture	12.99	NA	NA	8.16	8.16	1.76	090
24357	A	Repair elbow, perc	5.32	NA	NA	5.15	5.15	0.87	090
24358	A	Repair elbow w/deb, open	6.54	NA	NA	5.73	5.73	1.07	090
24359	A	Repair elbow deb/attch open	8.86	NA	NA	6.19	6.19	1.41	090
24545	A	Treat humerus fracture	12.99	NA	NA	8.36	8.36	1.83	090
24546	A	Treat humerus fracture	14.73	NA	NA	10.20	10.20	2.74	090
24575	A	Treat humerus fracture	9.53	NA	NA	7.68	7.68	1.87	090
24579	A	Treat humerus fracture	11.26	NA	NA	8.28	8.28	2.03	090
24635	A	Treat elbow fracture	8.64	NA	NA	10.29	10.29	2.29	090
24685	A	Treat ulnar fracture	8.21	NA	NA	7.01	7.01	1.52	090
25515	A	Treat fracture of radius	8.64	NA	NA	6.96	6.96	1.59	090
25525	A	Treat fracture of radius	10.37	NA	NA	8.70	8.70	2.13	090
25526	A	Treat fracture of radius	12.96	NA	NA	11.09	11.09	2.20	090
25545	A	Treat fracture of ulna	7.78	NA	NA	6.94	6.94	1.53	090
25574	A	Treat fracture radius & ulna	8.64	NA	NA	6.87	6.87	1.21	090
25575	A	Treat fracture radius/ulna	12.10	NA	NA	8.93	8.93	1.82	090
25628	A	Treat wrist bone fracture	9.51	NA	NA	7.33	7.33	1.37	090
26615	A	Treat metacarpal fracture	6.91	NA	NA	5.66	5.66	0.86	090
26650	A	Treat thumb fracture	5.19	NA	NA	5.78	5.78	0.94	090
26665	A	Treat thumb fracture	7.78	NA	NA	6.46	6.46	0.90	090
26685	A	Treat hand dislocation	6.91	NA	NA	6.05	6.05	1.09	090
26715	A	Treat knuckle dislocation	6.87	NA	NA	5.75	5.75	0.91	090
26735	A	Treat finger fracture, each	7.26	NA	NA	5.84	5.84	0.95	090
26746	A	Treat finger fracture, each	9.59	NA	NA	6.38	6.38	0.91	090
26765	A	Treat finger fracture, each	5.70	NA	NA	4.93	4.93	0.66	090
26785	A	Treat finger dislocation	6.44	NA	NA	5.15	5.15	0.68	090
27248	A	Treat thigh fracture	10.64	NA	NA	7.29	7.29	1.82	090
27267	A	Cltx thigh fx	5.38	NA	NA	4.39	4.39	0.89	090
27268	A	Cltx thigh fx w/mnpj	7.00	NA	NA	5.02	5.02	1.16	090
27269	A	Optx thigh fx	18.75	NA	NA	9.88	9.88	2.93	090
27416	A	Osteochondral knee autograft	14.00	NA	NA	8.38	8.38	2.32	090
27511	A	Treatment of thigh fracture	14.97	NA	NA	9.65	9.65	2.38	090
27513	A	Treatment of thigh fracture	19.11	NA	NA	11.81	11.81	3.13	090
27514	A	Treatment of thigh fracture	14.46	NA	NA	10.61	10.61	3.01	090
27519	A	Treat thigh fx growth plate	13.11	NA	NA	9.48	9.48	2.56	090
27535	A	Treat knee fracture	13.27	NA	NA	8.77	8.77	2.01	090
27540	A	Treat knee fracture	11.16	NA	NA	8.44	8.44	2.28	090
27556	A	Treat knee dislocation	12.86	NA	NA	9.45	9.45	2.51	090
27557	A	Treat knee dislocation	15.76	NA	NA	10.78	10.78	2.98	090
27558	A	Treat knee dislocation	18.25	NA	NA	11.16	11.16	3.09	090
27726	A	Repair fibula nonunion	14.20	NA	NA	7.67	7.67	1.43	090
27766	A	Optx medial ankle fx	7.73	NA	NA	6.67	6.67	1.44	090
27767	A	Cltx post ankle fx	2.50	3.62	3.62	3.65	3.65	0.30	090

ADDENDUM C.—CODES WITH INTERIM RVUS—Continued

CPT ¹ / HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facility PE RVUs ²	Mal- practice RVUs ²	Global
27768		A	Cltx post ankle fx w/mnpj	5.00	NA	NA	4.29	4.29	0.79	090
27769		A	Optx post ankle fx	10.00	NA	NA	6.07	6.07	1.45	090
27784		A	Treatment of fibula fracture	9.51	NA	NA	6.65	6.65	1.23	090
27792		A	Treatment of ankle fracture	9.55	NA	NA	6.88	6.88	1.32	090
27814		A	Treatment of ankle fracture	10.46	NA	NA	7.89	7.89	1.86	090
27822		A	Treatment of ankle fracture	11.03	NA	NA	9.42	9.42	1.92	090
27823		A	Treatment of ankle fracture	12.98	NA	NA	10.19	10.19	2.26	090
27826		A	Treat lower leg fracture	10.92	NA	NA	8.51	8.51	1.47	090
27827		A	Treat lower leg fracture	14.56	NA	NA	11.47	11.47	2.44	090
27828		A	Treat lower leg fracture	18.20	NA	NA	12.74	12.74	2.82	090
27829		A	Treat lower leg joint	8.64	NA	NA	6.87	6.87	0.95	090
27832		A	Treat lower leg dislocation	10.01	NA	NA	6.50	6.50	1.03	090
28415		A	Treat heel fracture	15.96	NA	NA	11.75	11.75	2.67	090
28420		A	Treat/graft heel fracture	17.29	NA	NA	11.59	11.59	2.81	090
28445		A	Treat ankle fracture	15.53	NA	NA	10.25	10.25	2.59	090
28446		A	Osteochondral talus autograft	17.50	NA	NA	10.34	10.34	2.45	090
28465		A	Treat midfoot fracture, each	8.64	NA	NA	6.18	6.18	1.10	090
28485		A	Treat metatarsal fracture	7.28	NA	NA	5.50	5.50	0.83	090
28505		A	Treat big toe fracture	7.28	8.27	8.27	4.36	4.36	0.56	090
28525		A	Treat toe fracture	5.46	7.81	7.81	3.87	3.87	0.49	090
28555		A	Repair foot dislocation	9.49	10.35	10.35	5.98	5.98	1.04	090
28585		A	Repair foot dislocation	10.92	9.44	9.44	6.40	6.40	1.25	090
28615		A	Repair foot dislocation	10.46	NA	NA	8.08	8.08	1.30	090
28645		A	Repair toe dislocation	7.28	6.64	6.64	3.94	3.94	0.57	090
28675		A	Repair of toe dislocation	5.46	7.68	7.68	3.90	3.90	0.45	090
29828		A	Arthroscopy biceps tenodesis	13.00	NA	NA	8.17	8.17	2.17	090
29904		A	Subtalar arthro w/fb rmvl	8.50	NA	NA	5.89	5.89	1.25	090
29905		A	Subtalar arthro w/exc	9.00	NA	NA	6.51	6.51	1.32	090
29906		A	Subtalar arthro w/deb	9.47	NA	NA	6.87	6.87	1.39	090
29907		A	Subtalar arthro w/fusion	12.00	NA	NA	7.86	7.86	1.90	090
31500		A	Insert emergency airway	2.33	NA	NA	0.48	0.48	0.17	000
33257		A	Ablate atria, lmted, add-on	9.63	NA	NA	5.46	5.46	0.89	ZZZ
33258		A	Ablate atria, x10sv, add-on	11.00	NA	NA	5.98	5.98	1.09	ZZZ
33259		A	Ablate atria w/bypass add-on	14.14	NA	NA	7.79	7.79	1.78	ZZZ
33864		A	Ascending aortic graft	60.00	NA	NA	20.09	20.09	6.73	090
34806		A	Aneurysm press sensor add-on	2.06	0.51	0.51	0.51	0.51	0.30	ZZZ
35523		A	Artery bypass graft	24.00	NA	NA	9.20	9.20	2.14	090
36591		T	Draw blood off venous device	0.00	0.54	0.54	NA	NA	0.01	XXX
36592		T	Collect blood from picc	0.00	0.67	0.67	NA	NA	0.01	XXX
36593		A	Declot vascular device	0.00	0.60	0.60	NA	NA	0.37	XXX
36620		A	Insertion catheter, artery	1.15	NA	NA	0.19	0.19	0.07	000
41019		A	Place needles h&n for rt	8.84	NA	NA	3.28	3.28	0.59	000
43760		A	Change gastrostomy tube	0.90	4.03	4.03	0.39	0.39	0.09	000
49203		A	Exc abd tum 5 cm or less	20.00	NA	NA	7.65	7.65	2.27	090
49204		A	Exc abd tum over 5 cm	26.00	NA	NA	9.26	9.26	2.94	090
49205		A	Exc abd tum over 10 cm	30.00	NA	NA	10.34	10.34	3.40	090
49440		A	Place gastrostomy tube perc	4.18	25.03	25.03	1.81	1.81	0.49	010
49441		A	Place duod/jej tube perc	4.77	30.10	30.10	2.00	2.00	0.29	010
49442		A	Place cecostomy tube perc	4.00	24.43	24.43	1.63	1.63	0.24	010
49446		A	Change g-tube to g-j perc	3.31	25.74	25.74	1.15	1.15	0.18	000
49450		A	Replace g/c tube perc	1.36	18.94	18.94	0.44	0.44	0.08	000
49451		A	Replace duod/jej tube perc	1.84	19.69	19.69	0.64	0.64	0.11	000
49452		A	Replace g-j tube perc	2.86	23.48	23.48	1.00	1.00	0.18	000
49460		A	Fix g/colon tube w/device	0.96	20.56	20.56	0.31	0.31	0.05	000
49465		A	Fluoro exam of g/colon tube	0.62	3.88	3.88	0.22	0.22	0.03	000
50385		A	Change stent via transureth	4.44	30.61	30.61	2.05	2.05	0.27	000
50386		A	Remove stent via transureth	3.30	19.36	19.36	1.60	1.60	0.20	000
50593		A	Perc cryo ablate renal tum	9.08	114.48	114.48	3.44	3.44	0.58	010
51797	26	A	Intraabdominal pressure test	0.80	0.41	0.41	0.41	0.41	0.12	ZZZ
52649		A	2Prostate laser enucleation	17.16	NA	NA	9.31	9.31	1.11	090
55920		A	Place needles pelvic for rt	8.31	NA	NA	3.13	3.13	0.58	000
57284		A	Repair paravag defect, open	14.25	NA	NA	6.56	6.56	1.41	090
57285		A	Repair paravag defect, vag	11.52	NA	NA	5.16	5.16	0.63	090
57423		A	Repair paravag defect, lap	16.00	NA	NA	6.51	6.51	1.65	090
58570		A	Tlh, uterus 250 g or less	15.75	NA	NA	6.45	6.45	1.82	090
58571		A	Tlh w/t/o 250 g or less	17.56	NA	NA	6.94	6.94	1.81	090
58572		A	Tlh, uterus over 250 g	19.96	NA	NA	7.59	7.59	2.31	090
58573		A	Tlh w/t/o uterus over 250 g	22.98	NA	NA	8.41	8.41	2.28	090
67041		A	Vit for macular pucker	19.00	NA	NA	10.36	10.36	0.86	090
67042		A	Vit for macular hole	22.13	NA	NA	11.48	11.48	1.00	090
67043		A	Vit for membrane dissect	22.94	NA	NA	12.34	12.34	1.04	090
67113		A	Repair retinal detach, cplx	22.49	NA	NA	12.75	12.75	1.13	090
67229		A	Tr retinal les preterm inf	16.00	NA	NA	9.51	9.51	0.71	090
68816		A	Probe nl duct w/balloon	3.00	12.73	12.73	2.51	2.51	0.16	010
75557	26	A	Cardiac mri for morph	2.35	0.94	0.94	0.94	0.94	0.10	XXX
75558	26	N	Cardiac mri flow/velocity	2.60	0.60	0.60	0.60	0.60	0.11	XXX
75559	26	A	Cardiac mri w/stress img	2.95	1.27	1.27	1.27	1.27	0.10	XXX
75560	26	N	Cardiac mri flow/vel/stress	3.00	0.69	0.69	0.69	0.69	0.11	XXX

ADDENDUM C.—CODES WITH INTERIM RVUS—Continued

CPT ¹ / HCPCS	Mod	Status	Description	Physician work RVUs ²	Fully imple- mented non-facility PE RVUs ²	Year 2008 transi- tional non- facility PE RVUs ²	Fully imple- mented facility PE RVUs ²	Year 2008 transi- tional facility PE RVUs ²	Mal- practice RVUs ²	Global
75561	26	A	Cardiac mri for morph w/dye	2.60	1.03	1.03	1.03	1.03	0.11	XXX
75562	26	N	Card mri flow/vel w/dye	2.86	0.66	0.66	0.66	0.66	0.11	XXX
75563	26	A	Card mri w/stress img & dye	3.00	1.38	1.38	1.38	1.38	0.11	XXX
75564	26	N	Ht mri w/flo/vel/strs & dye	3.35	0.77	0.77	0.77	0.77	0.13	XXX
78811	26	A	Pet image, ltd area	1.54	0.53	0.53	0.53	0.53	0.11	XXX
78812	26	A	Pet image, skull-thigh	1.93	0.66	0.66	0.66	0.66	0.11	XXX
78813	26	A	Pet image, full body	2.00	0.68	0.68	0.68	0.68	0.11	XXX
78814	26	A	Pet image w/ct, lmtd	2.20	0.75	0.75	0.75	0.75	0.11	XXX
78815	26	A	Pet image w/ct, skull-thigh	2.44	0.84	0.84	0.84	0.84	0.11	XXX
78816	26	A	Pet image w/ct, full body	2.50	0.85	0.85	0.85	0.85	0.11	XXX
86486		A	Skin test, nos antigen	0.00	0.13	0.13	NA	NA	0.02	XXX
88380	26	A	Microdissection, laser	1.56	0.43	0.43	0.43	0.43	0.07	XXX
88381	26	A	Microdissection, manual	1.18	0.32	0.32	0.32	0.32	0.06	XXX
90769		A	Sc ther infusion, up to 1 hr	0.21	3.92	3.92	NA	NA	0.06	XXX
90770		A	Sc ther infusion, addl hr	0.18	0.22	0.22	NA	NA	0.04	ZZZ
90771		A	Sc ther infusion, reset pump	0.00	1.86	1.86	NA	NA	0.01	ZZZ
93503		C	Insert/place heart catheter	0.00	NA	NA	NA	NA	0.00	000
93982		R	Aneurysm pressure sens study	0.30	0.80	0.80	NA	NA	0.01	XXX
95004		A	Percut allergy skin tests	0.01	0.13	0.13	NA	NA	0.01	XXX
95024		A	Id allergy test, drug/bug	0.01	0.16	0.16	NA	NA	0.01	XXX
95027		A	Id allergy titrate-airborne	0.01	0.12	0.12	NA	NA	0.01	XXX
95980		A	lo anal gast n-stim init	0.80	NA	NA	0.25	0.25	0.07	XXX
95981		A	lo anal gast n-stim subsq	0.30	0.44	0.44	0.12	0.12	0.02	XXX
95982		A	lo ga n-stim subsq w/reprog	0.65	0.47	0.47	0.18	0.18	0.05	XXX
96125		A	Cognitive test by hc pro	1.70	0.76	0.76	0.37	0.37	0.16	XXX
98966		N	Hc pro phone call 5-10 min	0.25	0.09	0.09	0.06	0.06	0.01	XXX
98967		N	Hc pro phone call 11-20 min	0.50	0.14	0.14	0.11	0.11	0.02	XXX
98968		N	Hc pro phone call 21-30 min	0.75	0.20	0.20	0.17	0.17	0.03	XXX
98969		N	Online service by hc pro	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99174		N	Ocular photoscreening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99366		B	Team conf w/pat by hc pro	0.82	0.20	0.20	0.19	0.19	0.06	XXX
99367		B	Team conf w/o pat by phys	1.10	0.25	0.25	0.25	0.25	0.05	XXX
99368		B	Team conf w/o pat by hc pro	0.72	0.16	0.16	0.16	0.16	0.03	XXX
99406		A	Behav chng smoking 3-10 min	0.24	0.10	0.10	0.08	0.08	0.01	XXX
99407		A	Behav chng smoking < 10 min	0.50	0.18	0.18	0.15	0.15	0.01	XXX
99408		N	Audit/dast, 15-30 min	0.65	0.19	0.19	0.15	0.15	0.01	XXX
99409		N	Audit/dast, over 30 min	1.30	0.34	0.34	0.30	0.30	0.03	XXX
99441		N	Phone e/m by phys 5-10 min	0.25	0.09	0.09	0.06	0.06	0.02	XXX
99442		N	Phone e/m by phys 11-20 min	0.50	0.14	0.14	0.11	0.11	0.02	XXX
99443		N	Phone e/m by phys 21-30 min	0.75	0.20	0.20	0.17	0.17	0.03	XXX
99444		N	Online e/m by phys	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99477		A	Init day hosp neonate care	7.00	1.98	1.98	1.98	1.98	0.32	XXX
G0396		A	Alcohol/subs interv 15-30 min	0.65	0.19	0.19	0.15	0.15	0.01	XXX
G0397		A	Alcohol/subs interv >30 min	1.30	0.34	0.34	0.29	0.29	0.03	XXX

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.

² If values are reflected for codes not payable by Medicare, please note that these values have been established as a courtesy to the general public and are not used for Medicare payment.

ADDENDUM D.—2008 GEOGRAPHIC ADJUSTMENT FACTORS (GAFs)

Carrier	Locality	Locality name	GAF
31140	06	San Mateo, CA	1.232
31140	05	San Francisco, CA	1.229
31140	09	Santa Clara, CA	1.207
00803	01	Manhattan, NY	1.174
00803	02	NYC Suburbs/Long I., NY	1.171
31140	07	Oakland/Berkley, CA	1.154
31143	01	Metropolitan Boston	1.143
14330	04	Queens, NY	1.137
31140	03	Marin/Napa/Solano, CA	1.133
00805	01	Northern NJ	1.130
00903	01	DC + MD/VA Suburbs	1.127
31146	26	Anaheim/Santa Ana, CA	1.124
31146	17	Ventura, CA	1.102
31146	18	Los Angeles, CA	1.100
00591	00	Connecticut	1.096
00952	16	Chicago, IL	1.093
00590	04	Miami, FL	1.092
00953	01	Detroit, MI	1.091
00805	99	Rest of New Jersey	1.078
00952	15	Suburban Chicago, IL	1.074
00865	01	Metropolitan Philadelphia, PA	1.072
00836	02	Seattle (King Cnty), WA	1.046

ADDENDUM D.—2008 GEOGRAPHIC ADJUSTMENT FACTORS (GAFs)—Continued

Carrier	Locality	Locality name	GAF
00831	01	Alaska	1.045
00833	01	Hawaii/Guam	1.044
31143	99	Rest of Massachusetts	1.042
00803	03	Poughkpsie/N NYC Suburbs, NY	1.040
00901	01	Baltimore/Surr. Cntys, MD	1.037
00590	03	Fort Lauderdale, FL	1.033
00524	01	Rhode Island	1.030
00511	01	Atlanta, GA	1.024
00900	11	Dallas, TX	1.022
00900	18	Houston, TX	1.021
00834	00	Nevada	1.019
31140	99	Rest of California *	1.015
31146	99	Rest of California *	1.015
00902	01	Delaware	1.012
00900	31	Austin, TX	1.001
00835	01	Portland, OR	0.997
00900	09	Brazoria, TX	0.995
00528	01	New Orleans, LA	0.993
31144	40	New Hampshire	0.993
00952	15	East St. Louis, IL	0.992
00900	28	Fort Worth, TX	0.990
00973	50	Virgin Islands	0.989
00900	15	Galveston, TX	0.985
00824	01	Colorado	0.983
00901	99	Rest of Maryland	0.981
31142	03	Southern Maine	0.981
03102	00	Arizona	0.980
00523	01	Metropolitan Kansas City, MO	0.980
00590	99	Rest of Florida	0.977
00953	99	Rest of Michigan	0.976
00836	99	Rest of Washington	0.973
00740	02	Metropolitan St. Louis, MO	0.971
00883	00	Ohio	0.969
00954	00	Minnesota	0.967
00865	99	Rest of Pennsylvania	0.956
31145	50	Vermont	0.953
00904	00	Virginia	0.950
03502	09	Utah	0.948
00900	20	Beaumont, TX	0.946
00801	99	Rest of New York	0.946
00951	00	Wisconsin	0.942
00952	99	Rest of Illinois	0.940
05535	00	North Carolina	0.937
00521	05	New Mexico	0.936
00630	00	Indiana	0.935
00511	99	Rest of Georgia	0.932
00900	99	Rest of Texas	0.931
00835	99	Rest of Oregon	0.930
00884	16	West Virginia	0.926
00528	99	Rest of Louisiana	0.923
05440	35	Tennessee	0.923
00880	01	South Carolina	0.921
00650	00	Kansas *	0.917
00740	04	Kansas *	0.917
31142	99	Rest of Maine	0.915
00660	00	Kentucky	0.912
00510	00	Alabama	0.910
05130	00	Idaho	0.909
03602	21	Wyoming	0.907
00826	00	Iowa	0.906
00512	00	Mississippi	0.903
00655	00	Nebraska	0.902
03202	01	Montana	0.898
00522	00	Oklahoma	0.898
00740	99	Rest of Missouri *	0.890
03402	02	South Dakota	0.890
00523	99	Rest of Missouri *	0.889
03302	01	North Dakota	0.888
00520	13	Arkansas	0.888
00973	20	Puerto Rico	0.789

ADDENDUM E.—2008*** GEOGRAPHIC PRACTICE COST INDICES BY STATE AND MEDICARE LOCALITY

Carrier	Locality	Locality name	2008 budget neutral GPCIs		
			Work	PE	MP
00510	00	Alabama	0.982	0.850	0.617
00831	01	Alaska	1.018	1.097	0.828
03102	00	Arizona	0.987	0.975	0.936
00520	13	Arkansas	0.961	0.839	0.439
31146	26	Anaheim/Santa Ana, CA	1.034	1.254	0.875
31146	18	Los Angeles, CA	1.041	1.192	0.871
31140	03	Marin/Napa/Solano, CA	1.035	1.304	0.535
31140	07	Oakland/Berkley, CA	1.054	1.330	0.532
31140	05	San Francisco, CA	1.060	1.494	0.526
31140	06	San Mateo, CA	1.073	1.486	0.511
31140	09	Santa Clara, CA	1.083	1.419	0.485
31146	17	Ventura, CA	1.028	1.223	0.749
31140	99	Rest of California *	1.008	1.056	0.634
31146	99	Rest of California *	.008	1.056	0.634
00824	01	Colorado	0.986	1.003	0.715
00591	00	Connecticut	1.038	1.179	0.934
00903	01	DC + MD/VA Suburbs	1.048	1.235	0.972
00902	01	Delaware	1.012	1.033	0.777
00590	03	Fort Lauderdale, FL	0.988	1.004	1.965
00590	04	Miami, FL	1.001	1.058	2.705
00590	99	Rest of Florida	0.973	0.937	1.490
00511	01	Atlanta, GA	1.010	1.052	0.893
00511	99	Rest of Georgia	0.979	0.879	0.889
00833	01	Hawaii/Guam	0.990	1.137	0.726
05130	00	Idaho	0.967	0.876	0.499
00952	16	Chicago, IL	1.025	1.104	1.889
00952	12	East St. Louis, IL	0.988	0.929	1.758
00952	15	Suburban Chicago, IL	1.018	1.092	1.628
00952	99	Rest of Illinois	0.974	0.877	1.197
00630	00	Indiana	0.985	0.913	0.515
00826	00	Iowa	0.966	0.870	0.506
00650	00	Kansas *	0.968	0.881	0.633
00740	04	Kansas *	0.968	0.881	0.633
00660	00	Kentucky	0.969	0.858	0.755
00528	01	New Orleans, LA	0.986	0.995	1.066
00528	99	Rest of Louisiana	0.970	0.863	0.966
31142	03	Southern Maine	0.980	1.019	0.558
31142	99	Rest of Maine	0.962	0.890	0.558
00901	01	Baltimore/Surr. Cntys, MD	1.013	1.068	1.010
00901	99	Rest of Maryland	0.993	0.981	0.812
31143	01	Metropolitan Boston	1.030	1.311	0.787
31143	99	Rest of Massachusetts	1.008	1.105	0.787
00953	01	Detroit, MI	1.037	1.048	2.300
00953	99	Rest of Michigan	0.998	0.922	1.287
00954	00	Minnesota	0.991	0.994	0.324
00512	00	Mississippi	0.959	0.848	0.760
00523	01	Metropolitan Kansas City, MO	0.989	0.961	1.061
00740	02	Metropolitan St. Louis, MO	0.992	0.943	1.001
00523	99	Rest of Missouri *	0.950	0.812	0.938
00740	99	Rest of Missouri *	0.951	0.812	0.938
03202	01	Montana	0.950	0.846	0.781
00655	00	Nebraska	0.959	0.883	0.345
00834	00	Nevada	1.003	1.035	1.067
31144	40	New Hampshire	0.981	1.034	0.693
00805	01	Northern NJ	1.058	1.225	1.038
00805	99	Rest of New Jersey	1.043	1.124	1.038
00521	05	New Mexico	0.972	0.889	0.989
00803	01	Manhattan, NY	1.065	1.299	1.243
00803	02	NYC Suburbs/Long I., NY	1.052	1.286	1.494
00803	03	Poughkpsie/N NYC Suburbs, NY	1.015	1.076	0.984
14330	04	Queens, NY	1.032	1.235	1.450
00801	99	Rest of New York	0.997	0.920	0.544
05535	00	North Carolina	0.971	0.923	0.632
03302	01	North Dakota	0.946	0.853	0.489
00883	00	Ohio	0.992	0.930	1.097
00522	00	Oklahoma	0.964	0.853	0.503
00835	01	Portland, OR	1.003	1.037	0.453
00835	99	Rest of Oregon	0.968	0.927	0.453
00865	01	Metropolitan Philadelphia, PA	1.017	1.101	1.492

ADDENDUM E.—2008 *** GEOGRAPHIC PRACTICE COST INDICES BY STATE AND MEDICARE LOCALITY—Continued

Carrier	Locality	Locality name	2008 budget neutral GPCIs		
			Work	PE	MP
00865	99	Rest of Pennsylvania	0.992	0.914	0.938
00973	20	Puerto Rico	0.905	0.697	0.253
00524	01	Rhode Island	1.029	1.039	0.946
00880	01	South Carolina	0.975	0.900	0.418
03402	02	South Dakota	0.942	0.871	0.390
05440	35	Tennessee	0.977	0.885	0.614
00900	31	Austin, TX	0.991	1.015	0.970
00900	20	Beaumont, TX	0.983	0.869	1.312
00900	09	Brazoria, TX	1.020	0.942	1.250
00900	11	Dallas, TX	1.010	1.032	1.078
00900	28	Fort Worth, TX	0.998	0.972	1.078
00900	15	Galveston, TX	0.990	0.956	1.250
00900	18	Houston, TX	1.017	1.000	1.311
00900	99	Rest of Texas	0.968	0.873	1.092
03502	09	Utah	0.977	0.922	0.841
31145	50	Vermont	0.968	0.976	0.497
00904	00	Virginia	0.981	0.942	0.613
00973	50	Virgin Islands	0.982	0.996	0.998
00836	02	Seattle (King Cnty), WA	1.015	1.109	0.755
00836	99	Rest of Washington	0.987	0.977	0.749
00884	16	West Virginia	0.973	0.824	1.437
00951	00	Wisconsin	0.987	0.920	0.592
03602	21	Wyoming	0.956	0.849	0.905

* Indicates multiple carriers.
 ** Transition value for work GPCI does not reflect the 2007 1.000 floor.
 *** 2008 GPCIs are the first year of the update transition.

ADDENDUM F.—CPT/HCPCS IMAGING CODES DEFINED BY DRA 5102(B)

HCPCS/CPT*	Short descriptor
31620	Endobronchial us add-on.
37250	Iv us first vessel add-on.
37251	Iv us each add vessel add-on.
51798	Us urine capacity measure.
70010	Contrast x-ray of brain.
70015	Contrast x-ray of brain.
70030	X-ray eye for foreign body.
70100	X-ray exam of jaw.
70110	X-ray exam of jaw.
70120	X-ray exam of mastoids.
70130	X-ray exam of mastoids.
70134	X-ray exam of middle ear.
70140	X-ray exam of facial bones.
70150	X-ray exam of facial bones.
70160	X-ray exam of nasal bones.
70170	X-ray exam of tear duct.
70190	X-ray exam of eye sockets.
70200	X-ray exam of eye sockets.
70210	X-ray exam of sinuses.
70220	X-ray exam of sinuses.
70240	X-ray exam, pituitary saddle.
70250	X-ray exam of skull.
70260	X-ray exam of skull.
70300	X-ray exam of teeth.
70310	X-ray exam of teeth.
70320	Full mouth x-ray of teeth.
70328	X-ray exam of jaw joint.
70330	X-ray exam of jaw joints.
70332	X-ray exam of jaw joint.
70336	Magnetic image, jaw joint.
70350	X-ray head for orthodontia.
70355	Panoramic x-ray of jaws.
70360	X-ray exam of neck.
70370	Throat x-ray & fluoroscopy.
70371	Speech evaluation, complex.
70373	Contrast x-ray of larynx.

ADDENDUM F.—CPT/HCPCS IMAGING CODES DEFINED BY DRA 5102(B)—Continued

HCPCS/CPT*	Short descriptor
70380	X-ray exam of salivary gland.
70390	X-ray exam of salivary duct.
70450	Ct head/brain w/o dye.
70460	Ct head/brain w/dye.
70470	Ct head/brain w/o & w/dye.
70480	Ct orbit/ear/fossa w/o dye.
70481	Ct orbit/ear/fossa w/dye.
70482	Ct orbit/ear/fossa w/o & w/dye.
70486	Ct maxillofacial w/o dye.
70487	Ct maxillofacial w/dye.
70488	Ct maxillofacial w/o & w/dye.
70490	Ct soft tissue neck w/o dye.
70491	Ct soft tissue neck w/dye.
70492	Ct sft tsue nck w/o & w/dye.
70496	Ct angiography, head.
70498	Ct angiography, neck.
70540	Mri orbit/face/neck w/o dye.
70542	Mri orbit/face/neck w/dye.
70543	Mri orbit/fac/nck w/o & w/dye.
70544	Mr angiography head w/o dye.
70545	Mr angiography head w/dye.
70546	Mr angiograph head w/o & w/dye.
70547	Mr angiography neck w/o dye.
70548	Mr angiography neck w/dye.
70549	Mr angiograph neck w/o & w/dye.
70551	Mri brain w/o dye.
70552	Mri brain w/dye.
70553	Mri brain w/o & w/dye.
70557	Mri brain w/o dye.
70558	Mri brain w/dye.
70559	Mri brain w/o & w/dye.
71010	Chest x-ray.

ADDENDUM F.—CPT/HCPCS IMAGING CODES DEFINED BY DRA 5102(B)—Continued

HCPCS/CPT*	Short descriptor
71015	Chest x-ray.
71020	Chest x-ray.
71021	Chest x-ray.
71022	Chest x-ray.
71023	Chest x-ray and fluoroscopy.
71030	Chest x-ray.
71034	Chest x-ray and fluoroscopy.
71035	Chest x-ray.
71040	Contrast x-ray of bronchi.
71060	Contrast x-ray of bronchi.
71090	X-ray & pacemaker insertion.
71100	X-ray exam of ribs.
71101	X-ray exam of ribs/chest.
71110	X-ray exam of ribs.
71111	X-ray exam of ribs/chest.
71120	X-ray exam of breastbone.
71130	X-ray exam of breastbone.
71250	Ct thorax w/o dye.
71260	Ct thorax w/dye.
71270	Ct thorax w/o & w/dye.
71275	Ct angiography, chest.
71550	Mri chest w/o dye.
71551	Mri chest w/dye.
71552	Mri chest w/o & w/dye.
71555	Mri angio chest w/ or w/o dye.
72010	X-ray exam of spine.
72020	X-ray exam of spine.
72040	X-ray exam of neck spine.
72050	X-ray exam of neck spine.
72052	X-ray exam of neck spine.
72069	X-ray exam of trunk spine.
72070	X-ray exam of thoracic spine.
72072	X-ray exam of thoracic spine.
72074	X-ray exam of thoracic spine.

ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
ContinuedADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
ContinuedADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued

HCPCS/ CPT*	Short descriptor	HCPCS/ CPT*	Short descriptor	HCPCS/ CPT*	Short descriptor
72080	X-ray exam of trunk spine.	73206	Ct angio upr extrm w/o & w/dye.	74260	X-ray exam of small bowel.
72090	X-ray exam of trunk spine.	73218	Mri upper extremity w/o dye.	74270	Contrast x-ray exam of colon.
72100	X-ray exam of lower spine.	73219	Mri upper extremity w/dye.	74280	Contrast x-ray exam of colon.
72110	X-ray exam of lower spine.	73220	Mri uppr extremity w/o & w/dye.	74283	Contrast x-ray exam of colon.
72114	X-ray exam of lower spine.	73221	Mri joint upr extrem w/o dye.	74290	Contrast x-ray, gallbladder.
72120	X-ray exam of lower spine.	73222	Mri joint upr extrem w/dye.	74291	Contrast x-rays, gallbladder.
72125	Ct neck spine w/o dye.	73223	Mri joint upr extr w/o & w/dye.	74300	X-ray bile ducts/pancreas.
72126	Ct neck spine w/dye.	73225	Mr angio upr extr w/o & w/dye.	74301	X-rays at surgery add-on.
72127	Ct neck spine w/o & w/dye.	73500	X-ray exam of hip.	74305	X-ray bile ducts/pancreas.
72128	Ct chest spine w/o dye.	73510	X-ray exam of hip.	74320	Contrast x-ray of bile ducts.
72129	Ct chest spine w/dye.	73520	X-ray exam of hips.	74327	X-ray bile stone removal.
72130	Ct chest spine w/o & w/dye.	73525	Contrast x-ray of hip.	74328	X-ray bile duct endoscopy.
72131	Ct lumbar spine w/o dye.	73530	X-ray exam of hip.	74329	X-ray for pancreas endoscopy.
72132	Ct lumbar spine w/dye.	73540	X-ray exam of pelvis & hips.	74330	X-ray bile/panc endoscopy.
72133	Ct lumbar spine w/o & w/dye.	73542	X-ray exam, sacroiliac joint.	74340	X-ray guide for GI tube.
72141	Mri neck spine w/o dye.	73550	X-ray exam of thigh.	74355	X-ray guide, intestinal tube.
72142	Mri neck spine w/dye.	73560	X-ray exam of knee, 1 or 2.	74360	X-ray guide, GI dilation.
72146	Mri chest spine w/o dye.	73562	X-ray exam of knee, 3.	74363	X-ray, bile duct dilation.
72147	Mri chest spine w/dye.	73564	X-ray exam, knee, 4 or more.	74400	Contrast x-ray, urinary tract.
72148	Mri lumbar spine w/o dye.	73565	X-ray exam of knees.	74410	Contrast x-ray, urinary tract.
72149	Mri lumbar spine w/dye.	73580	Contrast x-ray of knee joint.	74415	Contrast x-ray, urinary tract.
72156	Mri neck spine w/o & w/dye.	73590	X-ray exam of lower leg.	74420	Contrast x-ray, urinary tract.
72157	Mri chest spine w/o & w/dye.	73592	X-ray exam of leg, infant.	74425	Contrast x-ray, urinary tract.
72158	Mri lumbar spine w/o & w/dye.	73600	X-ray exam of ankle.	74430	Contrast x-ray, bladder.
72159	Mr angio spine w/o & w/dye.	73610	X-ray exam of ankle.	74440	X-ray, male genital tract.
72170	X-ray exam of pelvis.	73615	Contrast x-ray of ankle.	74445	X-ray exam of penis.
72190	X-ray exam of pelvis.	73620	X-ray exam of foot.	74450	X-ray, urethra/bladder.
72191	Ct angiograph pelv w/o & w/dye.	73630	X-ray exam of foot.	74455	X-ray, urethra/bladder.
72192	Ct pelvis w/o dye.	73650	X-ray exam of heel.	74470	X-ray exam of kidney lesion.
72193	Ct pelvis w/dye.	73660	X-ray exam of toe(s).	74475	X-ray control, cath insert.
72194	Ct pelvis w/o & w/dye.	73700	Ct lower extremity w/o dye.	74480	X-ray control, cath insert.
72195	Mri pelvis w/o dye.	73701	Ct lower extremity w/dye.	74485	X-ray guide, GU dilation.
72196	Mri pelvis w/dye.	73702	Ct lwr extremity w/o & w/dye.	74710	X-ray measurement of pelvis.
72197	Mri pelvis w/o & w/dye.	73706	Ct angio lwr extr w/o & w/dye.	74740	X-ray, female genital tract.
72198	Mr angio pelvis w/o & w/dye.	73718	Mri lower extremity w/o dye.	74742	X-ray, fallopian tube.
72200	X-ray exam sacroiliac joints.	73719	Mri lower extremity w/dye.	74775	X-ray exam of perineum.
72202	X-ray exam sacroiliac joints.	73720	Mri lwr extremity w/o & w/dye.	75557	Cardiac MRI w/o contrast.
72220	X-ray exam of tailbone.	73721	Mri jnt of lwr extre w/o dye.	75558	Cardiac MRI w/flow/velocity.
72240	Contrast x-ray of neck spine.	73722	Mri joint of lwr extr w/dye.	75559	Cardiac MRI w/stress imaging.
72255	Contrast x-ray, thorax spine.	73723	Mri joint lwr extr w/o & w/dye.	75560	Cardiac MRI w/flow/velocity/ stress.
72265	Contrast x-ray, lower spine.	73725	Mr ang lwr ext w or w/o dye.	75561	Cardiac MRI w/ & w/o contrast.
72270	Contrast x-ray, spine.	74000	X-ray exam of abdomen.	75562	Cardiac MRI w/flow velocity.
72275	Epidurography.	74010	X-ray exam of abdomen.	75563	Cardiac MRI w/stress imaging.
72285	X-ray c/t spine disk.	74020	X-ray exam of abdomen.	75564	Cardiac MRI w/flow/velocity/ stress.
72291	Percut vertebroplasty fluor.	74022	X-ray exam series, abdomen.	75600	Contrast x-ray exam of aorta.
72293	Percut vertebroplasty, ct.	74150	Ct abdomen w/o dye.	75605	Contrast x-ray exam of aorta.
72295	X-ray of lower spine disk.	74160	Ct abdomen w/dye.	75625	Contrast x-ray exam of aorta.
73000	X-ray exam of collar bone.	74170	Ct abdomen w/o & w/dye.	75630	X-ray aorta, leg arteries.
73010	X-ray exam of shoulder blade.	74175	Ct angio abdom w/o & w/dye.	75635	Ct angio abdominal arteries.
73020	X-ray exam of shoulder.	74181	Mri abdomen w/o dye.	75650	Artery x-rays, head & neck.
73030	X-ray exam of shoulder.	74182	Mri abdomen w/dye.	75658	Artery x-rays, arm.
73040	Contrast x-ray of shoulder.	74183	Mri abdomen w/o & w/dye.	75660	Artery x-rays, head & neck.
73050	X-ray exam of shoulders.	74185	Mri angio, abdom w/ or w/o dye.	75662	Artery x-rays, head & neck.
73060	X-ray exam of humerus.	74190	X-ray exam of peritoneum.	75665	Artery x-rays, head & neck.
73070	X-ray exam of elbow.	74210	Contrast x-ray exam of throat.	75671	Artery x-rays, head & neck.
73080	X-ray exam of elbow.	74220	Contrast x-ray, esophagus.	75676	Artery x-rays, neck.
73085	Contrast x-ray of elbow.	74230	Cine/vid x-ray, throat/esoph.	75680	Artery x-rays, neck.
73090	X-ray exam of forearm.	74235	Remove esophagus obstruction.	75685	Artery x-rays, spine.
73092	X-ray exam of arm, infant.	74240	X-ray exam, upper gi tract.	75705	Artery x-rays, spine.
73100	X-ray exam of wrist.	74241	X-ray exam, upper gi tract.	75710	Artery x-rays, arm/leg.
73110	X-ray exam of wrist.	74245	X-ray exam, upper gi tract.	75716	Artery x-rays, arms/legs.
73115	Contrast x-ray of wrist.	74246	Contrast x-ray uppr gi tract.	75722	Artery x-rays, kidney.
73120	X-ray exam of hand.	74247	Contrast x-ray uppr gi tract.	75724	Artery x-rays, kidneys.
73130	X-ray exam of hand.	74249	Contrast x-ray uppr gi tract.	75726	Artery x-rays, abdomen.
73140	X-ray exam of finger(s).	74250	X-ray exam of small bowel.	75731	Artery x-rays, adrenal gland.
73200	Ct upper extremity w/o dye.	74251	X-ray exam of small bowel.	75733	Artery x-rays, adrenals.
73201	Ct upper extremity w/dye.			75736	Artery x-rays, pelvis.
73202	Ct uppr extremity w/o & w/dye.				

ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
ContinuedADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
ContinuedADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued

HCPCS/ CPT*	Short descriptor	HCPCS/ CPT*	Short descriptor	HCPCS/ CPT*	Short descriptor
75741	Artery x-rays, lung.	76376	3d render w/o postprocess.	77001	Fluoroguide for vein device.
75743	Artery x-rays, lungs.	76377	3d rendering w/postprocess.	77002	Needle localization by x-ray.
75746	Artery x-rays, lung.	76380	CAT scan follow-up study.	77003	Fluoroguide for spine inject.
75756	Artery x-rays, chest.	76390	Mr spectroscopy.	77011	Ct scan for localization.
75774	Artery x-ray, each vessel.	76496	Fluoroscopic procedure.	77012	Ct scan for needle biopsy.
75790	Visualize A-V shunt.	76497	Ct procedure.	77013	Ct guide for tissue ablation.
75801	Lymph vessel x-ray, arm/leg.	76498	Mri procedure.	77014	Ct scan for therapy guide.
75803	Lymph vessel x-ray, arms/legs.	76506	Echo exam of head.	77021	Mr guidance for needle place.
75805	Lymph vessel x-ray, trunk.	76510	Ophth us, b & quant a.	77022	Mri for tissue ablation.
75807	Lymph vessel x-ray, trunk.	76511	Ophth us, quant a only.	77031	Stereotactic breast biopsy.
75809	Nonvascular shunt, x-ray.	76512	Ophth us, b w/non-quant a.	77032	X-ray of needle wire, breast.
75810	Vein x-ray, spleen/liver.	76513	Echo exam of eye, water bath.	77053	X-ray of mammary duct.
75820	Vein x-ray, arm/leg.	76514	Echo exam of eye, thickness.	77054	X-ray of mammary ducts.
75822	Vein x-ray, arms/legs.	76516	Echo exam of eye.	77058	Magnetic image, breast.
75825	Vein x-ray, trunk.	76519	Echo exam of eye.	77059	Magnetic image, both breasts.
75827	Vein x-ray, chest.	76529	Echo exam of eye.	77071	X-ray stress view.
75831	Vein x-ray, kidney.	76536	Us exam of head and neck.	77072	X-rays for bone age.
75833	Vein x-ray, kidneys.	76604	Us exam, chest, b-scan.	77073	X-rays, bone evaluation.
75840	Vein x-ray, adrenal gland.	76645	Us exam, breast(s).	77074	X-rays, bone survey.
75842	Vein x-ray, adrenal glands.	76700	Us exam, abdom, complete.	77075	X-rays, bone survey.
75860	Vein x-ray, neck.	76705	Echo exam of abdomen.	77076	X-rays, bone evaluation.
75870	Vein x-ray, skull.	76770	Us exam abdo back wall,	77077	Joint survey, single view.
75872	Vein x-ray, skull.		comp.	77078	Ct bone density, axial.
75880	Vein x-ray, eye socket.	76775	Us exam abdo back wall, lim.	77079	Ct bone density, peripheral.
75885	Vein x-ray, liver.	76778	Us exam kidney transplant.	77080	Dxa bone density, axial.
75887	Vein x-ray, liver.	76800	Us exam, spinal canal.	77081	Dxa bone density/peripheral.
75889	Vein x-ray, liver.	76801	Ob us < 14 wks, single fetus.	77082	Dxa bone density/v-fracture.
75891	Vein x-ray, liver.	76802	Ob us < 14 wks, addl fetus.	77083	Radiographic absorptiometry.
75893	Venous sampling by catheter.	76805	Ob us > 14 wks, snl fetus.	77084	Magnetic image, bone marrow.
75894	X-rays, transcath therapy.	76810	Ob us > 14 wks, addl fetus.	77417	Radiology port film(s).
75896	X-rays, transcath therapy.	76811	Ob us, detailed, snl fetus.	77421	Stereoscopic x-ray guidance.
75898	Follow-up angiography.	76812	Ob us, detailed, addl fetus.	78006	Thyroid imaging with uptake.
75900	Intravascular cath exchange.	76815	Ob us, limited, fetus(s).	78007	Thyroid image, mult uptakes.
75901	Remove cva device obstruct.	76816	Ob us, follow-up, per fetus.	78010	Thyroid imaging.
75902	Remove cva lumen obstruct.	76817	Transvaginal us, obstetric.	78011	Thyroid imaging with flow.
75940	X-ray placement, vein filter.	76818	Fetal biophys profile w/nst.	78015	Thyroid met imaging.
75945	Intravascular us.	76819	Fetal biophys profil w/o nst.	78016	Thyroid met imaging/studies.
75946	Intravascular us add-on.	76820	Umbilical artery echo.	78018	Thyroid met imaging, body.
75953	Abdom aneurysm endovas rpr.	76821	Middle cerebral artery echo.	78020	Thyroid met uptake.
75956	X-ray, endovasc thor ao repr.	76825	Echo exam of fetal heart.	78070	Parathryoid nuclear imaging.
75957	X-ray, endovasc thor ao repr.	76826	Echo exam of fetal heart.	78075	Adrenal nuclear imaging.
75958	X-ray, place prox ext thor ao.	76827	Echo exam of fetal heart.	78102	Bone marrow imaging, ltd.
75959	X-ray, place dist ext thor ao.	76828	Echo exam of fetal heart.	78103	Bone marrow imaging, mult.
75960	Transcath iv stent rs&i.	76830	Transvaginal us, non-ob.	78104	Bone marrow imaging, body.
75961	Retrieval, broken catheter.	76831	Echo exam, uterus.	78135	Red cell survival kinetics.
75962	Repair arterial blockage.	76856	Us exam, pelvic, complete.	78140	Red cell sequestration.
75964	Repair artery blockage, each.	76857	Us exam, pelvic, limited.	78185	Spleen imaging.
75966	Repair arterial blockage.	76870	Us exam, scrotum.	78190	Platelet survival, kinetics.
75968	Repair artery blockage, each.	76872	Us, transrectal.	78195	Lymph system imaging.
75970	Vascular biopsy.	76873	Echograp trans r, pros study.	78201	Liver imaging.
75978	Repair venous blockage.	76880	Us exam, extremity.	78202	Liver imaging with flow.
75980	Contrast x-ray exam bile duct.	76885	Us exam infant hips, dynamic.	78205	Liver imaging (3D).
75982	Contrast x-ray exam bile duct.	76886	Us exam infant hips, static.	78206	Liver image (3d) with flow.
75984	X-ray control catheter change.	76930	Echo guide, cardiocentesis.	78215	Liver and spleen imaging.
75989	Abscess drainage under x-ray.	76932	Echo guide for heart biopsy.	78216	Liver & spleen image/flow.
75992	Atherectomy, x-ray exam.	76936	Echo guide for artery repair.	78220	Liver function study.
76000	Fluoroscope examination.	76937	Us guide, vascular access.	78223	Hepatobiliary imaging.
76001	Fluoroscope exam, extensive.	76940	Us guide, tissue ablation.	78230	Salivary gland imaging.
76010	X-ray, nose to rectum.	76941	Echo guide for transfusion.	78231	Serial salivary imaging.
76080	X-ray exam of fistula.	76942	Echo guide for biopsy.	78232	Salivary gland function exam.
76098	X-ray exam, breast specimen.	76945	Echo guide, villus sampling.	78258	Esophageal motility study.
76100	X-ray exam of body section.	76946	Echo guide for amniocentesis.	78261	Gastric mucosa imaging.
76101	Complex body section x-ray.	76948	Echo guide, ova aspiration.	78262	Gastroesophageal reflux exam.
76102	Complex body section x-rays.	76950	Echo guidance radiotherapy.	78264	Gastric emptying study.
76120	Cine/video x-rays.	76965	Echo guidance radiotherapy.	78278	Acute GI blood loss imaging.
76125	Cine/video x-rays add-on.	76970	Ultrasound exam follow-up.	78282	GI protein loss exam.
76140	X-ray consultation.	76975	GI endoscopic ultrasound.	78290	Meckels divert exam.
76150	X-ray exam, dry process.	76977	Us bone density measure.	78291	Leveen/shunt patency exam.
76350	Special x-ray contrast study.	76998	Ultrasound guide intraoper.	78300	Bone imaging, limited area.

ADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
ContinuedADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
ContinuedADDENDUM F.—CPT/HCPCS IMAGING
CODES DEFINED BY DRA 5102(B)—
Continued

HCPCS/ CPT*	Short descriptor	HCPCS/ CPT*	Short descriptor	HCPCS/ CPT*	Short descriptor
78305	Bone imaging, multiple areas.	78660	Nuclear exam of tear flow.	93571	Heart flow reserve measure.
78306	Bone imaging, whole body.	78700	Kidney imaging, static.	93572	Heart flow reserve measure.
78315	Bone imaging, 3 phase.	78701	Kidney imaging with flow.	93880	Extracranial study.
78320	Bone imaging (3D).	78704	Imaging renogram.	93882	Extracranial study.
78350	Bone mineral, single photon.	78707	Kidney flow/function image.	93886	Intracranial study.
78351	Bone mineral, dual photon.	78708	Kidney flow/function image.	93888	Intracranial study.
78428	Cardiac shunt imaging.	78709	Kidney flow/function image.	93890	Tcd, vasoreactivity study.
78445	Vascular flow imaging.	78710	Kidney imaging (3D).	93892	Tcd, emboli detect w/o inj.
78456	Acute venous thrombus image.	78715	Renal vascular flow exam.	93893	Tcd, emboli detect w/inj.
78457	Venous thrombosis imaging.	78730	Urinary bladder retention.	93925	Lower extremity study.
78458	Ven thrombosis images, bilat.	78740	Ureteral reflux study.	93926	Lower extremity study.
78459	Heart muscle imaging (PET).	78760	Testicular imaging.	93930	Upper extremity study.
78460	Heart muscle blood, single.	78761	Testicular imaging/flow.	93931	Upper extremity study.
78461	Heart muscle blood, multiple.	78800	Tumor imaging, limited area.	93970	Extremity study.
78464	Heart image (3d), single.	78801	Tumor imaging, mult areas.	93971	Extremity study.
78465	Heart image (3d), multiple.	78802	Tumor imaging, whole body.	93975	Vascular study.
78466	Heart infarct image.	78803	Tumor imaging (3D).	93976	Vascular study.
78468	Heart infarct image (ef).	78804	Tumor imaging, whole body.	93978	Vascular study.
78469	Heart infarct image (3D).	78805	Abscess imaging, ltd area.	93979	Vascular study.
78472	Gated heart, planar, single.	78806	Abscess imaging, whole body.	93980	Penile vascular study.
78473	Gated heart, multiple.	78807	Nuclear localization/abscess.	93981	Penile vascular study.
78478	Heart wall motion add-on.	78811	Tumor imaging (pet), limited.	93990	Doppler flow testing.
78480	Heart function add-on.	78812	Tumor image (pet)/skul-thigh.	0028T	Dexa body composition study.
78481	Heart first pass, single.	78813	Tumor image (pet) full body.	0042T	Ct perfusion w/contrast, cbf.
78483	Heart first pass, multiple.	78814	Tumor image pet/ct, limited.	0066T	Ct colonography; screen.
78491	Heart image (pet), single.	78815	Tumorimage pet/ct skul-thigh.	0067T	Ct colonography; dx.
78492	Heart image (pet), multiple.	78816	Tumor image pet/ct full body.	0080T	Endovasc aort repr rad s&i.
78494	Heart image, spect.	78890	Nuclear medicine data proc.	0081T	Endovasc visc extnsn s&i.
78496	Heart first pass add-on.	78891	Nuclear med data proc.	0144T	CT heart wo dye; qual calc.
78580	Lung perfusion imaging.	92135	Scanning computer ophthalmic.	0145T	CT heart w/wo dye funct.
78584	Lung V/Q image single breath.	92235	Fluorocin angiography.	0146T	CCTA w/wo dye.
78585	Lung V/Q imaging.	92240	IDC green angiography.	0147T	CCTA w/wo, quan calcium.
78586	Aerosol lung image, single.	92250	Fundus photography.	0148T	CCTA w/wo, strxr.
78587	Aerosol lung image, multiple.	92285	External ocular photography.	0149T	CCTA w/wo, strxr quan calc.
78588	Perfusion lung image.	92286	Anterior segment photography.	0150T	CCTA w/wo, disease strxr.
78591	Vent image, 1 breath, 1 proj.	93303	Echo transthoracic.	0151T	CT heart funct add-on.
78593	Vent image, 1 proj, gas.	93304	Echo transthoracic.	0152T	Computer chest add-on.
78594	Vent image, mult proj, gas.	93307	Echo exam of heart.	G0120	Colon ca scrn; barium enema.
78596	Lung differential function.	93308	Echo exam of heart.	G0122	Colon ca scrn; barium enema.
78600	Brain imaging, ltd static.	93312	Echo transesophageal.	G0130	Single energy x-ray study.
78601	Brain imaging, ltd w/flow.	93313	Echo transesophageal.	G0219	PET img wholbod melano nonco.
78605	Brain imaging, complete.	93314	Echo transesophageal.	G0235	PET not otherwise specified.
78606	Brain imaging, compl w/flow.	93315	Echo transesophageal.	G0275	Renal angio, cardiac cath.
78607	Brain imaging (3D).	93316	Echo transesophageal.	G0278	Iliac art angio, cardiac cath.
78608	Brain imaging (PET).	93317	Echo transesophageal.	G0288	Recon, CTA for surg plan.
78609	Brain imaging (PET).	93318	Echo transesophageal intraop.	G0365	Vessel mapping hemo access.
78610	Brain flow imaging only.	93320	Doppler echo exam, heart.		
78630	Cerebrospinal fluid scan.	93321	Doppler echo exam, heart.		
78635	CSF ventriculography.	93325	Doppler color flow add-on.		
78645	CSF shunt evaluation.	93350	Echo transthoracic.		
78647	Cerebrospinal fluid scan.	93555	Imaging, cardiac cath.		
78650	CSF leakage imaging.	93556	Imaging, cardiac cath.		

*CPT codes are descriptors only are copy-right 2007 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS

CBSA code	Urban area (constituent counties)	Wage index
10180	Abilene, TX Callahan County, TX. Jones County, TX. Taylor County, TX.	0.8398
10380	Aguadilla-Isabela-San Sebastián, PR Aguada Municipio, PR. Aguadilla Municipio, PR. Añasco Municipio, PR. Isabela Municipio, PR. Lares Municipio, PR. Moca Municipio, PR. Rincón Municipio, PR. San Sebastián Municipio, PR.	0.7916
10420	Akron, OH Portage County, OH. Summit County, OH.	0.9282
10500	Albany, GA Baker County, GA. Dougherty County, GA. Lee County, GA. Terrell County, GA. Worth County, GA.	0.8986
10580	Albany-Schenectady-Troy, NY Albany County, NY. Rensselaer County, NY. Saratoga County, NY. Schenectady County, NY. Schoharie County, NY.	0.9064
10740	Albuquerque, NM Bernalillo County, NM. Sandoval County, NM. Torrance County, NM. Valencia County, NM.	1.0084
10780	Alexandria, LA Grant Parish, LA. Rapides Parish, LA.	0.8422
10900	Allentown-Bethlehem-Easton, PA-NJ Warren County, NJ. Carbon County, PA. Lehigh County, PA. Northampton County, PA.	1.0412
11020	Altoona, PA Blair County, PA.	0.9096
11100	Amarillo, TX Armstrong County, TX. Carson County, TX. Potter County, TX. Randall County, TX.	0.9622
11180	Ames, IA Story County, IA.	1.0603
11260	Anchorage, AK Anchorage Municipality, AK. Matanuska-Susitna Borough, AK.	1.2574
11300	Anderson, IN Madison County, IN.	0.9317
11340	Anderson, SC Anderson County, SC.	0.9590
11460	Ann Arbor, MI Washtenaw County, MI.	1.1124
11500	Anniston-Oxford, AL Calhoun County, AL.	0.8366
11540	Appleton, WI Calumet County, WI. Outagamie County, WI.	1.0130
11700	Asheville, NC Buncombe County, NC. Haywood County, NC. Henderson County, NC. Madison County, NC.	0.9695
12020	Athens-Clarke County, GA Clarke County, GA.	1.1100

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
12060	Madison County, GA. Oconee County, GA. Oglethorpe County, GA. Atlanta-Sandy Springs-Marietta, GA Barrow County, GA. Bartow County, GA. Butts County, GA. Carroll County, GA. Cherokee County, GA. Clayton County, GA. Cobb County, GA. Coweta County, GA. Dawson County, GA. DeKalb County, GA. Douglas County, GA. Fayette County, GA. Forsyth County, GA. Fulton County, GA. Gwinnett County, GA. Haralson County, GA. Heard County, GA. Henry County, GA. Jasper County, GA. Lamar County, GA. Meriwether County, GA. Newton County, GA. Paulding County, GA. Pickens County, GA. Pike County, GA. Rockdale County, GA. Spalding County, GA. Walton County, GA.	1.0373
12100	Atlantic City, NJ Atlantic County, NJ.	1.2875
12220	Auburn-Opelika, AL Lee County, AL.	0.8539
12260	Augusta-Richmond County, GA-SC Burke County, GA. Columbia County, GA. McDuffie County, GA. Richmond County, GA. Aiken County, SC. Edgefield County, SC.	1.0180
12420	Austin-Round Rock, TX Bastrop County, TX. Caldwell County, TX. Hays County, TX. Travis County, TX. Williamson County, TX.	1.0073
12540	Bakersfield, CA Kern County, CA.	1.1664
12580	Baltimore-Towson, MD Anne Arundel County, MD. Baltimore County, MD. Carroll County, MD. Harford County, MD. Howard County, MD. Queen Anne's County, MD. Baltimore City, MD.	1.0696
12620	Bangor, ME Penobscot County, ME.	1.0532
12700	Barnstable Town, MA Barnstable County, MA.	1.3302
12940	Baton Rouge, LA Ascension Parish, LA. East Baton Rouge Parish, LA. East Feliciana Parish, LA. Iberville Parish, LA. Livingston Parish, LA. Pointe Coupee Parish, LA. St. Helena Parish, LA.	0.8480

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
12980	West Baton Rouge Parish, LA. West Feliciana Parish, LA. Battle Creek, MI	1.0744
13020	Calhoun County, MI. Bay City, MI	0.9391
13140	Bay County, MI. Beaumont-Port Arthur, TX	0.9004
13380	Hardin County, TX. Jefferson County, TX. Orange County, TX. Bellingham, WA	1.2110
13460	Whatcom County, WA. Bend, OR	1.1549
13644	Deschutes County, OR. Bethesda-Frederick-Gaithersburg, MD	1.1094
13740	Frederick County, MD. Montgomery County, MD. Billings, MT	0.9147
13780	Carbon County, MT. Yellowstone County, MT. Binghamton, NY	0.9445
13820	Broome County, NY. Tioga County, NY. Birmingham-Hoover, AL	0.9392
13900	Bibb County, AL. Blount County, AL. Chilton County, AL. Jefferson County, AL. St. Clair County, AL. Shelby County, AL. Walker County, AL. Bismarck, ND	0.7916
13980	Burleigh County, ND. Morton County, ND. Blacksburg-Christiansburg-Radford, VA	0.8646
14020	Giles County, VA. Montgomery County, VA. Pulaski County, VA. Radford City, VA. Bloomington, IN	0.9410
14060	Greene County, IN. Monroe County, IN. Owen County, IN. Bloomington-Normal, IL	0.9842
14260	McLean County, IL. Boise City-Nampa, ID	0.9990
14484	Ada County, ID. Boise County, ID. Canyon County, ID. Gem County, ID. Owyhee County, ID. Boston-Quincy, MA	1.2285
14500	Norfolk County, MA. Plymouth County, MA. Suffolk County, MA. Boulder, CO	1.1004
14540	Boulder County, CO. Bowling Green, KY	0.8612
14740	Edmonson County, KY. Warren County, KY. Bremerton-Silverdale, WA	1.1509
14860	Kitsap County, WA. Bridgeport-Stamford-Norwalk, CT	1.3441
15180	Fairfield County, CT. Brownsville-Harlingen, TX	0.9408
15260	Cameron County, TX. Brunswick, GA	1.0001
15380	Brantley County, GA. Glynn County, GA. McIntosh County, GA. Buffalo-Niagara Falls, NY	1.0099

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
15500	Erie County, NY. Niagara County, NY. Burlington, NC	0.9232
15540	Alamance County, NC. Burlington-South Burlington, VT	1.0196
15764	Chittenden County, VT. Franklin County, VT. Grand Isle County, VT. Cambridge-Newton-Framingham, MA	1.1837
15804	Middlesex County, MA. Camden, NJ	1.0989
15940	Burlington County, NJ. Camden County, NJ. Gloucester County, NJ. Canton-Massillon, OH	0.9431
15980	Carroll County, OH. Stark County, OH. Cape Coral-Fort Myers, FL	0.9917
16180	Lee County, FL. Carson City, NV	1.0558
16220	Carson City, NV. Casper, WY	0.9906
16300	Natrona County, WY. Cedar Rapids, IA	0.9343
16580	Benton County, IA. Jones County, IA. Linn County, IA. Champaign-Urbana, IL	0.9913
16620	Champaign County, IL. Ford County, IL. Piatt County, IL. Charleston, WV	0.8749
16700	Boone County, WV. Clay County, WV. Kanawha County, WV. Lincoln County, WV. Putnam County, WV. Charleston-North Charleston, SC	0.9630
16740	Berkeley County, SC. Charleston County, SC. Dorchester County, SC. Charlotte-Gastonia-Concord, NC SC	1.0048
16820	Anson County, NC. Cabarrus County, NC. Gaston County, NC. Mecklenburg County, NC. Union County, NC. York County, SC. Charlottesville, VA	0.9792
16860	Albemarle County, VA. Fluvanna County, VA. Greene County, VA. Nelson County, VA. Charlottesville City, VA. Chattanooga, TN-GA	0.9493
16940	Catoosa County, GA. Dade County, GA. Walker County, GA. Hamilton County, TN. Marion County, TN. Sequatchie County, TN. Cheyenne, WY	0.9824
16974	Laramie County, WY. Chicago-Naperville-Joliet, IL	1.1331
.....	Cook County, IL. DeKalb County, IL. DuPage County, IL. Grundy County, IL. Kane County, IL. Kendall County, IL. McHenry County, IL.	

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
17020	Will County, IL. Chico, CA	1.1916
17140	Butte County, CA. Cincinnati-Middletown, OH-KY-IN	1.0327
17300	Dearborn County, IN. Franklin County, IN. Ohio County, IN. Boone County, KY. Bracken County, KY. Campbell County, KY. Gallatin County, KY. Grant County, KY. Kenton County, KY. Pendleton County, KY. Brown County, OH. Butler County, OH. Clermont County, OH. Hamilton County, OH. Warren County, OH.	0.8709
17420	Clarksville, TN-KY	0.8499
17460	Christian County, KY. Trigg County, KY. Montgomery County, TN. Stewart County, TN.	0.9857
17660	Cleveland, TN	1.0061
17780	Bradley County, TN. Polk County, TN.	0.9877
17820	Cleveland-Elyria-Mentor, OH	1.0258
17860	Cuyahoga County, OH. Geauga County, OH. Lake County, OH. Lorain County, OH. Medina County, OH.	0.9138
17900	Coeur d'Alene, ID	0.9288
17980	Kootenai County, ID. College Station-Bryan, TX	0.9213
18020	Brazos County, TX. Burlison County, TX. Robertson County, TX.	1.0066
18140	Colorado Springs, CO	1.0644
18580	El Paso County, CO. Teller County, CO.	0.9064
17860	Columbia, MO	0.9138
17900	Boone County, MO. Howard County, MO.	0.9288
17980	Columbia, SC	0.9213
18020	Calhoun County, SC. Fairfield County, SC. Kershaw County, SC. Lexington County, SC. Richland County, SC. Saluda County, SC.	1.0066
18140	Columbus, GA-AL	0.9213
18580	Russell County, AL. Chattahoochee County, GA. Harris County, GA. Marion County, GA. Muscogee County, GA.	1.0066
18020	Columbus, IN	1.0066
18140	Bartholomew County, IN. Columbus, OH	1.0644
18580	Delaware County, OH. Fairfield County, OH. Franklin County, OH. Licking County, OH. Madison County, OH. Morrow County, OH. Pickaway County, OH. Union County, OH.	1.0644
18580	Corpus Christi, TX	0.9064
18580	Aransas County, TX.	0.9064

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
18700	Nueces County, TX. San Patricio County, TX. Corvallis, OR	1.1567
19060	Benton County, OR. Cumberland, MD—WV	0.8754
19124	Allegany County, MD. Mineral County, WV. Dallas-Plano-Irving, TX	1.0465
19140	Collin County, TX. Dallas County, TX. Delta County, TX. Denton County, TX. Ellis County, TX. Hunt County, TX. Kaufman County, TX. Rockwall County, TX. Dalton, GA	0.9246
19180	Murray County, GA. Whitfield County, GA. Danville, IL	0.9454
19260	Vermilion County, IL. Danville, VA	0.8697
19340	Pittsylvania County, VA. Danville City, VA. Davenport-Moline-Rock Island, IA—IL	0.9320
19380	Henry County, IL. Mercer County, IL. Rock Island County, IL. Scott County, IA. Dayton, OH	0.9700
19460	Greene County, OH. Miami County, OH. Montgomery County, OH. Preble County, OH. Decatur, AL	0.8322
19500	Lawrence County, AL. Morgan County, AL. Decatur, IL	0.8522
19660	Macon County, IL. Deltona-Daytona Beach-Ormond Beach, FL	0.9532
19740	Volusia County, FL. Denver-Aurora, CO	1.1313
19780	Adams County, CO. Arapahoe County, CO. Broomfield County, CO. Clear Creek County, CO. Denver County, CO. Douglas County, CO. Elbert County, CO. Gilpin County, CO. Jefferson County, CO. Park County, CO. Des Moines-West Des Moines, IA	0.9738
19804	Dallas County, IA. Guthrie County, IA. Madison County, IA. Polk County, IA. Warren County, IA. Detroit-Livonia-Dearborn, MI	1.0554
20020	Wayne County, MI. Dothan, AL	0.7916
20100	Geneva County, AL. Henry County, AL. Houston County, AL. Dover, DE	1.0659
20220	Kent County, DE. Dubuque, IA	0.9560
20260	Dubuque County, IA. Duluth, MN—WI	1.0528
	Carlton County, MN. St. Louis County, MN.	

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
20500	Douglas County, WI. Durham, NC	1.0361
	Chatham County, NC. Durham County, NC. Orange County, NC. Person County, NC.	
20740	Eau Claire, WI	1.0001
	Chippewa County, WI. Eau Claire County, WI.	
20764	Edison, NJ	1.1801
	Middlesex County, NJ. Monmouth County, NJ. Ocean County, NJ. Somerset County, NJ.	
20940	El Centro, CA	0.9408
	Imperial County, CA.	
21060	Elizabethtown, KY	0.9194
	Hardin County, KY. Larue County, KY.	
21140	Elkhart-Goshen, IN	1.0144
	Elkhart County, IN.	
21300	Elmira, NY	0.8722
	Chemung County, NY.	
21340	El Paso, TX	0.9488
	El Paso County, TX.	
21500	Erie, PA	0.8966
	Erie County, PA.	
21660	Eugene-Springfield, OR	1.1538
	Lane County, OR.	
21780	Evansville, IN-KY	0.9143
	Gibson County, IN. Posey County, IN. Vanderburgh County, IN. Warrick County, IN. Henderson County, KY. Webster County, KY.	
21820	Fairbanks, AK	1.1663
	Fairbanks North Star Borough, AK.	
21940	Fajardo, PR	0.7916
	Ceiba Municipio, PR. Fajardo Municipio, PR. Luquillo Municipio, PR.	
22020	Fargo, ND-MN	0.8488
	Cass County, ND. Clay County, MN.	
22140	Farmington, NM	1.0119
	San Juan County, NM.	
22180	Fayetteville, NC	0.9888
	Cumberland County, NC. Hoke County, NC.	
22220	Fayetteville-Springdale-Rogers, AR-MO	0.9227
	Benton County, AR. Madison County, AR. Washington County, AR. McDonald County, MO.	
22380	Flagstaff, AZ	1.2335
	Coconino County, AZ.	
22420	Flint, MI	1.1842
	Genesee County, MI.	
22500	Florence, SC	0.8707
	Darlington County, SC. Florence County, SC.	
22520	Florence-Muscle Shoals, AL	0.8106
	Colbert County, AL. Lauderdale County, AL.	
22540	Fond du Lac, WI	1.0203
	Fond du Lac County, WI.	
22660	Fort Collins-Loveland, CO	1.0446
	Larimer County, CO.	
22744	Fort Lauderdale-Pompano Beach-Deerfield Beach, FL	1.0796
	Broward County, FL.	

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
22900	Fort Smith, AR—OK Crawford County, AR. Franklin County, AR. Sebastian County, AR. Le Flore County, OK. Sequoyah County, OK.	0.8373
23020	Fort Walton Beach-Crestview-Destin, FL Okaloosa County, FL.	0.9228
23060	Fort Wayne, IN Allen County, IN. Wells County, IN. Whitley County, IN.	0.9799
23104	Fort Worth-Arlington, TX Johnson County, TX. Parker County, TX. Tarrant County, TX. Wise County, TX.	1.0231
23420	Fresno, CA Fresno County, CA.	1.1603
23460	Gadsden, AL Etowah County, AL.	0.8612
23540	Gainesville, FL Alachua County, FL. Gilchrist County, FL.	0.9706
23580	Gainesville, GA Hall County, GA.	0.9727
23844	Gary, IN Jasper County, IN. Lake County, IN. Newton County, IN. Porter County, IN.	0.9736
24020	Glens Falls, NY Warren County, NY. Washington County, NY.	0.8714
24140	Goldsboro, NC Wayne County, NC.	0.9803
24220	Grand Forks, ND—MN Polk County, MN. Grand Forks County, ND.	0.8318
24300	Grand Junction, CO Mesa County, CO.	1.0411
24340	Grand Rapids-Wyoming, MI Barry County, MI. Ionia County, MI. Kent County, MI. Newaygo County, MI.	0.9832
24500	Great Falls, MT Cascade County, MT.	0.9156
24540	Greeley, CO Weld County, CO.	1.0194
24580	Green Bay, WI Brown County, WI. Kewaunee County, WI. Oconto County, WI.	1.0267
24660	Greensboro-High Point, NC Guilford County, NC. Randolph County, NC. Rockingham County, NC.	0.9510
24780	Greenville, NC Greene County, NC. Pitt County, NC.	0.9924
24860	Greenville-Mauldin-Easley, SC Greenville County, SC. Laurens County, SC. Pickens County, SC.	1.0407
25020	Guayama, PR Arroyo Municipio, PR. Guayama Municipio, PR. Patillas Municipio, PR.	0.7916
25060	Gulfport-Biloxi, MS Hancock County, MS.	0.9260

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
25180	Harrison County, MS. Stone County, MS. Hagerstown-Martinsburg, MD—WV Washington County, MD. Berkeley County, WV. Morgan County, WV.	0.9513
25260	Hanford-Corcoran, CA Kings County, CA.	1.1081
25420	Harrisburg-Carlisle, PA Cumberland County, PA. Dauphin County, PA. Perry County, PA.	0.9795
25500	Harrisonburg, VA Rockingham County, VA. Harrisonburg City, VA.	0.9359
25540	Hartford-West Hartford-East Hartford, CT Hartford County, CT. Litchfield County, CT. Middlesex County, CT. Tolland County, CT.	1.1536
25620	Hattiesburg, MS Forrest County, MS. Lamar County, MS. Perry County, MS.	0.7916
25860	Hickory-Lenoir-Morganton, NC Alexander County, NC. Burke County, NC. Caldwell County, NC. Catawba County, NC.	0.9529
25980	Hinesville-Fort Stewart, GA ³ Liberty County, GA. Long County, GA.	0.9697
26100	Holland-Grand Haven, MI Ottawa County, MI.	0.9506
26180	Honolulu, HI Honolulu County, HI.	1.2197
26300	Hot Springs, AR Garland County, AR.	0.9614
26380	Houma-Bayou Cane-Thibodaux, LA Lafourche Parish, LA. Terrebonne Parish, LA.	0.8330
26420	Houston-Sugar Land-Baytown, TX Austin County, TX. Brazoria County, TX. Chambers County, TX. Fort Bend County, TX. Galveston County, TX. Harris County, TX. Liberty County, TX. Montgomery County, TX. San Jacinto County, TX. Waller County, TX.	1.0490
26580	Huntington-Ashland, WV—KY—OH Boyd County, KY. Greenup County, KY. Lawrence County, OH. Cabell County, WV. Wayne County, WV.	0.9543
26620	Huntsville, AL Limestone County, AL. Madison County, AL.	0.9653
26820	Idaho Falls, ID Bonneville County, ID. Jefferson County, ID.	0.9778
26900	Indianapolis-Carmel, IN Boone County, IN. Brown County, IN. Hamilton County, IN. Hancock County, IN. Hendricks County, IN. Johnson County, IN.	1.0390

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
26980	Marion County, IN. Morgan County, IN. Putnam County, IN. Shelby County, IN. Iowa City, IA	1.0099
27060	Johnson County, IA. Washington County, IA. Ithaca, NY	1.0164
27100	Tompkins County, NY. Jackson, MI	0.9847
27140	Jackson County, MI. Jackson, MS	0.8455
27180	Copiah County, MS. Hinds County, MS. Madison County, MS. Rankin County, MS. Simpson County, MS. Jackson, TN	0.9157
27260	Chester County, TN. Madison County, TN. Jacksonville, FL	0.9521
27340	Baker County, FL. Clay County, FL. Duval County, FL. Nassau County, FL. St. Johns County, FL. Jacksonville, NC	0.8527
27500	Onslow County, NC. Janesville, WI	1.0240
27620	Rock County, WI. Jefferson City, MO	0.8948
27740	Callaway County, MO. Cole County, MO. Moniteau County, MO. Osage County, MO. Johnson City, TN	0.8103
27780	Carter County, TN. Unicoi County, TN. Washington County, TN. Johnstown, PA	0.7961
27860	Cambria County, PA. Jonesboro, AR	0.8222
27900	Craighead County, AR. Poinsett County, AR. Joplin, MO	0.9448
28020	Jasper County, MO. Newton County, MO. Kalamazoo-Portage, MI	1.1012
28100	Kalamazoo County, MI. Van Buren County, MI. Kankakee-Bradley, IL	1.0806
28140	Kankakee County, IL. Kansas City, MO-KS	1.0031
28420	Franklin County, KS. Johnson County, KS. Leavenworth County, KS. Linn County, KS. Miami County, KS. Wyandotte County, KS. Bates County, MO. Caldwell County, MO. Cass County, MO. Clay County, MO. Clinton County, MO. Jackson County, MO. Lafayette County, MO. Platte County, MO. Ray County, MO. Kennewick-Richland-Pasco, WA	1.0634
	Benton County, WA. Franklin County, WA.	

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
28660	Killeen-Temple-Fort Hood, TX Bell County, TX. Coryell County, TX. Lampasas County, TX.	0.8707
28700	Kingsport-Bristol-Bristol, TN-VA Hawkins County, TN. Sullivan County, TN. Bristol City, VA. Scott County, VA. Washington County, VA.	0.8083
28740	Kingston, NY Ulster County, NY.	1.0086
28940	Knoxville, TN Anderson County, TN. Blount County, TN. Knox County, TN. Loudon County, TN. Union County, TN.	0.8482
29020	Kokomo, IN Howard County, IN. Tipton County, IN.	1.0123
29100	La Crosse, WI-MN Houston County, MN. La Crosse County, WI.	1.0222
29140	Lafayette, IN Benton County, IN. Carroll County, IN. Tippecanoe County, IN.	0.9361
29180	Lafayette, LA Lafayette Parish, LA. St. Martin Parish, LA.	0.8704
29340	Lake Charles, LA Calcasieu Parish, LA. Cameron Parish, LA.	0.8208
29404	Lake County-Kenosha County, IL-WI Lake County, IL. Kenosha County, WI.	1.0887
29420	Lake Havasu City—Kingman, AZ Mohave County, AZ.	0.9851
29460	Lakeland, FL Polk County, FL.	0.9141
29540	Lancaster, PA Lancaster County, PA.	0.9765
29620	Lansing-East Lansing, MI Clinton County, MI. Eaton County, MI. Ingham County, MI.	1.0680
29700	Laredo, TX Webb County, TX.	0.8542
29740	Las Cruces, NM Dona Ana County, NM.	0.9157
29820	Las Vegas-Paradise, NV Clark County, NV.	1.2454
29940	Lawrence, KS Douglas County, KS.	0.8683
30020	Lawton, OK Comanche County, OK.	0.8470
30140	Lebanon, PA Lebanon County, PA.	0.8646
30300	Lewiston, ID-WA Nez Perce County, ID. Asotin County, WA.	0.9978
30340	Lewiston-Auburn, ME Androscoggin County, ME.	0.9703
30460	Lexington-Fayette, KY Bourbon County, KY. Clark County, KY. Fayette County, KY. Jessamine County, KY. Scott County, KY. Woodford County, KY.	0.9701

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
30620	Lima, OH Allen County, OH.	0.9947
30700	Lincoln, NE Lancaster County, NE. Seward County, NE.	1.0609
30780	Little Rock-North Little Rock-Conway, AR Faulkner County, AR. Grant County, AR. Lonoke County, AR. Perry County, AR. Pulaski County, AR. Saline County, AR.	0.9355
30860	Logan, UT-ID Franklin County, ID. Cache County, UT.	0.9692
30980	Longview, TX Gregg County, TX. Rusk County, TX. Upshur County, TX.	0.9201
31020	Longview, WA Cowlitz County, WA.	1.1428
31084	Los Angeles-Long Beach-Glendale, CA Los Angeles County, CA.	1.2424
31140	Louisville-Jefferson County, KY-IN Clark County, IN. Floyd County, IN. Harrison County, IN. Washington County, IN. Bullitt County, KY. Henry County, KY. Jefferson County, KY. Meade County, KY. Nelson County, KY. Oldham County, KY. Shelby County, KY. Spencer County, KY. Trimble County, KY.	0.9568
31180	Lubbock, TX Crosby County, TX. Lubbock County, TX.	0.9162
31340	Lynchburg, VA Amherst County, VA. Appomattox County, VA. Bedford County, VA. Campbell County, VA. Bedford City, VA. Lynchburg City, VA.	0.9216
31420	Macon, GA Bibb County, GA. Crawford County, GA. Jones County, GA. Monroe County, GA. Twiggs County, GA.	1.0070
31460	Madera, CA Madera County, CA.	0.8517
31540	Madison, WI Columbia County, WI. Dane County, WI. Iowa County, WI.	1.1542
31700	Manchester-Nashua, NH Hillsborough County, NH. Merrimack County, NH.	1.0621
31900	Mansfield, OH ¹ Richland County, OH.	0.9785
32420	Mayagüez, PR Hormigueros Municipio, PR. Mayagüez Municipio, PR.	0.7916
32580	McAllen-Edinburg-Mission, TX Hidalgo County, TX.	0.9629
32780	Medford, OR Jackson County, OR.	1.0890

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
32820	Memphis, TN—MS—AR Crittenden County, AR. DeSoto County, MS. Marshall County, MS. Tate County, MS. Tunica County, MS. Fayette County, TN. Shelby County, TN. Tipton County, TN.	0.9763
32900	Merced, CA Merced County, CA.	1.2792
33124	Miami-Miami Beach-Kendall, FL Miami-Dade County, FL.	1.0557
33140	Michigan City-La Porte, IN LaPorte County, IN.	0.9408
33260	Midland, TX Midland County, TX.	1.0573
33340	Milwaukee-Waukesha-West Allis, WI Milwaukee County, WI. Ozaukee County, WI. Washington County, WI. Waukesha County, WI.	1.0781
33460	Minneapolis-St. Paul-Bloomington, MN—WI Anoka County, MN. Carver County, MN. Chisago County, MN. Dakota County, MN. Hennepin County, MN. Isanti County, MN. Ramsey County, MN. Scott County, MN. Sherburne County, MN. Washington County, MN. Wright County, MN. Pierce County, WI. St. Croix County, WI.	1.1708
33540	Missoula, MT Missoula County, MT.	0.9450
33660	Mobile, AL Mobile County, AL.	0.8479
33700	Modesto, CA Stanislaus County, CA.	1.2626
33740	Monroe, LA Ouachita Parish, LA. Union Parish, LA.	0.8266
33780	Monroe, MI Monroe County, MI.	0.9936
33860	Montgomery, AL Autauga County, AL. Elmore County, AL. Lowndes County, AL. Montgomery County, AL.	0.8537
34060	Morgantown, WV Monongalia County, WV. Preston County, WV.	0.8783
34100	Morristown, TN Grainger County, TN. Hamblen County, TN. Jefferson County, TN.	0.7916
34580	Mount Vernon-Anacortes, WA Skagit County, WA.	1.1113
34620	Muncie, IN Delaware County, IN.	0.8670
34740	Muskegon-Norton Shores, MI Muskegon County, MI.	1.0382
34820	Myrtle Beach-Conway-North Myrtle Beach, SC Horry County, SC.	0.9113
34900	Napa, CA Napa County, CA.	1.5279
34940	Naples-Marco Island, FL Collier County, FL.	1.0013

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
34980	Nashville-Davidson-Murfreesboro, TN Cannon County, TN. Cheatham County, TN. Davidson County, TN. Dickson County, TN. Hickman County, TN. Macon County, TN. Robertson County, TN. Rutherford County, TN. Smith County, TN. Sumner County, TN. Trousdale County, TN. Williamson County, TN. Wilson County, TN.	1.0226
35004	Nassau-Suffolk, NY Nassau County, NY. Suffolk County, NY.	1.3341
35084	Newark-Union, NJ-PA Essex County, NJ. Hunterdon County, NJ. Morris County, NJ. Sussex County, NJ. Union County, NJ. Pike County, PA.	1.2520
35300	New Haven-Milford, CT New Haven County, CT.	1.2530
35380	New Orleans-Metairie-Kenner, LA Jefferson Parish, LA. Orleans Parish, LA. Plaquemines Parish, LA. St. Bernard Parish, LA. St. Charles Parish, LA. St. John the Baptist Parish, LA. St. Tammany Parish, LA.	0.9391
35644	New York-Wayne-White Plains, NY-NJ Bergen County, NJ. Hudson County, NJ. Passaic County, NJ. Bronx County, NY. Kings County, NY. New York County, NY. Putnam County, NY. Queens County, NY. Richmond County, NY. Rockland County, NY. Westchester County, NY.	1.3843
35660	Niles-Benton Harbor, MI Berrien County, MI.	0.9648
35980	Norwich-New London, CT New London County, CT.	1.2066
36084	Oakland-Fremont-Hayward, CA Alameda County, CA. Contra Costa County, CA.	1.6555
36100	Ocala, FL Marion County, FL.	0.9106
36140	Ocean City, NJ Cape May County, NJ.	1.1598
36220	Odessa, TX Ector County, TX.	1.0599
36260	Ogden-Clearfield, UT Davis County, UT. Morgan County, UT. Weber County, UT.	0.9499
36420	Oklahoma City, OK Canadian County, OK. Cleveland County, OK. Grady County, OK. Lincoln County, OK. Logan County, OK. McClain County, OK. Oklahoma County, OK.	0.9304

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
36500	Olympia, WA	1.2151
	Thurston County, WA.	
36540	Omaha-Council Bluffs, NE-IA	1.0091
	Harrison County, IA.	
	Mills County, IA.	
	Pottawattamie County, IA.	
	Cass County, NE.	
	Douglas County, NE.	
	Sarpy County, NE.	
	Saunders County, NE.	
	Washington County, NE.	
36740	Orlando-Kissimmee, FL	0.9738
	Lake County, FL.	
	Orange County, FL.	
	Osceola County, FL.	
	Seminole County, FL.	
36780	Oshkosh-Neenah, WI	1.0081
	Winnebago County, WI.	
36980	Owensboro, KY	0.9132
	Davies County, KY.	
	Hancock County, KY.	
	McLean County, KY.	
37100	Oxnard-Thousand Oaks-Ventura, CA	1.2509
	Ventura County, CA.	
37340	Palm Bay-Melbourne-Titusville, FL	0.9842
	Brevard County, FL.	
37380	Palm Coast, FL	0.9441
	Flagler County, FL.	
37460	Panama City-Lynn Haven, FL	0.8774
	Bay County, FL.	
37620	Parkersburg-Marietta-Vienna, WV-OH	0.8555
	Washington County, OH.	
	Pleasants County, WV.	
	Wirt County, WV.	
	Wood County, WV.	
37700	Pascagoula, MS	0.9127
	George County, MS.	
	Jackson County, MS.	
37764	Peabody, MA	1.1241
	Essex County, MA.	
37860	Pensacola-Ferry Pass-Brent, FL	0.8740
	Escambia County, FL.	
	Santa Rosa County, FL.	
37900	Peoria, IL	0.9815
	Marshall County, IL.	
	Peoria County, IL.	
	Stark County, IL.	
	Tazewell County, IL.	
	Woodford County, IL.	
37964	Philadelphia, PA	1.1531
	Bucks County, PA.	
	Chester County, PA.	
	Delaware County, PA.	
	Montgomery County, PA.	
	Philadelphia County, PA.	
38060	Phoenix-Mesa-Scottsdale, AZ	1.0833
	Maricopa County, AZ.	
	Pinal County, AZ.	
38220	Pine Bluff, AR	0.8274
	Cleveland County, AR.	
	Jefferson County, AR.	
	Lincoln County, AR.	
38300	Pittsburgh, PA	0.8998
	Allegheny County, PA.	
	Armstrong County, PA.	
	Beaver County, PA.	
	Butler County, PA.	
	Fayette County, PA.	
	Washington County, PA.	
	Westmoreland County, PA.	
38340	Pittsfield, MA	1.0651

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
38540	Berkshire County, MA. Pocatello, ID Bannock County, ID. Power County, ID.	0.9990
38660	Ponce, PR Juana Díaz Municipio, PR. Ponce Municipio, PR. Villalba Municipio, PR.	0.7916
38860	Portland-South Portland-Biddeford, ME Cumberland County, ME. Sagadahoc County, ME. York County, ME.	1.0599
38900	Portland-Vancouver-Beaverton, OR-WA Clackamas County, OR. Columbia County, OR. Multnomah County, OR. Washington County, OR. Yamhill County, OR. Clark County, WA. Skamania County, WA.	1.2136
38940	Port St. Lucie, FL Martin County, FL. St. Lucie County, FL.	1.0572
39100	Poughkeepsie-Newburgh-Middletown, NY Dutchess County, NY. Orange County, NY.	1.1591
39140	Prescott, AZ Yavapai County, AZ.	1.0576
39300	Providence-New Bedford-Fall River, RI-MA Bristol County, MA. Bristol County, RI. Kent County, RI. Newport County, RI. Providence County, RI. Washington County, RI.	1.1278
39340	Provo-Orem, UT Juab County, UT. Utah County, UT.	1.0087
39380	Pueblo, CO Pueblo County, CO.	0.9342
39460	Punta Gorda, FL Charlotte County, FL.	0.9767
39540	Racine, WI Racine County, WI.	1.0025
39580	Raleigh-Cary, NC Franklin County, NC. Johnston County, NC. Wake County, NC.	1.0385
39660	Rapid City, SD Meade County, SD. Pennington County, SD.	0.9300
39740	Reading, PA Berks County, PA.	0.9875
39820	Redding, CA Shasta County, CA.	1.4292
39900	Reno-Sparks, NV Storey County, NV. Washoe County, NV.	1.1309
40060	Richmond, VA Amelia County, VA. Caroline County, VA. Charles City County, VA. Chesterfield County, VA. Cumberland County, VA. Dinwiddie County, VA. Goochland County, VA. Hanover County, VA. Henrico County, VA. King and Queen County, VA. King William County, VA. Louisa County, VA.	0.9948

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
	New Kent County, VA. Powhatan County, VA. Prince George County, VA. Sussex County, VA. Colonial Heights City, VA. Hopewell City, VA. Petersburg City, VA. Richmond City, VA.	
40140	Riverside-San Bernardino-Ontario, CA Riverside County, CA. San Bernardino County, CA.	1.1716
40220	Roanoke, VA Botetourt County, VA. Craig County, VA. Franklin County, VA. Roanoke County, VA. Roanoke City, VA. Salem City, VA.	0.9173
40340	Rochester, MN Dodge County, MN. Olmsted County, MN. Wabasha County, MN.	1.1352
40380	Rochester, NY Livingston County, NY. Monroe County, NY. Ontario County, NY. Orleans County, NY. Wayne County, NY.	0.9349
40420	Rockford, IL Boone County, IL. Winnebago County, IL.	1.0358
40484	Rockingham County—Strafford County, NH Rockingham County, NH. Strafford County, NH.	1.0672
40580	Rocky Mount, NC Edgecombe County, NC. Nash County, NC.	0.9500
40660	Rome, GA Floyd County, GA.	0.9544
40900	Sacramento-Arden-Arcade-Roseville, CA El Dorado County, CA. Placer County, CA. Sacramento County, CA. Yolo County, CA.	1.4254
40980	Saginaw-Saginaw Township North, MI Saginaw County, MI.	0.9301
41060	St. Cloud, MN Benton County, MN. Stearns County, MN.	1.1134
41100	St. George, UT Washington County, UT.	0.9877
41140	St. Joseph, MO—KS Doniphan County, KS. Andrew County, MO. Buchanan County, MO. DeKalb County, MO.	0.9248
41180	St. Louis, MO—IL Bond County, IL. Calhoun County, IL. Clinton County, IL. Jersey County, IL. Macoupin County, IL. Madison County, IL. Monroe County, IL. St. Clair County, IL. Crawford County, MO. Franklin County, MO. Jefferson County, MO. Lincoln County, MO. St. Charles County, MO. St. Louis County, MO.	0.9525

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
41420	Warren County, MO. Washington County, MO. St. Louis City, MO. Salem, OR	1.1158
41500	Marion County, OR. Polk County, OR. Salinas, CA	1.5595
41540	Monterey County, CA. Salisbury, MD	0.9493
41620	Somerset County, MD. Wicomico County, MD. Salt Lake City, UT	0.9920
41660	Salt Lake County, UT. Summit County, UT. Tooele County, UT. San Angelo, TX	0.9055
41700	Irion County, TX. Tom Green County, TX. San Antonio, TX	0.9324
41740	Atascosa County, TX. Bandera County, TX. Bexar County, TX. Comal County, TX. Guadalupe County, TX. Kendall County, TX. Medina County, TX. Wilson County, TX. San Diego-Carlsbad-San Marcos, CA	1.2129
41780	San Diego County, CA. Sandusky, OH	0.9311
41884	Erie County, OH. San Francisco-San Mateo-Redwood City, CA	1.6038
41900	Marin County, CA. San Francisco County, CA. San Mateo County, CA. San Germán-Cabo Rojo, PR	0.7916
41940	Cabo Rojo Municipio, PR. Lajas Municipio, PR. Sabana Grande Municipio, PR. San Germán Municipio, PR. San Jose-Sunnyvale-Santa Clara, CA	1.6608
41980	San Benito County, CA. Santa Clara County, CA. San Juan-Caguas-Guaynabo, PR	0.7916
	Aguas Buenas Municipio, PR. Aibonito Municipio, PR. Arecibo Municipio, PR. Barceloneta Municipio, PR. Barranquitas Municipio, PR. Bayamón Municipio, PR. Caguas Municipio, PR. Camuy Municipio, PR. Canóvanas Municipio, PR. Carolina Municipio, PR. Cataño Municipio, PR. Cayey Municipio, PR. Ciales Municipio, PR. Cidra Municipio, PR. Comerio Municipio, PR. Corozal Municipio, PR. Dorado Municipio, PR. Florida Municipio, PR. Guaynabo Municipio, PR. Gurabo Municipio, PR. Hatillo Municipio, PR. Humacao Municipio, PR. Juncos Municipio, PR. Las Piedras Municipio, PR. Loíza Municipio, PR. Manatí Municipio, PR. Maunabo Municipio, PR.	

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
	Morovis Municipio, PR. Naguabo Municipio, PR. Naranjito Municipio, PR. Orocovis Municipio, PR. Quebradillas Municipio, PR. Río Grande Municipio, PR. San Juan Municipio, PR. San Lorenzo Municipio, PR. Toa Alta Municipio, PR. Toa Baja Municipio, PR. Trujillo Alto Municipio, PR. Vega Alta Municipio, PR. Vega Baja Municipio, PR. Yabucoa Municipio, PR.	
42020	San Luis Obispo-Paso Robles, CA San Luis Obispo County, CA.	1.3181
42044	Santa Ana-Anaheim-Irvine, CA Orange County, CA.	1.2419
42060	Santa Barbara-Santa Maria-Goleta, CA Santa Barbara County, CA.	1.2364
42100	Santa Cruz-Watsonville, CA Santa Cruz County, CA.	1.7016
42140	Santa Fe, NM Santa Fe County, NM.	1.1329
42220	Santa Rosa-Petaluma, CA Sonoma County, CA.	1.5511
42260	Sarasota-Bradenton-Venice, FL Manatee County, FL. Sarasota County, FL.	1.0484
42340	Savannah, GA Bryan County, GA. Chatham County, GA. Effingham County, GA.	0.9638
42540	Scranton-Wilkes-Barre, PA Lackawanna County, PA. Luzerne County, PA. Wyoming County, PA.	0.8926
42644	Seattle-Bellevue-Everett, WA King County, WA. Snohomish County, WA.	1.2214
42680	Sebastian-Vero Beach, FL Indian River County, FL.	0.9934
43100	Sheboygan, WI Sheboygan County, WI.	0.9473
43300	Sherman-Denison, TX Grayson County, TX.	0.8782
43340	Shreveport-Bossier City, LA Bossier Parish, LA. Caddo Parish, LA. De Soto Parish, LA.	0.8946
43580	Sioux City, IA-NE-SD Woodbury County, IA. Dakota County, NE. Dixon County, NE. Union County, SD.	0.9764
43620	Sioux Falls, SD Lincoln County, SD. McCook County, SD. Minnehaha County, SD. Turner County, SD.	1.0093
43780	South Bend-Mishawaka, IN-MI St. Joseph County, IN. Cass County, MI.	1.0150
43900	Spartanburg, SC Spartanburg County, SC.	0.9945
44060	Spokane, WA Spokane County, WA.	1.1035
44100	Springfield, IL Menard County, IL. Sangamon County, IL.	0.9440
44140	Springfield, MA	1.0941

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
44180	Franklin County, MA. Hampden County, MA. Hampshire County, MA. Springfield, MO	0.9177
44220	Christian County, MO. Dallas County, MO. Greene County, MO. Polk County, MO. Webster County, MO. Springfield, OH	0.9176
44300	Clark County, OH. State College, PA	0.9254
44700	Centre County, PA. Stockton, CA	1.2513
44940	San Joaquin County, CA. Sumter, SC	0.9076
45060	Sumter County, SC. Syracuse, NY	1.0460
45104	Madison County, NY. Onondaga County, NY. Oswego County, NY. Tacoma, WA	1.1668
45220	Pierce County, WA. Tallahassee, FL	0.9526
45300	Gadsden County, FL. Jefferson County, FL. Leon County, FL. Wakulla County, FL. Tampa-St. Petersburg-Clearwater, FL	0.9520
45460	Hernando County, FL. Hillsborough County, FL. Pasco County, FL. Pinellas County, FL. Terre Haute, IN	0.9293
45500	Clay County, IN. Sullivan County, IN. Vermillion County, IN. Vigo County, IN. Texarkana, TX-Texarkana, AR	0.8201
45780	Miller County, AR. Bowie County, TX. Toledo, OH	0.9954
45820	Fulton County, OH. Lucas County, OH. Ottawa County, OH. Wood County, OH. Topeka, KS	0.9012
45940	Jackson County, KS. Jefferson County, KS. Osage County, KS. Shawnee County, KS. Wabaunsee County, KS. Trenton-Ewing, NJ	1.1293
46060	Mercer County, NJ. Tucson, AZ	0.9758
46140	Pima County, AZ. Tulsa, OK	0.8803
46220	Creek County, OK. Okmulgee County, OK. Osage County, OK. Pawnee County, OK. Rogers County, OK. Tulsa County, OK. Wagoner County, OK. Tuscaloosa, AL	0.8764
46340	Greene County, AL. Hale County, AL. Tuscaloosa County, AL. Tyler, TX	0.9620
46540	Smith County, TX. Utica-Rome, NY	0.8957

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
46660	Herkimer County, NY. Oneida County, NY. Valdosta, GA Brooks County, GA. Echols County, GA. Lanier County, GA. Lowndes County, GA.	0.8547
46700	Vallejo-Fairfield, CA Solano County, CA.	1.5480
47020	Victoria, TX Calhoun County, TX. Goliad County, TX. Victoria County, TX.	0.8763
47220	Vineland-Millville-Bridgeton, NJ Cumberland County, NJ.	1.0695
47260	Virginia Beach-Norfolk-Newport News, VA-NC Currituck County, NC. Gloucester County, VA. Isle of Wight County, VA. James City County, VA. Mathews County, VA. Surry County, VA. York County, VA. Chesapeake City, VA. Hampton City, VA. Newport News City, VA. Norfolk City, VA. Poquoson City, VA. Portsmouth City, VA. Suffolk City, VA. Virginia Beach City, VA. Williamsburg City, VA.	0.9307
47300	Visalia-Porterville, CA Tulare County, CA.	1.0651
47380	Waco, TX McLennan County, TX.	0.8991
47580	Warner Robins, GA Houston County, GA.	0.9634
47644	Warren-Troy-Farmington Hills, MI Lapeer County, MI. Livingston County, MI. Macomb County, MI. Oakland County, MI. St. Clair County, MI.	1.0556
47894	Washington-Arlington-Alexandria, DC-VA-MD-WV District of Columbia, DC. Calvert County, MD. Charles County, MD. Prince George's County, MD. Arlington County, VA. Clarke County, VA. Fairfax County, VA. Fauquier County, VA. Loudoun County, VA. Prince William County, VA. Spotsylvania County, VA. Stafford County, VA. Warren County, VA. Alexandria City, VA. Fairfax City, VA. Falls Church City, VA. Fredericksburg City, VA. Manassas City, VA. Manassas Park City, VA. Jefferson County, WV.	1.1457
47940	Waterloo-Cedar Falls, IA Black Hawk County, IA. Bremer County, IA. Grundy County, IA.	0.8992
48140	Wausau, WI Marathon County, WI.	1.0216

ADDENDUM G.—CY 2008 ESRD WAGE INDEX FOR URBAN AREAS BASED ON CBSA LABOR MARKET AREAS—Continued

CBSA code	Urban area (constituent counties)	Wage index
48260	Weirton-Steubenville, WV-OH Jefferson County, OH. Brooke County, WV. Hancock County, WV.	0.8364
48300	Wenatchee, WA Chelan County, WA. Douglas County, WA.	1.2105
48424	West Palm Beach-Boca Raton-Boynton Beach, FL Palm Beach County, FL.	1.0268
48540	Wheeling, WV-OH Belmont County, OH. Marshall County, WV. Ohio County, WV.	0.7916
48620	Wichita, KS Butler County, KS. Harvey County, KS. Sedgwick County, KS. Sumner County, KS.	0.9565
48660	Wichita Falls, TX Archer County, TX. Clay County, TX. Wichita County, TX.	0.8359
48700	Williamsport, PA Lycoming County, PA.	0.8489
48864	Wilmington, DE-MD-NJ New Castle County, DE. Cecil County, MD. Salem County, NJ.	1.1424
48900	Wilmington, NC Brunswick County, NC. New Hanover County, NC. Pender County, NC.	0.9932
49020	Winchester, VA-WV Frederick County, VA. Winchester City, VA. Hampshire County, WV.	1.0463
49180	Winston-Salem, NC Davie County, NC. Forsyth County, NC. Stokes County, NC. Yadkin County, NC.	0.9624
49340	Worcester, MA Worcester County, MA.	1.1913
49420	Yakima, WA Yakima County, WA.	1.0837
49500	Yauco, PR Guánica Municipio, PR. Guayanilla Municipio, PR. Peñuelas Municipio, PR. Yauco Municipio, PR.	0.7916
49620	York-Hanover, PA York County, PA.	0.9878
49660	Youngstown-Warren-Boardman, OH-PA Mahoning County, OH. Trumbull County, OH. Mercer County, PA.	0.9501
49700	Yuba City, CA Sutter County, CA. Yuba County, CA.	1.1353
49740	Yuma, AZ Yuma County, AZ.	1.0014

¹ At this time, there are no hospitals located in this urban area on which to base a wage index.

ADDENDUM H.—CY 2008 ESRD WAGE INDEX BASED ON CBSA LABOR MARKET AREAS FOR RURAL AREAS

CBSA code	Nonurban area	Wage index
1	Alabama	0.7951
2	Alaska	1.2781
3	Arizona	0.8949
4	Arkansas	0.7916
5	California	1.2690
6	Colorado	1.0242
7	Connecticut	1.2361
8	Delaware	1.0267
10	Florida	0.8935
11	Georgia	0.8084
12	Hawaii	1.1201
13	Idaho	0.8359
14	Illinois	0.8797
15	Indiana	0.9052
16	Iowa	0.9041
17	Kansas	0.8424
18	Kentucky	0.8225
19	Louisiana	0.7916
20	Maine	0.8946
21	Maryland	0.9535
22	Massachusetts ¹	1.2290
23	Michigan	0.9450
24	Minnesota	0.9583
25	Mississippi	0.8127
26	Missouri	0.8370
27	Montana	0.8844
28	Nebraska	0.9340
29	Nevada	0.9786
30	New Hampshire	1.1466
31	New Jersey ¹	
32	New Mexico	0.9436
33	New York	0.8727
34	North Carolina	0.9080
35	North Dakota	0.7916
36	Ohio	0.9197
37	Oklahoma	0.7916
38	Oregon	1.0456
39	Pennsylvania	0.8850
40	Puerto Rico ¹	0.7916
41	Rhode Island ¹	
42	South Carolina	0.9136
43	South Dakota	0.9023
44	Tennessee	0.8151
45	Texas	0.8410
46	Utah	0.8566
47	Vermont	1.0469
48	Virgin Islands	0.7916
49	Virginia	0.8334
50	Washington	1.0828
51	West Virginia	0.7916
52	Wisconsin	1.0203
53	Wyoming	0.9802

¹ All counties within the State are classified as urban, with the exception of Massachusetts and Puerto Rico. Massachusetts and Puerto Rico have areas designated as rural; however, no short-term, acute care hospitals are located in the area(s) for FY 2008.

ADDENDUM I.—LIST OF CPT¹/HCPCS CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE CATEGORIES² UNDER SECTION 1877 OF THE SOCIAL SECURITY ACT
[Effective Date: January 1, 2008]

CLINICAL LABORATORY SERVICES

INCLUDE CPT codes for all clinical laboratory services in the 80000 series, except EXCLUDE CPT codes for the following blood component collection services:

86890	Autologous blood process.
86891	Autologous blood, op salvage.
86927	Plasma, fresh frozen.
86930	Frozen blood prep.
86931	Frozen blood thaw.
86932	Frozen blood freeze/thaw.
86945	Blood product/irradiation.
86950	Leukocyte transfusion.
86960	Vol reduction of blood/prod.
86965	Pooling blood platelets.
86985	Split blood or products.

INCLUDE the following CPT and HCPCS level 2 codes for other clinical laboratory services:

0026T	Measure remnant lipoproteins.
0030T	Antiprotrombin antibody.
0041T	Detect ur infect agnt w/cpas.
0043T	Co expired gas analysis.
0058T	Cryopreservation, ovary tiss.
0059T	Cryopreservation, oocyte.
0064T	Spectroscop eval expired gas.
0085T	Breath test heart reject.
0087T	Sperm eval hyaluronan.
0103T	Holotranscobalamin.
0104T	At rest cardio gas rebreath.
0111T	RBC membranes fatty acids.
0140T	Exhaled breath condensate ph.
36415	Routine venipuncture.
78110	Plasma volume, single.
78111	Plasma volume, multiple.
78120	Red cell mass, single.
78121	Red cell mass, multiple.
78122	Blood volume.
78130	Red cell survival study.
78191	Platelet survival.
78267	Breath tst attain/anal c-14.
78268	Breath test analysis c-14.
78270	Vit B-12 absorption exam.
78271	Vit B-12 absrp exam, int fac.
78272	Vit B-12 absrp, combined.
78725	Kidney function study.
G0027	Semen analysis.
G0103	Psa, total screening.
G0123	Screen cerv/vag thin layer.
G0124	Screen c/v thin layer by MD.
G0141	Scr c/v cyto,autosys and md.
G0143	Scr c/v cyto,thinlayer,rescr.
G0144	Scr c/v cyto,thinlayer,rescr.
G0145	Scr c/v cyto,thinlayer,rescr.
G0147	Scr c/v cyto, automated sys.
G0148	Scr c/v cyto, autosys, rescr.
G0306	CBC/diffwbc w/o platelet.
G0307	CBC without platelet.
G0328	Fecal blood scrn immunoassay.
G0394	Blood occult test colorectal.
P2028	Cephalin flocculation test.
P2029	Congo red blood test.
P2033	Blood thymol turbidity.
P2038	Blood mucoprotein.
P3000	Screen pap by tech w md supv.
P3001	Screening pap smear by phys.
P9612	Catheterize for urine spec.
P9615	Urine specimen collect mult.
Q0111	Wet mounts/w preparations.
Q0112	Potassium hydroxide preps.
Q0113	Pinworm examinations.
Q0114	Fern test.
Q0115	Post-coital mucous exam.

ADDENDUM I.—LIST OF CPT¹/HCPCS CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE CATEGORIES² UNDER SECTION 1877 OF THE SOCIAL SECURITY ACT—Continued
[Effective Date: January 1, 2008]

PHYSICAL THERAPY, OCCUPATIONAL THERAPY, AND SPEECH-LANGUAGE PATHOLOGY SERVICES

INCLUDE the following CPT and HCPCS codes for physical therapy/occupational therapy/speech-language pathology services:

0019T	Extracorp shock wv tx, ms nos.
0029T	Magnetic tx for incontinence.
64550	Apply neurostimulator.
90901	Biofeedback train, any meth.
90911	Biofeedback peri/uro/rectal.
92506	Speech/hearing evaluation.
92507	Speech/hearing therapy.
92508	Speech/hearing therapy.
92526	Oral function therapy.
92597	Oral speech device eval.
92607	Ex for speech device rx, 1hr.
92608	Ex for speech device rx addl.
92609	Use of speech device service.
92610	Evaluate swallowing function.
92611	Motion fluoroscopy/swallow.
92612	Endoscopy swallow tst (fees).
92614	Laryngoscopic sensory test.
92616	Fees w/laryngeal sense test.
93797	Cardiac rehab.
93798	Cardiac rehab/monitor.
94667	Chest wall manipulation.
94668	Chest wall manipulation.
95831	Limb muscle testing, manual.
95832	Hand muscle testing, manual.
95833	Body muscle testing, manual.
95834	Body muscle testing, manual.
95851	Range of motion measurements.
95852	Range of motion measurements.
96000	Motion analysis, video/3d.
96001	Motion test w/ft press meas.
96002	Dynamic surface emg.
96003	Dynamic fine wire emg.
96105	Assessment of aphasia.
96110	Developmental test, lim.
96111	Developmental test, extend.
96125	Cognitive test by HC pro.
97001	Pt evaluation.
97002	Pt re-evaluation.
97003	Ot evaluation.
97004	Ot re-evaluation.
97010	Hot or cold packs therapy.
97012	Mechanical traction therapy.
97016	Vasopneumatic device therapy.
97018	Paraffin bath therapy.
97022	Whirlpool therapy.
97024	Diathermy eg, microwave.
97026	Infrared therapy.
97028	Ultraviolet therapy.
97032	Electrical stimulation.
97033	Electric current therapy.
97034	Contrast bath therapy.
97035	Ultrasound therapy.
97036	Hydrotherapy.
97039	Physical therapy treatment.
97110	Therapeutic exercises.
97112	Neuromuscular reeducation.
97113	Aquatic therapy/exercises.
97116	Gait training therapy.
97124	Massage therapy.
97139	Physical medicine procedure.
97140	Manual therapy.
97150	Group therapeutic procedures.
97530	Therapeutic activities.
97532	Cognitive skills development.
97533	Sensory integration.
97535	Self care mngment training.
97537	Community/work reintegration.

ADDENDUM I.—LIST OF CPT¹/HCPCS
CODES USED TO DESCRIBE CER-
TAIN DESIGNATED HEALTH SERVICE
CATEGORIES² UNDER SECTION
1877 OF THE SOCIAL SECURITY
ACT—Continued

[Effective Date: January 1, 2008]

97542	Wheelchair mngmt training.
97545	Work hardening.
97546	Work hardening add-on.
97597	Active wound care/20cm or <.
97598	Active wound care > 20cm.
97602	Wound(s) care nonselective.
97605	Neg press wound tx, < 50 cm.
97606	Neg press wound tx, > 50 cm.
97750	Physical performance test.
97755	Assistive technology assess.
97760	Orthotic mgmt and training.
97761	Prosthetic training.
97762	C/O for orthotic/prosth use.
97799	Physical medicine procedure.
G0281	Elec stim unattend for press.
G0283	Elec stim other than wound.
G0329	Electromagnetic tx for ulcers.

**RADIOLOGY AND CERTAIN OTHER IMAGING
SERVICES**

INCLUDE the following CPT and HCPCS codes:

0028T	Dexa body composition study.
0042T	Ct perfusion w/contrast, cbf.
0067T	Ct colonography; dx.
0144T	Ct heart w/ dye; qual calc.
0145T	Ct heart w/wo dye funct.
0146T	Ccta w/wo dye 0147T Ccta w/ wo, quan calcium.
0148T	Ccta w/wo, strxr.
0149T	Ccta w/wo, strxr quan calc.
0150T	Ccta w/wo, disease strxr.
0151T	Ct heart funct add-on.
0159T	Cad breast mri.
0174T	Cad cxr with interp.
0175T	Cad cxr remote.
51798	Us urine capacity measure.
70100	X-ray exam of jaw.
70110	X-ray exam of jaw.
70120	X-ray exam of mastoids.
70130	X-ray exam of mastoids.
70134	X-ray exam of middle ear.
70140	X-ray exam of facial bones.
70150	X-ray exam of facial bones.
70160	X-ray exam of nasal bones.
70190	X-ray exam of eye sockets.
70200	X-ray exam of eye sockets.
70210	X-ray exam of sinuses.
70220	X-ray exam of sinuses.
70240	X-ray exam, pituitary saddle.
70250	X-ray exam of skull.
70260	X-ray exam of skull.
70300	X-ray exam of teeth.
70310	X-ray exam of teeth.
70320	Full mouth x-ray of teeth.
70328	X-ray exam of jaw joint.
70330	X-ray exam of jaw joints.
70336	Magnetic image, jaw joint.
70350	X-ray head for orthodontia.
70355	Panoramic x-ray of jaws.
70360	X-ray exam of neck.
70370	Throat x-ray & fluoroscopy.
70371	Speech evaluation, complex.
70380	X-ray exam of salivary gland.
70450	Ct head/brain w/o dye.
70460	Ct head/brain w/dye.
70470	Ct head/brain w/o & w/dye.
70480	Ct orbit/ear/fossa w/o dye.
70481	Ct orbit/ear/fossa w/dye.
70482	Ct orbit/ear/fossa w/ o& w/dye.
70486	Ct maxillofacial w/o dye.
70487	Ct maxillofacial w/dye.
70488	Ct maxillofacial w/o & w/dye.
70490	Ct soft tissue neck w/o dye.
70491	Ct soft tissue neck w/dye.
70492	Ct sft tsue nck w/o & w/dye.
70496	Ct angiography, head.

ADDENDUM I.—LIST OF CPT¹/HCPCS
CODES USED TO DESCRIBE CER-
TAIN DESIGNATED HEALTH SERVICE
CATEGORIES² UNDER SECTION
1877 OF THE SOCIAL SECURITY
ACT—Continued

[Effective Date: January 1, 2008]

70498	Ct angiography, neck.
70540	Mri orbit/face/neck w/o dye.
70542	Mri orbit/face/neck w/dye.
70543	Mri orb/fac/nck w/o & w/dye.
70544	Mr angiography head w/o dye.
70545	Mr angiography head w/dye.
70546	Mr angiograph head w/o&w/ dye.
70547	Mr angiography neck w/o dye.
70548	Mr angiography neck w/dye.
70549	Mr angiography neck w/o&w/ dye.
70551	Mri brain w/o dye.
70552	Mri brain w/dye.
70553	Mri brain w/o & w/dye.
70554	Fmri brain by tech.
70555	Fmri brain by phys/psych.
71010	Chest x-ray 71015 Chest x-ray.
71020	Chest x-ray.
71021	Chest x-ray.
71022	Chest x-ray.
71023	Chest x-ray and fluoroscopy.
71030	Chest x-ray.
71034	Chest x-ray and fluoroscopy.
71035	Chest x-ray.
71100	X-ray exam of ribs.
71101	X-ray exam of ribs/chest.
71110	X-ray exam of ribs.
71111	X-ray exam of ribs/chest.
71120	X-ray exam of breastbone.
71130	X-ray exam of breastbone.
71250	Ct thorax w/o dye.
71260	Ct thorax w/dye.
71270	Ct thorax w/o & w/dye.
71275	Ct angiography, chest.
71550	Mri chest w/o dye.
71551	Mri chest w/dye.
71552	Mri chest w/o & w/dye.
71555	Mri angio chest w/ or w/o dye.
72010	X-ray exam of spine.
72020	X-ray exam of spine.
72040	X-ray exam of neck spine.
72050	X-ray exam of neck spine.
72052	X-ray exam of neck spine.
72069	X-ray exam of trunk spine.
72070	X-ray exam of thoracic spine.
72072	X-ray exam of thoracic spine.
72074	X-ray exam of thoracic spine.
72080	X-ray exam of trunk spine.
72090	X-ray exam of trunk spine.
72100	X-ray exam of lower spine.
72110	X-ray exam of lower spine.
72114	X-ray exam of lower spine.
72120	X-ray exam of lower spine.
72125	Ct neck spine w/o dye.
72126	Ct neck spine w/dye.
72127	Ct neck spine w/o & w/dye.
72128	Ct chest spine w/o dye.
72129	Ct chest spine w/dye.
72130	Ct chest spine w/o & w/dye.
72131	Ct lumbar spine w/o dye.
72132	Ct lumbar spine w/dye.
72133	Ct lumbar spine w/o & w/dye.
72141	Mri neck spine w/o dye.
72142	Mri neck spine w/dye.
72146	Mri chest spine w/o dye.
72147	Mri chest spine w/dye.
72148	Mri lumbar spine w/o dye.
72149	Mri lumbar spine w/dye.
72156	Mri neck spine w/o & w/dye.
72157	Mri chest spine w/o & w/dye.
72158	Mri lumbar spine w/o & w/dye.
72170	X-ray exam of pelvis.
72190	X-ray exam of pelvis.
72191	Ct angiograph pelv w/o & w/ dye.

ADDENDUM I.—LIST OF CPT¹/HCPCS
CODES USED TO DESCRIBE CER-
TAIN DESIGNATED HEALTH SERVICE
CATEGORIES² UNDER SECTION
1877 OF THE SOCIAL SECURITY
ACT—Continued

[Effective Date: January 1, 2008]

72192	Ct pelvis w/o dye.
72193	Ct pelvis w/dye.
72194	Ct pelvis w/o & w/dye.
72195	Mri pelvis w/o dye.
72196	Mri pelvis w/dye.
72197	Mri pelvis w/o & w/dye.
72198	Mr angio pelvis w/o & w/dye.
72200	X-ray exam sacroiliac joints.
72202	X-ray exam of tailbone.
72200	X-ray exam of collar bone.
73010	X-ray exam of shoulder blade.
73020	X-ray exam of shoulder.
73030	X-ray exam of shoulder.
73050	X-ray exam of shoulders.
73060	X-ray exam of humerus.
73070	X-ray exam of elbow.
73080	X-ray exam of elbow.
73090	X-ray exam of forearm.
73092	X-ray exam of arm, infant.
73100	X-ray exam of wrist.
73110	X-ray exam of wrist.
73120	X-ray exam of hand.
73130	X-ray exam of hand.
73140	X-ray exam of finger(s).
73200	Ct upper extremity w/o dye.
73201	Ct upper extremity w/dye.
73202	Ct uppr extremity w/o & w/dye.
73206	Ct angio upr extrm w/o & w/ dye.
73218	Mri upper extremity w/o dye.
73219	Mri upper extremity w/dye.
73220	Mri uppr extremity w/o & w/dye.
73221	Mri joint upr extrem w/o dye.
73222	Mri joint upr extrem w/dye.
73223	Mri joint upr extr w/o & w/dye.
73500	X-ray exam of hip.
73510	X-ray exam of hip.
73520	X-ray exam of hips.
73540	X-ray exam of pelvis & hips.
73550	X-ray exam of thigh.
73560	X-ray exam of knee, 1 or 2.
73562	X-ray exam of knee, 3.
73564	X-ray exam, knee, 4 or more.
73565	X-ray exam of knees.
73590	X-ray exam of lower leg.
73592	X-ray exam of leg, infant.
73600	X-ray exam of ankle.
73610	X-ray exam of ankle.
73620	X-ray exam of foot.
73630	X-ray exam of foot.
73650	X-ray exam of heel.
73660	X-ray exam of toe(s).
73700	Ct lower extremity w/o dye.
73701	Ct lower extremity w/dye.
73702	Ct lwr extremity w/o & w/dye.
73706	Ct angio lwr extr w/o & w/dye.
73718	Mri lower extremity w/o dye.
73719	Mri lower extremity w/dye.
73720	Mri lwr extremity w/o & w/dye.
73721	Mri jnt of lwr extre w/o dye.
73722	Mri joint of lwr extr w/dye.
73723	Mri joint lwr extr w/o & w/dye.
73725	Mr ang lwr ext w/ or w/o dye.
74000	X-ray exam of abdomen.
74010	X-ray exam of abdomen.
74020	X-ray exam of abdomen.
74022	X-ray exam series, abdomen.
74150	Ct abdomen w/o dye.
74160	Ct abdomen w/dye.
74170	Ct abdomen w/o & w/dye.
74175	Ct angio abdom w/o & w/dye.
74181	Mri abdomen w/o dye.
74182	Mri abdomen w/dye.
74183	Mri abdomen w/o & w/dye.

ADDENDUM I.—LIST OF CPT¹/HCPCS
 CODES USED TO DESCRIBE CER-
 TAIN DESIGNATED HEALTH SERVICE
 CATEGORIES² UNDER SECTION
 1877 OF THE SOCIAL SECURITY
 ACT—Continued

[Effective Date: January 1, 2008]

74185	Mri angio, abdom w orw/o dye.
74210	Contrst x-ray exam of throat.
74220	Contrast x-ray, esophagus.
74230	Cine/vid x-ray, throat/esoph.
74240	X-ray exam, upper gi tract.
74241	X-ray exam, upper gi tract.
74245	X-ray exam, upper gi tract.
74246	Contrst x-ray uppr gi tract.
74247	Contrst x-ray uppr gi tract.
74249	Contrst x-ray uppr gi tract.
74250	X-ray exam of small bowel.
74290	Contrast x-ray, gallbladder.
74291	Contrast x-rays, gallbladder.
74710	X-ray measurement of pelvis.
75557	Cardiac MRI for morph.
75558	Cardiac MRI flow/velocity.
75559	Cardiac MRI w/stress img.
75560	Cardiac MRI flo/vel/stress.
75561	Cardiac MRI for morph w/dye.
75562	Card MRI flow/vel w/dye.
75563	Card MRI w/stress img & dye.
75564	Ht MRI w/flo/vel/strs & dye.
75635	Ct angio abdominal arteries.
76000	Fluoroscope examination.
76010	X-ray, nose to rectum.
76100	X-ray exam of body section.
76101	Complex body section x-ray.
76102	Complex body section x-rays.
76120	Cine/video x-rays.
76125	Cine/video x-rays add-on.
76150	X-ray exam, dry process.
76376	3d render w/o postprocess.
76377	3d rendering w/postprocess.
76380	CAT scan follow-up study.
76499	Radiographic procedure.
76506	Echo exam of head.
76510	Ophth us, b & quant a.
76511	Ophth us, quant a only.
76512	Ophth us, b w/non-quant a.
76513	Echo exam of eye, water bath.
76514	Echo exam of eye, thickness.
76516	Echo exam of eye.
76519	Echo exam of eye.
76536	Us exam of head and neck.
76604	Us exam, chest.
76645	Us exam, breast(s).
76700	Us exam, abdom, complete.
76705	Echo exam of abdomen
76770	Us exam abdo back wall, comp.
76775	Us exam abdo back wall, lim.
76776	Us exam k transl w/Doppler.
76800	Us exam, spinal canal.
76802	Ob us < 14 wks, add'l fetus.
76805	Ob us >= 14 wks, snl fetus.
76810	Ob us >= 14 wks, addl fetus.
76811	Ob us, detailed, snl fetus.
76812	Ob us, detailed, addl fetus.
76815	Ob us, limited, fetus(s).
76816	Ob us, follow-up, per fetus.
76818	Fetal biophys profile w/nst.
76819	Fetal biophys profile w/o nst.
76820	Umbilical artery echo.
76821	Middle cerebral artery echo.
76825	Echo exam of fetal heart.
76826	Echo exam of fetal heart.
76827	Echo exam of fetal heart.
76828	Echo exam of fetal heart.
76856	Us exam, pelvic, complete.
76857	Us exam, pelvic, limited.
76870	Us exam, scrotum.
76880	Us exam, extremity.
76885	Us exam infant hips, dynamic.
76886	Us exam infant hips, static.
76970	Ultrasound exam follow-up.

ADDENDUM I.—LIST OF CPT¹/HCPCS
 CODES USED TO DESCRIBE CER-
 TAIN DESIGNATED HEALTH SERVICE
 CATEGORIES² UNDER SECTION
 1877 OF THE SOCIAL SECURITY
 ACT—Continued

[Effective Date: January 1, 2008]

76977	Us bone density measure.
76999	Echo examination procedure.
77014	Ct scan for therapy guide.
77051	Computer dx mammogram add-on.
77052	Comp screen mammogram add-on.
77055	Mammogram, one breast.
77056	Mammogram, both breasts.
77057	Mammogram, screening.
77058	Mri, one breast.
77059	Mri, both breasts.
77071	X-ray stress view.
77072	X-rays for bone age.
77073	X-rays, bone length studies.
77074	X-rays, bone survey, limited.
77075	X-rays, bone survey complete.
77076	X-rays, bone survey, infant.
77077	Joint survey, single view.
77078	Ct bone density, axial.
77079	Ct bone density, peripheral.
77080	Dxa bone density, axial.
77081	Dxa bone density/peripheral.
77082	Dxa bone density, vert fx.
77083	Radiographic absorptiometry.
77084	Magnetic image, bone marrow.
78000	Thyroid, single uptake.
78001	Thyroid, multiple uptakes.
78003	Thyroid suppress/stimul.
78006	Thyroid imaging with uptake.
78007	Thyroid image, mult uptakes.
78010	Thyroid imaging.
78011	Thyroid imaging with flow.
78015	Thyroid met imaging.
78016	Thyroid met imaging/studies.
78018	Thyroid met imaging, body.
78020	Thyroid met uptake.
78070	Parathyroid nuclear imaging.
78075	Adrenal nuclear imaging.
78099	Endocrine nuclear procedure.
78102	Bone marrow imaging, ltd.
78103	Bone marrow imaging, mult.
78104	Bone marrow imaging, body.
78135	Red cell survival kinetics.
78140	Red cell sequestration.
78185	Spleen imaging.
78190	Platelet survival, kinetics.
78195	Lymph system imaging.
78199	Blood/lymph nuclear exam.
78201	Liver imaging.
78202	Liver imaging with flow.
78205	Liver imaging (3D).
78206	Liver image (3d) with flow.
78215	Liver and spleen imaging.
78216	Liver & spleen image/flow.
78220	Liver function study.
78223	Hepatobiliary imaging.
78230	Salivary gland imaging.
78231	Serial salivary imaging.
78232	Salivary gland function exam.
78258	Esophageal motility study.
78261	Gastric mucosa imaging.
78262	Gastroesophageal reflux exam.
78264	Gastric emptying study.
78278	Acute GI blood loss imaging.
78282	GI protein loss exam.
78290	Meckel's divert exam.
78291	Leveen/shunt patency exam.
78299	GI nuclear procedure.
78300	Bone imaging, limited area.
78305	Bone imaging, multiple areas.
78306	Bone imaging, whole body.
78315	Bone imaging, 3 phase.
78320	Bone imaging (3D).
78399	Musculoskeletal nuclear exam.

ADDENDUM I.—LIST OF CPT¹/HCPCS
 CODES USED TO DESCRIBE CER-
 TAIN DESIGNATED HEALTH SERVICE
 CATEGORIES² UNDER SECTION
 1877 OF THE SOCIAL SECURITY
 ACT—Continued

[Effective Date: January 1, 2008]

78414	Non-imaging heart function.
78428	Cardiac shunt imaging.
78445	Vascular flow imaging.
78456	Acute venous thrombus image.
78457	Venous thrombosis imaging.
78458	Ven thrombosis images, bilat.
78459	Heart muscle imaging (PET).
78460	Heart muscle blood, single.
78461	Heart muscle blood, multiple.
78464	Heart image (3d), single.
78465	Heart image (3d), multiple.
78466	Heart infarct image.
78468	Heart infarct image (ef).
78469	Heart infarct image (3D).
78472	Gated heart, planar, single.
78473	Gated heart, multiple.
78478	Heart wall motion add-on.
78480	Heart function add-on.
78481	Heart first pass, single.
78483	Heart first pass, multiple.
78491	Heart image (pet), single.
78492	Heart image (pet), multiple.
78494	Heart image, spect.
78496	Heart first pass add-on.
78499	Cardiovascular nuclear exam.
78580	Lung perfusion imaging.
78584	Lung V/Q image single breath.
78585	Lung V/Q imaging.
78586	Aerosol lung image, single.
78587	Aerosol lung image, multiple.
78588	Perfusion lung image.
78591	Vent image, 1 breath, 1 proj.
78593	Vent image, 1 proj, gas.
78594	Vent image, mult proj, gas.
78596	Lung differential function.
78599	Respiratory nuclear exam.
78600	Brain image < 4 views.
78601	Brain image w/flow < 4 views.
78605	Brain image 4+ views.
78606	Brain image w/flow 4 + views.
78607	Brain imaging (3D).
78608	Brain imaging (PET).
78610	Brain flow imaging only.
78630	Cerebrospinal fluid scan.
78635	CSF ventriculography.
78645	CSF shunt evaluation.
78647	Cerebrospinal fluid scan.
78650	CSF leakage imaging.
78660	Nuclear exam of tear flow.
78699	Nervous system nuclear exam.
78700	Kidney imaging, morphol.
78701	Kidney imaging with flow.
78707	K flow/funct image w/o drug.
78708	K flow/funct image w/drug.
78709	K flow/funct image, multiple.
78710	Kidney imaging (3D).
78730	Urinary bladder retention.
78740	Ureteral reflux study.
78761	Testicular imaging w/flow.
78799	Genitourinary nuclear exam.
78800	Tumor imaging, limited area.
78801	Tumor imaging, mult areas.
78802	Tumor imaging, whole body.
78803	Tumor imaging (3D).
78804	Tumor imaging, whole body.
78805	Abscess imaging, ltd area.
78806	Abscess imaging, whole body.
78807	Nuclear localization/abscess.
78811	PET image, ltd area.
78812	PET image, skull-thigh.
78813	PET image, full body.
78814	PET image w/ct, lmtd.
78815	PET image w/ct, skull-thigh.
78816	PET image w/ct, full body.
78890	Nuclear medicine data proc.

ADDENDUM I.—LIST OF CPT¹/HCPCS
CODES USED TO DESCRIBE CER-
TAIN DESIGNATED HEALTH SERVICE
CATEGORIES² UNDER SECTION
1877 OF THE SOCIAL SECURITY
ACT—Continued

[Effective Date: January 1, 2008]

78891	Nuclear med data proc.
78999	Nuclear diagnostic exam.
91110	Gi tract capsule endoscopy.
91111	Esophageal capsule endoscopy.
93303	Echo transthoracic.
93304	Echo transthoracic.
93307	Echo exam of heart.
93308	Echo exam of heart.
93320	Doppler echo exam, heart [if used in conjunction with 93303–93308].
93321	Doppler echo exam, heart [if used in conjunction with 93303–93308].
93325	Doppler color flow add-on [if used in conjunction with 93303–93308].
93875	Extracranial study.
93880	Extracranial study.
93882	Extracranial study.
93886	Intracranial study.
93888	Intracranial study.
93890	Tcd, vasoreactivity study.
93892	Tcd, emboli detect w/o inj.
93922	Extremity study.
93923	Extremity study.
93924	Extremity study.
93925	Lower extremity study.
93926	Lower extremity study.
93930	Upper extremity study.
93931	Upper extremity study.
93965	Extremity study.
93970	Extremity study.
93971	Extremity study.
93975	Vascular study.
93976	Vascular study.
93978	Vascular study.
93979	Vascular study.
93980	Penile vascular study.
93981	Penile vascular study.
93990	Doppler flow testing.
A4641	Radiopharm dx agent noc.
A4642	In111 satumomab.
A9500	Tc99m sestamibi.
A9501	Technitium TC–99m teboroxime.
A9502	Tc99m tetrofosmin.
A9503	Tc99m medronate.
A9504	Tc99m apcitide.
A9505	TL201 thallium.
A9507	In111 capromab.
A9508	I131 iodobenguante, dx.
A9509	Iodine I–123 sod iodide mil.
A9510	Tc99m disofenin.
A9512	Tc99m pertechnetate.
A9516	Iodine I–123 sod iodide mic.
A9521	Tc99m exametazime.
A9524	I131 serum albumin, dx.
A9526	Nitrogen N–13 ammonia.
A9528	Iodine I–131 iodide cap, dx.
A9529	I131 iodide sol, dx.
A9531	I131 max 100uCi.
A9532	I125 serum albumin, dx.
A9536	Tc99m depreotide.
A9537	Tc99m mebrofenin.
A9538	Tc99m pyrophosphate.
A9539	Tc99m pentetate.
A9540	Tc99m MAA.
A9541	Tc99m sulfur colloid.
A9542	In111 ibritumomab, dx.
A9544	I131 tositumomab, dx.
A9546	CO57/58.
A9547	In111 oxyquinoline.
A9548	In111 pentetate.

ADDENDUM I.—LIST OF CPT¹/HCPCS
CODES USED TO DESCRIBE CER-
TAIN DESIGNATED HEALTH SERVICE
CATEGORIES² UNDER SECTION
1877 OF THE SOCIAL SECURITY
ACT—Continued

[Effective Date: January 1, 2008]

A9550	Tc99m gluceptate.
A9551	Tc99m succimer.
A9552	F18 fdg.
A9553	Cr51 chromate.
A9554	I125 iothalamate, dx.
A9555	Rb82 rubidium.
A9556	Ga67 gallium.
A9557	Tc99m bicisate.
A9558	Xe133 xenon 10mci.
A9559	Co57 cyano.
A9560	Tc99m labeled rbc.
A9561	Tc99m oxidronate.
A9562	Tc99m mertiatide.
A9566	Tc99m fanolesomab.
A9567	Technetium TC–99m aerosol.
A9568	Technetium tc99m arcitumomab.
A9569	Technetium TC–99m auto WBC.
A9570	Indium In-111 auto WBC.
A9571	Indium In-111 auto platelet.
A9572	Indium In-111 pentetreotide.
A9576	Inj prohance multipack.
A9577	Inj multihance.
A9578	Inj multihance multipack.
A9579	Gad-base MR contrast NOS,1ml.
A9700	Echocardiography contrast.
G0130	Single energy x-ray study.
G0202	Screeningmammographydigital.
G0204	Diagnosticmammographydigital.
G0206	Diagnosticmammographydigital.
G0288	Recon, CTA for surg plan.
G0389	Ultrasound exam AAA screen.
Q0092	Set up port xray equipment.
Q9951	LOCM=400 mg/ml iodine,1ml.
Q9953	Inj Fe-base MR contrast,1ml.
Q9954	Oral MR contrast, 100ml.
Q9955	Inj perflaxane lip micros,ml.
Q9956	Inj octafluoropropane mic,ml.
Q9957	Inj perflutren lip micros,ml.
Q9958	HOCM <=149 mg/ml iodine, 1ml.
Q9959	HOCM 150–199mg/ml iodine,1ml.
Q9960	HOCM 200–249mg/ml iodine,1ml.
Q9961	HOCM 250–299mg/ml iodine,1ml.
Q9962	HOCM 300–349mg/ml iodine,1ml.
Q9963	HOCM 350–399mg/ml iodine,1ml.
Q9964	HOCM>= 400mg/ml iodine, 1ml.
Q9965	LOCM 100–199mg/ml iodine,1ml.
Q9966	LOCM 200–299mg/ml iodine,1ml.
Q9967	LOCM 300–399mg/ml iodine,1ml.
R0070	Transport portable x-ray.
R0075	Transport port x-ray multipl.

RADIATION THERAPY SERVICES AND SUPPLIES

INCLUDE the following CPT and HCPCS codes:

0073T	Delivery, comp imrt.
0182T	HDR elect brachytherapy.
19296	Place po breast cath for rad.
19297	Place breast cath for rad.
19298	Place breast rad tube/caths.
20555	Place ndl musc/tis for rt.
31643	Diag bronchoscope/catheter.
41019	Place needles h&n for rt.
55875	Transper needle place, pros.

ADDENDUM I.—LIST OF CPT¹/HCPCS
CODES USED TO DESCRIBE CER-
TAIN DESIGNATED HEALTH SERVICE
CATEGORIES² UNDER SECTION
1877 OF THE SOCIAL SECURITY
ACT—Continued

[Effective Date: January 1, 2008]

55876	Place rt device/marker, pros.
55920	Place needles pelvic for rt.
57155	Insert uteri tandems/ovoids.
58346	Insert heyman uteri capsule.
61770	Incise skull for treatment.
61793	Focus radiation beam.
77261	Radiation therapy planning.
77262	Radiation therapy planning.
77263	Radiation therapy planning.
77280	Set radiation therapy field.
77285	Set radiation therapy field.
77290	Set radiation therapy field.
77295	Set radiation therapy field.
77299	Radiation therapy planning.
77300	Radiation therapy dose plan.
77301	Radiotherapy dose plan, imrt.
77305	Teletx isodose plan simple.
77310	Teletx isodose plan intermed.
77315	Teletx isodose plan complex.
77321	Special teletx port plan.
77326	Brachytx isodose calc simp.
77327	Brachytx isodose calc interm.
77328	Brachytx isodose plan compl.
77331	Special radiation dosimetry.
77332	Radiation treatment aid(s).
77333	Radiation treatment aid(s).
77334	Radiation treatment aid(s).
77336	Radiation physics consult.
77370	Radiation physics consult.
77371	Srs, multisource.
77372	Srs, linear based.
77373	Sbrt delivery.
77399	External radiation dosimetry.
77401	Radiation treatment delivery.
77402	Radiation treatment delivery.
77403	Radiation treatment delivery.
77404	Radiation treatment delivery.
77406	Radiation treatment delivery.
77407	Radiation treatment delivery.
77408	Radiation treatment delivery.
77409	Radiation treatment delivery.
77411	Radiation treatment delivery.
77412	Radiation treatment delivery.
77413	Radiation treatment delivery.
77414	Radiation treatment delivery.
77416	Radiation treatment delivery.
77417	Radiology port film(s).
77418	Radiation tx delivery, imrt.
77421	Stereoscopic x-ray guidance.
77422	Neutron beam tx, simple.
77423	Neutron beam tx, complex.
77427	Radiation tx management, x5.
77431	Radiation therapy management.
77432	Stereotactic radiation trmt.
77435	Sbrt management.
77470	Special radiation treatment.
77499	Radiation therapy management.
77520	Proton trmt, simple w/o comp.
77522	Proton trmt, simple w/comp.
77523	Proton trmt, intermediate.
77525	Proton treatment, complex.
77600	Hyperthermia treatment.
77605	Hyperthermia treatment.
77610	Hyperthermia treatment.
77615	Hyperthermia treatment.
77620	Hyperthermia treatment.
77750	Infuse radioactive materials.
77761	Apply intrcav radiat simple.
77762	Apply intrcav radiat interm.
77763	Apply intrcav radiat compl.
77776	Apply interstit radiat simpl.
77777	Apply interstit radiat inter.
77778	Apply interstit radiat compl.

ADDENDUM I.—LIST OF CPT¹/HCPCS CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE CATEGORIES² UNDER SECTION 1877 OF THE SOCIAL SECURITY ACT—Continued

[Effective Date: January 1, 2008]

77781	High intensity brachytherapy.
77782	High intensity brachytherapy.
77783	High intensity brachytherapy.
77784	High intensity brachytherapy.
77789	Apply surface radiation.
77790	Radiation handling.
77799	Radium/radioisotope therapy.
79005	Nuclear rx, oral admin.
79101	Nuclear rx, iv admin.
79200	Nuclear rx, intracav admin.
79300	Nuclr rx, interstit colloid.
79403	Hematopoietic nuclear tx.
79440	Nuclear rx, intra-articular.
79445	Nuclear rx, intra-arterial.
79999	Nuclear medicine therapy.
92974	Cath place, cardio brachytx.
A9517	I131 iodide cap, rx.
A9527	Iodine I-125 sodium iodide.
A9530	I131 iodide sol, rx.
A9543	Y90 ibritumomab, rx.
A9545	I131 tositumomab, rx.
A9563	P32 Na phosphate.
A9564	P32 chromic phosphate.
A9600	Sr89 strontium.
A9605	Sm 153 lexidronm.
A9699	Radiopharm rx agent noc.
C1716	Brachytx source, Gold 198.
C1717	Brachytx source, HDR Ir-192.
C1719	Brachytx sour, Non-HDR Ir-192.
C2616	Brachytx source, Yttrium-9.
C2634	Brachytx source, HA, I-125.
C2635	Brachytx source, HA, P-13.
C2636	Brachytx linear source, P-13.
C2637	Brachytx, Ytterbium-169.
C2638	Brachytx, stranded, I-125.
C2639	Brachytx, non-stranded, I-125.
C2640	Brachytx, stranded, P-13.
C2641	Brachytx, non-stranded, P-13.
C2642	Brachytx, stranded, C-131.
C2643	Brachytx, non-stranded, C-131.
C2698	Brachytx, stranded, NOS.
C2699	Brachytx, non-stranded, NOS.
G0173	Linear acc stereo radsur com.
G0251	Linear acc based stero radio.
G0339	Robot lin-radsurg com, first.
G0340	Robt lin-radsurg fractx 2-5.
Q3001	Brachytherapy Radioelements.

EPO AND OTHER DIALYSIS-RELATED DRUGS

The physician self-referral prohibition does not apply to the following codes for EPO and other dialysis-related drugs furnished in or by an ESRD facility if the conditions in § 411.355(g) are satisfied:

ADDENDUM I.—LIST OF CPT¹/HCPCS CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE CATEGORIES² UNDER SECTION 1877 OF THE SOCIAL SECURITY ACT—Continued

[Effective Date: January 1, 2008]

J0630	Calcitonin salmon injection.
J0636	Inj calcitriol per 0.1 mcg.
J0882	Darbepoetin alfa, esrd use.
J0895	Deferoxamine mesylate inj.
J1270	Injection, doxercalciferol.
J1751	Iron dextran 165 injection.
J1752	Iron dextran 267 injection.
J1756	Iron sucrose injection.
J1955	Inj levocarnitine per 1 gm.
J2501	Paricalcitol.
J2916	Na ferric gluconate complex.
J2993	Reteplase injection.
J2995	Inj streptokinase/250000 IU.
J2997	Alteplase recombinant.
J3364	Urokinase 5000 IU injection.
P9041	Albumin (human), 5%, 50ml.
P9045	Albumin (human), 5%, 250ml.
P9046	Albumin (human), 25%, 20ml.
P9047	Albumin (human), 25%, 50ml.
Q4081	Epoetin alfa, 100 units ESRD.

PREVENTIVE SCREENING TESTS, IMMUNIZATIONS AND VACCINES

The physician self-referral prohibition does not apply to the following tests if they are performed for screening purposes and satisfy the conditions in § 411.355(h):

77052	Comp screen mammogram add-on.
77057	Mammogram, screening.
80061	Lipid panel [only when billed with one of the following ICD-9-CM codes: V81.0, V81.1, or V.81.2].
82270	Occult blood, feces.
82465	Assay, bld/serum cholesterol [only when billed with one of the following ICD-9-CM codes: V81.0, V81.1, or V.81.2].
82947	Assay, glucose, blood quant [only when billed with ICD-9-CM code V77.1].
82950	Glucose test [only when billed with ICD-9-CM code V77.1].
82951	Glucose tolerance test (GTT) [only when billed with ICD-9-CM code V77.1].
83718	Assay of lipoprotein [only when billed with one of the following ICD-9-CM codes: V81.0, V81.1, or V.81.2].

ADDENDUM I.—LIST OF CPT¹/HCPCS CODES USED TO DESCRIBE CERTAIN DESIGNATED HEALTH SERVICE CATEGORIES² UNDER SECTION 1877 OF THE SOCIAL SECURITY ACT—Continued

[Effective Date: January 1, 2008]

84478	Assay of triglycerides [only when billed with one of the following ICD-9-CM codes: V81.0, V81.1, or V.81.2].
G0103	Psa, total screening.
G0123	Screen cerv/vag thin layer.
G0124	Screen c/v thin layer by MD.
G0141	Scr c/v cyto, autosys and md.
G0143	Scr c/v cyto, thinlayer, resc.
G0144	Scr c/v cyto, thinlayer, resc.
G0145	Scr c/v cyto, thinlayer, resc.
G0147	Scr c/v cyto, automated sys.
G0148	Scr c/v cyto, autosys, resc.
G0202	Screening mammography digital.
G0328	Fecal blood scrn immunoassay.
G0389	Ultrasound exam AAA screen.
P3000	Screen pap by tech w md supv.
P3001	Screening pap smear by phys.
The physician self-referral prohibition does not apply to the following immunization and vaccine codes if they satisfy the conditions in § 411.355(h):	
90655	Flu vaccine no preserv 6-35m.
90656	Flu vaccine no preserv 3 & >.
90657	Flu vaccine, 3 yrs, im.
90658	Flu vaccine 3 yrs & >, im.
90660	Flu vaccine, nasal.
90669	Pneumococcal vacc, ped <5.
90732	Pneumococcal vaccine.
90740	Hepb vacc, ill pat 3 dose im.
90743	Hep b vacc, adol, 2 dose, im.
90744	Hepb vacc ped/adol 3 dose im.
90746	Hep b vaccine, adult, im.
90747	Hepb vacc, ill pat 4 dose im.

¹ CPT codes and descriptions only are copyright 2007 American Medical Association. All rights are reserved and applicable FARS/DFARS clauses apply.

² This list does not include codes for the following designated health service (DHS) categories: durable medical equipment and supplies; parenteral and enteral nutrients, equipment and supplies; prosthetics, orthotics, and prosthetic devices and supplies; home health services; outpatient prescription drugs; and inpatient and outpatient hospital services. For the definitions of these DHS categories, refer to § 411.351. For more information, refer to the CMS Web site at <http://www.cms.hhs.gov/PhysicianSelfReferral/>.

[FR Doc. 07-5506 Filed 11-1-07; 4:00 pm]

BILLING CODE 4120-01-P



Federal Register

**Tuesday,
November 27, 2007**

**Book 2 of 2 Books
Pages 66579–67226**

Part III

Department of Health and Human Services

Centers for Medicare & Medicaid Services

**42 CFR Parts 410, 411, 412, et al.
Medicare and Medicaid Programs; Interim
and Final Rule**

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Medicare & Medicaid Services**

42 CFR Parts 410, 411, 412, 413, 414, 416, 419, 482, and 485

[CMS-1392-FC], [CMS-1533-F2], and [CMS-1531-IFC2]

RIN 0938-AO71, RIN 0938-AO70, and RIN 0938-AO35

Medicare Program: Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates, the Ambulatory Surgical Center Payment System and CY 2008 Payment Rates, the Hospital Inpatient Prospective Payment System and FY 2008 Payment Rates; and Payments for Graduate Medical Education for Affiliated Teaching Hospitals in Certain Emergency Situations Medicare and Medicaid Programs: Hospital Conditions of Participation; Necessary Provider Designations of Critical Access Hospitals

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Interim and final rule with comment period.

SUMMARY: This final rule with comment period revises the Medicare hospital outpatient prospective payment system to implement applicable statutory requirements and changes arising from our continuing experience with this system. We describe the changes to the amounts and factors used to determine the payment rates for Medicare hospital outpatient services paid under the prospective payment system. These changes are applicable to services furnished on or after January 1, 2008. In addition, the rule sets forth the applicable relative payment weights and amounts for services furnished in ASCs, specific HCPCS codes to which the final policies of the ASC payment system apply, and other pertinent rate setting information for the CY 2008 ASC payment system. Furthermore, this final rule with comment period will make changes to the policies relating to the necessary provider designations of critical access hospitals and changes to several of the current conditions of participation requirements.

The attached document also incorporates the changes to the FY 2008 hospital inpatient prospective payment system (IPPS) payment rates made as a result of the enactment of the TMA, Abstinence Education, and QI Programs Extension Act of 2007, Public Law 110-

90. In addition, we are changing the provisions in our previously issued FY 2008 IPPS final rule and are establishing a new policy, retroactive to October 1, 2007, of not applying the documentation and coding adjustment to the FY 2008 hospital-specific rates for Medicare-dependent, small rural hospitals (MDHs) and sole community hospitals (SCHs). In the interim final rule with comment period in this document, we are modifying our regulations relating to graduate medical education (GME) payments made to teaching hospitals that have Medicare affiliation agreements for certain emergency situations.

DATES: *Effective Date:* The provisions of this rule are effective on January 1, 2008.

IPPS Payment Rates: The FY 2008 IPPS payment rates, provided in section XIX of the preamble of this document, became effective October 1, 2007.

Comment Period: We will consider comments on the payment classifications assigned to HCPCS codes identified in Addenda B, AA, and BB to this final rule with the "NI" comment indicator, and other areas specified throughout this rule, at the appropriate address, as provided below, no later than 5 p.m. EST on January 28, 2008. We will also consider comments relating to the Medicare GME teaching hospital affiliated agreement provisions, as provided below, no later than 5 p.m. EST on January 28, 2008.

Application Deadline—New Class of New Technology Intraocular Lenses: Requests for review of applications for a new class of new technology intraocular lenses must be received by 5 p.m. EST on April 1, 2008.

Deadline for Submission of Written Medicare GME Affiliation Agreements: Written Medicare GME affiliation agreements must be received by 5 p.m. EST on January 1, 2008.

ADDRESSES: In commenting, please refer to file codes CMS-1392-FC (for OPSS and ASC matters) or CMS-1531-IFC (for Medicare GME matters), as appropriate. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission.

You may submit comments in one of four ways (no duplicates, please):

1. *Electronically.* You may submit electronic comments on specific issues in this regulation to <http://www.cms.hhs.gov/eRulemaking>. Click on the link "Submit electronic comments on CMS regulations with an open comment period." (Attachments should be in Microsoft Word, WordPerfect, or Excel; however, we prefer Microsoft Word.)

2. *By regular mail.* You may mail written comments (one original and two copies) to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1392-FC (for OPSS and ASC matters), Attention: CMS-1531-IFC (for Medicare GME matters), P.O. Box 8013, Baltimore, MD 21244-1850.

Please allow sufficient time for mailed comments to be received before the close of the comment period.

3. *By express or overnight mail.* You may send written comments (one original and two copies) to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1392-FC (for OPSS and ASC matters), Attention: CMS-1531-IFC (for Medicare GME matters), Mail Stop C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850.

4. *By hand or courier.* If you prefer, you may deliver (by hand or courier) your written comments (one original and two copies) before the close of the comment period to one of the following addresses: Room 445-G, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201; or 7500 Security Boulevard, Baltimore, MD 21244-1850.

If you intend to deliver your comments to the Baltimore address, please call telephone number (410) 786-9994 in advance to schedule your arrival with one of our staff members.

(Because access to the interior of the Hubert H. Humphrey Building is not readily available to persons without Federal Government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of the building. A stamp-in clock is available for persons who wish to retain proof of filing by stamping in and retain an extra copy of the comments being filed.)

Comments mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received after the comment period.

For information on viewing public comments, see the beginning of the **SUPPLEMENTARY INFORMATION** section.

Applications for a new class of new technology intraocular lenses: Requests for review of applications for a new class of new technology intraocular lenses must be sent by regular mail to: ASC/NTIOL, Division of Outpatient Care, Mailstop C4-05-17, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244-1850.

Submissions of written Medicare GME affiliation agreements: Written

Medicare GME affiliation agreements must be sent by regular mail to: Centers for Medicare and Medicaid Services, Division of Acute Care, Attention: Elizabeth Troung or Renate Rockwell, Mailstop C4-08-06, 7500 Security Boulevard, Baltimore, MD 21244-1850.

FOR FURTHER INFORMATION CONTACT:

Alberta Dwivedi, (410) 786-0378, Hospital outpatient prospective payment issues.

Dana Burley, (410) 786-0378, Ambulatory surgical center issues.

Suzanne Asplen, (410) 786-4558, Partial hospitalization and community mental health center issues.

Sheila Blackstock, (410) 786-3502, Reporting of quality data issues.

Mary Collins, (410) 786-3189, and Jeannie Miller, (410) 786-3164, Necessary provider designations for CAHs issues.

Scott Cooper, (410) 786-9465, and Jeannie Miller, (410) 786-3164, Hospital conditions of participation issues.

Miechal Lefkowitz, (410) 786-5316, Hospital inpatient prospective payment system issues.

Tzvi Hefter, (410) 786-4487, Graduate medical education program issues.

SUPPLEMENTARY INFORMATION:

Submitting Comments: We welcome comments from the public on the OPPS APC assignments and/or status indicators assigned to HCPCS codes identified in Addendum B to this final rule with comment period with comment indicator "NI" and on the ASC payment indicators assigned to HCPCS codes identified in Addenda AA and BB to this final rule with comment period with comment indicator "NI" in order to assist us in fully considering issues and developing OPPS and ASC payment policies for those services. You can assist us by referencing file code CMS-1392-FC.

We also welcome comments from the public on all issues set forth regarding the revised regulations regarding the Medicare GME affiliation agreements to assist us in fully considering issues and developing policies. You can assist us by referencing the file code CMS-1531-IFC2 and the specific "issue identifier" that precedes the section on which you choose to comment.

Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following Web site as soon as possible after they have

been received: <http://www.cms.hhs.gov/eRulemaking>. Click on the link "Electronic Comments on CMS Regulations" on that Web site to view public comments.

Comments received timely will also be available for public inspection as they are received, generally beginning approximately 3 weeks after publication of a document, at the headquarters of the Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244, on Monday through Friday of each week from 8:30 a.m. to 4 p.m. To schedule an appointment to view public comments, phone 1-800-743-3951.

Electronic Access

This **Federal Register** document is also available from the **Federal Register** online database through *GPO Access*, a service of the U.S. Government Printing Office. Free public access is available on a Wide Area Information Server (WAIS) through the Internet and via asynchronous dial-in. Internet users can access the database by using the World Wide Web; the Superintendent of Documents' home page address is <http://www.gpoaccess.gov/index.html>, by using local WAIS client software, or by telnet to swais.access.gpo.gov, then login as guest (no password required). Dial-in users should use communications software and modem to call (202) 512-1661; type swais, then login as guest (no password required).

Alphabetical List of Acronyms Appearing in This Final Rule With Comment Period

ACEP American College of Emergency Physicians
 AHA American Hospital Association
 AHIMA American Health Information Management Association
 AMA American Medical Association
 APC Ambulatory payment classification
 AMP Average manufacturer price
 ASC Ambulatory Surgical Center
 ASP Average sales price
 AWP Average wholesale price
 BBA Balanced Budget Act of 1997, Pub. L. 105-33
 BBRA Medicare, Medicaid, and SCHIP [State Children's Health Insurance Program] Balanced Budget Refinement Act of 1999, Pub. L. 106-113
 BCA Blue Cross Association
 BCBSA Blue Cross and Blue Shield Association
 BIPA Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000, Pub. L. 106-554
 CAH Critical access hospital
 CAP Competitive Acquisition Program
 CBSA Core-Based Statistical Area
 CCR Cost-to-charge ratio
 CERT Comprehensive Error Rate Testing
 CMHC Community mental health center

CMS Centers for Medicare & Medicaid Services
 CoP [Hospital] Condition of participation
 CORF Comprehensive outpatient rehabilitation facility
 CPT [Physicians'] Current Procedural Terminology, Fourth Edition, 2007, copyrighted by the American Medical Association
 CRNA Certified registered nurse anesthetist
 CY Calendar year
 DMEPOS Durable medical equipment, prosthetics, orthotics, and supplies
 DMERC Durable medical equipment regional carrier
 DRA Deficit Reduction Act of 2005, Pub. L. 109-171
 DSH Disproportionate share hospital
 EACH Essential Access Community Hospital
 E/M Evaluation and management
 EPO Erythropoietin
 ESRD End-stage renal disease
 FACA Federal Advisory Committee Act, Pub. L. 92-463
 FAR Federal Acquisition Regulations
 FDA Food and Drug Administration
 FFS Fee-for-service
 FSS Federal Supply Schedule
 FTE Full-time equivalent
 FY Federal fiscal year
 GAO Government Accountability Office
 GME Graduate medical education
 HCPCS Healthcare Common Procedure Coding System
 HCRIS Hospital Cost Report Information System
 HHA Home health agency
 HIPAA Health Insurance Portability and Accountability Act of 1996, Pub. L. 104-191
 HOPD Hospital outpatient department
 HOP QDRP Hospital Outpatient Quality Data Reporting Program
 ICD-9-CM International Classification of Diseases, Ninth Edition, Clinical Modification
 IDE Investigational device exemption
 IME Indirect medical education
 IOL Intraocular lens
 IPPS [Hospital] Inpatient prospective payment system
 IVIG Intravenous immune globulin
 MAC Medicare Administrative Contractors
 MedPAC Medicare Payment Advisory Commission
 MDH Medicare-dependent, small rural hospital
 MIEA-TRHCA Medicare Improvements and Extension Act under Division B, Title I of the Tax Relief Health Care Act of 2006, Pub. L. 109-432
 MMA Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. 108-173
 MPFS Medicare Physician Fee Schedule
 MSA Metropolitan Statistical Area
 NCCI National Correct Coding Initiative
 NCD National Coverage Determination
 NTIOL New technology intraocular lens
 OCE Outpatient Code Editor
 OMB Office of Management and Budget
 OPD [Hospital] Outpatient department
 OPPS [Hospital] Outpatient prospective payment system
 PHP Partial hospitalization program

PM Program memorandum
 PPI Producer Price Index
 PPS Prospective payment system
 PPV Pneumococcal pneumonia vaccine
 PRA Paperwork Reduction Act
 QIO Quality Improvement Organization
 RFA Regulatory Flexibility Act
 RHQDAPU Reporting Hospital Quality Data for Annual Payment Update [Program]
 RHHI Regional home health intermediary
 SBA Small Business Administration
 SCH Sole community hospital
 SDP Single Drug Pricer
 SI Status indicator
 TEFRA Tax Equity and Fiscal Responsibility Act of 1982, Pub. L. 97-248
 TOPS Transitional outpatient payments
 USPDI United States Pharmacopoeia Drug Information
 WAC Wholesale acquisition cost

In this document, we address several payment systems under the Medicare program: The hospital outpatient prospective payment system (OPPS); the revised ambulatory surgical center (ASC) payment system; the hospital inpatient prospective payment system (IPPS); and payments for direct and indirect graduate medical education (GME). The provisions relating to the OPPS are included in sections I. through XV., XVII., XXI. through XXIV. of this final rule with comment period and in Addenda A, B, C (Addendum C is available on the Internet only; see section XXI. of this final rule with comment period), D1, D2, E, L, and M to this final rule with comment period. The provisions related to the revised ASC payment system are included in sections XVI., XVII., and XXI. through XXIV. of this final rule with comment period and in Addenda AA, BB, DD1, DD2, and EE (Addendum EE is available on the Internet only; see section XXI. of this final rule with comment period) to this final rule with comment period.

The provisions relating to the IPPS payment rates are included in section XIX., XXIV., and XXV. of this document. The provisions relating to policy changes to the Medicare GME affiliation provisions for teaching hospitals in certain emergency situations are included in sections XX., XXIV., and XXV. of this document.

Table of Contents

- I. Background for the OPPS
- A. Legislative and Regulatory Authority for the Hospital Outpatient Prospective Payment System
 - B. Excluded OPPS Services and Hospitals
 - C. Prior Rulemaking
 - D. APC Advisory Panel
 1. Authority of the APC Panel
 2. Establishment of the APC Panel
 3. APC Panel Meetings and Organizational Structure
 - E. Provisions of the Medicare Improvements and Extension Act under

- Division B, Title I of the Tax Relief and Health Care Act of 2006
- F. Summary of the Major Contents of the CY 2008 OPPS/ASC Proposed Rule
1. Updates Affecting OPPS Payments
 2. OPPS Ambulatory Payment Classification (APC) Group Policies
 3. OPPS Payment for Devices
 4. OPPS Payment for Drugs, Biologicals, and Radiopharmaceuticals
 5. Estimate of OPPS Transitional Pass-Through Spending for Drugs, Biologicals, and Devices
 6. OPPS Payment for Brachytherapy Sources
 7. OPPS Coding and Payment for Drug Administration Services
 8. OPPS Hospital Coding and Payment for Visits
 9. OPPS Payment for Blood and Blood Products
 10. OPPS Payment for Observation Services
 11. Procedures That Will Be Paid Only as Inpatient Services
 12. Nonrecurring Technical and Policy Changes
 13. OPPS Payment Status and Comment Indicators
 14. OPPS Policy and Payment Recommendations
 15. Update of the Revised ASC Payment System
 16. Quality Data for Annual Payment Updates
 17. Changes Affecting Necessary Provider Critical Access Hospitals (CAHs) and Hospital Conditions of Participation (CoPs)
 18. Regulatory Impact Analysis
- G. Public Comments Received in Response to the CY 2008 OPPS/ASC Proposed Rule
- H. Public Comments Received on the November 24, 2006 OPPS/ASC Final Rule with Comment Period
- II. Updates Affecting OPPS Payments
- A. Recalibration of APC Relative Weights
1. Database Construction
 - a. Database Source and Methodology
 - b. Use of Single and Multiple Procedure Claims
 - (1) Use of Date of Service Stratification and a Bypass List to Increase the Amount of Data Used to Determine Medians
 - (2) Exploration of Allocation of Packaged Costs to Separately Paid Procedure Codes
 - c. Calculation of CCRs
 2. Calculation of Median Costs
 3. Calculation of OPPS Scaled Payment Weights
 4. Changes to Packaged Services
 - a. Background
 - b. Addressing Growth in OPPS Volume and Spending
 - c. Packaging Approach
 - (1) Guidance Services
 - (2) Image Processing Services
 - (3) Intraoperative Services
 - (4) Imaging Supervision and Interpretation Services
 - (5) Diagnostic Radiopharmaceuticals
 - (6) Contrast Agents
 - (7) Observation Services
 - d. Development of Composite APCs

- (1) Background
 - (2) Low Dose Rate (LDR) Prostate Brachytherapy Composite APC
 - (a) Background
 - (b) Payment for LDR Prostate Brachytherapy
 - (3) Cardiac Electrophysiologic Evaluation and Ablation Composite APC
 - (a) Background
 - (b) Payment for Cardiac Electrophysiologic Evaluation and Ablation
 - e. Service-Specific Packaging Issues
 - B. Payment for Partial Hospitalization
 1. Background
 2. PHP APC Update
 3. Separate Threshold for Outlier Payments to CMHCs
 - C. Conversion Factor Update
 - D. Wage Index Changes
 - E. Statewide Average Default CCRs
 - F. OPPS Payments to Certain Rural Hospitals
 1. Hold Harmless Transitional Payment Changes Made by Pub. L. 109-171 (DRA)
 2. Adjustment for Rural SCHs Implemented in CY 2006 Related to Pub. L. 108-173 (MMA)
 - G. Hospital Outpatient Outlier Payments
 - H. Calculation of an Adjusted Medicare Payment from the National Unadjusted Medicare Payment
 - I. Beneficiary Copayments
 1. Background
 2. Copayment
 3. Calculation of an Adjusted Copayment Amount for an APC Group
- III. OPPS Ambulatory Payment Classification (APC) Group Policies
- A. Treatment of New HCPCS and CPT Codes
1. Treatment of New HCPCS Codes Included in the April and July Quarterly OPPS Updates for CY 2007
 - a. Background
 - b. Implantation of Interstitial Devices (APC 0156)
 - c. Other New HCPCS Codes Implemented in April or July 2007
 2. Treatment of New Category I and III CPT Codes and Level II HCPCS Codes
 - a. Establishment and Assignment of New Codes
 - b. Electronic Brachytherapy (New Technology APC 1519)
 - c. Other Mid-Year CPT Codes
- B. Variations within APCs
1. Background
 2. Application of the 2 Times Rule
 3. Exceptions to the 2 Times Rule
- C. New Technology APCs
1. Introduction
 2. Movement of Procedures from New Technology APCs to Clinical APCs
 - a. Positron Emission Tomography (PET)/Computed Tomography (CT) Scans (APC 0308)
 - b. IVIG Preadministration-Related Services (APC 0430)
 - c. Other Services in New Technology APCs
 - (1) Breast Brachytherapy Catheter Implantation (APC 0648)
 - (2) Preoperative Services for Lung Volume Reduction Surgery (LVRS) (APCs 0209 and 0213)
- D. APC Specific Policies
1. Cardiac Procedures

- a. Cardiac Computed Tomography and Computed Tomographic Angiography (APCs 0282 and 0383)
- b. Coronary and Non-Coronary Angioplasty (PTCA/PTA)(APCs 0082, 0083, and 0103)
- c. Implantation of Cardioverter-Defibrillators (APCs 0107 and 0108)
- d. Removal of Patient-Activated Cardiac Event Recorder (APC 0109)
- e. Stress Echocardiography (APC 0697)
- 2. Gastrointestinal Procedures
 - a. Computed Tomographic Colonography (APC 0332)
 - b. Laparoscopic Neurostimulator Electrode Implantation (APC 0130)
 - c. Screening Colonoscopies and Screening Flexible Sigmoidoscopies (APCs 0158 and 0159)
- 3. Genitourinary Procedures
 - a. Cystoscopy with Stent (APC 0163)
 - b. Percutaneous Renal Cryoablation (APC 0423)
 - c. Prostatic Thermotherapy (APC 0163)
 - d. Radiofrequency Ablation of Prostate (APC 0163)
 - e. Ultrasound Ablation of Uterine Fibroids with Magnetic Resonance Guidance (MRgFUS) (APC 0067)
 - f. Uterine Fibroid Embolization (APC 0202)
- 4. Nervous System Procedures
 - a. Chemodenervation (APC 0206)
 - b. Implantation of Intrathecal or Epidural Catheter (APC 0224)
 - c. Implantation of Spinal Neurostimulators (APC 0222)
- 5. Nuclear Medicine and Radiation Oncology Procedures
 - a. Adrenal Imaging (APC 0391)
 - b. Injection for Sentinel Node Identification (APC 0389)
 - c. Myocardial Positron Emission Tomography (PET) Scans (APC 0307)
 - d. Nonmyocardial Positron Emission Tomography (PET) Scans (APC 0308)
 - e. Proton Beam Therapy (APCs 0664 and 0667)
- 6. Ocular and Ear, Nose and Throat Procedures
 - a. Amniotic Membrane for Ocular Surface Reconstruction (APC 0244)
 - b. Keratoprosthesis (APC 0293)
 - c. Palatal Implant (New Technology APC 1510)
- 7. Orthopedic Procedures
 - a. Arthroscopic Procedures (APCs 0041 and 0042)
 - b. Closed Fracture Treatment (APC 0043)
 - c. Insertion of Posterior Spinous Process Distraction Device (APC 0050)
 - d. Intradiscal Annuloplasty (APC 0050)
 - e. Kyphoplasty Procedures (APC 0052)
- 8. Vascular Procedures
 - a. Blood Transfusion (APC 0110)
 - b. Endovenous Ablation (APC 0092)
 - c. Insertion of Central Venous Access Device (APC 0625)
 - d. Noninvasive Vascular Studies (APC 0267)
- 9. Other Procedures
 - a. Hyperbaric Oxygen Therapy (APC 0659)
 - b. Skin Repair Procedures (APCs 0133, 0134, 0135, 0136, and 0137)
 - c. Stereotactic Radiosurgery (SRS) Treatment Delivery Services (APCs 0065, 0066, and 0067)
- 10. Medical Services
 - a. Single Allergy Tests (APC 0381)
 - b. Continuous Glucose Monitoring (APC 0097)
 - c. Home International Normalized Ratio (INR) Monitoring (APC 0097)
 - d. Mental Health Services (APC 0322, 0323, 0324, 0325)
- IV. OPSS Payment for Devices
 - A. Treatment of Device Dependent APCs
 - 1. Background
 - 2. Payment under the OPSS
 - 3. Payment When Devices Are Replaced with Partial Credit to the Hospital
 - B. Pass-Through Payments for Devices
 - 1. Expiration of Transitional Pass Through Payments for Certain Devices
 - a. Background
 - b. Final Policy
 - 2. Provisions for Reducing Transitional Pass Through Payments to Offset Costs Packaged into APC Groups
 - a. Background
 - b. Final Policy
- V. OPSS Payment Changes for Drugs, Biologicals, and Radiopharmaceuticals
 - A. Transitional Pass-Through Payment for Additional Costs of Drugs and Biologicals
 - 1. Background
 - 2. Drugs and Biologicals with Expiring Pass-Through Status in CY 2007
 - 3. Drugs and Biologicals with Pass-Through Status in CY 2008
 - B. Payment for Drugs, Biologicals, and Radiopharmaceuticals without Pass Through Status
 - 1. Background
 - 2. Criteria for Packaging Payment for Drugs and Biologicals
 - 3. Payment for Drugs and Biologicals without Pass Through Status That Are Not Packaged
 - a. Payment for Specified Covered Outpatient Drugs
 - (1) Background
 - (2) Payment Policy
 - (3) Payment for Blood Clotting Factors
 - (a) Background
 - (b) Payment for Diagnostic Radiopharmaceuticals
 - (c) Payment for Therapeutic Radiopharmaceuticals
 - b. Payment for Nonpass-Through Drugs, Biologicals, and Radiopharmaceuticals with HCPCS Codes, But without OPSS Hospital Claims Data
- VI. Estimate of OPSS Transitional Pass Through Spending for Drugs, Biologicals, Radiopharmaceuticals, and Devices
 - A. Total Allowed Pass Through Spending
 - B. Estimate of Pass Through Spending
- VII. OPSS Payment for Brachytherapy Sources
 - A. Background
 - B. Payment for Brachytherapy Sources
- VIII. OPSS Drug Administration Coding and Payment
 - A. Background
 - B. Coding and Payment for Drug Administration Services
- IX. Hospital Coding and Payments for Visits
 - A. Background
 - B. Policies for Hospital Outpatient Visits
 - 1. Clinic Visits: New and Established Patient Visits and Consultations
 - 2. Emergency Department Visits
 - C. Visit Reporting Guidelines
 - 1. Background
 - 2. CY 2007 Work on Visit Guidelines
 - 3. Visit Guidelines
- X. OPSS Payment for Blood and Blood Products
 - A. Background
 - B. Payment for Blood and Blood Products
- XI. OPSS Payment for Observation Services
 - A. Observation Services (HCPCS Code G0378)
 - B. Direct Admission to Observation (HCPCS Code G0379)
- XII. Procedures That Will Be Paid Only as Inpatient Procedures
 - A. Background
 - B. Changes to the Inpatient List
- XIII. Nonrecurring Technical and Policy Changes
 - A. Outpatient Hospital Services and Supplies Incident to a Physician Service
 - B. Interrupted Procedures
 - C. Transitional Adjustments—Hold Harmless Provisions
 - D. Reporting of Wound Care Services
 - E. Reporting of Cardiac Rehabilitation Services
 - F. Reporting of Bone Marrow and Stem Cell Processing Services
 - G. Reporting of Alcohol and/or Substance Abuse Assessment and Intervention Services
- XIV. OPSS Payment Status and Comment Indicators
 - A. Payment Status Indicator Definitions
 - 1. Payment Status Indicators to Designate Services That Are Paid under the OPSS
 - 2. Payment Status Indicators to Designate Services That Are Paid under a Payment System Other Than the OPSS
 - 3. Payment Status Indicators to Designate Services That Are Not Recognized under the OPSS But That May Be Recognized by Other Institutional Providers
 - 4. Payment Status Indicators to Designate Services That Are Not Payable by Medicare
 - B. Comment Indicator Definitions
- XV. OPSS Policy and Payment Recommendations
 - A. MedPAC Recommendations
 - B. APC Panel Recommendations
- XVI. Update of the Revised Ambulatory Surgical Center Payment System
 - A. Legislative and Regulatory Authority for the ASC Payment System
 - B. Rulemaking for the Revised ASC Payment System
 - C. Revisions to the ASC Payment System Effective January 1, 2008
 - 1. Covered Surgical Procedures under the Revised ASC Payment System
 - a. Definition of Surgical Procedure
 - b. Identification of Surgical Procedures Eligible for Payment under the Revised ASC Payment System
 - c. Payment for Covered Surgical Procedures under the Revised ASC Payment System
 - (1) General Policies
 - (2) Office-Based Procedures
 - (3) Device-Intensive Procedures
 - (4) Multiple and Interrupted Procedure Discounting
 - (5) Transition to Revised ASC Payment Rates

2. Covered Ancillary Services under the Revised ASC Payment System
 - a. General Policies
 - b. Payment Policies for Specific Items and Services
 - (1) Radiology Services
 - (2) Brachytherapy Sources
 3. General Payment Policies
 - a. Adjustment for Geographic Wage Differences
 - b. Beneficiary Coinsurance
 - D. Treatment of New HCPCS Codes
 1. Treatment of New CY 2008 Category I and III CPT Codes and Level II HCPCS Codes
 2. Treatment of New Mid-Year Category III CPT Codes
 3. Treatment of Level II HCPCS Codes Released on a Quarterly Basis
 - E. Updates to Covered Surgical Procedures and Covered Ancillary Services
 1. Identification of Covered Surgical Procedures
 - a. General Policies
 - b. Changes in Designation of Covered Surgical Procedures as Office-Based
 - c. Changes in Designation of Covered Surgical Procedures as Device Intensive
 2. Changes in Identification of Covered Ancillary Services
 - F. Payment for Covered Surgical Procedures and Covered Ancillary Services
 1. Payment for Covered Surgical Procedures
 - a. Update to Payment Rates
 - b. Payment Policies When Devices Are Replaced at No Cost or with Credit
 - (1) Policy When Devices Are Replaced at No Cost or with Full Credit
 - (2) Policy When Implantable Devices Are Replaced with Partial Credit
 2. Payment for Covered Ancillary Services
 - G. Physician Payment for Procedures and Services Provided in ASC
 - H. Changes to Definitions of "Radiology and Certain Other Imaging Services" and "Outpatient Prescription Drugs"
 - I. New Technology Intraocular Lenses (NTIOLs)
 1. Background
 2. Changes to the NTIOL Determination Process Finalized for CY 2008
 3. NTIOL Application Process for CY 2008 Payment Adjustment
 4. Classes of NTIOLs Approved for Payment Adjustment
 5. Payment Adjustment
 6. CY 2008 ASC Payment for Insertion of IOLs
 - J. ASC Payment and Comment Indicators
 - K. ASC Policy and Payment Recommendations
 - L. Calculation of the ASC Conversion Factor and ASC Payment Rates
- XVII. Reporting Quality Data for Annual Payment Rate Updates
 - A. Background
 1. Reporting Hospital Outpatient Quality Data for Annual Payment Update
 2. Reporting ASC Quality Data for Annual Payment Increase
 3. Reporting Hospital Inpatient Quality Data for Annual Payment Update
 - B. Hospital Outpatient Measures
 - C. Other Hospital Outpatient Measures
 - D. Implementation of the HOP QDRP and Request for Additional Suggested Measures
 - E. Requirements for HOP Quality Data Reporting for CY 2009 and Subsequent Calendar Years
 1. Administrative Requirements
 2. Data Collection and Submission Requirements
 3. HOP QDRP Validation Requirements
 - F. Publication of HOP QDRP Data Collected
 - G. Attestation Requirement for Future Payment Years
 - H. HOP QDRP Reconsiderations
 - I. Reporting of ASC Quality Data
 - J. FY 2009 IPPS Quality Measures under the RHQDAPU Program
- XVIII. Changes Affecting Critical Access Hospitals (CAHs) and Hospital Conditions of Participation (CoPs)
 - A. Changes Affecting CAHs
 1. Background
 2. Co-Location of Necessary Provider CAHs
 3. Provider-Based Facilities of CAHs
 4. Termination of Provider Agreement
 5. Regulation Changes
 - B. Revisions to Hospital CoPs
 1. Background
 2. Provisions of the Final Regulation
 - a. Timeframes for Completion of the Medical History and Physical Examination
 - b. Requirements for Preanesthesia and Postanesthesia Evaluations
 - c. Technical Amendment to Nursing Services CoP
- XIX. Changes to the FY 2008 Hospital Inpatient Prospective Payment System (IPPS) Payment Rates
 - A. Background
 - B. Revised IPPS Payment Rates
 1. MS-DRG Documentation and Coding Adjustment
 2. Application of the Documentation and Coding Adjustment to the Hospital Specific Rates
- XX. Medicare Graduate Medical Education Affiliation Provisions for Teaching Hospitals in Certain Emergency Situations
 - A. Background
 1. Legislative Authority
 2. Existing Medicare Direct GME and Indirect GME Policies
 3. Regulatory Changes Issued in 2006 to Address Certain Emergency Situations
 - B. Additional Changes in This Interim Final Rule with Comment Period
 1. Summary of Regulatory Changes
 2. Discussion of Training in Nonhospital Settings
 - C. Responses to Comments on the April 12, 2006 Interim Final Rule with Comment Period and This Interim Final Rule with Comment Period
- XXI. Files Available to the Public Via the Internet
 - A. Information in Addenda Related to the Revised CY 2008 Hospital OPPS
 - B. Information in Addenda Related to the Revised CY 2008 ASC Payment System
- XXII. Collection of Information Requirements
- XXIII. Response to Comments
- XXIV. Regulatory Impact Analysis
 - A. Overall Impact of Changes to the OPPS and ASC Payment Systems
1. Executive Order 12866
2. Regulatory Flexibility Act (RFA)
3. Small Rural Hospitals
4. Unfunded Mandates
5. Federalism
- B. Effects of OPPS Changes in This Final Rule with Comment Period
 1. Alternatives Considered
 2. Limitation of Our Analysis
 3. Estimated Impact of This Final Rule with Comment Period on Hospitals and CMHCs
 4. Estimated Effect of This Final Rule with Comment Period on Beneficiaries
 5. Conclusion
 6. Accounting Statement
- C. Effects of ASC Payment System Changes in This Final Rule with Comment Period
 1. Alternatives Considered
 2. Limitations on Our Analysis
 3. Estimated Effects of This Final Rule with Comment Period on ASCs
 4. Estimated Effects of This Final Rule with Comment Period on Beneficiaries
 5. Conclusion
 6. Accounting Statement
- D. Effects of the Requirements for Reporting of Quality Data for Hospital Outpatient Settings
- E. Effects of the Policy on CAH Off-Campus and Co-Location Requirements
- F. Effects of the Policy Revisions to the Hospital CoPs
- G. Effects of the Changes to the Hospital Inpatient Prospective Payment System (IPPS) Payment Rates
 1. Overall Impact
 2. Objectives
 3. Limitations of Our Analysis
 4. Quantitative Effects of the IPPS Policy Changes on Operating Costs
 5. Analysis of Table I
 - a. Effects of All Changes with CMI Adjustment Prior to Estimated Growth (Columns 2a and 2b)
 - b. Effects of All Changes with CMI Adjustment and Estimated Growth (Column 3)
 6. Overall Conclusion
 7. Accounting Statement
 8. Executive order 12866
 - H. Impact of the Policy Revisions to the Emergency Medicare GME Affiliated Groups for Hospitals in Certain Declared Emergency Areas
 1. Overall Impact
 2. RFA
 3. Small Rural Hospitals
 4. Unfunded Mandates
 5. Federalism
 6. Anticipated Effects
 7. Alternatives Considered
 8. Conclusion
 9. Executive Order 12866
- XXV. Waiver of Proposed Rulemaking, Waiver of Delay in Effective Date, and Retroactive Effective Date
 - A. Requirements for Waivers and Retroactive Rulemaking
 - B. IPPS Payment Rate Policies
 - C. Medicare GME Affiliation Agreement Provisions

Regulation Text**Addenda**

Addendum A—OPPS APCs for CY 2008

Addendum AA—ASC Covered Surgical Procedures for CY 2008 (Including Surgical Procedures for Which Payment is Packaged)

Addendum B—OPPS Payment By HCPCS Code for CY 2008

Addendum BB—ASC Covered Ancillary Services Integral to Covered Surgical Procedures for CY 2008 (Including Ancillary Services for Which Payment Is Packaged)

Addendum D1—OPPS Payment Status Indicators

Addendum DD1—ASC Payment Indicators

Addendum D2—OPPS Comment Indicators

Addendum DD2—ASC Comment Indicators

Addendum E—HCPCS Codes That Would Be Paid Only as Inpatient Procedures for CY 2008

Addendum L—Out-Migration Adjustment

Addendum M—HCPCS Codes for Assignment to Composite APCs for CY 2008

I. Background for the OPPS

A. Legislative and Regulatory Authority for the Hospital Outpatient Prospective Payment System

When the Medicare statute was originally enacted, Medicare payment for hospital outpatient services was based on hospital-specific costs. In an effort to ensure that Medicare and its beneficiaries pay appropriately for services and to encourage more efficient delivery of care, the Congress mandated replacement of the reasonable cost-based payment methodology with a prospective payment system (PPS). The Balanced Budget Act (BBA) of 1997 (Pub. L. 105–33) added section 1833(t) to the Social Security Act (the Act) authorizing implementation of a PPS for hospital outpatient services.

The Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act (BBRA) of 1999 (Pub. L. 106–113) made major changes in the hospital outpatient prospective payment system (OPPS). The Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act (BIPA) of 2000 (Pub. L. 106–554) made further changes in the OPPS. Section 1833(t) of the Act was also amended by the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 (Pub. L. 108 173). The Deficit Reduction Act (DRA) of 2005 (Pub. L. 109–171), enacted on February 8, 2006, also made additional changes in the OPPS. In addition, the Medicare Improvements and Extension Act under Division B of Title I of the Tax Relief and Health Care Act (MIEA–TRHCA) of 2006 (Pub. L. 109–432), enacted on December 20, 2006, made further changes in the OPPS. A discussion of these changes is included in sections I.E., VII., and XVII. of this final rule with comment period.

The OPPS was first implemented for services furnished on or after August 1,

2000. Implementing regulations for the OPPS are located at 42 CFR part 419.

Under the OPPS, we pay for hospital outpatient services on a rate-per-service basis that varies according to the ambulatory payment classification (APC) group to which the service is assigned. We use the Healthcare Common Procedure Coding System (HCPCS) codes (which include certain Current Procedural Terminology (CPT) codes) and descriptors to identify and group the services within each APC group. The OPPS includes payment for most hospital outpatient services, except those identified in section I.B. of this final rule with comment period. Section 1833(t)(1)(B)(ii) of the Act provides for Medicare payment under the OPPS for hospital outpatient services designated by the Secretary (which includes partial hospitalization services furnished by community mental health centers (CMHCs)) and hospital outpatient services that are furnished to inpatients who have exhausted their Part A benefits, or who are otherwise not in a covered Part A stay. Section 611 of Pub. L. 108–173 added provisions for Medicare coverage of an initial preventive physical examination, coinsurance, as an outpatient department service, payable under the OPPS.

The OPPS rate is an unadjusted national payment amount that includes the Medicare payment and the beneficiary copayment. This rate is divided into a labor-related amount and a nonlabor-related amount. The labor-related amount is adjusted for area wage differences using the hospital inpatient wage index value for the locality in which the hospital or CMHC is located.

All services and items within an APC group are comparable clinically and with respect to resource use (section 1833(t)(2)(B) of the Act). In accordance with section 1833(t)(2) of the Act, subject to certain exceptions, services and items within an APC group cannot be considered comparable with respect to the use of resources if the highest median (or mean cost, if elected by the Secretary) for an item or service in the APC group is more than 2 times greater than the lowest median cost for an item or service within the same APC group (referred to as the “2 times rule”). In implementing this provision, we generally use the median cost of the item or service assigned to an APC group.

For new technology items and services, special payments under the OPPS may be made in one of two ways. Section 1833(t)(6) of the Act provides for temporary additional payments,

which we refer to as “transitional pass through payments,” for at least 2 but not more than 3 years for certain drugs, biological agents, brachytherapy devices used for the treatment of cancer, and categories of other medical devices. For new technology services that are not eligible for transitional pass through payments, and for which we lack sufficient data to appropriately assign them to a clinical APC group, we have established special APC groups based on costs, which we refer to as New Technology APCs. These New Technology APCs are designated by cost bands which allow us to provide appropriate and consistent payment for designated new procedures that are not yet reflected in our claims data. Similar to pass through payments, an assignment to a New Technology APC is temporary; that is, we retain a service within a New Technology APC until we acquire sufficient data to assign it to a clinically appropriate APC group.

B. Excluded OPPS Services and Hospitals

Section 1833(t)(1)(B)(i) of the Act authorizes the Secretary to designate the hospital outpatient services that are paid under the OPPS. While most hospital outpatient services are payable under the OPPS, section 1833(t)(1)(B)(iv) of the Act excludes payment for ambulance, physical and occupational therapy, and speech-language pathology services, for which payment is made under a fee schedule. Section 614 of Pub. L. 108–173 amended section 1833(t)(1)(B)(iv) of the Act to exclude payment for screening and diagnostic mammography services from the OPPS. The Secretary exercised the authority granted under the statute to also exclude from the OPPS those services that are paid under fee schedules or other payment systems. Such excluded services include, for example, the professional services of physicians and nonphysician practitioners paid under the Medicare Physician Fee Schedule (MPFS); laboratory services paid under the clinical diagnostic laboratory fee schedule (CLFS); services for beneficiaries with end stage renal disease (ESRD) that are paid under the ESRD composite rate; and services and procedures that require an inpatient stay that are paid under the hospital inpatient prospective payment system (IPPS). We set forth the services that are excluded from payment under the OPPS in § 419.22 of the regulations.

Under § 419.20(b) of the regulations, we specify the types of hospitals and entities that are excluded from payment under the OPPS. These excluded

entities include Maryland hospitals, but only for services that are paid under a cost containment waiver in accordance with section 1814(b)(3) of the Act; critical access hospitals (CAHs); hospitals located outside of the 50 States, the District of Columbia, and Puerto Rico; and Indian Health Service hospitals.

C. Prior Rulemaking

On April 7, 2000, we published in the **Federal Register** a final rule with comment period (65 FR 18434) to implement a prospective payment system for hospital outpatient services. The hospital OPSS was first implemented for services furnished on or after August 1, 2000. Section 1833(t)(9) of the Act requires the Secretary to review certain components of the OPSS, not less often than annually, and to revise the groups, relative payment weights, and other adjustments that take into account changes in medical practices, changes in technologies, and the addition of new services, new cost data, and other relevant information and factors.

Since initially implementing the OPSS, we have published final rules in the **Federal Register** annually to implement statutory requirements and changes arising from our continuing experience with this system. We published in the **Federal Register** on November 24, 2006 the CY 2007 OPSS/ASC final rule with comment period (71 FR 67960). In that final rule with comment period, we revised the OPSS to update the payment weights and conversion factor for services payable under the CY 2007 OPSS on the basis of claims data from January 1, 2005, through December 31, 2005, and to implement certain provisions of Pub. L. 108-173 and Pub. L. 109-171. In addition, we responded to public comments received on the provisions of the November 10, 2005 final rule with comment period (70 FR 86516) pertaining to the APC assignment of HCPCS codes identified in Addendum B of that rule with the new interim (NI) comment indicator; and public comments received on the August 23, 2006 OPSS/ASC proposed rule for CY 2007 (71 FR 49506).

On August 2, 2007, we issued in the **Federal Register** (72 FR 42628) a proposed rule for the CY 2008 OPSS/ASC to implement statutory requirements and changes arising from our continuing experience with both systems. We received approximately 2,180 pieces of timely correspondence in response to the proposed rule. A summary of the public comments we received and our responses to those

comments are included in the specific sections of this final rule with comment period.

D. APC Advisory Panel

1. Authority of the APC Panel

Section 1833(t)(9)(A) of the Act, as amended by section 201(h) of the BBRA, and redesignated by section 202(a)(2) of the BBRA, requires that we consult with an outside panel of experts to review the clinical integrity of the payment groups and their weights under the OPSS. The Act further specifies that the panel will act in an advisory capacity.

The Advisory Panel on Ambulatory Payment Classification (APC) Groups (the APC Panel), discussed under section I.D.2. of this final rule with comment period, fulfills these requirements. The APC Panel is not restricted to using data compiled by CMS, and may use data collected or developed by organizations outside the Department in conducting its review.

2. Establishment of the APC Panel

On November 21, 2000, the Secretary signed the initial charter establishing the APC Panel. This expert panel, which may be composed of up to 15 representatives of providers subject to the OPSS (currently employed full-time, not as consultants, in their respective areas of expertise), reviews clinical data and advises CMS about the clinical integrity of the APC groups and their payment weights. For purposes of this Panel, consultants or independent contractors are not considered to be full-time employees. The APC Panel is technical in nature, and is governed by the provisions of the Federal Advisory Committee Act (FACA). Since its initial chartering, the Secretary has renewed the APC Panel's charter three times: On November 1, 2002; on November 1, 2004; and effective November 21, 2006. The current charter specifies, among other requirements, that the APC Panel continue to be technical in nature; be governed by the provisions of the FACA; may convene up to three meetings per year; has a Designated Federal Officer (DFO); and is chaired by a Federal official designated by the Secretary.

The current APC Panel membership and other information pertaining to the APC Panel, including its charter, **Federal Register** notices, membership, meeting dates, agenda topics, and meeting reports can be viewed on the CMS Web site at: http://www.cms.hhs.gov/FACA/05_AdvisoryPanelonAmbulatoryPaymentClassificationGroups.asp#TopOfPage.

3. APC Panel Meetings and Organizational Structure

The APC Panel first met on February 27, February 28, and March 1, 2001. Since the initial meeting, the APC Panel has held 12 subsequent meetings, with the last meeting taking place on September 5 and 6, 2007. Prior to each meeting, we publish a notice in the **Federal Register** to announce the meeting, and when necessary, to solicit nominations for APC Panel membership, and to announce new members.

The APC Panel has established an operational structure that, in part, includes the use of three subcommittees to facilitate its required APC review process. The three current subcommittees are the Data Subcommittee, the Observation and Visit Subcommittee, and the Packaging Subcommittee. The Data Subcommittee is responsible for studying the data issues confronting the APC Panel, and for recommending options for resolving them. The Observation and Visit Subcommittee reviews and makes recommendations to the APC Panel on all technical issues pertaining to observation services and hospital outpatient visits paid under the OPSS (for example, APC configurations and APC payment weights). The Packaging Subcommittee studies and makes recommendations on issues pertaining to services that are not separately payable under the OPSS, but whose payments are bundled or packaged into APC payments. Each of these subcommittees was established by a majority vote from the full APC Panel during a scheduled APC Panel meeting, and their continuation as subcommittees was last approved at the September 2007 APC Panel meetings. All subcommittee recommendations are discussed and voted upon by the full APC Panel.

Discussions of the recommendations resulting from the APC Panel's March 2007 and September 2007 meetings are included in the sections of this final rule with comment period that are specific to each recommendation. For discussions of earlier APC Panel meetings and recommendations, we refer readers to previously published hospital OPSS final rules or the Web site mentioned earlier in this section.

E. Provisions of the Medicare Improvements and Extension Act under Division B of Title I of the Tax Relief and Health Care Act of 2006

The Medicare Improvements and Extension Act under Division B of Title I of the Tax Relief and Health Care Act

(MIEA–TRHCA) of 2006, Pub. L. 109–432, enacted on December 20, 2006, included the following provisions affecting the OPSS:

1. Section 107(a) of the MIEA–TRHCA amended section 1833(t)(16)(C) of the Act to extend the period for payment of brachytherapy devices based on the hospital's charges adjusted to cost for 1 additional year, through December 31, 2007.

2. Section 107(b)(1) of the MIEA–TRHCA amended section 1833(t)(2)(H) of the Act by adding stranded and non stranded devices furnished on or after July 1, 2007, as additional classifications of brachytherapy devices for which separate payment groups must be established for payment under the OPSS. Section 107(b)(2) of the MIEA TRHCA provides that the Secretary may implement the section 107(b)(1) amendment to section 1833(t)(2)(H) of the Act "by program instruction or otherwise."

3. Section 109(a) of the MIEA–TRHCA added new paragraph (17) to section 1833(t) of the Act which authorizes the Secretary, beginning in 2009 and each subsequent year, to reduce the OPSS full annual update by 2.0 percentage points if a hospital paid under the OPSS fails to submit data as required by the Secretary in the form and manner specified on selected measures of quality of care, including medication errors. In accordance with this provision, the selected measures are those that are appropriate for the measurement of quality of care furnished by hospitals in the outpatient setting, that reflect consensus among affected parties and, to the extent feasible and practicable, that include measures set forth by one or more of the national consensus entities, and that may be the same as those required for reporting by hospitals paid under the IPPS. This provision specifies that a reduction for 1 year cannot be taken into account when computing the OPSS update for a subsequent year. In addition, this provision requires the Secretary to establish a process for making the submitted data available for public review.

F. Summary of the Major Contents of the CY 2008 OPSS/ASC Proposed Rule

On August 2, 2007, we published a proposed rule in the **Federal Register** (72 FR 42628) that set forth proposed changes to the Medicare hospital OPSS for CY 2008 to implement statutory requirements and changes arising from our continuing experience with the system and to implement certain statutory provisions. In addition, we proposed changes to the revised

Medicare ASC payment system for CY 2008 such as adding procedures to the list of covered surgical procedures and adjusting the ASC rates so that the revised ASC payment system is budget neutral. We also proposed to make changes to the policies relating to the necessary provider designations of CAHs that are being recertified when a CAH enters into a new co-location arrangement with another hospital or CAH or when the CAH creates or acquires an off-campus location. Further, we proposed changes to several of the current conditions of participation that hospitals must meet to participate in the Medicare and Medicaid programs to require the completion and documentation in the medical record of medical histories and physical examinations of patients conducted after admission and prior to surgery or a procedure requiring anesthesia services and for postanesthesia evaluations of patients before discharge or transfer from the postanesthesia recovery area. Finally, we set forth proposed quality measures for a Hospital Outpatient Quality Data Reporting (HOP QDRP) program for reporting quality data for annual payment rate updates for CY 2009 and subsequent calendar years. We also briefly discussed the legislative provisions of the MIEA–TRHCA that give the Secretary authority to develop quality measures for reporting data by ASCs. The following is a summary of the major changes included in the CY 2008 OPSS/ASC proposed rule:

1. Updates Affecting OPSS Payments

In section II. of the proposed rule, we set forth—

- The methodology used to recalibrate the proposed APC relative payment weights.
- The proposed payment for partial hospitalization services, including the proposed separate threshold for outlier payments for CMHCs.
- The proposed update to the conversion factor used to determine payment rates under the OPSS.
- The proposed retention of our current policy to use the IPPS wage indices to adjust, for geographic wage differences, the portion of the OPSS payment rate and the copayment standardized amount attributable to labor related cost.
- The proposed update of statewide average default CCRs.
- The proposed application of hold harmless transitional outpatient payments (TOPs) for certain small rural hospitals.
- The proposed payment adjustment for rural SCHs.

- The proposed calculation of the hospital outpatient outlier payment.
- The calculation of the proposed national unadjusted Medicare OPSS payment.

- The proposed beneficiary copayments for OPSS services.

2. OPSS Ambulatory Payment Classification (APC) Group Policies

In section III. of the proposed rule, we discussed the proposed additions of new procedure codes to the APCs; our proposal to establish a number of new APCs; and our analyses of Medicare claims data and certain recommendations of the APC Panel. We also discussed the application of the 2 times rule and proposed exceptions to it; proposed changes to specific APCs; and the proposed movement of procedures from New Technology APCs to clinical APCs.

3. OPSS Payment for Devices

In section IV. of the proposed rule, we discussed proposed payment for device dependent APCs and pass-through payment for specific categories of devices.

4. OPSS Payment for Drugs, Biologicals, and Radiopharmaceuticals

In section V. of the proposed rule, we discussed the proposed CY 2008 OPSS payment for drugs, biologicals, and radiopharmaceuticals, including the proposed payment for drugs, biologicals, and radiopharmaceuticals with and without pass-through status.

5. Estimate of OPSS Transitional Pass-Through Spending for Drugs, Biologicals, and Devices

In section VI. of the proposed rule, we discussed the estimate of CY 2008 OPSS transitional pass-through spending for drugs, biologicals, and devices.

6. OPSS Payment for Brachytherapy Sources

In section VII. of the proposed rule, we discussed our proposal concerning coding and payment for brachytherapy sources.

7. OPSS Coding and Payment for Drug Administration Services

In section VIII. of the proposed rule, we set forth our proposed policy concerning coding and payment for drug administration services.

8. OPSS Hospital Coding and Payments for Visits

In section IX. of the proposed rule, we set forth our proposed policies for the coding and reporting of clinic and emergency department visits and

critical care services on claims paid under the OPSS.

9. OPSS Payment for Blood and Blood Products

In section X. of the proposed rule, we discussed our proposed payment for blood and blood products.

10. Proposed OPSS Payment for Observation Services

In section XI. of the proposed rule, we discussed the proposed payment policies for observation services furnished to patients on an outpatient basis.

11. Procedures That Will Be Paid Only as Inpatient Services

In section XII. of the proposed rule, we discussed the procedures that we proposed to remove from the inpatient list and assign to APCs.

12. Nonrecurring Technical and Policy Changes

In section XIII. of the proposed rule, we set forth our proposals for nonrecurring technical and policy changes and clarifications relating to outpatient services and supplies incident to physicians' services; payment for interrupted procedures prior to and after the administration of anesthesia; transitional adjustments to payments for covered outpatient services furnished by small rural hospitals and SCHs located in rural areas; and reporting requirements for wound care services, cardiac rehabilitation services, and bone marrow and stem cell processing services.

13. OPSS Payment Status and Comment Indicators

In section XIV. of the proposed rule, we discussed proposed changes to the definitions of status indicators assigned to APCs and presented our proposed comment indicators for the OPSS/ASC final rule with comment period.

14. OPSS Policy and Payment Recommendations

In section XV. of the proposed rule, we addressed recommendations made by the Medicare Payment Advisory Commission (MedPAC) in its March and June 2007 Reports to Congress and by the APC Panel regarding the OPSS for CY 2008.

15. Update of the Revised ASC Payment System

In section XVI. of the proposed rule, we discussed the proposed update of the revised ASC payment system payment rates for CY 2008. We also

discussed our proposed changes to our regulations at §§ 414.22(b)(5)(i)(A) and (B) regarding physician payment for performing excluded surgical procedures in ASCs. In addition, we set forth our proposal to revise the definitions of "radiology and certain other imaging services" and "outpatient prescription drugs" when provided integral to an ASC covered surgical procedure.

16. Reporting Quality Data for Annual Payment Rate Updates

In section XVII. of the proposed rule, we discussed the proposed quality measures for reporting hospital outpatient quality data for CY 2009 and subsequent years and set forth the requirements for data collection and submission for the annual payment update. We also briefly discussed the legislative provisions of the MIEA-TRHCA that give the Secretary authority to develop quality measures for reporting by ASCs. (We note that, as discussed in section XVII.J. of this final rule with comment period, we are also finalizing a proposal from the FY 2008 IPPS proposed rule relating to the FY 2009 RHQDAPU quality measures. Specifically, we are finalizing the inclusion of SCIP Infection 4: Cardiac Surgery Patients with Controlled 6AM Postoperative Serum Glucose and SCIP Infection 6: Surgery Patients with Appropriate Hair Removal in the FY 2009 RHQDAPU measure set, bringing the total number of measures in that measure set to 30.)

17. Changes Affecting Necessary Provider Critical Access Hospitals (CAHs) and Hospital Conditions of Participation (CoPs)

In section XVIII. of the proposed rule, we discussed our proposed changes affecting CAHs both when the CAH enters into a new co-location arrangement with another hospital or CAH and when the CAH creates or acquires a provider-based off campus location. We also discussed our proposed changes relating to several hospital CoPs to require the completion of physical examinations and medical histories and documentation in the medical records for patients after admission and prior to surgery or a procedure requiring anesthesia services, and for postanesthesia evaluations of patients after surgery or a procedure requiring anesthesia services but before discharge or transfer from the postanesthesia recovery area.

18. Regulatory Impact Analysis

In section XXII. of the proposed rule, we set forth an analysis of the impact

the proposed changes would have on affected entities and beneficiaries. (We note that this regulatory impact analysis section is redesignated as section XXIV. of this final rule with comment period.)

G. Public Comments Received in Response to the CY 2008 OPSS/ASC Proposed Rule

We received approximately 2,180 timely pieces of correspondence containing multiple comments on the CY 2008 OPSS/ASC proposed rule. We note that we received some comments that were outside the scope of the CY 2008 OPS/ASC proposed rule. These comments are not addressed in this CY 2008 OPSS/ASC final rule with comment period. Summaries of the public comments that are within the scope of the proposals and our responses to those comments are set forth in the various sections of this final rule with comment period under the appropriate headings.

H. Public Comments Received on the November 24, 2006 OPSS/ASC Final Rule with Comment Period

We received approximately 21 timely items of correspondence on the CY 2007 OPSS/ASC final rule with comment period, some of which contained multiple comments on the interim final APC assignments and/or status indicators of HCPCS codes identified with comment indicator "NI" in Addendum B to that final rule with comment period. Summaries of those public comments and our responses to them are set forth in the various sections of this final rule with comment period under the appropriate headings.

II. Updates Affecting OPSS Payments

A. Recalibration of APC Relative Weights

1. Database Construction

a. Database Source and Methodology

Section 1833(t)(9)(A) of the Act requires that the Secretary review and revise the relative payment weights for APCs at least annually. In the April 7, 2000 OPSS final rule with comment period (65 FR 18482), we explained in detail how we calculated the relative payment weights that were implemented on August 1, 2000 for each APC group. Except for some reweighting due to a small number of APC changes, these relative payment weights continued to be in effect for CY 2001. This policy is discussed in the November 13, 2000 interim final rule (65 FR 67824 through 67827).

In the CY 2008 OPSS/ASC proposed rule, we proposed to use the same basic methodology that we described in the

April 7, 2000 OPPS final rule with comment period to recalibrate the APC relative payment weights for services furnished on or after January 1, 2008 and before January 1, 2009. That is, we proposed to recalibrate the relative payment weights for each APC based on claims and cost report data for outpatient services. We proposed to use the most recent available data to construct the database for calculating APC group weights. For the purpose of recalibrating the proposed APC relative payment weights for CY 2008, we used approximately 131 million final action claims for hospital outpatient department (HOPD) services furnished on or after January 1, 2006 and before January 1, 2007. (For exact counts of claims used, we refer readers to the claims accounting narrative under supporting documentation for the proposed rule on the CMS Web site at: <http://www.cms.hhs.gov/HospitalOutpatientPPS/HORD/>).

Of the 141 million final action claims for services provided in hospital outpatient settings used to calculate the CY 2008 OPSS payment rates for this final rule with comment period, approximately 103 million claims were of the type of bill potentially appropriate for use in setting rates for OPSS services (but did not necessarily contain services payable under the OPSS). Of the 103 million claims, approximately 45 million were not for services paid under the OPSS or were excluded as not appropriate for use (for example, erroneous cost-to-charge ratios (CCRs) or no HCPCS codes reported on the claim). We were able to use approximately 54 million whole claims of the approximately 58 million claims that remained to set the OPSS APC relative weights for the CY 2008 OPSS. From the 54 million whole claims, we created approximately 97 million single records, of which approximately 65 million were "pseudo" single claims (created from multiple procedure claims using the process we discuss in this section). Approximately 926,000 claims trimmed out on cost or units in excess of ± 3 standard deviations from the geometric mean, yielding approximately 96 million single bills used for median setting. Ultimately, we were able to use for CY 2008 ratesetting some portion of 93 percent of the CY 2006 claims containing services payable under the OPSS. This is approximately the same percentage of CY 2005 claims where some portion could be used for CY 2007 ratesetting as described in the CY 2007 OPSS/ASC final rule with comment period (71 FR 67970).

As proposed, the final APC relative weights and payments for CY 2008 in

Addenda A and B to this final rule with comment period were calculated using claims from this period that were processed before June 30, 2007, and continue to be based on the median hospital costs for services in the APC groups. We selected claims for services paid under the OPSS and matched these claims to the most recent cost report filed by the individual hospitals represented in our claims data. We continue to believe that it is appropriate to use the most current full calendar year claims data and the most recently submitted cost reports to calculate the median costs which we proposed to convert to relative payment weights for purposes of calculating the CY 2008 payment rates.

We did not receive any comments on our proposal to base the CY 2008 APC relative weights on the most currently available cost reports and on claims for services furnished in CY 2006. Therefore, we are finalizing our data source for the recalibration of the CY 2008 APC relative payment weights as proposed, without modification, as described in this section of this final rule with comment period.

b. Use of Single and Multiple Procedure Claims

For CY 2008, in general, we proposed to continue to use single procedure claims to set the medians on which the APC relative payment weights would be based, with some exceptions as discussed below. We generally use single procedure claims to set the median costs for APCs because we believe that it is important that the OPSS relative weights on which payment rates are based be appropriate when one and only one procedure is furnished and because we are, so far, unable to ensure that packaged costs can be appropriately allocated across multiple procedures performed on the same date of service. We agree that, optimally, it is desirable to use the data from as many claims as possible to recalibrate the APC relative payment weights, including those claims for multiple procedures. We engaged in several efforts this year to improve our use of multiple procedure claims for ratesetting. As we have for several years, we continued to use date of service stratification and a list of codes to be bypassed to convert multiple procedure claims to "pseudo" single procedure claims. We also continued our internal efforts to better understand the patterns of services and costs from multiple bills toward the goal of using more multiple bill information by assessing the amount of packaging in the multiple bills and, specifically, by exploring the amount of

packaging for drug administration services in the single and multiple bill claims. Moreover, in many cases, the packaging approach that we proposed for the CY 2008 OPSS also allows the use of more claims data by enabling us to treat claims with multiple procedure codes as single claims. We refer readers to section II.A.4. of the proposed rule for a full discussion of the packaging approach for CY 2008.

We received several public comments on our proposed use of single bills to calculate the APC median costs for ratesetting under the CY 2008 OPSS. A summary of the public comments and our responses follow.

Comment: Some commenters supported the "natural" and "pseudo" single methodology but asked that CMS continue to refine the approach in order to improve the accuracy of the estimates because the medians are used to develop payment rates for services on both single and multiple procedure claims. Other commenters asserted that continued reliance on single procedure bills to establish the medians from which the rates were calculated failed to produce a statistically valid sample of services for ratesetting, in particular for brachytherapy services that are often provided in combination with one another in a single encounter. Other commenters requested that CMS explore additional revisions to the current methodology to ensure that OPSS payment would be based on a substantial number of accurate hospital claims.

Response: We generally base median costs for services on single procedure claims to ensure that the median cost captures the full cost of a service when it is the only service furnished. We recognize that this approach has limitations and, in some cases, prevents us from using many of the claims for services that are most commonly furnished at the same time as other services. For this reason, we have developed a number of different strategies, such as date of service stratification and the use of the bypass list, that enable us to break multiple procedure claims into "pseudo" single procedure claims where we have confidence that the "pseudo" single claim contains the full cost of the service, including related packaged costs. In recent years, however, we have increasingly used multiple procedure claims to develop median costs for individual services or groups of services. We have developed these methodologies so that we can use more naturally occurring claims data in cases in which care is most commonly reported with multiple major procedure

codes on the same date, such as observation services, hyperbaric oxygen therapy (HBOT), and single allergy tests.

Similarly, for CY 2008, we developed and proposed composite APCs for low dose rate prostate brachytherapy (APC 8001 (LDR Prostate Brachytherapy Composite)) and cardiac electrophysiology services (APC 8000 (Cardiac Electrophysiologic Evaluation and Ablation Composite)). These APCs are designed to use multiple procedure claims to establish a median cost and APC payment for multiple major procedures when they are furnished together. As we discuss in section II.A.4.d. of this final rule with comment period, we intend to explore the creation of additional composite APCs for services that frequently are provided in the same HOPD encounter. We also plan to continue to develop and refine methods to increase the amount of claims data that we can use for setting OPPS payment rates in a manner that gives us the most confidence that the costs derived from these approaches are valid reflections of the costs of the services described by HCPCS codes or, in the case of composite APCs, described by the APCs. We anticipate that the Data Subcommittee of the APC Panel will continue to provide us with valuable advice regarding possible methodologies for increasing the OPPS use of multiple procedure claims for ratesetting.

After consideration of the public comments received, we are finalizing our proposal, without modification, to calculate median costs for APCs using single and "pseudo" single procedure claims, except where otherwise specified.

(1) Use of Date of Service Stratification and a Bypass List To Increase the Amount of Data Used To Determine Medians

Through bypassing specified codes that we believe do not have significant packaged costs, we are able to use more data from multiple procedure claims. In many cases, this enables us to create multiple "pseudo" single claims from claims that, as submitted, contained numerous separately paid procedures reported on the same date on one claim. We refer to these newly created single procedure claims as "pseudo" single claims because they were submitted by providers as multiple procedure claims. The history of our use of a bypass list to generate "pseudo" single claims is well documented, most recently in the CY 2007 OPPS/ASC final rule with comment period (71 FR 67969 through 67970).

The date of service stratification (sorting the lines by date of service and treating all lines with the same date of service as a separate claim) and bypass list process we used for the CY 2007 OPPS (combined with the packaging changes we proposed in section II.A.4. of the proposed rule) resulted in our being able to use some part of approximately 92 percent of the total claims that were eligible for use in the OPPS ratesetting and modeling for the proposed rule. This process enabled us to create, for the CY 2008 proposed rule, approximately 58 million "pseudo" singles and approximately 30 million "natural" single bills. For the proposed rule, "pseudo" single procedure bills represented 66 percent of all single bills used to calculate median costs. This compared favorably to the CY 2007 OPPS final rule data in which "pseudo" single bills represented 68 percent of all single bills used to calculate the median costs on which the CY 2007 OPPS payment rates were based. We believed that the reduction in the percent of "pseudo" single bills and the corresponding increase in the proportion of "natural" single bills observed for the CY 2008 proposed rule occurred largely because of our proposal to increase packaging as discussed in section II.A.4. of the proposed rule. In many cases, the packaging proposal for CY 2008 enabled us to use claims that would otherwise have been considered to be multiple procedure claims and, absent the proposal for additional packaging, could have been used for ratesetting only if we had been able to create "pseudo" single claims from them.

For CY 2008, we proposed to bypass 425 HCPCS codes that are identified in Table 1 of the proposed rule. We proposed to continue the use of the codes on the CY 2007 OPPS bypass list but to remove codes we proposed to package for CY 2008. We also proposed to remove codes that were on the CY 2007 bypass list that ceased to meet the empirical criteria under the proposed packaging changes when clinical review confirmed that their removal would be appropriate in the context of the full proposal for the CY 2008 OPPS. Since the inception of the bypass list, we have calculated the percent of "natural" single bills that contained packaging for each code and the amount of packaging in each "natural" single bill for each code. We retained the codes on the previous year's bypass list and used the update year's data to determine whether it would be appropriate to add additional codes to the previous year's bypass list. The entire list (including the

codes that remained on the bypass list from prior years) was open to public comment. For the CY 2008 proposed rule, we explicitly reviewed all "natural" single bills against the empirical criteria for all codes on the CY 2007 bypass list because of the proposal for greater packaging discussed in section II.A.4. of the proposed rule, as this effort increased the packaging associated with some codes. We removed 106 HCPCS codes from the CY 2007 bypass list for the CY 2008 proposal. In addition, we note that many of the codes we proposed to newly package for CY 2008 were on the bypass list used for setting the OPPS payment rates for CY 2007 and were not proposed for bypass because we also proposed to package them. We proposed to add to the bypass list HCPCS codes that, using the proposed rule data, met the same previously established empirical criteria for the bypass list that are reviewed below or which our clinicians believed would have little associated packaging if the services were coded correctly.

The CY 2008 packaging proposal minimally reduced the percentage of total claims that we were able to use, in whole or in part, from 93 percent for CY 2007 to 92 percent for the proposed rule. The proposed packaging approach increased the number of "natural" single bills, in spite of reducing the universe of codes requiring single bills for ratesetting, but reduced the number of "pseudo" single bills. More "natural" single procedure bills can be created by the packaging of codes that always appear with another procedure because these dependent services are supportive of and ancillary to the primary independent procedures for which payment is being made. A claim containing two independent procedure codes on the same date of service and not on the bypass list previously could not be used for ratesetting, but packaging the cost of one of the codes on the claim frees the claim to be used to calculate the median cost of the procedure that is not packaged. On the other hand, our proposed packaging approach reduced the number of codes eligible for the bypass list because of the limitation on packaging set by our previously established empirical criteria. A smaller bypass list and the presence of greater packaging on claims reduced the final number of "pseudo" single claims. In prior years, roughly 68 percent of single bills were "pseudo" single bills, but based on the CY 2008 proposed rule data, 66 percent of single bills were "pseudo" singles. Similarly, for this final rule with comment period,

66 percent of single bills were “pseudo” singles. Moreover, the numbers of “natural” single bills and “pseudo” single bills were reduced by the volume of services that we proposed to package. Hence, our CY 2008 proposal to package payment for some HCPCS codes with relatively high frequencies would eliminate for ratesetting the number of available “natural” and “pseudo” single bills attributable to the codes that we proposed to package.

As in prior years, we proposed to use the following empirical criteria to determine the additional codes to add to the CY 2007 bypass list to create the CY 2008 bypass list. We assumed that the representation of packaging in the single claims for any given code was comparable to packaging for that code in the multiple claims:

- There are 100 or more single claims for the code. This number of single claims ensures that observed outcomes are sufficiently representative of packaging that might occur in the multiple claims.
- Five percent or fewer of the single claims for the code have packaged costs on that single claim for the code. This criterion results in limiting the amount of packaging being redistributed to the separately payable procedure remaining on the claim after the bypass code is removed and ensures that the costs associated with the bypass code represent the cost of the bypassed service.
- The median cost of packaging observed in the single claims is equal to or less than \$50. This limits the amount of error in redistributed costs.
- The code is not a code for an unlisted service.

In addition, we proposed to add to the bypass list codes that our clinicians believe have minimal associated packaging based on their clinical assessment of the complete CY 2008 OPPS proposal. As proposed, this list contained bypass codes that were appropriate to claims for services in CY 2006 and, therefore, included codes that were deleted for CY 2007. Moreover, there were codes on the proposed bypass list that were new for CY 2007 and which were appropriate additions to the bypass list in preparation for use of the CY 2007 claims for creation of the CY 2009 OPPS.

We received a number of public comments on the use of the bypass list for creation of “pseudo” single procedure claims. A summary of the comments and our responses follow.

Comment: Some commenters objected to the removal of HCPCS codes from the bypass list because the codes ceased to meet the criteria for the bypass list as a

result of increased packaging in the “natural” single claims due to the proposed packaging approach. The commenters objected to the removal of codes from the bypass list for this reason because they asserted that it caused claims that would otherwise have become “pseudo” single claims to not be used and, thereby, reduced the number of single bills that were available for ratesetting for certain services.

Response: We agree with the commenters, so we have reevaluated the bypass list for this final rule with comment period and restored a number of codes on the bypass list prior to the CY 2008 proposal to maximize the creation of single and “pseudo” single procedure bills. As we discuss later in this section and in section II.A.4. of this final rule with comment period, we have made changes to the data process to ensure that we capture as much data as possible for services assigned status indicator “Q.” Although we revised the process to apply the specific “Q” status indicator policies before assessment of the bypass list so that additional HCPCS codes could be considered for the bypass list without risk of losing their data regarding packaging, we determined that no codes with status indicator “Q” were appropriate for addition to the final CY 2008 bypass list because of their significant associated packaging.

Comment: Several commenters asked that CMS add certain HCPCS codes to the bypass list so that more single bills would be available for median setting. Some commenters specifically objected to the removal of the following radiation oncology services that they indicated should seldom have any associated packaging: CPT codes 77280 (Therapeutic radiology simulation-aided field setting; simple); 77285 (Therapeutic radiology simulation-aided field setting; intermediate); 77290 (Therapeutic radiology simulation-aided field setting; complex); 77295 (Therapeutic radiology simulation-aided field setting; 3-dimensional); 77332 (Treatment devices, design and construction; simple (simple block, simple bolus)); 77333 (Treatment devices, design and construction; intermediate (multiple blocks, stents, bite blocks, special bolus)); 77334 (Treatment devices, design and construction; complex (irregular blocks, special shields, compensators, wedges, molds or casts)); and 77417 (Therapeutic radiology port film(s)). One commenter explained that there was an interaction with the packaging of image guided radiation therapy codes that reduced the percentage of single

bills for high dose rate (HDR) brachytherapy from 62 percent to 48 percent of the total frequency. The commenter believed that the payment for APC 0313 (Brachytherapy) dropped from \$789.70 in CY 2007 to \$739.46 in the CY 2008 proposed rule because there were packaged costs on claims that could no longer be used because the multiple procedure claims included codes that were removed from the bypass list. The commenter asked that these codes be restored to the bypass list so that these claims could be used. Other commenters asked that CMS place CPT code 93017 (Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report) on the bypass list because it is typically performed with single photon emission computed tomography (SPECT) procedures (CPT code 78465 (Myocardial perfusion imaging; tomographic (SPECT), multiple studies (including attenuation correction when performed), at rest and/or stress (exercise and/or pharmacologic) and redistribution and/or rest injection, without or without quantification)). These commenters believed that significant data from multiple procedure claims were lost because CPT code 93017 was not bypassed. Other commenters asked that CMS add the following drug administration CPT codes to the bypass list because doing so would enable use of more multiple procedure claims data to establish median costs for drug administration services: CPT codes 90767 (Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion, up to 1 hour (List separately in addition to code for primary procedure)); 90768 (Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)); 90775 (Therapeutic, prophylactic or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)); 96411 (Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)); and 96417 (Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List

separately in addition to code for primary procedure)). A commenter asked that we add HCPCS code 88307 (Level V Surgical pathology, gross and microscopic examination) because it is so similar to HCPCS codes 88305 (Level III Surgical pathology, gross and microscopic examination) and 88306 (Level IV Surgical pathology, gross and microscopic examination) that were already included on the bypass list.

Response: We have reviewed the requests to add these codes to the bypass list and we have made the following decisions for CY 2008 for the reasons stated below:

We have added the radiation oncology services listed above, with the exception of CPT code 77417, to the bypass list because we agree that they are of the type that should not have packaging associated with them. We recognize that including them on the bypass list may yield significantly more single procedure bills and may also increase the number of claims that we can use for calculation of the low dose rate prostate brachytherapy composite APC (APC8001). We have not added CPT code 77417 to the CY 2008 bypass list because, based on its final CY 2008 unconditionally packaged status, the code would not be a candidate for the bypass list. Unconditionally packaged codes are not included on the bypass list because their presence on a claim does not make that claim a multiple procedure bill.

We have added CPT code 93017 to the bypass list because we agree that it should not have significant associated packaging, and we recognize that including it on the bypass list may yield significantly more single procedure bills for median setting.

We have not added the drug administration services listed above to the bypass list. Four of these five codes are for sequential drug infusion services or injections of additional drugs and, therefore, by definition, new drugs and medical supplies that are associated with these codes should be reported in all cases in which the services are furnished. We note that, beginning in CY 2007, we placed the CPT codes for additional hours of infusion on the bypass list, recognizing that all packaging related to these hours would be associated with the initial services on the claim. We proposed and finalized this approach for CY 2007, because we were unable to accurately assign representative portions of packaged costs to multiple different drug administration services. We expected that the packaging related to additional hours of infusion of drugs that spanned several hours would be appropriately

assigned to the code for the first hour of infusion on the same claim. If we had not placed the codes for additional hours of infusion on the bypass list, we would have had a substantial set of drug administration multiple procedure claims that were unusable for ratesetting purposes. However, adding the sequential drug administration services to the bypass list too would force all of the costs of the associated additional drugs and supplies to be packaged into the payment for the initial drug administration service for another drug, which we do not believe is an appropriate allocation of packaging. While we understand the concerns of the commenters regarding the challenges associated with setting appropriate payment rates for these sequential services reported on multiple procedure claims, we have very little CY 2006 claims data for the four codes because they were not recognized for payment under the CY 2006 OPSS. We will reconsider the treatment of these CPT codes for the CY 2009 OPSS update when CY 2007 data, where these codes were separately paid under the OPSS, are available. We have not added CPT code 90768 to the bypass list because our final CY 2008 policy unconditionally packages payment for this service and, therefore, it is not a candidate for the bypass list.

We agree that HCPCS code 88307 (which was on the proposed bypass list for the CY 2008 OPSS) is appropriate and we have added it to the final CY 2008 bypass list.

In addition to these responses to comments, we have added six other HCPCS codes to the final CY 2008 bypass list that met the empirical criteria for inclusion using the final rule data, and we have also added three HCPCS codes for clinical consistency with codes that are already on the bypass list. New bypass codes for this final rule with comment period are identified in Table 1 with an asterisk.

Comment: One commenter objected to the use of the bypass list to create "pseudo" single claims for median setting on the basis that it artificially lowers the median cost of the services on the bypass list by sending all packaging on the claim to the other major separately paid service on the claim. Specifically, the commenter believed that inclusion of CPT code 93880 (Duplex scan of extracranial arteries; complete bilateral study) on the bypass list resulted in the use of the cost data for the lowest cost services and, thereby, lowered the cost of this service. The commenter stated that CMS should work with stakeholders on use of the bypass list, its impact on median costs,

and ways that CMS could use data that were more reflective of the real costs for these procedures. The commenter believed that the median cost of CPT code 93880 should be based on the cost of the typical patient and not the least expensive patient because the OPSS payment caps payment in the physician's office for the service. The commenter explained that using the bypass list to generate more "pseudo" single claims without any packaging resulted in stagnation in payment that encouraged hospitals to pressure physicians to order more expensive tests and threatened access to care for beneficiaries who would be served well by simpler tests that were being underpaid as a result of inclusion of CPT code 93880 on the bypass list.

One commenter asked that CMS provide a code-specific analysis of the impact of bypassing each code on the bypass list because the commenter believed that removing and using the line item costs for the bypass codes to set the median costs for the APCs to which the bypass codes are assigned results in understatement of the median costs for those APCs.

Response: The bypass list has been very effective in enabling us to use claims data that would not otherwise be available for median calculation. Since its origin for the CY 2004 OPSS, we have been very careful in determining the codes to be placed on the bypass list. As described above, we use a standard set of criteria to select claims that seldom have packaging (that is, fewer than 5 percent of "natural" single bills); that have little packaging (that is, less than \$50); for which we have at least 100 "natural" single bills; and that are not unlisted codes (for which there is no specified service). In addition to codes that pass these criteria, we also have added HCPCS codes to the bypass list that have been recommended to us by members of the public, including the specialty societies that are most familiar with them, as services with which packaging should be seldom, if ever, associated. Therefore, we believe that we have been very prudent with regard to our selection of the codes to be added to the bypass list and with our use of the list. Moreover, we open the criteria and the list to public comment each year and we respond to comments in the final rule for the update year.

We also make available the claims data used to calculate the median costs on which the relative weights are based, and we provide an extensive narrative description of our data process. Hence, we provide commenters with the tools to conduct any further analyses they chose with regard to the codes on the

bypass list or otherwise. In the case of CPT code 93880, the median packaged cost on “natural” single procedure claims (of which there were 403,106) was \$0 and the percent of natural single procedure claims on which there was any packaging was 0.47 percent (1,899 claims out of 403,106). Therefore, the code meets the criteria for inclusion on the bypass list and will remain on it for CY 2008. We have no evidence that physicians or hospitals are billing more expensive tests as a result of the OPPS payment rate for CPT code 93880, and our data show there is very little packaging associated with the service in the typical case.

In order to keep the established empirical criteria for the bypass list constant, we specifically solicited public comment on whether we should adjust the \$50 packaging cost criterion for inflation each year and, if so, recommendations for the source of the adjustment. We believed that adding an inflation adjustment factor would ensure that the same amount of packaging associated with candidate codes for the bypass list was reviewed each year relative to nominal costs.

We received one public comment on the appropriateness of updating the \$50 packaging cost criteria for inclusion of a code on the bypass list to account for annual inflation. A summary of the comment and our response follow.

Comment: One commenter stated that CMS should update the \$50 maximum “natural” single bill median packaging cost criterion for including HCPCS codes on the bypass list on the basis of empirical criteria. The commenter did not suggest a methodology we might use for the update.

Response: We have not changed the \$50 maximum “natural” bill median packaging cost criterion for this final rule with comment period. However, we will consider whether to update the criterion and, if so, what methodology would be used, as part of the development of the proposals for the CY 2009 OPPS.

After consideration of the public comments received, we are adopting, as final, the proposed “pseudo” single claims process and the CY 2008 bypass codes listed in Table 1 below. This list has been modified from the CY 2008 proposed list, with the addition of HCPCS codes that meet the empirical criteria based on updated claims data and certain HCPCS codes recommended by commenters, as discussed above. As stated earlier, the new bypass codes for this final rule with comment period are identified in Table 1 with an asterisk.

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS

HCPCS code	Short description	Added for this final rule
11056	Trim skin lesions, 2 to 4.	
11057	Trim skin lesions, over 4.	
11300	Shave skin lesion.	
11301	Shave skin lesion.	
11719	Trim nail(s).	
11720	Debride nail, 1–5.	
11721	Debride nail, 6 or more.	
11954	Therapy for contour defects.	
17003	Destruct premalges, 2–14.	
31231	Nasal endoscopy, dx.	
31579	Diagnostic laryngoscopy.	
51798	Us urine capacity measure.	
53661	Dilation of urethra	*
54240	Penis study.	
56820	Exam of vulva w/ scope.	
57150	Treat vagina infection.	*
67820	Revise eyelashes.	
69210	Remove impacted ear wax.	
69220	Clean out mastoid cavity.	
70030	X-ray eye for foreign body.	
70100	X-ray exam of jaw.	
70110	X-ray exam of jaw.	
70120	X-ray exam of mastoids.	
70130	X-ray exam of mastoids.	
70140	X-ray exam of facial bones.	
70150	X-ray exam of facial bones.	
70160	X-ray exam of nasal bones.	
70200	X-ray exam of eye sockets.	
70210	X-ray exam of sinuses.	
70220	X-ray exam of sinuses.	
70250	X-ray exam of skull.	
70260	X-ray exam of skull.	
70328	X-ray exam of jaw joint.	
70330	X-ray exam of jaw joints.	
70336	Magnetic image, jaw joint.	
70355	Panoramic x-ray of jaws.	
70360	X-ray exam of neck.	
70370	Throat x-ray & fluoroscopy.	

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

HCPCS code	Short description	Added for this final rule
70371	Speech evaluation, complex.	
70450	Ct head/brain w/o dye.	
70480	Ct orbit/ear/fossa w/o dye.	
70486	Ct maxillofacial w/o dye.	
70490	Ct soft tissue neck w/o dye.	
70544	Mr angiography head w/o dye.	
70551	Mri brain w/o dye.	
71010	Chest x-ray.	
71015	Chest x-ray.	
71020	Chest x-ray.	
71021	Chest x-ray.	
71022	Chest x-ray.	
71023	Chest x-ray and fluoroscopy.	
71030	Chest x-ray.	
71034	Chest x-ray and fluoroscopy.	
71035	Chest x-ray.	
71100	X-ray exam of ribs.	
71101	X-ray exam of ribs/ chest.	
71110	X-ray exam of ribs.	
71111	X-ray exam of ribs/ chest.	
71120	X-ray exam of breastbone.	
71130	X-ray exam of breastbone.	
71250	Ct thorax w/o dye.	
72010	X-ray exam of spine.	
72020	X-ray exam of spine.	
72040	X-ray exam of neck spine.	
72050	X-ray exam of neck spine.	
72052	X-ray exam of neck spine.	
72069	X-ray exam of trunk spine.	
72070	X-ray exam of thoracic spine.	
72072	X-ray exam of thoracic spine.	
72074	X-ray exam of thoracic spine.	
72080	X-ray exam of trunk spine.	
72090	X-ray exam of trunk spine.	
72100	X-ray exam of lower spine.	
72110	X-ray exam of lower spine.	
72114	X-ray exam of lower spine.	
72120	X-ray exam of lower spine.	

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

HCPCS code	Short description	Added for this final rule	HCPCS code	Short description	Added for this final rule	HCPCS code	Short description	Added for this final rule
72125	Ct neck spine w/o dye.		73564	X-ray exam, knee, 4 or more.		76078	Radiographic absorptiometry.	
72128	Ct chest spine w/o dye.		73565	X-ray exam of knees.		76100	X-ray exam of body section.	
72131	Ct lumbar spine w/o dye.		73590	X-ray exam of lower leg.		76400	Magnetic image, bone marrow.	
72141	Mri neck spine w/o dye.		73600	X-ray exam of ankle.		76510	Ophth us, b & quant a.	
72146	Mri chest spine w/o dye.		73610	X-ray exam of ankle.		76511	Ophth us, quant a only.	
72148	Mri lumbar spine w/o dye.		73620	X-ray exam of foot.		76512	Ophth us, b w/non-quant a.	
72170	X-ray exam of pelvis.		73630	X-ray exam of foot.		76513	Echo exam of eye, water bath.	
72190	X-ray exam of pelvis.		73650	X-ray exam of heel.		76514	Echo exam of eye, thickness.	
72192	Ct pelvis w/o dye.		73660	X-ray exam of toe(s).		76516	Echo exam of eye.	
72202	X-ray exam sacroiliac joints.		73700	Ct lower extremity w/o dye.		76519	Echo exam of eye.	
72220	X-ray exam of tailbone.		73718	Mri lower extremity w/o dye.		76536	Us exam of head and neck.	
73000	X-ray exam of collar bone.		73721	Mri jnt of lwr extre w/o dye.		76645	Us exam, breast(s).	
73010	X-ray exam of shoulder blade.		74000	X-ray exam of abdomen.		76700	Us exam, abdom, complete.	
73020	X-ray exam of shoulder.		74010	X-ray exam of abdomen.		76705	Echo exam of abdomen.	
73030	X-ray exam of shoulder.		74020	X-ray exam of abdomen.		76770	Us exam abdo back wall, comp.	
73050	X-ray exam of shoulders.		74022	X-ray exam series, abdomen.		76775	Us exam abdo back wall, lim.	
73060	X-ray exam of humerus.		74150	Ct abdomen w/o dye.		76778	Us exam kidney transplant.	
73070	X-ray exam of elbow.		74210	Contrast x-ray exam of throat.		76801	Ob us < 14 wks, single fetus.	
73080	X-ray exam of elbow.		74220	Contrast x-ray, esophagus.		76805	Ob us >= 14 wks, snl fetus.	
73090	X-ray exam of forearm.		74230	Cine/vid x-ray, throat/esoph.		76811	Ob us, detailed, snl fetus.	
73100	X-ray exam of wrist.		74246	Contrast x-ray uppr gi tract.		76816	Ob us, follow-up, per fetus.	
73110	X-ray exam of wrist.		74247	Contrst x-ray uppr gi tract.		76817	Transvaginal us, obstetric.	
73120	X-ray exam of hand.		74249	Contrst x-ray uppr gi tract.		76830	Transvaginal us, non-ob.	
73130	X-ray exam of hand.		76020	X-rays for bone age.		76856	Us exam, pelvic, complete.	
73140	X-ray exam of finger(s).		76040	X-rays, bone evaluation.		76857	Us exam, pelvic, limited.	
73200	Ct upper extremity w/o dye.		76061	X-rays, bone survey.		76870	Us exam, scrotum.	
73218	Mri upper extremity w/o dye.		76062	X-rays, bone survey.		76880	Us exam, extremity.	
73221	Mri joint upr extrem w/o dye.		76065	X-rays, bone evaluation.		76970	Ultrasound exam follow-up.	
73510	X-ray exam of hip.		76066	Joint survey, single view.		76977	Us bone density measure.	
73520	X-ray exam of hips.		76070	Ct bone density, axial.		76999	Echo examination procedure.	
73540	X-ray exam of pelvis & hips.		76071	Ct bone density, peripheral.		77280	Set radiation therapy field.	*
73550	X-ray exam of thigh.		76075	Dxa bone density, axial.		77285	Set radiation therapy field.	*
73560	X-ray exam of knee, 1 or 2.		76076	Dxa bone density/peripheral.		77290	Set radiation therapy field.	*
73562	X-ray exam of knee, 3.		76077	Dxa bone density/v-fracture.		77295	Set radiation therapy field.	*
						77300	Radiation therapy dose plan.	

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

HCPCS code	Short description	Added for this final rule
77301	Radiotherapy dose plan, imrt.	
77315	Teletx isodose plan complex.	
77326	Brachytx isodose calc simp.	
77327	Brachytx isodose calc interm.	
77328	Brachytx isodose plan compl.	
77331	Special radiation dosimetry.	
77332	Radiation treatment aid(s).	*
77333	Radiation treatment aid(s).	*
77334	Radiation treatment aid(s).	*
77336	Radiation physics consult.	
77370	Radiation physics consult.	
77401	Radiation treatment delivery.	
77402	Radiation treatment delivery.	
77403	Radiation treatment delivery.	
77404	Radiation treatment delivery.	
77407	Radiation treatment delivery.	
77408	Radiation treatment delivery.	
77409	Radiation treatment delivery.	
77411	Radiation treatment delivery.	
77412	Radiation treatment delivery.	
77413	Radiation treatment delivery.	
77414	Radiation treatment delivery.	
77416	Radiation treatment delivery.	
77418	Radiation tx delivery, imrt.	
77470	Special radiation treatment.	
77520	Proton trmt, simple w/o comp.	
77523	Proton trmt, intermediate.	
80500	Lab pathology consultation.	
80502	Lab pathology consultation.	
85097	Bone marrow interpretation.	
86510	Histoplasmosis skin test.	
86850	RBC antibody screen.	
86870	RBC antibody identification.	

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

HCPCS code	Short description	Added for this final rule
86880	Coombs test, direct.	
86885	Coombs test, indirect, qual.	
86886	Coombs test, indirect, titer.	
86890	Autologous blood process.	
86900	Blood typing, ABO.	
86901	Blood typing, Rh (D).	
86903	Blood typing, antigen screen.	
86904	Blood typing, patient serum.	
86905	Blood typing, RBC antigens.	
86906	Blood typing, Rh phenotype.	
86930	Frozen blood prep.	
86970	RBC pretreatment.	
88104	Cytopath fl nongyn, smears.	
88106	Cytopath fl nongyn, filter.	
88107	Cytopath fl nongyn, sm/fltr.	
88108	Cytopath, concentrate tech.	
88112	Cytopath, cell enhance tech.	
88160	Cytopath smear, other source.	
88161	Cytopath smear, other source.	
88162	Cytopath smear, other source.	
88172	Cytopathology eval of fna.	
88173	Cytopath eval, fna, report.	
88182	Cell marker study.	
88184	Flowcytometry/ tc, 1 marker.	
88185	Flowcytometry/tc, add-on.	
88300	Surgical path, gross.	
88302	Tissue exam by pathologist.	
88304	Tissue exam by pathologist.	
88305	Tissue exam by pathologist.	
88307	Tissue exam by pathologist.	
88311	Decalcify tissue.	
88312	Special stains.	
88313	Special stains.	
88321	Microslide consultation.	
88323	Microslide consultation.	
88325	Comprehensive review of data.	

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

HCPCS code	Short description	Added for this final rule
88331	Path consult intraop, 1 bloc.	
88342	Immunohistochemistry.	
88346	Immunofluorescent study.	
88347	Immunofluorescent study.	
88348	Electron microscopy.	
88358	Analysis, tumor.	
88360	Tumor immunohistochem/manual.	
88361	Tumor immunohistochem/comput.	*
88365	Insitu hybridization (fish).	
88368	Insitu hybridization, manual.	
88399	Surgical pathology procedure.	
89049	Chct for mal hyperthermia.	
89230	Collect sweat for test.	
89240	Pathology lab procedure.	
90761	Hydrate iv infusion, add-on.	
90761	Hydrate iv infusion, add-on.	*
90766	Ther/proph/dg iv inf, add-on.	*
90801	Psy dx interview.	
90802	Intac psy dx interview.	
90804	Psytx, office, 20–30 min.	
90805	Psytx, off, 20–30 min w/e&m.	
90806	Psytx, off, 45–50 min.	
90807	Psytx, off, 45–50 min w/e&m.	
90808	Psytx, office, 75–80 min.	
90809	Psytx, off, 75–80, w/e&m.	
90810	Intac psytx, off, 20–30 min.	
90812	Intac psytx, off, 45–50 min.	
90816	Psytx, hosp, 20–30 min.	
90818	Psytx, hosp, 45–50 min.	
90826	Intac psytx, hosp, 45–50 min.	*
90845	Psychoanalysis.	
90846	Family psytx w/o patient.	
90847	Family psytx w/patient.	

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

HCPCS code	Short description	Added for this final rule	HCPCS code	Short description	Added for this final rule	HCPCS code	Short description	Added for this final rule
90853	Group psychotherapy.		93005	Electrocardiogram, tracing.		93975	Vascular study.	
90857	Intac group psytx.		93017	Cardiovascular stress test.	*	93976	Vascular study.	
90862	Medication management.		93225	ECG monitor/record, 24 hrs.		93978	Vascular study.	
92002	Eye exam, new patient.		93226	ECG monitor/report, 24 hrs.		93979	Vascular study.	
92004	Eye exam, new patient.		93231	Ecg monitor/record, 24 hrs.		93990	Doppler flow testing.	
92012	Eye exam established pat.		93232	ECG monitor/report, 24 hrs.		94015	Patient recorded spirometry.	
92014	Eye exam & treatment.		93236	ECG monitor/report, 24 hrs.		94690	Exhaled air analysis.	
92020	Special eye evaluation.		93270	ECG recording.		95115	Immunotherapy, one injection.	
92081	Visual field examination(s).		93271	Ecg/monitoring and analysis.		95117	Immunotherapy injections.	
92082	Visual field examination(s).		93278	ECG/signal-averaged.		95165	Antigen therapy services.	
92083	Visual field examination(s).		93727	Analyze ilr system.		95250	Glucose monitoring, cont.	*
92135	Ophth dx imaging post seg.		93731	Analyze pacemaker system.		95805	Multiple sleep latency test.	
92136	Ophthalmic biometry.		93732	Analyze pacemaker system.		95806	Sleep study, unattended.	
92225	Special eye exam, initial.		93733	Telephone analy, pacemaker.		95807	Sleep study, attended.	
92226	Special eye exam, subsequent.		93734	Analyze pacemaker system.		95808	Polysomnography, 1–3.	
92230	Eye exam with photos.		93735	Analyze pacemaker system.		95812	Eeg, 41–60 minutes.	
92240	Icg angiography.		93736	Telephonic analy, pacemaker.		95813	Eeg, over 1 hour.	
92250	Eye exam with photos.		93741	Analyze ht pace device snl.		95816	Eeg, awake and drowsy.	
92275	Electroretinography.		93742	Analyze ht pace device snl.		95819	Eeg, awake and asleep.	
92285	Eye photography.		93743	Analyze ht pace device dual.		95822	Eeg, coma or sleep only.	
92286	Internal eye photography.		93744	Analyze ht pace device dual.		95869	Muscle test, thor paraspinal.	
92520	Laryngeal function studies.		93786	Ambulatory BP recording.		95872	Muscle test, one fiber.	*
92541	Spontaneous nystagmus test.		93788	Ambulatory BP analysis.		95900	Motor nerve conduction test.	
92546	Sinusoidal rotational test.		93797	Cardiac rehab.		95921	Autonomic nerv function test.	
92548	Posturography.		93798	Cardiac rehab/monitor.		95925	Somatosensory testing.	
92552	Pure tone audiometry, air.		93875	Extracranial study.		95926	Somatosensory testing.	*
92553	Audiometry, air & bone.		93880	Extracranial study.		95930	Visual evoked potential test.	
92555	Speech threshold audiometry.		93882	Extracranial study.		95950	Ambulatory eeg monitoring.	
92556	Speech audiometry, complete.		93886	Intracranial study.		95953	EEG monitoring/computer.	
92557	Comprehensive hearing test.		93888	Intracranial study.		95970	Analyze neurostim, no prog.	
92567	Tympanometry.		93922	Extremity study.		95972	Analyze neurostim, complex.	
92582	Conditioning play audiometry.		93923	Extremity study.		95974	Cranial neurostim, complex.	
92585	Auditor evoke potent, compre.		93924	Extremity study.		95978	Analyze neurostim brain/1h.	
92603	Cochlear implt f/up exam 7 >.		93925	Lower extremity study.		96000	Motion analysis, video/3d.	
92604	Reprogram cochlear implt 7 >.		93926	Lower extremity study.		96101	Psycho testing by psych/phys.	
92626	Eval aud rehab status.		93930	Upper extremity study.				
			93931	Upper extremity study.				
			93965	Extremity study.				
			93970	Extremity study.				
			93971	Extremity study.				

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

HCPSC code	Short description	Added for this final rule
96111	Developmental test, extend.	
96116	Neurobehavioral status exam.	
96118	Neuropsych tst by psych/phys.	
96119	Neuropsych testing by tec.	
96150	Assess hlth/behave, init.	
96151	Assess hlth/behave, subseq.	
96152	Intervene hlth/behave, indiv.	
96153	Intervene hlth/behave, group.	
96415	Chemo, iv infusion, addl hr.	
96423	Chemo ia infuse each addl hr.	
96900	Ultraviolet light therapy.	
96910	Photochemotherapy with UV-B.	
96912	Photochemotherapy with UV-A.	
96913	Photochemotherapy, UV-A or B.	
96920	Laser tx, skin < 250 sq cm.	
98925	Osteopathic manipulation.	
98926	Osteopathic manipulation.	
98927	Osteopathic manipulation.	
98940	Chiropractic manipulation.	
98941	Chiropractic manipulation.	
98942	Chiropractic manipulation.	
99204	Office/outpatient visit, new.	
99212	Office/outpatient visit, est.	
99213	Office/outpatient visit, est.	
99214	Office/outpatient visit, est.	
99241	Office consultation.	
99242	Office consultation.	
99243	Office consultation.	
99244	Office consultation.	
99245	Office consultation.	
0144T	CT heart w/ dye; qual calc.	
C8951	IV inf, tx/dx, each addl hr.	
C8955	Chemotx adm, IV inf, addl hr.	
G0008	Admin influenza virus vac.	
G0101	CA screen; pelvic/breast exam.	
G0127	Trim nail(s).	

TABLE 1.—CY 2008 FINAL BYPASS CODES FOR CREATING “PSEUDO” SINGLE CLAIMS FOR CALCULATING MEDIAN COSTS—Continued

HCPSC code	Short description	Added for this final rule
G0130	Single energy x-ray study.	
G0166	Extrnl counterpulse, per tx.	
G0175	OPPS Service, sched team conf.	
G0332	Preadmin IV immunoglobulin.	
G0340	Robt lin-radsurg fractx 2-5.	
G0344	Initial preventive exam.	
G0365	Vessel mapping hemo access.	
G0367	EKG tracing for initial prev.	
G0376	Smoke/tobacco counseling >10.	
M0064	Visit for drug monitoring.	
Q0091	Obtaining screen pap smear.	

(2) Exploration of Allocation of Packaged Costs to Separately Paid Procedure Codes

During its August 23–24, 2006 meeting, the APC Panel recommended that CMS provide claims analysis of the contributions of packaged costs (including packaged revenue code charges and charges for packaged HCPCS codes) to the median cost of each drug administration service. (We refer readers to Recommendation #28 in the August 23–24, 2006 meeting recommendation summary on the CMS Web site at: http://www.cms.hhs.gov/FACA/05_Advisory_PanelonAmbulatoryPaymentClassificationGroups.asp#TopOfPage.) In our continued effort to better understand the multiple claims in order to extract single bill information from them, we examined the extent to which the packaging in multiple procedure claims differs from the packaging in the single procedure claims on which we base the median costs both in general and more specifically for drug administration services. We performed this analysis using the claims data on which we based the CY 2007 OPPS/ASC final rule with comment period. We examined the amount of packaging in multiple procedure versus single procedure claims in general and in claims for drug administration services in particular. We conducted this analysis without taking into account the

proposed packaging approach presented in the CY 2008 OPPS/ASC proposed rule. However, we did not expect the services newly proposed for packaged payment to commonly appear with a drug administration service. Therefore, we believed that the analysis conducted on the CY 2007 final rule with comment period data was sufficient to inform our development of the CY 2008 OPPS/ASC proposed rule.

In general, we did not believe that the proportionate amount of packaged costs in the multiple bills relative to the number of primary services would be greater than that in the single bills. Our findings supported our hypothesis. The costs in uncoded revenue codes and HCPCS codes with a packaged status indicator accounted for 22 percent of observed costs in the universe of all CY 2005 claims that we used to model the CY 2007 OPPS (including both the single and multiple procedure bills). Similarly, the costs in uncoded revenue codes and HCPCS codes with a packaged status indicator accounted for 18 percent of the total cost in the subset of CY 2005 single bills that we used to calculate the median costs on which the relative weights were based.

However, the bypass methodology creates a “pseudo” single bill for all claims for services or items on the bypass list, and these “pseudo” single bills have no associated packaging, by definition of the application of the bypass list. Excluding the total cost associated with bypass codes, 28 percent of observed costs in the single bills were attributable to packaged services, and 29 percent of observed costs across all claims were attributable to packaged services. Therefore, we concluded that, in general, the extent of packaging in all bills was similar to the amount of packaging in the single procedure bills we used to set median costs for most APCs.

In the CY 2008 proposed rule (72 FR 42640), we recognized that aggregate numbers do not address the packaging associated with single and multiple procedure claims for specific services. In past years, we received comments stating that the amount of packaging in the single bills for drug administration services was not representative of the typical packaged costs of these drug administration services, which were usually performed in combination with one another, because the single bills represented less complex and less resource-intensive services than the usual cases.

We published a study in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68120 through 68121) that discussed the amount of packaging on

the single bills for drug administration procedure codes, and we promised to replicate that study for the APC Panel. We discussed the results of this study with the APC Panel at its March 2007 meeting, in accordance with the APC Panel's August 2006 recommendation and also published the results in the CY 2008 OPPS/ASC proposed rule (72 FR 42640 through 42641).

As discussed in the proposed rule, we found that drug administration services demonstrated reasonable single bill representation in comparison with other OPPS services. Single bills for drug administration constituted, roughly, 30 percent of all observed occurrences of drug administration services, varying by code from 7 to 55 percent. The study also demonstrated that packaged costs substantially contributed to median cost estimates for the majority of drug administration HCPCS codes (72 FR 42640 through 42641).

For all single bills for CPT code 90780 (Intravenous infusion for therapy/diagnosis, administered by physician or under direct supervision of physician; up to one hour), on average, packaged costs were 31 percent of total cost (median 27 percent). For the same code, packaged drug and pharmacy costs comprised, on average, 23 percent of total costs (median 15 percent). Single bills made up 34 percent of all line-item occurrences of the service, suggesting that this single bill median cost was fairly robust and probably captured packaging adequately. On the other hand, CPT code 90784 (Therapeutic, prophylactic or diagnostic injection (specify material injected); subcutaneous or intramuscular) demonstrated limited packaging (median 0 percent and mean 17 percent), and the median cost for the code was derived from only 7 percent of all occurrences of the code. Across all drug administration codes, over half showed significant median packaged costs largely attributable to packaged drug and pharmacy costs.

By definition, we were unable to precisely assess the amount of packaging associated with drug administration codes in the multiple bills. As a proxy, we estimated packaging as a percent of total cost on each claim for two subsets of claims. Both analyses suggested the presence of moderate packaged costs, especially drug and pharmacy costs, associated with drug administration services in the multiple bills. We calculated measures of central tendency for packaging percentages in the multiple bills or portions of multiple bills remaining after "pseudo" singles were created. We referred to this group of the multiple

bills as the "hardcore" multiple bills. For the first subset of "hardcore" multiple bills with only drug administration codes, that is, where multiple drug administration codes were the only separately paid procedure codes on the claim, we estimated that packaged costs were 22 percent of total costs (27 percent, on average), where total costs consisted of costs for all payable codes. Costs for packaged drug HCPCS codes and pharmacy revenue codes comprised 13 percent of total cost at the median (19 percent, on average). For the second subset of "hardcore" multiple bills with any drug administration code, that is, where a drug administration code appeared with other payable codes (largely radiology services and visits), we estimated packaged costs were 13 percent of total cost at the median (19 percent, on average). Costs for packaged drugs and pharmacy revenue codes comprised 6 percent of total cost at the median (10 percent, on average). The amount of packaging in both proxy measures, but especially the first subset, closely resembled the packaged costs as a percentage of drug administration costs observed in the single bills for drug administration services. While finding a way to accurately use data from the "hardcore" multiple bills to estimate drug administration median costs undoubtedly would impact medians, these comparisons suggested that the multiple bill data probably would support current median estimates.

In the CY 2008 OPPS/ASC proposed rule (72 FR 42641), we noted that we had received several comments over the past few years offering algorithms for packaging the costs associated with specific revenue codes or packaging drugs with certain drug administration codes. Because of the complexity of even routine OPPS claims, prior research suggested that such algorithms have limited power to generate additional single bill claims and do little to change median cost estimates. In the proposed rule (72 FR 42641), we explained that we continue to look for simple, but powerful, methodologies like the bypass list and packaging of HCPCS codes for additional ancillary and supportive services to assign packaged costs to all services within the "hardcore" multiple bills. Ideally, these methodologies should be intuitive to the provider community, easily integrated into the complexity of OPPS median cost estimation, and simple to maintain from year to year. We specifically solicited methodologies for creation of single bills that meet these criteria.

We received several public comments with regard to the use of data from

single and multiple procedure claims for ratesetting. A summary of the public comments and our responses follow.

Comment: Several commenters expressed appreciation for CMS' analysis of packaged costs included on single and multiple procedure claims for drug administration services. One commenter encouraged CMS to further analyze the total amount and percentage of packaged costs associated with all packaged HCPCS codes, as well as other packaged services reported by hospitals, and examine this information on single versus multiple procedure claims in order to increase hospitals' understanding of the actual packaged costs used in the ratesetting process. Once again, several commenters encouraged CMS to consider specific packaging algorithms to allocate packaged costs on multiple procedures claims, in order to create additional "pseudo" single claims for ratesetting.

Response: The packaging of associated costs into payment for major procedures is a longstanding principle of the OPPS. The OPPS packages payment for the operating and capital-related costs that are directly related and integral to furnishing a service on an outpatient basis. These packaged costs have historically included costs related to use of an operating or treatment room, anesthesia, medical supplies, implantable devices, inexpensive drugs, etc. Our findings related to the packaged costs on single and multiple claims for drug administration services confirm that the packaging on the single bills used for ratesetting resembles the drug and pharmacy-related packaged costs on multiple procedure claims. The packaging associated with drug administration services on single and multiple claims has historically been of particular concern to the public, so we are reassured by this finding. We are not convinced that developing this information for all other HCPCS codes would provide further useful information to hospitals. Instead, we prefer to direct our analytic resources toward exploring additional approaches to using more cost data from multiple procedure claims for ratesetting. If we are eventually able to use all OPPS claims in developing median costs, then all packaged costs on claims would also be incorporated in ratesetting under the OPPS. We remind hospitals that they should continue to take into consideration all costs associated with providing HOPD services in establishing their charges for the services. In addition, hospitals should report packaged HCPCS codes and charges, consistent with all CPT, OPPS, and local

contractor instructions, whenever those services are provided to ensure that the associated costs are included in ratesetting for the major services.

As we have stated previously regarding our exploration of specific packaging algorithms, we have found that these approaches, while resource-intensive on our part, have limited power to generate additional single bill claims and do little to change median cost estimates. We received no other specific suggestions for other approaches to allocating packaged costs on “hardcore” multiple bills that would be intuitive to the provider community, easily integrated into the complexity of OPSS median cost estimation, and simple to maintain from year to year. We will continue to explore these data challenges with the assistance of the Data Subcommittee of the APC Panel. We believe that further progression toward encounter-based or episode-based payment for commonly provided combinations of services could reduce the number of these multiple claims and incorporate additional claims data, as discussed in section II.A.4.d. of this final rule with comment period regarding low dose rate prostate brachytherapy and cardiac electrophysiologic evaluation and ablation procedures.

After consideration of the public comments received, we are finalizing our CY 2008 proposal for the use of single and multiple procedure claims for ratesetting. We will continue to pursue additional methodologies that would allow use of cost data from “hardcore” multiple claims for ratesetting.

c. Calculation of CCRs

We calculated hospital-specific overall CCRs and hospital-specific departmental CCRs for each hospital for which we had claims data in the period of claims being used to calculate the median costs that we converted to scaled relative weights for purposes of setting the OPSS payment rates. We applied the hospital-specific CCR to the hospital's charges at the most detailed level possible, based on a revenue code to cost center crosswalk that contains a hierarchy of CCRs used to estimate costs from charges for each revenue code. That crosswalk is available for review and continuous comment on the CMS Web site at: http://www.cms.hhs.gov/HospitalOutpatientPPS/03_crosswalk.asp#TopOfPage. We calculated CCRs for the standard and nonstandard cost centers accepted by the electronic cost report database. In general, the most detailed level at which

we calculated CCRs was the hospital-specific departmental level.

Following the expiration of most medical devices from pass-through status in CY 2003, prior to which devices were paid at charges reduced to cost using the hospital's overall CCR, we received comments that our OPSS cost estimates for device implantation procedures systematically underestimate the cost of the devices included in the packaged payment for the procedures because hospitals routinely mark up charges for low cost items to a much greater extent than they mark up high cost items, and that these items are often combined in a single cost center on their Medicare cost report. This is commonly known as “charge compression.”

In CY 2006, the device industry commissioned a study to interpolate a device specific CCR from the medical supply CCR, using publicly available hospital claims and Medicare cost report data rather than proprietary data on device costs. After reviewing the device industry's data analysis and study model, CMS contracted with RTI International (RTI) to study the impact of charge compression on the cost-based weight methodology adopted in the FY 2007 IPPS final rule, to evaluate this model, and to propose solutions. For more information, interested individuals can view RTI's report on the CMS Web site at: <http://www.cms.hhs.gov/reports/downloads/Dalton.pdf>.

Any study of cost estimation in general, and charge compression specifically, has obvious importance for both the OPSS and the IPPS. RTI's research explicitly focused on the IPPS for several reasons, which include greater Medicare expenditures under the IPPS, a desire to evaluate the model quickly given IPPS regulation deadlines, and a focus on other components of the new FY 2007 IPPS cost-based weight methodology (CMS Contract No. 500–00–0024–T012, “A Study of Charge Compression in Calculating DRG Relative Weights,” page 5). The study first addressed the possibility of cross-aggregation bias in the CCRs used to estimate costs under the IPPS created by the IPPS methodology of aggregating cost centers into larger departments before calculating CCRs. The report also addressed potential bias created by estimating costs using a CCR that reflects the combined costs and charges of services with wide variation in the amount of hospital markup. In its assessment of the latter, RTI targeted its attempt to identify the presence of charge compression to those cost centers presumably associated with revenue

codes demonstrating significant IPPS expenditures and utilization. RTI assessed the correlation between cost report CCRs and the percent of charges in a cost center attributable to a set of similar services represented by a group of revenue codes. RTI did not examine the correlation between CCRs and revenue codes without significant IPPS expenditures or a demonstrated concentration in a specific Diagnosis Related Group (DRG). For example, RTI did not examine revenue code groups within the pharmacy cost center with low proportionate inpatient charges that might be important to the OPSS, such as “Pharmacy Incident to Radiology.” RTI states this limitation in its study and specifically recommends that disaggregated CCRs be reestimated for hospital outpatient charges.

Cost report CCRs combine both inpatient and outpatient services. Ideally, RTI would be able to examine the correlation between CCRs for Medicare inpatient services and inpatient claim charges and the correlation between CCRs for Medicare outpatient services and outpatient claim charges. However, the comprehensive nature of the cost report CCR (which combines inpatient and outpatient services) argues for an analysis of the correlation between CCRs and combined inpatient and outpatient claim charges. As noted, the RTI study accepted some measurement error in its analysis by matching an “all charges” CCR to inpatient estimates of charges for groups of similar services represented by revenue codes because of short timelines and because inpatient costs dominate outpatient costs in many ancillary cost centers. We believe that CCR adjustments used to calculate payment should be based on the comparison of cost report CCRs to combined inpatient and outpatient charges. An “all charges” model would reduce measurement error and estimate adjustments to disaggregated CCRs that could be used in both hospital inpatient and outpatient payment systems.

RTI made several short-term recommendations for improving the accuracy of DRG weight estimates from a cost-based methodology to address bias in combining cost centers and charge compression that could be considered in the context of OPSS policy. We discussed each recommendation within the context of the OPSS and provided our assessment of its application to the OPSS in the CY 2008 OPSS/ASC proposed rule (72 FR 42642). Of the four short term recommendations, we believe that only the recommendation to establish regression based estimates as a

temporary or permanent method for disaggregating national average CCRs for medical supplies, drugs, and radiology services under the IPPS has specific application to the OPSS (RTI study, pages 11 and 86). Moreover, with regard to radiology services, the OPSS already has partially implemented RTI's recommendation to use lower CCRs to estimate costs for those OPSS services allocated to MRI or CT Scan cost centers through its use of hospital-specific CCRs for nonstandard cost centers.

For reasons discussed below and in more detail in the proposed rule (72 FR 42642 through 42643), we proposed to develop an all charges model that would compare variation in CCRs with variation in combined inpatient and outpatient charges for sets of similar services and establish disaggregated regression-based CCRs that could be applied to both inpatient and outpatient charges. We proposed to evaluate the results of that methodology for purposes of determining whether the resulting regression-based CCRs should be proposed for use in developing the CY 2009 OPSS payment rates. As noted in the proposed rule (72 FR 42642), the revised all charges model and resulting regression-based CCRs were not available in time for use in developing this final rule with comment period.

Since publication of the proposed rule, we have contracted with RTI to determine whether the statistical model that RTI recommended in its January 2007 report for adjusting CCRs in inpatient cost computations can be expanded to include cost computations for significant categories of outpatient services that are paid under the OPSS and to assess the impact of any such changes on payment under the OPSS (HHSM 500–2005–00029I Task Order 0008, “Refining Cost-to-Charge Ratios for Calculating APC and DRG Relative Payment Weights”). Under this task order, RTI will assess the validity of the revenue code-to-cost center crosswalk used under the OPSS by comparing revenue code and cost center charges, make recommendations for changes to the crosswalk, and assess the OPSS use of nonstandard cost centers. RTI will estimate regression-based CCRs using charge data from both inpatient and outpatient claims for hospital ancillary departments. RTI will extend its recommended models to estimate regression-based CCRs for cost centers that are particularly relevant to APCs, working with CMS staff to analyze the sensitivity of APC weights to proposed adjustments. RTI also will convene a technical expert panel to review analyses, as it did for its first study.

There are several reasons why we did not propose to use the intradepartmental regression-based CCRs that RTI estimated using IPPS charges for the CY 2008 OPSS estimation of median costs. We agree with RTI that the intradepartmental CCRs calculated for the IPPS would not always be appropriate for application to the OPSS (RTI study, pages 34 and 35). While RTI recommends that the model be recalibrated for outpatient charges before it is applied to the OPSS, we believed that the combined nature of the CCRs available from the cost report prevents an accurate outpatient recalibration that would be appropriate for the OPSS alone. Therefore, we believed that an all charges model examining an expanded subset of revenue codes would be the most appropriate, and that this model should be developed before we could apply the resulting regression based CCRs to the charges for supplies paid under the OPSS.

Moreover, we were concerned that implementing the regression-based IPPS related CCRs in the OPSS that RTI estimated for CY 2008 could result in greater instability in relative payment weights for CY 2008 than would otherwise occur, and that a subsequent change to application of the regression-based CCRs resulting from development of an all charges model might also result in significant fluctuations in median costs and increased instability in payments from CY 2008 to CY 2009. Therefore, these sequential changes could result in significant increases in median costs in one year and significant declines in median costs in the next year.

Therefore, we did not propose to adopt the RTI regression-based CCRs under the CY 2008 OPSS. As indicated in the proposed rule (72 FR 42643), we stated that we would consider whether it would be appropriate to adopt regression-based CCRs for the OPSS after we received RTI's comprehensive review of the OPSS cost estimation methodology and reviewed the results of the use of both inpatient and outpatient charges across all payers to reestimate regression-based CCRs.

We received many public comments on the issue of application of the disaggregated CCRs that RTI estimated using regression analysis to calculate payments for the CY 2008 OPSS. A summary of the public comments and our responses follow.

Comment: The commenters made a number of requests for the CY 2008 OPSS. Some commenters asked specifically that CMS use the RTI regression-based CCRs to calculate the

costs of devices, implants, and drugs under the CY 2008 OPSS. Other commenters urged CMS not to apply this charge compression adjustment methodology to diagnostic radiology services because the application of the methodology to these capital intensive procedures has not been fully validated and would benefit from additional analysis. The commenters who supported the application of the adjustment methodology for CY 2008 asserted that CMS should disregard the fact that the estimated regression-based CCRs were calculated using only inpatient charge data because the commenters had found that using inpatient or outpatient charges yielded similar CCR estimates for implantable devices and all other supplies. These commenters believed that CMS should accept the RTI findings that were based on inpatient charges alone and apply them to the calculation of median costs for all OPSS weights. They explained that CMS could consider further refinements to the methodology in future years, such as estimating the regression-based CCRs using either outpatient or combined charges, but that CMS should not delay implementing this important change as it evaluates an all charges model.

Some commenters who supported the application of the adjustment for CY 2008 also stated that the most glaring cases of charge compression occur with high cost implantable devices that are reported by hospitals with low cost supplies in the same supply cost center. They asserted that the need for analysis of the extent of a problem in other cost centers should not stop CMS from applying the estimated regression-based CCRs for CY 2008 to charges for medical supplies, drugs, and radiology services. One commenter submitted a set of revised weights for all APCs reflecting regression-based CCRs for implantable devices and all other supplies, as well as its assumptions in developing the weights, and asked that CMS review the results. Some commenters stated that if CMS decides not to implement the RTI recommendations for regression-based CCRs for CY 2008, it should ensure that an all charges model is implemented in both the IPPS and the OPSS for CY 2009 through a joint IPPS/OPSS task force. Some commenters believed that CMS should either implement the regression-based adjustments in CY 2008 or begin a transition to them over a period of 2 to 3 years.

The MedPAC recommended that CMS use the RTI's estimated disaggregated, regression-based CCRs for medical supplies, drugs, and radiology as part of the OPSS ratesetting process for CY

2008. It stated that, although the application of the regression based CCR estimates is not a perfect solution to the problem of charge compression, the possibility of payment inaccuracies is sufficiently serious that CMS should implement this imperfect solution. The MedPAC also recommended that if CMS prefers to await the results of the all charges model and chooses not to correct for the effects of charge compression under the CY 2008 OPSS, CMS must do so for the CY 2009 OPSS.

Response: While the RTI recommendations for regression-based CCRs may have the potential to address issues of charge compression raised in the public comments about OPSS cost-based weights, we are not sufficiently convinced that we should adopt the regression-based CCR estimates for the CY 2008 OPSS from the January 2007 RTI short-term recommendations for several reasons. First, the focus of the RTI study on inpatient charges did more than just restrict the regression model dependent variables to inpatient percentages. The study also limited the cost centers addressed to those where the inpatient charges comprised a significant portion of the cost center charges and substantially contributed to the DRGs. The RTI analysis did not examine cost centers that have a much greater proportion of outpatient charges, and as such, are particularly important to APC weights, while also potentially having a residual impact for DRG weight calculations as well.

Second, adoption of regression-based CCRs in this final rule with comment period would produce significant changes to the proposed APC payment rates beyond those already introduced with our CY 2008 packaging approach. The lengthy discussion of public comments to our proposed packaging approach in section II.A.4. of this final rule with comment period reflects the public concern raised by a modest change in the methodology for estimating APC relative weights. Disaggregating drug and supply cost centers clearly would redistribute hospitals' resource costs among relative weights for different APCs. Estimated APC median costs calculated using regression-based CCRs for implantable devices and all other supplies, which were furnished by one commenter, showed increases for some services of as high as 28 percent, such as APC 0418 (Insertion of Left Ventricular Lead). Others would decline by as much as 11 percent, including APC 0674 (Prostate Cryoablation) and APC 0086 (Level III Electrophysiologic Procedures). An adjusted "all other supply" CCR would reduce the median cost of any service

with significant supply packaging. Adoption of regression-based CCRs could interact with other potential changes to the APC payment groups under the OPSS. Budget neutrality adjustments could further increase the magnitude of these observed differences. We believe that these significant redistributive effects would have to be confirmed through CMS analysis, modeled, and made available for public comment should CMS decide to adopt regression-based CCRs.

Third, we anticipate overall changes to our cost estimation methodology in the future, including changes to the revenue code-to-cost center crosswalk and use of nonstandard cost centers. We believe that a comprehensive review of cost estimation is an appropriate time to explore the potential use of disaggregated CCRs for the OPSS. For example, if we implemented only select regression-based CCRs or crosswalk refinements, we could inappropriately redistribute weight within the system.

Finally, as noted in the FY 2008 IPPS final rule (72 FR 47192 through 47200), despite commenters' support for the disaggregated CCRs developed from regression analysis, we remain concerned about the accuracy of using regression-based estimates to determine relative weights rather than the Medicare cost report. This is especially true for the OPSS, given the potential redistribution of resource costs among services. One commenter noted that poor capital allocation to MRI and CT Scan revenue code charges could explain the observed differences in CCRs for these services, and a regression-based adjustment based on incorrect capital allocation would be equally inaccurate. As discussed in the FY 2008 IPPS final rule (72 FR 47196), we fully support voluntary educational initiatives to improve uniformity in reporting costs and charges on the cost report. Participation in these educational initiatives by hospitals is voluntary. Hospitals are not required to change how they report costs and charges if their current cost reporting practices are consistent with rules and regulations and applicable instructions. However, both the IPPS and OPSS relative weight estimates will benefit from any steps taken to improve cost reporting. To the extent allowed under current regulations and cost report instructions, we encourage hospitals to report costs and charges consistently with how the data are used to determine relative weights. We believe this goal is of mutual benefit to both Medicare and hospitals.

In conclusion, we believe that it is important that the initial RTI estimation of regression-based CCRs be replicated with the inclusion of hospital outpatient charges, that the study examine the current OPSS revenue code-to-cost center crosswalk and the use of nonstandard cost centers, and that the analysis focus on the cost centers that have significant hospital outpatient charges. Regression-based CCRs may have potential to address issues of charge compression under the OPSS and possible mismatches between how costs and charges are reported in the cost reports and on OPSS claims. However, given the potential resulting change in APC weights and redistributive impact, we believe we would need to apply regression-based CCRs in all areas eligible for an adjustment, as well as implement appropriate crosswalk refinements, in order to not under- or overvalue relative weights within the system. We continue to have concerns about premature adoption of regression-based CCRs without the benefit of knowing how they would interact with other APC changes. We further believe that such methodological changes would need to be proposed, including presentation of our assessment of the possible impact of the methodology and solicitation of public comment. Once we have received the results of RTI's evaluation, we will analyze the findings and then consider whether it could be appropriate to propose to use regression-based CCRs under the OPSS. Once we have completed our analysis, we will then examine whether the educational activities being undertaken by the hospital community to improve cost reporting accuracy under the IPPS would help to mitigate charge compression under the OPSS, either as an adjunct to the application of regression-based CCRs or in lieu of such an adjustment. After the conclusion of our analysis of the RTI evaluation and our review of hospital educational activities, we will then determine whether any refinements should be proposed.

Comment: One commenter indicated that the standard hospital accounting methodology for treatment of high capital costs, including the costs of expensive nonmovable radiology equipment, results in CCRs for radiology services that understate the true costs of radiology services because the high capital costs are spread over all departments of the hospital on a square footage basis. The commenter argued that this understatement of the costs in the CCR for radiology-related

departments results in calculated costs for radiology services that are too low because flawed CCRs are applied to the charges for the services provided by the radiology department.

Response: We will consider the issue as part of our assessment of CCRs over the upcoming year, in the context of the RTI study as described earlier and the ongoing work that the hospital industry is undertaking with respect to cost reporting.

2. Calculation of Median Costs

In this section of this final rule with comment period, we discuss the use of claims to calculate the final OPSS payment rates for CY 2008. The hospital OPSS page on the CMS Web site on which this final rule with comment period is posted provides an accounting of claims used in the development of the final rates on the CMS Web site at: <http://www.cms.hhs.gov/>

HospitalOutpatientPPS. The accounting of claims used in the development of this final rule with comment period is included on the Web site under supplemental materials for the CY 2008 final rule with comment period. That accounting provides additional detail regarding the number of claims derived at each stage of the process. In addition, below we discuss the files of claims that comprise the data sets that are available for purchase under a CMS data user contract. Our CMS Web site, <http://www.cms.hhs.gov/> *HospitalOutpatientPPS*, includes information about purchasing the following two OPSS data files: "OPSS Limited Data Set" and "OPSS Identifiable Data Set." These files are available for both the claims that were used to calculate the proposed payment rates for the CY 2008 OPSS and also for the claims that were used to calculate the final payment rates for the CY 2008 OPSS.

As proposed, we used the following methodology to establish the relative weights used in calculating the OPSS payment rates for CY 2008 shown in Addenda A and B to this final rule with comment period. This methodology is as follows:

a. Claims Preparation

We used hospital outpatient claims for the full CY 2006, processed before June 30, 2007, to set the final relative weights for CY 2008. To begin the calculation of the relative weights for CY 2008, we pulled all claims for outpatient services furnished in CY 2006 from the national claims history file. This is not the population of claims paid under the OPSS, but all outpatient claims (including, for example, CAH

claims and hospital claims for clinical laboratory services for persons who are neither inpatients nor outpatients of the hospital).

We then excluded claims with condition codes 04, 20, 21, and 77. These are claims that providers submitted to Medicare knowing that no payment would be made. For example, providers submit claims with a condition code 21 to elicit an official denial notice from Medicare and document that a service is not covered. We then excluded claims for services furnished in Maryland, Guam, the U.S. Virgin Islands, American Samoa, and the Northern Mariana Islands because hospitals in those geographic areas are not paid under the OPSS.

We divided the remaining claims into the three groups shown below. Groups 2 and 3 comprise the 108 million claims that contain hospital bill types paid under the OPSS.

1. Claims that were not bill types 12X, 13X, 14X (hospital bill types), or 76X (CMHC bill types). Other bill types are not paid under the OPSS and, therefore, these claims were not used to set OPSS payment.

2. Claims that were bill types 12X, 13X, or 14X (hospital bill types). These claims are hospital outpatient claims.

3. Claims that were bill type 76X (CMHC). (These claims are later combined with any claims in item 2 above with a condition code 41 to set the per diem partial hospitalization rate determined through a separate process.)

For the CCR calculation process, we used the same general approach as we used in developing the final APC rates for CY 2007, using the revised CCR calculation which excluded the costs of paramedical education programs and weighted the outpatient charges by the volume of outpatient services furnished by the hospital. We refer readers to the CY 2007 OPSS/ASC final rule with comment period for more information (71 FR 67983 through 67985). We first limited the population of cost reports to only those for hospitals that filed outpatient claims in CY 2006 before determining whether the CCRs for such hospitals were valid.

We then calculated the CCRs for each cost center and the overall CCR for each hospital for which we had claims data. We did this using hospital-specific data from the Healthcare Cost Report Information System (HCRIS). We used the most recent available cost report data, in most cases, cost reports for CY 2005. As proposed, for this final rule with comment period, we used the most recently submitted cost reports to calculate the CCRs to be used to calculate median costs for the CY 2008

OPSS rates. If the most recent available cost report was submitted but not settled, we looked at the last settled cost report to determine the ratio of submitted to settled cost using the overall CCR, and we then adjusted the most recent available submitted but not settled cost report using that ratio. We calculated both an overall CCR and cost center-specific CCRs for each hospital. We used the final overall CCR calculation discussed in section II.A.1.c. of this final rule with comment period for all purposes that required use of an overall CCR.

We then flagged CAH claims, which are not paid under the OPSS, and claims from hospitals with invalid CCRs. The latter included claims from hospitals without a CCR; those from hospitals paid an all-inclusive rate; those from hospitals with obviously erroneous CCRs (greater than 90 or less than .0001); and those from hospitals with overall CCRs that were identified as outliers (3 standard deviations from the geometric mean after removing error CCRs). In addition, we trimmed the CCRs at the cost center (that is, departmental) level by removing the CCRs for each cost center as outliers if they exceeded +/-3 standard deviations from the geometric mean. We used a four tiered hierarchy of cost center CCRs to match a cost center to every possible revenue code appearing in the outpatient claims, with the top tier being the most common cost center and the last tier being the default CCR. If a hospital's cost center CCR was deleted by trimming, we set the CCR for that cost center to "missing" so that another cost center CCR in the revenue center hierarchy could apply. If no other cost center CCR could apply to the revenue code on the claim, we used the hospital's overall CCR for the revenue code in question. For example, if a visit was reported under the clinic revenue code, but the hospital did not have a clinic cost center, we mapped the hospital-specific overall CCR to the clinic revenue code. The hierarchy of CCRs is available for inspection and comment on the CMS Web site: <http://www.cms.hhs.gov/> *HospitalOutpatientPPS*. We then converted the charges to costs on each claim by applying the CCR that we believed was best suited to the revenue code indicated on the line with the charge. Table 4 of the proposed rule contained a list of the revenue codes we proposed to package. Revenue codes not included in Table 4 were those not allowed under the OPSS because their services could not be paid under the OPSS (for example, inpatient room and

board charges), and thus charges with those revenue codes were not packaged for creation of the OPSS median costs. One exception is the calculation of median blood costs, as discussed in section X. of this final rule with comment period.

Thus, we applied CCRs as described above to claims with bill types 12X, 13X, or 14X, excluding all claims from CAHs and hospitals in Maryland, Guam, the U.S. Virgin Islands, American Samoa, and the Northern Mariana Islands and claims from all hospitals for which CCRs were flagged as invalid.

We identified claims with condition code 41 as partial hospitalization services of hospitals and moved them to another file. These claims were combined with the 76X claims identified previously to calculate the partial hospitalization per diem rate.

We then excluded claims without a HCPCS code. We moved to another file claims that contained nothing but influenza and pneumococcal pneumonia ("PPV") vaccines. Influenza and PPV vaccines are paid at reasonable cost and, therefore, these claims are not used to set OPSS rates. We note that the separate file containing partial hospitalization claims is included in the files that are available for purchase as discussed above. Unlike years past, we did not create a separate file of claims containing observation services because we are packaging all observation care for the CY 2008 OPSS.

We next copied line-item costs for drugs, blood, and brachytherapy sources (the lines stay on the claim, but are copied onto another file) to a separate file. No claims were deleted when we copied these lines onto another file. These line-items are used to calculate a per unit mean and median and a per day mean and median for drugs, radiopharmaceutical agents, blood and blood products, and brachytherapy sources, as well as other information used to set payment rates, such as a unit-to-day ratio for drugs.

b. Splitting Claims and Creation of "Pseudo" Single Claims.

We then split the claims into five groups: single majors, multiple majors, single minors, multiple minors, and other claims. (Specific definitions of these groups follow below.) In years prior to the CY 2007 OPSS, we made a determination about whether each HCPCS code was a major code or a minor code or a code other than a major or minor code. We used those code-specific determinations to sort claims into the five groups identified above. For the CY 2007 OPSS, we used status indicators to sort the claims into these

groups. We defined major procedures as any procedure having a status indicator of "S," "T," "V," or "X;" defined minor procedures as any code having a status indicator of "N;" and classified "other" procedures as any code having a status indicator other than "S," "T," "V," "X," or "N." For the CY 2007 OPSS proposed rule limited data set and identifiable data set, these definitions excluded claims on which hospitals billed drugs and devices without also reporting separately paid procedure codes and, therefore, those public use files did not contain all claims used to calculate the drug and device frequencies and medians. We corrected this for the CY 2007 OPSS/ASC final rule with comment period limited data set and identifiable data set by extracting claims containing drugs and devices from the set of "other" claims and adding them to the public use files.

At its March 2007 meeting, the APC Panel recommended that CMS edit and return for correction claims that contain a HCPCS code for a separately paid drug or device but that also do not contain a HCPCS code assigned to a procedural APC (that is, those not assigned status indicator "S," "T," "V," or "X"). The APC Panel stated that this edit should improve the claims data and may increase the number of single bills available for ratesetting. We noted that such an edit would be broader than the device-to-procedure code edits we implemented for CY 2007 for selected devices, and we solicited comments on the impact of establishing such edits on hospital billing processes and related potential improvements to claims data. In the CY 2008 proposed rule (72 FR 42645), we explained that in view of the prior public comments and our desire to ensure that the public data files contained all appropriate data, for the CY 2008 OPSS, we proposed to define majors as HCPCS codes that have a status indicator of "S," "T," "V," or "X." We proposed to define minors as HCPCS codes that have a status indicator of "F," "G," "H," "K," "L," or "N" but, as discussed above, to make single bills out of any claims for single procedures with a minor code that also has an APC assignment. This ensured that the claims that contained only HCPCS codes for drugs and biologicals or devices but that did not contain codes for procedures were included in the limited data set and the identifiable data set. It also ensured that conditionally packaged services proposed to receive separate payment only when they were billed without any other separately payable OPSS services would be treated appropriately for

purposes of median cost calculations. We proposed to define "other" services as HCPCS codes that had a status indicator other than those defined as majors or minors.

We received several public comments regarding our proposal to continue to process OPSS claims for a separately paid drug or device that did not also report a procedural HCPCS code with a status indicator of "S," "T," "V," or "X." A summary of the public comments and our responses follow.

Comment: Several commenters requested that we adopt the recommendation of the APC Panel that CMS edit and return for correction claims that contained a HCPCS code for a separately paid drug or device but that did not also report a HCPCS code with a status indicator of "S," "T," "V," or "X." These commenters believed that this process would generally improve hospitals' coding and charging practices. One commenter indicated that, under some circumstances, a hospital may bill for a diagnostic radiopharmaceutical that is administered on one day but may not report the associated nuclear medicine procedure on the same claim because the procedure would be provided several days later. In this case, the bill for the diagnostic radiopharmaceutical would include no other services with a status indicator of "S," "T," "V," or "X" because the administration of the radiopharmaceutical would be considered to be a part of the nuclear medicine study.

Response: We have accepted this recommendation in selective situations. We currently edit claims in the Outpatient Code Editor (OCE) for selected devices for which our data show that hospitals have a history of reporting the HCPCS device code but not reporting the HCPCS procedure code that is necessary for the device to have therapeutic benefit. See the device-to-procedure edits on the OPSS Web page at <http://www.cms.hhs.gov/HospitalOutpatientPPS/>. Moreover, as discussed in more detail in section II.A.4.c.(5) of this final rule with comment period, effective for dates of service on or after January 1, 2008, we will implement OCE edits for diagnostic nuclear medicine services that will require that a HCPCS code for a diagnostic radiopharmaceutical must be on the claim for the claim to be processed to payment. Claims will be returned to the provider for correction if they contain a nuclear medicine service but the hospital does not also report a radiopharmaceutical on the same claim. We will continue to assess the need for OCE edits based upon the unique

circumstances of individual services or categories of services.

In the CY 2008 proposed rule (72 FR 42645), we explained our continued belief that using status indicators, with the proposed changes, was an appropriate way to sort the claims into these groups and also to make our process more transparent to the public. We further believed that this proposed method of sorting claims would enhance the public's ability to derive useful information for analysis and public comment on the proposed rule.

We used status indicator "Q" in Addendum B to the proposed rule to identify services that would receive separate HCPCS code-specific payment when specific criteria are met, and payment for the individual service would be packaged in all other circumstances. We proposed several different sets of criteria to determine whether separate payment would be made for specific services. For example, we proposed that HCPCS code G0379 (Direct admission of patient for hospital observation care) be assigned status indicator "Q" in Addendum B to the proposed rule because we proposed that it receive separate payment only if it is billed on the same date of service as HCPCS code G0378 (Hospital observation service, per hour), without any services with status indicator "T" or "V" or Critical Care (APC 0617). We also proposed to assign the specific services in the proposed composite APCs discussed in section II.A.4.d. of the proposed rule status indicator "Q" in Addendum B to the proposed rule because we proposed that their payment would be bundled into a single composite payment for a combination of major procedures under certain circumstances. As proposed, these services would only receive separate code-specific payment if certain criteria were met. The same is true for those less intensive outpatient mental health treatment services for which payment would be limited to the partial hospitalization per diem rate and which also were assigned status indicator "Q" in Addendum B to the proposed rule. According to longstanding OPPTS payment policy (65 FR 18455), payment for these individual mental health services is bundled into a single payment, APC 0034 (Mental Health Services Composite), when the sum of the individual mental health service payments for all of those mental health services provided on the same day would exceed payment for a day of partial hospitalization services. However, the largest number of specific HCPCS codes identified by status indicator "Q" in Addendum B to the

proposed rule were those codes that we identified as "special" packaged codes, where we proposed that a hospital would receive separate payment for providing one unit of a service when the "special" packaged code appears on the same day on a claim without another service that was assigned status indicator "S," "T," "V," or "X." We proposed to package payment for these HCPCS codes when the code appears on the same date of service on a claim with any other service that was assigned status indicator "S," "T," "V," or "X."

In response to public comments as discussed in detail in section II.A.4. of this final rule with comment period, we refined the proposed methodology for paying claims that contain "special" packaged codes with status indicator "Q" when there is a major separately paid procedure on the claim for the same date and when there are multiple "special" packaged codes with status indicator "Q" but no major procedure on the claim. This last and largest subset of conditionally packaged services, referred to as "special" packaged codes in the proposed rule, had to be integrated into the identification of single and multiple bills for ratesetting to ensure that the costs for these services were appropriately packaged when they appeared with any other separately paid service or paid separately when appearing by themselves.

We handled these "special" packaged "Q" status codes in the data for this final rule with comment period by assigning the HCPCS code an APC and a data status indicator of "N." This gives all special packaged codes an initial status of "minor" that is changed, when appropriate, through the split process. We identified two subsets of the "special" packaged codes for the purpose of payment and ratesetting. Imaging supervision and interpretation "special" packaged codes are now named "T-packaged" codes. All other "special" packaged codes are referred to as "STVX-packaged" codes. When an "STVX-packaged" code appeared with a HCPCS code with a status indicator of "S," "T," "V," or "X" on the same date of service, it retained its minor status and was treated as a packaged code and received a status indicator of "N." The costs that appeared on the lines with these codes were packaged into the cost of the HCPCS code with a status indicator of "S," "T," "V," or "X" in the single bills and contributed to the median cost for the primary service with which they appeared. When the "STVX packaged" code appeared by itself, without other special packaged codes on the same claim, and had a unit of one,

we changed the status indicator on the line to the status indicator of the APC to which the code was assigned, converting the service from a single minor to a single major. This created "natural" single bills for the "STVX-packaged" codes. In the case of multiple "STVX-packaged" codes reported on a claim on the same date of service but without a major separately paid procedure (that is, "S," "T," "V," or "X"), we first identified the "STVX-packaged" code with the highest CY 2007 OPPTS payment weight. We then changed the status indicator on the line to the status indicator of the APC to which this particular code was assigned, converting the service from a single minor to a single major, and we forced the units to be one to conform with our policy of paying only one unit of a "Q" status service. We extracted these claims from the multiple minors to create "pseudo" single bills. We summed all costs on the claim and associated the resulting cost with the payable "STVX-packaged" code that had the highest CY 2007 OPPTS payment weight. We used natural and "pseudo" single procedure claims for "STVX-packaged" codes to set the median costs for the APCs to which the codes were assigned when they would be separately paid.

We modified this methodology for the "T-packaged" codes (imaging supervision and interpretation services in CY 2008) because our final CY 2008 payment policy for these services differs from the policy for "STVX-packaged" codes. Although we treated all "special" packaged codes as "STVX-packaged" codes in the proposed rule, in this final rule with comment period, "T-packaged" services are packaged only when they appear with a service with a status indicator of "T" on the same date; otherwise, "T packaged" services are paid separately. We assessed all claims for the presence of "T packaged" services and determined their final payment disposition, packaged or separately paid, prior to splitting the claims into single and multiple majors and minors. When a "T-packaged" code appeared with a HCPCS code with a status indicator of "T" on the same date of service, the "T-packaged" code was treated as a packaged code and retained its minor status and a status indicator of "N." Otherwise, we designated a "T-packaged" service that would be separately paid by identifying the "T-packaged" code on the date of service with the highest CY 2007 payment weight. We changed the status indicator on the line of the "T-packaged" code with the highest CY 2007 payment weight to the status indicator of the APC

to which the code was assigned, converting it from a single minor to a single major. We forced the units to be one to conform with our policy of paying only one unit of a service with a status indicator of "Q." Any remaining "T-packaged" codes appearing on the same date of service retained their minor status and a status indicator of "N." In the single and "pseudo" single bills, the costs that appeared on the lines with these codes were packaged into the cost of the HCPCS code with a status indicator of "T." The remaining claims, "T-packaged" services on claims with another service with a status indicator of "S," "V," or "X" on the same date, became multiple majors. The bypass process for breaking multiple major claims created additional "pseudo" single bills for the "T-packaged" codes that had been converted to major status. When the "T-packaged" code appeared by itself with packaged services and one unit, we changed the status indicator on the line to the status indicator of the APC to which the code was assigned, converting the service to a single major procedure. In the case of multiple "T-packaged" codes reported on a claim on the same date of service but without a major separately paid procedure ("S," "T," "V," or "X"), we summed all costs on the claim, associated the resulting cost with the "T-packaged" or "STVX-packaged" code that had the highest 2007 OPPS payment weight, and forced the units to one. We extracted these claims from the multiple minors to created new single bills. These processes created "natural" and "pseudo" single bills for the "T-packaged" codes that were then used to set the median cost for each specific code and for the APCs to which the codes would be assigned when they were separately paid.

We added the logic necessary to deal with these codes as part of the split of the claims into the five groups defined below and in our review of the multiple minor claims. We evaluated the "T-packaged" codes that had been on the bypass list to see if they might be eligible for continuation on the list, as these codes would appear with their final payment disposition in the multiple majors. However, we determined that none of these codes should be returned to the bypass list because their associated packaging under their CY 2008 "Q" payment status exceeded the empirical criteria designed to limit error in the allocation of packaged costs through the bypass process.

Specifically, we divided the remaining claims into the following five groups:

1. *Single Major Claims:* Claims with a single separately payable procedure (that is, status indicator "S," "T," "V," or "X"). Claims with one unit of a status indicator "Q" code that was an "STVX-packaged" code or "T-packaged" code where there was no code on the claim with status indicator "S," "T," "V," or "X," or "T," respectively.

2. *Multiple Major Claims:* Claims with more than one separately payable procedure (that is, status indicator "S," "T," "V," or "X"), or multiple units of one payable procedure. As discussed below, some of these were used in median setting. These claims included those with a status indicator "Q" code that was a "T-packaged" code and no procedure with a status indicator "T" on the same date of service. We also included in this set claims that contained one unit of one code when the bilateral modifier was appended to the code and the code was conditionally or independently bilateral. In these cases, the claims represented more than one unit of the service described by the code, notwithstanding that only one unit was billed.

3. *Single Minor Claims:* Claims with a single HCPCS code that was assigned status indicator "F," "G," "H," "K," "L," or "N" and was not an "STVX-packaged" or "T packaged code."

4. *Multiple Minor Claims:* Claims with multiple HCPCS codes that were assigned status indicator "F," "G," "H," "K," "L," or "N." This set included "STVX packaged" and "T-packaged" codes with more than one unit of the code or more than one line of these codes on the same date of service. As noted above, we created "pseudo" singles from some of these claims when we broke the claim by date, packaged the costs into the code with the highest CY 2007 payment weight, and forced the units to one to match our payment policy of paying one unit.

5. *Non-OPPS Claims:* Claims that contained no services payable under the OPPS (that is, all status indicators other than those listed for major or minor status). These claims were excluded from the files used for the OPPS. Non-OPPS claims have codes paid under other fee schedules, for example, durable medical equipment or clinical laboratory tests, and do not contain either a code for a separately paid service or a code for a packaged service.

The claims listed in numbers 1, 2, 3, and 4 above were included in the data files that can be purchased as described above. "STVX-packaged" and "T-packaged" codes appear in the single

major file, the multiple major file, and the multiple minor file.

We set aside the single minor, multiple minor, and non-OPPS claims (numbers 3, 4, and 5 above) because we did not use these claims in calculating median costs of procedural APCs. We then used the bypass codes listed earlier in Table 1 and discussed in section II.A.1.b. of this final rule with comment period to remove separately payable procedures that we determined contained limited or no packaged costs or that were otherwise suitable for inclusion on the bypass list from a multiple procedure bill. When one of the two separately payable procedures on a multiple procedure claim was on the bypass list, we split the claim into two "pseudo" single procedure claim records. The single procedure claim record that contained the bypass code did not retain packaged services. The single procedure claim record that contained the other separately payable procedure (but no bypass code) retained the packaged revenue code charges and the packaged HCPCS code charges. We then examined the multiple major claims for dates of service to determine if we could break them into "pseudo" single procedure claims using the dates of service on all lines on the claim. If we could create claims with single major procedures by using dates of service, we created a single procedure claim record for each separately paid procedure on a different date of service (that is, a "pseudo" single).

We also removed lines that contained multiple units of codes on the bypass list and treated them as "pseudo" single claims by dividing the cost for the multiple units by the number of units on the line. Where one unit of a single, separately paid procedure code remained on the claim after removal of the multiple units of the bypass code, we created a "pseudo" single claim from that residual claim record, which retained the costs of packaged revenue codes and packaged HCPCS codes. This enabled us to use claims that would otherwise be multiple procedure claims and could not be used. We excluded those claims that we were not able to convert to single claims even after applying all of the techniques for creation of "pseudo" singles. Among those excluded were claims that contained codes that were viewed as independently or conditionally bilateral and that contained the bilateral modifier (Modifier 50 (Bilateral procedure)) because the line-item cost for the code represented the cost of two units of the procedure, notwithstanding that the code appeared with a unit of one. Therefore, the charge on the line

represented the charge for two services rather than a single service and using the line as reported would have overstated the cost of a single procedure.

c. Completion of Claim Records and Median Cost Calculations

We then packaged the costs of packaged HCPCS codes (codes with status indicator "N" listed in Addendum B to the proposed rule and the costs of those lines for "Q" status services that retained status indicator "N" through the split process as described above) and packaged revenue codes into the cost of the single major procedure remaining on the claim.

The final list of packaged revenue codes is shown in Table 2 below. At its March 2007 meeting, the APC Panel recommended that CMS review the final list of packaged revenue codes for consistency with OPSS policy and ensure that future versions of the OCE edit accordingly. We compared the packaged revenue codes in the OCE to the final list of packaged revenue codes for the CY 2007 OPSS (71 FR 67989 through 67990) that we used for packaging costs in median calculation. As a result of that analysis, we stated in the CY 2008 OPSS/ASC proposed rule (72 FR 42646) that we accepted the APC Panel's recommendation and we proposed to change the list of packaged revenue codes for the CY 2008 OPSS in the following manner. First, we proposed to remove revenue codes 0274 (Prosthetic/Orthotic devices) and 0290 (Durable Medical Equipment) from the list of packaged revenue codes because we do not permit hospitals to report implantable devices in these revenue codes (Internet Only Manual 100-4, Chapter 4, section 20.5.1.1). We also specifically proposed to add revenue code 0273 (Take Home Supplies) to the list of packaged revenue codes because we believed that the charges under this revenue code were for the incidental supplies that hospitals sometimes provided for patients who were discharged at a time when it was not possible to secure the supplies needed for a brief time at home. We proposed to conform the list of packaged revenue codes in the OCE to the OPSS for CY 2008. We made these changes in the calculation of the CY 2008 OPSS payment rates. The final CY 2008 packaged revenue codes are displayed in Table 2 below.

We packaged the costs of the HCPCS codes that were shown with status indicator "N" into the cost of the independent service to which the packaged service was ancillary or supportive. We refer readers to section

II.A.4. of this final rule with comment period for a more complete discussion of the final packaging changes for CY 2008.

We also excluded (1) claims that had zero costs after summing all costs on the claim and (2) claims containing packaging flag number 3. Effective for services furnished on or after July 1, 2004, the OCE assigned packaging flag number 3 to claims on which hospitals submitted token charges for a service with status indicator "S" or "T" (a major separately paid service under the OPSS) for which the fiscal intermediary was required to allocate the sum of charges for services with a status indicator equaling "S" or "T" based on the weight of the APC to which each code was assigned. We did not believe that these charges, which were token charges as submitted by the hospital, were valid reflections of hospital resources. Therefore, we deleted these claims. We also deleted claims for which the charges equaled the revenue center payment (that is, the Medicare payment) on the assumption that where the charge equaled the payment, to apply a CCR to the charge would not yield a valid estimate of relative provider cost.

For the remaining claims, we then standardized 60 percent of the costs of the claim (which we have previously determined to be the labor-related portion) for geographic differences in labor input costs. We made this adjustment by determining the wage index that applied to the hospital that furnished the service and dividing the cost for the separately paid HCPCS code furnished by the hospital by that wage index. As has been our policy since the inception of the OPSS, we used the pre-reclassified wage indices for standardization because we believed that they better reflected the true costs of items and services in the area in which the hospital was located than the post-reclassification wage indices and, therefore, would result in the most accurate unadjusted median costs.

We also excluded claims that were outside 3 standard deviations from the geometric mean of units for each HCPCS code on the bypass list (because, as discussed above, we used claims that contain multiple units of the bypass codes).

After removing claims for hospitals with error CCRs, claims without HCPCS codes, claims for immunizations not covered under the OPSS, and claims for services not paid under the OPSS, approximately 58 million claims were left for this final rule comment period. Of these 58 million claims, we were able to use some portion of approximately 54

million whole claims (93 percent of approximately 58 million potentially usable claims) to create approximately 97 million single and "pseudo" single claims, of which we used 96 million single bills (after trimming out just over 900,000 claims as discussed below) in the CY 2008 median development and ratesetting.

We used the remaining claims to calculate the CY 2008 median costs for each separately payable HCPCS code and each APC. The comparison of HCPCS and APC medians determines the applicability of the "2 times" rule. Section 1833(t)(2) of the Act provides that, subject to certain exceptions, the items and services within an APC group cannot be considered comparable with respect to the use of resources if the highest median (or mean cost, if elected by the Secretary) for an item or service in the group is more than 2 times greater than the lowest median cost for an item or service within the same group ("the 2 times rule"). Finally, we reviewed the medians and reassigned HCPCS codes to different APCs where we believed that it was appropriate. Section III. of this final rule with comment period includes a discussion of certain HCPCS code assignment changes that resulted from examination of the medians and for other reasons. The APC medians were recalculated after we reassigned the affected HCPCS codes. Both the HCPCS medians and the APC medians were weighted to account for the inclusion of multiple units of the bypass codes in the creation of "pseudo" single bills.

In the CY 2008 proposed rule (72 FR 42646), we explained that in our review of median costs for HCPCS codes and their assigned APCs, we had frequently noticed that some services were consistently rarely performed in the hospital outpatient setting for the Medicare population. In particular, there were a number of services, such as several procedures related to the care of pregnant women, that had annual Medicare claims volume of 100 or fewer occurrences. By definition, these services also had a small number of single bills from which to estimate median costs. In addition, in some cases, these codes had been historically assigned to clinical APCs where all the services were low volume. Therefore, the median costs for these services and APCs often fluctuated from year to year, in part due to the variability created by such a small number of claims. One of the benefits of basing payment on the median cost of many HCPCS codes with sufficient single bill representation in an APC is that such fluctuation would be moderated by the increased number of observations for similar services on

which the APC median cost was also based. We considered proposing a distinct methodology for calculation of the median cost of low total volume APCs in order to provide more stability in payment from year to year for these low total volume services. However, after examination of the low total volume OPPS services and their assigned APCs, we concluded that there were other clinical APCs with higher volumes of total claims to which these low total volume services could be reassigned, while ensuring the continued clinical and resource homogeneity of the clinical APCs to which they would be newly reassigned. Therefore, we believed that it would be more appropriate to reconfigure clinical APCs to eliminate most of the low total volume APCs. We observed that these low volume services differed from other OPPS services only because they were not often furnished to the Medicare population. Therefore, we proposed to reconfigure certain clinical APCs for CY 2008 as a way to promote stability and appropriate payment for the services assigned to them, including low total volume services. We believed that these proposed reconfigurations maintained APC clinical and resource homogeneity. We proposed these changes as an alternative to developing specific quantitative approaches to treating low total volume APCs differently for purposes of median calculation. Specifically, we proposed that 3 APCs (all of which are New Technology APCs) would have a total volume of services less than 100, and only 17 APCs would have a total volume of less than 1,000, in comparison with CY 2007 where 9 APCs (including 3 New Technology APCs) had a total volume of less than 100 and 36 APCs had a total volume of less than 1,000. In this final rule with comment period, 3 APCs (all New Technology APCs) have a total volume of less than 100 and 15 APCs have a total volume of less than 1,000.

We received a number of public comments on our proposed process for calculating the median costs on which our payment rates are based. A summary of the public comments and our responses follow.

Comment: Some commenters objected to the volatility of the OPPS rates from year to year. The commenters asserted that the absence of stability in the OPPS rates creates budgeting, planning, and operating problems for hospitals, and that as more care is provided on an outpatient, rather than inpatient basis, the need for stable payment rates from one year to the next becomes more important to hospitals. Some commenters asked that CMS permit no

payment rate to change by more than 5 percent from one year to the next.

Response: There are a number of factors pertinent to the OPPS that cause median costs to change from one year to the next. Some of these are a reflection of hospital behavior, and some of them are a reflection of fundamental characteristics of the OPPS as defined in statute. For example, the OPPS payment rates are based on hospital cost report and claims data. However, hospital costs and charges change each year and this results in both changes to the CCRs taken from the most currently available cost reports and also differences in the charges on the claims that are the basis of the calculation of the median costs on which OPPS rates are based. Similarly, hospitals adjust their mix of services from year to year by offering new services and ceasing to furnish services or changing the proportion of the various services they furnish, which has impact on the CCRs that we derive from their cost reports. CMS cannot stabilize these hospital-driven fundamental inputs to the calculation of OPPS payment rates. Moreover, there are other essential elements of the OPPS which contribute to the changes in relative weights each year. These include, but are not limited to, reassignments of HCPCS codes to APCs to rectify 2 times violations as required by the law, to address the costs of new services, and to respond to public comments. Moreover, for some services, we cannot avoid using small numbers of claims, either because the volume of services is naturally low or because the claims data do not facilitate the calculation of a median cost for a single service. Where there are small numbers of claims to be used in median calculation, there is more volatility in the median cost from one year to the next. Lastly, changes to OPPS payment policy (for example, changes to packaging) also contribute to some extent to the fluctuations in the OPPS payment rates for the same service from year to year.

We cannot avoid the naturally occurring volatility in the cost report and claims data that hospitals submit and on which the payment rates are based. Moreover (with limited exceptions), we are required by law to reassign HCPCS codes to APCs where it is necessary to avoid 2 times violations. However, we have made other changes to resolve some of the other potential reasons for instability from year to year. Specifically, we continue to seek ways to use more claims data so that we have fewer APCs for which there are small numbers of single bills used to set the APC median costs. Moreover, we have tried to eliminate APCs with very small

numbers of single bills where we could do so. We received no public comments that objected to our proposal to eliminate a number of very low volume APCs; therefore, we are adopting these reconfigurations for CY 2008. We recognize that changes to payment policies, such as the packaging of payment for ancillary and supportive services and the implementation of composite APCs, may contribute to volatility in payment rates in the short term, but we believe that larger payment packages and bundles will help to stabilize payments in future years by enabling us to use more claims data and by establishing payments for larger groups of services.

Comment: A commenter stated that CMS should crosswalk revenue code 0278 (Other implants, under the Medical/Surgical Supplies category) to cost center 3540 (Prosthetic Devices), which generally represents higher cost technology, instead of crosswalking it to cost center 5500 (Medical Supplies Charge to Patient), which often represents lower cost items. The commenter indicated that this change to the revenue code-to-cost center crosswalk would result in improved estimates of the costs of the devices billed under revenue code 0278 and, therefore, would result in more accurate payments.

Response: We will carefully examine the implications of making this change in the future. However, for CY 2008 this change would have a negligible effect on the median costs for services with charges reported under revenue code 0278. Only 20 providers out of 4,201 in the file of the 2005–2006 cost reports used cost center 3540.

Comment: Some commenters asked that CMS provide an adjustment for medical education costs under the OPPS because so much of the costs of teaching services are being incurred in the HOPD as many of the services previously furnished only in the inpatient setting are now being furnished in the HOPD. The commenters stated that CMS indicated that it would study the costs and payment differential among different classes of providers in the April 7, 2000 OPPS final rule with comment period but has not done so. The commenters also asserted that section 4523 of the BBA requires the Secretary to establish adjustments “as determined to be necessary to ensure equitable payments * * * for certain classes of hospitals” and, therefore, CMS should study whether the hospital outpatient costs of teaching hospitals are higher than the costs of other hospitals for purposes of determining whether there should be a teaching

hospital adjustment. The commenters explained that their internal analysis of 2004 Medicare cost reports showed that the average outpatient margins were – 20.2 percent for major teaching hospitals, – 10.1 percent for other teaching hospitals, and – 11.8 percent for non-teaching hospitals. They believed these findings demonstrated that the hospital outpatient costs of major teaching hospitals are significantly greater than the costs of other hospitals. The commenters requested that CMS conduct its own analysis, and added that if that analysis shows such a difference, CMS should add a teaching adjustment to the OPSS.

Response: Unlike payment under the IPPS, the law does not provide for payment for indirect medical education costs to be made through the OPSS. Section 1833(t)(2)(E) of the Act, as added by section 4523 of the BBA, states that the Secretary shall establish, in a budget neutral manner “ * * * other adjustments as determined to be necessary to ensure equitable payments, such as adjustments for certain classes of hospitals.” We have not found such an adjustment to be necessary to ensure equitable payments to teaching hospitals and, therefore, have not developed such an adjustment. We do not believe an indirect medical education add-on payment is appropriate in a budget neutral payment system where such changes would result in reduced payments to all other hospitals. Furthermore, in this final rule with comment period, we have developed payment weights that we believe provide appropriate and adequate payment for the complex medical services, such as visits requiring prolonged observation, new technology services and device-dependent procedures, which we understand are furnished largely by teaching hospitals. Teaching hospitals benefit from the recalibration of the APCs and the changes to packaging that are implemented in this final rule with comment period. The final CY 2008

impacts by class of hospital are displayed in Table 61 in section XXIV.B. of this final rule with comment period. Therefore, we do not believe that there is sufficient reason to develop an adjustment to the OPSS payment to teaching hospitals for the CY 2008 OPSS.

Comment: The MedPAC commented that while CMS proposed to apply a multiple procedure reduction to imaging services for CY 2006, CMS did not adopt this proposal as final but stated that it would continue to study whether such a reduction was appropriate. The MedPAC asked that CMS continue to examine ways to improve payment accuracy for imaging services, including considering applying a multiple procedure reduction to these services.

Response: The question of whether it would be appropriate to apply a multiple procedure reduction pertains only to those imaging services for which we make separate payment. It is not an issue for packaged imaging services, including the numerous imaging services that we are packaging for CY 2008 as part of our expanded payment bundles under the OPSS. The concern, therefore, is partially mitigated by our final CY 2008 packaging policies. Commenters responding to the CY 2006 proposal OPSS indicated that, in contrast to the MPFS payment rates, the hospital cost data used by CMS to set payment rates for imaging services already reflects savings due to the efficiencies of performing multiple procedures during the same session and that the proposal to discount second and subsequent procedures would be tantamount to discounting those procedures twice (70 FR 68707). As we indicated in our response to that comment, we were unable to disprove commenters’ contentions that there are already efficiencies included in hospitals’ costs and, therefore, in their CCRs and in the median costs on which the OPSS payments are based (70 FR 68708). However, we believe it is possible that there may be a relationship

between the extent to which efficiencies are incorporated into the median costs and the degree to which charge compression affects the median costs for imaging services. RTI’s study of charge compression using inpatient charges found that use of regression adjusted CCRs would reduce the costs of magnetic resonance imaging and computed tomography services. This is one of the categories of hospital services that has high outpatient utilization. Over the coming year, as discussed earlier in this section of this final rule with comment period, we will explore through the RTI contract the results of including hospital outpatient charges to determine regression-adjusted CCRs for calculation of the median costs for imaging services. We believe that this information could be useful in the reassessment of whether it would be appropriate to apply a multiple procedure reduction to separately paid imaging services.

A detailed discussion of the development of median costs for blood and blood products is included in section X. of this final rule with comment period. A discussion of the calculation of medians for APCs that require one or more implantable devices when the service is performed is provided in section IV.A. of this final rule with comment period. The methodology for developing the median costs for composite APCs is included below in section II.A.4.d. of this final rule with comment period. A description of the methodology for calculating the median cost for partial hospitalization services is presented below in section II.B. of this final rule with comment period.

After consideration of the public comments received, we are finalizing our proposed CY 2008 methodology for calculating the median costs upon which the CY 2008 OPSS payment rates are based, with the modifications described earlier regarding the treatment of services which are assigned status indicator “Q.”

TABLE 2.—CY 2008 PACKAGED REVENUE CODES

Revenue code	Description
0250	PHARMACY.
0251	GENERIC.
0252	NONGENERIC.
0254	PHARMACY INCIDENT TO OTHER DIAGNOSTIC.
0255	PHARMACY INCIDENT TO RADIOLOGY.
0257	NONPRESCRIPTION DRUGS.
0258	IV SOLUTIONS.
0259	OTHER PHARMACY.
0260	IV THERAPY, GENERAL CLASS.
0262	IV THERAPY/PHARMACY SERVICES.
0263	SUPPLY/DELIVERY.

TABLE 2.—CY 2008 PACKAGED REVENUE CODES—Continued

Revenue code	Description
0264	IV THERAPY/SUPPLIES.
0269	OTHER IV THERAPY.
0270	M&S SUPPLIES.
0271	NONSTERILE SUPPLIES.
0272	STERILE SUPPLIES.
0273	TAKE HOME SUPPLIES.
0275	PACEMAKER DRUG.
0276	INTRAOCULAR LENS SOURCE DRUG.
0278	OTHER IMPLANTS.
0279	OTHER M&S SUPPLIES.
0280	ONCOLOGY.
0289	OTHER ONCOLOGY.
0343	DIAGNOSTIC RADIOPHARMS.
0344	THERAPEUTIC RADIOPHARMS.
0370	ANESTHESIA.
0371	ANESTHESIA INCIDENT TO RADIOLOGY.
0372	ANESTHESIA INCIDENT TO OTHER DIAGNOSTIC.
0379	OTHER ANESTHESIA.
0390	BLOOD STORAGE AND PROCESSING.
0399	OTHER BLOOD STORAGE AND PROCESSING.
0560	MEDICAL SOCIAL SERVICES.
0569	OTHER MEDICAL SOCIAL SERVICES.
0621	SUPPLIES INCIDENT TO RADIOLOGY.
0622	SUPPLIES INCIDENT TO OTHER DIAGNOSTIC.
0624	INVESTIGATIONAL DEVICE (IDE).
0630	DRUGS REQUIRING SPECIFIC IDENTIFICATION, GENERAL CLASS.
0631	SINGLE SOURCE.
0632	MULTIPLE.
0633	RESTRICTIVE PRESCRIPTION.
0681	TRAUMA RESPONSE, LEVEL I.
0682	TRAUMA RESPONSE, LEVEL II.
0683	TRAUMA RESPONSE, LEVEL III.
0684	TRAUMA RESPONSE, LEVEL IV.
0689	TRAUMA RESPONSE, OTHER.
0700	CAST ROOM.
0709	OTHER CAST ROOM.
0710	RECOVERY ROOM.
0719	OTHER RECOVERY ROOM.
0720	LABOR ROOM.
0721	LABOR.
0732	TELEMETRY.
0762	OBSERVATION ROOM.
0801	HEMODIALYSIS.
0802	PERITONEAL DIALYSIS.
0803	CAPD.
0804	CCPD.
0809	OTHER INPATIENT DIALYSIS.
0810	ORGAN ACQUISITION.
0819	OTHER ORGAN ACQUISITION.
0821	HEMODIALYSIS COMP OR OTHER RATE.
0824	MAINTENANCE 100%.
0825	SUPPORT SERVICES.
0829	OTHER HEMO OUTPATIENT.
0942	EDUCATION/TRAINING.

3. Calculation of OPSS Scaled Payment Weights

Using the median APC costs discussed previously, we calculated the final relative payment weights for each APC for CY 2008 shown in Addenda A and B to this final rule with comment period. In years prior to CY 2007, we standardized all the relative payment weights to APC 0601 (Mid Level Clinic Visit) because it was one of the most frequently performed services in the hospital outpatient setting. We assigned

APC 0601 a relative payment weight of 1.00 and divided the median cost for each APC by the median cost for APC 0601 to derive the relative payment weight for each APC.

Beginning with the CY 2007 OPSS, we standardized all of the relative payment weights to APC 0606 (Level 3 Clinic Visits) because we deleted APC 0601 as part of the reconfiguration of the visit APCs. We chose APC 0606 as the base because APC 0606 was the middle level clinic visit APC (that is, Level 3 of

five levels). We had historically used the median cost of the middle level clinic visit APC (that is APC 0601 through CY 2006) to calculate unscaled weights because mid-level clinic visits were among the most frequently performed services in the hospital outpatient setting. As proposed for CY 2008, to maintain consistency in using a median for calculating unscaled weights representing the median cost of some of the most frequently provided services, we continued to use the

median cost of the mid-level clinic APC, proposed APC 0606, to calculate unscaled weights. Following our standard methodology, but using the CY 2008 median for APC 0606, for CY 2008 we assigned APC 0606 a relative payment weight of 1.00 and divided the median cost of each APC by the median cost for APC 0606 to derive the unscaled relative payment weight for each APC. The choice of the APC on which to base the relative weights for all other APCs does not affect the payments made under the OPSS because we scale the weights for budget neutrality.

Section 1833(t)(9)(B) of the Act requires that APC reclassification and recalibration changes, wage index changes, and other adjustments be made in a manner that assures that aggregate payments under the OPSS for CY 2008 are neither greater than nor less than the aggregate payments that would have been made without the changes. To comply with this requirement concerning the APC changes, we compared aggregate payments using the CY 2007 relative weights to aggregate payments using the CY 2008 final relative weights. This year, we included payments to CMHCs in our comparison. Based on this comparison, we adjusted the relative weights for purposes of budget neutrality. The final unscaled relative payment weights were adjusted by a weight scaler of 1.3226 for budget neutrality. In addition to adjusting for increases and decreases in weight due to the recalibration of APC medians, the scaler also accounts for any change in the base, other than changes in volume which are not a factor in the weight scaler. The decline in the weight scaler compared to the proposed weight scaler of 1.3665 results largely from the refinement for this final rule with comment period of the proposed packaging policy to package imaging supervision and interpretation services only if they are reported on the same date of service as a HCPCS code that has a status indicator of "T." This change both increased the median costs for these imaging supervision and interpretation services and added a significant number of units for these services that would be separately paid under the final CY 2008 policy. The other factors that contributed to the decline of the scaler from the proposed rule to this final rule with comment period include the creation of the observation composite APCs and the increase in the final CY 2008 payment rate for partial hospitalization services compared to the proposed payment rate.

The final relative payment weights listed in Addenda A and B to this final rule with comment period incorporate

the recalibration adjustments discussed in sections II.A.1. and 2. of this final rule with comment period.

Section 1833(t)(14)(H) of the Act, as added by section 621(a)(1) of Pub. L. 108-173, states that "Additional expenditures resulting from this paragraph shall not be taken into account in establishing the conversion factor, weighting and other adjustment factors for 2004 and 2005 under paragraph (9) but shall be taken into account for subsequent years." Section 1833(t)(14) of the Act provides the payment rates for certain "specified covered outpatient drugs." Therefore, the cost of those specified covered outpatient drugs (as discussed in section V. of this final rule with comment period) is included in the budget neutrality calculations for the CY 2008 OPSS. We did not receive any public comments on the methodology for calculating scaled weights from the median costs for the CY 2008 OPSS. Therefore, we are finalizing our proposed methodology, without modification, including updating of the budget neutrality scaler for the final rule as proposed.

4. Changes to Packaged Services

a. Background

When the Medicare program was first implemented, it paid for hospital services (inpatient and outpatient) based on hospital-specific reasonable costs attributable to furnishing services to Medicare beneficiaries. Later, the law was amended to limit payment to the lesser of the hospital's reasonable cost or customary charges for services furnished to Medicare beneficiaries. Specific service-based methodologies were then developed for certain types of services, such as clinical laboratory tests and durable medical equipment, while payments for outpatient surgical procedures and other diagnostic tests were based on a blend of the hospital's aggregate Medicare costs for these services and Medicare's payment for similar services in other ambulatory settings. While this mix of different payment methodologies was in use, hospital outpatient services were growing rapidly following the implementation of the IPPS in 1983. The brisk increase in hospital outpatient services led to an interest in creating payment incentives to promote more efficient delivery of hospital outpatient services through a Medicare prospective payment system for hospital outpatient services, and the final statutory requirements for the OPSS were established by the BBA and the BBRA. During the period of time when

different approaches to prospective payment for hospital outpatient services were being considered, a variety of reports to Congress (June 1988, September 1990, and March 1995) discussed three major issues related to defining the unit of payment for the payment system, specifically the extent to which clinically similar procedures should be grouped for payment purposes and the logic that should be used for the groupings; the extent to which payment for minor, ancillary services associated with a significant procedure should be packaged into a single payment for the procedure (which we refer to as "packaging"); and the extent to which payment for multiple significant procedures or multiple units of the same procedure related to an outpatient encounter or to an episode of care should be bundled into a single unit of payment (which we refer to as "bundling"). Both packaging and bundling were presented as approaches to creating incentives for efficiency, with their potential policy disadvantages including inconsistency with other ambulatory fee schedules, reduced transparency of service-specific payment, and the potential for hospitals shifting the delivery of packaged or bundled services to delivery settings other than the hospital outpatient department (HOPD).

The OPSS, like other prospective payment systems, relies on the concept of averaging, where the payment may be more or less than the estimated costs of providing a service or package of services for a particular patient, but with the exception of outlier cases, it is adequate to ensure access to appropriate care. Decisions about packaging and bundling payment involve a balance between ensuring some separate payment for individual services and establishing incentives for efficiency through larger units of payment. In many situations, the final payment rate for a package of services may do a better job of balancing variability in the relative costs of component services compared to individual rates covering a smaller unit of service without packaging or bundling. Packaging payments into larger payment bundles promotes the stability of payment for services over time, a characteristic that reportedly is very important to hospitals. Unlike packaged services, the costs of individual services typically show greater variation because the higher variability for some component items and services cannot be balanced with lower variability for others and because relative weights are typically estimated using a smaller set of claims.

When compared to service-specific payment, packaging or bundling payment for component services may change payment at the hospital level to the extent that there are systematic differences across hospitals in their performance of the services included in that unit of payment. Hospitals spending more per case than payment received would be encouraged to review their service patterns to ensure that they furnish services as efficiently as possible. Similarly, we believe that unpackaging services heightens the hospital's focus on pricing individual services, rather than the efficient delivery of those services. Over the past several years of the OPSS, greater unpackaging of payment has occurred simultaneously with continued tremendous growth in OPSS expenditures as a result of increasing volumes of individual services, as discussed in further detail below. Also discussed in further detail below, most recently in its comments to the CY 2007 OPSS/ASC proposed rule and in the context of this rapid spending growth, MedPAC encouraged CMS to broaden the payment bundles under the OPSS to encourage providers to use resources efficiently.

As permitted under section 1833(t)(2)(B) of the Act, the OPSS establishes groups of covered HOPD services, namely APC groups, and uses them as the basic unit of payment. During the evolution of the OPSS over the past 7 years, significant attention has been concentrated on service-specific payment for services furnished to particular patients, rather than on creating incentives for the efficient delivery of services through encounter or episode-of-care-based payment. Overall packaging included in the clinical APCs has decreased, and the procedure groupings have become smaller as the focus has shifted to refining service-level payment. Specifically, in the CY 2003 OPSS, there were 569 APCs, but by CY 2007, the number of APCs had grown to 862, a 51

percent increase in 4 years. Similarly, the percentage of CPT codes for procedural services that receive packaged payment declined by over 10 percent between CY 2003 and CY 2007.

Currently, the APC groups reflect a modest degree of packaging, including packaged payment for minor ancillary services, inexpensive drugs, medical supplies, implantable devices, capital-related costs, operating and recovery room use, and anesthesia services. Bundling payment for multiple significant services provided in the same hospital outpatient encounter or during an episode of care is not currently a common OPSS payment practice, because the APC groups generally reflect only the modest packaging associated with individual procedures or services. Unconditionally packaged services with HCPCS codes are identified by the status indicator "N." Conditionally packaged services, specifically those services whose payment is packaged unless specific criteria for separate payment are met, are assigned status indicator "Q." To the extent possible, hospitals may use HCPCS codes to report any packaged services that were performed, consistent with CPT or CMS coding guidelines, but packaged costs also may be uncoded and included in specific revenue code charges. Hospitals include charges for packaged services on their claims, and the costs associated with those packaged services are then added into the costs of separately payable procedures on the same claims in establishing payment rates for the separately payable services.

Packaging and bundling payment for multiple interrelated services into a single payment create incentives for providers to furnish services in the most efficient way by enabling hospitals to manage their resources with maximum flexibility, thereby encouraging long-term cost containment. For example, where there are a variety of supplies that could be used to furnish a service, some of which are more expensive than others, packaging encourages hospitals

to use the least expensive item that meets the patient's needs, rather than to routinely use a more expensive item. Packaging also encourages hospitals to negotiate carefully with manufacturers and suppliers to reduce the costs of purchased items and services or to explore alternative group purchasing arrangements, thereby encouraging the most economical health care. Similarly, packaging encourages hospitals to establish protocols that ensure that services are furnished only when they are important and to carefully scrutinize the services ordered by practitioners to maximize the efficient use of hospital resources. Finally, packaging payments into larger payment bundles promotes the stability of payment for services over time. Packaging and bundling also may reduce the importance of refining service-specific payment because there is more opportunity for hospitals to average payment across higher cost cases requiring many ancillary services and lower cost cases requiring fewer ancillary services.

b. Addressing Growth in OPSS Volume and Spending

Creating additional incentives for providing only necessary services in the most efficient manner is of vital importance to Medicare today, in view of the recent explosion of growth in program expenditures for hospital outpatient services paid under the OPSS. As illustrated in Table 3 below, total spending has been growing at a rate of roughly 10 percent per year under the OPSS, and the Medicare Trustees project that total spending under the OPSS will increase by more than \$3 billion from CY 2007 through CY 2008 to nearly \$35 billion. Implementation of the OPSS has not slowed outpatient spending growth over the past few years; in fact, double-digit spending growth has generally been occurring. We are greatly concerned with this rate of increase in program expenditures under the OPSS.

TABLE 3.—GROWTH IN EXPENDITURES UNDER OPSS FROM CY 2001—CY 2008
[Projected expenditures for CY 2006—CY 2008 in billions]

OPSS growth	CY 2001	CY 2002	CY 2003	CY 2004	CY 2005	CY 2006	CY 2007	CY 2008
Incurred Cost	17.702	19.561	21.156	23.866	26.572	29.741	32.714	36.072
Percent Increase		10.5	8.2	12.8	11.3	11.9	10.1	10.26

Based on the Midsession Review of the President's FY 2008 Budget.

As with the other Medicare fee-for-service payment systems that are experiencing rapid spending growth, brisk growth in the intensity and

utilization of services is the major reason for the current rates of growth in the OPSS, rather than general price or enrollment changes. Table 4 below

illustrates the increases in the volume and intensity of hospital outpatient services over the past several years.

TABLE 4.—PERCENTAGE INCREASE IN VOLUME AND INTENSITY OF HOSPITAL OUTPATIENT SERVICES

	CY 2002	CY 2003	CY 2004	CY 2005	CY 2006 (Est.)	CY 2007 (Est.)	CY 2008 (Est.)
Percent Increase	3.5	2.5	7.6	7.4	10.1	9.4	5.8

Based on the Midsession Review of the President's FY 2008 Budget.

For hospital outpatient services, the volume and intensity of services are estimated to have continued to increase significantly in recent years, at a rate of 10.1 percent between CY 2005 and CY 2006, the last two completed calendar years. As we discussed in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68189 through 68190), the rapid growth in utilization of services under the OPPS shows that Medicare is paying mainly for more services each year, regardless of their quality or impact on beneficiary health. In its March 2007 Report to Congress (pages 55 and 56), MedPAC confirmed that much of the growth in service volume from 2003 to 2005 resulted from increases in the number of services per beneficiary who received care, rather than from increases in the number of beneficiaries served. MedPAC found that while the rate of growth in service volume declined over that time period, the complexity of services, defined as the sum of the relative payment weights of all OPPS services divided by the volume of all services, increased, and that most of the growth was attributable to the insertion of devices and the provision of complex imaging services. MedPAC further found that regression analysis suggested that relatively complex hospital outpatient services may be more profitable for hospitals than less complex services. In addition, its analysis indicated that favorable payments for complex services give hospitals an incentive to provide more of those complex services rather than fewer basic services, which increases overall service complexity. MedPAC expressed concern about this relationship and concluded that the historically large increases in outpatient volume and service complexity suggest a need to recalibrate the OPPS. In the future, MedPAC plans to examine options for recalibrating the payment system to accurately match payments to the costs of individual services (Medicare Payment Advisory Commission Report to the Congress: Medicare Payment Policy, March 2007, pages 55 and 56).

As proposed for the CY 2007 OPPS and finalized for the CY 2009 OPPS, we developed a plan to promote higher quality services under the OPPS, so that Medicare spending would be directed

toward those higher quality services (71 FR 68189 through 68197). We believe that Medicare payments should encourage physicians and other providers in their efforts to achieve better health outcomes for Medicare beneficiaries at a lower cost. In the CY 2007 OPPS/ASC final rule with comment period, we discussed the concept of “value-based purchasing” in the OPPS as well as in other Medicare payment systems. “Value-based purchasing” may use a range of budget-neutral incentives to achieve identified quality and efficiency goals, as a means of promoting better quality of care and more effective resource use in the Medicare payment systems. In developing the concept of value-based purchasing for Medicare, we have been working closely with stakeholder partners.

We continue to believe that the collection and submission of performance data and the public reporting of comparative information are strong incentives for hospital accountability in general and quality improvement in particular, while encouraging the most efficient and effective care. Measurement and reporting can focus the attention of hospitals and consumers on specific goals and on hospitals’ performance relative to those goals. Development and implementation of performance measurement and reporting by hospitals can thus produce quality improvement in health care delivery. Hospital performance measures may also provide a foundation for performance-based rather than volume-based payments.

In the CY 2007 OPPS/ASC final rule with comment period, as a first step in the OPPS toward value-based purchasing, we finalized a policy that would employ our equitable adjustment authority under section 1833(t)(2)(E) of the Act to establish an OPPS Reporting Hospital Quality Data for Annual Payment Update (RHQDAPU) program based on measures specifically developed to characterize the quality of outpatient care (71 FR 68197). We finalized implementation of the program for CY 2009, when we would implement a 2.0 point reduction to the OPPS conversion factor update for those hospitals that do not meet the specific requirements of the CY 2009 program.

We described the CY 2009 program, which would be based upon CY 2008 hospital reporting of appropriate measures of the quality of hospital outpatient care that have been carefully developed and evaluated, and endorsed as appropriate, with significant input from stakeholders. We reiterated our belief that ensuring that Medicare beneficiaries receive the care they need and that such services are of high quality are the necessary initial steps to incorporating value-based purchasing into the OPPS. We explained that we are specifically seeking to encourage care that is both efficient and of high quality in the HOPD.

Subsequent to the publication of the CY 2007 OPPS/ASC final rule with comment period, section 109(a) of the MIEA–TRHCA, which added section 1833(t)(19) to the Act, specifies that in the case of a subsection (d) hospital (defined under section 1886(d)(1)(B) of the Act as hospitals that are located in the 50 States or the District of Columbia other than those categories of hospitals or hospital units that are specifically excluded from the IPPS, including psychiatric, rehabilitation, long-term care, children’s, and cancer hospitals or hospital units) that does not submit to the Secretary the quality reporting data required for CY 2009 and each subsequent year, the OPPS annual update factor shall be reduced by 2.0 percentage points. The quality reporting program proposed for CY 2008 according to this provision is referred to as the Hospital Outpatient Quality Data Reporting Program (HOP QDRP) and is discussed in detail in section XVII. of this final rule with comment period.

As the next step in our movement toward value-based purchasing under the OPPS and to complement the HOP QDRP for CY 2009, with measure reporting beginning in CY 2008, we believe it is important to initiate specific payment approaches to explicitly encourage efficiency in the hospital outpatient setting that we believe will control future growth in the volume of OPPS services. While the HOP QDRP will encourage the provision of higher quality hospital outpatient services that lead to improved health outcomes for Medicare beneficiaries, we believe that more targeted approaches are also necessary to encourage increased

hospital efficiency. Two alternatives we have considered that would be feasible under current law include establishing a methodology to measure the growth in volume and reduce OPPS payment rates to account for unnecessary increases in volume or developing payment incentives for hospitals to ensure that they provide necessary services as efficiently as possible.

With respect to the first alternative, section 1833(t)(2)(F) of the Act requires us to establish a methodology for controlling unnecessary increases in the volume of covered OPPS services, and section 1833(t)(9)(C) of the Act authorizes us to adjust the update to the conversion factor if, under section 1833(t)(2)(F) of the Act, we determine that there is growth in volume that exceeds established tolerances. As we indicated in the September 8, 1998 proposed rule proposing the establishment of the OPPS (63 FR 47585), we considered creating a system that mirrors the sustainable growth rate (SGR) methodology applied to the MPFS update to control unnecessary growth in service volume. However, implementing such a system could have the potentially undesirable effect of escalating service volume as payment rates stagnate and hospital costs rise, thus actually resulting in a growth in volume rather than providing an incentive to control volume. Therefore, this approach to addressing the volume growth under the OPPS could inadvertently result in the exact opposite of our desired outcome.

The second alternative we considered is to expand the packaging of supportive ancillary services and ultimately bundle payment for multiple independent services into a single OPPS payment. We believe that this would create incentives for hospitals to monitor and adjust the volume and efficiency of services themselves, by enabling them to manage their resources with maximum flexibility. Instead of external controls on volume, we believe that it is preferable for the OPPS to create payment incentives for hospitals to carefully scrutinize their service patterns to ensure that they furnish only those services that are necessary for high quality care and to ensure that they provide care as efficiently as possible. Specifically, we believe that increased packaging and bundling are the most appropriate payment strategies to establish such incentives in a prospective payment system, and that this approach is clearly preferable to the establishment of an SGR or other methodology that seeks to control spending by addressing significant

growth in volume and program spending with lower payments.

In its October 6, 2006 letter of comment on the CY 2007 OPPS/ASC proposed rule, MedPAC urged us to establish broader payment bundles in both the revised ASC payment system and the OPPS to promote efficient resource use and better align the two payment systems. In particular, our proposal for the CY 2008 revised ASC payment system proposed to package payment for all items and services directly related to the provision of covered surgical procedures into the ASC facility payment for the associated surgical procedure (71 FR 49468). These other items and services included all drugs, biologicals, contrast agents, implantable devices, and diagnostic services such as imaging. Because a number of these items and services are separately paid under the OPPS and the proposal included the establishment of most ASC payment weights based on the procedures' corresponding OPPS payment weights, MedPAC encouraged us to align the payment bundles in the two payment systems by increasing the size of the payment bundles under the OPPS.

Moreover, MedPAC staff indicated in testimony at the January 9, 2007 MedPAC public meeting that the growth in OPPS spending and volume raises questions about whether the OPPS should be changed to encourage greater efficiency (page 390 of the January 9, 2007 MedPAC meeting transcript available at the Web site at: <http://www.medpac.gov>). MedPAC staff explained at that time that MedPAC intends to perform a long term assessment of the design of the OPPS, including considering the bundling of payments for procedures and visits furnished over a period of time into a single payment, assessing whether there should be an expenditure target for hospital outpatient services, evaluating whether payments for multiple imaging services provided in the same session should be discounted, and reviewing the methodology used by CMS to determine relative payment weights for hospital outpatient services. We welcome MedPAC's study of these areas, particularly with regard to how we might develop appropriate payment rates for larger bundles of services.

Because we believe it is important that the OPPS create enhanced incentives for hospitals to provide only necessary, high quality care and to provide that care as efficiently as possible, we have given considerable thought to how we could increase packaging under the OPPS in a manner that would not place hospitals at

substantial financial risk but which would create incentives for efficiency and volume control, while providing hospitals with flexibility to provide care in the most appropriate way for each Medicare beneficiary. We are considering the possibility of greater bundling of payment for major hospital outpatient services, which could result in establishing OPPS payments for episodes of care, and for this reason we particularly welcome MedPAC's exploration of how such an approach might be incorporated into the OPPS payment methodology. We are particularly concerned about the potential for shifting higher cost bundled services to other ambulatory settings. We are currently considering the complex policy issues related to the possible development and implementation of a bundled payment policy for hospital outpatient services that involves significant services provided over a period of time which could be paid through an episode-based payment methodology, but we consider this possible approach to be a long-term policy objective.

We also are examining how we might possibly establish payments for same-day care encounters, building upon the current use of APCs for payment through greater packaging of supportive ancillary services. This could include conditional packaging of supportive ancillary services into payment for the procedure that is the reason for the OPPS encounter (for example, diagnostic tests performed on the day of a scheduled procedure). Another approach could include creation of composite APCs for frequently performed combinations of surgical procedures (for example, one APC payment for multiple cardiac electrophysiologic procedures performed on the same date). Not only could these encounter-based payment groups create enhanced incentives for efficiency, but they may also enable us to utilize for ratesetting many of the multiple procedure claims that are not now used in our establishment of OPPS rates for single procedures. (We refer readers to section II.A.1.b. of this final rule with comment period for a more detailed discussion of the treatment of multiple procedure claims in the ratesetting process.) In the CY 2008 OPPS/ASC proposed rule, we proposed two new composite APCs for CY 2008 payment of combinations of services in two clinical care areas, as discussed in section II.A.4.d. of this final rule with comment period. In that section, we summarize and respond to the public comments we received on this proposal

as we explore the possibility of moving toward basing OPPS payment on larger packages and bundles of services provided in a single hospital outpatient encounter.

We intend to involve the APC Panel in our future exploration of how we can develop encounter-based and episode-based payment groups, and we look forward to the findings and recommendations of MedPAC in this area. This is a significant change in direction for the OPPS, and we specifically seek the recommendations of all stakeholders with regard to which ancillary services could be packaged and those combinations of services provided in a single encounter or over time that could be bundled together for payment. We are hopeful that expanded packaging and, ultimately, greater bundling under the OPPS may result in sufficient moderation of growth in volume and spending that further controls would not be needed. However, if spending were to continue to escalate at the current rates, even after we have exhausted our options for increased packaging and bundling, we are considering multiple options under our authority to address these issues.

c. Packaging Approach

With the exception of the two composite APCs that we proposed for CY 2008 and discuss in detail in section II.A.4.d. of this final rule with comment period, we indicated in the CY 2008 OPPS/ASC proposed rule that we were not prepared to propose an episode-based or fully developed encounter-based payment methodology for CY 2008 as our next step in value-based purchasing for the OPPS. However, in reviewing our approach to revising payment packages and bundles for the proposed rule, we examined services currently provided under the OPPS, looking for categories of ancillary items and services for which we believed payment could be appropriately packaged into larger payment packages for the encounter. For this first step in creating larger payment groups, we examined the HCPCS code definitions (including CPT code descriptors) to see whether there were categories of codes for which packaging would be a logical expansion of the longstanding packaging policy that has been a part of the OPPS since its inception. In general, we have often packaged the costs of selected HCPCS codes into payment for services reported with other HCPCS codes where we believed that one code reported an item or service that was integral to the provision of care that was reported by another HCPCS code.

As an example of a previous change in the OPPS packaging status for a HCPCS code that is ancillary and supportive, under the CY 2007 OPPS, we note that CPT code 93641 (Electrophysiologic evaluation of single or dual chamber pacing cardioverter defibrillator leads including defibrillation threshold evaluation (induction of arrhythmia, evaluate of sensing an pacing for arrhythmia termination) at the time of initial implantation or replacement; with testing of single chamber or dual chamber cardioverter defibrillator) went from separate to packaged payment. This service is only performed during the course of a surgical procedure for implantation or replacement of implantable cardioverter-defibrillator (ICD) leads, and these surgical implantation procedures are currently assigned to APC 0106 (Insertion/Replacement/Repair of Pacemaker and/or Electrodes) and APC 0108 (Insertion/Replacement/Repair of Cardioverter-Defibrillator Leads). We considered the electrophysiologic evaluation service (CPT code 93641) to be an ancillary supportive service that may be performed only in the same operative session as a procedure that could otherwise be performed independently of the electrophysiologic evaluation service. In this particular case, the APC Panel recommended for CY 2007 that we package payment for this diagnostic test, and we adopted that recommendation for the CY 2007 OPPS. Making this payment change in this specific case resulted in the availability of significantly more claims data and, therefore, establishment of more valid and representative estimated median costs for the lead insertion and electrophysiologic evaluation services furnished in the single hospital encounter.

In the case of much of the care furnished in the HOPD, we believe that it is appropriate to view a complete service as potentially being reported by a combination of two or more HCPCS codes, rather than a single code, and to establish payment policy that supports this view. Ideally, we would consider a complete HOPD service to be the totality of care furnished in a hospital outpatient encounter or in an episode of care. In general, we believe that it is particularly appropriate to package payment for those items and services that are typically ancillary and supportive into the payment for the primary diagnostic or therapeutic modalities in which they are used. As a significant first step towards creating payment units that represent larger

units of service, in development of the proposed rule, we examined whether there were categories of HCPCS codes that are typically ancillary and supportive to diagnostic and therapeutic modalities.

Specifically, as our initial substantial step toward creating larger payment groups for hospital outpatient care, in the CY 2008 OPPS/ASC proposed rule (72 FR 42652), we proposed to package payment for items and services in the seven categories listed below into the payment for the primary diagnostic or therapeutic modality to which we believe these items and services are typically ancillary and supportive. We specifically chose these categories of HCPCS codes for packaging because we believe that the items and services described by the codes in these categories are the HCPCS codes that are typically ancillary and supportive to a primary diagnostic or therapeutic modality and, in those cases, are an integral part of the primary service they support. We proposed to assign status indicator "N" to those HCPCS codes that we believe are always integral to the performance of the primary modality and to package their costs into the costs of the separately paid primary services with which they are billed. We proposed to assign status indicator "Q" to those HCPCS codes that we believe are typically integral to the performance of the primary modality and to package payment for their costs into the costs of the separately paid primary services with which they are usually billed but to pay them separately in those uncommon cases in which no other separately paid primary service is furnished in the hospital outpatient encounter.

For ease of reference in our subsequent discussion in each of the seven areas, we refer to the HCPCS codes for which we proposed to package (or conditionally package) payment as dependent services. We use the term "independent service" to refer to the HCPCS codes that represent the primary therapeutic or diagnostic modality into which we are proposing to package payment for the dependent service. We note that, in future years as we consider the development of larger payment groups that more broadly reflect services provided in an encounter or episode of care, it is possible that we might propose to bundle payment for a service that we now refer to as "independent" in this final rule with comment period.

Specifically, we proposed to package the payment for HCPCS codes describing the dependent items and services in the following seven categories into the payment for the

independent services with which they are furnished:

- Guidance services
- Image processing services
- Intraoperative services
- Imaging supervision and interpretation services
- Diagnostic radiopharmaceuticals
- Contrast media
- Observation services

In the proposed rule, we identified the HCPCS codes we proposed to package for CY 2008, explained our rationale for proposing to package the codes in these categories, provided examples of how HCPCS and APC median costs and payments would change under these proposals, and discussed the impact of these changes under each category, as follows:

The median costs of services at the HCPCS level for many separately paid procedures changed as a result of our proposal because we proposed to change the composition of the payment packages associated with the HCPCS codes. Moreover, as a result of changes to the HCPCS median costs, we proposed to reassign some HCPCS codes to different clinical APCs for CY 2008 to avoid 2 times violations and to ensure continuing clinical and resource homogeneity of the APCs. Therefore, the proposed APC median costs changed not only as a result of the increased packaging itself but also as a result of the migration of HCPCS codes into and out of APCs through APC reconfiguration. The file of HCPCS code and APC median costs resulting from our proposal is found under supporting documentation for the proposed rule on the CMS Web site at <http://www.cms.hhs.gov/HospitalOutpatientPPS/HORD/list.asp#TopOfPage>.

Review of the HCPCS median costs for the proposed rule indicated that, while the proposed median costs rise for some HCPCS codes as a result of increased packaging that expands the costs included in the payment packages, there are also cases in which the proposed median costs decline as a result of these proposed changes. While it seems intuitive to believe that the proposed median costs of the remaining separately paid services should rise when the costs of services previously paid separately are packaged into larger payment groups, it is more challenging to understand why the proposed median costs of separately paid services would not change or would decline when the costs of previously paid services are packaged.

Medians are generally more stable than means because they are less sensitive to extreme observations, but

medians typically do not reflect subtle changes in cost distributions. The OPPS' use of medians rather than means usually results in relative weight estimates being less sensitive to packaging decisions. Specifically, the median cost for a particular independent procedure generally will be higher as a result of added packaging, but also could change little or be lower because median costs typically do not reflect small distributional changes and also because changes to the packaged HCPCS codes affect both the number and composition of single bills and the mix of hospitals contributing those single bills. Such a decline, no change, or an increase in the median cost at the HCPCS code level could result from a change in the number of single bills used to set the median cost. With greater packaging, more "natural" single bills are created for some codes but fewer "pseudo" single bills are created. Thus, some APCs gain single bills and some lose single bills due to packaging changes, as well as to the reassignment of some codes to different APCs. When more claims from a different mix of providers are used to set the median cost for the HCPCS code, the median cost could move higher or lower within the array of per claim costs.

Similarly, revisions to APC assignments that are necessary to resolve 2 times violations that could arise as a result of changes in the HCPCS median cost for one or more codes due to additional packaging may also result in increases or decreases to APC median costs and, therefore, to increases or decreases in the payments for HCPCS codes that would not be otherwise affected except for the CY 2008 proposed packaging approach for the seven categories of items and services.

We examined the aggregate impact of making these proposed changes on payment for CY 2008 in the proposed rule. Because the OPPS is a budget neutral payment system in which the amount of payment weight in the system is annually adjusted for changes in expenditures created by changes in APC weights and codes (but is not currently adjusted based on estimated growth in service volume), the effects of the packaging changes we proposed resulted in changes to scaled weights and, therefore, to the proposed payment rates for all separately paid procedures. These changes resulted from both shifts in median costs as a result of increased packaging, changes in multiple procedure discounting patterns, and a higher weight scaler that was applied to all unscaled APC weights. (We refer readers to section II.A.3. of this final

rule with comment period for an explanation of the weight scaler.) In a budget neutral system, the monies previously paid for services that were proposed to be packaged are not lost, but are redistributed to all other services. A higher weight scaler would increase payment rates relative to observed median costs for independent services by redistributing the lost weight of packaged items that historically have been paid separately and the lost weight when the median costs of independent services did not completely reflect the full incremental cost of the packaged services. The impact of the cumulative changes for the CY 2008 OPPS payments is discussed in section XXIV.B. of this final rule with comment period.

We estimated that our CY 2008 packaging proposal would redistribute approximately 1.2 percent of the estimated CY 2007 base year expenditures under the OPPS. The monies associated with this redistribution were in addition to any increases that would otherwise occur due to a higher median cost for the APC as a result of the expanded payment package. If the relative weight for a particular APC decreased as a result of the proposed packaging approach, the increased weight scaler may or may not result in a relative weight that is equal to or greater than the relative weight that would occur without the proposed packaging approach. In general, the packaging that we proposed would have more effect on payment for some services than on payment for others because the dependent items and services that we proposed for packaging are furnished more often with some independent services than with others. However, because of the amount of payment weight that would be redistributed by our proposal, there would be some impact on payments for all OPPS services whose rates are set based on payment weights, and the impact on any given hospital would vary based on the mix of services furnished by the hospital.

We received many, often widely diverging, public comments on the CY 2008 proposed packaging approach. In many cases the comments were generally applicable to the totality of the packaging proposal and, in other cases, the same general comments were made but only with regard to a specific category or set of services of interest to the commenter. We have addressed all similar public comments in the discussion of general comments, whether they were made in general or for specific categories of services, because the same response applies

whether the comment was on packaging in general or on a specific service. We have limited the summary of public comments and our responses in the individual category discussions to issues that pertain only to the category or specific services within the category.

During the September 2007 APC Panel meeting, the APC Panel supported packaging for contrast agents, image processing services, guidance (except for radiation oncology guidance procedures), diagnostic radiopharmaceuticals with a median per day cost of less than \$200, and intraoperative testing other than possibly for CPT code 96020 (Neurofunctional testing selection and administration during noninvasive imaging functional brain mapping, with test administered entirely by a physician or psychologist, with review of test results and report). The Panel recommended a delay in packaging for imaging supervision and interpretation services because of excessive payment reductions that the Panel believed would occur under the CMS proposal, particularly with regard to packaging payment for those supervision and interpretation services that already include packaged injection services. The Panel did not support packaging of observation services, although it suggested that if CMS were to package observation, it should instead create a composite APC (or a group of composite APCs) for observation and the related visit services, without restriction to specific clinical conditions. The APC Panel also recommended that CMS provide additional information in the CY 2008 final rule with comment period about packaging, including crosswalks and information clarifying how newly packaged services map back to primary procedures.

Comment: MedPAC generally supported the proposed packaging because the services proposed for packaging are typically furnished on the same day as a separately paid service and there is little potential for them to be furnished on another date to avoid the effects of packaging. MedPAC explained that packaging of observation services is logical because currently 70 percent of observation care is packaged. MedPAC's principal concern about the proposed packaging of observation was that this approach could result in hospitals' costs being higher than OPSS payments in some cases, and thereby create an incentive for inpatient admissions. It encouraged CMS to carefully monitor whether hospitals change their behavior with regard to inpatient admissions.

Some commenters supported encounter-based or episode-based payment, but asked that this approach be based on single encounter only and not span a period of time, because they believed that it would be very difficult to set rates for periods of recurring services. The commenters supported use of multiple procedure claims and payment for combinations of services but encouraged CMS to carefully evaluate the overall impact of packaging on all hospitals. Other commenters suggested that CMS package only services that are low cost and furnished at a high frequency with the independent service. Several commenters stated that CMS should not finalize the proposed packaging approach because it would lead to inappropriate payment, including both overpayments and underpayments.

Several commenters asked that CMS delay the packaging approach for at least a year because they believed the proposed rule did not furnish sufficient data analysis in support of the proposal. They asserted that the aggregate impact analysis provided no information that commenters could use to evaluate the individual codes proposed to be packaged, making it impossible for the public to determine how payment for services would be affected. Some commenters requested that CMS furnish the same level of impact discussion for each of the services in each of the categories as it did for the composite APCs. Other commenters asked CMS to identify the percent of charges for dependent services that were packaged into each independent procedure, identify all independent procedures into which cost was packaged from each packaged procedure, and identify the cost of each procedure code with and without the proposed packaging. They recommended that, before implementing the proposed packaging, CMS publish all HCPCS and revenue codes and the costs for each that enter into the consideration of packaging for every code proposed to be packaged. The commenters believed that the lack of transparency, together with late availability of a correct OPSS proposed rule claims data set, made it difficult to determine whether packaged costs were retained or lost in the median setting process.

Other commenters suggested that CMS explicitly crosswalk packaged services to identified independent services, rather than packaging payment into the independent service with which the packaged services is billed on each claim. They asserted that no service should be packaged unless it is furnished the majority of the time with

the specified independent service. The commenters stated that items and services should be packaged only where there are substitutable services that could be chosen by the hospital, and that no packaging should occur where there is only one dependent service that would be provided with the independent service.

Some commenters contended that CMS should not implement the proposed packaging changes until after it implements an adjustment for charge compression because errors in the proposed rates as a result of charge compression would result in too little payment being packaged into the independent service and would create disincentives for hospital to furnish the packaged services, thus harming beneficiary access to advanced technologies.

Some commenters requested that CMS develop and propose a set of criteria for packaging services that would be open to public comment and that would control whether and, if so, when CMS could package payment for a service. The commenters stated that the criteria in the proposed rule were too vague, undefined, and subjective to identify which codes should be packaged. The commenters provided criteria that they believe should govern whether a service should be packaged. The suggested criteria included, but were not limited to, requiring that packaging should only be adopted for high volume, low cost, minor and ancillary services that are very frequently performed with the specified independent service; no packaging of services that require specialized equipment or devices; no packaging of services that are only furnished in a small number of hospitals; no packaging of add-on services unless the service is furnished with its base code at least 50 percent or 75 percent of the time; packaging only when a service is being packaged into a specified service and, therefore, no general packaging of services into the service with which it is performed; no packaging unless CMS has provided the public with a full data assessment of the effects of packaging each service; and no packaging if the median cost for the code exceeds an established amount.

Other commenters suggested CMS not implement the proposed packaging because the 60-day comment period provided insufficient time for analysis and because the APC Panel recommendations and report were not posted on the Web site immediately after the meeting.

Response: We have reviewed all of the public comments we received on the

proposed packaging approach, and we have decided to finalize our proposal with significant modifications and refinements to address some of the concerns raised by commenters on our proposal to package payment for diagnostic radiopharmaceuticals, imaging supervision and interpretation services, contrast agents, and observation services. We refer readers to sections II.A.4.c.(4), (5), (6), and (7) of this final rule with comment period for detailed discussion of these modifications and section II.A.2 of this final rule with comment period for discussion of the changes we made to the data process in this regard. We are finalizing our proposal for guidance, image processing, and intraoperative services without substantial modification. Table 10, which appears in section II.A.4., contains a comprehensive list of all codes in the final seven categories for which we will package payment either unconditionally (to which we assign status indicator "N") or conditionally, providing separate payment if certain criteria are met (to which we assign status indicator "Q"). There is a category of conditionally packaged codes assigned status indicator "Q," which we previously referred to as "special" packaged codes because their payment was packaged when provided on the same date as a service that was assigned status indicator "S," "T," "V," or "X." These "special" packaged codes will now be referred to as "STVX-packaged codes." We have identified a new category of conditionally packaged codes that are called "T-packaged codes," whose payment is packaged when provided on the same date as another service that is assigned status indicator "T." The rationale for these changes are discussed in detail below in section II.A.4.c.(4) of this final rule with comment period.

We believe that it is appropriate and fully consistent with the principles of a prospective payment system to package payment for ancillary and supportive services into the payment for the independent service with which they are furnished as a means of making payment for a more comprehensive service package. Although separate payment will no longer be made for the packaged services, the payments for the independent services with which they are furnished will reflect the costs of the packaged services to the extent that the packaged services are provided with the independent service. We recognize that, in some cases, certain supportive and ancillary dependent services are furnished with only one independent

service, and in other cases they are furnished with many independent services. Similarly, in some cases they are furnished frequently with independent services, and in some cases they are uncommonly furnished with independent services.

We believe that packaging should reflect the reality of how the services are furnished and reported on claims by hospitals. We believe that nonspecific packaging (as opposed to selected code packaging) based on combinations of services observed on hospital claims is fully appropriate because of the myriad combinations of services that can be appropriately provided together. This approach to packaging payment has long existed in prospective payment systems, including the OPSS. For example, in the IPPS, Medicare's oldest prospective payment system, payment for all services furnished is packaged into a single payment for an entire hospital inpatient stay that is based on the diagnosis-related group (DRG) into which the stay is categorized. The DRG payment packages together all payment for routine care, drugs, biologicals, medical supplies, diagnostic tests, and all other covered services that were provided to the patient, regardless of the extent to which different patients in the same DRG received somewhat different services during their stay. We believe that a similar approach to nonspecific packaging under the OPSS is likewise fully appropriate. We have used this packaging approach for ratesetting throughout the history of the OPSS, and note that payment for APC groups currently reflects significant nonspecific packaging in many cases. Similarly, we believe that it is appropriate to establish under the OPSS a single payment for multiple independent procedures that are frequently furnished together. For that reason, we are adopting five composite APCs for CY 2008 and intend to explore developing others.

We do not agree with the commenters that we should not package a service unless it is a low cost ancillary and supportive service that appears frequently with an independent service. To establish that policy would negate the concept of averaging that is an underlying premise of a prospective payment system by packaging only services that will increase the payment for the independent service. To do that would also create incentives for hospitals to provide ancillary and dependent services that are higher cost or historically were infrequently furnished with an independent service and would remain separately paid. Similarly, we do not agree that we should not finalize the proposed

packaging approach because it will "overpay" some services and "underpay" others. Payment based on a measure of central tendency is also a principle of any prospective payment system. In some cases, payment in an individual case exceeds the average cost and in other cases payment is less than the average cost, but on balance, payment should approximate the relative cost of the average case, recognizing that the OPSS, as created in the statute, was not intended to pay the full cost of HOPD services.

We also do not agree that it would be beneficial to delay the implementation of the proposed packaging approach for a year because that would delay the implementation of incentives under the OPSS for hospitals to look carefully at ways that they could provide care more efficiently. We recognize that, as with any payment policy, there will be affected parties that will ask for changes to the policy, and we are always willing to hear their concerns and to make changes if the changes are appropriate. Moreover, both APC and status indicator assignments are open to public comment each year in the proposed rule, and hence affected parties may provide their arguments for separate payment as part of that process in the future.

We further disagree that we should delay or not finalize the proposed packaging approach pending provision of the extensive data that the commenters requested. We make available a considerable amount of data for public analysis each year and while we are not developing and providing the extensively detailed information that the commenters request, we provide the public use files of claims and a detailed narrative description of our data process that the public can use to perform any desired analyses. While we acknowledge that we needed to issue a second corrected file of claims data, the second file differed from the first only in that it deleted a relatively small number of duplicate claims for observation that would have been used to calculate an APC rate for separately payable observation, had we proposed to pay separately for observation, and hence we believe that the accidental inclusion of these duplicate claims for observation care should have had little or no effect on the majority of studies of the HCPCS codes we proposed to package.

With regard to the request for extensive data on all HCPCS codes we proposed to package, it would not be possible for us to anticipate the specific combinations of services of interest to the public. In addition, we believe that

the commenters must examine the data themselves to develop the specific arguments to support their requests for changes to payments under the OPSS. We note that we pay hospitals under the OPSS, and we showed the impact of the CY 2008 packaging proposal on payment to different classes of hospitals in Table 67 of the proposed rule (72 FR 42822 through 42824). We believe our estimate of the impact of these changes provided valuable information to the hospitals that would receive packaged payment for services that had been previously paid separately under the OPSS.

With regard to the public comments that we should explicitly crosswalk packaged codes to the independent codes into which the costs would be packaged, we do not believe that this is feasible, given the myriad combinations of services that are furnished in the HOPD, nor is it consistent with the principles of a prospective payment system, which bases payment on real occurrences of services that are furnished by hospitals and reported on claims. Moreover, creation of such a crosswalk would undoubtedly result in omissions of appropriate packaging of services and would create a maintenance task that would not be sustainable, given the number of changes to HCPCS codes each year and the ever changing way in which services are furnished. Similarly, it is not consistent with the concept of packaging within a prospective payment system to package only those services for which there are substitutes that could be furnished. In contrast, it is fully consistent with the principles of a prospective payment system for groups of services to package items and services that are always furnished with an independent service and for which there are no substitutes.

We also do not agree that we should delay creation of larger payment bundles through packaging until after there is adjustment for charge compression under the OPSS. As we discuss in section II.A.1.c. of this final rule with comment period, we will consider whether to use regression-adjusted CCRs to adjust for charge compression under the OPSS after RTI reviews the OPSS cost estimation process, including an assessment of the revenue code-to-cost center crosswalk and estimating regression-adjusted CCRs from a model that includes outpatient charges. There is no reason to delay the creation of incentives for encouraging cost-effective utilization and efficiency in the provision of HOPD services until a decision is made regarding the

appropriateness of using regression-adjusted CCRs to estimate OPSS costs.

We do not agree that we should develop and establish criteria with stakeholder input before we finalize the packaging proposal. Nor do we believe that the specific criteria the commenters recommended are appropriate for determining when services should be packaged. The criteria that the commenters provided are focused almost exclusively on preventing packaging, rather than on determining when packaging would be appropriate. We believe that packaging is appropriate when the nature of a service is such that it is supportive and ancillary to another service, whether the dependent service is frequently furnished with the independent service or not and regardless of the cost of the supportive ancillary service. This is largely a clinical decision based on the nature of the service being considered for packaging.

Lastly, we do not agree that we should not implement the proposed changes because the commenters believed that the 60 day comment period was insufficient or because the APC Panel recommendations and report were not posted to the Web site immediately after the public meeting. The 60 day comment period is generally the standard comment period for the proposed rule process. The availability of updated claims and cost report data necessary to develop the proposed rule and issue the final rule for the OPSS precludes a longer period for comment. Moreover, we do not believe that the Web site posting of the APC Panel recommendations and report is necessary for the public to provide meaningful comments, in light of the fact that the APC Panel meeting is open to the public.

We are not accepting the recommendation of the APC Panel to provide information in this final rule with comment period clarifying how newly packaged services map back to primary procedures because we would be unable to display in a meaningful way all of the many combinations of services that may be of interest to the public. Moreover, given the numerous new, refined, and interrelated payment policies finalized for CY 2008 involving APC reconfiguration, HCPCS migration, reduction in the numbers of low volume APCs, and others, to adopt the APC Panel's example of simulating median costs holding all other CY 2008 policies constant for HCPCS codes with and without the additional packaging of those services newly packaged for CY 2008 would not provide meaningful comparative information. Almost

certainly, if we were not to adopt packaging of the additional services for CY 2008, the APC configurations, bypass list, single claims available for ratesetting, and other important features upon which the final median costs depend would differ in significant ways from those aspects under our final CY 2008 policies.

Comment: A number of commenters disagreed with the CMS estimate of the amount of payment that would be redistributed under the proposed rule. The commenters indicated that the services proposed to be newly packaged constitute 6 percent of the OPSS costs, although CMS estimated that the packaging proposal would redistribute 1.2 percent of the CY 2008 expenditures under the OPSS. They attributed the difference in cost estimates to the methodology for applying status indicator "Q." The commenters believed that the resulting impact analysis would be quite different from CMS' estimated impact displayed in the proposed rule and, therefore, the implications of the policy are not fully understood. They objected to packaging of observation services in particular, but recommended that CMS reevaluate the entire packaging proposal in light of methodological and data concerns.

Response: In the proposed rule, we estimated that the proposed packaging approach would redistribute 1.2 percent of the CY 2007 base expenditures under the OPSS to other OPSS services as part of our budget neutrality adjustments for the proposed CY 2008 payment system. This 1.2 percent is the aggregate payment weight reduction from the packaging proposal, where the medians are marginally less than the costs for the individual services prior to packaging. This is not inconsistent with a finding that the total cost of services proposed to be packaged constitutes 6 percent of HOPD costs. These percentages measure different things. The first provides an estimate of money redistributed to other services and the second an estimate of the proportion of OPSS spending on services addressed by the policy. We understand, and intended, that the packaging proposal affect services responsible for significant OPSS spending, in order to provide hospitals with meaningful incentives to examine their patterns of care delivery and improve efficiency. The 1.2 percent reflects the difference in total weight with and without the packaging proposal relative to the CY 2007 total base weight. Whether or not the 1.2 percent of redistributed dollars was entirely attributable to the proposed policy for estimating the median cost for "Q" status indicator services cannot be

determined. For this final rule with comment period, we made modifications to the policy governing the handling of many services assigned status indicator "Q," as discussed in section II.A.4.c.(4) of this final rule with comment period, that resulted in use of more claims data and significant changes to the median costs for some services. We also accepted the public comments that recommended that we create a composite APC for observation services, as discussed in section II.A.4.c.(7) of this final rule with comment period.

Comment: Some commenters stated that CMS must undertake provider education and claims monitoring because providers will cease to bill HCPCS codes and charges for packaged services, which will result in lower payment rates than would otherwise be made if they reported all codes and charges and thus the costs of packaged services would be lost to the payment system in future years. They indicated that this presents huge operational challenges to hospitals to ensure that they bill and charge for the packaged codes. Other commenters believed that the implementation of increased packaging will be particularly difficult in CY 2008 because CMS is simultaneously implementing Medicare-Severity DRGs (MS-DRGs) for IPPS payment, which also poses operational challenges for hospitals.

Response: We do not believe that there will be a significant change in what hospitals charge and report for the services they furnish to Medicare beneficiaries and to others as a result of the increased packaging for the CY 2008 OPPS. Medicare cost reporting standards specify that hospitals must impose the same charges for Medicare patients as for other patients. We are often told by hospitals that many private payers pay based on a percentage of charges and that hospital chargemasters do not differentiate between the charges to Medicare patients and others. Therefore, we have no reason to believe that hospitals will cease to report charges and HCPCS codes for packaged services they provide to Medicare beneficiaries. We expect that hospitals, as other prudent businesses, will have a quality review process that ensures that they accurately and completely report the services they furnish, with the appropriate charges for those services to Medicare and all other payers. Therefore, we do not see either the need or the responsibility to undertake a special effort to educate providers to report and charge Medicare for the services they furnish, whether separately paid or packaged. According

to our longstanding policy, we will continue to encourage hospitals to report the HCPCS codes and associated charges for all services they provide, taking into consideration all CPT, OPPS, and local contracture instructions, regardless of whether payment for those HCPCS codes is packaged or separately provided. Similarly, we do not believe that the implementation of MS-DRGs will create operational issues for hospitals that would be complicated by increased packaging under the OPPS.

Comment: Some commenters asserted that increased packaging will create disincentives to provide certain services and that providers may stop furnishing these services to Medicare beneficiaries. The commenters stated that increased packaging would reduce expenditures, but the ultimate result would be reduced access to necessary care as the payment incentives to provide care are reduced. Other commenters believed that increased packaging will result in services being furnished on multiple days in order to maximize payment, which will increase, rather than decrease, volumes of services and provide a significant inconvenience to beneficiaries.

Response: We also do not agree that beneficiary access to care will be harmed by increased packaging. We believe that packaging will create incentives for hospitals and their physician partners to work together to establish appropriate protocols that will eliminate unnecessary services where they exist and will institutionalize approaches to providing necessary services more efficiently. Where this review results in reductions in services that are only marginally beneficial, we believe that this could improve rather than harm the quality of care for beneficiaries because every service furnished in a hospital carries some level of risk to the patient. Similarly, where this review results in the concentration of some services in a reduced number of hospitals in the community, we believe that the quality of care and hospital efficiency may both be enhanced as a result. The medical literature shows that concentration of services in certain hospitals often results in both greater efficiency and higher quality of care for patients.

Moreover, we do not believe that packaging will result in Medicare beneficiaries being treated differently from other patients with regard to the care they receive in the hospital. A hospital may have its provider agreement terminated by Medicare under 42 CFR 489.53(a)(2) if it places restrictions on the persons it accepts for treatment and either fails to exempt

Medicare beneficiaries from those restrictions or apply them to Medicare beneficiaries the same as to all other persons seeking care. We do not believe that a hospital would risk termination of its provider agreement by Medicare by refusing to furnish a medically necessary service to a Medicare beneficiary, although it provides the same service to other patients for the same clinical indications.

As we indicated in the proposed rule, we will examine our claims data for patterns of fragmented care and if we find a pattern in which a hospital appears to be fragmenting care across multiple days, we will refer it for investigation to the QIO or to the program safeguard contractor, as appropriate to the circumstances we find. However, we do not believe that, in general, hospitals would routinely, and for purposes of financial gain, require patients to return on multiple days to receive services that could have been furnished on the same day.

Comment: One commenter objected to the implication in the proposed rule that hospitals provide whatever services they wish at whatever cost, with their only concern being payment for the services, and that payment rates could motivate hospitals to report services on separate claims or split the service among different hospitals in order to be paid more. The commenter stated that 42 CFR 411.15(m) requires that hospitals must furnish and bill for services necessary to complete an outpatient encounter and that, therefore, it would be a violation of CMS regulations for a hospital to deliver part of the service at one hospital and the rest at another hospital.

Response: We believe that hospitals strive to provide the best care they can to the patients they serve. However, we are aware that there are financial pressures on hospitals that might motivate some of them to split services in such a way as to maximize payments. While we do not expect that hospitals would routinely change the way they furnish services or the way they bill in order to maximize payment, we do believe that it would be possible, and hence we offered the cautionary note in the proposed rule that we will consider that possibility as we review our claims data. Other commenters, as described in the preceding comment, stated that volumes of services and expenditures would increase because hospitals would provide services on multiple days to maximize payment.

We note that 42 CFR 411.15(m) specifies exclusions from Medicare coverage in cases in which the hospital does not furnish a service directly or

under arrangements as defined in 42 CFR 409.3 and, therefore, would not prohibit a hospital from discharging a patient and sending that patient to another hospital for a service that would otherwise be packaged if furnished during the same encounter. However, as noted above, a hospital that does not make available the same services to Medicare beneficiaries as to its other hospital patients can be terminated from Medicare under 42 CFR 489.53(a)(2). Additionally, we remind hospitals that any business models or arrangements they make for the provision of services intended to be billed by that hospital must comply with all applicable laws and regulations, including, but not limited to, the Stark law and other anti-kickback laws, the provider-based rules at 42 CFR 413.65, the "incident-to" rules at 42 CFR 410.27, and the conditions for outpatient diagnostic services at 42 CFR 410.28. In regard to hospital services provided under arrangements, as defined in 42 CFR 409.3, we have specified in the Eligibility and Entitlement Manual that, "In permitting providers to furnish services under arrangements, it was not intended that the provider merely serve as a billing mechanism for the other party. Accordingly, for services provided under arrangements to be covered, the provider must exercise professional responsibility over the arranged for services" (Pub. 100-1, Chapter 5, section 10.3). Therefore, we would not expect hospitals to send patients to a separate entity merely to avoid packaged payment, but, as stated above, we will consider that possibility as we review our claims data.

Comment: Some commenters suggested that CMS work with and through the AMA process in making any packaging decisions and not make any arbitrary and single-sided bundling decisions that have not been fully reviewed and analyzed for impact by the stakeholders. They suggested that CMS discuss with the AMA CPT Editorial Panel the potential for unintended consequences of proposed packaging or bundling on the establishment of CPT codes. For example, one commenter believed that packaging add-on codes, which the commenter viewed as integral to maintaining flexibility of CPT coding, would likely discourage future consideration of creating add-on codes as a means to describe code-specific procedures and resources. Other commenters objected to what they view as a "codebook" approach to determining what should be packaged. The commenters stated that CMS not

rely on CPT and HCPCS code descriptors because the descriptors are complex and many do not accurately describe the services furnished. Some commenters argued that CMS should pay across settings in the same way and, therefore, should not package under the OPSS services that are paid separately under the MPFS.

Response: Our general process for developing the OPSS, including making major payment policy decisions, is prescribed by the Administrative Procedure Act (APA) and the Federal Advisory Committee Act (FACA). As such, proposed payment rates and the attendant policies are open to public comment both through the **Federal Register** notice and comment rulemaking process and through the public meetings of the APC Panel, which is a Federal Advisory Committee chartered by the Secretary of Health and Human Services. Therefore, our proposed packaging for the CY 2008 OPSS and the decisions we are announcing in this final rule with comment period are neither arbitrary nor single-sided, as all stakeholders have had the opportunity to comment. In this final rule with comment period, we are responding to their comments. We note that the AMA, as a member of the public, has the same opportunity to comment on the packaging proposal in the proposed rule as any other member of the public.

We believe that it is entirely appropriate to rely on the HCPCS descriptors, including the AMA's CPT descriptors, for the definition of the services furnished for purposes of the proposed packaging approach and other payment policies. The OPSS is based on the definitions of services reported with HCPCS codes, of which the CPT code set is a fundamental part. The HCPCS codes are the only means by which hospitals report the services they furnish and the charges for those services and, therefore, they are basis of the OPSS. For that reason, we look to the HCPCS definition of the service to determine whether a particular service is ancillary and supportive of another service. To the extent that there are changes to the HCPCS codes and, by extension, to the CPT code descriptors, we will reevaluate the decisions we make with regard to packaging payment. However, we do not believe that the AMA's CPT Editorial Board is influenced by OPSS payment policy in its deliberations, nor should it be influenced by OPSS payment policy in its creation of CPT codes.

Moreover, we disagree that we should not package payment for ancillary and supportive services because the MPFS

pays separately for them. The OPSS is not a fee schedule, but a prospective payment system based on relative weights derived from costs and charges. Packaging of payments into appropriate groups is a fundamental principle that distinguishes a prospective payment system from a fee schedule and we do not believe that we should refrain from packaging payment for ancillary and supportive services into payment for the independent services with which they are furnished because they may be treated differently in the MPFS or because of the unlikely possibility that this policy may have some influence on the AMA CPT Editorial Panel's decisions regarding creation of codes.

Comment: One commenter stated that the concept of creating incentives for hospitals to negotiate better prices on goods and services through packaging is not applicable to small rural hospitals and, therefore, it should not apply to them. The commenter argued that smaller rural hospitals cannot negotiate for better prices on goods and services because they buy smaller amounts of products and lack the ability that large urban hospitals have to negotiate for better prices on goods and services.

Response: We believe that the creation of incentives for hospitals to seek more efficient ways of furnishing services is applicable to all hospitals, including small rural hospitals. Small rural hospitals and their physician partners have the same capacity and capability as other hospitals to evaluate the appropriateness and efficiency of the packaged services they furnish. Moreover, small rural hospitals can join in cooperatives and group purchasing organizations that can achieve purchasing efficiencies that they could not achieve by themselves. We recognize that some costs are higher for certain categories of rural hospitals, therefore we have provided the 7.1 percent rural adjustment for rural SCHs. Moreover, the law holds harmless rural hospitals with 100 or fewer beds. However, we also expect that small rural hospitals will be motivated by the packaging approach to seek ways of furnishing services as efficiently as possible and to eliminate services that are essential to the appropriate treatment of the patient in any clinical case.

Comment: Some commenters contended that the proposed packaging approach has the potential for systemwide net savings and redistribution of payments away from hospitals that invested in high-cost equipment and toward hospitals that do not have such costs. They believed that charge compression contributes to this

problem because hospitals are limited in what they can charge, and the allocation of radiology equipment capital costs exacerbates the problem. The commenters suggested that CMS not finalize the packaging proposal because packaging creates incentives for hospitals to divest themselves of important but expensive technologies because those technologies have ceased to be profitable.

Response: We agree that there is the potential for systemwide redistribution of payments away from hospitals that invested in costly equipment for services for which payment will be packaged and toward hospitals that do not have such costs. However, to the extent that packaging payment for ancillary and supportive services reduces the amount of payment weight in the system for separately paid services, that amount will be redistributed to all hospitals across all services paid under the OPSS through the budget neutral weight scaler. Any reduction in the growth of OPSS expenditures will result from slower growth in hospital costs in future years as a result of hospitals reducing the volume of certain services or finding more efficient ways to provide care. That potential future savings is one of the purposes of this packaging initiative and the exploration of episode-based or encounter-based payments under the OPSS. Similarly, if increased packaging causes hospitals to be more cautious in their decision making regarding investing in new equipment or incurring other large capital expenditures, we view that as a positive result of the policy. Hospitals make decisions regarding the equipment they buy for general business reasons, of which payment under the OPSS is only one factor among many, including, but not limited to, utilization and payments from other payers and payments from Medicare for IPPS services, which is the dominant source of Medicare payment for hospital care.

Comment: One commenter asserted that linking growth in volume to reduced payments is premature, inappropriate, and not supported by statutory authority. The commenter was particularly concerned about any methodology that would establish different update factors for different OPSS service categories, where the update factor is determined in a manner that takes into account utilization trends. Many commenters stated that HOPD utilization of services is only marginally within the control of hospitals. They explained that hospitals provide services ordered by their medical staff and community

physicians, and it would be inappropriate to penalize hospitals for performing services whose utilization is not within their control. The commenters believed that innovation and best practices have increased utilization, not the provision of excessive services.

Response: Section 1833(t)(2)(F) of the Act requires us to develop a method of controlling unnecessary increases in the volume of covered OPS services and section 1833(t)(9)(C) of the Act authorizes us to adjust the update to the conversion factor if under section 1833(t)(2)(F) of the Act, we determine that there is growth in volume that exceeds established tolerances. As we indicated in our proposed rule, we prefer not to take the approach of creating an SGR-type mechanism that could result in a reduced conversion factor under the OPSS and that could inadvertently result in actually increasing the volume of services. We prefer to establish larger packages of services on which to base OPSS payment in order to create incentives for hospitals and their physician partners to make thoughtful decisions regarding what services are medically necessary for their patients and to continuously reassess how they might be able to provide care more efficiently. We recognize that decisions regarding the care provided in HOPDs are not made unilaterally by the hospital, nor are they made unilaterally by the physician who is ordering the care. While physicians, rather than hospital staff, may order specific services for patients, hospitals decide what HOPD services they will and will not furnish, what drugs and supplies they will or will not buy and from whom they will buy them, what investments in equipment they will or will not make, and what programs they will open or close. Certainly, they make these decisions with significant input from their medical staff, but it is the hospital administration that makes the final decisions in this regard. Moreover, hospitals control, to some extent, the physicians on their medical staff and increasingly employ physicians to provide services to patients and to supervise the provision of hospital services. Hence, we do not agree with the argument that hospitals have no control over the services they furnish or that they have no influence over the physicians who order the specific services furnished to their patients.

Comment: Some commenters asked CMS to impose a payment floor to limit the amount of decline in any APC payment in at least the first year of implementation as a means of mitigating

the effects of no longer paying separately for the packaged services.

Response: We do not agree that we should impose a payment floor to limit the amount of decline in any APC payment as a means of mitigating the effects of no longer paying separately for the packaged services. The purpose of creating larger payment packages is to create incentives for hospitals to assess the services they are furnishing to ensure that they are furnishing only medically necessary services as efficiently as possible. To establish a payment floor that would artificially inflate payments for APCs that are declining would reduce what would otherwise be appropriate increases in payments for other APCs. We believe that this would be contrary to the stated goal of paying appropriately for all services through larger payment bundles that are intended to create incentives for efficiency.

Comment: Several commenters objected to the proposed packaging approach because they believed that it would be more difficult for new services to be approved for payment under New Technology APCs. One commenter believed that it would be difficult for new guidance services, in particular, to be approved for assignment to a New Technology APC if CMS considers guidance to be a supportive and ancillary service rather than a separately paid complete service. Therefore, the commenter concluded that the proposed packaging not only packages existing services but creates the potential for new technologies to not be approved for New Technology APC payment.

Response: We assess applications for New Technology APC placement on a case-by-case basis. The commenter is correct that, to qualify for New Technology APC placement, the service must be a complete service, by which we mean a comprehensive service that stands alone as a meaningful diagnostic or therapeutic service. To the extent that a service for which New Technology APC status is being requested is ancillary and supportive of another service, for example, a new intraoperative service or a new guidance service, we might not consider it to be a complete service because its value is as part of an independent service. However, if the entire, complete service, including the guidance component of the service, for example, is "truly new," as we explained that term at length in the November 30, 2001 final rule (66 FR 59898) which set forth the criteria for eligibility for assignment of services to New Technology APCs, we would consider the new complete procedure for New Technology APC assignment.

As stated in the November 30, 2001 final rule, by way of examples provided, "The use of a new expensive instrument for tissue debridement or a new, expensive wound dressing does not in and of itself warrant creation of a new HCPCS code to describe the instrument or dressing; rather, the existing wound repair code appropriately describes the service that is being furnished * * * " (66 FR 59898). This example may hold for some new guidance technologies as well.

The following discussions separately address each of the seven categories of items and services for which we proposed to package payment under the CY 2008 OPPS as part of our packaging proposal and which we are adopting in this final rule with comment period, with the modifications discussed under the applicable topic. Many codes that we proposed to package for CY 2008 could fit into more than one of those seven categories. For example, CPT code 93325 (Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)) could be included in both the intraoperative and image processing categories. Therefore, for organizational purposes, both to ensure that each code appears in only one category and to facilitate discussion of our CY 2008 proposed and final policy, we have created a hierarchy of categories that determines which category each code appropriately falls into. This hierarchy is organized from the most clinically specific to the most general type of category. The hierarchy of categories is as follows: guidance services; image processing services; intraoperative services; and imaging supervision and interpretation services. Therefore, while CPT code 93325 may logically be grouped with either image processing services or intraoperative services, it is treated as an image processing service because that group is more clinically specific and precedes intraoperative services in the hierarchy. We did not believe it was necessary to include diagnostic radiopharmaceuticals, contrast media, or observation categories in this list because those services generally map to only one of those categories. We note that there is no cost estimation or payment implications related to the assignment of a HCPCS code for purposes of discussion to any specific category.

Each HCPCS code we discuss in this section has a status indicator of either "N" or "Q." The payment for a HCPCS code with a status indicator of "N" is unconditionally packaged so that its payment is always incorporated into the

payments for the separately paid services with which it is reported. Payment for a HCPCS code with a status indicator of "Q" is either packaged or separately paid, depending on the services with which it is reported. Payment for a HCPCS code with a status indicator of "Q" that is "STVX-packaged" is packaged unless the HCPCS code is not reported on the same day with a service that has a status indicator of "S," "T," "V," or "X," in which case it would be paid separately. Payment for a HCPCS code with a status indicator of "Q" that is "T-packaged" is packaged unless the HCPCS code is not reported on the same day with a service that has a status indicator of "T," in which case it would be paid separately. Payment for a HCPCS code with a status indicator of "Q" that is assigned to a composite APC is packaged into the payment for the composite APC when the criteria for payment of the composite APC are met.

(1) Guidance Services

We proposed to package payment for HCPCS guidance codes for CY 2008, specifically those codes that are reported for supportive guidance services, such as ultrasound, fluoroscopic, and stereotactic navigation services, that aid the performance of an independent procedure. We performed a broad search for such services, relying upon the AMA's CY 2007 book of CPT codes and the CY 2007 book of Level II HCPCS codes, which identified specific HCPCS codes as guidance codes. Moreover, we performed a clinical review of all HCPCS codes to capture additional codes that are not necessarily identified as "guidance" services but describe services that provide directional information during the course of performing an independent procedure. For example, we proposed to package CPT code 61795 (Stereotactic computer-assisted volumetric (navigational) procedure, intracranial, extracranial, or spinal (List separately in addition to code for primary procedure)) because we consider it to be a guidance service that provides three-dimensional information to direct the performance of intracranial or other diagnostic or therapeutic procedures. We also included HCPCS codes that existed in CY 2006 but were deleted and were replaced in CY 2007. We included the CY 2006 HCPCS codes because we proposed to use the CY 2006 claims data to calculate the CY 2008 OPPS median costs on which the CY 2008 payment rates would be based. Many, although not all, of the CPT guidance codes we identified are designated in the CPT coding scheme as add-on codes that are

to be reported in addition to the CPT code for the primary procedure. We also note that there are a number of CPT codes describing independent surgical procedures that have code descriptors that indicate that guidance is included in the code reported for the surgical procedure if it is used and, therefore, packaged payment is already made for the associated guidance service under the OPPS. For example, the independent procedure described by CPT code 55873 (Cryosurgical ablation of the prostate (includes ultrasonic guidance for interstitial cryosurgical probe placement)) already includes the ultrasound guidance that may be used. We believed packaging payment for every guidance service under the OPPS would provide consistently packaged payment for all these services that are used to direct independent procedures, even if they are currently separately reported.

Because these dependent guidance procedures support the performance of an independent procedure and they are generally provided in the same operative session as the independent procedure, we believed that it would be appropriate to package their payment into the OPPS payment for the independent procedure performed. However, guidance services differ from some of the other categories of services that we proposed to package for CY 2008. Hospitals sometimes may have the option of choosing whether to perform a guidance service immediately preceding or during the main independent procedure, or not at all, unlike many of the imaging supervision and interpretation services, for example, which are generally always reported when the independent procedure is performed. Once a hospital decides that guidance is appropriate, the hospital may have several options regarding the type of guidance service that can be performed. For example, when inserting a central venous access device, hospitals have the option of using no guidance, ultrasound guidance, or fluoroscopic guidance, and the selection in any specific case will depend upon the specific clinical circumstances of the device insertion procedure. In fact, as we noted in the CY 2008 proposed rule, the historical hospital claims data demonstrated that various guidance services for the insertion of these devices, which have historically received packaged payment under the OPPS, are used frequently for the insertion of vascular access devices.

Thus, we recognized that hospitals have several options regarding the performance and types of guidance services they use. However, we believed

that hospitals utilize the most appropriate form of guidance for the specific procedure that is performed. We did not want to create payment incentives to use guidance for all independent procedures or to provide one form of guidance instead of another. Therefore, by proposing to package payment for all forms of guidance, we specifically encouraged hospitals to utilize the most cost effective and clinically advantageous method of guidance that is appropriate in each situation by providing them with the maximum flexibility associated with a single payment for the independent procedure. Similarly, hospitals may appropriately not utilize guidance services in certain situations based on clinical indications.

Because guidance services can be appropriately reported in association with many independent procedures, under our proposed packaging of guidance services for CY 2008, the costs associated with guidance services would be mapped to a larger number of independent procedures than some other categories of codes that we proposed to package. For example, CPT code 76001 (Fluoroscopy, physician time more than one hour, assisting a non-radiologic physician (*e.g.*, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)) can be reported with a wide range of services. According to the CPT code descriptor, these procedures include nephrostolithotomy, which may be reported with CPT code 50080 (Percutaneous nephrostolithotomy or pyelostolithotomy, with or without dilation, endoscopy, lithotripsy, stenting, or basket extraction; up to 2 cm), and endoscopic retrograde cholangiopancreatography, which may be reported with CPT code 43260 (Endoscopic retrograde cholangiopancreatography (ERCP); diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)). Therefore, the cost of the fluoroscopic guidance would be reflected in the payment for each of these independent services, in addition to numerous other procedures, rather than in the payment for only one or two independent services, as is the case for some of the other categories of codes that we proposed to package for CY 2008.

In addition, because independent procedures such as CPT code 20610 (Arthrocentesis, aspiration and/or injection; major joint or bursa (*e.g.*, shoulder, hip, knee joint, subacromial bursa)) may be reported with or without guidance, the cost for the guidance will be reflected in the median cost for the

independent procedure as a function of the frequency that guidance is reported with that procedure. As we stated previously, the median cost for a particular independent procedure generally will be higher as a result of added packaging, but also could change little or be lower because median costs typically do not reflect small distributional changes and because changes to the packaged HCPCS codes affect both the number and composition of single bills and the mix of hospitals contributing those single bills. In fact, the CY 2007 CPT book indicates that if guidance is performed with CPT code 20610, it may be appropriate to bill CPT code 76942 (Ultrasonic guidance for needle placement (*e.g.*, biopsy, aspiration, injection, localization device), imaging supervision and interpretation); 77002 (Fluoroscopic guidance for needle placement (*e.g.*, biopsy, aspiration, injection, localization device)); 77012 (Computed tomography guidance for needle placement (*e.g.*, biopsy, aspiration, injection, localization device), radiological supervision and interpretation); or 77021 (Magnetic resonance guidance for needle placement (*e.g.*, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation). The CY 2007 CPT book also implies that it is not always clinically necessary to use guidance in performing an arthrocentesis described by CPT code 20610.

The guidance procedures that we proposed to package for CY 2008 vary in their resource costs. Resource cost was not a factor we considered when proposing to package guidance procedures. Notably, most of the guidance procedures are relatively low cost in comparison to the independent services they frequently accompany.

The codes we proposed to identify as guidance codes for CY 2008 that would receive packaged payment were listed in Table 8 of the CY 2008 proposed rule (72 FR 42657). (Table 10 in this final rule with comment period contains a comprehensive list of all codes in the final seven categories for services that are packaged for CY 2008.)

Several of these codes, including CPT code 76937 (Ultrasonic guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent real time ultrasound visualization of vascular needle entry, with permanent recording and reporting (List separately in addition to code for primary procedure)), were already

unconditionally (that is, always) packaged under the CY 2007 OPPS, where they have been assigned status indicator "N." Payment for these services is currently made as part of the payment for the separately payable, independent services with which they are billed. No separate payment is made for services that we have assigned to status indicator "N." We did not propose status indicator changes for the five guidance procedures that were unconditionally packaged for CY 2007.

We proposed to change the status indicators for 31 guidance procedures from separately paid to unconditionally packaged (status indicator "N") for the CY 2008 OPPS. We believed that these services are always integral to and dependent upon the independent services that they support and, therefore, their payment would be appropriately packaged because they would generally be performed on the same date and in the same hospital as the independent services.

We proposed to change the status indicator for one guidance procedure from separately paid to conditionally packaged (status indicator "Q"), and to treat it as a "special" "packaged code for the CY 2008 OPPS, specifically, CPT code 76000 (Fluoroscopy (separate procedure), up to 1 hour physician time, other than 71023 or 71034 (*e.g.*, cardiac fluoroscopy)). This code was discussed in the past with the Packaging Subcommittee of the APC Panel, which determined that, consistent with its code descriptor as a separate procedure, this procedure could sometimes be provided alone, without any other services on the claim. We believe that this procedure will usually be provided by a hospital as guidance in conjunction with another significant independent procedure on the same date of service but may occasionally be provided without another independent service. As a "special" packaged code, if the fluoroscopy service were billed without any other service assigned status indicator "S," "T," "V," or "X" reported on the same date of service, under our proposal we would not treat the fluoroscopy procedure as a dependent service for purposes of payment. If we were to unconditionally package payment for this procedure, treating it as a dependent service, hospitals would receive no payment at all when providing this service alone, although the procedure would not be functioning as a guidance service in that case. However, according to our proposal, its conditionally packaged status with its designation as a "special" packaged code would allow payment to be provided for this "Q" status fluoroscopy

procedure, in which case it would be treated as an independent service under these limited circumstances. On the other hand, when the fluoroscopy service is furnished as a guidance procedure on the same day and in the same hospital as independent, separately paid services that are assigned status indicator "S," "T," "V," or "X," we proposed to package payment for it as a dependent service. In all cases, we proposed that hospitals that furnish independent services on the same date as dependent guidance services must bill them all on the same claim. We believed that when dependent guidance services and independent services are furnished on the same date and in the same facility, they are part of a single complete hospital outpatient service that is reported with more than one HCPCS code, and no separate payment should be made for the guidance service that supports the independent service.

The estimated overall impact of these changes presented in section XXII.B. of the proposed rule (section XXIV.B. in this final rule with comment period) was based on the assumption that hospital behavior would not change with regard to when these dependent services are performed on the same date and by the same hospital that performs the independent services. To the extent that hospitals could change their behavior and perform the guidance services more or less frequently, on subsequent dates, or at settings outside of the hospital, the data would show such a change in practice in future years and that change would be reflected in future budget neutrality adjustments. However, with respect to guidance services in particular, we believe that hospitals are limited in the extent to which they could change their behavior with regard to how they furnish these services. By their definition, these guidance services generally must be furnished on the same date and at the same operative location as the independent procedure in order for the guidance service to meaningfully contribute to the treatment of the patient in directing the performance of the independent procedure. We do not believe the clinical characteristics of the guidance services will change in the immediate future.

As we indicated earlier, in all cases, we proposed that hospitals that furnish the guidance service on the same date as the independent service must bill both services on the same claim. We indicated that we expected to carefully monitor any changes in billing practices on a service-specific and hospital-specific basis to determine whether

there is reason to request that QIOs review the quality of care furnished or to request that Program Safeguard Contractors review the claims against the medical record.

During the September 2007 APC Panel meeting, the Panel recommended that CMS finalize the proposal to package guidance services, with the exception of radiation oncology guidance procedures.

We received many public comments on our proposal to package guidance services for CY 2008. A summary of the public comments and our responses follow.

Comment: Many commenters requested that, if CMS elected to finalize the packaging status of the guidance codes proposed for packaging, CMS exclude radiation oncology guidance procedures, in accordance with the APC Panel recommendation. Specifically, many commenters requested that CMS pay separately for CPT codes 76950 (Ultrasonic guidance for placement of radiation therapy fields); 76965 (Ultrasonic guidance for interstitial radioelement application); 77014 (Computed tomography guidance for placement of radiation therapy fields); 77417 (Therapeutic radiology port film(s)); and 77421 (Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy). The commenters were concerned that packaging radiation oncology guidance procedures would encourage hospitals to decrease utilization of advanced technologies for localization used in radiation oncology treatment delivery. The commenters noted that packaging payment for radiation oncology guidance services offers a financial incentive to those hospitals that use little or no daily localization when providing radiation therapy. One commenter believed that packaging payment for these guidance services encourages hospitals to use older, less effective technologies, thereby discouraging development of new, more effective technologies. Another commenter noted that if hospitals are discouraged from using new technologies due to low payment rates, it will take many years to gather robust cost data that reflect these new technologies, likely even longer than New Technology APC and pass-through payments are available for new technologies.

Response: After reviewing these public comments, considering the recommendation of the APC Panel, and ensuring that CMS clinical staff analyzed the content of these comments, we have decided to finalize our proposal to package these guidance

services, as proposed. These services are ancillary and dependent in relation to the radiation therapy services with which they are most commonly furnished. Moreover, there are no unique clinical aspects to these radiation oncology guidance services that would differentiate them from other guidance services. Consistent with the principles of a prospective payment system, in some cases, payment in an individual case exceeds the average costs, and in other cases payment is less than the average cost, but on balance, payment should approximate the relative cost of the average case. We do not believe that beneficiary access to care will be harmed by increased packaging. We believe that packaging will create incentives for hospitals and their physician partners to work together to establish appropriate protocols that will eliminate unnecessary services where they exist and institutionalize approaches to providing necessary services more efficiently. Therefore, we see no basis for treating radiation oncology services differently from other guidance services that are ancillary and dependent to the procedure that they facilitate.

Comment: Many commenters were concerned with the proposal to package payment for electrodiagnostic guidance for chemodenervation procedures, specifically, CPT codes 95873 (Electrical stimulation for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)), and 95874 (Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure)). The commenters indicated that chemodenervation involves the injection of chemodenervation agents, such as botulinum toxin, to control the symptoms associated with dystonia and other disorders. According to the commenters, physicians often, but not always, use electromyography or electrical stimulation guidance to guide the needle to the most appropriate location. The commenters were concerned that the proposal to package payment for these guidance services may discourage utilization of this particular form of guidance, even when medically appropriate. Several commenters noted that the CY 2008 proposed payment rate for the injection and the associated guidance is a 15 percent decrease from the CY 2007 payment rate. Most commenters requested that CMS pay separately for electrodiagnostic guidance, several of whom specified that CMS assign the

three chemodenervation procedures to their own APC. The commenters noted that even if the median cost for the chemodenervation procedures increased, the payment rate would not increase because chemodenervation procedures are only a small proportion of all claims in their proposed APC 0204 (Level I Nervous System Injections). Several other commenters stated that the median costs for the chemodenervation procedures do not reflect the full cost of the guidance because the guidance is performed with the procedure infrequently.

Response: We note that the cost of the chemodenervation guidance services will be reflected in the median cost for the independent HCPCS code as a function of the frequency that chemodenervation services are reported with that particular HCPCS code. As noted above, we recognize that, in some cases, supportive and ancillary dependent services are furnished at high frequency with independent services, and in other cases, they are furnished with independent services at a low frequency. We believe that packaging should reflect the reality of how services are furnished. While the commenters are correct that the chemodenervation procedures reflect only approximately 10 percent of the services that comprise APC 0204, we note that they appropriately map to this APC both clinically and in terms of resource use. If the median costs for the individual chemodenervation procedures were to change dramatically, based on resource cost data, we would review these services as part of our annual review process to determine if a different APC were more appropriate. We also note that if these three chemodenervation procedures were mapped to their own APC, the estimated median cost of the APC would be in the same general cost range as the current median cost for APC 0204. Therefore, it is unnecessary to map these three services to their own APC for CY 2008.

Comment: Several commenters requested that CMS clarify how the DRA imaging cap for services paid under the MPFS would be applied to services that are packaged under the OPPS.

Response: If an imaging service is packaged under the OPPS, the DRA cap on the technical component payment for that service under the MPFS is not applicable.

Comment: Many commenters supported the proposal to package each of the guidance services that we identified in the proposed rule. The commenters also gave specific comments related to almost every guidance code that we proposed to

package. In general, each commenter requested that we pay separately for several of the guidance codes that we proposed to package. The commenters expressed concern in several areas, specifically, that insufficient payment rates would discourage new technologies; that guidance services used infrequently with specific services contribute very little to the payment rates for those services; that the expected decrease in utilization for guidance services could ultimately lead to increased costs, as a result of worse patient outcomes; that packaged payment under the OPPS and separate payment under the MPFS leads to payment disparity; and, in general, that the lack of published crosswalks makes it difficult to analyze the specific effects of this policy.

Response: We note that we did not receive any unique arguments specific to any particular code. We received many similar public comments regarding all the categories of codes that we proposed for packaged payment. Therefore, we have responded to these general comments above in section II.A.4.c. of this final rule with comment period. In light of the public comments we received, our clinical advisors reassessed every guidance code on the list to ensure that it was still appropriate for packaged payment.

For CY 2008, we are finalizing the CY 2008 proposal, without modification, to package payment for all guidance services for CY 2008. We are partially accepting the APC Panel recommendation. Specifically, we are packaging all guidance services for CY 2008, including radiation oncology services. The guidance codes that are packaged for CY 2008 are identified and displayed in Table 10 of this final rule with comment period. These services are assigned status indicator "N" to indicate their unconditional packaging, with the exception of CPT code 76000, which is an "STVX-packaged" code assigned status indicator "Q."

(2) Image Processing Services

We proposed to package payment for "image processing" HCPCS codes for CY 2008, specifically those codes that are reported as supportive dependent services to process and integrate diagnostic test data in the development of images, performed concurrently or after the independent service is complete. We performed a broad search for such services, relying upon the AMA's CY 2007 book of CPT codes and the CY 2007 book of Level II HCPCS codes, which identified specific codes as "processing" codes. In addition, we performed a clinical review of all

HCPCS codes to capture additional codes that we consider to be image processing. For example, we proposed to package payment for CPT code 93325 (Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)) because it is an image processing procedure, even though the code descriptor does not specifically indicate it as such.

An image processing service processes and integrates diagnostic test data that were captured during another independent procedure, usually one that is separately payable under the OPPS. The image processing service is not necessarily provided on the same date of service as the independent procedure. In fact, several of the image processing services that we proposed to package for CY 2008 do not need to be provided face-to-face with the patient in the same encounter as the independent service. While this approach to service delivery may be administratively advantageous from a hospital's perspective, providing separate payment for each image processing service whenever it is performed is not consistent with encouraging value-based purchasing under the OPPS. We believed it was important to package payment for supportive dependent services that accompany independent services but that may not need to be provided face-to-face with the patient in the same encounter because the supportive services utilize data that were collected during the preceding independent services and packaging their payment encourages the most efficient use of hospital resources. We are particularly concerned with any continuance of current OPPS payment policies that could encourage certain inefficient and more costly service patterns. As stated above, packaging encourages hospitals to establish protocols that ensure that services are furnished only when they are medically necessary and to carefully scrutinize the services ordered by practitioners to minimize unnecessary use of hospital resources. Our standard methodology to calculate median costs packages the costs of dependent services with the costs of independent services on "natural" single claims across different dates of service, so we are confident that we would capture the costs of the supportive image processing services for ratesetting when they are packaged according to our CY 2008 proposal, even if they were provided on a different date than the independent procedure.

We listed the image processing services that we proposed to be packaged for CY 2008 in Table 10 in the

CY 2008 proposed rule (72 FR 42659). As these services support the performance of an independent service, we believe it would be appropriate to package their payment into the OPPS payment for the independent service provided.

As many independent services may be reported with or without image processing services, the cost of the image processing services will be reflected in the median cost for the independent HCPCS code as a function of the frequency that image processing services are reported with that particular HCPCS code. Again, while the median cost for a particular independent procedure generally will be higher as a result of added packaging, it could also change little or be lower because median costs typically do not reflect small distributional changes and because changes to the packaged HCPCS codes affect both the number and composition of single bills and the mix of hospitals contributing those single bills. For example, CPT code 70450 (Computed tomography, head or brain; without contrast material) may be provided alone or in conjunction with CPT code 76376 (3D rendering with interpretation and reporting of computed tomography, magnetic resource imaging, ultrasound, or other tomographic modality; not requiring image post-processing on an independent workstation). In fact, CPT code 70450 was provided approximately 1.5 million times based on CY 2008 proposed rule claims data. CPT code 76376 was provided with CPT code 70450 less than 2 percent of the total instances that CPT code 70450 was billed. Therefore, as the frequency of CPT code 76376 provided in conjunction with CPT code 70450 increases, the median cost for CPT code 70450 would be more likely to reflect that additional cost.

The image processing services that we proposed to package vary in their hospital resource costs. Resource cost was not a factor we considered when we proposed to package supportive image processing services. Notably, the majority of image processing services that we proposed to package have modest median costs in relationship to the cost of the independent service that they typically accompany.

Several of these codes, including CPT code 76350 (Subtraction in conjunction with contrast studies), are already unconditionally (that is, always) packaged under the CY 2007 OPPS, where they have been assigned status indicator "N." Payment for these services is made as part of the payment for the separately payable, independent

services with which they are billed. No separate payment is made for services that we have assigned status indicator "N." We did not propose status indicator changes for the four image processing services that were unconditionally packaged for CY 2007.

We proposed to change the status indicator for seven image processing services from separately paid to unconditionally packaged (status indicator "N") for the CY 2008 OPPS. We believe that these services are always integral to and dependent upon the independent service that they support and, therefore, their payment would be appropriately packaged.

The estimated overall impact of these changes presented in section XXII.B. of the proposed rule (section XXIV.B. of this final rule with comment period) was based on the assumption that hospital behavior would not change with regard to when these dependent image processing services are performed on the same date and by the same hospital that performs the independent services. To the extent that hospitals could change their behavior and perform the image processing services more or less frequently, the data would show such a change in practice in future years and that change would be reflected in future budget neutrality adjustments.

As we indicated earlier, in all cases, we provided that hospitals that furnish the image processing procedure in association with the independent service must bill both services on the same claim. We indicated that we expected to carefully monitor any changes in billing practices on a service-specific and hospital-specific basis to determine whether there is reason to request that QIOs review the quality of care furnished or to request that Program Safeguard Contractors review the claims against the medical record.

The APC Panel recommended that all image processing services be packaged as proposed in the proposed rule.

We received a number of public comments on our proposal to package image processing service for CY 2008. A summary of the public comments and our responses follow.

Comment: Many commenters were concerned with the proposal to package payment for CPT code 93325 (Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)). The commenters noted that this service is often critical to decisionmaking and consumes significantly greater resources than the general echocardiography study process. Several commenters noted that the AMA is planning to

revise this CPT code for CY 2009, and that changing the payment status of this code may confuse hospital coding staff. Some commenters requested that CMS make no changes to the payment status of this code until this code's descriptor has been revised by the AMA, while others requested that CMS instruct hospitals not to use the new CPT code that will be created by the AMA.

Response: We acknowledge that this service may be an important clinical tool that is critical to decisionmaking. However, we continue to believe that packaged payment is appropriate for this dependent service that must, per the CY 2007 CPT book, be provided in conjunction with echocardiography. In fact, packaging the status of this code may make it easier to crosswalk the data from this code to the new CPT code that the AMA may create for CY 2009. We see no compelling reason to postpone packaging this service until CY 2009.

Comment: One commenter requested that CMS pay separately for HCPCS code G0288 (Reconstruction, computed tomographic angiography of aorta for surgical planning for vascular surgery) because it is different than the other image processing codes proposed for packaged payment. The commenter stated that the service is often an out-sourced service purchased by the hospital. The commenter was particularly concerned that hospitals would no longer continue to purchase this service if insufficient payment was provided. Another commenter requested separate payment for CPT code 95957 (Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis)). The commenter stated that this service is often performed on a different day than the EEG and by a technologist other than the one who performed the EEG.

Response: As noted above, we believe it is important to package payment for supportive dependent services that may not need to be provided face-to-face with the patient in the same encounter as the independent service. Packaging payment for supportive services that utilize data that were collected during the preceding independent services encourages the most efficient use of hospital resources. In fact, as part of our proposed CY 2008 packaging approach, we also proposed to unconditionally package payment in CY 2008 for several other image processing services that are not always performed face-to-face, including CPT codes 0174T (Computer aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of

film radiographic images, chest radiograph(s), performed concurrent with primary interpretation); 0175T ((Computer aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed remote from primary interpretation); and CPT code 76377 (3D rendering with interpretation and reporting of computed tomography, magnetic resource imaging, ultrasound, or other tomographic modality; requiring image postprocessing on an independent workstation).

We also believe it is likely that a hospital that performed the computed tomographic angiography diagnostic procedure but does not have the technology necessary to provide the preoperative image reconstruction would send the results to another hospital for performance of the reconstruction. In this situation, the second hospital would be providing the reconstruction under arrangement and, therefore, at least one service provided by the first hospital would be separately paid. We believe that packaged payment for image reconstruction under a prospective payment methodology for hospital outpatient services is most appropriate. The same situation occurs when hospitals provide the service described by CPT code 95957. We proposed to unconditionally package payment for HCPCS code G0288 and CPT code 95957 for CY 2008, fully consistent with the packaging approach for the CY 2008 OPPS. Because HCPCS code G0288 and CPT code 95957 are supportive ancillary services that fit into the image processing category, and we proposed to package payment for all image processing services for CY 2008, we believe it is appropriate to unconditionally package payment associated with these codes.

Specifically, we determined that these services are dependent services that are integral to independent services, in this case, the computed tomographic angiography and the EEG that we would expect to be provided. Even if the imaging process services were provided on another day than the independent services, our packaging methodology packages costs across dates of service on "natural" single claims, so that the costs of image process services would be captured.

For CY 2008, we are finalizing the packaged status of HCPCS code G0288 and CPT code 95957, as listed in Table 10 of the proposed rule. We note an inadvertent error in Addendum B to the

proposed rule. However, Table 10 of the proposed rule listed the accurate proposed payment status of HCPCS code G0288.

Comment: Many commenters supported the proposal to package each of the image processing services that was identified in the proposed rule. Numerous other commenters requested that CMS postpone packaging all the packaged codes included in all categories of the proposal until additional data were provided to the public. These commenters also submitted specific comments related to almost every image processing code that CMS proposed to package. The commenters expressed concern in several areas, specifically, that what they considered to be insufficient payment rates would discourage new technologies; that image processing services used infrequently with specific services contribute very little to the payment rates for those services; that the expected decrease in utilization for image processing services could ultimately lead to increased costs, as a result of worse patient outcomes; and in general, that the lack of published crosswalks makes it difficult to analyze the specific effects of this policy.

Several commenters requested a crosswalk that specified how the packaged costs were allocated from each dependent code to each independent code. Other commenters requested that CMS create edits to ensure that costs are appropriately mapped to independent codes. Several commenters requested that CMS consider resource cost when determining which codes to package. The commenters were concerned that what they considered to be insufficient payment would create a disincentive for hospitals to adopt new technology.

Response: We note that we did not receive any unique arguments specific to any particular code. These comments are similar to those received for all the categories of codes that we proposed for packaged payment. Therefore, we have responded to these general comments above in section II.A.4.c. of this final rule with comment period. In light of the public comments we received, our clinical advisors reassessed every image processing code on the list to ensure that it was still appropriate for packaged payment.

We received one comment related to CPT codes 0174T and 0175T. The comment summary and response related to those codes are located in section II.A.4.e. of this final rule with comment period.

For CY 2008, we are finalizing our proposal, without modification, to unconditionally package the payment

for all imaging processing codes listed in Table 10 of this final rule with comment period. We are accepting the APC Panel recommendation to package all image processing services. These services are assigned status indicator "N" to indicate their unconditional packaging.

(3) Intraoperative Services

We proposed to package payment for "intraoperative" HCPCS codes for CY 2008, specifically those codes that are reported for supportive dependent diagnostic testing or other minor procedures performed during independent procedures. We performed a broad search for possible intraoperative HCPCS codes, relying upon the AMA's CY 2007 book of CPT codes and the CY 2007 book of Level II HCPCS codes, to identify specific codes as "intraoperative" codes. Furthermore, we performed a clinical review of all HCPCS codes to capture additional supportive diagnostic testing or other minor intraoperative or intraprocedural codes that are not necessarily identified as "intraoperative" codes. For example, we proposed to package payment for CPT code 95955 (Electroencephalogram (EEG) during nonintracranial surgery (e.g., carotid surgery)) because it is a minor intraoperative diagnostic testing procedure even though the code descriptor does not indicate it as such. Although we use the term "intraoperative" to categorize these procedures, we also have included supportive dependent services in this group that are provided during an independent procedure, although that procedure may not necessarily be a surgical procedure. These dependent services clearly fit into this category because they are provided during, and are integral to, an independent procedure, like all the other intraoperative codes, but the independent procedure they accompany may not necessarily be a surgical procedure. For example, we proposed to package HCPCS code G0268 (Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing). While specific audiologic function testing procedures are not surgical procedures performed in an operating room, they are independent procedures that are separately payable under the OPPS, and HCPCS code G0268 is a supportive dependent service always provided in association with one of these independent services. All references to "intraoperative" below refer to services that are usually or always provided during a surgical procedure or other independent procedure.

By definition, a service that is performed intraoperatively is provided during and, therefore, on the same date of service as another procedure that is separately payable under the OPPS. Because these intraoperative services support the performance of an independent procedure and they are provided in the same operative session as the independent procedure, we believed it would be appropriate to package their payment into the OPPS payment for the independent procedure performed. Therefore, we did not propose to package payment for CY 2008 for those diagnostic services, such as CPT code 93005 (Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report) that are sometimes or only rarely performed and reported as supportive services in association with other independent procedures. Instead, we proposed to include those HCPCS codes that are usually or always performed intraoperatively, based upon our review of the codes described above. The intraoperative services that we proposed to package vary in hospital resource costs. Resource cost was not a factor we considered when determining which supportive intraoperative procedures to package.

The codes we proposed to identify as intraoperative services for CY 2008 that would receive packaged payment under the OPPS were listed in Table 12 of the proposed rule (72 FR 42661 through 42662).

Several of these codes, including CPT code 93640 (Electrophysiologic evaluation of single or dual chamber pacing cardioverter-defibrillator leads including defibrillation threshold evaluation (induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination) at the time of initial implantation or replacement), are already unconditionally (that is, always) packaged under the CY 2007 OPPS, where they have been assigned status indicator "N." Payment for these services is made through the payment for the separately payable, independent services with which they are billed. No separate payment is made for services that we have assigned status indicator "N." We did not propose status indicator changes for the five diagnostic intraoperative services that were unconditionally packaged for CY 2007.

We proposed to change the status indicator for 34 intraoperative services from separately paid to unconditionally packaged (status indicator "N") for the CY 2008 OPPS. As stated in the CY 2008 proposed rule, we believe that these services are always integral to and dependent upon the independent

services that they support and, therefore, their payment would be appropriately packaged because they would generally be performed on the same date and in the same hospital as the independent services.

We also proposed to change the status indicator for one intraoperative procedure from unconditionally packaged to conditionally packaged (status indicator "Q") as a "special" packaged code for the CY 2008 OPPS, specifically, CPT code 0126T (Common carotid intima-media thickness (IMT) study for evaluation of atherosclerotic burden or coronary heart disease risk factor assessment). This code was discussed in the past with the Packaging Subcommittee of the APC Panel, which determined that, consistent with its code descriptor as a separate procedure, this procedure could sometimes be provided alone, without any other OPPS services on the claim. We believed that this procedure would usually be provided by a hospital in conjunction with another independent procedure on the same date of service but may occasionally be provided without another independent service. As a "special" packaged code, if the study were billed without any other service assigned status indicator "S," "T," "V," or "X" reported on the same date of service, under our proposal we proposed not to treat the IMT study as a dependent service for purposes of payment. If we were to continue to unconditionally package payment for this procedure, treating it as a dependent service, hospitals would receive no payment at all when providing this service alone, although the procedure would not be functioning as an intraoperative service in that case. However, according to our proposal, its conditionally packaged status as a "special" packaged code would allow payment to be provided for this "Q" status IMT study when provided alone, in which case it would be treated as an independent service under these limited circumstances. On the other hand, when this service is furnished as an intraoperative procedure on the same day and in the same hospital as independent, separately paid services that are assigned status indicator "S," "T," "V," or "X," we proposed to package payment for it as a dependent service. In all cases, we proposed that hospitals that furnish independent services on the same date as this IMT procedure must bill them all on the same claim. We believed that when dependent and independent services are furnished on the same date and in the same facility, they are part of a single

complete hospital outpatient service that is reported with more than one HCPCS code, and no separate payment should be made for the intraoperative procedure that supports the independent service.

The estimated overall impact of these changes presented in section XXII.B. of the proposed rule (section XXIV.B. of this final rule with comment period) was based on the assumption that hospital behavior would not change with regard to when these intraoperative dependent services are performed on the same date and by the same hospital that performs the independent services. To the extent that hospitals could change their behavior and perform the intraoperative services more or less frequently, on subsequent dates, or at settings outside of the hospital, the data would show such a change in practice in future years and that change would be reflected in future budget neutrality adjustments. However, with respect to intraoperative services in particular, we believed that hospitals are limited in the extent to which they could change their behavior with regard to how they furnish these services. By their definition, these intraoperative services generally must be furnished on the same date and at the same operative location as the independent procedure in order to be considered intraoperative. For these codes, we assume that both the dependent and independent services would be furnished on the same date in the same hospital, and hospitals should bill them on the same claim with the same date of service.

As we indicated earlier, in all cases we provided that hospitals that furnish the intraoperative procedure on the same date as the independent service must bill both services on the same claim. We expect to carefully monitor any changes in billing practices on a service-specific and hospital-specific basis to determine whether there is reason to request that QIOs review the quality of care furnished or to request that Program Safeguard Contractors review the claims against the medical record.

During the September 2007 APC Panel meeting, the Panel recommended that CMS finalize the proposal to package intraoperative services and that CMS consider assigning status indicator "Q" to CPT code 96020 (Neurofunctional testing selection and administration during noninvasive imaging functional brain mapping, with test administered entirely by a physician or psychologist, with review of test results and report).

We received many public comments on our proposal to package

intraoperative services for CY 2008. A summary of the public comments and our responses follow.

Comment: Several commenters requested that CMS change the status of CPT code 96020 to conditionally packaged or separately payable instead of finalizing the proposal to unconditionally package this code. According to the commenters, functional brain mapping is often performed prior to epilepsy surgery. The commenters noted that functional brain mapping is performed by staff other than the neurologist or neuropsychologist who performs the accompanying functional MRI, reported with CPT code 70555 (Magnetic resonance imaging, brain, functional MRI; requiring physician or psychologist administration of entire neurofunctional testing). One commenter clarified that functional MRI is more commonly performed without functional brain mapping. If CPT code 96020 were conditionally packaged, the commenter believed that separate payment should be made for CPT code 96020 when it was provided with the functional MRI. Another commenter stated that functional brain mapping is a separate service from the functional MRI, and therefore should not be packaged.

Response: The AMA 2007 CPT book specifically states that CPT code 70555 can only be reported if CPT code 96020 is also performed. CPT code 70555 is separately payable under the CY 2008 OPPS. Therefore, whenever CPT code 70555, the independent procedure, is billed with CPT code 96020, the dependent procedure, the payment associated with CPT code 96020 is appropriately packaged into the payment for CPT code 70555. Even if CPT code 96020 were conditionally packaged, separate payment would not be made when it was billed with CPT code 70555. In addition, we believe that functional brain mapping is never provided to a patient as a sole service. Instead, it is always provided in conjunction with a functional MRI. Therefore, we continue to believe that unconditional packaging is appropriate for CPT code 96020.

Comment: Many commenters requested that CMS continue to pay separately for intravascular ultrasound (IVUS), fractional flow reserve (FFR), and intracardiac echocardiography (ICE) reported with CPT codes 37250 (Intravascular ultrasound (non-coronary vessel) during diagnostic evaluation and/or therapeutic intervention; initial vessel (List separately in addition to code for primary procedure)); 37251 (Intravascular ultrasound (non-coronary

vessel) during diagnostic evaluation and/or therapeutic intervention; each additional vessel (List separately in addition to code for primary procedure)); 75946 (Intravascular ultrasound (non coronary vessel), radiological supervision and interpretation; each additional non-coronary vessel (List separately in addition to code for primary procedure)); 92978 (Intravascular ultrasound (coronary vessel or graft) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; initial vessel (List separately in addition to code for primary procedure)); 92979 (Intravascular ultrasound (coronary vessel or graft) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; each additional vessel (List separately in addition to code for primary procedure)); 93571 (Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; initial vessel (List separately in addition to code for primary procedure)); 93572 (Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; each additional vessel (List separately in addition to code for primary procedure)); and 93662 (Intracardiac echocardiography during therapeutic/ diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)).

The commenters noted that, while use of these procedures often results in better patient outcomes and reduced need for subsequent procedures, they are only provided to a small proportion of patients who undergo stenting, angioplasty, and other related services. A number of commenters specified that IVUS is performed on 1 to 20 percent of patients who undergo a related diagnostic or therapeutic intervention, using Medicare claims and internal hospital assessments. Therefore, the commenters stated that the costs for IVUS, FFR, and ICE do not affect the payment rates for the independent procedures in a significant way, if at all. In addition, the commenters noted that IVUS, in particular, involves high resource costs because of expensive capital equipment, significant labor cost, and disposable supplies. Several commenters noted that the CY 2005

OPPS data included a median cost of \$2,000 for IVUS, with approximately \$800 of those costs related solely to the device component. One commenter stated that IVUS may be performed in conjunction with a diagnostic procedure that maps to an APC such as 0080 (Diagnostic Cardiac Catheterization); 0267 (Level III Diagnostic and Screening Ultrasound); or 0280 (Level III Angiography and Venography), rather than a major therapeutic procedure such as stenting or angioplasty, resulting in a total payment of \$150 to \$2,500, which would not cover the hospital's costs. Other commenters elaborated on the costs associated with ICE, which is reported with the corresponding independent services described by CPT codes 93621 (Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left atrial pacing and recording from coronary sinus or left atrium (List separately in addition to code for primary procedure)); 93622 (Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left ventricular pacing and recording (List separately in addition to code for primary procedure)); 93651 (Intracardiac catheter ablation of arrhythmogenic focus; for treatment of supraventricular tachycardia by ablation of fast or slow atrioventricular pathways, accessory atrioventricular connections or other atrial foci, singly or in combination); and 93652 (Intracardiac catheter ablation of arrhythmogenic focus; for treatment of ventricular tachycardia), in only 5 percent of the claims involving the above procedures. The commenters also noted that only 14 percent of hospitals billed ICE with the CPT codes listed above, indicating that the impact of packaged payment will affect a subset of hospitals who invested in this capital equipment. One commenter noted that IVUS and ICE are clearly not integral to any independent procedure because they are used infrequently. Other commenters noted that costs will be improperly allocated to hospitals that perform the independent procedure, regardless of whether they purchased the equipment for the dependent procedure. One commenter disputed describing FFR services as "ancillary" and stated that they are "decisional" and therefore should not be packaged. The commenters expressed concern that packaged payment will create a

significant financial disincentive to provide these services. The commenters also noted that these procedures should not be described as “intraoperative” because they precede the independent procedure, and may even result in canceling the independent procedure. One commenter requested that CMS assign status indicator “Q” to CPT codes 93571 and 93572. On the other hand, several commenters specified that these services are not stand alone procedures. One commenter stated that it is illegal under section 1833(t)(2)(G) of the Act to package payment for IVUS and FFR, which do not use contrast agents, into payment for coronary or peripheral angiography, which require contrast agents. Specifically, the commenter summarized the Act which states that CMS must create payment groups under the OPSS that “classify separately those procedures that utilize contrast agents from those that do not.”

Response: We appreciate the many thoughtful comments related to the packaged status of IVUS, FFR, and ICE services. We acknowledge that the costs associated with packaged services may contribute more or less to the median cost of the independent service, depending on how often the dependent service is billed with the independent service. It is our goal to adhere to the principles inherent in a prospective payment system and to encourage hospitals to utilize resources in a cost-effective manner. In this case, hospitals must choose whether to utilize IVUS, FFR, and ICE, balancing the needs of the patient with the costs associated with the services.

We continue to believe that IVUS, FFR, and ICE are dependent services that are always provided in association with independent services. This is different than stating that every angioplasty or other related independent procedure utilizes IVUS, FFR, or ICE. In fact, all of the codes about which we received comment are listed as add-on codes in the CY 2007 CPT book. While we agree that some of these services may contribute to decisionmaking, we still believe that these services are never provided without another independent service on the same day. Therefore, we do not believe it is appropriate to assign status indicator “Q” to CPT codes 93571 and 93572, or any of the other IVUS, FFR, or ICE services.

While the statute requires us to establish separate APCs for those services that require contrast and those that do not require contrast, the statute does not state a similar requirement for the packaged services that are ancillary and supportive to the main independent

procedure. In this case, IVUS, FFR, and ICE are not the services themselves that must be mapped to contrast or noncontrast APCs for payment. Instead, independent services must map to contrast or noncontrast APCs, as we have done. IVUS, FFR, and ICE are similar to other supportive packaged services, including drugs and anesthesia. Packaged codes never map to an APC, and, therefore, it is unnecessary to distinguish whether they require contrast agents or not. Instead, the independent procedure must map to a contrast or noncontrast APC.

For the reasons stated above, we are finalizing our proposal to unconditionally package payment for IVUS, FFR, and ICE services for CY 2008.

Comment: One commenter requested that CMS conditionally package payment for CPT code 75898 (Angiography through existing catheter for follow-up study for transcatheter therapy, embolization or infusion), instead of finalizing the proposal to unconditionally package payment for this service. The commenter clarified that this is often the only service performed when a patient has lengthy thrombolytic therapy.

Response: We agree with the commenter that this code should be conditionally packaged rather than unconditionally packaged, so that separate payment is made when this service is provided without any other separately payable services on the same date of service. We are changing the status indicator for CPT code 75898 to “Q” for CY 2008 and including it as an “STVX-packaged” code. When provided on the same date of service as other separately payable services, payment for CPT code 75898 will be packaged into payment for the other services.

Comment: One commenter requested that CMS continue to pay separately for CPT codes 67299 (Unlisted procedure, posterior segment) and 95999 (Unlisted neurological or neuromuscular diagnostic procedure). These codes describe unlisted procedures, and the commenter explained that it would be impossible to know whether the services they describe should be appropriately packaged or separately paid.

Response: We agree with the commenter that CPT codes 67299 and 95999 should not be packaged under the OPSS for CY 2008 because they are unlisted procedures. Therefore, we are finalizing a separately payable status indicator and APC assignment for them in Addendum B to this final rule with comment period.

Comment: Many commenters supported the proposal to package payment for all intraoperative services and recommended that CMS finalize the proposal without modification. Several commenters requested that CMS pay separately for other intraoperative services that it proposed to package for CY 2008, but did not present unique arguments specific to any code.

Response: We agree with commenters that packaging payment for intraoperative services is consistent with the principles of the OPSS and will help contain costs while creating an incentive for hospitals to utilize resources in a cost efficient manner. We understand that hospitals would prefer if certain intraoperative services were paid separately. In light of the public comments we received, our clinical advisors reassessed each intraoperative code on the list to ensure that it was still appropriate for packaged payment. However, we did not see any compelling reason to pay separately for any of the intraoperative services that were not already discussed and revised above.

For CY 2008, we are finalizing our CY 2008 proposal, with modification, to package the payment for all intraoperative HCPCS codes with three exceptions. Specifically, we are finalizing all of the packaging changes we proposed, with the exception of conditionally packaging CPT code 75898 as an “STVX-packaged” code and paying separately for CPT codes 67299 and 95999. Except as otherwise specified above, we are fully adopting the APC Panel recommendation to package all intraoperative services and to review the status indicator of CPT code 96020. Table 10 of this final rule with comment period includes the final comprehensive list of all codes in the seven categories that are packaged for CY 2008.

(4) Imaging Supervision and Interpretation Services

We proposed to change the packaging status of many imaging supervision and interpretation codes for CY 2008. We define “imaging supervision and interpretation codes” as HCPCS codes for services that are defined as “radiological supervision and interpretation” in the radiology series, 70000 through 79999, of the AMA CY 2007 book of CPT codes, with the addition of some services in other code ranges of CPT, Category III CPT tracking codes, or Level II HCPCS codes that are clinically similar or directly crosswalk to codes defined as radiological supervision and interpretation services in the CPT radiology range. We also

included HCPCS codes that existed in CY 2006 but were deleted and were replaced in CY 2007. We included the CY 2006 HCPCS codes because we proposed to use the CY 2006 claims data to calculate the CY 2008 OPPS median costs on which the CY 2008 payment rates would be based.

In its discussion of "radiological supervision and interpretation," CPT indicates that "when a procedure is performed by two physicians, the radiologic portion of the procedure is designated as 'radiological supervision and interpretation.'" In addition, CPT guidance notes that, "When a physician performs both the procedure and provides imaging supervision and interpretation, a combination of procedure codes outside the 70000 series and imaging supervision and interpretation codes are to be used." In the hospital outpatient setting, the concept of one or more than one physician performing related procedures does not apply to the reporting of these codes, but the radiological supervision and interpretation codes clearly are established for reporting in association with other procedural services outside the CPT 70000 series. Because these imaging supervision and interpretation codes are always reported for imaging services that support the performance of an independent procedure and they are, by definition, always provided in the same operative session as the independent procedure, we believe that it is appropriate to package their payment into the OPPS payment for the independent procedure performed.

In addition to radiological supervision and interpretation codes in the radiology range of CPT codes, there are CPT codes in other series that describe similar procedures that we proposed to include in the group of imaging supervision and interpretation codes proposed for packaging under the CY 2008 OPPS. For example, CPT code 93555 (Imaging supervision, interpretation and report for injection procedure(s) during cardiac catheterization; ventricular and/or atrial angiography) whose payment under the OPPS is currently packaged, is commonly reported with an injection procedure code, such as CPT code 93543 (Injection procedure during cardiac catheterization; for selective left ventricular or left atrial angiography), whose payment is also currently packaged under the OPPS, and a cardiac catheterization procedure code, such as CPT code 93526 (Combined right heart catheterization and retrograde left heart catheterization), that is separately paid. In the case of cardiac catheterization,

CPT code 93555 describes an imaging supervision and interpretation service in support of the cardiac catheterization procedure, and this dependent service is clinically quite similar to radiological supervision and interpretation codes in the radiology range of CPT. Payment for the cardiac catheterization imaging supervision and interpretation services has been packaged since the beginning of the OPPS. Therefore, in developing the proposal for the CY 2008 proposed rule, we conducted a comprehensive clinical review of all Category I and Category III CPT codes and Level II HCPCS codes to identify all codes that describe imaging supervision and interpretation services. The codes we proposed to identify as imaging supervision and interpretation codes for CY 2008 that would receive packaged payment were listed in Table 14 of the proposed rule (72 FR 42665–42667).

Several of these codes, including CPT code 93555 discussed above, are already unconditionally (that is, always) packaged under the CY 2007 OPPS, where they have been assigned status indicator "N." Payment for these services is made as part of the payment for the separately payable, independent services with which they are billed. No separate payment is made for services that we have assigned to status indicator "N." We did not propose status indicator changes for the six imaging supervision and interpretation services that were unconditionally packaged for CY 2007.

We proposed to change the status indicator for 33 imaging supervision and interpretation services from separately paid to unconditionally packaged (status indicator "N") for the CY 2008 OPPS. We believed that these services are always integral to and dependent upon the independent services that they support and, therefore, their payment would be appropriately packaged because they would generally be performed on the same date and in the same hospital as the independent services.

We proposed to change the status indicator for 93 imaging supervision and interpretation services from separately paid to conditionally packaged (status indicator "Q") as "special" packaged codes for the CY 2008 OPPS. These services may occasionally be provided at the same time and at the same hospital with one or more other procedures for which payment is currently packaged under the OPPS, most commonly injection procedures, and in these cases we would not treat the imaging supervision and interpretation services as dependent services for purposes of payment. If we

were to unconditionally package payment for these imaging supervision and interpretation services as dependent services, hospitals would receive no payment at all for providing the imaging supervision and interpretation service and the other minor procedure(s). However, according to our proposal, their conditional packaging status as "special" packaged codes would allow payment to be provided for these "Q" status imaging supervision and interpretation services as independent services in these limited circumstances, and for which payment for the accompanying minor procedure would be packaged. However, when these imaging supervision and interpretation dependent services are furnished on the same day and in the same hospital as independent separately paid services, specifically, any service assigned status indicator "S," "T," "V," or "X," we proposed to package payment for them as dependent services. In all cases, we proposed that hospitals that furnish the independent services on the same date as the dependent services must bill them all on the same claim. We believe that when the dependent and independent services are furnished on the same date and in the same hospital, they are part of a single complete hospital outpatient service that is reported with more than one HCPCS code, and no separate payment should be made for the imaging supervision and interpretation service that supports the independent service.

In the case of services for which we proposed conditional packaging, we indicated that we would expect that, although these services would always be performed in the same session as another procedure, in some cases that other procedure's payment would also be packaged. For example, CPT code 73525 (Radiological examination, hip, arthrography, radiological supervision and interpretation) and CPT code 27093 (Injection procedure for hip arthrography; without anesthesia) could be provided in a single hospital outpatient encounter and reported as the only two services on a claim. In the case where only these two services were performed, the conditionally packaged status of CPT code 73525 would appropriately allow for its separate payment as an independent imaging supervision and interpretation arthrography service, into which payment for the dependent injection procedure would be packaged.

The estimated overall impact of these changes presented in section XXII.B. of the proposed rule (section XXIV.B. of this final rule with comment period) was based on the assumption that

hospital behavior would not change with regard to when these dependent services are performed on the same date and by the same hospital that performs the independent services. To the extent that hospitals could change their behavior and perform the imaging supervision and interpretation services more or less frequently, on subsequent dates, or at settings outside of the hospital, the data would show such a change in practice in future years and that change would be reflected in future budget neutrality adjustments. However, with respect to the imaging supervision and interpretation services in particular, we believed that hospitals are limited in the extent to which they could change their behavior with regard to how they furnish these services. By their definition, these imaging and supervision services generally must be furnished on the same date and at the same operative location as the independent procedure in order for the imaging service to meaningfully contribute to the diagnosis or treatment of the patient. For those radiological supervision and interpretation codes in the radiology range of CPT in particular, if the same physician is able to perform both the procedure and the supervision and interpretation as stated by CPT, we assume that both the dependent and independent services would be furnished on the same date in the same hospital, and hospitals should bill them on the same claim with the same date of service.

As we indicated earlier in this section, in all cases, we are providing that hospitals that furnish the imaging supervision and interpretation service on the same date as the independent service must bill both services on the same claim. We expect to carefully monitor any changes in billing practices on a service-specific and hospital-specific basis to determine whether there is reason to request that QIOs review the quality of care furnished or to request that Program Safeguard Contractors review the claims against the medical record.

During the September 2007 APC Panel meeting, the APC Panel recommended that CMS delay packaging the imaging supervision and interpretation services because of the reductions in payment that would occur for services that would only be paid separately if they occurred with other minor procedures that are already packaged. The Panel was concerned about the proposed reductions in payment for typical combinations of expensive imaging services. The Panel asked that CMS develop an alternative

model for these services and present it at the next APC Panel meeting.

We received many public comments on our proposal to package imaging supervision and interpretation services for CY 2008. A summary of the public comments and our response follows.

Comment: Many commenters objected to the packaging of imaging supervision and interpretation services. They asserted that the proposal would, in many cases, excessively reduce payments because the proposal packaged the cost of the service into one or more services that are already packaged or would inappropriately package the cost of expensive imaging supervision and interpretation services into more minor services, like visits or minor diagnostic tests. The commenters believed that this would result in little or no payment being made for the more expensive services provided in an encounter. Other commenters suggested that CMS package only the 33 codes for which the associated surgical service is separately paid but not package the 93 codes proposed to be conditionally packaged because payments would be excessively reduced. As an alternative, one commenter suggested that CMS review claims data for the 93 imaging supervision and interpretation codes proposed to be assigned status indicator "Q" to identify high volume combinations of services and evaluate the combinations for creation of composite APCs. For example, the commenter suggested that CMS could create a composite APC for CPT codes 72265 (Myelography, lumbosacral, radiological supervision and interpretation) and 72132 (Computed tomography lumbar spine, with contrast material) that would ensure that the full payment for CPT code 72265 would always be made when furnished with CPT code 72132. The commenter was concerned that CMS could "overpay" lumbar CT when no myelography was furnished but could "underpay" when myelography is performed without lumbar computed tomography (CT) but in addition to another minor services such as an emergency department visit or other radiological service. Like others, the commenter was concerned that, as proposed, if an expensive imaging supervision and interpretation service is billed on the same date as a visit, the visit would be paid and the expensive service would not be paid.

Some commenters believed that the absence of consideration of how payment would be made when unrelated services or packaged services were the only other services on the claim demonstrated that the CMS proposal was not carefully or

sufficiently analyzed prior to being proposed and should not be made final. The commenters cited several examples of packaging with minor services or packaged services that they view as common, which they believe illuminate the problems with packaging imaging supervision and interpretation services. The commenters asserted that CMS should ensure that no service is packaged into a service that is already packaged. Some commenters believed that the proposed policy would reduce payment for important interventional imaging services by 25 percent in the aggregate, would cause CMS to use fewer claims for ratesetting, and would result in access problems for patients. Some commenters stated that the methodology reduces the number of records that could be used to value these imaging codes for separate payment, thereby resulting in costs that would be much lower than would be the case if the medians were calculated with a higher number of claims.

The commenters explained that some of the most common scenarios for the services that are assigned to APC 0280 (Level III Angiography and Venography) and are proposed for packaging are comparable to cardiac catheterization (APC 0080 (Diagnostic Cardiac Catheterization)) in time, equipment, supply, and labor but under the CMS proposal, the payment made under APC 0280 would be significantly less than the payment for APC 0080. Therefore, the commenters asked that the proposal to package services in APCs 0279 (Level II Angiography and Venography), 280, and 668 (Level I Angiography and Venography) not be adopted in CY 2008 because the packaging would result in payments that are much less than the cost of furnishing the services. One commenter added that it is methodologically circular and unreasonable to package payment for services that already include other packaged services.

Response: We have carefully considered the comments of the APC Panel and the many thoughtful public comments we received on the proposal to package imaging supervision and interpretation services for the CY 2008 OPPS. We spent considerable time and effort in analysis of the data as we developed our proposed rule, and we appreciate the helpful comments we received on this issue. We have decided to finalize our proposal to package these services after refining our methodology for estimating the median cost of conditionally packaged codes assigned status indicator "Q" to address concerns that packaging significant services into services that either are already packaged

or are minor services leads to underpayment and concerns that the proposal reduced the number of claims available for setting APC medians for these services. We agree that we should not pay for a more minor service, such as a visit or minor diagnostic procedure, when the conditionally packaged imaging supervision and interpretation services require more resources. We have modified the conditionally packaged status of these services to be specific to surgical procedures and called them "T-packaged services." The payment for these imaging supervision and interpretation codes will be packaged into the payment for services with a status indicator "T" when they appear on the same date as the surgical procedure. When these imaging supervision and interpretation services appear with other codes that have any other payable status indicator ("S," "V," or "X") or with other services that have

a status indicator "Q" on the same date, we would pay one unit of the "T-packaged" service with the highest relative payment weight. We discuss how we split the claims to acquire "T-packaged" single bills that represent all of the resource costs associated with the conditionally packaged service in greater detail in section II.A.2. of this final rule with comment period. The ratesetting methodology specifically includes single bill claims for T-packed services that represent the costs of multiple services with status indicator "Q" and other packaged services. We believe that this resolves many of the payment concerns with regard to our proposal to treat the majority of supervision and interpretation codes as conditionally packaged codes. These refinements to our methodology significantly raised the median costs for a number of these services compared to the proposed rule median costs.

Furthermore, the refinements, especially those creating single bills from multiple minor claims, allowed us to use many more claims to estimate a median cost for these conditionally packaged codes and, therefore, to develop an APC median cost estimate that better reflects the resources consumed by these services that are commonly performed in combination with one another.

We believe that our changes have resulted in resolution of many of the concerns raised by the commenters and the APC Panel. There were a number of specific examples cited by the commenters to illustrate their concerns on this issue. We include the commenters' examples below, expanded to add the CY 2008 final rule payment. In the examples below, "pkg" means payment is packaged; "na" means not applicable.

EXAMPLE 1.—MYLEOGRAPHY AND LUMBOSACRAL CT WITH CONTRAST

HCPCS Code	Descriptor	CY 2007 APC	CY 2007 SI	CY 2007 Payment	CY 2008 Proposed payment	CY 2008 APC	CY 2008 SI	CY 2008 Final payment
72265	Contrast X-ray lower spine	0274	S	\$157.01 ...	pkg	0274	Q	\$481.46
72132	CT lumbar spine w/dye	0283	S	\$250.94 ...	\$751.09	0283	S	\$277.48
Sum	\$407.95 ...	\$751.09	\$758.94

EXAMPLE 2.—ANGIOGRAPHY, CAROTID, CERVICAL, VERTEBRAL AND/OR INTRACRANIAL

HCPCS Code	Descriptor	CY 2007 APC	CY 2007 SI	CY 2007 Payment	CY 2008 Proposed payment	CY 2008 APC	CY 2008 SI	CY 2008 Final payment
36216	Place catheter in artery	N	pkg	pkg	na	N	pkg
36215	Place catheter in artery	N	pkg	pkg	na	N	pkg
36217	Place catheter in artery	N	pkg	pkg	na	N	pkg
36216-59	Place catheter in artery	N	pkg	pkg	na	N	pkg
75671	Artery Xrays head and neck	0280	S	\$1,279.92	pkg	0280	Q	\$2,847.85
75680	Artery Xrays, neck	0280	S	\$1,279.92	pkg	0279	Q	pkg
75685X2	Artery Xrays, spine	0280	S	\$2,559.84	\$1,442.28	0279	Q	pkg
Sum	\$5,119.68	\$1,442.28	\$2,847.85

Note: Several commenters submitted this example or this example with minor variation. The final payment for this service in its entirety is similar to the payment for cardiac catheterization (APC 0080), to which the commenters compared this service.

EXAMPLE 3.—EVALUATION AND PERCUTANEOUS REVASCULARIZATION OF GRAFT

HCPCS Code	Descriptor	CY 2007 APC	CY 2007 SI	CY 2007 Payment	CY 2008 Proposed payment	CY 2008 APC	CY 2008 SI	CY 2008 Final payment
36145X2	Place catheter in artery	na	N	pkg	pkg	na	N	pkg
75790	Visualize A-V shunt	0279	S	\$584.32 ...	pkg	0668	Q	pkg
G0393	A-V fistula or graft venous	0081	T	\$2,639.19	\$2,934.24	0083	T	\$2,890.72
75978X2	Repair venous blockage	0668	S	\$767.90 ...	pkg	0083	Q	pkg
35476	Repair venous blockage	0081	T	\$1,319.60	\$1,467.37	0083	T	\$1,445.36
Sum	\$5,311.01	\$4,401.61	\$4,336.08

EXAMPLE 4.—DIAGNOSTIC ANGIOGRAPHY WITH BALLOON ANGIOPLASTY OF SUPERFICIAL FEMORAL ARTERY

HCPCS Code	Descriptor	CY 2007 APC	CY 2007 SI	CY 2007 Payment	CY 2008 Proposed payment	CY 2008 APC	CY 2008 SI	CY 2008 Final payment
75625	Contrast Xray exam of aorta	0280	S	\$1,279.92	pkg	0279	Q	pkg
75716	Artery Xrays, arms/legs	0280	S	\$1,279.92	pkg	0279	Q	pkg
75774	Artery Xray, each vessel	0279	S	\$584.32 ...	pkg	na	N	pkg
75774	Artery Xray, each vessel	0279	S	\$584.32 ...	pkg	na	N	pkg
36247	Place catheter in artery		N		pkg	na	N	pkg
35474	Repair arterial blockage	0081	T	\$2,639.19	\$2,934.24	0083	T	\$2,890.72
35474	Repair arterial blockage	0081	T	\$1,319.60	\$1,467.37	0083	T	\$1,445.36
75962	Repair atrial blockage	0668	S	\$383.95 ...	pkg	0083	Q	pkg
75964	Repair artery blockage, each	0668	S	\$383.95 ...	pkg	na	N	pkg
Sum	\$8,455.17	\$4,401.61	\$4336.08

Comment: Some commenters believed that CMS should not package imaging supervision and interpretation services because CMS did not conduct a sufficiently thorough analysis of the many ways that CPT codes can be reported for services where there could be more than one surgical CPT code associated with a single imaging supervision and interpretation service. The commenters stated that these codes are created on a “component” basis to deal effectively with the huge variation in the combinations of services that could occur.

Response: We disagree with the commenters. We acknowledge that the APC Panel and the commenters raised concerns about the packaging of these services that we did not fully anticipate in development of the proposed rule. However, the purpose of the APC Panel and the exposure of the proposal to public comment are to raise issues for our consideration as we develop final policies for the final rule. We appreciate the assistance of the APC Panel and the many thoughtful public comments we received on the proposal to package these codes. We recognize that the codes are created as they exist, in order to describe many different treatment scenarios through the use of multiple and varied combinations of codes. As we discuss above, we have developed a methodology that addresses the concerns raised by the commenters and, as such, continue to believe that it is appropriate to package these services for CY 2008.

Comment: Some commenters believed that the revenue code to CCR mapping for these services is problematic because most are billed with revenue code 0361 and revenue code 0361 is mapped to the surgery cost center. However, as the commenters pointed out, most of these procedures are performed in the imaging department or the heart catheterization laboratory and,

therefore, their median cost calculation is highly suspect.

Response: We do not view the unknown amount of error that occurs as a result of a theoretical conflict between the revenue code reported for a service and the CCR used to reduce that charge to an estimated cost as justification to not package these services. The costs we calculate for purposes of establishing median costs for ratesetting are estimated costs and as such, in general, there is error in them to the extent that the charges are reported under a revenue code that maps to a cost center in which the costs for the services are not found. Hospitals select the revenue codes with which they report services to Medicare and other payers for a wide range of reasons over which CMS generally exercises no control. The CMS crosswalk of revenue codes to cost centers is available for inspection and comment at the CMS Web site at: <http://www.cms.hhs.gov/HospitalOutpatientPPS/>. Hospitals that want to ensure that the correct CCR is applied to a service could, if they chose, use this crosswalk to select either the revenue codes to report or the cost center to use for costs reported with a particular revenue code.

Comment: Some commenters believed that implementation of the imaging and supervision packaging would present huge operational challenges for hospitals to ensure that codes and charges continue to be billed so that the data in future years will be acceptable as the basis for setting relative weights for the OPSS. The commenters stated that hospitals will cease to report the codes and charges for the services that are no longer separately paid and that the costs of the services will then be lost to the payment system and the median costs for the services that should carry the packaging will be inappropriately low.

Response: The commenters did not articulate how implementation of the

imaging supervision and interpretation packaging proposal would present huge operational challenges for hospitals to ensure that the codes and charges continue to be billed so that future claims will contain the necessary costs for setting relative weights for the OPSS. Hospitals need only continue to report the codes and charges for all of the services they furnish. There are no new billing requirements associated with this change in payment policy. Moreover, hospitals are required to charge the same amount to all payers for the same services. We understand that many private payers continue to pay a percent of charges, creating incentives for hospitals to report and charge for all services furnished to all patients.

Comment: Some commenters suggested that CMS update the OPSS packaging policies to address newly added or deleted codes.

Response: We routinely review all new or revised HCPCS codes each year to determine what status indicator to assign and whether other changes to our files are needed. We also indicate new codes with a change indicator in Addendum B to this final rule with comment period, and we solicit public comments on the interim APC placement and status indicator we assign to them for those HCPCS codes designated with comment indicator “NI” in the final rule with comment period. We do not review deleted codes because they naturally fall out of the system, beginning in the claims for the period in which they are deleted, although we continue to assign their claims data for ratesetting purposes.

Comment: Some commenters expressed concerns with the treatment of the claims data for imaging supervision and interpretation codes with status indicator “Q” with regard to the impact on the number of multiple procedure claims. Some commenters stated that reporting packaged services

will create more multiple procedure bills that will not be used to set rates.

Response: The reporting of packaged services will not result in more multiple procedure claims because the packaged service, which has a status indicator of "N" for data purposes, unless it is changed to be separately paid, will not by itself cause a claim to be viewed as a multiple major procedure claim. Moreover, if packaged services and their charges are not reported, the payment for the services into which their cost is packaged may be understated. Therefore, it is important that hospitals report all services furnished and the associated charges.

Comment: Some commenters indicated that where there are multiple codes with status indicator "Q" on a claim and no separately paid services, they are assigned status indicator "N" and sent to multiple minors because the assignment of the status indicator "N" happens before the split. They suggested that if the assignment happened after the split and after the "pseudo" single creation, they could be used in the median calculation for the APC.

Response: The commenter correctly describes how codes with status indicator "Q" were treated in this circumstance for the proposed rule data. We agree that claims with multiple occurrences of codes with status indicator "Q" should be used to estimate the APC median cost through which they will be separately paid. In response to the public comments we received, we have revised the data process in several places to address the estimation of costs for services with a status indicator of "Q." (See section II.A.2.b. of this final rule with comment period for further discussion of the changes to the data process.) With regard to this particular comment, we continue to assign claims with multiple "Q" procedure or packaged services to the multiple minor file. We then create additional single bills from the multiple minor file by identifying which conditionally packaged code will be the prime code that will carry the packaging by selecting the conditionally packaged code with the highest payment for CY 2007 and packaging all costs of the other codes into the cost for that code. We also set the units to one for the prime code to reflect our policy of only paying one unit of a service for codes with a status indicator of "Q." That claim then becomes a single procedure claim assigned to the APC to which the prime code is assigned. These modifications have resulted in the use of many more claims than were used for the proposed rule to set APC medians where

conditionally packaged codes are assigned.

Comment: One commenter believed that the data for many single bills for the services with status indicator "Q" will be lost because CMS assesses the status of the status indicator "Q" code before applying the bypass list. The commenters stated that where there are three services on the claim, two of which are on the bypass list, the status indicator "Q" service will be changed to packaged before the bypass list is applied and the two bypass codes will leave the claim without packaging. The commenter added that there will then be no code to which to package the cost of the status indicator "Q" code and the data will neither be used nor packaged into anything (because nothing is left for it to be packaged with). The commenter believed that if CMS had made the assignment of the "Q" after the bypass codes were removed, the data could be used to set the APC median for the "Q" service and more claims could have been used.

Response: The commenter accurately described the treatment of a code with status indicator "Q" if it is on the same claim with two codes that are on the bypass list. However, we disagree with the commenter's recommendation. First, by definition, codes on the bypass list do not have significant packaging. We specifically reassessed the codes included on the bypass list in light of this packaging proposal to ensure removal of any services with significant packaging. The circumstances where "Q" service data would remain on a claim as "packaging" after removing the other two codes as bypass codes should be very limited. Second, we would not want to use that data to set the median cost for the "Q" status service because the final payment disposition of the code with status indicator "Q" on the claim would be packaged. Under this commenter's recommendation, we would be sending the data for the status indicator "Q" codes to the APC to which it is assigned even though, when the claim was processed, no separate payment would be made for the status indicator "Q" code.

Comment: One commenter found that its calculation of median costs using proposed rule data for the imaging supervision and interpretation services to which CMS proposed to assign status indicator "Q" resulted in median costs for these codes and the APCs to which they were assigned that were significantly higher than the median costs calculated by CMS for these codes and their APCs. The commenter was concerned that CMS may have inadvertently failed to include the

packaged costs in the calculation of the medians for these costs codes.

Response: The commenter is correct in that we inadvertently erred and did not include the packaged costs of "Q" status procedures in the calculation of the medians for these codes and their related APCs in the proposed rule. We have packaged these costs with the "Q" procedures for this final rule with comment period, in addition to making the other modifications to the calculation of the median costs for these codes as discussed in detail above and in section II.A.2. of this final rule with comment period.

For CY 2008, we are finalizing our proposal, with modification as discussed above, to unconditionally or conditionally packaged imaging supervision and interpretation services. These codes, with their assigned status indicator "N" as unconditionally packaged or "Q" as "T-packaged" codes, are listed in Table 10 of this final rule with comment period. We are not accepting the APC Panel recommendation to delay packaging of these services and provide an alternative model at the next Panel meeting, because we are finalizing a modified model. We will review the final CY 2008 policy, including the ratesetting methodology, with the APC Panel at its 2008 winter meeting.

(5) Diagnostic Radiopharmaceuticals

For CY 2008, we proposed to change the packaging status of diagnostic radiopharmaceuticals as part of our overall enhanced packaging approach for the CY 2008 OPPS. Packaging costs into a single aggregate payment for a service, encounter, or episode of care is a fundamental principle that distinguishes a prospective payment system from a fee schedule. In general, packaging the costs of supportive items and services into the payment for the independent procedure or service with which they are associated encourages hospital efficiencies and also enables hospitals to manage their resources with maximum flexibility. As we stated in the CY 2007 OPPS/ASC final rule with comment period, we believe that a policy to package payment for additional radiopharmaceuticals (other than those already packaged when their per day costs are below the packaging threshold for OPPS drugs, biologicals, and radiopharmaceuticals based on data for the update year) is consistent with OPPS packaging principles and would provide greater administrative simplicity for hospitals (71 FR 68094).

All nuclear medicine procedures require the use of at least one radiopharmaceutical, and there are only

a small number of radiopharmaceuticals that may be appropriately billed with each diagnostic nuclear medicine procedure. While examining the CY 2005 hospital claims data in preparation for the CY 2007 OPPTS/ASC proposed rule, we identified a significant number of diagnostic nuclear medicine procedure claims that were missing HCPCS codes for the associated radiopharmaceutical. At that time, we believed that there could be two reasons for the presence of these claims in the data. One reason could be that the radiopharmaceutical used for the procedure was packaged under the OPPTS and, therefore, some hospitals may have decided not to include the specific radiopharmaceutical HCPCS code and an associated charge on the claim. A second reason could be that the hospitals may have incorporated the cost of the radiopharmaceutical into the charges for the associated nuclear medicine procedures. A third possibility not offered in the CY 2007 OPPTS/ASC proposed rule is that hospitals may have included the charges for radiopharmaceuticals on an uncoded revenue code line.

In the CY 2007 OPPTS/ASC proposed rule, we did not propose packaging payment for radiopharmaceuticals with per day costs above the \$55 CY 2007 packaging threshold because we indicated that we were concerned that payments for certain nuclear medicine procedures could potentially be less than the costs of some of the packaged radiopharmaceuticals, especially those that are relatively expensive. At the same time, we also noted the GAO's comment in reference to the CY 2006 OPPTS proposed rule that stated a methodology that includes packaging all radiopharmaceutical costs into the payments for the nuclear medicine procedures may result in payments that exceed hospitals' acquisition costs for certain radiopharmaceuticals because there may be more than one radiopharmaceutical that may be used for a particular procedure. We also expressed concern that packaging payment for additional radiopharmaceuticals could provoke treatment decisions that may not reflect use of the most clinically appropriate radiopharmaceutical for a particular nuclear medicine procedure in any specific case (71 FR 68094).

After considering this issue further and examining our CY 2006 claims data for the CY 2008 OPPTS update, as we indicated in the CY 2008 OPPTS/ASC proposed rule, we believe that it is most appropriate to package payment for some radiopharmaceuticals, specifically diagnostic radiopharmaceuticals, into

the payment for diagnostic nuclear medicine procedures for CY 2008. We expect that packaging would encourage hospitals to use the most cost efficient diagnostic radiopharmaceutical products that are clinically appropriate. We anticipate that hospitals would continue to provide care that is aligned with the best interests of the patient. Furthermore, we believe that it would be the intent of most hospitals to provide both the diagnostic radiopharmaceutical and the associated diagnostic nuclear medicine procedure at the time the diagnostic radiopharmaceutical is administered and not to send patients to a different provider for administration of the radiopharmaceutical. As we indicated in the proposed rule, we do not believe that our packaging proposal would limit beneficiaries' ability to receive clinically appropriate diagnostic procedures. Again, the OPPTS is a system of averages, and payment in the aggregate is intended to be adequate, although payment for any one service may be higher or lower than a hospital's actual costs in that case.

For CY 2008, we have separated radiopharmaceuticals into two groupings. The first group includes diagnostic radiopharmaceuticals, while the second group includes therapeutic radiopharmaceuticals. We identified all diagnostic radiopharmaceuticals as those Level II HCPCS codes that include the term "diagnostic" along with a radiopharmaceutical in their long code descriptors. Therefore, we were able to distinguish therapeutic radiopharmaceuticals from diagnostic radiopharmaceuticals as those Level II HCPCS codes that have the term "therapeutic" along with a radiopharmaceutical in their long code descriptors. There currently are no HCPCS C-codes used to report radiopharmaceuticals under the OPPTS. For CY 2008, we proposed to package payment for all diagnostic radiopharmaceuticals that are not otherwise packaged according to the CY 2008 packaging threshold for drugs, biologicals, and radiopharmaceuticals that we proposed. We proposed this packaging approach for diagnostic radiopharmaceuticals, while we proposed to continue to pay separately for therapeutic radiopharmaceuticals with an average per day cost of more than \$60 as discussed in section V.B.3.a.(c) of this final rule with comment period. In that section, we review our reasons for treating diagnostic radiopharmaceuticals (as well as contrast media) differently from other types of specified covered

outpatient drugs identified in section 1833(t)(B) of the Act.

Diagnostic radiopharmaceuticals are always intended to be used with a diagnostic nuclear medicine procedure. In examining our CY 2006 claims data, we were able to match most diagnostic radiopharmaceuticals to their associated diagnostic procedures and most diagnostic nuclear medicine procedures to their associated diagnostic radiopharmaceuticals in the vast majority of single bills used for ratesetting. We estimate that less than 5 percent of all claims with a diagnostic radiopharmaceutical had no corresponding diagnostic nuclear medicine procedure. In addition, we found that only about 13 percent of all single bills with a diagnostic nuclear medicine procedure code had no corresponding diagnostic radiopharmaceutical billed. These statistics indicate that, in a majority of our single bills for diagnostic nuclear medicine procedures, a diagnostic radiopharmaceutical HCPCS code is included on the single bill. Table 15 in the proposed rule (72 FR 42668) presented the top 20 diagnostic nuclear medicine procedures in terms of the overall frequency with which they are reported in the OPPTS claims data. Among these high volume diagnostic nuclear medicine procedures, their single bills included a HCPCS code for a diagnostic radiopharmaceutical at least 84 percent of the time for 19 of the top 20 procedures. More specifically, 84 to 86 percent of the single bills for 4 diagnostic nuclear medicine procedures included a diagnostic radiopharmaceutical, 87 to 89 percent of the single bills for 8 diagnostic nuclear medicine procedures included a diagnostic radiopharmaceutical, and 90 percent or more of the single bills for 7 diagnostic nuclear medicine procedures included a diagnostic radiopharmaceutical.

Among the lower volume diagnostic nuclear medicine procedures (which were outside the top 20 in terms of volume), there was still good representation of diagnostic radiopharmaceutical HCPCS codes on the single bills for most procedures. About 40 percent of the low volume diagnostic nuclear medicine procedures had at least 80 percent of the single bills for that diagnostic procedure that included a diagnostic radiopharmaceutical HCPCS code; about 37 percent of the low volume diagnostic procedures had between 50 to 79 percent of the single bills that included a diagnostic radiopharmaceutical HCPCS code; and about 23 percent of the low volume diagnostic procedures

had less than 50 percent of the single bills that include a diagnostic radiopharmaceutical HCPCS code. For the few diagnostic nuclear medicine procedures where less than 50 percent of the single bills included a diagnostic radiopharmaceutical HCPCS code, we believed there could be several reasons why the percentage of single bills for the diagnostic nuclear medicine procedure with a diagnostic radiopharmaceutical HCPCS code was low.

As noted earlier, it is possible that hospitals may have included the charge for the radiopharmaceutical in the charge for the diagnostic nuclear medicine procedure itself or on an uncoded revenue code line instead of reporting charges for a specific diagnostic radiopharmaceutical HCPCS code. We found that 24 percent of all single bills for a diagnostic nuclear medicine procedure but without a coded diagnostic radiopharmaceutical had uncoded costs in a revenue code that might contain diagnostic radiopharmaceutical costs, specifically, revenue codes 0254 (Drugs Incident to Other Diagnostic Services), 0255 (Drugs Incident to Radiology), 0343 (Diagnostic Radiopharmaceuticals), 0621 (Supplies Incident to Radiology), and 0622 (Supplies Incident to Other Diagnostic Services). In comparison, we found that only 2 percent of diagnostic nuclear medicine single bills with a nuclear medicine procedure and a coded diagnostic radiopharmaceutical had uncoded costs in these revenue codes. It is also possible that some of these procedures typically used a diagnostic radiopharmaceutical subject to packaged payment under the CY 2006 OPBS, and hospitals may have chosen not to report a separate charge for the diagnostic radiopharmaceutical. Payment for diagnostic radiopharmaceuticals commonly used with some diagnostic nuclear medicine procedures would already be packaged because these diagnostic radiopharmaceuticals' average per day costs were less than \$50 in CY 2006. We stated in the proposed rule that the CY 2008 proposal to package additional diagnostic radiopharmaceuticals would have little impact on the payment for those diagnostic procedures that typically use inexpensive diagnostic radiopharmaceuticals that would be packaged under our proposed CY 2008 packaging threshold of \$60, except to the extent that the budget neutrality adjustment due to the broader packaging proposal leads to an increase in the scaler and an increase in the payment for procedures in general.

At its March 2007 meeting, the APC Panel recommended that CMS work

with stakeholders on issues related to payment for radiopharmaceuticals, including evaluating claims data for different classes of radiopharmaceuticals and ensuring that a nuclear medicine procedure claim always includes at least one reported radiopharmaceutical agent. In the proposed rule, we noted that we planned to accept the APC Panel's recommendation, and we specifically welcomed public comment on the hospitals' burden involved should we require such precise reporting. We also sought public comment on the importance of such a requirement in light of our above discussion on the representation of diagnostic radiopharmaceuticals in the single bills for diagnostic nuclear medicine procedures, the presence of uncoded revenue code charges specific to diagnostic radiopharmaceuticals on claims without a coded diagnostic radiopharmaceutical, and our proposal to package payment for all diagnostic radiopharmaceuticals.

As we indicated in the proposed rule, we are aware that several diagnostic radiopharmaceuticals may be used for multiple day studies; that is, a particular diagnostic radiopharmaceutical may be administered on one day and a related diagnostic nuclear medicine procedure may be performed on a subsequent day. While we understand that multiple day episodes for diagnostic radiopharmaceuticals and the related diagnostic nuclear medicine procedures occur, we expect that this would be a small proportion of all diagnostic nuclear medicine imaging procedures. We estimate that, roughly, 15 diagnostic radiopharmaceuticals have a half-life longer than one day such that they could support diagnostic nuclear medicine scans on different days. We believe these diagnostic radiopharmaceuticals would be concentrated in a specific set of diagnostic procedures. Excluding the 5 percent of diagnostic radiopharmaceutical claims with no matching diagnostic nuclear medicine scan for the same beneficiary, we found that a diagnostic nuclear medicine scan was reported on the same day as a coded diagnostic radiopharmaceutical 90 percent or more of the time for 10 of these 15 diagnostic radiopharmaceuticals. Further, between 80 and 90 percent single bills for each of the remaining 5 diagnostic radiopharmaceuticals had a diagnostic nuclear medicine scan on the same day. In the "natural" single bills we use for ratesetting, we package payment across dates of service. In light of such high

percentages of extended half-life diagnostic radiopharmaceuticals with same day diagnostic nuclear medicine scans and the ability of "natural" singles to package costs across days, we indicated in the proposed rule that we believe that our standard OPBS ratesetting methodology of using median costs calculated from claims data would adequately capture the costs of diagnostic radiopharmaceuticals associated with diagnostic nuclear medicine procedures that are not provided on the same date of service.

The packaging proposal we presented would have reduced the overall frequency of single bills for diagnostic nuclear medicine procedures, but the percent of single bills out of total claims remained robust for the majority of diagnostic nuclear medicine procedures. Typically, packaging more procedures should improve the number of single bill claims from which to derive median cost estimates because packaging reduces the number of separately paid procedures on a claim, thereby creating more single procedure bills. In the case of diagnostic nuclear medicine procedures, packaging diagnostic radiopharmaceuticals reduced the overall number of single bills available to calculate median costs by increasing packaged costs that previously were ignored in the bypass process. In prior years, we did not consider the costs of radiopharmaceuticals when we used our bypass methodology to extract "pseudo" single claims because we assumed that the cost of radiopharmaceutical overhead and handling would be included in the line-item charge for the radiopharmaceutical, and the diagnostic radiopharmaceuticals were subject to potential separate payment if their mean per day cost fell above the packaging threshold. The bypass process sets empirical and clinical criteria for minimal packaging for a specific list of procedures and services in order to assign packaged costs to other procedures on a claim and is discussed at length in section II.A.1. of the proposed rule, and this final rule with comment period. Generally, we found that changing the status of diagnostic radiopharmaceuticals to packaged increased the packaging on each claim. This would make it both harder for nuclear medicine procedures to qualify for the bypass list and more difficult to assign packaging to individual diagnostic nuclear medicine procedures, resulting in a possible reduction of the number of "pseudo" singles that are produced by the bypass process. Notwithstanding this potentiality, diagnostic nuclear medicine procedures

continued to have good representation in the single bills. On average, single bills as a percent of total occurrences remained substantial at 55 percent for individual procedures. We discuss our process for ratesetting, including the construction and use of single and multiple bills, in greater detail in section II.A.1. of this final rule with comment period.

We indicated in the proposed rule that we believe our CY 2006 claims data supported our CY 2008 proposal to package payment for all diagnostic radiopharmaceuticals and would lead to payment rates for diagnostic nuclear medicine procedures that appropriately reflect payment for the costs of the diagnostic radiopharmaceuticals that are administered to carry out those diagnostic nuclear medicine procedures. Among the top 20 high volume diagnostic nuclear medicine procedures, at least 84 percent of the single bills for almost every diagnostic nuclear medicine procedure included a diagnostic radiopharmaceutical HCPCS code. While a diagnostic radiopharmaceutical, by definition, would be anticipated to accompany 100 percent of the diagnostic nuclear medicine procedures, it is not unexpected that, while percentages in our claims data are high, they are less than 100 percent. As noted previously, we have heard anecdotal reports that some hospitals may include the charges for diagnostic radiopharmaceuticals in their charge for the diagnostic nuclear medicine procedure or on an uncoded revenue code line, rather than reporting a HCPCS code for the diagnostic radiopharmaceutical. Thus, it is likely that the frequency of diagnostic radiopharmaceutical costs reflected in our claims data were even higher than the percentages indicated. Furthermore, we note that the OPPS ratesetting methodology is based on medians, which are less sensitive to extremes than means and typically do not reflect subtle changes in cost distributions. Therefore, to the extent that the vast majority of single bills for a particular diagnostic nuclear medicine procedure included a diagnostic radiopharmaceutical HCPCS code, the fact that the percentage was somewhat less than 100 percent was likely to have minimal impact on the median cost of the procedure in most cases. Even in those few instances where we had a low total number of single bills, largely because of low overall volume, we had ample representation of diagnostic radiopharmaceutical HCPCS codes on the single bills for the majority of lower volume nuclear medicine procedures.

We also continued to have reasonable representation of single bills out of total claims in general. Finally, as noted previously, to the extent that the diagnostic radiopharmaceuticals commonly used with a particular diagnostic nuclear medicine procedure were already packaged, the proposal to package additional diagnostic radiopharmaceuticals would have had little impact on the payment for these procedures.

The estimated overall impact of these changes presented in section XXII.B. of the proposed rule (section XXIV.B. of this final rule with comment period) was based on the assumption that hospital behavior would not change with regard to whether the dependent diagnostic radiopharmaceutical services are provided by the same hospital that performs the independent services. In order to provide diagnostic nuclear medicine procedures under this policy, hospitals would either need to administer the necessary diagnostic radiopharmaceuticals themselves or refer patients elsewhere for the administration of the diagnostic radiopharmaceuticals. In the latter case, claims data would show such a change in practice in future years and that change would be reflected in future ratesetting. However, with respect to diagnostic radiopharmaceuticals, we believe that hospitals are limited in the extent to which they could change their behavior with regard to how they furnish these items because diagnostic radiopharmaceuticals are typically provided on the same day as a diagnostic nuclear medicine procedure. It would be difficult for Hospital A to send patients to receive diagnostic radiopharmaceuticals from Hospital B and then have the patients return to Hospital A for the diagnostic nuclear medicine procedure in the appropriate timeframe (given the radiopharmaceutical's half-life) to perform a high quality study. We expect that hospitals would always bill the diagnostic radiopharmaceutical on the same claim as the other independent services for which the radiopharmaceutical was administered.

The APC Panel recommended that CMS package radiopharmaceuticals with a median per day cost of less than \$200 but pay separately for radiopharmaceuticals with a per day cost of \$200 or more. The APC Panel also recommended that CMS should identify nuclear medicine procedure claims with and without radiopharmaceuticals and should present its findings to the Panel at the next meeting for consideration of whether an edit is needed to ensure that

the cost of the radiopharmaceutical is packaged into the payment for the nuclear medicine service.

We received many public comments on our proposal to package payment for diagnostic radiopharmaceuticals for CY 2008. A summary of the public comments and our responses follow.

Comment: Some commenters recommended that CMS package radiopharmaceuticals with a per day cost less than \$200 but pay separately for radiopharmaceuticals with a per day cost of \$200 or more. Other commenters objected to packaging diagnostic radiopharmaceuticals and asked that CMS continue to pay separately for radiopharmaceuticals with per day costs that exceed the packaging threshold for drugs. These commenters explained that FDA views radiopharmaceuticals to be drugs, they are defined as drugs for purposes of pass-through payment under OPPS in sections 1833(t)(6)(A)(iii) of the Act, and for purposes of payment as specified covered outpatient drugs (SCODs) and biologicals in section 1833(t)(14)(B)(i)(l) of the Act. The commenters argued that CMS should, therefore, pay separately for radiopharmaceuticals with a per day cost in excess of \$60, as it does for other drugs.

The commenters believed that section 1833(t)(14)(B)(i)(l) of the Act requires CMS to treat radiopharmaceuticals no differently from other SCODs and, therefore, CMS must pay radiopharmaceuticals actual acquisition costs or, failing that, charges adjusted to costs. Some commenters believed that there is no authority for CMS to package drugs that are incidental or ancillary to a procedure and that by doing so, CMS is relying on a form of "functional equivalence" which is expressly limited by statute under section 1833(t)(6)(F) of the Act. The commenters argued that the proposal will create an incentive for hospitals to not use advanced technologies and will harm patient care. Some commenters believed that packaging diagnostic radiopharmaceuticals could discourage hospitals from using the most appropriate drug for each patient and encourage them to use less clinically effective radiopharmaceuticals when there is a choice of radiopharmaceutical. Some commenters added that the proposal ignores medical indications and focuses solely on cost reduction, which could result in constraints on medical decisionmaking and would compromise medical care.

Response: After review of the public comments we received on this issue, we have decided to finalize our proposal to package payment for diagnostic

radiopharmaceuticals into the payment for the nuclear medicine services which cannot be performed without the administration of a radiopharmaceutical. We refer readers to section V.B.4.b. of this final rule with comment period for a discussion of the rationale to package payment for diagnostic radiopharmaceuticals as SCODs and our belief that the packaged payment provides payment at average acquisition cost for the products.

We find the argument that we are creating functional equivalence by packaging the payment for diagnostic radiopharmaceuticals into the payment for the nuclear medicine services without which they cannot be performed to be unconvincing. We are not establishing an equivalent payment for different products based on their function. We are instead packaging the cost of radiopharmaceuticals, however differential those costs may be, into the payment for nuclear medicine services to create an appropriate payment for the nuclear medicine services that use these products, whether there is one product or multiple products that could be used to furnish the service. This is analogous to our longstanding practice of packaging of medical devices into the payment for the procedure in which they are used, notwithstanding that there may be different devices that could be used to furnish the service.

Moreover, we do not agree with the argument that paying for radiopharmaceuticals as part of the payment for the nuclear medicine service to which they are essential will harm patient care. We believe that providing packaged payment for radiopharmaceuticals as part of the nuclear medicine service will cause hospitals and their physician partners to give even more careful consideration to the selection of the radiopharmaceutical that is the most appropriate for the patient whom they are treating.

We are not accepting the APC Panel recommendation to pay separately for radiopharmaceuticals with a per day cost in excess of \$200 because we could not determine an empirical basis for paying separately for radiopharmaceuticals with a per day cost in excess of \$200.

Comment: Many commenters stated that a diagnostic radiopharmaceutical is always needed to provide a nuclear medicine service and, therefore, CMS should use only claims in which both services were present to compute the median cost for the nuclear medicine procedure if CMS decides to package diagnostic radiopharmaceuticals. Some commenters suggested that CMS establish OCE edits that would require

a charge be reported under the diagnostic radiopharmaceutical revenue code 0343 when there was a charge in revenue codes 0340 or 0341 for a nuclear medicine procedure. Other commenters recommended that CMS establish OCE edits that would require a HCPCS code for a diagnostic radiopharmaceutical be reported on a claim for a diagnostic nuclear medicine procedure. Some commenters were concerned that the actual cost of radiopharmaceuticals would be lost because hospitals would not report the charges on the claim unless CMS mandates and enforces their reporting.

Response: We agree that it is important that the costs of radiopharmaceuticals be reported on the same claim with the nuclear medicine service so that we can have confidence that the payment for the nuclear medicine procedure reflects the cost of the radiopharmaceutical as well as the nuclear medicine service. Therefore, we have used only claims that contain a HCPCS code and charge for a diagnostic radiopharmaceutical to calculate the median costs of the nuclear medicine procedures for CY 2008. Moreover, effective for services furnished on and after January 1, 2008, the OCE will return for correction any claim for a nuclear medicine procedure that does not contain a HCPCS code and charge for a diagnostic radiopharmaceutical. These edits are similar to the edits we have had in place in the OCE since CY 2005 for medical devices. The significant difference, however, is that we recognize that, for some nuclear medicine procedures, there is a choice of radiopharmaceuticals that could be used and, therefore, the edits will not specify which radiopharmaceutical must be billed with any given nuclear medicine procedure. We also recognize that, in some cases, the radiopharmaceutical is administered several days before the nuclear medicine service is furnished. In these cases, the hospital will need to hold the claim until after the service is furnished so that the radiopharmaceutical can appear on the bill with the nuclear medicine procedure or the bill for the procedure will be returned for correction. We did not accept the comment that we should establish the edits using combinations of revenue codes because to do so would not provide specific information on the particular radiopharmaceutical being furnished and we could not be certain that the charges were for radiopharmaceuticals.

Comment: Some commenters asserted that, based on survey data they gathered, claims data fail to capture

hospital average acquisition costs for radiopharmaceuticals. The commenters, therefore, concluded that the costs of low volume, high cost radiopharmaceuticals are not captured in the claims data that is used to set the median costs on which the nuclear medicine services payment rates are based and the packaged payment for radiopharmaceuticals will be inadequate to pay for the cost of the drug. The commenters believed that these incorrectly priced products are unlikely to continue to be manufactured and thus will cease to be available. The commenters also stated that it is unlikely that the industry will develop new products for the market if they find that hospitals will not use them because of inadequate payment. The commenters believed that beneficiary care would suffer as hospitals ceased to furnish the service because payment would be inadequate to cover the cost. Some commenters explained that, while CMS implemented revenue codes for diagnostic and therapeutic radiopharmaceuticals in CY 2004, hospitals have not yet fully reflected these revenue codes in their billing practices and, therefore, the claims data are not correct or reliable and CMS should continue to pay separately for radiopharmaceuticals at charges adjusted to cost. Other commenters believed that the proposed changes would overestimate payments for some diagnostic radiopharmaceuticals, underestimate others, and create improper financial incentives for hospitals and physicians to select certain radiopharmaceuticals rather than others, potentially reducing the quality of care.

Response: We believe that we have appropriately calculated the radiopharmaceutical costs that we are packaging into the nuclear medicine services by using only claims for nuclear medicine services that contain a radiopharmaceutical, as noted above. This is analogous to our process for ensuring that the costs of devices are packaged into the payment for the APC in which they are used, and we believe that using only these claims will negate any existing problems with the use or lack of use of the radiopharmaceutical revenue codes.

With regard to the concern that packaging radiopharmaceuticals will result in overpayment in some cases and underpayment in others, we note that the most fundamental characteristic of a prospective payment system is that payment is to be set at an average for the service, which, by definition, means that some services are paid more or less than the average. However, the average

should provide adequate payment for the service, while creating incentives for hospitals to control costs and utilization of high cost services where it is appropriate to do so. We do not believe that either beneficiary access to care or the quality of care will be adversely affected because we pay for diagnostic radiopharmaceuticals as part of the payment for the procedure to which they are an integral part. With regard to the influence this may have on the development and production of radiopharmaceuticals, there are many aspects of the health care economy that influence what is developed and produced, of which Medicare payment under the OPSS is merely one.

Comment: Some commenters stated that CMS has not provided adequate information for specialty societies and others to adequately review the matching of the drugs with the services to determine whether an appropriate radiopharmaceutical is packaged into the nuclear medicine services. The commenters indicated that CMS should provide data on the percent of nuclear medicine claims that were reported with and without a corresponding radiopharmaceutical so that the public can determine whether an edit is indicated for reporting these services either through OCE or backend rate setting and, if so, what edit would be appropriate.

Response: We provided considerable information and data in support of our proposal. Moreover, we make available our claims data both for the proposed rule and the final rule so that the public can perform any analysis they choose. There are limits to our ability to provide specialized studies of interest. Therefore, we provide a narrative claims accounting that is intended to illuminate our data process for those who would like to use the claims data to explore alternatives.

Comment: Some commenters believed that packaging diagnostic radiopharmaceuticals would undermine the clinical and resource homogeneity of the nuclear medicine APCs, especially the cardiac imaging APCs, resulting in 2 times violations. The commenters stated that the APC revision that is proposed as a result of the proposed packaging results in a lack of resource and clinical homogeneity within the APCs. Specifically, the commenters believed that, by packaging diagnostic radiopharmaceuticals, CMS created a 2 times violation in APC 0408 because the median costs for the services assigned to the APC vary widely for the procedure code based on the radiopharmaceutical used.

Response: We agree that packaging costs into the median for a service to which they are an integral part can change the median cost for that service and result in 2 times violations. As we noted in the proposed rule, there were a significant number of APC reassignments to eliminate 2 times violations that would otherwise have resulted from the proposed packaging approach. However, we disagree that we should refrain from packaging payment for necessary items into the payment for the service in which they are required in order to prevent 2 times violations from occurring. Instead, we believe that we should make the necessary reassignments to different APCs where necessary to resolve 2 times violations where they occur. For example, to resolve 2 times violations that would otherwise have occurred when we used only those claims for nuclear medicine procedures reporting HCPCS code for diagnostic radiopharmaceuticals, we made the following APC reassignments for this final rule with comment period. We reassigned CPT code 78730 (Urinary bladder residual study (List separately in addition to code for primary procedure)) from APC 0340 (Minor Ancillary Procedures) to APC 0389 (Level I Non-Imaging Nuclear Medicine). We reassigned CPT code 78725 (Kidney function study, non-imaging radioisotopic study) from APC 0389 to APC 0392 (Level II Non-Imaging Nuclear Medicine). We reassigned CPT code 78006 (Thyroid imaging, with uptake; single determination) from APC 0390 (Level I Endocrine Imaging) to APC 0391 (Level II Endocrine Imaging). With regard to APC 0408 (Level III Tumor/Infection Imaging), that APC contained only one code for the proposed rule, CPT code 78804 (Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); whole body, requiring two or more days imaging), and it had a proposed median of approximately \$1,010. For this final rule with comment period, APC 0408 contains 3 CPT codes: 78804 (Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); whole body, requiring two or more days imaging); 78075 (Adrenal Imaging, cortex and/or medulla); and 78803 (Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(t); tomographic (SPECT)). For this final rule with comment period, APC 408 has a median cost of approximately \$969.

Because we have traditionally paid for a service package under the OPSS as

represented by a HCPCS code for the major procedure that is assigned to an APC group for payment, we assess the applicability of the 2 times rule to services at the HCPCS code level, not at a more specific level based on the individual diagnostic radiopharmaceuticals that may be utilized in a service reported with a single HCPCS code. If the use of a very expensive diagnostic radiopharmaceutical in a clinical scenario causes a specific procedure to be much more expensive for the hospital than the APC payment, we consider such a case to be the natural consequence of a prospective payment system that anticipates that some cases will be more costly and other less costly than the procedure payment. In addition, very high cost cases could be eligible for outlier payment. As we note elsewhere in this final rule with comment period, decisions about packaging and bundling payment involve a balance between ensuring some separate payment for individual services and establishing incentives for efficiency through larger units of payment. In the case of diagnostic radiopharmaceuticals, these products will be part of the OPSS payment package for the procedures in which they are used beginning in CY 2008.

Comment: One commenter objected to packaging of diagnostic radiopharmaceuticals because the commenter believed that including the payment for the item in the payment for the procedure would improperly subject the portion of the payment that is attributable to the diagnostic radiopharmaceutical to wage adjustment. The commenter indicated that there should be no wage adjustment applied to the cost of a diagnostic radiopharmaceutical.

Response: We disagree that we should not package the payment for a radiopharmaceutical into the payment for the procedure in which it is an integral part because part of the procedure payment will be wage adjusted. Since the inception of the OPSS, we have determined that, approximately 60 percent of the cost of an OPSS service is attributable to wage costs. That figure is an overall average percent that takes into account the extent to which there are costs in the OPSS payments that are not attributable to wages. We have a longstanding policy of wage adjusting 60 percent of the cost of the APC, regardless of whether it is an office visit (which is mostly wage costs) or an ICD replacement (in which most of the cost is a device), because our analysis shows that, overall, OPSS

services approximately 60 percent of the cost is attributable to wages.

Comment: Some commenters stated that diagnostic radiopharmaceuticals are not interchangeable and carry high costs because, if the patient for whom the hospital secures a radiopharmaceutical cannot use the product, the hospital cannot bill for it and must absorb the loss. The commenters stated that hospitals have little or no flexibility in determining the diagnostic radiopharmaceutical that they purchase and have little ability to achieve efficiency.

Response: We recognize that radiopharmaceuticals are specialized products that have unique costs associated with them. However, we believe that the costs should be reflected in the charges that hospitals set for them and in the cost report where the full costs of the services are carried. Therefore, the costs will be calculated like any other OPPS cost and packaged into the total cost of the nuclear medicine service to which they are an integral part and will be the basis for the payment rate for the nuclear medicine service in the same way that other packaged costs contribute to the payment rate for the services to which they are an integral part.

Comment: Several commenters stated that HCPCS codes A9542 (Indium IN-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries) and A9544 (Iodine I-131 tositumomab, diagnostic, per study dose) are not diagnostic radiopharmaceuticals and should not be packaged. The commenters reported that they are not used to diagnose the patient's disease but instead are used to assess the biodistribution of radioimmunotherapy agents or to calculate the therapeutic dose of those agents. The commenters contended that, although packaging is intended to create incentives for using the most cost-effective product, in these cases there are no other products that are available, and hence these products should always be paid separately. The commenters concluded that the proposed payments for these services are so low that hospitals will not offer the treatments to Medicare beneficiaries.

Response: We continue to believe that HCPCS codes A9542 and A9544 are diagnostic radiopharmaceuticals. While they are not used to diagnose disease, they are used to determine whether future therapeutic services would be beneficial to the patient and to determine how to proceed with therapy. This is analogous to the use of positron emission tomography (PET) scanning for staging purposes when there has already been a diagnosis of disease but the

physician is seeking information to use in planning a course of therapy. The scan is a diagnostic service, notwithstanding that the disease has previously been diagnosed and the diagnostic service is essential to planning therapy. While we recognize that these radiopharmaceuticals are sole source products, we do not believe that is sufficient to justify treating them differently from other diagnostic radiopharmaceuticals. Moreover, given that the Medicare population is such a dominant portion of the population to which these services are targeted, we do not believe that hospitals will cease to provide the service because the payment is packaged into the payment for the service to which the radiopharmaceutical is an integral part. We also note that, under 42 CFR 489.53(a)(2), CMS may terminate the provider agreement of any hospital that furnishes this or any other service to its patients but fails to also furnish it to Medicare patients who need it.

Comment: Some commenters asked that CMS pay hospitals separately for diagnostic radiopharmaceuticals based on acquisition costs. The commenters had a variety of recommendations regarding how CMS should acquire acquisition cost data on which CMS could base separate payment for radiopharmaceuticals. Some commenters recommended that CMS conduct surveys of radiopharmaceutical costs or rely on the external data from surveys conducted by outside entities to obtain cost data. Some commenters recommended that CMS work with stakeholders to develop a standardized radiopharmaceutical reporting format and base separate payment for radiopharmaceuticals on a radiopharmaceutical average selling nuclear pharmacy price (ASNPP), average acquisition cost (ACC), or another voluntarily reported amount if furnished by manufacturers and nuclear pharmacies, instead of claims data charges adjusted to cost by departmental CCRs. Other commenters suggested that CMS require hospitals to report acquisition costs for radiopharmaceuticals, instruct contractors to collect periodic reports from hospitals of diagnostic radiopharmaceutical costs, and gather and summarize nuclear pharmacy invoice data through CY 2008 that would be used to set CY 2009 rates. The commenters stated that separate payment of diagnostic radiopharmaceuticals for CY 2008 is critical to enable hospitals to account for the complex combinations of radiopharmaceuticals used to provide

nuclear medicine procedures. Some commenters indicated that continuation of the current payment at charges reduced to cost by the overall CCR, while not ideal, is a reasonable temporary solution until CMS can implement a long term solution to pay acquisition costs for radiopharmaceuticals as required by law. Some commenters supported CMS' use of its claims data alone to set the CY 2008 payment rates, but only if no external data source is available to pay actual acquisition costs for radiopharmaceuticals.

Response: As we previously stated, we have decided to package payment for diagnostic radiopharmaceuticals into the payment for nuclear medicine services. Therefore, proposals for gathering data on which separate payment could be based are not relevant. However, we note that when we proposed to acquire ASP data for radiopharmaceuticals for purposes of paying separately for them under the CY 2006 OPSP, commenters were virtually unanimous that the industry could not report valid sales price data on radiopharmaceuticals.

After consideration of the public comments received, we are finalizing our CY 2008 proposal to provide packaged payment for diagnostic radiopharmaceuticals, with modification to calculate the median costs for the APCs for nuclear medicine studies that require a diagnostic radiopharmaceutical using only claims on which at least one diagnostic radiopharmaceutical is present. We will implement edits in the OCE for services furnished on and after January 1, 2008, that will return to providers any claim for a nuclear medicine study that does not also report a HCPCS code and charge for a diagnostic radiopharmaceutical. We are not accepting the APC Panel's recommendation to set a packaging threshold for diagnostic radiopharmaceuticals at a median cost of \$200 per day. We are accepting the APC Panel's recommendation to provide information regarding claims for diagnostic radiopharmaceuticals reported with nuclear medicine procedures, and we will discuss that information with the Panel at the 2008 winter meeting. Diagnostic radiopharmaceuticals assigned status indicator "N" that will be unconditionally packaged are listed in Table 10 of this final rule with comment period.

(6) Contrast Agents

For CY 2008, we proposed to package payment for all contrast media into their

associated independent diagnostic and therapeutic procedures as part of our proposed packaging approach for the CY 2008 OPPS (72 FR 42672 through 42674). As noted in section II.A.4.c. of the proposed rule and this final rule with comment period, packaging the costs of supportive items and services into the payment for the independent procedure or service with which they are associated encourages hospital efficiencies and also enables hospitals to manage their resources with maximum flexibility. As stated in the proposed rule (72 FR 42672), we believe that contrast agents are particularly well suited for packaging because they are always provided in support of an independent diagnostic or therapeutic procedure that involves imaging, and thus payment for contrast agents can be packaged into the payment for the associated separately payable procedures.

Contrast agents are generally considered to be those substances introduced into or around a structure that, because of the differential absorption of x-rays, alteration of magnetic fields, or other effects of the contrast medium in comparison with surrounding tissues, permit visualization of the structure through an imaging modality. The use of certain contrast agents is generally associated with specific imaging modalities, including x-ray, computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI), for purposes of diagnostic testing or treatment. They are most commonly administered through an oral or intravascular route in association with the performance of the independent procedures involving imaging that are the basis for their administration. Even in the absence of this proposal to package payment for all contrast agents, we indicated that we would propose to package the majority of HCPCS codes for contrast agents recognized under the OPPS in CY 2008. We consider contrast agents to be drugs under the OPPS, and as a result they are packaged if their estimated mean per day cost is equal to or less than \$60 for CY 2008. (For more discussion of our drug packaging criteria, we refer readers to section V.B.2 of this final rule with comment period.) Seventy-five percent of contrast agents HCPCS codes have an estimated mean per day cost equal to or less than \$60 based on our CY 2006 proposed rule claims data.

At the time of the proposed rule, contrast agents were described by those Level II HCPCS codes in the range from Q9945 through Q9964. There were currently no HCPCS C-codes or other Level II HCPCS codes outside the range

specified above used to report contrast agents under the OPPS. As shown in Table 19 of the proposed rule, in CY 2007 we packaged 7 out of 20 of these contrast agent HCPCS codes based on the \$55 packaging threshold. For CY 2008, we proposed to package all drugs with a per day mean cost of \$60 or less. For CY 2008, the vast majority of contrast agents would be packaged under the traditional OPPS packaging methodology using the \$60 packaging threshold, based on the CY 2006 claims data available for the proposed rule. In fact, of the 20 contrast agent HCPCS codes we included in our proposed packaging approach, 15 would have been proposed to be packaged for CY 2008 under our drug packaging methodology. These 15 codes represent 94 percent of all occurrences of contrast agents billed under the OPPS, using proposed rule data. As stated in the proposed rule (72 FR 42672), we believe that this shift in the packaging status for several of these agents between CYs 2007 and 2008 may be because, in CY 2007, a number of the contrast agents exceeded the \$55 threshold by only a small amount and, based on our latest claims data for CY 2008, a number of these products have now fallen below the proposed \$60 threshold. Given that the vast majority of contrast agents billed would already be packaged under the OPPS in CY 2008, we stated in the proposed rule (72 FR 42672) that we believe it would be desirable to package payment for the remaining contrast agents as it promotes efficiency and results in a consistent payment policy across products that may be used in many of the same independent procedures. We also noted in the proposed rule (72 FR 42672) that the significant costs associated with these 15 contrast agents would already be reflected in the median costs for those independent procedures and, if we were to pay for the 5 remaining agents separately, we would be treating these 5 agents differently than the others. If the 5 agents remained separately payable, there would effectively be two payments for contrast agents when these 5 agents were billed—a separate payment and a payment for packaged contrast agents that was part of the procedure payment. This could potentially provide a payment incentive to administer certain contrast agents that might not be the most clinically appropriate or cost effective. Moreover, as noted previously, contrast agents are always provided with independent procedures and, under a consistent approach to packaging in keeping with our enhanced efforts to encourage hospital efficiency

and promote value-based purchasing under the OPPS, their payment would be appropriately packaged for CY 2008.

The estimated overall impact of these changes presented in section XXII.B. of the proposed rule (and section XXIV.B. of this final rule with comment period) was based on the assumption that hospital behavior would not change with regard to when these contrast agents are provided by the same hospital that performs the imaging procedure. Under this policy, in order to provide imaging procedures requiring contrast agents, hospitals will either need to administer the necessary contrast agent themselves or refer patients elsewhere for the administration of the contrast agent. In the latter case, claims data would show such a change in practice in future years and that change would be reflected in future ratesetting. However, with respect to contrast agents, we believe that hospitals are limited in the extent to which they could change their behavior with regard to how they furnish these services because contrast agents are typically provided on the same day immediately prior to an imaging procedure being performed. We expected that hospitals would always bill the contrast agent on the same claim as the other independent services for which the contrast agent was administered.

As we indicated earlier, in all cases we are providing that hospitals that furnish the supportive contrast agent in association with independent procedures involving imaging must bill both services on the same claim so that the cost of the contrast agent can be appropriately packaged into payment for the significant independent procedure. As noted in the proposed rule (72 FR 42673), we expect to carefully monitor any changes in billing practices on a service-specific and hospital-specific basis to determine whether there is reason to request that QIOs review the quality of care furnished or to request that Program Safeguard Contractors review the claims against the medical record.

During its September 2007 APC Panel meeting, the Panel recommended that contrast agents be packaged as proposed.

We received many public comments on the proposal to package payment for all contrast agents. A summary of the public comments and our responses follow.

Comment: Many commenters supported our proposal to package all contrast agents, while others requested that we pay separately for all contrast agents in accordance with the Average

Sales Price (ASP) payment methodology. Many commenters requested that we treat contrast agents in the same manner as we treat other drugs under the OPSS, thereby continuing to apply the proposed \$60 threshold to determine packaging status. One commenter expressed concern with the accuracy of CMS' cost data, and estimated that if contrast agents were packaged, hospitals would not receive any payment in addition to the payment for the procedure without contrast. Several commenters requested that CMS create edits to ensure that the costs for contrast agents are only packaged with appropriate procedures, rather than with any code that may appear on the claim. Other commenters requested that CMS implement edits to ensure that contrast agents are always billed with procedures that require contrast agents. Some commenters were concerned that CMS may not be accounting for the full cost of the contrast agent, because of the methodology used to determine the acquisition costs of the agents. One commenter noted that it is difficult for hospitals operationally to treat contrast agents as packaged, then separately payable the following year, and then packaged again. In addition, commenters were concerned that packaged status would encourage less coding accuracy, which would hinder the development of accurate future payment rates. One commenter expressed concern that patient access to more expensive contrast agents, such as gadolinium-based contrast agents, may be limited, if the proposal to package all contrast agents were finalized.

Response: We have considered all of the comments on this issue and have concluded that it is appropriate to package all contrast agents into payment for the procedure in which they are used. Many contrast agents are packaged currently under the OPSS and have been packaged since the inception of the OPSS. We have no reason to believe that the cost data that we developed for contrast agents are insufficient to result in an appropriate median cost for the services in which the contrast agent is used. Moreover, we are not convinced that there are benefits to making separate payment that would outweigh the incentives for appropriate utilization and efficiency that are created by packaging the payment for the contrast agent into the payment for the service in which it is used.

In addition, we do not believe it is necessary to create edits to ensure that contrast agents are billed in conjunction with services that require contrast agents. For example, we believe that the payment rates for CT with and without

contrast are accurate, further bolstering our perspective that hospitals are correctly billing the charges for contrast agents for those services that require them. There is currently a significant cost differential that appears to be appropriate between CT scans with and without contrast, and we have no reason to believe that this cost differential is inaccurate. For example, the CY 2008 median cost for CPT code 72192 (Computer tomographic angiography, pelvis, without contrast material) is approximately \$190. The CY 2008 median cost for CPT code 72193 (Computer tomographic angiography, pelvis, with contrast material) the same procedure, with contrast, is approximately \$249. The CY 2008 median costs for the services in APC 0332 (Computed Tomography Without Contrast) range from approximately \$164 to \$227. The CY 2008 proposed median costs for the services in APC 0283 (Computed Tomography with Contrast) range from approximately \$247 to \$333, significantly higher than the median costs for the procedures that do not involve contrast media.

Providers have several ways to report contrast agents, including uncoded charges on revenue code lines, including the charge for the contrast agent in the charge for the procedure, or reporting the appropriate HCPCS code for the contrast agent that was used. Prior to proposing to package payment for all contrast agents, we note that there were no concerns or complaints about the payment rates for imaging studies with and without contrast, when a number of the commonly used contrast agents were packaged. In addition, if we were to subset claims for procedures that require a contrast agent to use only those claims that included a coded contrast agent, we would be able to use many fewer claims, which would cause our median costs to be less accurate and representative.

Most of the contrast media would have been packaged in the absence of this packaging proposal, because 75 percent of all contrast agents fall below the \$60 threshold for CY 2008. However, we are interested to know whether the public thinks it would be beneficial from a ratesetting perspective to require hospitals to report contrast media by including HCPCS codes for contrast on all claims for procedures that use contrast. We are particularly concerned with unnecessarily burdening hospitals, and are seeking comments in this final rule with comment period related to how administratively burdensome this requirement would be for hospitals.

In response to the commenter who found it difficult operationally to manage changes in the packaged status of contrast media, we note that we do not anticipate regular changes to the packaged status of contrast media, now that we are finalizing our proposal to package payment for all contrast media.

In response to the commenter's concern about payment for expensive contrast agents like gadolinium-based contrast media, we note that the gadolinium-based contrast agents would be packaged under the \$60 packaging threshold, regardless of whether this proposal to package payment for all contrast media was finalized. Packaging payment for these products provides hospitals with an incentive to choose the most cost-effective contrast agent that meets the needs of the patient.

Comment: Several commenters questioned whether we have the authority under the Social Security Act to package all contrast agents.

Response: See section V.B.4.b. of this final rule with comment period for a discussion of the rationale to package payment for contrast agents as SCODs and our belief that the packaged payment provides payment at average acquisition cost for the products.

Comment: Several commenters requested that contrast agents used for echocardiography imaging procedures remain separately paid in CY 2008. These commenters were concerned that echocardiography procedure codes do not distinguish between services provided with contrast and those provided without contrast, although section 1833(t)(2)(G) of the Act requires that contrast and noncontrast procedures be paid through separate APC groups. As echocardiography procedures are not usually performed with contrast, the commenters asserted that the packaged payment for contrast and echocardiography would be insufficient to cover both costs, and that physicians would therefore be limited in their ability to use contrast when necessary.

Response: The commenters are correct; section 1833(t)(2)(G) of the Act requires us to create additional groups of services for procedures that use contrast agents. As contrast agents were eligible for separate payment in CY 2007 but subject to the OPSS drug packaging threshold, a distinction was made in payment between those procedures performed with contrast from those without contrast. However, as noted above, we are finalizing our proposal to package all contrast agents in CY 2008 regardless of if they meet the OPSS drug packaging threshold.

Because current CPT codes do not distinguish between echocardiography procedures performed without contrast from those performed with contrast, we calculated HCPCS-specific median costs for echocardiography procedures that were performed with contrast by isolating single and “pseudo” single claims with CPT codes 93303 through 93350 where there was also a contrast agent on the claim. Our analysis indicated that median costs for echocardiography procedures performed with contrast are similar both clinically

and in terms of resource use, as evidenced by similar HCPCS median costs. Therefore, pursuant to the statute, we have created APC 0128 (Echocardiogram With Contrast) to provide payment for echocardiography procedures that are performed with a contrast agent in CY 2008.

In order for hospitals to report echocardiography procedures performed with contrast, as all contrast will be packaged in CY 2008, we have also created the eight new HCPCS codes shown in Table 3 below. We have

assigned HCPCS codes C8921 through C8928 to the newly created APC 0128. Hospitals performing echocardiography procedures without contrast will continue to use the CPT codes indicated in Table 5, while echocardiography procedures performed with contrast will be reported with the newly developed C-codes also identified in Table 5. We will provide further instruction about reporting echocardiography procedures with and without contrast in the January 2007 OPPS update.

TABLE 5.—CY 2008 ECHOCARDIOGRAPHY HCPCS CODES FOR PROCEDURES WITH AND WITHOUT CONTRAST

Echocardiography without contrast				Echocardiography with contrast			
HCPCS	Descriptor	SI	APC	HCPCS	Descriptor	SI	APC
93303	Transthoracic echocardiography for congenital cardiac anomalies; complete.	S	0269	C8921	Transthoracic echocardiography with contrast for congenital cardiac anomalies; complete.	S	0128
93304	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study.	S	0697	C8922	Transthoracic echocardiography with contrast for congenital cardiac anomalies; follow-up or limited study.	S	0128
93307	Echocardiography, transthoracic, real-time with image documentation (2D) with or without M-mode recording; complete.	S	0269	C8923	Transthoracic echocardiography with contrast, real-time with image documentation (2D) with or without M-mode recording; complete.	S	0128
93308	Echocardiography, transthoracic, real-time with image documentation (2D) with or without M-mode recording; follow-up or limited study.	S	0697	C8924	Transthoracic echocardiography with contrast, real-time with image documentation (2D) with or without M-mode recording; follow-up or limited study.	S	0128
93312	Echocardiography, transesophageal, real time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report.	S	0270	C8925	Transesophageal echocardiography (TEE) with contrast, real time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report.	S	0128
93313	Echocardiography, transesophageal, real time with image documentation (2D) (with or without M-mode recording); placement of transesophageal probe only.	S	0270				
93314	Echocardiography, transesophageal, real time with image documentation (2D) (with or without M-mode recording); image acquisition, interpretation and report only.	N					
93315	Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report.	S	0270	C8926	Transesophageal echocardiography (TEE) with contrast for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report.	S	0128
93316	Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only.	S	0270				
93317	Transesophageal echocardiography for congenital cardiac anomalies; image acquisition, interpretation and report only.	N					
93318	Echocardiography, transesophageal (TEE) for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis.	S	0270	C8927	Transesophageal echocardiography (TEE) with contrast for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis.	S	0128

TABLE 5.—CY 2008 ECHOCARDIOGRAPHY HCPCS CODES FOR PROCEDURES WITH AND WITHOUT CONTRAST—Continued

Echocardiography without contrast				Echocardiography with contrast			
HCPCS	Descriptor	SI	APC	HCPCS	Descriptor	SI	APC
93320	Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete.	N					
93321	Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging).	N					
93325	Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography).	N					
93350	Echocardiography, transthoracic, real-time with image documentation (2D), with or without M-mode recording, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report.	S	0697	C8928	Transthoracic echocardiography with contrast, real-time with image documentation (2D), with or without M-mode recording, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report.	S	0128

In order to determine a payment rate for APC 0128 for CY 2008, we isolated single and “pseudo” single claims in our database that included those CPT codes in the range of 93303 through 93350 that correspond to the contrast studies described by the new C-codes. We created new C-codes for contrast studies only to parallel those CPT codes for procedures where we expected that the procedures could be provided with

or without contrast. For claims where an echocardiography procedure was billed with a contrast agent, we packaged the payment for the contrast agent into the echocardiography procedure and then calculated the median cost for this subset of claims. This became the median for APC 0128. In addition, we recalculated the medians for APCs 0269 (Level II Echocardiogram Without Contrast Except Transesophageal); 0270

(Transesophageal Echocardiogram Without Contrast); and 0697 (Level I Echocardiogram Without Contrast Except Transesophageal), as we needed to remove the claims from the ratesetting process that included contrast because they were used to set the median cost for APC 0128. The resulting CY 2008 APC medians are shown in Table 6.

TABLE 6.—CY 2008 FINAL RULE ECHOCARDIOGRAM APC MEDIANS

APC	Title	HCPCS Codes	Median
0269	Level II Echocardiogram Without Contrast Except Transesophageal	93303 93307	\$401
0270	Transesophageal Without Contrast Echocardiogram	93312 93313 93315 93316 93318	\$517
0697	Level I Echocardiogram Without Contrast Except Transesophageal	93304 93308 93350	\$210
0128	Echocardiogram With Contrast	C8921 C8922 C8923 C8924 C8925 C8926 C8927 C8928	\$534

We believe that these medians accurately reflect hospital costs when performing echocardiography procedures, both with and without

contrast. This final coding and payment methodology allows us to both adhere to the statutory requirement to create additional groups of services for

procedures that use contrast agents and to package payment contrast agents in CY 2008. Therefore, we are finalizing our policy to assign HCPCS codes C8921

through C8928 to APC 0128 and will instruct hospitals to use these contrast-specific HCPCS codes when submitting an OPPS claim for echocardiography procedures performed with contrast.

For CY 2008, we are finalizing our proposal to unconditionally packaged payment for all contrast agents, with modification as discussed above. We are fully adopting the APC Panel recommendation to package all contrast media for CY 2008. Consistent with the statute, we are also finalizing the creation of APC 0128, as well as eight Level II HCPCS codes that describe echocardiography procedures performed with contrast. Contrast agents that are packaged are assigned status indicator "N" and are listed in Table 10 of this final rule with comment period.

(7) Observation Services

We proposed to package payment for all observation care, reported under HCPCS code G0378 (Hospital observation services, per hour) for CY 2008. We proposed that payment for observation care would be packaged as part of the payment for the separately payable services with which it is billed. We have defined observation care as a well defined set of specific, clinically appropriate services that include ongoing short-term treatment, assessment, and reassessment before a decision can be made regarding whether patients will require further treatment as hospital inpatients or if they are able to be discharged from the hospital. Observation status is commonly assigned to patients who present to the emergency department and who then require a significant period of treatment or monitoring before a decision is made concerning their next placement or to patients with unexpectedly prolonged recovery after surgery. Throughout the proposed rule and in this final rule with comment period, as well as in our manuals and guidance documents, we use both of the terms "observation services" and "observation care" in reference to the services defined above.

Payment for all observation care under the OPPS was packaged prior to CY 2002. Since CY 2002, separate payment of a single unit of an observation APC for an episode of observation care has been provided in limited circumstances. Effective for services furnished on or after April 1, 2002, separate payment for observation was made if the beneficiary had chest pain, asthma, or congestive heart failure and met additional criteria for diagnostic testing, minimum and maximum limits to observation care time, physician care, and documentation in the medical record

(66 FR 59856, 59879). Payment for observation care that did not meet these specified criteria was packaged.

Between CY 2003 and CY 2006, several more changes were made to the OPPS policy regarding separate payment for observation services, such as: clarification that observation is not separately payable when billed with "T" status procedures on the day of or day before observation care; development of specific Level II HCPCS codes for hospital observation services and direct admission to observation care; and removal of the initially established diagnostic testing requirements for separately payable observation (67 FR 66794, 69 FR 65828, and 70 FR 68688). Throughout this time period, we maintained separate payment for observation care only for the three specified medical conditions, and OPPS payment for observation for all other clinical conditions remained packaged.

Since January 1, 2006, hospitals have reported observation services based on an hourly unit of care using HCPCS code G0378. This code has a status indicator of "Q" under the CY 2007 OPPS, meaning that the OPPS claims processing logic determines whether the observation is packaged or separately payable. The OCE's current logic determines whether observation services billed under HCPCS code G0378 are separately payable through APC 0339 (Observation) or whether payment for observation services will be packaged into the payment for other separately payable services provided by the hospital in the same encounter based on criteria discussed subsequently. (We note that if an HOPD directly admits a patient to observation, Medicare currently pays separately for that direct admission reported under HCPCS code G0379 (Direct admission of patient for hospital observation care) in situations where payment for the actual observation care reported under HCPCS code G0378 is packaged.) For CY 2008, as discussed in more detail later in this final rule with comment period (section XI.), we proposed to continue the coding and payment methodology for direct admission to observation status, with the exception of the requirement that HCPCS code G0379 is only eligible for separate payment if observation care reported under HCPCS code G0378 does not qualify for separate payment. As noted in the proposed rule (72 FR 42674), this requirement would no longer be applicable under our proposal to package all observation services reported under HCPCS code G0378.

For CY 2007, separate OPPS payment may be made for observation services

reported under HCPCS code G0378 provided to a patient when all of the following requirements are met. The hospital would receive a single separate payment for an episode of observation care (APC 0339) when:

1. Diagnosis Requirements

a. The beneficiary must have one of three medical conditions: congestive heart failure, chest pain, or asthma.

b. Qualifying ICD-9-CM diagnosis codes must be reported in Form Locator (FL) 76, Patient Reason for Visit, or FL 67, principal diagnosis, or both in order for the hospital to receive separate payment for APC 0339. If a qualifying ICD-9-CM diagnosis code(s) is reported in the secondary diagnosis field, but is not reported in either the Patient Reason for Visit field (FL 76) or in the principal diagnosis field (FL 67), separate payment for APC 0339 is not allowed.

2. Observation Time

a. Observation time must be documented in the medical record.

b. A beneficiary's time in observation (and hospital billing) begins with the beneficiary's admission to an observation bed.

c. A beneficiary's time in observation (and hospital billing) ends when all clinical or medical interventions have been completed, including follow-up care furnished by hospital staff and physicians that may take place after a physician has ordered the patient be released or admitted as an inpatient.

d. The number of units reported with HCPCS code G0378 must equal or exceed 8 hours.

3. Additional Hospital Services

a. The claim for observation services must include one of the following services in addition to the reported observation services. The additional services listed below must have a line-item date of service on the same day or the day before the date reported for observation:

- An emergency department visit (APC 0609, 0613, 0614, 0615, or 0616); or

- A clinic visit (APC 0604, 0605, 0606, 0607, or 0608); or

- Critical care (APC 0617); or

- Direct admission to observation reported with HCPCS code G0379 (APC 0604).

b. No procedure with a "T" status indicator can be reported on the same day or day before observation care is provided.

4. Physician Evaluation

a. The beneficiary must be in the care of a physician during the period of

observation, as documented in the medical record by admission, discharge, and other appropriate progress notes that are timed, written, and signed by the physician.

b. The medical record must include documentation that the physician explicitly assessed patient risk to determine that the beneficiary would benefit from observation care.

In the context of our proposed CY 2008 packaging approach, we indicated that we believed that it was appropriate to package payment for all observation services reported with HCPCS code G0378 under the CY 2008 OPSS. Primarily, observation services are ideal for packaging because they are always provided as a supportive service in conjunction with other independent separately payable hospital outpatient services such as an emergency department (ED) visit, surgical procedure, or another separately payable service, and thus observation costs can logically be packaged into OPSS payment for independent services. As discussed extensively in this section, packaging payment into larger payment bundles creates incentives for providers to furnish services in the most efficient way that meets the needs of the patient, encouraging long-term cost containment.

As we discussed in the general overview of the CY 2008 packaging approach (section II.A.4.b. of this final rule with comment period), there has been substantial growth in program expenditures for hospital outpatient services under the OPSS in recent years. The primary reason for this upsurge is growth in the intensity and utilization of services rather than the general price of services or enrollment changes. This observed trend is notably reflected in the frequency and costs of separately payable observation care for the last few years. While median costs for an episode of observation care that would meet the criteria for separate payment have remained relatively stable between CYs 2003 and 2006, the frequency of claims for separately payable observation services has rapidly increased. Comparing claims data for separately payable observation care available for proposed rules spanning from CYs 2005 to 2008 (that is, claims data reflecting services furnished from CYs 2003 to 2006), we saw substantial growth in separately payable observation care billed under the OPSS over that time. In CY 2003, the first full year that observation care was separately payable, there were approximately 56,000 claims for separately payable observation care. In

CY 2004, there were approximately 77,000 claims for separately payable observation care. By CY 2005, that number had increased to approximately 124,300 claims, representing an increase of approximately 61 percent over the previous calendar year. Based on the CY 2006 data available for issuance of the proposed rule, the frequency of claims for separately payable observation services increased to more than 271,200 claims which represents an increase of approximately 118 percent over CY 2005 and more than triple the number of claims for CY 2004. While it is not possible to discern the specific factors responsible for the growth in claims for separately payable observation services, as there have been minor changes in both the process and criteria for separate payment for these services over this time period, the substantial growth by itself is noteworthy.

In the proposed rule (72 FR 42675), we indicated that we were also concerned that the current criteria for separate payment for observation services may provide disincentives for efficiency. For CY 2007, in order for observation services to be separately payable, they must last at least 8 hours. While this criterion was put in place to ensure that separate payment is made only for observation services of a substantial duration, it may create a financial disincentive for an HOPD to make a timely determination regarding a patient's safe disposition after observation care ends. By packaging payment for all observation services, regardless of their duration, we would provide incentives for more efficient delivery of services and timely decision-making. The current criterion also prohibits separate payment for observation services when a "T" status procedure (generally a surgical procedure) is provided on the same day or the previous day by the HOPD to the same Medicare beneficiary. Again, this may create a financial disincentive for hospitals to provide minor surgical procedures during a patient's observation stay, unless those procedures are essential to the patient's care during that time period, even if the most efficient and effective performance of those procedures could be during the single HOPD encounter.

Currently, the OPSS pays separately for observation care for only the three original medical conditions designated in CY 2002, specifically chest pain, asthma, and congestive heart failure. As discussed in more detail in the observation section (section XI.) of this final rule with comment period, the APC Panel recommended at its March 2007 meeting that we consider

expanding separate payment for observation services to include two additional diagnoses, syncope and dehydration. As mentioned previously, we have defined observation care as a well-defined set of specific, clinically appropriate services, which include ongoing, short term treatment, assessment, and reassessment, that are furnished while a decision is being made regarding whether a patient will require further treatment as a hospital inpatient or if the individual is able to be discharged from the hospital. Given the definition of observation services, it is clear that, in certain circumstances, observation care could be appropriate for patients with a range of diagnoses. Both the APC Panel and numerous commenters to prior OPSS proposed rules have confirmed their agreement with this perspective. In addition, the June 2006 Institute of Medicine (IOM) Report entitled, "Hospital-Based Emergency Care: At the Breaking Point," encourages hospitals to apply tools to improve the flow of patients through emergency departments, including developing clinical decisions units where observation care is provided. The IOM's Committee on the Future of Emergency Care in the United States Health System recommended that CMS remove the current limitations on the medical conditions that are eligible for separate observation care payment in order to encourage the development of such observation units.

We indicated in the proposed rule (72 FR 42676) that, as packaging payment provides desirable incentives for greater efficiency in the delivery of health care and provides hospitals with significant flexibility to manage their resources, we believed it was most appropriate to treat observation care for all diagnoses similarly by packaging its costs into payment for the separately payable independent services with which the observation is associated. We noted in the proposed rule (72 FR 42676) that this consistent payment methodology would provide hospitals with the flexibility to assess their approaches to patient care and patient flow and provide observation care for patients with a variety of clinical conditions when hospitals conclude that observation services would improve their treatment of those patients. Approximately 70 percent of the occurrences of observation care billed under the OPSS are currently packaged, and this expansion would extend the incentives for efficiency already present for the vast majority of observation services that are already packaged under the OPSS to the remaining 30 percent of

observation services for which we currently make separate payment.

The estimated overall impact of these changes, presented in section XXII.B. of the proposed rule (and in section XXIV.B. of this final rule with comment period), was based on the assumption that hospital behavior would not change with regard to when the dependent observation care is provided in the same encounter and by the same hospital that performs the independent services. To the extent that hospitals could change their behavior and cease providing observation services, refer patients elsewhere for that care, or increase the frequency of observation services, the data would show such a change in practice in future years and that change would be reflected in future budget neutrality adjustments. However, with respect to observation care, we indicated that we believe that hospitals are limited in the extent to which they could change their behavior with regard to how they furnish these services because observation care, by definition, is short-term treatment, assessment, and reassessment before a decision can be made regarding whether patients will require further treatment as hospital inpatients or if they are able to be discharged from the hospital after receiving the independent services. We indicated that we believe it is unlikely that hospitals will cease providing medically necessary observation care or refer patients elsewhere for that care if they were unable to reach a decision that the patient could be safely discharged from the outpatient department. We stated in the proposed rule (72 FR 42677) that we expect that hospitals would always bill the supportive observation services on the same claim as the other independent services provided in the single hospital encounter.

As we indicated earlier, in all cases we proposed that hospitals that furnish the observation care in association with independent services must bill those services on the same claim so that the costs of the observation services can be appropriately packaged into payment for the independent services. We stated in the proposed rule (72 FR 42677) that we expected to carefully monitor any changes in billing practices on a service-specific and hospital-specific basis to determine whether there is reason to request that QIOs review the quality of care furnished or to request that Program Safeguard Contractors review the claims against the medical record.

During its September 2007 APC Panel meeting, the APC Panel recommended that CMS not package observation services as proposed, thereby

maintaining the CY 2007 payment policy. However, the APC Panel indicated that if CMS were to package observation, CMS should create a composite emergency department/clinic and observation APC (or group of composite APCs) that would be paid only when both services were furnished; if the composite APC were paid, neither the emergency department nor the clinic visit would be paid separately. The APC Panel recommended that coding and service requirements currently applicable to separately paid observation would remain the same, with the exception that there would be no clinical condition (that is, diagnosis) restrictions on payment for the composite APC. The APC Panel noted that payment rates for this (these) composite APC(s) would need to be adjusted based on readily available historical visit and observation data.

We received many public comments on our proposal to package payment for observation services into the payment for the services with which it is furnished. A summary of public comments and our responses follow.

Comment: Several commenters, including MedPAC, requested that CMS finalize its policy to package payment for all observation care. MedPAC specifically stated that packaging of observation care is logical because currently 70 percent of observation care is packaged. However, most commenters addressing observation packaging requested that CMS finalize its proposal to package all of the categories of codes that it identified in the proposed rule, with the exception of observation care. Many of these commenters stated that observation care is often a significant service and is not supportive and integral to an independent service. These commenters recommended that CMS implement various policies, such as paying separately for all observation care regardless of diagnosis, expanding the diagnoses that would enable separate payment, postponing packaging observation services, or creating a composite APC to allow separate payment for observation care in certain circumstances.

Response: Based on our review of the comments received, we continue to believe that observation services are usually ancillary and supportive to the other independent services that are provided to the patient on the same day. However, we accept the commenters' and the APC Panel's statements that observation care may sometimes rise to the level of a major component service, specifically, when it is provided for 8 hours or more in association with a high level clinic or ED visit, direct admission

to observation, or critical care services and it is not provided in conjunction with a surgical procedure. In addition, based on our review of the clinical circumstances provided by many commenters, we recognize that observation care can be a major component service when provided to patients with clinical conditions other than congestive heart pain, chest pain, and asthma for which separate observation payment may currently be provided under the OPSS.

Consistent with our statutory flexibility to define what constitutes a service under the OPSS, we proposed to view a service, in some cases, as the totality of care provided in a hospital outpatient encounter that would be reported with two or more HCPCS codes for component services with the proposal of composite APCs for low dose rate prostate brachytherapy and cardiac electrophysiological evaluation and ablation services. In general, we intend to request public comment on possible composite APCs in the annual OPSS proposed rulemaking cycle. This also includes creating composite APCs, as appropriate, in response to those public comments received during rulemaking.

Therefore, we have decided to create two composite APCs that will provide payment to hospitals in certain circumstances when extended assessment and management of a patient occur. These composite APCs describe an extended encounter for care provided to a patient. Specifically, we are creating two new composite APCs for CY 2008, APCs 8002 (Level I Extended Assessment and Management Composite) and 8003 (Level II Extended Assessment and Management Composite). APC 8002 describes an encounter for care provided to a patient that includes a high level (Level 5) clinic visit or direct admission to observation in conjunction with observation services of substantial duration. APC 8003 describes an encounter for care provided to a patient that includes a high level (Level 4 or 5) emergency department visit or critical care services in conjunction with observation services of substantial duration. As with the other composite APCs that we proposed, we anticipate that assignment to and payment through one of these two new composite APCs will be transparent from a billing perspective. The OCE will evaluate every claim received to determine if payment through a composite APC is appropriate. If payment through a composite APC is inappropriate, the OCE in conjunction with the PRICER, will determine the appropriate status

indicator, APC, and payment for every code on a claim. The specific logic associated with the two Extended Assessment and Management Composite APCs is detailed below.

APC 8002 will be assigned when 8 or more units of HCPCS code G0378 (Hospital observation service, per hour) are billed—

- On the same day as HCPCS code G0379 (Direct admission of patient for hospital observation care); or
- On the same day or the day after—
 - ++ CPT code 99205 (Office or other outpatient visit for the evaluation and management of a new patient (Level 5)); or
 - ++ CPT code 99215 (Office or other outpatient visit for the evaluation and management of an established patient (Level 5)).

If a hospital provides a service with status indicator “T” on the same date of service, or 1 day earlier than the date of service associated with HCPCS code G0378, the hospital will not be eligible for payment under APC 8002. There is no diagnosis requirement for purposes of this composite APC. Rather, patients with any diagnosis may trigger payment of APC 8002. If any of the criteria listed above are not met, payment would not be made through APC 8002. Instead, payment for any separately payable services, including the clinic visit, would be made through the usual associated APCs. Payment for a direct admission to observation would be made according to the usual HCPCS code G0379 payment criteria and payment for HCPCS code G0378 would remain packaged because we consider the observation care to be supportive and ancillary to whichever service(s) it accompanies.

APC 8003 will be assigned when eight or more units of HCPCS code G0378 (Hospital observation service, per hour) are billed on the same day or the day after CPT code 99284 (Emergency department visit for the evaluation and management of a patient (Level 4)), 99285 (Emergency department visit for the evaluation and management of a patient (Level 5)); or 99291 (Critical care, evaluation and management of the critically ill or critically injured patient; first 30–74 minutes). The remaining criteria are identical to the criteria associated with composite APC 8002. If a hospital provides a service with status indicator “T” on the same date of service, or one day earlier than the date of service associated with HCPCS code G0378, the composite APC 8003 would not apply. Instead, payment for the ED visit or critical care and any other separately payable services will be made through the usual associated APCs, and

payment for HCPCS code G0378 for observation services will remain packaged because we consider the observation care to be supportive and ancillary to whichever service(s) it accompanies. There is no diagnosis requirement for purposes of this composite APC either. Instead, patients with any diagnosis may trigger payment of APC 8003.

We note that HCPCS code G0378 will continue to be assigned status indicator “N,” signifying that its payment is always packaged. As stated above, in most circumstances, observation services are supportive and ancillary to the other services provided to a patient. In the circumstances when observation care is elevated to a major component service in conjunction with a high level visit or direct admission that is an integral part of a patient’s extended encounter for care, payment is made for the entire care encounter through APC 8002 or 8003, as appropriate.

We are retaining as general reporting requirements for all observation services those criteria related to physician order and evaluation, documentation, and observation beginning and ending time as listed in section XI. of this final rule with comment period. Those are more general requirements that encourage hospitals to provide medically reasonable and necessary care and help to ensure the proper reporting of observation services on correctly coded hospital claims that reflect the full charges associated with all hospital resources utilized to provide the reported services.

The CY 2008 median cost for APC 8002 (Level I Extended Assessment and Management Composite) is approximately \$347. The payment associated with APC 8002 is intended to pay the hospital for the costs associated with a single episode of extended assessment and management that includes a high level clinic visit or direct admission to the hospital for observation care, 8 hours or more of observation services, and any associated packaged services. We calculated this median cost using all CY 2006 single bill claims that met the criteria for APC 8002, as specified above. The CY 2008 median cost for APC 8003 (Level II Extended Assessment and Management Composite) is approximately \$631. The payment associated with APC 8003 is intended to pay the hospital for the costs associated with a single episode of more intense extended assessment and management that includes a high level emergency department visit or critical care services, 8 hours or more of observation services, and any associated packaged services. We calculated this

median cost using all CY 2006 single bill claims that met the criteria for APC 8003, as specified above.

While analyzing CY 2006 claims data, the most current full year claims data available, we observed that applying CY 2008 criteria for composite APCs resulted in payment for 55 percent more instances of observation care through a composite APC than if we had applied the CY 2007 criteria to those same claims. In addition, our CY 2006 claims data indicate that close to 30 percent of all observation care was paid separately. We estimate that roughly 90 percent of those instances of separately payable observation care reported in CY 2006 would be eligible for payment through composite APCs 8002 and 8003, using CY 2008 criteria. Those separately payable observation services that would not be eligible for payment through a composite APC involve observation services that were associated with low level clinic or emergency department visits. In addition, some of the packaged observation care that was provided in CY 2006 would be eligible for payment through composite APCs 8002 and 8003 because we are eliminating the diagnosis requirement for CY 2008.

As noted in detail in section IX.C of this final rule with comment period, we see a normal and stable distribution of clinic and ED visit levels. We do not expect this distribution to change due to the increase in claims for high level visits that may result from the new composite APCs. Depending on our CY 2008 claims data (which would be used for the CY 2010 OPPS), we may choose to modify the composite APCs that we are creating for CY 2008 or move to packaging observation care as we originally proposed to create further incentives for hospitals to operate in an efficient way.

In summary, for CY 2008, payment for observation services will remain packaged with status indicator “N.” We are creating two composite APCs for extended assessment and management, of which observation care is a component major service. When criteria for payment of the composite APCs are met, separate payment will be made to the hospital through the composite APC. This composite APC payment methodology will contribute to our goal of providing payment under the OPPS for a larger bundle of component services provided in a single hospital outpatient encounter, creating additional hospital incentives for efficiency and cost containment, while providing hospitals with the most flexibility to manage their resources.

d. Development of Composite APCs

(1) Background

As we discuss above in regard to our reasons for our packaging approach for the CY 2008 OPPS, we believe that it is crucial that the payment approach of the OPPS create incentives for hospitals to seek ways to provide services more efficiently than exist under the current OPPS structure and allow hospitals maximum flexibility to manage their resources. The current OPPS structure usually provides payment for individual services which are generally defined by individual HCPCS codes. We currently package the costs of some items and services (such as drugs and biologicals with an average per day cost of less than \$55) into the payment for separately payable individual services. However, because the extent of packaging in the OPPS is currently modest, furnishing many individual separately payable services increases total payment to the hospital. We believe that this aspect of the current OPPS structure is a significant factor in the growth in volume and spending that we discuss in our general overview and provides a primary rationale for the packaging approach for services that we proposed for the CY 2008 OPPS. While packaging payment for supportive dependent services into the payment for the independent services which they accompany promotes greater efficiency and gives hospitals some flexibility to manage their resources, we believe that payment for larger bundles of major separately paid services that are commonly performed in the same hospital outpatient encounter or as part of a multi-day episode of care would create even more incentives for efficiency, as discussed earlier. Moreover, defining the "service" paid under the OPPS by combinations of HCPCS codes for component services that are commonly performed in the same encounter and that result in the provision of a complete service would enable us to use more claims data and to establish payment rates that we believe more appropriately capture the costs of services paid under the OPPS.

Section 1833(t)(1)(B) of the Act permits us to define what constitutes a "service" for purposes of payment under the OPPS and is not restricted to defining a "service" as a single HCPCS code. For example, the OPPS currently packages payment for certain items and services reported with HCPCS codes into the payment for other separately payable services on the claim. Consistent with our statutory flexibility to define what constitutes a service under the OPPS, we proposed to view

a service, in some cases, as not just the diagnostic or treatment modality identified by one individual HCPCS code but as the totality of care provided in a hospital outpatient encounter that would be reported with two or more HCPCS codes for component services.

In view of this statutory flexibility to define what constitutes a "service" for purposes of OPPS payment, our desire to encourage efficiency in HOPD care, our focus on value-based purchasing, and our desire to use as much claims data as possible to set payment rates under the OPPS, we examined our claims data to determine how we could best use the multiple procedure claims ("hardcore" multiples) that are otherwise not available for ratesetting because they include multiple separately payable procedures furnished on the same date of service. As discussed in more detail in our discussion of single and multiple procedure claims in section II.A.1.b. of this final rule with comment period, we have focused in recent years on ways to convert multiple procedure claims to single procedure claims to maximize our use of the claims data in setting median costs for separately payable procedures. We have been successful in using the bypass list to generate "pseudo" single procedure claims for use in median setting, but this approach generally does not enable us to use the hardcore multiple claims that contain multiple separately payable procedures, all with associated packaging that cannot be split among them. We believe that we could use the data from many more multiple procedure claims by creating APCs for payment of those services defined as frequently occurring common combinations of HCPCS codes for component services that we see in correctly coded multiple procedure claims.

Our examination of data for multiple procedure claims identified two specific sets of services that we believe are good candidates for payment based on the naturally occurring common combinations of component codes that we see on the multiple procedure claims. These are low dose rate (LDR) prostate brachytherapy and cardiac electrophysiologic evaluation and ablation services.

Specifically, we have been told (and our data support) that claims for LDR prostate brachytherapy, when correctly coded, report at least two major separately payable procedure codes the majority of the time. For reasons discussed below, in the CY2008 OPPS/ASC proposed rule (72 FR 42678 through 42679), we proposed to use these correctly coded claims that would

otherwise be unusable hardcore multiples as the basis for an encounter-based composite APC that would make a single payment when both codes are reported with the same date of service. We also proposed to pay separately for these procedure codes in cases where only one of the two procedures is provided in a hospital encounter, through the APC associated with that component procedure code that is furnished.

Similarly, we have been told (and our data support) that multiple cardiac electrophysiologic evaluation, mapping, and ablation services are typically furnished on the same date of service and that the correctly coded claims are typically the multiple procedure claims that include several component services and that we are unable to use in our current claims process. The CY 2007 CPT book introductory discussion in the section entitled "Intracardiac Electrophysiological Procedures/ Studies" notes that, in many circumstances, patients with arrhythmias are evaluated and treated at the same encounter. Therefore, as discussed in detail below, we also proposed to establish an encounter based composite APC for these services that would provide a single payment for certain common combinations of component cardiac electrophysiologic services that are reported on the same date of service.

These composite APCs reflect an evolution in our approach to payment under the OPPS. Where the claims data show that combinations of services are commonly furnished together, in the future we will actively examine whether it would be more appropriate to establish a composite APC under which we would pay a single rate for the service reported with a combination of HCPCS codes on the same date of service (or different dates of service) than to continue to pay for these individual services under service-specific APCs. We proposed these specific encounter-based composite APCs for CY 2008 because we believe that this approach could move the OPPS toward possible payment based on an encounter or episode-of-care basis, enable us to use more valid and complete claims data, create hospital incentives for efficiency, and provide hospitals with significant flexibility to manage their resources that do not exist when we pay for services on a per service basis. As such, we indicated that these proposed composite APCs may serve as a prototype for future creation of more composite APCs, through which we could provide OPPS payment for other types of services in the future. We

noted that while these proposed composite APCs for CY 2008 are based on observed combinations of component HCPCS codes reported on the same date of service for a single encounter, we also would be exploring in the future how we could potentially set payments based on episodes of care involving services that extend beyond the same date but which are all supportive of a single, related course of treatment. While we did not propose to implement multiday episode-of-care APCs in CY 2008, we welcomed comments on the concept of developing these APCs to provide payment for such episodes in order to inform our future analyses in this area.

While we have never previously used the term "composite" APC under the OPPS, we have one historical payment policy that resembles the CY 2008 proposed composite APC policy. Since the inception of the OPPS, CMS has limited the aggregate payment for specified less intensive mental health services furnished on the same date to the payment for a day of partial hospitalization, which we considered to be the most resource intensive of all outpatient mental health treatment (65 FR 18455). The costs associated with administering a partial hospitalization program represent the most resource intensive of all outpatient mental health treatment, and we do not believe that we should pay more for a day of individual mental health services under the OPPS. Through the OCE, when the payment for specified mental health services provided by one hospital to a single beneficiary on one date of service based on the payment rates associated with the APCs for the individual services would exceed the per diem partial hospitalization payment (listed as APC 0033 (Partial Hospitalization)), those specified mental health services are assigned to APC 0034, which has the same payment rate as APC 0033, and the hospital is paid one unit of APC 0034. This longstanding policy regarding payment of APC 0034 for combinations of independent services provided in a single hospital encounter resembles the payment policy for composite APCs that we proposed for LDR prostate brachytherapy and cardiac electrophysiologic evaluation and ablation services for CY 2008. Similar to the logic for the proposed composite APCs, the OCE determines whether to pay these specified mental health services individually or to make a single payment at the same rate as the per diem rate for partial hospitalization for all of the specified mental health services furnished on that date of service. However, we note this

established policy for payment of APC 0034 differs from the proposed policies for the new CY 2008 composite APCs because APC 0034 is only paid if the sum of the individual payment rates for the specified mental health services provided on one date of service exceeds the APC 0034 payment rate, which equals the per diem rate of APC 0033 for partial hospitalization.

We did not propose to change this mental health services payment policy for CY 2008. However, we proposed to change the status indicator from "S" to "Q" for the HCPCS codes for the specified mental health services to which APC 0034 applies because those codes are conditionally packaged when the sum of the payment rates for the single code APCs to which they are assigned exceeds the per diem payment rate for partial hospitalization. While we have not published APC 0034 in Addendum A in the past, we are including it in Addendum A to this final rule with comment period entitled "Mental Health Composite," consistent with our naming taxonomy and publication of the two other composite APCs. We are also including the mental health composite APC 0034 and its member HCPCS codes in Addendum M to this final rule with comment period in the same way that we show the HCPCS codes to which the LDR Prostate Brachytherapy Composite APC and Cardiac Electrophysiologic Evaluation and Ablation Composite APC apply.

We solicited public comments on the concept of composite APCs in general and, specifically, the two new proposed encounter-based composite APCs for CY 2008, and we expressed our hope of involving the public and the APC Panel in the creation of additional composite APCs. As stated in the proposed rule (72 FR 42679), our goal is to use the many naturally occurring multiple procedure claims that cannot currently be incorporated under the existing APC structure, regardless of whether the naturally occurring pattern of multiple procedure claims prevents the development of single bills for individual services.

We received many comments on the concept of composite APCs in general and on the proposal to create the LDR Prostate Brachytherapy Composite and the Electrophysiologic Evaluation and Ablation Composite APC in particular. A summary of the comments and our responses follow.

Comment: In general, most commenters supported the creation of the two composite APCs that were proposed for CY 2008: Cardiac Electrophysiologic Evaluation and Ablation Composite (APC 8000) and

Low Dose Rate Prostate Brachytherapy Composite (APC 8001). Commenters, including MedPAC and the APC Panel, supported the implementation of the proposed composite APCs. Commenters stated that creation of these composites will enable use of more multiple claims data and enable the payment system to better reflect the reality of how services are commonly furnished. In particular, MedPAC indicated that it supports the proposed composite APCs because they will increase incentives for efficiency and can serve as a starting point for payment bundles that reflect encounters or episodes of care. MedPAC indicated that it will be exploring both packaging and bundling under the OPPS in its future work. Other commenters objected to the creation of composite APCs because they believed that they are dependent on proposed packaging changes that the commenters do not support. Other commenters supported the concept of composite APCs as long as a composite is limited to related services furnished on the same date of service. These commenters believed that the creation of composite APCs for discontinuous services that span multiple dates of service would present too many problems to be viable.

Response: We appreciate the commenters' support for the creation of the two proposed composite APCs and we will implement the proposed new composite APCs 8000 and 8001 for services furnished on and after January 1, 2008. We also acknowledge that the viability of the composite APCs is dependent on packaging of the supportive and ancillary services. However, as discussed above, we are finalizing the proposed packaging approach, with modifications, and therefore, we believe that it is appropriate to finalize the creation of these two composite APCs for the CY 2008 OPPS. We will take the commenters' concerns with regard to the possible creation of composite APCs for discontinuous services that span multiple dates of service into account in development of future proposals for composite APCs.

Comment: Some commenters asked that CMS provide a clear and transparent process for identifying and calculating payments for future composite APCs and asked that CMS evaluate closely the impact of the proposed composites on payment adequacy and access to care before expanding to other services. They asserted that any development of further composite APCs should include the views of all stakeholders.

Response: We expect that in the future, we would identify possible

composite APCs using the same process that we used to identify the codes in composite APCs 8000 and 8001. As we described in the proposed rule, we examined the multiple procedure claims that we could not convert to single procedure claims to identify common combinations of services for which we had relatively few single procedure claims. We then performed a clinical assessment of the combinations that we identified to determine whether our findings were consistent with our understanding of the services furnished. After we defined the minimal combination of services for which we would pay under the composite APC, we then identified claims for which the only separately paid codes were members of the composite, and we calculated the median cost for the package of services, including the costs of the packaged services. We intend to proceed carefully in examining the potential for creation of more composite APCs. In general, we intend to follow this process for creation of composite APCs and to request public comment in the rulemaking cycle, which is our standard process for securing the views of stakeholders. See section II.A.4.c.(7). for our discussion of the composite APCs we created for this final rule with comment period, specifically APC 8002 (Level I Extended Assessment and Management Composite) and APC 8003 (Level II Extended Assessment and Management Composite).

Comment: Some commenters asked that CMS ensure that all packaged costs are captured in the payment rate for the composite APC. Other commenters stated that there are many intraoperative services that we proposed to package that may or may not be done at the same time and whose costs, when packaged may not be fully accommodated in the composite payment and should therefore be paid separately in addition to the payment for the composite APCs. Some commenters identified services that CMS proposed to package for which they believed separate payment should be made outside of the composite APC payment. For example, one commenter asked that CPT code 93662 (Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)) continue to be paid separately and not as part of composite APC 8000 because its cost is high but the frequency of its use with the main procedures in APC 8000 is low.

Response: We capture the packaged costs in the creation of the composite APC medians to the extent that the packaged services are reported on the

claims that meet the criteria for composite payment. The effectiveness of the composite APCs is highly dependent upon the packaging of the ancillary and supportive services that are furnished at the same encounter with the services in the composite APC. By packaging guidance, imaging post processing, intraoperative, and imaging supervision and interpretation services we are able to identify many more services that contain only the separately paid procedures that are assigned to the composite APC that we can then use to calculate a median cost for the composite APC. Separate payment for guidance, imaging post processing, intraoperative, and imaging supervision and interpretation services would greatly reduce the number of claims that would be available for use in composite APCs because the HCPCS codes assigned to the composite APC would no longer be the only separately paid procedure codes on the claims and one of the benefits of using a composite APC (enabling use of more claims) would be lost. As with packaging of the costs of OPSS services in general, we package costs into the cost of the major separately paid service being furnished. In the case of the composite APCs, the costs of ancillary and dependent services are packaged into the payment for the composite APC to the extent that they are furnished with the services that are assigned to the composite APC. In general, the premise of the OPSS, like that of other claims-based prospective payment systems, is that hospitals report HCPCS codes and charges to reflect the reality of how they furnish services. In general, we believe we can rely on the claims data to be an accurate reflection of the services that were furnished to Medicare beneficiaries.

Comment: A commenter stated that the composite APCs differ significantly in concept from the conditionally packaged services to which CMS also proposed to assign status indicator "Q" and urged CMS to assign a status indicator other than "Q" to composites so that they would be more easily distinguishable from a conditionally packaged service. Other commenters stated that the definition of the status indicator Q was ill defined and confusing.

Response: For CY 2008, we will assign the status indicator "Q" to composite APCs, to codes that are packaged when billed on the same claim with a procedure that has status indicator "S," "T," "V," or "X," and to codes that are packaged only when billed on the same claim with a procedure that has a status indicator "T." We will consider for CY 2009

whether it would be more appropriate to assign status indicators based on the particular packaging policy that applies to the code.

We appreciate the comments on composite APCs. With respect to our treatment of mental health services, we are not making a change to the longstanding payment policy under which the OPSS pays one unit of APC 0034 in cases in which the total payments for specified mental health services provided on the same date of service would otherwise exceed the payment rate for APC 0033. However, we are changing the status indicator to "Q" for the HCPCS codes for mental health services to which this policy applies and which comprise this existing composite APC, because payment for these services would be packaged unless the sum of the individual payments assigned to the codes would be less than the payment for APC 0034.

(2) Low Dose Rate (LDR) Prostate Brachytherapy Composite APC

(a) Background

LDR prostate brachytherapy is a treatment for prostate cancer in which needles or catheters are inserted into the prostate, and then radioactive sources are permanently implanted into the prostate through the hollow needles or catheters. The needles or catheters are then removed from the body, leaving the radioactive sources in the prostate forever, where they slowly give off radiation to destroy the cancer cells until the sources are no longer radioactive. At least two CPT codes are used to report the composite treatment service because there are separate codes that describe placement of the needles or catheters and application of the brachytherapy sources. LDR prostate brachytherapy cannot be furnished without the services described by both of these codes. Generally, the component services represented by both codes occur in the same operative session in the same hospital on the same date of service. However, we have been told of uncommon cases in which they are furnished in different locations, with the patient being transported from one location to another for application of the sources. In addition, other services, commonly CPT code 76965 (Ultrasonic guidance for interstitial radioelement application) and CPT code 77290 (Therapeutic radiology simulation-aided field setting; complex) are often provided in the same hospital encounter.

CPT code 55875 (Transperineal placement of needles or catheters into

prostate for interstitial radioelement application, with or without cystoscopy) is used to report the placement of the needles or catheters for services furnished on or after January 1, 2007. Before this date, including in the claims for services furnished in CY 2006 that were used to develop the CY 2008 proposed rule, CPT code 55859 (Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy) reported this service. All of the claims for CPT code

55859 (as reported in the CY 2006 claims data) are for the placement of needles or catheters for prostate brachytherapy, although not all are related to permanent brachytherapy source application.

CPT code 77778 (Interstitial radiation source application; complex) is used to report the application of brachytherapy sources and, when billed with CPT code 55859 (or CPT code 55875 after January 1, 2007) for the same encounter, reports placement of the sources in the prostate. We have been told that application of

brachytherapy sources to the prostate is estimated to be about 85 percent of all occurrences of CPT code 77778 under the OPSS, consistent with our CY 2006 claims data used for CY 2008 ratesetting. CPT code 77778 is also used to report the application of sources of brachytherapy to body sites other than the prostate.

Historical coding, APC assignments, and payment rates for CPT codes 55859 (CPT code 55875 beginning in CY 2007) and 77778 are shown below in Table 7.

TABLE 7.—HISTORICAL PAYMENT RATES FOR COMPLEX INTERSTITIAL APPLICATION OF BRACHYTHERAPY SOURCES

OPPS CY	Combination APC	Payment rate for CPT code 77778	APC for HCPCS code 77778	Payment rate for CPT codes 55859/55875	APC for HCPCS code 55859	Brachytherapy source
2000	n/a	\$198.31	APC 0312	\$848.04	APC 0162	Pass-through
2001	n/a	\$205.49	APC 0312	\$878.72	APC 0162	Pass-through
2002	n/a	\$6,344.67	APC 0312	\$2,068.23	APC 0163	Pass-through with pro rata reduction
2003 (prostate brachytherapy with iodine sources).	G0261, APC 648, \$5,154.34.	n/a	n/a	n/a	n/a	Packaged
2003 (prostate brachytherapy with palladium sources).	G0256, APC 649, \$5,998.24.	n/a	n/a	n/a	n/a	Packaged
2003 (not prostate brachytherapy, not including sources).	N/A	\$2,853.58	APC 0651	\$1,479.60	APC 0163	Separate payment based on scaled median cost per source
2004	N/A	\$558.24	APC 0651	\$1,848.55	APC 0163	Cost
2005	N/A	\$1,248.93	APC 0651	\$2,055.63	APC 0163	Cost
2006	N/A	\$666.21	APC 0651	\$1,993.35	APC 0163	Cost
2007	N/A	\$1,035.50	APC 0651	\$2,146.84	APC 0163	Cost

Payment rates for CPT code 77778, in particular, have fluctuated over the years. We have frequently been informed by the public that reliance on single procedure claims to set the median costs for these services results in use of only incorrectly coded claims for LDR prostate brachytherapy because, for application of brachytherapy sources to the prostate, a correctly coded claim is a multiple procedure claim. Specifically, we have been informed that a correctly coded claim for LDR prostate brachytherapy should include, for the same date of service, both CPT codes 55859 and 77778, brachytherapy sources reported with Level II HCPCS codes, and typically separately coded imaging and radiation therapy planning services, and that we should use correctly coded claims to set the median for APC 0651 (Complex Interstitial Radiation Source Application) in particular (where CPT code 77778 is assigned). In presentations to the APC Panel at its March 2006 meeting, and in response to the CY 2006 OPSS proposed rule and CY 2007 OPSS/ASC proposed rule, commenters urged us to set the

payment rate for LDR prostate brachytherapy services using only multiple procedure claims. Specifically for CY 2007, they urged us to sum the costs on multiple procedure claims containing CPT codes 77778 and 55859 (and no other separately payable services not on the bypass list) and, excluding the costs of sources, split the resulting aggregate median cost on the multiple procedure claim according to a preestablished attribution ratio between CPT codes 77778 and 55859. They indicated that any claim for a brachytherapy service that did not also report a brachytherapy source should be considered to be incorrectly coded and thus not reflective of the hospital's resources required for the interstitial source application procedure. The presenters to the APC Panel believed that claims that did not contain both brachytherapy source and source application codes should be excluded from use in establishing the median cost for APC 0651. They believed that hospitals that reported the brachytherapy sources on their claims were more likely to report complete

charges for the associated brachytherapy source application procedure than hospitals that did not report the separately payable brachytherapy sources.

As a result of those comments, for both CYs 2006 and 2007, we used multiple procedure claims containing both CPT codes 55859 and 77778 to determine a median cost for the totality of both services (with both packaging and bypassing of the other commonly furnished services). We compared the median calculated from this subset of claims reflecting the most common clinical scenario to the single bill median costs for CPT codes 55859 and 77778 as a method of determining whether the total payment to the hospital for both services furnished to provide LDR prostate brachytherapy would be reasonable. In both years, we found that the sum of the single bill medians was reasonably close to the median cost of both services from multiple claims when they were treated as a single procedure and the supporting services were either packaged or bypassed for purposes of calculating the

median for the combined pair of codes. (We refer readers to the CY 2006 final rule with comment period (70 FR 68596) and the CY 2007 final rule with comment period (71 FR 68043) for specific discussion of these findings.) Hence, we concluded that the single bill median costs were reasonable and, for both the CYs 2006 and CY 2007 OPPS, we based payment for CPT codes 55859 and 77778 on single procedure claims.

(b) Payment for LDR Prostate Brachytherapy

For the CY 2008 OPPS, we proposed to create a composite APC 8001, titled "LDR Prostate Brachytherapy Composite," that would provide one bundled payment for LDR prostate brachytherapy when the hospital bills both CPT codes 55875 and 77778 as component services provided during the same hospital encounter. It is shown in Addendum A to this final rule with comment period as APC 8001 (LDR Prostate Brachytherapy Composite). As discussed in detail in section VII. of this final rule with comment period, as we proposed, we are continuing to pay sources of brachytherapy separately in accordance with the statute.

In the CY 2006 claims used to calculate the proposed CY 2008 median costs, CPT code 55859 was reported 14,083 times. The proposed rule median cost for CPT code 55859, calculated from 2,232 single and "pseudo" single bills, was approximately \$2,329. The CY 2008 proposed rule median cost for APC 0163 (Level IV Cystourethroscopy and other Genitourinary Procedures) to which CPT code 55859 was assigned for CY 2006 and to which CPT code 55875 is assigned for CY 2007 was approximately \$2,322. In the set of claims used to calculate the median cost for APC 0651, to which CPT code 77778 is the only assigned service, CPT code 77778 was reported 11,850 times. The CY 2008 proposed rule median cost for APC 0651 (and, therefore, for CPT code 77778) based on 339 single and "pseudo" single procedure bills was approximately \$970.

In examining the claims data used to calculate the median costs for the proposed rule, we found 9,807 claims on which both CPT code 55859 and CPT code 77778 were billed on the same date of service. These data suggest that LDR prostate brachytherapy constituted at least 70 percent of CY 2006 claims for CPT code 55859, with the remainder of claims representing the insertion of needles or catheters for high dose rate prostate brachytherapy or unusual clinical situations where the LDR sources were not applied in the same operative session as the insertion of the

needles or catheters. These data are consistent with our understanding of current clinical practice for prostate brachytherapy, and we believe that those multiple claims are correctly coded claims for this common clinical scenario. Similarly, 83 percent of the claims for complex interstitial brachytherapy source application CPT code 77778 also included the CPT code for inserting needles or catheters into the prostate, consistent with our understanding that the vast majority of cases of complex interstitial brachytherapy source application procedures are specifically for the treatment of prostate cancer, rather than other types of cancer.

Using the proposed packaging approach for imaging supervision and interpretation services and guidance services for CY 2008, we were able to identify 1,343 claims, 14 percent of all OPPS claims that reported these two procedures on the same date, that contain both CPT codes 55859 and 77778 on the same date of service and no other separately paid procedure code. We were not able to use more claims to develop this composite APC median cost because there are several radiation therapy planning codes that are commonly reported with CPT codes 55859 and 77778 and that are both separately paid and not on the bypass list because the amount of their associated packaging exceeds the threshold for inclusion on the bypass list. A complete discussion of the bypass list under our CY 2008 packaging policy is provided in section II.A. of this final rule with comment period.

We packaged the costs of packaged revenue codes and packaged HCPCS codes into the sum of the costs for CPT codes 55859 and 77778 to derive a total proposed median cost of approximately \$3,127 for the composite LDR prostate brachytherapy service based upon the 1,343 claims that contained both CPT codes and no other separately paid procedure codes. This is reasonably comparable to \$3,298, the sum of the CPT median costs we calculated using the single procedure bills for CPT codes 55859 and 77778 ((\$2,329 plus \$969). As stated in the proposed rule (72 FR 42680), we believe that the difference between the composite APC median cost based upon those claims that contain both codes and the sum of the median costs for the APCs to which the two individual CPT codes map is minimal and may be attributable to efficiencies in furnishing the services together during a single encounter.

In the proposed rule (72 FR 42681), we indicated our belief that creation of

the composite APC for the payment of LDR prostate brachytherapy is consistent with the statute and with our desire to use more claims data for ratesetting, particularly data from correctly coded claims that reflect typical clinical practice, and to make payment for larger packages and bundles of services to provide enhanced incentives for efficiency and cost containment under the OPPS and to maximize hospital flexibility in managing resources.

Under our proposal, hospitals that furnish LDR prostate brachytherapy would report CPT codes 55875 and 77778 and the codes for the applicable brachytherapy sources in the same manner that they currently report these items and services (in addition to reporting any other services provided), using the same HCPCS codes and reporting the same charges. We would require that hospitals report both CPT codes resulting in the composite APC payment on the same claim when they are furnished to a single Medicare beneficiary in the same facility on the same date of service, and we would make any necessary conforming changes to the billing instructions to ensure that they do not present an obstacle to correct reporting. We may implement edits to ensure that hospitals do not submit two separate claims for these two procedures when furnished on the same date in the same facility. When this combination of codes is reported, the OCE would assign the composite APC 8001 and the PRICER would pay based on the payment rate for the composite APC. The OCE would assign APC 0163 or APC 0651 only when both codes are not reported on the same claim with the same date of service, and we would expect this to be the atypical case. The composite APC would have a status indicator of "T" so that payment for other procedures also assigned to status indicator "T" with lower payment rates would be reduced by 50 percent when furnished on the same date of service as the composite service, in order to reflect the efficiency that occurs when multiple procedures are furnished to a Medicare beneficiary in a single operative session. We would not expect that the composite APC payment would be frequently reduced under the multiple procedure reduction policy because we believe that it is unlikely that a higher paid procedure would be performed on the same date.

We proposed to continue to establish separate payment rates for APC 0651 (to which only CPT code 77778 is assigned) and for APC 0163 (to which we proposed to continue to assign CPT code 55875). In some cases, CPT 55875

may be reported for the insertion of needles or catheters for high dose rate prostate brachytherapy, and the low dose rate brachytherapy source application procedure (CPT code 77778) would not be reported. In high dose rate prostate brachytherapy, the sources are applied temporarily several times over a few days while the needles or catheters remain in the prostate, and the needles or catheters are removed only after all the treatment fractions have been completed. We have also been told by hospitals that, even when LDR prostate brachytherapy is planned, there are occasions in which the needles or catheters are inserted in one facility and the patient is moved to another facility for the application of the sources. In those cases, we would need to be able to appropriately pay the hospital that inserted the needles or catheters before the patient was discharged prior to source application. Moreover, there are cases in which the needles or catheters are inserted but it is not possible to proceed to the application of the sources and, therefore, the hospital would correctly report only CPT code 55875. Similarly, more than 10 brachytherapy sources can be applied interstitially (as described by CPT code 77778) to sites other than the prostate and it is, therefore, necessary to have a separate payment rate for CPT code 77778. Hence, for CY 2008 we proposed to continue to pay for CPT code 55875 (the successor to CPT code 55859) through APC 0163 and to pay for CPT code 77778 through APC 0651 when the services are individually furnished other than on the same date of service in the same facility.

Comment: One commenter supported the creation of the composite APC for LDR Prostate Brachytherapy (APC 8001) but was concerned about the assignment of status indicator "T" to APC 8001. The commenter asked which codes would be reduced when furnished with the composite as a result of the assignment of the status indicator "T."

Response: We assigned status indicator "T" to APC 8001 because CPT code 55875 is a surgical service that has a status indicator "T" in APC 163. The multiple surgical reduction will apply only when other surgical procedures that have the status indicator of "T" are performed on the same date of service. Payment for the APC with the highest payment rate with status indicator "T" will not be reduced but payments for other codes on the same claim that also have a status indicator of "T" will be reduced by 50 percent under our standard multiple procedure reduction policy. Currently, when CPT code 55875 is reported with another procedure that

has a status indicator of "T," payment for the service with the lower payment rate would be reduced by 50 percent. Similarly, when CPT code 55875 is paid as part of composite APC 8001 and another procedure that has a status indicator of "T" is also reported on the claim, payment for the composite APC or the other procedure would be reduced by 50 percent, depending on which payment rate was lower. This is the standard OPPS multiple surgical procedure payment reduction policy.

As proposed, we are establishing a composite APC, shown in Addendum A as APC 8001, to provide payment for LDR prostate brachytherapy when the composite service, billed as CPT codes 55875 and 77778, is furnished in a single hospital encounter and to base the payment for the composite APC on the median cost derived from claims that contain both codes. These two CPT codes are assigned status indicator "Q" in Addendum B to this final rule with comment period to signify their conditionally packaged status, and their composite APC assignments are noted in Addendum M. This policy will permit us to base payment on claims for the most common clinical scenario for interstitial radiation source application to the prostate. We note that this payment bundle will also include payment for the commonly associated imaging guidance services, which will be newly packaged under our CY 2008 packaging approach. Most importantly, this composite APC payment methodology will contribute to our goal of providing payment under the OPPS for a larger bundle of component services provided in a single hospital outpatient encounter, creating additional hospital incentives for efficiency and cost containment, while providing hospitals with the most flexibility to manage their resources. In our final calculation of the median cost for this composite APC for CY 2008, we were able to use 7,870 claims that contained both CPT code 77778 and 55859 (the code in effect in 2006) and the median cost on which payment is based is approximately \$3,391. This compares favorably to the proposed rule in which we were able to use only 1,343 claims containing both codes and calculated a proposed median cost of approximately \$3,127. We believe that the number of usable claims increased so greatly as the result of the addition of related procedure codes to the bypass list as a result of public comments. The CY 2008 composite median is slightly less than \$3,410, the sum of the medians for APCs 163 and 651 (\$2,270 + \$1,140), which commenters have told us are

unreliable because they are calculated from single bills although there should never be single bills for this procedure. Hence, we believe that the median cost for the composite APC of approximately \$3,391, which is calculated from bills we believe to be correctly coded will result in a reasonable and appropriate payment rate for this service.

(3) Cardiac Electrophysiologic Evaluation and Ablation Composite APC

(a) Background

During its March 2007 meeting, members of the APC Panel indicated that the reason we found so few single bills for procedures assigned to APC 0087 (Cardiac Electrophysiologic Recording/Mapping), specifically 72 of 11,834 or 0.61 percent of all proposed rule CY 2006 claims, is that most of the services assigned to APCs 0085 (Level II Electrophysiologic Evaluation), 0086 (Ablate Heart Dysrhythm Focus), and 0087 are performed in varying combinations with one another. Therefore, correctly coded claims would most often include multiple codes for component services that are reported with different CPT codes and that are now paid separately through different APCs. There would never be many single bills and those that are reported as single bills would likely represent atypical cases or incorrectly coded claims.

We examined the combinations of services observed in our claims data across these three APCs to see whether there was the potential for handling the data differently so that we could use more claims data to set the payment rates for these procedures, particularly those services assigned to APC 0087 where we have had a persistent concern regarding the limited and reportedly unrepresentative single bills available for use in calculating the median cost according to our standard OPPS methodology. We initially developed and examined frequency distributions of unique combinations of codes on claims which contained at least one unit of any code assigned to APC 0085, 0086, or 0087 and then broadened these analysis to any combination of an electrophysiologic evaluation and ablation code.

Our initial frequency distributions supported the APC Panel members' description of their experiences. We identified and enumerated the most commonly appearing unique occurrences (either single procedures or combinations) of codes for services assigned to status indicator "S," "T," "V," or "X" that contained at least one

code assigned to APC 0085, 0086, or 0087. There were 7,379 claims in the top 100 occurrence types. Table 8 shows the 10 most common unique occurrences from CY 2006 proposed rule claims data available at that time.

TABLE 8.—TEN MOST FREQUENTLY OCCURRING UNIQUE OCCURRENCES OF CARDIAC ELECTROPHYSIOLOGIC EVALUATIONS, MAPPING, AND ABLATION PROCEDURES AND OTHER SEPARATELY PAYABLE SERVICES

Combination No.	Frequency	HCPCS code	Short descriptor	CY 2007 APC	CY 2007 SI
1	763	93620	Electrophysiology evaluation	0085	T
2	509	93609	Map tachycardia, add-on	0087	T
		93620	Electrophysiology evaluation	0085	T
		93621	Electrophysiology evaluation	0085	T
		93623	Stimulation, pacing heart	0087	T
		93651	Ablate heart dysrhythm focus	0086	T
3	398	93609	Map tachycardia, add-on	0087	T
		93620	Electrophysiology evaluation	0085	T
		93621	Electrophysiology evaluation	0085	T
		93651	Ablate heart dysrhythm focus	0086	T
4	381	93650	Ablate heart dysrhythm focus	0086	T
5	376	93620	Electrophysiology evaluation	0085	T
		93623	Stimulation, pacing heart	0087	T
6	248	93005	Electrocardiogram, tracing	0099	S
		93609	Map tachycardia, add-on	0087	T
		93620	Electrophysiology evaluation	0085	T
		93621	Electrophysiology evaluation	0085	T
		93623	Stimulation, pacing heart	0087	T
		93651	Ablate heart dysrhythm focus	0086	T
7	225	93005	Electrocardiogram, tracing	0099	S
		93609	Map tachycardia, add-on	0087	T
		93620	Electrophysiology evaluation	0085	T
		93621	Electrophysiology evaluation	0085	T
		93651	Ablate heart dysrhythm focus	0086	T
8	225	93613	Electrophys map 3d, add-on	0087	T
		93620	Electrophysiology evaluation	0085	T
		93621	Electrophysiology evaluation	0085	T
		93651	Ablate heart dysrhythm focus	0086	T
9	217	93005	Electrocardiogram, tracing	0099	S
		93620	Electrophysiology evaluation	0085	T
10	185	93613	Electrophys map 3d, add-on	0087	T
		93620	Electrophysiology evaluation	0085	T
		93621	Electrophysiology evaluation	0085	T
		93623	Stimulation, pacing heart	0087	T
		93651	Ablate heart dysrhythm focus	0086	T

Although the number of claims for each unique occurrence was modest, we were able to determine that there were certain combinations of codes that occurred most often together. Based on our review of the most frequently occurring combinations of codes on claims that also contained at least one code assigned to APC 0085, 0086 or 0087 and our clinical review of the codes, we proceeded to study combination claims that contained at least one code from group A for evaluation services and at least one code from group B for ablation services reported on the same date of service on an individual claim, as specified in Table 9 below.

TABLE 9.—GROUPS OF CARDIAC ELECTROPHYSIOLOGIC EVALUATION AND ABLATION PROCEDURES ON WHICH WE BASE THE COMPOSITE APC

Codes Used in Combinations: At Least One in Group A and One in Group B	HCPCS code	CY 2007 APC	CY 2007 SI
Group A Electrophysiology evaluation	93619	0085	T
Electrophysiology evaluation	93620	0085	T
Group B Ablate heart dysrhythm focus	93650	0086	T
Ablate heart dysrhythm focus	93651	0086	T
Ablate heart dysrhythm focus	93652	0086	T

When we studied proposed rule claims that contained a code in group A and also a code in group B, we found that there were 5,118 claims that met these criteria, and that of these 5,118 claims, 4,552 (89 percent) contained both CPT code 93620 (Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with right atrial pacing and recording, right ventricular pacing and recording, His bundle recording) from APC 0085 and CPT code 93651 (Intracardiac catheter ablation of arrhythmogenic focus; for treatment of supraventricular tachycardia by ablation of fast or slow atrioventricular pathways, accessory atrioventricular connections or other atrial foci, singly or in combination) from APC 0086 with the same date of service. Given that CPT code 93651 had a total frequency of 8,091, this means that more than 55 percent of the claims for CPT code 93651 also contained CPT

code 93620. CPT code 93620 had a total frequency of 12,624, approximately 50 percent higher than the total frequency for CPT code 93651, which is consistent with our expectations because CPT code 93620 describes a diagnostic service and CPT code 93651 is a treatment service that may be provided based upon the findings of the evaluation described by CPT code 93620. In addition to the codes for group A and group B services, the combination claims also contained costs for packaged services that were reported under revenue codes without HCPCS codes and under packaged HCPCS codes. As we discuss in considerable detail above, we lack a methodology that could be used to allocate these packaged costs to major separately paid procedures in a manner which gives us confidence that the costs would be attributed correctly. We have explored and will continue to explore an alternative strategy that would enable us to use these correctly coded multiple procedure claims for ratesetting.

In our review of these proposed rule claims, not only did we find a high number of claims on which there was one code from group A and one code from group B, but we also found that claims for procedures assigned to APC 0087 for CY 2007 usually appeared on claims that contained a code from APC 0085 or APC 0086, or both. The most frequently appearing CPT codes that were assigned to APC 0087 for CY 2007 were, as shown above, 93609 (Intraventricular and/or intra-atrial mapping of tachycardia site(s), with catheter manipulation to record from multiple sites to identify origin of tachycardia (List separately in addition to code for primary procedure)), 93613 (Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)), 93621 (Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left atrial pacing and recording from coronary sinus or left atrium (List separately in addition to code for primary procedure)), 93622 (Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left ventricular pacing and recording (List separately in addition to code for primary procedure)), and 93623 (Programmed simulation and pacing after intravenous drug infusion (List separately in addition to code for primary procedure)). These codes are all

CPT add-on codes that CPT indicates are to be reported in addition to the code for the primary procedure. Our clinical review of the services described by these five CPT codes determined that they are supportive dependent services that are provided most often as supplemental to procedures assigned to APCs 0085 and 0086. The procedures in APCs 0085 and 0086 can be performed without these supportive add-on procedures, but these dependent services cannot be done except as a supplement to another electrophysiologic procedure. Therefore, we proposed to unconditionally package all of these five CPT codes under the grouping of intraoperative services for the CY 2008 OPPS. We discuss the packaging of intraoperative services in general, including these services, in section II.A.4.c.(3) above.

However, packaging these supportive ancillary services that are so often reported with the cardiac electrophysiologic evaluation and ablation services did not, by itself, enable us to use many more claims because, as we noted previously, the claims on which these codes most commonly appeared typically also contained at least one separately paid code from APC 0085 and one code from APC 0086. Although the most common combination of codes from APCs 0085 and 0086 was the pair of CPT codes 93620 and 93651, there are numerous other combinations of services from APCs 0085 and 0086 that were performed and, while not as frequent, these combinations were also reflected in the multiple claims.

In order to use more claims and adequately reflect the varied, common combinations of electrophysiologic evaluation and ablation CPT codes, we calculated a composite median cost from all claims containing at least one code from group A and at least one code from group B as if they were a single service. We selected multiple procedure claims that contained at least one code in group A and one code in group B on the same date of service and calculated a median cost from the total costs on these claims. Some claims had more than one code from each group. Although the claim was required to contain at least one code from each group to be included, the claim could also contain any number of codes from either group and any number of units of those codes. In addition, the costs of the five supportive intraoperative services previously assigned to APC 0087 that we identify above were packaged, as well as the costs of the other items and services proposed to be packaged for the CY 2008 OPPS. This selection process

yielded 5,118 claims to use for the calculation. The proposed composite median cost for these claims using the CY 2008 proposed rule data was approximately \$8,529. We believe that this cost is attributable largely to the 4,552 claims that contain one unit each of CPT code 93620 and CPT code 93651 (and some unknown numbers and combinations of packaged services). In comparison, the sum of the CY 2008 proposed rule CPT code median costs for CPT code 93620 (which is \$3,111) and CPT code 93651 (which is \$5,644) is approximately \$8,756. If the 50 percent multiple procedure discount is applied to the CPT code median cost for the lower cost procedure based on its assignment to an APC with a "T" status, the adjusted sum of the median costs is \$7,200 (\$5,644 + \$1,556). These medians were calculated using only claims that contain correct devices and do not contain token charges or the "FB" modifier. We believe the significant positive difference between the composite and discounted costs still reflects efficiencies, as the sum of the discounted median costs does not take into account the cost of other procedures also provided that are assigned to APCs 0085 and 0086, while the composite median cost of \$8,528.83 does, to some extent, reflect the cost of other multiple procedures in APCs 0085 and 0086 that were also reported on the claims used to develop the composite median cost. In addition, these two calculations are based upon two different sets of claims, single procedure claims in one case (which do not represent the way the service is typically furnished) and the specified subset of clinically common combination claims in the second case. Moreover, while the 50 percent multiple procedure reduction is our best aggregate estimate of the overall degree of efficiency applicable to multiple surgeries, it may or may not be specifically appropriate to this particular combination of procedures.

By selecting the multiple procedure claims that contained at least one code in each group, we were able to use many more claims than were available to establish the individual APC medians. The percents by CPT code for the composite configuration in Table 24 of the proposed rule (72 FR 42684) represented the sum of the frequency of single bills used to set the medians for APCs 0085 and 0086 with packaging of the five intraoperative services and the frequency of multiple bills used to set the medians for the composite claims containing at least one code from each group and with packaging of the costs

of the five intraoperative services, divided by the total frequency of each CPT code.

Moreover, by packaging CPT codes 93609, 93613, 93621, 93622, and 93623, we were able to use many more of the claims for these codes from the most common clinical scenarios than would otherwise be possible if the supportive intraoperative services were separately paid. Wherever any of these codes appears on a claim that could be used for median setting, the cost data for these codes are packaged in the calculation of the median cost for the separately paid services on the claim.

(b) Payment for Cardiac Electrophysiologic Evaluation and Ablation

In view of our findings with regard to how often the codes in groups A and B appear together on the same claim, we proposed to establish one composite APC, shown in Addendum A of the proposed rule as APC 8000 (Cardiac Electrophysiologic Evaluation and Ablation Composite), for CY 2008 that would pay for a composite service made up of any number of services in groups A and B when at least one code from group A and at least one code from group B appear on the same claim with the same date of service. The five CPT codes involved in this composite APC are assigned to status indicator "Q" in Addendum B to the proposed rule to identify their conditionally packaged status, and their composite APC assignments were identified in Addendum M of the proposed rule. We proposed to use the composite median cost of approximately \$8,529 as the basis for establishing the relative weight for this newly created APC for the composite electrophysiology evaluation and ablation service. Under this composite APC, unlike most other APCs, we proposed to make a single payment for all services reported in groups A and B. We proposed that hospitals would continue to code using CPT codes to report these services and that the OCE would recognize when the criteria for payment of the composite APC are met and would assign the composite APC instead of the single procedure APCs as currently occurs. The PRICER would make a single payment for the composite APC that would encompass the program payment for the code in group A, the code in group B, and any other codes reported in groups A or B, as well as the packaged services furnished on the same date of service. The proposed composite APC would have a status indicator of "T" so that payment for other procedures also assigned to status

indicator "T" with lower payment rates would be reduced by 50 percent when furnished on the same date of service as the composite service, in order to reflect the efficiency that occurs when multiple procedures are furnished to a Medicare beneficiary in a single operative session. We would not expect that the proposed composite APC payment would be commonly reduced because we believe that it is unlikely that a higher paid procedure would be performed on the same date. We proposed to continue to pay separately for other separately paid services that are not reported under the codes in groups A and B (such as chest x-rays and electrocardiograms).

Moreover, where a service in group A is furnished on a date of service that is different from the date of service for a code in group B for the same beneficiary, we proposed that payments would be made under the single procedure APCs and the composite APC would not apply. Given our CY 2008 proposal to unconditionally package payment for five cardiac electrophysiologic CPT codes as members of the category of intraoperative services that were previously assigned to APCs 0085 and 0087, we also proposed to reconfigure APCs 0084 through 0087, where many of the cardiac electrophysiologic procedures that will be separately paid when they are not paid according to the composite APC are assigned. Specifically, we proposed to discontinue APC 0087, and reconfigure APCs 0084, 0085, and 0086, with proposed titles and median costs of Level I Electrophysiologic Procedures (APC 0084) at approximately \$603; Level II Electrophysiologic Procedures (APC 0085) at approximately \$2,976; and Level III Electrophysiologic Procedures (APC 0086) at approximately \$5,842, respectively. We refer readers to section IV.A.2. of this final rule with comment period rule for a discussion of calculation of median costs for device-dependent APCs. We believe this reconfiguration improved the clinical and resource homogeneity of these APCs which would provide payment for cardiac electrophysiologic procedures that would be individually paid when they do not meet the criteria for payment of the composite APC.

We believe that creation of the proposed composite APC for cardiac electrophysiology evaluation and ablation services is the most efficient and effective way to use the claims data for the majority of these services and best represents the hospital resources associated with performing the common combinations of these services that are clinically typical. We believe that the

proposed ratesetting methodology results in an appropriate median cost for the composite service when at least one evaluation service in group A is furnished on the same date as at least one ablation service in group B. This approach creates incentives for efficiency by providing a single payment for a larger bundle of major procedures when they are performed together, in contrast to continued separate payment for each of the individual procedures. We expect to develop additional composite APCs in the future as we learn more about major currently separately paid services that are commonly furnished together during the same hospital outpatient encounter.

We did not receive any public comments specific to the creation of the composite APC for cardiac electrophysiology evaluation and ablation other than those included in the general discussion of composite APCs above. Therefore, we are finalizing the creation of this APC as proposed. For this final rule with comment period, we recalculated the median cost of the APC as proposed. We were able to use 5,596 claims that met the criteria of having at least one code in group A and one code in group B, which had correct device codes, no token charges for devices and no FB modifiers on the claims. Using these 5,596 correctly coded claims from the final rule data, we calculated a median cost from the final rule data of approximately \$8,438. We note that while the number of usable claims for the final rule date increased to 5,596 from the 5,118 claims used in the proposed rule, the median cost declined slightly (approximately 1 percent) to approximately \$8,438 from the \$8,529 median cost calculated from proposed rule data. However, we believe that the median cost for this composite APC is a valid reflection of the estimated relative cost of these services when furnished in combination with one another.

After consideration of the public comments we received on the proposed composite APCs for LDR Prostate Brachytherapy and Cardiac Electrophysiology Evaluation and Ablation, we are finalizing our proposed policy regarding these composite APCs without modification.

In conclusion, we are finalizing our proposed packaging approach with the modifications discussed above for the CY 2008 OPPS. Table 10 in this final rule with comment period displays the list of packaged services in the categories of guidance, image processing, intraoperative services, radiopharmaceuticals, contrast media, imaging supervision and interpretation,

and observation services. Codes in composite APCs, including the two extended assessment and management APCs, are displayed in Addendum M. In Table 10, HCPCS codes with status indicator “N” are always packaged. HCPCS codes with status indicator “Q”

are conditionally packaged. Codes with status indicator “Q” that are for imaging supervision and interpretation are packaged only when reported on the same claim on the same day as a procedure with status indicator “T” and are identified as “T-packaged” in the

sixth column. Codes that are packaged when they are reported on the same claim with a code with status indicator “S,” “T,” “V,” or “X” on the same day are identified as “STVX-packaged” in the sixth column.

TABLE 10.—CY 2008 PACKAGED HCPCS CODES INCLUDED IN SEVEN PACKAGING CATEGORIES

2008 HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	Final CY 2008 SI	“STVX-packaged” or “T-packaged”	Final CY 2008 APC	Category
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
19295	Place breast clip, percut	S	0657	N	n/a	n/a	Guidance
20975	Electrical bone stimulation	X	0340	N	n/a	n/a	Intraoperative.
20985	Cptr-asst dir ms px	n/a	n/a	N	n/a	n/a	Guidance.
20986	Cptr-asst dir ms px io img	n/a	n/a	N	n/a	n/a	Guidance.
20987	Cptr-asst dir ms px pre img	n/a	n/a	N	n/a	n/a	Guidance.
31620	Endobronchial us add-on	S	0670	N	n/a	n/a	Intraoperative.
37250	Iv us first vessel add-on	S	0416	N	n/a	n/a	Intraoperative.
37251	Iv us each add vessel add-on	S	0416	N	n/a	n/a	Intraoperative.
58110	Bx done w/colposcopy add-on	T	0188	N	n/a	n/a	Intraoperative.
61795	Brain surgery using computer	S	0302	N	n/a	n/a	Guidance.
62160	Neuroendoscopy add-on	T	0122	N	n/a	n/a	Guidance.
70010	Contrast x-ray of brain	S	0274	Q	T	0274	Imaging S&I.
70015	Contrast x-ray of brain	S	0274	Q	T	0274	Imaging S&I.
70170	X-ray exam of tear duct	X	0264	Q	T	0317	Imaging S&I.
70332	X-ray exam of jaw joint	S	0275	Q	T	0275	Imaging S&I.
70373	Contrast x-ray of larynx	X	0263	Q	T	0263	Imaging S&I.
70390	X-ray exam of salivary duct	X	0263	Q	T	0263	Imaging S&I.
71040	Contrast x-ray of bronchi	X	0263	Q	T	0263	Imaging S&I.
71060	Contrast x-ray of bronchi	X	0263	Q	T	0317	Imaging S&I.
71090	X-ray & pacemaker insertion	X	0272	N	n/a	n/a	Imaging S&I.
72240	Contrast x-ray of neck spine	S	0274	Q	T	0274	Imaging S&I.
72255	Contrast x-ray, thorax spine	S	0274	Q	T	0274	Imaging S&I.
72265	Contrast x-ray, lower spine	S	0274	Q	T	0274	Imaging S&I.
72270	Contrast x-ray, spine	S	0274	Q	T	0274	Imaging S&I.
72275	Epidurography	S	0274	N	n/a	n/a	Imaging S&I.
72285	X-ray c/t spine disk	S	0388	Q	T	0388	Imaging S&I.
72291	Perq vertebroplasty, fluor	S	0274	N	n/a	n/a	Imaging S&I.
72292	Perq vertebroplasty, ct	S	0274	N	n/a	n/a	Imaging S&I.
72295	X-ray of lower spine disk	S	0388	Q	T	0388	Imaging S&I.
73040	Contrast x-ray of shoulder	S	0275	Q	T	0275	Imaging S&I.
73085	Contrast x-ray of elbow	S	0275	Q	T	0275	Imaging S&I.
73115	Contrast x-ray of wrist	S	0275	Q	T	0275	Imaging S&I.
73525	Contrast x-ray of hip	S	0275	Q	T	0275	Imaging S&I.
73530	X-ray exam of hip	X	0261	N	n/a	n/a	Intraoperative.
73542	X-ray exam, sacroiliac joint	S	0275	Q	T	0275	Imaging S&I.
73580	Contrast x-ray of knee joint	S	0275	Q	T	0275	Imaging S&I.
73615	Contrast x-ray of ankle	S	0275	Q	T	0275	Imaging S&I.
74190	X-ray exam of peritoneum	S	0264	Q	T	0317	Imaging S&I.
74235	Remove esophagus obstruction	S	0257	N	n/a	n/a	Imaging S&I.
74300	X-ray bile ducts/pancreas	X	0263	N	n/a	n/a	Intraoperative.
74301	X-rays at surgery add-on	X	0263	N	n/a	n/a	Intraoperative.
74305	X-ray bile ducts/pancreas	X	0263	N	n/a	n/a	Imaging S&I.
74320	Contrast x-ray of bile ducts	X	0264	Q	T	0317	Imaging S&I.
74327	X-ray bile stone removal	S	0296	N	n/a	n/a	Imaging S&I.
74328	X-ray bile duct endoscopy	N	n/a	N	n/a	n/a	Imaging S&I.
74329	X-ray for pancreas endoscopy	N	n/a	N	n/a	n/a	Imaging S&I.
74330	X-ray bile/panc endoscopy	N	n/a	N	n/a	n/a	Imaging S&I.
74340	X-ray guide for GI tube	X	0272	N	n/a	n/a	Imaging S&I.
74355	X-ray guide, intestinal tube	X	0263	N	n/a	n/a	Imaging S&I.
74360	X-ray guide, GI dilation	S	0257	N	n/a	n/a	Imaging S&I.
74363	X-ray, bile duct dilation	S	0297	N	n/a	n/a	Imaging S&I.
74425	Contrst x-ray, urinary tract	S	0278	Q	T	0278	Imaging S&I.
74430	Contrast x-ray, bladder	S	0278	Q	T	0278	Imaging S&I.
74440	X-ray, male genital tract	S	0278	Q	T	0278	Imaging S&I.
74445	X-ray exam of penis	S	0278	Q	T	0278	Imaging S&I.
74450	X-ray, urethra/bladder	S	0278	Q	T	0278	Imaging S&I.
74455	X-ray, urethra/bladder	S	0278	Q	T	0278	Imaging S&I.
74470	X-ray exam of kidney lesion	X	0263	Q	T	0263	Imaging S&I.
74475	X-ray control, cath insert	S	0297	Q	T	0317	Imaging S&I.

TABLE 10.—CY 2008 PACKAGED HCPCS CODES INCLUDED IN SEVEN PACKAGING CATEGORIES—Continued

2008 HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	Final CY 2008 SI	“STVX-packaged” or “T-packaged”	Final CY 2008 APC	Category
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
74480	X-ray control, cath insert	S	0296	Q	T	0317	Imaging S&I.
74485	X-ray guide, GU dilation	S	0296	Q	T	0317	Imaging S&I.
74740	X-ray, female genital tract	X	0264	Q	T	0263	Imaging S&I.
74742	X-ray, fallopian tube	X	0264	N	n/a	n/a	Imaging S&I.
75600	Contrast x-ray exam of aorta	S	0280	Q	T	0279	Imaging S&I.
75605	Contrast x-ray exam of aorta	S	0280	Q	T	0279	Imaging S&I.
75625	Contrast x-ray exam of aorta	S	0280	Q	T	0279	Imaging S&I.
75630	X-ray aorta, leg arteries	S	0280	Q	T	0279	Imaging S&I.
75635	Ct angio abdominal arteries	S	0662	Q	T	0662	Imaging S&I.
75650	Artery x-rays, head & neck	S	0280	Q	T	0280	Imaging S&I.
75658	Artery x-rays, arm	S	0279	Q	T	0279	Imaging S&I.
75660	Artery x-rays, head & neck	S	0668	Q	T	0280	Imaging S&I.
75662	Artery x-rays, head & neck	S	0280	Q	T	0280	Imaging S&I.
75665	Artery x-rays, head & neck	S	0280	Q	T	0279	Imaging S&I.
75671	Artery x-rays, head & neck	S	0280	Q	T	0280	Imaging S&I.
75676	Artery x-rays, neck	S	0280	Q	T	0279	Imaging S&I.
75680	Artery x-rays, neck	S	0280	Q	T	0279	Imaging S&I.
75685	Artery x-rays, spine	S	0280	Q	T	0279	Imaging S&I.
75705	Artery x-rays, spine	S	0668	Q	T	0279	Imaging S&I.
75710	Artery x-rays, arm/leg	S	0280	Q	T	0279	Imaging S&I.
75716	Artery x-rays, arms/legs	S	0280	Q	T	0279	Imaging S&I.
75722	Artery x-rays, kidney	S	0280	Q	T	0279	Imaging S&I.
75724	Artery x-rays, kidneys	S	0280	Q	T	0279	Imaging S&I.
75726	Artery x-rays, abdomen	S	0280	Q	T	0279	Imaging S&I.
75731	Artery x-rays, adrenal gland	S	0280	Q	T	0279	Imaging S&I.
75733	Artery x-rays, adrenals	S	0668	Q	T	0279	Imaging S&I.
75736	Artery x-rays, pelvis	S	0280	Q	T	0279	Imaging S&I.
75741	Artery x-rays, lung	S	0279	Q	T	0279	Imaging S&I.
75743	Artery x-rays, lungs	S	0280	Q	T	0279	Imaging S&I.
75746	Artery x-rays, lung	S	0279	Q	T	0668	Imaging S&I.
75756	Artery x-rays, chest	S	0279	Q	T	0668	Imaging S&I.
75774	Artery x-ray, each vessel	S	0279	N	n/a	n/a	Imaging S&I.
75790	Visualize A–V shunt	S	0279	Q	T	0668	Imaging S&I.
75801	Lymph vessel x-ray, arm/leg	X	0264	Q	T	0317	Imaging S&I.
75803	Lymph vessel x-ray, arms/legs	X	0264	Q	T	0317	Imaging S&I.
75805	Lymph vessel x-ray, trunk	X	0264	Q	T	0317	Imaging S&I.
75807	Lymph vessel x-ray, trunk	X	0264	Q	T	0317	Imaging S&I.
75809	Nonvascular shunt, x-ray	X	0263	Q	T	0263	Imaging S&I.
75810	Vein x-ray, spleen/liver	S	0279	Q	T	0279	Imaging S&I.
75820	Vein x-ray, arm/leg	S	0668	Q	T	0668	Imaging S&I.
75822	Vein x-ray, arms/legs	S	0668	Q	T	0668	Imaging S&I.
75825	Vein x-ray, trunk	S	0279	Q	T	0279	Imaging S&I.
75827	Vein x-ray, chest	S	0279	Q	T	0668	Imaging S&I.
75831	Vein x-ray, kidney	S	0279	Q	T	0279	Imaging S&I.
75833	Vein x-ray, kidneys	S	0279	Q	T	0279	Imaging S&I.
75840	Vein x-ray, adrenal gland	S	0280	Q	T	0279	Imaging S&I.
75842	Vein x-ray, adrenal glands	S	0280	Q	T	0279	Imaging S&I.
75860	Vein x-ray, neck	S	0668	Q	T	0668	Imaging S&I.
75870	Vein x-ray, skull	S	0668	Q	T	0668	Imaging S&I.
75872	Vein x-ray, skull	S	0279	Q	T	0668	Imaging S&I.
75880	Vein x-ray, eye socket	S	0668	Q	T	0668	Imaging S&I.
75885	Vein x-ray, liver	S	0280	Q	T	0279	Imaging S&I.
75887	Vein x-ray, liver	S	0279	Q	T	0668	Imaging S&I.
75889	Vein x-ray, liver	S	0280	Q	T	0279	Imaging S&I.
75891	Vein x-ray, liver	S	0279	Q	T	0279	Imaging S&I.
75893	Venous sampling by catheter	Q	0668	Q	T	0279	Imaging S&I.
75894	X-rays, transcath therapy	S	0298	N	n/a	n/a	Imaging S&I.
75896	X-rays, transcath therapy	S	0263	N	n/a	n/a	Imaging S&I.
75898	Follow-up angiography	X	0263	Q	STVX	0263	Intraoperative.
75901	Remove cva device obstruct	X	0263	N	n/a	n/a	Imaging S&I.
75902	Remove cva lumen obstruct	X	0263	N	n/a	n/a	Imaging S&I.
75940	X-ray placement, vein filter	S	0298	N	n/a	n/a	Imaging S&I.
75945	Intravascular us	S	0267	Q	T	0267	Imaging S&I.
75946	Intravascular us add-on	S	0266	N	n/a	n/a	Imaging S&I.
75960	Transcath iv stent rs&i	S	0668	N	n/a	n/a	Imaging S&I.
75961	Retrieval, broken catheter	S	0668	N	n/a	n/a	Imaging S&I.
75962	Repair arterial blockage	S	0668	Q	T	0083	Imaging S&I.

TABLE 10.—CY 2008 PACKAGED HCPCS CODES INCLUDED IN SEVEN PACKAGING CATEGORIES—Continued

2008 HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	Final CY 2008 SI	“STVX-packaged” or “T-packaged”	Final CY 2008 APC	Category
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
75964	Repair artery blockage, each	S	0668	N	n/a	n/a	Imaging S&I.
75966	Repair arterial blockage	S	0668	Q	T	0083	Imaging S&I.
75968	Repair artery blockage, each	S	0668	N	n/a	n/a	Imaging S&I.
75970	Vascular biopsy	S	0668	N	n/a	n/a	Imaging S&I.
75978	Repair venous blockage	S	0668	Q	T	0083	Imaging S&I.
75980	Contrast xray exam bile duct	S	0297	N	n/a	n/a	Imaging S&I.
75982	Contrast xray exam bile duct	S	0297	N	n/a	n/a	Imaging S&I.
75984	Xray control catheter change	X	0263	N	n/a	n/a	Imaging S&I.
75989	Abscess drainage under x-ray	N	N	n/a	n/a	Imaging S&I.
75992	Atherectomy, x-ray exam	S	0668	N	n/a	n/a	Imaging S&I.
75993	Atherectomy, x-ray exam	S	0668	N	n/a	n/a	Imaging S&I.
75994	Atherectomy, x-ray exam	S	0668	N	n/a	n/a	Imaging S&I.
75995	Atherectomy, x-ray exam	S	0668	N	n/a	n/a	Imaging S&I.
75996	Atherectomy, x-ray exam	S	0668	N	n/a	n/a	Imaging S&I.
76000	Fluoroscope examination	X	0272	Q	STVX	0272	Guidance.
76001	Fluoroscope exam, extensive	N	n/a	N	n/a	n/a	Guidance.
76080	X-ray exam of fistula	X	0263	Q	T	0263	Imaging S&I.
76125	Cine/video x-rays add-on	X	0260	N	n/a	n/a	Image Processing.
76350	Special x-ray contrast study	N	n/a	N	n/a	n/a	Image Processing.
76376	3d render w/o postprocess	X	0340	N	n/a	n/a	Image Processing.
76377	3d rendering w/postprocess	S	0282	N	n/a	n/a	Image Processing.
76930	Echo guide, cardiocentesis	S	0268	N	n/a	n/a	Guidance.
76932	Echo guide for heart biopsy	S	0309	N	n/a	n/a	Guidance.
76936	Echo guide for artery repair	S	0309	N	n/a	n/a	Guidance.
76937	Us guide, vascular access	N	n/a	N	n/a	n/a	Guidance.
76940	Us guide, tissue ablation	S	0268	N	n/a	n/a	Guidance.
76941	Echo guide for transfusion	S	0268	N	n/a	n/a	Guidance.
76942	Echo guide for biopsy	S	0268	N	n/a	n/a	Guidance.
76945	Echo guide, villus sampling	S	0268	N	n/a	n/a	Guidance.
76946	Echo guide for amniocentesis	S	0268	N	n/a	n/a	Guidance.
76948	Echo guide, ova aspiration	S	0309	N	n/a	n/a	Guidance.
76950	Echo guidance radiotherapy	S	0268	N	n/a	n/a	Guidance.
76965	Echo guidance radiotherapy	S	0308	N	n/a	n/a	Guidance.
76975	GI endoscopic ultrasound	S	0266	Q	T	0267	Imaging S&I.
76998	Us guide, intraop	S	0266	N	n/a	n/a	Guidance.
77001	Fluoro guide for vein device	N	n/a	N	n/a	n/a	Guidance.
77002	Needle localization by xray	N	n/a	N	n/a	n/a	Guidance.
77003	Fluoroguide for spine inject	N	n/a	N	n/a	n/a	Guidance.
77011	Ct scan for localization	S	0283	N	n/a	n/a	Guidance.
77012	Ct scan for needle biopsy	S	0283	N	n/a	n/a	Guidance.
77013	Ct guide for tissue ablation	S	0333	N	n/a	n/a	Guidance.
77014	Ct scan for therapy guide	S	0282	N	n/a	n/a	Guidance.
77021	Mr guidance for needle place	S	0335	N	n/a	n/a	Guidance.
77022	Mri for tissue ablation	S	0335	N	n/a	n/a	Guidance.
77031	Stereotact guide for brst bx	X	0264	N	n/a	n/a	Guidance.
77032	Guidance for needle, breast	X	0283	N	n/a	n/a	Guidance.
77053	X-ray of mammary duct	X	0263	Q	T	0263	Imaging S&I.
77054	X-ray of mammary ducts	X	0263	Q	T	0263	Imaging S&I.
77417	Radiology port film(s)	X	0260	N	n/a	n/a	Guidance.
77421	Stereoscopic x-ray guidance	S	0257	N	n/a	n/a	Guidance.
78020	Thyroid met uptake	S	0399	N	n/a	n/a	Intraoperative.
78478	Heart wall motion add-on	S	0399	N	n/a	n/a	Intraoperative.
78480	Heart function add-on	S	0399	N	n/a	n/a	Intraoperative.
78496	Heart first pass add-on1	S	0399	N	n/a	n/a	Intraoperative.
92547	Supplemental electrical test	X	0363	N	n/a	n/a	Intraoperative.
92978	Intravasc us, heart add-on	S	0670	N	n/a	n/a	Intraoperative.
92979	Intravasc us, heart add-on	S	0416	N	n/a	n/a	Intraoperative.
93320	Doppler echo exam, heart	S	0697	N	n/a	n/a	Intraoperative.
93321	Doppler echo exam, heart	S	0697	N	n/a	n/a	Intraoperative.
93325	Doppler color flow add-on	S	0697	N	n/a	Image Processing.
93555	Imaging, cardiac cath	N	n/a	N	n/a	n/a	Imaging S&I.
93556	Imaging, cardiac cath	N	n/a	N	n/a	n/a	Imaging S&I.
93571	Heart flow reserve measure	S	0670	N	n/a	n/a	Intraoperative.
93572	Heart flow reserve measure	S	0416	N	n/a	n/a	Intraoperative.
93609	Map tachycardia, add-on	T	0087	N	n/a	n/a	Intraoperative.
93613	Electrophys map 3d, add-on	T	0087	N	n/a	n/a	Image Processing.
93621	Electrophysiology evaluation	T	0085	N	n/a	n/a	Intraoperative.

TABLE 10.—CY 2008 PACKAGED HCPCS CODES INCLUDED IN SEVEN PACKAGING CATEGORIES—Continued

2008 HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	Final CY 2008 SI	“STVX-packaged” or “T-packaged”	Final CY 2008 APC	Category
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
93622	Electrophysiology evaluation	T	0085	N	n/a	n/a	Intraoperative.
93623	Stimulation, pacing heart	T	0087	N	n/a	n/a	Intraoperative.
93631	Heart pacing, mapping	T	0087	N	n/a	n/a	Intraoperative.
93640	Evaluation heart device	N	n/a	N	n/a	n/a	Intraoperative.
93641	Electrophysiology evaluation	N	n/a	N	n/a	n/a	Intraoperative.
93662	Intracardiac ecg (ice)	S	0670	N	n/a	n/a	Intraoperative.
95829	Surgery electrocorticogram	S	0214	N	n/a	n/a	Intraoperative.
95873	Guide nerv destr, elec stim	S	0215	N	n/a	n/a	Guidance.
95874	Guide nerv destr, needle emg	S	0215	N	n/a	n/a	Guidance.
95920	Intraop nerve test add-on	S	0216	N	n/a	n/a	Intraoperative.
95955	EEG during surgery	S	0213	N	n/a	n/a	Intraoperative.
95957	EEG digital analysis	S	0214	N	n/a	n/a	Image Processing.
95980	lo anal gast n-stim init	n/a	n/a	N	n/a	n/a	Intraoperative.
96020	Functional brain mapping	X	0373	N	n/a	n/a	Intraoperative.
0126T	Chd risk imt study	N	n/a	Q	STVX	0340	Intraoperative.
0159T	Cad breast MRI	N	n/a	N	n/a	n/a	Image Processing.
0173T	Iop monit io pressure	N	n/a	N	n/a	n/a	Intraoperative.
0174T	Cad cxr remote	N	n/a	N	n/a	n/a	Image Processing.
0175T	Cad cxr with interp	N	n/a	N	n/a	n/a	Image Processing.
A4641	Radiopharm dx agent noc	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A4642	In111 satumomab	H	0704	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9500	Tc99m sestamibi	H	1600	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9501	Technetium TC-99m teboroxime	n/a	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9502	Tc99m tetrofosmin	H	0705	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9503	Tc99m medronate	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9504	Tc99m apcitide	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9505	TL201 thallium	H	1603	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9507	In111 capromab	H	1604	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9508	I131 iodobenguante, dx	H	1045	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9509	Iodine I-123 sod iodide mil	n/a	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9510	Tc99m disofenin	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9512	Tc99m pertechnetate	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9516	I123 iodide cap, dx	H	9148	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9521	Tc99m exametazime	H	1096	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9524	I131 serum albumin, dx	H	9100	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9526	Nitrogen N-13 ammonia	H	0737	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9528	Iodine I-131 iodide cap, dx	H	1088	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9529	I131 iodide sol, dx	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9531	I131 max 100uCi	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9532	I125 serum albumin, dx	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9536	Tc99m depreotide	H	0739	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9537	Tc99m mebrofenin	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.
A9538	Tc99m pyrophosphate	N	n/a	N	n/a	n/a	Diagnostic Radio-pharmaceutical.

TABLE 10.—CY 2008 PACKAGED HCPCS CODES INCLUDED IN SEVEN PACKAGING CATEGORIES—Continued

2008 HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	Final CY 2008 SI	“STVX-packaged” or “T-packaged”	Final CY 2008 APC	Category
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
A9539	Tc99m pentetate	H	0722	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9540	Tc99m MAA	N	n/a	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9541	Tc99m sulfur colloid	N	n/a	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9542	In111 ibritumomab, dx	H	1642	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9544	I131 tositumomab, dx	H	1644	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9546	Co57/58	H	0723	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9547	In111 oxyquinoline	H	1646	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9548	In111 pentetate	H	1647	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9550	Tc99m gluceptate	H	0740	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9551	Tc99m succimer	H	1650	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9552	F18 fdg	H	1651	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9553	Cr51 chromate	H	0741	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9554	I125 iothalamate, dx	N	n/a	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9555	Rb82 rubidium	H	1654	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9556	Ga67 gallium	H	1671	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9557	Tc99m bismate	H	1672	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9558	Xe133 xenon 10mci	N	n/a	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9559	Co57 cyano	H	0724	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9560	Tc99m labeled rbc	H	0742	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9561	Tc99m oxidronate	N	n/a	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9562	Tc99m mertiatide	H	0743	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9566	Tc99m fanolesomab	H	1678	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9567	Technetium TC-99m aerosol	H	0829	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9568	Tc99m arcitumomab	H	1648	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9569	Technetium TC-99m auto WBC	n/a	n/a	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9570	Indium In-111 auto WBC	n/a	n/a	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9571	Indium In-111 auto platelet	n/a	n/a	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9572	Indium In-111 pentetate	n/a	n/a	N	n/a	n/a	Diagnostic Radiopharmaceutical.
A9576	Inj prohance multipack	n/a	n/a	N	n/a	n/a	Contrast Agent.
A9577	Inj multihance	n/a	n/a	N	n/a	n/a	Contrast Agent.
A9578	Inj multihance multipack	n/a	n/a	N	n/a	n/a	Contrast Agent.
A9579	Gad-base MR contrast NOS, 1ml	n/a	n/a	N	n/a	n/a	Contrast Agent.
G0268	Removal of impacted wax md	X	0340	N	n/a	n/a	Intraoperative.
G0275	Renal angio, cardiac cath	N	n/a	N	n/a	n/a	Intraoperative.
G0278	Iliac art angio, cardiac cath	N	n/a	N	n/a	n/a	Intraoperative.
G0288	Recon, CTA for surg plan	S	0417	N	n/a	n/a	Image Processing.
G0378	Hospital observation per hr	Q	339	N	n/a	n/a	Observation.
Q9951	LOCM >= 400 mg/ml iodine, 1ml	K	9163	N	n/a	n/a	Contrast Agent.
Q9953	Inj Fe-based MR contrast, 1ml	K	1713	N	n/a	n/a	Contrast Agent.

TABLE 10.—CY 2008 PACKAGED HCPCS CODES INCLUDED IN SEVEN PACKAGING CATEGORIES—Continued

2008 HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	Final CY 2008 SI	“STVX-packaged” or “T-packaged”	Final CY 2008 APC	Category
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Q9954	Oral MR contrast, 100 ml	K	9165	N	n/a	n/a	Contrast Agent.
Q9955	Inj perflerane lip micros, ml	K	9203	N	n/a	n/a	Contrast Agent.
Q9956	Inj octafluoropropane mic, ml	K	9202	N	n/a	n/a	Contrast Agent.
Q9957	Inj perflutren lip micros, ml	K	9112	N	n/a	n/a	Contrast Agent.
Q9958	HOCM <= 149 mg/ml iodine, 1ml	N	n/a	N	n/a	n/a	Contrast Agent.
Q9959	HOCM 150–199mg/ml iodine, 1ml	N	n/a	N	n/a	n/a	Contrast Agent.
Q9960	HOCM 200–249mg/ml iodine, 1ml	N	n/a	N	n/a	n/a	Contrast Agent.
Q9961	HOCM 250–299mg/ml iodine, 1ml	N	n/a	N	n/a	n/a	Contrast Agent.
Q9962	HOCM 300–349mg/ml iodine, 1ml	N	n/a	N	n/a	n/a	Contrast Agent.
Q9963	HOCM 350–399mg/ml iodine, 1ml	N	n/a	N	n/a	n/a	Contrast Agent.
Q9964	HOCM >= 400mg/ml iodine, 1ml	N	n/a	N	n/a	n/a	Contrast Agent.
Q9965	LOCM 100–199mg/ml iodine, 1ml	n/a	n/a	N	n/a	n/a	Contrast Agent.
Q9966	LOCM 200–299mg/ml iodine, 1ml	n/a	n/a	N	n/a	n/a	Contrast Agent.
Q9967	LOCM 300–399mg/ml iodine, 1ml	n/a	n/a	N	n/a	n/a	Contrast Agent.

e. Service-Specific Packaging Issues

As a result of requests from the public, a Packaging Subcommittee to the APC Panel was established to review all the procedural CPT codes with a status indicator of “N.” Commenters to past rules have suggested that certain packaged services could be provided alone, without any other separately payable services on the claim, and requested that these codes not be assigned status indicator “N.” In deciding whether to package a service or pay for a code separately, we have historically considered a variety of factors, including whether the service is normally provided separately or in conjunction with other services; how likely it is for the costs of the packaged code to be appropriately mapped to the separately payable codes with which it was performed; and whether the expected cost of the service is relatively low. As discussed above regarding our packaging approach for CY 2008, we have modified the historical considerations outlined above in developing our policy for the CY 2008 OPPS. The Packaging Subcommittee discussed many HCPCS codes during the March 2007 APC Panel meeting, prior to development of the packaging approach discussed above, and we have summarized and responded to the APC Panel’s packaging-related recommendations below. Three of the codes reviewed by the Packaging Subcommittee at the March 2007 APC Panel meeting are included in the seven categories of services identified for packaging under the CY 2008 OPPS. For those three codes, we specifically applied the proposed CY 2008 criteria for determining whether a code should be proposed as packaged or separately

payable for CY 2008. Specifically, we determined whether the service is a dependent service falling into one of the seven specified categories that is always or almost always provided integral to an independent service. For those four codes that were reviewed during the March 2007 APC Panel meeting but that do not fit into any of the seven categories of codes that are part of our CY 2008 proposed packaging approach, we applied the packaging criteria described above that were historically used under the OPPS. Moreover, we took into consideration our interest in exploring the possibility of expanding the size of payment groups for component services to provide encounter-based and episode-of-care-based payment in the future in order to encourage hospital efficiency and provide hospitals with maximal flexibility to manage their resources.

In accordance with a recommendation of the APC Panel, for the CY 2007 OPPS, we implemented a new policy that designates certain codes as “special” packaged codes, assigned to status indicator “Q” under the OPPS, where separate payment is provided if the code is reported without any other services that are separately payable under the OPPS on the same date of service. Otherwise, payment for the “special” packaged code is packaged into payment for the separately payable services provided by the hospital on the same date. We note that these “special” packaged codes are a subset of those HCPCS codes that are assigned to status indicator “Q,” which means that their payment is conditionally packaged under the OPPS. We proposed to update our criteria to determine packaged versus separate payment for “special”

packaged HCPCS codes assigned to status indicator “Q” for CY 2008. For CY 2008, payment for “special” packaged codes would be packaged when these HCPCS codes are billed on the same date of service as a code assigned to status indicator “S,” “T,” “V,” or “X.” When one of the “special” packaged codes assigned to status indicator “Q” is billed on a date of service without a code that is assigned to any of the four status indicators noted above, the “special” packaged code assigned to status indicator “Q” would be separately payable.

The Packaging Subcommittee identified areas for change for some currently packaged CPT codes that it believed could frequently be provided to patients as the sole service on a given date and that required significant hospital resources as determined from hospital claims data. Based on the comments received, additional issues, and new data that we shared with the Packaging Subcommittee concerning the packaging status of codes for CY 2008, the Packaging Subcommittee reviewed the packaging status of numerous HCPCS codes and reported its findings to the APC Panel at its March 2007 meeting. The APC Panel accepted the report of the Packaging Subcommittee, heard several presentations on certain packaged services, discussed the deliberations of the Packaging Subcommittee, and recommended that—

1. CMS place CPT code 76937 (Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent real-time ultrasound visualization of vascular needle entry, with permanent

recording and reporting (list separately in addition to code for primary procedure) on the list of "special" packaged codes (status indicator "Q"). (Recommendation 1)

2. CMS evaluate providing separate payment for trauma activation when it is reported on a claim for an ED visit, regardless of the level of the emergency department visit. (Recommendation 2)

3. CMS place CPT code 0175T (Computer aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed remote from primary interpretation) on the list of "special" packaged codes (status indicator "Q"). (Recommendation 3)

4. CMS place CPT code 0126T (Common carotid intima-media thickness (IMT) study for evaluation of atherosclerotic burden or coronary heart disease risk factor assessment) on the list of "special" packaged codes (status indicator "Q") and that CMS consider mapping the code to APC 340 (Minor Ancillary Procedures). (Recommendation 4)

5. CMS place CPT code 0069T (Acoustic heart sound recording and computer analysis only) on the list of "special" packaged codes (status indicator "Q") and that CMS exclude APC 0096 (Non-Invasive Vascular Studies) as a potential placement for this CPT code. (Recommendation 5)

6. CMS maintain the packaged status of HCPCS code A4306 (Disposable drug delivery system, flow rate of less than 50 ml per hour) and that CMS present additional data on this system to the APC Panel when available. (Recommendation 6)

7. CMS reevaluate the packaged OPPS payment for CPT code 99186 (Hypothermia; total body) based on current research and availability of new therapeutic modalities. (Recommendation 7)

8. The Packaging Subcommittee remains active until the next APC Panel meeting. (Recommendation 8)

In addition, the Packaging Subcommittee reported its findings to the APC Panel at its September 2007 meeting. The APC Panel accepted the report of the Packaging Subcommittee, heard presentations on certain packaged services, discussed the deliberations of the Packaging Subcommittee, and recommended that—

9. CMS provide more data at the next APC Panel meeting on HCPCS code A4306 (Disposable drug delivery

system, flow rate of less than 50 mL per hour). (Recommendation 9)

10. The Packaging Subcommittee remains active until the next APC Panel meeting. (Recommendation 10)

We address each of these recommendations in turn in the discussion that follows.

Recommendation 1

For CY 2008, we proposed to maintain CPT code 76937 as a packaged service. We are not adopting the APC Panel's recommendation to pay separately for this code in some circumstances as a "special" packaged code. In the CY 2006 OPPS final rule with comment period (70 FR 68544 through 68545), in response to several public comments, we reviewed in detail the claims data related to CPT code 76937. During its March 2006 APC Panel meeting, after reviewing data pertinent to CPT code 76937, the APC Panel recommended that CMS maintain the packaged status of this code for CY 2007, and we accepted that recommendation. During the March 2007 APC Panel meeting, after reviewing current data and listening to a public presentation, the Panel recommended that we treat this code as a "special" packaged code for CY 2008, noting that certain uncommon clinical scenarios could occur where it would be possible to bill this service alone on a claim, without any other separately payable OPPS services.

We proposed to maintain CPT code 76937 as an unconditionally packaged service for CY 2008, fully consistent with the proposed packaging approach for the CY 2008 OPPS, as discussed above. Because CPT code 76937 is a guidance procedure and we proposed to package payment for all guidance procedures for CY 2008, we believe it is still appropriate to maintain the unconditionally packaged status of this code, which is a CPT designated add-on procedure that we expected to be generally provided only in association with other independent services. We applied the updated criteria for determining whether this service should receive packaged or separately payment under the CY 2008 OPPS. Specifically, we determined that this service was a supportive ancillary service that was integral to an independent service, resulting in our CY 2008 proposal to packaged payment for the service.

We discussed this code extensively in both the CY 2006 and CY 2007 final rules with comment period (70 FR 68544 through 68545; 71 FR 67996 through 67997). Our hospital claims data demonstrated that guidance services were used frequently for the

insertion of vascular access devices, and we had no evidence that patients lacked appropriate access to guidance services necessary for the safe insertion of vascular access devices in the hospital outpatient setting. Because we believe that ultrasound guidance would almost always be provided with one or more separately payable independent procedures, its costs would be appropriately bundled with the handful of vascular access device insertion procedures with which it was most commonly performed. We further believe that hospital staff chose whether to use no guidance or fluoroscopic guidance or ultrasound guidance on an individual basis, depending on the clinical circumstances of the vascular access device insertion procedure.

Therefore, we do not believe that CPT code 76937 is an appropriate candidate for designation as a "special" packaged code. The CY 2007 CPT book indicates that this code is an add-on code and should be reported in addition to the code reported for the primary procedure. According to our CY 2006 claims data available for the proposed rule, this code was billed over 60,000 times, yet less than one-tenth of 1 percent of all claims for the procedure were billed without any separately payable OPPS service on the claim. Because this code is provided alone only extremely rarely, we believe this code would not be appropriately treated as a "special" packaged code. Therefore, we proposed to continue to unconditionally package CPT code 76937 for CY 2008.

We received several comments that referenced CPT code 76937 in discussions related to the packaged status of guidance services in general. Those comments are summarized and responded to in section II.4.c.1 of this final rule with comment period. As noted in that section, we are finalizing our proposal, without modification, to unconditionally package CPT code 76937 for CY 2008.

Recommendation 2

For CY 2008, we proposed to maintain the packaged status of revenue code 068x, trauma response, when the trauma response is provided without critical care services. During the August 2006 APC Panel meeting, the APC Panel encouraged CMS to pay differentially for critical care services provided with and without trauma activation. For CY 2007, as a result of the APC Panel's August 2006 discussion and our own data analysis, we finalized a policy to pay differentially for critical care provided with and without trauma activation. The CY 2007 payment rate

for critical care unassociated with trauma activation is \$405.04 (APC 0617, Critical Care), while the payment rate for critical care associated with trauma activation is \$899.58 (APC 0617 and APC 0618 (Trauma Response with Critical Care)). During the March 2007 APC Panel meeting, a presenter requested that CMS also pay differentially for emergency department visits provided with and without trauma activation. Two organizations that submitted comment letters for the APC Panel's review specifically requested separate payment for revenue code 068x every time it appears on a claim, regardless of the other services that were billed on that claim. The APC Panel recommended that CMS evaluate providing separate payment for trauma activation when it is reported on a claim for an emergency department visit, regardless of the level of the emergency department visit.

After accepting the APC Panel's recommendation and evaluating this issue, we continue to believe that, while it is currently appropriate to pay separately for trauma activation when billed in association with critical care services, it is also currently appropriate to maintain the packaged payment status of revenue code 068x when trauma response services are provided in association with both clinic and emergency department visits under the CY 2008 OPPS. As mentioned above, we are exploring the possibility of expanding the size of the payment groups under the OPPS to move toward encounter-based and episode-of-care-based payments in order to encourage maximum hospital efficiency with a focus on budget-neutral value-based purchasing. Because trauma activation in association with emergency department or clinic visits would always be provided in the same hospital outpatient encounter as the visit for care of the injured Medicare beneficiary, packaging payment for trauma activation when billed in association with both clinic and emergency department visits is most consistent with our proposed packaging approach. We are also concerned that unpackaging payment for trauma activation in those circumstances where the trauma response would be less likely to be essential to appropriately treating a Medicare beneficiary would reduce the incentive for hospitals to provide the most efficient and cost-effective care. We note that, while we proposed for CY 2008 to continue to provide separate payment for trauma activation in association with critical care services, we may reconsider this payment policy

for future OPPS updates as we explore the possibility of developing encounter based and episode-of-care-based payment approaches.

Furthermore, continued packaged payment for trauma activation when unassociated with critical care is consistent with the principles of the OPPS, where hospitals receive payment based on the median cost related to all of the hospital resources associated with the main service provided. In various situations, each hospital's costs may be higher or lower than the median cost used to set payment rates. In light of our packaging approach for the CY 2008 OPPS, we believe it is particularly important not to make any changes in our payment policies for other services that are not fully aligned with promoting efficient, judicious, and deliberate care decisions by hospitals that allow them maximum flexibility to manage their resources through encouraging the most cost-effective use of hospital resources in providing the care necessary for the treatment of Medicare beneficiaries. Packaging payment encourages hospitals to establish protocols that ensure that services are furnished only when they are medically necessary and to carefully scrutinize the services ordered by practitioners to minimize unnecessary use of hospital resources.

Therefore, we are adopting the APC Panel's recommendation that we evaluate providing separate payment for revenue code 068x when provided in association with emergency department visits. For CY 2008, after our thorough assessment, we proposed to maintain the packaged status of revenue code 068x, except when revenue code 068x is billed in association with critical care services.

We did not receive any comments on this proposal. Therefore, we are finalizing our proposal, without modification, to maintain the packaged status of revenue code 068x, trauma response, when the trauma response is provided without critical care services.

We note that we do not anticipate that the new composite Extended Assessment and Management APCs, 8002 and 8003, will affect this policy in any way.

Recommendation 3

For CY 2008, we proposed to maintain the unconditionally packaged status of CPT codes 0174T (Computer aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest

radiograph(s), performed concurrent with primary interpretation) and 0175T. These services involve the application of computer algorithms and classification technologies to chest x-ray images to acquire and display information regarding chest x-ray regions that may contain indications of cancer. CPT code 0152T (Computer aided detection (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation, with or without digitization of film radiographic images; chest radiograph(s) (List separately in addition to code for primary procedure)), the predecessor code to CPT codes 0174T and 0175T, was indicated as an add-on code to chest x-ray CPT codes for CY 2006, according to the AMA's CY 2006 CPT book. However, on July 1, 2006, the AMA released to the public an update that deleted CPT codes 0152T and replaced it with the two new Category III CPT codes 0174T and 0175T.

In its March 2006 presentation to the APC Panel, before the AMA had released the CY 2007 changes to CPT code 0152T, a presenter requested that we pay separately for this service and assign it to a New Technology APC with a payment rate of \$15, based on its estimated cost, clinical considerations, and similarity to other image post-processing services that are paid separately. We proposed to accept the APC Panel's recommendation to package CPT code 0152T for CY 2007.

In its August 2006 presentation to the APC Panel, after the AMA had released the CY 2007 code changes, the same presenter requested that we assign both of the two new codes to a New Technology APC with a payment rate of \$15. The APC Panel members discussed these codes extensively. They considered the possibility of treating CPT code 0175T as a "special" packaged code, thereby assigning payment to the code only when it was performed by a hospital without any other separately payable OPPS service also provided on the same day. They questioned the meaning of the word "remote" in the code descriptor for CPT code 0175T, noting that was unclear as to whether remote referred to time, geography, or a specific provider. They believed it was likely that a hospital without a CAD system that performed a chest x-ray and sent the x-ray to another hospital for performance of the CAD would be providing the CAD service under arrangement and, therefore, would be providing at least one other service (chest x-ray) that would be separately paid. Thus, even in these cases, payment for the CAD service

could be appropriately packaged. After significant and lengthy deliberation, the APC Panel recommended that we package payment for both of the new CPT codes, 0174T and 0175T, for CY 2007.

In its March 2007 presentation to the APC Panel, the same presenter requested that we pay separately for CPT codes 0174T and 0175T, mapping them to New Technology APC 1492, with a payment rate of \$15. The presenter indicated that chest x-ray CAD is not a screening tool and should only be billed to Medicare when applied to chest x-rays suspicious for lung cancer. The presenter also explained that additional and distinct hospital resources are required for chest x-ray CAD that are not required for a standard chest x-ray. In addition, remote chest x-ray CAD described by CPT code 0175T can be performed at a different time or location or by a different provider than the chest x-ray service. The presenter expressed concern that if hospitals were not paid separately for this technology, hospitals would not be able to provide it, thereby limiting beneficiary access to chest x-ray CAD. The APC Panel recommended conditional packaging as a "special" packaged code for CPT code 0175T, but did not recommend a change to the unconditionally packaged status of CPT code 0174T. We are not adopting the APC Panel's recommendation for designation of CPT code 0175T as a "special" packaged code under the CY 2008 OPPS.

We believed and continue to believe that packaged payment for diagnostic chest x-ray CAD under a prospective payment methodology for outpatient hospital services is most appropriate. We proposed to maintain CPT codes 0174T and 0175T as unconditionally packaged services for CY 2008, fully consistent with the packaging approach for the CY 2008 OPPS, as discussed above. Because CPT codes 0174T and 0175T are supportive ancillary services that fit into the "image processing" category, and we proposed to package payment for all image processing services for CY 2008, we believe it is appropriate to maintain the packaged status of these code. We applied the updated criteria for determining whether these two CAD services should receive packaged or separate payment. Specifically, we determined that this service is a dependent service that is integral to an independent service, in this case, the chest x-ray or other OPPS service that we would expect to be provided in addition to the CAD service.

After hearing many public presentations and discussions regarding the use of chest x-ray CAD, we continue

to believe that even the remote service would almost always be provided by a hospital either in conjunction with other separately payable services or under arrangement. For example, if a physician orders a chest x-ray and CAD service to be performed at hospital A and hospital A, which does not have the CAD technology, sends the chest x-ray to hospital B for the performance of chest x-ray CAD, hospital B could only provide the CAD service if it were provided under arrangement, to avoid the OPPS unbundling prohibition. Assuming that the CAD service was provided under arrangement, hospital A would bill for the chest x-ray CAD that was performed by hospital B and would pay hospital B for the service provided. In that case, hospital A would also bill the chest x-ray service that it provided. In another scenario that has been described to us, if a physician were to send a patient to a hospital clinic with the patient's chest x-ray for consultation, we believe that the patient would likely receive a visit service, in addition to the chest x-ray CAD. Therefore, in both of these circumstances, payment for the chest x-ray CAD would be appropriately packaged into payment for the separately payable services with which it was provided.

We also do not believe that CPT code 0175T should be treated as a "special" packaged code. As discussed earlier in this section with regard to our packaging approach for image processing services for CY 2008, we are concerned with establishing payment policies that could encourage certain inefficient and more costly service patterns, particularly for those services that do not need to be provided as a face-to-face encounter with the patient. If we were to assign CPT code 0175T to "special" packaged status, we would likely create an incentive for hospitals to perform chest x-ray CAD remotely, for example, several days after performance of the initial chest x-ray, rather than immediately following the chest x-ray on the same day, to enable the hospital to receive separate payment for the service. In CY 2005, there were approximately 7.3 million claims for all chest x-ray services in the HOPD, so a payment policy that could induce such changes in service delivery would be problematic in light of our commitment to encouraging the most efficient and cost-effective care for Medicare beneficiaries. Creating such perverse payment incentives through conditional packaging is a particular problem for those services that do not need a face-to-face encounter with the patient. In

fact, as part of our proposed CY 2008 packaging approach, we also proposed to unconditionally package payment in CY 2008 for several other image processing services that are not always performed face-to-face, including HCPCS code G0288 (Reconstruction, computer tomographic angiography of aorta for surgical planning for vascular surgery) and CPT code 76377 (3D rendering with interpretation and reporting of computed tomography, magnetic resource imaging, ultrasound, or other tomographic modality; requiring image postprocessing on an independent workstation). As noted in section II.A.4.c.(2) of this final rule with comment period, we are finalizing our proposal for those codes and they will be unconditionally packaged for CY 2008.

The proposed unconditionally packaged treatment of the two CPT codes for chest x-ray CAD is fully consistent with the packaging approach for the CY 2008 OPPS, as discussed above, and the principles and incentives for efficiency inherent in a prospective payment system based on groups of services. Packaging these services creates incentives for providers to furnish services in the most cost-effective way and provides them with the most flexibility to manage their resources. As stated above, packaging encourages hospitals to establish protocols that ensure that services are furnished only when they are medically necessary and to carefully scrutinize the services ordered by practitioners to minimize unnecessary use of hospital resources. Therefore, we proposed to continue to unconditionally package payment for CPT codes 0174T and 0175T for CY 2008.

Comment: One commenter requested that CPT codes 0174T and 0175T, which were provided interim assignments in CY 2007 be assigned to status indicator "S" and be paid separately with a payment rate of \$15. That commenter then requested conditional payment for both of these CPT codes, status indicator "Q" assignment, and a payment rate of \$15. The commenter indicated that this technology is an important diagnostic test for lung cancer patients, and that insufficient payment will limit access to this cost-effective diagnostic tool.

Response: As discussed extensively above, after thorough discussion with the APC Panel and repeated review by our clinical advisors, we continue to believe that these codes are appropriately unconditionally packaged.

For CY 2008, we are finalizing our proposal without modification to unconditionally package CPT codes

0174T and 0175T for CY 2008. We note that these codes fall into the category of the image processing codes that are packaged for the CY 2008 OPPS.

Recommendation 4

For CY 2008, we adopted the APC Panel's recommendation and proposed to add CPT code 0126T to the list of "special" packaged codes and assign this code to APC 0340 (Minor Ancillary Procedures).

This service describes an ultrasound procedure that measures common carotid intima-media thickness to evaluate a patient's degree of atherosclerosis. This code became effective January 1, 2006. We received a comment to the CY 2007 proposed rule requesting that this code become separately payable for CY 2007. At that point, we had no cost data for the service and, as discussed in the CY 2007 OPPS/ASC final rule with comment period (71 FR 67998), we reviewed this code with the Packaging Subcommittee, as is our standard procedure for codes that we are asked to review during the comment period. The APC Panel noted that this service could sometimes be provided to a patient without any other separately payable services. Therefore, the APC Panel recommended that we add this code to the list of "special" packaged codes and pay for it separately when it is provided without any other separately payable services on the same day. For circumstances when this code is paid separately, the APC Panel recommended that we consider assigning this code to APC 0340.

While we continue to believe that this procedure would not commonly be provided alone, we adopted the APC Panel recommendation and proposed to treat this code as a "special" packaged code subject to conditional packaging, mapping to APC 0340 for CY 2008 when it would be separately paid. This is fully consistent with the packaging approach for the CY 2008 OPPS, as discussed above. Because CPT code 0126T is almost always performed during another procedure, and we proposed to package payment for all intraoperative procedures for CY 2008, we believe it is appropriate to designate this CPT code as a "special" packaged code. We applied the updated criteria for determining whether this service should receive packaged or separate payment. Specifically, we determined that this service is usually a dependent service that is integral to an independent service, but that it could sometimes be provided without an independent service.

As with all "special" packaged codes, we will closely monitor cost data and

frequency of separate payment for this procedure as soon as we have more claims data available.

We did not receive any comments related to this proposal. Therefore, we are finalizing our proposal without modification to designate CPT code 0126T as a "special" packaged code for CY 2008. This code is an "STVX-packaged" code.

Recommendation 5

For CY 2008, we proposed to maintain the packaged status of CPT code 0069T, and we are not adopting the APC Panel's recommendation to designate this service as a "special" packaged code. This service uses signal processing technology to detect, interpret, and document acoustical activities of the heart through special sensors applied to a patient's chest. This code was a new Category III CPT code implemented in the CY 2005 OPPS. CPT code 0069T was an add-on code to an electrocardiography (EKG) service for CYs 2005 and 2006. However, effective January 1, 2007, the AMA changed the code descriptor to remove the add-on code designation for CPT code 0069T. This code has been packaged under the OPPS since CY 2005.

During the August 2005 APC Panel meeting, the APC Panel recommended packaging CPT code 0069T for CY 2005. In its March 2006 presentation to the APC Panel, a presenter requested that we pay separately for CPT code 0069T and assign it to APC 0099 (Electrocardiograms) based on its estimated cost and clinical characteristics. The presenter stated that the acoustic heart sound recording and analysis service may be provided with or without a separately reportable electrocardiogram. Members of the APC Panel engaged in extensive discussion of clinical scenarios as they considered whether CPT code 0069T could or could not be appropriately reported alone or in conjunction with several different procedure codes. Ultimately, the APC Panel recommended assigning this service to a separately payable status indicator. However, during the August 2006 meeting, the APC Panel further discussed CMS' proposal to package payment for CPT code 0069T for CY 2007 and considered the CY 2007 code descriptor change, finally recommending that CMS continue to package this code for CY 2007.

During the March 2007 APC Panel meeting, the same presenter requested that we pay separately for this service and assign it to APC 0096 (Non-Invasive Vascular Studies) or to APC 0097 (Cardiac and Ambulatory Blood Pressure Monitoring), with CY 2007

payment rates of \$94.06 and \$62.85, respectively. The presenter stated that the estimated true cost of this service lies between \$62 and \$94. The presenter clarified that this service is usually provided with an EKG, but noted that the test is sometimes provided without an EKG, according to its revised code descriptor for CY 2007. The presenter agreed that it would be rare for the acoustic heart sound procedure to be performed alone without any other separately payable OPPS services. The APC Panel recommended that we place CPT code on the list of "special" packaged codes and that we exclude APC 0096 as a potential placement for this CPT code.

Because this service does not fit into one of the seven identified categories of packaged codes proposed for the CY 2008 OPPS, we followed our historical packaging guidelines to determine whether to maintain the packaged status of this code or to pay for it separately. Based on the clinical uses that were described during the March 2007 and earlier APC Panel meetings, APC Panel discussions, and our claims data review, we continue to believe that it is highly unlikely that CPT code 0069T would be performed in the HOPD as a sole service without other separately payable OPPS services. In addition, our data indicate that this service is estimated to require only minimal hospital resources. Based on CY 2006 claims, we had only 8 single claims for CPT code 0069T, with a median line-item cost of approximately \$5, consistent with its low expected cost. Therefore, we believe that payment for CPT code 0069T is appropriately packaged because it would usually be closely linked to the performance of an EKG or other separately payable cardiac service, would rarely, if ever, be the only OPPS service provided to a patient in an encounter, and has a low estimated resource cost. The proposed packaged treatment of this code is consistent with the principles and incentives for efficiency inherent in a prospective payment system based on groups of services. Therefore, we proposed to continue to package payment for CPT code 0069T for CY 2008.

We did not receive any comments related to this proposal. Therefore, we are finalizing our proposal, without modification, to continue to package payment for CPT code 0069T for CY 2008.

Recommendation 6

For CY 2008, we proposed to adopt the APC Panel's recommendation and maintain the packaged status of HCPCS code A4306. We note that at its

September 2007 APC Panel meeting, the Panel recommended specifically that CMS provide more data at the next meeting on this code.

HCPCS code A4306 describes a disposable drug delivery system with a flow rate of less than 50 ml per hour. As discussed during the March 2007 APC Panel meeting, there is a particular disposable drug delivery system that is specifically used to treat postoperative pain. Since the implementation of the OPPS, this code was assigned to status indicator "A," indicating that it was payable according to another fee schedule, in this case, the Durable Medical Equipment (DME) fee schedule. There were discussions during CYs 2005 and 2006 between CMS and a manufacturer, and it was determined that this code should be removed from the DME fee schedule as this code does not describe DME. For CY 2007, HCPCS code A4306 is payable under the OPPS, with status indicator "N" indicating that its payment is unconditionally packaged.

One presenter to the APC Panel requested that we pay separately for this supply under the OPPS. For CY 2007, we packaged payment for this code because it is considered to be a supply, and since the inception of the OPPS the established payment policy packages payment for supplies because they are directly related and integral to an independent service furnished under the OPPS.

Our CY 2006 claims data indicate that HCPCS code A4306 was billed on OPPS claims 1,773 times, yielding a line-item median cost of approximately \$3. The APC Panel and a presenter believe that this code may not always be appropriately billed by hospitals as the data also show that this code was billed together with computed tomography (CT) scans of the thorax, abdomen, and pelvis approximately 40 percent of the time that this supply was reported. The APC Panel speculated that this code may be currently reported when other types of drug delivery devices are utilized for nonsurgical procedures or for purposes other than the treatment of postoperative pain. Therefore, the APC Panel requested that we share additional data when available.

In summary, because HCPCS code A4306 represents a supply and payment of supplies is packaged under the OPPS according to longstanding policy, we proposed to maintain the packaged status of HCPCS code A4306 for CY 2008.

Comment: A commenter supported CMS' proposal to maintain the packaged status of HCPCS code A4306 for CY 2008. The commenter suspected that

this code is misreported by hospitals and estimated that the true cost of the supply is between \$20 and \$60. The commenter requested that CMS provide instructions to hospitals on the appropriate revenue center for this supply and contact the AHA coding clinic regarding the need for better HCPCS code instructions for this supply.

Response: In general, we give hospitals the flexibility to report charges under whichever revenue code the hospital believes is most appropriate. In addition, it is not our usual practice to refer codes to the AHA coding clinic for review. Instead, we encourage the commenter to submit any questions or requests for clarification to the AHA coding clinic, if appropriate.

We are finalizing without modification our proposal to continue to package payment for HCPCS code A4306 for CY 2008. In addition, with respect to APC Panel Recommendation 9, we will provide the APC Panel with more cost data related to this code at its next meeting.

Recommendation 7

For CY 2008, we proposed to maintain the packaged status of CPT code 99186, consistent with the APC Panel's recommendation that we reevaluate the packaged OPPS payment for CPT code 99186 based on current research and the availability of new therapeutic modalities. This service describes induced total body hypothermia that is performed on some post-cardiac arrest patients to avoid or lessen brain damage. The service has been packaged since the implementation of the OPPS. One presenter to the APC Panel at the March 2007 meeting requested that this code be assigned a separately payable status indicator under the OPPS. The presenter expressed concern that hospitals that provide this service and subsequently transfer the patient to another hospital prior to admission are not adequately paid for their services.

Because this service does not fit into one of the seven identified categories of packaged codes proposed for the CY 2008 OPPS, we followed our historical packaging guidelines to determine whether to maintain the packaged status of this code or to pay for it separately. Claims data indicate that this code was billed 39 times under the OPPS in CY 2006 and was never billed without another separately payable service on the same date. The proposed CY 2008 median cost for this code was approximately \$35, with individual costs ranging from approximately \$17 to \$69, likely reflecting the costs

associated with traditional methods of inducing total body hypothermia, such as ice packs applied to the body. In fact, the presenter noted that a technologically advanced total body hypothermia system costs \$30,000, with an additional cost of \$1,600 per disposable body suit. As expected, our claims data showed that this service was provided most frequently with high level emergency department visits and critical care services.

As we noted in the CY 2008 proposed rule, we believed that the circumstances in which total body hypothermia would be provided to a Medicare beneficiary and billed under the OPPS were extremely rare, as patients requiring this therapy would almost always be admitted as inpatients if they survive. Moreover, in the uncommon situation where a patient presents to one hospital and then is cooled and transported to another hospital without admission to the first hospital, payment for the hypothermia service would be most appropriately packaged into payment for the many other separately payable services that it most likely accompanied and that would be paid to the first hospital under the OPPS.

In addition, consistent with the principles and incentives for efficiency inherent in a prospective payment system based on groups of services, packaging payment for this procedure that is highly integrated with other services provided in the hospital outpatient encounter creates incentives for providers to furnish services in the most cost-effective way. In situations where there are a variety of supplies that could be used to furnish a service, some of which are more expensive than others, packaging encourages hospitals to use the most cost-effective item that meets the patient's needs.

This code was discussed by the APC Panel members during the September 2007 APC Panel meeting, but they made no official recommendation.

We did not receive any comments related to our proposal. Therefore, we are finalizing our proposal to maintain the packaged status of CPT code 99186 for CY 2008.

Recommendation 8

We note that the Packaging Subcommittee remains active. See Recommendation 10 below.

Recommendation 9

As noted in Recommendation 6, in accordance with the APC Panel's recommendation, we will provide more cost data related to HCPCS code A4306 (Disposable drug delivery system, flow

rate of less than 50 mL per hour) for the APC Panel's review at its next meeting.

Recommendation 10

In response to the APC Panel's recommendation for the Packaging Subcommittee to remain active until the next APC Panel meeting, we note that the APC Panel Packaging Subcommittee remains active, and additional issues and new data concerning the packaging status of codes will be shared for its consideration as information becomes available. We continue to encourage submission of common clinical scenarios involving currently packaged HCPCS codes to the Packaging Subcommittee for its ongoing review, and we also encourage recommendations of specific services or procedures whose payment would be most appropriately packaged under the OPSS. Additional detailed suggestions for the Packaging Subcommittee should be submitted to APCPanel@cms.hhs.gov, with "Packaging Subcommittee" in the subject line.

B. Payment for Partial Hospitalization

1. Background

Partial hospitalization is an intensive outpatient program of psychiatric services provided to patients as an alternative to inpatient psychiatric care for beneficiaries who have an acute mental illness. A partial hospitalization program (PHP) may be provided by a hospital to its outpatients or by a Medicare-certified community mental health center (CMHC). Section 1833(t)(1)(B)(i) of the Act provides the Secretary with the authority to designate the hospital outpatient services to be covered under the OPSS. The Medicare regulations at § 419.21 that implement this provision specify that payments under the OPSS will be made for partial hospitalization services furnished by CMHCs as well as those furnished to hospital outpatients. Section 1833(t)(2)(C) of the Act requires that we establish relative payment weights based on median (or mean, at the election of the Secretary) hospital costs determined by 1996 claims data and data from the most recent available cost reports. Payment to providers under the OPSS for PHPs represents the provider's overhead costs associated with the program. Because a day of care is the unit that defines the structure and scheduling of partial hospitalization services, we established a per diem payment methodology for the PHP APC, effective for services furnished on or after August 1, 2000. For a detailed discussion, which includes a discussion of the decision to base relative payment

rates on median cost, we refer readers to the April 7, 2000 OPSS final rule with comment period (65 FR 18482).

Historically, the median per diem cost for CMHCs greatly exceeded the median per diem cost for hospital-based PHPs and fluctuated significantly from year to year, while the median per diem cost for hospital-based PHPs remained relatively constant (\$200–\$225). We believe that CMHCs may have increased and decreased their charges in response to Medicare payment policies. As discussed in more detail in section II.B.2. of this final rule with comment period and in the CY 2004 OPSS final rule with comment period (68 FR 63470), we also believe that some CMHCs manipulated their charges in order to inappropriately receive outlier payments.

For CY 2005, the PHP per diem amount was based on 12 months of hospital and CMHC PHP claims data (for services furnished from January 1, 2003, through December 31, 2003). We used data from all hospital bills reporting condition code 41, which identifies the claim as partial hospitalization, and all bills from CMHCs because CMHCs are Medicare providers only for the purpose of providing partial hospitalization services. We used CCRs from the most recently available hospital and CMHC cost reports to convert each provider's line-item charges as reported on bills to estimate the provider's cost for a day of PHP services. Per diem costs were then computed by summing the line-item costs on each bill and dividing by the number of days on the bill.

In the CY 2005 OPSS update, the CMHC median per diem cost was \$310, the hospital-based PHP median per diem cost was \$215, and the combined CMHC and hospital-based median per diem cost was \$289. We believed that the reduction in the CY 2005 CMHC median per diem cost compared to prior years indicated that the use of updated CCRs had accounted for the previous increase in CMHC charges and represented a more accurate estimate of CMHC per diem costs for PHP.

For the CY 2006 OPSS final rule with comment period, we analyzed 12 months of the most current claims data available for hospital and CMHC PHP services furnished between January 1, 2004, and December 31, 2004. We also used the most currently available CCRs to estimate costs. The median per diem cost for CMHCs dropped to \$154, while the median per diem cost for hospital-based PHPs was \$201. Based on the CY 2004 claims data, the average charge per day for CMHCs was \$760, considerably greater than hospital-based per day costs

but significantly lower than what it was in CY 2003 (\$1,184). We believed that a combination of reduced charges and slightly lower CCRs for CMHCs resulted in a significant decline in the CMHC median per diem cost between CY 2003 and CY 2004.

Following the methodology used for the CY 2005 OPSS update, the CY 2006 OPSS updated combined hospital-based and CMHC median per diem cost was \$161, a decrease of 44 percent compared to the CY 2005 combined median per diem amount.

Due to concern that this amount may not cover the cost for PHPs, as stated in the CY 2006 OPSS final rule with comment period (70 FR 68548 and 68549), we applied a 15-percent reduction to the combined hospital-based and CMHC median per diem cost to establish the CY 2006 PHP APC. (We refer readers to the CY 2006 OPSS final rule with comment period for a full discussion of how we established the CY 2006 PHP rate (70 FR 68548).) We stated our belief that a reduction in the CY 2005 median per diem cost would strike an appropriate balance between using the best available data and providing adequate payment for a program that often spans 5–6 hours a day. We stated that 15 percent was an appropriate reduction because it recognized decreases in median per diem costs in both the hospital data and the CMHC data, and also reduced the risk of any adverse impact on access to these services that might result from a large single-year rate reduction. However, we adopted this policy as a transitional measure, and stated in the CY 2006 OPSS final rule with comment period that we would continue to monitor CMHC costs and charges for these services and work with CMHCs to improve their reporting so that payments could be calculated based on better empirical data (70 FR 68548). To apply this methodology for CY 2006, we reduced the CY 2005 combined unscaled hospital-based and CMHC median per diem cost of \$289 by 15 percent, resulting in a combined median per diem cost of \$245.65 for CY 2006.

For the CY 2007 final rule with comment period, we analyzed 12 months of more current data for hospital and CMHC PHP claims for services furnished between January 1, 2005, and December 31, 2005, and used the most currently available CCRs to estimate costs. Using these updated data, we recreated the analysis performed for the CY 2007 proposed rule to determine if the significant factors we used in determining the proposed PHP rate had changed. The median per diem cost for CMHCs increased \$8 to \$173, while the

median per diem cost for hospital-based PHPs decreased \$19 to \$190. The CY 2005 average charge per day for CMHCs was \$675, similar to the figure noted in the CY 2007 proposed rule (\$673) but still significantly lower than what was noted as the average charge for CY 2003 (\$1,184).

The combined hospital-based and CMHC median per diem cost would have been \$175 for CY 2007. Rather than allowing the PHP median per diem cost to drop to this level, we proposed to reduce the PHP median cost by 15 percent, similar to the methodology used for the CY 2006 update. However, after considering all public comments received concerning the proposed CY 2007 PHP per diem rate and results obtained using the more current data, we modified our proposal. We made a 5-percent reduction to the CY 2006 median per diem rate to provide a transitional path to the per diem cost indicated by the data. This approach accounted for the downward direction of the data and addressed concerns raised by commenters about the magnitude of another 15-percent reduction in 1 year. Thus, to calculate the CY 2007 APC PHP per diem cost, we reduced \$245.65 (the CY 2005 combined hospital-based and CMHC median per diem cost of \$289 reduced by 15 percent) by 5 percent, which resulted in a combined per diem cost of \$233.37.

2. PHP APC Update for CY 2008

As noted in the CY 2008 OPPS/ASC proposed rule (72 FR 42691), for the past 2 years, we were concerned that we did not have sufficient evidence to support using the median per diem cost produced by the most current year's PHP data. After extensive analysis, we now believe the data reflects the level of cost for the type of services that are being provided. This analysis included an examination of revenue-to-cost center mapping, refinements to the per diem methodology, and an in-depth analysis of the number of units of service per day.

As stated in the CY 2008 proposed rule (72 FR 42691), the CY 2006 and CY 2007 OPPS updates data have produced median costs that we believed were too low to cover the cost of a program that typically spans 5 to 6 hours per day. However, we continued to observe a clear downward trend in the data. We stated that if the data continued to reflect a low PHP per diem cost in CY 2008, we expected to continue the transition of decreasing the PHP median per diem cost to an amount that is more reflective of the data.

We received a comment on the CY 2007 proposed rates that CMS

understated the PHP median cost by not using a hospital-specific CCR for partial hospitalization. In our response to this comment in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68000), we noted that, although most hospitals do not have a cost center for partial hospitalization, we used the CCR as specific to PHP as possible. The following CMS Web site contains the revenue-code-to-cost-center crosswalk: http://www.cms.hhs.gov/HospitalOutpatientPPS/03_crosswalk.asp#TopOfPage.

As noted in the proposed rule (72 FR 42691), this crosswalk indicates how charges on a claim are mapped to a cost center for the purpose of converting charges to cost. One or more cost centers are listed for most revenue codes that are used in the OPPS median calculations, starting with the most specific, and ending with the most general. Typically, we map the revenue code to the most specific cost center with a provider-specific CCR. However, if the hospital does not have a CCR for any of the listed cost centers, we consider the overall hospital CCR as the default. For partial hospitalization, the revenue center codes billed by PHPs are mapped to Primary Cost Center 3550 "Psychiatric/Psychological Services". If that cost center is not available, they are mapped to the Secondary Cost Center 6000 "Clinic." We use the overall facility CCR for CMHCs because PHPs are CMHCs' only Medicare cost, and CMHCs do not have the same cost structure as hospitals. Therefore, for CMHCs, we use the CCR from the outpatient provider-specific file.

As indicated in the proposed rule (72 FR 42691), closer examination of the revenue-code-to-cost-center crosswalk revealed that 10 of the revenue center codes (shown in the table below) that are common among hospital-based PHP claims did not map to a Primary Cost Center 3550 "Psychiatric/Psychological Services" or a Secondary Cost Center of 6000 "Clinic."

Revenue center code	Revenue center description
0430	Occupational Therapy.
0431	Occupational Therapy: Visit charge.
0432	Occupational Therapy: Hourly charge.
0433	Occupational Therapy: Group rate.
0434	Occupational Therapy: Evaluation/re-evaluation.
0439	Occupational Therapy: Other occupational therapy.
0904	Psychiatric/Psychological Treatment: Activity therapy.
0940	Other Therapeutic Services.

Revenue center code	Revenue center description
0941	Other Therapeutic Services: Recreation Rx.
0942	Other Therapeutic Services: Education/training.

We believed these 10 revenue center codes did not map to either a Primary Cost Center 3550 "Psychiatric/Psychological Services" or a Secondary Cost Center 6000 "Clinic" because these codes may be used for services that are not PHP or psychiatric related. For example, the majority of Occupational Therapy services are not furnished to PHP patients and, therefore, these services should be appropriately mapped to a Primary Cost Center 5100 "Occupation Therapy" (the general Occupational Therapy Cost Center). Another example would be claims for Diabetes Education, which is also not furnished to PHP patients.

For this final rule with comment period, we have updated this analysis using updated claims and CCR data for PHP claims. Again, we remapped the 10 revenue center codes described earlier in this section to a Primary Cost Center 3550 "Psychiatric/Psychological Services" or a Secondary Cost Center 6000 "Clinic". Once we remapped the codes, we computed an alternate cost for each line item of the CY 2006 hospital-based PHP claims. There are a total of 723,749 line items in the CY 2006 hospital-based PHP claims. Prior to remapping, there were 320,504 line items where a default CCR was used to estimate costs. After the remapping, there were 160,351 line items left defaulting to the hospitals' overall CCR. While this remapping creates a more accurate estimate of PHP per diem costs for a significant number of claims, again there was not a large change in the resulting median per diem cost. The median per diem costs for hospital-based PHPs increased by \$5 (from \$172 to \$177). We note that, unlike the proposed rule, this final rule analysis was done using the revised methodology for computing per diem costs described below. We received no public comments in opposition to the proposed change in remapping revenue codes to alternate cost centers. Therefore, we are adopting this proposed change beginning in CY 2008.

As part of our effort to produce the most accurate per diem cost estimate, we have reexamined our methodology for computing the PHP per diem cost. Section 1833(t)(2)(C) of the Act requires that we establish relative payment weights based on median (or mean, at

the election of the Secretary) hospital costs determined by 1996 claims data and data from the most recent available cost reports. As explained in section II.B.1. of this final rule with comment period, payment to providers under OPSS for PHP services represents the provider's overhead costs associated with the program. Because a day of care is the unit that defines the structure and scheduling of partial hospitalization services, we established a per diem payment methodology for the PHP APC. Other than being a per diem payment, we use the general OPSS ratesetting methodology for determining median cost.

As we have described in prior **Federal Register** notices, our current method for computing per diem costs is as follows: We use data from all hospital bills reporting condition code 41, which identifies the claim as partial hospitalization, and all bills from CMHCs. We use CCRs from the most recently available hospital and CMHC cost reports to convert each provider's line-item charges as reported on bills to estimate the provider's cost for a day of PHP services. Per diem costs are then computed by summing the line-item costs on each bill and dividing by the number of days of PHP care provided on the bill. These computed per diem costs are arrayed from lowest to highest and the middle value of the array is the median per diem cost.

As indicated in the proposed rule (72 FR 42692), we have developed an alternate way to determine median cost by computing a separate per diem cost for each day rather than for each bill. Under this method, a cost is computed separately for each day of PHP care. When there are multiple days of care entered on a claim, a unique cost is computed for each day of care. All of these costs are then arrayed from lowest to highest and the middle value of the array would be the median per diem cost.

We proposed to adopt this alternative method of computing PHP per diem median cost because we believe it produces a more accurate estimate because each day gets an equal weight towards computing the median. In light of the stabilizing trend in the data, and the robustness of recent data analysis, we believe it is now appropriate to adopt this method. We believe this method for computing a PHP per diem median cost more accurately reflects the costs of a PHP and uses all available PHP data. We received no public comments in opposition to the revised method for computing per diem cost, although we did receive a few public comments critical of our current method of computing per diem costs. (These public comments and our response are addressed below.) Therefore, we are adopting this proposed change beginning in CY 2008.

As noted previously, for the past 2 years, the data have produced median costs that we believed were too low to cover the cost of a program that typically spans 5 to 6 hours per day. This length of day would include five or six services with a break for lunch. We looked at the number of units of service being provided in a day of care, as a possible explanation for the low per diem cost for PHP. Our analysis revealed that both hospital based and CMHC PHPs have a significant number of days where fewer than 4 units of service were provided.

Using updated data from the CY 2008 proposed rule, specifically, 64 percent of the days that CMHCs were paid were for days where 3 or less units of services were provided, and 31 percent of the days that hospital-based PHPs were paid were for days where 3 or less units of service were provided. We continue to believe these findings are significant because they may explain a lower per diem cost. Based on these updated findings, we computed median per diem costs in two categories:

- (a) All days.
- (b) Days with 4 units of service or more (removing days with 3 services or less).

These updated median per diem costs were computed separately for CMHCs and hospital based PHPs and are shown in the table below:

	CMHCs	Hospital-based PHPs	Combined
All Days	\$172	\$177	\$172
Days with 4 units or more	192	189	192

As expected, excluding the low unit days resulted in a higher median per diem cost estimate. However, if the programs have many "low unit days," their cost and Medicare payment should reflect this level of service. It would not be appropriate to set the PHP rate to exclude the "low unit days" because these days are covered PHP days. We believe the analysis of the number of units of service per day supports a lower per diem cost. Therefore, including all days supports the data trend towards a lower per diem cost and we believe more accurately reflects the costs of providing PHP services.

Although the minimum number of PHP services required in a PHP day is three, it was never our intention that this represented the number of services to be provided in a typical PHP day. Our intention was to cover days that consisted of only three services, generally because a patient was

transitioning towards discharge (or a patient who is transitioning at the beginning of their PHP stay). Rather than set separate rates for half-days and full-days, we believed it was appropriate to set one rate that would be paid for all PHP days, including those for patients transitioning towards discharge (or admission). We intended that the PHP benefit is for a full day, with shorter days only occurring while a patient transitions into or out of the PHP.

However, as indicated in the data, many programs have these "low unit days," and we believe their cost and Medicare payment should reflect this level of service. It would not be appropriate to set the PHP rate excluding the low unit days because these days are covered. Again, we believe the data support the estimated per diem cost under \$200 that we have observed.

We believed the most appropriate payment rate for PHPs is computed using both hospital-based and CMHC PHP data, including the remapped data for all days, resulting in a median per diem cost of \$178. Therefore, we proposed a CY 2008 APC PHP per diem cost of \$178.

We received a large number of public comments on our proposal. A summary of the public comments received and our responses follow.

Comment: A number of commenters expressed concern about the magnitude of the PHP per diem rate reduction, particularly in light of the reductions over the past few years. Many commenters believe that such a reduction would reduce the financial viability and possibly lead to the closure of many PHPs, thus affecting access to this crucial service that serves vulnerable populations. Many commenters stated that PHPs are an

integral part of the continuum of care, and if programs were forced to close, there would be an increase in the length and number of more costly inpatient hospital stays. In addition, because hospital outpatient mental health services paid under the OPSS are capped at the PHP per diem rate, many commenters were concerned about overall access to outpatient mental health treatment. The majority of commenters requested that CMS freeze the PHP per diem rate at the CY 2007 level, and some suggested inflating this rate each year by the consumer price index or market basket update. In addition, several patients were concerned that the proposed 24-percent reduction in payment would negatively impact their ability to continue therapy. One commenter requested that CMS limit the annual reduction to 5 percent, phasing in the reduction over several years if necessary.

Response: For this CY 2008 final rule with comment period, we analyzed 12 months of more current data for hospital and CMHC PHP claims for PHP services furnished between January 1, 2006 and December 31, 2006. These claims data are more current than the CY 2008 proposed rule claims data because the data include claims paid through June 30, 2007. We also used the most currently available CCRs to estimate costs. Using these updated data, we recreated the analysis performed for the proposed rule to determine if the significant factors we used in determining the proposed PHP rate had changed. The median per diem cost for CMHCs decreased \$6 to \$172, while the median per diem cost for hospital based PHPs decreased \$9 to \$177. The combined median per diem cost, which is computed from both hospital-based and CMHC PHP data, decreased \$6 to \$172. The CY 2006 average charge per day for CMHCs was \$615, similar to the figure noted in the CY 2007 proposed rule (\$613) and slightly lower than the average charge per day for hospital-based PHPs (\$631).

The data in this area have been volatile in the past and CMS must establish a payment amount that reflects the intensity of the PHP, and that also considers that costs for providing PHP services are declining. We proposed two refinements to the methodology for computing the PHP median, however, these refinements did not appreciably impact the median per diem cost. We received no public comments in opposition to these refinements and, therefore, we are adopting them in this final rule with comment period. Thus, for CY 2008, we remapped the revenue codes to the most appropriate cost

centers and computed the median using a per day methodology (as described earlier in this section).

In addition, based on our data analysis, we have determined that CMHCs (and hospital-based PHPs to a lesser extent) are furnishing a substantial number of low unit days. Although these are all covered days in the context of existing Medicare guidelines, PHPs are furnished in lieu of psychiatric hospitalization and are intended to be more intensive than a half-day program. While the guidelines have allowed a minimum of three services per day, this was intended to be a floor, not the norm.

We conducted extensive data analysis, which included unit analysis, revenue code and HCPCS/CPT frequency analysis, and we have learned that PHPs often use the least costly staff and may not offer the full range of PHP services contemplated in section 1861(ff) of the Act. However, we believe the data accurately represent the level of service provided.

Because partial hospitalization is provided in lieu of inpatient care, it should be a highly structured and clinically-intensive program, usually lasting most of the day. Our goal is to improve the level of service furnished in a PHP day. We are concerned that the proposed decrease in PHP payment may not reflect the mix and quantity of services that should be provided under such an intensive program. In an effort to ensure access to this needed service to vulnerable populations, we are mitigating the reduction to 50 percent of the difference between the current APC amount (\$233) and the computed amount based on the PHP data (\$172), resulting in an APC median cost of \$203. We believe this payment amount will give the providers an opportunity to increase the intensity of their programs and maintain partial hospitalization as part of the continuum of mental health care.

We reiterate our expectation that hospitals and CMHCs will provide a comprehensive program consistent with the statutory intent. We intend to explore the changes to our regulations and claims processing systems in order to deny payment for low intensity days and we specifically invite public comment on the most appropriate threshold.

Comment: A few commenters disagreed with the CMS approach to establishing the median per diem cost by summarizing the line-item costs on each bill and dividing by the number of days on the bills. The commenters indicated that this calculation can severely dilute the rate and penalize

providers. The commenters stated that all programs are strongly encouraged by the fiscal intermediaries to submit all PHP service days on claims, even when the patient receives less than three services. They further stated that programs must report these days to be able to meet the 57 percent attendance threshold and avoid potential delays in the claim payment. The commenters were concerned that programs are only paid their per diem when three or more qualified services are presented for a day of service. The commenters stated that if only one or two services are assigned a cost and the day is divided into the aggregate data, the cost per day is significantly compromised and diluted. They claimed that even days that are paid but only have three services dilute the cost factors on the calculations.

Response: As discussed earlier in this section, we have refined our methodology for computing per diem costs. We have developed an alternate way to determine median cost by computing a separate per diem cost for each day rather than for each bill. Under this method, a cost is computed separately for each day of PHP care. When there are multiple days of care entered on a claim, a unique cost is computed for each day of care. We only assign costs for line items on days when a payment is made. All of these costs are then arrayed from lowest to highest and the middle value of the array would be the median per diem cost.

We adopted this alternative method of computing PHP per diem median cost because we believe it produces a more accurate estimate because each day gets an equal weight towards computing the median. This method for computing a PHP per diem median cost more accurately reflects the costs of a PHP and uses all available PHP data. Additionally, if a provider has charges on a bill for which the provider does not receive payment, this will be reflected in that provider's CCRs. This lower CCR will be applied to the larger charges and will result in the appropriate cost per diem.

To gauge the effect that days with one or two services had on the per diem cost, we trimmed all days with less than three services, and the recalculated median per diem cost only changed by \$2.00. As such, we do not believe the calculations are adversely affected by the inclusion of these days.

Comment: One commenter suggested that CMS set the PHP median per diem cost based on days when four or more services are provided and then pay a low-utilization payment adjustment amount for days when three or fewer

services are provided. The commenter also suggested that CMS establish frequency constraints for billing three or fewer services to prevent the bulk of days furnished by a provider from becoming low utilization days. The commenter urged CMS to further research this suggestion as a possible payment restructuring for CY 2009. Several commenters urged CMS to reevaluate the PHP payment methodology and to either refine the APC structure for PHP to reflect different service levels or to exclude the low-volume days from the calculation of the PHP rate and develop an alternate payment policy for low-volume days.

Response: The structure of partial hospitalization is a full day of treatment. We are concerned about providing an incentive for providers to structure their PHPs on a half-day basis. As discussed earlier in this section, in an effort to ensure access to this needed service to vulnerable populations, we are mitigating the reduction to the PHP rate for CY 2008. We think establishing a half-day rate is inconsistent with this policy. Therefore, we are not prepared to establish a half day rate at this time. However, we are willing to explore how we could utilize frequency controls to maintain the overall intensity of the partial hospitalization benefit.

Comment: One commenter noted that CMS did not respond to previous statements from commenters that the industry would welcome accreditation rules and/or stricter policies for PHPs.

Response: For the CY 2009 OPSS update, we are exploring proposing conditions of participation for CMHCs to establish minimum standards for patient rights, physical environment, staffing, and documentation requirements. In addition, we are considering changes that are necessary to our regulations and claims processing systems to deny payment for low intensity days. We specifically invite public comment on the most appropriate threshold.

Comment: Many commenters requested that the CMHC cost report data be included in the HCRIS so that the industry can review and analyze CMHC cost data.

Response: We understand the commenters' need to have CMHC data available through the HCRIS system and are working to accomplish this task.

Comment: With respect to the methodology used to establish the PHP APC amount, commenters were concerned that data from settled cost reports do not include costs reversed on appeal. The commenters stated that there are inherent problems in using claims data from a time period that is

different from that for the CCRs from settled cost reports. The commenters indicated this methodology would artificially lower the computed median costs, and that the data used to calculate the PHP rate should be revised to include costs that were subsequently allowed. The commenters also stated that CMS uses costs that are at least 1 to 3 years old to project rates 2 years forward and that this approach does not accurately reflect the true costs of the providers.

Response: We use the best available data in computing the APCs. On January 17, 2003, we issued Program Memorandum No. A-03-004 that directed fiscal intermediaries to update the CCRs on an on going basis whenever a more recent full year settled or tentatively settled cost report is available. In this way, we minimize the time lag between the CCRs and claims data and continue to use the best available data for ratesetting purposes.

Comment: Several commenters summed the payment rate for four Group Therapy sessions (APC 0325) and requested that amount as the minimum for a day of PHP (that is, 4 x \$64.45=\$257.80). Another commenter presented two different typical days using proposed CY 2008 rates. Typical Day 1 included three Group Therapy sessions (CPT code 90853, APC 0325, 3 x \$64.45) and one Individual Psychotherapy session (CPT code 90818, APC 0323, \$106.49). The commenter priced Typical Day 1 at \$299.84. Typical Day 2 included one Group Therapy session (CPT code 90853, APC 0325, \$64.45), one Individual Psychotherapy session (CPT code 90818, APC 0323, \$106.49), and one Family Therapy session (CPT code 90847, APC 0324, \$141.61). The commenter priced Typical Day 2 at \$312.55. Based on the commenter's presented material, the commenter stated that the typical days yield an average componentized rate of \$306. The commenter questioned how CMS can set rates for APCs 0322 through 0325, but is unable to determine a payment rate for a day that is comprised of a minimum of three to four of those services. Other commenters stated that while CMS requires a minimum of four treatments per day to qualify for a day of PHP, the proposed per diem rate of \$179.88 for PHP is less than what CMS would pay for four Group Therapy sessions.

Response: We do not believe this is an appropriate comparison. The commenter does not use the payment rate for the PHP APC, that is, APC 0033, in the calculations. The payment rates for APC services cited by the commenter

(APC 0323, APC 0324 and APC 0325) are not computed from PHP bills. As stated earlier, we used data from PHP programs (both hospitals and CMHCs) to determine the median cost of a day of PHP. PHP is a program of services where savings can be realized by hospitals and CMHCs over delivering individual psychotherapy services.

We structured the PHP APC (APC 0033) as a per diem methodology in which the day of care is the unit that reflects the structure and scheduling of PHPs and the composition of the PHP APC consists of the cost of all services provided each day. Although we require that each PHP day include a psychotherapy service, we do not specify the specific mix of other services provided and our payment methodology reflects the cost per day rather than the cost of each service furnished within the day.

CMS examined both CMHC and hospital-based PHP program data to determine what services these programs are providing to their patients. An important finding was that the days cited by the commenter are not typical days for most CMHCs. For CMHCs, 60 percent of services are Group Psychotherapy (CPTs 90853 and 90857), 26 percent of services are Training and Education (HCPCS G0177), 12 percent are Activity Therapy (HCPCS G0176), and only 1 percent of PHP days included Individual Therapy (Brief or Extended, CPTs 90816 or 90818).

The days cited by the commenter are not typical days for hospital-based PHPs either. For hospital-based PHPs, 47 percent of services are Group Psychotherapy (CPT codes 90853 and 90857), 27 percent of services are Training and Education (HCPCS code G0177), 16 percent are Activity Therapy (HCPCS code G0176), 3 percent are Occupational Therapy (HCPCS code G0129), 2 percent of PHP days include Brief Individual Psychotherapy (CPT code 90816), and only 1 percent of PHP days include Extended Individual Therapy (CPT code 90818).

We note that the APCs for Training and Education (HCPCS code G0177), Activity Therapy (HCPCS code G0176), and Occupational Therapy (HCPCS code G0129) are not separately payable under the OPSS. They are packaged services and only payable as part of a PHP day of care. In CMHCs, Training and Education (HCPCS code G0177) and Activity Therapy (HCPCS code G0176), account for 38 percent of PHP services. In hospital-based PHPs, Training and Education and Activity Therapy account for 43 percent of PHP services. In addition to not being separately payable, these services may be provided to

patients by less costly staff than staff that provide Psychotherapy and Occupational Therapy. Based on the mix of services provided on the majority of PHP days, we believe the data used for setting the PHP payment appropriately reflect the typical PHP day.

Comment: One commenter asked CMS to consider implementing a reimbursement level for intensive outpatient program (IOP) services because the commenter's State requires 3 hours of service for such programs.

Response: While some private insurers and some State Medicaid programs recognize IOP as a distinct benefit (like PHP), Medicare does not. However, hospitals that provide IOP services may bill Medicare under the OPSS for individual mental health services that are otherwise covered and billable under the OPSS.

Comment: Several commenters claimed that the costs of CMHCs are higher because "hospitals can share and spread their costs to other departments." The commenters believed that the CMHC patient acuity level is more intense than that for hospital patients because hospital outpatient departments need only provide one or two therapies, yet still receive the full PHP per diem.

Response: CMHCs are required to furnish an array of outpatient services including specialized outpatient services for children, the elderly, individuals with a serious mental illness, and residents of its service area who have been discharged from inpatient treatment. Accordingly, CMHCs have the same ability as hospitals to share costs among its programs as needed. Further, we believe hospital costs in some areas, for example, capital and 24-hour maintenance costs, greatly exceed comparable CMHC costs. Notably, we believe patient acuity across hospital-based and CMHC PHPs should be the same, that is, the patients would otherwise require inpatient psychiatric care regardless of setting (see sections 1861(ff) and 1835(a)(2)(F) of the Act).

Comment: A few commenters expressed concern that the current methodology used to calculate the daily rate does not capture all relevant data nor does it reflect the actual cost to providers to deliver these services. The commenters asked that CMS analyze the mapping of revenue-codes-to-cost centers for CMHCs similar to the analysis CMS completed for hospital-based programs and discussed in the CY 2007 OPSS/ASC final rule with comment period (71 FR 68000). The commenters indicated that CMHC PHP

services have higher cost-to-charge ratios than the overall CMHC cost-to-charge ratios.

Response: We are unable to conduct a revenue code mapping analysis for CMHCs because PHP is the CMHCs' only Medicare cost and CMHCs do not have the same cost centers as hospitals. Therefore, for CMHCs, we use the overall facility CCR from the outpatient provider-specific file.

Comment: Several commenters expressed concern that cost report data frequently do not reflect bad debt expense for the entire year. The commenters are concerned that these costs are not being considered in the CMS data and severely short change the rate calculations.

Response: While, the bad debt policy is outside the scope of this rule, we refer the commenter to § 413.89 and the Provider Reimbursement Manual Part I (PRM), Chapter 3, concerning our bad debt requirements.

Comment: One commenter stated that administrative costs for CMHCs continue to be a major impediment to operating PHPs for Medicare beneficiaries. The commenter was concerned that Medicare does not cover the cost of meals and transportation to and from programs. The commenter stated that almost all programs offer transportation because in most cases Medicare beneficiaries with serious mental illnesses would not be able to access these programs without the transportation.

Response: The services that are covered as part of a PHP are specified in section 1861(ff) of the Act. Meals and transportation are specifically excluded under section 1861(ff)(2)(I) of the Act.

Comment: One commenter requested that the same provisions given to rural HOPDs also be given to rural CMHCs. Several commenters urged CMS to reconsider the changes in funding for these programs, especially the programs in rural areas.

Response: We believe the commenter may be referring to the statutory hold harmless provisions. Section 1833(t)(7)(D) of the Act authorizes such payments, on a permanent basis, for children's hospitals and cancer hospitals and, through CY 2005, for rural hospitals having 100 or fewer beds and SCHs in rural areas. Section 1866(t)(7)(D) of the Act does not authorize hold harmless payments to CMHCs. In addition, although section 411 of Pub. L. 108-173 required CMS to determine the appropriateness of additional payments for certain rural hospitals, that authority also does not extend to CMHCs.

Comment: A few commenters stated that hospitals that offer partial hospitalization services should not be penalized for the instability in data reporting of CMHCs. Many commenters requested that CMS require that CMHCs improve their reporting or have that provider group face economic consequences.

Response: As described earlier in this section, after extensive analysis, we now believe we have determined the appropriate level of cost for the type of services that are being provided by PHPs. This analysis included an examination of revenue-to-cost center mapping, refinements to the per diem methodology, and an in-depth analysis of the number of units of service per day. We note that for CY 2006, the hospital-based PHPs per diem median cost is \$177 and for CMHCs, the per diem median cost is \$172. We have observed a stabilizing trend in CMHC data and similar per diem costs between hospital-based and CMHC PHPs.

Comment: Two national behavioral health care organizations expressed concern that contrary to congressional intent, the most intensive provider settings are being penalized. The commenters pointed out that CMS data show that PHP programs providing four or more units of service per day (programs that are highly intensive) have a substantially higher median cost for those days than the overall median cost per day. The commenters pointed out that hospital-based programs (66 percent of their days have 4 or more units of service) have a median cost of \$218 versus a median cost of \$186 for all days regardless of the number of units of service. They noted that CMS' use of the overall median cost per day understates the degree to which hospital-based programs are structured around four or more units of services, but acknowledge that on some days a patient may only get three services (due to leaving early for illness, transitioning out of the program, or other reasons). Similarly, according to one commenter, CMHCs have a median cost of \$191 for those days with 4 or more units of service provided versus a median cost of \$178 for all days. The commenter stated that CMHCs have 36 percent of their days with 4 or more units of service provided. The commenter indicated that its State's Medicaid program requires a minimum of four hours to qualify for a day of PHP and believed the CMS payment methodology is in conflict with its State's laws.

Several commenters stated that the CMS data, when it combines those programs that offer 3 units with those that offer 4 or more units, clearly

penalizes the programs that routinely offer 4 or more units.

Response: We refer the commenter to the table presented earlier in this section that provides updated figures to the ones cited by the commenter. We recognize that by definition, 50 percent of PHP days will have per diem costs higher than the median per diem cost, while 50 percent will have costs lower than the median per diem cost. It is likely that the programs providing 4 units of service are on the high side of the median per diem cost. In addition, we note that the final rate of \$203 is well above the combined median per diem cost for days with 4 units of service of more (\$192). Days where four services are provided are certainly within this amount.

Comment: One commenter asked that CMS change the Medicare lifetime maximum of 190 mental health days of stay in a psychiatric hospital, to unlimited. The commenter asserted that if a person is diagnosed with a mental health illness of various kinds the individual will need "maintenance" throughout his or her entire life.

Response: The 190-day lifetime limit on inpatient psychiatric care is statutory, and established in section 1812(b)(3) of the Act.

Comment: Many commenters, including a national behavioral health association, recommended that PHP be removed from the APC codes and created under an independent status using home health and hospice as examples. The commenters are concerned that the current methodology is not conducive to this APC code and asserted that there is precedent in other CMS OPSS service industries to exclude the service from the APC code listing and treat it independently.

Response: Section 1833(t)(1)(B)(i) of the Act provides the Secretary with the authority to designate the hospital outpatient services to be covered under the OPSS. The Medicare regulations at 42 CFR 419.21 that implement this provision specify that payments under the OPSS will be made for partial hospitalization services furnished by CMHCs as well as those furnished to hospital outpatients and thus, PHP is paid under the OPSS. However, it would require a statutory change to establish an independent payment system for partial hospitalization programs outside the OPSS. The statute provides specific separate and distinct payment systems for both home health and hospice services, which are also separate and distinct benefit categories.

Comment: One commenter asked why there are no CMHCs shown in the impact statements in the annual OPSS

updating documents published in the **Federal Register**. The commenter asked if this is required by regulation.

Response: CMHCs do not share the same characteristics as hospitals and do not fit into the traditional impact categories (like bed size). Therefore, we have not included them in the impact chart. As PHP is the only Medicare service CMHCs provide, the impact is the percentage change in the APC amount from year to year. Assuming that the number of PHP days provided by CMHCs stays the same as it was in CY 2006, the estimated impact on CMHCs as a result of the CY 2008 PHP payment rate compared to the CY 2007 PHP payment rate is a 13-percent decrease. In this year's impact table we have included CMHCs in the total count of providers, but they are not shown separately. (For additional information, see section XXIV, "Regulatory Impact Analysis" of this final rule with comment period.)

Comment: Several commenters suggested establishing a PHP rate calculation task force to develop a new rate methodology that captures all relevant data and reflects the actual costs to providers to deliver PHP services. The commenter recommended that the ratesetting task force be composed of CMS staff and a diverse group of stakeholder that include front-line providers of PHP services and representatives from national industry organizations. Other commenters requested that CMS further study the possibility of differentiating payment based on the intensity of services provided during a day of PHP services for CY 2009. These commenters also recommended that CMS establish quality criteria to judge performance and that would influence future rate reimbursement.

Response: We agree that the payment rate for PHP needs to be accurate and appropriate to sustain access to care. While we believe we provide an accurate and appropriate approach to payment for PHP, as changes to the current methodology are considered, input from the industry is an important part of that process. Therefore, we welcome any input and information that the industry can provide about the costs of their programs and encourage providers to submit information on their costs. We would also find information about the status of quality criteria useful and would encourage providers to submit that information as well.

Comment: A few commenters stated that the wage index adjustment does not accurately reflect the cost of labor in areas affected by Hurricanes Katrina and Rita. The commenters also pointed out

that the proposed wage index in Louisiana has decreased post-hurricane instead of increasing, which has resulted in a much lower payment rate in Louisiana. The commenters further stated that the time lag for wage indexing is a huge factor for Hurricane Zone providers and that the wage index decrease makes the assumption that the cost of labor has actually decreased since the hurricanes. Some commenters noted that the lack of facilities, trained professionals and inadequate reimbursement will make Louisiana worse off now than prior to Hurricanes Katrina and Rita. A few commenters asked that CMS freeze the 2005 level rates to maintain the Hurricane Zones at status quo until a realistic impact study can be commissioned.

Response: The hospital wage data used to compute the IPPS FY 2008 hospital wage index is from the FY 2004 hospital cost reports for all hospitals. This is the standard lag timeframe in determining the hospital wage index. It will be another year before FY 2005 data will be reflected in the IPPS FY 2009 hospital wage index. However, we note that the wage index is a relative measure of differences in area hourly wage levels. It compares a labor market's average hourly wage to the national average hourly wage. To the extent that post-hurricane hospital labor costs are higher relative to the national average, the wage index will reflect the higher relative labor cost beginning when the FY 2005 data will be used in the FY 2009 IPPS hospital wage index (which will be applied to the CY 2009 OPSS rate year). In addition, the statutory authority for the OPSS wage index policy in section 1833(t)(2)(D) of the Act requires that the wage adjustments be made in a budget neutral manner. Therefore, we cannot raise one wage area and still maintain budget neutrality. Finally, it should be noted that CMHCs located in Federal Emergency Management Agency (FEMA) designated disaster areas were provided with relief funds by the Department of Health and Human Services in 2007.

3. Separate Threshold for Outlier Payments to CMHCs

In the November 7, 2003 final rule with comment period (68 FR 63469), we indicated that, given the difference in PHP charges between hospitals and CMHCs, we did not believe it was appropriate to make outlier payments to CMHCs using the outlier percentage target amount and threshold established for hospitals. There was a significant difference in the amount of outlier payments made to hospitals and CMHCs

for PHP. In addition, further analysis indicated that using the same OPPS outlier threshold for both hospitals and CMHCs did not limit outlier payments to high cost cases and resulted in excessive outlier payments to CMHCs. Therefore, beginning in CY 2004, we established a separate outlier threshold for CMHCs. For CYs 2004 and 2005, we designated a portion of the estimated 2.0 percent outlier target amount specifically for CMHCs, consistent with the percentage of projected payments to CMHCs under the OPPS in each of those years, excluding outlier payments. For CY 2006, we set the estimated outlier target at 1.0 percent and allocated a portion of that 1.0 percent, 0.6 percent (or 0.006 percent of total OPPS payments), to CMHCs for PHP services. For CY 2007, we set the estimated outlier target at 1.0 percent and allocated a portion of that 1.0 percent, an amount equal to 0.15 percent of outlier payments and 0.0015 percent of total OPPS payments to CMHCs for PHP service outliers. The CY 2007 CMHC outlier threshold is met when the cost of furnishing services by a CMHC exceeds 3.40 times the PHP APC payment amount. The CY 2007 OPPS outlier payment percentage is 50 percent of the amount of costs in excess of the threshold.

The separate outlier threshold for CMHCs became effective January 1, 2004, and has resulted in more commensurate outlier payments. In CY 2004, the separate outlier threshold for CMHCs resulted in \$1.8 million in outlier payments to CMHCs. In CY 2005, the separate outlier threshold for CMHCs resulted in \$0.5 million in outlier payments to CMHCs. In contrast, in CY 2003, more than \$30 million was paid to CMHCs in outlier payments. We believe this difference in outlier payments indicates that the separate outlier threshold for CMHCs has been successful in keeping outlier payments to CMHCs in line with the percentage of OPPS payments made to CMHCs.

As noted in section II.G. of this final rule with comment period, for CY 2008, we proposed to continue our policy of setting aside 1.0 percent of the aggregate total payments under the OPPS for outlier payments. We proposed that a portion of that 1.0 percent, an amount equal to 0.03 percent of outlier payments and 0.0003 percent of total OPPS payments, would be allocated to CMHCs for PHP service outliers. As discussed in section II.G. of this final rule with comment period, we again proposed to set a dollar threshold in addition to an APC multiplier threshold for OPPS outlier payments. However, because the PHP is the only APC for

which CMHCs may receive payment under the OPPS, we would not expect to redirect outlier payments by imposing a dollar threshold. Therefore, we did not propose to set a dollar threshold for CMHC outliers. As noted above, we proposed to set the outlier threshold for CMHCs for CY 2008 at 3.40 times the APC payment amount and the CY 2008 outlier payment percentage applicable to costs in excess of the threshold at 50 percent.

We received no public comments on our proposal. As discussed in section II.G. of this final rule with comment period, using more recent data for this final rule with comment period, we set the target for hospital outpatient outlier payments at 1.0 percent of total OPPS payments. We allocate a portion of that 1.0 percent, an amount equal to 0.02 percent of outlier payments and 0.0002 percent of total OPPS payments to CMHCs for PHP service outliers. For CY 2008, we set the outlier threshold for CMHCs for CY 2008 at 3.40 times the APC payment amount and the CY 2008 outlier percentage applicable to costs in excess of the threshold at 50 percent.

C. Conversion Factor Update

Section 1833(t)(3)(C)(ii) of the Act requires us to update the conversion factor used to determine payment rates under the OPPS on an annual basis. Section 1833(t)(3)(C)(iv) of the Act provides that, for CY 2008, the update is equal to the hospital inpatient market basket percentage increase applicable to hospital discharges under section 1886(b)(3)(B)(iii) of the Act.

The final hospital market basket increase for FY 2008 published in the IPPS final rule with comment period on August 22, 2007 is 3.3 percent (72 FR 48173), the same as the forecast published in the FY 2008 IPPS proposed rule on May 3, 2007 (72 FR 24787). To set the OPPS conversion factor for CY 2008, we increased the CY 2007 conversion factor of \$61.468, as specified in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68003), by 3.3 percent.

In accordance with section 1833(t)(9)(B) of the Act, we further adjusted the conversion factor for CY 2007 to ensure that the revisions we are making to our updates for a revised wage index and rural adjustment are made on a budget neutral basis. We calculated an overall budget neutrality factor of 1.0019 for wage index changes by comparing total payments from our simulation model using the FY 2008 IPPS final wage index values as finalized to those payments using the current (FY 2007) IPPS wage index values. This adjustment reflected an

adjustment of 1.0001 for changes to the wage index and an additional 1.0018 to accommodate the IPPS budget neutrality adjustment for inclusion of the rural floor. As discussed further in section II.D. of this final rule with comment period, for the first time, the final FY 2008 IPPS wage indices included a blanket budget neutrality adjustment for including the rural floor provision, which previously had been applied to the IPPS standardized amount. For further discussion of this policy in its entirety, we refer readers to the FY 2008 IPPS proposed rule (72 FR 24787 through 24792) and the FY 2008 IPPS final rule with comment period (72 FR 47325 through 47330). This adjustment is specific to the IPPS. For the OPPS, we are increasing the conversion factor by the proportional amount of the rural floor budget neutrality adjustment to accommodate this change.

For this final rule with comment period, we estimated the rural adjustment for CY 2008 to reflect the extension of the adjustment to payment for brachytherapy sources as discussed in section II.F.2. of this final rule with comment period, but as the impact of the extension was negligible, we did not change the rural adjustment. Therefore, we calculated a budget neutrality factor of 1.000 for the rural adjustment. For CY 2008, in this final rule with comment period, we estimated that allowed pass through spending for both drugs and devices would equal approximately \$32 million, which represents 0.09 percent of total OPPS projected spending for CY 2008. The conversion factor was also adjusted by the difference between the 0.21 percent pass through dollars set aside in CY 2007 and the 0.09 percent estimate for CY 2008 pass through spending. Finally, estimated payments for outliers remain at 1.0 percent of total payments for CY 2008.

The market basket increase update factor of 3.3 percent for CY 2008, the required wage index and rural budget neutrality adjustment of approximately 1.0019, and the adjustment of 0.12 percent for the difference in the pass-through set aside resulted in a final standard OPPS conversion factor for CY 2008 of \$63.694.

We received one public comment on our proposed conversion factor update for CY 2008. A summary of the public comment and our response follow.

Comment: A commenter objected to the proposed market basket increase of 3.3 percent. The commenter stated that the average outpatient cost of service is projected to increase by at least 5 percent for CY 2008 due to increases in salaries and medical supply costs for services to Medicare beneficiaries. The

commenter recommended that the average payment to hospitals for outpatient services be increased by 5 percent, the actual amount by which the commenter believed costs would increase for CY 2008.

Response: Section 1833(t)(3)(C)(iv) of the Act requires that CMS update the conversion factor annually using an OPD fee schedule increase factor specific to the PPS year. However, the statute gives CMS the discretion to use the hospital inpatient update factor, the hospital inpatient operating market basket, as an appropriate substitute for the OPD fee schedule increase for purposes of the annual percentage increase specific to covered OPD services. The statute permits, and we continue to believe, that the hospital inpatient operating market basket is an appropriate measure of change in hospital input prices for goods and services required to provide hospital care, including that in the outpatient setting. Hospitals use similar resources in their hospital inpatient and outpatient departments. The hospital market basket is carefully estimated for each PPS year, and periodically rebased and revised. For these reasons, we have specified in the regulations governing the annual OPPS update at § 419.32 (b)(iv) that, for years beginning after CY 2003, the update factor for the OPPS equals the update factor for the IPPS. We disagree that the update factor for the CY 2008 OPPS should be 5 percent. For FY 2008, the IPPS update factor is the hospital market basket of 3.3 percent and, therefore, we have used this update factor in the establishment of the conversion factor for the CY 2008 OPPS.

After consideration of the public comment received, we are finalizing our CY 2008 proposal, without modification, to update the conversion factor by the FY 2008 IPPS market basket increase update factor of 3.3 percent, resulting in a final conversion factor of \$63.694.

D. Wage Index Changes

Section 1833(t)(2)(D) of the Act requires the Secretary to determine a wage adjustment factor to adjust, for geographic wage differences, the portion of the OPPS payment rate, which includes the copayment standardized amount, that is attributable to labor and labor related cost. Since the inception of the OPPS, CMS policy has been to wage adjust 60 percent of the OPPS payment, based on a regression analysis that determined that approximately 60 percent of the costs of services paid under the OPPS were attributable to wage costs. We confirmed that this labor-related share for outpatient

services is still appropriate during our regression analysis for the payment adjustment for rural hospitals in the CY 2006 OPPS final rule with comment period (70 FR 68553). Therefore, we did not propose to revise this policy for the CY 2008 OPPS. We refer readers to section II.H. of this final rule with comment period for a description and example of how the wage index for a particular hospital is used to determine the payment for the hospital. This adjustment must be made in a budget neutral manner. As we have done in prior years, we proposed to adopt the final IPPS wage indices for the OPPS and to extend these wage indices to hospitals that participate in the OPPS but not the IPPS (referred to in this section as "non-IPPS" hospitals).

As discussed in section II.A. of this final rule with comment period, we standardize 60 percent of estimated costs as labor-related costs for geographic area wage variation using the IPPS pre-reclassified wage indices in order to remove the effects of differences in area wage levels in determining the national unadjusted OPPS payment rate and the copayment amount.

As published in the original OPPS April 7, 2000 final rule with comment period (65 FR 18545), the OPPS has consistently adopted the final IPPS wage indices as the wage indices for adjusting the OPPS standard payment amounts for labor market differences. Thus, the wage index that applies to a particular hospital under the IPPS will also apply to that hospital under the OPPS. As initially explained in the September 8, 1998 OPPS proposed rule, we believed and continue to believe that using the IPPS wage index as the source of an adjustment factor for the OPPS is reasonable and logical, given the inseparable, subordinate status of the hospital outpatient department within the hospital overall. In accordance with section 1886(d)(3)(E) of the Act, the IPPS wage index is updated annually. In accordance with our established policy, we proposed to use the final FY 2008 final version of these wage indices to determine the wage adjustments for the OPPS payment rate and copayment standardized amount that would be published in our final rule with comment period for CY 2008.

We note that the FY 2008 IPPS wage indices continue to reflect a number of changes implemented over the past few years as a result of the revised Office of Management and Budget (OMB) standards for defining geographic statistical areas, the implementation of an occupational mix adjustment as part of the wage index, wage adjustments

provided for under Pub. L. 105–33 and Pub. L. 108–173, and clarification of our policy for multicampus hospitals. The following is a brief summary of the components of the FY 2008 IPPS wage indices and any adjustments that we are applying to the OPPS for CY 2008. We refer the reader to the FY 2008 IPPS final rule with comment period (72 FR 47308 through 47345) for a detailed discussion of the changes to the wage indices. In this final rule with comment period, we are not reprinting the final FY 2008 IPPS wage indices referenced in the discussion below, with the exception of the out migration wage adjustment table (Addendum L to this final rule with comment period), which includes non-IPPS providers paid under the OPPS. We also refer readers to the CMS Web site for the OPPS at: <http://www.cms.hhs.gov/providers/hopps>. At this link, the reader will find a link to the final FY 2008 IPPS wage indices tables.

1. *The continued use of the Core Based Statistical Areas (CBSAs) issued by the OMB as revised standards for designating geographical statistical areas based on the 2000 Census data, to define labor market areas for hospitals for purposes of the IPPS wage index.* The OMB revised standards were published in the **Federal Register** on December 27, 2000 (65 FR 82235), and OMB announced the new CBSAs on June 6, 2003, through an OMB bulletin. In the FY 2005 IPPS final rule, CMS adopted the new OMB definitions for wage index purposes. In the FY 2008 IPPS final rule with comment period, we again stated that hospitals located in Metropolitan Statistical Areas (MSAs) will be urban and hospitals that are located in Micropolitan Areas or outside CBSAs will be rural. We also reiterated our policy that when an MSA is divided into one or more Metropolitan Divisions, we use the Metropolitan Division for purposes of defining the boundaries of a particular labor market area. To help alleviate the decreased payments for previously urban hospitals that became rural under the new geographical definitions, we allowed these hospitals to maintain for the 3-year period from FY 2005 through FY 2007, the wage index of the MSA where they previously had been located. This hold harmless provision expired after FY 2007. We adopted the same policy for the OPPS, but because the OPPS operates on a calendar year, wage index policies are in effect through December 31, 2007. To be consistent with the IPPS, as finalized in the FY 2008 IPPS final rule with comment period, beginning in CY 2008 (January 1, 2008)

under the OPPS, these hospitals will receive their statewide rural wage index. Hospitals paid under the IPPS are eligible to apply for reclassification in FY 2008.

As noted above, for purposes of estimating an adjustment for the OPPS payment rates to accommodate geographic differences in labor costs in this final rule with comment period, we have used the wage indices identified in the FY 2008 IPPS final rule with comment period (and as corrected in the September 28, 2007 second FY 2008 IPPS correction notice that was printed in the October 10, 2007 **Federal Register** (72 FR 57634) that are fully adjusted for differences in occupational mix using the entire 6-month survey data collected in 2006.

2. *The reclassifications of hospitals to geographic areas for purposes of the wage index.* For purposes of the OPPS wage index, we proposed to adopt all of the IPPS reclassifications for FY 2008, including reclassifications that the Medicare Geographic Classification Review Board (MGCRB) approved. We note that reclassifications under section 508 of Pub. L. 108–173 were set to terminate March 31, 2007. However, section 106(a) of the MIEA–TRHCA extended any geographic reclassifications of hospitals that were made under section 508 and that would expire on March 31, 2007 until September 30, 2007. On March 23, 2007, we published a notice in the **Federal Register** (72 FR 13799) that indicated how we are implementing section 106 of the MIEA–TRHCA through September 30, 2007. Because the section 508 provision expired on September 30, 2007, the OPPS wage index will not include any reclassifications under section 508 for CY 2008.

3. *The out-migration wage adjustment to the wage index.* In the FY 2008 IPPS final rule with comment period (72 FR 473398 through 47341), we discussed the out migration adjustment under section 505 of Pub. L. 108–173 for counties under this adjustment. Hospitals paid under the IPPS located in the qualifying section 505 “out migration” counties receive a wage index increase unless they have already been otherwise reclassified. We note that in the FY 2008 IPPS final rule with comment period, we finalized our proposal to use the post-reclassified, rather than the pre-reclassified, wage indices in calculating the out-migration adjustment. (See the FY 2008 IPPS final rule with comment period and the second FY 2008 IPPS correction notice for further information on the out migration adjustment.) For OPPS purposes, we proposed to continue our

policy in CY 2008 to allow non-IPPS hospitals paid under the OPPS to qualify for the out-migration adjustment if they are located in a section 505 out migration county. Because non-IPPS hospitals cannot reclassify, they are eligible for the out-migration wage adjustment. Table 4J published in the Addendum to the FY 2008 IPPS final rule with comment period (and corrected in the second FY 2008 IPPS correction notice) identifies counties eligible for the out-migration adjustment and providers receiving the adjustment. As stated earlier, we are reprinting the final version of Table 4J, as corrected, in this final rule with comment period as Addendum L.

4. *Wage Index for Multicampus Hospitals.* As indicated in the CY 2008 OPPS/ASC proposed rule (72 FR 42695), we also wish to clarify that the IPPS policy for multicampus wage index payments also applies to the OPPS. As a result of the new labor market areas introduced in FY 2005, there are hospitals with multiple campuses previously located in a single MSA that are now in more than one CBSA. A multicampus hospital is an integrated institution. For this reason, the multicampus hospital has one CMS certification number (CCN) and submits a single cost report that combines the total wages and hours of each of its campuses in the manner described in the FY 2008 IPPS final rule with comment period (72 FR 47317).

In the FY 2008 IPPS final rule with comment period, we finalized our proposal to apportion wages and hours across multiple campuses using full-time equivalent (FTE) staff data or Medicare discharge data in order to include wage data for the individual campuses of a multicampus hospital in its local wage index calculation. We indicated our intent to collect campus locations and numbers of FTE staff by location by adding lines to Worksheet S–2 of the Medicare cost report submitted by hospitals. We stated that we would continue to use either Medicare discharge data or self-reported FTE data to apportion wage data by campus until revisions are made to Worksheet S–2 of the Medicare cost report to require reporting of FTE data by campus and until such data in the cost report can be used to calculate the wage index, at which time the wage data of a multicampus hospital will be allocated among its campuses based only on FTE counts by campus reported in the Medicare cost report. We stated that the effective date of the revised cost report is not expected until FY 2009. Therefore the FTE data reported by multicampus hospitals in the revised

Medicare cost report could not be used to allocate wages and hours to each labor market by FTEs until at least the FY 2013 wage index. As part of this policy, we would fully expect that an HOPD that is part of a multicampus hospital system would receive a wage index based on the geographic location of the inpatient campus with which it is associated. This would include cases where one inpatient campus reclassified. Affiliated outpatient facilities would receive the reclassified wage index of the inpatient campus. For further discussion of the FY 2008 IPPS final multicampus hospital policy in its entirety, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47317 through 47319).

5. *Rural Floor Provision.* Section 4410 of Pub. L. 105–33 provides that the area wage index applicable to any hospital that is located in an urban area of a State may not be less than the area wage index applicable to hospitals located in rural areas of the State (“the rural floor”). Table 4A in the FY 2008 IPPS final rule with comment period (72 FR 47503) (and as corrected in the September 28, 2007 second correction notice for the FY 2008 IPPS final rule, which appeared in the October 10, 2007 issue of the **Federal Register**) identifies urban areas where hospitals located in those areas are assigned the rural floor (noted by a superscript “2”). For CY 2008 under the OPPS, we proposed to continue our policy to allow non-IPPS hospitals paid under the OPPS to receive the rural floor wage index, when applicable under the IPPS for FY 2008. For the first time, the final FY 2008 IPPS wage indices include a blanket budget neutrality adjustment for including the rural floor provision, which previously had been applied to the IPPS standardized amount. For further discussion of this final policy in its entirety, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47325 through 47330) and the second FY 2008 IPPS correction notice (72 FR 57634).

We note that all changes to the wage index resulting from geographic labor market area reclassifications or other adjustments must be incorporated in a budget neutral manner. Accordingly, in calculating the OPPS budget neutrality estimates for CY 2008 in this final rule with comment period, we have included the wage index changes that would result from the MGCRB reclassifications, implementation of sections 4410 of Pub. L. 105–33 and 505 of Pub. L. 108–173, and other refinements adopted in the FY 2008 IPPS final rule with comment period. For the CY 2008 OPPS, we proposed to use the final FY 2008 IPPS

wage indices, including the budget neutrality adjustment for the rural floor, for calculating OPSS payment in CY 2008. We discuss how the OPSS conversion factor would compensate for the inclusion of this budget neutrality adjustment in the wage indices in section II.C. of this final rule with comment period relating to the conversion factor update.

Comment: Commenters supported the CMS proposal for CY 2008 to extend the IPPS wage indices to the OPSS as we had done in previous years. One commenter agreed with the proposal to adopt the IPPS wage index but suggested that it would be logical to adopt the same labor component percentage as applied under the IPPS. The commenter argued that the labor component is derived from hospital cost report information that does not separate inpatient from outpatient services for labor-related and nonlabor-related costs, and thus the labor component utilized in the IPPS is based on a combination of inpatient and outpatient costs. The commenter also suggested that the 60 percent labor-related share used in the OPSS was derived nearly 10 years ago and has never been supported by analysis. The commenter recommended that CMS revise the labor-related share from 60 percent to 69.731 percent to be consistent with the IPPS.

Response: We appreciate the support expressed by commenters concerning our proposed wage index policies for CY 2008. In response to the comment concerning the OPSS labor-related share, we do not believe that such a change to adopt the IPPS labor related share is appropriate. The current IPPS labor-related share of 69.731 percent was calculated by summing the relative weights for labor components in the IPPS operating market basket (70 FR 2339). The IPPS estimates a labor-related share that is specific to inpatient services; the OPSS estimates a labor-related share that is specific to outpatient services. The OPSS labor-related share was determined through regression analyses conducted for the initial OPSS proposed rule (63 FR 47581). Those analyses examined the extent of variability in hospital outpatient cost per unit explained by variability in the wage index, holding outpatient service mix under the proposed system, geographic location, volume, and other variables constant. The unit cost dependent variable in these analyses was derived by applying the CCRs for ancillary cost centers to charges, and those ancillary CCRs should reflect the proportional labor costs for ancillary services. The wage

index provides a measure of the wage level faced by a hospital relative to the national average, which should be roughly the same for the institution across inpatient and outpatient settings. Those initial analyses identified 60 percent as the appropriate labor-related share for outpatient services. We confirmed that this labor-related share is still appropriate during our regression analysis for the payment adjustment for rural hospitals, as discussed in the CY 2006 OPSS final rule with comment period (70 FR 68556). Further, we would expect services delivered in the HOPD to require proportionately less labor than more acute inpatient services that require greater nursing care and an extended stay. We believe that the 60 percent labor-related share for the OPSS compares favorably to the hospital inpatient labor-related share of 69.731 percent.

We are finalizing our proposal, without modification, to use the final IPPS FY 2008 wage indices to adjust the OPSS standard payment amounts for labor market differences under the CY 2008 OPSS.

E. Statewide Average Default CCRs

CMS uses CCRs to determine outlier payments, payments for pass-through devices, and monthly interim transitional corridor payments under the OPSS. Some hospitals do not have a valid CCR. These hospitals include, but are not limited to, hospitals that are new and have not yet submitted a cost report, hospitals that have a CCR that falls outside predetermined floor and ceiling thresholds for a valid CCR, or hospitals that have recently given up their all-inclusive rate status. Last year, we updated the default urban and rural CCRs for CY 2007 in our final rule with comment period (71 FR 68006 through 68009). As we proposed, in this final rule with comment period we have updated the default ratios for CY 2008 using the most recent cost report data.

We calculated the statewide default CCRs using the same overall CCRs that we use to adjust charges to costs on claims data. Table 25 published in the CY 2008 OPSS/ASC proposed rule listed the proposed CY 2008 default urban and rural CCRs by State and compared them to last year's default CCRs. These CCRs are the ratio of total costs to total charges from each provider's most recently submitted cost report, for those cost centers relevant to outpatient services weighted by Medicare Part B charges. We also adjusted ratios from submitted cost reports to reflect final settled status by applying the differential between settled to submitted costs and charges from the

most recent pair of final settled and submitted cost reports.

For the proposed rule, approximately 78 percent of the submitted cost reports represented data for CY 2005. We have since updated the cost report data we use to calculate CCRs with additional submitted cost reports for CY 2006. For this final rule with comment period, 47 percent of the submitted cost reports utilized in the default ratio calculation were for CY 2005 and 49 percent were for CY 2006. We only used valid CCRs to calculate these default ratios. That is, we removed the CCRs for all-inclusive hospitals, CAHs, and hospitals in Guam, and the U.S. Virgin Islands, American Samoa, and the Northern Mariana Islands because these entities are not paid under the OPSS, or in the case of all inclusive hospitals, because their CCRs are suspect. We further identified and removed any obvious error CCRs and trimmed any outliers. We limited the hospitals used in the calculation of the default CCRs to those hospitals that billed for services under the OPSS during CY 2006.

Finally, we calculated an overall average CCR, weighted by a measure of volume for CY 2006, for each State except Maryland. This measure of volume is the total lines on claims and is the same one that we use in our impact tables. For Maryland, we used an overall weighted average CCR for all hospitals in the nation as a substitute for Maryland CCRs. Few providers in Maryland are eligible to receive payment under the OPSS, which limits the data available to calculate an accurate and representative CCR. The observed differences between last year's and this year's default statewide CCRs largely reflect a general decline in the ratio between costs and charges widely observed in the cost report data. However, observed increases in some areas suggest that the decline in CCRs is moderating. Further, the addition of weighting by Medicare Part B charges to the overall CCR in CY 2007 slightly increases the variability of the overall CCR calculation.

As stated above, CMS uses default statewide CCRs for several groups of hospitals, including, but not limited to, hospitals that are new and have not yet submitted a cost report, hospitals that have a CCR that falls outside predetermined floor and ceiling thresholds for a valid CCR, and hospitals that have recently given up their all-inclusive rate status.

Prior to CY 2007, OPSS policy required hospitals that experienced a change of ownership, but that did not accept assignment of the previous hospital's provider agreement, to use the

previous provider's CCR. However, in CY 2007 we revised this policy and finalized our proposal to use default statewide CCRs for entities that had not accepted assignment of an existing hospital's provider agreement in accordance with § 489.18 and that had not yet submitted its first Medicare cost report. For CY 2008, we proposed to continue to apply this treatment of using the default statewide CCR, to include an entity that has not accepted assignment of an existing hospital's provider agreement in accordance with § 489.18 and that has not yet submitted

its first Medicare cost report. This policy is effective for hospitals experiencing a change of ownership on or after January 1, 2007. As stated in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68006), we believed that a hospital that has not accepted assignment of an existing hospital's provider agreement is similar to a new hospital that will establish its own costs and charges. We also believed that the hospital that has chosen not to accept assignment may have different costs and charges than the existing hospital. Furthermore, we believed that

the hospital should be provided time to establish its own costs and charges. Therefore, we proposed to use the default statewide CCR to determine cost-based payments until the hospital has submitted its first Medicare cost report.

We did not receive any public comments concerning this issue. Therefore, we are finalizing the statewide average default CCRs as shown in Table 11 below for OPPS services furnished on or after January 1, 2008, without modification.

TABLE 11.—CY 2008 STATEWIDE AVERAGE CCRs

State	Rural/urban	CY 2008 default CCR	Previous default CCR (CY 2007 OPPS final rule)
ALASKA	RURAL	0.537	0.534
ALASKA	URBAN	0.351	0.383
ALABAMA	RURAL	0.228	0.232
ALABAMA	URBAN	0.213	0.223
ARKANSAS	RURAL	0.266	0.264
ARKANSAS	URBAN	0.270	0.275
ARIZONA	RURAL	0.264	0.282
ARIZONA	URBAN	0.232	0.232
CALIFORNIA	RURAL	0.232	0.246
CALIFORNIA	URBAN	0.218	0.232
COLORADO	RURAL	0.355	0.370
COLORADO	URBAN	0.254	0.267
CONNECTICUT	RURAL	0.391	0.389
CONNECTICUT	URBAN	0.339	0.349
DISTRICT OF COLUMBIA	URBAN	0.346	0.339
DELAWARE	RURAL	0.302	0.323
DELAWARE	URBAN	0.400	0.395
FLORIDA	RURAL	0.219	0.219
FLORIDA	URBAN	0.198	0.199
GEORGIA	RURAL	0.279	0.285
GEORGIA	URBAN	0.269	0.289
HAWAII	RURAL	0.373	0.357
HAWAII	URBAN	0.317	0.320
IOWA	RURAL	0.349	0.349
IOWA	URBAN	0.325	0.343
IDAHO	RURAL	0.445	0.436
IDAHO	URBAN	0.414	0.416
ILLINOIS	RURAL	0.286	0.308
ILLINOIS	URBAN	0.271	0.288
INDIANA	RURAL	0.313	0.316
INDIANA	URBAN	0.301	0.320
KANSAS	RURAL	0.318	0.320
KANSAS	URBAN	0.240	0.252
KENTUCKY	RURAL	0.244	0.251
KENTUCKY	URBAN	0.262	0.270
LOUISIANA	RURAL	0.271	0.281
LOUISIANA	URBAN	0.277	0.273
MARYLAND	RURAL	0.308	0.318
MARYLAND	URBAN	0.284	0.298
MASSACHUSETTS	URBAN	0.338	0.349
MAINE	RURAL	0.433	0.457
MAINE	URBAN	0.424	0.429
MICHIGAN	RURAL	0.331	0.346
MICHIGAN	URBAN	0.318	0.329
MINNESOTA	RURAL	0.499	0.508
MINNESOTA	URBAN	0.342	0.338
MISSOURI	RURAL	0.289	0.294
MISSOURI	URBAN	0.292	0.303
MISSISSIPPI	RURAL	0.267	0.284
MISSISSIPPI	URBAN	0.217	0.231
MONTANA	RURAL	0.453	0.439

TABLE 11.—CY 2008 STATEWIDE AVERAGE CCRs—Continued

State	Rural/urban	CY 2008 default CCR	Previous default CCR (CY 2007 OPPS final rule)
MONTANA	URBAN	0.450	0.463
NORTH CAROLINA	RURAL	0.286	0.305
NORTH CAROLINA	URBAN	0.321	0.370
NORTH DAKOTA	RURAL	0.379	0.367
NORTH DAKOTA	URBAN	0.378	0.395
NEBRASKA	RURAL	0.347	0.376
NEBRASKA	URBAN	0.290	0.290
NEW HAMPSHIRE	RURAL	0.375	0.370
NEW HAMPSHIRE	URBAN	0.337	0.325
NEW JERSEY	URBAN	0.276	0.297
NEW MEXICO	RURAL	0.275	0.274
NEW MEXICO	URBAN	0.353	0.398
NEVADA	RURAL	0.329	0.335
NEVADA	URBAN	0.200	0.214
NEW YORK	RURAL	0.417	0.445
NEW YORK	URBAN	0.402	0.427
OHIO	RURAL	0.354	0.369
OHIO	URBAN	0.268	0.283
OKLAHOMA	RURAL	0.288	0.295
OKLAHOMA	URBAN	0.245	0.261
OREGON	RURAL	0.321	0.344
OREGON	URBAN	0.366	0.405
PENNSYLVANIA	RURAL	0.298	0.305
PENNSYLVANIA	URBAN	0.241	0.252
PUERTO RICO	URBAN	0.474	0.469
RHODE ISLAND	URBAN	0.308	0.309
SOUTH CAROLINA	RURAL	0.258	0.255
SOUTH CAROLINA	URBAN	0.244	0.248
SOUTH DAKOTA	RURAL	0.334	0.348
SOUTH DAKOTA	URBAN	0.289	0.304
TENNESSEE	RURAL	0.256	0.265
TENNESSEE	URBAN	0.241	0.249
TEXAS	RURAL	0.271	0.289
TEXAS	URBAN	0.242	0.258
UTAH	RURAL	0.416	0.441
UTAH	URBAN	0.406	0.416
VIRGINIA	RURAL	0.268	0.282
VIRGINIA	URBAN	0.275	0.280
VERMONT	RURAL	0.416	0.432
VERMONT	URBAN	0.340	0.338
WASHINGTON	RURAL	0.358	0.374
WASHINGTON	URBAN	0.368	0.372
WISCONSIN	RURAL	0.384	0.367
WISCONSIN	URBAN	0.362	0.364
WEST VIRGINIA	RURAL	0.298	0.316
WEST VIRGINIA	URBAN	0.360	0.369
WYOMING	RURAL	0.449	0.471
WYOMING	URBAN	0.351	0.352

F. OPSS Payments to Certain Rural Hospitals

1. Hold Harmless Transitional Payment Changes Made by Pub. L. 109–171 (DRA)

When the OPSS was implemented, every provider was eligible to receive an additional payment adjustment (called either transitional corridor payment or transitional outpatient payment) if the payments it received for covered outpatient department (OPD) services under the OPSS were less than the payments it would have received for the same services under the prior

reasonable cost-based system. Section 1833(t)(7) of the Act provides that the transitional corridor payments are temporary payments for most providers to ease their transition from the prior reasonable cost-based payment system to the OPSS system. There are two exceptions, cancer hospitals and children’s hospitals, to this provision and those hospitals receive the transitional corridor payments on a permanent basis. Section 1833(t)(7)(D)(i) of the Act originally provided for transitional corridor payments to rural hospitals with 100 or fewer beds for

covered OPD services furnished before January 1, 2004. However, section 411 of Pub. L. 108–173 amended section 1833(t)(7)(D)(i) of the Act to extend these payments through December 31, 2005, for rural hospitals with 100 or fewer beds. Section 411 also extended the transitional corridor payments to SCHs located in rural areas for services furnished during the period that begins with the provider’s first cost reporting period beginning on or after January 1, 2004, and ended on December 31, 2005. Accordingly, the authority for making transitional corridor payments under

section 1833(t)(7)(D)(i) of the Act, as amended by section 411 of Pub. L. 108–173, for rural hospitals having 100 or fewer beds and SCHs located in rural areas expired on December 31, 2005.

Section 5105 of Pub. L. 109–171 reinstated the hold harmless transitional outpatient payments (TOPs) for covered OPD services furnished on or after January 1, 2006, and before January 1, 2009, for rural hospitals having 100 or fewer beds that are not SCHs. When the OPDS payment is less than the payment the provider would have received under the previous reasonable cost-based system, the amount of payment is increased by 95 percent of the amount of the difference between the two payment systems for CY 2006, by 90 percent of the amount of that difference for CY 2007, and by 85 percent of the amount of that difference for CY 2008.

For CY 2006, we implemented section 5105 of Pub. L. 109–171 through Transmittal 877, issued on February 24, 2006. We did not specifically address whether TOPs apply to essential access community hospitals (EACHs), which are considered to be SCHs under section 1886(d)(5)(D)(iii)(III) of the Act. Accordingly, under the statute, EACHs are treated as SCHs. Therefore, we believed and continue to believe that EACHs are not currently eligible for TOPs under Pub. L. 109–171. However, they are eligible for the adjustment for rural SCHs. In the CY 2007 OPDS/ASC final rule with comment period, we updated § 419.70(d) to reflect the requirements of Pub. L. 109–171 (71 FR 68010 and 68228).

2. Adjustment for Rural SCHs Implemented in CY 2006 Related to Pub. L. 108–173 (MMA)

In the CY 2006 OPDS final rule with comment period (70 FR 68556), we finalized a payment increase for rural SCHs of 7.1 percent for all services and procedures paid under the OPDS, excluding drugs, biologicals, brachytherapy seeds, and services paid under pass-through payment policy in accordance with section 1833(t)(13)(B) of the Act, as added by section 411 of Pub. L. 108–173. Section 411 gave the Secretary the authority to make an adjustment to OPDS payments for rural hospitals, effective January 1, 2006, if justified by a study of the difference in costs by APC between hospitals in rural and urban areas. Our analysis showed a difference in costs for rural SCHs. Therefore, we implemented a payment adjustment for only those hospitals beginning January 1, 2006.

Last year, we became aware that we did not specifically address whether the

adjustment applies to EACHs, which are considered to be SCHs under section 1886(d)(5)(D)(iii)(III) of the Act. Thus, under the statute, EACHs are treated as SCHs. Therefore, in the CY 2007 OPDS/ASC final rule with comment period, for purposes of receiving this rural adjustment, we revised § 419.43(g) to clarify that EACHs are also eligible to receive the rural SCH adjustment, assuming these entities otherwise meet the rural adjustment criteria (71 FR 68010 and 68227). Currently, fewer than 10 hospitals are classified as EACHs and as of CY 1998, under section 4201(c) of Pub. L. 105–33, a hospital can no longer become newly classified as an EACH.

This adjustment for rural SCHs is budget neutral and applied before calculating outliers and copayment. As stated in the CY 2006 OPDS final rule with comment period (70 FR 68560), we would not reestablish the adjustment amount on an annual basis, but we note that we may review the adjustment in the future and, if appropriate, would revise the adjustment.

For CY 2008, we proposed to continue our current policy of a budget neutral 7.1 percent payment increase for rural SCHs, including EACHs, for all services and procedures paid under the OPDS, excluding drugs, biologicals, and services paid under the pass-through payment policy in accordance with section 1833(t)(13)(B) of the Act. This adjustment is in accordance with section 411 of the MMA, which gave the Secretary the authority to make an adjustment to OPDS payments for rural hospitals, if justified by a study of the difference in costs by APC between hospitals in rural and urban areas. Our analysis showed a difference in costs only for rural SCHs, and we implemented a payment adjustment for those hospitals beginning January 1, 2006. For CY 2008, we also proposed to include brachytherapy sources in the group of services eligible for the 7.1 percent payment increase because we proposed to pay them at prospective rates based on their median costs as calculated from historical claims data. Consequently, we proposed to revise § 419.43 to reflect our proposal to make brachytherapy sources eligible for the 7.1 percent payment increase for rural SCHs. As indicated in our proposed rule (72 FR 42698), we intend to reassess the 7.1 percent adjustment in the near future by examining differences between urban and rural costs using updated claims, cost, and provider information. In that process, we will include brachytherapy sources in each hospital's mix of services.

Comment: Several commenters supported our proposals to continue our

current policy of a budget neutral 7.1 percent payment increase for rural SCHs, including EACHs, for all services and procedures paid under the OPDS, excluding drugs, biologicals, and services paid under the pass-through payment policy, and to make brachytherapy sources eligible for the 7.1 percent payment increase for rural SCHs.

Response: We appreciate the commenters' support of the policy.

After consideration of the public comments received, we are finalizing, without modification, our policy to continue a payment adjustment for rural SCHs, including EACHs, of 7.1 percent for CY 2008. We also are finalizing our proposed revision of § 419.43 to make brachytherapy sources eligible for the 7.1 percent payment increase for rural SCHs, including EACHs, without modification.

G. Hospital Outpatient Outlier Payments

1. Background

Currently, the OPDS pays outlier payments on a service-by-service basis. For CY 2007, the outlier threshold is met when the cost of furnishing a service or procedure by a hospital exceeds 1.75 times the APC payment amount and exceeds the APC payment rate plus a \$1,825 fixed-dollar threshold. We introduced a fixed-dollar threshold in CY 2005 in addition to the traditional multiple threshold in order to better target outliers to those high cost and complex procedures where a very costly service could present a hospital with significant financial loss. If a provider meets both of these conditions, the multiple threshold and the fixed-dollar threshold, the outlier payment is calculated as 50 percent of the amount by which the cost of furnishing the service exceeds 1.75 times the APC payment rate.

As explained in the CY 2007 OPDS/ASC final rule with comment period (71 FR 68011 through 68012), we set our projected target for aggregate outlier payments at 1.0 percent of aggregate total payments under the OPDS for CY 2007. The outlier thresholds were set so that estimated CY 2007 aggregate outlier payments would equal 1.0 percent of aggregate total payments under the OPDS. In that final rule with comment period (71 FR 68010) we also published total outlier payments as a percent of total expenditures for CY 2005. In the past, we have received comments asking us to publish estimated outlier payments to provide a context for the proposed outlier thresholds for the update year. In the CY 2008 OPDS/ASC

proposed rule (72 FR 42698), we estimated, using available CY 2006 claims, that the outlier payments for CY 2006 would be approximately 1.1 percent of total CY 2006 OPSS payment. In the final CY 2006 claims, aggregated outlier payments were 1.1 percent of aggregated total OPSS payments. For CY 2006, the estimated outlier payments were set at 1.0 percent of the total aggregated OPSS payments. Therefore, for CY 2006 we paid 0.1 percent in excess of the CY 2006 outlier target of 1.0 percent of total aggregated OPSS payments. Using the final CY 2006 claims and CY 2007 payment rates, we currently estimate that outlier payments for CY 2007 would be approximately 0.7 percent of total CY 2007 OPSS payments and the difference between 1.0 percent and 0.7 percent is reflected in the regulatory impact analysis in section XXIV.B. of this final rule with comment period. We will not know the final amount of outlier payments as a percent of total payments until we have final CY 2007 claims. We note that we provide estimated CY 2008 outlier payments by hospital for hospitals with claims included in the claims data that we used to model impacts on the CMS Web site in the Hospital—Specific Impacts—Provider-Specific Data file on the CMS Web site at: <http://www.cms.hhs.gov/HospitalOutpatientPPS/>.

2. Proposed Outlier Calculation

For CY 2008, we proposed to continue our policy of setting aside 1.0 percent of aggregate total payments under the OPSS for outlier payments. We proposed that a portion of that 1.0 percent, 0.03 percent, would be allocated to CMHCs for partial hospitalization program service outliers. This amount is the amount of estimated outlier payments resulting from the proposed CMHC outlier threshold of 3.4 times the APC payment rate, as a proportion of all payments dedicated to outlier payments. For this final rule, we estimate that 0.02 percent of total outlier payments would be allocated to CMHC's for partial hospitalization program service outliers. For further discussion of CMHC outliers, we refer readers to section II.B.3. of this final rule with comment period.

In order to ensure that estimated CY 2008 aggregate outlier payments would equal 1.0 percent of estimated aggregate total payments under the OPSS, we proposed that the outlier threshold be set so that outlier payments would be triggered when the cost of furnishing a service or procedure by a hospital exceeds 1.75 times the APC payment amount and exceeds the APC payment

rate plus a \$2,000 fixed-dollar threshold. This proposed threshold reflected minor changes to the methodology discussed below as well as APC recalibration, including changes due in part to the CY 2008 packaging approach discussed in section II.A.4.c. of this final rule with comment period.

We calculated the fixed-dollar threshold for the CY 2008 proposed rule using largely the same methodology as we did in CY 2007, except that we proposed to adjust the overall CCRs to reflect the anticipated annual decline in overall CCRs, discussed below, and to use CCRs from the most recent update to the Outpatient Provider-Specific File (OPSF), rather than CCRs we calculate internally for ratesetting. As noted in the CY 2008 OPSS/ASC proposed rule (72 FR 42699), in November 2006 we issued Transmittal 1030, "Policy Changes to the Fiscal Intermediary (FI) Calculation of Hospital Outpatient Payment System (OPSS) and Community Mental Health Center (CMHC) Cost to Charge Ratios (CCRs)," instructing fiscal intermediaries (or, if applicable, MACs) to update the overall CCR calculation for outlier and other cost-based payments using the CCR calculation methodology that we finalized for CY 2007. As discussed in the CY 2007 OPSS/ASC proposed rule and final rule with comment period, this methodology aligned the fiscal intermediary's CCR calculation and the CCR calculation we previously used to model outlier thresholds by removing allied and nursing health costs for those hospitals with paramedical education programs from the fiscal intermediary's CCR calculation and weighting our "traditional" CCR calculation by total Medicare Part B charges. We believe that the OPSF best estimates the CCRs that fiscal intermediaries (or, if applicable, MACs) would use to determine outlier payments in CY 2008. For the proposed rule, we used the April update to the OPSF. We supplemented a CCR calculated internally for the handful of providers with claims in our claims dataset that were not listed in the April update to the OPSF.

The claims that we use to model each OPSS update lag by 2 years. For the proposed rule, we used CY 2006 claims to model the CY 2008 OPSS. In order to estimate CY 2008 outlier payments for the proposed rule, we inflated the charges on the CY 2006 claims using the same inflation factor of 1.1504 that we used to estimate the IPPS fixed-dollar outlier threshold for the FY 2008 IPPS proposed rule. For 1 year, the inflation factor is 1.0726. The methodology for determining this charge inflation factor

was discussed in the FY 2008 IPPS proposed rule (72 FR 24837) and in the FY 2008 IPPS final rule with comment period (72 FR 47417). As we stated in the CY 2005 OPSS final rule with comment period, we believe that the use of this charge inflation factor is appropriate for the OPSS because, with the exception of the routine service cost centers, hospitals use the same cost centers to capture costs and charges across inpatient and outpatient services (69 FR 65845).

In comments on the CY 2007 OPSS/ASC proposed rule, a commenter asked that CMS modify the charge methodology used to set the OPSS outlier threshold to account for the change in CCRs over time in a manner similar to that used for the FY 2007 IPPS. The commenter indicated that it would be appropriate to apply an inflation adjustment factor so that the CCRs that CMS uses to simulate OPSS outlier payments would more closely reflect the CCRs that would be used in CY 2007 to determine actual outlier payment. In the CY 2007 OPSS/ASC final rule with comment period, we expressed concern that cost increases between inpatient and outpatient departments could be different and indicated that we would study the issue and address any changes to the outlier methodology through future rulemaking (71 FR 68012).

In assessing the possibility of utilizing a cost inflation adjustment for the OPSS, we determined that we could not calculate an OPSS-specific reliable cost per unit, comparable to the cost per discharge component of the IPPS calculation, because of variability in definition of an OPSS unit of service across calendar years. However, we also believed that the costs and charges reported under the applicable cost centers largely are commingled inpatient and outpatient costs and charges. We did not want to systematically overestimate the OPSS outlier threshold as could occur if we did not apply a CCR inflation adjustment factor. Therefore, we proposed to apply the CCR adjustment factor that was proposed to be applied for IPPS outlier calculation to the CCRs used to simulate the CY 2008 OPSS outlier payments that determined the fixed-dollar threshold. Specifically, for CY 2008, we proposed to apply an adjustment of 0.9912 to the CCRs that are currently on the OPSF to trend them forward from CY 2007 to CY 2008. The methodology for calculating this adjustment is discussed in the FY 2008 IPPS proposed rule (72 FR 24837) and the FY 2008 IPPS final rule with comment period (72 FR 47417).

Therefore, for the CY 2008 proposed rule, we applied the overall CCRs from the April 2007 OPSF file after adjustment to approximate CY 2008 CCRs (using the proposed CCR inflation adjustment factor of 0.9912) to charges on CY 2006 claims that were adjusted to approximate CY 2008 charges (using the proposed charge inflation factor of 1.1504). We simulated aggregated CY 2008 outlier payments using these costs for several different fixed-dollar thresholds, holding the 1.75 multiple constant and assuming that outlier payment would continue to be made at 50 percent of the amount by which the cost of furnishing the service would exceed 1.75 times the APC payment amount, until the total outlier payments equaled 1.0 percent of aggregated estimated total CY 2008 OPSS payments. We estimated that a proposed fixed-dollar threshold of \$2,000, combined with the proposed multiple threshold of 1.75 times the APC payment rate, would allocate 1.0 percent of aggregated total OPSS payments to outlier payments. We proposed to continue to make an outlier payment that equals 50 percent of the amount by which the cost of furnishing the service exceeds 1.75 times the APC payment amount when both the 1.75 multiple threshold and the fixed-dollar \$2,000 threshold are met. For CMHCs, if a CMHC provider's cost for partial hospitalization exceeds 3.4 times the payment rate for APC 0033, the outlier payment is calculated as 50 percent of the amount by which the cost exceeds 3.4 times the APC payment rate.

We received several public comments related to this proposal. A summary of the public comments and our responses follow.

Comment: Several commenters requested that CMS publish annual outlier payments as a percentage of total OPSS payment.

Response: We currently publish the total outlier payments as a percent of total payment for past years in the annual OPSS/ASC proposed and final rules. We have projected outlier payments to be 1.1 percent of total OPSS payments for CY 2006, the most complete set of full year claims data that currently exists. We plan to continue to publish these numbers for future years, after we have full year cost data. For CY 2008, we estimate that outlier payments will be 1.0 percent of total payment.

Comment: One commenter agreed with our proposal to raise the fixed dollar outlier threshold accordingly so that the 1.0 percent target for outlier payments is met. Other commenters requested that CMS lower the fixed dollar threshold so that a greater

number of services would be eligible for outlier payments. One commenter noted that the proposed increased fixed dollar threshold significantly reduced the number of services that would be eligible for outlier payments. Another commenter expressed concern that increased OPSS packaging would cause CMS to pay less in outlier payments than in the past. Other commenters were concerned that the fixed dollar outlier threshold that CMS proposed was set too high and would result in CMS spending less money than allocated for the projected 1.0 percent outlier target. These commenters argued that the estimated outlier target amount has historically been greater than the actual need, and they asked that CMS either reduce the set-aside amount and retain that money in the base OPSS rates or reduce the threshold for qualification so that the outlier expenditures would be at a zero balance at the end of each year. Several commenters asked that CMS limit the increase in the outlier threshold to the amount of the market basket update each year, which would mean, for CY 2008, that the CY 2008 threshold would be increased by only 3.3 percent. Other commenters suggested that the outlier payment be increased from 50 percent to 80 percent of the difference between the APC payment and the cost of the service. They believed that this would more appropriately account for the additional cost of the service and make the outlier payment policy consistent with IPPS policy.

Response: Consistent with the views of most commenters, we are reducing the proposed fixed dollar outlier threshold based on our updated analysis for this final rule with comment period, where we use the most current claims and cost report data and final payment policies to estimate the threshold that would allow us to pay CY 2008 outlier payments of 1.0 percent of total CY 2008 OPSS payment.

In CY 2008, the OPSS outlier outlay is projected to be 1.0 percent of total payments. We note that our projections for CY 2008 outlier payments take into account the final packaging policies, as well as all other final payment policies, of the OPSS. We acknowledge that outlier payments are an integral component of the OPSS and could be particularly important as the APC payment bundles grow larger and hospitals potentially experience financially greater risk associated with individual patient encounters. In a movement toward encounter-based or episode-based payment, multiple service payments for a claim could become less common, and OPSS outlier

payments could come to be increasingly targeted toward clinical cases rather than individual services, consistent with the customary role of outlier payment in a prospective payment system. We prospectively set the outlier thresholds so that we will pay 1.0 percent of projected payment based on our best inflation assumptions and model of final payment policies. The final policy to increase packaging for the CY 2008 OPSS should not result in less aggregate outlier payment in CY 2008 than other years, although the distribution of payment across APCs will change.

We believe that the estimated total CY 2008 outlier payments will meet the target of 1.0 percent of total OPSS payments. In CY 2006, aggregated outlier payments were 1.1 percent of aggregated total spending, while the target was set at 1.0. As we indicated in the CY 2007 OPSS/ASC final rule with comment period (71 FR 68010), in the final set of CY 2005 OPSS claims, aggregated outlier payments were 2.39 percent of aggregated total OPSS payments, while the target was set at 2.0 percent. Similarly, using the final set of CY 2004 OPSS claims, aggregated outlier payments were 2.5 percent of total OPSS payments, while the target was set at 2 percent. Hence, our historic estimation of outlier payments has resulted in outlier payments that exceeded our target. As noted above, we currently estimate that we will pay 0.7 percent of total payments in outlier payments in CY 2007. We believe that our proposed methodology that applies charge and CCR inflation factors to updated CY 2006 claims and overall CCRs from the most recent OPSF file to approximate CY 2008 values yields an outlier threshold that will result in more accurate aggregate program outlier payments.

We did not increase the CY 2008 outlier threshold by the market basket update of 3.3 percent because our calculations are intended to best approximate the outlier target of 1.0 percent of CY 2008 OPSS expenditures. We continue to believe that an outlier target of 1.0 percent of total OPSS payment is appropriate for the OPSS. However, we will monitor outlier payments distributed during CY 2008 to determine whether a different outlier target would be more appropriate.

Similarly, we do not believe it is appropriate to increase the payment percentage to 80 percent of the difference between the APC payment and the cost of the service in order to align it with the IPPS outlier policy. In a budget neutral system with a specified payment target, the payment percentage

and fixed-dollar threshold have an inverse relationship. Raising the payment percentage would require us to significantly increase the fixed dollar threshold to ensure that the outlier target is not exceeded. We agree with most commenters that a relatively lower fixed-dollar threshold is more desirable for the OPSS than a higher fixed-dollar threshold, given the current size of the OPSS payment bundles.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, for the outlier calculation as outlined below.

3. Final Outlier Calculation

For CY 2008, we are applying the overall CCRs from the July 2007 OPSF file with a CCR adjustment factor of 1.0027 to approximate CY 2008 CCRs to charges on the final CY 2006 claims that were adjusted to approximate CY 2008 charges (using the final charge inflation factor of 1.1278). These are the same CCR adjustment and charge inflation factors that we used to set the IPPS fixed-dollar threshold for FY 2008 (72 FR 47418). We simulated aggregated CY 2008 outlier payments using these costs for several different fixed-dollar thresholds, holding the 1.75 multiple constant and assuming that outlier payment would continue to be made at 50 percent of the amount by which the cost of furnishing the service would exceed 1.75 times the APC payment amount, until the total outlier payments equaled 1.0 percent of aggregated estimated total CY 2008 OPSS payments. We estimate that a fixed-dollar threshold of \$1,575, combined with the multiple threshold of 1.75 times the APC payment rate, will allocate 1.0 percent of aggregated total OPSS payments to outlier payments.

In summary, for CY 2008 we will continue to make an outlier payment that equals 50 percent of the amount by which the cost of furnishing the service exceeds 1.75 times the APC payment amount when both the 1.75 multiple threshold and the fixed-dollar \$1,575 threshold are met. As discussed in section VII.B. of this final rule with comment period, brachytherapy sources will be eligible for outlier payment beginning in CY 2008. In addition, the costs of diagnostic radiopharmaceuticals and contrast media for which CY 2008 payment is packaged into the APC payments for nuclear medicine and other imaging procedures under the final packaging approach will contribute to a claim's eligibility for outlier payment in CY 2008. For CMHCs, if a CMHC provider's cost for partial hospitalization exceeds 3.4 times the

payment rate for APC 0033, the outlier payment is calculated as 50 percent of the amount by which the cost exceeds 3.4 times the APC payment rate.

H. Calculation of an Adjusted Medicare Payment From the National Unadjusted Medicare Payment

(We note that the title of this section has been changed from that used in the CY 2008 OPSS/ASC proposed rule. In that rule this section was entitled, "Proposed Calculation of the National Unadjusted Medicare Payment.")

The basic methodology for determining prospective payment rates for HOPD services under the OPSS is set forth in existing regulations at § 419.31 and § 419.32, and § 419.43 and § 419.44. The payment rate for services and procedures for which payment is made under the OPSS is the product of the conversion factor calculated in accordance with section II.C. of this final rule with comment period and the relative weight determined under section II.A. of this final rule with comment period. Therefore, the national unadjusted payment rate for each APC contained in Addendum A to this final rule with comment period and for HCPCS codes to which separate payment under the OPSS has been assigned in Addendum B to this final rule with comment period (Addendum B is provided as a convenience for readers) was calculated by multiplying the final CY 2008 scaled weight for the APC by the final CY 2008 conversion factor.

However, to determine the payment that will be made in a calendar year under the OPSS to a specific hospital for an APC for a service that has any of the status indicator assignments "S," "T," "V," or "X," as defined in Addendum D1 of this final rule with comment period, in a circumstance in which the multiple procedure discount does not apply and the procedure is not bilateral or discontinued, we take the following steps:

Step 1. Calculate 60 percent (the labor-related portion) of the national unadjusted payment rate. Since the initial implementation of the OPSS, we have used 60 percent to represent our estimate of that portion of costs attributable, on average, to labor. (We refer readers to the April 7, 2000 final rule with comment period (65 FR 18496 through 18497) for a detailed discussion of how we derived this percentage.) We confirmed that this labor-related share for hospital outpatient services is still appropriate during our regression analysis for the payment adjustment for rural hospitals in the CY 2006 OPSS

final rule with comment period (70 FR 68553).

Individual providers interested in calculating the final payment amount that they will receive for a specific service from the national payment rates presented in Addenda A and B to this final rule with comment period should follow the formulas presented in the following steps. The formula below is a mathematical representation of step 1 discussed above and identifies the labor-related portion of a specific payment rate for the specific service.

x—Labor-related portion of the national unadjusted payment rate

$x = .60 * (\text{national unadjusted payment rate})$

Step 2. Determine the wage index area in which the hospital is located and identify the wage index level that applies to the specific hospital. The wage index values assigned to each area reflect the new geographic statistical areas as a result of revised OMB standards (urban and rural) to which hospitals are assigned for FY 2008 under the IPPS, reclassifications through the MGRB, section 1886(d)(8)(B) "Lugar" hospitals, and section 401 of Pub. L. 108–173. We note that the reclassifications of hospitals under the one-time appeals process under section 508 of Pub. L. 108–173 expired on September 30, 2007, and is no longer applicable in this determination of appropriate wage values for the CY 2008 OPSS. The wage index values include the occupational mix adjustment described in section II.D. of this final rule with comment period that was developed for the final FY 2008 IPPS payment rates published in the **Federal Register** on August 22, 2007 (72 FR 47309 through 47315) and corrected in the correction notice to the FY 2008 IPPS final rule with comment period published in the **Federal Register** on October 10, 2007 (72 FR 57634 through 57738).

Step 3. Adjust the wage index of hospitals located in certain qualifying counties that have a relatively high percentage of hospital employees who reside in the county, but who work in a different county with a higher wage index, in accordance with section 505 of Pub. L. 108–173. Addendum L to this final rule with comment period contains the qualifying counties and the final wage index increase developed for the FY 2008 IPPS published in the FY 2008 IPPS final rule with comment period (72 FR 47339) and corrected in the correction notice to the FY 2008 IPPS final rule with comment period published in the **Federal Register** on October 10, 2007 (72 FR 57634 through 57738). This step is to be followed only

if the hospital has chosen not to accept reclassification under Step 2 above.

Step 4. Multiply the applicable wage index determined under Steps 2 and 3 by the amount determined under Step 1 that represents the labor-related portion of the national unadjusted payment rate.

The formula below is a mathematical representation of step 4 discussed above and adjusts the labor-related portion of the national payment rate for the specific service by the wage index.

x_a —Labor-related portion of the national unadjusted payment rate (wage adjusted)
 $x_a = 60 * (\text{national unadjusted payment rate}) * \text{applicable wage index}$.

Step 5. Calculate 40 percent (the nonlabor-related portion) of the national unadjusted payment rate and add that amount to the resulting product of Step 4. The result is the wage index adjusted payment rate for the relevant wage index area. The formula below is a mathematical representation of step 5 discussed above and calculates the remaining portion of the national payment rate, the amount not attributable to labor, and the adjusted payment for the specific service.

y —Nonlabor-related portion of the national unadjusted payment rate
 $y = .40 * (\text{national unadjusted payment rate})$
 Adjusted Medicare Payment = $y + x_a$

Step 6. If a provider is a SCH, as defined in § 412.92, or an EACH, which is considered to be a SCH under section 1886(d)(5)(D)(iii)(III) of the Act, and located in a rural area, as defined in § 412.64(b), or is treated as being located in a rural area under § 412.103, multiply the wage index adjusted payment rate by 1.071 to calculate the total payment.

The formula below is a mathematical representation of step 6 discussed above and applies the rural adjustment for rural SCHs.

Adjusted Medicare Payment (SCH or EACH)
 = Adjusted Medicare Payment * 1.071

We did not receive any public comments on our proposed methodology for calculating an adjusted payment from the national unadjusted Medicare payment amount for CY 2008. Therefore, we are finalizing our methodology as proposed for CY 2008, without modification.

I. Beneficiary Copayments

1. Background

Section 1833(t)(3)(B) of the Act requires the Secretary to set rules for determining copayment amounts to be paid by beneficiaries for covered OPD services. Section 1833(t)(8)(C)(ii) of the Act specifies that the Secretary must reduce the national unadjusted copayment amount for a covered OPD

service (or group of such services) furnished in a year in a manner so that the effective copayment rate (determined on a national unadjusted basis) for that service in the year does not exceed a specified percentage. For all services paid under the OPSS in CY 2008, and in calendar years thereafter, the specified percentage is 40 percent of the APC payment rate (section 1833(t)(8)(C)(ii)(V) of the Act). Section 1833(t)(3)(B)(ii) of the Act provides that, for a covered OPD service (or group of such services) furnished in a year, the national unadjusted copayment amount cannot be less than 20 percent of the OPD fee schedule amount. Sections 1834(d)(2)(C)(ii) and (d)(3)(C)(ii) of the Act further require that the copayment for screening flexible sigmoidoscopies and screening colonoscopies be equal to 25 percent of the payment amount. We have applied the 25-percent copayment to screening flexible sigmoidoscopies and screening colonoscopies since the beginning of the OPSS.

2. Copayment

For CY 2008, we proposed to determine copayment amounts for new and revised APCs using the same methodology that we implemented for CY 2004. (We refer readers to the November 7, 2003 OPSS final rule with comment period (68 FR 63458).) The unadjusted copayment amounts for services payable under the OPSS that will be effective January 1, 2008, are shown in Addendum A and Addendum B to this final rule with comment period.

We have historically used standard rounding principles to establish a 20 percent copayment for those few circumstances where the copayment rate was between 19.5 and 20 percent using our established copayment rules. For example, the CY 2008 proposed payment and copayment amounts for APC 9228 (Tigecycline injection) were \$0.91 and \$0.18, respectively. Twenty percent of \$0.91 is \$0.182. Because it would be impossible to set a copayment rate at exactly 20 percent in this case, that is, \$0.182, we proposed to round the amount, using standard rounding principles, to \$0.18. Also using standard rounding principles, 19.78 percent (\$0.18 as a percentage of \$0.91) rounds to 20 percent and meets the statutory requirement of a copayment amount of at least 20 percent. For CY 2008, APC 9046 (Iron Sucrose Injection) had a proposed payment amount and copayment amount of \$0.37 and \$0.08, respectively. Using our established copayment rules, 20 percent of \$0.37 is \$0.074. Normally, we would apply standard rounding principles to achieve

an amount that is payable, here \$0.07 rather than \$0.074. However, if we were to set a copayment amount of \$0.07, which is 18.9 percent of \$0.37, we would not be setting a copayment rate that is at least 20 percent of the OPSS payment rate. As proposed, we continue to believe that section 1833(t)(3)(B) of the Act requires us to set a copayment amount that is at least 20 percent of the OPSS payment amount, not less than 20 percent. Therefore, we proposed to set the copayment rate for APC 9046 at \$0.08. Eight cents represents the lowest amount that we could set that would bring the copayment rate to 20 percent or, in this case, just above 20 percent. We proposed to apply this same methodology in the future to instances where the application of our standard copayment methodology would result in a copayment amount that is under 20 percent and cannot be rounded, under standard rounding principles, to 20 percent.

We did not receive any public comments on this proposal, and, therefore, we are adopting it as final, without modification.

3. Calculation of an Adjusted Copayment Amount for an APC Group

To calculate the OPSS adjusted copayment amount for an APC group, take the following steps:

Step 1. Calculate the beneficiary payment percentage for the APC by dividing the APC's national unadjusted copayment by its payment rate. For example, using APC 0001, \$7.00 is 23 percent of \$30.61.

Individuals interested in calculating their final copayment liability for a given service from the national copayment rates presented in Addenda A and B should follow the formulas presented in the following steps. The formula below is a mathematical representation of step 1 discussed above and calculates national copayment as a percentage of national payment for a given service.

b —Beneficiary payment percentage
 $b = \text{national unadjusted copayment for APC} / \text{national unadjusted payment rate for APC}$

Step 2. Calculate the wage adjusted payment rate for the APC, for the provider in question, as indicated in section II.H. of this final rule with comment period. Calculate the rural adjustment for eligible providers as indicated in section II.H. of this final rule with comment period.

Step 3. Multiply the percentage calculated in Step 1 by the payment rate calculated in Step 2. The result is the wage-adjusted copayment amount for the APC.

The formula below is a mathematical representation of step 3 discussed above and applies the beneficiary percentage to the adjusted payment rate for a service calculated under II.H. above, with and without the rural adjustment, to calculate the final adjusted beneficiary copayment for a given service.

Wage-adjusted copayment amount for the APC = Adjusted Medicare Payment * *b*
 Wage-adjusted copayment amount for the APC (SCH or EACH) = (Adjusted Medicare Payment * 1.071) * *b*

The unadjusted copayments for services payable under the OPSS that will be effective January 1, 2008, are shown in Addenda A and B to this final rule with comment period.

We did not receive any public comments concerning the proposed methodology for calculating the unadjusted copayment amount for CY 2008. Therefore, we are finalizing our proposal without modification.

III. OPSS Ambulatory Payment Classification (APC) Group Policies

A. Treatment of New HCPCS and CPT Codes

1. Treatment of New HCPCS Codes Included in the April and July Quarterly OPSS Updates for CY 2007

a. Background

For the July quarter of CY 2007, we created a total of 16 new Level II HCPCS codes, specifically C2638, C2639, C2640, C2641, C2642, C2643, C2698, C2699, C9728, Q4087, Q4088, Q4089, Q4090, Q4091, Q4092, and Q4095 that were not addressed in the CY 2007 OPSS/ASC final rule with comment period that updated the CY 2007 OPSS. We designated the payment status of these codes and added them through the July 2007 update (Change Request 5623, Transmittal 1259, dated June 1, 2007). There were no new Level II HCPCS codes for the April 2007 update. In the CY 2008 OPSS/ASC proposed rule, we also solicited public comment on the status indicators, APC assignments, and payment rates of these codes, which were listed in Table 26A and Table 26B of that proposed rule, and now appear in Tables 10 and 11, respectively, of this final rule with comment period. Because of the timing of the proposed rule, the codes implemented through the July 2007 OPSS update were not included in Addendum B to that rule. In the CY 2008 OPSS/ASC proposed rule, we proposed to assign the new HCPCS codes for CY 2008 to APCs with the proposed rates as displayed in Tables 26A and 26B and incorporate them into Addendum B of this final rule

with comment period for CY 2008, which is consistent with our annual APC updating policy. As noted in Table 13 of this final rule with comment period, HCPCS codes Q4087, Q4088, Q4089, Q4090, Q4091, Q4092, and Q4095 will be deleted on December 31, 2007 and replaced with HCPCS J-codes effective January 1, 2008. Readers should refer to Table 13 for their replacement codes.

b. Implantation of Interstitial Devices (APC 0156)

Effective January 1, 2007, CPT code 55876 (Placement of interstitial device(s) for radiation therapy guidance (e.g., fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple) was implemented. We assigned this code to APC 0156 (Level III Urinary and Anal Procedures) for CY 2007 on an interim final basis. We then created a new Level II HCPCS code for a similar interstitial device implantation service for non-prostate sites, C9728 (Placement of interstitial device(s) for radiation therapy/surgery guidance (e.g., fiducial markers, dosimeter), other than prostate (any approach), single or multiple). We implemented HCPCS code C9728 effective July 1, 2007 via Program Transmittal 1259 dated June 1, 2007, as a result of information we received during our evaluation of an application for assignment of the implantation of a radiation dose verification system to a New Technology APC. We assigned HCPCS code C9728 to APC 0156 because we believed it was similar to CPT code 55876 from both clinical and resource perspectives. We proposed to maintain both CPT code 55876 and HCPCS code C9728 in APC 0156 for CY 2008, with a proposed payment rate of approximately \$195.

We received a number of comments on the APC assignments of these codes, both on the CY 2007 OPSS/ASC final rule with comment period and on the CY 2008 proposed rule. A summary of the comments and our response follow.

Comment: A few commenters expressed concern about CMS' interim final placement of CPT code 55876 in APC 0156 for CY 2007 as shown in Addendum B to the CY 2007 final rule with comment period. Several commenters expressed similar concern regarding the proposed CY 2008 APC assignment for this code. The commenters recommended that the payment rate for implanting the interstitial devices not incorporate the cost of the devices, because such items have a range of costs. Several commenters claimed that the costs of these devices range widely, from

approximately \$200 for gold markers, to \$900 for implantable dosimeters, to \$1200 for electromagnetic transponders, which they believed justified separate payment for the various types of interstitial devices.

Some commenters also expressed concern about the proposed CY 2008 APC placement of a new code that CMS created for non-prostate applications, specifically HCPCS code C9728 which was assigned to APC 0156, effective July 1, 2007, because it is similar to CPT code 55876. Several commenters asserted that the payment for HCPCS code C9728 should include the costs of dosimeter sensors, which they believed are currently excluded. These commenters also noted that payment for CPT code 55876 excludes the cost of dosimeter sensors. They recommended that CMS develop Level II HCPCS codes that permit hospitals to report the specific technologies associated with HCPCS code C9728 and CPT code 55876 in each clinical case and receive appropriate payment for the specific interstitial device implanted.

Several commenters pointed out that the CPT coding instructions for CPT code 55876 instruct coders to report the supply of devices for the implantation procedure separately from CPT code 55876. These commenters claimed that when the CPT Editorial Panel established the code, it did not include the implantable interstitial device and the imaging guidance for the implantation procedure in the code, and, therefore, both device costs and imaging guidance costs were excluded from the proposed CY 2008 APC payment for CPT code 55876. Because a dosimeter sensor could be implanted with CPT code 55876 for prostate applications, the commenters asserted that its costs are not reflected in that service. The commenters claimed that, unlike the instructions for CPT code 55876, the descriptor for HCPCS code C9728 does not direct coders to report the device separately. These commenters recommended that CMS assign the DVS® Dosimeter device for any body site to New Technology APC 1514 (New Technology—Level XIV (\$1200–\$1300)), with a payment rate of \$1250 for the device for CY 2008. Alternatively, they suggested that CMS package payment for all of the items and services needed to implant the dosimeter into payment for a single code which they recommended be assigned to New Technology APC 1522 (New Technology—Level XXII (\$2000–\$2500)). One commenter further claimed that CMS was required to set the APC assignment for the DVS® device based on the cost estimate

included in its New Technology APC application.

Response: Many procedures paid under the OPSS include payment for various implantable devices, where the procedure cost in an individual case would vary by the type of device. Our long-standing policy is to package the costs of implantable devices into payment for the procedures in which they are used, unless those devices are paid separately for a limited period of 2 to 3 years based on their transitional pass-through status. Payment for OPSS services includes payment for all costs that are directly related and integral to performing a procedure or furnishing a service on an outpatient basis, as set forth in § 419.2.

According to our usual practice, when we originally evaluated CPT code 55876 for APC assignment for CY 2007, we took into consideration all information available to us about the particular service, as well as other OPSS services for which we have claims-based cost data. In particular, we considered the probable utilization of the various devices, including fiducial markers and dosimeters, whose implantation could be reported with the CPT code, as well as possible implantation approaches, recognizing that a prospective payment system is based on principles of averaging. For established services paid under the OPSS, payment is generally based on the median cost of the service from claims data. Although CPT instructions state that the supply of the implantable device is to be reported separately, we considered the device costs associated with CPT code 55876, which would be packaged into payment for the implantation procedure under the OPSS even if the device were separately reported, when we assigned the CPT code to APC 0156. A previous pass-through device category, C1879 (Tissue marker (implantable)) for a device that we believe could be reported with CPT code 55876, was active from August 2000 through December 2002. After its expiration, the cost of tissue markers has been packaged into the OPSS payment for the procedures in which they are used. We note that the line-item CY 2006 median cost for HCPCS code C1879 for an implantable tissue marker was \$88 based on approximately 18,600 units of this device. Although there was no specific HCPCS device code for a dosimeter in CY 2007, we would consider payment for the dosimeter packaged under the OPSS into the implantation procedure and would have no need to establish a specific HCPCS code for the dosimeter for OPSS payment purposes. There may be other devices whose implantation

would also be reported with CPT code 55876 and, similarly, we would package their payment under the OPSS. We note that the CMS HCPCS Workgroup has created two related supply codes for CY 2008, specifically A4648 (Tissue marker, implantable, any type, each) and A4650 (Implantable radiation dosimeter, each), which will be packaged under the OPSS for CY 2008 and which could also be reported in association with CPT code 55876. Therefore, any of these HCPCS codes for devices or supplies, A4648, A4650 or C1879, are reportable with service codes 55876 or C9728.

In response to public comments on the CY 2007 OPSS/ASC final rule with comment period and on the CY 2008 proposed rule on the proposed assignment of CPT code 55876 for CY 2008, we once again examined information available to us regarding procedures that could be reported with the CPT code, along with updated claims data for other OPSS services. We continue to believe that APC 0156 is the most appropriate APC assignment for CPT code 55876, based on the expected median cost and utilization of all of the services that would be reported with the code under the OPSS. We will first have claims data for CPT code 55876 for the CY 2009 OPSS update, which we will review in the context of our CY 2009 update proposals.

We note that during CY 2007, we evaluated a New Technology APC application submitted by the manufacturer of the DVS® System for a service the applicant entitled "Implantation of the DVS® Dosimeter." We did not approve an item or service for payment specifically for the DVS® Dosimeter. However, we approved creation of a new code for a *service* for non-prostate placement of interstitial device(s) for radiation therapy or surgical guidance, using such devices as fiducial markers or dosimeters. As explained by the commenters, and similar to CPT code 55876, this procedure could implant devices with a wide range of costs, including dosimeters that commenters claimed ranged from \$900 to \$1200. Our general policy in creating a new service code under the OPSS, whether we assign it to a clinical or New Technology APC, is to develop a general service code so that it may be reported for a range of technologies, rather than only for a single proprietary service. This reduces potential barriers to payment under the OPSS for related new services and is consistent with the general coding practices of the CPT Editorial Panel and the CMS HCPCS Workgroup. When we approve a new service for assignment to

a New Technology APC, we are not required to set the payment rate based on the cost data presented in the New Technology APC application alone, as we have stated in our final rule published in the **Federal Register** on November 30, 2001. In that rule, we specifically explained that we do not limit our determination of the cost of a service to information submitted by the applicant. We obtain information on costs from other appropriate sources before making a determination of the cost of the procedure to hospitals (66 FR 59900). In addition, we note that only complete services are currently assigned to New Technology APCs, not items, such as drugs or devices.

In response to comments to the CY 2008 proposed rule on the proposed assignment of HCPCS code C9728, we examined all information available to us on procedures that could be reported with the code, as well as updated cost data from claims regarding other OPSS services. We continue to believe that the resources and utilization associated with HCPCS code C9728, including the cost of the various possible implantable devices that may be implanted in the service and the different approaches to the implantation, resemble those associated with CPT code 55876. Therefore, we will maintain HCPCS code C9728 in APC 0156 for CY 2008. We will first have data for HCPCS code C9728 for the CY 2009 OPSS update, which we will review in the context of our CY 2009 update proposals. We expect that these data will reflect the costs of the implantable devices utilized and, the extent that more costly devices, such as implantable dosimeters and electromagnetic transponders, are increasingly reported with this procedure, the cost of these devices will gradually be reflected in the median cost of HCPCS code C9728.

c. Other New HCPCS Codes Implemented in April or July 2007

While we received public comments on the proposed CY 2008 OPSS treatment of HCPCS code C9728 as discussed above and HCPCS codes C2638, C2639, C2640, C2641, C2642, C2643, C2698, and C2699 as discussed in section VII. of this final rule with comment period, we did not receive any public comments on the proposed APC assignments and status indicators for HCPCS codes Q4087, Q4088, Q4089, Q4090, Q4091, Q4092, and Q4095 that were implemented in July 2007. However, for CY 2008, the CMS HCPCS Workgroup decided to delete the drug codes described by Q-codes on December 31, 2007 and replace them with permanent J-codes effective

January 1, 2008. Consistent with our general policy of using permanent HCPCS codes for the reporting of drugs under the OPSS in order to streamline coding, we are displaying the J-codes in Table 13 that will replace the seven Q-codes, effective January 1, 2008. We note that Q codes are temporary national HCPCS codes. To avoid duplication, temporary national HCPCS codes, such as “C-,” “G-,” “K-,” and “Q-

codes,” are generally deleted once permanent national HCPCS codes are created that describe the same item, service, or procedure. The J-codes describe the same drugs and the same dosages as the Q-codes that will be deleted December 31, 2007. Because we did not receive any public comments on the proposed CY 2008 APC and status indicator assignments for the new HCPCS codes, with the exception of

HCPCS code C9728, that were implemented in July 2007, we are adopting our proposal as final, without modification, and are assigning the replacement HCPCS J codes to the same status indicators and APCs that were proposed for the predecessor Q-codes, as shown in Addendum B to this final rule with comment period.

TABLE 12.—NEW NON-DRUG HCPCS CODES IMPLEMENTED IN JULY 2007

HCPCS code	Long descriptor	Final CY 2008 status indicator	Final CY 2008 APC	Final CY 2008 median cost
C2638	Brachytherapy source, stranded, iodine-125, per source	K	2638	\$45
C2639	Brachytherapy source, non-stranded, iodine-125, per source	K	2639	32
C2640	Brachytherapy source, stranded, palladium-103, per source	K	2640	65
C2641	Brachytherapy source, non-stranded, palladium-103, per source	K	2641	51
C2642	Brachytherapy source, stranded, cesium-131, per source	K	2642	97
C2643	Brachytherapy source, non stranded, cesium-131, per source	K	2643	63
C2698	Brachytherapy source, stranded, not otherwise specified, per source	K	2698	45
C2699	Brachytherapy source, non-stranded, not otherwise specified, per source	K	2699	31
C9728	Placement of interstitial device(s) for radiation therapy/surgery guidance (eg, fiducial markers, dosimeter), other than prostate (any approach) single or multiple.	T	0156	192

TABLE 13.—NEW DRUG HCPCS CODES IMPLEMENTED IN JULY 2007

New HCPCS J-code effective January 1, 2008	HCPCS Q-code	Long descriptor	Final CY 2008 status indicator	Final CY 2008 APC
J1568	Q4087	Injection, immune globulin, (Octogam), intravenous, non-lyophilized, (e.g. liquid), 500 mg.	K	0943
J1569	Q4088	Injection, immune globulin, (Gammagard), intravenous, non-lyophilized, (e.g. liquid), 500 mg.	K	0944
J2791	Q4089	Injection, rho(d) immune globulin (human), (Rhophylac), intravenous, 100 iu	K	0945
J1571	Q4090	Injection, hepatitis b immune globulin (Hepagam B), intramuscular, 0.5 ml	K	0946
J1572	Q4091	Injection, immune globulin, (Flebogamma), intravenous, non-lyophilized, (e.g. liquid), 500 mg.	K	0947
J1561	Q4092	Injection, immune globulin, (Gamunex), intravenous, non-lyophilized, (e.g. liquid), 500 mg.	K	0948
J3488	Q4095	Injection, zoledronic acid (Reclast), 1 mg	K	0951

2. Treatment of New Category I and III CPT Codes and Level II HCPCS Codes

a. Establishment and Assignment of New Codes

As has been our practice in the past, we implement new Category I and III CPT codes and new Level II HCPCS codes through program transmittals, which are released in the summer through the fall of each year for annual updating, effective January 1, in the final rule updating the OPSS for the following calendar year. These codes are flagged with comment indicator “NI” in Addendum B to the OPSS/ASC final rule with comment period to indicate that we are assigning them an interim payment status which is subject to public comment following publication of the final rule that implements the

annual OPSS update. (We refer readers to the discussion immediately below concerning our policy for implementing new Category I and III mid-year CPT codes.) In the CY 2008 OPSS/ASC proposed rule, we proposed to continue this recognition and process for CY 2008. Therefore, new Category I and III CPT codes and new Level II HCPCS codes, effective January 1, 2008, are listed in Addendum B to this final rule with comment period and designated using comment indicator “NI.” The status indicator, the APC assignment, or both, for all such codes flagged with comment indicator “NI” is open to public comment in this final rule with comment period. As indicated in the CY 2008 OPSS/ASC proposed rule, we will respond to all comments received

concerning these codes in a subsequent final rule for the next calendar year’s OPSS/ASC update.

We did not receive any public comments on our proposal to assign a comment indicator of “NI” in Addendum B of the OPSS final rule with comment period to the new codes that are open to public comment. Therefore, we are finalizing our proposed treatment of new CY 2008 Category I and III CPT codes, as well as the Level II HCPCS codes, without modification.

We received some comments to the CY 2008 proposed rule regarding individual new HCPCS codes that commenters expected to be implemented for the first time in the CY 2008 OPSS. We could not discuss the CY 2008 codes, including their APC

and/or status indicator assignments, because the codes were not available when we developed and issued the proposed rule. For those new Category I CPT codes whose descriptors were not officially available during the comment period and development of the CY 2008 final rule with comment period, we do not specifically respond to those comments in this final rule with comment period. For those new Category III CPT codes that were released on July 1, 2007, for implementation January 1, 2008, we respond to those comments in this final rule with comment period because those codes were publicly available during the comment period to the proposed rule and the development of this final rule with comment period. Both of these groups of codes are flagged with comment indicator "NI" in this final rule with comment period, as discussed above, to signal that they are open to public comment.

Effective for January 1, 2008, we have created eight HCPCS C-codes that describe transthoracic echocardiography with contrast and transesophageal echocardiography with contrast to enable facilities to appropriately report contrast-enhanced echocardiography services. (See section II.A.4.c(6) of this final rule with comment period for further discussion of these codes). Effective January 1, 2008, these C-codes will be used by HOPDs to report contrast echocardiography services. These codes are assigned comment indicator "NI" in Addendum B to this final rule with comment period.

In the CY 2008 OPSS/ASC proposed rule, we also proposed to continue our policy of the last 2 years of recognizing new mid-year CPT codes, generally Category III CPT codes, that the AMA releases in January for implementation the following July through the OPSS quarterly update process. Therefore, for CY 2008, we proposed to include in Addendum B to the CY 2008 OPSS/ASC final rule with comment period the new Category III CPT codes released in January 2007 for implementation on July 1, 2007 (through the OPSS quarterly update process), and the new Category III codes released in July 2007 for implementation on January 1, 2008. However, as proposed, only those new Category III CPT codes implemented effective January 1, 2008, are flagged with comment indicator "NI" in Addendum B to this final rule with comment period, to indicate that we have assigned them an interim payment status which is subject to public comment. Category III CPT codes implemented in July 2007, which appeared in Table 27 of the proposed

rule and are displayed in Table 14 of this final rule with comment period, were subject to comment in the proposed rule, and we proposed to finalize their status in this final rule with comment period.

b. Electronic Brachytherapy Services (New Technology APC 1519)

The AMA's CPT Editorial Panel created a new Category III code, 0182T (High dose rate (HDR) electronic brachytherapy, per fraction), as of July 1, 2007. We assigned CPT code 0182T to New Technology APC 1519 (New Technology—Level IXX (\$1700–\$1800)), with a payment rate of \$1750, as of July 1, 2007 (via Program Transmittal 1259, Change Request 5623).

We received a wide variety of comments regarding the proposed assignment of CPT code 0182T to New Technology APC 1519. A summary of the comments and our response follows.

Comment: Some commenters thought the proposed assignment provided a payment that was too high, some believed the proposed payment was too low, while others agreed with the proposed APC assignment. A number of commenters believed that placement of CPT code 0182T into APC 1519 resulted in a payment amount much higher relative to existing APCs for application of brachytherapy sources, specifically, APCs 0312 (Radioelement Applications), 0313 (Brachytherapy), and 0651 (Complex Interstitial Radiation Source Application), with proposed CY 2008 payment rates of \$534.48, \$739.46, and \$981.88, respectively. One commenter indicated that only a very small number of patients would be treated using electronic brachytherapy. Another commenter expressed appreciation of CMS's prompt assignment of new technologies to APCs, while some commenters were concerned that the proposed payment for CPT code 0182T as a new technology service was between two and three times the payment rate for the other conventional brachytherapy service APCs cited above. These commenters believed that the proposed payment for electronic brachytherapy was excessive and, given that the risks of the treatment have yet to be clearly established, such conditions would encourage the early and possibly inappropriate adoption of this service. Some commenters recommended that CMS consult with specialty organizations regarding the pricing of new technology services prior to assigning them to APCs. Other commenters supported the proposed assignment of CPT code 0182T and recommended that the service reside in

that New Technology APC for at least 2 years.

Another commenter expressed concern that the payment level was too low for a single fraction treatment of electronic brachytherapy. The commenter pointed out that two applications for New Technology APCs were submitted to CMS for electronic brachytherapy with the following descriptions: (a) HDR electronic brachytherapy, complete course as a single fraction, and (b) HDR electronic brachytherapy, per fraction. The commenter claimed that the two forms of HDR electronic brachytherapy are each unique and should not be classified into the same APC. The commenter requested that a new HCPCS code for HDR electronic brachytherapy, complete course as a single fraction, be developed and assigned to APC 1529 (New Technology—Level XXIX (\$5,500–\$6,000)) for CY 2008.

Response: The CY 2008 proposed APC assignment of CPT code 0182T maintained our initial placement of HDR electronic brachytherapy. Consistent with our recent OPSS practice for Category III CPT codes that are implemented mid-year by the AMA, we recognized CPT code 0182T under the OPSS in July 2007. This recognition ensures timely collection of data pertinent to the service described by the code, ensures patient access to the service, and eliminates potential redundancy between Category III CPT codes and Level II HCPCS codes that are created by us in response to applications for new technology services.

Commenters did not provide analyses regarding the costs of the service; however, we received cost estimates from two manufacturers in their respective New Technology APC applications over the course of an extensive evaluation period. As is our customary practice, we also used claims data for related services and other sources of information to supplement information included in the New Technology APC applications in order to provide an APC assignment we believed to be appropriate at this time. Regarding the comments on potential complications or risks of the new service that has a higher payment rate than conventional brachytherapy procedures, we note that the APC assignment of a service based on its estimated cost is our usual practice for new services under the OPSS, which generally pays for services based on estimated hospital resources. In the absence of cost data from hospital claims, we believe that comparisons of OPSS payment for electronic

brachytherapy to payment for conventional brachytherapy services that are assigned to APCs 0312, 0313, and 0651 and that implant radioactive sources are not appropriate. The law specifically requires separate payment for the brachytherapy sources, and, therefore, these costs are not included in the procedure payment for conventional brachytherapy services that are reported for implanting the sources. We define brachytherapy sources as containing a radioactive isotope so, by definition, in the case of electronic brachytherapy treatment the New Technology APC payment for the procedure would include payment for the costs of the radiation actually delivered to the patient. Thus, it is not appropriate to compare the costs of conventional and electronic brachytherapy treatments based on a comparison of the treatment procedure costs alone.

In light of the commenters' concerns regarding safety of the new procedures, we reiterate that even though a service is assigned a HCPCS code and a payment rate under the OPSS, it does not imply coverage by the Medicare program but indicates only how the service may be paid if covered by the

program. Unless CMS has issued a national coverage determination (NCD), local contractors determine whether a service meets all program requirements for coverage. While we do not specifically consult with specialty organizations during the New Technology APC application evaluation process that may result in an initial APC assignment for a service, the APC assignments of new technology services, like all other OPSS services, are open to comment in the annual OPSS update, and we welcome public comments.

We will not create a new Level II HCPCS code for HDR electronic brachytherapy, complete course as a single fraction, and assign it to a different New Technology APC. We evaluated both New Technology APC applications at length and received input from both applicants. We believe that the two forms of HDR electronic brachytherapy, whether provided in a single fraction or multiple fractions depending on the technology, are both described by CPT code 0182T that is appropriately assigned to a single APC. We note that the payment is per fraction, and that would include a single fraction treatment as well.

After reviewing the public comments received and all current information available to us regarding HDR electronic brachytherapy and other hospital outpatient services, we continue to believe that New Technology APC 1519, with a payment rate of \$1750, is the most appropriate assignment for CPT code 0182T. Therefore, we are finalizing our proposal, without modification, to maintain the assignment of CPT code 0182T to New Technology APC 1519, with a payment rate of \$1750 for CY 2008.

c. Other Mid-Year CPT Codes

We did not receive any comments on the proposed CY 2008 APC and status indicator assignments of Category III CPT codes first implemented in July 2007 for services other than CPT code 0182T. After considering the public comments received on CPT code 0182T, we are finalizing our general proposal for the treatment of new mid-year CPT codes, including our proposed APC assignments for CPT code 0182T and other Category III CPT codes as displayed Table 14.

TABLE 14.—CATEGORY III CPT CODES IMPLEMENTED IN JULY 2007

CPT code	Long descriptor	Final CY 2008 status indicator	Final CY 2008 APC
0178T	Electrocardiogram, 64 leads or greater, with graphic presentation and analysis; with interpretation and report.	B	Not applicable.
0179T	Electrocardiogram, 64 leads or greater, with graphic presentation and analysis; tracing and graphics only, without interpretation and report.	X	0100
0180T	Electrocardiogram, 64 leads or greater, with graphic presentation and analysis; interpretation and report only.	B	Not applicable.
0181T	Corneal hysteresis determination, by air impulse stimulation, bilateral, with interpretation and report.	S	0230
0182T	High dose rate electronic brachytherapy, per fraction	S	1519

B. Variations Within APCs

1. Background

Section 1833(t)(2)(A) of the Act requires the Secretary to develop a classification system for covered hospital outpatient services. Section 1833(t)(2)(B) of the Act provides that this classification system may be composed of groups of services, so that services within each group are comparable clinically and with respect to the use of resources. In accordance with these provisions, we developed a grouping classification system, referred to as APCs, as set forth in § 419.31 of the regulations. We use Level I and Level II HCPCS codes and descriptors to identify and group the services within each APC. The APCs are organized such that each

group is homogeneous both clinically and in terms of resource use. Using this classification system, we have established distinct groups of similar services, as well as medical visits. We also have developed separate APC groups for certain medical devices, drugs, biologicals, radiopharmaceuticals, and brachytherapy devices.

We have packaged into payment for each procedure or service within an APC group the costs associated with those items or services that are directly related to and supportive of performing the main procedures or furnishing services. Therefore, we do not make separate payment for packaged items or services. For example, packaged items and services include: (1) Use of an

operating, treatment, or procedure room; (2) use of a recovery room; (3) most observation services; (4) anesthesia; (5) medical/surgical supplies; (6) pharmaceuticals (other than those for which separate payment may be allowed under the provisions discussed in section V. of this final rule with comment period); and (7) incidental services such as venipuncture. Our final packaging methodology for ancillary and supportive services is discussed in section II.A.4.c. of this final rule with comment period.

Under the OPSS, we pay for hospital outpatient services on a rate-per-service basis, where the service may be reported with one or more HCPCS codes. Payment varies according to the APC group to which the independent service

or combination of services is assigned. Each APC weight represents the hospital median cost of the services included in that APC relative to the hospital median cost of the services included in APC 0606. The APC weights are scaled to APC 0606 because it is the middle level clinic visit APC (that is, where the Level 3 Clinic Visit HCPCS code of five levels of clinic visits is assigned), and because middle level clinic visits are among the most frequently furnished services in the hospital outpatient setting.

Section 1833(t)(9)(A) of the Act requires the Secretary to review the components of the OPSS not less than annually and to revise the groups and relative payment weights and make other adjustments to take into account changes in medical practice, changes in technology, and the addition of new services, new cost data, and other relevant information and factors. Section 1833(t)(9)(A) of the Act, as amended by section 201(h) of the BBRA of 1999, also requires the Secretary, beginning in CY 2001, to consult with an outside panel of experts to review the APC groups and the relative payment weights (the APC Panel recommendations for specific services for the CY 2008 OPSS and our responses to them are discussed in the relevant specific sections throughout this final rule with comment period).

Finally, as discussed earlier, section 1833(t)(2) of the Act provides that, subject to certain exceptions, the items and services within an APC group cannot be considered comparable with respect to the use of resources if the highest median for an item or service in the group is more than 2 times greater than the lowest median cost for an item or service within the same group (referred to as the "2 times rule"). We use the median cost of the item or service in implementing this provision. The statute authorizes the Secretary to make exceptions to the 2 times rule in unusual cases, such as low-volume items and services.

2. Application of the 2 Times Rule

In accordance with section 1833(t)(2) of the Act and § 419.31 of the regulations, we annually review the items and services within an APC group to determine, with respect to comparability of the use of resources, if the median of the highest cost item or service within an APC group is more than 2 times greater than the median of the lowest cost item or service within that same group ("2 times rule"). We make exceptions to this limit on the variation of costs within each APC group in unusual cases such as low volume items and services.

During the APC Panel's March 2007 meeting, we presented median cost and utilization data for services furnished during the period of January 1, 2006, through September 30, 2006, about which we had concerns or about which the public had raised concerns regarding their APC assignments, status indicator assignments, or payment rates. The discussions of most service-specific issues, the APC Panel recommendations if any, and our proposals for CY 2008 are contained principally in sections III.C. and III.D. of this final rule with comment period.

In addition to the assignment of specific services to APCs that we discussed with the APC Panel, we also identified APCs with 2 times violations that were not specifically discussed with the APC Panel but for which we proposed changes to their HCPCS codes' APC assignments in Addendum B to the proposed rule. In these cases, to eliminate a 2 times violation or to improve clinical and resource homogeneity, we proposed to reassign the codes to APCs that contained services that were similar with regard to both their clinical and resource characteristics. We also proposed to rename existing APCs, discontinue existing APCs, or create new clinical APCs to complement proposed HCPCS code reassignments. In many cases, the proposed HCPCS code reassignments and associated APC reconfigurations for CY 2008 included in the proposed rule were related to changes in median costs of services and APCs resulting from our proposed bundling approach for CY 2008, as discussed in section II.A.4.c. of the proposed rule. We also proposed changes to the status indicators for some codes that were not specifically and separately discussed in the proposed rule. In these cases, we proposed to change the status indicators for some codes because we believed that another status indicator more accurately described their payment status from an OPSS perspective based on the policies that we proposed for CY 2008.

Addendum B to the proposed rule identified with a comment indicator "CH" those HCPCS codes for which we proposed a change to the APC assignment or status indicator as assigned in the April 2007 Addendum B update (via Change Request 5544, Transmittal 1209, dated March 21, 2007). Addendum B to this final rule with comment period identifies with the "CH" comment indicator the final CY 2008 changes compared to the codes' status as reflected in the October 2007 Addendum B update (via Change Request 5718, Transmittal 1336, dated September 14, 2007).

We received many public comments regarding the proposed APC and status indicator assignments for CY 2008 for specific HCPCS codes. These are discussed mainly in sections III.C. and III.D. of this final rule with comment period, and the final action for CY 2008 related to each HCPCS code is noted in those sections. We also received a number of specific comments about some of the procedures assigned to APCs that may have violated the 2 times rule. These comments are addressed elsewhere in the final rule with comment period, primarily in sections related to the types of procedures that were the subject of the comments.

3. Exceptions to the 2 Times Rule

As discussed earlier, we may make exceptions to the 2 times limit on the variation of costs within each APC group in unusual cases such as low-volume items and services. Taking into account the APC changes that we proposed for CY 2008 based on the APC Panel recommendations discussed mainly in sections III.C. and III.D. of this final rule with comment period, the proposed changes to status indicators and APC assignments as identified in Addendum B to the proposed rule, and the use of CY 2006 claims data to calculate the median costs of procedures classified in the APCs, we reviewed all the APCs to determine which APCs would not satisfy the 2 times rule. We used the following criteria to decide whether to propose exceptions to the 2 times rule for affected APCs:

- Resource homogeneity
- Clinical homogeneity
- Hospital concentration
- Frequency of service (volume)
- Opportunity for upcoding and code fragments

For a detailed discussion of these criteria, we refer readers to the April 7, 2000 OPSS final rule with comment period (65 FR 18457).

Table 28 of the proposed rule listed the APCs that we proposed to exempt from the 2 times rule for CY 2008 based on the criteria cited above. For cases in which a recommendation by the APC Panel appeared to result in or allow a violation of the 2 times rule, we generally accepted the APC Panel's recommendation because those recommendations were based on explicit consideration of resource use, clinical homogeneity, hospital specialization, and the quality of the data used to determine the APC payment rates that we proposed for CY 2008. The median costs for hospital outpatient services for these and all other APCs that were used in the development of the proposed rule can

be found on the CMS Web site at: <http://www.cms.hhs.gov>.

We did not receive any general public comments related to the list of proposed exceptions to the 2 times rule, specifically those listed in Table 28 of the proposed rule. For the proposed rule, the list of APCs excepted from the 2 times rule were based on data from January 1, 2006, through September 30, 2006. For this final rule with comment period, we used data from January 1, 2006 through December 1, 2006. Thus, after responding to all of the comments on the proposed rule and making changes to APC assignments based on the comments received, we analyzed the full CY 2006 data to identify APCs with 2 times rule violations. In contrast to previous years, for CY 2008 we have calculated a significant number of APC medians through customized methodologies, such as device-dependent APC, APCs to which nuclear medicine procedures are assigned, and Visit APCs, that are impacted by the Extended Assessment and Management Composite APCs. Therefore, for this final rule with comment period we assessed the HCPCS code-specific median costs for HCPCS codes that are part of these customized APC median cost calculations to accurately identify 2 times violations. We also have some APCs where the concept of a 2 times violation is not relevant, typically those set based on multiple claims, such as APC 0381 for single allergy tests and APC 0375 for ancillary services when a hospital outpatient dies. Table 15 below has been revised relative to prior years to remove APCs where a 2 times violation is not a relevant concept and to identify final APCs, including those with customized median cost methodologies, with 2 times violations.

Based on our final data, we found that there were 21 APCs with 2 times rule violations. We applied the criteria as described earlier to finalize the APCs that are exceptions to the 2 times rule for CY 2008. After consideration of all public comments received on the proposed rule and the careful review of the CY 2006 claims data for the full year, we are finalizing the list of APCs exempted from the 2 times rule. The final list of APCs that are exceptions to the 2 times rule for CY 2008 is displayed in Table 15 below.

TABLE 15.—FINAL APC EXCEPTIONS TO THE 2 TIMES RULE FOR CY 2008

APC	APC title
0043	Closed Treatment Fracture Finger/Toe/Trunk.

TABLE 15.—FINAL APC EXCEPTIONS TO THE 2 TIMES RULE FOR CY 2008—Continued

APC	APC title
0058	Level I Strapping and Cast Application.
0060	Manipulation Therapy.
0080	Diagnostic Cardiac Catheterization.
0093	Vascular Reconstruction/Fistula Repair Without Device.
0105	Repair/Revision/Removal of Pacemakers, AICDs, or Vascular Devices.
0106	Insertion/Replacement of Pacemaker Leads and/or Electrodes.
0141	Level I Upper GI Procedures.
0235	Level I Posterior Segment Eye Procedures.
0251	Level I ENT Procedures.
0256	Level V ENT Procedures.
0260	Level I Plain Film Except Teeth.
0303	Treatment Device Construction.
0323	Extended Individual Psychotherapy.
0330	Dental Procedures.
0409	Red Blood Cell Tests.
0432	Health and Behavior Services.
0437	Level II Drug Administration.
0438	Level III Drug Administration.
0604	Level 1 Hospital Clinic Visits.
0688	Revision/Removal of Neurostimulator Pulse Generator Receiver.

C. New Technology APCs

1. Introduction

In the November 30, 2001 final rule (66 FR 59903), we finalized changes to the time period a service was eligible for payment under a New Technology APC. Beginning in CY 2002, we retain services within New Technology APC groups until we gather sufficient claims data to enable us to assign the service to a clinically appropriate APC. This policy allows us to move a service from a New Technology APC in less than 2 years if sufficient data are available. It also allows us to retain a service in a New Technology APC for more than 3 years if sufficient data upon which to base a decision for reassignment have not been collected.

We note that the cost bands for New Technology APCs range from \$0 to \$50 in increments of \$10, from \$50 to \$100 in increments of \$50, from \$100 through \$2,000 in increments of \$100, and from \$2,000 through \$10,000 in increments of \$500. These increments, which are in two parallel sets of New Technology APCs, one with status indicator “S” and the other with status indicator “T,” allow us to price new technology services more appropriately and consistently.

2. Movement of Procedures From New Technology APCs to Clinical APCs

As we explained in the November 30, 2001 final rule (66 FR 59897), we generally keep a procedure in the New Technology APC to which it is initially assigned until we have collected data sufficient to enable us to move the procedure to a clinically appropriate APC. However, in cases where we find that our original New Technology APC assignment was based on inaccurate or inadequate information, or where the New Technology APCs are restructured, we may, based on more recent resource utilization information (including claims data) or the availability of refined New Technology APC cost bands, reassign the procedure or service to a different New Technology APC that most appropriately reflects its cost.

At its March 2007 meeting, the APC Panel recommended that CMS keep services in New Technology APCs until sufficient data are available to assign them to clinical APCs, but for no longer than 2 years. We note that because of the potential for quarterly assignment of new services to New Technology APCs and the 2-year time lag in claims data for an OPPTS update (that is, CY 2006 data are utilized for this CY 2008 OPPTS rulemaking cycle), if we were to accept the APC Panel’s recommendation, we would always reassign services from New Technology to clinical APCs based on 1 year or less of claims data. For example, if a new service was first assigned to a New Technology APC in July 2006, we would have 6 months of data for purposes of CY 2008 rulemaking but, in order to ensure that the service was in a New Technology APC for no longer than 2 years, we would need to move the service to a clinical APC for CY 2008. While we might have sufficient claims data from 6 months of CY 2006 to support a proposal for such a reassignment for CY 2008, we are not confident that this would always be the case for all new services, given our understanding of the dissemination of new technology procedures into medical practice and the diverse characteristics of new technology services that treat different clinical conditions. Therefore, we did not accept the APC Panel’s recommendation for CY 2008 because we believed that accepting the recommendation would limit our ability to individually assess the OPPTS treatment of each new technology service in the context of available hospital claims data. We are particularly concerned about continuing to provide appropriate payment for low volume new technology services that may be

expected to continue to be low volume under the OPSS due to the prevalence of the target conditions in the Medicare population. We appreciate the APC Panel's thoughtful discussion of new technology services, and we agree with the APC Panel that it should be our priority to regularly reassign services from New Technology APCs to clinical APCs under the OPSS, so that they are treated like most other OPSS services for purposes of ratesetting once hospitals have had sufficient experience with providing and reporting the new services. Rather, consistent with our current policy, for CY 2008 we proposed to retain services within New Technology APC groups until we gather sufficient claims data to enable us to assign the service to a clinically appropriate APC. The flexibility associated with this policy allows us to move a service from a New Technology APC in less than 2 years if sufficient data are available. It also allows us to retain a service in a New Technology APC for more than 2 years if sufficient hospital claims data upon which to base a decision for reassignment have not been collected.

We received a number of public comments on our OPSS treatment of New Technology services. A summary of the public comments and our responses follow.

Comment: Several commenters requested that CMS reconsider maintaining a new service in a New Technology APC for a minimum of at least 2 years, to ensure sufficient claims data, before assigning it to a clinical APC. These commenters were concerned that reassigning a new service from a New Technology APC to a clinical APC in less than 2 years may result in the collection of inaccurate claims data because integration of new technologies can be slow and hospitals need time to update their chargemasters to appropriately include charges that are related to the actual costs of the new service. Other commenters reported that while a new technology service may increase hospital outpatient costs, it could ultimately replace more invasive inpatient procedures that are more costly for the Medicare program.

In addition, several commenters recommended that CMS place all new HCPCS codes for new services in New Technology APCs, rather than assigning them directly to clinical APCs, until claims data are available in order to ensure access to these services. Some commenters also recommended that CMS consider alternatives to moving procedures from New Technology APCs to clinical APCs that would prevent excessive reductions in payment,

including moving procedures to different APCs, utilizing external data for ratesetting, or maintaining procedures in their current New Technology APCs.

Response: As we have stated previously, we generally keep a procedure in the New Technology APC to which it is initially assigned until we have collected sufficient claims data to enable us to move the procedure to a clinically appropriate APC. However, in cases where we find that our original New Technology APC assignment was based on inaccurate or inadequate information, or where the New Technology APCs are restructured, we may, based on more recent resource utilization information (including claims data) or the availability of refined New Technology APC bands, reassign the procedure or service to a different New Technology APC that most appropriately reflects its cost. This policy would allow us to retain a service in a New Technology APC for more than 3 years if sufficient data upon which to base a decision for reassignment have not been collected, and also allows us to move a service from a New Technology APC in less than 2 years if sufficient claims data are available. To retain a new service under a New Technology APC for a minimum of at least two years, especially for a service for which we have significant claims data, may result in inappropriate payment of the service. We want to ensure appropriate allocation of Medicare expenditures, and for a service that has been placed in a New Technology APC with significant claims data, we believe it is in the best interest of both the Medicare program and the beneficiary to reassign the service to an appropriate clinical APC based on clinical coherence and resource similarity.

In response to the different suggestions for transitioning new technology services from New Technology APCs to clinical APCs to prevent excessive reductions in payment, because we generally move new services from New Technology APCs to clinical APCs only when we have adequate data upon which to base a decision, we do not believe a transition would commonly be necessary in order to provide appropriate payment for the services based on their hospital costs. We have no need to utilize external data in these cases where we believe our claims data, developed according to the standard OPSS ratesetting methodology, are adequate to reassign the new services to clinical APCs. In a few past situations, we have moved services from one New

Technology APC to another New Technology APC with a lower payment rate if we believed that our data were not fully developed to support a final clinical APC assignment, but we expect these cases to continue to be rare. In addition, all reassignments of services out of New Technology APCs are proposed during the annual rulemaking cycle, allowing the opportunity for public comment prior to their movement.

When evaluating new services for payment under the OPSS, we use all information available to us regarding the clinical characteristics of the procedures and the expected hospital resource costs. We reserve New Technology APC assignments for those services where we do not believe there is an appropriate clinical APC for the new service. In many cases, new HCPCS codes describe services that are similar to existing services that are paid under the OPSS and for which we have robust cost data from hospital claims. We continue to believe that it is appropriate to assign similar new and existing services to the same clinical APC in such cases. We follow the claims data closely and carefully review the New Technology and clinical APC assignments of relatively new OPSS services for each update year when new claims data become available. In addition, the OPSS treatment of all new services is open to public comment in the annual OPSS/ASC rule (either proposed or final with comment period) that follows the service's implementation under the OPSS.

After consideration of all public comments received, we are finalizing our CY 2008 proposal, without modification, to maintain a new service in a New Technology APC until we gather sufficient claims data to assign the service to a clinically appropriate APC. Thus, a service can be assigned to a New Technology APC for more than 3 years if we have insufficient claims data to reassign the service to a clinical APC, or it could be reassigned to a clinical APC in less than 2 years if we have adequate claims data. We will continue to assess new services for potential assignment to clinical APCs before assigning them to New Technology APCs.

The procedures presented below in sections III.C.2.a., III.C.2.b., and III.C.2.c. represent services assigned to New Technology APCs for CY 2007 for which we stated in the CY 2008 proposed rule that we believed we had sufficient data to propose their reassignment to clinically appropriate APCs for CY 2008.

a. Positron Emission Tomography (PET)/Computed Tomography (CT) Scans (APC 0308)

From August 2000 through April 2005, we paid separately for PET and CT scans. In CY 2004, the payment rate for nonmyocardial PET scans was \$1,450, while it was \$193 for typical diagnostic CT scans. Prior to CY 2005, nonmyocardial PET and the PET portion of PET/CT scans were described by G-codes for billing to Medicare. Several commenters to the November 15, 2004 final rule with comment period (69 FR 65682) urged that we replace the G-codes for nonmyocardial PET and PET/CT scan procedures with the established CPT codes. These commenters stated that movement to the established CPT codes would greatly reduce the burden on hospitals of tracking and billing the G-codes which were not recognized by other payers and would allow for more uniform hospital billing of these scans. We agreed with the commenters that movement from the G-codes to the established CPT codes for nonmyocardial PET and PET/CT scans would allow for more uniform billing of these scans. As a result of a Medicare national coverage determination (Publication 100-3, Medicare Claims Processing Manual section 220.6) that was made effective January 28, 2005, we discontinued numerous G-codes that described myocardial PET and nonmyocardial PET procedures and replaced them with the established CPT codes. The CY 2005 payment rate for concurrent PET/CT scans using the CPT codes 78814 (Tumor imaging, positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization; limited area (eg, chest, head/neck)); 78815 (Tumor imaging, positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization; skull base to mid-thigh); and 78816 (Tumor imaging, positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization; whole body) was \$1,250, which was \$100 higher than the payment rate for PET scans alone. These PET/CT CPT codes were placed in New Technology APC 1514 (New Technology—Level XIV (\$1,200–\$1,300)) for CY 2005.

We continued with these coding and payment methodologies in CY 2006. For CY 2007, while we proposed to reassign both PET and PET/CT scans to the same new clinical APC, we finalized a policy

that reassigned conventional PET procedures to APC 0308 (Non-Myocardial Positron Emission Tomography (PET) Imaging) with a final median cost of approximately \$850. We also reassigned PET/CT services to a different New Technology APC for CY 2007, specifically New Technology APC 1511 (New Technology—Level XI (\$900–\$1000)), thereby maintaining the historical payment differential of about \$100 between PET and PET/CT procedures. Furthermore, we stated in the CY 2007 OP/ASC final rule with comment period (71 FR 68022) that we would wait for a full year of CPT-coded claims data prior to assigning the PET/CT services to a clinical APC and that maintaining a modest payment differential between PET and PET/CT procedures was warranted for CY 2007.

For CY 2008, we proposed the reassignment of concurrent PET/CT scans, specifically CPT codes 78814, 78815, and 78816, to a clinical APC because we believed we had adequate claims data from CY 2006 upon which to determine the median cost of performing these procedures. Based on our proposed rule analysis of approximately 117,000 CY 2006 single claims, the median cost of PET/CT scans was approximately \$1,094. We then examined approximately 34,000 single claims from CY 2006 for nonmyocardial PET scans, as described by CPT codes 78608, 78811, 78812, and 78813, and found that the median cost was also approximately \$1,094. In the proposed rule, we noted that a comparison of the median cost of PET/CT scans with the median cost of nonmyocardial PET scans, as derived from CY 2006 claims data, demonstrated that these costs were almost the same, thereby reflecting significant hospital resource equivalency between the two types of services. This result was not unexpected because many newer PET scanners also have the capability of rapidly acquiring CT images for attenuation correction and anatomical localization, sometimes with simultaneous image acquisition. The median costs for both PET and PET/CT scans were significantly higher for CY 2008 than for CY 2007 due to our CY 2008 proposal to package payment for all diagnostic radiopharmaceuticals as described in section II.A.4.c.(5) of this final rule with comment period that would package payment for the costs of the radiopharmaceuticals utilized similarly into the payment for both PET and PET/CT scans. As stated in the proposed rule (72 FR 42705), we believe that our claims data accurately reflected the comparable hospital resources required to provide nonmyocardial PET

and PET/CT procedures, and that the scans had obvious clinical similarity as well. Therefore, for CY 2008 we proposed to reassign the CPT codes for PET/CT scans to the clinical APC where nonmyocardial PET scans were also assigned, specifically APC 0308, with a proposed median cost of approximately \$1,094.

We noted in the proposed rule (72 FR 42705) that we had been paying separately for fluorodeoxyglucose (FDG), the radiopharmaceutical described by HCPCS code A9552 (F18 fdg), that is commonly administered during nonmyocardial PET and PET/CT procedures. For CY 2008, consistent with the proposed packaging approach as discussed in section II.A.4.c.(5) of the proposed rule, we proposed to package payment for the diagnostic radiopharmaceutical FDG into payment for the associated PET and PET/CT procedures. Because FDG was the most commonly used radiopharmaceutical for both PET and PET/CT scans and our single claims for these procedures included FDG more than 80 percent of the time, the packaging of this radiopharmaceutical fully maintained the clinical and resource homogeneity of the reconfigured APC 0308 that we proposed.

We received a number of public comments concerning our proposed reassignment of concurrent PET/CT scans for CY 2008. A summary of the public comments and our response follow.

Comment: Several commenters thanked CMS for proposing to increase the payment rate for concurrent PET/CT scans from the CY 2007 payment of approximately \$950 to approximately \$1,107 for CY 2008 and ensuring that these scans are assigned to a clinical APC with other services with similar median costs. However, these commenters were concerned that the proposed payment rate for the PET/CT scans for CY 2008 would be inadequate if the payment for the diagnostic radiopharmaceutical used in these procedures, specifically FDG, was packaged into the payment for the scans. Other commenters questioned the validity of the claims used to set the proposed payment rate for the concurrent PET/CT scan procedures. They indicated that the proposal to assign concurrent PET/CT scans from a New Technology APC to clinical APC 0308 was inappropriate and unsupported by reliable data. They believed that CMS did not have sufficient or accurate claims data to justify movement of the concurrent PET/CT services from New Technology APC 1514 to clinical APC 0308. Several

commenters suspected that the claims used to set the proposed payment rate were flawed because they believed that many hospitals had not yet updated their chargemasters to distinguish charges for the conventional nonmyocardial PET scans from charges for concurrent PET/CT scans. One commenter indicated that if CMS were to blend its own external data from the refined direct cost inputs used to establish the practice expense relative value units under the MPFS with OPSS claims data to establish a payment rate for PET/CT, the payment rate would be significantly higher than the proposed payment. Several commenters claimed that that proposed payment rate for the concurrent PET/CT procedures failed to recognize the differences in technology between the conventional nonmyocardial PET procedures and the concurrent PET/CT scans. They indicated that concurrent PET/CT scans used more advanced technology, resulting in greater capital equipment costs. Many commenters recommended that CMS continue to assign these PET/CT scans to a New Technology APC for one more year while CMS collects additional data on the cost of these procedures. Conversely, several commenters strongly urged CMS to assign the concurrent PET/CT scans to a separate clinical APC, distinct from the APC for conventional PET scans, to better reflect the incremental cost differences associated with this technology.

Response: As stated above, CPT codes 78814, 78815, and 78816 were new codes in CY 2005 and were assigned to New Technology APC 1514 with a payment rate of \$1,250. We continued with this same APC assignment in CY 2006. In CY 2007, we assigned these services to a different New Technology APC, specifically New Technology APC 1511, with a payment rate of \$950 in order to maintain the historical payment differential of about \$100 between the conventional PET and concurrent PET/CT procedures. For CY 2007 ratesetting, we had only 9 months of claims data and public commenters were concerned that these data did not yet reflect updated and appropriate hospital charges specifically for PET/CT scans. Therefore, concurrent PET/CT scan procedures have been assigned to a New Technology APC under the OPSS since CY 2005, a period of almost 3 years.

As we have stated in other sections of this final rule with comment period, such as in section III.D., comparisons between the MPFS and OPSS payments for services are not appropriate because the MPFS applies a very different methodology for establishing the

payment for the physician's office practice expenses associated with a procedure, based on direct cost inputs. Consequently, the application of the different methodologies results in different payment amounts in the two settings.

As noted previously, under the OPSS, we retain services within New Technology APC groups where they are assigned according to our estimates of their costs until we gather sufficient claims data to enable us to assign the services to clinically appropriate APCs based on hospital resource costs as calculated from claims. We disagree with the commenters' argument that we have insufficient claims data to justify movement of concurrent PET/CT scans from New Technology APC 1511 to clinical APC 0308. For this final rule with comment period, our updated claims data for concurrent PET/CT scans showed a total of over 149,000 services performed, with about 126,000 single claims available for ratesetting. The median cost for PET/CT scans alone was approximately \$1,076. Similarly, we had over 40,000 total claims for conventional PET scans, with approximately 35,000 single claims available for ratesetting. The median cost for conventional PET scans alone was approximately \$1,029, very close to the median cost of PET/CT scans. Based on their common clinical characteristics and the hospital resource similarity observed in our claims data for conventional PET and concurrent PET/CT scans, we believe that our claims data are sufficiently robust to support reassignment of PET/CT scans to the same clinical APC as conventional PET scans. The final median cost of APC 0308 of approximately \$1,044 appropriately reflects the similar costs of both conventional PET and concurrent PET/CT scans.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to assign concurrent PET/CT scan procedures described by CPT codes 78814, 78815, and 78816 to clinical APC 0308, with a CY 2008 median cost of approximately \$1,044, which includes packaged costs for diagnostic radiopharmaceuticals used in the scans. For further discussion of our final CY 2008 payment policy for diagnostic radiopharmaceuticals, refer to section II.A.4.c.(5) of this final rule with comment period.

b. IVIG Preadministration-Related Services (APC 0430)

In CY 2006, we created the temporary HCPCS code G0332 (Services for intravenous infusion of

immunoglobulin prior to administration (this service is to be billed in conjunction with administration of immunoglobulin)). Based on our estimate of the costs of this service in comparison with other services, HCPCS code G0332 was assigned to New Technology APC 1502 (New Technology—Level II, \$50–\$100), with a payment rate of \$75 effective January 1, 2006. In the CY 2007 OPSS/ASC final rule with comment period, we indicated our belief that it was appropriate to continue the temporary IVIG preadministration-related services payment through HCPCS code G0332 and its continued assignment to New Technology APC 1502 for CY 2007, in order to help ensure continued patient access to IVIG (71 FR 68092).

For CY 2008, we proposed to continue to provide separate payment for IVIG preadministration-related services through the assignment of HCPCS code G0332 to a clinical APC. This service has been assigned to a New Technology APC under the OPSS for 2-full years. As noted previously, under the OPSS, we retain services within New Technology APC groups where they are assigned according to our estimates of their costs until we gather sufficient claims data to enable us to assign the services to clinically appropriate APCs based on hospital resource costs as calculated from claims. According to our analysis of the hospital outpatient claims data, we noted we had adequate claims data from CY 2006 upon which to determine the median cost of performing IVIG preadministration related services and to reassign HCPCS code G0332 to an appropriate clinical APC for CY 2008. For the CY 2008 OPSS/ASC proposed rule, our claims data for this high volume service showed a total of over 49,000 services performed, with about 48,000 single claims available for ratesetting. Therefore, we proposed to reassign HCPCS code G0332 to new clinical APC 0430 (Drug Preadministration—Related Services) for CY 2008, with a proposed median cost of approximately \$39, where it would be the only service assigned to the APC at this time.

As noted in the proposed rule (72 FR 42705), IVIG preadministration-related services are always provided in conjunction with other separately payable services such as drug administration services, and thus are well suited for packaging into the payment for the separately payable services. While we did not make a determination about the appropriateness of continuing separate OPSS payment for HCPCS code G0332 after CY 2008, we stated in the proposed rule (72 FR

42705) that we would consider packaging payment for HCPCS code G0332 in future years if we determined that separate payment was no longer warranted. We intend to reevaluate the appropriateness of separate payment for IVIG preadministration-related services for the CY 2009 OPPS rulemaking cycle, especially as we explore the potential for greater packaging and possible encounter-based or episode-based OPPS payment approaches.

We received a number of public comments on our CY 2008 proposed payment for IVIG preadministration-related services. A summary of the public comments and our response follow.

Comment: Many commenters questioned the accuracy and reliability of the CY 2006 hospital outpatient claims data that were used to set the proposed payment rate for HCPCS code G0332. Some commenters indicated that because HCPCS code G0332 was a new code for CY 2006, it was clearly not well understood by many hospitals, and as a result, it took some time for hospitals to appropriately determine the cost and the reported charge for the service. Many commenters stated that the proposed payment rate of \$39 was likely based on flawed data, and as such, the data should not be used as a basis for reassigning HCPCS code G0332 from New Technology APC 1502 to APC 0430. These commenters believed that the low payment rate was due to underreporting of this service because their findings revealed that hospitals reported HCPCS code G0332 on only 49 percent of the claims for IVIG administration. One commenter believed that, based on an analysis of its hospital system's claims data for HCPCS code G0332, that claims data were distorted due to a number of factors, including revenue code selections by hospitals, differences in the CCRs mapped to those revenue codes, and the actual dollar charges reported by hospitals for this service. Several commenters explained that hospitals set widely varying charges for HCPCS code G0332, and some of these commenters believed that it would be appropriate to exclude from the ratesetting process claims where the reported charge is equal to or less than the \$75 payment rate.

Many commenters believed that reducing this add-on payment would have a negative impact on patient access to care, considering the short supply and high costs of acquiring IVIG. Several commenters suggested that CMS should maintain the \$75 add-on payment for HCPCS code G0332 to maintain parity with the proposed \$71

MPFS payment rate for this service. These commenters asserted that establishing a difference in payment for HCPCS code G0332 across systems could drive patients from one site of service to another. They further believed that maintaining payment parity for the service at comparable levels across these sites of service would mitigate potential disruptions to the sites of service where patients are now receiving care and would also allow the choice of site of care to be dictated by particular patient circumstances. Several commenters commended CMS for continued support in extending the add-on payment for HCPCS code G0332; however, they recommended that the \$75 separate payment under New Technology APC 1502 be continued for another year. Alternatively, several commenters requested that CMS reassign HCPCS code G0332 to a clinical APC whose payment rate is equivalent to \$75 to ensure that hospitals would continue to be paid appropriately for the full range of costs incurred in furnishing IVIG to their patients and to help mitigate the possible adverse financial impact on hospitals acquiring IVIG that could result from a lower payment for preadministration-related services.

Response: Just as our payment rates are updated annually, so too are billing codes (that is, ICD-9-CM, Level II HCPCS, and CPT). Annual updates to the HCPCS coding system (whether through addition of a new code, revision of a code descriptor, or deletion of a code), are a well-established and predictable process that has been in place for some time. Hospitals are well aware of this practice because they have successfully implemented these changes each year.

The MPFS applies a distinct methodology for establishing the payment for the physician's office practice expenses associated with a procedure that differs significantly from the OPPS methodology which generally pays based on relative payment weights calculated from hospitals' costs as determined from claims data. The application of the different methodologies results in different payment amounts in the two settings. Therefore, comparisons between OPPS and MPFS payments are not appropriate.

In determining the CY 2008 final rule median cost of approximately \$37 for HCPCS code G0332, we used the most recent claims data available under the OPPS, specifically CY 2006 claims. According to our standard OPPS methodology as described in section II.A.2. of this final rule with comment period, we excluded claims for HCPCS

code G0332 where the line-item charge was exactly equal to the CY 2006 payment rate, a process we followed for all OPPS services. We did not remove claims whose charges were less than \$75 because hospitals are free to set their own charges for individual services based on their own judgment.

Under the OPPS, the current payment methodology for IVIG treatments consists of three components, which include payment for the drug itself (described by a HCPCS J code), administration of the IVIG product (described by one or more CPT codes), and the preadministration-related services (HCPCS code G0332). As stated previously, this service has been assigned to New Technology APC 1502 under the OPPS for 2 full years. Under the OPPS, we retain services within New Technology APC groups where they are assigned according to our estimates of their costs until we gather sufficient claims data to enable us to assign the services to clinically appropriate APCs based on hospital resource costs as calculated from claims. We do not agree with the commenters' argument that underreporting of this service in CY 2006 is a compelling rationale for delaying reassignment to a clinical APC. Our CY 2006 claims data include approximately 59,000 total claims for HCPCS code G0332, and we have no reason to believe those claims do not accurately represent the costs to hospitals of providing the service in CY 2006. We believe that the approximately 57,000 single claims used to set the CY 2008 median cost of IVIG preadministration-related services at approximately \$37 accurately reflect hospitals' costs for the service and that the final CY 2008 payment rate for HCPCS code G0332 is adequate to ensure access to IVIG therapy.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to assign HCPCS code G0332 to APC 0430, with a median cost of approximately \$37. As we stated previously, we will consider packaging payment for HCPCS code G0332 in future years if we determine separate payment is no longer warranted. We intend to reevaluate the appropriateness of separate payment for IVIG preadministration-related services for the CY 2009 OPPS rulemaking cycle, especially as we explore the potential for greater packaging and possible encounter-based or episode-based OPPS payment approaches.

c. Other Services in New Technology APCs

Other than the concurrent PET/CT and IVIG preadministration-related new technology services discussed in sections III.C.2.a. and III.C.2.b. of this final rule with comment period, there are five procedures currently assigned to New Technology APCs for CY 2007 for which we believed we also had data that were adequate to support their reassignment to clinical APCs. For CY 2008, we proposed to reassign these procedures to clinically appropriate APCs, applying their CY 2006 claims data to develop their clinical APC median costs upon which payments would be based. These procedures and their proposed APC assignments were displayed in Table 29 of the proposed rule. This table has been reproduced as Table 16 at the end of this section and updated with the final status indicators, APC assignments, and median costs of these services.

(1) Breast Brachytherapy Catheter Implantation (APC 0648)

For CY 2008, we proposed to reassign CPT code 19298 (Placement of radiotherapy afterloading brachytherapy catheters (multiple tube and button type) into the breast for interstitial radioelement application following (at the time of or subsequent to) partial mastectomy, includes imaging guidance) from New Technology APC 1524 (New Technology—Level XXIV

(\$3,000–\$3,500)) to APC 0648 (Level IV Breast Surgery), with a proposed median cost of approximately \$3,417.

We received several public comments concerning the proposed reassignment of CPT code 19298. A summary of the public comments and our response follow.

Comment: Several commenters agreed with CMS’s proposal to reassign CPT code 19298 to APC 0648. They acknowledged that this proposed reassignment of CPT code 19298 would place the three surgical codes for the placement of catheters for breast brachytherapy in the same APC, that is, CPT codes 19296 (Placement of radiotherapy afterloading balloon catheter into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; on date separate from partial mastectomy); 19297 (Placement of radiotherapy afterloading balloon catheter into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; concurrent with partial mastectomy (List separately in addition to code for primary procedure)); and 19298.

Response: We thank the commenters for their input and support. Because of its clinical and resource characteristics similar to those other procedures also assigned to APC 0648, we are finalizing our CY 2008 proposal, without modification, to reassign CPT code

19298 to APC 0648, with a median cost of approximately \$3,560.

(2) Preoperative Services for Lung Volume Reduction Surgery (LVRS) (APCs 0209 and 0213)

As illustrated in Table 16 below, CY 2008, we proposed to reassign HCPCS codes G0302 (Pre operative pulmonary surgery services for preparation for LVRS, complete course of services, to include a minimum of 16 days of services) and G0303 (Pre-operative pulmonary surgery services for preparation for LVRS, 10 to 15 days of services) to APC 0209 (Level II Extended EEG and Sleep Studies). For CY 2008, we also proposed to reassign HCPCS codes G0304 (Pre-operative pulmonary surgery services for preparation for LVRS, 1 to 9 days of services) and G0305 (Post-discharge pulmonary surgery services after LVRS, minimum of 6 days of services) to APC 0213 (Level I Extended EEG and Sleep Studies).

We did not receive any public comments on these two proposals and, therefore, we are finalizing our CY 2008 proposals for HCPCS codes G0302, G0303, G0304, and G0305 without modification. Specifically, HCPCS codes G0302 and G0303 are assigned to APC 0209, with a CY 2008 median cost of approximately \$710. HCPCS codes G0304 and G0305 are assigned to APC 0213, with a CY 2008 median cost of approximately \$145.

TABLE 16.—FINAL CY 2008 APC REASSIGNMENTS OF OTHER NEW TECHNOLOGY PROCEDURES TO CLINICAL APCS

HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	CY 2007 APC payment rate	Final CY 2008 SI	Final CY 2008 APC	Final CY 2008 APC median cost
19298	Place breast rad tube/caths	S	1524	\$3,250	T	0648	\$3,560
G0302	Pre-op service LVRS complete	S	1509	750	S	0209	710
G0303	Pre-op service LVRS 10–15 dos	S	1507	550	S	0209	710
G0304	Pre-op service LVRS 1–9 dos	S	1504	250	S	0213	145
G0305	Post op service LVRS min 6	S	1504	250	S	0213	145

D. APC-Specific Policies

1. Cardiac Procedures

a. Cardiac Computed Tomography and Computed Tomographic Angiography (APCs 0282 and 0383)

Cardiac computed tomography (CCT) and cardiac computed tomography angiography (CCTA) are noninvasive diagnostic procedures that assist physicians in obtaining detailed images of coronary blood vessels. The data obtained from these procedures can be used for further diagnostic evaluations and/or appropriate therapy for coronary patients.

Currently, there are eight Category III CPT codes that describe CCT and CCTA procedures. The CPT codes, which were shown in Table 31 of the proposed rule, are 0144T through 0151T. These codes were new for CY 2006. In the CY 2006 OPPS final rule with comment period, we assigned the CCT and CCTA procedure codes to interim APCs, which were subject to public comment. In CY 2006, the CCT and CCTA procedure codes were assigned to four APCs, specifically, APC 0282 (Miscellaneous Computerized Axial Tomography), APC 0376 (Level II Cardiac Imaging), APC 0377 (Level III Cardiac Imaging), and APC 0398 (Level I Cardiac Imaging). We

did not receive any public comments on the interim APC assignments.

In the CY 2007 OPPS/ASC proposed rule, we proposed to retain the existing APC assignments for the CCT and CCTA procedure codes. We received several public comments on the proposed APCs assignments, which we addressed in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68038 and 68039). Several of the commenters requested that we either not assign the CCT and CCTA procedures to any APCs or assign them to appropriate New Technology APCs. In addition, some commenters were also concerned that CCT and CCTA procedures were not

clinically homogeneous with other procedures assigned to APCs 0282, 0376, 0377, and 0398, noting that the last three APCs previously contained only nuclear medicine cardiac imaging procedures.

In the CY 2007 OP/ASC final rule with comment period (71 FR 68038), we indicated our belief that the clinical characteristics and expected resource use associated with the CCT and CCTA procedures were sufficiently similar to the other procedures assigned to APCs 0282, 0376, 0377, and 0398 that we believed those APC assignments were appropriate. While several of those APCs also contained nuclear medicine imaging procedures, we had never designated those APCs as specific to nuclear medicine procedures. Therefore, for CY 2007, we continued with the CY 2006 APC assignments for CPT codes 0144T through 0151T. We did not agree with the commenters that use of CT and CTA for cardiac studies was a new technology for which we had no relevant OP/ASC cost information that could be used to estimate hospital resources for these procedures. We also believed these services could be potentially covered hospital outpatient services, so that it would not be appropriate for us to depart from our standard OP/ASC policy and not assign them to APCs. As we indicated in our CY 2007 OP/ASC proposed rule (71 FR 49549), some Category III CPT codes describe services that we have determined to be similar in clinical characteristics and resource use to HCPCS codes assigned to existing clinical APCs. In these instances, we may assign the Category III CPT code to the appropriate clinical APC. Other Category III CPT codes describe services that we have determined are not compatible with an existing clinical APC, yet are appropriately provided in the hospital outpatient setting. In these cases, we may assign the Category III CPT code to what we estimate is an appropriately priced New Technology APC. In other cases, we may assign a Category III CPT code to one of several nonseparately payable status indicators, including "N," "C," "B," or "E," which we believe is appropriate for the specific code. As we noted in the CY 2007 OP/ASC final rule with comment period, we believed that CCT and CCTA procedures were appropriate for separate payment under the OP/ASC should local contractors provide coverage for these procedures and, therefore, they warranted status indicator and APC assignments that would provide separate payment under the OP/ASC (71 FR 68038).

At its March 2007 meeting, the APC Panel recommended that CMS work with stakeholders to determine more appropriate APC placements for CCT and CCTA procedures. The APC Panel made no specific recommendations regarding the appropriate APC assignments for these services, although several different clinical APC configurations were discussed, along with the alternative of assigning these procedures to New Technology APCs.

We note that we generally meet with interested organizations concerning their views about OP/ASC payment policy issues with respect to specific technologies or services. Following the publication of the CY 2007 OP/ASC final rule with comment period, we received such information from interested individuals and organizations regarding the clinical and facility resource characteristics of CCT and CCTA procedures. In the CY 2008 OP/ASC proposed rule (72 FR 42711), we reiterated that we would consider the input of any individual or organization to the extent allowed by Federal law, including the Administrative Procedure Act (APA) and the FACA. We explained that we establish the OP/ASC payment rates for services through regulations, during our annual rulemaking cycle. We are required to consider the timely comments of interested organizations, establish the payment policies for the forthcoming year, and respond to the timely comments of all public commenters in the final rule in which we establish the payments for the forthcoming year.

During the development of the CY 2008 proposed rule, we noted that analysis of our hospital data for claims submitted for CY 2006 indicated that CCT and CCTA procedures were performed relatively frequently on Medicare patients. Our claims data showed a total of over 16,000 procedures performed, with about 11,000 single claims available for ratesetting. Based on our analysis of the robust hospital outpatient claims data at that time, we believed we had adequate claims data from CY 2006 upon which to determine the median costs of performing these procedures and to assign them to appropriate clinical APCs. We saw no rationale for reassigning these procedures to New Technology APCs in CY 2008, when we had claims-based cost information regarding these procedures, and they were clinically similar to other procedures paid under the OP/ASC.

We acknowledged the concerns that had been expressed to us regarding the clinical homogeneity of APCs 0376,

0377, and 0398, where some of the CCT and CCTA were assigned for CY 2007 along with nuclear medicine cardiac imaging procedures. Because we proposed to package payment for diagnostic radiopharmaceuticals into payment for diagnostic nuclear medicine procedures in CY 2008 as discussed in detail in section II.A.4.c.(5) of this final rule with comment period, we believed that to ensure the clinical and resource homogeneity of APCs 0376, 0377, and 0398 in CY 2008, it would be most appropriate to reassign the CCT and CCTA services currently residing in those APCs to other clinical APCs for CY 2008.

Therefore, for CY 2008, we proposed to assign the CCT and CCTA procedures to two clinical APCs, specifically new clinical APC 0383 (Cardiac Computed Tomographic Imaging) and APC 0282, as shown in Table 17 below. The proposed median cost of approximately \$314 for APC 0383 was based entirely on claims data for CPT codes 0145T, 0146T, 0147T, 0148T, 0149T, and 0150T that described CCT and CCTA services, a clinically homogeneous grouping of services. In addition, the individual median costs of these services ranged from a low of approximately \$277 to a high of \$437, reflecting their hospital resource similarity as well. We proposed to reassign the two other CCT CPT codes, specifically CPT codes 0144T and 0151T, to APC 0282. The inclusion of these two codes in APC 0282 resulted in a CY 2008 proposed APC median cost of about \$105.

We received a number of public comments concerning our CY 2008 proposals for CCT and CCTA procedures. A summary of the public comments and our responses follow.

Comment: While several commenters expressed appreciation for the proposed reassignment of CCT and CCTA procedures into their own clinically homogeneous APC groups, many commenters disagreed with the proposal to reassign these services from APCs 0282, 0376, 0377, and 0398 to APCs 0282 and 0383 for CY 2008. These commenters were especially concerned with the proposed payment rates for these procedures and asserted that the proposed median costs of \$105 for APC 0282 and \$314 for APC 0383 were inadequate because they were based on limited data, thereby undervaluing these new technology services. The commenters further believed that the CY 2008 proposed payment rates of \$107 for APC 0282 and \$318 for APC 0383 were unreasonably low based on only 16,000 total procedures, with about 11,000 single claims used for ratesetting. Some commenters pointed out that the

first year in which the new procedures were specifically reported by hospitals was CY 2006. They argued that because it takes time for hospitals to completely capture and report the full costs associated with new procedures in their charges, hospitals could not have reported these services accurately in CY 2006. One commenter believed that because most hospitals do not specifically allocate capital costs to the cost centers involved, the CCRs used to convert charges to costs for CCT and CCTA procedures were likely understated.

Many commenters expressed concern that there had not been sufficient time to develop accurate and reliable claims data for these new procedures and that additional measures were necessary to ensure appropriate payments. Some commenters recommended that CMS delay the implementation of the CY 2008 median costs until a full year of claims data were available from both multiple and single claims and suggested that CMS continue with the CY 2007 APC assignments for CCT and CCTA procedures. They argued that inadequate payment rates would unintentionally encourage the use of more expensive and invasive diagnostic procedures for Medicare beneficiaries. Some commenters further requested that CMS consult with stakeholders and utilize external data to determine the degree to which OPSS claims data accurately reflected the relative resource costs of these procedures and to make appropriate adjustments to the payment rates, especially for APC 0383. Other commenters requested that CMS reassign the CCT and CCTA procedures to appropriate New Technology APCs for CY 2008.

Some commenters requested that CMS reconsider the reassignment of CPT codes 0144T and 0151T whose median costs varied significantly, from \$86 and \$144, respectively, because these services did not appear to be clinically appropriate when compared to the other procedures assigned to APC 0282.

Response: While we acknowledge that the CPT codes for CCT and CCTA procedures were new for January 2006, we disagree with the commenters'

argument that our claims data are inadequate to support the reassignment of CCT and CCTA procedures to clinical APCs for CY 2008 based on hospital costs derived from claims. We used the approximately 12,000 single bills available for this final rule with comment period in determining the median costs for the CCT and CCTA procedures because the single bills provide us with the most accurate costs that are the foundation of our standard OPSS ratesetting methodology. As we discuss in section II.A.1.b. of this final rule with comment period, we are unable to appropriately allocate packaged costs on multiple procedure claims so we generally are not able to use them in setting payment rates. As we also discuss in that section, we are continuing to work on additional methodologies that would allow us to use claims data from more OPSS claims. While we recognize that reliance on single procedure claims may result in the use of fewer claims for some services than for others, in the case of CCT and CCTA procedures, in particular, we were able to use about two-thirds of all approximately 18,000 claims for ratesetting. These services were reported by many hospitals in CY 2006, and we have no reason to believe that costs based upon this large percentage of all claims do not accurately reflect the resource costs of these services to hospitals. Our standard OPSS methodology determines the relative costs of services from claims, with a specific focus on relative costs and not absolute costs, and we do not believe there is any need for us to utilize external data to determine the costs of these services. Additionally, we do not agree with the commenters' suggestion to place the CCT and CCTA procedures in New Technology APCs. We believe that, based on the clinical characteristics and resource use calculated from CY 2006 claims for CCT and CCTA procedures, our proposal would assign them to appropriate clinical APCs for CY 2008. In fact, several commenters acknowledged that the proposed APC assignments of these procedures were appropriate based on explicit consideration of clinical homogeneity.

Further, in the case of CPT codes 0144T and 0151T, the commenters mistakenly believed that the CY 2008 OPSS median costs for these procedures were \$86 and \$144, respectively. The CY 2008 proposed rule median cost for CPT code 0144T was approximately \$68 and approximately \$43 for CPT code 0151T, and their final rule median costs are approximately \$68 and \$54, respectively. The \$86 and \$144 figures reported by some commenters were based on the procedures' mean costs, not the median costs which are used for ratesetting under the OPSS. We believe that CPT codes 0144T and 0151T are appropriately assigned to APC 0282 as their median costs fall within the range of costs of other procedures also assigned to the APC, which has a final median cost of approximately \$100.

Comment: Some commenters were uncertain as to whether the costs of the contrast agents used in conjunction with CCT and CCTA procedures were included in the proposed payment rate calculations for APCs 0282 and 0383. They requested that CMS address this issue in this final rule with comment period. The commenters requested that CMS increase the payment rates for APCs 0282 and 0383 if the costs of the contrast agents were not included in the proposed payment rates.

Response: The proposed payment rates for APCs 0282 and 0383 included the costs of the contrast agents, because, as discussed further in section II.A.4.c.(6) of this final rule with comment period, we proposed to package payment for all contrast agents for CY 2008. Our final CY 2008 policy packages payment for all contrast agents and, therefore, the final payment rates for CCT and CCTA procedures include these costs.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to assign CCT and CCTA procedures to APCs 0282 and 0383, with CY 2008 median costs of approximately \$100 and approximately \$296, respectively. The final CY 2008 APC assignments and APC median costs for the specific CCT and CCTA procedures are displayed in Table 17.

TABLE 17.—FINAL CY 2008 APC ASSIGNMENTS OF CCT AND CCTA PROCEDURES

HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	CY 2007 APC median cost	Final CY 2008 SI	Final CY 2008 APC	Final CY 2008 APC median cost
0144T	CT heart wo dye; qual calc	S	0398	\$252	S	0282	\$100
0145T	CT heart w/wo dye funct	S	0376	305	S	0383	296
0146T	CCTA w/wo dye	S	0376	305	S	0383	296
0147T	CCTA w/wo, quan calcium	S	0376	305	S	0383	296
0148T	CCTA w/wo, strxr	S	0377	397	S	0383	296

TABLE 17.—FINAL CY 2008 APC ASSIGNMENTS OF CCT AND CCTA PROCEDURES—Continued

HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	CY 2007 APC median cost	Final CY 2008 SI	Final CY 2008 APC	Final CY 2008 APC median cost
0149T	CCTA w/wo, strxr quan calc	S	0377	397	S	0383	296
0150T	CCTA w/wo, disease strxr	S	0398	252	S	0383	296
0151T	CT heart funct add-on	S	0282	94	S	0282	100

b. Coronary and Non-Coronary Angioplasty (PTCA/PTA) (APCs 0082, 0083, and 0103)

For CY 2008, we proposed to delete APC 0081 (Noncoronary Angioplasty or Atherectomy) as a result of the effects of the proposed CY 2008 packaging approach on median costs (see section II.A.4.c. of this final rule with comment period for more discussion of our packaging approach). We proposed to reassign the procedures that mapped to this APC in CY 2007 to APCs that would be homogeneous with respect to clinical characteristics and resource use in CY 2008, specifically APCs 0082 (Coronary or Non-Coronary Atherectomy), 0083 (Coronary or Non-Coronary Angioplasty and Percutaneous Valvuloplasty), and 0103 (Miscellaneous Vascular Procedures). The CY 2008 proposed payment rates for these APCs were approximately \$5,654, \$2,934, and \$972, respectively. The CY 2007 payment rate for APC 0081 was approximately \$2,639.

We received one public comment on our CY 2008 proposal to delete APC 0081 and reassign the procedures that mapped to this APC to APCs 0082 and 0083. A summary of the public comment and our response follow.

Comment: One commenter stated that the proposed reassignment of some of the angioplasty procedures assigned to APC 0081 in CY 2007 to APC 0083 in CY 2008 fails to recognize the differences in median costs associated with the use of specialty balloons in certain coronary and non-coronary angioplasty (PTCA/PTA) procedures. According to the commenter, specialty balloons are defined as balloons that can be used for purposes other than inflation and deflation (eg, cutting balloons and cold therapy balloons). The commenter estimated from an analysis of the CY 2006 Medicare claims data that the median costs for PTCA/PTA procedures involving specialty balloons are approximately 55 percent higher than the median costs of all PTCA/PTA procedures in APC 0083, and represent approximately 4 percent of the cases. The commenter expressed concern that inadequate payment for PTCA/PTA procedures involving

specialty balloons could reduce beneficiary access to this technology.

The commenter urged CMS to reconsider its proposal to reassign all PTCA/PTA procedures to APC 0083. Specifically, the commenter requested that CMS establish a HCPCS Level II G-code to differentiate coronary and noncoronary PTCA/PTA procedures using specialty balloons from those PTCA/PTA procedures using standard, nonspecialty balloons, defining specialty balloons as those which have a median reported cost of more than \$800 based on CY 2006 hospital claims containing the Level II HCPCS C-code for PTCA/PTA balloons, C1725 (Catheter, transluminal angioplasty, non-laser). The commenter stated that nonspecialty balloons cost approximately \$200 to \$400. According to the commenter's suggestion, the new G-code would map to a new APC for coronary and noncoronary angioplasty procedures using specialty balloons, the payment for which would be based upon the median cost of procedures performed using specialty balloons, as indicated on CY 2006 claims by the reporting of C1725 where the reported catheter cost is more than \$800.

Response: We believe that the proposed reassignment of the procedures assigned to APC 0081 in CY 2007 to APC 0083 in CY 2008 is appropriate, both in terms of the clinical similarities and resource costs of the procedures involved. The HCPCS-specific median costs of significant procedures assigned to APC 0083 range from approximately \$2,621 to \$4,339. Even considering the information provided by the commenter about the expected differential cost between specialty and non-specialty balloons of \$400 to \$600, we would not expect Medicare beneficiaries to have problems with access to procedures with specialty balloons, when the APC 0083 CY 2008 median cost is approximately \$2,855. Packaging payment for the variety of implantable devices that are used in specific procedures is a well-established principle of the OPPS, and we expect that hospitals will carefully consider the clinical benefits and costs of all technologies when performing procedures on patients. Therefore, we

also believe that a policy to provide different payments for PTCA/PTA procedures involving specialty balloons would not be consistent with our overall strategy to encourage hospitals to use resources more efficiently by increasing the size of the payment bundles. If the use of a very expensive device in a clinical scenario, such as a specialty balloon, caused a specific procedure to be much more expensive for the hospital than the APC payment, we consider such a case to be the natural consequence of a prospective payment system that anticipates that some cases will be more costly and others less costly than the procedure payment. We will continue to monitor the costs of PTCA/PTA procedures over time based on the evolution of clinical practice and will consider proposing future modifications to the configuration of APC 0083 as necessary.

After consideration of the public comment received, we are finalizing our CY 2008 proposal, without modification, to reassign angioplasty procedures assigned to APC 0081 in CY 2007 to APC 0083 in CY 2008. The median cost of APC 0083 is approximately \$2,855.

c. Implantation of Cardioverter-Defibrillators (APCs 0107 and 0108)

In CY 2003, we created four Level II HCPCS codes for implantation of single and dual chamber cardioverter-defibrillators (ICDs) with and without leads because, for the CY 2004 OPPS, we deleted the device HCPCS codes and there was no other way of determining whether the device being implanted was a single chamber or dual chamber device. We were concerned that the costs of inserting single versus dual chamber ICDs could be sufficiently different due to the two types of devices implanted such that separate APC assignments for the insertion procedures could be appropriate in the future. The HCPCS codes are G0297 (Insertion of single chamber pacing cardioverter defibrillator pulse generator); G0298 (Insertion of dual chamber pacing cardioverter defibrillator pulse generator); G0299 (Insertion or repositioning of electrode lead for single chamber pacing cardioverter

defibrillator and insertion of pulse generator); and G0300 (Insertion or repositioning of electrode lead for dual chamber pacing cardioverter defibrillator and insertion of pulse generator). The pairs of codes were assigned to two different clinical APCs, depending on whether or not they included the possibility of electrode insertion, specifically APC 0107 (Insertion of Cardioverter-Defibrillator) and APC 0108 (Insertion/Replacement/Repair of Cardioverter-Defibrillator Leads).

In the same year, the OPSS ceased to recognize for payment the two CPT codes for insertion of ICDs with or without ICD leads. These CPT codes are 33240 (Insertion of single or dual chamber pacing cardioverter-defibrillator pulse generator) and 33249 (Insertion or repositioning of electrode lead(s) for single or dual chamber pacing cardioverter-defibrillator and insertion of pulse generator).

We reinstated the device category HCPCS codes on January 1, 2005. Moreover, since January 1, 2005, hospitals have been required to report devices they use or implant when there is a device code that describes the device. We began to edit to ensure that hospitals are correctly billing devices required for certain procedures in April 2005 and implemented the second phase of device edits on October 1, 2005. Therefore, we no longer need different procedural Level II HCPCS codes to identify whether hospitals inserted a single or dual chamber ICD device.

At its March 2007 meeting, the APC Panel recommended that CMS delete the Level II HCPCS codes for implantation of cardioverter-defibrillator pulse generators with or without repositioning or implantation of electrode lead(s) for CY 2008 and authorize hospitals to report the CPT codes. The APC Panel indicated that the requirement for reporting device codes would enable CMS to continue to identify costs when different types of devices are implanted if that were to be necessary.

We analyzed the median cost data associated with APCs 0107 and 0108 as part of our preparation for the APC Panel discussion. While there was a difference in the median cost when a single chamber versus a dual chamber device is implanted, the difference has never been great enough to justify differential APC assignments for the procedures. Table 34 included in the CY 2008 OPSS/ASC proposed rule presented a historical summary of all single claim median costs. (For purposes of this analysis, we displayed

the median costs for all single claims without regard to adjustment or to whether the claims met various selection criteria; these were not the median costs on which proposed payments were based.)

Hospitals have consistently indicated that they would prefer to report services furnished using the CPT codes that describe them, rather than the Level II HCPCS G-codes, because many private payers require that they bill the CPT codes. We also prefer to recognize CPT codes for procedures under the OPSS, when possible, to minimize the administrative coding burden on hospitals.

In the CY 2008 OPSS/ASC proposed rule (72 FR 42715), we stated our belief that the differences between the median costs for the two Level II HCPCS codes assigned to each APC (that is, G0297 and G0298 for APC 0107 and G0299 and G0300 for APC 0108) do not currently support differential APC assignments for single and dual chamber ICD insertion procedures. The required device coding would allow us to continue to follow the different costs over time by examining subsets of ICD implantation procedure claims based on the type of device reported on the claims. Moreover, we are sensitive to the benefits of minimizing the reporting burden on hospitals. Therefore, for CY 2008, we proposed to delete the Level II HCPCS codes for ICD insertion procedures and require hospitals to bill the appropriate CPT codes, along with the applicable device C-codes, for payment under the OPSS.

We received a number of public comments on our CY 2008 proposal for reporting ICD implantation procedures under the OPSS. A summary of the public comments and our responses follow.

Comment: Several commenters supported implementing the policy as proposed. One commenter favored the elimination of the Level II HCPCS codes for ICD implantation, citing the administrative burden these pose for hospitals, but remained concerned about the potential negative impact to hospitals when the more expensive dual chamber device is used for Medicare beneficiaries. The commenter suggested that CMS should consider creation of composite APCs for device-dependent procedures, such as ICD implantation, where the device costs can vary significantly based on the type of device used. The commenter suggested that payment for these composite APCs would be based on the combination of the device implantation CPT code and the existing Level II HCPCS code for the particular device. According to the

commenter, this would minimize the administrative burden for providers, allow coding to remain consistent across payers, and enable more appropriate payment for procedures with varying device costs.

Response: Composite APCs provide a single payment for two or more major procedures that are commonly performed together, in order to promote efficiency by increasing the size of the payment bundle. We do not agree that the payment methodology outlined by one commenter, to base payment for ICDs on the combination of the ICD implantation CPT code and the existing device code, is consistent with the concept of composite APCs as described in the proposed rule and as finalized in section II.A.4.d. of this final rule with comment period. The scenario described by the commenter largely describes the current packaging of device payment into the payment for the procedure, except that we generally base payment on all of the devices associated with a procedure as a mechanism to promote the efficient utilization of resources. The recommended approach could actually reduce packaging under the OPSS by creating small and more specific payment bundles, rather than increasing the size of the payment bundles to provide hospitals with the flexibility to manage their resources as they control costs. To establish a separate APC for each combination of a procedure and a particular device used, as described by the commenter, would create incentives for the use of the most expensive device rather than creating incentives for efficiency and therefore is contrary to the principles of a prospective payment system. As described above, we believe that the payment for the procedures and associated devices included in APCs 0107 and 0108 is appropriate, as the differences between the median costs for the two Level II HCPCS codes currently assigned to each APC do not currently support differential APC assignments for single and dual chamber ICD insertion procedures.

After consideration of the public comments received, we are adopting the March 2007 APC Panel recommendation and finalizing our CY 2008 proposal, without modification, to delete the Level II HCPCS codes (G0297, G0298, G0299, and G0300) for ICD insertion procedures and require hospitals to bill the appropriate CPT codes for ICD insertion, specifically CPT code 33240 or CPT code 33249, as appropriate, along with the applicable device C-codes, for payment under the OPSS in CY 2008.

d. Removal of Patient-Activated Cardiac Event Recorder (APC 0109)

In the CY 2008 OPPI/ASC proposed rule, we proposed to continue our CY 2007 assignment of CPT code 33284 (Removal of an implantable, patient-activated cardiac event recorder) to APC 0109 (Removal/Repair of Implanted Devices), with a proposed CY 2008 payment rate of approximately \$389. The CY 2007 payment rate for this service is approximately \$676.

We received one public comment on the CY 2008 proposed reconfiguration of APC 0109. A summary of the public comment and our response follow.

Comment: One commenter requested that CMS reexamine its proposed assignment of CPT code 33284 to APC 0109 in light of the proposed reassignment of CPT codes 36575 (Repair of tunneled or non-tunneled central venous access catheter, without subcutaneous port or pump, central or peripheral insertion site) and 36589 (Removal of tunneled central venous catheter, without subcutaneous port or pump) from APC 0621 (Level I Vascular Access Procedures) to APC 0109 for CY 2008. The commenter asserted that the proposed inclusion of CPT codes 36575 and 36589 in APC 0109 significantly altered the proposed median cost of APC 0109, to the extent that it was no longer representative of the resource requirements of CPT code 33284. The commenter requested that CMS create a separate APC for CPT code 33284 if CMS finalizes its proposal to reassign CPT codes 36575 and 36589 to APC 0109.

Response: We agree with the commenter that the change in composition of APC 0109 may no longer most accurately reflect the resource characteristics of CPT code 33284. CPT codes 36575 and 36589 have median costs of approximately \$319 and \$357, respectively, while CPT code 33284 has a median cost of approximately \$682. While we appreciate the commenter's suggestion for a new APC for CPT code 33284, we believe that an existing clinical APC may sufficiently account for the clinical and resource characteristics of the procedure described by CPT code 33284. The clinical characteristics of CPT code 33284 are similar to those procedures in APC 0020 (Level II Excision/Biopsy). CPT code 33284 and the other procedures assigned to APC 0020 generally require surgical incisions, local anesthesia, and suturing. In addition, we believe that APC 0020, with an APC median cost of approximately \$546, more closely aligns with the resources of CPT code 33284,

rather than its proposed assignment to APC 0109, with an APC median cost of approximately \$356.

After consideration of the public comment received, we are not finalizing our CY 2008 proposal to assign CPT code 33284 to APC 0109. Instead, we are reassigning CPT code 33284 to APC 0020 for CY 2008, with a median cost of approximately \$546.

e. Stress Echocardiography (APC 0697)

In the CY 2008 OPPI/ASC proposed rule, we proposed to assign CPT code 93350 (Echocardiography, transthoracic, real-time with image documentation (2D), with or without M-mode recording, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report) to APC 0697 (Level I Echocardiogram, Except Transesophageal), with a proposed payment rate of approximately \$306. Currently, this service is assigned to APC 0269 (Level II Echocardiogram Except Transesophageal), with a payment rate of approximately \$198 for CY 2007. The proposed packaging approach for CY 2008, as described further in section II.A.4.c. of this final rule with comment period, proposed to package significant additional costs for ancillary and supportive services into the CY 2008 payment for CPT code 93350.

We received a few public comments concerning our CY 2008 proposed reassignment of CPT code 93350 to APC 0697. A summary of the public comments and our response follow.

Comment: A few commenters requested that we continue to assign CPT code 93350 to APC 0269, instead of reassigning this procedure to APC 0697 as proposed. The commenters stated that the Level II APC is a more appropriate placement, as the procedure is comparable in clinical and resource characteristics to CPT code 93307 (Echocardiography, transthoracic, real-time with image documentation (2D) with or without M-mode recording; complete) that CMS proposed to retain in APC 0269.

Response: We have a significantly greater number of single and "pseudo" single claims available for CPT code 93350 for this final rule with comment period than we had for the proposed rule because, in response to the request of commenters, we added CPT code 93017 (Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation or report) to the

final CY 2008 bypass list, as described in section II.A.1.b. of this final rule with comment period. By adding CPT code 93017 to the CY 2008 bypass list, we did not attribute any packaged services that may be on the claim to this procedure, and we were therefore able to create single and "pseudo" single claims from claims that would have otherwise been considered multiple procedure claims. The availability of additional claims for ratesetting and our final policy for paying for contrast and noncontrast echocardiography through different APCs also contribute to the differences between the final rule median costs and the proposed rule median costs for echocardiography CPT codes.

For CY 2008, we are establishing a new APC for echocardiograms with contrast as described in section II.A.4.c.(6) of this final rule with comment period, specifically APC 0128 (Echocardiogram with Contrast). The median cost of CPT code 93350 for contrast studies is approximately \$527, while the median cost of CPT code 93307 for contrast studies is approximately \$545. When these studies are performed with contrast in CY 2008, they will be reported with HCPCS codes C8928 (Transthoracic echocardiography with contrast, real-time with image documentation (2D), with or without M-mode recording, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report); and C8923 (Transthoracic echocardiography with contrast, real-time with image documentation (2D) with or without M-mode recording; complete), respectively. Both of these C-codes are assigned to new APC 0128 based on their clinical and resource comparability, with a CY 2008 median cost of approximately \$534.

For this final rule with comment period, we have over 88,000 single bills for noncontrast studies reported with CPT code 93350 that have an updated median cost of approximately \$374. This median cost is quite close to the final rule median cost of CPT code 93307 for noncontrast studies of approximately \$404. We agree with the commenters that CPT code 93350 for noncontrast studies is more appropriately placed in the Level II noncontrast APC that has a median cost of approximately \$401, and where CPT code 93307 is also assigned. The two procedures are clinically similar, both representing comprehensive transthoracic echocardiography services.

Therefore, after consideration of the public comments received, we are not

finalizing our proposal to assign noncontrast studies reported with CPT code 93350 to APC 0697, which has the new APC title of "Level I Echocardiogram Without Contrast Except Esophageal". Instead, we are retaining the assignment of CPT code 93350 for noncontrast studies to APC 0269, which has the new APC title of "Level II Echocardiogram Without Contrast Except Transesophageal," because we believe this procedure is clinically similar to other procedures in the Level II APC and the median costs indicate that the noncontrast studies in this APC require similar hospital resources as well. Contrast studies reported with the corresponding C-code to CPT code 93350, specifically C8928, are assigned to APC 0128, with a CY 2008 median cost of approximately \$534.

f. Coronary or Non-Coronary Atherectomy (APC 0082)

Currently, APC 0082 is titled "Coronary Atherectomy" and contains only two CPT codes: 92995 (Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; single vessel) and 92996 (Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)). We proposed to reconfigure APC 0082 for the CY 2008 OPSS by adding 11 CPT codes, most of which were for percutaneous atherectomy procedures, and to change its title to "Coronary or Non-Coronary Atherectomy", as shown in Addendum A to the proposed rule (72 FR 42838), to better reflect the composition of procedures that we proposed to assign to this APC. The CY 2008 proposed payment rate for APC 0082 was approximately \$5,654, while its CY 2007 payment rate is approximately \$4,438.

We received one public comment on the CY 2008 proposed reconfiguration of APC 0082. A summary of the public comment and our response follow.

Comment: A commenter objected to the proposed composition of APC 0082 on the basis that it includes both coronary and noncoronary atherectomy procedures, as a result of the proposed packaging of imaging supervision and interpretation CPT codes. The commenter stated that, as proposed, APC 0082 no longer contains services that are comparable clinically and with respect to resource use and, therefore, believed that the coronary and noncoronary services should not be

assigned to the same APC. The commenter indicated that treatment of peripheral vascular disease is more diffuse, requires a different approach, and utilizes different resources than treatment of coronary disease. The commenter noted that it could not determine if the proposed payment rate for APC 0082 is appropriate, due to the proposed packaging of imaging supervision and interpretation codes for the noncoronary atherectomy procedures, and questioned whether the claims data could accurately reflect the costs associated with these different procedures.

Response: We believe that there is sufficient clinical homogeneity among all the services that we proposed to assign to APC 0082 for the CY 2008 OPSS and that the resources that those services require are sufficiently similar to justify assigning coronary and noncoronary atherectomy procedures to the same clinical APC. The CY 2006 claims data show that CPT codes 92995 and 92996 are very uncommon services in the HOPD, as they have a total combined frequency of 159 services for CY 2006. Moreover, the median costs for these codes (approximately \$5,696 for CPT code 92995 and \$3,924 for CPT code 92996) are very comparable to the median costs for the two highest volume noncoronary atherectomy codes in APC 0082: CPT code 35493 (Transluminal peripheral atherectomy, percutaneous; femoral-popliteal), which has a total frequency of 8,473 and a median cost of approximately \$5,956; and CPT code 37204 (Transcatheter occlusion or embolization (e.g., for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), percutaneous, any method, non-central nervous system, non-head or neck), which has a total frequency of 5,789 and a median cost of approximately \$4,867. The CY 2008 OPSS median cost for APC 0082 (with correct devices, no token claims, and no claims with the "FB" modifier) is approximately \$5,506 and the total frequency of services in the APC is 18,357.

There are no HCPCS codes in APC 0082, as proposed, that would cause the APC to violate the 2 times rule. We believe that it is appropriate to reassign the noncoronary atherectomy procedures to APC 0082 because we believe that the clinical characteristics and resource costs are sufficiently similar to warrant their placement in the same APC with coronary atherectomy procedures. We recognize that the similar resource costs may result, to some extent, from the packaging of guidance and imaging supervision and interpretation services under the CY

2008 OPSS. However, even absent our proposal to increase packaging for the CY 2008 OPSS, the median cost of virtually all codes for procedural services contains some costs for packaged services. Moreover, the movement of codes from one APC to another occurs for a variety of reasons, including changes in packaging from one year to another. In addition, as discussed further in section II.A.2. of this final rule with comment period, we proposed to reconfigure certain clinical APCs for CY 2008 as a way to promote stability and appropriate payment for the services assigned to them, including low total volume APCs, with a particular focus on APCs with total frequencies of less than 1,000. APC 0082, as configured for CY 2007, includes only 232 services. Therefore, the reconfiguration of APC 0082 for CY 2008, as a result of increased costs that occur with more packaging and our effort to minimize the number of low volume APCs, among other reasons, is a normal occurrence in the course of updating the OPSS from one year to another.

After consideration of the public comment received, we are finalizing our CY 2008 proposal, without modification, to reconfigure APC 0082 as proposed, with a median cost of approximately \$5,506.

2. Gastrointestinal Procedures

a. Computed Tomographic Colonography (APC 0332)

For CY 2008, we proposed to reassign diagnostic computed tomographic colonography, specifically described by CPT code 0067T (Computed tomographic (CT) colonography (i.e., virtual colonoscopy); diagnostic), from APC 0333 (Computed Tomography without Contrast followed by Contrast) to APC 0332 (Computed Tomography without Contrast), with a proposed payment rate of approximately \$201.

We received several public comments concerning this proposal. A summary of the public comments and our response follow.

Comment: Several commenters requested that CMS continue the CY 2007 APC assignment for CPT code 0067T, specifically APC 0333, rather than reassign it to APC 0332 for CY 2008 as proposed.

Response: CPT code 0067T was implemented on January 1, 2005, and initially assigned to APC 0332. As part of our annual APC review process, we subsequently reassigned CPT code 0067T to APC 0333 in CY 2006 and continued this APC assignment in CY 2007. Based on analysis of the CY 2006

hospital outpatient claims data, we proposed to reassign CPT code 0067T to APC 0332 for CY 2008 based on clinical homogeneity and resource considerations. Specifically, our hospital outpatient claims data from CY 2006 showed a median cost of approximately \$164 for CPT code 0067T based on 1,421 single claims (of 1,904 total claims). Based on the median costs of the significant procedures assigned to APC 0332 for CY 2008, which range from \$164 to \$227, we believe that CPT code 0067T most closely resembles other noncontrast CT procedures also assigned to APC 0332. We do not agree with the commenters' recommendation that APC 0333 is the most appropriate APC assignment for CPT code 0067T because the median cost of approximately \$322 for APC 0333, which contains significant procedures with HCPCS-specific median costs ranging from about \$272 to \$359, is much higher than the median cost of CPT code 0067T. In addition, as discussed in section II.A.4.c. of this final rule with comment period, we are finalizing our proposal to package payment for all contrast agents in CY 2008. Because the CT scans assigned to APC 0333 for CY 2008 all include the administration of contrast and CT colonography is a noncontrast study, we believe 0067T is most appropriately assigned to APC 0332, where other noncontrast CT scans reside.

After consideration of the public comments received, we are finalizing, without modification, the proposed assignment of CPT code 0067T to APC 0332, with a median cost of about \$189 for CY 2008.

b. Laparoscopic Neurostimulator Electrode Implantation (APC 0130)

In the CY 2008 OPPTS/ASC proposed rule, we proposed to continue our CY 2007 assignment of CPT code 43647 (Laparoscopy, surgical; implantation or replacement of gastric neurostimulators electrodes, antrum) to APC 0130 (Level I Laparoscopy), with a proposed payment rate of approximately \$2,217. CPT code 43647 was a new code for CY 2007, so it received an interim final CY 2007 assignment to APC 0130, with a payment rate of approximately \$1,975. In addition, during the September 2007 meeting of the APC Panel, the Panel recommended that CMS reevaluate its decision to assign the device-dependent procedure described by CPT code 43647 to APC 0130 because the procedure requires a device and APC 0130 is not a device-dependent APC. We accepted the APC Panel recommendation and reassessed the proposed CY 2008 APC assignment of CPT code 43647 for this

final rule with comment period. We respond to this recommendation below.

We received a number of public comments on our interim final CY 2007 and proposed CY 2008 assignments of CPT code 43647 to APC 0130, both on the CY 2007 OPPTS/ASC final rule with comment period and on the CY 2008 OPPTS/ASC proposed rule. A summary of the public comments and our response follow.

Comment: A few commenters objected to our assignment of CPT code 43647 to APC 0130, stating that APC 0130 does not accurately reflect the clinical and cost characteristics of CPT code 43647. The commenters noted that APC 0130 includes procedures for implanting minor devices that have modest costs, while the laparoscopic implantation of gastric neurostimulator electrodes is an invasive procedure that is comparable to the surgical implantation of neurostimulator electrodes via incision or laminectomy procedures that are assigned to APC 0061 (Laminectomy or Incision for Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve). The commenters requested that we assign CPT code 43647 to APC 0061, which they believed more accurately reflects the clinical and resource aspects of this procedure. In addition, the commenters noted that if CPT code 43647 is reassigned to APC 0061, then all peripheral neurostimulator lead implantations would be assigned to the same APC.

Response: We have no hospital claims data for CPT code 43647 because the code was new for CY 2007. However, we agree with the commenters that CPT code 43647 would be expected to have device costs that are similar to other procedures assigned to APC 0061 for CY 2007 because all of these procedures implant neurostimulator electrodes. In particular, the device percentage of device-dependent APC 0061 is about 60 percent, so that assignment of CPT code 43647 to an APC in the laparoscopic APC series as proposed may not provide the most appropriate payment for the procedure. While CPT code 43647 involves a different surgical approach to neurostimulator electrode implantation, in comparison with the potentially more invasive procedures currently assigned to APC 0061, we still believe the procedure's clinical characteristics more closely resemble the other procedures assigned to APC 0061 than the minimally invasive percutaneous neurostimulator electrode implantation procedures assigned to APC 0040 (Percutaneous Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve). Therefore, we agree with

commenters that APC 0061 would be an appropriate APC assignment for CPT code 43647 for CY 2008, taking into account the procedure's clinical characteristics and expected hospital resource costs. We will reassign CPT code 43647 to APC 0061 for CY 2008, while we await the opportunity to review its CY 2007 claims data in preparation for the CY 2009 rulemaking cycle.

After consideration of the public comments received, we are not finalizing our CY 2008 proposal to assign CPT code 43647 to APC 0130. Instead, we will reassign CPT code 43647 to APC 0061, with a median cost of approximately \$5,213. In addition, we are changing the title of APC 0061 to "Laminectomy, Laparoscopy, or Incision for Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve" to better reflect all of the procedures assigned to the APC for CY 2008.

c. Screening Colonoscopies and Screening Flexible Sigmoidoscopies (APCs 0158 and 0159)

Since the implementation of the OPPTS in August 2000, screening colonoscopies and screening flexible sigmoidoscopies have been paid separately. In the CY 2007 OPPTS/ASC final rule with comment period (71 FR 68013), we implemented certain changes associated with colorectal cancer screening services provided in HOPDs. First, section 5113 of Pub. L. 109-171 amended section 1833(b) of the Act to add colorectal cancer screening to the list of services for which the beneficiary deductible no longer applies. This provision applies to services furnished on or after January 1, 2007. Second, sections 1834(d)(2) and (d)(3) of the Act require Medicare to pay the lesser of the ASC or OPPTS payment amount for screening flexible sigmoidoscopies and screening colonoscopies. For CY 2007, the OPPTS payment for screening colonoscopies, HCPCS codes G0105 (Colorectal cancer screening; colonoscopy on individual at risk) and G0121 (Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk), developed in accordance with our standard OPPTS ratesetting methodology, would have slightly exceeded the CY 2007 ASC payment of \$446 for these procedures. Consistent with the requirements set forth in sections 1834(d)(2) and (d)(3) of the Act, the OPPTS payment rates for HCPCS codes G0105 and G0121 were set equal to the CY 2007 ASC rate of \$446 effective January 1, 2007. This requirement did not impact the OPPTS payment rate for

screening flexible sigmoidoscopies (G0104, Colorectal cancer screening; flexible sigmoidoscopy) because Medicare did not make payment to ASCs for screening flexible sigmoidoscopies in CY 2007, so there was no payment comparison to be made for those services.

According to the policy for the revised ASC payment system as described in the August 2007 final rule for the revised ASC payment system (72 FR 42493), ASCs will be paid for screening colonoscopies based on their ASC payment weights derived from the related OPSS APC payment weights and multiplied by the final ASC conversion factor (the product of the OPSS conversion factor and the ASC budget neutrality adjustment). As an office-based procedure added to the ASC list of covered surgical procedures for CY 2008, ASC payment for screening flexible sigmoidoscopies will be capped at the CY 2008 MPFS nonfacility practice expense amount (72 FR 42511). Sections 1834(d)(2) and (d)(3) of the Act would then require that the CY 2008 OPSS payment rates for these procedures be set equal to their significantly lower ASC payment rates.

However, for CY 2008, we proposed to use the equitable adjustment authority of section 1833(t)(2)(E) of the Act to adjust the OPSS payment rates for screening colonoscopies and screening flexible sigmoidoscopies. Section 1833(t)(2)(E) of the Act provides that the Secretary shall establish adjustments, in a budget neutral manner, as determined to be necessary to ensure equitable payments under the OPSS. Sections 1834(d)(2) and (d)(3) of the Act regarding payment for screening flexible sigmoidoscopies and screening colonoscopies under the OPSS and ASC payment systems were established by Congress in 1997, many years prior to the CY 2008 initial implementation of the revised ASC payment system. The payment policies of the revised ASC payment system, as summarized in section XVI.C. of this final rule with comment period, make fundamental changes to the methodology for developing ASC payment rates based on certain principles, specifically that the OPSS payment weight relativity is applicable to ASC procedures and that ASC costs are lower than HOPD costs for providing the same procedures, that contradict the original assumptions underlying these provisions. According to the findings of the GAO in its report, released on November 30, 2006 and entitled "Medicare: Payment for Ambulatory Surgical Centers Should Be Based on the Hospital Outpatient Payment System" (GAO-07-86), the

payment groups of the OPSS accurately reflect the relative costs of procedures performed in ASCs just as well as they reflect the relative costs of the same procedures provided in HOPDs. Screening colonoscopies were among the top 20 ASC procedures in terms of volume whose costs were specifically studied by the GAO in its work that led to this conclusion. We see no clinical or hospital resource explanation why the OPSS relative costs from CY 2006 OPSS claims data for screening flexible sigmoidoscopies and screening colonoscopies would not provide an appropriate basis for establishing their payment rates under both the OPSS and the revised ASC payment system, according to the standard ratesetting methodologies of each payment system for CY 2008. If we were to pay for these screening procedures under the OPSS according to their ASC rates in CY 2008, we would significantly distort their payment relativity in comparison with other OPSS services. We believed and continue to believe it would be inequitable to pay these screening services in HOPDs at their ASC rates for CY 2008, thereby ignoring the relativity of their costs in comparison with other OPSS services which have similar or different clinical and resource characteristics. Therefore, for CY 2008 when we will be paying for screening colonoscopies and screening flexible sigmoidoscopies performed in ASCs based upon their standard revised ASC payment rates, we proposed to adjust the payment rates under the OPSS to pay for the procedures according to the standard OPSS payment rates. We believed that the application of sections 1834(d)(2) and (d)(3) of the Act produces inequitable results because of the revised ASC payment system to be implemented in CY 2008. We believed this proposal would provide the most appropriate payment for these procedures in the context of the contemporary payment policies of the OPSS and the revised ASC payment system.

We received several public commenters concerning this proposal. A summary of the public comments and our response follow.

Comment: Several commenters agreed that it would be inequitable to pay for screening colonoscopies and screening flexible sigmoidoscopies services in the HOPD at their lower ASC payment rate. They supported CMS's use of the equitable adjustment authority to adjust the OPSS payment rates for these services.

Response: We appreciate commenters' support of our proposal. We acknowledge that sections 1834(d)(2)

and (d)(3) of the Act would otherwise require that the CY 2008 OPSS payment rates for screening colonoscopies and screening flexible sigmoidoscopies be set equal to their significantly lower ASC payment rates. However, we continue to believe it is necessary to invoke the equitable adjustment authority provided by section 1833(t)(2)(E) of the Act to adjust the OPSS payment rates for these procedures in order to establish the most appropriate payment for these procedures in the context of the contemporary payment policies of the OPSS and the revised ASC payment system.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to pay for screening colonoscopies and screening flexible sigmoidoscopies under the OPSS at payment rates developed according to the standard OPSS ratesetting methodology.

3. Genitourinary Procedures

a. Cystoscopy With Stent (APC 0163)

For CY 2008, we proposed to continue assignment of CPT code 52282 (Cystourethroscopy, with insertion of urethral stent) to APC 0163 (Level IV Cystourethroscopy and other Genitourinary Procedures), with a proposed payment rate of approximately \$2,351. Payment for APC 0163 in CY 2007 is approximately \$2,147.

We received one public comment on our CY 2008 proposed assignment of CPT code 52282 to APC 0163. A summary of the public comment and our response follow.

Comment: One commenter indicated that the procedure described by CPT code 52282 is inappropriately assigned to APC 0163, and that it should be reassigned to a new device-dependent APC for CY 2008. According to the commenter, the procedure described by CPT code 52282 is dissimilar to the other procedures that map to APC 0163, both clinically and in terms of cost. The commenter stated that this procedure is the only procedure in APC 0163 that involves an implant. In addition, the commenter asserted that the APC's CY 2008 proposed payment of approximately \$2,351 is inadequate to cover hospitals' costs for performing this procedure, and that as a result, hospitals may limit beneficiary access to this treatment. According to the commenter, the urethral stent that is placed during these procedures is approximately \$4,200. The commenter also noted that other stent placement procedures have device-dependent

status so that adequate costs can be tracked. The commenter recommended that CMS create a new device-dependent APC for CPT code 52282 with a payment rate of at least \$4,000.

Response: In response to the concerns raised by the commenter, we reviewed the clinical characteristics and hospital costs from CY 2006 claims data for all procedures proposed for CY 2008 assignment to APC 0163. The APC median cost is approximately \$2,270, while CPT code 52282 has a median cost of approximately \$2,016, based on 291 single claims out of a total of 900 claims for the procedure. Because of the commenter's concern about whether the stent costs were appropriately reflected in the procedure's median cost, we compared the median costs of CY 2006 claims that include both CPT code 52282 for cystoscopy with implant of a stent and a Level II HCPCS C code for a stent, to CY 2006 claims that include CPT code 52282 but do not include a device C-code for a stent. While a stent is always necessary for the procedure and we require that hospitals report device HCPCS codes whenever they implant a device that is described by an available device code, we found that hospitals did not always report a stent HCPCS code with CPT code 52282. This is similar to our findings in other cases of device-related procedures. We believe, however, that hospitals are usually otherwise accounting for the device cost in their charges on claims for CPT code 52282, either by incorporating the charge into the charge for the procedure or reporting a charge on an uncoded revenue code line. We found only a small difference in median costs of approximately \$500 for procedures reported with and without a device C-code. This difference in costs is well within an appropriate range for the APC group. Furthermore, the median cost for the claims billed with CPT code 52282 and a stent C-code was approximately \$2,369, very close to the CY 2008 median cost of APC 0163 of approximately \$2,270. We also believe that CPT code 52282 clinically resembles the other cystourethroscopic procedures also assigned to APC 0163. Therefore, we do not believe that there are sufficient differences in clinical characteristics or resources required to perform the procedure described by CPT code 52282 relative to the other procedures assigned to APC 0163 to warrant reassignment of CPT code 52282 to a new, device-dependent APC as the commenter suggested.

After consideration of the public comment received, we are finalizing our proposal, without modification, to assign CPT code 52282 to APC 0163,

with a CY 2008 median cost of approximately \$2,270.

b. Percutaneous Renal Cryoablation (APC 0423)

For CY 2008, we proposed to assign CPT code 0135T (Ablation renal tumor(s), unilateral, percutaneous, cryotherapy) to APC 0423 (Level II Percutaneous Abdominal and Biliary Procedures), with a proposed payment rate of approximately \$2,810. This code was new in CY 2006, when it was assigned to APC 0163 (Level IV Cystourethroscopy and other Genitourinary Procedures) on an interim final basis, with a payment rate of \$1,999. In CY 2007, based on the APC Panel's recommendation made at the March 2006 APC Panel meeting, we reassigned CPT code 0135T from APC 0163 to APC 0423 with a payment rate of approximately \$2,297. We expected hospitals, when billing CPT code 0135T, to also report the device HCPCS code, C2618 (Probe, cryoablation), associated with the procedure.

We received several public comments concerning this proposal. A summary of the public comments and our responses follow.

Comment: Several commenters disagreed with our proposed APC assignment for CPT code 0135T. They indicated that the proposed payment rate for APC 0423 does not cover the cost hospitals incur for the cryoprobes used in the procedure. One commenter reported that the average cost of one probe is about \$1,000, while several commenters indicated that a single procedure, on the average, uses about 2.5 probes but may involve up to 4 probes depending on the size of the tumor and the probe needle selected. Other commenters argued that CPT code 0135T requires more resources than the other procedures currently assigned to APC 0423, specifically CPT codes 47382 (Ablation, one or more liver tumor(s), percutaneous, radiofrequency) and 50592 (Ablation, one or more renal tumor(s), percutaneous, unilateral, radiofrequency). Several commenters highlighted the variance in the use of probes used for the procedures assigned to APC 0423. Specifically, these commenters asserted that CPT code 0135T requires the use of multiple probes while the radiofrequency ablation procedures require only a single probe in a procedure. Further, the commenters highlighted the various median costs associated with the procedures assigned to APC 0423. That is, they pointed out that the proposed median cost of about \$3,520 for CPT code 0135T was 30 to 32 percent more than the median cost for CPT code

47382, which had a proposed median cost of about \$2,706, or CPT code 50592, which had a proposed median cost of about \$2,658. The commenters urged CMS to reevaluate the proposed payment rate for APC 0423 and use acquisition cost data provided by manufacturers, as many of the claims used to set the payment rate do not contain the required device. Alternatively, some commenters requested that CMS consider creating a unique clinical APC for renal cryoablation that would be designated as device-dependent to appropriately distinguish the resource costs associated with renal cryoablation from radiofrequency ablation procedures.

Response: Based on our comprehensive review of the procedures assigned to APC 0423, public comments, and the CY 2006 recommendation of the APC Panel regarding renal cryoablation, we believe that we have appropriately assigned CPT code 0135T to APC 0423 for CY 2008 based on clinical and resource considerations. We disagree with the commenters' argument regarding the clinical dissimilarity of the renal cryoablation procedure from the radiofrequency ablation procedures in APC 0423. The commenters to the CY 2007 OPPTS proposed rule (71 FR 68049) acknowledged that cryoablation and radiofrequency percutaneous ablation procedures for renal tumors are clinically similar. We continue to believe that CPT code 0135T is appropriately assigned to APC 0423 because it is placed with other procedures that share its clinical and resource characteristics. If hospitals use more than one probe in performing the renal cryoablation procedure, we expect hospitals to report this information on the claim and adjust their charges accordingly. Hospitals should report the number of cryoablation probes used to perform CPT code 0135T as the units of HCPCS code C2618 which describes these devices, with their charges for the probes. Since CY 2005, we have required hospitals to report device HCPCS codes for all devices used in procedures if there are appropriate HCPCS codes available. In this way, we can be confident that hospitals have included charges on their claims for costly devices used in procedures when they submit claims for those procedures.

Comment: Several commenters informed us that the hospital claims data that we used to set the proposed payment rate for CPT code 0135T do not accurately capture the full costs related to this procedure. They believed that the omission on the claims for the device C-code, specifically HCPCS code C2618,

for the cryoprobes leads to omission of cryoprobe cost information and undervaluation of the cost of the procedure. Some commenters reported the results of their study of our hospital outpatient claims data which revealed that of the 110 Medicare claims submitted for CPT code 0135T, only 44 single claims included the device HCPCS C-code (C2618) on the claims. Because the procedure cannot be performed without the cryoprobe device, these commenters strongly urged CMS to designate the renal cryoablation procedure as a "device-dependent" procedure and require hospitals to submit claims with the appropriate HCPCS C-code. One commenter who acknowledged its experience with hospital billing reported that hospitals are not motivated to report the cost of the devices on the claim form unless a HCPCS C-code is required by a code edit for claim submission. Several commenters requested that CMS designate CPT code 0135T as a "device-dependent" procedure to ensure that future claims data more accurately reflect the total cost of the procedure.

Response: We acknowledge the concerns raised by the commenters regarding the hospitals' failure to report the device HCPCS code C2618 with the procedure. We further examined our CY 2006 hospital outpatient claims data to determine the frequency of billing CPT code 0135T with and without HCPCS code C2618. Our analysis revealed that the final rule median cost of approximately \$3,446 based on 48 single bills used for ratesetting falls within the range for those procedures billed with and without the device HCPCS code C2618. Specifically, our data showed a median cost of about \$4,402 based on 17 single bills for procedures billed with the device HCPCS code C2618 and a median cost of about \$2,834 based on 31 single bills for those procedures billed without the device C-code. Even considering only those claims for CPT code 0135T with the device HCPCS code and higher median cost, CPT code 0135T would be appropriately assigned to APC 0423 based on that cost.

Further, we do not believe that we should create a claims processing edit in this instance. We create device edits, when appropriate, for procedures assigned to device-dependent APCs, where those APCs have been historically identified under the OPPI as having very high device costs. Because APC 0423 is not a device-dependent APC and the costs of the procedure with and without HCPCS code C2618 are reasonably similar, we

will not create edits. We remind hospitals that they must report all of the HCPCS codes that appropriately describe the items used to provide services, regardless of whether the HCPCS codes are packaged or paid separately.

After further analysis of our CY 2006 hospital outpatient claims data, the APC Panel recommendation from the March 2006 meeting, and consideration of the public comments received, we are finalizing our proposal, without modification, to assign CPT code 0135T to APC 0423 for CY 2008 with a median cost of approximately \$2,705.

For CY 2008, the CPT Editorial Panel decided to delete CPT code 0135T on December 31, 2007, and replace it with CPT code 50593 (Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy). The replacement CPT code 50593 will be assigned to APC 0423 effective January 1, 2008. Similar to its predecessor code, we expect hospitals to report both the device HCPCS code C2618 and CPT code 50593 to appropriately report the renal cryoablation procedure.

c. Prostatic Thermotherapy (APC 0163)

For CY 2008, we proposed to reconfigure certain clinical APCs to eliminate most of the low total volume APCs as an alternative to developing specific quantitative approaches to treating low total volume APCs differently for purposes of median calculation. We further concluded that there were other clinical APCs with higher volumes of total claims to which these low total volume services could be reassigned, while maintaining the continued clinical and resource homogeneity of the clinical APCs to which they would be newly reassigned. As a result, we eliminated certain APCs and reassigned the procedures associated with these APCs to other clinical APCs with higher volumes of claims. Prostatic thermotherapy procedures were assigned to APC 0675 (Prostatic Thermotherapy) for CY 2007, with a payment rate of approximately \$2,529. For CY 2008, we proposed to reassign CPT codes 53850 (Transurethral destruction of prostate tissue; by microwave thermotherapy) and 53852 (Transurethral destruction of prostate tissue; by radiofrequency thermotherapy) from APC 0675 to APC 0163 (Level IV Cystourethroscopy and other Genitourinary Procedures), with a proposed payment rate of approximately \$2,351. We proposed to eliminate APC 0675, which would otherwise have included only approximately 550 total services based on CY 2006 claims.

We received some public comments on the proposed deletion of APC 0675 and the reassignment of the prostatic thermotherapy procedures in APC 0675 to APC 0163. A summary of the public comments and our response follow.

Comment: Specifically, some commenters requested clarification from CMS on the reassignment of CPT codes 53850 and 53852 from APC 0675 to APC 0163, as reflected in Addendum B of the CY 2008 OPPI proposed rule. One commenter urged CMS to investigate whether these procedures were correctly assigned to APC 0163 as the procedures described by CPT codes 53850 and 53852 seemed more appropriate, in terms of clinical characteristics and resource costs, for assignment to APC 0429 (Level V Cystourethroscopy and other Genitourinary Procedures). The commenter recommended that the APC Panel discuss this issue at its next meeting to further review the data before the proposed change is finalized.

Response: As part of our annual review, we examine the APC assignments for all items and services under the OPPI for appropriate placements in the context of our proposed policies for the update year. This review involves careful and extensive analysis of our hospital outpatient claims data, as well as input from our medical advisors and the APC Panel and recommendations from the public. Based on our analysis of the hospital outpatient claims from CY 2006, the final median cost for CPT code 53850 is approximately \$2,482 based on 199 single claims (223 total), and the final median cost for CPT code 53852 is approximately \$2,894 based on 195 single claims (315 total). We agree with the commenter who recommended reassignment of these CPT codes to APC 0429, which has a median cost of approximately \$2,844 for CY 2008 and includes several other procedures to destroy prostate tissue. We believe that APC 0429 is the most appropriate assignment for both CPT codes based on clinical and resource considerations.

After consideration of the public comments received, we are modifying our proposal and finalizing the CY 2008 assignments of CPT codes 53850 and 53852 to APC 0429, with a median cost of approximately \$2,844.

d. Radiofrequency Ablation of Prostate (APC 0163)

For CY 2008, we proposed to delete APC 0675 (Prostatic Thermotherapy) and reassign the two CPT codes that mapped to this APC in CY 2007, CPT code 53850 (Transurethral destruction of prostate tissue; by microwave thermotherapy) and CPT code 53852

(Transurethral destruction of prostate tissue; by radiofrequency thermotherapy) to APC 0163 (Level IV Cystourethroscopy and other Genitourinary Procedures). The CY 2007 payment rate for APC 0675 is approximately \$2,529, and the CY 2008 proposed payment rate for APC 0163 was approximately \$2,351.

Comment: One commenter asserted that the proposed reassignment of CPT code 53852 to APC 0163 is not clinically appropriate or consistent with the resource costs of other procedures assigned to APC 0163. The commenter suggested that CMS reassign CPT code 53852 to APC 0429 (Level V Cystourethroscopy and other Genitourinary Procedures), with a CY 2008 proposed payment rate of approximately \$2,924. According to the commenter, CMS cost data showed that the median cost of CPT code 53852 is 26 percent higher than the median cost of the APC 0163 to which CMS proposed to reassign the procedure. The commenter stated that the clinical characteristics of the procedure described by CPT code 53852 are more similar to the procedure described by CPT code 52647 (Laser coagulation of the prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included if performed)), which maps to APC 0429, than the procedures that are included in APC 0163. Specifically, the commenter stated that both procedures can be done under direct visualization, placement of the energies are customized, and there is no incision or cutting of the tissues involved. The commenter also argued that CMS data on intraservice procedure times and the direct costs of clinical labor, supplies, and equipment indicate that CPT code 53852 should be reassigned to APC 0429 rather than to APC 0163.

Response: We examined the clinical characteristics and claims-based resource costs of all procedures proposed for assignment to APC 0163 and APC 0429 for CY 2008. We agree with the commenter that APC 0429 would be an appropriate assignment for CPT code 53852 for CY 2008. CPT code 53852 appears to be more closely related, both in terms of clinical characteristics and resource costs, to the laser surgery procedures assigned to APC 0429 than to many of the cystourethroscopy and transurethral resection procedures assigned to APC 0163. CPT code 53852, like some other procedures assigned to APC 0429, is a minimally invasive procedure for the

destruction of prostate tissue, and we believe the procedure room time and recovery period for the services would be relatively comparable.

After consideration of the public comments received, we are modifying our CY 2008 proposal and will reassign CPT code 53852 to APC 0429, with a median cost of approximately \$2,844.

e. Ultrasound Ablation of Uterine Fibroids With Magnetic Resonance Guidance (MRgFUS) (APC 0067)

Magnetic resonance guided focused ultrasound (MRgFUS) is a noninvasive surgical procedure that uses high intensity focused ultrasound waves to destroy tissue in combination with magnetic resonance imaging (MRI) guidance. Currently, the two Category III CPT codes for this procedure are 0071T (Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue) and 0072T (Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue), which were implemented on January 1, 2005.

In the CY 2006 OPPS proposed rule, we proposed to continue to assign both codes to APC 0193 (Level V Female Reproductive Proc). However, at the August 2005 APC Panel meeting, the APC Panel recommended that CMS work with stakeholders to assign CPT codes 0071T and 0072T to appropriate New Technology APCs. Based on our review of several factors, which included information presented at the August 2005 APC Panel meeting, the public comments received on the CY 2006 OPPS proposed rule, and our analysis of OPPS claims data for different procedures, we reassigned CPT code 0071T from APC 0193 to APC 0195 (Level IX Female Reproductive Proc) and CPT code 0072T from APC 0193 to APC 0202 (Level X Female Reproductive Proc) effective January 1, 2006, to reflect the higher level of resources we estimated were required when performing the MRgFUS procedures.

In the CY 2007 OPPS/ASC proposed rule, we proposed to continue to assign CPT code 0071T to APC 0195 and CPT code 0072T to APC 0202. We received comments on the CY 2007 proposed APC assignments recommending that we revise the APC assignments for CPT codes 0071T and 0072T. The commenters indicated that, while MRgFUS treats anatomical sites that are similar to other procedures assigned to APCs 0195 and 0202, the resources utilized differed dramatically. Several commenters recommended that the

most appropriate APC assignment for the MRgFUS procedures would be APC 0127 (Level IV Stereotactic Radiosurgery), based on their analyses of the procedures' resource use and clinical characteristics.

As we stated in both the CY 2006 OPPS final rule with comment period and the CY 2007 OPPS/ASC final rule with comment period, we believe that MRgFUS treatment bears a significant relationship to technologies already in use in HOPDs (70 FR 68600 and 71 FR 68050, respectively). The use of focused ultrasound for thermal tissue ablation has been in development for decades, and the recent application of MRI to focused ultrasound therapy provides monitoring capabilities that may make the therapy more clinically useful. We continue to believe that, although MRgFUS therapy is relatively new, it is an integrated application of existing technologies (MRI and ultrasound), and its technology resembles other OPPS services that are assigned to clinical APCs for which we have significant OPPS claims data. In the CY 2007 OPPS/ASC final rule with comment period (71 FR 68050), we explained our belief that retaining MRgFUS procedures in clinical APCs with other female reproductive procedures would enable us both to set accurate payment rates and to maintain appropriate clinical homogeneity of the APCs. Furthermore, we did not agree with commenters that MRgFUS procedures shared sufficient clinical and resource characteristics with cobalt-based stereotactic radiosurgery (SRS) to reassign them to that particular clinical APC 0127, where only the single specific SRS procedure was assigned for CY 2007 and which had a CY 2007 APC median cost of approximately \$8,461. Consequently, in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68051), we finalized payment for these procedures in APCs 0195 and 0202 as proposed.

Analysis of our hospital outpatient data for claims submitted for CY 2006 during the development of the proposed rule indicated that MRgFUS procedures were rarely performed on Medicare patients. As we stated in the CY 2006 OPPS final rule with comment period and the CY 2007 OPPS/ASC final rule with comment period, because treatment of uterine fibroids is most common among women younger than 65 years of age, we did not expect that there ever would be many Medicare claims for the MRgFUS procedures (70 FR 68600 and 71 FR 68050, respectively). For OPPS claims submitted from CY 2005 through CY 2006, our claims data showed that there

were only two claims submitted for CPT code 0071T in CY 2005 and one in CY 2006. We had no hospital claims for CPT code 0072T from either of those years.

At its March 2007 meeting, the APC Panel recommended that, for CY 2008, CMS reassign CPT codes 0071T and 0072T from APCs 0195 and 0202 to APC 0067 (Level III Stereotactic Radiosurgery, MRgFUS, and MEG), which had a proposed APC median cost of approximately \$3,870 for CY 2008. The APC Panel discussed its general belief that while the MRgFUS procedures might not be performed frequently on Medicare patients, CMS should pay appropriately for the procedures to ensure access for Medicare beneficiaries. In addition, following discussion of the potential for reassignment of the CPT codes to New Technology APCs, the APC Panel specifically recommended that the procedures be assigned to a clinical APC at this point in their adoption into clinical practice, instead of a New Technology APC. Furthermore, following publication of the CY 2007 OPPS/ASC final rule with comment period, we received input from interested individuals and organizations regarding the clinical and resource characteristics of MRgFUS procedures. Based on our consideration of all information available to us regarding the necessary hospital resources for the MRgFUS procedures in comparison with other procedures for which we have historical hospital claims data, for CY 2008 we proposed to accept the APC Panel's recommendation to reassign these services to clinical APC 0067, an APC that currently contains two linear accelerator-based stereotactic radiosurgery (SRS) procedures. We agreed with the APC Panel that these SRS procedures share sufficient clinical and resource similarity with the MRgFUS services, including reliance on image guidance in a single treatment session to ablate abnormal tissue, to justify their assignment to the same clinical APC. Unlike the cobalt-based SRS service that we concluded in the CY 2007 OPPS/ASC final rule with comment period was not similar to MRgFUS procedures based on clinical

and resource considerations, these linear accelerator-based SRS procedures are not performed solely on intracranial lesions and generally do not require immobilization of the patient's head in a frame that is screwed into the skull, thereby exhibiting characteristics more consistent with MRgFUS treatments. In addition, based on our understanding of the MRgFUS procedures described by the two CPT codes which differ only in the volume of uterine leiomyomata treated, we believed it would be most appropriate to assign both of these procedures to the same clinical APC, as recommended by the APC Panel. Therefore, for CY 2008 we proposed to reassign CPT codes 0071T and 0072T to APC 0067, with a proposed APC median cost of approximately \$3,870, which was reflected in Table 32 of the proposed rule (72 FR 42713).

We received several public comments on our CY 2008 proposal concerning MRgFUS procedures. A summary of the public comments and our responses follow.

Comment: Several commenters agreed with CMS's proposal to assign the MRgFUS procedures, specifically CPT codes 0071T and 0072T, to APC 0067 because the services share similarities, both clinically and with regard to resource costs, with other procedures also assigned to APC 0067. However, many commenters disagreed with the proposed payment rate of approximately \$3,918 for APC 0067. They recommended that MRgFUS be placed in APC 0127 (Level IV Stereotactic Radiosurgery, MRgFUS, and MEG), which had a proposed payment rate of approximately \$7,864, as they believed that this APC accurately reflected the hospital charges and costs for this procedure. The commenters believed that the proposed payment rate for APC 0067 was far below the costs incurred to provide MRgFUS procedures and did not accurately reflect the treatment planning component that is part of the MRgFUS procedure. Other commenters disagreed with the placement of MRgFUS services in an APC that historically had contained only SRS procedures. These same commenters argued that the MRgFUS procedure is not similar to SRS treatment delivery services based on clinical coherence and

resource utilization. Some commenters suggested that CMS reassign these procedures, as previously done in CY 2007, to a female reproductive procedure APC.

Response: As we stated in the CY 2006 OPPS final rule with comment period and the CY 2007 OPPS/ASC final rule with comment period, because treatment of uterine fibroids is most common among women younger than 65 years of age, we did not expect that there ever would be many Medicare claims for the MRgFUS procedures (70 FR 68600 and 71 FR 68050, respectively). Analysis of hospital outpatient data for claims submitted for CY 2006 indicates that MRgFUS procedures were rarely performed on Medicare patients. For OPPS claims submitted from CY 2005 through CY 2006, our claims data showed that there were only two claims submitted for CPT code 0071T in CY 2005 and one in CY 2006. We had no hospital claims for CPT code 0072T from either of those years. While we have no information from hospital claims regarding the costs of MRgFUS procedures, we continue to believe that the clinical and expected resource characteristics of MRgFUS procedures resemble the first or complete session LINAC-based SRS treatment delivery services that are also assigned to APC 0067. The APC Panel also recommended that MRgFUS procedures be assigned to that clinical APC, instead of a New Technology APC. While commenters pointed to specific differences in the technologies utilized for MRgFUS and SRS procedures, both services are noninvasive and utilize specialized equipment and image guidance in the targeted ablation of abnormal tissue during a lengthy treatment session. Therefore, we believe that the services are sufficiently similar to reside in the same clinical APC.

After consideration of the public comments received and the APC Panel recommendation at its March 2007 meeting, we are finalizing our proposal, without modification, to assign CPT codes 0071T and 0072T to APC 0067, with a CY 2008 median cost of approximately \$3,882. Table 18 lists the final APC median costs for the MRgFUS CPT codes.

TABLE 18.—FINAL CY 2008 APC ASSIGNMENTS OF MRGFUS PROCEDURES

HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	CY 2007 APC median cost	Final CY 2008 SI	Final CY 2008 APC	Final CY 2008 APC median cost
0071T	U/s leiomyomata ablate <200	T	0195	\$1,742	S	0067	\$3,882
0072T	U/s leiomyomata ablate >200	T	0202	\$2,534	S	0067	\$3,882

f. Uterine Fibroid Embolization (APC 0202)

Prior to January 1, 2007, a specific CPT code did not exist to describe uterine fibroid embolization. CPT guidance suggests that hospitals previously reported this procedure using CPT codes 37204 (Transcatheter occlusion or embolization (eg, for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), percutaneous, any method, non-central nervous system, non-head or neck) and 75894 (Transcatheter therapy, embolization, any method, radiological supervision and interpretation). In CY 2006, the combined APC payment for these two procedures was approximately \$2,504. Effective January 1, 2007, the CPT Editorial Panel created CPT code 37210 (Uterine fibroid embolization (UFE, embolization of the uterine arteries to treat uterine fibroids, leiomyomata), percutaneous approach inclusive of vascular access, vessel selection, embolization, and all radiological supervision and interpretation, intraprocedural roadmapping, and image guidance necessary to complete the procedure) to describe this procedure. In the CY 2007 OPPTS/ASC final rule with comment period (71 FR 68317), we provided an interim final assignment of CPT code 37210 to APC 0202 (Level VII Female Reproductive Procedures), with a CY 2007 payment rate of approximately \$2,642. For CY 2008, we proposed continued assignment of CPT code 37210 to APC 0202 (72 FR 42936), with a proposed payment rate of approximately \$2,753. Because this is a new code for CY 2007, the CY 2006 claims data, upon which we set CY 2008 payment rates, do not reflect use of this code.

At the September 2007 meeting of the APC Panel, the Panel recommended that CMS consider moving CPT code 37210 to another APC, such as APC 0067 (Level III Stereotactic Radiosurgery), with a CY 2008 proposed payment rate of approximately \$3,918, or APC 0229 (Transcatheter Placement of Intravascular Shunts), with a CY 2008 proposed payment rate of approximately \$5,713, to improve the clinical and resource homogeneity of the procedure within its assigned APC.

We received several public comments on the CY 2007 OPPTS/ASC final rule with comment period and the CY 2008 OPPTS/ASC proposed rule regarding the placement of CPT code 37210 in APC 0202. A summary of the public comments and our response follow.

Comment: Several commenters requested that CMS consider the APC

Panel's recommendation to reassign CPT code 37210 to a different APC. The commenters argued that the uterine fibroid embolization procedure is clinically dissimilar to the other procedures assigned to APC 0202, which do not require the implantation of a device and do not utilize imaging resources. The commenters suggested that CMS create a new APC for CPT code 37210 or reassign it to APC 0229. The commenters stated that the uterine fibroid embolization procedure is similar to the other vascular procedures included in APC 0229, both clinically and in terms of resource utilization. Specifically, the commenters noted that the uterine fibroid embolization procedure is similar to the revision of transvenous intrahepatic portosystemic shunts, described by CPT code 37183 (Revision of transvenous intrahepatic portosystemic shunt(s) (TIPS) (includes venous access, hepatic and portal vein catheterization, portography with hemodynamic evaluation, intrahepatic tract recanalization/dilatation, stent placement and all associated imaging guidance and documentation)), which maps to APC 0229. According to the commenters, both uterine fibroid embolization and the revision of transvenous intrahepatic portosystemic shunts involve device implantation, selective catheterization, and radiological supervision and interpretation. The commenters stated that the hospital resource consumption related to the devices used in uterine fibroid embolization are also similar to other procedures in APC 0229, including those described by CPT code 37205 (Transcatheter placement of an intravascular stent(s) (except coronary, carotid, and vertebral vessel), percutaneous; initial vessel) and CPT code 37206 (Transcatheter placement of an intravascular stent(s) (except coronary, carotid, and vertebral vessel), percutaneous; each additional vessel).

Response: We reviewed the clinical characteristics and claims-based costs of all procedures also proposed for assignment to APC 0202 for CY 2008, as well as the recommendation of the APC Panel from its September 2007 meeting. We do not believe that the procedure described by CPT code 37210 sufficiently resembles the services assigned to APC 0067, one of the possibilities recommended by the APC Panel, for that clinical APC to be an appropriate assignment. The stereotactic radiosurgery, magnetic resonance-guided focused ultrasound ablation, and magnetoencephalography services assigned to APC 0067 all are noninvasive procedures that do not

require vascular catheterization or the use of implantable devices. We examined the clinical characteristics and resource costs of procedures assigned to APC 0229 and agree with some of the commenters that this APC would be an appropriate assignment for CPT code 37210 for CY 2008 while we await claims data that will be available for the CY 2009 OPPTS update. CPT code 37210, like other procedures assigned to APC 0229, requires the targeted use of intravascular catheters, imaging guidance, and implantable devices, and we believe the procedure room time and recovery period for the services would be relatively comparable. CPT code 37210 appears to be more closely related, both in terms of clinical characteristics and resource costs, to the minimally invasive interventional procedures assigned to APC 0229 than to many of the open surgical repair procedures of the female reproductive system assigned to APC 0202. We are unable to assign CPT code 37210 to a new clinical APC for CY 2008 because we would have no claims data for the procedure upon which to base the payment rate for that APC. Therefore, we have adopted the recommendation of the APC Panel to consider moving CPT code 37210 to APC 0229 and will reassign the procedure to that APC for CY 2008.

After consideration of the public comments received, we are modifying our CY 2008 proposal and will reassign CPT code 37210 for uterine fibroid embolization to APC 0229, with a median cost of approximately \$5,570.

4. Nervous System Procedures

a. Chemodenervation (APC 0206)

For CY 2008, we proposed to reassign two chemodenervation procedures, specifically those described by CPT codes 64650 (Chemodenervation of eccrine glands; both axillae) and 64653 (Chemodenervation of eccrine glands; other area(s) (eg, scalp, face, neck), per day) to APC 0206 (Level II Nerve Injections), with a proposed payment rate of approximately \$265. These services are currently assigned to APC 0204 (Level I Nerve Injections) for CY 2007, with a payment rate of approximately \$139.

We received one public comment on our CY 2008 proposed assignment of chemodenervation procedures to APC 0206. A summary of the public comment and our response follow.

Comment: One commenter was concerned that CMS proposed to reassign CPT codes 64650 and 64653 to APC 0206 for CY 2008, but retained other chemodenervation procedures in

APC 0204, specifically CPT codes 64612 (Chemodenervation of muscle(s); muscle(s) innervated by facial nerve (eg, for blepharospasm, hemifacial spasm); 64613 (Chemodenervation of muscle(s); cervical spinal muscle(s) (eg, for spasmodic torticollis); and 64614 (Chemodenervation of muscle(s); extremity(s) and/or trunk muscle(s) (eg, for dystonia, cerebral palsy, multiple sclerosis). The commenter believed that CPT codes 64650 and 64653 for chemodenervation of eccrine glands should be grouped with the other three cited chemodenervation codes based on clinical and resource considerations. Of note, many commenters stated that if CMS proceeded with the packaging of electrodiagnostic guidance for chemodenervation procedures, a new distinct APC should be established for CPT codes 64612, 64613, and 64614, but CPT codes 64650 and 64653 were not included in that request.

Response: CPT codes 64650 and 64653 were new codes in CY 2006, which were initially assigned to APC 0204 on an interim final basis, and subsequently retained in that APC for CY 2007. For CY 2008, we proposed to reassign them to APC 0206 based on analysis of our first limited claims data from CY 2006. The final rule median cost for APC 0204 is approximately \$146 and for APC 0206 is approximately \$258. Our claims data showed a median cost of approximately \$221 for CPT code 64650 and a median cost of approximately \$235 for CPT code 64653 based on only 7 claims (of 11 total claims) and 15 claims (of 22 total claims), respectively. We agree with the commenter that these two chemodenervation procedures are clinically similar to the three procedures reported for chemodenervation of the muscles. Given the final CY 2008 packaging policy as discussed section II.A.4.c.(1) of this final rule with comment period that will package payment for the electrodiagnostic guidance for chemodenervation services, we would expect that the hospital resources required for CPT codes 64612 through 64614, where this guidance is sometimes used, would be at least as great as those required for chemodenervation of eccrine glands. In view of the limited claims for CY 2006 for CPT codes 64650 and 64653, we agree with the commenters that these two CPT codes should be assigned to the same APC as the other three chemodenervation procedures, specifically CPT codes 64612 through 64614, whose median costs of approximately \$125 through \$187 are

within the range of costs for other significant services also assigned to APC 0204, where these muscle chemodenervation procedures were proposed for assignment in CY 2008. We do not see any need to establish a new APC for CPT codes 64612 through 64614 for CY 2008 based on clinical and resource considerations. Therefore, we believe that CPT codes 64650 and 64653 should remain in APC 0204 for CY 2008. As we accumulate additional claims data for these procedures we will reassess their resource utilization and APC placement.

After consideration of the public comment received, we are modifying the CY 2008 proposed assignments of CPT codes 64650 and 64653 and retaining these two CPT codes in APC 0204, with a median cost of approximately \$146, rather than reassigning them to APC 0206 as proposed.

b. Implantation of Intrathecal or Epidural Catheter (APC 0224)

For CY 2008, we proposed to delete APC 0223 (Implantation or Revision of Pain Management Catheter) and reassign CPT code 62350 (Implantation, revision, or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without laminectomy) to APC 0224 (Implantation of catheter/reservoir/shunt). The procedure described by CPT code 62350 is the only procedure assigned to APC 0223 in CY 2007, with a payment rate of approximately \$1,896. The CY 2008 proposed payment for APC 0224 was approximately \$2,364.

We received one public comment on our CY 2008 proposal to reassign CPT code 62350 to APC 0224. A summary of the public comment and our response follow.

Comment: One commenter supported the proposal to delete APC 0223 and reassign CPT code 62350 to APC 0224. According to the commenter, this policy would increase resource homogeneity and clinical coherence.

Response: We appreciate the commenter's support and agree that the deletion of APC 0223 and the reassignment of CPT code 62350 to APC 0224 would increase resource homogeneity and clinical coherence of the resulting APC configuration by assigning multiple similar procedures for the implantation of nervous system shunts and catheters to the same clinical APC. We also believe this proposal is consistent with our overall strategy to encourage hospitals to use resources more efficiently by increasing the size of

the payment bundles, and by eliminating, whenever possible, APCs comprised of few procedures.

Therefore, we are finalizing our proposal, without modification, to delete APC 0223 and reassign CPT code 62350 to APC 0224, with a median cost of approximately \$2,282.

c. Implantation of Spinal Neurostimulators (APC 0222)

The CPT code for insertion of a spinal neurostimulator (63685, Insertion or replacement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling), which is currently assigned to APC 0222 (Implantation of Neurological Device), is reported for both the insertion of a nonrechargeable neurostimulator and a rechargeable neurostimulator. The costs of a nonrechargeable neurostimulator from the CY 2005 claims are packaged into the payment for APC 0222 in CY 2007. We believe rechargeable neurostimulators are currently most commonly implanted for spinal neurostimulation, consistent with the information provided during our consideration of the device for pass-through designation. However, in response to hospital requests, in CY 2007 we expanded our procedure-to-device edits to allow device category code C1820 (Generator, neurostimulator (implantable), with rechargeable battery and charging system) to be reported with two other procedures. These procedures are CPT code 64590 (Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling), assigned to APC 0222, and CPT code 61885 (Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array), assigned to APC 0039 (Level I Implantation of Neurostimulator).

The rechargeable neurostimulator reported as device category code C1820 has received pass-through payment since January 1, 2006, and its pass-through status will expire on January 1, 2008, as discussed further in section IV.B. of this final rule with comment period. During the 2 years of pass-through payment when device category code C1820 has been paid at a hospital's charges reduced to cost using the overall hospital CCR, we have applied a device offset when device category code C1820 is reported with a CPT code assigned to APCs 0039 or 0222 in order to remove the costs of the predecessor nonrechargeable device from the payment for APCs 0039 and 0222. This device offset ensures that no duplicate

device payment is made. As a general policy, under the OPSS we package payment for the costs of devices into the payment for the procedure in which they are used.

Because we traditionally have paid for a service package under the OPSS as represented by a HCPCS code for the major procedure that is assigned to an APC group for payment, we assess the applicability of the 2 times rule to services at the HCPCS code level, not at a more specific level based on the individual devices that may be utilized in a service reported with a single HCPCS code. If the use of a very expensive device in a clinical scenario causes a specific procedure to be much more expensive for the hospital than the APC payment, we consider such a case to be the natural consequence of a prospective payment system that anticipates that some cases will be more costly and others less costly than the procedure payment. In addition, very high cost cases could be eligible for outlier payment. As we note in section II.A.4. of this final rule with comment period, decisions about packaging and bundling payment involve a balance between ensuring some separate payment for individual services and establishing incentives for efficiency through larger units of payment. In the case of implantable nonpass-through devices, these devices are part of the OPSS payment package for the procedures in which they are used.

Stakeholders encouraged us to deem as two distinct procedures neurostimulator implantation involving rechargeable and nonrechargeable devices, so in the CY 2008 proposed rule we conducted a review of our CY 2006 claims data for APC 0222. This examination showed that the median costs of the associated neurostimulator implantation procedures are higher for rechargeable neurostimulator implantation than for nonrechargeable neurostimulator implantation, as shown in Table 35 of the proposed rule (72 FR 42716). However, the difference in costs (approximately \$6,500 based on proposed rule data) was not so great that retaining the procedures for the implantation of both types of devices for spinal or peripheral neurostimulation in APC 0222 would cause a 2 times violation, even if we were to consider them to be distinct procedures. The data did not justify creating a new clinical APC. In addition, to pay differentially would require us to establish one or more Level II HCPCS codes for reporting under the OPSS, because the three CPT codes for which device category code C1820 is currently an allowed device do not differentiate among the device

implantation procedures based on the specific device used. The creation of special Level II HCPCS codes for OPSS reporting is generally undesirable, unless absolutely essential, because it increases hospital administrative burden as the codes may not be accepted by other payers. Establishing separate coding and payment would reduce the size of the APC payment groups in a year in which we proposed to increase packaging under the OPSS through expanded payment groups.

Therefore, for CY 2008 we proposed to package the costs of rechargeable neurostimulators into the payment for the CPT codes that describe the services furnished. Our proposed median cost for APC 0222 was approximately \$12,162. We thought this approach to be the most administratively simple, consistent with the OPSS packaging principles, and supportive of encouraging hospital efficiency, while also providing appropriate packaged payment for implantable neurostimulators. In the proposed rule (72 FR 42716), we specifically requested that commenters submit comments that address how this specific device implantation situation differed from many other scenarios under the OPSS, where relatively general HCPCS codes describe procedures that may utilize a variety of devices with different costs, and payment for those devices is packaged into the payment for the associated procedures.

We received many public comments in response to this proposal. A summary of the public comments and our response follow.

Comment: The commenters urged CMS to pay differentially for rechargeable and nonrechargeable neurostimulators by creating separate APCs for the implantation procedures. They argued that the 2 times rule is a sufficient but not necessary condition for splitting APCs, and they identified other factors apart from the 2 times rule that should be taken into consideration in determining APC assignments. The commenters argued that the resources required to implant rechargeable versus nonrechargeable neurostimulators vary substantially, and that a combined APC for these procedures would result in a payment that is inequitable for both technologies and may lead to incentives for facilities to furnish only the less costly technology, even when the more expensive technology is clinically indicated for a particular patient. The commenters stated that the prospect of hospitals limiting patient access to rechargeable neurostimulators is particularly troubling because this technology represents a substantial

clinical improvement for select patients and is more cost-effective compared to nonrechargeable neurostimulators. The commenters argued that paying more initially for rechargeable neurostimulators would save the Medicare program and beneficiaries money in the long term, and improve overall patient care and satisfaction. The commenters also pointed to provider concentration as an additional factor that should be considered in APC assignments. In the case of neurostimulators, commenters provided data that showed only 27 percent of the total number of hospitals that implant nonrechargeable neurostimulators also implant rechargeable neurostimulators, and stated that an APC payment that combines payment for rechargeable and nonrechargeable neurostimulator implantation procedures may bias the payment system against those hospitals.

The commenters disagreed with the assertion in the proposed rule that creating a new APC dedicated solely to rechargeable neurostimulator implantation procedures would be inconsistent with OPSS packaging principles. According to the commenters, distinct treatment of rechargeable and nonrechargeable neurostimulators is not an issue of packaging, because the technologies are not ancillary services or products. Instead, the commenters characterized them as alternative treatments depending on patient needs, and indicated that neither rechargeable nor nonrechargeable neurostimulators represent subordinate, supportive, or optional services relative to the other. The commenters also disagreed that as rechargeable neurostimulators become the dominant device implanted for neurostimulation, the median costs of APC 0222 would increase to reflect the costs of the technology. According to their analysis of claims data, approximately 60 percent of the CY 2006 single procedure claims for APC 0222 were for implantation of gastric, sacral, or other types of peripheral nerve neurostimulator devices, all of which utilize and are indicated for nonrechargeable technologies only. Therefore, the commenters claimed that the median costs for APC 0222 would continue to be dominated by nonrechargeable neurostimulator implantation procedures, even as the utilization of rechargeable neurostimulators grows.

The commenters responded to the proposed rule request to describe how this specific device implantation situation differed from many other scenarios under the OPSS, where relatively general HCPCS codes describe

procedures that may utilize a variety of devices with different costs, and payment for those devices is packaged into the payment for the associated procedures. The commenters stated that they were unaware of other APCs that include devices where the magnitude of the cost difference among packaged services is as substantial as proposed for neurostimulators. They also asserted that, unlike other OPPS services, rechargeable neurostimulators can reduce long-term costs. Rather than promoting efficiency, they argued, the CMS proposal to group payment for rechargeable neurostimulator implantation procedures with procedures involving nonrechargeable neurostimulators would discourage efficient resource utilization. They submitted economic models presented at special society meetings that concluded rechargeable spinal neurostimulators should reduce the number of reimplantation procedures due to battery depletion as well as reduce the number of complications associated with reimplantation procedures, and ultimately result in cost savings to payers and the health system.

The commenters offered various coding mechanisms that would enable the creation of unique APCs for rechargeable and nonrechargeable neurostimulator implantation procedures. Some commenters urged CMS to create new Level II HCPCS codes to differentiate between neurostimulator implantation procedures involving nonrechargeable and rechargeable devices, assign those HCPCS codes to separate APCs, and discontinue the use of CPT codes describing these procedures for OPPS payment purposes. These commenters stated that any administrative burden posed by new Level II HCPCS codes would be outweighed by the higher payment the hospital would receive for rechargeable neurostimulators, and that this methodology is consistent with previous CMS actions to identify and allow specific payment for services of importance to Medicare. Other commenters, however, supported the CMS proposal not to implement new Level II HCPCS codes, arguing that it is too much of an administrative burden for hospitals to follow coding rules for Medicare patients that are inconsistent with CPT coding guidelines. They suggested that neurostimulator implantation procedures that contain the existing C-code for the rechargeable device (C1820) map to a new APC with a higher payment rate, while claims for neurostimulator implantation procedures with the existing C-code for

the nonrechargeable device (C1767) continue to map to APC 0222. Other commenters requested that CMS pursue new CPT codes through the AMA rather than create new Level II HCPCS codes.

Response: After consideration of the comments received on this issue, we have decided to reconfigure the APC assignments of procedures involving implantation of neurostimulators in order to improve the resource homogeneity of these APCs and ensure appropriate payment for both rechargeable and nonrechargeable neurostimulators. Effective January 1, 2008, CMS will implement a revised APC configuration for neurostimulator implantation procedures that groups payment for certain procedures mainly involving nonrechargeable neurostimulator technology (that is, cranial, sacral, gastric, or other peripheral neurostimulators) into two clinical APCs (APCs 0039 and 0315), while establishing a single APC for spinal neurostimulator implantation, which may commonly utilize either rechargeable or nonrechargeable technologies (APC 0222). Specifically, CMS will reassign CPT code 64590 for implantation of peripheral neurostimulators from APC 0222 to APC 0039, which already includes CPT code 61885 for implantation of single array cranial neurostimulators. CPT code 63685 for the implantation of spinal neurostimulators will be the only code remaining in APC 0222. By moving CPT code 64590 to APC 0039, all procedures that generally use nonrechargeable technologies only will be removed from ratesetting for spinal neurostimulator implantation, for which both rechargeable and nonrechargeable neurostimulators are indicated and commonly utilized. This APC reconfiguration will not affect CPT code assignment to APC 0315 (Level II Implantation of Neurostimulators), which will continue to include only CPT code 61886 (Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to two or more electrode arrays), although we will rename all three APCs to accommodate this new configuration. The revised APC configuration and naming convention for neurostimulator implantation APCs are summarized in Table 19 below. We note that this approach does not require hospitals to alter their coding practices in any way to conform to the new payment policy.

We agree with commenters that there are other important factors we consider when deciding on APC assignments besides the 2 times rule. In our CY 2001 final rule, we recognized that resource

homogeneity is a fundamental criterion for evaluating changes to APC assignments. We wrote in the CY 2001 final rule that "if the procedures within an APC require widely varying resources, it would be difficult to develop equitable payment rates. Aggregated payments to a facility that performed a disproportionate share of either the expensive or inexpensive procedures within an APC would be distorted. Further, the facility might be encouraged to furnish only the less costly procedures within the APC, resulting in a potential access problem for the more costly services" (65 FR 18457). In the case of the neurostimulator implantation APC configuration that we are adopting for CY 2008, two of the APCs contain only one procedure and one APC contains only two CPT codes, with very close CPT code-specific median costs, so these three APCs reflect great resource homogeneity. We do not consider the implantation of rechargeable and nonrechargeable neurostimulators to be different procedures, so we see no need to adopt differential coding and/or payment for procedures that depend on the device implanted. We believe our final APC configuration will provide appropriate payment for neurostimulator implantation procedures that ensures access to the appropriate neurostimulator technologies under the OPPS for Medicare beneficiaries.

Just as we do not want to provide incentives for the underutilization of rechargeable neurostimulators, we also do not want to provide incentives for the overutilization of this expensive technology. According to information provided by the manufacturers of rechargeable neurostimulators, these devices are clinically indicated in only a subset of patients for whom spinal neurostimulation is a treatment option. They estimate that approximately 35 percent of these patients are candidates for rechargeable spinal neurostimulators, although this proportion may be higher. Our claims data from CY 2006, the first year of device pass-through for the rechargeable devices, already indicate that rechargeable neurostimulators are being implanted in about one-third of the spinal neurostimulator implantation cases. We received comments from many providers, however, who stated that they use or wish to use the rechargeable technology in all of their patients. We believe that creating a separate APC for rechargeable neurostimulator implantation, as was recommended by commenters, could

create incentives for hospitals to use the more expensive rechargeable technology, even when the more expensive technology is not clinically indicated. In contrast to the commenters' perspective, we believe that packaging payment for implantable devices into the related procedures is an important packaging principle that contributes to the size of the OPPS payment bundles. Although our CY 2008 proposal was to newly package payment for certain ancillary and supportive services, many other items and types of services that are fundamental to a procedure's therapeutic effect have been historically packaged under the payment system and will remain packaged for CY 2008. A policy to provide different payments for procedures according to the devices implanted would not be consistent with our overall strategy to encourage hospitals to use resources more efficiently by increasing the size of the payment bundles. However, we believe that the revised neurostimulator APC configuration that we are adopting for

CY 2008 will allow us to calculate payment rates for procedures involving spinal neurostimulators that reflect changes in surgical practice based on clinical, rather than financial, considerations. To the extent that rechargeable neurostimulators may become the dominant device implanted for spinal neurostimulation over time based on the evolution of clinical practice, the median costs for the spinal neurostimulator implantation APC may increase to reflect contemporary utilization patterns.

In summary, for CY 2008, we are finalizing our proposal, with modification, for payment of neurostimulator implantation procedures. We will implement a revised APC configuration for neurostimulator implantation procedures that packages payment for procedures involving mainly nonrechargeable neurostimulator technology (*i.e.*, cranial, sacral, gastric, or other peripheral neurostimulators) into two APCs (APCs 0039 and 0315), while establishing a single APC for

spinal neurostimulator implantation, which commonly utilizes either rechargeable or nonrechargeable technologies (APC 0222). We believe that this revised APC configuration best serves the principles of a prospective payment system by following our standard practice of retaining a single CPT code for neurostimulator implantation procedures that does not distinguish between the implantation of rechargeable and nonrechargeable neurostimulators, into which the costs of both types of devices are packaged in relationship to their OPPS utilization. We also believe the revised APC configuration is both consistent with our standard ratesetting practice for technologies coming off pass-through status, and reflective of the clinical and resource considerations presented by commenters. Because no new codes or coding practices will be required, hospitals will not experience any change in the administrative burden associated with reporting neurostimulator implantation procedures.

TABLE 19.—CY 2008 APC CONFIGURATION FOR PAYMENT OF RECHARGEABLE AND NONRECHARGEABLE NEUROSTIMULATOR IMPLANTATION PROCEDURES

APC	Revised title for CY 2008	Previous title	HCPCS codes included in CY 2008 median cost	HCPCS descriptor	CY 2008 CPT code median cost	CY 2008 APC median cost
0039	Level I Implantation of Neurostimulator.	Level I Implantation of Neurostimulator.	61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.	\$12,799	\$11,732
			64590	Insertion or replacement of peripheral neurostimulator pulse generator or receiver, direct or inductive coupling.		
0222	Level II Implantation of Neurostimulator.	Implantation of Neurological Device.	63685	Insertion or replacement of spinal neurostimulator pulse generation or receiver, direct or inductive coupling.	\$15,150	\$15,150
0315	Level III Implantation of Neurostimulator.	Level II Implantation of Neurostimulator.	61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to two or more electrode arrays.	\$16,988	\$16,988

5. Nuclear Medicine and Radiation Oncology Procedures

a. Adrenal Imaging (APC 0391)

For CY 2008, we proposed to assign CPT code 78075 (Adrenal imaging, cortex and/or medulla) to APC 0391 (Level II Endocrine Imaging), with a proposed payment rate of about \$233. Currently, this procedure is assigned to the same clinical APC for CY 2007.

We received several public comments concerning this proposal. A summary of the public comments and our response follow.

Comment: Some commenters requested that CMS recognize this code

as a high intensity multiday imaging procedure and reassign CPT code 78075 to APC 0408 (Level III Tumor/Infection Imaging), along with another multiday tumor imaging procedure code CPT code 78804 (Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); whole body, requiring two or more days imaging).

Response: Based on our review of the costs and clinical characteristics of CPT code 78075, we agree with the commenters that this procedure is similar to CPT code 78804, in terms of clinical homogeneity and resource costs.

Both procedures require nuclear medicine imaging several days following the injection of a diagnostic radiopharmaceutical. We note that these services are nuclear medicine procedures and, therefore, their final rule median costs are calculated according to the temporary special methodology that relies on the subset of claims reporting coded diagnostic radiopharmaceuticals, as described in section II.A.4.c. of this final rule with comment period. Our claims data from CY 2006 showed that the median cost for CPT code 78075 is approximately \$954 based on 124 single claims for

ratesetting, which is relatively similar to the median cost of approximately \$1,194 for the sole procedure code 78804 proposed for assignment to APC 0408. In contrast, the HCPCS-specific median costs for the individual significant procedures in APC 0391 range from approximately \$201 to \$243, resulting in an APC median cost of approximately \$217. The median cost of APC 0391 is significantly lower than the APC 0408 median cost of approximately \$969 and the CPT code 78075 median cost of approximately \$954.

After considering the public comments received, we are modifying our proposal and are reassigning CPT code 78075 to APC 0408, with a CY 2008 median cost of approximately \$969, rather than to APC 0391 as proposed.

b. Injection for Sentinel Node Identification (APC 0389)

For CY 2008, we proposed to assign the sentinel node identification procedure, specifically described by CPT code 38792 (Injection procedure; for identification of sentinel node), to APC 0389 (Level I Non-imaging Nuclear Medicine), with a proposed payment rate of approximately \$101. Currently, this procedure is assigned to the same clinical APC for CY 2007.

We received several public comments on our CY 2008 proposed assignment of CPT code 38792 to APC 0389. A summary of the public comments and our responses follow.

Comment: Some commenters recommended that CPT code 38792 be reassigned from APC 0389 to APC 0392 (Level II Non-imaging Nuclear Medicine), which had a proposed payment rate of approximately \$209. The commenters indicated that an injection for sentinel node identification is more resource intensive, as corroborated by the CMS hospital outpatient claims data, than other procedures also assigned to APC 0389. These commenters requested that CMS reassign CPT code 38792 to APC 0392 for CY 2008.

Response: Based on our review of the costs and clinical characteristics of CPT code 38792, we agree with the commenters that this procedure is most similar to those procedures assigned to APC 0392 for CY 2008. Our claims data from CY 2006 showed that the median cost for CPT code 38792 is approximately \$174 based on 390 single claims available for ratesetting, which is significantly higher than the median cost of approximately \$114 for APC 0389. The median cost of APC 0392 of \$183, which contains nuclear medicine procedures and, therefore, is calculated

according to the special methodology described in section II.A.4.c. of this final rule with comment period, is more consistent with the hospital resources required to perform CPT code 38792.

After consideration of the public comments received, we are modifying our proposal and reassigning CPT code 38792 to APC 0392, with a CY 2008 median cost of approximately \$183, rather than to APC 0389 as proposed.

c. Myocardial Positron Emission Tomography (PET) Scans (APC 0307)

From August 2000 to December 31, 2005, under the OPPS, we assigned one clinical APC to all myocardial positron emission tomography (PET) scan procedures, which were reported with multiple G-codes through March 31, 2005. Under the OPPS, effective April 1, 2005, myocardial PET scans were reported with three CPT codes, specifically CPT codes 78459 (Myocardial imaging, positron emission tomography (PET), metabolic evaluation), 78491 (Myocardial imaging, positron emission tomography (PET), perfusion; single study at rest or stress), and 78492 (Myocardial imaging, positron emission tomography (PET), perfusion; multiple studies at rest and/or stress). From April 1, 2005 through December 31, 2005, these three CPT codes were assigned to one APC, specifically APC 0285 (Myocardial Positron Emission Tomography (PET)), with a payment rate of approximately \$736. In CY 2006, in response to the public comments received on the CY 2006 OPPS proposed rule, and based on our claims information, myocardial PET services were assigned to two clinical APCs for the CY 2006 OPPS. The CPT codes for the single scans, specifically 78459 and 78491, were assigned to APC 0306 (Myocardial Positron Emission Tomography (PET) Imaging, Single Study, Metabolic Evaluation) with a payment rate of approximately \$801, and the multiple scan CPT code 78492 was assigned to APC 0307 (Myocardial Positron Emission Tomography (PET) Imaging, Multiple Studies) with a payment rate of approximately \$2,485, effective January 1, 2006. However, analysis of the CY 2005 claims data that were used to set the payment rates for CY 2007 revealed that when all the myocardial PET scan procedure codes were combined into a single clinical APC, as they were prior to CY 2006, the APC median cost for myocardial PET services was very similar to the median cost of their single CY 2005 clinical APC. Further, our analysis revealed that the updated differential median costs of the single and multiple study procedures no longer supported the

two-level APC payment structure. Therefore, for CY 2007, CPT codes 78459, 78491, and 78492, were assigned to a single clinical APC, specifically APC 0307, which was renamed "Myocardial Positron Emission Tomography (PET) Imaging," with a median cost of approximately \$727.

At its March 2007 meeting, the APC Panel recommended that CMS reassign CPT code 78492 to its own clinical APC, to distinguish this multiple study procedure that the APC Panel believed would require greater hospital resources from less resource intensive single study procedures. However, as indicated in the CY 2008 proposed rule (72 FR 42713), we did not accept the APC Panel's recommendation because, consistent with our observations from the CY 2005 claims data, our CY 2006 claims data available for the proposed rule did not support the creation of a clinical APC for CPT code 78492 alone. Analysis of the latest CY 2006 claims data continued to support a single level APC payment structure for the myocardial PET scan procedures because very few single scan studies were performed and we believed single and multiple scan procedures were clinically similar. Our claims data available for the proposed rule showed a total of 2,547 procedures reported with the multiple scan CPT code 78492. Alternatively, our claims data showed only a combined total of 249 procedures reported with the single scan CPT codes 78459 and 78491, less than 10 percent of all studies reported. A similar distribution was observed in the single bills available for ratesetting.

Similar to findings from the CY 2005 data, as we discussed in the proposed rule, our CY 2006 claims data revealed that more hospitals were not only providing multiple myocardial PET scan services, but most myocardial PET scans were multiple studies. Further, our most recent data analysis for this final rule with comment period revealed that multiple myocardial PET scan services were commonly performed in the same hospital encounter with a cardiovascular stress test, specifically CPT code 93017 (Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report).

In the CY 2008 OPPS/ASC proposed rule, we indicated our belief that the assignment of CPT codes 78459, 78491, and 78492 to a single clinical APC for CY 2008 was still appropriate because the CY 2006 claims data did not support a resource differential among significant

myocardial PET services that would necessitate the placement of single and multiple PET scan procedures into two separate clinical APCs. Therefore, we proposed to continue to assign both the single and multiple myocardial PET scan procedure codes to APC 0307, with a proposed APC median cost of approximately \$2,678 for CY 2008. We noted that the proposed CY 2008 median cost of APC 0307 was significantly higher than its CY 2007 median cost, in part because of our proposed CY 2008 packaging approach discussed in detail in section II.A.4.c.(5) of this final rule with comment period that would package payment for diagnostic radiopharmaceuticals into the payment for their related diagnostic nuclear medicine studies, such as myocardial PET scans. The myocardial PET scan CPT codes and their proposed CY 2008 APC assignments were displayed in Table 33 of the proposed rule, which has been reproduced as Table 20 below, and updated to show the final status indicators, APC assignments, and median costs for these services.

We received a number of public comments concerning our proposed payment for myocardial PET scans. A summary of the public comments and our response follow.

Comments: Some commenters disagreed with our proposal to assign CPT codes 78459, 78491, and 78492 to a single clinical APC even though the CY 2006 claims data did not support a resource differential. They requested that CMS separate single (rest or stress) from multiple (rest and stress) PET myocardial perfusion imaging studies. Specifically, these commenters requested that CMS assign the single myocardial PET codes, CPT codes 78459 and 78491, to APC 0307, and create a new clinical APC for CPT code 78492, which describes the multiple myocardial PET scan procedure. The commenters believed that maintaining the multiple myocardial PET scan in the same APC as the single myocardial PET scans significantly underpaid hospitals

for providing multiple myocardial PET scan procedures. They reported that multiple myocardial PET procedures require greater hospital resources than single myocardial PET scans.

Response: Based on our review of the hospital outpatient claims data from CY 2005 and CY 2006, as well as the clinical characteristics of CPT code 78492, we do not agree that we should establish a new clinical APC solely for the multiple myocardial PET scans. Our claims data for this final rule with comment period showed a total of 2,808 procedures reported with the multiple scan CPT code 78492. Conversely, our claims data showed only a combined total of 286 procedures reported with the single scan CPT codes 78459 and 78491.

We note that our final median cost for this APC is approximately \$1,384, which is significantly lower than the proposed rule median cost for the APC. According to our final ratesetting policies in which we included CPT code 93017 on the bypass list as discussed in section II.1.b of this final rule with comment period, we based APC 0307's final median cost on 1,832 single claims out of 3,094 CY 2006 claims for myocardial PET procedures. Due to our bypassing of CPT code 93017 for the cardiovascular stress test commonly reported with myocardial PET scans, we were able to use almost twice the number of claims to develop the final median cost based on claims from a large number of hospitals in comparison with the proposed rule, and almost all of those additional single claims were for multiple myocardial PET scan services. As discussed in section II.A.4.c.(5) of this final rule comment period, the final median cost for APC 0307 was also calculated only from those claims for myocardial PET scan procedures that also contained a HCPCS code for a diagnostic radiopharmaceutical. The median cost of approximately \$1,384 compares favorably to our CY 2007 estimated average total payment of \$1191 for these services, consisting of approximately

\$731 for the scan (APC 0307) and approximately \$460 (average estimate of charges reduced to cost) for the commonly used diagnostic radiopharmaceutical A9555 (Rubidium Rb-82-diagnostic, per study dose, up to 60 millicuries). Therefore, we believe that the final median cost of APC 0307 for the scans and associated diagnostic radiopharmaceuticals appropriately reflects the hospital resources associated with providing myocardial PET scans to Medicare beneficiaries in cost-efficient settings and is adequate to ensure appropriate access to these services for Medicare beneficiaries.

The CY 2008 median cost for APC 0307 of approximately \$1,384 is very similar to the median cost of CPT code 78492 of \$1,467, so we do not believe that the assignment of the relatively small number of generally lesser cost single scan claims to APC 0307 significantly reduces the payment rate for multiple scan studies. In addition, as discussed in section II.A.2. of this final rule with comment period, we are attempting to reduce the number of low volume APCs under the OPPS to promote the stability of payment rates. If we were to create a new clinical APC for multiple myocardial PET scans, APC 0307 for single scan studies would become a very low volume APC. We continue to believe that the assignment of CPT codes 78459, 78491, and 78492 to a single clinical APC for CY 2008 remains appropriate because the CY 2006 claims data do not support a resource differential among significant myocardial PET services that would necessitate the placement of single and multiple PET scan procedures into two separate clinical APCs.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to provide payment for all myocardial PET scans through APC 0307, with a CY 2008 median cost of approximately \$1,384, as shown in Table 20.

TABLE 20.—FINAL CY 2008 APC ASSIGNMENTS FOR MYOCARDIAL PET SCANS

HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	CY 2007 APC median cost	Final CY 2008 SI	Final CY 2008 APC	Final CY 2008 APC median cost
78459	Heart muscle imaging (PET)	S	0307	\$727	S	0307	\$ 1,384
78491	Heart image (pet), single	S	0307	\$727	S	0307	\$ 1,384
78492	Heart image (pet), multiple	S	0307	\$727	S	0307	\$ 1,384

d. Nonmyocardial Positron Emission Tomography (PET) Scans (APC 0308)

For CY 2008, we proposed to continue to assign the nonmyocardial PET scans to APC 0308 (Non-Myocardial Positron Emission Tomography (PET) Imaging), with a proposed payment rate of approximately \$1,107, specifically CPT codes 78811 (Tumor imaging, positron emission tomography (PET); limited area (eg, chest, head/neck)), 78812 (Tumor imaging, positron emission tomography (PET); skull base to mid-thigh)), 78813 (Tumor imaging, positron emission tomography (PET); whole body)), and 78608 (Brain imaging, positron emission tomography (PET); metabolic evaluation). We note that this proposed payment will include payment for the diagnostic radiopharmaceuticals used in the PET scans. APC 0308 will also include concurrent PET/CT procedures. Refer to section III.C.2.a. of this final rule with comment period for further discussion of the CY 2008 OPPS assignment of concurrent PET/CT procedures.

We received several public comments concerning this proposal. A summary of the public comments and our responses follow.

Comment: Several commenters agreed with the placement of CPT codes 78811, 78812, and 78813 in APC 0308; however, some commenters requested that CMS reassign CPT code 78608 to a new clinical APC for PET brain imaging.

Response: We disagree with the commenters' suggestion that we should create a separate clinical APC for CPT code 78608. Brain PET scan services have historically been assigned to the same APCs as other nonmyocardial PET services for a number of years, initially to the same New Technology APCs and for CY 2007 to the same clinical APC. Analysis of our hospital outpatient claims data from CY 2006 reveals that the median cost of approximately \$1,046 for CPT code 78608 falls within the range of the HCPCS-specific median costs, approximately \$1,004 to \$1,240, for the other PET procedures also assigned to APC 0308. We are not convinced that separating nonmyocardial PET scans according to the body site being examined is necessary for clinical homogeneity, and the result of such a distinction would be a single CPT code in one APC. The OPPS is a prospective payment system that provides payment for groups of services that share clinical and resource characteristics. We believe that PET scans for tumor imaging and brain imaging are similar in both respects and are appropriately assigned to the same clinical APC.

After considering the public comments received, we are finalizing our proposal, without modification, including assignment of CPT code 78608 to APC 0308, with a CY 2008 median cost of approximately \$1,044.

e. Proton Beam Therapy (APCs 0664 and 0667)

For CY 2008, we proposed to pay for the following four CPT codes for proton beam therapy: 77520 (Proton treatment delivery; simple, without compensation); 77522 (Proton treatment delivery; simple, with compensation); 77523 (Proton treatment delivery; intermediate); and CPT 77525 (Proton treatment delivery; complex). We proposed to continue to assign the simple proton beam therapy procedures to APC 0664 (Level I Proton Beam Radiation Therapy), with a proposed median cost of approximately \$845, and the intermediate and complex proton beam therapy procedures to APC 0667 (Level II Proton Beam Radiation Therapy), with a proposed median cost of approximately \$1,012. The CY 2007 payment rates for these APCs are approximately \$1,161 and \$1,389, respectively. We also proposed to make an exception to the 2 times rule for APC 0664, as we did in CYs 2006 and 2007.

We received several public comments concerning this proposal. A summary of the public comments and our responses follow.

Comment: One commenter expressed concern that the CY 2008 proposed payment rates for APCs 0664 and 0667 are approximately 27 percent lower than the CY 2007 payment rates for these same APCs. The commenter characterized proton beam therapy as an extremely complex and expensive technology that is currently offered in only two hospitals. The commenter asked CMS to reevaluate the claims data and its analysis of the median costs contained in those claims data for errors. The commenter asserted that if the data and rate calculations were verified as valid, CMS should take into consideration that for any service provided by only two hospitals, the payment rates for the service will be highly dependent on the idiosyncrasies of the billing and charging practices of those two facilities. The commenter stated that a 27 percent reduction in payment would discourage, if not eliminate, the adoption of this technology by other providers. In addition, the commenter offered support for the proposal to designate APC 0664 as an exception to the 2 times rule for CY 2008.

Another commenter reviewed its proton beam therapy claims, charges,

and cost data, and determined that the CY 2008 proposed median costs for APCs 0664 and 0667 appropriately reflect the cost of this technology.

Response: In response to one commenter's concern about the validity of our data and our ratesetting analyses, we examined the claims and cost reports for proton beam therapy and verified our calculations. Consistent with the other commenter's examination of its own claims, charges, and costs, we found both the data and our calculation of the median costs to be accurate for APCs 0664 and 0667. We note that the median costs for relatively low volume APCs, such as APCs 0664 and 0667, often fluctuate from year to year, in part due to the variability created by a small number of claims. We agree with the commenter that because our standard ratesetting methodology is based on OPPS claims, the payment rates for those services provided by only a few hospitals to Medicare beneficiaries are dependent on the particular costs and charging practices of that small subset of hospitals paid for the services under the OPPS. Therefore, the small number of hospitals providing proton beam therapy also may contribute to additional variation in payment rates as those hospitals' charging and cost reporting practices evolve over time. As more hospitals adopt this technology, we expect that the fluctuation in payment for APCs 0664 and 0667 will be moderated by the increased number of observations for similar services and the incorporation of claims from a larger number of hospitals in the ratesetting process.

We note that neither of these APCs violate the 2 times rule based on the CY 2008 final rule data because the volume of CPT code 77520 is such a small percentage of claims for APC 0664. The law permits exceptions to the 2 times rule for services that are low volume, which we generally have considered as having a single bill frequency that is less than or equal to 1,000, or less than or equal to 99 if the service constitutes less than 2 percent of the single bill frequency for an APC. CPT code 77520 has a single bill frequency of 188 in the CY 2008 OPPS data and constitutes only 1 percent of the single claims in the APC. Therefore, there is no 2 times violation in APC 0664.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to assign CPT codes 77520 and 77522 to APC 0664, with a median cost of approximately \$807, and to assign CPT codes 77523 and 77525 to APC 0667, with a median cost of approximately \$965.

6. Ocular and Ear, Nose, and Throat Procedures

a. Amniotic Membrane for Ocular Surface Reconstruction (APC 0244)

We proposed to assign HCPCS code V2790 (Amniotic membrane for surgical reconstruction, per procedure) status indicator "N" (packaged) for CY 2008 and to assign its related CPT procedure codes to APC 0244 (Corneal Transplant). The proposed status indicators for the item and procedures and the proposed APC assignments for the procedures were the same as their CY 2007 OPSS treatment.

We received several comments on the proposed OPSS treatment of HCPCS code V2790 for CY 2008. A summary of the public comments and our response follow.

Comment: Several commenters requested that CMS consider assigning a status indicator of "F" (paid at reasonable cost) to HCPCS code V2790 and creating a separate APC for amniotic membrane transplantation procedures that includes the costs of amniotic membrane tissue. They compared V2785 (Processing, preserving and transporting corneal tissue) and V2790, noting a difference in payment policy and status indicator assignments for the two types of tissues used for ocular surface transplant. That is, HCPCS code V2785, which is assigned status indicator "F" and HCPCS code V2790, which is assigned status indicator "N," are not treated similarly with regard to status indicator assignments and OPSS payment policy. Payment for items and services assigned status indicator "N" is packaged into payment for the associated procedures, while payment for items and services with status indicator "F" is made at reasonable cost, not under the OPSS. Another commenter requested that CMS reassign the CPT procedure codes associated with the amniotic tissue transplant from APC 0244 to a separate APC. This commenter indicated that the source tissue is not bundled into the payment for every CPT code in APC 0244, only the amniotic membrane tissue.

In addition, several commenters were concerned that paying separately for corneal tissue and not for amniotic membrane tissue could create a competitive disadvantage and a financial disincentive for hospitals to treat ocular surface diseases using amniotic membrane tissue and ultimately would impede beneficiary access to this ocular reconstructive procedure. Some commenters indicated that HCPCS code V2790 and its related procedure code, specifically CPT code

65780 (Ocular surface reconstruction; amniotic membrane transplantation), are not adequately represented in hospital claims data. Despite instructions from CMS that packaged items and services should be reported on claims, some commenters believed that hospitals often fail to report HCPCS code V2790 because payment for HCPCS code V2790 is packaged with its related procedure code. They argued that the underreporting of the use of amniotic membrane tissue, which includes the costs of procuring, processing, storing, and distributing the product, leads to inadequate payment for CPT code 65780. Some commenters recommended that CMS establish claims processing edits to ensure the presence of the tissue HCPCS code and a charge for the item on claims for the ocular reconstruction procedure. One commenter indicated that the costs for amniotic membrane tissue can vary widely, similar to corneal tissue, and that the procurement of the tissue adds to the highly variable costs because hospitals require different sized tissues to accommodate various treatment and patient requirements. These commenters requested that CMS reassign HCPCS code V2790 from status indicator "N" to "F" and also create a separate APC specifically for amniotic membrane transplantation procedures for CY 2008.

Response: The OPSS has provided separate payment for corneal tissue acquisition at reasonable cost since the beginning of the OPSS, due to the highly variable corneal tissue processing fees required for eye banks to provide safe corneal tissue from donors as needed for transplant, through special distribution channels. These costs may vary substantially and unpredictably, depending on philanthropic and in-kind service contributions to eye banks that vary from community-to-community and from year-to-year. Our understanding is that amniotic membrane retrieved from donated placental tissues is a processed, cryopreserved, and commercially marketed product used for ocular reconstruction that may be stocked and stored by hospitals. Unlike corneal tissue, we believe that amniotic tissue is a supply with stable and predictable costs. We do not consider the circumstances of amniotic tissue to be like those of corneal tissue, and consider it appropriate to continue to package the payment for amniotic tissue into payment for its related procedure code.

We examined CY 2008 proposed rule claims, derived from CY 2006, for CPT code 65780, with and without HCPCS

code V2790. While most claims did not specifically include HCPCS code V2790, the median costs for claims with and without HCPCS code V2790 were reasonably close and consistent with the costs of other services assigned to APC 0244. Specifically, claims with HCPCS code V2790 had a median cost of approximately \$2,553, while claims without HCPCS code V2790 had a median cost of approximately \$2,063. The median line-item cost of HCPCS code V2790 was \$506, relatively consistent with the difference in cost between the claims with and without HCPCS code V2790. Based on our analysis, the proposed rule median cost of approximately \$2,409 for all procedures in APC 0244, which would not include the costs of corneal tissue but would incorporate the costs of amniotic membrane tissue, is very close to the median cost of the amniotic tissue transplant procedure claims that include the HCPCS code for amniotic membrane tissue. The CY 2008 APC 0244 final rule median cost of approximately \$2,359 is consistent with the APC's proposed rule cost.

Based on our claims data from CY 2006, we believe that the current and proposed packaged status of HCPCS code V2790 is appropriate based on resource and clinical considerations. We also believe that the proposed composition of APC 0244, dominated by claims for corneal transplant procedures, reflects appropriate clinical and resource homogeneity. While some commenters were concerned with hospitals not reporting HCPCS code V2790 when reporting CPT code 65780, we do not believe that we should create a claims processing edit in this instance. We create device edits, when appropriate, for procedures assigned to device-dependent APCs, where those APCs have been historically identified under the OPSS as having very high device costs. Because APC 0244 is not a device-dependent APC and the costs of the procedure with and without HCPCS code V2790 are relatively close, we will not create edits. We remind hospitals that they must report all of the HCPCS codes that appropriately describe the items used to provide services, regardless of whether the HCPCS codes are packaged or paid separately.

After consideration of the public comments received, we are finalizing our proposed CY 2008 payment policies, without modification, for HCPCS codes V2785 and V2790 as reflected in their status indicators, as well as the proposed configuration of APC 0244. We are also changing the APC title for APC 0244 from "Corneal

Transplant” to “Corneal and Amniotic Membrane Transplant,” effective January 1, 2008, to ensure that the title better describes all procedures assigned to that APC.

b. Keratoprosthesis (APC 0293)

CPT code 65570 (Keratoprosthesis) describes the surgical procedure for implantation of an artificial cornea, also known as a keratoprosthesis. In the CY 2007 OPPS/ASC final rule with comment period, we indicated that we were implementing device edits in CY 2007 for CPT code 65570 to ensure that all claims for CPT code 65570 in CY 2007 and after include charges for a required device (71 FR 68053). For CY 2008, we proposed continued assignment of CPT code 65570 to APC 0293 (Level V Anterior Segment Eye Procedures), with a proposed payment rate of approximately \$5,290. The CY 2007 payment rate for APC 0293 is approximately \$3,196.

We received one public comment on our CY 2008 proposal for CPT code 65570. A summary of the public comment and our response follow.

Comment: One commenter expressed concern that the procedure described by CPT code 65570 required significant implantation of a costly device, but it was not assigned to a device-dependent APC. The commenter stated that assignment to a nondevice-dependent APC may result in inadequate payment rates in the ASC setting. The commenter noted that the revised ASC payment methodology, which will be implemented in CY 2008, includes an exception to the standard ratesetting methodology for device-intensive procedures that allows only the service portion of the procedure to be reduced by the ASC budget neutrality adjustment to reflect the relatively constant price of medical devices across hospital outpatient and ASC settings of care. Device-intensive procedures are defined as those procedures assigned to device-dependent APCs under the OPPS for payment purposes, where the APC device cost is greater than 50 percent of the APC median cost. The commenter pointed out that by assigning CPT code 65570 to a non-device-dependent APC under the OPPS, the procedure did not qualify as device intensive for ASC payment purposes. The commenter concluded that the entire payment rate for the procedure would be reduced by the ASC budget neutrality adjustment, rather than just the service portion, in contrast to other procedures assigned to APCs for which the device costs constitute a significant portion of the total procedure costs.

Response: We agree with the commenter that the procedure described by CPT code 65570 requires the implantation of a device, and that a significant portion of the total cost of keratoprosthesis implantation procedures is likely to be attributable to device costs. Currently CPT code 65570 is assigned to APC 0293 under the OPPS, where it is the only procedure in the APC. There also are two device codes for reporting keratoprostheses, HCPCS code C1818 (Integrated Keratoprosthesis) that describes the expired pass-through device category that was created in CY 2003 and HCPCS code L8609 (Artificial cornea) that was first available for reporting in CY 2007. It is not possible to calculate a device percentage for APC 0293 for CY 2008 that reflects the full costs of the devices implanted in CY 2006 because there was no device code that described all possible devices that could be implanted in the procedure at that time.

As we stated in the CY 2007 OPPS/ASC final rule with comment period, when there are device HCPCS codes for all possible devices that could be used to perform a procedure that always requires a device and the APC is designated a device-dependent APC, we commonly institute device edits that prevent payment of claims that do not include both the procedure and an acceptable device code (71 FR 68053). We implemented device edits in CY 2007 for APC 0293, the first year that device HCPCS codes that describe all possible devices that could be used to perform the procedure were available, and we agree with the commenter that it would be most consistent with our established device editing policy to designate APC 0293 as device-dependent. However, we are unable to consider only CY 2006 claims for CPT code 65570 that contain a device HCPCS code for CY 2008 ratesetting for the APC. If we were to follow our usual ratesetting methodology for device-dependent APCs, we could be systematically and incorrectly excluding claims for CPT code 65570 that may have been correctly coded at the time by hospitals implanting a two-part keratoprosthesis not described by the only available HCPCS code, specifically C1818.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, with modification. We are assigning CPT code 65570 to APC 0293 as proposed. In addition, we are designating APC 0293 as a device-dependent APC, with a median cost of approximately \$5,335.

c. Palatal Implant (APC 1510)

In Addendum B to the CY 2008 proposed rule (72 FR 43018), we proposed to pay \$850 for HCPCS code C9727 (Insertion of implants into the soft palate; minimum of three implants) through its assignment to New Technology APC 1510 (New Technology—Level X (\$800–\$900)). This is the same APC assignment for the service as its CY 2007 placement.

We received one comment on our CY 2008 payment proposal for HCPCS code C9727. A summary of the comment and our response follow.

Comment: One commenter considered the proposed CY 2008 payment rate for HCPCS code C9727 to be inappropriate based on the costs of the clinical staff, supplies, equipment, and overhead required to perform the procedure. The commenter reported that, based on its estimate that used the MPFS Practice Expense Database as a reference, the appropriate median cost for this procedure should be between \$1,100 and \$1,200. The commenter submitted a categorized list of items involved in performing the procedure to CMS, along with approximate costs for each category. In addition, the commenter asked CMS to reassign HCPCS code C9727 to New Technology APC 1514 (New Technology—Level XV (\$1200–\$1300)) for CY 2008 because the commenter believed that the payment for this APC would appropriately reflect the complexity and resource costs associated with performing this procedure.

Response: We assign a new procedure to a New Technology APC when we do not have adequate claims data upon which to determine the median cost of performing a procedure and there is no appropriate clinical APC for its assignment based on clinical and resource homogeneity considerations. We perform our own cost analysis and cost estimate, in addition to taking the project costs that may be submitted in a New Technology APC application into consideration. As we stated in our November 30, 2001 final rule (66 FR 59900), concerning the placement of new services into New Technology APCs in response to an application, “We will not limit our determination of the cost of the procedure to information submitted by the application. Our staff will obtain information on cost from other appropriate sources before making a determination of the cost of the procedure to hospitals.” We received a New Technology APC application from the manufacturer of palatal implants required for the Pillar® Procedure. Consistent with our customary practice,

we compared the estimated hospital resources, including procedure room time, personnel, device costs, and other resources of the new procedure to various other OPPS procedures for which we have historical claims data. We believed that, based on this analysis, a payment rate of \$850 was appropriate based on all cost and utilization information available to us regarding the palatal implant procedure and other services provided in the hospital outpatient setting. Consequently, we assigned HCPCS code C9727 to New Technology APC 1510, effective October 1, 2006.

Analysis of our hospital data for claims submitted for CY 2006 indicates that the palatal implant procedure was rarely performed on Medicare beneficiaries in the last quarter of that year when specific OPPS payment was first available. OPPS claims for services between October 1, 2006, and December 1, 2006, show that there were only two claims submitted for HCPCS code C9727. We reexamined the service's proposed CY 2008 assignment in light of all current information available to us for this final rule with comment period, and we conclude that its proposed assignment to New Technology APC 1510 remains appropriate. We will reexamine the claims data for this procedure next year when we review its APC placement in preparation for the annual CY 2009 OPPS update.

Furthermore, the MPFS applies a very different methodology for establishing the payment for the physician's office practice expenses associated with a procedure, specifically considering the individual costs of the inputs, whereas the OPPS generally pays based on relative payment weights calculated from hospitals' costs as determined from claims data. Thus, comparisons between the MPFS and OPPS payments for services are not appropriate. While the palatal implant procedure is a relatively new service under the OPPS, the procedure resembles other OPPS services for which cost data are currently available.

Therefore, after consideration of all the public comments received, we are finalizing our CY 2008 proposal, without modification, to assign HCPCS

code C9727 to New Technology APC 1510 with a payment rate of \$850.

7. Orthopedic Procedures

a. Arthroscopic Procedures (APCs 0041 and 0042)

For CY 2008, we proposed two primary APCs for arthroscopic procedures, APC 0041 (Level I Arthroscopy), comprised of 49 procedures with a CY 2008 proposed payment rate of approximately \$1,876, and APC 0042 (Level II Arthroscopy), comprised of 17 procedures with a proposed payment rate of approximately \$3,043. The CY 2007 payment rates for these APCs 0041 and 0042 are approximately \$1,759 and \$2,797, respectively. While we proposed to assign the majority of arthroscopic procedures to these APCs for CY 2008, we also proposed to continue the assignment of several arthroscopic procedures to APC 0053 (Level I Hand Musculoskeletal Procedures), with a proposed CY 2008 payment rate of approximately \$1,071. The CY 2007 payment rate for APC 0053 is approximately \$993.

We received one public comment on our CY 2008 proposed configuration of arthroscopy APCs. A summary of the public comment and our response follow.

Comment: A commenter stated that the current configuration of arthroscopic procedures assigned to APCs 0041, 0042, and 0053 fails to appropriately recognize the distinct clinical and resource features of the wide range of arthroscopic procedures now being provided to Medicare beneficiaries. The commenter requested that CMS create new arthroscopy APCs and reconfigure the current assignment of arthroscopic procedures to ensure that the arthroscopy APCs are clinically homogenous and contain only those procedure that are similar in resource utilization. Specifically, the commenter requested that CMS restructure the arthroscopy APCs to reflect the following clinical categories: diagnostic arthroscopies, lower extremity versus upper extremity arthroscopies, and arthroscopies with implants. The commenter suggested that each clinical distinction be divided further into three

levels of resource utilization, for a total of 9 new APCs for arthroscopy procedures with recommended payment ranging from \$1,530 to \$4,100. According to the commenter, these clinical distinctions parallel the distinctions CMS has created for other classes of procedures, including other orthopedic procedures, and would more accurately and equitably reflect the clinical characteristics and resource utilization of the services rendered.

Response: In response to the concerns raised by the commenter, we reviewed the clinical characteristics and hospital costs from CY 2006 claims data for all procedures proposed for CY 2008 assignment to APCs 0041, 0042, and 0053. In considering the commenter's recommended APC configurations, we identified several procedures that were assigned to APCs 0041 and 0053 with median costs and clinical characteristics that were more similar to procedures assigned to other clinical APCs than the APCs to which we proposed their assignment. Therefore, for CY 2008, we will reassign 11 arthroscopic procedures that are currently in APC 0041 to APC 0042, and we will reassign 3 arthroscopic procedures that are currently in APC 0053 to 0041, as reflected in Table 21 below. While we appreciate the commenter's suggestion for nine new APCs for arthroscopic procedures, we believe that the existing clinical APCs, with the modifications included in Table 21 that assign procedures to the larger groups in a way that is generally consistent with the commenter's more specific recommended groupings, sufficiently account for the different clinical and resource characteristics of these procedures. Furthermore, to reduce the size of the APC payment groups and establish new clinical APC payment groups to pay more precisely would be inconsistent with our overall strategy to encourage hospitals to use resources more efficiently by increasing the size of the payment bundles.

After consideration of the public comment received, we are modifying our CY 2008 proposal and will reassign several arthroscopic procedures to APCs 0041 and 0042, as displayed in Table 21 below.

TABLE 21.—CY 2008 APC REASSIGNMENT OF ARTHROSCOPIC PROCEDURES

HCPCS code	Short descriptor	CY 2007 APC assignment	CY 2007 APC median cost	CY 2008 APC assignment	CY 2008 APC median cost
29819	Shoulder arthroscopy/surgery	0041	\$1,749	0042	\$2,876
29820	Shoulder arthroscopy/surgery	0041	1,749	0042	2,876
29821	Shoulder arthroscopy/surgery	0041	1,749	0042	2,876
29823	Shoulder arthroscopy/surgery	0041	1,749	0042	2,876

TABLE 21.—CY 2008 APC REASSIGNMENT OF ARTHROSCOPIC PROCEDURES—Continued

HCPCS code	Short descriptor	CY 2007 APC assignment	CY 2007 APC median cost	CY 2008 APC assignment	CY 2008 APC median cost
29825	Shoulder arthroscopy/surgery	0041	1,749	0042	2,876
29847	Wrist arthroscopy/surgery	0041	1,749	0042	2,876
29856	Tibial arthroscopy/surgery	0041	1,749	0042	2,876
29860	Hip arthroscopy, dx	0041	1,749	0042	2,876
29861	Hip arthroscopy/surgery	0041	1,749	0042	2,876
29891	Ankle arthroscopy/surgery	0041	1,749	0042	2,876
29892	Ankle arthroscopy/surgery	0041	1,749	0042	2,876
29900	Mcp joint arthroscopy, dx	0053	987	0041	1,811
29901	Mcp joint arthroscopy, surg	0053	987	0041	1,811
29902	Mcp joint arthroscopy, surg	0053	987	0041	1,811

b. Closed Fracture Treatment (APC 0043)

For CY 2008, we proposed to continue the assignment of various CPT codes that describe closed treatment of fractures of the fingers, toes, and trunk to APC 0043 (Closed Treatment Fracture Finger/Toe/Trunk), with a proposed payment rate of about \$119. We did not propose any CPT code reassignment changes for APC 0043.

We received one public comment on our proposed CY 2008 configuration of APC 0043. A summary of the public comment and our response follow.

Comment: A commenter expressed concern about the wide variety of procedures assigned to APC 0043, which the commenter claimed ranged from \$1 to \$3,000 in cost. The commenter disapproved of CMS assigning one APC for various types of fracture treatments as the commenter asserted that the costs associated with finger treatments, hip dislocations, and spinal fractures vary significantly. The commenter indicated specifically that the costs associated with spinal fractures are significantly greater than the costs associated with finger or toe fractures. The commenter believed that grouping all of these procedures in one clinical APC violated the 2 times rule, and that continuing to except APC 0043 from the 2 times rule was not appropriate. To pay appropriately for these procedures under the current OPPS, the commenter recommended that CMS divide the procedures currently assigned to APC 0043 among several APCs, because of the existing large variations in resource costs for the procedures.

Response: We thank the commenter for bringing this concern to our attention. We agree with the commenter that grouping all of the closed fracture treatment procedures in one APC may not most accurately distinguish the more expensive from the less resource-intensive fracture treatment procedures.

We note that while there are about 150 procedures assigned to APC 0043, only 13 procedures are significant procedures with the frequency necessary to assess the APC's alignment with the 2 times rule. The remainder of the procedures are low volume and, therefore, not significant procedures in the APC for purposes of evaluating the APC by applying the 2 times rule. The median costs of the significant procedures in APC 0043 for CY 2008 range from about \$68 to \$248. This particular APC has been excepted from the 2 times rule for the past 6 years under the OPPS, and we have not previously received public comments regarding the structure of this APC over the past several years. The commenter did not make a specific recommendation regarding alternative APC configurations. Because APC 0043 contains so many different fracture treatment procedures with low volume, we are concerned that any restructuring for CY 2008 without the benefit of public comment could lead to APCs that do not reflect improved clinical and resource homogeneity over the proposed configuration; therefore, we will not establish a different APC configuration for CY 2008. However, we are specifically inviting public comment on potential alternative APC configurations for the services currently assigned to APC 0043 for the CY 2009 APC review process. We also plan to bring this APC issue to the attention of the APC Panel at its winter 2008 meeting and will request its input as to how to appropriately categorize the procedures in APC 0043.

After consideration of the public comment received, we are finalizing, without modification, our proposed configuration of APC 0043, with a median cost of about \$111 for CY 2008.

c. Insertion of Posterior Spinous Process Distraction Device (APC 0050)

We proposed to assign CPT codes 0171T (Insertion of posterior spinous process distraction device (including

necessary removal of bone or ligament for insertion and imaging guidance), lumbar; single level); and 0172T (Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; each additional level) to APC 0050 (Level II Musculoskeletal Procedures Except Hand and Foot), with a proposed payment rate of approximately \$1,868. These two codes were new in CY 2007, where they were assigned to APC 0050 on an interim final basis. We created a new device category, specifically, C1821 (Interspinous process distraction device (implantable)) for transitional pass-through payment, effective January 1, 2007, which we expected to be reported with CPT codes 0171T and 0172T. This pass-through device category will continue to be paid at hospital charges adjusted to cost for CY 2008, as discussed in section IV.A.1.b. of this final rule with comment period.

We received several public comments on our CY 2008 proposed APC assignments for CPT codes 0171T and 0172T. A summary of the public comments and our response follow.

Comment: Some commenters disagreed with our proposed APC assignments for CPT codes 0171T and 0172T, and indicated that these procedures should be reassigned from APC 0050 to APC 0208 (Laminotomies and Laminectomies), which had a proposed payment rate of approximately \$3,036 for CY 2008. The commenter asserted that the spinous distraction device insertion is clinically different and involves greater hospital resources than the other procedures assigned to APC 0050. This commenter cited one procedure in APC 0050, specifically vertebroplasty, claiming that its costs are significantly lower than the spinous process distraction device procedure. The commenter claimed that the vertebroplasty procedure is one that involves an injection procedure that is

performed in 30 minutes and does not involve implanting a spinal device. Alternatively, the commenter explained that inserting a spinous process distraction device requires an hour in the operating room and involves implanting a device in the spine. Several commenters reported that the spinous process distraction device insertion is similar to a laminectomy procedure in that both procedures involve the spinal processes and take approximately 1 hour to perform. These commenters requested that CMS reassign CPT codes 0171T and 0172T to APC 0208 based on clinical and cost considerations.

Response: We carefully analyzed the CY 2006 claims data for other musculoskeletal procedures under the OPSS, and we believe that CPT codes 0171T and 0172T are appropriately assigned to APC 0050, based on both clinical and expected resource considerations. We do not agree with some commenters that these minimally invasive procedures to insert a spinal device are similar to the procedures that are currently assigned to APC 0208, which are generally significant open surgical procedures on the spine. We believe that the hospital's nondevice costs and the clinical characteristics of CPT codes 0171T and 0172T more closely align with the less invasive musculoskeletal procedures presently assigned to APC 0050.

We will continue pass-through payment status, initially implemented in January 2007, for the spinous process distraction device (C1821) reported with CPT codes 0171T and 0172T through CY 2008. Separate payment for HCPCS code C1821 will be made under the OPSS for at least 2 and not more than 3 years of pass-through payment. After that period, payment for the cost of the device will be packaged into the procedural payment for its implantation, specifically CPT codes 0171T and 0172T.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to assign CPT codes 0171T and 0172T to APC 0050, with a median cost of approximately \$1,836.

d. Intradiscal Annuloplasty (APC 0050)

For CY 2008, we proposed to assign the intradiscal electrothermal (IDET) annuloplasty procedures, specifically those described by CPT codes 22526 (Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level) and 22527 (Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including

fluoroscopic guidance; one or more additional levels (List separately in addition to code for primary procedure)) to APC 0050 (Level II Musculoskeletal Procedures Except Hand and Foot), with a proposed payment rate of approximately \$1,868 for CY 2008. These CPT codes were new for CY 2007, when they were first assigned to APC 0050 under the OPSS on an interim final basis.

We received several public comments on our CY 2008 proposed APC assignments for CPT codes 22526 and 22527. A summary of the public comments and our response follow.

Comment: Several commenters disagreed with the proposed assignment for CPT codes 22526 and 22527 and recommended that these procedures be reassigned to APC 0051 (Level III Musculoskeletal Procedures Except Hand and Foot), which had a proposed CY 2008 payment rate of approximately \$2,777. These commenters believed that the hospital costs associated with IDET are relatively higher than the payment associated with APC 0050. One commenter who provided its price list reported that the cost of one disposable catheter used in the procedure is approximately \$1,800. The commenter indicated that APC 0051 would more accurately pay hospitals for the IDET procedure. Another commenter indicated that the other procedures in APC 0051 are similar to the IDET procedure based on clinical homogeneity and resource costs.

Response: CPT codes 22526 and 22527 were created effective January 1, 2007. Prior to CY 2007, the IDET procedure was described by CPT code 0062T, which was implemented on January 1, 2005. The initial code long descriptor for CPT code 0062T in CY 2005 was "Percutaneous intradiscal annuloplasty, any method, unilateral or bilateral including fluoroscopic guidance; single level." However, in CY 2007, the CPT Editorial Panel revised this descriptor to "Percutaneous intradiscal annuloplasty, any method except electrothermal, unilateral or bilateral including fluoroscopic guidance; single level" to appropriately differentiate between electrothermal and non-electrothermal methods. Following the descriptor revision, CPT codes 22526 and 22527 described the electrothermal methodology for percutaneous intradiscal annuloplasty, while CPT code 0062T described the non-electrothermal methodology.

Since the code descriptor change did not occur until CY 2007, hospital outpatient claims from CY 2006 for CPT code 0062T describe both electrothermal and non-electrothermal

methods. Based on our review of the hospital outpatient claims from CY 2006 and CY 2005, percutaneous intradiscal annuloplasty is performed infrequently in the hospital outpatient setting for the Medicare population. Claims from CY 2006 show a median cost of approximately \$1,019 for CPT code 0062T based on 44 single claims, and a median cost of approximately \$2,034 based on only 28 single claims for CY 2005.

We believe, based on our review of the clinical characteristics and historical hospital costs for percutaneous intradiscal annuloplasty and other musculoskeletal procedures assigned to APCs 0050 and 0051, that the most appropriate APC assignment for percutaneous intradiscal annuloplasty procedures, whether electrothermal or non-electrothermal, is APC 0050.

After considering the public comments received, we are finalizing our CY 2008 proposal, without modification, to assign CPT codes 22526 and 22527 to APC 0050, with a median cost of approximately \$1,836.

e. Kyphoplasty Procedures (APC 0052)

For CY 2008, we proposed to assign CPT codes 22523 (Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device, one vertebral body, unilateral or bilateral cannulation (eg, kyphoplasty); thoracic), 22524 (Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device, one vertebral body, unilateral or bilateral cannulation (eg, kyphoplasty); lumbar), and 22525 (Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device, one vertebral body, unilateral or bilateral cannulation (eg, kyphoplasty); each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)) to APC 0052 (Level IV Musculoskeletal Procedures Except Hand and Foot) with a proposed payment rate of approximately \$5,010.

We received one public comment on our CY 2008 proposal for CPT codes 22523, 22524, and 22525. A summary of the public comment and our response follow.

Comment: Some commenters expressed concern about the accuracy of hospital charge data for these procedures. Because of charge compression, the commenters believed that the current data collected from hospital charges do not accurately

reflect the true costs of the kyphoplasty procedures. The commenters appreciated CMS' attention in reviewing and placing these procedures in an appropriate APC for CY 2008; however, they believed that charge compression directly contributes to inaccurate and reduced payment rates for the services. One commenter explained that procedures that involve the use of expensive medical devices, whereby hospitals apply smaller mark-up rates to higher-cost medical devices than they do to lower-cost supplies used in procedures, results in charge compression. Because the current OPSS payment methodology is to calculate the payment weight for an APC based on hospital charges adjusted to cost, the commenters argued that charge compression results in the lowering of payment rates for procedures that involve the use of expensive medical devices. These commenters strongly urged CMS to continue to consider future refinements to the OPSS payment amounts for kyphoplasty procedures in light of the effects of charge compression.

Response: We thank the commenters for their suggestions and refer to section II.A.3. of this final rule with comment period for further discussion on charge compression. Consistent with our update process, we review hospital outpatient claims data and assign services and items to appropriate APCs on an annual basis.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to assign CPT codes 22523, 22524, and 22525 to APC 0052, with a median cost of approximately \$4,997.

8. Vascular Procedures

a. Blood Transfusion (APC 0110)

We have a longstanding policy under the OPSS that blood transfusion services are billed and paid on a per encounter basis and not by the number of units of blood products transfused (Internet Only Manual 100-4, Chapter 4, Section 231.8). Under this policy, a transfusion APC payment is made to the OPSS provider for transfusing blood products once per day, regardless of the number of units or different types of blood products transfused. The OCE ensures only one payment for APC 0110 (Transfusion), regardless of the number of units of CPT code 36430 (Transfusion, blood or blood components) reported by the hospital on a single date of service. The CPT code 36430 descriptor does not include "per unit." Hence, the median cost for CPT

code 36430, which is assigned to APC 0110, represents the costs of transfusion of blood or blood products on the same date of service, regardless of how many units of products are transfused. In addition, for payment of the transfusion service, the OCE also requires the claim to contain a Level II HCPCS P-code for a blood product on the same date of service as the transfusion procedure.

At its March 2007 meeting, the APC Panel recommended that CMS investigate whether CPT code 36430 should identify when multiple units are transfused and trigger a discounted payment for the second and subsequent administration of additional units of blood or blood components. The APC Panel indicated that the current payment for transfusion services does not adequately pay hospitals for the costs of these complex services, and that payment on a per unit basis rather than on a per encounter basis would result in more accurate and appropriate payment.

We did not agree with the APC Panel's recommendation, and we proposed to not accept this recommendation for the CY 2008 OPSS. As stated in the CY 2008 OPSS/ASC proposed rule (72 FR 42718), we believe that our current policy of providing a single payment for blood transfusion, regardless of the number of units transfused, is most consistent with the goals of a prospective payment system to encourage and create incentives for efficiency in providing services. Payment for transfusion services on a per encounter basis encourages the transfusion of only those blood products that are necessary for the beneficiary's treatment during the hospital outpatient encounter. Moreover, the current median cost for the transfusion service, associated with the transfusion of all blood products furnished on a date of service, has been set based on the historical reporting of all charges for transfusion on the same date of service and, therefore, represents the full cost of an episode of transfusion, rather than the cost of transfusion of a single unit of blood or blood product. Given our proposed packaging approach for the CY 2008 OPSS, it would be inconsistent for us to revise our current transfusion payment policy to provide separate payment for each unit of blood product transfused, thereby reducing the size of the current transfusion payment bundle (72 FR 42717 through 42718).

Therefore, for CY 2008 we proposed to maintain our current payment policy, which bases payment for transfusion on the costs of all transfusion services furnished on a single date of service and which examines hospital claims to ensure that payment is provided for

only one unit of CPT code 36430 on a date of service. However, we remind hospitals that a claim for a single unit of CPT code 36430 should include charges for all of the hospital resource costs associated with the totality of transfusion services furnished on the date of service, so that the payment for one unit of APC 0110 is based on the costs of all transfusion services provided in a hospital outpatient encounter.

We received several public comments on this proposal to maintain the current payment policy for blood transfusion services. A summary of the public comments and our response follow.

Comment: Several commenters requested that CMS reconsider the APC Panel's recommendation to provide separate payment for the transfusion of each unit of blood or blood products, as an alternative to CMS' current, encounter-based payment policy. They stated that the current policy does not pay OPSS providers adequately for the additional resources required for hospital outpatient visits involving multiple transfusions. They suggested that hospitals could report the "59" modifier (distinct procedural service) or another appropriate modifier to indicate that additional transfusions provided on the same day are distinct from the first transfusion. Some commenters argued that this would not conflict with the descriptor for CPT code 36430, as hospitals would only report multiple units of the code when they have performed more than one distinct transfusion. In contrast, another commenter noted that CPT guidelines indicate that CPT code 36430 should be reported once per transfusion regardless of the number of units administered, and supported CMS' proposal to continue provide one payment for blood transfusion services based on charges for all services provided in a hospital outpatient encounter.

One commenter also requested that CMS clarify that hospitals should charge for blood transfusion and administration services the same way for both hospital inpatients and outpatients. Another commenter indicated that hospitals should be able to base blood transfusion charges according to instructions published when Medicare was first created. According to the commenter, blood transfusion services were charged and paid on a per unit basis at that time.

Response: We believe that the current payment policy for blood transfusion services provides adequate and appropriate payment to OPSS providers for the additional resources required for hospital outpatient visits involving multiple transfusions. As described in

the proposed rule (72 FR 42718), we instruct hospitals to include charges for all of the hospital resource costs associated with the totality of transfusion services furnished on a date of service. While the CPT code descriptor would not preclude hospitals from reporting multiple units of the code when they have performed more than one distinct transfusion if they were to consider each unit of blood transfused to be a distinct transfusion, CPT coding guidelines indicate that CPT code 36430 should be reported only once per transfusion, regardless of the number of units administered. We believe that the median cost calculated from our claims data for blood transfusion services represents the full cost of an episode of transfusion, rather than the cost of the transfusion of a single unit of blood or blood product. We also believe that our current policy of providing a single payment for blood transfusion, regardless of the number of units transfused, is most consistent with the goals of a prospective payment system to encourage and create incentives for efficiency in providing services. Therefore, for CY 2008, we are implementing our proposal to maintain our current payment policy, which bases payment for transfusion on the costs of all transfusion services furnished on a single date of service and which examines hospital claims to ensure that payment is provided for only one unit of CPT code 36430 on a date of service.

Hospital inpatient departments and HOPDs have very different reporting structures that utilize different coding systems and vary in other significant ways. Inpatient charges for blood transfusion services are not relevant to the OPSS. Hospitals are free to set their charges for all items and services based on their own judgment. As is the case in other areas of CMS payment policy, reporting instructions for transfusion services reflect our current payment methodologies, which have evolved over time, and may not be the same as instructions published in the past.

In summary, for CY 2008, after consideration of the public comments received, we are finalizing our proposal, without modification, to continue to pay hospitals for only one unit of CPT code 36430 on a single date of service. We are not adopting the APC Panel's March 2007 recommendation to provide a separate payment for each unit of blood or blood product transfused. Because the payment for one unit of APC 0110, with a final CY 2008 median cost of approximately \$214, is based on the costs of all transfusion services provided in a hospital outpatient

encounter, we remind hospitals that a claim for a single unit of CPT code 36430 should include charges for all of the hospital resource costs associated with the totality of transfusion services furnished on the date of service.

b. Endovenous Ablation (APC 0092)

For CY 2008, we proposed to pay approximately \$1,684 for CPT code 36478 (Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; first vein treated) through its proposed assignment to APC 0092 (Level I Vascular Ligation). The proposed APC assignment for this service is the same as its CY 2007 APC assignment.

We received several public comments on the proposed CY 2008 payment for CPT code 36478. A summary of the public comments and our response follow.

Comment: Several commenters believed that the proposed payment rate for CPT code 36478 was considerably inadequate in view of the expense associated with the capital equipment required to perform this procedure. One commenter reported that, based on its estimate that used the MPFS Practice Expense Database as a reference, the appropriate placement for this procedure, in comparison with the practice expense of other endovenous procedures, would be APC 0091 (Level II Vascular Ligation), which had a CY 2008 proposed payment rate of approximately \$2,781. Another commenter asserted that the other procedures assigned to APC 0092 bear little resemblance to the procedure described by CPT code 36478, and that in terms of clinical homogeneity and resource costs, endovenous ablation therapy of incompetent veins is very similar to those procedures assigned to APC 0091. The commenter requested that CMS reassign CPT code 36478 from APC 0092 to APC 0091 for CY 2008.

Response: We disagree with the commenters' argument that CPT code 36478 is less clinically related to procedures in APC 0091 than to procedures assigned to APC 0092. Procedures assigned to both APCs 0091 and 0092 include a variety of surgical procedures involving veins, and both APCs include endovenous ablation procedures using different technologies. Analysis of our CY 2006 hospital claims data results in a median cost of approximately \$2,681 for APC 0091, which is considerably higher than the HCPCS-specific median cost of approximately \$1,713 for CPT code 36478 based on 984 single claims. However, the median cost of CPT code

36478 is quite close to the CY 2008 median cost of approximately \$1,626 for APC 0092. We believe that CPT code 36478 is most appropriately assigned to APC 0092 based on clinical and resource considerations.

We remind hospitals that in a budget neutral environment, Medicare does not make payments that fully cover hospitals' costs, including those for the purchase and maintenance of capital equipment. We rely on hospitals to make their business decisions regarding acquisition of expensive capital equipment taking into consideration their knowledge about their entire patient base (Medicare beneficiaries included) and an understanding of Medicare's and other payers' payment policies.

Furthermore, the MPFS applies a very different methodology for establishing the payment for the physician's office practice expenses associated with a procedure, specifically considering the individual costs of the inputs, whereas the OPSS generally pays based on relative payment weights calculated from hospitals' costs as determined from claims data. The application of the different methodologies results in different payment amounts in the two settings. Therefore, comparisons between the MPFS and OPSS payments for services are not appropriate.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to assign CPT code 36478 to APC 0092, with a median cost of about \$1,626.

c. Insertion of Central Venous Access Device (APC 0625)

For the CY 2008 OPSS, we proposed to assign CPT code 36566 (Insertion of tunneled centrally inserted central venous access device, requiring two catheters via two separate venous access sites; with subcutaneous port(s)) to APC 0625 (Level IV Vascular Access Procedures), as the only code in that APC. The procedure is for the purpose of implanting a vascular access device that is typically furnished to persons with end stage renal disease when there are no suitable access points for hemodialysis. The device that is implanted is reported under HCPCS code C1881 (Dialysis access system). For CY 2008, we proposed a national unadjusted payment of approximately \$5,562 for the service, compared to the CY 2007 national unadjusted payment of approximately \$5,130. As proposed, the payment for the device is packaged into the payment for APC 0625, a device-dependent APC.

We received several public comments on the proposed CY 2008 payment for APC 0625. A summary of the public comments and our responses follow.

Comment: Several commenters stated that the proposed CY 2008 payment for APC 0625 is excessive and recommended that the CY 2008 APC payment not exceed the CY 2007 payment. The commenters also recommended that CMS use external data to establish an appropriate benchmark cost for HCPCS code C1881. The commenters asked that CMS continue to require that hospitals must report HCPCS code C1881 on claims on which they report CPT code 36556. They also asked that CMS establish a payment for CPT code 36556 that is more stable from year to year. The commenters indicated that the low volume of these procedures may result in unstable payment rates over time and that use of external data to provide a benchmark for the cost of the device could help alleviate this problem. The commenters claimed that the cost of the device reported by HCPCS code C1881 is approximately \$3,500.

Response: For this final rule with comment period, the median cost for APC 0625 is approximately \$5,143, as compared with the proposed rule median cost of approximately \$5,493. Both the proposed and final rule medians were calculated using only 8 claims of 479 total bills for the proposed rule and 535 total bills (of which 325 were potentially usable single bills) for this final rule with comment period. This is, in part, because we used only claims that contained the correct device code, no token charges for the device, and no "FB" modifier. Procedure-to-device edits that return to providers those claims for CPT code 36556 that do not also contain HCPCS code C1881 did not go into place until January 1, 2007 and, therefore, were not in place for CY 2006. We recognize that the small number of claims that contain the HCPCS C-code for the device without which the procedure cannot be performed may result in a median that is more volatile than is desirable. However, given that the commenter advises us that the cost of the device is approximately \$3,500 and given that the median we calculated using final rule data is approximately \$5,143, we believe that it is a reasonable estimate of the cost of the procedure, including the packaged cost of the device. We expect that the data available for future OPSS updates, beginning in CY 2009, will include more claims that report the device HCPCS code and, therefore, future median costs for APC 0625 may

stabilize with additional claims available for ratesetting.

Comment: One commenter asked that CMS change the short descriptor for CPT code 36566 to read "Ins tunneled cath w/subq port" because the commenter believed that it is confusing to have multiple CPT codes with the same short descriptor. The commenter also asked that we revise the definition for HCPCS code C1881 to read "Dialysis access system with subcutaneous port or valve."

Response: The CPT codes, including the short descriptors, are owned by the AMA and any change to them is outside of the purview of CMS and should be addressed to the AMA CPT Editorial Board. HCPCS code C1881 describes the category of dialysis access devices, which is an existing pass-through device category that expired from pass through status as of the CY 2003 OPSS. As stated in the November 1, 2005 OPSS final rule with comment period (70 FR 68631), we revise a code that describes an existing category of devices (such as C1881) only if such revision is necessary to distinguish the existing category from a new category of pass-through devices in instances in which we must create a new category to describe a device that meets the criteria for pass-through payment. Therefore, there is no basis in policy to revise the definition of HCPCS code C1881.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to pay for CPT code 36566 through device-dependent APC 0625, with a median cost of approximately \$5,143. We will not change the short descriptor for pass-through device category C1881.

d. Noninvasive Vascular Studies (APC 0267)

For the CY 2008 OPSS, we proposed to pay approximately \$158 for procedures assigned to APC 0267 (Noninvasive Vascular Studies). We also proposed to pay approximately \$420 for services assigned to APC 0269 (Level II Echocardiogram Except Transesophageal).

We received one public comment on our CY 2008 proposal. A summary of the public comment and our response follow.

Comment: A commenter stated that the vascular ultrasound procedures included in APC 0267 are grossly underpaid and that the CY 2008 payment for this APC should be similar to the payment for APC 0269, for which CMS proposed to pay approximately \$417. The commenter indicated that the services in these two APCs require

virtually the same resource costs. Specifically, the commenter explained that the equipment and software are equivalent and have similar costs, and in some facilities, the same equipment is used for the services in both APCs. According to the commenter, the technicians performing the studies in both APCs are of the same skill level and the associated cost is the same. The commenter claimed that the pay scale that CMS uses for purposes of establishing the MPFS RVUs for the procedures differs by only 2 cents per hour. The commenter asserted that the time scheduled for the procedures is virtually identical and that the supplies are essentially the same for the services assigned to both APCs. Hence, the commenter concluded that there is no basis for the differences in calculated costs for the services under the OPSS and recommended that CMS study this differential to provide insight into situations where the OPSS CCR methodology to calculate costs does not result in an accurate measure of relative resource utilization.

Response: We agree that it appears that the resources required to perform the vascular ultrasound and echocardiography services in these APCs appear, from a clinical perspective, to be very similar. We performed a limited initial examination of elements of the CY 2006 claims data for these APCs to determine if we could identify the reason for the difference in estimated median costs. We first looked at the charges for the services in these APCs, because one of the most fundamental elements of the calculation of estimated costs is hospitals' charges for the services. The mean charge per service for the 17 HCPCS codes assigned to APC 0267 was approximately \$786. In contrast, the mean charge per service for the three procedure codes assigned to APC 0269 was approximately \$1,135. Clearly, on average hospitals charge much more for the services in APC 0269 than for the services in APC 0267. However, while the proposed payment for APC 0267 was 38 percent of the proposed payment for APC 0269, the mean charge for APC 0267 based upon the final rule data was 64 percent of the mean charge for APC 0269. Therefore, there is more of a disparity between the payments (and hence, between the median costs) than between the mean charges.

We next looked at the total frequency of services furnished in each APC and found that the total frequency of services was quite substantial in each APC. Therefore, it is unlikely that the disparity between the median costs for the two APCs is related to differences in

total volumes of services residing in those APCs. APC 0267 had a total frequency of approximately 1.2 million claims and APC 0269 had a total frequency of approximately 1 million claims in the final rule data from CY 2006 claims.

We then looked at single bills as a percentage of the total frequency and found that there is good representation in the single bills. For APC 0267, we were able to use approximately 99 percent of the total claims to set the median cost and for APC 0269, we were able to use approximately 75 percent of the total claims to set the median cost. Hence, the disparity is unlikely to be related to the variability associated with using a small percentage of total claims to calculate the median costs.

We also looked at the number of providers that furnish the highest volumes of services in each APC to see if there were significantly different counts of providers that might be a factor in the differences in estimated costs. CPT code 93880 (Duplex scan of intracranial arteries; complete bilateral study), assigned to APC 0267, was furnished by 3,119 hospitals and CPT code 93970 (Duplex scan of extremity veins including responses to compression and other maneuvers, complete bilateral study) was furnished by 3,160 hospitals in CY 2006. Similarly, CPT code 93307 (Echocardiography, transthoracic, real-time with imaging documentation (2D) with or without M-mode recording; complete), assigned to APC 0269, was furnished by 3,227 hospitals in CY 2006. These are a large number of the 4,089 hospitals whose claims were used for the final rule median cost calculations and, therefore, it is unlikely that idiosyncratic data from a few providers could be causing the disparity.

We note that the CY 2008 median cost of APC 0267 was about the same as its CY 2007 median cost, whereas the median cost of APC 0269 was almost double its CY 2007 median cost. We believe the increased cost of APC 0269 for CY 2008 may be a result of the CY 2008 packaging approach for ancillary and supportive services described in section II.A.4.c. of this final rule with comment period. In particular, the packaging of payment for doppler echocardiography and color flow velocity mapping, which are frequently reported with the CPT codes assigned to APC 0269 and which have been paid separately under the OPSS prior to CY 2008, may have contributed to the increased cost for APC 0269, whereas services assigned to APC 0267 had little

new packaging due to our CY 2008 packaging approach.

We note we wish to investigate further the specific packaging associated with services assigned to both APCs, the revenue codes under which the services were charged, the revenue centers to which these revenue codes mapped, and the CCRs that applied to the charges for these services. We intend to undertake this further analysis and to discuss our findings with the APC Panel at its winter 2008 meeting.

However, for CY 2008 we are basing payment for APCs 0267 and 0269 on the median costs calculated from our claims data according to our standard median cost calculation process because our investigation of the data does not reveal a problem with the methodology or with the data. At this point, it appears that the median costs may be different because of dissimilar packaging and because hospitals charge significantly less for the services in APC 0267 than they charge for the services in APC 0269, where this significant difference in charges is not neutralized by the application of the CCRs applicable to these charges. Therefore, the median cost for APC 0267 is significantly lower than the median cost for APC 0269.

After consideration of the public comment received, we are finalizing our CY 2008 proposal, without modification, to provide payment for APCs 0267 and 0269 based on costs from claims, according to the standard OPSS methodology, with median costs of approximately \$150 and \$404, respectively. We note that for CY 2008, APC 0269 will be paid specifically for noncontrast echocardiography studies. We plan to analyze these APCs further and discuss our findings with the APC Panel at its winter 2008 meeting.

9. Other Procedures

a. Hyperbaric Oxygen Therapy (APC 0659)

When hyperbaric oxygen therapy (HBOT) is prescribed for promoting the healing of chronic wounds, it typically is prescribed for 90 minutes and billed using multiple units of HBOT on a single line or multiple occurrences of HBOT on a claim. In addition to the therapeutic time spent at full hyperbaric oxygen pressure, treatment involves additional time for achieving full pressure (descent), providing air breaks to prevent neurological and other complications from occurring during the course of treatment, and returning the patient to atmospheric pressure (ascent). The OPSS recognizes HCPCS code C1300 (Hyperbaric oxygen under pressure, full body chamber, per 30

minute interval) for HBOT provided in the hospital outpatient setting.

In the CY 2005 final rule with comment period (69 FR 65758 through 65759), we finalized a "per unit" median cost calculation for APC 0659 (Hyperbaric Oxygen) using only claims with multiple units or multiple occurrences of HCPCS code C1300 because delivery of a typical HBOT service requires more than 30 minutes. We observed that claims with only a single occurrence of the code were anomalies, either because they reflected terminated sessions or because they were incorrectly coded with a single unit. In the same rule, we also established that HBOT would not generally be furnished with additional services that might be packaged under the standard OPSS APC median cost methodology. This enabled us to use claims with multiple units or multiple occurrences. Finally, we also used each hospital's overall CCR to estimate costs for HCPCS code C1300 from billed charges rather than the CCR for the respiratory therapy cost center. Comments on the CY 2005 proposed rule effectively demonstrated that hospitals report the costs and charges for HBOT in a wide variety of cost centers. We used this methodology to estimate payment for HBOT in CYs 2005, 2006, and 2007. For CY 2008, we proposed to continue using the same methodology to estimate a "per unit" median cost for HCPCS code C1300 of approximately \$99 using 60,775 claims with multiple units or multiple occurrences for the proposed rule.

CY 2008 is the fourth year in which we will have a special methodology to develop the median cost for HBOT services that removed obviously erroneous claims and deviated from our standard methodology of using departmental CCRs, when available, to convert hospitals' charges to costs. Prior to CY 2005, our inclusion of significant numbers of miscoded claims in the median calculation for HBOT and our exclusion of the claims for multiple units of treatment, the typical scenario, resulted in payment rates that were artificially elevated. As explained earlier, beginning in CY 2005 and continuing through the present, we have adjusted the CCR used in the conversion of charges to costs for these services so that claims data would more accurately reflect the relative costs of the services. The median costs of HBOT calculated using this methodology have been reasonably stable for the last 4 years. As stated in the proposed rule (72 FR 42706), we believe that this adjustment through use of the hospitals' overall CCRs is all that is necessary to yield a

valid median cost for establishing a scaled weight for HBOT services. Therefore, for CY 2008, we proposed to continue to use the same methodology that we have used since CY 2005 to estimate payment for HBOT.

We received one public comment on our proposal. A summary of the public comment and our response follow.

Comment: One commenter commended CMS for applying a consistent methodology of utilizing an overall hospital CCR to yield a valid median cost for HBOT services. However, the commenter also encouraged CMS to consider an alternative methodology for calculating a median cost for HBOT. Specifically, the commenter stated that a contractor for a wound care association had established and reproduced an accurate CCR for HBOT and encouraged CMS to consider this methodology for the near future.

Response: We appreciate the commenter's support for our proposed methodology for estimating a "per unit" median cost for HBOT. In response to the comment urging us to utilize an alternate calculation to estimate a median cost for HBOT services, we note, as we did in our CY 2005 OPPS final rule with comment period (69 FR 65759), that we are not confident that the external research produces a definitive CCR for HBOT. That final rule with comment period provided an extensive discussion of our concerns about using survey findings to set, rather than validate, APC medians. These concerns included a lack of subscribed cost centers in the electronic cost report database, the wide variability in observed CCRs, and the possibility of nonresponse bias. As also noted in the CY 2005 final rule with comment period, we agree that the previous study definitively demonstrated great diversity among hospitals in the subscribed location of reported hyperbaric oxygen costs on the cost report, which prompted us to use the hospital's overall CCR, rather than a specific cost center CCR that would be used in our standard ratesetting methodology. We continue to believe that the median cost for APC 0659 developed according to our established "per unit" median cost calculation for HBOT is an appropriate relative cost to be used to set the payment weight upon which the HBOT payment is based.

After consideration of the public comment received, we are finalizing our CY 2008 proposal, without modification, for estimating a "per unit" median cost for HCPCS code C1300, assigned to APC 0659, with a median cost of approximately \$98 based on

67,435 claims with multiple units or multiple occurrences.

b. Skin Repair Procedures (APCs 0133, 0134, 0135, 0136, and 0137)

For CY 2006, the AMA made comprehensive changes, including code additions, deletions, and revisions, accompanied by new and revised introductory language, parenthetical notes, subheadings and cross-references, to the Integumentary, Repair (Closure) subsection of surgery in the CPT book to facilitate more accurate reporting of skin grafts, skin replacements, skin substitutes, and local wound care. Specifically, the section of the CPT book previously titled "Free Skin Grafts" and containing codes for skin repair procedures was renamed, reorganized, and expanded. New and existing CPT codes related to skin replacement surgery and skin substitutes were organized into five subsections: Surgical Preparation, Autograft/Tissue Cultured Autograft, Acellular Dermal Replacement, Allograft/Tissue Cultured Allogeneic Skin Substitute, and Xenograft.

As part of the CY 2006 CPT code update in the newly named "Skin Replacement Surgery and Skin Substitutes" section, certain codes were deleted that previously described skin allograft and tissue cultured and acellular skin substitute procedures, 37 new CPT codes were created in the "Skin Replacement Surgery and Skin Substitutes" section, and these codes received interim final status indicators and APC assignments in the CY 2006 OPPS final rule with comment period and were subject to comment.

In considering the final CY 2007 APC assignments of these 37 "Skin Replacement Surgery and Skin Repair" codes, we reviewed the recommendations made by the APC Panel at its March 2006 meeting; presentations made to the APC Panel; comments received on the CY 2007 proposed rule; the CPT code descriptors, introductory explanations, cross-references, and parenthetical notes; the clinical characteristics of the procedures; and the code-specific median costs for all related CPT codes available from our CY 2005 claims data. A discussion of the final CY 2007 APC assignments of these procedures can be found in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68054 through 68057).

In the CY 2008 OPPS/ASC proposed rule, we observed that we now have CY 2006 data for the surgical procedures assigned to the 4 CY 2007 skin repair APCs, including the 37 codes considered last year that were new for

CY 2006. The CY 2007 skin repair APCs are: APC 0024 (Level I Skin Repair); APC 0025 (Level II Skin Repair); APC 0686 (Level III Skin Repair); and APC 0027 (Level IV Skin Repair). Based on CY 2006 data available for the proposed rule, the median costs for the APCs as configured for CY 2007 were approximately: \$93 for APC 0024; \$251 for APC 0025; \$1,027 for APC 0686; and \$1,340 for APC 0027. Both APCs 0024 and 0025 had 2 times violations based on CY 2006 claims data. The HCPCS-specific median costs of significant procedures in APC 0024 ranged from approximately \$83 to \$255. We noted that a number of the procedures currently assigned to APC 0024 were very low volume, with few single claims available for ratesetting. Similarly, the median costs of the significant procedures in APC 0025 ranged from a low of about \$119 to a high of about \$399. This APC also contained a number of low volume procedures, as well as some new CY 2007 CPT codes without CY 2006 claims data. There was also some variation in the median costs of the HCPCS codes assigned to APCs 0686 and 0027, but there were no 2 times violations in these two APCs.

At the March 2007 APC Panel meeting, we discussed with the APC Panel one possible reconfiguration of the skin repair APCs in order to address the 2 times violations in APCs 0024 and 0025 for CY 2008 by improving the resource homogeneity of the APCs, as well as ensuring their clinical homogeneity. We reviewed with the APC Panel the potential results associated with adding an additional level in this APC series and reallocating all of the procedures in the original four APCs among five new APCs, taking into account the frequency, resource utilization, and clinical characteristics of each procedure. We also gave particular attention to CPT code families in considering the clinical and resource homogeneity of each APC in the reconfigured series. The new configuration of APCs eliminated the 2 times violations that would have otherwise existed in APCs 0024 and 0025. It also more accurately attributed higher cost procedures to the Levels IV and V APCs, which contain the surgical procedures of the greatest intensity and resource requirements, leading to a more balanced distribution of APC median costs across the five new APC levels.

The APC Panel made a recommendation at its March 2007 meeting supporting the reorganization by CMS of the skin repair APCs into five levels. This recommendation also asked CMS to give special consideration to the

APC assignments of “add-on” codes; in the context of skin procedures, these are generally those CPT codes that report treatment of an additional body area and that are reported along with a primary procedure for treatment of the first body area. In the proposed rule (72 FR 42707), we stated that we accepted the APC Panel’s recommendation through this CY 2008 proposal to reconfigure the skin APCs into five levels, and we reexamined the placement of each of the add-on codes within the framework of the five APCs. We agreed with the APC Panel that, because these skin repair APCs were assigned to status indicator “T” so that add-on codes would typically be paid at 50 percent of their APC payment rate, these add-on codes warranted special examination with respect to their median costs and their appropriate APC assignments. As a result, several CPT code placements from the draft configuration discussed with the APC Panel were changed for the CY 2008 proposal.

In summary, for CY 2008 we proposed to eliminate the four CY 2007 skin repair APCs and replace them with five new APCs titled: APC 0133 (Level I Skin Repair); APC 0134 (Level II Skin Repair); APC 0135 (Level III Skin Repair); APC 0136 (Level IV Skin Repair); and APC 0137 (Level V Skin Repair). We proposed to redistribute each of the procedures assigned to the current four levels of skin repair APCs into the five proposed APCs, with one exception. Specifically, we proposed to reassign CPT code 15835 (Excision, excessive skin and subcutaneous tissue (including lipectomy); buttock) to APC 0022 (Level IV, Excision/Biopsy), where other CPT codes in its code family reside. The median costs of the five proposed APCs were approximately \$84 (APC 0133); \$133 (APC 0134); \$295 (APC 0135); \$971 (APC 0136); and \$1,317 (APC 0137). The proposed configurations of these new APCs were listed in Table 30 of the proposed rule.

At the September 2007 meeting of the APC Panel, one presenter requested that CPT codes 15340 (Tissue cultured allogeneic skin substitute; first 25 sq cm or less) and 15341 (Tissue cultured allogeneic skin substitute; each additional 25 sq cm) be moved from the proposed APC 0134 (Level II Skin Repair) to APC 0135 (Level III Skin Repair). The presenter stated that the CY 2008 proposal to reassign the CPT codes for the application of certain skin products to different APCs is premature because hospitals have been confused by the CY 2006 code descriptor changes made by the CPT Editorial Panel. Current CPT instructions state that hospitals should not bill these two

procedures in conjunction with the CPT codes for wound site preparation and debridement (CPT codes 15002–15005). The presenter stated that the CMS data used in the proposed rule do not reflect the true costs of performing CPT codes 15340 or 15341 because hospitals have been slow to adjust their charges based on the coding changes. The APC Panel made no recommendation at the September 2007 meeting related to the presenter’s recommendations or to the overall skin repair APC proposal.

We received numerous public comments concerning our CY 2008 proposals for these skin repair procedures. A summary of the public comments and our responses follow.

Comment: Many commenters provided recommendations regarding the CY 2008 proposed treatment of specific skin repair CPT codes. One commenter suggested delaying the proposed reconfiguration from four skin repair APCs to five. Many commenters submitted similar letters requesting that CPT codes 15340 and 15341 be moved from the proposed APC 0134 to APC 0135, expressing concern that their placement in proposed APC 0134 did not reflect the actual clinical resource use for the application of the single skin repair biological product currently described by HCPCS code J7340 (Dermal and epidermal, (substitute) tissue of human origin, with or without bioengineered or processed elements, per square centimeter) because hospitals have been confused about appropriate billing for these surgical procedures. The commenters expressed concern that the proposed changes to the skin repair APCs would negatively impact patient access to skin repair procedures, such as CPT codes 15340 and 15341.

One commenter believed that the proposed payments for the proposed five level APC series would create an inappropriate incentive to use specific competing skin replacement and skin substitute products, because in many cases different biologicals used for skin repair are reported with different CPT codes that were, in turn, proposed for assignment to various APC levels. The commenter requested that CMS move CPT codes 15340 and 15341 from the proposed APC 0134 to APC 0135 in order to treat the application of J7340 similarly to other skin repair procedures and to recognize the facility costs associated with wound site preparation for J7340. Alternatively, the commenter recommended that CMS delay restructuring the four CY 2007 APCs and except APCs 0024 and 0025 (based on their CY 2007 structure) from the 2 times rule until another year of claims data are available for the CPT codes that

were new in CY 2006. As a third alternative, the commenter suggested assigning all 16 skin repair CPT codes discussed by the APC Panel last year to a new and separate APC. (A complete listing and discussion of the codes and recommendations of the APC Panel for CY 2007 may be found in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68054 through 68057).) Finally, the commenter requested that CMS depart from CPT billing guidance and allow hospitals to report CPT codes for wound site preparation, such as CPT code 15002 (Surgical preparation or creation of recipient site by excision of open wounds, burn eschar, or scar (including subcutaneous tissues), or incisional release of scar contracture, trunk, arms, legs; first 100 sq cm or 1% of body area of infants and children), or create a new Level II HCPCS G-code, mapped APC 0135, to be used by hospitals to specifically report site preparation performed in conjunction with application of tissue cultured allogeneic skin substitutes described by HCPCS code J7340.

A few commenters also requested that the CPT skin repair codes related to application of the single skin repair biological product currently described by HCPCS code J7342 (Dermal (substitute) tissue of human origin, with or without other bioengineered or processed elements, with metabolically active elements, per square centimeter), specifically CPT code 15365 (Tissue cultured allogeneic dermal substitute, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children) and CPT code 15366 (Tissue cultured allogeneic dermal substitute, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)) be moved from the proposed APC 0134 to APC 0135. The commenters stated that the storage and handling of the product applied with these CPT codes is more resource-intensive than other products whose application procedures were proposed for assignment to APC 0135. They also explained that the claims data that CMS used for APC placement do not accurately reflect the costs associated with these procedures because the product was not available on the market from CY 2006 through the beginning of CY 2007. In addition, they argued that

hospital confusion about skin repair CPT coding changes has led to inaccurate claims.

Response: We have examined CY 2006 claims data available for the CY 2008 final rule with comment period, as well as each of the comments and the public presentation from the September 2007 APC Panel meeting, and find that the five level APC configuration we proposed most appropriately allocates the large number of skin repair and replacement procedures based on the frequency, resource utilization, and clinical characteristics of each procedure. The proposed configuration eliminates the 2 times violations in APCs 0024 and 0025 that would otherwise exist and more accurately attributes higher cost procedure codes to the proposed Levels IV and V APCs.

As for the specific CPT code assignments raised by commenters (CPT codes 15340/15341 and 15365/15366), these codes were all placed in the Level II Skin Repair APC for CY 2007 and were proposed to remain in the Level II Skin Repair APC for CY 2008. In addition to these codes, the following skin repair codes that were new for CY 2006 and discussed by the APC Panel in CY 2006 were also proposed to be assigned to proposed new APC 0134: CPT codes 15170 (Acellular dermal replacement, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children); CPT code 15171 (Acellular dermal replacement, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)); CPT code 15360 (Tissue cultured allogeneic dermal substitute, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children); and CPT code 15361 (Tissue cultured allogeneic dermal substitute, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)). Therefore, we disagree with commenters who believe that we have not treated CPT codes 15340, 15341, 15365 and 15366 similarly to other skin repair procedures. The other 10 skin repair and replacement codes proposed for assignment to APC 0135 have significantly higher median costs than the CPT codes discussed by the commenters. We note, in particular, that payment for HCPCS code J7341 (dermal

(substitute) tissue of non-human origin, with or without other bioengineered or processed with metabolically active elements, per square centimeter) whose application is reported with CPT codes 15430 (Acellular xenograft implant; first 100 sq cm or less, or 1% of body area of infants and children) and 15431 (Acellular xenograft implant; first 100 sq cm or less, or 1% of body area of infants and children; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)), is packaged for CY 2008 because the mean per day cost of J7341 is less than the final \$60 drug packaging threshold. Therefore, it is not surprising that these two CPT codes have higher median costs than CPT codes 15340, 15341, 15365 and 15366 and were proposed for assignment to the higher paying Level III APC 0135, rather than to APC 0134.

Further, we do not believe that it would be appropriate to maintain our CY 2007 structure for the skin repair APCs because we have significant claims data for the new CY 2006 CPT codes that capture the differential hospital costs associated with the procedures. We have no reason to except two of the four skin repair APCs from the 2 times rule based on their CY 2007 structure when the five level configuration that we proposed and that was supported by the APC Panel demonstrates clinical and resource homogeneity without 2 times violations. In particular, we have over 8,000 single claims for CPT code 15340, so we are confident that the procedure's final median cost of approximately \$162 falls within the range of costs for other procedures also assigned to APC 0134, and the APC's median cost of approximately \$132. Similarly, CPT code 15341 for the application of each additional area has a median cost of approximately \$100, so it would be appropriately paid based on the 50 percent multiple procedure reduction applicable to APC 0134. Likewise, we have almost 200 claims for CPT code 15365 from CY 2006, with a median cost of approximately \$147 that is consistent with the median costs of other procedures also assigned to APC 0134. We note one commenter requested that we provide higher payment for CPT codes 15365 and 15366 to apply J7342 because of the greater handling and storage costs of the particular biological. However, we pay for such pharmacy overhead through payment for the biological, not the associated procedures, because, as we describe in

section V.B. of this final rule with comment period, we believe that hospitals include the costs of pharmacy overhead in their charges for drugs and biologicals. Despite the commenter's concern about the integrity of the data because it reported that there was limited availability of the biological described by HCPCS code J7342 in CY 2006, our CY 2006 claims data include over 25,000 units of the product provided on almost 1,200 days of service under the OPSS. In summary, we are confident that our CY 2006 claims data for the procedures reported with CPT codes 15340, 15341, 15365, and 15366 accurately reflect the hospital costs of those procedures and that their proposed APC assignments are appropriate. We note that HCPCS codes J7340 and J7342 for the associated biologicals will be separately paid under the CY 2008 OPSS at ASP+5 percent, as discussed in section V.B.3. of this final rule with comment period.

We do not move CPT codes to higher paying APCs in anticipation of future changes in hospital billing practices, so we believe that it would be premature to reassign any of the four procedures of particular interest to commenters to APC 0135 and unnecessary to create a sixth APC specifically for the 16 skin substitute and skin replacement codes mentioned by the commenter. We also believe that it would be inappropriate in this case to depart from CPT instructions by allowing hospitals to separately report wound site preparation and debridement when services described by CPT codes 15340 and 15341 are performed, whether using the associated CPT codes or by creating a G code. We generally advise hospitals to follow CPT billing guidance, and we disagree with the commenter that the CPT guidance does not adequately reflect the hospital facility component of these services. CPT coding instructions package the wound site preparation into the two codes for application of the biological, and hospitals have been reporting the services since CY 2006 based on those CPT instructions. Given our commitment to greater packaging under the OPSS, it would be inconsistent to adopt a policy for payment of these skin repair procedures that would move away from encounter-based payment by unpackaging wound site preparation.

After consideration of the public comments received, we are finalizing our CY 2008 proposed reconfiguration of the skin substitute and skin replacement APCs, without modification, as shown in Table 22 below.

TABLE 22.—CY 2008 SKIN REPAIR APC CONFIGURATION

HCPCS code	Short descriptor	CY 2008 APC	CY 2008 APC median cost		
11950	Therapy for contour defects	0133	\$80		
11951	Therapy for contour defects.				
11952	Therapy for contour defects.				
11954	Therapy for contour defects.				
12001	Repair superficial wound(s).				
12002	Repair superficial wound(s).				
12004	Repair superficial wound(s).				
12005	Repair superficial wound(s).				
12006	Repair superficial wound(s).				
12007	Repair superficial wound(s).				
12011	Repair superficial wound(s).				
12013	Repair superficial wound(s).				
12014	Repair superficial wound(s).				
12015	Repair superficial wound(s).				
12016	Repair superficial wound(s).				
12017	Repair superficial wound(s).				
12018	Repair superficial wound(s).				
12031	Layer closure of wound(s).				
12041	Layer closure of wound(s).				
12051	Layer closure of wound(s).				
12052	Layer closure of wound(s).				
12053	Layer closure of wound(s).				
15775	Hair transplant punch grafts.				
15776	Hair transplant punch grafts.				
11760	Repair of nail bed			0134	132
11920	Correct skin color defects.				
11921	Correct skin color defects.				
11922	Correct skin color defects.				
12032	Layer closure of wound(s).				
12034	Layer closure of wound(s).				
12035	Layer closure of wound(s).				
12036	Layer closure of wound(s).				
12037	Layer closure of wound(s).				
12042	Layer closure of wound(s).				
12044	Layer closure of wound(s).				
12045	Layer closure of wound(s).				
12046	Layer closure of wound(s).				
12047	Layer closure of wound(s).				
12054	Layer closure of wound(s).				
12055	Layer closure of wound(s).				
12056	Layer closure of wound(s).				
12057	Layer closure of wound(s).				
13120	Repair of wound or lesion.				
13122	Repair wound/lesion add-on.				
13153	Repair wound/lesion add-on.				
15040	Harvest cultured skin graft.				
15170	Acell graft trunk/arms/legs.				
15171	Acell graft t/arm/leg add-on.				
15340	Apply cult skin substitute.				
15341	Apply cult skin sub add-on.				
15360	Apply cult derm sub, t/a/l.				
15361	Aply cult derm sub t/a/l add.				
15365	Apply cult derm sub f/n/hf/g.				
15366	Apply cult derm f/hf/g add.				
15819	Plastic surgery, neck.				
12020	Closure of split wound	0135	285		
12021	Closure of split wound.				
13100	Repair of wound or lesion.				
13101	Repair of wound or lesion.				
13102	Repair wound/lesion add-on.				
13121	Repair of wound or lesion.				
13131	Repair of wound or lesion.				
13132	Repair of wound or lesion.				
13133	Repair wound/lesion add-on.				
13150	Repair of wound or lesion.				
13151	Repair of wound or lesion.				
13152	Repair of wound or lesion.				
15000	Wound prep, 1st 100 sq cm.				
15001	Wound prep, addl 100 sq cm.				
15002	Wnd prep, ch/inf, trk/arm/lg.				

TABLE 22.—CY 2008 SKIN REPAIR APC CONFIGURATION—Continued

HCPCS code	Short descriptor	CY 2008 APC	CY 2008 APC median cost
15003	Wnd prep, ch/inf addl 100 cm.		
15004	Wnd prep ch/inf, f/n/hf/g.		
15005	Wnd prep, f/n/hf/g, addl cm.		
15050	Skin pinch graft.		
15110	Epidrm autogrft trnk/arm/leg.		
15111	Epidrm autogrft t/a/l add-on.		
15115	Epidrm a-grft face/nck/hf/g.		
15116	Epidrm a-grft f/n/hf/g addl.		
15150	Cult epiderm grft t/arm/leg.		
15151	Cult epiderm grft t/a/l addl.		
15152	Cult epiderm graft t/a/l +%.		
15155	Cult epiderm graft, f/n/hf/g.		
15156	Cult epiderm grft f/n/hfg add.		
15157	Cult epiderm grft f/n/hfg +%.		
15175	Acellular graft, f/n/hf/g.		
15176	Acell graft, f/n/hf/g add-on.		
15221	Skin full graft add-on.		
15241	Skin full graft add-on.		
15300	Apply skinallogrft, t/arm/lg.		
15301	Apply sknallogrft t/a/l addl.		
15320	Apply skin allogrft f/n/hf/g.		
15321	Aply sknallogrft f/n/hfg add.		
15330	Aply acell alogrft t/arm/leg.		
15331	Aply acell grft t/a/l add-on.		
15335	Apply acell graft, f/n/hf/g.		
15336	Aply acell grft f/n/hf/g add.		
15350	Skin homograft.		
15351	Skin homograft add-on.		
15400	Apply skin xenograft, t/a/l.		
15401	Apply skn xenogrft t/a/l add.		
15420	Apply skin xgrft, f/n/hf/g.		
15421	Apply skn xgrft f/n/hf/g add.		
15430	Apply acellular xenograft.		
15431	Apply acellular xgrft add.		
20926	Removal of tissue for graft.		
43887	Remove gastric port, open.		
11762	Reconstruction of nail bed	0136	947
14000	Skin tissue rearrangement.		
14001	Skin tissue rearrangement.		
14020	Skin tissue rearrangement.		
14021	Skin tissue rearrangement.		
14040	Skin tissue rearrangement.		
14041	Skin tissue rearrangement.		
14060	Skin tissue rearrangement.		
14061	Skin tissue rearrangement.		
15130	Derm autograft, trnk/arm/leg.		
15131	Derm autograft t/a/l add-on.		
15135	Derm autograft face/nck/hf/g.		
15136	Derm autograft, f/n/hf/g add.		
15200	Skin full graft, trunk.		
15201	Skin full graft trunk add-on.		
15220	Skin full graft sclp/arm/leg.		
15240	Skin full grft face/genit/hf.		
15260	Skin full graft een & lips.		
15261	Skin full graft add-on.		
15740	Island pedicle flap graft.		
15936	Remove sacrum pressure sore.		
15952	Remove thigh pressure sore.		
15953	Remove thigh pressure sore.		
15956	Remove thigh pressure sore.		
15958	Remove thigh pressure sore.		
20920	Removal of fascia for graft.		
20922	Removal of fascia for graft.		
23921	Amputation follow-up surgery.		
25929	Amputation follow-up surgery.		
33222	Revise pocket, pacemaker.		
33223	Revise pocket, pacing-defib.		
11960	Insert tissue expander(s)	0137	1,271
13160	Late closure of wound.		
14300	Skin tissue rearrangement.		

TABLE 22.—CY 2008 SKIN REPAIR APC CONFIGURATION—Continued

HCPCS code	Short descriptor	CY 2008 APC	CY 2008 APC median cost
14350	Skin tissue rearrangement.		
15100	Skin spl't grft, trnk/arm/leg.		
15101	Skin spl't grft t/a/l, add-on.		
15120	Skn spl't a-grft fac/nck/hf/g.		
15121	Skn spl't a-grft f/n/hf/g add.		
15570	Form skin pedicle flap.		
15572	Form skin pedicle flap.		
15574	Form skin pedicle flap.		
15576	Form skin pedicle flap.		
15600	Skin graft.		
15610	Skin graft.		
15620	Skin graft.		
15630	Skin graft.		
15650	Transfer skin pedicle flap.		
15731	Forehead flap w/vasc pedicle.		
15732	Muscle-skin graft, head/neck.		
15734	Muscle-skin graft, trunk.		
15736	Muscle-skin graft, arm.		
15738	Muscle-skin graft, leg.		
15750	Neurovascular pedicle graft.		
15760	Composite skin graft.		
15770	Derma-fat-fascia graft.		
15820	Revision of lower eyelid.		
15821	Revision of lower eyelid.		
15822	Revision of upper eyelid.		
15823	Revision of upper eyelid.		
15824	Removal of forehead wrinkles.		
15825	Removal of neck wrinkles.		
15826	Removal of brow wrinkles.		
15828	Removal of face wrinkles.		
15829	Removal of skin wrinkles.		
15840	Graft for face nerve palsy.		
15841	Graft for face nerve palsy.		
15842	Flap for face nerve palsy.		
15845	Skin and muscle repair, face.		
15876	Suction assisted lipectomy.		
15877	Suction assisted lipectomy.		
15878	Suction assisted lipectomy.		
15879	Suction assisted lipectomy.		
15922	Removal of tail bone ulcer.		
15934	Remove sacrum pressure sore.		
15935	Remove sacrum pressure sore.		
15937	Remove sacrum pressure sore.		
15944	Remove hip pressure sore.		
15945	Remove hip pressure sore.		
15946	Remove hip pressure sore.		
20101	Explore wound, chest.		
20102	Explore wound, abdomen.		
20910	Remove cartilage for graft.		
20912	Remove cartilage for graft.		
43886	Revise gastric port, open.		
43888	Change gastric port, open.		
44312	Revision of ileostomy.		
44340	Revision of colostomy.		

c. Stereotactic Radiosurgery (SRS) Treatment Delivery Services (APCs 0065, 0066, and 0067)

For CY 2007, the CPT Editorial Panel created four new SRS Category I CPT codes in the Radiation Oncology section of the 2007 CPT manual. Specifically, the CPT Editorial Panel created CPT codes 77371 (Radiation treatment delivery, stereotactic radiosurgery (SRS) (complete course of treatment of

cerebral lesion(s) consisting of 1 session); multi-source Cobalt 60 based); 77372 (Radiation treatment delivery, stereotactic radiosurgery (SRS) (complete course of treatment of cerebral lesion(s) consisting of 1 session); linear accelerator based); 77373 (Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5

fractions); and 77435 (Stereotactic body radiation therapy, treatment management, per treatment course, to one or more lesions, including image guidance, entire course not to exceed 5 fractions).

Of the four CPT codes, CPT codes 77371 and 77435 were recognized under the OPPS effective January 1, 2007, while CPT codes 77372 and 77373 were not. CPT code 77371 was assigned to the same APC and status indicator as its

predecessor code, HCPCS code G0243 (Multi-source photon stereotactic radiosurgery, delivery including collimator changes and custom plugging, complete course of treatment, all lesions). For CY 2007, CPT code 77371 was assigned to APC 0127 (Level IV Stereostatic Radiosurgery) with a status indicator of "S." Prior to CY 2007, CPT code 77435 was described under CPT code 0083T (Stereotactic body radiation therapy, treatment management, per day), which was assigned to status indicator "N" in the OPSS. The CPT Editorial Panel decided to delete CPT code 0083T on December 31, 2006, and replaced it with CPT code 77435. Because the costs of SRS treatment management were already packaged into the OPSS payment rates for SRS treatment delivery, we assigned CPT code 77435 to status indicator "N" which was the same status indicator that was assigned to its predecessor Category III CPT code (0083T), under the OPSS, effective January 1, 2007. In the CY 2008 OPSS/ASC proposed rule (72 FR 42716), we noted that the OPSS treatment of these new CPT codes was open to comment in the CY 2007 OPSS/ASC final rule with comment period, and indicated that we would specifically respond to those comments, according to our usual practice, in this final rule with comment period.

As we explained in the CY 2007 OPSS/ASC final rule with comment period (71 FR 68025), we did not recognize CPT codes 77372 and 77373 because they did not accurately and specifically describe the HCPCS G-codes that we used in prior years for linear accelerator (LINAC)-based SRS treatment delivery services under the OPSS. During CY 2006, CPT code 77372 was reported under one of two HCPCS codes, depending on the technology used, specifically, G0173 (Linear accelerator based stereotactic radiosurgery, complete course of therapy in one session) and G0339 (Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment). Because HCPCS codes G0173 and G0339 were more specific in their descriptors than CPT code 77372, we decided to continue using HCPCS codes G0173 and G0339 under the OPSS for CY 2007. For CY 2007, we assigned CPT code 77372 status indicator "B" under the OPSS. In addition, during CY 2006, CPT code 77373 was reported under one of three HCPCS codes depending on the circumstances and technology used, specifically, G0251 (Linear accelerator-based stereotactic

radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, maximum five sessions per course of treatment); G0339 (Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment); and G0340 (Image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatment). Because HCPCS codes G0251, G0339, and G0340 were more specific in their descriptors than CPT code 77373 and were also assigned to different clinical APCs for CY 2007, we decided to continue recognizing HCPCS codes G0251, G0339, and G0340 under the OPSS for CY 2007. Therefore, for CY 2007 we assigned CPT code 77373 status indicator "B" under the OPSS.

In the CY 2008 proposed rule (72 FR 42716 through 42717), we explained that while we had received requests from certain specialty societies and other stakeholders that we recognize CPT codes 77372 and 77373 under the OPSS rather than continuing to use the current Level II HCPCS codes for hospital outpatient facility reporting of these procedures, we had also heard from others that continued use of the G-codes under the OPSS would be the most appropriate way to recognize the facility resource differences between different types of LINAC-based procedures. For the past several years, we had collected information through our claims data regarding the hospital costs associated with the planning and delivery of SRS services. As new technology emerged in the field of SRS several years ago, public commenters urged CMS to recognize cost differences associated with the various methods of SRS planning and delivery. Beginning in CY 2001, we established G-codes to capture any such cost variations associated with the various methods of planning and delivery of SRS. Based on comments received on the CY 2004 OPSS proposed rule regarding the G-codes used for SRS, we made some modifications to the coding for CY 2004 (68 FR 63431 and 63432). First, we received comments regarding the descriptors for HCPCS codes G0173 and G0251, indicating that these codes did not accurately distinguish image-guided robotic SRS systems from other forms of linear accelerator-based SRS systems to account for the cost variation in

delivering these services. In response, for CY 2004 we modified the descriptor for G0173 and also created two HCPCS G-codes, G0339 and G0340, to describe complete and fractionated image-guided robotic linear accelerator-based SRS treatment. While all of these LINAC-based SRS procedures were originally assigned to New Technology APCs under the OPSS, we reassigned them to new clinical APCs for CY 2007 based on 2 full years of hospital claims data reflecting stable median costs based on significant volumes of single claims.

HCPCS codes G0173, G0251, G0339, and G0340 are more specific in their descriptors than either CPT code 77372 or 77373. As we discussed in the CY 2008 proposed rule (72 FR 42717), their hospital claims data continued to reflect significantly different hospital resources that would lead to violations of the 2 times rule were we to reassign certain procedures to the same clinical APCs in order to crosswalk the CY 2006 historical claims data for the 4 G-codes to develop the median costs of the APCs to which the 2 CPT codes would be assigned if we were to recognize them. Therefore, we believed that we should continue to use the G-codes for reporting LINAC-based SRS treatment delivery services for CY 2008 under the OPSS to ensure appropriate payment to hospitals for the different facility resources associated with providing these complex services. That is, we proposed to continue to assign HCPCS codes G0173 and G0339 to APC 0067 (Level III Stereotactic Radiosurgery, MRgFUS, and MEG), HCPCS code G0251 to APC 0065 (Level I Stereotactic Radiosurgery, MRgFUS, and MEG), and HCPCS code G0340 to APC 0066 (Level II Stereotactic Radiosurgery, MRgFUS, and MEG) for CY 2008.

Since we first established the full group of SRS treatment delivery codes in CY 2004, we note that we now have 3 years of hospital claims data reflecting the costs of each of these services. Based on the latest claims data from CY 2006 for the CY 2008 proposed rule, the proposed APC median cost for the complete course of therapy in one session or first fraction of image-guided, robotic LINAC-based SRS, as described by HCPCS codes G0173 and G0339 respectively in APC 0067, was approximately \$3,870 based on 1,946 single claims available for ratesetting. The proposed CY 2008 APC median cost for the second through fifth sessions of image-guided, robotic LINAC-based fractionated SRS treatment, reported by HCPCS code G0340 in APC 0066, was approximately \$2,980 based on 5,209 single claims. The proposed CY 2008 APC median cost for each fractionated

session of LINAC-based SRS, as described by HCPCS code G0251 in APC 0065, was approximately \$1,082 based on 1,938 single claims. Therefore, for CY 2008, we proposed to continue with the CY 2007 HCPCS coding for LINAC-based SRS treatment delivery services under the OPSS. The LINAC based SRS codes and their CY 2008 proposed APC assignments were displayed in Table 36 of the proposed rule (72 FR 42717).

We received several public comments concerning our treatment of new CPT codes for SRS treatment delivery discussed in the CY 2007 OPSS/ASC final rule with comment period and our CY 2008 proposal for these services. A summary of the public comments and our responses follow.

Comment: Several commenters agreed with CMS's proposed continued use of HCPCS codes G0173, G0251, G0339, and G0340 to report SRS services as these codes were more specific in their descriptors than either CPT code 77372 or 77373. However, these commenters requested that CMS further clarify the descriptors of these G-codes to more specifically differentiate image-guided robotic SRS from other LINAC systems. Other commenters to the CY 2008 proposed rule and the CY 2007 OPSS/ASC final rule with comment period disagreed with the use of the G-codes and requested that CMS recognize the CPT codes for ease of billing. Some commenters indicated that use of different codes for the same service for different payers is not consistent with government and industry goals for data uniformity and consistency, and is administratively burdensome for hospitals. One commenter explained that not all payers recognize Medicare's temporary HCPCS codes. This commenter recommended that APCs 0065, 0066 and 0067 be combined into a single APC containing the following codes: CPT codes 77372; 77373; 95966 (Magnetoencephalography (MEG), recording and analysis; for spontaneous brain magnetic activity (e.g., epileptic cerebral cortex localization)); 95967 (Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, single modality (e.g., sensory, motor, language, or visual cortex localization)); 95965 (Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, each additional modality (e.g., sensory, motor, language, or visual cortex localization) (List separately in addition to code for primary procedure)); 0071T (Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue); and 0072T (Focused

ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue). Another commenter requested that HCPCS code G0251 be reassigned from its proposed APC 0065 to APC 0067.

Additionally, several commenters disagreed with CMS's proposal to assign both the MRgFUS and MEG procedures to APCs 0065, 0066, and 0067. These commenters believed that MRgFUS and MEG procedures did not share the same clinical or resource characteristics as SRS procedures. They urged CMS to reassign the MRgFUS and MEG procedures to other APCs that more accurately reflected their clinical characteristics and resource use. Some commenters recommended that the MEG procedures be placed in an APC that described nerve and muscle tests rather than assigning them to an SRS APC. Other commenters did not understand why CMS included the words "MRgFUS" and/or "MEG" in the APC titles for APCs 0065 and 0066 when the proposed APCs did not include one or both of these procedures.

Response: We appreciate the various differences of opinion offered by commenters on coding and payment for LINAC-based SRS treatment delivery services under the OPSS. We will not recognize CPT codes 77372 and 77373 for CY 2008 because we continue to believe that they do not accurately and specifically describe the HCPCS G-codes that we currently use for reporting LINAC-based SRS treatment delivery services under the OPSS. Hospital claims data from CY 2006 for the current G codes demonstrate significant resource differences for the four different services, ranging from approximately \$994 to \$3,620, and these G-codes cannot be mapped in a one-to-one relationship to the CPT codes. We remain unclear about how we could use our historical hospital claims data as the basis for establishing appropriate payment rates for CPT codes 77372 and 77373. We believe that our CY 2008 proposed APC assignments for the four G-codes to APCs 0065, 0066, and 0067, consistent with their CY 2007 assignments, will provide the most appropriate payment for the SRS services described by these codes in CY 2008.

We note that we intend to reevaluate the appropriateness of the use of the HCPCS G-codes for LINAC-based SRS services for the CY 2009 OPSS rulemaking cycle. With that planned reevaluation in mind, we will not modify the G-code descriptors for LINAC based SRS treatment services. These codes have been in effect for the

past 4 years and, based on questions brought to our attention by hospitals, we have no reason to believe that hospitals are confused about the reporting of these codes. In addition, we see resource differences based on the median costs for the four codes that are reasonably consistent with our expectations based on the current code descriptors. We believe it would be confusing to hospitals if we were to modify these code descriptors at this point in time and could lead to instability in our median costs and inaccurate payments for some services. Therefore, we believe that modifying the G-code descriptors is not necessary for us to continue to provide appropriate payment for the services they describe.

We disagree with the recommendation of some commenters to combine all of the SRS, MEG, and MRgFUS procedures into one single clinical APC, when the median costs for these services vary from approximately \$663 to \$4,207. Such a single clinical APC would violate the 2 times rule based on the different hospital resources required for all of the services. With respect to the proposed assignment of MEG and MRgFUS services to APCs 0065 and 0067, we note that the APC Panel recommended at its March 2007 meeting that we assign both CPT codes for MRgFUS procedures to APC 0067. Although we have no single claims available for CPT codes 0071T and 0072T for CY 2008 ratesetting, we continue to believe that these services share sufficient clinical and resource similarity to LINAC-based SRS procedures based on their use of image-guidance and focused energy for tissue ablation that they should be assigned to APC 0067 for CY 2008 as the APC Panel recommended and as we proposed. With respect to MEG procedures, we also believe that, based on the clinical characteristics of these services and the procedures' median costs from claims data, these three services should also be assigned to APCs 0065 and 0067 as proposed.

In the case of the APC titles for APCs 0065, 0066, and 0067, because the titles specify three separate levels of the same series, we will follow our usual practice of maintaining the same APC title for each level for purposes of clarity and consistency, even if not all specific services are assigned to every level.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to continue the use of the current HCPCS G-codes for LINAC-based SRS treatment delivery services, specifically, HCPCS G-codes G0173, G0251, G0339, and G0340, under the

OPPS. We will not recognize CPT codes 77372 and 77373 under the CY 2008 OPPS. The HCPCS G-codes will continue to be assigned to the same CY

2007 APCs for CY 2008, specifically, APCs 0065, 0066, and 0067, with final APC median costs of approximately \$1,044, \$2,835, and \$3,882, respectively.

Table 23 displays the final APC median costs for the SRS treatment delivery HCPCS G-codes.

TABLE 23.—FINAL CY 2008 APC ASSIGNMENTS FOR LINAC-BASED SRS TREATMENT DELIVERY SERVICES

HCPCS code	Short descriptor	CY 2007 SI	CY 2007 APC	CY 2007 APC median cost	Final CY 2008 SI	Final CY 2008 APC final	Final CY 2008 APC median cost
G0173	Linear acc stereo radsur com	S	0067	\$3,873	S	0067	\$3,882
G0251	Linear acc based stero radio	S	0065	1,242	S	0065	1,044
G0339	Robot lin-radsurg com, first	S	0067	3,873	S	0067	3,882
G0340	Robt lin-radsurg fractx 2-5	S	0066	2,630	S	0066	2,835

10. Medical Services

a. Single Allergy Tests (APC 0381)

We proposed to continue with our methodology of differentiating single allergy tests (“per test”) from multiple allergy tests (“per visit”) by assigning these services to two different APCs to provide accurate payments for these tests in CY 2008. Multiple allergy tests are currently assigned to APC 0370 (Allergy Tests), with a median cost calculated based on the standard OPPS methodology. We provided billing guidance in CY 2006 in Transmittal 804 (issued on January 3, 2006) specifically clarifying that hospitals should report charges for the CPT codes that describe single allergy tests to reflect charges “per test” rather than “per visit” and should bill the appropriate number of units of these CPT codes to describe all of the tests provided. However, our CY 2006 claims data available for the CY 2008 proposed rule for APC 0381 (Single Allergy Tests) did not reflect improved and more consistent hospital billing practices of “per test” for single allergy tests. The median cost of APC 0381 calculated for the proposed rule according to the standard single claims OPPS methodology was approximately \$66, significantly higher than the CY 2007 median cost of APC 0381 calculated according to the “per unit” methodology of approximately \$16, and greater than we would expect for these procedures that are to be reported “per test” with the appropriate number of units. Some claims for single allergy tests still appeared to provide charges that represent a “per visit” charge, rather than a “per test” charge. Therefore, consistent with our payment policy for CYs 2006 and 2007, we calculated a “per unit” median cost for APC 0381, based upon 276 claims containing multiple units or multiple occurrences of a single CPT code, where packaging on the claims is allocated equally to each unit of the CPT code. Using this methodology, we calculated

a proposed median cost of approximately \$19 for APC 0381 for CY 2008. We noted in the CY 2008 OPPS/ASC proposed rule (72 FR 42713) that we will consider whether further instructions to hospitals for reporting these procedures would be beneficial, because we are concerned that our claims data for CY 2006 reflect no apparent change in hospitals’ billing practices following our January 2006 clarification. We remain hopeful that better and more accurate hospital reporting and charging practices for these single allergy test CPT codes in future years may allow us to calculate the median cost of APC 0381 using the standard OPPS process for future OPPS updates.

We did not receive any public comments on this proposal. Therefore, we are finalizing our CY 2008 proposal, without modification, to calculate a “per unit” median cost for APC 0381 as described above. The CY 2008 median cost of APC 0381 is approximately \$17.

b. Continuous Glucose Monitoring (APC 0097)

For CY 2008, we proposed to reassign CPT code 95250 (Ambulatory continuous glucose monitoring of interstitial fluid via a subcutaneous sensor for up to 72 hours; sensor placement, hook-up; calibration of monitor, patient training, removal of sensor, and printout of recording) to APC 0097 (Prolonged Physiologic and Ambulatory Monitoring), with a proposed payment rate of approximately \$66. CPT code 95250 is assigned to APC 0421 (Prolonged Physiologic Monitoring) for CY 2007, with a payment rate of approximately \$100. We also proposed to discontinue APC 0421 effective January 1, 2008. At the September 2007 APC Panel meeting, the APC Panel recommended that CMS retain APC 0421 with its CY 2007 composition, including maintaining CPT code 95250 in that APC for CY 2008.

We received one public comment on our CY 2008 proposed reassignment of CPT code 95250 to APC 0097. A summary of the public comment and our response follow.

Comment: One commenter considered the proposal to reassign CPT code 95250 to APC 0097 to be an apparent violation of the 2 times rule. The commenter further reported that placement of CPT code 95250 in APC 0097 was problematic with respect to ensuring resource comparability among all the procedures assigned to the APC for CY 2008, because continuous glucose monitoring involves significant patient training of 30 to 40 minutes, whereas there is minimal to no patient training associated with most of the other HCPCS codes in APC 0097. In addition, the commenter noted that the OPPS payment for CPT code 95250 should include payment for a sensor that costs approximately \$35, which would consume 53 percent of the proposed payment for the service. The commenter recommended that CMS not discontinue APC 0421 and maintain CPT code 95250 in APC 0421 for CY 2008. Alternatively, the commenter believed that CMS could split APC 0097 into two APCs for Level I and Level II services, assigning CPT code 95250 to the higher paying Level II APC. Another commenter also recommended that CMS maintain APC 0421 on the basis that the lower payment rate of APC 0097 would potentially result in limiting patient access to this monitoring approach for patients with diabetes.

Response: As described in section II.A.2. of this final rule with comment period, for CY 2008 we proposed to eliminate many APCs with low total claims volume in order to stabilize OPPS payments for these low volume services. We generally proposed to reassign the services residing in these low volume APCs to other clinical APCs, along with services that share clinical and resource characteristics. We note that APC 0421, as configured for

CY 2007 and where CPT code 95250 is currently assigned, is a low volume APC, which would have included only about 750 CY 2006 claims. We proposed to discontinue APC 0421 and reassign CPT code 95250 to APC 0097. Proposed APC 0097 consisted of 17 services, with approximately 487,000 CY 2006 claims for those services. Low volume services, including CPT code 95250, are not significant services in APCs and, therefore, do not result in violations of the 2 times rule.

We agree with the commenters that CPT code 95250 should not be assigned to APC 0097, based on our review of its clinical and resource characteristics. However, we will not maintain APC 0421 for CY 2008, given our interest in eliminating low volume APCs, and, therefore, we are not adopting the recommendation of the APC Panel. In addition, we will not separate APC 0097 into two levels because we believe that an alternative assignment of CPT code 95250 to another existing clinical APC would be more appropriate. Taking into consideration the patient training required in association with CPT code 95250, we believe that it would be appropriate to assign this service to APC 0607 (Level 4 Hospital Clinic Visits), which has a CY 2008 final median cost of approximately \$104. The median cost of CPT code 95250 of approximately \$100 is well within the range of approximately \$99 to \$122 for other significant procedures also assigned to that APC for CY 2008. This final reassignment of CPT code 95250 to APC 0607 should resolve any concerns about violations of the 2 times rule and leads to appropriate grouping of the service with other similar services that share clinical and resource characteristics.

After consideration of the public comment received, we are finalizing our CY 2008 proposal with modification. We are discontinuing APC 0421 and reassigning CPT code 95250 to APC 0607, with a CY 2008 median cost of approximately \$104, rather than to APC 0097 as proposed.

c. Home International Normalized Ratio (INR) Monitoring (APC 0097)

For CY 2008, we proposed to reassign the two following HCPCS codes to APC 0097 (Prolonged Physiologic and Ambulatory Monitoring), with a proposed payment rate of approximately \$66: G0248 (Demonstration at initial use, of home INR monitoring for patient with mechanical heart valve(s) who meets Medicare coverage criteria, under the direction of a physician; includes: demonstrating use and care of the INR monitor, obtaining at least one blood sample, provision of instructions for

reporting home INR test results, and documentation of patient ability to perform testing) and HCPCS code G0249 (Provision of test materials and equipment for home INR monitoring to patient with mechanical heart valve(s) who meets Medicare coverage criteria; includes provision of materials for use in the home and reporting of test results to physician; per 4 tests). Currently, HCPCS codes G0248 and G0249 are assigned to APC 0421 (Prolonged Physiologic Monitoring), with a payment rate of approximately \$100 for CY 2007. As stated in section III.D.10.b. of this final rule with comment period, we also proposed to discontinue APC 0421 effective January 1, 2008. At the September 2007 APC Panel meeting, the APC Panel recommended that CMS retain APC 0421 with its CY 2007 composition, including maintaining HCPCS codes G0248 and G0249 in that APC for CY 2008.

We received one public comment on our CY 2008 proposed reassignment of HCPCS codes G0248 and G0249 to APC 0097. A summary of the public comment and our response follow.

Comment: One commenter was concerned that CMS's proposal to reassign HCPCS codes G0248 and G0249 from APC 0421 to APC 0097 would substantially reduce payments for these services and would make it financially impossible for hospitals to offer these services, thereby reducing patient access to home INR monitoring. The commenter urged CMS to maintain APC 0421 or, as an alternative, to create a new APC that would include HCPCS codes G0248 and G0249 and two other higher cost procedures also proposed for CY 2008 assignment to APC 0097, specifically CPT code 93271 (Patient demand single or multiple event recording with presymptom memory loop, 24-hour attended monitoring, per 30 day period of time; monitoring, receipt of transmissions, and analysis) and CPT code 95250 (Ambulatory continuous glucose monitoring of interstitial fluid via a subcutaneous sensor for up to 72 hours; sensor placement, hook-up; calibration of monitor, patient training, removal of sensor, and printout of recording).

Response: As described in section II.A.2. of this final rule with comment period, for CY 2008 we proposed to eliminate many APCs with low total claims volume in order to stabilize OPSS payments for these low volume services. We generally proposed to reassign the services residing in these low volume APCs to other clinical APCs, along with services that share clinical and resource characteristics. We note that APC 0421, as configured for

CY 2007 and where HCPCS codes G0248 and G0249 are currently assigned, is a low volume APC, which would have included only about 750 CY 2006 claims. We proposed to discontinue APC 0421 and reassign HCPCS codes G0248 and G0249 to proposed APC 0097. Proposed APC 0097 consisted of 17 services, with approximately 487,000 CY 2006 claims for those services.

We agree with the commenter that HCPCS codes G0248 and G0249 should not be assigned to APC 0097, based on our reexamination of their clinical and resource characteristics. However, we will not maintain APC 0421 for CY 2008, given our interest in eliminating low volume APCs, and, therefore, we are not adopting the recommendation of the APC Panel. In addition, we will not create another new clinical APC consisting of four of the higher cost services proposed for CY 2008 assignment to APC 0097 because we believe that alternative assignments of those codes to other existing clinical APCs are more appropriate. We discuss the final CY 2008 reassignment of CPT code 95250 to APC 0607 (Level 4 Hospital Clinic Visits) in section III.D.10.b. of this final rule with comment period. In addition, we are reassigning CPT code 93271, which has a median cost of approximately \$93 to APC 0663 (Level I Electronic Analysis of Devices), with a CY 2008 median cost of approximately \$96. Taking into consideration the patient training required in association with HCPCS code G0248 in particular, we believe that it would be appropriate to assign both HCPCS codes G0248 and G0249 to APC 0607 (Level 4 Hospital Clinic Visits), which has a CY 2008 final median cost of approximately \$104. The median costs of HCPCS codes G0248 and G0249 are approximately \$72 and \$120, respectively, similar to the hospital costs for other services also assigned to that APC for CY 2008.

After consideration of the public comment received, we are finalizing our CY 2008 proposal, with modification. We are discontinuing APC 0421 and reassigning HCPCS codes G0248 and G0249 to APC 0607, with a CY 2008 median cost of approximately \$104, rather than to APC 0097 as proposed.

d. Mental Health Services (APCs 0322, 0323, 0324, and 0325)

For CY 2008, we did not propose any policy changes to the range or composition of APCs that describe psychotherapy services provided in HOPDs. These APCs include 0322 (Brief Individual Psychotherapy), which has a CY 2008 median cost of approximately

\$74; 0323 (Extended Individual Psychotherapy), which has a CY 2008 median cost of approximately \$101; 0324 (Family Psychotherapy), which has a CY 2008 median cost of approximately \$149; and 0325 (Group Psychotherapy), which has a CY 2008 median cost of approximately \$62. Proposals related to partial hospitalization programs are discussed in section II.B. of this final rule with comment period.

We note that since the inception of the OPSS, CMS has limited the aggregate payment for specified less intensive mental health services furnished on the same date to the payment for a day of partial hospitalization, which we considered to be the most intensive of all outpatient mental health treatment (65 FR 18455). The costs associated with administering a partial hospitalization program represent the most resource-intensive of all outpatient mental health treatment, and we do not believe that we should pay more for a day of individual mental health services under the OPSS.

We received several public comments regarding our CY 2008 proposed payment for APCs 0332, 0323, 0324, and 0325. A summary of the public comments and our responses follow.

Comment: Several commenters noted that the payment rates associated with APCs 0322, 0323, 0324, and 0325 have decreased in recent years. Specifically, the commenters stated that payment associated with APC 0325 decreased by 17 percent between CY 2006 and CY 2007 and was proposed to decline by an additional 3 percent for CY 2008. These commenters expressed concern that the payment rates are insufficient to cover their costs for mental health services. One commenter noted that it is more cost-effective to treat Medicare beneficiaries in HOPDs, rather than costly partial hospitalization programs, and encouraged CMS to provide adequate payment rates to the less intensive programs.

Response: We carefully analyzed several years of resource cost data associated with APCs 0322 through 0325. We note that the median costs of APCs 0322, 0323, and 0324 have remained fairly constant in recent years. APC 0323 has a small 2 times rule violation for CY 2008, and also had a small violation in CY 2007, but it is not clear how to best resolve the violation, while ensuring the clinical and resource homogeneity of reconfigured APCs. For CY 2007 and CY 2008, APC 0323 is excepted from the 2 times rule. We will review APC 0323 at the next APC Panel meeting and seek its guidance in reconfiguring this APC for CY 2009. As

the commenters noted, the median cost for APC 0325 declined significantly in CY 2007, and declined again for CY 2008, using full year CY 2006 claims data. We cannot speculate as to why this recent decline in the median cost of group psychotherapy services has occurred. We have robust claims data for the CPT codes that map to APC 0325. Specifically, we were able to use almost 80 percent of the 1.6 million claims submitted by hospitals to report group psychotherapy services. In general, we set payment rates using our standard OPSS methodology based on relative costs from hospital outpatient claims. In this case, we have no reason to discount our claims data, and it would appear that the relative cost of providing these mental health services in comparison with other HOPD services has decreased in recent years.

While reviewing the CY 2008 OPSS proposal for mental health services, we noted that CPT code 90862 (Pharmacologic management, including prescription, use, and review of medication with no more than minimal psychotherapy) and HCPCS code M0064 (Brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders) were proposed to map to APC 0605 (Level 2 Hospital Clinic Visits) for CY 2008, with a proposed payment of approximately \$64. These assignments were proposed changes from their CY 2007 assignments to APC 0374 (Monitoring Psychiatric Drugs), which has a payment rate of approximately \$70. We proposed to discontinue APC 0374 for CY 2008. Based on our reexamination of the claims data for this final rule with comment period, particularly the hospitals costs associated with these visits, we are reassigning HCPCS codes 90862 and M0064 to APC 0606 (Level 3 Hospital Clinic Visits) for CY 2008, with a median cost of approximately \$83.

Comment: Several commenters expressed concern that payment for mental health services provided on one date is capped at the partial hospitalization payment rate. One commenter noted that if an HOPD provides four particular mental health services in one day, that department would receive full payment for the first two services, partial payment for the third service, and no payment for the fourth service.

Response: We continue to believe that the costs associated with administering a partial hospitalization program represent the most resource intensive of all outpatient mental health treatment, and we do not believe that we should

pay more for a day of individual mental health services under the OPSS. We note that these commenters also submitted comments requesting that the partial hospitalization payment rate increase for CY 2008. The mental health payment limitation will rise and fall in the same manner as payment for partial hospitalization services.

After consideration of the public comments received, we will ask the APC Panel to provide advice at its next meeting regarding the possible reconfiguration of APC 0323 to resolve a small 2 times violation for CY 2009. For CY 2008, we are modifying our proposal for two medication management services and will reassign CPT code 90862 and HCPCS code M0064 from APC 0605 to APC 0606, with a median cost of approximately \$83.

IV. OPSS Payment for Devices

A. Treatment of Device-Dependent APCs

1. Background

Device-dependent APCs are populated by HCPCS codes that usually, but not always, require that a device be implanted or used to perform the procedure. For the CY 2002 OPSS, we used external data, in part, to establish the device-dependent APC medians used for weight setting. At that time, many devices were eligible for pass-through payment. For the CY 2002 OPSS, we estimated that the total amount of pass-through payments would far exceed the limit imposed by statute. To reduce the amount of a pro rata adjustment to all pass-through items, we packaged 75 percent of the cost of the devices, using external data furnished by commenters on the August 24, 2001 proposed rule and information furnished on applications for pass-through payment, into the median costs for the device-dependent APCs associated with these pass-through devices. The remaining 25 percent of the cost was considered to be pass-through payment.

In the CY 2003 OPSS, we determined APC medians for device-dependent APCs using a three-pronged approach. First, we used only claims with device codes on the claim to set the medians for these APCs. Second, we used external data, in part, to set the medians for selected device-dependent APCs by blending that external data with claims data to establish the APC medians. Finally, we also adjusted the median for any APC (whether device-dependent or not) that declined more than 15 percent. In addition, in the CY 2003 OPSS we deleted the device codes ("C" codes) from the HCPCS file because we

believed that hospitals would include the charges for the devices on their claims, notwithstanding the absence of specific codes for devices used.

In the CY 2004 OPPS, we used only claims containing device codes to set the medians for device-dependent APCs and again used external data in a 50/50 blend with claims data to adjust medians for a few device-dependent codes when it appeared that the adjustments were important to ensure access to care. However, hospital device code reporting was optional.

In the CY 2005 OPPS, which was based on CY 2003 claims data, there were no device codes on the claims and, therefore, we could not use device-coded claims in median calculations as a proxy for completeness of the coding and charges on the claims. For the CY 2005 OPPS, we adjusted device-dependent APC medians for those device dependent APCs for which the CY 2005 OPPS payment median was less than 95 percent of the CY 2004 OPPS payment median. In these cases, the CY 2005 OPPS payment median was adjusted to 95 percent of the CY 2004 OPPS payment median. We also reinstated the device codes and made the use of the device codes mandatory where an appropriate code exists to describe a device utilized in a procedure. In addition, we implemented HCPCS code edits to facilitate complete reporting of the charges for the devices used in the procedures assigned to the device dependent APCs.

In the CY 2006 OPPS, which was based on CY 2004 claims data, we set the median costs for device-dependent APCs for CY 2006 at the highest of: (1) The median cost of all single bills; (2) the median cost calculated using only claims that contained pertinent device codes and for which the device cost was greater than \$1; or (3) 90 percent of the payment median that was used to set the CY 2005 payment rates. We set 90 percent of the CY 2005 payment median as a floor rather than 85 percent as proposed, in consideration of public comments that stated that a 15 percent reduction from the CY 2005 payment median was too large of a transitional step. We noted in our CY 2006 proposed rule that we viewed our proposed 85 percent payment adjustment as a transitional step from the adjusted medians of past years to the use of unadjusted medians based solely on hospital claims data with device codes in future years (70 FR 42714). We also incorporated, as part of our CY 2006 methodology, the recommendation of commenters to base payment on medians that were calculated using only claims that passed the device edits. As

we stated in the CY 2006 OPPS final rule with comment period (70 FR 68620), we believed that this policy provided a reasonable transition to full use of claims data in CY 2007, which would include device coding and device editing, while better moderating the amount of decline from the CY 2005 OPPS payment rates.

For CY 2007, we based the device-dependent APC medians on CY 2005 claims, the most current data available at that time. In CY 2005 we reinstated hospital reporting of device codes and made the reporting of device codes mandatory where an appropriate code exists to describe a device utilized. In CY 2005, we also implemented HCPCS code procedure-to-device edits to facilitate complete reporting of the charges for the devices used in the procedures assigned to the device-dependent APCs. For CY 2007 ratesetting, we excluded claims for which the charge for a device was less than \$1.01, in part to recognize hospital charging practices due to a recall of cardioverter-defibrillator and pacemaker pulse generators in CY 2005 for which the manufacturers provided replacement devices without cost to the beneficiary or hospital. We also found that there were other devices for which the token charge was less than \$1.01, and we removed those claims from the set used to calculate the median costs of device-dependent APCs. In summary, for the CY 2007 OPPS we set the median costs for device-dependent APCs using only claims that passed the device edits and did not contain token charges for the devices. Therefore, the median costs for these APCs for CY 2007 were determined from claims data that generally represented the full cost of the required device.

2. Payment Under the CY 2008 OPPS

For CY 2008, we proposed to calculate the median costs for device-dependent APCs using three different sets of CY 2006 claims (72 FR 42719). We first calculated a median cost using all single procedure claims that contained appropriate device codes (where there are edits) for the procedure codes in those APCs. We then calculated a second median cost using only claims that contain allowed device HCPCS codes with charges for all device codes that were in excess of \$1.00 (nontoken charge device claims). Third, we calculated the APC median cost based only upon nontoken charge device claims with correct devices that did not also contain the HCPCS modifier "FB," reported in CY 2005 to identify that a procedure was performed using an item provided without cost to

the provider, supplier, or practitioner, or where a credit was received for a replaced device (examples include, but are not limited to, devices covered under warranty, devices replaced due to defects, and free samples).

As expected, the median costs calculated based upon single procedure bills that met all three criteria, that is, correct devices, no token charges, and no "FB" modifier, were generally higher than the median costs calculated using all single bills. We believed that the claims that met these three criteria (appropriate device codes, nontoken device charges, and no "FB" modifier) reflected the best estimated costs for these device-dependent APCs when the hospital pays the full cost of the device, and we proposed to base our CY 2008 median costs on the medians calculated based upon these claims.

As a result of the effects of the proposed CY 2008 packaging approach discussed in detail in section II.A.4. of the proposed rule on median costs, we proposed to make some changes to CY 2007 device-dependent APCs for CY 2008. Specifically, we proposed to delete APC 0081 (Noncoronary Angioplasty or Atherectomy); APC 0087 (Cardiac Electrophysiologic Recording/Mapping); and APC 0670 (Level II Intravascular and Intracardiac Ultrasound and Flow Reserve) due to the migration of HCPCS codes to other APCs. Some of the HCPCS codes assigned to these APCs in CY 2007 would be unconditionally packaged for CY 2008. The median costs of the remaining HCPCS codes proposed for separate payment in CY 2008 were significantly different than CY 2007 due to the proposed packaging of additional services. We believed that reconfiguration of the APCs was necessary to ensure that the HCPCS codes that would be separately paid in CY 2008 and that are assigned to these APCs in CY 2007 would be assigned to APCs that are homogeneous with regard to clinical characteristics and resource use in CY 2008. The APCs we proposed for deletion ceased to be appropriate as a result of the reassignment of the HCPCS codes that we proposed for continued separate payment in CY 2008.

As proposed, the following seven APCs remained device-dependent APCs for CY 2008, but we proposed to reassign certain HCPCS codes mapped to these APCs for CY 2007 either to other APCs or among these APCs for CY 2008 to ensure that, in view of the median costs that resulted from the proposed CY 2008 packaging approach, the HCPCS codes would be assigned to APCs that were homogeneous with regard to clinical characteristics and

resource use for CY 2008: APC 0082 (Coronary Atherectomy); APC 0083 (Coronary Angioplasty and Percutaneous Valvuloplasty); APC 0085 (Level II Electrophysiologic Evaluation); APC 0086 (Ablate Heart Dysrhythm Focus); APC 0115 (Cannula/Access Device Procedures); APC 0427 (Level III Tube Changes and Repositioning); and APC 0623 (Level III Vascular Access Procedures). We also proposed to consider APC 0084 (Level I Electrophysiologic Procedures) to be a device-dependent APC for CY 2008 because we proposed to reassign many of the HCPCS codes that were previously in APCs 0086 and 0087 to APC 0084.

As a result of the proposed APC reconfigurations resulting from HCPCS code migration, we noted that it was not appropriate to compare the proposed CY 2008 OPPS median costs for these eight APCs to the CY 2007 OPPS final rule median costs that were the basis for the CY 2007 OPPS payment rates. When we compared the median costs for the other device-dependent APCs with stable proposed CY 2008 configurations in comparison with CY 2007, the median costs for 26 APCs increased, some of them by significant amounts, and the median costs for 5 APCs decreased. We believed that these median costs represented valid estimates of the relative costs of the services in these APCs, both with regard to the increases and the decreases that appeared when the proposed CY 2008 median costs were compared to the CY 2007 median costs on which the payment rates for these APCs were based.

Therefore, we proposed to base the payment rates for CY 2008 for all device-dependent APCs on their median costs calculated using only single bills that meet the three selection criteria discussed in detail above. We did not believe that any special payment policies were needed, as we believed that the claims data we proposed to use for ratesetting would ensure that the costs of the implantable devices were adequately and appropriately reflected in the median costs for these device-dependent APCs.

We received a number of public comments on our CY 2008 proposed payment methodology for device-dependent APCs. A summary of the public comments and our responses follow.

Comment: Commenters supported the proposal to set the median costs for device-dependent APCs using only claims that meet the three selection criteria described in the proposed rule (that is, pass the device edits, do not contain token charges, and do not have

the without cost/full credit modifier “FB”), and urged CMS to continue to use device edits to ensure that hospitals bill Level II HCPCS device codes in addition to CPT codes for device-dependent procedures. Commenters also suggested certain refinements to CMS’ ratesetting methodology for device-dependent APCs. One commenter asked for implementation of the March 2007 APC Panel’s recommendation to edit and return for correction all claims that contain an HCPCS code for a separately payable device but do not contain a CPT code assigned to a procedural APC. Another commenter requested that at least 2 full years of data be used to set rates for device-dependent APCs, as it may take hospitals several months before they bill new Level II HCPCS device codes correctly, and also asked that we implement a payment floor to prevent large decreases in payment and promote stability in payment rates from year to year. Another commenter asked CMS to redefine “token charge” for cochlear implants to mean any amount lower than the amount the commenter specified should be charged.

Response: We agree that it is appropriate to base the median costs for device-dependent APCs on claims that contain the correct devices, do not contain token charges, and do not contain the “FB” modifier. However, we do not believe that it would be appropriate to define “token charge” at particular amounts for particular devices based on external data or otherwise because hospitals are free to set their charges for all items and services based on their own judgment. We encourage hospitals to develop their charges, revenue centers, and internal processes as they find appropriate. We have no reason to believe, in any given case other than a token charge reported according to CMS’ instructions, that the charge on a claim is not an appropriate charge by a hospital established for that specific service.

We agree that claims processing edits for services and items integral to the performance of certain OPPS procedures paid under the OPPS are an important element of our ratesetting methodology and, therefore, we will continue to require that correct devices be billed with certain HCPCS procedure codes for services that require devices. Moreover, we have expanded their use within and beyond device-dependent APCs (see sections II.A.2. and II.A.4.c.(5) of this final rule with comment period for a discussion of the March 2007 APC Panel’s recommendation and measures we are taking to improve claims data for diagnostic radiopharmaceuticals by

using edits). In general, however, we limit edits to the services, items, and procedures we believe require extra vigilance to capture all associated charges in recognition of the additional administrative burden these edits create for hospitals, and the inherent complexity of ensuring that the edits we do implement appropriately anticipate all clinical circumstances. Particularly for packaged items and services including expensive devices, we believe these edits ensure that high cost items are reported on appropriate claims, so that the procedural payment rates fully incorporate the costs of the items that are required for the procedures. For other items, services, and procedures, we believe that hospitals have strong incentives to report charges accurately to Medicare and all other payers, and that these charges are sufficient to provide accurate data. Another important component of ensuring we use the most accurate data available for OPPS device-dependent APC ratesetting is using the most current claims data and cost reports. Therefore, we believe that it would be inconsistent to wait until we have 2 full years of claims data before we update payment rates.

We also do not believe it is necessary to adjust our standard device-dependent ratesetting methodology for CY 2008 by implementing a payment floor to ensure beneficiary access. The only decline of more than 10 percent between the CY 2008 final rule APC medians and the CY 2007 final rule medians is found in APC 0418 (Insertion of Left Ventricular Pacing Electrode). As discussed in the proposed rule (72 FR 42720), we believe that this decline and variation in the median cost for APC 0418 was the result of improvements in provider billing and a relatively small number of single bills from a small number of providers furnishing the service. We believe that the median cost we calculated from the CY 2006 data is a reasonable estimate of the cost of the insertion of the left ventricular lead. Furthermore, the fluctuation of payment rates is to a certain degree inherent and expected in a prospective payment system (see section II.A of this final rule with comment period for a broader discussion of the variation in APC payment rates from year to year). We note that we have put into place reverse device edits for CY 2007 that will continue in CY 2008, where we require hospitals reporting certain implantable device HCPCS codes, such as ICDs, to report an appropriate procedure for the device’s use. We do not believe it is necessary to implement a payment floor for this procedure, or any other device-

dependent procedure, to prevent large decreases in payment.

Comment: One commenter suggested that CMS should consider creation of composite APCs for device-dependent procedures, such as ICD implantation, where the device costs can vary significantly based on the type of device used. The commenter suggested that payment for these composite APCs would be based on the combination of the device implantation CPT code and the existing Level II HCPCS code for the particular device. According to the commenter, this would minimize administrative burden for providers, allow coding to remain consistent across payers, and enable more appropriate payment for procedures with varying device costs.

Response: Composite APCs provide a single payment for two or more major procedures that are commonly performed together, in order to promote efficiency by increasing the size of the payment bundle. We do not agree that the payment methodology outlined by this commenter, to base payment on the combination of the device implantation CPT code and the existing device code, is consistent with the concept of composite APCs as described in the proposed rule and as finalized in section II.A.4.d. of this final rule with comment period. The scenario described by the commenter largely describes the current packaging of device payment into the payment for the procedure, except that we generally base payment on all of the devices associated with a procedure as a mechanism to promote the efficient utilization of resources. The recommended approach could actually reduce packaging under the OPPS by creating small and more specific payment bundles, rather than increasing the size of the payment bundles to provide hospitals with the flexibility to manage their resources as they control costs. To establish a separate APC for each combination of a procedure and a particular device used, as described by the commenter, would create incentives for the use of the most expensive device rather than creating incentives for efficiency and therefore is contrary to the principles of a prospective payment system.

Comment: Several commenters requested that CMS use external data for ratesetting. While some commenters called for the broad-scale use of external data to identify and adjust payment for technologies they perceived to be underpaid both in the past and under the current proposal, other commenters focused on the use of external data in ratesetting for particular APCs (for example, several commenters asked that

CMS redefine the token charge criteria and adjust payment for cochlear implants to reflect the device's estimated hospital invoice price). According to commenters, external data could be used to rectify the effects of charge compression, without committing CMS to reliance on any particular data source. In addition, commenters requested that CMS protect the confidentiality of any external data used in ratesetting, because manufacturers and hospitals may be unwilling to release proprietary information without assurances that CMS would not release that information to the public.

Response: We review all information that is brought to our attention by stakeholders as part of the public comment process, and we have a general policy that all data we consider in ratesetting, whether internal or external, will be made available to the public, including any personally identifiable or confidential business information (for example, see the discussion of Inspection of Public Comments in the CY 2008 OPPS/ASC proposed rule (72 FR 42628)). We have not systematically used external data to validate the median costs derived from claims data, because external data typically are furnished by parties with special interest in a particular item or service. The foundation of a system of relative weights is the relativity of the costs of all services to one another, as derived from a standardized system that uses standardized inputs and a consistent methodology. One of the principles behind the use of median costs for weight setting in a budget neutral payment system like the OPPS is to allow fair and equitable distribution of payment among hospitals, based on their mix of services provided to Medicare beneficiaries, by determining the appropriate relativity in resource use among services. The median costs are estimated relative costs that are converted to relative weights, scaled for budget neutrality, and then multiplied by a conversion factor to derive a payment under a prospective payment system that is not intended to pay reasonable costs. For these reasons, we believe that it is not appropriate to use external pricing information in place of the costs derived from the claims and Medicare cost report data, because we believe that to do so would distort the relativity that is so fundamental to the integrity of the OPPS. Similarly, we do not believe that it is reasonable or appropriate to exclude specific claims from ratesetting if the hospital charge for a particular

item does not exceed an established threshold such as the manufacturer's estimated cost of the item.

After considering the public comments received on this proposal, we are finalizing our proposed payment policies for device-dependent APCs, without modification, for CY 2008. The CY 2008 payment rates for device-dependent APCs are based on their median costs calculated from CY 2006 claims and the most recent cost report data, using only claims that pass the device edits, do not contain token charges for devices, and do not have a modifier signifying that the device was furnished without cost or with full credit. We do not think it is necessary or appropriate to apply a maximum payment reduction floor. Consistent with data from the proposed rule, payment rates based on final rule data show increases for the majority of APCs for which comparison to CY 2007 payment rates is appropriate. As discussed in the proposed rule (72 FR 42720 through 42721), we found these differences in payment rates from CY 2007 to CY 2008 to be attributable to a variety of factors, including the availability of more complete claims data for CY 2008 and the packaging approach that is new for CY 2008. Furthermore, as we have stated in the past, some variation in relative costs from year to year is expected in a prospective payment system, particularly for low volume device dependent APCs such as APC O681 (Knee Arthroplasty), which increases 37 percent from CY 2007 to CY 2008. However, even in the case of these low volume device dependent APCs, we continue to believe that the median costs calculated from the single bills that meet the three criteria represent the most valid estimated relative costs of these services to hospitals when they incur the full cost of the devices required to perform the procedures. In addition, we note that we will maintain established device edits for procedures previously assigned to device-dependent APCs that were packaged or moved to APCs that are not device-dependent for CY 2008, in order to ensure that the full costs associated with these services continue to be represented adequately in claims data.

Discussions of HCPCS code and APC-specific issues for device-dependent APCs are found in section III.D. of this preamble, where other APC-specific policies are also discussed. As discussed in detail in section III.D.6.b. of this final rule with comment period, we are adding APC 0293 (Level V Anterior Segment Eye Procedures) to the

list of device-dependent APCs for CY 2008, as reflected in Table 24 below.

TABLE 24.—CY 2008 MEDIAN COSTS FOR DEVICE-DEPENDENT APCs

[Note that N/A indicates APCs for which the CY 2007 OPps medians are not comparable to the CY 2008 medians, due to HCPCS code migration for CY 2008.]

APC	SI	APC title	CY 2007 final rule pass edit, nontoken median cost	CY 2008 final rule pass edit, nontoken median cost	CY 2008 final rule pass edit, nontoken frequency	Count of providers billing in the final CY 2008 data
0039	S	Level I Implantation of Neurostimulator	\$11,451	\$11,732	2,950	653
0040	S	Percutaneous Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve.	\$3,457	\$4,013	5,177	1,040
0061	S	Laminectomy or Incision for Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve.	\$5,145	\$5,213	1,413	462
0082	T	Coronary or Non Coronary Atherectomy	N/A	\$5,506	4,758	962
0083	T	Coronary or Non Coronary Angioplasty and Percutaneous Valvuloplasty.	N/A	\$2,855	41,944	1,728
0084	S	Level I Electrophysiologic Procedures	N/A	\$603	7,381	616
0085	T	Level II Electrophysiologic Evaluation	N/A	\$2,976	4,291	719
0086	T	Level III Electrophysiologic Procedures	N/A	\$5,842	420	164
0089	T	Insertion/Replacement of Permanent Pacemaker and Electrodes.	\$7,557	\$7,654	668	370
0090	T	Insertion/Replacement of Pacemaker Pulse Generator	\$6,007	\$6,344	584	334
0104	T	Transcatheter Placement of Intracoronary Stents	\$5,360	\$5,600	674	233
0106	T	Insertion/Replacement of Pacemaker Leads and/or Electrodes	\$3,138	\$4,374	406	281
0107	T	Insertion of Cardioverter-Defibrillator	\$18,607	\$21,001	501	228
0108	T	Insertion/Replacement/Repair of Cardioverter-Defibrillator Leads	\$23,205	\$25,471	3,719	616
0115	T	Cannula/Access Device Procedures	N/A	\$1,868	1,398	705
0202	T	Level VII Female Reproductive Proc	\$2,627	\$2,687	10,851	1,895
0222	S	Implantation of Neurological Device	\$11,099	\$15,150	1,465	612
0225	S	Implantation of Neurostimulator Electrodes, Cranial Nerve	\$13,514	\$13,889	254	168
0227	T	Implantation of Drug Infusion Device	\$10,658	\$11,569	1,117	477
0229	T	Transcatheter Placement of Intravascular Shunts	\$4,184	\$5,570	8,004	1,256
0259	T	Level VI ENT Procedures	\$25,351	\$24,739	868	174
0293	T	Level V Anterior Segment Eye Procedures	N/A	\$5,335*	N/A	N/A
0315	S	Level II Implantation of Neurostimulator	\$14,846	\$16,988	691	203
0384	T	GI Procedures with Stents	\$1,402	\$1,572	7,484	1,464
0385	S	Level I Prosthetic Urological Procedures	\$4,840	\$5,262	648	340
0386	S	Level II Prosthetic Urological Procedures	\$8,396	\$9,067	3,683	887
0418	T	Insertion of Left Ventricular Pacing Elect	\$18,778	\$16,342	219	152
0425	T	Level II Arthroplasty with Prosthesis	\$6,551	\$7,688	441	278
0427	T	Level III Tube Changes and Repositioning	N/A	\$966	13,556	1,293
0622	T	Level II Vascular Access Procedures	\$1,385	\$1,517	36,920	2,408
0623	T	Level III Vascular Access Procedures	N/A	\$1,817	54,632	2,746
0625	T	Level IV Vascular Access Procedures	\$5,100	\$5,143	8	7
0648	T	Level IV Breast Surgery	\$3,130	\$3,560	503	321
0652	T	Insertion of Intraperitoneal and Pleural Catheters	\$1,805	\$1,932	3,801	1,099
0653	T	Vascular Reconstruction/Fistula Repair with Device	\$1,979	\$2,546	1,700	713
0654	T	Insertion/Replacement of a permanent dual chamber pacemaker.	\$6,891	\$6,876	1,896	634
0655	T	Insertion/Replacement/Conversion of a permanent dual chamber pacemaker.	\$9,328	\$8,810	2,169	554
0656	T	Transcatheter Placement of Intracoronary Drug-Eluting Stents	\$6,618	\$7,451	3,486	399
0674	T	Prostate Cryoablation	\$6,646	\$7,720	2,222	383
0680	S	Insertion of Patient Activated Event Recorders	\$4,437	\$4,442	1,577	718
0681	T	Knee Arthroplasty	\$12,569	\$17,281	317	59

* In CY 2006, there were not HCPCS codes to describe all devices that could be used in this procedure.

3. Payment When Devices Are Replaced With Partial Credit to the Hospital

In recent years there have been several field actions and recalls as a result of implantable device failures. In many of these cases, the manufacturers have offered replacement devices without cost to the hospital or credit for the device being replaced if the patient required a more expensive device. In

order to ensure that the payment we proposed for CY 2008 pays hospitals appropriately when they incur the full cost of the device, we calculated the CY 2008 median costs for device dependent APCs using only claims that contain the correct device code for the procedure. We also did not use claims that contain token charges for these expensive devices or that contain the "FB" modifier, which would signify that the

device was replaced without cost or with a full credit for the cost of the device being replaced. Similarly, to ensure equitable payment when the hospital receives a device without cost or receives a full credit for the cost of the device being replaced, for CY 2007 we implemented a payment policy that reduces the payment for selected device-dependent APCs when the hospital receives certain replacement

devices without cost or receives a full credit for the device being replaced (71 FR 68077).

The CY 2007 final payment policy when devices are replaced without cost or when a full credit for a replaced device is furnished to the hospital applies to those APCs that meet three criteria as described in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68072 through 68077). Specifically, all procedures assigned to the selected APCs must require implantable devices that would be reported if device replacement procedures were performed, the required devices must be surgically inserted or implanted devices that remain in the patient's body after the conclusion of the procedures (at least temporarily), and the device offset amount must be significant, which for purposes of this policy is defined as exceeding 40 percent of the APC cost. We also restricted the devices to which the APC payment adjustment would apply to a specific set of costly devices to ensure that the adjustment would not be triggered by the replacement of an inexpensive device whose cost would not constitute a significant proportion of the total payment rate for an APC.

As discussed in the CY 2008 proposed rule (72 FR 42726), we examined the offset amounts calculated from the CY 2008 proposed rule data and the clinical characteristics of APCs to determine whether the APCs to which the no cost or full credit replacement policy applies in CY 2007 continue to meet the criteria for CY 2008 and to determine whether other APCs to which the policy does not apply in CY 2007 would meet the criteria for CY 2008. Based on data available for the proposed rule, we concluded that one additional APC met the criteria for inclusion under this policy and that one APC currently on the list ceases to meet the criteria. Specifically, we proposed to add APC 0625 (Level IV Vascular Access Procedures) to the list of APCs to be adjusted in cases of full or partial credit for replaced devices (as discussed below) and to add the device described by device code C1881 (Dialysis access system (implantable)) that is implanted in a procedure assigned to APC 0625 to the list of devices to which this policy applies. We proposed to add APC 0625 and device code C1881 for CY 2008 because they met the criteria for inclusion in this policy. In particular, the single surgical procedure (CPT code 36566 (Insertion of tunneled centrally inserted central venous access device, requiring two catheters via two separate venous access sites; with subcutaneous port(s)) assigned to APC 0625 always

requires an implantable device that is reported, the proposed CY 2008 APC device offset percent was greater than 40 percent, and the device is of a type that is surgically implanted in the patient, where it remains at least temporarily. Furthermore, costly devices described by device code C1881 are implanted in the procedure assigned to APC 0625. We also found that APC 0229 (Transcatheter Placement of Intravascular Shunts) ceased to meet the criteria because the device offset percent for this APC, when calculated from proposed rule data, was less than 40 percent. Moreover, we believed that the devices that would be implanted in the procedures assigned to this APC are not of a type that would be amenable to removal and replacement in a device recall or warranty situation. Therefore, we proposed to remove APC 0229 from the list of APCs to which the no cost or full credit and proposed partial credit reduction policies would be applicable for CY 2008. Table 38 of the proposed rule (42 CFR 42727) contained the device offset amounts that we proposed to apply to the specified APCs in cases of no cost or full or partial credit for replaced devices for the CY 2008 OPPS.

As discussed in the proposed rule (72 FR 42724), subsequent to the issuance of the CY 2007 OPPS/ASC final rule with comment period, we had many inquiries from hospitals that asked whether the reduction would also apply in cases in which there was a partial credit for the cost of a device that failed or was otherwise covered under a manufacturer warranty. Those inquiring explained that cases of partial credit are the vast majority of cases involving devices that have failed or otherwise must be replaced under warranty. They indicated that in some cases the devices failed, and in other situations the patient's energy needs exceeded the capacity of the device and thus the device ceased to be useful before the end of the warranty period. They told us that a typical industry practice for some types of devices was to provide a 50 percent credit in cases of device failure (including battery depletion) under warranty if a device failed at 3 years of use (failure during the first 3 years would result in a full device credit). The credit would be prorated further over time between 3 and 5 years after the initial device implantation, as the useful life of the device declined. As promulgated in the CY 2007 OPPS/ASC final rule with comment period and codified at § 419.45, the CY 2007 reduction policy does not apply to cases in which there is a partial credit toward the replacement of the device.

In addition to our concern over the replacement of implantable devices at no cost to hospitals due to device recalls, device failure, or other clinical situations, we believed that it is equally as important that timely information be reported and analyzed regarding the performance and longevity of devices replaced in partial credit situations. This issue is particularly timely due to the recent recall of 73,000 ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds) because of a faulty capacitor that can cause the batteries to deplete sooner than expected. In some cases, patients will require more frequent monitoring of their device function and early device replacement. (We refer readers to the Web site: <http://www.fda.gov/cdrh/news> for Questions and Answers posted April 20, 2007 on this recall.) Therefore, we believed that hospitals should report occurrences of devices being replaced under warranty or otherwise with a partial credit granted to the hospital so that we could identify systematic failures of devices or device problems through claims analysis and so that we could make appropriate payment adjustments in these cases. Collecting data on a wider set of device replacements under full and partial credit situations would assist in developing comprehensive summary data, not just a subset of data related to devices replaced without cost or with a full credit to the hospital. In the proposed rule, we explained that we are mindful of the need to use our claims history, where possible, to promote early awareness of problems with implantable medical devices and to promote high quality medical care with regard to the devices and the services in which they are used.

We also are concerned with the issue of the increased Medicare and beneficiary liability for the monitoring costs that are required as a result of the worldwide recall of these 73,000 devices. Specifically, the manufacturer of the devices that have been most recently recalled recommends that patients with the recalled device consult with their physician in each case and, in some cases, begin a routine of monthly evaluations. We would expect that not only could extra visits to physicians' offices or HOPDs be necessary, but additional diagnostic tests may also be needed to care for the beneficiaries who have the recalled devices. Thus, even when the device does not immediately require replacement, we are concerned that the potential greater costs to Medicare and to the beneficiary or his or her

secondary payor for these unforeseen extra services may be substantial and burdensome. We will be actively assessing how we can identify additional health care costs and Medicare expenditures associated with device recall actions and exploring what actions could be appropriate in the case of these additional monitoring and related expenses. In the proposed rule, we specifically invited public comment on this issue to inform our future review and analyses (72 FR 42724).

Moreover, the payment rates for the APCs into which the costs of the most expensive devices are packaged are set based on the assumption that the hospital incurs the full cost of the device. To continue to pay the full APC rate when the hospital receives a partial credit toward the cost of a very expensive device would result in excessive and inappropriate payment for the procedure and its packaged costs. Some hospitals have told us that they do not reduce their charges for the device being implanted or used in the procedure in cases in which they receive a partial credit for the device, even in cases in which the credit is for as much as 50 percent of the cost of an expensive device.

For CY 2008, we proposed to create an HCPCS modifier that would be reported in all cases in which the hospital receives a partial credit toward the replacement of a medical device listed in Table 39 of the proposed rule (72 FR 42727). These devices are the same devices to which our policy governing payment when the device is furnished to the provider without cost or with full credit would apply for CY 2008. As we discussed in the CY 2007 OP/ASC final rule with comment period (71 FR 68071), we selected these devices because they have substantial device costs and because the device is implanted in the beneficiary at least temporarily and, therefore, can be associated with an individual beneficiary. This proposed partial credit policy would enhance our ability to track the replacement of these implantable medical devices and may permit us to identify trends in device failure or limited longevity. Moreover, it would enable us to reduce the APC payment in cases in which the hospital receives a partial credit towards the cost of the replacement device being implanted. We believed that this proposal was a logical extension of our policy regarding reduction of the APC payment in cases in which the provider furnishes the device without cost or with a full credit to the hospital.

Specifically, as discussed in more detail below, we proposed to reduce the

payment for the APC into which the device cost is packaged by one half of the amount of the offset amount that would apply if the device were being replaced without cost or with full credit, but only where the amount of the device credit is greater than or equal to 20 percent of the cost of the new replacement device being implanted. We also proposed to base the beneficiary's copayment on the reduced APC payment rate so that the beneficiary shares in the hospital's reduced costs. We believed that it would be inequitable to set the payment rates for the procedures into which payment for these devices is packaged on the assumption that the hospital always incurs the full cost for these expensive devices but to not adjust the payment when the hospital receives a partial credit for a failed or otherwise replaced device. Accordingly, we believed that it would be appropriate to make an equitable adjustment to the APC payment to ensure that the Medicare program payment made for the service and the beneficiary's liability are appropriate in these cases in which the hospital's device costs are significantly reduced. We proposed changes to § 419.45(a) and (b) to reflect our proposed policy of reducing the OP/ASC payment when partial credit for the device cost is received by the hospital for a failed or otherwise replaced device.

Due to the absence of current reporting of the cases in which hospitals receive a partial credit for replaced devices and to our belief, based on conversations with hospital staff, that hospitals do not reduce their device charges to reflect the credits, we had no data to determine empirically by how much we should reduce the payment for the procedural APC into which the costs of these devices are packaged. However, device manufacturers and hospitals have told us that a common scenario is that, if a device fails 3 years after implantation, the hospital would receive a 50 percent credit towards a replacement device. Therefore, we proposed to reduce the payment for these device-dependent APCs by half of the reduction that would apply when the hospital receives a device without cost or receives a full credit for a device being replaced. That is, we proposed to reduce the payment for the APC by half of the offset amount that represents the cost of the device packaged into the APC payment. In the absence of claims data on which to base a reduction factor, but taking into consideration what we have been told is common industry practice, we believed that reducing the

amount of payment for the device dependent APC by half of the estimated cost of the device packaging represents a reasonable and equitable reduction in these cases.

In the proposed rule (72 FR 42725), we also considered whether to propose to require hospitals to reduce their charges in proportion to the partial credit they receive for the device so that, in future years, we would have cost data reported consistently on which we could consider basing the amount of reduction to the payment for the procedure in cases of a partial device credit. However, we were concerned that such a requirement could impose an administrative burden on hospitals that would outweigh the potential benefit of a more accurate reduction to payment in these cases. Therefore, we specifically requested comments on the extent to which any administrative burden would be balanced or compensated for by the potential payment accuracy benefit of an empirically based reduction to payment in these cases (72 FR 42725).

In addition, we proposed to take this reduction only when the credit is for 20 percent or more of the cost of the new replacement device, so that the reduction would not be taken in cases in which more than 80 percent of the cost of the replacement device has been incurred by the hospital. We were concerned that the burden to hospitals of requiring that they report cases in which the partial credit for the device being replaced is less than 20 percent of the cost of the new replacement device would be greater than the benefit to the Medicare program and the beneficiary. In addition, if the partial credit is less than 20 percent of the cost of the new replacement device, then reducing the APC payment for the device implantation procedure by 50 percent of the packaged device cost would provide too low a payment to hospitals providing the necessary device replacement procedures. Therefore, we proposed that the new HCPCS partial credit modifier would be reported and the partial credit reduction would be taken only in cases in which the credit is equal to or greater than 20 percent of the cost of the new replacement device.

As discussed in the proposed rule (72 FR 42725), even in the absence of specific instructions to reduce the device charges in partial credit cases, we could monitor the charges that are submitted for devices reported with the proposed partial credit modifier to see if hospitals appear to be reflecting partial device credits in their charges for these implantable devices. We believed that we could use pattern analysis to

determine if a hospital that is reporting the device with the partial credit modifier is charging at a lower rate for the same device when the modifier appears with the procedure in which the device is used than in cases without reporting of the modifier. As proposed, if we found that hospitals were adjusting their charges to reflect the reduced costs of these devices, we would explore whether revising the amount of the reduction could be appropriate.

In summary, we proposed the following: (1) To create a HCPCS modifier to be reported on a procedure code listed in Table 38 of the proposed rule if a device listed in Table 39 of that rule is replaced with partial credit from the manufacturer that is greater than or equal to 20 percent of the cost of the replacement device; and (2) to reduce the payment for the procedure by 50 percent of the amount of the estimated packaged cost of the device being replaced when the modifier is reported with a procedure code that is assigned to an APC in Table 38. We believed that this policy is necessary to pay equitably for these services when the hospital receives a partial credit for the cost of the device being implanted.

At the September 2007 meeting of the APC Panel, the Panel recommended that CMS explore whether hospitals could report a modifier to reflect the amount of a partial credit for a device as a percentage of the cost of the replacement device. According to the Panel, this approach could signify that there was a partial credit and provide data for use in determining the amount of reduction that could be taken in future years.

We received many public comments on our proposal to reduce the APC payment for certain implantation procedures when specific devices are replaced with a partial credit to the hospital. A summary of the public comments and our responses follow.

Comment: The majority of commenters agreed that neither Medicare nor beneficiaries should have to pay based on a device's full cost when the hospital receives a substantial credit from the manufacturer for that device, and supported the premise underpinning the proposed policy that hospitals' charges and OPPS payment rates based on those charges currently do not reflect partial credits for replaced devices. Some commenters argued, however, that all manufacturer rebates, from volume discounts to partial credits for replaced devices, are applied to hospitals' cost reports, and as such are reflected in hospitals' CCRs. Others said that hospitals often do adjust their

charges to reflect partial credits for replaced devices and that a payment adjustment in such cases was not necessary, because payment rates calculated according to the standard OPPS ratesetting methodology for device-dependent APCs already reflect such occurrences. Those opposed to the proposed policy in its entirety also noted that it would be operationally and administratively difficult to implement and that it would result in insufficient payment to hospitals.

Most commenters that agreed with the premise behind the proposed policy to reduce Medicare payment for devices replaced with partial credit supported implementation of the proposed policy, but requested modifications or a delay in implementation of the policy. The majority of these commenters argued that CMS should raise the partial credit threshold to which this policy would apply to 50 percent of the cost of the replacement device, consistent with the policy CMS recently implemented for devices replaced with partial credit for services paid under the FY 2008 IPPS. Commenters stated that consistency in policies across hospital inpatient and outpatient payment systems would reduce confusion, promote compliance, and decrease the administrative burden for hospitals. The commenters also argued that a threshold as low as a 20 percent credit toward the cost of the replacement device would not justify the operational and administrative burdens of returning the replaced devices to manufacturers for evaluation and applying manual billing adjustments. They were concerned that because of these administrative burdens, hospitals may not return the failed devices to manufacturers at all, thereby interfering with manufacturers' quality surveillance programs and preventing the type of data collection the proposed policy is meant to promote. According to commenters, a threshold of 50 percent would ensure that hospitals do not have to deal with these administrative burdens when the credit is nominal or relatively inconsequential relative to the overall procedure payment and unlikely to result in significant savings to the Medicare program. Some commenters noted that a partial credit threshold of 20 percent, with a payment reduction of 50 percent, would result in inadequate payment to hospitals when the credit received was anywhere between 20 percent and 50 percent of the cost of the device.

Response: We agree with the commenters' concerns regarding the threshold percentage to which a partial credit adjustment would be applied. We are increasing the threshold to which

the partial credit reduction policy will apply to cases involving a credit of 50 percent or more toward the total cost of the replacement device. Commenters expressed significant concerns about potential administrative and operational burdens associated with partial credits for small percentages of device costs, and we agree that the partial credit adjustment policy should not apply if only a nominal portion of the cost of the device is at issue. We also agree that consistency in payment policies across hospital inpatient and outpatient payment systems is important and should be maintained whenever appropriate, as is true in this case. Raising the partial credit threshold to which this policy will apply also addresses concerns that the 50 percent reduction to Medicare payment for the replaced device would be more than the partial credit received in some cases.

We disagree with assertions that OPPS payment for device-dependent APCs already reflects partial credits to hospitals for replaced devices. We go to great lengths to ensure that payment rates for device-dependent APCs reflect the full costs of devices by excluding claims that contain token charges and/or the "FB" modifier. We continue to believe that in most cases, hospitals charge the full amount for the replaced device, although they may have incurred much less than the full cost of the device. While it may be true that some hospitals adjust their charges to reflect the partial credits they receive for replaced devices, we believe this is a small minority. Therefore, we believe our ratesetting methodology generally results in median costs that reflect the full costs of these devices. We also continue to believe that it is likely the reduced hospital costs associated with steady, low volume warranty replacements of implantable devices may never be reflected in the CCRs used to adjust charges to costs for devices, because those CCRs are overwhelmed by the volume of other items attributed to the cost centers. Therefore, our median costs for device-dependent APCs would not reflect the reduced hospital costs associated with partial credit device replacement procedures.

As discussed in the proposed rule (72 FR 42725 through 42726), we also do not agree that hospitals would refrain from returning a device removed from a patient to a manufacturer in order to justify not reporting the partial credit modifier to Medicare. We continue to believe that hospitals have a strong interest in ensuring that manufacturers know as soon as possible when there are problems with the devices provided to their patients, whether the result would

be a full or partial credit for the failed device. In addition, we believe that hospitals, key participants in the broader healthcare system, are concerned with device performance, patient health, and health care quality from the broader public health perspective and are committed to appropriate reporting to improve the quality of future health care that leads to better health outcomes for patients. Moreover, we do not believe that hospitals would intentionally fail to report to Medicare the service furnished correctly and completely with the partial credit modifier when the modifier applies, because the hospital would then knowingly submit incorrect information on the claim.

Comment: Many commenters urged OPSS adoption of the same billing options for hospitals as are available under the IPPS for billing devices replaced with partial credit. Specifically, they requested hospitals be allowed to: (1) Submit the claims for replacement devices immediately without the HCPCS modifier signifying partial credit for a replacement device and later, if a credit is ultimately issued, submit a claim adjustment with the appropriate coding; or (2) hold the claim until a credit determination is made. According to the commenters, credits are determined after a case-by-case review by the manufacturer following explant and replacement of the device, which can take 8 weeks or longer. During this time, hospitals often do not know whether or how much credit the manufacturer will provide and cannot submit a bill for the replacement device implantation procedure, creating substantial payment delays. In addition, commenters were concerned about the administrative burden of providing paper invoices or other information to their fiscal intermediary or MAC indicating the hospital's normal cost of the device or the amount of the credit received.

Several commenters referenced the September 2007 meeting of the APC Panel, where the Panel recommended that CMS explore whether hospitals could report a modifier to reflect the amount of a partial credit for a device as a percentage of the amount of the replacement device. While one commenter supported this approach, other commenters expressed concerns about the administrative burden associated with this alternative. They stated that constructing a modifier in this way may be too easily confused with existing numeric modifiers used in conjunction with CPT coding. Commenters also shared CMS' concerns about hospitals reducing their charges

in proportion to the partial credit they receive for a replaced device. They encouraged CMS to work with providers to develop the least burdensome approach to incorporate payment reductions for devices replaced with partial credit based on empirical data.

Response: In order to report that they received a partial credit of 50 percent or more of the cost of a replacement device, hospitals will have the option of either: (1) Submitting the claims immediately without the HCPCS modifier signifying partial credit for a replacement device and submitting a claim adjustment with the HCPCS modifier at a later date once the credit determination is made; or (2) holding the claim until a determination is made on the level of credit. We understand commenters' concerns about potential delays that could occur while a returned device is being evaluated to determine whether and by how much a credit will be applied. We agree that hospitals should have the same billing options, when appropriate, under the OPSS as are available under the IPPS. As described in the FY 2008 IPPS final rule (72 FR 47250), we believe that these billing options will facilitate more efficient administration of the policy by allowing the hospital to gather and report all of the information it needs to be paid correctly by Medicare, without the need to suspend claims or delay payment.

We share commenters' concerns about the administrative and coding burdens that could be associated with the September 2007 APC Panel's recommendation to report a modifier to reflect the amount of a partial credit for a device as a percentage of the cost of the replacement device so we are not adopting that recommendation for CY 2008. We also note that the claims processing system for Part B hospital outpatient bills does not have the capacity to accommodate non-uniform HCPCS modifiers. Instead, CMS will recognize a new "FC" modifier, effective January 1, 2008, that reads: "Partial credit received for replaced device." Hospitals will be instructed to append the modifier to the HCPCS code for the procedure in which the device was inserted on claims when the device that was replaced with partial credit under warranty, recall, or field action is one of the devices in Table 26 below (hospitals should not append the modifier to the HCPCS procedure code if the device is not listed in Table 26). Claims containing the "FC" modifier will not be accepted unless the modifier is on a procedure code with status indicator "S," "T," "V," or "X." If the APC to which the procedure code is

assigned is one of the APCs listed in Table 25 below, the fiscal intermediary or MAC will reduce the unadjusted payment rate for the procedure by an amount equal to the percent in Table 26 for partial credit device replacement multiplied by the unadjusted payment rate (if the "FC" modifier is assigned to a procedure code that is not in Table 26, then no adjustment will be taken). The adjustment amounts for no cost, full credit, and partial credit cases are included in Table 25 below.

We believe that it is appropriate to treat the services subject to the APC payment reduction in cases of devices replaced with partial credit like any other service, and to apply the standard reduction policies. Therefore, the partial credit adjustment will occur before wage adjustment and before the assessment to determine if the reductions for multiple procedures (signified by the presence of more than one procedure on the claim with status indicator "T"), discontinued services (signified by modifier 73) or reduced services (signified by modifier 52) apply, similar to what occurs when a device is replaced at full credit or with no cost to the hospital (see 71 FR 68076 for more discussion).

Comment: Some commenters requested that we provide clarification of key elements of the proposal, stating that it was unclear what "cost" should be considered when determining the situations to which the partial credit policy should apply, and what constitutes a "replacement" device. For example, some commenters pointed out that volume discounts can result in reduced costs for hospitals, and that at times devices are replaced at full cost when a new, improved technology becomes available. Some commenters also expressed interest in any OPSS data we may have about the number of cases to which this policy would apply.

Response: The partial credit policy only applies when hospitals receive partial credit for the cost of a device that is replaced due to failure or other problems while the device is still under warranty, or when there is a recall or field action. The policy does not apply when hospitals receive routine rebates such as volume discounts. Hospitals should continue to incorporate these other types of rebates into their cost reports so that these savings will be reflected in the hospitals' CCRs. Neither the partial credit payment reduction for replaced devices, nor the payment reduction for devices replaced with full credit or at no cost, apply if the hospital pays the full price for the device.

We acknowledge the interest providers have in the data resulting

from our reporting requirements for devices replaced at no cost or with full or partial credit. We will consider what types of information could be of value to hospitals as we continue to analyze claims-based reporting of full and partial device credit cases, particularly when CY 2007 claims data become available.

Comment: One commenter objected to the application of a different offset percentage to APC 0385 (Level I Prosthetic Urological Procedures) than to APC 0386 (Level II Prosthetic Urological Procedures) for purposes of the adjustment when a device is replaced in cases of no cost or full or partial credit. The commenter stated that the ratio of device costs to overall procedure costs is identical in APCs 0385 and 0386, and that the device offset percentage should be at least 80 percent for both APCs.

Response: Our hospital claims data and cost reports indicate the device offset percentage for APC 0385 is 52 percent, and the device offset percentage for APC 0386 is 64 percent, calculated according to our standard methodology for establishing the device offset percentage (71 FR 68073). Because the surgical procedures assigned to these two APCs are different from one

another from clinical and resource perspectives as evidenced by the CY 2008 median costs of approximately \$5,262 and \$9,067 for APCs 0385 and 0386, respectively, and because the distinct HCPCS device codes allowed in the procedure-to-device-edits for the various services assigned to the two APCs are different, we would expect that their device offset percentages also would differ. Therefore, we conclude that the device cost in APC 0386 is higher than the device cost in APC 0385, and that neither device offset percentage should be equal to 80 percent.

After consideration of the public comments received, we are finalizing a modified policy for certain procedures involving partial credit for a replacement device. Specifically, we will reduce the payment for an implantation procedure assigned to APCs listed in Table 25, below, by one half of the device offset that would be applied if a replacement device were provided at no cost or with full credit, if the credit is 50 percent or more of the replacement device cost. We will recognize the new modifier "FC" for reporting these cases, and we are not adopting the recommendation of the APC Panel to utilize a modifier that

specifically reflects the amount of a partial credit for a device as a percentage of the cost of the replacement device. Accordingly, we are implementing the proposed changes to §§ 419.45(a) and (b) with modification to reflect the 50 percent partial device credit threshold to which the policy will apply. Beneficiary copayment will be based on the reduced payment amount. We will continue to evaluate how we might refine our methodology for reducing the payment for the procedural APCs into which the costs of the devices in 25 below are packaged based on the claims data we receive as this policy is implemented. We also will continue to monitor charges that are submitted for devices reported with the partial credit modifier "FC" to see if hospitals appear to be reflecting partial device credits in their charges for these implantable devices.

We also are implementing our proposals to add APC 0625 to the list of APCs to be adjusted in cases of no cost or full or partial credit for replaced devices, to remove APC 0229 from that list, and to add the device described by device code C1881 that is implanted in a procedure assigned to APC 0625 to the list of devices to which this policy applies.

TABLE 25.—ADJUSTMENTS TO APCs IN CASES OF NO COST OR FULL OR PARTIAL CREDIT FOR REPLACED DEVICES

APC	SI	APC title	CY 2007 reduction for full credit case (percent)	CY 2008 reduction for full credit case (percent)	CY 2008 reduction for partial credit case (percent)	CY 2008 payment rate	CY 2008 adjusted payment for full credit case	CY 2008 adjusted payment for partial credit case
0039	S	Level I Implantation of Neurostimulator.	78.85	82.73	41.37	\$11,877	\$2,051	\$6,964
0040	S	Percutaneous Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve.	54.06	56.27	28.14	4,063	1,777	2,920
0061	S	Laminectomy or Incision for Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve.	60.06	60.60	30.30	5,278	2,079	3,679
0089	T	Insertion/Replacement of Permanent Pacemaker and Electrodes.	77.11	72.99	36.50	7,748	2,093	4,921
0090	T	Insertion/Replacement of Pacemaker Pulse Generator.	74.74	76.01	38.01	6,423	1,541	3,982
0106	T	Insertion/Replacement/Repair of Pacemaker and/or Electrodes.	41.88	56.25	28.13	4,428	1,937	3,183
0107	T	Insertion of Cardioverter-Defibrillator.	90.44	89.11	44.56	21,262	2,315	11,789
0108	T	Insertion/Replacement/Repair of Cardioverter-Defibrillator Leads.	89.40	89.24	44.62	25,787	2,775	14,281
0222	S	Implantation of Neurological Device.	77.65	84.86	42.43	15,337	2,322	8,830
0225	S	Implantation of Neurostimulator Electrodes, Cranial Nerve.	79.04	80.57	40.29	14,061	2,732	8,397
0227	T	Implantation of Drug Infusion Device.	80.27	80.73	40.37	11,713	2,257	6,985
0259	T	Level VI ENT Procedures	84.61	82.94	41.47	25,046	4,273	14,659
0315	S	Level II Implantation of Neurostimulator.	76.03	86.15	43.08	17,199	2,382	9,790
0385	S	Level I Prosthetic Urological Procedures.	83.19	51.56	25.78	5,327	2,580	3,954

TABLE 25.—ADJUSTMENTS TO APCs IN CASES OF NO COST OR FULL OR PARTIAL CREDIT FOR REPLACED DEVICES—Continued

APC	SI	APC title	CY 2007 reduction for full credit case (percent)	CY 2008 reduction for full credit case (percent)	CY 2008 reduction for partial credit case (percent)	CY 2008 payment rate	CY 2008 adjusted payment for full credit case	CY 2008 adjusted payment for partial credit case
0386	S	Level II Prosthetic Urological Procedures.	61.16	63.53	31.77	9,180	3,348	6,264
0418	T	Insertion of Left Ventricular Pacing Elect.	87.32	82.52	41.26	16,544	2,892	9,718
0625	T	Level IV Vascular Access Procedures.	N/A	58.88	29.44	5,207	2,141	3,674
0654	T	Insertion/Replacement of a permanent dual chamber pacemaker.	77.35	77.13	38.57	6,961	1,592	4,276
0655	T	Insertion/Replacement/Conversion of a permanent dual chamber pacemaker.	76.59	74.62	37.31	8,919	2,264	5,591
0680	S	Insertion of Patient Activated Event Recorders.	76.40	73.15	36.58	4,497	1,208	2,852
0681	T	Knee Arthroplasty	73.37	82.86	41.43	17,495	2,993	10,244

TABLE 26.—DEVICES FOR WHICH THE “FB” OR “FC” MODIFIER MUST BE REPORTED WITH THE PROCEDURE CODE WHEN FURNISHED WITHOUT COST/FULL CREDIT OR PARTIAL CREDIT FOR A REPLACED DEVICE

Device HCPCS code	Short descriptor
C1721	AICD, dual chamber.
C1722	AICD, single chamber.
C1764	Event recorder, cardiac.
C1767	Generator, neurostim, imp.
C1771	Rep dev, urinary, w/sling.
C1772	Infusion pump, programmable.
C1776	Joint device (implantable).
C1777	Lead, AICD, endo single coil.
C1778	Lead, neurostimulator.
C1779	Lead, pmkr, transvenous VDD.
C1785	Pmkr, dual, rate-resp.
C1786	Pmkr, single, rate-resp.
C1813	Prosthesis, penile, inflatab.
C1815	Pros, urinary sph, imp.
C1820	Generator, neuro rechg bat sys.
C1881	Dialysis access system.
C1882	AICD, other than sing/dual.
C1891	Infusion pump, non-prog, perm.
C1895	Lead, AICD, endo dual coil.
C1896	Lead, AICD, non sing/dual.
C1897	Lead, neurostim, test kit.
C1898	Lead, pmkr, other than trans.
C1899	Lead, pmkr/AICD combination.
C1900	Lead coronary venous.
C2619	Pmkr, dual, non rate-resp.
C2620	Pmkr, single, non rate-resp.
C2621	Pmkr, other than sing/dual.
C2622	Prosthesis, penile, non-inf.
C2626	Infusion pump, non-prog, temp.
C2631	Rep dev, urinary, w/o sling.
L8614	Cochlear device/system.

B. Pass-Through Payments for Devices

1. Expiration of Transitional Pass-Through Payments for Certain Devices

a. Background

Section 1833(t)(6)(B)(iii) of the Act requires that, under the OPSS, a category of devices be eligible for transitional pass-through payments for at least 2, but not more than 3, years. This period begins with the first date on which a transitional pass-through payment is made for any medical device that is described by the category. The device category codes became effective April 1, 2001, under the provisions of the BIPA. Prior to pass-through device categories, Medicare payments for pass-through devices under the OPSS were made on a brand-specific basis. All of the initial 97 category codes that were established as of April 1, 2001, have expired; 95 categories expired after CY 2002, and 2 categories expired after CY 2003. In addition, nine new categories have expired since their creation. The three categories listed in Table 40 of the CY 2008 OPSS/ASC proposed rule, along with their expected expiration dates, were established for pass-through payment in CY 2006 or CY 2007, as noted. Under our established policy, we base the expiration dates for the category codes on the date on which a category was first eligible for pass-through payment.

Of these 3 device categories, there is 1 that would be eligible for pass-through payment for at least 2 years as of December 31, 2007; that is, device category code C1820 (Generator, neurostimulator (implantable), with rechargeable battery and charging system). In the CY 2007 OPSS/ASC final rule with comment period (71 FR

68078), we finalized our proposal to expire device category C1820 from pass-through device payment after December 31, 2007.

In the November 1, 2002 OPSS final rule, we established a policy for payment of devices included in pass-through categories that are due to expire (67 FR 66763). For CY 2003 through CY 2007, we packaged the costs of the devices no longer eligible for pass-through payments into the costs of the procedures with which the devices were reported in the claims data used to set the payment rates for those years. Brachytherapy sources, which are now separately paid in accordance with section 1833(t)(2)(H) of the Act, are an exception to this established policy (with the exception of brachytherapy sources for prostate brachytherapy, which were packaged in the CY 2003 OPSS only).

b. Final Policy

In the CY 2008 OPSS/ASC proposed rule, we stated that we were implementing in CY 2008 the final decision that we discussed in the CY 2007 OPSS/ASC final rule with comment period that finalized the expiration date of pass-through status for device category C1820 (71 FR 68078). Therefore, as of January 1, 2008, we will discontinue pass-through payment for device category code C1820. In accordance with our established policy, we will package the costs of the device assigned to this device category into the costs of the procedures with which the device was billed in CY 2006, the year of hospital claims data used for this OPSS update. See section III.D.8. of this final rule with comment period for a discussion of our

final CY 2008 payment for the implantation of neurostimulators.

The 2 device categories that were established for pass-through payment as of January 1, 2007, HCPCS code C1821 (Interspinous process distraction device (implantable)) and HCPCS code L8690 (Auditory osseointegrated device, includes all internal and external components), will be active categories for pass-through payment for 2 years as of December 31, 2008. Therefore, we proposed that these categories expire from pass through device payment as of December 31, 2008.

We received a number of public comments concerning this proposal. A summary of the public comments and our responses follow.

Comment: A number of commenters objected to our proposal to expire device category L8690 from pass-through payment after December 31, 2008 and recommended that we maintain category code L8690 on pass-through status until the end of CY 2009, allowing a third year of pass-through payment. These commenters claimed that one year of claims data, that is, CY 2007 (which would be used to develop the CY 2009 payment rates for the associated implantation procedures) would be insufficient to establish an accurate procedure payment rate that reflected the costs of implanting the device. They based this recommendation on several reasons. They claimed that there were low volumes of charges by hospitals to Medicare for HCPCS code L8690. One of the commenters, the applicant to establish the pass-through category, projected utilization of 525 devices in the first year of device pass-through payment at the time of the application, but stated that CMS CY 2006 claims data for the proposed rule included only 230 total claims for procedures to implant the device. The commenter indicated that it did not expect the number of implantation procedures to increase substantially in CYs 2007 and 2008. Commenters also claimed that given the history of hospital billing problems for implantable devices, the new code L8690 was generally unknown in CY 2006 and some data might not have been accurately reported. Several commenters explained that the four different procedure codes associated with implantation of osseointegrated devices, CPT codes 69714 (Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy) through 69718 (Replacement (including removal of existing device), osseointegrated

implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy) demonstrated wide variation in hospital costs, from \$5,200 through \$9,200, and this cost variation also pointed to current insufficient data for the procedures to implant osseointegrated devices. One commenter recommended that we extend pass-through status for L8690 through CY 2010.

Response: Several commenters reported that the procedures in which L8690 was implanted were low volume OPPS procedures. We agree that these procedures were low volume in CY 2006, with only 255 total claims under the OPPS. However, we would not expect that these procedures would ever be commonly performed in the Medicare population because the specific clinical indications for implantation of osseointegrated implants are most frequently found in younger populations. Therefore, the osseointegrated implant procedures would likely continue to exhibit low claim volumes relative to many other procedures paid under the OPPS. In fact, the projected utilization of 525 devices by one commenter for CY 2006 would also be considered low volume for the OPPS, but we regularly pay prospectively for many services where there are fewer than several hundred OPPS services performed each year. We believe that several hundred implantation procedure claims from CY 2007 should be sufficient for CY 2009 ratesetting, when we would first package payment for the device cost of osseointegrated devices that no longer had pass-through status. During CYs 2007 and 2008, hospitals have a strong financial incentive to report appropriate charges for the device's use, because they are paid separately for the device, based on charges adjusted to cost during the device's pass-through payment period. We note that while there are four CPT codes for the osseointegrated device implantation procedures, the vast majority of CY 2006 claims were for CPT code 69714, for which we had 240 total claims. The majority of these claims were single claims that would be available for use in establishing the procedure's median cost. While the other three procedures had only a few CY 2006 claims each and displayed the variable costs that commonly result from a small number of claims, we believe that they are similar to CPT code 69714 from both clinical and resource perspectives and note that all four procedures require the implantable device for their performance. Therefore,

we believe that our CY 2007 data for implantation of osseointegrated device procedures should be sufficient to allow accurate ratesetting for CY 2009 when the device cost would be packaged, so there would be no reason to continue the pass-through status of L8690 beyond the 2 year period that ends as of December 31, 2008. Moreover, as to the commenter who requested pass-through status for L8690 through CY 2010, we note that the statute at section 1833(t)(6)(C) precludes pass-through payments for a category of devices for more than 3 years.

Comment: A commenter stated that we should extend pass-through payment for HCPCS code C1821 (Interspinous process distraction device (implantable)), presumably for the additional year allowed under the statute.

Response: The commenter stated that we should continue pass-through payment for the spinous process distraction device reported with C1821 but provided no explicit rationale for this recommendation or for how much longer than the 2 years we proposed for the pass-through payment for C1821. We expect that there would be sufficient CY 2007 claims data that reflected the cost of the interspinous distraction device for the CY 2009 OPPS update, so that the device cost could be appropriately packaged into the APC payment for the associated implantation procedures with which the device was reported. During CYs 2007 and 2008, hospitals have a strong financial incentive to report appropriate charges for the device's use, because they are paid separately for the device, based on charges adjusted to cost during the device's pass-through payment period. The associated procedure codes, specifically CPT codes 0171T (Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; single level) and 0172T (Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; each additional level (List separately in addition to code for primary procedure)) were new for CY 2006, where they were assigned to APC 0050 (Level II Musculoskeletal Procedures Except Hand and Foot) on an interim final basis. See section III.D.8. of this final rule with comment period for a discussion of the final CY 2008 APC assignments of these procedures to APC 0050. After CY 2008, HCPCS code C1821 would have had 2 full years of pass-through payment, and we believe that it would be appropriate

to package the costs of C1821 into payment for the implantation procedures with which the device was billed, according to our standard methodology, for CY 2009. We see no reason to extend the period of pass through payment for C1821 beyond December 31, 2008.

After consideration of the public comments received, we are finalizing our proposal, without modification, to expire device categories L8690 and C1821 from transitional pass-through payment after December 31, 2008.

2. Provisions for Reducing Transitional Pass Through Payments to Offset Costs Packaged Into APC Groups

a. Background

In the November 30, 2001 OPSS final rule, we explained the methodology we used to estimate the portion of each APC payment rate that could reasonably be attributed to the cost of the associated devices that are eligible for pass-through payments (66 FR 59904). Beginning with the implementation of the CY 2002 OPSS quarterly update (April 1, 2002), we deducted from the pass-through payments for the identified devices an amount that reflected the portion of the APC payment amount that we determined was associated with the cost of the device, as required by section 1833(t)(6)(D)(ii) of the Act. In the November 1, 2002 interim final rule with comment period, we published the applicable offset amounts for CY 2003 (67 FR 66801).

For the CY 2002 and CY 2003 OPSS updates, to estimate the portion of each APC payment rate that could reasonably be attributed to the cost of an associated device eligible for pass-through payment, we used claims data from the period used for recalibration of the APC rates. That is, for CY 2002 OPSS updating, we used CY 2000 claims data, and for CY 2003 OPSS updating, we used CY 2001 claims data. For CY 2002, we used median cost claims data based on specific revenue centers used for device related costs because device C-code cost data were not available until CY 2003. For CY 2003, we calculated a median cost for every APC based on single claims with device codes but without packaging the costs of associated C-codes for device categories that were billed with the APC. We then calculated a median cost for every APC based on single claims with the costs of the associated device category C-codes that were billed with the APC packaged into the median. Comparing the median APC cost without device packaging to the median APC cost including device

packaging that was developed from the claims with device codes also reported enabled us to determine the percentage of the median APC cost that was attributable to the associated pass-through devices. By applying those percentages to the APC payment rates, we determined the applicable amount to be deducted from the pass-through payment, the "offset" amount. We created an offset list comprised of any APC for which the device cost was at least 1 percent of the APC's cost.

The offset list that we published for CY 2002 through CY 2004 was a list of offset amounts associated with those APCs with identified offset amounts developed using the methodology described above. As a rule, we do not know in advance which procedures residing in certain APCs may be billed with new device categories. Therefore, an offset amount was applied only when a new device category was billed with a HCPCS procedure code that was assigned to an APC appearing on the offset list.

For CY 2004, we modified our policy for applying offsets to device pass-through payments. Specifically, we indicated that we would apply an offset to a new device category only when we could determine that an APC contains costs associated with the device. We continued our existing methodology for determining the offset amount, described earlier. We were able to use this methodology to establish the device offset amounts for CY 2004 because providers reported device codes (generally C-codes) on the CY 2002 claims used for the CY 2004 OPSS update. For the CY 2005 update to the OPSS, our data consisted of CY 2003 claims that did not contain device codes and, therefore, for CY 2005, we utilized the device percentages as developed for CY 2004. In the CY 2004 OPSS update, we reviewed the device categories eligible for continuing pass-through payment in CY 2004 to determine whether the costs associated with the device categories were packaged into the existing APCs. Based on our review of the data for the device categories existing in CY 2004, we determined that there were no close or identifiable costs associated with the devices relating to the respective APCs that were normally billed with them. Therefore, for those device categories, we set the offset amount to \$0 for CY 2004. We continued this policy of setting the offset amount to \$0 for the device categories that continued to receive pass-through payment in CY 2005.

For the CY 2006 OPSS update, CY 2004 hospital claims were available for analysis. Hospitals billed device C-

codes in CY 2004 on a voluntary basis. We reviewed our CY 2004 data and found that the numbers of claims for services in many of the APCs for which we calculated device percentages using CY 2004 data were quite small. We also found that many of these APCs already had relatively few single claims available for median calculations compared with the total bill frequencies, because of our inability to use many multiple bills in establishing median costs for all APCs. In addition, we found that our claims demonstrated that relatively few hospitals specifically coded for devices utilized in CY 2004. Thus, we were not confident that CY 2004 claims reporting device HCPCS codes represented the typical costs of all hospitals providing the services. Therefore, we did not use CY 2004 claims with device codes to calculate CY 2006 device offset amounts. In addition, we did not use the CY 2005 methodology, for which we utilized the device percentages as developed for CY 2004. Two years had passed since we developed the device offsets for CY 2004, and the device offsets originally calculated from CY 2002 hospital claims data may either have overestimated or underestimated the contributions of device costs to total procedural costs in the outpatient hospital environment of CY 2006. In addition, a number of the APCs on the CY 2004 and CY 2005 device offset percent lists were either no longer in existence or were so significantly reconfigured that the past device offsets likely did not apply.

For CY 2006, we reviewed the single new device category established, C1820, to determine whether device costs associated with the new category were packaged into the existing APC structure based on partial CY 2005 claims data. Under our established policy, if we determine that the device costs associated with the new category are closely identifiable to device costs packaged into existing APCs, we set the offset amount for the new category to an amount greater than \$0. Our review of the service indicated that the median cost for the applicable APC 0222 (Implantation of Neurological Device) contained costs for neurostimulators that were similar to neurostimulators described by the new device category C1820. Therefore, we determined that a device offset would be appropriate. We announced a CY 2006 offset amount for that category in Program Transmittal No. 804, dated January 3, 2006. (We subsequently were informed that some rechargeable neurostimulators described by device category C1820 may also be used and billed with a CPT code that

maps to APC 0039 (Level I Implantation of Neurostimulator). We announced an offset amount for device category C1820 when billed with a procedure code that maps to APC 0039 in Program Transmittal No. 1209, dated March 21, 2007.)

For CY 2006, we used available partial year CY 2005 hospital claims data to calculate device percentages and potential offsets for CY 2006 applications for new device categories. Effective January 1, 2005, we require hospitals to report device HCPCS codes and their charges when hospitals bill for services that utilize devices described by the existing device category codes. In addition, during CY 2005 we implemented device edits for many services that require devices and for which appropriate device category HCPCS codes exist. Therefore, we expected that the number of claims that included device codes and their respective costs to be much more robust and representative for CY 2005 than for CY 2004.

For CY 2007, we reviewed the two new device categories, C1821 and L8690, to determine whether device costs associated with the new categories were packaged into the existing APC structure based on CY 2005 claims data. As indicated earlier, under our established policy, if we determine that the device costs associated with a new category are closely identifiable to device costs packaged into existing APCs, we set the offset amount for the new category to an amount greater than \$0. Our review of the related services indicated that the median costs for the applicable APC 0256 (Level V ENT Procedures (for L8690)) and APC 0050 (Level II Musculoskeletal Procedures Except Hand and Foot (for C1821)) did not contain costs for devices that were similar to those described by the new device categories. Therefore, we set the respective offsets to \$0.

We believed that use of the most current claims data to establish offset amounts when they are needed to ensure appropriate payment was consistent with our stated policy; therefore, we proposed to continue to do so for the CY 2008 OPPS. Specifically, if we created a new device category for payment in CY 2008, to calculate potential offsets we proposed to examine the most current available claims data, including device costs, to determine whether device costs associated with the new category were already packaged into the existing APC structure, as indicated earlier. If we concluded that some related device costs were packaged into existing APCs, we proposed to use the methodology

described earlier and first used for the CY 2003 OPPS to determine an appropriate device offset percent for those APCs with which the new category would be reported.

b. Final Policy

For CY 2008, we proposed to continue to review each new device category on a case-by-case basis as we have done since CY 2004, to determine whether device costs associated with the new category were packaged into the existing APC structure. If we determined that, for any new device category, no device costs associated with the new category were packaged into existing APCs, we proposed to continue our current policy of setting the offset amount for the new category to \$0 for CY 2008. There are currently two new device categories that will continue for pass through payment in CY 2008. These categories, described by HCPCS codes L8690 and C1821, currently have an offset amount equal to \$0 because we could not identify device related costs in the procedural APCs we expect would be billed with either of the two categories L8690 or C1821, that is, in APC 0256 or APC 0050, respectively. We proposed that the offsets for CY 2008 for L8690 and C1821 remain set to \$0, because we could not identify device costs packaged in the related procedural APCs that were closely identifiable with these device categories, based on the claims data for CY 2006, the claims data year for our CY 2008 OPPS update.

We proposed to continue our existing policy of establishing new categories in any quarter when we determined that the criteria for granting pass through status for a device category were met. If we created a new device category and determined that our CY 2006 claims data contained a sufficient number of claims with identifiable costs associated with the new category of devices in any APC with which it is billed, we proposed to establish an offset amount greater than \$0 and to reduce the transitional pass through payment for the device by the related procedural APC offset amount. If we determined that a device offset amount greater than \$0 was appropriate for any new category that we created, we proposed to announce the offset amount in the program transmittal that announced the new category.

In summary, for CY 2008, we proposed to use CY 2006 hospital claims data to calculate device percentages and potential offsets for new device categories established in CY 2008. We also proposed to publish through program transmittals any new or updated offsets that we calculated for

CY 2008, corresponding to newly created categories or existing categories eligible for pass-through payment, respectively.

We received no public comments on our proposed continuation of our current policy to establish offset amounts for new device categories eligible for pass-through payments, and, therefore, we are adopting our proposed policy stated above as final for CY 2008.

V. OPPS Payment Changes for Drugs, Biologicals, and Radiopharmaceuticals

A. Transitional Pass-Through Payment for Additional Costs of Drugs and Biologicals

1. Background

Section 1833(t)(6) of the Act provides for temporary additional payments or “transitional pass-through payments” for certain drugs and biological agents. As originally enacted by the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act (BBRA) of 1999 (Pub. L. 106–113), this provision requires the Secretary to make additional payments to hospitals for current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act (Pub. L. 107–186); current drugs and biological agents and brachytherapy sources used for the treatment of cancer; and current radiopharmaceutical drugs and biological products. For those drugs and biological agents referred to as “current,” the transitional pass-through payment began on the first date the hospital OPPS was implemented (before enactment of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act (BIPA) of 2000 (Pub. L. 106–554), on December 21, 2000).

Transitional pass-through payments are also provided for certain “new” drugs and biological agents that were not being paid for as an HOPD service as of December 31, 1996, and whose cost is “not insignificant” in relation to the OPPS payments for the procedures or services associated with the new drug or biological. For pass-through payment purposes, radiopharmaceuticals are included as “drugs.” Under the statute, transitional pass-through payments can be made for at least 2 years but not more than 3 years. CY 2008 pass-through drugs and biologicals are assigned status indicator “G” as indicated in Addenda A and B to the CY 2008 OPPS/ASC proposed rule and this final rule with comment period.

Section 1833(t)(6)(D)(i) of the Act specifies that the pass-through payment amount, in the case of a drug or biological, is the amount by which the amount determined under section 1842(o) of the Act (or, if the drug or

biological is covered under a competitive acquisition contract under section 1847B of the Act, an amount determined by the Secretary equal to the average price for the drug or biological for all competitive acquisition areas and year established under such section as calculated and adjusted by the Secretary) for the drug or biological exceeds the portion of the otherwise applicable Medicare OPD fee schedule that the Secretary determines is associated with the drug or biological. This methodology for determining the pass-through payment amount is set forth in § 419.64 of the regulations, which specifies that the pass-through payment equals the amount determined under section 1842(o) of the Act minus the portion of the APC payment that CMS determines is associated with the drug or biological. Section 1847A of the Act, as added by section 303(c) of Pub. L. 108-173, establishes the use of the average sales price (ASP) methodology as the basis for payment for drugs and biologicals described in section 1842(o)(1)(C) of the Act that are furnished on or after January 1, 2005. The ASP methodology uses several sources of data as a basis for payment, including ASP, wholesale acquisition cost (WAC), and average wholesale price (AWP). In this final rule with comment period, the term "ASP methodology" and "ASP-based" are inclusive of all data sources and methodologies described therein. Additional information on the ASP methodology can be found on the CMS Web site at: http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/01_overview.asp#TopOfPage.

As noted above, section 1833(t)(6)(D)(i) of the Act also states that if a drug or biological is covered under a competitive acquisition contract under section 1847B of the Act, the payment rate is equal to the average price for the drug or biological for all competitive acquisition areas and the year established as calculated and adjusted by the Secretary. Section 1847B of the Act, as added by section 303(d) of Pub. L. 108-173, establishes the payment methodology for Medicare Part B drugs and biologicals under the competitive acquisition program (CAP). The Part B drug CAP was implemented July 1, 2006, and includes approximately 180 of the most common Part B drugs provided in the physician's office setting. The list of drugs and biologicals covered under the Part B drug CAP, their associated payment rates, and the Part B drug CAP pricing methodology can be found on the CMS Web site at:

<http://www.cms.hhs.gov/CompetitiveAcquisforBios>.

For CYs 2005, 2006, and 2007, we estimated the OPPS pass-through payment amount for drugs and biologicals to be zero based on our interpretation that the "otherwise applicable Medicare OPD fee schedule" amount was equivalent to the amount to be paid for pass-through drugs and biologicals under section 1842(o) of the Act (or section 1847B of the Act, if the drug or biological is covered under a competitive acquisition contract). We concluded for those years that the resulting difference between these two rates would be zero. OPPS pass-through payment estimates for drugs and biologicals in CY 2008 can be found in section VI. of this final rule with comment period.

The pass through application and review process is explained on the CMS Web site at: http://www.cms.hhs.gov/HospitalOutpatientPPS/04_passthrough_payment.asp.

2. Drugs and Biologicals With Expiring Pass-Through Status in CY 2007

Section 1833(t)(6)(C)(i) of the Act specifies that the duration of transitional pass through payments for drugs and biologicals must be no less than 2 years and no longer than 3 years. In Table 41 of the CY 2008 OPPS/ASC proposed rule (72 FR 42730), we proposed to allow the expiration of the pass-through status for seven drugs and biologicals on December 31, 2007. While it is standard OPPS practice to delete temporary C-codes if an alternate permanent HCPCS code becomes available for purposes of OPPS billing and payment, there were no temporary C-codes used to identify the seven pass-through drugs that were proposed for expiring pass-through status on December 31, 2007. Table 27 below includes the CY 2008 permanent HCPCS codes of drugs and biologicals with expiring pass-through status as of December 31, 2007.

We received several public comments regarding a drug proposed to expire from pass-through status at the end of CY 2007. A summary of the comments and our responses follow.

Comment: A few commenters requested that CMS continue pass-through status for HCPCS code Q4079 (Injection, Natalizumab, 1 mg) for an additional year. The commenters stated that, while HCPCS code Q4079 was granted pass-through status beginning April 2005, the manufacturer of this drug voluntarily suspended sales of the drug prior to that date in February 2005. Therefore, the commenters believed that the period of pass-through under the

OPPS did not begin until the drug resumed marketing in June 2006 or until the manufacturer again began shipping the drug to providers in July 2006. The commenters noted that, under these circumstances, pass-through payment had not been made for the 2 year pass-through minimum. Therefore, they believed that pass-through status should continue through CY 2008.

Response: According to our regulations at 42 CFR 419.64, pass-through status begins on the date that CMS makes its first pass-through payment for the drug or biological. As the commenters noted, HCPCS code Q4079 was approved for OPPS pass-through status beginning in April 2005. However, the manufacturer of the product voluntarily suspended marketing of the product 2 months prior to April 2005. Therefore, in order to determine when pass-through payments were first made for this product, we examined OPPS claims data for HCPCS code Q4079 for the second, third and fourth quarters of CY 2005. While we found a few claims from this time period from several different hospitals, we believe that these claims were incorrectly coded. The typical dose of HCPCS code Q4079 is 300 mg infused every 4 weeks. The hospital claims billed during these three quarters of 2005 reported a median of only one unit per day, although the descriptor of HCPCS code Q4079 specifies "per 1 mg." In comparison, hospital claims show a median of 300 units per day billed after this product resumed marketing in July 2006. In addition, while there were a few hospital claims for HCPCS code Q4079 submitted in CY 2005, we received no claims for HCPCS code Q4079 during the first two quarters of CY 2006. Therefore, we believe that the CY 2005 claims were miscoded, so that the first pass-through payment for a correctly coded use for HCPCS code Q4079 was actually not made until July 2006. As a drug that began pass-through status in July 2006 would continue with pass-through status in CY 2008, we are continuing pass-through status in CY 2008 for HCPCS code Q4079.

In addition, in accordance with our standard practice to replace temporary HCPCS codes with permanent ones when a permanent HCPCS code becomes available, we are deleting HCPCS code Q4079 (Injection, Natalizumab, per 1 mg), effective December 31, 2007, and replacing it with HCPCS code J2323 (Injection, Natalizumab, 1 mg), effective January 1, 2008. We have identified this drug in Table 27 below and in Addendum B of this final rule with comment period

using HCPCS code J2323 and assigned its status indicator “G.”

After consideration of the public comments received, we are finalizing our proposed listing of drugs and

biologicals whose pass-through status expires on December 31, 2007, with modification so that pass-through status for HCPCS code Q4079 (HCPCS code J2323 beginning in CY 2008) continues

in CY 2008. In Table 27 below, we list the six drugs and biologicals whose pass-through status will expire on December 31, 2007.

TABLE 27.—DRUGS AND BIOLOGICALS FOR WHICH PASS-THROUGH STATUS EXPIRES DECEMBER 31, 2007

CY 2008 HCPCS	CY 2007 HCPCS	CY 2008 Descriptor	CY 2008 SI	CY 2008 APC
J2278	J2278	Ziconotide injection	K	1694
J2503	J2503*	Pegaptanib sodium injection	K	1697
J7311	J7311	Fluocinolone acetonide implt	K	9225
J8501	J8501	Oral aprepitant	K	0868
J9027	J9027	Clofarabine injection	K	1710
J9264	J9264*	Paclitaxel protein bound	K	1712

* Indicates that the drug was paid at a rate determined by the Part B drug CAP methodology while identified as pass-through under the OPSS.

3. Drugs and Biologicals With Pass-Through Status in CY 2008

In the CY 2008 OPSS/ASC proposed rule (72 FR 42731), we proposed to continue pass through status in CY 2008 for 13 drugs and biologicals. These items, which were approved for pass-through status between April 1, 2006 and July 1, 2007, were listed in Table 42 of the proposed rule. The APCs and HCPCS codes for these drugs and biologicals listed in Table 42 were assigned status indicator “G” in Addenda A and B to the proposed rule.

Section 1833(t)(6)(D)(i) of the Act sets the amount of pass-through payment for pass-through drugs and biologicals (the pass-through payment amount) as the difference between the amount authorized under section 1842(o) of the Act (or, if the drug or biological is covered under a CAP under section 1847B of the Act, an amount determined by the Secretary equal to the average price for the drug or biological for all competitive acquisition areas and year established under such section as calculated and adjusted by the Secretary) and the portion of the otherwise applicable fee schedule amount that the Secretary determines is associated with the drug or biological. Given our CY 2008 proposal to provide payment for nonpass-through separately payable drugs and biologicals at ASP+5 percent as described further in section V.B.3 of this final rule with comment period, in the proposed rule we stated our belief that it would be most consistent with the statute to provide payment for drugs and biologicals with pass through status that are not part of the Part B drug CAP at a rate of ASP+6 percent, compared to ASP+5 percent as the otherwise applicable fee schedule portion associated with the drug or biological. The difference between ASP+6 percent and ASP+5 percent, therefore, would be the CY 2008 pass-

through payment amount for these drugs and biologicals. Thus, for CY 2008, we proposed to pay for pass-through drugs and biologicals that are not part of the Part B drug CAP at ASP+6 percent, equivalent to the rate these drugs and biologicals would receive in the physician’s office setting in CY 2008.

Section 1842(o) of the Act also states that if a drug or biological is covered under a CAP under section 1847B of the Act, the payment rate is equal to the average price for the drug or biological for all competitive acquisition areas and year established as calculated and adjusted by the Secretary. For CY 2008, we proposed to provide payment for drugs and biologicals with pass-through status that are offered under the Part B drug CAP at a rate equal to the Part B drug CAP rate. Therefore, considering ASP+5 percent to be the otherwise applicable fee schedule portion associated with these drugs or biologicals, the difference between the Part B drug CAP rate and ASP+5 percent would be the pass-through payment amount for these drugs and biologicals. HCPCS codes that are offered under the CAP program as of April 1, 2007, are identified in Table 28 below with an asterisk.

In the CY 2008 OPSS/ASC proposed rule, we proposed to continue pass-through status for 13 drugs and biologicals. As stated previously, it is standard OPSS practice to delete temporary C-codes if an alternate permanent HCPCS code becomes available for purposes of OPSS billing and payment. For CY 2008, HCPCS code C9232 (Injection, idursulfase, 1 mg) is deleted and replaced with HCPCS code J1743 (Injection, idursulfase, 1 mg); HCPCS code C9233 (Injection, ranibizumab, 0.5 mg) is deleted and replaced with HCPCS code J2778 (Injection, ranibizumab, 0.1 mg); and

HCPCS code C9235 (Injection, panitumumab, 10 mg) is deleted and replaced with HCPCS code J9303 (Injection, panitumumab, 10 mg).

In addition, in order to be consistent with the naming conventions of the CMS HCPCS Workgroup, we have deleted HCPCS code C9350 (Microporous collagen tube of non-human origin, per centimeter length), and replaced this code with HCPCS codes C9352 (Microporous collagen implantable tube (Neuragen Nerve Guide), per centimeter length) and C9353 (Microporous collagen implantable slit tube (NeuraWrap Nerve Protector), per centimeter length) in order to more accurately identify the two products that were previously described by HCPCS code C9350. Similarly, we have deleted HCPCS code C9351 (Acellular dermal tissue matrix of nonhuman origin, per square centimeter (Do not report C9351 in conjunction with J7345)) for CY 2008 and replaced it with HCPCS codes J7348 (Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Tissuemend) per square centimeter) and J7349 (Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Primatrix) per square centimeter).

We received several public comments regarding our proposal to continue the pass-through status of certain drugs and biologicals for CY 2008. A summary of the comments and our responses follow.

Comment: Several commenters noted support for specific drugs and biologicals proposed for pass-through status in CY 2008 and urged CMS to finalize the proposal for these items. The commenters also commended CMS for proposing to provide payment for pass-through drugs and biologicals at a

rate equal to the rate these drugs and biologicals would receive under the Part B drug CAP program or in the physician's office setting.

Response: We appreciate the commenters' support for our proposed policy. We are finalizing our proposal to provide pass-through payments in CY 2008 for the drugs listed in Table 28 below. This table includes the continuation of pass-through status for HCPCS code Q4079, as discussed previously, and accounts for the coding changes presented above.

Comment: One commenter disagreed with the decision to grant pass-through status to HCPCS code J3473 (Injection, hyaluronidase, recombinant, 1 USP unit) beginning in January 2007 and to continue this drug in pass-through status through CY 2008. The commenter believed that the product described by HCPCS code J3473 fails to meet the pass-through criteria of newness and "not insignificant costs." The commenter claimed that hyaluronidase was available prior to December 31, 1996, and was captured in the initial OPPS payment rates and, therefore should not be considered new. In addition, the commenter explained that the FDA approval of this product was made based on the section 505(b)(2) criteria, meaning that the product claimed to be identical to products already approved by the FDA. This commenter also noted that the administration of HCPCS code J3473 is typically billed with ophthalmic procedures, not drug administration procedures. The commenter asserted that when the cost significance test is performed with APCs more likely to reflect ophthalmic procedures, such as APC 0246 (Cataract Procedures with IOL Insert), the cost significance test for drug and biological pass-through status is not met.

The commenter further noted that, as a result of this drug being granted pass through status, CMS created a market bias towards the use of this product, as all other hyaluronidase products are currently packaged. The commenter argued that this apparent market bias would be further exacerbated as a result of the revised ASC payment system policy of providing separate payment for OPPS separately payable drugs that are provided in the ASC setting beginning in CY 2008, because the majority of procedures that would be likely to use HCPCS code J3473 are frequently performed in ASCs.

Response: Our criteria for reviewing pass-through applications are available

on the CMS Web site at: http://www.cms.hhs.gov/HospitalOutpatientPPS/04_passthrough_payment.asp. Based on these criteria, we reviewed the application submitted to us for HCPCS code J3473 and approved pass-through status beginning on January 1, 2007. We do not agree with the commenter that our decision was in error. The drug met all criteria established for pass through payment for drugs and biologicals. Therefore, as this drug has not met the 2-year minimum pass-through time requirement, we are adopting our proposal to continue pass-through status for HCPCS code J3473 for CY 2008.

Comment: One commenter requested that CMS clarify how payment would be made for radiopharmaceutical products that are granted pass-through status during CY 2008.

Response: Currently, there are no radiopharmaceuticals that would have pass-through status in CY 2008. Consistent with OPPS payment for drugs, biologicals, and radiopharmaceuticals without HCPCS codes, in CY 2008, payment for radiopharmaceuticals that are granted pass-through status would be based on the ASP methodology. As stated above, for purposes of pass-through payment, we consider radiopharmaceuticals to be drugs under the OPPS. Therefore, if a radiopharmaceutical receives pass through status during CY 2008, we will follow the standard ASP methodology to determine its pass-through payment rate under the OPPS. Because ASP data are not available for radiopharmaceuticals, we will base the pass-through payment on the product's WAC. If WAC data are also not available, we will then provide payment for the pass-through radiopharmaceutical at 95 percent of its most recent AWP.

In the OPPS/ASC CY 2008 proposed rule, we used payment rates for drugs with pass-through status based on the ASP data from the fourth quarter of CY 2006 for budget neutrality estimates, impact analyses, and completion of Addenda A and B to the proposed rule because these were the most recent data available to us at that time. These payment rates were the basis for drug payments in the physician's office setting, effective April 1, 2007. As proposed, we used updated data in the development of this final rule with comment period. That is, we used the ASP data from the second quarter of CY 2007 (which are the basis for drug payments in the physician's office

setting, effective October 1, 2007) in budget neutrality estimates, impact analyses, and completion of Addenda A and B to this final rule with comment period. In addition, we are finalizing our proposal to update these pass-through payment rates on a quarterly basis on our Web site during CY 2008 if later quarter ASP submissions (or more recent WAC or AWP data, as applicable) indicate that adjustments to the payment rates for these pass-through drugs and biologicals are necessary. Although there are no pass-through radiopharmaceuticals at this time for CY 2008, the payment rate for a radiopharmaceutical with pass-through status would also be adjusted accordingly.

As proposed, if a drug that has been granted pass-through status for CY 2008 becomes covered under the Part B drug CAP, we will make the appropriate adjustments to the payment rates for these drugs and biologicals on a quarterly basis. For drugs and biologicals that are currently covered under the CAP, we proposed to use the payment rates calculated under that program that are in effect as of April 1, 2007, which is the most recent update of these payment rates. We proposed to update these payment rates if the rates change in the future.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to make separate payment in CY 2008 for new drugs and biologicals with a HCPCS code, consistent with the provisions of section 1842(o) of the Act, at a rate that is equivalent to the payment they would receive in a physician's office setting (or under section 1847B of the Act, if the drug or biological is covered under a CAP) only if we receive a pass-through application for the drug or biological and pass-through status is subsequently granted. Otherwise, we will pay ASP+5 percent for these products in CY 2008. New radiopharmaceuticals with pass-through status will be paid based on WAC or, if WAC is not available, based on 95 percent of the product's most recent AWP. We will update the payment rates for pass-through drugs and biologicals quarterly, as new data become available.

The drugs and biologicals that are continuing pass-through status or have been granted pass-through status as of January 2008 for CY 2008 are included in Table 28 below.

TABLE 28.—DRUGS AND BIOLOGICALS WITH PASS-THROUGH STATUS IN CY 2008

CY 2007 HCPCS	CY 2008 HCPCS	CY 2008 Descriptor	CY 2008 SI	CY 2008 APC
	C9239	Inj, temsirolimus	G	1168
C9350	C9352	Neuragen nerve guide, per cm	G	9350
C9350	C9353	Neurawrap nerve protector, cm	G	1169
J0129	J0129	Abatacept injection	G	9230
J0348	J0348	Anadulafungin injection	G	0760
J0894*	J0894*	Decitabine injection	G	9231
C9236	J1300	Ecuzumab injection	G	9236
J1740	J1740	Ibandronate sodium injection	G	9229
C9232	J1743	Idursulfase injection	G	9232
J2248	J2248	Micafungin sodium injection	G	9227
Q4079	J2323	Natalizumab injection	G	9126
C9233	J2778	Ranibizumab injection	G	9233
J3243	J3243	Tigecycline injection	G	9228
J3473	J3473	Hyaluronidase recombinant	G	0806
Q4095	J3488	Reclast injection	G	0951
C9351	J7348	Tissuemend tissue	G	9351
C9351	J7349	Primatrix tissue	G	1141
J9261	J9261	Nelarabine injection	G	0825
C9235	J9303	Panimumab injection	G	9235

* Indicates that the drug was paid at a rate determined by the Part B drug CAP methodology while identified as pass-through under the OPSS.

B. Payment for Drugs, Biologicals, and Radiopharmaceuticals Without Pass Through Status

1. Background

Under the CY 2007 OPSS, we currently pay for drugs, biologicals, and radiopharmaceuticals that do not have pass-through status in one of two ways: packaged payment within the payment for the associated service or separate payment (individual APCs). We explained in the April 7, 2000 OPSS final rule with comment period (65 FR 18450) that we generally package the cost of drugs and radiopharmaceuticals into the APC payment rate for the procedure or treatment with which the products are usually furnished. Hospitals do not receive separate payment from Medicare for packaged items and supplies, and hospitals may not bill beneficiaries separately for any packaged items and supplies whose costs are recognized and paid within the national OPSS payment rate for the associated procedure or service. (Program Memorandum Transmittal A-01-133, issued on November 20, 2001, explains in greater detail the rules regarding separate payment for packaged services.)

Packaging costs into a single aggregate payment for a service, procedure, or episode of care is a fundamental principle that distinguishes a prospective payment system from a fee schedule. In general, packaging the costs of items and services into the payment for the primary procedure or service with which they are associated encourages hospital efficiencies and

also enables hospitals to manage their resources with maximum flexibility.

Section 1833(t)(16)(B) of the Act, as added by section 621(a)(2) of Pub. L. 108-173, sets the threshold for establishing separate APCs for drugs and biologicals at \$50 per administration for CYs 2005 and 2006. Therefore, for CYs 2005 and 2006, we paid separately for drugs, biologicals, and radiopharmaceuticals whose per day cost exceeded \$50 and packaged the costs of drugs, biologicals, and radiopharmaceuticals whose per day cost was equal to or less than \$50 into the procedures with which they were billed. For CY 2007, the packaging threshold for drugs, biologicals, and radiopharmaceuticals that are not new and do not have pass-through status was established at \$55. The methodology used to establish the \$55 threshold for CY 2007 and our proposed approach for future years are discussed in more detail in section V.B.2. of this final rule with comment period.

In addition, for CY 2005 to CY 2007, we have provided an exemption to this packaging determination for oral and injectable 5HT3 forms of anti-emetic products. We discuss in section V.B.2. of this final rule with comment period our final CY 2008 payment policy for these anti-emetic products.

2. Criteria for Packaging Payment for Drugs and Biologicals

As indicated above, in accordance with section 1833(t)(16)(B) of the Act, the threshold for establishing separate APCs for drugs and biologicals was set to \$50 per administration during CYs 2005 and 2006. In CY 2007, we used the

fourth quarter moving average Producer Price Index (PPI) levels for prescription preparations to trend the \$50 threshold forward from the third quarter of CY 2005 (when the Pub. L. 108-173 mandated threshold became effective) to the third quarter of CY 2007. We then rounded the resulting dollar amount to the nearest \$5 increment in order to determine the CY 2007 threshold adjustment amount of \$55.

Following the CY 2007 methodology (which is discussed in more detail in the CY 2007 OPSS/ASC final rule with comment period (71 FR 68085 through 68086)), as proposed, we used updated fourth quarter moving average PPI levels to trend the \$50 threshold forward from the third quarter of CY 2005 to the third quarter of CY 2008 and again rounded the resulting dollar amount (\$57.78) to the nearest \$5 increment, which yielded a figure of \$60. In performing this calculation, we used the most up-to-date forecasted, quarterly PPI estimates from CMS' Office of the Actuary (OACT). As actual inflation for past quarters replaced forecasted amounts, the PPI estimates for prior quarters were revised (compared with those used in the CY 2007 OPSS/ASC final rule with comment period) and were incorporated into our calculation. Based on the calculations described above, we proposed a packaging threshold for CY 2008 of \$60. As stated in the CY 2007 OPSS/ASC final rule with comment period (71 FR 68086), we believe that packaging certain items is a fundamental component of a prospective payment system, that packaging these items does not lead to

beneficiary access issues and does not create a problematic site of service differential, that the packaging threshold is reasonable based on the initial establishment in law of a \$50 threshold for the CY 2005 OPPS, that updating the \$50 threshold is consistent with industry and government practices, and that the PPI is an appropriate mechanism to gauge Part B drug inflation. As indicated in the proposed rule, we did not propose for CY 2008 to change this established approach to establishing the general packaging threshold for drugs, biologicals, and radiopharmaceuticals, in view of our proposed packaging approach for the CY 2008 OPPS as outlined in section II.A.4. of that proposed rule and our desire to move the OPPS toward a more encounter-based and episode-based payment in the future. However, as noted in the proposed rule, we will consider expanded packaging of payment for drugs, biologicals, and radiopharmaceuticals for a future OPPS update (72 FR 42732). We believe that consideration of expanded packaging for drugs and biologicals is particularly important, given the substantial increase that has occurred in recent years in the proportion of HCPCS codes for drugs, biologicals, and radiopharmaceuticals that are paid separately, from 30 percent in CY 2003 to 50 percent in CY 2007. We proposed for CY 2008 to expand the packaging of certain drugs and radiopharmaceuticals, specifically contrast agents and diagnostic radiopharmaceuticals as discussed in detail in section II.A.4.c.(5) and (6) of this final rule with comment period. However, we continue to believe that increased packaging of payment for drugs, biologicals, and radiopharmaceuticals more generally under the OPPS could provide significant incentives for hospital efficiency in adopting the most cost-effective approaches to patient care, while providing hospitals with maximum flexibility in managing their resources. Therefore, in the proposed rule, we specifically solicited public comment regarding recommended approaches to increase packaging of these products under the OPPS and issues we should consider as we evaluate alternative methodologies for the future (72 FR 42732).

For the third year, we proposed to continue exempting the oral and injectable forms of 5HT3 anti-emetics products from packaging, thereby making separate payment for all of these products. As we stated in the CY 2005 OPPS final rule with comment period (69 FR 65779 through 65780), it is our

understanding that chemotherapy is very difficult for many patients to tolerate, as the side effects are often debilitating. In order for Medicare beneficiaries to achieve the maximum therapeutic benefit from chemotherapy and other therapies with side effects of nausea and vomiting, anti-emetic use is often an integral part of the treatment regimen. In the proposed rule, we stated our belief that we should continue to ensure that Medicare payment rules do not impede a beneficiary's access to the particular anti-emetic that is most effective for him or her, as determined by the beneficiary and the treating physician.

Comment: A few commenters disagreed with the proposed increase of the packaging threshold to \$60 and asked CMS to retain the \$55 threshold for CY 2008. The commenters noted that the threshold has experienced a 20 percent increase over 2 years, and that an increased threshold threatens hospitals' ability to provide quality care without compromising the range of services they offer. One commenter suggested that CMS implement a contingency that would limit increases to the drug packaging amount to the rate of increase in the ASP amount. Other commenters suggested increasing the OPPS drug packaging threshold either for a subset of items, or for all drugs, biologicals, and radiopharmaceuticals. Another commenter recommended that CMS consider a drug packaging methodology based on the relative cost of a drug in comparison with the associated procedure, instead of continuing the absolute cost methodology, proposed for CY 2008 at \$60.

Response: We continue to believe that our approach of applying an annual inflation adjustment factor to update the packaging threshold is consistent with the practices of many health care payment policy areas, and many other areas of government policy, that acknowledge real costs by using an inflation adjustment factor instead of static dollar values. We continue to be concerned that, absent a mechanism to update the threshold, current relatively inexpensive drugs would begin to receive separate payment over time. While we understand the commenters' concerns that substantial increases in the threshold over a short period of time may be undesirable, we do not believe that the changes we have implemented over the past 2 years have jeopardized hospitals' ability to provide quality patient care. In addition, we again note that the updates to the OPPS drug packaging threshold have been predicated on relevant inflation rates for

prescription drugs. Therefore, we continue to believe that our update methodology is aligned closely with national industry figures and standards.

We agree with some commenters that an increased packaging threshold would be supportive of our overall increased packaging efforts to increase the size of the OPPS payment bundles. As stated above, we believe that there are many benefits of increasing the drug packaging threshold beyond the current level, one benefit being that items within a group of drugs would potentially be paid according to a similar methodology. During the September 2007 APC Panel meeting, the Panel engaged in a discussion regarding a higher drug packaging threshold for the OPPS, and while this discussion did not yield a recommendation, the Panel expressed interest in the idea of an increased drug packaging threshold. While we understand that there may be benefits to hospitals when the drug packaging threshold is relatively low because they would be paid separately for many drugs, we believe that a higher packaging threshold could encourage efficiencies and provide hospitals more flexibility in managing their resources associated with drug administration services.

In addition, while we are unsure how a drug packaging threshold based on relative drug costs in comparison to the associated procedure costs would operate in a hospital outpatient setting, we believe that further investigation of such a methodology could be warranted. Therefore, in an effort to gain more information that may help us determine the potential effects of an increased drug packaging threshold based on either an absolute dollar amount or on a relative dollar amount, we are again specifically requesting comments from hospital stakeholders and interested individuals on the impact that such a change would have on hospitals, and how such a methodology could be developed, implemented, and updated.

Comment: Several commenters requested that CMS eliminate the drug packaging threshold and provide separate payment for all Part B drugs. The commenters noted that this would eliminate payment disparities between the OPPS and the physician's office setting, so there would be no site-of-service differential in providing drug therapies.

Response: We continue to believe that unpackaging payment for all drugs, biologicals, and radiopharmaceuticals is inconsistent with the concept of a prospective payment system and that such a change could create an additional reporting burden for

hospitals. The OPSS and the MPFS that apply to physician's office services are fundamentally different payment systems with essential differences in their payment policies. Specifically, the OPSS is a prospective payment system, based on the concept of paying for groups of services that share clinical and resource characteristics. Payment is made under the OPSS according to prospectively established payment rates that are related to the relative costs of hospital resources for services. The MPFS is a fee schedule that generally provides payment for each individual component of a service. Consistent with the MPFS approach, separate payment is made for each drug provided in the physician's office, but the OPSS packages payment for certain drugs into the associated procedure payments for the APC group. Because of the different payment policies, differences in the degrees of packaged payment and separate payment between these two systems are only to be expected. In general, we do not believe that our packaging methodology under the OPSS results in limited beneficiary access to drug administration services.

We note that, in CYs 2005 and 2006, the statutorily mandated drug packaging threshold was set at \$50, and we believe it is currently appropriate to continue a modest drug packaging threshold for the CY 2008 OPSS. Therefore, because of our continued belief that packaging is a fundamental component of a prospective payment system that contributes to important flexibility and efficiency in the delivery of high quality outpatient hospital services, we are not adopting the recommendation to pay separately for all drugs, biologicals, and radiopharmaceuticals for CY 2008.

Comment: Several commenters supported the proposal to continue to exempt the oral and injectable forms of 5HT3 anti-emetic products (that were listed in Table 43 of the proposed rule that is reprinted as Table 29 below) from packaging, thereby making separate payment for all of the 5HT3 anti-emetic products. In addition, a few commenters requested that CMS apply the same principle to other groups of drugs in order to equalize payment methodologies across drugs in the same clinical group. One commenter recommended that payment for all hyaluronidase products be packaged.

Response: We appreciate the support of our proposal to continue exempting the 5HT3 anti-emetic products from our packaging determination. However, as discussed in the CY 2008 OPSS/ASC proposed rule, as we consider moving to additional encounter based and episode-based payment in future years, we may

consider additional options for packaging in the future. If we were to increase the OPSS drug packaging threshold, we might no longer require a special exemption for these products because all these products might be packaged under such an approach. Similarly, a higher drug packaging threshold could eliminate existing disparities in payment methodologies for other drug groups and provide similar methods of payment across items in a group. Nevertheless, while we may be interested in alternative threshold methodologies for future ratesetting purposes, we realize that there are existing situations where drugs in a particular category vary in their payment treatment under the OPSS, with some drugs packaged and other separately paid. We believe the challenges associated with categorizing drugs to assess them for disparities are significant, and we are not convinced that ensuring the same payment treatment for other drug categories is essential at this time, beyond the proposal we made for 5HT3 anti-emetics. Therefore, we do not believe that it would be appropriate for CY 2008 to take any additional steps to ensure that all drugs in a specific category are either separately paid or packaged, as requested by some commenters.

After considering the public comments received, we are finalizing our CY 2008 proposal, without modification, to again exempt the oral and injectable forms of 5HT3 anti-emetic products listed in Table 29 below from our packaging methodology for CY 2008.

TABLE 29.—ANTI-EMETICS EXEMPTED FROM CY 2008 \$60 PACKAGING THRESHOLD

HCPSC code	Short descriptor
J1260	Dolasetron mesylate
J1626	Granisetron HCl injection
J2405	Ondansetron hcl injection
J2469	Palonosetron HCl
Q0166	Granisetron HCl 1 mg oral
Q0179	Ondansetron HCl 8 mg oral
Q0180	Dolasetron mesylate oral

For CY 2008, we proposed to calculate the per day cost of all drugs, biologicals, and radiopharmaceuticals that had a HCPSC code in CY 2006 and were paid (via packaged or separate payment) under the OPSS using claims data from January 1, 2006, to December 31, 2006, to determine their CY 2008 packaging status. In order to calculate the per day costs for drugs, biologicals, and radiopharmaceuticals to determine their packaging status in CY 2008, we

proposed to use the methodology that was described in detail in the CY 2006 OPSS proposed rule (70 FR 42723 through 42724) and finalized in the CY 2006 OPSS final rule with comment period (70 FR 68636 through 70 FR 68638). To calculate the proposed CY 2008 per day costs, we used an estimated payment rate for each drug and biological of ASP+5 percent (which is the payment rate we proposed for separately payable drugs and biologicals in CY 2008, as discussed in more detail subsequently). As noted in the CY 2008 OPSS/ASC proposed rule (72 FR 42733), we used the manufacturer submitted ASP data from the fourth quarter of CY 2006 (rates that were used for payment purposes in the physician's office setting, effective April 1, 2007) to determine the proposed per day cost. For items that did not have an ASP based payment rate, we used their mean unit cost derived from the CY 2006 hospital claims data to determine their per day cost. As described in the proposed rule, we packaged items with a per day cost less than or equal to \$60 and identified items with a per day cost greater than \$60 as separately payable. Consistent with our past practice, we crosswalked historical OPSS claims data from the CY 2006 HCPCS codes that were reported to the CY 2007 HCPCS codes that we displayed in Addendum B to the proposed rule for payment in CY 2008.

Our policy during previous cycles of the OPSS has been to use updated data to establish final determinations of the packaging status of drugs, biologicals, and radiopharmaceuticals. We note that it is also our policy to make an annual packaging determination only when we develop the OPSS/ASC final rule for the update year. As indicated in the proposed rule (72 FR 42733), only items that are identified as separately payable in this final rule with comment period will be subject to quarterly updates. As proposed, for our calculation of per day costs of drugs, biologicals, and radiopharmaceuticals in this final rule with comment period, we used ASP data from the first quarter of CY 2007, which is the basis for calculating payment rates for drugs and biologicals in the physician's office setting using the ASP methodology, effective July 1, 2007, along with updated hospital claims data from CY 2006.

Consequently, the packaging status for drugs, biologicals, and radiopharmaceuticals in this final rule with comment period using the updated data may be different from their packaged status determined based on the data used for the proposed rule. Under such circumstances, we have

applied the following policies to these drugs, biologicals, and radiopharmaceuticals whose relationship to the \$60 threshold changes based on the final updated data:

- Drugs, biologicals, and radiopharmaceuticals that were paid separately in CY 2007 and that were proposed for separate payment in CY 2008, and then have per day costs equal to or less than \$60, based on the updated ASPs and hospital claims data used for the CY 2008 final rule with comment period, would continue to receive separate payment in CY 2008.

- Drugs, biologicals, and radiopharmaceuticals that were packaged in CY 2007 and that were proposed for separate payment in CY 2008, and then have per day costs equal to or less than \$60, based on the updated ASPs and hospital claims data used for the CY 2008 final rule with comment period, would remain packaged in CY 2008.

- Drugs, biologicals, and radiopharmaceuticals for which we proposed packaged payment in CY 2008 but then have per day costs greater than \$60, based on the updated ASPs and hospital claims data used for the CY 2008 final rule with comment period, would receive separate payment in CY 2008.

We note that HCPCS code J0594 (Injection, busulfan, 1 mg) was paid separately in CY 2007 and was proposed for separate payment in CY 2008, but had a final per day cost of approximately \$37, which is less than the \$60 threshold, based on the updated ASPs and hospital claims data used for this CY 2008 final rule with comment period. HCPCS code J0594 will continue to receive separate payment in CY 2008 according to the established methodology set forth above.

In addition, there were several drugs and biologicals that we proposed to package in the proposed rule and that now have per day costs greater than \$60 using updated ASPs and all of the hospital claims data from CY 2006 used for this final rule with comment period. In accordance with our established policy for such cases, for CY 2008 we will pay for these drugs and biologicals separately. Table 30 lists the drugs and biologicals that were proposed as packaged, but that will be paid separately in CY 2008.

TABLE 30.—DRUGS AND BIOLOGICALS PROPOSED AS PACKAGED BUT WITH FINAL PER DAY COSTS ABOVE \$60, FOR WHICH SEPARATE PAYMENT WILL BE MADE IN CY 2008

HCPCS	Description
J0190	Inj biperiden lactate/5 mg
J0600	Edetate calcium disodium inj
J1595	Injection glatiramer acetate
J2730	Pralidoxime chloride inj
J9270	Plicamycin (mithramycin) inj

Also, according to our packaging policy described above, two drugs, specifically HCPCS codes J0520 (injection, bethanechol chloride, myotonachol or urecholine, up to 5 mg) and J3364 (injection, urokinase, 5000 iu vial), were packaged in CY 2007, proposed for separate payment in CY 2008, but had final per day costs equal to or less than \$60 based on the updated ASPs and hospital claims data used for the CY 2008 final rule with comment period. Therefore, in accordance with our methodology, these two drugs will continue to be packaged in CY 2008.

In sections II.A.4.c.(5) and (6) of the CY 2008 OPPS/ASC proposed rule, we proposed to package payment for all diagnostic radiopharmaceuticals and contrast agents that would not otherwise be packaged according to the proposed CY 2008 packaging threshold for drugs, biologicals and radiopharmaceuticals. Tables 17 and 19 in sections II.A.4.c.(5) and (6) of that proposed rule (72 FR 42671 and 42673 through 42674) listed the diagnostic radiopharmaceuticals and contrast agents, respectively, that we proposed to package in CY 2008. In section V.B.3.a.(4) of this final rule with comment period, we discuss our CY 2008 policies for providing payment for diagnostic and therapeutic radiopharmaceuticals.

We note that HCPCS code A9568 (Technetium Tc-99 arcitumomab, diagnostic, per study dose, up to 45 millicuries) replaced HCPCS code A9549 (Technetium Tc-99 arcitumomab, diagnostic, per study dose, up to 25 millicuries) beginning January 1, 2007. Our CY 2006 claims data indicate that HCPCS code A9549 was billed an average of one time per day. As we did not have claims data available for ratesetting purposes for HCPCS code A9568, we estimated the number of units per day to also be one.

3. Payment for Drugs and Biologicals Without Pass-Through Status That Are Not Packaged

a. Payment for Specified Covered Outpatient Drugs

(1) Background

Section 1833(t)(14) of the Act, as added by section 621(a)(1) of Pub. L. 108–173, requires special classification of certain separately paid radiopharmaceuticals, drugs, and biologicals and mandates specific payments for these items. Under section 1833(t)(14)(B)(i) of the Act, a “specified covered outpatient drug” is a covered outpatient drug, as defined in section 1927(k)(2) of the Act, for which a separate APC has been established and that either is a radiopharmaceutical agent or is a drug or biological for which payment was made on a pass-through basis on or before December 31, 2002.

Under section 1833(t)(14)(B)(ii) of the Act, certain drugs and biologicals are designated as exceptions and are not included in the definition of “specified covered outpatient drugs,” known as SCODs. These exceptions are—

- A drug or biological for which payment is first made on or after January 1, 2003, under the transitional pass-through payment provision in section 1833(t)(6) of the Act.

- A drug or biological for which a temporary HCPCS code has not been assigned.

- During CYs 2004 and 2005, an orphan drug (as designated by the Secretary).

Section 1833(t)(14)(A)(iii) of the Act, as added by section 621(a)(1) of Pub. L. 108–173, requires that payment for SCODs in CY 2006 and subsequent years be equal to the average acquisition cost for the drug for that year as determined by the Secretary, subject to any adjustment for overhead costs and taking into account the hospital acquisition cost survey data collected by the Government Accountability Office (GAO) in CYs 2004 and 2005. If hospital acquisition cost data are not available, the law requires that payment be equal to payment rates established under the methodology described in section 1842(o), section 1847A, or section 1847B of the Act, as calculated and adjusted by the Secretary as necessary.

In establishing the CY 2006 payment rates, we evaluated the three data sources that were available to us for setting the CY 2006 payment rates for drugs and biologicals. As described in the CY 2006 OPPS final rule with comment period (70 FR 68639 through 68644), these data sources were the GAO reported average purchase prices

for 55 SCOD categories for the period July 1, 2003, to June 30, 2004, collected via a survey of 1,400 acute care Medicare-certified hospitals; ASP data; and mean costs derived from CY 2004 hospital claims data. For the CY 2006 OPSS final rule with comment period, we used ASP data from the second quarter of CY 2005, which were used to set payment rates for drugs and biologicals in the physician's office setting effective October 1, 2005, and updated claims data.

In our data analysis for the CY 2006 OPSS final rule with comment period, we compared the payment rates for drugs and biologicals using data from all three sources described above. We estimated aggregate expenditures for all drugs and biologicals that would be separately payable in CY 2006 and for the 55 drugs and biologicals reported by the GAO using mean costs from the claims data, the GAO mean purchase prices, and the ASP-based payment amounts (ASP+6 percent in most cases), and then calculated the equivalent average ASP-based payment rate under each of the three payment methodologies. We excluded radiopharmaceuticals in our analysis because they were paid at hospital charges reduced to cost during CY 2006. The results based on updated ASP and claims data were published in Table 24 of the CY 2006 OPSS final rule with comment period. For a full discussion of our reasons for using these data, we refer readers to section V.B.3.a. of the CY 2006 OPSS final rule with comment period (70 FR 68639 through 68644).

As we noted in the CY 2006 OPSS final rule with comment period, findings from a MedPAC survey of hospital charging practices indicated that hospitals set charges for drugs, biologicals, and radiopharmaceuticals high enough to reflect their pharmacy handling costs as well as their acquisition costs. In consideration of this information, we stated in the CY 2006 OPSS final rule with comment period that payment rates derived from hospital claims data also included acquisition and pharmacy handling costs because they are derived directly from hospital charges (70 FR 68642). In CYs 2006 and 2007, we finalized a policy of providing payment to HOPDs for drugs, biologicals, and associated pharmacy handling costs at a rate of ASP+6 percent. In addition, in CY 2006 we had proposed to collect pharmacy overhead charge data via special pharmacy overhead HCPCS codes that hospitals would report. We did not finalize this proposal for CY 2006 because of hospital concerns regarding the administrative burden associated

with reporting pharmacy overhead with these special HCPCS codes (70 FR 68657 through 68665).

(2) Final Payment Policy

The provision in section 1833(t)(14)(A)(iii) of the Act, as described above, continues to be applicable to determining payments for SCODs for CY 2008. This provision requires that, in CY 2008, payment for SCODs be equal to the average acquisition cost for the drug for that year as determined by the Secretary, subject to any adjustment for overhead costs and taking into account the hospital acquisition cost survey data collected by the GAO in CYs 2004 and 2005. If hospital acquisition cost data are not available, the law requires that payment be equal to payment rates established under the methodology described in section 1842(o), section 1847A, or section 1847B of the Act, as calculated and adjusted by the Secretary as necessary. In addition, section 1833(t)(14)(E)(ii) authorizes the Secretary to adjust APC weights for SCODs to take into account the MedPAC report relating to overhead and related expenses, such as pharmacy services and handling costs.

We considered several options for payment for drug acquisition costs and pharmacy overhead for CY 2008 (72 FR 42735). First, we considered proposing again the methodology we had proposed for CY 2006, which involved the establishment of three drug overhead categories that hospitals would use to report pharmacy overhead charges associated with a drug provided in the HOPD. Until such data were available for ratesetting purposes, we considered continuing our CY 2007 methodology of bundling average hospital acquisition and pharmacy overhead payments. While this approach has the advantage of not paying separately for pharmacy overhead until we would have claims data on which to establish separate payment rates for drug acquisition costs and pharmacy overhead, its goal would still be to ultimately unpackage OPSS payment for pharmacy overhead. We decided not to propose this option because we believed and continue to believe that it is undesirable to take steps that would ultimately lead to pharmacy overhead being unpackaged at the same time that we have proposed measures to expand packaging under the OPSS and have considered moving toward more episode-based and encounter-based payment. Furthermore, we note that as we considered this approach, we were mindful of the comments we received in response to our CY 2006 proposed rule expressing

concern about the additional administrative burden on staff and coders that this methodology might cause.

The second option we presented in the proposed rule was to continue our CY 2007 methodology of providing a single bundled payment representing average hospital acquisition costs and associated pharmacy overhead costs. As stated previously, we believe that hospitals are including pharmacy overhead costs in their charges for drugs, consistent with MedPAC's findings. While we continue to believe that a combined payment amount for drug acquisition costs and pharmacy overhead based on our claims data is a reasonable methodology, adequately accounts for acquisition costs and overhead, and is consistent with our broader packaging efforts, we proposed a slight variant of this approach for CY 2008 instead.

For CY 2008, we proposed to continue our methodology of providing a combined payment rate for drug and biological acquisition costs and pharmacy overhead. However, in addition, we proposed to instruct hospitals to remove the pharmacy overhead charge from the charge for the drug or biological and instead report the pharmacy overhead charge on an uncoded revenue code line on the claim beginning in CY 2008. We believed that this proposed change, from a CY 2007 policy where hospitals include pharmacy overhead in their charges for the drug or biological to a CY 2008 policy of including the pharmacy overhead charges on an uncoded revenue code line, would allow us to package pharmacy overhead costs for drugs and biologicals into payment for the associated procedure, likely a drug administration procedure, in future years when the CY 2008 claims data become available for ratesetting. We proposed to apply this policy to the reporting of charges for all drugs and biologicals, including contrast agents, irrespective of the item's packaged or separately payable status for the CY 2008 OPSS. We did not propose to apply this policy to the reporting of overhead charges for radiopharmaceuticals, given the explicit instructions we gave hospitals beginning in CY 2006 to include the charges for radiopharmaceutical overhead and handling in the charges for the radiopharmaceutical product.

We note that, in the case of current OPSS payment for packaged drugs, payment for both the drugs and their associated pharmacy overhead costs is already packaged into payment for the associated separately payable

procedures, including drug administration services as discussed in detail in section II.A.1.b.(2) of this final rule with comment period. In addition, this methodology is consistent with the increased packaging efforts discussed earlier in section II.A.4. of this final rule with comment period. Because we would not expect to have claims data reflecting these reporting changes until CY 2010, we proposed to continue to provide a combined payment rate for acquisition costs and pharmacy overhead for separately payable drugs and biologicals in CY 2008, similar to the combined payment rate provided in CYs 2006 and 2007 that represents the average hospital acquisition cost and pharmacy overhead cost.

During the March 2007 APC Panel meeting, the APC Panel recommended that CMS implement a three-phase plan to address OPPS payment for pharmacy overhead costs. The first phase of the recommended plan involves CMS working with interested stakeholders to develop a system of defining pharmacy overhead categories for outpatient drugs that require different levels of pharmacy resources. In addition, this phase includes a provision recommending that CMS provide payment for pharmacy overhead costs by setting payment rates for the developed categories through New Technology APCs, presumably while collecting hospital cost data on these services. The second phase of the recommended plan calls for CMS to review estimates of pharmacy overhead costs as identified by the GAO and MedPAC, and to consider external survey data from stakeholders. The third and final phase of the recommended plan calls for specific billing of pharmacy overhead costs using HCPCS codes (corresponding to the categories developed in phase one, with payment rates resulting from submitted hospital claims data) on the same claim as a drug administration service. The APC Panel recommended that the overhead payments be made in addition to the current 2007 ASP+6 percent payment rates for separately payable drugs and biologicals that do not have pass-through status.

During the September 2007 APC Panel meeting, the Panel recommended that hospitals not be required to separately report charges for pharmacy overhead and handling, and that pharmacy overhead and handling costs be recognized within drug charges and paid through the packaged or separate drug payment (as appropriate based on the drug packaging threshold). In addition, the Panel recommended that we continue to evaluate alternative methods to standardize the capture of

pharmacy overhead costs in a manner that is simple to implement at the organizational level, similar to the three-phase approach recommended by the Panel during the March 2007 meeting. We discuss our responses to these recommendations below.

We received many public comments on our CY 2008 proposal to have hospitals report charges for pharmacy overhead on uncoded revenue code line. A summary of the public comments and our responses follow.

Comment: MedPAC supported the proposal to collect pharmacy overhead data via uncoded revenue code lines because it would allow hospitals to be paid more accurately for the variation in pharmacy overhead costs when payment for those costs would be packaged into the costs of the associated independent services. However, the vast majority of commenters echoed the APC Panel's recommendation to not require hospitals to separately report charges for pharmacy overhead and handling and the Panel's further recommendation that pharmacy overhead and handling costs be recognized within drug charges and be paid through the packaged or separate drug payment (as appropriate based on the drug packaging threshold). In general, the commenters cited overwhelming implementation issues, including administrative reporting burdens, challenges involved with identifying and splitting current charges for drugs and biologicals into acquisition costs and overhead, inflexible hospital accounting systems that are unable to combine and differentiate charges depending on the insurer, complexity requiring manual changes to individual claims, and beneficiary confusion regarding these charges on their bills. In addition, some commenters were concerned that secondary private insurers may not accept the charges when the claim is submitted after being processed by Medicare. The commenters noted that, due to these complex issues and the relatively short timeframe in which hospitals would have to make these changes, data obtained through this proposal are likely to be unreliable.

A few commenters expressed disappointment that CMS did not propose to adopt various methodologies they shared with CMS for capturing pharmacy overhead data. Several commenters reiterated their proposals for a three-phase system, similar to the three-phase plan recommended by the APC Panel and discussed above. The commenters also suggested that this plan could be altered, and that the survey contained in the second phase survey could be replaced with direct

adoption of median costs from hospital claims data as long as prospective payments based on claims data were not implemented prematurely.

One commenter suggested a modification to the current hospital cost report by splitting the "Pharmacy" and "Drugs Sold to Patient" cost centers into two lines each—one for drug acquisition costs and the other for drug-related pharmacy and overhead costs. The commenters stated that providers would then apportion their drug charges between these two lines, and CMS would use the cost report to determine the relative cost of pharmacy overhead to total drug costs.

Other commenters suggested that CMS conduct hospital surveys, gather information through the fiscal intermediaries, or attach an additional worksheet to the hospital cost report.

Several commenters requested that, if CMS were to finalize this proposal, CMS should limit the reporting requirement to drugs with significant pharmacy overhead and administrative costs.

In addition to these suggested methodologies, several commenters expressed confusion regarding the phrases "uncoded revenue code line" and "overhead and handling costs" and requested clarification, while others requested that, if CMS finalized the proposed policy for pharmacy overhead services, CMS should delay the implementation date and provide hospitals additional time to update their systems.

Response: We appreciate the commenters' many suggestions on ways to collect hospital pharmacy data and the commenters' concerns regarding our proposal. While we considered the APC Panel's March 2007 recommendation, as well as similar suggestions from other stakeholders, we did not propose to adopt this recommendation (nor are we adopting this recommendation in this final rule with comment period) to implement a three-phase plan to address OPPS payment for pharmacy overhead costs. For CY 2008, we proposed to expand packaging under the OPPS by packaging payment for certain ancillary and supportive services as discussed in section II.A.4.c. of this final rule with comment period. Given our belief that packaging can be helpful in promoting hospital efficiency and long-term cost containment and our belief that pharmacy handling is ancillary and supportive to the administration of drugs and biologicals in the HOPD, we do not believe it would be desirable to take steps that would ultimately lead to payment for pharmacy overhead costs being unpackaged under the OPPS.

As noted in the proposed rule (72 FR 42734 through 42735), the APC Panel recommended that CMS establish separate payment amounts for pharmacy overhead in addition to the current CY 2007 combined payment for drug acquisition costs and pharmacy overhead of ASP+6 percent. As we discussed in the CY 2006 OPSS final rule with comment period (70 FR 68657) and in the CY 2007 OPSS/ASC final rule with comment period (71 FR 68089 through 68092), findings from a MedPAC survey of hospital charging practices indicated that hospitals set charges for drugs, biologicals, and radiopharmaceuticals high enough to reflect their pharmacy handling costs as well as their acquisition costs. We continue to believe that our payment rates for drug acquisition costs and pharmacy overhead should be determined based on the costs reflected in our claims data, as these costs reflect both acquisition costs and overhead costs. We also believe that establishing additional payment for pharmacy overhead beyond our proposed payment rates based on claims data would distort the relative relationship of costs across HOPD services, which is the basis of the OPSS. As we do consider the Panel's March 2007 recommendation to be aligned with the current OPSS trend towards increasing the size of payment bundles, we are accepting the Panel's September 2007 recommendation to continue to evaluate alternate methods to standardize the capture of pharmacy overhead costs in a manner that is simple to implement at the organizational level. As such, we are interested in continuing our dialogue with hospital stakeholders regarding the issue of pharmacy overhead. We generally accept requests from interested organizations to discuss their views about OPSS payment policy issues, including pharmacy handling issues. In addition, we establish the OPSS rates through regulations and, as such, consider the timely comments of interested organizations, establish the payment policies for the forthcoming year, and respond to the timely comments of all public commenters in the final rule in which we establish the payment for the forthcoming year.

After reviewing the public comments we received on the CY 2008 proposal, we have a better understanding of the scope of our proposal and the burden that it would have on hospitals. While we continue to believe that packaging pharmacy overhead costs into the associated independent procedures for administration of the drugs could pay hospitals more appropriately for the

variable pharmacy overhead costs associated with different types of drugs, we are concerned about the operational challenges and administrative burdens that hospitals would face in reporting drugs provided in the HOPD. Therefore, we are not finalizing our proposal to require hospitals to remove pharmacy overhead costs from drug acquisition costs and to report pharmacy overhead costs in an uncoded revenue code line.

We appreciate the suggestions to implement a hospital survey or to include a pharmacy overhead worksheet on the hospital cost report. However, we do not believe that it would be administratively feasible or reasonable from a resource perspective to develop and update information regarding pharmacy overhead costs through either of these methodologies. Presumably the commenters believe that, by collecting these data, we would provide additional separate payments to hospitals for pharmacy overhead services. As explained above, separate payment for pharmacy overhead would decrease the current size of the drug payment bundles and would not be aligned with the additional packaging we have implemented in this final rule with comment period.

In addition, several commenters expressed their preference to retain the pharmacy overhead payment packaged with the payment for the drug, stating that this is the most logical and appropriate grouping for payment purposes. We agree with these commenters and believe that a single OPSS payment that represents both drug acquisition and associated pharmacy overhead costs is the most reasonable and logical method of payment for these services. Therefore, we are adopting the September 2007 recommendation of the APC Panel that pharmacy overhead and handling costs be recognized within drug charges and be paid through the packaged or separate drug payment (as appropriate based on the drug packaging threshold). We do not believe that we need to provide specific guidance on the elements of pharmacy handling and overhead that hospitals should consider in setting their charges for drugs, because, as MedPAC found and many commenters confirmed, hospitals are currently including the costs of pharmacy overhead in their charges for drugs and biologicals.

After consideration of the public comments received, we are finalizing our proposal to provide a single bundled payment for separately payable drugs and biologicals, inclusive of both drug acquisition and pharmacy overhead costs. Hospitals should continue to consider the costs of

pharmacy overhead in developing and reporting their charges for drugs and biologicals, maintaining their current practice.

For the CY 2008 OPSS/ASC proposed rule, we evaluated two data sources that we have available to us for setting the CY 2008 payment rates for drugs and biologicals. The first source of drug pricing information that we have is the ASP data from the fourth quarter of CY 2006, which were used to set payment rates for drugs and biologicals in the physician's office setting, effective April 1, 2007. We have ASP-based prices for approximately 500 drugs and biologicals (including contrast agents) payable under the OPSS. However, we currently do not have any ASP data on radiopharmaceuticals.

The second source of cost data that we have for drugs, biologicals, and radiopharmaceuticals is the mean and median costs derived from the CY 2006 hospital claims data. As section 1833(t)(14)(A)(iii) of the Act clearly specifies that payment for SCODs in CY 2008 be equal to the "average" acquisition cost for the drug, we limited our analysis to the mean costs of drugs determined using the hospital claims data, instead of using median costs.

In our data analysis, we compared the payment rates for drugs and biologicals using data from both sources described above. After determining the proposed CY 2008 packaging status of drugs and biologicals, we estimated aggregate expenditures for all drugs and biologicals (excluding radiopharmaceuticals) that would be separately payable in CY 2008 using mean costs from the hospital claims data and the ASP-based payment amounts, and calculated the equivalent average ASP-based payment amount under both payment methodologies.

The results of our proposed rule data analysis for the proposed rule indicated that using mean unit cost to set the payment rates for the drugs and biologicals that would be separately payable in CY 2008 would be equivalent to basing their payment rates, on average, at ASP+5 percent. Therefore, we proposed to continue to provide a bundled payment for the acquisition costs of drugs and biologicals and the associated pharmacy overhead in CY 2008 at ASP+5 percent, where the ASP add-on percent was calculated based on mean costs from hospital claims data. In addition, as described in section II.A.4.c.(6) of this final rule with comment period, for contrast agents, we proposed a supplemental approach that would package payment for all contrast media under the CY 2008 OPSS.

During the September 2007 meeting of the APC Panel, the Panel recommended that we continue to provide payment for separately payable drugs at a rate of ASP+6 percent for CY 2008. We discuss our response to this recommendation below.

We received many public comments on our proposal to pay for separately payable drugs and biologicals and their pharmacy overhead at ASP+5 percent in CY 2008. A summary of the public comments and our responses follow.

Comment: Many commenters agreed with the Panel's recommendation to continue providing payment for separately payable drugs, including several specific groups of drugs such as blood clotting factors and IVIG, at ASP+6 percent. Some commenters noted that this would eliminate a site-of-service differential that would otherwise exist between the hospital outpatient and physicians' office settings if HOPDs were paid at ASP+5 percent while physicians' offices were paid at ASP+6 percent. The commenters also cited issues of charge compression. Specifically, the commenters explained that many lower cost packaged drugs have a higher markup and the relative ASP number is not inclusive of this pricing practice because only separately payable drugs are used in the comparison. A few commenters also noted that CMS has not demonstrated that concerns that led to a continuation of the ASP+6 percent methodology in CY 2007, such as a limited understanding of pharmacy overhead costs and their relationship to hospital outpatient drugs, have been resolved. Finally, some commenters expressed concern that, even at ASP+6 percent, hospitals may not be receiving adequate payments to account for both acquisition costs and overhead costs. Furthermore, some of these commenters requested payment increases for certain groups of drugs, such as IVIG and blood products.

Response: In analyzing data for the CY 2008 final rule with comment period, we again performed the analysis described in the CY 2008 proposed rule by comparing aggregate expenditures for separately payable drugs and biologicals to the ASP-based payment rates, weighting these HCPCS codes by their OPPS volumes, and calculating an equivalent average ASP-based payment rate for drugs and biologicals provided in HOPDs for CY 2008. As we did for our final rule analysis to determine the final packaging status for each drug, we used updated CY 2006 mean unit costs and drug volumes and updated ASP data. The result of our final analysis using updated hospital claims data for

the full CY 2006 year and updated CCRs is that the equivalent average ASP-based payment amount for separately payable drugs and biologicals, including pharmacy handling costs, is equal to ASP+3 percent for CY 2008. Therefore, according to our CY 2008 proposal for payment of separately payable drugs and biologicals which includes pharmacy overhead payment, based on mean costs from CY 2006 hospital claims, the OPSS payment rate for separately payable drugs and biologicals would be ASP+3 percent.

We acknowledge that different payment rates for drugs and biologicals provided in the physician's office and HOPD settings are of concern to some commenters. However, the OPSS, the MPFS physician's office payments for services and physician's office payments for Part B drugs are based on very different payment methodologies. In particular, the OPSS relies upon costs from the most updated claims and Medicare cost report data to develop payment rates. On the other hand, the MPFS pays for services based on estimates of input costs and pays for drugs and biologicals at ASP+6 percent, as required by statute. Therefore, it is not surprising to us that the estimated costs of drug and biologicals and their associated pharmacy overhead, like many other OPSS services, could be different in the HOPD than in the physician's office, resulting in different payments in the two settings. We do not believe that different payment rates for drugs and biologicals in the HOPD or physician's office settings will create problems for beneficiaries regarding access to drug administration services because we have not seen problems with access in the two settings for other types of services, including diagnostic studies, surgical procedures, and visits, which generally have different payment rates under the two payment systems (unless there is an applicable externally applied statutory cap to payment, such as the cap on payment for imaging services provided in the physician's office based on the OPSS rates).

In response to the commenters' concerns regarding the effects of charge compression on drug payment, as described further in section II.A.1.c. of this final rule with comment period, we have contracted with RTI to estimate regression-based CCRs using charge data from both inpatient and outpatient claims for hospital ancillary departments. We will consider whether it would be appropriate to adopt regression-based CCRs for the OPSS in the future after we receive RTI's comprehensive review of the OPSS cost estimation methodology and review the

results of the use of both inpatient and outpatient charges across all payers to reestimate regression-based CCRs.

After a period of continuing ASP+6 percent payment in CY 2007 while we gathered additional information regarding pharmacy overhead costs, we believe that it is most appropriate at this point to continue to pay for drugs and biologicals and their associated pharmacy overhead costs using an ASP-based system, but to determine the relative ASP percent based on mean costs from claims rather than continue to use ASP+6 percent. Therefore, we are not accepting the recommendation of the APC Panel to continue to pay for separately payable drugs and biologicals at ASP+6 percent for CY 2008. After reviewing the commenters' responses to our CY 2008 proposal, we are reassured that hospitals currently capture pharmacy overhead costs in their charges for drugs, and we have clear guidance from the APC Panel and some commenters that pharmacy overhead and handling costs should continue to be recognized within drug charges and paid through the drug payment.

Our claims data for the CY 2007 and CY 2008 final rules consistently have shown equivalent average ASP-based amounts for separately payable drugs and biologicals that are lower than ASP+6 percent, specifically ASP+4 percent and APC+3 percent, respectively. However, because we have been paying ASP+6 percent for separately payable drugs and biologicals under the OPSS for the last 2 years, we believe it is appropriate to transition to the use of hospital claims data as the basis for the relative ASP percent. Therefore, we will provide a 2-year transition, with a one year transitional payment rate in CY 2008, and pay for separately payable drugs and biologicals and associated pharmacy overhead based on a 50/50 blend of their CY 2007 payment rate of ASP+6 percent and their final CY 2008 equivalent average ASP-based payment amount of ASP+3 percent. This blend results in a payment amount of ASP+4.5 percent. However, because we pay based on whole percentages in relation to ASP, we are rounding the blend to ASP+5 percent for CY 2008. In summary, we will provide a transitional payment of ASP+5 percent for separately payable drugs and biologicals and associated pharmacy overhead in CY 2008 as we move toward a relative ASP percent based on mean costs from claims for CY 2009.

Comment: Several commenters disagreed with our calculation of an average ASP-based payment amount for drugs and biologicals and associated

pharmacy overhead costs based on aggregate costs from claims. One commenter stated that instead of an aggregate amount across all drugs, each drug should be individually examined in order to determine average hospital acquisition cost. This commenter noted that, by aggregating drug costs across all separately paid drugs to determine the equivalent average ASP-based payment rate, some drugs could be underpaid while others could be overpaid. Other commenters suggested that CMS include relatively inexpensive drugs, including drugs that are usually packaged as well as drugs that may not have their own HCPCS codes but are reported with charges on uncoded revenue code lines. The commenters noted that, because of charge compression and hospital billing practices, these drugs typically receive the highest markups because they are relatively inexpensive. Other commenters recommended that CMS include packaged drugs with HCPCS codes that are currently packaged in determining the average ASP-based amount. The commenters noted that if all drugs were paid separately in the HOPD, there would be better representation of pharmacy overhead costs associated with lower cost drugs in the average ASP-based amount calculated. The commenters explained that hospitals often attribute higher markups to lower cost drugs and lower markups to higher cost drugs, an issue known as charge compression. By providing separate payment for all drugs, the OPSS would then consider the full set of Part B drugs and their associated overhead as part of the average ASP-based amount, rather than relying on only separately paid, and therefore more expensive, drugs to perform this calculation. The commenters claimed that this change would more accurately account for the actual pharmacy overhead charges that hospitals have built into their accounting systems, and, as a result, the equivalent average ASP-based amount would be higher. A few commenters expressed concern that ASP reflects prices and discounts not passed along to providers and that ASP is a measure of sales to all entities, not just hospitals. Other commenters noted that the two quarter lag in updated ASP data is problematic for hospitals that experience varying purchasing conditions from quarter to quarter.

Response: We continue to believe that use of ASP as a payment methodology is appropriate under the OPSS because these rates are updated quarterly and are therefore more reflective of current market conditions that influence

hospital purchasing prices than hospital claims data. Furthermore, comparison of the ASP data to our hospital claims data serves to ensure that we are paying for drugs in the OPSS in general at rates that are reflective of hospitals' costs for acquisition and overhead. While we understand that, by aggregating the costs of separately payable drugs and biologicals prior to developing an equivalent average ASP-based payment rate, the result could be that some drugs could be relatively underpaid in a given clinical scenario while others could be relatively overpaid, we continue to believe that ASP data are our best proxy for average hospital acquisition costs under the OPSS and that the calculation should be performed using aggregated drug costs. Given the information provided by commenters regarding hospitals' diverse charging practices and the differential inclusion of pharmacy overhead costs in charges for low and high cost drugs, we do not believe that it would be reasonable to conduct this comparison on a drug-specific level to calculate a distinct equivalent ASP-based payment for each drug under the OPSS that would reflect the acquisition and overhead costs of that particular drug. Instead, we continue to believe that it is more appropriate to develop an equivalent average ASP-based payment rate that determines the ASP add-on percent based on the aggregated hospital costs of separately payable drugs and biologicals calculated from claims data, recognizing that the OPSS is a system based on the averaging of costs for services.

In addition, we do not include packaged drugs and biologicals in this analysis because cost data for these items are already accounted for within the APC ratesetting process through the median cost calculation methodology discussed in section II.A.2. of this final rule with comment period. To include the costs of packaged drugs in both our APC ratesetting process (for associated procedures present on the same claim) and in our ratesetting process to establish a relative ASP-based payment amount for drugs and biologicals would give these data disproportionate emphasis in the OPSS system by skewing our analyses, as the costs of these packaged items would be, in effect, counted twice. Accordingly, we are not implementing the suggestion from commenters that we include all packaged and separately payable drugs and biologicals when establishing an average ASP-based rate to provide payment for the hospital acquisition and pharmacy handling costs of drugs and biologicals. However, we remind

commenters that because the costs of packaged drugs, including their pharmacy overhead costs, are packaged into the payments for the procedures in which they are administered, the OPSS provides payment for both the drugs and the associated pharmacy overhead costs through the applicable procedural APC payments.

As noted in the CY 2007 OPSS final rule with comment period, the ASP methodology has been established through rulemaking, and specific requests regarding methodological changes to this established system are outside the scope of this final rule with comment period. We believe that updating drug payment rates quarterly based on the most currently available ASP, given that ASP data include sales to hospitals in addition to others, provides the most up-to-date payment possible that is reflective of contemporary market trends and hospital acquisition costs.

Comment: One commenter requested that CMS create a HCPCS J-code for tositumomab, currently provided under a radioimmunotherapy regimen and billed as part of HCPCS code G3001 (Administration and supply of tositumomab, 450 mg). The commenter argued that because tositumomab is listed in compendia, is approved by the FDA as part of the BEXXAR® regimen, and has its own National Drug Code (NDC) number, it should be recognized as a drug and, therefore, paid as other drugs are paid under the OPSS methodology instead of having a payment rate determined by hospital claims data. The commenter suggested that a payment rate could be established using the ASP methodology.

Response: As we have noted in the November 10, 2005 final rule with comment period for CY 2006 (70 FR 68654) and the November 7, 2003 final rule with comment period for CY 2004 (68 FR 63443), unlabeled tositumomab is not approved as either a drug or a radiopharmaceutical, but it is a supply that is required as part of the radioimmunotherapy treatment regimen. We do not make separate payment for supplies used in services provided under the OPSS. Payments for necessary supplies are packaged into payments for the separately payable services provided by the hospital. Specifically, administration of unlabeled tositumomab is a complete service that qualifies for separate payment under its own clinical APC. This complete service is currently described by HCPCS code G3001. Therefore, we do not agree with the commenter's recommendation that we should assign a separate HCPCS code to

the supply of unlabeled tositumomab. Rather, we will continue to make separate payment for the administration of tositumomab, and payment for the supply of unlabeled tositumomab is packaged into the administration payment.

After consideration of the public comments received, we are finalizing our CY 2008 proposal with a modification to provide a 2-year transition for payment for separately payable drugs and biologicals under the OPSS based on the equivalent average ASP-based payment amount calculated from aggregate costs from hospitals claims. While the payment amount without a transition would be ASP+3 percent for CY 2008, we will be providing a transitional payment of ASP+5 percent for these products in CY 2008.

(3) Payment for Blood Clotting Factors

For CY 2007, we are providing payment for blood clotting factors under the OPSS at ASP+6 percent, plus an additional payment for the furnishing fee that is also a part of the payment for blood clotting factors furnished in physicians' offices under Medicare Part B. The CY 2007 updated furnishing fee is \$0.152 per unit.

For the CY 2008 OPSS, we proposed to pay for blood clotting factors at ASP+5 percent and to continue our policy for payment of the furnishing fee using the updated amount for CY 2008. For CY 2008, the furnishing fee increases by 4.0 percent to \$0.158.

As indicated in the CY 2008 OPSS/ASC proposed rule (72 FR 42736), we have consistently noted that we would update the payment amount for the furnishing fee each year (based on the Consumer Price Index (CPI)) so that the payment amount for the furnishing fee is equal to the furnishing fee payment amount noted in the MPFS final rule. As discussed in greater detail in the CY 2008 MPFS proposed rule (72 FR 38152), the CPI data for the 12-month period ending in June 2007 were not available when we developed the OPSS and the MPFS proposed rules.

Because the furnishing fee update is based on the percentage increase in the CPI for medical care for the 12-month period ending with June of the previous year and the Bureau of Labor Statistics releases the applicable CPI data after the OPSS and MPFS proposed rules are published, we have not been able to include the actual updated furnishing fee in the CY 2006 through CY 2008 OPSS and MPFS proposed rules. Rather, we announced in these proposed rules that we intended to include the actual figure for the percent change in the

applicable CPI, and the updated furnishing fee calculated based on that figure, in the associated final rule. Given the timing of the availability of the applicable data and our timeframe for preparing proposed rules, this process is unavoidable and likely to remain unchanged in the future. We believed that including a discussion of the furnishing fee update in annual rulemaking does not provide an advantage over other means of announcing this information, so long as the current statutory update methodology continues in effect. We believed that the public's need for information and adequate notice regarding the updated furnishing fee could be better met by issuing program instructions which would eliminate the discussion of the furnishing fee update annually in rulemaking. In addition, by communicating the updated furnishing fee in program instructions, the actual figure for the percent change in the applicable CPI and the updated furnishing fee calculated based on that figure could be announced more timely than when included as part of the annual rulemaking process. Because the furnishing fee update process is statutorily determined and is based on an index that is not affected by administrative discretion or public comment, we do not believe our proposed means of communicating the update would adversely affect stakeholders or the public. Therefore, for CY 2009 and thereafter, until such time as the update methodology may be modified, we proposed to announce the blood clotting factor furnishing fee using applicable program instructions and posting on the CMS Web site.

We received a few public comments on our proposal for the blood clotting factor furnishing fee. A summary of the public comments and our responses follow.

Comment: Several commenters supported our proposal to announce the blood clotting factor furnishing fee using program instructions. The commenters agreed that, by communicating the updated furnishing fee in program instructions, the actual figure for the percent change in the applicable CPI and the updated furnishing fee calculated based on that figure could be announced more timely. To that end, the commenters also suggested that CMS post this information on the CMS Web site.

Response: We appreciate the support of these commenters for our proposal. We believe that program instructions allow additional flexibility regarding the announcement of the blood clotting factor furnishing fee. Therefore, we are

finalizing the proposal, without modification, and in future years we will announce the updated blood clotting factor furnishing fee using applicable program instructions and posting on the CMS Web site. (We refer readers to the CY 2008 MPFS final rule for further discussion of this issue.)

(4) Payment for Radiopharmaceuticals

(a) Background

Section 303(h) of Pub. L. 108-173 exempted radiopharmaceuticals from ASP pricing in the physician's office setting. Beginning in the CY 2005 OPSS final rule with comment period, we have exempted radiopharmaceutical manufacturers from reporting ASP data for payment purposes under the OPSS (for more information, we refer readers to the CY 2005 OPSS final rule with comment period and the CY 2006 OPSS final rule with comment period, 69 FR 65811 and 70 FR 68655, respectively). Consequently, we did not have ASP data for radiopharmaceuticals for consideration for CY 2008 OPSS ratesetting. In accordance with section 1833(t)(14)(B)(i)(I) of the Act, we have classified radiopharmaceuticals under the OPSS as SCODs. As such, we have paid for radiopharmaceuticals at average acquisition cost as determined by the Secretary and subject to any adjustment for overhead costs.

Radiopharmaceuticals are also subject to the policies affecting all similarly classified OPSS drugs and biologicals, such as pass-through payments and packaging determinations, discussed earlier in this final rule with comment period.

For CYs 2006 and 2007, we used mean unit cost data from hospital claims to determine each radiopharmaceutical's packaging status and implemented a temporary policy to pay for separately payable radiopharmaceuticals based on the hospital's charge for each radiopharmaceutical adjusted to cost using the hospital's overall CCR. This methodology was finalized as an interim proxy for average acquisition cost because of the unique circumstances associated with providing radiopharmaceutical products to Medicare beneficiaries. The single OPSS payment represented Medicare payment for both the acquisition cost of the radiopharmaceutical and its associated pharmacy overhead costs. We clearly stated in both the CY 2006 and CY 2007 OPSS/ASC final rules with comment period that we did not intend to maintain this methodology permanently (70 FR 68656 and 71 FR 68096, respectively), and that we would

continue to actively seek other methodologies for setting payments for radiopharmaceuticals in future years.

During the CY 2006 and CY 2007 rulemaking processes, we encouraged hospitals and the radiopharmaceutical stakeholders to assist us in developing a viable long-term prospective payment methodology for these products under the OPSS. As discussed in the CY 2008 proposed rule, we are pleased to note that we have had many discussions over this past year with interested parties regarding the availability and limitations of radiopharmaceutical cost data. In addition, we have received several suggestions from interested parties on how to structure future payment methodologies. Many of the proposals we have received have suggested that we consider differentiating radiopharmaceutical products into two different categories by cost, at least in part because stakeholders have speculated that charge compression leads to inappropriately low calculated costs for expensive radiopharmaceuticals. For CY 2008, we made separate payment proposals for diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. While we have not grouped radiopharmaceuticals based on cost, we note that the therapeutic radiopharmaceuticals typically are more expensive than the diagnostic radiopharmaceuticals. We identified all diagnostic radiopharmaceuticals specifically as those Level II HCPCS codes that include the term "diagnostic" along with a radiopharmaceutical in their long code descriptors. Therefore, we were able to distinguish therapeutic radiopharmaceuticals from diagnostic radiopharmaceuticals as those Level II HCPCS codes that have the term "therapeutic" along with a radiopharmaceutical in their long code descriptors. We note that all radiopharmaceutical products fall into one category or the other; their use as a diagnostic radiopharmaceutical or therapeutic radiopharmaceutical is mutually exclusive.

(b) Payment for Diagnostic Radiopharmaceuticals

As discussed in section II.A.4.c.(5) and (6) of the CY 2008 OPSS/ASC proposed rule, we proposed to package payment for diagnostic radiopharmaceuticals and contrast agents with per day costs over \$60 as part of our packaging proposal for CY 2008. Radiopharmaceuticals and contrast agents currently are included as SCODs in section 1833(t)(14)(B) of the Act, and we currently package payment for diagnostic radiopharmaceuticals and

contrast agents with per day costs of \$55 or less. However, our proposal for CY 2008 also included packaging payment for all diagnostic radiopharmaceuticals and contrast agents, regardless of their per day cost. Packaging costs into a single aggregate payment for a service, encounter, or episode of care is a fundamental principle that distinguishes a prospective payment system from a fee schedule. In general, packaging the costs of items and services into the payment for the primary procedure or service with which they are associated encourages hospital efficiencies and also enables hospitals to manage their resources with maximum flexibility. The proportion of drugs, biologicals, and radiopharmaceuticals that are separately paid has increased in recent years, from 30 percent of HCPCS codes for these products in CY 2003 to 50 percent in CY 2007, a pattern that has been noted previously for procedural services as well. Our proposal to package payment for diagnostic radiopharmaceuticals and contrast agents regardless of per day cost furthers the fundamental principles of a prospective payment system.

In the proposed rule, we stated our belief that our proposed treatment of diagnostic radiopharmaceuticals and contrast agents differently from other SCODs was appropriate for several reasons. First, the statutory requirement that we must pay separately for drugs and biologicals for which the per day cost exceeds \$50 under section 1833(t)(16)(B) of the Act has expired. Therefore, we are not restricted to the extent to which we can package payment for SCODs and other drugs, nor are we required to treat all classes of drugs in the same manner with regard to whether they are packaged or separately paid. We have used this flexibility to make different packaging determinations for several years with regard to specific anti-emetic drugs. While we proposed to continue to establish an updated cost threshold for packaging drugs, biologicals, and radiopharmaceuticals, we also proposed an approach specific to diagnostic radiopharmaceuticals and contrast agents that would otherwise be separately paid.

Second, diagnostic radiopharmaceuticals and contrast agents function effectively as supplies that enable the provision of an independent service. More specifically, contrast agents are always provided in support of a diagnostic or therapeutic procedure that involves imaging, and diagnostic radiopharmaceuticals are always provided in support of a diagnostic nuclear medicine scan. This

is different from many other SCODs, for example, therapeutic radiopharmaceuticals, where the therapeutic radiopharmaceutical itself is the primary therapeutic modality. Given the inherent function of contrast agents and diagnostic radiopharmaceuticals as supportive to the performance of an independent procedure, we view the packaging of payment for contrast agents and diagnostic radiopharmaceuticals as a logical initial step to expand packaging for SCODs. As we consider moving to additional encounter-based and episode-based payment in future years, we may consider additional options for packaging more SCODs in the future.

Third, section 1833(t)(14)(A)(iii) of the Act requires that payment for SCODs be set prospectively based on a measure of average hospital acquisition cost. While we have ASP data for contrast agents, the lack of ASP data as a source of average acquisition cost for radiopharmaceuticals and the varying inclusion of overhead and handling costs in the charge for a radiopharmaceutical resulted in payment for radiopharmaceuticals at charges reduced to cost on a temporary basis for CYs 2006 and 2007.

We now believe our claims data offer an acceptable proxy for average hospital acquisition cost and associated handling and preparation costs for radiopharmaceuticals. We believe that hospitals have adapted to the CY 2006 coding changes for radiopharmaceuticals and responded to our instructions to include charges for radiopharmaceutical handling in their charges for the radiopharmaceutical products. We have relied on mean unit costs derived from our claims data as one proxy for average acquisition cost and pharmacy overhead, and we use these data to determine the packaging status for SCODs. However, in light of improved data for radiopharmaceuticals in the CY 2006 claims, we believed that the line-item estimated cost for a diagnostic radiopharmaceutical in our claims data is a reasonable approximation of average acquisition and preparation and handling costs for diagnostic radiopharmaceuticals. Further, because the standard OPSS packaging methodology packages the total estimated cost for each radiopharmaceutical on each claim (including the full range of costs observed on the claims) with the cost of associated nuclear medicine procedures for ratesetting, this packaging approach is consistent with considering the average cost for radiopharmaceuticals, rather than the median. We also noted our belief that our improved claims data

could support the establishment of separate, prospective payment rates for diagnostic radiopharmaceuticals with per day costs exceeding our general packaging threshold (analogous to our proposal for therapeutic radiopharmaceuticals). However, we proposed to package all diagnostic radiopharmaceuticals because we believed additional packaging of payment for supportive and ancillary services, including diagnostic radiopharmaceuticals, would provide additional incentives for efficiency and greater flexibility for hospitals to manage their resources.

In the case of contrast agents, while we have ASP data that can be a proxy for average hospital acquisition cost and associated handling and preparation costs, payment for almost all contrast agents would be packaged under the OPSS for CY 2008 based on the \$60 per day packaging threshold. Therefore, as discussed in more detail in section V.B.3.a.(4) of this final rule with comment period, we believed it would be most appropriate to package payment for all contrast agents for CY 2008, to better provide for accurate payment for the associated tests and procedures that promotes hospital efficiency.

In summary, in the context of our CY 2008 proposal, we viewed diagnostic radiopharmaceuticals and contrast agents as ancillary and supportive of the diagnostic tests and therapeutic procedures in which they are used. In light of our authority to make different packaging determinations, and the improved reporting of hospital charges for radiopharmaceutical handling in the CY 2006 claims data, we proposed to package payment for contrast agents and diagnostic radiopharmaceuticals for CY 2008.

For more information on how rates were set for procedures in which diagnostic radiopharmaceuticals or contrast agents are used, and for a further discussion regarding our final packaging methodology for CY 2008, we refer readers to section II.B. of this final rule with comment period.

During its March 2007 meeting, the APC Panel made a recommendation that CMS work with stakeholders on issues related to payment for radiopharmaceuticals, including evaluating claims data for different classes of radiopharmaceuticals and ensuring that a nuclear medicine procedure claim always includes at least one reported radiopharmaceutical agent. As discussed in section II.A.4.c.(5) of the proposed rule, we proposed to accept the APC Panel's recommendation, and we welcomed public comment on the burden hospitals

would experience should we require such precise reporting. We also solicited comment specifically on the importance of such a requirement in light of our discussion in the proposed rule on the representation of radiopharmaceuticals in the single claims for diagnostic nuclear medicine procedures, the presence of uncoded revenue code charges specific to diagnostic radiopharmaceuticals on claims without a coded radiopharmaceutical, and our proposal to package payment for all diagnostic radiopharmaceuticals for CY 2008. A summary of the public comments we received on this issue, our responses, and our response to the APC Panel recommendation can be found in section II.A.4.c.(5) of this final rule with comment period.

We received many comments on our proposal to package payment for all diagnostic radiopharmaceuticals and contrast agents for CY 2008. A summary of the public comments and our responses follow.

Comment: A number of commenters stated that diagnostic radiopharmaceuticals and contrast agents with per day costs over the proposed OPSS drug packaging threshold are defined as SCODs and, therefore, should be assigned separate APC payments. In particular, the commenters questioned CMS's authority to classify groups of drugs, such as diagnostic radiopharmaceuticals and contrast agents, and implement packaging and payment policies that do not reflect their status as SCODs. In addition, the commenters objected to the proposal to package payment for diagnostic radiopharmaceuticals and contrast agents because, as SCODs, the commenters believed these products were required by statute to be paid at average acquisition cost. The commenters explained that, when several different diagnostic radiopharmaceuticals or contrast agents may be used for a particular procedure, the costs of these diagnostic radiopharmaceuticals or contrast agents are averaged together and added to the amount for the procedure in order to determine the payment rate for the associated procedural APC. Therefore, the commenters argued that the amount added to the procedure cost through packaging, representing the cost of the diagnostic radiopharmaceutical or contrast agent, does not reflect the average acquisition cost of any one particular item but, rather, reflects the average cost of whatever items may be used with that particular procedure.

Response: As discussed above, we based our proposal to treat diagnostic radiopharmaceuticals and contrast

agents differently from other SCODs upon our reasoning that the statutorily required OPSS drug packaging threshold has expired and our view that diagnostic radiopharmaceuticals and contrast agents function effectively as supplies that enable the provision of an independent service, rather than serving themselves as the therapeutic modality. We sought to package their payment as ancillary and supportive services in order to provide incentives for greater efficiency and to provide hospitals with additional flexibility in managing their resources. We note that we currently classify different groups of drugs for specific payment purposes, as evidenced by our policy regarding the oral and injectable forms of the 5HT3 anti-emetics and our fixed price drug packaging threshold.

Although our final CY 2008 policy, as described in section II.A.4.c.(5) and (6) of this final rule with comment period, packages payment for all diagnostic radiopharmaceuticals and contrast agents into the payment for their associated procedures, we will continue to provide payment for these items in CY 2008 based on a proxy for average acquisition cost. We believe that the line-item estimated cost for a diagnostic radiopharmaceutical in our claims data is a reasonable approximation of average acquisition and preparation and handling costs for diagnostic radiopharmaceuticals. Further, because the standard OPSS packaging methodology packages the total estimated cost for each radiopharmaceutical on each claim (including the full range of costs observed on the claims) with the cost of associated nuclear medicine procedures for rate setting, this packaging approach is consistent with considering the average cost for radiopharmaceuticals, rather than the median cost.

We further note that these drugs, biologicals, or radiopharmaceuticals for which we have not established a separate APC and, therefore, for which payment would be packaged rather than separately provided under the OPSS, could be considered to not be SCODs. Similarly, drugs, biologicals, and therapeutic radiopharmaceuticals with mean per day costs of less than \$60 that are packaged and for which a separate APC has not been established would also not be SCODs. This reading is consistent with our final payment policy whereby we package payment for diagnostic radiopharmaceuticals and contrast agents and provide payment for these products through payment for their associated procedures.

Comment: A few commenters suggested that CMS misclassified

HCPCS codes A9542 (Indium In-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries) and A9544 (Iodine I-131 tositumomab, diagnostic, per study dose) as "diagnostic" radiopharmaceuticals. The commenters explained that these are radiopharmaceutical products that are used as part of a therapeutic regimen and, therefore, should be considered therapeutic for OPPS payment purposes.

Response: As discussed above, for the proposed rule, we classified each radiopharmaceutical into one of two groups according to whether its long descriptor contained the term "diagnostic" or "therapeutic." HCPCS codes A9542 and A9544 both contain the term "diagnostic" in their long code descriptors. Therefore, according to this methodology, we classified them as diagnostic for the purposes of OPPS payment. While we understand that these items are provided in conjunction with additional supplies, imaging tests, and therapeutic radiopharmaceuticals for patients already diagnosed with cancer, we continue to believe that the purpose of HCPCS codes A9542 and A9544 is diagnostic in nature. While the group of services may be considered a therapeutic regimen by the commenters, HCPCS codes A9542 and A9544 are provided in conjunction with a series of imaging scans. Many nuclear medicine studies using diagnostic radiopharmaceuticals are provided to patients who already have an established diagnosis. We would not consider HCPCS codes A9542 and A9544 to be therapeutic because these items are provided immediately prior to the furnishing of a diagnostic imaging procedure, and are used to identify the proper dose of the therapeutic agent at a later date.

Comment: One commenter requested that CMS reassign the dosage descriptor for HCPCS code A9524 (Iodine I-131 iodinated serum albumin, diagnostic, per 5 microcuries) to reflect the usual package size of this item. The commenter noted that there is only one manufacturer for this product, and it is only available in a single-unit, single-use, calibrated dose of 25 microcuries. The commenter claimed that many hospitals have been mistakenly billing one unit for this product, instead of correctly billing five units. Therefore, the commenter requested that the dosage descriptor reflect the single-unit, single-use, calibrated 25 microcurie dose.

Response: As we discussed in the CY 2008 proposed rule, at its March 2007 meeting, the APC Panel recommended that we consider the use of external data and work with stakeholders to

determine the correct code descriptor units for each radiopharmaceutical, including HCPCS code A9524. As stated in the proposed rule (72 FR 42741), we appreciate the APC Panel's recommendation. We are always open to meeting with interested stakeholders and examining any data they may provide to us. However, we were unable to accept the APC Panel's recommendation concerning the development of specific code descriptors because decisions regarding the creation of permanent Level II HCPCS codes, including code descriptors, are coordinated by the CMS HCPCS Workgroup and are outside the scope of the OPPS. For further information on the HCPCS coding process, we refer readers to the CMS Web site at: http://www.cms.hhs.gov/MedHCPCSGenInfo/01_Overview.asp#TopOfPage. We encouraged interested parties to submit requests for revisions of code descriptors to the CMS HCPCS Workgroup for its consideration.

We have learned that the commenter requested the CMS HCPCS Workgroup to change the descriptor for HCPCS code A9524 to more accurately reflect the dosing of this product. However, the CMS HCPCS Workgroup, under its authority and responsibility to create and maintain Level II HCPCS codes and their descriptors, has decided to retain the current descriptor that includes the "per 5 microcuries" dosage descriptor. Therefore, hospitals are reminded to ensure that units of drugs, biologicals, and radiopharmaceuticals administered to patients are accurately reported in terms of the dosage specified in the full HCPCS code descriptor. That is, units should be reported in multiples of the units included in the HCPCS descriptor. For example, if the descriptor of the drug code includes 5 mg, and 5 mg of the drug was administered to the patient, the units billed should be 1. If the descriptor of the drug code includes 5 mg, but 25 mg of the drug was administered to the patient, the units billed should be 5. Hospitals should not bill the units for HCPCS codes based on the way the drug, biological, or radiopharmaceutical is packaged, stored, or stocked. HCPCS short descriptors are limited to 28 characters, including spaces, so short descriptors do not always capture the complete description of the products. Therefore, before submitting Medicare claims for drugs, biologicals, and radiopharmaceuticals, we remind commenters that it is extremely important for hospitals to review the complete long descriptors for the

applicable HCPCS codes in order to determine the appropriate units to be reported.

After consideration of the public comments received, we are finalizing our proposal, without modification, to identify diagnostic radiopharmaceuticals as those radiopharmaceuticals with the term "diagnostic" in their long code descriptors and therapeutic radiopharmaceuticals as those radiopharmaceuticals with the term "therapeutic" in their long code descriptors. Our final payment policy packages payment for all diagnostic radiopharmaceuticals in CY 2008. The related public comments and our responses to the proposed payment methodology for diagnostic radiopharmaceuticals are presented in section II.A.4.c.(5) of this final rule with comment period.

In the case of contrast agents, while we have ASP data that can be a proxy for average hospital acquisition cost and associated handling and preparation costs, payment for almost all contrast agents is packaged under the OPPS for CY 2008 based on the \$60 per day packaging threshold. Therefore, as discussed in the proposed rule, we believed that it is most appropriate to package payment for all contrast agents for CY 2008 to better provide for payment for the associated tests and procedures that promotes hospital efficiency. Our final policy to package payment for all contrast agents in CY 2008, and the related public comments and our responses to the proposed payment methodology, is presented in section II.A.4.c.(6) of this final rule with comment period.

In summary, we view diagnostic radiopharmaceuticals and contrast agents as ancillary and supportive to the diagnostic tests and therapeutic procedures in which they are used. In light of our authority to make different packaging determinations for groups of items, and the improved reporting of hospital charges for radiopharmaceutical handling in the CY 2006 claims data, we are finalizing our proposal, without modification, to package payment for contrast agents and diagnostic radiopharmaceuticals for CY 2008. Additional discussion of our rationale and further response to public comments received and the APC Panel recommendations regarding our proposal to package payment for diagnostic radiopharmaceuticals and contrast agents appears in sections II.A.4.c.(5) and II.A.4.c.(6), respectively, of this final rule with comment period.

(c) Payment for Therapeutic Radiopharmaceuticals

For CY 2008, we proposed to continue separate payment for therapeutic radiopharmaceuticals that have a mean per day cost of more than \$60, consistent with the packaging methodology applied to other nonpass-through drugs and biologicals. We believed that therapeutic radiopharmaceuticals are distinct from diagnostic radiopharmaceuticals because the primary purpose of providing a therapeutic radiopharmaceutical is the radiopharmaceutical treatment itself, whereas a diagnostic radiopharmaceutical is administered in support of the performance of a diagnostic nuclear medicine study that is the primary service. For separately payable therapeutic radiopharmaceuticals, we proposed to establish CY 2008 payment rates based on their mean unit costs from our CY 2006 OPSS claims data.

In the CY 2007 OPSS/ASC final rule with comment period (71 FR 68095), we again reiterated our intent to develop a suitable prospective payment methodology for radiopharmaceutical products paid under the OPSS in future years, beginning in CY 2008. Since the start of the temporary cost-based payment methodology for radiopharmaceuticals in CY 2006, we have met with several interested parties on this topic and have received several suggestions from these stakeholders regarding payment methodologies that we could employ for future use under the OPSS.

In considering payment options for therapeutic radiopharmaceuticals for CY 2008, we examined several alternatives. First, we considered retaining the CY 2007 methodology of providing payment for therapeutic radiopharmaceuticals at a hospital's charges reduced to cost using the hospital's overall CCR. While this option would provide consistency in the payment methodology from year to year, we have noted on several occasions, including in the CY 2007 OPSS/ASC final rule with comment period and in various public forums such as the APC Panel meetings, that this methodology was not intended to be the basis of providing payment to hospitals for these products beyond CY 2007. Payment on a claim-specific cost basis is not consistent with the payment of items and services on a prospective basis under the OPSS and may lead to extremely high or low payments to hospitals for radiopharmaceuticals, even when those products would be expected

to have relatively predictable and consistent acquisition and handling costs across individual clinical cases and hospitals. In addition, we have stated that we believe using hospitals' overall CCRs to determine payments could result in an overstatement of radiopharmaceutical costs, which are likely reported in several cost centers, such as diagnostic radiology, that have lower CCRs than hospitals' overall CCRs (71 FR 68095). For these reasons, we did not propose to use this methodology to set their payment rates for CY 2008.

The second option we considered, and proposed, as a methodology for providing payment for therapeutic radiopharmaceuticals in CY 2008, is to establish prospective payment rates for separately payable therapeutic radiopharmaceuticals using mean costs derived from the CY 2006 claims data, where the costs are determined using our standard methodology of applying hospital-specific departmental CCRs to radiopharmaceutical charges, defaulting to hospital-specific overall CCRs only if appropriate departmental CCRs are unavailable. As we stated in the CY 2007 OPSS/ASC proposed rule, we believe this methodology provides us with the most consistent, accurate, and efficient methodology for prospectively establishing payment rates for separately payable therapeutic radiopharmaceuticals (71 FR 49587). As discussed in the CY 2008 OPSS/ASC proposed rule, we believe that adopting prospective payment based on historical hospital claims data is appropriate because it serves as our most accurate available proxy for the average hospital acquisition cost of separately payable therapeutic radiopharmaceutical products (72 FR 42739). In addition, we have found that our general prospective payment methodology based on historical hospital claims data results in more consistent, predictable, and equitable payment amounts across hospitals and likely provides incentives to hospitals for efficiently and economically providing these outpatient services. Therefore, we expect that the hospital-specific payment variability found under a charges-reduced-to-cost methodology would no longer affect these products under our CY 2008 proposal.

Although we received public comments on our CY 2007 proposed rule indicating that CY 2005 claims data used for that update did not incorporate associated overhead charges into the radiopharmaceutical charge, in the CY 2007 OPSS/ASC final rule with comment period (71 FR 68095), we stated that we expected that hospitals would have adapted to the CY 2006

HCPCS coding changes for some radiopharmaceuticals and responded to our instructions to include their charges for radiopharmaceutical handling in their charges for the radiopharmaceutical products so these costs would be reflected in the CY 2008 ratesetting process. This continues to be our expectation, and, as discussed in the CY 2008 OPSS/ASC proposed rule, we believed that the CY 2006 claims data that we are using to set the proposed CY 2008 OPSS payment rates reflect both the radiopharmaceutical charge and associated overhead charges. As discussed at the March 2007 APC Panel meeting, our CY 2006 claims data show that a greater proportion of radiopharmaceuticals experienced an increase in their median costs from CY 2005 to CY 2006 than experienced a decrease. We indicated that this trend is consistent with the agency's expectations that hospitals would comply with our instructions to include charges for radiopharmaceutical handling in their charges for the radiopharmaceutical products for CY 2006. Therefore, we believed that setting CY 2008 prospective payment rates based on CY 2006 hospital claims data as described above serves as an acceptable combined proxy for average hospital acquisition costs and radiopharmaceutical handling.

As we discussed in the CY 2008 OPSS/ASC proposed rule, during meetings with external stakeholders over the past year, we have been presented with several other suggestions regarding OPSS payment for therapeutic radiopharmaceuticals in CY 2008. One of these options included a suggestion that we employ alternative trimming methodologies in order to produce a claims-based mean cost that would more accurately reflect hospital purchase prices for these products. We did not propose a methodology based on special OPSS data trimming for CY 2008 for the following reasons. First, the OPSS has a standard data trimming methodology to calculate drug, biological, and radiopharmaceutical per day costs from hospital claims data. This includes both a specific trim on units for drugs, biologicals, and radiopharmaceuticals that is ± 3 standard deviations from the geometric mean, and a standard trim of any line-item with a cost per unit that is ± 3 standard deviations from the geometric mean that is applied across all items and services. Both trims are conducted on the transformed variable, taking the natural log of both units and cost per unit, in order to trim evenly relative to the center of the distribution. Both units

and costs per unit are never negative, and there are some therapeutic radiopharmaceuticals with very high units and high costs per unit in our hospital claims data. These trims are conservative and typically eliminate only the most egregious observations, ones that could be due to erroneous reporting. For therapeutic radiopharmaceuticals at the time of the proposed rule, the unit trim alone removed all items that would have been eliminated under the cost trim, and with the exception of HCPCS code A9563 (Sodium phosphate P-32, therapeutic, per millicurie), this trim removed observations with unit costs below the mean unit cost. That is, overall, the result of applying our systematic trimming methodology increased the mean unit cost reported in Table 44 of the proposed rule (72 FR 42740).

As a payment system based on relative payment weights, altering the trimming methodology for a particular set of services could unduly influence the relativity of the resulting payment weights for those particular services and could inappropriately redistribute payments in a budget neutral OPSS. We have no reason to believe that hospitals report costs differently for radiopharmaceuticals than they do for other items. As we discussed further in section II.A.1. of this final rule with comment period, what is important for setting appropriate payment rates for most services under a prospective payment system is accuracy in estimating the relative costliness of services, and not the nominal value of the observed cost. Second, we are not convinced that employing an alternative overall trimming methodology would result in the most appropriate cost estimates for therapeutic radiopharmaceuticals. We have noted our belief that because hospitals were paid in CY 2006 for each therapeutic radiopharmaceutical they reported according to a claim-specific charge that was reduced to cost for payment, hospitals had an incentive to accurately account for the full costs of these products in establishing their charges. In addition, we have no way of knowing the specific clinical scenario that resulted in any given claim with certain reported units and charges for a therapeutic radiopharmaceutical. Therefore, we did not believe it would be appropriate to utilize a ratesetting methodology that could disregard correctly coded claims. While we appreciated this recommendation, we did not propose a payment methodology that included additional trimming of hospital claims data for therapeutic

radiopharmaceutical products for CY 2008.

Recommendations other than trimming centered around providing CMS with external data on radiopharmaceutical costs. One specific recommendation that we received from interested stakeholders suggested that we allow hospitals to submit their invoices to CMS. With the invoice information, CMS could establish a prospective payment rate for radiopharmaceuticals that would be calculated taking into consideration the total amount invoiced for the radiopharmaceutical, transportation costs, and applicable rebates. While this payment rate would not include payment for certain radiopharmaceutical overhead and handling costs, stakeholders suggested that costs could be packaged into the associated procedure payment for the radiopharmaceutical. Stakeholders also generally recommended that we could collect external data from various sources (such as manufacturers, nuclear pharmacies, and others) to use for therapeutic radiopharmaceuticals.

At its September 2007 meeting, the Panel recommended that CMS create a composite for BEXXAR® or related therapies and present it for the Panel's consideration at the next APC Panel meeting. We are accepting this recommendation and will provide information and analyses regarding commonly observed combinations of services provided with radioimmunotherapy treatments to the APC Panel at its 2008 winter meeting.

We received many public comments on our CY 2008 proposal to establish payments for separately payable therapeutic radiopharmaceuticals based on their mean unit costs from hospitals claims. A summary of the public comments and our responses follow.

Comment: Many commenters asked CMS to continue the CY 2007 CCR methodology for payments for all radiopharmaceutical products in CY 2008. The commenters cited inaccurate and incomplete data from hospitals as a reason to continue this methodology.

Response: For the CY 2007 rulemaking cycle, we also received many comments that we should not proceed with our CY 2007 proposal to establish a prospective payment methodology for radiopharmaceuticals. At that time, the commenters were concerned that hospital claims data may be inaccurate due to hospitals slow adoption of our billing guidance to include radiopharmaceutical pharmacy overhead charges in the charge for the radiopharmaceutical. Because of these and other concerns, we concluded that,

for CY 2007, there was sufficient reason to extend the temporary policy of paying for radiopharmaceuticals at charges reduced to cost for one additional year. We noted that it was still our intention to move toward a prospective payment methodology for radiopharmaceuticals in the OPSS (71 FR 68095). In the CY 2008 OPSS/ASC proposed rule, we again noted our intent to move to a prospective payment for therapeutic radiopharmaceuticals under the OPSS and did not propose to continue providing payment for therapeutic radiopharmaceuticals at hospital charges reduced to cost using the hospital's overall CCR for the reasons cited previously. In particular, payment on a claim-specific cost basis is not consistent with the payment of items and services on a prospective basis under the OPSS and may lead to extremely high or low payments to hospitals for radiopharmaceuticals, even when those products would be expected to have relatively predictable and consistent acquisition and handling costs across individual clinical cases and hospitals.

Comment: Several commenters requested that CMS implement a policy that would accept external data submissions from various groups, including nuclear pharmacies, hospitals, and manufacturers. The commenters recommended that CMS collect Estimated Average Acquisition Cost (EAAC), Calculated Pharmacy Sales Price (CPSP), or average selling nuclear pharmacy price (ADNPP) data through this process. In addition, the commenters suggested that CMS could collect hospital invoice data to establish a prospective payment rate for radiopharmaceuticals that would be calculated, taking into consideration the total amount invoiced for the radiopharmaceutical, transportation costs, and applicable rebates.

Some commenters also recommended that, as CMS proposed the reporting of pharmacy overhead charges for drugs and biologicals on uncoded revenue code lines for CY 2008, CMS should change its instructions for reporting radiopharmaceutical handling charges. Some commenters suggested that the radiopharmaceutical handling charges be reported separately on uncoded revenue code lines instead of being included in the charge for the radiopharmaceutical under current CMS instructions. The commenters believed this would allow the costs of radiopharmaceutical handling to be packaged into payment for the associated procedure, such as a radiopharmaceutical administration procedure, in future years when CY

2008 claims data become available for ratesetting.

Response: We did not propose a therapeutic radiopharmaceutical payment methodology using external data for CY 2008 for the following reasons. First, any approach relying on external data has the disadvantage of differentially influencing the relativity of payment weights for radiopharmaceuticals in the budget neutral OPSS payment system where we utilize a standard ratesetting methodology for other services. In addition, it is not clear that invoice information from hospitals or cost information from nuclear pharmacies or manufacturers would be more accurate than hospitals' costs for radiopharmaceuticals that we currently calculate based on hospitals' charges reduced to cost by application of a CCR, and such external information would generally exclude the costs of the hospital's handling of the radiopharmaceuticals. However, as noted in the CY 2008 OPSS/ASC proposed rule (72 FR 42740), we do not currently identify separate costs for this radiopharmaceutical handling that we could then package into the costs of the associated diagnostic nuclear medicine studies and treatment procedures. Moreover, hospitals currently have the flexibility to set their charges for therapeutic radiopharmaceuticals, taking into account a variety of factors, including acquisition costs and transportation costs. Therefore, we believed, and continue to believe, it is likely that hospitals are already taking this information into consideration when establishing their charges. Further, we have already instructed hospitals to include overhead charges for radiopharmaceuticals in the charge for the radiopharmaceutical product. We have received several reports that hospitals have made these changes, when necessary, and that other changes are in process to conform to our instructions. A ratesetting approach based on external data could be inconsistent with the charging practices of those hospitals that have been working over the past 2 years to align their charging practices with our stated instructions. Moreover, adoption of any methodology systematically relying on external data also would be administratively burdensome for us because we would need to collect, process, and review external information to ensure that it was valid, reliable, and representative of a diverse group of hospitals so that it could be used to establish rates for all hospitals. For these reasons, we did not propose

and are not finalizing a policy to collect hospital invoices or otherwise rely on external data in order to establish prospective payment rates for therapeutic radiopharmaceuticals for CY 2008.

We are not adopting our proposal to have hospitals separately report charges for pharmacy overhead associated with drugs and biologicals on uncoded revenue code lines, as discussed earlier. Therefore, we also do not believe it would be appropriate to provide instructions to hospitals to separately report their radiopharmaceutical handling charges in addition to the charge for the radiopharmaceutical. Hospitals have recently become accustomed to our CY 2006 guidance that they should consider all handling costs in setting their charges for radiopharmaceuticals, and we see no reason for them to change this practice. We will continue to provide payment for the handling costs of radiopharmaceuticals through the packaged or separate payment for the products in CY 2008, just as we will for the pharmacy handling costs of drugs and biologicals.

Comment: Many commenters expressed concern over the proposed payment rates for very high cost therapeutic radiopharmaceuticals. The commenters stated that the proposed payment rates are inadequate to cover the cost of the therapeutic radiopharmaceutical itself, let alone the added costs of handling, shipping, and compounding. The commenters noted that inadequate payment rates may lead to beneficiary access issues. Some commenters suggested that systematic special trimming of claims data should be considered in order to products costs that reflect actual hospital purchase prices for radiopharmaceuticals. A few commenters recommended using ASP as an alternative payment methodology for the very costly therapeutic radiopharmaceuticals or other methodologies based on external data. One commenter noted its intent to submit ASP information for an expensive therapeutic radiopharmaceutical so that CMS would have an alternative methodology with which to price the product.

Response: While we understand the commenters' concerns regarding the unique circumstances associated with radiopharmaceutical products, especially very high cost therapeutic radiopharmaceuticals, for the majority of services under the OPSS, payment is made according to prospectively established payment rates that are related to hospitals' costs for those services as calculated from claims data.

For the past 2 years, hospitals have been paid on a CCR methodology for separately payable therapeutic radiopharmaceuticals. Therefore, hospitals had every incentive to submit a charge representative of their acquisition cost and associated handling costs for these radiopharmaceuticals. To that extent, we believe that the hospital claims data that we have available for ratesetting purposes in CY 2008 are reliable and accurate.

We note that, for CY 2008, separately payable therapeutic radiopharmaceuticals meet the definition of SCODs and therefore are to be paid at average acquisition cost. While we are implementing a policy to provide payment for therapeutic radiopharmaceuticals through the standard OPSS methodology relying on hospital claims data for CY 2008 as a proxy for average acquisition cost as described below, we note that there is an established process already in place for submitting pricing data for other SCODs to be used for payment purposes. While we understand that the standard ASP methodology may not work for all therapeutic radiopharmaceuticals, we received comments that this approach would work for certain products. Therefore, to the extent that manufacturers or stakeholders believe that the ASP methodology that we currently use for the payment of separately payable drugs and biologicals under the OPSS is appropriate for their particular product, we seek comments on that approach and comments on how radiopharmaceutical ASP information could be used in future ratesetting.

As we discussed in the proposed rule (72 FR 42739), we do not agree with the suggestion of some commenters that special trimming methodologies should be applied to develop claims-based means costs for therapeutic radiopharmaceuticals. No commenters provided specific approaches for our consideration. We believe the standard OPSS data trimming methodology is appropriate for establishing the payment rates for therapeutic radiopharmaceuticals. Altering the systematic trimming methodology for these products in particular could inappropriately redistribute payments in the budget neutral OPSS, and we have no reason to believe that hospitals report costs differently for radiopharmaceuticals than they do for other items. We continue to believe that because hospitals were paid in CY 2006 for each therapeutic radiopharmaceutical according to a claim-specific charge that was adjusted to cost for payment, hospitals had an

incentive to accurately account for the full costs of these products in establishing their charges.

We examined the final rule claims data for the eight therapeutic radiopharmaceuticals that we proposed for separate payment in CY 2008 after we applied the standard OPPS data trimming methodology of ± 3 standard deviations from the geometric mean. The standard trim removes data outliers, which are rare observations with extremely different units and costs from most occurrences in the distribution. Our analysis showed that in the case of HCPCS code A9543 (Yttrium Y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries) and A9545 (Iodine I-131 tositumomab, therapeutic, per treatment dose), there were one and three providers, respectively, who consistently (more than 2 times) reported charges in the CY 2006 claims data that were less than \$100 when converted to costs as part of the usual ratesetting process. In addition, we had relatively few claims overall for these two products from CY 2006, only 456 line-item charges on 455 days for HCPCS code A9543 (458 units) and 262 line-item charges on 261 days for HCPCS code A9545 (342 units). The numerous repetitive claims with exceptionally low costs had not been removed in the standard OPPS mean cost calculation because the significant number of these aberrant claims increased the standard deviation and were not rare observations. In light of

the specialized nature of these radioimmunotherapy agents, we believe that these claims were incorrectly coded based on their extremely low costs. Therefore, these claims from the several providers with very low costs are highly unlikely to represent claims for treatment with the products described by HCPCS codes A9543 and A9545. After removing these likely incorrectly coded claims in the ratesetting process, we were left with 360 line-item charges on 359 days for HCPCS code A9543 (354 units) and 237 line-item charges on 326 days for HCPCS code A9545 (238 units). These very low cost claims constituted between one quarter and one third of the units for HCPCS codes A9543 and A9545, contributing significantly to the calculation of the products' mean unit costs. While the mean per unit cost was approximately \$11,926 for HCPCS code A9543 based on all claims, when the repetitive claims from one provider with very low costs were removed, the mean per day cost was approximately \$15,024. Similarly, while the mean per unit cost was approximately \$7,844 for HCPCS code A9545 based on all claims, when the repetitive claims from three providers with very low costs were removed, the mean per day cost was approximately \$11,264. We continue to believe that providing prospective payment for the costs of the eight separately payable therapeutic radiopharmaceuticals and their handling is the most appropriate payment methodology for CY 2008,

because we believe that hospitals have set their charges for these products while taking into account a variety of factors, including acquisition and transportation costs. We believe this methodology provides us with the most consistent, accurate, and efficient methodology for prospectively establishing payment rates for separately payable therapeutic radiopharmaceuticals. The adoption of prospective payment based on historical hospital claims data is appropriate because it currently serves as our most accurate available proxy for the average hospital acquisition cost of separately payable therapeutic radiopharmaceutical products. In addition, in the cases of HCPCS codes A9543 and A9445, we have specifically removed the likely incorrectly coded claims from several providers before applying our standard ratesetting methodology to calculating their mean costs from CY 2006 claims.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, with modification to eliminate likely incorrectly coded claims from several providers for HCPCS codes A9543 and A9545 as described above, to provide payment for separately payable therapeutic radiopharmaceuticals based on their mean unit costs from CY 2007 claims. These therapeutic radiopharmaceuticals and their final CY 2008 payment rates are shown in Table 31 below.

TABLE 31.—CY 2008 SEPARATELY PAYABLE THERAPEUTIC RADIOPHARMACEUTICALS

HCPCS Code	Short descriptor	Final CY 2008 APC	Final CY 2008 SI	Final CY 2008 payment rate
A9517	I131 iodide cap, rx	1064	K	\$15.24
A9530	I131 iodide sol, rx	1150	K	11.22
A9543	Y90 ibritumomab, rx	1643	K	15,023.91
A9545	I131 tositumomab, rx	1645	K	11,264.25
A9563	P32 Na phosphate	1675	K	113.60
A9564	P32 chromic phosphate	1676	K	119.18
A9600	Sr89 strontium	0701	K	612.06
A9605	Sm 153 lexidronm	0702	K	1,361.07

Comment: Several commenters stated that charge compression may be adversely affecting estimates of the mean cost for expensive radiopharmaceuticals.

Response: As discussed in more detail in section II.A.1.c. of this final rule with comment period, while we did not propose to implement adjustments for charge compression for CY 2008 based on the RTI report for inpatient services, which focused only on inpatient charges, we planned steps to explore this issue further for the future. Under

contract with RTI, we are currently examining an all-charges model that would compare variation in CCRs with variation in charges to establish regression-adjusted CCRs that could be applied to both inpatient and outpatient charges. We will consider whether it would be appropriate to adopt regression-based CCRs for the OPPS in the future after we receive RTI's comprehensive review of the OPPS cost estimation methodology and review the results of the use of both inpatient and

outpatient charges across all payers to reestimate regression-based CCRs.

b. Payment for Nonpass-Through Drugs, Biologicals, and Radiopharmaceuticals with HCPCS Codes, but without OPPS Hospital Claims Data

Pub. L. 108-173 does not address the OPPS payment in CY 2005 and after for drugs, biologicals, and radiopharmaceuticals that have assigned HCPCS codes, but that do not have a reference AWP or approval for payment as pass-through drugs or biologicals.

Because there is no statutory provision that dictated payment for such drugs and biologicals in CY 2005, and because we had no hospital claims data to use in establishing a payment rate for them, we investigated several payment options for CY 2005 and discussed them in detail in the CY 2005 OPPS final rule with comment period (69 FR 65797 through 65799).

For CYs 2005, 2006, and 2007, we finalized our policy to provide separate payment for new drugs, biologicals, and radiopharmaceuticals with HCPCS codes, but which did not have pass through status at a rate that was equivalent to the payment they received in the physician's office setting, established in accordance with the ASP methodology.

As discussed in the CY 2005 OPPS final rule with comment period (69 FR 65797), and the CY 2006 OPPS final rule with comment period (70 FR 68666), new drugs, biologicals, and radiopharmaceuticals may be expensive, and we are concerned that packaging these new items might jeopardize beneficiary access to them. In addition, we do not want to delay separate payment for these items solely because a pass-through application was not submitted. However, for CY 2008 we proposed to explicitly account for the pass-through payment amount associated with pass-through drugs and biologicals, in the context of our CY 2008 proposal for the payment of separately payable nonpass-through drugs and biologicals at ASP+5 percent.

We did not receive any public comments explicitly on the topic of our proposed payment methodology for nonpass-through drugs, biologicals, and radiopharmaceuticals with HCPCS codes, but without OPPS hospital claims data. Therefore, we are finalizing our proposal, without modification, to provide payment for these new drugs

and biologicals with HCPCS codes as of January 1, 2008, but which do not have pass through status and are without OPPS hospital claims data, at ASP+5 percent, consistent with our final payment methodology for other separately payable nonpass-through drugs and biologicals. This policy ensures that new nonpass-through drugs and biologicals are treated like other drugs and biologicals under the OPPS, unless they are granted pass-through status. Only pass through drugs and biologicals receive a different payment for CY 2008, generally equivalent to the payment these drugs and biologicals receive in the physician's office setting, consistent with the requirements of the statute. Payment for all new nonpass through diagnostic radiopharmaceuticals will be packaged.

In accordance with the ASP methodology, in the absence of ASP data, we proposed, for CY 2008, to continue the policy we implemented during CYs 2005, 2006, and 2007 of using the WAC for the product to establish the initial payment rate for new nonpass through drugs, and biologicals with HCPCS codes, but which are without OPPS claims data. As discussed in the proposed rule (72 FR 42741), if the WAC is also unavailable, we would make payment at 95 percent of the product's most recent AWP. We received no comments on this proposal and are finalizing it without modification.

We also proposed to assign status indicator "K" to HCPCS codes for new drugs and biologicals for which we have not received a pass-through application. Again, we received no comments and we are finalizing this proposal without modification. We further note that with respect to new items for which we do not have ASP data, once their ASP data become available in later quarter submissions, their payment rates under

the OPPS will be adjusted so that the rates are based on the ASP methodology and set to ASP+5 percent.

For CY 2008, we also proposed to base payment for new therapeutic radiopharmaceuticals with HCPCS codes as of January 1, 2008, but which do not have pass-through status, on the WACs for these products as ASP data for radiopharmaceuticals are not available. As proposed, if the WACs are also unavailable, we would make payment for the therapeutic radiopharmaceuticals at 95 percent of their most recent AWP. Analogous to new drugs and biologicals, we proposed to assign status indicator "K" to HCPCS codes for new therapeutic radiopharmaceuticals for which we have not received a pass-through application. We received no comments and are finalizing this proposal without modification.

Consistent with other ASP-based payments, for CY 2008, we proposed to make any appropriate adjustments to the payment amounts for drugs and biologicals in this final rule with comment period and also on a quarterly basis on our Web site during CY 2008 if later quarter ASP submissions (or more recent WACs or AWP) indicate that adjustments to the payment rates for these drugs and biologicals are necessary. As proposed, the payment rates for new therapeutic radiopharmaceuticals would also be adjusted accordingly. We also proposed to make appropriate adjustments to the payment rates for new drugs and biologicals in the event that they become covered under the CAP in the future. As noted in the proposed rule (72 FR 42741), the new CY 2008 HCPCS codes for drugs, biologicals, and therapeutic radiopharmaceuticals were not available at the time we developed the proposed rule. We have included these changes in Table 32 below.

TABLE 32.—NEW CY 2008 HCPCS CODES FOR DRUGS, BIOLOGICALS, AND RADIOPHARMACEUTICALS

CY 2007 HCPCS	CY 2008 SI for CY 2007 HCPCS code	CY 2008 HCPCS	CY 2008 SI	CY 2008 APC	CY 2008 long descriptor
A9565	D	A9572	N	—	Indium IN-111 pentetreotide, diagnostic, per study dose, up to 6 millicuries.
C9232	D	J1743	G	9232	Injection, idursulfase, 1mg.
C9233	D	J2778	G	9233	Injection, ranibizumab, 0.1 mg.
C9234	D	J0220	K	9234	Injection, aglucosidase alfa, 10 mg.
C9235	D	J9303	G	9235	Injection, panitumumab, 10 mg.
C9236	D	J1300	G	9236	Injection, eculizumab, 10 mg.
C9350	D	C9352	G	9350	Microporous collagen implantable tube (Neuragen Nerve Guide), per centimeter length.
C9350	D	C9353	G	1169	Microporous collagen implantable slit tube (NeuraWrap Nerve Protector), per centimeter length.
C9351	D	J7348	G	9351	Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (TissueMend) per square centimeter.

TABLE 32.—NEW CY 2008 HCPCS CODES FOR DRUGS, BIOLOGICALS, AND RADIOPHARMACEUTICALS—Continued

CY 2007 HCPCS	CY 2008 SI for CY 2007 HCPCS code	CY 2008 HCPCS	CY 2008 SI	CY 2008 APC	CY 2008 long descriptor
C9351	D	J7349	G	1141	Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (PriMatrix) per square centimeter.
J1567	D	J1561	K	0948	Injection, immune globulin, (Gamunex), intravenous, non-lyophilized (e.g. liquid), 500 mg.
J1567	D	J1568	K	0943	Injection, immune globulin, (Octagam), intravenous, non-lyophilized, (e.g. liquid), 500 mg.
J1567	D	J1569	K	0944	Injection, immune globulin, (Gammagard Liquid), intravenous, non-lyophilized, (e.g. liquid), 500 mg.
J1567	D	J1572	K	0947	Injection, immune globulin, (Flebogamma), intravenous, non-lyophilized (e.g. liquid), 500 mg.
J7319	D	J7321	K	0873	Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose.
J7319	D	J7322	K	0874	Hyaluronan or derivative, Synvisc, for intra-articular injection, per dose.
J7319	D	J7323	K	0875	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose.
J7319	D	J7324	K	0877	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose.
J7345	D	J7348	G	9351	Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Tissuemend) per square centimeter.
J7345	D	J7349	G	1141	Dermal (substitute) tissue of nonhuman origin, with or without other bioengineered or processed elements, without metabolically active elements (Primatrix) per square centimeter.
Q4079	D	J2323	G	9126	Injection, natalizumab, 1 mg.
Q4083	D	J7321	K	0873	Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose.
Q4084	D	J7322	K	0874	Hyaluronan or derivative, Synvisc, for intra-articular injection, per dose.
Q4085	D	J7323	K	0875	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose.
Q4086	D	J7324	K	0877	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose.
Q4087	D	J1568	K	0943	Injection, immune globulin, (Octagam), intravenous, non-lyophilized, (e.g. liquid), 500 mg.
Q4088	D	J1569	K	0944	Injection, immune globulin, (Gammagard Liquid), intravenous, non-lyophilized, (e.g. liquid), 500 mg.
Q4089	D	J2791	K	0945	Injection, rho(d) immune globulin (human), (Rhophylac), intravenous, 100 iu.
Q4090	D	J1571	K	0946	Injection, hepatitis b immune globulin (Hepagam B), intramuscular, 0.5 ml.
Q4091	D	J1572	K	0947	Injection, immune globulin, (Flebogamma), intravenous, non-lyophilized (e.g. liquid), 500 mg.
Q4092	D	J1561	K	0948	Injection, immune globulin, (Gamunex), intravenous, non-lyophilized (e.g. liquid), 500 mg.
Q4095	D	J3488	G	0951	Injection, zoledronic acid (Reclast), 1 mg.
Q9945	D	Q9965	N	Low osmolar contrast material, 100–199 mg/ml iodine concentration, per ml.
Q9946	D	Q9965	N	Low osmolar contrast material, 100–199 mg/ml iodine concentration, per ml.
Q9947	D	Q9966	N	Low osmolar contrast material, 200–299 mg/ml iodine concentration, per ml.
Q9948	D	Q9966	N	Low osmolar contrast material, 200–299 mg/ml iodine concentration, per ml.
Q9949	D	Q9967	N	Low osmolar contrast material, 300–399 mg/ml iodine concentration, per ml.
Q9950	D	Q9967	N	Low osmolar contrast material, 300–399 mg/ml iodine concentration, per ml.
Q9952	D	A9579	N	Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml.
		A9501	N	Technetium TC–99M teboroxime, diagnostic, per study dose.
		A9509	N	Iodine I–123 sodium iodide, diagnostic, per millicurie.
		A9569	N	Technetium TC–99M exametazime labeled autologous white blood cells, diagnostic, per study dose.
		A9570	N	Indium IN–111 labeled autologous white blood cells, diagnostic, per study dose.
		A9571	N	Indium IN–111 labeled autologous platelets, diagnostic, per study dose.
		A9576	N	Injection, gadoteridol, (ProHance Multipack), per ml.
		A9577	N	Injection, gadobenate dimeglumine (MultiHance), per ml.
		A9578	N	Injection, gadobenate dimeglumine (MultiHance Multipack), per ml.
		C9238	K	9238	Injection, levetiracetam, 10 mg.
		C9239	G	1168	Injection, temsirolimus, 1 mg.
		J0400	K	1165	Injection, aripiprazole, intramuscular, 0.25 mg.
		J1573	K	1138	Injection, hepatitis b immune globulin (Hepagam B), intravenous, 0.5 ml.
		J2724	K	1139	Injection, protein c concentrate, intravenous, human, 10 iu.
		J9226	K	1142	Histrelin implant (Supprelin LA), 50 mg.

There are several nonpass-through drugs and biologicals that were payable in CY 2006 and/or CY 2007 for which

we do not have any CY 2006 hospital claims data. These items were shown in Table 45A of the proposed rule (72 FR

42762). In order to determine the packaging status of these items for CY 2008, we calculated an estimate of the

per day cost of each of these items by multiplying the payment rate for each product based on ASP+5 percent, similar to other nonpass-through drugs and biologicals paid separately under the OPPS, by an estimated average number of units of each product that would typically be furnished to a patient during one administration in the hospital outpatient setting. We proposed to package items for which we estimate the per administration cost to be less than or equal to \$60, which is the

general packaging threshold that we proposed for drugs, biologicals, and radiopharmaceuticals in CY 2008. We proposed that the CY 2008 payment for separately payable items without CY 2006 claims data would be based on ASP+5 percent, similar to other separately payable nonpass-through drugs and biologicals under the OPPS. In accordance with the ASP methodology used in the physician's office setting, in the absence of ASP data, we would use the WAC for the

product to establish the initial payment rate. However, we note that if the WAC is also unavailable, we would make payment at 95 percent of the most recent AWP available.

We did not receive any public comments on this proposal and, therefore, are finalizing the proposal without modification. Table 33 lists all of the nonpass-through drugs and biologicals without available CY 2006 claims data to which these final policies would apply in CY 2008.

TABLE 33.—DRUGS AND BIOLOGICALS WITHOUT CY 2006 CLAIMS DATA

HCPCS code	Short descriptor	ASP-based payment rate	Estimated average number of units per administration	Final CY 2008 SI	CY 2008 APC
J0288	Ampho b cholesteryl sulfate	\$11.89	35	K	0735
J0364	Apomorphine hydrochloride	6	N	
J1324	Enfuvirtide injection	\$0.40	180	K	0767
J2170	Mecasermin injection	\$15.62	15.6	K	0805
J2315	Naltrexone, depot form	\$1.87	380	K	0759
J3355	Urofollitropin, 75 iu	\$50.22	2	K	1741
J8650	Nabilone oral	\$16.80	6	K	0808

During the March 2007 APC Panel meeting, the APC Panel reiterated its August 2006 recommendation to allow hospitals to report all HCPCS codes for drugs. In general, OPPS recognizes the lowest available administrative dose of a drug if multiple HCPCS codes exist for the drug; for the remainder of the doses, we assign a status indicator "B" indicating that another code exists for OPPS purposes. For example, if drug X has 2 HCPCS codes, 1 for a 1 ml dose and a second for a 5 ml dose, the OPPS would assign a payable status indicator to the 1 ml dose and status indicator "B" to the 5 ml dose. Hospitals would then need to bill the appropriate number of units for the 1 ml dose in order to receive payment under the OPPS. While we were not prepared to accept this recommendation when we developed the CY 2007 OPP/ASC final rule with comment period, we indicated in that rule that we would continue to consider the APC Panel's recommendation for future OPPS updates (71 FR 68083 through 68084).

After further consideration of this issue, we stated in the CY 2008 OPPS/ASC proposed rule that we are now accepting the APC Panel's recommendation because we have concluded that recognizing all of these HCPCS codes for payment under the OPPS should not have a significant effect on our payment methodology for drugs (72 FR 42742). We proposed to allow hospitals to submit claims by reporting any HCPCS code for a Part B drug that is covered under the OPPS,

regardless of the unit determination in the HCPCS code descriptor, beginning in CY 2008. Stakeholders have told us that this policy would reduce the administrative burden associated with our current requirement that hospitals report drugs using only the HCPCS codes with the lowest increments in their code descriptors. Whenever possible, we seek to reduce hospitals' administrative burden in submitting claims for payment under the OPPS, and we appreciate the APC Panel's recommendation in this area.

As these HCPCS codes were previously unrecognized in the OPPS, we do not have claims data to determine the appropriate packaging status. Therefore, we proposed to assign these HCPCS codes the same status indicator as the associated recognized HCPCS code (that is, the lowest dose), as shown in Table 45B of the proposed rule (72 FR 42743). We believed that this approach is the most appropriate and reasonable way to implement this proposed change without impacting payment. However, once claims data are available for these previously unrecognized HCPCS codes, we will determine the packaging status and resulting status indicator for each HCPCS code according to the general code-specific methodology for determining a code's packaging status for a given update year. We plan to closely follow our claims data to ensure that our annual packaging determinations for the different HCPCS codes describing the same drug do not create inappropriate payment incentives

for hospitals to report certain HCPCS codes instead of others. In our analysis for the proposed rule, we also estimated the packaging status of these currently unrecognized HCPCS codes by adjusting the calculated average number of units per day for the associated recognized HCPCS code with claims data to account for the different dosage descriptors. We then multiplied this adjusted average number of units per day value by the most recent ASP data available for the unrecognized HCPCS code (listed in Table 45B of the proposed rule). As noted in the proposed rule (72 FR 42742), this methodology yielded the same packaging determinations and resulting status indicators for the currently unrecognized HCPCS codes for CY 2008 as for the recognized HCPCS code for the same drug.

We received a number of public comments on our proposal to recognize all HCPCS codes Part B drugs for payment under the OPPS. A summary of the public comments and our responses follow.

Comment: Many commenters supported the proposal to allow hospitals to submit claims by reporting any HCPCS code for a Part B drug that is covered under the OPPS, regardless of the unit determination in the HCPCS code descriptor, beginning in CY 2008. Some commenters supported this proposal so long as it was not mandatory to report all HCPCS codes. One commenter disagreed with our

proposal and expressed concern that this would increase hospital burden.
Response: We appreciate the general support of our proposal to allow hospitals to submit claims by reporting any HCPCS code for a Part B drug that

is covered under the OPPS, regardless of the unit determination in the HCPCS code descriptor. Hospitals that may be burdened by reporting multiple HCPCS codes need not change their current

billing practices, but hospitals that would like additional flexibility when billing for drugs with multiple HCPCS dosages may implement these changes beginning in CY 2008.

TABLE 34.—PREVIOUSLY UNRECOGNIZED HCPCS CODES AND STATUS INDICATORS FOR CY 2008

HCPCS codes newly recognized in CY 2008	CY 2007 SI	Long descriptor	Associated HCPCS Code recognized in CY 2007	Final CY 2008 SI
J1470	B	Injection, gamma globulin, intramuscular, 2 cc	J1460	K
J1480	B	Injection, gamma globulin, intramuscular, 3 cc		K
J1490	B	Injection, gamma globulin, intramuscular, 4 cc		K
J1500	B	Injection, gamma globulin, intramuscular, 5 cc		K
J1510	B	Injection, gamma globulin, intramuscular, 6 cc		K
J1520	B	Injection, gamma globulin, intramuscular, 7 cc		K
J1530	B	Injection, gamma globulin, intramuscular, 8 cc		K
J1540	B	Injection, gamma globulin, intramuscular, 9 cc		K
J1550	B	Injection, gamma globulin, intramuscular, 10 cc		K
J1560	B	Injection, gamma globulin, intramuscular, over 10 cc		K
J8521	B	Capecitabine, oral, 500 mg	J8520	K
J9094	B	Cyclophosphamide lyophilized, 200 mg	J9093	N
J9095	B	Cyclophosphamide lyophilized, 500 mg		N
J9096	B	Cyclophosphamide lyophilized, 1g		N
J9097	B	Cyclophosphamide lyophilized, 2g		N
J9140	B	Dacarbazine, 200 mg	J9130	N
J9290	B	Mitomycin, 20 mg	J9280	K
J9291	B	Mitomycin, 40 mg		K
J9062	B	Cisplatin, 50 mg	J9060	N
J9080	B	Cyclophosphamide, 200 mg	J9070	N
J9090	B	Cyclophosphamide, 500 mg		N
J9091	B	Cyclophosphamide, 1g		N
J9092	B	Cyclophosphamide, 2 g		N
J9110	B	Cytarabine, 500 mg	J9100	N
J9182	B	Etoposide, 100 mg	J9181	N
J9260	B	Methotrexate sodium, 50 mg	J9250	N
J9375	B	Vincristine sulfate, 2 mg	J9370	N
J9380	B	Vincristine sulfate, 5 mg		N

Finally, in Table 45C of the proposed rule (72 FR 42743), we proposed to package seven drugs and biologicals that were payable in CY 2006 because we lacked CY 2006 claims data and any other data related to the ASP methodology and, therefore, we were unable to determine the per day cost of these products. As in previous years of the OPPS, when we are unable to determine a drug's packaging status and payment rate due to the unavailability of hospital claims data and payment information at the time of the final rule, we package payment for those drugs. We did not receive any public comments on our proposal to apply this

methodology to the seven drugs included in the proposed rule. As stated elsewhere in this rule, it is our policy to use updated claims data to inform our final rule. Since the time of the proposed rule, we have received hospital claims data for HCPCS code J0200 (Injection, alatrofloxacin mesylate, 100 mg). Therefore, as we now have payment information for HCPCS code J0200, we have determined its final CY 2008 packaging status based on hospital claims data and we will not finalize our proposal to package this drug for CY 2008 because of the lack of hospital claims data and payment rate information. Hospital claims data for

HCPCS code J0200 indicate that there were a total of 100 units billed over 1 day, with a mean cost of \$0.16 per unit. Therefore, the average per day cost estimate of HCPCS code J0200 is approximately \$16. As this cost is below the \$60 packaging threshold, its status is packaged for CY 2008, according to the standard OPPS packaging methodology for drugs and biologicals.

Therefore, we are finalizing our proposal, with modification to exclude HCPCS code J0200, to package payment for the drugs and biologicals listed in Table 35 below, due to missing data critical to calculating a per day cost.

TABLE 35.—DRUGS AND BIOLOGICALS WITHOUT INFORMATION ON PER DAY COST THAT ARE PACKAGED IN CY 2008

HCPCS code	Short descriptor	Final CY 2008 SI
90393	Vaccina ig, im	N
90477	Adenovirus vaccine, type 7	N
90581	Anthrax vaccine, sc	N
90727	Plague vaccine, im	N
J0395	Arbutamine HCl injection	N

TABLE 35.—DRUGS AND BIOLOGICALS WITHOUT INFORMATION ON PER DAY COST THAT ARE PACKAGED IN CY 2008—Continued

HCPCS code	Short descriptor	Final CY 2008 SI
J1452	Intraocular Fomivirsen na	N

VI. Estimate of OPPS Transitional Pass-Through Spending for Drugs, Biologicals, Radiopharmaceuticals, and Devices

A. Total Allowed Pass-Through Spending

Section 1833(t)(6)(E) of the Act limits the total projected amount of transitional pass-through payments for drugs, biologicals, radiopharmaceuticals, and categories of devices for a given year to an “applicable percentage” of projected total Medicare and beneficiary payments under the hospital OPPS. For a year before CY 2004, the applicable percentage was 2.5 percent; for CY 2004 and subsequent years, we specify the applicable percentage up to 2.0 percent.

If we estimate before the beginning of the calendar year that the total amount of pass-through payments in that year would exceed the applicable percentage, section 1833(t)(6)(E)(iii) of the Act requires a uniform reduction in the amount of each of the transitional pass-through payments made in that year to ensure that the limit is not exceeded. We make an estimate of pass-through spending to determine not only whether payments exceed the applicable percentage, but also to determine the appropriate reduction to the conversion factor for the projected level of pass-through spending in the following year.

For devices, developing an estimate of pass-through spending in CY 2008 entails estimating spending for two groups of items. The first group of items consists of those device categories that were eligible for pass-through payment in CY 2006 or CY 2007, or both years, and that would continue to be eligible for pass-through payment in CY 2008. The second group contains items that we know are newly eligible, or project would be newly eligible, for device pass-through payment in the remainder of CY 2007 or beginning in CY 2008.

For drugs and biologicals, section 1833(t)(6)(D)(i) of the Act establishes the

pass-through payment amount for drugs and biologicals eligible for pass-through payment as the amount by which the amount authorized under section 1842(o) of the Act (or, if the drug or biological is covered under a competitive acquisition contract under section 1847B of the Act, an amount determined by the Secretary equal to the average price for the drug or biological for all competitive acquisition areas and year established under such section as calculated and adjusted by the Secretary) exceeds the portion of the otherwise applicable fee schedule amount that the Secretary determines is associated with the drug or biological. Because we are finalizing our CY 2008 proposal to pay for nonpass-through separately payable drugs and biologicals under the CY 2008 OPPS at ASP+5 percent, which represents the otherwise applicable fee schedule amount associated with a pass-through drug or biological, while we would pay for pass-through drugs and biologicals at ASP+6 percent or the Part B drug CAP rate, if applicable, our estimate of drug and biological pass-through payment for CY 2008 is not zero. Similar to estimates for devices, the first group of drugs and biologicals requiring a pass-through payment estimate consists of those products that were eligible for pass-through payment in CY 2006 or CY 2007, or both years, and that would continue to be eligible for pass-through payment in CY 2008. The second group contains drugs and biologicals that we know are newly eligible, or project would be newly eligible, beginning in CY 2008. The sum of the CY 2008 pass-through estimates for these two groups of drugs and biologicals would equal the total CY 2008 pass-through spending estimate for drugs and biologicals with pass-through status.

B. Estimate of CY 2008 Pass-Through Spending

As we proposed, in this final rule with comment period, we are setting the

applicable percentage limit at 2.0 percent of the total OPPS projected payments for CY 2008, consistent with our OPPS policy from CY 2004 through CY 2007.

As we discuss in section IV.B. of this final rule with comment period, there are two device categories receiving pass-through payment in CY 2007 that will continue for payment during CY 2008. In accordance with the methodology we have used to make estimates in previous years, in cases where we have relevant claims data for the procedures associated with a device category, we proposed to project these data forward using inflation and utilization factors based on total growth in OPPS services as projected by CMS’ Office of the Actuary (OACT) to estimate the upcoming year’s pass through spending for this first group of device categories. As we stated in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68101), we may use an alternate growth factor for any specific device category based on our claims data or the device’s clinical characteristics, or both. We developed estimated OPPS utilization of the procedures and costs associated with the two device categories continuing for pass-through payment into CY 2008, based upon examination of our historical claims data, information provided in the pass-through device category applications, and the devices’ clinical characteristics. Based on these analyses, our final estimate of pass-through spending attributable to the first group (that is, the two device categories continuing in CY 2008) described above is \$18.1 million for CY 2008. The two device categories continuing in CY 2008, which are reflected in this \$18.1 million estimate for CY 2008 pass-through spending, are listed in Table 36 below.

TABLE 36.—CY 2008 DEVICES WITH CURRENT PASS-THROUGH CATEGORIES CONTINUING INTO CY 2008

HCPCS code	APC	Current pass-through device category
C1821	1821	Interspinous process distraction device (implantable).
L8690	1032	Auditory osseointegrated device, includes all internal and external components.

In estimating CY 2008 pass-through spending for device categories in the second group (that is, device categories that we know at the time of the development of this final rule with comment period will be newly eligible for pass-through payment in CY 2008 (of which there are none)) and contingent projections for new categories in the second through fourth quarters of CY 2008, we used the general methodology as described above, while also taking into account recent OPPS experience in approving new pass through device categories. The final estimate of CY 2008 pass-through spending for this second group is \$7.5 million. Employing our proposed methodology that the estimate of pass through device spending in CY 2008 incorporates CY 2008 estimates of pass through spending for device categories continuing in CY 2008, those first effective January 1, 2008, and those device categories projected to be approved during subsequent quarters of CY 2007 and CY 2008, our total pass-through estimate for device categories for CY 2008 is \$25.6 million.

We did not receive any public comments on our proposed methodology to estimate transitional pass-through spending for device categories in CY 2008. Therefore, we are finalizing our methodology for estimating pass-through spending for categories of devices in CY 2008 as proposed, without modification, resulting in a total pass-through spending estimate of \$25.6 million for device categories in CY 2008.

In accordance with the methodology we proposed in the CY 2008 OPPS/ASC proposed rule, to estimate CY 2008 pass-through spending for drugs and biologicals in the first group, specifically those drugs and biologicals initially eligible for pass-through status in CY 2006 or CY 2007 and proposed for continuation of pass-through payment in CY 2008, we utilized the most recent Medicare physician's office data regarding their utilization, information provided in the respective pass-through applications, historical hospital claims data, pharmaceutical industry information, and clinical information regarding the drugs or biologicals, in order to project the CY 2008 OPPS utilization of the products. For the known drugs and biologicals that will continue on pass-through status in CY 2008, we then estimated the total pass through payment amount as the difference between ASP+6 percent or the Part B drug CAP rate, as applicable, and ASP+5 percent, aggregated across the projected CY 2008 OPPS utilization of these products. Based on these

analyses, we estimated pass-through spending attributable to the first group (that is, the drugs and biological continuing with pass-through eligibility in CY 2008) described above to be about \$1.2 million for CY 2008. This \$1.2 million estimate of CY 2008 pass through spending for the first group of pass-through drugs reflects the current pass-through drugs that are continuing on pass-through status into CY 2008, which are displayed in Table 27 in section V.A.3. of this final rule with comment period.

To estimate CY 2008 pass-through spending for drugs and biologicals in the second group (that is, drugs and biologicals that we know at the time of development of this final rule with comment period are newly eligible for pass-through payment as of January 1, 2008, and projections for new drugs and biologicals that could be initially eligible for pass-through payment in the second through fourth quarters of CY 2008), we used utilization estimates from applicants, pharmaceutical industry data, and clinical information as the basis for pass through spending estimates for these drugs and biologicals for CY 2008, while also considering the most recent OPPS experience in approving new pass through drugs and biologicals. Based on these analyses, we estimate pass-through spending attributable to this second group of drugs and biologicals will be \$5.4 million for CY 2008.

In the CY 2008 OPPS/ASC proposed rule, we proposed that the estimate of pass through drug and biological spending in CY 2008 incorporate CY 2008 estimates of pass-through spending for drugs and biologicals with pass-through status in CY 2007 that would continue for CY 2008, those first effective January 1, 2008, and those drugs and biologicals projected to be approved during subsequent quarters of CY 2008.

We did not receive any public comments on our proposed methodology to estimate pass-through spending for drugs and biologicals in CY 2008. Therefore, we are finalizing our methodology for estimating pass-through spending for drugs and biologicals in CY 2008 as proposed, without modification, resulting in a total pass-through spending estimate of \$6.6 million for drugs and biologicals in CY 2008.

In the CY 2005 OPPS final rule with comment period (69 FR 65810), we indicated that we are accepting pass-through applications for new radiopharmaceuticals that are assigned a HCPCS code on or after January 1, 2005. (Prior to this date, radiopharmaceuticals

were not included in the category of drugs paid under the OPPS, and, therefore, were not eligible for pass-through status.) There are no radiopharmaceuticals that are eligible for pass-through payment at the time of publication of this final rule with comment period. In addition, we have no information identifying new radiopharmaceuticals to which a HCPCS code might be assigned on or after January 1, 2008, for which pass through payment status would be sought. We also have no historical data regarding payment for new radiopharmaceuticals with pass-through status under the methodology that we specified for the CY 2005 OPPS or the CY 2008 methodology that we describe in section V.A.3. of this final rule with comment period. However, we do not believe that pass through spending for new radiopharmaceuticals in CY 2008 will be significant enough to materially affect our estimate of total pass-through spending in CY 2008. Therefore, we are not including radiopharmaceuticals in our final estimate of pass through spending for CY 2008. We discuss the methodology for determining the CY 2008 payment amount for new radiopharmaceuticals without pass through status in section V.B.3.b. of this final rule with comment period.

We did not receive any public comments on our proposal to estimate that pass-through spending for radiopharmaceuticals in CY 2008 will be zero. Therefore, we are finalizing our methodology for estimating pass-through spending for radiopharmaceuticals in CY 2008 as proposed, without modification, resulting in a total pass-through spending estimate of zero for radiopharmaceuticals in CY 2008.

In accordance with the comprehensive methodology described above, we estimate that total pass through spending for the two device categories and the drugs and biologicals that are continuing for pass-through payment into CY 2008 and those devices, drugs, biologicals, and radiopharmaceuticals that first become eligible for pass-through status during CY 2008 will approximate \$32.2 million, which represents 0.09 percent of total OPPS projected payments for CY 2008.

Because we estimate that pass-through spending in CY 2008 will not amount to 2.0 percent of total projected OPPS CY 2008 spending, we will return 1.91 percent of the pass-through pool to adjust the conversion factor, as we discuss in section II.C. of this final rule with comment period.

Accordingly, we are finalizing our proposed methodology for estimating CY 2008 OPPS pass-through spending for drugs, biologicals, radiopharmaceuticals, and categories of devices. Our final total pass-through estimate for CY 2008 is \$32.2 million.

VII. OPPS Payment for Brachytherapy Sources

A. Background

Section 1833(t)(2)(H) of the Act, as added by section 621(b)(2)(C) of Pub. L. 108–173, mandated the creation of separate groups of covered OPD services that classify brachytherapy devices separately from other services or groups of services. The additional groups must reflect the number, isotope, and radioactive intensity of the devices of brachytherapy furnished, including separate groups for palladium-103 and iodine-125 devices.

Section 1833(t)(16)(C) of the Act, as added by section 621(b)(1) of Pub. L. 108–173, established payment for devices of brachytherapy consisting of a seed or seeds (or radioactive source) based on a hospital's charges for the service, adjusted to cost. The period of payment under this provision is for brachytherapy sources furnished from January 1, 2004, through December 31, 2006. Under section 1833(t)(16)(C) of the Act, charges for the brachytherapy devices may not be used in determining any outlier payments under the OPPS for that period of payment. Consistent with our practice under the OPPS to exclude items paid at cost from budget neutrality consideration, these items were excluded from budget neutrality for that time period as well.

In the OPPS interim final rule with comment period published on January 6, 2004 (69 FR 827), we implemented sections 621(b)(1) and (b)(2)(C) of Pub. L. 108–173. In that rule, we stated that we would pay for the brachytherapy sources (that is, brachytherapy devices) listed in Table 4 of the interim final rule with comment period (69 FR 828) on a cost basis, as required by the statute. Since January 1, 2004, we have used status indicator “H” to denote nonpass through brachytherapy sources paid on a cost basis, a policy that we finalized in the CY 2005 final rule with comment period (69 FR 65838).

Furthermore, we adopted a standard policy for brachytherapy code descriptors, beginning January 1, 2005. We included “per source” in the HCPCS code descriptors for all those brachytherapy source descriptors for which units of payment were not already delineated.

Section 621(b)(3) of Pub. L. 108–173 required the GAO to conduct a study to determine appropriate payment amounts for devices of brachytherapy, and to submit a report on its study to the Congress and the Secretary, including recommendations on the appropriate payments for such devices. This report was due to Congress and to the Secretary no later than January 1, 2005. The GAO's final report, “Medicare Outpatient Payments: Rates for Certain Radioactive Sources Used in Brachytherapy Could Be Set Prospectively” (GAO–06–635), was published on July 24, 2006. We summarized and discussed the report's findings and recommendations in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68103 through 68105). The GAO report principally recommended that we use OPPS historical claims data to determine prospective payment rates for two of the most frequently used brachytherapy sources, iodine-125 and palladium-103, and also recommended that we consider using claims data for the third source studied, high dose rate (HDR) iridium-192.

The GAO report concluded that CMS could set prospective payment rates based on claims data for iodine and palladium sources, because the sources' unit costs are generally stable, both sources have identifiable unit costs that do not vary substantially and unpredictably over time, and reasonably accurate claims data are available. On the other hand, the GAO report explained that it was not able to determine a suitable methodology for paying separately for HDR iridium. The report noted that iridium is reused across multiple patients, making its unit cost more difficult to determine. However, the report also indicated that CMS has outpatient claims data from all hospitals that have used iridium and that in order to identify a suitable methodology for separate payment, CMS would be able to use these data to establish an average cost and evaluate whether that cost varies substantially and unpredictably.

In our CY 2007 annual OPPS rulemaking, we proposed and finalized a policy of prospective payment based on median costs for the 11 brachytherapy sources for which we had claims data. We based the prospective rates on median costs for each source from our CY 2005 claims data (71 FR 68102 through 71 FR 68114). We also indicated that we would assign future new HCPCS codes for new brachytherapy sources to their own APCs, with prospective payment rates set based on our consideration of

external data and other relevant information regarding the expected costs of the sources to hospitals (71 FR 68112). We changed the definition of status indicator “K” to ensure that “K” appropriately described brachytherapy sources to accommodate the use of “K” for prospective payment for brachytherapy sources (71 FR 68110).

Subsequent to publication of the CY 2007 OPPS/ASC final rule with comment period, section 107(a) of the MIEA–TRHCA amended section 1833(t)(16)(C) of the Act by extending the payment period for brachytherapy sources based on a hospital's charges adjusted to cost for one additional year. This requirement for cost-based payment ends after December 31, 2007. Therefore, we were required to continue payment for sources based on charges adjusted to cost through CY 2007. We also have continued using status indicator “H” to denote nonpass through brachytherapy sources paid on a cost basis as a result of enactment of this provision rather than using status indicator “K” to denote prospective payment for nonpass-through brachytherapy sources, as finalized in the CY 2007 OPPS/ASC final rule with comment period.

Section 107(b)(1) of the MIEA–TRHCA also amended section 1833(t)(2)(H) of the Act by adding a requirement for the establishment of separate payment groups for “stranded and non-stranded” brachytherapy devices beginning July 1, 2007. Section 107(b)(2) of the MIEA–TRHCA authorized the Secretary to implement this new requirement by “program instruction or otherwise.” This new requirement is in addition to the requirement for separate payment groups based on the number, isotope, and radioactive intensity of brachytherapy devices that was previously established by section 1833(t)(2)(H) of the Act. We note that commenters on the CY 2007 proposed rule asserted that stranded sources, which they described as embedded into the stranded suture material and separated within the strand by material of an absorbable nature at specified intervals, had greater production costs than non-stranded sources (71 FR 68113 through 68114).

As a result of the statutory requirement to create separate groups for stranded and non-stranded sources as of July 1, 2007, we established several coding changes via program transmittal, effective July 1, 2007 (Program Transmittal No. 1259, dated June 1, 2007). As indicated in the CY 2008 proposed rule, based upon comments to our CY 2007 proposed rule and industry

input, we are presently aware of three sources that are currently available in stranded and non-stranded forms: iodine-125; palladium-103; and cesium-131 (72 FR 42746).

Therefore, in Program Transmittal No. 1259, we created six new HCPCS codes to differentiate the stranded and non-stranded versions of these three sources. These six new HCPCS codes replaced the three prior brachytherapy source HCPCS codes for iodine, palladium and cesium (C1718, C1720, and C2633, all of which were deleted as of July 1, 2007), respectively, effective July 1, 2007. In this program transmittal, we also provided specific billing instructions to hospitals on how to report stranded sources. We instructed providers, when billing for stranded sources, to bill the number of units of the appropriate source HCPCS C-code according to the number of brachytherapy sources in the strands and specifically *not* to bill as one unit per strand. If a hospital applies both stranded and non-stranded sources to a patient in a single treatment, the hospital should bill the stranded and non-stranded sources separately, according to the differentiated HCPCS codes listed in the table found in that program transmittal and included in Table 48 of the proposed rule. We expected that these instructions would clearly indicate how hospitals should bill for stranded and non-stranded brachytherapy sources, and that hospital reporting of sources according to these instructions would promote accurate claims data for the various source codes in the future. In Program Transmittal No. 1259, we also added the term “non-stranded” to the descriptors for all sources that currently have only non-stranded versions of a source.

In Program Transmittal No. 1259, we indicated that if we receive information that any of the other sources now designated as non-stranded are marketed as a stranded source, we would create a code for the stranded source. We also established two “Not Otherwise Specified” (NOS) codes for billing stranded and non-stranded sources that are not yet known to us and for which we do not have source-specific codes. If a hospital purchases an FDA-approved and marketed radioactive source consisting of a radioactive isotope (consistent with our definition of a brachytherapy source eligible for separate payment as discussed below), for which we do not yet have a separate source code established, it should bill such sources using the appropriate NOS code listed in Program Transmittal No. 1259, that is, C2698 (Brachytherapy source, stranded, not otherwise specified, per

source) for stranded NOS sources, or C2699 (Brachytherapy source, non-stranded, not otherwise specified, per source) for non-stranded NOS sources, which are also listed in Table 37 below. For example, if a new FDA-approved stranded source comes onto the market and there is currently only a billing code for the non-stranded source, the hospital should bill the stranded source under C2698 (stranded NOS source) until a specific stranded billing code for the source is established.

In Program Transmittal No. 1259, we reiterated our longstanding policy that hospitals and other parties are invited to submit recommendations to us for new HCPCS codes to describe new sources consisting of a radioactive isotope, including a detailed rationale to support recommended new sources. We will continue our endeavor to add new brachytherapy source codes and descriptors to our systems for payment on a quarterly basis. Such recommendations should be directed to the Division of Outpatient Care, Mail Stop C4-05-17, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244.

Finally, we noted that in the CY 2007 OPPTS/ASC final rule with comment period, we established a definition for brachytherapy source for which separate payment under section 1833(t)(2)(H) of the Act is required (71 FR 68113). We considered the definition of “brachytherapy source” in the context of current medical practice and in regard to the language in section 1833(t)(2)(H) of the Act, which refers to brachytherapy sources as “a seed or seeds (or radioactive source).” We believed that this provision of the Act mandating separate payment refers to sources that are themselves radioactive, meaning that the source contains a radioactive isotope. Furthermore, we indicated that the statutory language is likewise clear that devices of brachytherapy paid separately must reflect the number, isotope, and radioactive intensity of such devices furnished. Accordingly, we further believed that section 1833(t)(2)(H) of the Act applies only to radioactive devices of brachytherapy. In the CY 2007 OPPTS/ASC final rule with comment period, we also stated that we would not consider specific devices, beams of radiation, or equipment that do not constitute separate sources that utilize radioactive isotopes to deliver radiation to be brachytherapy sources for separate payment, as such items do not meet the statutory requirements provided in section 1833(t)(2)(H) of the Act (71 FR 68113).

B. Payment for Brachytherapy Sources

As indicated above, the provision to pay for brachytherapy sources at charges adjusted to cost expires after December 31, 2007, in accordance with section 1833(t)(16)(C) of the Act, as amended by section 107(a) of the MIEA-TRHCA. However, under section 1833(t)(2)(H) of the Act, we are still required to create APC groupings that classify devices of brachytherapy separately from other services or groups of services in a manner reflecting the number, isotope, and radioactive intensity of the devices of brachytherapy furnished. In addition, section 1833(t)(2)(H) of the Act, as amended by section 107(b)(1) of the MIEA-TRHCA, requires separate payment groups based on stranded and non-stranded brachytherapy devices on or after July 1, 2007.

In the CY 2008 proposed rule, we proposed to pay separately for each of the sources listed in Table 48 of that rule on a prospective basis for CY 2008, with payment rates to be determined using the CY 2006 claims-based median cost per source for each brachytherapy device. Consistent with our policy regarding APC payments made on a prospective basis, we proposed that the cost of brachytherapy sources be subject to the outlier provision of section 1833(t)(5) of the Act. As indicated in section II.A.2. of the proposed rule, for CY 2008 we proposed specific prospective payment rates for brachytherapy sources, which would be subject to scaling for budget neutrality.

We stated that we believe that adopting prospective payment for brachytherapy sources would be appropriate for a number of reasons. The general OPPTS payment methodology is a prospective payment system using median costs based on claims data. This prospective payment methodology results in more consistent, predictable, and equitable payment amounts per source across hospitals, and it prevents some of the extremely high and low payment amounts found under a charges adjusted to cost methodology. The proposed prospective payment would also provide hospitals with incentives for efficiency in the provision of brachytherapy services to Medicare beneficiaries. Moreover, the proposed approach is consistent with our payment methodology for the vast majority of items and services paid under the OPPTS. Indeed, section 1833(t)(2)(C) of the Act requires us to establish prospective payment rates for the OPPTS system based on median costs (or mean costs if elected by the Secretary). As of CY 2007, only pass-through devices, radiopharmaceuticals,

and brachytherapy sources were paid at charges adjusted to cost. Based on the proposals in the CY 2008 proposed rule, only pass-through devices would continue to be paid at charges adjusted to cost for CY 2008. As noted earlier, section 107(a) of the MIEA-TRHCA specifically extended the payment period for brachytherapy sources based on a hospital's charges adjusted to cost for only one additional year, CY 2007.

As explained in the proposed rule, the proposal to adopt prospective payment for brachytherapy sources provides opportunities for hospitals to receive additional payments under certain circumstances through the outlier provisions and the 7.1 percent rural SCH adjustment (72 FR 42748). Consistent with our policy regarding APC payments made on a prospective basis, we proposed that the cost of brachytherapy sources be subject to the outlier provision of section 1833(t)(5) of the Act. Therefore, sources could receive outlier payments if the costs of furnishing brachytherapy sources exceed the outlier threshold. Also, as discussed in section II.F. of the proposed rule, as a result of our CY 2008 proposal to pay prospectively for brachytherapy sources, we also proposed to include brachytherapy sources in the group of services eligible for the 7.1 percent payment increase for rural SCHs, including EACHs.

We proposed a payment methodology for separately paid brachytherapy sources for CY 2008 based upon their median unit costs calculated using CY 2006 claims data. Because we are required to create separate APC groups for stranded and non-stranded sources and because our CY 2006 billing codes do not differentiate stranded and non-stranded sources, we proposed to make certain assumptions when we estimate the median costs for stranded and non-stranded (low activity) iodine-125, palladium-103, and cesium-131 sources based on our CY 2006 aggregate claims data. As stated earlier, commenters to our CY 2007 proposed rule explained that the costs of stranded iodine, palladium and cesium sources are higher than non-stranded versions of these sources but provided no data regarding the relative cost relationships. Given the reported cost differences between stranded and non-stranded sources and the statutory requirement that we establish separate payment groups for stranded and non-stranded sources, we believed it would be appropriate to establish different stranded and non stranded payment rates for iodine-125, palladium-103, and cesium-131 sources. However, in order to establish separate stranded and non-

stranded payment rates for these three sources, we proposed to make the following assumptions in our calculation of their median costs. Assuming that the reportedly lower cost non-stranded sources would be unlikely to be in the top 20 percent of the cost distribution in our aggregate (stranded and non-stranded) CY 2006 claims data, we proposed to calculate the median cost for these 3 non-stranded sources based on the bottom 80 percent of the cost distribution in our aggregate claims data for each source. Likewise, assuming that the reportedly higher cost stranded sources would be unlikely to be in the bottom 20 percent of the cost distribution in our aggregate CY 2006 claims data, we proposed to calculate the median cost for these 3 stranded sources based on the top 80 percent of the cost distribution for our aggregate data. This approach to calculating median costs for stranded and non-stranded iodine-125, palladium-103, and cesium-131 sources resulted in proposed Medicare payment rates based on the 60th percentile of our aggregate data for stranded sources and the 40th percentile of our aggregate data for non-stranded sources, which, after examining the range of our cost data for these sources, appeared to provide a reasonable cost differential between stranded and non-stranded sources until such time when we have claims data reported separately for stranded and non-stranded sources.

We proposed this approach for stranded and non-stranded iodine-125, palladium-103, and cesium-131 sources as a transitional measure, until we have sufficient claims data for separately coded stranded and non-stranded sources upon which to calculate the median costs for these sources specifically. (The first partial year claims data for separately coded stranded and non-stranded sources will be available in CY 2007 claims data for ratesetting in CY 2009.) This methodology has the benefits of a prospective payment methodology as discussed above and complies with the requirements of the MIEA-TRHCA to provide separate payment for stranded and non-stranded sources.

Table 48 of the proposed rule (72 FR 42750) included a complete listing of the HCPCS codes, long descriptors, and APC assignments that we currently use for brachytherapy sources paid under the OPSS as of July 1, 2007, and the status indicators, estimated median costs, and payment rates that we proposed for CY 2008. We noted that some of the HCPCS codes for which we proposed payment rates for CY 2008 were not shown in Addendum B of the

proposed rule because that addendum was based on HCPCS codes effective as of April 2007. As explained earlier, there are some brachytherapy source HCPCS codes that were added as of July 1, 2007. While these HCPCS codes were not shown in Addendum B, the proposed payment rates for all brachytherapy sources were shown in Table 48 of the proposed rule.

We invited public comment on all aspects of our proposed brachytherapy source payment for CY 2008. We particularly encouraged public comment on our proposed median costs estimates for stranded and non-stranded iodine-125, palladium-103, and cesium-131 sources, including the submission of any available information or data on cost differences between stranded and non stranded sources. We also indicated in the proposed rule that we were interested in receiving information regarding the historical and current relative market share for stranded versus non-stranded sources, particularly as used in the care of Medicare beneficiaries and with respect to brachytherapy treatments for different clinical conditions (72 FR 42749).

Comment: A number of commenters recommended that CMS continue payment for brachytherapy sources using the charges adjusted to cost methodology for CYs 2008 and 2009. Some commenters claimed that establishing a single prospective payment rate per source would not account for the variable costs associated with the different sources used in brachytherapy. A commenter claimed that, based upon historical hospital claims data, it does not appear that hospitals are charging enough to recover their acquisition costs for expensive products in particular. Some commenters stated that some products have low volumes of claims from small numbers of hospitals, based on recent claims analyses. They explained their belief that the low volume of claims for certain sources and the wide variation in submitted charges for most sources demonstrate that equitable payment rates that approximate true acquisition costs for brachytherapy sources cannot be established using Medicare claims. Several commenters asserted that CMS' brachytherapy source claims data have unresolved problems, such as: (a) The cost of renewable high dose rate (HDR) iridium, which may be used to treat a number of people, is difficult to estimate, because the cost per source depends on the number of patients treated; (b) a lack of meaningful data to establish payment rates for stranded brachytherapy sources; (c) large variations in per unit costs across

sources; (d) a lack of sufficient claims to establish rates in the cases of 6 sources: ytterbium-169 (C2637), linear palladium (C2636), iodine-125 solution (C2632 correctly—coded in CY 2007 as A9527), gold-198 (C1716), cesium-131 (C2633), and non-HDR iridium (C1719); (e) two-thirds of the current sources have proposed payment rates based on claims from a small number (for example, fewer than 50 or 66) hospitals; and (f) a rank order anomaly exists between the proposed median costs of iodine-125 (\$37.71) and high activity I-125 (\$29.56), with the high activity source appearing to cost less than the low activity source, when high activity sources are reportedly more expensive. The commenters also explained that while claims data may be improving over time, the majority of hospitals still do not include a brachytherapy source code on brachytherapy treatment claims, even though a source is required, claiming that only about 31 percent of the claims for APC 0312 (Radioelement Applications), 73 percent of the claims for APC 0313 (Brachytherapy), and 36 percent of the claims for APC 0651 (Complex Interstitial Source Application) include a brachytherapy source code.

Some commenters supported the proposal to establish prospective payment rates for brachytherapy in CY 2008 using costs derived from CY 2006 claims data, rather than through cost-based reimbursement. A commenter supported the development of prospective payment rates for brachytherapy sources based on CMS' claims data but was concerned that the 2-year time lag between the hospital claims data used to establish the proposed payment rates for brachytherapy sources and the payment year of the proposed update would lead to CY 2008 payments that would not reflect the actual CY 2008 costs of brachytherapy sources. The commenters recommended the use of historical claims data, in addition to an annual inflation rate, to determine the prospective payment rates.

Regarding specific brachytherapy sources, a commenter claimed that the proposed payment rate of \$11,944 per source for yttrium-90 is below the acquisition cost and provides no compensation to providers for storage, handling and disposal costs. Two commenters indicated that setting a fixed payment rate for High Dose Rate (HDR) iridium-192 is problematic, because the source can be used to treat multiple patients during its 90-day period of decay. They pointed out that the cost per use of the source, therefore, depends on the number of patients

treated by a hospital during this period. Thus, they concluded there would be great variability in the cost of HDR iridium treatment so CMS should continue to pay for this source based on the charges adjusted to cost payment methodology.

Response: We believe that median costs based on our hospital claims data for brachytherapy sources have produced reasonably consistent per source cost estimates over the past several years, comparable to the patterns we have observed for many other OPSS services whose payments are set based upon relative payment weights from claims data. Concerning the claim that a single prospective payment per source would not account for the variable costs across sources used, we believe that our per source payment methodology specific to each source's radioisotope, radioactive intensity, and stranded or non-stranded configuration, supplemented by payment based on the number of sources used in a specific clinical case, adequately accounts for the major expected sources of variability across treatments.

As a prospective payment system, the OPSS relies on the concept of averaging, where the payment may be more or less than the estimated costs of providing a service for a particular patient, but with the exception of outlier cases, it is adequate to ensure access to appropriate care. In the case of brachytherapy sources for which the law requires separate payment groups, without packaging, the costs of these individual items could be expected to show greater variation than some other APCs under the OPSS because higher variability in costs for some component items and services is not balanced with lower variability for others and because relative weights are typically estimated using a smaller set of claims. Nevertheless, we believe that prospective payment for brachytherapy sources based on median costs from claims calculated according to the standard OPSS methodology is appropriate at this point in time and would provide hospitals with the greatest incentives for efficiency in providing brachytherapy treatment. Under the budget neutral OPSS, it is the relativity of costs of services, not their absolute costs, that is important, and we believe that brachytherapy sources can now be appropriately paid according to the standard OPSS payment approach. All services are similarly subjected to the same 2-year lag in costs from claims data available for ratesetting, so we believe the relative costs of OPSS services should generally be appropriate. It is important that the

same measure of central tendency (median cost) from claims be used to establish the payment weights for all OPSS services in order to provide appropriate payment for all of these services. The inflation rate of medical services is taken into consideration through the conversion factor, which is updated annually to account for inflation and used to calculate payment rates from the relative payment weights based on median costs.

When the statutory requirement for payment of brachytherapy sources at charges adjusted to cost ends on December 31, 2007, prospective payment for brachytherapy sources based on their median costs would make the source payment an integral part of the OPSS, rather than a separate cost-based payment methodology within the OPSS. We believe that consistent and predictable prospectively established payment rates under the OPSS for brachytherapy sources are appropriate because we do not believe that the hospital resource costs associated with specific brachytherapy sources would vary greatly across hospitals or clinical conditions under treatment, other than through differences in the numbers of source utilized which would be accounted for in the standard OPSS payment methodology as proposed. We particularly note that, under the final CY 2008 payment policies for all OPSS services, only a few pass-through devices that we have determined result in significant clinical improvement would continue to be paid based on charges adjusted to cost, as required under section 1833(t)(6)(D)(ii) of the Act for these items.

Sources of brachytherapy have been separately paid for virtually all of the 7 year history of the OPSS, and hospitals have now had 7 years of experience in reporting the sources separately to receive payment for these relatively costly items. Therefore, hospitals historically have had a strong incentive to bill for sources at charges that reflected the costs of the sources, leading to CY 2006 data that are sufficient to provide the basis for prospective payment. Evolution of brachytherapy source technology, just like advances in the provision of other OPSS services, would be reflected in updated cost data for those sources over time, and those updated costs would be considered each year in the annual update cycle for the OPSS. We do not believe that special accommodation to support brachytherapy source innovation is necessary. We believe that hospitals and physicians regularly balance the additional benefits to

patients of improved products with the additional costs, if any, of those products. One of the functions of a prospective payment system is to encourage wise purchasing while simultaneously making appropriate payments for the services being furnished. We believe that payments based on the median unit costs of brachytherapy sources support this goal.

Because HDR iridium has a fixed active life and must be replaced every 90 days, we agree with commenters that hospitals' costs for the source will be highly dependent on the number of treatments provided by a hospital during that time period. The source cost must be amortized over the life of the sources so, in establishing their charges for the HDR iridium source, we expect that hospitals would project the number of treatments that would be provided over the life of the source and establish their charges accordingly. For most such OPPS services, our practice is to establish prospective payment rates based on the median hospital costs as calculated from claims data, to provide incentives for efficient and cost-effective delivery of these services. Under a prospective payment system methodology, payments generally account for the average costs of services and do not specifically account for varying circumstances. We believe that hospitals understand this prospective payment methodology and should recognize that a prospective payment system could pay more or less than the cost of delivering a specific service in an individual case. We have no reason to believe that a CY 2008 payment based on the median unit cost for HDR iridium would place continued access to this source at risk. Furthermore, as discussed earlier in this section and in section II.F. of this final rule with comment period, prospective payment for brachytherapy sources means that there would be opportunities for hospitals to receive additional payments under the outlier provisions and the rural adjustment.

We disagree that we are not able to set equitable rates per source because of low volumes for some sources and variability of source costs in our claims data. The prospective rates we proposed and are finalizing would be applied equitably to all sources of the same type (for example, all non-stranded iodine-125 sources, all stranded iodine-125 sources, and so on). The nature of basing payment weights on median costs is that the volume of services, by definition, controls the median cost because the median is the 50th percentile of the array of data. However, use of the median cost also

simultaneously eliminates the influence of not only the highest but also the lowest values in the array. If the use of currently low volume sources increases in succeeding years or expands to other hospitals, these additional claims would be represented in our claims data in future years, leading to more robust claims data for each such source.

Comment: One commenter claimed that CMS' claims data for the cesium-131 source show significant variation in per unit costs reported on claims across hospitals. In addition, the commenter believed that the number of claims and the number of hospitals submitting data for cesium-131 sources are too low to be the basis of appropriate payment rates for CY 2008. The commenter also indicated that it has submitted a request for a new code for high activity cesium-131 to be effective for separate payment as of January 1, 2008.

Response: We disagree that the number of cesium claims is too low and the variability is too high to proceed with prospective payment for cesium sources. Our CY 2006 claims data used for the proposed rule included 7,435 sources and our final rule claims data include 8,652 cesium sources. The modest variability of costs observed on claims for cesium-131 is similar to the variability we observe for other items and services under the OPPS. We expect that some of the cost differences associated with claims for the single HCPCS code for cesium-131 sources reported in CY 2006 may be associated with the use of stranded versus non-stranded sources, and we have accounted for that potential variation through our proposal to utilize the 40th and 60th percentiles of aggregate cost data for the single source code for ratesetting for non-stranded and stranded sources, respectively.

We note that we have received a request for a new code for separate payment of high activity cesium-131 sources and are currently evaluating that request.

Comment: A number of comments expressed varying opinions concerning the proposed payment methodology for stranded versus non-stranded sources for iodine-125, palladium-103, and cesium-131 sources. Some commenters explained that the CY 2006 claims data do not distinguish between stranded and non-stranded devices, and that no meaningful data exist to support CMS' assumptions underpinning the payment proposal for stranded and non-stranded sources. They asserted that CMS' reasoning that these assumptions appear to provide a reasonable cost differential between stranded and non-stranded sources is not supported by data and is

merely guesswork. Therefore, these commenters recommended that CMS not establish prospective payment rates for stranded and non-stranded configurations, especially when appropriate specific codes are now in place to collect data on these sources. The commenters also doubted that the assumptions CMS made should apply equally to the three isotopes with stranded and non-stranded configurations (iodine, palladium, and cesium). Those commenters recommended that CMS continue to pay for stranded and non-stranded sources based on charges adjusted to cost until accurate data are collected and available for ratesetting.

Several commenters specifically urged CMS not to modify the proposed payment rates based on "anecdotal comments that the Agency may receive" regarding stranded versus non-stranded sources. They believed that CMS should wait until a "comprehensive database" of accurate data is available. Many of these commenters generally recommended that not only should CMS pay for stranded and non-stranded brachytherapy sources based on charges adjusted to cost until robust data on the different costs of these sources are available, but that CMS should provide payment for all brachytherapy sources using the same cost-based methodology in CY 2008.

One commenter claimed that CMS does not have meaningful data for stranded and high activity cesium-131 to establish prospective payment levels. The commenter also stated that the stranded versus non-stranded cost estimate for cesium does not reflect the fact that this cost differential can vary significantly based on the radioactive half-life of the source, which is significant for cesium-131. In addition, the commenter explained that cesium decays at the rate of 7 percent per day and thus the cost differential between its loose seed and stranded seed configurations would not be consistent with the cost differential for stranded and non-stranded iodine and palladium sources, which also have different decay rates. The commenter believed that using the same cost assumptions for all sources would have a significant negative impact on the payment for brachytherapy sources and argued that the impact on cesium sources would be disproportionate in comparison to other sources, due to the radioactive isotope half-life alone.

This commenter offered information as to the actual cost differential between stranded and non-stranded sources, a specific request that was made of the public in the proposed rule. This

commenter stated that the cost of non-stranded cesium sources was \$61 to \$75 per source, and of stranded cesium sources, \$82 to \$94 per source, in comparison with proposed payment rates of approximately \$51 and \$97, respectively. Therefore, the commenter concluded that the proposed payment rates would provide a disincentive to utilize non-stranded cesium relative to stranded cesium sources, encouraging a shift of usage to stranded cesium sources. The commenter believed that CMS should not rush to establish prospective payment rates for stranded and non stranded cesium sources, especially when newly established specific source codes are now available.

Response: We agree with the commenters that our CY 2006 claims data do not differentiate between stranded and non-stranded sources, as we explained in the proposed rule. We proposed to apply certain assumptions that would allow us to make prospective payment for these sources while our newly established codes (as of July 1, 2007) would allow us to collect specific stranded and non-stranded cost data. In the CY 2008 OPPS/ASC proposed rule, we reiterated our intent that the proposed payment methodology for stranded and non-stranded sources would be a temporary payment methodology, and that we would use the newly established codes to collect differential cost data for stranded and non-stranded sources for future use.

While some commenters urged us not to modify the proposed payment levels based on "anecdotal comments that the Agency may receive," many of those same commenters provided only anecdotal claims that the proposed payment levels are inappropriate and not based on meaningful data. Additionally, such commenters did not specifically define what they would consider to be a comprehensive database. Of note, for many of the brachytherapy sources without stranded configurations, we have a significant volume of claims that have demonstrated consistent hospital costs over the last several years, and our claims data for these sources is directly applicable to the currently reported HCPCS codes.

We thank the commenter for reporting invoice cost data on stranded versus non-stranded cesium sources. We have received no information on the cost differential between stranded versus

non-stranded sources in previous comments or correspondence. We note that the median cost based on the 40th percentile for non-stranded cesium sources for this final rule with comment period is \$63, increased from the proposed \$51 based on proposed rule data, while the final rule 60th percentile for stranded cesium sources is \$97, consistent with both the proposed and final rule data. Therefore, for the only case in which we received information from the public regarding the costs of stranded and non-stranded sources, the final rule 40th and 60th percentiles of aggregate source data are aligned with the cost information provided by the commenter for the two source configurations. While this limited comparison with external data does not allow us to draw definitive conclusions, it provides validation of our proposal to base the payment for stranded versus non-stranded cesium sources on the 60th versus 40th cost percentile from the source's aggregate CY 2006 claims data.

Comment: Other commenters were generally supportive of prospective payment of stranded and non-stranded iodine, palladium, and cesium sources, as well as other brachytherapy sources. Some of these commenters believed, however, that the payment differential for stranded versus non-stranded sources that resulted from our methodology to use the 60th percentile cost for stranded and the 40th percentile cost for non-stranded sources was too great. The likely result, one commenter explained, was to encourage the use of stranded sources for financial rather than clinical reasons. One commenter pointed out that while the payment differential might not appear to be significant on a per source basis, when the number of sources per procedure is considered (for example, 50–100 sources), the cost difference to providers would be significant. Another commenter asserted that all seed-type sources are essentially the same and that any price differential between stranded and non-stranded sources is a result of a successful marketing strategy by stranded source manufacturers, creating a price differential between stranded and non stranded sources as a result of customer loyalty to specific products with certain features that were initially provided at no additional cost.

Response: Prospective payment rates under the OPPS are based on the

median cost for each APC from historical hospital claims, with trimming of claims data only at those extremes to eliminate those claims of exceptionally high or low cost from contributing to APC median cost development. The statute requires us to pay for stranded and non-stranded sources through different payment groups. As stated earlier, our proposal to pay at the 40th and 60th cost percentiles of aggregate data for the predecessor HCPCS codes for the three products with two clinical configurations is a temporary payment methodology that would provide appropriate prospective payment for these sources until more specific claims data are available. We note that partial year data will be available for CY 2009 ratesetting purposes. Information on the costs of stranded and non-stranded configurations of one source is consistent with our proposed costs for the two configurations. Therefore, we believe that our proposed assumptions about the distribution of non-stranded and stranded source costs in the CY 2006 aggregate data are reasonable and consistent with the standard OPPS ratesetting methodology, until more specific data become available. We do not believe, based on our claims data and review of public comments, that delaying implementation of prospective payment for any brachytherapy sources while we are waiting for more detailed cost information is reasonable. Coding changes occur on a regular basis, and we routinely account for them by crosswalking historical claims data from predecessor HCPCS codes to the newly available codes for purposes of payment.

After consideration of the public comments received, we are finalizing our proposal, without modification, to pay brachytherapy sources prospectively for CY 2008, based on median costs from our CY 2006 claims data. For stranded sources, that median cost is set at the 60th percentile of the aggregate claims data for the predecessor code for this source, and for non-stranded sources, that median cost is set at the 40th percentile of the aggregate claims data for the predecessor code for this source. The final brachytherapy source HCPCS codes, APC assignments, status indicators, and median costs are displayed in Table 37 below.

TABLE 37.—SEPARATELY PAYABLE BRACHYTHERAPY SOURCES

HCPCS code	Long descriptor	APC	CY 2008 median cost	CY 2008 status indicator
A9527	Iodine I-125, sodium iodide solution, therapeutic, per millicurie	2632	\$27	K
C1716	Brachytherapy source, non-stranded, Gold-198, per source	1716	33	K
C1717	Brachytherapy source, non-stranded, High Dose Rate Iridium-192, per source	1717	173	K
C1719	Brachytherapy source, non-stranded, Non-High Dose Rate Iridium-192, per source	1719	64	K
C2616	Brachytherapy source, non-stranded, Yttrium-90, per source	2616	11,621	K
C2634	Brachytherapy source, non-stranded, High Activity, Iodine-125, greater than 1.01 mCi (NIST), per source.	2634	31	K
C2635	Brachytherapy source, non-stranded, High Activity, Palladium-103, greater than 2.2 mCi (NIST), per source.	2635	46	K
C2636	Brachytherapy linear source, non-stranded, Palladium-103, per 1MM	2636	42	K
C2637	Brachytherapy source, non-stranded, Ytterbium-169, per source	2637	N/A	B
C2638	Brachytherapy source, stranded, Iodine-125, per source	2638	*45	K
C2639	Brachytherapy source, non-stranded, Iodine-125, per source	2639	**32	K
C2640	Brachytherapy source, stranded, Palladium-103, per source	2640	*65	K
C2641	Brachytherapy source, non-stranded, Palladium-103, per source	2641	**51	K
C2642	Brachytherapy source, stranded, Cesium-131, per source	2642	*97	K
C2643	Brachytherapy source, non-stranded, Cesium-131, per source	2643	**63	K
C2698	Brachytherapy source, stranded, not otherwise specified, per source	2698	45	K
C2699	Brachytherapy source, non-stranded, not otherwise specified, per source	2699	31	K

* Estimated median cost for stranded version is based on the 60th percentile of the aggregate (stranded and non-stranded) claims data for this source.

** Estimated median cost for non-stranded version is based on the 40th percentile of the aggregate (stranded and non-stranded) claims data for this source.

Furthermore, we proposed to pay the two NOS codes, C2698 and C2699, based on a rate equal to the lowest stranded or non-stranded prospective payment rate for such sources, respectively, on a per source basis (as opposed, for example, to per mCi). This proposed payment methodology for NOS sources would provide payment to a hospital for new sources, while encouraging interested parties to quickly bring new sources to our attention so specific coding and payment could be established. As explained earlier, we may establish new brachytherapy source codes on a quarterly basis.

Comment: Some commenters recommended that CMS pay for all brachytherapy sources at charges adjusted to cost, including new sources. One commenter commended CMS for establishing two NOS codes for billing stranded and non-stranded sources, C2698 and C2699, until specific coding for new sources can be established.

Response: As discussed earlier in this final rule with comment period, we are finalizing our proposal to pay for specific brachytherapy sources prospectively based on median costs from claims. We also believe it is most appropriate to pay for new brachytherapy sources based on specific codes that reflect the number, radioisotope, radioactive intensity, and stranded or non-stranded configurations of those sources. Furthermore, we may establish new source codes on a quarterly basis to permit separate

reporting of new sources. No commenters recommended an alternative prospective payment methodology for NOS source codes. It is most consistent with our payment policy for other NOS services under the OPSS to pay for NOS brachytherapy source codes at the same payment rate as the lowest level clinically related APC. In the case of these NOS sources that would be paid through their own APCs, we continue to believe it is most appropriate to pay for them at the lowest stranded or non-stranded brachytherapy source payment rate, as applicable to each NOS code. This payment policy should encourage prompt requests for more specific Level II HCPCS codes for new brachytherapy sources to ensure more accurate payment for those new sources.

After consideration of the public comments received, we are finalizing our proposal, without modification, to pay for the two NOS codes, C2698 and C2699, based on a rate equal to the lowest stranded or non-stranded prospective payment rate for such sources, respectively, on a per source basis. For CY 2008, C2698 for unspecified stranded sources will be paid at the same rate as C2638 (Brachytherapy source, stranded, Iodine-125, per source) and C2699 will be paid at the same rate as C2634 (Brachytherapy source, non-stranded, High Activity, Iodine-125, greater than 1.01 mCi (NIST), per source).

Because brachytherapy sources will no longer be paid on the basis of their

charges adjusted to cost after December 31, 2007, we proposed to discontinue our use of payment status indicator "H" for APCs assigned to brachytherapy sources. For CY 2008, we proposed to use status indicator "K" for all brachytherapy source APCs. As described earlier, the definition of status indicator "K" was changed for CY 2007 to accommodate prospective payment for brachytherapy sources.

We received no comments specific to the proposal to change the status indicator for brachytherapy source APCs. Therefore, we are finalizing our proposal, without modification, to use status indicator "K" for all brachytherapy source APCs for CY 2008.

For CY 2008, we also proposed to implement the policy we established in the CY 2007 OPSS/ASC final rule with comment period (which was superseded by section 107 of the MIEA-TRHCA) regarding payment for new brachytherapy sources for which we have no claims data. As discussed earlier, we proposed to assign future new HCPCS codes for new brachytherapy sources to their own APCs, with prospective payment rates set based on our consideration of external data and other relevant information regarding the expected costs of the sources to hospitals. Because we proposed to pay prospectively for brachytherapy sources beginning in CY 2008, we proposed to implement this policy beginning in CY 2008.

In the CY 2008 proposed rule (72 FR 42749), we pointed out that there is currently one brachytherapy source, ytterbium-169 (HCPCS code C2637, Brachytherapy source, ytterbium-169, per source), which has its own HCPCS code, but for which we believed we lacked claims data on its costs. In the CY 2007 OPPS/ASC proposed rule (71 FR 49598 through 49599), we explained that it was our understanding that ytterbium-169 had not yet been marketed, and furthermore that we had no CY 2005 claims data, external data, or other information on its pricing on which to base its payment rate for CY 2007. In response to the CY 2007 proposed rule, we received no cost data or other information that we could use to establish an informed prospective payment rate for ytterbium-169. Therefore, in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68112), we finalized a policy of assigning HCPCS code C2637 the nonpayable status indicator "B" and indicated that if we later received relevant information, we could establish a payable status indicator and appropriate payment rate for the ytterbium source in a future OPPS quarterly update. This policy was superseded by section 107(a) of the MIEA-TRHCA, which required payment for brachytherapy sources in CY 2007 based on charges adjusted to cost. For the CY 2008 proposed rule, we believed that we continued to lack claims data or other information on the costs of ytterbium-169 on which to base an informed prospective payment rate. We noted that our CY 2006 claims data showed three claims for HCPCS code C2637. We believed these three CY 2006 claims may have been incorrectly coded claims that did not represent claims for ytterbium, as its manufacturer commented on the CY 2007 OPPS proposed rule that ytterbium-169 would first become available for market in CY 2007. Consequently, for CY 2008 we again proposed to not recognize HCPCS code C2637 and to assign it status indicator "B" under the OPPS. However, as indicated in the proposed rule, if in public comments to the proposed rule or later in CYs 2007 or 2008, we would receive relevant and reliable information on the hospital cost for ytterbium-169 and information that this source is being marketed, we could establish a prospective payment rate for the source in the CY 2008 final rule with comment period or in a quarterly OPPS update, respectively (72 FR 42749).

Comment: A few commenters recommended that CMS continue to pay

for new brachytherapy sources (as well as established sources when there are no reliable claims-based cost data) at charges adjusted to cost, rather than adopting the proposed methodology of using external data and other relevant cost data on the expected cost to hospitals.

Response: As with other brachytherapy sources and other services under the OPPS, the development of cost data for new services through our claims data is an ongoing process. We regularly price new services, placing them in what we consider to be appropriate New Technology or clinical APCs. We make ongoing adjustments to their assignments as necessary, depending on information and data we develop or receive from interested stakeholders. We do not feel that initially having no or small amounts of Medicare claims data for new brachytherapy sources or established sources with lower volumes than other sources in our claims data is a compelling argument to deviate from our prospective payment methodology and pay for some sources at charges adjusted to cost while others would be paid prospectively based on their median cost. We note that we had no additional claims for ytterbium-169 for this final rule with comment period, beyond the three likely incorrectly coded CY 2006 claims discussed in the proposed rule.

After consideration of the public comments received, we are finalizing our proposal, without modification, to assign future new HCPCS codes for new brachytherapy sources to their own APCs, with prospective payment rates set based on our consideration of external data and other relevant information regarding the expected costs of the sources to hospitals. This policy will apply to the existing HCPCS code C2637 for the ytterbium-169 source, as well, which is assigned status indicator "B" in Addendum B to this final rule with comment period. We received no additional information on this source in comments to the CY 2008 proposed rule. In the event that we receive information regarding the costs and current marketing of HCPCS code C2637, we will consider changing its status indicator to "K" in a quarterly OPPS update and setting a prospective payment rate for this source.

Comment: Several commenters requested that CMS implement the APC Panel's March 2007 recommendation to edit and return for correction claims that contain a HCPCS code for a separately paid drug or device without a HCPCS code assigned to a procedural APC.

Response: We note that brachytherapy treatment services are paid separately from brachytherapy sources and do not have the costs of the brachytherapy sources packaged into the payment for the associated treatment services. While we encourage hospitals to code correctly in accordance with all CPT, CMS, and local contractor guidance, in general we have historically implemented claims processing edits under the OPPS when we believe that these edits help ensure complete claims data for ratesetting. In the case of OCE edits for drugs and devices, including brachytherapy sources, which are separately paid, it is unclear to us that these edits would improve our claims data for median cost calculation because the items receive separate payment and do not result in multiple procedure claims when they are reported. We also understand that there may be some clinical or operational circumstances that could result in a hospital submitting an OPPS claim that only reported a separately paid drug or device, and we would not want to delay a hospital's ability to submit a claim timely because of claims edits that do not have the potential to improve the accuracy of OPPS ratesetting. Therefore, we are not adopting this APC Panel recommendation for broad claims processing edits.

Comment: A few commenters recommended that CMS revise the definition of brachytherapy sources to include all "brachytherapy sources," without limitation to a device of brachytherapy.

Response: We finalized our definition of a source of brachytherapy in the CY 2007 final rule with comment period (71 FR 68113) in the context of current medical practice and with regard to the statutory language. We considered all comments, including some of the same arguments presented in comments to the CY 2008 proposed rule. We made no proposal to change this definition in our CY 2008 proposed rule and are not considering any changes to the established definition at this time.

Comment: One commenter opposed the proposal to include the costs of brachytherapy sources in the budget neutrality formula, if CMS adopted the proposal to pay for the sources on a prospective basis. The commenter believed that brachytherapy treatment is very costly and inclusion of the costs would decrease the payment for other OPPS services. The commenter also claimed that CMS has not factored into payment for brachytherapy treatment the special handling costs of radioactive materials.

Response: We take into account the estimated costs of brachytherapy sources under the methodology of charges adjusted to cost in calculating budget neutrality for the OPSS and have continued to do so under the prospective payment methodology for the sources that we are finalizing for CY 2008. The costs related to supervision, handling, and loading of brachytherapy sources are, in fact, also considered under the OPSS. As we have previously instructed, these costs are to be included by hospitals on claims in one of two ways, either reported as a separate charge using CPT code 77790 (Supervision, handling, loading of radiation source) or included in the charge reported with the HCPCS procedure code(s) for application of the radiation source. Reporting in either of these ways results in the costs of special handling being packaged into payments for brachytherapy treatment procedures.

VIII. OPSS Drug Administration Coding and Payment

A. Background

From the start of the OPSS until the end of CY 2004, three HCPCS codes were used to bill drug administration services provided in the hospital outpatient department (HOPD):

- Q0081 (Infusion therapy, using other than chemotherapeutic drugs, per visit)
- Q0083 (Chemotherapy administration by other than infusion technique only, (EG subcutaneous, Intramuscular, Push), per visit)
- Q0084 (Chemotherapy administration by infusion technique only, per visit).

A fourth OPSS drug administration HCPCS code, Q0085 (Administration of chemotherapy by both infusion and another route, per visit), was active from the beginning of the OPSS through the end of CY 2003.

Each of these four HCPCS codes mapped to an APC (that is, Q0081 mapped to APC 0120, Q0083 mapped to APC 0116, Q0084 mapped to APC 0117, and Q0085 mapped to APC 0118), and the APC payment rates for these codes were made on a per-visit basis. The per-visit payment included payment for all hospital resources (except separately payable drugs) associated with the drug administration procedures. For CY 2004, we discontinued using HCPCS code Q0085 to identify drug administration services and moved to a combination of HCPCS codes Q0083 and Q0084 that allowed more accurate calculations when determining OPSS payment rates.

In CY 2005, in response to the recommendations made by commenters and the hospital industry, OPSS transitioned to the use of CPT codes for drug administration services. These CPT codes allowed for more specific reporting of services, especially regarding the number of hours for an infusion, and provided consistency in coding between Medicare and other payers. However, at that time, we did not have any data to revise the CY 2005 per-visit APC payment structure for infusion services. In order to collect data for future ratesetting purposes, we implemented claims processing logic that collapsed payments for drug administration services and paid a single APC amount for those services for each visit, unless a modifier was used to identify drug administration services provided in a separate encounter on the same day. Hospitals were instructed to bill all applicable CPT codes for drug administration services provided in a HOPD, without regard to whether or not the CPT code would receive a separate APC payment during OPSS claims processing.

While hospitals just began adopting CPT codes for outpatient drug administration services in CY 2005, physicians paid under the MPFS were using HCPCS G-codes in CY 2005 to report office-based drug administration services. These G-codes were developed in anticipation of substantial revisions to the drug administration CPT codes by the CPT Editorial Panel that were expected for CY 2006.

In CY 2006, as anticipated, the CPT Editorial Panel revised its coding structure for drug administration services, incorporating new concepts such as initial, sequential, and concurrent services into a structure that previously distinguished services based on type of administration (chemotherapy/nonchemotherapy), method of administration (injection/infusion/push), and for infusion services, first hour and additional hours. For CY 2006, we implemented 20 of the 33 CY 2006 drug administration CPT codes that did not reflect the concepts of initial, sequential, and concurrent services, and we created 6 new HCPCS C-codes that generally paralleled the CY 2005 CPT codes for the same services. We chose not to implement the full set of CY 2006 CPT codes because of our concerns regarding the interface between the complex claims processing logic required for correct payments and hospitals' challenges in correctly coding their claims to receive accurate payments for these services.

For CY 2007, as a result of comments to our proposed rule and feedback from

the hospital community and the APC Panel, we implemented the full set of CPT codes, including the concepts of initial, sequential and concurrent. In addition, the CY 2007 update process offered us the first opportunity to consider data gathered from the use of CY 2005 CPT codes for purposes of ratesetting. For CY 2007, we used CY 2005 claims data to implement a six-level APC structure for drug administration services. We assigned all CY 2007 HCPCS codes for drug administration services to six new drug administration APCs (as listed in Table 34 of the CY 2007 OPSS/ASC final rule with comment period), with payment rates based on median costs for the APCs as calculated from CY 2005 claims data. In that final rule with comment period, we provided a crosswalk that illustrated how we performed our annual payment rate update methodology for these services using CY 2005 data.

As indicated in the CY 2007 OPSS/ASC final rule with comment period (71 FR 68122), because the newly recognized CPT codes discriminated among services more specifically than the CY 2006 C-codes, as was the case when the OPSS transitioned from more general Q-codes to more specific CPT codes for the reporting of drug administration services in CY 2005, for a period of 2 years drug administration services were paid based on the costs of their predecessor HCPCS codes until updated data were available for review.

B. Coding and Payment for Drug Administration Services

During the March 2007 APC Panel meeting, the APC Panel recommended that CMS pay separately for CPT code 90768 (Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (list separately in addition to code for primary procedure)) at the same rate as CPT code 90767 (Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion, up to 1 hour (list separately in addition to code for primary procedure)). We proposed to continue to package payment for CPT code 90768 for CY 2008.

Comment: In addition to the APC Panel's recommendation to unpackage CPT code 90768, a few commenters also requested that CMS provide separate payment for it in CY 2008.

Response: As we discuss in section II.A.4.e. of this final rule with comment period, in deciding whether to package a service or pay for it separately, we consider a variety of factors, including

whether the service is normally provided separately or in conjunction with other services; how likely it is for the costs of the packaged code to be appropriately mapped to the separately payable codes with which it was performed; and whether the expected cost of the service is relatively low. CPT code 90768, by definition, is always provided in association with other intravenous infusions. As we discussed in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68122), CPT code 90768 was first introduced in the CY 2007 OPPS and, consistent with our established ratesetting methodology, we do not anticipate OPPS hospital claims data from CY 2007 to be available for ratesetting purposes until CY 2009. In addition, as noted in the CY 2008 OPPS/ASC proposed rule (72 FR 42751), because the services identified with CPT code 90768 were provided in previous years, we determined that these costs are already represented in our currently available hospital claims data. Payment for these services was provided in previous years through the billing of more general drug administration codes. Although more exhaustive codes for drug administration services are now available, all of these services were paid under the OPPS in previous years.

As data are not available for all current CPT codes for drug administration services for purposes of CY 2008 ratesetting, and as we believe that the costs for the drug administration services identified by CPT code 90768 are included in our hospital claims data used for ratesetting purposes, we are not accepting the APC Panel's recommendation nor the commenters' request to provide a separate APC payment for this service. Furthermore, we describe in section II.A.4. of this final rule with comment period our CY 2008 packaging approach for certain (non-drug administration) services. We believe that continuing to package payment for CPT code 90768 is consistent with these broader efforts. Therefore, we are finalizing our proposal to assign status indicator "N" to CPT code 90768 for CY 2008.

For CY 2008, we examined CY 2006 claims data available for the proposed rule and continued to believe the CY 2007 drug administration APC configuration reflects clinical and resource homogeneous groupings of procedures. We noted in the proposed rule (72 FR 42751) that there is a violation of the 2 times rule in APC 0438 (Level III Drug Administration) as proposed for CY 2008. (For additional information on the 2 times rule, we refer readers to section III.B. of this final rule

with comment period.) For this CY 2008 OPPS/ASC final rule with comment period, this 2 times violation continues to exist based upon updated data. The violation is related to the comparatively low median cost of CPT code 90773 (Therapeutic, prophylactic or diagnostic injection (specify substance or drug); intra-arterial) for which we have a significantly greater number of CY 2006 single claims available for ratesetting than in previous years. The CY 2005 predecessor code for this service, CPT code 90783 (Therapeutic, prophylactic or diagnostic injection (specify material injected); intra-arterial), had a higher median cost that was more similar to the costs of other services also assigned to APC 0438. We continue to believe that this intra arterial injection procedure is similar from both clinical and hospital resource perspectives to the related intravenous push injection procedures that are assigned to the same clinical APC and, therefore, we proposed to except APC 0438 from the 2 times rule for CY 2008.

We did not receive any public comments on this proposal. Therefore, for CY 2008, we are finalizing our proposed exception to the 2 times rule for APC 0438, without modification.

In the proposed rule, we also continued to ask hospitals to report all CPT drug administration codes, and indicated that we expect hospitals to report CPT codes consistently with CPT coding guidelines and applicable instructions.

Comment: Several commenters expressed appreciation for CMS' proposal to continue the CPT coding structure for drug administration services for CY 2008. These commenters noted that the changes made to coding and payment for these services in past years has put a burden on hospitals to train staff on frequent changes. Other commenters expressed frustration over complex CPT coding for drug administration services, noting that reporting requirements placed an unreasonable burden on hospitals to code correctly and increased hospital staffing needs. One commenter suggested that CMS return to simpler coding, such as the historical single per-episode-of-care code to report a "nonchemotherapy infusion." The commenter noted that this methodology aligns with CMS' efforts to increase packaging for services and simplifies hospital coding requirements.

Response: We appreciate hospitals' continuing efforts to work with us to implement changes to drug administration coding and payment over the past few years. We believe that our individual and collaborative efforts

to refine the codes used and ensure their accurate reporting have led to a robust dataset that accurately reflects hospital outpatient costs for these common services and results in appropriate payment. We understand that it requires significant hospital resources to ensure proper coding for drug administration services, and hospitals have worked diligently over the past several years to ensure that CMS' data appropriately reflect drug administration services provided in the HOPD. While we recognize the continued efforts that are necessary to accurately document and report drug administration services using CPT codes, we believe that hospitals have had sufficient experience with these codes, first for non Medicare insurers in CY 2006 and then for the Medicare OPPS in CY 2007, that the initial confusion corresponding to the new concepts of "initial," "sequential," and "concurrent" has subsided.

We agree with the commenter that a return to a single episode-of-care payment could align with the OPPS shift toward larger payment bundles, but we believe that a change in our approach toward drug administration payment would be premature at this time. While additional packaging for drug administration services could be warranted in a prospective payment system such as the OPPS in a movement toward encounter-based or episode-based payment, hospital stakeholders continue to express their preference for a single set of drug administration codes for use by all insurers. Currently, the CPT drug administration codes sufficiently meet the needs of non-Medicare insurers and Medicare. We do not have any reason to believe that hospitals generally would want to implement a per-episode-of-care set of drug administration codes for use only under the OPPS, nor do we have an operational need for such codes. Therefore, we are finalizing our proposal, without modification, to recognize all active CY 2008 CPT codes for drug administration services under the CY 2008 OPPS.

Comment: One commenter requested that CMS review payment methodologies for drug administration services across the hospital outpatient and physician's office settings. This commenter suggested that the OPPS consider implementing a methodology similar to the physician's office payment methodology, basing payment rates on the time and resource utilization required by the service. The commenter believed that standardizing payment rates across sites of care would eliminate site of service differentials

and allow beneficiaries the option of receiving care in either setting.

Response: We understand that the commenter is concerned about differences in payment methodologies and rates across ambulatory settings when some of the same services are provided to Medicare beneficiaries. Even though both settings use the standard CPT codeset for drug administration services, the costs of providing these services in one setting may not be the same as the costs in another setting. The OPSS and the MPFS are fundamentally different payment systems with essential differences in their payment policies. Specifically, the OPSS is a prospective payment system, based on the concept of paying for groups of services that share clinical and resource characteristics. Payment is made under the OPSS according to prospectively established payment rates that are related to the relative costs of hospital resources for services, as calculated from claims data and Medicare cost reports. The MPFS is a fee schedule that generally provides separate payment for each individual component of a service, reflecting the expected typical inputs into these services. The OPSS methodology allows hospitals to

actively contribute on an ongoing basis to the ratesetting process through its annual updates and to influence future payment rates for services by submitting correctly coded and accurately priced claims for the services they provide.

Comment: A few commenters recommended that CMS create two new Level II HCPCS codes for IVIG infusion services, one for the first hour and the other for additional hours of infusion. The commenter cited additional complexities associated with IVIG infusion and increased chances of adverse events that are not fully captured in the CPT codes currently reported by hospitals for these infusions.

Response: While we acknowledge these concerns regarding IVIG administration, we believe that the current CPT coding structure and OPSS payment rates adequately provide for the possible complexities associated with IVIG administration services. Hospital costs for IVIG administration are taken into account during the ratesetting process, as claims for IVIG administration are used in that process for the pertinent CPT codes. Hospitals continue to note their strong preference for reporting CPT codes for drug administration services, as opposed to

OPSS-specific Level II HCPCS codes that could be more specifically developed for certain services. In addition, in view of the shift toward larger payment bundles under the OPSS, we do not believe it would be appropriate to create even more specific coding for drug administration services than is available through the codeset developed by the CPT Editorial Panel.

As stated earlier, after consideration of the public comment received, we are finalizing our proposal, without modification, to recognize all active CY 2008 CPT codes for drug administration services under the OPSS for CY 2008. In addition, we are finalizing our proposal, without modification, to assign status indicator “N” to CPT code 90768 for CY 2008.

IX. Hospital Coding and Payments for Visits

A. Background

Currently, CMS instructs hospitals to use the CY 2007 CPT codes, as well as six HCPCS codes that became effective January 1, 2007, to report clinic and emergency department visits, and critical care services on claims paid under the OPSS. The codes are listed below in Table 38. These codes are unchanged for CY 2008.

TABLE 38.—CY 2007 CPT EVALUATION AND MANAGEMENT (E/M) AND LEVEL II HCPCS CODES USED TO REPORT CLINIC AND EMERGENCY DEPARTMENT VISITS

HCPCS code	Descriptor
Clinic Visit HCPCS Codes	
99201	Office or other outpatient visit for the evaluation and management of a new patient (Level 1).
99202	Office or other outpatient visit for the evaluation and management of a new patient (Level 2).
99203	Office or other outpatient visit for the evaluation and management of a new patient (Level 3).
99204	Office or other outpatient visit for the evaluation and management of a new patient (Level 4).
99205	Office or other outpatient visit for the evaluation and management of a new patient (Level 5).
99211	Office or other outpatient visit for the evaluation and management of an established patient (Level 1).
99212	Office or other outpatient visit for the evaluation and management of an established patient (Level 2).
99213	Office or other outpatient visit for the evaluation and management of an established patient (Level 3).
99214	Office or other outpatient visit for the evaluation and management of an established patient (Level 4).
99215	Office or other outpatient visit for the evaluation and management of an established patient (Level 5).
99241	Office consultation for a new or established patient (Level 1).
99242	Office consultation for a new or established patient (Level 2).
99243	Office consultation for a new or established patient (Level 3).
99244	Office consultation for a new or established patient (Level 4).
99245	Office consultation for a new or established patient (Level 5).
Emergency Department Visit HCPCS Codes	
99281	Emergency department visit for the evaluation and management of a patient (Level 1).
99282	Emergency department visit for the evaluation and management of a patient (Level 2).
99283	Emergency department visit for the evaluation and management of a patient (Level 3).
99284	Emergency department visit for the evaluation and management of a patient (Level 4).
99285	Emergency department visit for the evaluation and management of a patient (Level 5).
G0380	Type B emergency department visit (Level 1).
G0381	Type B emergency department visit (Level 2).
G0382	Type B emergency department visit (Level 3).
G0383	Type B emergency department visit (Level 4).
G0384	Type B emergency department visit (Level 5).

TABLE 38.—CY 2007 CPT EVALUATION AND MANAGEMENT (E/M) AND LEVEL II HCPCS CODES USED TO REPORT CLINIC AND EMERGENCY DEPARTMENT VISITS—Continued

HCPCS code	Descriptor
Critical Care Services HCPCS Codes	
99291	Critical care, evaluation and management of the critically ill or critically injured patient; first 30–74 minutes.
99292	Each additional 30 minutes.
G0390	Trauma response associated with hospital critical care services.

Presently, there are three types of visit codes to describe three types of services: clinic visits, emergency department visits, and critical care services. CPT indicates that office or other outpatient visit codes are used to report E/M services provided in the physician’s office or in an outpatient or other ambulatory facility. For OPSS purposes, we refer to these as clinic visit codes. CPT also indicates that emergency department visit codes are used to report E/M services provided in the emergency department, defined as an “organized hospital-based facility for the provision of unscheduled episodic services to patients who present for immediate medical attention. The facility must be available 24 hours a day.” For OPSS purposes, we refer to these as emergency department visit codes that specifically apply to the reporting of visits to Type A emergency departments on or after January 1, 2007, as discussed in further detail later in this section. We established five new Level II HCPCS codes to report visits to Type B emergency departments beginning in CY 2007 because there were no CPT codes at that time that fully described services provided in this type of facility. CPT defines critical care services as the “direct delivery by a physician(s) of medical care for a critically ill or critically injured patient.” It also states that “critical care is usually, but not always, given in a critical care area, such as . . . the emergency care facility.” In addition to reporting critical care services, hospitals may utilize G0390 (Trauma response team associated with hospital critical care service) for the reporting of a trauma response in association with critical care services.

The majority of CPT code descriptors are applicable to both physician and facility resources associated with specific services. However, we have acknowledged from the beginning of the OPSS that we believe that CPT E/M codes were defined to reflect the activities of physicians and do not necessarily fully describe the range and mix of services provided by hospitals during visits of clinic and emergency department patients and critical care

encounters. In the April 7, 2000 OPSS final rule with comment period (65 FR 18434), we instructed hospitals to report facility resources for clinic and emergency department visits using CPT E/M codes, and to develop internal hospital guidelines to determine what level of visit to report for each patient. While awaiting the development of a national set of facility-specific codes and guidelines, we have advised hospitals that each hospital’s internal guidelines should follow the intent of the CPT code descriptors, in that the guidelines should be designed to reasonably relate the intensity of hospital resources to the different levels of effort represented by the codes.

Critical care services are considered to be outpatient visits, and our current payment policy for trauma activation ties separate payment to the reporting of hospital critical care services. In the CY 2008 OPSS/ASC proposed rule, we did not propose to change our OPSS payment policy for critical care services for CY 2008. Our CY 2008 proposed and final policies for payment for trauma activation are described in section II.A.4. of this final rule with comment period.

B. Policies for Hospital Outpatient Visits

1. Clinic Visits: New and Established Patient Visits and Consultations

As discussed earlier, the majority of all CPT code descriptors are applicable to both physician and facility resources associated with specific services. However, we believe that CPT E/M codes were defined to reflect the activities of physicians, and do not fully describe the range and mix of services provided by hospitals during visits of clinic and emergency department patients. While awaiting the development of a national set of guidelines, we have advised hospitals that each hospital’s internal guidelines should follow the intent of the CPT code descriptors, in that the guidelines should be designed to reasonably relate the intensity of hospital resources to the different levels of effort represented by the codes. In the CY 2007 OPSS/ASC proposed rule (71 FR 49607), we

proposed to establish five new codes to replace hospitals’ reporting of the CPT clinic visit E/M codes for new and established patients listed earlier in Table 38. In the CY 2007 OPSS/ASC final rule with comment period (71 FR 68127 through 68128), we specified that we would not create new codes to replace existing CPT E/M codes for reporting hospital visits until national guidelines were developed, in response to commenters who were concerned about implementing hospital-specific Level II HCPCS codes without national guidelines. We also discussed our intention to reconsider whether G-codes would be appropriate for the OPSS once national guidelines were established.

In that same CY 2007 final rule with comment period (71 FR 68138), we finalized our proposal to make payment for clinic visits at five payment rates, rather than three payment rates. Prior to CY 2007, under the OPSS, outpatient visits provided by hospitals were paid at three payment levels for clinic visits, even though hospitals reported five resource-based coding levels of clinic visits using CPT E/M codes. Because the three payment rates for clinic visits were based on five levels of CPT codes, in general the two lowest levels of CPT codes (Levels 1 and 2) were assigned to the low-level visit APC and the two highest levels of CPT codes (Levels 4 and 5) were assigned to the high-level visit APC. The single middle level CPT code (Level 3) was assigned to the mid-level visit APC. Historical hospital claims data have generally reflected significantly different median costs for the two levels of services assigned to the low- and high-level visit APCs. We noted that payment at only three levels might not be the most accurate method of payment for those very common hospital levels of visits that clearly demonstrate differential hospital resources. Consequently, for the CY 2007 OPSS, we mapped the data from the CY 2005 CPT E/M codes and other HCPCS codes assigned previously to the three clinic visit APCs to five new clinic visit APCs to develop median costs for these APCs. We mapped the CPT E/M codes and other HCPCS codes to the clinic visit APCs based on their median

costs and clinical homogeneity considerations. Table 50 of the CY 2008 OPSS/ASC proposed rule, which is reprinted below as Table 39, includes

the median costs based on CY 2006 claims data processed through December 31, 2006, and displays the proposed HCPCS codes and APC

median costs at the five payment levels that we proposed for the CY 2008 OPSS.

TABLE 39.—PROPOSED RULE ASSIGNMENT OF CLAIMS DATA FROM CY 2006 CPT E/MLEVEL II HCPCS CODES TO VISIT APCs FOR CY 2008

CY 2008 APC title	CY 2008 APC	Proposed CY 2008 APC median	APC service frequency (in millions)	HCPCS code	Short descriptor
Level 1 Hospital Clinic Visits	0604	\$52.72	3.8	92012 99201 99211 99241 G0101 G0245 G0379	Eye exam established pat. Office/outpatient visit, new (Level 1). Office/outpatient visit, est (Level 1). Office consultation (Level 1). CA screen; pelvic/breast exam. Initial foot exam pt lops. Direct admit hospital observ.
Level 2 Hospital Clinic Visits	0605	63.01	7.3	90862 92002 92014 99202 99212 99213 99242 99243 99431 G0246 G0344 M0064	Medication management. Eye exam, new patient Eye exam and treatment. Office/outpatient visit, new (Level 2). Office/outpatient visit, est (Level 2). Office/outpatient visit, est (Level 3). Office Consultation (Level 2). Office Consultation (Level 3). Initial care, normal newborn. Followup eval of foot pt lop. Initial preventive exam. Visit for drug monitoring.
Level 3 Hospital Clinic Visits	0606	85.96	2.9	92004 99203 99214 99244	Eye exam, new patient. Office/outpatient visit, new (Level 3). Office/outpatient visit, est (Level 4). Office consultation (Level 4).
Level 4 Hospital Clinic Visits	0607	108.08	.8	99204 99215 99245	Office/outpatient visit, new (Level 4). Office/outpatient visit, est (Level 5). Office consultation (Level 5).
Level 5 Hospital Clinic Visits	0608	138.88	.08	99205 G0175	Office/outpatient visit, new (Level 5). OPSS service, sched team conf.

In the CY 2007 OPSS/ASC proposed rule (71 FR 49617), we solicited comment as to whether a distinction between new and established visits was necessary because we were planning to transition to G-codes and did not want to unnecessarily create codes for both new and established patients. The AMA defines an established patient as “one who has received professional services from the physician or another physician of the same specialty who belongs to the same group practice, within the past 3 years.” To apply this definition to hospital visits, we stated in the April 7, 2000 OPSS final rule with comment period (65 FR 18451) that the meanings of “new” and “established” pertain to whether or not the patient already has a hospital medical record number. If the patient has a hospital medical record that was created within the past 3 years, that patient is considered an established patient to the hospital. The same patient

could be “new” to the physician but an “established” patient to the hospital. The opposite could be true if the physician has a longstanding relationship with the patient, in which case the patient would be an “established” patient with respect to the physician and a “new” patient with respect to the hospital.

During CY 2006 and earlier, there was no payment difference between new and established patient visits of the same level because both were always mapped to the same clinical APC. However, hospital claims data regarding the median costs of the specific CPT clinic visit E/M codes consistently indicated that new patients were more resource-intensive than established patients across all visit levels. The CY 2006 claims data available for the CY 2008 rulemaking confirmed that the cost difference between new and established

patient visits increases as the visit level increases.

Some commenters who responded to prior OPSS rules have stated that the hospital resources used for new and established patients to provide a specific level of service are very similar, and that it is unnecessary and burdensome from a coding perspective to distinguish between the two types of visits. On the other hand, other commenters have noted, and CY 2005 and CY 2006 claims data have shown, that it may be appropriate to continue using different codes for new and established patients because of the observed median cost differences in the claims data. During the March 2007 APC Panel meeting, the Observation and Visit Subcommittee of the APC Panel discussed whether the coding distinction between new and established patient visits was necessary. Ultimately, the APC Panel

recommended that CMS eliminate the “new” and “established” patient distinctions in the reporting of hospital clinic visits. During its discussion, the APC Panel suggested that hospitals bill the appropriate level clinic visit code according to the resources expended while treating the beneficiary based on each hospital’s internal guidelines. The APC Panel also suggested that each hospital’s internal guidelines reflect resource cost differences (if a difference exists) between new and established patients. For example, a visit that involves certain interventions may be coded as Level 3 for a new patient and Level 2 for an established patient. The APC Panel also made another recommendation, which was contingent upon CMS adopting its recommendation to eliminate the new and established patient distinction reporting requirement. The APC Panel recommended that CMS map each of the five levels of outpatient clinic visit codes (which do not distinguish between new and established patients) to five separate APCs, thereby paying at five payment rates. For example, the APC Panel recommended mapping the Level 1 patient visit to the Level 1 Clinic Visit APC, mapping the Level 2 patient visit to the Level 2 Clinic Visit APC, and

mapping the Level 3 patient visit to the Level 3 Clinic Visit APC. In the CY 2008 proposed clinic visit APC configuration, as indicated in Table 50 of the CY 2008 OPPTS/ASC proposed rule (72 FR 42753), the APC level assignment did not always correspond to the visit level described by each code. For example, CPT code 99213 is a Level 3 clinic visit code for an established patient, which would seem to logically map to the Level 3 Clinic Visit APC. However, because CPT code 99213 had a proposed rule median cost of \$65, we proposed to map this code to the Level 2 Clinic Visit APC, which had a median cost of \$63. The APC Panel indicated that its recommendation would ensure that each visit level would receive its own payment rate, rather than both the Level 2 and 3 patient visit codes receiving the same payment rate.

In both the CY 2007 OPPTS/ASC proposed and final rules (71 FR 49617 and 71 FR 68128, respectively), we solicited public comment on the potential differences in hospital clinic resource consumption between new and established patient visits. We received only a few comments related to this distinction in response to the CY 2007 OPPTS/ASC proposed rule and even fewer comments in response to the CY

2007 OPPTS/ASC final rule with comment period. For CY 2008, because hospitals would be reporting CPT E/M codes which distinguish between new and established patients for clinic visits and because we saw meaningful and consistent cost differences between visits for new and established patients, we proposed to continue to recognize the CPT codes for new and established patient clinic visits under the OPPTS, consistent with their CPT code descriptors. Further, we did not propose to adopt the recommendation of the APC Panel to eliminate this differentiation for the reasons noted. We proposed to reexamine whether the coding distinction between new and established patient visits was necessary as we further considered national guidelines. We continued to encourage public comment about hospitals’ experiences with assigning visit levels to new and established patients according to their own internal guidelines.

Table 51 of the CY 2008 OPPTS/ASC proposed rule, which is reprinted below as Table 40, lists the CY 2008 proposed median costs of new and established patient clinic visit codes, which were based on CY 2006 claims data processed through December 31, 2006.

TABLE 40.—CY 2008 PROPOSED MEDIAN COSTS OF NEW AND ESTABLISHED PATIENT VISIT CPT CODES

Clinic visit level	CY 2008 new patient visit proposed median cost	CY 2008 established patient visit proposed median cost
Level 1	\$56.08	\$50.70
Level 2	63.18	58.84
Level 3	74.99	64.73
Level 4	109.12	84.17
Level 5	138.06	102.89

Comment: Most commenters on the proposals requested that CMS eliminate the need for hospitals to distinguish between new and established patient visits because they found it cumbersome to bill a different code for each type of visit. Specifically, the commenters asked CMS not to implement new and established patient visit codes. The commenters suggested that hospitals bill the appropriate code, based on the resources expended in the visit. Several commenters suggested that CMS require hospitals to bill the established patient visit code exclusively and change the status of the new patient visit codes to nonpayable. The commenters suggested setting the payment rate for the established patient visit code at a blend of the new and established patient visit

rates. One commenter requested that both the new and established patient visit codes remain payable, but that the OPPTS pay the same rate for the new and established patient visit, at each level, an approach which would remove any financial incentive for reporting one code instead of another. Several commenters supported the proposal to continue requiring hospitals to distinguish between new and established patient visits. Some of the commenters suggested that the AMA create hospital-specific Category I CPT visit codes that do not distinguish between new and established patient visits, as appropriate for reporting hospital resource use.

Response: Because hospitals will be reporting CPT codes for CY 2008 and we

continue to observe significant cost differences between new and established patient visits of the same level, we will continue to recognize new and established patient visit codes under the CY 2008 OPPTS, consistent with their CPT code descriptors. We agree with the commenters that it could be simpler and less burdensome from a coding perspective if hospitals only needed to report one set of codes and could report code levels that reflected their resources used, rather than distinguishing between new and established patient visits. However, in the absence of hospital-specific CPT codes for the reporting of visits in the HOPD, hospitals should continue to distinguish between new and established patient visits, consistent

with their CPT code descriptors. We will reexamine whether the coding distinction between new and established patient visits is necessary as we continue to explore national guidelines.

Comment: Several commenters requested that CMS define a new patient as a patient who does not have a hospital medical record, rather than a patient who does not have a medical record that was created within the past 3 years. The commenters cited the definitions of new and established patients that we discussed in the CY 2007 OPPTS/ASC final rule with comment period (71 FR 68128) where CMS stated that if the patient had a hospital medical record that was created within the past 3 years, that patient would be considered an established patient to the hospital. Several of the commenters believed that the “new” patient definition described in the April 7, 2000 OPPTS final rule with comment period (65 FR 18451) did not require hospitals to determine if a medical record had been created for the patient within the past 3 years.

Response: We note that we neither proposed a change to the definitions of new and established patient visits in the CY 2008 OPPTS/ASC proposed rule nor solicited comment on the definitions of new and established patient visits. While several commenters asked us to revise these definitions, we are reluctant to make these changes without hearing additional perspectives from the larger hospital community. Therefore, we are specifically soliciting comment on the definitions of new and established patient visits in the HOPD.

For CY 2008, we are finalizing our proposal, without modification, to continue to recognize the CPT codes for new and established patient clinic visits under the OPPTS, consistent with their CPT code descriptors. Further, we are not adopting the recommendation of the APC Panel to eliminate this differentiation for the reasons noted above. We continue to encourage hospitals to submit comments regarding

their experiences with assigning visit levels to new and established patients according to their own internal guidelines. In addition, as noted above, we are specifically soliciting comment on the definitions of new and established patient visits in the HOPD.

As noted above, the APC Panel also recommended that CMS map each level of patient visits to its corresponding APC, thereby paying at five payment levels. The APC Panel members noted that this mapping system would eliminate any payment incentive to distinguish between new and established patients, but would ensure five payment levels.

In the CY 2008 OPPTS/ASC proposed rule, we proposed to maintain the CY 2007 mapping for the clinic visit codes for established patients. As indicated in Table 50 of the proposed rule, which is reprinted earlier as Table 39 in this final rule with comment period, we proposed to map the Level 1 established patient visit to the Level 1 Clinic Visit APC, which resulted in the Level 1 Clinic Visit APC containing both the Level 1 new and established patient visit codes, in accordance with the APC Panel’s recommendation. Similarly, we proposed to map both the Level 2 new and established patient visit codes to the Level 2 Clinic Visit APC. However, we also proposed to map the Level 3 established patient visit code to the Level 2 Clinic Visit APC because our cost data indicated that the costs associated with a Level 3 established patient visit most closely resembled the costs associated with the Level 2 Clinic Visit APC and the Level 2 new and established patient visits. If CPT code 99213 for an established Level 3 clinic visit were mapped to the Level 3 Clinic Visit APC, which had a proposed median cost of approximately \$86, we would significantly overpay CPT code 99213 every time it was billed. Therefore, we proposed to map the Level 3 new patient visit to the Level 3 Clinic Visit APC, consistent with the APC Panel’s recommendation. We also proposed to map the Level 4 established

patient visit to the Level 3 Clinic Visit APC, and the Level 5 established patient visit to the Level 4 Clinic Visit APC. The only CPT E/M code that we proposed to map to the Level 5 Clinic Visit APC for CY 2008 payment was the Level 5 new patient visit. These APC assignments which were proposed for CY 2008 consistent with their CY 2007 APC assignments, were determined for each HCPCS code based on CY 2006 claims data available for CY 2008 ratesetting and clinical considerations. In the CY 2008 OPPTS/ASC proposed rule, we indicated that we were not persuaded by the APC Panel’s recommendation, which would have required us to ignore significant cost differences based on resource data that were clinically consistent and, therefore, we did not propose to map each code to its corresponding level APC.

In the proposed rule, we noted that historical cost data for these frequently provided services were extremely consistent. In addition, from a clinical perspective, we believed that in some cases, in the context of a five-level structure for visit reporting, the hospital resources required for a given visit level might only be slightly different from those used for a visit that was one level higher or lower. For example, it was not surprising that particularly among visits for established patients in the middle of the range, such as a Level 2 established patient visit and a Level 3 established patient visit, the hospital resource costs calculated from claims data were similar because these patients would often utilize reasonably comparable hospital resources.

In the proposed rule, we performed data analyses using proposed rule data to determine how the median costs of the clinic visit APCs would have changed if we fully adopted the APC Panel’s recommendation, and mapped all of the new and established patient visit codes to the corresponding level of clinic visit APC. Our results were shown in Table 52 of the CY 2008 OPPTS/ASC proposed rule, which is reprinted below as Table 41.

TABLE 41.—CY 2008 MEDIAN COST COMPARISON OF CLINIC VISIT APCs IN TWO DIFFERENT CONFIGURATIONS USING CY 2006 PROPOSED RULE DATA

APC	APC Median cost in the proposed CY 2008 configuration	APC Median cost in the recommended APC panel configuration
Level 1 Clinic Visit	\$53	\$53
Level 2 Clinic Visit	63	60
Level 3 Clinic Visit	86	66
Level 4 Clinic Visit	108	88
Level 5 Clinic Visit	139	110

In the CY 2008 OP/ASC proposed rule, we concluded that the APC median cost distribution did not improve when each new and established patient visit code was mapped to its corresponding level of APC. In fact, the APC Panel's recommended configuration resulted in lower payment rates for the Levels 2 through 5 Clinic Visit APCs, and an identical payment rate for the Level 1 Clinic Visit APC because our proposed mapping and the APC Panel's recommendation for this APC were the same. In general, under the OP/ASC, we rely on resource cost data calculated from hospital claims data to determine appropriate APC mapping of HCPCS codes, and to set payment rates. While we acknowledged in the proposed rule that it might be more predictable for hospitals to receive the same payment rate for new and established patients of the same visit level, robust cost data clearly indicated that this would not be the most accurate payment method. Historical hospital cost data demonstrated that new patient visits were more costly than established patient visits of the same level, a finding that was consistent with the perspective of our medical advisors. Because we proposed that hospitals continue to use CPT E/M codes to report clinic visits for CY 2008, including separate codes for new and established patients, we saw no reason to adjust the clinic visit APC configurations. Therefore, for CY 2008, we proposed to map the CPT E/M codes and other Level II HCPCS codes to the Clinic Visit APCs as configured in Table 50 of the proposed rule, and not fully adopt the APC Panel's recommendation to map each code to its corresponding APC level. We indicated that we would re-examine this issue using the claims data for CY 2009 OP/ASC ratesetting, and would also reconsider whether this mapping is appropriate in the future as we continue to work on developing national guidelines.

Comment: A few commenters opposed the proposal to map the CPT E/M codes and other Level II HCPCS codes to the Clinic Visit APCs based on resource cost and clinical homogeneity and stated that it made sense for each code to map to the corresponding APC level. For example, the commenters requested that the Level 3 new and established patient visit codes both map to the Level 3 Visits APC.

Response: While we understand that it would be more straightforward if each

code mapped to its corresponding APC level, we did not receive any compelling reasons to ignore significant cost differences based on robust resource data that are clinically consistent. We note that we will not be adopting the APC Panel's recommendation that each code map to its corresponding APC level for CY 2008.

We are finalizing the proposed Clinic Visit APC configuration, with minor modification for CY 2008. Specifically, we are mapping the CPT E/M codes and other Level II HCPCS to the appropriate Clinic Visit APCs, based on resource costs. Several HCPCS codes more appropriately map to different Clinic Visit APCs than proposed in Table 50 as a result of analyzing the full year final rule resource cost data. In addition, several other HCPCS codes for services resembling visits have been assigned to the Clinic Visit APCs for CY 2008. We refer readers to Addendum B to this final rule with comment period for the complete listing of visit codes and their placements for CY 2008. Furthermore, as discussed in detail in section II.A.4.c.(7) of this final rule with comment period, in some cases when high-level visits are reported with a new or established patient Level 5 CPT E/M code, a Level 4 or 5 emergency department visit CPT code, a critical care CPT code, or direct admission to observation HCPCS code in association with 8 or more hours of nonsurgical observation services, we will provide a single payment in CY 2008 for the encounter through one of two new composite APCs, specifically APCs 8002 (Level I Extended Assessment and Management) and 8003 (Level II Extended Assessment and Management).

The APC Panel also recommended that CMS not recognize the CPT consultation codes: CPT code 99241 (Office consultation for a new or established patient (Level 1)), CPT code 99242 (Office consultation for a new or established patient (Level 2)), CPT code 99243 (Office consultation for a new or established patient (Level 3)), CPT code 99244 (Office consultation for a new or established patient (Level 4)), and CPT code 99245 (Office consultation for a new or established patient (Level 5)). The APC Panel recommended that CMS instruct hospitals to build consultation services into their internal hospital guidelines related to reporting outpatient clinic visit levels based on

the complexity and resources used for these outpatient visits.

CPT defines a consultation as "a type of service provided by a physician whose opinion or advice regarding evaluation and/or management of a specific problem is requested by another physician or other appropriate source." CPT recognizes two subcategories of consultations, specifically office or other outpatient and inpatient consultations, although only the office consultations would be applicable under the OP/ASC. As we observed in the CY 2008 OP/ASC proposed rule, the differentiation of consultations from new and established patient clinic visits would appear to be clinically unnecessary under the OP/ASC in order to provide proper OP/ASC payment for hospital outpatient visits.

In the CY 2007 OP/ASC final rule with comment period (71 FR 68128), we stated our belief that it might be unnecessary for hospitals to report consultation CPT codes if either a new or established patient visit code accurately described the service provided. We stated that we were particularly interested in hearing whether consultation codes were a useful measure of hospital resource use under the OP/ASC, and how consultation visits were different, from a hospital resource perspective, from new patient visits and established patient visits. We observed that we did not want to create an incentive for hospitals to bill a consultation code instead of a new or established patient code because we did not believe that consultation codes necessarily reflected different resource utilization than either new or established patient codes (71 FR 68138). Therefore, for CY 2007, we finalized a payment policy that assigned the consultation code to the same clinical APC as the established patient visit code for each level of service. For example, CPT code 99242, the Level 2 consultation code, was mapped to APC 0605 (Level 2 Clinic Visits), which was where CPT code 99212, the Level 2 established patient code, was also assigned for CY 2007. Moving the consultation codes to the same APCs as the corresponding established patient visit codes eliminated any incentive for hospitals to bill a consultation code instead of a new or established patient code.

TABLE 42.—CY 2008 MEDIAN COSTS AND FREQUENCIES OF CPT CONSULTATION VISIT CODES USING CY 2006 PROPOSED RULE DATA

Code descriptor	Median cost	Frequency
Level 1 Consultation	\$66.48	62,000
Level 2 Consultation	65.78	73,000
Level 3 Consultation	81.95	155,000
Level 4 Consultation	109.96	176,000
Level 5 Consultation	139.61	94,000

Consultation services were provided with much less frequency than all levels of established patient visits and low-level new patient visits in CY 2006 but were provided more frequently than high-level new patient visits. The median costs for consultation codes were generally similar to, or slightly higher than, the corresponding median costs of the same level of new patient visits.

Aside from the APC Panel's recommendation, we received a few public comments on the CY 2007 OPPS/ASC final rule related to this issue. In the CY 2008 OPPS/ASC proposed rule, we noted our continued belief that consultation codes were unnecessary and superfluous in the hospital outpatient setting because hospitals could appropriately bill either a new or established patient visit code, instead of a consultation code, as appropriate in these cases. In the interest of simplifying billing, for CY 2008, we proposed to assign status indicator "B" to the consultation codes (that is, not paid under the OPPS), and instructed hospitals to bill a new or established visit code instead of an office consultation code, thereby adopting the APC Panel's recommendation not to recognize these consultation codes. As appropriate, hospitals could build consultation services into their internal hospital guidelines related to reporting clinic visit levels, based on the complexity and resources used for these visits.

Comment: Many commenters supported the proposal to change the status of the consultation codes so that they are no longer recognized under the OPPS. The commenters stated that this would simplify outpatient hospital billing, and remove the option of reporting unnecessary codes. A few commenters requested that the consultation codes continue to be recognized under the OPPS because of the administrative burden involved with analyzing each consultation to determine if the visit should be new or established. In addition, the commenters noted that there is a resource cost difference between consultations and new and established

patient visits. The commenters stated that the cognitive intensity and the time to fully establish a diagnosis and a treatment plan for consultation types of visits are much greater than that of established patient visits.

Response: We agree with the commenters who requested that we finalize our proposal not to recognize consultation codes under the OPPS for CY 2008. As described above, we do not believe consultation codes are a useful or necessary indicator of hospital resource use under the OPPS. The commenters who requested that CMS continue to recognize consultation codes may have been measuring physician resource use, rather than hospital resource use. In addition, if consultation services are more resource-intensive than established patient visits of the same level, our proposal would permit hospitals to factor this into their internal hospital guidelines that would determine the appropriate level of established patient visit to report.

In summary, we are finalizing our CY 2008 proposal, without modification, that hospitals continue to use CPT codes to bill for clinic visits, and to distinguish between new and established patient visits. For CY 2008, the CPT codes for new and established visits will continue to be payable under the OPPS, but we will reconsider in the future whether there should be a distinction between new and established patient visits as we continue to work on developing national guidelines. In the meantime, we will assign these clinic visits to different levels of Clinic Visit APCs based on the costs we observe from historical hospital claims data. For CY 2008, we are also finalizing our proposal, without modification, to change the status of the consultation codes so that these codes are no longer recognized for payment under the OPPS.

2. Emergency Department Visits

As described above, CPT defines an emergency department as "an organized hospital based facility for the provision of unscheduled episodic services to patients who present for immediate medical attention. The facility must be

available 24 hours a day." Prior to CY 2007, under the OPPS we restricted the billing of emergency department CPT codes to services furnished at facilities that met this CPT definition. Facilities open less than 24 hours a day should not have reported the emergency department CPT codes.

Sections 1866(a)(1)(I), 1866(a)(1)(N), and 1867 of the Act impose specific obligations on Medicare-participating hospitals and CAHs that offer emergency services. These obligations concern individuals who come to a hospital's dedicated emergency department and request examination or treatment for medical conditions, and apply to all of these individuals, regardless of whether or not they are beneficiaries of any program under the Act. Section 1867(h) of the Act specifically prohibits a delay in providing required screening or stabilization services in order to inquire about the individual's payment method or insurance status. Section 1867(d) of the Act provides for the imposition of civil monetary penalties on hospitals and physicians responsible for failing to meet the provisions listed above. These provisions, taken together, are frequently referred to as the Emergency Medical Treatment and Labor Act (EMTALA). EMTALA was passed in 1986 as part of the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA), Pub. L. 99-272.

Section 489.24 of the EMTALA regulations defines "dedicated emergency department" as any department or facility of the hospital, regardless of whether it is located on or off the main hospital campus, that meets at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under the regulations is

being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment.

In the CY 2008 OPPTS/ASC proposed rule, we reiterated our belief that every emergency department that meets the CPT definition of emergency department also qualifies as a dedicated emergency department under EMTALA. However, we indicated that we were aware that there are some departments or facilities of hospitals that meet the definition of a dedicated emergency department under the EMTALA regulations, but that do not meet the more restrictive CPT definition of an emergency department. For example, a hospital department or facility that meets the definition of a dedicated emergency department may not be available 24 hours a day, 7 days a week. Nevertheless, hospitals with such departments or facilities incur EMTALA obligations with respect to an individual who presents to the department and requests, or has requested on his or her behalf, examination or treatment for an emergency medical condition. However, because they did not meet the CPT requirements for reporting emergency visit E/M codes, prior to CY 2007, these facilities were required to bill clinic visit codes for the services they furnished under the OPPTS. We had no way to distinguish in our hospital claims data the costs of visits provided in dedicated emergency departments that did not meet the CPT definition of

emergency department from the costs of clinic visits.

Prior to CY 2007, some hospitals requested that they be permitted to bill emergency department visit codes under the OPPTS for services furnished in a facility that met the CPT definition for reporting emergency department visit E/M codes, except that they were not available 24 hours a day. These hospitals believed that their resource costs were more similar to those of emergency departments that met the CPT definition than they were to the resource costs of clinics. Representatives of such facilities argued that emergency department visit payments would be more appropriate, on the grounds that their facilities treated patients with emergency conditions whose costs exceeded the resources reflected in the clinic visit APC payments, even though these emergency departments were not available 24 hours per day. In addition, these hospital representatives indicated that their facilities had EMTALA obligations and should, therefore, be able to receive emergency department visit payments. While these emergency departments may have provided a broader range and intensity of hospital services, and required significant resources to assure their availability and capabilities in comparison with typical hospital outpatient clinics, the fact that they did not operate with all capabilities full-time suggested that hospital resources associated with visits to emergency departments or facilities available less than 24 hours a day might not be as great as the resources associated with emergency departments

or facilities that were available 24 hours a day, and that fully met the CPT definition.

To determine whether visits to emergency departments or facilities (referred to as Type B emergency departments) that incur EMTALA obligations, but do not meet more prescriptive expectations that are consistent with the CPT definition of an emergency department (referred to as Type A emergency departments), have different resource costs than visits to either clinics or Type A emergency departments, in the CY 2007 OPPTS/ASC final rule with comment period (71 FR 68132), we finalized a set of five G-codes for use by hospitals to report visits to all entities that meet the definition of a dedicated emergency department under the EMTALA regulations in § 489.24, but that are not Type A emergency departments, as described in Table 43 below. These codes are called "Type B emergency department visit codes." We believed the creation of G-codes for Type B emergency departments was necessary because there were no CPT codes that fully described this type of facility. If we were to continue instructing Type B emergency departments to bill clinic visit codes, we would have no way to track resource costs for Type B emergency department visits as distinct from clinic visits. In that final rule, we explained that these new G-codes would serve as a vehicle to capture median cost and resource differences among visits provided by Type A emergency departments, Type B emergency departments, and clinics (71 FR 68132).

TABLE 43.—CY 2007 FINAL LEVEL II HCPCS CODES TO BE USED TO REPORT EMERGENCY DEPARTMENT VISITS PROVIDED IN TYPE B EMERGENCY DEPARTMENTS

HCPCS code	Short descriptor	Long descriptor
G0380	Lev 1 hosp type B ED visit.	Level 1 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under this section is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).
G0381	Lev 2 hosp type B ED visit.	Level 2 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under this section is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).

TABLE 43.—CY 2007 FINAL LEVEL II HCPCS CODES TO BE USED TO REPORT EMERGENCY DEPARTMENT VISITS PROVIDED IN TYPE B EMERGENCY DEPARTMENTS—Continued

HCPCS code	Short descriptor	Long descriptor
G0382	Lev 3 hosp type B ED visit.	Level 3 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under this section is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its out-patient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).
G0383	Lev 4 hosp type B ED visit.	Level 4 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under this section is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its out-patient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).
G0384	Lev 5 hosp type B ED visit.	Level 5 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under this section is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its out-patient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).

For CY 2007, we assigned the five new Type B emergency department visit codes for services provided in a Type B emergency department to the five newly-established Clinic Visit APCs, 0604, 0605, 0606, 0607, and 0608 (71 FR 68140). This payment policy for Type B emergency department visits was similar to our previous policy, which required services furnished in emergency departments that had an EMTALA obligation, but did not meet the CPT definition of emergency department to be reported using CPT clinic visit E/M codes, resulting in payments based upon clinic visit APCs. As mentioned above, CPT and CMS required an emergency department to be open 24 hours per day in order for it to be eligible to bill emergency department E/M codes. While maintaining the same payment policy for Type B emergency department visits in CY 2007, we believed the reporting of specific G-codes for emergency department visits provided in Type B emergency departments would permit us to specifically collect, and analyze the hospital resource costs of visits to these facilities in order to determine if in the future a proposal for an alternative payment policy might be warranted. We expected hospitals to adjust their charges appropriately to reflect differences in Type A and Type B emergency departments. We noted that

the OPPS rulemaking cycle for CY 2009 would be the first year that we would have cost data for these new Type B emergency department HCPCS codes available for analysis.

In the CY 2007 OPPS/ASC proposed rule (71 FR 49609), we proposed to create five G codes to be reported by the subset of provider-based emergency departments or facilities of the hospital, called Type A emergency departments, that are available to provide services 24 hours a day, 7 days per week, and meet one or both of the following requirements related to the EMTALA definition of a dedicated emergency department, specifically: (1) It is licensed by the State in which it is located under the applicable State law as an emergency room or emergency department; or (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment. These codes were called “Type A emergency visit codes” and were proposed to replace hospitals’ reporting of the CPT emergency department visit E/M codes. Our intention was to allow hospital-based emergency departments or facilities that were historically appropriately reporting CPT emergency department visit E/M codes to bill these

new Type A emergency department visit codes. In the CY 2007 OPPS/ASC final rule with comment period (71 FR 68132), we postponed finalizing G codes to replace CPT codes for Type A emergency department visits until national guidelines are established, and stated that we would again consider their possible utility once national guidelines are adopted. However, for CY 2007, we finalized the definition of Type A emergency departments to distinguish them from Type B emergency departments. For CY 2007 (71 FR 68140), we assigned the five CPT E/M emergency department visit codes for services provided in Type A emergency departments to the five newly-created Emergency Department Visit APCs, 0609, 0613, 0614, 0615, and 0616.

We believed that our distinction between Type A and Type B emergency departments refined and clarified the CPT definition of “emergency department” for use in the hospital context. As we have previously noted, the CPT codes are defined to reflect the activities of physicians, and do not always fully describe the range and mix of services provided by hospitals during visits of emergency department patients. For example, one feature that distinguishes Type A hospital emergency departments from other departments of the hospital is that Type

A emergency departments do not generally provide scheduled care, but rather regularly operate to provide immediately available unscheduled services.

We were pleased that the majority of commenters to the CY 2007 OPPS/ASC proposed rule agreed with our general distinction between Type A and Type B emergency departments. We noted that after the publication of the CY 2007 OPPS/ASC final rule with comment period, numerous readers requested clarification about one paragraph that appeared in that final rule. The paragraph is reprinted below (71 FR 68132).

“We are aware that hospitals operate many types of facilities which they view in aggregate as an integrated healthcare system. For purposes of determining EMTALA obligations, under § 489.24(b) of the regulations, each hospital is evaluated individually to determine its own particular obligations. As we have discussed previously, hospital facilities or departments of the hospital that meet the definition of a dedicated emergency department consistent with the EMTALA regulations may bill Type A emergency department codes (CPT emergency department visit codes) or Type B emergency department codes (HCPCS G-codes), depending on whether or not the dedicated emergency department meets the definition of a Type A emergency department, which includes operating 24 hours per day, 7 days a week. For purposes of determining whether to bill Type A or Type B emergency department codes, each hospital must be evaluated individually and should make a decision specific to each area of the hospital to determine which codes would be appropriate. Where a hospital maintains a separately identifiable area or part of a facility which does not operate on the same schedule (that is, 24 hours per day, 7 days a week) as its emergency department, that area or facility would not be considered an integral part of the emergency department that operates 24 hours per day, 7 days a week for purposes of determining its emergency department type for reporting emergency visit services. Instead, the facility or area would be evaluated separately to determine whether it is a Type A emergency department, Type B emergency department, or clinic. We would expect the hospital providing services in such facilities or areas to evaluate the status of those areas and bill accordingly. In general, it is not appropriate to consider a satellite emergency department or an area of the emergency department as if it were available 24 hours a day simply because the main emergency department is available 24 hours a day. It may be appropriate for a Type A emergency department to ‘carve out’ portions of the emergency department that are not available 24 hours a day, where visits would be more appropriately billed with Type B emergency department codes.”

In response to the questions we received, in CY 2007 we posted on the

CMS Web site a “Frequently Asked Questions” list that described various examples of treating an emergency department as either a Type A emergency department or a Type B emergency department. In each case, the posted answer stated that hospitals should contact their fiscal intermediary to ensure that the fiscal intermediary and the hospital are in agreement regarding the emergency room status as either Type A or Type B. The response to the posted examples has been positive, and the number of inquiries we are receiving has subsided.

Notwithstanding our subsequent clarification, we did not propose to modify the definitions of Type A or Type B emergency departments for CY 2008 because we believed that our current definition accurately distinguished between these two types of emergency departments. While we would not know definitively until CY 2009 how the costs of services provided in Type A emergency departments differed from the costs of services provided in Type B emergency departments, we believed that our current distinction between Type A and Type B emergency departments was appropriate, and was most likely to capture any resource cost differences between the two types of emergency departments. However, we specifically solicited public comment regarding any additional operational clarifications that we could provide to assist hospitals in determining whether an emergency department is considered to be Type A or Type B.

We specifically indicated for CY 2007 that hospitals should individually consider separately identifiable areas or parts of facilities that did not operate on the same schedule as the main emergency department that was open 24 hours a day, 7 days per week to determine the appropriate codes for reporting services provided in those separately identifiable areas. Because we considered the main distinguishing feature between Type A and Type B emergency departments to be the full-time versus part-time availability of staffed areas for emergency medical care, not the process of care or the site of care (on the hospital’s main campus or offsite), our final CY 2007 policy explained that hospitals needed to assess separately identifiable areas individually for their status as Type A or Type B emergency departments. In the CY 2008 OPPS/ASC proposed rule, we specifically solicited comments that described how this policy could be further clarified in light of hospitals’ operational responsibility to efficiently provide emergency services, holding

constant the definitions that were developed for CY 2007 and described above. We did not believe a policy change in the reporting of these Type A and Type B emergency department codes would be appropriate for CY 2008, in light of our desire to capture consistent and accurate hospital cost data by HCPCS code for consideration for the CY 2009 OPPS. For CY 2008, we proposed that Type A emergency department visits would continue to be paid based on the five Emergency Department Visit APCs, while Type B emergency department visits would continue to be paid based on the five Clinic Visit APCs.

Comment: Many commenters requested that CMS adjust the policy to broaden the definition of Type A emergency departments, specifically to revise the rule that hospitals must carve out portions of the emergency department that are not available 24 hours a day. The commenters specifically requested that the definition be adjusted so that a “fast track” area of an emergency department, located within the same building as a Type A emergency department, would be considered Type A, regardless of its hours of operation, if it provides unscheduled emergency services and shares a common patient registration system with the Type A emergency department. Many of the commenters expressed concern that hospitals are currently overcrowded, and payment at clinic visit rates may cause hospitals to shut down their “fast track” or other areas of the hospital that deliver expedited care, yet are open less than 24 hours a day. The commenters noted that if these areas of the hospital were closed, emergency department overcrowding would be exacerbated. Other commenters requested that we allow hospitals to operate in the most efficient manner and not penalize them for creating efficiencies. Several commenters requested additional clarification regarding the difference between Type A and Type B emergency departments, but did not specifically describe which part of the policy was unclear. Several commenters noted that five payment levels for emergency department visits was appropriate and would continue to support a stable distribution of visit levels.

Response: As noted above, we consider the main distinguishing feature between Type A and Type B emergency departments to be the full-time versus part-time availability of staffed areas for emergency medical care, not the process of care or the site of care (on the hospital’s main campus or offsite). We continue to believe that emergency

departments or areas of the emergency department that are available less than 24 hours a day may have lower resource costs than emergency departments or areas of the emergency department that are available 24 hours a day. We do not believe a policy change in the reporting of these Type A and Type B emergency department codes would be appropriate for CY 2008, in light of our desire to capture consistent and accurate hospital cost data by HCPCS code for consideration for the CY 2009 OPPIs. In

addition, if our Type A emergency department payments provide support for 24 hour a day availability of services, then services provided in areas of the hospital that are not staffed 24 hours a day could be overpaid. This could also have the effect of diluting, and ultimately decreasing, the median resource costs associated with Type A emergency departments. We encourage hospitals that need more specific information related to the distinction between Type A and Type B emergency

departments to contact their local fiscal intermediaries.

In response to several questions, we are slightly modifying the long descriptors of HCPCS codes G0380, G0381, G0382, G0383, and G0384 by replacing the words "this section" with "42 CFR § 489.24" in order to clarify the reference. The short descriptors remain unchanged for CY 2008. Table 44 lists the CY 2008 short and long descriptors for the Type B emergency department Visit HCPCS codes.

TABLE 44.—CY 2008 FINAL LEVEL II HCPCS CODES TO BE USED TO REPORT EMERGENCY DEPARTMENT VISITS PROVIDED IN TYPE B EMERGENCY DEPARTMENTS

HCPCS code	Short descriptor	Long descriptor
G0380	Lev 1 hosp type B ED visit.	Level 1 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under 42 CFR § 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).
G0381	Lev 2 hosp type B ED visit.	Level 2 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under 42 CFR § 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).
G0382	Lev 3 hosp type B ED visit.	Level 3 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under 42 CFR § 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).
G0383	Lev 4 hosp type B ED visit.	Level 4 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under 42 CFR § 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).
G0384	Lev 5 hosp type B ED visit.	Level 5 hospital emergency department visit provided in a Type B emergency department. (The ED must meet at least one of the following requirements: (1) It is licensed by the State in which it is located under applicable State law as an emergency room or emergency department; (2) It is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) During the calendar year immediately preceding the calendar year in which a determination under 42 CFR § 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment).

In summary, we did not receive any public comments that described how the payment policy could be further clarified in light of hospitals' operational responsibility to efficiently provide emergency services, holding

constant the definitions that were developed for CY 2007. Therefore, we are finalizing our CY 2008 proposal, without modification, to pay for Type A emergency department visits at the five Emergency Department Visit APC rates,

while Type B emergency department visits will continue to be paid based on the five Clinic Visit APCs. We are also slightly modifying the long descriptors of HCPCS codes G0380 through G0384 for clarification.

C. Visit Reporting Guidelines

1. Background

As described in section IX.A. of this final rule with comment period, since April 7, 2000, we have instructed hospitals to report facility resources for clinic and emergency department hospital outpatient visits using the CPT E/M codes and to develop internal hospital guidelines for reporting the appropriate visit level.

During the January 2002 APC Panel meeting, the APC Panel recommended that CMS adopt the American College of Emergency Physicians' (ACEP) intervention-based guidelines for facility coding of emergency department visits and develop guidelines for clinic visits that are modeled on the ACEP guidelines.

In the August 9, 2002 OPSS proposed rule (67 FR 52133), we proposed 10 new G-codes (Levels 1–5 Facility Emergency Services and Levels 1–5 Facility Clinic Services) for use in the OPSS to report hospital visits, with the goal of ultimately applying national guidelines to these codes and discontinuing the use of CPT E/M codes under the OPSS. We also solicited public comments regarding national guidelines for hospital coding of emergency department and clinic visits. We discussed different types of models, reflecting on the advantages and disadvantages of each. We reviewed in detail the considerations around various discrete types of specific guidelines, including guidelines based on staff interventions, based upon staff time spent with the patient, based on resource intensity point scoring, and based on severity acuity point scoring related to patient complexity. In that proposed rule, we also stated that we were concerned about counting separately paid services (for example, intravenous infusions, x rays, electrocardiograms, and laboratory tests) as “interventions,” or including their associated “staff time” in determining the level of service. We believed that the level of service should be determined by resource consumption that is not otherwise captured in payments for other separately payable services.

In response to comments, in the November 1, 2002 OPSS final rule (67 FR 66793), we stated that we would not create new codes to replace existing CPT E/M codes for reporting hospital visits until national guidelines are developed. We noted that an independent panel of experts would be an appropriate forum to develop codes and guidelines that are simple to understand and implement. We explained that organizations such as the

American Hospital Association (AHA) and the American Health Information Management Association (AHIMA) had such expertise and would be capable of creating hospital visit guidelines and providing ongoing provider education. We also articulated a set of principles that any national guidelines for facility visit coding should satisfy, including that coding guidelines should be based on facility resources, should be clear to facilitate accurate payments and be usable for compliance purposes and audits, should meet HIPAA

requirements, should only require documentation that is clinically necessary for patient care, and should not facilitate upcoding or gaming. We stated that the distribution of codes reported for each type of hospital outpatient visit (clinic or emergency department) should result in a normal curve. We concluded that we believed the most appropriate forum for development of code definitions and guidelines was an independent expert panel that would make recommendations to CMS.

The AHA and AHIMA originally supported the ACEP model for emergency department visit coding. However, we expressed concern that the ACEP guidelines allowed counting of separately payable services in determining a service level, which could result in the double counting of hospital resources in establishing visit payment rates and payment rates for those separately payable services. Subsequently, on their own initiative, the AHA and AHIMA formed an independent expert panel, the Hospital Evaluation and Management Coding Panel, comprised of members with coding, health information management, documentation, billing, nursing, finance, auditing, and medical experience. This panel included representatives from the AHA, AHIMA, ACEP, Emergency Nurses Association, and American Organization of Nurse Executives. CMS and AMA representatives observed the meetings. On June 24, 2003, the AHA and AHIMA submitted their recommended guidelines, hereafter referred to as the AHA/AHIMA guidelines, for reporting three levels of hospital clinic and emergency department visits and a single level of critical care services to CMS, with the hope that CMS would publish the guidelines in the CY 2004 OPSS proposed rule. The AHA and AHIMA acknowledged that “continued refinement will be required as in all coding systems. The Panel * * * looks forward to working with CMS to incorporate any recommendations

raised during the public comment period” (AHA/AHIMA guidelines report, page 9). The AHA and AHIMA indicated that the guidelines were field-tested several times by panel members at different stages of their development. The guidelines are based on an intervention model, where the levels are determined by the numbers and types of interventions performed by nursing or ancillary hospital staff. Higher levels of services are reported as the number and/or complexity of staff interventions increase.

Although we did not publish the guidelines, the AHA and AHIMA released the guidelines through their Web sites. Consequently, in CY 2003 we received numerous comments from providers and associations, some in favor and some opposed to the guidelines. We undertook a critical review of the recommendations from the AHA and AHIMA and made some modifications to the guidelines based on comments we received from other hospitals and associations on the AHA/AHIMA guidelines, clinical review, and changing payment policies under the OPSS regarding some separately payable services.

In an attempt to validate the modified AHA/AHIMA guidelines and examine the distribution of services that would result from their application to hospital clinic and emergency department visits paid under the OPSS, we contracted for a study that began in September 2004 and concluded in September 2005 to retrospectively code, under the modified AHA/AHIMA guidelines, hospital visits by reviewing hospital visit medical chart documentation gathered through Comprehensive Error Rate Testing (CERT) work. While a review of documentation and assignment of visit levels based on the modified AHA/AHIMA guidelines to 12,500 clinic and emergency department visits was initially planned, the study was terminated after a pilot review of only 750 visits. The contractor identified a number of elements in the guidelines that were difficult for coders to interpret, poorly defined, nonspecific, or regularly unavailable in the medical records. The contractor's coders were unable to determine any level for about 25 percent of the clinic cases and about 20 percent of the emergency department cases reviewed. The only agreement observed between the levels reported on the claims and levels according to the modified AHA/AHIMA guidelines was the classification of Level 1 services, where the review supported the level on the claims 54 to 70 percent of the time. In addition, the vast majority of the clinic and emergency department visits

reviewed were assigned to Level 1 during the review. Based on these findings, we believed that it was not necessary to review additional records after the initial sample. The contractor advised that multiple terms in the guidelines required clearer definition and believed that more examples would be helpful. Although we believed that all of the visit documentation for each case was available for the contractor's review, we were unable to determine definitively that this was the case. Thus, there was some possibility that the contractor's assignments would have differed if additional documentation from the medical records were available for the visits. In summary, while testing of the modified AHA/AHIMA guidelines was helpful in illuminating areas of the guidelines that would benefit from refinement, we were unable to draw conclusions about the relationship between the distribution of hospital reporting of visits using CPT E/M codes that were assigned according to each hospital's internal guidelines and the distribution of codes under the AHA/AHIMA guidelines, nor were we able to demonstrate a normal distribution of visit levels under the modified AHA/AHIMA guidelines. In CY 2007, we posted to the CMS Web site a summary of the contractor's report.

Despite the inconclusive findings from the validation study, after reviewing the AHA/AHIMA guidelines, as well as approximately a dozen other guidelines for outpatient visits submitted by various hospitals and hospital associations, we stated in the CY 2007 OPSS/ASC final rule with comment period (71 FR 68141) that we believed that the AHA/AHIMA guidelines were the most appropriate and well-developed guidelines for use in the OPSS of which we were aware. Our particular interest in these guidelines was based upon the broad-based input into their development, the desire for CMS to move to promulgate national hospital outpatient visit coding guidelines in the near future, and full consideration of the characteristics of alternative types of guidelines. We also believed that hospitals would react favorably to guidelines developed and supported by the AHA and AHIMA, national organizations that have great interest in hospital coding and payment issues, and possess significant medical, technical and practical expertise due to their broad membership, which includes hospitals and health information management professionals. Anecdotally, we noted that we had been told that a number of hospitals were

successfully utilizing the AHA/AHIMA guidelines to report levels of hospital visits. However, other organizations had expressed concern that the AHA/AHIMA guidelines might result in a significant redistribution of hospital visits to higher levels, reducing the ability of the OPSS to discriminate among the hospital resources required for various different levels of visits. We, too, remained concerned about the potential redistributive effect on OPSS payments for other services or among levels of hospital visits when national guidelines for outpatient visit coding are adopted. As we explained in the CY 2008 OPSS/ASC proposed rule (72 FR 42761), we recognized that there could be difficulty crosswalking historical hospital claims data from current CPT E/M codes reported based on individual internal hospital guidelines to payments for any new coding system developed, in order to provide appropriate payment levels for hospital visits reported based on national guidelines in the future.

In the CY 2008 OPSS/ASC proposed rule (72 FR 42761), we noted that there were several types of concerns with the AHA/AHIMA guidelines that had been identified based upon extensive staff review and contractor use of the guidelines during the validation study. We believed that the AHA/AHIMA guidelines would require refinement prior to their adoption by the OPSS, as well as continued refinement over time after their implementation. Our modified version of the AHA/AHIMA guidelines provided some possibilities for addressing certain issues. We reviewed our eight general areas of concern regarding the AHA/AHIMA model as outlined below. In addition, we posted on the CMS Web site both the original AHA/AHIMA guidelines and our modified draft version.

In the CY 2008 OPSS/ASC proposed rule (72 FR 42761), we reiterated our commitment to provide a minimum of 6 to 12 months notice to hospitals prior to implementation of national guidelines to provide sufficient time for providers to make the necessary systems changes and educate their staff.

2. CY 2007 Work on Visit Guidelines

There were several areas of the AHA/AHIMA guidelines that we identified in the CY 2007 OPSS/ASC final rule with comment period that would require refinement and further input from the public prior to implementation as national guidelines. These areas include the need for five rather than three levels of codes for clinic and emergency department visits to accommodate the CY 2007 five levels of OPSS payment; clarification of documentation that

would support certain interventions; reconsideration of the inclusion of separately payable services as proxies for hospital resources used in visits; examination of the valuing of certain interventions; assessment of the need for modifications to address the different clinical characteristics of specialty clinic visits; consistency with the Americans with Disabilities Act; re-evaluation of the way in which additional hospital resources required for the treatment of new patients were captured; and recommendations for guidelines for the reporting of visits to Type B emergency departments.

In CY 2007, we had a number of meetings and discussions with interested stakeholders regarding the AHA/AHIMA guidelines, the CMS modified draft version, the contractor pilot work to test the guidelines, the concerns we identified in the CY 2007 OPSS/ASC final rule with comment period, and alternative guidelines. In the CY 2008 OPSS/ASC proposed rule (72 FR 42761), we indicated our awareness that the AHA and AHIMA were conducting an ongoing dialogue with members of their Hospital Evaluation and Management Coding Panel and reviewing their previously recommended model guidelines as well as other models currently in use. We had not received any additional suggestions or modifications from the AHA and AHIMA at the time of the development of the CY 2008 proposed rule. We had received a number of new suggestions for guidelines from other stakeholders, including individual hospitals and associations, that had engaged in a variety of data collection and pilot application activities in preparing their recommendations. For example, one wound care organization created and presented an independent model that could apply to certain specialty clinics. The organization claimed that several hospital outpatient specialty clinics had already successfully implemented these as their internal guidelines, but requested that CMS designate them as the national wound care clinic guidelines. One provider group tested several sets of guidelines that resembled the ACEP model and compared the results across a set of hospitals. This provider group believed that an ACEP-type model would be the most successful type of national guidelines, assuming that the guidelines were flexible in serving as a guide to visit level reporting. While using several varieties of ACEP-type guidelines in different hospitals, the group noted that across hospitals a specific intervention was almost always

assigned to the same clinic visit level. The group concluded that this demonstrated that the ACEP model and its variations could likely be successfully implemented as national guidelines. Another association reviewed and tested the CMS modified AHA/AHIMA guidelines that were posted on the CMS Web site. This association found it cumbersome to assign the Level 2 and Level 4 clinic visit codes because those levels could only be assigned when a certain number of interventions and/or contributory factors were performed. The association suggested changes to the CMS modified AHA/AHIMA guidelines for ease of use and application to specialty clinics, particularly oncology clinics. One developer of national clinic and emergency department visit guidelines noted that many hospitals had successfully used the presenting problem-based guidelines that it had created. The developer noted that its system was easy to use, produced consistent coding decisions resulting in a normal distribution of visits, and even served as a tool to track effectiveness and efficiency.

In the CY 2008 OPPS/ASC proposed rule (72 FR 42761), we expressed our appreciation of the thoughtful information that had been provided to us up to that time regarding hospitals'

experiences and the insightful responses by the public to our concerns about the AHA/AHIMA model. We reiterated that we were actively engaged in evaluating and comparing various guideline models and suggestions that had been provided to us, and that we continued to welcome additional public input on this important and complex area of the OPPS. The public input we had received continued to reflect a wide variety of perspectives on the types and content of the guidelines different commenters recommended that we should implement nationally for the OPPS, and no single approach appeared to be broadly endorsed by the stakeholder community. In addition, we explained that commenters had described the successful application of many types of internal hospital guidelines with diverse characteristics for the reporting of hospital clinic and emergency department visit levels that they believed accurately captured the required hospital resources.

3. Visit Guidelines


In preparation for the CY 2008 OPPS/ASC proposed rule, we performed data analyses with the goal of studying the current and historical distribution of each level of clinic and emergency department visit codes billed nationally, as well as the distribution among

various classes of hospitals. We analyzed frequency data from claims with dates of service from March 1, 2002 through December 31, 2006, including those claims that were processed through December 31, 2006. To determine the national clinic visit distribution, we reviewed frequency data for each level of new patient visits, established patient visits, and consultation codes. To determine the national emergency department visit distribution, we reviewed frequency data for the five CPT emergency department visit codes. We did not include the five G-codes that describe Type B emergency departments because they became effective January 1, 2007, and we do not yet have a full year of frequency data for those codes.

The clinic visit data, displayed below in Figure 1 that is reprinted from the CY 2008 OPPS/ASC proposed rule, revealed a fairly normal national distribution of clinic visits, with the curve somewhat skewed to the left, consistent with our previous analysis of these data in CY 2002 (67 FR 66791). In addition, we noted that the visit distributions had been quite stable over the past 5 years.

Figure 1.—Frequency Distribution of New and Established Patient Clinic Visits, by Level of Code

Figure 1.--Frequency Distribution of New and Established Patient Clinic Visits, by Level of Code



The graph shown in Figure 1 indicated that hospitals, on average, were billing all five levels of visit codes with varying frequency, in a consistent pattern over time. It was striking to note how similar the annual distributions appeared from CY 2002 through CY 2006. We were not surprised that hospitals reported a relatively high proportion of low-level visits, given the typical clinical care provided in HOPDs during these visits. Many Medicare patients are evaluated regularly in clinics by hospitals' clinical staff to determine the status of their chronic medical conditions and to make adjustments to treatment plans, and those visits may frequently be reported as a low-level visit if that is consistent with the hospital's internal guidelines and fiscal intermediary instructions.

Some patients may receive minor services during low-level visits that are not described by more specific HCPCS codes. We noted that, in general, billing a visit in addition to another service merely because the patient interacted with hospital staff or spent time in a room for that service would be inappropriate. If a visit and another service were both billed, such as chemotherapy, a diagnostic test, or a surgical procedure, the visit should be separately identifiable from the other service because the resources used to provide nonvisit services, including staff time, equipment, and supplies, among others, were captured in the line item for that service. We believed that hospitals by and large were abiding by this guidance because more than 90 percent of the CY 2006 claims for Level

1 established patient visits available for the CY 2008 OPPTS/ASC proposed rule were single claims.

In the CY 2008 OPPTS/ASC proposed rule (72 FR 42761), we also examined the billing patterns for various classes of hospitals, grouped by the hospital categories shown in the impact table (Table 61) in section XXIV.B. of this final rule with comment period, to see how the clinic visit distributions of levels reported for these various categories compared to the national distribution of clinic visit levels. For these subcategories, we specifically focused on the number of established patient visits billed at each level. Generally, the distribution for major teaching hospitals, minor teaching hospitals, and nonteaching hospitals looked remarkably similar to the


national distribution of established patient visits. Nonteaching hospitals tended to bill a greater proportion of Level 1 and 2 patient visits as compared to major teaching hospitals, as would be expected if their general patient acuity was slightly lower. Nonteaching hospitals include many community hospitals that treat a wide variety of patients, likely including a larger proportion of patients with minor ailments. Major teaching hospitals reported a slightly higher proportion of Level 4 and 5 visits. This too correlated positively with our knowledge of the

patient case-mix of large teaching hospitals, which tend to treat a higher proportion of very sick patients than nonteaching hospitals. The distributions for urban and rural hospitals also closely resembled the national distribution, including the rural SCH visit level distribution. The smallest rural hospitals predictably reported a higher proportion of Level 1 and 2 visit codes and a lower proportion of higher level visit codes, as compared to the national average, consistent with their generally lower case-mix severity.

The national emergency department visit data, displayed below in Figure 2 that is reprinted from the CY 2008 OPSS/ASC proposed rule, similarly revealed a normal national distribution of emergency department visit levels that was even more symmetrical than the national clinic visit distribution. The national distributions were stable over the past 5 years as well.

Figure 2.—Frequency Distribution of Emergency Department Visits, by Level of Code

Figure 2.--Frequency Distribution of Emergency Department Visits, by Level of Code



In the CY 2008 OPSS/ASC proposed rule (72 FR 42761), we also looked at various classes of hospitals, grouped by the hospital categories that we show in the impact table in section XXIV.B. of this final rule with comment period, to

see how the emergency department visit distributions of levels billed by hospitals in each of these various categories compared to the national distribution of emergency department visit levels. The emergency department

visit distributions for major teaching hospitals, minor teaching hospitals, and nonteaching hospitals were almost identical to the national distribution of emergency department visits. No significant differences were noted. The

emergency department visit distributions for urban and rural hospitals also closely resembled the national distribution of emergency department visits. Rural hospitals in the aggregate reported slightly higher proportions of Level 2 and 3 emergency department visits than the national average, and slightly fewer Level 4 and 5 visits. When subdividing rural hospitals into groupings based on size, the distribution for small, medium, and large rural hospitals closely mirrored the national average distribution. Large rural hospitals tended to report higher level emergency department visits than smaller rural hospitals. All of these observations regarding the patterns of reporting for rural hospitals were consistent with our expectations for care delivery at those hospitals.

Overall, both the clinic and emergency department visit distributions indicated that hospitals were billing consistently over time and in a manner that distinguished between visit levels, resulting in relatively normal distributions nationally for the OPSS, as well as for smaller classes of hospitals. These proposed rule analyses were generally consistent with our understanding of the clinical and resource characteristics of different levels of hospital outpatient clinic and emergency department visits.

In the CY 2008 OPSS/ASC proposed rule, we specifically invited public comment as to whether a pressing need for national guidelines continued at this point in the maturation of the OPSS, or if the current system where hospitals create and apply their own internal guidelines to report visits was currently more practical and appropriately flexible for hospitals. We explained that although we have reiterated our goal since CY 2000 to create national guidelines, this complex undertaking for these important and common hospital services was proving more challenging than we initially thought as we received new and expanded information from the public on current hospital reporting practices that led to appropriate payment for the hospital resources associated with clinic and emergency department visits. We believed that many hospitals had worked diligently and carefully to develop and implement their own internal guidelines that reflected the scope and types of services they provided throughout the hospital outpatient system. Based on public comments, as well as our own knowledge of how clinics operate, it seemed unlikely that one set of straightforward national guidelines could apply to the reporting of visits in all hospitals and specialty clinics. In

addition, the stable distribution of clinic and emergency department visits reported under the OPSS over the past several years indicated that hospitals, both nationally in the aggregate and grouped by specific hospital classes, were generally billing in an appropriate and consistent manner as we would expect in a system that accurately distinguished among different levels of service based on the associated hospital resources.

Therefore, while we explained in the CY 2008 OPSS/ASC proposed rule that we would continue to evaluate the information and input we had received from the public during CY 2007, as well as comments on the CY 2008 OPSS/ASC proposed rule, regarding the necessity and feasibility of implementing different types of national guidelines, we did not propose to implement national visit guidelines for clinic or emergency department visits for CY 2008. Instead, hospitals would continue to report visits during CY 2008 according to their own internal hospital guidelines.

In the absence of national guidelines, we will continue to regularly reevaluate patterns of hospital outpatient visit reporting at varying levels of disaggregation below the national level to ensure that hospitals continued to bill appropriately and differentially for these services. In addition, we note our expectation that hospitals' internal guidelines would comport with the principles listed below.

(1) The coding guidelines should follow the intent of the CPT code descriptor in that the guidelines should be designed to reasonably relate the intensity of hospital resources to the different levels of effort represented by the code (65 FR 18451).

(2) The coding guidelines should be based on hospital facility resources. The guidelines should not be based on physician resources (67 FR 66792).

(3) The coding guidelines should be clear to facilitate accurate payments and be usable for compliance purposes and audits (67 FR 66792).

(4) The coding guidelines should meet the HIPAA requirements (67 FR 66792).

(5) The coding guidelines should only require documentation that is clinically necessary for patient care (67 FR 66792).

(6) The coding guidelines should not facilitate upcoding or gaming (67 FR 66792).

We also proposed the following five additional principles for application to hospital-specific guidelines, based on our evolving understanding of the important issues addressed by many hospitals in developing their internal guidelines that now have been used for a number of years. We believed that it

was reasonable to elaborate upon the standards for hospitals' internal guidelines that we proposed to apply in CY 2008, based on our knowledge of hospitals' experiences to date with guidelines for visits.

(7) The coding guidelines should be written or recorded, well-documented, and provide the basis for selection of a specific code.

(8) The coding guidelines should be applied consistently across patients in the clinic or emergency department to which they apply.

(9) The coding guidelines should not change with great frequency.

(10) The coding guidelines should be readily available for fiscal intermediary (or, if applicable, MAC) review.

(11) The coding guidelines should result in coding decisions that could be verified by other hospital staff, as well as outside sources.

In the CY 2008 OPSS/ASC proposed rule, we invited public comment on these principles, specifically, whether hospitals' guidelines currently met these principles, how difficult it would be for hospitals' guidelines to meet these principles if they did not meet them already, and whether hospitals believed that certain standards should be added or removed. We considered stating that a hospital must use one set of emergency department visit guidelines for all emergency departments in the hospital but thought that some departments that might be considered emergency departments, such as the obstetrics department, might find it more practical and appropriate to use a different set of guidelines than the general emergency department. Similarly, we believed that it was possible that various specialty clinics in a hospital could have their own set of guidelines, specific to the services offered in those specialty clinics. However, if different guidelines were implemented for different clinics, we stated that hospitals should ensure that these guidelines reflected comparable resource use at each level to the other clinic guidelines that the hospital might apply.

Comment: A number of commenters were divided as to whether there is a need for national guidelines. The majority of the commenters requested that CMS continue work on national guidelines to ensure consistent reporting of hospital visits. Some of the commenters requested that the guidelines be implemented as soon as possible, ensuring 6 to 12 months of advance notice. Other commenters suggested that guidelines would be helpful, but that it was preferable to invest significant time reviewing and

perfecting guidelines rather than to quickly implement guidelines that could later prove to be problematic. Several commenters requested that CMS create national guidelines and then request the development of CPT codes specific to hospital visits. Several commenters offered their assistance in creating specialty clinic guidelines, reviewing guidelines, or helping in other ways, with the ultimate goal of creating national guidelines. One commenter believed it is absolutely necessary to create national guidelines, particularly because CMS is moving toward greater packaging.

Other commenters stated that the principles that were included in the CY 2008 OPPTS/ASC proposed rule were appropriate, reasonable, and sufficient, and that it was unnecessary to implement national guidelines. The commenters stated that hospital specific guidelines are practical and appropriately flexible. Several of the commenters noted that their own internal guidelines already met all of the principles, or that the internal guidelines used by member hospitals or their associations likely already comply with these principles. Other commenters requested that the AMA include these principles in the CPT book to clarify that the CPT E/M code descriptors do not fully describe hospital resources, and that it is appropriate for hospitals to use their internal guidelines to code hospital outpatient visits.

Several commenters asked for clarification of details related to the principles, such as how often the guidelines should be updated, how "readily available" is defined, and whether hospitals can use physician guidelines to report hospital visits. Some commenters believed the principles were too vague and strongly encouraged the creation of national guidelines. Several commenters requested that CMS inform the fiscal intermediaries and MACs that they should use each hospital's internal guidelines as a reference when auditing hospital records, rather than using only the fiscal intermediary's own set of guidelines. One commenter requested clarification related to how a hospital could create several sets of guidelines for various areas of the hospital. Many commenters requested clarification about whether separately payable services could be included in internal guidelines, in the absence of national guidelines.

Response: We appreciate all the thoughtful comments that we received related to the creation of national guidelines, as well as offers from

hospitals and associations to help create guidelines. We acknowledge that it would be desirable to many hospitals to have one set of national guidelines. However, we also understand that it would be disruptive to other hospitals that have successfully adopted internal guidelines to implement any new set of national guidelines, while we address the problems that would be inevitable in the case of any new set of guidelines that would be applied by thousands of hospitals. Creating national guidelines has proven more difficult than initially anticipated, as detailed above, and some hospitals have expressed significant concerns about virtually all of the models we have discussed.

Based on our analyses for the CY 2008 proposed rule, both clinic and emergency department national visit distributions appear normal and relatively stable over time, indicating that hospitals as a whole are billing the full range of visit codes in an appropriate manner, a reassuring finding. We noted similar distributions for subclasses of hospitals, as well. We will continue to work on national guidelines, and we continue to encourage comments and submission of successful models. In the meantime, before national guidelines are implemented, we will require each hospital's internal guidelines to meet the principles stated above. We agree with commenters that it could be useful for the AMA to publish these principles in order to clarify that it is appropriate for hospitals to apply different guidelines than physicians' guidelines to report visits provided in HOPDs. We encourage interested parties to contact the AMA to determine whether there is an appropriate forum to publish these principles, so that they are broadly distributed and readily available.

We will elaborate on the principles that were commented on by several commenters. The second principle states that the guidelines should not be based on physician resources. Hospitals are responsible for reporting the CPT E/M visit code that appropriately represents the resources utilized by the hospital, rather than the resources utilized by the physician. This does not preclude a hospital from using or adapting the physician guidelines if the hospital believes that such guidelines adequately describe hospital resources. We note that the first principle states that coding guidelines should follow the *intent* of the CPT code descriptor to relate the intensity of resources to different levels of effort represented by the code, not that the hospital's guidelines need to specifically consider the three factors included in the CPT

E/M codes for consideration regarding physician visit reporting.

Regarding principle 8, a hospital with multiple clinics (for example, primary care, oncology, wound care, etc.) may have different coding guidelines for each clinic, but the guidelines must be applied uniformly within each separate clinic. We note that the hospital's assorted set of internal guidelines must measure resource use in a relative manner, in relation to each other. For example, the hospital resources required for a Level 3 established patient visit under one set of guidelines should be comparable to the resources required for a Level 3 established patient visit under all other sets of clinic visit guidelines used by the hospital.

Regarding principle 9, we would generally expect hospitals to adjust their guidelines less frequently than every few months, and we believe it would be reasonable for hospitals to adjust their guidelines annually, if necessary.

Regarding principle 10, hospitals should use their judgment to ensure that coding guidelines are readily available, in an appropriate and reasonable format. We would encourage fiscal intermediaries and MACs to review a hospital's internal guidelines when an audit occurs.

Regarding principle 11, hospitals should use their judgment to ensure that their coding guidelines can produce results that are reproducible by others.

In the absence of national visit guidelines, hospitals have the flexibility to determine whether or not to include separately payable services as a proxy to measure hospital resource use that is not associated with those separately payable services. The costs of hospital resource use associated with those separately payable services would be paid through separate OPPTS payment for the other services. We encourage hospitals with more specific questions related to the creation of internal guidelines to contact their local fiscal intermediary or MAC.

Comment: Many commenters requested that CMS allow hospitals to bill critical care without a minimum time requirement or with a time requirement of 15 minutes. The commenters noted that the hospital may have its greatest resource use in the first 10 minutes of critical care, much earlier than the 30-minute minimum required in the code descriptor.

Response: The CPT instructions for reporting of critical care services with CPT code 99291 (Critical care, evaluation and management of the critically ill or critically injured patient; first 30–74 minutes) and the CPT code descriptor specify that the code can only

be billed if 30 minutes or more of critical care services are provided. Because hospitals will be reporting CPT codes for critical care services for CY 2008, they must continue to provide a minimum of 30 minutes of critical care services in order to bill CPT code 99291, according to the CPT code descriptor and CPT instructions. We note that hospitals can report the appropriate clinic or emergency department visit code consistent with their internal guidelines if fewer than 30 minutes of critical care is provided.

We appreciate all of the comments we have received in the past from the public on visit guidelines, and we encourage at any time continued submission of comments that will assist us and other stakeholders interested in the development of national guidelines. Until national guidelines are established, hospitals should continue using their own internal guidelines to determine the appropriate reporting of different levels of clinic and emergency department visits. We would not expect individual hospitals to necessarily experience a normal distribution of visit levels across their claims, although we would expect a normal distribution across all hospitals as currently observed and as we would also expect if national guidelines were implemented. We understand that, based on different patterns of care, we could expect that a small community hospital might provide a greater percentage of low-level services than high-level services, while an academic medical center or trauma center might provide a greater percentage of high-level services than low-level services. We would also expect national guidelines to provide for five levels of coding, to parallel the five payment levels that currently exist.

In addition, we are adopting our CY 2008 proposal, without modification, that all hospital-specific guidelines for reporting visits should meet the 11 guideline principles listed earlier in this final rule with comment period.

While we understand the interest of some hospitals in our moving quickly to promulgate national guidelines that will ensure standardized reporting of hospital outpatient visit levels, we believe that the issues and concerns identified both by us and others that may arise are important and require serious consideration prior to the implementation of national guidelines. Because of our commitment to provide hospitals with 6 to 12 months notice prior to implementation of national guidelines, we would not implement national guidelines prior to CY 2009. Our goal is to ensure that OPSS national

or hospital-specific visit guidelines continue to facilitate consistent and accurate reporting of hospital outpatient visits in a manner that is resource-based and supportive of appropriate OPSS payments for the efficient and effective provision of visits in hospital outpatient settings.

X. OPSS Payment for Blood and Blood Products

A. Background

Since the implementation of the OPSS in August 2000, separate payments have been made for blood and blood products through APCs rather than packaging them into payments for the procedures with which they were administered. Hospital payments for the costs of blood and blood products, as well as the costs of collecting, processing, and storing blood and blood products, are made through the OPSS payments for specific blood product APCs. On April 12, 2001, CMS issued the original billing guidance for blood products to hospitals (Program Transmittal A-01-50). In response to requests for clarification of these instructions, CMS issued Program Transmittal 496 on March 4, 2005. The comprehensive billing guidelines in Program Transmittal 496 also addressed specific concerns and issues related to billing for blood-related services, which the public had brought to our attention.

In the CY 2000 OPSS, payments for blood and blood products were established based on external data provided by commenters due to limited Medicare claims data. From the CY 2000 OPSS to the CY 2002 OPSS, payment rates for blood and blood products were updated for inflation. For the CY 2003 OPSS, as described in the November 1, 2002 final rule with comment period (67 FR 66773), we applied a special adjustment methodology to blood and blood products that had significant reductions in payment rates from the CY 2002 OPSS to the CY 2003 OPSS, when median costs were first calculated from hospital claims. Using the adjustment methodology, we limited the decrease in payment rates for blood and blood products to approximately 15 percent. For the CY 2004 OPSS, as recommended by the APC Panel, we froze payment rates for blood and blood products at CY 2003 levels as we studied concerns raised by commenters and presenters at the August 2003 and February 2004 APC Panel meetings.

For the CY 2005 OPSS, we established new APCs that allowed each blood product to be assigned to its own separate APC, as several of the previous blood product APCs contained multiple blood products with no clinical

homogeneity or whose product specific median costs may not have been similar. Some of the blood product HCPCS codes were reassigned to the new APCs (Table 34 of the November 15, 2004 final rule with comment period (69 FR 65819)).

We also noted in the November 15, 2004 final rule with comment period that public comments on previous OPSS rules had stated that the CCRs that were used to adjust charges to costs for blood products in past years were too low. Past commenters indicated that this approach resulted in an underestimation of the true hospital costs for blood and blood products. In response to these comments and the APC Panel recommendations from its February 2004 and September 2004 meetings, we conducted a thorough analysis of the CY 2003 claims (used to calculate the CY 2005 APC payment rates) to compare CCRs between those hospitals reporting a blood-specific cost center and those hospitals defaulting to the overall hospital CCR in the conversion of their blood product charges to costs. As a result of this analysis, we observed a significant difference in CCRs utilized for conversion of blood product charges to costs for those hospitals with and without blood-specific cost centers. The median hospital blood-specific CCR was almost two times the median overall hospital CCR. As discussed in the November 15, 2004 final rule with comment period, we applied a special methodology for hospitals not reporting a blood-specific cost center, which simulated a blood-specific CCR for each hospital that we then used to convert charges to costs for blood products. Thus, we developed simulated medians for all blood and blood products based on CY 2003 hospital claims data (69 FR 65816).

For the CY 2005 OPSS, we also identified a subset of blood products that had less than 1,000 units billed in CY 2003. For these low-volume blood products, we based the CY 2005 OPSS payment rate on a 50/50 blend of the CY 2004 OPSS product-specific OPSS median costs and the CY 2005 OPSS simulated medians based on the application of blood-specific CCRs to all claims. We were concerned that, given the low frequency in which these products were billed, a few occurrences of coding or billing errors may have led to significant variability in the median calculation. The claims data may not have captured the complete costs of these products to hospitals as fully as possible. This low-volume adjustment methodology also allowed us to further study the issues raised by commenters

and by presenters at the September 2004 APC Panel meeting, without putting beneficiary access to these low volume blood products at risk. We have adopted the use of this modified CCR process for calculating unadjusted median costs for blood and blood products each year since the CY 2005 OPPS.

Overall, median costs from CY 2003 (used for the CY 2005 OPPS) to CY 2004 (used for the CY 2006 OPPS) were relatively stable, with a few significant increases and decreases from the CY 2005 adjusted median costs for some specific blood products. For the CY 2006 OPPS, we adopted a payment adjustment policy that limited significant decreases in APC payment rates for blood and blood products from the CY 2005 OPPS to the CY 2006 OPPS to not more than 5 percent. We applied this adjustment to 11 blood and blood product APCs for the CY 2006 OPPS, which we identified in Table 33 of the CY 2006 OPPS final rule with comment period (70 FR 68687).

In the CY 2007 OPPS, we established payment rates for blood and blood products by using the same simulation methodology described in the November 15, 2004 final rule with comment period (69 FR 65816), which utilizes hospital-specific actual or simulated CCRs for blood cost centers to convert hospital charges for blood and blood products to costs. However, we provided a payment transition for those blood products for which the difference between their CY 2006 adjusted median cost and their CY 2007 simulated median cost was greater than 25 percent. Specifically, we set the CY 2007 median costs upon which payments for blood and blood products are based at the higher of the CY 2007 unadjusted simulated median cost or 75 percent of the CY 2006 adjusted median cost on which the CY 2006 payment was based.

B. Payment for Blood and Blood Products

In the CY 2008 OPPS/ASC proposed rule (72 FR 42766 through 42767), we proposed to set the payment rates for blood and blood products for CY 2008 at the unadjusted median cost for these products, calculated using the hospital-specific simulated blood CCR for each hospital that does not have a blood cost center. For the proposed rule, we calculated median costs for blood and blood products using claims for services furnished on or after January 1, 2006, and before January 1, 2007, using the actual or simulated CCRs from the most recently available hospital cost reports. The median costs derived from this data process were relatively stable compared to the median costs on which payment

is based for CY 2007. Of the 34 blood and blood products, the proposed median costs increased for 24 products and declined for 10 products compared to the adjusted medians on which payment is based in CY 2007. Products with the largest proposed declines were, like the products with the greatest increases, mostly those products with low volume use in the hospital outpatient setting. The products whose proposed costs declined more than 5 percent account for less than 1 percent of the total volume of blood and blood products in the claims used to calculate the proposed rates. No product's median cost declined by more than 18 percent in the proposed rule data. The products whose proposed median costs increased account for 79 percent of the total volume of blood and blood products in the claims used to calculate the proposed rates.

As we indicated in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68147), we believe that the simulated CCR methodology results in accurate reflections of the relative estimated costs of these products for hospitals without blood cost centers and, therefore, for these products in general. Our 1-year adjustment to the median costs for CY 2007, where the median costs for blood and blood products decreased by more than 25 percent from the CY 2006 adjusted median costs, was intended to provide a reasonable transition to use of the simulated median costs for payment of blood and blood products under the OPPS without further adjustment. The medians that result from the use of the simulated CCR process and the CY 2006 claims available for the proposed rule generally result in median costs that we believe provide an appropriate basis for the relative weights on which the CY 2008 payments for blood and blood products would be based. Therefore, we proposed to use the median costs derived from the application of blood cost center CCRs for those hospitals that have blood cost centers or simulated blood cost center CCRs for those hospitals that do not have blood cost centers as the basis for the CY 2008 payments for blood and blood products, without further adjustment.

We received several public comments regarding this proposal. A summary of the comments and our responses follows.

Comment: Some commenters supported CMS' proposal to increase the APC payment rates for many blood products. One commenter expressed support for our methodology of utilizing hospital-specific actual or simulated CCRs for blood cost centers to convert

hospital charges for blood and blood products to costs, noting that this methodology is consistent with the principles of a prospective payment system.

Other commenters, however, stated that the payment rates for many blood and blood products do not adequately reflect their acquisition, management, and processing costs. They noted that the costs of blood and blood products continue to increase due to safety requirements, technological advances, and donor recruitment and retention challenges, and that the 2-year lag inherent in OPPS ratesetting would not allow these costs to be captured.

In particular, these commenters were concerned that the median unit cost published in the proposed rule for the blood product with the highest Medicare volume, leukocyte-reduced red blood cells, is less than the acquisition cost of the product and would fail to pay hospitals for overhead costs (for example, storage, handling, inventory management). One commenter referred to data submitted by 1,600 hospitals in response to a survey of 2004 blood costs that was conducted by the Department of Health and Human Services under a contract with the American Association of Blood Banks (AABB). According to the AABB survey, the proposed CY 2008 payment for leukocyte reduced red blood cells is less than what hospitals paid for this product in 2004.

Response: The median costs for blood and blood products in this final rule with comment period are derived from the CY 2006 hospital outpatient claims data and have the benefit of reflecting the reporting clarifications that were provided through CMS Program Transmittal 496, dated March 4, 2005. This instruction articulated and clarified many questions that had been raised by hospitals and others about how hospitals should report charges for blood and blood products. CY 2006 claims are the first OPPS claims that represent a full year of hospitals' reporting consistent with our detailed blood billing guidelines issued in CY 2005. Thus, we expect that the reporting of charges and units for blood and blood products in CY 2006 has improved over past years, especially with respect to hospitals' inclusion of all charges related to acquisition, processing, and handling of blood and blood products as specifically described in each of the relevant HCPCS P-code descriptors. As such, we believe that the median costs for blood and blood products from the CY 2006 claims data reflect this improved reporting of charges and units for these products, particularly with

regard to the most commonly furnished blood and blood products, such as leukocyte-reduced red blood cells. We do not believe it is necessary or appropriate to incorporate external data such as the AABB survey into our ratesetting process for blood and blood products because in a relative weight system, it is the relativity of costs to one another, rather than absolute cost, that is most important. External data lack relativity to the estimated costs derived from the claims and cost report data and generally are not appropriate for determining relative weights that result in payment rates.

Comment: One commenter noted that charges billed under revenue code 0391 are mapped to the blood bank cost center under cost reporting rules and in the revenue code to cost center crosswalk that we use to reduce charges to estimated costs. According to the commenter, blood transfusion or blood administration services billed under this revenue code represent charges for nursing costs to administer the blood products, rather than blood bank costs for the products themselves. The commenter stated that the CCR used by CMS to calculate median unit costs for blood is lowered as a result of revenue code 0391 mapping to the blood bank cost center, because charges associated with blood administration are included in the divisor for the blood bank CCR. Accordingly, the commenter requested that CMS not map charges billed under 0391 to the blood bank cost center.

Response: Revenue code 0391 maps to cost report center 4700, Blood Storing, Processing, and Transfusing. Because this cost center includes transfusion services in its title, it is appropriate for hospitals to report charges under revenue code 0391 for nursing costs to administer blood products, as well as for blood storage and processing, and for revenue code 0391 to map to this cost center. We do not agree that we should change our revenue code to cost center crosswalk.

After consideration of the public comments received on this proposal, we

are finalizing, without modification, our proposal to establish payment rates for blood and blood products by using the same simulation methodology described in the November 15, 2004 final rule with comment period (69 FR 65816), which utilizes hospital-specific actual or simulated CCRs for blood cost centers to convert hospital charges for blood and blood products to costs. We continue to believe that using blood-specific CCRs applied to hospital claims data will result in payments that more fully reflect hospitals' true costs of providing blood and blood products than our general methodology of defaulting to the overall hospital CCR when more specific CCRs are unavailable.

Table 45 below reflects the final median unit costs developed using the methodology described above and compares the difference between the CY 2008 simulated CCR median unit costs and the CY 2007 adjusted simulated CCR median unit costs. Of the 34 blood products, median costs per unit (calculated using the simulated blood-specific CCR methodology) for CY 2008 rise for 19 of them compared to their CY 2007 adjusted simulated median unit costs. These 19 products account for about 77 percent of all units of blood and blood products furnished to Medicare beneficiaries in the HOPD as reflected in our CY 2006 claims data. The median costs decline for 15 products, which constitute approximately 23 percent of all units of blood and blood products furnished to Medicare beneficiaries in the HOPD in CY 2006. Unlike in previous years, none of the high-volume products experience decreases of more than 25 percent. While it is true that more blood and blood products experienced a decline compared to CY 2007 adjusted simulated median costs using final rule data compared with proposed rule data, these changes are relatively minor and consistent with normal fluctuations due to CCR changes and inclusion of claims from additional providers that are commonly observed for OPSS services

when additional data are considered for the final rule.

As has been the case in the past, the low-volume products (which we have historically defined as fewer than 1,000 units per year) show the most volatility, with medians increasing as much as 84 percent compared to CY 2007 adjusted simulated median costs. Overall, of the 11 low-volume products, 7 products show increases in their median unit costs compared to their CY 2007 adjusted simulated median unit costs, and 4 products show decreases in their median unit costs compared to their CY 2007 adjusted simulated median unit costs. The 4 low-volume products for which the median costs decline compared to their CY 2007 adjusted simulated median unit costs represent only 0.18 percent of the total units of blood products furnished in the CY 2006 OPSS claims data.

In summary, we are setting the final payment rates for blood and blood products for CY 2008 based on the unadjusted medians for blood and blood products (calculated using the simulated blood-specific CCR methodology) that are derived from CY 2006 claims data as we have described. We are reassured by the relatively stable or slightly increasing median costs from CY 2005 to CY 2006 claims data for most blood products, a pattern that we believe may reflect more accurate and complete hospital reporting and charging practices for these products. Consistent with our billing guidelines, hospitals may now be taking into consideration all appropriate costs associated with providing blood and blood products when charging for those products under the OPSS. Unlike in previous years, we do not believe it is necessary to provide a transitional payment adjustment. Under this final policy, we expect that payments would increase for approximately 77 percent of blood and blood product units if patterns of furnishing blood products in CY 2008 remain similar to those in CY 2006.

TABLE 45.—CY 2008 MEDIAN COSTS FOR BLOOD AND BLOOD PRODUCTS

HCPCS code*	Short descriptor	CY 2008 units	CY 2007 Payment median: Higher of CY 2007 simulated CCR median unit cost or 75% of CY 2006 adjusted median unit cost	CY 2008 simulated CCR median unit cost
P9010	Whole blood for transfusion	2,687	\$131	\$252
P9011	Blood split unit	330	136	147
P9012	Cryoprecipitate each unit	5,811	48	41

TABLE 45.—CY 2008 MEDIAN COSTS FOR BLOOD AND BLOOD PRODUCTS—Continued

HCPCS code*	Short descriptor	CY 2008 units	CY 2007 Payment median: Higher of CY 2007 simulated CCR median unit cost or 75% of CY 2006 adjusted median unit cost	CY 2008 simulated CCR median unit cost
P9016	RBC leukocytes reduced	624,120	175	183
P9017	Plasma 1 donor frz w/in 8 hr	47,159	70	66
P9019	Platelets, each unit	21,160	59	69
P9020*	Platelet rich plasma unit	791	208	359
P9021	Red blood cells unit	155,886	129	128
P9022	Washed red blood cells unit	2,473	210	274
P9023*	Frozen plasma, pooled, sd	376	57	73
P9031	Platelets leukocytes reduced	18,608	95	106
P9032	Platelets, irradiated	10,940	129	120
P9033	Platelets leukoreduced irradiad	4,970	125	138
P9034	Platelets, pheresis	9,858	450	436
P9035	Platelet pheres leukoreduced	51,624	486	493
P9036	Platelet pheresis irradiated	1,437	416	413
P9037	Plate pheres leukoredu irradiad	26,026	614	622
P9038	RBC irradiated	6,091	196	193
P9039	RBC deglycerolized	908	356	343
P9040	RBC leukoreduced irradiated	79,642	216	237
P9043*	Plasma protein fract, 5%, 50ml	24	51	93
P9044	Cryoprecipitate reduced plasma	5,437	82	83
P9048*	Plasmaprotein fract, 5%, 250ml	624	237	213
P9050*	Granulocytes, pheresis unit	13	746	1,371
P9051*	Blood, l/r, cmv-neg	3,831	156	146
P9052	Platelets, hla-m, l/r, unit	1,723	668	638
P9053	Plt, pher, l/r cmv-neg, irr	1,627	701	678
P9054	Blood, l/r, froz/degly/wash	668	210	216
P9055*	Plt, aph/pher, l/r, cmv-neg	922	395	483
P9056	Blood, l/r, irradiated	3,986	143	145
P9057	RBC, frz/deg/wsh, l/r, irradiad	156	493	369
P9058	RBC, l/r, cmv-neg, irradiad	3,552	261	260
P9059	Plasma, frz between 8–24hour	3,480	74	77
P9060	Fr frz plasma donor retested	319	74	52

* Indicates CY 2007 payment at 75 percent of CY 2006 adjusted median cost.

XI. OPSS Payment for Observation Services

A. Observation Services (HCPCS code G0378)

Observation care is a well-defined set of specific, clinically appropriate services that include ongoing short-term treatment, assessment, and reassessment before a decision can be made regarding whether patients will require further treatment as hospital inpatients or if they are able to be discharged from the hospital. Observation status is commonly assigned to patients with unexpectedly prolonged recovery after surgery and to patients who present to the emergency department and who then require a significant period of treatment or monitoring before a decision is made concerning their next placement.

Payment for all observation care under the OPSS was packaged prior to CY 2002. Since CY 2002, separate payment of a single unit of an

observation APC for an episode of observation care has been provided in limited circumstances. Effective for services furnished on or after April 1, 2002, separate payment for observation was made if the beneficiary had chest pain, asthma, or congestive heart failure and met additional criteria for diagnostic testing, minimum and maximum limits to observation care time, physician care, and documentation in the medical record (66 FR 59879). Payment for observation care that did not meet these specified criteria was packaged. Between CY 2003 and CY 2006, several more changes were made to the OPSS policy regarding separate payment for observation care, such as: clarification that observation is not separately payable when billed with “T” status procedures on the day of or day before observation care; development of specific Level II HCPCS codes for hospital observation care and direct admission to observation care; and removal of the initially established

diagnostic testing requirements for separately payable observation (67 FR 66794, 69 FR 65828, and 70 FR 68688). Throughout this time period, we maintained separate payment for observation care only for the three specified medical conditions, and OPSS payment for observation for all other clinical conditions remained packaged.

Since January 1, 2006, hospitals have reported observation services based on an hourly unit of care using HCPCS code G0378 (Hospital observation services, per hour). This code has a status indicator of “Q” under the CY 2007 OPSS, meaning that the OPSS claims processing logic determines whether the observation is packaged or separately payable. The OCE’s current logic determines whether observation services billed under HCPCS code G0378 is separately payable through APC 0339 (Observation), or whether payment for observation services will be packaged into the payment for other separately payable services provided by

the hospital in the same encounter based on criteria discussed below. Also since January 1, 2006, hospitals have reported HCPCS code G0379 (Direct admission of patient for hospital observation care) for a direct admission of a patient to observation care. The OPSS pays separately for that direct admission reported under HCPCS code G0379 in situations where payment for the actual observation services reported under HCPCS G0378 are packaged and where the direct admission meets certain other criteria. The OCE logic determines when HCPCS code G0379 is separately payable under the OPSS.

For CY 2007, we continued to apply the criteria for separate payment for observation care and the coding and payment methodology for observation care that were implemented in CY 2006. Observation care is reported using HCPCS code G0378 and observation that meets the criteria for separate payment maps to APC 0339 (Observation). The current criteria for separate payment for observation (APC 0339) are:

A. Diagnosis Requirements

1. The beneficiary must have one of three medical conditions: congestive heart failure (CHF), chest pain, or asthma.

2. Qualifying ICD-9-CM diagnosis codes must be reported in Form Locator (FL) 76, Patient Reason for Visit, or FL 67, principal diagnosis, or both in order for the hospital to receive separate payment for APC 0339. If a qualifying ICD-9-CM diagnosis code(s) is reported in the secondary diagnosis field, but is not reported in either the Patient Reason for Visit field (FL 76) or in the principal diagnosis field (FL 67), separate payment for APC 0339 is not allowed.

B. Observation Time

1. Observation time must be documented in the medical record.

2. A beneficiary's time in observation (and hospital billing) begins with the beneficiary's admission to an observation bed.

3. A beneficiary's time in observation (and hospital billing) ends when all clinical or medical interventions have been completed, including followup care furnished by hospital staff and physicians that may take place after a physician has ordered the patient to be released or admitted as an inpatient.

4. The number of units reported with HCPCS code G0378 must equal or exceed 8 hours.

C. Additional Hospital Services

1. The claim for observation services must include one of the following services in addition to the reported

observation services. The additional services listed below must have a line item date of service on the same day or the day before the date reported for observation:

- An emergency department visit (APC 0609, 0613, 0614, 0615, or 0616); or
- A clinic visit (APC 0604, 0605, 0606, 0607, or 0608); or
- Critical care (APC 0617); or
- Direct admission to observation reported with HCPCS code G0379 (APC 0604).

2. No procedure with a "T" status indicator can be reported on the same day or day before observation care is provided.

D. Physician Evaluation

1. The beneficiary must be in the care of a physician during the period of observation, as documented in the medical record by admission, discharge, and other appropriate progress notes that are timed, written, and signed by the physician.

2. The medical record must include documentation that the physician explicitly assessed patient risk to determine that the beneficiary would benefit from observation care.

The CY 2007 list of diagnoses eligible as a criterion for separate payment for observation services may be found in Table 44 of the CY 2007 OPSS/ASC final rule with comment period (71 FR 68152).

For CY 2007, we made one minor change in payment for direct admission to observation. As part of the changes in APC assignments and payments for clinic and emergency department visits, low level clinic visits were moved from APC 0600 (Low Level Clinic Visits) to APC 0604 (Level 1 Clinic Visits), with a CY 2007 payment rate of approximately \$51. Under the circumstances where direct admission to observation is separately payable, we finalized our CY 2007 assignment of HCPCS code G0379 to APC 0604, consistent with its CY 2006 placement in the APC for Low Level Clinic Visits.

During the APC Panel's August 2006 meeting, the Observation Subcommittee made several recommendations regarding observation services. The first recommendation was that CMS consider adding syncope and dehydration to the list of diagnoses for which observation services would qualify for separate payment. Second, the Observation Subcommittee recommended that CMS perform claims analyses and present data that would allow CMS to consider revising criteria for separately payable observation care when certain procedures that are assigned status

indicator "T," for example, insertion of a bladder catheter or laceration repair, are reported on the same claim with an emergency department visit and observation care, and all other criteria for separate observation payment (for example, qualifying diagnosis code, number of hours) are met. The Panel also voted to change the name of the Observation Subcommittee to the Observation and Visit Subcommittee, based on the Panel's interest in expanding the scope of the subcommittee's work.

In response to the August 2006 APC Panel recommendations and public comments on the CY 2007 OPSS/ASC proposed rule, we stated in the CY 2007 OPSS/ASC final rule with comment period that we intended to perform a series of analyses over the upcoming year to explore the potential effects of adding syncope and dehydration as qualifying diagnoses for separately payable observation care, as well as the possibility of allowing separate observation payment for claims for observation care that also included specific minor or routine procedures that have "T" status indicators (71 FR 68150).

At the March 2007 APC Panel meeting, we discussed with the Observation and Visit Subcommittee and the full Panel the results of the requested data analyses regarding syncope and dehydration, as well as the occurrences of claims for observation care that also include specific minor or routine procedures that have "T" status indicators. With respect to the diagnosis analyses, the data presented to the Subcommittee and Panel (consisting of partial year 2006 claims data that were less complete than the claims data available for the proposed rule) showed that there were 136,977 claims for separately payable observation services for the currently eligible conditions of chest pain, asthma, and congestive heart failure, with a median cost of \$453. The frequency of claims for observation services for the diagnoses of syncope and dehydration, when all other criteria for separate payment of observation services (other than diagnosis) were met, was 46,961 claims, with a somewhat lower median cost of \$416. The effect of adding both syncope and dehydration to the current diagnoses eligible for separate payment would be to lower the median cost for APC 0339 slightly to \$443, based on the early partial 2006 data presented to the Subcommittee and Panel. For the study of "T" status procedures in relation to observation, we identified relatively few instances (5,162) where observation met all of the criteria for separate payment,

including the current three conditions of CHF, asthma, chest pain, except for the presence of a "T" status procedure. Of these claims, very few had any significant frequency. The most common procedures were those relating to heart catheterization, angioplasty procedures, and endoscopies. As we have stated in the past, we believe that the observation services in these cases may be related to these procedures, and we have no way of discerning from our data whether the procedure happened before or after the observation services.

The APC Panel made three recommendations related to these topics. First, the Panel recommended that CMS add syncope and dehydration to the list of clinical conditions eligible for separate observation payment. However, the Panel requested that, if CMS added syncope and dehydration to the list of conditions eligible for separate observation payment, CMS reexamine the claims data once CMS collects a year of observation claims data, including the additional conditions, so the Panel could reconsider this recommendation at a future meeting. Second, the Panel recommended that CMS continue to evaluate the types of diagnostic conditions that might qualify for separate observation payment in the future. Third, the Panel recommended that CMS make no changes to the criteria for separate observation payment related to the performance of "T" status procedures.

We have also taken into consideration the June 2006 IOM Report entitled, "Hospital-Based Emergency Care: At the Breaking Point." This report encourages hospitals to apply tools to improve the flow of patients through emergency departments, especially through the use of observation units (clinical decision units). The IOM report also recommends that separate OPSS payment be made for all conditions for which observation is indicated.

In the CY 2008 OPSS/ASC proposed rule, we indicated that, in light of the broader CY 2008 OPSS proposal to move toward expanded packaging of payment for supportive, dependent HOPD services, we were not accepting the Panel's recommendation related to adding syncope and dehydration to the list of diagnoses eligible for separate payment or to consider other clinical conditions for separate payment for observation care. Instead, we proposed to package all observation services (reported with HCPCS code G0378) as part of the proposed changes to packaged services discussed in section II.A.4. of the proposed rule. Because we proposed to package payment for all

observation services, we did not propose to adopt the Panel's recommendation to study claims data for separately payable observation care (including claims for observation for syncope and dehydration) that also include specific minor or routine procedures that have "T" status indicators. We agreed with the APC Panel and the IOM that there is currently no compelling rationale for a different OPSS payment approach for observation care for only three specific clinical conditions. We recognized that observation care may play an important role in the treatment of many Medicare beneficiaries in the HOPD, decreasing the need for short inpatient admissions and ensuring safe discharges of patients to their homes. Therefore, we stated that we believe that the proposed CY 2008 payment policy that would package payment for all observation services consistently for Medicare beneficiaries regardless of their diagnoses is the most appropriate approach in every case of observation care. We stated in the proposed rule that the proposed methodology encourages hospital efficiency and provides a consistent payment policy that allows hospitals to thoughtfully plan for the role of observation services in the emergency and postsurgical care of patients with many different clinical conditions.

As discussed in section II.A.4.c. of the CY 2008 OPSS/ASC proposed rule (and discussed in the same section of this final rule with comment period), observation care is one of seven categories of services for which we proposed to make packaged payment in CY 2008. In view of the recent rapid growth in HOPD services, we proposed to move toward larger payment packages and bundles under the OPSS because we believe that packaging creates incentives for providers to furnish services in the most efficient way by maximizing their flexibility to manage their resources, thereby encouraging cost containment.

We proposed to package observation care reported with HCPCS code G0378 for CY 2008 because of our belief that the facility portion of observation care is supportive and ancillary to other primary services being furnished in the HOPD. Payment for observation would be made as part of the payment for the separately payable independent services with which it is billed. We indicated in the CY 2008 OPSS/ASC proposed rule that, as part of this proposal, we would change the status indicator for HCPCS code G0378 from "Q" to "N." Although we would discontinue recognizing the criteria for separate payment related to hospital visits and qualifying

conditions, we indicated that we would retain as general reporting requirements the criteria related to physician evaluation, documentation and observation beginning and ending time because those are more general requirements that help to ensure proper reporting of observation on hospital claims. The criteria for reporting of observation services under HCPCS code G0378 that we proposed to retain are:

A. Observation Time

1. Observation time must be documented in the medical record.
2. A beneficiary's time in observation (and hospital billing) begins with the beneficiary's admission to an observation bed.
3. A beneficiary's time in observation (and hospital billing) ends when all clinical or medical interventions have been completed, including followup care furnished by hospital staff and physicians that may take place after a physician has ordered the patient to be released or admitted as an inpatient.

B. Physician Evaluation

1. The beneficiary must be in the care of a physician during the period of observation, as documented in the medical record by admission, discharge, and other appropriate progress notes that are timed, written, and signed by the physician.

2. The medical record must include documentation that the physician explicitly assessed patient risk to determine that the beneficiary would benefit from observation care.

At the September 2007 APC Panel meeting, the Observation and Visit Subcommittee and the full Panel recommended that the work of the subcommittee continue. After two presentations and robust discussion of the proposal to package observation services, the Panel made two additional recommendations. First, the Panel recommended that CMS not finalize the proposal to implement observation services packaging for CY 2008, stating that it would be detrimental for patients receiving medically necessary services and would increase costs. The Panel also requested that CMS provide specific data on observation in order to understand trends and utilization for review at the 2008 winter meeting of the Panel. This includes data related to inappropriate reporting or overutilization of observation services; frequency and utilization data for the three conditions for which observation services are now separately payable; association of observation services with emergency department and clinic visits; analysis of the frequency of claims for

observation services compared with the inpatient error rate; and a frequency distribution showing length of stay data for observation services.

Second, the Panel recommended that, if CMS finalizes the packaging of observation services, CMS should create a composite emergency department/clinic and observation APC (or a group of composite APCs) that is only paid when both services are provided. The Panel added that, if the composite APC is paid, neither the clinic nor emergency department visit would be paid separately. Also, coding and service requirements currently applicable to separately payable observation would remain the same, with the exception that there would be no clinical condition restriction on payment for the composite APC and payment rates for this composite APC would need to be adjusted based on readily available historical data. Finally, the Panel recommended that CMS evaluate any potential negative impact that the CY 2008 packaging proposal and the component specifically concerning observation would have on Medicare beneficiaries. We accept the Panel's request that CMS provide the Panel with further data related to observation services at the next meeting of the APC Panel.

After considering the APC Panel presentations, the Panel recommendations, and the public comments we received, we will neither maintain the current CY 2007 payment methodology for observation services nor implement the packaging proposal as proposed. Instead, we are accepting the recommendation of the APC Panel and the commenters to package observation services and provide payment through a composite APC methodology when the specified criteria apply, as discussed in detail in section II.A.4.c.(7) of this final rule with comment period. We note that this payment methodology will require no changes to the reporting practices of hospitals, so there should be no associated administrative burden on hospitals. The OCE will determine the payment for observation as packaged into a composite APC payment or packaged into payment for other separately payable services provided in the encounter.

As discussed earlier in section II.A.4.c.(7) of this final rule with comment period, HCPCS code G0378 is assigned a status indicator "N," meaning that its payment will always be packaged, either into one of the two composite APCs or, when the composite criteria are not met, into the payment for the major services on the claim. In

addition, we no longer require a qualifying diagnosis but, for the purposes of composite APC payment, will retain all other criteria required in CY 2007 for separate observation care payment, including: a minimum number of 8 hours; a qualifying visit, direct admission to observation care, or critical care; and no "T" status procedure reported on the day before or day of observation services.

Additionally, we are retaining the general reporting requirements for all observation services. These are the requirements related to the physician order and evaluation, documentation, and observation beginning and ending times. They are more general criteria that ensure the proper reporting of observation care on correctly coded hospital claims that reflect the charges associated with all hospital resources utilized to provide the reported services.

Comment: Many commenters, as well as the APC Panel, urged CMS to consider the inpatient error rate as well as QIO review practices before packaging observation services. Many commenters pointed to a decrease in inpatient admissions as evidence of the impact of separate payment for observation services on the decrease in hospital admissions. In addition, several commenters were concerned about pressure to bill 1 to 2 day stays as outpatient claims with observation, resulting in confusion as to the appropriate billing for observation services. For example, one commenter stated that care provided during outpatient observation is no different than the care and monitoring provided to an inpatient, often because patients in observation may be placed in a bed within the inpatient setting. One commenter requested that CMS review 1 to 2 day inpatient QIO denials for accuracy of observation status utilization and denial appropriateness.

Response: We appreciate the commenters' thoughts regarding the impact of our OPSS payment policy to pay separately for observation care for three clinical conditions on brief inpatient admissions. We continue to believe that observation care is a clinically appropriate hospital outpatient service that includes ongoing short-term treatment, assessment, and reassessment before a decision can be made regarding whether patients will require further treatment as hospital inpatients, or if they are able to be discharged from the hospital. We expect that Medicare beneficiaries who require an inpatient level of care will be admitted to the hospital as inpatients by the physicians who care for them. We also believe that our final CY 2008

payment policy to pay for extended assessment and management services that involve lengthy observation through composite APCs should pay hospitals appropriately for the services they provide as they are caring for patients until a decision about inpatient admission or safe discharge can be made.

We will work to further educate hospitals, physicians, and all Medicare contractors on appropriate billing for observation services. We also will analyze the effects of our final CY 2008 OPSS payment policy for observation services over time on patterns of Medicare beneficiary inpatient admissions, high level clinic and ED visits, and observation care.

Comment: Several commenters discussed the typical length of observation stays as support for separate payment of observation care. The stays in the comments ranged from 12 to 16 hours (in reference to patients with chest pain) to 23 hours (in reference to patients in dedicated observation units versus 2 to 3 day stays for inpatient care). The topic was also discussed by the APC Panel, which requested that CMS provide a frequency distribution of observation lengths of stay at the next APC Panel meeting.

Response: We have stated in past rules and in the Internet Only Manual (IOM) that, "in only rare and exceptional cases do reasonable and necessary outpatient observation services span more than 48 hours. In the majority of cases, the decision whether to discharge the patient from the hospital * * * or to admit the patient as an inpatient can be made in less than 48 hours, usually in less than 24 hours." We refer readers to the Medicare Claims Processing Manual, Pub. 100-4, Chapter 4, Section 290.1 for more information. We will conduct a study of observation lengths of stay for the next APC Panel meeting. However, preliminary analyses of CY 2006 claims for observation show that, of all observation claims (packaged and paid separately), 43 percent lasted 13 to 24 hours (about 358,600 claims), 37 percent lasted 24 to 48 hours (about 303,000 claims), and 3 percent lasted more than 48 hours (about 26,000 claims). Less than 10 percent of claims were for observation lasting less than 8 hours, and about 8 percent of claims were for stays of 8 to 12 hours. With respect to separately payable observation, the numbers were very similar: 45 percent lasted 13 to 24 hours (133,000 claims), 38 percent lasted 24 to 48 hours (112,000 claims), and 3 percent lasted more than 48 hours (8,600 claims). The mean and median number of hours were the same for packaged

and separately payable observation services: a mean of 25 hours and a median of 22 hours.

We are concerned about the significant number of beneficiaries who are receiving observation services for more than 24 hours, especially the 26,000 with stays of more than 48 hours. This finding seems to indicate that the latter stays are not as rare and exceptional as we have stated they should be in the context of contemporary hospital outpatient clinical practice. As we stated earlier in section II.A.4.c.(7) of this final rule with comment period, we do not expect to see an increase in claims for high level visits as a result of the new composite APCs adopted for CY 2008. We also do not expect to see a large increase in the number of claims or lengths of stay for observation care. Depending on our future claims data, we may choose to modify the composite APCs that we are adopting for CY 2008, or to move to packaging observation services more broadly into payment for all other associated services as we originally proposed, if we see that observation care is being provided to many more patients than reflected in our current data. Since we first established HCPCS code G0378 as an hourly code for hospitals to report observation services beginning in CY 2006, in accordance with our reporting instructions, hospitals have been asked to report all observation services provided with HCPCS code G0378.

Comment: Several commenters stated that providing care through outpatient observation versus inpatient admission saves beneficiary inpatient benefit days and decreases beneficiary expenses for the inpatient deductible and coinsurance. The APC Panel also recommended that we evaluate the effect of packaging on beneficiaries.

Response: We intend to evaluate the effects of packaging payment for services, including observation care, on Medicare beneficiaries, but note that it is not clear whether care provided through a hospital outpatient observation stay would increase or decrease a beneficiary's expenditures in comparison with an inpatient admission. In addition, as stated earlier, we do not consider observation services and inpatient care to be the same level of care and, therefore, they would not be interchangeable and appropriate for the same clinical scenario. Under the OPSS, the beneficiary copayment increases as the number and payment amount of separately payable services on the claim increase. The OPSS beneficiary copayment is 20 to 40 percent, depending on the service provided. Therefore, to the extent that the

resulting APC payments for a specific set of services are less under the packaging approach we have adopted for CY 2008, as many commenters have indicated they would be, beneficiary copayment could be reduced. Additionally, the length of stay may greatly impact beneficiary OPSS copayment as the number of diagnostic tests and services provided may increase as the stay lengthens. Also, self-administered drugs are excluded from Part B payment by statute, whereas payment for those costs would be included in an inpatient DRG payment. Therefore, a beneficiary placed in observation care for an extended period could have a greater or lesser out-of-pocket expense than for an inpatient stay, once all direct beneficiary expenses are included.

In summary, we are adopting our proposal to package payment for observation care reported with HCPCS code G0378 for CY 2008, with a modification to establish two new composite APCs for extended assessment and management. For CY 2008, payment for observation services reported with HCPCS code G0378 will remain packaged with status indicator "N." We are creating two composite APCs for extended assessment and management, of which observation care is a component. In addition, we will not require a qualifying diagnosis for composite APC payment, but for the purposes of composite APC payment, will retain all other criteria, including a minimum number of eight hours; a qualifying visit, direct admission, or critical care; and no "T" status procedure reported on the day before or day of observation services. Additionally, we are retaining the general reporting requirements for all observation services, whether fully packaged or included in the composite APC payment. These are criteria related to the physician order and evaluation, documentation, and observation beginning and ending times. These are the more general requirements that ensure the proper reporting of observation care on correctly coded hospital claims that reflect the charges associated with all hospital resources utilized to provide the reported services.

B. Direct Admission to Observation (HCPCS code G0379)

For CY 2007, direct admission to observation (HCPCS code G0379 (Direct admission of patient for hospital observation care)) is assigned to APC 0604 (Level 1 Hospital Clinic Visits) when the criteria are met for separate payment. For CY 2008, the proposed median cost of APC 0604 was

approximately \$53. We proposed to continue the current coding and payment methodology for direct admission to observation, with the exception of the prior requirement that HCPCS code G0379 is only eligible for separate payment if observation care reported with HCPCS code G0378 does not qualify for separate payment. That requirement would no longer be applicable, given our CY 2008 proposal to provide packaged payment for all observation care. Hospitals report HCPCS code G0379 when a patient is admitted directly to observation care after being seen by a physician in the community. Thus, for CY 2008, we proposed that in order to receive separate payment for a direct admission into observation (APC 0604), the claim must show:

1. Both HCPCS codes G0378 (Hospital observation services, per hr) and G0379 (Direct admission of patient for hospital observation care) with the same date of service.

2. That no services with a status indicator "T" or "V" or Critical Care (APC 0617) were provided on the same day of service as HCPCS code G0379.

Even though we proposed to package payment for all observation services reported by HCPCS code G0378, we indicated in the proposed rule that we believe it is necessary to continue the OCE claims processing logic in order to make appropriate payment for direct admission.

We did not receive any public comments specific to our proposed payment policy for HCPCS code G0379.

As explained in section II.A.4.c.(7) of this final rule with comment period, payment for direct admission to observation will be made either under composite APC 8002 (Level I Prolonged Assessment and Management Composite) or under APC 0604. The composite APC will apply, regardless of the patient's particular clinical condition, if the hours of observation services (HCPCS code G0378) are greater than or equal to eight and billed on the same date as HCPCS code G0378 and there is not a "T" status procedure on the same date or day before the date of HCPCS code G0378. If the composite is not applicable, payment for HCPCS code G0379 may be made under APC 0604. In general, this would occur when the units of observation reported under HCPCS code G0378 are less than eight and no services with a status indicator "T" or "V" or Critical Care (APC 0617) were provided on the same day of service as HCPCS code G0379. The final median cost of APC 0604 for CY 2008 is approximately \$53. The criteria for payment of HCPCS code G0379 under

APC 0604 will be the same as in CY 2007:

1. Both HCPCS codes G0378 (Hospital observation services, per hr) and G0379 (Direct admission of patient for hospital observation care) with the same date of service.

2. No service with a status indicator of "T" or "V" or Critical Care (APC 0617) is provided on the same day of service as HCPCS code G0379.

If either of the above criteria is not met, HCPCS code G0379 will be assigned status indicator "N."

Comment: One commenter asked CMS to clarify whether there is a discrepancy between language describing observation time in the current CY 2007 criteria for separate payment of observation services through APC 0339, listed on page 42768 of the CY 2008 OPPTS/ASC proposed rule (72 FR 42628) and language in the Medicare Claims Processing Manual, Pub. 100-4, Chapter 4, Section 290.2.2. The commenter requested clarification as to whether a physician order is still required for observation.

Response: The language cited in the CY 2008 OPPTS/ASC proposed rule and earlier in this section is also located in the Medicare Claims Processing Manual, Pub. 100-4, Chapter 4, section 290.4.3 "Separate and Packaged Payment for Observation." Sections 290.2.2 and 290.4.3 do not conflict, although the language is not identical. Section 290.2.2 is overarching guidance for the reporting of observation services that supports and explains section 290.4.3. In regard to the requirement of a physician order, although the words "physician order" are not written in section 290.4.3, a physician order is clearly contemplated, as the language in criterion number 4, Physician Evaluation, states, "1. The beneficiary must be in the care of a physician during the period of observation, as documented in the medical record by admission, discharge, and other appropriate progress notes that are timed, written, and signed by the physician. 2. The medical record must include documentation that the physician explicitly assessed patient risk to determine that the beneficiary would benefit from observation care." This criterion will be retained under the new payment methodology, as we proposed. Additionally, section 290.1 "Observation Services Overview" explicitly states that "Observation services are only covered when provided by the order of a physician or another individual authorized by State licensure law and hospital staff bylaws to admit patients to the hospital or to order outpatient services." We are not

removing the physician order requirement. The IOM will be revised to reflect the payment changes finalized in this final rule with comment period. We will revise all sections for consistency and accuracy, but we also remind hospitals that Section 290 of the Claims Processing Manual should be read in its totality.

In summary, CY 2008 payment for HCPCS code G0379, direct admission for hospital observation care, will be made either through composite APC 8002 (Level I Extended Assessment and Management Composite) or APC 0604 (Level 1 Hospital Clinic Visits). In cases where the criteria for payment under either APC are not met, HCPCS code G0379 is assigned status indicator "N."

XII. Procedures That Will Be Paid Only as Inpatient Procedures

A. Background

Section 1833(t)(1)(B)(i) of the Act gives the Secretary broad authority to determine the services to be covered and paid for under the OPPTS. Before implementation of the OPPTS in August 2000, Medicare paid reasonable costs for services provided in the outpatient department. The claims submitted were subject to medical review by the fiscal intermediaries to determine the appropriateness of providing certain services in the outpatient setting. We did not specify in regulations those services that were appropriate to provide only in the inpatient setting and that, therefore, should be payable only when provided in that setting.

In the April 7, 2000 final rule with comment period, we identified procedures that are typically provided only in an inpatient setting and, therefore, would not be paid by Medicare under the OPPTS (65 FR 18455). These procedures comprise what is referred to as the "inpatient list." The inpatient list specifies those services that are only paid when provided in an inpatient setting because of the nature of the procedure, the need for at least 24 hours of postoperative recovery time or monitoring before the patient can be safely discharged, or the underlying physical condition of the patient. As we discussed in the April 7, 2000 final rule with comment period (65 FR 18455) and the November 30, 2001 final rule (66 FR 59856), we may use any of the following criteria when reviewing procedures to determine whether or not they should be moved from the inpatient list and assigned to an APC group for payment under the OPPTS:

- Most outpatient departments are equipped to provide the services to the Medicare population.

- The simplest procedure described by the code may be performed in most outpatient departments.

- The procedure is related to codes that we have already removed from the inpatient list.

In the November 1, 2002 final rule with comment period (67 FR 66741), we added the following criteria for use in reviewing procedures to determine whether they should be removed from the inpatient list and assigned to an APC group for payment under the OPPTS:

- We have determined that the procedure is being performed in numerous hospitals on an outpatient basis; or

- We have determined that the procedure can be appropriately and safely performed in an ASC and is on the list of approved ASC procedures or has been proposed by us for addition to the ASC list.

We believe that these additional criteria help us to identify procedures that are appropriate for removal from the inpatient list.

B. Changes to the Inpatient List

For the CY 2008 OPPTS, we used the same methodology as described in the November 15, 2004 final rule with comment period (69 FR 65835) to identify a subset of procedures currently on the inpatient list that are being widely performed on an outpatient basis. These procedures were then clinically reviewed for possible removal from the inpatient list. We solicited input from the APC Panel on the appropriateness of removing 14 procedures from the OPPTS inpatient list at its March 2007 meeting. Prior to publishing the CY 2008 OPPTS/ASC proposed rule, we received one other candidate HCPCS code for removal from the OPPTS inpatient list based on a recommendation from the public that was presented to the APC Panel during its meeting on March 8, 2007. The APC Panel recommended that 13 of the 14 procedures that CMS identified for possible removal be removed from the OPPTS inpatient list. It also recommended that CMS obtain additional utilization data about 1 of the 14 procedures identified for possible removal from the OPPTS inpatient list, specifically CPT code 64818 (Sympathectomy, lumbar); and for another procedure presented for possible removal from the OPPTS inpatient list by the public, specifically, CPT code 20660 (Application of cranial tongs caliper, or stereotactic frame,

including removal (separate procedure)). The APC Panel requested that CMS provide that additional information to the APC Panel at its next meeting.

Therefore, in the CY 2008 OPPS/ASC proposed rule (72 FR 42771), we proposed to accept the APC Panel's recommendation to remove the 13 procedures from the OPPS inpatient list for CY 2008 and to assign them to clinically appropriate APCs as shown in Table 56 of the proposed rule and republished in this final rule with comment period as Table 46. In the proposed rule, we indicated that we also are accepting the recommendation from the APC Panel to gather additional utilization information for CPT codes 20660 and 64818, which we would provide to the APC Panel at its next meeting.

We received several comments in response to our proposal for the CY 2008 OPPS inpatient list. A summary of the comments and our responses follows.

Comment: A few commenters supported the proposal to remove the 13 codes listed in Table 56 of the proposed rule from the inpatient list for CY 2008. One commenter requested that, for CY 2009, CMS reassess the APC assignment for CPT code 61770 (Stereotactic localization, including burr hole(s), with insertion of catheter(s) or probe(s) for placement of radiation source). The commenter supported the proposed CY 2008 assignment of CPT code 61770 to APC 0221 (Level II Nerve Procedures) but asked CMS to ensure that, as data become available, CMS makes appropriate adjustments to the APC assignment for this CPT code.

Response: We appreciate the commenters' support and will review the APC assignment for CPT code 61770, and all other procedures payable under the OPPS, when updating the OPPS for CY 2009, in order to maintain clinical and resource homogeneity within APCs.

After consideration of the public comments received, we are finalizing our proposal, without modification, to remove 13 procedures from the OPPS inpatient list for CY 2008 and to assign them to clinically appropriate APCs as shown in Table 46 below. Also, as stated earlier, we will present data regarding CPT codes 20660 and 64818 to the APC Panel at its winter 2008 meeting. We note that we did not have additional new data available for CPT code 20660 for the APC Panel to consider at its September 2007 meeting.

TABLE 46.—HCPCS CODES FOR REMOVAL FROM INPATIENT LIST AND THEIR APC ASSIGNMENTS FOR CY 2008

HCPCS code	Long descriptor	CY 2008 APC	CY 2008 SI
21360	Open treatment of depressed malar fracture, including zygomatic arch and malar tripod	0254	T
21365	Open treatment of complicated (e.g., comminuted or involving cranial nerve foramina) fracture(s) of malar area, including zygomatic arch and malar tripod; with internal fixation and multiple surgical approaches.	0256	T
21385	Open treatment of orbital floor blowout fracture; transantral approach (Caldwell-Luc type operation).	0256	T
25931	Transmetacarpal amputation; re-amputation	0049	T
27006	Tenotomy, abductors and/or extensor(s) of hip, open (separate procedure)	0050	T
27720	Repair of nonunion or malunion, tibia; without graft, (eg, compression technique)	0063	T
27722	Repair of nonunion or malunion, tibia; with sliding graft	0064	T
50580	Renal endoscopy through nephrotomy or pyelotomy, with or without irrigation, instillation or ureteropyelography, exclusive of radiologic service; with removal of foreign body or calculus.	0161	T
51535	Cystotomy for excision, incision, or repair of ureterocele	0162	T
58805	Drainage of ovarian cyst(s), unilateral or bilateral, (separate procedure); abdominal approach	0195	T
60271	Thyroidectomy, including substernal thyroid; cervical approach	0256	T
61770	Stereotactic localization, including burr hole(s), with insertion of catheter(s) or probe(s) for placement of radiation source.	0221	T
69970	Removal of tumor, temporal bone	0256	T

Comment: Several commenters submitted recommendations for improving the effectiveness of the inpatient list. One commenter stated that although CMS believes that the inpatient list is serving a protective purpose, the payment policy and the format for the list limit its effectiveness. The commenter recommended a number of steps that CMS could take to improve the usefulness of the inpatient list. The first of these recommendations was for CMS to provide the CPT code long descriptors for the procedures on the inpatient list instead of listing the procedures' CPT code short descriptors. The commenter stated that the short descriptors do not provide enough information for hospital staff and physicians to readily determine in a specific clinical case whether a planned

procedure is, or is not, on the inpatient list. The commenter believed that inclusion of the long descriptors would make the CMS inpatient list a more useful and readily available tool that could be used during outpatient scheduling. Further, the commenter believed that easier access to the long descriptors would assist hospital staff in scheduling, promote appropriate physician planning, and provide time to notify any affected beneficiary of his or her liability if an inpatient list procedure is to be performed in the OPD.

In addition, the commenter recommended that CMS consider developing a code that would enable hospitals to indicate to Medicare those cases in which the physician failed, or refused, to notify the patient that the

procedure was on the inpatient list and would not be paid by Medicare if performed in the hospital outpatient setting. The commenter suggested that the physician could then be held accountable for those cases, and Medicare could track physicians who repeatedly chose inappropriate admission status for procedures on the inpatient list. Further, the commenter recommended that CMS implement financial disincentives for physicians' performance of the inpatient list procedures in the HOPD through proposed professional payment reductions and/or practice audits of physicians who repeatedly perform these procedures in inappropriate settings.

The commenter also recommended that CMS consider expanding the ability

of hospital staff and utilization review committees to overturn outpatient status orders when procedures on the inpatient list are performed, but the services are either not reported timely by the attending physician or are not revised upon notification of the status conflict.

Finally, the commenter recommended that if CMS is not willing to refocus the payment policy associated with the inpatient list to address physician behavior, it should drop the inpatient list altogether because the list presents a financial burden that beneficiaries and hospitals are no longer willing to bear on behalf of noncompliant and noncooperative physicians.

A number of other commenters also recommended that CMS discontinue use of the inpatient list. They stated that the continuing problem associated with the list is that the list is not binding on physicians and that, therefore, efforts by hospitals to educate them are useless.

Response: We appreciate the recommendations for improving the effectiveness of the inpatient list. We continue to believe that the inpatient list serves an important purpose in identifying those procedures that cannot be safely and effectively provided to Medicare beneficiaries in the HOPD. We are concerned that elimination of the inpatient list could result in unsafe or uncomfortable care for Medicare beneficiaries and, therefore, we will not discontinue our use of the inpatient list at this time. While we are aware that there are ongoing hospital concerns related to inpatient procedures being performed inappropriately for beneficiaries who are not inpatients and that, as a result, beneficiaries may be liable for the charges for the services, among the potential results of eliminating the list are long observation stays after some procedures and imposition of OPSS copayments that could differ significantly from a beneficiary's inpatient cost-sharing responsibilities.

In addition, we have no current plans to develop coding that would permit us to identify cases of the outpatient performance of inpatient listed procedures on Medicare beneficiaries because information on such occurrences is currently available in our OPSS claims data. Payment for physicians' services and monitoring of physicians' practice patterns are outside of the scope of this OPSS/ASC final rule with comment period. We continue to believe that it is very important for hospitals to educate physicians on Medicare services covered under the OPSS to avoid inadvertently providing services in a hospital outpatient setting

that only are covered during an inpatient stay.

We will explore the feasibility of the commenter's recommendation that CMS could assist hospitals in this effort by providing the CPT code long descriptors for the inpatient list (Addendum E to this final rule with comment period). CMS' use of CPT code short and long descriptors is governed by its agreement with the AMA, the owner and maintainer of the CPT codeset. If we are able to provide a listing of long descriptors for the inpatient list procedures, we will post that information to the CMS Web site as soon as it is available. We believe that enhanced information regarding specific procedures may foster increased understanding by physicians about the status of the inpatient list procedures and the payment implications for beneficiaries and hospitals when the procedures are performed on beneficiaries who are not admitted to the hospital.

Comment: Several commenters recommended that if CMS does not eliminate the inpatient list, it should consider developing an appeals process to address those circumstances in which payment for a service is denied because it is on the inpatient list. One commenter asserted that the process would provide an opportunity for the hospital to submit documentation to appeal the denial, such as physician intent, patient clinical condition, and the circumstances that allowed the patient to be sent home safely without an inpatient admission.

Response: We appreciate these comments and suggestions. As we stated in the immediately preceding response, we continue to believe that the inpatient list is a valuable tool that is appropriate for the OPSS, and we will not eliminate it at this time. We intend to continue to encourage physicians' awareness of the implications for beneficiaries of performing the inpatient list procedures on beneficiaries who are not inpatients. We do not plan to adopt a specific appeals process for claims related to inpatient list procedures performed in the HOPD, as recommended by some commenters, at this time. However, the existing established processes for a beneficiary or provider to appeal a specific claim remain in effect.

Comment: Two commenters requested that CMS remove certain procedures from the inpatient list. One commenter requested that CMS remove the following three CPT codes that were proposed for removal from the inpatient list in the CY 2008 proposed rule: 25931 (Transmetacarpal amputation; re-amputation), 27006 (Tenotomy,

abductors and/or extensor(s) of hip, open (separate procedure), and 27720 (Repair of nonunion or malunion, tibia; without graft, (eg, compression technique)).

The other commenter requested that CMS remove the following four additional CPT codes from the inpatient list: 20660 (Application of cranial tongs, caliper, or stereotactic frame, including removal), 27886 (Amputation, leg, through tibia and fibula; reamputation), 43420 (Closure of esophagostomy or fistula; cervical approach) and 50727 (Revision of urinary-cutaneous anastomosis (any type urostomy)).

Response: As discussed earlier in this section, we are finalizing our proposal to remove CPT codes 25931, 27006, and 27720 from the OPSS inpatient list for CY 2008.

We appreciate the additional recommendations for procedures to be removed from the inpatient list. We note that CPT code 20660 was discussed at the APC Panel's March 2007 meeting and, in accordance with the APC Panel's recommendation, we will provide utilization information regarding this service at the APC Panel's winter 2008 meeting for its consideration. We will undertake a clinical review of the additional procedures requested for removal from the inpatient list for CY 2008. However, we will not remove those procedures from the inpatient list without obtaining additional input from the APC Panel. We will provide appropriate information on CPT codes 27886, 43420, and 50727 to the APC for its review of these procedures at the APC Panel's winter 2008 meeting, along with other procedures that we may identify as candidates for proposed removal from the inpatient list for CY 2009.

XIII. Nonrecurring Technical and Policy Changes

A. Outpatient Hospital Services and Supplies Incident to a Physician Service

In the CY 2008 OPSS/ASC proposed rule (72 FR 42771), we proposed to make a technical change to § 410.27(a)(1)(iii) and (f) of the regulations relating to outpatient hospital services and supplies incident to a physician service to remove an outdated reference to "designation of a department of a provider" by CMS and replace it with language that conforms to current policy under the provider-based rules as stated in § 413.65 of the regulations. We proposed to remove from both paragraphs (a)(1)(iii) and (f) the phrase "at a location (other than an RHC or an FQHC) that CMS designates as a department of a provider under

§ 413.65 of this chapter” and replace it with “at a department of a provider, as defined in § 413.65(a)(2) of this subchapter, that has provider-based status in relation to a hospital under § 413.65 of this subchapter.”

Section 410.27 was codified in the April 7, 2000 OPSS final rule with comment period. The provider-based rules at § 413.65 were also codified in the April 7, 2000 rule, but were subsequently amended in the August 1, 2002 IPSS final rule (67 FR 50078 through 50096 and 50114 through 50118). The proposed deletion of the reference in § 410.27(a)(1)(iii) and (f) to CMS “designating” a department of a provider under § 413.65 would make those sections consistent with the 2002 amendments to the provider-based rules, in that under the amended provider-based rules, a main provider is no longer required to ask CMS to make a determination that a facility or organization is provider-based before the main provider can bill for services of the facility as if the facility were provider-based, or before the main provider can include the costs of those services in its cost report.

In the proposed rule, we also reminded hospitals of the requirements of § 410.27 concerning services and supplies furnished incident to a physician’s service to hospital outpatients. Section 410.27 applies to all “incident to” services covered under section 1861(s)(2)(B) of the Act. This provision does not apply to services covered under other benefit categories, such as clinical diagnostic laboratory services covered under section 1833(h)(1) of the Act or diagnostic services covered under section 1861(s)(2)(C) of the Act. Section 410.27(a)(1) currently states that Medicare Part B pays for hospital services and supplies furnished incident to a physician service to outpatients, including drugs and biologicals that cannot be self-administered, if they are furnished by or under arrangements made by a participating hospital, except in the case of a resident of a skilled nursing facility as provided in § 411.15(p); as an integral though incidental part of a physician’s services; and in the hospital or at a location (other than a rural health clinic or a Federally qualified health center) that CMS designates as a department of a provider under § 413.65.

As discussed in the CY 2008 OPSS/ASC proposed rule, we recognize that hospitals consider a variety of business models in their efforts to supply efficient and high quality health care services to Medicare beneficiaries and the general public, and we support such

efforts to the extent that they comply with all applicable laws and regulations, including, but not limited to, the Stark law and other anti-kickback laws. Recently, we have received an increasing number of questions about a number of hypothetical business arrangements between hospitals and other entities, including ASCs. We remind hospitals contemplating various business models that involve “incident to” services provided to hospital outpatients to consider the requirements of § 410.27. Under § 410.27, “incident to” services that are provided to hospital outpatients must be furnished in the hospital or at a department of a provider as described in more detail earlier in our proposed technical update to § 410.27(a)(1)(iii) and (f).

With regard to the potential for ASCs to provide “incident to” services under arrangements with HOPDs, in the proposed rule, we noted that the provider-based rules set forth at § 413.65 do not apply to ASCs. In addition, our longstanding policy codified at § 416.30(f) for ASCs operated by hospitals requires that “the ASC participates and is paid only as an ASC, without the option of converting to or being paid as a hospital outpatient department, unless CMS determines there is good cause to do otherwise.” In the proposed rule, we indicated that we did not believe good cause exists such that a Medicare-certified ASC would be able to provide “incident to” services under arrangement to hospital outpatients under § 410.27. Section 410.27 contains longstanding policy codified in the CY 2000 OPSS final rule with comment period and applies to all “incident to” services covered under section 1861(s)(2)(B) of the Act. While the hypothetical example we discussed above involves ASCs providing services under arrangement to an HOPD, the provision of § 410.27 applies more broadly to all “incident to” services provided either directly or under arrangements made by the hospital with another entity.

Comment: One commenter generally supported the proposed technical change to § 410.27(a)(1)(iii) and (f), but cautioned CMS against precluding a hospital’s ability to offer the best patient care by limiting physician and hospital relationships.

Response: We appreciate the commenter’s support for the proposed technical change. We do support hospitals’ efforts to develop business models that lead to the provision of high quality patient care to the extent that these models comply with all applicable laws and regulations, including, but not

limited to, the Stark law and other anti-kickback laws.

After consideration of the public comment received, we are finalizing our CY 2008 proposal, without modification, to remove from both paragraphs (a)(1)(iii) and (f) of § 410.27 the phrase “at a location (other than an RHC or an FQHC) that CMS designates as a department of a provider under § 413.65 of this chapter.” In place of the deleted phrase, we are inserting the phrase “at a department of a provider, as defined in § 413.65(a)(2) of this subchapter, that has provider-based status in relation to a hospital under § 413.65 of this subchapter.” This finalized technical change removes an outdated reference to “designation of a department of a provider” by CMS and replaces it with language that conforms to current policy under the provider-based rules specified in § 413.65 of the regulations.

B. Interrupted Procedures

Currently, when a procedure is interrupted after its initiation or the administration of anesthesia, hospitals append modifier 74 (Discontinued outpatient procedure after anesthesia administration) to the interrupted procedure, and the full OPSS payment for the procedure is made. In addition, when a procedure requiring anesthesia is discontinued after the beneficiary is prepared for the procedure and taken to the room where the procedure is to be performed, but before the administration of anesthesia, hospitals currently append modifier 73 (Discontinued outpatient procedure prior to anesthesia administration) to the discontinued procedure and receive 50-percent of the OPSS payment for the planned procedure. Hospitals also report modifier 52 to signify that a service that did not require anesthesia was partially reduced or discontinued at the physician’s discretion. Modifier 52 is reported under the OPSS for a variety of types of interrupted services, such as radiology services. Under the OPSS, we apply a 50-percent reduction to the facility payment for interrupted procedures and services reported with modifier 52.

In the CY 2008 OPSS/ASC proposed rule (72 FR 42772), we proposed to amend § 419.44 (Payment reductions for surgical procedures) to more accurately reflect the current OPSS payment policy for interrupted procedures. First, we proposed to make a technical conforming change to the title of § 419.44 by removing the word “surgical,” in order to encompass all the procedures performed in HOPDs. Second, we proposed to change the

heading of § 419.44(b) from “Terminated procedures” to “Interrupted procedures.” We proposed to make further technical conforming changes to paragraphs (b)(1) and (b)(2) by removing the words “surgical” to encompass all the procedures performed in HOPDs. Finally, we proposed to add a new paragraph (b)(3) to reflect the current policy of the application of a 50-percent reduction to the OPPTS payment when a hospital reports modifier 52 for interrupted or discontinued services that do not require anesthesia.

Comment: One comment supported our proposed changes to § 419.44.

Response: We appreciate the commenter’s support of our proposed changes.

After consideration of the public comment received, we are finalizing the proposed changes to § 419.44, as described above, without modification.

C. Transitional Adjustments—Hold Harmless Provisions

Section 419.70(d) of the regulations relating to transitional adjustments to payments for covered outpatient services furnished by small rural hospitals and SCHs located in rural areas contains two outdated cross-references to § 412.63(b) (the definition of a hospital located in a “rural area”). Several years ago, we made § 412.63 applicable from FY 1984 through FY 2004 and established a new § 412.64, effective for FY 2005 and subsequent fiscal years, to incorporate provisions to reflect our adoption of OMB’s revised CBSAs as geographic area applicable under Medicare. In the CY 2008 OPPTS/ASC proposed rule (72 FR 42772), we proposed to make a technical correction to the regulations by replacing the cross-reference to § 412.63(b) in §§ 419.70(d)(1)(i), (d)(2)(i), and (d)(4)(ii) with the more current applicable cross-reference to § 412.64(b).

We did not receive any public comments on our proposal. Therefore, we are finalizing the proposed technical correction, without modification, for CY 2008.

D. Reporting of Wound Care Services

Section 1834(k) of the Act, as added by section 4541 of the BBA, requires payment under a prospective payment system for all outpatient therapy services, that is, physical therapy services, speech-language pathology services, and occupational therapy services. As provided under section 1834(k)(5) of the Act, we created a therapy code list based on a uniform coding system (that is, the HCPCS) to identify and track these outpatient therapy services paid under the MPFS.

We provide this list of therapy codes along with their respective designation in the Medicare Claims Processing Manual Pub. 100–04, Chapter 5, section 20. Two of the designations that we use in that manual denote whether the listed therapy code is an “always therapy” service or a “sometimes therapy” service. We define an “always therapy” service as a service that must be performed by a qualified therapist under a certified therapy plan of care, and a “sometimes therapy” service as a service that may be performed by an individual outside of a certified therapy plan of care.

In the CY 2006 OPPTS final rule with comment period (70 FR 68617), we stated that the following CPT codes were classified as “sometimes therapy” services that may be appropriately provided under either a certified therapy plan of care or without a certified therapy plan of care: 97597 (Removal of devitalized tissue from wound(s), selective debridement, without anesthesia (e.g., high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps) with or without topical application(s) for ongoing care, may include use of a whirlpool, per session; total wound(s) surface area less than or equal to 20 square centimeters); 97598 (Removal of devitalized tissue from wound(s), selective debridement, without anesthesia (e.g., high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps) with or without topical application(s) for ongoing care, may include use of a whirlpool, per session; total wound(s) surface area greater than 20 square centimeters); 97602 (Removal of revitalized tissue from wound(s), non-selective debridement, without anesthesia (e.g., wet-to-moist dressings, enzymatic, abrasion) including topical application(s), wound assessment, and instruction(s) for ongoing care, per session); 97605 (Negative pressure wound therapy (e.g., vacuum assisted drainage collection), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters); and 97606 (Negative pressure wound therapy (e.g., vacuum assisted drainage collection), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters). We further stated that hospitals would receive separate payment under the OPPTS when they bill for wound care

services described by CPT codes 97597, 97598, 97602, 97605, and 97606 that are furnished to hospital outpatients by individuals independent of a therapy plan of care. In contrast, when such services are performed by a qualified therapist under a certified therapy plan of care, providers should attach an appropriate therapy modifier (that is, GP for physical therapy, GO for occupational therapy, and GN for speech language pathology) or report their charges under a therapy revenue code (that is, 0420, 0430, or 0440), or both, to receive payment under the MPFS. The OCE logic assigns these services to the appropriate APC for payment under the OPPTS if the services are not provided under a certified therapy plan of care or directs contractors to the MPFS established payment rates if the services are identified on hospital claims with a therapy modifier or therapy revenue code as therapy services.

In the CY 2008 OPPTS/ASC proposed rule (72 FR 42772), we proposed to revise the list of therapy revenue codes that may be reported with CPT codes 97597, 97598, 97602, 97605, and 97606 to designate them as services that are performed by a qualified therapist under a certified therapy plan of care, and thus payable under the MPFS, to be consistent with the current billing practices of hospitals and to ensure that we are making separate payment under the OPPTS only in appropriate situations. We proposed to revise the list of therapy revenue codes for reporting these five CPT wound care codes as therapy services to include all revenue codes in the 042X series, which incorporates all revenue codes that begin with 042, such as 0420, 0421, 0422, 0423, 0424, and 0429; the 043X series, which includes all revenue codes that begin with 043, such as 0430, 0431, 0432, 0434, and 0439; and the 044X series, which includes all revenue codes that begin with 044, such as 0440, 0441, 0442, 0443, 0444, and 0449. Therefore, for CY 2008, we proposed that when services reported with CPT codes 97597, 97598, 97602, 97605, and 97606 are performed by a qualified therapist under a certified therapy plan of care, providers should attach an appropriate therapy modifier (that is, GP for physical therapy, GO for occupational therapy, and GN for speech-language pathology) or report their charge under a therapy revenue code (that is, 042X, 043X, or 044X), or both, to receive payment under the MPFS. Under other circumstances, we proposed that hospitals would receive separate payment under the OPPTS when they bill for wound care services

described by CPT codes 97597, 97598, 97602, 97605, and 97606 that are furnished to hospital outpatients by individuals independent of a certified therapy plan of care.

We received several comments on our proposal to modify the list of therapy revenue codes that are reported with certain wound care services to signify that those services were provided by a qualified therapist under a certified therapy plan of care.

Comment: Several commenters supported the proposal to modify the revenue code list to conform to hospital billing practices. One commenter opposed the proposal; the commenter stated that changing CPT codes 97597, 97598, 97602, 97605, and 97606 to “always therapy” codes and revising the list of revenue codes that may be reported with these wound care codes would unreasonably restrict the use of the codes to a limited group of health care providers, thereby limiting beneficiaries’ access to care.

Response: We appreciate the commenters’ support for our proposal. We believe the commenter who expressed concern about the proposal has misunderstood our explanation of the proposal. We did not propose to change the five CPT codes for wound care from “sometimes therapy” to “always therapy” codes. Hospitals will be paid for these wound care codes under either the OPPS or the MPFS in CY 2008, just as they have been since CY 2006. When hospital outpatients receive wound care services by individuals outside of a certified therapy plan of care, the hospital reports the appropriate CPT code and nontherapy revenue code and is paid under the OPPS. When these services are provided to hospital outpatients by a qualified therapist under a therapy plan of care and reported using either one of the appropriate therapy modifiers, the therapy revenue code series (42X, 43X, or 44X), or both, hospitals are paid based on the MPFS. We proposed to make this minor conforming change to make our billing policy consistent with the current billing practices of hospitals. Therefore, we do not expect the change to affect Medicare beneficiaries’ access to wound care services provided by hospitals.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to pay for certain wound care services as therapy services when they are reported with any revenue code in the 42X, 43X, or 44X series.

E. Reporting of Cardiac Rehabilitation Services

Since the initiation of the OPPS, Medicare has paid for cardiac rehabilitation services in HOPDs using CPT code 93797 (Physician services for outpatient cardiac rehabilitation, without continuous ECG monitoring (per session)) and CPT code 93798 (Physician services for outpatient cardiac rehabilitation, with continuous ECG monitoring (per session)). Both codes are assigned status indicator “S” and are currently mapped to APC 0095 (Cardiac Rehabilitation) for payment.

In the CY 2008 OPPS/ASC proposed rule (72 FR 42773), for CY 2008, we proposed to discontinue recognizing the current CPT codes for cardiac rehabilitation services and to establish two new Level II HCPCS codes that we believed would be more appropriate for specifically reporting cardiac rehabilitation services under the OPPS. The proposed HCPCS codes were: GXXX1 (Physician services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per hour)) and GXXX2 (Physician services for outpatient cardiac rehabilitation; with continuous ECG monitoring (per hour)). In contrast with the current CPT codes, we indicated that we believed the descriptors of these proposed G-codes more specifically reflect the way cardiac rehabilitation services are provided in HOPDs so that reporting would be more straightforward for hospitals and would result in more accurate data for OPPS ratesetting in 2 years. Consistent with the current APC assignments of the cardiac rehabilitation CPT codes, we proposed to assign these new HCPCS codes to APC 0095 for CY 2008, with a status indicator of “S.” Accordingly, we proposed to change the status indicators for CPT codes 93797 and 93798 from “S” to “B” to indicate that alternative codes (GXXX1 and GXXX2) for cardiac rehabilitation services would be recognized for payment under the OPPS.

At the September 2007 meeting of the APC Panel, after a public presentation pertaining to the proposed coding change, the Panel recommended that CMS continue to use the existing CPT codes for cardiac rehabilitation services (CPT codes 93797 and 93798) and not replace them with the proposed per hour HCPCS G-codes, GXXX1 and GXXX2.

We received many public comments on our CY 2008 proposal to adopt two new G-codes, rather than continue to use the two available CPT codes, for the reporting of cardiac rehabilitation

services under the OPPS. A summary of the public comments and our responses follow.

Comment: Some commenters supported the proposal to use G-codes for the reporting of cardiac rehabilitation services under the CY 2008 OPPS. They believed that this proposed coding change would allow for more appropriate coding and payment for cardiac rehabilitation services in those cases where intensive programs provide multiple sessions each day. The commenters argued that appropriate payment for these programs was particularly important because of their success in improving the health and health outcomes of patients through secondary prevention. In addition, the commenters requested that CMS explicitly state that multiple sessions of cardiac rehabilitation can be paid for the same date of service when modifier 59 is reported. They also requested that CMS crosswalk the payments for both of the proposed G-codes to the higher cost CPT code 93798 to ensure that the full range of modalities provided in certain intensive cardiac rehabilitation programs are available.

Many commenters opposed the proposed change to G-codes under the OPPS for several reasons. First, they stated that the proposed change would pose an administrative burden on hospitals, which would have to report G-codes on Medicare claims and CPT codes on claims to all other payers. Although the commenters asserted that most cardiac rehabilitation sessions last for approximately 1 hour, they explained that it would be difficult to accurately crosswalk codes reported for each hour of service to codes reported for each session, in order to ensure that Medicare and other payers were charged the same for like services. Second, some commenters argued that CMS would gather no new useful data with the reporting of “per hour” codes because over 90 percent of cardiac rehabilitation programs provide sessions lasting about 1 hour (specifically 45 minutes to 1½ hours), and costs from historical hospital claims data and payment rates for the “per session” CPT codes have been stable for years. A few commenters also stated that this proposal conflicts with the National Coverage Determination (NCD) for cardiac rehabilitation, which describes cardiac rehabilitation coverage in terms of sessions. They also stated that the proposal does not comport with CMS’ CY 2008 proposed packaging approach and CMS’ stated goal of using CPT codes and CPT coding guidelines.

Almost all of the commenters, both supporting and opposing the proposal,

were concerned that the use of the term “physician services” in the G-code descriptors could be misinterpreted by Medicare contractors as requiring a physician to directly deliver the care or be in attendance during each service episode.

Some commenters who recommended the adoption of the proposed G-codes requested that CMS provide additional guidance related to reporting of the cardiac rehabilitation G-codes, such as: (1) Explaining that it is likely to be reasonable and necessary to cover 72 cardiac rehab sessions when multiple sessions are provided in one day; (2) encouraging contractors to factor the “proven results” of a program into coverage decisions and that 72 sessions should be “presumptively covered” when they are furnished by a certain intensive cardiac rehabilitation program; and (3) providing further clarification and expansion of nutritional counseling by registered dietitians, indicating that they could independently bill for nutritional counseling within cardiac rehabilitation programs using the medical nutrition therapy codes because the NCD does not specifically mention these services.

Response: We understand hospitals’ concerns related to the administrative burden associated with reporting cardiac rehabilitation services for Medicare differently from other payers and related to the potential reporting confusion that could be caused by moving to G-codes for the many hospitals whose program sessions last about 1 hour per day. However, we also are aware of several intensive cardiac rehabilitation programs that provide multiple sessions in a day, lasting several hours total. Current OPSS payment policy would provide payment for only one session per day for cardiac rehabilitation. The NCD for cardiac rehabilitation currently states that cardiac rehabilitation programs are covered for certain categories of patients and they must be comprehensive. To be comprehensive, the programs must include a medical evaluation, a program to modify cardiac risk factors (for example, nutritional counseling), prescribed exercise, education, and counseling. The NCD does not distinguish between different approaches to the delivery of cardiac rehabilitation services, whether the more common practice of two sessions per week or the more intensive programs of several sessions per day. We have not been prescriptive regarding the precise amount of time that must be spent on each component of the program to allow for flexibility and tailoring based on patient needs.

Regarding intensity, we expect the intensity of cardiac rehabilitation programs to vary by patient and by program.

We believe that it is important that our CY 2008 OPSS payment policy provide appropriate payment for cardiac rehabilitation services. In order to minimize the administrative burden on hospitals related to our proposal but permit accurate reporting and payment for cardiac rehabilitation programs that provide more than one session per day, we believe that continuing the use of CPT codes 93797 and 93798 and allowing hospitals to bill more than one session per day under some circumstances would be the most appropriate course. Therefore, for CY 2008, we will allow hospitals to report more than one unit for a date of service if more than one cardiac rehabilitation session lasting at least 1 hour each is provided on the same day. We will provide a separate APC payment for each reported session.

We note that the concern of some commenters regarding crosswalking of payment for the two proposed “per hour” G-codes to CPT code 93798 is not an issue under the OPSS because we will be continuing to use both CPT codes that map to the same clinical APC for payment in CY 2008. With respect to the commenters’ concerns about the use of the term “physician services” in the proposed G-code descriptors, we note that these codes were proposed to be parallel to the descriptors of the CPT codes for cardiac rehabilitation sessions that contain the term “physician services” in their descriptors. We are not aware that hospitals have problems with Medicare contractors’ interpretation of the CPT codes, which we will continue to use for CY 2008.

This approach adopts the recommendation of the APC Panel and many commenters, as well as addresses some commenters’ concerns about payment for appropriate cardiac rehabilitation services. We expect that most cardiac rehabilitation programs will continue to provide approximately 1 hour long session per date of service. We will monitor the trends in our claims data to ensure that reporting of cardiac rehabilitation remains consistent with expected patterns of utilization. We will provide coding and payment instructions for cardiac rehabilitation services in the program instructions implementing the January 2008 OPSS update. We will not provide the additional coverage-related guidance requested by some commenters, such as presumptive coverage and independent billing for registered dietitians. These recommendations effectively request

changes to the NCD and, therefore, are outside of the scope of the OPSS and this final rule with comment period.

After consideration of the public comments received, we are not finalizing our proposal to establish two new G-codes for reporting cardiac rehabilitation services. Instead, we will continue to use CPT codes 93797 and 93798 to report cardiac rehabilitation services under the CY 2008 OPSS. CPT codes 93797 and 93798 are assigned to APC 0095 (Cardiac Rehabilitation), with a CY 2008 median cost of approximately \$36 and status indicator “S.” Beginning in CY 2008, we will allow hospitals to report more than one unit of service per day if more than one cardiac rehabilitation session lasting at least 1 hour each is provided on the same day, but will monitor the claims data to ensure that utilization of cardiac rehabilitation services remains appropriate.

F. Reporting of Bone Marrow and Stem Cell Processing Services

The OPSS has historically recognized HCPCS code G0267 (Bone marrow or peripheral stem cell harvest, modification or treatment to eliminate cell type(s)) for depletion services for hematopoietic progenitor cells, instead of the more specific CPT codes that describe these services, including CPT codes 38210 (Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion); 38211 (Transplant preparation of hematopoietic progenitor cells; tumor cell depletion); 38212 (Transplant preparation of hematopoietic progenitor cells; red blood cell removal); 38213 (Transplant preparation of hematopoietic progenitor cells; platelet depletion); 38214 (Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion); and 38215 (Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, of buffy coat layer). These six CPT codes are currently assigned to status indicator “B,” while HCPCS code G0267 is assigned to APC 0110 (Transfusion) for payment, with a status indicator of “S.”

In the CY 2008 OPSS/ASC proposed rule (72 FR 42774), we proposed to discontinue recognizing HCPCS code G0267, assign it status indicator “B,” and recognize the six more specific CPT codes, which we proposed to assign to APC 0110 with a status indicator of “S.” We also proposed to continue to assign the historical claims data for HCPCS code G0267 to APC 0110. Historically, under the OPSS, we recognized the single G-code rather than the CPT codes

for the individual transplant cell preparation services because we believed that the services would be uncommonly provided to Medicare beneficiaries in the outpatient setting and would likely require similar resources, so that distinguishing among the services would not be necessary to ensure appropriate OPPS payment. Stakeholders have brought to our attention that the current hospital resources associated with the six different bone marrow and stem cell processing procedures described by these CPT codes may vary widely. While we recognize that the services currently reported with G0267 under the OPPS are not common HOPD procedures, the total volume of these procedures has been increasing over the past several years. Therefore, we stated that we believe that, by recognizing the six CPT codes for bone marrow and stem cell processing services, we would obtain more specific claims data for ratesetting that would enable us to pay more appropriately for these services in the future. Consistent with our general OPPS practice, we proposed to assign the newly recognized CPT codes to the clinical APC that is most appropriate based on historical claims data for the predecessor HCPCS code until we have more specific hospital resource data available to assess the specific CPT codes for possible reassignment.

In addition, in the CY 2008 OPPS/ASC proposed rule (72 FR 42774), we proposed to discontinue recognition of HCPCS code G0265 (Cryopreservation, freezing and storage of cells for therapeutic use) and G0266 (Thawing and expansion of frozen cells for therapeutic use), currently assigned status indicator "A" under the OPPS and paid according to the Medicare Clinical Laboratory Fee Schedule (CLFS), by assigning them status indicator "B" for CY 2008. We proposed to recognize, instead, CPT codes 38207 (Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage); 38208 (Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing); and 38209 (Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing) for payment under the OPPS. We believed these services were similar to blood processing services that are currently paid under the OPPS. We proposed to assign CPT codes 38207 through 38209 to APC 0344 (Level IV Pathology) based on their clinical characteristics and resource costs from historical hospital

claims data for HCPCS codes G0265 and G0266, which would have been assigned to the same clinical APC if they were to be paid under the OPPS. Although HCPCS codes G0265 and G0266 have not historically been paid under the OPPS, we have a small number of HOPD single claims from CY 2006 for these two predecessor HCPCS codes (when they were paid off the CLFS), respectively, and similar laboratory tissue cryopreservation and thawing services also were proposed for assignment to APC 0344 under the CY 2008 OPPS. We indicated in the CY 2008 OPPS/ASC proposed rule that we believe this proposal would allow us to pay appropriately for all of these bone marrow and stem cell processing services and to collect more specific hospital resource data.

At the September 2007 meeting of the APC Panel, following a public presentation regarding these bone marrow and stem cell processing services, the APC Panel recommended that CMS reevaluate its decision to place CPT codes 38210, 38211, 38212, 38213, 38214 and 38215 in APC 0110 and also to reevaluate its decision to place CPT codes 38207, 38208, and 38209 in APC 0344.

We received several public comments on our proposal to recognize the nine CPT codes for bone marrow and stem cell processing services under the CY 2008, as well on their proposed APC assignments. A summary of the comments and our response follows.

Comment: Commenters universally supported the proposal to discontinue using HCPCS codes G0265, G0266, and G0267) and to recognize the nine existing CPT codes for bone marrow and stem cell processing services. Several commenters also urged reconsideration of the proposed APC assignments of the CPT codes. Some commenters objected to the placement of CPT codes 38207 through 38209, for cryopreservation and thawing, in APC 0344 because they believed that the bone marrow and stem cell cryopreservation and thawing services require much greater hospital resources than the preparation of laboratory tissue specimens. Instead, they recommended that CMS place these codes in APC 0111 (Blood Product Exchange) because the proposed payment rate of approximately \$777 for that APC would pay an average amount for the services as a whole, paying less than the commenters' estimated costs of freezing and storing the products based upon their survey data from hospital centers that perform bone marrow transplantation services and substantially more than their average estimated cost of thawing the material.

A few commenters also disagreed with the proposed assignments of CPT codes 38210 through 38215 to APC 0110. They argued that the APC is populated mainly by transfusion procedures that do not resemble the bone marrow and stem cell depletion services either from the clinical or hospital resource perspective. The commenters also believed that, of the few single claims for G0267 that were available for ratesetting, most of those claims were for the lower cost depletion services instead of the much more uncommon and costly services reported with CPT codes 38210, for T-cell depletion, and 38211, for tumor cell depletion. Based on external cost data they collected from hospital transplant centers performing specialized bone marrow and stem cell processing services, the commenters presented two options for CPT codes 38210 and 38211: (1) Place them in APC 0112 (Apheresis and Stem Cell procedures); or (2) pay for them based on the hospital's charges adjusted to cost using the hospital's overall CCR, similar to the payment methodology for pass-through devices. The commenters recommended that the remaining CPT codes, 38212 through 38215, be placed in a separate APC as an interim step, using the median cost data for the predecessor HCPCS code G0267 to establish the APC payment rate.

Response: We appreciate the support of commenters and the APC Panel for our proposal to discontinue use of the three G-codes currently used to report bone marrow and stem cell processing services and recognize CPT codes 38207 through 38215 instead. We agree with the commenters that using the most specific CPT codes for reporting these bone marrow and stem cell processing services would reduce the administrative reporting burden for hospitals and provide more specific claims-based costs for future ratesetting. We also accept the APC Panel's recommendations to reconsider our proposed placements of these bone marrow and stem cell processing codes. We have reviewed available claims data in view of the comments, as discussed below.

After reviewing our claims data available for this final rule with comment period, we agree with the commenters that, in order to ensure clinical and resource homogeneity, it would be preferable to group CPT codes 38207 through 38209 for cryopreservation, thawing, and washing procedures with other services that involve the handling of blood products, rather than to APC 0344, where most procedures involve the processing of

tissue specimens for laboratory analysis. However, we disagree with the commenters that APC 0111, with a median cost of approximately \$724 for apheresis and autologous progenitor cell harvesting services, is an appropriate assignment. We do not believe that CPT codes 38207 through 38209 are clinically similar to apheresis services. We note that the limited claims data we have for the predecessor codes, specifically HCPCS codes G0265 and G0266, reveal median costs of approximately \$118 and \$244 based on 23 and 548 single claims, respectively. Even though these services were previously paid in the HOPD through the CLFS, CY 2006 claims data are available for OPPS ratesetting. Instead, we believe that CPT codes 38207 through 38209 should be assigned, along with other procedures involving blood products, to APC 0110 with a status indicator of "S" and an APC median cost of approximately \$214. This is consistent with the historical hospital costs for the cryopreservation and thawing services as reported under the G-codes.

Additionally, we are assigning CPT codes 38210 through 38215, reported for bone marrow and stem cell depletion services, to APC 0393 with other services that involve red blood cells and plasma. We are renaming APC 0393 "Hematologic Processing and Studies" so that the title more accurately describes all the services assigned to the APC. We are maintaining a status indicator of "S." for APC 0393. The median cost of APC 0393 is approximately \$358, the same median cost as HCPCS code G0267, the predecessor code recognized under the OPPS. We agree with the commenters that, based on our proposed assignment of the depletion services to APC 0110 according to the data for their predecessor code, while there was no violation of the 2 times rule, HCPCS code G0267 had a high median cost compared to the proposed median cost of approximately \$220 for that APC. Our reassignment of CPT codes 38210 through 38215 to APC 0393 will pay appropriately for these CPT codes while we collect more specific data on their individual resource costs.

We do not agree with the commenters that the two specific services for T-cell or tumor depletion, which that they believe are particularly costly, would be appropriately paid through APC 0112, which contains procedures for extracorporeal adsorption of cells during apheresis and reinfusion into the patient. Furthermore, we believe that a cost-based methodology for payment of these procedures would not be

consistent with the principles of a prospective payment system that provides prospectively established payment for services. The cost-based payment methodology is statutorily required for payment of pass-through devices. As we stated in the proposed rule, it is consistent with our general practice under the OPSS to make payment based on historical claims data for the predecessor HCPCS code until we have more specific hospital resource data available to assess the specific CPT codes for possible reassignment.

After consideration of the public comments received and the recommendations of the APC Panel, we are finalizing our proposal, without modification, to discontinue use of HCPCS codes G0265, G0266, and G0267 and recognize CPT codes 38207 through 38215 to report bone marrow and stem cell processing services under the OPSS. However, we are not finalizing the APC assignments of these services as proposed. Instead, we are assigning CPT codes 38207, 38208 and 38209 for cryopreserving, thawing and washing bone marrow and stem cells to APC 0110, with a median cost of approximately \$214 and a status indicator of "S." In addition, we are assigning CPT codes 38210 through 38215, reported for depletion services of bone marrow and stem cells, to APC 0393, which is renamed "Hematologic Processing and Studies," with a median cost of approximately \$358 and a status indicator of "S."

G. Reporting of Alcohol and/or Substance Abuse Assessment and Intervention Services

For CY 2008, the CPT Editorial Panel has created two new Category I CPT codes for reporting alcohol and/or substance abuse screening. They are CPT code 99408 (Alcohol and/or substance (other than tobacco) abuse structured screening (e.g., AUDIT, DAST), and brief intervention (SBI) services; 15 to 30 minutes); and CPT code 99409 (Alcohol and/or substance (other than tobacco) abuse structured screening (e.g., AUDIT, DAST), and brief intervention (SBI) services; greater than 30 minutes).

The code descriptions for these CPT codes suggest that these CPT codes may describe services that include screening services. For Medicare purposes, screening services are typically considered to be provided to beneficiaries in the absence of signs or symptoms of illness or injury; therefore, to the extent that services described by these two CPT codes have a screening element, the screening component would not meet the statutory

requirements for coverage under section 1862(a)(1)(A) of the Act. Screening services are not covered by Medicare without specific statutory authority, such as has been provided for mammography, diabetes, and colorectal cancer screening. Accordingly, we will not recognize these CPT codes that incorporate screening for payment under the OPSS.

Therefore, for CY 2008, we have created two parallel G-codes to allow for appropriate Medicare reporting and payment for alcohol and substance abuse assessment and intervention services that are not provided as screening services, but that are performed in the context of the diagnosis or treatment of illness or injury. The codes are HCPCS code G0396 (Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST) and brief intervention, 15 to 30 minutes); and HCPCS code G0397 (Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST) and intervention, greater than 30 minutes). We will instruct Medicare contractors to pay for these codes only when considered reasonable and necessary. We will also provide coding and payment instructions for these assessment and intervention services in the program instructions implementing the January 2008 OPSS update.

CPT codes 99408 and 99409 are assigned status indicator "E" for CY 2008 on an interim final basis under the OPSS, meaning that they will not be recognized for payment under the OPSS or any other Medicare payment system. HCPCS codes G0396 and G0397 are assigned status indicator "S." They are assigned, on an interim final basis, with other health and behavioral assessment and intervention services to APC 0432 (Health and Behavioral Services). We believe that HCPCS codes G0396 and G0397 share significant clinical and resources characteristics with other services also assigned to APC 0432 for CY 2008, thereby ensuring the clinical and resource homogeneity of the APC. The final CY 2008 median cost of APC 0432 is approximately \$20. Because these CPT and Level II HCPCS codes were not available for the CY 2008 OPSS/ASC proposed rule, we have flagged them with comment indicator "NI" in Addendum B of this OPSS final rule with comment period to signify that their interim payment status is subject to public comment following publication of the final rule that implements the annual OPSS update.

XIV. OPSS Payment Status and Comment Indicators

A. Payment Status Indicator Definitions

The OPSS payment status indicators (SIs) that we assign to HCPCS codes and APCs play an important role in determining payment for services under the OPSS. They indicate whether a

service represented by a HCPCS code is payable under the OPSS or another payment system and also whether particular OPSS policies apply to the code. Our final CY 2008 status indicator assignments for APCs and HCPCS codes are shown in Addendum A and Addendum B, respectively, to this final rule with comment period. As we

proposed in the CY 2008 OPSS/ASC proposed rule, in this final rule with comment period we are using the status indicators and definitions that are listed in Addendum D1, which we discuss below in greater detail.

1. Payment Status Indicators To Designate Services That Are Paid Under the OPSS

Indicator	Item/code/service	OPSS payment status
G	Pass-Through Drugs and Biologicals	(1) Paid under OPSS; separate APC payment.
H	Pass-Through Device Categories	Separate cost-based pass-through payment; not subject to co-payment.
K	(1) Non-Pass-Through Drugs and Biologicals	(1) Paid under OPSS; separate APC payment.
	(2) Therapeutic Radiopharmaceuticals	(2) Paid under OPSS; separate APC payment.
	(3) Brachytherapy Sources	(3) Paid under OPSS; separate APC payment.
	(4) Blood and Blood Products	(4) Paid under OPSS; separate APC payment.
N	Items and Services Packaged into APC Rates	Paid under OPSS; payment is packaged into payment for other services, including outliers. Therefore, there is no separate APC payment.
P	Partial Hospitalization	Paid under OPSS; per diem APC payment.
Q	Packaged Services Subject to Separate Payment under OPSS Payment Criteria.	Paid under OPSS; Addendum B displays APC assignments when services are separately payable. (1) Separate APC payment based on OPSS payment criteria. (2) If criteria are not met, payment is packaged into payment for other services, including outliers. Therefore, there is no separate APC payment.
S	Significant Procedure, Not Discounted when Multiple	Paid under OPSS; separate APC payment.
T	Significant Procedure, Multiple Reduction Applies	Paid under OPSS; separate APC payment.
V	Clinic or Emergency Department Visit	Paid under OPSS; separate APC payment.
X	Ancillary Services	Paid under OPSS; separate APC payment.

As discussed in section VII.A. of the proposed rule and this final rule with comment period, subsequent to the publication of the CY 2007 OPSS/ASC final rule with comment period, section 107(a) of the MIEA-TRHCA extended the payment period for brachytherapy sources paid under the OPSS based on a hospital's charges adjusted to cost under section 1833(t)(16)(C) of the Act for one additional year. This requirement for cost-based payment ends after December 31, 2007. Therefore, we continued the OPSS cost-based payment for brachytherapy sources through CY 2007, and are using status indicator "H" during CY 2007 to designate non-pass-through brachytherapy sources paid on a cost basis.

However, as discussed in detail in section VII.A. of this final rule with comment period, we are implementing prospective payment for brachytherapy sources paid under the OPSS in CY 2008. In accordance with this final policy, as proposed we also are discontinuing our use of payment status indicator "H" for APCs assigned to brachytherapy sources. As indicated in section VII.A. of this final rule with comment period, for CY 2008 we are using payment status indicator "K" to designate all brachytherapy source APCs that will be paid under the OPSS.

As discussed in detail in section V.B.3.a.(4)(c) of this final rule with comment period, we are implementing prospective payment for therapeutic radiopharmaceuticals separately paid under the OPSS in CY 2008. In accordance with this final policy, as proposed, we also are discontinuing our use of payment status indicator "H" for APCs assigned to therapeutic radiopharmaceuticals. Similar to the identification of other non-pass-through drugs and biologicals, for CY 2008, we are using payment status indicator "K" to designate all therapeutic radiopharmaceutical APCs that will be paid under the OPSS.

We received several public comments regarding the appropriateness of the status indicator assignments for specific HCPCS codes that are discussed in the sections of this final rule with comment period that are specific to those topics. There were also recommendations about specific payment policies for certain items and services and recommended status indicators that are discussed elsewhere in this final rule with comment period.

Comment: One commenter believed that composite APCs differ significantly from the conditional packaging methodology for special packaged codes, where CMS provides a payment for a service only if there is no other

service on the claim for the same date with status indicator "X," "V," "S," or "T." The commenter believed that CMS should assign a status indicator other than "Q" to services that may be subject to a composite APC methodology, where the service would be paid through the composite APC payment for two or more services on the same date.

Response: We appreciate the commenter's interest in refining the use of status indicator "Q" under the OPSS. However, we are adopting our proposal, without modification, to identify HCPCS codes that are members of composite APCs with status indicator "Q" for CY 2008, because we believe the definition of this status indicator appropriately describes the payment policy for these codes as well as special packaged codes, specifically that separate payment is only made if certain criteria are met. As we continue to explore the possibilities of greater packaging and encounter- and episode-based payment under the OPSS, we will consider how to further refine the OPSS status indicators to provide the most relevant information concerning payment of OPSS services.

After considering the public comments received concerning the proposed use of status indicators for services that are paid under the OPSS, we are adopting as final, without

modification, the status indicators for payable OPPS services for CY 2008 as displayed in the table above.

2. Payment Status Indicators To Designate Services That Are Paid Under a Payment System Other Than the OPPS

Indicator	Item/code/service	OPPS payment status
A	Services furnished to a hospital outpatient that are paid under a fee schedule or payment system other than OPPS, for example: <ul style="list-style-type: none"> • Ambulance Services. • Clinical Diagnostic Laboratory Services • Non-Implantable Prosthetic and Orthotic Devices. • EPO for ESRD Patients. • Physical, Occupational, and Speech Therapy. • Routine Dialysis Services for ESRD Patients Provided in a Certified Dialysis Unit of a Hospital. • Diagnostic Mammography. • Screening Mammography 	Not paid under OPPS. Paid by fiscal intermediaries/MACs under a fee schedule or payment system other than OPPS. Not subject to deductible or coinsurance.
C	Inpatient Procedures	Not paid under OPPS. Admit patient. Bill as inpatient.
F	Corneal Tissue Acquisition; Certain CRNA Services; and Hepatitis B Vaccines.	Not paid under OPPS. Paid at reasonable cost.
L	Influenza Vaccine; Pneumococcal Pneumonia Vaccine	Not paid under OPPS. Paid at reasonable cost; not subject to deductible or coinsurance.
M	Items and Services Not Billable to the Fiscal Intermediary/MAC	Not paid under OPPS.
Y	Non-Implantable Durable Medical Equipment	Not paid under OPPS. All institutional providers other than home health agencies bill to DMERC.

We did not receive any public comments regarding the status indicators to designate services paid under a payment system other than the OPPS. Therefore, we are finalizing our

CY 2008 proposal, without modification. The final status indicators are displayed in the table above.

3. Payment Status Indicators To Designate Services That Are Not Recognized Under the OPPS But That May Be Recognized by Other Institutional Providers

Indicator	Item/code/service	OPPS payment status
B	Codes that are not recognized by OPPS when submitted on an outpatient hospital Part B bill type (12x and 13x).	Not paid under OPPS. <ul style="list-style-type: none"> • May be paid by intermediaries/MACs when submitted on a different bill type, for example, 75x (CORF), but not paid under OPPS. • An alternate code that is recognized by OPPS when submitted on an outpatient hospital Part B bill type (12x and 13x) may be available.

We did not receive any public comments regarding the status indicators to designate services that are not recognized under the OPPS but that may be recognized by other institutional

providers. Therefore, we are finalizing our CY 2008 proposal, without modification. The final status indicators are displayed in the table above.

4. Payment Status Indicators to Designate Services That Are Not Payable by Medicare

Indicator	Item/code/service	OPPS payment status
D	Discontinued Codes	Not paid under OPPS or any other Medicare payment system.
E	Items, Codes, and Services: <ul style="list-style-type: none"> • That are not covered by Medicare based on statutory exclusion. • That are not covered by Medicare for reasons other than statutory exclusion. • That are not recognized by Medicare but for which an alternate code for the same item or service may be available. • For which separate payment is not provided by Medicare. 	Not paid under OPPS or any other Medicare payment system.

We did not receive any public comments regarding the status indicators to designate services that are not payable by Medicare. Therefore, we are finalizing our CY 2008 proposal, without modification. The final status indicators are displayed in the table above.

To address providers' broader interests and to make the published Addendum B more convenient for public use, we are displaying in Addendum B to this final rule with comment period all active HCPCS codes for CY 2008 and currently active HCPCS codes that will be discontinued at the end of CY 2007 that describe items or services that are: (1) Payable under the OPSS; (2) paid under a payment system other than the OPSS; (3) not recognized under the OPSS but that may be recognized by other institutional providers; and (4) not payable by Medicare. The universe of CY 2008 status indicators that we proposed for these items and services and are adopting as final without modification in this final rule with comment period are listed in the tables above.

A complete listing of HCPCS codes with payment status indicators and APC assignments for CY 2008 is also available electronically on the CMS Web site at <http://www.cms.hhs.gov/HospitalOutpatientPPS/HORD/list.asp#TopOfPage>.

B. Comment Indicator Definitions

In the November 15, 2004 final rule with comment period (69 FR 65827 and 65828), we made final our policy to use two comment indicators to identify in an OPSS final rule the assignment status of a specific HCPCS code to an APC and the timeframe when comments on the HCPCS APC assignment would be accepted. These two comment indicators are listed below.

- "NF"—New code, final APC assignment; Comments were accepted on a proposed APC assignment in the Proposed Rule; APC assignment is no longer open to comment.
- "NI"—New code, interim APC assignment; Comments will be accepted on the interim APC assignment for the new code.

In the November 10, 2005 final rule with comment period (70 FR 68702 and 68703), we adopted a new comment indicator:

- "CH"—Active HCPCS codes in current and next calendar year; status indicator and/or APC assignment have changed or active HCPCS code that will be discontinued at the end of the current calendar year.

We implemented comment indicator "CH" to designate a change in payment

status indicator and/or APC assignment for HCPCS codes in Addendum B of the CY 2006 final rule with comment period. We also stated that codes flagged with the "CH" indicator in that final rule would not be open to comment because the changes generally were previously subject to comment during the proposed rule comment period. In the CY 2008 OPSS/ASC proposed rule, for CY 2008, we proposed to continue that policy which we are now adopting in this CY 2008 OPSS/ASC final rule with comment period. When used in this OPSS/ASC final rule with comment period, the "CH" indicator is only intended to facilitate the public's review of changes made from one calendar year to another.

Only HCPCS codes with comment indicator "NI" in this CY 2008 OPSS/ASC final rule with comment period are subject to comment during the comment period for this final rule with comment period.

We are using the "CH" indicator in this final rule with comment period to call attention to changes in the payment status indicator and/or APC assignment for HCPCS codes for CY 2008 compared to their assignment as of December 31, 2007 and to identify HCPCS codes that will be discontinued at the end of CY 2007. The use of the comment indicator "CH" in association with a composite APC in this final rule with comment period indicates that the configuration of the composite APC is changed from CY 2007. We believe that using the "CH" indicator in this final rule with comment period will facilitate the public's review of the changes that we are making final for CY 2008.

As we proposed, we are terminating comment indicator "NF" because we believe its use is not relevant in the final rule.

We did not receive any public comments regarding the CY 2008 proposed OPSS comment indicators. Therefore, we are finalizing our proposed use of comment indicators for the CY 2008 OPSS/ASC final rule with comment period, without modification. The two comment indicators, "NI" and "CH," that are finalized for continued use in CY 2008 and their definitions are listed in Addendum D2 to this final rule with comment period.

XV. OPSS Policy and Payment Recommendations

A. MedPAC Recommendations

MedPAC is an independent Federal commission established under section 1805 of the Act to advise the U.S. Congress on issues affecting the Medicare program. As required under

the statute, MedPAC submits reports to Congress in March and June of each year that present its payment policy recommendations. The March 2007 MedPAC report, "Report to the Congress: Medicare Payment Policy," included the following recommendation relating specifically to the hospital OPSS:

Recommendation 2A-1: The Congress should increase payment rates for the * * * outpatient prospective payment system in 2008 by the projected rate-of-increase in the hospital market basket index, concurrent with the implementation of a quality incentive payment program.

CMS Response: As proposed in the CY 2008 OPSS/ASC proposed rule, in this final rule with comment period, we are increasing the payment rates for the CY 2008 OPSS by the projected rate-of-increase in the hospital market basket index (as discussed in section II.C. of this final rule with comment period). We are also implementing, effective for CY 2009, the reduction in the annual update factor by 2.0 percentage points for hospitals that are defined under section 1886(d)(1)(B) of the Act and that do not meet the hospital outpatient quality data reporting required by section 1833(t)(17) of the Act, as added by section 109(a) of the MIEA-TRHCA. Our adoption and implementation of hospital quality measure reporting for the CY 2008 OPSS are discussed in detail in section XVII. of this final rule with comment period.

In its June 2007 "Report to the Congress: Promoting Greater Efficiency in Medicare," MedPAC did not make any recommendations specific to the OPSS for CY 2008. As noted in the FY 2008 IPPS final rule with comment period (72 FR 47344), the June 2007 MedPAC report includes analysis and recommendations on alternatives to the method to compute the IPPS wage index for FY 2009. (See chapter 6 of the June 2007 MedPAC report to Congress.) Under our current policy, we adopt the same wage index for the OPSS as the IPPS, and, therefore, such analysis and recommendations may have possible implications for the CY 2009 OPSS. As indicated in the FY 2008 IPPS final rule with comment period (72 FR 47344), we will consider MedPAC's recommendations and analysis in making a proposal (or proposals) to revise the IPPS wage index in the FY 2009 IPPS proposed rule, as required by section 106(b)(2) of the MIEA-TRHCA. The full report can be downloaded from MedPAC's Web site at: http://www.medpac.gov/document/Jun07_EntireReport.pdf.

MedPAC submitted comments to CMS on the CY 2008 OPPS/ASC proposed rule. We have responded to these comments in each relevant section of this final rule with comment period.

B. APC Panel Recommendations

Recommendations made by the APC Panel at its March 2007 meeting are discussed in sections of this final rule with comment period that correspond to topics addressed by the APC Panel. The report and recommendations from the APC Panel's March 7–8, 2007 meeting are available on the CMS Web site at: http://www.cms.hhs.gov/FACA/05_AdvisoryPanelonAmbulatoryPaymentClassificationGroups.asp.

Recommendations made by the APC Panel at its September 2007 meeting, when it met to discuss the CY 2008 OPPS/ASC proposed rule and to hear testimony from concerned members of the public, are also discussed in sections of this final rule with comment period that correspond to topics addressed by the APC Panel. The report and recommendations of the APC Panel's September 5–6, 2007 meeting are also available on the CMS Web site at: http://www.cms.hhs.gov/FACA/05_AdvisoryPanelonAmbulatoryPaymentClassificationGroups.asp.

XVI. Update of the Revised Ambulatory Surgical Center Payment System

A. Legislative and Regulatory Authority for the ASC Payment System

Section 1832(a)(2)(F)(i) of the Act provides that benefits under the Medicare Part B include payment for facility services furnished in connection with surgical procedures specified by the Secretary that are performed in an ASC. To participate in the Medicare program as an ASC, a facility must meet the standards specified in section 1832(a)(2)(F)(i) of the Act, which are implemented in 42 CFR part 416, subpart B and subpart C of our regulations. The regulations at 42 CFR 416, subpart B set forth general conditions and requirements for ASCs, and the regulations at subpart C provide specific conditions for coverage for ASCs.

To establish the reasonable estimated allowances for ASC facility services, section 1833(i)(2)(A)(i) of the Act required us to take into account the audited costs incurred by ASCs to perform a procedure, in accordance with a survey. The ASC services benefit was enacted by Congress through the Omnibus Reconciliation Act of 1980 (Pub. L. 96–499). For a detailed discussion of the legislative history related to ASCs, we refer readers to the

June 12, 1998 proposed rule (63 FR 32291).

Section 141(b) of the Social Security Act Amendments of 1994, Pub. L. 103–432, requires us to establish a process for reviewing the appropriateness of the payment amount provided under section 1833(i)(2)(A)(iii) of the Act for intraocular lenses (IOLs) that belong to a class of new technology intraocular lenses (NTIOLs). That process was the subject of a separate final rule entitled “Adjustment in Payment Amounts for New Technology Intraocular Lenses Furnished by Ambulatory Surgical Centers,” published on June 16, 1999, in the **Federal Register** (64 FR 32198).

Section 626(b) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. 108–173, (MMA) repealed the requirement formerly found in section 1833(i)(2)(A) of the Act that the Secretary conduct a survey of ASC costs for purposes of updating ASC payment rates and required the Secretary to implement a revised ASC payment system, to be effective not later than January 1, 2008.

Section 626(c) of the MMA amended section 1833(a)(1) of the Act to require that beginning with implementation of the revised ASC payment system, payment for surgical procedures furnished in ASCs shall be 80 percent of the lesser of the actual charge for the services or the amount determined by the Secretary under the revised payment system.

Section 5103 of the Deficit Reduction Act of 2005, Pub. L. 109–171 (DRA), amended section 1833(i)(2) of the Act by adding a new subparagraph (E) to place a limitation on payments for surgical procedures in ASCs. The amended language provides that if the standard overhead amount under section 1833(i)(2)(A) of the Act for an ASC facility service for such surgical procedures, without application of any geographic adjustment, exceeds the Medicare payment amount under the hospital OPPS for the service for that year, without application of any geographic adjustment, the Secretary shall substitute the OPPS payment amount for the ASC standard overhead amount. This provision applies to surgical procedures furnished in ASCs on or after January 1, 2007, and before the effective date of the revised ASC payment system (that is, January 1, 2008).

Section 109(b) of the Medicare Improvements and Extension Act of 2006 of the Tax Relief and Health Care Act of 2006, Pub. L. 109–432 (MIEA–TRHCA), amended section 1833(i) of the Act, in part, by adding new clause (iv) to paragraph (2)(D) and by also adding

new paragraph (7)(A), which provides that the Secretary may reduce the annual ASC update by 2 percentage points if an ASC fails to submit data as required by the Secretary on selected measures of quality of care, including medication errors. Section 109(b) of the MIEA–TRCHA requires that certain quality of care reporting requirements mandated for hospitals paid under the OPPS by section 109(a) of the MIEA–TRCHA be applied in a similar manner to ASCs unless otherwise specified by the Secretary. We refer readers to sections XVII.A. and H. of this final rule with comment period for further discussion of this provision and our plans for future ASC implementation.

B. Rulemaking for the Revised ASC Payment System

On August 2, 2007, we published in the **Federal Register** (72 FR 42470) the final rule for the revised ASC payment system, effective January 1, 2008. In that final rule, we established that we would address two components of the ASC payment system annually as part of the OPPS rulemaking cycle. Section 1833(i)(1) of the Act requires us to specify, in consultation with appropriate medical organizations, surgical procedures that are appropriately performed on an inpatient basis in a hospital but that can be safely performed in an ASC, CAH, or an HOPD and to review and update the list of ASC procedures at least every 2 years.

In the August 2, 2007 revised ASC payment system final rule, we also adopted the method we will use to set payment rates for ASC services furnished in association with covered surgical procedures beginning in CY 2008. Updating covered surgical procedures and covered ancillary services, as well as their payment rates, in association with the annual OPPS rulemaking cycle is particularly important because the OPPS relative payment weights and rates will be used as the basis for the payment of most covered surgical procedures and covered ancillary services under the revised ASC payment system. This joint update process will ensure that the ASC updates occur in a regular, predictable, and timely manner. The final rule included applicable regulatory changes to 42 CFR Parts 410 and 416.

On August 2, 2007, we published in the **Federal Register** (72 FR 42778) a proposed rule which proposed to update the revised ASC payment system, along with the OPPS. We also proposed to revise the ASC regulations to provide practice expense payments to physicians who perform noncovered ASC procedures in ASCs based on the

facility practice expense (PE) relative value units (RVUs) and to exclude covered ancillary radiology services and covered ancillary drugs and biologicals from the categories of designated health services (DHS) that are subject to the physician self-referral prohibition. We note that the reference throughout the August 2, 2007 OPSS/ASC proposed rule to the final rule for the CY 2008 revised ASC payment system erroneously cited that final rule as the July 2007 final rule.

In this CY 2008 OPSS/ASC final rule with comment period, we are performing our annual update of the revised ASC payment system for CY 2008.

C. Revisions to the ASC Payment System Effective January 1, 2008

1. Covered Surgical Procedures Under the Revised ASC Payment System

a. Definition of Surgical Procedure

In order to delineate the scope of procedures that constitute "outpatient surgical procedures" for payment under the revised ASC payment system, in the August 2, 2007 revised ASC payment system final rule, we clarified what we consider to be a "surgical" procedure. Under the ASC payment system existing through CY 2007, we define a surgical procedure as any procedure described within the range of Category I CPT codes that the CPT Editorial Panel of the AMA defines as "surgery" (CPT codes 10000 through 69999). Under the revised payment system, we continue to define "surgery" using that standard. We also include within the scope of surgical procedures payable in an ASC those procedures that are described by Level II HCPCS codes or by Category III CPT codes that directly crosswalk or are clinically similar to procedures in the CPT surgical range that we have determined do not pose a significant safety risk and that we would not expect to require an overnight stay when performed in an ASC. Having established what we consider to be a "surgical procedure," we defined criteria that enable us to identify procedures that could pose a significant safety risk when performed in an ASC or that we expect would require an overnight stay within the bounds of prevailing medical practice.

b. Identification of Surgical Procedures Eligible for Payment under the Revised ASC Payment System

ASC "covered surgical procedures" are those surgical procedures for which payment is made under the revised ASC payment system. Our final policy for identifying surgical procedures eligible

for ASC payment excludes those surgical procedures that are on the OPSS inpatient list, procedures that are packaged under the OPSS, CPT unlisted surgical procedure codes, and surgical procedures that are not recognized for payment under the OPSS. Further, we exclude from ASC payment any procedure for which standard medical practice dictates that the beneficiary would typically be expected to require active medical monitoring and care at midnight following the procedure (overnight stay), and all surgical procedures that could pose a significant safety risk to Medicare beneficiaries. The criteria used under the revised ASC payment system to identify procedures that could pose a significant safety risk when performed in an ASC include those procedures that: Generally result in extensive blood loss; require major or prolonged invasion of body cavities; directly involve major blood vessels; are emergent or life-threatening in nature; or commonly require systemic thrombolytic therapy. These criteria for evaluating surgical procedures are set forth in § 416.166(c).

The list of surgical procedures that we have excluded from payment in ASCs may be found in Addendum EE posted on the CMS Web site at: <http://www.cms.hhs./ASCPayment>. As discussed above, the surgical procedures on that exclusionary list are those that are on the OPSS inpatient list, CPT unlisted codes, surgical procedures that are not recognized for payment under Medicare, and those that our clinical staff determined are not safe for Medicare beneficiaries or would be expected to require an overnight stay when provided in ASCs.

c. Payment for Covered Surgical Procedures under the Revised ASC Payment System

(1) General Policies

To make payment for most covered surgical procedures, beginning in CY 2008, we utilize the OPSS APCs as a "grouper" and the APC relative payment weights as the basis for ASC relative payment weights and for calculating ASC payment rates under the revised payment system, by applying a uniform ASC conversion factor to the ASC payment weights. For this first year of the revised ASC payment system, we adopted the OPSS relative payment weights as the ASC relative payment weights for most covered surgical procedures.

For CY 2009 and beyond, according to our established methodology, we will update the ASC relative payment weights annually using the OPSS

relative payment weights for that calendar year, as well as the practice expense payment amounts under the MPFS schedule for that calendar year, because some covered office-based surgical procedures and covered ancillary services will be paid according to MPFS amounts if those amounts are less than the rates calculated under the standard methodology of the revised ASC payment system.

Just as we scale the OPSS relative payment weights each year to ensure that the OPSS is budget neutral from one year to the next, we will rescale relative weights each year for the revised ASC payment system, beginning with the CY 2009 payment year. The purpose of scaling the relative weights is to ensure that the estimated aggregate payments under the ASC payment system for an upcoming year will be neither greater than nor less than the aggregate payments that would be made in the prior year, taking into consideration any changes or recalibrations for the upcoming year. Rescaling enables us to compensate for the effects of changes in the OPSS relative payment weights from year to year for services that are not performed in ASCs (for example, due to sudden increases or decreases in the costs of hospital outpatient emergency department visits) that could inappropriately cause the estimated ASC expenditures to increase or decrease as a function of those changes.

To establish the budget neutrality adjustment for the revised ASC payment system, we used a model that accounts for the migration of surgical procedures between ASCs, physicians' offices, and HOPDs, as discussed in the August 2, 2007 revised ASC payment system final rule (72 FR 42470). The budget neutrality adjustment for CY 2008 is based on updated CY 2008 OPSS and MPFS rates, along with updated utilization data. The ASC CY 2008 budget neutrality adjustment is multiplied by the OPSS conversion factor to establish the ASC conversion factor. The standard ASC payment for most of the covered surgical procedures displayed in Addendum AA of this final rule with comment period is calculated as the product of that ASC conversion factor multiplied by the OPSS relative payment weight for each separately payable procedure. A more detailed discussion of the methodology is provided in section XVI.L. of this final rule with comment period.

Beginning in CY 2010, we will update the ASC conversion factor for the revised ASC payment system by the percentage increase in the CPI-U (U.S. city average), as estimated for the 12-

month period ending with the midpoint of the year involved (72 FR 42519).

(2) Office-Based Procedures

Among the procedures newly identified as covered surgical procedures for payment in ASCs beginning in CY 2008 are many procedures that are performed most of the time in physicians' offices. These procedures neither pose a significant safety risk nor are they expected to require an overnight stay when performed in ASCs, and they generally require a lower level of resource intensity than do most other ASC covered surgical procedures. For those reasons, in the August 2, 2007 revised ASC payment system final rule, we adopted a policy to include them as covered surgical procedures but to ensure that payment for the facility resources associated with the procedures identified as "office-based" would not be greater when provided in ASCs than when furnished in physicians' offices (72 FR 42509).

Under the August 2, 2007 revised ASC payment system final rule, we finalized our policy to cap payment for office-based surgical procedures for which ASC payment would first be allowed beginning in CY 2008 or later years at the lesser of the MPFS nonfacility PE RVU amount or the ASC rate developed according to the standard methodology of the revised ASC payment system. For those office-based procedures for which there is no available MPFS nonfacility PE RVU amount, we will implement the cap, as appropriate, once a MPFS nonfacility PE RVU amount is available. When procedures are finalized as being office based procedures, they remain designated as office-based in future updates. We may propose that additional HCPCS codes be classified as office-based in a proposed rule for an annual ASC update after review of the most recently available utilization data. We consider for additional designation as office-based those procedures newly paid in ASCs in CY 2008 or later years that our review concludes are performed predominantly (more than 50 percent of the time) in physicians' offices, based on our consideration of volume and site of service utilization data for the procedures, as well as clinical information and comparable data for related procedures, if appropriate.

Procedures designated as office-based for CY 2008 are identified in Addendum AA to this final rule with comment period and assigned payment indicators "P2" (Office-based surgical procedures added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs;

payment based on OPSS relative surgical weight); "P3" (Office based surgical procedure added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on MPFS nonfacility PE RVUs); and "R2" (Office-based surgical procedure added to ASC list in CY 2008 or later without MPFS nonfacility PE RVUs; payment based on OPSS relative payment weight). Those procedures for which the payment indicator designation as office-based is temporary for CY 2008 are identified in Addendum AA by an asterisk. We use the temporary designation to indicate that the office-based payment indicator ("P2," "P3," or "R2") assigned to the procedure is subject to change because the HCPCS code is new and we believe we have insufficient data upon which to base a final decision regarding the code's office-based status. We will reevaluate the procedure during the next annual rulemaking cycle, and when there are data upon which to base a proposal for a final payment indicator, we will include that in our proposed rule. The remainder of the office-based procedure designations that are not identified as temporary were either already finalized in the August 2, 2007 revised ASC payment system final rule or are being finalized in this CY 2008 OPSS/ASC final rule with comment period.

(3) Device-Intensive Procedures

Under the payment policy finalized in the revised ASC payment system final rule, we use a modified payment methodology to establish the ASC payment rates for device-intensive procedures (72 FR 42503). We identify device-intensive procedures under the revised ASC payment system as covered surgical procedures that, under the OPSS, are assigned to those device-dependent APCs for which the "device offset percentage" is greater than 50 percent of the APC's median cost. The device offset percentage is our best estimate of the percentage of device cost that is included in an APC payment under the OPSS. The CY 2008 OPSS final device-dependent APCs and device offset percentages are discussed in section IV.A. of this final rule with comment period.

According to the final ASC policy, payment for implantable devices is packaged into payment for the covered surgical procedures, but we utilize a modified ASC methodology based on OPSS data to establish payment rates for the device-intensive procedures under the revised ASC payment system. According to that modified payment methodology, we apply the OPSS device offset percentage to the OPSS national

unadjusted payment to determine the device cost included in the OPSS payment rate for a device-intensive ASC covered surgical procedure, which we then set as equal to the device portion of the national unadjusted ASC payment rate for the procedure. We then calculate the service portion of the ASC payment for device-intensive procedures by applying the uniform ASC conversion factor to the service (nondevice) portion of the OPSS relative payment weight for the device-intensive procedure. Finally, we sum the ASC device portion and ASC service portion to establish the full payment for the device intensive procedure under the revised ASC payment system. For example, if the OPSS device offset percentage for the procedure is 80 percent and the OPSS national unadjusted payment is \$100, the device cost included in that payment is \$80. Under the revised ASC payment system, we also pay \$80 for the device portion of the procedure but the service portion of the OPSS payment, \$20, is adjusted by the budget neutrality adjustment (for example, using the final ASC budget neutrality adjustment, the calculation is $\$20 \times 0.65 = \13) and, if it is subject to the transition (as set forth in section XVI.C.1.c.(5) of this final rule with comment period), it is also adjusted accordingly. If the procedure in the example is not subject to the transition, its CY 2008 payment is equal to approximately \$93 ($\$80 + \13). This example illustrates the contributions of the device and service payment amounts to the national unadjusted ASC payment rate; payment to an ASC for the device-intensive service is subject to the 50 percent geographic adjustment.

We also reduce the amount of payment made to ASCs for device-intensive procedures assigned to certain OPSS APCs in those cases in which the necessary device is furnished without cost to the ASC or the beneficiary, or with a full credit for the cost of the device being replaced. A full discussion of that policy may be found in section XVI.F. of this final rule with comment period.

(4) Multiple and Interrupted Procedure Discounting

Under the revised ASC payment system, we discount payment for certain multiple and interrupted procedures performed in ASCs. While most covered surgical procedures are subject to a 50 percent reduction in ASC payment for the lower-paying procedure when more than one procedure is performed in a single operative session, those covered surgical procedures that are exempt from the multiple procedure reduction

in ASCs because they are not subject to this reduction under the OPSS, are identified in Addendum AA to this final rule with comment period with an "N" in the column labeled "Subject to multiple procedure discounting." Procedures requiring anesthesia that are terminated after the patient has been prepared for surgery and taken to the operating room but before the administration of anesthesia are reported with modifier 73, and the ASC payment for the covered surgical procedure is reduced by 50 percent. Procedures requiring anesthesia that are terminated after administration of anesthesia or initiation of the procedure are reported with modifier 74, and the ASC payment for the covered surgical procedure is made at 100 percent of the established payment rate. Procedures and services not requiring anesthesia that are partially reduced or discontinued at the physician's discretion are reported with modifier 52, and the ASC payment for the covered surgical procedure or covered ancillary service is reduced by 50 percent.

(5) Transition to Revised ASC Payment Rates

Under the revised ASC payment system, we are providing a payment transition over 4 years for all services on the CY 2007 ASC list of covered surgical procedures (72 FR 42519). Beginning in CY 2008, the contribution of CY 2007 ASC payment rates to the blended transitional rates will decrease by 25 percentage point increments each year of transitional payment, until CY 2011, when we will fully implement the revised ASC payment rates calculated under the final methodology of the revised payment system. While we do not subject the device payment portion of the total ASC payment for a device-intensive procedure to the transition policy, we transition the service payment portion of the total ASC payment for the procedure over the 4 year phase-in period. Procedures new to ASC payment for CY 2008 or later calendar years receive payments determined according to the final methodology of the revised ASC payment system, without a transition.

ASC covered surgical procedures listed in Addendum AA to this final rule with comment period that are subject to the transition are assigned payment indicators "A2" (Surgical procedure on ASC list in CY 2007; payment based on OPSS relative payment weight) and "H8" (Device-intensive procedure on ASC list in CY 2007; paid at adjusted rate). ASC covered surgical procedures listed in

Addendum AA to this final rule with comment period that are not subject to the transition are assigned payment indicators "G2" (Nonoffice-based surgical procedure added to ASC list in CY 2008 or later; payment based on OPSS relative payment weight); "J8" (Device-intensive procedure added to ASC list in CY 2008 or later; paid at adjusted rate); "P2" (Office-based surgical procedure added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on OPSS relative payment weight); "P3" (Office-based surgical procedure added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on MPFS nonfacility PE RVUs); and "R2" (Office-based surgical procedure added to ASC list in CY 2008 or later without MPFS nonfacility PE RVUs; payment based on OPSS relative payment weight).

We received many public comments on the final payment policies for covered surgical procedures under the revised ASC payment system. A summary of the public comments and our responses follow.

Comment: A number of commenters suggested that CMS: (1) Alter the definition for surgical procedures and the criteria for evaluating procedures for exclusion from the list of covered procedures; (2) not implement the office-based designations for procedures; (3) use a lower threshold to designate which procedures are eligible for payment as device-intensive; (4) allow procedures with high supply costs to go to fully implemented revised payment system rates rather than being paid at the transitional rates during the first 3 years under the revised system; and (5) use either a higher budget neutrality adjustment or differential adjustments for high and low volume procedures. Within those topics, the commenters made a range of recommendations for changes to our final policies.

Response: We appreciate the commenters' suggestions. However, the payment policies for the revised ASC payment system that are addressed by the commenters were finalized in the August 2, 2007 revised ASC payment system final rule after we received and addressed public comments. Therefore, we are not addressing these comments in this final rule with comment period. Only the comments we received during the comment period related to the proposed annual update of the revised ASC payment system that were included in the August 2, 2007 OPSS/ASC proposed rule are addressed in this final rule with comment period. Any additional changes to the payment

policies in that final rule would need to be subjected to the notice and comment rulemaking procedures through issuance of a proposed rule before any such changes could be finalized.

Comment: Several commenters recommended that CMS establish an advisory group of clinically-trained ASC experts to work with CMS staff prior to release of the annual proposed rule to review and provide clinical safety and procedure-specific data on procedures that CMS may initially deem a safety risk.

Response: We appreciate the commenters' suggestion. However, we believe that the current process for identifying procedures for exclusion from the list of covered procedures is sufficient. The process we have established allows for clinical review by our medical staff and expert advisors, as well as comments from the public on an annual basis prior to making final decisions regarding surgical procedures for exclusion from the list of ASC covered surgical procedures. Further, in contrast to the biennial process to update the ASC list under the existing ASC payment system in effect through CY 2007, the process for updating the list annually under the revised payment system increases opportunities for the public to comment on our proposed changes to the list and other aspects of the payment system that may be included in the proposed rule.

Comment: One commenter suggested CMS should develop and implement modifiers for hospitals and ASCs to use to monitor beneficiaries who, after undergoing procedures in ASCs, are discharged to hospitals. The commenter stated that, with the greatly expanded list of covered surgical procedures in place, ASCs will be prone to provide services that are beyond their capabilities. The commenter believed that ASCs may underestimate the severity of certain types of patients or cases, or both, and that as a result, beneficiaries requiring continued care will be transferred to the hospital. The commenter argued that this would result in increased health care costs. The commenter believed that, in this way, the revised ASC payment system may introduce payment inequities whereby hospitals lose money by caring for patients transferred from ASCs, many times for hospital outpatient services that would not be paid by Medicare under existing OPSS payment policy. Further, the commenter was concerned that transferred beneficiaries also may be exposed to increased financial liability for hospital services not covered by Medicare under the OPSS and that the quality of care would

suffer due to the transfer, which would require the involvement of multiple providers. For those reasons, the commenter suggested that CMS develop and implement a method to monitor ASC-to-hospital transfer activity.

Response: We do not anticipate a significant influx of transfers from ASCs to hospitals to accompany implementation of the revised payment system. As discussed above, we have an established review policy to identify and exclude from ASC payment those procedures that could pose a significant safety risk to beneficiaries when performed in the ASC setting or that are expected to require an overnight stay. We have expanded the ASC list of covered surgical procedures in order to increase physicians' choices when selecting the most appropriate place of care for beneficiaries. To this end, the implementation of the revised ratesetting methodology removes site-of-service payment differentials that may have affected physicians' decisions in the past. We believe that, under the revised payment system, physicians will choose the setting for a procedure that best suits the needs of the individual beneficiary, and that beneficiaries will benefit from expanded access to surgical services in the most efficient and appropriate setting available.

Thus, although we are sensitive to the commenter's concerns, we see no reason to implement modifiers as suggested by the commenter at this time. We will continue to analyze claims and other available data during our annual rulemaking cycle to assess the effectiveness of our policies and to make our annual updates.

2. Covered Ancillary Services Under the Revised ASC Payment System

a. General Policies

As described in § 416.163, payment is made under the revised ASC payment system for ASC services furnished in connection with covered surgical procedures. As set forth in § 416.2, ASC services include both facility services, which are defined as services that are furnished in connection with a covered surgical procedure performed in an ASC and for which payment is packaged into the ASC payment for the covered surgical procedure, and covered ancillary services, which are defined as those items and services that are integral to a covered surgical procedure performed in an ASC, for which separate payment is made under the revised ASC payment system.

"Covered ancillary services" include the following, as specified in § 416.164(b): brachytherapy sources;

certain implantable items that have pass-through status under the OPPS; certain items and services that we designate as contractor-priced (payment rate is determined by the Medicare contractor) including, but not limited to, the procurement of corneal tissue; certain drugs and biologicals for which separate payment is allowed under the OPPS; and certain radiology services for which separate payment is allowed under the OPPS.

Under the revised ASC payment system, we designate specific services that are separately payable under the OPPS as "covered ancillary services" and make separate payment to ASCs when any of the services so designated are provided on the same day as integral to a covered surgical procedure provided in the ASC (72 FR 42477). Payment for ancillary services that are packaged under the OPPS also is packaged under the revised ASC payment system (and those services are not considered to be ASC covered ancillary services). Furthermore, only the ASC can receive payment for the facility resources required to provide the covered ancillary radiology or other covered ancillary services, and ASCs are no longer able to bill as independent diagnostic testing facility (IDTF) suppliers to receive payment for ancillary radiology services that are integral to the performance of a covered surgical procedure for which the ASC is billing Medicare.

We continue to consider to be outside the scope of ASC services, as set forth in § 416.164(c), the following items and services, including, but not limited to: physicians' services (including surgical procedures and all preoperative and postoperative services that are performed by a physician); anesthesiologists' services; radiology services (other than those integral to performance of a covered surgical procedure); diagnostic procedures (other than those directly related to performance of a covered surgical procedure); ambulance services; leg arm, back, and neck braces other than those that serve the function of a cast or splint; artificial limbs; and nonimplantable prosthetic devices and DME.

We received one public comment specific to our general final payment policy for separate payment of covered ancillary services in ASCs under the revised ASC payment system. A summary of the public comment and our response follow.

Comment: MedPAC expressed concern regarding our final payment policy under the revised ASC payment system for covered ancillary services. The revised ASC payment system pays

separately for covered ancillary services in order to align the ASC payment bundles with the OPPS. However, MedPAC was concerned that separate payment for these services for which payment is currently packaged under the existing ASC payment system may lead to growth of the covered ancillary services in ASCs. MedPAC recommended that CMS pursue broader packaging policies for both ASCs and the OPPS to promote efficient resource use in both settings.

Response: We appreciate this comment from MedPAC, and as evidenced by the packaging approach that we are finalizing for the CY 2008 OPPS, as described in section II.A.4.c. of this final rule with comment period, we are expanding the packaging of ancillary services to increase the size of the payment bundles in both the OPPS and ASC settings. In particular, there are a number of radiology services, including guidance procedures, that are newly packaged under the OPPS, but which otherwise would have been paid separately in the ASC setting as covered ancillary services. We do not expect significant growth of separately payable covered ancillary services in ASCs as a direct result of providing separate payment for these services beginning in CY 2008 because, to be paid, these services must always be provided integral to covered surgical procedures in ASCs.

As discussed above, we have revised the ASC payment system to more appropriately pay for surgical procedures that are covered in that setting; that is, those procedures we have determined do not pose a significant risk to beneficiary safety and would not be expected to require an overnight stay. Because we are paying for these surgical procedures using the OPPS APCs as the grouper, we believe it is most appropriate to align the payment bundles under the OPPS and the revised ASC payment system. Increased packaging under the OPPS that alters the OPPS payment bundles will also occur under the revised ASC payment system. We believe that the changes to the ASC payment system will allow beneficiaries to receive the care they require in the most appropriate setting and ASCs to be appropriately paid for that care. We have no reason to believe that increased service growth for covered ancillary services provided in ASCs will be more likely than growth for those services provided in other settings.

b. Payment Policies for Specific Items and Services

(1) Radiology Services

Under the revised ASC payment system, we designate as “covered ancillary services” those ancillary radiology services that are separately payable under the OPSS. Thus, ASCs receive a separate payment for a covered ancillary radiology service which, by definition, is provided in the ASC integral to the performance of a covered surgical procedure. ASC payment for those covered ancillary services is at the lower of the rate developed according to the standard methodology of the revised ASC payment system or the MPFS nonfacility PE RVU amount (specifically for the technical component (TC) if the service is assigned a TC under the MPFS). No separate payment is made for ancillary services that are designated as packaged under the OPSS. We specify that a covered ancillary radiology service is integral to the performance of a covered surgical procedure if it is required for the successful performance of the surgery and is performed in the ASC immediately preceding, during, or immediately following the covered surgical procedure. Payment under the revised ASC payment system for covered ancillary radiology services is subject to geographic adjustment, like payment for ASC surgical procedures. Only the ASC can receive payment for the facility resources required to provide the covered ancillary radiology services, and ASCs are no longer able to bill as independent diagnostic testing facility (IDTF) suppliers to receive payment for any ancillary radiology services that are integral to the performance of a covered surgical procedure for which the ASC is billing Medicare. Because the packaging status of radiology services under the revised ASC payment system parallels the OPSS, any changes to the packaging of radiology services under the OPSS will also occur under the revised ASC payment system.

Ancillary radiology services include all Category I CPT codes in the radiology range established by CPT, from 70000 to 79999, and Category III CPT codes and Level II HCPCS codes that describe radiology services that crosswalk or are clinically similar to procedures in the radiology range established by CPT. This revised ASC payment system policy for each calendar year applies to all radiology services that are separately payable under the OPSS in that same calendar year. A list that includes all covered ancillary radiology services may be found in Addendum BB to this final rule with comment period. Covered ancillary radiology services are assigned payment indicator “Z2” (Radiology service paid separately when provided integral to a surgical procedure on ASC list; payment based on OPSS relative payment weight) or “Z3” (Radiology service paid separately when provided integral to a surgical procedure on ASC list; payment based on MPFS nonfacility PE RVUs). Payment for ancillary radiology services that are packaged under the OPSS is packaged under the revised ASC payment system, and those services are identified in Addendum BB to this final rule with comment period with payment indicator “N1” (Packaged service/item; no separate payment made). ASC payment for covered ancillary radiology services is not subject to the 4-year transition.

(2) Brachytherapy Sources

Under the revised ASC payment system, we designate as “covered ancillary services” those brachytherapy sources that are separately payable under the OPSS. Thus, ASCs receive separate payment for those covered ancillary brachytherapy sources that are implanted in conjunction with covered surgical procedures billed by ASCs. The application of the brachytherapy sources is integrally related to the covered surgical procedures for insertion of brachytherapy needles and catheters. There is a statutory requirement that the OPSS establish

separate payment groups for brachytherapy sources related to their number, radioisotope, and radioactive intensity, as well as for stranded and non-stranded sources as of July 1, 2007. OPSS procedure payments specifically do not include payment for brachytherapy sources. The ASC brachytherapy source payment rate for a given calendar year is the same as the OPSS payment rate for that year, without application of the ASC budget neutrality adjustment or, if specific OPSS prospective payment rates are unavailable, ASC payments for brachytherapy sources are contractor-priced. In addition, consistent with the payment of brachytherapy sources under the OPSS, the ASC payment rates for brachytherapy sources are not adjusted for geographic wage differences. The Level II HCPCS codes for brachytherapy sources and their payment rates under the CY 2008 revised ASC payment system, the same as those finalized for the CY 2008 OPSS, are included in Addendum BB to this final rule with comment period. Brachytherapy sources are assigned payment indicator “H2” (Brachytherapy source paid separately when provided integral to a surgical procedure on ASC list; payment based on OPSS rate). We note that we are finalizing our proposal to change the brachytherapy source payment indicator from “H4,” defined as “Brachytherapy source paid separately when provided integral to a surgical procedure on ASC list; payment contractor-priced” to “H2,” in order to be consistent with the final CY 2008 OPSS policy for payment of brachytherapy sources, as described in section VII. of this final rule with comment period. For CY 2008, we are paying under the OPSS at prospective rates calculated from historical claims data and, therefore, the ASC payment for brachytherapy sources will be at those same rates. The HCPCS codes for all brachytherapy sources and their ASC payment amounts and ASC payment indicators are listed in Table 47 below.

TABLE 47.—CY 2008 PAYMENTS FOR BRACHYTHERAPY SOURCES IMPLANTED IN ASCS

HCPCS code	Short descriptor	ASC payment indicator	CY 2008 ASC payment rate
A9527	Iodine I-125 sodium iodide	H2	\$27.55
C1716	Brachytx, non-str, Gold-198	H2	33.30
C1717	Brachytx, non-str, HDR Ir-192	H2	175.19
C1719	Brachytx, NS, Non-HDR Ir-192	H2	65.13
C2616	Brachytx, non-str, Yttrium-90	H2	11,764.95
C2634	Brachytx, non-str, HA, I-125	H2	30.94
C2635	Brachytx, non-str, HA, P-103	H2	46.92
C2636	Brachy linear, non-str, P-103	H2	42.04
C2638	Brachytx, stranded, I-125	H2	45.31

TABLE 47.—CY 2008 PAYMENTS FOR BRACHYTHERAPY SOURCES IMPLANTED IN ASCS—Continued

HCPCS code	Short descriptor	ASC payment indicator	CY 2008 ASC payment rate
C2639	Brachytx, non-stranded, I-125	H2	32.10
C2640	Brachytx, stranded, P-103	H2	65.66
C2641	Brachytx, non-stranded, P-103	H2	51.45
C2642	Brachytx, stranded, C-131	H2	97.72
C2643	Brachytx, non-stranded, C-131	H2	64.08
C2698	Brachytx, stranded, NOS	H2	45.31
C2699	Brachytx, non-stranded, NOS	H2	30.94

(3) Drugs and Biologicals

Under the revised ASC payment system, we designate as “covered ancillary services” all drugs and biologicals that are separately paid under the OPPS. Thus, ASCs receive separate payment for those covered ancillary drugs and biologicals which, by definition, are provided integral to a covered surgical procedure performed in an ASC. We specify that a drug or biological is integral to a covered surgical procedure if it is required for the successful performance of the surgery and is provided to the beneficiary in the ASC immediately preceding, during, or immediately following the covered surgical procedure. Payments for covered ancillary drugs and biologicals under the revised ASC payment system for a calendar year are equal to the OPPS payment rates for those drugs and biologicals that same year, without application of the ASC budget neutrality adjustment. In addition, consistent with the payment of drugs and biologicals under the OPPS, the ASC payment rates for these items are not adjusted for geographic wage differences.

A list of the covered ancillary drugs and biologicals under the CY 2008 revised ASC payment system and their payment rates are included in Addendum BB to this final rule with comment period. Covered ancillary drugs and biologicals are assigned payment indicator “K2” (Drugs and biologicals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate). Ancillary drugs and biologicals for which payment is packaged into the ASC payment for the covered surgical procedure in CY 2008 are also listed in Addendum BB, and are assigned payment indicator “N1” (Packaged service/item; no separate payment made).

(4) Implantable Devices With Pass-Through Status Under the OPPS

Under the revised ASC payment system, we provide separate payment at

contractor-priced rates for devices that are included in device categories with pass through status under the OPPS when the devices are an integral part of a covered surgical procedure. As we have specified for other services designated as covered ancillary services, a pass-through device would be considered integral to the covered surgical procedure when it is required for the successful performance of the procedure; is provided in the ASC immediately before, during, or immediately following the covered surgical procedure; and is billed by the ASC on the same day as the covered surgical procedure.

In the future, new device categories may be established that will have OPPS pass through status during all or a portion of any calendar year. For CY 2008, there are two device categories with OPPS pass-through status that are continuing in that status under the OPPS for CY 2008, specifically HCPCS code C1821 (Interspinous process distraction device (implantable)) and HCPCS code L8690 (Auditory osseointegrated device, includes all internal and external components). We note that only the surgical procedures associated with the implantation of HCPCS code L8690 are ASC covered surgical procedures for CY 2008. As under the OPPS, ASC payment for covered ancillary services, including pass-through devices, is not subject to the geographic wage adjustment.

The pass-through device category HCPCS codes are included in Addendum BB to this final rule with comment period and are assigned payment indicator “J7” (OPPS pass through device paid separately when provided integral to a surgical procedure on ASC list; payment contractor-priced). Implantable devices that receive packaged payment because they do not have OPPS pass-through status are also listed in Addendum BB to this final rule with comment period, where they are assigned payment indicator “N1” (Packaged service/item; no separate payment made).

The associated nondevice facility resources for the device implantation procedures are paid through the ASC surgical procedure service payment, based upon the payment weight for the nondevice portion of the related OPPS APC payment weight.

(5) Corneal Tissue Acquisition

Under the revised ASC payment system, we pay separately for corneal tissue procurement provided integral to the performance of an ASC covered surgical procedure based on invoice costs. The HCPCS code for corneal tissue acquisition, V2785 (Processing, preserving and transporting corneal tissue), is listed in Addendum BB to this final rule with comment period rule, and it is assigned payment indicator “F4” (Corneal tissue processing; paid at reasonable cost).

3. General Payment Policies

a. Adjustment for Geographic Wage Differences

Under the revised ASC payment system policy, we utilize 50 percent as the labor related share to adjust national ASC payment rates for geographic wage differences. Fifty percent is significantly higher than the labor-related share used for the ASC payment system through CY 2007 (34.45 percent) but is also lower than the OPPS labor-related share of 60 percent, a differential we believe is appropriate given the broader range of labor-intensive services provided in the HOPD setting.

We apply to ASC payments the IPPS pre-reclassification wage index values associated with the June 2003 OMB geographic localities, as recognized under the IPPS and OPPS, in order to adjust the labor-related portion of the national ASC payment rates for geographic wage differences. b. Beneficiary Coinsurance

Under the revised ASC payment system, beneficiary coinsurance remains at 20 percent for ASC services, except for screening flexible sigmoidoscopy and screening colonoscopy procedures. The coinsurance for screening

colonoscopies and screening flexible sigmoidoscopies is 25 percent, as required by section 1834(d) of the Act, with no deductible for those services under the revised ASC payment system.

Comment: Several commenters suggested that CMS limit the beneficiary coinsurance amount for ASC services to the Medicare Part A hospital deductible, as occurs under the OPSS. The commenters stated that the potential for higher coinsurance in the ASC setting could have a negative financial impact on beneficiaries.

Response: Although this comment is outside of the scope for this final rule with comment period, we are responding in order to provide further clarification to interested stakeholders. The revised ASC payment system results in many different payment rates effective January 1, 2008, some lower than under the existing system and some higher. The final beneficiary coinsurance policy may be found in the August 2, 2007 revised ASC payment system final rule (72 FR 42519). For the first year of the revised payment system in CY 2008, there are 171 procedures with payment rates higher than \$1,339, the highest rate under the existing ASC payment system. That means that beneficiary liability for those procedures will be greater under the revised payment system than under the existing ASC payment system. Of those procedures, 27 will result in beneficiary liability that is greater than the CY 2008 Medicare Part A hospital deductible amount of \$1,024.

While we have statutory authority to limit beneficiary copayments under the OPSS to no more than the Medicare Part A deductible for the year, Medicare program payments to ASCs are required by section 1833(a)(1)(G) of the Act to be 80 percent of the lesser of the payment amount or actual ASC charges, and beneficiaries are responsible for the remaining 20 percent. We have no authority to revise those policies. However, we point out that the coinsurance amounts under the revised ASC payment system are limited to 20 percent of the payment rate and, as such, other than for the 27 procedures noted above, are almost without exception lower than the copayment amounts under the OPSS because most of the ASC rates are lower than OPSS rates and because beneficiary copayments vary from 20 to 40 percent under the OPSS. We note that, just like under the OPSS, the ASC coinsurance amounts are applied to each separate payment made for covered surgical procedures and covered ancillary services.

D. Treatment of New HCPCS Codes

1. Treatment of New CY 2008 Category I and III CPT Codes and Level II HCPCS Codes

We finalized a policy in the August 2, 2007 revised ASC payment system final rule to evaluate each year all new HCPCS codes that describe surgical procedures to make preliminary determinations in the annual OPSS/ASC final rule with comment period regarding whether or not they meet the criteria for payment in the ASC setting and, if so, whether they are office-based procedures. These interim determinations must be made in the OPSS/ASC final rule with comment period because the new HCPCS codes and their descriptors for the upcoming calendar year are not available at the time of development of the OPSS/ASC proposed rule. In the absence of claims data that indicate where procedures described by new codes are being performed and reflect the facility resources required to perform them, we use other available information to make interim decisions regarding assignment of payment indicators for the new codes. The other sources available to us include our clinical advisors' judgment, data regarding predecessor and related HCPCS codes, information submitted by representatives of specialty societies and professional associations, and information submitted by commenters during the public comment period following publication of the final rule with comment period in the **Federal Register**. Each year, we will publish in the annual OPSS/ASC payment update final rule the interim ASC determinations for the new codes to be effective January 1 of the update year. The interim payment indicators assigned to new codes under the revised ASC payment system will be subject to comment on that final rule. We will respond to those comments in the OPSS/ASC update final rule for the following calendar year, just as we currently respond to comments about APC and status indicator assignments for new procedure codes in the OPSS update final rule for the year following publication of the code's interim OPSS treatment.

After our review of public comments and in the absence of physicians' claims data, our determination that a new code is an office based procedure and is, thereby, subject to the payment limitation, will remain temporary and subject to review, until there are adequate data available to assess the procedure's predominant sites of service. Using those data, if we confirm our determination that the new code is

office-based after taking into account the volume and utilization data for the procedure code and/or, if appropriate, the clinical characteristics, utilization, and volume of related codes, the code will be assigned permanently to the list of office-based procedures subject to the ASC payment limitation, as discussed in section XVI.C.1.c.(2) of this final rule with comment period.

New HCPCS codes for ASC implementation on January 1, 2008 are designated in Addenda AA and BB to this OPSS/ASC final rule with comment period with comment indicator "NI." The "NI" comment indicator is used to identify those HCPCS codes for which the assigned ASC payment indicator is subject to public comment. (We refer readers to section XVI.J. of this final rule with comment period for a discussion of the ASC payment and comment indicators.)

2. Treatment of New Mid-Year Category III CPT Codes

Twice each year, the AMA issues Category III CPT codes, which the AMA defines as temporary codes for emerging technology, services, and procedures. The AMA established Category III CPT codes to allow collection of data specific to the service described by the code which otherwise only could be reported using a Category I CPT unlisted code. The AMA releases Category III CPT codes in January, for implementation beginning the following July, and in July, for implementation beginning the following January.

CMS provides predictable quarterly updates for the OPSS throughout each calendar year (January, April, July, and October), and the final payment policies of the revised ASC payment system parallel, in many cases, the OPSS treatment of HCPCS codes. As discussed in the August 2, 2007 revised ASC payment system final rule, we also provide quarterly ASC updates for each calendar quarter to recognize newly created HCPCS codes for ASC payment and to update the payment rates for separately paid drugs and biologicals based on the most recently submitted ASP data.

Under the OPSS and MPFS, CMS allows Category III CPT codes that are released by the AMA in January to be effective beginning July of the same calendar year in which they are issued, rather than deferring implementation of those codes to the following calendar year update of the payment systems, as is the case for the CPT Category I and Category III codes that are released in July by the AMA for implementation in January of the upcoming calendar year. Thus, new Category III CPT codes are

made effective under the MPFS and OPFS biannually. In order to be consistent in this regard across the three payment systems, in the CY 2008 OPFS/ASC proposed rule (72 FR 42783), we proposed to adopt that same policy under the revised ASC payment system.

Some of the new Category III CPT codes may describe services that our clinical advisors determine directly crosswalk or are clinically similar to HCPCS codes that describe ASC covered surgical procedures. In those instances, we may allow ASC payment for new Category III CPT codes as covered surgical procedures. Similarly, a new code may represent an ancillary service that directly crosswalks or is clinically similar to an ancillary service for which separate ASC payment is allowed when it is performed integral to an ASC covered surgical procedure, and, as such, the new code also may be determined to be eligible for ASC payment as a covered ancillary service.

We did not receive any public comments regarding our proposal to recognize for ASC payment new CPT Category III codes, as appropriate, in July of each year as we do under the OPFS and MPFS. Therefore, beginning in CY 2008, we are including in the July quarterly update to the ASC payment system, the ASC payment indicators for new Category III CPT codes that the AMA releases in January, and that we determine are appropriate ASC covered surgical procedures or covered ancillary services for implementation, as payable in ASCs beginning in July of the same year. Likewise, as described above, we will implement annually for payment in the January update of the ASC payment system any of the Category III CPT codes that the AMA released the previous July, along with new Category I CPT codes that are determined to be appropriate for ASC payment. Interim ASC payment indicators will be assigned to those new mid-year Category III CPT codes that are released in January for implementation in July of a given calendar year, and the interim ASC indicators will be open to comment in the OPFS/ASC proposed rule for the following calendar year and their status will be made final in the update year's final rule.

Of the Category III CPT codes the AMA released January 1, 2007, we have determined that only one is appropriate for payment in ASCs as a covered ancillary radiology service. The new CPT code is 0182T (High dose rate

electronic brachytherapy, per fraction), and we proposed to assign it to the list of covered ancillary services with payment indicator "Z2" for payment in ASCs beginning January 1, 2008. This service has no MPFS nonfacility PE RVUs assigned to it. Therefore, we proposed that its CY 2008 ASC payment be calculated according to the standard ASC payment system methodology, based on the code's OPFS relative payment weight.

We do not believe that any of the other Category III CPT codes released in January 2007 for implementation in July 2007 meet the criteria for inclusion on the ASC list of covered surgical procedures or covered ancillary services because they do not directly crosswalk and are not clinically similar to established covered ASC services.

We did not receive any public comments about our proposed assignment of ASC payment indicator "Z2" to CPT code 0182T. Therefore, we are finalizing our assignment of ASC payment indicator "Z2" to CPT code 0182T for CY 2008.

3. Treatment of Level II HCPCS Codes Released on a Quarterly Basis

In addition to the Category III CPT codes that are released twice each year, new Level II HCPCS codes may be created more frequently and are implemented for the MPFS and OPFS on a quarterly basis. Level II HCPCS codes are most commonly created for the purpose of reporting new drugs and biologicals but also are created for reporting some surgical procedures and other services for which payment may be made under the revised ASC payment system, as it is under the OPFS.

We base the ASC payment policies for covered surgical procedures, drugs, biologicals, and certain other covered ancillary services integral to ASC covered surgical procedures on the OPFS. Therefore, we proposed to update the coding and payment for the services in ASCs at the same time that the OPFS is updated. We proposed to recognize newly created Level II HCPCS codes under the revised ASC payment system for payment on a quarterly basis, consistent with the quarterly updates to the OPFS. Just as we provide a predictable quarterly update for the OPFS occurring throughout each calendar year (January, April, July, and October), we also would provide predictable quarterly updates for ASCs to recognize newly created Level II

HCPCS codes for ASC payment and to update the payment rates for separately paid drugs and biologicals based on the most recently submitted ASP data.

In the CY 2008 OPFS/ASC proposed rule, we also proposed to update the lists of covered surgical procedures and ancillary services that qualify for separate payment in ASCs in CY 2008 by adding eight new CY 2007 Level II HCPCS codes that were implemented in the OPFS in July 2007. Because of the timing of the proposed rule, the new Level II HCPCS codes implemented through the July 2007 OPFS update were not included in Addendum BB to the proposed rule.

We did not receive any comments regarding the proposed payment indicators for the eight new CY 2007 Level II HCPCS codes that were implemented in the OPFS in July 2007. Therefore, we are finalizing our payment for them in the ASC setting, as proposed. The eight codes are listed in Table 48 below, as well as in Addendum BB to this final rule with comment. Beginning in CY 2008, with implementation of the revised ASC payment system, the Level II HCPCS codes describing new procedures, drugs, and biologicals will be payable in ASCs in the same calendar quarter as they are initially paid under the OPFS.

We assigned payment indicator "K2" to seven of the eight new codes for drugs to indicate that separate payment will be made for those drugs when they are provided to beneficiaries in ASCs integral to covered surgical procedures. Level II HCPCS code C9728 (Placement of interstitial device(s) for radiation/surgery guidance (e.g., fiducial markers, dosimeter), other than prostate (any approach), single or multiple) is a covered surgical procedure with payment indicator "R2" because it is clinically similar to CPT code 55876 (Placement of interstitial device(s) for radiation therapy guidance (e.g., fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple) that we have included on the list of covered surgical procedures with a payment indicator of "P3." While we believe both procedures are office-based, there are currently no MPFS nonfacility PE RVUs available for the Level II HCPCS code C9728, which was initially established in response to a New Technology APC application under the OPFS, and, therefore, its payment indicator is "R2."

TABLE 48.—LEVEL II HCPCS CODES IMPLEMENTED UNDER THE OPPTS IN JULY 2007 THAT WILL BE PAID IN CY 2008 IN ASCS

CY 2007 HCPCS code	CY 2008 HCPCS code	Descriptor	CY 2008 ASC payment indicator
C9728	C9728	Placement of interstitial device(s) for radiation therapy/surgery guidance (e.g., fiducial markers, dosimeter), other than prostate (any approach), single or multiple.	R2
Q4087	J1568	Injection, immune globulin, (Octagam), intravenous, non-lyophilized, (e.g. liquid), 500 mg	K2
Q4088	J1569	Injection, immune globulin, (Gammagard Liquid), intravenous, non-lyophilized, (e.g. liquid), 500 mg.	K2
Q4089	J2791	Injection, rho(d) immune globulin (human), (Rhophylac), intravenous, 100 iu	K2
Q4090	J1571	Injection, hepatitis b immune globulin (Hepagam B), intramuscular, 0.5 ml	K2
Q4091	J1572	Injection, immune globulin, (Flebogamma), intravenous, non-lyophilized (e.g. liquid), 500 mg	K2
Q4092	J1561	Injection, immune globulin, (Gamunex), intravenous, non-lyophilized (e.g. liquid), 500 mg	K2
Q4095	J3488	Injection, zoledronic acid (Reclast), 1 mg	K2

We did not receive any public comments regarding our proposal to implement new Level II HCPCS codes for ASC payment on a quarterly basis each year and new Category III CPT codes on a semiannual basis, to parallel the policies under the MPFS and OPPTS for the recognition of those codes. Therefore, beginning in CY 2008 with implementation of the revised ASC payment system, we are implementing new Level II HCPCS codes for ASC payment on a quarterly basis each year and new Category III CPT codes on a semiannual basis, to parallel the policies under the MPFS and OPPTS for the recognition of those codes. Also, consistent with the MPFS and OPPTS policies, our final policy with regard to HCPCS codes implemented on January 1 of a calendar year is to publish the new codes and interim payment indicators annually in the OPPTS/ASC final rule with comment period.

E. Updates to Covered Surgical Procedures and Covered Ancillary Services

1. Identification of Covered Surgical Procedures

a. General Policies

We published Addendum AA to the August 2, 2007 revised ASC payment system final rule as an illustrative list of covered surgical procedures and payment rates for the revised ASC payment system to be implemented January 1, 2008. The final rule established our policies for determining which procedures are eligible to be considered ASC covered surgical procedures and, of those, which are excluded from ASC payment because they pose a significant risk to beneficiary safety or would be expected to require an overnight stay. We adopted a definition of surgical procedure for the revised ASC payment system as those procedures described by all Category I

CPT codes in the surgical range from 10000 through 69999 except unlisted procedure codes, as well as those Category III CPT codes and Level II HCPCS codes that crosswalk or are clinically similar to ASC covered surgical procedures.

Section 1833(i)(1) of the Act requires us to review and update the list of ASC procedures at least every 2 years. We finalized our policy to update the ASC list of covered surgical procedures annually, in conjunction with annual proposed and final rulemaking to update the OPPTS and ASC payment systems. Each year we undertake a review of excluded procedures, new procedures, and procedures for which there is revised coding to identify any that we believe are appropriate for coverage in ASCs because they do not pose significant risks to beneficiary safety and would not be expected to require overnight stays.

In the August 2, 2007 revised ASC payment system final rule, we finalized the addition of approximately 790 new covered surgical procedures for payment under the revised ASC payment system beginning in CY 2008. In the CY 2008 OPPTS/ASC proposed rule, we proposed to remove 13 procedures from the OPPTS inpatient list and, of those 13, we believe that 3 are safe for performance in ASCs. Therefore, we proposed to add the following three additional surgical procedures to the ASC list of covered surgical procedures eligible for Medicare ASC payment in CY 2008: CPT codes 25931 (Amputation, forearm, through radius and ulna; re-amputation); 50580 (Renal endoscopy through nephrotomy or pyelotomy, with or without irrigation, instillation, or uteropyelography, exclusive of radiologic service; with removal of foreign body or calculus); and 58805 (Drainage of ovarian cyst(s), unilateral or bilateral, (separate procedure); abdominal approach).

We did not receive any public comments about our proposal to designate CPT codes 25931, 50580, and 58805 as payable in ASCs as covered surgical procedures beginning CY 2008. Therefore, we are finalizing our proposal to designate the three procedures as payable in ASCs as covered surgical procedures, assigning them payment indicator “G2,” beginning in CY 2008.

In the CY 2008 OPPTS/ASC proposed rule, we also solicited comments and recommendations regarding additional surgical procedures that commenters believe should not be excluded from ASC payment beginning in CY 2008. We specifically encouraged commenters to provide evidence, to the extent possible, to support their recommendations regarding procedures and services they believe should not be excluded from ASC payment.

We received many public comments from individuals and organizations requesting that specific procedures be added or removed from the CY 2008 proposed list of ASC covered surgical procedures. A summary of the public comments and our responses follow.

Comment: Some commenters stated that certain procedures CMS had proposed to exclude from coverage as payable in ASCs do not pose a risk to beneficiary safety and are not expected to require an overnight stay, and as such, should not be excluded from the ASC list. Table 49 below includes a list of all procedures for which the commenters requested designation as covered surgical procedures in ASCs.

TABLE 49.—SPECIFIC PROCEDURES THAT COMMENTERS REQUESTED NOT BE EXCLUDED FROM ASC PAYMENT IN CY 2008

HCPCS code	Short descriptor
0088T ...	Rf tongue base vol reduxn
0135T ...	Perq cryoablate renal tumor.
0137T ...	Prostate saturation sampling.
0170T ...	Anorectal fistula plug rpr.
0184T ...	Transanal resect rectal tumor.
0186T ...	Suprachoroidal drug delivery.
15170 ...	Acell graft trunk/arms/legs.
15171 ...	Acell graft t/arm/leg add-on.
15175 ...	Acellular graft, f/n/hf/g.
15176 ...	Acell graft, f/n/hf/g add-on.
21360 ...	Treat cheek bone fracture.
21365 ...	Treat cheek bone fracture.
21385 ...	Treat eye socket fracture.
21386 ...	Treat eye socket fracture.
21387 ...	Treat eye socket fracture.
22526 ...	Idet, single level.
22527 ...	Idet, 1 or more levels.
27093 ...	Injection for hip x-ray.
27096 ...	Inject sacroiliac joint.
29866 ...	Autgrft implnt, knee w/scope.
29867 ...	Allgrft implnt, knee w/scope.
29868 ...	Meniscal trnspl, knee w/scope.
32998 ...	Perq rf ablate tx, pul tumor.
35470 ...	Repair arterial blockage.
35471 ...	Repair arterial blockage.
35472 ...	Repair arterial blockage.
35490 ...	Atherectomy, percutaneous.
35491 ...	Atherectomy, percutaneous.
35493 ...	Atherectomy, percutaneous.
35494 ...	Atherectomy, percutaneous.
35495 ...	Atherectomy, percutaneous.
37182 ...	Insert hepatic shunt (tips).
37182 ...	Remove hepatic shunt (tips).
37201 ...	Transcatheter therapy infuse.
37202 ...	Transcatheter therapy infuse.
37204 ...	Transcatheter occlusion.
37205 ...	Transcath iv stent, precut.
37206 ...	Transcath iv stent/perc addl.
37209 ...	Change iv cath at thromb tx.
37210 ...	Embolization uterine fibroid.
37620 ...	Revision of major vein.
44300 ...	Open bowel to skin.
44500 ...	Intro, gastrointestinal tube.
44901 ...	Drain app abscess, precut.
47011 ...	Percut drain, liver lesion.
47490 ...	Incision of gallbladder.
48511 ...	Drain pancreatic pseudocyst.
49021 ...	Drain abdominal abscess.
49041 ...	Drain, percut, abdom abscess.
49061 ...	Drain, percut, retroper absc.
50021 ...	Renal abscess, percut drain.
50080 ...	Removal of kidney stone.
50081 ...	Removal of kidney stone.
58823 ...	Drain pelvic abscess, precut.
62290 ...	Inject for spine disk x-ray.
62291 ...	Inject for spine disk x-ray.
63020 ...	Neck spine disk surgery.
63030 ...	Low back disk surgery.
63035 ...	Spinal disk surgery add-on.
63040 ...	Laminotomy, single cervical.
63042 ...	Laminotomy, single lumbar.
63044 ...	Laminotomy, add'l lumbar.
63047 ...	Removal of spinal lamina.
63056 ...	Decompress spinal cord.
64448 ...	N block inj fem, cont inf.
64449 ...	N block inj, lumbar plexus.
64910 ...	Nerve repair w/allograft.

TABLE 49.—SPECIFIC PROCEDURES THAT COMMENTERS REQUESTED NOT BE EXCLUDED FROM ASC PAYMENT IN CY 2008—Continued

HCPCS code	Short descriptor
G0289 ..	Arthro, loose body + chondro.
0171T ...	Lumbar spine process distract.
0172T ...	Lumbar spine process addl.

Response: In response to the public comments received, our clinical advisors evaluated each of the procedures listed in Table 49 to determine whether it poses a significant safety risk to beneficiaries or would be expected to require an overnight stay. Several of those procedures, specifically CPT codes 27093 (Injection procedure for hip arthrography); 62290 (Injection procedure for discography, each level; lumbar) 62291 (Injection procedure for discography, each level; cervical or thoracic); and G0289 (Arthroscopy, knee, surgical, for removal of loose body, foreign body, debridement/shaving of articular cartilage (chondroplasty) at the time of other surgical knee arthroscopy in a different compartment of the same knee), are packaged procedures under the OPPS and, therefore, are not eligible for designation as separately payable procedures under the revised ASC payment system. However, we note that these packaged procedures are also not excluded from Medicare payment when performed in the ASC setting. Their payment will be packaged into payment for the ASC covered surgical procedure performed in the ASC.

As a result of our review of the other procedures listed in Table 49 that would be candidates for separate ASC payment according to their OPPS payment policies, we are not excluding 11 additional procedures from Medicare payment when performed in the ASC setting in CY 2008. In making our determinations, even where procedures had high inpatient utilization due to their frequent performance on hospital inpatients, we considered the clinical characteristics of the surgical procedure itself. As we stated in the August 2, 2007 revised ASC payment system final rule, we examine all the clinical information regarding the surgical procedure, including its inpatient utilization, to determine whether or not a procedure would pose a significant risk to beneficiary safety or would be expected to require an overnight stay if performed in an ASC (72 FR 42482). Of the procedures that commenters requested not be excluded from the list of covered surgical procedures, those

that we determined are appropriate for payment in an ASC and their final CY 2008 payment indicators are displayed in Table 50.

TABLE 50.—SPECIFIC PROCEDURES NEWLY DESIGNATED AS COVERED ASC SURGICAL PROCEDURES FOR CY 2008

HCPCS code	Short descriptor	CY 2008 payment indicator
0088T ...	Rf tongue vol reduxn	G2
0137T ...	Prostate saturation sampling.	G2
0170T ...	Anorectal fistula plug rpr.	G2
0186T ...	Suprachoroidal drug delivery.	G2
21360 ...	Treat cheek bone fracture.	G2
22526 ...	Idet, single level	G2
22527 ...	Idet, 1 or more levels	G2
29866 ...	Autgrt implnt, knee w/scope.	G2
32998 ...	Perq rf ablate tx, pul tumor.	G2
44500 ...	Intro, gastrointestinal tube.	G2
64910 ...	Nerve repair w/allograft.	G2

We determined that each of the remaining 57 procedures (those not packaged or listed in Table 50) requested by the commenters and listed in Table 49 would pose a significant risk to beneficiary safety or be expected to require an overnight stay, so they will continue to be excluded from the list of ASC covered surgical procedures for CY 2008. A complete list of surgical procedures that are excluded from Medicare payment when provided in ASCs may be found in Addendum EE posted on the CMS Web site at: <http://www.cms.hhs.gov/ASCPayment>.

Comment: Several commenters requested that specific procedures be removed from the ASC list of covered procedures in order to enhance the safety and quality of care that is delivered by ASCs. The commenters stated that CMS should exercise caution in granting patients and physicians the flexibility to determine appropriate sites of care, particularly for procedures that could have catastrophic outcomes if the appropriate emergent care equipment and training are not available in the site where care is delivered. Specifically, the commenters requested removal of percutaneous transluminal angioplasty procedures, transvenous electrode procedures, and certain cardiac electrophysiology procedures, as well as palatal surgical procedures. Table 51 below lists the procedures for which the

commenters requested removal from the ASC list of covered surgical procedures.

TABLE 51.—PROCEDURES RECOMMENDED BY COMMENTERS FOR REMOVAL FROM THE ASC LIST OF COVERED SURGICAL PROCEDURES

HCCPS code	Short descriptor
33206 ...	Insertion of heart pacemaker.
33207 ...	Insertion of heart pacemaker.
33208 ...	Insertion of heart pacemaker.
33214 ...	Upgrade of pacemaker system.
33215 ...	Reposition pacing-defib lead.
33216 ...	Insert lead pace-defib, one.
33217 ...	Insert lead pace-defib, dual.
33218 ...	Repair lead pace-defib, one.
33220 ...	Repair lead pace-defib, dual.
33224 ...	Insert pacing lead & connect.
33225 ...	L ventric pacing lead add-on.
33226 ...	Reposition l ventric lead.
33234 ...	Removal of pacemaker system.
33235 ...	Removal pacemaker electrode.
33249 ...	Eltrd/insert pace-defib.
35473 ...	Repair arterial blockage.
35474 ...	Repair arterial blockage.
35476 ...	Repair venous blockage.
35492 ...	Atherectomy, percutaneous.
42200 ...	Reconstruct cleft palate.
42205 ...	Reconstruct cleft palate.
42210 ...	Reconstruct cleft palate.
42215 ...	Reconstruct cleft palate.
42220 ...	Reconstruct cleft palate.

Response: In response to the public comments received, our clinical advisors reevaluated each of the procedures listed in Table 51 to determine whether it poses a significant safety risk to beneficiaries or would be expected to require an overnight stay. We note that while CPT codes 42200 (Palatoplasty for left palate, soft and/or hard palate only); 42205 (Palatoplasty for cleft palate, with closure of alveolar ridge; soft tissue only); 42210 (Palatoplasty for cleft palate; with closure of alveolar ridge; with bone graft to alveolar ridge (includes obtaining graft)); 42215 (Palatoplasty for cleft palate; major revision); and 42220 (Palatoplasty for cleft palate; attachment pharyngeal flap) were eligible for payment when performed in the ASC in CY 2007, the remainder of the codes listed in Table 51 were added to the ASC list of covered surgical procedures in the August 2, 2007 revised ASC payment system final rule for CY 2008.

We continue to believe that these palatoplasty procedures that have been on the ASC list of covered surgical procedures for more than 5 years do not pose a significant risk to beneficiary safety in the ASC setting, nor would they be expected to require an overnight stay. We are not aware of any safety problems regarding the performance of these procedures in ASCs over the years

Medicare has included them on the list of ASC covered surgical procedures.

With respect to the pacemaker and ICD lead placement, repositioning, and removal procedures, we proposed a number of these procedures for addition to the ASC list for CY 2008 in the August 23, 2006 proposed rule for the revised ASC payment system. We received a number of comments on the proposed rule regarding these procedures, as well as related surgical procedures, which we carefully reviewed prior to placing them on the ASC list of covered surgical procedures in the August 2, 2007 revised ASC payment system final rule. We have once again examined these procedures in light of comments received on the CY 2008 OPPTS/ASC proposed rule and, we believe, under the safety and overnight stay criteria that were adopted to exclude procedures from ASC payment, all of these procedures are appropriate for ASC performance. In particular, we do not believe they pose a significant safety risk, nor would be expected to require an overnight stay when provided in ASCs.

We also closely reexamined the transluminal balloon angioplasty services described by CPT codes 35473 (Transluminal balloon angioplasty, percutaneous; iliac); 35474 (Transluminal balloon angioplasty, percutaneous; femoral-popliteal); and 35476 (Transluminal balloon angioplasty, percutaneous; venous). All three of these procedures were proposed for addition to the ASC list for CY 2008 in the August 23, 2006 OPPTS/ASC proposed rule. We received requests to add CPT code 36476 to the ASC list for CY 2007, but we did not add this code at that point, based on the evaluation criteria for the existing ASC payment system. We then added all three codes to the CY 2008 ASC list in the August 2, 2007 revised ASC payment system final rule after evaluating the public comments and concluding that the procedures should not be excluded from ASC performance, consistent with the final exclusion criteria for the revised system. In response to the comments on the CY 2008 OPPTS/ASC proposed rule that reflected the commenters' ongoing concerns about the safety of these procedures in ASCs, our clinical advisors engaged in a comprehensive assessment of their safety based on current clinical practice patterns and the contemporary medical literature. We have concluded that CPT codes 35473 and 35476 do not pose a significant safety risk to beneficiaries nor would either procedure be expected to require an overnight stay in ASCs. Therefore, we are including CPT codes 35473 and

35476 on the CY 2008 ASC list of covered surgical procedures. However, we have determined that CPT code 35474 would pose a significant safety risk to beneficiaries when performed in an ASC. Therefore, we are excluding CPT code 35474 from the CY 2008 ASC list of covered surgical procedures.

In summary, as a result of our review of the procedures the commenters requested that we remove from the proposed CY 2008 ASC list of covered surgical procedures, we are retaining all of the procedures in Table 51 on the final CY 2008 list of ASC covered surgical procedures except CPT code 35474. The full CY 2008 list of ASC covered surgical procedures is included in Addendum AA to this final rule with comment period.

b. Change in Designation of Covered Surgical Procedures as Office-Based

According to our final policy for the revised ASC payment system, we designate as office-based procedures those that are added to the ASC list of covered surgical procedures in CY 2008 or later years and that we determine are predominantly performed in physicians' offices based on consideration of the most recent available volume and utilization data for each individual procedure code and/or, if appropriate, the clinical characteristics, utilization, and volume of related codes.

The list of codes that we identified as office-based in the August 2, 2007 revised ASC payment system final rule took into account the most recently available CY 2005 volume and utilization data for each individual procedure code or related codes. In that rule, we finalized our policy to apply the office-based designation only to procedures that would no longer be excluded from ASC payment beginning in CY 2008 or later years and to exempt all procedures on the CY 2007 ASC list from application of the office-based classification. We believe that the resulting list accurately reflected Medicare practice patterns and was clinically consistent. In Addendum AA to the August 2, 2007 revised ASC payment system final rule, each of the office-based procedures was identified by payment indicator "P2," "P3," or "R2," depending on whether we estimated it would be paid according to the standard ASC payment methodology based on its OPPTS relative payment weight or at the MPFS nonfacility PE RVU amount.

Consistent with our final ASC policy to review and update annually the surgical procedures for which ASC payment is made and to identify new procedures that may be appropriate for

ASC payment, in developing the CY 2008 OP/ASC proposed rule, we reviewed the CY 2006 utilization data for all those surgical procedures newly added for ASC payment in CY 2008 that were assigned payment indicator "G2" as nonoffice-based additions in the August 2, 2007 revised ASC payment system final rule. We based our evaluation of the potential designation of a procedure as office-based on the most recent available volume and utilization data for each individual procedure code and/or, as appropriate, the clinical characteristics, utilization, and volume of related codes. As a result of that review, we identified 19 procedures that were assigned payment indicator "G2" in the August 2, 2007 revised ASC payment system final rule that we proposed to assign to the office-based procedure list, effective January 1, 2008, with payment indicator "P2," "P3," or "R2," as appropriate. We refer readers to Addendum DD1 to this final rule with comment period for the definitions of the ASC payment indicators.

In the CY 2008 OP/ASC proposed rule, we indicated that we would consider comments submitted timely on the proposed designation of these 19 new procedures as office-based for CY 2008. For example, in the August 2, 2007 revised ASC payment system final rule, payment indicator "G2" was assigned to CPT code 64650 (Chemodestruction of eccrine glands; both axillae). After reviewing more recent CY 2006 data, we discovered that the procedure is performed predominantly in physicians' offices and we believed the procedure should be designated as an office-based procedure. Therefore, we proposed to assign payment indicator "P3" to CPT code 64650, effective for CY 2008. In the proposed rule, we proposed to assign an office based payment indicator for CPT code 64650 and 18 other procedures.

We also reviewed the five procedures that were assigned temporary office-based payment indicators in the August 2, 2007 revised ASC payment system final rule. Using CY 2006 data, we believed there were adequate claims data for two of those procedures upon which to base assignment of permanent payment indicators. Therefore, we proposed to assign CPT code 36598 (Contrast injection(s) for radiologic evaluation of existing central venous access device, including fluoroscopy, image documentation and report) permanently to the office-based list, with payment indicator "P3" for CY 2008. In the case of the second procedure, CPT code 58110 (Endometrial sampling (biopsy)

performed in conjunction with colposcopy), in accordance with the CY 2008 OP/ASC proposal to package its payment, we also proposed to package payment for that procedure under the ASC payment system and assign it payment indicator "N1."

We proposed to maintain the temporary office-based payment indicator assignments for the other three procedures. We have only a few claims for CPT code 0099T (Implantation of intrastromal corneal ring segments) and no claims for CPT code 0124T (Conjunctival incision with posterior juxtasccleral placement of pharmacological agent (does not include supply of medication)) or CPT code 55876 (Placement of interstitial device(s) for radiation therapy guidance (e.g., fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple). We continue to believe these procedures are predominantly office-based. Therefore, we proposed not to make any change to the temporary office-based designation of these procedures at that time.

We received many public comments on our general payment policy for office-based surgical procedures under the revised ASC payment system and on our proposal to add 19 additional procedures to the office-based list for CY 2008. A summary of the public comments and our responses follow.

Comment: Many commenters opposed the policies related to the designation of procedures as office-based and the subsequent payment limitations for procedures that are so designated. Some commenters recommended that, if CMS is going to maintain a list of office-based procedures, it should restrict the criteria used to make office-based determinations. They stated that designation of a procedure as office-based should be made either based on utilization data for multiple years or on the frequency of performance of the procedure in the HOPD or ASC settings. The commenters stated that CMS's consideration of clinical information and utilization data for related procedures is not transparent, making it impossible for the public to assess whether its determinations are rational and fair.

Several commenters specifically requested that one or more of the 19 additional procedures proposed for designation as office-based not receive that designation. The commenters recommended that CMS not finalize the proposal to designate 15 of the 19 procedures as office-based because commenters believe they are not performed in physicians' offices 50 percent or more of the time. Each of

those codes the commenters recommended not be designated as office-based is marked by a plus (+) in Table 52 below.

Several commenters recommended that CMS not finalize the proposal to designate CPT code 28890 (Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia) as office-based because they believe the CMS data that indicate the procedure's performance in physicians' offices more than 50 percent of the time are erroneous. The commenters stated that CMS assigned payment indicator "G2" to three high energy extracorporeal shock wave therapy (ESWT) procedures, CPT codes 28890, 0101T (Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy); and 0102T (Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle) in the August 2, 2007 revised ASC payment system final rule but then proposed to designate only CPT code 28890 as office-based in the CY 2008 OP/ASC proposed rule. They stated that CMS provided no explanation for the proposed change to the payment indicator of CPT code 28890. Furthermore, the commenters argued that the procedure is most appropriately provided in a facility setting and that the proposed ASC payment for the procedure would be limited to the MPFS nonfacility PE RVU amount, which is too low to cover the costs associated with providing the procedure. The commenters recommended that, because the CPT code was new for CY 2006, CMS should wait until sufficient time has passed to collect and review adequate Medicare data for its decision-making.

Another commenter requested that CMS not designate CPT codes 64650 (Chemodestruction of eccrine glands; both axillae) and 64653 (Chemodestruction of eccrine glands; other area(s) (e.g., scalp, face, neck), per day) as office-based procedures because the codes were new for CY 2006 and there are not yet adequate data on which to base that determination.

Response: While we appreciate the concerns of commenters regarding the limitation on payment for office-based procedures under the revised ASC payment system, we note that we finalized that payment policy in the August 2, 2007 revised ASC payment system final rule that set forth the final policies for the revised system after receiving and responding to public

comments (72 FR 42486). In that rule, we also finalized the evaluation criteria for the designation of surgical procedures as office-based (72 FR 42512). Therefore, the evaluation criteria and payment policy for office-based procedures were not open to comment in the CY 2008 OP/ASC proposed rule and we are not addressing additional comments in this final rule with comment period.

Based on the public comments we received, we reexamined the relevant data and clinical characteristics for each of the 15 procedures for which we received comments. Although, as the commenters asserted, many of the 15 procedures are performed in physicians' offices somewhat less than 50 percent of the time, our final policy for designating ASC procedures as office-based allows us to take into account the clinical characteristics, volume, and utilization data of related HCPCS codes to supplement our consideration of data specific to the codes of interest (72 FR 42512). Our review of the clinical characteristics of the 15 procedures and volume and utilization data for them and for similar procedures convinced us that our proposed designations are correct for all but 1 of the procedures.

We are not finalizing our proposal to designate CPT code 46505 (Chemodenervation of internal anal sphincter) as an office-based procedure. After reviewing the currently available utilization data for this code and related codes, we believe this procedure is not predominantly performed in physicians' offices and should maintain the "G2" payment indicator assigned to CPT code

46505 in the August 2, 2007 revised ASC payment system final rule for CY 2008.

In the case of CPT code 28890, although Medicare utilization data show that over 70 percent of CY 2006 utilization occurred in the physician's office, we are persuaded by commenters that this code was new for CY 2006 and some providers may have confused this service with the performance of low energy ESWT procedures. Stakeholders have explained to us that, although the physician utilization data may reflect that the service is performed mainly in the physician's office, this finding could be due to miscoding of low energy procedures that use only local anesthesia, rather than correct use of the CPT code 28890 to report high energy procedures that require anesthesia other than local. Nevertheless, we do not believe it would be appropriate to consider CPT code 28890 to be nonoffice-based for CY 2008 based on the significant utilization reported for the physician's office setting. Under the MPFS, this service has been priced specifically for performance in the office; therefore, we believe it can be appropriately performed in the physician's office. Furthermore, we note that there is an existing Category III CPT code for reporting the low energy services, specifically CPT code 0019T (Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, low energy), for which the facility resources would be expected to differ. Nevertheless, given the concerns over the utilization data in the code's first year of use, while we follow the

utilization of CPT code 28890 for another year, we will maintain the office-based designation of this procedure as temporary to allow for the possibility that coding for high energy ESWT for the plantar fascia will improve as providers gain more experience with the CPT code. This designation is indicated with an asterisk in Table 52 below. When we have sufficient data, we will either propose to finalize the office-based designation of the service or propose to change its payment indicator to "G2" as a nonoffice-based procedure.

While we are aware of the existence of CPT codes 0101T and 0102T for high energy ESWT for body areas other than treatment of the plantar fascia, utilization data available for the proposed rule did not support a proposal to designate those codes as office-based for CY 2008. Furthermore, these services have no MPFS nonfacility PE RVUs at this time. Therefore, a payment limitation based on the MPFS nonfacility PE RVUs could not be applied. We will review their utilization data for the next ASC annual update.

The procedures proposed for designation as office-based and their final CY 2008 payment indicators are listed in Table 52 below. All office-based designations are final, with the exception of the designation of CPT code 28890 as office-based, which will remain temporary until we have adequate utilization data to support a proposal to remove it from the office-based list or finalize the office-based designation.

TABLE 52.—CY 2008 FINAL NEW DESIGNATIONS OF ASC COVERED SURGICAL PROCEDURES PROPOSED AS OFFICE-BASED

HCPCS code (+ indicates procedures commenters recommended not be designated as office-based)	Short descriptor	Proposed CY 2008 payment indicator	Final CY 2008 payment indicator (* if designation is temporary for CY 2008)
24640+	Treat elbow dislocation	P3	P3
26641+	Treat thumb dislocation	P2	P2
26670+	Treat hand dislocation	P2	P2
26700+	Treat knuckle dislocation	P2	P2
26775+	Treat finger dislocation	P3	P3
28630+	Treat toe dislocation	P3	P3
28660+	Treat toe dislocation	P3	P3
28890+	High energy eswt, plantar fascia	P3	P3*
29035	Application of body cast	P2	P2
29305	Application of hip cast	P2	P2
29325	Application of hip casts	P2	P2
29505+	Application, long leg splint	P3	P3
29515+	Application lower leg splint	P3	P3
36469+	Injection(s), spider veins	R2	R2
46505+	Chemodenervation anal misc	P3	G2
62292	Injection into disk lesion	R2	R2
64447+	Nblock inj fem, single	R2	R2
64650+	Chemodenerv, eccrine glands	P3	P3

TABLE 52.—CY 2008 FINAL NEW DESIGNATIONS OF ASC COVERED SURGICAL PROCEDURES PROPOSED AS OFFICE-BASED—Continued

HCPCS code (+ indicates procedures commenters recommended not be designated as office-based)	Short descriptor	Proposed CY 2008 payment indicator	Final CY 2008 payment indicator (* if designation is temporary for CY 2008)
64653+	Chemodenerv, eccrine glands	P3	P3

We did not receive any public comments regarding our proposal to maintain as temporary the office-based designation for CPT codes 0099T (Implantation of intrastromal corneal ring segments); 0124T (Conjunctival incision with posterior juxtasclear placement of pharmacological agent (does not include supply of medication)); and 55876 (Placement of interstitial device(s) for radiation therapy guidance (e.g., fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple) or our proposal to make permanent the designation of CPT code 36598 (Contrast injection(s) for radiologic evaluation of existing central venous access device, including

fluoroscopy, image documentation and report) as office-based. Although we received public comments about the proposed policy to package more procedures for CY 2008 under the OPPS, we did not receive any specific public comments regarding the designation of CPT code 58110 (Endometrial sampling (biopsy) with or without endocervical sampling (biopsy), without cervical dilation, any method (separate procedure)) as packaged for CY 2008.

Therefore, we are finalizing our CY 2008 proposals, without modification, to maintain the temporary office-based designations of CPT codes 0099T, 0124T, and 55876, the permanent office-

based designation of CPT code 36598, and the packaged status of CPT code 58110. The procedures and the final payment indicators for CY 2008 are displayed below in Table 53.

Displayed in Table 53 are the new CY 2008 HCPCS codes (excluding renumbered codes) to which we have assigned temporary office-based payment indicators. Those designations are temporary and are open to comment during the 60-day comment period for this final rule with comment period. We will respond to public comments on those designations in the OPPS/ASC final rule with comment period for CY 2009.

TABLE 53.—CY 2008 PAYMENT INDICATORS FOR PROCEDURES ASSIGNED TEMPORARY OFFICE-BASED PAYMENT INDICATORS IN THE AUGUST 2, 2007 REVISED ASC PAYMENT SYSTEM FINAL RULE

HCPCS code	Short descriptor	Final CY 2008 ASC payment indicator (* if designation is temporary for CY 2008)
0099T	Implant corneal ring	R2*
0124T	Conjunctival drug placement	R2*
36598	Inj w/fluor, eval cv device	P3
55876	Place rt device/marker, pros	P3*
58110	Bx done w/colposcopy add-on	N1

TABLE 54.—CY 2008 PAYMENT INDICATORS FOR NEW CY 2008 ASC COVERED SURGICAL PROCEDURES ASSIGNED TEMPORARY OFFICE-BASED PAYMENT INDICATORS ON AN INTERIM FINAL BASIS

HCPCS code	Short descriptor	Final CY 2008 ASC payment indicator (* if designation is temporary for CY 2008)
21073	Mnpj of tmj w/anesth	P3*
67229	Tr retinal les preterm inf	R2*
68816	Probe nl duct w/balloon	P3*

c. Changes in Designation of Covered Surgical Procedures as Device-Intensive

As explained in section XVI.C.1.c.(3) of this final rule with comment period, we adopted a modified payment methodology for calculating the ASC payment rates for ASC covered surgical

procedures that are assigned to the subset of device-dependent APCs under the OPPS with a device offset percentage greater than 50 percent under the OPPS to ensure that payment for the procedure is adequate to provide packaged payment for the high-cost

implantable devices used in those procedures. In the August 2, 2007 revised ASC payment system final rule, we identified 24 procedures that were on the CY 2007 ASC list of covered surgical procedures that would be subject to this policy, as well as 15 new

ASC covered surgical procedures for CY 2008, to which we expected the final policy to apply.

As a result of the proposed CY 2008 reconfiguration of several device-dependent APCs under the OPPS and the proposed updated APC device offset percentages in the CY 2008 OPPS/ASC proposed rule, we proposed to designate as device-intensive for ASC payment in CY 2008 an additional 10 ASC covered surgical procedures. We also proposed to remove 4 procedures from their estimated designation as device-intensive because we proposed to recognize CPT codes instead of Level II HCPCS codes for ICD implantation procedures as discussed in section III.D.1.c. of this final rule with comment period. We proposed to assign payment indicators "H8" or "J8," as appropriate, to the covered surgical procedures identified as device-intensive so that payment would be made consistent with our final revised ASC payment system payment policy.

We received a number of public comments on our proposal for payment of device-intensive procedures in ASCs for CY 2008. A summary of the public comments and our responses follow.

Comment: Most commenters were generally pleased with the final payment policy, but several commenters requested that CMS apply the device-intensive payment methodology to either all ASC covered procedures assigned to device-dependent APCs or to those assigned to APCs with a lower offset percentage threshold than 50 percent so that more ASC covered surgical procedure rates would be calculated using the device-intensive methodology. Many commenters requested that covered procedures for which ASCs billed separately for implantable prosthetic devices under the CY 2007 payment system also be treated like those procedures CMS has identified as device-intensive, even though the device offset percentage under the OPPS for the procedures may

be less than the 50 percent threshold. Specifically, some of the commenters requested that the ASC payment rates for the CPT codes listed in Table 55 of this final rule with comment period be calculated as device-intensive procedure rates, that they be allowed to be paid at revised ASC rates without being subject to the transitional ASC rates for CYs 2008, 2009, and 2010 or that the device cost be added to the CY 2007 ASC rate which would be used to calculate the transitional rate. The commenters stated that the payment rates during the transition period for procedures like these, that require high cost implantable products, are too low for ASCs to be able to continue to provide the services. The commenters advised CMS to monitor the migration of these procedures, and others like them, into the higher cost HOPD setting during the first years under the revised ASC payment system.

TABLE 55.—SPECIFIC PROCEDURES FOR WHICH COMMENTERS REQUESTED CY 2008 PAYMENT RATES THAT FULLY RECOGNIZE THE COSTS OF IMPLANTABLE DEVICES

HCPCS code	Long descriptor	Final CY 2008 payment indicator
51715	Endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck	A2
57288	Sling operation for stress incontinence (e.g., fascia or synthetic)	A2
65105	Enucleation of eye; within implant, muscles attached to implant	A2
65140	Insertion of ocular implant secondary; after enucleation, muscles attached to implant	A2
65155	Reinsertion of ocular implant; with use of foreign material for reinforcement and/or attachment of muscles to implant.	A2
65770	Keratoprosthesis	A2
66180	Aqueous shunt to extraocular reservoir (e.g., Molteno, Schocket, Denver-Krupin)	A2
67912	Correction of lagophthalmos, with implantation of upper eyelid lid load (e.g., gold weight)	A2

Response: We appreciate the information shared by the commenters and their suggestions for payment policies for ASC procedures included on the CY 2007 ASC list for which separate payment is currently made for implantable prosthetic devices. Nonetheless, the policy for payment of these procedures was made final in the August 2, 2007 revised ASC payment system final rule after we received and addressed public comments (72 FR 42503). Only two of the procedures cited by the commenter, CPT codes 57288 and 65770, are assigned to device-dependent APCs under the OPPS, and neither APC has a device offset percentage above 50 percent. Payment will be made for all of these services at the transitional rates for CY 2008, based on their status as nondevice-intensive procedures.

Comment: Several commenters suggested that CMS should create additional payment policies to provide

special payment for new technologies, procedures on the CY 2007 ASC list of covered procedures that never were provided in ASCs, and previous pass-through devices. The commenters were concerned about procedures included on the CY 2007 ASC list that are not currently provided in ASCs. They stated that the very low payment amounts under the existing system precluded the performance of those procedures and, therefore, the procedures should not be subject to the transitional payment rates. In effect, the commenters explained, those procedures are new to the ASC list for CY 2008 and as such, they should be allowed to bypass the transition to be paid at the revised ASC rates in CY 2008. For example, one commenter suggested that CPT code 55873 (Cryosurgical ablation of the prostate (includes ultrasonic guidance for interstitial cryosurgical probe placement)), a device-intensive procedure, should not be subject to the

transition at all because it was not performed in ASCs prior to CY 2008, even though it was included on the ASC list of covered surgical procedures beginning in CY 2005.

The commenter who suggested additional policies for new technology and pass through payments under the ASC payment system stated that adequate payment for newer advanced technologies in the most appropriate setting would ensure beneficiary access to optimum care.

Response: The payment policies for the revised ASC payment system to be implemented January 1, 2008 were finalized in the August 2, 2007 revised ASC payment system final rule after we received and addressed public comments (72 FR 42493). With respect to device-intensive procedures such as CPT codes 55873 that were on the CY 2008 ASC list, the device portion of the payment is not subject to the transition, while the payment portion will receive

transitional payment. The final policies do not incorporate a methodology to exclude from the transitional payment any procedures on the CY 2007 ASC list. We will not consider any changes to those policies in this final rule with comment period.

The final policies for the revised ASC payment system will pay separately for those implantable devices with pass-through status under the OPSS and will pay for new technology surgical procedures described by Category III

CPT codes or Level II HCPCS codes that crosswalk directly or are clinically similar to established procedures already on the ASC list of covered surgical procedures. In this way, we believe these policies will serve to appropriately incorporate payment for new technologies under the revised ASC payment system.

In summary, after consideration of the public comments received, we are implementing, without modification, the proposal to designate the procedures

listed in Table 56 as device-intensive ASC covered surgical procedures for CY 2008, based on their CY 2008 final assignments to APCs under the OPSS that are device-dependent and which have device offset percentages greater than 50 percent. We are not making any changes to our final ASC policies related to the designation of device-intensive procedures, transitional payment for procedures covered in the ASC setting in CY 2007, or payment for new technologies.

TABLE 56.—ASC COVERED SURGICAL PROCEDURES DESIGNATED AS DEVICE-INTENSIVE FOR CY 2008

HCPCS code	Short descriptor	CY 2008 OPSS APC	CY 2008 device-dependent APC offset percentage
33206	Insertion of heart pacemaker	0089	72.99
33207	Insertion of heart pacemaker	0089	72.99
33208	Insertion of heart pacemaker	0655	74.62
33210	Insertion of heart electrode	0106	56.25
33211	Insertion of heart electrode	0106	56.25
33212	Insertion of pulse generator	0090	76.01
33213	Insertion of pulse generator	0654	77.13
33214	Upgrade of pacemaker system	0655	74.62
33216	Insert lead pace-defib, one	0106	56.25
33217	Insert lead pace-defib, dual	0106	56.25
33224	Insert pacing lead & connect	0418	82.52
33225	Lventric pacing lead add-on	0418	82.52
33240	Insert pulse generator	0107	89.11
33249	Eltrd/insert pace-defib	0108	89.24
33282	Implant pat-active ht record	0680	73.15
36566	Insert tunneled cv cath	0625	58.88
53440	Male sling procedure	0385	51.56
53444	Insert tandem cuff	0385	51.56
53445	Insert uro/ves nck sphincter	0386	63.53
53447	Remove/replace ur sphincter	0386	63.53
54400	Insert semi-rigid prosthesis	0385	51.56
54401	Insert self-contd prosthesis	0386	63.53
54405	Insert multi-comp penis pros	0386	63.53
54410	Remove/replace penis prosth	0386	63.53
54416	Remv/repl penis contain pros	0386	63.53
55873	Cryoablate prostate	0674	60.27
61885	Insrt/redo neurostim 1 array	0039	82.73
61886	Implant neurostim arrays	0315	86.15
62361	Implant spine infusion pump	0227	80.73
62362	Implant spine infusion pump	0227	80.73
63650	Implant neuroelectrodes	0040	56.27
63655	Implant neuroelectrodes	0061	60.60
63685	Insrt/redo spine n generator	0222	84.86
64553	Implant neuroelectrodes	0225	80.57
64555	Implant neuroelectrodes	0040	56.27
64560	Implant neuroelectrodes	0040	56.27
64561	Implant neuroelectrodes	0040	56.27
64565	Implant neuroelectrodes	0040	56.27
64573	Implant neuroelectrodes	0225	80.57
64575	Implant neuroelectrodes	0061	60.60
64577	Implant neuroelectrodes	0061	60.60
64580	Implant neuroelectrodes	0061	60.60
64581	Implant neuroelectrodes	0061	60.60
64590	Insrt/redo pn/gastr stimul	0222	84.86
69930	Implant cochlear device	0259	82.94

2. Changes for Identification of Covered Ancillary Services

In the August 2, 2007 revised ASC payment system final rule, we set forth our policy to make separate ASC

payments for certain ancillary services, for which separate payment is made under the OPSS, when they are provided integral to ASC covered surgical procedures. Under the revised

ASC payment system, we exclude from the scope of ASC facility services, for which payment is packaged into the ASC payment for the covered surgical procedure, the following ancillary

services that are integral to a covered surgical procedure: brachytherapy sources; certain implantable items that have pass-through status under the OPPS; certain items and services that we designate as contractor-priced, including, but not limited to, procurement of corneal tissue; certain drugs and biologicals for which separate payment is allowed under the OPPS; and certain radiology services for which separate payment is allowed under the OPPS. These covered ancillary services are specified in § 416.164(b) and fall within the scope of ASC services, so they are eligible for separate ASC payment.

In the CY 2008 OPPS/ASC proposed rule (72 FR 42788), we proposed to make changes to the list of covered ancillary services eligible for separate ASC payment, as proposed in Addendum BB to that proposed rule, to comport with their proposed treatment under the OPPS according to the final payment policies of the revised ASC payment system, and to add new Category III CPT code 0182T (High dose rate electronic brachytherapy, per fraction), as discussed in section XVI.D.2. of this final rule with comment period. Accordingly, we are finalizing changes to the list of covered ancillary services eligible for ASC payment in Addendum BB of this final rule with comment period to reflect the policies finalized for the CY 2008 OPPS and to add Category III CPT code 0182T to the list of covered ancillary services.

F. Payment for Covered Surgical Procedures and Covered Ancillary Services

1. Payment for Covered Surgical Procedures

a. Update to Payment Rates

Our final payment policy for covered surgical procedures under the revised ASC payment system is described in section XVI.C. of this final rule with comment period. In the CY 2008 OPPS/ASC proposed rule (72 FR 42788), for CY 2008, we proposed to update payment for procedures with payment indicators “G2” and “A2,” using CY 2006 utilization data. We did not propose to make any changes to the final policies established in the August 2, 2007 revised ASC payment system final rule related to the methodology for developing the relative payment weights

and rates. The differences in the payment rates for covered surgical procedures with “G2” and “A2” payment indicators, reflected in Addendum AA to the proposed rule, compared with the August 2, 2007 revised ASC payment system final rule, were due to our use of updated CY 2006 utilization data, proposed payment policy changes for the CY 2008 OPPS, including APC reassignments and changes to packaged services, and the proposed OPPS update factor.

We also proposed to update the payment amounts for the office-based procedures in the CY 2008 OPPS/ASC proposed rule. Using the most recent available MPFS and OPPS data, including the proposed CY 2008 rates, we compared the estimated CY 2008 rate for each of the office-based procedures calculated according to the standard methodology of the revised ASC payment system and to the MPFS nonfacility PE RVUs to determine which is the lower payment amount that, therefore, is the rate we proposed for payment of the procedure according to the final policy of the revised ASC payment system. The proposed update to the rates resulted in changes to the payment indicators, as well as the rates, for several of the office-based procedures. For example, a procedure with payment indicator “P2” in the August 2, 2007 revised ASC payment system final rule may have been assigned payment indicator “P3” in the CY 2008 OPPS/ASC proposed rule, depending on the outcome of that rate comparison.

In addition, we proposed to update the payment amounts for the device intensive procedures in the proposed rule, based on the CY 2008 OPPS proposal and updated OPPS claims data.

We received many public comments on the proposed CY 2008 payment rates for covered surgical procedures. A summary of the public comments and our responses follow.

Comment: Many commenters were concerned that the proposed ASC rates for covered surgical procedures that require expensive equipment and single-use, disposable supplies would not be adequate to cover the costs, especially during the first 3 years of the revised payment system. The commenters offered a number of suggestions, such as establishing a class

of procedures that are “equipment-intensive” for which an alternate payment methodology similar to that for “device-intensive” procedures could be used to set rates, to address their concern that payments, even at the revised ASC rates, would be inadequate for procedures like lithotripsy (CPT code 50590 (Lithotripsy, extracorporeal shock wave)), which requires equipment that costs the same wherever the procedure is performed. Other commenters suggested that procedures that include use of expensive single-use supplies be paid at the fully implemented rate beginning in CY 2008.

Response: We appreciate the commenters’ concerns. However, the payment methodologies for the revised ASC payment system were made final in the revised ASC payment system final rule published on August 2, 2007 after we received and addressed public comments. As explained in that final rule (72 FR 42503), we believe that it would not be appropriate to provide separate payment for aspects of procedures (for example, implantable prosthetics or equipment) that are packaged into the ASC payment rates for the procedures under the revised payment system.

Comment: None of the commenters opposed updating the payment rates for covered surgical procedures by using the most recent available MPFS and OPPS data. However, several commenters asked that CMS review the proposed payment rate for CPT code 64517 (Injection, anesthetic agent; superior hypogastric plexus) because they believed that the proposed CY 2008 rate included in Addendum AA to the proposed rule might be erroneous.

Response: We reviewed the proposed rate for CPT code 64517, which is assigned payment indicator “A2,” and found that the rate for CY 2008 displayed in Addendum AA of the proposed rule was correct. The method for calculating the rate for procedures with “A2” payment indicator, like CPT code 64517, is displayed in Table 57. As can be seen in the table, the proposed rate of \$178.12 for CPT code 64517 included in the CY 2008 OPPS/ASC proposed rule Addendum AA was correct. We believe the example presented is helpful in understanding the transitional payment rate calculations.

TABLE 57.—SAMPLE CALCULATION OF YEAR ONE (CY 2008) NATIONAL UNADJUSTED TRANSITIONAL PAYMENT RATE FOR COVERED SURGICAL PROCEDURES ASSIGNED PAYMENT INDICATOR “A2”

Steps in calculation of year one (CY 2008) transitional ASC payment rate	CY 2008 rate calculation for procedures with payment indicator “A2”	CY 2008 proposed rule calculation for CPT code 64517
Step 1	Multiply transition year one CY 2007 ASC portion of blended rate by the CY 2007 ASC rate.	0.75 x \$139 = \$104.25.
Step 2	Calculate CY 2008 fully implemented ASC rate by multiplying ASC relative weight by ASC conversion factor.	7.1370 x \$41.400 = \$295.4718.
Step 3	Multiply transition year one CY 2008 portion of blended rate by the fully implemented ASC rate.	0.25 x \$295.4718 = \$73.86795.
Step 4	Add the 75 percent and 25 percent amounts of the blended rate to equal the year one (CY 2008) transitional rate; round to two decimal places.	\$104.25 + \$73.86795 = \$178.11795 which rounds to \$178.12.

Therefore, after consideration of all public comments received, we are implementing our policy to update the CY 2008 ASC rates using the most recently available OPSS and MPFS data. The ASC national unadjusted rates for all covered surgical procedures are displayed in Addendum AA to this final rule with comment period.

b. Payment Policies When Devices Are Replaced at No Cost or With Credit

(1) Policy When Devices Are Replaced at No Cost or With Full Credit

Our final ASC policy with regard to payment for costly devices implanted in ASCs is fully consistent with the current OPSS policy. The ASC policy includes adoption of the OPSS policy for payment to providers when a device is replaced without cost or with full credit for the cost of the device being replaced, for those ASC covered surgical procedures that are assigned to APCs under the OPSS to which this policy applies. In the case of no cost or full credit cases under the OPSS, we reduce the APC payment to the hospital by the device offset amount that we estimate represents the cost of the device. Therefore, in accordance with the OPSS policy implemented in CY 2007, and the ASC policy as finalized in the August 2, 2007 revised ASC payment system final rule, beginning in CY 2008, we reduce the amount of payment made to ASCs for certain covered surgical procedures when the necessary device is furnished without cost to the ASC or the beneficiary or with a full credit for the cost of the device being replaced. We provide the same amount of payment reduction based on the device offset amount in ASCs that would apply under the OPSS for performance of those procedures under the same circumstances. Specifically, when a procedure that is listed in Table 58 below is performed in an ASC and the

case involves implantation of a no cost or full credit device listed in Table 59, the ASC must report the HCPCS “FB” modifier on the line with the covered surgical procedure code to indicate that an implantable device in Table 59 was furnished without cost. The devices listed in Table 59 are the same devices to which the policy applies under the OPSS, and the procedures listed in Table 58 are those ASC covered surgical procedures assigned to APCs under the OPSS to which the policy applies.

As finalized in the August 2, 2007 revised ASC payment system final rule (72 FR 42506), when the “FB” modifier is reported with a procedure code that is listed in Table 58, the contractor reduces the ASC payment by the amount of payment that we attributed to the device when the ASC payment rate was calculated. The reduction of ASC payment in this circumstance is necessary to pay appropriately for the covered surgical procedure being furnished by the ASC.

(2) Policy When Implantable Devices Are Replaced with Partial Credit

Consistent with our CY 2008 OPSS proposal discussed in section IV.A.3. of this final rule with comment period, we proposed to reduce the ASC payment by one half of the device offset amount for certain surgical procedures into which the device cost is packaged, when an ASC receives a partial credit toward replacement of an implantable device (72 FR 42788). We proposed that the partial payment reduction would apply to covered surgical procedures in which the amount of the device credit is greater than or equal to 20 percent of the cost of the new replacement device being implanted. We also proposed to base the beneficiary’s coinsurance on the reduced ASC payment rate so that the beneficiary shares the benefit of the ASC’s reduced costs.

We have no OPSS data to empirically determine by how much we should reduce the payment for ASC surgical procedures into which the costs of these devices are packaged. Device manufacturers and hospitals have told us that a common scenario is that, if a device fails 3 years after implantation, the hospital would receive a 50 percent credit towards a replacement device. We do not believe that hospitals reduce their device charges to reflect the credits that may have been received, so the lower facility costs associated with the partial credit scenarios would likely not be reflected in our proposed OPSS rates for these device-dependent procedures. Therefore, we proposed under the OPSS to reduce the payment for the relevant device dependent APCs and, under the revised ASC payment system, to reduce the payment for those ASC covered surgical procedures assigned to those APCs under the OPSS by half of the reduction that applies when the hospital or ASC receives a device without cost or receives a full credit for a device being replaced. That is, we proposed to reduce the payments by half of the offset amount that represents the cost of the device packaged into the procedure payment. In the absence of OPSS claims data on which to base a reduction factor, but taking into consideration what we have been told is common industry practice, we believe that reducing the amount of payment for the device dependent APC and the related ASC covered surgical procedure by half of the estimated cost of the device packaging represents a reasonable reduction in these cases. We listed the ASC procedures to which this proposed policy would apply in Table 64 of the CY 2008 OPSS/ASC proposed rule (72 FR 42790).

Moreover, we proposed to take this reduction only when the credit is for 20 percent or more of the cost of the new replacement device, so that the

reduction is not taken in cases in which more than 80 percent of the cost of the replacement device has been incurred by the facility. If the partial credit is less than 20 percent of the cost of the new replacement device, we believe that reducing the payment for the device implantation procedure by 50 percent of the packaged device cost would provide too low a payment for necessary device replacement procedures. Accordingly, we proposed that the new HCPCS partial credit modifier must be reported for cases in which the device credit is equal to or greater than 20 percent of the cost of the new replacement device if the device was listed in Table 65 of the CY 2008 OPPS/ASC proposed rule with comment period (72 FR 42790). We selected these devices because they have substantial costs and because each device is implanted in one beneficiary at least temporarily and, therefore, can be associated with an individual beneficiary.

The proposed policy related to partial device credits applies to the same devices and procedures to which our policy governing payment when the device is furnished to the ASC without cost or with full credit applies. We believe that this policy is a logical extension of our established policy regarding reduction of the ASC payment in cases in which the facility furnishes the device without cost or with a full credit to the ASC and ensures that beneficiary and Medicare payments are appropriate and consistent with costs incurred by ASCs.

This partial device credit policy that we proposed would enhance our ability to track the replacement of these implantable medical devices and may enable us to identify patterns of device failure or limited longevity early in their natural history so that appropriate strategies to reduce future problems for our beneficiaries may be developed. We also are mindful of the opportunity to use our claims history data to promote high quality medical care with regard to the devices and the services in which they are used. Collecting data on a wider set of device replacements under full and partial credit situations in all sites of outpatient surgery, including ASCs, would assist in developing comprehensive summary data, not just a subset of data related to devices replaced without cost or with a full credit to facilities.

Comment: As described in section IV.A.3. of this final rule with comment period, we received several public comments on our proposal to reduce payment if an expensive implantable device is replaced and the facility receives a partial credit toward the cost

of the replacement device. Principally, the commenters agreed that neither Medicare nor beneficiaries should have to pay based on a device's full cost when the hospital receives a substantial credit from the manufacturer for that device and supported the premise underpinning the proposed policy that hospitals' charges and the payment rates based on those charges currently do not reflect partial credits for replaced devices. However, the commenters argued that CMS should raise the partial credit threshold to which this policy would apply to 50 percent of the cost of the replacement device, consistent with the policy CMS recently implemented for devices replaced with partial credit for services paid under the FY 2008 IPPS. Many commenters also urged adoption of the same billing options that are available under the IPPS for billing devices replaced with partial credit. Specifically, they requested that hospitals and ASCs be allowed to: (1) Submit the claims for replacement devices immediately without the HCPCS modifier signifying partial credit for a replacement device and later, if a credit is ultimately issued, submit a claim adjustment with the appropriate coding; or (2) hold the claim until a credit determination is made. We refer readers to section IV.A.3. of this final rule with comment period for a more detailed summary of the comments we received on this proposal.

Response: After consideration of the public comments received, we are adopting a modified policy for certain procedures involving partial credit for a replacement device. Consistent with the final CY 2008 OPPS policy described in detail in section IV.A.3. of this final rule with comment period, and the recently implemented FY 2008 IPPS policy, we will reduce the ASC payment for implantation procedures listed in Table 58 below by one half of the device offset that would be applied if a replacement device were provided at no cost or with full credit, if the credit is 50 percent or more of the replacement device cost, rather than the proposed 20 percent. We believe that payment policies across hospital payment systems, including the OPPS, the IPPS, and the revised ASC payment system, should align whenever possible and appropriate, as is true in this case. We refer readers to section IV.A.3. of this final rule with comment period for a more detailed discussion of our decision to implement a 50 percent rather than 20 percent threshold to which the partial credit policy will apply.

ASCs will be instructed to append the new "FC" modifier to the HCPCS code for the procedure in which the device

was inserted on claims when the device that was replaced with partial credit under warranty, recall, or field action is one of the devices in Table 59 below (ASCs should not append the modifier to the HCPCS procedure code if the device is not listed in Table 59 below). The partial credit adjustment will be made to the national unadjusted rate, similar to what occurs when a device is replaced at full credit or with no cost, and beneficiary coinsurance will be adjusted to reflect the reduced payment amount.

As discussed in section IV.A.3. of this final rule with comment period, we understand commenters' concerns about potential delays that could occur while a returned device is being evaluated to determine whether and by how much a credit will be applied. In order to report that they received a partial credit of 50 percent or more of the cost of a replacement device, ASCs will have the option of either: (1) Submitting the claim for the device replacement procedure to their Medicare contractor after the procedure's performance but prior to manufacturer acknowledgment of credit for a replacement device, and subsequently contacting the contractor regarding a claims adjustment once the credit determination is made; or (2) holding the claim for the device replacement procedure until a determination is made by the manufacturer on the partial credit and submitting the claim with the "FC" modifier appended to the implantation procedure HCPCS code if the partial credit is 50 percent or more of the cost of the replacement device. If choosing the first billing option, to request a claim adjustment once the credit determination is made, ASCs should keep in mind that the initial Medicare payment for the procedure involving the replacement device is conditional and subject to adjustment. These billing instructions are consistent with instructions issued for billing under the IPPS and OPPS. We will issue additional billing instructions in a separate transmittal after publication of this final rule with comment period.

In summary, after consideration of the public comments received, we are finalizing a modified policy for certain procedures involving partial credit for a replacement device. Specifically, we will reduce the payment for implantation procedures listed in Table 58 below by one half of the device offset that would be applied if a replacement device were provided at no cost or with full credit, if the credit is 50 percent or more of the replacement device cost. In order to implement this policy, we will require ASCs to report the new modifier

“FC” in all cases in which the ASC receives a partial credit toward the replacement of a medical device listed in Table 59 below when used in a surgical procedure listed in Table 58 for which the ASC received at least a 50 percent credit. In order to report that they received a partial credit of 50 percent or more of the cost of a replacement device, ASCs will have the

option of either: (1) Submitting the claim for the device replacement procedure to their Medicare contractor after the procedure’s performance but prior to manufacturer acknowledgment of credit for a replacement device, and subsequently contacting the contractor regarding a claims adjustment once the credit determination is made; or (2) holding the claim for the device

replacement procedure until a determination is made by the manufacturer on the partial credit and submitting the claim with the “FC” modifier appended to the implantation procedure HCPCS code if the partial credit is 50 percent or more of the cost of the replacement device. Beneficiary coinsurance will be based on the reduced payment amount.

TABLE 58.—ADJUSTMENTS TO PAYMENTS FOR ASC COVERED SURGICAL PROCEDURES IN CY 2008 IN CASES OF DEVICES REPORTED WITHOUT COST OR FOR WHICH FULL OR PARTIAL CREDIT IS RECEIVED

HCPCS code	Short descriptor	CY 2008 OPPS APC	APC title	CY 2008 OPPS offset percentage	50 percent of CY 2008 OPPS offset percentage
61885	Insrt/redo neurostim 1 array	0039	Level I Implantation of Neurostimulator	82.73	41.37
64590	Insrt/redo perph n generator.				
63650	Implant neuroelectrodes	0040	Percutaneous Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve.	56.27	28.14
64555	Implant neuroelectrodes.				
64560	Implant neuroelectrodes.				
64561	Implant neuroelectrodes.				
64565	Implant neuroelectrodes.				
63655	Implant neuroelectrodes	0061	Laminectomy or Incision for Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve.	60.60	30.30
64575	Implant neuroelectrodes.				
64577	Implant neuroelectrodes.				
64580	Implant neuroelectrodes.				
64581	Implant neuroelectrodes.				
33206	Insertion of heart pacemaker	0089	Insertion/Replacement of Permanent Pacemaker and Electrodes.	72.99	36.50
33207	Insertion of heart pacemaker.				
33212	Insertion of pulse generator	0090	Insertion/Replacement of Pacemaker Pulse Generator.	76.01	38.01
33210	Insertion of heart electrode	0106	Insertion/Replacement/Repair of Pacemaker and/or Electrodes.	56.25	28.13
33211	Insertion of heart electrode.				
33216	Insert lead pace-defib, one.				
33217	Insert lead pace-defib, dual.				
33240	Insert pulse generator	0107	Insertion of Cardioverter-Defibrillator	89.11	44.56
33249	Eltrd/insert pace-defib	0108	Insertion/Replacement/Repair of Cardioverter-Defibrillator Leads.	89.24	44.62
63685	Insrt/redo spine n generator	0222	Implantation of Neurological Device	84.86	42.43
64553	Implant neuroelectrodes	0225	Implantation of Neurostimulator Electrodes, Cranial Nerve.	80.57	40.29
64573	Implant neuroelectrodes.				
62361	Implant spine infusion pump	0227	Implantation of Drug Infusion Device	80.73	40.37
62362	Implant spine infusion pump.				
69930	Implant cochlear device	0259	Level VI ENT Procedures	82.94	41.47
61886	Implant neurostim arrays	0315	Level II Implantation of Neurostimulator	86.15	43.08
53440	Male sling procedure	0385	Level I Prosthetic Urological Procedures ..	51.56	25.78
53444	Insert tandem cuff.				
54400	Insert semi-rigid prosthesis.				

TABLE 58.—ADJUSTMENTS TO PAYMENTS FOR ASC COVERED SURGICAL PROCEDURES IN CY 2008 IN CASES OF DEVICES REPORTED WITHOUT COST OR FOR WHICH FULL OR PARTIAL CREDIT IS RECEIVED—Continued

HCPCS code	Short descriptor	CY 2008 OPPS APC	APC title	CY 2008 OPPS offset percentage	50 percent of CY 2008 OPPS offset percentage
53445	Insert uro/ves nck sphincter	0386	Level II Prosthetic Urological Procedures	63.53	31.77
53447	Remove/replace ur sphincter.				
54401	Insert self-contd prosthesis.				
54405	Insert multi-comp penis pros.				
54410	Remove/replace penis prosth.				
54416	Remv/repl penis contain pros.				
33224	Insert pacing lead & connect	0418	Insertion of Left Ventricular Pacing Elect	82.52	41.26
33225	L ventric pacing lead add-on.				
36566	Insert tunneled cv cath	0625	Level IV Vascular Access Procedures	58.88	29.44
33213	Insertion of pulse generator	0654	Insertion/Replacement of a permanent dual chamber pacemaker.	77.13	38.57
33214	Upgrade of pacemaker system	0655	Insertion/Replacement/Conversion of a permanent dual chamber pacemaker.	74.62	37.31
33208	Insertion of heart pacemaker.				
33282	Implant pat-active ht record	0680	Insertion of Patient Activated Event Recorders.	73.15	36.58

TABLE 59.—DEVICES FOR WHICH THE “FB” OR “FC” MODIFIER MUST BE REPORTED WITH THE PROCEDURE CODE WHEN FURNISHED WITHOUT COST OR FOR WHICH FULL OR PARTIAL CREDIT IS RECEIVED

Device HCPCS code	Short descriptor
C1721	AICD, dual chamber.
C1722	AICD, single chamber.
C1764	Event recorder, cardiac.
C1767	Generator, neurostim, imp.
C1771	Rep dev, urinary, w/sling.
C1772	Infusion pump, programmable.
C1776	Joint device (implantable).
C1777	Lead, AICD, endo single coil.
C1778	Lead, neurostimulators.
C1779	Lead, pmkr, transvenous VDD.
C1785	Pmkr, dual, rate- resp.
C1786	Pmkr, single, rate- resp.
C1813	Prosthesis, penile, inflatab.
C1815	Pros, urinary sph, imp.
C1820	Generator, neuro rechg bat sys.
C1881	Dialysis access system.
C1882	AICD, other than sing/dual.
C1891	Infusion pump, non-prog, perm.
C1895	Lead, AICD, endo dual coil.
C1896	Lead, AICD, non sing/dual.
C1897	Lead, neurostim, test kit.
C1898	Lead, pmkr, other than trans.
C1899	Lead, pmkr/AICD combination.
C1900	Lead coronary venous.
C2619	Pmkr, dual, non rate- resp.
C2620	Pmkr, single, non rate- resp.
C2621	Pmkr, other than sing/dual.
C2622	Prosthesis, penile, non-inf.
C2626	Infusion pump, non-prog, temp.
C2631	Rep dev, urinary, w/o sling.
L8614	Cochlear device/system.

2. Payment for Covered Ancillary Services

Our final CY 2008 payment policies under the revised ASC payment system for covered ancillary services vary according to the particular type of service and its payment policy under the OPPS. Our overall policy provides for separate ASC payment for certain ancillary services integrally related to the provision of ASC covered surgical procedures if those services are paid separately under the OPPS. Thus, we established a policy to align ASC payment bundles with those under the OPPS. Specifically, our final ASC payment policies provide separate ASC payment for brachytherapy sources and drugs and biologicals that are separately paid under the OPPS at the OPPS rates, while we pay for radiology services at the lower of the MPFS nonfacility PE RVU (or technical component) amount or the rate calculated according to the standard methodology of the revised ASC payment system based on the OPPS relative payment weight for the service.

As evidenced by our final policies for the CY 2008 revised ASC payment system, our intention is to maintain consistent payment and packaging policies across HOPD and ASC settings for covered ancillary services that are integral to covered surgical procedures performed in ASCs. Therefore, consistent with our policy to pay separately only for those ancillary services that are paid separately under the OPPS, in the CY 2008 OPPS/ASC proposed rule (72 FR 42790), we also

proposed to package into the ASC payment for covered surgical procedures the costs of those ancillary services that are proposed to be packaged under the OPPS for CY 2008. Certain covered ancillary services that we proposed to package for the CY 2008 OPPS were assigned payment indicator “Z2” or “Z3” in the August 2, 2007 revised ASC payment system final rule, but they were assigned payment indicator “N1” in Addendum BB to the CY 2008 OPPS/ASC proposed rule. We refer readers to section II.A.4.c. of this final rule with comment period for a description of the CY 2008 OPPS proposed packaging approach that we also proposed to adopt in ASCs. In addition, OPPS payments for brachytherapy sources and separately payable drugs and biologicals are discussed in sections VII.B. and V. of this final rule with comment period, respectively. Other separately paid covered ancillary services in ASCs, specifically corneal tissue acquisition and devices with OPPS pass-through status, do not have prospectively established ASC payment rates according to the final policies of the revised ASC payment system. Payments for devices with pass through status under the OPPS, for which separate payment would be made to ASCs at contractor-priced rates, are discussed in detail in section VI. of this final rule with comment period.

We received many public comments on our proposal for payment of covered ancillary services under the CY 2008 revised ASC payment system. A

summary of the public comments and our response follow.

Comment: Many commenters disagree with the proposal to package payment for CPT codes 72285 (Discography, cervical or thoracic, radiologic supervision and interpretation) and 72295 (Discography, lumbar, radiological supervision and interpretation), in accordance with the proposed packaging policy under the OPPS. The commenters were concerned that the surgical procedures that are packaged into CPT codes 72285 and 72295 (Injection procedure for discography, each level; lumbar) and 62291 (Injection procedure for discography, each level; cervical or thoracic), as well as a number of other surgical procedures that are packaged into other codes in the range of CPT codes for radiology services, will no longer be available in ASCs as a result of the new packaging policy. The commenters requested that CMS develop a payment policy like that applied to these codes under the OPPS to allow separate payment for the services when they are provided without a covered surgical procedure.

Response: As explained in the August 2, 2007 revised ASC payment system final rule (72 FR 42485), we continue to believe that packaging payment for those surgical procedures that are packaged under the OPPS is appropriate under the revised ASC payment system. Our policy is aligned with the recommendation of the Practicing Physicians Advisory Council (PPAC) to apply payment policies uniformly in the ASC and HOPD settings. It also maintains comparable payment bundles under the OPPS and the revised ASC payment system for the services, consistent with the recommendation of MedPAC to maintain consistent payment bundles under both payment systems.

Under the OPPS, the services described by CPT codes 72285 and 72295 may be provided without another separately paid surgical procedure and, therefore, have been assigned to the OPPS status indicator "Q" to indicate that payment for the service is usually packaged into payment for another procedure but that under some circumstances, the service may be paid separately. For example, in the HOPD, if the service described by CPT code 72285 is provided without another separately paid service (into which it usually would be packaged), then a separate payment is made for it under the OPPS.

According to the revised ASC payment system policies, there is no instance in which payment for a service

is packaged only sometimes. The services that are packaged into covered surgical procedures are always packaged; that is, they are unconditionally packaged. There is no payment policy for ASCs that parallels the OPPS policy for the "Q" status indicator which, under OPPS conditional packaging policies, provides packaged payment for the service unless it is billed without any other separately payable OPPS service (or in some cases, without any other separately payable surgical procedure) on the same day, in which case separate OPPS payment is allowed for the status indicator "Q" service. In ASCs, there is no circumstance in which Medicare would make separate payment to an ASC for a service if it was not performed with a covered surgical procedure. Only covered surgical procedures may be paid when billed alone, without other separately payable services. Our policy is to make separate payment for all covered surgical procedures and for all covered ancillary services which, by definition, are provided integral to a covered surgical procedure performed in an ASC. Therefore, under the revised ASC payment system, the radiology services of concern to the commenters are packaged for CY 2008.

After consideration of the public comments received, we are providing CY 2008 payment for covered ancillary procedures in accordance with their final payment policies under the revised ASC payment system as described in the August 2, 2007 revised ASC payment system final rule and their final treatment under the CY 2008 OPPS. Covered ancillary services and their final payment indicators are listed in Addendum BB to this final rule with comment period.

G. Physician Payment for Procedures and Services Provided in ASCs

Under current policy, when physicians perform surgical procedures in ASCs that are included on the ASC list of covered surgical procedures, they are paid under the MPFS for the PE component using the facility PE RVUs. This is appropriate because the surgical procedures are those for which Medicare allows facility payment to ASCs. However, when physicians perform surgical procedures in ASCs that are not included on the ASC list of covered surgical procedures and for which Medicare does not allow facility payments to ASCs, physicians are paid for the PE component at the higher MPFS nonfacility PE RVUs (unless a nonfacility rate does not exist, in which case Medicare pays the physician at the facility rate). These policies are set forth

in §§ 414.22(b)(5)(i)(A) and (b)(5)(i)(B), respectively. Furthermore, physician payment for nonsurgical services provided in ASCs, for which no facility payment is made to ASCs under the existing ASC payment system, varies based on local Medicare contractor policy. Some contractors pay physicians only for the professional component (PC) of the service and others make payment to the physician for the technical component (TC) as well. Under the current policy, as described in the CY 2002 Physician Fee Schedule final rule with comment period (66 FR 55264), Medicare payment to the physician for a noncovered surgical procedure performed in an ASC constitutes payment in full. This is so even if the physician is paid the facility rate (because there is no nonfacility rate). In this case, there is no beneficiary liability other than the deductible and copayment for the physician's services.

According to the policy adopted in the August 2, 2007 revised ASC payment system final rule, Medicare will make facility payments to ASCs for all covered surgical procedures except those that could pose a significant risk to beneficiary safety or would be expected to require active medical monitoring and care at midnight following the procedure (that is, an overnight stay). The revised policy will result in a significant expansion in the number and type of surgical procedures for which Medicare will make an ASC facility payment. The final payment policy for the revised ASC payment system also allows separate payments to ASCs for certain covered ancillary services (for example, some drugs, brachytherapy sources, and certain radiology services) that are provided integral to an ASC covered surgical procedure. According to the final policy, when covered ancillary services, which are integral to the performance of a covered surgical procedure and are performed on the same day as the covered surgery, immediately before, during or following the procedure, Medicare will allow separate ASC payment for those services.

The revised ASC payment system is based on the APC groups and payment weights of the OPPS. We believe ASCs are facilities that are similar, insofar as the delivery of surgical and related nonsurgical services, to HOPDs. Specifically, when services are provided in ASCs, the ASC, not the physician, bears responsibility for the facility costs associated with the service. This situation parallels the hospital facility resource responsibility for hospital outpatient services. Therefore, as explained in the CY 2008 OPPS/ASC

proposed rule, we believe it would be more appropriate for physicians to be paid for all services furnished in ASCs just as they would be paid for all services furnished in the hospital outpatient setting. In addition, because we have adopted a final policy for the revised ASC payment system that identifies and excludes from ASC payment only those procedures that could pose a significant risk to beneficiary safety or would be expected to require an overnight stay, we believe that it would be incongruous with the revised ASC payment system methodology to continue to pay the higher nonfacility rate to physicians who furnish excluded ASC procedures. Because these excluded procedures have been specifically identified by CMS as procedures that could pose a significant risk to beneficiary safety or would be expected to require an overnight stay, we do not believe it would be appropriate to provide payment based on the higher nonfacility PE RVUs to physicians who furnish them. In fact, we do not expect that the excluded procedures will be performed in ASCs after the revised ASC payment system is implemented on January 1, 2008. Therefore, we proposed to revise §§ 414.22(b)(5)(i)(A) and (b)(5)(i)(B) to reflect this proposed policy.

We believe that the proposed revised policy would provide appropriate payment to physicians for services provided in the ASC facility setting and would encourage the most appropriate utilization of ASCs. For procedures that are not excluded from coverage under the revised ASC payment system, the ASC would be paid for the covered surgical procedure and associated covered ancillary services, and the physician would be paid for the professional work and facility PE associated with performing the procedure. In the case of noncovered surgical procedures or other noncovered services provided in ASCs, Medicare would make no payment to the ASC under the revised ASC payment system and no payment to the physician under the MPFS for the facility resources associated with providing those services. Although the current MPFS payment policy provides payment to the physician for some facility costs as if the service were being furnished in a physician's office, according to the final policy of the revised payment system, the services would not be covered ASC services. Consistent with Medicare payment policy in other care settings, no payment for facility costs would be made for the noncovered services. In this case, the noncovered services have

been excluded from ASC payment for safety reasons, because they are expected to require an overnight stay, or because they are not surgical procedures, and they would not be covered by Medicare either directly, under the ASC payment system, or indirectly, through PE payments to the physicians who perform them.

In summary, under the proposed policy, physicians would receive payment for all surgical and nonsurgical services furnished in ASCs based on the facility PE RVUs and excluding the TC payment, if applicable, consistent with physician payment for HOPD services. Medicare would make no payment for facility services to ASCs or physicians for procedures or services that are performed in ASCs but that are excluded from the list of covered ASC surgical procedures or that are not covered ancillary services. While physicians would be paid for these services based on the facility PE RVUs, physicians would no longer receive the additional payment for the associated facility resources.

Consistent with the current OPPI payment policy that prohibits facility payments to the hospital for noncovered services (such as those surgical procedures on the OPPI inpatient list) and makes the beneficiary liable for those charges, this proposed policy would make beneficiaries responsible for the ASC charges for noncovered services furnished to them in ASCs.

We received a number of public comments on our proposal to pay physicians at the facility PE rate instead of the nonfacility PE amount for excluded procedures, to not pay physicians the technical component (TC) payment for ancillary services, and to make beneficiaries responsible for the ASC charges for noncovered services furnished to them in ASCs. A summary of the public comments and our responses follow.

Comment: Several commenters requested that CMS not proceed with the proposal and continue the existing payment policy for excluded services performed in ASCs and payment for the TC associated with ancillary services to physicians who provide those services. One commenter stated that he provides permanent seed prostate brachytherapy services to Medicare beneficiaries in hospital and ASC settings. Under current Medicare payment policy, the commenter received the TC payment for a number of services in the radiology range of CPT codes because he brought the necessary equipment to the facility with him when he came to provide the brachytherapy procedures. The commenter stated that he would be able

to provide prostate brachytherapy services to a larger number of Medicare patients if he could continue to receive the TC payment for the ancillary services.

Response: Our proposed policy for physician payment would preclude physicians from receiving the TC payment for procedures performed in ASCs because, under the revised ASC payment system, Medicare will make payment only to ASCs for ancillary services provided integral to covered surgical procedures. The costs associated with the provision of covered ancillary services are facility resources, and Medicare will provide separate ASC payment for those costs. However, the ASC is not precluded from contracting with another entity to provide the equipment and supplies required to provide specific services. The ASC would make payment to its contractors.

Comment: Some commenters stated that beneficiaries should not be liable for the costs of procedures and services that are not covered when performed in ASCs. A few commenters believed that the beneficiary should only be liable for his or her deductible and coinsurance amounts, just as he or she would be for covered procedures in ASCs. One commenter stated that the course of a planned, covered procedure cannot always be determined in advance because the physician may have to alter the procedure intraoperatively, and sometimes that alteration results in performance of an excluded, noncovered procedure. The commenter did not believe it would be fair to hold the beneficiary liable in such cases. One commenter suggested that CMS create a modifier that the ASC would use to identify cases in which the planned, covered procedure was altered intraoperatively due to unexpected circumstances. The commenter indicated that payment in those cases could be priced by the contractor based on review of the operative report. The commenter stated that use of the modifier would enable CMS to track such occurrences and could audit as needed.

Response: We appreciate the commenters' concern regarding beneficiary liability for excluded ASC procedures. However, because we have adopted a final policy for the revised ASC payment system that identifies and excludes from ASC payment only those procedures that pose a significant risk to beneficiary safety or would be expected to require an overnight stay, we continue to believe that it would be incongruous with the revised ASC payment system methodology to continue to pay the higher nonfacility

rate to physicians who furnish excluded ASC procedures. Therefore, consistent with Medicare payment policy in other care settings, no payment for facility costs would be made for the noncovered services, and the beneficiary would be liable. As we explained in the CY 2008 OPPS/ASC proposed rule, because of the significant expansion of the ASC list of covered surgical procedures, we expect that excluded procedures will not be performed in ASCs beginning in CY 2008.

After consideration of the public comments received, we are finalizing our CY 2008 proposal, without modification, to pay physicians only the facility PE amount and exclude payment of the TC if applicable, for the performance of surgical procedures and nonsurgical services in ASCs and to make beneficiaries liable for the facility charges for procedures provided in the ASC that are excluded from ASC payment.

H. Changes to Definitions of "Radiology and Certain Other Imaging Services" and "Outpatient Prescription Drugs"

In section 1877(h)(6) of the Act, the Congress defined the "designated health services" (DHS) that are subject to the physician self-referral prohibition to include 11 broad categories of services. In our regulations at § 411.351, we define each of the 11 DHS categories, including "radiology and certain other imaging services" and "outpatient prescription drugs." The definition of "designated health services" at § 411.351 excludes "services that are reimbursed by Medicare as part of a composite rate (for example, ASC services or SNF Part A services)," except to the extent that the DHS categories are themselves payable through a composite rate. In the definition of "radiology and certain other imaging services" at § 411.351, we previously excluded x-ray, fluoroscopy, and ultrasound procedures that require the insertion of a needle, catheter, tube, or probe through the skin or into a body orifice. In addition, the definition of "radiology and certain other imaging services" excludes radiology procedures that are integral to the performance of a nonradiological medical procedure and (1) performed during the nonradiological medical procedure or (2) performed immediately following the nonradiological medical procedure when necessary to confirm placement of an item placed during the nonradiological medical procedure. Radiology and certain other imaging services performed before a nonradiological medical procedure have

been subject to the physician self-referral prohibition.

Taken together, these provisions effectively excluded from the physician self-referral prohibition referrals for: (1) Radiology and certain other imaging services that were paid through the ASC composite payment rate; and (2) radiology procedures that were integral to the performance of an ASC covered surgical procedure, that were paid separately, and that were performed in the ASC either (a) during the surgical procedure or (b) immediately after the surgical procedure if required to confirm placement of an item placed during the nonradiological medical procedure. (For physician self-referral purposes, we have considered radiology and certain other imaging services that are performed while the patient is still in the operating room to confirm that ASC surgery is effective to be performed during the surgical procedure.)

Under the August 2, 2007 revised ASC payment system final rule (72 FR 42470), effective January 1, 2008, Medicare makes a bundled or composite payment for facility services and a separate payment for each covered ancillary service that is integral to a covered surgical procedure and performed in the ASC on the same day. Because facility services continue to be paid under a composite rate, a physician referral for any radiology or other imaging service or outpatient prescription drug that is paid for as a facility service under § 416.164(a) is excluded from the physician self-referral prohibition under paragraph (2) of the definition of "designated health services" at § 411.351.

Covered ancillary services for which separate payment is made per item or service include many radiology and certain other imaging services. The August 2, 2007 revised ASC payment system final rule discusses the radiology services that are included in new § 416.164(b) as covered ancillary services integral to, and furnished on the same day as the ASC surgical procedure (72 FR 42496 through 42498).

Under the revised ASC payment system, a greater variety of surgical procedures than previously allowed can be provided as ASC services, and, thus, a greater number of "radiology and certain other imaging services" would be subject to the physician self-referral prohibition. Accordingly, in the August 2, 2007 rule proposing changes to both the outpatient hospital prospective payment system and the ASC payment system, we proposed to revise the physician self-referral definition of "radiology and certain other imaging services" to exclude those radiology and

imaging services that are "covered ancillary services," as defined at 416.164(b), for which separate payment is made under the revised ASC payment system (72 FR 42792). That is, we proposed that those radiology and imaging procedures that are integral to a covered ASC surgical procedure and that are performed immediately before, during, or immediately following the surgical procedure (that is, on the same day) would not constitute "radiology and certain other imaging procedures" for purposes of the physician self-referral law. We noted that if we did not revise the definition of "radiology and certain other imaging services" for physician self-referral purposes to exclude these radiology and other imaging procedures, the physician self-referral law would prohibit an ASC from billing Medicare for these separately payable, integral ancillary services rendered to patients who had been referred by a physician with an ownership or investment interest in, or compensation relationship with, an ASC unless an exception applies.

For the reasons that warrant our revising the definition of "radiology and certain other imaging services," we also proposed to exclude from the definition of "outpatient prescription drugs" at § 411.351, drugs that are "covered as ancillary services" as defined at new § 416.164(b) under the revised ASC payment system. These drugs are furnished, for example, during the immediate postoperative recovery period to a patient to reduce suffering from nausea or pain. Under our proposal, such drugs would not constitute DHS, although the physician self-referral provisions would continue to be applicable when an ASC furnishes outpatient prescription drugs for use in the patient's home.

Although we believe that physician referrals to entities with which they have a financial relationship are susceptible to abuse, we believe that our revision to the definitions of "radiology and certain other imaging services" and "outpatient prescription drugs" promote quality of care without posing a risk of abuse. The change will promote quality of care by allowing patients timely, convenient access to outpatient drugs and radiology and imaging services that are integral to an ASC procedure and necessary for its safe performance in an ASC. The risk of program abuse is avoided by the requirement that the items and services must be "integral to" the ASC procedure (that is, performed in the ASC immediately preceding, during, or immediately following the covered surgical procedure). We caution that only those items and services that

are integral to an ASC procedure and performed on the same day as the covered surgical procedure will qualify for the exclusion from the definitions of "radiology and certain other imaging services" and "outpatient prescription drugs." Other separately billable services that do not satisfy these conditions will remain subject to the physician self-referral prohibition. We will continue to monitor the provision of services in ASCs for potential abuse.

In addition, for clarity, we proposed to make a technical correction to paragraph (2) of the definition of "radiology and certain other imaging services" at § 411.351 to exclude from the definition not only "radiology procedures" that are integral to the performance of a "nonradiological procedure," but also to exclude "radiology and certain other imaging services" that are integral to the performance of "a medical procedure that is not identified on the List of CPT/HCPCS Codes as a 'radiology or certain other imaging service.'"

We received one public comment supporting the proposed change in the definition of "radiology and other imaging services." Two additional public comments concern radioactive seeds and ribbons (radioactive sources) implanted during brachytherapy procedures performed in an ASC. These items are included within the DHS category of "radiation therapy and supplies."

Comment: Two commenters asked CMS to exclude from the definition of DHS radioactive sources (including seeds and ribbons) furnished during a brachytherapy procedure performed in an ASC because DHS, as defined at § 411.351, does not include "services that are reimbursed by Medicare as part of a composite rate (for example, ambulatory surgical center services * * *)." In addition, the commenter suggested that, consistent with our proposal to exclude radiology services and outpatient prescription drugs that are "covered ancillary services" furnished on the same day as an ASC procedure, we should exclude from the definition of "radiation therapy services and supplies" brachytherapy sources that are also ASC covered ancillary services integral to a covered surgical procedure for which separate payment is made under new § 416.164(b). The commenters pointed out that, if these radioactive sources were not excluded from the physician self-referral prohibition, many urologist-owners of ASCs would not be able to order and furnish brachytherapy services because the ASC must bill Medicare for the

radioactive sources and they are not included in a composite rate.

Response: The DHS category "radiation therapy services and supplies" includes radioactive sources used in connection with brachytherapy procedures. The commenters are correct that a urologist or other type of physician who has an ownership or investment interest in, or a compensation relationship with, an ASC may not refer a Medicare patient to the ASC for a brachytherapy procedure, unless an exception is satisfied.

Previously, except for brachytherapy procedures performed as inpatient or outpatient hospital procedures, Medicare made payment for the radioactive sources to the individual or entity that furnished the radioactive sources. Under the ASC payment system effective for procedures performed on or after January 1, 2008, Medicare pays the ASC for facility services that are packaged into the ASC payment. In addition, Medicare makes a separate payment to an ASC for certain ancillary items and services, including brachytherapy sources.

The commenters are correct that, without an exception under the physician self-referral provisions, a urologist who refers a Medicare patient for an ASC-covered brachytherapy procedure may not have either an ownership or investment interest in the ASC or a compensation relationship with the ASC because the brachytherapy sources are DHS.

Although we did not propose to exclude, nor are we excluding in this final rule with comment period, brachytherapy sources supplied in connection with an ASC-covered brachytherapy procedure, we intend to consider this issue, and if we decide to propose an exception, we will include such changes in a proposed rule and seek public comment.

We are adopting the proposed physician self-referral provisions without change and we are making one additional technical, nonsubstantive change. We are revising the definition of "designated health services" at § 411.351 to reflect the fact that CMS no longer pays for all ASC procedures under a composite rate. Specifically, the definition will refer to "SNF Part A payments or ASC services identified at § 416.164(a)" as examples of services that Medicare pays as part of a composite rate. Section 416.164(a) sets forth the facility services for which a bundled or composite payment is made under the revised ASC payment system.

I. New Technology Intraocular Lenses

1. Background

At the inception of the ASC benefit on September 7, 1982, Medicare paid 80 percent of the reasonable charge for IOLs supplied for insertion concurrent with or following cataract surgery performed in an ASC (47 FR 34082, August 5, 1982). Section 4063(b) of OBRA 1987, Pub. L. 100-203, amended the Act to mandate that we include payment for an IOL furnished by an ASC for insertion during or following cataract surgery as part of the ASC facility fee for insertion of the IOL, and that the facility fee include payment that is reasonable and related to the cost of acquiring the class of lens involved in the procedure.

Section 4151(c)(3) of the Omnibus Budget Reconciliation Act of 1990 (OBRA 1990), Pub. L. 101-508, froze the IOL payment amount at \$200 for IOLs furnished by ASCs in conjunction with surgery performed during the period beginning November 5, 1990, and ending December 31, 1992. We continued paying an IOL allowance of \$200 from January 1, 1993, through December 31, 1993.

Section 13533 of the Omnibus Budget Reconciliation Act of 1993 (OBRA 1993), Pub. L. 103-66, mandated that payment for an IOL furnished by an ASC be equal to \$150 beginning January 1, 1994, through December 31, 1998. Section 141(b)(1) of the Social Security Act Amendments of 1994 (SSAA 1994), Pub. L. 103-432, required us to develop and implement a process under which interested parties may request a review of the appropriateness of the payment amount for insertion of an IOL, to ensure that the facility fee for the procedure includes payment that is reasonable and related to the cost of acquiring a lens that belongs to a class of NTIOLs.

In the February 8, 1990 **Federal Register** (55 FR 4526), we published a final notice entitled "Revision of Ambulatory Surgery Center Payment Rate Methodology," which implemented Medicare payment for an IOL furnished at an ASC as part of the ASC facility fee for insertion of the IOL. In the June 16, 1999 **Federal Register** (64 FR 32198), we published a final rule entitled "Adjustment in Payment Amounts for New Technology Intraocular Lenses Furnished by Ambulatory Surgical Centers," to add Subpart F (§§ 416.180 through 416.200) to 42 CFR Part 416, which established a process for adjusting payment amounts for insertion of a class of NTIOLs furnished by ASCs.

Since June 16, 1999, we have issued a series of **Federal Register** notices to list lenses for which we received requests for an NTIOL payment adjustment and to solicit comments on those requests, or to announce the lenses that we have determined meet the criteria and definition of NTIOLs. We last published a **Federal Register** notice pertaining specifically to NTIOLs on April 28, 2006 (71 FR 25176).

2. Changes to the NTIOL Determination Process Finalized for CY 2008

In the CY 2007 OPPS/ASC final rule with comment period, we finalized our proposal to update and streamline the process for recognizing IOLs inserted during or subsequent to cataract extraction as belonging to a new, active NTIOL class that is qualified for a payment adjustment. The following is a summary of the changes beginning for CY 2008 that were finalized in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68176 through 68181).

We modified the historical process of using separate **Federal Register** notices to notify the public of requests to review lenses for membership in new NTIOL classes, to solicit public comment on requests, and to notify the public of CMS's determinations concerning lenses assigned to classes of NTIOLs for which an ASC payment adjustment would be made. In the CY 2007 OPPS/ASC final rule with comment period (71 FR 68176), we specified that these NTIOL-related notifications will be fully integrated into the annual notice and comment rulemaking cycle for updating the ASC payment rates, the specific payment system in which NTIOL payment adjustments are made. Our final policy for updating the revised ASC payment system to be implemented in January 2008 will utilize an annual update process in coordination with notice and comment rulemaking for the OPPS. Aligning the NTIOL process with this annual update will promote coordination and efficiency, thereby streamlining and expediting the NTIOL notification, comment, and review process.

Specifically, we established the following process:

- We will announce annually in the **Federal Register** document that proposes the update of ASC payment rates for the following calendar year, a list of all requests to establish new NTIOL classes accepted for review during the calendar year in which the proposal is published and the deadline for submission of public comments regarding those requests. The deadline for receipt of public comments will be

30 days following publication of the list of requests.

- In the **Federal Register** document that finalizes the update of ASC payment rates for the following calendar year, we will—

- + Provide a list of determinations made as a result of our review of all requests and public comments; and
- + Publish the deadline for submitting requests for review in the following calendar year.

In determining whether a lens belongs to a new class of NTIOLs and whether the ASC payment amount for insertion of that lens in conjunction with cataract surgery is appropriate, we expect that the insertion of the candidate IOL would result in significantly improved clinical outcomes compared to currently available IOLs. In addition, to establish a new NTIOL class, the candidate lens must be distinguishable from lenses already approved as members of active or expired classes of NTIOLs that share a predominant characteristic associated with improved clinical outcomes that was identified for each class. In the CY 2007 final rule, we finalized our proposal to base our determinations on consideration of the following factors:

- The IOL must have been approved by the FDA and claims of specific clinical benefits and/or lens characteristics with established clinical relevance in comparison with currently available IOLs must have been approved by the FDA for use in labeling and advertising.

- The IOL is not described by an active or expired NTIOL class; that is, it does not share the predominant, class-defining characteristic associated with improved clinical outcomes with designated members of an active or expired NTIOL class.

- Evidence demonstrates that use of the IOL results in measurable, clinically meaningful, improved outcomes in comparison with use of currently available IOLs. According to the statute, and consistent with previous examples provided by CMS, superior outcomes that would be considered include the following:

- + Reduced risk of intraoperative or postoperative complication or trauma;
- + Accelerated postoperative recovery;
- + Reduced induced astigmatism;
- + Improved postoperative visual acuity;
- + More stable postoperative vision;
- + Other comparable clinical advantages, such as—

- ++ Reduced dependence on other eyewear (for example, spectacles, contact lenses, and reading glasses);
- ++ Decreased rate of subsequent diagnostic or therapeutic interventions,

such as the need for YAG laser treatment;

- ++ Decreased incidence of subsequent IOL exchange;
- ++ Decreased blurred vision, glare, other quantifiable symptom or vision deficiency.

For a request to be considered complete, we require submission of the information that is found in the guidance document entitled "Application Process and Information Requirements for Requests for a New Class of New Technology Intraocular Lens (NTIOL)" posted on the CMS Web site at: http://www.cms.hhs.gov/ASCPayment/05_NTIOls.asp.

As stated in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68180), there are three possible outcomes from our review of a request for determination of a new NTIOL class. As appropriate, for each completed request for a candidate IOL that is received by the established deadline, one of the following determinations would be announced annually in the final rule updating the ASC payment rates for the next calendar year:

- The request for a payment adjustment is approved for the IOL for 5 full years as a member of a new NTIOL class described by a new HCPCS code.
- The request for a payment adjustment is approved for the IOL for the balance of time remaining as a member of an active NTIOL class.
- The request for a payment adjustment is not approved.

We also discussed our plan to summarize briefly in the final rule the evidence that was reviewed, the public comments, and the basis for our determinations. We established that when a new NTIOL class is created, we would identify the predominant characteristic of NTIOLs in that class that sets them apart from other IOLs (including those previously approved as members of other expired or active NTIOL classes) and is associated with improved clinical outcomes. The date of implementation of a payment adjustment in the case of approval of an IOL as a member of a new NTIOL class would be set prospectively as of 30 days after publication of the ASC payment update final rule, consistent with the statutory requirement.

3. NTIOL Application Process for CY 2008 Payment Adjustment

To provide process and information requirements for applications requesting a review of the appropriateness of the payment amount for insertion of an IOL to ensure that the ASC payment for covered surgical procedures includes

payment that is reasonable and related to the cost of acquiring a lens that is approved as belonging to a new class of NTIOLs, in February 2007 we posted the guidance document to the CMS Web site regarding such requests as described above. We did not receive any review requests by the deadline of April 1, 2007, in response to the announcement made in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68181) soliciting CY 2008 requests for review of the appropriateness of the payment amount for new classes of IOLs furnished in ASCs.

We note that we have also issued a guidance document entitled "Revised Process for Recognizing Intraocular Lenses Furnished by Ambulatory Surgery Centers (ASCs) as Belonging to an Active Subset of New Technology

Intraocular Lenses (NTIOLs)." This guidance document can be accessed on the CMS Web site at: http://www.cms.hhs.gov/ASCPayment/05_NTIOLs.asp.

This guidance document provides specific details regarding requests for recognition of IOLs as belonging to an existing, active NTIOL class, the review process, and information required for a request to review. Currently, there is one active NTIOL class whose defining characteristic is the reduction of spherical aberration. CMS accepts requests throughout the year to review the appropriateness of recognizing an IOL as a member of an active class of NTIOLs. That is, review of candidate lenses for membership in an existing, active NTIOL class is ongoing and not limited to the annual review process

that applies to the establishment of new NTIOL classes. We ordinarily complete the review of such a request within 90 days of receipt, and upon completion of our review, we notify the requestor of our determination and post on the CMS Web site notification of a lens newly approved for a payment adjustment as an NTIOL belonging to an active NTIOL class when furnished in an ASC.

4. Classes of NTIOLs Approved for Payment Adjustment

Since implementation of the process for adjustment of payment amounts for NTIOLs that was established in the June 16, 1999 **Federal Register**, we have approved three classes of NTIOLs, as shown in the following table:

NTIOL category	HCPCS code	\$50 approved for services furnished on or after	NTIOL characteristic	IOLs eligible for adjustment
1	Q1001	May 18, 2000, through May 18, 2005.	Multifocal	Allergan AMO Array Multifocal lens, model SA40N.
2	Q1002	May 18, 2000, through May 18, 2005.	Reduction in Preexisting Astigmatism.	STAAR Surgical Elastic Ultraviolet-Absorbing Silicone Posterior Chamber IOL with Toric Optic, models AA4203T, AA4203TF, and AA4203TL.
3	Q1003	February 27, 2006, through February 26, 2011.	Reduced Spherical Aberration.	Advanced Medical Optics (AMO) Tecnis® IOL models Z9000, Z9001, Z9002, ZA9003 and AR40xEM; Alcon Acrysof® IQ Model SN60WF and Acrysert Delivery System Model SN60WS; Bausch & Lomb Sofport AO model LI61AOV.

5. Payment Adjustment

The current payment adjustment for a 5-year period from the implementation date of a new NTIOL class is \$50. In the CY 2007 OPPS/ASC final rule with comment period, we revised § 416.200(a) through (c) to clarify how the IOL payment adjustment will be made and how an NTIOL will be paid after expiration of the payment adjustment, as well as made minor editorial changes to § 416.200(d). For CY 2008, we did not propose to revise, nor are we revising in this final rule with comment period, the current payment adjustment amount, but we reiterate our intention, as stated in the CY 2007 final rule, to reevaluate whether or not the ASC payment rates established for cataract surgery with IOL insertion are appropriate when a lens determined to be an NTIOL is furnished after we have implemented the revised ASC payment system in CY 2008.

6. CY 2008 ASC Payment for Insertion of IOLs

In accordance with the final policies of the revised ASC payment system for CY 2008, payment for IOL insertion services will be established according to the standard payment methodology of

the revised payment system, which applies the ASC budget neutrality adjustment to the OPPS conversion factor to calculate an ASC conversion factor that is then multiplied by the ASC payment weight for the surgical procedure to implant the IOL. CY 2008 ASC payment for the cost of a conventional lens will be packaged into the payment for the associated covered surgical procedure performed by the ASC. We included the proposed CY 2008 ASC payment rates for IOL insertion procedures in Table 66 of the proposed rule (72 FR 42795) that is reprinted, with final CY 2008 ASC payment rates, below.

Comment: Several commenters supported the revision to the process for recognizing IOLs inserted during or subsequent to cataract extraction as belonging to a new or active NTIOL class. One commenter suggested that, for purposes of administrative simplicity, CMS should make the comment period on requests for new NTIOL classes 60 days, rather than 30 days as proposed. The commenter believed that Congress intended that CMS provide at least a 30-day comment period and argued that further adjusting the comment period for NTIOLs to 60 days would be consistent with the

comment period for the rest of the OPPS/ASC proposed rule.

Response: We appreciate the commenters' continuing support regarding our recent revision to the process for recognizing IOLs inserted during or subsequent to cataract extraction as belonging to a new or active NTIOL class. We continue to believe that aligning the NTIOL process with annual updates to the OPPS and the revised ASC payment system promotes coordination and efficiency, thereby streamlining and expediting the NTIOL notification, comment, and review process. In response to the comment urging us to adjust the comment period regarding requests to establish new classes of NTIOLs to 60 days, we note that section 141(b)(3) of the Social Security Act Amendments of 1994 (SSAA 1994), Pub. L. 103-432, clearly requires us to provide a 30-day comment period on lenses that are the subject of requests for recognition as belonging to a new class of NTIOLs. Therefore, we will continue to provide a 30-day comment period on lenses that are the subject of requests for recognition as members of a new class of NTIOLs.

After considering the public comments received, we are finalizing,

without modification, the process and timelines proposed for NTIOL consideration under the ASC payment system. The payment adjustment for NTIOLs will continue to be \$50 for CY 2008.

7. Announcement of CY 2008 Deadline for Submitting Requests for CMS Review of Appropriateness of ASC Payment for Insertion of an NTIOL Following Cataract Surgery

In accordance with § 416.185(a) of our regulations, as revised by the CY 2007 OPSS/ASC final rule with comment period, CMS announces that, in order to be considered for payment effective January 1, 2009, requests for a review of an application for a new class of new

technology IOLs must be received at CMS by 5 p.m., EST, on March 14, 2008. Send requests to: ASC/NTIOL, Division of Outpatient Care, Mailstop C4-05-17, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244-1850.

To be considered, requests for NTIOL reviews must include the information posted on the CMS Web site at http://cms.hhs.gov/ASCPayment/05_NTIOLs.asp#TopOfPage.

TABLE 60.—INSERTION OF IOL PROCEDURES AND THEIR CY 2008 ASC PAYMENT RATES

HCPCS code	Long descriptor	CY 2008 ASC payment
66983	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (one stage procedure)	\$976.76
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (one stage procedure), manual or mechanical technique (e.g., irrigation and aspiration or phacoemulsification).	976.76
66985	Insertion of intraocular lens prosthesis (secondary implant), not associated with concurrent cataract removal	866.51
66986	Exchange of intraocular lens	866.51

J. ASC Payment and Comment Indicators

In addition to the payment indicators that we introduced in the August 2, 2007 revised ASC payment system final rule, we also introduced comment indicators for the ASC payment system in the CY 2008 OPSS/ASC proposed rule (72 FR 42795). We created Addendum DD1 to define ASC payment indicators that we will use in Addenda AA and BB to provide payment information regarding covered surgical procedures and covered ancillary services, respectively, under the revised ASC payment system. Analogous to the OPSS payment status indicators that we define in Addendum D1 to the annual OPSS proposed and final rules, the ASC payment indicators in Addendum DD1 are intended to capture policy-relevant characteristics of HCPCS codes that may receive packaged or separate payment in ASCs, including: their ASC payment status prior to CY 2008; their designations as device-intensive; their designations as office-based and the corresponding ASC payment methodology; and their classifications as separately payable radiology services, brachytherapy sources, OPSS pass-through devices, corneal tissue acquisition services, drugs or biologicals, or NTIOLs.

We have also created new Addendum DD2 that lists the ASC comment indicators. Like the comment indicators used in the OPSS, the ASC comment indicators used in Addenda AA and BB to this OPSS/ASC final rule with comment period serve to identify, for the revised ASC payment system, the status of a specific HCPCS code and its

payment indicator with respect to the timeframe when comments would be accepted. The comment indicator “NI” is used in this final rule with comment period to indicate new HCPCS codes for which the interim payment indicator assigned is subject to comment in this final rule.

The changes for CY 2008 that we proposed to the payment indicators assigned to HCPCS codes for procedures and services in the August 2, 2007 revised ASC payment system final rule were identified with a “CH” in the OPSS/ASC proposed rule and were subject to comment during the 60-day comment period provided for that proposed rule. “CH” is used in Addenda AA and BB to this CY 2008 OPSS/ASC final rule with comment period to indicate that a new payment indicator (in comparison with that in the August 2, 2007 revised ASC payment system final rule) has been assigned to an active HCPCS code for the next calendar year; that an active HCPCS code has been added to the list of procedures or services payable in ASCs; or that an active HCPCS code will be deleted at the end of the current calendar year. The “CH” comment indicators that are published in this CY 2008 OPSS/ASC final rule with comment period are provided to alert our readers that a change has been made since the August 2, 2007 revised ASC payment system final rule, but do not indicate that the change is subject to comment. The full definitions for the comment indicators are provided in Addendum DD2 to this final rule with comment period.

We did not receive any comments that addressed our proposal related to implementation and use of comment indicators for the revised ASC payment system. Therefore, we are finalizing our proposal, without modification, to adopt the comment indicators as defined in Addendum DD2 to this final rule with comment period.

K. ASC Policy and Payment Recommendations

The GAO published the statutorily mandated report entitled, “Medicare: Payment for Ambulatory Surgical Centers Should Be Based on the Hospital Outpatient Payment System” (GAO-07-86) on November 30, 2006. We considered the report’s methodology, findings, and recommendations in the development of the August 2, 2007 revised ASC payment system final rule. The GAO methodology, results, and recommendations are summarized below.

The GAO was directed to conduct a study comparing the relative costs of procedures furnished in ASCs to those furnished in HOPDs paid under the OPSS, including examining the accuracy of the APC with respect to surgical procedures furnished in ASCs. Section 626(d) of Pub. L. 108-173 indicated that the report should include recommendations on the following matters:

1. Appropriateness of using groups of covered services and relative weights established for the OPSS as the basis of payment for ASCs.
2. If the OPSS relative weights are appropriate for this purpose, whether

the ASC payments should be based on a uniform percentage of the payment rates or weights under the OPSS, or should vary, or the weights should be revised based on specific procedures or types of services.

3. Whether a geographic adjustment should be used for ASC payment and, if so, the labor and nonlabor shares of such payment.

Based on its extensive analyses, the GAO determined that the APC groups in the OPSS accurately reflect the relative costs of the procedures performed in ASCs. The GAO's analysis of the cost ratios showed that the ASC-to-APC cost ratios were more tightly distributed around their median cost ratio than were the OPSS-to-APC cost ratios. The ASC-to-APC median cost ratio is a comparison of the median cost of each of the 20 surgical procedures with the highest ASC claims volume to the median cost of the APC group in which it would be placed under the OPSS, while the OPSS-to-APC cost ratio is a comparison of the median cost of each of those same procedures under the OPSS with the median cost of its assigned APC group. These patterns demonstrated that the APC groups reflect the relative costs of procedures performed by ASCs as they do for procedures performed in HOPDs and, therefore, that the APC groups could be used as the basis for an ASC payment system. The GAO determined, in fact, that there was less variation in the ASC setting between individual procedures' costs and the costs of their assigned APC groups than there is in the HOPD setting. It concluded that, as a group, the costs of procedures performed in ASCs have a relatively consistent relationship with the costs of the APC groups to which they are assigned under the OPSS. The GAO's analysis also found that procedures in the ASC setting had substantially lower costs than those same procedures in the HOPD. While ASC costs for individual procedures varied, in general, the median costs for procedures were lower in ASCs, relative to the median costs of their APC groups, than the median costs for the same procedures in HOPDs. The median cost ratio among all ASC procedures was 0.39 (0.84 when weighted by Medicare volume based on CY 2004 claims), whereas the median cost ratio among all OPSS procedures was 1.04.

The GAO found many similarities in the additional items and services provided by ASCs and HOPDs for the top 20 ASC procedures. However, of these additional items and services, few resulted in additional payment in one setting but not the other. HOPDs were paid for some of the related services

separately, while in the ASC setting, other Part B suppliers billed Medicare and received payment for many of the related services.

Finally, in its analysis of labor-related costs, the GAO determined that the mean labor-related proportion of costs was 50 percent. The range of the labor-related costs for the middle 50 percent of responding ASCs was 43 percent to 57 percent of total costs.

Based on its findings from the study, the GAO recommended that CMS implement a payment system for procedures performed in ASCs based on the OPSS, taking into account the lower relative costs of procedures performed in ASCs compared to HOPDs in determining ASC payment rates.

Comment: One commenter expressed concern that the public was denied time to analyze and respond to the findings in the congressionally mandated GAO report on ASC costs. The commenter believed that CMS' reliance on the GAO Report findings in finalizing the development of the revised payment system for ASCs, without also considering comments from the public about those findings, potentially violated principles of fairness and transparency. The commenter specifically stated that the report's findings are flawed and that the OPSS is not a relative cost proxy for ASCs' costs for gastrointestinal (GI) procedures.

Response: As we discussed in our response to comments on this topic in the August 2, 2007 revised ASC payment system final rule (72 FR 42475), in accordance with section 1833(i)(2)(D)(i) of the Act, we did take into account the recommendations made in the GAO Report in developing the final policies for the revised ASC payment system. We appreciate the public's interest in providing us with detailed input regarding the revised ASC payment system from a variety of perspectives. We noted that the GAO's recommendations were in complete accord with our proposal for the revised ASC payment system (71 FR 49635), and we provided a 90-day comment period on our proposal for CY 2008. We believe that the comment period for the August 23, 2006 proposed rule provided the public with ample opportunity to comment on the policies that ultimately were recommended by the GAO.

L. Calculation of the ASC Conversion Factor and ASC Payment Rates

1. Overview

As discussed in section XVI.C. of this final rule with comment period, we finalized our policy to base ASC relative

payment weights and payment rates under the revised ASC payment system on APC groups and relative payment weights. In the August 2, 2007 revised ASC payment system final rule, we made final our proposal to set the ASC relative payment weight for certain office-based surgical procedures so that the national unadjusted ASC payment rate does not exceed the MPFS unadjusted nonfacility PE RVU amount. Our final policy is to calculate ASC payment rates by multiplying the ASC relative payment weights by the ASC conversion factor. In the August 2, 2007 revised ASC payment system final rule, our estimate of the CY 2008 budget neutral ASC conversion factor was \$42,542. In the CY 2008 OPSS/ASC proposed rule, the proposed ASC conversion factor for CY 2008 was \$41,400. For this final rule with comment period, the ASC conversion factor for CY 2008 is \$41,401. Although this final ASC conversion factor differs little from the estimate in the August 2, 2007 revised ASC payment system final rule and the CY 2008 OPSS/ASC proposed rule, it reflects several changes, including: (1) Use of the final OPSS relative payment weights for CY 2008; (2) use of the final MPFS nonfacility PE RVU amounts for CY 2008; (3) use of updated utilization data from CY 2006; and (4) application of an adjustment to reflect differences in the geographic wage adjustment policy between the current and revised systems (discussed in further detail below). As in the proposed rule, in this final rule with comment period, we use the final methodology described in the August 2, 2007 revised ASC payment system final rule (72 FR 42522) to calculate the final CY 2008 ASC conversion factor and the final ASC relative payment weights and rates.

2. Budget Neutrality Requirement

Section 626(b) of Pub. L. 108-173 amended section 1833(i)(2) of the Act by adding subparagraph (D) to require that in the year the revised ASC payment system is implemented:

“[S]uch system shall be designed to result in the same aggregate amount of expenditures for such services as would be made if this subparagraph did not apply, as estimated by the Secretary * * *”

As discussed in the August 2, 2007 revised ASC payment system final rule, the ASC conversion factor is calculated so that estimated total Medicare payments under the revised ASC payment system would be budget neutral to estimated total Medicare payments under the current ASC payment system as required by the

statute. That is, application of the ASC conversion factor is designed to result in aggregate expenditures under the revised ASC payment system in CY 2008 equal to aggregate expenditures that would have occurred in CY 2008 in the absence of the revised system, taking into consideration the cap on payments in CY 2007 as required under section 5103 of Pub. L. 109–171.

We note that we consider the term “expenditures” in the context of the budget neutrality requirement under section 626(b) of Pub. L. 108–173 to mean expenditures from the Medicare Part B Trust Fund. We do not consider expenditures to include beneficiary coinsurance and copayments.

3. Calculation of the ASC Payment Rates for CY 2008

The following is a step-by-step illustration of the final budget neutrality adjustment calculation as finalized in the August 2, 2007 revised ASC payment system final rule and as applied to updated data available for this final rule with comment period.

The final methodology for establishing budget neutrality under the revised ASC payment system takes into account a 4-year transition to full implementation of the revised payment rates and the effects of several assumptions regarding migration of services across ASCs, HOPDs, and physicians’ offices. Payments during the 4-year transition to the fully implemented revised ASC payment rates will be based on a blend of the CY 2007 ASC payment rates and the revised ASC payment rates at 75/25 in CY 2008, 50/50 in CY 2009, and 25/75 in CY 2010, with payment at 100 percent of the revised ASC payment rates in 2011. The methodology assumes no net cost or savings to Medicare from the migration of existing ASC services among ASCs, HOPDs, and physicians’ offices. It includes assumptions that 15 percent of physicians’ office utilization for new ASC procedures, specifically those first added for ASC payment beginning in CY 2008, will migrate to ASCs over a 4-year period (3.75 percent each year) and that 25 percent of the new procedures’ HOPD utilization will migrate over the first 2 years under the revised payment system (12.5 percent each year) and accounts for the Medicare costs and savings associated with that movement. A detailed explanation of the model may be found in section V.C. of the August 2, 2007 revised ASC payment system final rule (72 FR 42521).

a. Estimated CY 2008 Medicare Program Payments (Excluding Beneficiary Coinsurance) Under the Existing ASC Payment System

Step 1: Migration from HOPDs to ASCs is valued using CY 2008 OPSS payment rates.

(a) We multiply the estimated CY 2008 HOPD utilization for each new ASC procedure by 0.125, consistent with our assumption that 25 percent of the HOPD utilization for new ASC procedures will migrate to the ASC over the first 2 years of the revised ASC payment system, only half of which would occur in CY 2008. In estimating HOPD utilization for CY 2008, we take into account the impact of the multiple procedure discount (as discussed in more detail in section V.C.3. the August 2, 2007 revised ASC payment system final rule).

(b) For each new ASC procedure, we multiply the results of Step 1(a) by the CY 2008 OPSS payment rate for the procedure, and then subtract beneficiary coinsurance for the procedure.

(c) We sum the results of Step 1(b) across all new ASC procedures.

Step 2: Migration of procedures from physicians’ offices to ASCs is valued using CY 2008 physician in-office payment rates. “Physician in-office payment rate” is equal to the MPFS nonfacility PE RVUs multiplied by the CY 2008 MPFS conversion factor.

(a) We multiply the estimated physician office utilization for CY 2008 for each new ASC procedure by 0.0375, consistent with our assumption that 15 percent of the physician’s office utilization for new ASC procedures will migrate to the ASC over the full 4-year transition period.

(b) For each new ASC procedure, we multiply the results of Step 2(a) by the CY 2008 physician in-office payment rate for the procedure, and then subtract beneficiary coinsurance for the procedure.

(c) We sum the results of Step 2(b) across all new ASC procedures.

Step 3: CY 2007 ASC services are valued using the estimated CY 2008 ASC payment rates under the current ASC system.

To estimate the aggregate expenditures that would be made in CY 2008 under the existing ASC payment system:

(a) We multiply the estimated CY 2008 ASC utilization for each HCPCS code on the CY 2007 ASC list by the estimated CY 2008 ASC payment rate for the HCPCS code under the existing ASC payment system, and then subtract beneficiary coinsurance for the procedure. The estimated CY 2008 ASC

payment rates are based on the CY 2007 ASC payment rates, which were listed in Addendum AA to the CY 2007 OPSS/ASC final rule with comment period (71 FR 68243 through 68283) and take into account the OPSS cap on payment for ASC services as required by section 5103 of Pub. L. 109–171 and reflect the zero percent CY 2008 update for ASC services mandated by section 1833(i)(2)(C) of the Act. In estimating ASC utilization for CY 2008, we take into account the impact of the multiple procedure discount (as discussed in section V.C.3. of the August 2, 2007 revised ASC payment system final rule).

(b) We estimate the amount the Medicare program would pay in CY 2008 for implantable prosthetic devices and implantable DME for which ASCs currently receive separate payment under the DMEPOS fee schedule.

(c) We sum the results of Steps 3(a) and 3(b) to estimate the aggregate amount of expenditures that would be made in CY 2008 for current covered surgical procedures under the existing ASC payment system.

Step 4: Sum the results of Steps 1–3.

b. Estimated Medicare Program Payments (Excluding Beneficiary Coinsurance) Under the Revised ASC Payment System

Step 5: HOPD migration is valued using CY 2008 OPSS payment rates.

This step is the same as Step 1, above.

Step 6: We identify new ASC procedures that are office-based (as discussed in section III.C. of the August 2, 2007 revised ASC payment system final rule).

Step 7: Migration of new ASC office-based procedures from physicians’ offices to ASCs is valued based on CY 2008 OPSS payment rates capped at the CY 2008 physician in-office payment rates, if appropriate.

(a) For each new ASC procedure determined to be office-based, we multiply the results of Step 2(a) above by the lesser of—

(1) The CY 2008 OPSS rate for the procedure; or

(2) The CY 2008 physician in-office payment rate for the procedure, and then subtract beneficiary coinsurance for the procedure.

(b) The results of Step 7(a) are summed across all new ASC procedures considered to be office based.

Step 8: Migration of new ASC procedures not determined to be office-based from physicians’ offices to ASCs is valued using the CY 2008 OPSS rates.

(a) For each new ASC procedure not considered to be office-based, we multiply the results of Step 2(a) above by the CY 2008 OPSS rate for the

procedure, and then subtract beneficiary coinsurance for the procedure.

(b) The results of Step 8(a) are summed across all new ASC procedures not considered to be office-based.

Step 9: Migration of new ASC procedures from physicians' offices to ASCs is valued using the CY 2008 MPFS physician out-of-office payment rate. "Physician out-of-office payment rate" is equal to the facility PE RVUs multiplied by the CY 2008 MFPS conversion factor.

(a) For each new ASC procedure, we multiply the results of Step 2(a) from above by the CY 2008 physician out-of-office payment rate for the procedure, and then subtract beneficiary coinsurance for the procedure.

(b) The results of Step 9(a) are summed across all new ASC procedures.

Step 10: Current ASC services are valued using the CY 2008 OPFS payment rates.

To estimate the aggregate amount of expenditures that would be made in CY 2008, we use CY 2008 OPFS payment amounts instead of estimated CY 2008 ASC payment amounts under the current system, and we multiply the estimated CY 2008 ASC volume for each HCPCS code on the CY 2007 ASC list of covered surgical procedures by the CY 2008 OPFS payment rate for the HCPCS code, and then subtract beneficiary coinsurance for the procedure. We sum the results over all services on that ASC list.

Step 11: The results of Steps 5 and 7–10 are summed.

c. Calculation of the CY 2008 Budget Neutrality Adjustment

Step 12: The result of Step 4 is divided by the result of Step 11.

Step 13: The application of the cap at the CY 2008 physician in-office payment rates that occurs in Step 7 is dependent on the ASC conversion factor. The ASC budget neutrality adjustment resulting from Step 12 is calibrated to take into account the interactive nature of the ASC conversion factor and the physician's office payment cap. The ASC budget neutrality calculation is also calibrated to take into account the fact that the additional physician out-of-office payment rates under the revised ASC payment system calculated in Step 9 must be fully offset by the budget neutrality adjustment to ASC services under the revised payment system. Furthermore, the budget neutrality calculation is calibrated to take into account the CY 2008 transitional payment rates for procedures on the CY

2007 ASC list of covered surgical procedures.

The application of the above methodology to the data available for this final rule with comment period results in a budget neutrality adjustment of 0.65. This number does not differ from the estimated budget neutrality adjustment of 0.65 for the CY 2008 OPFS/ASC proposed rule for the revised ASC payment system that was based on partial year CY 2006 utilization and proposed CY 2008 OPFS and MPFS payment rates (72 FR 42797).

We built an estimate of differences in total payment created by differences in the geographic adjustment policy between current and revised systems into the above model. Medicare currently accounts for geographic wage variations when calculating individual ASC payments under the existing payment system by applying the relevant IPPS wage index values and localities that were established under the IPPS prior to the implementation of Core Based Statistical Areas (CBSAs) issued by the Office of Management and Budget in June 2003 to a labor-related portion of 34.45 percent of the ASC payment amount. As discussed in the August 2, 2007 revised ASC payment system final rule (72 FR 42518), the revised payment system will account for geographic wage variations when calculating individual ASC payments by applying the pre-reclassification wage index to a labor-related portion of 50 percent of the ASC payment amount.

In the CY 2008 OPFS/ASC proposed rule, we noted that we did not have a provider-level dataset of ASC utilization that accurately identified unique ASCs and their geographic information and that this prevented us from calculating a budget-neutral wage adjustment. In our August 2, 2007 revised ASC payment system final rule, we estimated that the change in the wage policy would not significantly change aggregate ASC payment. We have since constructed this provider-level database using several sources to verify the validity of geographic information on the file. We have also crosswalked deleted HCPCS codes and their associated utilization to the CY 2008 HCPCS codes. Items previously paid under the ASC system, for which payment was not adjusted for differences in labor costs (for example, NTIOLs), were not included in this analysis. Using this provider-level dataset of CY 2006 ASC claims, we estimated total CY 2008 payment using revised ASC payment rates, the existing payment system labor-related portion of 34.45 percent, and the existing payment system wage index values. Using the

same dataset, we also estimated total CY 2008 payment using revised ASC payment rates, a labor-related portion of 50 percent, and the pre-reclassification wage index values based on CBSAs. Comparing the two totals, we calculated an adjustment of 1.00464, suggesting that the revised wage index values and labor-related portion would modestly reduce payments under the revised wage policy compared to the current policy. We built this adjustment factor into our budget neutrality model to calculate the final budget neutrality adjustment for the revised ASC payment system. Incorporating an adjustment for geographic wage differences did not change the final budget neutrality adjustment.

The final budget neutrality adjustment of 0.65 for the CY 2008 revised ASC payment system reflects updated data, including complete CY 2006 utilization and final CY 2008 OPFS and MPFS payment rates, as well as the addition of an adjustment for the final geographic wage adjustment policy of the revised ASC payment system.

d. Calculation of the CY 2008 ASC Payment Rates

After developing the final CY 2008 budget neutrality adjustment of 0.65 according to the policies established in the August 2, 2007 revised ASC payment system final rule, to determine the final CY 2008 ASC conversion factor, we multiplied the final CY 2008 OPFS conversion factor by the ASC budget neutrality adjustment. The final CY 2008 OPFS conversion factor is \$63.694, and multiplying that by the 0.65 budget neutrality adjustment yields our final CY 2008 ASC conversion factor of \$41.401. To determine the fully implemented ASC payment rates for this final rule with comment period, including beneficiary coinsurance, according to the final payment methodology that applies to most covered surgical procedures and certain covered ancillary services under the revised ASC payment system, we multiplied the ASC conversion factor by the ASC relative payment weight (which equals the OPFS payment weight in CY 2008) for each procedure or service. As further discussed in section XVI.C. of this final rule with comment period, the ASC relative payment weights for certain office-based surgical procedures and covered ancillary radiology services are set so that the national unadjusted ASC payment rate does not exceed the MPFS unadjusted nonfacility PE RVU amount. In addition, the ASC relative payment weights for device-intensive covered surgical procedures are set according to a modified payment

methodology to ensure the same device payment under the revised ASC payment system as under the OPSS. The CY 2008 ASC payment rates of covered ancillary drugs and biologicals and brachytherapy sources are set equal to their final CY 2008 OPSS payment rates, so the ASC conversion factor is not applicable to these items. We then calculated the CY 2008 payment rate for procedures on the CY 2007 ASC list of covered surgical procedures using a blend of 75 percent of the final CY 2007 ASC payment rate and 25 percent of the final CY 2008 ASC payment rate developed according to the methodology of the revised ASC payment system, applying the special transition treatment to device-intensive procedures as discussed in section XVI.C of this final rule with comment period. We refer readers to Addenda AA and BB to this final rule with comment period for the final CY 2008 ASC payment weights and payment rates for covered surgical procedures and covered ancillary services that are expected to be paid separately under the CY 2008 revised ASC payment system.

4. Calculation of the ASC Payment Rates for CY 2009 and Future Years

a. Updating the ASC Relative Payment Weights

In the August 2, 2007 revised ASC payment system final rule, we finalized our policy to update the ASC relative payment weights in the revised ASC payment system each year using the national OPSS relative payment weights (and MPFS nonfacility PE RVU amounts, as applicable) for that same calendar year and to uniformly scale the ASC relative payment weights for each update year to make them budget neutral (72 FR 42531). For example, holding ASC utilization and the mix of services constant, for CY 2009, we will compare the total weight using the CY 2008 ASC relative payment weights under the 75/25 blend (of the CY 2007 payment rate and the revised payment rate) with the total weight using CY 2009 relative payment weights under the 50/50 blend (of the CY 2007 payment rate and the revised payment rate), taking into account the changes in the OPSS relative payment weights between CY 2008 and CY 2009. We will use the ratio of CY 2008 to CY 2009 total weight to scale the ASC relative payment weights for CY 2009. Scaling of ASC relative payment weights would apply to covered surgical procedures and covered ancillary services whose payment rates are related to OPSS relative payment weights. Scaling would not apply in the case of ASC

payment for separately payable covered ancillary services that have a predetermined national payment amount (that is, their national payment amounts are not based on OPSS relative payment weights) such as drugs and biologicals that are separately paid under the OPSS. Any service with a predetermined national payment amount would be included in the budget neutrality comparison, but scaling of the relative payment weights would not apply to those services. The ASC payment weights for those services without predetermined national payment amounts (that is, their national payment amounts would be based on OPSS relative payment weights if a payment limitation did not apply) would be scaled to eliminate any difference in the total payment weight between the current year and the update year.

b. Updating the ASC Conversion Factor

Section 1833(i)(2)(C) of the Act requires that, if the Secretary has not updated the ASC payment amounts in a calendar year after CY 2009, the payment amounts shall be increased by the percentage increase in the CPI-U as estimated by the Secretary for the 12-month period ending with the midpoint of the year involved. Therefore, as discussed in the August 2, 2007 revised ASC payment system final rule, we adopted a final policy to update the ASC conversion factor using the CPI-U in order to adjust ASC payment rates for inflation (72 FR 42518). We will implement the annual updates through an adjustment to the conversion factor under the revised ASC payment system, beginning in CY 2010 when the statutory requirement for a zero update no longer applies.

We received a number of public comments regarding the update of the ASC conversion factor using the CPI-U. A summary of the public comments and our responses follow.

Comment: Several commenters were concerned that updating the conversion factor for the revised ASC payment system using the CPI-U would cause divergence in the relationship between payment to HOPDs (the OPSS is updated annually as the statute requires, using the hospital market basket percentage increase, as described in section II.C. of this final rule with comment period) and ASCs over time that would not be based on growing differences between the costs of providing procedures in those two different settings. The commenters believed that hospitals and ASCs experienced similar inflationary pressures. Therefore, they

recommended that CMS use the hospital market basket as the update for inflation under the revised ASC payment system because that update would more appropriately reflect inflation in the costs of providing surgical services. In addition, the commenters believed that the same update under the two payment systems would allow for a consistent relationship between their payment for the same surgical procedures.

Response: While we appreciate the commenters' concerns, the update policy for the revised ASC payment system was not open to comment in the CY 2008 OPSS/ASC proposed rule because we finalized that policy in the August 2, 2007 revised ASC payment system final rule after we received and addressed public comments (72 FR 42519). Beginning in CY 2010, when the period of the zero update for ASCs that the statute requires ends, we will apply the CPI-U to update the ASC conversion factor for inflation under the revised ASC payment system.

M. Annual Updates

Under the revised ASC payment system, we update on an annual calendar year basis the ASC conversion factor, the relative payment weights and APC assignments, the ASC payment rates, and the list of procedures for which Medicare would not make ASC payment. To the extent possible under the rules and policies of the revised ASC payment system, we maintain consistency between the OPSS and the ASC payment system in the way we treat new and revised HCPCS and CPT codes for payment under the ASC payment system. We also will invite comment as part of the annual update cycle to determine if there are procedures that we exclude from payment in the ASC setting that merit reconsideration as a result of changes in clinical practice or innovations in technology.

We update the ASC list of covered surgical procedures and payment system as part of the annual proposed and final rulemaking cycle updating the hospital OPSS. We believe that including the ASC update as part of the OPSS rulemaking cycle will ensure that updates of the ASC payment rates and the list of covered surgical procedures for which Medicare makes payment to ASCs will be issued in a regular, predictable, and timely manner. Moreover, the ASC payment system will be updated concurrent with changes in the APC groups and the OPSS inpatient list, making it easier to predict changes in payment for particular services from year to year.

In addition, we evaluate each year all new HCPCS codes that describe surgical procedures to make preliminary determinations regarding whether or not they should be payable in the ASC setting and, if so, whether they are office-based procedures. In the absence of claims data that would indicate where procedures described by new codes are being performed and identify the facility resources required to perform them, we proposed to use other available information, including our clinical advisors' judgment, predecessor CPT and Level II HCPCS codes, information submitted by representatives of specialty societies and professional associations, and information submitted by commenters during the public comment period following publication of the final rule with comment period in the **Federal Register**. We publish in the annual OP/ASC payment update final rule those interim determinations for the new codes to be active January 1 of the update year. The ASC payment system treatment of those procedures will be open to comment on that final rule, and we will respond to comments about our interim determinations in the OP/ASC final rule for the following year. After our review of public comments and in the absence of physicians' claims data, if our determination regarding a new code was that it should be included on the ASC list of covered surgical procedures as an office based procedure subject to the payment limitation, this determination would remain preliminary until we are able to consider more recent volume and utilization data for each individual procedure code or, if appropriate, the clinical characteristics, utilization, and volume of related codes. Using that information, if we confirm our determination that the new code was appropriately assigned to an office-based payment indicator, it will then be permanently assigned to the list of office-based procedures subject to the payment limitation.

Accordingly, this annual rulemaking and publication of revised payment methodologies and payment rates are reflected in § 416.173 of the regulations.

Comment: A few commenters urged us to complete the alignment of the OP/ASC and ASC by migrating from the CMS-1500 form to the UB-04 billing form for ASC claims submission, the same claim form that is used by HOPDs for Medicare payment and by ASCs for some other payers. They recommended that CMS initiate a transition process for providers and the agency's administrative contractors to implement the UB-04 form for ASCs in CY 2010.

The commenters stated that during CYs 2008 and 2009 ASCs would gain experience with the revised payment system and reporting quality measures and by CY 2010 could be ready to adopt the UB-04 for submitting their Medicare claims.

Response: This same comment was addressed in the August 2, 2007 revised ASC payment system final rule (72 FR 42534). As we discussed in that final rule, we will explore the feasibility of adopting the ASC billing change recommended by commenters. We reiterate here that a policy change that requires ASCs to use a different billing format would have to allow adequate time for CMS and ASCs to make the necessary systems changes and for CMS to provide training for contractors and ASCs prior to implementing the new format. We plan to pursue the feasibility of this option and to coordinate any possible change to ASC billing requirements with CMS' overall contracting transition. We welcome additional information from the public regarding recommendations for ASC billing modifications or improvements that we should consider once the revised payment system is implemented.

XVII. Reporting Quality Data for Annual Payment Rate Updates

A. Background

1. Reporting Hospital Outpatient Quality Data for Annual Payment Update

Section 109(a) of the MIEA-TRHCA (Pub. L. 109 432) amended section 1833(t) of the Act by adding a new subsection (17) that affects the payment rate update applicable to OP/ASC payments for services furnished by hospitals in outpatient settings on or after January 1, 2009. New section 1833(t)(17)(A) of the Act, which applies to hospitals as defined under section 1886(d)(1)(B) of the Act, requires that hospitals that fail to report data required for the quality measures selected by the Secretary in the form and manner required by the Secretary under section 1833(t)(17)(B) of the Act will incur a reduction in their annual payment update factor by 2.0 percentage points. New section 1833(t)(17)(B) of the Act requires that hospitals submit quality data in a form and manner, and at a time that the Secretary specifies. New sections 1833(t)(17)(C)(i) and (ii) of the Act require the Secretary to develop measures appropriate for the measurement of the quality of care (including medication errors) furnished by hospitals in outpatient settings and that these measures reflect consensus

among affected parties and, to the extent feasible and practicable, include measures set forth by one or more national consensus building entities. The Secretary is not prevented from selecting measures that are the same as (or a subset of) the measures for which data are required to be submitted under section 1886(b)(3)(B)(viii) of the Act for the IPPS Reporting Hospital Quality Data for Annual Payment Update (RHQDAPU) program. New section 1833(t)(17)(D) of the Act gives the Secretary the authority to replace measures or indicators as appropriate, such as when all hospitals are effectively in compliance or when the measures or indicators have been subsequently shown not to represent the best clinical practice. New section 1833(t)(17)(E) of the Act requires the Secretary to establish procedures for making data submitted available to the public. Such procedures must give hospitals the opportunity to review data before these data are released.

In the CY 2007 OP/ASC final rule with comment period (71 FR 68189), we indicated our intent to establish, in CY 2009, an OP/ASC RHQDAPU program modeled after the current IPPS RHQDAPU program. We stated our belief that the quality of hospital outpatient services would be most appropriately and fairly rewarded through the reporting of quality measures developed specifically for application in the hospital outpatient setting. We agreed with the commenters that assessment of hospital outpatient performance would ultimately be most appropriately based on reporting of hospital outpatient measures developed specifically for this purpose. We stated our intent to condition the full OP/ASC payment rate update beginning in CY 2009 based upon hospital reporting of quality data beginning in CY 2008, using effective measures of the quality of hospital outpatient care that have been carefully developed and evaluated, and endorsed as appropriate, with significant input from stakeholders.

The amendments to the Act made by section 109(a) of the MIEA-TRHCA are consistent with our intent and direction outlined in the CY 2007 OP/ASC final rule with comment period. Under these amendments, we are now statutorily required to establish a program under which hospitals will report data on the quality of hospital outpatient care using standardized measures of care in order to receive the full annual update to the OP/ASC payment rate, effective for payments beginning in CY 2009. We will refer to the program established under these amendments as

the Hospital Outpatient Quality Data Reporting Program (HOP QDRP).

In reviewing the measures currently available for care in the hospital outpatient settings, we continue to believe that it would be most appropriate and desirable to use measures that have been specifically developed for application in the hospital outpatient setting. Although we still believe that hospitals generally function as integrated systems in inpatient and outpatient settings, we do not believe it is appropriate to use participation in the IPPS RHQDAPU program for the purpose of implementing section 1833(t)(17) of the Act in the hospital outpatient setting. Nonetheless, section 1833(t)(17)(C)(ii) of the Act indicates that the Secretary is not prevented "from selecting measures that are the same as (or a subset of) the measures for which data are required to be submitted" under the IPPS RHQDAPU program. In the CY 2008 OPPS/ASC proposed rule (72 FR 42799), we proposed to establish a separate reporting program and proposed quality measures that are appropriate for measuring hospital outpatient quality of care, that reflect consensus among affected parties, and are set forth by one or more of the national consensus building entities.

2. Reporting ASC Quality Data for Annual Payment Increase

Section 109(b) of the MIEA-TRHCA, Pub. L. 109-432 amended section 1833(i) of the Act by adding new sections 1833(i)(2)(D)(iv) and 1833(i)(7) to the Act. These amendments may affect ASC payments for services furnished in ASC settings on or after January 1, 2009. New section 1833(i)(2)(D)(iv) of the Act authorizes the Secretary to implement the revised payment system for services furnished in ASCs (established under section 1833(i)(2)(D) of the Act), "so as to provide for a reduction in any annual payment increase for failure to report on quality measures."

New section 1833(i)(7)(A) of the Act authorizes the Secretary to provide that any ASC that fails to report data required for the quality measures selected by the Secretary in the form and manner required by the Secretary under new section 1833(i)(7) of the Act will incur a reduction in any annual payment increase of 2.0 percentage points. New section 1833(i)(7)(A) of the Act also specifies that a reduction for one year cannot be taken into account in computing the ASC update for a subsequent year.

New section 1833(i)(7)(B) of the Act provides that, "except as the Secretary

may otherwise provide," the hospital outpatient quality data provisions of section 1833(t)(17)(B) through (E) of the Act, summarized above, shall apply to ASCs.

We refer readers to section XVII.I. of this final rule with comment period for a discussion of our decision to introduce implementation of ASC quality data reporting in a later rulemaking.

3. Reporting Hospital Inpatient Quality Data for Annual Payment Update

Section 5001(a) of the Deficit Reduction Act of 2005, Pub. L. 109-171, set out the current requirements for the IPPS RHQDAPU program. We established the RHQDAPU program in order to implement section 501(b) of Pub. L. 108-173. The program builds on our ongoing voluntary Hospital Quality Initiative. The Initiative is intended to empower consumers with quality of care information so that they can make more informed decisions about their health care while also encouraging hospitals and clinicians to improve the quality of their care. Under the current statutory provisions found in section 1886(b)(3)(B)(viii) of the Act, the IPPS annual payment update for "subsection (d)" hospitals that do not submit inpatient quality data in a form, and manner, and at a time specified by the Secretary is reduced by 2.0 percentage points.

We used an initial "starter set" of 10 quality measures for the IPPS RHQDAPU program under section 501(b) of Pub. L. 108-173 and have expanded the measures as required under section 1886(b)(3)(B)(viii)(IV) and (V) of the Act, as added by section 5001(a) of Pub. L. 109-171. We initially added measures as a part of the annual IPPS rulemaking process. In response to public comments asking that we issue IPPS RHQDAPU program quality measures and other requirements as far in advance as possible, we also have used the OPPS annual payment update rulemaking process to adopt IPPS RHQDAPU program measures and requirements. In the CY 2007 OPPS final rule (71 FR 68201), we added six additional IPPS RHQDAPU program quality measures for FY 2008 update.

Most recently, in the FY 2008 IPPS proposed rule (72 FR 24805), we proposed adding 5 additional quality measures in for the FY 2009 update. However, in the FY 2008 IPPS final rule with comment period (72 FR 47351), we only adopted one of the proposed additional five measures. We indicated that we intended to adopt three additional measures in this CY 2008 OPPS/ASC final rule with comment

period, but only if the measures were adopted by the National Quality Forum (NQF). The NQF is a voluntary consensus standard-setting organization established to standardize health care quality measurement and reporting through its consensus development process. Under section 1886(b)(3)(B)(viii)(V) of the Act, we are required, to the extent feasible and practicable, to use measures set forth by entities such as NQF when adding new measures.

Section XVII.J. of this final rule with comment period contains a discussion of our decision to add two additional NQF-endorsed quality measures to the IPPS RHQDAPU program, with reporting to begin with the first calendar quarter of 2008 discharges, for the FY 2009 annual payment update.

B. Hospital Outpatient Measures

For the initial implementation of the HOP QDRP, we proposed 10 quality measures that we believed to be both applicable to care provided in hospital outpatient settings and likely to be sufficiently developed to permit data collection consistent with the timeframes defined by statute. These measures address care provided to a large number of adult patients in hospital outpatient settings, across a diverse set of conditions, and were selected for the initial set of HOP QDRP measures based on their relevance as a set to all hospitals.

The first five of these measures capture the quality of outpatient care in hospital emergency departments (EDs), specifically for those adult patients with acute myocardial infarction (AMI) who are treated and then transferred to another facility for further care. These patients receive many of the same interventions as patients who are evaluated and admitted at the same facility, whose care is currently assessed in measures that are endorsed by the National Quality Forum (NQF). NQF is a voluntary consensus standard setting organization established to standardize health care quality measurement and reporting through its consensus development process. Moreover, these are also inpatient AMI measures that have long been reported under the IPPS RHQDAPU program, and are published on the Hospital Compare Web site at: www.HospitalCompare.hhs.gov.

Transferred AMI patients historically have not been included with the directly-admitted patients for purposes of the calculation of the inpatient AMI measures because of differences in data collection and reporting for the two groups. With the input of provider and practitioner experts in the field, we

developed specifications for related emergency department transfer measures that, while consistent with the measure specifications for the related hospital inpatient measures, reflect the unique operational and clinical aspects of care in hospital outpatient settings. The processes of care encompassed by these measures address care on arrival, the promptness of interventions, and discharge care for patients presenting to a hospital with an AMI.

In addition to the five ED-AMI measures, CMS identified five quality measures that were directly related to conditions treated or interventions provided in hospital outpatient settings and that we believed were also appropriate and fully developed for use in the HOP QDRP. These measures were specified in a form that assessed the care provided by physicians, however, these measures are also relevant to assessing care at the facility level. CMS was engaged in reviewing, and where appropriate, revising these measure specifications so that they explicitly assess care provided in hospital outpatient settings. The five measures included one measure related to treatment of heart failure, two measures related to surgical care improvement, one measure addressing treatment of community-acquired pneumonia, and one measure related to diabetes care.

Therefore, for hospitals to receive the full OPPS payment update for services furnished in CY 2009, in the CY 2008 OPPS/ASC proposed rule (72 FR 42800) we proposed to require that hospital outpatient settings submit data on the following 10 measures, effective with hospital outpatient services furnished on or after January 1, 2008.

- ED-AMI-1—Aspirin at Arrival.
- ED-AMI-2—Median Time to Fibrinolysis.
- ED-AMI-3—Fibrinolytic Therapy Received Within 30 Minutes of Arrival.
- ED-AMI-4—Median Time to Electrocardiogram (ECG).
- ED-AMI-5—Median Time to Transfer for Primary PCI.
- PQRI #5 Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD).
- PQRI #20 Perioperative Care: Timing of Antibiotic Prophylaxis.
- PQRI #21 Perioperative Care: Selection of Prophylactic Antibiotic.
- PQRI #59 Empiric Antibiotic for Community-Acquired Pneumonia.
- PQRI #1 Hemoglobin A1c Poor Control in Type 1 or 2 Diabetes Mellitus.

As required by statute, consensus was reached by affected parties, as the measures were identified as appropriate for reporting on hospital outpatient care in collaboration with professionals and providers with experience in hospital outpatient settings as well as with the Hospital Quality Alliance (HQA), a hospital-industry led, public-private collaboration established to promote public reporting on hospital quality of care. The specifications for outpatient measures were then completed for hospital data collection using the same format that is used for inpatient measures. CMS finalized the specifications for these 10 measures and released them publicly on August 28, 2007. In addition these 10 measures have gone through the NQF steering committee process.

Nine of the ten proposed measures are process measures, while one measure—Hemoglobin A1c >9.0 percent—is an intermediate outcome measure that has not been risk adjusted. While poor quality of care can lead to poor diabetes control and elevated A1c levels, CMS recognizes that patient noncompliance with prescribed treatment regimen can also lead to poor diabetes control and elevated A1c levels. Patients with comorbidities or diabetes complications may also have a harder time controlling their diabetes and thus have higher A1c levels. Therefore, we specifically requested comments on this intermediate outcome measure and whether it may lead to unintended consequences.

CMS believes that an A1c level higher than 9.0 percent represents a level of control that is sufficiently poor enough that it should not result in any unintended consequences. The scientific literature would suggest that an A1c level of 8.0 percent or less might represent the best control that could be expected for some patients; therefore, CMS believes that an A1c level of > 9.0 percent represents a level of control that is poor enough that risk-adjustment is not warranted. Additionally, this A1c measure was endorsed by the National Quality Forum (NQF) in 2006. One of the criteria for evaluation of measures within the NQF process is “scientific acceptability,” which includes appropriate risk-adjustment. Some measures are not endorsed by NQF if risk-adjustment is determined to be appropriate and is found to be inadequate. CMS believes that additional risk-adjustment is not necessary because the NQF endorsed this measure. We invited public comment on our rationale for choosing a diabetes outcome measure rather than a process measure.

Comment: Several commenters supported collecting quality measure data for outpatient hospital services. Several commenters agreed with not using any inpatient quality measures for the outpatient hospital setting. One commenter stated that the proposed indicators are things that providers should be achieving for patients, and if done correctly, this endeavor will help to drive down the overall expenditures in health care.

Response: We thank the commenters for their support.

Comment: Several commenters supported the emergency room measures. However, the commenters also expressed concern that these measures would most affect smaller facilities that may not have the resources required for such data collection. One commenter stated that its facility does not transfer such patients and would not have any data for this set of measures.

Response: We appreciate the support expressed by commenters for the five ED-AMI measures. We agree that these measures will mostly apply to smaller facilities that do not admit such patients, transferring them instead. In fact, these measures were designed specifically for smaller facilities that were not included under quality measure reporting for inpatient measures. We recognize that some facilities, usually larger ones, do not transfer such patients; information on these patients for these facilities is captured under quality measure reporting for inpatient measures. Including the five ED-AMI measures in the required measure set for HOP QDRP will allow smaller facilities the opportunity to report quality measure data. We acknowledge that there are resource costs associated with collecting quality measure data, however, we also view it important that an opportunity to report such data be provided to smaller facilities and that consumers have information available from this type of facility. There is no penalty for not reporting quality measure data in the event that the provider does not have relevant cases.

Comment: One commenter did not support the use of the ED-AMI-4—Median Time to Electrocardiogram as this measure has not been adopted by NQF, nor is it collected for inpatients and, thus, is not ready for reporting.

Response: As statutorily required, affected parties reached consensus on the 10 proposed quality measures for outpatient hospital services. In addition, the ED-AMI-4 measure has been submitted for NQF endorsement with the other ED-AMI measures; all of these

measures have gone through the NQF steering committee process and have been recommended for endorsement.

Comment: One commenter expressed concern that for the five ED-AMI measures, the specifications contain no mention of observation patients.

Response: Observation care is a well-defined set of specific, clinically appropriate services, which include ongoing short-term treatment, assessment, and reassessment, before a decision can be made regarding whether a patient will require further treatment as a hospital inpatient. Observation status is commonly assigned to patients who present to the emergency room. Thus, the five ED-AMI measures are specifically designed to capture care rendered to such patients; patients that receive care but are not admitted as inpatients, that is, have outpatient status.

Comment: Many comments addressed the use of the Hemoglobin A1c measure. Several commenters expressed opinions ranging from concern with to strong opposition to the use of the Hemoglobin A1c measure for measuring outpatient hospital quality of care. While agreeing with the importance of hemoglobin A1c levels as a clinical measure for diabetes care, some commenters viewed this as more reflective of physician care and patient compliance. As the proposed Hemoglobin A1c measure is an outcome measure that is not risk adjusted; the need to use only process measures or risk adjust any outcome measures was also stated. One commenter agreed with the use of the proposed Hemoglobin A1c measure and that this measure did not require risk adjustment, but stated that this measure does need definition of the expected frequency of what the inclusion and exclusion criteria are. One commenter supported the Hemoglobin A1c measure but suggested a revision to being <7 percent, consistent with clinical guidelines.

Response: We agree with these comments regarding the Hemoglobin A1c measure. As noted in the proposed rule, the Hemoglobin A1c measure is an intermediate outcome measure that has not been risk adjusted. Recognizing the individual patient challenges with regard to this measure, as well as the need to otherwise modify the measure, we will not include the Hemoglobin A1c measure in the final HOP QDRP measure set at this time.

Comment: Several commenters stated that, except for the ED patients, it was unclear what the patient populations of interest are under the proposed outpatient hospital measures. For example, surgery patients could come from several areas of the hospital and

PQRI #1 and #5 could apply to outpatients that present for services unrelated to their conditions. Two commenters expressed concerns about patients that walk out from the ED and requested that these patients be excluded from any ED measures.

Response: As discussed previously and noted below, data collection on the PQRI #1 measure will not be required for any CY 2009 HOP QDRP determinations. We thank the commenters for raising the issue of patients that walk out from the ED and will consider this issue in the formulation of future measure specifications. We are also concerned about the comments received concerning the administrative burden for collection on PQRI #5-Heart failure and PQRI #59-community acquired pneumonia. We agree with the commenters that, at this point, those proposed quality measures may not be sufficiently refined for use in the outpatient setting. Therefore, we are not adopting PQRI #5 and PQRI #59 at this point as quality measures for the HOP QDRP.

Comment: Several commenters disagreed with the use of any or all of the five, non-ED-AMI measures as measures of quality of care for hospital outpatient services on the grounds that these measures were more indicative of the care provided by other settings, especially physician practices.

Response: We acknowledge that the five non-ED AMI measures were initially developed for measurement of quality of care provided by physician practices, and are all part of CMS' physician quality reporting initiative. However, the two surgical infection prevention measures would also apply to patients who have surgery in the hospital outpatient department. The diabetes measure and the heart failure measure apply to hospital outpatient department clinics that provide primary care services, and the pneumonia measure applies to hospital outpatient clinic departments and patients who are seen in an emergency department and discharged to home from the ED. Thus, it is our view that all of these measures could be fairly applied to hospital outpatient services as these patients are seen and services are rendered in this setting. However, in understanding of various concerns with some of these measures, we have decided to not include collection of data for the proposed heart failure, pneumonia, and diabetes measures as discussed in this section, for making HOP QDRP decisions for the CY 2009 payment update determinations. Data for the two

perioperative care measures will be required.

Comment: Commenters supported some of the non-ED measures. One commenter stated that perioperative care and timing of antibiotics (PQRI #20) are currently captured for inpatients and would be suitable reporting indicators for outpatient surgical cases if hospitals are provided specific surgical procedures to be included, are informed whether interventional procedures would be included, and are notified which prophylactic antibiotics would be included. One commenter stated that the proposed pneumonia measure was logical for measuring quality of care related to antibiotic administration in the ED and for patients under observation status.

Response: We thank the commenters for their support of these quality measures and intend to provide necessary specifications for data collection. At this time, there are no requirements to sample cases for the perioperative care measures by surgery type and thus there is no need to separate out specific surgical procedures for the purposes of selecting cases for the perioperative measures.

Comment: Several commenters expressed concern about the administrative and financial burden that would be associated with collecting outpatient hospital quality measure data, and indicated that the effort to be expended to collect such information would outweigh the benefit of this collection. Two commenters stated that data should be collected to improve clinical practice not just for payment purposes.

Response: We recognize that there are administrative and financial costs associated with collecting quality measure data. The reporting of quality measures for hospital outpatient services builds on our previous efforts in the inpatient arena, having the same purpose. Reporting is intended to encourage hospitals and clinicians to improve their quality of care and to empower consumers with quality of care information to make more informed decisions about their health care. We also note the requirement to report hospital outpatient quality measure data is statutory with the payment implication contingent upon the reporting of such information.

Comment: Several commenters stated that the infrastructure did not exist to support collecting outpatient hospital data as it did for collecting inpatient hospital data. The commenters stated that it would be extremely difficult if not impossible to meet the

implementation timeline due to the complexities of building data collection information systems. In particular, some of the commenters pointed out differences in storage of outpatient hospital services information and the possible need to connect information systems and people from different parts of a hospital and the lack of existing vendors as important differences.

Response: We recognize that the data infrastructure necessary to support collecting outpatient hospital data varies considerably among hospitals. To lessen the burden associated with this effort and recognizing the need for further refinement of some of the proposed measures for the outpatient setting, we have reduced the number of required measures and delayed implementation as discussed later in this final rule with comment period. Also, to aid hospitals in collecting these data, we will be providing a data collection tool in sufficient advance timing of required data submission.

Comment: Several commenters expressed concerns for training/support. For example, the commenters asked if a Quest or Quest-like entity would be provided and whether QIOs would be involved for the HOP QDRP. One commenter urged that QIOs be involved in providing support to hospitals for the HOP QDRP.

Response: We recognize the need for hospital support under the HOP QDRP. It is our intent that a Quest or Quest-like entity be provided to support this effort. In addition, we are in the process of procuring a contractor to assist in supporting implementation of HOP QDRP. Under the initial implementation of the HOP QDRP, there will be no QIO involvement.

Comment: Several commenters asked questions related to the source of required data, in particular, what claim submission form would be the data source, what is the definition of outpatient hospital services, what is the population or universe for sampling purposes, what is considered a hospital-based outpatient clinic (for example if a hospital owns an outside clinic, are these cases included or are only the clinics within the hospital to be included).

Response: Under MIEA-TRCHA, Quality Measure Reporting for Outpatient Hospital Services applies to "subsection (d)" hospitals subject to the OPSS. The Medicare Benefit Policy Manual, Chapter 6, under Hospital Services Covered Under Part B, provides the following definition of "hospital outpatient": "A hospital outpatient is a person who has not been admitted by the hospital as an inpatient but is

registered on the hospital records as an outpatient and received services (rather than supplies alone) from the hospital." Under this definition, such services must be directly received from the hospital. Thus, the population of interest consists of services rendered to Medicare beneficiaries reimbursed to hospitals under the OPSS or comparable services rendered under other payers. For Medicare beneficiaries, the claims data source for this information would be the UB-04, formally known as the UB-92. The UB-04 is a uniform institutional provider bill suitable for use in billing multiple third party payers. All other information necessary would come from the medical record.

Comment: Several commenters asked when the algorithms used for the measures would be available for review. In particular, they asked if the algorithms would be available for review at least 120 days prior to any start date to allow for vendor programming.

Response: The measure specifications were posted on August 28, 2007, far in advance of any proposed data reporting requirements. The following Web site includes the 10 proposed Hospital Outpatient (HOP) Measures: http://www.cms.hhs.gov/QualityInitiativesGenInfo/01_overview.asp. These measure specifications are final for April 2008 discharges forward. As discussed later in this section, data collection will begin with services rendered beginning April 2008 rather than beginning January 2008. From our perspective, the specifications for the final HOP measures finalized in this final rule with comment period are ready to use for programming purposes. It is possible that we will issue a revised version of the measure specifications for services after April 2008, but sufficient time for programming and data submission will be allowed.

Comment: One commenter asked whether vendor tools would be required to have reporting capabilities.

Response: We do not supply external vendors with requirements; we provide the measure specifications. We will consider providing such functionality in any reporting tool supplied by CMS.

Comment: Several commenters asked whether critical access hospitals would be required to report quality measures for hospital outpatient services. One commenter stated that critical access hospitals should be required to report data on the five ED-AMI measures proposed.

Response: The statute specifically notes the entities subject to the reporting quality measure data

requirement for OPSS annual payment updates. Section 1833(t)(17)(A)(i) of the Act, as added by section 109(a) of the MIEA-TRHCA (Pub. L. 109-432), requires a 2.0 percentage point reduction to the OPSS conversion factor update for those "subsection (d)" hospitals that do not submit to the Secretary data required to be submitted on measures selected in a form and manner, and at a time, specified by the Secretary. Subsection (d) hospitals are defined in section 1886(d)(1)(B) of the Act and do not include critical access hospitals. Additionally, outpatient hospital services at critical access hospitals are not reimbursed under the OPSS, so a reduction in the OPSS update factor would not affect critical access hospitals.

Comment: Several commenters asked whether the proposed payment reduction would apply to all services reported in CY 2009.

Response: As stated in the statute, the payment reduction would affect the annual OPSS payment increase by 2.0 percentage points. Thus, all hospital outpatient services subject to this update would be affected.

Comment: Several commenters urged CMS to not proceed with implementation of measures that have not received NQF endorsement and to wait until HQA finalizes their list of measures; field testing of measures was also recommended.

Response: The statute requires that we develop measures appropriate for the measurement of the quality of care furnished by hospitals in outpatient settings and that these measures reflect consensus among affected parties and, to the extent feasible and practicable, we include measures set forth by one or more national consensus building entities. The five ED-AMI measures address care provided to outpatients that receive many of the same interventions as inpatients who are evaluated and admitted at the same facility, and whose care is currently assessed in measures that are endorsed by NQF. Also, these five ED-AMI measures are inpatient AMI measures that have long been reported under the IPPS RHQDAPU program. As of the publication of this final rule with comment period, the two perioperative measures, Perioperative Care: Timing of Antibiotic Prophylaxis and Perioperative Care: Selection of Prophylactic Antibiotic, have received NQF endorsement. As discussed in this final rule with comment period, data collection for the remaining three proposed measures for heart failure, pneumonia, and diabetes mellitus will

not be required for CY 2009 payment decisions.

We utilize field-testing to the extent it is feasible and practical. The five ED-AMI transfer measures have been extensively tested for use in the inpatient setting. We have removed the transfer exclusion in order to incorporate the ED-AMI measure into the outpatient hospital setting. We believe the five ED-AMI measures are optimal for use in the outpatient hospital setting and will help fulfill our MIEA-TRCHA requirements for outpatient quality measure reporting. We intend to begin additional field testing in November 2007 and plan to make changes as necessary to specifications for future reporting.

Comment: One commenter recommended that any CMS-supplied tool should have separate modules for inpatient and outpatient data collection and reporting.

Response: It is our intent that the CMS-supplied tool will have separate modules for inpatient and outpatient data collection and reporting.

Comment: Several commenters noted that in the specifications of the two surgical measures in the Specifications Manual for hospital outpatient measures, CPT codes as opposed to ICD-9 codes were used to define the relevant procedures and questioned this approach. Several commenters also suggested that for any NQF-endorsed measures, the "all codes" versions should be used.

Response: CPT, E/M (Evaluation and Management) and ICD-9-CM Codes are used to identify eligible cases in the outpatient measures. Because the set of measures crosses settings (clinic, emergency department, hospital outpatient surgery department), it is necessary to utilize a variety of codes to adequately capture and sample the appropriate populations. For the surgical measures, each procedure is assigned a CPT code on the claim form and hospitals will use this information to pull the charts to be abstracted. The CPT-4 is a uniform coding system consisting of descriptive terms and identifying codes that are used primarily to identify medical services and procedures furnished by physicians and other health care professionals. More information regarding coding can be found on the CMS Web site at: http://www.cms.hhs.gov/MedHCPCSGenInfo/20_HCPCS_Coding_Questions.asp.

Comment: Several commenters expressed concerns about OPPS data reliability due to coding disparities from the high volume of many closely related codes.

Response: We understand the complexities of coding for outpatient services and have designed specifications with this in consideration. While data validation will not be used in the CY 2009 HOP QDRP determinations, as discussed below, future validation efforts can help to reduce coding disparities.

After consideration of the public comments received and as discussed in the above responses to those comments, for the CY 2009 annual payment update we are requiring HOP QDRP reporting using 7 of the proposed measures—the five ED-AMI measures as well as the two Perioperative Care measures, PQRI #20 Perioperative Care: Timing of Antibiotic Prophylaxis and PQRI #21 Perioperative Care: Selection of Prophylactic Antibiotic. As noted previously, we have decided to not implement three of the proposed measures, specifically those related to heart failure, diabetes, and community-acquired pneumonia for CY 2009 payment decisions. These decisions are based upon the recognition of the burden placed on providers in developing systems to collect outpatient quality measure data and need to utilize quality measures sufficiently refined for use in the outpatient setting.

C. Other Hospital Outpatient Measures

In addition to the 10 measures discussed above, we are considering a number of other possible quality measures for use in assessing the care provided by hospital outpatient settings, for the HOP QDRP determinations for CY 2010 or subsequent calendar year payment updates. These measures are, for the most part, either currently in use or were developed for use in settings other than hospital outpatient. However, we believe that these measures are applicable to the hospital outpatient settings.

These measures have not received formal review by either the HQA or the NQF as measures of HOP performance. As noted in the chart, however, the inpatient or ambulatory versions of these measures have all been either recommended by an NQF subgroup for endorsement, are pending endorsement by the NQF, or are currently endorsed by the NQF. The measures present the

diversity of services and clinical topics provided to adult patients in hospital outpatient settings. The measures address some aspects of care provided to cancer patients, patients presenting with diabetes, pneumonia, chest pains, syncope, or depression, and patients receiving services related to bones, eyes, and problems associated with aging. While some of the measures relate to acute care provided in a hospital outpatient setting, others assess care that a hospital outpatient clinic might provide on an ongoing basis. In the CY 2008 OPPS/ASC proposed rule, (72 FR 42801), we expressed interest in receiving comments from the public concerning all dimensions of these measures.

We expect that once the HOP QDRP is established, we will expand the set of measures on which hospital outpatient settings must report data. In the CY 2008 OPPS/ASC proposed rule, (72 FR 42801), we also expressed interest in receiving comments concerning the relative priority that should be assigned to each of the measures or topics identified in the list below, as well as any additional measures, measure sets, or topics that should be developed for future reporting.

We would like to note that, while we are committed to identifying measures that are relevant to care in hospital outpatient settings, it is also our intent to develop, where feasible, hospital outpatient measures that are "harmonized" with measures for assessing comparable inpatient and ambulatory care—that is, measures that are similar in both the care that is assessed and the manner in which data are collected, regardless of the setting. The goal of harmonization is to assure that comparable care in different care settings can be evaluated in similar ways, which further assures that quality measurement and improvement can focus more on the needs of a patient with a particular condition than on the specific program or policy attributes of the setting at which the care is provided.

Therefore, we sought public comment on the following 30 additional measures, which have been identified as hospital outpatient-appropriate measures and are under consideration for inclusion in the HOP QDRP measure set, for CY 2010 or subsequent calendar years:

	Measure	NQF endorsed for inpatient or ambulatory setting	Description
1	PQRI #2 Low Density Lipoprotein Control in Type 1 or 2 Diabetes Mellitus.	Endorsed 2006	Percentage of patients aged 18–75 years with diabetes (type 1 or type 2) who had most recent LDL-C level in control (less than 100 mg/dl).
2	PQRI #3 High Blood Pressure Control in Type 1 or 2 Diabetes Mellitus.	Endorsed 2006	Percentage of patients aged 18–75 years with diabetes (type 1 or type 2) who had most recent blood pressure in control (less than 140/80 mm Hg).
3	PQRI #4 Screening for Fall Risk	2 year Endorsement until May 8, 2009.	Percentage of patients aged 65 years and older who were screened for fall risk (2 or more falls in the past year or any fall with injury in the past year) at least once within 12 months.
4	PQRI #9 Antidepressant Medication During Acute Phase for Patient with New Episode of Major Depression.	Endorsed 2006	Percentage of patients aged 18 years and older diagnosed with new episode of major depressive disorder (MDD) and documented as treated with antidepressant medication during the entire 84-day (12 week) acute treatment phase.
5	PQRI #10 Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports.	2 year Endorsement until May 8, 2009.	Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke or transient ischemic attack (TIA) or intracranial hemorrhage undergoing CT or MRI of the brain within 24 hours of arrival to the hospital whose final report of the CT or MRI includes documentation of the presence or absence of each of the following: Hemorrhage and mass lesion and acute infarction.
6	PQRI #11 Stroke and Stroke Rehabilitation: Carotid Imaging Reports.	2 year Endorsement until May 8, 2009.	Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke or transient ischemic attack (TIA) whose final reports of the carotid imaging studies performed, with characterization of internal carotid stenosis in the 30–99 percent range, include reference to measurements of distal internal carotid diameter as the denominator for stenosis measurement.
7	PQRI #24 Osteoporosis: Communication with the Physician Managing Ongoing Care Post Fracture.	2 year Endorsement until May 8, 2009.	Percentage of patients aged 50 years and older treated for a hip, spine or distal radial fracture with documentation of communication with the physician managing the patient's ongoing care that a fracture occurred and that the patient was or should be tested or treated for osteoporosis.
8	PQRI #46 Medication Reconciliation	2 year Endorsement until May 8, 2009.	Percentage of patients aged 65 years and older discharged from any inpatient facility (e.g., hospital skilled nursing facility, or rehabilitation facility) and seen within 60 days following discharge in the office by the physician providing on-going care who had a reconciliation of the discharge medications with the current medication list in the medical record documented.
9	PQRI #53 Asthma Pharmacological Therapy	Endorsed 2006	Percentage of patients aged 5 to 40 with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred long-term control medication (inhaled corticosteroid) or an acceptable alternative treatment.
10	PQRI #58 Assessment of Mental Status for Community-acquired Pneumonia.	2 year Endorsement until May 8, 2009.	Percentage of patients aged 18 years and older with a diagnosis of community-acquired bacterial pneumonia with mental status assessed.
11	Radiation therapy is administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.	Endorsed May 9, 2007 ...	Radiation therapy to the breast initiated within 1 year of date of diagnosis.
12	Adjuvant chemotherapy is considered or administered within 4 months of surgery to patients under the age of 80 with AJCC III (lymph node positive) colon cancer.	Endorsed May 9, 2007 ...	Consideration or administration of chemotherapy initiated within 4 months of date of diagnosis.
13	Adjuvant hormonal therapy	Endorsed May 9, 2007 ...	Cancer—Breast—consideration or administration of accompanying hormonal therapy for treatment of breast cancer.
14	Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection.	Endorsed May 9, 2007 ...	Patient whose date of needle biopsy precedes the date of surgery.
15	Osteo-Q2: Screening or Therapy for Women Aged 65 years and Older.	2 year Endorsement until May 8, 2009.	Bone and joint conditions (osteoporosis)—Screening or therapy for women aged 65 years and older.

	Measure	NQF endorsed for inpatient or ambulatory setting	Description
16	Osteo-03: Management following fracture	2 year Endorsement until May 8, 2009.	Bone and joint conditions (osteoporosis)—Management following fracture.
17	Osteo-04: Pharmacologic Therapy	2 year Endorsement until May 8, 2009.	Bone and joint conditions (osteoporosis)—Pharmacologic therapy.
18	EC-01: Electrocardiogram (ECG) for Patients with Non-Traumatic Chest Pain.	2 year Endorsement until May 8, 2009.	Percentage of patients aged 40 years and older with an emergency department discharge diagnosis of nontraumatic chest pain who had an electrocardiogram (ECG).
19	EC-03: ECG Performed for Patients with Syncope	2 year Endorsement until May 8, 2009.	Percentage of patients aged 18 to 60 years with an emergency department discharge diagnosis of syncope who had an ECG performed.
20	EC-04: Vital Signs Recorded and Reviewed for Patients with Community-Acquired Bacterial Pneumonia.	2 year Endorsement until May 8, 2009.	Percentage of patients aged 18 years and older with a diagnosis of community-acquired bacterial pneumonia with vital signs recorded and reviewed.
21	Eye-01: Primary Open Angle Glaucoma—Optic Nerve Evaluation.	2 year Endorsement until May 8, 2009.	Primary open angle glaucoma—optic nerve evaluation.
22	Eye-02: Age-Related Macular Degeneration—Antioxidant Supplement Prescribed/Recommended.	Recommended for Endorsement.	Age-related macular degeneration—antioxidant supplement prescribed/recommended.
23	Eye-03: Age-Related Macular Degeneration—Dilated Macular Examination.	2 year Endorsement until May 8, 2009.	Age-related macular degeneration—dilated macular examination.
24	Eye-07: Diabetic Retinopathy—Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy.	2 year Endorsement until May 8, 2009.	Documentation of presence or absence of macular edema and level of severity of retinopathy.
25	Eye-08: Diabetic Retinopathy—Communication with the Physician Managing Ongoing Diabetes Care.	2 year Endorsement until May 8, 2009.	Communication with the physician managing ongoing diabetes care.
26	GI-09: Colonoscopy for Polyp Surveillance—Description of Polyp Characteristics.	Recommended for Endorsement.	Colonoscopy for polyp surveillance—description of polyp characteristics.
27	GER-02: Advance Care Plan	Recommended for Endorsement.	Advance care plan.
28	GER-03: Urinary Incontinence—Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older.	2 year Endorsement until May 8, 2009.	Assessment of presence or absence of urinary incontinence in women aged 65 years and older.
29	GER-04: Urinary Incontinence—Characterization of Urinary Incontinence in Women Aged 65 Years and Older.	2 year Endorsement until May 8, 2009.	Characterization of urinary incontinence in women aged 65 years and older.
30	GER-05: Urinary Incontinence—Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older.	2 year Endorsement until May 8, 2009.	Plan of care for urinary incontinence in women aged 65 years and older.

As with the Hemoglobin A1c diabetes intermediate outcome measure described in XVII.B of this preamble, we included two diabetes intermediate outcome measures in this list of 30 additional measures—that is, good control of blood pressure (less than 140/80 mm Hg) and LDL-C levels (less than 100 mg/dl). We specifically invited comment on these outcome measures.

We solicited comments on these 30 additional measures for inclusion in the HOP QDRP for CY 2010 or subsequent calendar years and welcomed comments on whether any of these additional measures should be included effective for services furnished on or after January 1, 2008 for the CY 2009 update.

Comment: Several commenters questioned in general the appropriateness of the proposed measures for hospital outpatient care. In particular, several commenters stated that the listed additional 30 measures were not suitable for hospital outpatient care in their present form and that the

measures should be refined to be more specific to the hospital outpatient setting. The commenters viewed the listed additional 30 measures as more relevant to care provided in other settings, especially physician-based settings.

Response: We acknowledged in the proposed rule that the listed additional 30 measures are either in use or were developed for use in settings other than hospital outpatient (72 FR 42801). As we stated, it is our intent to develop, where feasible, hospital outpatient measures that are “harmonized,” with measures for assessing comparable inpatient and ambulatory care, that is, comparable care rendered in different settings can be evaluated in similar ways. We intend to expand the set of measures on which hospital outpatient settings must report data for payment decisions for CY 2010 and subsequent calendar years.

Comment: Several commenters stated that it was difficult to comment on the

additional 30 measures proposed for future use as it was difficult to know if any of them would be considered best practice in the near future, noting the period of endorsement was short for many. Several commenters stated that any quality measure chosen for public reporting and pay for performance should be generally accepted as best practice. One commenter stated that quality measures with longer “shelf-life” be used.

Response: We agree with the commenters’ position that any quality measures chosen for public reporting and pay for performance should be generally accepted as best practice. We understand that it is more desirable to utilize quality measures with more longevity. We will take these comments into consideration when we review additional measures for possible inclusion in the HOP QDRP measure set.

Comment: Three commenters stated that the requirement to collect

information that affected hospital payment that was dependent on physician activity fostered a hostile environment. One commenter emphasized that there is no financial incentive for physicians to participate in improving hospital outpatient quality measures. One commenter stated that creation of this hostile environment affected larger hospitals to a lesser extent and made recruitment/retention more difficult for smaller hospitals.

Response: Under section 1833(t)(17) of the Act, as added by section 109(a) of the MIEA-TRHCA, CMS is statutorily required to establish a hospital outpatient care data reporting program. We will continue to utilize a consensus process in devising measures applicable to the hospital outpatient setting. As discussed in this final rule with comment period, a sampling scheme devised around hospital outpatient volume will be devised to lessen the burden for smaller hospitals. It is our intent that quality measure reporting will encourage providers and clinicians to improve their quality of care.

Comment: One commenter provided strong support for one potential indicator, "Radiation therapy is administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer."

Response: We thank the commenter for supplying information supporting this quality measure and will consider it in the selection of future HOP QDRP measures.

Comment: Several commenters stated that in regard to the 30 additional measures listed, given the lack of operational data collection processes for outpatient hospital data and the associated costs of collecting quality measure data, CMS should not consider any additional measures, especially for the first year of reporting.

Response: We acknowledge that there is a burden with collecting quality measure data. As stated in the proposed rule, we indicated that we were considering the additional listed 30 measures for CY 2010 or subsequent calendar year reporting requirements, although we also solicited comments on whether any of the listed 30 additional measures should be included in reporting for the CY 2009 payment year. Further, as discussed elsewhere in this final rule with comment period, we have reduced the number of required reporting measures for the CY 2009 payment year from the 10 we proposed. However, given the importance of outpatient hospital quality measure reporting it is our intent to propose additional measures in the future.

Comment: One commenter expressed concern with the use of PQRI #2 and PQRI #3 as these are outcome measures and as such should not be used as a basis for determining payment. One commenter strongly opposed the PQRI #14 measure, stating that a needle biopsy is not always appropriate. One commenter strongly opposed the PQRI #18 measure, stating that ordering an ECG is a judgment call, and that an ECG is not always indicated with non-traumatic chest pain. Several commenters expressed support for cancer care related measures.

Response: We thank the commenters for expressing these concerns and will hold these concerns in consideration of future measure requirements.

Comment: One commenter strongly supported imaging-related quality measures.

Response: CMS appreciates this comment and intends to incorporate imaging measures in the future.

Comment: One commenter stated that the term "outpatient" needed to be more clearly defined and that an approach that narrowed the population of interest for outpatient care by service as do the five ED-AMI measures and the surgical day care measures (PQRI #21 and PQRI #22) should be used for other measures.

Response: Although PQRI #21 and PQRI #22 were not in the list of 30 measures included in the proposed rule, we understand the commenter's intent and thank the commenter for this suggestion. We will keep it in mind as we consider future measures.

Comment: Several commenters recommended that the same numbering system be used in the specifications manuals for both the inpatient and outpatient data tables and in particular, that CMS use of the same number for corresponding tables.

Response: We thank the commenters for this suggestion and will look to aligning the specification manuals for inpatient and outpatient quality measures to the extent possible.

Comment: Several commenters suggested that osteoporosis measures (PQRI #24, #39, #40, and #41) be included in the HOP QDRP; and also asked that data collection for these measures begin in CY 2008. One commenter stated that CMS should promote the prevention of fragility fractures by distinguishing DXA testing from pharmacologic therapy in HOP QDRP measures.

Response: We thank the commenters for support of these measures and for the suggestions. As noted above, to reduce provider burden and recognizing the need for further refinement of some of the proposed measures for the

outpatient setting, the number of required measures has been reduced for CY 2008 quality data reporting efforts. We will consider these measures for future implementation.

Comment: One commenter stated that with respect to the 30 additional listed measures, populations to be included must be carefully defined so that any public reporting will compare like populations, to the extent that outcomes data are reported, risk adjustment was critical, and that process measures be reasonable.

Response: We thank the commenter for these comments to be used in consideration of future measures.

After consideration of the public comments received and as noted in the above responses to those comments, we are not collecting data for any of the additional 30 listed measures under the HOP QDRP for purposes of the CY 2009 update.

D. Implementation of the HOP QDRP and Request for Additional Suggested Measures

In the CY 2008 OPPI/ASC proposed rule, (72 FR 42803), we stated that for purposes of CY 2009 payments, we would require hospitals to begin to submit data on the 10 measures that we identified under section XVII.B. of the proposed rule. We also noted that, while we would expect to focus on these 10 measures and would consider comments on them for the CY 2009 payment year, we would also consider the comments received from the public on the list of 30 additional measures cited above in developing the final lists of measures for future payment years.

As described below, procedures for submission of hospital outpatient quality information will mirror as closely as possible all procedures for submission of inpatient quality information. The inpatient procedures are identified on the QualityNet Web site, at <http://www.qualitynet.org>. As required by new section 1833(t)(17)(E) of the Act, we will develop procedures to publicly report the measure results obtained under the HOP QDRP. Hospitals will have an opportunity to review the information that is to be made available to the public prior to its being made public.

We believe that ensuring that Medicare beneficiaries receive the care they need and that such services are of appropriately high quality are the necessary initial steps to the incorporation of value-based purchasing into the OPPI. We seek to encourage care that is both efficient and of high quality in the hospital outpatient setting. We plan to work quickly and

collaboratively with the hospital community to develop and implement quality measures for the OPPS that are fully and specifically reflective of the quality of hospital outpatient services.

In the CY 2008 OPPS/ASC proposed rule, (72 FR 42803), we welcomed suggestions of other additional measures and topics relevant to the hospital outpatient setting for future development of the measure set, particularly measures from other settings (such as hospital inpatient, physician office, and emergency care settings) that would contribute to better coordination and harmonization of high quality patient care.

Comment: Two commenters asked for the consideration of the PQRI #4 Screening for Future Fall Risk outpatient quality measure as well as the following occupational therapist measures, Patient Co-Development of Plan of Care, Pain Assessment Prior to Initiation of Patient Treatment, and Universal Documentation and Verification of Current Medications in the Medical Record. One commenter suggested measures for preventive care for future use. Several commenters suggested the inclusion of administration of anti-platelet therapy for patients with coronary artery disease. One commenter suggested the inclusion of measures on venous thromboembolism and care coordination. One commenter suggested the inclusion of additional medical prophylaxis safety measures including 2 SCIP measures (SCIP-VTE1, venous thromboembolism prophylaxis ordered for a surgery patient and SCIP-VTE2, prophylaxis within 24 hours pre/post surgery). One commenter suggested the development of additional VTE measures. One commenter suggested that in addition to quality measures, the hospital component of the Consumer Assessment of Health Providers and Systems (HCAHPS) has several questions directed to patients that are applicable to hospital outpatient care and, thus, could provide useful information about outpatient quality care.

Response: We thank the commenters for supplying additional, potential quality measures for consideration in the HOP QDRP measure set.

Comment: One commenter noted that there is a discrepancy between the SCIP VTE-1 and PQRI #23 measures and that while these are not proposed measures under this rule, CMS should review all of its quality measures to ensure compatibility and lack of conflict. One commenter suggested aligning the PQRI measures with the outpatient quality measures.

Response: We thank the commenters for these observations, and we will continue to strive to ensure compatibility and alignment of measures across settings.

Comment: Several commenters suggested that any financial implications related to outpatient quality measure reporting be deferred.

Response: Under section 1833(t)(17)(A)(i) of the Act, as added by section 109(a) of the MIEA-TRHCA, the HOP QDRP is established to affect payments effective beginning in CY 2009.

E. Requirements for HOP QDRP for CY 2009 and Subsequent Calendar Years

In the CY 2008 OPPS/ASC proposed rule, (72 FR 42803), we stated that in order to participate in the HOP QDRP for CY 2009 and subsequent calendar years, hospitals must meet administrative, data collection and submission, and data validation requirements. Hospitals not participating in the program or that withdraw from the program will not receive the full OPPS payment rate update. Instead, in accordance with the law, those hospitals would receive a reduction of 2.0 percentage points in their updates for the affected payment year.

Hospitals not meeting the requirements of the HOP QDRP also will not receive the full OPPS payment rate update. Instead, in accordance with the law, those hospitals also would receive a reduction of 2.0 percentage points in their payment update factor for the affected payment year.

We proposed the following requirements for participation in the HOP QDRP:

1. Administrative Requirements

To participate in the HOP QDRP, the hospital must complete several administrative steps. These steps, as in the current IPPS RHQDAPU program, require the hospital to:

- Identify a QualityNet Exchange administrator who follows the registration process and submits the information through the CMS-designated contractor. The same person may be the QualityNet Exchange administrator for both the IPPS RHQDAPU program and the HOP QDRP. This designation must be kept current and must be done, regardless of whether the hospital submits data directly to the CMS designated contractor or uses a vendor for transmission of data.
- Register with the QualityNet Exchange, regardless of the method used for data submission.

- Complete the Notice of Participation form. All hospitals must send the form to a CMS-designated contractor no later than November 15, 2007 for the CY 2009 HOP QDRP. At this time, the participation form for the HOP QDRP is separate from the IPPS RHQDAPU program and completing a submission form for each program is required. Agreeing to participate includes acknowledging that the data submitted to the CMS designated contractor will be submitted to CMS and may be shared with a CMS contractor or contractors supporting the implementation of this program.

Hospitals not wishing to participate must submit a nonparticipation form. Hospitals that have completed a notice of participation form and subsequently wish to stop participating must submit a withdrawal form.

To reduce the burden on hospitals, once a hospital has indicated its intent to participate or not participate, we will consider the hospital to be in that status (either a participant or nonparticipant) until the hospital indicates a change in status by submitting a notice of participation or a withdrawal form.

Comment: Several commenters requested delays in implementation in general, though the November 15, 2007 date for submitting the Notice of Participation form was not mentioned. One commenter urged that communication of this requirement be made clearly and frequently so that all hospitals are aware of the steps they need to take to participate in the HOP QDRP.

Response: We understand the concerns of these commenters and have decided to delay the deadline for completing the Notice of Participation form. The deadline for submission of the Notice of Participation form will be revised from November 15, 2007 to January 31, 2008. It is our intent that the forms for the inpatient and outpatient programs will be available on the same Web site. We understand the difficulties inherent in implementing a new data collection system and have revised the deadline for completion of the Notice of Participation form as part of efforts to reduce hospital burden as discussed further later in this section.

Comment: Several commenters expressed appreciation that CMS was working to utilize existing processes in implementing data collection of hospital outpatient quality measures.

Response: We thank the commenters for their support of our efforts.

Comment: One commenter suggested that small or low volume hospitals be held harmless on the reporting of outpatient hospital quality measure data

due to the undue burden of an essentially unfunded mandate.

Response: We acknowledge the commenter's concern regarding burden on smaller hospitals, but continue to view the importance of quality measure data from all providers of comparable services. As discussed throughout this section of the final rule with comment period, in response to such burden concerns, several aspects of the HOP QDRP have been revised for the first reporting year.

Comment: One commenter asked that there be a single Notice of Participation form for reporting inpatient and outpatient hospital quality measure data.

Response: We agree that it would be preferable to have a single Notice of Participation form for the inpatient and outpatient hospital quality measure data reporting programs. However, a single form is not possible at this time due to separations of the data and administrative systems for the two programs. We will seek to consolidate processes as much as possible in the future to ease burdens associated with meeting the different requirements of these two programs.

We are finalizing the administrative requirements as proposed, with the modification of changing the deadline for the Notice of Participation form to January 31, 2008.

2. Data Collection and Submission Requirements

We proposed that, to be eligible for the full OPSS payment update in CY 2009 and subsequent years, hospitals must:

- Collect data required for the finalized set of measures, beginning with the specifications of the finalized set of measures that will be identified in the CY 2008 OPSS/ASC final rule (for payment updates for CY 2009 services) and that will be published and maintained in a specifications manual to be found on the Web site at: <http://www.qualitynet.org>.

- Submit the data according to a data submission schedule that will be available on the QualityNet Exchange Web site. We proposed to have HOP data submitted through the QualityNet Exchange secure Web site (<https://www.qnetexchange.org>). This Web site meets or exceeds all current Health Insurance Portability and Accountability Act requirements. The submission deadline for January 2008 discharges was May 31, 2008 with proposed submission deadlines for all other data submissions being 4 months after the last day of the calendar quarter. Data would be submitted to the CMS

designated contractor using either the CMS Abstraction and Reporting Tool for Outpatient Department measures (CART-OPD) or another third-party vendor that has a tool which has met the measure specification requirements for data transmission to the QualityNet Exchange.

HOP QDRP data submission will be through the CMS contractor's secure Web site. Detailed information about the Web site for submitting quality measure data under the HOP QDRP is not available as of the publication of this final rule with comment period. We anticipate awarding the contract to design and manage the OPSS Clinical Warehouse in the near future. We expect the CMS contractor's Web site to meet or exceed all current Health Insurance Portability and Accountability Act requirements for security of personal health information.

The OPSS Clinical Warehouse will submit the data to CMS on behalf of the hospitals. While the CMS contract for managing the OPSS Clinical Warehouse was not awarded prior to publishing the proposed rule, we noted it was possible that a QIO contractor (or subcontractor) would manage the OPSS Clinical Warehouse. Because the information in the OPSS Clinical Warehouse also may be considered QIO information, it may be subject to the stringent QIO confidentiality regulations in 42 CFR part 480.

For purposes of the CY 2009 annual payment update, we proposed to require hospitals to submit data, for the finalized set of measures, beginning with services furnished on or after January 1, 2008. The deadline for submission of data for January 2008 discharges would be 4 months from the last day of the month, May 31, 2008. The deadline for submission for February–March 2008 discharges would be August 1, 2008. Thereafter, participating hospitals would be required to submit quarterly data on finalized measures 4 months from the last day of the calendar quarter for as long as the hospitals participated in the HOP QDRP.

In the CY 2008 OPSS/ASC proposed rule (72 FR 42804), we stated our expectation that hospitals will submit data under the HOP QDRP on outpatient episodes of care to which the required measures apply. For the purposes of the HOP QDRP, an outpatient episode of care is defined as care provided to a patient who has not been admitted as an inpatient but who is registered on the hospital's medical records as an outpatient and receives services (rather than supplies alone) directly from the hospital. Every effort will be made to

assure that data elements common to both inpatient and outpatient settings are defined consistently (such as "time of arrival"). However, HOP QDRP quality data, not quality data required to be submitted for a patient treated under the IPPS RHQDAPU program, would be submitted under the HOP QDRP.

To be accepted by the CMS designated contractor, submissions would, at a minimum, need to be accurate, timely, and complete. Data are considered to have been "accepted" by the CMS designated contractor, for purposes of determining eligibility for the full payment rate update, only when data are submitted prior to the reporting deadline and after they have passed all CMS designated contractor edits.

In addition to collecting and submitting data as noted above, we proposed that, to be eligible for the full OPSS payment update in CY 2009 and subsequent years, hospitals must also:

- Submit complete and accurate data. A "complete" submission would be determined based on sampling criteria that will be published and maintained in a specifications manual to be found on the Web site at <http://www.qualitynet.org>, and must correspond to both the aggregate number of cases submitted by a hospital and the number of Medicare claims it submits for payment.

- Submit the aggregate numbers of outpatient episodes of care which were eligible for submission under the HOP QDRP. These numbers would indicate the number of outpatient episodes of care in the universe to which sampling criteria are applied.

New hospitals are expected to begin reporting data as soon as possible, but no later than beginning with services provided the first day of the calendar quarter immediately following a hospital's receipt of its Medicare provider number and the hospital's timely completion of the administrative requirements for participating in the HOP QDRP.

Comment: Several commenters recommended that CMS adopt some delay in implementation. The commenters suggested that this delay could be accomplished by phasing in or reducing the number of measures that hospitals would be required to collect data and delaying the deadline for initial data submission. Several commenters viewed some or all of the additional five non-emergency department measures as an unnecessary, additional burden, asking for delay or elimination of some or all of these five measures until a system for collecting and reporting can be evaluated.

Response: As noted previously, we have revised the number of required outpatient hospital measure information by reducing the required measure set from 10 to 7 measures for initial implementation. For the reporting of quality measures for HOPD affecting CY 2009 payments, data will be required only for the five ED-AMI measures and the two perioperative care measures (PQRI #20 Perioperative Care: Timing of Antibiotic Prophylaxis and PQRI #21 Perioperative Care: Selective of Prophylactic Antibiotic). For reasons discussed above related to hospital burden and refinement of measures for the outpatient setting, data collection on PQRI #5 Heart Failure: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) for Left Ventricular Systolic Dysfunction (LSVD), PQRI #59: Empiric Antibiotic for Community-Acquired Pneumonia, and PQRI #1: Hemoglobin A1c Poor Control in Type I or II Diabetes Mellitus will not be required in the initial HOP QDRP measure set.

With regard to commenters' requests that we delay the deadline for initial data submission, we agree. Due to the importance of the HOP QDRP and the need for accurate and timely submission of required data, we are revising our proposed submission period and deadline. Rather than requiring initial submission for services furnished on or after January 1, 2008, we are requiring initial submission for services furnished on or after April 1, 2008. The data submission deadline for April to June 2008 discharges is November 1, 2008, 4 months from the last day of the calendar quarter. As proposed, thereafter, participating hospitals would be required to submit quarterly data on finalized measures 4 months from the last day of the calendar quarter for as long as the hospitals participate in the HOP QDRP. As noted, we are statutorily required to establish a program under which hospitals will report data on the quality of hospital outpatient care using standardized measures of care in order to receive the full annual OPSS update effective for payments beginning in CY 2009. In balancing the commenters' concerns and the statutory requirements, we have delayed the initial data submission as much as we believe is possible while still meeting statutory deadline. For the subsequent data submissions for CY 2008 services the submission deadlines will be February 1, 2009 for July to September 2008 services and May 1, 2009 for October to December 2008 services.

Comment: One commenter asked if the quarterly data submission was due November 1, 2009, as stated in the

proposed rule, or if this date should be November 1, 2008.

Response: As stated above, the deadline for submitting data for the initial quarterly data submission of April-June 2008 services will be November 1, 2008.

Comment: One commenter noted that the OPSS appeared to have 1st of the month data submission deadlines, whereas, the inpatient measures have a 15th of the month submission deadline and asked for alignment of the submission deadlines for both.

Response: We understand that there is an interest in alignment to reduce confusion and data submission errors. However, the dates were deliberately chosen and spaced accordingly to avoid issues with concurrent submission of large amounts of data.

Comment: Due to the large volume of outpatient services potentially involved for quality measure reporting, several commenters suggested the use of sampling of cases.

Response: We agree with the idea of sampling of cases for reporting under the HOP QDRP and it is our intent to devise a methodology for determining sample size requirements based on hospital volume as is done for inpatient quality measure reporting.

We are finalizing the proposed data collection and submission requirements with modifications. The initial submission will be for services furnished on or after April 1, 2008. The final submission date for the initial quarterly data for April-June 2008 services is November 1, 2008.

3. HOP QDRP Validation Requirements

In the CY 2008 OPSS/ASC proposed rule, we proposed that data submitted under this program meet validation requirements. The proposed validation requirements were similar to the FY 2006 IPPS RHQDAPU program validation requirement (the initial year validation requirement was added to the IPPS RHQDAPU program) and included independent re-abstraction of medical record data elements by a clinical data abstraction center (CDAC). The CMS contractor would randomly select 5 medical records from all January 2008 discharge cases successfully submitted to the OPSS Clinical Warehouse. The CDAC would mail requests to the hospitals to send the selected medical records to the CDAC within 30 calendar days. The CDAC would independently re-abstract the medical record data elements. We proposed to provide abstraction feedback to all hospitals on abstracted data elements.

We also proposed the following chart audit validation requirements for full CY 2009 payment updates:

- Apply to January 2008 discharges only.
- Require submission of 5 charts sampled from each hospital.
- Establish a passing threshold of 80 percent reliability reflecting the accuracy of submitted data elements used to calculate quality measures.
- Use an upper bound of 95 percent confidence interval to measure accuracy.
- Incorporate clustering of variability at the chart level into the confidence interval.

Validation is intended to provide some assurance of the accuracy of the hospital abstracted data. We have specifically chosen these validation requirements and thresholds to allow this assurance, provide sufficient time to fully process validation data, and minimize the burden on hospitals.

To receive the full OPSS payment rate update in CY 2009, CMS proposed that the hospital must pass our validation requirement of a minimum of 80 percent reliability, based upon our chart-audit validation process, for the January 2008 discharges. The 80-percent reliability threshold is consistent with the IPPS RHQDAPU program validation reliability threshold. Based on our previous IPPS RHQDAPU program experience, we believe that this threshold is reasonable and attainable by the vast majority of hospitals. Several of the measures used in the OPSS HOP QDRP are similar in construction to inpatient measures used in the current IPPS RHQDAPU program. Based on the similar nature of the inpatient and outpatient measure sets, we believe that the 80-percent reliability threshold is applicable in the OPSS HOP QDRP.

We proposed that the data for the first reporting period would be due to the CMS designated contractor by May 31, 2008. We would use confidence intervals, as discussed below, to determine if a hospital has achieved an 80-percent reliability. The use of confidence intervals would allow us to establish an appropriate range below the 80-percent reliability threshold that would demonstrate a sufficient level of reliability to allow the data to still be considered validated. We note that, for both timing and burden reasons, we proposed to apply the validation requirements only to January 2008 discharges for purposes of determining eligibility for the full CY 2009 OPSS payment rate update. However, hospitals would still be required to submit data for subsequent time periods.

We proposed to use January 2008 discharges to estimate the hospitals' validation score for the CY 2009 validation proposed requirement. The timeframe for data collection, abstraction, and validation tasks total about nine to ten months between patient discharges to completion of validation appeals. We believe that using later discharges for the CY 2009 annual payment update would adversely impact CMS' ability to complete these tasks and apply the results to the CY 2009 annual payment update.

Based on our proposed methodology, the confidence interval would be slightly wider than is currently utilized for the IPPS RHQDAPU program due to the smaller sample size. However, given this is the first year of the HOP QDRP, we believe this would be appropriate. We would estimate the percent reliability based upon a review of five charts and then calculate the upper 95 percent confidence limit for that estimate. If this upper limit is above the required 80 percent reliability threshold, the hospital data would be considered validated. We proposed to use the design specific estimate of the variance for the confidence interval calculation, which, in this case, is a single stage cluster sample, with unequal cluster sizes. (For reference, see Cochran, William G. (1977) Sampling Techniques, John Wiley & Sons, New York, chapter 3, section 3.12.) Each sampled medical record is considered as a cluster for variance estimation purposes, as documentation and abstraction errors are believed to be clustered within specific medical records.

Comment: Many commenters asked that validation not be used in determining payment decisions; that is, that receipt of full OPPS payment update be attached only to the submission of quality data, especially for the first year of the program. Commenters urged that for the CY 2009 HOP QDRP, data validation should be conducted only as a learning tool for hospitals.

Response: In response to the many comments received on the validation requirement, acknowledging this is a new data collection effort, and consistent with the initial implementation of the IPPS RHQDAPU program, we have decided not to use the HOP QDRP validation requirement for purposes of the CY 2009 payment update. Thus, there will be no validation requirement for April–June 2008 services for the CY 2009 payment update. However, it is our intent to use

validation requirements for determining the CY 2010 payment update.

Comment: Several commenters addressed the reliability threshold set for validation. Some commenters suggested that reliability thresholds should start at lower levels and gradually be raised to 80 percent.

Response: We understand that there may be difficulties with validation levels due to this being a new data collection effort. As discussed in this final rule with comment period, validation will not be required for payment decisions affecting the CY 2009 payment update. We continue to believe that a reliability threshold of 80 percent for data validation purposes for future years is appropriate, and we intend to use it beginning with the CY 2010 payment update.

Comment: Several commenters expressed concern about validating data from a single month for determining payment. Several commenters stated that at least 6 months of reporting should be required for any measure before any data validation is done or any decisions regarding payment are made.

Response: As noted previously, in response to comments on data volume for determining payment and validation concerns, for purposes of the CY 2009 payment update, we will consider data reported for the second calendar quarter of 2008, April to June 2008 without any validation requirement. It is our intent to use at least 6 months of reported data for the HOP QDRP for purposes of the CY 2010 payment update and for subsequent calendar years. Thus, we intend to begin validation efforts on data submitted from July–September 2008 services forward.

We are revising our validation requirements from our proposal and not requiring validation for purposes of the CY 2009 payment update. We intend to use validation for purposes of the CY 2010 HOP QDRP, beginning with July–September 2008 services and for subsequent services.

In summary, after consideration of the public comments received and as discussed in the above responses to those comments, we are requiring hospitals to meet the below outlined administrative, data collection, and submission requirements under the HOP QDRP for payment determinations affecting the CY 2009 payment update.

1. Administrative Requirements

- Identify a QualityNet Exchange administrator who follows the registration process and submits the information through the CMS-designated contractor. The same person

may be the QualityNet Exchange administrator for both the IPPS RHQDAPU program and the HOP QDRP. This designation must be kept current and must be done, regardless of whether the hospital submits data directly to the CMS designated contractor or uses a vendor for transmission of data.

- Register with the QualityNet Exchange, regardless of the method used for data submission.

- Complete the Notice of Participation form. All hospitals must send the form to a CMS-designated contractor no later than January 31, 2008 for the CY 2009 HOP QDRP. At this time, the participation form for the HOP QDRP is separate from the IPPS RHQDAPU program, and completing a submission form for each program is required. Agreeing to participate includes acknowledging that the data submitted to the CMS-designated contractor will be submitted to CMS and may be shared with a CMS contractor or contractors supporting the implementation of this program.

Hospitals not wishing to participate must submit a Notice of Participation form indicating non-participation in the HOP QDRP. Hospitals that have completed a notice of participation form and subsequently wish to stop participating must submit a withdrawal form. Hospitals not participating in the HOP QDRP program or that withdraw from the program will not receive the full OPPS payment rate update. Instead, in accordance with the law, those hospitals would receive a reduction of 2.0 percentage points in their updates for the affected payment year.

To reduce the burden on hospitals, once a hospital has indicated its intent to participate or not participate, we will consider the hospital to be in that status (either a participant or nonparticipant) until the hospital indicates a change in status by submitting a notice of participation or a withdrawal form.

2. Data Collection and Submission Requirements

- Collect data required for the finalized set of 7 measures outlined below, beginning with the specifications of the finalized set of measures identified in this final rule for payment updates for CY 2009 services and that will be published and maintained in a specifications manual to be found on the Web site at: <http://www.cms.hhs.gov>.

Participating hospitals must collect data on the 7 required measures listed below if they have cases meeting the data collection specifications. Hospitals will be allowed to sample cases and this

sampling scheme will be provided in advance of required data collection.

- ED-AMI-1—Aspirin at Arrival.
- ED-AMI-2—Median Time to Fibrinolysis.

Fibrinolysis.

- ED-AMI-3—Fibrinolytic Therapy Received Within 30 Minutes of Arrival.
- ED-AMI-4—Median Time to Electrocardiogram (ECG).

Electrocardiogram (ECG).

- ED-AMI-5—Median Time to Transfer for Primary PCI.

Timing of Antibiotic Prophylaxis.

- PQRI #20 Perioperative Care: Selection of Prophylactic Antibiotic.

Providers must collect data for the required finalized set of measures identified in this final rule to receive the full payment update for CY 2009 OPPS services. The measure specifications will be published and maintained in a specifications manual to be found on the CMS Web site at: <http://www.cms.hhs.gov>.

- Submit the data according to a data submission schedule that will be available on the QualityNet Exchange Web site. HOP data will be submitted through the QualityNet Exchange secure Web site (<https://www.qnetexchange.org>). This Web site meets or exceeds all current Health Insurance Portability and Accountability Act requirements. Data for the 7 quality measures finalized in this rule from services occurring during second calendar quarter of 2008 (April–June 2008) are to be collected. The submission deadline for April–June 2008 service data will be November 1, 2008. All submission deadlines will be 4 months after the last day of the calendar quarter. Data must be submitted to the CMS designated contractor using either the CMS Abstraction and Reporting Tool for Outpatient Department measures (CART–OPD) or another third-party vendor that has a tool which has met the measure specification requirements for data transmission to the QualityNet Exchange.

Hospitals must submit quality data through the CMS contractor's secure Web site. Detailed information about the Web site for submitting quality measure data under the HOP QDRP is not available as of the publication of this final rule with comment period. We anticipate awarding the contract to design and manage the OPPS Clinical Warehouse in the near future. We expect the CMS contractor's Web site to meet or exceed all current Health Insurance Portability and Accountability Act requirements for security of personal health information.

The OPPS Clinical Warehouse will submit the data to CMS on behalf of the

hospitals. It is possible that the information in the OPPS Clinical Warehouse may be considered QIO information. If so, it may be subject to the stringent QIO confidentiality regulations in 42 CFR part 480.

Hospitals are expected to submit data under the HOP QDRP on outpatient episodes of care to which the required measures apply. For the purposes of the HOP QDRP, an outpatient episode of care is defined as care provided to a patient who has not been admitted as an inpatient but who is registered on the hospital's medical records as an outpatient and receives services (rather than supplies alone) directly from the hospital. Every effort will be made to assure that data elements common to both inpatient and outpatient settings are defined consistently (such as "time of arrival"). However, HOP QDRP quality data, not quality data required to be submitted for a patient treated under the IPPS RHQDAPU program, would be submitted under the HOP QDRP.

To be accepted by the CMS designated contractor, submissions must be, at a minimum, accurate, timely, and complete. Data are considered to have been "accepted" by the CMS designated contractor, for purposes of determining eligibility for the full payment rate update, only when data are submitted prior to the reporting deadline and after they have passed all CMS designated contractor edits.

In addition to collecting and submitting data as noted above, to be eligible for the full OPPS payment update in CY 2009 and subsequent years, hospitals must also:

- Submit complete and accurate data. A "complete" submission is determined based on sampling criteria that will be published and maintained in a specifications manual to be found on the Web site at <http://www.qualitynet.org>, and must correspond to both the aggregate number of cases submitted by a hospital and the number of Medicare claims it submits for payment. To be considered "accurate," submissions must pass validation. As stated previously in this section, we are revising our validation requirement from the proposed rule for purposes of the CY 2009 payment update. Thus, there is no validation requirement for the initial reporting period (April to June 2008) affecting the CY 2009 payment update. It is our intention that there will be validation requirements under the HOP QDRP as outlined in this section for reporting periods beginning July–September 2008 services forward that will be considered for payment decisions beginning with the CY 2010 payment update.

- Submit the aggregate numbers of outpatient episodes of care which were eligible for submission under the HOP QDRP beginning with the first reporting period (April–June 2008) forward. These numbers would indicate the number of outpatient episodes of care in the universe to which sampling criteria are applied.

New hospitals are expected to begin reporting data as soon as possible, but no later than beginning with services provided the first day of the calendar quarter immediately following a hospital's receipt of its Medicare provider number and the hospital's timely completion of the administrative requirements for participating in the HOP QDRP.

Hospitals must submit data under the HOP QDRP on outpatient episodes of care to which the required measures apply. Data submission deadlines for the submission of this data will be the same as for submission of quality measure data, will begin with the submission of April–June 2008 services forward, and will be due 4 months from the last day of the calendar quarter. For the purposes of the HOP QDRP, an outpatient episode of care is defined as care provided to a patient who has not been admitted as an inpatient but who is registered on the hospital's medical records as an outpatient and receives services (rather than supplies alone) directly from the hospital.

3. HOP QDRP Validation Requirements

As discussed above, we are not implementing a data validation requirement for data submitted for the April–June 2008 time period for the purposes of the CY 2009 annual payment update. It is our intention that there will be validation requirements as discussed previously and outlined below for data submitted for July 2008 services forward to affect payment determinations for CY 2010 and subsequent calendar years. The validation requirements include independent reabstraction of medical data elements by a clinical data abstraction center (CDAC). The CMS contractor will randomly select 5 cases from all cases successfully submitted to the OPPS Clinical Warehouse for any relevant time period. The CDAC will mail requests to the hospitals to send the selected medical records or other supporting documentation to the CDAC within 30 calendar days. The CDAC will independently reabstract the medical record data elements. Abstraction feedback will be provided to all hospitals on abstracted data elements.

At this time, the following audit validation requirements are intended to

apply for full CY 2010 payment updates forward:

- A time period of services after the initial April to June 2008 time period will be determined. At this time, we intend to use data from July 2008 services forward for the HOP QDRP for the CY 2010 payment update.
- Submission of supporting documentation for 5 selected cases sampled from each hospital is required.
- A passing threshold of 80 percent reliability reflecting the accuracy of submitted data elements is set to calculate quality measures.
- An upper bound of 95 percent confidence interval to measure accuracy is set.
- Clustering of variability at the chart level will be incorporated into the confidence interval.

To receive the full OPSS payment rate update, the hospital must pass our validation requirement of a minimum of 80 percent reliability, based upon our audit validation process, for the designated time periods.

The methodology to be used for calculating the confidence intervals under the HOP QDRP is that currently utilized for the IPSS RHQDAPU program. Due to the small sample sizes during CY 2010 (as noted above, data from only 5 cases will be used), we anticipate that the calculated confidence intervals will be larger. However, as CY 2010 is only the second year of the HOP QDRP, we view this as appropriate. We anticipate estimating the percent reliability based upon a review of 5 documentation audits and then calculating the upper 95 percent confidence limit for that estimate. If that upper limit is above the required 80 percent reliability threshold, we anticipate considering the hospital's data valid for payment update purposes for CY 2010 forward. As proposed, we intend to use the design specific estimate of the variance for the confidence interval calculation, which, in this case, is a single stage cluster sample, with unequal cluster sizes. (For reference, see Cochran, William G. (1977) *Sampling Techniques*, John Wiley & Sons, New York, chapter 3, section 3.12.) Each sampled medical record is considered as a cluster for variance estimation purposes, as documentation and abstraction errors are believed to be clustered within specific medical records.

F. Publication of HOP QDRP Data Collected

New section 1833(t)(17)(E) of the Act requires that the Secretary establish procedures to make data collected under this program available to the public and

to report the quality measures on the CMS Web site. Our intent is to make this information public in CY 2009 by posting it on the CMS Web site. Participating hospitals will be granted the opportunity to preview this information prior to its public posting as we have recorded it.

Comment: Several commenters provided thoughts on the publication of quality data collected. The commenters believed that consumers should be able to access quality data and cost information electronically that is organized to allow comparison of information that is correct, current, and clear. They suggested that the information be presented on all available sites of service so consumers can compare a hospital outpatient department with an ASC for a procedure that can be performed in both settings. They also suggested that there be a provider narrative section to address information regarding reliability or accuracy, and provider-specific information such as accreditation status.

Response: We thank the commenters for their support of providing public access to hospital outpatient quality data. We strive to present information contained on Web sites in as complete and clear manner possible. We also thank the commenters for their thoughts on additional information that could be included that would aid consumers in assessing a provider's quality measure data.

After consideration of the public comments received and as discussed in the above responses to those comments, we intend that information collected under the HOP QDRP will be made public in CY 2009 by posting it on the CMS Web site. Information from non-validated data, including the initial reporting period (April–June 2008) will not be posted. Participating hospitals will be granted the opportunity to preview this information prior to its public posting as we have recorded it.

G. Attestation Requirement for Future Payment Years

CMS also solicited comments on whether to implement an HOP QDRP attestation requirement in CY 2010 and subsequent payment years similar to the proposed attestation requirement in the IPSS RHQDAPU program set out in the FY 2008 IPSS proposed rule (72 FR 24808). Hospitals would be required to submit a written form to a CMS contractor indicating that they formally attest to the accuracy and completeness of their data, including the volume of data submitted to the OPSS Data Warehouse. We anticipated that the attestation form submission deadlines

would parallel the HOP QDRP periodic data submission deadlines.

Comment: One commenter stated that an attestation statement would be acceptable as long as providers have sufficient time to review and verify that data were submitted accurately. No comments against the requirement of an attestation statement were received.

Response: Under any attestation procedure we implement, providers would have time to review and verify that data were submitted accurately.

In light of the public comments received we intend that an attestation procedure similar to the attestation requirement utilized in the IPSS RHQDAPU program will be included in the HOP QDRP for CY 2010 and subsequent payment years.

H. HOP QDRP Reconsiderations

When the IPSS RHQDAPU program was initially implemented, it did not include a reconsideration submission process for hospitals. Subsequently, we received many requests for reconsideration of those payment decisions, and as a result identified a process by which participating hospitals would submit requests for reconsideration. We anticipate similar concerns with the HOP QDRP and, therefore, in the CY 2008 OPSS/ASC proposed rule (72 FR 42805) we proposed to establish a reconsideration process for the HOP QDRP for those hospitals that fail to meet the CY 2009 HOP QDRP requirements with the procedural details of that process posted to the QualityNet Exchange Web site, <https://www.qnetexchange.org>. In the CY 2008 OPSS/ASC proposed rule (72 FR 42805), we sought public comment specifically on the need for a structured reconsideration process for CY 2009 and subsequent calendar years. We also requested comment on what such a process should entail. For example, such a process, if established, could include—

- A limited time, such as 30 days from the public release of the decision, for requesting a reconsideration;
- Specific individuals or functions in a hospital organization that can request such a reconsideration and that would be notified of its outcome;
- The specific factors that CMS will consider in such a reconsideration, such as an inability to submit data timely due to CMS systems failures;
- Specific requirements for submitting a reconsideration request, such as a written request for reconsideration specifically stating all reasons and factors why the hospital believes it did meet the HOP QDRP program requirements;

- Suggestions regarding the type of entity that should conduct the reconsideration process; and
- The timeframe, such as 60 days, for CMS to provide its reconsideration decision to the hospital.

We also requested comments on the reasons for not establishing such a reconsideration process. We indicated that we planned to establish procedures that are as similar as possible to those used by the IPPS RHQDAPU program should we finalize our proposal to implement a reconsideration process for HOP QDRP.

Comment: While we did not receive any comments opposing a reconsideration process, two commenters suggested that the reconsideration process be straightforward, transparent, and timely. One commenter requested that clear guidance on how to submit appeals be provided, and that any appeals be expedited. One commenter stated that it was important to have a reconsideration process in the case of disputes regarding submitted data. One commenter supported having a reconsideration process similar to the one used under the inpatient quality measure reporting program.

Response: We thank the commenters for voicing their support for a reconsideration process. CMS always strives to implement processes that are straightforward, transparent, and timely and fully intend to provide guidance on any reconsideration process used for outpatient hospital data. It is our intent to model a reconsideration process for the HOP QDRP similar to the one used under the inpatient quality measure reporting program.

Comment: Several commenters stated there should be an expeditious mechanism for corrections or resolution of disagreements about any information posted for public presentation.

Response: We intend that any process put in place for corrections or resolution of disagreements about any information posted for public presentation will be as expeditious as possible.

After consideration of the public comments received and as discussed in the above responses to those comments, we intend that a reconsideration process modeled after that for reporting inpatient quality measures will be included in the HOP QDRP for CY 2009 and subsequent calendar years.

I. Reporting of ASC Quality Data

As discussed in section XVII.A.2. of this final rule with comment period, section 109(b) of the MIEA-TRHCA (Pub. L. 109-432) amended section 1833(i) of the Act by redesignating

clause (iv) as clause (v), adding new section 1833(i)(2)(D)(iv), and adding new section 1833(i)(7) to the Act. These amendments authorize the Secretary to require ASCs to submit data on quality measures and to reduce the annual increase in a year by 2.0 percentage points for ASCs that fail to do so. These provisions permit, but do not require, the Secretary to require ASCs to submit such data and to reduce any annual increase for non-compliant ASCs.

In the CY 2008 OPPS/ASC proposed rule, we did not propose to introduce quality measures for reporting in ASCs for CY 2008 as we did for the OPPS as described in sections XVII.B. through H. of the proposed rule. We believe that promoting high quality care in the ASC setting through quality reporting is highly desirable and fully in line with our efforts under other payment systems. However, we also believe that the transition to the revised ASC payment system in CY 2008 poses such a significant challenge to ASCs that it would be most appropriate to allow some experience with the revised payment system before introducing other new requirements.

Implementation of quality reporting at this time would require systems changes and other accommodations by ASCs, facilities which do not have prior experience with quality reporting as hospitals already have for inpatient quality measures, at a time when they are implementing a significantly revised payment system. We believe that our CY 2008 proposal to implement quality reporting for HOPDs prior to establishing quality reporting for ASCs would allow time for ASCs to adjust to the changes in payment and case-mix that are anticipated under the revised payment system. We would also gain experience with quality measurement in the ambulatory setting in order to identify the most appropriate measures for quality reporting in ASCs prior to the introduction of the requirement in ASCs. We intend to implement the provisions of section 109(b) of the MIEA-TRHCA, Pub. L. 109-432, in a future rulemaking.

Comment: Several commenters agreed with our decisions to delay implementation of quality measures for ASCs. However, one commenter urged CMS to implement a quality reporting system for ASCs as soon as possible as all providers that perform the same services should be held to the same accountability standards with respect to the quality of the care they deliver. There were no other comments in disagreement with the planned delay.

Response: We appreciate these commenters' support for our decision to

delay implementation of collection of ASC quality measure data. We also recognize the necessity of equal accountability for providers of the same services and appreciate this reminder.

Comment: Several commenters stated that an administrative claims-based quality measure reporting system should be implemented for ASCs, similar to that in place for physician reporting. Commenters suggested that a claims-based system would reduce the financial and administrative burden for these smaller facilities that more resemble physician offices than hospitals, noting that ASCs will continue submitting Medicare claims using the CMS 1500 form as do physicians at least through 2008, providing ASCs the ability to report data in the same manner as physicians. One commenter suggested CMS work with ASC leaders to develop HCPCS level II G codes that would allow facility-level quality measures to be reported using an administrative claims-based approach.

Response: We thank the commenters for their suggestions for our consideration in implementing a quality measure program for ASCs.

Comment: Several commenters stated that CMS should consider the use of five ASC measures currently under development if the five were NQF-endorsed. These five measures focus on patient falls, patient burns, hospital transfer/admission, wrong site/patient/procedure/implant situations, and prophylactic antibiotic timing similar to PQRI #20 and #21.

Response: We thank the commenters for supplying this information for our consideration in developing quality measures for ASCs.

After consideration of the public comments received, and as discussed in the above responses to those comments, we are finalizing our decision to delay implementation of ASC quality measure reporting. We expect to implement the provisions of section 109(b) of the MIEA-TRHCA, Pub. L. 109-432, in a future rulemaking.

J. FY 2009 IPPS Quality Measures Under the RHQDAPU Program

As stated in FY 2008 IPPS proposed rule (72 FR 24805), we proposed to add 1 outcome measure and 4 process measures to the existing 27 measure set to establish a new set of 32 quality measures to be used under the RHQDAPU program for the FY 2009 IPPS annual payment determination. We proposed to add the following five measures for the FY 2009 IPPS annual payment determination:

- PNE 30-day mortality measure (Medicare patients)

- SCIP Infection 4: Cardiac Surgery Patients With Controlled 6AM Postoperative Serum Glucose
- SCIP Infection 6: Surgery Patients With Appropriate Hair Removal
- SCIP Infection 7: Colorectal Patients With Immediate Postoperative Normothermia
- SCIP Cardiovascular 2: Surgery Patients on a Beta-Blocker Prior to Arrival Who Received a Beta-blocker During the Perioperative Period

We stated that we planned to formally adopt these measures a year in advance in order to provide time for hospitals to prepare for changes related to the RHQDAPU program. We also stated that we anticipated that the proposed measures would be endorsed by the NQF. Finally, we stated that any proposed measure that was not endorsed by the NQF by the time that we published the FY 2008 IPPS final

rule would not be finalized in that final rule.

At the time we published the FY 2008 IPPS final rule, only the PNE 30-day mortality measure had been endorsed by the NQF. Therefore, we finalized only that measure as part of the FY 2009 IPPS measure set and stated that we would further address adding additional measures in the CY 2008 OPSS final rule (that is, this CY 2008 OPSS/ASC final rule with comment period) and, if necessary, in the FY 2009 IPPS proposed and final rules. We also responded to comments we had received on the 5 proposed measures. (72 FR 47348 through 47351)

The NQF has endorsed the following additional process measures that we proposed to include in the FY 2009 RHQDAPU measure set:

- SCIP Infection 4: Cardiac Surgery Patients With Controlled 6AM Postoperative Serum Glucose
 - SCIP Infection 6: Surgery Patients With Appropriate Hair Removal
- As we stated in the FY 2008 IPPS proposed rule (72 FR 24805), these measures reflect our continuing commitment to quality improvement in both clinical care and quality, and they demonstrate our commitment to include in the RHQDAPU program only those quality measures that reflect consensus among affected parties and that have been reviewed by a consensus building process. Because these measures are now endorsed by the NQF, we are finalizing them for the FY 2009 measure set, bringing the total number of measures in that measure set to 30.

The measure set to be used for FY 2009 annual payment determination is as follows:

Topic	Quality measure
Heart Attack (Acute Myocardial Infarction)	<ul style="list-style-type: none"> • Aspirin at arrival.* • Aspirin prescribed at discharge.* • ACE inhibitor (ACE-I) or Angiotensin Receptor Blocker (ARBs) for left ventricular systolic dysfunction.* • Beta blocker at arrival.* • Beta blocker prescribed at discharge.* • Fibrinolytic (thrombolytic) agent received within 30 minutes of hospital arrival.** • Primary Percutaneous Coronary Intervention (PCI) received within 120 minutes of hospital arrival.** • Adult smoking cessation advice/counseling.**
Heart Failure (HF)	<ul style="list-style-type: none"> • Left ventricular function assessment.* • ACE inhibitor (ACE-I) or Angiotensin Receptor Blocker (ARBs) for left ventricular systolic dysfunction.* • Discharge instructions.** • Adult smoking cessation advice/counseling.**
Pneumonia (PNE)	<ul style="list-style-type: none"> • Initial antibiotic received within 4 hours of hospital arrival.* • Oxygenation assessment.* • Pneumococcal vaccination status.* • Blood culture performed before first antibiotic received in hospital.** • Adult smoking cessation advice/counseling.** • Appropriate initial antibiotic selection.** • Influenza vaccination status.**
Surgical Care Improvement Project (SCIP) named SIP for discharges prior to July 2006 (3Q06).	<ul style="list-style-type: none"> • Prophylactic antibiotic received within 1 hour prior to surgical incision.** • Prophylactic antibiotics discontinued within 24 hours after surgery end time.** • SCIP-VTE 1: Venous thromboembolism (VTE) prophylaxis ordered for surgery patients.*** • SCIP-VTE 2: VTE prophylaxis within 24 hours pre/post surgery.*** • SCIP-Infection 2: Prophylactic antibiotic selection for surgical patients.*** • SCIP-Infection 4: Cardiac Surgery Patients with Controlled 6AM Postoperative Serum Glucose.***** • SCIP-Infection 6: Surgery Patients with Appropriate Hair Removal.*****
Mortality Measures (Medicare patients)	<ul style="list-style-type: none"> • Acute Myocardial Infarction 30-day mortality Medicare patients.*** • Heart Failure 30-day mortality Medicare patients.*** • Pneumonia 30-day mortality Medicare patients.****
Patients' Experience of Care	<ul style="list-style-type: none"> • HCAHPS patient survey.***

* Measure included in 10 measure starter set.
 ** Measure included in 21 measure expanded set.
 *** Measure added in CY 2007 OPSS final rule.
 **** Measure added in FY 2008 IPPS final rule.
 ***** Measure added in CY 2008 OPSS final rule.

We also stated in the FY 2008 final rule that the RHQDAPU participation requirements for the FY 2009 program would apply to additional measures we adopt for that year's program (72 FR 47361).

Therefore, hospitals must start submitting data for SCIP Infection 4 and SCIP Infection 6 starting with first quarter calendar year 2008 discharges and subsequent quarters until further notice, and hospitals must submit their aggregate population and sample size counts for Medicare and non-Medicare patients. These requirements are consistent with the requirements for the other 24 AMI, HF, PN, and SCIP process measures included in the FY 2009 measure set. The complete list of procedures for participating in the RHQDAPU program for FY 2009 is provided in the FY 2008 final rule (72 FR 47359–47361).

We plan to propose in the FY 2009 IPPS proposed rule that we will add these two measures to the current 24 process measures included in the RHQDAPU chart audit validation requirement starting with first quarter 2008 calendar year discharges. These validation results would be included as part of a RHQDAPU FY 2010 chart validation requirement if they are finalized in the FY 2009 IPPS final rule. We are announcing our intention to make this proposal to provide hospitals with sufficient advance notice when abstracting and submitting these measures to CMS.

Since SCIP Cardiovascular 2 is not currently endorsed by the NQF, CMS will not adopt this measure as part of the official FY 2009 IPPS measure set for annual payment determination at this time. In addition, as stated in the FY 2008 IPPS final rule, CMS is not adopting the SCIP Infection 7 measure as part of the FY 2009 IPPS measure set for annual payment determination at this time.

XVIII. Changes Affecting Critical Access Hospitals (CAHs) and Hospital Conditions of Participation (CoPs)

A. Changes Affecting CAHs

1. Background

CAHs are subject to different participation requirements than are hospitals. Among other requirements, a CAH must be located in a rural area (or an area treated as rural) and, under section 1820(c)(2)(B)(i)(I) of the Act and § 485.610(c) of our regulations, must meet an additional distance-related location requirement. Under this requirement, a CAH must be located at least 35-miles (or, in the case of mountainous terrain or in areas with

only secondary roads, 15-miles) from the nearest hospital or other CAH. In addition, CAHs receive payment for services furnished to Medicare beneficiaries differently. CAHs receive cost-based payment for 101 percent of their reasonable costs.

Prior to January 1, 2006, the CAH minimum distance eligibility requirement was not applicable to entities States had certified as necessary provider CAHs. Approximately 850 current CAHs have been designated by their States as necessary providers. The criteria used to qualify a CAH as a necessary provider were established by each State in its Medicare Rural Hospital Flexibility Program (MRHFP). The State's MRHFP rural health care plan contains the necessary assurances that the plan was developed to further the goals of the statute and regulations to ensure access to essential health care services for rural residents. States, in consultation with their hospital associations and Offices of Rural Health, have defined those CAHs that provide necessary services to a particular patient community in the event that the facility did not meet the required 35-mile (or, in the case of mountainous terrain or in areas with only secondary roads, 15-mile) distance requirement from the nearest hospital or CAH. Each State's criteria are different, but the criteria share certain similarities and all define a necessary provider related to the facility location.

However, section 405(h)(1) of Public Law 108–173 amended section 1820(c)(2)(B)(i)(II) of the Act by adding language that ended States' authority to certify a CAH as a necessary provider, effective January 1, 2006. In addition, section 405(h)(2) of Public Law 108–173 amended section 1820(h) of the Act to include a grandfathering provision for CAHs that were certified as necessary providers prior to January 1, 2006. We incorporated these amendments in § 485.610(c) of our regulations in the FY 2005 IPPS final rule (69 FR 49220). Because those regulations did not address the situation where the grandfathered CAH is no longer the same facility due to relocation, in the FY 2006 IPPS final rule (70 FR 47490), we amended § 485.610 of our regulations to add a new § 485.610(d) that addressed the relocation criteria a necessary provider CAH has to meet to retain its necessary provider designation.

Additional circumstances concerning CAHs with existing necessary provider designations have come to our attention that we believe also need to be addressed. Specifically, we have learned that some CAHs with grandfathered

necessary provider designations are co-located with other hospitals, which typically are PPS-excluded inpatient psychiatric facilities or inpatient rehabilitation facilities. We are also aware that there is interest in the creation or acquisition by CAHs with necessary provider designation of off-campus facilities that they do not believe would be subject to CAH location requirements.

For the reasons noted below, in the CY 2008 OPPI/ASC proposed rule (72 FR 42806), we took a proactive approach by proposing a change in the regulation to be consistent with our belief that the intent of the CAH program is to maintain hospital level services in rural communities while ensuring access to care. We believe that this proposed change to the regulations will help to maintain the integrity of the MRHFP within the statutory requirements.

2. Co-location of Necessary Provider CAHs

Some necessary provider CAHs are co-located with other hospitals, particularly specialty psychiatric and/or rehabilitation hospitals. Prior to the enactment of section 405(g) of Public Law 108–173, it is understandable that a State MRHFP might have allowed co-location of a CAH with a necessary provider designation with the specialized services of a psychiatric and/or an inpatient rehabilitation hospital. The State may have believed that beneficiary access to care would be enhanced through the provision of both CAH and these specialized services at the same location, and the CAH itself might have had difficulty in providing such services within its permitted bed limits. However, section 405 of Public Law 108–173 included several provisions that permit CAHs themselves to address such access to care issues.

Specifically, section 405(e) of Public Law 108–173 amended sections 1820(c)(2)(B)(iii) and 1820(f) of the Act to increase the permitted number of CAH inpatient beds from 15 to 25. In addition, section 405(g) of Public Law 108–173 added section 1820(c)(2)(E) to the Act, which permits a CAH to operate distinct part inpatient psychiatric and/or rehabilitation units, each subject to a 10-bed limit that is not included as part of the CAH's 25-bed limit. Therefore, a CAH can operate a 45-bed facility addressing a wide range of needs in the rural community it serves. We believe that CAHs seeking to provide access to specialized services should avail themselves of the statutory provisions governing distinct part units in CAHs rather than making arrangements with

other hospital providers to share space at the CAH location.

In light of these changes to the statute, we proposed to no longer allow a necessary provider CAH to enter into co-location arrangements between CAHs and hospitals, unless such arrangements were in effect before January 1, 2008, and the type and scope of services offered by the facility co-located with the necessary provider CAH do not change.

Currently, co-location arrangements seem to involve psychiatric or rehabilitation hospitals. However, we are concerned that, without this change, there may be situations where more necessary provider CAHs will co-locate with PPS hospitals. We also cannot rule out a scenario where two necessary provider CAHs could co-locate after relocation. We believe the co location of a necessary provider CAH with another hospital or necessary provider CAH is not consistent with the CAH statutory framework that establishes requirements for a CAH to be a certain minimum distance from other hospitals or CAHs. We believe that the elimination of States' authority to designate necessary provider CAHs and the new authority for CAHs to operate psychiatric and rehabilitation units in addition to their expanded ceiling for inpatient beds should provide sufficient flexibility for necessary provider CAHs to operate within the statutory framework without engaging in additional arrangements.

We also proposed to clarify that, under certain circumstances, a change of ownership of any of the facilities (either the CAH or the existing co-located facility) with a co-location arrangement that was in effect before January 1, 2008, will not be considered to be a new co-location arrangement. If a change of ownership should occur in a CAH with a grandfathered co-location arrangement on or after January 1, 2008, the provider agreement will be assigned to the new owner unless the new owner rejects assignment of the provider agreement. Grandfathered necessary provider CAH status, including grandfathered co-location arrangements, would not transfer to a new CAH owner who does not assume the provider agreement from the previous owner. To obtain CAH designation, the new provider would have to comply with all the CAH designation requirements, including the location requirements relative to other providers, that is, more than a 35-mile drive (or 15 miles in areas of mountainous terrain or secondary roads).

3. CAH Provider-Based Facilities

We have consistently taken the position that the intent of the CAH program is to keep hospital-level services in rural communities, thereby ensuring access to care (FY 2006 IPPS final rule (70 FR 47469)). A CAH is permitted to create or acquire an off-campus location, including a distinct part unit that satisfies the location criteria for a CAH and operates under the CAH's provider agreement under the provider-based regulations at 42 CFR 413.65. We note that, under section 1820(c)(2)(B)(i)(II) of the Act, a CAH does not have to meet the distance requirements relative to other hospitals or CAHs if it was certified as a necessary provider by the State prior to January 1, 2006. We stated in the FY 2006 IPPS final rule (70 FR 47472), when addressing the relocation criteria for a necessary provider CAH, that the "necessary provider" designation is specific to the physical location(s) of the CAH in existence at the time of the designation. We believe the necessary provider CAH designation cannot be considered to extend to any new facilities not in existence when the CAH received its original necessary provider designation. Accordingly, we believe the creation of any new location that would cause any part of the CAH to be situated at a location not in compliance with the distance requirements at 42 CFR 485.610 would cause the entire CAH to violate the distance requirements.

Of the approximately 1,300 CAHs, 453 CAHs have health clinics, 81 have psychiatric units, and 20 have rehabilitation units. We do not know how many of the existing clinics and distinct part units are at off-site locations. However, we are concerned with CAHs creating or acquiring off-campus locations, including distinct part psychiatric and rehabilitation units, that do not comply with the CAH location requirement relative to other facilities. Therefore, when such off-campus facilities are created by a CAH with a necessary provider designation, there is no reason to assume that the distance exemption given to the CAH should be extended without qualification to any location for that CAH's off-campus facilities. Accordingly, any CAH off-campus locations must satisfy the current statutory CAH distance requirements, without exception, regardless of whether the main provider CAH is a necessary provider CAH.

Therefore, in the CY 2008 OPSS/ASC proposed rule (72 FR 42807), we proposed to clarify that if a necessary

provider CAH, or a CAH that does not have a necessary provider designation, operates a provider-based facility as defined in § 413.65(a)(2), or a psychiatric or rehabilitation distinct part unit as defined in § 485.647 that was created or acquired on or after January 1, 2008, it must comply with the distance requirement of a 35-mile drive to the nearest hospital or CAH (or 15 miles in the case of mountainous terrain or in areas with only secondary roads). (In the proposed § 485.610(e)(2), we inadvertently used the phrase "after January 1, 2008" instead of "on or after January 1, 2008." We have corrected this language in this final rule with comment period. We also included the words "off-campus" before the words "provider-based locations" in the same regulation to conform to the references in the section for off campus location.)

4. Termination of Provider Agreement

In the event that a CAH with a necessary provider designation enters into a co location arrangement on or after January 1, 2008, or acquires or creates an off-campus facility on or after January 1, 2008, that does not satisfy the CAH distance requirements in § 485.610(c), we proposed that we would terminate that CAH's provider agreement, in accordance with the provisions of § 489.53(a)(3). (In proposed § 485.610(e)(3), we inadvertently used the phrase "after January 1, 2008" instead of "on or after January 1, 2008." We have corrected this language in this final rule with comment period.) The necessary provider CAH could avoid termination by converting to a hospital that is paid under the IPPS, assuming that the facility satisfies all requirements for participation as a hospital in the Medicare program under the provisions in 42 CFR Part 482. We also noted that if the necessary provider CAH corrects the situation that led to the noncompliance, a termination action will not be triggered. A CAH that is not a necessary provider CAH could not have a co-location situation due to the distance requirements it is required to meet at § 485.610(c).

5. Regulation Changes

In the CY 2008 OPSS/ASC proposed rule (72 FR 42807), we proposed to amend § 485.610 by adding a new paragraph (e) to address situations under our proposal relating to off-campus and co-location requirements for all CAHs (including CAHs with necessary provider designations).

Comment: Several commenters stated that while it is a good policy to eliminate future co-location

arrangements between CAHs and acute care hospitals, they do not believe it is a good policy to eliminate relationships between CAHs and other hospitals in opening psychiatric or rehabilitation services. They indicated that such a policy change would only limit access to care without providing cost savings or improving efficiency. The commenters stated that co-locating with other providers would lead to cost-effective high quality delivery of health care services to Medicare beneficiaries and others who need the services. Another commenter stated that CMS provided no basis for this proposal in the background material to the proposed rule.

Response: We disagree with the comment that we did not provide a basis for the proposed requirements. Additionally, we are not seeking to eliminate Medicare beneficiary access to inpatient psychiatric and rehabilitation services specifically, or access to any type of care in general. As we explained in the preamble to the proposed rule, we proposed the revisions to § 485.610 in light of recent changes to the statute. These statutory changes allow for: (1) An increase in the number of CAH inpatient beds from 15 to 25; and (2) a CAH to operate distinct part inpatient psychiatric and/or rehabilitation units, each with a 10-bed limit that is not included as part of the CAH's 25-bed limit. By allowing a CAH to operate a 45-bed facility, these amendments to the statute permit CAHs themselves to address the access to care issues mentioned by the commenters.

These statutory provisions clearly provide an opportunity for the CAH to directly meet the wide range of needs in the rural community it serves. However, co-location arrangements between CAHs and hospitals that were in effect before January 1, 2008 would still be permitted, provided that there is no change in the type and scope of services offered by the facility co-located with the necessary provider CAH.

Comment: One commenter expressed complete support for the proposal, and saw it as a clarification of existing policy. The commenter stated that a CAH provider-based clinic was built across the street from its outpatient clinic to increase market share as its population was dwindling. The commenter stated that CAHs were financed and designed to serve the needs of the underserved, not to compete in the market against not-for-profit hospitals that are not subsidized like CAHs. The commenter also stated that since the regulation is a clarification and is not new, the existing

provider-based clinics should not be grandfathered.

Another commenter stated that it valued the cost-based financial support that CMS extends to CAHs. The commenter supported CMS' proposed rule and viewed the proposed policy changes as a step towards restoring the "intended spirit" of the CAH designation.

Response: We appreciate the commenters' support. However, we disagree with the comment that existing provider-based clinics should not be grandfathered. The current regulations did not explicitly address the issue of necessary provider CAHs from acquiring or creating off-campus facilities that do not meet the minimum distance requirements. However, our policy has been that CAHs are required to meet the distance requirement, including any off-campus facilities. In light of the statutory change to the designations for necessary provider CAHs, we believe that it is necessary to grandfather existing provider-based clinics.

Comment: Numerous commenters requested that rural health clinics (RHCs) be excluded from the category of provider-based entities that must comply with the proposed change. Some commenters stated that operating an RHC is the only way to provide healthcare to the medically underserved population in their service area. One commenter stated that if CMS does not exempt RHCs from the proposed policy, CMS should allow grandfathered CAH/provider-based RHCs to move the location of the RHC without jeopardizing the CAH status of the parent provider.

Response: To be certified as an RHC, the clinic must be located in an area designated, either by population or geographic area or location, as a Medically Underserved Area (MUA) or Health Professional Shortage Area (HPSA). In addition, State governors are allowed to designate areas with a shortage of professional health services through the use of statewide shortage designation plans approved by HRSA's Bureau of Health Professions. Because RHCs have their own location requirements and because, unlike other provider-based clinics, a provider-based RHC is a separate entity which undergoes a separate certification process and has a unique provider identification number from the base provider, we believe that our concerns leading to our provider based proposal do not apply to CAH provider-based RHCs. Accordingly, in this final rule with comment period, we are excluding RHCs from the list of provider-based

facilities at § 413.65(a)(2) that must comply with this requirement.

Comment: One commenter stated that for any CAH that is landlocked against future growth, this proposed change would severely restrict the CAH's ability to provide the quality services required by the community. At the very least, the commenter urged that CMS increase the current on-campus yards from 250 yards to 500 or 750 yards. Another commenter stated that it is reasonable that CAHs are prohibited from creating new services that are close to competing organizations, but believed that limiting all off-campus services to only those in place by the end of the year, would freeze the CAH into an increasingly out-of-date delivery modality.

Response: We acknowledge the CAH's constraints of having to locate a provider-based clinic on its campus. However, this rule will not restrict a CAH from building or obtaining an off-site provider-based clinic on or after January 1, 2008. The CAH can have a provider-based clinic that complies with the provider-based rules in § 413.65. In addition, the off-site clinic must be located more than a 35-mile (or 15-mile) drive from another CAH or hospital. For example, the CAH could have a provider-based clinic located 2 miles or 10 miles from the provider CAH, providing the clinic complies with the distance requirements and is 35 (or 15) miles away from another CAH or hospital. The regional offices will evaluate these issues on a case-by-case basis, consistent with all existing regulations. Also, as discussed above, because we are now excluding RHCs from these CAH provider-based requirements, a CAH would have even more flexibility in choosing the location of its provider-based RHC.

Comment: Several commenters stated that they have started plans (and, in some cases, construction) for a new provider-based facility that will not be completed by January 1, 2008. They have requested an exemption to be able to move forward with their plans that were initiated prior to the publication of the proposed rule.

Response: We recognize that a number of CAHs have plans underway to build or acquire provider-based facilities that will not be completed before January 1, 2008. For those CAHs that demonstrate that they have begun such planning and/or construction, our regional offices will evaluate those issues on a case-by-case basis. A demonstration that construction plans were "under development" prior to January 1, 2008 could include supporting documentation such as the drafting of architectural specifications,

the letting of bids for construction, the purchase of land and building supplies, documented efforts to secure financing for construction, expenditure of funds for construction, and compliance with State requirements for construction such as zoning requirements, application for a certificate of need, and architectural review. However, we recognize that it may not have been feasible for a CAH to have completed all of these activities noted above as examples prior to January 1, 2008. Thus, we expect the CMS Regional Offices to consider all of the factors involved in each CAH's plan and make case by case determinations of whether a CAH can continue its plans to acquire or construct an off-campus provider-based clinic. We note that we have also used the above documentation guidelines in Publication 100–20 for grandfathered specialty hospitals to determine if construction plans were “under development.”

Comment: Many commenters stated that CMS should not adopt the provisions in the proposed rule because limiting off-site clinics would impede the provision of health care in their surrounding communities due to the fact that it could not be provided without cost-based reimbursements. Also, the commenters suggested that as physicians cannot be paid competitively without cost-based reimbursement, this would further compound the difficulties in recruiting healthcare providers to work in rural areas. Other commenters stated that the only way to recruit and maintain physicians is for hospitals to offer the competitive salaries that are afforded through a provider-based arrangement. A few commenters stated that denying CAHs the opportunity to invest in physician offices in communities where physicians are desperately needed will disadvantage the patients living in those areas. One commenter requested that CMS not adopt the provisions of the proposed rule and enter into a dialogue with CAHs about an approach that would allow for the level of community-based access and collaboration being called for by the Institute of Medicine (IOM), the National Advisory Committee on Rural Health and Human Services, and other national bodies.

Response: We do not agree that CMS should not adopt the provisions in the proposed rule because, in addition to grandfathering the existing provider-based clinics, CAHs will still be able to provide needed services in their communities through existing and new provider-based clinics that meet the distance requirements and through on-campus facilities. In addition, and perhaps most importantly for those

CAHs concerned about access to primary care services in the communities that they serve, we have revised our initial proposal in order to permit CAHs to continue to operate provider-based RHCs. Additionally, physician offices, owned by CAHs, that are not provider-based (billed under the CAH's provider number) can continue to be operated by CAHs.

We agree with the IOM and other national bodies that contend that quality of care in rural areas can be maximized through collaboration. The IOM report entitled, “Quality through Collaboration: The Future of Rural Health”¹ states that some of the quality shortcomings in rural areas stem from the lack of access to “core health care services” such as primary care in the community, emergency medical services, and hospital care. We believe that CAH provider-based facilities that are located in the immediate communities of the CAH will help to ensure that the people in those communities have access to primary care. Also, CAHs will be able to utilize provider-based RHCs to provide primary care to Medicare beneficiaries.

Comment: By providing specific details and scenarios about their own CAHs, many commenters expressed other reasons for requesting that CMS not adopt this proposal. Overall, the commenters believed that the proposed requirements, if implemented, would have the unintended effect of limiting access to healthcare services for the residents of their communities. The reasons these commenters gave for requesting that CMS not adopt the proposal were as follows:

- Several commenters stated that the rule would have a devastating impact on many senior citizens who do not drive and who would therefore not have access to quality health care in their rural community. One commenter stated that the proposed change would take away their organization's opportunity to be cost reimbursed from Medicare and Medicaid. The commenters stated that this would be a roadblock to increased access to care for the elderly and low income.

- One commenter expressed concern about linking an off-campus or distinct part unit's compliance to the CAH distance requirements with the hospital's continued designation as a CAH and believed that such applications of the distance requirements could result in decreasing patients' access to surgical and other procedures that are provided in the

CAH. Other commenters were concerned that this proposed rule would ban necessary provider CAHs from operating an off-site facility.

- One commenter stated that its Medicare designation as a sole community hospital has geographic limitations, but that it should not be threatened with loss of its special reimbursement status if it meets community needs by developing provider-based or off-campus services. The commenter questioned why CMS is treating CAHs differently.

- Several commenters stated that access will be diminished in many rural communities because those areas are experiencing an increasing inability to recruit or retain physicians in non-provider-based practices due to perceived inadequate Medicare and Medicaid payment to free-standing RHCs, insufficient payment for physicians under the fee-schedule, and healthcare professional workforce shortages. One commenter stated that to continue to apply the “necessary provider” designation to off-site services will preserve one of the only methods that a CAH has to recruit physicians to rural service areas. The commenter stated that CMS should allow the necessary provider CAH to have a waiver provision for off-site services beyond January 1, 2008 if other hospitals within the radius have no objections to the services.

- One commenter stated that the proposed rule indicates CMS' interest in constraining CAHs. The commenter encouraged CMS to adopt a philosophy that limits unnecessary constraints and enables CAHs to serve their patients. The commenter urged CMS to remain supportive of the CAH program. Additionally, one commenter stated that CMS has already weighed in on the issues where cost-based reimbursement could be a major advantage and has eliminated cost-based reimbursement for certain lab services. The commenter noted that there may be situations where other services need to be considered, but that they should be dealt with on a case-by-case basis. If competitive advantage for CAHs is a concern for CMS, the commenter asked that examples be given of such arrangements and suggested that a more narrowly tailored rule should be designed to address such issues.

- Several commenters stated that the purpose of the CAH program is to provide financial stability for small rural hospitals to serve their communities. The commenters believed that this rule would eliminate the CAH's ability to provide care to rural seniors. Another commenter stated that the

¹ Institute of Medicine of the National Academies of Science; Report released on November 1, 2004.

regulation would be devastating to many provider-based clinics because they would be unable to provide the same level of care, services, and staffing as independent sites. Several commenters stated that by forcing CAHs to have services on-campus, CMS will be leaving some community members without access to services.

Response: We appreciate the varied comments. We first note that the proposed change will not eliminate the 101 percent reasonable cost reimbursement that CAHs currently receive. As stated earlier, we do not believe access to these needed services will be diminished as CAHs will still be able to increase access to care for the population of its community through a variety of means. Both the grandfathering provision of this rule, which allows for provider-based locations and off-campus distinct part psychiatric and rehabilitation units that were created or acquired before January 1, 2008, and the exclusion of provider-based RHCs from the rule provide CAHs with excellent opportunities to not only maintain access to care but to expand it as well. The role that RHCs play in providing rural communities with essential access to primary care services cannot be overemphasized.

From the inception of the CAH program, which started with the essential access community hospitals and rural primary care hospitals (EACH/RPCH) 7-State demonstration program, we have been sensitive to the special needs of, not only the CAH program, but of all rural and remote providers. This sensitivity has been demonstrated in regulations we recently adopted that provide flexibility in staffing requirements and physician oversight of nonphysician practitioners in CAHs.

Ultimately though, the distance-based requirement, as one of the requirements to become certified as a CAH, is provided for in the statute and in the regulation. We believe the distance requirement is a statutory requirement that reflects the intent of the CAH program to provide hospital-level services in essentially small rural communities. Our proposal reflects this understanding and the special status of CAHs (as opposed to other rural entities) and should not limit access to care. In addition, as the distance requirement is statutory, a waiver of the distance requirement for some CAHs, as one commenter requested, would not be allowed under the statute. However, CAHs (including necessary provider CAHs) will still be able to acquire and create new provider-based clinics as long as those provider-based clinics are either RHCs or entities that comply with

the distance requirements for a CAH that are allowed under the Act and under the requirements. In addition, all CAHs will be able to establish provider-based entities on their campus.

Comment: One commenter requested that CMS clarify provider-based location and indicate whether it includes on-campus.

Response: Provider-based status means the relationship between a main provider and a provider-based entity or a department of a provider (with all terms being defined in detail under § 413.65(a)(2)). Provider-based locations can be both on-campus and off-campus. This rule would not restrict CAHs from having a provider-based entity on campus.

Comment: One commenter stated that if CMS adopted the proposed change for CAHs it should apply to all providers, such as RHCs and Federally qualified health centers (FQHCs).

Response: We appreciate the commenter's opinion regarding treatment of all rural providers; however, we note that RHCs and FQHCs have different requirements for participating in the Medicare/Medicaid programs than those for CAHs. As we noted previously, we are excluding RHCs from the CAH provider-based requirement in light of the specific RHC certification requirements.

Comment: One commenter stated that the proposed change would limit CAH's ability to compete on a level playing field with PPS or other for-profit providers who have no restrictions on location of facilities. Another commenter stated that it is cheaper for the CAH or other hospitals to move offsite the care that does not need high cost hospital wing space, such as that provided in physical therapy. The commenters suggested that it would save CMS money on the cost-report to allow CAHs to open these offsite locations. A few commenters also stated that offsite locations may be secured much more reasonably to offer additional services than additional space which may be obtained through construction of new facilities on campus.

Response: As stated previously, there are statutory requirements that dictate the location of CAHs. These statutory location requirements support the original intent of the CAH program, that is, to ensure and extend access to healthcare services for rural and remote communities. The program was never intended to encourage competition between CAHs and PPS hospitals. However, it might be a reasonable course of action for a CAH to reevaluate whether the CAH program still meets

the needs of the immediate and surrounding communities. If the community's needs have changed, the facility may want to reconsider their CAH status and may elect to become a PPS acute care hospital without the location limitations that are imposed on CAHs and their provider-based locations.

Comment: A few commenters stated that since all of their CAHs are necessary provider CAHs, it would be geographically impossible to find a new off-campus location that would meet the 35-mile requirement and that this rule should not apply to necessary provider CAHs.

Response: We believe that there are other options for necessary provider CAHs that cannot meet the mileage requirements. Some examples that we have previously discussed are on-campus clinics, provider-based RHCs, or non-provider-based physician offices owned by CAHs.

Comment: One commenter stated that instead of a 35 (or 15)-mile restriction, a minimum mileage limitation (for example 10 miles) would be effective without the potential effect of reducing and/or limiting resources for rural citizens. Additionally, one commenter stated that it objected to CMS' classification of this new policy as a "clarification."

Response: As we have stated previously, the statute, at section 1820(c)(2)(B)(i)(I) of the Act, and the regulation, at 42 CFR § 485.610, both state that the criteria for designation as a CAH is that it must be located more than a 35-mile drive (or, in the case of mountainous terrain or in areas with only secondary roads available, a 15-mile drive) from a hospital, or another CAH. We note a provider-based clinic (other than an RHC) is considered part of the CAH and it is paid the same as the CAH, that is, 101 percent of reasonable cost. As stated above, CAHs by statute and regulation must comply with the distance requirements. As such, we view this rule as a clarification on the distance requirements of participation for CAHs and their provider-based locations and off-campus distinct part units in light of the change in statute concerning necessary provider designations.

Comment: One commenter objected to CMS proposing these changes in the hospital OPPIs proposed rule because they believed that many CAHs will not evaluate, pay attention to, or read the OPPIs proposed rule. The commenter believed that such proposed changes should be the subject of a separate proposed rule. They also believe that, as a result of CMS proposing these changes

in the OPSS rule, CMS might not have all the information necessary to finish the rulemaking on the proposed requirements.

Response: On occasion, we have proposed changes to the CAH program in an OPSS rulemaking. We point out that the subject of the CAH proposed changes was included in the title of the OPSS rule. In addition, CMS has announced the proposed changes during its Open Door Forums. Having received comments from approximately 200 commenters (including various rural health and hospital associations), we are confident that we have received sufficient information, through the public comment process, necessary to complete the rulemaking process.

Comment: One commenter requested clarification on what CMS means in the termination discussion of the proposed rule and suggested that clarification was needed to explain how such a process would work in practice and how a CAH could avoid losing CAH status. In addition the commenter believed that the threat of closure is an unduly harsh punishment when payment for an offending facility could be withheld.

Response: Failure to substantially meet one or more conditions of participation is a cause for termination in the Medicare program, not closure of the CAH. A CAH with a necessary provider designation that enters into a co-location arrangement on or after January 1, 2008, or acquires or creates an off-campus facility on or after January 1, 2008, that does not satisfy the CAH distance requirements in § 485.610(c), will be placed on a 90-day termination track as outlined in section 3012 of the State Operations Manual. During this 90-day period, the CAH will be afforded every opportunity to come back into compliance and meet all conditions of participation. As we noted in the proposed rule, if the CAH corrects the situation that led to the non-compliance, the termination action against the CAH will cease.

Comment: Several commenters asked if current facilities would be allowed to relocate or be replaced and keep the current relationship under the grandfather provisions.

Response: We have addressed in greater detail the situation of a relocated CAH in the FY 2006 IPPS final rule (70 FR 47490). Generally, we believe that it would be reasonable for a CAH to be able to move its facility as long as the new facility can meet the relocation requirements contained under § 485.610(d), which specify the criteria a necessary provider CAH must satisfy upon relocation in order to retain its Medicare provider agreement as a CAH.

The requirements permit such CAHs to relocate as long as they remain essentially the same provider and continue to provide services to the same rural service area.

Comment: Several commenters requested that we state which types of entities to which this policy applies.

Response: While we do not provide a complete list of provider-based entities in this final rule with comment period, we define a provider-based entity at § 413.65(a)(2). Generally, with the exception of RHCs, this CAH provider-based rule will apply to an entity that is provider-based to a CAH that will bill Medicare under its provider number for services rendered.

After consideration of the public comments received, we are finalizing the requirements as proposed with the following revisions. For the reasons noted previously, in § 485.610(e)(2), we have revised the language of the regulation to exclude RHCs, as defined under § 405.2401(b), from the list of provider-based facilities that must comply with this requirement. We revised proposed § 485.610(e)(2) and § 485.610(e)(3) to correct the date references to “on or after January 1, 2008.” Finally, we also added the words “off-campus” before the words “provider-based locations” in § 485.610(e)(2) and § 485.610(e)(3) to conform these references to the preamble language.

B. Revisions to Hospital CoPs

1. Background

On November 27, 2006, we published a final rule in the **Federal Register** entitled “Medicare and Medicaid Programs; Hospital Conditions of Participation: Requirements for History and Physical Examinations; Authentication of Verbal Orders; Securing Medications; and Postanesthesia Evaluations” (71 FR 68672). In that final rule (also frequently referred to as the “Carve-out rule”), we finalized changes, which were based on timely public comments submitted on the proposed rule published in the March 25, 2005 **Federal Register** (70 FR 15266), to four of the requirements (or conditions of participation (CoPs)) that hospitals must meet to participate in the Medicare and Medicaid programs. Specifically, that final rule revised and updated our CoP requirements for: completion of the history and physical examination in the Medical staff and the Medical record services CoPs; authentication of verbal orders in the Nursing services and the Medical record services CoPs; securing medications in the Pharmaceutical services CoP; and,

completion of the postanesthesia evaluation in the Anesthesia services CoP. This action was initiated in response to broad criticism from the medical community that the then-current requirements governing these areas were burdensome and did not reflect current practice.

Since this final rule became effective on January 26, 2007, we have received a great number of comments and questions from providers about the timeframe requirements (for both the initial medical history and physical examination and its update) as well as about the postanesthesia evaluation requirements. In both areas, commenters have sought clarification on the application of these requirements for patients undergoing outpatient surgeries and procedures. While the new requirements contained in the Carve-out rule provide hospitals greater flexibility in ensuring the quality of *inpatient* care, the issues surrounding *outpatient* care in the hospital setting, particularly with regard to outpatient surgeries and procedures, are not clear. After conducting a thorough review of the hospital CoPs and the interpretive guidelines, we isolated the relevant issues regarding outpatient care and proposed revisions to the current regulations to address these concerns.

According to the most recent data, 30 million surgical procedures are performed each year in the United States with over 60 percent done as outpatient procedures and another 10 to 15 percent performed on a same-day admission basis. These figures combined translate to approximately 21 million surgical procedures performed each year in the U.S. on patients who are admitted to the hospital on the day of their procedure. A majority of these patients are also discharged from the hospital the same day that they are admitted. It is unclear whether these numbers also include other procedures, such as diagnostic ones, which also require anesthesia services, and which include all of the risks to patient safety inherent in such procedures. In either case, significant numbers of patients undergo surgeries and other procedures each year as either outpatients or same-day admission patients.

The current requirements for the completion of the medical history and physical examination are found in the regulations at § 482.22 (Medical staff CoP), § 482.24 (Medical record services CoP), and § 482.51 (Surgical services CoP). We believe that these requirements do not adequately address the patient who is admitted for outpatient or same-day surgery or a procedure requiring anesthesia services.

The standards at § 482.22(c), Medical staff bylaws, and § 482.24(c), Content of record, both contain requirements for a medical history and physical examination, and an update of the medical history and physical examination documenting any changes in a patient's condition if the medical history and physical examination was completed within 30 days before admission, to be completed and documented within 24 hours after admission. Under the Surgical services CoP at § 482.51(b)(1), there is a provision that requires a complete history and physical workup to be in the chart of every patient prior to surgery. However, there is currently no requirement for an updated examination of the patient, including any changes to the patient's condition, to be completed and documented after admission or registration, and prior to any surgery or procedure being performed. For patients who are admitted as inpatients for surgery to be performed in the next day or so, this does not pose a problem. These inpatients will be followed while in the hospital with both daily progress and nursing notes made in their medical record. In addition, as required under the current regulations, these patients will also have an updated examination for any changes in their condition within 24 hours after their admission.

As evidenced by the numbers of outpatient and same day admission inpatient procedures discussed above, procedures that were once done only on an inpatient basis are now routinely performed in outpatient settings. Therefore, the patient is not admitted or registered as an outpatient until the day of the procedure. Often this admission or registration is just hours before the procedure is performed. In addition, there are many patients who are admitted as inpatients on the same day that they are scheduled for more complex procedures, which will then require postoperative hospital stays. However, for patients admitted or registered for outpatient procedures as well as for those patients admitted on the same day as their surgery, there is currently no mechanism to ensure that these patients are examined for any changes in their condition prior to undergoing a procedure. Paragraph (b)(1) of § 482.51 currently requires that every patient have a complete medical history and physical examination documented in the chart prior to surgery, except in emergencies. However, the timeframe requirements for this medical history and physical examination contained under both § 482.22(c)(5) and § 482.24(c)(2)(i)(A)

allow for a medical history and physical examination that may be as much as 30 days old. Without a requirement that an updated examination be completed after admission and prior to surgery or other procedure, any changes in a patient's condition would most likely be missed by hospital staff. Failing to identify changes in a patient's condition prior to surgery may adversely impact not only the procedure but also consequently, and perhaps more significantly, the outcome of the procedure for the patient.

In the CY 2008 OPPS/ASC proposed rule (72 FR 42808), we proposed revisions to §§ 482.22, 482.24, and 482.51 that would require an updated examination, including any changes in a patient's condition, to be completed and documented for each patient after admission or registration and prior to surgery or to a procedure requiring anesthesia services. These revisions would ensure that any changes in the patient's condition are discovered before a procedure is performed. With the most up-to-date information regarding a patient's condition readily available to hospital staff prior to a procedure, the risks to patient safety should be minimized and a poor outcome for the patient would be avoided. However, under these proposed requirements, it is not our intent to include those minor procedures that only require the administration of local anesthetics, as might be the case for procedures such as biopsies of skin lesions or suturing of noncomplex lacerations.

Conversely, the current requirements at § 482.52, Anesthesia services, still distinguish between inpatients and outpatients with regard to postanesthesia evaluation, with the requirements for outpatient evaluation actually being less stringent than those for inpatients. When the current hospital regulations were originally written in 1986, these differences in regulatory oversight may have been entirely appropriate. At that time there were still very clear differences between inpatient and outpatient procedures, with inpatient procedures (and the anesthesia services required) considered much more serious and complex in nature. Since that time, there has been a gradual blurring of the distinctions between what were previously termed "inpatient" procedures and those that were classified as "outpatient" procedures. Procedures that were once done only on an inpatient basis are now routinely performed in outpatient settings. While advances in medical technology and surgical technique have allowed for this shift, the complexity

and seriousness of these procedures still remain as do the risks to patient health and safety. Along with the increased complexity and types of outpatient procedures being performed today, come the higher levels of sedation and anesthesia required for these procedures. Thus, distinctions between inpatients and outpatients in the requirements for postanesthesia evaluations are less relevant than ever.

In addition, the current language regarding the completion and documentation of an evaluation "within 48 hours after surgery" assumes that all patients receiving anesthesia services have undergone surgery. It also assumes that they have not been discharged from the hospital prior to the end of this 48-hour timeframe and that they are still available for evaluation. Many patients who have received anesthesia services (either general anesthesia or monitored anesthesia care) have undergone diagnostic or therapeutic procedures as opposed to surgical ones and are discharged within hours after such procedures. Diagnostic and therapeutic procedures that require anesthesia services (either general anesthesia or monitored anesthesia care) include esophagogastroduodenoscopy (EGD), colonoscopy, endoscopic retrograde cholangiopancreatography (ERCP), and electroconvulsive therapy (ECT). Furthermore, and as noted above, even those patients who have undergone inpatient surgical procedures are often discharged well before 48 hours after surgery.

Therefore, in the CY 2008 OPPS/ASC proposed rule (72 FR 42809), we proposed revisions to § 482.52(b) that would ensure that all patients who have received anesthesia services, regardless of inpatient or outpatient status, have a postanesthesia evaluation completed and documented by an individual qualified to administer anesthesia before they are discharged or transferred from the postanesthesia recovery area.

Finally, in our review of the CoPs, we discovered a cross-reference under § 482.23, Nursing services, that is no longer valid. We took the opportunity in the proposed rule to correct this error through a proposed technical amendment.

2. Provisions of the Final Regulations

a. Timeframes for Completion and Documentation of the Medical History and Physical Examination

The proposed revisions to § 482.22(c)(5) retained the requirement that the medical staff bylaws include a requirement that a medical history and physical examination be completed no

more than 30 days before or 24 hours after admission for each patient. We proposed to revise this provision to include the requirement that the completion and documentation of the medical history and physical examination (and the updated examination) would also be required prior to surgery or a procedure requiring anesthesia services.

We also proposed to retain the current provision that the medical staff bylaws contain a requirement for the completion and documentation of an updated examination within 24 hours after admission (when the medical history and physical examination has been completed within 30 days before admission). However, we proposed to delete the language regarding the placement of the medical history and physical examination and the updated examination in the medical record within 24 hours after admission because we believed that the proposed language requiring not only the completion, but also the documentation, of both the medical history and physical examination and the updated examination, would achieve this purpose. In addition, requirements for the physical placement of the medical history and physical examination and the updated examination in the patient's medical record are currently, and more appropriately, contained under the "Medical record services" CoP at § 482.24(c)(2), which we proposed to retain under the proposed rule.

Further, we proposed to separate the requirements for the medical history and physical examination and for the updated examination under two provisions at § 482.22(c)(5)(i) and § 482.22(c)(5)(ii), respectively. At § 482.22(c)(5)(i), we proposed to retain the current requirement that the medical history and physical examination be completed by a physician (as defined in section 1861(r) of the Act), an oromaxillofacial surgeon, or other qualified individual in accordance with State law and hospital policy. However, we proposed to add the words "and documented" after "be completed" as well as the word "licensed" after "qualified" to further clarify this requirement. In addition, we proposed to revise § 482.22(c)(5)(ii) to require that the updated examination of the patient must be completed and documented by the same individuals as proposed above. We also proposed to add the words "or registration" to follow "after admission" to reflect differences in terminology that may exist with the admission of patients for outpatient procedures. We proposed this revision here as well as in § 482.24 and § 482.51, where appropriate.

We proposed to revise the words "for any changes in the patient's condition" to "including any changes in the patient's condition" at both § 482.22(c)(5) and § 482.24(c)(2)(i)(B).

Under § 482.24(c), Content of record, we proposed to revise both § 482.24(c)(2)(i)(A) and § 482.24(c)(2)(i)(B) by adding the language "but prior to surgery or a procedure requiring anesthesia services" with regard to both the completion and the documentation of the medical history and physical examination and the updated examination.

We proposed to revise the Surgical services CoP at § 482.51(b)(1) by deleting the language regarding medical histories and physical examinations that have been dictated but which are not yet recorded in the patient's chart. Our overall intent in the proposed rule was to require that the most current information regarding a patient's condition be available to the hospital staff prior to surgery or a procedure requiring anesthesia services so that risks to patient safety can be minimized and potential adverse outcomes can be avoided.

We proposed to retain the language regarding the requirement for a medical history and physical examination prior to surgery, except in the case of emergencies, and proposed to extend this to a requirement for an updated examination. We proposed to divide the requirements for the medical history physical examination and the updated examination under two separate provisions at § 482.51(b)(1)(i) and § 482.51(b)(1)(ii) in the Surgical services CoP.

b. Requirements for Preanesthesia and Postanesthesia Evaluations

In the CY 2008 OPPI/ASC proposed rule (72 FR 42810), we proposed to revise the requirement at § 482.52(b)(1), under the "Delivery of services" standard of the "Anesthesia services" CoP for a preanesthesia evaluation to include the language "or a procedure requiring anesthesia services." We proposed this revision in order to include the range of procedures that require anesthesia services but that are not necessarily surgical in nature. We proposed to add this language under § 482.52(b)(3) for the postanesthesia evaluation requirement.

Further, we proposed to revise this standard by deleting both the words "with respect to inpatients" at § 482.52(b)(3) and the entire provision at § 482.52(b)(4), which are the current requirements for postanesthesia evaluations for patients. We proposed to

revise § 482.52(b)(3) by requiring that the postanesthesia evaluation be completed and documented before discharge or transfer from the postanesthesia recovery area. As discussed above, the intent of this section of the proposed rule was to eliminate the distinctions currently found in the regulations between inpatients and outpatients with regard to anesthesia services.

Comment: One commenter supported CMS's efforts to eliminate the distinctions, currently found in the hospital CoPs, between inpatients and outpatients with regard to history and physical examinations, examination updates, and anesthesia evaluations. They noted that the proposed changes would help to dispel misconceptions regarding documentation completion and timeframe requirements. Additionally, the commenter expressed the opinion that such revisions to the CoPs would not only ensure complete, accurate, and timely documentation, which is vital for the protection of patients and for the monitoring of the quality of care provided by clinical staff but would also ensure the efficient and effective coordination of care by case managers, discharge planners, and social services staff.

Response: We appreciate the commenter's support of the proposed changes and agree that the accurate and timely documentation of patient medical information is an essential component of quality across the spectrum of patient care.

Comment: One commenter stated that the proposed requirements for an updated examination of the patient to be completed and documented in the patient's medical record within 24 hours after admission or registration but prior to surgery or any procedure requiring anesthesia services, would be operationally and unnecessarily burdensome on hospitals. The commenter noted that the requirement would lead to surgical scheduling inefficiencies, since surgeons would need to stop procedures so that they could dictate a medical history and physical examination or an update. The commenter also expressed the opinion that it was operationally difficult, if not impossible, to ensure that documentation of a medical history and physical examination or an update was placed in the patient's medical record prior to the beginning of surgery. The commenter requested clarification on these proposed changes, particularly on which provider could complete the update and whether it would need to be dictated.

Response: The changes contained in the proposal are a clarification of the current medical history and physical examination requirements, which were contained in the Carve-out rule (71 FR 68672) published November 27, 2006, and which were discussed above. At the time of the publication of that final rule, we explained in the preamble that if the patient's medical history and physical examination was completed before admission to the hospital, the updated examination must be completed and documented within 24 hours after admission but before a surgical procedure. This original intention from the Carve-out rule has been clarified in this final rule with comment period.

Both the medical history and physical examination and the update can be completed and documented by a physician (as defined in section 1861(r) of the Act), an oromaxillofacial surgeon, or other qualified licensed individual in accordance with State law and hospital policy. The individual who completes the update does not have to be the same individual who did the medical history and physical examination. Both documents may be handwritten, dictated and transcribed, or completed electronically. Under these requirements, hospitals have the flexibility to establish their own policies for the format in which this essential patient information is documented in the medical record.

Comment: One commenter stated that they were opposed to the removal of the language in the current CoPs that requires that the medical history and physical examination be documented and placed "on the medical record" [sic] within 24 hours. The commenter expressed concerns about physicians who continue to believe that a dictated, but not yet transcribed, medical history and physical examination is adequate because it is "in the system," even though it is not yet physically in the patient's medical record. The commenter stated that the current JCAHO standards require that the medical history and physical examination be in the medical record. The commenter believed that this requirement should be reinforced in the Medicare hospital CoPs.

Response: As we stated in our discussion of the proposed change, we believe that the requirements for the physical placement of the medical history and physical examination, as well as those for its update, are more appropriately located where they currently are, that is, under the Medical record services CoP at § 482.24(c)(2), which we will retain under this rule. Furthermore, we appreciate the

commenter's concerns regarding medical histories and physical examinations that have been dictated but not yet transcribed, and, thus, are not physically present in the patient's medical record. Supporting the overall intent of this rule to require that the most current information regarding a patient's condition be *available* to hospital staff *prior* to surgery or a procedure requiring anesthesia services, we proposed to delete the language currently contained under the Surgical services CoP at § 482.51(b)(1) which allows for medical histories and physical examinations that have been dictated but which are not yet recorded in the chart. Additionally, the proposed revisions at §§ 482.22, 482.24, and 482.51 all require that the medical history and physical examination (and its update) be completed and documented in the patient's medical record within 24 hours after admission or registration but prior to surgery or a procedure requiring anesthesia services (and except in the case of emergencies as allowed for under § 482.51(b)(1)). We intend to finalize the proposed requirements without further revision. We believe that these requirements will address concerns regarding documentation and will emphasize the important role that the timely and complete documentation of patient information plays in reducing patient risk.

Comment: One commenter stated that the term "anesthesia services" should be defined in the requirements and that it should include standard terminology such as moderate sedation, deep sedation, and general anesthesia. The commenter also asked whether CMS intends to apply the same requirements regarding medical histories and physical examinations and postanesthesia evaluations to moderate sedation administered by a physician or surgeon and to general anesthesia administered by an anesthesiologist.

Response: We expect hospitals, which furnish anesthesia services, to follow the current standards of anesthesia care, along with the accepted definitions of such care, that have been established by nationally recognized bodies such as the American Society of Anesthesiologists (ASA) and the American Association of Nurse Anesthetists (AANA). We also expect that those established guidelines should be reflected in the hospital's policies and procedures regarding anesthesia services as appropriate to the scope of services offered.

The requirements for H&Ps and postanesthesia evaluations are not the same. As previously discussed, a medical history and physical

examination (and its update, if applicable) is required for each patient admitted or registered to the hospital. This requirement is not based on whether the patient is undergoing surgery or a procedure requiring anesthesia services. However, the medical history and physical examination (and its update) are required prior to surgery or a procedure requiring anesthesia services, except in the case of emergencies.

A postanesthesia evaluation would be required after surgery or a procedure requiring anesthesia services and must be completed and documented by an individual qualified to administer anesthesia. The list of individuals who are qualified to administer anesthesia is set out at § 482.52(a).

Comment: One commenter supported the proposed changes to the preanesthesia and postanesthesia evaluation requirements and believed that they reflected current standards of care. The commenter agreed with CMS' decision to remove the distinctions between inpatients and outpatients with regard to the postanesthesia evaluation. The commenter also agreed with the application of the standards to all patients receiving anesthesia services regardless of whether they were undergoing surgical or non-surgical procedures.

However, several commenters took exception to the proposed requirement that the postanesthesia evaluation be completed and documented before the patient is discharged or transferred from the postanesthesia recovery area. Several commenters stated that this part of the provision does not reflect current standards of postanesthesia care. One commenter noted that its State's regulations allow for the use of approved medical staff postanesthesia recovery area criteria, which means that qualified postanesthesia recovery area staff can discharge patients from the recovery area if they meet certain standards established by qualified anesthesia practitioners.

Another commenter pointed out that, as proposed, § 482.52(b)(3) would create a situation where patients who could be safely transferred to another unit of the hospital or discharged home would be held for hours in the recovery area. The commenter further stated that completing the postanesthesia evaluation in the recovery area is simply too soon to fully capture or address the patient's complete postanesthesia experience, including any anesthesia-related complications, which is more effectively done by anesthesia providers who make follow-up visits or phone

calls to patients either later that day or the next.

One commenter stressed that it is the surgeon or lead physician who determines when the patient is ready for discharge or transfer and that this decision is based on the monitoring and documentation of the patient by the recovery nurse. This commenter noted that though there may be some residual effects from anesthesia, this does not mean that it is inappropriate to discharge or transfer the patient from the recovery area. This commenter believed that with proper discharge instructions specific to that patient, a patient may be safely discharged home to rest following a procedure and that follow-up over the phone by the anesthesia provider would then complete the postanesthesia evaluation.

Two commenters also stated that the proposed requirement for the timing of the postanesthesia evaluation would place an undue burden on small rural hospitals where there are a limited number of anesthesia providers. They argued that such constraints would limit access to surgical services in these communities by significantly slowing down the number of cases each day. These commenters argued that such hospitals would have to hire an additional provider to comply with this requirement without yielding any benefits to patient safety or access to care.

Response: We appreciate the comments received. After consideration of the public comments and a further review of the current standards of anesthesia care, we agree that our proposed changes to the postanesthesia evaluation requirements may not truly reflect current and safe anesthesia practice, may in fact impose a burden on hospitals and anesthesia providers, and, as an unintended consequence, limit some patients' access to health care services. Therefore, we have revised the proposed requirements for the postanesthesia evaluation in this final rule with comment period to better reflect current standards of care. We are requiring that the postanesthesia evaluation must be completed and documented by an individual qualified to administer anesthesia no later than 48 hours after surgery or a procedure requiring anesthesia services, and that the postanesthesia evaluation for anesthesia recovery must be completed in accordance with State law and with hospital policies and procedures that have been approved by the medical staff and that reflect current standards of anesthesia care.

Comment: One commenter requested that CMS regularly update the online

Interpretive Guidelines to reflect changes in the hospital CoPs and that healthcare professionals and their professional associations be notified by CMS on a timely basis regarding such updates.

Response: This request is outside of the scope of this rule. However, we will forward this comment to the appropriate component within CMS responsible for the Interpretive Guidelines.

c. Technical Amendment to Nursing Services CoP

In the CY 2008 OPPTS/ASC proposed rule (72 FR 42810), we proposed to revise the cross-reference to § 405.1910(c) currently found under the nursing services CoP at § 482.23(b)(1), as this citation has been changed and is no longer valid. We proposed a technical amendment to this provision to correct the cross-reference to § 488.54(c).

We did not receive any public comments on this proposed change.

After consideration of the public comments received, we are finalizing the proposed changes without revision, with the exception of those under § 482.52(b)(3). We are revising the proposed revision to require that the postanesthesia evaluation must be completed and documented by an individual qualified to administer anesthesia no later than 48 hours after surgery or a procedure requiring anesthesia services, and that the postanesthesia evaluation for anesthesia recovery must be in accordance with State law and with hospital policies and procedures, which have been approved by the medical staff and which reflect current standards of anesthesia care. As finalized in this final rule with comment period, these requirements will provide hospitals greater flexibility while ensuring the quality and safety of care provided to patients.

XIX. Changes to the FY 2008 Hospital Inpatient Prospective Payment System (IPPS) Payment Rates

A. Background

On August 1, 2007, we issued a final rule with comment period to update the hospital inpatient prospective payment system (IPPS) for FY 2008. (This rule was printed in the August 22, 2007 **Federal Register** at 72 FR 47130 through 48175.) In that final rule with comment period, as part of the annual update of policies and payment rates under the IPPS, we adopted a new patient diagnosis classification system, the Medicare severity diagnosis-related group (MS-DRG) system, to replace the existing CMS-DRG system, effective October 1, 2007. To maintain budget

neutrality for the transition to the MS-DRG patient classification system, using the Secretary's authority under section 1886(d)(3)(A)(vi) of the Act to adjust the standardized amount to eliminate the effect of changes in coding or classification that do not reflect real change in case-mix, we also provided for a documentation and coding adjustment to the IPPS payment rates of -1.2 percent. On September 28, 2007, we issued a correction notice to the FY 2008 IPPS final rule with comment period that corrected an inadvertent technical calculation error made in the FY 2008 IPPS final rule with comment period that affected IPPS payment rates, factors, and thresholds. (This notice, which we will refer to as the "second FY 2008 IPPS correction notice," was printed in the October 10, 2007 **Federal Register** at 72 FR 57634.)

On September 29, 2007, the TMA, Abstinence Education, and QI Programs Extension Act of 2007 (TMA), Public Law 110-90, was enacted. As discussed in more detail in section XIX.B. of this final rule, section 7 of Public Law 110-90 included a provision that reduces the -1.2 percent documentation and coding adjustment for the MS-DRG system that we adopted in the FY 2008 IPPS final rule to -0.6 percent. To comply with the provision of section 7 of Public Law 110-90, we are revising certain FY 2008 IPPS payment rate, thresholds, and factors that were included in the October 10, 2007 correction notice for the FY 2008 final rule with comment period.

In addition, in this final rule, we are making a policy change to the IPPS that was not part of Public Law 110-90. In the FY 2008 IPPS final rule, we established a policy of applying the documentation and coding adjustment to the hospital-specific rates for Medicare-dependent, small rural hospitals (MDHs) and sole community hospitals (SCHs) for FY 2008. We have determined that application of the documentation and coding adjustment to the hospital-specific rates is not consistent with the plain meaning of section 1886(d)(3)(A)(vi) of the Act. Therefore, we have decided to change this policy, effective October 1, 2007, as discussed in section XIX.B.2. of this final rule.

B. Revised IPPS Payment Rates

1. MS-DRG Documentation and Coding Adjustment

As stated earlier, we adopted the new MS-DRG patient classification system for the IPPS, effective October 1, 2007. The intent of the MS-DRG system is to better recognize severity of illness in

Medicare payment rates. Adoption of the MS-DRGs resulted in the expansion of the number of DRGs from 538 to 745. By increasing the number of DRGs and more fully taking into account severity of illness in Medicare payment rates, the MS-DRGs encourage hospitals to improve their documentation and coding of patient diagnoses. Because of the incentives that the MS-DRGs provide for improved documentation and coding of patient diagnoses, we indicated in the FY 2008 IPPS final rule that we believe the adoption of the MS-DRGs would lead to increases in aggregate payments due to improved documentation and coding without a corresponding increase in actual patient severity of illness. To maintain budget neutrality, using the Secretary's authority under section 1886(d)(3)(A)(vi) of the Act to adjust the standardized amount to eliminate the effect of changes in coding or classification that do not reflect real change in case-mix, we established a documentation and coding adjustment of -1.2 percent for FY 2008.

Section 7 of Public Law 110-90 included a provision concerning this documentation and coding adjustment for the MS-DRGs. Specifically, section 7 of Public Law 110-90 requires the Secretary to apply a prospective documentation and coding adjustment for discharges during FY 2008 of -0.6 percent rather than the -1.2 percent adjustment specified in the FY 2008 IPPS final rule. To comply with the provision of section 7 of Public Law 110-90, we are changing the IPPS documentation and coding adjustment for FY 2008 to -0.6 percent and recalculating the operating standardized amounts, capital standard Federal payment rates, the outlier threshold, the offset factors that are applied to the standardized amounts to account for projected outlier payments, and the thresholds that are used to evaluate applications for new technology add-on payments for FY 2008. All of these revised rates, factors, and thresholds are effective October 1, 2007. These revised rates, factors, and thresholds replace those rates, factors, and thresholds published in the FY 2008 IPPS final rule and in the second FY 2008 IPPS correction notice. We issued the second FY 2008 IPPS correction notice prior to enactment of Public Law 110-90 and, consequently, that correction notice did not reflect the change from the -1.2 percent to the -0.6 percent documentation and coding adjustment for FY 2008.

The revised standardized amounts are shown in Table 1A, 1B, 1C, and 1D. As expected, the standardized amounts

have increased by about 0.6 percent as a result of changes in the documentation and coding adjustment required under section 7 of Public Law 110-90.

We also have recalculated the outlier threshold based on the revised standardized amounts. As a result of the change made by section 7 of Public Law 110-90, the revised outlier threshold for FY 2008 is \$22,185. This represents a decrease of \$275 from the previously published FY 2008 outlier threshold. The revised outlier factors are: 0.948983 for operating national; 0.964060 for operating Puerto Rico; 0.952336 for capital national; and 0.959464 for capital Puerto Rico.

In addition, we have recalculated the thresholds that are being used to evaluate applications for new technology add-on payments for FY 2008 under the IPPS, as shown in Table 10 below. (We note that, for ease of reference, we have retained the original table numbering from the FY 2008 IPPS final rule and the second FY 2008 IPPS correction notice. As a result, table numbering in this section is not sequential because only certain tables from the FY 2008 IPPS final rule and the second FY 2008 IPPS correction notice require changes to comply with the provisions of section 7 of Public Law 110-90.) These thresholds, which are equal to the geometric mean standardized charges plus the lesser of 75 percent of the national adjusted operating standardized payment amount (increased to reflect the differences between costs and charges) or 75 percent of 1 standard deviation of mean charges by MS-DRG, were recalculated due to the change in the standardized operating amount resulting from the change made by section 7 of Public Law 110-90. Depending on the particular MS-DRG, the revised new technology thresholds are either the same as, or have increased slightly from, the previously published amounts.

Both the FY 2008 IPPS final rule and the second FY 2008 IPPS correction notice included a table entitled "Comparison of FY 2007 Standardized Amounts to the FY 2008 Single Standardized Amount with Full Update and Reduced Update." We are including an updated version of that table in this final rule, which reflects the payment rates, factors, and thresholds that have been revised to comply with section 7 of Public Law 110-90.

We note that section 7 of Public Law 110-90 includes provisions concerning documentation and coding adjustments to payment rates for years after FY 2008. We will address those provisions in future years' rulemaking for the IPPS.

2. Application of the Documentation and Coding Adjustment to the Hospital-Specific Rates

Under section 1886(d)(5)(D)(i) of the Act, SCHs are paid based on whichever of the following rates yields the greatest aggregate payment: the Federal national rate; the updated hospital-specific rate based on FY 1982 costs per discharge; the updated hospital-specific rate based on FY 1987 costs per discharge; or the updated hospital-specific rate based on FY 1996 costs per discharge. Under section 1886(d)(5)(G) of the Act, MDHs are paid based on the Federal national rate or, if higher, the Federal national rate plus 75 percent of the difference between the Federal national rate and the updated hospital-specific rate based on either the FY 1982, 1987, or 2002 costs per discharge. When we recalculated the FY 2008 IPPS rates to comply with the provision of section 7 of Public Law 110-90, we reviewed the policy we established in the FY 2008 IPPS final rule of applying the document and coding adjustment to the hospital-specific rates for MDHs and SCHs. In that final rule, we stated that we believe the hospital-specific rates for MDHs and SCHs should be subject to the documentation and coding adjustment that we were applying under section 1886(d)(3)(A)(vi) of the Act to maintain budget neutrality for the adoption of the MS-DRGs. That is, as these hospitals use the same DRG system as all other hospitals, we believe they should be equally subject to the budget neutrality adjustment that we were applying for adoption of the MS-DRGs to all other hospitals.

After further review of this issue, we have decided that the application of the documentation and coding adjustment to the hospital-specific rates is not consistent with the plain meaning of the statute. Section 1886(d)(3)(A)(vi) of the Act provides the Secretary with the authority to adjust "the average standardized amounts" so as to eliminate the effect of changes in coding or classification of discharges that do not reflect real changes in case-mix. However, section 1886(d)(3)(A)(vi) of the Act only provides authority to adjust the average standardized amounts, and does not refer to the hospital-specific rates. We continue to believe that it would be appropriate to apply the documentation and coding adjustment to the hospital-specific rates because we believe that aggregate IPPS payments will increase after implementation of the MS-DRGs due to incentives to improve coding and documentation. However, we believe that such an adjustment is not authorized under

section 1886(d)(3)(A)(vi) of the Act. As a result, we are establishing a policy of not applying the documentation and coding adjustment to the hospital-specific rates for FY 2008. Consequently, the revised DRG classification and recalibration factor of

0.995743, established in the October 10, 2007 correction notice for the FY 2008 IPPS final rule, which corrected the budget neutrality factor established in the FY 2008 IPPS final rule (72 FR 47416 and 47423), will be applied to the hospital-specific rates of MDHs and

SCHs for FY 2008 without application of a -1.2 percent or a -0.6 percent documentation and coding adjustment. This policy is effective October 1, 2007, for FY 2008.

TABLE 1A.—NATIONAL ADJUSTED OPERATING STANDARDIZED AMOUNTS; LABOR/NONLABOR

[69.7 Percent Labor Share/30.3 Percent Nonlabor Share if Wage Index Greater Than 1]

Full update (3.3 percent)		Reduced update (1.3 percent)	
Labor-related	Nonlabor-related	Labor-related	Nonlabor-related
\$3,478.45	\$1,512.15	\$3,411.10	\$1,482.87

TABLE 1B.—NATIONAL ADJUSTED OPERATING STANDARDIZED AMOUNTS, LABOR/NONLABOR

[62 Percent Labor Share/38 Percent Nonlabor Share if Wage Index Less Than Or Equal to 1]

Full update (3.3 percent)		Reduced update (1.3 percent)	
Labor-related	Nonlabor-related	Labor-related	Nonlabor-related
\$3,094.17	\$1,896.43	\$3,034.26	\$1,859.71

TABLE 1C.—ADJUSTED OPERATING STANDARDIZED AMOUNTS FOR PUERTO RICO, LABOR/NONLABOR

	Rates if wage index greater than 1		Rates if wage index less than or equal to 1	
	Labor	Nonlabor	Labor	Nonlabor
National	\$3,478.45	\$1,512.15	\$3,094.17	\$1,896.43
Puerto Rico	1,462.27	896.23	1,384.44	974.06

TABLE 1D.—CAPITAL STANDARD FEDERAL PAYMENT RATE

	Rate
National	\$426.14
Puerto Rico	201.67

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

MS-DRG	Number of cases	Threshold (\$)	MS-DRG	Number of cases	Threshold (\$)
11	1,297	71,694	36	7,454	36,602
12	1,956	51,613	37	4,803	51,825
13	1,476	37,000	38	16,531	32,848
20	910	138,461	39	53,619	23,940
21	566	108,125	40	4,585	57,599
22	249	74,864	41	8,005	39,541
23	3,564	81,082	42	5,216	34,291
24	2,168	57,415	52	1,188	29,379
25	8,493	77,774	53	590	21,941
26	12,059	52,410	54	4,750	30,273
27	14,191	41,344	55	16,945	24,952
28	1,623	74,228	56	7,800	28,358
29	3,089	45,957	57	48,665	18,154
30	3,592	30,059	58	796	28,750
31	1,061	60,385	59	2,676	21,475
32	3,064	35,538	60	4,240	16,415
33	4,237	28,788	61	1,368	53,087
34	821	58,431	62	2,320	42,059
35	2,911	41,625	63	1,150	36,344

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹

MS-DRG	Number of cases	Threshold (\$)
1	652	\$345,031
2	335	178,142
3	24,400	248,318
4	21,825	149,288
5	634	167,763
6	296	92,366
7	378	134,606
8	583	92,357
9	1,388	97,098
10	182	73,504

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

MS-DRG	Number of cases	Threshold (\$)	MS-DRG	Number of cases	Threshold (\$)	MS-DRG	Number of cases	Threshold (\$)
64	56,448	33,903	138	926	17,071	218	2,963	97,926
65	115,423	26,274	139	1,710	19,625	219	10,112	131,361
66	91,644	19,975	146	696	35,254	220	14,302	93,832
67	1,403	30,850	147	1,457	25,264	221	7,644	81,272
68	12,512	21,801	148	924	17,390	222	2,862	150,295
69	104,325	17,613	149	39,487	14,828	223	5,774	116,655
70	7,165	33,429	150	945	25,286	224	1,930	138,362
71	10,283	26,043	151	6,840	12,717	225	5,882	109,348
72	5,811	19,097	152	2,363	22,142	226	7,078	112,911
73	8,728	27,072	153	16,167	14,126	227	50,687	88,751
74	32,760	19,857	154	1,857	28,071	228	3,099	124,543
75	1,229	34,005	155	4,431	20,298	229	4,351	88,368
76	861	22,530	156	4,969	14,819	230	1,797	72,722
77	1,112	33,155	157	1,164	28,432	231	1,484	138,797
78	1,386	23,660	158	3,158	19,955	232	1,799	107,899
79	896	18,688	159	2,365	14,144	233	16,996	118,324
80	2,095	24,178	163	13,502	78,360	234	39,349	86,766
81	8,250	15,979	164	18,484	48,016	235	9,680	95,767
82	1,664	34,288	165	14,267	37,961	236	33,005	68,343
83	2,070	28,476	166	20,398	57,329	237	22,981	84,187
84	2,527	21,042	167	21,074	39,878	238	43,967	53,516
85	5,383	34,836	168	5,555	30,256	239	13,900	59,293
86	10,921	26,197	175	12,032	33,180	240	13,862	40,658
87	11,827	18,483	176	40,330	25,127	241	2,927	30,323
88	730	30,589	177	57,526	35,918	242	17,243	63,797
89	2,836	22,350	178	72,497	29,908	243	40,609	50,067
90	3,285	16,402	179	26,495	23,293	244	65,831	42,281
91	6,763	29,413	180	22,628	33,071	245	6,081	54,243
92	15,467	20,636	181	32,425	26,996	246	41,300	65,115
93	15,043	15,988	182	6,085	21,762	247	272,543	46,643
94	1,533	55,314	183	1,679	29,948	248	5,558	58,161
95	1,101	41,950	184	4,279	21,041	249	29,332	41,991
96	749	35,573	185	2,607	14,730	250	5,768	53,663
97	1,266	50,432	186	8,586	31,572	251	39,992	38,522
98	1,065	35,836	187	10,362	25,688	252	44,846	48,444
99	637	30,059	188	4,840	19,425	253	52,457	42,864
100	16,012	28,517	189	105,009	28,936	254	53,894	34,709
101	57,312	17,754	190	57,361	27,734	255	2,624	38,540
102	1,373	24,528	191	126,608	22,656	256	3,944	29,847
103	15,199	15,977	192	193,798	17,011	257	694	21,430
113	592	31,418	193	88,637	29,505	258	599	50,000
114	593	19,667	194	274,002	23,196	259	7,342	35,334
115	1,110	25,665	195	142,476	16,909	260	872	47,409
116	715	23,533	196	5,173	30,869	261	2,921	28,499
117	1,406	15,540	197	7,087	25,433	262	3,284	21,635
121	609	21,777	198	4,822	19,617	263	792	29,116
122	666	12,422	199	3,279	33,401	264	30,336	39,332
123	2,865	17,881	200	8,321	23,384	280	61,020	35,621
124	684	24,261	201	3,470	16,338	281	62,050	27,981
125	4,742	15,308	202	32,849	19,060	282	57,249	21,202
129	1,401	38,113	203	40,990	13,891	283	16,022	31,225
130	1,063	27,826	204	26,244	16,200	284	5,089	23,429
131	895	36,667	205	5,816	26,248	285	3,008	16,066
132	910	26,200	206	22,615	17,512	286	23,379	40,375
133	2,057	31,674	207	46,394	81,181	287	173,151	27,701
134	3,781	19,478	208	79,797	41,263	288	3,262	48,462
135	430	34,472	215	154	151,824	289	1,471	35,223
136	503	21,916	216	8,437	161,730	290	447	27,620
137	847	27,054	217	7,940	116,752	291	184,689	29,043

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

MS-DRG	Number of cases	Threshold (\$)
292	245,075	22,187
293	200,858	16,283
294	1,756	20,506
295	1,631	12,987
296	1,844	26,712
297	893	18,216
298	518	11,608
299	17,570	27,717
300	49,533	20,057
301	37,733	14,452
302	7,919	23,176
303	81,896	14,065
304	2,116	24,314
305	36,019	13,919
306	1,385	27,686
307	6,479	17,568
308	33,741	27,391
309	85,320	19,164
310	156,223	13,820
311	25,143	12,408
312	170,267	16,986
313	222,163	13,782
314	60,587	30,529
315	33,354	22,371
316	18,077	15,239
326	11,616	86,300
327	11,348	49,623
328	8,994	31,842
329	48,381	78,446
330	68,497	46,925
331	29,611	34,940
332	1,897	72,565
333	6,490	45,834
334	3,751	34,051
335	7,194	67,395
336	12,815	43,093
337	8,636	32,710
338	1,513	58,176
339	3,289	39,849
340	3,551	29,763
341	878	43,074
342	2,662	32,095
343	6,796	22,560
344	897	51,758
345	3,090	33,808
346	2,758	25,650
347	1,577	36,724
348	4,295	27,903
349	5,539	17,498
350	1,802	41,307
351	4,663	28,433
352	8,835	18,578
353	3,076	44,840
354	9,041	30,936
355	16,621	21,562
356	8,411	57,588
357	8,336	39,793
358	2,477	30,966
368	3,069	31,708

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

MS-DRG	Number of cases	Threshold (\$)
369	4,850	24,300
370	3,104	18,383
371	16,940	32,006
372	23,722	26,630
373	14,227	19,299
374	9,505	34,394
375	20,165	26,552
376	4,486	20,960
377	50,797	30,805
378	118,928	22,456
379	95,521	17,322
380	2,934	32,459
381	5,702	25,732
382	4,681	18,936
383	1,307	28,384
384	8,723	19,941
385	2,119	33,612
386	7,449	24,853
387	5,105	19,162
388	18,375	29,468
389	47,827	21,609
390	47,010	15,176
391	47,836	25,010
392	308,502	16,603
393	24,053	29,116
394	48,058	22,377
395	24,695	16,159
405	3,949	82,266
406	5,420	49,216
407	2,195	36,325
408	1,682	68,612
409	1,771	46,946
410	693	35,927
411	985	65,669
412	1,098	47,894
413	850	37,530
414	5,643	59,314
415	7,154	40,716
416	6,018	30,467
417	16,735	46,569
418	28,654	36,593
419	37,427	27,109
420	738	62,636
421	1,118	37,131
422	359	28,797
423	1,528	64,794
424	934	44,801
425	148	35,332
432	16,397	30,728
433	9,146	21,794
434	931	15,756
435	12,004	32,834
436	14,157	26,609
437	4,304	23,809
438	14,497	31,835
439	25,932	25,153
440	26,506	17,450
441	14,036	29,059
442	13,192	22,508

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

MS-DRG	Number of cases	Threshold (\$)
443	6,445	16,775
444	12,529	31,163
445	17,390	25,361
446	16,434	18,758
453	852	162,946
454	1,700	108,994
455	1,715	84,036
456	770	132,720
457	2,084	93,391
458	1,282	76,799
459	3,212	91,603
460	51,227	61,623
461	1,071	78,604
462	14,292	59,135
463	5,317	58,718
464	6,589	40,875
465	2,748	30,484
466	3,914	70,332
467	14,340	53,276
468	21,479	45,819
469	29,879	56,126
470	412,628	41,706
471	2,241	71,743
472	6,629	48,496
473	22,659	39,769
474	2,857	47,857
475	3,709	34,489
476	1,560	23,529
477	2,262	56,532
478	7,379	41,594
479	10,118	33,437
480	25,993	50,104
481	74,669	37,466
482	49,780	31,682
483	6,572	44,289
484	17,287	37,116
485	1,152	55,664
486	2,066	41,511
487	1,345	33,504
488	2,541	33,357
489	6,198	25,879
490	21,668	34,253
491	57,424	22,157
492	4,761	47,754
493	16,833	36,159
494	29,419	27,047
495	1,888	49,306
496	5,499	34,296
497	7,196	26,140
498	1,258	36,549
499	1,173	20,709
500	1,359	47,311
501	3,956	30,725
502	6,635	21,338
503	743	38,573
504	2,274	30,902
505	3,142	22,627
506	921	23,455
507	840	33,200

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

MS-DRG	Number of cases	Threshold (\$)
508	2,717	24,377
509	674	24,413
510	994	38,968
511	4,183	30,425
512	12,088	21,576
513	1,104	28,511
514	1,175	18,054
515	3,601	50,850
516	11,512	37,284
517	17,926	30,578
533	835	26,707
534	3,647	14,482
535	6,888	26,510
536	34,492	14,330
537	694	19,017
538	1,139	12,077
539	3,397	33,275
540	4,317	26,909
541	1,787	20,216
542	6,196	32,603
543	18,834	24,660
544	12,389	16,758
545	4,061	33,895
546	6,159	23,684
547	4,717	16,961
548	592	32,830
549	1,139	25,116
550	855	16,440
551	9,580	29,166
552	88,568	17,262
553	2,820	24,459
554	20,429	13,865
555	2,006	21,701
556	19,316	13,456
557	3,196	28,928
558	14,252	17,984
559	1,646	27,945
560	4,208	19,203
561	7,439	12,631
562	5,051	26,500
563	36,361	14,373
564	1,622	27,272
565	3,385	19,726
566	2,673	14,394
573	5,721	44,240
574	12,468	32,357
575	6,221	24,293
576	563	45,021
577	2,305	31,260
578	3,228	21,726
579	3,359	42,843
580	11,019	29,022
581	12,249	19,890
582	5,787	22,538
583	9,356	17,024
584	801	29,827
585	1,687	19,824
592	4,026	29,402
593	13,080	21,992

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

MS-DRG	Number of cases	Threshold (\$)
594	2,828	15,050
595	1,092	29,735
596	5,792	18,108
597	555	29,944
598	1,502	23,666
599	342	14,643
600	611	21,165
601	841	13,706
602	21,456	26,755
603	132,037	16,799
604	2,652	25,338
605	22,943	15,043
606	1,371	23,134
607	7,242	13,623
614	1,429	44,434
615	1,594	32,741
616	1,145	57,824
617	6,944	36,311
618	268	26,622
619	675	60,418
620	2,007	41,247
621	6,560	35,467
622	1,241	43,164
623	3,392	32,438
624	392	23,639
625	1,107	40,382
626	2,751	27,124
627	14,146	17,672
628	3,297	50,999
629	4,125	39,920
630	551	30,418
637	16,431	26,770
638	46,657	17,852
639	36,178	12,405
640	56,149	24,007
641	189,293	15,306
642	1,570	23,279
643	5,072	30,747
644	12,220	23,221
645	8,140	17,134
652	10,695	57,657
653	1,591	83,632
654	3,387	53,616
655	1,514	40,319
656	3,739	56,790
657	7,946	38,780
658	7,957	31,512
659	4,484	50,404
660	7,985	36,216
661	4,264	28,963
662	998	41,878
663	2,288	29,568
664	4,543	21,878
665	693	47,261
666	2,405	30,788
667	3,765	17,825
668	3,768	39,776
669	13,307	27,864
670	12,685	17,652

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007¹—Continued

MS-DRG	Number of cases	Threshold (\$)
671	917	28,789
672	940	17,260
673	12,678	43,365
674	13,848	38,562
675	8,371	31,105
682	76,428	30,069
683	128,229	25,154
684	28,358	16,191
685	2,520	18,480
686	1,596	31,266
687	3,467	24,382
688	1,098	16,621
689	55,794	25,693
690	201,347	16,948
691	908	32,141
692	653	23,510
693	2,256	27,791
694	19,345	16,454
695	982	24,103
696	10,646	13,740
697	585	16,016
698	21,255	27,734
699	27,064	21,858
700	11,141	15,265
707	6,053	34,784
708	15,996	27,483
709	796	33,829
710	2,015	28,079
711	953	34,060
712	793	18,806
713	12,009	24,773
714	32,647	14,452
715	662	34,122
716	1,367	26,199
717	666	31,542
718	601	17,543
722	881	29,202
723	2,078	23,886
724	648	14,696
725	808	23,735
726	3,956	15,110
727	1,106	26,438
728	6,224	15,600
729	603	22,575
730	533	13,176
734	1,528	39,574
735	1,278	24,152
736	842	68,949
737	3,487	39,556
738	912	26,791
739	980	48,297
740	4,638	31,766
741	6,330	22,182
742	11,685	29,942
743	34,686	19,452
744	1,634	28,687
745	2,080	18,005
746	2,664	27,898
747	11,073	19,176

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007 ¹—Continued

MS-DRG	Number of cases	Threshold (\$)
748	21,289	18,499
749	1,048	42,978
750	477	22,403
754	1,097	31,885
755	3,219	24,350
756	783	15,311
757	1,326	31,206
758	1,659	24,086
759	1,141	17,474
760	1,815	17,766
761	1,844	12,285
765	2,606	19,738
766	2,664	13,500
767	123	14,158
768	10	28,544
769	87	30,064
770	188	15,884
774	1,476	11,268
775	5,343	8,224
776	495	14,028
777	180	17,674
778	494	7,925
779	107	12,859
780	50	5,097
781	3,062	11,922
782	129	7,495
790	1	10,892
793	1	7,090
799	631	76,408
800	730	45,534
801	581	35,405
802	693	51,922
803	1,030	33,848
804	978	23,443
808	8,276	34,018
809	15,783	25,043
810	3,694	19,852
811	18,481	24,822
812	83,743	16,735
813	15,112	25,412
814	1,649	29,868
815	3,483	23,384
816	2,274	16,506
820	1,490	83,924
821	2,593	40,916
822	2,108	28,993
823	2,452	64,964
824	3,130	40,720
825	1,940	29,726
826	566	77,536
827	1,354	40,320
828	851	29,066
829	1,386	44,486
830	520	24,753
834	5,293	50,536

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007 ¹—Continued

MS-DRG	Number of cases	Threshold (\$)
835	1,458	30,848
836	1,554	23,636
837	1,638	86,041
838	942	41,650
839	1,368	27,174
840	15,248	37,709
841	11,355	28,818
842	7,431	22,926
843	1,498	32,726
844	2,893	25,240
845	988	19,989
846	2,498	37,638
847	23,816	25,436
848	1,695	18,894
849	1,507	27,052
853	31,591	74,820
854	6,945	49,005
855	429	35,456
856	6,215	64,154
857	10,284	36,043
858	3,362	28,370
862	7,481	32,201
863	21,957	20,215
864	19,959	19,205
865	2,032	28,153
866	9,474	15,750
867	5,387	37,627
868	2,507	24,427
869	1,129	18,549
870	13,815	88,107
871	204,810	33,501
872	92,533	25,285
876	971	40,709
880	10,578	14,303
881	4,636	10,640
882	1,673	11,353
883	799	16,323
884	21,747	17,521
885	78,937	14,233
886	377	13,044
887	427	17,908
894	4,627	7,335
895	6,777	14,018
896	5,447	25,226
897	36,860	12,339
901	924	48,983
902	2,217	31,794
903	1,687	22,773
904	980	39,791
905	779	24,032
906	751	22,406
907	8,164	53,029
908	8,553	34,813
909	5,427	25,547
913	828	26,581

TABLE 10.—GEOMETRIC MEAN PLUS THE LESSER OF .75 OF THE NATIONAL ADJUSTED OPERATING STANDARDIZED PAYMENT AMOUNT (INCREASED TO REFLECT THE DIFFERENCE BETWEEN COSTS AND CHARGES) OR .75 OF ONE STANDARD DEVIATION OF MEAN CHARGES BY MEDICARE SEVERITY-DIAGNOSIS-RELATED GROUP (MS DRG) OCTOBER 2007 ¹—Continued

MS-DRG	Number of cases	Threshold (\$)
914	7,082	15,123
915	928	24,288
916	5,418	9,886
917	14,498	28,189
918	35,052	13,329
919	10,672	28,054
920	14,259	20,512
921	9,672	13,742
922	1,027	26,694
923	4,264	14,600
927	187	176,359
928	819	59,807
929	448	32,905
933	158	31,820
934	701	23,903
935	2,209	21,647
939	428	42,892
940	732	32,945
941	1,058	25,659
945	5,485	19,140
946	2,759	16,452
947	6,597	22,649
948	34,624	14,331
949	767	17,139
950	463	11,233
951	1,008	13,228
955	456	82,569
956	3,769	54,324
957	1,324	98,399
958	1,221	65,730
959	295	44,733
963	1,509	46,426
964	2,538	32,437
965	1,105	23,186
969	676	74,072
970	159	41,796
974	6,358	38,864
975	4,516	27,898
976	2,770	20,952
977	5,016	23,376
981	26,444	75,197
982	19,320	52,409
983	6,143	37,918
984	671	56,061
985	1,108	38,816
986	833	27,982
987	8,040	53,190
988	12,302	35,697
989	6,162	25,762
999	30	11,270

¹ Cases taken from the FY 2006 MedPAR file; MS-DRGs are from GROUPER Version 25.0.

COMPARISON OF FY 2007 STANDARDIZED AMOUNTS TO THE FY 2008 SINGLE STANDARDIZED AMOUNT WITH FULL UPDATE AND REDUCED UPDATE

	Full update (3.3 percent); wage index is greater than 1.0000	Full update (3.3 percent); wage index is less than 1.0000	Reduced update (1.3 percent); wage index is greater than 1.0000	Reduced update (1.3 percent); wage index is less than 1.0000
FY 2007 Base Rate, after removing reclassification budget neutrality, demonstration budget neutrality, wage index transition budget neutrality factors and outlier offset (based on the labor and market share percentage for FY 2008).	Labor: \$3,609.23 Nonlabor: \$1,569.01 ...	Labor: \$3,210.51 Nonlabor: \$1,967.73 ...	Labor: \$3,609.23 Nonlabor: \$1,569.01 ...	Labor: \$3,210.51 Nonlabor: \$1,967.73.
FY 2008 Update Factor	1.033	1.033	1.013	1.013.
FY 2008 DRG Recalibrations and Wage Index Budget Neutrality Factor.	0.996383	0.996383	0.996383	0.996383.
FY 2008 Reclassification Budget Neutrality Factor.	0.991290	0.991290	0.991290	0.991290.
Adjusted for Blend of FY 2007 DRG Recalibration and Wage Index Budget Neutrality Factors.	Labor: \$3,682.49 Nonlabor: \$1,600.86 ...	Labor: \$3,275.68 Nonlabor: \$2,007.67 ...	Labor: \$3,611.20 Nonlabor: \$1,569.86 ...	Labor: \$3,212.26. Nonlabor: \$1,968.80.
Imputed Rural Floor Budget Neutrality Factor.	0.999265	0.999265	0.999265	0.999265.
FY 2008 Outlier Factor	0.948983	0.948983	0.948983	0.948983.
Rural Demonstration Budget Neutrality Factor.	0.999902	0.999902	0.999902	0.999902.
FY 2008 Documentation and Coding Adjustment.	0.994	0.994	0.994	0.994.
Rural Floor Adjustment	1.002214	1.002214	1.002214	1.002214.
Rate for FY 2008	Labor: \$3,478.45 Nonlabor: \$1,512.15 ...	Labor: \$3,094.17 Nonlabor: \$1,896.43 ...	Labor: \$3,411.10 Nonlabor: \$1,482.87 ...	Labor: \$3,034.26. Nonlabor: \$1,859.71.

XX. Medicare Graduate Medical Education Affiliation Provisions for Teaching Hospitals in Certain Emergency Situations

If you choose to comment on issues in this section, please include the caption "Medicare GME Affiliations" at the beginning of your comment.

A. Background

1. Legislative Authority

The stated purpose of section 1135 of the Act is to enable the Secretary to ensure, to the maximum extent feasible, in any emergency area and during an emergency period, that sufficient health care items and services are available to meet the needs of enrollees in Medicare, Medicaid, and the State Children's Health Insurance Program (SCHIP). Section 1135 of the Act authorizes the Secretary, to the extent necessary to accomplish the statutory purpose, to temporarily waive or modify the application of certain types of statutory and regulatory provisions (such as conditions of participation or other certification requirements, program participation or similar requirements, or preapproval requirements) with respect to health care items and services furnished by health care provider(s) in an emergency area during an emergency period.

The Secretary's authority under section 1135 of the Act arises in the

event there is an "emergency area" and continues during an "emergency period" as those terms are defined in the statute. Under section 1135(g) of the Act, an emergency area is a geographic area in which there exists an emergency or disaster that is declared by the President according to the National Emergencies Act or the Robert T. Stafford Disaster Relief and Emergency Assistance Act, and a public health emergency declared by the Secretary according to section 319 of the Public Health Service Act. (Section 319 of the Public Health Service Act authorizes the Secretary to declare a public health emergency and take the appropriate action to respond to the emergency, consistent with existing authorities.) Throughout the remainder of this discussion, we will refer to such emergency areas and emergency periods as "section 1135" emergency areas and emergency periods.

Under section 1886(h) of the Act, as amended by section 9202 of the Consolidated Omnibus Budget Reconciliation Act (COBRA) of 1985 (Public Law 99-272), the Secretary is authorized to make payments to hospitals for the direct costs of approved GME programs. Section 1886(d)(5)(B) of the Act provides for an additional payment per Medicare discharge for acute care hospitals paid under the inpatient prospective payment system (IPPS) that have

residents in an approved GME program. This additional payment is to reflect the higher patient care costs of teaching hospitals, that is, the indirect graduate medical education (IME) costs. Sections 1886(h)(4)(F) and 1886(d)(5)(B)(v) of the Act establish limits on the number of allopathic and osteopathic residents that hospitals may count for purposes of calculating direct GME payments and the IME adjustment, respectively, establishing hospital-specific direct GME and IME full-time equivalent (FTE) resident caps. Under the authority granted by section 1886(h)(4)(H)(ii) of the Act, the Secretary has issued rules to allow institutions that are members of the same affiliated group to apply their direct GME and IME FTE resident caps on an aggregate basis through a Medicare GME affiliation agreement. The Medicare regulations at §§ 413.75 and 413.79 permit hospitals, through a Medicare GME affiliation agreement, to adjust IME and direct GME FTE resident caps to reflect the rotation of residents among affiliated hospitals.

2. Existing Medicare Direct GME and Indirect GME Policies

The Medicare program makes payments to teaching hospitals to account for two types of costs, the direct costs (direct GME) and the indirect costs (IME) of a hospital's GME program. Direct GME payments represent the direct costs of training residents (for

example, resident salaries and fringe benefits, and teaching physician costs associated with an approved GME program) and generally are calculated by determining the product of the Medicare patient load (that is, the Medicare percentage of the hospital's inpatient days), the hospital's per resident payment amount, and the weighted number of FTE residents training at the hospital.

The IME adjustment is made to teaching hospitals for the additional indirect patient care costs attributable to teaching activities. For example, teaching hospitals typically offer more technologically advanced treatments to their patients, and therefore, patients who are sicker and need more sophisticated treatment are more likely to go to teaching hospitals. Furthermore, there are additional costs associated with teaching residents resulting from the additional tests or procedures ordered by residents and the demands put on physicians who supervise, and staff who support, the residents. IME payments are made as a percentage add-on adjustment to the per discharge IPPS payment, and are calculated based on the hospital's ratio of FTE residents to available beds as defined at § 412.105(b). The statutory formula for calculating the IME adjustment is: $c \times [(1 + r)^{405} - 1]$, where "r" represents the hospital's ratio of FTE residents to beds, and "c" represents an IME multiplier, which is set by the Congress.

The amount of IME payment a hospital receives for a particular discharge is dependent upon the number of FTE residents the hospital trains, the hospital's number of available beds, the current level of the statutory IME multiplier, and the otherwise payable per discharge IPPS payment. Sections 1886(d)(5)(B)(v) and 1886(h)(4)(F) of the Act established hospital-specific limits (that is, caps) on the number of allopathic and osteopathic FTE residents that hospitals may count for purposes of calculating indirect and direct GME payments, respectively.

3. Regulatory Changes Issued in 2006 To Address Certain Emergency Situations

As explained above, when Hurricane Katrina occurred on August 29, 2005, disrupting health care operations and medical residency training programs at teaching hospitals in New Orleans and the surrounding area, the conditions were met to establish an emergency area and emergency period under section 1135(g) of the Act. Shortly after Hurricane Katrina occurred, we were informed by hospitals in New Orleans that the training programs at many

teaching hospitals in the city were closed as a result of the disaster and that the displaced residents were being transferred to training programs at host hospitals in other parts of the country. For purposes of discussion in this rule, a host hospital is a hospital that trains residents displaced from a training program in a section 1135 emergency area. Also, a home hospital is one that meets all of the following: (1) Is located in a section 1135 emergency area (2) had its inpatient bed occupancy decreased by 20 percent or more due to the disaster so that it is unable to train the number of residents it originally intended to train in that academic year, and (3) needs to send the displaced residents to train at a host hospital.

Section 413.79(h) allows a hospital that closed, or that closed one or more of its residency training programs, to temporarily transfer FTE residents and part or all of its FTE resident caps to another hospital in order to allow the accepting hospital to count the displaced residents for direct GME and IME payment and to enable the displaced residents to complete their training despite closure of either the hospital or the residency training program in which they were originally training. In the aftermath of Hurricanes Katrina and Rita, the training programs at many teaching hospitals in New Orleans and surrounding areas were temporarily closed (or substantially reduced), and the displaced residents were even transferred to other hospitals in other parts of the country to continue their training programs. We initially suggested that hospitals whose GME programs were affected by Hurricanes Katrina and Rita could use these "closed hospital" and "closed program" regulations to address issues relating to displaced residents. (We refer readers to the CMS Q&A's Web site at: <http://questions.cms.hhs.gov>. The Web site link is located at ID 5696.)

While a number of the residents have since returned to the hurricane-affected hospitals, others remain displaced to other hospitals, including hospitals located in States outside of the section 1135 emergency area. In response to immediate concerns relating to displaced residents, CMS issued regulations on April 12, 2006 in an interim final rule with comment period published in the **Federal Register** (71 FR 18654). The regulatory changes in that rule allowed home and host hospitals under certain circumstances to form emergency Medicare GME affiliations. The purpose of these emergency Medicare GME affiliation rules was to permit Medicare GME support to be maintained while

displaced residents are training at various hospitals, even as the hurricane affected hospitals are rebuilding their training programs. The modifications to the regulations at § 413.75(b) and § 413.79(f) provided flexibility for home hospitals whose residency programs have been disrupted in an emergency area to enter into *emergency* Medicare GME affiliation agreements with host hospitals where the hospitals may not meet the regulatory requirements for regular Medicare GME affiliations. Due to the infrastructure damage and continued disruption of operations experienced by medical facilities, and the consequent disruption in residency training, caused by Hurricanes Katrina and Rita in 2005, there became an urgent need for these regulation changes to be applied retroactively.

Section 1871(e)(1)(A) of the Act, as amended by section 903(a)(1) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Public Law 108-173), generally prohibits the Secretary from making retroactive substantive changes in policy unless retroactive application of the change is necessary to comply with statutory requirements, or failure to apply the change retroactively would be contrary to the public interest. Because existing regulations did not adequately address the issues faced by hospitals that are located in the emergency areas, or hospitals that assisted by training displaced residents from the emergency area, and because we believed hospitals affected by Hurricanes Katrina and Rita would otherwise have faced dramatic financial hardship and the recovery of graduate medical education programs in the emergency area would have been impeded, we found that failure to apply the regulatory changes in the April 12, 2006, interim final rule retroactively would be contrary to the public interest. Thus, the provisions of this interim final rule were made effective retroactively as of August 29, 2005.

To provide regulatory relief, especially in situations not addressed under existing regulations (for example, where hospitals had initially closed, but were in the process of gradually reopening their programs, or where hospitals had severely reduced but never completely closed their programs after Hurricanes Katrina and Rita), we established the emergency Medicare GME affiliation provisions in the April 12, 2006 interim final rule with comment period. In summary, the April 12, 2006 interim final rule with comment period made changes as follows:

- To provide hospitals with more flexibility to train displaced residents at various sites, and to allow host hospitals to count displaced residents for IME and direct GME payment purposes, home hospitals were permitted to enter into emergency Medicare GME affiliation agreements effective retroactive to the date of the first day of the section 1135 emergency period.

- Home hospitals were permitted to affiliate with host hospitals anywhere in the country. That is, a host hospital may be located in any State and may receive a temporary adjustment to its FTE caps to reflect displaced residents added or subtracted because the hospital is participating in an emergency Medicare GME affiliated group as defined at § 413.75(b).

- Emergency Medicare GME affiliation agreements were required to be submitted to CMS with a copy to the CMS fiscal intermediary or Medicare administrative contractor (MAC) by the later of 180 days after the section 1135 emergency period begins or by July 1 of the academic year in which the emergency Medicare GME affiliation agreement is effective. However, for hospitals affected by Hurricanes Katrina and Rita, the deadline was subsequently extended to October 9, 2006. (We refer readers to the final rule published in the **Federal Register** on July 6, 2006, for a detailed discussion (71 FR 38264 through 38266).

- The effective period of the emergency Medicare GME affiliation agreement was permitted to begin on or after the first day of a section 1135 emergency period, and must terminate no later than at the conclusion of 2 academic years following the academic year during which the section 1135 emergency period began.

- During the effective period of the emergency Medicare GME affiliation agreement, hospitals in the emergency Medicare GME affiliated group were not required to participate in a shared rotational arrangement (as they would be under a regular Medicare GME affiliation agreement).

- Host hospitals were allowed an exception from the otherwise applicable rolling average resident count for FTE residents added as a result of an emergency Medicare GME affiliation agreement, but only during the period from August 29, 2005 to June 30, 2006.

For a detailed discussion on each of the above emergency Medicare GME affiliation provisions, we refer readers to the April 12, 2006 interim final rule with comment period. (71 FR 18654 through 18667).

In the April 12, 2006 interim final rule with comment period, we revised

the regulations at § 413.79(f) to provide for more flexibility than would have been possible under regular Medicare GME affiliations to allow home hospitals to efficiently find training sites for displaced residents. Under the flexibility provided by the emergency Medicare GME affiliated group provisions as specified at § 413.79(f)(6), decisions regarding the transfer of FTE resident cap slots, including how to distribute slots up to the home hospital's FTE resident caps in situations where the home hospital was training a number of residents in excess of its cap before the disaster, as well as the tracking of those FTE resident slots, was left to the home and host hospitals to work out among themselves. However, the home and host hospitals were required to include much of this information in their emergency Medicare GME affiliation agreements submitted both to CMS and the CMS contractor, as specified under § 413.79(f)(6). Furthermore, since hospitals were permitted to amend their emergency Medicare GME affiliation agreements (on or before June 30 of the relevant academic year) to reflect the actual training situation among the hospitals participating in the emergency Medicare GME affiliated group, hospitals were provided with a great degree of flexibility to accommodate any changing residency training circumstances within the emergency Medicare GME affiliated group. We note that the emergency Medicare GME affiliation provisions are intended for the purpose of enabling the continued training of residents displaced from a section 1135 emergency area, and *not* to enable hospitals to take advantage of the increased flexibility in order to shift FTE resident cap slots to other hospitals in the country (for instance, in order to maximize Medicare IME and direct GME payments).

We stated in the April 12, 2006 interim final rule with comment period that, in developing a policy to provide hospitals increased flexibility in response to a disaster, we intended to address two priorities. First, we believe that in disaster situations, to the extent that the statute permits, the policy should facilitate the continuity of GME, minimizing the disruption of residency training. Second, the policy should take into account that the training programs in the section 1135 emergency area have been severely disrupted by a disaster and that the hospitals affected by the disaster will usually want to rebuild their GME programs as soon as possible.

B. Additional Changes in This Interim Final Rule With Comment Period

1. Summary of Regulatory Changes

Since the establishment of the emergency provisions in the April 12, 2006 interim final rule with comment period, we have been monitoring the application of the emergency Medicare GME affiliation agreement rules in order to assess whether those regulatory changes were adequate to address the needs of hospitals located in the section 1135 emergency area in the aftermath of Hurricanes Katrina and Rita. We understand that hospitals with GME programs in the section 1135 area continue to find it necessary to adjust the location of resident training both within and outside the emergency area, as affected hospitals continue to reopen beds at different rates, and as feedback from accreditation surveys warrants educational adjustments. Furthermore, stakeholders in Louisiana have informed CMS that they believe fluidity in GME programs will continue for several more years, and are not likely to stabilize until permanent replacement facilities are established and functioning in the emergency area. As a result, we believe the provisions first established in the April 12, 2006 interim final rule need to be further modified to meet the two priorities stated earlier. Therefore, through this interim final rule with comment period, we are modifying the regulations for emergency Medicare GME affiliated groups at § 413.79(f)(6) to provide continuing relief to home and host hospitals affected by disruptions in residency programs in the section 1135 emergency area declared after Hurricanes Katrina and Rita, as well as to provide relief for similar challenges in any future emergency situation. We note that we did receive a number of comments on the interim final rule with comment period issued on April 12, 2006. However, we believe it would be beneficial to provide the public with the opportunity to submit formal comments on these latest changes in the context of the current training situation in the area affected by Hurricanes Katrina and Rita. We intend to respond to comments submitted on both this interim final rule with comment period and the April 12, 2006 interim final rule with comment period in a future final rule.

Under existing regulations, the emergency Medicare GME affiliation agreement must be written, signed, and dated by responsible representatives of each participating hospital and must: (1) List each participating hospital and its provider number, and specify whether the hospital is a home or host hospital; (2) specify the effective period of the

emergency Medicare GME affiliation agreement (which must, in any event, terminate at the conclusion of two academic years following the academic year in which the section 1135 emergency period began); (3) list each participating hospital's IME and direct GME FTE caps in effect for the current academic year before the emergency Medicare GME affiliation (that is, if the hospital was already a member of a regular Medicare GME affiliated group before entering into the emergency Medicare GME affiliation, the emergency Medicare GME affiliation must be premised on the FTE caps of the hospital as adjusted per the regular Medicare GME affiliation agreement, and not include any slots gained under section 422 of the MMA); and (4) specify the total adjustment to each hospital's FTE caps in each year that the emergency Medicare GME affiliation agreement is in effect, for both direct GME and IME, that reflects a positive adjustment to the host hospital's direct and indirect FTE caps that is offset by a negative adjustment to the home hospital's (or hospitals') direct and indirect FTE caps of at least the same amount. The sum total of all the participating hospitals' FTE caps under the emergency Medicare GME affiliation agreement may not exceed the aggregate adjusted caps of the hospitals participating in the emergency Medicare GME affiliated group. A home hospital's IME and direct GME FTE cap reduction under an emergency Medicare GME affiliation agreement is limited to the home hospital's IME and direct GME FTE resident caps in effect for the academic year, in accordance with regulations at § 413.79(c) or § 413.79(f)(1) through (f)(5), that is, the hospital's base year FTE resident caps as adjusted by any and all existing affiliation agreements in effect as of the first day of the section 1135 period. Finally, as we stated in the April 12, 2006 interim final rule with comment period, amendments to the emergency Medicare GME affiliation agreement to adjust the distribution of the FTE resident caps specified in the original emergency Medicare GME affiliation among the hospitals that are part of the emergency Medicare GME affiliated group in order to reflect the actual placement of residents can be made through June 30 of the academic year for which it is effective. [71 FR 18662]

In this interim final rule with comment period, we are further modifying the regulations at § 413.75(b) and § 413.79(f) to allow hospitals to enter into emergency Medicare GME affiliation agreements with the

following increased flexibility. First, for emergency Medicare GME affiliation agreements involving a host hospital located in a different State from the home hospital (hereinafter, an "out-of-State host hospital"), the permissible effective period for such agreements is extended from up to 3 years (i.e., the year in which the section 1135 emergency period began plus two subsequent academic years) to up to 5 years (i.e., the year in which the section 1135 emergency period began plus four subsequent academic years). However, emergency Medicare GME affiliation agreements involving out of State host hospitals during these two additional periods may only apply with respect to the actual residents that were displaced from training in a hospital located in the section 1135 emergency area. By "actual residents that were displaced from training in a hospital located in the section 1135 area," we mean residents in an approved medical residency training program at a home hospital at the time of the disaster that were either actually training at the home hospital or were scheduled to rotate to the home hospital during the training program. For emergency Medicare GME affiliation agreements involving a host hospital located in the same State as the home hospital (hereinafter, an "in-State host hospital"), the permissible effective period for such agreements is extended from up to 3 years to up to 5 years for any resident (even those not displaced from training in a hospital located in the 1135 emergency area). Emergency Medicare GME affiliation agreements involving in-State host hospitals during these additional two academic years need not apply only with respect to the actual residents that were displaced immediately following the disaster. In other words, such agreements may apply with respect to residents that were actually displaced as a result of the disaster, as well as to new residents that were not training in the program at the time the disaster occurred. With the 2-year extension described above, the effective period of an emergency Medicare GME affiliation agreement may begin with the first day of a section 1135 emergency period, and must terminate no later than at the end of the fourth academic year following the academic year during which the section 1135 emergency period began (for Hurricanes Katrina and Rita, this would be June 30, 2010). As home hospitals recover the ability to train residents after a disaster, the effective period for emergency Medicare GME affiliation agreements is intended to allow home hospitals to balance their desire to

return residents to their original training sites, with their need to be given the opportunity to rebuild their programs incrementally. We believe extending the applicability of emergency affiliations for out of State host hospitals for 2 years (for a total of up to 5 years) only for the actual residents displaced from home hospitals allows such displaced residents to complete their training outside the affected area while providing an incentive for home hospitals to begin training new incoming residents locally (or closer to the home hospital), increasing the likelihood for the residents to stay and practice in the area after their training is completed. Affected hospitals in the New Orleans area have informed CMS that residents will tend to go into practice where they train. We believe this makes intuitive sense and the policy established in this interim final rule with comment period will provide additional impetus for residents to return to the State where their "home hospital" is located, increasing the odds that the physicians will stay and practice there, and encouraging regeneration of the health care system affected by the section 1135 emergency. We note that this is consistent with needs expressed by affected hospitals in the New Orleans area for more physicians to replace the large numbers that left immediately after the hurricane. Furthermore, after the expiration of the initial 3 years of the emergency Medicare GME affiliation agreement effective period, we believe it would be appropriate to begin bringing emergency Medicare GME affiliation rules into accord with regular Medicare GME affiliation rules which specify geographical limits. That is, regular Medicare GME affiliation rules limit hospitals geographically to affiliations with other hospitals that are located in the same urban or rural area (as those terms are defined under § 412.62(f)) or in a contiguous area.

In addition, home or host hospitals that have emergency Medicare GME affiliation agreements and are training displaced residents in nonhospital sites are permitted to submit written agreements with nonhospital sites, as described under § 413.78, that may be effective beginning with the first day of the section 1135 emergency period to cover the displaced residents training at nonhospital sites. We discuss the policy for training that occurs in the nonhospital setting and the requirements for written agreements in further detail in the following section. However, in brief, this interim final rule with comment period provides hospitals

that are participating in emergency Medicare GME affiliation agreements with increased flexibility in submitting written agreements relating to training that occurs in nonhospital sites. Home or host hospitals with valid emergency Medicare GME affiliation agreements training displaced residents in a nonhospital site may submit a copy of the written agreement, as specified under § 413.78(e)(iii) and (f)(iii) as applicable, to the CMS contractor servicing the hospital by 180 days after the first day the resident began training at the nonhospital site. We note that, as with the existing rules for written agreements specified at § 413.78(f), adjustments to the amounts specified (in other words, the total program costs and the portion of certain costs to be incurred by the hospital) in the written agreement can be made through June 30 of the academic year for which it is effective.

Furthermore, under current rules, hospitals that are training residents at nonhospital sites have two options as specified by the regulations at § 413.78(e). That is, hospitals must either have a written agreement in place before the training occurs or they must pay “all or substantially all” of the costs for the training program in the nonhospital setting attributable to training that occurs during a month by the end of the third month following the month in which the training in the nonhospital site occurred. We discuss this “concurrent payment” option in more detail in the following section. In this interim final rule with comment period, we are providing additional flexibility in the “concurrent payment” option for home or host hospitals that have emergency Medicare GME affiliation agreements and are training displaced residents in nonhospital sites by extending the time allowable for “concurrent payment” from 3 months to 6 months. That is, a home or host hospital with a valid emergency Medicare GME affiliation agreement is permitted to incur “all or substantially all” of the costs for the training program in the nonhospital setting attributable to training that occurs during a month by the end of the sixth month following the month in which the training in the nonhospital site occurred.

In the case of the section 1135 emergency resulting from Hurricanes Katrina and Rita, the time limit we are adopting to submit written agreements or to meet the “concurrent payment” requirement may have already passed. Therefore, as discussed in detail in the following section, we are providing that, for residents training in nonhospital sites during the period of August 29,

2005, to November 1, 2007, home or host hospitals with valid emergency Medicare GME affiliation agreements may submit written agreements or incur “all or substantially all” of the costs of the training program (that is, the “concurrent payment” option) to cover those specific residents by April 29, 2008.

Based on what we have learned about the impact of a disaster on teaching hospitals, we continue to believe it is necessary to provide hospitals with greater flexibility to distribute FTE resident caps within a group of home and host hospitals if there is an emergency at a home hospital resulting in the designation of a section 1135 emergency area. We believe that this modified emergency Medicare GME affiliation policy will allow affected hospitals an appropriate degree of flexibility following the disaster so that residents displaced by the disaster can continue their residency training at other hospitals, while the home hospitals can remain committed to reopening their programs.

Emergency Medicare GME affiliation agreements should be submitted to: Centers for Medicare & Medicaid Services, Division of Acute Care, Attention: Elizabeth Truong or Renate Rockwell, Mailstop C4-08-06, 7500 Security Boulevard, Baltimore, MD 21244.

“Emergency Medicare GME Affiliation Agreement” should be clearly labeled on the outside envelope.

2. Discussion of Training in Nonhospital Settings

Under the existing regulations at § 413.78(e) and (f), for portions of cost reporting periods occurring on or after October 1, 2004, the time residents spend in nonhospital settings such as freestanding clinics, nursing homes, and physicians’ offices in connection with approved programs may be included in determining the hospital’s number of FTE residents for purposes of calculating both direct GME and IME payments, if all of the following conditions are met:

(1) The resident spends his or her time in patient care activities.

(2) The hospital incurs “all or substantially all” of the costs for the training program in the nonhospital setting. In the May 11, 2007 final rule (72 FR 26948), we revised the definition of “all or substantially all of the costs for the training program in the nonhospital setting” to mean: (a) Effective on or after January 1, 1999 and for cost reporting periods beginning before July 1, 2007, the residents’ salaries and fringe benefits (including

travel and lodging where applicable) and the portion of the cost of teaching physicians’ salaries and fringe benefits attributable to direct graduate medical education (GME); and (b) effective for cost reporting periods beginning on or after July 1, 2007, at least 90 percent of the total of the costs of the residents’ salaries and fringe benefits (including travel and lodging where applicable) and the portion of the cost of teaching physicians’ salaries attributable to non-patient care direct GME activities.

(3) There is a written agreement between the hospital and the nonhospital site that indicates that the hospital will incur the costs of the resident’s salary and fringe benefits while the resident is training in the nonhospital site, and the hospital is providing reasonable compensation to the nonhospital site for supervisory teaching activities. The agreement must indicate the compensation the hospital is providing to the nonhospital site for supervisory teaching activities. In addition, in the same May 11, 2007 final rule cited above, we clarified the regulations at § 413.78(f)(3)(ii) to specify that the written agreement must be in place between the hospital and the nonhospital site before the training begins in that nonhospital site. We also specified that the written agreement must specify the total cost of the training program in the nonhospital site, the amount of the total cost that the hospital will incur (at least 90 percent of the total cost of the training program), and must indicate the portion of the amount the hospital will incur that reflects residents’ salaries and fringe benefits (and travel and lodging where applicable), and the portion of the amount the hospital will incur that reflects teaching physician compensation. Furthermore, we revised the regulations to indicate that the amounts specified in the written agreement may be modified by June 30 of the applicable academic year.

(4) Alternatively, for portions of cost reporting periods occurring on or after October 1, 2004, hospitals have two options as specified by the regulations at § 413.78(e). Hospitals must either have a written agreement in place before the training occurs or they must incur “all or substantially all” of the costs for the training program in the nonhospital setting attributable to training that occurs during a month by the end of the third month following the month in which the training in the nonhospital site occurred (the “concurrent payment” option).

For a more detailed discussion on the requirements a hospital must meet in order to count residents training in

nonhospital sites for IME and direct GME payment purposes, we refer readers to the May 11, 2007 final rule (72 FR 26948 through 26977).

Recently, it has come to our attention that in the wake of Hurricanes Katrina and Rita, host hospitals, many of which received large numbers of displaced residents, were hard-pressed to find training sites for these unanticipated residents. Many host hospitals called upon community physician practices, clinics, and other nonhospital settings to supplement existing training locations and accommodate the displaced residents. Some of the host hospitals that took in displaced residents had never before had any residency training programs, and were therefore new to Medicare rules regarding graduate medical education. In the haste and confusion surrounding this unprecedented displacement of residents, many host hospitals arranged for displaced residents to begin training in nonhospital sites without first establishing a written agreement, as specified in § 413.78(e), between the hospital and nonhospital site. Similarly, home hospitals that may have sent some of their residents away to train at host hospitals while continuing to train a reduced number of residents in the home hospital program, may find that the usual nonhospital sites for the residents in that program have also been negatively affected by the disaster. Consequently, home hospitals may have hastily arranged for displaced residents to begin training in nonhospital sites and due to the reduced administrative capability in the aftermath of the disaster, home hospitals may not have been able to establish a written agreement, as specified in § 413.78(e), with the nonhospital site before residents started training in the nonhospital site. Also, in the confusion and haste under which arrangements were made for displaced residents to train in nonhospital sites, many hospitals did not actually incur all or substantially all of the costs of the training program in the nonhospital site in accordance with our regulations at § 413.78(e)(3)(i) or (f)(3)(i).

In the April 12, 2006 interim final rule with comment period, we did not specifically mention the policies that pertain to training in nonhospital sites, although we did indicate that, to determine direct GME and IME payments under an emergency Medicare GME affiliation, all of the normal rules for counting FTEs as specified at § 413.78 apply. Based on what we have learned since the occurrence of Hurricanes Katrina and Rita, we believe it would be appropriate to provide home

hospitals that have been adversely affected by the disaster and host hospitals that accept residents pursuant to an emergency Medicare GME affiliation agreement greater flexibility in the timeframes for compliance with our nonhospital site policies. Consequently, we are providing additional flexibility in regards to the submission of written agreements by home and host hospitals by specifying in this interim final rule with comment period that home or host hospitals with a valid emergency Medicare GME affiliation agreement may submit the written agreement required under our regulations even after the residents have begun training at the nonhospital site. The submission deadline for written agreements after a disaster is subject to the following requirements: (1) A home or host hospital must be participating in a valid emergency Medicare GME affiliation and (2) a home or host hospital training displaced residents in a nonhospital site must submit a copy of the written agreement, subject to the requirements of a written agreement as specified under § 413.78 (e)(iii) or (f)(iii) as applicable, to the CMS fiscal intermediary or MAC servicing the hospital by 180 days after the first day the resident began training at the nonhospital site. We are also specifying that amendments to the written agreement can be made through June 30 of the academic year for which it is effective.

Furthermore, as we discussed above, under current rules hospitals that are training residents at nonhospital sites have the option of paying “all or substantially all” of the costs for the training program in the nonhospital setting attributable to training that occurs during a month by the end of the third month following the month in which the training in the nonhospital site occurred. For the same reasons cited above supporting our belief that it is appropriate to extend the deadline to submit written agreements after a disaster, we are also providing additional flexibility in the “concurrent payment” option for home or host hospitals that have emergency Medicare GME affiliation agreements and are training displaced residents in nonhospital sites by extending the time allowable for “concurrent payment” from 3 months to 6 months. That is, a home or host hospital with a valid emergency Medicare GME affiliation agreement is permitted to pay “all or substantially all” of the costs for the training program in the nonhospital setting attributable to training that occurs during a month by the end of the

sixth month following the month in which the training in the nonhospital site occurred.

In the case of Hurricanes Katrina and Rita, the time limits we are adopting regarding the submission of written agreements to cover residents training in nonhospital sites for home or host hospitals with a valid emergency Medicare GME affiliation agreement may have already passed. Therefore, we are providing that a home or host hospital with valid emergency Medicare GME affiliation agreements may submit written agreements to cover residents training in nonhospital sites during the period of August 29, 2005, to November 1, 2007, by April 29, 2008. Similarly, for residents training in nonhospital sites during the period of August 29, 2005, to November 1, 2007, home or host hospitals with valid emergency Medicare GME affiliation agreements may pay “all or substantially all” of the costs of the training program (i.e., the “concurrent payment” option) to cover those specific residents by April 29, 2008.

C. Response to Comments on the April 12, 2006 Interim Final Rule With Comment Period and This Interim Final Rule With Comment Period

We note that we did receive a number of comments on the interim final rule with comment issued on April 12, 2006. We believe it would be beneficial to provide the public with the opportunity to submit formal comments on the latest changes in this interim final rule with comment period in the context of the current training situation in the area affected by Hurricanes Katrina and Rita. We intend to respond to comments submitted on both this interim final rule with comment period (to be submitted as specified in the **ADDRESSES** section of this document) and the April 12, 2006 interim final rule with comment period in a future final rule.

XXI. Files Available to the Public Via the Internet

A. Information in Addenda Related to the Revised CY 2008 Hospital OPPS

Addenda A and B to this final rule with comment period provide various data pertaining to the CY 2008 payment for items and services under the OPPS. Addendum A, which includes a complete list of all APCs payable under the OPPS, and Addendum B, which includes a complete list of all active HCPCS codes for CY 2008 and all currently active HCPCS codes that will be discontinued at the end of CY 2007 with assigned payment status and comment indicators, are available to the

public by clicking "Addendum A and Addendum B Updates" on the CMS Web site at: <http://www.cms.hhs.gov/HospitalOutpatientPPS/>.

For the convenience of the public, we are also including on the CMS Web site a table that displays the HCPCS data in Addendum B sorted by APC assignment, identified as Addendum C.

Addendum D1 defines payment status indicators that are used in Addenda A and B. Addendum D2 defines comment indicators that are used in Addendum B. Addendum E lists HCPCS codes that are only payable as inpatient procedures and are not payable under the OPSS. Addendum L contains the out-migration wage adjustment for CY 2008.

Addendum M lists the HCPCS codes that are members of a composite APC and identifies the composite APC to which they are assigned. This addendum also identifies the status indicator for the code and a comment indicator if there has been a change in the code's status with regard to its membership in the composite APC. Each of the HCPCS codes included in Addendum M has a single procedure payment APC, listed in Addendum B, to which it is assigned when the criteria for assignment to the composite APC are not met. When the criteria for payment of the code through the composite APC are met, one unit of the composite APC payment is paid, thereby providing packaged payment for all services that are assigned to the composite APC according to the specific Outpatient Code Editor (OCE) logic that applies to the APC. We refer readers to the discussion of composite APCs in section II.A.4.d of this final rule with comment period for a complete description of the composite APCs.

Those addenda and other supporting OPSS data files are available on the CMS Web site at: <http://www.cms.hhs.gov/HospitalOutpatientPPS/>.

B. Information in Addenda Related to the Revised CY 2008 ASC Payment System

Addenda AA, BB, DD1, and DD2 to this final rule with comment period provide various data pertaining to the ASC covered surgical procedures and the covered ancillary services for which ASCs may receive separate payment beginning in CY 2008 when the ancillary service provided in the ASC is integral to a covered surgical procedure and provided immediately before, during, or immediately following the covered surgical procedure. All relative payment weights and payment rates are final for CY 2008 as a result of applying the revised ASC payment system

methodology established in the final rule for the revised ASC payment system published in the **Federal Register** on August 2, 2007 (72 FR 42470) to the final CY 2008 OPSS and MPFS ratesetting information.

Addendum DD1 defines the payment indicators that are used in Addenda AA and BB to this final rule with comment period. Addenda AA and BB provide payment information regarding covered surgical procedures and covered ancillary services under the revised ASC payment system. Addendum DD2 defines the comment indicators that we are using to provide additional information about the status of ASC covered surgical procedures and covered ancillary services.

Addendum EE (available only on the Internet) lists the surgical procedures that are excluded from Medicare payment in ASCs. The excluded procedures listed in Addendum EE are surgical procedures that either are assigned to the OPSS inpatient list, are not covered by Medicare, are reported using a CPT unlisted code, or are determined to pose a significant safety risk or are expected to require an overnight stay when performed in ASCs.

Those addenda and other supporting ASC data files are included on the CMS Web site at: <http://www.cms.hhs.gov/ASCPayment/> in a format that can be easily downloaded and manipulated. The final ASC relative weights and payment rates for CY 2008 are published in this CY 2008 OPSS/ASC final rule with comment period, and related data files are included on the CMS Web site as noted above. MPFS data files are located at <http://www.cms.hhs.gov/PhysicianFeeSched/>.

The links to all of the FY 2008 IPSS wage index related tables (that are used for the CY 2008 OPSS) from the FY 2008 IPSS final rule with comment period (72 FR 47436 through 47539) as corrected in the October 10, 2007 **Federal Register** notice to the FY 2008 IPSS final rule with comment period (72 FR 57634 through 57738) are accessible on the CMS Web site at: <http://www.cms.hhs.gov/AcuteInpatientPPS/WIFN/list.asp#TopOfPage>.

For additional assistance, contact Chuck Braver, (410) 786-6719.

XXII. Collection of Information Requirements

Under the Paperwork Reduction Act of 1995, we are required to provide 30-day notice in the **Federal Register** and solicit public comment when a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate

whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 (PRA) requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

In the CY 2008 OPSS/ASC proposed rule, we solicited public comment on each of these issues for the following sections included in the proposed rule that contain information collection requirements.

Section 419.43(h) Adjustment to national program payment and beneficiary copayment amounts: Applicable adjustments to conversion factor for CY 2009 and for subsequent calendar years

Section 419.43(h) requires hospitals, in order to qualify for the full annual update, to submit quality data to CMS, as specified by CMS. In the proposed rule, we proposed the specific requirements related to the data that must be submitted for the update for CY 2009. The burden associated with this section is the time and effort associated with collecting and submitting the data, completing participating forms and submitting charts. We estimate that there will be approximately 3,500 respondents per year.

For hospitals to collect and submit the information on the required measures, we estimate it will take 30 minutes per sampled case. Further, based on an estimated ten percent sample size and estimated populations of 2.5-5 million outpatient visits per measure, we estimate a total of 1,800,000 cases per year. In addition, we estimate that completing participation forms with require approximately 4 hours per hospital per year. We expect the burden for all of these hospitals to total 914,000 hours per year.

In this final rule with comment period, for CY 2009, we have delayed implementation of our validation process which will require participating hospitals to submit 5 charts. The burden associated with this requirement is the time and effort associated with collecting, copying, and submitting these charts. It will take approximately 2 hours per hospital to submit the 5 charts. There will be a total of approximately 17,500 charts (3,500

hospitals × 5 charts per hospital) submitted by the hospitals to CMS for a total burden of 7,000 hours. However, as noted above, this validation process will not apply for the CY 2009 update. Therefore, we expect the total burden for all hospitals for the CY 2009 updates to be 921,000 hours per year.

In section XVII.J. of this final rule with comment period, we are finalizing a provision from the FY 2008 IPPS final rule with comment period relating to the FY 2009 RHQDAPU quality measure set to include SCIP Infection 4: Cardiac Surgery Patients with Controlled 6AM Postoperative Serum Glucose and SCIP Infection 6: Surgery Patients with Appropriate Hair Removal, bringing the total number of measures in that measure set to 30.) The burden associated with the collection of these two measures was included in the burden estimates in the FY 2008 IPPS final rule with comment period (72 FR 47409 and 48169). There is no additional burden imposed in this final rule with comment period.

Section 482.22 Condition of participation: Medical staff

We proposed under § 482.22(c)(5)(i) to require that a medical history and physical examination be completed and documented no more than 30 days before or 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia services, for each patient by a physician (as defined in section 1861(r) of the Act), an oromaxillofacial surgeon, or other qualified licensed individual in accordance with State law and hospital policy.

The burden associated with this requirement is the time and effort it would take for medical staff to document the patient's medical history and the results of a physical examination. While the burden associated with this proposed requirement is subject to the PRA, we believe the burden is exempt as defined in 5 CFR 1320.3(b)(2) because the time, effort, and financial resources necessary to comply with the requirement would be incurred by persons in the normal course of their activities.

We proposed under § 482.22(c)(5)(ii) to require that an updated examination of the patient, including any changes in the patient's condition, be completed and documented within 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia services, when the medical history and physical examination are completed within 30 days before admission or registration. The updated examination must also be completed

and documented by the individuals as required under § 482.22(c)(5)(i).

The burden associated with this proposed requirement is the time and effort it would take for medical staff to document any changes in the patient's condition. While the burden associated with this proposed requirement is subject to the PRA, we believe the burden is exempt as defined in 5 CFR 1320.3(b)(2) because the time, effort, and financial resources necessary to comply with the requirement would be incurred by persons in the normal course of their activities.

Section 482.24 Condition of participation: Medical record services

We proposed under § 482.24(c)(2)(i) to require evidence of:

(A) A medical history and physical examination completed and documented no more than 30 days before or 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia services. The medical history and physical examination must be placed in the patient's medical record within 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia.

(B) An updated examination of the patient, including any changes in the patient's condition, when the medical history and physical examination are completed within 30 days before admission or registration. Documentation of the updated examination must be placed in the patient's medical record within 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia services.

While the burden associated with these two proposed requirements is subject to the PRA, we believe the burden is exempt as defined in 5 CFR 1320.3(b)(2) because the time, effort, and financial resources necessary to comply with the requirement would be incurred by persons in the normal course of their activities.

Section 482.51 Condition of participation: Surgical services

We proposed under § 482.51(b)(1) to require medical staff, prior to surgery or a procedure requiring anesthesia services, and except in the case of emergencies, to document no more than 30 days before or 24 hours after admission or registration a patient's medical history, the results of the patient's physical examination, and any changes in the patient's condition.

While the burden associated with these requirements is subject to the PRA, we believe the burden is exempt as defined in 5 CFR 1320.3(b)(2) because the time, effort, and financial resources

necessary to comply with the requirement would be incurred by persons in the normal course of their activities.

Section 482.52 Condition of participation: Anesthesia services

We proposed under § 482.52(b)(1) to require a preanesthesia evaluation to be completed and documented by an individual qualified to administer anesthesia, performed within 48 hours prior to surgery or a procedure requiring anesthesia services. We proposed under § 482.52(b)(3) to require a postanesthesia evaluation to be completed and documented by an individual qualified to administer anesthesia, after surgery or a procedure requiring anesthesia services, but before discharge or transfer from the postanesthesia recovery area.

As discussed in section XVIII.B.2. of this final rule with comment period, in response to public comments, we have revised § 482.52(b)(3) to specify that a postanesthesia evaluation must be completed and documented no later than 48 hours after surgery or a procedure requiring anesthesia services. The postanesthesia evaluation must be completed in accordance with State law and with hospital policies and procedures that are approved by the medical staff and that reflect current standards of anesthesia care.

While the burden associated with these requirements is subject to the PRA, we believe the burden is exempt as defined in 5 CFR 1320.3(b)(2) because the time, effort, and financial resources necessary to comply with the requirement would be incurred by persons in the normal course of their activities.

In section XX. of this document, we are specifying the requirement for the submittal of emergency Medicare GME affiliation agreements under the provisions of § 413.79(f) of the regulations by hospitals in declared emergency areas. The burden associated with this requirement is the time and effort it would take for the GME affiliated hospital to develop and submit the emergency Medicare GME affiliation agreement. It is difficult for us to determine estimated annual burden because we do not know how many hospitals will be affected in any given disaster. It would depend on what resources are available to the affected hospitals after sustaining damage from the disaster. This could take a few hours per hospital or much longer depending on if they keep records available and current. Hospitals also have to coordinate with other hospitals to draw up an affiliation agreement which may

take more time if the hospitals have to negotiate.

We have submitted a copy of this final rule with comment period and this interim final rule with comment period to OMB for its review of the information collection requirements described above. These requirements are not effective until they have been approved by OMB.

If you comment on these information collection and recordkeeping requirements, please mail copies directly to the following:

Centers for Medicare & Medicaid Services, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, Attn: Melissa Musotto, (CMS-1392-FC for OPPTS/ASC matters, or CMS-1531-IFC2, for Medicare GME Affiliation Agreement matters) Room C4-26-05, 7500 Security Boulevard, Baltimore, MD 21244-1850; and Office of Information and Regulatory Affairs, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503, Attn: Carolyn Lovett, CMS Desk Officer, CMS-1392-FC for OPPTS/ASC matters, or CMS-1531-IFC2, for Medicare GME Affiliation Agreement matters *carolyn_lovett@omb.eop.gov*. Fax (202) 395-6974.

XXIII. Response to Comments

Because of the large number of public comments we normally receive on **Federal Register** documents, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the **DATES** section of this final rule with comment period, and, when we proceed with a subsequent document(s), we will respond to those comments in the preamble to that document(s).

XXIV. Regulatory Impact Analysis

A. Overall Impact

We have examined the impacts of this final rule with comment period as required by Executive Order 12866 (September 1993, Regulatory Planning and Review), the Regulatory Flexibility Act (RFA) (September 19, 1980, Public Law 96-354), section 1102(b) of the Social Security Act, the Unfunded Mandates Reform Act of 1995 (Public Law 104-4), and Executive Order 13132.

1. Executive Order 12866

Executive Order 12866 (as amended by Executive Order 13258, which merely reassigns responsibility of duties) directs agencies to assess all costs and benefits of available regulatory

alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). A regulatory impact analysis (RIA) must be prepared for major rules with economically significant effects (\$100 million or more in any 1 year).

We estimate that the effects of the OPPTS provisions that would be implemented by this final rule with comment period will result in expenditures exceeding \$100 million in any 1 year. We estimate the total increase (from changes in this final rule with comment period as well as enrollment, utilization, and case-mix changes) in expenditures under the OPPTS for CY 2008 compared to CY 2007 to be approximately \$3.4 billion.

We estimate that implementing the revised ASC payment system in CY 2008 based on the August 2, 2007 final rule for the revised ASC payment system and the final policies in this CY 2008 OPPTS/ASC final rule with comment period (such as adding 11 procedures to the ASC list of covered surgical procedures and designating 18 additional procedures as office-based) will have no net effect on Medicare expenditures in CY 2008 compared to the level of expenditures that would have occurred in CY 2008 in the absence of the revised payment system. A more detailed discussion of the effects of the changes to the ASC list of covered surgical procedures and the effects of the revisions to the ASC payment system in CY 2008 is provided in section XXIV.C. of this final rule with comment period.

While we estimate that there will be no net change in Medicare expenditures in CY 2008 as a result of implementing the revised ASC payment system and the ASC provisions of this final rule with comment period, we estimate that the revised system will result in savings of \$220 million over 5 years due to migration of new ASC covered surgical procedures from HOPDs and physicians' offices to ASCs over time. In addition, we note that there will be a total increase in Medicare payments to ASCs of approximately \$240 million for CY 2008 compared to Medicare expenditures that would have occurred in the absence of the revised payment system. These additional payments to ASCs of approximately \$240 million in CY 2008 will be fully offset by savings from reduced Medicare spending in HOPDs and physicians' offices on services that migrate from these settings to ASCs, as described in detail in

section XVI.L. of this final rule with comment period.

Our estimate in this final rule with comment period of 5-year savings as a result of the revised ASC payment system and our estimate of additional payments to ASCs in CY 2008 differ slightly from the estimates presented in the August 2, 2007 revised ASC payment system final rule. The ASC budget neutrality adjustment and the resulting savings estimates in the August 2, 2007 final rule are calculated using CY 2005 utilization data, the current CY 2007 OPPTS relative weights with an estimated update factor for CY 2008, and the CY 2007 MPFS PE RVUs trended forward to CY 2008. The ASC budget neutrality adjustment and the resulting savings estimates in this final rule with comment period are calculated using the newly available CY 2006 utilization data, the CY 2008 OPPTS relative payment weights finalized in this final rule with comment period, and the CY 2008 MPFS PE RVUs finalized in the CY 2008 MPFS final rule. As we indicated in the August 2, 2007 revised ASC payment system final rule, the estimates in that rule were meant to be illustrative of the final policies only, in large part because we used the existing CY 2007 OPPTS relative payment weights and the existing CY 2007 MPFS PE RVUs to estimate the CY 2008 values. Because the savings estimates in this final rule with comment period are based on the final CY 2008 OPPTS relative payment weights that have just become available in this final rule with comment period and the final CY 2008 MPFS PE RVUs that recently became available in the CY 2008 MPFS final rule with comment period, the estimates in this final rule with comment period based on that newly available information represent our best estimates at this time.

This final rule with comment period is an economically significant rule under Executive Order 12866, and a major rule under 5 U.S.C. 804(2).

2. Regulatory Flexibility Act (RFA)

The RFA requires agencies to determine whether a rule would have a significant economic impact on a substantial number of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small governmental jurisdictions. Most hospitals and most other providers and suppliers are small entities, either by nonprofit status or by having average annual revenues of \$31 million or less.

For purposes of the RFA, we have determined that approximately 37 percent of hospitals and 73 percent of

ASCs would be considered small entities according to the Small Business Administration (SBA) size standards. (We refer readers to the standards at the Web site: http://www.sba.gov/idc/groups/public/documents/serv_sstd_tablepdf.pdf). Individuals and States are not included in the definition of a small entity.

Not-for-profit organizations are also considered to be small entities under the RFA. There are 2,141 voluntary hospitals that we consider to be not for-profit organizations to which this final rule with comment period applies.

3. Small Rural Hospitals

In addition, section 1102(b) of the Act requires us to prepare a regulatory impact analysis if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 604 of the RFA. With the exception of hospitals located in certain New England counties, for purposes of section 1102(b) of the Act, we previously defined a small rural hospital as a hospital with fewer than 100 beds that is located outside of a Metropolitan Statistical Area (MSA) (or New England County Metropolitan Area (NECMA)). However, under the new labor market definitions that we adopted in the CY 2005 final rule with comment period (consistent with the FY 2005 IPPS final rule), we no longer employ NECMAs to define urban areas in New England. Therefore, we now define a small rural hospital as a hospital with fewer than 100 beds that is located outside of an MSA. Section 601(g) of the Social Security Amendments of 1983 (Public Law 98–21) designated hospitals in certain New England counties as belonging to the adjacent NECMA. Thus, for purposes of the OPSS, we classify these hospitals as urban hospitals. We believe that the changes to the OPSS in this final rule with comment period will affect both a substantial number of rural hospitals as well as other classes of hospitals and that the effects on some may be significant. The changes to the ASC payment system for CY 2008 will have no effect on small rural hospitals. Therefore, we conclude that this final rule with comment period will have a significant impact on a substantial number of small rural hospitals.

4. Unfunded Mandates

Section 202 of the Unfunded Mandates Reform Act of 1995 (Public Law 104–4) also requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of \$100

million in 1995 dollars, updated annually for inflation. That threshold level is currently approximately \$120 million. This final rule with comment period does not mandate any requirements for State, local, or tribal government, nor does it affect private sector costs.

5. Federalism

Executive Order 13132 establishes certain requirements that an agency must meet when it publishes any rule (proposed or final) that imposes substantial direct costs on State and local governments, preempts State law, or otherwise has Federalism implications.

We have examined this final rule with comment period in accordance with Executive Order 13132, Federalism, and have determined that it will not have an impact on the rights, roles, and responsibilities of State, local or tribal governments. As reflected in Table 61, we estimate that OPSS payments to governmental hospitals (including State and local governmental hospitals) will increase by 3.9 percent under this final rule with comment period. The provisions related to payments to ASCs in CY 2008 will not affect payments to government hospitals.

B. Effects of OPSS Changes in This Final Rule With Comment Period

We are making several changes to the OPSS that are required by the statute. We are required under section 1833(t)(3)(C)(ii) of the Act to update annually the conversion factor used to determine the APC payment rates. We are also required under section 1833(t)(9)(A) of the Act to revise, not less often than annually, the wage index and other adjustments. In addition, we must review the clinical integrity of payment groups and weights at least annually. Accordingly, in this final rule with comment period, we are updating the conversion factor and the wage index adjustment for hospital outpatient services furnished beginning January 1, 2008, as we discuss in sections II.C. and II.D., respectively, of this final rule with comment period. We also are revising the relative APC payment weights using claims data from January 1, 2006, through December 31, 2006, and updated cost report information. In response to a provision in Public Law 108–173 that we analyze the cost of outpatient services in rural hospitals relative to urban hospitals, we are continuing increased payments to rural SCHs, including EACHs. Section II.F. of this final rule with comment period provides greater detail on this rural adjustment. Finally, we are removing

one device category, HCPCS code C1820 (Generator, neurostimulator, (implantable), with rechargeable battery and charging system), from pass through payment status in CY 2008.

Under this final rule with comment period, the update change to the conversion factor as provided by statute will increase total OPSS payments by 3.3 percent in CY 2008. The one time wage reclassification under section 508 expired September 30, 2007, and therefore, is not contemplated in this final rule with comment period. The changes to the APC weights, including the changes that will result from the expansion of packaging, changes to the wage indices, and the continuation of a payment adjustment for rural SCHs and EACHs with extension to brachytherapy sources in CY 2008 will not increase OPSS payments because these changes to the OPSS are budget neutral. However, these updates do change the distribution of payments within the budget neutral system as shown in Table 61 and described in more detail in this section.

1. Alternatives Considered

Alternatives to the changes we are making and the reasons that we have chosen the options are discussed throughout this final rule with comment period. Some of the major issues discussed in this final rule with comment period and the options considered are discussed below.

a. Alternatives Considered for the Packaging Policies for CY 2008 OPSS

In section II.A.4.c. of this final rule with comment period, we are packaging payment for the following seven categories of ancillary and supportive services into payment for the independent service with which they are billed. We are also making payment for several composite APCs in which a single payment is made for multiple major services that are commonly performed on the same date. We discuss below each category of services that we are packaging and each set of services for which we are establishing a composite APC.

(1) Guidance Services

We are packaging payment for supportive guidance services into the payment for the independent procedure to which the guidance service is ancillary and supportive. In the case of one particular guidance procedure, which would usually be provided in conjunction with another independent procedure but may occasionally be provided without another independent service on the same date of service, we

will permit separate payment if the service is billed without an independent procedure on the same date of service. We refer readers to section II.A.4.c.(1) of this final rule with comment period for the complete discussion of this final policy. We considered several policy options for the payment of guidance services in CY 2008.

The first alternative we considered was to not make any changes to packaging for the CY 2008 OPPS. Under this alternative, codes that were packaged for CY 2007 would have remained packaged for CY 2008 and codes that were separately paid for CY 2007 would have remained separately paid for CY 2008. There are a number of CPT codes that describe independent surgical procedures for which the code descriptors indicate that guidance is included in the code reported for the surgical procedure if it is used and, therefore, for which the OPPS already makes packaged payment for the associated guidance service. With a number of guidance services already packaged, we did not select this option in part because we did not want to create financial incentives for hospitals to use one form of guidance instead of another or to use guidance all the time, even if a procedure could be safely provided without guidance. Furthermore, we believe this alternative would not provide additional incentives for hospitals to utilize the most cost-effective and clinically advantageous method of guidance that is appropriate in each situation.

The second alternative we considered was to package the costs of guidance services in all cases, without regard to the possibility of the service being furnished without an independent service on the same date of service. We did not select this alternative because we believe that in the case of one particular guidance procedure, the procedure may sometimes be appropriately furnished without other independent services on the same date and in these cases, we believe that there should be separate payment for the guidance service.

The third alternative we considered, and the alternative we selected, was to unconditionally package payment for most supportive guidance services, while allowing separate payment for one particular guidance service when that guidance service is furnished without an independent service. When guidance services are furnished as an ancillary and supportive adjunct to an independent procedure, we are packaging payment for all guidance procedures. When one specific guidance service (which is occasionally not

provided in conjunction with an independent procedure on the same date of service) is not provided on the same date as an independent procedure, we will pay separately for that service. We believe that this alternative will provide the most appropriate incentives to control volume and spending for these services, without discouraging the performance of the service in those infrequent cases when one particular guidance service is provided without an independent procedure.

(2) Image Processing

We are packaging payment for image processing services into the payment for the major independent service to which the image processing service is ancillary and supportive. We refer readers to section II.A.4.c.(2) of this final rule with comment period for the complete discussion of this final policy. We considered several policy options for the payment of image processing services in CY 2008.

The first alternative we considered was to make no changes to packaging for the CY 2008 OPPS. Under this alternative, codes that were packaged for CY 2007 would have remained packaged for CY 2008 and codes that were separately paid for CY 2007 would have remained separately paid for CY 2008. We did not select this alternative because we believe it would not provide additional incentives for hospitals to utilize the most cost-effective and clinically advantageous image processing services that are appropriate in each situation.

The second alternative we considered was to package the costs of image processing services in cases in which the image processing service is furnished on the same date as an independent service to which the image processing service is ancillary and supportive but to pay separately for the image processing service when it is furnished without an independent service on the same date of service. We did not select this alternative because it would not have provided substantial additional incentives for hospitals to utilize image processing in the most cost-effective and clinically advantageous manner.

The third alternative we considered, and ultimately selected, was to package payment for the costs of image processing services in all cases, without regard to the possibility of the service being furnished without an independent service on the same date of service. While an image processing service is not necessarily provided on the same date of service as the independent procedure to which it is ancillary and supportive,

providing separate payment for each imaging processing service whenever it is performed is not consistent with encouraging value-based purchasing under the OPPS. We believe it is important to package payment for supportive dependent services that accompany independent procedures but that may not need to be provided face-to-face with the patient in the same encounter as the independent service. Packaging encourages hospitals to establish protocols that ensure that services are furnished only when they are medically necessary and to carefully scrutinize the services ordered by practitioners to minimize unnecessary use of hospital resources. Therefore, we believe that this alternative will provide additional appropriate incentives to control volume and spending for these services, without discouraging the use of the service in those infrequent cases when it is provided with an independent procedure but on a different date of service.

(3) Intraoperative Services

We are packaging payment for intraoperative services into the payment for the independent procedure to which the intraoperative service is ancillary and supportive. In the case of two intraoperative services, which would usually be provided in conjunction with another independent procedure but may occasionally be provided without another independent service on the same date of service, we will permit separate payment if the services are billed without an independent procedure on the same date of service. We refer readers to section II.A.4.c.(3) of this final rule with comment period for the complete discussion of this final policy. We considered several policy options for the payment of intraoperative services in CY 2008.

The first alternative we considered was to make no changes to packaging for the CY 2008 OPPS. Under this alternative, codes that were packaged for CY 2007 would have remained packaged for CY 2008 and codes that were separately paid for CY 2007 would have remained separately paid for CY 2008. We did not select this alternative because we believe it would not provide additional incentives for hospitals to utilize the most cost-effective and clinically advantageous intraoperative services that are appropriate in each situation.

The second alternative we considered was to package payment for the costs of intraoperative services in all cases, without regard to the possibility of the service being furnished without an independent service on the same date of

service. We did not select this alternative because we believe that, in the case of two particular intraoperative procedures, those procedures may sometimes be appropriately furnished without other independent services on the same date and, in these cases, we believe that there should be separate payment for the intraoperative services.

The third alternative we considered, and ultimately selected, was to unconditionally package the costs of intraoperative services in all cases except two, to allow for the possibility of these two intraoperative services being furnished without an independent service on the same date of service. We believe that there is some possibility that these procedures could be appropriately performed without another independent procedure on the same date of service. We do not believe this to be true of the other intraoperative services that we proposed to unconditionally package. We selected this alternative because we believe it unlikely that intraoperative services other than the two particular services would ever be provided without an independent service. Packaging encourages hospitals to establish protocols that ensure that services are furnished only when they are medically necessary and to carefully scrutinize the services ordered by practitioners to minimize unnecessary use of hospital resources. We believe that this is the most appropriate alternative because, in general, it creates additional incentives for hospitals to provide intraoperative services only when both medically necessary and cost efficient for the individual patient. Therefore, we believe that this alternative will provide the most appropriate incentives to control volume and spending for these services.

(4) Imaging Supervision and Interpretation Services

We are unconditionally packaging payment for some imaging supervision and interpretation services into the payment for the independent service to which the imaging supervision and interpretation service is ancillary and supportive and conditionally packaging payment for other imaging supervision and interpretation services when the independent service has a status indicator of "T." For this latter subset of codes, we are permitting separate payment if there is no service with status indicator of "T" billed the same date of service. We refer readers to section II.A.4.c.(4) of this final rule with comment period for the complete discussion of this final policy. We considered several policy options for

the payment of imaging supervision and interpretation services in CY 2008.

The first alternative we considered was to make no changes to packaging for the CY 2008 OPPS. Under this alternative, codes that were packaged for CY 2007 would have remained packaged and codes that were separately paid for CY 2007 would have remained separately paid for CY 2008. We did not select this alternative because we believe it would not provide additional incentives for hospitals to utilize the most cost effective and clinically advantageous imaging supervision and interpretation services that are appropriate in each situation.

The second alternative we considered was to unconditionally package imaging supervision and interpretation procedures that we believe are always integral to and dependent upon an independent separately payable procedure, but to conditionally package payment for those imaging supervision and interpretation services that we believe are sometimes furnished without another separately payable service on the same date. We did not accept this alternative because commenters convinced us that to do this would sometimes result in packaging these services with services for which packaging of the imaging supervision and interpretation services was inappropriate (for example, visits and minor diagnostic tests).

The third alternative we considered, and the alternative we selected, was to unconditionally package imaging supervision and interpretation procedures that we believe are always integral to and dependent upon an independent separately payable procedure, but to conditionally package payment for certain imaging supervision and interpretation services only when they are provided on the same date of service as a service with a status indicator of "T." We believe that this alternative is the most appropriate choice because it creates additional incentives for hospitals to provide services only when medically necessary to an individual patient when the supervision and interpretation service is furnished as an ancillary and supportive adjunct to the independent procedural service and does not package the payment for the supervision and interpretation service with the payment for a visit or other service. We will pay separately for some imaging supervision and interpretation services in those cases where they are not furnished on the same date as a service with status indicator of "T." Therefore, we believe that this alternative will provide the most appropriate incentives to control

volume and spending for these services, without discouraging the performance of the services in those cases when they are furnished with a service with a status indicator other than "T."

(5) Diagnostic Radiopharmaceuticals

We are packaging payment for diagnostic radiopharmaceuticals into the payment for their associated nuclear medicine procedures. In response to comments, we are using only claims for nuclear medicine procedures that contain a Level II HCPCS code for a diagnostic radiopharmaceutical to set the median costs for the nuclear medicine services, and we are implementing claims processing edits that require that a nuclear medicine service must have a diagnostic radiopharmaceutical HCPCS code on the same claim to be accepted for processing. We refer readers to section II.A.4.c.(5) of this final rule with comment period for the complete discussion of this final policy. We considered several policy options for the payment of diagnostic radiopharmaceuticals in CY 2008.

The first alternative we considered was to make no changes to our packaging methodology for diagnostic radiopharmaceuticals in the CY 2008 OPPS. Under this alternative, diagnostic radiopharmaceuticals with a mean per-day cost of \$60 or less would be packaged into the payment for associated procedures present on the claim. Diagnostic radiopharmaceuticals with a per-day cost over \$60 would receive separate payment. We did not select this alternative because we believe it would not provide additional incentives for hospitals to utilize the most cost-effective and clinically advantageous diagnostic radiopharmaceuticals that are appropriate in each situation.

The second alternative we considered was to package the costs of diagnostic radiopharmaceuticals in cases in which the diagnostic radiopharmaceutical is furnished on the same date as an independent service to which the diagnostic radiopharmaceutical is ancillary and supportive, but to pay separately for the diagnostic radiopharmaceutical when it is furnished without an independent service on the same date of service. We did not select this alternative because diagnostic radiopharmaceuticals are always intended to be used with a diagnostic nuclear medicine procedure. Our claims data indicate that diagnostic radiopharmaceuticals are infrequently provided on a different date of service from a nuclear medicine procedure. Because our standard OPPS ratesetting

methodology packages costs across dates of service on "natural" single claims, we believe that our standard methodology adequately captures the costs of diagnostic radiopharmaceuticals associated with diagnostic nuclear medicine procedures that are not provided on the same date of service.

The third alternative we considered, and the alternative we selected, was to package the costs of diagnostic radiopharmaceuticals with their associated nuclear medicine procedures, to calculate the median costs of nuclear medicine procedures using only claims that contain a Level II HCPCS code for a diagnostic radiopharmaceutical, and to implement claims processing edits that require that a claim that reports a code for a nuclear medicine procedure must also contain a code for a diagnostic radiopharmaceutical to be accepted for processing. Packaging the costs of supportive items and services into the payment for the independent procedure or service with which they are associated encourages additional hospital efficiencies and enables hospitals to better manage their resources with maximum flexibility. Diagnostic radiopharmaceuticals are always intended to be used with a diagnostic nuclear medicine procedure, and are, therefore, particularly well suited for packaging under the OPSS for the reasons identified in section II.A.4.c.(5) of this final rule with comment period. Moreover, calculating the median cost of nuclear medicine procedures using only claims that also contain at least one diagnostic radiopharmaceutical will ensure that the cost of the radiopharmaceuticals used in the procedure will be captured in the median cost. In addition, implementing a claims processing edit that will require that a claim that contains a code for a nuclear medicine procedure must also contain a code for a diagnostic radiopharmaceutical will ensure that in future years, all claims for nuclear medicine procedures will include the cost of the radiopharmaceuticals used to furnish the service.

(6) Contrast Media

We are packaging payment for contrast media into their associated independent diagnostic and therapeutic procedures. We refer readers to section II.A.4.c.(6) of this final rule with comment period for the complete discussion of this final policy. We considered several policy options for the payment of contrast media in CY 2008.

The first alternative we considered was to make no changes to our

packaging methodology for contrast media in the CY 2008 OPSS. Under this alternative, contrast media with a mean per-day cost of \$60 or less would be packaged into the payment for associated procedures present on the claim. Contrast media with a per-day cost over \$60 would receive separate payment. We did not select this alternative because we believe it would not provide additional incentives for hospitals to utilize contrast media in the most cost-effective and clinically advantageous manner. With most contrast media already packaged based on our \$60 packaging threshold, this alternative would potentially maintain inconsistent payment incentives across similar products.

The second alternative we considered was to package the costs of contrast media in cases in which the contrast medium is furnished on the same date as an independent service but to pay separately for the contrast medium when it is furnished without an independent service on the same date of service. We did not select this alternative because we believe it is unlikely that contrast media would ever be provided without an independent service on the same date of service.

The third alternative we considered, and the alternative we selected, was to unconditionally package the costs of contrast media with their associated independent diagnostic and therapeutic procedures. The vast majority of contrast media will currently be packaged under the \$60 packaging threshold. Given that most contrast agents will already be packaged under the OPSS in CY 2008, we believe it would be desirable to package payment for the remaining contrast agents, as this approach promotes additional efficiency and results in a more consistent payment policy across products that may be used in many of the same independent procedures. In the case of echocardiography procedures that are performed with contrast, we have established separate Level II HCPCS codes to report these services, so that we will pay for contrast and noncontrast studies through separate APC groups as section 1833(t)(2)(G) of the Act requires. The median cost of the APC for noncontrast echocardiography services was set based on those claims for the studies that also reported a contrast agent, to ensure that the procedure payment includes the cost of the necessary contrast agent.

(7) Observation Services

We are packaging payment for all observation care, reported under HCPCS code G0378 (Hospital observation

services, per hour) for CY 2008. Payment for observation will be packaged as part of the payment for the separately payable services with which it is billed. In addition, we created two additional composite APCs for extended assessment and management, of which observation care is a component. We refer readers to section II.A.4.c.(7) of this final rule with comment period for the complete discussion of this final policy. We considered several policy options for the payment of observation services in CY 2008.

The first alternative we considered was to make no changes to payment of observation services for the CY 2008 OPSS. Since January 1, 2006, hospitals have reported observation services based on an hourly unit of care using HCPCS code G0378. This code has a status indicator of "Q" under the CY 2007 OPSS, meaning that the OPSS claims processing logic determines whether the observation is packaged or separately payable. The OCE's current logic determines whether observation care billed under G0378 is separately payable through APC 0339 (Observation), or whether payment for observation services will be packaged into the payment for other separately payable services provided by the hospital in the same encounter based on criteria discussed in more detail in section II.A.4.c.(7) of this final rule with comment period. For CY 2007, we continued to apply the criteria for separate payment for observation care and the coding and payment methodology for observation care that were implemented in CY 2006. We did not select this alternative because the current criteria for separate payment for observation services treat payment for observation care for various clinical conditions differently and may provide disincentives for efficiency. In addition, there has been substantial growth in program expenditures for hospital outpatient services under the OPSS in recent years, a trend that is reflected in the rapidly increasing volume of claims for separately payable observation services. This alternative would not provide additional incentives for hospitals to utilize observation services in the most cost effective and clinically advantageous manner.

The second alternative we considered was to accept the APC Panel's recommendations to add syncope and dehydration to the list of diagnoses eligible for separate payment or to consider other clinical conditions for separate payment for observation care. We believe that, in certain circumstances, observation could be appropriate for patients with a range of

diagnoses. Both the APC Panel and numerous commenters to prior OPPS proposed rules have confirmed their agreement with this perspective. However, as packaging payment provides additional desirable incentives for more efficient delivery of health care and provides hospitals with significant flexibility to manage their resources, we believe it is most appropriate to treat observation care for all diagnoses similarly by packaging its costs into payment for the separately payable procedures with which the observation is associated. Consequently, we did not select this alternative to expand separate observation payment to additional diagnoses.

The third alternative we considered was to package payment for all observation services reported with HCPCS code G0378 under the CY 2008 OPPS. We believe this is the most appropriate alternative within the context of our packaging approach because observation is always provided as a supportive service in conjunction with other independent separately payable hospital outpatient services such as an emergency department visit, surgical procedure, or another separately payable service, and thus its costs can be packaged into the OPPS payment for such services. We believe that packaging payment into larger payment bundles creates incentives for providers to furnish services in the most efficient way that meets the needs of the patient, encouraging long-term cost containment. With approximately 70 percent of the occurrences of observation care billed under the OPPS currently packaged, this alternative will extend the incentives for efficiency already present for the vast majority of observation care that is already packaged under the OPPS to the remaining 30 percent of observation care for which we currently make separate payment.

However, based on the public comments we received, while we are adopting our proposal to package payment for all observation services reported with HCPCS code G0378 under the CY 2008 OPPS, we will also create two additional composite APCs for extended assessment and management, of which observation care is a major component. This refinement of the third alternative responds to commenters who stated that observation care is sometimes a major component of a patient's visit. We continue to believe that observation services are usually ancillary and supportive to the other independent services that are provided to the patient on the same day. However, we believe that observation

care may sometimes rise to the level of a major component service, specifically, when it is provided for 8 hours or more in association with a high level clinic or emergency department visit, direct admission to observation, or critical care services and it is not provided in conjunction with a surgical procedure. Therefore, we have created two composite APCs that will provide payment to hospitals in certain circumstances when extended assessment and management of a patient occur. These composite APCs describe an extended encounter for care provided to a patient. Specifically, we are creating two new composite APCs for CY 2008, APC 8002 (Level I Extended Assessment and Management Composite) and APC 8003 (Level II Extended Assessment and Management Composite). The payment associated with APCs 8002 and 8003 is intended to pay the hospital for the costs associated with a single episode of care involving more intense extended assessment and management that includes a high level clinic or emergency department visit, direct admission to observation, or critical care services; 8 hours or more of observation services; and any associated packaged services.

In summary, for CY 2008, payment for observation services will remain packaged with a status indicator "N." We are creating two composite APCs for extended assessment and management, of which observation care is a major component service. When criteria for payment of one of the composite APCs are met, separate payment will be made to the hospital through the composite APC. This composite APC payment methodology will contribute to our goal of providing payment under the OPPS for a larger bundle of component services provided in a single hospital outpatient encounter, creating additional hospital incentives for efficiency and cost containment, while providing hospitals with the most flexibility to manage their resources.

(8) Composite APCs

We are establishing five composite APCs for the CY 2008 OPPS. In addition to the two composite APCs that we proposed for the CY 2008 OPPS and for which we discuss the alternatives considered in this section, we have also created two composite APCs for extended assessment and management (of which observation care is a part), and we identify APC 0034 (Mental Health Services Composite), the longstanding limit on per diem payment for mental health services, as a composite APC. We refer readers to the discussion of alternatives considered for

observation services, above, and to section II.A.4.c.(7) of this final rule with comment period for further discussion of the composite APCs of which observation is a part. We refer readers to section II.A.4.d. of this final rule with comment period for a discussion of APC 0034.

A composite APC is an APC that provides a single payment for several independent services when they are furnished on the same date of service. Composite APCs are intended to establish APC payment rates for combinations of services that are frequently furnished together so that the multiple procedure claims on which they are submitted may be used to set the payment rates for them and so that the payment for the services provides greater incentives for efficient use of hospital resources. Specifically, as proposed, we are establishing composite APC 8000 for low dose rate prostate brachytherapy (which will be paid when CPT codes 55875 (Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy) and 77778 (Interstitial radiation source application; complex) are billed on the same date of service) and APC 8001 for cardiac electrophysiologic evaluation and ablation services (which will be paid when at least one designated cardiac electrophysiologic evaluation service is billed on the same date as at least one designated cardiac ablation service). We refer readers to sections II.A.4.d.(2) and II.A.4.d.(3) of this final rule with comment period for a detailed discussion of the policies for these APCs. We note that we will continue to pay individual services under their single procedure APCs as we have in the past, in those clinical circumstances in which the combinations of services proposed for payment through the composite APCs are not furnished on the same date. We considered two alternatives with regard to creating composite APCs.

The first alternative we considered was to make no change to how we pay for these services. If we were to make no change, we could continue to pay separately for each service. We did not select this alternative because the payment rates would continue to be based on single procedure claims, which we have been told by stakeholders do not represent the typical treatment scenario. Interested parties have repeatedly told us, and our examination of claims data supports, that these services are typically furnished in combination with one another and, therefore, this may suggest that the use of single procedure claims

to establish the median costs that form the basis for payment for these services may result in our using clinically unusual or incorrectly coded claims as the basis for payment.

The second alternative we considered, and the alternative we selected, is to create composite APCs for these services, which are commonly furnished in combination with one another, and to make a single payment for the multiple services specified in the composite APC at a prospectively established rate based on the total cost of the combination of services furnished. This alternative responds to public comments that multiple procedure claims for these services that we have heretofore been unable to use for ratesetting reflect the most common treatment scenarios. It also provides additional incentives for efficient provision of services by bundling payment for multiple services into a single payment. Composite APCs enable us to use more of our claims data and to use single procedure claims only to set payment rates for the uncommon circumstances in which a particular service is not furnished in combination with other related independent services. Therefore, we are establishing composite APCs 0034, 8000, 8001, 8002, and 8003 for the CY 2008 OPSPS.

b. Partial Device Credits

We are reducing payment by 50 percent of the device offset amount for specified APCs when hospitals report that they have received a credit for a replacement device of greater than or equal to 50 percent of the cost of the new replacement device being implanted, if the device is on a list of specified devices. We refer readers to section IV.A.3. of this final rule with comment period for a complete discussion of this final policy. This is an extension of the current policy that reduces the APC payment by the full device offset amount when the hospital receives a replacement device without cost or receives a credit for the full cost of the device being replaced. We considered several alternatives in developing this partial device credit policy for CY 2008.

The first alternative we considered was to make no change to the current policy. Under this alternative, Medicare and the beneficiary would continue to pay the full APC rate, which is calculated using only claims for which the full cost of a device is billed by the hospital, even if the hospital received a substantial credit towards the cost of the replacement device. We did not select this alternative because we believe that, as long as the APC payment amount is initially established to reflect the full

cost of the device when there is no credit, there should be a reduction in the Medicare payment amount when the hospital receives a substantial credit toward cost of the replacement device. Similarly, we believe that the beneficiary cost sharing should be based on an amount that also reflects the credit.

The second alternative we considered was to extend the current policy to cases of partial credit without change. This would reduce the payment in all cases in which the hospital received a credit by the full offset amount for the APC, that is, by 100 percent of the estimated device cost contained in the APC. We considered this alternative because, in our discussions with hospitals about partial credits for devices, they advised us that hospitals generally charge the same amount for a device regardless of whether they receive a significant amount in credit towards the cost of that device. Hence, in such a case the costs that are packaged into the APC payment for the applicable procedure contain the same amount of device cost as if the hospital incurred the full cost of the device. We did not select this alternative because we did not believe it was appropriate to reduce the payment to the hospital by the full cost of a device if the hospital only received a partial credit, and not a full credit, towards the cost of the device.

The third alternative we considered was to reduce the APC payment by 50 percent of the offset amount (that would be applied if the hospital received full credit) in cases in which the hospital receives a partial credit of 20 percent or more of the cost of the new replacement device being implanted. We would require hospitals to report a new modifier when the hospital receives a partial credit that is 20 percent or more of the cost of the device being replaced. We are not adopting this policy, which we proposed in the CY 2008 OPSPS/ASC proposed rule, for several reasons. We note it would not be consistent with the FY 2008 IPSPS partial credit device policy, and we were concerned that 20 percent is a nominal portion of the cost of a device and would not justify the administrative and operational burden posed by the policy and, accordingly, the 50-percent payment reduction would be more than the partial credit received in some cases.

The fourth alternative, which we are adopting, is a modification of the third alternative described above. This alternative is to reduce the APC payment by 50 percent of the offset amount (that would be applied if the hospital received full credit) in cases in which the hospital receives a partial

credit of 50 percent or more of the cost of the new replacement device being implanted. We are requiring hospitals to report the "FC" modifier when the hospital receives a partial credit that is 50 percent or more of the cost of the device being replaced. We are adopting this alternative because we believe that this approach provides an appropriate and equitable payment to the hospital from Medicare and, depending on the service, may reduce the beneficiary's cost sharing for the service.

c. Brachytherapy Sources

Pursuant to sections 1833(t)(2)(H) and 1833(t)(16)(C) of the Act, we paid for brachytherapy sources furnished from January 1, 2004 through December 31, 2006, on a per source basis at an amount equal to the hospital's charge adjusted to cost by application of the hospital-specific overall CCR. Moreover, pursuant to section 107(a) of the MIEA-TRHCA, which amended section 1833(t)(16)(C) of the Act by extending the payment period for brachytherapy sources based on a hospital's charges adjusted to cost, we are paying for brachytherapy sources using the charges adjusted to cost methodology through December 31, 2007. Section 107(b)(1) of the MIEA-TRHCA amended section 1833(t)(2)(H) of the Act, by adding a requirement for the establishment of separate payment groups for "stranded and non-stranded" brachytherapy devices beginning July 1, 2007. In section VII.B. of this final rule with comment period, we are adopting prospective payment for all brachytherapy sources under the CY 2008 OPSPS, including separate payment for stranded and non-stranded versions of sources currently known to us, that is, iodine-125, palladium-103 and cesium-131. For each of the sources for which we have information that only non-stranded source versions are marketed, we are making payment based on the median cost per source based on our CY 2006 claims data. For sources for which we have information that both stranded and non-stranded versions are marketed and for which our CY 2006 billing codes do not differentiate stranded and non-stranded sources, we are basing payment for stranded and non-stranded brachytherapy sources on the 60th percentile and 40th percentile of our claims data, respectively, for CY 2008. We discuss each alternative we considered below.

The first alternative we considered was to pay for each source of brachytherapy based on our CY 2006 median costs, with the exception of the 3 sources for which we do not have separately reported cost data for their

stranded and non-stranded versions, that is, iodine-125, palladium-103, and cesium-131. Under this option, for these six stranded and non-stranded sources, we considered payment based on hospital charges reduced to cost for CY 2008. This approach would be a step toward prospective payment for brachytherapy sources, as the sources that only have non-stranded versions would receive prospective payment consistent with the overall OPPS methodology. However, payment for stranded and non-stranded iodine-125, palladium-103 and cesium-131 would deviate from the overall OPPS framework for prospective payment and from the prospective payment of the non-stranded only sources specifically. This approach would subject similar items that are essential to brachytherapy treatments to different payment methodologies and could potentially create financial incentives for the use of some products over others.

The second alternative we considered was to continue making payments for all sources based on hospital charges reduced to cost. Although hospitals are familiar with this payment methodology and this methodology would be consistent with the requirement that brachytherapy sources be paid separately, we believe that to continue to pay on this basis would be inconsistent with the general methodology of a prospective payment system and would provide no incentive for hospitals to provide brachytherapy treatments in the most cost-effective and clinically advantageous manner.

The third alternative we considered, and the alternative we selected, is to provide prospective payment for each brachytherapy source based on its median costs. For the sources which only have non-stranded versions, we are using our standard median cost methodology. For the 3 sources that have stranded and non-stranded versions and for which we do not yet have separately reported stranded and non-stranded claims data, we are calculating the median costs based on the assumption that the reportedly lower cost non-stranded sources would be unlikely to be in the top 20 percent of the cost distribution of our aggregate CY 2006 claims data for each respective source, and on the assumption that the reportedly higher cost stranded sources would be unlikely to be in the bottom 20 percent of the CY 2006 cost distribution for each source. This approach to calculating median costs for stranded and non-stranded iodine-125, palladium-103, and cesium-131 sources results in Medicare payment rates based on the 60th percentile of our aggregate

data for stranded sources and the 40th percentile of our aggregate data for non-stranded sources. This methodology provides for separate payment of all sources, including stranded and non-stranded sources, recognizes a cost differential between stranded and non-stranded sources, is consistent with our prospective payment methodology for setting payment rates for other services, and is consistent with the expiration of the requirement of the MIEA-TRHCA that payment for brachytherapy sources be made at charges reduced to cost through December 31, 2007.

2. Limitations of Our Analysis

The distributional impacts presented here are the projected effects of the policy changes on various hospital groups. We post our hospital-specific estimated payments for CY 2008 with the other supporting documentation for this final rule with comment period. To view the hospital-specific estimates, we refer readers to the Web site at: <http://www.cms.hhs.gov/HospitalOutpatientPPS/>. Select "regulations and notices" from the left side of the page and then select CMS-1392-FC from the list of regulations and notices. The hospital-specific file layout and the hospital-specific file are listed with the other supporting documentation for this final rule with comment period. We show hospital-specific data only for hospitals whose claims were used for modeling the impacts shown in Table 61. We do not show hospital-specific impacts for hospitals whose claims we were unable to use. We refer readers to Section II.A.2. of this final with comment period for a discussion of the hospitals whose claims we do not use for ratesetting and impact purposes.

We estimate the effects of individual policy changes by estimating payments per service, while holding all other payment policies constant. We use the best data available but do not attempt to predict behavioral responses to our policy changes. In addition, we do not make adjustments for future changes in variables such as service volume, service-mix, or number of encounters. As we have done in previous rules, we solicited comments and information about the anticipated effect of the changes on hospitals and our methodology for estimating them. We discuss below several specific limitations of our analysis.

One limitation of our analysis is our inability to estimate behavioral responses to our increase in packaging and our payment for multiple procedures based on one composite payment rate. Specifically, it is possible

that there could be a behavioral response to our final policy to package payment for guidance services, image processing services, intraoperative services, imaging supervision and interpretation services, diagnostic radiopharmaceuticals, contrast agents, and observation services, and to pay for certain services through composite APCs when the services are furnished in specified combinations. However, we are unable to estimate what the effect of possible behavioral responses may be on payment to hospitals. We refer readers to section II.A.4. of this final rule with comment period for further discussion of the packaging approach. The purpose of packaging these services and creating composite APCs is to remove financial incentives to furnish additional services and, instead, to provide greater incentives for hospitals to assess the most cost-effective and appropriate means to furnish necessary services. In addition, we expect that hospitals will negotiate for lower prices from suppliers to maximize the margin between their cost of providing services and the Medicare payment for the services. We recognize that it is also possible that hospitals could change behavior in a manner that seeks to overcome any reductions in total payments by ceasing to provide certain packaged services on the same date of service and instead requiring patients to receive those services on different dates of service or at different locations, so as to either receive separate additional payment for services that would otherwise be packaged or to not incur the additional costs of those services. However, we believe that this will be uncommon for several reasons. We anticipate that hospitals will continue to provide care that is aligned with the best interests of the patient. In the vast majority of cases for the services that are newly unconditionally packaged in CY 2008, the services need to be provided in the same facility and during the same encounter as the independent procedure they support. Furthermore, in the case of conditionally packaged services, we note that the supportive services that we have included in our packaging policies are typically services that are provided during or shortly preceding the independent procedure to which they are ancillary and supportive, and thus it is unlikely that the supportive service that is packaged and the independent procedure will be performed in different locations. However, we are unable to quantify the extent to which such behavioral change may impact Medicare payments to hospitals.

Secondly, we are not able to estimate the impact on hospitals of our policy to reduce payment when a hospital receives a partial credit for a medical device that fails while under warranty or otherwise. We do not currently require hospitals to notify us when they received a partial credit for a device for which they are billing. In addition, hospitals have informed us that hospitals generally do not currently reduce the charge for a device when they receive a partial credit toward the device for which they are billing Medicare. Therefore, we have no means of knowing the frequency with which this happens or the extent to which hospitals' costs for the devices being replaced are reduced as a result of the partial credits and cannot estimate the impact of the policy on hospital payments under the OPSS in CY 2008.

Third, we are unable to estimate the extent to which hospitals will incur no cost for devices or will receive full or partial credits for devices being replaced as a result of the failure of the device. In CY 2006, hospitals reported the "FB" modifier on codes for devices that they received without cost or for which they received a full credit. However, we are unable to forecast the extent to which the frequency or the type of device for which this occurred in CY 2006 will recur for CY 2008. We believe that most of these occurrences were the result of specific activity that we have no reason to believe will occur in CY 2008 at the same frequency at which it occurred in CY 2006, and hence we have made no estimates of how such activity may impact payments to hospitals. Similarly, we have no estimate of the extent to which hospitals will receive partial credits for devices under warranty actions in CY 2008. Beginning January 1, 2008, hospitals will report cases in which they receive a partial credit for a device if the credit is 50 percent or more of the cost of the replacement device. However, these data will not be available until the development of the CY 2010 OPSS, which will be based on CY 2008 claims.

Fourth, for purposes of this impact analysis, for those brachytherapy sources with new codes to distinguish between stranded and non-stranded version, we assume that half of the brachytherapy sources that hospitals will use in CY 2008 will be stranded sources and that half of them will be non-stranded sources. The statute requires us to pay for stranded and non-stranded sources through different APC groups, but given the lack of separately reported claims data for stranded and non-stranded sources, for the purposes of this impact analysis, we make this

assumption. In the CY 2008 OPSS/ASC proposed rule, we welcomed data that would provide the expected CY 2008 ratio of stranded sources to non-stranded sources for purposes of this CY 2008 final rule impact analysis. We did not receive any information regarding the ratio of stranded to non-stranded sources in the public comments on the proposed rule.

The final limitation of our analysis is that we cannot predict the utilization of new CY 2007 and CY 2008 CPT codes that replace existing CY 2006 CPT codes for which we have cost data on which we base the CY 2008 OPSS payment rates. In years past, we have estimated the impact of these code changes as if the deleted codes would continue to exist for the applicable year for which we were estimating impacts. For this final rule with comment period, we applied the AMA's estimates of new code utilization which are used for the MPFS final rule with comment period. However, we do not know whether these estimates of physician utilization are equally applicable to hospital outpatient services.

In the CY 2008 OPSS/ASC proposed rule, we requested comments regarding whether it would be appropriate for us to use the AMA estimates of utilization for new codes in the estimation of the impact of the final CY 2008 payments for hospitals. We received no comments on this issue.

3. Estimated Impacts of This Final Rule With Comment Period on Hospitals and CMHCs

Table 61 below shows the estimated impacts of this final rule with comment period on hospitals. Historically, the first line of the impact table, which estimates the change in payments to all hospitals, has always included cancer and children's hospitals, which are held harmless to their pre-BBA payment to cost ratio. This year, for the first time, we are also including CMHCs in the first line that includes all providers because we included CMHCs in our weight scaler estimate. We are not showing the estimated impact of the changes on CMHCs alone because CMHCs bill only one service under the OPSS, partial hospitalization, and each CMHC can easily estimate the impact of the changes by referencing payment for APC 0033 (Partial Hospitalization) in Addendum A to this final rule with comment period. As discussed in section II.B. of this final rule with comment period, the payment for APC 0033 (Partial Hospitalization) for CY 2008 will decline by 13 percent compared to the payment for APC 0033 for CY 2007.

The estimated increase in the total payments made under the OPSS is limited by the increase to the conversion factor set under the methodology in the statute. The distributional impacts presented do not include assumptions about changes in volume and service-mix. The enactment of Public Law 108-173 on December 8, 2003, provided for the additional payment outside of the budget neutrality requirement for wage indices for specific hospitals reclassified under section 508. The amounts attributable to this reclassification are incorporated into the CY 2007 estimates but because section 508 expired for CY 2008 rates, no additional payments under section 508 are considered for CY 2008 in this impact analysis.

Table 61 shows the estimated redistribution of hospital and CMHC payments among providers as a result of APC reconfiguration and recalibration including the expansion of packaging; wage indices, and continuation of the adjustment for rural SCHs and EACHs with extension to brachytherapy sources in CY 2008; the estimated distribution of increased payments in CY 2008 resulting from the combined impact of the APC recalibration with the expansion of packaging, wage effects, the rural SCH and EACH adjustment, and the market basket update to the conversion factor; and, finally, estimated payments considering all payments for CY 2008 relative to all payments for CY 2007, including the impact of expiring wage provisions of section 508, changes in the outlier threshold, and changes to the pass-through estimate. Because updates to the conversion factor, including the update of the market basket and the addition of money not dedicated to pass-through payments, are applied uniformly, observed redistributions of payments in the impact table for hospitals largely depend on the mix of services furnished by a hospital (for example, how the APCs for the hospital's most frequently furnished services would change), the impact of the wage index changes on the hospital, and the impact of the payment adjustment for rural SCHs, including EACHs. However, total payments made under this system and the extent to which this final rule with comment period will redistribute money during implementation also would depend on changes in volume, practice patterns, and the mix of services billed between CY 2007 and CY 2008, which CMS cannot forecast.

Overall, the final OPSS rates for CY 2008 will have a positive effect for providers paid under the OPSS,

resulting in a 3.6 percent increase in Medicare payments. Removing cancer and children's hospitals because their payments are held harmless to the pre-BBA ratio between payment and cost, and CMHCs, suggests that changes will result in a 3.8 percent increase in Medicare payments to all other hospitals, exclusive of transitional pass-through payments.

To illustrate the impact of the final CY 2008 changes, our analysis begins with a baseline simulation model that uses the final CY 2007 weights, the FY 2007 final post-reclassification IPPS wage indices, and the final CY 2007 conversion factor. Column 2 in Table 61 shows the independent effect of changes resulting from the reclassification of services among APC groups, the recalibration of APC weights and the changes to packaging that we adopted for this final rule with comment period, based on 12 months of CY 2006 hospital OPSS claims data and more recent cost report data. We modeled the effect of APC recalibration and packaging changes for CY 2008 by varying only the weights (the final CY 2007 weights versus the estimated CY 2008 weights including expanded packaging in our baseline model) and calculating the percent difference in payments. Column 2 also reflects the effect of changes resulting from the APC reclassification and recalibration changes and changes in multiple procedure discount patterns that occur as a result of the changes to packaging. When services are packaged, the resulting median costs at the HCPCS code level often change, requiring migration of HCPCS codes to different APCs to address violations of the 2 times rule (that is, to ensure that the HCPCS codes within the APC remain homogeneous with regard to clinical and resource characteristics). The placement of the HCPCS code in a new APC as a result of the effect of the packaging approach often changes the APC median cost. Furthermore, changing the cost of a service subject to the multiple procedure discount policy, as well as packaging some services previously subject to the multiple procedure discount policy, changes the relative weight ranking of services on a claim subject to the multiple procedure discount policy, significantly changing discounting patterns in some cases.

Column 3 reflects the independent effects of updated wage indices, including the new occupational mix data described in the FY 2008 IPPS final rule, and the 7.1 percent rural adjustment for SCHs and EACHs with extension to brachytherapy sources. The OPSS wage index for CY 2008 includes the budget neutrality adjustment for the

rural floor, as discussed in section II.D. of this final rule with comment period. We modeled the independent effect of updating the wage index and the rural adjustment by varying only the wage index, using the CY 2008 scaled weights, and a CY 2007 conversion factor that included a budget neutrality adjustment for changes in wage effects and the rural adjustment between CY 2007 and CY 2008.

Column 4 demonstrates the combined "budget neutral" impact of APC recalibration with the packaging policy (that is, Column 2), the wage index update and the adjustment for rural SCHs and EACHs (that is, Column 3), as well as the impact of updating the conversion factor with the market basket update. We modeled the independent effect of the budget neutrality adjustments and the market basket update by using the weights and wage indices for each year, and using a CY 2007 conversion factor that included the market basket update and budget neutrality adjustments for differences in wages and the adjustment for rural SCHs and EACHs.

Finally, Column 5 depicts the full impact of the CY 2008 policy on each hospital group by including the effect of all the changes for CY 2008 (including the APC reconfiguration and recalibration with the packaging changes shown in Column 2) and comparing them to all estimated payments in CY 2007, including changes to the wage index under section 508 of Public Law 108 173. Column 5 shows the combined budget neutral effects of Columns 2 through 4, plus the impact of the change to the fixed outlier threshold from \$1,825 to \$1,575, expiring section 508 reclassification wage index increases, and the impact of reducing the percentage of total payments dedicated to transitional pass-through payments. We estimate that these cumulative changes increase payments by 3.6 percent. We modeled the independent effect of all changes in Column 5 using the final weights for CY 2007 and the final weights for CY 2008. We used the final conversion factor for CY 2007 of \$61.468 and the final CY 2008 conversion factor of \$63.694. Column 5 also contains simulated outlier payments for each year. We used the charge inflation factor used in the FY 2008 IPPS final rule of 6.2 percent (1.062) to increase individual costs on the CY 2006 claims to reflect CY 2007 dollars, and we used the most recent overall CCR in the July 2007 Outpatient Provider-Specific File. Using the CY 2006 claims and a 6.2 percent charge inflation factor, we currently estimate that outlier payments for CY 2007, using

a multiple threshold of 1.75 and a fixed-dollar threshold of \$1,825 would be approximately 0.73 percent of total payments. Outlier payments of 0.73 percent appear in the CY 2007 comparison in Column 5. We used the same set of claims and a charge inflation factor of 12.78 percent (1.1278) and the CCRs on the July 2007 Outpatient Provider-Specific File, with an adjustment of 1.0027 to reflect relative changes in cost and charge inflation between CY 2006 and CY 2008, to model the CY 2008 outliers at 1.0 percent of total payments using a multiple threshold of 1.75 and a fixed dollar threshold of \$1,575.

Column 1: Total Number of Hospitals

The first line in Column 1 in Table 61 shows the total number of providers (4,250), including cancer and children's hospitals and CMHCs for which we were able to use CY 2006 hospital outpatient claims to model CY 2007 and CY 2008 payments by classes of hospitals. We excluded all hospitals for which we could not accurately estimate CY 2007 or CY 2008 payment and entities that are not paid under the OPSS. The latter entities include CAHs, all-inclusive hospitals, and hospitals located in Guam, the U.S. Virgin Islands, Northern Mariana Islands, American Samoa, and the State of Maryland. This process is discussed in greater detail in section II.A. of this final rule with comment period. At this time, we are unable to calculate a disproportionate share (DSH) variable for hospitals not participating in the IPPS. Hospitals for which we do not have a DSH variable are grouped separately and generally include psychiatric hospitals, rehabilitation hospitals, and LTCHs. We show the total number (3,984) of OPSS hospitals, excluding the hold-harmless cancer and children's hospitals, and CMHCs, on the second line of the table. We excluded cancer and children's hospitals because section 1833(t)(7)(D) of the Act permanently holds harmless cancer hospitals and children's hospitals to a proportion of their pre-BBA payment relative to their pre-BBA costs and, therefore, we removed them from our impact analyses. We excluded CMHCs because they only bill one service under the OPSS, and thus they can easily determine the impact of the changes.

Column 2: APC Changes Due to Reassignment, Recalibration and Packaging

This column shows the combined effects of reconfiguration, recalibration, finalizing the packaging proposal and other policies (for example, changes to

payment for brachytherapy sources and therapeutic radiopharmaceuticals). In many cases, the redistribution created by the reduction in the partial hospitalization payment offsets other recalibration losses. Specifically, the reduction in partial hospitalization payment is redistributed to hospitals and reflected in the 0.2 percent increase for the 3,984 hospitals that remain after excluding hospitals held harmless and CMHCs. Overall, these changes will increase payments to urban hospitals by 0.3 percent. We estimate that large urban hospitals will see an increase of 0.1 percent and other urban hospitals will see a 0.4 percent increase in payments attributable to all recalibration.

Overall, rural hospitals will show a modest 0.2 percent decrease as a result of changes to the APC structure and the expansion of packaging. Rural hospitals of all bed sizes will experience no change or will experience decreases ranging from 0.1 to 0.6 percent. The declines for rural hospitals for this final rule with public comment period compared to the projected increases of 0.2 to 0.6 for rural hospitals in the proposed rule is attributable to the changes in packaging that we made as a result of public comments with regard to observation and imaging supervision and interpretation services. The proposed packaging of these services into payment for any service with a status indicator of "S," "T," "V," or "X" would have increased OPPS payments for visits and other services provided in rural hospitals. However, in response to public comments, we created composite APCs for extended assessment and management involving significant observation stays and we are packaging imaging supervision and interpretation services only into services with a status indicator of "T." The services for which the median costs are increased as a result of these final policies are performed more often in urban hospitals than in rural hospitals, and this utilization is reflected in the negative percents in Column 2.

Among teaching hospitals, the largest observed impacts resulting from APC recalibration and the expansion of packaging include an increase of 0.2 percent for major teaching hospitals and an increase of 0.4 percent for minor teaching hospitals.

Classifying hospitals by type of ownership suggests that proprietary hospitals will see an increase of 0.3 percent while governmental and voluntary hospitals will each see an increase of 0.2 percent.

We note also that both low volume urban and rural hospitals with less than

5,000 lines and hospitals for which DSH payments are not available will experience decreases of 3.7 to 5.5 percent as a result of the decline in payment for partial hospitalization from CY 2007 to CY 2008. These declines are somewhat moderated in Column 5 as a result of the increased outlier payments that result from the lower payment rates.

Column 3: New Wage Indices and the Effect of the Rural Adjustment

This column estimates the impact of applying the final IPPS FY 2008 wage indices for CY 2008, continuing the rural adjustment for CY 2008, and extending the rural adjustment to include brachytherapy sources. Overall, these changes will not change the payments to urban hospitals. Overall, rural hospitals show a decrease of 0.1 percent.

Among teaching hospitals, the largest observed impacts resulting from changes to the wage indices and the continuation of the rural adjustment include a decrease of 0.1 percent for major teaching hospitals and no change for minor teaching hospitals.

Classifying hospitals by type of ownership suggests that proprietary hospitals will gain 0.1 percent and that governmental hospitals and voluntary hospitals will each experience no change.

Column 4: All Budget Neutrality Changes and Market Basket Update

The addition of the market basket update of 3.3 percent alleviates any negative impacts on payments for CY 2008 created by the budget neutrality adjustments made in Columns 2 and 3, with the exception of urban and rural hospitals with the lowest volume of services and hospitals not paid under the IPPS, including psychiatric hospitals, rehabilitation hospitals, and long term care hospitals (DSH not available). In general, all hospitals see an increase of 3.5 percent, attributable to the 3.3 percent market basket increase and the 0.2 percent increase in payment weight created by the reduction in payment for partial hospitalization that is then redistributed to other services.

Overall, these changes will increase payments to urban hospitals by 3.6 percent. We estimate that large urban hospitals will see an increase of 3.5 percent and other urban hospitals will see a 3.7 percent increase. In contrast, small urban hospitals that bill fewer than 5,000 lines per year will experience a decrease in payment of 0.4 percent, largely as a result of the decrease in payment for partial

hospitalization and mental health services appearing in Column 2.

Overall, rural hospitals show a 3.0 percent increase as a result of the market basket update. Rural hospitals that bill less than 5,000 lines will see a 1.8 percent decrease, also as a result of decreases in payment for partial hospitalization appearing in Column 2. Rural hospitals that bill more than 5,000 lines will experience increases of 2.8 to 3.5 percent.

Among teaching hospitals, the observed impacts resulting from the market basket update include an increase of 3.6 percent for minor teaching hospitals and an increase of 3.3 percent for major teaching hospitals.

Classifying hospitals by type of ownership suggests that proprietary hospitals will increase 3.8 percent and governmental and voluntary hospitals will experience an increase of 3.5 percent.

Column 5: All Changes for CY 2008

Column 5 compares all changes for CY 2008 to final payment for CY 2007 and includes the expired section 508 reclassification wage indices, the change in the outlier threshold, and the difference in pass through estimates which are not included in the combined percentages shown in Column 4. Overall, we estimate that providers will see an increase of 3.6 percent under this final rule with comment period in CY 2008 relative to total spending in CY 2007. The 3.6 percent increase for all providers in Column 5, which is rounded from 3.56 percent, reflects the 3.3 percent market basket increase, plus 0.12 percent for the change in the pass-through estimate between CY 2007 and CY 2008, plus 0.27 percent for the difference in estimated outlier payments between CY 2007 (0.73 percent) and CY 2008 (1.0 percent), less 0.13 percent for the expired section 508 wage payments. When we exclude cancer and children's hospitals (which are held harmless to their pre-OPPS costs), and CMHCs, the gain becomes 3.8 percent.

The combined effect of all changes for CY 2008 will increase payments to urban hospitals by 3.9 percent. We estimate that large urban hospitals will see a 3.9 percent increase, while "other" urban hospitals will experience an increase of 3.8 percent. Urban hospitals that bill less than 5,000 lines will experience an increase of 0.8 percent, up from the 0.4 percent decrease in Column 4 due to increases in outlier payments for partial hospitalization.

Overall, rural hospitals will show a 3.1 percent increase as a result of the combined effects of all changes for CY 2008. Rural hospitals will experience a

lower increase than the 3.8 percent overall hospital increase as a result of the combined effects of the changes to the packaging policies that were made in response to public comments and the expiration of the section 508 reclassification wage indices. Rural hospitals that bill less than 5,000 lines experience a decrease of 1.5 percent, which is less than the 1.8 percent

decrease in Column 4 due to an increase in outlier payments for partial hospitalization. All rural hospitals that bill greater than 5,000 lines experience increases ranging from 2.9 percent to 3.7 percent.

Among teaching hospitals, the largest observed impacts resulting from the combined effects of all changes include an increase of 3.8 percent for major

teaching hospitals and minor teaching hospitals.

Classifying hospitals by type of ownership suggests that proprietary hospitals will gain 4.1 percent, governmental hospitals will experience an increase of 3.9 percent, and voluntary hospitals will experience an increase of 3.7 percent.

TABLE 61.—IMPACT OF CHANGES FOR CY 2008 HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM

	Number of hospitals	APC changes	New wage index and rural adjustment	Combined (cols 2,3) with market basket update	All changes
	(1)	(2)	(3)	(4)	(5)
ALL PROVIDERS *	4,250	0.0	0.0	3.3	3.6
ALL HOSPITALS (excludes hospitals held harmless and CMHCs)	3,984	0.2	0.0	3.5	3.8
URBAN HOSPITALS	2,978	0.3	0.0	3.6	3.9
Large urban (GT 1 MILL.)	1,620	0.1	0.1	3.5	3.9
Other urban (LE 1 MILL.)	1,358	0.4	0.0	3.7	3.8
RURAL HOSPITALS	1,006	-0.2	-0.1	3.0	3.1
Sole community	407	-0.2	0.1	3.1	3.0
Other rural	599	-0.2	-0.3	2.8	3.1
BEDS (URBAN):					
0-99 Beds	1,002	0.3	0.1	3.7	3.9
100-199 Beds	919	0.1	0.1	3.5	3.6
200-299 Beds	476	0.4	0.0	3.7	4.0
300-499 Beds	399	0.3	0.1	3.7	4.0
500 + Beds	182	0.3	-0.1	3.5	3.9
BEDS (RURAL):					
0-49 Beds ***	350	-0.1	-0.2	3.1	3.3
50-100 Beds ***	391	-0.2	0.0	3.1	3.3
101-149 Beds	156	0.0	-0.1	3.2	3.4
150-199 Beds	66	-0.2	-0.7	2.4	2.5
200 + Beds	43	-0.6	0.1	2.8	2.6
VOLUME (URBAN):					
LT 5,000 Lines	616	-3.7	0.0	-0.4	0.8
5,000-10,999 Lines	174	0.2	0.1	3.6	4.0
11,000-20,999 Lines	247	0.6	0.1	4.0	4.4
21,000-42,999 Lines	526	0.5	0.2	4.0	4.2
GT 42,999 Lines	1,415	0.3	0.0	3.6	3.9
VOLUME (RURAL):					
LT 5,000 Lines	83	-4.8	-0.3	-1.8	-1.5
5,000-10,999 Lines	92	-0.1	-0.1	3.1	3.6
11,000-20,999 Lines	189	0.1	-0.1	3.3	3.4
21,000-42,999 Lines	314	0.1	0.1	3.5	3.7
GT 42,999 Lines	328	-0.3	-0.2	2.8	2.9
REGION (URBAN):					
New England	157	-0.3	0.2	3.2	3.3
Middle Atlantic	378	0.2	-0.1	3.4	3.5
South Atlantic	462	0.2	-0.1	3.5	3.8
East North Cent.	469	0.4	-0.1	3.6	3.7
East South Cent.	194	0.4	-0.3	3.5	3.8
West North Cent.	186	0.4	0.1	3.8	4.1
West South Cent.	493	0.6	-0.4	3.5	3.8
Mountain	189	0.7	0.0	4.0	4.4
Pacific	398	-0.1	0.9	4.2	4.7
Puerto Rico	52	1.0	0.0	4.3	4.7
REGION (RURAL):					
New England	25	-0.5	-0.6	2.2	2.6
Middle Atlantic	70	-0.7	0.0	2.7	2.9
South Atlantic	172	-0.3	-0.2	2.7	3.0
East North Cent.	129	-0.1	-0.1	3.2	3.0
East South Cent.	177	-0.1	-0.4	2.8	3.0
West North Cent.	115	-0.2	0.0	3.1	3.1
West South Cent.	205	-0.1	-0.8	2.4	2.7
Mountain	76	0.0	0.3	3.6	3.8
Pacific	37	0.0	1.9	5.2	5.1
TEACHING STATUS:					
Non-teaching	2,956	0.1	0.1	3.5	3.7

TABLE 61.—IMPACT OF CHANGES FOR CY 2008 HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM—Continued

	Number of hospitals	APC changes	New wage index and rural adjustment	Combined (cols 2,3) with market basket update	All changes
	(1)	(2)	(3)	(4)	(5)
Minor	748	0.4	0.0	3.6	3.8
Major	280	0.2	-0.1	3.3	3.8
DSH PATIENT PERCENT:					
0	5	4.4	-0.5	7.3	7.5
GT 0-0.10	416	0.3	0.1	3.6	3.9
0.10-0.16	451	0.3	-0.1	3.4	3.4
0.16-0.23	796	0.3	0.0	3.6	3.7
0.23-0.35	948	0.2	0.0	3.4	3.7
GE 0.35	754	0.3	0.1	3.7	4.2
DSH not available **	614	-5.5	0.4	-1.9	-1.3
URBAN TEACHING/DSH:					
Teaching & DSH	920	0.3	-0.1	3.6	3.9
No teaching/DSH	1,472	0.3	0.1	3.7	4.0
No teaching/no DSH	5	4.4	-0.5	7.3	7.5
DSH not available **	581	-5.5	0.4	-1.8	-1.3
TYPE OF OWNERSHIP:					
Voluntary	2,141	0.2	0.0	3.5	3.7
Proprietary	1,255	0.3	0.1	3.8	4.1
Government	588	0.2	0.0	3.5	3.9

Column (1) shows total hospitals.

Column (2) shows the impact of changes resulting from the reclassification of HCPCS codes among APC groups and the recalibration of APC weights based on 2006 hospital claims data.

Column (3) shows the budget neutral impact of updating the wage index and rural adjustment by applying the FY 2008 hospital inpatient wage index and extended to rural adjustment to brachytherapy sources.

Column (4) shows the impact of all budget neutrality adjustments and the addition of the market basket update.

Column (5) shows the additional adjustments to the conversion factor resulting from a change in the pass-through estimate, and adds outlier payments. The change in outlier payments reflects a decrease in the fixed dollar threshold resulting from updated claim, CCR, and inflation estimates. This column also shows the impact of the expired section 508 wage reclassification, which ended on September 30, 2007.

[†] These 4,250 providers include children and cancer hospitals, which are held harmless to pre-BBA payments, and CMHCs.

** Complete DSH numbers are not available for providers that are not paid under IPPS, including rehabilitation, psychiatric, and long-term care hospitals.

*** Section 1833(t)(7)(D) of the Act specifies that rural hospitals with 100 or fewer beds (that are not also SCHs) receive additional payment for covered hospital outpatient services furnished during CY 2008 for which the prospective payment system amount is less than the pre-BBA amount. The amount of payment is increased by 85 percent of the difference for CY 2008.

4. Estimated Effect of This Final Rule With Comment Period on Beneficiaries

For services for which the beneficiary pays a copayment of 20 percent of the payment rate, the beneficiary share of payment will increase for services for which the OPPS payments will rise and will decrease for services for which the OPPS payments will fall. For example, for an electrocardiogram (APC 0099), the minimum unadjusted copayment in CY 2007 was \$4.66. In this final rule with comment period, the minimum unadjusted copayment for APC 0099 is \$4.96 because the OPPS payment for the service will increase under this final rule with comment period. In another example, for a service assigned to Level IV Needle Biopsy/Aspiration Except Bone Marrow (APC 0037) in the CY 2007 OPPS, the national unadjusted copayment was \$228.76, and the minimum unadjusted copayment was \$126.20. In this final rule with comment period, the national unadjusted copayment for APC 0037 is \$228.76, the same national unadjusted copayment in

effect for CY 2007. The minimum unadjusted copayment for APC 0037 is \$172.95, or 20 percent of the payment for APC 0037. The minimum unadjusted copayment will rise because the payment rate for APC 0037 will rise. In all cases, the statute limits beneficiary liability for copayment for a service to the inpatient hospital deductible for the applicable year. For CY 2008, the inpatient deductible is \$1,024.

In order to better understand the impact of changes in copayment on beneficiaries, we modeled the percent change in total copayment liability using CY 2006 claims. We estimate, using the claims of the 4,250 hospitals and CMHCs on which our modeling is based, that total beneficiary liability for copayments will decline as an overall percentage of total payments from 26.5 percent in CY 2007 to 25.1 percent in CY 2008. This estimated decline in beneficiary liability is a consequence of the APC recalibration and reconfiguration we are making for CY 2008.

With respect to partial hospitalization, the copayment in CY 2007 of \$46.95 will decline to \$41.03 under this final rule with comment period as a result of the decline in the per diem payment for partial hospitalization from \$234.73 in CY 2007 to \$205.16 for CY 2008.

5. Conclusion

The changes in this final rule with comment period will affect all classes of hospitals. Some classes of hospitals experience significant gains and others less significant gains, but almost all classes of hospitals will experience positive updates in OPPS payments in CY 2008. Table 61 demonstrates the estimated distributional impact of the OPPS budget neutrality requirements and an additional 3.6 percent increase in payments for CY 2008, after considering all changes to APC reconfiguration and recalibration, including those resulting from the expansion of packaging and the payment for brachytherapy sources on a prospective payment basis, as well as

the market basket increase, and the estimated cost of outliers and changes to the pass through estimate. The accompanying discussion, in combination with the rest of this final rule with comment period constitutes a regulatory impact analysis.

6. Accounting Statement

As required by OMB Circular A-4 (available at <http://www.whitehouse.gov/omb/circulars/a004/a-4.pdf>), in Table 62, we have prepared an accounting statement showing the CY 2008 estimated hospital

OPPS incurred benefit impact associated with the CY 2008 outpatient hospital market basket update shown in this final rule with comment period, based on the Mid-Session Review of the FY 2008 President's Budget baseline. All estimated impacts are classified as transfers.

TABLE 62.—ACCOUNTING STATEMENT: CY 2008 ESTIMATED HOSPITAL OPPS INCURRED BENEFIT IMPACT ASSOCIATED WITH THE CY 2008 HOSPITAL OUTPATIENT MARKET BASKET UPDATE
[In billions]

Category	Transfers
Annualized Monetized Transfers	\$0.9.
From Whom To Whom?	Federal Government to outpatient hospitals and other providers who receive payment under the hospital OPPS.

C. Effects of ASC Payment System Changes in This Final Rule With Comment Period

On August 2, 2007, we published in the **Federal Register** the final rule for the revised ASC payment system, effective January 1, 2008 (72 FR 42470). In that final rule for the revised ASC payment system, we adopted the methodologies we will use to set payment rates for ASC services furnished in association with covered surgical procedures and covered ancillary procedures beginning January 1, 2008, and established that the OPPS relative payment weights will be used as the basis for the payment of most covered surgical procedures and covered ancillary services under the revised ASC payment system.

In the August 2, 2007 revised ASC payment system final rule, we established that we will update the ASC payment system annually as part of the annual OPPS rulemaking cycle. As part of the annual OPPS rulemaking cycle, we indicated we will update the lists of ASC covered surgical procedures and covered ancillary services, as well as their payment rates. Such an update is very important because the OPPS relative payment weights will be used as the basis for the payment of most covered surgical procedures and covered ancillary services under the revised ASC payment system. This joint update process will ensure that the ASC updates occur in a regular, predictable, and timely manner, and that the ASC payment rates immediately reflect the updated OPPS relative payment weights.

In the CY 2008 OPPS/ASC proposed rule, we proposed to update the revised ASC payment system for CY 2008 to reflect the CY 2008 OPPS relative payment weights and rates, as well as update the lists of covered surgical and

covered ancillary services (72 FR 42778). We also proposed to revise the regulations to make practice expense payment to physicians who perform noncovered ASC procedures in ASCs based on the MPFS facility PE RVUs (72 FR 42791) and to exclude covered ancillary radiology services and covered ancillary drugs and biologicals from the categories of DHS that are subject to the physician self-referral prohibition (72 FR 42792). We are finalizing those proposals in this final rule with comment period.

The revised Medicare ASC payment system that we are implementing beginning January 1, 2008, could have a far-reaching effect on the provision of outpatient surgical services for a number of years to come for several reasons. First, the list of procedures that will be eligible for payment under the revised ASC payment system is greatly expanded from the list of surgical procedures eligible for payment under the ASC payment system in CY 2007 and earlier years. In addition, we are moving from a limited fee schedule based on nine disparate payment groups to a payment system incorporating relative payment weights for groups of procedures with similar clinical and resource characteristics, that is, the APC groups that are the unit of payment in the OPPS.

Implementation by January 1, 2008 of a revised ASC payment system designed to result in budget neutrality is mandated by section 626 of Public Law 108-173. To set ASC payment rates for CY 2008 under the revised payment system, we are multiplying ASC relative payment weights for surgical procedures by an ASC conversion factor that we calculated to result in the same amount of aggregate Medicare expenditures in CY 2008 as we estimate would have been made if the revised payment

system were not implemented (72 FR 42796).

The effects of the expanded number and types of procedures for which an ASC payment may be made and other policy changes that affect the revised payment system, combined with significant changes in payment rates for covered surgical procedures, will vary across ASCs, depending on whether or not the ASC limits its services to those in a particular surgical specialty area, the volume of specific services provided by the ASC, the extent to which ASCs will offer different services, and the percentage of its patients that are Medicare beneficiaries.

In the August 2, 2007 OPPS/ASC proposed rule (42 FR 42628), we estimated the CY 2008 ASC payment rates, budget neutrality adjustment factor, and impacts using the proposed CY 2008 OPPS relative payment weights and update factor for CY 2008, the proposed CY 2008 MPFS PE RVUs, and partial CY 2006 utilization data projected forward to CY 2008. In this final rule with comment period, we are establishing the final CY 2008 ASC payment rates and budget neutrality adjustment in accordance with the methodology for calculating budget neutrality established in the August 2, 2007 revised ASC payment system final rule and based on the final CY 2008 OPPS payment weights, the final CY 2008 MPFS PE RVUs, and updated CY 2006 utilization data projected forward to CY 2008.

Our final methodology for calculating the budget neutrality adjustment established in the August 2, 2007 revised ASC payment system final rule considered not only the effects of the new payment rates to be implemented under the revised ASC payment system, but also the estimated net effect of migration of new ASC procedures across ambulatory care settings. Both the

proposed budget neutrality adjustment presented in the August 2, 2007 OPPTS/ASC proposed rule and the budget neutrality adjustment in this final rule with comment period are based on that methodology, which takes into account projected migration. In the final model, we assume that over the first 2 years of the revised payment system, approximately 25 percent of the HOPD volume of new ASC procedures will migrate from the HOPD service setting to ASCs, and that over the 4-year transition period, approximately 15 percent of the physicians' office volume of new ASC procedures will migrate to ASCs.

We estimate that the revised ASC payment system will result in neither savings nor costs to the Medicare program in CY 2008. That is, because it is designed to be budget neutral, in CY 2008, the revised ASC payment system will neither increase nor decrease expenditures under Part B of Medicare. We further estimate that beneficiaries will save approximately \$20 million under the revised ASC payment system in CY 2008, because ASC payment rates will, in most cases, be lower than OPPTS payment rates for the same services and because, except for screening flexible sigmoidoscopy and screening colonoscopy procedures, beneficiary coinsurance for ASC services is 20 percent rather than 20 to 40 percent as is the case under the OPPTS. (The only possible instance in which an ASC coinsurance amount could exceed the OPPTS copayment amount will be when the coinsurance amount for a procedure under the revised ASC payment system exceeds the hospital inpatient deductible. Section 1833(t)(8)(C)(i) of the Act provides that the copayment amount for a procedure paid under the OPPTS cannot exceed the inpatient deductible established for the year in which the procedure is performed, but there is no such requirement related to the ASC coinsurance amount.) Beneficiary coinsurance for services migrating from physicians' offices to ASCs may decrease or increase under the revised ASC payment system, depending on the particular service and whether the Medicare payment to the physician for providing that service in his or her office is higher or lower than the sum of the Medicare payment to the ASC for providing the facility portion of that service and the Medicare payment to the physician for providing that service in a facility (non-office) setting. As noted previously, the net effect of the revised ASC payment system on beneficiary coinsurance, taking into account the migration of services from

HOPDs and physicians' offices, is estimated to be \$20 million in beneficiary savings in CY 2008.

1. Alternatives Considered

Alternatives to the changes we are making and the reasons that we have chosen the options are discussed throughout this final rule with comment period. Some of the major issues discussed in this final rule with comment period and the options considered are discussed below.

a. Office-Based Procedures

According to our final policy for the revised ASC payment system, we designate as office-based those procedures that are added to the ASC list of covered surgical procedures in CY 2008 or later years and that we determine are predominantly performed in physicians' offices based on consideration of the most recent available volume and utilization data for each individual procedure code and/or, if appropriate, the clinical characteristics, utilization, and volume of related codes. We establish payment for procedures designated as office-based at the lesser of the MPFS nonfacility PE RVU amount or the ASC rate developed according to the standard methodology of the revised ASC payment system. In the August 2, 2007 OPPTS/ASC proposed rule, we proposed to designate 19 additional procedures as office-based, based on our evaluation of the most recent available CY 2006 volume and utilization data for each individual procedure code and/or related codes. In developing this final rule with comment period, we reviewed the newly available CY 2006 utilization data for all the surgical procedures we proposed to designate as office-based. Based on that review, we are designating 18 additional procedures as office-based for CY 2008. We considered two alternatives in developing this policy.

The first alternative we considered was to make no change to the current policy for these 19 procedures. This would mean that we would continue to pay these procedures at the standard ASC payment rate developed according to the standard methodology of the revised ASC payment system. We did not select this alternative because our analysis of data for these services and related procedures indicated that 18 of the procedures we proposed to designate as office-based could be considered to be predominantly performed in physicians' offices. Consistent with our final policy adopted in the August 2, 2007 revised ASC payment system final rule (72 FR

42509), we were concerned that if these services were not designated as office-based, it could create financial incentives for the procedures to shift from physicians' offices to ASCs for reasons unrelated to the most appropriate setting for surgical care.

The second alternative we considered, and the alternative we selected, is to designate 18 additional procedures as office-based for CY 2008. We selected this alternative because our claims data indicate that these procedures could be considered to be predominantly performed in physicians' offices. We believe that designating these procedures as office-based, which results in the ASC payment rate for these procedures being capped at the physician's office rate (that is, the MPFS nonfacility practice PE RVU amount), if applicable, is an appropriate step to ensure that Medicare payment policy does not create financial incentives for such procedures to shift unnecessarily from physicians' offices to ASCs, consistent with our final policy adopted in the August 2, 2007 revised ASC payment system final rule.

b. Partial Device Credits

We are reducing the ASC payment by one half of the device offset amount for certain surgical procedures into which the device cost is packaged, when an ASC receives a partial credit toward replacement of specific implantable devices. This partial payment reduction will apply when the amount of the device credit is greater than or equal to 50 percent of the cost of the new replacement device being implanted. Under this policy, both the Medicare payment to the ASC and the beneficiary coinsurance liability will be reduced when an ASC receives a partial device credit. This policy is an extension of the policy established in the August 2, 2007 revised ASC payment system final rule, which reduces the ASC payment by the full device offset amount for certain devices when the ASC receives a replacement device without cost or receives a credit for the full cost of the device being replaced. The final partial device credit policy for ASCs mirrors the final partial device credit for the OPPTS in this final rule with comment period. We considered several alternatives in developing this partial device credit policy for CY 2008.

The first alternative we considered was to make no change to the current policy. Under this alternative, Medicare and the beneficiary would continue to pay the ASC the full payment rate for the device implantation procedure even if the ASC received a substantial credit towards the cost of the replacement

device. The ASC payment for the device implantation procedure is based on the OPPS relative weight for the procedure, which is calculated using only OPPS claims for which the full cost of a device is billed. We did not select this alternative because we believe that, as long as the ASC payment amount is established based on an OPPS relative weight that is calculated using only claims that reflect the full cost of the device when there is no credit, there should be a reduction in the Medicare payment amount when the ASC receives a substantial credit toward the cost of the replacement device. Similarly, we believe that the beneficiary cost sharing should be based on an amount that also reflects the device credit.

The second alternative we considered was to extend the current no cost/full credit reduction policy to cases of partial credit, without change. This would reduce the payment in all cases in which the ASC received a credit by the full offset amount for the device implantation procedure, that is, by 100 percent of the estimated device cost included in the procedure payment rate. We did not select this alternative because we did not believe it was appropriate to reduce the payment to the ASC by the full cost of a device if the ASC only received a partial credit, and not a full credit, towards the cost of the device.

The third alternative, which we are adopting in this final rule with comment period, is to reduce the ASC procedure payment by 50 percent of the offset amount (that will be applied if the ASC received full credit) in cases in which the ASC receives a partial credit greater than or equal to 50 percent of the cost of the new replacement device being implanted. This is consistent with the final CY 2008 OPPS policy described in detail in section IV.A.3. of this final rule with comment period. We will reduce the ASC payment for the specific procedure to implant the device by one-half of the device offset that would be applied if a replacement device were provided at no cost or with full credit, if the credit is 50 percent or more of the new replacement device cost, rather than the proposed 20 percent. We believe that payment policies across the OPPS and the ASC payment system should align whenever possible and appropriate, as is true in this case. Moreover, we are requiring the ASC to report a new modifier when the ASC receives a partial credit that is greater than or equal to 50 percent of the cost of the device being replaced. We are selecting this alternative because we believe that this approach provides an appropriate and equitable payment to

the ASC from Medicare and will reduce the beneficiary's cost sharing for the service.

c. Payment to Physicians for Services Not on the ASC List of Covered Surgical Procedures

Under current policy, when physicians perform surgical procedures in ASCs that are included on the ASC list of covered surgical procedures, they are paid under the MPFS for the PE component using the facility PE RVUs. When physicians perform surgical procedures in ASCs that are not included on the ASC list of covered surgical procedures and for which Medicare does not allow facility payments to ASCs, physicians currently are paid for the PE component at the higher nonfacility rate (unless a nonfacility rate does not exist, in which case Medicare pays the facility rate). In this final rule with comment period, we are providing that regardless of whether a procedure is on the ASC list of covered surgical procedures, a physician performing that procedure in an ASC will receive payment based on the facility PE RVUs and excluding the technical component (TC) payment, if applicable. We considered two alternatives in developing this policy.

The first alternative we considered was to make no change to the current policy concerning physician payment for services performed in ASCs that are not on the ASC list of covered surgical procedures. Under current policy, the physician is paid the higher nonfacility PE amount for performing a service in an ASC that is not on the ASC list of covered surgical procedures (unless a nonfacility rate does not exist in which case Medicare pays the facility PE rate). We adopted a final policy to identify and exclude from ASC payment only those procedures that could pose a significant risk to beneficiary safety or would be expected to require an overnight stay. Because the excluded procedures have been specifically identified by CMS as procedures that are unsafe for Medicare beneficiaries in ASCs because they could pose a significant risk to beneficiary safety or would be expected to require an overnight stay, we do not believe it would be appropriate to provide payment based on the higher nonfacility PE RVUs to physicians who furnish them. Consequently, we did not select this alternative.

The second alternative that we considered, and that we selected, was to provide payment to physicians for performing procedures in ASCs based on the facility PE RVUs and excluding the TC payment, if applicable,

regardless of whether a procedure is on the ASC list of covered surgical procedures. We selected this alternative for several reasons. We believe ASCs are facilities that are similar, insofar as the delivery of surgical and related nonsurgical services, to HOPDs. Specifically, when services are provided in ASCs, the ASC, not the physician, bears responsibility for the facility costs associated with the service. This situation parallels the hospital facility resource responsibility for hospital outpatient services. Therefore, we believe it would be more appropriate for physicians to be paid for all services furnished in ASCs just as they would be paid for all services furnished in the hospital outpatient setting. In addition, because we have adopted a final policy for the revised ASC payment system that identifies and excludes from ASC payment only those procedures that could pose a significant risk to beneficiary safety or would be expected to require an overnight stay, we believe that it would be incongruous with the revised ASC payment system methodology to continue to pay the higher nonfacility rate to physicians who furnish excluded ASC procedures.

2. Limitations of Our Analysis

Presented here are the projected effects of the policy and statutory changes that will be effective for CY 2008 on aggregate ASC utilization and Medicare payments. One limitation is our lack of information on ASC resource use. ASCs are not required to file Medicare cost reports and, therefore, we do not have cost information to evaluate whether or not the payments for ASC services coincide with the resources required by ASCs to provide those services. A second limitation of our analysis is our inability to predict changes in service mix between CY 2006 and CY 2008 with precision. The aggregated impact tables below are based upon a methodology that assumes no changes in service mix with respect to the CY 2006 ASC data used for this final rule with comment period. We believe that the net effect on Medicare expenditures resulting from changes in service mix for current ASC covered surgical procedures will be negligible in the aggregate. Such changes may have differential effects across surgical specialties as ASCs adjust to payment rates. However, we are unable to accurately project such changes at a disaggregated level. Clearly, individual ASCs will experience changes in payment that differ from the aggregated estimated changes presented below.

3. Estimated Effects of This Final Rule With Comment Period on ASCs

a. Payment to ASCs

Some ASCs are multispecialty facilities that perform the gamut of surgical procedures, from excision of lesions to hernia repair to cataract extraction; others focus on a single specialty and perform only a limited range of surgical procedures, such as eye, digestive system, or orthopedic procedures. The combined effect on an individual ASC of the CY 2008 revised payment system and the expanded ASC list of covered surgical procedures will depend on a number of factors, including, but not limited to, the mix of services the ASC provides, the volume of specific services provided by the ASC, the percentage of its patients who are Medicare beneficiaries, and the extent to which an ASC will choose to provide different services. The following discussion presents tables that provide estimates of the impact of the revised ASC payment system on Medicare payments to ASCs for current ASC services, assuming the same mix of services as reflected in our CY 2006 claims data. Table 63 depicts the aggregate percent change in payment by surgical specialty group and Table 64 shows a comparison of payment for procedures that we estimate would receive the most Medicare payment in CY 2008 under the current payment system.

In section XVI.C.1.c.(5) of this final rule with comment period, we reiterate the transition of 4 years under the revised ASC payment system, where payments for most surgical procedures will be made using a blend of the rates based on the CY 2007 ASC payment rate and the revised ASC payment rate. In CY 2008, we will pay ASCs using a 75/25 blend, in which payment will be calculated by adding 75 percent of the CY 2007 ASC rate for a surgical procedure on the CY 2007 ASC list of covered surgical procedures and 25 percent of the CY 2008 revised ASC rate for the same procedure. For CYs 2009 and 2010, we will transition the blend

first to 50/50 and then to a 25/75 blend of the CY 2007 ASC rate and the revised ASC payment rate. Beginning in CY 2011, we will pay ASCs for covered surgical procedures on the CY 2007 ASC list at the fully implemented revised ASC payment rates. We will not transition payment for procedures that were not included on the ASC list of covered surgical procedures in CY 2007; we will pay for these procedures at the fully implemented ASC rate, beginning in CY 2008.

Table 63 shows the effects on aggregate Medicare payments under the revised ASC payment system by surgical specialty group. We have aggregated the surgical HCPCS codes by specialty group and estimated the effect on aggregated payment for surgical specialty groups, considering separately the CY 2008 transitional rate and the fully implemented revised ASC payment rate discussed above. The groups are sorted for display in descending order by estimated Medicare program payment to ASCs for CY 2008 in the absence of the revised ASC payment system. The following is an explanation of the information presented in Table 63.

- Column 1—*Surgical Specialty Group* indicates the surgical specialties into which ASC procedures are grouped. We used the CPT code range definitions and Level II HCPCS codes and Category III CPT codes, as appropriate, to account for all surgical procedures to which the Medicare program payments are attributed.

- Column 2—*Estimated CY 2008 ASC Payments* in the absence of the revised ASC payment system were calculated by multiplying the CY 2007 ASC payment rate by CY 2008 ASC utilization (which is based on CY 2006 ASC utilization multiplied by a factor of 1.176 to take into account expected volume growth with volume adjustment, as appropriate, for the multiple procedure discount). The resulting amount was then multiplied by 0.8 to estimate the Medicare program's share of the total payments to the ASC. The estimated CY

2008 payment amounts are expressed in millions of dollars.

- Column 3—*Estimated CY 2008 Percent Change with Transition (75/25 Blend)* is the aggregate percentage increase or decrease in Medicare program payment to ASCs for each surgical specialty group that is attributable to changes in the ASC payment rates for CY 2008 under the 75/25 blend of the CY 2007 ASC payment rate and the CY 2008 revised ASC payment rate.

- Column 4—*Estimated CY 2008 Percent Change without Transition (Fully Implemented)* is the aggregate percentage increase or decrease in Medicare program payment to ASCs for each surgical specialty group that is attributable to changes in the ASC payment rates for CY 2008 if there were no transition period to the revised payment rates. The percentages appearing in Column 4 are presented as comparisons to the percentage changes under the transition policy in column 3 and do not depict the impact of the fully implemented policy in 2011.

As seen in Table 63, for all but digestive system procedures, if an ASC offers the same mix of services in CY 2008 that is reflected in our national CY 2006 claims data, Medicare payments to the ASC for services in that surgical specialty group are expected to increase under the revised payment system. If the revised payment system was fully implemented in CY 2008, we expect all but digestive system procedures and nervous system procedures to receive greater Medicare payment. In addition to the effects on Medicare payments for current ASC procedures shown in Table 63, it is important to note that estimated CY 2008 payments to ASCs are estimated to increase by more than \$240 million in CY 2008 due to projected migration of new ASC services from HOPDs and physicians' offices to ASC. This increased spending in ASCs is projected to be fully offset by savings from reduced spending in HOPDs and physicians' offices due to service migration.

TABLE 63.—ESTIMATED CY 2008 IMPACT OF THE REVISED ASC PAYMENT SYSTEM ON ESTIMATED AGGREGATE CY 2008 MEDICARE PROGRAM PAYMENTS UNDER THE 75/25 TRANSITION BLEND AND WITHOUT A TRANSITION, BY SURGICAL SPECIALTY GROUP

Surgical specialty group (1)	Estimated CY 2008 ASC payments (in millions) (2)	Estimated CY 2008 percent change with transition (75/25 Blend) (3)	Estimated CY 2008 percent change without transition (fully implemented) (4)
Eye and ocular adnexa	\$1,247	2	3

TABLE 63.—ESTIMATED CY 2008 IMPACT OF THE REVISED ASC PAYMENT SYSTEM ON ESTIMATED AGGREGATE CY 2008 MEDICARE PROGRAM PAYMENTS UNDER THE 75/25 TRANSITION BLEND AND WITHOUT A TRANSITION, BY SURGICAL SPECIALTY GROUP—Continued

Surgical specialty group (1)	Estimated CY 2008 ASC payments (in millions) (2)	Estimated CY 2008 percent change with transition (75/25 Blend) (3)	Estimated CY 2008 percent change without transition (fully implemented) (4)
Digestive system	708	-4	-16
Nervous system	260	3	-4
Musculoskeletal system	165	24	94
Integumentary system	75	8	32
Genitourinary system	74	11	43
Respiratory system	18	16	64
Cardiovascular system	8	24	94
Auditory system	4	23	80
Hemic and lymphatic systems	2	31	124
Other systems	0.1	27	108

Table 64 below shows the estimated impact of the revised payment system on aggregate ASC payments for selected procedures during the first year of implementation (CY 2008) with and without the transitional blended rate. The table displays 30 of the procedures receiving the most Medicare estimated CY 2008 ASC payments under the existing Medicare payment system. The HCPCS codes are sorted in descending order by estimated program payment.

- Column 1—*HCPCS code*
- Column 2—*Short Descriptor* of the HCPCS code
- Column 3—*Estimated CY 2008 ASC Payments* in the absence of the revised payment system were calculated by multiplying the CY 2007 ASC payment

rate by CY 2008 ASC utilization (which is based on CY 2006 ASC utilization multiplied by a factor of 1.176 to take into account expected volume growth with volume adjustment, as appropriate, for the multiple procedure discount). The resulting amount was then multiplied by 0.8 to estimate the Medicare program's share of the total payments to the ASC. The estimated CY 2008 payment amounts are expressed in millions of dollars.

- Column 4—*CY 2008 Percent Change with Transition (75/25 Blend)* reflects the percent differences between the estimated ASC payment rates for CY 2008 under the current system and the payment rates for CY 2008 under the revised system, incorporating a 75/25

blend of the estimated ASC payment using the CY 2007 ASC payment rate and the CY 2008 revised ASC payment rate.

- Column 5—*CY 2008 Percent Change without Transition (Fully Implemented)* reflects the percent differences between the estimated ASC payment rates for CY 2008 under the current system and the estimated payment rates for CY 2008 under the revised payment system if there were no transition period to the revised payment rates. The percentages appearing in Column 5 are presented as a comparison to the percentage changes under the transition policy in Column 4 and do not depict the impact of the fully implemented policy in 2011.

TABLE 64.—ESTIMATED CY 2008 IMPACT OF REVISED ASC PAYMENT SYSTEM ON AGGREGATE PAYMENTS FOR PROCEDURES WITH THE MOST MEDICARE ESTIMATED CY 2008 PAYMENTS UNDER THE CURRENT SYSTEM

HCPCS code	Short descriptor	Estimated CY 2008 ASC payments (in millions)	Estimated CY 2008 percent change (75/25 blend)	Estimated CY 2008 percent changes without transition (fully implemented)
66984	Cataract surg w/iol, 1 stage	1,017	0	1
43239	Upper GI endoscopy, biopsy	156	-5	-17
45378	Diagnostic colonoscopy	141	-4	-14
45380	Colonoscopy and biopsy	115	-4	-14
45385	Lesion removal colonoscopy	95	-4	-14
66821	After cataract laser surgery	89	-8	-25
62311	Inject spine l/s (cd)	75	-3	-10
64483	Inj foramen epidural l/s	43	-3	-10
66982	Cataract surgery, complex	39	0	1
45384	Lesion remove colonoscopy	39	-4	-14
G0121	Colon ca scrn not hi rsk ind	36	-7	-22
G0105	Colorectal scrn; hi risk ind	28	-7	-22
15823	Revision of upper eyelid	26	4	12
43235	Uppr gi endoscopy, diagnosis	24	1	4
52000	Cystoscopy	23	-6	-21
64475	Inj paravertebral l/s	23	-3	-10

TABLE 64.—ESTIMATED CY 2008 IMPACT OF REVISED ASC PAYMENT SYSTEM ON AGGREGATE PAYMENTS FOR PROCEDURES WITH THE MOST MEDICARE ESTIMATED CY 2008 PAYMENTS UNDER THE CURRENT SYSTEM—Continued

HCPCS code	Short descriptor	Estimated CY 2008 ASC payments (in millions)	Estimated CY 2008 percent change (75/25 blend)	Estimated CY 2008 percent changes without transition (fully implemented)
64476	Inj paravertebral l/s ADD-on	22	-18	-65
29881	Knee arthroscopy/surgery	17	22	55
64721	Carpal tunnel surgery	16	17	43
43248	Uppr gi endoscopy/guide wire	14	-5	-17
62310	Inject spine c/t	13	-3	-10
67904	Repair eyelid defect	12	6	16
29880	Knee arthroscopy/surgery	12	22	55
64484	Inj foramen epidural ADD-on	12	-12	-42
28285	Repair of hammertoe	10	17	44
G0260	Inj for sacroiliac jt anesth	10	-3	-10
29848	Wrist endoscopy/surgery	9	-3	-8
64623	Destr paravertebral n ADD-on	9	-3	-10
45383	Lesion removal colonoscopy	8	-4	-14
26055	Incise finger tendon sheath	8	13	35

Over time, we believe that the current ASC payment system has served as an incentive to ASCs to focus on providing procedures for which they determine Medicare payments will support the ASC's continued operation. We note that, under the existing payment system, the ASC payment rates for many of the most frequently performed procedures in ASCs are similar to the OPPS payment rates for the same procedures. Conversely, we note that procedures with existing ASC payment rates that are substantially lower than the OPPS rates are performed least often in ASCs. We believe the revised ASC payment system represents a major stride towards encouraging greater efficiency in ASCs and promoting a significant increase in the breadth of surgical procedures performed in ASCs, because it distributes payments across the entire spectrum of covered surgical procedures, based on a coherent system of relative payment weights that are related to the clinical and facility resource characteristics of those procedures.

Table 64 identifies a number of ASC procedures receiving the most Medicare estimated CY 2008 payment under the current system and shows that most of them will experience payment decreases in CY 2008 under the revised ASC payment system. This contrasts with the estimated aggregate payment increases at the surgical specialty group level displayed in Table 63. In fact, Table 63 shows only one surgical specialty group of procedures for which the payments are expected to decrease in the first year under the revised ASC payment system, and only two groups for which a

decrease would be expected if there were no transition period to the revised CY 2008 payment rates. The estimated increased payments at the full group level are due to the moderating effect of the payment increases for the less frequently performed procedures within the surgical specialty group. The exception to this is the surgical specialty group of eye and ocular adnexa where the projected aggregate increase in CY 2008 under the revised system is driven by a very small increase, less than 1 percent, in payment for the highest volume procedure (CPT code 66984, Extracapsular cataract removal with insertion of intraocular lens prosthesis (one stage procedures), manual or mechanical technique (e.g., irrigation and aspiration or phacoemulsification)).

As a result of the redistribution of payments across the expanded breadth of surgical procedures for which Medicare will provide an ASC payment, we believe that ASCs may change the mix of services they provide over the next several years. The revised ASC payment system should encourage ASCs to expand their service-mix beyond the handful of the highest paying procedures which comprise the majority of ASC utilization under the existing ASC payment system. For example, although the payment rate for cystoscopy (CPT code 52000), the highest volume ASC genitourinary procedure, is 6 percent less for CY 2008 than under the existing payment system, overall payment to ASCs for the group of genitourinary procedures currently performed in ASCs is expected to increase by 11 percent. Although a

urology specialty ASC may currently perform more cystoscopy procedures than any other genitourinary procedure, we believe that under the revised ASC payment system, each ASC has the opportunity to adapt to the payment decrease for its most frequently performed procedures by offering an increased breadth of procedures, still within the clinical specialty area, and receive payments that are adequate to support continued operations. Similarly, payment for all of the highest volume pain management injection procedures are expected to decrease in CY 2008, although payment for nervous system procedures overall are expected to increase. However, if there were no transition period, we estimate that CY 2008 payments also would decrease slightly for the nervous system surgical specialty group.

We note that the estimated percent changes in payment under the revised ASC payment system for the surgical procedures with the highest aggregate Medicare ASC payments closely resemble those presented in the CY 2008 OPPS/ASC proposed rule, with the exception of CPT codes 64476 (Injection, anesthetic agent and/or steroid, paravertebral facet joint or facet joint nerve; lumbar or sacral, each additional level (List separately in addition to code for primary procedure)); and 64484 (Injection, anesthetic agent and/or steroid, transforaminal epidural; lumbar or sacral, each additional level (List separately in addition to code for primary procedure)). Our estimates of the percent changes in ASC payment for these two injection procedures are

considerably greater for this final rule than they were for the CY 2008 OPPS/ASC proposed rule. Both of these nervous system procedures had significantly more single claims available for OPPS ratesetting for this final rule with comment period, reflecting much lower costs than their median costs for the proposed rule. These data resulted in the reassignment of CPT codes 64476 and 64484 to different clinical APCs for CY 2008 than proposed, in order to ensure the clinical and resource homogeneity of the OPPS APCs for CY 2008. Their lower OPPS payment rates in turn resulted in lower payments than those estimated in the proposed rule for the two services under the revised ASC payment system. However, as shown in Table 63, above, the final estimated decrease in ASC payment for nervous system procedures overall without the transition is estimated to be 4 percent in this final rule with comment period, very close to the CY 2008 OPPS/ASC proposed rule estimated decrease of 2 percent for nervous system procedures. Thus, we believe that our final policies will continue to ensure Medicare beneficiary access to surgical procedures involving the nervous system in ASCs under the revised ASC payment system in CY 2008.

For those procedures that will be paid a significantly lower amount under the revised payment system than they are currently paid, we believe that their current payment rates, which are closer to the OPPS payment rates than are the rates for other ASC procedures, are likely to be generous relative to ASC costs, so ASCs would, in all likelihood, continue performing those procedures under the revised payment system. We also note that the majority of the most frequently performed ASC procedures specifically studied by the GAO for its report to Congress on ASC costs, as described in the August 2, 2007 revised ASC payment system final rule (72 FR 42474), appear in Table 64 with payment decreases under the revised ASC payment system. The GAO concluded that for those procedures the OPPS APC groups accurately reflect the relative costs of procedures performed at ASCs and that ASCs have substantially lower costs.

For some procedures, the payment amounts in CY 2008 are much higher than the CY 2007 rates currently paid to ASCs. For example, payments for CPT codes 29880 (Arthroscopy, knee, surgical; with meniscectomy (medial AND lateral, including any meniscal shaving)) and 29881 (Arthroscopy, knee, surgical; with meniscectomy (medial OR lateral, including meniscal shaving))

increase by 22 percent. For these two procedures and the other procedures with estimated payment increases greater than 10 percent, the increases are due to the comparatively higher OPPS rates which, when adjusted by the ASC budget neutrality factor and blended with the CY 2007 ASC payment amounts, generate CY 2008 ASC payment rates that are substantially above the current CY 2007 ASC payment amounts.

As indicated elsewhere in this final rule with comment period, payments for most of the highest volume colonoscopy and upper gastrointestinal endoscopy procedures will decrease under the revised payment system. Table 63 estimates that payment decreases also are expected for the digestive system surgical specialty group overall. We believe that the reason for decreased payments for so many of the digestive system procedures is that the current ASC payment rates are close to the OPPS rates. Procedures with current payment rates that are nearly as high as their OPPS rates are negatively affected under the revised payment system while procedures for which ASC rates have historically been much lower than the comparable OPPS rates are positively affected. The payment decreases expected in the first year under the revised ASC payment system for some of the high volume digestive system procedures are not large (all less than or equal to 7 percent). We believe that ASCs can generally continue to cover their costs for these procedures, and that ASCs specializing in providing those services will be able to adapt their business practices and case mix to manage declines for individual procedures.

In addition to the procedures currently on the ASC list of covered surgical procedures discussed above, in CY 2008 we also are adding hundreds of surgical procedures to the already extensive list of procedures for which Medicare allows payment to ASCs, creating new opportunities for ASCs to expand their range of covered surgical procedures. For the first time, ASCs will be paid separately for covered ancillary services that are integral to covered surgical procedures, including certain radiology procedures, costly drugs and biologicals, devices with pass-through status under the OPPS, and brachytherapy sources. While separately paid radiology services will be paid based on their ASC relative payment weight calculated according to the standard ratesetting methodology of the revised ASC payment system or the MPFS nonfacility PE RVU amount, whichever is lower, the other covered

ancillary items and services newly eligible for separate payment in ASCs will be paid comparably to their OPPS rates because we would not expect ASCs to experience efficiencies in providing them. Lastly, the August 2, 2007 revised ASC payment system final rule established a specific payment methodology for device-intensive procedures that provides the same packaged payment for the device as under the OPPS, while providing a reduced service payment that is subject to the 4-year transition if the device-intensive procedure is on the CY 2007 ASC list of covered surgical procedures. We expect that this final methodology will allow ASCs to continue to expand their provision of device-intensive services and to begin performing new device-intensive ASC procedures.

b. Payment to Physicians for Performing Excluded ASC Procedures in an ASC

As discussed in section XVI.G. of this final rule with comment period, we are paying physicians at the facility rate for furnishing procedures in ASCs that are excluded from the ASC list of covered procedures. This policy reduces site of service (facility versus nonfacility) differentials that currently exist and aligns physician payment policies for services furnished in ASCs and HOPDs.

We believe that the effect of the change will be small. Currently, physicians are paid for procedures performed in ASCs that are not on the list of ASC covered surgical procedures based on the nonfacility PE RVUs, unless a nonfacility rate does not exist, in which case they are paid based on the facility rate. For CY 2008, we excluded procedures from the ASC list of covered surgical procedures because they could pose a significant risk to beneficiary safety or would be expected to require an overnight stay and, as such, the excluded procedures are generally more complex than procedures furnished in physicians' offices. Consequently, most surgical procedures that are excluded from the list of ASC covered surgical procedures in CY 2008 do not have nonfacility PE RVUs. Specifically, only about 46 of approximately 2,000 excluded ASC procedures for CY 2008 have nonfacility PE RVUs. As a result, even under our current policy, physicians performing an excluded ASC procedure in an ASC would be paid for most excluded procedures based on the facility PE RVUs. Thus, our policy to pay physicians for excluded ASC procedures performed in ASCs based on the facility PE RVUs will only affect Medicare payment rates for the small proportion of excluded procedures that have nonfacility PE RVUs.

4. Estimated Effects of This Final Rule With Comment Period on Beneficiaries

a. Payment to ASCs

We estimate that the changes for CY 2008 will be positive for beneficiaries in at least two respects. Except for screening colonoscopy and flexible sigmoidoscopy procedures, the ASC coinsurance rate for all procedures is 20 percent. This contrasts with procedures performed in HOPDs where the beneficiary is responsible for copayments that range from 20 percent to 40 percent. In addition, ASC payment rates under the revised payment system are lower than payment rates for the same procedures under the OPPTS, so the beneficiary coinsurance amount under the ASC payment system almost always will be less than the OPPTS copayment amount for the same services. (The only exceptions will be when the ASC coinsurance amount exceeds the inpatient deductible. The statute requires that copayment amounts under the OPPTS not exceed the inpatient deductible.) Beneficiary coinsurance for services migrating from physicians' offices to ASCs may decrease or increase under the revised ASC payment system, depending on the particular service and the relative payment amounts for that service in the physician's office compared with the ASC. As noted previously, the net effect of the revised ASC payment system on beneficiary coinsurance, taking into account the migration of services from HOPDs and physicians' offices, is estimated to be \$20 million in beneficiary savings in CY 2008.

In addition to the lower out-of-pocket expenses, we believe that beneficiaries also will have access to more services in ASCs as a result of the addition of approximately 800 surgical procedures to the ASC list of covered surgical services eligible for Medicare payment in CY 2008. We expect that ASCs will provide a broader range of surgical services under the revised payment system and that beneficiaries will benefit from having access to a greater variety of surgical procedures in ASCs.

b. Payment to ASCs for Excluded Procedures Performed in an ASC

In addition, the revision to §§ 414.22(b)(5)(i)(A) and (B) will impose beneficiary liability for facility costs associated with surgical procedures that are not Medicare covered surgical procedures in ASCs. In the August 2, 2007 revised ASC payment system final rule, CMS determined that the only surgical procedures that will be excluded from ASC payment in CY 2008 are those that could pose a significant

safety risk to beneficiaries when furnished in an ASC or are expected to require an overnight stay when furnished in ASCs and, therefore, Medicare provides no payment to ASCs for these procedures. The revision to §§ 414.22(b)(5)(i)(A) and (B) will also provide for no payment to physicians for the facility resources required to furnish excluded services in ASCs, leaving the beneficiary liable for the facility payment if a surgical procedure excluded by Medicare from ASC payment is, in fact, performed in the ASC setting. We do not expect that the change will result in a meaningful increase in beneficiary liability because we do not expect that excluded services, which we have determined could pose a significant risk to beneficiary safety or would be expected to require an overnight stay, will be furnished to Medicare beneficiaries in ASCs. Furthermore, we expect that physicians and ASCs will advise beneficiaries of all of the possible consequences (including denial of Medicare payment with concomitant beneficiary liability and significant surgical risk) if surgical procedures excluded from ASC payment are provided in ASCs.

5. Conclusion

The changes to the ASC payment system for CY 2008 will affect each of the approximately 4,800 ASCs currently approved for participation in the Medicare program. The effect on an individual ASC will depend on the ASC's mix of patients, the proportion of the ASC's patients that are Medicare beneficiaries, the degree to which the payments for the procedures offered by the ASC are changed under the revised payment system, and the degree to which the ASC chooses to provide a different set of procedures.

The revised ASC payment system is designed to result in the same aggregate amount of Medicare expenditures in CY 2008 that would be made in the absence of the revised ASC payment system. As mentioned previously, we estimate that the revised ASC payment system and the expanded ASC list of covered surgical procedures that we are implementing in CY 2008 will have no net effect on Medicare expenditures compared to the level of Medicare expenditures that would have occurred in CY 2008 in the absence of the revised payment system. However, there will be a total increase in Medicare payments to ASCs for CY 2008 of approximately \$240 million as a result of the revised ASC payment system, which will be fully offset by savings from reduced Medicare spending in HOPDs and physicians' offices on services that

migrate from these settings to ASCs (as discussed in detail in section XVI.L. of this final rule with comment period). Furthermore, we estimate that the revised ASC payment system will result in Medicare savings of \$220 million over 5 years due to migration of new ASC services from HOPDs and physicians' offices to ASCs over time. We anticipate that this final rule with comment period will have a significant economic impact on a substantial number of small entities.

6. Accounting Statement

As required by OMB Circular A-4 (available at <http://www.whitehouse.gov/omb/circulars/a004/a-4.pdf>), in Table 65 below, we have prepared an accounting statement showing the classification of the expenditures associated with the implementation of the CY 2008 revised ASC payment system, based on the provisions of this final rule with comment period. As explained above, we estimate that Medicare payments to ASCs for CY 2008 will be about \$240 million higher than they otherwise would be in the absence of the revised ASC payment system. This \$240 million in additional payments to ASCs will be fully offset by savings from reduced Medicare spending in HOPDs and physicians' offices on services that migrate from these settings to ASCs. This table provides our best estimate of Medicare payments to providers and suppliers as a result of the CY 2008 revised ASC payment system, as presented in this final rule with comment period. All expenditures are classified as transfers.

TABLE 65.—ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED EXPENDITURES FROM CY 2007 TO CY 2008 AS A RESULT OF THE CY 2008 REVISED ASC PAYMENT SYSTEM

Category	Transfers
Annualized Monetized Transfers. From Whom to Whom	\$0 Million. Federal Government to Medicare Providers and Suppliers.
Annualized Monetized Transfer. From Whom to Whom	\$0 Million. Premium Payments from Beneficiaries to Federal Government.
Total	\$0 Million.

D. Effects of the Requirements for Reporting of Quality Data for Hospital Outpatient Settings

In section XVII. of this final rule with comment period, we discuss our measures and requirements for reporting of quality data to CMS for services furnished in hospital outpatient settings under the HOP QDRP. We note that we have reduced the number of initial quality measures to be reported from the 10 we proposed to 7. We have also modified the date for which the initial submission of quality data begins from services furnished on or after January 2008 to services furnished on or after April 2008. The initial submission for data for April–June 2008 services is due to the OPDS Clinical Warehouse by November 1, 2008. CMS and its contractors will provide assistance to all hospitals that wish to submit data. In addition, we have modified our proposal for the CY 2009 payment update, so that hospitals are not required to submit charts for or pass our validation requirement of a minimum of 80 percent reliability, based upon our chart-audit validation process for January 2008 services. As noted in section XVII.E. of this final rule with comment period, we are providing validation criteria for services furnished on or after July 1, 2008 for purposes of the CY 2010 and subsequent years' payment updates to ensure that the quality data being sent to CMS are accurate. The requirement of five charts per hospital per quarter will result in the submission of approximately 21,500 charts per quarter for services furnished on or after July 1, 2008 to the agency. We believe that a requirement for five charts per hospital per quarter for services furnished on or after July 1, 2008, represents a minimal burden to the participating hospital.

E. Effects of Policy Revisions on CAH Off-Campus and Co-Location Requirements

In section XVIII.A. of the preamble of this final rule with comment period, we discuss our changes regarding a CAH's ability to co-locate with another acute care hospital or establish an off-campus location that does not comply with the location requirements (more than a 35-mile drive, or in the case of mountainous terrain or in areas with only secondary roads available, a 15-mile drive) for CAHs. We clarified in this final rule with comment period that if a CAH with a necessary provider designation has a co-location arrangement with another hospital or CAH that was in effect before January 1, 2008, and the type and scope of services

offered by the facilities co-located with the necessary provider CAH do not change, the CAH can continue those arrangements. In addition, if a CAH (including one with a necessary provider designation) acquires or creates an off-campus provider-based location or an off-campus distinct part psychiatric or rehabilitation unit on or after January 1, 2008, the CAH off-campus provider-based facility must comply with the location requirements. We revised the language of the regulation to exclude RHCs, as defined under § 405.2401(b), from the list of provider-based facilities that must comply with this regulation. Because CAHs can continue current co-location and off-campus arrangements that are in place before January 1, 2008, we believe there is no burden associated with this regulation.

F. Effects of Policy Revisions to the Hospital CoPs

In section XVIII.B. of the preamble of this final rule with comment, we discuss changes to the hospital CoPs relating to timeframes for completion of medical history and physical examinations and requirements for preanesthesia and postanesthesia evaluations of Medicare beneficiaries. We believe that these revisions would impose minimal additional costs on hospitals. In fact, hospitals may realize some minimal cost savings. The cost of implementing these changes would largely be limited to the one-time cost related to the revision of a hospital's medical staff bylaws and its policies and procedures as they relate to the requirements for medical history and physical examinations and for preanesthesia and postanesthesia evaluations. There also may be some minimal cost associated with communicating these changes to affected hospital staff. However, we believe that these costs would be offset by the benefits derived from the overall intent of these revisions to require that the most current information regarding a patient's condition be available to hospital staff so that risks to patient safety can be minimized and potential adverse outcomes can be avoided. Furthermore, the changes would clarify existing hospital CoPs to make them more consistent with current practice, while still retaining the flexibility and reduction in burden that hospitals are currently provided in meeting those CoPs. Therefore, no burden is being assessed on the revision of medical staff bylaws and hospital policies and procedures or on the communication of these revisions to staff that would be required by these revisions as these

practices are usual and customary business practices.

In accordance with the provisions of Executive Order 12866, this final rule with comment period was reviewed by the OMB.

G. Impact of the Changes to the Hospital Inpatient Prospective Payment System (IPPS) Payment Rates

1. Overall Impact

We have examined the impacts of this final rule relating to the changes to hospital inpatient prospective payment system payment rates as required by Executive Order 12866 (September 1993, Regulatory Planning and Review), section 1102(b) of the Social Security Act, the Unfunded Mandates Reform Act of 1995 (Public Law 104–4), and Executive Order 13132. We have also examined the impacts of this final rule in the context of the Regulatory Flexibility Act (RFA) (September 19, 1980, Public Law 96–354).

Based on the IPPS provisions specified in section XIX. of this final rule, we have determined that this rule is a major rule as defined in 5 U.S.C. 804(2). This final rule includes changes in FY 2008 IPPS payments due to the enactment of Public Law 110–90, which requires the Secretary to apply a prospective documentation and coding adjustment for discharges during FY 2008 of –0.6 percent rather than the –1.2 percent specified in the FY 2008 IPPS final rule. In addition, this final rule includes a change in policy to not apply the documentation and coding adjustment to the hospital-specific payment rates. We estimate that the increase in FY 2008 IPPS operating and capital payments to hospitals resulting from the provisions of this final rule will be in excess of \$100 million.

With the exception of the IPPS changes included in this final rule, all FY 2008 IPPS payment policies were established in the FY 2008 IPPS final rule (72 FR 47130) issued on August 1, 2007. As noted in section XIX. of this document, on September 28, 2007, we issued a notice relating to the FY 2008 IPPS final rule that corrected a technical calculation and typographical errors in that final rule. The correction notice appeared in the October 10, 2007 **Federal Register** and is hereinafter referred to as the “second FY 2008 IPPS correction notice.” In the second FY 2008 IPPS correction notice, we estimated a \$4.0 billion increase in FY 2008 operating and capital payments as a result of the market basket update to the FY 2008 IPPS rates required by the statute, in conjunction with the other payment policies established in the FY

2008 IPPS final rule. In this final rule, we have updated our estimate of the increase in FY 2008 IPPS operating and capital payments based on the policies and market basket update established in the FY 2008 IPPS final rule and the addition of the IPPS provisions included in this final rule. We now estimate an increase in FY 2008 operating and capital payments of approximately \$4.6 billion, an increase of about \$665 million over our prior estimate. Our current estimate includes the statutorily mandated -0.6 percent adjustment for documentation and coding changes to the IPPS standardized amounts and capital Federal rates for FY 2008 under section 7 of Public Law 110-90, and the removal of the application of the documentation and coding adjustment to the hospital-specific rates. For purposes of the impact analysis, we also assume a 1.2 percent increase in case-mix growth, as determined by the Office of the Actuary, because we believe the adoption of the MS-DRGs will result in case-mix growth due to documentation and coding changes that do not reflect real changes in patient severity of illness. The estimates do not reflect any other changes in hospital admissions or case-mix intensity in operating PPS payments, which will also affect overall payment changes.

The RFA requires agencies to analyze options for regulatory relief of small businesses for any rule for which the agency publishes a general notice of proposed rulemaking. Since we have waived notice and comment rulemaking for the IPPS provisions in this final rule as discussed in section XIX.C. of this final rule, we do not believe the Regulatory Flexibility Act requires a regulatory flexibility analysis in this case. While we do not believe we are required to perform a regulatory flexibility analysis, we are including in section XIX. of this final rule and in this impact analysis section final rule all of the components that would be required of a final regulatory flexibility analysis.

For purposes of the RFA, small entities include small businesses, nonprofit organizations, and government agencies. Most hospitals and most other providers and suppliers are considered to be small entities, either by nonprofit status or by having revenues of \$31.5 million or less in any 1 year. (For details on the latest standards for health care providers, we refer readers to page 33 of the Table of Small Business Size Standards at the Small Business Administration Web site at: <http://www.sba.gov/services/contractingopportunities/sizestandardstocps/tableofsize/>

index.html.) For purposes of the RFA, all hospitals and other providers and suppliers are considered to be small entities. Individuals and States are not included in the definition of a small entity. We believe that the IPPS payment rate changes in this final rule will have a significant impact on small entities as explained subsequently.

In addition, section 1102(b) of the Act requires us to prepare a regulatory impact analysis for any proposed or final rule that may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 604 of the RFA. With the exception of hospitals located in certain New England counties, for purposes of section 1102(b) of the Act, we now define a small rural hospital as a hospital that is located outside of an urban area and has fewer than 100 beds. Section 601(g) of the Social Security Amendments of 1983 (Public Law 98-21) designated hospitals in certain New England counties as belonging to the adjacent urban area. Thus, for purposes of the IPPS, we continue to classify these hospitals as urban hospitals.

Section 202 of the Unfunded Mandates Reform Act of 1995 (Public Law 104-4) also requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of \$100 million in 1995 dollars, updated annually for inflation. That threshold level is currently approximately \$120 million. This IPPS changes in this final rule will not mandate any requirements for State, local, or tribal governments, nor will it affect private sector costs.

Executive Order 13132 establishes certain requirements that an agency must meet when it promulgates a proposed rule (and subsequent final rule) that imposes substantial direct requirement costs on State and local governments, preempts State law, or otherwise has Federalism implications. As stated above, the IPPS changes in this final rule will not have a substantial effect on State and local governments.

The following analysis, in conjunction with the section XIX. of this document, demonstrates that this rule is consistent with the regulatory philosophy and principles identified in Executive Order 12866, the RFA, and section 1102(b) of the Act. The rule will affect payments to a substantial number of small rural hospitals, as well as other classes of hospitals, and the effects on some hospitals may be significant.

2. Objectives

The primary objective of the IPPS is to create incentives for hospitals to

operate efficiently and minimize unnecessary costs while at the same time ensuring that payments are sufficient to adequately compensate hospitals for their legitimate costs. In addition, we share national goals of preserving the Medicare Hospital Insurance Trust Fund.

We believe that the policies established in the FY 2008 IPPS final rule and the IPPS provisions of this final rule will further each of these goals while maintaining the financial viability of the hospital industry and ensuring access to high quality health care for Medicare beneficiaries. We expect that these changes will ensure that the outcomes of this payment system are reasonable and equitable while avoiding or minimizing unintended adverse consequences.

3. Limitations of Our Analysis

The following quantitative analysis presents the projected effects of our IPPS policy changes, as well as statutory changes effective for FY 2008, on various hospital groups. We use the best available data, but generally do not attempt to make adjustments for future changes in such variables as admissions, length of stay, or case-mix. However, as stated in the FY 2008 IPPS final rule, we believe that adoption of the MS-DRGs will create a risk of increased aggregate levels of payment as a result of more comprehensive documentation and coding. As explained in section XIX. of this final rule, the FY 2008 IPPS final rule established a documentation and coding adjustment of -1.2 percent to maintain budget neutrality for the transition to the MS-DRGs. Subsequently, Congress enacted Public Law 110-90, which reduced the FY 2008 IPPS documentation and coding adjustment from -1.2 percent to -0.6 percent. Therefore, in section XIX. of this final rule, we have revised the payment rates, factors and thresholds to reflect the -0.6 percent documentation and coding adjustment. While the documentation and coding adjustment has been changed for payment purposes, we continue to believe that an increase in case mix of 1.2 percent in FY 2008 is likely as a result of the adoption of the MS-DRGs. The impacts shown below illustrate the impact of the FY 2008 IPPS changes on hospital operating payments, including the -0.6 percent documentation and coding adjustment to the IPPS standardized amounts, both prior to and following the projected 1.2 percent growth in case-mix.

4. Quantitative Effects of the IPPS Policy Changes for Operating Costs

In this final rule, we are employing the same operating payment simulation model as used in the FY 2008 IPPS final rule. Our methodology underlying the simulation model is discussed in detail in the FY 2008 IPPS final rule (72 FR 48158 through 48159). The difference between the impact estimates in this final rule and the FY 2008 IPPS final rule reflects the application of a documentation and coding adjustment of -0.6 percent (instead of -1.2 percent) and the removal of the application of the documentation and coding adjustment to the hospital-specific rates. Our impact estimates in this final rule also reflect a technical correction to a calculation error made in our previously published impact estimates, as discussed in more detail subsequently.

5. Analysis of Table I

Table I displays the estimated increase in IPPS operating payments between FY 2007 and FY 2008. It compares the impact estimates previously published in the second FY 2008 IPPS correction notice to the FY 2008 IPPS final rule, which is based on the payment policies and market basket update established in the FY 2008 IPPS final rule, with our current impact estimates, which are based on both the IPPS policies established in the FY 2008 IPPS final rule and the IPPS policy changes included in this final rule.

As noted previously, we believe that the adoption of the MS-DRGs in FY 2008 will create a financial risk of increased aggregate payments as a result of more comprehensive documentation and coding. To maintain budget neutrality, the FY 2008 IPPS final rule established a documentation and coding adjustment of -1.2 percent for FY 2008. Subsequently, Public Law 110-90 was enacted, which reduces the FY 2008 documentation and coding adjustment

from -1.2 percent to -0.6 percent. Thus, our previously published impact estimates reflect a -1.2 percent documentation and coding adjustment and our current impact estimates reflect a -0.6 percent adjustment. While the documentation and coding adjustment has been changed for payment purposes, we continue to believe that an increase in case-mix of 1.2 percent for FY 2008 is likely to occur. Table 1 illustrates the impact of the FY 2008 IPPS changes on hospital payments, including the documentation and coding adjustment to the IPPS standardized amounts, both prior to and following the projected 1.2 percent growth in case-mix.

The table categorizes hospitals by various geographic and special payment considerations to illustrate the varying impacts on different types of hospitals. The top row of the table shows the overall impact on the 3,534 hospitals included in the analysis.

The next four rows of Table I contain hospitals categorized according to their geographic location: All urban, which is further divided into large urban and other urban; and rural. There are 2,539 hospitals located in urban areas included in our analysis. Among these, there are 1,406 hospitals located in large urban areas (populations over 1 million), and 1,133 hospitals in other urban areas (populations of 1 million or fewer). In addition, there are 995 hospitals in rural areas. The next two groupings are by bed size categories, shown separately for urban and rural hospitals. The final groupings by geographic location are by census divisions, also shown separately for urban and rural hospitals.

The second part of Table I shows hospital groups based on hospitals' FY 2008 payment classifications, including any reclassifications under section 1886(d)(10) of the Act. For example, the rows labeled urban, large urban, other urban, and rural show that the number of hospitals paid based on these categorizations after consideration of

geographic reclassifications (including reclassifications under section 1886(d)(8)(B) and section 1886(d)(8)(E) of the Act that have implications for capital payments) are 2,578, 1,425, 1,153, and 956, respectively.

The next three groupings examine the impacts of the changes on hospitals grouped by whether or not they have GME residency programs (teaching hospitals that receive an IME adjustment) or receive DSH payments, or some combination of these two adjustments. There are 2,480 nonteaching hospitals in our analysis, 815 teaching hospitals with fewer than 100 residents, and 239 teaching hospitals with 100 or more residents.

In the DSH categories, hospitals are grouped according to their DSH payment status, and whether they are considered urban or rural for DSH purposes. The next category groups together hospitals considered urban after geographic reclassification, in terms of whether they receive the IME adjustment, the DSH adjustment, both, or neither.

The next five rows examine the impacts of the changes on rural hospitals by special payment groups (SCHs, RRCs, and MDHs), as well as rural hospitals not receiving a special payment designation. There were 194 RRCs, 367 SCHs, 150 MDHs, 99 hospitals that are both SCHs and RRCs, and 8 hospitals that are both an MDH and an RRC.

The next series of groupings concern the geographic reclassification status of hospitals. The first grouping displays all urban hospitals that were reclassified by the MGCRB for FY 2008. The second grouping shows the MGCRB rural reclassifications.

The final two groupings are based on the type of ownership and the hospital's Medicare utilization expressed as a percent of total patient days. These data were taken from the FY 2004 Medicare cost reports.

TABLE I.—IMPACT ANALYSIS OF CHANGES FOR FY 2008

	No. of hospitals	Previously published all FY 2008 changes w/ CMI adjustment prior to estimated growth ¹¹	Current estimate of all FY 2008 changes w/ CMI adjustment prior to estimated growth ¹²	Previously published all FY 2008 changes w/ CMI adjustment and estimated growth ¹³	Current estimate of all FY 2008 changes w/ CMI adjustment and estimated growth ¹⁴
	(1)	(2a)	(2b)	(3a)	(3b)
All Hospitals	3,534	2.5	3.1	3.7	4.3
By Geographic Location:					
Urban hospitals	2,539	2.6	3.3	3.9	4.5
Large urban areas	1,406	3.1	3.7	4.3	5.0
Other urban areas	1,133	2	2.7	3.3	3.9

TABLE I.—IMPACT ANALYSIS OF CHANGES FOR FY 2008—Continued

	No. of hospitals	Previously published all FY 2008 changes w/ CMI adjustment prior to estimated growth ¹¹	Current estimate of all FY 2008 changes w/ CMI adjustment prior to estimated growth ¹²	Previously published all FY 2008 changes w/ CMI adjustment and estimated growth ¹³	Current estimate of all FY 2008 changes w/ CMI adjustment and estimated growth ¹⁴
	(1)	(2a)	(2b)	(3a)	(3b)
Rural hospitals	995	1.2	1.7	2.4	2.9
Bed Size (Urban):					
0–99 beds	630	1	1.6	2.2	2.8
100–199 beds	851	2.3	2.9	3.6	4.2
200–299 beds	480	2.5	3.1	3.8	4.4
300–499 beds	411	3	3.6	4.2	4.8
500 or more beds	167	2.9	3.5	4.1	4.8
Bed Size (Rural):					
0–49 beds	337	0.1	0.5	1.3	1.7
50–99 beds	372	1.2	1.6	2.4	2.9
100–149 beds	173	1.2	1.8	2.5	3.0
150–199 beds	68	1.2	1.8	2.5	3.0
200 or more beds	45	1.8	2.3	3.1	3.6
Urban by Region:					
New England	122	2.4	3.0	3.7	4.3
Middle Atlantic	350	2.2	2.9	3.5	4.1
South Atlantic	390	2.7	3.4	4	4.6
East North Central	395	2.4	3.0	3.7	4.3
East South Central	166	2.1	2.7	3.3	3.9
West North Central	157	2.4	3.0	3.6	4.2
West South Central	355	2.6	3.2	3.8	4.4
Mountain	153	2.6	3.2	3.8	4.4
Pacific	398	4	4.6	5.2	5.8
Puerto Rico	53	2.9	3.5	4.1	4.8
Rural by Region:					
New England	23	1.2	1.6	2.4	2.8
Middle Atlantic	72	1.4	1.8	2.6	3.0
South Atlantic	173	1.6	2.2	2.8	3.4
East North Central	122	1.4	1.8	2.7	3.1
East South Central	177	0.9	1.5	2.1	2.7
West North Central	115	1.4	1.8	2.6	3.0
West South Central	199	–0.3	0.3	0.9	1.5
Mountain	77	2	2.4	3.2	3.6
Pacific	37	2.9	3.3	4.2	4.6
By Payment Classification:					
Urban hospitals	2,578	2.6	3.3	3.9	4.5
Large urban areas	1,425	3.1	3.7	4.3	4.9
Other urban areas	1,153	2	2.6	3.3	3.9
Rural areas	956	1.3	1.7	2.5	3.0
Teaching Status:					
Nonteaching	2,480	2.1	2.7	3.3	3.9
Fewer than 100 residents	815	2.5	3.1	3.8	4.4
100 or more residents	239	3.1	3.8	4.4	5.0
Urban DSH:					
Non-DSH	859	1.7	2.3	3	3.6
100 or more beds	1,512	2.9	3.5	4.1	4.7
Less than 100 beds	355	1.9	2.5	3.1	3.7
Rural DSH:					
SCH	384	1.6	2.0	2.9	3.2
RRC	203	1.3	1.9	2.5	3.1
100 or more beds	46	1.4	2.0	2.6	3.3
Less than 100 beds	175	0.2	0.8	1.4	2.1
Urban teaching and DSH:					
Both teaching and DSH	807	3	3.6	4.2	4.8
Teaching and no DSH	186	1.9	2.5	3.2	3.8
No teaching and DSH	1,060	2.6	3.2	3.8	4.4
No teaching and no DSH	525	1.7	2.3	2.9	3.6
Special Hospital Types:					
RRC	194	1.5	2.1	2.7	3.3
SCH	367	1.3	1.6	2.5	2.8
MDH	150	2	2.3	3.2	3.6
SCH and RRC	99	1.7	2.0	2.9	3.3
MDH and RRC	8	1.3	1.5	2.6	2.7
Type of Ownership:					

TABLE I.—IMPACT ANALYSIS OF CHANGES FOR FY 2008—Continued

	No. of hospitals	Previously published all FY 2008 changes w/ CMI adjustment prior to estimated growth ¹¹	Current estimate of all FY 2008 changes w/ CMI adjustment prior to estimated growth ¹²	Previously published all FY 2008 changes w/ CMI adjustment and estimated growth ¹³	Current estimate of all FY 2008 changes w/ CMI adjustment and estimated growth ¹⁴
	(1)	(2a)	(2b)	(3a)	(3b)
Voluntary	2,064	2.4	3.0	3.6	4.2
Proprietary	823	2.7	3.3	4	4.6
Government	597	2.7	3.3	3.9	4.5
Medicare Utilization as a Percent of Inpatient Days:					
0–25	230	4.2	4.9	5.5	6.1
25–50	1,289	3.1	3.7	4.3	4.9
50–65	1,451	1.9	2.4	3.1	3.7
Over 65	440	1.2	1.8	2.5	3.0
FY 2008 Reclassifications by the Medicare Geographic Classification Review Board:					
All Reclassified Hospitals	738	2.2	2.8	3.4	4.0
Non-Reclassified Hospitals	2,796	2.6	3.2	3.8	4.4
Urban Hospitals Reclassified	372	2.4	3.1	3.7	4.3
Urban Nonreclassified, FY 2008:	2,147	2.7	3.3	3.9	4.5
All Rural Hospitals Reclassified Full Year FY 2008:	366	1.6	2.1	2.8	3.3
Rural Nonreclassified Hospitals Full Year FY 2008:	566	0.4	0.9	1.7	2.1
All Section 401 Reclassified Hospitals:	26	0.6	0.8	1.8	2.0
Other Reclassified Hospitals (Section 1886(d)(8)(B))	63	1.5	2.0	2.8	3.3
Former 508 Hospitals	107	–0.6	0.0	0.6	1.2
Specialty Hospitals:					
Cardiac specialty Hospitals	22	–0.4	0.2	0.8	1.4

¹¹ This column shows our previous estimate published in the second FY 2008 IPPS correction notice of the changes in payments from FY 2007 to FY 2008 including a 0.988 CMI adjustment for coding and documentation improvements that are anticipated with the adoption of the MS–DRGs prior to the estimated growth occurring. It also reflects all FY 2008 IPPS policies adopted in the FY 2008 IPPS final rule.

¹² This column shows our current estimate of the changes in payments from FY 2007 to FY 2008 including a 0.994 CMI adjustment for coding and documentation improvements that are anticipated with the adoption of the MS–DRGs prior to the estimated growth occurring. It also reflects all FY 2008 IPPS policies adopted in the FY 2008 IPPS final rule and this final rule.

¹³ This column shows our previous estimate published in CMS–1533–CN2 of the changes in payments from FY 2007 to FY 2008 including a .988 CMI adjustment and the estimated case-mix growth of 1.2 percent as a result of improvements in documentation and coding. It also reflects all FY 2008 IPPS policies adopted in the FY 2008 IPPS final rule.

¹⁴ This column shows our current estimate of the changes in payments from FY 2007 to FY 2008 including a .994 CMI adjustment and the estimated case-mix growth of 1.2 percent (when comparing column 2b to column 3b) as a result of improvements in documentation and coding. It also reflects all FY 2008 IPPS policies adopted in the FY 2008 IPPS final rule and this final rule.

a. Effects of All Changes With CMI Adjustment Prior to Estimated Growth (Columns 2a and 2b)

Columns 2a and 2b show our previously published and current estimates of the change in IPPS payments from FY 2007 to FY 2008, reflecting all FY 2008 IPPS policies including a documentation and coding adjustment to the FY 2008 rates, but not taking into account the expected 1.2 percent growth in case-mix due to the anticipated improvement in documentation and coding as a result of the MS–DRGs. Because columns 2a and 2b model the impact to include the documentation and coding adjustment for anticipated case-mix increase without accounting for the actual case-mix increase itself, these columns illustrate a total payment change that is less than what is anticipated to occur.

Column 2a shows our previously published estimate in the October 10, 2007 correction notice to the FY 2008

IPPS proposed rule based on the policies established in the FY 2008 IPPS final rule, including a –1.2 percent documentation and coding adjustment. Column 2b shows our current estimate based on the same FY 2008 IPPS payment policies, except it also includes the policy changes established in this final rule (that is, the statutorily mandated –0.6 percent documentation and coding adjustment and the change in policy of not applying the documentation and coding adjustment to the hospital specific rates). Column 2b also corrects for a technical error that occurred in the second FY 2008 IPPS correction notice that inadvertently overestimated FY 2008 payments to providers that receive the hospital specific rate.

Comparing columns 2a and 2b, the average increase in FY 2008 IPPS payment for all hospitals is approximately 0.6 percentage points higher than in the second FY 2008 IPPS correction notice, as would be expected

with the statutorily mandated change in the documentation and coding adjustment from –1.2 percent to –0.6 percent. As a result of the combination of the law change and a policy of not applying the documentation and coding adjustment to the hospital-specific rates for MDHs and SCHs, certain categories of hospitals (MDHs, SCHs, rural hospitals, and certain rural geographic areas with relatively large numbers of SCHs and MDHs) are estimated to experience an increase in their operating payments of slightly more than 0.6 percentage points compared with the policies articulated in the FY 2008 IPPS final rule. However, column 2b shows an increase in operating payments for these categories of hospitals of only about 0.2 to 0.5 percentage points greater than our previously published impact estimates in column 2a (rather than more than 0.6 percentage points) due to a technical error in our previously published impact estimates that had overstated the

FY 2008 increase in payments to these hospitals.

b. Effects of All Changes With CMI Adjustment and Estimated Growth (Column 3)

Columns 3a and 3b show our previously published and current estimates of the change in IPPS payments from FY 2007 to FY 2008, reflecting all FY 2008 IPPS policies including a documentation and coding adjustment to the FY 2008 rates and taking into account the expected 1.2 percent growth in case-mix in FY 2008 due to anticipated improvements in documentation and coding as a result of the MS-DRGs.

Column 3a shows our previously published estimate in the correction notice to the FY 2008 IPPS proposed rule of the FY 2008 increase in operating payments based on the policies established in the FY 2008 IPPS final rule, including a -1.2 percent documentation and coding adjustment which is assumed to be fully offset by a 1.2 percent increase in case-mix. Column 3b shows our current estimate based on the same FY 2008 IPPS payment policies, except it also includes the policy changes established in this final rule (that is, the statutorily mandated -0.6 percent documentation and coding adjustment and the change in policy of not applying the documentation and coding adjustment to the hospital-specific rates). In column 3b, even though the documentation and coding adjustment reduces the standardized amount by 0.6 percent, this column assumes a 1.2 percent increase in case-mix due to improved documentation and coding that is estimated to occur equally across all hospitals as determined by the Office of the Actuary. Furthermore, it assumes that a 1.2 percent increase in case-mix from improved documentation and coding will occur for hospitals that receive the hospital-specific rate. Similar to column 2b, column 3b also corrects for a technical error that occurred in the second FY 2008 IPPS correction notice that inadvertently overstated the FY 2008 increase in payments to providers that receive the hospital specific-rate.

Column 3b reflects our current estimate of the impact of all FY 2008 changes relative to FY 2007. The average increase for all hospitals is approximately 4.3 percent. This is a 0.6 percent increase in expected payments compared to the 3.7 percent average increase to all hospitals published in the second FY 2008 IPPS correction notice. This estimated increase in payments can be attributed to the statutorily mandated

change in the documentation and coding adjustment to the standardized amounts from -1.2 percent to -0.6 percent. As shown in table 1, columns 3a and 3b, most classes of hospitals are estimated to experience an additional 0.6 percent increase in payments in FY 2008 compared with our previously published estimates with the increases shown in the table sometimes appearing to be slightly more (0.7 percentage points) due to rounding. As noted previously, as a result of the combination of the law change and a policy change to not apply the documentation and coding adjustment to the hospital-specific rates for MDHs and SCHs, certain categories of hospitals (MDHs, SCHs, rural hospitals, and certain rural geographic areas with relatively large numbers of SCHs and MDHs) are estimated to experience an increase in their operating payments of slightly more than 0.6 percentage points compared with the policies articulated in the FY 2008 IPPS final rule. However, column 3b shows an increase in operating payments for these categories of hospitals of only about 0.1 to 0.5 percentage points greater than our previously published impact estimates in column 3a (rather than more than 0.6 percentage points) due to a technical error in our previously published impact estimates that had overstated the FY 2008 increase in payments to these hospitals.

6. Overall Conclusion

The IPPS changes we are making in this final rule will affect all classes of hospitals. All classes of hospitals are expected to experience increases in their FY 2008 IPPS payments as a result of the provisions of this final rule. Table I of this section demonstrates the statutorily mandated change to the documentation and coding adjustment applied to the standardized amount, the policy change of the nonapplication of the documentation and coding adjustment to the hospital-specific rate and all other policies reflected in the FY 2008 IPPS final rule. Table I also shows an overall increase of 4.3 percent in operating payments, an estimated increase of \$4.29 billion, which includes hospital reporting of quality data program costs (\$1.89 million) and all operating payment policies as described in this section XXIV.G. Capital payments are estimated to increase by 1.2 percent per case from FY 2007 to FY 2008. The average increase in FY 2008 capital IPPS payments for all hospitals is approximately 0.6 percentage points higher than in the second FY 2008 IPPS correction notice, as expected based on the statutorily

mandated change in the FY 2008 documentation and coding adjustment from -1.2 percent to -0.6 percent. Therefore, we project that capital payments will increase by \$342 million in FY 2008 compared to FY 2007. The operating and capital payments should result in a net increase of \$4.635 billion to IPPS providers. This is an additional increase in estimated payments by \$665 million compared to the estimated increase in payments published in the second FY 2008 IPPS correction notice. The discussions presented in the previous subsections, in combination with section XIX. of this final rule, constitute a regulatory impact analysis.

7. Accounting Statement

As required by OMB Circular A-4 (available at <http://www.whitehouse.gov/omb/circulars/a004/a-4.pdf>), in Table II below, we have prepared an accounting statement showing the classification of the expenditures associated with the IPPS provisions of this final rule. This table provides our best estimate of the increase in Medicare payments to providers from FY 2007 to FY 2008 as a result of the IPPS policies established in the FY 2008 IPPS final rule and in section XIX. of this final rule. All expenditures are classified as transfers to Medicare providers.

TABLE II.—ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED EXPENDITURES FROM FY 2007 TO FY 2008

Category	Transfers
Annualized Monetized Transfers.	\$4.635 Billion.
From Whom to Whom	Federal Government to IPPS Medicare Providers.
Total	\$4.635 Billion.

8. Executive Order 12866

In accordance with the provisions of Executive Order 12866, this final rule was reviewed by the Office of Management and Budget.

H. Impact of the Policy Revisions Related to Emergency Medicare GME Affiliated Groups for Hospitals in Certain Declared Emergency Areas

As we discussed in detail in section XX. of this document, we are issuing an interim final rule with comment period that modifies the current GME regulations as they apply to emergency Medicare GME affiliated groups to provide for greater flexibility in training residents in approved residency programs during times of disaster.

Specifically, the interim final rule with comment period modifies provisions for “emergency Medicare GME affiliated groups” to address the needs of teaching hospitals that are forced to find alternate training sites for residents that were displaced by a disaster.

1. Overall Impact

This interim final rule with comment period rule is not a major rule under Executive Order 12866 because we anticipate that the cost to the Medicare program will be negligible under the provisions included in this rule.

2. RFA

For purposes of the RFA, we believe that the impact on the affected hospitals will not be significant and will not affect a substantial number of small entities.

3. Small Rural Hospitals

For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of a Metropolitan Statistical Area and has fewer than 100 beds. This interim final rule with comment period is not anticipated to have a significant effect on small rural hospitals because the provisions of this interim final rule with comment period are most likely to be used by large teaching hospitals that have established residency programs and the capacity to train a larger complement of displaced residents. The majority of this type of teaching hospital is located in non-rural areas.

4. Unfunded Mandates

Section 202 of the Unfunded Mandates Reform Act of 1995 requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of \$100 million in 1995 dollars, updated annually for inflation. That threshold level is currently approximately \$120 million. This interim final rule with comment period will not have an effect on State, local, or tribal governments in the aggregate and the private sector costs will be less than the \$120 million threshold.

5. Federalism

Executive Order 13132 establishes certain requirements that an agency must meet when it promulgates a proposed rule (and subsequent final rule) that imposes substantial direct requirement costs on State and local governments, preempts State law, or otherwise has Federalism implications. This interim final rule with comment period will not have a substantial effect on State or local governments.

6. Anticipated Effects

We believe that there are limited effects associated with modifying the existing emergency Medicare GME affiliation regulations to extend the effective period as well as to permit certain written agreements for training that occurs in the nonhospital setting to be submitted retroactively. We note that these changes do not allow hospitals to count for Medicare IME or direct GME payment purposes additional FTE residents that had not been counted by Medicare before a qualifying emergency. Hospitals participating in emergency Medicare GME affiliated groups are held to their respective FTE resident caps as specified by the emergency affiliation agreement. IME and direct GME payments to the hospitals under this provision will not be based upon any FTE residents in excess of the caps specified under the emergency Medicare GME affiliation agreements.

7. Alternatives Considered

We considered making no changes at this time to the existing emergency Medicare GME affiliation provisions. However, teaching hospitals affected by Hurricanes Katrina and Rita have reported to us that they are still experiencing difficulties in reestablishing their training programs and they have requested the extension of the effective period for emergency Medicare GME affiliation agreements to continue beyond June 30, 2008. We understand that GME programs in the affected area are finding it necessary to continue to adjust the location of resident training both within the emergency area and in other States, as affected hospitals in the section 1135 emergency area continue to reopen beds at different rates, and as feedback from accreditation surveys warrant educational adjustments. Extending the effective period of emergency Medicare GME affiliation agreements for two more academic years (for a total effective period of up to 5 academic years) would allow these hospitals the time to stabilize their training programs. Furthermore, we considered the option of extending the effective period for emergency Medicare GME affiliations for two additional academic years without limiting the out of State emergency affiliations to apply to only the residents that were immediately displaced following the disaster. However, we ultimately specified that in the additional 2 years, only the residents that were immediately displaced following the disaster would be eligible to participate in out of State emergency affiliations while residents

that entered the program after the disaster occurred would be limited to in State emergency affiliations. We believe that the policy established in this interim final rule with comment period extends additional flexibility while providing an incentive for home hospitals to bring displaced residents back to train in the State in which the home hospital is located, increasing the probability that the physicians would stay and practice locally after their training is completed. In addition, we believe that providing for flexibility in submitting written agreements after residents begin training in the nonhospital sites for hospitals participating in emergency Medicare GME affiliation agreements alleviates an additional deadline burden and allows appropriate GME payments to be made to those hospitals that are facing financial and programmatic hardships due to a disaster. We believe failure to apply the regulatory changes in this interim final rule with comment would be contrary to the public interest because hospitals affected by Hurricanes Katrina and Rita could otherwise face dramatic disruptions in their Medicare GME funding, with possible dire effects on their GME programs and financial stability.

8. Conclusion

For these reasons, we are not preparing analyses for either the RFA or section 1102(b) of the Act because we have determined that this interim final rule with comment period would not have a significant economic impact on a substantial number of small entities or a significant impact on the operations of a substantial number of small rural hospitals.

9. Executive Order 12866

In accordance with the provisions of Executive Order 12866, this interim final rule with comment period was reviewed by the Office of Management and Budget.

XXV. Waiver of Proposed Rulemaking, Waiver of Delay in Effective Date, and Retroactive Effective Date

A. Requirements for Waivers and Retroactive Rulemaking

We ordinarily publish a notice of proposed rulemaking in the **Federal Register** to provide for public comment before the provisions of a rule take effect in accordance with section 553(b) of the Administrative Procedure Act (APA). However, we can waive notice-and-comment procedures if the Secretary finds, for good cause, that the notice-and-comment process is impracticable,

unnecessary, or contrary to the public interest, and incorporates a statement of the finding and the reasons therefore in the rule. Section 553(d) of the APA also ordinarily requires a 30-day delay in effective date of final rules after the date of their publication. However, this 30-day delay in effective date can be waived if an agency finds for good cause that the delay is impracticable, unnecessary, or contrary to the public interest, and the agency incorporates a statement of the findings and its reasons in the rule issued. Moreover, section 1871(e)(1)(A) of the Act generally prohibits the Secretary from making retroactive substantive changes in policy unless retroactive application of the change is necessary to comply with statutory requirements or failure to apply the change retroactively would be contrary to the public interest.

B. IPPS Payment Rate Policies

We are waiving notice-and-comment procedures and the 30-day delay in effective date with respect to the revised payment factors, rates, and thresholds discussed in section XIX.B.1. of this final rule. In section XIX.B.1. of this final rule, we are revising certain payment factors, rates, and thresholds under the IPPS to reflect the changes to the documentation and coding adjustment mandated under section 7 of Public Law 110–90. The policies adopted in the FY 2008 IPPS final rule were subjected to notice-and-comment procedures. The payment factors, rates, and thresholds discussed in section XIX.B.1. of this final rule reflect the payment policies adopted in the FY 2008 IPPS final rule, but have been recalculated using the reduced coding and documentation adjustment to the standardized amounts. Therefore, we find that it would be unnecessary and contrary to the public interest to delay correction of payment factors and rates under the IPPS by undertaking further notice-and-comment procedures. For the same reasons, we are also waiving the 30-day delay in effective date with respect to the revised payment factors, rates, and thresholds discussed in section XIX.B.1. of this final rule. We believe that it is in the public interest to ensure that these revised payment factors, rates, and thresholds are effective as of the October 1, 2007 effective date of the FY 2008 IPPS final rule.

The revised payment factors, rates, and thresholds discussed in section XIX.B.1. of this final rule do not substantively change policies adopted in the FY 2008 IPPS final rule. Under section 7 of Public Law 110–90, we are required to reduce the documentation

and coding adjustment that we adopted in the FY 2008 IPPS final rule and, as a result, the standardized amounts for FY 2008 will be higher. In section XIX.B.1. of this final rule, we merely are announcing new payment factors, rates, and thresholds that result from applying the statutorily mandated documentation and coding adjustment of -0.6 percent to the payment policies we adopted in the FY 2008 IPPS final rule. Therefore, we do not believe these changes implicate section 1871(e)(1)(A) of the Act.

With respect to the application of the documentation and coding adjustment to hospital-specific rates discussed in section XIX.B.2. of this final rule, we are waiving notice-and-comment procedures, the 30-day delay in effective date, and making a retroactive substantive change to a policy adopted in the FY 2008 IPPS final rule. As discussed in section XIX.B.2. of this final rule, we believe that the policy we adopted in the FY 2008 IPPS final rule was not consistent with the plain meaning of section 1886(d)(3)(A)(vi) of the Act. Therefore, we are waiving notice-and-comment procedures with respect to this policy change because we believe it would be unnecessary and contrary to the public interest to undertake notice-and-comment procedures prior to changing our policy to make the policy consistent with the plain meaning of the statute. For the same reasons, we are waiving the 30-day delay in effective date because we believe it would be unnecessary and contrary to the public interest to delay the policy change beyond the October 1, 2007 effective date of the FY 2008 IPPS final rule. We are also applying this policy change retroactive to October 1, 2007 under section 1871(e)(1)(A)(i) of the Act because it would be contrary to the public interest for our policy not to be consistent with the plain meaning of the statute. Furthermore, because an adjustment to the hospital-specific rates to account for changes in documentation and coding is not authorized under section 1886(d)(3)(A)(vi) of the Act, retroactive application of this change is necessary to comply with the statute.

C. Medicare GME Affiliation Agreement Provisions

We find that failure to apply the provisions of this interim final rule with comment period retroactively to August 29, 2005, which is the first date on which there was an emergency area and emergency period under section 1135 of the Act resulting from the impact of Hurricane Katrina, would be contrary to the public interest. Due to the

infrastructure damage and disruption of operations experienced by medical facilities, and the consequent and continuing disruption in residency training, caused by Hurricanes Katrina and Rita in August of 2005, there is an urgent need for the regulation changes provided in this interim final rule with comment period to be applied retroactively. The existing regulations specify that the effective period for emergency Medicare GME affiliation agreements must end no later than June 30, 2008, even though many hospitals within the section 1135 emergency area have not fully recovered from the disruption caused by Hurricanes Katrina and Rita. Hospitals have informed CMS that it is critical for the permissible effective period for emergency Medicare GME affiliation agreements to be extended because the current regulations do not adequately address the continuing issues relating to Medicare GME payment policy faced by both home and host hospitals. Specifically, where home or host hospitals with valid emergency Medicare GME affiliation agreements have been training displaced residents in non-hospital sites at any time since August 29, 2005, the provisions in this interim final rule with comment period allow these home or host hospitals to submit written agreements or incur all or substantially all of the costs of the program at the nonhospital site retroactive to that date in order to permit the home or host hospitals to count the FTE residents training in non-hospital sites for direct GME and IME payment purposes. We believe failure to apply the regulatory changes contained in this interim final rule with comment period retroactively would be contrary to the public interest because hospitals whose graduate medical education programs were affected by Hurricanes Katrina and Rita could otherwise face dramatic disruptions in their Medicare GME funding, with possible dire effects on the residency training programs and financial stability of the hospitals, and possible adverse consequences for the Medicare program in terms of access to hospital and physician health care resources.

Furthermore, the training programs at many teaching hospitals in New Orleans and surrounding areas were temporarily closed or significantly reduced in the aftermath of the hurricanes, and the displaced residents were transferred to other hospitals to continue their training programs in other parts of the country. While some residents have returned to the hurricane-affected hospitals, others remain displaced from their home

hospitals to hospitals located out-of-state. Immediate regulatory changes are required in order to maintain Medicare GME funding relating to displaced residents training at various hospitals outside of the emergency area, and at the same time, to encourage re-establishment of residency training within the hurricane-affected State, and to assist home hospitals to rebuild incrementally their GME programs. Existing regulations relating to closed hospitals and closed residency training programs, and relating to regular and emergency Medicare GME affiliation agreements, as well as to residency training that occurs in non-hospital settings, contain certain limitations that render them inapplicable or ineffective to address the issues faced by hospitals as a result of disruptions caused by Hurricanes Katrina and Rita.

We also ordinarily publish a notice of proposed rulemaking in the **Federal Register** and invite public comment on the proposed rule. The notice of proposed rulemaking includes a reference to the legal authority under which the rule is proposed, and the terms and substance of the proposed rule or a description of the subjects and issues involved. However, this procedure can be waived if an agency finds good cause that a notice-and-comment procedure is impracticable, unnecessary or contrary to the public interest and incorporates a statement of the finding and supporting reasons in the rule issued. We find that good cause exists to waive the requirement for publication of a notice of proposed rulemaking and public comment prior to the effective date of this rule because such a procedure would be impracticable and contrary to the public interest. As explained above, in order to respond to the urgent needs of the hospitals and GME programs affected by Hurricanes Katrina and Rita, particularly in the provision regarding the retroactive submission of written agreements or payment of all or substantially all of the costs of the program at the non-hospital site to allow hospitals that have been training residents in non-hospital sites since the first day of the section 1135 emergency period relating to Hurricanes Katrina and Rita on August 29, 2005, it is necessary for the regulation to take effect retroactively to August 29, 2005. Furthermore, as hospitals engage in planning for the training of residents in programs for the upcoming academic year which begins on July 1, 2008, hospitals need adequate time to arrange emergency Medicare GME affiliation agreements with respect to remaining

displaced residents training at host hospitals. The ordinary notice-and-comment procedures would serve to delay (or, in certain cases, preclude) hurricane-affected hospitals and GME programs from responding effectively to their circumstances by availing themselves of the flexibility permitted under this interim final rule with comment period.

List of Subjects

42 CFR Part 410

Health facilities, Health professions, Laboratories, Medicare, Rural areas, X rays

42 CFR Part 411

Kidney diseases, Medicare, Physician referral, Reporting and recordkeeping requirements

42 CFR Part 413

Health facilities, Kidney diseases, Medicare, Puerto Rico, Reporting and recordkeeping requirements.

42 CFR Part 414

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare, Reporting and recordkeeping requirements

42 CFR Part 416

Health facilities, Kidney diseases, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 419

Hospitals, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 482

Grant program-health, Hospitals, Medicaid, Medicare, Reporting and recordkeeping requirements

42 CFR Part 485

Grant program-health, Health facilities, Medicaid, Medicare, Reporting and recordkeeping requirements.

■ For reasons stated in the preamble of this final rule with comment period, the Centers for Medicare & Medicaid Services is amending 42 CFR Chapter IV as set forth below:

PART 410—SUPPLEMENTARY MEDICAL INSURANCE (SMI) BENEFITS

■ 1. The authority citation for Part 410 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

■ 2. Section 410.27 is amended by—

- a. Revising paragraph (a)(1)(iii).
 - b. Revising paragraph (f).
- The revisions read as follows:

§ 410.27 Outpatient hospital services and supplies incident to a physician service: Conditions.

(a) * * *

(1) * * *

(iii) In the hospital or at a department of a provider, as defined in § 413.65(a)(2) of this subchapter, that has provider-based status in relation to a hospital under § 413.65 of this subchapter; and

* * * * *

(f) Services furnished at a department of a provider, as defined in § 413.65(a)(2) of this subchapter, that has provider-based status in relation to a hospital under § 413.65 of this subchapter, must be under the direct supervision of a physician. “Direct supervision” means the physician must be present and on the premises of the location and immediately available to furnish assistance and direction throughout the performance of the procedure. It does not mean that the physician must be present in the room when the procedure is performed.

PART 411—EXCLUSIONS FROM MEDICARE AND LIMITATIONS ON MEDICARE PAYMENT

■ 3. The authority citation for Part 411 continues to read as follows:

Authority: Secs. 1102, 1860D–1 through 1860D–42, 1871, and 1877 of the Social Security Act (42 U.S.C. 1302, 1395w–101 through 1395w–152, and 1395nn).

■ 4. Section 411.351 is amended by revising paragraph (2) of the definition of “designated health services” and the definitions of “outpatient prescription drugs” and “radiology and certain other imaging services” to read as follows:

§ 411.351 Definitions.

* * * * *

Designated health services (DHS) means * * *

(2) Except as otherwise noted in this subpart, the term “designated health services” or DHS means only DHS payable, in whole or in part, by Medicare. DHS do not include services that are reimbursed by Medicare as part of a composite rate (for example, SNF Part A payments or ASC services identified at § 416.164(a)), except to the extent that services listed in paragraphs (1)(i) through (1)(x) of this definition are themselves payable through a composite rate (for example, all services provided as home health services or inpatient and outpatient hospital services are DHS).

* * * * *

Outpatient prescription drugs means all drugs covered by Medicare Part B or D, except for those drugs that are “covered ancillary services,” as defined at § 416.164(b) of this chapter, for which separate payment is made to an ambulatory surgical center.

* * * * *

Radiology and certain other imaging services means those particular services so identified on the List of CPT/HCPCS Codes. All services identified on the List of CPT/HCPCS Codes are radiology and certain other imaging services for purposes of this subpart. Any service not specifically identified as radiology and certain other imaging services on the List of CPT/HCPCS Codes is not a radiology or certain other imaging service for purposes of this subpart. The list of codes identifying radiology and certain other imaging services includes the professional and technical components of any diagnostic test or procedure using x-rays, ultrasound, computerized axial tomography, magnetic resonance imaging, nuclear medicine (effective January 1, 2007), or other imaging services. All codes identified as radiology and certain other imaging services are covered under section 1861(s)(3) of the Act and § 410.32 and § 410.34 of this chapter, but do not include—

(1) X-ray, fluoroscopy, or ultrasound procedures that require the insertion of a needle, catheter, tube, or probe through the skin or into a body orifice;

(2) Radiology or certain other imaging services that are integral to the performance of a medical procedure that is not identified on the list of CPT/HCPCS codes as a radiology or certain other imaging service and is performed—

(i) Immediately prior to or during the medical procedure; or

(ii) Immediately following the medical procedure when necessary to confirm placement of an item placed during the medical procedure.

(3) Radiology and certain other imaging services that are “covered ancillary services,” as defined at § 416.164(b), for which separate payment is made to an ASC.

* * * * *

PART 413—PRINCIPLES OF REASONABLE COST REIMBURSEMENT; PAYMENT FOR END-STAGE RENAL DISEASE SERVICES; PROSPECTIVELY DETERMINED PAYMENT RATES FOR SKILLED NURSING FACILITIES

■ 5. The authority citation for Part 413 is revised to read as follows:

Authority: Secs. 1102, 1812(d), 1814(b), 1815, 1833(a), (i), and (n), 1861(v), 1871, 1881, 1883, and 1886 of the Social Security Act (42 U.S.C. 1302, 1395d(d), 1395f(b), 1395g, 1395l(a), (i), and (n), 1395x(v), 1395hh, 1395rr, 1395tt, and 1395ww); and sec. 124 of Public Law 106–133 (113 Stat. 1501A–332).

■ 6. Section 413.75(b) is amended by revising paragraph (2) under the definition of “Emergency Medicare GME affiliated group” to read as follows:

§ 413.75 Direct GME payments: General requirements.

* * * * *

(b) * * *
Emergency Medicare GME affiliated group * * *

(2) *Host hospital* means a hospital training residents displaced from a home hospital.

(a) *In-State host hospital* means a host hospital located in the same State as a home hospital.

(b) *Out-of-State host hospital* means a host hospital located in a different State from the home hospital.

* * * * *

■ 7. Section 413.78 is amended by—

■ a. Removing the semicolon and the word “or” at the end of paragraph (e)(3)(i) and replacing them with a period.

■ b. Adding a new paragraph (e)(3)(iii).

■ c. Removing the semicolon and the word “or” at the end of paragraph (f)(3)(i) and replacing them with a period.

■ d. Adding a new paragraph (f)(3)(iii).

The additions read as follows:

§ 413.78 Direct GME payments: Determination of the total number of FTE residents.

* * * * *

(e) * * *

(3) * * *

(iii) If the hospital has in place an emergency Medicare GME affiliation agreement in accordance with § 413.79(f)(6), during the period covered by the emergency Medicare GME affiliation agreement—

(A) The hospital must pay all or substantially all of the costs of the training program in a nonhospital setting(s) attributable to training that occurs during a month by the end of the sixth month following the month in which the training in the nonhospital site occurred. For the costs that would otherwise be required to be paid by the hospital during the period of August 29, 2005 through November 1, 2007, the participating hospital must pay the costs by April 29, 2008; or

(B) There is a written agreement that specifies that the hospital is incurring

the cost of the resident’s salary and fringe benefits while the resident is training in the nonhospital site and the hospital is providing reasonable compensation to the nonhospital site for supervisory teaching activities. The agreement must indicate the compensation the hospital is providing to the nonhospital site for supervisory teaching activities. The written agreement must be submitted to the contractor by 180 days after the training at the nonhospital site begins. For written agreements that would otherwise be required to be submitted prior to the date the resident(s) begin training at the nonhospital site during the period of August 29, 2005 through November 1, 2007, the written agreement must be submitted to the CMS contractor by April 29, 2008.

* * * * *

(f) * * *

(3) * * *

(iii) If the hospital has in place an emergency Medicare GME affiliation agreement in accordance with § 413.79(f)(6), during the period covered by the emergency Medicare GME affiliation agreement—

(A) The hospital must pay all or substantially all of the costs of the training program in a nonhospital setting(s) attributable to training that occurs during a month by the end of the sixth month after the month in which the training in the nonhospital site occurs. For the costs that would otherwise be required to be incurred by the hospital during the period of August 29, 2005 through November 1, 2007, the participating hospital must incur the costs by April 29, 2008; or

(B) There is a written agreement that specifies that the hospital will incur at least 90 percent of the total of the costs of the resident’s salary and fringe benefits (and travel and lodging where applicable) while the resident is training in the nonhospital site and the portion of the cost of the teaching physician’s salary attributable to nonpatient care direct GME activities. The written agreement must specify the total cost of the training program at the nonhospital site, and the amount the hospital will incur (at least 90 percent of the total), and must indicate the portion of the amount the hospital will incur that reflects residents’ salaries and fringe benefits (and travel and lodging where applicable), and the portion of this amount that reflects teaching physician compensation. The written agreement must be submitted to the contractor by 180 days after the training at the nonhospital site begins. Hospitals may modify the amounts specified in the

written agreement by the end of the academic year (that is, June 30) to reflect that at least 90 percent of the costs of the training program in the nonhospital site has been incurred. For written agreements that would otherwise be required to be submitted prior to the date the training begins in the nonhospital site during the period of August 29, 2005 through November 1, 2007, the hospital must submit the written agreement to its contractor by April 29, 2008.

* * * * *

- 8. Section 413.79 is amended by—
- a. Revising the introductory text of paragraph (f)(6).
- b. Revising paragraph (f)(6)(i)(D).
- c. Revising paragraph (f)(6)(ii)(A)(2).

The revisions read as follows:

§ 413.79 Direct GME payments: Determination of the weighted number of FTE residents.

* * * * *

(f) * * *

(6) *Emergency Medicare GME affiliated group.* Effective on or after August 29, 2005, home and host hospitals as defined in § 413.75(b) may form an emergency Medicare GME affiliated group by meeting the requirements provided in this section. The emergency Medicare GME affiliation agreements may be made effective beginning on or after the first day of a section 1135 emergency period, and must terminate no later than at the conclusion of 4 academic years following the academic year during which the section 1135 emergency period began.

* * * * *

(j) * * *

(D) Specify the total adjustment to each participating hospital's FTE caps in each academic year that the emergency Medicare GME affiliation agreement is in effect, for both direct GME and IME, that reflects a positive adjustment to the host hospital's direct and indirect FTE caps that is offset by a negative adjustment to the home hospital's (or hospitals') direct and indirect FTE caps of at least the same amount subject to the following—

(1) The sum total of adjustments to all the participating hospitals' FTE caps under the emergency Medicare GME affiliation agreement may not exceed the aggregate adjusted FTE caps of the hospitals participating in the emergency Medicare GME affiliated group.

(2) A home hospital's IME and direct GME FTE cap reductions in an emergency Medicare GME affiliation agreement are limited to the home hospital's IME and direct GME FTE

resident caps at § 413.79(c) or § 413.79(f)(1) through (f)(5), that is, as adjusted by any and all existing affiliation agreements as applicable.

(3) For emergency Medicare GME affiliation agreements for the third or fourth academic years subsequent to the year in which the section 1135 emergency period began and involving an out-of-State host hospital, the positive adjustment to the out-of-State host hospital's direct and indirect FTE caps pursuant to the agreement shall reflect only FTE residents that were actually displaced from a home hospital immediately following the emergency.

* * * * *

(ii) * * *

(A) * * *

(2) *Four subsequent academic years.* The later of 180 days after the section 1135 emergency period begins, or by July 1 of each academic year for 4 subsequent years.

* * * * *

PART 414—PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES

- 9. The authority citation for Part 414 continues to read as follows:

Authority: Secs. 1102, 1871, and 1881(b)(1) of the Social Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(1)).

- 10. Section 414.22 is amended by revising paragraphs (b)(5)(i)(A) and (B) to read as follows:

§ 414.22 Relative value units (RVUs).

* * * * *

(b) * * *

(5) * * *

(i) * * *

(A) *Facility practice expense RVUs.* The lower facility practice expense RVUs apply to services furnished to patients in the hospital, skilled nursing facility, community mental health center, or in an ambulatory surgical center. (The facility practice expense RVUs for a particular code may not be greater than the nonfacility RVUs for the code.)

(B) *Nonfacility practice expense RVUs.* The higher nonfacility practice expense RVUs apply to services performed in a physician's office, a patient's home, a nursing facility, or a facility or institution other than a hospital or skilled nursing facility, community mental health center, or ASC.

* * * * *

PART 416—AMBULATORY SURGICAL SERVICES

- 11. The authority citation for Part 416 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

- 12. Section 416.179 is amended by—
- a. Revising the section heading.
- b. Revising paragraphs (a)(1) and (a)(2).
- c. Adding new paragraph (a)(3).
- d. Revising paragraph (b).

The revisions and additions read as follows:

§ 416.179 Payment and coinsurance reduction for devices replaced without cost or when full or partial credit is received.

(a) * * *

(1) The device is replaced without cost to the ASC or the beneficiary;

(2) The ASC receives full credit for the cost of a replaced device; or

(3) The ASC receives partial credit for the cost of a replaced device but only where the amount of the device credit is greater than or equal to 50 percent of the cost of the new replacement device being implanted.

(b) *Amount of reduction to the ASC payment for the covered surgical procedure.*

(1) The amount of the reduction to the ASC payment made under paragraphs (a)(1) and (a)(2) of this section is calculated in the same manner as the device payment reduction that would be applied to the ASC payment for the covered surgical procedure in order to remove predecessor device costs so that the ASC payment amount for a device with pass-through status under § 419.66 of this subchapter represents the full cost of the device, and no packaged device payment is provided through the ASC payment for the covered surgical procedure.

(2) The amount of the reduction to the ASC payment made under paragraph (a)(3) of this section is 50 percent of the payment reduction that would be calculated under paragraph (b)(1) of this section.

* * * * *

PART 419—PROSPECTIVE PAYMENT SYSTEM FOR HOSPITAL OUTPATIENT DEPARTMENT SERVICES

- 13. The authority citation for Part 419 continues to read as follows:

Authority: Secs. 1102, 1833(t), and 1871 of the Social Security Act (42 U.S.C. 1302, 1395l(t), and 1395hh).

- 14. Section 419.43 is amended by revising paragraph (g)(4) to read as follows:

§ 419.43 Adjustments to national program payment and beneficiary copayment amounts.

* * * * *

(g) * * *
(4) *Excluded services and groups.*

Drugs and biologicals that are paid under a separate APC and devices paid under § 419.66 are excluded from qualification for the payment adjustment in paragraph (g)(2) of this section.

* * * * *

- 15. Section 419.44 is amended by—
 - a. Revising the section heading.
 - b. Revising paragraph (b).
- The revisions and addition read as follows:

§ 419.44 Payment reductions for procedures.

* * * * *

(b) *Interrupted procedures.* When a procedure is terminated prior to completion due to extenuating circumstances or circumstances that threaten the well-being of the patient, the Medicare program payment amount and the beneficiary copayment amount are based on—

(1) The full program and beneficiary copayment amounts if the procedure for which anesthesia is planned is discontinued after the induction of anesthesia or after the procedure is started;

(2) One-half the full program and the beneficiary copayment amounts if the procedure for which anesthesia is planned is discontinued after the patient is prepared and taken to the room where the procedure is to be performed but before anesthesia is induced; or

(3) One-half of the full program and beneficiary copayment amounts if a procedure for which anesthesia is not planned is discontinued after the patient is prepared and taken to the room where the procedure is to be performed.

- 16. Section 419.45 is amended by—
- a. Revising the section heading.
- b. Revising paragraph (a)(1).
- c. Revising paragraph (a)(2).
- d. Adding new paragraph (a)(3).
- e. Revising paragraph (b).

The revisions and additions read as follows:

§ 419.45 Payment and copayment reduction for devices replaced without cost or when full or partial credit is received.

(a) * * *

- (1) The device is replaced without cost to the provider or the beneficiary;
- (2) The provider receives full credit for the cost of a replaced device; or
- (3) The provider receives partial credit for the cost of a replaced device

but only where the amount of the device credit is greater than or equal to 50 percent of the cost of the new replacement device being implanted.

(b) *Amount of reduction to the APC payment.*

(1) The amount of the reduction to the APC payment made under paragraphs (a)(1) and (a)(2) of this section is calculated in the same manner as the offset amount that would be applied if the device implanted during a procedure assigned to the APC had transitional pass-through status under § 419.66.

(2) The amount of the reduction to the APC payment made under paragraph (a)(3) of this section is 50 percent of the offset amount that would be applied if the device implanted during a procedure assigned to the APC had transitional pass-through status under § 419.66.

* * * * *

§ 419.70 [Amended]

- 17. Section 419.70 is amended by—
- a. In paragraph (d)(1)(i), removing the cross-reference “§ 412.63(b)” and adding the cross-reference “§ 412.64(b)” in its place.
- b. In paragraph (d)(2)(i), removing the cross-reference “§ 412.63(b)” and adding the cross-reference “§ 412.64(b)” in its place.
- c. In paragraph (d)(4)(ii), removing the cross-reference “§ 412.63(b)” and adding the phrase “§ 412.63(b) or § 412.64(b), as applicable,” in its place.

PART 482—CONDITIONS OF PARTICIPATION FOR HOSPITALS

- 18. The authority citation for Part 482 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

- 19. Section 482.22 is amended by revising paragraph (c)(5) to read as follows:

§ 482.22 Condition of participation: Medical staff.

* * * * *

(c) * * *

(5) Include a requirement that—
(i) A medical history and physical examination be completed and documented for each patient no more than 30 days before or 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia services. The medical history and physical examination must be completed and documented by a physician (as defined in section 1861(r) of the Act), an oromaxillofacial surgeon, or other qualified licensed individual in

accordance with State law and hospital policy.

(ii) An updated examination of the patient, including any changes in the patient’s condition, be completed and documented within 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia services, when the medical history and physical examination are completed within 30 days before admission or registration. The updated examination of the patient, including any changes in the patient’s condition, must be completed and documented by a physician (as defined in section 1861(r) of the Act), an oromaxillofacial surgeon, or other qualified licensed individual in accordance with State law and hospital policy.

* * * * *

§ 482.23 [Amended]

- 20. In § 482.23(b)(1), the cross-reference “§ 405.1910(c)” is removed and the cross-reference “§ 488.54(c)” is added in its place.

- 21. Section 482.24 is amended by revising paragraph (c)(2)(i) to read as follows:

§ 482.24 Condition of participation: Medical record services.

* * * * *

(c) * * *

(2) * * *

(i) Evidence of—
(A) A medical history and physical examination completed and documented no more than 30 days before or 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia services. The medical history and physical examination must be placed in the patient’s medical record within 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia services.

(B) An updated examination of the patient, including any changes in the patient’s condition, when the medical history and physical examination are completed within 30 days before admission or registration. Documentation of the updated examination must be placed in the patient’s medical record within 24 hours after admission or registration, but prior to surgery or a procedure requiring anesthesia services.

* * * * *

- 22. Section 482.51 is amended by revising paragraph (b)(1) to read as follows:

§ 482.51 Condition of participation: Surgical services.

* * * * *

(b) * * *
 (1) Prior to surgery or a procedure requiring anesthesia services and except in the case of emergencies:

(i) A medical history and physical examination must be completed and documented no more than 30 days before or 24 hours after admission or registration.

(ii) An updated examination of the patient, including any changes in the patient's condition, must be completed and documented within 24 hours after admission or registration when the medical history and physical examination are completed within 30 days before admission or registration.

- * * * * *
- 23. Section 482.52 is amended by—
- a. Revising paragraph (b)(1).
 - b. Revising paragraph (b)(3).
 - c. Removing paragraph (b)(4).
- The revisions read as follows:

§ 482.52 Condition of participation: Anesthesia services.

* * * * *

(b) * * *
 (1) A preanesthesia evaluation completed and documented by an individual qualified to administer anesthesia, as specified in paragraph (a) of this section, performed within 48 hours prior to surgery or a procedure requiring anesthesia services.

* * * * *

(3) A postanesthesia evaluation completed and documented by an individual qualified to administer anesthesia, as specified in paragraph (a) of this section, no later than 48 hours after surgery or a procedure requiring anesthesia services. The postanesthesia evaluation for anesthesia recovery must be completed in accordance with State law and with hospital policies and procedures that have been approved by

the medical staff and that reflect current standards of anesthesia care.

PART 485—CONDITIONS OF PARTICIPATION: SPECIALIZED PROVIDERS

■ 24. The authority citation for Part 485 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

■ 25. Section 485.610 is amended by adding new paragraph (e) to read as follows:

§ 485.610 Condition of participation: Status and location.

* * * * *

(e) *Standard: Off-campus and co-location requirements for CAHs.* A CAH may continue to meet the location requirement of paragraph (c) of this section based only if the CAH meets the following:

(1) If a CAH with a necessary provider designation is co-located (that is, it shares a campus, as defined in § 413.65(a)(2) of this chapter, with another hospital or CAH), the necessary provider CAH can continue to meet the location requirement of paragraph (c) of this section only if the co-location arrangement was in effect before January 1, 2008, and the type and scope of services offered by the facility co-located with the necessary provider CAH do not change. A change of ownership of any of the facilities with a co-location arrangement that was in effect before January 1, 2008, will not be considered to be a new co-location arrangement.

(2) If a CAH or a necessary provider CAH operates an off-campus provider-based location, excluding an RHC as defined in § 405.2401(b) of this chapter, but including a department or remote

location, as defined in § 413.65(a)(2) of this chapter, or an off-campus distinct part psychiatric or rehabilitation unit, as defined in § 485.647, that was created or acquired by the CAH on or after January 1, 2008, the CAH can continue to meet the location requirement of paragraph (c) of this section only if the off-campus provider-based location or off-campus distinct part unit is located more than a 35-mile drive (or, in the case of mountainous terrain or in areas with only secondary roads available, a 15-mile drive) from a hospital or another CAH.

(3) If either a CAH or a CAH that has been designated as a necessary provider by the State does not meet the requirements in paragraph (e)(1) of this section, by co-locating with another hospital or CAH on or after January 1, 2008, or creates or acquires an off-campus provider-based location or off-campus distinct part unit on or after January 1, 2008, that does not meet the requirements in paragraph (e)(2) of this section, the CAH's provider agreement will be subject to termination in accordance with the provisions of § 489.53(a)(3) of this subchapter, unless the CAH terminates the off-campus arrangement or the co-location arrangement, or both.

Authority: (Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program).

(Catalog of Federal Domestic Assistance Program No. 93.778, Medical Assistance Program)

Dated: October 25, 2007.

Kerry Weems,

Acting Administrator, Centers for Medicare & Medicaid Services.

Dated: October 30, 2007.

Michael O. Leavitt,

Secretary.

ADDENDUM A.—OPPS APCS FOR CY 2008

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0001	Level I Photochemotherapy	S	0.4806	\$30.61	\$7.00	\$6.12
0002	Level I Fine Needle Biopsy/Aspiration	T	1.1097	\$70.68		\$14.14
0003	Bone Marrow Biopsy/Aspiration	T	3.1008	\$197.50		\$39.50
0004	Level I Needle Biopsy/ Aspiration Except Bone Marrow	T	4.3270	\$275.60		\$55.12
0005	Level II Needle Biopsy/Aspiration Except Bone Marrow	T	7.1147	\$453.16		\$90.63
0006	Level I Incision & Drainage	T	1.4066	\$89.59		\$17.92
0007	Level II Incision & Drainage	T	11.5594	\$736.26		\$147.25
0008	Level III Incision and Drainage	T	18.3197	\$1,166.85		\$233.37
0012	Level I Debridement & Destruction	T	0.2963	\$18.87		\$3.77
0013	Level II Debridement & Destruction	T	0.7930	\$50.51		\$10.10
0015	Level III Debridement & Destruction	T	1.4595	\$92.96		\$18.59
0016	Level IV Debridement & Destruction	T	2.6604	\$169.45		\$33.89
0017	Level VI Debridement & Destruction	T	19.9041	\$1,267.77		\$253.55
0019	Level I Excision/ Biopsy	T	4.3039	\$274.13	\$71.87	\$54.83
0020	Level II Excision/ Biopsy	T	8.6850	\$553.18		\$110.64
0021	Level III Excision/ Biopsy	T	16.1001	\$1,025.48	\$219.48	\$205.10
0022	Level IV Excision/ Biopsy	T	21.1098	\$1,344.57	\$354.45	\$268.91

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0023	Exploration Penetrating Wound	T	9.6341	\$613.63		\$122.73
0028	Level I Breast Surgery	T	20.6417	\$1,314.75	\$303.74	\$262.95
0029	Level II Breast Surgery	T	31.7134	\$2,019.95	\$581.52	\$403.99
0030	Level III Breast Surgery	T	39.8191	\$2,536.24	\$747.07	\$507.25
0031	Smoking Cessation Services	X	0.1648	\$10.50		\$2.10
0033	Partial Hospitalization	P	3.2211	\$205.16		\$41.03
0034	Mental Health Services Composite	P	3.2211	\$205.16		\$41.03
0035	Arterial/Venous Puncture	T	0.2143	\$13.65		\$2.73
0037	Level IV Needle Biopsy/Aspiration Except Bone Marrow	T	13.5764	\$864.74	\$228.76	\$172.95
0039	Level I Implantation of Neurostimulator	S	186.4739	\$11,877.27		\$2,375.45
0040	Percutaneous Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve.	S	63.7866	\$4,062.82		\$812.56
0041	Level I Arthroscopy	T	28.7803	\$1,833.13		\$366.63
0042	Level II Arthroscopy	T	45.7072	\$2,911.27	\$804.74	\$582.25
0043	Closed Treatment Fracture Finger/Toe/Trunk	T	1.7682	\$112.62		\$22.52
0045	Bone/Joint Manipulation Under Anesthesia	T	14.7658	\$940.49	\$268.47	\$188.10
0047	Arthroplasty without Prosthesis	T	35.9040	\$2,286.87	\$537.03	\$457.37
0048	Level I Arthroplasty with Prosthesis	T	50.8876	\$3,241.23		\$648.25
0049	Level I Musculoskeletal Procedures Except Hand and Foot	T	21.2689	\$1,354.70		\$270.94
0050	Level II Musculoskeletal Procedures Except Hand and Foot	T	29.1900	\$1,859.23		\$371.85
0051	Level III Musculoskeletal Procedures Except Hand and Foot	T	42.9850	\$2,737.89		\$547.58
0052	Level IV Musculoskeletal Procedures Except Hand and Foot	T	79.4244	\$5,058.86		\$1,011.77
0053	Level I Hand Musculoskeletal Procedures	T	16.4637	\$1,048.64	\$253.49	\$209.73
0054	Level II Hand Musculoskeletal Procedures	T	26.3105	\$1,675.82		\$335.16
0055	Level I Foot Musculoskeletal Procedures	T	20.8284	\$1,326.64	\$355.34	\$265.33
0056	Level II Foot Musculoskeletal Procedures	T	44.2687	\$2,819.65		\$563.93
0057	Bunion Procedures	T	29.4167	\$1,873.67	\$475.91	\$374.73
0058	Level I Strapping and Cast Application	S	1.0931	\$69.62		\$13.92
0060	Manipulation Therapy	S	0.4482	\$28.55		\$5.71
0061	Laminectomy, Laparoscopy, or Incision for Implantation of Neurostimulator Electrodes, Excluding Cranial Nerve.	S	82.8597	\$5,277.67		\$1,055.53
0062	Level I Treatment Fracture/Dislocation	T	26.1592	\$1,666.18	\$372.87	\$333.24
0063	Level II Treatment Fracture/Dislocation	T	41.1091	\$2,618.40	\$548.33	\$523.68
0064	Level III Treatment Fracture/Dislocation	T	59.2233	\$3,772.17	\$835.79	\$754.43
0065	Level I Stereotactic Radiosurgery, MRgFUS, and MEG	S	16.5911	\$1,056.75		\$211.35
0066	Level II Stereotactic Radiosurgery, MRgFUS, and MEG	S	45.0693	\$2,870.64		\$574.13
0067	Level III Stereotactic Radiosurgery, MRgFUS, and MEG	S	61.6965	\$3,929.70		\$785.94
0069	Thoracoscopy	T	32.5666	\$2,074.30	\$591.64	\$414.86
0070	Thoracentesis/Lavage Procedures	T	5.2024	\$331.36		\$66.27
0071	Level I Endoscopy Upper Airway	T	0.8224	\$52.38	\$11.20	\$10.48
0072	Level II Endoscopy Upper Airway	T	1.6115	\$102.64	\$21.27	\$20.53
0073	Level III Endoscopy Upper Airway	T	3.9940	\$254.39	\$69.15	\$50.88
0074	Level IV Endoscopy Upper Airway	T	17.0160	\$1,083.82	\$292.25	\$216.76
0075	Level V Endoscopy Upper Airway	T	22.7191	\$1,447.07	\$445.92	\$289.41
0076	Level I Endoscopy Lower Airway	T	9.9575	\$634.23	\$189.82	\$126.85
0077	Level I Pulmonary Treatment	S	0.3877	\$24.69	\$7.74	\$4.94
0078	Level II Pulmonary Treatment	S	1.3362	\$85.11		\$17.02
0079	Ventilation Initiation and Management	S	2.4783	\$157.85		\$31.57
0080	Diagnostic Cardiac Catheterization	T	38.9204	\$2,479.00	\$838.92	\$495.80
0082	Coronary or Non-Coronary Atherectomy	T	87.5137	\$5,574.10		\$1,114.82
0083	Coronary or Non-Coronary Angioplasty and Percutaneous Valvuloplasty	T	45.3845	\$2,890.72		\$578.14
0084	Level I Electrophysiologic Procedures	S	9.5834	\$610.41		\$122.08
0085	Level II Electrophysiologic Procedures	T	47.2949	\$3,012.40		\$602.48
0086	Level III Electrophysiologic Procedures	T	92.8564	\$5,914.40		\$1,182.88
0088	Thrombectomy	T	38.7673	\$2,469.24	\$655.22	\$493.85
0089	Insertion/Replacement of Permanent Pacemaker and Electrodes	T	121.6508	\$7,748.43	\$1,682.28	\$1,549.69
0090	Insertion/Replacement of Pacemaker Pulse Generator	T	100.8341	\$6,422.53	\$1,612.80	\$1,284.51
0091	Level II Vascular Ligation	T	42.6114	\$2,714.09		\$542.82
0092	Level I Vascular Ligation	T	25.8410	\$1,645.92		\$329.18
0093	Vascular Reconstruction/Fistula Repair without Device	T	30.1294	\$1,919.06		\$383.81
0094	Level I Resuscitation and Cardioversion	S	2.4590	\$156.62	\$46.29	\$31.32
0095	Cardiac Rehabilitation	S	0.5685	\$36.21	\$13.86	\$7.24
0096	Non-Invasive Vascular Studies	S	1.4689	\$93.56	\$37.42	\$18.71
0097	Cardiac and Ambulatory Blood Pressure Monitoring	X	1.0015	\$63.79	\$23.79	\$12.76
0099	Electrocardiograms	S	0.3892	\$24.79		\$4.96
0100	Cardiac Stress Tests	X	2.5547	\$162.72	\$41.44	\$32.54
0101	Tilt Table Evaluation	S	4.1973	\$267.34	\$100.24	\$53.47
0103	Miscellaneous Vascular Procedures	T	14.6576	\$933.60		\$186.72
0104	Transcatheter Placement of Intracoronary Stents	T	89.0159	\$5,669.78		\$1,133.96
0105	Repair/Revision/Removal of Pacemakers, AICDs, or Vascular Devices	T	23.9802	\$1,527.39		\$305.48
0106	Insertion/Replacement of Pacemaker Leads and/or Electrodes	T	69.5217	\$4,428.12		\$885.62
0107	Insertion of Cardioverter-Defibrillator	T	333.8096	\$21,261.67		\$4,252.33
0108	Insertion/Replacement/Repair of Cardioverter-Defibrillator Leads	T	404.8543	\$25,786.79		\$5,157.36
0109	Removal/Repair of Implanted Devices	T	5.6614	\$360.60		\$72.12
0110	Transfusion	S	3.3967	\$216.35		\$43.27
0111	Blood Product Exchange	S	11.5058	\$732.85	\$198.40	\$146.57
0112	Apheresis and Stem Cell Procedures	S	30.6035	\$1,949.26	\$433.29	\$389.85
0113	Excision Lymphatic System	T	22.9584	\$1,462.31		\$292.46
0114	Thyroid/Lymphadenectomy Procedures	T	44.3240	\$2,823.17		\$564.63
0115	Cannula/Access Device Procedures	T	29.6965	\$1,891.49		\$378.30

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0121	Level I Tube changes and Repositioning	T	3.2383	\$206.26	\$43.80	\$41.25
0125	Refilling of Infusion Pump	T	2.3544	\$149.96		\$29.99
0126	Level I Urinary and Anal Procedures	T	1.0356	\$65.96	\$16.21	\$13.19
0127	Level IV Stereotactic Radiosurgery, MRgFUS, and MEG	S	126.4653	\$8,055.08		\$1,611.02
0128	Echocardiogram with Contrast	S	8.4896	\$540.74	\$216.29	\$108.15
0130	Level I Laparoscopy	T	34.3958	\$2,190.81	\$659.53	\$438.16
0131	Level II Laparoscopy	T	45.5317	\$2,900.10	\$1,001.89	\$580.02
0132	Level III Laparoscopy	T	69.6652	\$4,437.26	\$1,239.22	\$887.45
0133	Level I Skin Repair	T	1.2792	\$81.48	\$25.67	\$16.30
0134	Level II Skin Repair	T	2.1051	\$134.08	\$42.24	\$26.82
0135	Level III Skin Repair	T	4.5263	\$288.30		\$57.66
0136	Level IV Skin Repair	T	15.0458	\$958.33		\$191.67
0137	Level V Skin Repair	T	20.2069	\$1,287.06		\$257.41
0140	Esophageal Dilatation without Endoscopy	T	5.8431	\$372.17	\$91.40	\$74.43
0141	Level I Upper GI Procedures	T	8.5030	\$541.59	\$143.38	\$108.32
0142	Small Intestine Endoscopy	T	9.5292	\$606.95	\$152.78	\$121.39
0143	Lower GI Endoscopy	T	8.8486	\$563.60	\$186.06	\$112.72
0146	Level I Sigmoidoscopy and Anoscopy	T	5.0972	\$324.66		\$64.93
0147	Level II Sigmoidoscopy and Anoscopy	T	8.7031	\$554.34		\$110.87
0148	Level I Anal/Rectal Procedures	T	4.7935	\$305.32		\$61.06
0149	Level III Anal/Rectal Procedures	T	22.7451	\$1,448.73	\$293.06	\$289.75
0150	Level IV Anal/Rectal Procedures	T	30.1606	\$1,921.05	\$437.12	\$384.21
0151	Endoscopic Retrograde Cholangio-Pancreatography (ERCP)	T	20.9510	\$1,334.45		\$266.89
0152	Level I Percutaneous Abdominal and Biliary Procedures	T	28.6884	\$1,827.28		\$365.46
0153	Peritoneal and Abdominal Procedures	T	25.6947	\$1,636.60	\$397.95	\$327.32
0154	Hernia/Hydrocele Procedures	T	30.6788	\$1,954.06	\$464.85	\$390.81
0155	Level II Anal/Rectal Procedures	T	10.9132	\$695.11		\$139.02
0156	Level III Urinary and Anal Procedures	T	3.0469	\$194.07		\$38.81
0157	Colorectal Cancer Screening: Barium Enema	S	2.0651	\$131.53		\$26.31
0158	Colorectal Cancer Screening: Colonoscopy	T	7.8504	\$500.02		\$125.01
0159	Colorectal Cancer Screening: Flexible Sigmoidoscopy	S	4.7010	\$299.43		\$74.86
0160	Level I Cystourethroscopy and other Genitourinary Procedures	T	5.9735	\$380.48		\$76.10
0161	Level II Cystourethroscopy and other Genitourinary Procedures	T	17.9420	\$1,142.80	\$241.15	\$228.56
0162	Level III Cystourethroscopy and other Genitourinary Procedures	T	24.7749	\$1,578.01		\$315.60
0163	Level IV Cystourethroscopy and other Genitourinary Procedures	T	36.0774	\$2,297.91		\$459.58
0164	Level II Urinary and Anal Procedures	T	2.0077	\$127.88		\$25.58
0165	Level IV Urinary and Anal Procedures	T	19.3414	\$1,231.93		\$246.39
0166	Level I Urethral Procedures	T	19.1505	\$1,219.77		\$243.95
0168	Level II Urethral Procedures	T	29.7864	\$1,897.21	\$388.16	\$379.44
0169	Lithotripsy	T	41.5299	\$2,645.21	\$997.74	\$529.04
0170	Dialysis	S	6.5383	\$416.45		\$83.29
0181	Level II Male Genital Procedures	T	33.9306	\$2,161.18	\$621.82	\$432.24
0183	Level I Male Genital Procedures	T	22.3251	\$1,421.97		\$284.39
0184	Prostate Biopsy	T	11.0338	\$702.79		\$140.56
0188	Level II Female Reproductive Proc	T	1.3520	\$86.11		\$17.22
0189	Level III Female Reproductive Proc	T	2.7584	\$175.69		\$35.14
0190	Level I Hysteroscopy	T	21.6576	\$1,379.46	\$424.28	\$275.89
0191	Level I Female Reproductive Proc	T	0.1309	\$8.34	\$2.36	\$1.67
0192	Level IV Female Reproductive Proc	T	6.0783	\$387.15		\$77.43
0193	Level V Female Reproductive Proc	T	19.0203	\$1,211.48		\$242.30
0195	Level VI Female Reproductive Procedures	T	32.4237	\$2,065.20	\$483.80	\$413.04
0202	Level VII Female Reproductive Procedures	T	42.7099	\$2,720.36	\$981.50	\$544.07
0203	Level IV Nerve Injections	T	14.4879	\$922.79	\$240.33	\$184.56
0204	Level I Nerve Injections	T	2.3213	\$147.85	\$40.13	\$29.57
0206	Level II Nerve Injections	T	4.0964	\$260.92	\$56.01	\$52.18
0207	Level III Nerve Injections	T	7.0546	\$449.34		\$89.87
0208	Laminotomies and Laminectomies	T	46.7724	\$2,979.12		\$595.82
0209	Level II Extended EEG and Sleep Studies	S	11.2822	\$718.61	\$268.73	\$143.72
0212	Nervous System Injections	T	8.5263	\$543.07		\$108.61
0213	Level I Extended EEG and Sleep Studies	S	2.2980	\$146.37	\$53.58	\$29.27
0215	Level I Nerve and Muscle Tests	S	0.5804	\$36.97		\$7.39
0216	Level III Nerve and Muscle Tests	S	2.6846	\$170.99		\$34.20
0218	Level II Nerve and Muscle Tests	S	1.1550	\$73.57		\$14.71
0220	Level I Nerve Procedures	T	18.0518	\$1,149.79		\$229.96
0221	Level II Nerve Procedures	T	33.2707	\$2,119.14	\$463.62	\$423.83
0222	Level II Implantation of Neurostimulator	S	240.7990	\$15,337.45		\$3,067.49
0224	Implantation of Catheter/Reservoir/Shunt	T	36.2768	\$2,310.61		\$462.12
0225	Implantation of Neurostimulator Electrodes, Cranial Nerve	S	220.7642	\$14,061.35		\$2,812.27
0227	Implantation of Drug Infusion Device	T	183.8928	\$11,712.87		\$2,342.57
0229	Transcatheter Placement of Intravascular Shunts	T	88.5367	\$5,639.26		\$1,127.85
0230	Level I Eye Tests & Treatments	S	0.5903	\$37.60		\$7.52
0231	Level III Eye Tests & Treatments	S	2.1790	\$138.79		\$27.76
0232	Level I Anterior Segment Eye Procedures	T	5.1169	\$325.92	\$81.65	\$65.18
0233	Level II Anterior Segment Eye Procedures	T	16.1710	\$1,030.00	\$266.33	\$206.00
0234	Level III Anterior Segment Eye Procedures	T	23.1758	\$1,476.16	\$511.31	\$295.23
0235	Level I Posterior Segment Eye Procedures	T	4.1331	\$263.25	\$58.93	\$52.65
0236	Level II Posterior Segment Eye Procedures	T	18.2350	\$1,161.46		\$232.29
0237	Level III Posterior Segment Eye Procedures	T	27.8450	\$1,773.56		\$354.71
0238	Level I Repair and Plastic Eye Procedures	T	2.9022	\$184.85		\$36.97
0239	Level II Repair and Plastic Eye Procedures	T	7.2847	\$463.99		\$92.80

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0240	Level III Repair and Plastic Eye Procedures	T	18.7307	\$1,193.03	\$309.52	\$238.61
0241	Level IV Repair and Plastic Eye Procedures	T	24.3077	\$1,548.25	\$383.45	\$309.65
0242	Level V Repair and Plastic Eye Procedures	T	37.7243	\$2,402.81	\$597.36	\$480.56
0243	Strabismus/Muscle Procedures	T	24.1291	\$1,536.88	\$430.35	\$307.38
0244	Corneal and Amniotic Membrane Transplant	T	37.4896	\$2,387.86	\$803.26	\$477.57
0245	Level I Cataract Procedures without IOL Insert	T	14.9171	\$950.13	\$217.05	\$190.03
0246	Cataract Procedures with IOL Insert	T	23.8649	\$1,520.05	\$495.96	\$304.01
0247	Laser Eye Procedures	T	5.2001	\$331.22	\$104.31	\$66.24
0249	Level II Cataract Procedures without IOL Insert	T	28.7035	\$1,828.24	\$524.67	\$365.65
0250	Nasal Cauterization/Packing	T	1.1251	\$71.66	\$25.10	\$14.33
0251	Level I ENT Procedures	T	2.5002	\$159.25		\$31.85
0252	Level II ENT Procedures	T	7.4474	\$474.35	\$109.16	\$94.87
0253	Level III ENT Procedures	T	16.3288	\$1,040.05	\$282.29	\$208.01
0254	Level IV ENT Procedures	T	23.9765	\$1,527.16	\$321.35	\$305.43
0256	Level V ENT Procedures	T	39.8776	\$2,539.96		\$507.99
0258	Tonsil and Adenoid Procedures	T	22.2557	\$1,417.55	\$437.25	\$283.51
0259	Level VI ENT Procedures	T	393.2242	\$25,046.02	\$8,543.66	\$5,009.20
0260	Level I Plain Film Except Teeth	X	0.6954	\$44.29		\$8.86
0261	Level II Plain Film Except Teeth Including Bone Density Measurement	X	1.1570	\$73.69		\$14.74
0262	Plain Film of Teeth	X	0.5749	\$36.62		\$7.32
0263	Level I Miscellaneous Radiology Procedures	X	2.6838	\$170.94		\$34.19
0265	Level I Diagnostic and Screening Ultrasound	S	0.9570	\$60.96	\$22.35	\$12.19
0266	Level II Diagnostic and Screening Ultrasound	S	1.5094	\$96.14	\$37.80	\$19.23
0267	Level III Diagnostic and Screening Ultrasound	S	2.3792	\$151.54	\$60.50	\$30.31
0269	Level II Echocardiogram Without Contrast Except Transesophageal	S	6.3751	\$406.06		\$81.21
0270	Transesophageal Echocardiogram Without Contrast	S	8.2165	\$523.34	\$141.32	\$104.67
0272	Fluoroscopy	X	1.3271	\$84.53	\$31.64	\$16.91
0274	Myelography	S	7.5589	\$481.46		\$96.29
0275	Arthrography	S	4.0031	\$254.97	\$69.09	\$50.99
0276	Level I Digestive Radiology	S	1.3834	\$88.11	\$34.97	\$17.62
0277	Level II Digestive Radiology	S	2.2222	\$141.54	\$54.52	\$28.31
0278	Diagnostic Urography	S	2.6121	\$166.38	\$59.40	\$33.28
0279	Level II Angiography and Venography	S	28.8788	\$1,839.41		\$367.88
0280	Level III Angiography and Venography	S	44.7114	\$2,847.85		\$569.57
0282	Miscellaneous Computed Axial Tomography	S	1.5839	\$100.88	\$37.81	\$20.18
0283	Computed Tomography with Contrast	S	4.3564	\$277.48	\$100.37	\$55.50
0284	Magnetic Resonance Imaging and Magnetic Resonance Angiography with Contrast	S	6.2350	\$397.13	\$148.40	\$79.43
0288	Bone Density:Axial Skeleton	S	1.1384	\$72.51	\$28.90	\$14.50
0293	Level V Anterior Segment Eye Procedures	T	84.8039	\$5,401.50	\$1,128.29	\$1,080.30
0299	Hyperthermia and Radiation Treatment Procedures	S	5.7996	\$369.40		\$73.88
0300	Level I Radiation Therapy	S	1.4229	\$90.63		\$18.13
0301	Level II Radiation Therapy	S	2.2167	\$141.19		\$28.24
0303	Treatment Device Construction	X	2.8878	\$183.94	\$66.95	\$36.79
0304	Level I Therapeutic Radiation Treatment Preparation	X	1.5576	\$99.21	\$38.68	\$19.84
0305	Level II Therapeutic Radiation Treatment Preparation	X	3.9276	\$250.16	\$91.38	\$50.03
0307	Myocardial Positron Emission Tomography (PET) imaging	S	21.9955	\$1,400.98	\$292.49	\$280.20
0308	Non-Myocardial Positron Emission Tomography (PET) imaging	S	16.6001	\$1,057.33		\$211.47
0310	Level III Therapeutic Radiation Treatment Preparation	X	13.5621	\$863.82	\$325.27	\$172.76
0312	Radioelement Applications	S	8.5140	\$542.29		\$108.46
0313	Brachytherapy	S	11.6779	\$743.81		\$148.76
0315	Level III Implantation of Neurostimulator	S	270.0190	\$17,198.59		\$3,439.72
0317	Level II Miscellaneous Radiology Procedures	X	5.3623	\$341.55	\$77.89	\$68.31
0320	Electroconvulsive Therapy	S	5.7299	\$364.96	\$80.06	\$72.99
0322	Brief Individual Psychotherapy	S	1.1729	\$74.71		\$14.94
0323	Extended Individual Psychotherapy	S	1.6044	\$102.19		\$20.44
0324	Family Psychotherapy	S	2.3616	\$150.42		\$30.08
0325	Group Psychotherapy	S	0.9913	\$63.14	\$13.81	\$12.63
0330	Dental Procedures	S	9.1677	\$583.93		\$116.79
0332	Computed Tomography without Contrast	S	3.0109	\$191.78	\$75.24	\$38.36
0333	Computed Tomography without Contrast followed by Contrast	S	5.1125	\$325.64	\$119.01	\$65.13
0335	Magnetic Resonance Imaging, Miscellaneous	S	4.8830	\$311.02	\$111.92	\$62.20
0336	Magnetic Resonance Imaging and Magnetic Resonance Angiography without Contrast	S	5.3933	\$343.52	\$137.40	\$68.70
0337	Magnetic Resonance Imaging and Magnetic Resonance Angiography without Contrast followed by Contrast	S	8.2463	\$525.24	\$199.53	\$105.05
0340	Minor Ancillary Procedures	X	0.6310	\$40.19		\$8.04
0341	Skin Tests	X	0.0844	\$5.38	\$2.14	\$1.08
0342	Level I Pathology	X	0.0969	\$6.17	\$2.02	\$1.23
0343	Level III Pathology	X	0.5142	\$32.75	\$10.84	\$6.55
0344	Level IV Pathology	X	0.8167	\$52.02	\$15.66	\$10.40
0345	Level I Transfusion Laboratory Procedures	X	0.2140	\$13.63	\$2.87	\$2.73
0346	Level II Transfusion Laboratory Procedures	X	0.3346	\$21.31	\$4.37	\$4.26
0347	Level III Transfusion Laboratory Procedures	X	0.7739	\$49.29	\$11.28	\$9.86
0350	Administration of flu and PPV vaccine	S	0.3945	\$25.13		\$0.00
0360	Level I Alimentary Tests	X	1.5330	\$97.64	\$33.88	\$19.53
0361	Level II Alimentary Tests	X	3.9276	\$250.16	\$83.23	\$50.03
0363	Level I Otorhinolaryngologic Function Tests	X	0.8067	\$51.38	\$17.10	\$10.28
0364	Level I Audiometry	X	0.4490	\$28.60	\$7.06	\$5.72
0365	Level II Audiometry	X	1.2549	\$79.93	\$18.52	\$15.99

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0366	Level III Audiometry	X	1.7624	\$112.25	\$25.79	\$22.45
0367	Level I Pulmonary Test	X	0.5677	\$36.16	\$13.76	\$7.23
0368	Level II Pulmonary Tests	X	0.9253	\$58.94	\$22.77	\$11.79
0369	Level III Pulmonary Tests	X	2.7550	\$175.48	\$44.18	\$35.10
0370	Allergy Tests	X	1.0430	\$66.43		\$13.29
0373	Level I Neuropsychological Testing	X	1.2448	\$79.29		\$15.86
0375	Ancillary Outpatient Services When Patient Expires	S	78.5966	\$5,006.13		\$1,001.23
0377	Level II Cardiac Imaging	S	11.8512	\$754.85	\$158.84	\$150.97
0378	Level II Pulmonary Imaging	S	4.9509	\$315.34	\$125.33	\$63.07
0379	Injection adenosine 6 MG	K		\$25.10		\$5.02
0381	Single Allergy Tests	X	0.2773	\$17.66		\$3.53
0382	Level II Neuropsychological Testing	X	2.6169	\$166.68		\$33.34
0383	Cardiac Computed Tomographic Imaging	S	4.7005	\$299.39	\$117.06	\$59.88
0384	GI Procedures with Stents	T	24.9814	\$1,591.17		\$318.23
0385	Level I Prosthetic Urological Procedures	S	83.6366	\$5,327.15		\$1,065.43
0386	Level II Prosthetic Urological Procedures	S	144.1246	\$9,179.87		\$1,835.97
0387	Level II Hysteroscopy	T	34.2048	\$2,178.64	\$655.55	\$435.73
0388	Discography	S	20.1823	\$1,285.49	\$289.72	\$257.10
0389	Level I Non-imaging Nuclear Medicine	S	1.8190	\$115.86	\$33.81	\$23.17
0390	Level I Endocrine Imaging	S	2.0471	\$130.39	\$52.15	\$26.08
0391	Level II Endocrine Imaging	S	3.4513	\$219.83	\$66.18	\$43.97
0392	Level II Non-imaging Nuclear Medicine	S	2.9022	\$184.85	\$49.31	\$36.97
0393	Hematologic Processing & Studies	S	5.6921	\$362.55	\$82.04	\$72.51
0394	Hepatobiliary Imaging	S	4.4603	\$284.09	\$102.61	\$56.82
0395	GI Tract Imaging	S	3.7911	\$241.47	\$89.73	\$48.29
0396	Bone Imaging	S	3.8039	\$242.29	\$95.02	\$48.46
0397	Vascular Imaging	S	3.1433	\$200.21	\$49.58	\$40.04
0398	Level I Cardiac Imaging	S	4.8620	\$309.68	\$100.06	\$61.94
0400	Hematopoietic Imaging	S	3.9293	\$250.27	\$93.22	\$50.05
0401	Level I Pulmonary Imaging	S	3.3954	\$216.27	\$78.19	\$43.25
0402	Level II Nervous System Imaging	S	8.8235	\$562.00	\$114.12	\$112.40
0403	Level I Nervous System Imaging	S	3.2295	\$205.70	\$79.87	\$41.14
0404	Renal and Genitourinary Studies	S	5.0824	\$323.72	\$84.11	\$64.74
0406	Level I Tumor/Infection Imaging	S	5.0681	\$322.81	\$98.18	\$64.56
0407	Level I Radionuclide Therapy	S	3.3020	\$210.32	\$78.13	\$42.06
0408	Level III Tumor/Infection Imaging	S	15.4033	\$981.10		\$196.22
0409	Red Blood Cell Tests	X	0.1190	\$7.58	\$2.20	\$1.52
0412	IMRT Treatment Delivery	S	5.4582	\$347.65		\$69.53
0413	Level II Radionuclide Therapy	S	5.2741	\$335.93		\$67.19
0414	Level II Tumor/Infection Imaging	S	8.4176	\$536.15	\$214.44	\$107.23
0415	Level II Endoscopy Lower Airway	T	24.0654	\$1,532.82	\$459.92	\$306.56
0418	Insertion of Left Ventricular Pacing Elect	T	259.7486	\$16,544.43		\$3,308.89
0422	Level II Upper GI Procedures	T	25.3233	\$1,612.94	\$448.81	\$322.59
0423	Level II Percutaneous Abdominal and Biliary Procedures	T	42.9980	\$2,738.71		\$547.74
0425	Level II Arthroplasty with Prosthesis	T	122.2057	\$7,783.77		\$1,556.75
0426	Level II Strapping and Cast Application	S	2.2910	\$145.92		\$29.18
0427	Level II Tube Changes and Repositioning	T	15.3545	\$977.99		\$195.60
0428	Level III Sigmoidoscopy and Anoscopy	T	21.4632	\$1,367.08		\$273.42
0429	Level V Cystourethroscopy and other Genitourinary Procedures	T	45.2042	\$2,879.24		\$575.85
0430	Drug Preadministration-Related Services	S	0.5921	\$37.71		\$7.54
0432	Health and Behavior Services	S	0.3128	\$19.92		\$3.98
0433	Level II Pathology	X	0.2397	\$15.27	\$5.17	\$3.05
0434	Cardiac Defect Repair	T	132.4129	\$8,433.91		\$1,686.78
0436	Level I Drug Administration	S	0.2545	\$16.21		\$3.24
0437	Level II Drug Administration	S	0.3945	\$25.13		\$5.03
0438	Level III Drug Administration	S	0.8041	\$51.22		\$10.24
0439	Level IV Drug Administration	S	1.6544	\$105.38		\$21.08
0440	Level V Drug Administration	S	1.7998	\$114.64		\$22.93
0441	Level VI Drug Administration	S	2.3446	\$149.34		\$29.87
0442	Dosimetric Drug Administration	S	27.4298	\$1,747.11		\$349.42
0604	Level 1 Hospital Clinic Visits	V	0.8388	\$53.43		\$10.69
0605	Level 2 Hospital Clinic Visits	V	0.9964	\$63.46		\$12.69
0606	Level 3 Hospital Clinic Visits	V	1.3226	\$84.24		\$16.85
0607	Level 4 Hospital Clinic Visits	V	1.6604	\$105.76		\$21.15
0608	Level 5 Hospital Clinic Visits	V	2.1740	\$138.47		\$27.69
0609	Level 1 Emergency Visits	V	0.7970	\$50.76	\$12.70	\$10.15
0613	Level 2 Emergency Visits	V	1.3137	\$83.67	\$21.06	\$16.73
0614	Level 3 Emergency Visits	V	2.0750	\$132.17	\$34.50	\$26.43
0615	Level 4 Emergency Visits	V	3.3377	\$212.59	\$48.49	\$42.52
0616	Level 5 Emergency Visits	V	4.9535	\$315.51	\$72.86	\$63.10
0617	Critical Care	S	7.3166	\$466.02	\$111.59	\$93.20
0618	Trauma Response with Critical Care	S	5.1854	\$330.28	\$132.11	\$66.06
0621	Level I Vascular Access Procedures	T	10.9092	\$694.85		\$138.97
0622	Level II Vascular Access Procedures	T	24.1069	\$1,535.46		\$307.09
0623	Level III Vascular Access Procedures	T	28.8743	\$1,839.12		\$367.82
0624	Phlebotomy and Minor Vascular Access Device Procedures	X	0.5689	\$36.24	\$12.65	\$7.25
0625	Level IV Vascular Access Procedures	T	81.7482	\$5,206.87		\$1,041.37
0648	Level IV Breast Surgery	S	56.5774	\$3,603.64		\$720.73
0651	Complex Interstitial Radiation Source Application	S	18.1228	\$1,154.31		\$230.86
0652	Insertion of Intraperitoneal and Pleural Catheters	T	30.7096	\$1,956.02		\$391.20

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0653	Vascular Reconstruction/Fistula Repair with Device	T	40.4667	\$2,577.49		\$515.50
0654	Insertion/Replacement of a permanent dual chamber pacemaker	T	109.2851	\$6,960.81		\$1,392.16
0655	Insertion/Replacement/Conversion of a permanent dual chamber pacemaker.	T	140.0317	\$8,919.18		\$1,783.84
0656	Transcatheter Placement of Intracoronary Drug-Eluting Stents	T	118.4265	\$7,543.06		\$1,508.61
0659	Hyperbaric Oxygen	S	1.5579	\$99.23		\$19.85
0660	Level II Otorhinolaryngologic Function Tests	X	1.4312	\$91.16	\$28.06	\$18.23
0661	Level V Pathology	X	2.6949	\$171.65	\$62.09	\$34.33
0662	CT Angiography	S	5.1641	\$328.92	\$118.88	\$65.78
0663	Level I Electronic Analysis of Devices	S	1.5313	\$97.53		\$19.51
0664	Level I Proton Beam Radiation Therapy	S	12.8205	\$816.59		\$163.32
0665	Bone Density:AppendicularSkeleton	S	0.5087	\$32.40	\$12.95	\$6.48
0667	Level II Proton Beam Radiation Therapy	S	15.3404	\$977.09		\$195.42
0668	Level I Angiography and Venography	S	9.3506	\$595.58		\$119.12
0672	Level IV Posterior Segment Eye Procedures	T	37.2078	\$2,369.91		\$473.98
0673	Level IV Anterior Segment Eye Procedures	T	39.7101	\$2,529.30	\$649.56	\$505.86
0674	Prostate Cryoablation	T	122.7133	\$7,816.10		\$1,563.22
0676	Thrombolysis and Thrombectomy	T	2.4824	\$158.11		\$31.62
0678	External Counterpulsation	T	1.7187	\$109.47		\$21.89
0679	Level II Resuscitation and Cardioversion	S	5.4502	\$347.15	\$95.30	\$69.43
0680	Insertion of Patient Activated Event Recorders	S	70.6073	\$4,497.26		\$899.45
0681	Knee Arthroplasty	T	274.6715	\$17,494.93		\$3,498.99
0682	Level V Debridement & Destruction	T	6.8816	\$438.32	\$158.65	\$87.66
0683	Level II Photochemotherapy	S	2.6045	\$165.89		\$33.18
0685	Level III Needle Biopsy/Aspiration Except Bone Marrow	T	9.3354	\$594.61		\$118.92
0687	Revision/Removal of Neurostimulator Electrodes	T	22.4734	\$1,431.42	\$438.47	\$286.28
0688	Revision/Removal of Neurostimulator Pulse Generator Receiver	T	34.4166	\$2,192.13	\$874.57	\$438.43
0689	Electronic Analysis of Cardioverter-defibrillators	S	0.5946	\$37.87		\$7.57
0690	Electronic Analysis of Pacemakers and other Cardiac Devices	S	0.3504	\$22.32	\$8.67	\$4.46
0691	Level III Electronic Analysis of Devices	S	2.3269	\$148.21	\$50.49	\$29.64
0692	Level II Electronic Analysis of Devices	S	1.8376	\$117.04	\$29.72	\$23.41
0694	Mohs Surgery	T	3.6321	\$231.34	\$91.69	\$46.27
0697	Level I Echocardiogram Without Contrast Except Transesophageal	S	3.3401	\$212.74		\$42.55
0698	Level II Eye Tests & Treatments	S	0.8696	\$55.39		\$11.08
0699	Level IV Eye Tests & Treatments	T	13.7453	\$875.49		\$175.10
0701	Sr89 strontium	K	9.6094	\$612.06		\$122.41
0702	Sm 153 lexidronm	K	21.3689	\$1,361.07		\$272.21
0726	Dexrazoxane HCl injection	K		\$162.11		\$32.42
0728	Filgrastim 300 mcg injection	K		\$193.79		\$38.76
0730	Pamidronate disodium	K		\$28.31		\$5.66
0731	Sargramostim injection	K		\$24.86		\$4.97
0732	Mesna injection	K		\$7.97		\$1.59
0735	Ampho b cholesteryl sulfate	K		\$11.89		\$2.38
0736	Amphotericin b liposome inj	K		\$16.21		\$3.24
0738	Rasburicase	K		\$144.43		\$28.89
0747	Chlorothiazide sodium inj	K		\$141.07		\$28.21
0748	Bleomycin sulfate injection	K		\$42.93		\$8.59
0750	Dolasetron mesylate	K		\$4.66		\$0.93
0751	Mechlorethamine hcl inj	K		\$143.08		\$28.62
0752	Dactinomycin actinomycin d	K		\$488.78		\$97.76
0759	Naltrexone, depot form	K		\$1.87		\$0.37
0760	Anadulafungin injection	G		\$1.91		\$0.38
0763	Dolasetron mesylate oral	K		\$43.77		\$8.75
0764	Granisetron HCl injection	K		\$5.74		\$1.15
0765	Granisetron HCl 1 mg oral	K		\$49.96		\$9.99
0767	Enfuvirtide injection	K		\$0.40		\$0.08
0768	Ondansetron hcl injection	K		\$0.26		\$0.06
0769	Ondansetron HCl 8mg oral	K		\$18.37		\$3.67
0800	Leuprolide acetate	K		\$452.58		\$90.52
0802	Etoposide oral	K		\$29.46		\$5.89
0804	Vivaglobin, inj	K		\$7.01		\$1.40
0805	Mecasermin injection	K		\$15.62		\$3.12
0806	Hyaluronidase recombinant	G		\$0.40		\$0.08
0807	Aldesleukin/single use vial	K		\$788.84		\$157.77
0808	Nabilone oral	K		\$16.80		\$3.36
0809	Bcg live intravesical vac	K		\$113.75		\$22.75
0810	Goserelin acetate implant	K		\$192.29		\$38.46
0811	Carboplatin injection	K		\$7.44		\$1.49
0812	Carmus bischl nitro inj	K		\$152.24		\$30.45
0814	Asparaginase injection	K		\$54.26		\$10.85
0820	Daunorubicin	K		\$19.33		\$3.87
0821	Daunorubicin citrate liposom	K		\$55.23		\$11.05
0823	Docetaxel	K		\$310.85		\$62.17
0825	Nelarabine injection	G		\$86.84		\$17.37
0827	Floxuridine injection	K		\$54.63		\$10.93
0828	Gemcitabine HCl	K		\$127.31		\$25.46
0830	Irinotecan injection	K		\$124.61		\$24.92
0831	Ifosfomide injection	K		\$38.13		\$7.63
0832	Idarubicin hcl injection	K		\$302.42		\$60.48
0834	Interferon alfa-2a inj	K		\$41.37		\$8.27

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0835	Inj cosyntropin	K		\$64.01		\$12.80
0836	Interferon alfa-2b inj	K		\$13.92		\$2.78
0838	Interferon gamma 1-b inj	K		\$306.66		\$61.33
0840	Inj melphalan hydrochl	K		\$1,548.88		\$309.78
0842	Fludarabine phosphate inj	K		\$226.67		\$45.33
0843	Pegaspargase/singl dose vial	K		\$2,080.19		\$416.04
0844	Pentostatin injection	K		\$2,051.68		\$410.34
0849	Rituximab cancer treatment	K		\$504.40		\$100.88
0850	Streptozocin injection	K		\$146.93		\$29.39
0851	Thiotepa injection	K		\$41.12		\$8.22
0852	Topotecan	K		\$859.62		\$171.92
0855	Vinorelbine tartrate	K		\$21.41		\$4.28
0856	Porfimer sodium	K		\$2,532.53		\$506.51
0858	Inj cladribine	K		\$32.04		\$6.41
0861	Leuprolide acetate injeciton	K		\$7.98		\$1.60
0862	Mitomycin 5 MG inj	K		\$14.39		\$2.88
0863	Paclitaxel injection	K		\$14.57		\$2.91
0864	Mitoxantrone hydrochl	K		\$107.96		\$21.59
0865	Interferon alfa-n3 inj	K		\$9.03		\$1.81
0868	Oral aprepitant	K		\$4.99		\$1.00
0873	Hyalgan/supartz inj per dose	K		\$101.81		\$20.36
0874	Synvisc inj per dose	K		\$178.11		\$35.62
0875	Euflexxa inj per dose	K		\$110.95		\$22.19
0877	Orthovisc inj per dose	K		\$174.50		\$34.90
0878	Gallium nitrate injection	K		\$1.61		\$0.32
0880	Pentastarch 10% solution	K		\$21.98		\$4.40
0882	Melphalan oral	K		\$4.14		\$0.83
0883	Fondaparinux sodium	K		\$5.92		\$1.18
0884	Rho d immune globulin inj	K		\$80.79		\$16.16
0887	Azathioprine parenteral	K		\$47.88		\$9.58
0888	Cyclosporine oral	K		\$3.52		\$0.70
0890	Lymphocyte immune globulin	K		\$336.10		\$67.22
0891	Tacrolimus oral	K		\$3.69		\$0.74
0898	Gamma globulin 2 CC inj	K		\$23.82		\$4.76
0899	Gamma globulin 3 CC inj	K		\$35.72		\$7.14
0900	Alglucerase injection	K		\$38.85		\$7.77
0901	Alpha 1 proteinase inhibitor	K		\$3.28		\$0.66
0902	Botulinum toxin a per unit	K		\$5.21		\$1.04
0903	Cytomegalovirus imm IV /vial	K		\$870.53		\$174.11
0904	Gamma globulin 4 CC inj	K		\$47.64		\$9.53
0906	RSV-ivig	K		\$16.02		\$3.20
0910	Interferon beta-1b / .25 MG	K		\$106.57		\$21.31
0911	Inj streptokinase /250000 IU	K		\$129.75		\$25.95
0912	Interferon alfacon-1	K		\$4.62		\$0.92
0913	Ganciclovir long act implant	K		\$4,707.90		\$941.58
0916	Injection imiglucerase /unit	K		\$3.89		\$0.78
0917	Adenosine injection	K		\$67.89		\$13.58
0919	Gamma globulin 5 CC inj	K		\$59.54		\$11.91
0920	Gamma globulin 6 CC inj	K		\$71.50		\$14.30
0921	Gamma globulin 7 CC inj	K		\$83.30		\$16.66
0922	Gamma globulin 8 CC inj	K		\$95.27		\$19.05
0923	Gamma globulin 9 CC inj	K		\$107.25		\$21.45
0924	Gamma globulin 10 CC inj	K		\$119.09		\$23.82
0925	Factor viii	K		\$0.75		\$0.15
0927	Factor viii recombinant	K		\$1.07		\$0.21
0928	Factor ix complex	K		\$0.80		\$0.16
0929	Anti-inhibitor	K		\$1.42		\$0.28
0930	Antithrombin iii injection	K		\$1.82		\$0.36
0931	Factor IX non-recombinant	K		\$0.89		\$0.18
0932	Factor IX recombinant	K		\$0.99		\$0.20
0933	Gamma globulin ≤ 10 CC inj	K		\$119.09		\$23.82
0934	Capecitabine, oral	K		\$14.19		\$2.84
0935	Clonidine hydrochloride	K		\$62.78		\$12.56
0941	Mitomycin 20 MG inj	K		\$57.56		\$11.51
0942	Mitomycin 40 MG inj	K		\$115.11		\$23.02
0943	Octagam injection	K		\$33.19		\$6.64
0944	Gammagard liquid injection	K		\$31.06		\$6.21
0945	Rhophylac injection	K		\$5.29		\$1.06
0946	HepaGam B IM injection	K		\$63.51		\$12.70
0947	Flebogamma injection	K		\$32.27		\$6.45
0948	Gamunex injection	K		\$32.06		\$6.41
0949	Frozen plasma, pooled, sd	K	1.1598	\$73.87		\$14.77
0950	Whole blood for transfusion	K	4.0011	\$254.85		\$50.97
0951	Reclast injection	G		\$220.81		\$44.16
0952	Cryoprecipitate each unit	K	0.6474	\$41.24		\$8.25
0954	RBC leukocytes reduced	K	2.9069	\$185.15		\$37.03
0955	Plasma, frz between 8-24hour	K	1.2235	\$77.93		\$15.59
0956	Plasma protein fract,5%,50ml	K	1.4739	\$93.88		\$18.78
0957	Platelets, each unit	K	1.0911	\$69.50		\$13.90
0958	Plaelet rich plasma unit	K	5.7070	\$363.50		\$72.70

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0959	Red blood cells unit	K	2.0356	\$129.66		\$25.93
0960	Washed red blood cells unit	K	4.3494	\$277.03		\$55.41
0961	Albumin (human), 5%, 50ml	K	0.3413	\$21.74		\$4.35
0963	Albumin (human), 5%, 250 ml	K	1.0987	\$69.98		\$14.00
0964	Albumin (human), 25%, 20 ml	K	0.4118	\$26.23		\$5.25
0965	Albumin (human), 25%, 50ml	K	1.1362	\$72.37		\$14.47
0966	Plasmaprotein fract, 5%, 250ml	K	3.3792	\$215.23		\$43.05
0967	Blood split unit	K	2.3409	\$149.10		\$29.82
0968	Platelets leukoreduced irradiated	K	2.1971	\$139.94		\$27.99
0969	RBC leukoreduced irradiated	K	3.7722	\$240.27		\$48.05
0998	Inj biperiden lactate/5 mg	K		\$88.15		\$17.63
0999	Edetate calcium disodium inj	K		\$49.64		\$9.93
1009	Cryoprecipitatereduced plasma	K	1.3139	\$83.69		\$16.74
1010	Blood, l/r, cmv-neg	K	2.3221	\$147.90		\$29.58
1011	Platelets, hla-m, l/r, unit	K	10.1413	\$645.94		\$129.19
1013	Platelets leukocytes reduced	K	1.6879	\$107.51		\$21.50
1015	Injection glatiramer acetate	K		\$52.04		\$10.41
1016	Blood, l/r, froz/degly/wash	K	3.4353	\$218.81		\$43.76
1017	Plt, aph/pher, l/r, cmv-neg	K	7.6733	\$488.74		\$97.75
1018	Blood, l/r, irradiated	K	2.3099	\$147.13		\$29.43
1019	Plate pheres leukoredu irradiated	K	9.8923	\$630.08		\$126.02
1020	Plt, pher, l/r cmv-neg, irr	K	10.7787	\$686.54		\$137.31
1021	RBC, frz/deg/wsh, l/r, irradiated	K	5.8716	\$373.99		\$74.80
1022	RBC, l/r, cmv-neg, irradiated	K	4.1363	\$263.46		\$52.69
1023	Pralidoxime chloride inj	K		\$35.20		\$7.04
1032	Aud osseo dev, int/ext comp	H				
1041	Plicamycin (mithramycin) inj	K		\$172.41		\$34.48
1052	Injection, voriconazole	K		\$4.93		\$0.99
1064	I131 iodide cap, rx	K	0.2393	\$15.24		\$3.05
1083	Adalimumab injection	K		\$329.58		\$65.92
1084	Denileukin difitox	K		\$1,386.59		\$277.32
1086	Temozolomide	K		\$7.49		\$1.50
1138	Hepagam B intravenous, inj	K		\$63.51		\$12.70
1139	Protein C concentrate	K		\$12.08		\$2.42
1140	Integra matrix tissue	K		\$33.14		\$6.63
1141	Primatrix tissue	G		\$67.96		\$13.59
1142	Supprelin LA implant	K		\$14,700.00		\$2,940.00
1150	I131 iodide sol, rx	K	0.1762	\$11.22		\$2.24
1165	Aripiprazole injection	K		\$0.28		\$0.06
1166	Cytarabine liposome	K		\$412.21		\$82.44
1167	Inj, epirubicin hcl	K		\$19.79		\$3.96
1168	Inj, temsirolimus	G		\$48.41		\$9.68
1169	Neurawrap nerve protector, cm	G		\$482.56		\$96.51
1178	Busulfan injection	K		\$9.17		\$1.83
1203	Verteporfin injection	K		\$8.99		\$1.80
1207	Octreotide injection, depot	K		\$99.04		\$19.81
1280	Corticotropin injection	K		\$169.77		\$33.95
1436	Etidronate disodium inj	K		\$70.73		\$14.15
1491	New Technology—Level IA (\$0–\$10)	S		\$5.00		\$1.00
1492	New Technology—Level IB (\$10–\$20)	S		\$15.00		\$3.00
1493	New Technology—Level IC (\$20–\$30)	S		\$25.00		\$5.00
1494	New Technology—Level ID (\$30–\$40)	S		\$35.00		\$7.00
1495	New Technology—Level IE (\$40–\$50)	S		\$45.00		\$9.00
1496	New Technology—Level IA (\$0–\$10)	T		\$5.00		\$1.00
1497	New Technology—Level IB(\$10–\$20)	T		\$15.00		\$3.00
1498	New Technology—Level IC (\$20–\$30)	T		\$25.00		\$5.00
1499	New Technology—Level ID(\$30–\$40)	T		\$35.00		\$7.00
1500	New Technology—Level IE (\$40–\$50)	T		\$45.00		\$9.00
1502	New Technology—Level II (\$50–\$100)	S		\$75.00		\$15.00
1503	New Technology—Level III (\$100–\$200)	S		\$150.00		\$30.00
1504	New Technology—Level IV (\$200–\$300)	S		\$250.00		\$50.00
1505	New Technology—Level V (\$300–\$400)	S		\$350.00		\$70.00
1506	New Technology—Level VI (\$400–\$500)	S		\$450.00		\$90.00
1507	New Technology—Level VII (\$500–\$600)	S		\$550.00		\$110.00
1508	New Technology—Level VIII (\$600–\$700)	S		\$650.00		\$130.00
1509	New Technology—Level IX (\$700–\$800)	S		\$750.00		\$150.00
1510	New Technology—Level X (\$800–\$900)	S		\$850.00		\$170.00
1511	New Technology—Level XI (\$900–\$1000)	S		\$950.00		\$190.00
1512	New Technology—Level XII (\$1000–\$1100)	S		\$1,050.00		\$210.00
1513	New Technology—Level XIII (\$1100–\$1200)	S		\$1,150.00		\$230.00
1514	New Technology—Level XIV(\$1200–\$1300)	S		\$1,250.00		\$250.00
1515	New Technology—Level XV (\$1300–\$1400)	S		\$1,350.00		\$270.00
1516	New Technology—Level XVI (\$1400–\$1500)	S		\$1,450.00		\$290.00
1517	New Technology—Level XVII (\$1500–\$1600)	S		\$1,550.00		\$310.00
1518	New Technology—Level XVIII (\$1600–\$1700)	S		\$1,650.00		\$330.00
1519	New Technology—Level XIX (\$1700–\$1800)	S		\$1,750.00		\$350.00
1520	New Technology—Level XX (\$1800–\$1900)	S		\$1,850.00		\$370.00
1521	New Technology—Level XXI (\$1900–\$2000)	S		\$1,950.00		\$390.00
1522	New Technology—Level XXII (\$2000–\$2500)	S		\$2,250.00		\$450.00
1523	New Technology—Level XXIII (\$2500–\$3000)	S		\$2,750.00		\$550.00

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
1524	New Technology—Level XXIV (\$3000–\$3500)	S		\$3,250.00		\$650.00
1525	New Technology—Level XXV (\$3500–\$4000)	S		\$3,750.00		\$750.00
1526	New Technology—Level XXVI (\$4000–\$4500)	S		\$4,250.00		\$850.00
1527	New Technology—Level XXVII (\$4500–\$5000)	S		\$4,750.00		\$950.00
1528	New Technology—Level XXVIII (\$5000–\$5500)	S		\$5,250.00		\$1,050.00
1529	New Technology—Level XXIX (\$5500–\$6000)	S		\$5,750.00		\$1,150.00
1530	New Technology—Level XXX (\$6000–\$6500)	S		\$6,250.00		\$1,250.00
1531	New Technology—Level XXXI (\$6500–\$7000)	S		\$6,750.00		\$1,350.00
1532	New Technology—Level XXXII (\$7000–\$7500)	S		\$7,250.00		\$1,450.00
1533	New Technology—Level XXXIII (\$7500–\$8000)	S		\$7,750.00		\$1,550.00
1534	New Technology—Level XXXIV (\$8000–\$8500)	S		\$8,250.00		\$1,650.00
1535	New Technology—Level XXXV (\$8500–\$9000)	S		\$8,750.00		\$1,750.00
1536	New Technology—Level XXXVI (\$9000–\$9500)	S		\$9,250.00		\$1,850.00
1537	New Technology—Level XXXVII (\$9500–\$10000)	S		\$9,750.00		\$1,950.00
1539	New Technology—Level II (\$50–\$100)	T		\$75.00		\$15.00
1540	New Technology—Level III (\$100–\$200)	T		\$150.00		\$30.00
1541	New Technology—Level IV (\$200–\$300)	T		\$250.00		\$50.00
1542	New Technology—Level V (\$300–\$400)	T		\$350.00		\$70.00
1543	New Technology—Level VI (\$400–\$500)	T		\$450.00		\$90.00
1544	New Technology—Level VII (\$500–\$600)	T		\$550.00		\$110.00
1545	New Technology—Level VIII (\$600–\$700)	T		\$650.00		\$130.00
1546	New Technology—Level IX (\$700–\$800)	T		\$750.00		\$150.00
1547	New Technology—Level X (\$800–\$900)	T		\$850.00		\$170.00
1548	New Technology—Level XI (\$900–\$1000)	T		\$950.00		\$190.00
1549	New Technology—Level XII (\$1000–\$1100)	T		\$1,050.00		\$210.00
1550	New Technology—Level XIII (\$1100–\$1200)	T		\$1,150.00		\$230.00
1551	New Technology—Level XIV (\$1200–\$1300)	T		\$1,250.00		\$250.00
1552	New Technology—Level XV (\$1300–\$1400)	T		\$1,350.00		\$270.00
1553	New Technology—Level XVI (\$1400–\$1500)	T		\$1,450.00		\$290.00
1554	New Technology—Level XVII (\$1500–\$1600)	T		\$1,550.00		\$310.00
1555	New Technology—Level XVIII (\$1600–\$1700)	T		\$1,650.00		\$330.00
1556	New Technology—Level XIX (\$1700–\$1800)	T		\$1,750.00		\$350.00
1557	New Technology—Level XX (\$1800–\$1900)	T		\$1,850.00		\$370.00
1558	New Technology—Level XXI (\$1900–\$2000)	T		\$1,950.00		\$390.00
1559	New Technology—Level XXII (\$2000–\$2500)	T		\$2,250.00		\$450.00
1560	New Technology—Level XXIII (\$2500–\$3000)	T		\$2,750.00		\$550.00
1561	New Technology—Level XXIV (\$3000–\$3500)	T		\$3,250.00		\$650.00
1562	New Technology—Level XXV (\$3500–\$4000)	T		\$3,750.00		\$750.00
1563	New Technology—Level XXVI (\$4000–\$4500)	T		\$4,250.00		\$850.00
1564	New Technology—Level XXVII (\$4500–\$5000)	T		\$4,750.00		\$950.00
1565	New Technology—Level XXVIII (\$5000–\$5500)	T		\$5,250.00		\$1,050.00
1566	New Technology—Level XXIX (\$5500–\$6000)	T		\$5,750.00		\$1,150.00
1567	New Technology—Level XXX (\$6000–\$6500)	T		\$6,250.00		\$1,250.00
1568	New Technology—Level XXXI (\$6500–\$7000)	T		\$6,750.00		\$1,350.00
1569	New Technology—Level XXXII (\$7000–\$7500)	T		\$7,250.00		\$1,450.00
1570	New Technology—Level XXXIII (\$7500–\$8000)	T		\$7,750.00		\$1,550.00
1571	New Technology—Level XXXIV (\$8000–\$8500)	T		\$8,250.00		\$1,650.00
1572	New Technology—Level XXXV (\$8500–\$9000)	T		\$8,750.00		\$1,750.00
1573	New Technology—Level XXXVI (\$9000–\$9500)	T		\$9,250.00		\$1,850.00
1574	New Technology—Level XXXVII (\$9500–\$10000)	T		\$9,750.00		\$1,950.00
1605	Abciximab injection	K		\$420.17		\$84.03
1606	Injection anistreplase 30 u	K		\$2,693.80		\$538.76
1607	Eptifibatide injection	K		\$17.67		\$3.53
1608	Etanercept injection	K		\$167.12		\$33.42
1609	Rho(D) immune globulin h, sd	K		\$15.62		\$3.12
1612	Daclizumab, parenteral	K		\$322.28		\$64.46
1613	Trastuzumab	K		\$58.51		\$11.70
1629	Nonmetabolic act d/e tissue	K		\$20.22		\$4.04
1630	Hep b ig, im	K		\$122.02		\$24.40
1631	Baclofen intrathecal trial	K		\$69.73		\$13.95
1632	Metabolic active D/E tissue	K		\$28.45		\$5.69
1633	Alefacept	K		\$26.47		\$5.29
1643	Y90 ibritumomab, rx	K	235.8764	\$15,023.91		\$3,004.78
1645	I131 tositumomab, rx	K	176.8495	\$11,264.25		\$2,252.85
1670	Tetanus immune globulin inj	K		\$103.46		\$20.69
1675	P32 Na phosphate	K	1.7835	\$113.60		\$22.72
1676	P32 chromic phosphate	K	1.8711	\$119.18		\$23.84
1682	Aprotonin, 10,000 kiu	K		\$2.66		\$0.53
1683	Basiliximab	K		\$1,541.03		\$308.21
1684	Corticotrelin ovine triflutal	K		\$4.43		\$0.89
1685	Darbepoetin alfa, non-esrd	K		\$2.88		\$0.58
1686	Epoetin alfa, non-esrd	K		\$8.97		\$1.79
1687	Digoxin immune fab (ovine)	K		\$478.88		\$95.78
1688	Ethanolamine oleate	K		\$79.23		\$15.85
1689	Fomepizole	K		\$12.80		\$2.56
1690	Hemin	K		\$7.08		\$1.42
1691	Iron dextran 165 injection	K		\$11.82		\$2.36
1692	Iron dextran 267 injection	K		\$10.30		\$2.06
1693	Lepirudin	K		\$159.44		\$31.89
1694	Ziconotide injection	K		\$6.46		\$1.29

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
1695	Nesiritide injection	K		\$32.95		\$6.59
1696	Palifermin injection	K		\$11.24		\$2.25
1697	Pegaptanib sodium injection	K		\$1,035.69		\$207.14
1700	Inj secretin synthetic human	K		\$20.12		\$4.02
1701	Treprostinil injection	K		\$55.36		\$11.07
1703	Ovine, 1000 USP units	K		\$133.77		\$26.75
1704	Humate-P, inj	K		\$0.88		\$0.18
1705	Factor viia	K		\$1.15		\$0.23
1709	Azacitidine injection	K		\$4.35		\$0.87
1710	Clofarabine injection	K		\$114.41		\$22.88
1711	Vantas implant	K		\$1,412.46		\$282.49
1712	Paclitaxel protein bound	K		\$8.79		\$1.76
1716	Brachytx, non-str, Gold-198	K	0.5228	\$33.30		\$6.66
1717	Brachytx, non-str, HDR Ir-192	K	2.7505	\$175.19		\$35.04
1719	Brachytx, NS, Non-HDR Ir-192	K	1.0226	\$65.13		\$13.03
1738	Oxaliplatin	K		\$9.15		\$1.83
1739	Pegademase bovine, 25 iu	K		\$197.51		\$39.50
1740	Diazoxide injection	K		\$113.24		\$22.65
1741	Urofollitropin, 75 iu	K		\$50.22		\$10.04
1821	Interspinous implant	H				
2210	Methyldopate hcl injection	K		\$13.04		\$2.61
2616	Brachytx, non-str, Yttrium-90	K	184.7105	\$11,764.95		\$2,352.99
2632	Iodine I-125 sodium iodide	K	0.4325	\$27.55		\$5.51
2634	Brachytx, non-str, HA, I-125	K	0.4858	\$30.94		\$6.19
2635	Brachytx, non-str, HA, P-103	K	0.7366	\$46.92		\$9.38
2636	Brachy linear, non-str, P-103	K	0.6600	\$42.04		\$8.41
2638	Brachytx, stranded, I-125	K	0.7113	\$45.31		\$9.06
2639	Brachytx, non-stranded, I-125	K	0.5039	\$32.10		\$6.42
2640	Brachytx, stranded, P-103	K	1.0308	\$65.66		\$13.13
2641	Brachytx, non-stranded, P-103	K	0.8077	\$51.45		\$10.29
2642	Brachytx, stranded, C-131	K	1.5342	\$97.72		\$19.54
2643	Brachytx, non-stranded, C-131	K	1.0060	\$64.08		\$12.82
2698	Brachytx, stranded, NOS	K	0.7113	\$45.31		\$9.06
2699	Brachytx, non-stranded, NOS	K	0.4858	\$30.94		\$6.19
2731	Immune globulin, powder	K		\$26.89		\$5.38
2770	Quinupristin/dalfopristin	K		\$126.44		\$25.29
2940	Somatrem injection	K		\$168.90		\$33.78
3030	Sumatriptan succinate	K		\$61.27		\$12.25
3041	Bivalirudin	K		\$1.84		\$0.37
3043	Gamma globulin 1 CC inj	K		\$11.91		\$2.38
3050	Sermorelin acetate injection	K		\$1.74		\$0.35
7000	Amifostine	K		\$490.93		\$98.19
7005	Gonadorelin hydroch	K		\$178.59		\$35.72
7011	Oprelvekin injection	K		\$247.02		\$49.40
7015	Oral busulfan	K		\$2.26		\$0.45
7028	Fosphenytoin	K		\$5.76		\$1.15
7034	Somatropin injection	K		\$48.52		\$9.70
7035	Teniposide	K		\$280.26		\$56.05
7036	Urokinase 250,000 IU inj	K		\$453.41		\$90.68
7038	Monoclonal antibodies	K		\$977.75		\$195.55
7041	Tirofiban HCl	K		\$7.56		\$1.51
7042	Capecitabine, oral	K		\$4.28		\$0.86
7043	Infliximab injection	K		\$54.42		\$10.88
7045	Inj trimetrexate glucuronate	K		\$148.30		\$29.66
7046	Doxorubicin hcl liposome inj	K		\$396.15		\$79.23
7048	Alteplase recombinant	K		\$33.39		\$6.68
7049	Filgrastim 480 mcg injection	K		\$298.39		\$59.68
7051	Leuprolide acetate implant	K		\$1,648.41		\$329.68
7308	Aminolevulinic acid hcl top	K		\$109.92		\$21.98
8000	Cardiac Electrophysiologic Evaluation and Ablation Composite	T	134.1189	\$8,542.57		\$1,708.51
8001	LDR Prostate Brachytherapy Composite	T	53.8937	\$3,432.71		\$686.54
8002	Level I Extended Assessment & Management Composite	V	5.5113	\$351.04		\$70.21
8003	Level II Extended Assessment & Management Composite	V	10.0270	\$638.66		\$127.73
9001	Linezolid injection	K		\$25.17		\$5.03
9002	Tenecteplase injection	K		\$2,034.65		\$406.93
9003	Palivizumab	K		\$810.67		\$162.13
9004	Gemtuzumab ozogamicin	K		\$2,411.98		\$482.40
9005	Reteplase injection	K		\$841.28		\$168.26
9006	Tacrolimus injection	K		\$138.64		\$27.73
9012	Arsenic trioxide	K		\$34.44		\$6.89
9015	Mycophenolate mofetil oral	K		\$2.66		\$0.53
9018	Botulinum toxin type B	K		\$8.63		\$1.73
9019	Caspofungin acetate	K		\$24.05		\$4.81
9020	Sirolimus, oral	K		\$7.50		\$1.50
9022	IM inj interferon beta 1-a	K		\$118.84		\$23.77
9023	Rho d immune globulin	K		\$26.41		\$5.28
9024	Amphotericin b lipid complex	K		\$10.40		\$2.08
9032	Baclofen 10 MG injection	K		\$193.29		\$38.66
9033	Cidofovir injection	K		\$754.39		\$150.88
9038	Inj estrogen conjugate	K		\$66.64		\$13.33

ADDENDUM A.—OPPS APCS FOR CY 2008—Continued

APC	Group title	SI	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
9042	Glucagon hydrochloride	K		\$68.84		\$13.77
9044	Ibutilide fumarate injection	K		\$287.15		\$57.43
9046	Iron sucrose injection	K		\$0.36		\$0.08
9047	Itraconazole injection	K		\$39.68		\$7.94
9051	Urea injection	K		\$74.16		\$14.83
9054	Metabolically active tissue	K		\$36.40		\$7.28
9104	Antithymocyte globulin rabbit	K		\$337.82		\$67.56
9108	Thyrotropin injection	K		\$834.18		\$166.84
9110	Alemtuzumab injection	K		\$549.77		\$109.95
9115	Zoledronic acid	K		\$205.76		\$41.15
9119	Injection, pegfilgrastim 6mg	K		\$2,145.12		\$429.02
9120	Injection, Fulvestrant	K		\$80.60		\$16.12
9121	Injection, argatroban	K		\$18.96		\$3.79
9122	Triptorelin pamoate	K		\$159.38		\$31.88
9124	Daptomycin injection	K		\$0.35		\$0.07
9125	Risperidone, long acting	K		\$4.86		\$0.97
9126	Natalizumab injection	G		\$7.51		\$1.50
9133	Rabies ig, im/sc	K		\$68.22		\$13.64
9134	Rabies ig, heat treated	K		\$71.69		\$14.34
9135	Varicella-zoster ig, im	K		\$122.74		\$24.55
9137	Bcg vaccine, percut	K		\$118.98		\$23.80
9139	Rabies vaccine, im	K		\$150.80		\$30.16
9140	Rabies vaccine, id	K		\$119.86		\$23.97
9141	Measles-rubella vaccine, sc	K		\$45.53		\$9.11
9143	Meningococcal vaccine, sc	K		\$85.29		\$17.06
9144	Encephalitis vaccine, sc	K		\$98.17		\$19.63
9145	Meningococcal vaccine, im	K		\$82.00		\$16.40
9156	Nonmetabolic active tissue	K		\$94.53		\$18.91
9167	Valrubicin, 200 mg	K		\$77.96		\$15.59
9207	Bortezomib injection	K		\$33.20		\$6.64
9208	Agalsidase beta injection	K		\$126.00		\$25.20
9209	Laronidase injection	K		\$23.64		\$4.73
9210	Palonosetron HCl	K		\$16.45		\$3.29
9213	Pemetrexed injection	K		\$44.49		\$8.90
9214	Bevacizumab injection	K		\$56.93		\$11.39
9215	Cetuximab injection	K		\$49.43		\$9.89
9216	Abarelix injection	K		\$67.97		\$13.59
9217	Leuprolide acetate suspnsion	K		\$236.06		\$47.21
9219	Mycophenolic acid	K		\$2.41		\$0.48
9222	Injectable human tissue	K		\$774.46		\$154.89
9224	Galsulfase injection	K		\$306.88		\$61.38
9225	Fluocinolone acetonide implt	K		\$19,162.50		\$3,832.50
9227	Micafungin sodium injection	G		\$1.44		\$0.29
9228	Tigecycline injection	G		\$0.96		\$0.19
9229	Ibandronate sodium injection	G		\$138.96		\$27.79
9230	Abatacept injection	G		\$18.69		\$3.74
9231	Decitabine injection	G		\$26.48		\$5.30
9232	Idursulfase injection	G		\$455.03		\$91.01
9233	Ranibizumab injection	G		\$2,030.23		\$406.05
9234	Aglucosidase alfa injection	K		\$126.00		\$25.20
9235	Panitumumab injection	G		\$83.15		\$16.63
9236	Eculizumab injection	G		\$176.38		\$35.28
9238	Inj, levetiracetam	K		\$6.30		\$1.26
9300	Omalizumab injection	K		\$17.12		\$3.42
9350	Neuragen nerve guide, per cm	G		\$482.56		\$96.51
9351	Tissuemend tissue	G		\$67.96		\$13.59
9500	Platelets, irradiated	K	1.9110	\$121.72		\$24.34
9501	Platelet pheres leukoreduced	K	7.8426	\$499.53		\$99.91
9502	Platelet pheresis irradiated	K	6.5581	\$417.71		\$83.54
9503	Fr frz plasma donor retested	K	0.8264	\$52.64		\$10.53
9504	RBC deglycerolized	K	5.4516	\$347.23		\$69.45
9505	RBC irradiated	K	3.0643	\$195.18		\$39.04
9506	Granulocytes, pheresis unit	K	21.7847	\$1,387.55		\$277.51
9507	Platelets, pheresis	K	6.9242	\$441.03		\$88.21
9508	Plasma 1 donor frz w/in 8 hr	K	1.0524	\$67.03		\$13.41

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008

[Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
0016T	Thermotx choroid vas lesion	Y		R2		4.1331	\$171.11	\$171.11
0017T	Photocoagulat macular drusen	Y		R2		4.1331	\$171.11	\$171.11
0027T	Endoscopic epidural lysis	Y		G2		18.0518	\$747.36	\$747.36
0031T	Speculoscopy	N		N1				
0032T	Speculoscopy w/direct sample	N		N1				
0046T	Cath lavage, mammary duct(s)	Y		R2		16.1001	\$666.56	\$666.56
0047T	Cath lavage, mammary duct(s)	Y		R2		16.1001	\$666.56	\$666.56
0062T	Rep intradisc annulus;1 lev	Y		G2		29.19	\$1,208.50	\$1,208.50
0063T	Rep intradisc annulus;>1lev	Y		G2		29.19	\$1,208.50	\$1,208.50
0084T	Temp prostate urethral stent	Y		G2		2.0077	\$83.12	\$83.12
0088T	Rf tongue base vol reduxn	Y	CH	G2		16.3288	\$676.03	\$676.03
0099T*	Implant corneal ring	Y		R2		16.171	\$669.50	\$669.50
0100T	Prosth retina receive&gen	Y		G2		37.2078	\$1,540.44	\$1,540.44
0101T	Extracorp shockwv tx,hi enrg	Y		G2		29.19	\$1,208.50	\$1,208.50
0102T	Extracorp shockwv tx,anesth	Y		G2		29.19	\$1,208.50	\$1,208.50
0123T	Scleral fistulization	Y		G2		23.1758	\$959.50	\$959.50
0124T*	Conjunctival drug placement	Y		R2		5.1169	\$211.84	\$211.84
0137T	Prostate saturation sampling	Y	CH	G2		11.0338	\$456.81	\$456.81
0170T	Anorectal fistula plug rpr	Y	CH	G2		30.1606	\$1,248.68	\$1,248.68
0176T	Aqu canal dilat w/o retent	Y		A2	\$1,339.00	39.7101	\$1,644.04	\$1,415.26
0177T	Aqu canal dilat w retent	Y		A2	\$1,339.00	39.7101	\$1,644.04	\$1,415.26
0186T	Suprachoroidal drug delivery	Y	NI	G2		18.235	\$754.95	\$754.95
10021	Fna w/o image	Y		P2		1.1097	\$45.94	\$45.94
10022	Fna w/image	Y		G2		4.327	\$179.14	\$179.14
10040	Acne surgery	Y		P2		0.793	\$32.83	\$32.83
10060	Drainage of skin abscess	Y		P3		1.1108	\$45.99	\$45.99
10061	Drainage of skin abscess	Y		P2		1.4066	\$58.23	\$58.23
10080	Drainage of pilonidal cyst	Y		P2		1.4066	\$58.23	\$58.23
10081	Drainage of pilonidal cyst	Y		P3		3.1023	\$128.44	\$128.44
10120	Remove foreign body	Y		P2		1.4066	\$58.23	\$58.23
10121	Remove foreign body	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
10140	Drainage of hematoma/fluid	Y		P3		1.6541	\$68.48	\$68.48
10160	Puncture drainage of lesion	Y	CH	P3		1.4154	\$58.60	\$58.60
10180	Complex drainage, wound	Y		A2	\$446.00	18.3197	\$758.45	\$524.11
11000	Debride infected skin	Y		P3		0.5348	\$22.14	\$22.14
11001	Debride infected skin add-on	Y		P3		0.1894	\$7.84	\$7.84
11010	Debride skin, fx	Y		A2	\$251.52	4.3039	\$178.19	\$233.19
11011	Debride skin/muscle, fx	Y		A2	\$251.52	4.3039	\$178.19	\$233.19
11012	Debride skin/muscle/bone, fx	Y		A2	\$251.52	4.3039	\$178.19	\$233.19
11040	Debride skin, partial	Y		P3		0.4937	\$20.44	\$20.44
11041	Debride skin, full	Y		P3		0.5679	\$23.51	\$23.51
11042	Debride skin/tissue	Y		A2	\$164.42	2.6604	\$110.14	\$150.85
11043	Debride tissue/muscle	Y		A2	\$164.42	2.6604	\$110.14	\$150.85
11044	Debride tissue/muscle/bone	Y		A2	\$423.10	6.8816	\$284.91	\$388.55
11055	Trim skin lesion	Y		P3		0.5596	\$23.17	\$23.17
11056	Trim skin lesions, 2 to 4	Y		P3		0.6253	\$25.89	\$25.89
11057	Trim skin lesions, over 4	Y		P3		0.7077	\$29.30	\$29.30
11100	Biopsy, skin lesion	Y		P2		0.793	\$32.83	\$32.83
11101	Biopsy, skin add-on	Y		P3		0.3046	\$12.61	\$12.61
11200	Removal of skin tags	Y	CH	P2		0.793	\$32.83	\$32.83
11201	Remove skin tags add-on	Y		P3		0.1316	\$5.45	\$5.45
11300	Shave skin lesion	Y		P2		0.793	\$32.83	\$32.83
11301	Shave skin lesion	Y		P2		0.793	\$32.83	\$32.83
11302	Shave skin lesion	Y		P2		0.793	\$32.83	\$32.83
11303	Shave skin lesion	Y		P3		1.4811	\$61.32	\$61.32
11305	Shave skin lesion	Y		P3		0.7901	\$32.71	\$32.71
11306	Shave skin lesion	Y	CH	P2		0.793	\$32.83	\$32.83
11307	Shave skin lesion	Y		P2		0.793	\$32.83	\$32.83
11308	Shave skin lesion	Y		P2		0.793	\$32.83	\$32.83
11310	Shave skin lesion	Y	CH	P2		0.793	\$32.83	\$32.83
11311	Shave skin lesion	Y		P2		0.793	\$32.83	\$32.83
11312	Shave skin lesion	Y		P2		0.793	\$32.83	\$32.83
11313	Shave skin lesion	Y	CH	P2		0.793	\$32.83	\$32.83
11400	Exc tr-ext b9+marg 0.5 < cm	Y		P3		1.5963	\$66.09	\$66.09
11401	Exc tr-ext b9+marg 0.6-1 cm	Y		P3		1.7444	\$72.22	\$72.22
11402	Exc tr-ext b9+marg 1.1-2 cm	Y		P3		1.9009	\$78.70	\$78.70
11403	Exc tr-ext b9+marg 2.1-3 cm	Y		P3		2.0326	\$84.15	\$84.15
11404	Exc tr-ext b9+marg 3.1-4 cm	Y		A2	\$333.00	16.1001	\$666.56	\$416.39
11406	Exc tr-ext b9+marg > 4.0 cm	Y		A2	\$446.00	16.1001	\$666.56	\$501.14

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
11420	Exc h-f-nk-sp b9+marg 0.5 <	Y		P3		1.4729	\$60.98	\$60.98
11421	Exc h-f-nk-sp b9+marg 0.6-1	Y		P3		1.7611	\$72.91	\$72.91
11422	Exc h-f-nk-sp b9+marg 1.1-2	Y		P3		1.9256	\$79.72	\$79.72
11423	Exc h-f-nk-sp b9+marg 2.1-3	Y		P3		2.156	\$89.26	\$89.26
11424	Exc h-f-nk-sp b9+marg 3.1-4	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
11426	Exc h-f-nk-sp b9+marg > 4 cm	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11440	Exc face-mm b9+marg 0.5 < cm	Y		P3		1.728	\$71.54	\$71.54
11441	Exc face-mm b9+marg 0.6-1 cm	Y		P3		1.9338	\$80.06	\$80.06
11442	Exc face-mm b9+marg 1.1-2 cm	Y		P3		2.1313	\$88.24	\$88.24
11443	Exc face-mm b9+marg 2.1-3 cm	Y		P3		2.3864	\$98.80	\$98.80
11444	Exc face-mm b9+marg 3.1-4 cm	Y		A2	\$333.00	8.685	\$359.57	\$339.64
11446	Exc face-mm b9+marg > 4 cm	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11450	Removal, sweat gland lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11451	Removal, sweat gland lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11462	Removal, sweat gland lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11463	Removal, sweat gland lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11470	Removal, sweat gland lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11471	Removal, sweat gland lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11600	Exc tr-ext mlg+marg 0.5 < cm	Y		P3		2.2135	\$91.64	\$91.64
11601	Exc tr-ext mlg+marg 0.6-1 cm	Y		P3		2.5263	\$104.59	\$104.59
11602	Exc tr-ext mlg+marg 1.1-2 cm	Y		P3		2.7403	\$113.45	\$113.45
11603	Exc tr-ext mlg+marg 2.1-3 cm	Y		P3		2.9294	\$121.28	\$121.28
11604	Exc tr-ext mlg+marg 3.1-4 cm	Y		A2	\$418.49	8.685	\$359.57	\$403.76
11606	Exc tr-ext mlg+marg > 4 cm	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
11620	Exc h-f-nk-sp mlg+marg 0.5 <	Y		P3		2.2384	\$92.67	\$92.67
11621	Exc h-f-nk-sp mlg+marg 0.6-1	Y		P3		2.5509	\$105.61	\$105.61
11622	Exc h-f-nk-sp mlg+marg 1.1-2	Y		P3		2.8224	\$116.85	\$116.85
11623	Exc h-f-nk-sp mlg+marg 2.1-3	Y		P3		3.061	\$126.73	\$126.73
11624	Exc h-f-nk-sp mlg+marg 3.1-4	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
11626	Exc h-f-nk-sp mlg+marg > 4 cm	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11640	Exc face-mm malig+marg 0.5 <	Y		P3		2.3451	\$97.09	\$97.09
11641	Exc face-mm malig+marg 0.6-1	Y		P3		2.7403	\$113.45	\$113.45
11642	Exc face-mm malig+marg 1.1-2	Y		P3		3.061	\$126.73	\$126.73
11643	Exc face-mm malig+marg 2.1-3	Y		P3		3.3246	\$137.64	\$137.64
11644	Exc face-mm malig+marg 3.1-4	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
11646	Exc face-mm mlg+marg > 4 cm	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
11719	Trim nail(s)	Y		P3		0.2551	\$10.56	\$10.56
11720	Debride nail, 1-5	Y		P3		0.3292	\$13.63	\$13.63
11721	Debride nail, 6 or more	Y		P3		0.4031	\$16.69	\$16.69
11730	Removal of nail plate	Y	CH	P2		0.793	\$32.83	\$32.83
11732	Remove nail plate, add-on	Y		P3		0.4031	\$16.69	\$16.69
11740	Drain blood from under nail	Y	CH	P2		0.2963	\$12.27	\$12.27
11750	Removal of nail bed	Y		P3		2.1065	\$87.21	\$87.21
11752	Remove nail bed/finger tip	Y		P3		2.8965	\$119.92	\$119.92
11755	Biopsy, nail unit	Y		P3		1.4729	\$60.98	\$60.98
11760	Repair of nail bed	Y		G2		2.1051	\$87.15	\$87.15
11762	Reconstruction of nail bed	Y	CH	P3		2.7072	\$112.08	\$112.08
11765	Excision of nail fold, toe	Y		P2		1.4595	\$60.42	\$60.42
11770	Removal of pilonidal lesion	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
11771	Removal of pilonidal lesion	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
11772	Removal of pilonidal lesion	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
11900	Injection into skin lesions	Y		P3		0.6418	\$26.57	\$26.57
11901	Added skin lesions injection	Y		P3		0.6831	\$28.28	\$28.28
11920	Correct skin color defects	Y		P2		2.1051	\$87.15	\$87.15
11921	Correct skin color defects	Y		P2		2.1051	\$87.15	\$87.15
11922	Correct skin color defects	Y		P3		0.8476	\$35.09	\$35.09
11950	Therapy for contour defects	Y		P3		0.8311	\$34.41	\$34.41
11951	Therapy for contour defects	Y		P3		0.9792	\$40.54	\$40.54
11952	Therapy for contour defects	Y	CH	P2		1.2792	\$52.96	\$52.96
11954	Therapy for contour defects	Y		P2		1.2792	\$52.96	\$52.96
11960	Insert tissue expander(s)	Y		A2	\$446.00	20.2069	\$836.59	\$543.65
11970	Replace tissue expander	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
11971	Remove tissue expander(s)	Y		A2	\$333.00	21.1098	\$873.97	\$468.24
11976	Removal of contraceptive cap	Y		P3		1.4154	\$58.60	\$58.60
11980	Implant hormone pellet(s)	N		P2		0.631	\$26.12	\$26.12
11981	Insert drug implant device	N		P2		0.631	\$26.12	\$26.12
11982	Remove drug implant device	N		P2		0.631	\$26.12	\$26.12
11983	Remove/insert drug implant	N		P2		0.631	\$26.12	\$26.12
12001	Repair superficial wound(s)	Y		P2		1.2792	\$52.96	\$52.96
12002	Repair superficial wound(s)	Y		P2		1.2792	\$52.96	\$52.96
12004	Repair superficial wound(s)	Y		P2		1.2792	\$52.96	\$52.96
12005	Repair superficial wound(s)	Y		A2	\$91.24	1.2792	\$52.96	\$81.67
12006	Repair superficial wound(s)	Y		A2	\$91.24	1.2792	\$52.96	\$81.67

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
12007	Repair superficial wound(s)	Y		A2	\$91.24	1.2792	\$52.96	\$81.67
12011	Repair superficial wound(s)	Y		P2		1.2792	\$52.96	\$52.96
12013	Repair superficial wound(s)	Y		P2		1.2792	\$52.96	\$52.96
12014	Repair superficial wound(s)	Y		P2		1.2792	\$52.96	\$52.96
12015	Repair superficial wound(s)	Y		G2		1.2792	\$52.96	\$52.96
12016	Repair superficial wound(s)	Y		A2	\$91.24	1.2792	\$52.96	\$81.67
12017	Repair superficial wound(s)	Y		A2	\$91.24	1.2792	\$52.96	\$81.67
12018	Repair superficial wound(s)	Y		A2	\$91.24	1.2792	\$52.96	\$81.67
12020	Closure of split wound	Y		A2	\$91.24	4.5263	\$187.39	\$115.28
12021	Closure of split wound	Y		A2	\$91.24	4.5263	\$187.39	\$115.28
12031	Layer closure of wound(s)	Y		P2		2.1051	\$87.15	\$87.15
12032	Layer closure of wound(s)	Y		P2		2.1051	\$87.15	\$87.15
12034	Layer closure of wound(s)	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
12035	Layer closure of wound(s)	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
12036	Layer closure of wound(s)	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
12037	Layer closure of wound(s)	Y		A2	\$323.28	2.1051	\$87.15	\$264.25
12041	Layer closure of wound(s)	Y		P2		2.1051	\$87.15	\$87.15
12042	Layer closure of wound(s)	Y		P2		2.1051	\$87.15	\$87.15
12044	Layer closure of wound(s)	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
12045	Layer closure of wound(s)	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
12046	Layer closure of wound(s)	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
12047	Layer closure of wound(s)	Y		A2	\$323.28	2.1051	\$87.15	\$264.25
12051	Layer closure of wound(s)	Y		P2		2.1051	\$87.15	\$87.15
12052	Layer closure of wound(s)	Y		P2		2.1051	\$87.15	\$87.15
12053	Layer closure of wound(s)	Y		P2		2.1051	\$87.15	\$87.15
12054	Layer closure of wound(s)	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
12055	Layer closure of wound(s)	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
12056	Layer closure of wound(s)	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
12057	Layer closure of wound(s)	Y		A2	\$323.28	2.1051	\$87.15	\$264.25
13100	Repair of wound or lesion	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
13101	Repair of wound or lesion	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
13102	Repair wound/lesion add-on	Y		A2	\$91.24	4.5263	\$187.39	\$115.28
13120	Repair of wound or lesion	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
13121	Repair of wound or lesion	Y		A2	\$91.24	4.5263	\$187.39	\$115.28
13122	Repair wound/lesion add-on	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
13131	Repair of wound or lesion	Y		A2	\$91.24	4.5263	\$187.39	\$115.28
13132	Repair of wound or lesion	Y		A2	\$91.24	4.5263	\$187.39	\$115.28
13133	Repair wound/lesion add-on	Y		A2	\$91.24	4.5263	\$187.39	\$115.28
13150	Repair of wound or lesion	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
13151	Repair of wound or lesion	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
13152	Repair of wound or lesion	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
13153	Repair wound/lesion add-on	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
13160	Late closure of wound	Y		A2	\$446.00	20.2069	\$836.59	\$543.65
14000	Skin tissue rearrangement	Y		A2	\$446.00	15.0458	\$622.91	\$490.23
14001	Skin tissue rearrangement	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
14020	Skin tissue rearrangement	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
14021	Skin tissue rearrangement	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
14040	Skin tissue rearrangement	Y		A2	\$446.00	15.0458	\$622.91	\$490.23
14041	Skin tissue rearrangement	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
14060	Skin tissue rearrangement	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
14061	Skin tissue rearrangement	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
14300	Skin tissue rearrangement	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
14350	Skin tissue rearrangement	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15002	Wnd prep, ch/inf, trk/arm/leg	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15003	Wnd prep, ch/inf addl 100 cm	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15004	Wnd prep ch/inf, f/n/hf/g	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15005	Wnd prep, f/n/hf/g, addl cm	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15040	Harvest cultured skin graft	Y		A2	\$91.24	2.1051	\$87.15	\$90.22
15050	Skin pinch graft	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15100	Skin spl't grft, trnk/arm/leg	Y		A2	\$446.00	20.2069	\$836.59	\$543.65
15101	Skin spl't grft t/a/l, add-on	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15110	Epidrm autogrft trnk/arm/leg	Y		A2	\$446.00	4.5263	\$187.39	\$381.35
15111	Epidrm autogrft t/a/l add-on	Y		A2	\$333.00	4.5263	\$187.39	\$296.60
15115	Epidrm a-grft fac/nck/hf/g	Y		A2	\$446.00	4.5263	\$187.39	\$381.35
15116	Epidrm a-grft f/n/hf/g addl	Y		A2	\$333.00	4.5263	\$187.39	\$296.60
15120	Skn spl't a-grft fac/nck/hf/g	Y		A2	\$446.00	20.2069	\$836.59	\$543.65
15121	Skn spl't a-grft f/n/hf/g addl	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15130	Derm autogrft, trnk/arm/leg	Y		A2	\$446.00	15.0458	\$622.91	\$490.23
15131	Derm autogrft t/a/l add-on	Y		A2	\$333.00	15.0458	\$622.91	\$405.48
15135	Derm autogrft face/nck/hf/g	Y		A2	\$446.00	15.0458	\$622.91	\$490.23
15136	Derm autogrft, f/n/hf/g addl	Y		A2	\$333.00	15.0458	\$622.91	\$405.48
15150	Cult epiderm grft t/arm/leg	Y		A2	\$446.00	4.5263	\$187.39	\$381.35
15151	Cult epiderm grft t/a/l addl	Y		A2	\$333.00	4.5263	\$187.39	\$296.60

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
15152	Cult epiderm graft t/a/l +%	Y		A2	\$333.00	4.5263	\$187.39	\$296.60
15155	Cult epiderm graft, f/n/hf/g	Y		A2	\$446.00	4.5263	\$187.39	\$381.35
15156	Cult epiderm grft f/n/hfg add	Y		A2	\$333.00	4.5263	\$187.39	\$296.60
15157	Cult epiderm grft f/n/hfg +%	Y		A2	\$333.00	4.5263	\$187.39	\$296.60
15200	Skin full graft, trunk	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
15201	Skin full graft trunk add-on	Y		A2	\$323.28	15.0458	\$622.91	\$398.19
15220	Skin full graft scip/arm/leg	Y		A2	\$446.00	15.0458	\$622.91	\$490.23
15221	Skin full graft add-on	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15240	Skin full grft face/genit/hf	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
15241	Skin full graft add-on	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15260	Skin full graft een & lips	Y		A2	\$446.00	15.0458	\$622.91	\$490.23
15261	Skin full graft add-on	Y		A2	\$323.28	15.0458	\$622.91	\$398.19
15300	Apply skinallogrft, t/arm/ig	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15301	Apply sknallogrft t/a/l addl	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15320	Apply skin allogrft f/n/hf/g	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15321	Aply sknallogrft f/n/hfg add	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15330	Aply acell alogrft t/arm/leg	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15331	Aply acell grft t/a/l add-on	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15335	Apply acell graft, f/n/hf/g	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15336	Aply acell grft f/n/hfg add	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15340	Apply cult skin substitute	Y	CH	G2		2.1051	\$87.15	\$87.15
15341	Apply cult skin sub add-on	Y		G2		2.1051	\$87.15	\$87.15
15360	Apply cult derm sub, t/a/l	Y		G2		2.1051	\$87.15	\$87.15
15361	Aply cult derm sub t/a/l add	Y		G2		2.1051	\$87.15	\$87.15
15365	Apply cult derm sub f/n/hf/g	Y		G2		2.1051	\$87.15	\$87.15
15366	Apply cult derm f/hf/g add	Y		G2		2.1051	\$87.15	\$87.15
15400	Apply skin xenograft, t/a/l	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15401	Apply skn xenogrft t/a/l add	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15420	Apply skin xgrft, f/n/hf/g	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15421	Apply skn xgrft f/n/hf/g add	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15430	Apply acellular xenograft	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15431	Apply acellular xgrft add	Y		A2	\$323.28	4.5263	\$187.39	\$289.31
15570	Form skin pedicle flap	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15572	Form skin pedicle flap	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15574	Form skin pedicle flap	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15576	Form skin pedicle flap	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15600	Skin graft	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15610	Skin graft	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15620	Skin graft	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
15630	Skin graft	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15650	Transfer skin pedicle flap	Y		A2	\$717.00	20.2069	\$836.59	\$746.90
15731	Forehead flap w/vasc pedicle	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15732	Muscle-skin graft, head/neck	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15734	Muscle-skin graft, trunk	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15736	Muscle-skin graft, arm	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15738	Muscle-skin graft, leg	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15740	Island pedicle flap graft	Y		A2	\$446.00	15.0458	\$622.91	\$490.23
15750	Neurovascular pedicle graft	Y		A2	\$446.00	20.2069	\$836.59	\$543.65
15760	Composite skin graft	Y		A2	\$446.00	20.2069	\$836.59	\$543.65
15770	Derma-fat-fascia graft	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15775	Hair transplant punch grafts	Y		A2	\$323.28	1.2792	\$52.96	\$255.70
15776	Hair transplant punch grafts	Y		A2	\$323.28	1.2792	\$52.96	\$255.70
15780	Abrasion treatment of skin	Y		P3		9.3563	\$387.36	\$387.36
15781	Abrasion treatment of skin	Y		P2		4.3039	\$178.19	\$178.19
15782	Abrasion treatment of skin	Y		P2		4.3039	\$178.19	\$178.19
15783	Abrasion treatment of skin	Y		P2		2.6604	\$110.14	\$110.14
15786	Abrasion, lesion, single	Y		P2		0.793	\$32.83	\$32.83
15787	Abrasion, lesions, add-on	Y		P3		0.7901	\$32.71	\$32.71
15788	Chemical peel, face, epiderm	Y		P2		0.793	\$32.83	\$32.83
15789	Chemical peel, face, dermal	Y		P2		1.4595	\$60.42	\$60.42
15792	Chemical peel, nonfacial	Y		P2		1.4595	\$60.42	\$60.42
15793	Chemical peel, nonfacial	Y		P2		0.793	\$32.83	\$32.83
15819	Plastic surgery, neck	Y		G2		2.1051	\$87.15	\$87.15
15820	Revision of lower eyelid	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15821	Revision of lower eyelid	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15822	Revision of upper eyelid	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15823	Revision of upper eyelid	Y		A2	\$717.00	20.2069	\$836.59	\$746.90
15824	Removal of forehead wrinkles	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15825	Removal of neck wrinkles	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15826	Removal of brow wrinkles	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15828	Removal of face wrinkles	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15829	Removal of skin wrinkles	Y		A2	\$717.00	20.2069	\$836.59	\$746.90
15830	Exc skin abd	Y		A2	\$510.00	21.1098	\$873.97	\$600.99

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
15832	Excise excessive skin tissue	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
15833	Excise excessive skin tissue	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
15834	Excise excessive skin tissue	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
15835	Excise excessive skin tissue	Y		A2	\$323.28	21.1098	\$873.97	\$460.95
15836	Excise excessive skin tissue	Y		A2	\$510.00	16.1001	\$666.56	\$549.14
15837	Excise excessive skin tissue	Y		G2		16.1001	\$666.56	\$666.56
15838	Excise excessive skin tissue	Y		G2		16.1001	\$666.56	\$666.56
15839	Excise excessive skin tissue	Y		A2	\$510.00	16.1001	\$666.56	\$549.14
15840	Graft for face nerve palsy	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
15841	Graft for face nerve palsy	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
15842	Flap for face nerve palsy	Y		G2		20.2069	\$836.59	\$836.59
15845	Skin and muscle repair, face	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
15847	Exc skin abd add-on	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
15850	Removal of sutures	Y		G2		2.6604	\$110.14	\$110.14
15851	Removal of sutures	Y		P3		1.2343	\$51.10	\$51.10
15852	Dressing change not for burn	N		G2		0.631	\$26.12	\$26.12
15860	Test for blood flow in graft	N		G2		0.631	\$26.12	\$26.12
15876	Suction assisted lipectomy	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15877	Suction assisted lipectomy	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15878	Suction assisted lipectomy	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15879	Suction assisted lipectomy	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15920	Removal of tail bone ulcer	Y		A2	\$251.52	4.3039	\$178.19	\$233.19
15922	Removal of tail bone ulcer	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
15931	Remove sacrum pressure sore	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
15933	Remove sacrum pressure sore	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
15934	Remove sacrum pressure sore	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15935	Remove sacrum pressure sore	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
15936	Remove sacrum pressure sore	Y		A2	\$630.00	15.0458	\$622.91	\$628.23
15937	Remove sacrum pressure sore	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
15940	Remove hip pressure sore	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
15941	Remove hip pressure sore	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
15944	Remove hip pressure sore	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
15945	Remove hip pressure sore	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
15946	Remove hip pressure sore	Y		A2	\$630.00	20.2069	\$836.59	\$681.65
15950	Remove thigh pressure sore	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
15951	Remove thigh pressure sore	Y		A2	\$630.00	21.1098	\$873.97	\$690.99
15952	Remove thigh pressure sore	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
15953	Remove thigh pressure sore	Y		A2	\$630.00	15.0458	\$622.91	\$628.23
15956	Remove thigh pressure sore	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
15958	Remove thigh pressure sore	Y		A2	\$630.00	15.0458	\$622.91	\$628.23
16000	Initial treatment of burn(s)	Y		P3		0.65	\$26.91	\$26.91
16020	Dress/debrid p-thick burn, s	Y		P3		0.9874	\$40.88	\$40.88
16025	Dress/debrid p-thick burn, m	Y		A2	\$67.11	2.6604	\$110.14	\$77.87
16030	Dress/debrid p-thick burn, l	Y		A2	\$99.83	2.6604	\$110.14	\$102.41
16035	Incision of burn scab, initi	Y		G2		2.6604	\$110.14	\$110.14
17000	Destruct premalg lesion	Y		P2		0.793	\$32.83	\$32.83
17003	Destruct premalg les, 2-14	Y		P3		0.0906	\$3.75	\$3.75
17004	Destroy premig lesions 15+	Y		P3		1.9502	\$80.74	\$80.74
17106	Destruction of skin lesions	Y		P2		2.6604	\$110.14	\$110.14
17107	Destruction of skin lesions	Y		P2		2.6604	\$110.14	\$110.14
17108	Destruction of skin lesions	Y		P2		2.6604	\$110.14	\$110.14
17110	Destruct b9 lesion, 1-14	Y		P2		0.793	\$32.83	\$32.83
17111	Destruct lesion, 15 or more	Y		P2		1.4595	\$60.42	\$60.42
17250	Chemical cautery, tissue	Y		P3		1.0451	\$43.27	\$43.27
17260	Destruction of skin lesions	Y		P3		1.1026	\$45.65	\$45.65
17261	Destruction of skin lesions	Y		P2		1.4595	\$60.42	\$60.42
17262	Destruction of skin lesions	Y		P2		1.4595	\$60.42	\$60.42
17263	Destruction of skin lesions	Y		P2		1.4595	\$60.42	\$60.42
17264	Destruction of skin lesions	Y		P2		1.4595	\$60.42	\$60.42
17266	Destruction of skin lesions	Y		P3		2.4685	\$102.20	\$102.20
17270	Destruction of skin lesions	Y		P2		1.4595	\$60.42	\$60.42
17271	Destruction of skin lesions	Y		P2		1.4595	\$60.42	\$60.42
17272	Destruction of skin lesions	Y		P2		1.4595	\$60.42	\$60.42
17273	Destruction of skin lesions	Y	CH	P3		2.2299	\$92.32	\$92.32
17274	Destruction of skin lesions	Y		P3		2.5345	\$104.93	\$104.93
17276	Destruction of skin lesions	Y		P2		2.6604	\$110.14	\$110.14
17280	Destruction of skin lesions	Y	CH	P2		1.4595	\$60.42	\$60.42
17281	Destruction of skin lesions	Y	CH	P3		1.9091	\$79.04	\$79.04
17282	Destruction of skin lesions	Y	CH	P3		2.1724	\$89.94	\$89.94
17283	Destruction of skin lesions	Y	CH	P3		2.5098	\$103.91	\$103.91
17284	Destruction of skin lesions	Y		P2		2.6604	\$110.14	\$110.14
17286	Destruction of skin lesions	Y		P2		2.6604	\$110.14	\$110.14
17311	Mohs, 1 stage, h/n/hf/g	Y		P2		3.6321	\$150.37	\$150.37

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
17312	Mohs addl stage	Y		P2		3.6321	\$150.37	\$150.37
17313	Mohs, 1 stage, t/a/l	Y		P2		3.6321	\$150.37	\$150.37
17314	Mohs, addl stage, t/a/l	Y		P2		3.6321	\$150.37	\$150.37
17315	Mohs surg, addl block	Y		P3		0.9381	\$38.84	\$38.84
17340	Cryotherapy of skin	Y		P3		0.2961	\$12.26	\$12.26
17360	Skin peel therapy	Y		P2		0.793	\$32.83	\$32.83
17380	Hair removal by electrolysis	Y		R2		0.793	\$32.83	\$32.83
19000	Drainage of breast lesion	Y		P3		1.6046	\$66.43	\$66.43
19001	Drain breast lesion add-on	Y		P3		0.2058	\$8.52	\$8.52
19020	Incision of breast lesion	Y		A2	\$446.00	18.3197	\$758.45	\$524.11
19030	Injection for breast x-ray	N		N1				
19100	Bx breast percut w/o image	Y		A2	\$240.00	4.327	\$179.14	\$224.79
19101	Biopsy of breast, open	Y		A2	\$446.00	20.6417	\$854.59	\$548.15
19102	Bx breast percut w/image	Y		A2	\$240.00	7.1147	\$294.56	\$253.64
19103	Bx breast percut w/device	Y		A2	\$395.77	13.5764	\$562.08	\$437.35
19105	Cryosurg ablate fa, each	Y		G2		31.7134	\$1,312.97	\$1,312.97
19110	Nipple exploration	Y		A2	\$446.00	20.6417	\$854.59	\$548.15
19112	Excise breast duct fistula	Y		A2	\$510.00	20.6417	\$854.59	\$596.15
19120	Removal of breast lesion	Y		A2	\$510.00	20.6417	\$854.59	\$596.15
19125	Excision, breast lesion	Y		A2	\$510.00	20.6417	\$854.59	\$596.15
19126	Excision, addl breast lesion	Y		A2	\$510.00	20.6417	\$854.59	\$596.15
19290	Place needle wire, breast	N		N1				
19291	Place needle wire, breast	N		N1				
19295	Place breast clip, percut	N	CH	N1				
19296	Place po breast cath for rad	Y		A2	\$1,339.00	56.5774	\$2,342.36	\$1,589.84
19297	Place breast cath for rad	Y		A2	\$1,339.00	56.5774	\$2,342.36	\$1,589.84
19298	Place breast rad tube/caths	Y		A2	\$1,339.00	56.5774	\$2,342.36	\$1,589.84
19300	Removal of breast tissue	Y		A2	\$630.00	20.6417	\$854.59	\$686.15
19301	Partial mastectomy	Y		A2	\$510.00	20.6417	\$854.59	\$596.15
19302	P-mastectomy w/in removal	Y		A2	\$995.00	39.8191	\$1,648.55	\$1,158.39
19303	Mast, simple, complete	Y		A2	\$630.00	31.7134	\$1,312.97	\$800.74
19304	Mast, subq	Y		A2	\$630.00	31.7134	\$1,312.97	\$800.74
19316	Suspension of breast	Y		A2	\$630.00	31.7134	\$1,312.97	\$800.74
19318	Reduction of large breast	Y		A2	\$630.00	39.8191	\$1,648.55	\$884.64
19324	Enlarge breast	Y		A2	\$630.00	39.8191	\$1,648.55	\$884.64
19325	Enlarge breast with implant	Y		A2	\$1,339.00	56.5774	\$2,342.36	\$1,589.84
19328	Removal of breast implant	Y		A2	\$333.00	31.7134	\$1,312.97	\$577.99
19330	Removal of implant material	Y		A2	\$333.00	31.7134	\$1,312.97	\$577.99
19340	Immediate breast prosthesis	Y		A2	\$446.00	39.8191	\$1,648.55	\$746.64
19342	Delayed breast prosthesis	Y		A2	\$510.00	56.5774	\$2,342.36	\$968.09
19350	Breast reconstruction	Y		A2	\$630.00	20.6417	\$854.59	\$686.15
19355	Correct inverted nipple(s)	Y		A2	\$630.00	31.7134	\$1,312.97	\$800.74
19357	Breast reconstruction	Y		A2	\$717.00	56.5774	\$2,342.36	\$1,123.34
19366	Breast reconstruction	Y		A2	\$717.00	31.7134	\$1,312.97	\$865.99
19370	Surgery of breast capsule	Y		A2	\$630.00	31.7134	\$1,312.97	\$800.74
19371	Removal of breast capsule	Y		A2	\$630.00	31.7134	\$1,312.97	\$800.74
19380	Revise breast reconstruction	Y		A2	\$717.00	39.8191	\$1,648.55	\$949.89
19396	Design custom breast implant	Y		G2		31.7134	\$1,312.97	\$1,312.97
20000	Incision of abscess	Y		P2		1.4066	\$58.23	\$58.23
20005	Incision of deep abscess	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
20103	Explore wound, extremity	Y		G2		9.6341	\$398.86	\$398.86
20150	Excise epiphyseal bar	Y		G2		42.985	\$1,779.62	\$1,779.62
20200	Muscle biopsy	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
20205	Deep muscle biopsy	Y		A2	\$510.00	16.1001	\$666.56	\$549.14
20206	Needle biopsy, muscle	Y		A2	\$240.00	7.1147	\$294.56	\$253.64
20220	Bone biopsy, trocar/needle	Y		A2	\$251.52	8.685	\$359.57	\$278.53
20225	Bone biopsy, trocar/needle	Y		A2	\$418.49	8.685	\$359.57	\$403.76
20240	Bone biopsy, excisional	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
20245	Bone biopsy, excisional	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
20250	Open bone biopsy	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
20251	Open bone biopsy	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
20500	Injection of sinus tract	Y		P3		1.4811	\$61.32	\$61.32
20501	Inject sinus tract for x-ray	N		N1				
20520	Removal of foreign body	Y		P3		2.2712	\$94.03	\$94.03
20525	Removal of foreign body	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
20526	Ther injection, carp tunnel	Y		P3		0.7323	\$30.32	\$30.32
20550	Inj tendon sheath/ligament	Y		P3		0.5514	\$22.83	\$22.83
20551	Inj tendon origin/insertion	Y		P3		0.5432	\$22.49	\$22.49
20552	Inj trigger point, 1/2 muscl	Y		P3		0.5348	\$22.14	\$22.14
20553	Inject trigger points, => 3	Y		P3		0.6007	\$24.87	\$24.87
20555	Place ndl musc/tis for rt	Y	NI	G2		29.19	\$1,208.50	\$1,208.50
20600	Drain/inject, joint/bursa	Y		P3		0.5432	\$22.49	\$22.49
20605	Drain/inject, joint/bursa	Y		P3		0.6171	\$25.55	\$25.55

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
20610	Drain/inject, joint/bursa	Y		P3		0.8311	\$34.41	\$34.41
20612	Aspirate/inj ganglion cyst	Y		P3		0.5761	\$23.85	\$23.85
20615	Treatment of bone cyst	Y	CH	P3		2.5591	\$105.95	\$105.95
20650	Insert and remove bone pin	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
20662	Application of pelvis brace	Y		R2		21.2689	\$880.55	\$880.55
20663	Application of thigh brace	Y		R2		21.2689	\$880.55	\$880.55
20665	Removal of fixation device	N		G2		0.631	\$26.12	\$26.12
20670	Removal of support implant	Y		A2	\$333.00	16.1001	\$666.56	\$416.39
20680	Removal of support implant	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
20690	Apply bone fixation device	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
20692	Apply bone fixation device	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
20693	Adjust bone fixation device	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
20694	Remove bone fixation device	Y		A2	\$333.00	21.2689	\$880.55	\$469.89
20822	Replantation digit, complete	Y		G2		26.3105	\$1,089.28	\$1,089.28
20900	Removal of bone for graft	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
20902	Removal of bone for graft	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
20910	Remove cartilage for graft	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
20912	Remove cartilage for graft	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
20920	Removal of fascia for graft	Y		A2	\$630.00	15.0458	\$622.91	\$628.23
20922	Removal of fascia for graft	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
20924	Removal of tendon for graft	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
20926	Removal of tissue for graft	Y		A2	\$630.00	4.5263	\$187.39	\$519.35
20950	Fluid pressure, muscle	Y		G2		1.4066	\$58.23	\$58.23
20972	Bone/skin graft, metatarsal	Y		G2		44.2687	\$1,832.77	\$1,832.77
20973	Bone/skin graft, great toe	Y		R2		44.2687	\$1,832.77	\$1,832.77
20975	Electrical bone stimulation	N	CH	N1				
20979	Us bone stimulation	N		P3		0.5843	\$24.19	\$24.19
20982	Ablate, bone tumor(s) perq	Y		G2		42.985	\$1,779.62	\$1,779.62
20985	Cptr-asst dir ms px	N	NI	N1				
20986	Cptr-asst dir ms px io img	N	NI	N1				
20987	Cptr-asst dir ms px pre img	N	NI	N1				
21010	Incision of jaw joint	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
21015	Resection of facial tumor	Y		A2	\$510.00	16.3288	\$676.03	\$551.51
21025	Excision of bone, lower jaw	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
21026	Excision of facial bone(s)	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
21029	Contour of face bone lesion	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
21030	Excise max/zygoma b9 tumor	Y		P3		5.5627	\$230.30	\$230.30
21031	Remove exostosis, mandible	Y		P3		4.5588	\$188.74	\$188.74
21032	Remove exostosis, maxilla	Y		P3		4.6823	\$193.85	\$193.85
21034	Excise max/zygoma mlg tumor	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
21040	Excise mandible lesion	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
21044	Removal of jaw bone lesion	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
21046	Remove mandible cyst complex	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
21047	Excise lwr jaw cyst w/repair	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
21048	Remove maxilla cyst complex	Y		R2		39.8776	\$1,650.97	\$1,650.97
21050	Removal of jaw joint	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
21060	Remove jaw joint cartilage	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
21070	Remove coronoid process	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
21073*	Mnpj of tmj w/anesth	Y	NI	P3		4.526	\$187.38	\$187.38
21076	Prepare face/oral prosthesis	Y		P3		8.3769	\$346.81	\$346.81
21077	Prepare face/oral prosthesis	Y		P3		20.457	\$846.94	\$846.94
21079	Prepare face/oral prosthesis	Y		P3		14.5815	\$603.69	\$603.69
21080	Prepare face/oral prosthesis	Y		P3		16.7129	\$691.93	\$691.93
21081	Prepare face/oral prosthesis	Y		P3		15.3467	\$635.37	\$635.37
21082	Prepare face/oral prosthesis	Y		P3		14.0796	\$582.91	\$582.91
21083	Prepare face/oral prosthesis	Y		P3		13.8492	\$573.37	\$573.37
21084	Prepare face/oral prosthesis	Y		P3		16.1532	\$668.76	\$668.76
21085	Prepare face/oral prosthesis	Y		P3		6.254	\$258.92	\$258.92
21086	Prepare face/oral prosthesis	Y		P3		15.067	\$623.79	\$623.79
21087	Prepare face/oral prosthesis	Y		P3		14.9354	\$618.34	\$618.34
21088	Prepare face/oral prosthesis	Y		R2		39.8776	\$1,650.97	\$1,650.97
21100	Maxillofacial fixation	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
21110	Interdental fixation	Y		P2		7.4474	\$308.33	\$308.33
21116	Injection, jaw joint x-ray	N		N1				
21120	Reconstruction of chin	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
21121	Reconstruction of chin	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
21122	Reconstruction of chin	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
21123	Reconstruction of chin	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
21125	Augmentation, lower jaw bone	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
21127	Augmentation, lower jaw bone	Y		A2	\$1,339.00	39.8776	\$1,650.97	\$1,416.99
21137	Reduction of forehead	Y		G2		23.9765	\$992.65	\$992.65
21138	Reduction of forehead	Y		G2		39.8776	\$1,650.97	\$1,650.97
21139	Reduction of forehead	Y		G2		39.8776	\$1,650.97	\$1,650.97

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
21150	Reconstruct midface, lefort	Y		G2		39.8776	\$1,650.97	\$1,650.97
21181	Contour cranial bone lesion	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
21198	Reconstr lwr jaw segment	Y		G2		39.8776	\$1,650.97	\$1,650.97
21199	Reconstr lwr jaw w/advance	Y		G2		39.8776	\$1,650.97	\$1,650.97
21206	Reconstruct upper jaw bone	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
21208	Augmentation of facial bones	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21209	Reduction of facial bones	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
21210	Face bone graft	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21215	Lower jaw bone graft	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21230	Rib cartilage graft	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21235	Ear cartilage graft	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
21240	Reconstruction of jaw joint	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
21242	Reconstruction of jaw joint	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
21243	Reconstruction of jaw joint	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
21244	Reconstruction of lower jaw	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21245	Reconstruction of jaw	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21246	Reconstruction of jaw	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21248	Reconstruction of jaw	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21249	Reconstruction of jaw	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21260	Revise eye sockets	Y		G2		39.8776	\$1,650.97	\$1,650.97
21267	Revise eye sockets	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21270	Augmentation, cheek bone	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
21275	Revision, orbitofacial bones	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
21280	Revision of eyelid	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
21282	Revision of eyelid	Y		A2	\$717.00	16.3288	\$676.03	\$706.76
21295	Revision of jaw muscle/bone	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
21296	Revision of jaw muscle/bone	Y		A2	\$333.00	23.9765	\$992.65	\$497.91
21310	Treatment of nose fracture	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
21315	Treatment of nose fracture	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
21320	Treatment of nose fracture	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
21325	Treatment of nose fracture	Y		A2	\$630.00	23.9765	\$992.65	\$720.66
21330	Treatment of nose fracture	Y		A2	\$717.00	23.9765	\$992.65	\$785.91
21335	Treatment of nose fracture	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
21336	Treat nasal septal fracture	Y		A2	\$630.00	26.1592	\$1,083.02	\$743.26
21337	Treat nasal septal fracture	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
21338	Treat nasoethmoid fracture	Y		A2	\$630.00	23.9765	\$992.65	\$720.66
21339	Treat nasoethmoid fracture	Y		A2	\$717.00	23.9765	\$992.65	\$785.91
21340	Treatment of nose fracture	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
21345	Treat nose/jaw fracture	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
21355	Treat cheek bone fracture	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
21356	Treat cheek bone fracture	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
21360	Treat cheek bone fracture	Y	CH	G2		23.9765	\$992.65	\$992.65
21390	Treat eye socket fracture	Y		G2		39.8776	\$1,650.97	\$1,650.97
21400	Treat eye socket fracture	Y		A2	\$446.00	7.4474	\$308.33	\$411.58
21401	Treat eye socket fracture	Y		A2	\$510.00	16.3288	\$676.03	\$551.51
21406	Treat eye socket fracture	Y		G2		39.8776	\$1,650.97	\$1,650.97
21407	Treat eye socket fracture	Y		G2		39.8776	\$1,650.97	\$1,650.97
21421	Treat mouth roof fracture	Y		A2	\$630.00	23.9765	\$992.65	\$720.66
21440	Treat dental ridge fracture	Y		P3		7.0605	\$292.31	\$292.31
21445	Treat dental ridge fracture	Y		A2	\$630.00	23.9765	\$992.65	\$720.66
21450	Treat lower jaw fracture	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
21451	Treat lower jaw fracture	Y		A2	\$464.15	7.4474	\$308.33	\$425.20
21452	Treat lower jaw fracture	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
21453	Treat lower jaw fracture	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
21454	Treat lower jaw fracture	Y		A2	\$717.00	23.9765	\$992.65	\$785.91
21461	Treat lower jaw fracture	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
21462	Treat lower jaw fracture	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
21465	Treat lower jaw fracture	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
21480	Reset dislocated jaw	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
21485	Reset dislocated jaw	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
21490	Repair dislocated jaw	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
21495	Treat hyoid bone fracture	Y		G2		16.3288	\$676.03	\$676.03
21497	Interdental wiring	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
21501	Drain neck/chest lesion	Y		A2	\$446.00	18.3197	\$758.45	\$524.11
21502	Drain chest lesion	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
21550	Biopsy of neck/chest	Y		G2		8.685	\$359.57	\$359.57
21555	Remove lesion, neck/chest	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
21556	Remove lesion, neck/chest	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
21557	Remove tumor, neck/chest	Y		G2		21.1098	\$873.97	\$873.97
21600	Partial removal of rib	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
21610	Partial removal of rib	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
21685	Hyoid myotomy & suspension	Y		G2		7.4474	\$308.33	\$308.33
21700	Revision of neck muscle	Y		A2	\$446.00	21.2689	\$880.55	\$554.64

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
21720	Revision of neck muscle	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
21725	Revision of neck muscle	Y		A2	\$88.46	1.4066	\$58.23	\$80.90
21800	Treatment of rib fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
21805	Treatment of rib fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
21820	Treat sternum fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
21920	Biopsy soft tissue of back	Y		P3		3.1763	\$131.50	\$131.50
21925	Biopsy soft tissue of back	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
21930	Remove lesion, back or flank	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
21935	Remove tumor, back	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
22102	Remove part, lumbar vertebra	Y		G2		46.7724	\$1,936.42	\$1,936.42
22103	Remove extra spine segment	Y		G2		46.7724	\$1,936.42	\$1,936.42
22305	Treat spine process fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
22310	Treat spine fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
22315	Treat spine fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
22505	Manipulation of spine	Y		A2	\$446.00	14.7658	\$611.32	\$487.33
22520	Percut vertebroplasty thor	Y		A2	\$1,339.00	29.19	\$1,208.50	\$1,306.38
22521	Percut vertebroplasty lumb	Y		A2	\$1,339.00	29.19	\$1,208.50	\$1,306.38
22522	Percut vertebroplasty add 1	Y		A2	\$1,339.00	29.19	\$1,208.50	\$1,306.38
22523	Percut kyphoplasty, thor	Y		G2		79.4244	\$3,288.25	\$3,288.25
22524	Percut kyphoplasty, lumbar	Y		G2		79.4244	\$3,288.25	\$3,288.25
22525	Percut kyphoplasty, add-on	Y		G2		79.4244	\$3,288.25	\$3,288.25
22526	Idet, single level	Y	CH	G2		29.19	\$1,208.50	\$1,208.50
22527	Idet, 1 or more levels	Y	CH	G2		29.19	\$1,208.50	\$1,208.50
22900	Remove abdominal wall lesion	Y		A2	\$630.00	21.1098	\$873.97	\$690.99
23000	Removal of calcium deposits	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
23020	Release shoulder joint	Y		A2	\$446.00	42.985	\$1,779.62	\$779.41
23030	Drain shoulder lesion	Y		A2	\$333.00	18.3197	\$758.45	\$439.36
23031	Drain shoulder bursa	Y		A2	\$510.00	18.3197	\$758.45	\$572.11
23035	Drain shoulder bone lesion	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
23040	Exploratory shoulder surgery	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
23044	Exploratory shoulder surgery	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
23065	Biopsy shoulder tissues	Y		P3		2.2384	\$92.67	\$92.67
23066	Biopsy shoulder tissues	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
23075	Removal of shoulder lesion	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
23076	Removal of shoulder lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
23077	Remove tumor of shoulder	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
23100	Biopsy of shoulder joint	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
23101	Shoulder joint surgery	Y		A2	\$995.00	29.19	\$1,208.50	\$1,048.38
23105	Remove shoulder joint lining	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
23106	Incision of collarbone joint	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
23107	Explore treat shoulder joint	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
23120	Partial removal, collar bone	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
23125	Removal of collar bone	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
23130	Remove shoulder bone, part	Y		A2	\$717.00	42.985	\$1,779.62	\$982.66
23140	Removal of bone lesion	Y		A2	\$630.00	21.2689	\$880.55	\$692.64
23145	Removal of bone lesion	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
23146	Removal of bone lesion	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
23150	Removal of humerus lesion	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
23155	Removal of humerus lesion	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
23156	Removal of humerus lesion	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
23170	Remove collar bone lesion	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
23172	Remove shoulder blade lesion	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
23174	Remove humerus lesion	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
23180	Remove collar bone lesion	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
23182	Remove shoulder blade lesion	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
23184	Remove humerus lesion	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
23190	Partial removal of scapula	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
23195	Removal of head of humerus	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
23330	Remove shoulder foreign body	Y		A2	\$333.00	8.685	\$359.57	\$339.64
23331	Remove shoulder foreign body	Y		A2	\$333.00	21.1098	\$873.97	\$468.24
23350	Injection for shoulder x-ray	N		N1				
23395	Muscle transfer, shoulder/arm	Y		A2	\$717.00	42.985	\$1,779.62	\$982.66
23397	Muscle transfers	Y		A2	\$995.00	79.4244	\$3,288.25	\$1,568.31
23400	Fixation of shoulder blade	Y		A2	\$995.00	29.19	\$1,208.50	\$1,048.38
23405	Incision of tendon & muscle	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
23406	Incise tendon(s) & muscle(s)	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
23410	Repair rotator cuff, acute	Y		A2	\$717.00	42.985	\$1,779.62	\$982.66
23412	Repair rotator cuff, chronic	Y		A2	\$995.00	42.985	\$1,779.62	\$1,191.16
23415	Release of shoulder ligament	Y		A2	\$717.00	42.985	\$1,779.62	\$982.66
23420	Repair of shoulder	Y		A2	\$995.00	42.985	\$1,779.62	\$1,191.16
23430	Repair biceps tendon	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
23440	Remove/transplant tendon	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
23450	Repair shoulder capsule	Y		A2	\$717.00	79.4244	\$3,288.25	\$1,359.81

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
23455	Repair shoulder capsule	Y		A2	\$995.00	79.4244	\$3,288.25	\$1,568.31
23460	Repair shoulder capsule	Y		A2	\$717.00	79.4244	\$3,288.25	\$1,359.81
23462	Repair shoulder capsule	Y		A2	\$995.00	42.985	\$1,779.62	\$1,191.16
23465	Repair shoulder capsule	Y		A2	\$717.00	79.4244	\$3,288.25	\$1,359.81
23466	Repair shoulder capsule	Y		A2	\$995.00	42.985	\$1,779.62	\$1,191.16
23480	Revision of collar bone	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
23485	Revision of collar bone	Y		A2	\$995.00	79.4244	\$3,288.25	\$1,568.31
23490	Reinforce clavicle	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
23491	Reinforce shoulder bones	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
23500	Treat clavicle fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23505	Treat clavicle fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23515	Treat clavicle fracture	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
23520	Treat clavicle dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23525	Treat clavicle dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23530	Treat clavicle dislocation	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
23532	Treat clavicle dislocation	Y		A2	\$630.00	26.1592	\$1,083.02	\$743.26
23540	Treat clavicle dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23545	Treat clavicle dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23550	Treat clavicle dislocation	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
23552	Treat clavicle dislocation	Y		A2	\$630.00	41.1091	\$1,701.96	\$897.99
23570	Treat shoulder blade fx	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23575	Treat shoulder blade fx	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23585	Treat scapula fracture	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
23600	Treat humerus fracture	Y		P2		1.7682	\$73.21	\$73.21
23605	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23615	Treat humerus fracture	Y		A2	\$630.00	59.2233	\$2,451.90	\$1,085.48
23616	Treat humerus fracture	Y		A2	\$630.00	59.2233	\$2,451.90	\$1,085.48
23620	Treat humerus fracture	Y		P2		1.7682	\$73.21	\$73.21
23625	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23630	Treat humerus fracture	Y		A2	\$717.00	59.2233	\$2,451.90	\$1,150.73
23650	Treat shoulder dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23655	Treat shoulder dislocation	Y		A2	\$333.00	14.7658	\$611.32	\$402.58
23660	Treat shoulder dislocation	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
23665	Treat dislocation/fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23670	Treat dislocation/fracture	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
23675	Treat dislocation/fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
23680	Treat dislocation/fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
23700	Fixation of shoulder	Y		A2	\$333.00	14.7658	\$611.32	\$402.58
23800	Fusion of shoulder joint	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
23802	Fusion of shoulder joint	Y		A2	\$995.00	42.985	\$1,779.62	\$1,191.16
23921	Amputation follow-up surgery	Y		A2	\$323.28	15.0458	\$622.91	\$398.19
23930	Drainage of arm lesion	Y		A2	\$333.00	18.3197	\$758.45	\$439.36
23931	Drainage of arm bursa	Y		A2	\$446.00	18.3197	\$758.45	\$524.11
23935	Drain arm/elbow bone lesion	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
24000	Exploratory elbow surgery	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
24006	Release elbow joint	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
24065	Biopsy arm/elbow soft tissue	Y		P3		3.0282	\$125.37	\$125.37
24066	Biopsy arm/elbow soft tissue	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
24075	Remove arm/elbow lesion	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
24076	Remove arm/elbow lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
24077	Remove tumor of arm/elbow	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
24100	Biopsy elbow joint lining	Y		A2	\$333.00	21.2689	\$880.55	\$469.89
24101	Explore/treat elbow joint	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
24102	Remove elbow joint lining	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
24105	Removal of elbow bursa	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
24110	Remove humerus lesion	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
24115	Remove/graft bone lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
24116	Remove/graft bone lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
24120	Remove elbow lesion	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
24125	Remove/graft bone lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
24126	Remove/graft bone lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
24130	Removal of head of radius	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
24134	Removal of arm bone lesion	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
24136	Remove radius bone lesion	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
24138	Remove elbow bone lesion	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
24140	Partial removal of arm bone	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
24145	Partial removal of radius	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
24147	Partial removal of elbow	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
24149	Radical resection of elbow	Y		G2		29.19	\$1,208.50	\$1,208.50
24152	Extensive radius surgery	Y		G2		42.985	\$1,779.62	\$1,779.62
24153	Extensive radius surgery	Y		G2		79.4244	\$3,288.25	\$3,288.25
24155	Removal of elbow joint	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
24160	Remove elbow joint implant	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
24164	Remove radius head implant	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
24200	Removal of arm foreign body	Y		P3		2.5263	\$104.59	\$104.59
24201	Removal of arm foreign body	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
24220	Injection for elbow x-ray	N		N1				
24300	Manipulate elbow w/anesth	Y		G2		14.7658	\$611.32	\$611.32
24301	Muscle/tendon transfer	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
24305	Arm tendon lengthening	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
24310	Revision of arm tendon	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
24320	Repair of arm tendon	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
24330	Revision of arm muscles	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
24331	Revision of arm muscles	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
24332	Tenolysis, triceps	Y		G2		21.2689	\$880.55	\$880.55
24340	Repair of biceps tendon	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
24341	Repair arm tendon/muscle	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
24342	Repair of ruptured tendon	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
24343	Repr elbow lat ligmnt w/tiss	Y		G2		29.19	\$1,208.50	\$1,208.50
24344	Reconstruct elbow lat ligmnt	Y		G2		79.4244	\$3,288.25	\$3,288.25
24345	Repr elbw med ligmnt w/tissu	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
24346	Reconstruct elbow med ligmnt	Y		G2		42.985	\$1,779.62	\$1,779.62
24350	Repair of tennis elbow	N	CH	D5				
24351	Repair of tennis elbow	N	CH	D5				
24352	Repair of tennis elbow	N	CH	D5				
24354	Repair of tennis elbow	N	CH	D5				
24356	Revision of tennis elbow	N	CH	D5				
24357	Repair elbow, perc	Y	NI	G2		29.19	\$1,208.50	\$1,208.50
24358	Repair elbow w/deb, open	Y	NI	G2		29.19	\$1,208.50	\$1,208.50
24359	Repair elbow deb/atch open	Y	NI	G2		29.19	\$1,208.50	\$1,208.50
24360	Reconstruct elbow joint	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
24361	Reconstruct elbow joint	Y		A2	\$717.00	122.2057	\$5,059.44	\$1,802.61
24362	Reconstruct elbow joint	Y		A2	\$717.00	50.8876	\$2,106.80	\$1,064.45
24363	Replace elbow joint	Y		A2	\$995.00	122.2057	\$5,059.44	\$2,011.11
24365	Reconstruct head of radius	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
24366	Reconstruct head of radius	Y		A2	\$717.00	122.2057	\$5,059.44	\$1,802.61
24400	Revision of humerus	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
24410	Revision of humerus	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
24420	Revision of humerus	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
24430	Repair of humerus	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
24435	Repair humerus with graft	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
24470	Revision of elbow joint	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
24495	Decompression of forearm	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
24498	Reinforce humerus	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
24500	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24505	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24515	Treat humerus fracture	Y		A2	\$630.00	59.2233	\$2,451.90	\$1,085.48
24516	Treat humerus fracture	Y		A2	\$630.00	59.2233	\$2,451.90	\$1,085.48
24530	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24535	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24538	Treat humerus fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
24545	Treat humerus fracture	Y		A2	\$630.00	59.2233	\$2,451.90	\$1,085.48
24546	Treat humerus fracture	Y		A2	\$717.00	59.2233	\$2,451.90	\$1,150.73
24560	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24565	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24566	Treat humerus fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
24575	Treat humerus fracture	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
24576	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24577	Treat humerus fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24579	Treat humerus fracture	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
24582	Treat humerus fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
24586	Treat elbow fracture	Y		A2	\$630.00	59.2233	\$2,451.90	\$1,085.48
24587	Treat elbow fracture	Y		A2	\$717.00	59.2233	\$2,451.90	\$1,150.73
24600	Treat elbow dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24605	Treat elbow dislocation	Y		A2	\$446.00	14.7658	\$611.32	\$487.33
24615	Treat elbow dislocation	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
24620	Treat elbow fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24635	Treat elbow fracture	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
24640	Treat elbow dislocation	Y	CH	P3		1.3823	\$57.23	\$57.23
24650	Treat radius fracture	Y		P2		1.7682	\$73.21	\$73.21
24655	Treat radius fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24665	Treat radius fracture	Y		A2	\$630.00	41.1091	\$1,701.96	\$897.99
24666	Treat radius fracture	Y		A2	\$630.00	59.2233	\$2,451.90	\$1,085.48
24670	Treat ulnar fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24675	Treat ulnar fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
24685	Treat ulnar fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
24800	Fusion of elbow joint	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
24802	Fusion/graft of elbow joint	Y		A2	\$717.00	42.985	\$1,779.62	\$982.66
24925	Amputation follow-up surgery	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
25000	Incision of tendon sheath	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
25001	Incise flexor carpi radialis	Y		G2		21.2689	\$880.55	\$880.55
25020	Decompress forearm 1 space	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
25023	Decompress forearm 1 space	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25024	Decompress forearm 2 spaces	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25025	Decompress forearm 2 spaces	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25028	Drainage of forearm lesion	Y		A2	\$333.00	21.2689	\$880.55	\$469.89
25031	Drainage of forearm bursa	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
25035	Treat forearm bone lesion	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
25040	Explore/treat wrist joint	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
25065	Biopsy forearm soft tissues	Y		P3		3.1023	\$128.44	\$128.44
25066	Biopsy forearm soft tissues	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
25075	Removal forearm lesion subcu	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
25076	Removal forearm lesion deep	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
25077	Remove tumor, forearm/wrist	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
25085	Incision of wrist capsule	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
25100	Biopsy of wrist joint	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
25101	Explore/treat wrist joint	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25105	Remove wrist joint lining	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
25107	Remove wrist joint cartilage	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25109	Excise tendon forearm/wrist	Y		G2		21.2689	\$880.55	\$880.55
25110	Remove wrist tendon lesion	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
25111	Remove wrist tendon lesion	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
25112	Reremove wrist tendon lesion	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
25115	Remove wrist/forearm lesion	Y		A2	\$630.00	21.2689	\$880.55	\$692.64
25116	Remove wrist/forearm lesion	Y		A2	\$630.00	21.2689	\$880.55	\$692.64
25118	Excise wrist tendon sheath	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
25119	Partial removal of ulna	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25120	Removal of forearm lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25125	Remove/graft forearm lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25126	Remove/graft forearm lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25130	Removal of wrist lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25135	Remove & graft wrist lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25136	Remove & graft wrist lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25145	Remove forearm bone lesion	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
25150	Partial removal of ulna	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
25151	Partial removal of radius	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
25210	Removal of wrist bone	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
25215	Removal of wrist bones	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
25230	Partial removal of radius	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
25240	Partial removal of ulna	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
25246	Injection for wrist x-ray	N		N1				
25248	Remove forearm foreign body	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
25250	Removal of wrist prosthesis	Y		A2	\$333.00	29.19	\$1,208.50	\$551.88
25251	Removal of wrist prosthesis	Y		A2	\$333.00	29.19	\$1,208.50	\$551.88
25259	Manipulate wrist w/anesthes	Y		G2		1.7682	\$73.21	\$73.21
25260	Repair forearm tendon/muscle	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
25263	Repair forearm tendon/muscle	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
25265	Repair forearm tendon/muscle	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25270	Repair forearm tendon/muscle	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
25272	Repair forearm tendon/muscle	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25274	Repair forearm tendon/muscle	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
25275	Repair forearm tendon sheath	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
25280	Revise wrist/forearm tendon	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
25290	Incise wrist/forearm tendon	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25295	Release wrist/forearm tendon	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
25300	Fusion of tendons at wrist	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25301	Fusion of tendons at wrist	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25310	Transplant forearm tendon	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25312	Transplant forearm tendon	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
25315	Revise palsy hand tendon(s)	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25316	Revise palsy hand tendon(s)	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
25320	Repair/revise wrist joint	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25332	Revise wrist joint	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
25335	Realignment of hand	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25337	Reconstruct ulna/radioulnar	Y		A2	\$717.00	42.985	\$1,779.62	\$982.66
25350	Revision of radius	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
25355	Revision of radius	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25360	Revision of ulna	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25365	Revise radius & ulna	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
25370	Revise radius or ulna	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25375	Revise radius & ulna	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
25390	Shorten radius or ulna	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25391	Lengthen radius or ulna	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
25392	Shorten radius & ulna	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
25393	Lengthen radius & ulna	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
25394	Repair carpal bone, shorten	Y		G2		16.4637	\$681.61	\$681.61
25400	Repair radius or ulna	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
25405	Repair/graft radius or ulna	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
25415	Repair radius & ulna	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
25420	Repair/graft radius & ulna	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
25425	Repair/graft radius or ulna	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25426	Repair/graft radius & ulna	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
25430	Vasc graft into carpal bone	Y		G2		26.3105	\$1,089.28	\$1,089.28
25431	Repair nonunion carpal bone	Y		G2		26.3105	\$1,089.28	\$1,089.28
25440	Repair/graft wrist bone	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
25441	Reconstruct wrist joint	Y		A2	\$717.00	122.2057	\$5,059.44	\$1,802.61
25442	Reconstruct wrist joint	Y		A2	\$717.00	122.2057	\$5,059.44	\$1,802.61
25443	Reconstruct wrist joint	Y		A2	\$717.00	50.8876	\$2,106.80	\$1,064.45
25444	Reconstruct wrist joint	Y		A2	\$717.00	50.8876	\$2,106.80	\$1,064.45
25445	Reconstruct wrist joint	Y		A2	\$717.00	50.8876	\$2,106.80	\$1,064.45
25446	Wrist replacement	Y		A2	\$995.00	122.2057	\$5,059.44	\$2,011.11
25447	Repair wrist joint(s)	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
25449	Remove wrist joint implant	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
25450	Revision of wrist joint	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25455	Revision of wrist joint	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25490	Reinforce radius	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25491	Reinforce ulna	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25492	Reinforce radius and ulna	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
25500	Treat fracture of radius	Y		P2		1.7682	\$73.21	\$73.21
25505	Treat fracture of radius	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25515	Treat fracture of radius	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
25520	Treat fracture of radius	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25525	Treat fracture of radius	Y		A2	\$630.00	41.1091	\$1,701.96	\$897.99
25526	Treat fracture of radius	Y		A2	\$717.00	41.1091	\$1,701.96	\$963.24
25530	Treat fracture of ulna	Y		P2		1.7682	\$73.21	\$73.21
25535	Treat fracture of ulna	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25545	Treat fracture of ulna	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
25560	Treat fracture radius & ulna	Y		P2		1.7682	\$73.21	\$73.21
25565	Treat fracture radius & ulna	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25574	Treat fracture radius & ulna	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
25575	Treat fracture radius/ulna	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
25600	Treat fracture radius/ulna	Y		P2		1.7682	\$73.21	\$73.21
25605	Treat fracture radius/ulna	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25606	Treat fx distal radial	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
25607	Treat fx rad extra-articul	Y		A2	\$717.00	59.2233	\$2,451.90	\$1,150.73
25608	Treat fx rad intra-articul	Y		A2	\$717.00	59.2233	\$2,451.90	\$1,150.73
25609	Treat fx radial 3+ frag	Y		A2	\$717.00	59.2233	\$2,451.90	\$1,150.73
25622	Treat wrist bone fracture	Y		P2		1.7682	\$73.21	\$73.21
25624	Treat wrist bone fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25628	Treat wrist bone fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
25630	Treat wrist bone fracture	Y		P2		1.7682	\$73.21	\$73.21
25635	Treat wrist bone fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25645	Treat wrist bone fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
25650	Treat wrist bone fracture	Y		P2		1.7682	\$73.21	\$73.21
25651	Pin ulnar styloid fracture	Y		G2		26.1592	\$1,083.02	\$1,083.02
25652	Treat fracture ulnar styloid	Y		G2		41.1091	\$1,701.96	\$1,701.96
25660	Treat wrist dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25670	Treat wrist dislocation	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
25671	Pin radioulnar dislocation	Y		A2	\$333.00	26.1592	\$1,083.02	\$520.51
25675	Treat wrist dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25676	Treat wrist dislocation	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
25680	Treat wrist fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25685	Treat wrist fracture	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
25690	Treat wrist dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
25695	Treat wrist dislocation	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
25800	Fusion of wrist joint	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
25805	Fusion/graft of wrist joint	Y		A2	\$717.00	42.985	\$1,779.62	\$982.66
25810	Fusion/graft of wrist joint	Y		A2	\$717.00	79.4244	\$3,288.25	\$1,359.81
25820	Fusion of hand bones	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
25825	Fuse hand bones with graft	Y		A2	\$717.00	79.4244	\$3,288.25	\$1,359.81
25830	Fusion, radioulnar jnt/ulna	Y		A2	\$717.00	79.4244	\$3,288.25	\$1,359.81
25907	Amputation follow-up surgery	Y		A2	\$510.00	21.2689	\$880.55	\$602.64

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
25922	Amputate hand at wrist	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
25929	Amputation follow-up surgery	Y		A2	\$510.00	15.0458	\$622.91	\$538.23
25931	Amputation follow-up surgery	Y	CH	G2		21.2689	\$880.55	\$880.55
26010	Drainage of finger abscess	Y		P2		1.4066	\$58.23	\$58.23
26011	Drainage of finger abscess	Y		A2	\$333.00	11.5594	\$478.57	\$369.39
26020	Drain hand tendon sheath	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26025	Drainage of palm bursa	Y		A2	\$333.00	16.4637	\$681.61	\$420.15
26030	Drainage of palm bursa(s)	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26034	Treat hand bone lesion	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26035	Decompress fingers/hand	Y		G2		16.4637	\$681.61	\$681.61
26040	Release palm contracture	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26045	Release palm contracture	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26055	Incise finger tendon sheath	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26060	Incision of finger tendon	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26070	Explore/treat hand joint	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26075	Explore/treat finger joint	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
26080	Explore/treat finger joint	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
26100	Biopsy hand joint lining	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26105	Biopsy finger joint lining	Y		A2	\$333.00	16.4637	\$681.61	\$420.15
26110	Biopsy finger joint lining	Y		A2	\$333.00	16.4637	\$681.61	\$420.15
26115	Removal hand lesion subcut	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
26116	Removal hand lesion, deep	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
26117	Remove tumor, hand/finger	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
26121	Release palm contracture	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26123	Release palm contracture	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26125	Release palm contracture	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
26130	Remove wrist joint lining	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26135	Revise finger joint, each	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26140	Revise finger joint, each	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26145	Tendon excision, palm/finger	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26160	Remove tendon sheath lesion	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26170	Removal of palm tendon, each	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26180	Removal of finger tendon	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26185	Remove finger bone	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
26200	Remove hand bone lesion	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26205	Remove/graft bone lesion	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26210	Removal of finger lesion	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26215	Remove/graft finger lesion	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26230	Partial removal of hand bone	Y		A2	\$992.95	16.4637	\$681.61	\$915.12
26235	Partial removal, finger bone	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26236	Partial removal, finger bone	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26250	Extensive hand surgery	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26255	Extensive hand surgery	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26260	Extensive finger surgery	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26261	Extensive finger surgery	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26262	Partial removal of finger	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26320	Removal of implant from hand	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
26340	Manipulate finger w/anesth	Y		G2		1.7682	\$73.21	\$73.21
26350	Repair finger/hand tendon	Y		A2	\$333.00	26.3105	\$1,089.28	\$522.07
26352	Repair/graft hand tendon	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26356	Repair finger/hand tendon	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26357	Repair finger/hand tendon	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26358	Repair/graft hand tendon	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26370	Repair finger/hand tendon	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26372	Repair/graft hand tendon	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26373	Repair finger/hand tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26390	Revise hand/finger tendon	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26392	Repair/graft hand tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26410	Repair hand tendon	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26412	Repair/graft hand tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26415	Excision, hand/finger tendon	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26416	Graft hand or finger tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26418	Repair finger tendon	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
26420	Repair/graft finger tendon	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26426	Repair finger/hand tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26428	Repair/graft finger tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26432	Repair finger tendon	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26433	Repair finger tendon	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26434	Repair/graft finger tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26437	Realignment of tendons	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26440	Release palm/finger tendon	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26442	Release palm & finger tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26445	Release hand/finger tendon	Y		A2	\$510.00	16.4637	\$681.61	\$552.90

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
26449	Release forearm/hand tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26450	Incision of palm tendon	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26455	Incision of finger tendon	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26460	Incise hand/finger tendon	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26471	Fusion of finger tendons	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26474	Fusion of finger tendons	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26476	Tendon lengthening	Y		A2	\$333.00	16.4637	\$681.61	\$420.15
26477	Tendon shortening	Y		A2	\$333.00	16.4637	\$681.61	\$420.15
26478	Lengthening of hand tendon	Y		A2	\$333.00	16.4637	\$681.61	\$420.15
26479	Shortening of hand tendon	Y		A2	\$333.00	16.4637	\$681.61	\$420.15
26480	Transplant hand tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26483	Transplant/graft hand tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26485	Transplant palm tendon	Y		A2	\$446.00	26.3105	\$1,089.28	\$606.82
26489	Transplant/graft palm tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26490	Revise thumb tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26492	Tendon transfer with graft	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26494	Hand tendon/muscle transfer	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26496	Revise thumb tendon	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26497	Finger tendon transfer	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26498	Finger tendon transfer	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26499	Revision of finger	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26500	Hand tendon reconstruction	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
26502	Hand tendon reconstruction	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26508	Release thumb contracture	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26510	Thumb tendon transfer	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26516	Fusion of knuckle joint	Y		A2	\$333.00	26.3105	\$1,089.28	\$522.07
26517	Fusion of knuckle joints	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26518	Fusion of knuckle joints	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26520	Release knuckle contracture	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26525	Release finger contracture	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26530	Revise knuckle joint	Y		A2	\$510.00	35.904	\$1,486.46	\$754.12
26531	Revise knuckle with implant	Y		A2	\$995.00	50.8876	\$2,106.80	\$1,272.95
26535	Revise finger joint	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
26536	Revise/implant finger joint	Y		A2	\$717.00	50.8876	\$2,106.80	\$1,064.45
26540	Repair hand joint	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
26541	Repair hand joint with graft	Y		A2	\$995.00	26.3105	\$1,089.28	\$1,018.57
26542	Repair hand joint with graft	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
26545	Reconstruct finger joint	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26546	Repair nonunion hand	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26548	Reconstruct finger joint	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26550	Construct thumb replacement	Y		A2	\$446.00	26.3105	\$1,089.28	\$606.82
26555	Positional change of finger	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26560	Repair of web finger	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26561	Repair of web finger	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26562	Repair of web finger	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26565	Correct metacarpal flaw	Y		A2	\$717.00	26.3105	\$1,089.28	\$810.07
26567	Correct finger deformity	Y		A2	\$717.00	26.3105	\$1,089.28	\$810.07
26568	Lengthen metacarpal/finger	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26580	Repair hand deformity	Y		A2	\$717.00	16.4637	\$681.61	\$708.15
26587	Reconstruct extra finger	Y		A2	\$717.00	16.4637	\$681.61	\$708.15
26590	Repair finger deformity	Y		A2	\$717.00	16.4637	\$681.61	\$708.15
26591	Repair muscles of hand	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26593	Release muscles of hand	Y		A2	\$510.00	16.4637	\$681.61	\$552.90
26596	Excision constricting tissue	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26600	Treat metacarpal fracture	Y		P2		1.7682	\$73.21	\$73.21
26605	Treat metacarpal fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
26607	Treat metacarpal fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
26608	Treat metacarpal fracture	Y		A2	\$630.00	26.1592	\$1,083.02	\$743.26
26615	Treat metacarpal fracture	Y		A2	\$630.00	41.1091	\$1,701.96	\$897.99
26641	Treat thumb dislocation	Y	CH	P2		1.7682	\$73.21	\$73.21
26645	Treat thumb fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
26650	Treat thumb fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
26665	Treat thumb fracture	Y		A2	\$630.00	41.1091	\$1,701.96	\$897.99
26670	Treat hand dislocation	Y	CH	P2		1.7682	\$73.21	\$73.21
26675	Treat hand dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
26676	Pin hand dislocation	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
26685	Treat hand dislocation	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
26686	Treat hand dislocation	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
26700	Treat knuckle dislocation	Y	CH	P2		1.7682	\$73.21	\$73.21
26705	Treat knuckle dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
26706	Pin knuckle dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
26715	Treat knuckle dislocation	Y		A2	\$630.00	26.1592	\$1,083.02	\$743.26
26720	Treat finger fracture, each	Y		P2		1.7682	\$73.21	\$73.21

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
26725	Treat finger fracture, each	Y		P2		1.7682	\$73.21	\$73.21
26727	Treat finger fracture, each	Y		A2	\$995.00	26.1592	\$1,083.02	\$1,017.01
26735	Treat finger fracture, each	Y		A2	\$630.00	26.1592	\$1,083.02	\$743.26
26740	Treat finger fracture, each	Y		P2		1.7682	\$73.21	\$73.21
26742	Treat finger fracture, each	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
26746	Treat finger fracture, each	Y		A2	\$717.00	26.1592	\$1,083.02	\$808.51
26750	Treat finger fracture, each	Y		P2		1.7682	\$73.21	\$73.21
26755	Treat finger fracture, each	Y		G2		1.7682	\$73.21	\$73.21
26756	Pin finger fracture, each	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
26765	Treat finger fracture, each	Y		A2	\$630.00	26.1592	\$1,083.02	\$743.26
26770	Treat finger dislocation	Y		G2		1.7682	\$73.21	\$73.21
26775	Treat finger dislocation	Y	CH	P3		4.032	\$166.93	\$166.93
26776	Pin finger dislocation	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
26785	Treat finger dislocation	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
26820	Thumb fusion with graft	Y		A2	\$717.00	26.3105	\$1,089.28	\$810.07
26841	Fusion of thumb	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26842	Thumb fusion with graft	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26843	Fusion of hand joint	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26844	Fusion/graft of hand joint	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26850	Fusion of knuckle	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26852	Fusion of knuckle with graft	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26860	Fusion of finger joint	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26861	Fusion of finger jnt, add-on	Y		A2	\$446.00	26.3105	\$1,089.28	\$606.82
26862	Fusion/graft of finger joint	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
26863	Fuse/graft added joint	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26910	Amputate metacarpal bone	Y		A2	\$510.00	26.3105	\$1,089.28	\$654.82
26951	Amputation of finger/thumb	Y		A2	\$446.00	16.4637	\$681.61	\$504.90
26952	Amputation of finger/thumb	Y		A2	\$630.00	16.4637	\$681.61	\$642.90
26990	Drainage of pelvis lesion	Y		A2	\$333.00	21.2689	\$880.55	\$469.89
26991	Drainage of pelvis bursa	Y		A2	\$333.00	21.2689	\$880.55	\$469.89
27000	Incision of hip tendon	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27001	Incision of hip tendon	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27003	Incision of hip tendon	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27033	Exploration of hip joint	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27035	Denervation of hip joint	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27040	Biopsy of soft tissues	Y		A2	\$333.00	8.685	\$359.57	\$339.64
27041	Biopsy of soft tissues	Y		A2	\$418.49	8.685	\$359.57	\$403.76
27047	Remove hip/pelvis lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
27048	Remove hip/pelvis lesion	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
27049	Remove tumor, hip/pelvis	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
27050	Biopsy of sacroiliac joint	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27052	Biopsy of hip joint	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27060	Removal of ischial bursa	Y		A2	\$717.00	21.2689	\$880.55	\$757.89
27062	Remove femur lesion/bursa	Y		A2	\$717.00	21.2689	\$880.55	\$757.89
27065	Removal of hip bone lesion	Y		A2	\$717.00	21.2689	\$880.55	\$757.89
27066	Removal of hip bone lesion	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
27067	Remove/graft hip bone lesion	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
27080	Removal of tail bone	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27086	Remove hip foreign body	Y		A2	\$333.00	8.685	\$359.57	\$339.64
27087	Remove hip foreign body	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27093	Injection for hip x-ray	N		N1				
27095	Injection for hip x-ray	N		N1				
27097	Revision of hip tendon	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27098	Transfer tendon to pelvis	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27100	Transfer of abdominal muscle	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27105	Transfer of spinal muscle	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27110	Transfer of iliopsoas muscle	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27111	Transfer of iliopsoas muscle	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27193	Treat pelvic ring fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27194	Treat pelvic ring fracture	Y		A2	\$446.00	14.7658	\$611.32	\$487.33
27200	Treat tail bone fracture	Y	CH	P3		1.7693	\$73.25	\$73.25
27202	Treat tail bone fracture	Y		A2	\$446.00	41.1091	\$1,701.96	\$759.99
27220	Treat hip socket fracture	Y		G2		1.7682	\$73.21	\$73.21
27230	Treat thigh fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27238	Treat thigh fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27246	Treat thigh fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27250	Treat hip dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27252	Treat hip dislocation	Y		A2	\$446.00	14.7658	\$611.32	\$487.33
27256	Treat hip dislocation	Y		G2		1.7682	\$73.21	\$73.21
27257	Treat hip dislocation	Y		A2	\$510.00	14.7658	\$611.32	\$535.33
27265	Treat hip dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27266	Treat hip dislocation	Y		A2	\$446.00	14.7658	\$611.32	\$487.33
27267	Cltx thigh fx	Y	NI	G2		1.7682	\$73.21	\$73.21

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
27275	Manipulation of hip joint	Y		A2	\$446.00	14.7658	\$611.32	\$487.33
27301	Drain thigh/knee lesion	Y		A2	\$510.00	18.3197	\$758.45	\$572.11
27305	Incise thigh tendon & fascia	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27306	Incision of thigh tendon	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27307	Incision of thigh tendons	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27310	Exploration of knee joint	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27323	Biopsy, thigh soft tissues	Y		A2	\$333.00	8.685	\$359.57	\$339.64
27324	Biopsy, thigh soft tissues	Y		A2	\$333.00	21.1098	\$873.97	\$468.24
27325	Neurectomy, hamstring	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
27326	Neurectomy, popliteal	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
27327	Removal of thigh lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
27328	Removal of thigh lesion	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
27329	Remove tumor, thigh/knee	Y		A2	\$630.00	21.1098	\$873.97	\$690.99
27330	Biopsy, knee joint lining	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27331	Explore/treat knee joint	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27332	Removal of knee cartilage	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27333	Removal of knee cartilage	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27334	Remove knee joint lining	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27335	Remove knee joint lining	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27340	Removal of kneecap bursa	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27345	Removal of knee cyst	Y		A2	\$630.00	21.2689	\$880.55	\$692.64
27347	Remove knee cyst	Y		A2	\$630.00	21.2689	\$880.55	\$692.64
27350	Removal of kneecap	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27355	Remove femur lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27356	Remove femur lesion/graft	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27357	Remove femur lesion/graft	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
27358	Remove femur lesion/fixation	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
27360	Partial removal, leg bone(s)	Y		A2	\$717.00	29.19	\$1,208.50	\$839.88
27370	Injection for knee x-ray	N		N1				
27372	Removal of foreign body	Y		A2	\$995.00	21.1098	\$873.97	\$964.74
27380	Repair of kneecap tendon	Y		A2	\$333.00	21.2689	\$880.55	\$469.89
27381	Repair/graft kneecap tendon	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27385	Repair of thigh muscle	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27386	Repair/graft of thigh muscle	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27390	Incision of thigh tendon	Y		A2	\$333.00	21.2689	\$880.55	\$469.89
27391	Incision of thigh tendons	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27392	Incision of thigh tendons	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27393	Lengthening of thigh tendon	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27394	Lengthening of thigh tendons	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27395	Lengthening of thigh tendons	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27396	Transplant of thigh tendon	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27397	Transplants of thigh tendons	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27400	Revise thigh muscles/tendons	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27403	Repair of knee cartilage	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27405	Repair of knee ligament	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27407	Repair of knee ligament	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
27409	Repair of knee ligaments	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27416	Osteochondral knee autograft	Y	NI	G2		42.985	\$1,779.62	\$1,779.62
27418	Repair degenerated kneecap	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27420	Revision of unstable kneecap	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27422	Revision of unstable kneecap	Y		A2	\$995.00	42.985	\$1,779.62	\$1,191.16
27424	Revision/removal of kneecap	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27425	Lat retinacular release open	Y		A2	\$995.00	29.19	\$1,208.50	\$1,048.38
27427	Reconstruction, knee	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27428	Reconstruction, knee	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
27429	Reconstruction, knee	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
27430	Revision of thigh muscles	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27435	Incision of knee joint	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27437	Revise kneecap	Y		A2	\$630.00	35.904	\$1,486.46	\$844.12
27438	Revise kneecap with implant	Y		A2	\$717.00	50.8876	\$2,106.80	\$1,064.45
27440	Revision of knee joint	Y		G2		35.904	\$1,486.46	\$1,486.46
27441	Revision of knee joint	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
27442	Revision of knee joint	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
27443	Revision of knee joint	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
27446	Revision of knee joint	Y		G2		274.6715	\$11,371.67	\$11,371.67
27496	Decompression of thigh/knee	Y		A2	\$717.00	21.2689	\$880.55	\$757.89
27497	Decompression of thigh/knee	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27498	Decompression of thigh/knee	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27499	Decompression of thigh/knee	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27500	Treatment of thigh fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27501	Treatment of thigh fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27502	Treatment of thigh fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27503	Treatment of thigh fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
27508	Treatment of thigh fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27509	Treatment of thigh fracture	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
27510	Treatment of thigh fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27516	Treat thigh fx growth plate	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27517	Treat thigh fx growth plate	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27520	Treat kneecap fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27530	Treat knee fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27532	Treat knee fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27538	Treat knee fracture(s)	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27550	Treat knee dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27552	Treat knee dislocation	Y		A2	\$333.00	14.7658	\$611.32	\$402.58
27560	Treat kneecap dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27562	Treat kneecap dislocation	Y		A2	\$333.00	14.7658	\$611.32	\$402.58
27566	Treat kneecap dislocation	Y		A2	\$446.00	41.1091	\$1,701.96	\$759.99
27570	Fixation of knee joint	Y		A2	\$333.00	14.7658	\$611.32	\$402.58
27594	Amputation follow-up surgery	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27600	Decompression of lower leg	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27601	Decompression of lower leg	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27602	Decompression of lower leg	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27603	Drain lower leg lesion	Y		A2	\$446.00	18.3197	\$758.45	\$524.11
27604	Drain lower leg bursa	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27605	Incision of achilles tendon	Y		A2	\$333.00	20.8284	\$862.32	\$465.33
27606	Incision of achilles tendon	Y		A2	\$333.00	21.2689	\$880.55	\$469.89
27607	Treat lower leg bone lesion	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27610	Explore/treat ankle joint	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27612	Exploration of ankle joint	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27613	Biopsy lower leg soft tissue	Y		P3		2.9376	\$121.62	\$121.62
27614	Biopsy lower leg soft tissue	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
27615	Remove tumor, lower leg	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27618	Remove lower leg lesion	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
27619	Remove lower leg lesion	Y		A2	\$510.00	21.1098	\$873.97	\$600.99
27620	Explore/treat ankle joint	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27625	Remove ankle joint lining	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27626	Remove ankle joint lining	Y		A2	\$630.00	29.19	\$1,208.50	\$774.63
27630	Removal of tendon lesion	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27635	Remove lower leg bone lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27637	Remove/graft leg bone lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27638	Remove/graft leg bone lesion	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27640	Partial removal of tibia	Y		A2	\$446.00	42.985	\$1,779.62	\$779.41
27641	Partial removal of fibula	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27647	Extensive ankle/heel surgery	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27648	Injection for ankle x-ray	N		N1				
27650	Repair achilles tendon	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27652	Repair/graft achilles tendon	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
27654	Repair of achilles tendon	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27656	Repair leg fascia defect	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27658	Repair of leg tendon, each	Y		A2	\$333.00	21.2689	\$880.55	\$469.89
27659	Repair of leg tendon, each	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27664	Repair of leg tendon, each	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27665	Repair of leg tendon, each	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27675	Repair lower leg tendons	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27676	Repair lower leg tendons	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27680	Release of lower leg tendon	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27681	Release of lower leg tendons	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27685	Revision of lower leg tendon	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27686	Revise lower leg tendons	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27687	Revision of calf tendon	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27690	Revise lower leg tendon	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27691	Revise lower leg tendon	Y		A2	\$630.00	42.985	\$1,779.62	\$917.41
27692	Revise additional leg tendon	Y		A2	\$510.00	42.985	\$1,779.62	\$827.41
27695	Repair of ankle ligament	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27696	Repair of ankle ligaments	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27698	Repair of ankle ligament	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27700	Revision of ankle joint	Y		A2	\$717.00	35.904	\$1,486.46	\$909.37
27704	Removal of ankle implant	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27705	Incision of tibia	Y		A2	\$446.00	42.985	\$1,779.62	\$779.41
27707	Incision of fibula	Y		A2	\$446.00	21.2689	\$880.55	\$554.64
27709	Incision of tibia & fibula	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27726	Repair fibula nonunion	Y	NI	G2		26.1592	\$1,083.02	\$1,083.02
27730	Repair of tibia epiphysis	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27732	Repair of fibula epiphysis	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27734	Repair lower leg epiphyses	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63
27740	Repair of leg epiphyses	Y		A2	\$446.00	29.19	\$1,208.50	\$636.63

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
27742	Repair of leg epiphyses	Y		A2	\$446.00	42.985	\$1,779.62	\$779.41
27745	Reinforce tibia	Y		A2	\$510.00	79.4244	\$3,288.25	\$1,204.56
27750	Treatment of tibia fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27752	Treatment of tibia fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27756	Treatment of tibia fracture	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
27758	Treatment of tibia fracture	Y		A2	\$630.00	41.1091	\$1,701.96	\$897.99
27759	Treatment of tibia fracture	Y		A2	\$630.00	59.2233	\$2,451.90	\$1,085.48
27760	Cltx medial ankle fx	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27762	Cltx med ankle fx w/mnpj	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27766	Optx medial ankle fx	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
27767	Cltx post ankle fx	Y	NI	G2		1.7682	\$73.21	\$73.21
27768	Cltx post ankle fx w/mnpj	Y	NI	G2		1.7682	\$73.21	\$73.21
27769	Optx post ankle fx	Y	NI	G2		41.1091	\$1,701.96	\$1,701.96
27780	Treatment of fibula fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27781	Treatment of fibula fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27784	Treatment of fibula fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
27786	Treatment of ankle fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27788	Treatment of ankle fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27792	Treatment of ankle fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
27808	Treatment of ankle fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27810	Treatment of ankle fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27814	Treatment of ankle fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
27816	Treatment of ankle fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27818	Treatment of ankle fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27822	Treatment of ankle fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
27823	Treatment of ankle fracture	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
27824	Treat lower leg fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27825	Treat lower leg fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27826	Treat lower leg fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
27827	Treat lower leg fracture	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
27828	Treat lower leg fracture	Y		A2	\$630.00	59.2233	\$2,451.90	\$1,085.48
27829	Treat lower leg joint	Y		A2	\$446.00	41.1091	\$1,701.96	\$759.99
27830	Treat lower leg dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27831	Treat lower leg dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27832	Treat lower leg dislocation	Y		A2	\$446.00	41.1091	\$1,701.96	\$759.99
27840	Treat ankle dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
27842	Treat ankle dislocation	Y		A2	\$333.00	14.7658	\$611.32	\$402.58
27846	Treat ankle dislocation	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
27848	Treat ankle dislocation	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
27860	Fixation of ankle joint	Y		A2	\$333.00	14.7658	\$611.32	\$402.58
27870	Fusion of ankle joint, open	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
27871	Fusion of tibiofibular joint	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
27884	Amputation follow-up surgery	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27889	Amputation of foot at ankle	Y		A2	\$510.00	29.19	\$1,208.50	\$684.63
27892	Decompression of leg	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27893	Decompression of leg	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
27894	Decompression of leg	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
28001	Drainage of bursa of foot	Y		P3		2.8719	\$118.90	\$118.90
28002	Treatment of foot infection	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
28003	Treatment of foot infection	Y		A2	\$510.00	21.2689	\$880.55	\$602.64
28005	Treat foot bone lesion	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28008	Incision of foot fascia	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28010	Incision of toe tendon	Y		P3		2.156	\$89.26	\$89.26
28011	Incision of toe tendons	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28020	Exploration of foot joint	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28022	Exploration of foot joint	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28024	Exploration of toe joint	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28035	Decompression of tibia nerve	Y		A2	\$630.00	18.0518	\$747.36	\$659.34
28043	Excision of foot lesion	Y		A2	\$446.00	21.1098	\$873.97	\$552.99
28045	Excision of foot lesion	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28046	Resection of tumor, foot	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28050	Biopsy of foot joint lining	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28052	Biopsy of foot joint lining	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28054	Biopsy of toe joint lining	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28055	Neurectomy, foot	Y		A2	\$630.00	18.0518	\$747.36	\$659.34
28060	Partial removal, foot fascia	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28062	Removal of foot fascia	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28070	Removal of foot joint lining	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28072	Removal of foot joint lining	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28080	Removal of foot lesion	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28086	Excise foot tendon sheath	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28088	Excise foot tendon sheath	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28090	Removal of foot lesion	Y		A2	\$510.00	20.8284	\$862.32	\$598.08

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
28092	Removal of toe lesions	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28100	Removal of ankle/heel lesion	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28102	Remove/graft foot lesion	Y		A2	\$510.00	44.2687	\$1,832.77	\$840.69
28103	Remove/graft foot lesion	Y		A2	\$510.00	44.2687	\$1,832.77	\$840.69
28104	Removal of foot lesion	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28106	Remove/graft foot lesion	Y		A2	\$510.00	44.2687	\$1,832.77	\$840.69
28107	Remove/graft foot lesion	Y		A2	\$510.00	44.2687	\$1,832.77	\$840.69
28108	Removal of toe lesions	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28110	Part removal of metatarsal	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28111	Part removal of metatarsal	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28112	Part removal of metatarsal	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28113	Part removal of metatarsal	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28114	Removal of metatarsal heads	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28116	Revision of foot	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28118	Removal of heel bone	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28119	Removal of heel spur	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28120	Part removal of ankle/heel	Y		A2	\$995.00	20.8284	\$862.32	\$961.83
28122	Partial removal of foot bone	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28124	Partial removal of toe	Y		P3		4.8385	\$200.32	\$200.32
28126	Partial removal of toe	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28130	Removal of ankle bone	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28140	Removal of metatarsal	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28150	Removal of toe	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28153	Partial removal of toe	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28160	Partial removal of toe	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28171	Extensive foot surgery	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28173	Extensive foot surgery	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28175	Extensive foot surgery	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28190	Removal of foot foreign body	Y		P3		3.0446	\$126.05	\$126.05
28192	Removal of foot foreign body	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
28193	Removal of foot foreign body	Y		A2	\$418.49	8.685	\$359.57	\$403.76
28200	Repair of foot tendon	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28202	Repair/graft of foot tendon	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28208	Repair of foot tendon	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28210	Repair/graft of foot tendon	Y		A2	\$510.00	44.2687	\$1,832.77	\$840.69
28220	Release of foot tendon	Y		P3		4.5588	\$188.74	\$188.74
28222	Release of foot tendons	Y		A2	\$333.00	20.8284	\$862.32	\$465.33
28225	Release of foot tendon	Y		A2	\$333.00	20.8284	\$862.32	\$465.33
28226	Release of foot tendons	Y		A2	\$333.00	20.8284	\$862.32	\$465.33
28230	Incision of foot tendon(s)	Y		P3		4.4929	\$186.01	\$186.01
28232	Incision of toe tendon	Y		P3		4.2955	\$177.84	\$177.84
28234	Incision of foot tendon	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28238	Revision of foot tendon	Y		A2	\$510.00	44.2687	\$1,832.77	\$840.69
28240	Release of big toe	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28250	Revision of foot fascia	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28260	Release of midfoot joint	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28261	Revision of foot tendon	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28262	Revision of foot and ankle	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28264	Release of midfoot joint	Y		A2	\$333.00	44.2687	\$1,832.77	\$707.94
28270	Release of foot contracture	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28272	Release of toe joint, each	Y		P3		4.1144	\$170.34	\$170.34
28280	Fusion of toes	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28285	Repair of hammertoe	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28286	Repair of hammertoe	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28288	Partial removal of foot bone	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28289	Repair hallux rigidus	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28290	Correction of bunion	Y		A2	\$446.00	29.4167	\$1,217.88	\$638.97
28292	Correction of bunion	Y		A2	\$446.00	29.4167	\$1,217.88	\$638.97
28293	Correction of bunion	Y		A2	\$510.00	29.4167	\$1,217.88	\$686.97
28294	Correction of bunion	Y		A2	\$510.00	29.4167	\$1,217.88	\$686.97
28296	Correction of bunion	Y		A2	\$510.00	29.4167	\$1,217.88	\$686.97
28297	Correction of bunion	Y		A2	\$510.00	29.4167	\$1,217.88	\$686.97
28298	Correction of bunion	Y		A2	\$510.00	29.4167	\$1,217.88	\$686.97
28299	Correction of bunion	Y		A2	\$717.00	29.4167	\$1,217.88	\$842.22
28300	Incision of heel bone	Y		A2	\$446.00	44.2687	\$1,832.77	\$792.69
28302	Incision of ankle bone	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28304	Incision of midfoot bones	Y		A2	\$446.00	44.2687	\$1,832.77	\$792.69
28305	Incise/graft midfoot bones	Y		A2	\$510.00	44.2687	\$1,832.77	\$840.69
28306	Incision of metatarsal	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28307	Incision of metatarsal	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28308	Incision of metatarsal	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28309	Incision of metatarsals	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28310	Revision of big toe	Y		A2	\$510.00	20.8284	\$862.32	\$598.08

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
28312	Revision of toe	Y		A2	\$510.00	20.8284	\$862.32	\$598.08
28313	Repair deformity of toe	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28315	Removal of sesamoid bone	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28320	Repair of foot bones	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28322	Repair of metatarsals	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28340	Resect enlarged toe tissue	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28341	Resect enlarged toe	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28344	Repair extra toe(s)	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28345	Repair webbed toe(s)	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28400	Treatment of heel fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
28405	Treatment of heel fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
28406	Treatment of heel fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
28415	Treat heel fracture	Y		A2	\$510.00	59.2233	\$2,451.90	\$995.48
28420	Treat/graft heel fracture	Y		A2	\$630.00	41.1091	\$1,701.96	\$897.99
28430	Treatment of ankle fracture	Y		P2	1.7682	1.7682	\$73.21	\$73.21
28435	Treatment of ankle fracture	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
28436	Treatment of ankle fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
28445	Treat ankle fracture	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
28446	Osteochondral talus autograft	Y	NI	G2		44.2687	\$1,832.77	\$1,832.77
28450	Treat midfoot fracture, each	Y		P2		1.7682	\$73.21	\$73.21
28455	Treat midfoot fracture, each	Y		P2		1.7682	\$73.21	\$73.21
28456	Treat midfoot fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
28465	Treat midfoot fracture, each	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
28470	Treat metatarsal fracture	Y		P2		1.7682	\$73.21	\$73.21
28475	Treat metatarsal fracture	Y		P2		1.7682	\$73.21	\$73.21
28476	Treat metatarsal fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
28485	Treat metatarsal fracture	Y		A2	\$630.00	41.1091	\$1,701.96	\$897.99
28490	Treat big toe fracture	Y		P3		1.6869	\$69.84	\$69.84
28495	Treat big toe fracture	Y		P2		1.7682	\$73.21	\$73.21
28496	Treat big toe fracture	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
28505	Treat big toe fracture	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
28510	Treatment of toe fracture	Y		P3		1.3166	\$54.51	\$54.51
28515	Treatment of toe fracture	Y		P3		1.6951	\$70.18	\$70.18
28525	Treat toe fracture	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
28530	Treat sesamoid bone fracture	Y		P3		1.2589	\$52.12	\$52.12
28531	Treat sesamoid bone fracture	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
28540	Treat foot dislocation	Y		P2		1.7682	\$73.21	\$73.21
28545	Treat foot dislocation	Y		A2	\$333.00	26.1592	\$1,083.02	\$520.51
28546	Treat foot dislocation	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
28555	Repair foot dislocation	Y		A2	\$446.00	41.1091	\$1,701.96	\$759.99
28570	Treat foot dislocation	Y		P2		1.7682	\$73.21	\$73.21
28575	Treat foot dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
28576	Treat foot dislocation	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
28585	Repair foot dislocation	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
28600	Treat foot dislocation	Y		P2		1.7682	\$73.21	\$73.21
28605	Treat foot dislocation	Y		A2	\$103.62	1.7682	\$73.21	\$96.02
28606	Treat foot dislocation	Y		A2	\$446.00	26.1592	\$1,083.02	\$605.26
28615	Repair foot dislocation	Y		A2	\$510.00	41.1091	\$1,701.96	\$807.99
28630	Treat toe dislocation	Y	CH	P3		1.399	\$57.92	\$57.92
28635	Treat toe dislocation	Y		A2	\$333.00	14.7658	\$611.32	\$402.58
28636	Treat toe dislocation	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
28645	Repair toe dislocation	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
28660	Treat toe dislocation	Y	CH	P3		1.0534	\$43.61	\$43.61
28665	Treat toe dislocation	Y		A2	\$333.00	14.7658	\$611.32	\$402.58
28666	Treat toe dislocation	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
28675	Repair of toe dislocation	Y		A2	\$510.00	26.1592	\$1,083.02	\$653.26
28705	Fusion of foot bones	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28715	Fusion of foot bones	Y		A2	\$630.00	79.4244	\$3,288.25	\$1,294.56
28725	Fusion of foot bones	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28730	Fusion of foot bones	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28735	Fusion of foot bones	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28737	Revision of foot bones	Y		A2	\$717.00	44.2687	\$1,832.77	\$995.94
28740	Fusion of foot bones	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28750	Fusion of big toe joint	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28755	Fusion of big toe joint	Y		A2	\$630.00	20.8284	\$862.32	\$688.08
28760	Fusion of big toe joint	Y		A2	\$630.00	44.2687	\$1,832.77	\$930.69
28810	Amputation toe & metatarsal	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28820	Amputation of toe	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28825	Partial amputation of toe	Y		A2	\$446.00	20.8284	\$862.32	\$550.08
28890*	High energy eswt, plantar f	Y	CH	P3		4.2296	\$175.11	\$175.11
29000	Application of body cast	N		G2		1.0931	\$45.26	\$45.26
29010	Application of body cast	N		P2		2.291	\$94.85	\$94.85
29015	Application of body cast	N		P2		2.291	\$94.85	\$94.85

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
29020	Application of body cast	N		G2		1.0931	\$45.26	\$45.26
29025	Application of body cast	N		P2		1.0931	\$45.26	\$45.26
29035	Application of body cast	N	CH	P2		2.291	\$94.85	\$94.85
29040	Application of body cast	N		G2		1.0931	\$45.26	\$45.26
29044	Application of body cast	N		P2		2.291	\$94.85	\$94.85
29046	Application of body cast	N		G2		2.291	\$94.85	\$94.85
29049	Application of figure eight	N		P3		0.9956	\$41.22	\$41.22
29055	Application of shoulder cast	N		P2		2.291	\$94.85	\$94.85
29058	Application of shoulder cast	N		P2		1.0931	\$45.26	\$45.26
29065	Application of long arm cast	N		P3		1.0698	\$44.29	\$44.29
29075	Application of forearm cast	N		P3		1.0203	\$42.24	\$42.24
29085	Apply hand/wrist cast	N		P3		1.0451	\$43.27	\$43.27
29086	Apply finger cast	N		P3		0.8394	\$34.75	\$34.75
29105	Apply long arm splint	N		P3		0.9546	\$39.52	\$39.52
29125	Apply forearm splint	N		P3		0.8147	\$33.73	\$33.73
29126	Apply forearm splint	N		P3		0.9135	\$37.82	\$37.82
29130	Application of finger splint	N		P3		0.3703	\$15.33	\$15.33
29131	Application of finger splint	N		P3		0.5432	\$22.49	\$22.49
29200	Strapping of chest	N		P3		0.5432	\$22.49	\$22.49
29220	Strapping of low back	N		P3		0.5596	\$23.17	\$23.17
29240	Strapping of shoulder	N		P3		0.6253	\$25.89	\$25.89
29260	Strapping of elbow or wrist	N		P3		0.5761	\$23.85	\$23.85
29280	Strapping of hand or finger	N		P3		0.6007	\$24.87	\$24.87
29305	Application of hip cast	N	CH	P2		2.291	\$94.85	\$94.85
29325	Application of hip casts	N	CH	P2		2.291	\$94.85	\$94.85
29345	Application of long leg cast	N		P3		1.4072	\$58.26	\$58.26
29355	Application of long leg cast	N		P3		1.3659	\$56.55	\$56.55
29358	Apply long leg cast brace	N		P3		1.6705	\$69.16	\$69.16
29365	Application of long leg cast	N		P3		1.3331	\$55.19	\$55.19
29405	Apply short leg cast	N		P3		0.9874	\$40.88	\$40.88
29425	Apply short leg cast	N		P3		1.0038	\$41.56	\$41.56
29435	Apply short leg cast	N		P3		1.2674	\$52.47	\$52.47
29440	Addition of walker to cast	N		P3		0.5514	\$22.83	\$22.83
29445	Apply rigid leg cast	N		P3		1.3823	\$57.23	\$57.23
29450	Application of leg cast	N		P2		1.0931	\$45.26	\$45.26
29505	Application, long leg splint	N	CH	P3		0.9217	\$38.16	\$38.16
29515	Application lower leg splint	N	CH	P3		0.7488	\$31.00	\$31.00
29520	Strapping of hip	N		P3		0.6171	\$25.55	\$25.55
29530	Strapping of knee	N		P3		0.5925	\$24.53	\$24.53
29540	Strapping of ankle and/or ft	N		P3		0.3949	\$16.35	\$16.35
29550	Strapping of toes	N		P3		0.4031	\$16.69	\$16.69
29580	Application of paste boot	N		P3		0.5596	\$23.17	\$23.17
29590	Application of foot splint	N		P3		0.4526	\$18.74	\$18.74
29700	Removal/revision of cast	N		P3		0.757	\$31.34	\$31.34
29705	Removal/revision of cast	N		P3		0.65	\$26.91	\$26.91
29710	Removal/revision of cast	N		P3		1.1686	\$48.38	\$48.38
29715	Removal/revision of cast	N		P3		0.971	\$40.20	\$40.20
29720	Repair of body cast	N		P3		0.9546	\$39.52	\$39.52
29730	Windowing of cast	N		P3		0.6336	\$26.23	\$26.23
29740	Wedging of cast	N		P3		0.8968	\$37.13	\$37.13
29750	Wedging of clubfoot cast	N		P3		0.8722	\$36.11	\$36.11
29800	Jaw arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29804	Jaw arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29805	Shoulder arthroscopy, dx	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29806	Shoulder arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29807	Shoulder arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29819	Shoulder arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29820	Shoulder arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29821	Shoulder arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29822	Shoulder arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29823	Shoulder arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29824	Shoulder arthroscopy/surgery	Y		A2	\$717.00	28.7803	\$1,191.53	\$835.63
29825	Shoulder arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29826	Shoulder arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29827	Arthroscop rotator cuff repr	Y		A2	\$717.00	45.7072	\$1,892.32	\$1,010.83
29828	Arthroscopy biceps tenodesis	Y	NI	G2		45.7072	\$1,892.32	\$1,892.32
29830	Elbow arthroscopy	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29834	Elbow arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29835	Elbow arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29836	Elbow arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29837	Elbow arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29838	Elbow arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29840	Wrist arthroscopy	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
29843	Wrist arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29844	Wrist arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29845	Wrist arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29846	Wrist arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29847	Wrist arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29848	Wrist endoscopy/surgery	Y		A2	\$1,339.00	28.7803	\$1,191.53	\$1,302.13
29850	Knee arthroscopy/surgery	Y		A2	\$630.00	28.7803	\$1,191.53	\$770.38
29851	Knee arthroscopy/surgery	Y		A2	\$630.00	45.7072	\$1,892.32	\$945.58
29855	Tibial arthroscopy/surgery	Y		A2	\$630.00	45.7072	\$1,892.32	\$945.58
29856	Tibial arthroscopy/surgery	Y		A2	\$630.00	45.7072	\$1,892.32	\$945.58
29860	Hip arthroscopy, dx	Y		A2	\$630.00	45.7072	\$1,892.32	\$945.58
29861	Hip arthroscopy/surgery	Y		A2	\$630.00	45.7072	\$1,892.32	\$945.58
29862	Hip arthroscopy/surgery	Y		A2	\$1,339.00	45.7072	\$1,892.32	\$1,477.33
29863	Hip arthroscopy/surgery	Y		A2	\$630.00	45.7072	\$1,892.32	\$945.58
29866	Autgrft implnt, knee w/scope	Y	CH	G2		45.7072	\$1,892.32	\$1,892.32
29870	Knee arthroscopy, dx	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29871	Knee arthroscopy/drainage	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29873	Knee arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29874	Knee arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29875	Knee arthroscopy/surgery	Y		A2	\$630.00	28.7803	\$1,191.53	\$770.38
29876	Knee arthroscopy/surgery	Y		A2	\$630.00	28.7803	\$1,191.53	\$770.38
29877	Knee arthroscopy/surgery	Y		A2	\$630.00	28.7803	\$1,191.53	\$770.38
29879	Knee arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29880	Knee arthroscopy/surgery	Y		A2	\$630.00	28.7803	\$1,191.53	\$770.38
29881	Knee arthroscopy/surgery	Y		A2	\$630.00	28.7803	\$1,191.53	\$770.38
29882	Knee arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29883	Knee arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29884	Knee arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29885	Knee arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29886	Knee arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29887	Knee arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29888	Knee arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29889	Knee arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29891	Ankle arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29892	Ankle arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29893	Scope, plantar fasciotomy	Y		A2	\$1,255.56	20.8284	\$862.32	\$1,157.25
29894	Ankle arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29895	Ankle arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29897	Ankle arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29898	Ankle arthroscopy/surgery	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29899	Ankle arthroscopy/surgery	Y		A2	\$510.00	45.7072	\$1,892.32	\$855.58
29900	Mcp joint arthroscopy, dx	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29901	Mcp joint arthroscopy, surg	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29902	Mcp joint arthroscopy, surg	Y		A2	\$510.00	28.7803	\$1,191.53	\$680.38
29904	Subtalar arthro w/fb rmlv	Y	NI	G2		28.7803	\$1,191.53	\$1,191.53
29905	Subtalar arthro w/exc	Y	NI	G2		28.7803	\$1,191.53	\$1,191.53
29906	Subtalar arthro w/deb	Y	NI	G2		28.7803	\$1,191.53	\$1,191.53
29907	Subtalar arthro w/fusion	Y	NI	G2		45.7072	\$1,892.32	\$1,892.32
30000	Drainage of nose lesion	Y		P2		2.5002	\$103.51	\$103.51
30020	Drainage of nose lesion	Y		P2		2.5002	\$103.51	\$103.51
30100	Intranasal biopsy	Y		P3		1.8763	\$77.68	\$77.68
30110	Removal of nose polyp(s)	Y		P3		2.9376	\$121.62	\$121.62
30115	Removal of nose polyp(s)	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
30117	Removal of intranasal lesion	Y		A2	\$510.00	16.3288	\$676.03	\$551.51
30118	Removal of intranasal lesion	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
30120	Revision of nose	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
30124	Removal of nose lesion	Y		R2		7.4474	\$308.33	\$308.33
30125	Removal of nose lesion	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
30130	Excise inferior turbinate	Y		A2	\$510.00	16.3288	\$676.03	\$551.51
30140	Resect inferior turbinate	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
30150	Partial removal of nose	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
30160	Removal of nose	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
30200	Injection treatment of nose	Y		P3		1.4975	\$62.00	\$62.00
30210	Nasal sinus therapy	Y		P3		1.8927	\$78.36	\$78.36
30220	Insert nasal septal button	Y		A2	\$464.15	7.4474	\$308.33	\$425.20
30300	Remove nasal foreign body	N		P2		0.631	\$26.12	\$26.12
30310	Remove nasal foreign body	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
30320	Remove nasal foreign body	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
30400	Reconstruction of nose	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
30410	Reconstruction of nose	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
30420	Reconstruction of nose	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
30430	Revision of nose	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
30435	Revision of nose	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPSC code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
30450	Revision of nose	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
30460	Revision of nose	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
30462	Revision of nose	Y		A2	\$1,339.00	39.8776	\$1,650.97	\$1,416.99
30465	Repair nasal stenosis	Y		A2	\$1,339.00	39.8776	\$1,650.97	\$1,416.99
30520	Repair of nasal septum	Y		A2	\$630.00	23.9765	\$992.65	\$720.66
30540	Repair nasal defect	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
30545	Repair nasal defect	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
30560	Release of nasal adhesions	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
30580	Repair upper jaw fistula	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
30600	Repair mouth/nose fistula	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
30620	Intranasal reconstruction	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
30630	Repair nasal septum defect	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
30801	Ablate inf turbinate, superf	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
30802	Cauterization, inner nose	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
30901	Control of nosebleed	Y		P3		1.078	\$44.63	\$44.63
30903	Control of nosebleed	Y		A2	\$72.48	1.1251	\$46.58	\$66.01
30905	Control of nosebleed	Y		A2	\$72.48	1.1251	\$46.58	\$66.01
30906	Repeat control of nosebleed	Y		A2	\$72.48	1.1251	\$46.58	\$66.01
30915	Ligation, nasal sinus artery	Y		A2	\$446.00	25.841	\$1,069.84	\$601.96
30920	Ligation, upper jaw artery	Y		A2	\$510.00	25.841	\$1,069.84	\$649.96
30930	Ther fx, nasal inf turbinate	Y		A2	\$630.00	16.3288	\$676.03	\$641.51
31000	Irrigation, maxillary sinus	Y		P3		2.4934	\$103.23	\$103.23
31002	Irrigation, sphenoid sinus	Y		R2		7.4474	\$308.33	\$308.33
31020	Exploration, maxillary sinus	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
31030	Exploration, maxillary sinus	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
31032	Explore sinus, remove polyps	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
31040	Exploration behind upper jaw	Y		R2		23.9765	\$992.65	\$992.65
31050	Exploration, sphenoid sinus	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
31051	Sphenoid sinus surgery	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
31070	Exploration of frontal sinus	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
31075	Exploration of frontal sinus	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
31080	Removal of frontal sinus	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
31081	Removal of frontal sinus	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
31084	Removal of frontal sinus	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
31085	Removal of frontal sinus	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
31086	Removal of frontal sinus	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
31087	Removal of frontal sinus	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
31090	Exploration of sinuses	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
31200	Removal of ethmoid sinus	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
31201	Removal of ethmoid sinus	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
31205	Removal of ethmoid sinus	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
31231	Nasal endoscopy, dx	Y		P2		1.6115	\$66.72	\$66.72
31233	Nasal/sinus endoscopy, dx	Y		A2	\$86.39	1.6115	\$66.72	\$81.47
31235	Nasal/sinus endoscopy, dx	Y		A2	\$333.00	17.016	\$704.48	\$425.87
31237	Nasal/sinus endoscopy, surg	Y		A2	\$446.00	17.016	\$704.48	\$510.62
31238	Nasal/sinus endoscopy, surg	Y		A2	\$333.00	17.016	\$704.48	\$425.87
31239	Nasal/sinus endoscopy, surg	Y		A2	\$630.00	22.7191	\$940.59	\$707.65
31240	Nasal/sinus endoscopy, surg	Y		A2	\$446.00	17.016	\$704.48	\$510.62
31254	Revision of ethmoid sinus	Y		A2	\$510.00	22.7191	\$940.59	\$617.65
31255	Removal of ethmoid sinus	Y		A2	\$717.00	22.7191	\$940.59	\$772.90
31256	Exploration maxillary sinus	Y		A2	\$510.00	22.7191	\$940.59	\$617.65
31267	Endoscopy, maxillary sinus	Y		A2	\$510.00	22.7191	\$940.59	\$617.65
31276	Sinus endoscopy, surgical	Y		A2	\$510.00	22.7191	\$940.59	\$617.65
31287	Nasal/sinus endoscopy, surg	Y		A2	\$510.00	22.7191	\$940.59	\$617.65
31288	Nasal/sinus endoscopy, surg	Y		A2	\$510.00	22.7191	\$940.59	\$617.65
31300	Removal of larynx lesion	Y		A2	\$717.00	23.9765	\$992.65	\$785.91
31320	Diagnostic incision, larynx	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
31400	Revision of larynx	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
31420	Removal of epiglottis	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
31500	Insert emergency airway	N		G2		2.459	\$101.81	\$101.81
31502	Change of windpipe airway	N		G2		1.3362	\$55.32	\$55.32
31505	Diagnostic laryngoscopy	Y		P2		0.8224	\$34.05	\$34.05
31510	Laryngoscopy with biopsy	Y		A2	\$446.00	17.016	\$704.48	\$510.62
31511	Remove foreign body, larynx	Y		A2	\$86.39	1.6115	\$66.72	\$81.47
31512	Removal of larynx lesion	Y		A2	\$446.00	17.016	\$704.48	\$510.62
31513	Injection into vocal cord	Y		A2	\$86.39	1.6115	\$66.72	\$81.47
31515	Laryngoscopy for aspiration	Y		A2	\$333.00	17.016	\$704.48	\$425.87
31520	Dx laryngoscopy, newborn	Y		G2		1.6115	\$66.72	\$66.72
31525	Dx laryngoscopy excl nb	Y		A2	\$333.00	17.016	\$704.48	\$425.87
31526	Dx laryngoscopy w/oper scope	Y		A2	\$446.00	22.7191	\$940.59	\$569.65
31527	Laryngoscopy for treatment	Y		A2	\$333.00	22.7191	\$940.59	\$484.90
31528	Laryngoscopy and dilation	Y		A2	\$446.00	17.016	\$704.48	\$510.62
31529	Laryngoscopy and dilation	Y		A2	\$446.00	17.016	\$704.48	\$510.62

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPSC codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
31530	Laryngoscopy w/fb removal	Y		A2	\$446.00	22.7191	\$940.59	\$569.65
31531	Laryngoscopy w/fb & op scope	Y		A2	\$510.00	22.7191	\$940.59	\$617.65
31535	Laryngoscopy w/biopsy	Y		A2	\$446.00	22.7191	\$940.59	\$569.65
31536	Laryngoscopy w/bx & op scope	Y		A2	\$510.00	22.7191	\$940.59	\$617.65
31540	Laryngoscopy w/exc of tumor	Y		A2	\$510.00	22.7191	\$940.59	\$617.65
31541	Larynsco w/tumr exc + scope	Y		A2	\$630.00	22.7191	\$940.59	\$707.65
31545	Remove vc lesion w/scope	Y		A2	\$630.00	22.7191	\$940.59	\$707.65
31546	Remove vc lesion scope/graft	Y		A2	\$630.00	22.7191	\$940.59	\$707.65
31560	Laryngoscopy w/arytenoidectomy	Y		A2	\$717.00	22.7191	\$940.59	\$772.90
31561	Larynsco, remove cart + scop	Y		A2	\$717.00	22.7191	\$940.59	\$772.90
31570	Laryngoscope w/vc inj	Y		A2	\$446.00	17.016	\$704.48	\$510.62
31571	Laryngoscopy w/vc inj + scope	Y		A2	\$446.00	22.7191	\$940.59	\$569.65
31575	Diagnostic laryngoscopy	Y		P3		1.4811	\$61.32	\$61.32
31576	Laryngoscopy with biopsy	Y		A2	\$446.00	22.7191	\$940.59	\$569.65
31577	Remove foreign body, larynx	Y		A2	\$236.42	3.994	\$165.36	\$218.66
31578	Removal of larynx lesion	Y		A2	\$446.00	22.7191	\$940.59	\$569.65
31579	Diagnostic laryngoscopy	Y		P3		2.7321	\$113.11	\$113.11
31580	Revision of larynx	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
31582	Revision of larynx	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
31588	Revision of larynx	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
31590	Reinnervate larynx	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
31595	Larynx nerve surgery	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
31603	Incision of windpipe	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
31605	Incision of windpipe	Y		G2		7.4474	\$308.33	\$308.33
31611	Surgery/speech prosthesis	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
31612	Puncture/clear windpipe	Y		A2	\$333.00	23.9765	\$992.65	\$497.91
31613	Repair windpipe opening	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
31614	Repair windpipe opening	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
31615	Visualization of windpipe	Y		A2	\$333.00	9.9575	\$412.25	\$352.81
31620	Endobronchial us add-on	N	CH	N1				
31622	Dx bronchoscope/wash	Y		A2	\$333.00	9.9575	\$412.25	\$352.81
31623	Dx bronchoscope/brush	Y		A2	\$446.00	9.9575	\$412.25	\$437.56
31624	Dx bronchoscope/lavage	Y		A2	\$446.00	9.9575	\$412.25	\$437.56
31625	Bronchoscopy w/biopsy(s)	Y		A2	\$446.00	9.9575	\$412.25	\$437.56
31628	Bronchoscopy/lung bx, each	Y		A2	\$446.00	9.9575	\$412.25	\$437.56
31629	Bronchoscopy/needle bx, each	Y		A2	\$446.00	9.9575	\$412.25	\$437.56
31630	Bronchoscopy dilate/fx repr	Y		A2	\$446.00	24.0654	\$996.33	\$583.58
31631	Bronchoscopy, dilate w/stent	Y		A2	\$446.00	24.0654	\$996.33	\$583.58
31632	Bronchoscopy/lung bx, add?!	Y		G2		9.9575	\$412.25	\$412.25
31633	Bronchoscopy/needle bx add?!	Y		G2		9.9575	\$412.25	\$412.25
31635	Bronchoscopy w/fb removal	Y		A2	\$446.00	9.9575	\$412.25	\$437.56
31636	Bronchoscopy, bronch stents	Y		A2	\$446.00	24.0654	\$996.33	\$583.58
31637	Bronchoscopy, stent add-on	Y		A2	\$333.00	9.9575	\$412.25	\$352.81
31638	Bronchoscopy, revise stent	Y		A2	\$446.00	24.0654	\$996.33	\$583.58
31640	Bronchoscopy w/tumor excise	Y		A2	\$446.00	24.0654	\$996.33	\$583.58
31641	Bronchoscopy, treat blockage	Y		A2	\$446.00	24.0654	\$996.33	\$583.58
31643	Diag bronchoscope/catheter	Y		A2	\$446.00	9.9575	\$412.25	\$437.56
31645	Bronchoscopy, clear airways	Y		A2	\$333.00	9.9575	\$412.25	\$352.81
31646	Bronchoscopy, reclear airway	Y		A2	\$333.00	9.9575	\$412.25	\$352.81
31656	Bronchoscopy, inj for x-ray	Y		A2	\$333.00	9.9575	\$412.25	\$352.81
31715	Injection for bronchus x-ray	N		N1				
31717	Bronchial brush biopsy	Y		A2	\$236.42	3.994	\$165.36	\$218.66
31720	Clearance of airways	N		A2	\$47.32	0.3877	\$16.05	\$39.50
31730	Intro, windpipe wire/tube	Y		A2	\$236.42	3.994	\$165.36	\$218.66
31750	Repair of windpipe	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
31755	Repair of windpipe	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
31820	Closure of windpipe lesion	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
31825	Repair of windpipe defect	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
31830	Revise windpipe scar	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
32000	Drainage of chest	N	CH	D5				
32002	Treatment of collapsed lung	N	CH	D5				
32019	Insert pleural catheter	N	CH	D5				
32400	Needle biopsy chest lining	Y		A2	\$333.00	9.3354	\$386.49	\$346.37
32405	Biopsy, lung or mediastinum	Y		A2	\$333.00	9.3354	\$386.49	\$346.37
32420	Puncture/clear lung	Y		A2	\$222.78	5.2024	\$215.38	\$220.93
32421	Thoracentesis for aspiration	Y	NI	A2	\$222.78	5.2024	\$215.38	\$220.93
32422	Thoracentesis w/tube insert	Y	NI	G2		5.2024	\$215.38	\$215.38
32550	Insert pleural cath	Y	NI	G2		30.7096	\$1,271.41	\$1,271.41
32960	Therapeutic pneumothorax	Y		G2		5.2024	\$215.38	\$215.38
32998	Perq rf ablate tx, pul tumor	Y	CH	G2		42.998	\$1,780.16	\$1,780.16
33010	Drainage of heart sac	Y		A2	\$222.78	5.2024	\$215.38	\$220.93
33011	Repeat drainage of heart sac	Y		A2	\$222.78	5.2024	\$215.38	\$220.93
33206	Insertion of heart pacemaker	Y		J8		169.4628	\$7,015.93	\$7,015.93

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
33207	Insertion of heart pacemaker	Y		J8		169.4628	\$7,015.93	\$7,015.93
33208	Insertion of heart pacemaker	Y		J8		196.2967	\$8,126.88	\$8,126.88
33210	Insertion of heart electrode	Y	CH	J8		90.579	\$3,750.06	\$3,750.06
33211	Insertion of heart electrode	Y	CH	J8		90.579	\$3,750.06	\$3,750.06
33212	Insertion of pulse generator	Y		H8	\$510.00	142.1043	\$5,883.26	\$5,514.64
33213	Insertion of pulse generator	Y		H8	\$510.00	154.6733	\$6,403.63	\$6,010.06
33214	Upgrade of pacemaker system	Y		J8		196.2967	\$8,126.88	\$8,126.88
33215	Reposition pacing-defib lead	Y		G2		23.9802	\$992.80	\$992.80
33216	Insert lead pace-defib, one	Y	CH	J8		90.579	\$3,750.06	\$3,750.06
33217	Insert lead pace-defib, dual	Y	CH	J8		90.579	\$3,750.06	\$3,750.06
33218	Repair lead pace-defib, one	Y		G2		23.9802	\$992.80	\$992.80
33220	Repair lead pace-defib, dual	Y		G2		23.9802	\$992.80	\$992.80
33222	Revise pocket, pacemaker	Y		A2	\$446.00	15.0458	\$622.91	\$490.23
33223	Revise pocket, pacing-defib	Y		A2	\$446.00	15.0458	\$622.91	\$490.23
33224	Insert pacing lead & connect	Y		J8		375.1658	\$15,532.24	\$15,532.24
33225	L ventric pacing lead add-on	Y		J8		375.1658	\$15,532.24	\$15,532.24
33226	Reposition I ventric lead	Y		G2		23.9802	\$992.80	\$992.80
33233	Removal of pacemaker system	Y		A2	\$446.00	23.9802	\$992.80	\$582.70
33234	Removal of pacemaker system	Y		G2		23.9802	\$992.80	\$992.80
33235	Removal pacemaker electrode	Y		G2		23.9802	\$992.80	\$992.80
33240	Insert pulse generator	Y	CH	J8		493.9803	\$20,451.28	\$20,451.28
33241	Remove pulse generator	Y		G2		23.9802	\$992.80	\$992.80
33249	Eltrd/insert pace-defib	Y	CH	J8		599.3974	\$24,815.65	\$24,815.65
33282	Implant pat-active ht record	N		J8		98.4186	\$4,074.63	\$4,074.63
33284	Remove pat-active ht record	Y		G2		8.685	\$359.57	\$359.57
33508	Endoscopic vein harvest	N		N1				
35188	Repair blood vessel lesion	Y		A2	\$630.00	38.7673	\$1,605.00	\$873.75
35207	Repair blood vessel lesion	Y		A2	\$630.00	38.7673	\$1,605.00	\$873.75
35473	Repair arterial blockage	Y		G2		45.3845	\$1,878.96	\$1,878.96
35476	Repair venous blockage	Y		G2		45.3845	\$1,878.96	\$1,878.96
35492	Atherectomy, percutaneous	Y		G2		87.5137	\$3,623.15	\$3,623.15
35572	Harvest femoropopliteal vein	N		N1				
35761	Exploration of artery/vein	Y		G2		29.6965	\$1,229.46	\$1,229.46
35875	Removal of clot in graft	Y		A2	\$1,339.00	38.7673	\$1,605.00	\$1,405.50
35876	Removal of clot in graft	Y		A2	\$1,339.00	38.7673	\$1,605.00	\$1,405.50
36000	Place needle in vein	N		N1				
36002	Pseudoaneurysm injection trt	N		G2		2.3792	\$98.50	\$98.50
36005	Injection ext venography	N		N1				
36010	Place catheter in vein	N		N1				
36011	Place catheter in vein	N		N1				
36012	Place catheter in vein	N		N1				
36013	Place catheter in artery	N		N1				
36014	Place catheter in artery	N		N1				
36015	Place catheter in artery	N		N1				
36100	Establish access to artery	N		N1				
36120	Establish access to artery	N		N1				
36140	Establish access to artery	N		N1				
36145	Artery to vein shunt	N		N1				
36160	Establish access to aorta	N		N1				
36200	Place catheter in aorta	N		N1				
36215	Place catheter in artery	N		N1				
36216	Place catheter in artery	N		N1				
36217	Place catheter in artery	N		N1				
36218	Place catheter in artery	N		N1				
36245	Place catheter in artery	N		N1				
36246	Place catheter in artery	N		N1				
36247	Place catheter in artery	N		N1				
36248	Place catheter in artery	N		N1				
36260	Insertion of infusion pump	Y		A2	\$510.00	28.8743	\$1,195.42	\$681.36
36261	Revision of infusion pump	Y		A2	\$446.00	23.9802	\$992.80	\$582.70
36262	Removal of infusion pump	Y		A2	\$333.00	23.9802	\$992.80	\$497.95
36400	BI draw < 3 yrs fem/jugular	N		N1				
36405	BI draw < 3 yrs scalp vein	N		N1				
36406	BI draw < 3 yrs other vein	N		N1				
36410	Non-routine bl draw > 3 yrs	N		N1				
36416	Capillary blood draw	N		N1				
36420	Vein access cutdown < 1 yr	Y		G2		0.2143	\$8.87	\$8.87
36425	Vein access cutdown > 1 yr	Y		R2		0.2143	\$8.87	\$8.87
36430	Blood transfusion service	N		P3		0.7983	\$33.05	\$33.05
36440	BI push transfuse, 2 yr or <	N		R2		3.3967	\$140.63	\$140.63
36450	BI exchange/transfuse, nb	N		R2		3.3967	\$140.63	\$140.63
36468	Injection(s), spider veins	Y		R2		0.793	\$32.83	\$32.83
36469	Injection(s), spider veins	Y	CH	R2		0.793	\$32.83	\$32.83

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
36470	Injection therapy of vein	Y		P2		0.793	\$32.83	\$32.83
36471	Injection therapy of veins	Y		P2		0.793	\$32.83	\$32.83
36475	Endovenous rf, 1st vein	Y		A2	\$1,339.00	42.6114	\$1,764.15	\$1,445.29
36476	Endovenous rf, vein add-on	Y		A2	\$1,339.00	25.841	\$1,069.84	\$1,271.71
36478	Endovenous laser, 1st vein	Y		A2	\$1,339.00	25.841	\$1,069.84	\$1,271.71
36479	Endovenous laser vein add-on	Y		A2	\$1,339.00	25.841	\$1,069.84	\$1,271.71
36481	Insertion of catheter, vein	N		N1				
36500	Insertion of catheter, vein	N		N1				
36510	Insertion of catheter, vein	N		N1				
36511	Apheresis wbc	N		G2		11.5058	\$476.35	\$476.35
36512	Apheresis rbc	N		G2		11.5058	\$476.35	\$476.35
36513	Apheresis platelets	N		G2		11.5058	\$476.35	\$476.35
36514	Apheresis plasma	N		G2		11.5058	\$476.35	\$476.35
36515	Apheresis, adsorp/reinfuse	N		G2		30.6035	\$1,267.02	\$1,267.02
36516	Apheresis, selective	N		G2		30.6035	\$1,267.02	\$1,267.02
36522	Photopheresis	N		G2		30.6035	\$1,267.02	\$1,267.02
36540	Collect blood venous device	N	CH	D5				
36550	Declot vascular device	N	CH	D5				
36555	Insert non-tunnel cv cath	Y		A2	\$333.00	10.9092	\$451.65	\$362.66
36556	Insert non-tunnel cv cath	Y		A2	\$333.00	10.9092	\$451.65	\$362.66
36557	Insert tunneled cv cath	Y		A2	\$446.00	24.1069	\$998.05	\$584.01
36558	Insert tunneled cv cath	Y		A2	\$446.00	24.1069	\$998.05	\$584.01
36560	Insert tunneled cv cath	Y		A2	\$510.00	28.8743	\$1,195.42	\$681.36
36561	Insert tunneled cv cath	Y		A2	\$510.00	28.8743	\$1,195.42	\$681.36
36563	Insert tunneled cv cath	Y		A2	\$510.00	28.8743	\$1,195.42	\$681.36
36565	Insert tunneled cv cath	Y		A2	\$510.00	28.8743	\$1,195.42	\$681.36
36566	Insert tunneled cv cath	Y		H8	\$510.00	107.6665	\$4,457.50	\$3,796.23
36568	Insert picc cath	Y		A2	\$333.00	10.9092	\$451.65	\$362.66
36569	Insert picc cath	Y		A2	\$333.00	10.9092	\$451.65	\$362.66
36570	Insert picvad cath	Y		A2	\$510.00	24.1069	\$998.05	\$632.01
36571	Insert picvad cath	Y		A2	\$510.00	24.1069	\$998.05	\$632.01
36575	Repair tunneled cv cath	Y		A2	\$446.00	5.6614	\$234.39	\$393.10
36576	Repair tunneled cv cath	Y		A2	\$446.00	10.9092	\$451.65	\$447.41
36578	Replace tunneled cv cath	Y		A2	\$446.00	24.1069	\$998.05	\$584.01
36580	Replace cvad cath	Y		A2	\$333.00	10.9092	\$451.65	\$362.66
36581	Replace tunneled cv cath	Y		A2	\$446.00	24.1069	\$998.05	\$584.01
36582	Replace tunneled cv cath	Y		A2	\$510.00	28.8743	\$1,195.42	\$681.36
36583	Replace tunneled cv cath	Y		A2	\$510.00	28.8743	\$1,195.42	\$681.36
36584	Replace picc cath	Y		A2	\$333.00	10.9092	\$451.65	\$362.66
36585	Replace picvad cath	Y		A2	\$510.00	24.1069	\$998.05	\$632.01
36589	Removal tunneled cv cath	Y		A2	\$333.00	5.6614	\$234.39	\$308.35
36590	Removal tunneled cv cath	Y		A2	\$333.00	10.9092	\$451.65	\$362.66
36591	Draw blood off venous device	N	NI	N1				
36592	Collect blood from picc	N	NI	N1				
36593	Declot vascular device	Y	NI	P3		0.4937	\$20.44	\$20.44
36595	Mech remov tunneled cv cath	Y		G2		24.1069	\$998.05	\$998.05
36596	Mech remov tunneled cv cath	Y		G2		10.9092	\$451.65	\$451.65
36597	Reposition venous catheter	Y		G2		10.9092	\$451.65	\$451.65
36598	Inj w/fluor, eval cv device	Y	CH	P3		1.9997	\$82.79	\$82.79
36600	Withdrawal of arterial blood	N		N1				
36620	Insertion catheter, artery	N		N1				
36625	Insertion catheter, artery	N		N1				
36640	Insertion catheter, artery	Y		A2	\$333.00	28.8743	\$1,195.42	\$548.61
36680	Insert needle, bone cavity	Y		G2		1.1097	\$45.94	\$45.94
36800	Insertion of cannula	Y		A2	\$510.00	29.6965	\$1,229.46	\$689.87
36810	Insertion of cannula	Y		A2	\$510.00	29.6965	\$1,229.46	\$689.87
36815	Insertion of cannula	Y		A2	\$510.00	29.6965	\$1,229.46	\$689.87
36818	Av fuse, uppr arm, cephalic	Y		A2	\$510.00	38.7673	\$1,605.00	\$783.75
36819	Av fuse, uppr arm, basilic	Y		A2	\$510.00	38.7673	\$1,605.00	\$783.75
36820	Av fusion/forearm vein	Y		A2	\$510.00	38.7673	\$1,605.00	\$783.75
36821	Av fusion direct any site	Y		A2	\$510.00	38.7673	\$1,605.00	\$783.75
36825	Artery-vein autograft	Y		A2	\$630.00	38.7673	\$1,605.00	\$873.75
36830	Artery-vein nonautograft	Y		A2	\$630.00	38.7673	\$1,605.00	\$873.75
36831	Open thrombect av fistula	Y		A2	\$1,339.00	38.7673	\$1,605.00	\$1,405.50
36832	Av fistula revision, open	Y		A2	\$630.00	38.7673	\$1,605.00	\$873.75
36833	Av fistula revision	Y		A2	\$630.00	38.7673	\$1,605.00	\$873.75
36834	Repair a-v aneurysm	Y		A2	\$510.00	38.7673	\$1,605.00	\$783.75
36835	Artery to vein shunt	Y		A2	\$630.00	29.6965	\$1,229.46	\$779.87
36860	External cannula declotting	Y		A2	\$127.40	2.4824	\$102.77	\$121.24
36861	Cannula declotting	Y		A2	\$510.00	29.6965	\$1,229.46	\$689.87
36870	Percut thrombect av fistula	Y		A2	\$1,339.00	40.4667	\$1,675.36	\$1,423.09
37184	Prim art mech thrombectomy	Y		G2		38.7673	\$1,605.00	\$1,605.00
37185	Prim art m-thrombect add-on	Y		G2		38.7673	\$1,605.00	\$1,605.00

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
37186	Sec art m-thrombect add-on	Y		G2		38.7673	\$1,605.00	\$1,605.00
37187	Venous mech thrombectomy	Y		G2		38.7673	\$1,605.00	\$1,605.00
37188	Venous m-thrombectomy add-on	Y		G2		38.7673	\$1,605.00	\$1,605.00
37200	Transcatheter biopsy	Y		G2		28.8743	\$1,195.42	\$1,195.42
37203	Transcatheter retrieval	Y		G2		28.8743	\$1,195.42	\$1,195.42
37250	Iv us first vessel add-on	N		CH N1				
37251	Iv us each add vessel add-on	N		CH N1				
37500	Endoscopy ligate perf veins	Y		A2	\$510.00	42.6114	\$1,764.15	\$823.54
37607	Ligation of a-v fistula	Y		A2	\$510.00	25.841	\$1,069.84	\$649.96
37609	Temporal artery procedure	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
37650	Revision of major vein	Y		A2	\$446.00	25.841	\$1,069.84	\$601.96
37700	Revise leg vein	Y		A2	\$446.00	25.841	\$1,069.84	\$601.96
37718	Ligate/strip short leg vein	Y		A2	\$510.00	25.841	\$1,069.84	\$649.96
37722	Ligate/strip long leg vein	Y		A2	\$510.00	42.6114	\$1,764.15	\$823.54
37735	Removal of leg veins/lesion	Y		A2	\$510.00	42.6114	\$1,764.15	\$823.54
37760	Ligation, leg veins, open	Y		A2	\$510.00	25.841	\$1,069.84	\$649.96
37765	Phleb veins extrem 10-20	Y		R2		25.841	\$1,069.84	\$1,069.84
37766	Phleb veins extrem 20+	Y		R2		25.841	\$1,069.84	\$1,069.84
37780	Revision of leg vein	Y		A2	\$510.00	25.841	\$1,069.84	\$649.96
37785	Ligate/divide/excise vein	Y		A2	\$510.00	25.841	\$1,069.84	\$649.96
37790	Penile venous occlusion	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
38200	Injection for spleen x-ray	N		N1				
38204	BI donor search management	N		N1				
38205	Harvest allogenic stem cells	N		G2		11.5058	\$476.35	\$476.35
38206	Harvest auto stem cells	N		G2		11.5058	\$476.35	\$476.35
38220	Bone marrow aspiration	Y		CH P3		2.6333	\$109.02	\$109.02
38221	Bone marrow biopsy	Y		CH P3		2.7649	\$114.47	\$114.47
38230	Bone marrow collection	N		G2		30.6035	\$1,267.02	\$1,267.02
38241	Bone marrow/stem transplant	N		G2		30.6035	\$1,267.02	\$1,267.02
38242	Lymphocyte infuse transplant	N		R2		11.5058	\$476.35	\$476.35
38300	Drainage, lymph node lesion	Y		A2	\$333.00	11.5594	\$478.57	\$369.39
38305	Drainage, lymph node lesion	Y		A2	\$446.00	18.3197	\$758.45	\$524.11
38308	Incision of lymph channels	Y		A2	\$446.00	22.9584	\$950.50	\$572.13
38500	Biopsy/removal, lymph nodes	Y		A2	\$446.00	22.9584	\$950.50	\$572.13
38505	Needle biopsy, lymph nodes	Y		A2	\$240.00	7.1147	\$294.56	\$253.64
38510	Biopsy/removal, lymph nodes	Y		A2	\$446.00	22.9584	\$950.50	\$572.13
38520	Biopsy/removal, lymph nodes	Y		A2	\$446.00	22.9584	\$950.50	\$572.13
38525	Biopsy/removal, lymph nodes	Y		A2	\$446.00	22.9584	\$950.50	\$572.13
38530	Biopsy/removal, lymph nodes	Y		A2	\$446.00	22.9584	\$950.50	\$572.13
38542	Explore deep node(s), neck	Y		A2	\$446.00	44.324	\$1,835.06	\$793.27
38550	Removal, neck/arpit lesion	Y		A2	\$510.00	22.9584	\$950.50	\$620.13
38555	Removal, neck/arpit lesion	Y		A2	\$630.00	22.9584	\$950.50	\$710.13
38570	Laparoscopy, lymph node biop	Y		A2	\$1,339.00	45.5317	\$1,885.06	\$1,475.52
38571	Laparoscopy, lymphadenectomy	Y		A2	\$1,339.00	69.6652	\$2,884.21	\$1,725.30
38572	Laparoscopy, lymphadenectomy	Y		A2	\$1,339.00	45.5317	\$1,885.06	\$1,475.52
38700	Removal of lymph nodes, neck	Y		G2		22.9584	\$950.50	\$950.50
38740	Remove armpit lymph nodes	Y		A2	\$446.00	44.324	\$1,835.06	\$793.27
38745	Remove armpit lymph nodes	Y		A2	\$630.00	44.324	\$1,835.06	\$931.27
38760	Remove groin lymph nodes	Y		A2	\$446.00	22.9584	\$950.50	\$572.13
38790	Inject for lymphatic x-ray	N		N1				
38792	Identify sentinel node	N		N1				
38794	Access thoracic lymph duct	N		N1				
40490	Biopsy of lip	Y		P3		1.5224	\$63.03	\$63.03
40500	Partial excision of lip	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
40510	Partial excision of lip	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
40520	Partial excision of lip	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
40525	Reconstruct lip with flap	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
40527	Reconstruct lip with flap	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
40530	Partial removal of lip	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
40650	Repair lip	Y		A2	\$464.15	7.4474	\$308.33	\$425.20
40652	Repair lip	Y		A2	\$464.15	7.4474	\$308.33	\$425.20
40654	Repair lip	Y		A2	\$464.15	7.4474	\$308.33	\$425.20
40700	Repair cleft lip/nasal	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
40701	Repair cleft lip/nasal	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
40702	Repair cleft lip/nasal	Y		R2		39.8776	\$1,650.97	\$1,650.97
40720	Repair cleft lip/nasal	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
40761	Repair cleft lip/nasal	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
40800	Drainage of mouth lesion	Y		P2	1.4066		\$58.23	\$58.23
40801	Drainage of mouth lesion	Y		A2	\$446.00	7.4474	\$308.33	\$411.58
40804	Removal, foreign body, mouth	N		P2		0.631	\$26.12	\$26.12
40805	Removal, foreign body, mouth	Y		P3		3.9499	\$163.53	\$163.53
40806	Incision of lip fold	Y		P3		1.7529	\$72.57	\$72.57
40808	Biopsy of mouth lesion	Y		P2		2.5002	\$103.51	\$103.51

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
40810	Excision of mouth lesion	Y		P3		2.699	\$111.74	\$111.74
40812	Excise/repair mouth lesion	Y		P3		3.3985	\$140.70	\$140.70
40814	Excise/repair mouth lesion	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
40816	Excision of mouth lesion	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
40818	Excise oral mucosa for graft	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
40819	Excise lip or cheek fold	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
40820	Treatment of mouth lesion	Y		P3		3.7934	\$157.05	\$157.05
40830	Repair mouth laceration	Y		G2		2.5002	\$103.51	\$103.51
40831	Repair mouth laceration	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
40840	Reconstruction of mouth	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
40842	Reconstruction of mouth	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
40843	Reconstruction of mouth	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
40844	Reconstruction of mouth	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
40845	Reconstruction of mouth	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
41000	Drainage of mouth lesion	Y		P3		1.9997	\$82.79	\$82.79
41005	Drainage of mouth lesion	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
41006	Drainage of mouth lesion	Y		A2	\$333.00	23.9765	\$992.65	\$497.91
41007	Drainage of mouth lesion	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
41008	Drainage of mouth lesion	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
41009	Drainage of mouth lesion	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
41010	Incision of tongue fold	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
41015	Drainage of mouth lesion	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
41016	Drainage of mouth lesion	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
41017	Drainage of mouth lesion	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
41018	Drainage of mouth lesion	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
41019	Place needles h&n for rt	Y	NI	G2		23.9765	\$992.65	\$992.65
41100	Biopsy of tongue	Y		P3		2.0983	\$86.87	\$86.87
41105	Biopsy of tongue	Y		P3		2.049	\$84.83	\$84.83
41108	Biopsy of floor of mouth	Y		P3		1.8927	\$78.36	\$78.36
41110	Excision of tongue lesion	Y		P3		2.7321	\$113.11	\$113.11
41112	Excision of tongue lesion	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
41113	Excision of tongue lesion	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
41114	Excision of tongue lesion	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
41115	Excision of tongue fold	Y		P3		3.0777	\$127.42	\$127.42
41116	Excision of mouth lesion	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
41120	Partial removal of tongue	Y		A2	\$717.00	23.9765	\$992.65	\$785.91
41250	Repair tongue laceration	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
41251	Repair tongue laceration	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
41252	Repair tongue laceration	Y		A2	\$446.00	7.4474	\$308.33	\$411.58
41500	Fixation of tongue	Y		A2	\$333.00	23.9765	\$992.65	\$497.91
41510	Tongue to lip surgery	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
41520	Reconstruction, tongue fold	Y		A2	\$446.00	7.4474	\$308.33	\$411.58
41800	Drainage of gum lesion	Y		A2	\$88.46	1.4066	\$58.23	\$80.90
41805	Removal foreign body, gum	Y		P3		3.0036	\$124.35	\$124.35
41806	Removal foreign body,jawbone	Y		P3		3.8675	\$160.12	\$160.12
41820	Excision, gum, each quadrant	Y		R2		7.4474	\$308.33	\$308.33
41821	Excision of gum flap	Y		G2		7.4474	\$308.33	\$308.33
41822	Excision of gum lesion	Y		P3		3.5714	\$147.86	\$147.86
41823	Excision of gum lesion	Y		P3		4.9455	\$204.75	\$204.75
41825	Excision of gum lesion	Y		P3		2.7731	\$114.81	\$114.81
41826	Excision of gum lesion	Y		P3		3.0941	\$128.10	\$128.10
41827	Excision of gum lesion	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
41828	Excision of gum lesion	Y		P3		3.2422	\$134.23	\$134.23
41830	Removal of gum tissue	Y		P3		4.5011	\$186.35	\$186.35
41850	Treatment of gum lesion	Y		R2		16.3288	\$676.03	\$676.03
41870	Gum graft	Y		G2		23.9765	\$992.65	\$992.65
41872	Repair gum	Y		P3		4.5506	\$188.40	\$188.40
41874	Repair tooth socket	Y		P3		4.3202	\$178.86	\$178.86
42000	Drainage mouth roof lesion	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
42100	Biopsy roof of mouth	Y		P3		1.7939	\$74.27	\$74.27
42104	Excision lesion, mouth roof	Y		P3		2.5181	\$104.25	\$104.25
42106	Excision lesion, mouth roof	Y		P3		3.1516	\$130.48	\$130.48
42107	Excision lesion, mouth roof	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
42120	Remove palate/lesion	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
42140	Excision of uvula	Y		A2	\$446.00	7.4474	\$308.33	\$411.58
42145	Repair palate, pharynx/uvula	Y		A2	\$717.00	23.9765	\$992.65	\$785.91
42160	Treatment mouth roof lesion	Y		P3		3.2997	\$136.61	\$136.61
42180	Repair palate	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
42182	Repair palate	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
42200	Reconstruct cleft palate	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
42205	Reconstruct cleft palate	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
42210	Reconstruct cleft palate	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
42215	Reconstruct cleft palate	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
42220	Reconstruct cleft palate	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
42226	Lengthening of palate	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
42235	Repair palate	Y		A2	\$717.00	16.3288	\$676.03	\$706.76
42260	Repair nose to lip fistula	Y		A2	\$630.00	23.9765	\$992.65	\$720.66
42280	Preparation, palate mold	Y		P3		1.728	\$71.54	\$71.54
42281	Insertion, palate prosthesis	Y		G2		16.3288	\$676.03	\$676.03
42300	Drainage of salivary gland	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
42305	Drainage of salivary gland	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
42310	Drainage of salivary gland	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
42320	Drainage of salivary gland	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
42330	Removal of salivary stone	Y		P3		2.6908	\$111.40	\$111.40
42335	Removal of salivary stone	Y		P3		4.3859	\$181.58	\$181.58
42340	Removal of salivary stone	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
42400	Biopsy of salivary gland	Y		P3		1.4975	\$62.00	\$62.00
42405	Biopsy of salivary gland	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
42408	Excision of salivary cyst	Y		A2	\$510.00	16.3288	\$676.03	\$551.51
42409	Drainage of salivary cyst	Y		A2	\$510.00	16.3288	\$676.03	\$551.51
42410	Excise parotid gland/lesion	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
42415	Excise parotid gland/lesion	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
42420	Excise parotid gland/lesion	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
42425	Excise parotid gland/lesion	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
42440	Excise submaxillary gland	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
42450	Excise sublingual gland	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
42500	Repair salivary duct	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
42505	Repair salivary duct	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
42507	Parotid duct diversion	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
42508	Parotid duct diversion	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
42509	Parotid duct diversion	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
42510	Parotid duct diversion	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
42550	Injection for salivary x-ray	N		N1				
42600	Closure of salivary fistula	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
42650	Dilation of salivary duct	Y		P3		0.9792	\$40.54	\$40.54
42660	Dilation of salivary duct	Y		P3		1.1521	\$47.70	\$47.70
42665	Ligation of salivary duct	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
42700	Drainage of tonsil abscess	Y		A2	\$150.72	2.5002	\$103.51	\$138.92
42720	Drainage of throat abscess	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
42725	Drainage of throat abscess	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
42800	Biopsy of throat	Y		P3		1.9091	\$79.04	\$79.04
42802	Biopsy of throat	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
42804	Biopsy of upper nose/throat	Y		A2	\$333.00	16.3288	\$676.03	\$418.76
42806	Biopsy of upper nose/throat	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
42808	Excise pharynx lesion	Y		A2	\$446.00	16.3288	\$676.03	\$503.51
42809	Remove pharynx foreign body	N		G2		0.631	\$26.12	\$26.12
42810	Excision of neck cyst	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
42815	Excision of neck cyst	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
42820	Remove tonsils and adenoids	Y		A2	\$510.00	22.2557	\$921.41	\$612.85
42821	Remove tonsils and adenoids	Y		A2	\$717.00	22.2557	\$921.41	\$768.10
42825	Removal of tonsils	Y		A2	\$630.00	22.2557	\$921.41	\$702.85
42826	Removal of tonsils	Y		A2	\$630.00	22.2557	\$921.41	\$702.85
42830	Removal of adenoids	Y		A2	\$630.00	22.2557	\$921.41	\$702.85
42831	Removal of adenoids	Y		A2	\$630.00	22.2557	\$921.41	\$702.85
42835	Removal of adenoids	Y		A2	\$630.00	22.2557	\$921.41	\$702.85
42836	Removal of adenoids	Y		A2	\$630.00	22.2557	\$921.41	\$702.85
42860	Excision of tonsil tags	Y		A2	\$510.00	22.2557	\$921.41	\$612.85
42870	Excision of lingual tonsil	Y		A2	\$510.00	22.2557	\$921.41	\$612.85
42890	Partial removal of pharynx	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
42892	Revision of pharyngeal walls	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
42900	Repair throat wound	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
42950	Reconstruction of throat	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
42955	Surgical opening of throat	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
42960	Control throat bleeding	Y		A2	\$72.48	1.1251	\$46.58	\$66.01
42962	Control throat bleeding	Y		A2	\$446.00	39.8776	\$1,650.97	\$747.24
42970	Control nose/throat bleeding	Y		R2		1.1251	\$46.58	\$46.58
42972	Control nose/throat bleeding	Y		A2	\$510.00	16.3288	\$676.03	\$551.51
43030	Throat muscle surgery	Y		G2		16.3288	\$676.03	\$676.03
43200	Esophagus endoscopy	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43201	Esoph scope w/submucous inj	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43202	Esophagus endoscopy, biopsy	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43204	Esoph scope w/sclerosis inj	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43205	Esophagus endoscopy/ligation	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43215	Esophagus endoscopy	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43216	Esophagus endoscopy/lesion	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43217	Esophagus endoscopy	Y		A2	\$333.00	8.503	\$352.03	\$337.76

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
43219	Esophagus endoscopy	Y		A2	\$333.00	24.9814	\$1,034.25	\$508.31
43220	Esoph endoscopy, dilation	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43226	Esoph endoscopy, dilation	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43227	Esoph endoscopy, repair	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43228	Esoph endoscopy, ablation	Y		A2	\$446.00	25.3233	\$1,048.41	\$596.60
43231	Esoph endoscopy w/us exam	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43232	Esoph endoscopy w/us fn bx	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43234	Upper gi endoscopy, exam	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43235	Uppr gi endoscopy, diagnosis	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43236	Uppr gi scope w/submuc inj	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43237	Endoscopic us exam, esoph	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43238	Uppr gi endoscopy w/us fn bx	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43239	Uppr gi endoscopy, biopsy	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43240	Esoph endoscope w/drain cyst	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43241	Upper gi endoscopy with tube	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43242	Uppr gi endoscopy w/us fn bx	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43243	Upper gi endoscopy & inject	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43244	Uppr gi endoscopy/ligation	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43245	Uppr gi scope dilate strict	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43246	Place gastrostomy tube	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43247	Operative upper gi endoscopy	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43248	Uppr gi endoscopy/guide wire	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43249	Esoph endoscopy, dilation	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43250	Upper gi endoscopy/tumor	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43251	Operative upper gi endoscopy	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43255	Operative upper gi endoscopy	Y		A2	\$446.00	8.503	\$352.03	\$422.51
43256	Uppr gi endoscopy w/stent	Y		A2	\$510.00	24.9814	\$1,034.25	\$641.06
43257	Uppr gi scope w/thrml txmnt	Y		A2	\$510.00	25.3233	\$1,048.41	\$644.60
43258	Operative upper gi endoscopy	Y		A2	\$510.00	8.503	\$352.03	\$470.51
43259	Endoscopic ultrasound exam	Y		A2	\$510.00	8.503	\$352.03	\$470.51
43260	Endo cholangiopancreatograph	Y		A2	\$446.00	20.951	\$867.39	\$551.35
43261	Endo cholangiopancreatograph	Y		A2	\$446.00	20.951	\$867.39	\$551.35
43262	Endo cholangiopancreatograph	Y		A2	\$446.00	20.951	\$867.39	\$551.35
43263	Endo cholangiopancreatograph	Y		A2	\$446.00	20.951	\$867.39	\$551.35
43264	Endo cholangiopancreatograph	Y		A2	\$446.00	20.951	\$867.39	\$551.35
43265	Endo cholangiopancreatograph	Y		A2	\$446.00	20.951	\$867.39	\$551.35
43267	Endo cholangiopancreatograph	Y		A2	\$446.00	20.951	\$867.39	\$551.35
43268	Endo cholangiopancreatograph	Y		A2	\$446.00	24.9814	\$1,034.25	\$593.06
43269	Endo cholangiopancreatograph	Y		A2	\$446.00	24.9814	\$1,034.25	\$593.06
43271	Endo cholangiopancreatograph	Y		A2	\$446.00	20.951	\$867.39	\$551.35
43272	Endo cholangiopancreatograph	Y		A2	\$446.00	20.951	\$867.39	\$551.35
43450	Dilate esophagus	Y		A2	\$333.00	5.8431	\$241.91	\$310.23
43453	Dilate esophagus	Y		A2	\$333.00	5.8431	\$241.91	\$310.23
43456	Dilate esophagus	Y		A2	\$335.41	5.8431	\$241.91	\$312.04
43458	Dilate esophagus	Y		A2	\$335.41	8.503	\$352.03	\$339.57
43600	Biopsy of stomach	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43653	Laparoscopy, gastrostomy	Y		A2	\$1,339.00	45.5317	\$1,885.06	\$1,475.52
43750	Place gastrostomy tube	N	CH	D5				
43760	Change gastrostomy tube	Y		A2	\$144.98	3.2383	\$134.07	\$142.25
43761	Reposition gastrostomy tube	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43870	Repair stomach opening	Y		A2	\$333.00	8.503	\$352.03	\$337.76
43886	Revise gastric port, open	Y		G2		20.2069	\$836.59	\$836.59
43887	Remove gastric port, open	Y		G2		4.5263	\$187.39	\$187.39
43888	Change gastric port, open	Y		G2		20.2069	\$836.59	\$836.59
44100	Biopsy of bowel	Y		A2	\$333.00	8.503	\$352.03	\$337.76
44312	Revision of ileostomy	Y		A2	\$333.00	20.2069	\$836.59	\$458.90
44340	Revision of colostomy	Y		A2	\$510.00	20.2069	\$836.59	\$591.65
44360	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44361	Small bowel endoscopy/biopsy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44363	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44364	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44365	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44366	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44369	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44370	Small bowel endoscopy/stent	Y		A2	\$1,339.00	24.9814	\$1,034.25	\$1,262.81
44372	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44373	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44376	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44377	Small bowel endoscopy/biopsy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44378	Small bowel endoscopy	Y		A2	\$446.00	9.5292	\$394.52	\$433.13
44379	S bowel endoscope w/stent	Y		A2	\$1,339.00	24.9814	\$1,034.25	\$1,262.81
44380	Small bowel endoscopy	Y		A2	\$333.00	9.5292	\$394.52	\$348.38
44382	Small bowel endoscopy	Y		A2	\$333.00	9.5292	\$394.52	\$348.38

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPSC code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
44383	Ileoscopy w/stent	Y		A2	\$1,339.00	24.9814	\$1,034.25	\$1,262.81
44385	Endoscopy of bowel pouch	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
44386	Endoscopy, bowel pouch/biops	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
44388	Colonoscopy	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
44389	Colonoscopy with biopsy	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
44390	Colonoscopy for foreign body	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
44391	Colonoscopy for bleeding	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
44392	Colonoscopy & polypectomy	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
44393	Colonoscopy, lesion removal	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
44394	Colonoscopy w/snare	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
44397	Colonoscopy w/stent	Y		A2	\$333.00	24.9814	\$1,034.25	\$508.31
44500	Intro, gastrointestinal tube	Y	CH	G2		3.2383	\$134.07	\$134.07
44701	Intraop colon lavage add-on	N		N1				
45000	Drainage of pelvic abscess	Y		A2	\$312.07	10.9132	\$451.82	\$347.01
45005	Drainage of rectal abscess	Y		A2	\$446.00	10.9132	\$451.82	\$447.46
45020	Drainage of rectal abscess	Y		A2	\$446.00	10.9132	\$451.82	\$447.46
45100	Biopsy of rectum	Y		A2	\$333.00	22.7451	\$941.67	\$485.17
45108	Removal of anorectal lesion	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
45150	Excision of rectal stricture	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
45160	Excision of rectal lesion	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
45170	Excision of rectal lesion	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
45190	Destruction, rectal tumor	Y		A2	\$1,339.00	22.7451	\$941.67	\$1,239.67
45300	Proctosigmoidoscopy dx	Y		P3		1.4318	\$59.28	\$59.28
45303	Proctosigmoidoscopy dilate	Y		P2		8.7031	\$360.32	\$360.32
45305	Proctosigmoidoscopy w/bx	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45307	Proctosigmoidoscopy fb	Y		A2	\$333.00	21.4632	\$888.60	\$471.90
45308	Proctosigmoidoscopy removal	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45309	Proctosigmoidoscopy removal	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45315	Proctosigmoidoscopy removal	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45317	Proctosigmoidoscopy bleed	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45320	Proctosigmoidoscopy ablate	Y		A2	\$333.00	21.4632	\$888.60	\$471.90
45321	Proctosigmoidoscopy volvul	Y		A2	\$333.00	21.4632	\$888.60	\$471.90
45327	Proctosigmoidoscopy w/stent	Y		A2	\$333.00	24.9814	\$1,034.25	\$508.31
45330	Diagnostic sigmoidoscopy	Y		P3		1.9748	\$81.76	\$81.76
45331	Sigmoidoscopy and biopsy	Y		A2	\$299.24	5.0972	\$211.03	\$277.19
45332	Sigmoidoscopy w/fb removal	Y		A2	\$299.24	5.0972	\$211.03	\$277.19
45333	Sigmoidoscopy & polypectomy	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45334	Sigmoidoscopy for bleeding	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45335	Sigmoidoscopy w/submuc inj	Y		A2	\$299.24	5.0972	\$211.03	\$277.19
45337	Sigmoidoscopy & decompress	Y		A2	\$299.24	5.0972	\$211.03	\$277.19
45338	Sigmoidoscopy w/tumr remove	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45339	Sigmoidoscopy w/ablate tumr	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45340	Sig w/balloon dilation	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45341	Sigmoidoscopy w/ultrasound	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45342	Sigmoidoscopy w/us guide bx	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
45345	Sigmoidoscopy w/stent	Y		A2	\$333.00	24.9814	\$1,034.25	\$508.31
45355	Surgical colonoscopy	Y		A2	\$333.00	8.8486	\$366.34	\$341.34
45378	Diagnostic colonoscopy	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45379	Colonoscopy w/fb removal	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45380	Colonoscopy and biopsy	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45381	Colonoscopy, submucous inj	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45382	Colonoscopy/control bleeding	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45383	Lesion removal colonoscopy	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45384	Lesion remove colonoscopy	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45385	Lesion removal colonoscopy	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45386	Colonoscopy dilate stricture	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45387	Colonoscopy w/stent	Y		A2	\$333.00	24.9814	\$1,034.25	\$508.31
45391	Colonoscopy w/endoscope us	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45392	Colonoscopy w/endoscopic fnb	Y		A2	\$446.00	8.8486	\$366.34	\$426.09
45500	Repair of rectum	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
45505	Repair of rectum	Y		A2	\$446.00	30.1606	\$1,248.68	\$646.67
45520	Treatment of rectal prolapse	Y		P2		0.793	\$32.83	\$32.83
45560	Repair of rectocele	Y		A2	\$446.00	30.1606	\$1,248.68	\$646.67
45900	Reduction of rectal prolapse	Y		A2	\$312.07	4.7935	\$198.46	\$283.67
45905	Dilation of anal sphincter	Y		A2	\$333.00	22.7451	\$941.67	\$485.17
45910	Dilation of rectal narrowing	Y		A2	\$333.00	22.7451	\$941.67	\$485.17
45915	Remove rectal obstruction	Y		A2	\$312.07	10.9132	\$451.82	\$347.01
45990	Surg dx exam, anorectal	Y		A2	\$312.07	22.7451	\$941.67	\$469.47
46020	Placement of seton	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46030	Removal of rectal marker	Y		A2	\$312.07	4.7935	\$198.46	\$283.67
46040	Incision of rectal abscess	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46045	Incision of rectal abscess	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
46050	Incision of anal abscess	Y		A2	\$312.07	10.9132	\$451.82	\$347.01

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPSC codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
46060	Incision of rectal abscess	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
46070	Incision of anal septum	Y		G2		10.9132	\$451.82	\$451.82
46080	Incision of anal sphincter	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46083	Incise external hemorrhoid	Y		P3		2.0079	\$83.13	\$83.13
46200	Removal of anal fissure	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
46210	Removal of anal crypt	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
46211	Removal of anal crypts	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
46220	Removal of anal tag	Y		A2	\$333.00	22.7451	\$941.67	\$485.17
46221	Ligation of hemorrhoid(s)	Y		P3		2.6251	\$108.68	\$108.68
46230	Removal of anal tags	Y		A2	\$333.00	22.7451	\$941.67	\$485.17
46250	Hemorrhoidectomy	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46255	Hemorrhoidectomy	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46257	Remove hemorrhoids & fissure	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46258	Remove hemorrhoids & fistula	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46260	Hemorrhoidectomy	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46261	Remove hemorrhoids & fissure	Y		A2	\$630.00	22.7451	\$941.67	\$707.92
46262	Remove hemorrhoids & fistula	Y		A2	\$630.00	22.7451	\$941.67	\$707.92
46270	Removal of anal fistula	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46275	Removal of anal fistula	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46280	Removal of anal fistula	Y		A2	\$630.00	22.7451	\$941.67	\$707.92
46285	Removal of anal fistula	Y		A2	\$333.00	22.7451	\$941.67	\$485.17
46288	Repair anal fistula	Y		A2	\$630.00	22.7451	\$941.67	\$707.92
46320	Removal of hemorrhoid clot	Y		P3		1.8596	\$76.99	\$76.99
46500	Injection into hemorrhoid(s)	Y		P3		2.3536	\$97.44	\$97.44
46505	Chemodenervation anal musc	Y		G2		4.7935	\$198.46	\$198.46
46600	Diagnostic anoscopy	N		P2		0.631	\$26.12	\$26.12
46604	Anoscopy and dilation	Y		P2		8.7031	\$360.32	\$360.32
46606	Anoscopy and biopsy	Y		P3		3.1434	\$130.14	\$130.14
46608	Anoscopy, remove for body	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
46610	Anoscopy, remove lesion	Y		A2	\$333.00	21.4632	\$888.60	\$471.90
46611	Anoscopy	Y		A2	\$333.00	8.7031	\$360.32	\$339.83
46612	Anoscopy, remove lesions	Y		A2	\$333.00	21.4632	\$888.60	\$471.90
46614	Anoscopy, control bleeding	Y		P3		1.7529	\$72.57	\$72.57
46615	Anoscopy	Y		A2	\$446.00	21.4632	\$888.60	\$556.65
46700	Repair of anal stricture	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46706	Repr of anal fistula w/glue	Y		A2	\$333.00	30.1606	\$1,248.68	\$561.92
46750	Repair of anal sphincter	Y		A2	\$510.00	30.1606	\$1,248.68	\$694.67
46753	Reconstruction of anus	Y		A2	\$510.00	22.7451	\$941.67	\$617.92
46754	Removal of suture from anus	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
46760	Repair of anal sphincter	Y		A2	\$446.00	30.1606	\$1,248.68	\$646.67
46761	Repair of anal sphincter	Y		A2	\$510.00	30.1606	\$1,248.68	\$694.67
46762	Implant artificial sphincter	Y		A2	\$995.00	30.1606	\$1,248.68	\$1,058.42
46900	Destruction, anal lesion(s)	Y		P3		2.5673	\$106.29	\$106.29
46910	Destruction, anal lesion(s)	Y		P3		2.7895	\$115.49	\$115.49
46916	Cryosurgery, anal lesion(s)	Y		P2		1.4595	\$60.42	\$60.42
46917	Laser surgery, anal lesions	Y		A2	\$333.00	19.9041	\$824.05	\$455.76
46922	Excision of anal lesion(s)	Y		A2	\$333.00	19.9041	\$824.05	\$455.76
46924	Destruction, anal lesion(s)	Y		A2	\$333.00	19.9041	\$824.05	\$455.76
46934	Destruction of hemorrhoids	Y		P3		4.3695	\$180.90	\$180.90
46935	Destruction of hemorrhoids	Y		P3		3.0118	\$124.69	\$124.69
46936	Destruction of hemorrhoids	Y		P3		4.567	\$189.08	\$189.08
46937	Cryotherapy of rectal lesion	Y		A2	\$446.00	22.7451	\$941.67	\$569.92
46938	Cryotherapy of rectal lesion	Y		A2	\$446.00	30.1606	\$1,248.68	\$646.67
46940	Treatment of anal fissure	Y		P3		1.9915	\$82.45	\$82.45
46942	Treatment of anal fissure	Y		P3		1.9091	\$79.04	\$79.04
46945	Ligation of hemorrhoids	Y		P3		3.3161	\$137.29	\$137.29
46946	Ligation of hemorrhoids	Y		A2	\$333.00	10.9132	\$451.82	\$362.71
46947	Hemorrhoidopexy by stapling	Y		A2	\$995.00	30.1606	\$1,248.68	\$1,058.42
47000	Needle biopsy of liver	Y		A2	\$333.00	9.3354	\$386.49	\$346.37
47001	Needle biopsy, liver add-on	N		N1				
47382	Percut ablate liver rf	Y		G2		42.998	\$1,780.16	\$1,780.16
47500	Injection for liver x-rays	N		N1				
47505	Injection for liver x-rays	N		N1				
47510	Insert catheter, bile duct	Y		A2	\$446.00	28.6884	\$1,187.73	\$631.43
47511	Insert bile duct drain	Y		A2	\$1,245.85	28.6884	\$1,187.73	\$1,231.32
47525	Change bile duct catheter	Y		A2	\$333.00	15.3545	\$635.69	\$408.67
47530	Revise/reinsert bile tube	Y		A2	\$333.00	15.3545	\$635.69	\$408.67
47552	Biliary endoscopy thru skin	Y		A2	\$446.00	28.6884	\$1,187.73	\$631.43
47553	Biliary endoscopy thru skin	Y		A2	\$510.00	28.6884	\$1,187.73	\$679.43
47554	Biliary endoscopy thru skin	Y		A2	\$510.00	28.6884	\$1,187.73	\$679.43
47555	Biliary endoscopy thru skin	Y		A2	\$510.00	28.6884	\$1,187.73	\$679.43
47556	Biliary endoscopy thru skin	Y		A2	\$1,245.85	28.6884	\$1,187.73	\$1,231.32
47560	Laparoscopy w/cholangio	Y		A2	\$510.00	34.3958	\$1,424.02	\$738.51

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
47561	Laparo w/cholangio/biopsy	Y		A2	\$510.00	34.3958	\$1,424.02	\$738.51
47562	Laparoscopic cholecystectomy	Y		G2		45.5317	\$1,885.06	\$1,885.06
47563	Laparo cholecystectomy/graph	Y		G2		45.5317	\$1,885.06	\$1,885.06
47564	Laparo cholecystectomy/explr	Y		G2		45.5317	\$1,885.06	\$1,885.06
47630	Remove bile duct stone	Y		A2	\$510.00	28.6884	\$1,187.73	\$679.43
48102	Needle biopsy, pancreas	Y		A2	\$333.00	9.3354	\$386.49	\$346.37
49080	Puncture, peritoneal cavity	Y		A2	\$222.78	5.2024	\$215.38	\$220.93
49081	Removal of abdominal fluid	Y		A2	\$222.78	5.2024	\$215.38	\$220.93
49180	Biopsy, abdominal mass	Y		A2	\$333.00	9.3354	\$386.49	\$346.37
49250	Excision of umbilicus	Y		A2	\$630.00	25.6947	\$1,063.79	\$738.45
49320	Diag laparo separate proc	Y		A2	\$510.00	34.3958	\$1,424.02	\$738.51
49321	Laparoscopy, biopsy	Y		A2	\$630.00	34.3958	\$1,424.02	\$828.51
49322	Laparoscopy, aspiration	Y		A2	\$630.00	34.3958	\$1,424.02	\$828.51
49400	Air injection into abdomen	N		N1				
49402	Remove foreign body, abdomen	Y		A2	\$446.00	25.6947	\$1,063.79	\$600.45
49419	Insrt abdom cath for chemotx	Y		A2	\$333.00	29.6965	\$1,229.46	\$557.12
49420	Insert abdom drain, temp	Y		A2	\$333.00	30.7096	\$1,271.41	\$567.60
49421	Insert abdom drain, perm	Y		A2	\$333.00	30.7096	\$1,271.41	\$567.60
49422	Remove perm cannula/catheter	Y		A2	\$333.00	23.9802	\$992.80	\$497.95
49423	Exchange drainage catheter	Y		G2		15.3545	\$635.69	\$635.69
49424	Assess cyst, contrast inject	N		N1				
49426	Revise abdomen-venous shunt	Y		A2	\$446.00	25.6947	\$1,063.79	\$600.45
49427	Injection, abdominal shunt	N		N1				
49429	Removal of shunt	Y		G2		23.9802	\$992.80	\$992.80
49440	Place gastrostomy tube perc	Y	NI	G2		8.503	\$352.03	\$352.03
49441	Place duod/jej tube perc	Y	NI	G2		8.503	\$352.03	\$352.03
49446	Change g-tube to g-j perc	Y	NI	G2		8.503	\$352.03	\$352.03
49450	Replace g/c tube perc	Y	NI	G2		3.2383	\$134.07	\$134.07
49451	Replace duod/jej tube perc	Y	NI	G2		3.2383	\$134.07	\$134.07
49452	Replace g-j tube perc	Y	NI	G2		3.2383	\$134.07	\$134.07
49460	Fix g/colon tube w/device	Y	NI	G2		3.2383	\$134.07	\$134.07
49465	Fluoro exam of g/colon tube	N	NI	N1				
49495	Rpr ing hernia baby, reduc	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49496	Rpr ing hernia baby, blocked	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49500	Rpr ing hernia, init, reduce	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49501	Rpr ing hernia, init blocked	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49505	Prp i/hern init reduc >5 yr	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49507	Prp i/hern init block >5 yr	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49520	Rerepair ing hernia, reduce	Y		A2	\$995.00	30.6788	\$1,270.13	\$1,063.78
49521	Rerepair ing hernia, blocked	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49525	Repair ing hernia, sliding	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49540	Repair lumbar hernia	Y		A2	\$446.00	30.6788	\$1,270.13	\$652.03
49550	Rpr rem hernia, init, reduce	Y		A2	\$717.00	30.6788	\$1,270.13	\$855.28
49553	Rpr fem hernia, init blocked	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49555	Rerepair fem hernia, reduce	Y		A2	\$717.00	30.6788	\$1,270.13	\$855.28
49557	Rerepair fem hernia, blocked	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49560	Rpr ventral hern init, reduc	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49561	Rpr ventral hern init, block	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49565	Rerepair ventrl hern, reduce	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49566	Rerepair ventrl hern, block	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49568	Hernia repair w/mesh	Y		A2	\$995.00	30.6788	\$1,270.13	\$1,063.78
49570	Rpr epigastric hern, reduce	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49572	Rpr epigastric hern, blocked	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49580	Rpr umbil hern, reduc < 5 yr	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49582	Rpr umbil hern, block < 5 yr	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49585	Rpr umbil hern, reduc > 5 yr	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49587	Rpr umbil hern, block > 5 yr	Y		A2	\$1,339.00	30.6788	\$1,270.13	\$1,321.78
49590	Repair spigelian hernia	Y		A2	\$510.00	30.6788	\$1,270.13	\$700.03
49600	Repair umbilical lesion	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
49650	Laparo hernia repair initial	Y		A2	\$630.00	45.5317	\$1,885.06	\$943.77
49651	Laparo hernia repair recur	Y		A2	\$995.00	45.5317	\$1,885.06	\$1,217.52
50200	Biopsy of kidney	Y		A2	\$333.00	9.3354	\$386.49	\$346.37
50382	Change ureter stent, percut	Y		G2		24.7749	\$1,025.71	\$1,025.71
50384	Remove ureter stent, percut	Y		G2		17.942	\$742.82	\$742.82
50385	Change stent via transureth	Y	NI	G2		17.942	\$742.82	\$742.82
50386	Remove stent via transureth	Y	NI	G2		5.9735	\$247.31	\$247.31
50387	Change ext/int ureter stent	Y		G2		15.3545	\$635.69	\$635.69
50389	Remove renal tube w/fluoro	Y		G2		5.9735	\$247.31	\$247.31
50390	Drainage of kidney lesion	Y		A2	\$333.00	9.3354	\$386.49	\$346.37
50391	Instll rx agnt into mal tub	Y		P2		1.0356	\$42.87	\$42.87
50392	Insert kidney drain	Y		A2	\$333.00	17.942	\$742.82	\$435.46
50393	Insert ureteral tube	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
50394	Injection for kidney x-ray	N		N1				

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
50395	Create passage to kidney	Y		A2	\$333.00	17.942	\$742.82	\$435.46
50396	Measure kidney pressure	Y		A2	\$131.50	2.0077	\$83.12	\$119.41
50398	Change kidney tube	Y		A2	\$333.00	15.3545	\$635.69	\$408.67
50551	Kidney endoscopy	Y		A2	\$333.00	5.9735	\$247.31	\$311.58
50553	Kidney endoscopy	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
50555	Kidney endoscopy & biopsy	Y		A2	\$333.00	5.9735	\$247.31	\$311.58
50557	Kidney endoscopy & treatment	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
50561	Kidney endoscopy & treatment	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
50562	Renal scope w/tumor resect	Y		G2		5.9735	\$247.31	\$247.31
50570	Kidney endoscopy	Y		G2		5.9735	\$247.31	\$247.31
50572	Kidney endoscopy	Y		G2		5.9735	\$247.31	\$247.31
50574	Kidney endoscopy & biopsy	Y		G2		5.9735	\$247.31	\$247.31
50575	Kidney endoscopy	Y		G2		36.0774	\$1,493.64	\$1,493.64
50576	Kidney endoscopy & treatment	Y		G2		17.942	\$742.82	\$742.82
50580	Kidney endoscopy & treatment	Y	CH	G2		17.942	\$742.82	\$742.82
50590	Fragmenting of kidney stone	Y		G2		41.5299	\$1,719.38	\$1,719.38
50592	Perc rf ablate renal tumor	Y		G2		42.998	\$1,780.16	\$1,780.16
50684	Injection for ureter x-ray	N		N1				
50686	Measure ureter pressure	Y		P2		1.0356	\$42.87	\$42.87
50688	Change of ureter tube/stent	Y		A2	\$333.00	15.3545	\$635.69	\$408.67
50690	Injection for ureter x-ray	N		N1				
50947	Laparo new ureter/bladder	Y		A2	\$1,339.00	45.5317	\$1,885.06	\$1,475.52
50948	Laparo new ureter/bladder	Y		A2	\$1,339.00	45.5317	\$1,885.06	\$1,475.52
50951	Endoscopy of ureter	Y		A2	\$333.00	5.9735	\$247.31	\$311.58
50953	Endoscopy of ureter	Y		A2	\$333.00	5.9735	\$247.31	\$311.58
50955	Ureter endoscopy & biopsy	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
50957	Ureter endoscopy & treatment	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
50961	Ureter endoscopy & treatment	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
50970	Ureter endoscopy	Y		A2	\$333.00	5.9735	\$247.31	\$311.58
50972	Ureter endoscopy & catheter	Y		A2	\$333.00	5.9735	\$247.31	\$311.58
50974	Ureter endoscopy & biopsy	Y		A2	\$333.00	17.942	\$742.82	\$435.46
50976	Ureter endoscopy & treatment	Y		A2	\$333.00	17.942	\$742.82	\$435.46
50980	Ureter endoscopy & treatment	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
51000	Drainage of bladder	N	CH	D5				
51005	Drainage of bladder	N	CH	D5				
51010	Drainage of bladder	N	CH	D5				
51020	Incise & treat bladder	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
51030	Incise & treat bladder	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
51040	Incise & drain bladder	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
51045	Incise bladder/drain ureter	Y		A2	\$399.24	5.9735	\$247.31	\$361.26
51050	Removal of bladder stone	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
51065	Remove ureter calculus	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
51080	Drainage of bladder abscess	Y		A2	\$333.00	18.3197	\$758.45	\$439.36
51100	Drain bladder by needle	Y		P3		0.757	\$31.34	\$31.34
51101	Drain bladder by trocar/cath	Y	NI	P2		1.0356	\$42.87	\$42.87
51102	Drain bl w/cath insertion	Y	NI	A2	\$333.00	19.3414	\$800.75	\$449.94
51500	Removal of bladder cyst	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
51520	Removal of bladder lesion	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
51600	Injection for bladder x-ray	N		N1				
51605	Preparation for bladder xray	N		N1				
51610	Injection for bladder x-ray	N		N1				
51700	Irrigation of bladder	Y		P3		1.2756	\$52.81	\$52.81
51701	Insert bladder catheter	N		P2		0.631	\$26.12	\$26.12
51702	Insert temp bladder cath	N		P2		0.631	\$26.12	\$26.12
51703	Insert bladder cath, complex	Y		P2		1.0356	\$42.87	\$42.87
51705	Change of bladder tube	Y		P3		1.7693	\$73.25	\$73.25
51710	Change of bladder tube	Y		A2	\$333.00	15.3545	\$635.69	\$408.67
51715	Endoscopic injection/implant	Y		A2	\$510.00	29.7864	\$1,233.19	\$690.80
51720	Treatment of bladder lesion	Y		P3		1.3823	\$57.23	\$57.23
51725	Simple cystometrogram	Y		P2		3.0469	\$126.14	\$126.14
51726	Complex cystometrogram	Y		A2	\$209.48	3.0469	\$126.14	\$188.65
51736	Urine flow measurement	Y		P3		0.4444	\$18.40	\$18.40
51741	Electro-uroflowmetry, first	Y		P3		0.5101	\$21.12	\$21.12
51772	Urethra pressure profile	Y		A2	\$131.50	2.0077	\$83.12	\$119.41
51784	Anal/urinary muscle study	Y		P2		1.0356	\$42.87	\$42.87
51785	Anal/urinary muscle study	Y		A2	\$66.92	2.0077	\$83.12	\$70.97
51792	Urinary reflex study	Y		P2		1.0356	\$42.87	\$42.87
51795	Urine voiding pressure study	Y		P2		2.0077	\$83.12	\$83.12
51797	Intraabdominal pressure test	Y		P2		2.0077	\$83.12	\$83.12
51798	Us urine capacity measure	N		P3		0.3867	\$16.01	\$16.01
51880	Repair of bladder opening	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
51992	Laparo sling operation	Y		A2	\$717.00	45.5317	\$1,885.06	\$1,009.02
52000	Cystoscopy	Y		A2	\$333.00	5.9735	\$247.31	\$311.58

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
52001	Cystoscopy, removal of clots	Y		A2	\$399.24	17.942	\$742.82	\$485.14
52005	Cystoscopy & ureter catheter	Y		A2	\$446.00	17.942	\$742.82	\$520.21
52007	Cystoscopy and biopsy	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52010	Cystoscopy & duct catheter	Y		A2	\$399.24	5.9735	\$247.31	\$361.26
52204	Cystoscopy w/biopsy(s)	Y		A2	\$446.00	17.942	\$742.82	\$520.21
52214	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52224	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52234	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52235	Cystoscopy and treatment	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52240	Cystoscopy and treatment	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52250	Cystoscopy and radiotracer	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
52260	Cystoscopy and treatment	Y		A2	\$446.00	17.942	\$742.82	\$520.21
52265	Cystoscopy and treatment	Y		P2		5.9735	\$247.31	\$247.31
52270	Cystoscopy & revise urethra	Y		A2	\$446.00	17.942	\$742.82	\$520.21
52275	Cystoscopy & revise urethra	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52276	Cystoscopy and treatment	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52277	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52281	Cystoscopy and treatment	Y		A2	\$446.00	17.942	\$742.82	\$520.21
52282	Cystoscopy, implant stent	Y		A2	\$1,339.00	36.0774	\$1,493.64	\$1,377.66
52283	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52285	Cystoscopy and treatment	Y		A2	\$446.00	17.942	\$742.82	\$520.21
52290	Cystoscopy and treatment	Y		A2	\$446.00	17.942	\$742.82	\$520.21
52300	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52301	Cystoscopy and treatment	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52305	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52310	Cystoscopy and treatment	Y		A2	\$399.24	17.942	\$742.82	\$485.14
52315	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52317	Remove bladder stone	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
52318	Remove bladder stone	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52320	Cystoscopy and treatment	Y		A2	\$717.00	24.7749	\$1,025.71	\$794.18
52325	Cystoscopy, stone removal	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
52327	Cystoscopy, inject material	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52330	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52332	Cystoscopy and treatment	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52334	Create passage to kidney	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52341	Cysto w/ureter stricture tx	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52342	Cysto w/up stricture tx	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52343	Cysto w/renal stricture tx	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52344	Cysto/uretero, stricture tx	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52345	Cysto/uretero w/up stricture	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52346	Cystouretero w/renal strict	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52351	Cystouretero & or pyeloscope	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52352	Cystouretero w/stone remove	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
52353	Cystouretero w/lithotripsy	Y		A2	\$630.00	36.0774	\$1,493.64	\$845.91
52354	Cystouretero w/biopsy	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
52355	Cystouretero w/excise tumor	Y		A2	\$630.00	24.7749	\$1,025.71	\$728.93
52400	Cystouretero w/congen repr	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52402	Cystourethro cut ejacul duct	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52450	Incision of prostate	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52500	Revision of bladder neck	Y		A2	\$510.00	24.7749	\$1,025.71	\$638.93
52510	Dilation prostatic urethra	N	CH	D5				
52601	Prostatectomy (turp)	Y		A2	\$630.00	36.0774	\$1,493.64	\$845.91
52606	Control postop bleeding	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
52612	Prostatectomy, first stage	Y		A2	\$446.00	36.0774	\$1,493.64	\$707.91
52614	Prostatectomy, second stage	Y		A2	\$333.00	36.0774	\$1,493.64	\$623.16
52620	Remove residual prostate	Y		A2	\$333.00	36.0774	\$1,493.64	\$623.16
52630	Remove prostate regrowth	Y		A2	\$446.00	36.0774	\$1,493.64	\$707.91
52640	Relieve bladder contracture	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
52647	Laser surgery of prostate	Y		A2	\$1,339.00	45.2042	\$1,871.50	\$1,472.13
52648	Laser surgery of prostate	Y		A2	\$1,339.00	45.2042	\$1,871.50	\$1,472.13
52700	Drainage of prostate abscess	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
53000	Incision of urethra	Y		A2	\$333.00	19.1505	\$792.85	\$447.96
53010	Incision of urethra	Y		A2	\$333.00	19.1505	\$792.85	\$447.96
53020	Incision of urethra	Y		A2	\$333.00	19.1505	\$792.85	\$447.96
53025	Incision of urethra	Y		R2		19.1505	\$792.85	\$792.85
53040	Drainage of urethra abscess	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
53060	Drainage of urethra abscess	Y		P3		1.7198	\$71.20	\$71.20
53080	Drainage of urinary leakage	Y		A2	\$510.00	19.1505	\$792.85	\$580.71
53085	Drainage of urinary leakage	Y		G2		19.1505	\$792.85	\$792.85
53200	Biopsy of urethra	Y		A2	\$333.00	19.1505	\$792.85	\$447.96
53210	Removal of urethra	Y		A2	\$717.00	29.7864	\$1,233.19	\$846.05
53215	Removal of urethra	Y		A2	\$717.00	19.1505	\$792.85	\$735.96
53220	Treatment of urethra lesion	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
53230	Removal of urethra lesion	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53235	Removal of urethra lesion	Y		A2	\$510.00	19.1505	\$792.85	\$580.71
53240	Surgery for urethra pouch	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53250	Removal of urethra gland	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
53260	Treatment of urethra lesion	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
53265	Treatment of urethra lesion	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
53270	Removal of urethra gland	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
53275	Repair of urethra defect	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
53400	Revise urethra, stage 1	Y		A2	\$510.00	29.7864	\$1,233.19	\$690.80
53405	Revise urethra, stage 2	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53410	Reconstruction of urethra	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53420	Reconstruct urethra, stage 1	Y		A2	\$510.00	29.7864	\$1,233.19	\$690.80
53425	Reconstruct urethra, stage 2	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53430	Reconstruction of urethra	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53431	Reconstruct urethra/bladder	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53440	Male sling procedure	N	CH	H8	\$446.00	106.8568	\$4,423.98	\$3,500.50
53442	Remove/revise male sling	Y		A2	\$333.00	29.7864	\$1,233.19	\$558.05
53444	Insert tandem cuff	N	CH	H8	\$446.00	106.8568	\$4,423.98	\$3,500.50
53445	Insert uro/ves nck sphincter	N		H8	\$333.00	193.4277	\$8,008.10	\$6,625.75
53446	Remove uro sphincter	Y		A2	\$333.00	29.7864	\$1,233.19	\$558.05
53447	Remove/replace ur sphincter	N		H8	\$333.00	193.4277	\$8,008.10	\$6,625.75
53449	Repair uro sphincter	Y		A2	\$333.00	29.7864	\$1,233.19	\$558.05
53450	Revision of urethra	Y		A2	\$333.00	29.7864	\$1,233.19	\$558.05
53460	Revision of urethra	Y		A2	\$333.00	19.1505	\$792.85	\$447.96
53502	Repair of urethra injury	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
53505	Repair of urethra injury	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53510	Repair of urethra injury	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
53515	Repair of urethra injury	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53520	Repair of urethra defect	Y		A2	\$446.00	29.7864	\$1,233.19	\$642.80
53600	Dilate urethra stricture	Y		P3	0.9381		\$38.84	\$38.84
53601	Dilate urethra stricture	Y	CH	P2		1.0356	\$42.87	\$42.87
53605	Dilate urethra stricture	Y		A2	\$446.00	17.942	\$742.82	\$520.21
53620	Dilate urethra stricture	Y		P3	1.5142		\$62.69	\$62.69
53621	Dilate urethra stricture	Y		P3	1.5963		\$66.09	\$66.09
53660	Dilation of urethra	Y	CH	P2		1.0356	\$42.87	\$42.87
53661	Dilation of urethra	Y	CH	P2		1.0356	\$42.87	\$42.87
53665	Dilation of urethra	Y		A2	\$333.00	19.1505	\$792.85	\$447.96
53850	Prostatic microwave thermotx	Y		P2		45.2042	\$1,871.50	\$1,871.50
53852	Prostatic rf thermotx	Y		P2		45.2042	\$1,871.50	\$1,871.50
53853	Prostatic water thermother	Y		P2		24.7749	\$1,025.71	\$1,025.71
54000	Slitting of prepuce	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
54001	Slitting of prepuce	Y		A2	\$446.00	19.1505	\$792.85	\$532.71
54015	Drain penis lesion	Y		A2	\$630.00	18.3197	\$758.45	\$662.11
54050	Destruction, penis lesion(s)	Y		P2		1.4595	\$60.42	\$60.42
54055	Destruction, penis lesion(s)	Y		P3		1.4565	\$60.30	\$60.30
54056	Cryosurgery, penis lesion(s)	Y		P2		0.793	\$32.83	\$32.83
54057	Laser surg, penis lesion(s)	Y		A2	\$333.00	19.9041	\$824.05	\$455.76
54060	Excision of penis lesion(s)	Y		A2	\$333.00	19.9041	\$824.05	\$455.76
54065	Destruction, penis lesion(s)	Y		A2	\$333.00	19.9041	\$824.05	\$455.76
54100	Biopsy of penis	Y		A2	\$333.00	16.1001	\$666.56	\$416.39
54105	Biopsy of penis	Y		A2	\$333.00	21.1098	\$873.97	\$468.24
54110	Treatment of penis lesion	Y		A2	\$446.00	33.9306	\$1,404.76	\$685.69
54111	Treat penis lesion, graft	Y		A2	\$446.00	33.9306	\$1,404.76	\$685.69
54112	Treat penis lesion, graft	Y		A2	\$446.00	33.9306	\$1,404.76	\$685.69
54115	Treatment of penis lesion	Y		A2	\$333.00	18.3197	\$758.45	\$439.36
54120	Partial removal of penis	Y		A2	\$446.00	33.9306	\$1,404.76	\$685.69
54150	Circumcision w/regionl block	Y		A2	\$333.00	22.3251	\$924.28	\$480.82
54160	Circumcision, neonate	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
54161	Circum 28 days or older	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
54162	Lysis penil circumic lesion	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
54163	Repair of circumcision	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
54164	Frenulotomy of penis	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
54200	Treatment of penis lesion	Y		P3		1.5635	\$64.73	\$64.73
54205	Treatment of penis lesion	Y		A2	\$630.00	33.9306	\$1,404.76	\$823.69
54220	Treatment of penis lesion	Y		A2	\$131.50	2.0077	\$83.12	\$119.41
54230	Prepare penis study	N		N1				
54231	Dynamic cavernosometry	Y		P3		1.3741	\$56.89	\$56.89
54235	Penile injection	Y		P3		0.9628	\$39.86	\$39.86
54240	Penis study	Y		P3		0.6667	\$27.60	\$27.60
54250	Penis study	Y		P3		0.2304	\$9.54	\$9.54
54300	Revision of penis	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54304	Revision of penis	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54308	Reconstruction of urethra	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPSC code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
54312	Reconstruction of urethra	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54316	Reconstruction of urethra	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54318	Reconstruction of urethra	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54322	Reconstruction of urethra	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54324	Reconstruction of urethra	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54326	Reconstruction of urethra	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54328	Revise penis/urethra	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54340	Secondary urethral surgery	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54344	Secondary urethral surgery	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54348	Secondary urethral surgery	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54352	Reconstruct urethra/penis	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54360	Penis plastic surgery	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54380	Repair penis	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54385	Repair penis	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54400	Insert semi-rigid prosthesis	N	CH	H8	\$510.00	106.8568	\$4,423.98	\$3,548.50
54401	Insert self-contd prosthesis	N		H8	\$510.00	193.4277	\$8,008.10	\$6,758.50
54405	Insert multi-comp penis pros	N		H8	\$510.00	193.4277	\$8,008.10	\$6,758.50
54406	Remove multi-comp penis pros	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54408	Repair multi-comp penis pros	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54410	Remove/replace penis prosth	N		H8	\$510.00	193.4277	\$8,008.10	\$6,758.50
54415	Remove self-contd penis pros	Y		A2	\$510.00	33.9306	\$1,404.76	\$733.69
54416	Remv/repl penis contain pros	N		H8	\$510.00	193.4277	\$8,008.10	\$6,758.50
54420	Revision of penis	Y		A2	\$630.00	33.9306	\$1,404.76	\$823.69
54435	Revision of penis	Y		A2	\$630.00	33.9306	\$1,404.76	\$823.69
54440	Repair of penis	Y		A2	\$630.00	33.9306	\$1,404.76	\$823.69
54450	Preputial stretching	Y		A2	\$209.48	3.0469	\$126.14	\$188.65
54500	Biopsy of testis	Y		A2	\$333.00	13.5764	\$562.08	\$390.27
54505	Biopsy of testis	Y		A2	\$333.00	22.3251	\$924.28	\$480.82
54512	Excise lesion testis	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
54520	Removal of testis	Y		A2	\$510.00	22.3251	\$924.28	\$613.57
54522	Orchiectomy, partial	Y		A2	\$510.00	22.3251	\$924.28	\$613.57
54530	Removal of testis	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
54550	Exploration for testis	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
54560	Exploration for testis	Y		G2		22.3251	\$924.28	\$924.28
54600	Reduce testis torsion	Y		A2	\$630.00	22.3251	\$924.28	\$703.57
54620	Suspension of testis	Y		A2	\$510.00	22.3251	\$924.28	\$613.57
54640	Suspension of testis	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
54660	Revision of testis	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
54670	Repair testis injury	Y		A2	\$510.00	22.3251	\$924.28	\$613.57
54680	Relocation of testis(es)	Y		A2	\$510.00	22.3251	\$924.28	\$613.57
54690	Laparoscopy, orchiectomy	Y		A2	\$1,339.00	45.5317	\$1,885.06	\$1,475.52
54692	Laparoscopy, orchiopexy	Y		G2		69.6652	\$2,884.21	\$2,884.21
54700	Drainage of scrotum	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
54800	Biopsy of epididymis	Y		A2	\$127.16	4.327	\$179.14	\$140.16
54830	Remove epididymis lesion	Y		A2	\$510.00	22.3251	\$924.28	\$613.57
54840	Remove epididymis lesion	Y		A2	\$630.00	22.3251	\$924.28	\$703.57
54860	Removal of epididymis	Y		A2	\$510.00	22.3251	\$924.28	\$613.57
54861	Removal of epididymis	Y		A2	\$630.00	22.3251	\$924.28	\$703.57
54865	Explore epididymis	Y		A2	\$333.00	22.3251	\$924.28	\$480.82
54900	Fusion of spermatic ducts	Y		A2	\$630.00	22.3251	\$924.28	\$703.57
54901	Fusion of spermatic ducts	Y		A2	\$630.00	22.3251	\$924.28	\$703.57
55000	Drainage of hydrocele	Y		P3		1.6128	\$66.77	\$66.77
55040	Removal of hydrocele	Y		A2	\$510.00	30.6788	\$1,270.13	\$700.03
55041	Removal of hydroceles	Y		A2	\$717.00	30.6788	\$1,270.13	\$855.28
55060	Repair of hydrocele	Y		A2	\$630.00	22.3251	\$924.28	\$703.57
55100	Drainage of scrotum abscess	Y		A2	\$333.00	11.5594	\$478.57	\$369.39
55110	Explore scrotum	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
55120	Removal of scrotum lesion	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
55150	Removal of scrotum	Y		A2	\$333.00	22.3251	\$924.28	\$480.82
55175	Revision of scrotum	Y		A2	\$333.00	22.3251	\$924.28	\$480.82
55180	Revision of scrotum	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
55200	Incision of sperm duct	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
55250	Removal of sperm duct(s)	Y		A2	\$446.00	22.3251	\$924.28	\$565.57
55300	Prepare, sperm duct x-ray	N		N1				
55400	Repair of sperm duct	Y		A2	\$333.00	22.3251	\$924.28	\$480.82
55450	Ligation of sperm duct	Y		P3		5.1182	\$211.90	\$211.90
55500	Removal of hydrocele	Y		A2	\$510.00	22.3251	\$924.28	\$613.57
55520	Removal of sperm cord lesion	Y		A2	\$630.00	22.3251	\$924.28	\$703.57
55530	Revise spermatic cord veins	Y		A2	\$630.00	22.3251	\$924.28	\$703.57
55535	Revise spermatic cord veins	Y		A2	\$630.00	30.6788	\$1,270.13	\$790.03
55540	Revise hernia & sperm veins	Y		A2	\$717.00	30.6788	\$1,270.13	\$855.28
55550	Laparo ligate spermatic vein	Y		A2	\$1,339.00	45.5317	\$1,885.06	\$1,475.52
55600	Incise sperm duct pouch	Y		R2		22.3251	\$924.28	\$924.28

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPSC codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
55680	Remove sperm pouch lesion	Y		A2	\$333.00	22.3251	\$924.28	\$480.82
55700	Biopsy of prostate	Y		A2	\$345.83	11.0338	\$456.81	\$373.58
55705	Biopsy of prostate	Y		A2	\$345.83	11.0338	\$456.81	\$373.58
55720	Drainage of prostate abscess	Y		A2	\$333.00	24.7749	\$1,025.71	\$506.18
55725	Drainage of prostate abscess	Y		A2	\$446.00	24.7749	\$1,025.71	\$590.93
55860	Surgical exposure, prostate	Y		G2		19.3414	\$800.75	\$800.75
55870	Electroejaculation	Y		P3		1.6541	\$68.48	\$68.48
55873	Cryoablate prostate	Y		H8	\$1,339.00	162.5379	\$6,729.23	\$6,219.63
55875	Transperi needle place, pros	N		A2	\$1,339.00	36.0774	\$1,493.64	\$1,377.66
55876*	Place rt device/marker, pros	Y		P3		1.7033	\$70.52	\$70.52
55920	Place needles pelvic for rt	Y	NI	G2		25.6947	\$1,063.79	\$1,063.79
56405	I & d of vulva/perineum	Y		P3		1.0287	\$42.59	\$42.59
56420	Drainage of gland abscess	Y		P2		1.352	\$55.97	\$55.97
56440	Surgery for vulva lesion	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
56441	Lysis of labial lesion(s)	Y		A2	\$333.00	19.0203	\$787.46	\$446.62
56442	Hymenotomy	Y		A2	\$333.00	19.0203	\$787.46	\$446.62
56501	Destroy, vulva lesions, sim	Y		P3		1.4072	\$58.26	\$58.26
56515	Destroy vulva lesion/s compl	Y		A2	\$510.00	19.9041	\$824.05	\$588.51
56605	Biopsy of vulva/perineum	Y		P3		0.8229	\$34.07	\$34.07
56606	Biopsy of vulva/perineum	Y		P3		0.3456	\$14.31	\$14.31
56620	Partial removal of vulva	Y		A2	\$717.00	19.0203	\$787.46	\$734.62
56625	Complete removal of vulva	Y		A2	\$995.00	19.0203	\$787.46	\$943.12
56700	Partial removal of hymen	Y		A2	\$333.00	19.0203	\$787.46	\$446.62
56740	Remove vagina gland lesion	Y		A2	\$510.00	19.0203	\$787.46	\$579.37
56800	Repair of vagina	Y		A2	\$510.00	19.0203	\$787.46	\$579.37
56805	Repair clitoris	Y		G2		19.0203	\$787.46	\$787.46
56810	Repair of perineum	Y		A2	\$717.00	19.0203	\$787.46	\$734.62
56820	Exam of vulva w/scope	Y		P3		1.0287	\$42.59	\$42.59
56821	Exam/biopsy of vulva w/scope	Y		P3		1.3495	\$55.87	\$55.87
57000	Exploration of vagina	Y		A2	\$333.00	19.0203	\$787.46	\$446.62
57010	Drainage of pelvic abscess	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57020	Drainage of pelvic fluid	Y		A2	\$409.33	6.0783	\$251.65	\$369.91
57022	I & d vaginal hematoma, pp	Y		G2		11.5594	\$478.57	\$478.57
57023	I & d vag hematoma, non-ob	Y		A2	\$333.00	18.3197	\$758.45	\$439.36
57061	Destroy vag lesions, simple	Y		P3		1.3002	\$53.83	\$53.83
57065	Destroy vag lesions, complex	Y		A2	\$333.00	19.0203	\$787.46	\$446.62
57100	Biopsy of vagina	Y		P3		0.8311	\$34.41	\$34.41
57105	Biopsy of vagina	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57130	Remove vagina lesion	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57135	Remove vagina lesion	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57150	Treat vagina infection	Y	CH	P3		0.6913	\$28.62	\$28.62
57155	Insert uteri tandems/ovoids	Y		A2	\$409.33	6.0783	\$251.65	\$369.91
57160	Insert pessary/other device	Y		P3		0.8476	\$35.09	\$35.09
57170	Fitting of diaphragm/cap	Y		P2		0.1309	\$5.42	\$5.42
57180	Treat vaginal bleeding	Y		A2	\$178.05	1.352	\$55.97	\$147.53
57200	Repair of vagina	Y		A2	\$333.00	19.0203	\$787.46	\$446.62
57210	Repair vagina/perineum	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57220	Revision of urethra	Y		A2	\$510.00	42.7099	\$1,768.23	\$824.56
57230	Repair of urethral lesion	Y		A2	\$510.00	32.4237	\$1,342.37	\$718.09
57240	Repair bladder & vagina	Y		A2	\$717.00	32.4237	\$1,342.37	\$873.34
57250	Repair rectum & vagina	Y		A2	\$717.00	32.4237	\$1,342.37	\$873.34
57260	Repair of vagina	Y		A2	\$717.00	32.4237	\$1,342.37	\$873.34
57265	Extensive repair of vagina	Y		A2	\$995.00	42.7099	\$1,768.23	\$1,188.31
57267	Insert mesh/pelvic fir addon	Y		A2	\$995.00	32.4237	\$1,342.37	\$1,081.84
57268	Repair of bowel bulge	Y		A2	\$510.00	32.4237	\$1,342.37	\$718.09
57287	Revise/remove sling repair	Y		G2		32.4237	\$1,342.37	\$1,342.37
57288	Repair bladder defect	Y		A2	\$717.00	42.7099	\$1,768.23	\$979.81
57289	Repair bladder & vagina	Y		A2	\$717.00	32.4237	\$1,342.37	\$873.34
57291	Construction of vagina	Y		A2	\$717.00	32.4237	\$1,342.37	\$873.34
57300	Repair rectum-vagina fistula	Y		A2	\$510.00	32.4237	\$1,342.37	\$718.09
57320	Repair bladder-vagina lesion	Y		G2		32.4237	\$1,342.37	\$1,342.37
57400	Dilation of vagina	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57410	Pelvic examination	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57415	Remove vaginal foreign body	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57420	Exam of vagina w/scope	Y		P3		1.0616	\$43.95	\$43.95
57421	Exam/biopsy of vag w/scope	Y		P3		1.4154	\$58.60	\$58.60
57452	Exam of cervix w/scope	Y		P3		1.0121	\$41.90	\$41.90
57454	Bx/curett of cervix w/scope	Y		P3		1.2425	\$51.44	\$51.44
57455	Biopsy of cervix w/scope	Y		P3		1.3248	\$54.85	\$54.85
57456	Endocerv curettage w/scope	Y		P3		1.2756	\$52.81	\$52.81
57460	Bx of cervix w/scope, leep	Y		P3		4.1639	\$172.39	\$172.39
57461	Conz of cervix w/scope, leep	Y		P3		4.3859	\$181.58	\$181.58
57500	Biopsy of cervix	Y		P3		1.8763	\$77.68	\$77.68

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPSC code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
57505	Endocervical curettage	Y		P3		1.1437	\$47.35	\$47.35
57510	Cauterization of cervix	Y		P3		1.1768	\$48.72	\$48.72
57511	Cryocautery of cervix	Y		P2		1.352	\$55.97	\$55.97
57513	Laser surgery of cervix	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57520	Conization of cervix	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57522	Conization of cervix	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
57530	Removal of cervix	Y		A2	\$510.00	32.4237	\$1,342.37	\$718.09
57550	Removal of residual cervix	Y		A2	\$510.00	32.4237	\$1,342.37	\$718.09
57556	Remove cervix, repair bowel	Y		A2	\$717.00	42.7099	\$1,768.23	\$979.81
57558	D&c of cervical stump	Y		A2	\$510.00	19.0203	\$787.46	\$579.37
57700	Revision of cervix	Y		A2	\$333.00	19.0203	\$787.46	\$446.62
57720	Revision of cervix	Y		A2	\$510.00	19.0203	\$787.46	\$579.37
57800	Dilation of cervical canal	Y		P3		0.6089	\$25.21	\$25.21
58100	Biopsy of uterus lining	Y		P3		1.0121	\$41.90	\$41.90
58110	Bx done w/colposcopy add-on	N	CH	N1				
58120	Dilation and curettage	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
58145	Myomectomy vag method	Y		A2	\$717.00	32.4237	\$1,342.37	\$873.34
58301	Remove intrauterine device	Y		P3		0.971	\$40.20	\$40.20
58321	Artificial insemination	Y		P3		0.8558	\$35.43	\$35.43
58322	Artificial insemination	Y		P3		0.9135	\$37.82	\$37.82
58323	Sperm washing	Y		P3		0.2797	\$11.58	\$11.58
58340	Catheter for hystero-graphy	N		N1				
58345	Reopen fallopian tube	Y		R2		19.0203	\$787.46	\$787.46
58346	Insert heyman uteri capsule	Y		A2	\$446.00	19.0203	\$787.46	\$531.37
58350	Reopen fallopian tube	Y		A2	\$510.00	32.4237	\$1,342.37	\$718.09
58353	Endometr ablate, thermal	Y		A2	\$995.00	32.4237	\$1,342.37	\$1,081.84
58356	Endometrial cryoablation	Y		P3		43.0862	\$1,783.81	\$1,783.81
58545	Laparoscopic myomectomy	Y		A2	\$1,339.00	34.3958	\$1,424.02	\$1,360.26
58546	Laparo-myomectomy, complex	Y		A2	\$1,339.00	45.5317	\$1,885.06	\$1,475.52
58550	Laparo-asst vag hysterectomy	Y		A2	\$1,339.00	69.6652	\$2,884.21	\$1,725.30
58552	Laparo-vag hyst incl t/o	Y		G2		45.5317	\$1,885.06	\$1,885.06
58555	Hysteroscopy, dx, sep proc	Y		A2	\$333.00	21.6576	\$896.65	\$473.91
58558	Hysteroscopy, biopsy	Y		A2	\$510.00	21.6576	\$896.65	\$606.66
58559	Hysteroscopy, lysis	Y		A2	\$446.00	21.6576	\$896.65	\$558.66
58560	Hysteroscopy, resect septum	Y		A2	\$510.00	34.2048	\$1,416.11	\$736.53
58561	Hysteroscopy, remove myoma	Y		A2	\$510.00	34.2048	\$1,416.11	\$736.53
58562	Hysteroscopy, remove fb	Y		A2	\$510.00	21.6576	\$896.65	\$606.66
58563	Hysteroscopy, ablation	Y		A2	\$1,339.00	34.2048	\$1,416.11	\$1,358.28
58565	Hysteroscopy, sterilization	Y		A2	\$1,339.00	42.7099	\$1,768.23	\$1,446.31
58600	Division of fallopian tube	Y		G2		32.4237	\$1,342.37	\$1,342.37
58615	Occlude fallopian tube(s)	Y		G2		19.0203	\$787.46	\$787.46
58660	Laparoscopy, lysis	Y		A2	\$717.00	45.5317	\$1,885.06	\$1,009.02
58661	Laparoscopy, remove adnexa	Y		A2	\$717.00	45.5317	\$1,885.06	\$1,009.02
58662	Laparoscopy, excise lesions	Y		A2	\$717.00	45.5317	\$1,885.06	\$1,009.02
58670	Laparoscopy, tubal cautery	Y		A2	\$510.00	45.5317	\$1,885.06	\$853.77
58671	Laparoscopy, tubal block	Y		A2	\$510.00	45.5317	\$1,885.06	\$853.77
58672	Laparoscopy, fimbrioplasty	Y		A2	\$717.00	45.5317	\$1,885.06	\$1,009.02
58673	Laparoscopy, salpingostomy	Y		A2	\$717.00	45.5317	\$1,885.06	\$1,009.02
58800	Drainage of ovarian cyst(s)	Y		A2	\$510.00	19.0203	\$787.46	\$579.37
58805	Drainage of ovarian cyst(s)	Y	CH	G2		32.4237	\$1,342.37	\$1,342.37
58820	Drain ovary abscess, open	Y		A2	\$510.00	32.4237	\$1,342.37	\$718.09
58900	Biopsy of ovary(s)	Y		A2	\$510.00	19.0203	\$787.46	\$579.37
58970	Retrieval of oocyte	Y		A2	\$245.92	2.7584	\$114.20	\$212.99
58974	Transfer of embryo	Y		A2	\$245.92	2.7584	\$114.20	\$212.99
58976	Transfer of embryo	Y		A2	\$245.92	2.7584	\$114.20	\$212.99
59000	Amniocentesis, diagnostic	Y	CH	P3		1.5717	\$65.07	\$65.07
59001	Amniocentesis, therapeutic	Y		R2		6.0783	\$251.65	\$251.65
59012	Fetal cord puncture, prenatal	Y		G2		2.7584	\$114.20	\$114.20
59015	Chorion biopsy	Y		P3		1.2178	\$50.42	\$50.42
59020	Fetal contract stress test	Y		P3		0.5761	\$23.85	\$23.85
59025	Fetal non-stress test	Y		P3		0.2961	\$12.26	\$12.26
59070	Transabdom amnioinfus w/us	Y		G2		2.7584	\$114.20	\$114.20
59072	Umbilical cord occlud w/us	Y		G2		2.7584	\$114.20	\$114.20
59076	Fetal shunt placement, w/us	Y		G2		2.7584	\$114.20	\$114.20
59100	Remove uterus lesion	Y		R2		32.4237	\$1,342.37	\$1,342.37
59150	Treat ectopic pregnancy	Y		G2		45.5317	\$1,885.06	\$1,885.06
59151	Treat ectopic pregnancy	Y		G2		45.5317	\$1,885.06	\$1,885.06
59160	D & c after delivery	Y		A2	\$510.00	19.0203	\$787.46	\$579.37
59200	Insert cervical dilator	Y		P3		0.8722	\$36.11	\$36.11
59300	Episiotomy or vaginal repair	Y		P3		1.7939	\$74.27	\$74.27
59320	Revision of cervix	Y		A2	\$333.00	19.0203	\$787.46	\$446.62
59412	Antepartum manipulation	Y		G2		19.0203	\$787.46	\$787.46
59414	Deliver placenta	Y		G2		19.0203	\$787.46	\$787.46

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPSC codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
59812	Treatment of miscarriage	Y		A2	\$717.00	19.0203	\$787.46	\$734.62
59820	Care of miscarriage	Y		A2	\$717.00	19.0203	\$787.46	\$734.62
59821	Treatment of miscarriage	Y		A2	\$717.00	19.0203	\$787.46	\$734.62
59840	Abortion	Y		A2	\$717.00	19.0203	\$787.46	\$734.62
59841	Abortion	Y		A2	\$717.00	19.0203	\$787.46	\$734.62
59866	Abortion (mpr)	Y		G2		2.7584	\$114.20	\$114.20
59870	Evacuate mole of uterus	Y		A2	\$717.00	19.0203	\$787.46	\$734.62
59871	Remove cerclage suture	Y		A2	\$717.00	19.0203	\$787.46	\$734.62
60000	Drain thyroid/tongue cyst	Y		A2	\$333.00	7.4474	\$308.33	\$326.83
60001	Aspirate/inject thyroid cyst	N	CH	D5				
60100	Biopsy of thyroid	Y		P3		1.1108	\$45.99	\$45.99
60200	Remove thyroid lesion	Y		A2	\$446.00	44.324	\$1,835.06	\$793.27
60280	Remove thyroid duct lesion	Y		A2	\$630.00	44.324	\$1,835.06	\$931.27
60281	Remove thyroid duct lesion	Y		A2	\$630.00	44.324	\$1,835.06	\$931.27
60300	Aspir/inj thyroid cyst	Y	NI	P3		1.3741	\$56.89	\$56.89
61000	Remove cranial cavity fluid	Y		R2		8.5263	\$353.00	\$353.00
61001	Remove cranial cavity fluid	Y		R2		8.5263	\$353.00	\$353.00
61020	Remove brain cavity fluid	Y		A2	\$183.83	8.5263	\$353.00	\$226.12
61026	Injection into brain canal	Y		A2	\$183.83	8.5263	\$353.00	\$226.12
61050	Remove brain canal fluid	Y		A2	\$183.83	8.5263	\$353.00	\$226.12
61055	Injection into brain canal	Y		A2	\$183.83	8.5263	\$353.00	\$226.12
61070	Brain canal shunt procedure	Y		A2	\$183.83	3.2383	\$134.07	\$171.39
61215	Insert brain-fluid device	Y		A2	\$510.00	36.2768	\$1,501.90	\$757.98
61330	Decompress eye socket	Y		G2		39.8776	\$1,650.97	\$1,650.97
61334	Explore orbit/remove object	Y		G2		39.8776	\$1,650.97	\$1,650.97
61790	Treat trigeminal nerve	Y		A2	\$510.00	18.0518	\$747.36	\$569.34
61791	Treat trigeminal tract	Y		A2	\$351.92	14.4879	\$599.81	\$413.89
61795	Brain surgery using computer	N	CH	N1				
61880	Revise/remove neuroelectrode	Y		G2		22.4734	\$930.42	\$930.42
61885	Insrt/redo neurostim 1 array	N		H8	\$446.00	269.543	\$11,159.35	\$10,493.89
61886	Implant neurostim arrays	N		H8	\$510.00	395.2777	\$16,364.89	\$15,586.16
61888	Revise/remove neuroreceiver	Y		A2	\$333.00	34.4166	\$1,424.88	\$605.97
62194	Replace/irrigate catheter	Y		A2	\$333.00	8.5263	\$353.00	\$338.00
62225	Replace/irrigate catheter	Y		A2	\$333.00	15.3545	\$635.69	\$408.67
62230	Replace/revise brain shunt	Y		A2	\$446.00	36.2768	\$1,501.90	\$709.98
62252	Csf shunt reprogram	N		P3		1.0698	\$44.29	\$44.29
62263	Epidural lysis mult sessions	Y		A2	\$333.00	14.4879	\$599.81	\$399.70
62264	Epidural lysis on single day	Y		A2	\$333.00	14.4879	\$599.81	\$399.70
62268	Drain spinal cord cyst	Y		A2	\$183.83	8.5263	\$353.00	\$226.12
62269	Needle biopsy, spinal cord	Y		A2	\$333.00	9.3354	\$386.49	\$346.37
62270	Spinal fluid tap, diagnostic	Y		A2	\$139.00	4.0964	\$169.60	\$146.65
62272	Drain cerebro spinal fluid	Y		A2	\$139.00	4.0964	\$169.60	\$146.65
62273	Inject epidural patch	Y		A2	\$333.00	4.0964	\$169.60	\$292.15
62280	Treat spinal cord lesion	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
62281	Treat spinal cord lesion	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
62282	Treat spinal canal lesion	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
62284	Injection for myelogram	N		N1				
62287	Percutaneous diskectomy	Y		A2	\$1,339.00	33.2707	\$1,377.44	\$1,348.61
62290	Inject for spine disk x-ray	N		N1				
62291	Inject for spine disk x-ray	N		N1				
62292	Injection into disk lesion	Y	CH	R2		8.5263	\$353.00	\$353.00
62294	Injection into spinal artery	Y		A2	\$183.83	8.5263	\$353.00	\$226.12
62310	Inject spine c/t	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
62311	Inject spine l/s (cd)	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
62318	Inject spine w/cath, c/t	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
62319	Inject spine w/cath l/s (cd)	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
62350	Implant spinal canal cath	Y		A2	\$446.00	36.2768	\$1,501.90	\$709.98
62355	Remove spinal canal catheter	Y		A2	\$446.00	14.4879	\$599.81	\$484.45
62360	Insert spine infusion device	Y		A2	\$446.00	36.2768	\$1,501.90	\$709.98
62361	Implant spine infusion pump	Y		H8	\$446.00	263.8315	\$10,922.89	\$10,157.07
62362	Implant spine infusion pump	Y		H8	\$446.00	263.8315	\$10,922.89	\$10,157.07
62365	Remove spine infusion device	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
62367	Analyze spine infusion pump	N		P3		0.428	\$17.72	\$17.72
62368	Analyze spine infusion pump	N		P3		0.5183	\$21.46	\$21.46
63600	Remove spinal cord lesion	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
63610	Stimulation of spinal cord	Y		A2	\$333.00	18.0518	\$747.36	\$436.59
63615	Remove lesion of spinal cord	Y		R2		18.0518	\$747.36	\$747.36
63650	Implant neuroelectrodes	N		H8	\$446.00	83.1135	\$3,440.98	\$2,909.36
63655	Implant neuroelectrodes	N		J8		109.8976	\$4,549.87	\$4,549.87
63660	Revise/remove neuroelectrode	Y		A2	\$333.00	22.4734	\$930.42	\$482.36
63685	Insrt/redo spine n generator	N		H8	\$446.00	350.8302	\$14,524.72	\$13,727.20
63688	Revise/remove neuroreceiver	Y		A2	\$333.00	34.4166	\$1,424.88	\$605.97
63744	Revision of spinal shunt	Y		A2	\$510.00	36.2768	\$1,501.90	\$757.98

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
63746	Removal of spinal shunt	Y		A2	\$446.00	5.6614	\$234.39	\$393.10
64400	N block inj, trigeminal	Y		P3		1.3577	\$56.21	\$56.21
64402	N block inj, facial	Y		P3		1.2425	\$51.44	\$51.44
64405	N block inj, occipital	Y		P3		1.078	\$44.63	\$44.63
64408	N block inj, vagus	Y		P3		1.2425	\$51.44	\$51.44
64410	N block inj, phrenic	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64412	N block inj, spinal accessor	Y		P3		1.9666	\$81.42	\$81.42
64413	N block inj, cervical plexus	Y		P3		1.292	\$53.49	\$53.49
64415	N block inj, brachial plexus	Y		A2	\$139.00	4.0964	\$169.60	\$146.65
64416	N block cont infuse, b plex	Y		G2		7.0546	\$292.07	\$292.07
64417	N block inj, axillary	Y		A2	\$139.00	4.0964	\$169.60	\$146.65
64418	N block inj, suprascapular	Y		P3		1.8596	\$76.99	\$76.99
64420	N block inj, intercost, sng	Y		A2	\$139.00	4.0964	\$169.60	\$146.65
64421	N block inj, intercost, mlt	Y		A2	\$333.00	4.0964	\$169.60	\$292.15
64425	N block inj, ilio-ing/hypogi	Y		P3		1.2096	\$50.08	\$50.08
64430	N block inj, pudendal	Y		A2	\$139.00	7.0546	\$292.07	\$177.27
64435	N block inj, paracervical	Y		P3		1.8596	\$76.99	\$76.99
64445	N block inj, sciatic, sng	Y		P3		1.7693	\$73.25	\$73.25
64446	N blk inj, sciatic, cont inf	Y		G2		14.4879	\$599.81	\$599.81
64447	N block inj fem, single	Y	CH	R2		4.0964	\$169.60	\$169.60
64450	N block, other peripheral	Y		P3		1.0287	\$42.59	\$42.59
64470	Inj paravertebral c/t	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64472	Inj paravertebral c/t add-on	Y		A2	\$333.00	4.0964	\$169.60	\$292.15
64475	Inj paravertebral l/s	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64476	Inj paravertebral l/s add-on	Y		A2	\$333.00	2.3213	\$96.10	\$273.78
64479	Inj foramen epidural c/t	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64480	Inj foramen epidural add-on	Y		A2	\$333.00	4.0964	\$169.60	\$292.15
64483	Inj foramen epidural l/s	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64484	Inj foramen epidural add-on	Y		A2	\$333.00	4.0964	\$169.60	\$292.15
64505	N block, sphenopalatine gangl	Y		P3		0.971	\$40.20	\$40.20
64508	N block, carotid sinus s/p	Y		P3		2.2053	\$91.30	\$91.30
64510	N block, stellate ganglion	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64517	N block inj, hypogas plxs	Y		A2	\$139.00	7.0546	\$292.07	\$177.27
64520	N block, lumbar/thoracic	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64530	N block inj, celiac pelus	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64553	Implant neuroelectrodes	N		H8	\$333.00	316.5407	\$13,105.10	\$12,022.95
64555	Implant neuroelectrodes	N		J8		83.1135	\$3,440.98	\$3,440.98
64560	Implant neuroelectrodes	N		J8		83.1135	\$3,440.98	\$3,440.98
64561	Implant neuroelectrodes	N		H8	\$510.00	83.1135	\$3,440.98	\$2,957.36
64565	Implant neuroelectrodes	N		J8		83.1135	\$3,440.98	\$3,440.98
64573	Implant neuroelectrodes	N		H8	\$333.00	316.5407	\$13,105.10	\$12,022.95
64575	Implant neuroelectrodes	N		H8	\$333.00	109.8976	\$4,549.87	\$3,785.92
64577	Implant neuroelectrodes	N		H8	\$333.00	109.8976	\$4,549.87	\$3,785.92
64580	Implant neuroelectrodes	N		H8	\$333.00	109.8976	\$4,549.87	\$3,785.92
64581	Implant neuroelectrodes	N		H8	\$510.00	109.8976	\$4,549.87	\$3,918.67
64585	Revise/remove neuroelectrode	Y		A2	\$333.00	22.4734	\$930.42	\$482.36
64590	Insr/redo pn/gastr stim	N		H8	\$446.00	269.543	\$11,159.35	\$10,493.89
64595	Revise/rmv pn/gastr stim	Y		A2	\$333.00	34.4166	\$1,424.88	\$605.97
64600	Injection treatment of nerve	Y		A2	\$333.00	14.4879	\$599.81	\$399.70
64605	Injection treatment of nerve	Y		A2	\$333.00	14.4879	\$599.81	\$399.70
64610	Injection treatment of nerve	Y		A2	\$333.00	14.4879	\$599.81	\$399.70
64612	Destroy nerve, face muscle	Y		P3		1.6705	\$69.16	\$69.16
64613	Destroy nerve, neck muscle	Y		P3		1.7693	\$73.25	\$73.25
64614	Destroy nerve, extrem musc	Y		P3		1.9915	\$82.45	\$82.45
64620	Injection treatment of nerve	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64622	Destr paravertebrl nerve l/s	Y		A2	\$333.00	14.4879	\$599.81	\$399.70
64623	Destr paravertebrl n add-on	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
64626	Destr paravertebrl nerve c/t	Y		A2	\$333.00	14.4879	\$599.81	\$399.70
64627	Destr paravertebrl n add-on	Y		A2	\$333.00	2.3213	\$96.10	\$273.78
64630	Injection treatment of nerve	Y		A2	\$351.92	7.0546	\$292.07	\$336.96
64640	Injection treatment of nerve	Y		P3		2.7156	\$112.43	\$112.43
64650	Chemodenerv eccrine glands	Y	CH	P3		0.65	\$26.91	\$26.91
64653	Chemodenerv eccrine glands	Y	CH	P3		0.6831	\$28.28	\$28.28
64680	Injection treatment of nerve	Y		A2	\$390.95	14.4879	\$599.81	\$443.17
64681	Injection treatment of nerve	Y		A2	\$446.00	14.4879	\$599.81	\$484.45
64702	Revise finger/toe nerve	Y		A2	\$333.00	18.0518	\$747.36	\$436.59
64704	Revise hand/foot nerve	Y		A2	\$333.00	18.0518	\$747.36	\$436.59
64708	Revise arm/leg nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64712	Revision of sciatic nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64713	Revision of arm nerve(s)	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64714	Revise low back nerve(s)	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64716	Revision of cranial nerve	Y		A2	\$510.00	18.0518	\$747.36	\$569.34
64718	Revise ulnar nerve at elbow	Y		A2	\$446.00	18.0518	\$747.36	\$521.34

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
64719	Revise ulnar nerve at wrist	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64721	Carpal tunnel surgery	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64722	Relieve pressure on nerve(s)	Y		A2	\$333.00	18.0518	\$747.36	\$436.59
64726	Release foot/toe nerve	Y		A2	\$333.00	18.0518	\$747.36	\$436.59
64727	Internal nerve revision	Y		A2	\$333.00	18.0518	\$747.36	\$436.59
64732	Incision of brow nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64734	Incision of cheek nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64736	Incision of chin nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64738	Incision of jaw nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64740	Incision of tongue nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64742	Incision of facial nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64744	Incise nerve, back of head	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64746	Incise diaphragm nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64761	Incision of pelvis nerve	Y		G2		18.0518	\$747.36	\$747.36
64763	Incise hip/thigh nerve	Y		G2		18.0518	\$747.36	\$747.36
64766	Incise hip/thigh nerve	Y		G2		33.2707	\$1,377.44	\$1,377.44
64771	Sever cranial nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64772	Incision of spinal nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64774	Remove skin nerve lesion	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64776	Remove digit nerve lesion	Y		A2	\$510.00	18.0518	\$747.36	\$569.34
64778	Digit nerve surgery add-on	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64782	Remove limb nerve lesion	Y		A2	\$510.00	18.0518	\$747.36	\$569.34
64783	Limb nerve surgery add-on	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64784	Remove nerve lesion	Y		A2	\$510.00	18.0518	\$747.36	\$569.34
64786	Remove sciatic nerve lesion	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64787	Implant nerve end	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64788	Remove skin nerve lesion	Y		A2	\$510.00	18.0518	\$747.36	\$569.34
64790	Removal of nerve lesion	Y		A2	\$510.00	18.0518	\$747.36	\$569.34
64792	Removal of nerve lesion	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64795	Biopsy of nerve	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64802	Remove sympathetic nerves	Y		A2	\$446.00	18.0518	\$747.36	\$521.34
64820	Remove sympathetic nerves	Y		G2		18.0518	\$747.36	\$747.36
64821	Remove sympathetic nerves	Y		A2	\$630.00	26.3105	\$1,089.28	\$744.82
64822	Remove sympathetic nerves	Y		G2		26.3105	\$1,089.28	\$1,089.28
64823	Remove sympathetic nerves	Y		G2		26.3105	\$1,089.28	\$1,089.28
64831	Repair of digit nerve	Y		A2	\$630.00	33.2707	\$1,377.44	\$816.86
64832	Repair nerve add-on	Y		A2	\$333.00	33.2707	\$1,377.44	\$594.11
64834	Repair of hand or foot nerve	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64835	Repair of hand or foot nerve	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64836	Repair of hand or foot nerve	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64837	Repair nerve add-on	Y		A2	\$333.00	33.2707	\$1,377.44	\$594.11
64840	Repair of leg nerve	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64856	Repair/transpose nerve	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64857	Repair arm/leg nerve	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64858	Repair sciatic nerve	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64859	Nerve surgery	Y		A2	\$333.00	33.2707	\$1,377.44	\$594.11
64861	Repair of arm nerves	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64862	Repair of low back nerves	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64864	Repair of facial nerve	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64865	Repair of facial nerve	Y		A2	\$630.00	33.2707	\$1,377.44	\$816.86
64870	Fusion of facial/other nerve	Y		A2	\$630.00	33.2707	\$1,377.44	\$816.86
64872	Subsequent repair of nerve	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64874	Repair & revise nerve add-on	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64876	Repair nerve/shorten bone	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64885	Nerve graft, head or neck	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64886	Nerve graft, head or neck	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64890	Nerve graft, hand or foot	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64891	Nerve graft, hand or foot	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64892	Nerve graft, arm or leg	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64893	Nerve graft, arm or leg	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64895	Nerve graft, hand or foot	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64896	Nerve graft, hand or foot	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64897	Nerve graft, arm or leg	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64898	Nerve graft, arm or leg	Y		A2	\$510.00	33.2707	\$1,377.44	\$726.86
64901	Nerve graft add-on	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64902	Nerve graft add-on	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64905	Nerve pedicle transfer	Y		A2	\$446.00	33.2707	\$1,377.44	\$678.86
64907	Nerve pedicle transfer	Y		A2	\$333.00	33.2707	\$1,377.44	\$594.11
64910	Nerve repair w/allograft	Y	CH	G2		18.0518	\$747.36	\$747.36
65091	Revise eye	Y		A2	\$510.00	37.7243	\$1,561.82	\$772.96
65093	Revise eye with implant	Y		A2	\$510.00	37.7243	\$1,561.82	\$772.96
65101	Removal of eye	Y		A2	\$510.00	37.7243	\$1,561.82	\$772.96
65103	Remove eye/insert implant	Y		A2	\$510.00	37.7243	\$1,561.82	\$772.96

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
65105	Remove eye/attach implant	Y		A2	\$630.00	37.7243	\$1,561.82	\$862.96
65110	Removal of eye	Y		A2	\$717.00	37.7243	\$1,561.82	\$928.21
65112	Remove eye/revise socket	Y		A2	\$995.00	37.7243	\$1,561.82	\$1,136.71
65114	Remove eye/revise socket	Y		A2	\$995.00	37.7243	\$1,561.82	\$1,136.71
65125	Revise ocular implant	Y		G2		18.7307	\$775.47	\$775.47
65130	Insert ocular implant	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09
65135	Insert ocular implant	Y		A2	\$446.00	24.3077	\$1,006.36	\$586.09
65140	Attach ocular implant	Y		A2	\$510.00	37.7243	\$1,561.82	\$772.96
65150	Revise ocular implant	Y		A2	\$446.00	24.3077	\$1,006.36	\$586.09
65155	Reinsert ocular implant	Y		A2	\$510.00	37.7243	\$1,561.82	\$772.96
65175	Removal of ocular implant	Y		A2	\$333.00	18.7307	\$775.47	\$443.62
65205	Remove foreign body from eye	N		P3		0.4937	\$20.44	\$20.44
65210	Remove foreign body from eye	N		P3		0.6253	\$25.89	\$25.89
65220	Remove foreign body from eye	N		G2		0.8696	\$36.00	\$36.00
65222	Remove foreign body from eye	N		P3		0.6831	\$28.28	\$28.28
65235	Remove foreign body from eye	Y		A2	\$446.00	16.171	\$669.50	\$501.88
65260	Remove foreign body from eye	Y		A2	\$510.00	18.235	\$754.95	\$571.24
65265	Remove foreign body from eye	Y		A2	\$630.00	27.845	\$1,152.81	\$760.70
65270	Repair of eye wound	Y		A2	\$446.00	18.7307	\$775.47	\$528.37
65272	Repair of eye wound	Y		A2	\$446.00	23.1758	\$959.50	\$574.38
65275	Repair of eye wound	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
65280	Repair of eye wound	Y		A2	\$630.00	18.235	\$754.95	\$661.24
65285	Repair of eye wound	Y		A2	\$630.00	37.2078	\$1,540.44	\$857.61
65286	Repair of eye wound	Y		P2		5.1169	\$211.84	\$211.84
65290	Repair of eye socket wound	Y		A2	\$510.00	24.1291	\$998.97	\$632.24
65400	Removal of eye lesion	Y		A2	\$333.00	16.171	\$669.50	\$417.13
65410	Biopsy of cornea	Y		A2	\$446.00	16.171	\$669.50	\$501.88
65420	Removal of eye lesion	Y		A2	\$446.00	16.171	\$669.50	\$501.88
65426	Removal of eye lesion	Y		A2	\$717.00	23.1758	\$959.50	\$777.63
65430	Corneal smear	N	CH	P2		0.8696	\$36.00	\$36.00
65435	Curette/treat cornea	Y		P3		0.7652	\$31.68	\$31.68
65436	Curette/treat cornea	Y		G2		16.171	\$669.50	\$669.50
65450	Treatment of corneal lesion	N		G2		2.179	\$90.21	\$90.21
65600	Revision of cornea	Y		P3		3.8758	\$160.46	\$160.46
65710	Corneal transplant	Y		A2	\$995.00	37.4896	\$1,552.11	\$1,134.28
65730	Corneal transplant	Y		A2	\$995.00	37.4896	\$1,552.11	\$1,134.28
65750	Corneal transplant	Y		A2	\$995.00	37.4896	\$1,552.11	\$1,134.28
65755	Corneal transplant	Y		A2	\$995.00	37.4896	\$1,552.11	\$1,134.28
65770	Revise cornea with implant	Y		A2	\$995.00	84.8039	\$3,510.97	\$1,623.99
65772	Correction of astigmatism	Y		A2	\$630.00	16.171	\$669.50	\$639.88
65775	Correction of astigmatism	Y		A2	\$630.00	16.171	\$669.50	\$639.88
65780	Ocular reconst, transplant	Y		A2	\$717.00	37.4896	\$1,552.11	\$925.78
65781	Ocular reconst, transplant	Y		A2	\$717.00	37.4896	\$1,552.11	\$925.78
65782	Ocular reconst, transplant	Y		A2	\$717.00	37.4896	\$1,552.11	\$925.78
65800	Drainage of eye	Y		A2	\$333.00	16.171	\$669.50	\$417.13
65805	Drainage of eye	Y		A2	\$333.00	16.171	\$669.50	\$417.13
65810	Drainage of eye	Y		A2	\$510.00	23.1758	\$959.50	\$622.38
65815	Drainage of eye	Y		A2	\$446.00	23.1758	\$959.50	\$574.38
65820	Relieve inner eye pressure	Y		A2	\$333.00	5.1169	\$211.84	\$302.71
65850	Incision of eye	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
65855	Laser surgery of eye	Y		P3		3.2011	\$132.53	\$132.53
65860	Incise inner eye adhesions	Y		P3		2.9953	\$124.01	\$124.01
65865	Incise inner eye adhesions	Y		A2	\$333.00	16.171	\$669.50	\$417.13
65870	Incise inner eye adhesions	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
65875	Incise inner eye adhesions	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
65880	Incise inner eye adhesions	Y		A2	\$630.00	16.171	\$669.50	\$639.88
65900	Remove eye lesion	Y		A2	\$717.00	16.171	\$669.50	\$705.13
65920	Remove implant of eye	Y		A2	\$995.00	23.1758	\$959.50	\$986.13
65930	Remove blood clot from eye	Y		A2	\$717.00	23.1758	\$959.50	\$777.63
66020	Injection treatment of eye	Y		A2	\$333.00	16.171	\$669.50	\$417.13
66030	Injection treatment of eye	Y		A2	\$333.00	5.1169	\$211.84	\$302.71
66130	Remove eye lesion	Y		A2	\$995.00	23.1758	\$959.50	\$986.13
66150	Glaucoma surgery	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
66155	Glaucoma surgery	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
66160	Glaucoma surgery	Y		A2	\$446.00	23.1758	\$959.50	\$574.38
66165	Glaucoma surgery	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
66170	Glaucoma surgery	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
66172	Incision of eye	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
66180	Implant eye shunt	Y		A2	\$717.00	39.7101	\$1,644.04	\$948.76
66185	Revise eye shunt	Y		A2	\$446.00	39.7101	\$1,644.04	\$745.51
66220	Repair eye lesion	Y		A2	\$510.00	37.2078	\$1,540.44	\$767.61
66225	Repair/graft eye lesion	Y		A2	\$630.00	39.7101	\$1,644.04	\$883.51
66250	Follow-up surgery of eye	Y		A2	\$446.00	16.171	\$669.50	\$501.88

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
66500	Incision of iris	Y		A2	\$333.00	5.1169	\$211.84	\$302.71
66505	Incision of iris	Y		A2	\$333.00	5.1169	\$211.84	\$302.71
66600	Remove iris and lesion	Y		A2	\$510.00	23.1758	\$959.50	\$622.38
66605	Removal of iris	Y		A2	\$510.00	23.1758	\$959.50	\$622.38
66625	Removal of iris	Y		A2	\$372.94	5.1169	\$211.84	\$332.67
66630	Removal of iris	Y		A2	\$510.00	23.1758	\$959.50	\$622.38
66635	Removal of iris	Y		A2	\$510.00	23.1758	\$959.50	\$622.38
66680	Repair iris & ciliary body	Y		A2	\$510.00	23.1758	\$959.50	\$622.38
66682	Repair iris & ciliary body	Y		A2	\$446.00	23.1758	\$959.50	\$574.38
66700	Destruction, ciliary body	Y		A2	\$446.00	16.171	\$669.50	\$501.88
66710	Ciliary transsleral therapy	Y		A2	\$446.00	16.171	\$669.50	\$501.88
66711	Ciliary endoscopic ablation	Y		A2	\$446.00	16.171	\$669.50	\$501.88
66720	Destruction, ciliary body	Y		A2	\$446.00	16.171	\$669.50	\$501.88
66740	Destruction, ciliary body	Y		A2	\$446.00	23.1758	\$959.50	\$574.38
66761	Revision of iris	Y		P3		4.3612	\$180.56	\$180.56
66762	Revision of iris	Y		P3		4.419	\$182.95	\$182.95
66770	Removal of inner eye lesion	Y		P3		4.7728	\$197.60	\$197.60
66820	Incision, secondary cataract	Y		G2		5.1169	\$211.84	\$211.84
66821	After cataract laser surgery	Y		A2	\$312.50	5.2001	\$215.29	\$288.20
66825	Reposition intraocular lens	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
66830	Removal of lens lesion	Y		A2	\$372.94	5.1169	\$211.84	\$332.67
66840	Removal of lens material	Y		A2	\$630.00	14.9171	\$617.58	\$626.90
66850	Removal of lens material	Y		A2	\$995.00	28.7035	\$1,188.35	\$1,043.34
66852	Removal of lens material	Y		A2	\$630.00	28.7035	\$1,188.35	\$769.59
66920	Extraction of lens	Y		A2	\$630.00	28.7035	\$1,188.35	\$769.59
66930	Extraction of lens	Y		A2	\$717.00	28.7035	\$1,188.35	\$834.84
66940	Extraction of lens	Y		A2	\$717.00	14.9171	\$617.58	\$692.15
66982	Cataract surgery, complex	Y		A2	\$973.00	23.8649	\$988.03	\$976.76
66983	Cataract surg w/iol, 1 stage	Y		A2	\$973.00	23.8649	\$988.03	\$976.76
66984	Cataract surg w/iol, 1 stage	Y		A2	\$973.00	23.8649	\$988.03	\$976.76
66985	Insert lens prosthesis	Y		A2	\$826.00	23.8649	\$988.03	\$866.51
66986	Exchange lens prosthesis	Y		A2	\$826.00	23.8649	\$988.03	\$866.51
66990	Ophthalmic endoscope add-on	N		N1				
67005	Partial removal of eye fluid	Y		A2	\$630.00	27.845	\$1,152.81	\$760.70
67010	Partial removal of eye fluid	Y		A2	\$630.00	27.845	\$1,152.81	\$760.70
67015	Release of eye fluid	Y		A2	\$333.00	27.845	\$1,152.81	\$537.95
67025	Replace eye fluid	Y		A2	\$333.00	27.845	\$1,152.81	\$537.95
67027	Implant eye drug system	Y		A2	\$630.00	37.2078	\$1,540.44	\$857.61
67028	Injection eye drug	N		P3		1.9915	\$82.45	\$82.45
67030	Incise inner eye strands	Y		A2	\$333.00	18.235	\$754.95	\$438.49
67031	Laser surgery, eye strands	Y		A2	\$312.50	5.2001	\$215.29	\$288.20
67036	Removal of inner eye fluid	Y		A2	\$630.00	37.2078	\$1,540.44	\$857.61
67038	Strip retinal membrane	N	CH	D5				
67039	Laser treatment of retina	Y		A2	\$995.00	37.2078	\$1,540.44	\$1,131.36
67040	Laser treatment of retina	Y		A2	\$995.00	37.2078	\$1,540.44	\$1,131.36
67041	Vit for macular pucker	Y		NI		37.2078	\$1,540.44	\$1,540.44
67042	Vit for macular hole	Y		NI		37.2078	\$1,540.44	\$1,540.44
67043	Vit for membrane dissect	Y		NI		37.2078	\$1,540.44	\$1,540.44
67101	Repair detached retina	Y		P3		7.2414	\$299.80	\$299.80
67105	Repair detached retina	Y		P2		5.2001	\$215.29	\$215.29
67107	Repair detached retina	Y		A2	\$717.00	37.2078	\$1,540.44	\$922.86
67108	Repair detached retina	Y		A2	\$995.00	37.2078	\$1,540.44	\$1,131.36
67110	Repair detached retina	Y		P3		7.8749	\$326.03	\$326.03
67112	Rerepair detached retina	Y		A2	\$995.00	37.2078	\$1,540.44	\$1,131.36
67113	Repair retinal detach, cplx	Y		NI		37.2078	\$1,540.44	\$1,540.44
67115	Release encircling material	Y		A2	\$446.00	18.235	\$754.95	\$523.24
67120	Remove eye implant material	Y		A2	\$446.00	18.235	\$754.95	\$523.24
67121	Remove eye implant material	Y		A2	\$446.00	27.845	\$1,152.81	\$622.70
67141	Treatment of retina	Y		A2	\$241.77	4.1331	\$171.11	\$224.11
67145	Treatment of retina	Y		P3		4.5506	\$188.40	\$188.40
67208	Treatment of retinal lesion	Y		P3		4.8385	\$200.32	\$200.32
67210	Treatment of retinal lesion	Y		CH		5.1349	\$212.59	\$212.59
67218	Treatment of retinal lesion	Y		A2	\$717.00	18.235	\$754.95	\$726.49
67220	Treatment of choroid lesion	Y		P2		4.1331	\$171.11	\$171.11
67221	Ocular photodynamic ther	Y		P3		2.9789	\$123.33	\$123.33
67225	Eye photodynamic ther add-on	Y		P3		0.1976	\$8.18	\$8.18
67227	Treatment of retinal lesion	Y		A2	\$333.00	27.845	\$1,152.81	\$537.95
67228	Treatment of retinal lesion	Y		P2		5.2001	\$215.29	\$215.29
67229*	Tr retinal les preterm inf	Y		NI		5.2001	\$215.29	\$215.29
67250	Reinforce eye wall	Y		A2	\$510.00	18.7307	\$775.47	\$576.37
67255	Reinforce/graft eye wall	Y		A2	\$510.00	27.845	\$1,152.81	\$670.70
67311	Revise eye muscle	Y		A2	\$510.00	24.1291	\$998.97	\$632.24
67312	Revise two eye muscles	Y		A2	\$630.00	24.1291	\$998.97	\$722.24

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
67314	Revise eye muscle	Y		A2	\$630.00	24.1291	\$998.97	\$722.24
67316	Revise two eye muscles	Y		A2	\$630.00	24.1291	\$998.97	\$722.24
67318	Revise eye muscle(s)	Y		A2	\$630.00	24.1291	\$998.97	\$722.24
67320	Revise eye muscle(s) add-on	Y		A2	\$630.00	24.1291	\$998.97	\$722.24
67331	Eye surgery follow-up add-on	Y		A2	\$630.00	24.1291	\$998.97	\$722.24
67332	Rerevise eye muscles add-on	Y		A2	\$630.00	24.1291	\$998.97	\$722.24
67334	Revise eye muscle w/suture	Y		A2	\$630.00	24.1291	\$998.97	\$722.24
67335	Eye suture during surgery	Y		A2	\$630.00	24.1291	\$998.97	\$722.24
67340	Revise eye muscle add-on	Y		A2	\$630.00	24.1291	\$998.97	\$722.24
67343	Release eye tissue	Y		A2	\$995.00	24.1291	\$998.97	\$995.99
67345	Destroy nerve of eye muscle	Y		P3		1.9584	\$81.08	\$81.08
67346	Biopsy, eye muscle	Y		A2	\$333.00	13.7453	\$569.07	\$392.02
67400	Explore/biopsy eye socket	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09
67405	Explore/drain eye socket	Y		A2	\$630.00	24.3077	\$1,006.36	\$724.09
67412	Explore/treat eye socket	Y		A2	\$717.00	24.3077	\$1,006.36	\$789.34
67413	Explore/treat eye socket	Y		A2	\$717.00	24.3077	\$1,006.36	\$789.34
67414	Explr/decompress eye socket	Y		G2		37.7243	\$1,561.82	\$1,561.82
67415	Aspiration, orbital contents	Y		A2	\$333.00	18.7307	\$775.47	\$443.62
67420	Explore/treat eye socket	Y		A2	\$717.00	37.7243	\$1,561.82	\$928.21
67430	Explore/treat eye socket	Y		A2	\$717.00	37.7243	\$1,561.82	\$928.21
67440	Explore/drain eye socket	Y		A2	\$717.00	37.7243	\$1,561.82	\$928.21
67445	Explr/decompress eye socket	Y		A2	\$717.00	37.7243	\$1,561.82	\$928.21
67450	Explore/biopsy eye socket	Y		A2	\$717.00	37.7243	\$1,561.82	\$928.21
67500	Inject/treat eye socket	N		G2		2.179	\$90.21	\$90.21
67505	Inject/treat eye socket	Y		G2		2.9022	\$120.15	\$120.15
67515	Inject/treat eye socket	Y		P3		0.5596	\$23.17	\$23.17
67550	Insert eye socket implant	Y		A2	\$630.00	37.7243	\$1,561.82	\$862.96
67560	Revise eye socket implant	Y		A2	\$446.00	24.3077	\$1,006.36	\$586.09
67570	Decompress optic nerve	Y		A2	\$630.00	37.7243	\$1,561.82	\$862.96
67700	Drainage of eyelid abscess	Y		P2		2.9022	\$120.15	\$120.15
67710	Incision of eyelid	Y		P3		3.7277	\$154.33	\$154.33
67715	Incision of eyelid fold	Y		A2	\$333.00	18.7307	\$775.47	\$443.62
67800	Remove eyelid lesion	Y		P3		1.2343	\$51.10	\$51.10
67801	Remove eyelid lesions	Y		P3		1.4975	\$62.00	\$62.00
67805	Remove eyelid lesions	Y		P3		1.9338	\$80.06	\$80.06
67808	Remove eyelid lesion(s)	Y		A2	\$446.00	18.7307	\$775.47	\$528.37
67810	Biopsy of eyelid	Y		P2		2.9022	\$120.15	\$120.15
67820	Revise eyelashes	N		P3		0.428	\$17.72	\$17.72
67825	Revise eyelashes	Y		P3		1.292	\$53.49	\$53.49
67830	Revise eyelashes	Y		A2	\$446.00	7.2847	\$301.59	\$409.90
67835	Revise eyelashes	Y		A2	\$446.00	18.7307	\$775.47	\$528.37
67840	Remove eyelid lesion	Y		P3		3.8593	\$159.78	\$159.78
67850	Treat eyelid lesion	Y		P3		2.7403	\$113.45	\$113.45
67875	Closure of eyelid by suture	Y		G2		7.2847	\$301.59	\$301.59
67880	Revision of eyelid	Y		A2	\$510.00	16.171	\$669.50	\$549.88
67882	Revision of eyelid	Y		A2	\$510.00	18.7307	\$775.47	\$576.37
67900	Repair brow defect	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
67901	Repair eyelid defect	Y		A2	\$717.00	18.7307	\$775.47	\$731.62
67902	Repair eyelid defect	Y		A2	\$717.00	18.7307	\$775.47	\$731.62
67903	Repair eyelid defect	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
67904	Repair eyelid defect	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
67906	Repair eyelid defect	Y		A2	\$717.00	18.7307	\$775.47	\$731.62
67908	Repair eyelid defect	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
67909	Revise eyelid defect	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
67911	Revise eyelid defect	Y		A2	\$510.00	18.7307	\$775.47	\$576.37
67912	Correction eyelid w/implant	Y		A2	\$510.00	18.7307	\$775.47	\$576.37
67914	Repair eyelid defect	Y		A2	\$510.00	18.7307	\$775.47	\$576.37
67915	Repair eyelid defect	Y		P3		4.2378	\$175.45	\$175.45
67916	Repair eyelid defect	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
67917	Repair eyelid defect	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
67921	Repair eyelid defect	Y		A2	\$510.00	18.7307	\$775.47	\$576.37
67922	Repair eyelid defect	Y		P3		4.139	\$171.36	\$171.36
67923	Repair eyelid defect	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
67924	Repair eyelid defect	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
67930	Repair eyelid wound	Y		P3		4.1472	\$171.70	\$171.70
67935	Repair eyelid wound	Y		A2	\$446.00	18.7307	\$775.47	\$528.37
67938	Remove eyelid foreign body	N		P2		2.179	\$90.21	\$90.21
67950	Revision of eyelid	Y		A2	\$446.00	18.7307	\$775.47	\$528.37
67961	Revision of eyelid	Y		A2	\$510.00	18.7307	\$775.47	\$576.37
67966	Revision of eyelid	Y		A2	\$510.00	18.7307	\$775.47	\$576.37
67971	Reconstruction of eyelid	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09
67973	Reconstruction of eyelid	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09
67974	Reconstruction of eyelid	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
67975	Reconstruction of eyelid	Y		A2	\$510.00	18.7307	\$775.47	\$576.37
68020	Incise/drain eyelid lining	Y		P3		1.0862	\$44.97	\$44.97
68040	Treatment of eyelid lesions	N		P3		0.5348	\$22.14	\$22.14
68100	Biopsy of eyelid lining	Y		P3		2.3041	\$95.39	\$95.39
68110	Remove eyelid lining lesion	Y		P3		2.9458	\$121.96	\$121.96
68115	Remove eyelid lining lesion	Y		A2	\$446.00	18.7307	\$775.47	\$528.37
68130	Remove eyelid lining lesion	Y		A2	\$446.00	16.171	\$669.50	\$501.88
68135	Remove eyelid lining lesion	Y		P3		1.399	\$57.92	\$57.92
68200	Treat eyelid by injection	N		P3		0.4031	\$16.69	\$16.69
68320	Revise/graft eyelid lining	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
68325	Revise/graft eyelid lining	Y		A2	\$630.00	24.3077	\$1,006.36	\$724.09
68326	Revise/graft eyelid lining	Y		A2	\$630.00	24.3077	\$1,006.36	\$724.09
68328	Revise/graft eyelid lining	Y		A2	\$630.00	24.3077	\$1,006.36	\$724.09
68330	Revise eyelid lining	Y		A2	\$630.00	23.1758	\$959.50	\$712.38
68335	Revise/graft eyelid lining	Y		A2	\$630.00	24.3077	\$1,006.36	\$724.09
68340	Separate eyelid adhesions	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
68360	Revise eyelid lining	Y		A2	\$446.00	23.1758	\$959.50	\$574.38
68362	Revise eyelid lining	Y		A2	\$446.00	23.1758	\$959.50	\$574.38
68371	Harvest eye tissue, alograft	Y		A2	\$446.00	16.171	\$669.50	\$501.88
68400	Incise/drain tear gland	Y		P2		2.9022	\$120.15	\$120.15
68420	Incise/drain tear sac	Y		P3		4.4354	\$183.63	\$183.63
68440	Incise tear duct opening	Y		P3		1.3741	\$56.89	\$56.89
68500	Removal of tear gland	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09
68505	Partial removal, tear gland	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09
68510	Biopsy of tear gland	Y		A2	\$333.00	18.7307	\$775.47	\$443.62
68520	Removal of tear sac	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09
68525	Biopsy of tear sac	Y		A2	\$333.00	18.7307	\$775.47	\$443.62
68530	Clearance of tear duct	Y		P3		5.6615	\$234.39	\$234.39
68540	Remove tear gland lesion	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09
68550	Remove tear gland lesion	Y		A2	\$510.00	24.3077	\$1,006.36	\$634.09
68700	Repair tear ducts	Y		A2	\$446.00	24.3077	\$1,006.36	\$586.09
68705	Revise tear duct opening	Y		P2		2.9022	\$120.15	\$120.15
68720	Create tear sac drain	Y		A2	\$630.00	24.3077	\$1,006.36	\$724.09
68745	Create tear duct drain	Y		A2	\$630.00	24.3077	\$1,006.36	\$724.09
68750	Create tear duct drain	Y		A2	\$630.00	24.3077	\$1,006.36	\$724.09
68760	Close tear duct opening	N		P2		2.179	\$90.21	\$90.21
68761	Close tear duct opening	N		P3		1.6869	\$69.84	\$69.84
68770	Close tear system fistula	Y		A2	\$630.00	18.7307	\$775.47	\$666.37
68801	Dilate tear duct opening	N		P2		0.8696	\$36.00	\$36.00
68810	Probe nasolacrimal duct	N		A2	\$131.86	2.179	\$90.21	\$121.45
68811	Probe nasolacrimal duct	Y		A2	\$446.00	18.7307	\$775.47	\$528.37
68815	Probe nasolacrimal duct	Y		A2	\$446.00	18.7307	\$775.47	\$528.37
68816*	Probe nl duct w/balloon	Y	NI	P3		10.4754	\$433.69	\$433.69
68840	Explore/irrigate tear ducts	N	CH	P3		1.2756	\$52.81	\$52.81
68850	Injection for tear sac x-ray	N		N1				
69000	Drain external ear lesion	Y		P2		1.4066	\$58.23	\$58.23
69005	Drain external ear lesion	Y		P3		2.4357	\$100.84	\$100.84
69020	Drain outer ear canal lesion	Y		P2		1.4066	\$58.23	\$58.23
69100	Biopsy of external ear	Y		P3		1.4647	\$60.64	\$60.64
69105	Biopsy of external ear canal	Y		P3		2.049	\$84.83	\$84.83
69110	Remove external ear, partial	Y		A2	\$333.00	16.1001	\$666.56	\$416.39
69120	Removal of external ear	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
69140	Remove ear canal lesion(s)	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
69145	Remove ear canal lesion(s)	Y		A2	\$446.00	16.1001	\$666.56	\$501.14
69150	Extensive ear canal surgery	Y		A2	\$464.15	7.4474	\$308.33	\$425.20
69200	Clear outer ear canal	N		P2		0.631	\$26.12	\$26.12
69205	Clear outer ear canal	Y		A2	\$333.00	21.1098	\$873.97	\$468.24
69210	Remove impacted ear wax	N		P3		0.4937	\$20.44	\$20.44
69220	Clean out mastoid cavity	Y		P2		0.793	\$32.83	\$32.83
69222	Clean out mastoid cavity	Y		P3		3.2176	\$133.21	\$133.21
69300	Revise external ear	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
69310	Rebuild outer ear canal	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
69320	Rebuild outer ear canal	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69400	Inflate middle ear canal	Y		P3		2.049	\$84.83	\$84.83
69401	Inflate middle ear canal	Y		P3		1.1355	\$47.01	\$47.01
69405	Catheterize middle ear canal	Y		P3		2.9458	\$121.96	\$121.96
69420	Incision of eardrum	Y		P2		2.5002	\$103.51	\$103.51
69421	Incision of eardrum	Y		A2	\$510.00	16.3288	\$676.03	\$551.51
69424	Remove ventilating tube	Y		P3		1.8596	\$76.99	\$76.99
69433	Create eardrum opening	Y		P3		2.6333	\$109.02	\$109.02
69436	Create eardrum opening	Y		A2	\$510.00	16.3288	\$676.03	\$551.51
69440	Exploration of middle ear	Y		A2	\$510.00	23.9765	\$992.65	\$630.66
69450	Eardrum revision	Y		A2	\$333.00	39.8776	\$1,650.97	\$662.49

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
69501	Mastoidectomy	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69502	Mastoidectomy	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
69505	Remove mastoid structures	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69511	Extensive mastoid surgery	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69530	Extensive mastoid surgery	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69540	Remove ear lesion	Y		P3		3.1434	\$130.14	\$130.14
69550	Remove ear lesion	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69552	Remove ear lesion	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69601	Mastoid surgery revision	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69602	Mastoid surgery revision	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69603	Mastoid surgery revision	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69604	Mastoid surgery revision	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69605	Mastoid surgery revision	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69610	Repair of eardrum	Y		P3		4.3038	\$178.18	\$178.18
69620	Repair of eardrum	Y		A2	\$446.00	23.9765	\$992.65	\$582.66
69631	Repair eardrum structures	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69632	Rebuild eardrum structures	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69633	Rebuild eardrum structures	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69635	Repair eardrum structures	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69636	Rebuild eardrum structures	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69637	Rebuild eardrum structures	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69641	Revise middle ear & mastoid	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69642	Revise middle ear & mastoid	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69643	Revise middle ear & mastoid	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69644	Revise middle ear & mastoid	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69645	Revise middle ear & mastoid	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69646	Revise middle ear & mastoid	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69650	Release middle ear bone	Y		A2	\$995.00	23.9765	\$992.65	\$994.41
69660	Revise middle ear bone	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69661	Revise middle ear bone	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69662	Revise middle ear bone	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69666	Repair middle ear structures	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
69667	Repair middle ear structures	Y		A2	\$630.00	39.8776	\$1,650.97	\$885.24
69670	Remove mastoid air cells	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
69676	Remove middle ear nerve	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
69700	Close mastoid fistula	Y		A2	\$510.00	39.8776	\$1,650.97	\$795.24
69711	Remove/repair hearing aid	Y		A2	\$333.00	39.8776	\$1,650.97	\$662.49
69714	Implant temple bone w/stimul	Y		A2	\$1,339.00	39.8776	\$1,650.97	\$1,416.99
69715	Temple bone implant w/stimulat	Y		A2	\$1,339.00	39.8776	\$1,650.97	\$1,416.99
69717	Temple bone implant revision	Y		A2	\$1,339.00	39.8776	\$1,650.97	\$1,416.99
69718	Revise temple bone implant	Y		A2	\$1,339.00	39.8776	\$1,650.97	\$1,416.99
69720	Release facial nerve	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69740	Repair facial nerve	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69745	Repair facial nerve	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69801	Incise inner ear	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69802	Incise inner ear	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69805	Explore inner ear	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69806	Explore inner ear	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69820	Establish inner ear window	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69840	Revise inner ear window	Y		A2	\$717.00	39.8776	\$1,650.97	\$950.49
69905	Remove inner ear	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69910	Remove inner ear & mastoid	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69915	Incise inner ear nerve	Y		A2	\$995.00	39.8776	\$1,650.97	\$1,158.99
69930	Implant cochlear device	Y		H8	\$995.00	568.8394	\$23,550.52	\$22,213.76
69990	Microsurgery add-on	N		N1				
C9716	Radiofrequency energy to anu	Y		G2		30.1606	\$1,248.68	\$1,248.68
C9724	EPS gast cardia plic	Y		G2		25.3233	\$1,048.41	\$1,048.41
C9725	Place endorectal app	N		G2		8.6351	\$357.50	\$357.50
C9726	Rxt breast appl place/remov	N		G2		10.2051	\$422.50	\$422.50
C9727	Insert palate implants	N		G2		13.3451	\$552.50	\$552.50
C9728	Place device/marker, non pro	N		R2		3.0469	\$126.14	\$126.14
G0104	CA screen;flexi sigmoidscope	Y	CH	P3		1.9748	\$81.76	\$81.76
G0105	Colorectal scrn; hi risk ind	Y		A2	\$446.00	7.8504	\$325.01	\$415.75
G0121	Colon ca scrn not hi rsk ind	Y		A2	\$446.00	7.8504	\$325.01	\$415.75
G0127	Trim nail(s)	Y		P3		0.2633	\$10.90	\$10.90
G0186	Dstry eye lesn, fdr vssl tech	Y		R2		4.1331	\$171.11	\$171.11
G0247	Routine footcare pt w lops	Y		P3		0.4937	\$20.44	\$20.44
G0259	Injct for sacroiliac joint	N		N1				
G0260	Inj for sacroiliac jt anesth	Y		A2	\$333.00	7.0546	\$292.07	\$322.77
G0268	Removal of impacted wax md	N	CH	N1				
G0269	Occlusive device in vein art	N		N1				
G0289	Arthro, loose body + chondro	N		N1				
G0364	Bone marrow aspirate & biopsy	Y		P3		0.1234	\$5.11	\$5.11

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM AA.—ASC COVERED SURGICAL PROCEDURES FOR CY 2008—Continued
 [Including surgical procedures for which payment is packaged]

HCPCS code	Short descriptor	Subject to multiple procedure discounting	Comment indicator	Payment indicator	CY 2007 ASC payment rate	CY 2008 fully implemented payment weight	CY 2008 fully implemented payment	CY 2008 first transition year payment
G0392	AV fistula or graft arterial	Y		A2	\$1,339.00	45.3845	\$1,878.96	\$1,473.99
G0393	AV fistula or graft venous	Y		A2	\$1,339.00	45.3845	\$1,878.96	\$1,473.99

Note: The Medicare program payment is 80 percent of the total payment amount and beneficiary coinsurance is 20 percent of the total payment amount, except for screening flexible sigmoidoscopies and screening colonoscopies for which the program payment is 75 percent and the beneficiary coinsurance is 25 percent.

* Refers to HCPCS codes designated as "office-based," whose designation as office-based is temporary because we have insufficient claims data. We will reconsider this designation when new claims data become available.

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0001F	Heart failure composite		M					
0005F	Osteoarthritis composite		M					
00100	Anesth, salivary gland		N					
00102	Anesth, repair of cleft lip		N					
00103	Anesth, blepharoplasty		N					
00104	Anesth, electroshock		N					
00120	Anesth, ear surgery		N					
00124	Anesth, ear exam		N					
00126	Anesth, tympanotomy		N					
0012F	Cap bacterial assess		M					
00140	Anesth, procedures on eye		N					
00142	Anesth, lens surgery		N					
00144	Anesth, corneal transplant		N					
00145	Anesth, vitreoretinal surg		N					
00147	Anesth, iridectomy		N					
00148	Anesth, eye exam		N					
0014F	Comp preop assess cat surg	NI	M					
0015F	Melan follow-up complete	NI	M					
00160	Anesth, nose/sinus surgery		N					
00162	Anesth, nose/sinus surgery		N					
00164	Anesth, biopsy of nose		N					
0016T	Thermotx choroid vasc lesion		T	0235	4.1331	\$263.25	\$58.93	\$52.65
00170	Anesth, procedure on mouth		N					
00172	Anesth, cleft palate repair		N					
00174	Anesth, pharyngeal surgery		N					
00176	Anesth, pharyngeal surgery		C					
0017T	Photocoagulat macular drusen		T	0235	4.1331	\$263.25	\$58.93	\$52.65
00190	Anesth, face/skull bone surg		N					
00192	Anesth, facial bone surgery		C					
0019T	Extracorp shock wv tx,ms nos		A					
00210	Anesth, open head surgery		N					
00212	Anesth, skull drainage		N					
00214	Anesth, skull drainage		C					
00215	Anesth, skull repair/fract		C					
00216	Anesth, head vessel surgery		N					
00218	Anesth, special head surgery		N					
00220	Anesth, intrcrn nerve		N					
00222	Anesth, head nerve surgery		N					
0026T	Measure remnant lipoproteins		A					
0027T	Endoscopic epidural lysis		T	0220	18.0518	\$1,149.79		\$229.96
0028T	Dexa body composition study		N					
0029T	Magnetic tx for incontinence		A					
00300	Anesth, head/neck/ptrunk		N					
0030T	Antiprothrombin antibody		A					
0031T	Speculoscopy		N					
00320	Anesth, neck organ, 1 & over		N					
00322	Anesth, biopsy of thyroid		N					
00326	Anesth, larynx/trach, < 1 yr		N					
0032T	Speculoscopy w/direct sample		N					
00350	Anesth, neck vessel surgery		N					
00352	Anesth, neck vessel surgery		N					
00400	Anesth, skin, ext/per/atrukn		N					
00402	Anesth, surgery of breast		N					
00404	Anesth, surgery of breast		N					
00406	Anesth, surgery of breast		N					
00410	Anesth, correct heart rhythm		N					
0041T	Detect ur infect agnt w/cpas		A					
0042T	Ct perfusion w/contrast, cbf		N					
0043T	Co expired gas analysis		A					
00450	Anesth, surgery of shoulder		N					
00452	Anesth, surgery of shoulder		C					
00454	Anesth, collar bone biopsy		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0046T	Cath lavage, mammary duct(s)		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
00470	Anesth, removal of rib		N					
00472	Anesth, chest wall repair		N					
00474	Anesth, surgery of rib(s)		C					
0047T	Cath lavage, mammary duct(s)		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
0048T	Implant ventricular device		C					
0049T	External circulation assist		C					
00500	Anesth, esophageal surgery		N					
0050T	Removal circulation assist		C					
0051T	Implant total heart system		C					
00520	Anesth, chest procedure		N					
00522	Anesth, chest lining biopsy		N					
00524	Anesth, chest drainage		C					
00528	Anesth, chest partition view		N					
00529	Anesth, chest partition view		N					
0052T	Replace component heart syst		C					
00530	Anesth, pacemaker insertion		N					
00532	Anesth, vascular access		N					
00534	Anesth, cardioverter/defib		N					
00537	Anesth, cardiac electrophys		N					
00539	Anesth, trach-bronch reconst		N					
0053T	Replace component heart syst		C					
00540	Anesth, chest surgery		C					
00541	Anesth, one lung ventilation		N					
00542	Anesth, release of lung		C					
00546	Anesth, lung,chest wall surg		C					
00548	Anesth, trachea,bronchi surg		N					
0054T	Bone surgery using computer	CH	D					
00550	Anesth, sternal debridement		N					
0055T	Bone surgery using computer	CH	D					
00560	Anesth, heart surg w/o pump		C					
00561	Anesth, heart surg < age 1		C					
00562	Anesth, heart surg w/pump		C					
00563	Anesth, heart surg w/arrest		N					
00566	Anesth, cabg w/o pump		N					
0056T	Bone surgery using computer	CH	D					
00580	Anesth, heart/lung transplt		C					
0058T	Cryopreservation, ovary tiss	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
0059T	Cryopreservation, oocyte	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
00600	Anesth, spine, cord surgery		N					
00604	Anesth, sitting procedure		C					
0060T	Electrical impedance scan		B					
0061T	Destruction of tumor, breast		B					
00620	Anesth, spine, cord surgery		N					
00622	Anesth, removal of nerves		C					
00625	Anes spine tranthor w/o vent		N					
00626	Anes, spine tranthor w/vent		N					
0062T	Rep intradisc annulus;1 lev		T	0050	29.1900	\$1,859.23		\$371.85
00630	Anesth, spine, cord surgery		N					
00632	Anesth, removal of nerves		C					
00634	Anesth for chemonucleolysis		N					
00635	Anesth, lumbar puncture		N					
0063T	Rep intradisc annulus;>1lev		T	0050	29.1900	\$1,859.23		\$371.85
00640	Anesth, spine manipulation		N					
0064T	Spectroscop eval expired gas		X	0367	0.5677	\$36.16	\$13.76	\$7.23
0065T	Ocular photoscreen bilat	CH	D					
0066T	Ct colonography;screen		E					
00670	Anesth, spine, cord surgery		C					
0067T	Ct colonography;dx	CH	S	0332	3.0109	\$191.78	\$75.24	\$38.36
0068T	Interp/rept heart sound		B					
0069T	Analysis only heart sound		N					
00700	Anesth, abdominal wall surg		N					
00702	Anesth, for liver biopsy		N					
0070T	Interp only heart sound		B					
0071T	U/s leiomyomata ablate <200	CH	S	0067	61.6965	\$3,929.70		\$785.94
0072T	U/s leiomyomata ablate >200	CH	S	0067	61.6965	\$3,929.70		\$785.94
00730	Anesth, abdominal wall surg		N					
0073T	Delivery, comp imrt		S	0412	5.4582	\$347.65		\$69.53
00740	Anesth, upper gi visualize		N					
0074T	Online physician e/m	CH	D					
00750	Anesth, repair of hernia		N					
00752	Anesth, repair of hernia		N					
00754	Anesth, repair of hernia		N					
00756	Anesth, repair of hernia		N					
0075T	Perq stent/chest vert art		C					
0076T	S&i stent/chest vert art		C					
00770	Anesth, blood vessel repair		N					
0077T	Cereb therm perfusion probe		C					
0078T	Endovasc aort repr w/device		C					
00790	Anesth, surg upper abdomen		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
00792	Anesth, hemorr/excise liver		C					
00794	Anesth, pancreas removal		C					
00796	Anesth, for liver transplant		C					
00797	Anesth, surgery for obesity		N					
0079T	Endovasc visc extnsn repr		C					
00800	Anesth, abdominal wall surg		N					
00802	Anesth, fat layer removal		C					
0080T	Endovasc aort repr rad s&i		C					
00810	Anesth, low intestine scope		N					
0081T	Endovasc visc extnsn s&i		C					
00820	Anesth, abdominal wall surg		N					
00830	Anesth, repair of hernia		N					
00832	Anesth, repair of hernia		N					
00834	Anesth, hernia repair< 1 yr		N					
00836	Anesth hernia repair preemie		N					
00840	Anesth, surg lower abdomen		N					
00842	Anesth, amniocentesis		N					
00844	Anesth, pelvis surgery		C					
00846	Anesth, hysterectomy		C					
00848	Anesth, pelvic organ surg		C					
0084T	Temp prostate urethral stent		T	0164	2.0077	\$127.88		\$25.58
00851	Anesth, tubal ligation		N					
0085T	Breath test heart reject		X	0340	0.6310	\$40.19		\$8.04
00860	Anesth, surgery of abdomen		N					
00862	Anesth, kidney/ureter surg		N					
00864	Anesth, removal of bladder		C					
00865	Anesth, removal of prostate		C					
00866	Anesth, removal of adrenal		C					
00868	Anesth, kidney transplant		C					
0086T	L ventricle fill pressure		N					
00870	Anesth, bladder stone surg		N					
00872	Anesth kidney stone destruct		N					
00873	Anesth kidney stone destruct		N					
0087T	Sperm eval hyaluronan	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
00880	Anesth, abdomen vessel surg		N					
00882	Anesth, major vein ligation		T					
0088T	Rf tongue base vol reduxn		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
0089T	Actigraphy testing, 3-day		S	0218	1.1550	\$73.57		\$14.71
00902	Anesth, anorectal surgery		N					
00904	Anesth, perineal surgery		C					
00906	Anesth, removal of vulva		N					
00908	Anesth, removal of prostate		C					
0090T	Cervical artific disc		C					
00910	Anesth, bladder surgery		N					
00912	Anesth, bladder tumor surg		N					
00914	Anesth, removal of prostate		N					
00916	Anesth, bleeding control		N					
00918	Anesth, stone removal		N					
00920	Anesth, genitalia surgery		N					
00921	Anesth, vasectomy		N					
00922	Anesth, sperm duct surgery		N					
00924	Anesth, testis exploration		N					
00926	Anesth, removal of testis		N					
00928	Anesth, removal of testis		N					
0092T	Artific disc addl		C					
00930	Anesth, testis suspension		N					
00932	Anesth, amputation of penis		C					
00934	Anesth, penis, nodes removal		C					
00936	Anesth, penis, nodes removal		C					
00938	Anesth, insert penis device		N					
0093T	Cervical artific disectomy		C					
00940	Anesth, vaginal procedures		N					
00942	Anesth, surg on vag/urethral		N					
00944	Anesth, vaginal hysterectomy		C					
00948	Anesth, repair of cervix		N					
00950	Anesth, vaginal endoscopy		N					
00952	Anesth, hysteroscope/graph		N					
0095T	Artific disectomy addl		C					
0096T	Rev cervical artific disc		C					
0098T	Rev artific disc addl		C					
0099T	Implant corneal ring		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
0100T	Prosth retina receive&gen		T	0672	37.2078	\$2,369.91		\$473.98
0101T	Extracorp shockwv tx,hi enrg		T	0050	29.1900	\$1,859.23		\$371.85
0102T	Extracorp shockwv tx,anesth		T	0050	29.1900	\$1,859.23		\$371.85
0103T	Holotranscobalamin		A					
0104T	At rest cardio gas rebreathe		A					
0105T	Exerc cardio gas rebreathe		A					
0106T	Touch quant sensory test		X	0341	0.0844	\$5.38	\$2.14	\$1.08
0107T	Vibrate quant sensory test		X	0341	0.0844	\$5.38	\$2.14	\$1.08
0108T	Cool quant sensory test		X	0341	0.0844	\$5.38	\$2.14	\$1.08

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0109T	Heat quant sensory test		X	0341	0.0844	\$5.38	\$2.14	\$1.08
0110T	Nos quant sensory test		X	0341	0.0844	\$5.38	\$2.14	\$1.08
01112	Anesth, bone aspirate/bx		N					
0111T	Rbc membranes fatty acids		A					
01120	Anesth, pelvis surgery		N					
01130	Anesth, body cast procedure		N					
01140	Anesth, amputation at pelvis		C					
01150	Anesth, pelvic tumor surgery		C					
0115T	Med tx mngmt 15 min	CH	D					
01160	Anesth, pelvis procedure		N					
0116T	Med tx mngmt subsqt	CH	D					
01170	Anesth, pelvis surgery		N					
01173	Anesth, fx repair, pelvis		N					
0117T	Med tx mngmt addl 15 min	CH	D					
01180	Anesth, pelvis nerve removal		N					
01190	Anesth, pelvis nerve removal		N					
01200	Anesth, hip joint procedure		N					
01202	Anesth, arthroscopy of hip		N					
01210	Anesth, hip joint surgery		N					
01212	Anesth, hip disarticulation		C					
01214	Anesth, hip arthroplasty		C					
01215	Anesth, revise hip repair		N					
01220	Anesth, procedure on femur		N					
01230	Anesth, surgery of femur		N					
01232	Anesth, amputation of femur		C					
01234	Anesth, radical femur surg		C					
0123T	Scleral fistulization		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
0124T	Conjunctival drug placement		T	0232	5.1169	\$325.92	\$81.65	\$65.18
01250	Anesth, upper leg surgery		N					
01260	Anesth, upper leg veins surg		N					
0126T	Chd risk imt study	CH	Q	0340	0.6310	\$40.19		\$8.04
01270	Anesth, thigh arteries surg		N					
01272	Anesth, femoral artery surg		C					
01274	Anesth, femoral embolectomy		C					
0130T	Chron care drug investigatn		B					
01320	Anesth, knee area surgery		N					
01340	Anesth, knee area procedure		N					
0135T	Perq cryoablate renal tumor	CH	D					
01360	Anesth, knee area surgery		N					
0137T	Prostate saturation sampling		T	0184	11.0338	\$702.79		\$140.56
01380	Anesth, knee joint procedure		N					
01382	Anesth, dx knee arthroscopy		N					
01390	Anesth, knee area procedure		N					
01392	Anesth, knee area surgery		N					
01400	Anesth, knee joint surgery		N					
01402	Anesth, knee arthroplasty		C					
01404	Anesth, amputation at knee		C					
0140T	Exhaled breath condensate ph		A					
0141T	Perq islet transplant		E					
01420	Anesth, knee joint casting		N					
0142T	Open islet transplant		E					
01430	Anesth, knee veins surgery		N					
01432	Anesth, knee vessel surg		N					
0143T	Laparoscopic islet transplnt		E					
01440	Anesth, knee arteries surg		N					
01442	Anesth, knee artery surg		C					
01444	Anesth, knee artery repair		C					
0144T	CT heart wo dye; qual calc	CH	S	0282	1.5839	\$100.88	\$37.81	\$20.18
0145T	CT heart w/wo dye funct	CH	S	0383	4.7005	\$299.39	\$117.06	\$59.88
01462	Anesth, lower leg procedure		N					
01464	Anesth, ankle/ft arthroscopy		N					
0146T	CCTA w/wo dye	CH	S	0383	4.7005	\$299.39	\$117.06	\$59.88
01470	Anesth, lower leg surgery		N					
01472	Anesth, achilles tendon surg		N					
01474	Anesth, lower leg surgery		N					
0147T	CCTA w/wo, quan calcium	CH	S	0383	4.7005	\$299.39	\$117.06	\$59.88
01480	Anesth, lower leg bone surg		N					
01482	Anesth, radical leg surgery		N					
01484	Anesth, lower leg revision		N					
01486	Anesth, ankle replacement		C					
0148T	CCTA w/wo, strxr	CH	S	0383	4.7005	\$299.39	\$117.06	\$59.88
01490	Anesth, lower leg casting		N					
0149T	CCTA w/wo, strxr quan calc	CH	S	0383	4.7005	\$299.39	\$117.06	\$59.88
01500	Anesth, leg arteries surg		N					
01502	Anesth, lwr leg embolectomy		C					
0150T	CCTA w/wo, disease strxr	CH	S	0383	4.7005	\$299.39	\$117.06	\$59.88
0151T	CT heart funct add-on		S	0282	1.5839	\$100.88	\$37.81	\$20.18
01520	Anesth, lower leg vein surg		N					
01522	Anesth, lower leg vein surg		N					
0153T	Tcath sensor aneurysm sac	CH	D					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
0154T	Study sensor aneurysm sac	CH	D					
0155T	Lap impl gast curve electr		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
0156T	Lap remv gast curve electr		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
0157T	Open impl gast curve electr		C					
0158T	Open remv gast curve electr		C					
0159T	Cad breast mri		N					
0160T	Tcranial magn stim tx plan		S	0216	2.6846	\$170.99		\$34.20
01610	Anesth, surgery of shoulder		N					
0161T	Tcranial magn stim tx deliv		S	0216	2.6846	\$170.99		\$34.20
01620	Anesth, shoulder procedure		N					
01622	Anes dx shoulder arthroscopy		N					
0162T	Anal program gast neurostim		S	0692	1.8376	\$117.04	\$29.72	\$23.41
01630	Anesth, surgery of shoulder		N					
01632	Anesth, surgery of shoulder		C					
01634	Anesth, shoulder joint amput		C					
01636	Anesth, forequarter amput		C					
01638	Anesth, shoulder replacement		C					
0163T	Lumb artif disectomy addl		C					
0164T	Remove lumb artif disc addl		C					
01650	Anesth, shoulder artery surg		N					
01652	Anesth, shoulder vessel surg		C					
01654	Anesth, shoulder vessel surg		C					
01656	Anesth, arm-leg vessel surg		C					
0165T	Revise lumb artif disc addl		C					
0166T	Tcath vsd close w/o bypass		C					
01670	Anesth, shoulder vein surg		N					
0167T	Tcath vsd close w bypass		C					
01680	Anesth, shoulder casting		N					
01682	Anesth, airplane cast		N					
0168T	Rhinophototx light app bilat		T	0251	2.5002	\$159.25		\$31.85
0169T	Place stereo cath brain		C					
0170T	Anorectal fistula plug rpr		T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
01710	Anesth, elbow area surgery		N					
01712	Anesth, uppr arm tendon surg		N					
01714	Anesth, uppr arm tendon surg		N					
01716	Anesth, biceps tendon repair		N					
0171T	Lumbar spine proces distract		T	0050	29.1900	\$1,859.23		\$371.85
0172T	Lumbar spine process addl		T	0050	29.1900	\$1,859.23		\$371.85
01730	Anesth, uppr arm procedure		N					
01732	Anesth, dx elbow arthroscopy		N					
0173T	lop monit io pressure		N					
01740	Anesth, upper arm surgery		N					
01742	Anesth, humerus surgery		N					
01744	Anesth, humerus repair		N					
0174T	Cad cxr with interp		N					
01756	Anesth, radical humerus surg		C					
01758	Anesth, humeral lesion surg		N					
0175T	Cad cxr remote		N					
01760	Anesth, elbow replacement		N					
0176T	Aqu canal dilat w/o retent		T	0673	39.7101	\$2,529.30	\$649.56	\$505.86
01770	Anesth, uppr arm artery surg		N					
01772	Anesth, uppr arm embolectomy		N					
0177T	Aqu canal dilat w retent		T	0673	39.7101	\$2,529.30	\$649.56	\$505.86
01780	Anesth, upper arm vein surg		N					
01782	Anesth, uppr arm vein repair		N					
0178T	64 lead ecg w i&r	NF	B					
0179T	64 lead ecg w tracing	NF	X	0100	2.5547	\$162.72	\$41.44	\$32.54
0180T	64 lead ecg w i&r only	NF	B					
01810	Anesth, lower arm surgery		N					
0181T	Corneal hysteresis	NF	S	0230	0.5903	\$37.60		\$7.52
01820	Anesth, lower arm procedure		N					
01829	Anesth, dx wrist arthroscopy		N					
0182T	Hdr elect brachytherapy	NF	S	1519		\$1,750.00		\$350.00
01830	Anesth, lower arm surgery		N					
01832	Anesth, wrist replacement		N					
0183T	Wound ultrasound	NI	T	0015	1.4595	\$92.96		\$18.59
01840	Anesth, lwr arm artery surg		N					
01842	Anesth, lwr arm embolectomy		N					
01844	Anesth, vascular shunt surg		N					
0184T	Exc rectal tumor endoscopic	NI	C					
01850	Anesth, lower arm vein surg		N					
01852	Anesth, lwr arm vein repair		N					
0185T	Comptr probability analysis	NI	N					
01860	Anesth, lower arm casting		N					
0186T	Suprachoroidal drug delivery	NI	T	0236	18.2350	\$1,161.46		\$232.29
0187T	Ophthalmic dx image anterior	NI	S	0230	0.5903	\$37.60		\$7.52
01905	Anes, spine inject, x-ray/re	CH	D					
01916	Anesth, dx arteriography		N					
01920	Anesth, catheterize heart		N					
01922	Anesth, cat or MRI scan		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
01924	Anes, ther interven rad, art		N					
01925	Anes, ther interven rad, car		N					
01926	Anes, tx interv rad hrt/cran		N					
01930	Anes, ther interven rad, vei		N					
01931	Anes, ther interven rad, tip		N					
01932	Anes, tx interv rad, th vein		N					
01933	Anes, tx interv rad, cran v		N					
01935	Anesth, perc img dx sp proc	NI	N					
01936	Anesth, perc img tx sp proc	NI	N					
01951	Anesth, burn, less 4 percent		N					
01952	Anesth, burn, 4-9 percent		N					
01953	Anesth, burn, each 9 percent		N					
01958	Anesth, antepartum manipul		N					
01960	Anesth, vaginal delivery		N					
01961	Anesth, cs delivery		N					
01962	Anesth, emer hysterectomy		N					
01963	Anesth, cs hysterectomy		N					
01965	Anesth, inc/missed ab proc		N					
01966	Anesth, induced ab procedure		N					
01967	Anesth/analg, vag delivery		N					
01968	Anes/analg cs deliver add-on		N					
01969	Anesth/analg cs hyst add-on		N					
01990	Support for organ donor		C					
01991	Anesth, nerve block/inj		N					
01992	Anesth, n block/inj, prone		N					
01996	Hosp manage cont drug admin		N					
01999	Unlisted anesth procedure		N					
0500F	Initial prenatal care visit		M					
0501F	Prenatal flow sheet		M					
0502F	Subsequent prenatal care		M					
0503F	Postpartum care visit		M					
0505F	Hemodialysis plan doc'd		M					
0507F	Periton dialysis plan doc'd		M					
0509F	Urine incon plan doc'd		M					
0513F	Elev BP plan of care doc'd	NI	M					
0514F	Care plan Hgb doc'd ESA pt	NI	M					
0516F	Anemia plan of care doc'd	NI	M					
0517F	Glaucoma plan of care doc'd	NI	M					
0518F	Fall plan of care doc'd	NI	M					
0519F	Plan'd chemo doc'd b/4 txmnt	NI	M					
0520F	Tissue dose done w/in 5 days	NI	M					
0521F	Plan of care 4 pain doc'd	NI	M					
1000F	Tobacco use assessed		M					
10021	Fna w/o image		T	0002	1.1097	\$70.68		\$14.14
10022	Fna w/image	CH	T	0004	4.3270	\$275.60		\$55.12
1002F	Assess anginal symptom/level		M					
1003F	Level of activity assess		M					
10040	Acne surgery	CH	T	0013	0.7930	\$50.51		\$10.10
1004F	Clin symp vol ovrlid assess		M					
1005F	Asthma symptoms evaluate		M					
10060	Drainage of skin abscess		T	0006	1.4066	\$89.59		\$17.92
10061	Drainage of skin abscess		T	0006	1.4066	\$89.59		\$17.92
1006F	Osteoarthritis assess		M					
1007F	Anti-inflm/anlgsc otc assess		M					
10080	Drainage of pilonidal cyst		T	0006	1.4066	\$89.59		\$17.92
10081	Drainage of pilonidal cyst		T	0007	11.5594	\$736.26		\$147.25
1008F	Gi/renal risk assess		M					
10120	Remove foreign body		T	0006	1.4066	\$89.59		\$17.92
10121	Remove foreign body		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
10140	Drainage of hematoma/fluid		T	0007	11.5594	\$736.26		\$147.25
1015F	Copd symptoms assess		M					
10160	Puncture drainage of lesion	CH	T	0006	1.4066	\$89.59		\$17.92
10180	Complex drainage, wound		T	0008	18.3197	\$1,166.85		\$233.37
1018F	Assess dyspnea not present		M					
1019F	Assess dyspnea present		M					
1022F	Pneumo imm status assess		M					
1026F	Co-morbid condition assess		M					
1030F	Influenza imm status assess		M					
1034F	Current tobacco smoker		M					
1035F	Smokeless tobacco user		M					
1036F	Tobacco non-user		M					
1038F	Persistent asthma		M					
1039F	Intermittent asthma		M					
1040F	DSM-IV info MDD doc'd		M					
1050F	History of mole changes		M					
1055F	Visual funct status assess		M					
1060F	Doc perm/cont/parox atr fib		M					
1061F	Doc lack perm+cont+parox fib		M					
1065F	Ischm stroke symp lt3 hrsb/4		M					
1066F	Ischm stroke symp ge3 hrsb/4		M					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
1070F	Alarm symp assessed-absent		M					
1071F	Alarm symp assessed-1+ prsnt		M					
1080F	Decis mkr/advncd plan doc'd	CH	D					
1090F	Pres/absn urine incon assess		M					
1091F	Urine incon characterized		M					
11000	Debride infected skin		T	0013	0.7930	\$50.51		\$10.10
11001	Debride infected skin add-on	CH	T	0013	0.7930	\$50.51		\$10.10
11004	Debride genitalia & perineum		C					
11005	Debride abdom wall		C					
11006	Debride genit/per/abdom wall		C					
11008	Remove mesh from abd wall		C					
1100F	Ptfalls assess-doc'd ge2+/yr		M					
11010	Debride skin, fx		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11011	Debride skin/muscle, fx		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11012	Debride skin/muscle/bone, fx		T	0019	4.3039	\$274.13	\$71.87	\$54.83
1101F	Pt falls assess-doc'd le1/yr		M					
11040	Debride skin, partial		T	0015	1.4595	\$92.96		\$18.59
11041	Debride skin, full		T	0015	1.4595	\$92.96		\$18.59
11042	Debride skin/tissue		T	0016	2.6604	\$169.45		\$33.89
11043	Debride tissue/muscle		T	0016	2.6604	\$169.45		\$33.89
11044	Debride tissue/muscle/bone		T	0682	6.8816	\$438.32	\$158.65	\$87.66
11055	Trim skin lesion	CH	T	0013	0.7930	\$50.51		\$10.10
11056	Trim skin lesions, 2 to 4	CH	T	0013	0.7930	\$50.51		\$10.10
11057	Trim skin lesions, over 4	CH	T	0015	1.4595	\$92.96		\$18.59
11100	Biopsy, skin lesion	CH	T	0013	0.7930	\$50.51		\$10.10
11101	Biopsy, skin add-on	CH	T	0013	0.7930	\$50.51		\$10.10
1110F	Pt lft inpt fac w/in 60 days		M					
1111F	Dschrg med/current med merge		M					
1116F	Auric/peri pain assessed		M					
1118F	GERD symps assessed 12 month	NI	M					
1119F	Init. Eval for condition	NI	M					
11200	Removal of skin tags		T	0013	0.7930	\$50.51		\$10.10
11201	Remove skin tags add-on		T	0015	1.4595	\$92.96		\$18.59
1121F	Subs. Eval for condition	NI	M					
1123F	ACP discuss/dscn mkr doc'd	NI	M					
1124F	ACP discuss-no dscnmkr doc'd	NI	M					
1125F	Amnt Pain noted; pain prsnt	NI	M					
1126F	Amnt Pain noted; none prsnt	NI	M					
1127F	New episode for condition	NI	M					
1128F	Subs. episode for condition	NI	M					
11300	Shave skin lesion	CH	T	0013	0.7930	\$50.51		\$10.10
11301	Shave skin lesion	CH	T	0013	0.7930	\$50.51		\$10.10
11302	Shave skin lesion		T	0013	0.7930	\$50.51		\$10.10
11303	Shave skin lesion		T	0015	1.4595	\$92.96		\$18.59
11305	Shave skin lesion		T	0013	0.7930	\$50.51		\$10.10
11306	Shave skin lesion		T	0013	0.7930	\$50.51		\$10.10
11307	Shave skin lesion		T	0013	0.7930	\$50.51		\$10.10
11308	Shave skin lesion		T	0013	0.7930	\$50.51		\$10.10
11310	Shave skin lesion		T	0013	0.7930	\$50.51		\$10.10
11311	Shave skin lesion		T	0013	0.7930	\$50.51		\$10.10
11312	Shave skin lesion		T	0013	0.7930	\$50.51		\$10.10
11313	Shave skin lesion	CH	T	0013	0.7930	\$50.51		\$10.10
11400	Exc tr-ext b9+marg 0.5 < cm		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11401	Exc tr-ext b9+marg 0.6-1 cm		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11402	Exc tr-ext b9+marg 1.1-2 cm		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11403	Exc tr-ext b9+marg 2.1-3 cm		T	0020	8.6850	\$553.18		\$110.64
11404	Exc tr-ext b9+marg 3.1-4 cm		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
11406	Exc tr-ext b9+marg > 4.0 cm		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
11420	Exc h-f-nk-sp b9+marg 0.5 <		T	0020	8.6850	\$553.18		\$110.64
11421	Exc h-f-nk-sp b9+marg 0.6-1		T	0020	8.6850	\$553.18		\$110.64
11422	Exc h-f-nk-sp b9+marg 1.1-2		T	0020	8.6850	\$553.18		\$110.64
11423	Exc h-f-nk-sp b9+marg 2.1-3		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
11424	Exc h-f-nk-sp b9+marg 3.1-4		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
11426	Exc h-f-nk-sp b9+marg > 4 cm		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11440	Exc face-mm b9+marg 0.5 < cm		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11441	Exc face-mm b9+marg 0.6-1 cm		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11442	Exc face-mm b9+marg 1.1-2 cm		T	0020	8.6850	\$553.18		\$110.64
11443	Exc face-mm b9+marg 2.1-3 cm		T	0020	8.6850	\$553.18		\$110.64
11444	Exc face-mm b9+marg 3.1-4 cm		T	0020	8.6850	\$553.18		\$110.64
11446	Exc face-mm b9+marg > 4 cm		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11450	Removal, sweat gland lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11451	Removal, sweat gland lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11462	Removal, sweat gland lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11463	Removal, sweat gland lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11470	Removal, sweat gland lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11471	Removal, sweat gland lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11600	Exc tr-ext mlg+marg 0.5 < cm		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11601	Exc tr-ext mlg+marg 0.6-1 cm		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11602	Exc tr-ext mlg+marg 1.1-2 cm		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11603	Exc tr-ext mlg+marg 2.1-3 cm		T	0020	8.6850	\$553.18		\$110.64

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
11604	Exc tr-ext mlg+marg 3.1–4 cm		T	0020	8.6850	\$553.18		\$110.64
11606	Exc tr-ext mlg+marg > 4 cm		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
11620	Exc h-f-nk-sp mlg+marg 0.5 <		T	0020	8.6850	\$553.18		\$110.64
11621	Exc h-f-nk-sp mlg+marg 0.6–1		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11622	Exc h-f-nk-sp mlg+marg 1.1–2		T	0020	8.6850	\$553.18		\$110.64
11623	Exc h-f-nk-sp mlg+marg 2.1–3	CH	T	0020	8.6850	\$553.18		\$110.64
11624	Exc h-f-nk-sp mlg+marg 3.1–4		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
11626	Exc h-f-nk-sp mlg+mar > 4 cm		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11640	Exc face-mm malig+marg 0.5 <	CH	T	0019	4.3039	\$274.13	\$71.87	\$54.83
11641	Exc face-mm malig+marg 0.6–1	CH	T	0019	4.3039	\$274.13	\$71.87	\$54.83
11642	Exc face-mm malig+marg 1.1–2		T	0020	8.6850	\$553.18		\$110.64
11643	Exc face-mm malig+marg 2.1–3		T	0020	8.6850	\$553.18		\$110.64
11644	Exc face-mm malig+marg 3.1–4		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
11646	Exc face-mm mlg+marg > 4 cm		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11719	Trim nail(s)	CH	T	0013	0.7930	\$50.51		\$10.10
11720	Debride nail, 1–5	CH	T	0013	0.7930	\$50.51		\$10.10
11721	Debride nail, 6 or more	CH	T	0013	0.7930	\$50.51		\$10.10
11730	Removal of nail plate		T	0013	0.7930	\$50.51		\$10.10
11732	Remove nail plate, add-on	CH	T	0013	0.7930	\$50.51		\$10.10
11740	Drain blood from under nail	CH	T	0012	0.2963	\$18.87		\$3.77
11750	Removal of nail bed		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11752	Remove nail bed/finger tip		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11755	Biopsy, nail unit		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11760	Repair of nail bed	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
11762	Reconstruction of nail bed	CH	T	0136	15.0458	\$958.33		\$191.67
11765	Excision of nail fold, toe		T	0015	1.4595	\$92.96		\$18.59
11770	Removal of pilonidal lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11771	Removal of pilonidal lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11772	Removal of pilonidal lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11900	Injection into skin lesions	CH	T	0013	0.7930	\$50.51		\$10.10
11901	Added skin lesions injection	CH	T	0013	0.7930	\$50.51		\$10.10
11920	Correct skin color defects	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
11921	Correct skin color defects	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
11922	Correct skin color defects	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
11950	Therapy for contour defects	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
11951	Therapy for contour defects	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
11952	Therapy for contour defects	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
11954	Therapy for contour defects	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
11960	Insert tissue expander(s)	CH	T	0137	20.2069	\$1,287.06		\$257.41
11970	Replace tissue expander		T	0051	42.9850	\$2,737.89		\$547.58
11971	Remove tissue expander(s)		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
11975	Insert contraceptive cap	E						
11976	Removal of contraceptive cap		T	0019	4.3039	\$274.13	\$71.87	\$54.83
11977	Removal/reinsert contra cap	E						
11980	Implant hormone pellet(s)	X		0340	0.6310	\$40.19		\$8.04
11981	Insert drug implant device	X		0340	0.6310	\$40.19		\$8.04
11982	Remove drug implant device	X		0340	0.6310	\$40.19		\$8.04
11983	Remove/insert drug implant	X		0340	0.6310	\$40.19		\$8.04
12001	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12002	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12004	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12005	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12006	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12007	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12011	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12013	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12014	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12015	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12016	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12017	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12018	Repair superficial wound(s)	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
12020	Closure of split wound	CH	T	0135	4.5263	\$288.30		\$57.66
12021	Closure of split wound	CH	T	0135	4.5263	\$288.30		\$57.66
12031	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12032	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12034	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12035	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12036	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12037	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12041	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12042	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12044	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12045	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12046	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12047	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12051	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12052	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12053	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12054	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12055	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
12056	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
12057	Layer closure of wound(s)	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
13100	Repair of wound or lesion	CH	T	0135	4.5263	\$288.30		\$57.66
13101	Repair of wound or lesion	CH	T	0135	4.5263	\$288.30		\$57.66
13102	Repair wound/lesion add-on	CH	T	0135	4.5263	\$288.30		\$57.66
13120	Repair of wound or lesion	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
13121	Repair of wound or lesion	CH	T	0135	4.5263	\$288.30		\$57.66
13122	Repair wound/lesion add-on	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
13131	Repair of wound or lesion	CH	T	0135	4.5263	\$288.30		\$57.66
13132	Repair of wound or lesion	CH	T	0135	4.5263	\$288.30		\$57.66
13133	Repair wound/lesion add-on	CH	T	0135	4.5263	\$288.30		\$57.66
13150	Repair of wound or lesion	CH	T	0135	4.5263	\$288.30		\$57.66
13151	Repair of wound or lesion	CH	T	0135	4.5263	\$288.30		\$57.66
13152	Repair of wound or lesion	CH	T	0135	4.5263	\$288.30		\$57.66
13153	Repair wound/lesion add-on	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
13160	Late closure of wound	CH	T	0137	20.2069	\$1,287.06		\$257.41
14000	Skin tissue rearrangement	CH	T	0136	15.0458	\$958.33		\$191.67
14001	Skin tissue rearrangement	CH	T	0136	15.0458	\$958.33		\$191.67
14020	Skin tissue rearrangement	CH	T	0136	15.0458	\$958.33		\$191.67
14021	Skin tissue rearrangement	CH	T	0136	15.0458	\$958.33		\$191.67
14040	Skin tissue rearrangement	CH	T	0136	15.0458	\$958.33		\$191.67
14041	Skin tissue rearrangement	CH	T	0136	15.0458	\$958.33		\$191.67
14060	Skin tissue rearrangement	CH	T	0136	15.0458	\$958.33		\$191.67
14061	Skin tissue rearrangement	CH	T	0136	15.0458	\$958.33		\$191.67
14300	Skin tissue rearrangement	CH	T	0137	20.2069	\$1,287.06		\$257.41
14350	Skin tissue rearrangement	CH	T	0137	20.2069	\$1,287.06		\$257.41
15002	Wnd prep, ch/inf, trk/arm/leg	CH	T	0135	4.5263	\$288.30		\$57.66
15003	Wnd prep, ch/inf addl 100 cm	CH	T	0135	4.5263	\$288.30		\$57.66
15004	Wnd prep ch/inf, f/n/hf/g	CH	T	0135	4.5263	\$288.30		\$57.66
15005	Wnd prep, f/n/hf/g, addl cm	CH	T	0135	4.5263	\$288.30		\$57.66
15040	Harvest cultured skin graft	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15050	Skin pinch graft	CH	T	0135	4.5263	\$288.30		\$57.66
15100	Skin spl t grft, trnk/arm/leg	CH	T	0137	20.2069	\$1,287.06		\$257.41
15101	Skin spl t grft t/a/l, add-on	CH	T	0137	20.2069	\$1,287.06		\$257.41
15110	Epidrm autogrft trnk/arm/leg	CH	T	0135	4.5263	\$288.30		\$57.66
15111	Epidrm autogrft t/a/l add-on	CH	T	0135	4.5263	\$288.30		\$57.66
15115	Epidrm a-grft face/nck/hf/g	CH	T	0135	4.5263	\$288.30		\$57.66
15116	Epidrm a-grft f/n/hf/g addl	CH	T	0135	4.5263	\$288.30		\$57.66
15120	Skn spl t a-grft fac/nck/hf/g	CH	T	0137	20.2069	\$1,287.06		\$257.41
15121	Skn spl t a-grft f/n/hf/g add	CH	T	0137	20.2069	\$1,287.06		\$257.41
15130	Derm autogrft, trnk/arm/leg	CH	T	0136	15.0458	\$958.33		\$191.67
15131	Derm autogrft t/a/l add-on	CH	T	0136	15.0458	\$958.33		\$191.67
15135	Derm autogrft face/nck/hf/g	CH	T	0136	15.0458	\$958.33		\$191.67
15136	Derm autogrft, f/n/hf/g add	CH	T	0136	15.0458	\$958.33		\$191.67
15150	Cult epiderm grft t/arm/leg	CH	T	0135	4.5263	\$288.30		\$57.66
15151	Cult epiderm grft t/a/l addl	CH	T	0135	4.5263	\$288.30		\$57.66
15152	Cult epiderm grft t/a/l +%	CH	T	0135	4.5263	\$288.30		\$57.66
15155	Cult epiderm grft, f/n/hf/g	CH	T	0135	4.5263	\$288.30		\$57.66
15156	Cult epidrm grft f/n/hfg add	CH	T	0135	4.5263	\$288.30		\$57.66
15157	Cult epiderm grft f/n/hfg +%	CH	T	0135	4.5263	\$288.30		\$57.66
15170	Acell graft trunk/arms/legs	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15171	Acell graft t/arm/leg add-on	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15175	Acellular graft, f/n/hf/g	CH	T	0135	4.5263	\$288.30		\$57.66
15176	Acell graft, f/n/hf/g add-on	CH	T	0135	4.5263	\$288.30		\$57.66
15200	Skin full graft, trunk	CH	T	0136	15.0458	\$958.33		\$191.67
15201	Skin full graft trunk add-on	CH	T	0136	15.0458	\$958.33		\$191.67
15220	Skin full graft scpl/arm/leg	CH	T	0136	15.0458	\$958.33		\$191.67
15221	Skin full graft add-on	CH	T	0135	4.5263	\$288.30		\$57.66
15240	Skin full grft face/genit/hf	CH	T	0136	15.0458	\$958.33		\$191.67
15241	Skin full graft add-on	CH	T	0135	4.5263	\$288.30		\$57.66
15260	Skin full graft een & lips	CH	T	0136	15.0458	\$958.33		\$191.67
15261	Skin full graft add-on	CH	T	0136	15.0458	\$958.33		\$191.67
15300	Apply skin allogrft, t/arm/leg	CH	T	0135	4.5263	\$288.30		\$57.66
15301	Apply sknalogrft t/a/l addl	CH	T	0135	4.5263	\$288.30		\$57.66
15320	Apply skin allogrft f/n/hf/g	CH	T	0135	4.5263	\$288.30		\$57.66
15321	Aply sknalogrft f/n/hfg add	CH	T	0135	4.5263	\$288.30		\$57.66
15330	Aply acell alogrft t/arm/leg	CH	T	0135	4.5263	\$288.30		\$57.66
15331	Aply acell grft t/a/l add-on	CH	T	0135	4.5263	\$288.30		\$57.66
15335	Apply acell graft, f/n/hf/g	CH	T	0135	4.5263	\$288.30		\$57.66
15336	Aply acell grft f/n/hf/g add	CH	T	0135	4.5263	\$288.30		\$57.66
15340	Apply cult skin substitute	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15341	Apply cult skin sub add-on	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15360	Apply cult derm sub, t/a/l	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15361	Aply cult derm sub t/a/l add	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15365	Apply cult derm sub f/n/hf/g	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15366	Apply cult derm f/hf/g add	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15400	Apply skin xenograft, t/a/l	CH	T	0135	4.5263	\$288.30		\$57.66
15401	Apply skn xenogrft t/a/l add	CH	T	0135	4.5263	\$288.30		\$57.66
15420	Apply skin xgrft, f/n/hf/g	CH	T	0135	4.5263	\$288.30		\$57.66
15421	Apply skn xgrft f/n/hf/g add	CH	T	0135	4.5263	\$288.30		\$57.66

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
15430	Apply acellular xenograft	CH	T	0135	4.5263	\$288.30		\$57.66
15431	Apply acellular xgraft add	CH	T	0135	4.5263	\$288.30		\$57.66
15570	Form skin pedicle flap	CH	T	0137	20.2069	\$1,287.06		\$257.41
15572	Form skin pedicle flap	CH	T	0137	20.2069	\$1,287.06		\$257.41
15574	Form skin pedicle flap	CH	T	0137	20.2069	\$1,287.06		\$257.41
15576	Form skin pedicle flap	CH	T	0137	20.2069	\$1,287.06		\$257.41
15600	Skin graft	CH	T	0137	20.2069	\$1,287.06		\$257.41
15610	Skin graft	CH	T	0137	20.2069	\$1,287.06		\$257.41
15620	Skin graft	CH	T	0137	20.2069	\$1,287.06		\$257.41
15630	Skin graft	CH	T	0137	20.2069	\$1,287.06		\$257.41
15650	Transfer skin pedicle flap	CH	T	0137	20.2069	\$1,287.06		\$257.41
15731	Forehead flap w/vasc pedicle	CH	T	0137	20.2069	\$1,287.06		\$257.41
15732	Muscle-skin graft, head/neck	CH	T	0137	20.2069	\$1,287.06		\$257.41
15734	Muscle-skin graft, trunk	CH	T	0137	20.2069	\$1,287.06		\$257.41
15736	Muscle-skin graft, arm	CH	T	0137	20.2069	\$1,287.06		\$257.41
15738	Muscle-skin graft, leg	CH	T	0137	20.2069	\$1,287.06		\$257.41
15740	Island pedicle flap graft	CH	T	0136	15.0458	\$958.33		\$191.67
15750	Neurovascular pedicle graft	CH	T	0137	20.2069	\$1,287.06		\$257.41
15756	Free myo/skin flap microvasc		C					
15757	Free skin flap, microvasc		C					
15758	Free fascial flap, microvasc		C					
15760	Composite skin graft	CH	T	0137	20.2069	\$1,287.06		\$257.41
15770	Derma-fat-fascia graft	CH	T	0137	20.2069	\$1,287.06		\$257.41
15775	Hair transplant punch grafts	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
15776	Hair transplant punch grafts	CH	T	0133	1.2792	\$81.48	\$25.67	\$16.30
15780	Abrasion treatment of skin		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15781	Abrasion treatment of skin		T	0019	4.3039	\$274.13	\$71.87	\$54.83
15782	Abrasion treatment of skin		T	0019	4.3039	\$274.13	\$71.87	\$54.83
15783	Abrasion treatment of skin		T	0016	2.6604	\$169.45		\$33.89
15786	Abrasion, lesion, single		T	0013	0.7930	\$50.51		\$10.10
15787	Abrasion, lesions, add-on		T	0013	0.7930	\$50.51		\$10.10
15788	Chemical peel, face, epiderm	CH	T	0013	0.7930	\$50.51		\$10.10
15789	Chemical peel, face, dermal		T	0015	1.4595	\$92.96		\$18.59
15792	Chemical peel, nonfacial	CH	T	0015	1.4595	\$92.96		\$18.59
15793	Chemical peel, nonfacial	CH	T	0013	0.7930	\$50.51		\$10.10
15819	Plastic surgery, neck	CH	T	0134	2.1051	\$134.08	\$42.24	\$26.82
15820	Revision of lower eyelid	CH	T	0137	20.2069	\$1,287.06		\$257.41
15821	Revision of lower eyelid	CH	T	0137	20.2069	\$1,287.06		\$257.41
15822	Revision of upper eyelid	CH	T	0137	20.2069	\$1,287.06		\$257.41
15823	Revision of upper eyelid	CH	T	0137	20.2069	\$1,287.06		\$257.41
15824	Removal of forehead wrinkles	CH	T	0137	20.2069	\$1,287.06		\$257.41
15825	Removal of neck wrinkles	CH	T	0137	20.2069	\$1,287.06		\$257.41
15826	Removal of brow wrinkles	CH	T	0137	20.2069	\$1,287.06		\$257.41
15828	Removal of face wrinkles	CH	T	0137	20.2069	\$1,287.06		\$257.41
15829	Removal of skin wrinkles	CH	T	0137	20.2069	\$1,287.06		\$257.41
15830	Exc skin abd		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15832	Excise excessive skin tissue		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15833	Excise excessive skin tissue		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15834	Excise excessive skin tissue		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15835	Excise excessive skin tissue	CH	T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15836	Excise excessive skin tissue		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
15837	Excise excessive skin tissue		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
15838	Excise excessive skin tissue		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
15839	Excise excessive skin tissue		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
15840	Graft for face nerve palsy	CH	T	0137	20.2069	\$1,287.06		\$257.41
15841	Graft for face nerve palsy	CH	T	0137	20.2069	\$1,287.06		\$257.41
15842	Flap for face nerve palsy	CH	T	0137	20.2069	\$1,287.06		\$257.41
15845	Skin and muscle repair, face	CH	T	0137	20.2069	\$1,287.06		\$257.41
15847	Exc skin abd add-on		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15850	Removal of sutures		T	0016	2.6604	\$169.45		\$33.89
15851	Removal of sutures		T	0016	2.6604	\$169.45		\$33.89
15852	Dressing change not for burn		X	0340	0.6310	\$40.19		\$8.04
15860	Test for blood flow in graft		X	0340	0.6310	\$40.19		\$8.04
15876	Suction assisted lipectomy	CH	T	0137	20.2069	\$1,287.06		\$257.41
15877	Suction assisted lipectomy	CH	T	0137	20.2069	\$1,287.06		\$257.41
15878	Suction assisted lipectomy	CH	T	0137	20.2069	\$1,287.06		\$257.41
15879	Suction assisted lipectomy	CH	T	0137	20.2069	\$1,287.06		\$257.41
15920	Removal of tail bone ulcer		T	0019	4.3039	\$274.13	\$71.87	\$54.83
15922	Removal of tail bone ulcer	CH	T	0137	20.2069	\$1,287.06		\$257.41
15931	Remove sacrum pressure sore		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15933	Remove sacrum pressure sore		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15934	Remove sacrum pressure sore	CH	T	0137	20.2069	\$1,287.06		\$257.41
15935	Remove sacrum pressure sore	CH	T	0137	20.2069	\$1,287.06		\$257.41
15936	Remove sacrum pressure sore	CH	T	0136	15.0458	\$958.33		\$191.67
15937	Remove sacrum pressure sore	CH	T	0137	20.2069	\$1,287.06		\$257.41
15940	Remove hip pressure sore		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15941	Remove hip pressure sore		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15944	Remove hip pressure sore	CH	T	0137	20.2069	\$1,287.06		\$257.41
15945	Remove hip pressure sore	CH	T	0137	20.2069	\$1,287.06		\$257.41
15946	Remove hip pressure sore	CH	T	0137	20.2069	\$1,287.06		\$257.41

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
15950	Remove thigh pressure sore		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15951	Remove thigh pressure sore		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
15952	Remove thigh pressure sore	CH	T	0136	15.0458	\$958.33		\$191.67
15953	Remove thigh pressure sore	CH	T	0136	15.0458	\$958.33		\$191.67
15956	Remove thigh pressure sore	CH	T	0136	15.0458	\$958.33		\$191.67
15958	Remove thigh pressure sore	CH	T	0136	15.0458	\$958.33		\$191.67
15999	Removal of pressure sore		T	0019	4.3039	\$274.13	\$71.87	\$54.83
16000	Initial treatment of burn(s)	CH	T	0013	0.7930	\$50.51		\$10.10
16020	Dress/debrid p-thick burn, s	CH	T	0015	1.4595	\$92.96		\$18.59
16025	Dress/debrid p-thick burn, m	CH	T	0016	2.6604	\$169.45		\$33.89
16030	Dress/debrid p-thick burn, l	CH	T	0016	2.6604	\$169.45		\$33.89
16035	Incision of burn scab, initi		T	0016	2.6604	\$169.45		\$33.89
16036	Escharotomy; add'l incision		C					
17000	Destruct premalg lesion	CH	T	0013	0.7930	\$50.51		\$10.10
17003	Destruct premalg les, 2-14	CH	T	0012	0.2963	\$18.87		\$3.77
17004	Destroy premalg lesions 15+	CH	T	0016	2.6604	\$169.45		\$33.89
17106	Destruction of skin lesions	CH	T	0016	2.6604	\$169.45		\$33.89
17107	Destruction of skin lesions	CH	T	0016	2.6604	\$169.45		\$33.89
17108	Destruction of skin lesions	CH	T	0016	2.6604	\$169.45		\$33.89
17110	Destruct b9 lesion, 1-14	CH	T	0013	0.7930	\$50.51		\$10.10
17111	Destruct lesion, 15 or more	CH	T	0015	1.4595	\$92.96		\$18.59
17250	Chemical cautery, tissue	CH	T	0015	1.4595	\$92.96		\$18.59
17260	Destruction of skin lesions		T	0015	1.4595	\$92.96		\$18.59
17261	Destruction of skin lesions		T	0015	1.4595	\$92.96		\$18.59
17262	Destruction of skin lesions		T	0015	1.4595	\$92.96		\$18.59
17263	Destruction of skin lesions		T	0015	1.4595	\$92.96		\$18.59
17264	Destruction of skin lesions		T	0015	1.4595	\$92.96		\$18.59
17266	Destruction of skin lesions		T	0016	2.6604	\$169.45		\$33.89
17270	Destruction of skin lesions		T	0015	1.4595	\$92.96		\$18.59
17271	Destruction of skin lesions	CH	T	0015	1.4595	\$92.96		\$18.59
17272	Destruction of skin lesions		T	0015	1.4595	\$92.96		\$18.59
17273	Destruction of skin lesions	CH	T	0016	2.6604	\$169.45		\$33.89
17274	Destruction of skin lesions		T	0016	2.6604	\$169.45		\$33.89
17276	Destruction of skin lesions		T	0016	2.6604	\$169.45		\$33.89
17280	Destruction of skin lesions		T	0015	1.4595	\$92.96		\$18.59
17281	Destruction of skin lesions	CH	T	0016	2.6604	\$169.45		\$33.89
17282	Destruction of skin lesions	CH	T	0016	2.6604	\$169.45		\$33.89
17283	Destruction of skin lesions	CH	T	0016	2.6604	\$169.45		\$33.89
17284	Destruction of skin lesions		T	0016	2.6604	\$169.45		\$33.89
17286	Destruction of skin lesions	CH	T	0016	2.6604	\$169.45		\$33.89
17311	Mohs, 1 stage, h/n/hf/g		T	0694	3.6321	\$231.34	\$91.69	\$46.27
17312	Mohs addl stage		T	0694	3.6321	\$231.34	\$91.69	\$46.27
17313	Mohs, 1 stage, t/a/l		T	0694	3.6321	\$231.34	\$91.69	\$46.27
17314	Mohs, addl stage, t/a/l		T	0694	3.6321	\$231.34	\$91.69	\$46.27
17315	Mohs surg, addl block		T	0694	3.6321	\$231.34	\$91.69	\$46.27
17340	Cryotherapy of skin	CH	T	0013	0.7930	\$50.51		\$10.10
17360	Skin peel therapy		T	0013	0.7930	\$50.51		\$10.10
17380	Hair removal by electrolysis		T	0013	0.7930	\$50.51		\$10.10
17999	Skin tissue procedure		T	0012	0.2963	\$18.87		\$3.77
19000	Drainage of breast lesion		T	0004	4.3270	\$275.60		\$55.12
19001	Drain breast lesion add-on		T	0002	1.1097	\$70.68		\$14.14
19020	Incision of breast lesion		T	0008	18.3197	\$1,166.85		\$233.37
19030	Injection for breast x-ray		N					
19100	Bx breast percut w/o image	CH	T	0004	4.3270	\$275.60		\$55.12
19101	Biopsy of breast, open		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
19102	Bx breast percut w/image		T	0005	7.1147	\$453.16		\$90.63
19103	Bx breast percut w/device	CH	T	0037	13.5764	\$864.74	\$228.76	\$172.95
19105	Cryosurg ablate fa, each		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19110	Nipple exploration		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
19112	Excise breast duct fistula		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
19120	Removal of breast lesion		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
19125	Excision, breast lesion		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
19126	Excision, addl breast lesion		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
19260	Removal of chest wall lesion		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
19271	Revision of chest wall		C					
19272	Extensive chest wall surgery		C					
19290	Place needle wire, breast		N					
19291	Place needle wire, breast		N					
19295	Place breast clip, percut	CH	N					
19296	Place po breast cath for rad		T	0648	56.5774	\$3,603.64		\$720.73
19297	Place breast cath for rad		T	0648	56.5774	\$3,603.64		\$720.73
19298	Place breast rad tube/caths	CH	T	0648	56.5774	\$3,603.64		\$720.73
19300	Removal of breast tissue		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
19301	Partial mastectomy		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
19302	P-mastectomy w/lv removal	CH	T	0030	39.8191	\$2,536.24	\$747.07	\$507.25
19303	Mast, simple, complete		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19304	Mast, subq		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19305	Mast, radical		C					
19306	Mast, rad, urban type		C					
19307	Mast, mod rad		T	0030	39.8191	\$2,536.24	\$747.07	\$507.25

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
19316	Suspension of breast		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19318	Reduction of large breast	CH	T	0030	39.8191	\$2,536.24	\$747.07	\$507.25
19324	Enlarge breast	CH	T	0030	39.8191	\$2,536.24	\$747.07	\$507.25
19325	Enlarge breast with implant		T	0648	56.5774	\$3,603.64		\$720.73
19328	Removal of breast implant		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19330	Removal of implant material		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19340	Immediate breast prosthesis		T	0030	39.8191	\$2,536.24	\$747.07	\$507.25
19342	Delayed breast prosthesis		T	0648	56.5774	\$3,603.64		\$720.73
19350	Breast reconstruction		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
19355	Correct inverted nipple(s)		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19357	Breast reconstruction		T	0648	56.5774	\$3,603.64		\$720.73
19361	Breast reconstr w/lat flap		C					
19364	Breast reconstruction		C					
19366	Breast reconstruction		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19367	Breast reconstruction		C					
19368	Breast reconstruction		C					
19369	Breast reconstruction		C					
19370	Surgery of breast capsule		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19371	Removal of breast capsule		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19380	Revise breast reconstruction		T	0030	39.8191	\$2,536.24	\$747.07	\$507.25
19396	Design custom breast implant		T	0029	31.7134	\$2,019.95	\$581.52	\$403.99
19499	Breast surgery procedure		T	0028	20.6417	\$1,314.75	\$303.74	\$262.95
20000	Incision of abscess		T	0006	1.4066	\$89.59		\$17.92
20005	Incision of deep abscess		T	0049	21.2689	\$1,354.70		\$270.94
2000F	Blood pressure measure		M					
2001F	Weight recorded		M					
2002F	Clin sign vol ovrd assess		M					
2004F	Initial exam involved joints		M					
20100	Explore wound, neck		T	0023	9.6341	\$613.63		\$122.73
20101	Explore wound, chest	CH	T	0137	20.2069	\$1,287.06		\$257.41
20102	Explore wound, abdomen	CH	T	0137	20.2069	\$1,287.06		\$257.41
20103	Explore wound, extremity		T	0023	9.6341	\$613.63		\$122.73
2010F	Vital signs recorded		M					
2014F	Mental status assess		M					
20150	Excise epiphyseal bar		T	0051	42.9850	\$2,737.89		\$547.58
2018F	Hydration status assess		M					
2019F	Dilated macul exam done		M					
20200	Muscle biopsy		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
20205	Deep muscle biopsy		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
20206	Needle biopsy, muscle		T	0005	7.1147	\$453.16		\$90.63
2020F	Dilated fundus eval done		M					
2021F	Dilat macul+ exam done		M					
20220	Bone biopsy, trocar/needle	CH	T	0020	8.6850	\$553.18		\$110.64
20225	Bone biopsy, trocar/needle		T	0020	8.6850	\$553.18		\$110.64
2022F	Dil retina exam interp rev		M					
20240	Bone biopsy, excisional		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
20245	Bone biopsy, excisional		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
2024F	7 field photo interp doc rev		M					
20250	Open bone biopsy		T	0049	21.2689	\$1,354.70		\$270.94
20251	Open bone biopsy		T	0049	21.2689	\$1,354.70		\$270.94
2026F	Eye image valid to dx rev		M					
2027F	Optic nerve head eval done		M					
2028F	Foot exam performed		M					
2029F	Complete phys skin exam done		M					
2030F	H2O stat doc'd, normal		M					
2031F	H2O stat doc'd, dehydrated		M					
2035F	Tymp memb motion exam'd		M					
20500	Injection of sinus tract		T	0251	2.5002	\$159.25		\$31.85
20501	Inject sinus tract for x-ray		N					
20520	Removal of foreign body		T	0019	4.3039	\$274.13	\$71.87	\$54.83
20525	Removal of foreign body		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
20526	Ther injection, carp tunnel		T	0204	2.3213	\$147.85	\$40.13	\$29.57
20550	Inj tendon sheath/ligament		T	0204	2.3213	\$147.85	\$40.13	\$29.57
20551	Inj tendon origin/insertion		T	0204	2.3213	\$147.85	\$40.13	\$29.57
20552	Inj trigger point, 1/2 muscl		T	0204	2.3213	\$147.85	\$40.13	\$29.57
20553	Inject trigger points, => 3		T	0204	2.3213	\$147.85	\$40.13	\$29.57
20555	Place ndl musc/tis for rt	NI	T	0050	29.1900	\$1,859.23		\$371.85
20600	Drain/inject, joint/bursa		T	0204	2.3213	\$147.85	\$40.13	\$29.57
20605	Drain/inject, joint/bursa		T	0204	2.3213	\$147.85	\$40.13	\$29.57
20610	Drain/inject, joint/bursa		T	0204	2.3213	\$147.85	\$40.13	\$29.57
20612	Aspirate/inj ganglion cyst		T	0204	2.3213	\$147.85	\$40.13	\$29.57
20615	Treatment of bone cyst		T	0004	4.3270	\$275.60		\$55.12
20650	Insert and remove bone pin		T	0049	21.2689	\$1,354.70		\$270.94
20660	Apply, rem fixation device		C					
20661	Application of head brace		C					
20662	Application of pelvis brace		T	0049	21.2689	\$1,354.70		\$270.94
20663	Application of thigh brace		T	0049	21.2689	\$1,354.70		\$270.94
20664	Halo brace application		C					
20665	Removal of fixation device		X	0340	0.6310	\$40.19		\$8.04
20670	Removal of support implant		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
20680	Removal of support implant		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
20690	Apply bone fixation device		T	0050	29.1900	\$1,859.23		\$371.85
20692	Apply bone fixation device		T	0050	29.1900	\$1,859.23		\$371.85
20693	Adjust bone fixation device		T	0049	21.2689	\$1,354.70		\$270.94
20694	Remove bone fixation device		T	0049	21.2689	\$1,354.70		\$270.94
20802	Replantation, arm, complete		C					
20805	Replant forearm, complete		C					
20808	Replantation hand, complete		C					
20816	Replantation digit, complete		C					
20822	Replantation digit, complete		T	0054	26.3105	\$1,675.82		\$335.16
20824	Replantation thumb, complete		C					
20827	Replantation thumb, complete		C					
20838	Replantation foot, complete		C					
20900	Removal of bone for graft		T	0050	29.1900	\$1,859.23		\$371.85
20902	Removal of bone for graft		T	0050	29.1900	\$1,859.23		\$371.85
20910	Remove cartilage for graft	CH	T	0137	20.2069	\$1,287.06		\$257.41
20912	Remove cartilage for graft	CH	T	0137	20.2069	\$1,287.06		\$257.41
20920	Removal of fascia for graft	CH	T	0136	15.0458	\$958.33		\$191.67
20922	Removal of fascia for graft	CH	T	0136	15.0458	\$958.33		\$191.67
20924	Removal of tendon for graft		T	0050	29.1900	\$1,859.23		\$371.85
20926	Removal of tissue for graft	CH	T	0135	4.5263	\$288.30		\$57.66
20930	Sp bone algrft morsel add-on		C					
20931	Sp bone algrft struct add-on		C					
20936	Sp bone agrft local add-on		C					
20937	Sp bone agrft morsel add-on		C					
20938	Sp bone agrft struct add-on		C					
20950	Fluid pressure, muscle		T	0006	1.4066	\$89.59		\$17.92
20955	Fibula bone graft, microvasc		C					
20956	Iliac bone graft, microvasc		C					
20957	Mt bone graft, microvasc		C					
20962	Other bone graft, microvasc		C					
20969	Bone/skin graft, microvasc		C					
20970	Bone/skin graft, iliac crest		C					
20972	Bone/skin graft, metatarsal		T	0056	44.2687	\$2,819.65		\$563.93
20973	Bone/skin graft, great toe		T	0056	44.2687	\$2,819.65		\$563.93
20974	Electrical bone stimulation		A					
20975	Electrical bone stimulation	CH	N					
20979	Us bone stimulation		X	0340	0.6310	\$40.19		\$8.04
20982	Ablate, bone tumor(s) perq		T	0051	42.9850	\$2,737.89		\$547.58
20985	Cptr-asst dir ms px	NI	N					
20986	Cptr-asst dir ms px io img	NI	N					
20987	Cptr-asst dir ms px pre img	NI	N					
20999	Musculoskeletal surgery		T	0049	21.2689	\$1,354.70		\$270.94
21010	Incision of jaw joint		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21015	Resection of facial tumor		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21025	Excision of bone, lower jaw		T	0256	39.8776	\$2,539.96		\$507.99
21026	Excision of facial bone(s)		T	0256	39.8776	\$2,539.96		\$507.99
21029	Contour of face bone lesion		T	0256	39.8776	\$2,539.96		\$507.99
21030	Excise max/zygoma b9 tumor		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21031	Remove exostosis, mandible		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21032	Remove exostosis, maxilla		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21034	Excise max/zygoma mlg tumor		T	0256	39.8776	\$2,539.96		\$507.99
21040	Excise mandible lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21044	Removal of jaw bone lesion		T	0256	39.8776	\$2,539.96		\$507.99
21045	Extensive jaw surgery		C					
21046	Remove mandible cyst complex		T	0256	39.8776	\$2,539.96		\$507.99
21047	Excise lwr jaw cyst w/repair		T	0256	39.8776	\$2,539.96		\$507.99
21048	Remove maxilla cyst complex		T	0256	39.8776	\$2,539.96		\$507.99
21049	Excis uppr jaw cyst w/repair		T	0256	39.8776	\$2,539.96		\$507.99
21050	Removal of jaw joint		T	0256	39.8776	\$2,539.96		\$507.99
21060	Remove jaw joint cartilage		T	0256	39.8776	\$2,539.96		\$507.99
21070	Remove coronoid process		T	0256	39.8776	\$2,539.96		\$507.99
21073	Mnpj of tmj w/anesth	NI	T	0252	7.4474	\$474.35	\$109.16	\$94.87
21076	Prepare face/oral prosthesis		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21077	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21079	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21080	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21081	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21082	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21083	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21084	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21085	Prepare face/oral prosthesis		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21086	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21087	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21088	Prepare face/oral prosthesis		T	0256	39.8776	\$2,539.96		\$507.99
21089	Prepare face/oral prosthesis		T	0251	2.5002	\$159.25		\$31.85
21100	Maxillofacial fixation		T	0256	39.8776	\$2,539.96		\$507.99
21110	Interdental fixation		T	0252	7.4474	\$474.35	\$109.16	\$94.87
21116	Injection, jaw joint x-ray		N					
21120	Reconstruction of chin		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
21121	Reconstruction of chin		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21122	Reconstruction of chin		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21123	Reconstruction of chin		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21125	Augmentation, lower jaw bone		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21127	Augmentation, lower jaw bone		T	0256	39.8776	\$2,539.96		\$507.99
21137	Reduction of forehead		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21138	Reduction of forehead		T	0256	39.8776	\$2,539.96		\$507.99
21139	Reduction of forehead		T	0256	39.8776	\$2,539.96		\$507.99
21141	Reconstruct midface, lefort		C					
21142	Reconstruct midface, lefort		C					
21143	Reconstruct midface, lefort		C					
21145	Reconstruct midface, lefort		C					
21146	Reconstruct midface, lefort		C					
21147	Reconstruct midface, lefort		C					
21150	Reconstruct midface, lefort		T	0256	39.8776	\$2,539.96		\$507.99
21151	Reconstruct midface, lefort		C					
21154	Reconstruct midface, lefort		C					
21155	Reconstruct midface, lefort		C					
21159	Reconstruct midface, lefort		C					
21160	Reconstruct midface, lefort		C					
21172	Reconstruct orbit/forehead		C					
21175	Reconstruct orbit/forehead		T	0256	39.8776	\$2,539.96		\$507.99
21179	Reconstruct entire forehead		C					
21180	Reconstruct entire forehead		C					
21181	Contour cranial bone lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21182	Reconstruct cranial bone		C					
21183	Reconstruct cranial bone		C					
21184	Reconstruct cranial bone		C					
21188	Reconstruction of midface		C					
21193	Reconst lwr jaw w/o graft		C					
21194	Reconst lwr jaw w/graft		C					
21195	Reconst lwr jaw w/o fixation		T	0256	39.8776	\$2,539.96		\$507.99
21196	Reconst lwr jaw w/fixation		C					
21198	Reconst lwr jaw segment		T	0256	39.8776	\$2,539.96		\$507.99
21199	Reconst lwr jaw w/advance		T	0256	39.8776	\$2,539.96		\$507.99
21206	Reconstruct upper jaw bone		T	0256	39.8776	\$2,539.96		\$507.99
21208	Augmentation of facial bones		T	0256	39.8776	\$2,539.96		\$507.99
21209	Reduction of facial bones		T	0256	39.8776	\$2,539.96		\$507.99
21210	Face bone graft		T	0256	39.8776	\$2,539.96		\$507.99
21215	Lower jaw bone graft		T	0256	39.8776	\$2,539.96		\$507.99
21230	Rib cartilage graft		T	0256	39.8776	\$2,539.96		\$507.99
21235	Ear cartilage graft		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21240	Reconstruction of jaw joint		T	0256	39.8776	\$2,539.96		\$507.99
21242	Reconstruction of jaw joint		T	0256	39.8776	\$2,539.96		\$507.99
21243	Reconstruction of jaw joint		T	0256	39.8776	\$2,539.96		\$507.99
21244	Reconstruction of lower jaw		T	0256	39.8776	\$2,539.96		\$507.99
21245	Reconstruction of jaw		T	0256	39.8776	\$2,539.96		\$507.99
21246	Reconstruction of jaw		T	0256	39.8776	\$2,539.96		\$507.99
21247	Reconstruct lower jaw bone		C					
21248	Reconstruction of jaw		T	0256	39.8776	\$2,539.96		\$507.99
21249	Reconstruction of jaw		T	0256	39.8776	\$2,539.96		\$507.99
21255	Reconstruct lower jaw bone		C					
21256	Reconstruction of orbit		C					
21260	Revise eye sockets		T	0256	39.8776	\$2,539.96		\$507.99
21261	Revise eye sockets		T	0256	39.8776	\$2,539.96		\$507.99
21263	Revise eye sockets		T	0256	39.8776	\$2,539.96		\$507.99
21267	Revise eye sockets		T	0256	39.8776	\$2,539.96		\$507.99
21268	Revise eye sockets		C					
21270	Augmentation, cheek bone		T	0256	39.8776	\$2,539.96		\$507.99
21275	Revision, orbitofacial bones		T	0256	39.8776	\$2,539.96		\$507.99
21280	Revision of eyelid		T	0256	39.8776	\$2,539.96		\$507.99
21282	Revision of eyelid		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21295	Revision of jaw muscle/bone		T	0252	7.4474	\$474.35	\$109.16	\$94.87
21296	Revision of jaw muscle/bone		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21299	Cranio/maxillofacial surgery		T	0251	2.5002	\$159.25		\$31.85
21310	Treatment of nose fracture		T	0251	2.5002	\$159.25		\$31.85
21315	Treatment of nose fracture		T	0251	2.5002	\$159.25		\$31.85
21320	Treatment of nose fracture	CH	T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21325	Treatment of nose fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21330	Treatment of nose fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21335	Treatment of nose fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21336	Treat nasal septal fracture	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
21337	Treat nasal septal fracture		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21338	Treat nasoethmoid fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21339	Treat nasoethmoid fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21340	Treatment of nose fracture		T	0256	39.8776	\$2,539.96		\$507.99
21343	Treatment of sinus fracture		C					
21344	Treatment of sinus fracture		C					
21345	Treat nose/jaw fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21346	Treat nose/jaw fracture		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
21347	Treat nose/jaw fracture		C					
21348	Treat nose/jaw fracture		C					
21355	Treat cheek bone fracture		T	0256	39.8776	\$2,539.96		\$507.99
21356	Treat cheek bone fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21360	Treat cheek bone fracture	CH	T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21365	Treat cheek bone fracture	CH	T	0256	39.8776	\$2,539.96		\$507.99
21366	Treat cheek bone fracture		C					
21385	Treat eye socket fracture	CH	T	0256	39.8776	\$2,539.96		\$507.99
21386	Treat eye socket fracture		C					
21387	Treat eye socket fracture		C					
21390	Treat eye socket fracture		T	0256	39.8776	\$2,539.96		\$507.99
21395	Treat eye socket fracture		C					
21400	Treat eye socket fracture		T	0252	7.4474	\$474.35	\$109.16	\$94.87
21401	Treat eye socket fracture		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21406	Treat eye socket fracture		T	0256	39.8776	\$2,539.96		\$507.99
21407	Treat eye socket fracture		T	0256	39.8776	\$2,539.96		\$507.99
21408	Treat eye socket fracture		T	0256	39.8776	\$2,539.96		\$507.99
21421	Treat mouth roof fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21422	Treat mouth roof fracture		C					
21423	Treat mouth roof fracture		C					
21431	Treat craniofacial fracture		C					
21432	Treat craniofacial fracture		C					
21433	Treat craniofacial fracture		C					
21435	Treat craniofacial fracture		C					
21436	Treat craniofacial fracture		C					
21440	Treat dental ridge fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21445	Treat dental ridge fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21450	Treat lower jaw fracture		T	0251	2.5002	\$159.25		\$31.85
21451	Treat lower jaw fracture		T	0252	7.4474	\$474.35	\$109.16	\$94.87
21452	Treat lower jaw fracture		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21453	Treat lower jaw fracture		T	0256	39.8776	\$2,539.96		\$507.99
21454	Treat lower jaw fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
21461	Treat lower jaw fracture		T	0256	39.8776	\$2,539.96		\$507.99
21462	Treat lower jaw fracture		T	0256	39.8776	\$2,539.96		\$507.99
21465	Treat lower jaw fracture		T	0256	39.8776	\$2,539.96		\$507.99
21470	Treat lower jaw fracture		T	0256	39.8776	\$2,539.96		\$507.99
21480	Reset dislocated jaw		T	0251	2.5002	\$159.25		\$31.85
21485	Reset dislocated jaw		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21490	Repair dislocated jaw		T	0256	39.8776	\$2,539.96		\$507.99
21495	Treat hyoid bone fracture		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21497	Interdental wiring		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
21499	Head surgery procedure		T	0251	2.5002	\$159.25		\$31.85
21501	Drain neck/chest lesion		T	0008	18.3197	\$1,166.85		\$233.37
21502	Drain chest lesion		T	0049	21.2689	\$1,354.70		\$270.94
21510	Drainage of bone lesion		C					
21550	Biopsy of neck/chest		T	0020	8.6850	\$553.18		\$110.64
21555	Remove lesion, neck/chest		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
21556	Remove lesion, neck/chest		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
21557	Remove tumor, neck/chest		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
21600	Partial removal of rib		T	0050	29.1900	\$1,859.23		\$371.85
21610	Partial removal of rib		T	0050	29.1900	\$1,859.23		\$371.85
21615	Removal of rib		C					
21616	Removal of rib and nerves		C					
21620	Partial removal of sternum		C					
21627	Sternal debridement		C					
21630	Extensive sternum surgery		C					
21632	Extensive sternum surgery		C					
21685	Hyoid myotomy & suspension		T	0252	7.4474	\$474.35	\$109.16	\$94.87
21700	Revision of neck muscle		T	0049	21.2689	\$1,354.70		\$270.94
21705	Revision of neck muscle/rib		C					
21720	Revision of neck muscle		T	0049	21.2689	\$1,354.70		\$270.94
21725	Revision of neck muscle		T	0006	1.4066	\$89.59		\$17.92
21740	Reconstruction of sternum		C					
21742	Repair sternum/nuss w/o scope		T	0051	42.9850	\$2,737.89		\$547.58
21743	Repair sternum/nuss w/scope		T	0051	42.9850	\$2,737.89		\$547.58
21750	Repair of sternum separation		C					
21800	Treatment of rib fracture		T	0043	1.7682	\$112.62		\$22.52
21805	Treatment of rib fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
21810	Treatment of rib fracture(s)		C					
21820	Treat sternum fracture		T	0043	1.7682	\$112.62		\$22.52
21825	Treat sternum fracture		C					
21899	Neck/chest surgery procedure		T	0251	2.5002	\$159.25		\$31.85
21920	Biopsy soft tissue of back		T	0020	8.6850	\$553.18		\$110.64
21925	Biopsy soft tissue of back		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
21930	Remove lesion, back or flank		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
21935	Remove tumor, back		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
22010	I&d, p-spine, c/t/cerv-thor		C					
22015	I&d, p-spine, l/s/l		C					
22100	Remove part of neck vertebra		T	0208	46.7724	\$2,979.12		\$595.82
22101	Remove part, thorax vertebra		T	0208	46.7724	\$2,979.12		\$595.82

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
22102	Remove part, lumbar vertebra		T	0208	46.7724	\$2,979.12		\$595.82
22103	Remove extra spine segment		T	0208	46.7724	\$2,979.12		\$595.82
22110	Remove part of neck vertebra		C					
22112	Remove part, thorax vertebra		C					
22114	Remove part, lumbar vertebra		C					
22116	Remove extra spine segment		C					
22206	Cut spine 3 col, thor	NI	C					
22207	Cut spine 3 col, lumb	NI	C					
22208	Cut spine 3 col, addl seg	NI	C					
22210	Revision of neck spine		C					
22212	Revision of thorax spine		C					
22214	Revision of lumbar spine		C					
22216	Revise, extra spine segment		C					
22220	Revision of neck spine		C					
22222	Revision of thorax spine		T	0208	46.7724	\$2,979.12		\$595.82
22224	Revision of lumbar spine		C					
22226	Revise, extra spine segment		C					
22305	Treat spine process fracture		T	0043	1.7682	\$112.62		\$22.52
22310	Treat spine fracture		T	0043	1.7682	\$112.62		\$22.52
22315	Treat spine fracture		T	0043	1.7682	\$112.62		\$22.52
22318	Treat odontoid fx w/o graft		C					
22319	Treat odontoid fx w/graft		C					
22325	Treat spine fracture		C					
22326	Treat neck spine fracture		C					
22327	Treat thorax spine fracture		C					
22328	Treat each add spine fx		C					
22505	Manipulation of spine		T	0045	14.7658	\$940.49	\$268.47	\$188.10
22520	Percut vertebroplasty thor		T	0050	29.1900	\$1,859.23		\$371.85
22521	Percut vertebroplasty lumb		T	0050	29.1900	\$1,859.23		\$371.85
22522	Percut vertebroplasty add'l		T	0050	29.1900	\$1,859.23		\$371.85
22523	Percut kyphoplasty, thor		T	0052	79.4244	\$5,058.86		\$1,011.77
22524	Percut kyphoplasty, lumbar		T	0052	79.4244	\$5,058.86		\$1,011.77
22525	Percut kyphoplasty, add-on		T	0052	79.4244	\$5,058.86		\$1,011.77
22526	Idet, single level		T	0050	29.1900	\$1,859.23		\$371.85
22527	Idet, 1 or more levels		T	0050	29.1900	\$1,859.23		\$371.85
22532	Lat thorax spine fusion		C					
22533	Lat lumbar spine fusion		C					
22534	Lat thor/lumb, add'l seg		C					
22548	Neck spine fusion		C					
22554	Neck spine fusion		C					
22556	Thorax spine fusion		C					
22558	Lumbar spine fusion		C					
22585	Additional spinal fusion		C					
22590	Spine & skull spinal fusion		C					
22595	Neck spinal fusion		C					
22600	Neck spine fusion		C					
22610	Thorax spine fusion		C					
22612	Lumbar spine fusion		T	0208	46.7724	\$2,979.12		\$595.82
22614	Spine fusion, extra segment		T	0208	46.7724	\$2,979.12		\$595.82
22630	Lumbar spine fusion		C					
22632	Spine fusion, extra segment		C					
22800	Fusion of spine		C					
22802	Fusion of spine		C					
22804	Fusion of spine		C					
22808	Fusion of spine		C					
22810	Fusion of spine		C					
22812	Fusion of spine		C					
22818	Kyphectomy, 1-2 segments		C					
22819	Kyphectomy, 3 or more		C					
22830	Exploration of spinal fusion		C					
22840	Insert spine fixation device		C					
22841	Insert spine fixation device		C					
22842	Insert spine fixation device		C					
22843	Insert spine fixation device		C					
22844	Insert spine fixation device		C					
22845	Insert spine fixation device		C					
22846	Insert spine fixation device		C					
22847	Insert spine fixation device		C					
22848	Insert pelv fixation device		C					
22849	Reinsert spinal fixation		C					
22850	Remove spine fixation device		C					
22851	Apply spine prosth device		T	0049	21.2689	\$1,354.70		\$270.94
22852	Remove spine fixation device		C					
22855	Remove spine fixation device		C					
22857	Lumbar artif disectomy		C					
22862	Revise lumbar artif disc		C					
22865	Remove lumb artif disc		C					
22899	Spine surgery procedure		T	0049	21.2689	\$1,354.70		\$270.94
22900	Remove abdominal wall lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
22999	Abdomen surgery procedure		T	0049	21.2689	\$1,354.70		\$270.94

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
23000	Removal of calcium deposits		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
23020	Release shoulder joint		T	0051	42.9850	\$2,737.89		\$547.58
23030	Drain shoulder lesion		T	0008	18.3197	\$1,166.85		\$233.37
23031	Drain shoulder bursa		T	0008	18.3197	\$1,166.85		\$233.37
23035	Drain shoulder bone lesion		T	0049	21.2689	\$1,354.70		\$270.94
23040	Exploratory shoulder surgery		T	0050	29.1900	\$1,859.23		\$371.85
23044	Exploratory shoulder surgery		T	0050	29.1900	\$1,859.23		\$371.85
23065	Biopsy shoulder tissues		T	0020	8.6850	\$553.18		\$110.64
23066	Biopsy shoulder tissues		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
23075	Removal of shoulder lesion		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
23076	Removal of shoulder lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
23077	Remove tumor of shoulder		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
23100	Biopsy of shoulder joint		T	0049	21.2689	\$1,354.70		\$270.94
23101	Shoulder joint surgery		T	0050	29.1900	\$1,859.23		\$371.85
23105	Remove shoulder joint lining		T	0050	29.1900	\$1,859.23		\$371.85
23106	Incision of collarbone joint		T	0050	29.1900	\$1,859.23		\$371.85
23107	Explore treat shoulder joint		T	0050	29.1900	\$1,859.23		\$371.85
23120	Partial removal, collar bone	CH	T	0050	29.1900	\$1,859.23		\$371.85
23125	Removal of collar bone	CH	T	0050	29.1900	\$1,859.23		\$371.85
23130	Remove shoulder bone, part		T	0051	42.9850	\$2,737.89		\$547.58
23140	Removal of bone lesion		T	0049	21.2689	\$1,354.70		\$270.94
23145	Removal of bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
23146	Removal of bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
23150	Removal of humerus lesion		T	0050	29.1900	\$1,859.23		\$371.85
23155	Removal of humerus lesion		T	0050	29.1900	\$1,859.23		\$371.85
23156	Removal of humerus lesion		T	0050	29.1900	\$1,859.23		\$371.85
23170	Remove collar bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
23172	Remove shoulder blade lesion		T	0050	29.1900	\$1,859.23		\$371.85
23174	Remove humerus lesion		T	0050	29.1900	\$1,859.23		\$371.85
23180	Remove collar bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
23182	Remove shoulder blade lesion		T	0050	29.1900	\$1,859.23		\$371.85
23184	Remove humerus lesion		T	0050	29.1900	\$1,859.23		\$371.85
23190	Partial removal of scapula		T	0050	29.1900	\$1,859.23		\$371.85
23195	Removal of head of humerus		T	0050	29.1900	\$1,859.23		\$371.85
23200	Removal of collar bone		C					
23210	Removal of shoulder blade		C					
23220	Partial removal of humerus		C					
23221	Partial removal of humerus		C					
23222	Partial removal of humerus		C					
23330	Remove shoulder foreign body		T	0020	8.6850	\$553.18		\$110.64
23331	Remove shoulder foreign body		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
23332	Remove shoulder foreign body		C					
23350	Injection for shoulder x-ray		N					
23395	Muscle transfer, shoulder/arm		T	0051	42.9850	\$2,737.89		\$547.58
23397	Muscle transfers		T	0052	79.4244	\$5,058.86		\$1,011.77
23400	Fixation of shoulder blade		T	0050	29.1900	\$1,859.23		\$371.85
23405	Incision of tendon & muscle		T	0050	29.1900	\$1,859.23		\$371.85
23406	Incise tendon(s) & muscle(s)		T	0050	29.1900	\$1,859.23		\$371.85
23410	Repair rotator cuff, acute		T	0051	42.9850	\$2,737.89		\$547.58
23412	Repair rotator cuff, chronic		T	0051	42.9850	\$2,737.89		\$547.58
23415	Release of shoulder ligament		T	0051	42.9850	\$2,737.89		\$547.58
23420	Repair of shoulder		T	0051	42.9850	\$2,737.89		\$547.58
23430	Repair biceps tendon		T	0051	42.9850	\$2,737.89		\$547.58
23440	Remove/transplant tendon		T	0051	42.9850	\$2,737.89		\$547.58
23450	Repair shoulder capsule		T	0052	79.4244	\$5,058.86		\$1,011.77
23455	Repair shoulder capsule		T	0052	79.4244	\$5,058.86		\$1,011.77
23460	Repair shoulder capsule		T	0052	79.4244	\$5,058.86		\$1,011.77
23462	Repair shoulder capsule		T	0051	42.9850	\$2,737.89		\$547.58
23465	Repair shoulder capsule		T	0052	79.4244	\$5,058.86		\$1,011.77
23466	Repair shoulder capsule		T	0051	42.9850	\$2,737.89		\$547.58
23470	Reconstruct shoulder joint		T	0425	122.2057	\$7,783.77		\$1,556.75
23472	Reconstruct shoulder joint		C					
23480	Revision of collar bone		T	0051	42.9850	\$2,737.89		\$547.58
23485	Revision of collar bone		T	0052	79.4244	\$5,058.86		\$1,011.77
23490	Reinforce clavicle		T	0051	42.9850	\$2,737.89		\$547.58
23491	Reinforce shoulder bones		T	0052	79.4244	\$5,058.86		\$1,011.77
23500	Treat clavicle fracture		T	0043	1.7682	\$112.62		\$22.52
23505	Treat clavicle fracture		T	0043	1.7682	\$112.62		\$22.52
23515	Treat clavicle fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
23520	Treat clavicle dislocation		T	0043	1.7682	\$112.62		\$22.52
23525	Treat clavicle dislocation		T	0043	1.7682	\$112.62		\$22.52
23530	Treat clavicle dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
23532	Treat clavicle dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
23540	Treat clavicle dislocation		T	0043	1.7682	\$112.62		\$22.52
23545	Treat clavicle dislocation		T	0043	1.7682	\$112.62		\$22.52
23550	Treat clavicle dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
23552	Treat clavicle dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
23570	Treat shoulder blade fx		T	0043	1.7682	\$112.62		\$22.52
23575	Treat shoulder blade fx		T	0043	1.7682	\$112.62		\$22.52
23585	Treat scapula fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
23600	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
23605	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
23615	Treat humerus fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
23616	Treat humerus fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
23620	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
23625	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
23630	Treat humerus fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
23650	Treat shoulder dislocation		T	0043	1.7682	\$112.62		\$22.52
23655	Treat shoulder dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
23660	Treat shoulder dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
23665	Treat dislocation/fracture		T	0043	1.7682	\$112.62		\$22.52
23670	Treat dislocation/fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
23675	Treat dislocation/fracture		T	0043	1.7682	\$112.62		\$22.52
23680	Treat dislocation/fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
23700	Fixation of shoulder		T	0045	14.7658	\$940.49	\$268.47	\$188.10
23800	Fusion of shoulder joint		T	0052	79.4244	\$5,058.86		\$1,011.77
23802	Fusion of shoulder joint		T	0051	42.9850	\$2,737.89		\$547.58
23900	Amputation of arm & girdle		C					
23920	Amputation at shoulder joint		C					
23921	Amputation follow-up surgery	CH	T	0136	15.0458	\$958.33		\$191.67
23929	Shoulder surgery procedure		T	0043	1.7682	\$112.62		\$22.52
23930	Drainage of arm lesion		T	0008	18.3197	\$1,166.85		\$233.37
23931	Drainage of arm bursa		T	0008	18.3197	\$1,166.85		\$233.37
23935	Drain arm/elbow bone lesion		T	0049	21.2689	\$1,354.70		\$270.94
24000	Exploratory elbow surgery		T	0050	29.1900	\$1,859.23		\$371.85
24006	Release elbow joint		T	0050	29.1900	\$1,859.23		\$371.85
24065	Biopsy arm/elbow soft tissue		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
24066	Biopsy arm/elbow soft tissue		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
24075	Remove arm/elbow lesion		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
24076	Remove arm/elbow lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
24077	Remove tumor of arm/elbow		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
24100	Biopsy elbow joint lining		T	0049	21.2689	\$1,354.70		\$270.94
24101	Explore/treat elbow joint		T	0050	29.1900	\$1,859.23		\$371.85
24102	Remove elbow joint lining		T	0050	29.1900	\$1,859.23		\$371.85
24105	Removal of elbow bursa		T	0049	21.2689	\$1,354.70		\$270.94
24110	Remove humerus lesion		T	0049	21.2689	\$1,354.70		\$270.94
24115	Remove/graft bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
24116	Remove/graft bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
24120	Remove elbow lesion		T	0049	21.2689	\$1,354.70		\$270.94
24125	Remove/graft bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
24126	Remove/graft bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
24130	Removal of head of radius		T	0050	29.1900	\$1,859.23		\$371.85
24134	Removal of arm bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
24136	Remove radius bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
24138	Remove elbow bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
24140	Partial removal of arm bone		T	0050	29.1900	\$1,859.23		\$371.85
24145	Partial removal of radius		T	0050	29.1900	\$1,859.23		\$371.85
24147	Partial removal of elbow		T	0050	29.1900	\$1,859.23		\$371.85
24149	Radical resection of elbow		T	0050	29.1900	\$1,859.23		\$371.85
24150	Extensive humerus surgery		T	0051	42.9850	\$2,737.89		\$547.58
24151	Extensive humerus surgery		T	0052	79.4244	\$5,058.86		\$1,011.77
24152	Extensive radius surgery		T	0051	42.9850	\$2,737.89		\$547.58
24153	Extensive radius surgery		T	0052	79.4244	\$5,058.86		\$1,011.77
24155	Removal of elbow joint		T	0051	42.9850	\$2,737.89		\$547.58
24160	Remove elbow joint implant		T	0050	29.1900	\$1,859.23		\$371.85
24164	Remove radius head implant		T	0050	29.1900	\$1,859.23		\$371.85
24200	Removal of arm foreign body		T	0019	4.3039	\$274.13	\$71.87	\$54.83
24201	Removal of arm foreign body		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
24220	Injection for elbow x-ray		N					
24300	Manipulate elbow w/anesth		T	0045	14.7658	\$940.49	\$268.47	\$188.10
24301	Muscle/tendon transfer		T	0050	29.1900	\$1,859.23		\$371.85
24305	Arm tendon lengthening		T	0050	29.1900	\$1,859.23		\$371.85
24310	Revision of arm tendon		T	0049	21.2689	\$1,354.70		\$270.94
24320	Repair of arm tendon		T	0051	42.9850	\$2,737.89		\$547.58
24330	Revision of arm muscles		T	0052	79.4244	\$5,058.86		\$1,011.77
24331	Revision of arm muscles		T	0051	42.9850	\$2,737.89		\$547.58
24332	Tenolysis, triceps		T	0049	21.2689	\$1,354.70		\$270.94
24340	Repair of biceps tendon		T	0051	42.9850	\$2,737.89		\$547.58
24341	Repair arm tendon/muscle		T	0051	42.9850	\$2,737.89		\$547.58
24342	Repair of ruptured tendon		T	0051	42.9850	\$2,737.89		\$547.58
24343	Repr elbow lat ligmnt w/tiss		T	0050	29.1900	\$1,859.23		\$371.85
24344	Reconstruct elbow lat ligmnt		T	0052	79.4244	\$5,058.86		\$1,011.77
24345	Repr elbw med ligmnt w/tissu		T	0050	29.1900	\$1,859.23		\$371.85
24346	Reconstruct elbow med ligmnt		T	0051	42.9850	\$2,737.89		\$547.58
24350	Repair of tennis elbow	CH	D					
24351	Repair of tennis elbow	CH	D					
24352	Repair of tennis elbow	CH	D					
24354	Repair of tennis elbow	CH	D					
24356	Revision of tennis elbow	CH	D					
24357	Repair elbow, perc	NI	T	0050	29.1900	\$1,859.23		\$371.85

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
24358	Repair elbow w/deb, open	NI	T	0050	29.1900	\$1,859.23		\$371.85
24359	Repair elbow deb/attach open	NI	T	0050	29.1900	\$1,859.23		\$371.85
24360	Reconstruct elbow joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
24361	Reconstruct elbow joint		T	0425	122.2057	\$7,783.77		\$1,556.75
24362	Reconstruct elbow joint		T	0048	50.8876	\$3,241.23		\$648.25
24363	Replace elbow joint		T	0425	122.2057	\$7,783.77		\$1,556.75
24365	Reconstruct head of radius		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
24366	Reconstruct head of radius		T	0425	122.2057	\$7,783.77		\$1,556.75
24400	Revision of humerus		T	0050	29.1900	\$1,859.23		\$371.85
24410	Revision of humerus		T	0050	29.1900	\$1,859.23		\$371.85
24420	Revision of humerus		T	0051	42.9850	\$2,737.89		\$547.58
24430	Repair of humerus		T	0052	79.4244	\$5,058.86		\$1,011.77
24435	Repair humerus with graft		T	0052	79.4244	\$5,058.86		\$1,011.77
24470	Revision of elbow joint		T	0051	42.9850	\$2,737.89		\$547.58
24495	Decompression of forearm		T	0050	29.1900	\$1,859.23		\$371.85
24498	Reinforce humerus		T	0052	79.4244	\$5,058.86		\$1,011.77
24500	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
24505	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
24515	Treat humerus fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24516	Treat humerus fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24530	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
24535	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
24538	Treat humerus fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
24545	Treat humerus fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24546	Treat humerus fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24560	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
24565	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
24566	Treat humerus fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
24575	Treat humerus fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24576	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
24577	Treat humerus fracture		T	0043	1.7682	\$112.62		\$22.52
24579	Treat humerus fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24582	Treat humerus fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
24586	Treat elbow fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24587	Treat elbow fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24600	Treat elbow dislocation		T	0043	1.7682	\$112.62		\$22.52
24605	Treat elbow dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
24615	Treat elbow dislocation		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24620	Treat elbow fracture		T	0043	1.7682	\$112.62		\$22.52
24635	Treat elbow fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24640	Treat elbow dislocation		T	0043	1.7682	\$112.62		\$22.52
24650	Treat radius fracture		T	0043	1.7682	\$112.62		\$22.52
24655	Treat radius fracture		T	0043	1.7682	\$112.62		\$22.52
24665	Treat radius fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
24666	Treat radius fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
24670	Treat ulnar fracture		T	0043	1.7682	\$112.62		\$22.52
24675	Treat ulnar fracture		T	0043	1.7682	\$112.62		\$22.52
24685	Treat ulnar fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
24800	Fusion of elbow joint		T	0051	42.9850	\$2,737.89		\$547.58
24802	Fusion/graft of elbow joint		T	0051	42.9850	\$2,737.89		\$547.58
24900	Amputation of upper arm	C						
24920	Amputation of upper arm	C						
24925	Amputation follow-up surgery	T		0049	21.2689	\$1,354.70		\$270.94
24930	Amputation follow-up surgery	C						
24931	Amputate upper arm & implant	C						
24935	Revision of amputation	T		0052	79.4244	\$5,058.86		\$1,011.77
24940	Revision of upper arm	C						
24999	Upper arm/elbow surgery	T		0043	1.7682	\$112.62		\$22.52
25000	Incision of tendon sheath	T		0049	21.2689	\$1,354.70		\$270.94
25001	Incise flexor carpi radialis	T		0049	21.2689	\$1,354.70		\$270.94
25020	Decompress forearm 1 space	T		0049	21.2689	\$1,354.70		\$270.94
25023	Decompress forearm 1 space	T		0050	29.1900	\$1,859.23		\$371.85
25024	Decompress forearm 2 spaces	T		0050	29.1900	\$1,859.23		\$371.85
25025	Decompress forearm 2 spaces	T		0050	29.1900	\$1,859.23		\$371.85
25028	Drainage of forearm lesion	T		0049	21.2689	\$1,354.70		\$270.94
25031	Drainage of forearm bursa	T		0049	21.2689	\$1,354.70		\$270.94
25035	Treat forearm bone lesion	T		0049	21.2689	\$1,354.70		\$270.94
25040	Explore/treat wrist joint	T		0050	29.1900	\$1,859.23		\$371.85
25065	Biopsy forearm soft tissues	T		0020	8.6850	\$553.18		\$110.64
25066	Biopsy forearm soft tissues	T		0022	21.1098	\$1,344.57	\$354.45	\$268.91
25075	Removal forearm lesion subcu	T		0021	16.1001	\$1,025.48	\$219.48	\$205.10
25076	Removal forearm lesion deep	T		0022	21.1098	\$1,344.57	\$354.45	\$268.91
25077	Remove tumor, forearm/wrist	T		0022	21.1098	\$1,344.57	\$354.45	\$268.91
25085	Incision of wrist capsule	T		0049	21.2689	\$1,354.70		\$270.94
25100	Biopsy of wrist joint	T		0049	21.2689	\$1,354.70		\$270.94
25101	Explore/treat wrist joint	T		0050	29.1900	\$1,859.23		\$371.85
25105	Remove wrist joint lining	T		0050	29.1900	\$1,859.23		\$371.85
25107	Remove wrist joint cartilage	T		0050	29.1900	\$1,859.23		\$371.85
25109	Excise tendon forearm/wrist	T		0049	21.2689	\$1,354.70		\$270.94
25110	Remove wrist tendon lesion	T		0049	21.2689	\$1,354.70		\$270.94

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
25111	Remove wrist tendon lesion		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
25112	Reremove wrist tendon lesion		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
25115	Remove wrist/forearm lesion		T	0049	21.2689	\$1,354.70		\$270.94
25116	Remove wrist/forearm lesion		T	0049	21.2689	\$1,354.70		\$270.94
25118	Excise wrist tendon sheath		T	0050	29.1900	\$1,859.23		\$371.85
25119	Partial removal of ulna		T	0050	29.1900	\$1,859.23		\$371.85
25120	Removal of forearm lesion		T	0050	29.1900	\$1,859.23		\$371.85
25125	Remove/graft forearm lesion		T	0050	29.1900	\$1,859.23		\$371.85
25126	Remove/graft forearm lesion		T	0050	29.1900	\$1,859.23		\$371.85
25130	Removal of wrist lesion		T	0050	29.1900	\$1,859.23		\$371.85
25135	Remove & graft wrist lesion		T	0050	29.1900	\$1,859.23		\$371.85
25136	Remove & graft wrist lesion		T	0050	29.1900	\$1,859.23		\$371.85
25145	Remove forearm bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
25150	Partial removal of ulna		T	0050	29.1900	\$1,859.23		\$371.85
25151	Partial removal of radius		T	0050	29.1900	\$1,859.23		\$371.85
25170	Extensive forearm surgery		T	0051	42.9850	\$2,737.89		\$547.58
25210	Removal of wrist bone		T	0054	26.3105	\$1,675.82		\$335.16
25215	Removal of wrist bones		T	0054	26.3105	\$1,675.82		\$335.16
25230	Partial removal of radius		T	0050	29.1900	\$1,859.23		\$371.85
25240	Partial removal of ulna		T	0050	29.1900	\$1,859.23		\$371.85
25246	Injection for wrist x-ray		N					
25248	Remove forearm foreign body		T	0049	21.2689	\$1,354.70		\$270.94
25250	Removal of wrist prosthesis		T	0050	29.1900	\$1,859.23		\$371.85
25251	Removal of wrist prosthesis		T	0050	29.1900	\$1,859.23		\$371.85
25259	Manipulate wrist w/anesthes		T	0043	1.7682	\$112.62		\$22.52
25260	Repair forearm tendon/muscle		T	0050	29.1900	\$1,859.23		\$371.85
25263	Repair forearm tendon/muscle		T	0050	29.1900	\$1,859.23		\$371.85
25265	Repair forearm tendon/muscle		T	0050	29.1900	\$1,859.23		\$371.85
25270	Repair forearm tendon/muscle		T	0050	29.1900	\$1,859.23		\$371.85
25272	Repair forearm tendon/muscle		T	0050	29.1900	\$1,859.23		\$371.85
25274	Repair forearm tendon/muscle		T	0050	29.1900	\$1,859.23		\$371.85
25275	Repair forearm tendon sheath		T	0050	29.1900	\$1,859.23		\$371.85
25280	Revise wrist/forearm tendon		T	0050	29.1900	\$1,859.23		\$371.85
25290	Incise wrist/forearm tendon		T	0050	29.1900	\$1,859.23		\$371.85
25295	Release wrist/forearm tendon		T	0049	21.2689	\$1,354.70		\$270.94
25300	Fusion of tendons at wrist		T	0050	29.1900	\$1,859.23		\$371.85
25301	Fusion of tendons at wrist		T	0050	29.1900	\$1,859.23		\$371.85
25310	Transplant forearm tendon		T	0051	42.9850	\$2,737.89		\$547.58
25312	Transplant forearm tendon		T	0051	42.9850	\$2,737.89		\$547.58
25315	Revise palsy hand tendon(s)		T	0051	42.9850	\$2,737.89		\$547.58
25316	Revise palsy hand tendon(s)		T	0052	79.4244	\$5,058.86		\$1,011.77
25320	Repair/revise wrist joint		T	0051	42.9850	\$2,737.89		\$547.58
25332	Revise wrist joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
25335	Realignment of hand		T	0051	42.9850	\$2,737.89		\$547.58
25337	Reconstruct ulna/radioulnar		T	0051	42.9850	\$2,737.89		\$547.58
25350	Revision of radius		T	0052	79.4244	\$5,058.86		\$1,011.77
25355	Revision of radius		T	0051	42.9850	\$2,737.89		\$547.58
25360	Revision of ulna		T	0050	29.1900	\$1,859.23		\$371.85
25365	Revise radius & ulna		T	0050	29.1900	\$1,859.23		\$371.85
25370	Revise radius or ulna		T	0051	42.9850	\$2,737.89		\$547.58
25375	Revise radius & ulna		T	0051	42.9850	\$2,737.89		\$547.58
25390	Shorten radius or ulna		T	0050	29.1900	\$1,859.23		\$371.85
25391	Lengthen radius or ulna		T	0051	42.9850	\$2,737.89		\$547.58
25392	Shorten radius & ulna		T	0050	29.1900	\$1,859.23		\$371.85
25393	Lengthen radius & ulna		T	0051	42.9850	\$2,737.89		\$547.58
25394	Repair carpal bone, shorten		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
25400	Repair radius or ulna	CH	T	0052	79.4244	\$5,058.86		\$1,011.77
25405	Repair/graft radius or ulna	CH	T	0052	79.4244	\$5,058.86		\$1,011.77
25415	Repair radius & ulna	CH	T	0052	79.4244	\$5,058.86		\$1,011.77
25420	Repair/graft radius & ulna		T	0052	79.4244	\$5,058.86		\$1,011.77
25425	Repair/graft radius or ulna		T	0051	42.9850	\$2,737.89		\$547.58
25426	Repair/graft radius & ulna		T	0051	42.9850	\$2,737.89		\$547.58
25430	Vasc graft into carpal bone		T	0054	26.3105	\$1,675.82		\$335.16
25431	Repair nonunion carpal bone		T	0054	26.3105	\$1,675.82		\$335.16
25440	Repair/graft wrist bone		T	0052	79.4244	\$5,058.86		\$1,011.77
25441	Reconstruct wrist joint		T	0425	122.2057	\$7,783.77		\$1,556.75
25442	Reconstruct wrist joint		T	0425	122.2057	\$7,783.77		\$1,556.75
25443	Reconstruct wrist joint		T	0048	50.8876	\$3,241.23		\$648.25
25444	Reconstruct wrist joint		T	0048	50.8876	\$3,241.23		\$648.25
25445	Reconstruct wrist joint		T	0048	50.8876	\$3,241.23		\$648.25
25446	Wrist replacement		T	0425	122.2057	\$7,783.77		\$1,556.75
25447	Repair wrist joint(s)		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
25449	Remove wrist joint implant		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
25450	Revision of wrist joint		T	0051	42.9850	\$2,737.89		\$547.58
25455	Revision of wrist joint		T	0051	42.9850	\$2,737.89		\$547.58
25490	Reinforce radius		T	0051	42.9850	\$2,737.89		\$547.58
25491	Reinforce ulna		T	0051	42.9850	\$2,737.89		\$547.58
25492	Reinforce radius and ulna		T	0051	42.9850	\$2,737.89		\$547.58
25500	Treat fracture of radius		T	0043	1.7682	\$112.62		\$22.52
25505	Treat fracture of radius		T	0043	1.7682	\$112.62		\$22.52

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
25515	Treat fracture of radius		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
25520	Treat fracture of radius		T	0043	1.7682	\$112.62		\$22.52
25525	Treat fracture of radius		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
25526	Treat fracture of radius		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
25530	Treat fracture of ulna		T	0043	1.7682	\$112.62		\$22.52
25535	Treat fracture of ulna		T	0043	1.7682	\$112.62		\$22.52
25545	Treat fracture of ulna		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
25560	Treat fracture radius & ulna		T	0043	1.7682	\$112.62		\$22.52
25565	Treat fracture radius & ulna		T	0043	1.7682	\$112.62		\$22.52
25574	Treat fracture radius & ulna		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
25575	Treat fracture radius/ulna		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
25600	Treat fracture radius/ulna		T	0043	1.7682	\$112.62		\$22.52
25605	Treat fracture radius/ulna		T	0043	1.7682	\$112.62		\$22.52
25606	Treat fx distal radial		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
25607	Treat fx rad extra-articul		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
25608	Treat fx rad intra-articul		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
25609	Treat fx radial 3+ frag		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
25622	Treat wrist bone fracture		T	0043	1.7682	\$112.62		\$22.52
25624	Treat wrist bone fracture		T	0043	1.7682	\$112.62		\$22.52
25628	Treat wrist bone fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
25630	Treat wrist bone fracture		T	0043	1.7682	\$112.62		\$22.52
25635	Treat wrist bone fracture		T	0043	1.7682	\$112.62		\$22.52
25645	Treat wrist bone fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
25650	Treat wrist bone fracture		T	0043	1.7682	\$112.62		\$22.52
25651	Pin ulnar styloid fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
25652	Treat fracture ulnar styloid		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
25660	Treat wrist dislocation		T	0043	1.7682	\$112.62		\$22.52
25670	Treat wrist dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
25671	Pin radioulnar dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
25675	Treat wrist dislocation		T	0043	1.7682	\$112.62		\$22.52
25676	Treat wrist dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
25680	Treat wrist fracture		T	0043	1.7682	\$112.62		\$22.52
25685	Treat wrist fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
25690	Treat wrist dislocation		T	0043	1.7682	\$112.62		\$22.52
25695	Treat wrist dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
25800	Fusion of wrist joint		T	0052	79.4244	\$5,058.86		\$1,011.77
25805	Fusion/graft of wrist joint		T	0051	42.9850	\$2,737.89		\$547.58
25810	Fusion/graft of wrist joint		T	0052	79.4244	\$5,058.86		\$1,011.77
25820	Fusion of hand bones		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
25825	Fuse hand bones with graft	CH	T	0052	79.4244	\$5,058.86		\$1,011.77
25830	Fusion, radioulnar jnt/ulna		T	0052	79.4244	\$5,058.86		\$1,011.77
25900	Amputation of forearm		C					
25905	Amputation of forearm		C					
25907	Amputation follow-up surgery		T	0049	21.2689	\$1,354.70		\$270.94
25909	Amputation follow-up surgery		C					
25915	Amputation of forearm		C					
25920	Amputate hand at wrist		C					
25922	Amputate hand at wrist		T	0049	21.2689	\$1,354.70		\$270.94
25924	Amputation follow-up surgery		C					
25927	Amputation of hand		C					
25929	Amputation follow-up surgery	CH	T	0136	15.0458	\$958.33		\$191.67
25931	Amputation follow-up surgery	CH	T	0049	21.2689	\$1,354.70		\$270.94
25999	Forearm or wrist surgery		T	0043	1.7682	\$112.62		\$22.52
26010	Drainage of finger abscess		T	0006	1.4066	\$89.59		\$17.92
26011	Drainage of finger abscess		T	0007	11.5594	\$736.26		\$147.25
26020	Drain hand tendon sheath		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26025	Drainage of palm bursa		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26030	Drainage of palm bursa(s)		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26034	Treat hand bone lesion		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26035	Decompress fingers/hand		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26037	Decompress fingers/hand		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26040	Release palm contracture		T	0054	26.3105	\$1,675.82		\$335.16
26045	Release palm contracture		T	0054	26.3105	\$1,675.82		\$335.16
26055	Incise finger tendon sheath		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26060	Incision of finger tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26070	Explore/treat hand joint		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26075	Explore/treat finger joint		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26080	Explore/treat finger joint		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26100	Biopsy hand joint lining		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26105	Biopsy finger joint lining		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26110	Biopsy finger joint lining		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26115	Removal hand lesion subcut		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
26116	Removal hand lesion, deep		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
26117	Remove tumor, hand/finger		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
26121	Release palm contracture		T	0054	26.3105	\$1,675.82		\$335.16
26123	Release palm contracture		T	0054	26.3105	\$1,675.82		\$335.16
26125	Release palm contracture		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26130	Remove wrist joint lining		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26135	Revise finger joint, each		T	0054	26.3105	\$1,675.82		\$335.16
26140	Revise finger joint, each		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
26145	Tendon excision, palm/finger		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26160	Remove tendon sheath lesion		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26170	Removal of palm tendon, each		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26180	Removal of finger tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26185	Remove finger bone		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26200	Remove hand bone lesion		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26205	Remove/graft bone lesion		T	0054	26.3105	\$1,675.82		\$335.16
26210	Removal of finger lesion		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26215	Remove/graft finger lesion		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26230	Partial removal of hand bone		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26235	Partial removal, finger bone		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26236	Partial removal, finger bone		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26250	Extensive hand surgery		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26255	Extensive hand surgery		T	0054	26.3105	\$1,675.82		\$335.16
26260	Extensive finger surgery		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26261	Extensive finger surgery		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26262	Partial removal of finger		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26320	Removal of implant from hand		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
26340	Manipulate finger w/anesth		T	0043	1.7682	\$112.62		\$22.52
26350	Repair finger/hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26352	Repair/graft hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26356	Repair finger/hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26357	Repair finger/hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26358	Repair/graft hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26370	Repair finger/hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26372	Repair/graft hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26373	Repair finger/hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26390	Revise hand/finger tendon		T	0054	26.3105	\$1,675.82		\$335.16
26392	Repair/graft hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26410	Repair hand tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26412	Repair/graft hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26415	Excision, hand/finger tendon		T	0054	26.3105	\$1,675.82		\$335.16
26416	Graft hand or finger tendon		T	0054	26.3105	\$1,675.82		\$335.16
26418	Repair finger tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26420	Repair/graft finger tendon		T	0054	26.3105	\$1,675.82		\$335.16
26426	Repair finger/hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26428	Repair/graft finger tendon		T	0054	26.3105	\$1,675.82		\$335.16
26432	Repair finger tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26433	Repair finger tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26434	Repair/graft finger tendon		T	0054	26.3105	\$1,675.82		\$335.16
26437	Realignment of tendons		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26440	Release palm/finger tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26442	Release palm & finger tendon		T	0054	26.3105	\$1,675.82		\$335.16
26445	Release hand/finger tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26449	Release forearm/hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26450	Incision of palm tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26455	Incision of finger tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26460	Incise hand/finger tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26471	Fusion of finger tendons		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26474	Fusion of finger tendons		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26476	Tendon lengthening		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26477	Tendon shortening		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26478	Lengthening of hand tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26479	Shortening of hand tendon		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26480	Transplant hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26483	Transplant/graft hand tendon		T	0054	26.3105	\$1,675.82		\$335.16
26485	Transplant palm tendon		T	0054	26.3105	\$1,675.82		\$335.16
26489	Transplant/graft palm tendon		T	0054	26.3105	\$1,675.82		\$335.16
26490	Revise thumb tendon		T	0054	26.3105	\$1,675.82		\$335.16
26492	Tendon transfer with graft		T	0054	26.3105	\$1,675.82		\$335.16
26494	Hand tendon/muscle transfer		T	0054	26.3105	\$1,675.82		\$335.16
26496	Revise thumb tendon		T	0054	26.3105	\$1,675.82		\$335.16
26497	Finger tendon transfer		T	0054	26.3105	\$1,675.82		\$335.16
26498	Finger tendon transfer		T	0054	26.3105	\$1,675.82		\$335.16
26499	Revision of finger		T	0054	26.3105	\$1,675.82		\$335.16
26500	Hand tendon reconstruction		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26502	Hand tendon reconstruction		T	0054	26.3105	\$1,675.82		\$335.16
26508	Release thumb contracture		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26510	Thumb tendon transfer		T	0054	26.3105	\$1,675.82		\$335.16
26516	Fusion of knuckle joint		T	0054	26.3105	\$1,675.82		\$335.16
26517	Fusion of knuckle joints		T	0054	26.3105	\$1,675.82		\$335.16
26518	Fusion of knuckle joints		T	0054	26.3105	\$1,675.82		\$335.16
26520	Release knuckle contracture		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26525	Release finger contracture		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26530	Revise knuckle joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
26531	Revise knuckle with implant		T	0048	50.8876	\$3,241.23		\$648.25
26535	Revise finger joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
26536	Revise/implant finger joint		T	0048	50.8876	\$3,241.23		\$648.25
26540	Repair hand joint		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26541	Repair hand joint with graft		T	0054	26.3105	\$1,675.82		\$335.16

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
26542	Repair hand joint with graft		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26545	Reconstruct finger joint		T	0054	26.3105	\$1,675.82		\$335.16
26546	Repair nonunion hand		T	0054	26.3105	\$1,675.82		\$335.16
26548	Reconstruct finger joint		T	0054	26.3105	\$1,675.82		\$335.16
26550	Construct thumb replacement		T	0054	26.3105	\$1,675.82		\$335.16
26551	Great toe-hand transfer		C					
26553	Single transfer, toe-hand		C					
26554	Double transfer, toe-hand		C					
26555	Positional change of finger		T	0054	26.3105	\$1,675.82		\$335.16
26556	Toe joint transfer		C					
26560	Repair of web finger		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26561	Repair of web finger		T	0054	26.3105	\$1,675.82		\$335.16
26562	Repair of web finger		T	0054	26.3105	\$1,675.82		\$335.16
26565	Correct metacarpal flaw		T	0054	26.3105	\$1,675.82		\$335.16
26567	Correct finger deformity		T	0054	26.3105	\$1,675.82		\$335.16
26568	Lengthen metacarpal/finger		T	0054	26.3105	\$1,675.82		\$335.16
26580	Repair hand deformity		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26587	Reconstruct extra finger		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26590	Repair finger deformity		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26591	Repair muscles of hand		T	0054	26.3105	\$1,675.82		\$335.16
26593	Release muscles of hand		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26596	Excision constricting tissue		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26600	Treat metacarpal fracture		T	0043	1.7682	\$112.62		\$22.52
26605	Treat metacarpal fracture		T	0043	1.7682	\$112.62		\$22.52
26607	Treat metacarpal fracture		T	0043	1.7682	\$112.62		\$22.52
26608	Treat metacarpal fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26615	Treat metacarpal fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
26641	Treat thumb dislocation		T	0043	1.7682	\$112.62		\$22.52
26645	Treat thumb fracture		T	0043	1.7682	\$112.62		\$22.52
26650	Treat thumb fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26665	Treat thumb fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
26670	Treat hand dislocation		T	0043	1.7682	\$112.62		\$22.52
26675	Treat hand dislocation		T	0043	1.7682	\$112.62		\$22.52
26676	Pin hand dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26685	Treat hand dislocation	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26686	Treat hand dislocation		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
26700	Treat knuckle dislocation		T	0043	1.7682	\$112.62		\$22.52
26705	Treat knuckle dislocation		T	0043	1.7682	\$112.62		\$22.52
26706	Pin knuckle dislocation		T	0043	1.7682	\$112.62		\$22.52
26715	Treat knuckle dislocation	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26720	Treat finger fracture, each		T	0043	1.7682	\$112.62		\$22.52
26725	Treat finger fracture, each		T	0043	1.7682	\$112.62		\$22.52
26727	Treat finger fracture, each		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26735	Treat finger fracture, each	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26740	Treat finger fracture, each		T	0043	1.7682	\$112.62		\$22.52
26742	Treat finger fracture, each		T	0043	1.7682	\$112.62		\$22.52
26746	Treat finger fracture, each	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26750	Treat finger fracture, each		T	0043	1.7682	\$112.62		\$22.52
26755	Treat finger fracture, each		T	0043	1.7682	\$112.62		\$22.52
26756	Pin finger fracture, each		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26765	Treat finger fracture, each	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26770	Treat finger dislocation		T	0043	1.7682	\$112.62		\$22.52
26775	Treat finger dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
26776	Pin finger dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26785	Treat finger dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
26820	Thumb fusion with graft		T	0054	26.3105	\$1,675.82		\$335.16
26841	Fusion of thumb		T	0054	26.3105	\$1,675.82		\$335.16
26842	Thumb fusion with graft		T	0054	26.3105	\$1,675.82		\$335.16
26843	Fusion of hand joint		T	0054	26.3105	\$1,675.82		\$335.16
26844	Fusion/graft of hand joint		T	0054	26.3105	\$1,675.82		\$335.16
26850	Fusion of knuckle		T	0054	26.3105	\$1,675.82		\$335.16
26852	Fusion of knuckle with graft		T	0054	26.3105	\$1,675.82		\$335.16
26860	Fusion of finger joint		T	0054	26.3105	\$1,675.82		\$335.16
26861	Fusion of finger jnt, add-on		T	0054	26.3105	\$1,675.82		\$335.16
26862	Fusion/graft of finger joint		T	0054	26.3105	\$1,675.82		\$335.16
26863	Fuse/graft added joint		T	0054	26.3105	\$1,675.82		\$335.16
26910	Amputate metacarpal bone		T	0054	26.3105	\$1,675.82		\$335.16
26951	Amputation of finger/thumb		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26952	Amputation of finger/thumb		T	0053	16.4637	\$1,048.64	\$253.49	\$209.73
26989	Hand/finger surgery		T	0043	1.7682	\$112.62		\$22.52
26990	Drainage of pelvis lesion		T	0049	21.2689	\$1,354.70		\$270.94
26991	Drainage of pelvis bursa		T	0049	21.2689	\$1,354.70		\$270.94
26992	Drainage of bone lesion		C					
27000	Incision of hip tendon		T	0049	21.2689	\$1,354.70		\$270.94
27001	Incision of hip tendon		T	0050	29.1900	\$1,859.23		\$371.85
27003	Incision of hip tendon		T	0050	29.1900	\$1,859.23		\$371.85
27005	Incision of hip tendon		C					
27006	Incision of hip tendons	CH	T	0050	29.1900	\$1,859.23		\$371.85
27025	Incision of hip/thigh fascia		C					
27030	Drainage of hip joint		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
27033	Exploration of hip joint		T	0051	42.9850	\$2,737.89		\$547.58
27035	Deneration of hip joint		T	0051	42.9850	\$2,737.89		\$547.58
27036	Excision of hip joint/muscle		C					
27040	Biopsy of soft tissues		T	0020	8.6850	\$553.18		\$110.64
27041	Biopsy of soft tissues		T	0020	8.6850	\$553.18		\$110.64
27047	Remove hip/pelvis lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27048	Remove hip/pelvis lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27049	Remove tumor, hip/pelvis		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27050	Biopsy of sacroiliac joint		T	0049	21.2689	\$1,354.70		\$270.94
27052	Biopsy of hip joint		T	0049	21.2689	\$1,354.70		\$270.94
27054	Removal of hip joint lining		C					
27060	Removal of ischial bursa		T	0049	21.2689	\$1,354.70		\$270.94
27062	Remove femur lesion/bursa		T	0049	21.2689	\$1,354.70		\$270.94
27065	Removal of hip bone lesion		T	0049	21.2689	\$1,354.70		\$270.94
27066	Removal of hip bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
27067	Remove/graft hip bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
27070	Partial removal of hip bone		C					
27071	Partial removal of hip bone		C					
27075	Extensive hip surgery		C					
27076	Extensive hip surgery		C					
27077	Extensive hip surgery		C					
27078	Extensive hip surgery		C					
27079	Extensive hip surgery		C					
27080	Removal of tail bone		T	0050	29.1900	\$1,859.23		\$371.85
27086	Remove hip foreign body		T	0020	8.6850	\$553.18		\$110.64
27087	Remove hip foreign body		T	0049	21.2689	\$1,354.70		\$270.94
27090	Removal of hip prosthesis		C					
27091	Removal of hip prosthesis		C					
27093	Injection for hip x-ray		N					
27095	Injection for hip x-ray		N					
27096	Inject sacroiliac joint		B					
27097	Revision of hip tendon		T	0050	29.1900	\$1,859.23		\$371.85
27098	Transfer tendon to pelvis		T	0050	29.1900	\$1,859.23		\$371.85
27100	Transfer of abdominal muscle		T	0051	42.9850	\$2,737.89		\$547.58
27105	Transfer of spinal muscle		T	0051	42.9850	\$2,737.89		\$547.58
27110	Transfer of iliopectus muscle		T	0051	42.9850	\$2,737.89		\$547.58
27111	Transfer of iliopectus muscle		T	0051	42.9850	\$2,737.89		\$547.58
27120	Reconstruction of hip socket		C					
27122	Reconstruction of hip socket		C					
27125	Partial hip replacement		C					
27130	Total hip arthroplasty		C					
27132	Total hip arthroplasty		C					
27134	Revise hip joint replacement		C					
27137	Revise hip joint replacement		C					
27138	Revise hip joint replacement		C					
27140	Transplant femur ridge		C					
27146	Incision of hip bone		C					
27147	Revision of hip bone		C					
27151	Incision of hip bones		C					
27156	Revision of hip bones		C					
27158	Revision of pelvis		C					
27161	Incision of neck of femur		C					
27165	Incision/fixation of femur		C					
27170	Repair/graft femur head/neck		C					
27175	Treat slipped epiphysis		C					
27176	Treat slipped epiphysis		C					
27177	Treat slipped epiphysis		C					
27178	Treat slipped epiphysis		C					
27179	Revise head/neck of femur		C					
27181	Treat slipped epiphysis		C					
27185	Revision of femur epiphysis		C					
27187	Reinforce hip bones		C					
27193	Treat pelvic ring fracture		T	0043	1.7682	\$112.62		\$22.52
27194	Treat pelvic ring fracture		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27200	Treat tail bone fracture		T	0043	1.7682	\$112.62		\$22.52
27202	Treat tail bone fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27215	Treat pelvic fracture(s)		C					
27216	Treat pelvic ring fracture		T	0050	29.1900	\$1,859.23		\$371.85
27217	Treat pelvic ring fracture		C					
27218	Treat pelvic ring fracture		C					
27220	Treat hip socket fracture		T	0043	1.7682	\$112.62		\$22.52
27222	Treat hip socket fracture		C					
27226	Treat hip wall fracture		C					
27227	Treat hip fracture(s)		C					
27228	Treat hip fracture(s)		C					
27230	Treat thigh fracture		T	0043	1.7682	\$112.62		\$22.52
27232	Treat thigh fracture		C					
27235	Treat thigh fracture		T	0050	29.1900	\$1,859.23		\$371.85
27236	Treat thigh fracture		C					
27238	Treat thigh fracture		T	0043	1.7682	\$112.62		\$22.52

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
27240	Treat thigh fracture		C					
27244	Treat thigh fracture		C					
27245	Treat thigh fracture		C					
27246	Treat thigh fracture		T	0043	1.7682	\$112.62		\$22.52
27248	Treat thigh fracture		C					
27250	Treat hip dislocation		T	0043	1.7682	\$112.62		\$22.52
27252	Treat hip dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27253	Treat hip dislocation		C					
27254	Treat hip dislocation		C					
27256	Treat hip dislocation		T	0043	1.7682	\$112.62		\$22.52
27257	Treat hip dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27258	Treat hip dislocation		C					
27259	Treat hip dislocation		C					
27265	Treat hip dislocation		T	0043	1.7682	\$112.62		\$22.52
27266	Treat hip dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27267	Cltx thigh fx	NI	T	0043	1.7682	\$112.62		\$22.52
27268	Cltx thigh fx w/mnpj	NI	C					
27269	Optx thigh fx	NI	C					
27275	Manipulation of hip joint		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27280	Fusion of sacroiliac joint		C					
27282	Fusion of pubic bones		C					
27284	Fusion of hip joint		C					
27286	Fusion of hip joint		C					
27290	Amputation of leg at hip		C					
27295	Amputation of leg at hip		C					
27299	Pelvis/hip joint surgery		T	0043	1.7682	\$112.62		\$22.52
27301	Drain thigh/knee lesion		T	0008	18.3197	\$1,166.85		\$233.37
27303	Drainage of bone lesion		C					
27305	Incise thigh tendon & fascia		T	0049	21.2689	\$1,354.70		\$270.94
27306	Incision of thigh tendon		T	0049	21.2689	\$1,354.70		\$270.94
27307	Incision of thigh tendons		T	0049	21.2689	\$1,354.70		\$270.94
27310	Exploration of knee joint		T	0050	29.1900	\$1,859.23		\$371.85
27323	Biopsy, thigh soft tissues		T	0020	8.6850	\$553.18		\$110.64
27324	Biopsy, thigh soft tissues		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27325	Neurectomy, hamstring		T	0220	18.0518	\$1,149.79		\$229.96
27326	Neurectomy, popliteal		T	0220	18.0518	\$1,149.79		\$229.96
27327	Removal of thigh lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27328	Removal of thigh lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27329	Remove tumor, thigh/knee		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27330	Biopsy, knee joint lining		T	0050	29.1900	\$1,859.23		\$371.85
27331	Explore/treat knee joint		T	0050	29.1900	\$1,859.23		\$371.85
27332	Removal of knee cartilage		T	0050	29.1900	\$1,859.23		\$371.85
27333	Removal of knee cartilage		T	0050	29.1900	\$1,859.23		\$371.85
27334	Remove knee joint lining		T	0050	29.1900	\$1,859.23		\$371.85
27335	Remove knee joint lining		T	0050	29.1900	\$1,859.23		\$371.85
27340	Removal of kneecap bursa		T	0049	21.2689	\$1,354.70		\$270.94
27345	Removal of knee cyst		T	0049	21.2689	\$1,354.70		\$270.94
27347	Remove knee cyst		T	0049	21.2689	\$1,354.70		\$270.94
27350	Removal of kneecap		T	0050	29.1900	\$1,859.23		\$371.85
27355	Remove femur lesion		T	0050	29.1900	\$1,859.23		\$371.85
27356	Remove femur lesion/graft		T	0050	29.1900	\$1,859.23		\$371.85
27357	Remove femur lesion/graft		T	0050	29.1900	\$1,859.23		\$371.85
27358	Remove femur lesion/fixation		T	0050	29.1900	\$1,859.23		\$371.85
27360	Partial removal, leg bone(s)		T	0050	29.1900	\$1,859.23		\$371.85
27365	Extensive leg surgery		C					
27370	Injection for knee x-ray		N					
27372	Removal of foreign body		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27380	Repair of kneecap tendon		T	0049	21.2689	\$1,354.70		\$270.94
27381	Repair/graft kneecap tendon		T	0049	21.2689	\$1,354.70		\$270.94
27385	Repair of thigh muscle		T	0049	21.2689	\$1,354.70		\$270.94
27386	Repair/graft of thigh muscle		T	0049	21.2689	\$1,354.70		\$270.94
27390	Incision of thigh tendon		T	0049	21.2689	\$1,354.70		\$270.94
27391	Incision of thigh tendons		T	0049	21.2689	\$1,354.70		\$270.94
27392	Incision of thigh tendons		T	0049	21.2689	\$1,354.70		\$270.94
27393	Lengthening of thigh tendon		T	0050	29.1900	\$1,859.23		\$371.85
27394	Lengthening of thigh tendons		T	0050	29.1900	\$1,859.23		\$371.85
27395	Lengthening of thigh tendons		T	0051	42.9850	\$2,737.89		\$547.58
27396	Transplant of thigh tendon		T	0050	29.1900	\$1,859.23		\$371.85
27397	Transplants of thigh tendons		T	0051	42.9850	\$2,737.89		\$547.58
27400	Revise thigh muscles/tendons		T	0051	42.9850	\$2,737.89		\$547.58
27403	Repair of knee cartilage		T	0050	29.1900	\$1,859.23		\$371.85
27405	Repair of knee ligament		T	0051	42.9850	\$2,737.89		\$547.58
27407	Repair of knee ligament		T	0052	79.4244	\$5,058.86		\$1,011.77
27409	Repair of knee ligaments		T	0051	42.9850	\$2,737.89		\$547.58
27412	Autochondrocyte implant knee		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
27415	Osteochondral knee allograft		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
27416	Osteochondral knee autograft	NI	T	0051	42.9850	\$2,737.89		\$547.58
27418	Repair degenerated kneecap		T	0051	42.9850	\$2,737.89		\$547.58
27420	Revision of unstable kneecap		T	0051	42.9850	\$2,737.89		\$547.58
27422	Revision of unstable kneecap		T	0051	42.9850	\$2,737.89		\$547.58

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
27424	Revision/removal of kneecap		T	0051	42.9850	\$2,737.89		\$547.58
27425	Lat retinacular release open		T	0050	29.1900	\$1,859.23		\$371.85
27427	Reconstruction, knee		T	0051	42.9850	\$2,737.89		\$547.58
27428	Reconstruction, knee		T	0052	79.4244	\$5,058.86		\$1,011.77
27429	Reconstruction, knee		T	0052	79.4244	\$5,058.86		\$1,011.77
27430	Revision of thigh muscles		T	0051	42.9850	\$2,737.89		\$547.58
27435	Incision of knee joint		T	0051	42.9850	\$2,737.89		\$547.58
27437	Revise kneecap		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
27438	Revise kneecap with implant		T	0048	50.8876	\$3,241.23		\$648.25
27440	Revision of knee joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
27441	Revision of knee joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
27442	Revision of knee joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
27443	Revision of knee joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
27444	Revision of knee joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
27445	Revision of knee joint		C					
27446	Revision of knee joint		T	0681	274.6715	\$17,494.93		\$3,498.99
27447	Total knee arthroplasty		C					
27448	Incision of thigh		C					
27450	Incision of thigh		C					
27454	Realignment of thigh bone		C					
27455	Realignment of knee		C					
27457	Realignment of knee		C					
27465	Shortening of thigh bone		C					
27466	Lengthening of thigh bone		C					
27468	Shorten/lengthen thighs		C					
27470	Repair of thigh		C					
27472	Repair/graft of thigh		C					
27475	Surgery to stop leg growth		T	0050	29.1900	\$1,859.23		\$371.85
27477	Surgery to stop leg growth		C					
27479	Surgery to stop leg growth		C					
27485	Surgery to stop leg growth		C					
27486	Revise/replace knee joint		C					
27487	Revise/replace knee joint		C					
27488	Removal of knee prosthesis		C					
27495	Reinforce thigh		C					
27496	Decompression of thigh/knee		T	0049	21.2689	\$1,354.70		\$270.94
27497	Decompression of thigh/knee		T	0049	21.2689	\$1,354.70		\$270.94
27498	Decompression of thigh/knee		T	0049	21.2689	\$1,354.70		\$270.94
27499	Decompression of thigh/knee		T	0049	21.2689	\$1,354.70		\$270.94
27500	Treatment of thigh fracture		T	0043	1.7682	\$112.62		\$22.52
27501	Treatment of thigh fracture		T	0043	1.7682	\$112.62		\$22.52
27502	Treatment of thigh fracture		T	0043	1.7682	\$112.62		\$22.52
27503	Treatment of thigh fracture		T	0043	1.7682	\$112.62		\$22.52
27506	Treatment of thigh fracture		C					
27507	Treatment of thigh fracture		C					
27508	Treatment of thigh fracture		T	0043	1.7682	\$112.62		\$22.52
27509	Treatment of thigh fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
27510	Treatment of thigh fracture		T	0043	1.7682	\$112.62		\$22.52
27511	Treatment of thigh fracture		C					
27513	Treatment of thigh fracture		C					
27514	Treatment of thigh fracture		C					
27516	Treat thigh fx growth plate		T	0043	1.7682	\$112.62		\$22.52
27517	Treat thigh fx growth plate		T	0043	1.7682	\$112.62		\$22.52
27519	Treat thigh fx growth plate		C					
27520	Treat kneecap fracture		T	0043	1.7682	\$112.62		\$22.52
27524	Treat kneecap fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27530	Treat knee fracture		T	0043	1.7682	\$112.62		\$22.52
27532	Treat knee fracture		T	0043	1.7682	\$112.62		\$22.52
27535	Treat knee fracture		C					
27536	Treat knee fracture		C					
27538	Treat knee fracture(s)		T	0043	1.7682	\$112.62		\$22.52
27540	Treat knee fracture		C					
27550	Treat knee dislocation		T	0043	1.7682	\$112.62		\$22.52
27552	Treat knee dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27556	Treat knee dislocation		C					
27557	Treat knee dislocation		C					
27558	Treat knee dislocation		C					
27560	Treat kneecap dislocation		T	0043	1.7682	\$112.62		\$22.52
27562	Treat kneecap dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27566	Treat kneecap dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27570	Fixation of knee joint		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27580	Fusion of knee		C					
27590	Amputate leg at thigh		C					
27591	Amputate leg at thigh		C					
27592	Amputate leg at thigh		C					
27594	Amputation follow-up surgery		T	0049	21.2689	\$1,354.70		\$270.94
27596	Amputation follow-up surgery		C					
27598	Amputate lower leg at knee		C					
27599	Leg surgery procedure		T	0043	1.7682	\$112.62		\$22.52
27600	Decompression of lower leg		T	0049	21.2689	\$1,354.70		\$270.94
27601	Decompression of lower leg		T	0049	21.2689	\$1,354.70		\$270.94

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
27602	Decompression of lower leg		T	0049	21.2689	\$1,354.70		\$270.94
27603	Drain lower leg lesion		T	0008	18.3197	\$1,166.85		\$233.37
27604	Drain lower leg bursa		T	0049	21.2689	\$1,354.70		\$270.94
27605	Incision of achilles tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
27606	Incision of achilles tendon		T	0049	21.2689	\$1,354.70		\$270.94
27607	Treat lower leg bone lesion		T	0049	21.2689	\$1,354.70		\$270.94
27610	Explore/treat ankle joint		T	0050	29.1900	\$1,859.23		\$371.85
27612	Exploration of ankle joint		T	0050	29.1900	\$1,859.23		\$371.85
27613	Biopsy lower leg soft tissue		T	0020	8.6850	\$553.18		\$110.64
27614	Biopsy lower leg soft tissue		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27615	Remove tumor, lower leg		T	0050	29.1900	\$1,859.23		\$371.85
27618	Remove lower leg lesion		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
27619	Remove lower leg lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
27620	Explore/treat ankle joint		T	0050	29.1900	\$1,859.23		\$371.85
27625	Remove ankle joint lining		T	0050	29.1900	\$1,859.23		\$371.85
27626	Remove ankle joint lining		T	0050	29.1900	\$1,859.23		\$371.85
27630	Removal of tendon lesion		T	0049	21.2689	\$1,354.70		\$270.94
27635	Remove lower leg bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
27637	Remove/graft leg bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
27638	Remove/graft leg bone lesion		T	0050	29.1900	\$1,859.23		\$371.85
27640	Partial removal of tibia		T	0051	42.9850	\$2,737.89		\$547.58
27641	Partial removal of fibula		T	0050	29.1900	\$1,859.23		\$371.85
27645	Extensive lower leg surgery		C					
27646	Extensive lower leg surgery		C					
27647	Extensive ankle/heel surgery		T	0051	42.9850	\$2,737.89		\$547.58
27648	Injection for ankle x-ray		N					
27650	Repair achilles tendon		T	0051	42.9850	\$2,737.89		\$547.58
27652	Repair/graft achilles tendon		T	0052	79.4244	\$5,058.86		\$1,011.77
27654	Repair of achilles tendon		T	0051	42.9850	\$2,737.89		\$547.58
27656	Repair leg fascia defect		T	0049	21.2689	\$1,354.70		\$270.94
27658	Repair of leg tendon, each		T	0049	21.2689	\$1,354.70		\$270.94
27659	Repair of leg tendon, each		T	0049	21.2689	\$1,354.70		\$270.94
27664	Repair of leg tendon, each		T	0049	21.2689	\$1,354.70		\$270.94
27665	Repair of leg tendon, each		T	0050	29.1900	\$1,859.23		\$371.85
27675	Repair lower leg tendons		T	0049	21.2689	\$1,354.70		\$270.94
27676	Repair lower leg tendons		T	0050	29.1900	\$1,859.23		\$371.85
27680	Release of lower leg tendon		T	0050	29.1900	\$1,859.23		\$371.85
27681	Release of lower leg tendons		T	0050	29.1900	\$1,859.23		\$371.85
27685	Revision of lower leg tendon		T	0050	29.1900	\$1,859.23		\$371.85
27686	Revise lower leg tendons		T	0050	29.1900	\$1,859.23		\$371.85
27687	Revision of calf tendon		T	0050	29.1900	\$1,859.23		\$371.85
27690	Revise lower leg tendon		T	0051	42.9850	\$2,737.89		\$547.58
27691	Revise lower leg tendon		T	0051	42.9850	\$2,737.89		\$547.58
27692	Revise additional leg tendon		T	0051	42.9850	\$2,737.89		\$547.58
27695	Repair of ankle ligament		T	0050	29.1900	\$1,859.23		\$371.85
27696	Repair of ankle ligaments		T	0050	29.1900	\$1,859.23		\$371.85
27698	Repair of ankle ligament		T	0050	29.1900	\$1,859.23		\$371.85
27700	Revision of ankle joint		T	0047	35.9040	\$2,286.87	\$537.03	\$457.37
27702	Reconstruct ankle joint		C					
27703	Reconstruction, ankle joint		C					
27704	Removal of ankle implant		T	0049	21.2689	\$1,354.70		\$270.94
27705	Incision of tibia		T	0051	42.9850	\$2,737.89		\$547.58
27707	Incision of fibula		T	0049	21.2689	\$1,354.70		\$270.94
27709	Incision of tibia & fibula		T	0050	29.1900	\$1,859.23		\$371.85
27712	Realignment of lower leg		C					
27715	Revision of lower leg		C					
27720	Repair of tibia	CH	T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27722	Repair/graft of tibia	CH	T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
27724	Repair/graft of tibia		C					
27725	Repair of lower leg		C					
27726	Repair fibula nonunion	NI	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
27727	Repair of lower leg		C					
27730	Repair of tibia epiphysis		T	0050	29.1900	\$1,859.23		\$371.85
27732	Repair of fibula epiphysis		T	0050	29.1900	\$1,859.23		\$371.85
27734	Repair lower leg epiphyses		T	0050	29.1900	\$1,859.23		\$371.85
27740	Repair of leg epiphyses		T	0050	29.1900	\$1,859.23		\$371.85
27742	Repair of leg epiphyses		T	0051	42.9850	\$2,737.89		\$547.58
27745	Reinforce tibia		T	0052	79.4244	\$5,058.86		\$1,011.77
27750	Treatment of tibia fracture		T	0043	1.7682	\$112.62		\$22.52
27752	Treatment of tibia fracture		T	0043	1.7682	\$112.62		\$22.52
27756	Treatment of tibia fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
27758	Treatment of tibia fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27759	Treatment of tibia fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
27760	Cltx medial ankle fx		T	0043	1.7682	\$112.62		\$22.52
27762	Cltx med ankle fx w/mnpj		T	0043	1.7682	\$112.62		\$22.52
27766	Optx medial ankle fx		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27767	Cltx post ankle fx	NI	T	0043	1.7682	\$112.62		\$22.52
27768	Cltx post ankle fx w/mnpj	NI	T	0043	1.7682	\$112.62		\$22.52
27769	Optx post ankle fx	NI	T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27780	Treatment of fibula fracture		T	0043	1.7682	\$112.62		\$22.52

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
27781	Treatment of fibula fracture		T	0043	1.7682	\$112.62		\$22.52
27784	Treatment of fibula fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27786	Treatment of ankle fracture		T	0043	1.7682	\$112.62		\$22.52
27788	Treatment of ankle fracture		T	0043	1.7682	\$112.62		\$22.52
27792	Treatment of ankle fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27808	Treatment of ankle fracture		T	0043	1.7682	\$112.62		\$22.52
27810	Treatment of ankle fracture		T	0043	1.7682	\$112.62		\$22.52
27814	Treatment of ankle fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27816	Treatment of ankle fracture		T	0043	1.7682	\$112.62		\$22.52
27818	Treatment of ankle fracture		T	0043	1.7682	\$112.62		\$22.52
27822	Treatment of ankle fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27823	Treatment of ankle fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
27824	Treat lower leg fracture		T	0043	1.7682	\$112.62		\$22.52
27825	Treat lower leg fracture		T	0043	1.7682	\$112.62		\$22.52
27826	Treat lower leg fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27827	Treat lower leg fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
27828	Treat lower leg fracture		T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
27829	Treat lower leg joint		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27830	Treat lower leg dislocation		T	0043	1.7682	\$112.62		\$22.52
27831	Treat lower leg dislocation		T	0043	1.7682	\$112.62		\$22.52
27832	Treat lower leg dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27840	Treat ankle dislocation		T	0043	1.7682	\$112.62		\$22.52
27842	Treat ankle dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27846	Treat ankle dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27848	Treat ankle dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
27860	Fixation of ankle joint		T	0045	14.7658	\$940.49	\$268.47	\$188.10
27870	Fusion of ankle joint, open		T	0052	79.4244	\$5,058.86		\$1,011.77
27871	Fusion of tibiofibular joint		T	0052	79.4244	\$5,058.86		\$1,011.77
27880	Amputation of lower leg		C					
27881	Amputation of lower leg		C					
27882	Amputation of lower leg		C					
27884	Amputation follow-up surgery		C	0049	21.2689	\$1,354.70		\$270.94
27886	Amputation follow-up surgery		C					
27888	Amputation of foot at ankle		C					
27889	Amputation of foot at ankle		T	0050	29.1900	\$1,859.23		\$371.85
27892	Decompression of leg		T	0049	21.2689	\$1,354.70		\$270.94
27893	Decompression of leg		T	0049	21.2689	\$1,354.70		\$270.94
27894	Decompression of leg		T	0049	21.2689	\$1,354.70		\$270.94
27899	Leg/ankle surgery procedure		T	0043	1.7682	\$112.62		\$22.52
28001	Drainage of bursa of foot		T	0007	11.5594	\$736.26		\$147.25
28002	Treatment of foot infection		T	0049	21.2689	\$1,354.70		\$270.94
28003	Treatment of foot infection		T	0049	21.2689	\$1,354.70		\$270.94
28005	Treat foot bone lesion		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28008	Incision of foot fascia		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28010	Incision of toe tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28011	Incision of toe tendons		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28020	Exploration of foot joint		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28022	Exploration of foot joint		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28024	Exploration of toe joint		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28035	Decompression of tibia nerve		T	0220	18.0518	\$1,149.79		\$229.96
28043	Excision of foot lesion		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
28045	Excision of foot lesion		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28046	Resection of tumor, foot		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28050	Biopsy of foot joint lining		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28052	Biopsy of foot joint lining		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28054	Biopsy of toe joint lining		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28055	Neurectomy, foot		T	0220	18.0518	\$1,149.79		\$229.96
28060	Partial removal, foot fascia		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28062	Removal of foot fascia		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28070	Removal of foot joint lining		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28072	Removal of foot joint lining		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28080	Removal of foot lesion		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28086	Excise foot tendon sheath		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28088	Excise foot tendon sheath		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28090	Removal of foot lesion		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28092	Removal of toe lesions		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28100	Removal of ankle/heel lesion		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28102	Remove/graft foot lesion		T	0056	44.2687	\$2,819.65		\$563.93
28103	Remove/graft foot lesion		T	0056	44.2687	\$2,819.65		\$563.93
28104	Removal of foot lesion		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28106	Remove/graft foot lesion		T	0056	44.2687	\$2,819.65		\$563.93
28107	Remove/graft foot lesion		T	0056	44.2687	\$2,819.65		\$563.93
28108	Removal of toe lesions		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28110	Part removal of metatarsal		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28111	Part removal of metatarsal		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28112	Part removal of metatarsal		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28113	Part removal of metatarsal		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28114	Removal of metatarsal heads		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28116	Revision of foot		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28118	Removal of heel bone		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
28119	Removal of heel spur		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28120	Part removal of ankle/heel		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28122	Partial removal of foot bone		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28124	Partial removal of toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28126	Partial removal of toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28130	Removal of ankle bone		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28140	Removal of metatarsal		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28150	Removal of toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28153	Partial removal of toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28160	Partial removal of toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28171	Extensive foot surgery		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28173	Extensive foot surgery		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28175	Extensive foot surgery		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28190	Removal of foot foreign body		T	0019	4.3039	\$274.13	\$71.87	\$54.83
28192	Removal of foot foreign body		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
28193	Removal of foot foreign body		T	0020	8.6850	\$553.18		\$110.64
28200	Repair of foot tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28202	Repair/graft of foot tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28208	Repair of foot tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28210	Repair/graft of foot tendon		T	0056	44.2687	\$2,819.65		\$563.93
28220	Release of foot tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28222	Release of foot tendons		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28225	Release of foot tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28226	Release of foot tendons		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28230	Incision of foot tendon(s)		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28232	Incision of toe tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28234	Incision of foot tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28238	Revision of foot tendon		T	0056	44.2687	\$2,819.65		\$563.93
28240	Release of big toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28250	Revision of foot fascia		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28260	Release of midfoot joint		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28261	Revision of foot tendon		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28262	Revision of foot and ankle		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28264	Release of midfoot joint		T	0056	44.2687	\$2,819.65		\$563.93
28270	Release of foot contracture		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28272	Release of toe joint, each		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28280	Fusion of toes		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28285	Repair of hammertoe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28286	Repair of hammertoe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28288	Partial removal of foot bone		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28289	Repair hallux rigidus		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28290	Correction of bunion		T	0057	29.4167	\$1,873.67	\$475.91	\$374.73
28292	Correction of bunion		T	0057	29.4167	\$1,873.67	\$475.91	\$374.73
28293	Correction of bunion		T	0057	29.4167	\$1,873.67	\$475.91	\$374.73
28294	Correction of bunion		T	0057	29.4167	\$1,873.67	\$475.91	\$374.73
28296	Correction of bunion		T	0057	29.4167	\$1,873.67	\$475.91	\$374.73
28297	Correction of bunion		T	0057	29.4167	\$1,873.67	\$475.91	\$374.73
28298	Correction of bunion		T	0057	29.4167	\$1,873.67	\$475.91	\$374.73
28299	Correction of bunion		T	0057	29.4167	\$1,873.67	\$475.91	\$374.73
28300	Incision of heel bone		T	0056	44.2687	\$2,819.65		\$563.93
28302	Incision of ankle bone		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28304	Incision of midfoot bones		T	0056	44.2687	\$2,819.65		\$563.93
28305	Incise/graft midfoot bones		T	0056	44.2687	\$2,819.65		\$563.93
28306	Incision of metatarsal		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28307	Incision of metatarsal		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28308	Incision of metatarsal		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28309	Incision of metatarsals		T	0056	44.2687	\$2,819.65		\$563.93
28310	Revision of big toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28312	Revision of toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28313	Repair deformity of toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28315	Removal of sesamoid bone		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28320	Repair of foot bones		T	0056	44.2687	\$2,819.65		\$563.93
28322	Repair of metatarsals		T	0056	44.2687	\$2,819.65		\$563.93
28340	Resect enlarged toe tissue		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28341	Resect enlarged toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28344	Repair extra toe(s)		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28345	Repair webbed toe(s)		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28360	Reconstruct cleft foot		T	0056	44.2687	\$2,819.65		\$563.93
28400	Treatment of heel fracture		T	0043	1.7682	\$112.62		\$22.52
28405	Treatment of heel fracture		T	0043	1.7682	\$112.62		\$22.52
28406	Treatment of heel fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28415	Treat heel fracture	CH	T	0064	59.2233	\$3,772.17	\$835.79	\$754.43
28420	Treat/graft heel fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
28430	Treatment of ankle fracture		T	0043	1.7682	\$112.62		\$22.52
28435	Treatment of ankle fracture		T	0043	1.7682	\$112.62		\$22.52
28436	Treatment of ankle fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28445	Treat ankle fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
28446	Osteochondral talus autogrt	NI	T	0056	44.2687	\$2,819.65		\$563.93
28450	Treat midfoot fracture, each		T	0043	1.7682	\$112.62		\$22.52
28455	Treat midfoot fracture, each		T	0043	1.7682	\$112.62		\$22.52

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
28456	Treat midfoot fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28465	Treat midfoot fracture, each		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
28470	Treat metatarsal fracture		T	0043	1.7682	\$112.62		\$22.52
28475	Treat metatarsal fracture		T	0043	1.7682	\$112.62		\$22.52
28476	Treat metatarsal fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28485	Treat metatarsal fracture		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
28490	Treat big toe fracture		T	0043	1.7682	\$112.62		\$22.52
28495	Treat big toe fracture		T	0043	1.7682	\$112.62		\$22.52
28496	Treat big toe fracture		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28505	Treat big toe fracture	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28510	Treatment of toe fracture		T	0043	1.7682	\$112.62		\$22.52
28515	Treatment of toe fracture		T	0043	1.7682	\$112.62		\$22.52
28525	Treat toe fracture	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28530	Treat sesamoid bone fracture		T	0043	1.7682	\$112.62		\$22.52
28531	Treat sesamoid bone fracture	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28540	Treat foot dislocation		T	0043	1.7682	\$112.62		\$22.52
28545	Treat foot dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28546	Treat foot dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28555	Repair foot dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
28570	Treat foot dislocation		T	0043	1.7682	\$112.62		\$22.52
28575	Treat foot dislocation		T	0043	1.7682	\$112.62		\$22.52
28576	Treat foot dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28585	Repair foot dislocation	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28600	Treat foot dislocation		T	0043	1.7682	\$112.62		\$22.52
28605	Treat foot dislocation		T	0043	1.7682	\$112.62		\$22.52
28606	Treat foot dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28615	Repair foot dislocation		T	0063	41.1091	\$2,618.40	\$548.33	\$523.68
28630	Treat toe dislocation		T	0043	1.7682	\$112.62		\$22.52
28635	Treat toe dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
28636	Treat toe dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28645	Repair toe dislocation	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28660	Treat toe dislocation		T	0043	1.7682	\$112.62		\$22.52
28665	Treat toe dislocation		T	0045	14.7658	\$940.49	\$268.47	\$188.10
28666	Treat toe dislocation		T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28675	Repair of toe dislocation	CH	T	0062	26.1592	\$1,666.18	\$372.87	\$333.24
28705	Fusion of foot bones		T	0056	44.2687	\$2,819.65		\$563.93
28715	Fusion of foot bones	CH	T	0052	79.4244	\$5,058.86		\$1,011.77
28725	Fusion of foot bones		T	0056	44.2687	\$2,819.65		\$563.93
28730	Fusion of foot bones		T	0056	44.2687	\$2,819.65		\$563.93
28735	Fusion of foot bones		T	0056	44.2687	\$2,819.65		\$563.93
28737	Revision of foot bones		T	0056	44.2687	\$2,819.65		\$563.93
28740	Fusion of foot bones		T	0056	44.2687	\$2,819.65		\$563.93
28750	Fusion of big toe joint		T	0056	44.2687	\$2,819.65		\$563.93
28755	Fusion of big toe joint		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28760	Fusion of big toe joint		T	0056	44.2687	\$2,819.65		\$563.93
28800	Amputation of midfoot		C					
28805	Amputation thru metatarsal		C					
28810	Amputation toe & metatarsal		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28820	Amputation of toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28825	Partial amputation of toe		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
28890	High energy eswt, plantar f		T	0050	29.1900	\$1,859.23		\$371.85
28899	Foot/toes surgery procedure		T	0043	1.7682	\$112.62		\$22.52
29000	Application of body cast		S	0058	1.0931	\$69.62		\$13.92
29010	Application of body cast		S	0426	2.2910	\$145.92		\$29.18
29015	Application of body cast		S	0426	2.2910	\$145.92		\$29.18
29020	Application of body cast		S	0058	1.0931	\$69.62		\$13.92
29025	Application of body cast		S	0058	1.0931	\$69.62		\$13.92
29035	Application of body cast		S	0426	2.2910	\$145.92		\$29.18
29040	Application of body cast		S	0058	1.0931	\$69.62		\$13.92
29044	Application of body cast		S	0426	2.2910	\$145.92		\$29.18
29046	Application of body cast		S	0426	2.2910	\$145.92		\$29.18
29049	Application of figure eight		S	0058	1.0931	\$69.62		\$13.92
29055	Application of shoulder cast		S	0426	2.2910	\$145.92		\$29.18
29058	Application of shoulder cast		S	0058	1.0931	\$69.62		\$13.92
29065	Application of long arm cast		S	0426	2.2910	\$145.92		\$29.18
29075	Application of forearm cast		S	0426	2.2910	\$145.92		\$29.18
29085	Apply hand/wrist cast		S	0058	1.0931	\$69.62		\$13.92
29086	Apply finger cast		S	0058	1.0931	\$69.62		\$13.92
29105	Apply long arm splint		S	0058	1.0931	\$69.62		\$13.92
29125	Apply forearm splint		S	0058	1.0931	\$69.62		\$13.92
29126	Apply forearm splint		S	0058	1.0931	\$69.62		\$13.92
29130	Application of finger splint		S	0058	1.0931	\$69.62		\$13.92
29131	Application of finger splint		S	0058	1.0931	\$69.62		\$13.92
29200	Strapping of chest		S	0058	1.0931	\$69.62		\$13.92
29220	Strapping of low back		S	0058	1.0931	\$69.62		\$13.92
29240	Strapping of shoulder		S	0058	1.0931	\$69.62		\$13.92
29260	Strapping of elbow or wrist		S	0058	1.0931	\$69.62		\$13.92
29280	Strapping of hand or finger		S	0058	1.0931	\$69.62		\$13.92
29305	Application of hip cast		S	0426	2.2910	\$145.92		\$29.18
29325	Application of hip casts		S	0426	2.2910	\$145.92		\$29.18

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
29345	Application of long leg cast		S	0426	2.2910	\$145.92		\$29.18
29355	Application of long leg cast		S	0426	2.2910	\$145.92		\$29.18
29358	Apply long leg cast brace		S	0426	2.2910	\$145.92		\$29.18
29365	Application of long leg cast		S	0426	2.2910	\$145.92		\$29.18
29405	Apply short leg cast		S	0426	2.2910	\$145.92		\$29.18
29425	Apply short leg cast		S	0426	2.2910	\$145.92		\$29.18
29435	Apply short leg cast		S	0426	2.2910	\$145.92		\$29.18
29440	Addition of walker to cast		S	0058	1.0931	\$69.62		\$13.92
29445	Apply rigid leg cast		S	0426	2.2910	\$145.92		\$29.18
29450	Application of leg cast		S	0058	1.0931	\$69.62		\$13.92
29505	Application, long leg splint		S	0058	1.0931	\$69.62		\$13.92
29515	Application lower leg splint		S	0058	1.0931	\$69.62		\$13.92
29520	Strapping of hip		S	0058	1.0931	\$69.62		\$13.92
29530	Strapping of knee		S	0058	1.0931	\$69.62		\$13.92
29540	Strapping of ankle and/or ft		S	0058	1.0931	\$69.62		\$13.92
29550	Strapping of toes		S	0058	1.0931	\$69.62		\$13.92
29580	Application of paste boot		S	0058	1.0931	\$69.62		\$13.92
29590	Application of foot splint		S	0058	1.0931	\$69.62		\$13.92
29700	Removal/revision of cast		S	0058	1.0931	\$69.62		\$13.92
29705	Removal/revision of cast		S	0058	1.0931	\$69.62		\$13.92
29710	Removal/revision of cast		S	0426	2.2910	\$145.92		\$29.18
29715	Removal/revision of cast		S	0058	1.0931	\$69.62		\$13.92
29720	Repair of body cast		S	0058	1.0931	\$69.62		\$13.92
29730	Windowing of cast		S	0058	1.0931	\$69.62		\$13.92
29740	Wedging of cast		S	0058	1.0931	\$69.62		\$13.92
29750	Wedging of clubfoot cast		S	0058	1.0931	\$69.62		\$13.92
29799	Casting/strapping procedure		S	0058	1.0931	\$69.62		\$13.92
29800	Jaw arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29804	Jaw arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29805	Shoulder arthroscopy, dx		T	0041	28.7803	\$1,833.13		\$366.63
29806	Shoulder arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29807	Shoulder arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29819	Shoulder arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29820	Shoulder arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29821	Shoulder arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29822	Shoulder arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29823	Shoulder arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29824	Shoulder arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29825	Shoulder arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29826	Shoulder arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29827	Arthroscop rotator cuff repr		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29828	Arthroscopy biceps tenodesis	NI	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29830	Elbow arthroscopy		T	0041	28.7803	\$1,833.13		\$366.63
29834	Elbow arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29835	Elbow arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29836	Elbow arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29837	Elbow arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29838	Elbow arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29840	Wrist arthroscopy		T	0041	28.7803	\$1,833.13		\$366.63
29843	Wrist arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29844	Wrist arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29845	Wrist arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29846	Wrist arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29847	Wrist arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29848	Wrist endoscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29850	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29851	Knee arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29855	Tibial arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29856	Tibial arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29860	Hip arthroscopy, dx	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29861	Hip arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29862	Hip arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29863	Hip arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29866	Autgrft implnt, knee w/scope		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29867	Allgrft implnt, knee w/scope		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29868	Meniscal trnspl, knee w/scope		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29870	Knee arthroscopy, dx		T	0041	28.7803	\$1,833.13		\$366.63
29871	Knee arthroscopy/drainage		T	0041	28.7803	\$1,833.13		\$366.63
29873	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29874	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29875	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29876	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29877	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29879	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29880	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29881	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29882	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29883	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29884	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29885	Knee arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
29886	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29887	Knee arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29888	Knee arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29889	Knee arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29891	Ankle arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29892	Ankle arthroscopy/surgery	CH	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29893	Scope, plantar fasciotomy		T	0055	20.8284	\$1,326.64	\$355.34	\$265.33
29894	Ankle arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29895	Ankle arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29897	Ankle arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29898	Ankle arthroscopy/surgery		T	0041	28.7803	\$1,833.13		\$366.63
29899	Ankle arthroscopy/surgery		T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29900	Mcp joint arthroscopy, dx	CH	T	0041	28.7803	\$1,833.13		\$366.63
29901	Mcp joint arthroscopy, surg	CH	T	0041	28.7803	\$1,833.13		\$366.63
29902	Mcp joint arthroscopy, surg	CH	T	0041	28.7803	\$1,833.13		\$366.63
29904	Subtalar arthro w/fb rrmvl	NI	T	0041	28.7803	\$1,833.13		\$366.63
29905	Subtalar arthro w/exc	NI	T	0041	28.7803	\$1,833.13		\$366.63
29906	Subtalar arthro w/deb	NI	T	0041	28.7803	\$1,833.13		\$366.63
29907	Subtalar arthro w/fusion	NI	T	0042	45.7072	\$2,911.27	\$804.74	\$582.25
29999	Arthroscopy of joint		T	0041	28.7803	\$1,833.13		\$366.63
30000	Drainage of nose lesion		T	0251	2.5002	\$159.25		\$31.85
30020	Drainage of nose lesion		T	0251	2.5002	\$159.25		\$31.85
3006F	Cxr doc rev		M					
30100	Intranasal biopsy		T	0252	7.4474	\$474.35	\$109.16	\$94.87
30110	Removal of nose polyp(s)		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
30115	Removal of nose polyp(s)		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
30117	Removal of intranasal lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
30118	Removal of intranasal lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
3011F	Lipid panel doc rev		M					
30120	Revision of nose		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
30124	Removal of nose lesion		T	0252	7.4474	\$474.35	\$109.16	\$94.87
30125	Removal of nose lesion		T	0256	39.8776	\$2,539.96		\$507.99
30130	Excise inferior turbinate		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
30140	Resect inferior turbinate		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
3014F	Screen mammo doc rev		M					
30150	Partial removal of nose		T	0256	39.8776	\$2,539.96		\$507.99
30160	Removal of nose		T	0256	39.8776	\$2,539.96		\$507.99
3017F	Colorectal ca screen doc rev		M					
30200	Injection treatment of nose		T	0252	7.4474	\$474.35	\$109.16	\$94.87
3020F	Lvf assess		M					
30210	Nasal sinus therapy		T	0252	7.4474	\$474.35	\$109.16	\$94.87
3021F	Lvef mod/sever deprs syst		M					
30220	Insert nasal septal button		T	0252	7.4474	\$474.35	\$109.16	\$94.87
3022F	Lvef >=40% systolic		M					
3023F	Spirom doc rev		M					
3025F	Spirom fev/fvc<70% w copd		M					
3027F	Spirom fev/fvc>=70%/w/o copd		M					
3028F	O2 saturation doc rev		M					
30300	Remove nasal foreign body		X	0340	0.6310	\$40.19		\$8.04
30310	Remove nasal foreign body		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
30320	Remove nasal foreign body		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
3035F	O2 saturation<=88%/pao<=55		M					
3037F	O2 saturation >88%/pao>55		M					
30400	Reconstruction of nose		T	0256	39.8776	\$2,539.96		\$507.99
3040F	Fev<40% predicted value		M					
30410	Reconstruction of nose		T	0256	39.8776	\$2,539.96		\$507.99
30420	Reconstruction of nose		T	0256	39.8776	\$2,539.96		\$507.99
3042F	Fev>= 40% predicted value		M					
30430	Revision of nose		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
30435	Revision of nose		T	0256	39.8776	\$2,539.96		\$507.99
3044F	Hg a1c level lt 7.0%		M					
30450	Revision of nose		T	0256	39.8776	\$2,539.96		\$507.99
3045F	HG a1c level 7.0–9.0%		M					
30460	Revision of nose		T	0256	39.8776	\$2,539.96		\$507.99
30462	Revision of nose		T	0256	39.8776	\$2,539.96		\$507.99
30465	Repair nasal stenosis		T	0256	39.8776	\$2,539.96		\$507.99
3046F	Hemoglobin a1c level > 9.0%		M					
3048F	Ldl-c <100 mg/dl		M					
3049F	Ldl-c 100–129 mg/dl		M					
3050F	Ldl-c >= 130 mg/dl		M					
30520	Repair of nasal septum		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
30540	Repair nasal defect		T	0256	39.8776	\$2,539.96		\$507.99
30545	Repair nasal defect		T	0256	39.8776	\$2,539.96		\$507.99
30560	Release of nasal adhesions		T	0251	2.5002	\$159.25		\$31.85
30580	Repair upper jaw fistula		T	0256	39.8776	\$2,539.96		\$507.99
30600	Repair mouth/nose fistula		T	0256	39.8776	\$2,539.96		\$507.99
3060F	Pos microalbuminuria rev		M					
3061F	Neg microalbuminuria rev		M					
30620	Intranasal reconstruction		T	0256	39.8776	\$2,539.96		\$507.99
3062F	Pos macroalbuminuria rev		M					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
30630	Repair nasal septum defect		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
3066F	Nephropathy doc tx		M					
3072F	Low risk for retinopathy		M					
3073F	Pre-surg eye measures doc'd		M					
3074F	Syst bp lt 130 mm hg		M					
3075F	Syst bp ge 130 - 139mm hg		M					
3077F	Syst bp >= 140 mm hg6 it		M					
3078F	Diast bp < 80 mm hg		M					
3079F	Diast bp 80–89 mm hg		M					
30801	Ablate inf turbinate, superf		T	0252	7.4474	\$474.35	\$109.16	\$94.87
30802	Cauterization, inner nose		T	0252	7.4474	\$474.35	\$109.16	\$94.87
3080F	Diast bp >= 90 mm hg		M					
3082F	Kt/v lt 1.2		M					
3083F	Kt/v ge 1.2 and <1.7		M					
3084F	Kt/v ge 1.7		M					
3085F	Suicide risk assessed		M					
3088F	MDD, mild		M					
3089F	MDD, moderate		M					
30901	Control of nosebleed		T	0250	1.1251	\$71.66	\$25.10	\$14.33
30903	Control of nosebleed		T	0250	1.1251	\$71.66	\$25.10	\$14.33
30905	Control of nosebleed		T	0250	1.1251	\$71.66	\$25.10	\$14.33
30906	Repeat control of nosebleed		T	0250	1.1251	\$71.66	\$25.10	\$14.33
3090F	MDD, severe; w/o psych		M					
30915	Ligation, nasal sinus artery		T	0092	25.8410	\$1,645.92		\$329.18
3091F	Mdd, severe; w/ psych		M					
30920	Ligation, upper jaw artery		T	0092	25.8410	\$1,645.92		\$329.18
3092F	MDD, in remission		M					
30930	Ther fx, nasal inf turbinate		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
3093F	Doc new diag 1st/addl mdd		M					
3095F	Central dexa results doc'd		M					
3096F	Central dexa ordered		M					
30999	Nasal surgery procedure		T	0251	2.5002	\$159.25		\$31.85
31000	Irrigation, maxillary sinus		T	0251	2.5002	\$159.25		\$31.85
31002	Irrigation, sphenoid sinus		T	0252	7.4474	\$474.35	\$109.16	\$94.87
3100F	Image test ref carot diam		M					
31020	Exploration, maxillary sinus		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31030	Exploration, maxillary sinus		T	0256	39.8776	\$2,539.96		\$507.99
31032	Explore sinus, remove polyps		T	0256	39.8776	\$2,539.96		\$507.99
31040	Exploration behind upper jaw		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31050	Exploration, sphenoid sinus		T	0256	39.8776	\$2,539.96		\$507.99
31051	Sphenoid sinus surgery		T	0256	39.8776	\$2,539.96		\$507.99
31070	Exploration of frontal sinus		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31075	Exploration of frontal sinus		T	0256	39.8776	\$2,539.96		\$507.99
31080	Removal of frontal sinus		T	0256	39.8776	\$2,539.96		\$507.99
31081	Removal of frontal sinus		T	0256	39.8776	\$2,539.96		\$507.99
31084	Removal of frontal sinus		T	0256	39.8776	\$2,539.96		\$507.99
31085	Removal of frontal sinus		T	0256	39.8776	\$2,539.96		\$507.99
31086	Removal of frontal sinus		T	0256	39.8776	\$2,539.96		\$507.99
31087	Removal of frontal sinus		T	0256	39.8776	\$2,539.96		\$507.99
31090	Exploration of sinuses		T	0256	39.8776	\$2,539.96		\$507.99
3110F	Pres/absn hmrhg/lesion doc'd		M					
3111F	Ct/mri brain done w/in 24hrs		M					
3112F	Ct/mri brain done gt 24 hrs		M					
31200	Removal of ethmoid sinus		T	0256	39.8776	\$2,539.96		\$507.99
31201	Removal of ethmoid sinus		T	0256	39.8776	\$2,539.96		\$507.99
31205	Removal of ethmoid sinus		T	0256	39.8776	\$2,539.96		\$507.99
3120F	12-lead ecg performed		M					
31225	Removal of upper jaw		C					
31230	Removal of upper jaw		C					
31231	Nasal endoscopy, dx		T	0072	1.6115	\$102.64	\$21.27	\$20.53
31233	Nasal/sinus endoscopy, dx		T	0072	1.6115	\$102.64	\$21.27	\$20.53
31235	Nasal/sinus endoscopy, dx		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31237	Nasal/sinus endoscopy, surg		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31238	Nasal/sinus endoscopy, surg		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31239	Nasal/sinus endoscopy, surg		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31240	Nasal/sinus endoscopy, surg		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31254	Revision of ethmoid sinus		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31255	Removal of ethmoid sinus		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31256	Exploration maxillary sinus		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31267	Endoscopy, maxillary sinus		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31276	Sinus endoscopy, surgical		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31287	Nasal/sinus endoscopy, surg		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31288	Nasal/sinus endoscopy, surg		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31290	Nasal/sinus endoscopy, surg		C					
31291	Nasal/sinus endoscopy, surg		C					
31292	Nasal/sinus endoscopy, surg		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31293	Nasal/sinus endoscopy, surg		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31294	Nasal/sinus endoscopy, surg		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31299	Sinus surgery procedure		T	0251	2.5002	\$159.25		\$31.85
31300	Removal of larynx lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
3130F	Upper gi endoscopy performed		M					
31320	Diagnostic incision, larynx		T	0256	39.8776	\$2,539.96		\$507.99
3132F	Doc ref upper gi endoscopy		M					
31360	Removal of larynx		C					
31365	Removal of larynx		C					
31367	Partial removal of larynx		C					
31368	Partial removal of larynx		C					
31370	Partial removal of larynx		C					
31375	Partial removal of larynx		C					
31380	Partial removal of larynx		C					
31382	Partial removal of larynx		C					
31390	Removal of larynx & pharynx		C					
31395	Reconstruct larynx & pharynx		C					
31400	Revision of larynx		T	0256	39.8776	\$2,539.96		\$507.99
3140F	Upper gi endo shows barrtt's		M					
3141F	Upper gi endo not barrtt's		M					
31420	Removal of epiglottis		T	0256	39.8776	\$2,539.96		\$507.99
3142F	Barium swallow test ordered		M					
31500	Insert emergency airway		S	0094	2.4590	\$156.62	\$46.29	\$31.32
31502	Change of windpipe airway	CH	S	0078	1.3362	\$85.11		\$17.02
31505	Diagnostic laryngoscopy		T	0071	0.8224	\$52.38	\$11.20	\$10.48
3150F	Forceps esoph biopsy done		M					
31510	Laryngoscopy with biopsy		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31511	Remove foreign body, larynx		T	0072	1.6115	\$102.64	\$21.27	\$20.53
31512	Removal of larynx lesion		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31513	Injection into vocal cord		T	0072	1.6115	\$102.64	\$21.27	\$20.53
31515	Laryngoscopy for aspiration		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31520	Dx laryngoscopy, newborn		T	0072	1.6115	\$102.64	\$21.27	\$20.53
31525	Dx laryngoscopy excl nb		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31526	Dx laryngoscopy w/oper scope		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31527	Laryngoscopy for treatment		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31528	Laryngoscopy and dilation		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31529	Laryngoscopy and dilation		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31530	Laryngoscopy w/fb removal		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31531	Laryngoscopy w/fb & op scope		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31535	Laryngoscopy w/biopsy		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31536	Laryngoscopy w/bx & op scope		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31540	Laryngoscopy w/exc of tumor		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31541	Larynsco w/tumr exc + scope		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31545	Remove vc lesion w/scope		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31546	Remove vc lesion scope/graft		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
3155F	Cytogen test marrow b/4 tx		M					
31560	Laryngoscopy w/arytenoidectom		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31561	Larynsco, remove cart + scop		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31570	Laryngoscope w/vc inj		T	0074	17.0160	\$1,083.82	\$292.25	\$216.76
31571	Laryngoscopy w/vc inj + scope		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31575	Diagnostic laryngoscopy		T	0072	1.6115	\$102.64	\$21.27	\$20.53
31576	Laryngoscopy with biopsy		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31577	Remove foreign body, larynx		T	0073	3.9940	\$254.39	\$69.15	\$50.88
31578	Removal of larynx lesion		T	0075	22.7191	\$1,447.07	\$445.92	\$289.41
31579	Diagnostic laryngoscopy		T	0073	3.9940	\$254.39	\$69.15	\$50.88
31580	Revision of larynx		T	0256	39.8776	\$2,539.96		\$507.99
31582	Revision of larynx		T	0256	39.8776	\$2,539.96		\$507.99
31584	Treat larynx fracture		C					
31587	Revision of larynx		C					
31588	Revision of larynx		T	0256	39.8776	\$2,539.96		\$507.99
31590	Reinnervate larynx		T	0256	39.8776	\$2,539.96		\$507.99
31595	Larynx nerve surgery		T	0256	39.8776	\$2,539.96		\$507.99
31599	Larynx surgery procedure		T	0251	2.5002	\$159.25		\$31.85
31600	Incision of windpipe		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31601	Incision of windpipe		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31603	Incision of windpipe		T	0252	7.4474	\$474.35	\$109.16	\$94.87
31605	Incision of windpipe		T	0252	7.4474	\$474.35	\$109.16	\$94.87
3160F	Doc fe+ stores b/4 epo thx		M					
31610	Incision of windpipe		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31611	Surgery/speech prosthesis		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31612	Puncture/clear windpipe		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31613	Repair windpipe opening		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31614	Repair windpipe opening		T	0256	39.8776	\$2,539.96		\$507.99
31615	Visualization of windpipe		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31620	Endobronchial us add-on	CH	N					
31622	Dx bronchoscope/wash		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31623	Dx bronchoscope/brush		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31624	Dx bronchoscope/lavage		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31625	Bronchoscopy w/biopsy(s)		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31628	Bronchoscopy/lung bx, each		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31629	Bronchoscopy/needle bx, each		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31630	Bronchoscopy dilate/fx repr		T	0415	24.0654	\$1,532.82	\$459.92	\$306.56
31631	Bronchoscopy, dilate w/stent		T	0415	24.0654	\$1,532.82	\$459.92	\$306.56
31632	Bronchoscopy/lung bx, add'l		T	0076	9.9575	\$634.23	\$189.82	\$126.85

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
31633	Bronchoscopy/needle bx add'l		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31635	Bronchoscopy w/fb removal		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31636	Bronchoscopy, bronch stents		T	0415	24.0654	\$1,532.82	\$459.92	\$306.56
31637	Bronchoscopy, stent add-on		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31638	Bronchoscopy, revise stent		T	0415	24.0654	\$1,532.82	\$459.92	\$306.56
31640	Bronchoscopy w/tumor excise		T	0415	24.0654	\$1,532.82	\$459.92	\$306.56
31641	Bronchoscopy, treat blockage		T	0415	24.0654	\$1,532.82	\$459.92	\$306.56
31643	Diag bronchoscope/catheter		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31645	Bronchoscopy, clear airways		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31646	Bronchoscopy, reclear airway		T	0076	9.9575	\$634.23	\$189.82	\$126.85
31656	Bronchoscopy, inj for x-ray		T	0076	9.9575	\$634.23	\$189.82	\$126.85
3170F	Flow cyto done b/4 tx		M					
31715	Injection for bronchus x-ray		N					
31717	Bronchial brush biopsy		T	0073	3.9940	\$254.39	\$69.15	\$50.88
31720	Clearance of airways	CH	S	0077	0.3877	\$24.69	\$7.74	\$4.94
31725	Clearance of airways		C					
31730	Intro, windpipe wire/tube		T	0073	3.9940	\$254.39	\$69.15	\$50.88
31750	Repair of windpipe		T	0256	39.8776	\$2,539.96		\$507.99
31755	Repair of windpipe		T	0256	39.8776	\$2,539.96		\$507.99
31760	Repair of windpipe		C					
31766	Reconstruction of windpipe		C					
31770	Repair/graft of bronchus		C					
31775	Reconstruct bronchus		C					
31780	Reconstruct windpipe		C					
31781	Reconstruct windpipe		C					
31785	Remove windpipe lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31786	Remove windpipe lesion		C					
31800	Repair of windpipe injury		C					
31805	Repair of windpipe injury		C					
31820	Closure of windpipe lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
31825	Repair of windpipe defect		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31830	Revise windpipe scar		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
31899	Airways surgical procedure		T	0076	9.9575	\$634.23	\$189.82	\$126.85
32000	Drainage of chest	CH	D					
32002	Treatment of collapsed lung	CH	D					
32005	Treat lung lining chemically	CH	D					
3200F	Barium swallow test not req		M					
32019	Insert pleural catheter	CH	D					
32020	Insertion of chest tube	CH	D					
32035	Exploration of chest		C					
32036	Exploration of chest		C					
32095	Biopsy through chest wall		C					
32100	Exploration/biopsy of chest		C					
3210F	Grp a strep test performed		M					
32110	Explore/repair chest		C					
32120	Re-exploration of chest		C					
32124	Explore chest free adhesions		C					
32140	Removal of lung lesion(s)		C					
32141	Remove/treat lung lesions		C					
32150	Removal of lung lesion(s)		C					
32151	Remove lung foreign body		C					
3215F	Pt immunity to hep A doc'd		M					
32160	Open chest heart massage		C					
3216F	Pt immunity to hep B doc'd		M					
3218F	Rna tstng hep c doc'd-done		M					
32200	Drain, open, lung lesion		C					
32201	Drain, percut, lung lesion		T	0070	5.2024	\$331.36		\$66.27
3220F	Hep C quant rna tstng doc'd		M					
32215	Treat chest lining		C					
32220	Release of lung		C					
32225	Partial release of lung		C					
3230F	Note hring tst w/in 6 mon		M					
32310	Removal of chest lining		C					
32320	Free/remove chest lining		C					
32400	Needle biopsy chest lining		T	0685	9.3354	\$594.61		\$118.92
32402	Open biopsy chest lining		C					
32405	Biopsy, lung or mediastinum		T	0685	9.3354	\$594.61		\$118.92
32420	Puncture/clear lung		T	0070	5.2024	\$331.36		\$66.27
32421	Thoracentesis for aspiration	NI	T	0070	5.2024	\$331.36		\$66.27
32422	Thoracentesis w/tube insert	NI	T	0070	5.2024	\$331.36		\$66.27
32440	Removal of lung		C					
32442	Sleeve pneumonectomy		C					
32445	Removal of lung		C					
32480	Partial removal of lung		C					
32482	Bilobectomy		C					
32484	Segmentectomy		C					
32486	Sleeve lobectomy		C					
32488	Completion pneumonectomy		C					
32491	Lung volume reduction		C					
32500	Partial removal of lung		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
32501	Repair bronchus add-on		C					
32503	Resect apical lung tumor		C					
32504	Resect apical lung tum/chest		C					
32540	Removal of lung lesion		C					
32550	Insert pleural cath	NI	T	0652	30.7096	\$1,956.02		\$391.20
32551	Insertion of chest tube	NI	T	0070	5.2024	\$331.36		\$66.27
32560	Treat lung lining chemically	NI	T	0070	5.2024	\$331.36		\$66.27
32601	Thoracoscopy, diagnostic		T	0069	32.5666	\$2,074.30	\$591.64	\$414.86
32602	Thoracoscopy, diagnostic		T	0069	32.5666	\$2,074.30	\$591.64	\$414.86
32603	Thoracoscopy, diagnostic		T	0069	32.5666	\$2,074.30	\$591.64	\$414.86
32604	Thoracoscopy, diagnostic		T	0069	32.5666	\$2,074.30	\$591.64	\$414.86
32605	Thoracoscopy, diagnostic		T	0069	32.5666	\$2,074.30	\$591.64	\$414.86
32606	Thoracoscopy, diagnostic		T	0069	32.5666	\$2,074.30	\$591.64	\$414.86
3260F	Pt cat/pn cat/hist grd doc'd		M					
32650	Thoracoscopy, surgical		C					
32651	Thoracoscopy, surgical		C					
32652	Thoracoscopy, surgical		C					
32653	Thoracoscopy, surgical		C					
32654	Thoracoscopy, surgical		C					
32655	Thoracoscopy, surgical		C					
32656	Thoracoscopy, surgical		C					
32657	Thoracoscopy, surgical		C					
32658	Thoracoscopy, surgical		C					
32659	Thoracoscopy, surgical		C					
3265F	RNA tstng HepC vir ord/doc'd	NI	M					
32660	Thoracoscopy, surgical		C					
32661	Thoracoscopy, surgical		C					
32662	Thoracoscopy, surgical		C					
32663	Thoracoscopy, surgical		C					
32664	Thoracoscopy, surgical		C					
32665	Thoracoscopy, surgical		C					
3266F	HepC gn tstng doc'd b/4txmnt	NI	M					
3268F	PSA/T/G1Sc doc'd b/4 txmnt	NI	M					
3269F	Bone scn b/4 txmnt/aftr Dx	NI	M					
3270F	No bone scn b/4 txmnt/aftrDx	NI	M					
3271F	Low risk, prostate cancer	NI	M					
3272F	Med. risk, prostate cancer	NI	M					
3273F	High risk, prostate cancer	NI	M					
3274F	Prost Cncr rsk not lw/md/hgh	NI	M					
3278F	Serum lvls CA/PTH/lpd ord	NI	M					
3279F	Hgb lvl >=13 g/dL	NI	M					
32800	Repair lung hernia		C					
3280F	Hgb lvl 11-12.9 g/dL	NI	M					
32810	Close chest after drainage		C					
32815	Close bronchial fistula		C					
3281F	Hgb lvl <11 g/dL	NI	M					
32820	Reconstruct injured chest		C					
3284F	IOP down >15% of pre-svc lvl	NI	M					
32850	Donor pneumonectomy		C					
32851	Lung transplant, single		C					
32852	Lung transplant with bypass		C					
32853	Lung transplant, double		C					
32854	Lung transplant with bypass		C					
32855	Prepare donor lung, single		C					
32856	Prepare donor lung, double		C					
3285F	IOP down <15% of pre-svc lvl	NI	M					
3288F	Fall risk assessment doc'd	NI	M					
32900	Removal of rib(s)		C					
32905	Revise & repair chest wall		C					
32906	Revise & repair chest wall		C					
3290F	Pt=D(Rh)- and unsensitized	NI	M					
3291F	Pt=D(Rh)+or sensitized	NI	M					
3292F	HIV tstng asked/doc'd/revw'd	NI	M					
32940	Revision of lung		C					
32960	Therapeutic pneumothorax		T	0070	5.2024	\$331.36		\$66.27
32997	Total lung lavage		C					
32998	Perq rf ablate tx, pul tumor		T	0423	42.9980	\$2,738.71		\$547.74
32999	Chest surgery procedure		T	0070	5.2024	\$331.36		\$66.27
3300F	AJCC stage doc'd b/4 thxpy	NI	M					
33010	Drainage of heart sac		T	0070	5.2024	\$331.36		\$66.27
33011	Repeat drainage of heart sac		T	0070	5.2024	\$331.36		\$66.27
33015	Incision of heart sac		C					
3301F	Cancer stage doc'd, metast	NI	M					
33020	Incision of heart sac		C					
33025	Incision of heart sac		C					
3302F	AJCC stage 0 doc'd	NI	M					
33030	Partial removal of heart sac		C					
33031	Partial removal of heart sac		C					
3303F	AJCC stage IA doc'd	NI	M					
3304F	AJCC stage IB doc'd	NI	M					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
33050	Removal of heart sac lesion		C					
3305F	AJCC stage IC doc'd	NI	M					
3306F	AJCC stage IIA doc'd	NI	M					
3307F	AJCC stage IIB doc'd	NI	M					
3308F	AJCC stage IIC doc'd	NI	M					
3309F	AJCC stage IIIA doc'd	NI	M					
3310F	AJCC stage IIIB doc'd	NI	M					
3311F	AJCC stage IIIC doc'd	NI	M					
33120	Removal of heart lesion		C					
3312F	AJCC stage IVA doc'd	NI	M					
33130	Removal of heart lesion		C					
3313F	AJCC stage IVB doc'd	NI	M					
33140	Heart revascularize (tmr)		C					
33141	Heart tmr w/other procedure		C					
3314F	AJCC stage IVC doc'd	NI	M					
3315F	ER +or PR +breast cancer	NI	M					
3316F	ER- or PR- breast cancer	NI	M					
3317F	Path rpt malig cancer doc'd	NI	M					
3318F	Path rpt malig cancer doc'd	NI	M					
3319F	X-ray/CT/Ultrsnd et al ord'd	NI	M					
33202	Insert epicard eltrd, open		C					
33203	Insert epicard eltrd, endo		C					
33206	Insertion of heart pacemaker		T	0089	121.6508	\$7,748.43	\$1,682.28	\$1,549.69
33207	Insertion of heart pacemaker		T	0089	121.6508	\$7,748.43	\$1,682.28	\$1,549.69
33208	Insertion of heart pacemaker		T	0655	140.0317	\$8,919.18		\$1,783.84
3320F	No Xray/CT/ et al ord'd	NI	M					
33210	Insertion of heart electrode		T	0106	69.5217	\$4,428.12		\$885.62
33211	Insertion of heart electrode		T	0106	69.5217	\$4,428.12		\$885.62
33212	Insertion of pulse generator		T	0090	100.8341	\$6,422.53	\$1,612.80	\$1,284.51
33213	Insertion of pulse generator		T	0654	109.2851	\$6,960.81		\$1,392.16
33214	Upgrade of pacemaker system		T	0655	140.0317	\$8,919.18		\$1,783.84
33215	Reposition pacing-defib lead		T	0105	23.9802	\$1,527.39		\$305.48
33216	Insert lead pace-defib, one		T	0106	69.5217	\$4,428.12		\$885.62
33217	Insert lead pace-defib, dual		T	0106	69.5217	\$4,428.12		\$885.62
33218	Repair lead pace-defib, one		T	0105	23.9802	\$1,527.39		\$305.48
33220	Repair lead pace-defib, dual		T	0105	23.9802	\$1,527.39		\$305.48
33222	Revise pocket, pacemaker	CH	T	0136	15.0458	\$958.33		\$191.67
33223	Revise pocket, pacing-defib	CH	T	0136	15.0458	\$958.33		\$191.67
33224	Insert pacing lead & connect		T	0418	259.7486	\$16,544.43		\$3,308.89
33225	L ventric pacing lead add-on		T	0418	259.7486	\$16,544.43		\$3,308.89
33226	Reposition l ventric lead		T	0105	23.9802	\$1,527.39		\$305.48
33233	Removal of pacemaker system		T	0105	23.9802	\$1,527.39		\$305.48
33234	Removal of pacemaker system		T	0105	23.9802	\$1,527.39		\$305.48
33235	Removal pacemaker electrode		T	0105	23.9802	\$1,527.39		\$305.48
33236	Remove electrode/thoracotomy		C					
33237	Remove electrode/thoracotomy		C					
33238	Remove electrode/thoracotomy		C					
33240	Insert pulse generator	CH	T	0107	333.8096	\$21,261.67		\$4,252.33
33241	Remove pulse generator		T	0105	23.9802	\$1,527.39		\$305.48
33243	Remove eltrd/thoracotomy		C					
33244	Remove eltrd, transven		T	0105	23.9802	\$1,527.39		\$305.48
33249	Eltrd/insert pace-defib	CH	T	0108	404.8543	\$25,786.79		\$5,157.36
33250	Ablate heart dysrhythm focus		C					
33251	Ablate heart dysrhythm focus		C					
33254	Ablate atria, lmtd		C					
33255	Ablate atria w/o bypass, ext		C					
33256	Ablate atria w/bypass, exten		C					
33257	Ablate atria, lmtd, add-on	NI	C					
33258	Ablate atria, x10sv, add-on	NI	C					
33259	Ablate atria w/bypass add-on	NI	C					
3325F	Preop asses 4 cataract surg	NI	M					
33261	Ablate heart dysrhythm focus		C					
33265	Ablate atria, lmtd, endo		C					
33266	Ablate atria, x10sv, endo		C					
33282	Implant pat-active ht record		S	0680	70.6073	\$4,497.26		\$899.45
33284	Remove pat-active ht record	CH	T	0020	8.6850	\$553.18		\$110.64
33300	Repair of heart wound		C					
33305	Repair of heart wound		C					
33310	Exploratory heart surgery		C					
33315	Exploratory heart surgery		C					
33320	Repair major blood vessel(s)		C					
33321	Repair major vessel		C					
33322	Repair major blood vessel(s)		C					
33330	Insert major vessel graft		C					
33332	Insert major vessel graft		C					
33335	Insert major vessel graft		C					
33400	Repair of aortic valve		C					
33401	Valvuloplasty, open		C					
33403	Valvuloplasty, w/cp bypass		C					
33404	Prepare heart-aorta conduit		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
33405	Replacement of aortic valve		C					
33406	Replacement of aortic valve		C					
33410	Replacement of aortic valve		C					
33411	Replacement of aortic valve		C					
33412	Replacement of aortic valve		C					
33413	Replacement of aortic valve		C					
33414	Repair of aortic valve		C					
33415	Revision, subvalvular tissue		C					
33416	Revise ventricle muscle		C					
33417	Repair of aortic valve		C					
33420	Revision of mitral valve		C					
33422	Revision of mitral valve		C					
33425	Repair of mitral valve		C					
33426	Repair of mitral valve		C					
33427	Repair of mitral valve		C					
33430	Replacement of mitral valve		C					
33460	Revision of tricuspid valve		C					
33463	Valvuloplasty, tricuspid		C					
33464	Valvuloplasty, tricuspid		C					
33465	Replace tricuspid valve		C					
33468	Revision of tricuspid valve		C					
33470	Revision of pulmonary valve		C					
33471	Valvotomy, pulmonary valve		C					
33472	Revision of pulmonary valve		C					
33474	Revision of pulmonary valve		C					
33475	Replacement, pulmonary valve		C					
33476	Revision of heart chamber		C					
33478	Revision of heart chamber		C					
33496	Repair, prosth valve clot		C					
33500	Repair heart vessel fistula		C					
33501	Repair heart vessel fistula		C					
33502	Coronary artery correction		C					
33503	Coronary artery graft		C					
33504	Coronary artery graft		C					
33505	Repair artery w/tunnel		C					
33506	Repair artery, translocation		C					
33507	Repair art, intramural		C					
33508	Endoscopic vein harvest		N					
33510	CABG, vein, single		C					
33511	CABG, vein, two		C					
33512	CABG, vein, three		C					
33513	CABG, vein, four		C					
33514	CABG, vein, five		C					
33516	Cabg, vein, six or more		C					
33517	CABG, artery-vein, single		C					
33518	CABG, artery-vein, two		C					
33519	CABG, artery-vein, three		C					
33521	CABG, artery-vein, four		C					
33522	CABG, artery-vein, five		C					
33523	Cabg, art-vein, six or more		C					
33530	Coronary artery, bypass/reop		C					
33533	CABG, arterial, single		C					
33534	CABG, arterial, two		C					
33535	CABG, arterial, three		C					
33536	Cabg, arterial, four or more		C					
33542	Removal of heart lesion		C					
33545	Repair of heart damage		C					
33548	Restore/remodel, ventricle		C					
33572	Open coronary endarterectomy		C					
33600	Closure of valve		C					
33602	Closure of valve		C					
33606	Anastomosis/artery-aorta		C					
33608	Repair anomaly w/conduit		C					
33610	Repair by enlargement		C					
33611	Repair double ventricle		C					
33612	Repair double ventricle		C					
33615	Repair, modified fontan		C					
33617	Repair single ventricle		C					
33619	Repair single ventricle		C					
33641	Repair heart septum defect		C					
33645	Revision of heart veins		C					
33647	Repair heart septum defects		C					
33660	Repair of heart defects		C					
33665	Repair of heart defects		C					
33670	Repair of heart chambers		C					
33675	Close mult vsd		C					
33676	Close mult vsd w/resection		C					
33677	CI mult vsd w/rem pul band		C					
33681	Repair heart septum defect		C					
33684	Repair heart septum defect		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
33688	Repair heart septum defect		C					
33690	Reinforce pulmonary artery		C					
33692	Repair of heart defects		C					
33694	Repair of heart defects		C					
33697	Repair of heart defects		C					
33702	Repair of heart defects		C					
33710	Repair of heart defects		C					
33720	Repair of heart defect		C					
33722	Repair of heart defect		C					
33724	Repair venous anomaly		C					
33726	Repair pul venous stenosis		C					
33730	Repair heart-vein defect(s)		C					
33732	Repair heart-vein defect		C					
33735	Revision of heart chamber		C					
33736	Revision of heart chamber		C					
33737	Revision of heart chamber		C					
33750	Major vessel shunt		C					
33755	Major vessel shunt		C					
33762	Major vessel shunt		C					
33764	Major vessel shunt & graft		C					
33766	Major vessel shunt		C					
33767	Major vessel shunt		C					
33768	Cavopulmonary shunting		C					
33770	Repair great vessels defect		C					
33771	Repair great vessels defect		C					
33774	Repair great vessels defect		C					
33775	Repair great vessels defect		C					
33776	Repair great vessels defect		C					
33777	Repair great vessels defect		C					
33778	Repair great vessels defect		C					
33779	Repair great vessels defect		C					
33780	Repair great vessels defect		C					
33781	Repair great vessels defect		C					
33786	Repair arterial trunk		C					
33788	Revision of pulmonary artery		C					
33800	Aortic suspension		C					
33802	Repair vessel defect		C					
33803	Repair vessel defect		C					
33813	Repair septal defect		C					
33814	Repair septal defect		C					
33820	Revise major vessel		C					
33822	Revise major vessel		C					
33824	Revise major vessel		C					
33840	Remove aorta constriction		C					
33845	Remove aorta constriction		C					
33851	Remove aorta constriction		C					
33852	Repair septal defect		C					
33853	Repair septal defect		C					
33860	Ascending aortic graft		C					
33861	Ascending aortic graft		C					
33863	Ascending aortic graft		C					
33864	Ascending aortic graft	NI	C					
33870	Transverse aortic arch graft		C					
33875	Thoracic aortic graft		C					
33877	Thoracoabdominal graft		C					
33880	Endovasc taa repr incl subcl		C					
33881	Endovasc taa repr w/o subcl		C					
33883	Insert endovasc prosth, taa		C					
33884	Endovasc prosth, taa, add-on		C					
33886	Endovasc prosth, delayed		C					
33889	Artery transpose/endovas taa		C					
33891	Car-car bp grft/endovas taa		C					
33910	Remove lung artery emboli		C					
33915	Remove lung artery emboli		C					
33916	Surgery of great vessel		C					
33917	Repair pulmonary artery		C					
33920	Repair pulmonary atresia		C					
33922	Transect pulmonary artery		C					
33924	Remove pulmonary shunt		C					
33925	Rpr pul art unifocal w/o cpb		C					
33926	Repr pul art, unifocal w/cpb		C					
33930	Removal of donor heart/lung		C					
33933	Prepare donor heart/lung		C					
33935	Transplantation, heart/lung		C					
33940	Removal of donor heart		C					
33944	Prepare donor heart		C					
33945	Transplantation of heart		C					
33960	External circulation assist		C					
33961	External circulation assist		C					
33967	Insert ia percut device		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
33968	Remove aortic assist device		C					
33970	Aortic circulation assist		C					
33971	Aortic circulation assist		C					
33973	Insert balloon device		C					
33974	Remove intra-aortic balloon		C					
33975	Implant ventricular device		C					
33976	Implant ventricular device		C					
33977	Remove ventricular device		C					
33978	Remove ventricular device		C					
33979	Insert intracorporeal device		C					
33980	Remove intracorporeal device		C					
33999	Cardiac surgery procedure		T	0070	5.2024	\$331.36		\$66.27
34001	Removal of artery clot		C					
34051	Removal of artery clot		C					
34101	Removal of artery clot		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34111	Removal of arm artery clot		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34151	Removal of artery clot		C					
34201	Removal of artery clot		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34203	Removal of leg artery clot		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34401	Removal of vein clot		C					
34421	Removal of vein clot		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34451	Removal of vein clot		C					
34471	Removal of vein clot		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34490	Removal of vein clot		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34501	Repair valve, femoral vein		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34502	Reconstruct vena cava		C					
34510	Transposition of vein valve		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34520	Cross-over vein graft		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34530	Leg vein fusion		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
34800	Endovas aaa repr w/sm tube		C					
34802	Endovas aaa repr w/2-p part		C					
34803	Endovas aaa repr w/3-p part		C					
34804	Endovas aaa repr w/1-p part		C					
34805	Endovas aaa repr w/long tube		C					
34806	Aneurysm press sensor add-on	NI	C					
34808	Endovas iliac a device addon		C					
34812	Xpose for endoprosth, femorl		C					
34813	Femoral endovas graft add-on		C					
34820	Xpose for endoprosth, iliac		C					
34825	Endovasc extend prosth, init		C					
34826	Endovasc exten prosth, add'l		C					
34830	Open aortic tube prosth repr		C					
34831	Open aortoiliac prosth repr		C					
34832	Open aortofemor prosth repr		C					
34833	Xpose for endoprosth, iliac		C					
34834	Xpose, endoprosth, brachial		C					
34900	Endovasc iliac repr w/graft		C					
35001	Repair defect of artery		C					
35002	Repair artery rupture, neck		C					
35005	Repair defect of artery		C					
35011	Repair defect of artery		T	0653	40.4667	\$2,577.49		\$515.50
35013	Repair artery rupture, arm		C					
35021	Repair defect of artery		C					
35022	Repair artery rupture, chest		C					
35045	Repair defect of arm artery		C					
35081	Repair defect of artery		C					
35082	Repair artery rupture, aorta		C					
35091	Repair defect of artery		C					
35092	Repair artery rupture, aorta		C					
35102	Repair defect of artery		C					
35103	Repair artery rupture, groin		C					
35111	Repair defect of artery		C					
35112	Repair artery rupture, spleen		C					
35121	Repair defect of artery		C					
35122	Repair artery rupture, belly		C					
35131	Repair defect of artery		C					
35132	Repair artery rupture, groin		C					
35141	Repair defect of artery		C					
35142	Repair artery rupture, thigh		C					
35151	Repair defect of artery		C					
35152	Repair artery rupture, knee		C					
35180	Repair blood vessel lesion		T	0093	30.1294	\$1,919.06		\$383.81
35182	Repair blood vessel lesion		C					
35184	Repair blood vessel lesion		T	0093	30.1294	\$1,919.06		\$383.81
35188	Repair blood vessel lesion		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
35189	Repair blood vessel lesion		C					
35190	Repair blood vessel lesion		T	0093	30.1294	\$1,919.06		\$383.81
35201	Repair blood vessel lesion		T	0093	30.1294	\$1,919.06		\$383.81
35206	Repair blood vessel lesion		T	0093	30.1294	\$1,919.06		\$383.81
35207	Repair blood vessel lesion		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
35211	Repair blood vessel lesion		C					
35216	Repair blood vessel lesion		C					
35221	Repair blood vessel lesion		C					
35226	Repair blood vessel lesion		T	0093	30.1294	\$1,919.06		\$383.81
35231	Repair blood vessel lesion		T	0093	30.1294	\$1,919.06		\$383.81
35236	Repair blood vessel lesion		T	0093	30.1294	\$1,919.06		\$383.81
35241	Repair blood vessel lesion		C					
35246	Repair blood vessel lesion		C					
35251	Repair blood vessel lesion		C					
35256	Repair blood vessel lesion		T	0093	30.1294	\$1,919.06		\$383.81
35261	Repair blood vessel lesion		T	0653	40.4667	\$2,577.49		\$515.50
35266	Repair blood vessel lesion		T	0653	40.4667	\$2,577.49		\$515.50
35271	Repair blood vessel lesion		C					
35276	Repair blood vessel lesion		C					
35281	Repair blood vessel lesion		C					
35286	Repair blood vessel lesion		T	0653	40.4667	\$2,577.49		\$515.50
35301	Rechanneling of artery		C					
35302	Rechanneling of artery		C					
35303	Rechanneling of artery		C					
35304	Rechanneling of artery		C					
35305	Rechanneling of artery		C					
35306	Rechanneling of artery		C					
35311	Rechanneling of artery		C					
35321	Rechanneling of artery		T	0093	30.1294	\$1,919.06		\$383.81
35331	Rechanneling of artery		C					
35341	Rechanneling of artery		C					
35351	Rechanneling of artery		C					
35355	Rechanneling of artery		C					
35361	Rechanneling of artery		C					
35363	Rechanneling of artery		C					
35371	Rechanneling of artery		C					
35372	Rechanneling of artery		C					
35390	Reoperation, carotid add-on		C					
35400	Angioscopy		C					
35450	Repair arterial blockage		C					
35452	Repair arterial blockage		C					
35454	Repair arterial blockage		C					
35456	Repair arterial blockage		C					
35458	Repair arterial blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35459	Repair arterial blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35460	Repair venous blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35470	Repair arterial blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35471	Repair arterial blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35472	Repair arterial blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35473	Repair arterial blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35474	Repair arterial blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35475	Repair arterial blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35476	Repair venous blockage	CH	T	0083	45.3845	\$2,890.72		\$578.14
35480	Atherectomy, open		C					
35481	Atherectomy, open		C					
35482	Atherectomy, open		C					
35483	Atherectomy, open		C					
35484	Atherectomy, open	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
35485	Atherectomy, open	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
35490	Atherectomy, percutaneous	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
35491	Atherectomy, percutaneous	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
35492	Atherectomy, percutaneous	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
35493	Atherectomy, percutaneous	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
35494	Atherectomy, percutaneous	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
35495	Atherectomy, percutaneous	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
35500	Harvest vein for bypass	CH	T	0103	14.6576	\$933.60		\$186.72
35501	Artery bypass graft		C					
35506	Artery bypass graft		C					
35508	Artery bypass graft		C					
35509	Artery bypass graft		C					
35510	Artery bypass graft		C					
35511	Artery bypass graft		C					
35512	Artery bypass graft		C					
35515	Artery bypass graft		C					
35516	Artery bypass graft		C					
35518	Artery bypass graft		C					
35521	Artery bypass graft		C					
35522	Artery bypass graft		C					
35523	Artery bypass graft	NI	C					
35525	Artery bypass graft		C					
35526	Artery bypass graft		C					
35531	Artery bypass graft		C					
35533	Artery bypass graft		C					
35536	Artery bypass graft		C					
35537	Artery bypass graft		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
35538	Artery bypass graft		C					
35539	Artery bypass graft		C					
35540	Artery bypass graft		C					
35548	Artery bypass graft		C					
35549	Artery bypass graft		C					
35551	Artery bypass graft		C					
35556	Artery bypass graft		C					
35558	Artery bypass graft		C					
35560	Artery bypass graft		C					
35563	Artery bypass graft		C					
35565	Artery bypass graft		C					
35566	Artery bypass graft		C					
35571	Artery bypass graft		C					
35572	Harvest femoropopliteal vein		N					
35583	Vein bypass graft		C					
35585	Vein bypass graft		C					
35587	Vein bypass graft		C					
35600	Harvest art for cabg add-on		C					
35601	Artery bypass graft		C					
35606	Artery bypass graft		C					
35612	Artery bypass graft		C					
35616	Artery bypass graft		C					
35621	Artery bypass graft		C					
35623	Bypass graft, not vein		C					
35626	Artery bypass graft		C					
35631	Artery bypass graft		C					
35636	Artery bypass graft		C					
35637	Artery bypass graft		C					
35638	Artery bypass graft		C					
35642	Artery bypass graft		C					
35645	Artery bypass graft		C					
35646	Artery bypass graft		C					
35647	Artery bypass graft		C					
35650	Artery bypass graft		C					
35651	Artery bypass graft		C					
35654	Artery bypass graft		C					
35656	Artery bypass graft		C					
35661	Artery bypass graft		C					
35663	Artery bypass graft		C					
35665	Artery bypass graft		C					
35666	Artery bypass graft		C					
35671	Artery bypass graft		C					
35681	Composite bypass graft		C					
35682	Composite bypass graft		C					
35683	Composite bypass graft		C					
35685	Bypass graft patency/patch		T	0093	30.1294	\$1,919.06		\$383.81
35686	Bypass graft/av fist patency		T	0093	30.1294	\$1,919.06		\$383.81
35691	Arterial transposition		C					
35693	Arterial transposition		C					
35694	Arterial transposition		C					
35695	Arterial transposition		C					
35697	Reimplant artery each		C					
35700	Reoperation, bypass graft		C					
35701	Exploration, carotid artery		C					
35721	Exploration, femoral artery		C					
35741	Exploration popliteal artery		C					
35761	Exploration of artery/vein		T	0115	29.6965	\$1,891.49		\$378.30
35800	Explore neck vessels		C					
35820	Explore chest vessels		C					
35840	Explore abdominal vessels		C					
35860	Explore limb vessels		T	0093	30.1294	\$1,919.06		\$383.81
35870	Repair vessel graft defect		C					
35875	Removal of clot in graft		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
35876	Removal of clot in graft		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
35879	Revise graft w/vein		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
35881	Revise graft w/vein		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
35883	Revise graft w/nonauto graft		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
35884	Revise graft w/vein		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
35901	Excision, graft, neck		C					
35903	Excision, graft, extremity		T	0115	29.6965	\$1,891.49		\$378.30
35905	Excision, graft, thorax		C					
35907	Excision, graft, abdomen		C					
36000	Place needle in vein		N					
36002	Pseudoaneurysm injection trt		S	0267	2.3792	\$151.54	\$60.50	\$30.31
36005	Injection ext venography		N					
36010	Place catheter in vein		N					
36011	Place catheter in vein		N					
36012	Place catheter in vein		N					
36013	Place catheter in artery		N					
36014	Place catheter in artery		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
36015	Place catheter in artery		N					
36100	Establish access to artery		N					
36120	Establish access to artery		N					
36140	Establish access to artery		N					
36145	Artery to vein shunt		N					
36160	Establish access to aorta		N					
36200	Place catheter in aorta		N					
36215	Place catheter in artery		N					
36216	Place catheter in artery		N					
36217	Place catheter in artery		N					
36218	Place catheter in artery		N					
36245	Place catheter in artery		N					
36246	Place catheter in artery		N					
36247	Place catheter in artery		N					
36248	Place catheter in artery		N					
36260	Insertion of infusion pump		T	0623	28.8743	\$1,839.12		\$367.82
36261	Revision of infusion pump	CH	T	0105	23.9802	\$1,527.39		\$305.48
36262	Removal of infusion pump	CH	T	0105	23.9802	\$1,527.39		\$305.48
36299	Vessel injection procedure		N					
36400	Bl draw < 3 yrs fem/jugular		N					
36405	Bl draw < 3 yrs scalp vein		N					
36406	Bl draw < 3 yrs other vein		N					
36410	Non-routine bl draw > 3 yrs		N					
36415	Routine venipuncture		A					
36416	Capillary blood draw		N					
36420	Vein access cutdown < 1 yr		T	0035	0.2143	\$13.65		\$2.73
36425	Vein access cutdown > 1 yr		T	0035	0.2143	\$13.65		\$2.73
36430	Blood transfusion service		S	0110	3.3967	\$216.35		\$43.27
36440	Bl push transfuse, 2 yr or <		S	0110	3.3967	\$216.35		\$43.27
36450	Bl exchange/transfuse, nb		S	0110	3.3967	\$216.35		\$43.27
36455	Bl exchange/transfuse non-nb		S	0110	3.3967	\$216.35		\$43.27
36460	Transfusion service, fetal		S	0110	3.3967	\$216.35		\$43.27
36468	Injection(s), spider veins	CH	T	0013	0.7930	\$50.51		\$10.10
36469	Injection(s), spider veins	CH	T	0013	0.7930	\$50.51		\$10.10
36470	Injection therapy of vein	CH	T	0013	0.7930	\$50.51		\$10.10
36471	Injection therapy of veins	CH	T	0013	0.7930	\$50.51		\$10.10
36475	Endovenous rf, 1st vein		T	0091	42.6114	\$2,714.09		\$542.82
36476	Endovenous rf, vein add-on	CH	T	0092	25.8410	\$1,645.92		\$329.18
36478	Endovenous laser, 1st vein		T	0092	25.8410	\$1,645.92		\$329.18
36479	Endovenous laser vein add-on		T	0092	25.8410	\$1,645.92		\$329.18
36481	Insertion of catheter, vein		N					
36500	Insertion of catheter, vein		N					
36510	Insertion of catheter, vein		N					
36511	Apheresis wbc		S	0111	11.5058	\$732.85	\$198.40	\$146.57
36512	Apheresis rbc		S	0111	11.5058	\$732.85	\$198.40	\$146.57
36513	Apheresis platelets		S	0111	11.5058	\$732.85	\$198.40	\$146.57
36514	Apheresis plasma		S	0111	11.5058	\$732.85	\$198.40	\$146.57
36515	Apheresis, adsorp/reinfuse		S	0112	30.6035	\$1,949.26	\$433.29	\$389.85
36516	Apheresis, selective		S	0112	30.6035	\$1,949.26	\$433.29	\$389.85
36522	Photopheresis		S	0112	30.6035	\$1,949.26	\$433.29	\$389.85
36540	Collect blood venous device	CH	D					
36550	Declot vascular device	CH	D					
36555	Insert non-tunnel cv cath		T	0621	10.9092	\$694.85		\$138.97
36556	Insert non-tunnel cv cath		T	0621	10.9092	\$694.85		\$138.97
36557	Insert tunneled cv cath		T	0622	24.1069	\$1,535.46		\$307.09
36558	Insert tunneled cv cath		T	0622	24.1069	\$1,535.46		\$307.09
36560	Insert tunneled cv cath		T	0623	28.8743	\$1,839.12		\$367.82
36561	Insert tunneled cv cath		T	0623	28.8743	\$1,839.12		\$367.82
36563	Insert tunneled cv cath		T	0623	28.8743	\$1,839.12		\$367.82
36565	Insert tunneled cv cath		T	0623	28.8743	\$1,839.12		\$367.82
36566	Insert tunneled cv cath		T	0625	81.7482	\$5,206.87		\$1,041.37
36568	Insert picc cath		T	0621	10.9092	\$694.85		\$138.97
36569	Insert picc cath		T	0621	10.9092	\$694.85		\$138.97
36570	Insert picvad cath		T	0622	24.1069	\$1,535.46		\$307.09
36571	Insert picvad cath		T	0622	24.1069	\$1,535.46		\$307.09
36575	Repair tunneled cv cath	CH	T	0109	5.6614	\$360.60		\$72.12
36576	Repair tunneled cv cath		T	0621	10.9092	\$694.85		\$138.97
36578	Replace tunneled cv cath		T	0622	24.1069	\$1,535.46		\$307.09
36580	Replace cvad cath		T	0621	10.9092	\$694.85		\$138.97
36581	Replace tunneled cv cath		T	0622	24.1069	\$1,535.46		\$307.09
36582	Replace tunneled cv cath		T	0623	28.8743	\$1,839.12		\$367.82
36583	Replace tunneled cv cath		T	0623	28.8743	\$1,839.12		\$367.82
36584	Replace picc cath		T	0621	10.9092	\$694.85		\$138.97
36585	Replace picvad cath		T	0622	24.1069	\$1,535.46		\$307.09
36589	Removal tunneled cv cath	CH	T	0109	5.6614	\$360.60		\$72.12
36590	Removal tunneled cv cath		T	0621	10.9092	\$694.85		\$138.97
36591	Draw blood off venous device	NI	Q	0624	0.5689	\$36.24	\$12.65	\$7.25
36592	Collect blood from picc	NI	N					
36593	Declot vascular device	NI	T	0676	2.4824	\$158.11		\$31.62
36595	Mech remov tunneled cv cath		T	0622	24.1069	\$1,535.46		\$307.09

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
36596	Mech remov tunneled cv cath		T	0621	10.9092	\$694.85		\$138.97
36597	Reposition venous catheter		T	0621	10.9092	\$694.85		\$138.97
36598	Inj w/fluor, eval cv device	CH	T	0676	2.4824	\$158.11		\$31.62
36600	Withdrawal of arterial blood		Q	0035	0.2143	\$13.65		\$2.73
36620	Insertion catheter, artery		N					
36625	Insertion catheter, artery		N					
36640	Insertion catheter, artery		T	0623	28.8743	\$1,839.12		\$367.82
36660	Insertion catheter, artery		C					
36680	Insert needle, bone cavity		T	0002	1.1097	\$70.68		\$14.14
36800	Insertion of cannula		T	0115	29.6965	\$1,891.49		\$378.30
36810	Insertion of cannula		T	0115	29.6965	\$1,891.49		\$378.30
36815	Insertion of cannula		T	0115	29.6965	\$1,891.49		\$378.30
36818	Av fuse, uppr arm, cephalic		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36819	Av fuse, uppr arm, basilic		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36820	Av fusion/forearm vein		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36821	Av fusion direct any site		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36822	Insertion of cannula(s)		C					
36823	Insertion of cannula(s)		C					
36825	Artery-vein autograft		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36830	Artery-vein nonautograft		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36831	Open thrombect av fistula		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36832	Av fistula revision, open		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36833	Av fistula revision		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36834	Repair A-V aneurysm		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36835	Artery to vein shunt		T	0115	29.6965	\$1,891.49		\$378.30
36838	Dist revas ligation, hemo		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
36860	External cannula declotting		T	0676	2.4824	\$158.11		\$31.62
36861	Cannula declotting		T	0115	29.6965	\$1,891.49		\$378.30
36870	Percut thrombect av fistula		T	0653	40.4667	\$2,577.49		\$515.50
37140	Revision of circulation		C					
37145	Revision of circulation		C					
37160	Revision of circulation		C					
37180	Revision of circulation		C					
37181	Splice spleen/kidney veins		C					
37182	Insert hepatic shunt (tips)		C					
37183	Remove hepatic shunt (tips)		T	0229	88.5367	\$5,639.26		\$1,127.85
37184	Prim art mech thrombectomy		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
37185	Prim art m-thrombect add-on		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
37186	Sec art m-thrombect add-on		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
37187	Venous mech thrombectomy		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
37188	Venous m-thrombectomy add-on		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
37195	Thrombolytic therapy, stroke		T	0676	2.4824	\$158.11		\$31.62
37200	Transcatheter biopsy	CH	T	0623	28.8743	\$1,839.12		\$367.82
37201	Transcatheter therapy infuse	CH	T	0103	14.6576	\$933.60		\$186.72
37202	Transcatheter therapy infuse	CH	T	0103	14.6576	\$933.60		\$186.72
37203	Transcatheter retrieval	CH	T	0623	28.8743	\$1,839.12		\$367.82
37204	Transcatheter occlusion	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
37205	Transcath iv stent, percut		T	0229	88.5367	\$5,639.26		\$1,127.85
37206	Transcath iv stent/perc addl		T	0229	88.5367	\$5,639.26		\$1,127.85
37207	Transcath iv stent, open		T	0229	88.5367	\$5,639.26		\$1,127.85
37208	Transcath iv stent/open addl		T	0229	88.5367	\$5,639.26		\$1,127.85
37209	Change iv cath at thromb tx	CH	T	0623	28.8743	\$1,839.12		\$367.82
37210	Embolization uterine fibroid	CH	T	0229	88.5367	\$5,639.26		\$1,127.85
37215	Transcath stent, cca w/eps		E					
37216	Transcath stent, cca w/o eps		C					
37250	Iv us first vessel add-on	CH	N					
37251	Iv us each add vessel add-on	CH	N					
37500	Endoscopy ligate perf veins		T	0091	42.6114	\$2,714.09		\$542.82
37501	Vascular endoscopy procedure		T	0092	25.8410	\$1,645.92		\$329.18
37565	Ligation of neck vein		T	0093	30.1294	\$1,919.06		\$383.81
37600	Ligation of neck artery		T	0093	30.1294	\$1,919.06		\$383.81
37605	Ligation of neck artery		T	0091	42.6114	\$2,714.09		\$542.82
37606	Ligation of neck artery		T	0092	25.8410	\$1,645.92		\$329.18
37607	Ligation of a-v fistula		T	0092	25.8410	\$1,645.92		\$329.18
37609	Temporal artery procedure		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
37615	Ligation of neck artery		T	0092	25.8410	\$1,645.92		\$329.18
37616	Ligation of chest artery		C					
37617	Ligation of abdomen artery		C					
37618	Ligation of extremity artery		C					
37620	Revision of major vein		T	0091	42.6114	\$2,714.09		\$542.82
37650	Revision of major vein		T	0092	25.8410	\$1,645.92		\$329.18
37660	Revision of major vein		C					
37700	Revise leg vein	CH	T	0092	25.8410	\$1,645.92		\$329.18
37718	Ligate/strip short leg vein	CH	T	0092	25.8410	\$1,645.92		\$329.18
37722	Ligate/strip long leg vein		T	0091	42.6114	\$2,714.09		\$542.82
37735	Removal of leg veins/lesion		T	0091	42.6114	\$2,714.09		\$542.82
37760	Ligation, leg veins, open		T	0092	25.8410	\$1,645.92		\$329.18
37765	Phleb veins extrem 10-20		T	0092	25.8410	\$1,645.92		\$329.18
37766	Phleb veins extrem 20+		T	0092	25.8410	\$1,645.92		\$329.18
37780	Revision of leg vein		T	0092	25.8410	\$1,645.92		\$329.18

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
37785	Ligate/divide/excise vein		T	0092	25.8410	\$1,645.92		\$329.18
37788	Revascularization, penis		C					
37790	Penile venous occlusion		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
37799	Vascular surgery procedure		T	0103	14.6576	\$933.60		\$186.72
38100	Removal of spleen, total		C					
38101	Removal of spleen, partial		C					
38102	Removal of spleen, total		C					
38115	Repair of ruptured spleen		C					
38120	Laparoscopy, splenectomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
38129	Laparoscopy proc, spleen		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
38200	Injection for spleen x-ray		N					
38204	BI donor search management		N					
38205	Harvest allogenic stem cells		S	0111	11.5058	\$732.85	\$198.40	\$146.57
38206	Harvest auto stem cells		S	0111	11.5058	\$732.85	\$198.40	\$146.57
38207	Cryopreserve stem cells	CH	S	0110	3.3967	\$216.35		\$43.27
38208	Thaw preserved stem cells	CH	S	0110	3.3967	\$216.35		\$43.27
38209	Wash harvest stem cells	CH	S	0110	3.3967	\$216.35		\$43.27
38210	T-cell depletion of harvest	CH	S	0393	5.6921	\$362.55	\$82.04	\$72.51
38211	Tumor cell deplete of harvest	CH	S	0393	5.6921	\$362.55	\$82.04	\$72.51
38212	Rbc depletion of harvest	CH	S	0393	5.6921	\$362.55	\$82.04	\$72.51
38213	Platelet deplete of harvest	CH	S	0393	5.6921	\$362.55	\$82.04	\$72.51
38214	Volume deplete of harvest	CH	S	0393	5.6921	\$362.55	\$82.04	\$72.51
38215	Harvest stem cell concentrate	CH	S	0393	5.6921	\$362.55	\$82.04	\$72.51
38220	Bone marrow aspiration		T	0003	3.1008	\$197.50		\$39.50
38221	Bone marrow biopsy		T	0003	3.1008	\$197.50		\$39.50
38230	Bone marrow collection	CH	S	0112	30.6035	\$1,949.26	\$433.29	\$389.85
38240	Bone marrow/stem transplant	CH	S	0112	30.6035	\$1,949.26	\$433.29	\$389.85
38241	Bone marrow/stem transplant	CH	S	0112	30.6035	\$1,949.26	\$433.29	\$389.85
38242	Lymphocyte infuse transplant		S	0111	11.5058	\$732.85	\$198.40	\$146.57
38300	Drainage, lymph node lesion		T	0007	11.5594	\$736.26		\$147.25
38305	Drainage, lymph node lesion		T	0008	18.3197	\$1,166.85		\$233.37
38308	Incision of lymph channels		T	0113	22.9584	\$1,462.31		\$292.46
38380	Thoracic duct procedure		C					
38381	Thoracic duct procedure		C					
38382	Thoracic duct procedure		C					
38500	Biopsy/removal, lymph nodes		T	0113	22.9584	\$1,462.31		\$292.46
38505	Needle biopsy, lymph nodes		T	0005	7.1147	\$453.16		\$90.63
38510	Biopsy/removal, lymph nodes		T	0113	22.9584	\$1,462.31		\$292.46
38520	Biopsy/removal, lymph nodes		T	0113	22.9584	\$1,462.31		\$292.46
38525	Biopsy/removal, lymph nodes		T	0113	22.9584	\$1,462.31		\$292.46
38530	Biopsy/removal, lymph nodes		T	0113	22.9584	\$1,462.31		\$292.46
38542	Explore deep node(s), neck		T	0114	44.3240	\$2,823.17		\$564.63
38550	Removal, neck/armpit lesion		T	0113	22.9584	\$1,462.31		\$292.46
38555	Removal, neck/armpit lesion		T	0113	22.9584	\$1,462.31		\$292.46
38562	Removal, pelvic lymph nodes		C					
38564	Removal, abdomen lymph nodes		C					
38570	Laparoscopy, lymph node biop		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
38571	Laparoscopy, lymphadenectomy		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
38572	Laparoscopy, lymphadenectomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
38589	Laparoscopy proc, lymphatic		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
38700	Removal of lymph nodes, neck		T	0113	22.9584	\$1,462.31		\$292.46
38720	Removal of lymph nodes, neck		T	0113	22.9584	\$1,462.31		\$292.46
38724	Removal of lymph nodes, neck		C					
38740	Remove armpit lymph nodes		T	0114	44.3240	\$2,823.17		\$564.63
38745	Remove armpit lymph nodes		T	0114	44.3240	\$2,823.17		\$564.63
38746	Remove thoracic lymph nodes		C					
38747	Remove abdominal lymph nodes		C					
38760	Remove groin lymph nodes		T	0113	22.9584	\$1,462.31		\$292.46
38765	Remove groin lymph nodes		C					
38770	Remove pelvis lymph nodes		C					
38780	Remove abdomen lymph nodes		C					
38790	Inject for lymphatic x-ray		N					
38792	Identify sentinel node	CH	Q	0392	2.9022	\$184.85	\$49.31	\$36.97
38794	Access thoracic lymph duct		N					
38999	Blood/lymph system procedure		S	0110	3.3967	\$216.35		\$43.27
39000	Exploration of chest		C					
39010	Exploration of chest		C					
39200	Removal chest lesion		C					
39220	Removal chest lesion		C					
39400	Visualization of chest		T	0069	32.5666	\$2,074.30	\$591.64	\$414.86
39499	Chest procedure		C					
39501	Repair diaphragm laceration		C					
39502	Repair paraesophageal hernia		C					
39503	Repair of diaphragm hernia		C					
39520	Repair of diaphragm hernia		C					
39530	Repair of diaphragm hernia		C					
39531	Repair of diaphragm hernia		C					
39540	Repair of diaphragm hernia		C					
39541	Repair of diaphragm hernia		C					
39545	Revision of diaphragm		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
39560	Resect diaphragm, simple		C					
39561	Resect diaphragm, complex		C					
39599	Diaphragm surgery procedure		C					
4000F	Tobacco use txmnt counseling		M					
4001F	Tobacco use txmnt, pharmacol		M					
4002F	Statin therapy, rx		M					
4003F	Pt ed write/oral, pts w/ hf		M					
4005F	Pharm thx for op rx'd		M					
4006F	Beta-blocker therapy rx		M					
4007F	Areds/anitox vit/min rx'd	CH	D					
4009F	Ace/arb inhibitor therapy rx		M					
4011F	Oral antiplatelet therapy rx		M					
4012F	Warfarin therapy rx		M					
4014F	Written discharge instr prvd		M					
4015F	Persist asthma medicine ctrl		M					
4016F	Anti-inflm/angsc agent rx		M					
4017F	Gi prophylaxis for nsaid rx		M					
4018F	Therapy exercise joint rx		M					
4019F	Doc recept counsl vit d/calc+		M					
4025F	Inhaled bronchodilator rx		M					
4030F	Oxygen therapy rx		M					
4033F	Pulmonary rehab rec		M					
4035F	Influenza imm rec		M					
4037F	Influenza imm order/admin		M					
4040F	Pneumoc imm order/admin		M					
4041F	Doc order cefazolin/cefurox		M					
4042F	Doc antibio not given		M					
4043F	Doc order given stop antibio		M					
4044F	Doc order given vte prophylx		M					
4045F	Empiric antibiotic rx		M					
4046F	Doc antibio given b/4 surg		M					
4047F	Doc antibio given b/4 surg		M					
4048F	Doc antibio given b/4 surg		M					
40490	Biopsy of lip		T	0251	2.5002	\$159.25		\$31.85
4049F	Doc order given stop antibio		M					
40500	Partial excision of lip		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
4050F	Ht care plan doc		M					
40510	Partial excision of lip		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
4051F	Referred for an AV fistula		M					
40520	Partial excision of lip		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
40525	Reconstruct lip with flap		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
40527	Reconstruct lip with flap		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
4052F	Hemodialysis via AV fistula		M					
40530	Partial removal of lip		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
4053F	Hemodialysis via AV graft		M					
4054F	Hemodialysis via catheter		M					
4055F	Pt rcvng periton dialysis		M					
4056F	Approp oral rehyd recomm'd		M					
4058F	Ped gastro ed given, caregvr		M					
4060F	Psych svcs provided		M					
4062F	Pt referral psych doc'd		M					
4064F	Antidepressant rx		M					
40650	Repair lip		T	0252	7.4474	\$474.35	\$109.16	\$94.87
40652	Repair lip		T	0252	7.4474	\$474.35	\$109.16	\$94.87
40654	Repair lip		T	0252	7.4474	\$474.35	\$109.16	\$94.87
4065F	Antipsychotic rx		M					
4066F	ECT provided		M					
4067F	Pt referral for ECT doc'd		M					
40700	Repair cleft lip/nasal		T	0256	39.8776	\$2,539.96		\$507.99
40701	Repair cleft lip/nasal		T	0256	39.8776	\$2,539.96		\$507.99
40702	Repair cleft lip/nasal		T	0256	39.8776	\$2,539.96		\$507.99
4070F	Dvt prophylx recv'd day 2		M					
40720	Repair cleft lip/nasal		T	0256	39.8776	\$2,539.96		\$507.99
4073F	Oral antiplat thx rx dischrg		M					
4075F	Anticoag thx rx at dischrg		M					
40761	Repair cleft lip/nasal		T	0256	39.8776	\$2,539.96		\$507.99
4077F	Doc t-pa admin considered		M					
40799	Lip surgery procedure		T	0251	2.5002	\$159.25		\$31.85
4079F	Doc rehab svcs considered		M					
40800	Drainage of mouth lesion		T	0006	1.4066	\$89.59		\$17.92
40801	Drainage of mouth lesion		T	0252	7.4474	\$474.35	\$109.16	\$94.87
40804	Removal, foreign body, mouth		X	0340	0.6310	\$40.19		\$8.04
40805	Removal, foreign body, mouth		T	0252	7.4474	\$474.35	\$109.16	\$94.87
40806	Incision of lip fold		T	0251	2.5002	\$159.25		\$31.85
40808	Biopsy of mouth lesion		T	0251	2.5002	\$159.25		\$31.85
40810	Excision of mouth lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
40812	Excise/repair mouth lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
40814	Excise/repair mouth lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
40816	Excision of mouth lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
40818	Excise oral mucosa for graft		T	0251	2.5002	\$159.25		\$31.85

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
40819	Excise lip or cheek fold		T	0252	7.4474	\$474.35	\$109.16	\$94.87
40820	Treatment of mouth lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
40830	Repair mouth laceration		T	0251	2.5002	\$159.25		\$31.85
40831	Repair mouth laceration		T	0252	7.4474	\$474.35	\$109.16	\$94.87
40840	Reconstruction of mouth		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
40842	Reconstruction of mouth		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
40843	Reconstruction of mouth		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
40844	Reconstruction of mouth		T	0256	39.8776	\$2,539.96		\$507.99
40845	Reconstruction of mouth		T	0256	39.8776	\$2,539.96		\$507.99
4084F	Aspirin recv'd w/in 24 hrs		M					
40899	Mouth surgery procedure		T	0251	2.5002	\$159.25		\$31.85
4090F	Pt rcvng epo thxpy		M					
4095F	Pt not rcvng epo thxpy		M					
41000	Drainage of mouth lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41005	Drainage of mouth lesion		T	0251	2.5002	\$159.25		\$31.85
41006	Drainage of mouth lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
41007	Drainage of mouth lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41008	Drainage of mouth lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41009	Drainage of mouth lesion		T	0251	2.5002	\$159.25		\$31.85
4100F	Biphos thxpy vein ord/rec'vd		M					
41010	Incision of tongue fold		T	0252	7.4474	\$474.35	\$109.16	\$94.87
41015	Drainage of mouth lesion		T	0251	2.5002	\$159.25		\$31.85
41016	Drainage of mouth lesion		T	0252	7.4474	\$474.35	\$109.16	\$94.87
41017	Drainage of mouth lesion		T	0252	7.4474	\$474.35	\$109.16	\$94.87
41018	Drainage of mouth lesion		T	0252	7.4474	\$474.35	\$109.16	\$94.87
41019	Place needles h&n for rt	NI	T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
41100	Biopsy of tongue		T	0252	7.4474	\$474.35	\$109.16	\$94.87
41105	Biopsy of tongue		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41108	Biopsy of floor of mouth		T	0252	7.4474	\$474.35	\$109.16	\$94.87
4110F	Int mam art used for cabg		M					
41110	Excision of tongue lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41112	Excision of tongue lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41113	Excision of tongue lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41114	Excision of tongue lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
41115	Excision of tongue fold		T	0252	7.4474	\$474.35	\$109.16	\$94.87
41116	Excision of mouth lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41120	Partial removal of tongue		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
41130	Partial removal of tongue		C					
41135	Tongue and neck surgery		C					
41140	Removal of tongue		C					
41145	Tongue removal, neck surgery		C					
41150	Tongue, mouth, jaw surgery		C					
41153	Tongue, mouth, neck surgery		C					
41155	Tongue, jaw, & neck surgery		C					
4115F	Beta blckr admin w/in 24 hrs		M					
4120F	Antibiot rx'd/given		M					
4124F	Antibiot not rx'd/given		M					
41250	Repair tongue laceration		T	0251	2.5002	\$159.25		\$31.85
41251	Repair tongue laceration		T	0251	2.5002	\$159.25		\$31.85
41252	Repair tongue laceration		T	0252	7.4474	\$474.35	\$109.16	\$94.87
4130F	Topical prep rx, AOE		M					
4131F	Syst antimicrobial thx rx		M					
4132F	No syst antimicrobial thx rx		M					
4133F	Antihist/decong rx/recom		M					
4134F	No antihist/decong rx/recom		M					
4135F	Systemic corticosteroids rx		M					
4136F	Syst corticosteroids not rx		M					
41500	Fixation of tongue		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
4150F	Pt rcvng antivir txmnt hepc		M					
41510	Tongue to lip surgery		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
4151F	Pt not rcvng antiv hep c		M					
41520	Reconstruction, tongue fold		T	0252	7.4474	\$474.35	\$109.16	\$94.87
4152F	Doc'd pegintf/rib thxy consd		M					
4153F	Combo pegintf/rib rx		M					
4154F	Hep A vac series recommended		M					
4155F	Hep A vac series prev recvd		M					
4156F	Hep B vac series recommended		M					
4157F	Hep B vac series prev recvd		M					
4158F	Pt edu re: alcoh drnkng done		M					
41599	Tongue and mouth surgery		T	0251	2.5002	\$159.25		\$31.85
4159F	Contrcp talk b/4 antiv txmnt		M					
4163F	Pt couns. 4 txmnt opt, prost		M					
4164F	Adjv hrmln thxpy Rx'd	NI	M					
4165F	3D-CRT/IMRT received	NI	M					
4167F	Hd Bed tilted, 1st day vent	NI	M					
4168F	Pt care, ICU&vent w/in 24hrs	NI	M					
4169F	No pt care ICU/vent in 24hrs	NI	M					
4171F	Pt. rcvng ESA thxpy	NI	M					
4172F	Pt. not rcvng ESA thxpy	NI	M					
4174F	Couns., potent. Glauco impact	NI	M					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
4175F	Vis of >=20/40 w/in 90 days	NI	M					
4176F	Talk re UV light, pt/crgvr	NI	M					
4177F	Talk pt/crgvr re: AREDS,prev	NI	M					
4178F	AntiD glbln rcv'd w/in 26wks	NI	M					
4179F	Tamoxifen/AI prescribed	NI	M					
41800	Drainage of gum lesion		T	0006	1.4066	\$89.59		\$17.92
41805	Removal foreign body, gum		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
41806	Removal foreign body, jawbone		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
4180F	Adjv thxpyRx'd/rcv'd Stg3A-C	NI	M					
4181F	Conformal rad'n thxpy rcv'd	NI	M					
41820	Excision, gum, each quadrant		T	0252	7.4474	\$474.35	\$109.16	\$94.87
41821	Excision of gum flap		T	0252	7.4474	\$474.35	\$109.16	\$94.87
41822	Excision of gum lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41823	Excision of gum lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
41825	Excision of gum lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41826	Excision of gum lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41827	Excision of gum lesion		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
41828	Excision of gum lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
4182F	No conformal rad'n thxpy	NI	M					
41830	Removal of gum tissue		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41850	Treatment of gum lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
4185F	Continuous PPI or H2RA rcv'd	NI	M					
4186F	No Cont. PPI or H2RA rcv'd	NI	M					
41870	Gum graft		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
41872	Repair gum		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
41874	Repair tooth socket		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
4187F	Anti rheum DrugthxpyRx'd/gvn	NI	M					
4188F	Approp ACE/ARB tstng done	NI	M					
41899	Dental surgery procedure		T	0251	2.5002	\$159.25		\$31.85
4189F	Approp dogoxin tstng done	NI	M					
4190F	Approp diuretic tstng done	NI	M					
4191F	Approp anticonvuls tstng	NI	M					
42000	Drainage mouth roof lesion		T	0251	2.5002	\$159.25		\$31.85
4200F	External beam to prost only	NI	M					
4201F	Extrl beam other than prost	NI	M					
42100	Biopsy roof of mouth		T	0252	7.4474	\$474.35	\$109.16	\$94.87
42104	Excision lesion, mouth roof		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42106	Excision lesion, mouth roof		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42107	Excision lesion, mouth roof		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
4210F	ACE/ARB thxpy for >= 6 mons	NI	M					
42120	Remove palate/lesion		T	0256	39.8776	\$2,539.96		\$507.99
42140	Excision of uvula		T	0252	7.4474	\$474.35	\$109.16	\$94.87
42145	Repair palate, pharynx/uvula		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
42160	Treatment mouth roof lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42180	Repair palate		T	0251	2.5002	\$159.25		\$31.85
42182	Repair palate		T	0256	39.8776	\$2,539.96		\$507.99
42200	Reconstruct cleft palate		T	0256	39.8776	\$2,539.96		\$507.99
42205	Reconstruct cleft palate		T	0256	39.8776	\$2,539.96		\$507.99
4220F	Digoxin thxpy for >= 6 mons	NI	M					
42210	Reconstruct cleft palate		T	0256	39.8776	\$2,539.96		\$507.99
42215	Reconstruct cleft palate		T	0256	39.8776	\$2,539.96		\$507.99
4221F	Diuretic thxpy for >= 6 mons	NI	M					
42220	Reconstruct cleft palate		T	0256	39.8776	\$2,539.96		\$507.99
42225	Reconstruct cleft palate		T	0256	39.8776	\$2,539.96		\$507.99
42226	Lengthening of palate		T	0256	39.8776	\$2,539.96		\$507.99
42227	Lengthening of palate		T	0256	39.8776	\$2,539.96		\$507.99
42235	Repair palate		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42260	Repair nose to lip fistula		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
42280	Preparation, palate mold		T	0251	2.5002	\$159.25		\$31.85
42281	Insertion, palate prosthesis		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42299	Palate/uvula surgery		T	0251	2.5002	\$159.25		\$31.85
42300	Drainage of salivary gland		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42305	Drainage of salivary gland		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
4230F	Anticonv thxpy for >= 6 mons	NI	M					
42310	Drainage of salivary gland		T	0251	2.5002	\$159.25		\$31.85
42320	Drainage of salivary gland		T	0251	2.5002	\$159.25		\$31.85
42330	Removal of salivary stone		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42335	Removal of salivary stone		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42340	Removal of salivary stone		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42400	Biopsy of salivary gland		T	0005	7.1147	\$453.16		\$90.63
42405	Biopsy of salivary gland		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42408	Excision of salivary cyst		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42409	Drainage of salivary cyst		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42410	Excise parotid gland/lesion		T	0256	39.8776	\$2,539.96		\$507.99
42415	Excise parotid gland/lesion		T	0256	39.8776	\$2,539.96		\$507.99
42420	Excise parotid gland/lesion		T	0256	39.8776	\$2,539.96		\$507.99
42425	Excise parotid gland/lesion		T	0256	39.8776	\$2,539.96		\$507.99
42426	Excise parotid gland/lesion		C					
42440	Excise submaxillary gland		T	0256	39.8776	\$2,539.96		\$507.99
42450	Excise sublingual gland		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
42500	Repair salivary duct		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
42505	Repair salivary duct		T	0256	39.8776	\$2,539.96		\$507.99
42507	Parotid duct diversion		T	0256	39.8776	\$2,539.96		\$507.99
42508	Parotid duct diversion		T	0256	39.8776	\$2,539.96		\$507.99
42509	Parotid duct diversion		T	0256	39.8776	\$2,539.96		\$507.99
42510	Parotid duct diversion		T	0256	39.8776	\$2,539.96		\$507.99
42550	Injection for salivary x-ray		N					
42600	Closure of salivary fistula		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42650	Dilation of salivary duct		T	0252	7.4474	\$474.35	\$109.16	\$94.87
42660	Dilation of salivary duct		T	0251	2.5002	\$159.25		\$31.85
42665	Ligation of salivary duct		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
42699	Salivary surgery procedure		T	0251	2.5002	\$159.25		\$31.85
42700	Drainage of tonsil abscess		T	0251	2.5002	\$159.25		\$31.85
42720	Drainage of throat abscess		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42725	Drainage of throat abscess		T	0256	39.8776	\$2,539.96		\$507.99
42800	Biopsy of throat		T	0252	7.4474	\$474.35	\$109.16	\$94.87
42802	Biopsy of throat		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42804	Biopsy of upper nose/throat		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42806	Biopsy of upper nose/throat		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
42808	Excise pharynx lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42809	Remove pharynx foreign body		X	0340	0.6310	\$40.19		\$8.04
42810	Excision of neck cyst		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
42815	Excision of neck cyst		T	0256	39.8776	\$2,539.96		\$507.99
42820	Remove tonsils and adenoids		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42821	Remove tonsils and adenoids		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42825	Removal of tonsils		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42826	Removal of tonsils		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42830	Removal of adenoids		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42831	Removal of adenoids		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42835	Removal of adenoids		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42836	Removal of adenoids		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42842	Extensive surgery of throat		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
42844	Extensive surgery of throat		T	0256	39.8776	\$2,539.96		\$507.99
42845	Extensive surgery of throat		C					
42860	Excision of tonsil tags		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42870	Excision of lingual tonsil		T	0258	22.2557	\$1,417.55	\$437.25	\$283.51
42890	Partial removal of pharynx		T	0256	39.8776	\$2,539.96		\$507.99
42892	Revision of pharyngeal walls		T	0256	39.8776	\$2,539.96		\$507.99
42894	Revision of pharyngeal walls		C					
42900	Repair throat wound		T	0252	7.4474	\$474.35	\$109.16	\$94.87
42950	Reconstruction of throat		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
42953	Repair throat, esophagus		C					
42955	Surgical opening of throat		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
42960	Control throat bleeding		T	0250	1.1251	\$71.66	\$25.10	\$14.33
42961	Control throat bleeding		C					
42962	Control throat bleeding		T	0256	39.8776	\$2,539.96		\$507.99
42970	Control nose/throat bleeding		T	0250	1.1251	\$71.66	\$25.10	\$14.33
42971	Control nose/throat bleeding		C					
42972	Control nose/throat bleeding		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
42999	Throat surgery procedure		T	0251	2.5002	\$159.25		\$31.85
43020	Incision of esophagus		T	0252	7.4474	\$474.35	\$109.16	\$94.87
43030	Throat muscle surgery		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
43045	Incision of esophagus		C					
43100	Excision of esophagus lesion		C					
43101	Excision of esophagus lesion		C					
43107	Removal of esophagus		C					
43108	Removal of esophagus		C					
43112	Removal of esophagus		C					
43113	Removal of esophagus		C					
43116	Partial removal of esophagus		C					
43117	Partial removal of esophagus		C					
43118	Partial removal of esophagus		C					
43121	Partial removal of esophagus		C					
43122	Partial removal of esophagus		C					
43123	Partial removal of esophagus		C					
43124	Removal of esophagus		C					
43130	Removal of esophagus pouch		T	0256	39.8776	\$2,539.96		\$507.99
43135	Removal of esophagus pouch		C					
43200	Esophagus endoscopy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43201	Esoph scope w/submucous inj		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43202	Esophagus endoscopy, biopsy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43204	Esoph scope w/sclerosis inj		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43205	Esophagus endoscopy/ligation		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43215	Esophagus endoscopy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43216	Esophagus endoscopy/lesion		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43217	Esophagus endoscopy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43219	Esophagus endoscopy		T	0384	24.9814	\$1,591.17		\$318.23
43220	Esoph endoscopy, dilation		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43226	Esoph endoscopy, dilation		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43227	Esoph endoscopy, repair		T	0141	8.5030	\$541.59	\$143.38	\$108.32

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
43228	Esoph endoscopy, ablation		T	0422	25.3233	\$1,612.94	\$448.81	\$322.59
43231	Esoph endoscopy w/us exam		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43232	Esoph endoscopy w/us fn bx		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43234	Upper GI endoscopy, exam		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43235	Uppr gi endoscopy, diagnosis		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43236	Uppr gi scope w/submuc inj		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43237	Endoscopic us exam, esoph		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43238	Uppr gi endoscopy w/us fn bx		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43239	Upper GI endoscopy, biopsy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43240	Esoph endoscope w/drain cyst		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43241	Upper GI endoscopy with tube		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43242	Uppr gi endoscopy w/us fn bx		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43243	Upper gi endoscopy & inject		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43244	Upper GI endoscopy/ligation		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43245	Uppr gi scope dilate strictr		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43246	Place gastrostomy tube		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43247	Operative upper GI endoscopy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43248	Uppr gi endoscopy/guide wire		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43249	Esoph endoscopy, dilation		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43250	Upper GI endoscopy/tumor		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43251	Operative upper GI endoscopy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43255	Operative upper GI endoscopy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43256	Uppr gi endoscopy w/stent		T	0384	24.9814	\$1,591.17		\$318.23
43257	Uppr gi scope w/thrml txmnt		T	0422	25.3233	\$1,612.94	\$448.81	\$322.59
43258	Operative upper GI endoscopy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43259	Endoscopic ultrasound exam		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43260	Endo cholangiopancreatograph		T	0151	20.9510	\$1,334.45		\$266.89
43261	Endo cholangiopancreatograph		T	0151	20.9510	\$1,334.45		\$266.89
43262	Endo cholangiopancreatograph		T	0151	20.9510	\$1,334.45		\$266.89
43263	Endo cholangiopancreatograph		T	0151	20.9510	\$1,334.45		\$266.89
43264	Endo cholangiopancreatograph		T	0151	20.9510	\$1,334.45		\$266.89
43265	Endo cholangiopancreatograph		T	0151	20.9510	\$1,334.45		\$266.89
43267	Endo cholangiopancreatograph		T	0151	20.9510	\$1,334.45		\$266.89
43268	Endo cholangiopancreatograph		T	0384	24.9814	\$1,591.17		\$318.23
43269	Endo cholangiopancreatograph		T	0384	24.9814	\$1,591.17		\$318.23
43271	Endo cholangiopancreatograph		T	0151	20.9510	\$1,334.45		\$266.89
43272	Endo cholangiopancreatograph		T	0151	20.9510	\$1,334.45		\$266.89
43280	Laparoscopy, fundoplasty		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
43289	Laparoscope proc, esoph		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
43300	Repair of esophagus		C					
43305	Repair esophagus and fistula		C					
43310	Repair of esophagus		C					
43312	Repair esophagus and fistula		C					
43313	Esophagoplasty congenital		C					
43314	Tracheo-esophagoplasty cong		C					
43320	Fuse esophagus & stomach		C					
43324	Revise esophagus & stomach		C					
43325	Revise esophagus & stomach		C					
43326	Revise esophagus & stomach		C					
43330	Repair of esophagus		C					
43331	Repair of esophagus		C					
43340	Fuse esophagus & intestine		C					
43341	Fuse esophagus & intestine		C					
43350	Surgical opening, esophagus		C					
43351	Surgical opening, esophagus		C					
43352	Surgical opening, esophagus		C					
43360	Gastrointestinal repair		C					
43361	Gastrointestinal repair		C					
43400	Ligate esophagus veins		C					
43401	Esophagus surgery for veins		C					
43405	Ligate/staple esophagus		C					
43410	Repair esophagus wound		C					
43415	Repair esophagus wound		C					
43420	Repair esophagus opening		C					
43425	Repair esophagus opening		C					
43450	Dilate esophagus		T	0140	5.8431	\$372.17	\$91.40	\$74.43
43453	Dilate esophagus		T	0140	5.8431	\$372.17	\$91.40	\$74.43
43456	Dilate esophagus		T	0140	5.8431	\$372.17	\$91.40	\$74.43
43458	Dilate esophagus	CH	T	0141	8.5030	\$541.59	\$143.38	\$108.32
43460	Pressure treatment esophagus		C					
43496	Free jejunum flap, microvasc		C					
43499	Esophagus surgery procedure		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43500	Surgical opening of stomach		C					
43501	Surgical repair of stomach		C					
43502	Surgical repair of stomach		C					
43510	Surgical opening of stomach		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43520	Incision of pyloric muscle		C					
43600	Biopsy of stomach		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43605	Biopsy of stomach		C					
43610	Excision of stomach lesion		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
43611	Excision of stomach lesion		C					
43620	Removal of stomach		C					
43621	Removal of stomach		C					
43622	Removal of stomach		C					
43631	Removal of stomach, partial		C					
43632	Removal of stomach, partial		C					
43633	Removal of stomach, partial		C					
43634	Removal of stomach, partial		C					
43635	Removal of stomach, partial		C					
43640	Vagotomy & pylorus repair		C					
43641	Vagotomy & pylorus repair		C					
43644	Lap gastric bypass/roux-en-y		C					
43645	Lap gastr bypass incl smll i		C					
43647	Lap impl electrode, antrum	CH	S	0061	82.8597	\$5,277.67		\$1,055.53
43648	Lap revise/remv eltrd antrum		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
43651	Laparoscopy, vagus nerve		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
43652	Laparoscopy, vagus nerve		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
43653	Laparoscopy, gastrostomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
43659	Laparoscope proc, stom		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
43750	Place gastrostomy tube	CH	D					
43752	Nasal/orogastric w/stent		X	0272	1.3271	\$84.53	\$31.64	\$16.91
43760	Change gastrostomy tube		T	0121	3.2383	\$206.26	\$43.80	\$41.25
43761	Reposition gastrostomy tube	CH	T	0141	8.5030	\$541.59	\$143.38	\$108.32
43770	Lap place gastr adj device		C					
43771	Lap revise gastr adj device		C					
43772	Lap rmvl gastr adj device		C					
43773	Lap replace gastr adj device		C					
43774	Lap rmvl gastr adj all parts		C					
43800	Reconstruction of pylorus		C					
43810	Fusion of stomach and bowel		C					
43820	Fusion of stomach and bowel		C					
43825	Fusion of stomach and bowel		C					
43830	Place gastrostomy tube		T	0422	25.3233	\$1,612.94	\$448.81	\$322.59
43831	Place gastrostomy tube		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43832	Place gastrostomy tube		C					
43840	Repair of stomach lesion		C					
43842	V-band gastroplasty		E					
43843	Gastroplasty w/o v-band		C					
43845	Gastroplasty duodenal switch		C					
43846	Gastric bypass for obesity		C					
43847	Gastric bypass incl small i		C					
43848	Revision gastroplasty		C					
43850	Revise stomach-bowel fusion		C					
43855	Revise stomach-bowel fusion		C					
43860	Revise stomach-bowel fusion		C					
43865	Revise stomach-bowel fusion		C					
43870	Repair stomach opening		T	0141	8.5030	\$541.59	\$143.38	\$108.32
43880	Repair stomach-bowel fistula		C					
43881	Impl/redo electrd, antrum		C					
43882	Revise/remove electrd antrum		C					
43886	Revise gastric port, open	CH	T	0137	20.2069	\$1,287.06		\$257.41
43887	Remove gastric port, open	CH	T	0135	4.5263	\$288.30		\$57.66
43888	Change gastric port, open	CH	T	0137	20.2069	\$1,287.06		\$257.41
43999	Stomach surgery procedure		T	0141	8.5030	\$541.59	\$143.38	\$108.32
44005	Freeing of bowel adhesion		C					
44010	Incision of small bowel		C					
44015	Insert needle cath bowel		C					
44020	Explore small intestine		C					
44021	Decompress small bowel		C					
44025	Incision of large bowel		C					
44050	Reduce bowel obstruction		C					
44055	Correct malrotation of bowel		C					
44100	Biopsy of bowel		T	0141	8.5030	\$541.59	\$143.38	\$108.32
44110	Excise intestine lesion(s)		C					
44111	Excision of bowel lesion(s)		C					
44120	Removal of small intestine		C					
44121	Removal of small intestine		C					
44125	Removal of small intestine		C					
44126	Enterectomy w/o taper, cong		C					
44127	Enterectomy w/taper, cong		C					
44128	Enterectomy cong, add-on		C					
44130	Bowel to bowel fusion		C					
44132	Enterectomy, cadaver donor		C					
44133	Enterectomy, live donor		C					
44135	Intestine transplnt, cadaver		C					
44136	Intestine transplant, live		C					
44137	Remove intestinal allograft		C					
44139	Mobilization of colon		C					
44140	Partial removal of colon		C					
44141	Partial removal of colon		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
44143	Partial removal of colon		C					
44144	Partial removal of colon		C					
44145	Partial removal of colon		C					
44146	Partial removal of colon		C					
44147	Partial removal of colon		C					
44150	Removal of colon		C					
44151	Removal of colon/ileostomy		C					
44155	Removal of colon/ileostomy		C					
44156	Removal of colon/ileostomy		C					
44157	Colectomy w/ileoanal anast		C					
44158	Colectomy w/neo-rectum pouch		C					
44160	Removal of colon		C					
44180	Lap, enterolysis		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
44186	Lap, jejunostomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
44187	Lap, ileo/jejuno-stomy		C					
44188	Lap, colostomy		C					
44202	Lap, enterectomy		C					
44203	Lap resect s/intestine, addl		C					
44204	Laparo partial colectomy		C					
44205	Lap colectomy part w/ileum		C					
44206	Lap part colectomy w/stoma		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
44207	L colectomy/coloproctostomy		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
44208	L colectomy/coloproctostomy		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
44210	Laparo total proctocolectomy		C					
44211	Lap colectomy w/proctectomy		C					
44212	Laparo total proctocolectomy		C					
44213	Lap, mobil splenic fl add-on		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
44227	Lap, close enterostomy		C					
44238	Laparoscopy proc, intestine		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
44300	Open bowel to skin		C					
44310	Ileostomy/jejunostomy		C					
44312	Revision of ileostomy	CH	T	0137	20.2069	\$1,287.06		\$257.41
44314	Revision of ileostomy		C					
44316	Devise bowel pouch		C					
44320	Colostomy		C					
44322	Colostomy with biopsies		C					
44340	Revision of colostomy	CH	T	0137	20.2069	\$1,287.06		\$257.41
44345	Revision of colostomy		C					
44346	Revision of colostomy		C					
44360	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44361	Small bowel endoscopy/biopsy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44363	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44364	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44365	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44366	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44369	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44370	Small bowel endoscopy/stent		T	0384	24.9814	\$1,591.17		\$318.23
44372	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44373	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44376	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44377	Small bowel endoscopy/biopsy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44378	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44379	S bowel endoscope w/stent		T	0384	24.9814	\$1,591.17		\$318.23
44380	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44382	Small bowel endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
44383	Ileoscopy w/stent		T	0384	24.9814	\$1,591.17		\$318.23
44385	Endoscopy of bowel pouch		T	0143	8.8486	\$563.60	\$186.06	\$112.72
44386	Endoscopy, bowel pouch/biop		T	0143	8.8486	\$563.60	\$186.06	\$112.72
44388	Colonoscopy		T	0143	8.8486	\$563.60	\$186.06	\$112.72
44389	Colonoscopy with biopsy		T	0143	8.8486	\$563.60	\$186.06	\$112.72
44390	Colonoscopy for foreign body		T	0143	8.8486	\$563.60	\$186.06	\$112.72
44391	Colonoscopy for bleeding		T	0143	8.8486	\$563.60	\$186.06	\$112.72
44392	Colonoscopy & polypectomy		T	0143	8.8486	\$563.60	\$186.06	\$112.72
44393	Colonoscopy, lesion removal		T	0143	8.8486	\$563.60	\$186.06	\$112.72
44394	Colonoscopy w/snare		T	0143	8.8486	\$563.60	\$186.06	\$112.72
44397	Colonoscopy w/stent		T	0384	24.9814	\$1,591.17		\$318.23
44500	Intro, gastrointestinal tube		T	0121	3.2383	\$206.26	\$43.80	\$41.25
44602	Suture, small intestine		C					
44603	Suture, small intestine		C					
44604	Suture, large intestine		C					
44605	Repair of bowel lesion		C					
44615	Intestinal stricturoplasty		C					
44620	Repair bowel opening		C					
44625	Repair bowel opening		C					
44626	Repair bowel opening		C					
44640	Repair bowel-skin fistula		C					
44650	Repair bowel fistula		C					
44660	Repair bowel-bladder fistula		C					
44661	Repair bowel-bladder fistula		C					
44680	Surgical revision, intestine		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
44700	Suspend bowel w/prosthesis		C					
44701	Intraop colon lavage add-on		N					
44715	Prepare donor intestine		C					
44720	Prep donor intestine/venous		C					
44721	Prep donor intestine/artery		C					
44799	Unlisted procedure intestine		T	0153	25.6947	\$1,636.60	\$397.95	\$327.32
44800	Excision of bowel pouch		C					
44820	Excision of mesentery lesion		C					
44850	Repair of mesentery		C					
44899	Bowel surgery procedure		C					
44900	Drain app abscess, open		C					
44901	Drain app abscess, percut		T	0037	13.5764	\$864.74	\$228.76	\$172.95
44950	Appendectomy		C					
44955	Appendectomy add-on		C					
44960	Appendectomy		C					
44970	Laparoscopy, appendectomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
44979	Laparoscope proc, app		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
45000	Drainage of pelvic abscess	CH	T	0155	10.9132	\$695.11		\$139.02
45005	Drainage of rectal abscess		T	0155	10.9132	\$695.11		\$139.02
45020	Drainage of rectal abscess		T	0155	10.9132	\$695.11		\$139.02
45100	Biopsy of rectum		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45108	Removal of anorectal lesion		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45110	Removal of rectum		C					
45111	Partial removal of rectum		C					
45112	Removal of rectum		C					
45113	Partial proctectomy		C					
45114	Partial removal of rectum		C					
45116	Partial removal of rectum		C					
45119	Remove rectum w/reservoir		C					
45120	Removal of rectum		C					
45121	Removal of rectum and colon		C					
45123	Partial proctectomy		C					
45126	Pelvic exenteration		C					
45130	Excision of rectal prolapse		C					
45135	Excision of rectal prolapse		C					
45136	Excise ileoanal reservoir		C					
45150	Excision of rectal stricture		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45160	Excision of rectal lesion		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45170	Excision of rectal lesion		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45190	Destruction, rectal tumor		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45300	Proctosigmoidoscopy dx		T	0146	5.0972	\$324.66		\$64.93
45303	Proctosigmoidoscopy dilate		T	0147	8.7031	\$554.34		\$110.87
45305	Proctosigmoidoscopy w/bx		T	0147	8.7031	\$554.34		\$110.87
45307	Proctosigmoidoscopy fb		T	0428	21.4632	\$1,367.08		\$273.42
45308	Proctosigmoidoscopy removal		T	0147	8.7031	\$554.34		\$110.87
45309	Proctosigmoidoscopy removal		T	0147	8.7031	\$554.34		\$110.87
45315	Proctosigmoidoscopy removal		T	0147	8.7031	\$554.34		\$110.87
45317	Proctosigmoidoscopy bleed		T	0147	8.7031	\$554.34		\$110.87
45320	Proctosigmoidoscopy ablate		T	0428	21.4632	\$1,367.08		\$273.42
45321	Proctosigmoidoscopy volvul		T	0428	21.4632	\$1,367.08		\$273.42
45327	Proctosigmoidoscopy w/stent		T	0384	24.9814	\$1,591.17		\$318.23
45330	Diagnostic sigmoidoscopy		T	0146	5.0972	\$324.66		\$64.93
45331	Sigmoidoscopy and biopsy		T	0146	5.0972	\$324.66		\$64.93
45332	Sigmoidoscopy w/fb removal		T	0146	5.0972	\$324.66		\$64.93
45333	Sigmoidoscopy & polypectomy		T	0147	8.7031	\$554.34		\$110.87
45334	Sigmoidoscopy for bleeding		T	0147	8.7031	\$554.34		\$110.87
45335	Sigmoidoscopy w/submuc inj		T	0146	5.0972	\$324.66		\$64.93
45337	Sigmoidoscopy & decompress		T	0146	5.0972	\$324.66		\$64.93
45338	Sigmoidoscopy w/tumr remove		T	0147	8.7031	\$554.34		\$110.87
45339	Sigmoidoscopy w/ablate tumr		T	0147	8.7031	\$554.34		\$110.87
45340	Sig w/balloon dilation		T	0147	8.7031	\$554.34		\$110.87
45341	Sigmoidoscopy w/ultrasound		T	0147	8.7031	\$554.34		\$110.87
45342	Sigmoidoscopy w/us guide bx		T	0147	8.7031	\$554.34		\$110.87
45345	Sigmoidoscopy w/stent		T	0384	24.9814	\$1,591.17		\$318.23
45355	Surgical colonoscopy		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45378	Diagnostic colonoscopy		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45379	Colonoscopy w/fb removal		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45380	Colonoscopy and biopsy		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45381	Colonoscopy, submucous inj		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45382	Colonoscopy/control bleeding		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45383	Lesion removal colonoscopy		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45384	Lesion remove colonoscopy		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45385	Lesion removal colonoscopy		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45386	Colonoscopy dilate stricture		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45387	Colonoscopy w/stent		T	0384	24.9814	\$1,591.17		\$318.23
45391	Colonoscopy w/endscope us		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45392	Colonoscopy w/endoscopic fnb		T	0143	8.8486	\$563.60	\$186.06	\$112.72
45395	Lap, removal of rectum		C					
45397	Lap, remove rectum w/pouch		C					
45400	Laparoscopic proc		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
45402	Lap proctopexy w/sig resect		C					
45499	Laparoscope proc, rectum		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
45500	Repair of rectum		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45505	Repair of rectum		T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
45520	Treatment of rectal prolapse	CH	T	0013	0.7930	\$50.51		\$10.10
45540	Correct rectal prolapse		C					
45541	Correct rectal prolapse		T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
45550	Repair rectum/remove sigmoid		C					
45560	Repair of rectocele		T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
45562	Exploration/repair of rectum		C					
45563	Exploration/repair of rectum		C					
45800	Repair rect/bladder fistula		C					
45805	Repair fistula w/colostomy		C					
45820	Repair rectourethral fistula		C					
45825	Repair fistula w/colostomy		C					
45900	Reduction of rectal prolapse		T	0148	4.7935	\$305.32		\$61.06
45905	Dilation of anal sphincter		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45910	Dilation of rectal narrowing		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45915	Remove rectal obstruction	CH	T	0155	10.9132	\$695.11		\$139.02
45990	Surg dx exam, anorectal	CH	T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
45999	Rectum surgery procedure		T	0148	4.7935	\$305.32		\$61.06
46020	Placement of seton		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46030	Removal of rectal marker		T	0148	4.7935	\$305.32		\$61.06
46040	Incision of rectal abscess		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46045	Incision of rectal abscess		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46050	Incision of anal abscess	CH	T	0155	10.9132	\$695.11		\$139.02
46060	Incision of rectal abscess		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46070	Incision of anal septum		T	0155	10.9132	\$695.11		\$139.02
46080	Incision of anal sphincter		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46083	Incise external hemorrhoid		T	0164	2.0077	\$127.88		\$25.58
46200	Removal of anal fissure		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46210	Removal of anal crypt		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46211	Removal of anal crypts		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46220	Removal of anal tag		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46221	Ligation of hemorrhoid(s)		T	0148	4.7935	\$305.32		\$61.06
46230	Removal of anal tags		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46250	Hemorrhoidectomy		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46255	Hemorrhoidectomy		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46257	Remove hemorrhoids & fissure		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46258	Remove hemorrhoids & fistula		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46260	Hemorrhoidectomy		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46261	Remove hemorrhoids & fissure		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46262	Remove hemorrhoids & fistula		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46270	Removal of anal fistula		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46275	Removal of anal fistula		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46280	Removal of anal fistula		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46285	Removal of anal fistula		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46288	Repair anal fistula		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46320	Removal of hemorrhoid clot	CH	T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46500	Injection into hemorrhoid(s)		T	0155	10.9132	\$695.11		\$139.02
46505	Chemodenervation anal musc		X	0148	4.7935	\$305.32		\$61.06
46600	Diagnostic anoscopy		X	0340	0.6310	\$40.19		\$8.04
46604	Anoscopy and dilation		T	0147	8.7031	\$554.34		\$110.87
46606	Anoscopy and biopsy		T	0146	5.0972	\$324.66		\$64.93
46608	Anoscopy, remove for body		T	0147	8.7031	\$554.34		\$110.87
46610	Anoscopy, remove lesion		T	0428	21.4632	\$1,367.08		\$273.42
46611	Anoscopy		T	0147	8.7031	\$554.34		\$110.87
46612	Anoscopy, remove lesions		T	0428	21.4632	\$1,367.08		\$273.42
46614	Anoscopy, control bleeding		T	0146	5.0972	\$324.66		\$64.93
46615	Anoscopy		T	0428	21.4632	\$1,367.08		\$273.42
46700	Repair of anal stricture		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46705	Repair of anal stricture		C					
46706	Repr of anal fistula w/glue		T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
46710	Repr per/vag pouch sngl proc		C					
46712	Repr per/vag pouch dbl proc		C					
46715	Rep perf anoper fistu		C					
46716	Rep perf anoper/vestib fistu		C					
46730	Construction of absent anus		C					
46735	Construction of absent anus		C					
46740	Construction of absent anus		C					
46742	Repair of imperforated anus		C					
46744	Repair of cloacal anomaly		C					
46746	Repair of cloacal anomaly		C					
46748	Repair of cloacal anomaly		C					
46750	Repair of anal sphincter	CH	T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
46751	Repair of anal sphincter		C					
46753	Reconstruction of anus		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46754	Removal of suture from anus		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46760	Repair of anal sphincter	CH	T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
46761	Repair of anal sphincter	CH	T	0150	30.1606	\$1,921.05	\$437.12	\$384.21

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
46762	Implant artificial sphincter	CH	T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
46900	Destruction, anal lesion(s)		T	0016	2.6604	\$169.45		\$33.89
46910	Destruction, anal lesion(s)		T	0017	19.9041	\$1,267.77		\$253.55
46916	Cryosurgery, anal lesion(s)	CH	T	0015	1.4595	\$92.96		\$18.59
46917	Laser surgery, anal lesions	CH	T	0017	19.9041	\$1,267.77		\$253.55
46922	Excision of anal lesion(s)	CH	T	0017	19.9041	\$1,267.77		\$253.55
46924	Destruction, anal lesion(s)	CH	T	0017	19.9041	\$1,267.77		\$253.55
46934	Destruction of hemorrhoids		T	0155	10.9132	\$695.11		\$139.02
46935	Destruction of hemorrhoids		T	0155	10.9132	\$695.11		\$139.02
46936	Destruction of hemorrhoids		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46937	Cryotherapy of rectal lesion		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46938	Cryotherapy of rectal lesion		T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
46940	Treatment of anal fissure		T	0149	22.7451	\$1,448.73	\$293.06	\$289.75
46942	Treatment of anal fissure		T	0148	4.7935	\$305.32		\$61.06
46945	Ligation of hemorrhoids		T	0155	10.9132	\$695.11		\$139.02
46946	Ligation of hemorrhoids		T	0155	10.9132	\$695.11		\$139.02
46947	Hemorrhoidopexy by stapling		T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
46999	Anus surgery procedure		T	0148	4.7935	\$305.32		\$61.06
47000	Needle biopsy of liver		T	0685	9.3354	\$594.61		\$118.92
47001	Needle biopsy, liver add-on		N					
47010	Open drainage, liver lesion		C					
47011	Percut drain, liver lesion		T	0037	13.5764	\$864.74	\$228.76	\$172.95
47015	Inject/aspirate liver cyst		C					
47100	Wedge biopsy of liver		C					
47120	Partial removal of liver		C					
47122	Extensive removal of liver		C					
47125	Partial removal of liver		C					
47130	Partial removal of liver		C					
47133	Removal of donor liver		C					
47135	Transplantation of liver		C					
47136	Transplantation of liver		C					
47140	Partial removal, donor liver		C					
47141	Partial removal, donor liver		C					
47142	Partial removal, donor liver		C					
47143	Prep donor liver, whole		C					
47144	Prep donor liver, 3-segment		C					
47145	Prep donor liver, lobe split		C					
47146	Prep donor liver/venous		C					
47147	Prep donor liver/arterial		C					
47300	Surgery for liver lesion		C					
47350	Repair liver wound		C					
47360	Repair liver wound		C					
47361	Repair liver wound		C					
47362	Repair liver wound		C					
47370	Laparo ablate liver tumor rf		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
47371	Laparo ablate liver cryosurg		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
47379	Laparoscope procedure, liver		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
47380	Open ablate liver tumor rf		C					
47381	Open ablate liver tumor cryo		C					
47382	Percut ablate liver rf		T	0423	42.9980	\$2,738.71		\$547.74
47399	Liver surgery procedure		T	0004	4.3270	\$275.60		\$55.12
47400	Incision of liver duct		C					
47420	Incision of bile duct		C					
47425	Incision of bile duct		C					
47460	Incise bile duct sphincter		C					
47480	Incision of gallbladder		C					
47490	Incision of gallbladder		T	0152	28.6884	\$1,827.28		\$365.46
47500	Injection for liver x-rays		N					
47505	Injection for liver x-rays		N					
47510	Insert catheter, bile duct		T	0152	28.6884	\$1,827.28		\$365.46
47511	Insert bile duct drain		T	0152	28.6884	\$1,827.28		\$365.46
47525	Change bile duct catheter		T	0427	15.3545	\$977.99		\$195.60
47530	Revise/reinsert bile tube		T	0427	15.3545	\$977.99		\$195.60
47550	Bile duct endoscopy add-on		C					
47552	Biliary endoscopy thru skin		T	0152	28.6884	\$1,827.28		\$365.46
47553	Biliary endoscopy thru skin		T	0152	28.6884	\$1,827.28		\$365.46
47554	Biliary endoscopy thru skin		T	0152	28.6884	\$1,827.28		\$365.46
47555	Biliary endoscopy thru skin		T	0152	28.6884	\$1,827.28		\$365.46
47556	Biliary endoscopy thru skin		T	0152	28.6884	\$1,827.28		\$365.46
47560	Laparoscopy w/cholangio		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
47561	Laparo w/cholangio/biopsy		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
47562	Laparoscopic cholecystectomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
47563	Laparo cholecystectomy/graph		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
47564	Laparo cholecystectomy/explr		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
47570	Laparo cholecystoenterostomy		C					
47579	Laparoscope proc, biliary		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
47600	Removal of gallbladder		C					
47605	Removal of gallbladder		C					
47610	Removal of gallbladder		C					
47612	Removal of gallbladder		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
47620	Removal of gallbladder		C					
47630	Remove bile duct stone		T	0152	28.6884	\$1,827.28		\$365.46
47700	Exploration of bile ducts		C					
47701	Bile duct revision		C					
47711	Excision of bile duct tumor		C					
47712	Excision of bile duct tumor		C					
47715	Excision of bile duct cyst		C					
47719	Fusion of bile duct cyst	CH	D					
47720	Fuse gallbladder & bowel		C					
47721	Fuse upper gi structures		C					
47740	Fuse gallbladder & bowel		C					
47741	Fuse gallbladder & bowel		C					
47760	Fuse bile ducts and bowel		C					
47765	Fuse liver ducts & bowel		C					
47780	Fuse bile ducts and bowel		C					
47785	Fuse bile ducts and bowel		C					
47800	Reconstruction of bile ducts		C					
47801	Placement, bile duct support		C					
47802	Fuse liver duct & intestine		C					
47900	Suture bile duct injury		C					
47999	Bile tract surgery procedure		T	0152	28.6884	\$1,827.28		\$365.46
48000	Drainage of abdomen		C					
48001	Placement of drain, pancreas		C					
48020	Removal of pancreatic stone		C					
48100	Biopsy of pancreas, open		C					
48102	Needle biopsy, pancreas		T	0685	9.3354	\$594.61		\$118.92
48105	Resect/debride pancreas		C					
48120	Removal of pancreas lesion		C					
48140	Partial removal of pancreas		C					
48145	Partial removal of pancreas		C					
48146	Pancreatectomy		C					
48148	Removal of pancreatic duct		C					
48150	Partial removal of pancreas		C					
48152	Pancreatectomy		C					
48153	Pancreatectomy		C					
48154	Pancreatectomy		C					
48155	Removal of pancreas		C					
48160	Pancreas removal/transplant		E					
48400	Injection, intraop add-on		C					
48500	Surgery of pancreatic cyst		C					
48510	Drain pancreatic pseudocyst		C					
48511	Drain pancreatic pseudocyst		T	0037	13.5764	\$864.74	\$228.76	\$172.95
48520	Fuse pancreas cyst and bowel		C					
48540	Fuse pancreas cyst and bowel		C					
48545	Pancreatorrhaphy		C					
48547	Duodenal exclusion		C					
48548	Fuse pancreas and bowel		C					
48550	Donor pancreatectomy		E					
48551	Prep donor pancreas		C					
48552	Prep donor pancreas/venous		C					
48554	Transpl allograft pancreas		C					
48556	Removal, allograft pancreas		C					
48999	Pancreas surgery procedure		T	0004	4.3270	\$275.60		\$55.12
49000	Exploration of abdomen		C					
49002	Reopening of abdomen		C					
49010	Exploration behind abdomen		C					
49020	Drain abdominal abscess		C					
49021	Drain abdominal abscess		T	0037	13.5764	\$864.74	\$228.76	\$172.95
49040	Drain, open, abdom abscess		C					
49041	Drain, percut, abdom abscess		T	0037	13.5764	\$864.74	\$228.76	\$172.95
49060	Drain, open, retroper abscess		C					
49061	Drain, percut, retroper abscess		T	0037	13.5764	\$864.74	\$228.76	\$172.95
49062	Drain to peritoneal cavity		C					
49080	Puncture, peritoneal cavity		T	0070	5.2024	\$331.36		\$66.27
49081	Removal of abdominal fluid		T	0070	5.2024	\$331.36		\$66.27
49180	Biopsy, abdominal mass		T	0685	9.3354	\$594.61		\$118.92
49200	Removal of abdominal lesion	CH	D					
49201	Remove abdom lesion, complex	CH	D					
49203	Exc abd tum 5 cm or less	NI	C					
49204	Exc abd tum over 5 cm	NI	C					
49205	Exc abd tum over 10 cm	NI	C					
49215	Excise sacral spine tumor		C					
49220	Multiple surgery, abdomen		C					
49250	Excision of umbilicus		T	0153	25.6947	\$1,636.60	\$397.95	\$327.32
49255	Removal of omentum		C					
49320	Diag laparo separate proc		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
49321	Laparoscopy, biopsy		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
49322	Laparoscopy, aspiration		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
49323	Laparo drain lymphocele		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
49324	Lap insertion perm ip cath		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
49325	Lap revision perm ip cath		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
49326	Lap w/omentopexy add-on		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
49329	Laparo proc, abdm/per/oment		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
49400	Air injection into abdomen		N					
49402	Remove foreign body, abdomen		T	0153	25.6947	\$1,636.60	\$397.95	\$327.32
49419	Insrt abdom cath for chemotx		T	0115	29.6965	\$1,891.49		\$378.30
49420	Insert abdom drain, temp		T	0652	30.7096	\$1,956.02		\$391.20
49421	Insert abdom drain, perm		T	0652	30.7096	\$1,956.02		\$391.20
49422	Remove perm cannula/catheter		T	0105	23.9802	\$1,527.39		\$305.48
49423	Exchange drainage catheter		T	0427	15.3545	\$977.99		\$195.60
49424	Assess cyst, contrast inject		N					
49425	Insert abdomen-venous drain		C					
49426	Revise abdomen-venous shunt		T	0153	25.6947	\$1,636.60	\$397.95	\$327.32
49427	Injection, abdominal shunt		N					
49428	Ligation of shunt		C					
49429	Removal of shunt		T	0105	23.9802	\$1,527.39		\$305.48
49435	Insert subq exten to ip cath		T	0427	15.3545	\$977.99		\$195.60
49436	Embedded ip cath exit-site		T	0427	15.3545	\$977.99		\$195.60
49440	Place gastrostomy tube perc	NI	T	0141	8.5030	\$541.59	\$143.38	\$108.32
49441	Place duod/jej tube perc	NI	T	0141	8.5030	\$541.59	\$143.38	\$108.32
49442	Place cecostomy tube perc	NI	T	0155	10.9132	\$695.11		\$139.02
49446	Change g-tube to g-j perc	NI	T	0141	8.5030	\$541.59	\$143.38	\$108.32
49450	Replace g/c tube perc	NI	T	0121	3.2383	\$206.26	\$43.80	\$41.25
49451	Replace duod/jej tube perc	NI	T	0121	3.2383	\$206.26	\$43.80	\$41.25
49452	Replace g-j tube perc	NI	T	0121	3.2383	\$206.26	\$43.80	\$41.25
49460	Fix g/colon tube w/device	NI	T	0121	3.2383	\$206.26	\$43.80	\$41.25
49465	Fluoro exam of g/colon tube	NI	Q	0276	1.3834	\$88.11	\$34.97	\$17.62
49491	Rpr hern preemie reduc		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49492	Rpr ing hern premie, blocked		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49495	Rpr ing hernia baby, reduc		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49496	Rpr ing hernia baby, blocked		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49500	Rpr ing hernia, init, reduce		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49501	Rpr ing hernia, init blocked		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49505	Prp i/hern init reduc >5 yr		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49507	Prp i/hern init block >5 yr		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49520	Rerepair ing hernia, reduce		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49521	Rerepair ing hernia, blocked		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49525	Repair ing hernia, sliding		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49540	Repair lumbar hernia		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49550	Rpr rem hernia, init, reduce		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49553	Rpr fem hernia, init blocked		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49555	Rerepair fem hernia, reduce		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49557	Rerepair fem hernia, blocked		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49560	Rpr ventral hern init, reduc		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49561	Rpr ventral hern init, block		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49565	Rerepair ventrl hern, reduce		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49566	Rerepair ventrl hern, block		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49568	Hernia repair w/mesh		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49570	Rpr epigastric hern, reduce		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49572	Rpr epigastric hern, blocked		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49580	Rpr umbil hern, reduc < 5 yr		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49582	Rpr umbil hern, block < 5 yr		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49585	Rpr umbil hern, reduc > 5 yr		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49587	Rpr umbil hern, block > 5 yr		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49590	Repair spigelian hernia		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49600	Repair umbilical lesion		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
49605	Repair umbilical lesion		C					
49606	Repair umbilical lesion		C					
49610	Repair umbilical lesion		C					
49611	Repair umbilical lesion		C					
49650	Laparo hernia repair initial		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
49651	Laparo hernia repair recur		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
49659	Laparo proc, hernia repair		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
49900	Repair of abdominal wall		C					
49904	Omental flap, extra-abdom		C					
49905	Omental flap, intra-abdom		C					
49906	Free omental flap, microvasc		C					
49999	Abdomen surgery procedure		T	0153	25.6947	\$1,636.60	\$397.95	\$327.32
50010	Exploration of kidney		C					
50020	Renal abscess, open drain		T	0162	24.7749	\$1,578.01		\$315.60
50021	Renal abscess, percut drain		T	0037	13.5764	\$864.74	\$228.76	\$172.95
50040	Drainage of kidney		C					
50045	Exploration of kidney		C					
5005F	Pt counsid on exam for moles		M					
50060	Removal of kidney stone		C					
50065	Incision of kidney		C					
50070	Incision of kidney		C					
50075	Removal of kidney stone		C					
50080	Removal of kidney stone		T	0429	45.2042	\$2,879.24		\$575.85
50081	Removal of kidney stone		T	0429	45.2042	\$2,879.24		\$575.85

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
50100	Revise kidney blood vessels		C					
5010F	Macul+ findngs to dr mng dm		M					
50120	Exploration of kidney		C					
50125	Explore and drain kidney		C					
50130	Removal of kidney stone		C					
50135	Exploration of kidney		C					
5015F	Doc fx & test/bxmnt for op		M					
50200	Biopsy of kidney		T	0685	9.3354	\$594.61		\$118.92
50205	Biopsy of kidney		C					
5020F	Txmnts 2 main Dr by 1 mon	NI	M					
50220	Remove kidney, open		C					
50225	Removal kidney open, complex		C					
50230	Removal kidney open, radical		C					
50234	Removal of kidney & ureter		C					
50236	Removal of kidney & ureter		C					
50240	Partial removal of kidney		C					
50250	Cryoablate renal mass open		C					
50280	Removal of kidney lesion		C					
50290	Removal of kidney lesion		C					
50300	Remove cadaver donor kidney		C					
50320	Remove kidney, living donor		C					
50323	Prep cadaver renal allograft		C					
50325	Prep donor renal graft		C					
50327	Prep renal graft/venous		C					
50328	Prep renal graft/arterial		C					
50329	Prep renal graft/ureteral		C					
50340	Removal of kidney		C					
50360	Transplantation of kidney		C					
50365	Transplantation of kidney		C					
50370	Remove transplanted kidney		C					
50380	Reimplantation of kidney		C					
50382	Change ureter stent, percut	CH	T	0162	24.7749	\$1,578.01		\$315.60
50384	Remove ureter stent, percut		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
50385	Change stent via transureth	NI	T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
50386	Remove stent via transureth	NI	T	0160	5.9735	\$380.48		\$76.10
50387	Change ext/int ureter stent	CH	T	0427	15.3545	\$977.99		\$195.60
50389	Remove renal tube w/fluoro	CH	T	0160	5.9735	\$380.48		\$76.10
50390	Drainage of kidney lesion		T	0685	9.3354	\$594.61		\$118.92
50391	Instill rx agnt into renal tub		T	0126	1.0356	\$65.96	\$16.21	\$13.19
50392	Insert kidney drain		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
50393	Insert ureteral tube	CH	T	0162	24.7749	\$1,578.01		\$315.60
50394	Injection for kidney x-ray		N					
50395	Create passage to kidney		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
50396	Measure kidney pressure		T	0164	2.0077	\$127.88		\$25.58
50398	Change kidney tube	CH	T	0427	15.3545	\$977.99		\$195.60
50400	Revision of kidney/ureter		C					
50405	Revision of kidney/ureter		C					
50500	Repair of kidney wound		C					
5050F	Plan 2 main Dr. by 1 month	NI	M					
50520	Close kidney-skin fistula		C					
50525	Repair renal-abdomen fistula		C					
50526	Repair renal-abdomen fistula		C					
50540	Revision of horseshoe kidney		C					
50541	Laparo ablate renal cyst		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
50542	Laparo ablate renal mass		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
50543	Laparo partial nephrectomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
50544	Laparoscopy, pyeloplasty		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
50545	Laparo radical nephrectomy		C					
50546	Laparoscopic nephrectomy		C					
50547	Laparo removal donor kidney		C					
50548	Laparo remove w/ureter		C					
50549	Laparoscope proc, renal		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
50551	Kidney endoscopy		T	0160	5.9735	\$380.48		\$76.10
50553	Kidney endoscopy	CH	T	0162	24.7749	\$1,578.01		\$315.60
50555	Kidney endoscopy & biopsy		T	0160	5.9735	\$380.48		\$76.10
50557	Kidney endoscopy & treatment		T	0162	24.7749	\$1,578.01		\$315.60
50561	Kidney endoscopy & treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
50562	Renal scope w/tumor resect		T	0160	5.9735	\$380.48		\$76.10
50570	Kidney endoscopy		T	0160	5.9735	\$380.48		\$76.10
50572	Kidney endoscopy		T	0160	5.9735	\$380.48		\$76.10
50574	Kidney endoscopy & biopsy		T	0160	5.9735	\$380.48		\$76.10
50575	Kidney endoscopy		T	0163	36.0774	\$2,297.91		\$459.58
50576	Kidney endoscopy & treatment		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
50580	Kidney endoscopy & treatment	CH	T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
50590	Fragmenting of kidney stone		T	0169	41.5299	\$2,645.21	\$997.74	\$529.04
50592	Perc rf ablate renal tumor		T	0423	42.9980	\$2,738.71		\$547.74
50593	Perc cryo ablate renal tum	NI	T	0423	42.9980	\$2,738.71		\$547.74
50600	Exploration of ureter		C					
50605	Insert ureteral support		C					
50610	Removal of ureter stone		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
50620	Removal of ureter stone		C					
50630	Removal of ureter stone		C					
50650	Removal of ureter		C					
50660	Removal of ureter		C					
50684	Injection for ureter x-ray		N					
50686	Measure ureter pressure		T	0126	1.0356	\$65.96	\$16.21	\$13.19
50688	Change of ureter tube/stent	CH	T	0427	15.3545	\$977.99		\$195.60
50690	Injection for ureter x-ray		N					
50700	Revision of ureter		C					
50715	Release of ureter		C					
50722	Release of ureter		C					
50725	Release/revise ureter		C					
50727	Revise ureter		C					
50728	Revise ureter		C					
50740	Fusion of ureter & kidney		C					
50750	Fusion of ureter & kidney		C					
50760	Fusion of ureters		C					
50770	Splicing of ureters		C					
50780	Reimplant ureter in bladder		C					
50782	Reimplant ureter in bladder		C					
50783	Reimplant ureter in bladder		C					
50785	Reimplant ureter in bladder		C					
50800	Implant ureter in bowel		C					
50810	Fusion of ureter & bowel		C					
50815	Urine shunt to intestine		C					
50820	Construct bowel bladder		C					
50825	Construct bowel bladder		C					
50830	Revise urine flow		C					
50840	Replace ureter by bowel		C					
50845	Appendico-vesicostomy		C					
50860	Transplant ureter to skin		C					
50900	Repair of ureter		C					
50920	Closure ureter/skin fistula		C					
50930	Closure ureter/bowel fistula		C					
50940	Release of ureter		C					
50945	Laparoscopy ureterolithotomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
50947	Laparo new ureter/bladder		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
50948	Laparo new ureter/bladder		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
50949	Laparoscope proc, ureter		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
50951	Endoscopy of ureter		T	0160	5.9735	\$380.48		\$76.10
50953	Endoscopy of ureter		T	0160	5.9735	\$380.48		\$76.10
50955	Ureter endoscopy & biopsy	CH	T	0162	24.7749	\$1,578.01		\$315.60
50957	Ureter endoscopy & treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
50961	Ureter endoscopy & treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
50970	Ureter endoscopy		T	0160	5.9735	\$380.48		\$76.10
50972	Ureter endoscopy & catheter		T	0160	5.9735	\$380.48		\$76.10
50974	Ureter endoscopy & biopsy		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
50976	Ureter endoscopy & treatment		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
50980	Ureter endoscopy & treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
51000	Drainage of bladder	CH	D					
51005	Drainage of bladder	CH	D					
51010	Drainage of bladder	CH	D					
51020	Incise & treat bladder		T	0162	24.7749	\$1,578.01		\$315.60
51030	Incise & treat bladder		T	0162	24.7749	\$1,578.01		\$315.60
51040	Incise & drain bladder		T	0162	24.7749	\$1,578.01		\$315.60
51045	Incise bladder/drain ureter		T	0160	5.9735	\$380.48		\$76.10
51050	Removal of bladder stone		T	0162	24.7749	\$1,578.01		\$315.60
51060	Removal of ureter stone		C					
51065	Remove ureter calculus		T	0162	24.7749	\$1,578.01		\$315.60
51080	Drainage of bladder abscess		T	0008	18.3197	\$1,166.85		\$233.37
51100	Drain bladder by needle	NI	T	0164	2.0077	\$127.88		\$25.58
51101	Drain bladder by trocar/cath	NI	T	0126	1.0356	\$65.96	\$16.21	\$13.19
51102	Drain bl w/cath insertion	NI	T	0165	19.3414	\$1,231.93		\$246.39
51500	Removal of bladder cyst		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
51520	Removal of bladder lesion		T	0162	24.7749	\$1,578.01		\$315.60
51525	Removal of bladder lesion		C					
51530	Removal of bladder lesion		C					
51535	Repair of ureter lesion	CH	T	0162	24.7749	\$1,578.01		\$315.60
51550	Partial removal of bladder		C					
51555	Partial removal of bladder		C					
51565	Revise bladder & ureter(s)		C					
51570	Removal of bladder		C					
51575	Removal of bladder & nodes		C					
51580	Remove bladder/revise tract		C					
51585	Removal of bladder & nodes		C					
51590	Remove bladder/revise tract		C					
51595	Remove bladder/revise tract		C					
51596	Remove bladder/create pouch		C					
51597	Removal of pelvic structures		C					
51600	Injection for bladder x-ray		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
51605	Preparation for bladder xray		N					
51610	Injection for bladder x-ray		N					
51700	Irrigation of bladder		T	0164	2.0077	\$127.88		\$25.58
51701	Insert bladder catheter		X	0340	0.6310	\$40.19		\$8.04
51702	Insert temp bladder cath		X	0340	0.6310	\$40.19		\$8.04
51703	Insert bladder cath, complex		T	0126	1.0356	\$65.96	\$16.21	\$13.19
51705	Change of bladder tube	CH	T	0164	2.0077	\$127.88		\$25.58
51710	Change of bladder tube	CH	T	0427	15.3545	\$977.99		\$195.60
51715	Endoscopic injection/implant		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
51720	Treatment of bladder lesion		T	0164	2.0077	\$127.88		\$25.58
51725	Simple cystometrogram	CH	T	0156	3.0469	\$194.07		\$38.81
51726	Complex cystometrogram		T	0156	3.0469	\$194.07		\$38.81
51736	Urine flow measurement		T	0126	1.0356	\$65.96	\$16.21	\$13.19
51741	Electro-uroflowmetry, first		T	0126	1.0356	\$65.96	\$16.21	\$13.19
51772	Urethra pressure profile		T	0164	2.0077	\$127.88		\$25.58
51784	Anal/urinary muscle study		T	0126	1.0356	\$65.96	\$16.21	\$13.19
51785	Anal/urinary muscle study	CH	T	0164	2.0077	\$127.88		\$25.58
51792	Urinary reflex study		T	0126	1.0356	\$65.96	\$16.21	\$13.19
51795	Urine voiding pressure study		T	0164	2.0077	\$127.88		\$25.58
51797	Intraabdominal pressure test		T	0164	2.0077	\$127.88		\$25.58
51798	Us urine capacity measure		X	0340	0.6310	\$40.19		\$8.04
51800	Revision of bladder/urethra		C					
51820	Revision of urinary tract		C					
51840	Attach bladder/urethra		C					
51841	Attach bladder/urethra		C					
51845	Repair bladder neck		C					
51860	Repair of bladder wound		C					
51865	Repair of bladder wound		C					
51880	Repair of bladder opening		T	0162	24.7749	\$1,578.01		\$315.60
51900	Repair bladder/vagina lesion		C					
51920	Close bladder-uterus fistula		C					
51925	Hysterectomy/bladder repair		C					
51940	Correction of bladder defect		C					
51960	Revision of bladder & bowel		C					
51980	Construct bladder opening		C					
51990	Laparo urethral suspension		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
51992	Laparo sling operation		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
51999	Laparoscope proc, bla		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
52000	Cystoscopy		T	0160	5.9735	\$380.48		\$76.10
52001	Cystoscopy, removal of clots	CH	T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
52005	Cystoscopy & ureter catheter		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
52007	Cystoscopy and biopsy	CH	T	0162	24.7749	\$1,578.01		\$315.60
52010	Cystoscopy & duct catheter		T	0160	5.9735	\$380.48		\$76.10
52204	Cystoscopy w/biopsy(s)		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
52214	Cystoscopy and treatment		T	0162	24.7749	\$1,578.01		\$315.60
52224	Cystoscopy and treatment		T	0162	24.7749	\$1,578.01		\$315.60
52234	Cystoscopy and treatment		T	0162	24.7749	\$1,578.01		\$315.60
52235	Cystoscopy and treatment		T	0162	24.7749	\$1,578.01		\$315.60
52240	Cystoscopy and treatment		T	0162	24.7749	\$1,578.01		\$315.60
52250	Cystoscopy and radiotracer		T	0162	24.7749	\$1,578.01		\$315.60
52260	Cystoscopy and treatment		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
52265	Cystoscopy and treatment		T	0160	5.9735	\$380.48		\$76.10
52270	Cystoscopy & revise urethra		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
52275	Cystoscopy & revise urethra	CH	T	0162	24.7749	\$1,578.01		\$315.60
52276	Cystoscopy and treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
52277	Cystoscopy and treatment		T	0162	24.7749	\$1,578.01		\$315.60
52281	Cystoscopy and treatment		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
52282	Cystoscopy, implant stent		T	0163	36.0774	\$2,297.91		\$459.58
52283	Cystoscopy and treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
52285	Cystoscopy and treatment		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
52290	Cystoscopy and treatment		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
52300	Cystoscopy and treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
52301	Cystoscopy and treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
52305	Cystoscopy and treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
52310	Cystoscopy and treatment	CH	T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
52315	Cystoscopy and treatment	CH	T	0162	24.7749	\$1,578.01		\$315.60
52317	Remove bladder stone		T	0162	24.7749	\$1,578.01		\$315.60
52318	Remove bladder stone		T	0162	24.7749	\$1,578.01		\$315.60
52320	Cystoscopy and treatment		T	0162	24.7749	\$1,578.01		\$315.60
52325	Cystoscopy, stone removal		T	0162	24.7749	\$1,578.01		\$315.60
52327	Cystoscopy, inject material		T	0162	24.7749	\$1,578.01		\$315.60
52330	Cystoscopy and treatment		T	0162	24.7749	\$1,578.01		\$315.60
52332	Cystoscopy and treatment		T	0162	24.7749	\$1,578.01		\$315.60
52334	Create passage to kidney		T	0162	24.7749	\$1,578.01		\$315.60
52341	Cysto w/ureter stricture tx		T	0162	24.7749	\$1,578.01		\$315.60
52342	Cysto w/up stricture tx		T	0162	24.7749	\$1,578.01		\$315.60
52343	Cysto w/renal stricture tx		T	0162	24.7749	\$1,578.01		\$315.60
52344	Cysto/uretero, stricture tx		T	0162	24.7749	\$1,578.01		\$315.60
52345	Cysto/uretero w/up stricture		T	0162	24.7749	\$1,578.01		\$315.60
52346	Cystouretero w/renal strict		T	0162	24.7749	\$1,578.01		\$315.60

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
52351	Cystouretero & or pyeloscope	CH	T	0162	24.7749	\$1,578.01		\$315.60
52352	Cystouretero w/stone remove		T	0162	24.7749	\$1,578.01		\$315.60
52353	Cystouretero w/lithotripsy		T	0163	36.0774	\$2,297.91		\$459.58
52354	Cystouretero w/biopsy		T	0162	24.7749	\$1,578.01		\$315.60
52355	Cystouretero w/excise tumor		T	0162	24.7749	\$1,578.01		\$315.60
52400	Cystouretero w/congen repr		T	0162	24.7749	\$1,578.01		\$315.60
52402	Cystourethro cut ejacul duct		T	0162	24.7749	\$1,578.01		\$315.60
52450	Incision of prostate		T	0162	24.7749	\$1,578.01		\$315.60
52500	Revision of bladder neck		T	0162	24.7749	\$1,578.01		\$315.60
52510	Dilation prostatic urethra	CH	D					
52601	Prostatectomy (TURP)		T	0163	36.0774	\$2,297.91		\$459.58
52606	Control postop bleeding		T	0162	24.7749	\$1,578.01		\$315.60
52612	Prostatectomy, first stage		T	0163	36.0774	\$2,297.91		\$459.58
52614	Prostatectomy, second stage		T	0163	36.0774	\$2,297.91		\$459.58
52620	Remove residual prostate		T	0163	36.0774	\$2,297.91		\$459.58
52630	Remove prostate regrowth		T	0163	36.0774	\$2,297.91		\$459.58
52640	Relieve bladder contracture		T	0162	24.7749	\$1,578.01		\$315.60
52647	Laser surgery of prostate		T	0429	45.2042	\$2,879.24		\$575.85
52648	Laser surgery of prostate		T	0429	45.2042	\$2,879.24		\$575.85
52649	Prostate laser enucleation	NI	T	0429	45.2042	\$2,879.24		\$575.85
52700	Drainage of prostate abscess		T	0162	24.7749	\$1,578.01		\$315.60
53000	Incision of urethra		T	0166	19.1505	\$1,219.77		\$243.95
53010	Incision of urethra		T	0166	19.1505	\$1,219.77		\$243.95
53020	Incision of urethra		T	0166	19.1505	\$1,219.77		\$243.95
53025	Incision of urethra		T	0166	19.1505	\$1,219.77		\$243.95
53040	Drainage of urethra abscess		T	0166	19.1505	\$1,219.77		\$243.95
53060	Drainage of urethra abscess		T	0166	19.1505	\$1,219.77		\$243.95
53080	Drainage of urinary leakage		T	0166	19.1505	\$1,219.77		\$243.95
53085	Drainage of urinary leakage		T	0166	19.1505	\$1,219.77		\$243.95
53200	Biopsy of urethra		T	0166	19.1505	\$1,219.77		\$243.95
53210	Removal of urethra		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53215	Removal of urethra		T	0166	19.1505	\$1,219.77		\$243.95
53220	Treatment of urethra lesion		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53230	Removal of urethra lesion		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53235	Removal of urethra lesion		T	0166	19.1505	\$1,219.77		\$243.95
53240	Surgery for urethra pouch		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53250	Removal of urethra gland		T	0166	19.1505	\$1,219.77		\$243.95
53260	Treatment of urethra lesion		T	0166	19.1505	\$1,219.77		\$243.95
53265	Treatment of urethra lesion		T	0166	19.1505	\$1,219.77		\$243.95
53270	Removal of urethra gland		T	0166	19.1505	\$1,219.77		\$243.95
53275	Repair of urethra defect		T	0166	19.1505	\$1,219.77		\$243.95
53400	Revise urethra, stage 1		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53405	Revise urethra, stage 2		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53410	Reconstruction of urethra		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53415	Reconstruction of urethra	C						
53420	Reconstruct urethra, stage 1		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53425	Reconstruct urethra, stage 2		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53430	Reconstruction of urethra		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53431	Reconstruct urethra/bladder		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53440	Male sling procedure		S	0385	83.6366	\$5,327.15		\$1,065.43
53442	Remove/revise male sling		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53444	Insert tandem cuff		S	0385	83.6366	\$5,327.15		\$1,065.43
53445	Insert uro/ves nck sphincter		S	0386	144.1246	\$9,179.87		\$1,835.97
53446	Remove uro sphincter		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53447	Remove/replace ur sphincter		S	0386	144.1246	\$9,179.87		\$1,835.97
53448	Remov/replic ur sphinctr comp		C					
53449	Repair uro sphincter		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53450	Revision of urethra		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53460	Revision of urethra		T	0166	19.1505	\$1,219.77		\$243.95
53500	Urethrlly, transvag w/ scope		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53502	Repair of urethra injury		T	0166	19.1505	\$1,219.77		\$243.95
53505	Repair of urethra injury		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53510	Repair of urethra injury		T	0166	19.1505	\$1,219.77		\$243.95
53515	Repair of urethra injury		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53520	Repair of urethra defect		T	0168	29.7864	\$1,897.21	\$388.16	\$379.44
53600	Dilate urethra stricture		T	0156	3.0469	\$194.07		\$38.81
53601	Dilate urethra stricture		T	0126	1.0356	\$65.96	\$16.21	\$13.19
53605	Dilate urethra stricture		T	0161	17.9420	\$1,142.80	\$241.15	\$228.56
53620	Dilate urethra stricture		T	0165	19.3414	\$1,231.93		\$246.39
53621	Dilate urethra stricture		T	0164	2.0077	\$127.88		\$25.58
53660	Dilation of urethra		T	0126	1.0356	\$65.96	\$16.21	\$13.19
53661	Dilation of urethra		T	0126	1.0356	\$65.96	\$16.21	\$13.19
53665	Dilation of urethra		T	0166	19.1505	\$1,219.77		\$243.95
53850	Prostatic microwave thermotx	CH	T	0429	45.2042	\$2,879.24		\$575.85
53852	Prostatic rf thermotx	CH	T	0429	45.2042	\$2,879.24		\$575.85
53853	Prostatic water thermother		T	0162	24.7749	\$1,578.01		\$315.60
53899	Urology surgery procedure		T	0126	1.0356	\$65.96	\$16.21	\$13.19
54000	Slitting of prepuce		T	0166	19.1505	\$1,219.77		\$243.95
54001	Slitting of prepuce		T	0166	19.1505	\$1,219.77		\$243.95
54015	Drain penis lesion		T	0008	18.3197	\$1,166.85		\$233.37

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
54050	Destruction, penis lesion(s)	CH	T	0015	1.4595	\$92.96		\$18.59
54055	Destruction, penis lesion(s)		T	0017	19.9041	\$1,267.77		\$253.55
54056	Cryosurgery, penis lesion(s)	CH	T	0013	0.7930	\$50.51		\$10.10
54057	Laser surg, penis lesion(s)		T	0017	19.9041	\$1,267.77		\$253.55
54060	Excision of penis lesion(s)		T	0017	19.9041	\$1,267.77		\$253.55
54065	Destruction, penis lesion(s)	CH	T	0017	19.9041	\$1,267.77		\$253.55
54100	Biopsy of penis		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
54105	Biopsy of penis		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
54110	Treatment of penis lesion		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54111	Treat penis lesion, graft		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54112	Treat penis lesion, graft		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54115	Treatment of penis lesion		T	0008	18.3197	\$1,166.85		\$233.37
54120	Partial removal of penis		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54125	Removal of penis		C					
54130	Remove penis & nodes		C					
54135	Remove penis & nodes		C					
54150	Circumcision w/regionl block	CH	T	0183	22.3251	\$1,421.97		\$284.39
54160	Circumcision, neonate	CH	T	0183	22.3251	\$1,421.97		\$284.39
54161	Circum 28 days or older	CH	T	0183	22.3251	\$1,421.97		\$284.39
54162	Lysis penil circumic lesion	CH	T	0183	22.3251	\$1,421.97		\$284.39
54163	Repair of circumcision	CH	T	0183	22.3251	\$1,421.97		\$284.39
54164	Frenulotomy of penis	CH	T	0183	22.3251	\$1,421.97		\$284.39
54200	Treatment of penis lesion		T	0164	2.0077	\$127.88		\$25.58
54205	Treatment of penis lesion		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54220	Treatment of penis lesion		T	0164	2.0077	\$127.88		\$25.58
54230	Prepare penis study		N					
54231	Dynamic cavernosometry		T	0165	19.3414	\$1,231.93		\$246.39
54235	Penile injection		T	0164	2.0077	\$127.88		\$25.58
54240	Penis study		T	0126	1.0356	\$65.96	\$16.21	\$13.19
54250	Penis study		T	0164	2.0077	\$127.88		\$25.58
54300	Revision of penis		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54304	Revision of penis		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54308	Reconstruction of urethra		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54312	Reconstruction of urethra		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54316	Reconstruction of urethra		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54318	Reconstruction of urethra		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54322	Reconstruction of urethra		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54324	Reconstruction of urethra		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54326	Reconstruction of urethra		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54328	Revise penis/urethra		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54332	Revise penis/urethra		C					
54336	Revise penis/urethra		C					
54340	Secondary urethral surgery		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54344	Secondary urethral surgery		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54348	Secondary urethral surgery		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54352	Reconstruct urethra/penis		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54360	Penis plastic surgery		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54380	Repair penis		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54385	Repair penis		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54390	Repair penis and bladder		C					
54400	Insert semi-rigid prosthesis		S	0385	83.6366	\$5,327.15		\$1,065.43
54401	Insert self-contd prosthesis		S	0386	144.1246	\$9,179.87		\$1,835.97
54405	Insert multi-comp penis pros		S	0386	144.1246	\$9,179.87		\$1,835.97
54406	Remove multi-comp penis pros		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54408	Repair multi-comp penis pros		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54410	Remove/replace penis prosth		S	0386	144.1246	\$9,179.87		\$1,835.97
54411	Remov/replc penis pros, comp		C					
54415	Remove self-contd penis pros		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54416	Remv/replc penis contain pros		S	0386	144.1246	\$9,179.87		\$1,835.97
54417	Remv/replc penis pros, compl		C					
54420	Revision of penis		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54430	Revision of penis		C					
54435	Revision of penis		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54440	Repair of penis		T	0181	33.9306	\$2,161.18	\$621.82	\$432.24
54450	Preputial stretching		T	0156	3.0469	\$194.07		\$38.81
54500	Biopsy of testis		T	0037	13.5764	\$864.74	\$228.76	\$172.95
54505	Biopsy of testis		T	0183	22.3251	\$1,421.97		\$284.39
54512	Excise lesion testis		T	0183	22.3251	\$1,421.97		\$284.39
54520	Removal of testis		T	0183	22.3251	\$1,421.97		\$284.39
54522	Orchiectomy, partial		T	0183	22.3251	\$1,421.97		\$284.39
54530	Removal of testis		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
54535	Extensive testis surgery		C					
54550	Exploration for testis		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
54560	Exploration for testis		T	0183	22.3251	\$1,421.97		\$284.39
54600	Reduce testis torsion		T	0183	22.3251	\$1,421.97		\$284.39
54620	Suspension of testis		T	0183	22.3251	\$1,421.97		\$284.39
54640	Suspension of testis		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
54650	Orchiopexy (Fowler-Stephens)		C					
54660	Revision of testis		T	0183	22.3251	\$1,421.97		\$284.39
54670	Repair testis injury		T	0183	22.3251	\$1,421.97		\$284.39

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
54680	Relocation of testis(es)		T	0183	22.3251	\$1,421.97		\$284.39
54690	Laparoscopy, orchiectomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
54692	Laparoscopy, orchiopexy		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
54699	Laparoscope proc, testis		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
54700	Drainage of scrotum		T	0183	22.3251	\$1,421.97		\$284.39
54800	Biopsy of epididymis		T	0004	4.3270	\$275.60		\$55.12
54830	Remove epididymis lesion		T	0183	22.3251	\$1,421.97		\$284.39
54840	Remove epididymis lesion		T	0183	22.3251	\$1,421.97		\$284.39
54860	Removal of epididymis		T	0183	22.3251	\$1,421.97		\$284.39
54861	Removal of epididymis		T	0183	22.3251	\$1,421.97		\$284.39
54865	Explore epididymis		T	0183	22.3251	\$1,421.97		\$284.39
54900	Fusion of spermatic ducts		T	0183	22.3251	\$1,421.97		\$284.39
54901	Fusion of spermatic ducts		T	0183	22.3251	\$1,421.97		\$284.39
55000	Drainage of hydrocele		T	0004	4.3270	\$275.60		\$55.12
55040	Removal of hydrocele		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
55041	Removal of hydroceles		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
55060	Repair of hydrocele		T	0183	22.3251	\$1,421.97		\$284.39
55100	Drainage of scrotum abscess		T	0007	11.5594	\$736.26		\$147.25
55110	Explore scrotum		T	0183	22.3251	\$1,421.97		\$284.39
55120	Removal of scrotum lesion		T	0183	22.3251	\$1,421.97		\$284.39
55150	Removal of scrotum		T	0183	22.3251	\$1,421.97		\$284.39
55175	Revision of scrotum		T	0183	22.3251	\$1,421.97		\$284.39
55180	Revision of scrotum		T	0183	22.3251	\$1,421.97		\$284.39
55200	Incision of sperm duct		T	0183	22.3251	\$1,421.97		\$284.39
55250	Removal of sperm duct(s)		T	0183	22.3251	\$1,421.97		\$284.39
55300	Prepare, sperm duct x-ray		N					
55400	Repair of sperm duct		T	0183	22.3251	\$1,421.97		\$284.39
55450	Ligation of sperm duct		T	0183	22.3251	\$1,421.97		\$284.39
55500	Removal of hydrocele		T	0183	22.3251	\$1,421.97		\$284.39
55520	Removal of sperm cord lesion		T	0183	22.3251	\$1,421.97		\$284.39
55530	Revise spermatic cord veins		T	0183	22.3251	\$1,421.97		\$284.39
55535	Revise spermatic cord veins		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
55540	Revise hernia & sperm veins		T	0154	30.6788	\$1,954.06	\$464.85	\$390.81
55550	Laparo ligate spermatic vein		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
55559	Laparo proc, spermatic cord		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
55600	Incise sperm duct pouch		T	0183	22.3251	\$1,421.97		\$284.39
55605	Incise sperm duct pouch		C					
55650	Remove sperm duct pouch		C					
55680	Remove sperm pouch lesion		T	0183	22.3251	\$1,421.97		\$284.39
55700	Biopsy of prostate		T	0184	11.0338	\$702.79		\$140.56
55705	Biopsy of prostate		T	0184	11.0338	\$702.79		\$140.56
55720	Drainage of prostate abscess		T	0162	24.7749	\$1,578.01		\$315.60
55725	Drainage of prostate abscess		T	0162	24.7749	\$1,578.01		\$315.60
55801	Removal of prostate		C					
55810	Extensive prostate surgery		C					
55812	Extensive prostate surgery		C					
55815	Extensive prostate surgery		C					
55821	Removal of prostate		C					
55831	Removal of prostate		C					
55840	Extensive prostate surgery		C					
55842	Extensive prostate surgery		C					
55845	Extensive prostate surgery		C					
55860	Surgical exposure, prostate		T	0165	19.3414	\$1,231.93		\$246.39
55862	Extensive prostate surgery		C					
55865	Extensive prostate surgery		C					
55866	Laparo radical prostatectomy		C					
55870	Electroejaculation	CH	T	0189	2.7584	\$175.69		\$35.14
55873	Cryoablate prostate		T	0674	122.7133	\$7,816.10		\$1,563.22
55875	Transperi needle place, pros	CH	Q	0163	36.0774	\$2,297.91		\$459.58
55876	Place rt device/marker, pros		T	0156	3.0469	\$194.07		\$38.81
55899	Genital surgery procedure		T	0126	1.0356	\$65.96	\$16.21	\$13.19
55920	Place needles pelvic for rt	NI	T	0153	25.6947	\$1,636.60	\$397.95	\$327.32
55970	Sex transformation, M to F		E					
55980	Sex transformation, F to M		E					
56405	I & D of vulva/perineum		T	0189	2.7584	\$175.69		\$35.14
56420	Drainage of gland abscess		T	0188	1.3520	\$86.11		\$17.22
56440	Surgery for vulva lesion	CH	T	0193	19.0203	\$1,211.48		\$242.30
56441	Lysis of labial lesion(s)		T	0193	19.0203	\$1,211.48		\$242.30
56442	Hymenotomy		T	0193	19.0203	\$1,211.48		\$242.30
56501	Destroy, vulva lesions, sim		T	0017	19.9041	\$1,267.77		\$253.55
56515	Destroy vulva lesion/s compl	CH	T	0017	19.9041	\$1,267.77		\$253.55
56605	Biopsy of vulva/perineum	CH	T	0189	2.7584	\$175.69		\$35.14
56606	Biopsy of vulva/perineum	CH	T	0188	1.3520	\$86.11		\$17.22
56620	Partial removal of vulva	CH	T	0193	19.0203	\$1,211.48		\$242.30
56625	Complete removal of vulva	CH	T	0193	19.0203	\$1,211.48		\$242.30
56630	Extensive vulva surgery		C					
56631	Extensive vulva surgery		C					
56632	Extensive vulva surgery		C					
56633	Extensive vulva surgery		C					
56634	Extensive vulva surgery		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
56637	Extensive vulva surgery		C					
56640	Extensive vulva surgery		C					
56700	Partial removal of hymen	CH	T	0193	19.0203	\$1,211.48		\$242.30
56740	Remove vagina gland lesion	CH	T	0193	19.0203	\$1,211.48		\$242.30
56800	Repair of vagina	CH	T	0193	19.0203	\$1,211.48		\$242.30
56805	Repair clitoris		T	0193	19.0203	\$1,211.48		\$242.30
56810	Repair of perineum	CH	T	0193	19.0203	\$1,211.48		\$242.30
56820	Exam of vulva w/scope		T	0188	1.3520	\$86.11		\$17.22
56821	Exam/biopsy of vulva w/scope	CH	T	0188	1.3520	\$86.11		\$17.22
57000	Exploration of vagina		T	0193	19.0203	\$1,211.48		\$242.30
57010	Drainage of pelvic abscess		T	0193	19.0203	\$1,211.48		\$242.30
57020	Drainage of pelvic fluid		T	0192	6.0783	\$387.15		\$77.43
57022	I & d vaginal hematoma, pp		T	0007	11.5594	\$736.26		\$147.25
57023	I & d vag hematoma, non-ob		T	0008	18.3197	\$1,166.85		\$233.37
57061	Destroy vag lesions, simple	CH	T	0193	19.0203	\$1,211.48		\$242.30
57065	Destroy vag lesions, complex	CH	T	0193	19.0203	\$1,211.48		\$242.30
57100	Biopsy of vagina		T	0192	6.0783	\$387.15		\$77.43
57105	Biopsy of vagina	CH	T	0193	19.0203	\$1,211.48		\$242.30
57106	Remove vagina wall, partial	CH	T	0193	19.0203	\$1,211.48		\$242.30
57107	Remove vagina tissue, part		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57109	Vaginectomy partial w/nodes		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57110	Remove vagina wall, complete		C					
57111	Remove vagina tissue, compl		C					
57112	Vaginectomy w/nodes, compl		C					
57120	Closure of vagina		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57130	Remove vagina lesion	CH	T	0193	19.0203	\$1,211.48		\$242.30
57135	Remove vagina lesion	CH	T	0193	19.0203	\$1,211.48		\$242.30
57150	Treat vagina infection	CH	T	0188	1.3520	\$86.11		\$17.22
57155	Insert uteri tandems/ovoids		T	0192	6.0783	\$387.15		\$77.43
57160	Insert pessary/other device		T	0188	1.3520	\$86.11		\$17.22
57170	Fitting of diaphragm/cap		T	0191	0.1309	\$8.34	\$2.36	\$1.67
57180	Treat vaginal bleeding	CH	T	0188	1.3520	\$86.11		\$17.22
57200	Repair of vagina	CH	T	0193	19.0203	\$1,211.48		\$242.30
57210	Repair vagina/perineum	CH	T	0193	19.0203	\$1,211.48		\$242.30
57220	Revision of urethra		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
57230	Repair of urethral lesion		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57240	Repair bladder & vagina		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57250	Repair rectum & vagina		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57260	Repair of vagina		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57265	Extensive repair of vagina		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
57267	Insert mesh/pelvic flr addon		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57268	Repair of bowel bulge		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57270	Repair of bowel pouch		C					
57280	Suspension of vagina		C					
57282	Colpopexy, extraperitoneal		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
57283	Colpopexy, intraperitoneal		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
57284	Repair paravag defect, open		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
57285	Repair paravag defect, vag	NI	T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57287	Revise/remove sling repair		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57288	Repair bladder defect		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
57289	Repair bladder & vagina		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57291	Construction of vagina		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57292	Construct vagina with graft		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57295	Revise vag graft via vagina	CH	T	0193	19.0203	\$1,211.48		\$242.30
57296	Revise vag graft, open abd		C					
57300	Repair rectum-vagina fistula		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57305	Repair rectum-vagina fistula		C					
57307	Fistula repair & colostomy		C					
57308	Fistula repair, transperine		C					
57310	Repair urethrovaginal lesion		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
57311	Repair urethrovaginal lesion		C					
57320	Repair bladder-vagina lesion		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57330	Repair bladder-vagina lesion		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57335	Repair vagina		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57400	Dilation of vagina	CH	T	0193	19.0203	\$1,211.48		\$242.30
57410	Pelvic examination		T	0193	19.0203	\$1,211.48		\$242.30
57415	Remove vaginal foreign body	CH	T	0193	19.0203	\$1,211.48		\$242.30
57420	Exam of vagina w/scope		T	0189	2.7584	\$175.69		\$35.14
57421	Exam/biopsy of vag w/scope		T	0189	2.7584	\$175.69		\$35.14
57423	Repair paravag defect, lap	NI	T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
57425	Laparoscopy, surg, colpopexy		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
57452	Exam of cervix w/scope	CH	T	0189	2.7584	\$175.69		\$35.14
57454	Bx/curett of cervix w/scope		T	0189	2.7584	\$175.69		\$35.14
57455	Biopsy of cervix w/scope		T	0189	2.7584	\$175.69		\$35.14
57456	Endocerv curettage w/scope		T	0189	2.7584	\$175.69		\$35.14
57460	Bx of cervix w/scope, leep		T	0193	19.0203	\$1,211.48		\$242.30
57461	Conz of cervix w/scope, leep	CH	T	0193	19.0203	\$1,211.48		\$242.30
57500	Biopsy of cervix	CH	T	0192	6.0783	\$387.15		\$77.43
57505	Endocervical curettage	CH	T	0192	6.0783	\$387.15		\$77.43
57510	Cauterization of cervix		T	0193	19.0203	\$1,211.48		\$242.30

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
57511	Cryocautery of cervix		T	0188	1.3520	\$86.11		\$17.22
57513	Laser surgery of cervix		T	0193	19.0203	\$1,211.48		\$242.30
57520	Conization of cervix	CH	T	0193	19.0203	\$1,211.48		\$242.30
57522	Conization of cervix	CH	T	0193	19.0203	\$1,211.48		\$242.30
57530	Removal of cervix		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57531	Removal of cervix, radical		C					
57540	Removal of residual cervix		C					
57545	Remove cervix/repair pelvis		C					
57550	Removal of residual cervix		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57555	Remove cervix/repair vagina		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
57556	Remove cervix, repair bowel		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
57558	D&c of cervical stump	CH	T	0193	19.0203	\$1,211.48		\$242.30
57700	Revision of cervix	CH	T	0193	19.0203	\$1,211.48		\$242.30
57720	Revision of cervix	CH	T	0193	19.0203	\$1,211.48		\$242.30
57800	Dilation of cervical canal		T	0193	19.0203	\$1,211.48		\$242.30
58100	Biopsy of uterus lining		T	0188	1.3520	\$86.11		\$17.22
58110	Bx done w/colposcopy add-on	CH	N					
58120	Dilation and curettage	CH	T	0193	19.0203	\$1,211.48		\$242.30
58140	Myomectomy abdom method		C					
58145	Myomectomy vag method		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58146	Myomectomy abdom complex		C					
58150	Total hysterectomy		C					
58152	Total hysterectomy		C					
58180	Partial hysterectomy		C					
58200	Extensive hysterectomy		C					
58210	Extensive hysterectomy		C					
58240	Removal of pelvis contents		C					
58260	Vaginal hysterectomy		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58262	Vag hyst including t/o		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58263	Vag hyst w/t/o & vag repair		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58267	Vag hyst w/urinary repair		C					
58270	Vag hyst w/enterocele repair		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58275	Hysterectomy/revise vagina		C					
58280	Hysterectomy/revise vagina		C					
58285	Extensive hysterectomy		C					
58290	Vag hyst complex		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
58291	Vag hyst incl t/o, complex		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
58292	Vag hyst t/o & repair, compl		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
58293	Vag hyst w/uro repair, compl		C					
58294	Vag hyst w/enterocele, compl		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
58300	Insert intrauterine device		E					
58301	Remove intrauterine device		T	0188	1.3520	\$86.11		\$17.22
58321	Artificial insemination	CH	T	0189	2.7584	\$175.69		\$35.14
58322	Artificial insemination	CH	T	0189	2.7584	\$175.69		\$35.14
58323	Sperm washing	CH	T	0189	2.7584	\$175.69		\$35.14
58340	Catheter for hystero-graphy		N					
58345	Reopen fallopian tube		T	0193	19.0203	\$1,211.48		\$242.30
58346	Insert heyman uteri capsule		T	0193	19.0203	\$1,211.48		\$242.30
58350	Reopen fallopian tube		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58353	Endometr ablate, thermal		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58356	Endometrial cryoablation		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
58400	Suspension of uterus		C					
58410	Suspension of uterus		C					
58520	Repair of ruptured uterus		C					
58540	Revision of uterus		C					
58541	Lsh, uterus 250 g or less		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58542	Lsh w/t/o ut 250 g or less		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58543	Lsh uterus above 250 g		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58544	Lsh w/t/o uterus above 250 g		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58545	Laparoscopic myomectomy		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
58546	Laparo-myomectomy, complex		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58548	Lap radical hyst		C					
58550	Laparo-asst vag hysterectomy		T	0132	69.6652	\$4,437.26	\$1,239.22	\$887.45
58552	Laparo-vag hyst incl t/o		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58553	Laparo-vag hyst, complex		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58554	Laparo-vag hyst w/t/o, compl		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58555	Hysteroscopy, dx, sep proc		T	0190	21.6576	\$1,379.46	\$424.28	\$275.89
58558	Hysteroscopy, biopsy		T	0190	21.6576	\$1,379.46	\$424.28	\$275.89
58559	Hysteroscopy, lysis		T	0190	21.6576	\$1,379.46	\$424.28	\$275.89
58560	Hysteroscopy, resect septum		T	0387	34.2048	\$2,178.64	\$655.55	\$435.73
58561	Hysteroscopy, remove myoma		T	0387	34.2048	\$2,178.64	\$655.55	\$435.73
58562	Hysteroscopy, remove fb		T	0190	21.6576	\$1,379.46	\$424.28	\$275.89
58563	Hysteroscopy, ablation		T	0387	34.2048	\$2,178.64	\$655.55	\$435.73
58565	Hysteroscopy, sterilization		T	0202	42.7099	\$2,720.36	\$981.50	\$544.07
58570	Tlh, uterus 250 g or less		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58571	Tlh w/t/o 250 g or less	NI	T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58572	Tlh, uterus over 250 g	NI	T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58573	Tlh w/t/o uterus over 250 g	NI	T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58578	Laparo proc, uterus		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
58579	Hysteroscope procedure		T	0190	21.6576	\$1,379.46	\$424.28	\$275.89

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
58600	Division of fallopian tube		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58605	Division of fallopian tube		C					
58611	Ligate oviduct(s) add-on		C					
58615	Occlude fallopian tube(s)	CH	T	0193	19.0203	\$1,211.48		\$242.30
58660	Laparoscopy, lysis		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58661	Laparoscopy, remove adnexa		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58662	Laparoscopy, excise lesions		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58670	Laparoscopy, tubal cauterly		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58671	Laparoscopy, tubal block		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58672	Laparoscopy, fimbrioplasty		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58673	Laparoscopy, salpingostomy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
58679	Laparo proc, oviduct-ovary		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
58700	Removal of fallopian tube		C					
58720	Removal of ovary/tube(s)		C					
58740	Revise fallopian tube(s)		C					
58750	Repair oviduct		C					
58752	Revise ovarian tube(s)		C					
58760	Remove tubal obstruction		C					
58770	Create new tubal opening		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58800	Drainage of ovarian cyst(s)		T	0193	19.0203	\$1,211.48		\$242.30
58805	Drainage of ovarian cyst(s)	CH	T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58820	Drain ovary abscess, open		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58822	Drain ovary abscess, percut		C					
58823	Drain pelvic abscess, percut		T	0193	19.0203	\$1,211.48		\$242.30
58825	Transposition, ovary(s)		C					
58900	Biopsy of ovary(s)		T	0193	19.0203	\$1,211.48		\$242.30
58920	Partial removal of ovary(s)		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58925	Removal of ovarian cyst(s)		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
58940	Removal of ovary(s)		C					
58943	Removal of ovary(s)		C					
58950	Resect ovarian malignancy		C					
58951	Resect ovarian malignancy		C					
58952	Resect ovarian malignancy		C					
58953	Tah, rad dissect for debulk		C					
58954	Tah rad debulk/lymph remove		C					
58956	Bso, omentectomy w/tah		C					
58957	Resect recurrent gyn mal		C					
58958	Resect recur gyn mal w/lym		C					
58960	Exploration of abdomen		C					
58970	Retrieval of oocyte	CH	T	0189	2.7584	\$175.69		\$35.14
58974	Transfer of embryo	CH	T	0189	2.7584	\$175.69		\$35.14
58976	Transfer of embryo	CH	T	0189	2.7584	\$175.69		\$35.14
58999	Genital surgery procedure		T	0191	0.1309	\$8.34	\$2.36	\$1.67
59000	Amniocentesis, diagnostic	CH	T	0189	2.7584	\$175.69		\$35.14
59001	Amniocentesis, therapeutic		T	0192	6.0783	\$387.15		\$77.43
59012	Fetal cord puncture, prenatal	CH	T	0189	2.7584	\$175.69		\$35.14
59015	Chorion biopsy	CH	T	0189	2.7584	\$175.69		\$35.14
59020	Fetal contract stress test	CH	T	0188	1.3520	\$86.11		\$17.22
59025	Fetal non-stress test	CH	T	0188	1.3520	\$86.11		\$17.22
59030	Fetal scalp blood sample	CH	T	0189	2.7584	\$175.69		\$35.14
59050	Fetal monitor w/report		M					
59051	Fetal monitor/interpret only		B					
59070	Transabdom amnioinfus w/us	CH	T	0189	2.7584	\$175.69		\$35.14
59072	Umbilical cord occlud w/us	CH	T	0189	2.7584	\$175.69		\$35.14
59074	Fetal fluid drainage w/us	CH	T	0189	2.7584	\$175.69		\$35.14
59076	Fetal shunt placement, w/us	CH	T	0189	2.7584	\$175.69		\$35.14
59100	Remove uterus lesion		T	0195	32.4237	\$2,065.20	\$483.80	\$413.04
59120	Treat ectopic pregnancy		C					
59121	Treat ectopic pregnancy		C					
59130	Treat ectopic pregnancy		C					
59135	Treat ectopic pregnancy		C					
59136	Treat ectopic pregnancy		C					
59140	Treat ectopic pregnancy		C					
59150	Treat ectopic pregnancy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
59151	Treat ectopic pregnancy		T	0131	45.5317	\$2,900.10	\$1,001.89	\$580.02
59160	D & c after delivery	CH	T	0193	19.0203	\$1,211.48		\$242.30
59200	Insert cervical dilator		T	0189	2.7584	\$175.69		\$35.14
59300	Episiotomy or vaginal repair		T	0193	19.0203	\$1,211.48		\$242.30
59320	Revision of cervix	CH	T	0193	19.0203	\$1,211.48		\$242.30
59325	Revision of cervix		C					
59350	Repair of uterus		C					
59400	Obstetrical care		B					
59409	Obstetrical care	CH	T	0193	19.0203	\$1,211.48		\$242.30
59410	Obstetrical care		B					
59412	Antepartum manipulation	CH	T	0193	19.0203	\$1,211.48		\$242.30
59414	Deliver placenta		T	0193	19.0203	\$1,211.48		\$242.30
59425	Antepartum care only		B					
59426	Antepartum care only		B					
59430	Care after delivery		B					
59510	Cesarean delivery		B					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
59514	Cesarean delivery only		C					
59515	Cesarean delivery		B					
59525	Remove uterus after cesarean		C					
59610	Vbac delivery		B					
59612	Vbac delivery only	CH	T	0193	19.0203	\$1,211.48		\$242.30
59614	Vbac care after delivery		B					
59618	Attempted vbac delivery		B					
59620	Attempted vbac delivery only		C					
59622	Attempted vbac after care		B					
59812	Treatment of miscarriage	CH	T	0193	19.0203	\$1,211.48		\$242.30
59820	Care of miscarriage	CH	T	0193	19.0203	\$1,211.48		\$242.30
59821	Treatment of miscarriage	CH	T	0193	19.0203	\$1,211.48		\$242.30
59830	Treat uterus infection		C					
59840	Abortion	CH	T	0193	19.0203	\$1,211.48		\$242.30
59841	Abortion	CH	T	0193	19.0203	\$1,211.48		\$242.30
59850	Abortion		C					
59851	Abortion		C					
59852	Abortion		C					
59855	Abortion		C					
59856	Abortion		C					
59857	Abortion		C					
59866	Abortion (mpr)	CH	T	0189	2.7584	\$175.69		\$35.14
59870	Evacuate mole of uterus	CH	T	0193	19.0203	\$1,211.48		\$242.30
59871	Remove cerclage suture	CH	T	0193	19.0203	\$1,211.48		\$242.30
59897	Fetal invas px w/us	CH	T	0189	2.7584	\$175.69		\$35.14
59898	Laparo proc, ob care/deliver		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
59899	Maternity care procedure	CH	T	0191	0.1309	\$8.34	\$2.36	\$1.67
60000	Drain thyroid/tongue cyst		T	0252	7.4474	\$474.35	\$109.16	\$94.87
60001	Aspirate/inject thyroid cyst	CH	D					
6005F	Care level rationale doc		M					
60100	Biopsy of thyroid		T	0004	4.3270	\$275.60		\$55.12
6010F	Dysphag test done b/4 eating		M					
6015F	Dysphag test done b/4 eating		M					
60200	Remove thyroid lesion		T	0114	44.3240	\$2,823.17		\$564.63
6020F	Npo (nothing-mouth) ordered		M					
60210	Partial thyroid excision		T	0114	44.3240	\$2,823.17		\$564.63
60212	Partial thyroid excision		T	0114	44.3240	\$2,823.17		\$564.63
60220	Partial removal of thyroid		T	0114	44.3240	\$2,823.17		\$564.63
60225	Partial removal of thyroid		T	0114	44.3240	\$2,823.17		\$564.63
60240	Removal of thyroid		T	0114	44.3240	\$2,823.17		\$564.63
60252	Removal of thyroid		T	0256	39.8776	\$2,539.96		\$507.99
60254	Extensive thyroid surgery		C					
60260	Repeat thyroid surgery		T	0256	39.8776	\$2,539.96		\$507.99
60270	Removal of thyroid		C					
60271	Removal of thyroid	CH	T	0256	39.8776	\$2,539.96		\$507.99
60280	Remove thyroid duct lesion		T	0114	44.3240	\$2,823.17		\$564.63
60281	Remove thyroid duct lesion		T	0114	44.3240	\$2,823.17		\$564.63
60300	Aspir/inj thyroid cyst	NI	T	0004	4.3270	\$275.60		\$55.12
6030F	Max sterile barriers follw'd	NI	M					
60500	Explore parathyroid glands		T	0256	39.8776	\$2,539.96		\$507.99
60502	Re-explore parathyroids		T	0256	39.8776	\$2,539.96		\$507.99
60505	Explore parathyroid glands		C					
60512	Autotransplant parathyroid		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
60520	Removal of thymus gland		T	0256	39.8776	\$2,539.96		\$507.99
60521	Removal of thymus gland		C					
60522	Removal of thymus gland		C					
60540	Explore adrenal gland		C					
60545	Explore adrenal gland		C					
60600	Remove carotid body lesion		C					
60605	Remove carotid body lesion		C					
60650	Laparoscopy adrenalectomy		C					
60659	Laparo proc, endocrine		T	0130	34.3958	\$2,190.81	\$659.53	\$438.16
60699	Endocrine surgery procedure		T	0114	44.3240	\$2,823.17		\$564.63
61000	Remove cranial cavity fluid		T	0212	8.5263	\$543.07		\$108.61
61001	Remove cranial cavity fluid		T	0212	8.5263	\$543.07		\$108.61
61020	Remove brain cavity fluid		T	0212	8.5263	\$543.07		\$108.61
61026	Injection into brain canal		T	0212	8.5263	\$543.07		\$108.61
61050	Remove brain canal fluid		T	0212	8.5263	\$543.07		\$108.61
61055	Injection into brain canal		T	0212	8.5263	\$543.07		\$108.61
61070	Brain canal shunt procedure	CH	T	0121	3.2383	\$206.26	\$43.80	\$41.25
61105	Twist drill hole		C					
61107	Drill skull for implantation		C					
61108	Drill skull for drainage		C					
61120	Burr hole for puncture		C					
61140	Pierce skull for biopsy		C					
61150	Pierce skull for drainage		C					
61151	Pierce skull for drainage		C					
61154	Pierce skull & remove clot		C					
61156	Pierce skull for drainage		C					
61210	Pierce skull, implant device		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
61215	Insert brain-fluid device		T	0224	36.2768	\$2,310.61		\$462.12
61250	Pierce skull & explore		C					
61253	Pierce skull & explore		C					
61304	Open skull for exploration		C					
61305	Open skull for exploration		C					
61312	Open skull for drainage		C					
61313	Open skull for drainage		C					
61314	Open skull for drainage		C					
61315	Open skull for drainage		C					
61316	Implt cran bone flap to abdo		C					
61320	Open skull for drainage		C					
61321	Open skull for drainage		C					
61322	Decompressive craniotomy		C					
61323	Decompressive lobectomy		C					
61330	Decompress eye socket		T	0256	39.8776	\$2,539.96		\$507.99
61332	Explore/biopsy eye socket		C					
61333	Explore orbit/remove lesion		C					
61334	Explore orbit/remove object		T	0256	39.8776	\$2,539.96		\$507.99
61340	Subtemporal decompression		C					
61343	Incise skull (press relief)		C					
61345	Relieve cranial pressure		C					
61440	Incise skull for surgery		C					
61450	Incise skull for surgery		C					
61458	Incise skull for brain wound		C					
61460	Incise skull for surgery		C					
61470	Incise skull for surgery		C					
61480	Incise skull for surgery		C					
61490	Incise skull for surgery		C					
61500	Removal of skull lesion		C					
61501	Remove infected skull bone		C					
61510	Removal of brain lesion		C					
61512	Remove brain lining lesion		C					
61514	Removal of brain abscess		C					
61516	Removal of brain lesion		C					
61517	Implt brain chemotx add-on		C					
61518	Removal of brain lesion		C					
61519	Remove brain lining lesion		C					
61520	Removal of brain lesion		C					
61521	Removal of brain lesion		C					
61522	Removal of brain abscess		C					
61524	Removal of brain lesion		C					
61526	Removal of brain lesion		C					
61530	Removal of brain lesion		C					
61531	Implant brain electrodes		C					
61533	Implant brain electrodes		C					
61534	Removal of brain lesion		C					
61535	Remove brain electrodes		C					
61536	Removal of brain lesion		C					
61537	Removal of brain tissue		C					
61538	Removal of brain tissue		C					
61539	Removal of brain tissue		C					
61540	Removal of brain tissue		C					
61541	Incision of brain tissue		C					
61542	Removal of brain tissue		C					
61543	Removal of brain tissue		C					
61544	Remove & treat brain lesion		C					
61545	Excision of brain tumor		C					
61546	Removal of pituitary gland		C					
61548	Removal of pituitary gland		C					
61550	Release of skull seams		C					
61552	Release of skull seams		C					
61556	Incise skull/sutures		C					
61557	Incise skull/sutures		C					
61558	Excision of skull/sutures		C					
61559	Excision of skull/sutures		C					
61563	Excision of skull tumor		C					
61564	Excision of skull tumor		C					
61566	Removal of brain tissue		C					
61567	Incision of brain tissue		C					
61570	Remove foreign body, brain		C					
61571	Incise skull for brain wound		C					
61575	Skull base/brainstem surgery		C					
61576	Skull base/brainstem surgery		C					
61580	Craniofacial approach, skull		C					
61581	Craniofacial approach, skull		C					
61582	Craniofacial approach, skull		C					
61583	Craniofacial approach, skull		C					
61584	Orbitocranial approach/skull		C					
61585	Orbitocranial approach/skull		C					
61586	Resect nasopharynx, skull		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
61590	Infratemporal approach/skull		C					
61591	Infratemporal approach/skull		C					
61592	Orbitocranial approach/skull		C					
61595	Trans temporal approach/skull		C					
61596	Transcochlear approach/skull		C					
61597	Transcondylar approach/skull		C					
61598	Transpetrosal approach/skull		C					
61600	Resect/excise cranial lesion		C					
61601	Resect/excise cranial lesion		C					
61605	Resect/excise cranial lesion		C					
61606	Resect/excise cranial lesion		C					
61607	Resect/excise cranial lesion		C					
61608	Resect/excise cranial lesion		C					
61609	Transect artery, sinus		C					
61610	Transect artery, sinus		C					
61611	Transect artery, sinus		C					
61612	Transect artery, sinus		C					
61613	Remove aneurysm, sinus		C					
61615	Resect/excise lesion, skull		C					
61616	Resect/excise lesion, skull		C					
61618	Repair dura		C					
61619	Repair dura		C					
61623	Endovasc tempory vessel occl	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
61624	Transcath occlusion, cns		C					
61626	Transcath occlusion, non-cns	CH	T	0082	87.5137	\$5,574.10		\$1,114.82
61630	Intracranial angioplasty		E					
61635	Intracran angioplasty w/stent		E					
61640	Dilate ic vasospasm, init		E					
61641	Dilate ic vasospasm add-on		E					
61642	Dilate ic vasospasm add-on		E					
61680	Intracranial vessel surgery		C					
61682	Intracranial vessel surgery		C					
61684	Intracranial vessel surgery		C					
61686	Intracranial vessel surgery		C					
61690	Intracranial vessel surgery		C					
61692	Intracranial vessel surgery		C					
61697	Brain aneurysm repr, complx		C					
61698	Brain aneurysm repr, complx		C					
61700	Brain aneurysm repr, simple		C					
61702	Inner skull vessel surgery		C					
61703	Clamp neck artery		C					
61705	Revise circulation to head		C					
61708	Revise circulation to head		C					
61710	Revise circulation to head		C					
61711	Fusion of skull arteries		C					
61720	Incise skull/brain surgery		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
61735	Incise skull/brain surgery		C					
61750	Incise skull/brain biopsy		C					
61751	Brain biopsy w/ct/mr guide		C					
61760	Implant brain electrodes		C					
61770	Incise skull for treatment	CH	T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
61790	Treat trigeminal nerve		T	0220	18.0518	\$1,149.79		\$229.96
61791	Treat trigeminal tract	CH	T	0203	14.4879	\$922.79	\$240.33	\$184.56
61793	Focus radiation beam		B					
61795	Brain surgery using computer	CH	N					
61850	Implant neuroelectrodes		C					
61860	Implant neuroelectrodes		C					
61863	Implant neuroelectrode		C					
61864	Implant neuroelectrde, addl		C					
61867	Implant neuroelectrode		C					
61868	Implant neuroelectrde, add'l		C					
61870	Implant neuroelectrodes		C					
61875	Implant neuroelectrodes		C					
61880	Revise/remove neuroelectrode		T	0687	22.4734	\$1,431.42	\$438.47	\$286.28
61885	Insrt/redo neurostim 1 array		S	0039	186.4739	\$11,877.27		\$2,375.45
61886	Implant neurostim arrays	CH	S	0315	270.0190	\$17,198.59		\$3,439.72
61888	Revise/remove neuroreceiver		T	0688	34.4166	\$2,192.13	\$874.57	\$438.43
62000	Treat skull fracture		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
62005	Treat skull fracture		C					
62010	Treatment of head injury		C					
62100	Repair brain fluid leakage		C					
62115	Reduction of skull defect		C					
62116	Reduction of skull defect		C					
62117	Reduction of skull defect		C					
62120	Repair skull cavity lesion		C					
62121	Incise skull repair		C					
62140	Repair of skull defect		C					
62141	Repair of skull defect		C					
62142	Remove skull plate/flap		C					
62143	Replace skull plate/flap		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
62145	Repair of skull & brain		C					
62146	Repair of skull with graft		C					
62147	Repair of skull with graft		C					
62148	Retr bone flap to fix skull		C					
62160	Neuroendoscopy add-on	CH	N					
62161	Dissect brain w/scope		C					
62162	Remove colloid cyst w/scope		C					
62163	Neuroendoscopy w/fb removal		C					
62164	Remove brain tumor w/scope		C					
62165	Remove pituit tumor w/scope		C					
62180	Establish brain cavity shunt		C					
62190	Establish brain cavity shunt		C					
62192	Establish brain cavity shunt		C					
62194	Replace/irrigate catheter	CH	T	0212	8.5263	\$543.07		\$108.61
62200	Establish brain cavity shunt		C					
62201	Brain cavity shunt w/scope		C					
62220	Establish brain cavity shunt		C					
62223	Establish brain cavity shunt		C					
62225	Replace/irrigate catheter		T	0427	15.3545	\$977.99		\$195.60
62230	Replace/revise brain shunt		T	0224	36.2768	\$2,310.61		\$462.12
62252	Csf shunt reprogram		S	0691	2.3269	\$148.21	\$50.49	\$29.64
62256	Remove brain cavity shunt		C					
62258	Replace brain cavity shunt		C					
62263	Epidural lysis mult sessions		T	0203	14.4879	\$922.79	\$240.33	\$184.56
62264	Epidural lysis on single day		T	0203	14.4879	\$922.79	\$240.33	\$184.56
62268	Drain spinal cord cyst		T	0212	8.5263	\$543.07		\$108.61
62269	Needle biopsy, spinal cord		T	0685	9.3354	\$594.61		\$118.92
62270	Spinal fluid tap, diagnostic	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
62272	Drain cerebro spinal fluid	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
62273	Inject epidural patch		T	0206	4.0964	\$260.92	\$56.01	\$52.18
62280	Treat spinal cord lesion		T	0207	7.0546	\$449.34		\$89.87
62281	Treat spinal cord lesion		T	0207	7.0546	\$449.34		\$89.87
62282	Treat spinal canal lesion		T	0207	7.0546	\$449.34		\$89.87
62284	Injection for myelogram		N					
62287	Percutaneous diskectomy		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
62290	Inject for spine disk x-ray		N					
62291	Inject for spine disk x-ray		N					
62292	Injection into disk lesion		T	0212	8.5263	\$543.07		\$108.61
62294	Injection into spinal artery		T	0212	8.5263	\$543.07		\$108.61
62310	Inject spine c/t		T	0207	7.0546	\$449.34		\$89.87
62311	Inject spine l/s (cd)		T	0207	7.0546	\$449.34		\$89.87
62318	Inject spine w/cath, c/t		T	0207	7.0546	\$449.34		\$89.87
62319	Inject spine w/cath l/s (cd)		T	0207	7.0546	\$449.34		\$89.87
62350	Implant spinal canal cath	CH	T	0224	36.2768	\$2,310.61		\$462.12
62351	Implant spinal canal cath		T	0208	46.7724	\$2,979.12		\$595.82
62355	Remove spinal canal catheter		T	0203	14.4879	\$922.79	\$240.33	\$184.56
62360	Insert spine infusion device	CH	T	0224	36.2768	\$2,310.61		\$462.12
62361	Implant spine infusion pump		T	0227	183.8928	\$11,712.87		\$2,342.57
62362	Implant spine infusion pump		T	0227	183.8928	\$11,712.87		\$2,342.57
62365	Remove spine infusion device		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
62367	Analyze spine infusion pump		S	0691	2.3269	\$148.21	\$50.49	\$29.64
62368	Analyze spine infusion pump		S	0691	2.3269	\$148.21	\$50.49	\$29.64
63001	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63003	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63005	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63011	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63012	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63015	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63016	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63017	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63020	Neck spine disk surgery		T	0208	46.7724	\$2,979.12		\$595.82
63030	Low back disk surgery		T	0208	46.7724	\$2,979.12		\$595.82
63035	Spinal disk surgery add-on		T	0208	46.7724	\$2,979.12		\$595.82
63040	Laminotomy, single cervical		T	0208	46.7724	\$2,979.12		\$595.82
63042	Laminotomy, single lumbar		T	0208	46.7724	\$2,979.12		\$595.82
63043	Laminotomy, add'l cervical		C					
63044	Laminotomy, add'l lumbar		C					
63045	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63046	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63047	Removal of spinal lamina		T	0208	46.7724	\$2,979.12		\$595.82
63048	Remove spinal lamina add-on		T	0208	46.7724	\$2,979.12		\$595.82
63050	Cervical laminoplasty		C					
63051	C-laminoplasty w/graff/plate		C					
63055	Decompress spinal cord		T	0208	46.7724	\$2,979.12		\$595.82
63056	Decompress spinal cord		T	0208	46.7724	\$2,979.12		\$595.82
63057	Decompress spine cord add-on		T	0208	46.7724	\$2,979.12		\$595.82
63064	Decompress spinal cord		T	0208	46.7724	\$2,979.12		\$595.82
63066	Decompress spine cord add-on		T	0208	46.7724	\$2,979.12		\$595.82
63075	Neck spine disk surgery		T	0208	46.7724	\$2,979.12		\$595.82
63076	Neck spine disk surgery		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
63077	Spine disk surgery, thorax		C					
63078	Spine disk surgery, thorax		C					
63081	Removal of vertebral body		C					
63082	Remove vertebral body add-on		C					
63085	Removal of vertebral body		C					
63086	Remove vertebral body add-on		C					
63087	Removal of vertebral body		C					
63088	Remove vertebral body add-on		C					
63090	Removal of vertebral body		C					
63091	Remove vertebral body add-on		C					
63101	Removal of vertebral body		C					
63102	Removal of vertebral body		C					
63103	Remove vertebral body add-on		C					
63170	Incise spinal cord tract(s)		C					
63172	Drainage of spinal cyst		C					
63173	Drainage of spinal cyst		C					
63180	Revise spinal cord ligaments		C					
63182	Revise spinal cord ligaments		C					
63185	Incise spinal column/nerves		C					
63190	Incise spinal column/nerves		C					
63191	Incise spinal column/nerves		C					
63194	Incise spinal column & cord		C					
63195	Incise spinal column & cord		C					
63196	Incise spinal column & cord		C					
63197	Incise spinal column & cord		C					
63198	Incise spinal column & cord		C					
63199	Incise spinal column & cord		C					
63200	Release of spinal cord		C					
63250	Revise spinal cord vessels		C					
63251	Revise spinal cord vessels		C					
63252	Revise spinal cord vessels		C					
63265	Excise intraspinal lesion		C					
63266	Excise intraspinal lesion		C					
63267	Excise intraspinal lesion		C					
63268	Excise intraspinal lesion		C					
63270	Excise intraspinal lesion		C					
63271	Excise intraspinal lesion		C					
63272	Excise intraspinal lesion		C					
63273	Excise intraspinal lesion		C					
63275	Biopsy/excise spinal tumor		C					
63276	Biopsy/excise spinal tumor		C					
63277	Biopsy/excise spinal tumor		C					
63278	Biopsy/excise spinal tumor		C					
63280	Biopsy/excise spinal tumor		C					
63281	Biopsy/excise spinal tumor		C					
63282	Biopsy/excise spinal tumor		C					
63283	Biopsy/excise spinal tumor		C					
63285	Biopsy/excise spinal tumor		C					
63286	Biopsy/excise spinal tumor		C					
63287	Biopsy/excise spinal tumor		C					
63290	Biopsy/excise spinal tumor		C					
63295	Repair of laminectomy defect		C					
63300	Removal of vertebral body		C					
63301	Removal of vertebral body		C					
63302	Removal of vertebral body		C					
63303	Removal of vertebral body		C					
63304	Removal of vertebral body		C					
63305	Removal of vertebral body		C					
63306	Removal of vertebral body		C					
63307	Removal of vertebral body		C					
63308	Remove vertebral body add-on		C					
63600	Remove spinal cord lesion		T	0220	18.0518	\$1,149.79		\$229.96
63610	Stimulation of spinal cord		T	0220	18.0518	\$1,149.79		\$229.96
63615	Remove lesion of spinal cord		T	0220	18.0518	\$1,149.79		\$229.96
63650	Implant neuroelectrodes		S	0040	63.7866	\$4,062.82		\$812.56
63655	Implant neuroelectrodes		S	0061	82.8597	\$5,277.67		\$1,055.53
63660	Revise/remove neuroelectrode		T	0687	22.4734	\$1,431.42	\$438.47	\$286.28
63685	Instl/reedo spine n generator	CH	S	0222	240.7990	\$15,337.45		\$3,067.49
63688	Revise/remove neuroreceiver		T	0688	34.4166	\$2,192.13	\$874.57	\$438.43
63700	Repair of spinal herniation		C					
63702	Repair of spinal herniation		C					
63704	Repair of spinal herniation		C					
63706	Repair of spinal herniation		C					
63707	Repair spinal fluid leakage		C					
63709	Repair spinal fluid leakage		C					
63710	Graft repair of spine defect		C					
63740	Install spinal shunt		C					
63741	Install spinal shunt	CH	T	0224	36.2768	\$2,310.61		\$462.12
63744	Revision of spinal shunt	CH	T	0224	36.2768	\$2,310.61		\$462.12
63746	Removal of spinal shunt		T	0109	5.6614	\$360.60		\$72.12

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
64400	N block inj, trigeminal		T	0204	2.3213	\$147.85	\$40.13	\$29.57
64402	N block inj, facial		T	0204	2.3213	\$147.85	\$40.13	\$29.57
64405	N block inj, occipital	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64408	N block inj, vagus	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64410	N block inj, phrenic	CH	T	0207	7.0546	\$449.34		\$89.87
64412	N block inj, spinal accessor	CH	T	0207	7.0546	\$449.34		\$89.87
64413	N block inj, cervical plexus	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64415	N block inj, brachial plexus	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64416	N block cont infuse, b plex	CH	T	0207	7.0546	\$449.34		\$89.87
64417	N block inj, axillary	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64418	N block inj, suprascapular	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64420	N block inj, intercost, sng	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64421	N block inj, intercost, mlt		T	0206	4.0964	\$260.92	\$56.01	\$52.18
64425	N block inj, ilio-ing/hypogi	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64430	N block inj, pudendal	CH	T	0207	7.0546	\$449.34		\$89.87
64435	N block inj, paracervical	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64445	N block inj, sciatic, sng	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64446	N blk inj, sciatic, cont inf	CH	T	0203	14.4879	\$922.79	\$240.33	\$184.56
64447	N block inj fem, single	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64448	N block inj fem, cont inf	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64449	N block inj, lumbar plexus	CH	T	0207	7.0546	\$449.34		\$89.87
64450	N block, other peripheral	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64470	Inj paravertebral c/t		T	0207	7.0546	\$449.34		\$89.87
64472	Inj paravertebral c/t add-on		T	0206	4.0964	\$260.92	\$56.01	\$52.18
64475	Inj paravertebral l/s		T	0207	7.0546	\$449.34		\$89.87
64476	Inj paravertebral l/s add-on	CH	T	0204	2.3213	\$147.85	\$40.13	\$29.57
64479	Inj foramen epidural c/t		T	0207	7.0546	\$449.34		\$89.87
64480	Inj foramen epidural add-on	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64483	Inj foramen epidural l/s		T	0207	7.0546	\$449.34		\$89.87
64484	Inj foramen epidural add-on	CH	T	0206	4.0964	\$260.92	\$56.01	\$52.18
64505	N block, sphenopalatine gangl		T	0204	2.3213	\$147.85	\$40.13	\$29.57
64508	N block, carotid sinus s/p		T	0204	2.3213	\$147.85	\$40.13	\$29.57
64510	N block, stellate ganglion		T	0207	7.0546	\$449.34		\$89.87
64517	N block inj, hypogas plxs	CH	T	0207	7.0546	\$449.34		\$89.87
64520	N block, lumbar/thoracic		T	0207	7.0546	\$449.34		\$89.87
64530	N block inj, celiac pelus		T	0207	7.0546	\$449.34		\$89.87
64550	Apply neurostimulator		A					
64553	Implant neuroelectrodes		S	0225	220.7642	\$14,061.35		\$2,812.27
64555	Implant neuroelectrodes		S	0040	63.7866	\$4,062.82		\$812.56
64560	Implant neuroelectrodes		S	0040	63.7866	\$4,062.82		\$812.56
64561	Implant neuroelectrodes		S	0040	63.7866	\$4,062.82		\$812.56
64565	Implant neuroelectrodes		S	0040	63.7866	\$4,062.82		\$812.56
64573	Implant neuroelectrodes		S	0225	220.7642	\$14,061.35		\$2,812.27
64575	Implant neuroelectrodes		S	0061	82.8597	\$5,277.67		\$1,055.53
64577	Implant neuroelectrodes		S	0061	82.8597	\$5,277.67		\$1,055.53
64580	Implant neuroelectrodes		S	0061	82.8597	\$5,277.67		\$1,055.53
64581	Implant neuroelectrodes		S	0061	82.8597	\$5,277.67		\$1,055.53
64585	Revise/remove neuroelectrode		T	0687	22.4734	\$1,431.42	\$438.47	\$286.28
64590	Insrt/redo pn/gastr stimul	CH	S	0039	186.4739	\$11,877.27		\$2,375.45
64595	Revise/rmv pn/gastr stimul		T	0688	34.4166	\$2,192.13	\$874.57	\$438.43
64600	Injection treatment of nerve		T	0203	14.4879	\$922.79	\$240.33	\$184.56
64605	Injection treatment of nerve		T	0203	14.4879	\$922.79	\$240.33	\$184.56
64610	Injection treatment of nerve		T	0203	14.4879	\$922.79	\$240.33	\$184.56
64612	Destroy nerve, face muscle		T	0204	2.3213	\$147.85	\$40.13	\$29.57
64613	Destroy nerve, neck muscle		T	0204	2.3213	\$147.85	\$40.13	\$29.57
64614	Destroy nerve, extrem musc		T	0204	2.3213	\$147.85	\$40.13	\$29.57
64620	Injection treatment of nerve	CH	T	0207	7.0546	\$449.34		\$89.87
64622	Destr paravertebrl nerve l/s		T	0203	14.4879	\$922.79	\$240.33	\$184.56
64623	Destr paravertebral n add-on		T	0207	7.0546	\$449.34		\$89.87
64626	Destr paravertebrl nerve c/t		T	0203	14.4879	\$922.79	\$240.33	\$184.56
64627	Destr paravertebral n add-on	CH	T	0204	2.3213	\$147.85	\$40.13	\$29.57
64630	Injection treatment of nerve	CH	T	0207	7.0546	\$449.34		\$89.87
64640	Injection treatment of nerve	CH	T	0207	7.0546	\$449.34		\$89.87
64650	Chemodenerg eccrine glands		T	0204	2.3213	\$147.85	\$40.13	\$29.57
64653	Chemodenerg eccrine glands		T	0204	2.3213	\$147.85	\$40.13	\$29.57
64680	Injection treatment of nerve	CH	T	0203	14.4879	\$922.79	\$240.33	\$184.56
64681	Injection treatment of nerve		T	0203	14.4879	\$922.79	\$240.33	\$184.56
64702	Revise finger/toe nerve		T	0220	18.0518	\$1,149.79		\$229.96
64704	Revise hand/foot nerve		T	0220	18.0518	\$1,149.79		\$229.96
64708	Revise arm/leg nerve		T	0220	18.0518	\$1,149.79		\$229.96
64712	Revision of sciatic nerve		T	0220	18.0518	\$1,149.79		\$229.96
64713	Revision of arm nerve(s)		T	0220	18.0518	\$1,149.79		\$229.96
64714	Revise low back nerve(s)		T	0220	18.0518	\$1,149.79		\$229.96
64716	Revision of cranial nerve		T	0220	18.0518	\$1,149.79		\$229.96
64718	Revise ulnar nerve at elbow		T	0220	18.0518	\$1,149.79		\$229.96
64719	Revise ulnar nerve at wrist		T	0220	18.0518	\$1,149.79		\$229.96
64721	Carpal tunnel surgery		T	0220	18.0518	\$1,149.79		\$229.96
64722	Relieve pressure on nerve(s)		T	0220	18.0518	\$1,149.79		\$229.96
64726	Release foot/toe nerve		T	0220	18.0518	\$1,149.79		\$229.96
64727	Internal nerve revision		T	0220	18.0518	\$1,149.79		\$229.96

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
64732	Incision of brow nerve		T	0220	18.0518	\$1,149.79		\$229.96
64734	Incision of cheek nerve		T	0220	18.0518	\$1,149.79		\$229.96
64736	Incision of chin nerve		T	0220	18.0518	\$1,149.79		\$229.96
64738	Incision of jaw nerve		T	0220	18.0518	\$1,149.79		\$229.96
64740	Incision of tongue nerve		T	0220	18.0518	\$1,149.79		\$229.96
64742	Incision of facial nerve		T	0220	18.0518	\$1,149.79		\$229.96
64744	Incise nerve, back of head		T	0220	18.0518	\$1,149.79		\$229.96
64746	Incise diaphragm nerve		T	0220	18.0518	\$1,149.79		\$229.96
64752	Incision of vagus nerve		C					
64755	Incision of stomach nerves		C					
64760	Incision of vagus nerve		C					
64761	Incision of pelvis nerve		T	0220	18.0518	\$1,149.79		\$229.96
64763	Incise hip/thigh nerve		T	0220	18.0518	\$1,149.79		\$229.96
64766	Incise hip/thigh nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64771	Sever cranial nerve		T	0220	18.0518	\$1,149.79		\$229.96
64772	Incision of spinal nerve		T	0220	18.0518	\$1,149.79		\$229.96
64774	Remove skin nerve lesion		T	0220	18.0518	\$1,149.79		\$229.96
64776	Remove digit nerve lesion		T	0220	18.0518	\$1,149.79		\$229.96
64778	Digit nerve surgery add-on		T	0220	18.0518	\$1,149.79		\$229.96
64782	Remove limb nerve lesion		T	0220	18.0518	\$1,149.79		\$229.96
64783	Limb nerve surgery add-on		T	0220	18.0518	\$1,149.79		\$229.96
64784	Remove nerve lesion		T	0220	18.0518	\$1,149.79		\$229.96
64786	Remove sciatic nerve lesion		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64787	Implant nerve end		T	0220	18.0518	\$1,149.79		\$229.96
64788	Remove skin nerve lesion		T	0220	18.0518	\$1,149.79		\$229.96
64790	Removal of nerve lesion		T	0220	18.0518	\$1,149.79		\$229.96
64792	Removal of nerve lesion		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64795	Biopsy of nerve		T	0220	18.0518	\$1,149.79		\$229.96
64802	Remove sympathetic nerves		T	0220	18.0518	\$1,149.79		\$229.96
64804	Remove sympathetic nerves		T	0220	18.0518	\$1,149.79		\$229.96
64809	Remove sympathetic nerves		C					
64818	Remove sympathetic nerves		C					
64820	Remove sympathetic nerves		T	0220	18.0518	\$1,149.79		\$229.96
64821	Remove sympathetic nerves		T	0054	26.3105	\$1,675.82		\$335.16
64822	Remove sympathetic nerves		T	0054	26.3105	\$1,675.82		\$335.16
64823	Remove sympathetic nerves		T	0054	26.3105	\$1,675.82		\$335.16
64831	Repair of digit nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64832	Repair nerve add-on		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64834	Repair of hand or foot nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64835	Repair of hand or foot nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64836	Repair of hand or foot nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64837	Repair nerve add-on		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64840	Repair of leg nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64856	Repair/transpose nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64857	Repair arm/leg nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64858	Repair sciatic nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64859	Nerve surgery		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64861	Repair of arm nerves		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64862	Repair of low back nerves		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64864	Repair of facial nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64865	Repair of facial nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64866	Fusion of facial/other nerve		C					
64868	Fusion of facial/other nerve		C					
64870	Fusion of facial/other nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64872	Subsequent repair of nerve		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64874	Repair & revise nerve add-on		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64876	Repair nerve/shorten bone		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64885	Nerve graft, head or neck		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64886	Nerve graft, head or neck		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64890	Nerve graft, hand or foot		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64891	Nerve graft, hand or foot		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64892	Nerve graft, arm or leg		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64893	Nerve graft, arm or leg		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64895	Nerve graft, hand or foot		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64896	Nerve graft, hand or foot		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64897	Nerve graft, arm or leg		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64898	Nerve graft, arm or leg		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64901	Nerve graft add-on		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64902	Nerve graft add-on		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64905	Nerve pedicle transfer		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64907	Nerve pedicle transfer		T	0221	33.2707	\$2,119.14	\$463.62	\$423.83
64910	Nerve repair w/allograft		T	0220	18.0518	\$1,149.79		\$229.96
64911	Neurography w/vein autograft		T	0220	18.0518	\$1,149.79		\$229.96
64999	Nervous system surgery		T	0204	2.3213	\$147.85	\$40.13	\$29.57
65091	Revise eye		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
65093	Revise eye with implant		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
65101	Removal of eye		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
65103	Remove eye/insert implant		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
65105	Remove eye/attach implant		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
65110	Removal of eye		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
65112	Remove eye/revise socket		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
65114	Remove eye/revise socket		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
65125	Revise ocular implant		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
65130	Insert ocular implant		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
65135	Insert ocular implant		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
65140	Attach ocular implant		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
65150	Revise ocular implant		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
65155	Reinsert ocular implant		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
65175	Removal of ocular implant		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
65205	Remove foreign body from eye		S	0698	0.8696	\$55.39		\$11.08
65210	Remove foreign body from eye		S	0698	0.8696	\$55.39		\$11.08
65220	Remove foreign body from eye		S	0698	0.8696	\$55.39		\$11.08
65222	Remove foreign body from eye		S	0698	0.8696	\$55.39		\$11.08
65235	Remove foreign body from eye		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65260	Remove foreign body from eye		T	0236	18.2350	\$1,161.46		\$232.29
65265	Remove foreign body from eye		T	0237	27.8450	\$1,773.56		\$354.71
65270	Repair of eye wound		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
65272	Repair of eye wound		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
65273	Repair of eye wound		C					
65275	Repair of eye wound		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
65280	Repair of eye wound		T	0236	18.2350	\$1,161.46		\$232.29
65285	Repair of eye wound		T	0672	37.2078	\$2,369.91		\$473.98
65286	Repair of eye wound		T	0232	5.1169	\$325.92	\$81.65	\$65.18
65290	Repair of eye socket wound		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
65400	Removal of eye lesion		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65410	Biopsy of cornea		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65420	Removal of eye lesion		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65426	Removal of eye lesion		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
65430	Corneal smear		S	0698	0.8696	\$55.39		\$11.08
65435	Curette/treat cornea		T	0239	7.2847	\$463.99		\$92.80
65436	Curette/treat cornea		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65450	Treatment of corneal lesion		S	0231	2.1790	\$138.79		\$27.76
65600	Revision of cornea		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
65710	Corneal transplant		T	0244	37.4896	\$2,387.86	\$803.26	\$477.57
65730	Corneal transplant		T	0244	37.4896	\$2,387.86	\$803.26	\$477.57
65750	Corneal transplant		T	0244	37.4896	\$2,387.86	\$803.26	\$477.57
65755	Corneal transplant		T	0244	37.4896	\$2,387.86	\$803.26	\$477.57
65760	Revision of cornea		E					
65765	Revision of cornea		E					
65767	Corneal tissue transplant		E					
65770	Revise cornea with implant		T	0293	84.8039	\$5,401.50	\$1,128.29	\$1,080.30
65771	Radial keratotomy		E					
65772	Correction of astigmatism		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65775	Correction of astigmatism		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65780	Ocular reconst, transplant		T	0244	37.4896	\$2,387.86	\$803.26	\$477.57
65781	Ocular reconst, transplant		T	0244	37.4896	\$2,387.86	\$803.26	\$477.57
65782	Ocular reconst, transplant		T	0244	37.4896	\$2,387.86	\$803.26	\$477.57
65800	Drainage of eye		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65805	Drainage of eye		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65810	Drainage of eye		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
65815	Drainage of eye		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
65820	Relieve inner eye pressure		T	0232	5.1169	\$325.92	\$81.65	\$65.18
65850	Incision of eye		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
65855	Laser surgery of eye		T	0247	5.2001	\$331.22	\$104.31	\$66.24
65860	Incise inner eye adhesions		T	0247	5.2001	\$331.22	\$104.31	\$66.24
65865	Incise inner eye adhesions		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65870	Incise inner eye adhesions		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
65875	Incise inner eye adhesions		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
65880	Incise inner eye adhesions		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65900	Remove eye lesion		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
65920	Remove implant of eye		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
65930	Remove blood clot from eye		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66020	Injection treatment of eye		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
66030	Injection treatment of eye		T	0232	5.1169	\$325.92	\$81.65	\$65.18
66130	Remove eye lesion		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66150	Glaucoma surgery		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66155	Glaucoma surgery		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66160	Glaucoma surgery		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66165	Glaucoma surgery		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66170	Glaucoma surgery		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66172	Incision of eye		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66180	Implant eye shunt		T	0673	39.7101	\$2,529.30	\$649.56	\$505.86
66185	Revise eye shunt		T	0673	39.7101	\$2,529.30	\$649.56	\$505.86
66220	Repair eye lesion		T	0672	37.2078	\$2,369.91		\$473.98
66225	Repair/graft eye lesion		T	0673	39.7101	\$2,529.30	\$649.56	\$505.86
66250	Follow-up surgery of eye		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
66500	Incision of iris		T	0232	5.1169	\$325.92	\$81.65	\$65.18
66505	Incision of iris		T	0232	5.1169	\$325.92	\$81.65	\$65.18
66600	Remove iris and lesion		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66605	Removal of iris		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
66625	Removal of iris		T	0232	5.1169	\$325.92	\$81.65	\$65.18
66630	Removal of iris		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66635	Removal of iris		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66680	Repair iris & ciliary body		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66682	Repair iris & ciliary body		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66700	Destruction, ciliary body		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
66710	Ciliary transsleral therapy		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
66711	Ciliary endoscopic ablation		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
66720	Destruction, ciliary body		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
66740	Destruction, ciliary body		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66761	Revision of iris		T	0247	5.2001	\$331.22	\$104.31	\$66.24
66762	Revision of iris		T	0247	5.2001	\$331.22	\$104.31	\$66.24
66770	Removal of inner eye lesion		T	0247	5.2001	\$331.22	\$104.31	\$66.24
66820	Incision, secondary cataract		T	0232	5.1169	\$325.92	\$81.65	\$65.18
66821	After cataract laser surgery		T	0247	5.2001	\$331.22	\$104.31	\$66.24
66825	Reposition intraocular lens		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
66830	Removal of lens lesion		T	0232	5.1169	\$325.92	\$81.65	\$65.18
66840	Removal of lens material		T	0245	14.9171	\$950.13	\$217.05	\$190.03
66850	Removal of lens material		T	0249	28.7035	\$1,828.24	\$524.67	\$365.65
66852	Removal of lens material		T	0249	28.7035	\$1,828.24	\$524.67	\$365.65
66920	Extraction of lens		T	0249	28.7035	\$1,828.24	\$524.67	\$365.65
66930	Extraction of lens		T	0249	28.7035	\$1,828.24	\$524.67	\$365.65
66940	Extraction of lens		T	0245	14.9171	\$950.13	\$217.05	\$190.03
66982	Cataract surgery, complex		T	0246	23.8649	\$1,520.05	\$495.96	\$304.01
66983	Cataract surg w/iol, 1 stage		T	0246	23.8649	\$1,520.05	\$495.96	\$304.01
66984	Cataract surg w/iol, 1 stage		T	0246	23.8649	\$1,520.05	\$495.96	\$304.01
66985	Insert lens prosthesis		T	0246	23.8649	\$1,520.05	\$495.96	\$304.01
66986	Exchange lens prosthesis		T	0246	23.8649	\$1,520.05	\$495.96	\$304.01
66990	Ophthalmic endoscope add-on		N					
66999	Eye surgery procedure		T	0232	5.1169	\$325.92	\$81.65	\$65.18
67005	Partial removal of eye fluid		T	0237	27.8450	\$1,773.56		\$354.71
67010	Partial removal of eye fluid		T	0237	27.8450	\$1,773.56		\$354.71
67015	Release of eye fluid		T	0237	27.8450	\$1,773.56		\$354.71
67025	Replace eye fluid		T	0237	27.8450	\$1,773.56		\$354.71
67027	Implant eye drug system		T	0672	37.2078	\$2,369.91		\$473.98
67028	Injection eye drug	CH	S	0231	2.1790	\$138.79		\$27.76
67030	Incise inner eye strands		T	0236	18.2350	\$1,161.46		\$232.29
67031	Laser surgery, eye strands		T	0247	5.2001	\$331.22	\$104.31	\$66.24
67036	Removal of inner eye fluid		T	0672	37.2078	\$2,369.91		\$473.98
67038	Strip retinal membrane	CH	D					
67039	Laser treatment of retina		T	0672	37.2078	\$2,369.91		\$473.98
67040	Laser treatment of retina		T	0672	37.2078	\$2,369.91		\$473.98
67041	Vit for macular pucker	NI	T	0672	37.2078	\$2,369.91		\$473.98
67042	Vit for macular hole	NI	T	0672	37.2078	\$2,369.91		\$473.98
67043	Vit for membrane dissect	NI	T	0672	37.2078	\$2,369.91		\$473.98
67101	Repair detached retina		T	0236	18.2350	\$1,161.46		\$232.29
67105	Repair detached retina	CH	T	0247	5.2001	\$331.22	\$104.31	\$66.24
67107	Repair detached retina		T	0672	37.2078	\$2,369.91		\$473.98
67108	Repair detached retina		T	0672	37.2078	\$2,369.91		\$473.98
67110	Repair detached retina		T	0236	18.2350	\$1,161.46		\$232.29
67112	Rerepair detached retina		T	0672	37.2078	\$2,369.91		\$473.98
67113	Repair retinal detach, cplx	NI	T	0672	37.2078	\$2,369.91		\$473.98
67115	Release encircling material		T	0236	18.2350	\$1,161.46		\$232.29
67120	Remove eye implant material		T	0236	18.2350	\$1,161.46		\$232.29
67121	Remove eye implant material		T	0237	27.8450	\$1,773.56		\$354.71
67141	Treatment of retina		T	0235	4.1331	\$263.25	\$58.93	\$52.65
67145	Treatment of retina	CH	T	0247	5.2001	\$331.22	\$104.31	\$66.24
67208	Treatment of retinal lesion		T	0236	18.2350	\$1,161.46		\$232.29
67210	Treatment of retinal lesion	CH	T	0247	5.2001	\$331.22	\$104.31	\$66.24
67218	Treatment of retinal lesion		T	0236	18.2350	\$1,161.46		\$232.29
67220	Treatment of choroid lesion		T	0235	4.1331	\$263.25	\$58.93	\$52.65
67221	Ocular photodynamic ther		T	0235	4.1331	\$263.25	\$58.93	\$52.65
67225	Eye photodynamic ther add-on		T	0235	4.1331	\$263.25	\$58.93	\$52.65
67227	Treatment of retinal lesion		T	0237	27.8450	\$1,773.56		\$354.71
67228	Treatment of retinal lesion	CH	T	0247	5.2001	\$331.22	\$104.31	\$66.24
67229	Tr retinal les preterm inf	NI	T	0247	5.2001	\$331.22	\$104.31	\$66.24
67250	Reinforce eye wall		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67255	Reinforce/graft eye wall		T	0237	27.8450	\$1,773.56		\$354.71
67299	Eye surgery procedure		T	0235	4.1331	\$263.25	\$58.93	\$52.65
67311	Revise eye muscle		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67312	Revise two eye muscles		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67314	Revise eye muscle		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67316	Revise two eye muscles		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67318	Revise eye muscle(s)		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67320	Revise eye muscle(s) add-on		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67331	Eye surgery follow-up add-on		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67332	Rerevise eye muscles add-on		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67334	Revise eye muscle w/suture		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67335	Eye suture during surgery		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67340	Revise eye muscle add-on		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
67343	Release eye tissue		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67345	Destroy nerve of eye muscle		T	0238	2.9022	\$184.85		\$36.97
67346	Biopsy, eye muscle		T	0699	13.7453	\$875.49		\$175.10
67399	Eye muscle surgery procedure		T	0243	24.1291	\$1,536.88	\$430.35	\$307.38
67400	Explore/biopsy eye socket		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
67405	Explore/drain eye socket		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
67412	Explore/treat eye socket		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
67413	Explore/treat eye socket		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
67414	Explr/decompress eye socket		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
67415	Aspiration, orbital contents		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67420	Explore/treat eye socket		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
67430	Explore/treat eye socket		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
67440	Explore/drain eye socket		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
67445	Explr/decompress eye socket		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
67450	Explore/biopsy eye socket		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
67500	Inject/treat eye socket		S	0231	2.1790	\$138.79		\$27.76
67505	Inject/treat eye socket		T	0238	2.9022	\$184.85		\$36.97
67515	Inject/treat eye socket		T	0238	2.9022	\$184.85		\$36.97
67550	Insert eye socket implant		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
67560	Revise eye socket implant		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
67570	Decompress optic nerve		T	0242	37.7243	\$2,402.81	\$597.36	\$480.56
67599	Orbit surgery procedure		T	0238	2.9022	\$184.85		\$36.97
67700	Drainage of eyelid abscess		T	0238	2.9022	\$184.85		\$36.97
67710	Incision of eyelid		T	0239	7.2847	\$463.99		\$92.80
67715	Incision of eyelid fold		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67800	Remove eyelid lesion		T	0238	2.9022	\$184.85		\$36.97
67801	Remove eyelid lesions		T	0239	7.2847	\$463.99		\$92.80
67805	Remove eyelid lesions		T	0238	2.9022	\$184.85		\$36.97
67808	Remove eyelid lesion(s)		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67810	Biopsy of eyelid		T	0238	2.9022	\$184.85		\$36.97
67820	Revise eyelashes		S	0698	0.8696	\$55.39		\$11.08
67825	Revise eyelashes		T	0238	2.9022	\$184.85		\$36.97
67830	Revise eyelashes		T	0239	7.2847	\$463.99		\$92.80
67835	Revise eyelashes		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67840	Remove eyelid lesion		T	0239	7.2847	\$463.99		\$92.80
67850	Treat eyelid lesion		T	0239	7.2847	\$463.99		\$92.80
67875	Closure of eyelid by suture		T	0239	7.2847	\$463.99		\$92.80
67880	Revision of eyelid		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
67882	Revision of eyelid		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67900	Repair brow defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67901	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67902	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67903	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67904	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67906	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67908	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67909	Revise eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67911	Revise eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67912	Correction eyelid w/implant		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67914	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67915	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67916	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67917	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67921	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67922	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67923	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67924	Repair eyelid defect		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67930	Repair eyelid wound		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67935	Repair eyelid wound		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67938	Remove eyelid foreign body	CH	S	0231	2.1790	\$138.79		\$27.76
67950	Revision of eyelid		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67961	Revision of eyelid		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67966	Revision of eyelid		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67971	Reconstruction of eyelid		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
67973	Reconstruction of eyelid		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
67974	Reconstruction of eyelid		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
67975	Reconstruction of eyelid		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
67999	Revision of eyelid		T	0238	2.9022	\$184.85		\$36.97
68020	Incise/drain eyelid lining		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68040	Treatment of eyelid lesions		S	0698	0.8696	\$55.39		\$11.08
68100	Biopsy of eyelid lining		T	0232	5.1169	\$325.92	\$81.65	\$65.18
68110	Remove eyelid lining lesion		T	0699	13.7453	\$875.49		\$175.10
68115	Remove eyelid lining lesion		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68130	Remove eyelid lining lesion		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
68135	Remove eyelid lining lesion		T	0239	7.2847	\$463.99		\$92.80
68200	Treat eyelid by injection	CH	S	0698	0.8696	\$55.39		\$11.08
68320	Revise/graft eyelid lining		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68325	Revise/graft eyelid lining		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68326	Revise/graft eyelid lining		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68328	Revise/graft eyelid lining		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
68330	Revise eyelid lining		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
68335	Revise/graft eyelid lining		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68340	Separate eyelid adhesions		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68360	Revise eyelid lining		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
68362	Revise eyelid lining		T	0234	23.1758	\$1,476.16	\$511.31	\$295.23
68371	Harvest eye tissue, alograft		T	0233	16.1710	\$1,030.00	\$266.33	\$206.00
68399	Eyelid lining surgery		T	0238	2.9022	\$184.85		\$36.97
68400	Incise/drain tear gland		T	0238	2.9022	\$184.85		\$36.97
68420	Incise/drain tear sac		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68440	Incise tear duct opening		T	0238	2.9022	\$184.85		\$36.97
68500	Removal of tear gland		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68505	Partial removal, tear gland		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68510	Biopsy of tear gland		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68520	Removal of tear sac		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68525	Biopsy of tear sac		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68530	Clearance of tear duct		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68540	Remove tear gland lesion		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68550	Remove tear gland lesion		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68700	Repair tear ducts		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68705	Revise tear duct opening		T	0238	2.9022	\$184.85		\$36.97
68720	Create tear sac drain		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68745	Create tear duct drain		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68750	Create tear duct drain		T	0241	24.3077	\$1,548.25	\$383.45	\$309.65
68760	Close tear duct opening		S	0231	2.1790	\$138.79		\$27.76
68761	Close tear duct opening		S	0231	2.1790	\$138.79		\$27.76
68770	Close tear system fistula		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68801	Dilate tear duct opening		S	0698	0.8696	\$55.39		\$11.08
68810	Probe nasolacrimal duct		S	0231	2.1790	\$138.79		\$27.76
68811	Probe nasolacrimal duct		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68815	Probe nasolacrimal duct		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68816	Probe nl duct w/balloon		T	0240	18.7307	\$1,193.03	\$309.52	\$238.61
68840	Explore/irrigate tear ducts	NI CH	S	0231	2.1790	\$138.79		\$27.76
68850	Injection for tear sac x-ray		N					
68899	Tear duct system surgery		T	0238	2.9022	\$184.85		\$36.97
69000	Drain external ear lesion		T	0006	1.4066	\$89.59		\$17.92
69005	Drain external ear lesion		T	0008	18.3197	\$1,166.85		\$233.37
69020	Drain outer ear canal lesion		T	0006	1.4066	\$89.59		\$17.92
69090	Pierce earlobes		E					
69100	Biopsy of external ear	CH	T	0251	2.5002	\$159.25		\$31.85
69105	Biopsy of external ear canal		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
69110	Remove external ear, partial		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
69120	Removal of external ear		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
69140	Remove ear canal lesion(s)		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
69145	Remove ear canal lesion(s)		T	0021	16.1001	\$1,025.48	\$219.48	\$205.10
69150	Extensive ear canal surgery		T	0252	7.4474	\$474.35	\$109.16	\$94.87
69155	Extensive ear/neck surgery		C					
69200	Clear outer ear canal		X	0340	0.6310	\$40.19		\$8.04
69205	Clear outer ear canal		T	0022	21.1098	\$1,344.57	\$354.45	\$268.91
69210	Remove impacted ear wax		X	0340	0.6310	\$40.19		\$8.04
69220	Clean out mastoid cavity	CH	T	0013	0.7930	\$50.51		\$10.10
69222	Clean out mastoid cavity	CH	T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
69300	Revise external ear		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
69310	Rebuild outer ear canal		T	0256	39.8776	\$2,539.96		\$507.99
69320	Rebuild outer ear canal		T	0256	39.8776	\$2,539.96		\$507.99
69399	Outer ear surgery procedure		T	0251	2.5002	\$159.25		\$31.85
69400	Inflate middle ear canal		T	0251	2.5002	\$159.25		\$31.85
69401	Inflate middle ear canal		T	0251	2.5002	\$159.25		\$31.85
69405	Catheterize middle ear canal		T	0252	7.4474	\$474.35	\$109.16	\$94.87
69420	Incision of eardrum		T	0251	2.5002	\$159.25		\$31.85
69421	Incision of eardrum		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
69424	Remove ventilating tube	CH	T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
69433	Create eardrum opening		T	0252	7.4474	\$474.35	\$109.16	\$94.87
69436	Create eardrum opening		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
69440	Exploration of middle ear		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
69450	Eardrum revision		T	0256	39.8776	\$2,539.96		\$507.99
69501	Mastoidectomy		T	0256	39.8776	\$2,539.96		\$507.99
69502	Mastoidectomy		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
69505	Remove mastoid structures		T	0256	39.8776	\$2,539.96		\$507.99
69511	Extensive mastoid surgery		T	0256	39.8776	\$2,539.96		\$507.99
69530	Extensive mastoid surgery		T	0256	39.8776	\$2,539.96		\$507.99
69535	Remove part of temporal bone		C					
69540	Remove ear lesion		T	0253	16.3288	\$1,040.05	\$282.29	\$208.01
69550	Remove ear lesion		T	0256	39.8776	\$2,539.96		\$507.99
69552	Remove ear lesion		T	0256	39.8776	\$2,539.96		\$507.99
69554	Remove ear lesion		C					
69601	Mastoid surgery revision		T	0256	39.8776	\$2,539.96		\$507.99
69602	Mastoid surgery revision		T	0256	39.8776	\$2,539.96		\$507.99
69603	Mastoid surgery revision		T	0256	39.8776	\$2,539.96		\$507.99
69604	Mastoid surgery revision		T	0256	39.8776	\$2,539.96		\$507.99
69605	Mastoid surgery revision		T	0256	39.8776	\$2,539.96		\$507.99

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
69610	Repair of eardrum		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
69620	Repair of eardrum		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
69631	Repair eardrum structures		T	0256	39.8776	\$2,539.96		\$507.99
69632	Rebuild eardrum structures		T	0256	39.8776	\$2,539.96		\$507.99
69633	Rebuild eardrum structures		T	0256	39.8776	\$2,539.96		\$507.99
69635	Repair eardrum structures		T	0256	39.8776	\$2,539.96		\$507.99
69636	Rebuild eardrum structures		T	0256	39.8776	\$2,539.96		\$507.99
69637	Rebuild eardrum structures		T	0256	39.8776	\$2,539.96		\$507.99
69641	Revise middle ear & mastoid		T	0256	39.8776	\$2,539.96		\$507.99
69642	Revise middle ear & mastoid		T	0256	39.8776	\$2,539.96		\$507.99
69643	Revise middle ear & mastoid		T	0256	39.8776	\$2,539.96		\$507.99
69644	Revise middle ear & mastoid		T	0256	39.8776	\$2,539.96		\$507.99
69645	Revise middle ear & mastoid		T	0256	39.8776	\$2,539.96		\$507.99
69646	Revise middle ear & mastoid		T	0256	39.8776	\$2,539.96		\$507.99
69650	Release middle ear bone		T	0254	23.9765	\$1,527.16	\$321.35	\$305.43
69660	Revise middle ear bone		T	0256	39.8776	\$2,539.96		\$507.99
69661	Revise middle ear bone		T	0256	39.8776	\$2,539.96		\$507.99
69662	Revise middle ear bone		T	0256	39.8776	\$2,539.96		\$507.99
69666	Repair middle ear structures		T	0256	39.8776	\$2,539.96		\$507.99
69667	Repair middle ear structures		T	0256	39.8776	\$2,539.96		\$507.99
69670	Remove mastoid air cells		T	0256	39.8776	\$2,539.96		\$507.99
69676	Remove middle ear nerve		T	0256	39.8776	\$2,539.96		\$507.99
69700	Close mastoid fistula		T	0256	39.8776	\$2,539.96		\$507.99
69710	Implant/replace hearing aid		E					
69711	Remove/repair hearing aid		T	0256	39.8776	\$2,539.96		\$507.99
69714	Implant temple bone w/stimul		T	0256	39.8776	\$2,539.96		\$507.99
69715	Temple bne implint w/stimulat		T	0256	39.8776	\$2,539.96		\$507.99
69717	Temple bone implant revision		T	0256	39.8776	\$2,539.96		\$507.99
69718	Revise temple bone implant		T	0256	39.8776	\$2,539.96		\$507.99
69720	Release facial nerve		T	0256	39.8776	\$2,539.96		\$507.99
69725	Release facial nerve		T	0256	39.8776	\$2,539.96		\$507.99
69740	Repair facial nerve		T	0256	39.8776	\$2,539.96		\$507.99
69745	Repair facial nerve		T	0256	39.8776	\$2,539.96		\$507.99
69799	Middle ear surgery procedure		T	0251	2.5002	\$159.25		\$31.85
69801	Incise inner ear		T	0256	39.8776	\$2,539.96		\$507.99
69802	Incise inner ear		T	0256	39.8776	\$2,539.96		\$507.99
69805	Explore inner ear		T	0256	39.8776	\$2,539.96		\$507.99
69806	Explore inner ear		T	0256	39.8776	\$2,539.96		\$507.99
69820	Establish inner ear window		T	0256	39.8776	\$2,539.96		\$507.99
69840	Revise inner ear window		T	0256	39.8776	\$2,539.96		\$507.99
69905	Remove inner ear		T	0256	39.8776	\$2,539.96		\$507.99
69910	Remove inner ear & mastoid		T	0256	39.8776	\$2,539.96		\$507.99
69915	Incise inner ear nerve		T	0256	39.8776	\$2,539.96		\$507.99
69930	Implant cochlear device		T	0259	393.2242	\$25,046.02	\$8,543.66	\$5,009.20
69949	Inner ear surgery procedure		T	0251	2.5002	\$159.25		\$31.85
69950	Incise inner ear nerve		C					
69955	Release facial nerve		T	0256	39.8776	\$2,539.96		\$507.99
69960	Release inner ear canal		T	0256	39.8776	\$2,539.96		\$507.99
69970	Remove inner ear lesion	CH	T	0256	39.8776	\$2,539.96		\$507.99
69979	Temporal bone surgery		T	0251	2.5002	\$159.25		\$31.85
69990	Microsurgery add-on		N					
70010	Contrast x-ray of brain	CH	Q	0274	7.5589	\$481.46		\$96.29
70015	Contrast x-ray of brain	CH	Q	0274	7.5589	\$481.46		\$96.29
70030	X-ray eye for foreign body		X	0260	0.6954	\$44.29		\$8.86
70100	X-ray exam of jaw		X	0260	0.6954	\$44.29		\$8.86
7010F	Pt info into recall system	NI	M					
70110	X-ray exam of jaw		X	0260	0.6954	\$44.29		\$8.86
70120	X-ray exam of mastoids		X	0260	0.6954	\$44.29		\$8.86
70130	X-ray exam of mastoids		X	0260	0.6954	\$44.29		\$8.86
70134	X-ray exam of middle ear		X	0261	1.1570	\$73.69		\$14.74
70140	X-ray exam of facial bones		X	0260	0.6954	\$44.29		\$8.86
70150	X-ray exam of facial bones		X	0260	0.6954	\$44.29		\$8.86
70160	X-ray exam of nasal bones		X	0260	0.6954	\$44.29		\$8.86
70170	X-ray exam of tear duct	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
70190	X-ray exam of eye sockets		X	0260	0.6954	\$44.29		\$8.86
70200	X-ray exam of eye sockets		X	0260	0.6954	\$44.29		\$8.86
70210	X-ray exam of sinuses		X	0260	0.6954	\$44.29		\$8.86
70220	X-ray exam of sinuses		X	0260	0.6954	\$44.29		\$8.86
70240	X-ray exam, pituitary saddle		X	0260	0.6954	\$44.29		\$8.86
70250	X-ray exam of skull		X	0260	0.6954	\$44.29		\$8.86
70260	X-ray exam of skull		X	0261	1.1570	\$73.69		\$14.74
70300	X-ray exam of teeth		X	0262	0.5749	\$36.62		\$7.32
70310	X-ray exam of teeth		X	0262	0.5749	\$36.62		\$7.32
70320	Full mouth x-ray of teeth		X	0262	0.5749	\$36.62		\$7.32
70328	X-ray exam of jaw joint		X	0260	0.6954	\$44.29		\$8.86
70330	X-ray exam of jaw joints		X	0260	0.6954	\$44.29		\$8.86
70332	X-ray exam of jaw joint	CH	Q	0275	4.0031	\$254.97	\$69.09	\$50.99
70336	Magnetic image, jaw joint		S	0335	4.8830	\$311.02	\$111.92	\$62.20
70350	X-ray head for orthodontia		X	0260	0.6954	\$44.29		\$8.86
70355	Panoramic x-ray of jaws		X	0260	0.6954	\$44.29		\$8.86

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
70360	X-ray exam of neck		X	0260	0.6954	\$44.29		\$8.86
70370	Throat x-ray & fluoroscopy		X	0272	1.3271	\$84.53	\$31.64	\$16.91
70371	Speech evaluation, complex		X	0272	1.3271	\$84.53	\$31.64	\$16.91
70373	Contrast x-ray of larynx	CH	Q	0263	2.6838	\$170.94		\$34.19
70380	X-ray exam of salivary gland		X	0260	0.6954	\$44.29		\$8.86
70390	X-ray exam of salivary duct	CH	Q	0263	2.6838	\$170.94		\$34.19
70450	Ct head/brain w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
70460	Ct head/brain w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
70470	Ct head/brain w/o & w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
70480	Ct orbit/ear/fossa w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
70481	Ct orbit/ear/fossa w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
70482	Ct orbit/ear/fossa w/o&w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
70486	Ct maxillofacial w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
70487	Ct maxillofacial w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
70488	Ct maxillofacial w/o & w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
70490	Ct soft tissue neck w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
70491	Ct soft tissue neck w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
70492	Ct sft tsue nck w/o & w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
70496	Ct angiography, head		S	0662	5.1641	\$328.92	\$118.88	\$65.78
70498	Ct angiography, neck		S	0662	5.1641	\$328.92	\$118.88	\$65.78
70540	Mri orbit/face/neck w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
70542	Mri orbit/face/neck w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
70543	Mri orbit/fac/nck w/o & w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
70544	Mr angiography head w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
70545	Mr angiography head w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
70546	Mr angiograph head w/o&w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
70547	Mr angiography neck w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
70548	Mr angiography neck w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
70549	Mr angiograph neck w/o&w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
70551	Mri brain w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
70552	Mri brain w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
70553	Mri brain w/o & w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
70554	Fmri brain by tech		S	0336	5.3933	\$343.52	\$137.40	\$68.70
70555	Fmri brain by phys/psych		S	0336	5.3933	\$343.52	\$137.40	\$68.70
70557	Mri brain w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
70558	Mri brain w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
70559	Mri brain w/o & w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
71010	Chest x-ray		X	0260	0.6954	\$44.29		\$8.86
71015	Chest x-ray		X	0260	0.6954	\$44.29		\$8.86
71020	Chest x-ray		X	0260	0.6954	\$44.29		\$8.86
71021	Chest x-ray		X	0260	0.6954	\$44.29		\$8.86
71022	Chest x-ray		X	0260	0.6954	\$44.29		\$8.86
71023	Chest x-ray and fluoroscopy		X	0272	1.3271	\$84.53	\$31.64	\$16.91
71030	Chest x-ray		X	0260	0.6954	\$44.29		\$8.86
71034	Chest x-ray and fluoroscopy		X	0272	1.3271	\$84.53	\$31.64	\$16.91
71035	Chest x-ray		X	0260	0.6954	\$44.29		\$8.86
71040	Contrast x-ray of bronchi	CH	Q	0263	2.6838	\$170.94		\$34.19
71060	Contrast x-ray of bronchi	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
71090	X-ray & pacemaker insertion	CH	N					
71100	X-ray exam of ribs		X	0260	0.6954	\$44.29		\$8.86
71101	X-ray exam of ribs/chest		X	0260	0.6954	\$44.29		\$8.86
71110	X-ray exam of ribs		X	0260	0.6954	\$44.29		\$8.86
71111	X-ray exam of ribs/chest		X	0261	1.1570	\$73.69		\$14.74
71120	X-ray exam of breastbone		X	0260	0.6954	\$44.29		\$8.86
71130	X-ray exam of breastbone		X	0260	0.6954	\$44.29		\$8.86
71250	Ct thorax w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
71260	Ct thorax w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
71270	Ct thorax w/o & w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
71275	Ct angiography, chest		S	0662	5.1641	\$328.92	\$118.88	\$65.78
71550	Mri chest w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
71551	Mri chest w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
71552	Mri chest w/o & w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
71555	Mri angio chest w or w/o dye		B					
72010	X-ray exam of spine		X	0260	0.6954	\$44.29		\$8.86
72020	X-ray exam of spine		X	0260	0.6954	\$44.29		\$8.86
72040	X-ray exam of neck spine		X	0260	0.6954	\$44.29		\$8.86
72050	X-ray exam of neck spine		X	0261	1.1570	\$73.69		\$14.74
72052	X-ray exam of neck spine		X	0261	1.1570	\$73.69		\$14.74
72069	X-ray exam of trunk spine		X	0260	0.6954	\$44.29		\$8.86
72070	X-ray exam of thoracic spine		X	0260	0.6954	\$44.29		\$8.86
72072	X-ray exam of thoracic spine		X	0260	0.6954	\$44.29		\$8.86
72074	X-ray exam of thoracic spine		X	0260	0.6954	\$44.29		\$8.86
72080	X-ray exam of trunk spine		X	0260	0.6954	\$44.29		\$8.86
72090	X-ray exam of trunk spine		X	0261	1.1570	\$73.69		\$14.74
72100	X-ray exam of lower spine		X	0260	0.6954	\$44.29		\$8.86
72110	X-ray exam of lower spine		X	0261	1.1570	\$73.69		\$14.74
72114	X-ray exam of lower spine		X	0261	1.1570	\$73.69		\$14.74
72120	X-ray exam of lower spine		X	0261	1.1570	\$73.69		\$14.74
72125	Ct neck spine w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
72126	Ct neck spine w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
72127	Ct neck spine w/o & w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
72128	Ct chest spine w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
72129	Ct chest spine w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
72130	Ct chest spine w/o & w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
72131	Ct lumbar spine w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
72132	Ct lumbar spine w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
72133	Ct lumbar spine w/o & w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
72141	Mri neck spine w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
72142	Mri neck spine w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
72146	Mri chest spine w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
72147	Mri chest spine w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
72148	Mri lumbar spine w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
72149	Mri lumbar spine w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
72156	Mri neck spine w/o & w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
72157	Mri chest spine w/o & w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
72158	Mri lumbar spine w/o & w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
72159	Mr angio spine w/o&w/dye		E					
72170	X-ray exam of pelvis		X	0260	0.6954	\$44.29		\$8.86
72190	X-ray exam of pelvis		X	0260	0.6954	\$44.29		\$8.86
72191	Ct angiograph pelv w/o&w/dye		S	0662	5.1641	\$328.92	\$118.88	\$65.78
72192	Ct pelvis w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
72193	Ct pelvis w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
72194	Ct pelvis w/o & w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
72195	Mri pelvis w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
72196	Mri pelvis w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
72197	Mri pelvis w/o & w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
72198	Mr angio pelvis w/o & w/dye		B					
72200	X-ray exam sacroiliac joints		X	0260	0.6954	\$44.29		\$8.86
72202	X-ray exam sacroiliac joints		X	0260	0.6954	\$44.29		\$8.86
72220	X-ray exam of tailbone		X	0260	0.6954	\$44.29		\$8.86
72240	Contrast x-ray of neck spine	CH	Q	0274	7.5589	\$481.46		\$96.29
72255	Contrast x-ray, thorax spine	CH	Q	0274	7.5589	\$481.46		\$96.29
72265	Contrast x-ray, lower spine	CH	Q	0274	7.5589	\$481.46		\$96.29
72270	Contrast x-ray, spine	CH	Q	0274	7.5589	\$481.46		\$96.29
72275	Epidurography	CH	N					
72285	X-ray c/t spine disk	CH	Q	0388	20.1823	\$1,285.49	\$289.72	\$257.10
72291	Perq vertebroplasty, fluor	CH	N					
72292	Perq vertebroplasty, ct	CH	N					
72295	X-ray of lower spine disk	CH	Q	0388	20.1823	\$1,285.49	\$289.72	\$257.10
73000	X-ray exam of collar bone		X	0260	0.6954	\$44.29		\$8.86
73010	X-ray exam of shoulder blade		X	0260	0.6954	\$44.29		\$8.86
73020	X-ray exam of shoulder		X	0260	0.6954	\$44.29		\$8.86
73030	X-ray exam of shoulder		X	0260	0.6954	\$44.29		\$8.86
73040	Contrast x-ray of shoulder	CH	Q	0275	4.0031	\$254.97	\$69.09	\$50.99
73050	X-ray exam of shoulders		X	0260	0.6954	\$44.29		\$8.86
73060	X-ray exam of humerus		X	0260	0.6954	\$44.29		\$8.86
73070	X-ray exam of elbow		X	0260	0.6954	\$44.29		\$8.86
73080	X-ray exam of elbow		X	0260	0.6954	\$44.29		\$8.86
73085	Contrast x-ray of elbow	CH	Q	0275	4.0031	\$254.97	\$69.09	\$50.99
73090	X-ray exam of forearm		X	0260	0.6954	\$44.29		\$8.86
73092	X-ray exam of arm, infant		X	0260	0.6954	\$44.29		\$8.86
73100	X-ray exam of wrist		X	0260	0.6954	\$44.29		\$8.86
73110	X-ray exam of wrist		X	0260	0.6954	\$44.29		\$8.86
73115	Contrast x-ray of wrist	CH	Q	0275	4.0031	\$254.97	\$69.09	\$50.99
73120	X-ray exam of hand		X	0260	0.6954	\$44.29		\$8.86
73130	X-ray exam of hand		X	0260	0.6954	\$44.29		\$8.86
73140	X-ray exam of finger(s)		X	0260	0.6954	\$44.29		\$8.86
73200	Ct upper extremity w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
73201	Ct upper extremity w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
73202	Ct uppr extremity w/o&w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
73206	Ct angio upr extrm w/o&w/dye		S	0662	5.1641	\$328.92	\$118.88	\$65.78
73218	Mri upper extremity w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
73219	Mri upper extremity w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
73220	Mri uppr extremity w/o&w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
73221	Mri joint upr extrem w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
73222	Mri joint upr extrem w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
73223	Mri joint upr extr w/o&w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
73225	Mr angio upr extr w/o&w/dye		E					
73500	X-ray exam of hip		X	0260	0.6954	\$44.29		\$8.86
73510	X-ray exam of hip		X	0260	0.6954	\$44.29		\$8.86
73520	X-ray exam of hips		X	0261	1.1570	\$73.69		\$14.74
73525	Contrast x-ray of hip	CH	Q	0275	4.0031	\$254.97	\$69.09	\$50.99
73530	X-ray exam of hip	CH	N					
73540	X-ray exam of pelvis & hips		X	0260	0.6954	\$44.29		\$8.86
73542	X-ray exam, sacroiliac joint	CH	Q	0275	4.0031	\$254.97	\$69.09	\$50.99
73550	X-ray exam of thigh		X	0260	0.6954	\$44.29		\$8.86
73560	X-ray exam of knee, 1 or 2		X	0260	0.6954	\$44.29		\$8.86
73562	X-ray exam of knee, 3		X	0260	0.6954	\$44.29		\$8.86
73564	X-ray exam, knee, 4 or more		X	0260	0.6954	\$44.29		\$8.86
73565	X-ray exam of knees		X	0260	0.6954	\$44.29		\$8.86

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
73580	Contrast x-ray of knee joint	CH	Q	0275	4.0031	\$254.97	\$69.09	\$50.99
73590	X-ray exam of lower leg		X	0260	0.6954	\$44.29		\$8.86
73592	X-ray exam of leg, infant		X	0260	0.6954	\$44.29		\$8.86
73600	X-ray exam of ankle		X	0260	0.6954	\$44.29		\$8.86
73610	X-ray exam of ankle		X	0260	0.6954	\$44.29		\$8.86
73615	Contrast x-ray of ankle	CH	Q	0275	4.0031	\$254.97	\$69.09	\$50.99
73620	X-ray exam of foot		X	0260	0.6954	\$44.29		\$8.86
73630	X-ray exam of foot		X	0260	0.6954	\$44.29		\$8.86
73650	X-ray exam of heel		X	0260	0.6954	\$44.29		\$8.86
73660	X-ray exam of toe(s)		X	0260	0.6954	\$44.29		\$8.86
73700	Ct lower extremity w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
73701	Ct lower extremity w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
73702	Ct lwr extremity w/o&w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
73706	Ct angio lwr extr w/o&w/dye		S	0662	5.1641	\$328.92	\$118.88	\$65.78
73718	Mri lower extremity w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
73719	Mri lower extremity w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
73720	Mri lwr extremity w/o&w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
73721	Mri jnt of lwr extre w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
73722	Mri joint of lwr extr w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
73723	Mri joint lwr extr w/o&w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
73725	Mr ang lwr ext w or w/o dye		B					
74000	X-ray exam of abdomen		X	0260	0.6954	\$44.29		\$8.86
74010	X-ray exam of abdomen		X	0260	0.6954	\$44.29		\$8.86
74020	X-ray exam of abdomen		X	0260	0.6954	\$44.29		\$8.86
74022	X-ray exam series, abdomen		X	0261	1.1570	\$73.69		\$14.74
74150	Ct abdomen w/o dye		S	0332	3.0109	\$191.78	\$75.24	\$38.36
74160	Ct abdomen w/dye		S	0283	4.3564	\$277.48	\$100.37	\$55.50
74170	Ct abdomen w/o & w/dye		S	0333	5.1125	\$325.64	\$119.01	\$65.13
74175	Ct angio abdom w/o & w/dye		S	0662	5.1641	\$328.92	\$118.88	\$65.78
74181	Mri abdomen w/o dye		S	0336	5.3933	\$343.52	\$137.40	\$68.70
74182	Mri abdomen w/dye		S	0284	6.2350	\$397.13	\$148.40	\$79.43
74183	Mri abdomen w/o & w/dye		S	0337	8.2463	\$525.24	\$199.53	\$105.05
74185	Mri angio, abdom w or w/o dye		B					
74190	X-ray exam of peritoneum	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
74210	Contrst x-ray exam of throat		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74220	Contrast x-ray, esophagus		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74230	Cine/vid x-ray, throat/esoph		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74235	Remove esophagus obstruction	CH	N					
74240	X-ray exam, upper gi tract		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74241	X-ray exam, upper gi tract		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74245	X-ray exam, upper gi tract		S	0277	2.2222	\$141.54	\$54.52	\$28.31
74246	Contrst x-ray uppr gi tract		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74247	Contrst x-ray uppr gi tract		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74249	Contrst x-ray uppr gi tract		S	0277	2.2222	\$141.54	\$54.52	\$28.31
74250	X-ray exam of small bowel		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74251	X-ray exam of small bowel		S	0277	2.2222	\$141.54	\$54.52	\$28.31
74260	X-ray exam of small bowel		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74270	Contrast x-ray exam of colon		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74280	Contrast x-ray exam of colon		S	0277	2.2222	\$141.54	\$54.52	\$28.31
74283	Contrast x-ray exam of colon		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74290	Contrast x-ray, gallbladder		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74291	Contrast x-rays, gallbladder		S	0276	1.3834	\$88.11	\$34.97	\$17.62
74300	X-ray bile ducts/pancreas	CH	N					
74301	X-rays at surgery add-on	CH	N					
74305	X-ray bile ducts/pancreas	CH	N					
74320	Contrast x-ray of bile ducts	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
74327	X-ray bile stone removal	CH	N					
74328	X-ray bile duct endoscopy		N					
74329	X-ray for pancreas endoscopy		N					
74330	X-ray bile/panc endoscopy		N					
74340	X-ray guide for GI tube	CH	N					
74350	X-ray guide, stomach tube	CH	D					
74355	X-ray guide, intestinal tube	CH	N					
74360	X-ray guide, GI dilation	CH	N					
74363	X-ray, bile duct dilation	CH	N					
74400	Contrst x-ray, urinary tract		S	0278	2.6121	\$166.38	\$59.40	\$33.28
74410	Contrst x-ray, urinary tract		S	0278	2.6121	\$166.38	\$59.40	\$33.28
74415	Contrst x-ray, urinary tract		S	0278	2.6121	\$166.38	\$59.40	\$33.28
74420	Contrst x-ray, urinary tract		S	0278	2.6121	\$166.38	\$59.40	\$33.28
74425	Contrst x-ray, urinary tract	CH	Q	0278	2.6121	\$166.38	\$59.40	\$33.28
74430	Contrast x-ray, bladder	CH	Q	0278	2.6121	\$166.38	\$59.40	\$33.28
74440	X-ray, male genital tract	CH	Q	0278	2.6121	\$166.38	\$59.40	\$33.28
74445	X-ray exam of penis	CH	Q	0278	2.6121	\$166.38	\$59.40	\$33.28
74450	X-ray, urethra/bladder	CH	Q	0278	2.6121	\$166.38	\$59.40	\$33.28
74455	X-ray, urethra/bladder	CH	Q	0278	2.6121	\$166.38	\$59.40	\$33.28
74470	X-ray exam of kidney lesion	CH	Q	0263	2.6838	\$170.94		\$34.19
74475	X-ray control, cath insert	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
74480	X-ray control, cath insert	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
74485	X-ray guide, GU dilation	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
74710	X-ray measurement of pelvis		X	0261	1.1570	\$73.69		\$14.74

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
74740	X-ray, female genital tract	CH	Q	0263	2.6838	\$170.94		\$34.19
74742	X-ray, fallopian tube	CH	N					
74775	X-ray exam of perineum		S	0278	2.6121	\$166.38	\$59.40	\$33.28
75552	Heart mri for morph w/o dye	CH	D					
75553	Heart mri for morph w/dye	CH	D					
75554	Cardiac MRI/function	CH	D					
75555	Cardiac MRI/limited study	CH	D					
75556	Cardiac MRI/flow mapping	CH	D					
75557	Cardiac mri for morph	NI	S	0336	5.3933	\$343.52	\$137.40	\$68.70
75558	Cardiac mri flow/velocity	NI	E					
75559	Cardiac mri w/stress img	NI	S	0336	5.3933	\$343.52	\$137.40	\$68.70
75560	Cardiac mri flow/vel/stress	NI	E					
75561	Cardiac mri for morph w/dye	NI	S	0337	8.2463	\$525.24	\$199.53	\$105.05
75562	Card mri flow/vel w/dye	NI	E					
75563	Card mri w/stress img & dye	NI	S	0337	8.2463	\$525.24	\$199.53	\$105.05
75564	Ht mri w/flo/vel/strs & dye	NI	E					
75600	Contrast x-ray exam of aorta	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75605	Contrast x-ray exam of aorta	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75625	Contrast x-ray exam of aorta	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75630	X-ray aorta, leg arteries	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75635	Ct angio abdominal arteries	CH	Q	0662	5.1641	\$328.92	\$118.88	\$65.78
75650	Artery x-rays, head & neck	CH	Q	0280	44.7114	\$2,847.85		\$569.57
75658	Artery x-rays, arm	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75660	Artery x-rays, head & neck	CH	Q	0280	44.7114	\$2,847.85		\$569.57
75662	Artery x-rays, head & neck	CH	Q	0280	44.7114	\$2,847.85		\$569.57
75665	Artery x-rays, head & neck	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75671	Artery x-rays, head & neck	CH	Q	0280	44.7114	\$2,847.85		\$569.57
75676	Artery x-rays, neck	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75680	Artery x-rays, neck	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75685	Artery x-rays, spine	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75705	Artery x-rays, spine	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75710	Artery x-rays, arm/leg	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75716	Artery x-rays, arms/legs	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75722	Artery x-rays, kidney	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75724	Artery x-rays, kidneys	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75726	Artery x-rays, abdomen	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75731	Artery x-rays, adrenal gland	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75733	Artery x-rays, adrenals	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75736	Artery x-rays, pelvis	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75741	Artery x-rays, lung	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75743	Artery x-rays, lungs	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75746	Artery x-rays, lung	CH	Q	0668	9.3506	\$595.58		\$119.12
75756	Artery x-rays, chest	CH	Q	0668	9.3506	\$595.58		\$119.12
75774	Artery x-ray, each vessel	CH	N					
75790	Visualize A-V shunt	CH	Q	0668	9.3506	\$595.58		\$119.12
75801	Lymph vessel x-ray, arm/leg	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
75803	Lymph vessel x-ray, arms/legs	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
75805	Lymph vessel x-ray, trunk	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
75807	Lymph vessel x-ray, trunk	CH	Q	0317	5.3623	\$341.55	\$77.89	\$68.31
75809	Nonvascular shunt, x-ray	CH	Q	0263	2.6838	\$170.94		\$34.19
75810	Vein x-ray, spleen/liver	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75820	Vein x-ray, arm/leg	CH	Q	0668	9.3506	\$595.58		\$119.12
75822	Vein x-ray, arms/legs	CH	Q	0668	9.3506	\$595.58		\$119.12
75825	Vein x-ray, trunk	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75827	Vein x-ray, chest	CH	Q	0668	9.3506	\$595.58		\$119.12
75831	Vein x-ray, kidney	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75833	Vein x-ray, kidneys	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75840	Vein x-ray, adrenal gland	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75842	Vein x-ray, adrenal glands	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75860	Vein x-ray, neck	CH	Q	0668	9.3506	\$595.58		\$119.12
75870	Vein x-ray, skull	CH	Q	0668	9.3506	\$595.58		\$119.12
75872	Vein x-ray, skull	CH	Q	0668	9.3506	\$595.58		\$119.12
75880	Vein x-ray, eye socket	CH	Q	0668	9.3506	\$595.58		\$119.12
75885	Vein x-ray, liver	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75887	Vein x-ray, liver	CH	Q	0668	9.3506	\$595.58		\$119.12
75889	Vein x-ray, liver	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75891	Vein x-ray, liver	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75893	Venous sampling by catheter	CH	Q	0279	28.8788	\$1,839.41		\$367.88
75894	X-rays, transcath therapy	CH	N					
75896	X-rays, transcath therapy	CH	N					
75898	Follow-up angiography	CH	Q	0263	2.6838	\$170.94		\$34.19
75900	Intravascular cath exchange		C					
75901	Remove cva device obstruct	CH	N					
75902	Remove cva lumen obstruct	CH	N					
75940	X-ray placement, vein filter	CH	N					
75945	Intravascular us	CH	Q	0267	2.3792	\$151.54	\$60.50	\$30.31
75946	Intravascular us add-on	CH	N					
75952	Endovasc repair abdom aorta		C					
75953	Abdom aneurysm endovas rpr		C					
75954	Iliac aneurysm endovas rpr		C					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
75956	Xray, endovasc thor ao repr		C					
75957	Xray, endovasc thor ao repr		C					
75958	Xray, place prox ext thor ao		C					
75959	Xray, place dist ext thor ao		C					
75960	Transcath iv stent rs&i	CH	N					
75961	Retrieval, broken catheter	CH	N					
75962	Repair arterial blockage	CH	Q	0083	45.3845	\$2,890.72		\$578.14
75964	Repair artery blockage, each	CH	N					
75966	Repair arterial blockage	CH	Q	0083	45.3845	\$2,890.72		\$578.14
75968	Repair artery blockage, each	CH	N					
75970	Vascular biopsy	CH	N					
75978	Repair venous blockage	CH	Q	0083	45.3845	\$2,890.72		\$578.14
75980	Contrast xray exam bile duct	CH	N					
75982	Contrast xray exam bile duct	CH	N					
75984	Xray control catheter change	CH	N					
75989	Abscess drainage under x-ray		N					
75992	Atherectomy, x-ray exam	CH	N					
75993	Atherectomy, x-ray exam	CH	N					
75994	Atherectomy, x-ray exam	CH	N					
75995	Atherectomy, x-ray exam	CH	N					
75996	Atherectomy, x-ray exam	CH	N					
76000	Fluoroscope examination	CH	Q	0272	1.3271	\$84.53	\$31.64	\$16.91
76001	Fluoroscope exam, extensive		N					
76010	X-ray, nose to rectum		X	0260	0.6954	\$44.29		\$8.86
76080	X-ray exam of fistula	CH	Q	0263	2.6838	\$170.94		\$34.19
76098	X-ray exam, breast specimen		X	0260	0.6954	\$44.29		\$8.86
76100	X-ray exam of body section		X	0261	1.1570	\$73.69		\$14.74
76101	Complex body section x-ray		X	0263	2.6838	\$170.94		\$34.19
76102	Complex body section x-rays	CH	X	0263	2.6838	\$170.94		\$34.19
76120	Cine/video x-rays		X	0272	1.3271	\$84.53	\$31.64	\$16.91
76125	Cine/video x-rays add-on	CH	N					
76140	X-ray consultation		E					
76150	X-ray exam, dry process		X	0260	0.6954	\$44.29		\$8.86
76350	Special x-ray contrast study		N					
76376	3d render w/o postprocess	CH	N					
76377	3d rendering w/postprocess	CH	N					
76380	CAT scan follow-up study		S	0282	1.5839	\$100.88	\$37.81	\$20.18
76390	Mr spectroscopy		E					
76496	Fluoroscopic procedure		X	0272	1.3271	\$84.53	\$31.64	\$16.91
76497	Ct procedure		S	0282	1.5839	\$100.88	\$37.81	\$20.18
76498	Mri procedure		S	0335	4.8830	\$311.02	\$111.92	\$62.20
76499	Radiographic procedure		X	0260	0.6954	\$44.29		\$8.86
76506	Echo exam of head		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76510	Ophth us, b & quant a	CH	T	0232	5.1169	\$325.92	\$81.65	\$65.18
76511	Ophth us, quant a only		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76512	Ophth us, b w/non-quant a		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76513	Echo exam of eye, water bath		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76514	Echo exam of eye, thickness	CH	S	0230	0.5903	\$37.60		\$7.52
76516	Echo exam of eye		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76519	Echo exam of eye		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76529	Echo exam of eye		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76536	Us exam of head and neck		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76604	Us exam, chest		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76645	Us exam, breast(s)		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76700	Us exam, abdom, complete		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76705	Echo exam of abdomen		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76770	Us exam abdo back wall, comp		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76775	Us exam abdo back wall, lim		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76776	Us exam k transpl w/doppler		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76800	Us exam, spinal canal		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76801	Ob us < 14 wks, single fetus		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76802	Ob us < 14 wks, add'l fetus		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76805	Ob us >= 14 wks, snl fetus		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76810	Ob us >= 14 wks, addl fetus		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76811	Ob us, detailed, snl fetus		S	0267	2.3792	\$151.54	\$60.50	\$30.31
76812	Ob us, detailed, addl fetus		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76813	Ob us nuchal meas, 1 gest		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76814	Ob us nuchal meas, add-on		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76815	Ob us, limited, fetus(s)		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76816	Ob us, follow-up, per fetus		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76817	Transvaginal us, obstetric		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76818	Fetal biophys profile w/nst		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76819	Fetal biophys profil w/o nst		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76820	Umbilical artery echo		S	0096	1.4689	\$93.56	\$37.42	\$18.71
76821	Middle cerebral artery echo		S	0096	1.4689	\$93.56	\$37.42	\$18.71
76825	Echo exam of fetal heart	CH	S	0266	1.5094	\$96.14	\$37.80	\$19.23
76826	Echo exam of fetal heart	CH	S	0265	0.9570	\$60.96	\$22.35	\$12.19
76827	Echo exam of fetal heart	CH	S	0265	0.9570	\$60.96	\$22.35	\$12.19
76828	Echo exam of fetal heart	CH	S	0265	0.9570	\$60.96	\$22.35	\$12.19
76830	Transvaginal us, non-ob		S	0266	1.5094	\$96.14	\$37.80	\$19.23

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
76831	Echo exam, uterus		S	0267	2.3792	\$151.54	\$60.50	\$30.31
76856	Us exam, pelvic, complete		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76857	Us exam, pelvic, limited		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76870	Us exam, scrotum		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76872	Us, transrectal		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76873	Echograp trans r, pros study		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76880	Us exam, extremity		S	0266	1.5094	\$96.14	\$37.80	\$19.23
76885	Us exam infant hips, dynamic		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76886	Us exam infant hips, static		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76930	Echo guide, cardiocentesis	CH	N					
76932	Echo guide for heart biopsy	CH	N					
76936	Echo guide for artery repair	CH	N					
76937	Us guide, vascular access		N					
76940	Us guide, tissue ablation	CH	N					
76941	Echo guide for transfusion	CH	N					
76942	Echo guide for biopsy	CH	N					
76945	Echo guide, villus sampling	CH	N					
76946	Echo guide for amniocentesis	CH	N					
76948	Echo guide, ova aspiration	CH	N					
76950	Echo guidance radiotherapy	CH	N					
76965	Echo guidance radiotherapy	CH	N					
76970	Ultrasound exam follow-up		S	0265	0.9570	\$60.96	\$22.35	\$12.19
76975	GI endoscopic ultrasound	CH	Q	0267	2.3792	\$151.54	\$60.50	\$30.31
76977	Us bone density measure		X	0340	0.6310	\$40.19		\$8.04
76998	Us guide, intraop	CH	N					
76999	Echo examination procedure		S	0265	0.9570	\$60.96	\$22.35	\$12.19
77001	Fluoroguide for vein device		N					
77002	Needle localization by xray		N					
77003	Fluoroguide for spine inject		N					
77011	Ct scan for localization	CH	N					
77012	Ct scan for needle biopsy	CH	N					
77013	Ct guide for tissue ablation	CH	N					
77014	Ct scan for therapy guide	CH	N					
77021	Mr guidance for needle place	CH	N					
77022	Mri for tissue ablation	CH	N					
77031	Stereotact guide for brst bx	CH	N					
77032	Guidance for needle, breast	CH	N					
77051	Computer dx mammogram add-on		A					
77052	Comp screen mammogram add-on		A					
77053	X-ray of mammary duct	CH	Q	0263	2.6838	\$170.94		\$34.19
77054	X-ray of mammary ducts	CH	Q	0263	2.6838	\$170.94		\$34.19
77055	Mammogram, one breast		A					
77056	Mammogram, both breasts		A					
77057	Mammogram, screening		A					
77058	Mri, one breast		B					
77059	Mri, both breasts		B					
77071	X-ray stress view		X	0260	0.6954	\$44.29		\$8.86
77072	X-rays for bone age		X	0260	0.6954	\$44.29		\$8.86
77073	X-rays, bone length studies		X	0260	0.6954	\$44.29		\$8.86
77074	X-rays, bone survey, limited		X	0261	1.1570	\$73.69		\$14.74
77075	X-rays, bone survey complete		X	0261	1.1570	\$73.69		\$14.74
77076	X-rays, bone survey, infant		X	0260	0.6954	\$44.29		\$8.86
77077	Joint survey, single view		X	0260	0.6954	\$44.29		\$8.86
77078	Ct bone density, axial		S	0288	1.1384	\$72.51	\$28.90	\$14.50
77079	Ct bone density, peripheral		S	0282	1.5839	\$100.88	\$37.81	\$20.18
77080	Dxa bone density, axial		S	0288	1.1384	\$72.51	\$28.90	\$14.50
77081	Dxa bone density/peripheral		S	0665	0.5087	\$32.40	\$12.95	\$6.48
77082	Dxa bone density, vert fx		X	0260	0.6954	\$44.29		\$8.86
77083	Radiographic absorptiometry		X	0261	1.1570	\$73.69		\$14.74
77084	Magnetic image, bone marrow		S	0335	4.8830	\$311.02	\$111.92	\$62.20
77261	Radiation therapy planning		B					
77262	Radiation therapy planning		B					
77263	Radiation therapy planning		B					
77280	Set radiation therapy field		X	0304	1.5576	\$99.21	\$38.68	\$19.84
77285	Set radiation therapy field		X	0305	3.9276	\$250.16	\$91.38	\$50.03
77290	Set radiation therapy field		X	0305	3.9276	\$250.16	\$91.38	\$50.03
77295	Set radiation therapy field		X	0310	13.5621	\$863.82	\$325.27	\$172.76
77299	Radiation therapy planning		X	0304	1.5576	\$99.21	\$38.68	\$19.84
77300	Radiation therapy dose plan		X	0304	1.5576	\$99.21	\$38.68	\$19.84
77301	Radiotherapy dose plan, imrt		X	0310	13.5621	\$863.82	\$325.27	\$172.76
77305	Teletx isodose plan simple		X	0304	1.5576	\$99.21	\$38.68	\$19.84
77310	Teletx isodose plan intermed		X	0305	3.9276	\$250.16	\$91.38	\$50.03
77315	Teletx isodose plan complex		X	0305	3.9276	\$250.16	\$91.38	\$50.03
77321	Special teletx port plan		X	0305	3.9276	\$250.16	\$91.38	\$50.03
77326	Brachytx isodose calc simp		X	0304	1.5576	\$99.21	\$38.68	\$19.84
77327	Brachytx isodose calc interm		X	0305	3.9276	\$250.16	\$91.38	\$50.03
77328	Brachytx isodose plan compl		X	0305	3.9276	\$250.16	\$91.38	\$50.03
77331	Special radiation dosimetry		X	0304	1.5576	\$99.21	\$38.68	\$19.84
77332	Radiation treatment aid(s)		X	0303	2.8878	\$183.94	\$66.95	\$36.79
77333	Radiation treatment aid(s)		X	0303	2.8878	\$183.94	\$66.95	\$36.79

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
77334	Radiation treatment aid(s)		X	0303	2.8878	\$183.94	\$66.95	\$36.79
77336	Radiation physics consult		X	0304	1.5576	\$99.21	\$38.68	\$19.84
77370	Radiation physics consult		X	0304	1.5576	\$99.21	\$38.68	\$19.84
77371	Srs, multisource		S	0127	126.4653	\$8,055.08		\$1,611.02
77372	Srs, linear based		B					
77373	Sbrt delivery		B					
77399	External radiation dosimetry		X	0304	1.5576	\$99.21	\$38.68	\$19.84
77401	Radiation treatment delivery		S	0300	1.4229	\$90.63		\$18.13
77402	Radiation treatment delivery		S	0300	1.4229	\$90.63		\$18.13
77403	Radiation treatment delivery		S	0300	1.4229	\$90.63		\$18.13
77404	Radiation treatment delivery		S	0300	1.4229	\$90.63		\$18.13
77406	Radiation treatment delivery		S	0300	1.4229	\$90.63		\$18.13
77407	Radiation treatment delivery		S	0300	1.4229	\$90.63		\$18.13
77408	Radiation treatment delivery		S	0300	1.4229	\$90.63		\$18.13
77409	Radiation treatment delivery		S	0300	1.4229	\$90.63		\$18.13
77411	Radiation treatment delivery		S	0301	2.2167	\$141.19		\$28.24
77412	Radiation treatment delivery		S	0301	2.2167	\$141.19		\$28.24
77413	Radiation treatment delivery		S	0301	2.2167	\$141.19		\$28.24
77414	Radiation treatment delivery		S	0301	2.2167	\$141.19		\$28.24
77416	Radiation treatment delivery		S	0301	2.2167	\$141.19		\$28.24
77417	Radiology port film(s)	CH	N					
77418	Radiation tx delivery, lmrt		S	0412	5.4582	\$347.65		\$69.53
77421	Stereoscopic x-ray guidance	CH	N					
77422	Neutron beam tx, simple		S	0301	2.2167	\$141.19		\$28.24
77423	Neutron beam tx, complex		S	0301	2.2167	\$141.19		\$28.24
77427	Radiation tx management, x5		B					
77431	Radiation therapy management		B					
77432	Stereotactic radiation trmt		B					
77435	Sbrt management		N					
77470	Special radiation treatment		S	0299	5.7996	\$369.40		\$73.88
77499	Radiation therapy management		B					
77520	Proton trmt, simple w/o comp		S	0664	12.8205	\$816.59		\$163.32
77522	Proton trmt, simple w/comp		S	0664	12.8205	\$816.59		\$163.32
77523	Proton trmt, intermediate		S	0667	15.3404	\$977.09		\$195.42
77525	Proton treatment, complex		S	0667	15.3404	\$977.09		\$195.42
77600	Hyperthermia treatment	CH	S	0299	5.7996	\$369.40		\$73.88
77605	Hyperthermia treatment	CH	S	0299	5.7996	\$369.40		\$73.88
77610	Hyperthermia treatment	CH	S	0299	5.7996	\$369.40		\$73.88
77615	Hyperthermia treatment	CH	S	0299	5.7996	\$369.40		\$73.88
77620	Hyperthermia treatment	CH	S	0299	5.7996	\$369.40		\$73.88
77750	Infuse radioactive materials		S	0301	2.2167	\$141.19		\$28.24
77761	Apply intrcav radiat simple		S	0312	8.5140	\$542.29		\$108.46
77762	Apply intrcav radiat interm		S	0312	8.5140	\$542.29		\$108.46
77763	Apply intrcav radiat compl		S	0312	8.5140	\$542.29		\$108.46
77776	Apply interstit radiat simpl		S	0312	8.5140	\$542.29		\$108.46
77777	Apply interstit radiat inter		S	0312	8.5140	\$542.29		\$108.46
77778	Apply interstit radiat compl	CH	Q	0651	18.1228	\$1,154.31		\$230.86
77781	High intensity brachytherapy		S	0313	11.6779	\$743.81		\$148.76
77782	High intensity brachytherapy		S	0313	11.6779	\$743.81		\$148.76
77783	High intensity brachytherapy		S	0313	11.6779	\$743.81		\$148.76
77784	High intensity brachytherapy		S	0313	11.6779	\$743.81		\$148.76
77789	Apply surface radiation		S	0300	1.4229	\$90.63		\$18.13
77790	Radiation handling		N					
77799	Radium/radioisotope therapy		S	0312	8.5140	\$542.29		\$108.46
78000	Thyroid, single uptake		S	0389	1.8190	\$115.86	\$33.81	\$23.17
78001	Thyroid, multiple uptakes		S	0389	1.8190	\$115.86	\$33.81	\$23.17
78003	Thyroid suppress/stimul		S	0392	2.9022	\$184.85	\$49.31	\$36.97
78006	Thyroid imaging with uptake	CH	S	0391	3.4513	\$219.83	\$66.18	\$43.97
78007	Thyroid image, mult uptakes		S	0391	3.4513	\$219.83	\$66.18	\$43.97
78010	Thyroid imaging		S	0390	2.0471	\$130.39	\$52.15	\$26.08
78011	Thyroid imaging with flow		S	0390	2.0471	\$130.39	\$52.15	\$26.08
78015	Thyroid met imaging		S	0406	5.0681	\$322.81	\$98.18	\$64.56
78016	Thyroid met imaging/studies		S	0406	5.0681	\$322.81	\$98.18	\$64.56
78018	Thyroid met imaging, body		S	0406	5.0681	\$322.81	\$98.18	\$64.56
78020	Thyroid met uptake	CH	N					
78070	Parathyroid nuclear imaging		S	0391	3.4513	\$219.83	\$66.18	\$43.97
78075	Adrenal nuclear imaging	CH	S	0408	15.4033	\$981.10		\$196.22
78099	Endocrine nuclear procedure		S	0390	2.0471	\$130.39	\$52.15	\$26.08
78102	Bone marrow imaging, ltd		S	0400	3.9293	\$250.27	\$93.22	\$50.05
78103	Bone marrow imaging, mult		S	0400	3.9293	\$250.27	\$93.22	\$50.05
78104	Bone marrow imaging, body		S	0400	3.9293	\$250.27	\$93.22	\$50.05
78110	Plasma volume, single		S	0393	5.6921	\$362.55	\$82.04	\$72.51
78111	Plasma volume, multiple		S	0393	5.6921	\$362.55	\$82.04	\$72.51
78120	Red cell mass, single		S	0393	5.6921	\$362.55	\$82.04	\$72.51
78121	Red cell mass, multiple		S	0393	5.6921	\$362.55	\$82.04	\$72.51
78122	Blood volume		S	0393	5.6921	\$362.55	\$82.04	\$72.51
78130	Red cell survival study		S	0393	5.6921	\$362.55	\$82.04	\$72.51
78135	Red cell survival kinetics		S	0393	5.6921	\$362.55	\$82.04	\$72.51
78140	Red cell sequestration		S	0393	5.6921	\$362.55	\$82.04	\$72.51
78185	Spleen imaging		S	0400	3.9293	\$250.27	\$93.22	\$50.05

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
78190	Platelet survival, kinetics		S	0392	2.9022	\$184.85	\$49.31	\$36.97
78191	Platelet survival		S	0392	2.9022	\$184.85	\$49.31	\$36.97
78195	Lymph system imaging		S	0400	3.9293	\$250.27	\$93.22	\$50.05
78199	Blood/lymph nuclear exam		S	0400	3.9293	\$250.27	\$93.22	\$50.05
78201	Liver imaging		S	0394	4.4603	\$284.09	\$102.61	\$56.82
78202	Liver imaging with flow		S	0394	4.4603	\$284.09	\$102.61	\$56.82
78205	Liver imaging (3D)		S	0394	4.4603	\$284.09	\$102.61	\$56.82
78206	Liver image (3d) with flow		S	0394	4.4603	\$284.09	\$102.61	\$56.82
78215	Liver and spleen imaging		S	0394	4.4603	\$284.09	\$102.61	\$56.82
78216	Liver & spleen image/flow		S	0394	4.4603	\$284.09	\$102.61	\$56.82
78220	Liver function study		S	0394	4.4603	\$284.09	\$102.61	\$56.82
78223	Hepatobiliary imaging		S	0394	4.4603	\$284.09	\$102.61	\$56.82
78230	Salivary gland imaging		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78231	Serial salivary imaging		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78232	Salivary gland function exam		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78258	Esophageal motility study		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78261	Gastric mucosa imaging		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78262	Gastroesophageal reflux exam		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78264	Gastric emptying study		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78267	Breath tst attain/anal c-14		A					
78268	Breath test analysis, c-14		A					
78270	Vit B-12 absorption exam		S	0392	2.9022	\$184.85	\$49.31	\$36.97
78271	Vit b-12 abstrp exam, int fac		S	0392	2.9022	\$184.85	\$49.31	\$36.97
78272	Vit B-12 absorp, combined		S	0392	2.9022	\$184.85	\$49.31	\$36.97
78278	Acute GI blood loss imaging		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78282	GI protein loss exam		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78290	Meckel's divert exam		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78291	Leveen/shunt patency exam		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78299	GI nuclear procedure		S	0395	3.7911	\$241.47	\$89.73	\$48.29
78300	Bone imaging, limited area		S	0396	3.8039	\$242.29	\$95.02	\$48.46
78305	Bone imaging, multiple areas		S	0396	3.8039	\$242.29	\$95.02	\$48.46
78306	Bone imaging, whole body		S	0396	3.8039	\$242.29	\$95.02	\$48.46
78315	Bone imaging, 3 phase		S	0396	3.8039	\$242.29	\$95.02	\$48.46
78320	Bone imaging (3D)		S	0396	3.8039	\$242.29	\$95.02	\$48.46
78350	Bone mineral, single photon		E					
78351	Bone mineral, dual photon		E					
78399	Musculoskeletal nuclear exam		S	0396	3.8039	\$242.29	\$95.02	\$48.46
78414	Non-imaging heart function		S	0398	4.8620	\$309.68	\$100.06	\$61.94
78428	Cardiac shunt imaging		S	0398	4.8620	\$309.68	\$100.06	\$61.94
78445	Vascular flow imaging		S	0397	3.1433	\$200.21	\$49.58	\$40.04
78456	Acute venous thrombus image		S	0397	3.1433	\$200.21	\$49.58	\$40.04
78457	Venous thrombosis imaging		S	0397	3.1433	\$200.21	\$49.58	\$40.04
78458	Ven thrombosis images, bilat		S	0397	3.1433	\$200.21	\$49.58	\$40.04
78459	Heart muscle imaging (PET)		S	0307	21.9955	\$1,400.98	\$292.49	\$280.20
78460	Heart muscle blood, single	CH	S	0377	11.8512	\$754.85	\$158.84	\$150.97
78461	Heart muscle blood, multiple	CH	S	0377	11.8512	\$754.85	\$158.84	\$150.97
78464	Heart image (3d), single	CH	S	0377	11.8512	\$754.85	\$158.84	\$150.97
78465	Heart image (3d), multiple		S	0377	11.8512	\$754.85	\$158.84	\$150.97
78466	Heart infarct image		S	0398	4.8620	\$309.68	\$100.06	\$61.94
78468	Heart infarct image (ef)		S	0398	4.8620	\$309.68	\$100.06	\$61.94
78469	Heart infarct image (3D)		S	0398	4.8620	\$309.68	\$100.06	\$61.94
78472	Gated heart, planar, single		S	0398	4.8620	\$309.68	\$100.06	\$61.94
78473	Gated heart, multiple	CH	S	0398	4.8620	\$309.68	\$100.06	\$61.94
78478	Heart wall motion add-on	CH	N					
78480	Heart function add-on	CH	N					
78481	Heart first pass, single		S	0398	4.8620	\$309.68	\$100.06	\$61.94
78483	Heart first pass, multiple	CH	S	0398	4.8620	\$309.68	\$100.06	\$61.94
78491	Heart image (pet), single		S	0307	21.9955	\$1,400.98	\$292.49	\$280.20
78492	Heart image (pet), multiple		S	0307	21.9955	\$1,400.98	\$292.49	\$280.20
78494	Heart image, spect		S	0398	4.8620	\$309.68	\$100.06	\$61.94
78496	Heart first pass add-on	CH	N					
78499	Cardiovascular nuclear exam		S	0398	4.8620	\$309.68	\$100.06	\$61.94
78580	Lung perfusion imaging		S	0401	3.3954	\$216.27	\$78.19	\$43.25
78584	Lung V/Q image single breath		S	0378	4.9509	\$315.34	\$125.33	\$63.07
78585	Lung V/Q imaging		S	0378	4.9509	\$315.34	\$125.33	\$63.07
78586	Aerosol lung image, single		S	0401	3.3954	\$216.27	\$78.19	\$43.25
78587	Aerosol lung image, multiple		S	0401	3.3954	\$216.27	\$78.19	\$43.25
78588	Perfusion lung image		S	0378	4.9509	\$315.34	\$125.33	\$63.07
78591	Vent image, 1 breath, 1 proj		S	0401	3.3954	\$216.27	\$78.19	\$43.25
78593	Vent image, 1 proj, gas		S	0401	3.3954	\$216.27	\$78.19	\$43.25
78594	Vent image, mult proj, gas		S	0401	3.3954	\$216.27	\$78.19	\$43.25
78596	Lung differential function		S	0378	4.9509	\$315.34	\$125.33	\$63.07
78599	Respiratory nuclear exam		S	0401	3.3954	\$216.27	\$78.19	\$43.25
78600	Brain image < 4 views	CH	S	0403	3.2295	\$205.70	\$79.87	\$41.14
78601	Brain image w/flow < 4 views	CH	S	0403	3.2295	\$205.70	\$79.87	\$41.14
78605	Brain image 4+ views	CH	S	0403	3.2295	\$205.70	\$79.87	\$41.14
78606	Brain image w/flow 4 + views		S	0402	8.8235	\$562.00	\$114.12	\$112.40
78607	Brain imaging (3D)		S	0402	8.8235	\$562.00	\$114.12	\$112.40
78608	Brain imaging (PET)		S	0308	16.6001	\$1,057.33		\$211.47
78609	Brain imaging (PET)		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
78610	Brain flow imaging only		S	0402	8.8235	\$562.00	\$114.12	\$112.40
78615	Cerebral vascular flow image	CH	D					
78630	Cerebrospinal fluid scan	CH	S	0402	8.8235	\$562.00	\$114.12	\$112.40
78635	CSF ventriculography	CH	S	0402	8.8235	\$562.00	\$114.12	\$112.40
78645	CSF shunt evaluation		S	0403	3.2295	\$205.70	\$79.87	\$41.14
78647	Cerebrospinal fluid scan	CH	S	0402	8.8235	\$562.00	\$114.12	\$112.40
78650	CSF leakage imaging	CH	S	0402	8.8235	\$562.00	\$114.12	\$112.40
78660	Nuclear exam of tear flow		S	0403	3.2295	\$205.70	\$79.87	\$41.14
78699	Nervous system nuclear exam	CH	S	0403	3.2295	\$205.70	\$79.87	\$41.14
78700	Kidney imaging, morphol		S	0404	5.0824	\$323.72	\$84.11	\$64.74
78701	Kidney imaging with flow		S	0404	5.0824	\$323.72	\$84.11	\$64.74
78707	K flow/funct image w/o drug		S	0404	5.0824	\$323.72	\$84.11	\$64.74
78708	K flow/funct image w/drug	CH	S	0404	5.0824	\$323.72	\$84.11	\$64.74
78709	K flow/funct image, multiple	CH	S	0404	5.0824	\$323.72	\$84.11	\$64.74
78710	Kidney imaging (3D)		S	0404	5.0824	\$323.72	\$84.11	\$64.74
78725	Kidney function study	CH	S	0392	2.9022	\$184.85	\$49.31	\$36.97
78730	Urinary bladder retention	CH	S	0389	1.8190	\$115.86	\$33.81	\$23.17
78740	Ureteral reflux study		S	0404	5.0824	\$323.72	\$84.11	\$64.74
78761	Testicular imaging w/flow		S	0404	5.0824	\$323.72	\$84.11	\$64.74
78799	Genitourinary nuclear exam		S	0404	5.0824	\$323.72	\$84.11	\$64.74
78800	Tumor imaging, limited area		S	0406	5.0681	\$322.81	\$98.18	\$64.56
78801	Tumor imaging, mult areas		S	0406	5.0681	\$322.81	\$98.18	\$64.56
78802	Tumor imaging, whole body	CH	S	0414	8.4176	\$536.15	\$214.44	\$107.23
78803	Tumor imaging (3D)	CH	S	0408	15.4033	\$981.10		\$196.22
78804	Tumor imaging, whole body		S	0408	15.4033	\$981.10		\$196.22
78805	Abscess imaging, ltd area	CH	S	0414	8.4176	\$536.15	\$214.44	\$107.23
78806	Abscess imaging, whole body	CH	S	0414	8.4176	\$536.15	\$214.44	\$107.23
78807	Nuclear localization/abscess	CH	S	0414	8.4176	\$536.15	\$214.44	\$107.23
78811	Pet image, ltd area		S	0308	16.6001	\$1,057.33		\$211.47
78812	Pet image, skull-thigh		S	0308	16.6001	\$1,057.33		\$211.47
78813	Pet image, full body		S	0308	16.6001	\$1,057.33		\$211.47
78814	Pet image w/ct, lmted	CH	S	0308	16.6001	\$1,057.33		\$211.47
78815	Pet image w/ct, skull-thigh	CH	S	0308	16.6001	\$1,057.33		\$211.47
78816	Pet image w/ct, full body	CH	S	0308	16.6001	\$1,057.33		\$211.47
78890	Nuclear medicine data proc		N					
78891	Nuclear med data proc		N					
78999	Nuclear diagnostic exam		S	0389	1.8190	\$115.86	\$33.81	\$23.17
79005	Nuclear rx, oral admin		S	0407	3.3020	\$210.32	\$78.13	\$42.06
79101	Nuclear rx, iv admin		S	0407	3.3020	\$210.32	\$78.13	\$42.06
79200	Nuclear rx, intracav admin		S	0413	5.2741	\$335.93		\$67.19
79300	Nucl rx, interstit colloid		S	0407	3.3020	\$210.32	\$78.13	\$42.06
79403	Hematopoietic nuclear tx		S	0413	5.2741	\$335.93		\$67.19
79440	Nuclear rx, intra-articular		S	0413	5.2741	\$335.93		\$67.19
79445	Nuclear rx, intra-arterial		S	0407	3.3020	\$210.32	\$78.13	\$42.06
79999	Nuclear medicine therapy		S	0407	3.3020	\$210.32	\$78.13	\$42.06
80047	Metabolic panel ionized ca	NI	A					
80048	Metabolic panel total ca		A					
80050	General health panel		E					
80051	Electrolyte panel		A					
80053	Comprehen metabolic panel		A					
80055	Obstetric panel		E					
80061	Lipid panel		A					
80069	Renal function panel		A					
80074	Acute hepatitis panel		A					
80076	Hepatic function panel		A					
80100	Drug screen, qualitate/multi		A					
80101	Drug screen, single		A					
80102	Drug confirmation		A					
80103	Drug analysis, tissue prep		N					
80150	Assay of amikacin		A					
80152	Assay of amitriptyline		A					
80154	Assay of benzodiazepines		A					
80156	Assay, carbamazepine, total		A					
80157	Assay, carbamazepine, free		A					
80158	Assay of cyclosporine		A					
80160	Assay of desipramine		A					
80162	Assay of digoxin		A					
80164	Assay, dipropylacetic acid		A					
80166	Assay of doxepin		A					
80168	Assay of ethosuximide		A					
80170	Assay of gentamicin		A					
80172	Assay of gold		A					
80173	Assay of haloperidol		A					
80174	Assay of imipramine		A					
80176	Assay of lidocaine		A					
80178	Assay of lithium		A					
80182	Assay of nortriptyline		A					
80184	Assay of phenobarbital		A					
80185	Assay of phenytoin, total		A					
80186	Assay of phenytoin, free		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
80188	Assay of primidone		A					
80190	Assay of procainamide		A					
80192	Assay of procainamide		A					
80194	Assay of quinidine		A					
80195	Assay of sirolimus		A					
80196	Assay of salicylate		A					
80197	Assay of tacrolimus		A					
80198	Assay of theophylline		A					
80200	Assay of tobramycin		A					
80201	Assay of topiramate		A					
80202	Assay of vancomycin		A					
80299	Quantitative assay, drug		A					
80400	Acth stimulation panel		A					
80402	Acth stimulation panel		A					
80406	Acth stimulation panel		A					
80408	Aldosterone suppression eval		A					
80410	Calcitonin stimul panel		A					
80412	CRH stimulation panel		A					
80414	Testosterone response		A					
80415	Estradiol response panel		A					
80416	Renin stimulation panel		A					
80417	Renin stimulation panel		A					
80418	Pituitary evaluation panel		A					
80420	Dexamethasone panel		A					
80422	Glucagon tolerance panel		A					
80424	Glucagon tolerance panel		A					
80426	Gonadotropin hormone panel		A					
80428	Growth hormone panel		A					
80430	Growth hormone panel		A					
80432	Insulin suppression panel		A					
80434	Insulin tolerance panel		A					
80435	Insulin tolerance panel		A					
80436	Metyrapone panel		A					
80438	TRH stimulation panel		A					
80439	TRH stimulation panel		A					
80440	TRH stimulation panel		A					
80500	Lab pathology consultation	X		0433	0.2397	\$15.27	\$5.17	\$3.05
80502	Lab pathology consultation	X		0342	0.0969	\$6.17	\$2.02	\$1.23
81000	Urinalysis, nonauto w/scope		A					
81001	Urinalysis, auto w/scope		A					
81002	Urinalysis nonauto w/o scope		A					
81003	Urinalysis, auto, w/o scope		A					
81005	Urinalysis		A					
81007	Urine screen for bacteria		A					
81015	Microscopic exam of urine		A					
81020	Urinalysis, glass test		A					
81025	Urine pregnancy test		A					
81050	Urinalysis, volume measure		A					
81099	Urinalysis test procedure		A					
82000	Assay of blood acetaldehyde		A					
82003	Assay of acetaminophen		A					
82009	Test for acetone/ketones		A					
82010	Acetone assay		A					
82013	Acetylcholinesterase assay		A					
82016	Acylcarnitines, qual		A					
82017	Acylcarnitines, quant		A					
82024	Assay of acth		A					
82030	Assay of adp & amp		A					
82040	Assay of serum albumin		A					
82042	Assay of urine albumin		A					
82043	Microalbumin, quantitative		A					
82044	Microalbumin, semiquant		A					
82045	Albumin, ischemia modified		A					
82055	Assay of ethanol		A					
82075	Assay of breath ethanol		A					
82085	Assay of aldolase		A					
82088	Assay of aldosterone		A					
82101	Assay of urine alkaloids		A					
82103	Alpha-1-antitrypsin, total		A					
82104	Alpha-1-antitrypsin, pheno		A					
82105	Alpha-fetoprotein, serum		A					
82106	Alpha-fetoprotein, amniotic		A					
82107	Alpha-fetoprotein I3		A					
82108	Assay of aluminum		A					
82120	Amines, vaginal fluid qual		A					
82127	Amino acid, single qual		A					
82128	Amino acids, mult qual		A					
82131	Amino acids, single quant		A					
82135	Assay, aminolevulinic acid		A					
82136	Amino acids, quant, 2-5		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
82139	Amino acids, quan, 6 or more	A						
82140	Assay of ammonia	A						
82143	Amniotic fluid scan	A						
82145	Assay of amphetamines	A						
82150	Assay of amylase	A						
82154	Androstenediol glucuronide	A						
82157	Assay of androstenedione	A						
82160	Assay of androsterone	A						
82163	Assay of angiotensin II	A						
82164	Angiotensin I enzyme test	A						
82172	Assay of apolipoprotein	A						
82175	Assay of arsenic	A						
82180	Assay of ascorbic acid	A						
82190	Atomic absorption	A						
82205	Assay of barbiturates	A						
82232	Assay of beta-2 protein	A						
82239	Bile acids, total	A						
82240	Bile acids, cholyglycine	A						
82247	Bilirubin, total	A						
82248	Bilirubin, direct	A						
82252	Fecal bilirubin test	A						
82261	Assay of biotinidase	A						
82270	Occult blood, feces	A						
82271	Occult blood, other sources	A						
82272	Occult bld feces, 1-3 tests	A						
82274	Assay test for blood, fecal	A						
82286	Assay of bradykinin	A						
82300	Assay of cadmium	A						
82306	Assay of vitamin D	A						
82307	Assay of vitamin D	A						
82308	Assay of calcitonin	A						
82310	Assay of calcium	A						
82330	Assay of calcium	A						
82331	Calcium infusion test	A						
82340	Assay of calcium in urine	A						
82355	Calculus analysis, qual	A						
82360	Calculus assay, quant	A						
82365	Calculus spectroscopy	A						
82370	X-ray assay, calculus	A						
82373	Assay, c-d transfer measure	A						
82374	Assay, blood carbon dioxide	A						
82375	Assay, blood carbon monoxide	A						
82376	Test for carbon monoxide	A						
82378	Carcinoembryonic antigen	A						
82379	Assay of carnitine	A						
82380	Assay of carotene	A						
82382	Assay, urine catecholamines	A						
82383	Assay, blood catecholamines	A						
82384	Assay, three catecholamines	A						
82387	Assay of cathepsin-d	A						
82390	Assay of ceruloplasmin	A						
82397	Chemiluminescent assay	A						
82415	Assay of chloramphenicol	A						
82435	Assay of blood chloride	A						
82436	Assay of urine chloride	A						
82438	Assay, other fluid chlorides	A						
82441	Test for chlorohydrocarbons	A						
82465	Assay, bld/serum cholesterol	A						
82480	Assay, serum cholinesterase	A						
82482	Assay, rbc cholinesterase	A						
82485	Assay, chondroitin sulfate	A						
82486	Gas/liquid chromatography	A						
82487	Paper chromatography	A						
82488	Paper chromatography	A						
82489	Thin layer chromatography	A						
82491	Chromotography, quant, sing	A						
82492	Chromotography, quant, mult	A						
82495	Assay of chromium	A						
82507	Assay of citrate	A						
82520	Assay of cocaine	A						
82523	Collagen crosslinks	A						
82525	Assay of copper	A						
82528	Assay of corticosterone	A						
82530	Cortisol, free	A						
82533	Total cortisol	A						
82540	Assay of creatine	A						
82541	Column chromatography, qual	A						
82542	Column chromatography, quant	A						
82543	Column chromatograph/isotope	A						
82544	Column chromatograph/isotope	A						

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
82550	Assay of ck (cpk)		A					
82552	Assay of cpk in blood		A					
82553	Creatine, MB fraction		A					
82554	Creatine, isoforms		A					
82565	Assay of creatinine		A					
82570	Assay of urine creatinine		A					
82575	Creatinine clearance test		A					
82585	Assay of cryofibrinogen		A					
82595	Assay of cryoglobulin		A					
82600	Assay of cyanide		A					
82607	Vitamin B-12		A					
82608	B-12 binding capacity		A					
82610	Cystatin c	NI	A					
82615	Test for urine cystines		A					
82626	Dehydroepiandrosterone		A					
82627	Dehydroepiandrosterone		A					
82633	Desoxycorticosterone		A					
82634	Deoxycortisol		A					
82638	Assay of dibucaine number		A					
82646	Assay of dihydrocodeinone		A					
82649	Assay of dihydromorphinone		A					
82651	Assay of dihydrotestosterone		A					
82652	Assay of dihydroxyvitamin d		A					
82654	Assay of dimethadione		A					
82656	Pancreatic elastase, fecal		A					
82657	Enzyme cell activity		A					
82658	Enzyme cell activity, ra		A					
82664	Electrophoretic test		A					
82666	Assay of epiandrosterone		A					
82668	Assay of erythropoietin		A					
82670	Assay of estradiol		A					
82671	Assay of estrogens		A					
82672	Assay of estrogen		A					
82677	Assay of estriol		A					
82679	Assay of estrone		A					
82690	Assay of ethchlorvynol		A					
82693	Assay of ethylene glycol		A					
82696	Assay of etiocholanolone		A					
82705	Fats/lipids, feces, qual		A					
82710	Fats/lipids, feces, quant		A					
82715	Assay of fecal fat		A					
82725	Assay of blood fatty acids		A					
82726	Long chain fatty acids		A					
82728	Assay of ferritin		A					
82731	Assay of fetal fibronectin		A					
82735	Assay of fluoride		A					
82742	Assay of flurazepam		A					
82746	Blood folic acid serum		A					
82747	Assay of folic acid, rbc		A					
82757	Assay of semen fructose		A					
82759	Assay of rbc galactokinase		A					
82760	Assay of galactose		A					
82775	Assay galactose transferase		A					
82776	Galactose transferase test		A					
82784	Assay of gammaglobulin igm		A					
82785	Assay of gammaglobulin ige		A					
82787	Igg 1, 2, 3 or 4, each		A					
82800	Blood pH		A					
82803	Blood gases: pH, pO2 & pCO2		A					
82805	Blood gases w/o2 saturation		A					
82810	Blood gases, O2 sat only		A					
82820	Hemoglobin-oxygen affinity		A					
82926	Assay of gastric acid		A					
82928	Assay of gastric acid		A					
82938	Gastrin test		A					
82941	Assay of gastrin		A					
82943	Assay of glucagon		A					
82945	Glucose other fluid		A					
82946	Glucagon tolerance test		A					
82947	Assay, glucose, blood quant		A					
82948	Reagent strip/blood glucose		A					
82950	Glucose test		A					
82951	Glucose tolerance test (GTT)		A					
82952	GTT-added samples		A					
82953	Glucose-tolbutamide test		A					
82955	Assay of g6pd enzyme		A					
82960	Test for G6PD enzyme		A					
82962	Glucose blood test		A					
82963	Assay of glucosidase		A					
82965	Assay of gdh enzyme		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
82975	Assay of glutamine		A					
82977	Assay of GGT		A					
82978	Assay of glutathione		A					
82979	Assay, rbc glutathione		A					
82980	Assay of glutethimide		A					
82985	Glycated protein		A					
83001	Gonadotropin (FSH)		A					
83002	Gonadotropin (LH)		A					
83003	Assay, growth hormone (hgh)		A					
83008	Assay of guanosine		A					
83009	H pylori (c-13), blood		A					
83010	Assay of haptoglobin, quant		A					
83012	Assay of haptoglobins		A					
83013	H pylori (c-13), breath		A					
83014	H pylori drug admin		A					
83015	Heavy metal screen		A					
83018	Quantitative screen, metals		A					
83020	Hemoglobin electrophoresis		A					
83021	Hemoglobin chromatography		A					
83026	Hemoglobin, copper sulfate		A					
83030	Fetal hemoglobin, chemical		A					
83033	Fetal hemoglobin assay, qual		A					
83036	Glycosylated hemoglobin test		A					
83037	Glycosylated hb, home device		A					
83045	Blood methemoglobin test		A					
83050	Blood methemoglobin assay		A					
83051	Assay of plasma hemoglobin		A					
83055	Blood sulfhemoglobin test		A					
83060	Blood sulfhemoglobin assay		A					
83065	Assay of hemoglobin heat		A					
83068	Hemoglobin stability screen		A					
83069	Assay of urine hemoglobin		A					
83070	Assay of hemosiderin, qual		A					
83071	Assay of hemosiderin, quant		A					
83080	Assay of b hexosaminidase		A					
83088	Assay of histamine		A					
83090	Assay of homocystine		A					
83150	Assay of for hva		A					
83491	Assay of corticosteroids		A					
83497	Assay of 5-hiaa		A					
83498	Assay of progesterone		A					
83499	Assay of progesterone		A					
83500	Assay, free hydroxyproline		A					
83505	Assay, total hydroxyproline		A					
83516	Immunoassay, nonantibody		A					
83518	Immunoassay, dipstick		A					
83519	Immunoassay, nonantibody		A					
83520	Immunoassay, RIA		A					
83525	Assay of insulin		A					
83527	Assay of insulin		A					
83528	Assay of intrinsic factor		A					
83540	Assay of iron		A					
83550	Iron binding test		A					
83570	Assay of idh enzyme		A					
83582	Assay of ketogenic steroids		A					
83586	Assay 17- ketosteroids		A					
83593	Fractionation, ketosteroids		A					
83605	Assay of lactic acid		A					
83615	Lactate (LD) (LDH) enzyme		A					
83625	Assay of ldh enzymes		A					
83630	Lactoferrin, fecal (qual)		A					
83631	Lactoferrin, fecal (quant)		A					
83632	Placental lactogen		A					
83633	Test urine for lactose		A					
83634	Assay of urine for lactose		A					
83655	Assay of lead		A					
83661	L/s ratio, fetal lung		A					
83662	Foam stability, fetal lung		A					
83663	Fluoro polarize, fetal lung		A					
83664	Lamellar bdy, fetal lung		A					
83670	Assay of lap enzyme		A					
83690	Assay of lipase		A					
83695	Assay of lipoprotein(a)		A					
83698	Assay lipoprotein pla2		A					
83700	Lipopro bld, electrophoretic		A					
83701	Lipoprotein bld, hr fraction		A					
83704	Lipoprotein, bld, by nmr		A					
83718	Assay of lipoprotein		A					
83719	Assay of blood lipoprotein		A					
83721	Assay of blood lipoprotein		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
83727	Assay of lrh hormone		A					
83735	Assay of magnesium		A					
83775	Assay of md enzyme		A					
83785	Assay of manganese		A					
83788	Mass spectrometry qual		A					
83789	Mass spectrometry quant		A					
83805	Assay of meprobamate		A					
83825	Assay of mercury		A					
83835	Assay of metanephrines		A					
83840	Assay of methadone		A					
83857	Assay of methemalbumin		A					
83858	Assay of methsuximide		A					
83864	Mucopolysaccharides		A					
83866	Mucopolysaccharides screen		A					
83872	Assay synovial fluid mucin		A					
83873	Assay of csf protein		A					
83874	Assay of myoglobin		A					
83880	Natriuretic peptide		A					
83883	Assay, nephelometry not spec		A					
83885	Assay of nickel		A					
83887	Assay of nicotine		A					
83890	Molecule isolate		A					
83891	Molecule isolate nucleic		A					
83892	Molecular diagnostics		A					
83893	Molecule dot/slot/blot		A					
83894	Molecule gel electrophor		A					
83896	Molecular diagnostics		A					
83897	Molecule nucleic transfer		A					
83898	Molecule nucleic ampli, each		A					
83900	Molecule nucleic ampli 2 seq		A					
83901	Molecule nucleic ampli addon		A					
83902	Molecular diagnostics		A					
83903	Molecule mutation scan		A					
83904	Molecule mutation identify		A					
83905	Molecule mutation identify		A					
83906	Molecule mutation identify		A					
83907	Lyse cells for nucleic ext		A					
83908	Nucleic acid, signal ampli		A					
83909	Nucleic acid, high resolute		A					
83912	Genetic examination		A					
83913	Molecular, rna stabilization		A					
83914	Mutation ident ola/sbce/aspe		A					
83915	Assay of nucleotidase		A					
83916	Oligoclonal bands		A					
83918	Organic acids, total, quant		A					
83919	Organic acids, qual, each		A					
83921	Organic acid, single, quant		A					
83925	Assay of opiates		A					
83930	Assay of blood osmolality		A					
83935	Assay of urine osmolality		A					
83937	Assay of osteocalcin		A					
83945	Assay of oxalate		A					
83950	Oncoprotein, her-2/neu		A					
83970	Assay of parathormone		A					
83986	Assay of body fluid acidity		A					
83992	Assay for phencyclidine		A					
83993	Assay for calprotectin fecal	NI	A					
84022	Assay of phenothiazine		A					
84030	Assay of blood pku		A					
84035	Assay of phenylketones		A					
84060	Assay acid phosphatase		A					
84061	Phosphatase, forensic exam		A					
84066	Assay prostate phosphatase		A					
84075	Assay alkaline phosphatase		A					
84078	Assay alkaline phosphatase		A					
84080	Assay alkaline phosphatases		A					
84081	Amniotic fluid enzyme test		A					
84085	Assay of rbc pg6d enzyme		A					
84087	Assay phosphohexose enzymes		A					
84100	Assay of phosphorus		A					
84105	Assay of urine phosphorus		A					
84106	Test for porphobilinogen		A					
84110	Assay of porphobilinogen		A					
84119	Test urine for porphyrins		A					
84120	Assay of urine porphyrins		A					
84126	Assay of feces porphyrins		A					
84127	Assay of feces porphyrins		A					
84132	Assay of serum potassium		A					
84133	Assay of urine potassium		A					
84134	Assay of prealbumin		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
84135	Assay of pregnanediol		A					
84138	Assay of pregnanetriol		A					
84140	Assay of pregnenolone		A					
84143	Assay of 17-hydroxypregнено		A					
84144	Assay of progesterone		A					
84146	Assay of prolactin		A					
84150	Assay of prostaglandin		A					
84152	Assay of psa, complexed		A					
84153	Assay of psa, total		A					
84154	Assay of psa, free		A					
84155	Assay of protein, serum		A					
84156	Assay of protein, urine		A					
84157	Assay of protein, other		A					
84160	Assay of protein, any source		A					
84163	Pappa, serum		A					
84165	Protein e-phoresis, serum		A					
84166	Protein e-phoresis/urine/csf		A					
84181	Western blot test		A					
84182	Protein, western blot test		A					
84202	Assay RBC protoporphyrin		A					
84203	Test RBC protoporphyrin		A					
84206	Assay of proinsulin		A					
84207	Assay of vitamin b-6		A					
84210	Assay of pyruvate		A					
84220	Assay of pyruvate kinase		A					
84228	Assay of quinine		A					
84233	Assay of estrogen		A					
84234	Assay of progesterone		A					
84235	Assay of endocrine hormone		A					
84238	Assay, nonendocrine receptor		A					
84244	Assay of renin		A					
84252	Assay of vitamin b-2		A					
84255	Assay of selenium		A					
84260	Assay of serotonin		A					
84270	Assay of sex hormone globul		A					
84275	Assay of sialic acid		A					
84285	Assay of silica		A					
84295	Assay of serum sodium		A					
84300	Assay of urine sodium		A					
84302	Assay of sweat sodium		A					
84305	Assay of somatomedin		A					
84307	Assay of somatostatin		A					
84311	Spectrophotometry		A					
84315	Body fluid specific gravity		A					
84375	Chromatogram assay, sugars		A					
84376	Sugars, single, qual		A					
84377	Sugars, multiple, qual		A					
84378	Sugars, single, quant		A					
84379	Sugars multiple quant		A					
84392	Assay of urine sulfate		A					
84402	Assay of testosterone		A					
84403	Assay of total testosterone		A					
84425	Assay of vitamin b-1		A					
84430	Assay of thiocyanate		A					
84432	Assay of thyroglobulin		A					
84436	Assay of total thyroxine		A					
84437	Assay of neonatal thyroxine		A					
84439	Assay of free thyroxine		A					
84442	Assay of thyroid activity		A					
84443	Assay thyroid stim hormone		A					
84445	Assay of tsi		A					
84446	Assay of vitamin e		A					
84449	Assay of transcortin		A					
84450	Transferase (AST) (SGOT)		A					
84460	Alanine amino (ALT) (SGPT)		A					
84466	Assay of transferrin		A					
84478	Assay of triglycerides		A					
84479	Assay of thyroid (t3 or t4)		A					
84480	Assay, triiodothyronine (t3)		A					
84481	Free assay (FT-3)		A					
84482	T3 reverse		A					
84484	Assay of troponin, quant		A					
84485	Assay duodenal fluid trypsin		A					
84488	Test feces for trypsin		A					
84490	Assay of feces for trypsin		A					
84510	Assay of tyrosine		A					
84512	Assay of troponin, qual		A					
84520	Assay of urea nitrogen		A					
84525	Urea nitrogen semi-quant		A					
84540	Assay of urine/urea-n		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
84545	Urea-N clearance test		A					
84550	Assay of blood/uric acid		A					
84560	Assay of urine/uric acid		A					
84577	Assay of feces/urobilinogen		A					
84578	Test urine urobilinogen		A					
84580	Assay of urine urobilinogen		A					
84583	Assay of urine urobilinogen		A					
84585	Assay of urine vma		A					
84586	Assay of vip		A					
84588	Assay of vasopressin		A					
84590	Assay of vitamin a		A					
84591	Assay of nos vitamin		A					
84597	Assay of vitamin k		A					
84600	Assay of volatiles		A					
84620	Xylose tolerance test		A					
84630	Assay of zinc		A					
84681	Assay of c-peptide		A					
84702	Chorionic gonadotropin test		A					
84703	Chorionic gonadotropin assay		A					
84704	Hcg, free betachain test	NI	A					
84830	Ovulation tests		A					
84999	Clinical chemistry test		A					
85002	Bleeding time test		A					
85004	Automated diff wbc count		A					
85007	Bl smear w/diff wbc count		A					
85008	Bl smear w/o diff wbc count		A					
85009	Manual diff wbc count b-coat		A					
85013	Spun microhematocrit		A					
85014	Hematocrit		A					
85018	Hemoglobin		A					
85025	Complete cbc w/auto diff wbc		A					
85027	Complete cbc, automated		A					
85032	Manual cell count, each		A					
85041	Automated rbc count		A					
85044	Manual reticulocyte count		A					
85045	Automated reticulocyte count		A					
85046	Reticyte/hgb concentrate		A					
85048	Automated leukocyte count		A					
85049	Automated platelet count		A					
85055	Reticulated platelet assay		A					
85060	Blood smear interpretation		B					
85097	Bone marrow interpretation		X	0343	0.5142	\$32.75	\$10.84	\$6.55
85130	Chromogenic substrate assay		A					
85170	Blood clot retraction		A					
85175	Blood clot lysis time		A					
85210	Blood clot factor II test		A					
85220	Blood clot factor V test		A					
85230	Blood clot factor VII test		A					
85240	Blood clot factor VIII test		A					
85244	Blood clot factor VIII test		A					
85245	Blood clot factor VIII test		A					
85246	Blood clot factor VIII test		A					
85247	Blood clot factor VIII test		A					
85250	Blood clot factor IX test		A					
85260	Blood clot factor X test		A					
85270	Blood clot factor XI test		A					
85280	Blood clot factor XII test		A					
85290	Blood clot factor XIII test		A					
85291	Blood clot factor XIII test		A					
85292	Blood clot factor assay		A					
85293	Blood clot factor assay		A					
85300	Antithrombin III test		A					
85301	Antithrombin III test		A					
85302	Blood clot inhibitor antigen		A					
85303	Blood clot inhibitor test		A					
85305	Blood clot inhibitor assay		A					
85306	Blood clot inhibitor test		A					
85307	Assay activated protein c		A					
85335	Factor inhibitor test		A					
85337	Thrombomodulin		A					
85345	Coagulation time		A					
85347	Coagulation time		A					
85348	Coagulation time		A					
85360	Euglobulin lysis		A					
85362	Fibrin degradation products		A					
85366	Fibrinogen test		A					
85370	Fibrinogen test		A					
85378	Fibrin degrade, semiquant		A					
85379	Fibrin degradation, quant		A					
85380	Fibrin degradation, vte		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
85384	Fibrinogen		A					
85385	Fibrinogen		A					
85390	Fibrinolysins screen		A					
85396	Clotting assay, whole blood		N					
85400	Fibrinolytic plasmin		A					
85410	Fibrinolytic antiplasmin		A					
85415	Fibrinolytic plasminogen		A					
85420	Fibrinolytic plasminogen		A					
85421	Fibrinolytic plasminogen		A					
85441	Heinz bodies, direct		A					
85445	Heinz bodies, induced		A					
85460	Hemoglobin, fetal		A					
85461	Hemoglobin, fetal		A					
85475	Hemolysin		A					
85520	Heparin assay		A					
85525	Heparin neutralization		A					
85530	Heparin-protamine tolerance		A					
85536	Iron stain peripheral blood		A					
85540	Wbc alkaline phosphatase		A					
85547	RBC mechanical fragility		A					
85549	Muramidase		A					
85555	RBC osmotic fragility		A					
85557	RBC osmotic fragility		A					
85576	Blood platelet aggregation		A					
85597	Platelet neutralization		A					
85610	Prothrombin time		A					
85611	Prothrombin test		A					
85612	Viper venom prothrombin time		A					
85613	Russell viper venom, diluted		A					
85635	Reptilase test		A					
85651	Rbc sed rate, nonautomated		A					
85652	Rbc sed rate, automated		A					
85660	RBC sickle cell test		A					
85670	Thrombin time, plasma		A					
85675	Thrombin time, titer		A					
85705	Thromboplastin inhibition		A					
85730	Thromboplastin time, partial		A					
85732	Thromboplastin time, partial		A					
85810	Blood viscosity examination		A					
85999	Hematology procedure		A					
86000	Agglutinins, febrile		A					
86001	Allergen specific igg		A					
86003	Allergen specific IgE		A					
86005	Allergen specific IgE		A					
86021	WBC antibody identification		A					
86022	Platelet antibodies		A					
86023	Immunoglobulin assay		A					
86038	Antinuclear antibodies		A					
86039	Antinuclear antibodies (ANA)		A					
86060	Antistreptolysin o, titer		A					
86063	Antistreptolysin o, screen		X					
86077	Physician blood bank service		X	0433	0.2397	\$15.27	\$5.17	\$3.05
86078	Physician blood bank service		X	0343	0.5142	\$32.75	\$10.84	\$6.55
86079	Physician blood bank service		X	0433	0.2397	\$15.27	\$5.17	\$3.05
86140	C-reactive protein		A					
86141	C-reactive protein, hs		A					
86146	Glycoprotein antibody		A					
86147	Cardiolipin antibody		A					
86148	Phospholipid antibody		A					
86155	Chemotaxis assay		A					
86156	Cold agglutinin, screen		A					
86157	Cold agglutinin, titer		A					
86160	Complement, antigen		A					
86161	Complement/function activity		A					
86162	Complement, total (CH50)		A					
86171	Complement fixation, each		A					
86185	Counterimmunoelectrophoresis		A					
86200	Ccp antibody		A					
86215	Deoxyribonuclease, antibody		A					
86225	DNA antibody		A					
86226	DNA antibody, single strand		A					
86235	Nuclear antigen antibody		A					
86243	Fc receptor		A					
86255	Fluorescent antibody, screen		A					
86256	Fluorescent antibody, titer		A					
86277	Growth hormone antibody		A					
86280	Hemagglutination inhibition		A					
86294	Immunoassay, tumor, qual		A					
86300	Immunoassay, tumor, ca 15-3		A					
86301	Immunoassay, tumor, ca 19-9		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
86304	Immunoassay, tumor, ca 125		A					
86308	Heterophile antibodies		A					
86309	Heterophile antibodies		A					
86310	Heterophile antibodies		A					
86316	Immunoassay, tumor other		A					
86317	Immunoassay, infectious agent		A					
86318	Immunoassay, infectious agent		A					
86320	Serum immunoelectrophoresis		A					
86325	Other immunoelectrophoresis		A					
86327	Immunoelectrophoresis assay		A					
86329	Immunodiffusion		A					
86331	Immunodiffusion ouchterlony		A					
86332	Immune complex assay		A					
86334	Immunofix e-phoresis, serum		A					
86335	Immunifix e-phorsis/urine/csf		A					
86336	Inhibin A		A					
86337	Insulin antibodies		A					
86340	Intrinsic factor antibody		A					
86341	Islet cell antibody		A					
86343	Leukocyte histamine release		A					
86344	Leukocyte phagocytosis		A					
86353	Lymphocyte transformation		A					
86355	B cells, total count		A					
86356	Mononuclear cell antigen	NI	A					
86357	Nk cells, total count		A					
86359	T cells, total count		A					
86360	T cell, absolute count/ratio		A					
86361	T cell, absolute count		A					
86367	Stem cells, total count		A					
86376	Microsomal antibody		A					
86378	Migration inhibitory factor		A					
86382	Neutralization test, viral		A					
86384	Nitroblue tetrazolium dye		A					
86403	Particle agglutination test		A					
86406	Particle agglutination test		A					
86430	Rheumatoid factor test		A					
86431	Rheumatoid factor, quant		A					
86480	Tb test, cell immun measure		A					
86485	Skin test, candida		X	0341	0.0844	\$5.38	\$2.14	\$1.08
86486	Skin test, nos antigen	NI	A					
86490	Coccidioidomycosis skin test		X	0341	0.0844	\$5.38	\$2.14	\$1.08
86510	Histoplasmosis skin test		X	0341	0.0844	\$5.38	\$2.14	\$1.08
86580	TB intradermal test		X	0341	0.0844	\$5.38	\$2.14	\$1.08
86586	Skin test, unlisted	CH	D					
86590	Streptokinase, antibody		A					
86592	Blood serology, qualitative		A					
86593	Blood serology, quantitative		A					
86602	Antinomyces antibody		A					
86603	Adenovirus antibody		A					
86606	Aspergillus antibody		A					
86609	Bacterium antibody		A					
86611	Bartonella antibody		A					
86612	Blastomyces antibody		A					
86615	Bordetella antibody		A					
86617	Lyme disease antibody		A					
86618	Lyme disease antibody		A					
86619	Borrelia antibody		A					
86622	Bruceella antibody		A					
86625	Campylobacter antibody		A					
86628	Candida antibody		A					
86631	Chlamydia antibody		A					
86632	Chlamydia igm antibody		A					
86635	Coccidioides antibody		A					
86638	Q fever antibody		A					
86641	Cryptococcus antibody		A					
86644	CMV antibody		A					
86645	CMV antibody, IgM		A					
86648	Diphtheria antibody		A					
86651	Encephalitis antibody		A					
86652	Encephalitis antibody		A					
86653	Encephalitis antibody		A					
86654	Encephalitis antibody		A					
86658	Enterovirus antibody		A					
86663	Epstein-barr antibody		A					
86664	Epstein-barr antibody		A					
86665	Epstein-barr antibody		A					
86666	Ehrlichia antibody		A					
86668	Francisella tularensis		A					
86671	Fungus antibody		A					
86674	Giardia lamblia antibody		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
86677	Helicobacter pylori		A					
86682	Helminth antibody		A					
86684	Hemophilus influenza		A					
86687	Htlv-i antibody		A					
86688	Htlv-ii antibody		A					
86689	HTLV/HIV confirmatory test		A					
86692	Hepatitis, delta agent		A					
86694	Herpes simplex test		A					
86695	Herpes simplex test		A					
86696	Herpes simplex type 2		A					
86698	Histoplasma		A					
86701	HIV-1		A					
86702	HIV-2		A					
86703	HIV-1/HIV-2, single assay		A					
86704	Hep b core antibody, total		A					
86705	Hep b core antibody, igm		A					
86706	Hep b surface antibody		A					
86707	Hep be antibody		A					
86708	Hep a antibody, total		A					
86709	Hep a antibody, igm		A					
86710	Influenza virus antibody		A					
86713	Legionella antibody		A					
86717	Leishmania antibody		A					
86720	Leptospira antibody		A					
86723	Listeria monocytogenes ab		A					
86727	Lymph choriomeningitis ab		A					
86729	Lympho venereum antibody		A					
86732	Mucormycosis antibody		A					
86735	Mumps antibody		A					
86738	Mycoplasma antibody		A					
86741	Neisseria meningitidis		A					
86744	Nocardia antibody		A					
86747	Parvovirus antibody		A					
86750	Malaria antibody		A					
86753	Protozoa antibody nos		A					
86756	Respiratory virus antibody		A					
86757	Rickettsia antibody		A					
86759	Rotavirus antibody		A					
86762	Rubella antibody		A					
86765	Rubeola antibody		A					
86768	Salmonella antibody		A					
86771	Shigella antibody		A					
86774	Tetanus antibody		A					
86777	Toxoplasma antibody		A					
86778	Toxoplasma antibody, igm		A					
86781	Treponema pallidum, confirm		A					
86784	Trichinella antibody		A					
86787	Varicella-zoster antibody		A					
86788	West Nile virus ab, igm		A					
86789	West Nile virus antibody		A					
86790	Virus antibody nos		A					
86793	Yersinia antibody		A					
86800	Thyroglobulin antibody		A					
86803	Hepatitis c ab test		A					
86804	Hep c ab test, confirm		A					
86805	Lymphocytotoxicity assay		A					
86806	Lymphocytotoxicity assay		A					
86807	Cytotoxic antibody screening		A					
86808	Cytotoxic antibody screening		A					
86812	HLA typing, A, B, or C		A					
86813	HLA typing, A, B, or C		A					
86816	HLA typing, DR/DQ		A					
86817	HLA typing, DR/DQ		A					
86821	Lymphocyte culture, mixed		A					
86822	Lymphocyte culture, primed		A					
86849	Immunology procedure		A					
86850	RBC antibody screen		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86860	RBC antibody elution		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86870	RBC antibody identification		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86880	Coombs test, direct		X	0409	0.1190	\$7.58	\$2.20	\$1.52
86885	Coombs test, indirect, qual		X	0409	0.1190	\$7.58	\$2.20	\$1.52
86886	Coombs test, indirect, titer		X	0409	0.1190	\$7.58	\$2.20	\$1.52
86890	Autologous blood process		X	0347	0.7739	\$49.29	\$11.28	\$9.86
86891	Autologous blood, op salvage		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86900	Blood typing, ABO		X	0409	0.1190	\$7.58	\$2.20	\$1.52
86901	Blood typing, Rh (D)		X	0409	0.1190	\$7.58	\$2.20	\$1.52
86903	Blood typing, antigen screen		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86904	Blood typing, patient serum		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86905	Blood typing, RBC antigens		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86906	Blood typing, Rh phenotype		X	0345	0.2140	\$13.63	\$2.87	\$2.73

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
86910	Blood typing, paternity test		E					
86911	Blood typing, antigen system		E					
86920	Compatibility test, spin		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86921	Compatibility test, incubate		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86922	Compatibility test, antiglob		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86923	Compatibility test, electric		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86927	Plasma, fresh frozen		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86930	Frozen blood prep		X	0347	0.7739	\$49.29	\$11.28	\$9.86
86931	Frozen blood thaw		X	0347	0.7739	\$49.29	\$11.28	\$9.86
86932	Frozen blood freeze/thaw		X	0347	0.7739	\$49.29	\$11.28	\$9.86
86940	Hemolysins/agglutinins, auto		A					
86941	Hemolysins/agglutinins		A					
86945	Blood product/irradiation		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86950	Leukocyte transfusion		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86960	Vol reduction of blood/prod		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86965	Pooling blood platelets		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86970	RBC pretreatment		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86971	RBC pretreatment		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86972	RBC pretreatment		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86975	RBC pretreatment, serum		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86976	RBC pretreatment, serum		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86977	RBC pretreatment, serum		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86978	RBC pretreatment, serum		X	0346	0.3346	\$21.31	\$4.37	\$4.26
86985	Split blood or products		X	0345	0.2140	\$13.63	\$2.87	\$2.73
86999	Transfusion procedure		X	0345	0.2140	\$13.63	\$2.87	\$2.73
87001	Small animal inoculation		A					
87003	Small animal inoculation		A					
87015	Specimen concentration		A					
87040	Blood culture for bacteria		A					
87045	Feces culture, bacteria		A					
87046	Stool cultr, bacteria, each		A					
87070	Culture, bacteria, other		A					
87071	Culture bacteri aerobic othr		A					
87073	Culture bacteria anaerobic		A					
87075	Cultr bacteria, except blood		A					
87076	Culture anaerobe ident, each		A					
87077	Culture aerobic identify		A					
87081	Culture screen only		A					
87084	Culture of specimen by kit		A					
87086	Urine culture/colony count		A					
87088	Urine bacteria culture		A					
87101	Skin fungi culture		A					
87102	Fungus isolation culture		A					
87103	Blood fungus culture		A					
87106	Fungi identification, yeast		A					
87107	Fungi identification, mold		A					
87109	Mycoplasma		A					
87110	Chlamydia culture		A					
87116	Mycobacteria culture		A					
87118	Mycobacteric identification		A					
87140	Culture type immunofluoresc		A					
87143	Culture typing, glc/hplc		A					
87147	Culture type, immunologic		A					
87149	Culture type, nucleic acid		A					
87152	Culture type pulse field gel		A					
87158	Culture typing, added method		A					
87164	Dark field examination		A					
87166	Dark field examination		A					
87168	Macroscopic exam arthropod		A					
87169	Macroscopic exam parasite		A					
87172	Pinworm exam		A					
87176	Tissue homogenization, cultr		A					
87177	Ova and parasites smears		A					
87181	Microbe susceptible, diffuse		A					
87184	Microbe susceptible, disk		A					
87185	Microbe susceptible, enzyme		A					
87186	Microbe susceptible, mic		A					
87187	Microbe susceptible, mlc		A					
87188	Microbe suscept, macrobroth		A					
87190	Microbe suscept, mycobacteri		A					
87197	Bactericidal level, serum		A					
87205	Smear, gram stain		A					
87206	Smear, fluorescent/acid stai		A					
87207	Smear, special stain		A					
87209	Smear, complex stain		A					
87210	Smear, wet mount, saline/ink		A					
87220	Tissue exam for fungi		A					
87230	Assay, toxin or antitoxin		A					
87250	Virus inoculate, eggs/animal		A					
87252	Virus inoculation, tissue		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
87253	Virus inoculate tissue, addl		A					
87254	Virus inoculation, shell via		A					
87255	Genet virus isolate, hsv		A					
87260	Adenovirus ag, if		A					
87265	Pertussis ag, if		A					
87267	Enterovirus antibody, dfa		A					
87269	Giardia ag, if		A					
87270	Chlamydia trachomatis ag, if		A					
87271	Cytomegalovirus dfa		A					
87272	Cryptosporidium ag, if		A					
87273	Herpes simplex 2, ag, if		A					
87274	Herpes simplex 1, ag, if		A					
87275	Influenza b, ag, if		A					
87276	Influenza a, ag, if		A					
87277	Legionella micdadei, ag, if		A					
87278	Legion pneumophila ag, if		A					
87279	Parainfluenza, ag, if		A					
87280	Respiratory syncytial ag, if		A					
87281	Pneumocystis carinii, ag, if		A					
87283	Rubeola, ag, if		A					
87285	Treponema pallidum, ag, if		A					
87290	Varicella zoster, ag, if		A					
87299	Antibody detection, nos, if		A					
87300	Ag detection, polyval, if		A					
87301	Adenovirus ag, eia		A					
87305	Aspergillus ag, eia		A					
87320	Chylmd trach ag, eia		A					
87324	Clostridium ag, eia		A					
87327	Cryptococcus neoform ag, eia		A					
87328	Cryptosporidium ag, eia		A					
87329	Giardia ag, eia		A					
87332	Cytomegalovirus ag, eia		A					
87335	E coli O157 ag, eia		A					
87336	Entamoeb hist dispr, ag, eia		A					
87337	Entamoeb hist group, ag, eia		A					
87338	Hpylori, stool, eia		A					
87339	H pylori ag, eia		A					
87340	Hepatitis b surface ag, eia		A					
87341	Hepatitis b surface, ag, eia		A					
87350	Hepatitis be ag, eia		A					
87380	Hepatitis delta ag, eia		A					
87385	Histoplasma capsul ag, eia		A					
87390	Hiv-1 ag, eia		A					
87391	Hiv-2 ag, eia		A					
87400	Influenza a/b, ag, eia		A					
87420	Resp syncytial ag, eia		A					
87425	Rotavirus ag, eia		A					
87427	Shiga-like toxin ag, eia		A					
87430	Strep a ag, eia		A					
87449	Ag detect nos, eia, mult		A					
87450	Ag detect nos, eia, single		A					
87451	Ag detect polyval, eia, mult		A					
87470	Bartonella, dna, dir probe		A					
87471	Bartonella, dna, amp probe		A					
87472	Bartonella, dna, quant		A					
87475	Lyme dis, dna, dir probe		A					
87476	Lyme dis, dna, amp probe		A					
87477	Lyme dis, dna, quant		A					
87480	Candida, dna, dir probe		A					
87481	Candida, dna, amp probe		A					
87482	Candida, dna, quant		A					
87485	Chylmd pneum, dna, dir probe		A					
87486	Chylmd pneum, dna, amp probe		A					
87487	Chylmd pneum, dna, quant		A					
87490	Chylmd trach, dna, dir probe		A					
87491	Chylmd trach, dna, amp probe		A					
87492	Chylmd trach, dna, quant		A					
87495	Cytomeg, dna, dir probe		A					
87496	Cytomeg, dna, amp probe		A					
87497	Cytomeg, dna, quant		A					
87498	Enterovirus, dna, amp probe		A					
87500	Vanomycin, dna, amp probe	NI	A					
87510	Gardner vag, dna, dir probe		A					
87511	Gardner vag, dna, amp probe		A					
87512	Gardner vag, dna, quant		A					
87515	Hepatitis b, dna, dir probe		A					
87516	Hepatitis b, dna, amp probe		A					
87517	Hepatitis b, dna, quant		A					
87520	Hepatitis c, rna, dir probe		A					
87521	Hepatitis c, rna, amp probe		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
87522	Hepatitis c, ma, quant		A					
87525	Hepatitis g, dna, dir probe		A					
87526	Hepatitis g, dna, amp probe		A					
87527	Hepatitis g, dna, quant		A					
87528	Hsv, dna, dir probe		A					
87529	Hsv, dna, amp probe		A					
87530	Hsv, dna, quant		A					
87531	Hhv-6, dna, dir probe		A					
87532	Hhv-6, dna, amp probe		A					
87533	Hhv-6, dna, quant		A					
87534	Hiv-1, dna, dir probe		A					
87535	Hiv-1, dna, amp probe		A					
87536	Hiv-1, dna, quant		A					
87537	Hiv-2, dna, dir probe		A					
87538	Hiv-2, dna, amp probe		A					
87539	Hiv-2, dna, quant		A					
87540	Legion pneumo, dna, dir prob		A					
87541	Legion pneumo, dna, amp prob		A					
87542	Legion pneumo, dna, quant		A					
87550	Mycobacteria, dna, dir probe		A					
87551	Mycobacteria, dna, amp probe		A					
87552	Mycobacteria, dna, quant		A					
87555	M.tuberculo, dna, dir probe		A					
87556	M.tuberculo, dna, amp probe		A					
87557	M.tuberculo, dna, quant		A					
87560	M.avium-intra, dna, dir prob		A					
87561	M.avium-intra, dna, amp prob		A					
87562	M.avium-intra, dna, quant		A					
87580	M.pneumon, dna, dir probe		A					
87581	M.pneumon, dna, amp probe		A					
87582	M.pneumon, dna, quant		A					
87590	N.gonorrhoeae, dna, dir prob		A					
87591	N.gonorrhoeae, dna, amp prob		A					
87592	N.gonorrhoeae, dna, quant		A					
87620	Hpv, dna, dir probe		A					
87621	Hpv, dna, amp probe		A					
87622	Hpv, dna, quant		A					
87640	Staph a, dna, amp probe		A					
87641	Mr-staph, dna, amp probe		A					
87650	Strep a, dna, dir probe		A					
87651	Strep a, dna, amp probe		A					
87652	Strep a, dna, quant		A					
87653	Strep b, dna, amp probe		A					
87660	Trichomonas vagin, dir probe		A					
87797	Detect agent nos, dna, dir		A					
87798	Detect agent nos, dna, amp		A					
87799	Detect agent nos, dna, quant		A					
87800	Detect agnt mult, dna, direc		A					
87801	Detect agnt mult, dna, ampli		A					
87802	Strep b assay w/optic		A					
87803	Clostridium toxin a w/optic		A					
87804	Influenza assay w/optic		A					
87807	Rsv assay w/optic		A					
87808	Trichomonas assay w/optic		A					
87809	Adenovirus assay w/optic	NI	A					
87810	Chylmd trach assay w/optic		A					
87850	N. gonorrhoeae assay w/optic		A					
87880	Strep a assay w/optic		A					
87899	Agent nos assay w/optic		A					
87900	Phenotype, infect agent drug		A					
87901	Genotype, dna, hiv reverse t		A					
87902	Genotype, dna, hepatitis C		A					
87903	Phenotype, dna hiv w/culture		A					
87904	Phenotype, dna hiv w/clt add		A					
87999	Microbiology procedure		A					
88000	Autopsy (necropsy), gross		E					
88005	Autopsy (necropsy), gross		E					
88007	Autopsy (necropsy), gross		E					
88012	Autopsy (necropsy), gross		E					
88014	Autopsy (necropsy), gross		E					
88016	Autopsy (necropsy), gross		E					
88020	Autopsy (necropsy), complete		E					
88025	Autopsy (necropsy), complete		E					
88027	Autopsy (necropsy), complete		E					
88028	Autopsy (necropsy), complete		E					
88029	Autopsy (necropsy), complete		E					
88036	Limited autopsy		E					
88037	Limited autopsy		E					
88040	Forensic autopsy (necropsy)		E					
88045	Coroner's autopsy (necropsy)		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
88099	Necropsy (autopsy) procedure		E					
88104	Cytopath fl nongyn, smears		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88106	Cytopath fl nongyn, filter		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88107	Cytopath fl nongyn, sm/fltr	CH	X	0343	0.5142	\$32.75	\$10.84	\$6.55
88108	Cytopath, concentrate tech	CH	X	0343	0.5142	\$32.75	\$10.84	\$6.55
88112	Cytopath, cell enhance tech		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88125	Forensic cytopathology		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88130	Sex chromatin identification		A					
88140	Sex chromatin identification		A					
88141	Cytopath, c/v, interpret		N					
88142	Cytopath, c/v, thin layer		A					
88143	Cytopath c/v thin layer redo		A					
88147	Cytopath, c/v, automated		A					
88148	Cytopath, c/v, auto rescreen		A					
88150	Cytopath, c/v, manual		A					
88152	Cytopath, c/v, auto redo		A					
88153	Cytopath, c/v, redo		A					
88154	Cytopath, c/v, select		A					
88155	Cytopath, c/v, index add-on		A					
88160	Cytopath smear, other source		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88161	Cytopath smear, other source		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88162	Cytopath smear, other source	CH	X	0343	0.5142	\$32.75	\$10.84	\$6.55
88164	Cytopath tbs, c/v, manual		A					
88165	Cytopath tbs, c/v, redo		A					
88166	Cytopath tbs, c/v, auto redo		A					
88167	Cytopath tbs, c/v, select		A					
88172	Cytopathology eval of fna		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88173	Cytopath eval, fna, report		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88174	Cytopath, c/v auto, in fluid		A					
88175	Cytopath c/v auto fluid redo		A					
88182	Cell marker study		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88184	Flowcytometry/ tc, 1 marker		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88185	Flowcytometry/tc, add-on		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88187	Flowcytometry/read, 2-8		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88188	Flowcytometry/read, 9-15		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88189	Flowcytometry/read, 16 & >		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88199	Cytopathology procedure		X	0342	0.0969	\$6.17	\$2.02	\$1.23
88230	Tissue culture, lymphocyte		A					
88233	Tissue culture, skin/biopsy		A					
88235	Tissue culture, placenta		A					
88237	Tissue culture, bone marrow		A					
88239	Tissue culture, tumor		A					
88240	Cell cryopreserve/storage		A					
88241	Frozen cell preparation		A					
88245	Chromosome analysis, 20-25		A					
88248	Chromosome analysis, 50-100		A					
88249	Chromosome analysis, 100		A					
88261	Chromosome analysis, 5		A					
88262	Chromosome analysis, 15-20		A					
88263	Chromosome analysis, 45		A					
88264	Chromosome analysis, 20-25		A					
88267	Chromosome analys, placenta		A					
88269	Chromosome analys, amniotic		A					
88271	Cytogenetics, dna probe		A					
88272	Cytogenetics, 3-5		A					
88273	Cytogenetics, 10-30		A					
88274	Cytogenetics, 25-99		A					
88275	Cytogenetics, 100-300		A					
88280	Chromosome karyotype study		A					
88283	Chromosome banding study		A					
88285	Chromosome count, additional		A					
88289	Chromosome study, additional		A					
88291	Cyto/molecular report		M					
88299	Cytogenetic study		X	0342	0.0969	\$6.17	\$2.02	\$1.23
88300	Surgical path, gross		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88302	Tissue exam by pathologist		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88304	Tissue exam by pathologist		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88305	Tissue exam by pathologist		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88307	Tissue exam by pathologist		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88309	Tissue exam by pathologist		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88311	Decalcify tissue		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88312	Special stains		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88313	Special stains		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88314	Histochemical stain	CH	X	0433	0.2397	\$15.27	\$5.17	\$3.05
88318	Chemical histochemistry		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88319	Enzyme histochemistry	CH	X	0433	0.2397	\$15.27	\$5.17	\$3.05
88321	Microslide consultation		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88323	Microslide consultation		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88325	Comprehensive review of data		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88329	Path consult introp		X	0433	0.2397	\$15.27	\$5.17	\$3.05

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
88331	Path consult intraop, 1 bloc		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88332	Path consult intraop, add'l		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88333	Intraop cyto path consult, 1		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88334	Intraop cyto path consult, 2		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88342	Immunohistochemistry		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88346	Immunofluorescent study		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88347	Immunofluorescent study		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88348	Electron microscopy		X	0661	2.6949	\$171.65	\$62.09	\$34.33
88349	Scanning electron microscopy		X	0661	2.6949	\$171.65	\$62.09	\$34.33
88355	Analysis, skeletal muscle		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88356	Analysis, nerve		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88358	Analysis, tumor		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88360	Tumor immunohistochem/manual		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88361	Tumor immunohistochem/comput		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88362	Nerve teasing preparations		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88365	Insitu hybridization (fish)		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88367	Insitu hybridization, auto		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88368	Insitu hybridization, manual	CH	X	0343	0.5142	\$32.75	\$10.84	\$6.55
88371	Protein, western blot tissue		A					
88372	Protein analysis w/probe		A					
88380	Microdissection, laser		N					
88381	Microdissection, manual	NI	N					
88384	Eval molecular probes, 11–50		X	0433	0.2397	\$15.27	\$5.17	\$3.05
88385	Eval molecu probes, 51–250		X	0343	0.5142	\$32.75	\$10.84	\$6.55
88386	Eval molecu probes, 251–500		X	0344	0.8167	\$52.02	\$15.66	\$10.40
88399	Surgical pathology procedure		X	0342	0.0969	\$6.17	\$2.02	\$1.23
88400	Bilirubin total transcut		A					
89049	Chct for mal hyperthermia		X	0343	0.5142	\$32.75	\$10.84	\$6.55
89050	Body fluid cell count		A					
89051	Body fluid cell count		A					
89055	Leukocyte assessment, fecal		A					
89060	Exam,synovial fluid crystals		A					
89100	Sample intestinal contents		X	0360	1.5330	\$97.64	\$33.88	\$19.53
89105	Sample intestinal contents		X	0360	1.5330	\$97.64	\$33.88	\$19.53
89125	Specimen fat stain		A					
89130	Sample stomach contents		X	0360	1.5330	\$97.64	\$33.88	\$19.53
89132	Sample stomach contents		X	0360	1.5330	\$97.64	\$33.88	\$19.53
89135	Sample stomach contents		X	0360	1.5330	\$97.64	\$33.88	\$19.53
89136	Sample stomach contents		X	0360	1.5330	\$97.64	\$33.88	\$19.53
89140	Sample stomach contents		X	0360	1.5330	\$97.64	\$33.88	\$19.53
89141	Sample stomach contents		X	0360	1.5330	\$97.64	\$33.88	\$19.53
89160	Exam feces for meat fibers		A					
89190	Nasal smear for eosinophils		A					
89220	Sputum specimen collection		X	0343	0.5142	\$32.75	\$10.84	\$6.55
89225	Starch granules, feces		A					
89230	Collect sweat for test	CH	X	0343	0.5142	\$32.75	\$10.84	\$6.55
89235	Water load test		A					
89240	Pathology lab procedure		X	0342	0.0969	\$6.17	\$2.02	\$1.23
89250	Cultr oocyte/embryo <4 days	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89251	Cultr oocyte/embryo <4 days	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89253	Embryo hatching	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89254	Oocyte identification	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89255	Prepare embryo for transfer	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89257	Sperm identification	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89258	Cryopreservation; embryo(s)	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89259	Cryopreservation, sperm	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89260	Sperm isolation, simple	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89261	Sperm isolation, complex	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89264	Identify sperm tissue	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89268	Insemination of oocytes	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89272	Extended culture of oocytes	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89280	Assist oocyte fertilization	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89281	Assist oocyte fertilization	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89290	Biopsy, oocyte polar body	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89291	Biopsy, oocyte polar body	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89300	Semen analysis w/huhner		A					
89310	Semen analysis w/count		A					
89320	Semen anal vol/count/mot		A					
89321	Semen anal, sperm detection		A					
89322	Semen anal, strict criteria	NI	A					
89325	Sperm antibody test		A					
89329	Sperm evaluation test		A					
89330	Evaluation, cervical mucus		A					
89331	Retrograde ejaculation anal	NI	A					
89335	Cryopreserve testicular tiss	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89342	Storage/year; embryo(s)	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89343	Storage/year; sperm/semen	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89344	Storage/year; reprod tissue	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89346	Storage/year; oocyte(s)	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89352	Thawing cryopresrvd; embryo	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
89353	Thawing cryopresrvd; sperm	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89354	Thaw cryoprsrvd; reprod tiss	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
89356	Thawing cryopresrvd; oocyte	CH	X	0344	0.8167	\$52.02	\$15.66	\$10.40
90281	Human ig, im		E					
90283	Human ig, iv		E					
90284	Human ig, sc	NI	E					
90287	Botulinum antitoxin		E					
90288	Botulism ig, iv		E					
90291	Cmv ig, iv		E					
90296	Diphtheria antitoxin		N					
90371	Hep b ig, im		K	1630		\$122.02		\$24.40
90375	Rabies ig, im/sc		K	9133		\$68.22		\$13.64
90376	Rabies ig, heat treated		K	9134		\$71.69		\$14.34
90378	Rsv ig, im, 50mg		E					
90379	Rsv ig, iv		E					
90384	Rh ig, full-dose, im		E					
90385	Rh ig, minidose, im		N					
90386	Rh ig, iv		E					
90389	Tetanus ig, im		E					
90393	Vaccina ig, im		N					
90396	Varicella-zoster ig, im		K	9135		\$122.74		\$24.55
90399	Immune globulin		E					
90465	Immune admin 1 inj, < 8 yrs		B					
90466	Immune admin addl inj, < 8 y		B					
90467	Immune admin o or n, < 8 yrs		B					
90468	Immune admin o/n, addl < 8 y		B					
90471	Immunization admin		S	0437	0.3945	\$25.13		\$5.03
90472	Immunization admin, each add		S	0436	0.2545	\$16.21		\$3.24
90473	Immune admin oral/nasal		S	0436	0.2545	\$16.21		\$3.24
90474	Immune admin oral/nasal addl		S	0436	0.2545	\$16.21		\$3.24
90476	Adenovirus vaccine, type 4		N					
90477	Adenovirus vaccine, type 7		N					
90581	Anthrax vaccine, sc		N					
90585	Bcg vaccine, percut		K	9137		\$118.98		\$23.80
90586	Bcg vaccine, intravesical		B					
90632	Hep a vaccine, adult im		N					
90633	Hep a vacc, ped/adol, 2 dose		N					
90634	Hep a vacc, ped/adol, 3 dose		N					
90636	Hep a/hep b vacc, adult im		N					
90645	Hib vaccine, hboc, im		N					
90646	Hib vaccine, prp-d, im		N					
90647	Hib vaccine, prp-omp, im		N					
90648	Hib vaccine, prp-t, im		N					
90649	H papilloma vacc 3 dose im		B					
90655	Flu vaccine no preserv 6-35m		L					
90656	Flu vaccine no preserv 3 & >		L					
90657	Flu vaccine, 3 yrs, im		L					
90658	Flu vaccine, 3 yrs & >, im		L					
90660	Flu vaccine, nasal		L					
90661	Flu vacc cell cult prsv free	NI	L					
90662	Flu vacc prsv free inc antig	NI	L					
90663	Flu vacc pandemic	NI	L					
90665	Lyme disease vaccine, im		N					
90669	Pneumococcal vacc, ped <5	CH	L					
90675	Rabies vaccine, im		K	9139		\$150.80		\$30.16
90676	Rabies vaccine, id		K	9140		\$119.86		\$23.97
90680	Rotovirus vacc 3 dose, oral		N					
90690	Typhoid vaccine, oral		N					
90691	Typhoid vaccine, im		N					
90692	Typhoid vaccine, h-p, sc/id		N					
90693	Typhoid vaccine, akd, sc		B					
90698	Dtap-hib-ip vaccine, im		N					
90700	Dtap vaccine, < 7 yrs, im		N					
90701	Dtp vaccine, im		N					
90702	Dt vaccine < 7, im		N					
90703	Tetanus vaccine, im		N					
90704	Mumps vaccine, sc		N					
90705	Measles vaccine, sc		N					
90706	Rubella vaccine, sc		N					
90707	Mmr vaccine, sc		N					
90708	Measles-rubella vaccine, sc		K	9141		\$45.53		\$9.11
90710	Mmr vaccine, sc		N					
90712	Oral poliovirus vaccine		N					
90713	Poliovirus, ipv, sc/im		N					
90714	Td vaccine no prsv >= 7 im		N					
90715	Tdap vaccine >7 im		N					
90716	Chicken pox vaccine, sc		B					
90717	Yellow fever vaccine, sc		N					
90718	Td vaccine > 7, im		N					
90719	Diphtheria vaccine, im		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
90720	Dtp/hib vaccine, im	CH	N					
90721	Dtap/hib vaccine, im		N					
90723	Dtap-hep b-ipv vaccine, im		E					
90725	Cholera vaccine, injectable		N					
90727	Plague vaccine, im	CH	N					
90732	Pneumococcal vaccine		L					
90733	Meningococcal vaccine, sc		K	9143		\$85.29		\$17.06
90734	Meningococcal vaccine, im		K	9145		\$82.00		\$16.40
90735	Encephalitis vaccine, sc		K	9144		\$98.17		\$19.63
90736	Zoster vacc, sc		B					
90740	Hepb vacc, ill pat 3 dose im		F					
90743	Hep b vacc, adol, 2 dose, im		F					
90744	Hepb vacc ped/adol 3 dose im		F					
90746	Hep b vaccine, adult, im		F					
90747	Hepb vacc, ill pat 4 dose im		F					
90748	Hep b/hib vaccine, im		E					
90749	Vaccine toxoid		N					
90760	Hydration iv infusion, init		S	0440	1.7998	\$114.64		\$22.93
90761	Hydrate iv infusion, add-on		S	0437	0.3945	\$25.13		\$5.03
90765	Ther/proph/diag iv inf, init		S	0440	1.7998	\$114.64		\$22.93
90766	Ther/proph/dg iv inf, add-on		S	0437	0.3945	\$25.13		\$5.03
90767	Tx/proph/dg addl seq iv inf		S	0437	0.3945	\$25.13		\$5.03
90768	Ther/diag concurrent inf		N					
90769	Sc ther infusion, up to 1 hr	NI	S	0440	1.7998	\$114.64		\$22.93
90770	Sc ther infusion, addl hr	NI	S	0437	0.3945	\$25.13		\$5.03
90771	Sc ther infusion, reset pump	NI	S	0438	0.8041	\$51.22		\$10.24
90772	Ther/proph/diag inj, sc/im		S	0437	0.3945	\$25.13		\$5.03
90773	Ther/proph/diag inj, ia		S	0438	0.8041	\$51.22		\$10.24
90774	Ther/proph/diag inj, iv push		S	0438	0.8041	\$51.22		\$10.24
90775	Tx/pro/dx inj new drug addon		S	0438	0.8041	\$51.22		\$10.24
90776	Tx/pro/dx inj same drug addon	NI	N					
90779	Ther/proph/diag inj/inf proc		S	0436	0.2545	\$16.21		\$3.24
90801	Psy dx interview	CH	Q	0323	1.6044	\$102.19		\$20.44
90802	Intac psy dx interview	CH	Q	0323	1.6044	\$102.19		\$20.44
90804	Psytx, office, 20–30 min	CH	Q	0322	1.1729	\$74.71		\$14.94
90805	Psytx, off, 20–30 min w/e&m	CH	Q	0322	1.1729	\$74.71		\$14.94
90806	Psytx, off, 45–50 min	CH	Q	0323	1.6044	\$102.19		\$20.44
90807	Psytx, off, 45–50 min w/e&m	CH	Q	0323	1.6044	\$102.19		\$20.44
90808	Psytx, office, 75–80 min	CH	Q	0323	1.6044	\$102.19		\$20.44
90809	Psytx, off, 75–80, w/e&m	CH	Q	0323	1.6044	\$102.19		\$20.44
90810	Intac psytx, off, 20–30 min	CH	Q	0322	1.1729	\$74.71		\$14.94
90811	Intac psytx, 20–30, w/e&m	CH	Q	0322	1.1729	\$74.71		\$14.94
90812	Intac psytx, off, 45–50 min	CH	Q	0323	1.6044	\$102.19		\$20.44
90813	Intac psytx, 45–50 min w/e&m	CH	Q	0323	1.6044	\$102.19		\$20.44
90814	Intac psytx, off, 75–80 min	CH	Q	0323	1.6044	\$102.19		\$20.44
90815	Intac psytx, 75–80 w/e&m	CH	Q	0323	1.6044	\$102.19		\$20.44
90816	Psytx, hosp, 20–30 min	CH	Q	0322	1.1729	\$74.71		\$14.94
90817	Psytx, hosp, 20–30 min w/e&m	CH	Q	0322	1.1729	\$74.71		\$14.94
90818	Psytx, hosp, 45–50 min	CH	Q	0323	1.6044	\$102.19		\$20.44
90819	Psytx, hosp, 45–50 min w/e&m	CH	Q	0323	1.6044	\$102.19		\$20.44
90821	Psytx, hosp, 75–80 min	CH	Q	0323	1.6044	\$102.19		\$20.44
90822	Psytx, hosp, 75–80 min w/e&m	CH	Q	0323	1.6044	\$102.19		\$20.44
90823	Intac psytx, hosp, 20–30 min	CH	Q	0322	1.1729	\$74.71		\$14.94
90824	Intac psytx, hsp 20–30 w/e&m	CH	Q	0322	1.1729	\$74.71		\$14.94
90826	Intac psytx, hosp, 45–50 min	CH	Q	0323	1.6044	\$102.19		\$20.44
90827	Intac psytx, hsp 45–50 w/e&m	CH	Q	0323	1.6044	\$102.19		\$20.44
90828	Intac psytx, hosp, 75–80 min	CH	Q	0323	1.6044	\$102.19		\$20.44
90829	Intac psytx, hsp 75–80 w/e&m	CH	Q	0323	1.6044	\$102.19		\$20.44
90845	Psychoanalysis	CH	Q	0323	1.6044	\$102.19		\$20.44
90846	Family psytx w/o patient	CH	Q	0324	2.3616	\$150.42		\$30.08
90847	Family psytx w/patient	CH	Q	0324	2.3616	\$150.42		\$30.08
90849	Multiple family group psytx	CH	Q	0325	0.9913	\$63.14	\$13.81	\$12.63
90853	Group psychotherapy	CH	Q	0325	0.9913	\$63.14	\$13.81	\$12.63
90857	Intac group psytx	CH	Q	0325	0.9913	\$63.14	\$13.81	\$12.63
90862	Medication management	CH	Q	0606	1.3226	\$84.24		\$16.85
90865	Narcosynthesis	CH	Q	0323	1.6044	\$102.19		\$20.44
90870	Electroconvulsive therapy		S	0320	5.7299	\$364.96	\$80.06	\$72.99
90875	Psychophysiological therapy		E					
90876	Psychophysiological therapy		E					
90880	Hypnotherapy	CH	Q	0323	1.6044	\$102.19		\$20.44
90882	Environmental manipulation		E					
90885	Psy evaluation of records		N					
90887	Consultation with family		N					
90889	Preparation of report		Q					
90899	Psychiatric service/therapy	CH	Q	0322	1.1729	\$74.71		\$14.94
90901	Biofeedback train, any meth		A					
90911	Biofeedback peri/uro/rectal	CH	T	0126	1.0356	\$65.96	\$16.21	\$13.19
90918	ESRD related services, month		E					
90919	ESRD related services, month		E					
90920	ESRD related services, month		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
90921	ESRD related services, month		E					
90922	ESRD related services, day		E					
90923	Esrd related services, day		E					
90924	Esrd related services, day		E					
90925	Esrd related services, day		E					
90935	Hemodialysis, one evaluation		S	0170	6.5383	\$416.45		\$83.29
90937	Hemodialysis, repeated eval		B					
90940	Hemodialysis access study		N					
90945	Dialysis, one evaluation		S	0170	6.5383	\$416.45		\$83.29
90947	Dialysis, repeated eval		B					
90989	Dialysis training, complete		B					
90993	Dialysis training, incompl		B					
90997	Hemoperfusion		B					
90999	Dialysis procedure		B					
91000	Esophageal intubation		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91010	Esophagus motility study		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91011	Esophagus motility study		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91012	Esophagus motility study		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91020	Gastric motility studies		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91022	Duodenal motility study		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91030	Acid perfusion of esophagus		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91034	Gastroesophageal reflux test		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91035	G-esoph reflx tst w/electrod		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91037	Esoph impeded function test		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91038	Esoph impeded funct test > 1h		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91040	Esoph balloon distension tst		X	0360	1.5330	\$97.64	\$33.88	\$19.53
91052	Gastric analysis test		X	0361	3.9276	\$250.16	\$83.23	\$50.03
91055	Gastric intubation for smear		X	0360	1.5330	\$97.64	\$33.88	\$19.53
91065	Breath hydrogen test		X	0360	1.5330	\$97.64	\$33.88	\$19.53
91100	Pass intestine bleeding tube		X	0360	1.5330	\$97.64	\$33.88	\$19.53
91105	Gastric intubation treatment		X	0360	1.5330	\$97.64	\$33.88	\$19.53
91110	Gi tract capsule endoscopy		T	0142	9.5292	\$606.95	\$152.78	\$121.39
91111	Esophageal capsule endoscopy		T	0141	8.5030	\$541.59	\$143.38	\$108.32
91120	Rectal sensation test		T	0126	1.0356	\$65.96	\$16.21	\$13.19
91122	Anal pressure record		T	0164	2.0077	\$127.88		\$25.58
91123	Irrigate fecal impaction		N					
91132	Electrogastrography		X	0360	1.5330	\$97.64	\$33.88	\$19.53
91133	Electrogastrography w/test		X	0360	1.5330	\$97.64	\$33.88	\$19.53
91299	Gastroenterology procedure		X	0360	1.5330	\$97.64	\$33.88	\$19.53
92002	Eye exam, new patient		V	0605	0.9964	\$63.46		\$12.69
92004	Eye exam, new patient		V	0606	1.3226	\$84.24		\$16.85
92012	Eye exam established pat		V	0604	0.8388	\$53.43		\$10.69
92014	Eye exam & treatment		V	0605	0.9964	\$63.46		\$12.69
92015	Refraction		E					
92018	New eye exam & treatment		T	0699	13.7453	\$875.49		\$175.10
92019	Eye exam & treatment		T	0699	13.7453	\$875.49		\$175.10
92020	Special eye evaluation		S	0230	0.5903	\$37.60		\$7.52
92025	Corneal topography		S	0698	0.8696	\$55.39		\$11.08
92060	Special eye evaluation	CH	S	0698	0.8696	\$55.39		\$11.08
92065	Orthoptic/pleoptic training	CH	S	0698	0.8696	\$55.39		\$11.08
92070	Fitting of contact lens		N					
92081	Visual field examination(s)		S	0230	0.5903	\$37.60		\$7.52
92082	Visual field examination(s)	CH	S	0698	0.8696	\$55.39		\$11.08
92083	Visual field examination(s)	CH	S	0698	0.8696	\$55.39		\$11.08
92100	Serial tonometry exam(s)		N					
92120	Tonography & eye evaluation	CH	S	0698	0.8696	\$55.39		\$11.08
92130	Water provocation tonography		S	0230	0.5903	\$37.60		\$7.52
92135	Ophth dx imaging post seg		S	0230	0.5903	\$37.60		\$7.52
92136	Ophthalmic biometry		S	0698	0.8696	\$55.39		\$11.08
92140	Glaucoma provocative tests		S	0230	0.5903	\$37.60		\$7.52
92225	Special eye exam, initial		S	0230	0.5903	\$37.60		\$7.52
92226	Special eye exam, subsequent	CH	S	0698	0.8696	\$55.39		\$11.08
92230	Eye exam with photos		S	0231	2.1790	\$138.79		\$27.76
92235	Eye exam with photos		S	0231	2.1790	\$138.79		\$27.76
92240	Icg angiography		S	0231	2.1790	\$138.79		\$27.76
92250	Eye exam with photos	CH	S	0698	0.8696	\$55.39		\$11.08
92260	Ophthalmoscopy/dynamometry		S	0230	0.5903	\$37.60		\$7.52
92265	Eye muscle evaluation	CH	S	0698	0.8696	\$55.39		\$11.08
92270	Electro-oculography		S	0230	0.5903	\$37.60		\$7.52
92275	Electroretinography		S	0231	2.1790	\$138.79		\$27.76
92283	Color vision examination		S	0230	0.5903	\$37.60		\$7.52
92284	Dark adaptation eye exam		S	0698	0.8696	\$55.39		\$11.08
92285	Eye photography	CH	S	0698	0.8696	\$55.39		\$11.08
92286	Internal eye photography	CH	S	0231	2.1790	\$138.79		\$27.76
92287	Internal eye photography	CH	S	0231	2.1790	\$138.79		\$27.76
92310	Contact lens fitting		E					
92311	Contact lens fitting	CH	S	0698	0.8696	\$55.39		\$11.08
92312	Contact lens fitting	CH	S	0698	0.8696	\$55.39		\$11.08
92313	Contact lens fitting	CH	S	0230	0.5903	\$37.60		\$7.52
92314	Prescription of contact lens		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
92315	Prescription of contact lens	CH	S	0230	0.5903	\$37.60		\$7.52
92316	Prescription of contact lens	CH	S	0698	0.8696	\$55.39		\$11.08
92317	Prescription of contact lens	CH	S	0230	0.5903	\$37.60		\$7.52
92325	Modification of contact lens	CH	S	0230	0.5903	\$37.60		\$7.52
92326	Replacement of contact lens	CH	S	0698	0.8696	\$55.39		\$11.08
92340	Fitting of spectacles		E					
92341	Fitting of spectacles		E					
92342	Fitting of spectacles		E					
92352	Special spectacles fitting	CH	S	0698	0.8696	\$55.39		\$11.08
92353	Special spectacles fitting	CH	S	0230	0.5903	\$37.60		\$7.52
92354	Special spectacles fitting	CH	S	0230	0.5903	\$37.60		\$7.52
92355	Special spectacles fitting	CH	S	0230	0.5903	\$37.60		\$7.52
92358	Eye prosthesis service	CH	S	0230	0.5903	\$37.60		\$7.52
92370	Repair & adjust spectacles		E					
92371	Repair & adjust spectacles	CH	S	0230	0.5903	\$37.60		\$7.52
92499	Eye service or procedure		S	0230	0.5903	\$37.60		\$7.52
92502	Ear and throat examination		T	0251	2.5002	\$159.25		\$31.85
92504	Ear microscopy examination		N					
92506	Speech/hearing evaluation		A					
92507	Speech/hearing therapy		A					
92508	Speech/hearing therapy		A					
92511	Nasopharyngoscopy		T	0071	0.8224	\$52.38	\$11.20	\$10.48
92512	Nasal function studies		X	0363	0.8067	\$51.38	\$17.10	\$10.28
92516	Facial nerve function test		X	0660	1.4312	\$91.16	\$28.06	\$18.23
92520	Laryngeal function studies		X	0660	1.4312	\$91.16	\$28.06	\$18.23
92526	Oral function therapy		A					
92531	Spontaneous nystagmus study		N					
92532	Positional nystagmus test		N					
92533	Caloric vestibular test		N					
92534	Optokinetic nystagmus test		N					
92541	Spontaneous nystagmus test		X	0363	0.8067	\$51.38	\$17.10	\$10.28
92542	Positional nystagmus test		X	0363	0.8067	\$51.38	\$17.10	\$10.28
92543	Caloric vestibular test		X	0660	1.4312	\$91.16	\$28.06	\$18.23
92544	Optokinetic nystagmus test		X	0363	0.8067	\$51.38	\$17.10	\$10.28
92545	Oscillating tracking test		X	0363	0.8067	\$51.38	\$17.10	\$10.28
92546	Sinusoidal rotational test		X	0660	1.4312	\$91.16	\$28.06	\$18.23
92547	Supplemental electrical test	CH	N					
92548	Posturography		X	0660	1.4312	\$91.16	\$28.06	\$18.23
92551	Pure tone hearing test, air		E					
92552	Pure tone audiometry, air		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92553	Audiometry, air & bone		X	0365	1.2549	\$79.93	\$18.52	\$15.99
92555	Speech threshold audiometry		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92556	Speech audiometry, complete		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92557	Comprehensive hearing test		X	0365	1.2549	\$79.93	\$18.52	\$15.99
92559	Group audiometric testing		E					
92560	Bekesy audiometry, screen		E					
92561	Bekesy audiometry, diagnosis		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92562	Loudness balance test		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92563	Tone decay hearing test		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92564	Sisi hearing test		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92565	Stenger test, pure tone		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92567	Tympanometry		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92568	Acoustic refl threshold tst		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92569	Acoustic reflex decay test		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92571	Filtered speech hearing test		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92572	Staggered spondaic word test		X	0366	1.7624	\$112.25	\$25.79	\$22.45
92575	Sensorineural acuity test		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92576	Synthetic sentence test		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92577	Stenger test, speech		X	0366	1.7624	\$112.25	\$25.79	\$22.45
92579	Visual audiometry (vra)		X	0365	1.2549	\$79.93	\$18.52	\$15.99
92582	Conditioning play audiometry		X	0365	1.2549	\$79.93	\$18.52	\$15.99
92583	Select picture audiometry		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92584	Electrocochleography	CH	S	0216	2.6846	\$170.99		\$34.20
92585	Auditor evoke potent, compre		S	0216	2.6846	\$170.99		\$34.20
92586	Auditor evoke potent, limit		S	0218	1.1550	\$73.57		\$14.71
92587	Evoked auditory test		X	0363	0.8067	\$51.38	\$17.10	\$10.28
92588	Evoked auditory test		X	0660	1.4312	\$91.16	\$28.06	\$18.23
92590	Hearing aid exam, one ear		E					
92591	Hearing aid exam, both ears		E					
92592	Hearing aid check, one ear		E					
92593	Hearing aid check, both ears		E					
92594	Electro hearing aid test, one		E					
92595	Electro hearing aid tst, both		E					
92596	Ear protector evaluation		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92597	Oral speech device eval		A					
92601	Cochlear implt f/up exam < 7		X	0366	1.7624	\$112.25	\$25.79	\$22.45
92602	Reprogram cochlear implt < 7		X	0366	1.7624	\$112.25	\$25.79	\$22.45
92603	Cochlear implt f/up exam > 7		X	0366	1.7624	\$112.25	\$25.79	\$22.45
92604	Reprogram cochlear implt > 7		X	0366	1.7624	\$112.25	\$25.79	\$22.45
92605	Eval for nonspeech device rx		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
92606	Non-speech device service		A					
92607	Ex for speech device rx, 1hr		A					
92608	Ex for speech device rx addl		A					
92609	Use of speech device service		A					
92610	Evaluate swallowing function		A					
92611	Motion fluoroscopy/swallow		A					
92612	Endoscopy swallow tst (fees)		A					
92613	Endoscopy swallow tst (fees)		B					
92614	Laryngoscopic sensory test		A					
92615	Eval laryngoscopy sense tst		E					
92616	Fees w/laryngeal sense test		A					
92617	Interprt fees/laryngeal test		E					
92620	Auditory function, 60 min		X	0365	1.2549	\$79.93	\$18.52	\$15.99
92621	Auditory function, + 15 min		N					
92625	Tinnitus assessment		X	0365	1.2549	\$79.93	\$18.52	\$15.99
92626	Eval aud rehab status		X	0365	1.2549	\$79.93	\$18.52	\$15.99
92627	Eval aud status rehab add-on		N					
92630	Aud rehab pre-ling hear loss		E					
92633	Aud rehab postling hear loss		E					
92640	Aud brainstem implt program		X	0365	1.2549	\$79.93	\$18.52	\$15.99
92700	Ent procedure/service		X	0364	0.4490	\$28.60	\$7.06	\$5.72
92950	Heart/lung resuscitation cpr		S	0094	2.4590	\$156.62	\$46.29	\$31.32
92953	Temporary external pacing		S	0094	2.4590	\$156.62	\$46.29	\$31.32
92960	Cardioversion electric, ext		S	0679	5.4502	\$347.15	\$95.30	\$69.43
92961	Cardioversion, electric, int		S	0679	5.4502	\$347.15	\$95.30	\$69.43
92970	Cardioassist, internal		C					
92971	Cardioassist, external		C					
92973	Percut coronary thrombectomy		T	0088	38.7673	\$2,469.24	\$655.22	\$493.85
92974	Cath place, cardio brachytx		T	0103	14.6576	\$933.60		\$186.72
92975	Dissolve clot, heart vessel		C					
92977	Dissolve clot, heart vessel		T	0676	2.4824	\$158.11		\$31.62
92978	Intravasc us, heart add-on	CH	N					
92979	Intravasc us, heart add-on	CH	N					
92980	Insert intracoronary stent		T	0104	89.0159	\$5,669.78		\$1,133.96
92981	Insert intracoronary stent		T	0104	89.0159	\$5,669.78		\$1,133.96
92982	Coronary artery dilation		T	0083	45.3845	\$2,890.72		\$578.14
92984	Coronary artery dilation		T	0083	45.3845	\$2,890.72		\$578.14
92986	Revision of aortic valve		T	0083	45.3845	\$2,890.72		\$578.14
92987	Revision of mitral valve		T	0083	45.3845	\$2,890.72		\$578.14
92990	Revision of pulmonary valve		T	0083	45.3845	\$2,890.72		\$578.14
92992	Revision of heart chamber		C					
92993	Revision of heart chamber		C					
92995	Coronary atherectomy		T	0082	87.5137	\$5,574.10		\$1,114.82
92996	Coronary atherectomy add-on		T	0082	87.5137	\$5,574.10		\$1,114.82
92997	Pul art balloon repr, percut	CH	T	0083	45.3845	\$2,890.72		\$578.14
92998	Pul art balloon repr, percut	CH	T	0083	45.3845	\$2,890.72		\$578.14
93000	Electrocardiogram, complete		B					
93005	Electrocardiogram, tracing		S	0099	0.3892	\$24.79		\$4.96
93010	Electrocardiogram report		B					
93012	Transmission of ecg		N					
93014	Report on transmitted ecg		B					
93015	Cardiovascular stress test		B					
93016	Cardiovascular stress test		B					
93017	Cardiovascular stress test		X	0100	2.5547	\$162.72	\$41.44	\$32.54
93018	Cardiovascular stress test		B					
93024	Cardiac drug stress test		X	0100	2.5547	\$162.72	\$41.44	\$32.54
93025	Microvolt t-wave assess		X	0100	2.5547	\$162.72	\$41.44	\$32.54
93040	Rhythm ECG with report		B					
93041	Rhythm ECG, tracing		S	0099	0.3892	\$24.79		\$4.96
93042	Rhythm ECG, report		B					
93224	ECG monitor/report, 24 hrs		B					
93225	ECG monitor/record, 24 hrs		X	0097	1.0015	\$63.79	\$23.79	\$12.76
93226	ECG monitor/report, 24 hrs		X	0097	1.0015	\$63.79	\$23.79	\$12.76
93227	ECG monitor/review, 24 hrs		B					
93230	ECG monitor/report, 24 hrs		B					
93231	Ecg monitor/record, 24 hrs		X	0097	1.0015	\$63.79	\$23.79	\$12.76
93232	ECG monitor/report, 24 hrs		X	0097	1.0015	\$63.79	\$23.79	\$12.76
93233	ECG monitor/review, 24 hrs		B					
93235	ECG monitor/report, 24 hrs		B					
93236	ECG monitor/report, 24 hrs		X	0097	1.0015	\$63.79	\$23.79	\$12.76
93237	ECG monitor/review, 24 hrs		B					
93268	ECG record/review		B					
93270	ECG recording		X	0097	1.0015	\$63.79	\$23.79	\$12.76
93271	Ecg/monitoring and analysis	CH	S	0663	1.5313	\$97.53		\$19.51
93272	Ecg/review, interpret only		B					
93278	ECG/signal-averaged	CH	X	0340	0.6310	\$40.19		\$8.04
93303	Echo transthoracic		S	0269	6.3751	\$406.06		\$81.21
93304	Echo transthoracic		S	0697	3.3401	\$212.74		\$42.55
93307	Echo exam of heart		S	0269	6.3751	\$406.06		\$81.21
93308	Echo exam of heart		S	0697	3.3401	\$212.74		\$42.55

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
93312	Echo transesophageal		S	0270	8.2165	\$523.34	\$141.32	\$104.67
93313	Echo transesophageal		S	0270	8.2165	\$523.34	\$141.32	\$104.67
93314	Echo transesophageal		N					
93315	Echo transesophageal		S	0270	8.2165	\$523.34	\$141.32	\$104.67
93316	Echo transesophageal		S	0270	8.2165	\$523.34	\$141.32	\$104.67
93317	Echo transesophageal		N					
93318	Echo transesophageal intraop		S	0270	8.2165	\$523.34	\$141.32	\$104.67
93320	Doppler echo exam, heart	CH	N					
93321	Doppler echo exam, heart	CH	N					
93325	Doppler color flow add-on	CH	N					
93350	Echo transthoracic		S	0269	6.3751	\$406.06		\$81.21
93501	Right heart catheterization		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93503	Insert/place heart catheter		T	0103	14.6576	\$933.60		\$186.72
93505	Biopsy of heart lining		T	0103	14.6576	\$933.60		\$186.72
93508	Cath placement, angiography		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93510	Left heart catheterization		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93511	Left heart catheterization		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93514	Left heart catheterization		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93524	Left heart catheterization		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93526	Rt & Lt heart catheters		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93527	Rt & Lt heart catheters		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93528	Rt & Lt heart catheters		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93529	Rt, It heart catheterization		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93530	Rt heart cath, congenital		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93531	R & I heart cath, congenital		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93532	R & I heart cath, congenital		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93533	R & I heart cath, congenital		T	0080	38.9204	\$2,479.00	\$838.92	\$495.80
93539	Injection, cardiac cath		N					
93540	Injection, cardiac cath		N					
93541	Injection for lung angiogram		N					
93542	Injection for heart x-rays		N					
93543	Injection for heart x-rays		N					
93544	Injection for aortography		N					
93545	Inject for coronary x-rays		N					
93555	Imaging, cardiac cath		N					
93556	Imaging, cardiac cath		N					
93561	Cardiac output measurement		N					
93562	Cardiac output measurement		N					
93571	Heart flow reserve measure	CH	N					
93572	Heart flow reserve measure	CH	N					
93580	Transcath closure of asd		T	0434	132.4129	\$8,433.91		\$1,686.78
93581	Transcath closure of vsd		T	0434	132.4129	\$8,433.91		\$1,686.78
93600	Bundle of His recording	CH	S	0084	9.5834	\$610.41		\$122.08
93602	Intra-atrial recording	CH	S	0084	9.5834	\$610.41		\$122.08
93603	Right ventricular recording	CH	S	0084	9.5834	\$610.41		\$122.08
93609	Map tachycardia, add-on	CH	N					
93610	Intra-atrial pacing	CH	S	0084	9.5834	\$610.41		\$122.08
93612	Intraventricular pacing	CH	S	0084	9.5834	\$610.41		\$122.08
93613	Electrophys map 3d, add-on	CH	N					
93615	Esophageal recording	CH	S	0084	9.5834	\$610.41		\$122.08
93616	Esophageal recording	CH	S	0084	9.5834	\$610.41		\$122.08
93618	Heart rhythm pacing	CH	S	0084	9.5834	\$610.41		\$122.08
93619	Electrophysiology evaluation	CH	Q	0085	47.2949	\$3,012.40		\$602.48
93620	Electrophysiology evaluation	CH	Q	0085	47.2949	\$3,012.40		\$602.48
93621	Electrophysiology evaluation	CH	N					
93622	Electrophysiology evaluation	CH	N					
93623	Stimulation, pacing heart	CH	N					
93624	Electrophysiologic study		T	0085	47.2949	\$3,012.40		\$602.48
93631	Heart pacing, mapping	CH	N					
93640	Evaluation heart device		N					
93641	Electrophysiology evaluation		N					
93642	Electrophysiology evaluation		S	0084	9.5834	\$610.41		\$122.08
93650	Ablate heart dysrhythm focus	CH	Q	0085	47.2949	\$3,012.40		\$602.48
93651	Ablate heart dysrhythm focus	CH	Q	0086	92.8564	\$5,914.40		\$1,182.88
93652	Ablate heart dysrhythm focus	CH	Q	0086	92.8564	\$5,914.40		\$1,182.88
93660	Tilt table evaluation		S	0101	4.1973	\$267.34	\$100.24	\$53.47
93662	Intracardiac ecg (ice)	CH	N					
93668	Peripheral vascular rehab		E					
93701	Bioimpedance, thoracic		S	0099	0.3892	\$24.79		\$4.96
93720	Total body plethysmography		B					
93721	Plethysmography tracing		X	0368	0.9253	\$58.94	\$22.77	\$11.79
93722	Plethysmography report		B					
93724	Analyze pacemaker system		S	0690	0.3504	\$22.32	\$8.67	\$4.46
93727	Analyze ilr system		S	0690	0.3504	\$22.32	\$8.67	\$4.46
93731	Analyze pacemaker system		S	0690	0.3504	\$22.32	\$8.67	\$4.46
93732	Analyze pacemaker system		S	0690	0.3504	\$22.32	\$8.67	\$4.46
93733	Telephone analy, pacemaker		S	0690	0.3504	\$22.32	\$8.67	\$4.46
93734	Analyze pacemaker system		S	0690	0.3504	\$22.32	\$8.67	\$4.46
93735	Analyze pacemaker system		S	0690	0.3504	\$22.32	\$8.67	\$4.46
93736	Telephonic analy, pacemaker		S	0690	0.3504	\$22.32	\$8.67	\$4.46

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
93740	Temperature gradient studies		X	0368	0.9253	\$58.94	\$22.77	\$11.79
93741	Analyze ht pace device snl		S	0689	0.5946	\$37.87		\$7.57
93742	Analyze ht pace device snl		S	0689	0.5946	\$37.87		\$7.57
93743	Analyze ht pace device dual		S	0689	0.5946	\$37.87		\$7.57
93744	Analyze ht pace device dual		S	0689	0.5946	\$37.87		\$7.57
93745	Set-up cardiovert-defibrill		S	0689	0.5946	\$37.87		\$7.57
93760	Cephalic thermogram		E					
93762	Peripheral thermogram		E					
93770	Measure venous pressure		N					
93784	Ambulatory BP monitoring		E					
93786	Ambulatory BP recording		X	0097	1.0015	\$63.79	\$23.79	\$12.76
93788	Ambulatory BP analysis		X	0097	1.0015	\$63.79	\$23.79	\$12.76
93790	Review/report BP recording		B					
93797	Cardiac rehab		S	0095	0.5685	\$36.21	\$13.86	\$7.24
93798	Cardiac rehab/monitor		S	0095	0.5685	\$36.21	\$13.86	\$7.24
93799	Cardiovascular procedure		X	0097	1.0015	\$63.79	\$23.79	\$12.76
93875	Extracranial study		S	0096	1.4689	\$93.56	\$37.42	\$18.71
93880	Extracranial study		S	0267	2.3792	\$151.54	\$60.50	\$30.31
93882	Extracranial study		S	0267	2.3792	\$151.54	\$60.50	\$30.31
93886	Intracranial study		S	0267	2.3792	\$151.54	\$60.50	\$30.31
93888	Intracranial study		S	0265	0.9570	\$60.96	\$22.35	\$12.19
93890	Tcd, vasoreactivity study		S	0266	1.5094	\$96.14	\$37.80	\$19.23
93892	Tcd, emboli detect w/o inj		S	0266	1.5094	\$96.14	\$37.80	\$19.23
93893	Tcd, emboli detect w/inj		S	0266	1.5094	\$96.14	\$37.80	\$19.23
93922	Extremity study		S	0096	1.4689	\$93.56	\$37.42	\$18.71
93923	Extremity study		S	0096	1.4689	\$93.56	\$37.42	\$18.71
93924	Extremity study		S	0096	1.4689	\$93.56	\$37.42	\$18.71
93925	Lower extremity study		S	0267	2.3792	\$151.54	\$60.50	\$30.31
93926	Lower extremity study		S	0266	1.5094	\$96.14	\$37.80	\$19.23
93930	Upper extremity study		S	0267	2.3792	\$151.54	\$60.50	\$30.31
93931	Upper extremity study		S	0266	1.5094	\$96.14	\$37.80	\$19.23
93965	Extremity study		S	0096	1.4689	\$93.56	\$37.42	\$18.71
93970	Extremity study		S	0267	2.3792	\$151.54	\$60.50	\$30.31
93971	Extremity study		S	0266	1.5094	\$96.14	\$37.80	\$19.23
93975	Vascular study		S	0267	2.3792	\$151.54	\$60.50	\$30.31
93976	Vascular study		S	0267	2.3792	\$151.54	\$60.50	\$30.31
93978	Vascular study	CH	S	0267	2.3792	\$151.54	\$60.50	\$30.31
93979	Vascular study		S	0266	1.5094	\$96.14	\$37.80	\$19.23
93980	Penile vascular study		S	0267	2.3792	\$151.54	\$60.50	\$30.31
93981	Penile vascular study	CH	S	0267	2.3792	\$151.54	\$60.50	\$30.31
93982	Aneurysm pressure sens study	NI	X	0097	1.0015	\$63.79	\$23.79	\$12.76
93990	Doppler flow testing		S	0266	1.5094	\$96.14	\$37.80	\$19.23
94002	Vent mgmt inpat, init day		S	0079	2.4783	\$157.85		\$31.57
94003	Vent mgmt inpat, subq day		S	0079	2.4783	\$157.85		\$31.57
94004	Vent mgmt nf per day		B					
94005	Home vent mgmt supervision		B					
94010	Breathing capacity test		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94014	Patient recorded spirometry		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94015	Patient recorded spirometry		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94016	Review patient spirometry		A					
94060	Evaluation of wheezing		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94070	Evaluation of wheezing		X	0369	2.7550	\$175.48	\$44.18	\$35.10
94150	Vital capacity test		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94200	Lung function test (MBC/MVV)		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94240	Residual lung capacity		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94250	Expired gas collection		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94260	Thoracic gas volume		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94350	Lung nitrogen washout curve		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94360	Measure airflow resistance		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94370	Breath airway closing volume		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94375	Respiratory flow volume loop	CH	X	0368	0.9253	\$58.94	\$22.77	\$11.79
94400	CO2 breathing response curve		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94450	Hypoxia response curve		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94452	Hast w/report		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94453	Hast w/oxygen titrate		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94610	Surfactant admin thru tube		S	0077	0.3877	\$24.69	\$7.74	\$4.94
94620	Pulmonary stress test/simple		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94621	Pulm stress test/complex		X	0369	2.7550	\$175.48	\$44.18	\$35.10
94640	Airway inhalation treatment		S	0077	0.3877	\$24.69	\$7.74	\$4.94
94642	Aerosol inhalation treatment		S	0078	1.3362	\$85.11		\$17.02
94644	Cbt, 1st hour		S	0078	1.3362	\$85.11		\$17.02
94645	Cbt, each addl hour		S	0078	1.3362	\$85.11		\$17.02
94660	Pos airway pressure, CPAP	CH	S	0078	1.3362	\$85.11		\$17.02
94662	Neg press ventilation, cnp		S	0079	2.4783	\$157.85		\$31.57
94664	Evaluate pt use of inhaler		S	0077	0.3877	\$24.69	\$7.74	\$4.94
94667	Chest wall manipulation		S	0077	0.3877	\$24.69	\$7.74	\$4.94
94668	Chest wall manipulation		S	0077	0.3877	\$24.69	\$7.74	\$4.94
94680	Exhaled air analysis, o2	CH	X	0368	0.9253	\$58.94	\$22.77	\$11.79
94681	Exhaled air analysis, o2/co2		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94690	Exhaled air analysis		X	0367	0.5677	\$36.16	\$13.76	\$7.23

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
94720	Monoxide diffusing capacity		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94725	Membrane diffusion capacity		X	0368	0.9253	\$58.94	\$22.77	\$11.79
94750	Pulmonary compliance study	CH	X	0368	0.9253	\$58.94	\$22.77	\$11.79
94760	Measure blood oxygen level		N					
94761	Measure blood oxygen level		N					
94762	Measure blood oxygen level	CH	Q	0097	1.0015	\$63.79	\$23.79	\$12.76
94770	Exhaled carbon dioxide test		X	0367	0.5677	\$36.16	\$13.76	\$7.23
94772	Breath recording, infant		X	0369	2.7550	\$175.48	\$44.18	\$35.10
94774	Ped home apnea rec, compl		B					
94775	Ped home apnea rec, hk-up		X	0097	1.0015	\$63.79	\$23.79	\$12.76
94776	Ped home apnea rec, downld		X	0097	1.0015	\$63.79	\$23.79	\$12.76
94777	Ped home apnea rec, report		B					
94799	Pulmonary service/procedure		X	0367	0.5677	\$36.16	\$13.76	\$7.23
95004	Percut allergy skin tests		X	0381	0.2773	\$17.66		\$3.53
95010	Percut allergy titrate test		X	0381	0.2773	\$17.66		\$3.53
95012	Exhaled nitric oxide meas		X	0367	0.5677	\$36.16	\$13.76	\$7.23
95015	Id allergy titrate-drug/bug		X	0381	0.2773	\$17.66		\$3.53
95024	Id allergy test, drug/bug		X	0381	0.2773	\$17.66		\$3.53
95027	Id allergy titrate-airborne		X	0381	0.2773	\$17.66		\$3.53
95028	Id allergy test-delayed type		X	0381	0.2773	\$17.66		\$3.53
95044	Allergy patch tests		X	0381	0.2773	\$17.66		\$3.53
95052	Photo patch test		X	0381	0.2773	\$17.66		\$3.53
95056	Photosensitivity tests		X	0370	1.0430	\$66.43		\$13.29
95060	Eye allergy tests		X	0370	1.0430	\$66.43		\$13.29
95065	Nose allergy test		X	0381	0.2773	\$17.66		\$3.53
95070	Bronchial allergy tests		X	0369	2.7550	\$175.48	\$44.18	\$35.10
95071	Bronchial allergy tests		X	0369	2.7550	\$175.48	\$44.18	\$35.10
95075	Ingestion challenge test		X	0361	3.9276	\$250.16	\$83.23	\$50.03
95115	Immunotherapy, one injection		S	0436	0.2545	\$16.21		\$3.24
95117	Immunotherapy injections		S	0437	0.3945	\$25.13		\$5.03
95120	Immunotherapy, one injection	CH	E					
95125	Immunotherapy, many antigens	CH	E					
95130	Immunotherapy, insect venom	CH	E					
95131	Immunotherapy, insect venoms	CH	E					
95132	Immunotherapy, insect venoms	CH	E					
95133	Immunotherapy, insect venoms	CH	E					
95134	Immunotherapy, insect venoms	CH	E					
95144	Antigen therapy services		S	0437	0.3945	\$25.13		\$5.03
95145	Antigen therapy services		S	0437	0.3945	\$25.13		\$5.03
95146	Antigen therapy services		S	0437	0.3945	\$25.13		\$5.03
95147	Antigen therapy services		S	0437	0.3945	\$25.13		\$5.03
95148	Antigen therapy services		S	0437	0.3945	\$25.13		\$5.03
95149	Antigen therapy services		S	0437	0.3945	\$25.13		\$5.03
95165	Antigen therapy services		S	0437	0.3945	\$25.13		\$5.03
95170	Antigen therapy services		S	0437	0.3945	\$25.13		\$5.03
95180	Rapid desensitization		X	0370	1.0430	\$66.43		\$13.29
95199	Allergy immunology services		X	0381	0.2773	\$17.66		\$3.53
95250	Glucose monitoring, cont	CH	V	0607	1.6604	\$105.76		\$21.15
95251	Gluc monitor, cont, phys i&r		B					
95805	Multiple sleep latency test		S	0209	11.2822	\$718.61	\$268.73	\$143.72
95806	Sleep study, unattended		S	0213	2.2980	\$146.37	\$53.58	\$29.27
95807	Sleep study, attended		S	0209	11.2822	\$718.61	\$268.73	\$143.72
95808	Polysomnography, 1-3		S	0209	11.2822	\$718.61	\$268.73	\$143.72
95810	Polysomnography, 4 or more		S	0209	11.2822	\$718.61	\$268.73	\$143.72
95811	Polysomnography w/cpap		S	0209	11.2822	\$718.61	\$268.73	\$143.72
95812	Eeg, 41-60 minutes		S	0213	2.2980	\$146.37	\$53.58	\$29.27
95813	Eeg, over 1 hour		S	0213	2.2980	\$146.37	\$53.58	\$29.27
95816	Eeg, awake and drowsy		S	0213	2.2980	\$146.37	\$53.58	\$29.27
95819	Eeg, awake and asleep		S	0213	2.2980	\$146.37	\$53.58	\$29.27
95822	Eeg, coma or sleep only		S	0213	2.2980	\$146.37	\$53.58	\$29.27
95824	Eeg, cerebral death only	CH	S	0216	2.6846	\$170.99		\$34.20
95827	Eeg, all night recording		S	0213	2.2980	\$146.37	\$53.58	\$29.27
95829	Surgery electrocorticogram	CH	N					
95830	Insert electrodes for EEG		B					
95831	Limb muscle testing, manual		A					
95832	Hand muscle testing, manual		A					
95833	Body muscle testing, manual		A					
95834	Body muscle testing, manual		A					
95851	Range of motion measurements		A					
95852	Range of motion measurements		A					
95857	Tensilon test		S	0218	1.1550	\$73.57		\$14.71
95860	Muscle test, one limb		S	0218	1.1550	\$73.57		\$14.71
95861	Muscle test, 2 limbs		S	0218	1.1550	\$73.57		\$14.71
95863	Muscle test, 3 limbs		S	0218	1.1550	\$73.57		\$14.71
95864	Muscle test, 4 limbs		S	0218	1.1550	\$73.57		\$14.71
95865	Muscle test, larynx		S	0218	1.1550	\$73.57		\$14.71
95866	Muscle test, hemidiaphragm		S	0218	1.1550	\$73.57		\$14.71
95867	Muscle test cran nerv unilat		S	0218	1.1550	\$73.57		\$14.71
95868	Muscle test cran nerve bilat		S	0218	1.1550	\$73.57		\$14.71
95869	Muscle test, thor paraspinal	CH	S	0218	1.1550	\$73.57		\$14.71

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
95870	Muscle test, nonparaspinal		S	0215	0.5804	\$36.97		\$7.39
95872	Muscle test, one fiber		S	0218	1.1550	\$73.57		\$14.71
95873	Guide nerv destr, elec stim	CH	N					
95874	Guide nerv destr, needle emg	CH	N					
95875	Limb exercise test		S	0215	0.5804	\$36.97		\$7.39
95900	Motor nerve conduction test		S	0215	0.5804	\$36.97		\$7.39
95903	Motor nerve conduction test		S	0215	0.5804	\$36.97		\$7.39
95904	Sense nerve conduction test		S	0215	0.5804	\$36.97		\$7.39
95920	Intraop nerve test add-on	CH	N					
95921	Autonomic nerv function test	CH	S	0218	1.1550	\$73.57		\$14.71
95922	Autonomic nerv function test	CH	S	0218	1.1550	\$73.57		\$14.71
95923	Autonomic nerv function test	CH	S	0218	1.1550	\$73.57		\$14.71
95925	Somatosensory testing		S	0216	2.6846	\$170.99		\$34.20
95926	Somatosensory testing		S	0216	2.6846	\$170.99		\$34.20
95927	Somatosensory testing		S	0216	2.6846	\$170.99		\$34.20
95928	C motor evoked, uppr limbs		S	0218	1.1550	\$73.57		\$14.71
95929	C motor evoked, lwr limbs		S	0218	1.1550	\$73.57		\$14.71
95930	Visual evoked potential test		S	0216	2.6846	\$170.99		\$34.20
95933	Blink reflex test		S	0215	0.5804	\$36.97		\$7.39
95934	H-reflex test		S	0215	0.5804	\$36.97		\$7.39
95936	H-reflex test		S	0215	0.5804	\$36.97		\$7.39
95937	Neuromuscular junction test	CH	S	0218	1.1550	\$73.57		\$14.71
95950	Ambulatory eeg monitoring		S	0209	11.2822	\$718.61	\$268.73	\$143.72
95951	EEG monitoring/videorecord		S	0209	11.2822	\$718.61	\$268.73	\$143.72
95953	EEG monitoring/computer		S	0209	11.2822	\$718.61	\$268.73	\$143.72
95954	EEG monitoring/giving drugs	CH	S	0218	1.1550	\$73.57		\$14.71
95955	EEG during surgery	CH	N					
95956	Eeg monitoring, cable/radio		S	0209	11.2822	\$718.61	\$268.73	\$143.72
95957	EEG digital analysis	CH	N					
95958	EEG monitoring/function test		S	0213	2.2980	\$146.37	\$53.58	\$29.27
95961	Electrode stimulation, brain		S	0216	2.6846	\$170.99		\$34.20
95962	Electrode stim, brain add-on		S	0216	2.6846	\$170.99		\$34.20
95965	Meg, spontaneous	CH	S	0067	61.6965	\$3,929.70		\$785.94
95966	Meg, evoked, single	CH	S	0065	16.5911	\$1,056.75		\$211.35
95967	Meg, evoked, each add'l	CH	S	0065	16.5911	\$1,056.75		\$211.35
95970	Analyze neurostim, no prog		S	0218	1.1550	\$73.57		\$14.71
95971	Analyze neurostim, simple		S	0692	1.8376	\$117.04	\$29.72	\$23.41
95972	Analyze neurostim, complex	CH	S	0663	1.5313	\$97.53		\$19.51
95973	Analyze neurostim, complex		S	0663	1.5313	\$97.53		\$19.51
95974	Cranial neurostim, complex	CH	S	0663	1.5313	\$97.53		\$19.51
95975	Cranial neurostim, complex		S	0692	1.8376	\$117.04	\$29.72	\$23.41
95978	Analyze neurostim brain/1h		S	0692	1.8376	\$117.04	\$29.72	\$23.41
95979	Analyz neurostim brain addon		S	0663	1.5313	\$97.53		\$19.51
95980	lo anal gast n-stim init	NI	N					
95981	lo anal gast n-stim subsq	NI	S	0218	1.1550	\$73.57		\$14.71
95982	lo ga n-stim subsq w/reprog	NI	S	0692	1.8376	\$117.04	\$29.72	\$23.41
95990	Spin/brain pump refill & main		T	0125	2.3544	\$149.96		\$29.99
95991	Spin/brain pump refill & main		T	0125	2.3544	\$149.96		\$29.99
95999	Neurological procedure		S	0215	0.5804	\$36.97		\$7.39
96000	Motion analysis, video/3d		S	0216	2.6846	\$170.99		\$34.20
96001	Motion test w/ft press meas		S	0216	2.6846	\$170.99		\$34.20
96002	Dynamic surface emg		S	0218	1.1550	\$73.57		\$14.71
96003	Dynamic fine wire emg		S	0215	0.5804	\$36.97		\$7.39
96004	Phys review of motion tests		B					
96020	Functional brain mapping	CH	N					
96040	Genetic counseling, 30 min		B					
96101	Psycho testing by psych/phys	CH	Q	0382	2.6169	\$166.68		\$33.34
96102	Psycho testing by technician	CH	Q	0382	2.6169	\$166.68		\$33.34
96103	Psycho testing admin by comp	CH	Q	0373	1.2448	\$79.29		\$15.86
96105	Assessment of aphasia		A					
96110	Developmental test, lim	CH	Q	0373	1.2448	\$79.29		\$15.86
96111	Developmental test, extend	CH	Q	0382	2.6169	\$166.68		\$33.34
96116	Neurobehavioral status exam	CH	Q	0382	2.6169	\$166.68		\$33.34
96118	Neuropsych tst by psych/phys	CH	Q	0382	2.6169	\$166.68		\$33.34
96119	Neuropsych testing by tec	CH	Q	0382	2.6169	\$166.68		\$33.34
96120	Neuropsych tst admin w/comp	CH	Q	0373	1.2448	\$79.29		\$15.86
96125	Cognitive test by hc pro	NI	A					
96150	Assess hlth/behav, init	CH	Q	0432	0.3128	\$19.92		\$3.98
96151	Assess hlth/behav, subseq	CH	Q	0432	0.3128	\$19.92		\$3.98
96152	Intervene hlth/behav, indiv	CH	Q	0432	0.3128	\$19.92		\$3.98
96153	Intervene hlth/behav, group	CH	Q	0432	0.3128	\$19.92		\$3.98
96154	Interv hlth/behav, fam w/pt	CH	Q	0432	0.3128	\$19.92		\$3.98
96155	Interv hlth/behav fam no pt		E					
96401	Chemo, anti-neopl, sq/im		S	0438	0.8041	\$51.22		\$10.24
96402	Chemo hormon antineopl sq/im		S	0438	0.8041	\$51.22		\$10.24
96405	Chemo intralesional, up to 7		S	0438	0.8041	\$51.22		\$10.24
96406	Chemo intralesional over 7		S	0438	0.8041	\$51.22		\$10.24
96409	Chemo, iv push, snl drug		S	0439	1.6544	\$105.38		\$21.08
96411	Chemo, iv push, addl drug		S	0439	1.6544	\$105.38		\$21.08
96413	Chemo, iv infusion, 1 hr		S	0441	2.3446	\$149.34		\$29.87

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
96415	Chemo, iv infusion, addl hr		S	0438	0.8041	\$51.22		\$10.24
96416	Chemo prolong infuse w/pump		S	0441	2.3446	\$149.34		\$29.87
96417	Chemo iv infus each addl seq		S	0438	0.8041	\$51.22		\$10.24
96420	Chemo, ia, push technique		S	0439	1.6544	\$105.38		\$21.08
96422	Chemo ia infusion up to 1 hr		S	0441	2.3446	\$149.34		\$29.87
96423	Chemo ia infuse each addl hr		S	0438	0.8041	\$51.22		\$10.24
96425	Chemotherapy,infusion method		S	0441	2.3446	\$149.34		\$29.87
96440	Chemotherapy, intracavitary		S	0441	2.3446	\$149.34		\$29.87
96445	Chemotherapy, intracavitary		S	0441	2.3446	\$149.34		\$29.87
96450	Chemotherapy, into CNS		S	0441	2.3446	\$149.34		\$29.87
96521	Refill/maint, portable pump		S	0440	1.7998	\$114.64		\$22.93
96522	Refill/maint pump/resvr syst		S	0440	1.7998	\$114.64		\$22.93
96523	Irrig drug delivery device		Q	0624	0.5689	\$36.24	\$12.65	\$7.25
96542	Chemotherapy injection		S	0438	0.8041	\$51.22		\$10.24
96549	Chemotherapy, unspecified		S	0436	0.2545	\$16.21		\$3.24
96567	Photodynamic tx, skin	CH	T	0013	0.7930	\$50.51		\$10.10
96570	Photodynamic tx, 30 min		T	0015	1.4595	\$92.96		\$18.59
96571	Photodynamic tx, addl 15 min		T	0015	1.4595	\$92.96		\$18.59
96900	Ultraviolet light therapy		S	0001	0.4806	\$30.61	\$7.00	\$6.12
96902	Trichogram		N					
96904	Whole body photography		N					
96910	Photochemotherapy with UV-B		S	0001	0.4806	\$30.61	\$7.00	\$6.12
96912	Photochemotherapy with UV-A		S	0001	0.4806	\$30.61	\$7.00	\$6.12
96913	Photochemotherapy, UV-A or B		S	0683	2.6045	\$165.89		\$33.18
96920	Laser tx, skin < 250 sq cm	CH	T	0015	1.4595	\$92.96		\$18.59
96921	Laser tx, skin 250-500 sq cm	CH	T	0015	1.4595	\$92.96		\$18.59
96922	Laser tx, skin > 500 sq cm	CH	T	0015	1.4595	\$92.96		\$18.59
96999	Dermatological procedure	CH	T	0012	0.2963	\$18.87		\$3.77
97001	Pt evaluation		A					
97002	Pt re-evaluation		A					
97003	Ot evaluation		A					
97004	Ot re-evaluation		A					
97005	Athletic train eval		E					
97006	Athletic train reeval		E					
97010	Hot or cold packs therapy		A					
97012	Mechanical traction therapy		A					
97014	Electric stimulation therapy		E					
97016	Vasopneumatic device therapy		A					
97018	Paraffin bath therapy		A					
97022	Whirlpool therapy		A					
97024	Diathermy eg, microwave		A					
97026	Infrared therapy		A					
97028	Ultraviolet therapy		A					
97032	Electrical stimulation		A					
97033	Electric current therapy		A					
97034	Contrast bath therapy		A					
97035	Ultrasound therapy		A					
97036	Hydrotherapy		A					
97039	Physical therapy treatment		A					
97110	Therapeutic exercises		A					
97112	Neuromuscular reeducation		A					
97113	Aquatic therapy/exercises		A					
97116	Gait training therapy		A					
97124	Massage therapy		A					
97139	Physical medicine procedure		A					
97140	Manual therapy		A					
97150	Group therapeutic procedures		A					
97530	Therapeutic activities		A					
97532	Cognitive skills development		A					
97533	Sensory integration		A					
97535	Self care mngment training		A					
97537	Community/work reintegration		A					
97542	Wheelchair mngment training		A					
97545	Work hardening		A					
97546	Work hardening add-on		A					
97597	Active wound care/20 cm or <	CH	T	0015	1.4595	\$92.96		\$18.59
97598	Active wound care > 20 cm	CH	T	0015	1.4595	\$92.96		\$18.59
97602	Wound(s) care non-selective	CH	T	0015	1.4595	\$92.96		\$18.59
97605	Neg press wound tx, < 50 cm	CH	T	0013	0.7930	\$50.51		\$10.10
97606	Neg press wound tx, > 50 cm	CH	T	0015	1.4595	\$92.96		\$18.59
97750	Physical performance test		A					
97755	Assistive technology assess		A					
97760	Orthotic mgmt and training		A					
97761	Prosthetic training		A					
97762	C/o for orthotic/prosth use		A					
97799	Physical medicine procedure		A					
97802	Medical nutrition, indiv, in		A					
97803	Med nutrition, indiv, subseq		A					
97804	Medical nutrition, group		A					
97810	Acupunct w/o stimul 15 min		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
97811	Acupunct w/o stimul addl 15m		E					
97813	Acupunct w/stimul 15 min		E					
97814	Acupunct w/stimul addl 15m		E					
98925	Osteopathic manipulation		S	0060	0.4482	\$28.55		\$5.71
98926	Osteopathic manipulation		S	0060	0.4482	\$28.55		\$5.71
98927	Osteopathic manipulation		S	0060	0.4482	\$28.55		\$5.71
98928	Osteopathic manipulation		S	0060	0.4482	\$28.55		\$5.71
98929	Osteopathic manipulation		S	0060	0.4482	\$28.55		\$5.71
98940	Chiropractic manipulation		S	0060	0.4482	\$28.55		\$5.71
98941	Chiropractic manipulation		S	0060	0.4482	\$28.55		\$5.71
98942	Chiropractic manipulation		S	0060	0.4482	\$28.55		\$5.71
98943	Chiropractic manipulation		E					
98960	Self-mgmt educ & train, 1 pt		E					
98961	Self-mgmt educ/train, 2-4 pt		E					
98962	Self-mgmt educ/train, 5-8 pt		E					
98966	Hc pro phone call 5-10 min	NI	E					
98967	Hc pro phone call 11-20 min	NI	E					
98968	Hc pro phone call 21-30 min	NI	E					
98969	Online service by hc pro	NI	E					
99000	Specimen handling		E					
99001	Specimen handling		E					
99002	Device handling		B					
99024	Postop follow-up visit		B					
99026	In-hospital on call service		E					
99027	Out-of-hosp on call service		E					
99050	Medical services after hrs		B					
99051	Med serv, eve/wkend/holiday		B					
99053	Med serv 10pm-8am, 24 hr fac		B					
99056	Med service out of office		B					
99058	Office emergency care		B					
99060	Out of office emerg med serv		B					
99070	Special supplies		B					
99071	Patient education materials		B					
99075	Medical testimony		E					
99078	Group health education		N					
99080	Special reports or forms		B					
99082	Unusual physician travel		B					
99090	Computer data analysis		B					
99091	Collect/review data from pt		N					
99100	Special anesthesia service		B					
99116	Anesthesia with hypothermia		B					
99135	Special anesthesia procedure		B					
99140	Emergency anesthesia		B					
99143	Mod cs by same phys, < 5 yrs		N					
99144	Mod cs by same phys, 5 yrs +		N					
99145	Mod cs by same phys add-on		N					
99148	Mod cs diff phys < 5 yrs		N					
99149	Mod cs diff phys 5 yrs +		N					
99150	Mod cs diff phys add-on		N					
99170	Anogenital exam, child		T	0191	0.1309	\$8.34	\$2.36	\$1.67
99172	Ocular function screen		E					
99173	Visual acuity screen		E					
99174	Ocular photoscreening	NI	E					
99175	Induction of vomiting		N					
99183	Hyperbaric oxygen therapy		B					
99185	Regional hypothermia		N					
99186	Total body hypothermia		N					
99190	Special pump services		C					
99191	Special pump services		C					
99192	Special pump services		C					
99195	Phlebotomy	CH	X	0624	0.5689	\$36.24	\$12.65	\$7.25
99199	Special service/proc/report		B					
99201	Office/outpatient visit, new		V	0604	0.8388	\$53.43		\$10.69
99202	Office/outpatient visit, new		V	0605	0.9964	\$63.46		\$12.69
99203	Office/outpatient visit, new		V	0606	1.3226	\$84.24		\$16.85
99204	Office/outpatient visit, new		V	0607	1.6604	\$105.76		\$21.15
99205	Office/outpatient visit, new	CH	Q	0608	2.1740	\$138.47		\$27.69
99211	Office/outpatient visit, est		V	0604	0.8388	\$53.43		\$10.69
99212	Office/outpatient visit, est		V	0605	0.9964	\$63.46		\$12.69
99213	Office/outpatient visit, est		V	0605	0.9964	\$63.46		\$12.69
99214	Office/outpatient visit, est		V	0606	1.3226	\$84.24		\$16.85
99215	Office/outpatient visit, est	CH	Q	0607	1.6604	\$105.76		\$21.15
99217	Observation care discharge		B					
99218	Observation care		B					
99219	Observation care		B					
99220	Observation care		B					
99221	Initial hospital care		B					
99222	Initial hospital care		B					
99223	Initial hospital care		B					
99231	Subsequent hospital care		B					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
99232	Subsequent hospital care		B					
99233	Subsequent hospital care		B					
99234	Observ/hosp same date		B					
99235	Observ/hosp same date		B					
99236	Observ/hosp same date		B					
99238	Hospital discharge day		B					
99239	Hospital discharge day		B					
99241	Office consultation	CH	B					
99242	Office consultation	CH	B					
99243	Office consultation	CH	B					
99244	Office consultation	CH	B					
99245	Office consultation	CH	B					
99251	Inpatient consultation		C					
99252	Inpatient consultation		C					
99253	Inpatient consultation		C					
99254	Inpatient consultation		C					
99255	Inpatient consultation		C					
99281	Emergency dept visit		V	0609	0.7970	\$50.76	\$12.70	\$10.15
99282	Emergency dept visit		V	0613	1.3137	\$83.67	\$21.06	\$16.73
99283	Emergency dept visit		V	0614	2.0750	\$132.17	\$34.50	\$26.43
99284	Emergency dept visit	CH	Q	0615	3.3377	\$212.59	\$48.49	\$42.52
99285	Emergency dept visit	CH	Q	0616	4.9535	\$315.51	\$72.86	\$63.10
99288	Direct advanced life support		B					
99289	Ped crit care transport		N					
99290	Ped crit care transport addl		N					
99291	Critical care, first hour	CH	Q	0617	7.3166	\$466.02	\$111.59	\$93.20
99292	Critical care, add'l 30 min		N					
99293	Ped critical care, initial		C					
99294	Ped critical care, subseq		C					
99295	Neonate crit care, initial		C					
99296	Neonate critical care subseq		C					
99298	lc for lbw infant < 1500 gm		C					
99299	lc, lbw infant 1500–2500 gm		C					
99300	lc, infant pbw 2501–5000 gm		N					
99304	Nursing facility care, init		B					
99305	Nursing facility care, init		B					
99306	Nursing facility care, init		B					
99307	Nursing fac care, subseq		B					
99308	Nursing fac care, subseq		B					
99309	Nursing fac care, subseq		B					
99310	Nursing fac care, subseq		B					
99315	Nursing fac discharge day		B					
99316	Nursing fac discharge day		B					
99318	Annual nursing fac assessmnt		B					
99324	Domicil/r-home visit new pat		B					
99325	Domicil/r-home visit new pat		B					
99326	Domicil/r-home visit new pat		B					
99327	Domicil/r-home visit new pat		B					
99328	Domicil/r-home visit new pat		B					
99334	Domicil/r-home visit est pat		B					
99335	Domicil/r-home visit est pat		B					
99336	Domicil/r-home visit est pat		B					
99337	Domicil/r-home visit est pat		B					
99339	Domicil/r-home care supervis		B					
99340	Domicil/r-home care supervis		B					
99341	Home visit, new patient		B					
99342	Home visit, new patient		B					
99343	Home visit, new patient		B					
99344	Home visit, new patient		B					
99345	Home visit, new patient		B					
99347	Home visit, est patient		B					
99348	Home visit, est patient		B					
99349	Home visit, est patient		B					
99350	Home visit, est patient		B					
99354	Prolonged service, office		N					
99355	Prolonged service, office		N					
99356	Prolonged service, inpatient		C					
99357	Prolonged service, inpatient		C					
99358	Prolonged serv, w/o contact		N					
99359	Prolonged serv, w/o contact		N					
99360	Physician standby services		B					
99361	Physician/team conference	CH	D					
99362	Physician/team conference	CH	D					
99363	Anticoag mgmt, init		B					
99364	Anticoag mgmt, subseq		B					
99366	Team conf w/pat by hc pro	NI	N					
99367	Team conf w/o pat by phys	NI	N					
99368	Team conf w/o pat by hc pro	NI	N					
99371	Physician phone consultation	CH	D					
99372	Physician phone consultation	CH	D					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
99373	Physician phone consultation	CH	D					
99374	Home health care supervision		B					
99375	Home health care supervision		E					
99377	Hospice care supervision		B					
99378	Hospice care supervision		E					
99379	Nursing fac care supervision		B					
99380	Nursing fac care supervision		E					
99381	Init pm e/m, new pat, inf		E					
99382	Init pm e/m, new pat 1–4 yrs		E					
99383	Prev visit, new, age 5–11		E					
99384	Prev visit, new, age 12–17		E					
99385	Prev visit, new, age 18–39		E					
99386	Prev visit, new, age 40–64		E					
99387	Init pm e/m, new pat 65+ yrs		E					
99391	Per pm reeval, est pat, inf		E					
99392	Prev visit, est, age 1–4		E					
99393	Prev visit, est, age 5–11		E					
99394	Prev visit, est, age 12–17		E					
99395	Prev visit, est, age 18–39		E					
99396	Prev visit, est, age 40–64		E					
99397	Per pm reeval est pat 65+ yr		E					
99401	Preventive counseling, indiv		E					
99402	Preventive counseling, indiv		E					
99403	Preventive counseling, indiv		E					
99404	Preventive counseling, indiv		E					
99406	Behav chng smoking 3–10 min	NI	X	0031	0.1648	\$10.50		\$2.10
99407	Behav chng smoking < 10 min	NI	X	0031	0.1648	\$10.50		\$2.10
99408	Audit/dast, 15–30 min	NI	E					
99409	Audit/dast, over 30 min	NI	E					
99411	Preventive counseling, group		E					
99412	Preventive counseling, group		E					
99420	Health risk assessment test		E					
99429	Unlisted preventive service		E					
99431	Initial care, normal newborn		V	0605	0.9964	\$63.46		\$12.69
99432	Newborn care, not in hosp		N					
99433	Normal newborn care/hospital		C					
99435	Newborn discharge day hosp		B					
99436	Attendance, birth		N					
99440	Newborn resuscitation		S	0094	2.4590	\$156.62	\$46.29	\$31.32
99441	Phone e/m by phys 5–10 min	NI	E					
99442	Phone e/m by phys 11–20 min	NI	E					
99443	Phone e/m by phys 21–30 min	NI	E					
99444	Online e/m by phys	NI	E					
99450	Basic life disability exam		E					
99455	Work related disability exam		B					
99456	Disability examination		B					
99477	Init day hosp neonate care	NI	C					
99499	Unlisted e&m service		B					
99500	Home visit, prenatal		E					
99501	Home visit, postnatal		E					
99502	Home visit, nb care		E					
99503	Home visit, resp therapy		E					
99504	Home visit mech ventilator		E					
99505	Home visit, stoma care		E					
99506	Home visit, im injection		E					
99507	Home visit, cath maintain		E					
99509	Home visit day life activity		E					
99510	Home visit, sing/m/fam couns		E					
99511	Home visit, fecal/enema mgmt		E					
99512	Home visit for hemodialysis		E					
99600	Home visit nos		E					
99601	Home infusion/visit, 2 hrs		E					
99602	Home infusion, each addtl hr		E					
99605	Mtms by pharm, np, 15 min	NI	E					
99606	Mtms by pharm, est, 15 min	NI	E					
99607	Mtms by pharm, addl 15 min	NI	E					
A0021	Outside state ambulance serv		E					
A0080	Noninterest escort in non er		E					
A0090	Interest escort in non er		E					
A0100	Nonemergency transport taxi		E					
A0110	Nonemergency transport bus		E					
A0120	Noner transport mini-bus		E					
A0130	Noner transport wheelch van		E					
A0140	Nonemergency transport air		E					
A0160	Noner transport case worker		E					
A0170	Transport parking fees/tolls		E					
A0180	Noner transport lodgng recip		E					
A0190	Noner transport meals recip		E					
A0200	Noner transport lodgng escrt		E					
A0210	Noner transport meals escort		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
A0225	Neonatal emergency transport	CH	E					
A0380	Basic life support mileage	CH	E					
A0382	Basic support routine suppl		A					
A0384	Bls defibrillation supplies		A					
A0390	Advanced life support mileag	CH	E					
A0392	Als defibrillation supplies		A					
A0394	Als IV drug therapy supplies		A					
A0396	Als esophageal intub suppl		A					
A0398	Als routine dispoible suppl		A					
A0420	Ambulance waiting 1/2 hr		A					
A0422	Ambulance 02 life sustaining		A					
A0424	Extra ambulance attendant		A					
A0425	Ground mileage		A					
A0426	Als 1		A					
A0427	ALS1-emergency		A					
A0428	bls		A					
A0429	BLS-emergency		A					
A0430	Fixed wing air transport		A					
A0431	Rotary wing air transport		A					
A0432	PI volunteer ambulance co		A					
A0433	als 2		A					
A0434	Specialty care transport		A					
A0435	Fixed wing air mileage		A					
A0436	Rotary wing air mileage		A					
A0888	Noncovered ambulance mileage		E					
A0998	Ambulance response/treatment		E					
A0999	Unlisted ambulance service		A					
A4206	1 CC sterile syringe&needle		E					
A4207	2 CC sterile syringe&needle		E					
A4208	3 CC sterile syringe&needle		E					
A4209	5+ CC sterile syringe&needle		E					
A4210	Nonneedle injection device		E					
A4211	Supp for self-adm injections		E					
A4212	Non coring needle or stylet		B					
A4213	20+ CC syringe only		E					
A4215	Sterile needle		E					
A4216	Sterile water/saline, 10 ml		A					
A4217	Sterile water/saline, 500 ml		A					
A4218	Sterile saline or water		N					
A4220	Infusion pump refill kit		N					
A4221	Maint drug infus cath per wk		Y					
A4222	Infusion supplies with pump		Y					
A4223	Infusion supplies w/o pump		E					
A4230	Infus insulin pump non needl		Y					
A4231	Infusion insulin pump needle		Y					
A4232	Syringe w/needle insulin 3cc		E					
A4233	Alkaln batt for glucose mon		Y					
A4234	J-cell batt for glucose mon		Y					
A4235	Lithium batt for glucose mon		Y					
A4236	Silvr oxide batt glucose mon		Y					
A4244	Alcohol or peroxide per pint		E					
A4245	Alcohol wipes per box		E					
A4246	Betadine/phisohex solution		E					
A4247	Betadine/iodine swabs/wipes		E					
A4248	Chlorhexidine antisept		N					
A4250	Urine reagent strips/tablets		E					
A4252	Blood ketone test or strip	NI	E					
A4253	Blood glucose/reagent strips		Y					
A4255	Glucose monitor platforms		Y					
A4256	Calibrator solution/chips		Y					
A4257	Replace Lensshield Cartridge		Y					
A4258	Lancet device each		Y					
A4259	Lancets per box		Y					
A4261	Cervical cap contraceptive		E					
A4262	Temporary tear duct plug		N					
A4263	Permanent tear duct plug		N					
A4265	Paraffin		Y					
A4266	Diaphragm		E					
A4267	Male condom		E					
A4268	Female condom		E					
A4269	Spermicide		E					
A4270	Disposable endoscope sheath		N					
A4280	Brst prsths adhsv attchmnt		A					
A4281	Replacement breastpump tube		E					
A4282	Replacement breastpump adpt		E					
A4283	Replacement breastpump cap		E					
A4284	Replcmnt breast pump shield		E					
A4285	Replcmnt breast pump bottle		E					
A4286	Replcmnt breastpump lok ring		E					
A4290	Sacral nerve stim test lead		B					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
A4300	Cath impl vasc access portal		N					
A4301	Implantable access syst perc		N					
A4305	Drug delivery system >=50 ML		N					
A4306	Drug delivery system <=50 ml		N					
A4310	Insert tray w/o bag/cath		A					
A4311	Catheter w/o bag 2-way latex		A					
A4312	Cath w/o bag 2-way silicone		A					
A4313	Catheter w/bag 3-way		A					
A4314	Cath w/drainage 2-way latex		A					
A4315	Cath w/drainage 2-way silcne		A					
A4316	Cath w/drainage 3-way		A					
A4320	Irrigation tray		A					
A4321	Cath therapeutic irrig agent		A					
A4322	Irrigation syringe		A					
A4326	Male external catheter		A					
A4327	Fem urinary collect dev cup		A					
A4328	Fem urinary collect pouch		A					
A4330	Stool collection pouch		A					
A4331	Extension drainage tubing		A					
A4332	Lube sterile packet		A					
A4333	Urinary cath anchor device		A					
A4334	Urinary cath leg strap		A					
A4335	Incontinence supply		A					
A4338	Indwelling catheter latex		A					
A4340	Indwelling catheter special		A					
A4344	Cath indw foley 2 way silicn		A					
A4346	Cath indw foley 3 way		A					
A4349	Disposable male external cat		A					
A4351	Straight tip urine catheter		A					
A4352	Coude tip urinary catheter		A					
A4353	Intermittent urinary cath		A					
A4354	Cath insertion tray w/bag		A					
A4355	Bladder irrigation tubing		A					
A4356	Ext ureth clmp or compr dvc		A					
A4357	Bedside drainage bag		A					
A4358	Urinary leg or abdomen bag		A					
A4361	Ostomy face plate		A					
A4362	Solid skin barrier		A					
A4363	Ostomy clamp, replacement		A					
A4364	Adhesive, liquid or equal		A					
A4365	Adhesive remover wipes		A					
A4366	Ostomy vent		A					
A4367	Ostomy belt		A					
A4368	Ostomy filter		A					
A4369	Skin barrier liquid per oz		A					
A4371	Skin barrier powder per oz		A					
A4372	Skin barrier solid 4x4 equiv		A					
A4373	Skin barrier with flange		A					
A4375	Drainable plastic pch w fcpl		A					
A4376	Drainable rubber pch w fcpl		A					
A4377	Drainable plstic pch w/o fp		A					
A4378	Drainable rubber pch w/o fp		A					
A4379	Urinary plastic pouch w fcpl		A					
A4380	Urinary rubber pouch w fcpl		A					
A4381	Urinary plastic pouch w/o fp		A					
A4382	Urinary hvy plstc pch w/o fp		A					
A4383	Urinary rubber pouch w/o fp		A					
A4384	Ostomy faceplt/silicone ring		A					
A4385	Ost skn barrier sld ext wear		A					
A4387	Ost clsd pouch w att st barr		A					
A4388	Drainable pch w ex wear barr		A					
A4389	Drainable pch w st wear barr		A					
A4390	Drainable pch ex wear convex		A					
A4391	Urinary pouch w ex wear barr		A					
A4392	Urinary pouch w st wear barr		A					
A4393	Urine pch w ex wear bar conv		A					
A4394	Ostomy pouch liq deodorant		A					
A4395	Ostomy pouch solid deodorant		A					
A4396	Peristomal hernia supprt blt		A					
A4397	Irrigation supply sleeve		A					
A4398	Ostomy irrigation bag		A					
A4399	Ostomy irrig cone/cath w brs		A					
A4400	Ostomy irrigation set		A					
A4402	Lubricant per ounce		A					
A4404	Ostomy ring each		A					
A4405	Nonpectin based ostomy paste		A					
A4406	Pectin based ostomy paste		A					
A4407	Ext wear ost skn barr <=4sq*		A					
A4408	Ext wear ost skn barr >4sq		A					
A4409	Ost skn barr convex <=4 sq i		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
A4410	Ost skn barr extnd >4 sq		A					
A4411	Ost skn barr extnd =4sq		A					
A4412	Ost pouch drain high output		A					
A4413	2 pc drainable ost pouch		A					
A4414	Ost sknbar w/o conv<=4 sq in		A					
A4415	Ost skn barr w/o conv >4 sqi		A					
A4416	Ost pch clsd w barrier/filtr		A					
A4417	Ost pch w bar/bltinconv/fltr		A					
A4418	Ost pch clsd w/o bar w filtr		A					
A4419	Ost pch for bar w flange/fltr		A					
A4420	Ost pch clsd for bar w lk fl		A					
A4421	Ostomy supply misc		E					
A4422	Ost pouch absorbent material		A					
A4423	Ost pch for bar w lk fl/fltr		A					
A4424	Ost pch drain w bar & filter		A					
A4425	Ost pch drain for barrier fl		A					
A4426	Ost pch drain 2 piece system		A					
A4427	Ost pch drain/barr lk flng/f		A					
A4428	Urine ost pouch w faucet/tap		A					
A4429	Urine ost pouch w bltinconv		A					
A4430	Ost urine pch w b/bltin conv		A					
A4431	Ost pch urine w barrier/tapv		A					
A4432	Os pch urine w bar/fange/tap		A					
A4433	Urine ost pch bar w lock fln		A					
A4434	Ost pch urine w lock flng/ft		A					
A4450	Non-waterproof tape		A					
A4452	Waterproof tape		A					
A4455	Adhesive remover per ounce		A					
A4458	Reusable enema bag		E					
A4461	Surgicl dress hold non-reuse		A					
A4463	Surgical dress holder reuse		A					
A4465	Non-elastic extremity binder		A					
A4470	Gravlee jet washer		A					
A4480	Vabra aspirator		A					
A4481	Tracheostoma filter		A					
A4483	Moisture exchanger		A					
A4490	Above knee surgical stocking		E					
A4495	Thigh length surg stocking		E					
A4500	Below knee surgical stocking		E					
A4510	Full length surg stocking		E					
A4520	Incontinence garment anytype		E					
A4550	Surgical trays		B					
A4554	Disposable underpads		E					
A4556	Electrodes, pair		Y					
A4557	Lead wires, pair		Y					
A4558	Conductive gel or paste		Y					
A4559	Coupling gel or paste		Y					
A4561	Pessary rubber, any type		N					
A4562	Pessary, non rubber,any type		N					
A4565	Slings		A					
A4570	Splint		E					
A4575	Hyperbaric o2 chamber disps		E					
A4580	Cast supplies (plaster)		E					
A4590	Special casting material		E					
A4595	TENS suppl 2 lead per month		Y					
A4600	Sleeve, inter limb comp dev		Y					
A4601	Lith ion batt, non-pros use		Y					
A4604	Tubing with heating element		Y					
A4605	Trach suction cath close sys		Y					
A4606	Oxygen probe used w oximeter		A					
A4608	Transtracheal oxygen cath		Y					
A4611	Heavy duty battery		Y					
A4612	Battery cables		Y					
A4613	Battery charger		Y					
A4614	Hand-held PEFR meter		N					
A4615	Cannula nasal		Y					
A4616	Tubing (oxygen) per foot		Y					
A4617	Mouth piece		Y					
A4618	Breathing circuits		Y					
A4619	Face tent		Y					
A4620	Variable concentration mask		Y					
A4623	Tracheostomy inner cannula		A					
A4624	Tracheal suction tube		Y					
A4625	Trach care kit for new trach		A					
A4626	Tracheostomy cleaning brush		A					
A4627	Spacer bag/reservoir		E					
A4628	Oropharyngeal suction cath		Y					
A4629	Tracheostomy care kit		A					
A4630	Repl bat t.e.n.s. own by pt		Y					
A4633	Uvl replacement bulb		Y					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
A4634	Replacement bulb th lightbox		A					
A4635	Underarm crutch pad		Y					
A4636	Handgrip for cane etc		Y					
A4637	Repl tip cane/crutch/walker		Y					
A4638	Repl batt pulse gen sys		Y					
A4639	Infrared ht sys replmnt pad		Y					
A4640	Alternating pressure pad		Y					
A4641	Radiopharm dx agent noc		N					
A4642	In111 satumomab	CH	N					
A4648	Implantable tissue marker	NI	N					
A4649	Surgical supplies		A					
A4650	Implant radiation dosimeter	NI	N					
A4651	Calibrated microcap tube		A					
A4652	Microcapillary tube sealant		A					
A4653	PD catheter anchor belt		A					
A4657	Syringe w/wo needle		A					
A4660	Sphyg/bp app w cuff and stet		A					
A4663	Dialysis blood pressure cuff		A					
A4670	Automatic bp monitor, dial		E					
A4671	Disposable cycler set		B					
A4672	Drainage ext line, dialysis		B					
A4673	Ext line w easy lock connect		B					
A4674	Chem/antisept solution, 8oz		B					
A4680	Activated carbon filter, ea		A					
A4690	Dialyzer, each		A					
A4706	Bicarbonate conc sol per gal		A					
A4707	Bicarbonate conc pow per pac		A					
A4708	Acetate conc sol per gallon		A					
A4709	Acid conc sol per gallon		A					
A4714	Treated water per gallon		A					
A4719	≥Y set≥ tubing		A					
A4720	Dialysat sol fld vol > 249cc		A					
A4721	Dialysat sol fld vol > 999cc		A					
A4722	Dialys sol fld vol > 1999cc		A					
A4723	Dialys sol fld vol > 2999cc		A					
A4724	Dialys sol fld vol > 3999cc		A					
A4725	Dialys sol fld vol > 4999cc		A					
A4726	Dialys sol fld vol > 5999cc		A					
A4728	Dialysate solution, non-dex		B					
A4730	Fistula cannulation set, ea		A					
A4736	Topical anesthetic, per gram		A					
A4737	Inj anesthetic per 10 ml		A					
A4740	Shunt accessory		A					
A4750	Art or venous blood tubing		A					
A4755	Comb art/venous blood tubing		A					
A4760	Dialysate sol test kit, each		A					
A4765	Dialysate conc pow per pack		A					
A4766	Dialysate conc sol add 10 ml		A					
A4770	Blood collection tube/vacuum		A					
A4771	Serum clotting time tube		A					
A4772	Blood glucose test strips		A					
A4773	Occult blood test strips		A					
A4774	Ammonia test strips		A					
A4802	Protamine sulfate per 50 mg		A					
A4860	Disposable catheter tips		A					
A4870	Plumb/elec wk hm hemo equip		A					
A4890	Repair/maint cont hemo equip		A					
A4911	Drain bag/bottle		A					
A4913	Misc dialysis supplies noc		A					
A4918	Venous pressure clamp		A					
A4927	Non-sterile gloves		A					
A4928	Surgical mask		A					
A4929	Tourniquet for dialysis, ea		A					
A4930	Sterile, gloves per pair		A					
A4931	Reusable oral thermometer		A					
A4932	Reusable rectal thermometer		E					
A5051	Pouch clsd w barr attached		A					
A5052	Clsd ostomy pouch w/o barr		A					
A5053	Clsd ostomy pouch faceplate		A					
A5054	Clsd ostomy pouch w/flange		A					
A5055	Stoma cap		A					
A5061	Pouch drainable w barrier at		A					
A5062	Drnble ostomy pouch w/o barr		A					
A5063	Drain ostomy pouch w/flange		A					
A5071	Urinary pouch w/barrier		A					
A5072	Urinary pouch w/o barrier		A					
A5073	Urinary pouch on barr w/flng		A					
A5081	Continent stoma plug		A					
A5082	Continent stoma catheter		A					
A5083	Stoma absorptive cover	NI	A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
A5093	Ostomy accessory convex inse		A					
A5102	Bedside drain btl w/wo tube		A					
A5105	Urinary suspensory		A					
A5112	Urinary leg bag		A					
A5113	Latex leg strap		A					
A5114	Foam/fabric leg strap		A					
A5120	Skin barrier, wipe or swab		A					
A5121	Solid skin barrier 6x6		A					
A5122	Solid skin barrier 8x8		A					
A5126	Disk/foam pad +or- adhesive		A					
A5131	Appliance cleaner		A					
A5200	Percutaneous catheter anchor		A					
A5500	Diab shoe for density insert		Y					
A5501	Diabetic custom molded shoe		Y					
A5503	Diabetic shoe w/roller/rockr		Y					
A5504	Diabetic shoe with wedge		Y					
A5505	Diab shoe w/metatarsal bar		Y					
A5506	Diabetic shoe w/off set heel		Y					
A5507	Modification diabetic shoe		Y					
A5508	Diabetic deluxe shoe		Y					
A5510	Compression form shoe insert		E					
A5512	Multi den insert direct form		Y					
A5513	Multi den insert custom mold		Y					
A6000	Wound warming wound cover		E					
A6010	Collagen based wound filler		A					
A6011	Collagen gel/paste wound fil		A					
A6021	Collagen dressing <=16 sq in		A					
A6022	Collagen drsg>6<=48 sq in		A					
A6023	Collagen dressing >48 sq in		A					
A6024	Collagen dsq wound filler		A					
A6025	Silicone gel sheet, each		E					
A6154	Wound pouch each		A					
A6196	Alginate dressing <=16 sq in		A					
A6197	Alginate drsg >16 <=48 sq in		A					
A6198	alginate dressing > 48 sq in		A					
A6199	Alginate drsg wound filler		A					
A6200	Compos drsg <=16 no border		E					
A6201	Compos drsg >16<=48 no bdr		E					
A6202	Compos drsg >48 no border		E					
A6203	Composite drsg <= 16 sq in		A					
A6204	Composite drsg >16<=48 sq in		A					
A6205	Composite drsg > 48 sq in		A					
A6206	Contact layer <= 16 sq in		A					
A6207	Contact layer >16<= 48 sq in		A					
A6208	Contact layer > 48 sq in		A					
A6209	Foam drsg <=16 sq in w/o bdr		A					
A6210	Foam drg >16<=48 sq in w/o b		A					
A6211	Foam drg > 48 sq in w/o brdr		A					
A6212	Foam drg <=16 sq in w/border		A					
A6213	Foam drg >16<=48 sq in w/bdr		A					
A6214	Foam drg > 48 sq in w/border		A					
A6215	Foam dressing wound filler		A					
A6216	Non-sterile gauze<=16 sq in		A					
A6217	Non-sterile gauze>16<=48 sq		A					
A6218	Non-sterile gauze > 48 sq in		A					
A6219	Gauze <= 16 sq in w/border		A					
A6220	Gauze >16 <=48 sq in w/bordr		A					
A6221	Gauze > 48 sq in w/border		A					
A6222	Gauze <=16 in no w/sal w/o b		A					
A6223	Gauze >16<=48 no w/sal w/o b		A					
A6224	Gauze > 48 in no w/sal w/o b		A					
A6228	Gauze <= 16 sq in water/sal		A					
A6229	Gauze >16<=48 sq in watr/sal		A					
A6230	Gauze > 48 sq in water/salne		A					
A6231	Hydrogel dsq<=16 sq in		A					
A6232	Hydrogel dsq>16<=48 sq in		A					
A6233	Hydrogel dressing >48 sq in		A					
A6234	Hydrocolld drg <=16 w/o bdr		A					
A6235	Hydrocolld drg >16<=48 w/o b		A					
A6236	Hydrocolld drg > 48 in w/o b		A					
A6237	Hydrocolld drg <=16 in w/bdr		A					
A6238	Hydrocolld drg >16<=48 w/bdr		A					
A6239	Hydrocolld drg > 48 in w/bdr		A					
A6240	Hydrocolloid drg filler paste		A					
A6241	Hydrocolloid drg filler dry		A					
A6242	Hydrogel drg <=16 in w/o bdr		A					
A6243	Hydrogel drg >16<=48 w/o bdr		A					
A6244	Hydrogel drg >48 in w/o bdr		A					
A6245	Hydrogel drg <= 16 in w/bdr		A					
A6246	Hydrogel drg >16<=48 in w/b		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
A6247	Hydrogel drg > 48 sq in w/b		A					
A6248	Hydrogel drsg gel filler		A					
A6250	Skin seal protect moisturizr		A					
A6251	Absorpt drg <=16 sq in w/o b		A					
A6252	Absorpt drg >16 <=48 w/o bdr		A					
A6253	Absorpt drg > 48 sq in w/o b		A					
A6254	Absorpt drg <=16 sq in w/bdr		A					
A6255	Absorpt drg >16<=48 in w/bdr		A					
A6256	Absorpt drg > 48 sq in w/bdr		A					
A6257	Transparent film <= 16 sq in		A					
A6258	Transparent film >16<=48 in		A					
A6259	Transparent film > 48 sq in		A					
A6260	Wound cleanser any type/size		A					
A6261	Wound filler gel/paste /oz		A					
A6262	Wound filler dry form / gram		A					
A6266	Impreg gauze no h20/sal/yard		A					
A6402	Sterile gauze <= 16 sq in		A					
A6403	Sterile gauze>16 <= 48 sq in		A					
A6404	Sterile gauze > 48 sq in		A					
A6407	Packing strips, non-impreg		A					
A6410	Sterile eye pad		A					
A6411	Non-sterile eye pad		A					
A6412	Occlusive eye patch		E					
A6413	Adhesive bandage, first-aid	NI	E					
A6441	Pad band w>=3+ <5+/yd		A					
A6442	Conform band n/s w<3+/yd		A					
A6443	Conform band n/s w>=3+<5+/yd		A					
A6444	Conform band n/s w>=5+/yd		A					
A6445	Conform band s w <3+/yd		A					
A6446	Conform band s w>=3+ <5+/yd		A					
A6447	Conform band s w >=5+/yd		A					
A6448	Lt compres band <3+/yd		A					
A6449	Lt compres band >=3+ <+/yd		A					
A6450	Lt compres band >=5+/yd		A					
A6451	Mod compres band w>=3+<5+/yd		A					
A6452	High compres band w>=3+<5+/yd		A					
A6453	Self-adher band w <3+/yd		A					
A6454	Self-adher band w>=3+ <5+/yd		A					
A6455	Self-adher band >=5+/yd		A					
A6456	Zinc paste band w >=3+<5+/yd		A					
A6457	Tubular dressing		A					
A6501	Compres burngarment bodysuit		A					
A6502	Compres burngarment chinstrp		A					
A6503	Compres burngarment facehood		A					
A6504	Cmprsburngarment glove-wrist		A					
A6505	Cmprsburngarment glove-elbow		A					
A6506	Cmprsburngrmnt glove-axilla		A					
A6507	Cmprs burngarment foot-knee		A					
A6508	Cmprs burngarment foot-thigh		A					
A6509	Compres burn garment jacket		A					
A6510	Compres burn garment leotard		A					
A6511	Compres burn garment panty		A					
A6512	Compres burn garment, noc		A					
A6513	Compress burn mask face/neck		B					
A6530	Compression stocking BK18-30		E					
A6531	Compression stocking BK30-40		A					
A6532	Compression stocking BK40-50		A					
A6533	Gc stocking thighlngh 18-30		E					
A6534	Gc stocking thighlngh 30-40		E					
A6535	Gc stocking thighlngh 40-50		E					
A6536	Gc stocking full lngh 18-30		E					
A6537	Gc stocking full lngh 30-40		E					
A6538	Gc stocking full lngh 40-50		E					
A6539	Gc stocking waistlngh 18-30		E					
A6540	Gc stocking waistlngh 30-40		E					
A6541	Gc stocking waistlngh 40-50		E					
A6542	Gc stocking custom made		E					
A6543	Gc stocking lymphedema		E					
A6544	Gc stocking garter belt		E					
A6549	G compression stocking		E					
A6550	Neg pres wound ther drsg set		Y					
A7000	Disposable canister for pump		Y					
A7001	Nondisposable pump canister		Y					
A7002	Tubing used w suction pump		Y					
A7003	Nebulizer administration set		Y					
A7004	Disposable nebulizer sml vol		Y					
A7005	Nondisposable nebulizer set		Y					
A7006	Filtered nebulizer admin set		Y					
A7007	Lg vol nebulizer disposable		Y					
A7008	Disposable nebulizer prefill		Y					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
A7009	Nebulizer reservoir bottle		Y					
A7010	Disposable corrugated tubing		Y					
A7011	Nondispos corrugated tubing		Y					
A7012	Nebulizer water collec devic		Y					
A7013	Disposable compressor filter		Y					
A7014	Compressor nondispos filter		Y					
A7015	Aerosol mask used w nebulizer		Y					
A7016	Nebulizer dome & mouthpiece		Y					
A7017	Nebulizer not used w oxygen		Y					
A7018	Water distilled w/nebulizer		Y					
A7025	Replace chest compress vest		Y					
A7026	Replace chst cmprrs sys hose		Y					
A7027	Combination oral/nasal mask	NI	Y					
A7028	Repl oral cushion combo mask	NI	Y					
A7029	Repl nasal pillow comb mask	NI	Y					
A7030	CPAP full face mask		Y					
A7031	Replacement facemask interfa		Y					
A7032	Replacement nasal cushion		Y					
A7033	Replacement nasal pillows		Y					
A7034	Nasal application device		Y					
A7035	Pos airway press headgear		Y					
A7036	Pos airway press chinstrap		Y					
A7037	Pos airway pressure tubing		Y					
A7038	Pos airway pressure filter		Y					
A7039	Filter, non disposable w pap		Y					
A7040	One way chest drain valve	A						
A7041	Water seal drain container	A						
A7042	Implanted pleural catheter	A						
A7043	Vacuum drainagebottle/tubing	A						
A7044	PAP oral interface	Y						
A7045	Repl exhalation port for PAP	Y						
A7046	Repl water chamber, PAP dev	Y						
A7501	Tracheostoma valve w diaphra	A						
A7502	Replacement diaphragm/fplate	A						
A7503	HMES filter holder or cap	A						
A7504	Tracheostoma HMES filter	A						
A7505	HMES or trach valve housing	A						
A7506	HMES/trachvalve adhesivedisk	A						
A7507	Integrated filter & holder	A						
A7508	Housing & Integrated Adhesiv	A						
A7509	Heat & moisture exchange sys	A						
A7520	Trach/laryn tube non-cuffed	A						
A7521	Trach/laryn tube cuffed	A						
A7522	Trach/laryn tube stainless	A						
A7523	Tracheostomy shower protect	A						
A7524	Tracheostoma stent/stud/btn	A						
A7525	Tracheostomy mask	A						
A7526	Tracheostomy tube collar	A						
A7527	Trach/laryn tube plug/stop	A						
A8000	Soft protect helmet prefab	Y						
A8001	Hard protect helmet prefab	Y						
A8002	Soft protect helmet custom	Y						
A8003	Hard protect helmet custom	Y						
A8004	Repl soft interface, helmet	Y						
A9150	Misc/exper non-prescript dru		E					
A9152	Single vitamin nos		E					
A9153	Multi-vitamin nos		E					
A9155	Artificial saliva	NI	B					
A9180	Lice treatment, topical		E					
A9270	Non-covered item or service		E					
A9274	Ext amb insulin delivery sys	NI	E					
A9275	Disp home glucose monitor		E					
A9276	Disposable sensor, CGM sys	NI	E					
A9277	External transmitter, CGM	NI	E					
A9278	External receiver, CGM sys	NI	E					
A9279	Monitoring feature/deviceNOC		E					
A9280	Alert device, noc		E					
A9281	Reaching/grabbing device		E					
A9282	Wig any type		E					
A9283	Foot press off load supp dev	NI	E					
A9300	Exercise equipment		E					
A9500	Tc99m sestamibi	CH	N					
A9501	Technetium TC-99m teboroxime	NI	N					
A9502	Tc99m tetrofosmin	CH	N					
A9503	Tc99m medronate		N					
A9504	Tc99m apcitide		N					
A9505	TL201 thallium	CH	N					
A9507	In111 capromab	CH	N					
A9508	I131 iodobenguante, dx	CH	N					
A9509	Iodine I-123 sod iodide mil	NI	N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
A9510	Tc99m disofenin		N					
A9512	Tc99m pertechnetate		N					
A9516	Iodine I-123 sod iodide mic	CH	N					
A9517	I131 iodide cap, rx	CH	K	1064	0.2393	\$15.24		\$3.05
A9521	Tc99m exametazime	CH	N					
A9524	I131 serum albumin, dx	CH	N					
A9526	Nitrogen N-13 ammonia	CH	N					
A9527	Iodine I-125 sodium iodide	CH	K	2632	0.4325	\$27.55		\$5.51
A9528	Iodine I-131 iodide cap, dx	CH	N					
A9529	I131 iodide sol, dx		N					
A9530	I131 iodide sol, rx	CH	K	1150	0.1762	\$11.22		\$2.24
A9531	I131 max 100uCi		N					
A9532	I125 serum albumin, dx		N					
A9535	Injection, methylene blue		N					
A9536	Tc99m depreotide	CH	N					
A9537	Tc99m mebrofenin		N					
A9538	Tc99m pyrophosphate		N					
A9539	Tc99m pentetate	CH	N					
A9540	Tc99m MAA		N					
A9541	Tc99m sulfur colloid		N					
A9542	In111 ibritumomab, dx	CH	N					
A9543	Y90 ibritumomab, rx	CH	K	1643	235.8764	\$15,023.91		\$3,004.78
A9544	I131 tositumomab, dx	CH	N					
A9545	I131 tositumomab, rx	CH	K	1645	176.8495	\$11,264.25		\$2,252.85
A9546	Co57/58	CH	N					
A9547	In111 oxyquinoline	CH	N					
A9548	In111 pentetate	CH	N					
A9550	Tc99m gluceptate	CH	N					
A9551	Tc99m succimer	CH	N					
A9552	F18 fdg	CH	N					
A9553	Cr51 chromate	CH	N					
A9554	I125 iothalamate, dx		N					
A9555	Rb82 rubidium	CH	N					
A9556	Ga67 gallium	CH	N					
A9557	Tc99m bicisate	CH	N					
A9558	Xe133 xenon 10mci		N					
A9559	Co57 cyano	CH	N					
A9560	Tc99m labeled rbc	CH	N					
A9561	Tc99m oxidronate		N					
A9562	Tc99m mertiatide	CH	N					
A9563	P32 Na phosphate	CH	K	1675	1.7835	\$113.60		\$22.72
A9564	P32 chromic phosphate	CH	K	1676	1.8711	\$119.18		\$23.84
A9565	In111 pentetreotide	CH	D					
A9566	Tc99m fanolesomab	CH	N					
A9567	Technetium TC-99m aerosol	CH	N					
A9568	Technetium tc99m arctiomomab	CH	N					
A9569	Technetium TC-99m auto WBC	NI	N					
A9570	Indium In-111 auto WBC	NI	N					
A9571	Indium IN-111 auto platelet	NI	N					
A9572	Indium In-111 pentetreotide	NI	N					
A9576	Inj prohance multipack	NI	N					
A9577	Inj multihance	NI	N					
A9578	Inj multihance multipack	NI	N					
A9579	Gad-base MR contrast NOS,1ml	NI	N					
A9600	Sr89 strontium	CH	K	0701	9.6094	\$612.06		\$122.41
A9605	Sm 153 lexidronm	CH	K	0702	21.3689	\$1,361.07		\$272.21
A9698	Non-rad contrast materialNOC		N					
A9699	Radiopharm rx agent noc		N					
A9700	Echocardiography Contrast		B					
A9900	Supply/accessory/service		Y					
A9901	Delivery/set up/dispensing		A					
A9999	DME supply or accessory, nos		Y					
B4034	Enter feed supkit syr by day		Y					
B4035	Enteral feed supp pump per d		Y					
B4036	Enteral feed sup kit grav by		Y					
B4081	Enteral ng tubing w/ stylet		Y					
B4082	Enteral ng tubing w/o stylet		Y					
B4083	Enteral stomach tube levine		Y					
B4086	Gastrostomy/jejunostomy tube	CH	D					
B4087	Gastro/jejuno tube, std	NI	A					
B4088	Gastro/jejuno tube, low-pro	NI	A					
B4100	Food thickener oral		E					
B4102	EF adult fluids and electro		Y					
B4103	EF ped fluid and electrolyte		Y					
B4104	Additive for enteral formula		E					
B4149	EF blenderized foods		Y					
B4150	EF complet w/intact nutrient		Y					
B4152	EF calorie dense>=1.5Kcal		Y					
B4153	EF hydrolyzed/amino acids		Y					
B4154	EF spec metabolic noninherit		Y					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
B4155	EF incomplete/modular		Y					
B4157	EF special metabolic inherit		Y					
B4158	EF ped complete intact nut		Y					
B4159	EF ped complete soy based		Y					
B4160	EF ped caloric dense>=0.7kc		Y					
B4161	EF ped hydrolyzed/amino acid		Y					
B4162	EF ped specmetabolic inherit		Y					
B4164	Parenteral 50% dextrose solu		Y					
B4168	Parenteral sol amino acid 3.		Y					
B4172	Parenteral sol amino acid 5.		Y					
B4176	Parenteral sol amino acid 7-		Y					
B4178	Parenteral sol amino acid >		Y					
B4180	Parenteral sol carb > 50%		Y					
B4185	Parenteral sol 10 gm lipids		B					
B4189	Parenteral sol amino acid &		Y					
B4193	Parenteral sol 52-73 gm prot		Y					
B4197	Parenteral sol 74-100 gm pro		Y					
B4199	Parenteral sol > 100gm prote		Y					
B4216	Parenteral nutrition additiv		Y					
B4220	Parenteral supply kit premix		Y					
B4222	Parenteral supply kit homemi		Y					
B4224	Parenteral administration ki		Y					
B5000	Parenteral sol renal-amirosy		Y					
B5100	Parenteral sol hepatic-fream		Y					
B5200	Parenteral sol stres-brnch c		Y					
B9000	Enter infusion pump w/o alrm		Y					
B9002	Enteral infusion pump w/ ala		Y					
B9004	Parenteral infus pump portab		Y					
B9006	Parenteral infus pump statio		Y					
B9998	Enteral supp not otherwise c		Y					
B9999	Parenteral supp not othrws c		Y					
C1300	HYPERBARIC Oxygen		S	0659	1.5579	\$99.23		\$19.85
C1713	Anchor/screw bn/bn.tis/bn		N					
C1714	Cath, trans atherectomy, dir		N					
C1715	Brachytherapy needle		N					
C1716	Brachytx, non-str, Gold-198	CH	K	1716	0.5228	\$33.30		\$6.66
C1717	Brachytx, non-str,HDR Ir-192	CH	K	1717	2.7505	\$175.19		\$35.04
C1719	Brachytx, NS, Non-HDRIr-192	CH	K	1719	1.0226	\$65.13		\$13.03
C1721	AICD, dual chamber		N					
C1722	AICD, single chamber		N					
C1724	Cath, trans atherec,rotation		N					
C1725	Cath, translumin non-laser		N					
C1726	Cath, bal dil, non-vascular		N					
C1727	Cath, bal tis dis, non-vas		N					
C1728	Cath, brachytx seed adm		N					
C1729	Cath, drainage		N					
C1730	Cath, EP, 19 or few elect		N					
C1731	Cath, EP, 20 or more elec		N					
C1732	Cath, EP, diag/abl, 3D/vect		N					
C1733	Cath, EP, othr than cool-tip		N					
C1750	Cath, hemodialysis,long-term		N					
C1751	Cath, inf, per/cent/midline		N					
C1752	Cath,hemodialysis,short-term		N					
C1753	Cath, intravas ultrasound		N					
C1754	Catheter, intradiscal		N					
C1755	Catheter, intraspinal		N					
C1756	Cath, pacing, transesoph		N					
C1757	Cath, thrombectomy/embolect		N					
C1758	Catheter, ureteral		N					
C1759	Cath, intra echocardiography		N					
C1760	Closure dev, vas		N					
C1762	Conn tiss, human(inc fascia)		N					
C1763	Conn tiss, non-human		N					
C1764	Event recorder, cardiac		N					
C1765	Adhesion barrier		N					
C1766	Intro/sheath, strble, non-peel		N					
C1767	Generator, neuro non-recharg		N					
C1768	Graft, vascular		N					
C1769	Guide wire		N					
C1770	Imaging coil, MR, insertable		N					
C1771	Rep dev, urinary, w/sling		N					
C1772	Infusion pump, programmable		N					
C1773	Ret dev, insertable		N					
C1776	Joint device (implantable)		N					
C1777	Lead, AICD, endo single coil		N					
C1778	Lead, neurostimulator		N					
C1779	Lead, pmkr, transvenous VDD		N					
C1780	Lens, intraocular (new tech)		N					
C1781	Mesh (implantable)		N					
C1782	Morcellator		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
C1783	Ocular imp, aqueous drain de		N					
C1784	Ocular dev, intraop, det ret		N					
C1785	Pmkr, dual, rate-resp		N					
C1786	Pmkr, single, rate-resp		N					
C1787	Patient progr, neurostim		N					
C1788	Port, indwelling, imp		N					
C1789	Prosthesis, breast, imp		N					
C1813	Prosthesis, penile, inflatab		N					
C1814	Retinal tamp, silicone oil		N					
C1815	Pros, urinary sph, imp		N					
C1816	Receiver/transmitter, neuro		N					
C1817	Septal defect imp sys		N					
C1818	Integrated keratoprosthesis		N					
C1819	Tissue localization-excision		N					
C1820	Generator neuro rechg bat sy	CH	N					
C1821	Interspinous implant		H	1821				
C1874	Stent, coated/cov w/del sys		N					
C1875	Stent, coated/cov w/o del sy		N					
C1876	Stent, non-coa/non-cov w/del		N					
C1877	Stent, non-coat/cov w/o del		N					
C1878	Matrl for vocal cord		N					
C1879	Tissue marker, implantable		N					
C1880	Vena cava filter		N					
C1881	Dialysis access system		N					
C1882	AICD, other than sing/dual		N					
C1883	Adapt/ext, pacing/neuro lead		N					
C1884	Embolization Protect syst		N					
C1885	Cath, translumin angio laser		N					
C1887	Catheter, guiding		N					
C1888	Endovas non-cardiac abl cath		N					
C1891	Infusion pump,non-prog, perm		N					
C1892	Intro/sheath, fixed, peel-away		N					
C1893	Intro/sheath, fixed, non-peel		N					
C1894	Intro/sheath, non-laser		N					
C1895	Lead, AICD, endo dual coil		N					
C1896	Lead, AICD, non sing/dual		N					
C1897	Lead, neurostim test kit		N					
C1898	Lead, pmkr, other than trans		N					
C1899	Lead, pmkr/AICD combination		N					
C1900	Lead, coronary venous		N					
C2614	Probe, perc lumb disc		N					
C2615	Sealant, pulmonary, liquid		N					
C2616	Brachytx, non-str, Yttrium-90	CH	K	2616	184.7105	\$11,764.95		\$2,352.99
C2617	Stent, non-cor, tem w/o del		N					
C2618	Probe, cryoablation		N					
C2619	Pmkr, dual, non rate-resp		N					
C2620	Pmkr, single, non rate-resp		N					
C2621	Pmkr, other than sing/dual		N					
C2622	Prosthesis, penile, non-inf		N					
C2625	Stent, non-cor, tem w/del sy		N					
C2626	Infusion pump, non-prog, temp		N					
C2627	Cath, suprapubic/cystoscopic		N					
C2628	Catheter, occlusion		N					
C2629	Intro/sheath, laser		N					
C2630	Cath, EP, cool-tip		N					
C2631	Rep dev, urinary, w/o sling		N					
C2634	Brachytx, non-str, HA, I-125	CH	K	2634	0.4858	\$30.94		\$6.19
C2635	Brachytx, non-str, HA, P-103	CH	K	2635	0.7366	\$46.92		\$9.38
C2636	Brachy linear, non-str, P-103	CH	K	2636	0.6600	\$42.04		\$8.41
C2637	Brachy, non-str, Ytterbium-169	CH	B					
C2638	Brachytx, stranded, I-125	NF	K	2638	0.7113	\$45.31		\$9.06
C2639	Brachytx, non-stranded, I-125	NF	K	2639	0.5039	\$32.10		\$6.42
C2640	Brachytx, stranded, P-103	NF	K	2640	1.0308	\$65.66		\$13.13
C2641	Brachytx, non-stranded, P-103	NF	K	2641	0.8077	\$51.45		\$10.29
C2642	Brachytx, stranded, C-131	NF	K	2642	1.5342	\$97.72		\$19.54
C2643	Brachytx, non-stranded, C-131	NF	K	2643	1.0060	\$64.08		\$12.82
C2698	Brachytx, stranded, NOS	NF	K	2698	0.7113	\$45.31		\$9.06
C2699	Brachytx, non-stranded, NOS	NF	K	2699	0.4858	\$30.94		\$6.19
C8900	MRA w/cont, abd		S	0284	6.2350	\$397.13	\$148.40	\$79.43
C8901	MRA w/o cont, abd		S	0336	5.3933	\$343.52	\$137.40	\$68.70
C8902	MRA w/o fol w/cont, abd		S	0337	8.2463	\$525.24	\$199.53	\$105.05
C8903	MRI w/cont, breast, uni		S	0284	6.2350	\$397.13	\$148.40	\$79.43
C8904	MRI w/o cont, breast, uni		S	0336	5.3933	\$343.52	\$137.40	\$68.70
C8905	MRI w/o fol w/cont, brst, un		S	0337	8.2463	\$525.24	\$199.53	\$105.05
C8906	MRI w/cont, breast, bi		S	0284	6.2350	\$397.13	\$148.40	\$79.43
C8907	MRI w/o cont, breast, bi		S	0336	5.3933	\$343.52	\$137.40	\$68.70
C8908	MRI w/o fol w/cont, breast,		S	0337	8.2463	\$525.24	\$199.53	\$105.05
C8909	MRA w/cont, chest		S	0284	6.2350	\$397.13	\$148.40	\$79.43
C8910	MRA w/o cont, chest		S	0336	5.3933	\$343.52	\$137.40	\$68.70
C8911	MRA w/o fol w/cont, chest		S	0337	8.2463	\$525.24	\$199.53	\$105.05

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
C8912	MRA w/cont, lwr ext		S	0284	6.2350	\$397.13	\$148.40	\$79.43
C8913	MRA w/o cont, lwr ext		S	0336	5.3933	\$343.52	\$137.40	\$68.70
C8914	MRA w/o fol w/cont, lwr ext		S	0337	8.2463	\$525.24	\$199.53	\$105.05
C8918	MRA w/cont, pelvis		S	0284	6.2350	\$397.13	\$148.40	\$79.43
C8919	MRA w/o cont, pelvis		S	0336	5.3933	\$343.52	\$137.40	\$68.70
C8920	MRA w/o fol w/cont, pelvis		S	0337	8.2463	\$525.24	\$199.53	\$105.05
C8921	Comp transtho echo w/contr	NI	S	0128	8.4896	\$540.74	\$216.29	\$108.15
C8922	Limit transtho echo w/contr	NI	S	0128	8.4896	\$540.74	\$216.29	\$108.15
C8923	2D com transtho echo w/contr	NI	S	0128	8.4896	\$540.74	\$216.29	\$108.15
C8924	2D lim transtho echo w/contr	NI	S	0128	8.4896	\$540.74	\$216.29	\$108.15
C8925	2D TEE w/contrast, int/rept	NI	S	0128	8.4896	\$540.74	\$216.29	\$108.15
C8926	Cong TEE w/contr, int/rept	NI	S	0128	8.4896	\$540.74	\$216.29	\$108.15
C8927	TEE w/contrast; monitor	NI	S	0128	8.4896	\$540.74	\$216.29	\$108.15
C8928	2D transtho w/contr; stress	NI	S	0128	8.4896	\$540.74	\$216.29	\$108.15
C8957	Prolonged IV inf, req pump		S	0441	2.3446	\$149.34		\$29.87
C9003	Palivizumab, per 50 mg		K	9003		\$810.67		\$162.13
C9113	Inj pantoprazole sodium, via		N					
C9121	Injection, argatroban		K	9121		\$18.96		\$3.79
C9232	Injection, idursulfase	CH	D					
C9233	Injection, ranibizumab	CH	D					
C9234	Inj, alglucosidase alfa	CH	D					
C9235	Injection, panitumumab	CH	D					
C9236	Injection, eculizumab	CH	D					
C9238	Inj, levetiracetam	NI	K	9238		\$6.30		\$1.26
C9239	Inj, temsirolimus	NI	G	1168		\$48.41		\$9.68
C9350	Porous collagen tube per cm	CH	D					
C9351	Acellular derm tissue percm2	CH	D					
C9352	Neuragen nerve guide, per cm	NI	G	9350		\$482.56		\$96.51
C9353	Neurawrap nerve protector,cm	NI	G	1169		\$482.56		\$96.51
C9399	Unclassified drugs or biolog		A					
C9716	Radiofrequency energy to anu		T	0150	30.1606	\$1,921.05	\$437.12	\$384.21
C9723	Dyn IR Perf Img		S	1502		\$75.00		\$15.00
C9724	EPS gast cardia plic		T	0422	25.3233	\$1,612.94	\$448.81	\$322.59
C9725	Place endorectal app		S	1507		\$550.00		\$110.00
C9726	Rxt breast appl place/remov		S	1508		\$650.00		\$130.00
C9727	Insert palate implants		S	1510		\$850.00		\$170.00
C9728	Place device/marker, non pro	NF	T	0156	3.0469	\$194.07		\$38.81
D0120	Periodic oral evaluation		E					
D0140	Limit oral eval problm focus		E					
D0145	Oral evaluation, pt < 3yrs		E					
D0150	Comprehensve oral evaluation		S	0330	9.1677	\$583.93		\$116.79
D0160	Extensv oral eval prob focus		E					
D0170	Re-eval,est pt,problem focus		E					
D0180	Comp periodontal evaluation		E					
D0210	Intraor complete film series		E					
D0220	Intraoral periapical first f		E					
D0230	Intraoral periapical ea add		E					
D0240	Intraoral occlusal film		S	0330	9.1677	\$583.93		\$116.79
D0250	Extraoral first film		S	0330	9.1677	\$583.93		\$116.79
D0260	Extraoral ea additional film		S	0330	9.1677	\$583.93		\$116.79
D0270	Dental bitewing single film		S	0330	9.1677	\$583.93		\$116.79
D0272	Dental bitewings two films		S	0330	9.1677	\$583.93		\$116.79
D0273	Bitewings - three films		E					
D0274	Dental bitewings four films		S	0330	9.1677	\$583.93		\$116.79
D0277	Vert bitewings-sev to eight		S	0330	9.1677	\$583.93		\$116.79
D0290	Dental film skull/facial bon		E					
D0310	Dental saligraphy		E					
D0320	Dental tmj arthrogram incl i		E					
D0321	Dental other tmj films		E					
D0322	Dental tomographic survey		E					
D0330	Dental panoramic film		E					
D0340	Dental cephalometric film		E					
D0350	Oral/facial photo images		E					
D0360	Cone beam ct		E					
D0362	Cone beam, two dimensional		E					
D0363	Cone beam, three dimensional		E					
D0415	Collection of microorganisms		E					
D0416	Viral culture		B					
D0421	Gen tst suscept oral disease		B					
D0425	Caries susceptibility test		E					
D0431	Diag tst detect mucos abnorm		B					
D0460	Pulp vitality test		S	0330	9.1677	\$583.93		\$116.79
D0470	Diagnostic casts		E					
D0472	Gross exam, prep & report		B					
D0473	Micro exam, prep & report		B					
D0474	Micro w exam of surg margins		B					
D0475	Decalcification procedure		B					
D0476	Spec stains for microorganis		B					
D0477	Spec stains not for microorg		B					
D0478	Immunohistochemical stains		B					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
D0479	Tissue in-situ hybridization		B					
D0480	Cytopath smear prep & report		B					
D0481	Electron microscopy diagnost		B					
D0482	Direct immunofluorescence		B					
D0483	Indirect immunofluorescence		B					
D0484	Consult slides prep elsewhere		B					
D0485	Consult inc prep of slides		B					
D0486	Accession of brush biopsy		E					
D0502	Other oral pathology procedu		B					
D0999	Unspecified diagnostic proce		B					
D1110	Dental prophylaxis adult		E					
D1120	Dental prophylaxis child		E					
D1203	Topical fluor w/o prophy chi		E					
D1204	Topical fluor w/o prophy adu		E					
D1206	Topical fluoride varnish		E					
D1310	Nutri counsel-control caries		E					
D1320	Tobacco counseling		E					
D1330	Oral hygiene instruction		E					
D1351	Dental sealant per tooth		E					
D1510	Space maintainer fxd unilat		S	0330	9.1677	\$583.93		\$116.79
D1515	Fixed bilat space maintainer		S	0330	9.1677	\$583.93		\$116.79
D1520	Remove unilat space maintain		S	0330	9.1677	\$583.93		\$116.79
D1525	Remove bilat space maintain		S	0330	9.1677	\$583.93		\$116.79
D1550	Recement space maintainer		S	0330	9.1677	\$583.93		\$116.79
D1555	Remove fix space maintainer		E					
D2140	Amalgam one surface permanen		E					
D2150	Amalgam two surfaces permane		E					
D2160	Amalgam three surfaces perma		E					
D2161	Amalgam 4 or > surfaces perm		E					
D2330	Resin one surface-anterior		E					
D2331	Resin two surfaces-anterior		E					
D2332	Resin three surfaces-anterio		E					
D2335	Resin 4/> surf or w incis an		E					
D2390	Ant resin-based cmpst crown		E					
D2391	Post 1 srfc resinbased cmpst		E					
D2392	Post 2 srfc resinbased cmpst		E					
D2393	Post 3 srfc resinbased cmpst		E					
D2394	Post >=4srfc resinbase cmpst		E					
D2410	Dental gold foil one surface		E					
D2420	Dental gold foil two surface		E					
D2430	Dental gold foil three surfa		E					
D2510	Dental inlay metallic 1 surf		E					
D2520	Dental inlay metallic 2 surf		E					
D2530	Dental inlay metl 3/more sur		E					
D2542	Dental onlay metallic 2 surf		E					
D2543	Dental onlay metallic 3 surf		E					
D2544	Dental onlay metl 4/more sur		E					
D2610	Inlay porcelain/ceramic 1 su		E					
D2620	Inlay porcelain/ceramic 2 su		E					
D2630	Dental onlay porc 3/more sur		E					
D2642	Dental onlay porcelin 2 surf		E					
D2643	Dental onlay porcelin 3 surf		E					
D2644	Dental onlay porc 4/more sur		E					
D2650	Inlay composite/resin one su		E					
D2651	Inlay composite/resin two su		E					
D2652	Dental inlay resin 3/mre sur		E					
D2662	Dental onlay resin 2 surface		E					
D2663	Dental onlay resin 3 surface		E					
D2664	Dental onlay resin 4/mre sur		E					
D2710	Crown resin-based indirect		E					
D2712	Crown 3/4 resin-based compos		E					
D2720	Crown resin w/ high noble me		E					
D2721	Crown resin w/ base metal		E					
D2722	Crown resin w/ noble metal		E					
D2740	Crown porcelain/ceramic subs		E					
D2750	Crown porcelain w/ h noble m		E					
D2751	Crown porcelain fused base m		E					
D2752	Crown porcelain w/ noble met		E					
D2780	Crown 3/4 cast hi noble met		E					
D2781	Crown 3/4 cast base metal		E					
D2782	Crown 3/4 cast noble metal		E					
D2783	Crown 3/4 porcelain/ceramic		E					
D2790	Crown full cast high noble m		E					
D2791	Crown full cast base metal		E					
D2792	Crown full cast noble metal		E					
D2794	Crown-titanium		E					
D2799	Provisional crown		E					
D2910	Recement inlay onlay or part		E					
D2915	Recement cast or prefab post		E					
D2920	Dental recement crown		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
D2930	Prefab stnlss steel crwn pri		E					
D2931	Prefab stnlss steel crown pe		E					
D2932	Prefabricated resin crown		E					
D2933	Prefab stainless steel crown		E					
D2934	Prefab steel crown primary		E					
D2940	Dental sedative filling		E					
D2950	Core build-up incl any pins		E					
D2951	Tooth pin retention		E					
D2952	Post and core cast + crown		E					
D2953	Each addtnl cast post		E					
D2954	Prefab post/core + crown		E					
D2955	Post removal		E					
D2957	Each addtnl prefab post		E					
D2960	Laminate labial veneer		E					
D2961	Lab labial veneer resin		E					
D2962	Lab labial veneer porcelain		E					
D2970	Temp crown (fractured tooth)		E					
D2971	Add proc construct new crown		E					
D2975	Coping		E					
D2980	Crown repair		E					
D2999	Dental unspec restorative pr		S	0330	9.1677	\$583.93		\$116.79
D3110	Pulp cap direct		E					
D3120	Pulp cap indirect		E					
D3220	Therapeutic pulpotomy		E					
D3221	Gross pulpal debridement		E					
D3230	Pulpal therapy anterior prim		E					
D3240	Pulpal therapy posterior pri		E					
D3310	Anterior		E					
D3320	Root canal therapy 2 canals		E					
D3330	Root canal therapy 3 canals		E					
D3331	Non-surg tx root canal obs		E					
D3332	Incomplete endodontic tx		E					
D3333	Internal root repair		E					
D3346	Retreat root canal anterior		E					
D3347	Retreat root canal bicuspid		E					
D3348	Retreat root canal molar		E					
D3351	Apexification/recalc initial		E					
D3352	Apexification/recalc interim		E					
D3353	Apexification/recalc final		E					
D3410	Apicoect/perirad surg anter		E					
D3421	Root surgery bicuspid		E					
D3425	Root surgery molar		E					
D3426	Root surgery ea add root		E					
D3430	Retrograde filling		E					
D3450	Root amputation		E					
D3460	Endodontic endosseous implan		S	0330	9.1677	\$583.93		\$116.79
D3470	Intentional replantation		E					
D3910	Isolation- tooth w rubb dam		E					
D3920	Tooth splitting		E					
D3950	Canal prep/fitting of dowel		E					
D3999	Endodontic procedure		S	0330	9.1677	\$583.93		\$116.79
D4210	Gingivectomy/plasty per quad		E					
D4211	Gingivectomy/plasty per toot		E					
D4230	Ana crown exp 4 or> per quad		E					
D4231	Ana crown exp 1-3 per quad		E					
D4240	Gingival flap proc w/ planin		E					
D4241	Gngvl flap w rootplan 1-3 th		E					
D4245	Apically positioned flap		E					
D4249	Crown lengthen hard tissue		E					
D4260	Osseous surgery per quadrant		S	0330	9.1677	\$583.93		\$116.79
D4261	Osseous surgl-3teethperquad		E					
D4263	Bone replce graft first site		S	0330	9.1677	\$583.93		\$116.79
D4264	Bone replce graft each add		S	0330	9.1677	\$583.93		\$116.79
D4265	Bio mtrls to aid soft/os reg		E					
D4266	Guided tiss regen resorb		E					
D4267	Guided tiss regen nonresorb		E					
D4268	Surgical revision procedure		S	0330	9.1677	\$583.93		\$116.79
D4270	Pedicle soft tissue graft pr		S	0330	9.1677	\$583.93		\$116.79
D4271	Free soft tissue graft proc		S	0330	9.1677	\$583.93		\$116.79
D4273	Subepithelial tissue graft		S	0330	9.1677	\$583.93		\$116.79
D4274	Distal/proximal wedge proc		E					
D4275	Soft tissue allograft		E					
D4276	Con tissue w dble ped graft		E					
D4320	Provision splnt intracoronal		E					
D4321	Provisional splint extracoro		E					
D4341	Periodontal scaling & root		E					
D4342	Periodontal scaling 1-3teeth		E					
D4355	Full mouth debridement		S	0330	9.1677	\$583.93		\$116.79
D4381	Localized delivery antimicro		S	0330	9.1677	\$583.93		\$116.79
D4910	Periodontal maint procedures		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
D4920	Unscheduled dressing change		E					
D4999	Unspecified periodontal proc		E					
D5110	Dentures complete maxillary		E					
D5120	Dentures complete mandible		E					
D5130	Dentures immediat maxillary		E					
D5140	Dentures immediat mandible		E					
D5211	Dentures maxill part resin		E					
D5212	Dentures mand part resin		E					
D5213	Dentures maxill part metal		E					
D5214	Dentures mandibl part metal		E					
D5225	Maxillary part denture flex		E					
D5226	Mandibular part denture flex		E					
D5281	Removable partial denture		E					
D5410	Dentures adjust cmplt maxil		E					
D5411	Dentures adjust cmplt mand		E					
D5421	Dentures adjust part maxill		E					
D5422	Dentures adjust part mandbl		E					
D5510	Dentur repr broken compl bas		E					
D5520	Replace denture teeth complt		E					
D5610	Dentures repair resin base		E					
D5620	Rep part denture cast frame		E					
D5630	Rep partial denture clasp		E					
D5640	Replace part denture teeth		E					
D5650	Add tooth to partial denture		E					
D5660	Add clasp to partial denture		E					
D5670	Replc th&acrlc on mtl frmwk		E					
D5671	Replc th&acrlc mandibular		E					
D5710	Dentures rebase cmplt maxil		E					
D5711	Dentures rebase cmplt mand		E					
D5720	Dentures rebase part maxill		E					
D5721	Dentures rebase part mandbl		E					
D5730	Denture reln cmplt maxil ch		E					
D5731	Denture reln cmplt mand chr		E					
D5740	Denture reln part maxil chr		E					
D5741	Denture reln part mand chr		E					
D5750	Denture reln cmplt max lab		E					
D5751	Denture reln cmplt mand lab		E					
D5760	Denture reln part maxil lab		E					
D5761	Denture reln part mand lab		E					
D5810	Denture interm cmplt maxill		E					
D5811	Denture interm cmplt mandbl		E					
D5820	Denture interm part maxill		E					
D5821	Denture interm part mandbl		E					
D5850	Denture tiss conditn maxill		E					
D5851	Denture tiss conditin mandbl		E					
D5860	Overdenture complete		E					
D5861	Overdenture partial		E					
D5862	Precision attachment		E					
D5867	Replacement of precision att		E					
D5875	Prosthesis modification		E					
D5899	Removable prosthodontic proc		E					
D5911	Facial moulage sectional		S	0330	9.1677	\$583.93		\$116.79
D5912	Facial moulage complete		S	0330	9.1677	\$583.93		\$116.79
D5913	Nasal prosthesis		E					
D5914	Auricular prosthesis		E					
D5915	Orbital prosthesis		E					
D5916	Ocular prosthesis		E					
D5919	Facial prosthesis		E					
D5922	Nasal septal prosthesis		E					
D5923	Ocular prosthesis interim		E					
D5924	Cranial prosthesis		E					
D5925	Facial augmentation implant		E					
D5926	Replacement nasal prosthesis		E					
D5927	Auricular replacement		E					
D5928	Orbital replacement		E					
D5929	Facial replacement		E					
D5931	Surgical obturator		E					
D5932	Postsurgical obturator		E					
D5933	Refitting of obturator		E					
D5934	Mandibular flange prosthesis		E					
D5935	Mandibular denture prosth		E					
D5936	Temp obturator prosthesis		E					
D5937	Trismus appliance		E					
D5951	Feeding aid		E					
D5952	Pediatric speech aid		E					
D5953	Adult speech aid		E					
D5954	Superimposed prosthesis		E					
D5955	Palatal lift prosthesis		E					
D5958	Intraoral con def inter plt		E					
D5959	Intraoral con def mod palat		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
D5960	Modify speech aid prosthesis		E					
D5982	Surgical stent		E					
D5983	Radiation applicator		S	0330	9.1677	\$583.93		\$116.79
D5984	Radiation shield		S	0330	9.1677	\$583.93		\$116.79
D5985	Radiation cone locator		S	0330	9.1677	\$583.93		\$116.79
D5986	Fluoride applicator		E					
D5987	Commissure splint		S	0330	9.1677	\$583.93		\$116.79
D5988	Surgical splint		E					
D5999	Maxillofacial prosthesis		E					
D6010	Odontics endosteal implant		E					
D6012	Endosteal implant		E					
D6040	Odontics eposteal implant		E					
D6050	Odontics transosteal implnt		E					
D6053	Implnt/abtmnt spprt remv dnt		E					
D6054	Implnt/abtmnt spprt remvprtl		E					
D6055	Implant connecting bar		E					
D6056	Prefabricated abutment		E					
D6057	Custom abutment		E					
D6058	Abutment supported crown		E					
D6059	Abutment supported mtl crown		E					
D6060	Abutment supported mtl crown		E					
D6061	Abutment supported mtl crown		E					
D6062	Abutment supported mtl crown		E					
D6063	Abutment supported mtl crown		E					
D6064	Abutment supported mtl crown		E					
D6065	Implant supported crown		E					
D6066	Implant supported mtl crown		E					
D6067	Implant supported mtl crown		E					
D6068	Abutment supported retainer		E					
D6069	Abutment supported retainer		E					
D6070	Abutment supported retainer		E					
D6071	Abutment supported retainer		E					
D6072	Abutment supported retainer		E					
D6073	Abutment supported retainer		E					
D6074	Abutment supported retainer		E					
D6075	Implant supported retainer		E					
D6076	Implant supported retainer		E					
D6077	Implant supported retainer		E					
D6078	Implnt/about suprted fixd dent		E					
D6079	Implnt/about suprted fixd dent		E					
D6080	Implant maintenance		E					
D6090	Repair implant		E					
D6091	Repl semi/precision attach		E					
D6092	Recement supp crown		E					
D6093	Recement supp part denture		E					
D6094	Abut support crown titanium		E					
D6095	Odontics repr abutment		E					
D6100	Removal of implant		E					
D6190	Radio/surgical implant index		E					
D6194	Abut support retainer titani		E					
D6199	Implant procedure		E					
D6205	Pontic-indirect resin based		E					
D6210	Prosthodont high noble metal		E					
D6211	Bridge base metal cast		E					
D6212	Bridge noble metal cast		E					
D6214	Pontic titanium		E					
D6240	Bridge porcelain high noble		E					
D6241	Bridge porcelain base metal		E					
D6242	Bridge porcelain nobel metal		E					
D6245	Bridge porcelain/ceramic		E					
D6250	Bridge resin w/high noble		E					
D6251	Bridge resin base metal		E					
D6252	Bridge resin w/noble metal		E					
D6253	Provisional pontic		E					
D6545	Dental retainr cast metl		E					
D6548	Porcelain/ceramic retainer		E					
D6600	Porcelain/ceramic inlay 2srf		E					
D6601	Porc/ceram inlay >= 3 surfac		E					
D6602	Cst hgh nble mtl inlay 2 srf		E					
D6603	Cst hgh nble mtl inlay >=3srf		E					
D6604	Cst bse mtl inlay 2 surfaces		E					
D6605	Cst bse mtl inlay >= 3 surfa		E					
D6606	Cast noble metal inlay 2 sur		E					
D6607	Cst noble mtl inlay >=3 surf		E					
D6608	Onlay porc/crmc 2 surfaces		E					
D6609	Onlay porc/crmc >=3 surfaces		E					
D6610	Onlay cst hgh nbl mtl 2 srfc		E					
D6611	Onlay cst hgh nbl mtl >=3srf		E					
D6612	Onlay cst base mtl 2 surface		E					
D6613	Onlay cst base mtl >=3 surfa		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
D6614	Onlay cst nbl mtl 2 surfaces		E					
D6615	Onlay cst nbl mtl >=3 surfac		E					
D6624	Inlay titanium		E					
D6634	Onlay titanium		E					
D6710	Crown-indirect resin based		E					
D6720	Retain crown resin w hi nble		E					
D6721	Crown resin w/base metal		E					
D6722	Crown resin w/noble metal		E					
D6740	Crown porcelain/ceramic		E					
D6750	Crown porcelain high noble		E					
D6751	Crown porcelain base metal		E					
D6752	Crown porcelain noble metal		E					
D6780	Crown 3/4 high noble metal		E					
D6781	Crown 3/4 cast based metal		E					
D6782	Crown 3/4 cast noble metal		E					
D6783	Crown 3/4 porcelain/ceramic		E					
D6790	Crown full high noble metal		E					
D6791	Crown full base metal cast		E					
D6792	Crown full noble metal cast		E					
D6793	Provisional retainer crown		E					
D6794	Crown titanium		E					
D6920	Dental connector bar		S	0330	9.1677	\$583.93		\$116.79
D6930	Dental recement bridge		E					
D6940	Stress breaker		E					
D6950	Precision attachment		E					
D6970	Post & core plus retainer		E					
D6972	Prefab post & core plus reta		E					
D6973	Core build up for retainer		E					
D6975	Coping metal		E					
D6976	Each addtnl cast post		E					
D6977	Each addtl prefab post		E					
D6980	Bridge repair		E					
D6985	Pediatric partial denture fx		E					
D6999	Fixed prosthodontic proc		E					
D7111	Extraction coronal remnants		S	0330	9.1677	\$583.93		\$116.79
D7140	Extraction erupted tooth/exr		S	0330	9.1677	\$583.93		\$116.79
D7210	Rem imp tooth w mucoper flp		S	0330	9.1677	\$583.93		\$116.79
D7220	Impact tooth remov soft tiss		S	0330	9.1677	\$583.93		\$116.79
D7230	Impact tooth remov part bony		S	0330	9.1677	\$583.93		\$116.79
D7240	Impact tooth remov comp bony		S	0330	9.1677	\$583.93		\$116.79
D7241	Impact tooth rem bony w/comp		S	0330	9.1677	\$583.93		\$116.79
D7250	Tooth root removal		S	0330	9.1677	\$583.93		\$116.79
D7260	Oral antral fistula closure		S	0330	9.1677	\$583.93		\$116.79
D7261	Primary closure sinus perf		S	0330	9.1677	\$583.93		\$116.79
D7270	Tooth reimplantation		E					
D7272	Tooth transplantation		E					
D7280	Exposure impact tooth orthod		E					
D7282	Mobilize erupted/malpos toot		E					
D7283	Place device impacted tooth		B					
D7285	Biopsy of oral tissue hard		E					
D7286	Biopsy of oral tissue soft		E					
D7287	Exfoliative cytolog collect		E					
D7288	Brush biopsy		B					
D7290	Repositioning of teeth		E					
D7291	Transseptal fiberotomy		S	0330	9.1677	\$583.93		\$116.79
D7292	Screw retained plate		E					
D7293	Temp anchorage dev w flap		E					
D7294	Temp anchorage dev w/o flap		E					
D7310	Alveoplasty w/ extraction		E					
D7311	Alveoloplasty w/extract 1-3		E					
D7320	Alveoplasty w/o extraction		E					
D7321	Alveoloplasty not w/extracts		B					
D7340	Vestibuloplasty ridge extens		E					
D7350	Vestibuloplasty exten graft		E					
D7410	Rad exc lesion up to 1.25 cm		E					
D7411	Excision benign lesion>1.25c		E					
D7412	Excision benign lesion compl		E					
D7413	Excision malig lesion<=1.25c		E					
D7414	Excision malig lesion>1.25cm		E					
D7415	Excision malig les complicat		E					
D7440	Malig tumor exc to 1.25 cm		E					
D7441	Malig tumor > 1.25 cm		E					
D7450	Rem odontogen cyst to 1.25cm		E					
D7451	Rem odontogen cyst > 1.25 cm		E					
D7460	Rem nonodonto cyst to 1.25cm		E					
D7461	Rem nonodonto cyst > 1.25 cm		E					
D7465	Lesion destruction		E					
D7471	Rem exostosis any site		E					
D7472	Removal of torus palatinus		E					
D7473	Remove torus mandibularis		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
D7485	Surg reduct osseoustuberosit		E					
D7490	Maxilla or mandible resectio		E					
D7510	I&d absc intraoral soft tiss		E					
D7511	Incision/drain abscess intra		B					
D7520	I&d abscess extraoral		E					
D7521	Incision/drain abscess extra		B					
D7530	Removal fb skin/areolar tiss		E					
D7540	Removal of fb reaction		E					
D7550	Removal of sloughed off bone		E					
D7560	Maxillary sinusotomy		E					
D7610	Maxilla open reduct simple		E					
D7620	Clsd reduct simpl maxilla fx		E					
D7630	Open red simpl mandible fx		E					
D7640	Clsd red simpl mandible fx		E					
D7650	Open red simp malar/zygom fx		E					
D7660	Clsd red simp malar/zygom fx		E					
D7670	Closd rductn splint alveolus		E					
D7671	Alveolus open reduction		E					
D7680	Reduct simple facial bone fx		E					
D7710	Maxilla open reduct compound		E					
D7720	Clsd reduct compd maxilla fx		E					
D7730	Open reduct compd mandble fx		E					
D7740	Clsd reduct compd mandble fx		E					
D7750	Open red comp malar/zygma fx		E					
D7760	Clsd red comp malar/zygma fx		E					
D7770	Open reduc compd alveolus fx		E					
D7771	Alveolus clsd reduc stblz te		E					
D7780	Reduct compnd facial bone fx		E					
D7810	Tmj open reduct-dislocation		E					
D7820	Closed tmp manipulation		E					
D7830	Tmj manipulation under anest		E					
D7840	Removal of tmj condyle		E					
D7850	Tmj meniscectomy		E					
D7852	Tmj repair of joint disc		E					
D7854	Tmj excisn of joint membrane		E					
D7856	Tmj cutting of a muscle		E					
D7858	Tmj reconstruction		E					
D7860	Tmj cutting into joint		E					
D7865	Tmj reshaping components		E					
D7870	Tmj aspiration joint fluid		E					
D7871	Lysis + lavage w catheters		E					
D7872	Tmj diagnostic arthroscopy		E					
D7873	Tmj arthroscopy lysis adhesn		E					
D7874	Tmj arthroscopy disc reposit		E					
D7875	Tmj arthroscopy synovectomy		E					
D7876	Tmj arthroscopy discectomy		E					
D7877	Tmj arthroscopy debridement		E					
D7880	Occlusal orthotic appliance		E					
D7899	Tmj unspecified therapy		E					
D7910	Dent suture recent wnd to 5cm		E					
D7911	Dental suture wound to 5 cm		E					
D7912	Suture complicate wnd > 5 cm		E					
D7920	Dental skin graft		E					
D7940	Reshaping bone orthognathic		S	0330	9.1677	\$583.93		\$116.79
D7941	Bone cutting ramus closed		E					
D7943	Cutting ramus open w/graft		E					
D7944	Bone cutting segmented		E					
D7945	Bone cutting body mandible		E					
D7946	Reconstruction maxilla total		E					
D7947	Reconstruct maxilla segment		E					
D7948	Reconstruct midface no graft		E					
D7949	Reconstruct midface w/graft		E					
D7950	Mandible graft		E					
D7951	Sinus aug w bone/bone sup		E					
D7953	Bone replacement graft		E					
D7955	Repair maxillofacial defects		E					
D7960	Frenulectomy/frenulotomy		E					
D7963	Frenuloplasty		E					
D7970	Excision hyperplastic tissue		E					
D7971	Excision pericoronaral gingiva		E					
D7972	Surg reduct fibrous tuberosit		E					
D7980	Sialolithotomy		E					
D7981	Excision of salivary gland		E					
D7982	Sialodochoplasty		E					
D7983	Closure of salivary fistula		E					
D7990	Emergency tracheotomy		E					
D7991	Dental coronoidectomy		E					
D7995	Synthetic graft facial bones		E					
D7996	Implant mandible for augment		E					
D7997	Appliance removal		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
D7998	Intraoral place of fix dev		E					
D7999	Oral surgery procedure		E					
D8010	Limited dental tx primary		E					
D8020	Limited dental tx transition		E					
D8030	Limited dental tx adolescent		E					
D8040	Limited dental tx adult		E					
D8050	Intercep dental tx primary		E					
D8060	Intercep dental tx transitn		E					
D8070	Compre dental tx transition		E					
D8080	Compre dental tx adolescent		E					
D8090	Compre dental tx adult		E					
D8210	Orthodontic rem appliance tx		E					
D8220	Fixed appliance therapy habt		E					
D8660	Preorthodontic tx visit		E					
D8670	Periodic orthodontc tx visit		E					
D8680	Orthodontic retention		E					
D8690	Orthodontic treatment		E					
D8691	Repair ortho appliance		E					
D8692	Replacement retainer		E					
D8693	Rebond/cement/repair retain		E					
D8999	Orthodontic procedure		E					
D9110	Tx dental pain minor proc		N					
D9120	Fix partial denture section		E					
D9210	Dent anesthesia w/o surgery		E					
D9211	Regional block anesthesia		E					
D9212	Trigeminal block anesthesia		E					
D9215	Local anesthesia		E					
D9220	General anesthesia		E					
D9221	General anesthesia ea ad 15m		E					
D9230	Analgesia		N					
D9241	Intravenous sedation		E					
D9242	IV sedation ea ad 30 m		E					
D9248	Sedation (non-iv)		N					
D9310	Dental consultation		E					
D9410	Dental house call		E					
D9420	Hospital call		E					
D9430	Office visit during hours		E					
D9440	Office visit after hours		E					
D9450	Case presentation tx plan		E					
D9610	Dent therapeutic drug inject		E					
D9612	Thera par drugs 2 or > admin		E					
D9630	Other drugs/medicaments		S	0330	9.1677	\$583.93		\$116.79
D9910	Dent appl desensitizing med		E					
D9911	Appl desensitizing resin		E					
D9920	Behavior management		E					
D9930	Treatment of complications		S	0330	9.1677	\$583.93		\$116.79
D9940	Dental occlusal guard		S	0330	9.1677	\$583.93		\$116.79
D9941	Fabrication athletic guard		E					
D9942	Repair/reline occlusal guard		E					
D9950	Occlusion analysis		S	0330	9.1677	\$583.93		\$116.79
D9951	Limited occlusal adjustment		S	0330	9.1677	\$583.93		\$116.79
D9952	Complete occlusal adjustment		S	0330	9.1677	\$583.93		\$116.79
D9970	Enamel microabrasion		E					
D9971	Odontoplasty 1-2 teeth		E					
D9972	Extrnl bleaching per arch		E					
D9973	Extrnl bleaching per tooth		E					
D9974	Intrnl bleaching per tooth		E					
D9999	Adjunctive procedure		E					
E0100	Cane adjust/fixd with tip		Y					
E0105	Cane adjust/fixd quad/3 pro		Y					
E0110	Crutch forearm pair		Y					
E0111	Crutch forearm each		Y					
E0112	Crutch underarm pair wood		Y					
E0113	Crutch underarm each wood		Y					
E0114	Crutch underarm pair no wood		Y					
E0116	Crutch underarm each no wood		Y					
E0117	Underarm springassist crutch		Y					
E0118	Crutch substitute		E					
E0130	Walker rigid adjust/fixd ht		Y					
E0135	Walker folding adjust/fixd		Y					
E0140	Walker w trunk support		Y					
E0141	Rigid wheeled walker adj/fix		Y					
E0143	Walker folding wheeled w/o s		Y					
E0144	Enclosed walker w rear seat		Y					
E0147	Walker variable wheel resist		Y					
E0148	Heavyduty walker no wheels		Y					
E0149	Heavy duty wheeled walker		Y					
E0153	Forearm crutch platform atta		Y					
E0154	Walker platform attachment		Y					
E0155	Walker wheel attachment,pair		Y					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
E0156	Walker seat attachment		Y					
E0157	Walker crutch attachment		Y					
E0158	Walker leg extenders set of 4		Y					
E0159	Brake for wheeled walker		Y					
E0160	Sitz type bath or equipment		Y					
E0161	Sitz bath/equipment w/faucet		Y					
E0162	Sitz bath chair		Y					
E0163	Commode chair with fixed arm		Y					
E0165	Commode chair with detacharm		Y					
E0167	Commode chair pail or pan		Y					
E0168	Heavyduty/wide commode chair		Y					
E0170	Commode chair electric		Y					
E0171	Commode chair non-electric		Y					
E0172	Seat lift mechanism toilet		E					
E0175	Commode chair foot rest		Y					
E0181	Press pad alternating w/ pum		Y					
E0182	Replace pump, alt press pad		Y					
E0184	Dry pressure mattress		Y					
E0185	Gel pressure mattress pad		Y					
E0186	Air pressure mattress		Y					
E0187	Water pressure mattress		Y					
E0188	Synthetic sheepskin pad		Y					
E0189	Lambswool sheepskin pad		Y					
E0190	Positioning cushion		E					
E0191	Protector heel or elbow		Y					
E0193	Powered air flotation bed		Y					
E0194	Air fluidized bed		Y					
E0196	Gel pressure mattress		Y					
E0197	Air pressure pad for mattres		Y					
E0198	Water pressure pad for mattr		Y					
E0199	Dry pressure pad for mattres		Y					
E0200	Heat lamp without stand		Y					
E0202	Phototherapy light w/ photom		Y					
E0203	Therapeutic lightbox tabletp	CH	E					
E0205	Heat lamp with stand		Y					
E0210	Electric heat pad standard		Y					
E0215	Electric heat pad moist		Y					
E0217	Water circ heat pad w pump		Y					
E0218	Water circ cold pad w pump		Y					
E0220	Hot water bottle		Y					
E0221	Infrared heating pad system		Y					
E0225	Hydrocollator unit		Y					
E0230	Ice cap or collar		Y					
E0231	Wound warming device		E					
E0232	Warming card for NWT		E					
E0235	Paraffin bath unit portable		Y					
E0236	Pump for water circulating p		Y					
E0238	Heat pad non-electric moist		Y					
E0239	Hydrocollator unit portable		Y					
E0240	Bath/shower chair		E					
E0241	Bath tub wall rail		E					
E0242	Bath tub rail floor		E					
E0243	Toilet rail		E					
E0244	Toilet seat raised		E					
E0245	Tub stool or bench		E					
E0246	Transfer tub rail attachment		E					
E0247	Trans bench w/wo comm open		E					
E0248	HDtrans bench w/wo comm open		E					
E0249	Pad water circulating heat u		Y					
E0250	Hosp bed fixed ht w/ mattres		E					
E0251	Hosp bed fixd ht w/o mattres		E					
E0255	Hospital bed var ht w/ mattr		E					
E0256	Hospital bed var ht w/o matt		E					
E0260	Hosp bed semi-electr w/ matt		E					
E0261	Hosp bed semi-electr w/o mat		E					
E0265	Hosp bed total electr w/ mat		E					
E0266	Hosp bed total elec w/o matt		E					
E0270	Hospital bed institutional t		E					
E0271	Mattress innerspring		E					
E0272	Mattress foam rubber		E					
E0273	Bed board		E					
E0274	Over-bed table		E					
E0275	Bed pan standard		Y					
E0276	Bed pan fracture		Y					
E0277	Powered pres-redu air mattrs		Y					
E0280	Bed cradle		Y					
E0290	Hosp bed fx ht w/o rails w/m		E					
E0291	Hosp bed fx ht w/o rail w/o		E					
E0292	Hosp bed var ht w/o rail w/o		Y					
E0293	Hosp bed var ht w/o rail w/		Y					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
E0294	Hosp bed semi-elect w/ matr		E					
E0295	Hosp bed semi-elect w/o matt		Y					
E0296	Hosp bed total elect w/ matt		E					
E0297	Hosp bed total elect w/o mat		Y					
E0300	Enclosed ped crib hosp grade		Y					
E0301	HD hosp bed, 350–600 lbs		Y					
E0302	Ex hd hosp bed > 600 lbs		Y					
E0303	Hosp bed hvy dty xtra wide		E					
E0304	Hosp bed xtra hvy dty x wide		E					
E0305	Rails bed side half length		E					
E0310	Rails bed side full length		E					
E0315	Bed accessory brd/tbl/supprt		E					
E0316	Bed safety enclosure		Y					
E0325	Urinal male jug-type		Y					
E0326	Urinal female jug-type		Y					
E0328	Ped hospital bed, manual	NI	Y					
E0329	Ped hospital bed semi/elect	NI	Y					
E0350	Control unit bowel system		E					
E0352	Disposable pack w/bowel syst		E					
E0370	Air elevator for heel		E					
E0371	Nonpower mattress overlay		Y					
E0372	Powered air mattress overlay		Y					
E0373	Nonpowered pressure mattress		Y					
E0424	Stationary compressed gas O2		Y					
E0425	Gas system stationary compre		E					
E0430	Oxygen system gas portable		E					
E0431	Portable gaseous O2		Y					
E0434	Portable liquid O2		Y					
E0435	Oxygen system liquid portabl		E					
E0439	Stationary liquid O2		Y					
E0440	Oxygen system liquid station		E					
E0441	Oxygen contents, gaseous		Y					
E0442	Oxygen contents, liquid		Y					
E0443	Portable O2 contents, gas		Y					
E0444	Portable O2 contents, liquid		Y					
E0445	Oximeter non-invasive		A					
E0450	Vol control vent invasiv int		Y					
E0455	Oxygen tent excl croup/ped t		Y					
E0457	Chest shell		Y					
E0459	Chest wrap		Y					
E0460	Neg press vent portabl/statn		Y					
E0461	Vol control vent noninv int		Y					
E0462	Rocking bed w/ or w/o side r		Y					
E0463	Press supp vent invasive int		Y					
E0464	Press supp vent noninv int		Y					
E0470	RAD w/o backup non-inv intrfc		Y					
E0471	RAD w/backup non inv intrfc		Y					
E0472	RAD w backup invasive intrfc		Y					
E0480	Percussor elect/pneum home m		Y					
E0481	Intrpulgny percuss vent sys		E					
E0482	Cough stimulating device		Y					
E0483	Chest compression gen system		Y					
E0484	Non-elec oscillatory pep dvc		Y					
E0485	Oral device/appliance prefab		Y					
E0486	Oral device/appliance cusfab		Y					
E0500	Ippb all types		Y					
E0550	Humidif extens suppl w ippb		Y					
E0555	Humidifier for use w/ regula		Y					
E0560	Humidifier supplemental w/ i		Y					
E0561	Humidifier nonheated w PAP		Y					
E0562	Humidifier heated used w PAP		Y					
E0565	Compressor air power source		Y					
E0570	Nebulizer with compression		Y					
E0571	Aerosol compressor for svneb		Y					
E0572	Aerosol compressor adjust pr		Y					
E0574	Ultrasonic generator w svneb		Y					
E0575	Nebulizer ultrasonic		Y					
E0580	Nebulizer for use w/ regulat		Y					
E0585	Nebulizer w/ compressor & he		Y					
E0600	Suction pump portab hom modl		Y					
E0601	Cont airway pressure device		Y					
E0602	Manual breast pump		Y					
E0603	Electric breast pump		A					
E0604	Hosp grade elec breast pump		A					
E0605	Vaporizer room type		Y					
E0606	Drainage board postural		Y					
E0607	Blood glucose monitor home		Y					
E0610	Pacemaker monitr audible/vis		Y					
E0615	Pacemaker monitr digital/vis		Y					
E0616	Cardiac event recorder		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
E0617	Automatic ext defibrillator		Y					
E0618	Apnea monitor		A					
E0619	Apnea monitor w recorder		A					
E0620	Cap bld skin piercing laser		Y					
E0621	Patient lift sling or seat		Y					
E0625	Patient lift bathroom or toi		E					
E0627	Seat lift incorp lift-chair		Y					
E0628	Seat lift for pt furn-electr		Y					
E0629	Seat lift for pt furn-non-el		Y					
E0630	Patient lift hydraulic		Y					
E0635	Patient lift electric		Y					
E0636	PT support & positioning sys		Y					
E0637	Combination sit to stand sys		E					
E0638	Standing frame sys		E					
E0639	Moveable patient lift system		E					
E0640	Fixed patient lift system		E					
E0641	Multi-position stnd fram sys		E					
E0642	Dynamic standing frame		E					
E0650	Pneuma compressor non-segment		Y					
E0651	Pneum compressor segmental		Y					
E0652	Pneum compres w/cal pressure		Y					
E0655	Pneumatic appliance half arm		Y					
E0660	Pneumatic appliance full leg		Y					
E0665	Pneumatic appliance full arm		Y					
E0666	Pneumatic appliance half leg		Y					
E0667	Seg pneumatic appl full leg		Y					
E0668	Seg pneumatic appl full arm		Y					
E0669	Seg pneumatic appli half leg		Y					
E0671	Pressure pneum appl full leg		Y					
E0672	Pressure pneum appl full arm		Y					
E0673	Pressure pneum appl half leg		Y					
E0675	Pneumatic compression device		Y					
E0676	Inter limb compress dev NOS		Y					
E0691	Uvl pnl 2 sq ft or less		Y					
E0692	Uvl sys panel 4 ft		Y					
E0693	Uvl sys panel 6 ft		Y					
E0694	Uvl md cabinet sys 6 ft		Y					
E0700	Safety equipment		E					
E0705	Transfer device		B					
E0710	Restraints any type		E					
E0720	Tens two lead		Y					
E0730	Tens four lead		Y					
E0731	Conductive garment for tens/		Y					
E0740	Incontinence treatment systm		Y					
E0744	Neuromuscular stim for scoli		Y					
E0745	Neuromuscular stim for shock		Y					
E0746	Electromyograph biofeedback		A					
E0747	Elec osteogen stim not spine		Y					
E0748	Elec osteogen stim spinal		Y					
E0749	Elec osteogen stim implanted		N					
E0755	Electronic salivary reflex s		E					
E0760	Osteogen ultrasound stimltor		Y					
E0761	Nontherm electromgntc device		E					
E0762	Trans elec jt stim dev sys		B					
E0764	Functional neuromuscularstim		Y					
E0765	Nerve stimulator for tx n&v		Y					
E0769	Electric wound treatment dev		B					
E0776	Iv pole		Y					
E0779	Amb infusion pump mechanical		Y					
E0780	Mech amb infusion pump <8hrs		Y					
E0781	External ambulatory infus pu		Y					
E0782	Non-programable infusion pump		N					
E0783	Programmable infusion pump		N					
E0784	Ext amb infusn pump insulin		Y					
E0785	Replacement impl pump cathet		N					
E0786	Implantable pump replacement		N					
E0791	Parenteral infusion pump sta		Y					
E0830	Ambulatory traction device		N					
E0840	Tract frame attach headboard		Y					
E0849	Cervical pneum trac equip		Y					
E0850	Traction stand free standing		Y					
E0855	Cervical traction equipment		Y					
E0856	Cervic collar w air bladder	NI	Y					
E0860	Tract equip cervical tract		Y					
E0870	Tract frame attach footboard		Y					
E0880	Trac stand free stand extrem		Y					
E0890	Traction frame attach pelvic		Y					
E0900	Trac stand free stand pelvic		Y					
E0910	Trapeze bar attached to bed		Y					
E0911	HD trapeze bar attach to bed		Y					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
E0912	HD trapeze bar free standing		Y					
E0920	Fracture frame attached to b		Y					
E0930	Fracture frame free standing		Y					
E0935	Cont pas motion exercise dev		Y					
E0936	CPM device, other than knee		E					
E0940	Trapeze bar free standing		Y					
E0941	Gravity assisted traction de		Y					
E0942	Cervical head harness/halter		Y					
E0944	Pelvic belt/harness/boot		Y					
E0945	Belt/harness extremity		Y					
E0946	Fracture frame dual w cross		Y					
E0947	Fracture frame attachmnts pe		Y					
E0948	Fracture frame attachmnts ce		Y					
E0950	Tray		A					
E0951	Loop heel		A					
E0952	Toe loop/holder, each		A					
E0955	Cushioned headrest		Y					
E0956	W/c lateral trunk/hip suppor		Y					
E0957	W/c medial thigh support		Y					
E0958	Whlchr att-conv 1 arm drive		A					
E0959	Amputee adapter		B					
E0960	W/c shoulder harness/straps		Y					
E0961	Wheelchair brake extension		B					
E0966	Wheelchair head rest extensi		B					
E0967	Manual wc hand rim w project		Y					
E0968	Wheelchair commode seat		Y					
E0969	Wheelchair narrowing device		Y					
E0970	Wheelchair no. 2 footplates	CH	E					
E0971	Wheelchair anti-tipping devi		B					
E0973	W/Ch access det adj armrest		B					
E0974	W/Ch access anti-rollback		B					
E0978	W/C acc,saf belt pelv strap		B					
E0980	Wheelchair safety vest		Y					
E0981	Seat upholstery, replacement		Y					
E0982	Back upholstery, replacement		Y					
E0983	Add pwr joystick		Y					
E0984	Add pwr tiller		Y					
E0985	W/c seat lift mechanism		Y					
E0986	Man w/c push-rim pow assist		Y					
E0990	Wheelchair elevating leg res		B					
E0992	Wheelchair solid seat insert		B					
E0994	Wheelchair arm rest		Y					
E0995	Wheelchair calf rest		B					
E1002	Pwr seat tilt		Y					
E1003	Pwr seat recline		Y					
E1004	Pwr seat recline mech		Y					
E1005	Pwr seat recline pwr		Y					
E1006	Pwr seat combo w/o shear		Y					
E1007	Pwr seat combo w/shear		Y					
E1008	Pwr seat combo pwr shear		Y					
E1009	Add mech leg elevation		Y					
E1010	Add pwr leg elevation		Y					
E1011	Ped wc modify width adjustm		Y					
E1014	Reclining back add ped w/c		Y					
E1015	Shock absorber for man w/c		Y					
E1016	Shock absorber for power w/c		Y					
E1017	HD shck absbr for hd man wc		Y					
E1018	HD shck absbr for hd powwc		Y					
E1020	Residual limb support system		Y					
E1028	W/c manual swingaway		Y					
E1029	W/c vent tray fixed		Y					
E1030	W/c vent tray gimbaled		Y					
E1031	Rollabout chair with casters		Y					
E1035	Patient transfer system		Y					
E1037	Transport chair, ped size		Y					
E1038	Transport chair pt wt<=300lb		Y					
E1039	Transport chair pt wt >300lb		Y					
E1050	Whelchr fxd full length arms		A					
E1060	Wheelchair detachable arms		A					
E1070	Wheelchair detachable foot r		A					
E1083	Hemi-wheelchair fixed arms		A					
E1084	Hemi-wheelchair detachable a		A					
E1085	Hemi-wheelchair fixed arms	CH	E					
E1086	Hemi-wheelchair detachable a	CH	E					
E1087	Wheelchair lightwt fixed arm		A					
E1088	Wheelchair lightweight det a		A					
E1089	Wheelchair lightwt fixed arm	CH	E					
E1090	Wheelchair lightweight det a	CH	E					
E1092	Wheelchair wide w/ leg rests		A					
E1093	Wheelchair wide w/ foot rest		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
E1100	Whchr s-recl fxd arm leg res		A					
E1110	Wheelchair semi-recl detach		A					
E1130	Whlchr stand fxd arm ft rest	CH	E					
E1140	Wheelchair standard detach a	CH	E					
E1150	Wheelchair standard w/ leg r		Y					
E1160	Wheelchair fixed arms		A					
E1161	Manual adult wc w tiltinspac		A					
E1170	Whlchr ampu fxd arm leg rest		A					
E1171	Wheelchair amputee w/o leg r		A					
E1172	Wheelchair amputee detach ar		A					
E1180	Wheelchair amputee w/ foot r		A					
E1190	Wheelchair amputee w/ leg re		A					
E1195	Wheelchair amputee heavy dut		A					
E1200	Wheelchair amputee fixed arm		A					
E1220	Whlchr special size/constrc		A					
E1221	Wheelchair spec size w foot		A					
E1222	Wheelchair spec size w/ leg		A					
E1223	Wheelchair spec size w foot		A					
E1224	Wheelchair spec size w/ leg		A					
E1225	Manual semi-reclining back		Y					
E1226	Manual fully reclining back		B					
E1227	Wheelchair spec sz spec ht a		Y					
E1228	Wheelchair spec sz spec ht b		Y					
E1229	Pediatric wheelchair NOS		Y					
E1230	Power operated vehicle		Y					
E1231	Rigid ped w/c tilt-in-space		Y					
E1232	Folding ped wc tilt-in-space		Y					
E1233	Rig ped wc tiltspc w/o seat		Y					
E1234	Fld ped wc tiltspc w/o seat		Y					
E1235	Rigid ped wc adjustable		Y					
E1236	Folding ped wc adjustable		Y					
E1237	Rgd ped wc adjstabl w/o seat		Y					
E1238	Fld ped wc adjstabl w/o seat		Y					
E1239	Ped power wheelchair NOS		Y					
E1240	Whchr litwt det arm leg rest		A					
E1250	Wheelchair lightwt fixed arm	CH	E					
E1260	Wheelchair lightwt foot rest	CH	E					
E1270	Wheelchair lightweight leg r		A					
E1280	Whchr h-duty det arm leg res		A					
E1285	Wheelchair heavy duty fixed	CH	E					
E1290	Wheelchair hvy duty detach a	CH	E					
E1295	Wheelchair heavy duty fixed		A					
E1296	Wheelchair special seat heig		Y					
E1297	Wheelchair special seat dept		Y					
E1298	Wheelchair spec seat depth/w		Y					
E1300	Whirlpool portable		E					
E1310	Whirlpool non-portable		Y					
E1340	Repair for DME, per 15 min		Y					
E1353	Oxygen supplies regulator		Y					
E1355	Oxygen supplies stand/rack		Y					
E1372	Oxy suppl heater for nebuliz		Y					
E1390	Oxygen concentrator		Y					
E1391	Oxygen concentrator, dual		Y					
E1392	Portable oxygen concentrator		Y					
E1399	Durable medical equipment mi		Y					
E1405	O2/water vapor enrich w/heat		Y					
E1406	O2/water vapor enrich w/o he		Y					
E1500	Centrifuge		A					
E1510	Kidney dialysate delivry sys		A					
E1520	Heparin infusion pump		A					
E1530	Replacement air bubble detec		A					
E1540	Replacement pressure alarm		A					
E1550	Bath conductivity meter		A					
E1560	Replace blood leak detector		A					
E1570	Adjustable chair for esrd pt		A					
E1575	Transducer protect/fld bar		A					
E1580	Unipuncture control system		A					
E1590	Hemodialysis machine		A					
E1592	Auto interm peritoneal dialy		A					
E1594	Cycler dialysis machine		A					
E1600	Deli/install chrg hemo equip		A					
E1610	Reverse osmosis h2o puri sys		A					
E1615	Deionizer H2O puri system		A					
E1620	Replacement blood pump		A					
E1625	Water softening system		A					
E1630	Reciprocating peritoneal dia		A					
E1632	Wearable artificial kidney		A					
E1634	Peritoneal dialysis clamp		B					
E1635	Compact travel hemodialyzer		A					
E1636	Sorbent cartridges per 10		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
E1637	Hemostats for dialysis, each		A					
E1639	Dialysis scale		A					
E1699	Dialysis equipment noc		A					
E1700	Jaw motion rehab system		Y					
E1701	Repl cushions for jaw motion		Y					
E1702	Repl measr scales jaw motion		Y					
E1800	Adjust elbow ext/flex device		Y					
E1801	SPS elbow device		Y					
E1802	Adjst forearm pro/sup device		Y					
E1805	Adjust wrist ext/flex device		Y					
E1806	SPS wrist device		Y					
E1810	Adjust knee ext/flex device		Y					
E1811	SPS knee device		Y					
E1812	Knee ext/flex w act res ctrl		Y					
E1815	Adjust ankle ext/flex device		Y					
E1816	SPS ankle device		Y					
E1818	SPS forearm device		Y					
E1820	Soft interface material		Y					
E1821	Replacement interface SPSPD		Y					
E1825	Adjust finger ext/flex devc		Y					
E1830	Adjust toe ext/flex device		Y					
E1840	Adj shoulder ext/flex device		Y					
E1841	Static str shldr dev rom adj		Y					
E1902	AAC non-electronic board		A					
E2000	Gastric suction pump hme mdl		Y					
E2100	Bld glucose monitor w voice		Y					
E2101	Bld glucose monitor w lance		Y					
E2120	Pulse gen sys tx endolymp fl		Y					
E2201	Man w/ch acc seat w>=20+<24+		Y					
E2202	Seat width 24–27 in		Y					
E2203	Frame depth less than 22 in		Y					
E2204	Frame depth 22 to 25 in		Y					
E2205	Manual wc accessory, handrim		Y					
E2206	Complete wheel lock assembly		Y					
E2207	Crutch and cane holder		Y					
E2208	Cylinder tank carrier		Y					
E2209	Arm trough each		Y					
E2210	Wheelchair bearings		Y					
E2211	Pneumatic propulsion tire		Y					
E2212	Pneumatic prop tire tube		Y					
E2213	Pneumatic prop tire insert		Y					
E2214	Pneumatic caster tire each		Y					
E2215	Pneumatic caster tire tube		Y					
E2216	Foam filled propulsion tire		Y					
E2217	Foam filled caster tire each		Y					
E2218	Foam propulsion tire each		Y					
E2219	Foam caster tire any size ea		Y					
E2220	Solid propulsion tire each		Y					
E2221	Solid caster tire each		Y					
E2222	Solid caster integrated whl		Y					
E2223	Valve replacement only each		Y					
E2224	Propulsion whl excludes tire		Y					
E2225	Caster wheel excludes tire		Y					
E2226	Caster fork replacement only		Y					
E2227	Gear reduction drive wheel	NI	Y					
E2228	Mwc acc, wheelchair brake	NI	Y					
E2291	Planar back for ped size wc		Y					
E2292	Planar seat for ped size wc		Y					
E2293	Contour back for ped size wc		Y					
E2294	Contour seat for ped size wc		Y					
E2300	Pwr seat elevation sys		Y					
E2301	Pwr standing		Y					
E2310	Electro connect btw control		Y					
E2311	Electro connect btw 2 sys		Y					
E2312	Mini-prop remote joystick	NI	Y					
E2313	PWC harness, expand control	NI	Y					
E2321	Hand interface joystick		Y					
E2322	Mult mech switches		Y					
E2323	Special joystick handle		Y					
E2324	Chin cup interface		Y					
E2325	Sip and puff interface		Y					
E2326	Breath tube kit		Y					
E2327	Head control interface mech		Y					
E2328	Head/extremity control inter		Y					
E2329	Head control nonproportional		Y					
E2330	Head control proximity switc		Y					
E2331	Attendant control		Y					
E2340	W/c wdth 20–23 in seat frame		Y					
E2341	W/c wdth 24–27 in seat frame		Y					
E2342	W/c dpth 20–21 in seat frame		Y					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
E2343	W/c dpth 22–25 in seat frame		Y					
E2351	Electronic SGD interface		Y					
E2360	22nf nonsealed leadacid		Y					
E2361	22nf sealed leadacid battery		Y					
E2362	Gr24 nonsealed leadacid		Y					
E2363	Gr24 sealed leadacid battery		Y					
E2364	U1nonsealed leadacid battery		Y					
E2365	U1 sealed leadacid battery		Y					
E2366	Battery charger, single mode		Y					
E2367	Battery charger, dual mode		Y					
E2368	Power wc motor replacement		Y					
E2369	Pwr wc gear box replacement		Y					
E2370	Pwr wc motor/gear box combo		Y					
E2371	Gr27 sealed leadacid battery		Y					
E2372	Gr27 non-sealed leadacid		Y					
E2373	Hand/chin ctrl spec joystick		Y					
E2374	Hand/chin ctrl std joystick		Y					
E2375	Non-expandable controller		Y					
E2376	Expandable controller, repl		Y					
E2377	Expandable controller, initl		Y					
E2381	Pneum drive wheel tire		Y					
E2382	Tube, pneum wheel drive tire		Y					
E2383	Insert, pneum wheel drive		Y					
E2384	Pneumatic caster tire		Y					
E2385	Tube, pneumatic caster tire		Y					
E2386	Foam filled drive wheel tire		Y					
E2387	Foam filled caster tire		Y					
E2388	Foam drive wheel tire		Y					
E2389	Foam caster tire		Y					
E2390	Solid drive wheel tire		Y					
E2391	Solid caster tire		Y					
E2392	Solid caster tire, integrate		Y					
E2393	Valve, pneumatic tire tube		Y					
E2394	Drive wheel excludes tire		Y					
E2395	Caster wheel excludes tire		Y					
E2396	Caster fork		Y					
E2397	Pwc acc, lith-based battery	NI	Y					
E2399	Noc interface		Y					
E2402	Neg press wound therapy pump		Y					
E2500	SGD digitized pre-rec <=8min		Y					
E2502	SGD prerec msg >8min <=20min		Y					
E2504	SGD prerec msg>20min <=40min		Y					
E2506	SGD prerec msg > 40 min		Y					
E2508	SGD spelling phys contact		Y					
E2510	SGD w multi methods msg/accs		Y					
E2511	SGD sftwre prgrm for PC/PDA		Y					
E2512	SGD accessory, mounting sys		Y					
E2599	SGD accessory noc		Y					
E2601	Gen w/c cushion wdth < 22 in		Y					
E2602	Gen w/c cushion wdth >=22 in		Y					
E2603	Skin protect wc cus wd <22in		Y					
E2604	Skin protect wc cus wd>=22in		Y					
E2605	Position wc cush wdth <22 in		Y					
E2606	Position wc cush wdth>=22 in		Y					
E2607	Skin pro/pos wc cus wd <22in		Y					
E2608	Skin pro/pos wc cus wd>=22in		Y					
E2609	Custom fabricate w/c cushion		Y					
E2610	Powered w/c cushion		B					
E2611	Gen use back cush wdth <22in		Y					
E2612	Gen use back cush wdth>=22in		Y					
E2613	Position back cush wd <22in		Y					
E2614	Position back cush wd>=22in		Y					
E2615	Pos back post/lat wdth <22in		Y					
E2616	Pos back post/lat wdth>=22in		Y					
E2617	Custom fab w/c back cushion		Y					
E2618	Wc acc solid seat supp base	CH	D					
E2619	Replace cover w/c seat cush		Y					
E2620	WC planar back cush wd <22in		Y					
E2621	WC planar back cush wd>=22in		Y					
E8000	Posterior gait trainer		E					
E8001	Upright gait trainer		E					
E8002	Anterior gait trainer		E					
G0008	Admin influenza virus vac		S	0350	0.3945	\$25.13		
G0009	Admin pneumococcal vaccine		S	0350	0.3945	\$25.13		
G0010	Admin hepatitis b vaccine		B					
G0027	Semen analysis		A					
G0101	CA screen;pelvic/breast exam		V	0604	0.8388	\$53.43		\$10.69
G0102	Prostate ca screening; dre		N					
G0103	PSA screening		A					
G0104	CA screen;flexi sigmoidscope		S	0159	4.7010	\$299.43		\$74.86

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
G0105	Colorectal scrn; hi risk ind		T	0158	7.8504	\$500.02		\$125.01
G0106	Colon CA screen;barium enema		S	0157	2.0651	\$131.53		\$26.31
G0108	Diab manage trn per indiv		A					
G0109	Diab manage trn ind/group		A					
G0117	Glaucoma scrn high risk direc	CH	S	0698	0.8696	\$55.39		\$11.08
G0118	Glaucoma scrn high risk direc		S	0230	0.5903	\$37.60		\$7.52
G0120	Colon ca scrn; barium enema		S	0157	2.0651	\$131.53		\$26.31
G0121	Colon ca scrn not hi rsk ind		T	0158	7.8504	\$500.02		\$125.01
G0122	Colon ca scrn; barium enema		E					
G0123	Screen cerv/vag thin layer		A					
G0124	Screen c/v thin layer by MD		B					
G0127	Trim nail(s)	CH	T	0013	0.7930	\$50.51		\$10.10
G0128	CORF skilled nursing service		B					
G0129	Partial hosp prog service		P	0033				
G0130	Single energy x-ray study		X	0260	0.6954	\$44.29		\$8.86
G0141	Scr c/v cyto,autosys and md		B					
G0143	Scr c/v cyto,thinlayer,rescr		A					
G0144	Scr c/v cyto,thinlayer,rescr		A					
G0145	Scr c/v cyto,thinlayer,rescr		A					
G0147	Scr c/v cyto, automated sys		A					
G0148	Scr c/v cyto, autosys, rescr		A					
G0151	HHCP-serv of pt,ea 15 min		B					
G0152	HHCP-serv of ot,ea 15 min		B					
G0153	HHCP-svs of s/l path,ea 15mn		B					
G0154	HHCP-svs of m,ea 15 min		B					
G0155	HHCP-svs of csw,ea 15 min		B					
G0156	HHCP-svs of aide,ea 15 min		B					
G0166	Extrnl counterpulse, per tx		T	0678	1.7187	\$109.47		\$21.89
G0168	Wound closure by adhesive		B					
G0173	Linear acc stereo radsur com		S	0067	61.6965	\$3,929.70		\$785.94
G0175	OPPS Service,sched team conf		V	0608	2.1740	\$138.47		\$27.69
G0176	OPPS/PHP;activity therapy		P	0033				
G0177	OPPS/PHP; train & educ serv	CH	N					
G0179	MD recertification HHA PT		M					
G0180	MD certification HHA patient		M					
G0181	Home health care supervision		M					
G0182	Hospice care supervision		M					
G0186	Dstry eye lesn, fdr vssl tech		T	0235	4.1331	\$263.25	\$58.93	\$52.65
G0202	Screeningmammographydigital		A					
G0204	Diagnosticmammographydigital		A					
G0206	Diagnosticmammographydigital		A					
G0219	PET img wholbod melano nonco		E					
G0235	PET not otherwise specified		E					
G0237	Therapeutic procd strg endure	CH	S	0077	0.3877	\$24.69	\$7.74	\$4.94
G0238	Oth resp proc, indiv	CH	S	0077	0.3877	\$24.69	\$7.74	\$4.94
G0239	Oth resp proc, group	CH	S	0077	0.3877	\$24.69	\$7.74	\$4.94
G0245	Initial foot exam pt lops		V	0604	0.8388	\$53.43		\$10.69
G0246	Followup eval of foot pt lop		V	0605	0.9964	\$63.46		\$12.69
G0247	Routine footcare pt w lops	CH	T	0013	0.7930	\$50.51		\$10.10
G0248	Demonstrate use home inr mon	CH	V	0607	1.6604	\$105.76		\$21.15
G0249	Provide test material,equpim	CH	V	0607	1.6604	\$105.76		\$21.15
G0250	MD review interpret of test		M					
G0251	Linear acc based stero radio		S	0065	16.5911	\$1,056.75		\$211.35
G0252	PET imaging initial dx		E					
G0255	Current percep threshold tst		E					
G0257	Unsched dialysis ESRD pt hos		S	0170	6.5383	\$416.45		\$83.29
G0259	Inject for sacroiliac joint		N					
G0260	Inj for sacroiliac jt anesth	CH	T	0207	7.0546	\$449.34		\$89.87
G0265	Cryopresevation Freeze+stora	CH	D					
G0266	Thawing + expansion froz cel	CH	D					
G0267	Bone marrow or psc harvest	CH	D					
G0268	Removal of impacted wax md	CH	N					
G0269	Occlusive device in vein art		N					
G0270	MNT subs tx for change dx		A					
G0271	Group MNT 2 or more 30 mins		A					
G0275	Renal angio, cardiac cath		N					
G0278	Iliac art angio,cardiac cath		N					
G0281	Elec stim unattend for press		A					
G0282	Elect stim wound care not pd		E					
G0283	Elec stim other than wound		A					
G0288	Recon, CTA for surg plan	CH	N					
G0289	Arthro, loose body + chondro		N					
G0290	Drug-eluting stents, single		T	0656	118.4265	\$7,543.06		\$1,508.61
G0291	Drug-eluting stents,each add		T	0656	118.4265	\$7,543.06		\$1,508.61
G0293	Non-cov surg proc,clin trial		X	0340	0.6310	\$40.19		\$8.04
G0294	Non-cov proc, clinical trial		X	0340	0.6310	\$40.19		\$8.04
G0295	Electromagnetic therapy onc		E					
G0297	Insert single chamber/cd	CH	D					
G0298	Insert dual chamber/cd	CH	D					
G0299	Inser/repos single icd+leads	CH	D					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
G0300	Insert reposit lead dual-gen	CH	D					
G0302	Pre-op service LVRS complete	CH	S	0209	11.2822	\$718.61	\$268.73	\$143.72
G0303	Pre-op service LVRS 10–15dos	CH	S	0209	11.2822	\$718.61	\$268.73	\$143.72
G0304	Pre-op service LVRS 1–9 dos	CH	S	0213	2.2980	\$146.37	\$53.58	\$29.27
G0305	Post op service LVRS min 6	CH	S	0213	2.2980	\$146.37	\$53.58	\$29.27
G0306	CBC/diffwbc w/o platelet		A					
G0307	CBC without platelet		A					
G0308	ESRD related svc 4+mo < 2yrs		B					
G0309	ESRD related svc 2–3mo <2yrs		B					
G0310	ESRD related svc 1 vst <2yrs		B					
G0311	ESRD related svcs 4+mo 2–11yr		B					
G0312	ESRD relate svcs 2–3 mo 2–11y		B					
G0313	ESRD related svcs 1 mon 2–11y		B					
G0314	ESRD related svcs 4+ mo 12–19		B					
G0315	ESRD related svcs 2–3mo/12–19		B					
G0316	ESRD related svcs 1vis/12–19y		B					
G0317	ESRD related svcs 4+mo 20+yrs		B					
G0318	ESRD related svcs 2–3 mo 20+y		B					
G0319	ESRD related svcs 1visit 20+y		B					
G0320	ESD related svcs home undr 2		B					
G0321	ESRDrelatedsvcs home mo 2–11y		B					
G0322	ESRD related svcs hom mo12–19		B					
G0323	ESRD related svcs home mo 20+		B					
G0324	ESRD relate svcs home/dy <2yr		B					
G0325	ESRD relate home/day/ 2–11yr		B					
G0326	ESRD relate home/day 12–19yr		B					
G0327	ESRD relate home/day 20+yrs		B					
G0328	Fecal blood scrn immunoassay		A					
G0329	Electromagntic tx for ulcers		A					
G0332	Preadmin IV immunoglobulin	CH	S	0430	0.5921	\$37.71		\$7.54
G0333	Dispense fee initial 30 day		M					
G0337	Hospice evaluation preelecti		B					
G0339	Robot lin-radsurg com, first		S	0067	61.6965	\$3,929.70		\$785.94
G0340	Robt lin-radsurg fractx 2–5		S	0066	45.0693	\$2,870.64		\$574.13
G0341	Percutaneous islet celltrans		C					
G0342	Laparoscopy islet cell trans		C					
G0343	Laparotomy islet cell transp		C					
G0344	Initial preventive exam		V	0605	0.9964	\$63.46		\$12.69
G0364	Bone marrow aspirate & biopsy		T	0002	1.1097	\$70.68		\$14.14
G0365	Vessel mapping hemo access		S	0267	2.3792	\$151.54	\$60.50	\$30.31
G0366	EKG for initial prevent exam		B					
G0367	EKG tracing for initial prev		S	0099	0.3892	\$24.79		\$4.96
G0368	EKG interpret & report preve		M					
G0372	MD service required for PMD		M					
G0375	Smoke/tobacco counselng 3–10	CH	D					
G0376	Smoke/tobacco counseling >10	CH	D					
G0377	Administra Part D vaccine		S	0437	0.3945	\$25.13		\$5.03
G0378	Hospital observation per hr	CH	N					
G0379	Direct admit hospital observ	CH	Q	0604	0.8388	\$53.43		\$10.69
G0380	Lev 1 hosp type B ED visit		V	0604	0.8388	\$53.43		\$10.69
G0381	Lev 2 hosp type B ED visit		V	0605	0.9964	\$63.46		\$12.69
G0382	Lev 3 hosp type B ED visit		V	0606	1.3226	\$84.24		\$16.85
G0383	Lev 4 hosp type B ED visit		V	0607	1.6604	\$105.76		\$21.15
G0384	Lev 5 hosp type B ED visit		V	0608	2.1740	\$138.47		\$27.69
G0389	Ultrasound exam AAA screen		S	0266	1.5094	\$96.14	\$37.80	\$19.23
G0390	Trauma Respons w/hosp criti		S	0618	5.1854	\$330.28	\$132.11	\$66.06
G0392	AV fistula or graft arterial	CH	T	0083	45.3845	\$2,890.72		\$578.14
G0393	AV fistula or graft venous	CH	T	0083	45.3845	\$2,890.72		\$578.14
G0394	Blood occult test,colorectal		A					
G0396	Alcohol/subs interv 15–30mn	NI	S	0432	0.3128	\$19.92		\$3.98
G0397	Alcohol/subs interv >30 min	NI	S	0432	0.3128	\$19.92		\$3.98
G3001	Admin + supply, tositumomab		S	0442	27.4298	\$1,747.11		\$349.42
G8006	AMI pt recd aspirin at arriv		M					
G8007	AMI pt did not receiv aspiri		M					
G8008	AMI pt ineligible for aspiri		M					
G8009	AMI pt recd Bblock at arr		M					
G8010	AMI pt did not rec bblock		M					
G8011	AMI pt inelig Bbloc at arriv		M					
G8012	Pneum pt recv antibiotic 4 h		M					
G8013	Pneum pt w/o antibiotic 4 hr		M					
G8014	Pneum pt not elig antibiotic		M					
G8015	Diabetic pt w/ HBA1c>9%		M					
G8016	Diabetic pt w/ HBA1c<or=9%		M					
G8017	DM pt inelig for HBA1c measu		M					
G8018	Care not provided for Hba1c		M					
G8019	Diabetic pt w/LDL>= 100mg/dl		M					
G8020	Diab pt w/LDL< 100mg/dl		M					
G8021	Diab pt inelig for LDL meas		M					
G8022	Care not provided for LDL		M					
G8023	DM pt w BP>=140/80		M					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
G8024	Diabetic pt wBP<140/80		M					
G8025	Diabetic pt inelig for BP me		M					
G8026	Diabet pt w no care re BP me		M					
G8027	HF p w/LVSD on ACE-I/ARB		M					
G8028	HF pt w/LVSD not on ACE-I/AR		M					
G8029	HF pt not elig for ACE-I/ARB		M					
G8030	HF pt w/LVSD on Bblocker		M					
G8031	HF pt w/LVSD not on Bblocker		M					
G8032	HF pt not elig for Bblocker		M					
G8033	PMI-CAD pt on Bblocker		M					
G8034	PMI-CAD pt not on Bblocker		M					
G8035	PMI-CAD pt inelig Bblocker		M					
G8036	AMI-CAD pt doc on antiplatelet		M					
G8037	AMI-CAD pt not docu on antip		M					
G8038	AMI-CAD inelig antiplate mea		M					
G8039	CAD pt w/LDL>100mg/dl		M					
G8040	CAD pt w/LDL<or=100mg/dl		M					
G8041	CAD pt not eligible for LDL		M					
G8051	Osteoporosis assess		M					
G8052	Osteopor pt not assess		M					
G8053	Pt inelig for osteopor meas		M					
G8054	Falls assess not docum 12 mo		M					
G8055	Falls assess w/ 12 mon		M					
G8056	Not elig for falls assessmen		M					
G8057	Hearing assess receive		M					
G8058	Pt w/o hearing assess		M					
G8059	Pt inelig for hearing assess		M					
G8060	Urinary incont pt assess		M					
G8061	Pt not assess for urinary in		M					
G8062	Pt not elig for urinary inco		M					
G8075	ESRD pt w/ dialy of URR>=65%		M					
G8076	ESRD pt w/ dialy of URR<65%		M					
G8077	ESRD pt not elig for URR/KtV		M					
G8078	ESRD pt w/Hct>or=33		M					
G8079	ESRD pt w/Hct<33		M					
G8080	ESRD pt inelig for HCT/Hgb		M					
G8081	ESRD pt w/ auto AV fistula		M					
G8082	ESRD pt w other fistula		M					
G8085	ESRD PT inelig auto AV FISTU		M					
G8093	COPD pt rec smoking cessat		M					
G8094	COPD pt w/o smoke cessat int		M					
G8099	Osteopo pt given Ca+VitD sup		M					
G8100	Osteop pt inelig for Ca+VitD		M					
G8103	New dx osteo pt w/antiresorp		M					
G8104	Osteo pt inelig for antireso		M					
G8106	Bone dens meas test perf		M					
G8107	Bone dens meas test inelig		M					
G8108	Pt receiv influenza vacc		M					
G8109	Pt w/o influenza vacc		M					
G8110	Pt inelig for influenza vacc		M					
G8111	Pt receiv mammogram		M					
G8112	Pt not doc mammogram		M					
G8113	Pt ineligible mammography		M					
G8114	Care not provided for mamogr		M					
G8115	Pt receiv pneumo vacc		M					
G8116	Pt did not rec pneumo vacc		M					
G8117	Pt was inelig for pneumo vac		M					
G8126	Pt treat w/antidepress12wks		M					
G8127	Pt not treat w/antidpres12w		M					
G8128	Pt inelig for antidepres med		M					
G8129	Pt treat w/antidpres for 6m		M					
G8130	Pt not treat w/antidpres 6m		M					
G8131	Pt inelig for antidepres med		M					
G8152	Pt w/AB 1 hr prior to incisi		M					
G8153	Pt not doc for AB 1 hr prior		M					
G8154	Pt ineligi for AB therapy		M					
G8155	Pt recd thromboemb prophylax		M					
G8156	Pt did not rec thromboembo		M					
G8157	Pt ineligi for thrombolism		M					
G8159	Pt w/CABG w/o IMA		M					
G8162	Iso CABG pt w/o preop Bblock		M					
G8164	Iso CABG pt w/prolong intub		M					
G8165	Iso CABG pt w/o prolong intub		M					
G8166	Iso CABG req surg rexplo		M					
G8167	Iso CABG w/o surg explo		M					
G8170	CEA/ext bypass pt on aspirin		M					
G8171	Pt w/carot endarct/ext bypas		M					
G8172	CEA/ext bypass pt not on asp		M					
G8182	CAD pt care not prov LDL		M					
G8183	HF/atrial fib pt on warfarin		M					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
G8184	HF/atrial fib pt inelig warf		M					
G8185	Osteoarth pt w/ assess pain		M					
G8186	Osteoarth pt inelig assess		M					
G8193	Antibio not doc prior surg		M					
G8196	Antibio not docum prior surg		M					
G8200	Cefazolin not docum prophy		M					
G8204	MD not doc order to d/c anti		M					
G8209	Clinician did not doc		M					
G8214	Clini not doc order VTE		M					
G8217	Pt not received DVT proph		M					
G8219	Received DVT proph day 2		M					
G8220	Pt not rec DVT proph day 2		M					
G8221	Pt inelig for DVT proph		M					
G8223	Pt not doc for presc antipla		M					
G8226	Pt no prescr anticoa at D/C		M					
G8231	Pt not doc for admin t-PA		M					
G8234	Pt not doc dysphagia screen		M					
G8238	Pt not doc to rec rehab serv		M					
G8240	Inter carotid stenosis30-99%		M					
G8243	Pt not doc MRI/CT w/o lesion		M					
G8246	Pt inelig hx w new/chg mole		M					
G8248	Pt w/one alarm symp not doc		M					
G8251	Pt not doc w/Barretts, endo		M					
G8254	Pt w/no doc order for barium		M					
G8257	Pt not doc rev meds D/C		M					
G8260	Pt not doc to have dec maker		M					
G8263	Pt not doc assess urinary in		M					
G8266	Pt not doc charc urin incon		M					
G8268	Pt not doc rec care urin inc		M					
G8271	Pt no doc screen fall		M					
G8274	Clini not doc pres/abs alarm		M					
G8276	Pt not doc mole change		M					
G8279	Pt not doc rec PE		M					
G8282	Pt not doc to rec couns		M					
G8285	Pt did not rec pres osteo		M					
G8289	Pt not doc rec Ca/Vit D		M					
G8293	COPD pt w/o spir results		M					
G8296	COPD pt not doc bronch ther		M					
G8298	Pt doc optic nerve eval		M					
G8299	Pt not doc optic nerv eval		M					
G8302	Pt doc w/ target IOP		M					
G8303	Pt not doc w/ IOP		M					
G8304	Clin doc pt inelig IOP		M					
G8305	Clin not prov care POAG		M					
G8306	POAG w/ IOP rec care plan		M					
G8307	POAG w/ IOP no care plan		M					
G8308	POAG w/ IOP not doc plan		M					
G8310	Pt not doc rec antiox		M					
G8314	Pt not doc to rec mac exam		M					
G8318	Pt doc not have visual func		M					
G8322	Pt not doc pre axial leng		M					
G8326	Pt not doc rec fundus exam		M					
G8330	Pt not doc rec dilated mac		M					
G8334	Doc of macular not giv MD		M					
G8338	Clin not doc pt test osteo		M					
G8341	Pt not doc for DEXA		M					
G8345	Pt not doc have DEXA		M					
G8351	Pt not doc ECG		M					
G8354	Pt not rec aspirin prior ER		M					
G8357	Pt not doc to have ECG		M					
G8360	Pt not doc vital signs recor		M					
G8362	Pt not doc 02 SAT assess		M					
G8365	Pt not doc mental status		M					
G8367	Pt not doc have empiric AB		M					
G8370	Asthma pt w survey not docum		M					
G8371	Chemother not rec stg3 colon		M					
G8372	Chemother rec stg 3 colon ca		M					
G8373	Chemo plan docum prior chemo		M					
G8374	Chemo plan not doc prior che		M					
G8375	CLL pt w/o doc flow cytometr		M					
G8376	Brst ca pt inelig tamoxifen		M					
G8377	MD doc colon ca pt inelig ch		M					
G8378	MD doc pt inelig rad therapy		M					
G8379	Radiat tx recom doc12mo ov		M					
G8380	Pt w stgIC-3Brst ca w/o tam		M					
G8381	Pt w stgIC-3Brst ca rec tam		M					
G8382	MM pt w/o doc IV bisphophon		M					
G8383	Radiation rec not doc 12 mo		M					
G8384	MDS pt w/o base cytogen test		M					
G8385	Diab pt w nodoc Hgb A1c 12m		M					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
G8386	Diab pt w nodoc LDL 12m		M					
G8387	ESRD pt w Hct/Hgb not docume		M					
G8388	ESRD pt w URR/Ktv not doc el		M					
G8389	MDS pt no doc Fe prior EPO		M					
G8390	Diabetic w/o document BP 12m		M					
G8391	Pt w asthma no doc med or tx		M					
G8395	LVEF>=40% doc normal or mild	NI	M					
G8396	LVEF not performed	NI	M					
G8397	Dil macula/fundus exam/w doc	NI	M					
G8398	Dil macular/fundus not perfo	NI	M					
G8399	Pt w/DXA document or order	NI	M					
G8400	Pt w/DXA no document or orde	NI	M					
G8401	Pt inelig osteo screen measu	NI	M					
G8402	Smoke preven interven counse	NI	M					
G8403	Smoke preven nocounsel	NI	M					
G8404	Low extemity neur exam docum	NI	M					
G8405	Low extemity neur not perfor	NI	M					
G8406	Pt inelig lower extrem neuro	NI	M					
G8407	ABI documented	NI	M					
G8408	ABI not documented	NI	M					
G8409	Pt inelig for ABI measure	NI	M					
G8410	Eval on foot documented	NI	M					
G8415	Eval on foot not performed	NI	M					
G8416	Pt inelig footwear evaluatio	NI	M					
G8417	BMI >=30 calculate w/followup	NI	M					
G8418	BMI < 22 calculate w/followup	NI	M					
G8419	BMI>=30or<22 cal no followup	NI	M					
G8420	BMI<30 and >=22 calc & docu	NI	M					
G8421	BMI not calculated	NI	M					
G8422	Pt inelig BMI calculation	NI	M					
G8423	Pt screen flu vac & counsel	NI	M					
G8424	Flu vaccine not screen	NI	M					
G8425	Flu vaccine screen not curre	NI	M					
G8426	Pt not approp screen & couns	NI	M					
G8427	Doc meds verified w/pt or re	NI	M					
G8428	Meds document w/o verifica	NI	M					
G8429	Incomplete doc pt on meds	NI	M					
G8430	Pt inelig med check	NI	M					
G8431	Clin depression screen doc	NI	M					
G8432	Clin depression screen not d	NI	M					
G8433	Pt inelig for depression scr	NI	M					
G8434	Cognitive impairment screen	NI	M					
G8435	Cognitive screen not documen	NI	M					
G8436	Pt inelig for cognitive impa	NI	M					
G8437	Tx plan develop & document	NI	M					
G8438	Tx plan develop & not docum	NI	M					
G8439	Pt inelig for co-develp tx p	NI	M					
G8440	Pain assessment document	NI	M					
G8441	No document of pain assess	NI	M					
G8442	Pt inelig pain assessment	NI	M					
G8443	Prescription by E-Prescrib s	NI	M					
G8445	Prescrip not gen at encounte	NI	M					
G8446	Some prescrib handwritten or	NI	M					
G8447	Pt visit doc using CCHIT cer	NI	M					
G8448	Pt visit docum w/non-CCHIT c	NI	M					
G8449	Pt not doc w/EMR due to syst	NI	M					
G8450	Beta-bloc rx pt w/abn lvef	NI	M					
G8451	Pt w/abn lvef inelig b-bloc	NI	M					
G8452	Pt w/abn lvef b-bloc no rx	NI	M					
G8453	Tob use cess int counsel	NI	M					
G8454	Tob use cess int no counsel	NI	M					
G8455	Current tobacco smoker	NI	M					
G8456	Smokeless tobacco user	NI	M					
G8457	Tobacco non-user	NI	M					
G8458	Pt inelig geno no antivir tx	NI	M					
G8459	Doc pt rec antivir treat	NI	M					
G8460	Pt inelig RNA no antivir tx	NI	M					
G8461	Pt rec antivir treat hep c	NI	M					
G8462	Pt inelig couns no antivir tx	NI	M					
G8463	Pt rec antiviral treat doc	NI	M					
G8464	Pt inelig; lo to no dter rsk	NI	M					
G8465	High risk recurrence pro ca	NI	M					
G8466	Pt inelig suic; MDD remis	NI	M					
G8467	New dx init/rec episode MDD	NI	M					
G8468	ACE/ARB rx pt w/abn lvef	NI	M					
G8469	Pt w/abn lvef inelig ACE/ARB	NI	M					
G8470	Pt w/ normal lvef	NI	M					
G8471	LVEF not performed/doc	NI	M					
G8472	ACE/ARB no rx pt w/abn lvef	NI	M					
G8473	ACE/ARB thxpy rx'd	NI	M					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
G8474	ACE/ARB not rx'd; doc reas	NI	M					
G8475	ACE/ARB thxpy not rx'd	NI	M					
G8476	BP sys <130 and dias <80	NI	M					
G8477	BP sys>=130 and/or dias >=80	NI	M					
G8478	BP not performed/doc	NI	M					
G8479	MD rx'd ACE/ARB thxpy	NI	M					
G8480	Pt inelig ACE/ARB thxpy	NI	M					
G8481	MD not rx'd ACE/ARB thxpy	NI	M					
G8482	Flu immunize order/admin	NI	M					
G8483	Flu imm no ord/admin doc rea	NI	M					
G8484	Flu immunize no order/admin	NI	M					
G9001	MCCD, initial rate		B					
G9002	MCCD,maintenance rate		B					
G9003	MCCD, risk adj hi, initial		B					
G9004	MCCD, risk adj lo, initial		B					
G9005	MCCD, risk adj, maintenance		B					
G9006	MCCD, Home monitoring		B					
G9007	MCCD, sch team conf		B					
G9008	Mccd,phys coor-care ovrsght		B					
G9009	MCCD, risk adj, level 3		B					
G9010	MCCD, risk adj, level 4		B					
G9011	MCCD, risk adj, level 5		B					
G9012	Other Specified Case Mgmt		B					
G9013	ESRD demo bundle level I		E					
G9014	ESRD demo bundle-level II		E					
G9016	Demo-smoking cessation coun		E					
G9017	Amantadine HCL 100mg oral		A					
G9018	Zanamivir,inhalation pwd 10m		A					
G9019	Oseltamivir phosphate 75mg		A					
G9020	Rimantadine HCL 100mg oral		A					
G9033	Amantadine HCL oral brand		A					
G9034	Zanamivir, inh pwdr, brand		A					
G9035	Oseltamivir phosp, brand		A					
G9036	Rimantadine HCL, brand		A					
G9041	Low vision rehab occupationa		A					
G9042	Low vision rehab orient/mobi		A					
G9043	Low vision lowvision therapi		A					
G9044	Low vision rehabilitate teache		A					
G9050	Oncology work-up evaluation		E					
G9051	Oncology tx decision-mgmt		E					
G9052	Onc surveillance for disease		E					
G9053	Onc expectant management pt		E					
G9054	Onc supervision palliative		E					
G9055	Onc visit unspecified NOS		E					
G9056	Onc prac mgmt adheres guide		E					
G9057	Onc pract mgmt differs trial		E					
G9058	Onc prac mgmt disagree w/gui		E					
G9059	Onc prac mgmt pt opt alterna		E					
G9060	Onc prac mgmt dif pt comorb		E					
G9061	Onc prac cond noadd by guide		E					
G9062	Onc prac guide differs nos		E					
G9063	Onc dx nsclc stg1 no progres		M					
G9064	Onc dx nsclc stg2 no progres		M					
G9065	Onc dx nsclc stg3A no progre		M					
G9066	Onc dx nsclc stg3B-4 metasta		M					
G9067	Onc dx nsclc dx unknown nos		M					
G9068	Onc dx sclc/nsclc limited		M					
G9069	Onc dx sclc/nsclc ext at dx		M					
G9070	Onc dx sclc/nsclc ext unknwn		M					
G9071	Onc dx brst stg1-2B HR,nopro		M					
G9072	Onc dx brst stg1-2 noprogres		M					
G9073	Onc dx brst stg3-HR, no pro		M					
G9074	Onc dx brst stg3-noprogress		M					
G9075	Onc dx brst metastatic/ recur		M					
G9077	Onc dx prostate T1no progres		M					
G9078	Onc dx prostate T2no progres		M					
G9079	Onc dx prostate T3b-T4nopro		M					
G9080	Onc dx prostate w/rise PSA		M					
G9083	Onc dx prostate unknwn nos		M					
G9084	Onc dx colon t1-3,n1-2,no pr		M					
G9085	Onc dx colon T4, N0 w/o prog		M					
G9086	Onc dx colon T1-4 no dx prog		M					
G9087	Onc dx colon metas evid dx		M					
G9088	Onc dx colon metas noevid dx		M					
G9089	Onc dx colon extent unknown		M					
G9090	Onc dx rectal T1-2 no progr		M					
G9091	Onc dx rectal T3 N0 no prog		M					
G9092	Onc dx rectal T1-3,N1-2nopr		M					
G9093	Onc dx rectal T4,N,M0 no pr		M					
G9094	Onc dx rectal M1 w/mets prog		M					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
G9095	Onc dx rectal extent unknwn		M					
G9096	Onc dx esophag T1-T3 noprog		M					
G9097	Onc dx esophageal T4 no prog		M					
G9098	Onc dx esophageal mets recur		M					
G9099	Onc dx esophageal unknown		M					
G9100	Onc dx gastric no recurrence		M					
G9101	Onc dx gastric p R1-R2noprog		M					
G9102	Onc dx gastric unresectable		M					
G9103	Onc dx gastric recurrent		M					
G9104	Onc dx gastric unknown NOS		M					
G9105	Onc dx pancreatic p R0 res no		M					
G9106	Onc dx pancreatic p R1/R2 no		M					
G9107	Onc dx pancreatic unresectab		M					
G9108	Onc dx pancreatic unknwn NOS		M					
G9109	Onc dx head/neck T1-T2no prg		M					
G9110	Onc dx head/neck T3-4 noprog		M					
G9111	Onc dx head/neck M1 mets rec		M					
G9112	Onc dx head/neck ext unknown		M					
G9113	Onc dx ovarian stg1A-B no pr		M					
G9114	Onc dx ovarian stg1A-B or 2		M					
G9115	Onc dx ovarian stg3/4 noprog		M					
G9116	Onc dx ovarian recurrence		M					
G9117	Onc dx ovarian unknown NOS		M					
G9123	Onc dx CML chronic phase		M					
G9124	Onc dx CML acceler phase		M					
G9125	Onc dx CML blast phase		M					
G9126	Onc dx CML remission		M					
G9128	Onc dx multi myeloma stage I		M					
G9129	Onc dx mult myeloma stg2 hig		M					
G9130	Onc dx multi myeloma unknown		M					
G9131	Onc dx brst unknown NOS		M					
G9132	Onc dx prostate mets no cast		M					
G9133	Onc dx prostate clinical met		M					
G9134	Onc NHLstg 1-2 no relap no		M					
G9135	Onc dx NHL stg 3-4 not relap		M					
G9136	Onc dx NHL trans to lg Bcell		M					
G9137	Onc dx NHL relapse/refractor		M					
G9138	Onc dx NHL stg unknown		M					
G9139	Onc dx CML dx status unknown		M					
G9140	Frontier extended stay demo	NI	M					
J0120	Tetracyclin injection		N					
J0128	Abarelix injection		K	9216		\$67.97		\$13.59
J0129	Abatacept injection		G	9230		\$18.69		\$3.74
J0130	Abciximab injection		K	1605		\$420.17		\$84.03
J0132	Acetylcysteine injection	CH	N					
J0133	Acyclovir injection		N					
J0135	Adalimumab injection		K	1083		\$329.58		\$65.92
J0150	Injection adenosine 6 MG		K	0379		\$25.10		\$5.02
J0152	Adenosine injection		K	0917		\$67.89		\$13.58
J0170	Adrenalin epinephrin inject		N					
J0180	Agalsidase beta injection		K	9208		\$126.00		\$25.20
J0190	Inj biperiden lactate/5 mg	CH	K	0998		\$88.15		\$17.63
J0200	Alatofloxacin mesylate		N					
J0205	Alglucerase injection		K	0900		\$38.85		\$7.77
J0207	Amifostine		K	7000		\$490.93		\$98.19
J0210	Methyldopate hcl injection		K	2210		\$13.04		\$2.61
J0215	Alefacept		K	1633		\$26.47		\$5.29
J0220	Aglycosidase alfa injection	NI	K	9234		\$126.00		\$25.20
J0256	Alpha 1 proteinase inhibitor		K	0901		\$3.28		\$0.66
J0270	Alprostadil for injection		B					
J0275	Alprostadil urethral suppos		B					
J0278	Amikacin sulfate injection		N					
J0280	Aminophyllin 250 MG inj		N					
J0282	Amiodarone HCl		N					
J0285	Amphotericin B		N					
J0287	Amphotericin b lipid complex		K	9024		\$10.40		\$2.08
J0288	Ampho b cholesteryl sulfate		K	0735		\$11.89		\$2.38
J0289	Amphotericin b liposome inj		K	0736		\$16.21		\$3.24
J0290	Ampicillin 500 MG inj		N					
J0295	Ampicillin sodium per 1.5 gm		N					
J0300	Amobarbital 125 MG inj		N					
J0330	Succinylcholine chloride inj		N					
J0348	Anadulafungin injection		G	0760		\$1.91		\$0.38
J0350	Injection anistreplase 30 u		K	1606		\$2,693.80		\$538.76
J0360	Hydralazine hcl injection		N					
J0364	Apomorphine hydrochloride	CH	N					
J0365	Aprotonin, 10,000 kiu		K	1682		\$2.66		\$0.53
J0380	Inj metaraminol bitartrate	CH	N					
J0390	Chloroquine injection		N					
J0395	Arbutamine HCl injection	CH	N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
J0400	Aripiprazole injection	NI	K	1165		\$0.28		\$0.06
J0456	Azithromycin		N					
J0460	Atropine sulfate injection		N					
J0470	Dimecaprol injection		N					
J0475	Baclofen 10 MG injection		K	9032		\$193.29		\$38.66
J0476	Baclofen intrathecal trial		K	1631		\$69.73		\$13.95
J0480	Basiliximab		K	1683		\$1,541.03		\$308.21
J0500	Dicyclomine injection		N					
J0515	Inj benzotropine mesylate		N					
J0520	Bethanechol chloride inject		N					
J0530	Penicillin g benzathine inj		N					
J0540	Penicillin g benzathine inj		N					
J0550	Penicillin g benzathine inj		N					
J0560	Penicillin g benzathine inj		N					
J0570	Penicillin g benzathine inj		N					
J0580	Penicillin g benzathine inj		N					
J0583	Bivalirudin		K	3041		\$1.84		\$0.37
J0585	Botulinum toxin a per unit		K	0902		\$5.21		\$1.04
J0587	Botulinum toxin type B		K	9018		\$8.63		\$1.73
J0592	Buprenorphine hydrochloride		N					
J0594	Busulfan injection		K	1178		\$9.17		\$1.83
J0595	Butorphanol tartrate 1 mg		N					
J0600	Edetate calcium disodium inj	CH	K	0999		\$49.64		\$9.93
J0610	Calcium gluconate injection		N					
J0620	Calcium glycer & lact/10 ML		N					
J0630	Calcitonin salmon injection		N					
J0636	Inj calcitriol per 0.1 mcg		N					
J0637	Caspofungin acetate		K	9019		\$24.05		\$4.81
J0640	Leucovorin calcium injection		N					
J0670	Inj mepivacaine HCL/10 ml		N					
J0690	Cefazolin sodium injection		N					
J0692	Cefepime HCl for injection		N					
J0694	Cefoxitin sodium injection		N					
J0696	Ceftriaxone sodium injection		N					
J0697	Sterile cefuroxime injection		N					
J0698	Cefotaxime sodium injection		N					
J0702	Betamethasone acet&sod phosph		N					
J0704	Betamethasone sod phosph/4 MG		N					
J0706	Caffeine citrate injection	CH	N					
J0710	Cephapirin sodium injection		N					
J0713	Inj ceftazidime per 500 mg		N					
J0715	Ceftizoxime sodium / 500 MG		N					
J0720	Chloramphenicol sodium injec		N					
J0725	Chorionic gonadotropin/1000u		N					
J0735	Clonidine hydrochloride		K	0935		\$62.78		\$12.56
J0740	Cidofovir injection		K	9033		\$754.39		\$150.88
J0743	Cilastatin sodium injection		N					
J0744	Ciprofloxacin iv		N					
J0745	Inj codeine phosphate /30 MG		N					
J0760	Colchicine injection		N					
J0770	Colistimethate sodium inj		N					
J0780	Prochlorperazine injection		N					
J0795	Corticotropin ovine triflural		K	1684		\$4.43		\$0.89
J0800	Corticotropin injection		K	1280		\$169.77		\$33.95
J0835	Inj cosyntropin per 0.25 MG		K	0835		\$64.01		\$12.80
J0850	Cytomegalovirus imm IV /vial		K	0903		\$870.53		\$174.11
J0878	Daptomycin injection		K	9124		\$0.35		\$0.07
J0881	Darbepoetin alfa, non-esrd		K	1685		\$2.88		\$0.58
J0882	Darbepoetin alfa, esrd use		A					
J0885	Epoetin alfa, non-esrd		K	1686		\$8.97		\$1.79
J0886	Epoetin alfa 1000 units ESRD		A					
J0894	Decitabine injection		G	9231		\$26.48		\$5.30
J0895	Deferoxamine mesylate inj	CH	N					
J0900	Testosterone enanthate inj		N					
J0945	Brompheniramine maleate inj		N					
J0970	Estradiol valerate injection		N					
J1000	Depo-estradiol cypionate inj		N					
J1020	Methylprednisolone 20 MG inj		N					
J1030	Methylprednisolone 40 MG inj		N					
J1040	Methylprednisolone 80 MG inj		N					
J1051	Medroxyprogesterone inj		N					
J1055	Medroxyprogester acetate inj		E					
J1056	MA/EC contraceptive injection		E					
J1060	Testosterone cypionate 1 ML		N					
J1070	Testosterone cypionat 100 MG		N					
J1080	Testosterone cypionat 200 MG		N					
J1094	Inj dexamethasone acetate		N					
J1100	Dexamethasone sodium phos		N					
J1110	Inj dihydroergotamine mesylt		N					
J1120	Acetazolamid sodium injectio		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
J1160	Digoxin injection		N					
J1162	Digoxin immune fab (ovine)		K	1687		\$478.88		\$95.78
J1165	Phenytoin sodium injection		N					
J1170	Hydromorphone injection		N					
J1180	Dyphylline injection		N					
J1190	Dexrazoxane HCl injection		K	0726		\$162.11		\$32.42
J1200	Diphenhydramine hcl injectio		N					
J1205	Chlorothiazide sodium inj		K	0747		\$141.07		\$28.21
J1212	Dimethyl sulfoxide 50% 50 ML		N					
J1230	Methadone injection		N					
J1240	Dimenhydrinate injection		N					
J1245	Dipyridamole injection		N					
J1250	Inj dobutamine HCL/250 mg		N					
J1260	Dolasetron mesylate		K	0750		\$4.66		\$0.93
J1265	Dopamine injection		N					
J1270	Injection, doxercalciferol		N					
J1300	Eculizumab injection	NI	G	9236		\$176.38		\$35.28
J1320	Amitriptyline injection		N					
J1324	Enfuvirtide injection		K	0767		\$0.40		\$0.08
J1325	Epoprostenol injection		N					
J1327	Eptifibatide injection		K	1607		\$17.67		\$3.53
J1330	Ergonovine maleate injection	CH	N					
J1335	Ertapenem injection		N					
J1364	Erythro lactobionate /500 MG		N					
J1380	Estradiol valerate 10 MG inj		N					
J1390	Estradiol valerate 20 MG inj		N					
J1410	Inj estrogen conjugate 25 MG		K	9038		\$66.64		\$13.33
J1430	Ethanolamine oleate 100 mg		K	1688		\$79.23		\$15.85
J1435	Injection estrone per 1 MG		N					
J1436	Etidronate disodium inj		K	1436		\$70.73		\$14.15
J1438	Etanercept injection		K	1608		\$167.12		\$33.42
J1440	Filgrastim 300 mcg injection		K	0728		\$193.79		\$38.76
J1441	Filgrastim 480 mcg injection		K	7049		\$298.39		\$59.68
J1450	Fluconazole		N					
J1451	Fomepizole, 15 mg		K	1689		\$12.80		\$2.56
J1452	Intraocular Fomivirsen na	CH	N					
J1455	Foscarnet sodium injection	CH	N					
J1457	Gallium nitrate injection	CH	K	0878		\$1.61		\$0.32
J1458	Galsulfase injection		K	9224		\$306.88		\$61.38
J1460	Gamma globulin 1 CC inj		K	3043		\$11.91		\$2.38
J1470	Gamma globulin 2 CC inj	CH	K	0898		\$23.82		\$4.76
J1480	Gamma globulin 3 CC inj	CH	K	0899		\$35.72		\$7.14
J1490	Gamma globulin 4 CC inj	CH	K	0904		\$47.64		\$9.53
J1500	Gamma globulin 5 CC inj	CH	K	0919		\$59.54		\$11.91
J1510	Gamma globulin 6 CC inj	CH	K	0920		\$71.50		\$14.30
J1520	Gamma globulin 7 CC inj	CH	K	0921		\$83.30		\$16.66
J1530	Gamma globulin 8 CC inj	CH	K	0922		\$95.27		\$19.05
J1540	Gamma globulin 9 CC inj	CH	K	0923		\$107.25		\$21.45
J1550	Gamma globulin 10 CC inj	CH	K	0924		\$119.09		\$23.82
J1560	Gamma globulin > 10 CC inj	CH	K	0933		\$119.09		\$23.82
J1561	Gamunex injection	NI	K	0948		\$32.06		\$6.41
J1562	Vivaglobin, inj		K	0804		\$7.01		\$1.40
J1565	RSV-ivig		K	0906		\$16.02		\$3.20
J1566	Immune globulin, powder		K	2731		\$26.89		\$5.38
J1567	Immune globulin, liquid	CH	D					
J1568	Octagam injection	NI	K	0943		\$33.19		\$6.64
J1569	Gammagard liquid injection	NI	K	0944		\$31.06		\$6.21
J1570	Ganciclovir sodium injection		N					
J1571	HepaGam B IM injection	NI	K	0946		\$63.51		\$12.70
J1572	Flebogamma injection	NI	K	0947		\$32.27		\$6.45
J1573	Hepagam B intravenous, inj	NI	K	1138		\$63.51		\$12.70
J1580	Garamycin gentamicin inj		N					
J1590	Gatifloxacin injection		N					
J1595	Injection glatiramer acetate	CH	K	1015		\$52.04		\$10.41
J1600	Gold sodium thiomaleate inj		N					
J1610	Glucagon hydrochloride/1 MG		K	9042		\$68.84		\$13.77
J1620	Gonadorelin hydroch/ 100 mcg		K	7005		\$178.59		\$35.72
J1626	Granisetron HCl injection		K	0764		\$5.74		\$1.15
J1630	Haloperidol injection		N					
J1631	Haloperidol decanoate inj		N					
J1640	Hemin, 1 mg		K	1690		\$7.08		\$1.42
J1642	Inj heparin sodium per 10 u		N					
J1644	Inj heparin sodium per 1000u		N					
J1645	Dalteparin sodium		N					
J1650	Inj enoxaparin sodium		N					
J1652	Fondaparinux sodium	CH	K	0883		\$5.92		\$1.18
J1655	Tinzaparin sodium injection	CH	N					
J1670	Tetanus immune globulin inj		K	1670		\$103.46		\$20.69
J1675	Histrelin acetate		B					
J1700	Hydrocortisone acetate inj		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
J1710	Hydrocortisone sodium ph inj		N					
J1720	Hydrocortisone sodium succ i		N					
J1730	Diazoxide injection		K	1740		\$113.24		\$22.65
J1740	Ibandronate sodium injection		G	9229		\$138.96		\$27.79
J1742	Ibutilide fumarate injection		K	9044		\$287.15		\$57.43
J1743	Idursulfase injection	NI	G	9232		\$455.03		\$91.01
J1745	Infliximab injection		K	7043		\$54.42		\$10.88
J1751	Iron dextran 165 injection		K	1691		\$11.82		\$2.36
J1752	Iron dextran 267 injection		K	1692		\$10.30		\$2.06
J1756	Iron sucrose injection		K	9046		\$0.36		\$0.08
J1785	Injection imiglucerase /unit		K	0916		\$3.89		\$0.78
J1790	Droperidol injection		N					
J1800	Propranolol injection		N					
J1810	Droperidol/fentanyl inj		E					
J1815	Insulin injection		N					
J1817	Insulin for insulin pump use		N					
J1825	Interferon beta-1a		E					
J1830	Interferon beta-1b / .25 MG		K	0910		\$106.57		\$21.31
J1835	Itraconazole injection		K	9047		\$39.68		\$7.94
J1840	Kanamycin sulfate 500 MG inj		N					
J1850	Kanamycin sulfate 75 MG inj		N					
J1885	Ketorolac tromethamine inj		N					
J1890	Cephalothin sodium injection		N					
J1931	Laronidase injection		K	9209		\$23.64		\$4.73
J1940	Furosemide injection		N					
J1945	Lepirudin		K	1693		\$159.44		\$31.89
J1950	Leuprolide acetate /3.75 MG		K	0800		\$452.58		\$90.52
J1955	Inj levocarnitine per 1 gm		B					
J1956	Levofloxacin injection		N					
J1960	Levorphanol tartrate inj		N					
J1980	Hyoscyamine sulfate inj		N					
J1990	Chlordiazepoxide injection		N					
J2001	Lidocaine injection		N					
J2010	Lincomycin injection		N					
J2020	Linezolid injection		K	9001		\$25.17		\$5.03
J2060	Lorazepam injection		N					
J2150	Mannitol injection		N					
J2170	Mecasermin injection		K	0805		\$15.62		\$3.12
J2175	Meperidine hydrochl /100 MG		N					
J2180	Meperidine/promethazine inj		N					
J2185	Meropenem	CH	N					
J2210	Methylergonovin maleate inj		N					
J2248	Micafungin sodium injection		G	9227		\$1.44		\$0.29
J2250	Inj midazolam hydrochloride		N					
J2260	Inj milrinone lactate / 5 MG		N					
J2270	Morphine sulfate injection		N					
J2271	Morphine so4 injection 100mg		N					
J2275	Morphine sulfate injection		N					
J2278	Ziconotide injection	CH	K	1694		\$6.46		\$1.29
J2280	Inj, moxifloxacin 100 mg		N					
J2300	Inj nalbuphine hydrochloride		N					
J2310	Inj naloxone hydrochloride		N					
J2315	Naltrexone, depot form		K	0759		\$1.87		\$0.37
J2320	Nandrolone decanoate 50 MG		N					
J2321	Nandrolone decanoate 100 MG		N					
J2322	Nandrolone decanoate 200 MG		N					
J2323	Natalizumab injection	NI	G	9126		\$7.51		\$1.50
J2325	Nesiritide injection		K	1695		\$32.95		\$6.59
J2353	Octreotide injection, depot		K	1207		\$99.04		\$19.81
J2354	Octreotide inj, non-depot		N					
J2355	Oprelvekin injection		K	7011		\$247.02		\$49.40
J2357	Omalizumab injection		K	9300		\$17.12		\$3.42
J2360	Orphenadrine injection		N					
J2370	Phenylephrine hcl injection		N					
J2400	Chlorprocaine hcl injection		N					
J2405	Ondansetron hcl injection		K	0768		\$0.26		\$0.06
J2410	Oxymorphone hcl injection		N					
J2425	Palifermin injection		K	1696		\$11.24		\$2.25
J2430	Pamidronate disodium /30 MG		K	0730		\$28.31		\$5.66
J2440	Papaverin hcl injection		N					
J2460	Oxytetracycline injection		N					
J2469	Palonosetron HCl		K	9210		\$16.45		\$3.29
J2501	Paricalcitol		N					
J2503	Pegaptanib sodium injection	CH	K	1697		\$1,035.69		\$207.14
J2504	Pegademase bovine, 25 iu		K	1739		\$197.51		\$39.50
J2505	Injection, pegfilgrastim 6mg		K	9119		\$2,145.12		\$429.02
J2510	Penicillin g procaine inj		N					
J2513	Pentastarch 10% solution	CH	K	0880		\$21.98		\$4.40
J2515	Pentobarbital sodium inj		N					
J2540	Penicillin g potassium inj		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
J2543	Piperacillin/tazobactam		N					
J2545	Pentamidine non-comp unit		B					
J2550	Promethazine hcl injection		N					
J2560	Phenobarbital sodium inj		N					
J2590	Oxytocin injection		N					
J2597	Inj desmopressin acetate		N					
J2650	Prednisolone acetate inj		N					
J2670	Totazoline hcl injection		N					
J2675	Inj progesterone per 50 MG		N					
J2680	Fluphenazine decanoate 25 MG		N					
J2690	Procainamide hcl injection		N					
J2700	Oxacillin sodium injecton		N					
J2710	Neostigmine methylsifte inj		N					
J2720	Inj protamine sulfate/10 MG		N					
J2724	Protein C concentrate	NI	K	1139		\$12.08		\$2.42
J2725	Inj protirelin per 250 mcg		N					
J2730	Pralidoxime chloride inj	CH	K	1023		\$35.20		\$7.04
J2760	Phentolaine mesylate inj		N					
J2765	Metoclopramide hcl injection		N					
J2770	Quinupristin/dalfopristin		K	2770		\$126.44		\$25.29
J2778	Ranibizumab injection	NI	G	9233		\$2,030.23		\$406.05
J2780	Ranitidine hydrochloride inj		N					
J2783	Rasburicase		K	0738		\$144.43		\$28.89
J2788	Rho d immune globulin 50 mcg		K	9023		\$26.41		\$5.28
J2790	Rho d immune globulin inj		K	0884		\$80.79		\$16.16
J2791	Rhophylac injection	NI	K	0945		\$5.29		\$1.06
J2792	Rho(D) immune globulin h, sd		K	1609		\$15.62		\$3.12
J2794	Risperidone, long acting		K	9125		\$4.86		\$0.97
J2795	Ropivacaine HCl injection		N					
J2800	Methocarbamol injection		N					
J2805	Sinacalide injection		N					
J2810	Inj theophylline per 40 MG		N					
J2820	Sargramostim injection		K	0731		\$24.86		\$4.97
J2850	Inj secretin synthetic human		K	1700		\$20.12		\$4.02
J2910	Aurothioglucose injecton		N					
J2916	Na ferric gluconate complex		N					
J2920	Methylprednisolone injection		N					
J2930	Methylprednisolone injection		N					
J2940	Somatrem injection		K	2940		\$168.90		\$33.78
J2941	Somatropin injection		K	7034		\$48.52		\$9.70
J2950	Promazine hcl injection		N					
J2993	Retepase injection		K	9005		\$841.28		\$168.26
J2995	Inj streptokinase /250000 IU		K	0911		\$129.75		\$25.95
J2997	Alteplase recombinant		K	7048		\$33.39		\$6.68
J3000	Streptomycin injection		N					
J3010	Fentanyl citrate injecton		N					
J3030	Sumatriptan succinate / 6 MG		K	3030		\$61.27		\$12.25
J3070	Pentazocine injection		N					
J3100	Tenecteplase injection		K	9002		\$2,034.65		\$406.93
J3105	Terbutaline sulfate inj		N					
J3110	Teriparatide injection		B					
J3120	Testosterone enanthate inj		N					
J3130	Testosterone enanthate inj		N					
J3140	Testosterone suspension inj		N					
J3150	Testosteron propionate inj		N					
J3230	Chlorpromazine hcl injection		N					
J3240	Thyrotropin injection		K	9108		\$834.18		\$166.84
J3243	Tigecycline injection		G	9228		\$0.96		\$0.19
J3246	Tirofiban HCl		K	7041		\$7.56		\$1.51
J3250	Trimethobenzamide hcl inj		N					
J3260	Tobramycin sulfate injection		N					
J3265	Injection torsemide 10 mg/ml		N					
J3280	Thiethylperazine maleate inj		N					
J3285	Treprostinil injection		K	1701		\$55.36		\$11.07
J3301	Triamcinolone acetonide inj		N					
J3302	Triamcinolone diacetate inj		N					
J3303	Triamcinolone hexacetonol inj		N					
J3305	Inj trimetrexate glucuronate		K	7045		\$148.30		\$29.66
J3310	Perphenazine injecton		N					
J3315	Triptorelin pamoate		K	9122		\$159.38		\$31.88
J3320	Spectinomycin di-hcl inj	CH	N					
J3350	Urea injection		K	9051		\$74.16		\$14.83
J3355	Urofollitropin, 75 iu		K	1741		\$50.22		\$10.04
J3360	Diazepam injection		N					
J3364	Urokinase 5000 IU injection		N					
J3365	Urokinase 250,000 IU inj		K	7036		\$453.41		\$90.68
J3370	Vancomycin hcl injection		N					
J3396	Verteporfin injection		K	1203		\$8.99		\$1.80
J3400	Triflupromazine hcl inj		N					
J3410	Hydroxyzine hcl injection		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
J3411	Thiamine hcl 100 mg		N					
J3415	Pyridoxine hcl 100 mg		N					
J3420	Vitamin b12 injection		N					
J3430	Vitamin k phytonadione inj		N					
J3465	Injection, voriconazole		K	1052		\$4.93		\$0.99
J3470	Hyaluronidase injection		N					
J3471	Ovine, up to 999 USP units		N					
J3472	Ovine, 1000 USP units		K	1703		\$133.77		\$26.75
J3473	Hyaluronidase recombinant		G	0806		\$0.40		\$0.08
J3475	Inj magnesium sulfate		N					
J3480	Inj potassium chloride		N					
J3485	Zidovudine		N					
J3486	Ziprasidone mesylate		N					
J3487	Zoledronic acid		K	9115		\$205.76		\$41.15
J3488	Reclast injection	NI	G	0951		\$220.81		\$44.16
J3490	Drugs unclassified injection		N					
J3520	Edetate disodium per 150 mg		E					
J3530	Nasal vaccine inhalation		N					
J3535	Metered dose inhaler drug		E					
J3570	Laetrile amygdalin vit B17		E					
J3590	Unclassified biologics		N					
J7030	Normal saline solution infus		N					
J7040	Normal saline solution infus		N					
J7042	5% dextrose/normal saline		N					
J7050	Normal saline solution infus		N					
J7060	5% dextrose/water		N					
J7070	D5w infusion		N					
J7100	Dextran 40 infusion		N					
J7110	Dextran 75 infusion		N					
J7120	Ringers lactate infusion		N					
J7130	Hypertonic saline solution		N					
J7187	Humate-P, inj		K	1704		\$0.88		\$0.18
J7189	Factor viia		K	1705		\$1.15		\$0.23
J7190	Factor viii		K	0925		\$0.75		\$0.15
J7191	Factor VIII (porcine)	CH	N					
J7192	Factor viii recombinant		K	0927		\$1.07		\$0.21
J7193	Factor IX non-recombinant		K	0931		\$0.89		\$0.18
J7194	Factor ix complex		K	0928		\$0.80		\$0.16
J7195	Factor IX recombinant		K	0932		\$0.99		\$0.20
J7197	Antithrombin iii injection		K	0930		\$1.82		\$0.36
J7198	Anti-inhibitor		K	0929		\$1.42		\$0.28
J7199	Hemophilia clot factor noc		B					
J7300	Intraut copper contraceptive		E					
J7302	Levonorgestrel iu contracept		E					
J7303	Contraceptive vaginal ring		E					
J7304	Contraceptive hormone patch		E					
J7306	Levonorgestrel implant sys		E					
J7307	Etonogestrel implant system	NI	E					
J7308	Aminolevulinic acid hcl top		K	7308		\$109.92		\$21.98
J7310	Ganciclovir long act implant		K	0913		\$4,707.90		\$941.58
J7311	Fluocinolone acetone implt	CH	K	9225		\$19,162.50		\$3,832.50
J7321	Hyalgan/supartz inj per dose	NI	K	0873		\$101.81		\$20.36
J7322	Synvisc inj per dose	NI	K	0874		\$178.11		\$35.62
J7323	Euflexxa inj per dose	NI	K	0875		\$110.95		\$22.19
J7324	Orthovisc inj per dose	NI	K	0877		\$174.50		\$34.90
J7330	Cultured chondrocytes implnt		B					
J7340	Metabolic active D/E tissue		K	1632		\$28.45		\$5.69
J7341	Non-human, metabolic tissue	CH	N					
J7342	Metabolically active tissue		K	9054		\$36.40		\$7.28
J7343	Nonmetabolic act d/e tissue		K	1629		\$20.22		\$4.04
J7344	Nonmetabolic active tissue		K	9156		\$94.53		\$18.91
J7345	Non-human, non-metab tissue	CH	D					
J7346	Injectable human tissue		K	9222		\$774.46		\$154.89
J7347	Integra matrix tissue	NI	K	1140		\$33.14		\$6.63
J7348	Tissuemend tissue	NI	G	9351		\$67.96		\$13.59
J7349	Primatrix tissue	NI	G	1141		\$67.96		\$13.59
J7500	Azathioprine oral 50mg		N					
J7501	Azathioprine parenteral		K	0887		\$47.88		\$9.58
J7502	Cyclosporine oral 100 mg		K	0888		\$3.52		\$0.70
J7504	Lymphocyte immune globulin		K	0890		\$336.10		\$67.22
J7505	Monoclonal antibodies		K	7038		\$977.75		\$195.55
J7506	Prednisone oral		N					
J7507	Tacrolimus oral per 1 MG		K	0891		\$3.69		\$0.74
J7509	Methylprednisolone oral		N					
J7510	Prednisolone oral per 5 mg		N					
J7511	Antithymocyte globulin rabbit		K	9104		\$337.82		\$67.56
J7513	Daclizumab, parenteral		K	1612		\$322.28		\$64.46
J7515	Cyclosporine oral 25 mg		N					
J7516	Cyclosporin parenteral 250mg		N					
J7517	Mycophenolate mofetil oral		K	9015		\$2.66		\$0.53

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
J7518	Mycophenolic acid		K	9219		\$2.41		\$0.48
J7520	Sirolimus, oral		K	9020		\$7.50		\$1.50
J7525	Tacrolimus injection		K	9006		\$138.64		\$27.73
J7599	Immunosuppressive drug noc		N					
J7602	Albuterol inh non-comp con	NI	M					
J7603	Albuterol inh non-comp u d	NI	M					
J7604	Acetylcysteine comp unit	NI	M					
J7605	Arformoterol non-comp unit	NI	M					
J7607	Levalbuterol comp con	CH	M					
J7608	Acetylcysteine non-comp unit	CH	M					
J7609	Albuterol comp unit	CH	M					
J7610	Albuterol comp con	CH	M					
J7611	Albuterol non-comp con	CH	D					
J7612	Levalbuterol non-comp con	CH	D					
J7613	Albuterol non-comp unit	CH	D					
J7614	Levalbuterol non-comp unit	CH	D					
J7615	Levalbuterol comp unit	CH	M					
J7620	Albuterol ipratrop non-comp	CH	M					
J7622	Beclomethasone comp unit	CH	M					
J7624	Betamethasone comp unit	CH	M					
J7626	Budesonide non-comp unit	CH	M					
J7627	Budesonide comp unit	CH	M					
J7628	Bitolterol mesylate comp con	CH	M					
J7629	Bitolterol mesylate comp unit	CH	M					
J7631	Cromolyn sodium noncomp unit	CH	M					
J7632	Cromolyn sodium comp unit	NI	M					
J7633	Budesonide non-comp con	CH	M					
J7634	Budesonide comp con	CH	M					
J7635	Atropine comp con	CH	M					
J7636	Atropine comp unit	CH	M					
J7637	Dexamethasone comp con	CH	M					
J7638	Dexamethasone comp unit	CH	M					
J7639	Dornase alpha non-comp unit	CH	M					
J7640	Formoterol comp unit		E					
J7641	Flunisolide comp unit	CH	M					
J7642	Glycopyrrrolate comp con	CH	M					
J7643	Glycopyrrrolate comp unit	CH	M					
J7644	Ipratropium bromide non-comp	CH	M					
J7645	Ipratropium bromide comp	CH	M					
J7647	Isoetharine comp con	CH	M					
J7648	Isoetharine non-comp con	CH	M					
J7649	Isoetharine non-comp unit	CH	M					
J7650	Isoetharine comp unit	CH	M					
J7657	Isoproterenol comp con	CH	M					
J7658	Isoproterenol non-comp con	CH	M					
J7659	Isoproterenol non-comp unit	CH	M					
J7660	Isoproterenol comp unit	CH	M					
J7667	Metaproterenol comp con	CH	M					
J7668	Metaproterenol non-comp con	CH	M					
J7669	Metaproterenol non-comp unit	CH	M					
J7670	Metaproterenol comp unit	CH	M					
J7674	Methacholine chloride, neb		N					
J7676	Pentamidine comp unit dose	NI	M					
J7680	Terbutaline sulf comp con	CH	M					
J7681	Terbutaline sulf comp unit	CH	M					
J7682	Tobramycin non-comp unit	CH	M					
J7683	Triamcinolone comp con	CH	M					
J7684	Triamcinolone comp unit	CH	M					
J7685	Tobramycin comp unit	CH	M					
J7699	Inhalation solution for DME	CH	N					
J7799	Non-inhalation drug for DME		N					
J8498	Antiemetic rectal/supp NOS		B					
J8499	Oral prescrip drug non chemo		E					
J8501	Oral apreipitant	CH	K	0868		\$4.99		\$1.00
J8510	Oral busulfan		K	7015		\$2.26		\$0.45
J8515	Cabergoline, oral 0.25mg		E					
J8520	Capecitabine, oral, 150 mg		K	7042		\$4.28		\$0.86
J8521	Capecitabine, oral, 500 mg	CH	K	0934		\$14.19		\$2.84
J8530	Cyclophosphamide oral 25 MG		N					
J8540	Oral dexamethasone		N					
J8560	Etoposide oral 50 MG		K	0802		\$29.46		\$5.89
J8565	Gefitinib oral		E					
J8597	Antiemetic drug oral NOS		N					
J8600	Melphalan oral 2 MG	CH	K	0882		\$4.14		\$0.83
J8610	Methotrexate oral 2.5 MG		N					
J8650	Nabilone oral		K	0808		\$16.80		\$3.36
J8700	Temozolomide		K	1086		\$7.49		\$1.50
J8999	Oral prescription drug chemo		B					
J9000	Doxorubic hcl 10 MG vl chemo	CH	N					
J9001	Doxorubicin hcl liposome inj		K	7046		\$396.15		\$79.23

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
J9010	Alemtuzumab injection		K	9110		\$549.77		\$109.95
J9015	Aldesleukin/single use vial		K	0807		\$788.84		\$157.77
J9017	Arsenic trioxide		K	9012		\$34.44		\$6.89
J9020	Asparaginase injection		K	0814		\$54.26		\$10.85
J9025	Azacitidine injection		K	1709		\$4.35		\$0.87
J9027	Clofarabine injection	CH	K	1710		\$114.41		\$22.88
J9031	Bcg live intravesical vac		K	0809		\$113.75		\$22.75
J9035	Bevacizumab injection		K	9214		\$56.93		\$11.39
J9040	Bleomycin sulfate injection		K	0748		\$42.93		\$8.59
J9041	Bortezomib injection		K	9207		\$33.20		\$6.64
J9045	Carboplatin injection		K	0811		\$7.44		\$1.49
J9050	Carmus bischl nitro inj		K	0812		\$152.24		\$30.45
J9055	Cetuximab injection		K	9215		\$49.43		\$9.89
J9060	Cisplatin 10 MG injection		N					
J9062	Cisplatin 50 MG injection	CH	N					
J9065	Inj cladribine per 1 MG		K	0858		\$32.04		\$6.41
J9070	Cyclophosphamide 100 MG inj		N					
J9080	Cyclophosphamide 200 MG inj	CH	N					
J9090	Cyclophosphamide 500 MG inj	CH	N					
J9091	Cyclophosphamide 1.0 grm inj	CH	N					
J9092	Cyclophosphamide 2.0 grm inj	CH	N					
J9093	Cyclophosphamide lyophilized	CH	N					
J9094	Cyclophosphamide lyophilized	CH	N					
J9095	Cyclophosphamide lyophilized	CH	N					
J9096	Cyclophosphamide lyophilized	CH	N					
J9097	Cyclophosphamide lyophilized	CH	N					
J9098	Cytarabine liposome		K	1166		\$412.21		\$82.44
J9100	Cytarabine hcl 100 MG inj		N					
J9110	Cytarabine hcl 500 MG inj	CH	N					
J9120	Dactinomycin actinomycin d		K	0752		\$488.78		\$97.76
J9130	Dacarbazine 100 mg inj	CH	N					
J9140	Dacarbazine 200 MG inj	CH	N					
J9150	D Daunorubicin		K	0820		\$19.33		\$3.87
J9151	D Daunorubicin citrate liposom		K	0821		\$55.23		\$11.05
J9160	Denileukin diftitox, 300 mcg		K	1084		\$1,386.59		\$277.32
J9165	Diethylstilbestrol injection		N					
J9170	Docetaxel		K	0823		\$310.85		\$62.17
J9175	Elliotts b solution per ml		N					
J9178	Inj, epirubicin hcl, 2 mg		K	1167		\$19.79		\$3.96
J9181	Etoposide 10 MG inj		N					
J9182	Etoposide 100 MG inj	CH	N					
J9185	Fludarabine phosphate inj		K	0842		\$226.67		\$45.33
J9190	Fluorouracil injection		N					
J9200	Floxuridine injection		K	0827		\$54.63		\$10.93
J9201	Gemcitabine HCl		K	0828		\$127.31		\$25.46
J9202	Goserelin acetate implant		K	0810		\$192.29		\$38.46
J9206	Irinotecan injection		K	0830		\$124.61		\$24.92
J9208	Ifosfomide injection		K	0831		\$38.13		\$7.63
J9209	Mesna injection		K	0732		\$7.97		\$1.59
J9211	Idarubicin hcl injection		K	0832		\$302.42		\$60.48
J9212	Interferon alfacon-1		K	0912		\$4.62		\$0.92
J9213	Interferon alfa-2a inj		K	0834		\$41.37		\$8.27
J9214	Interferon alfa-2b inj		K	0836		\$13.92		\$2.78
J9215	Interferon alfa-n3 inj		K	0865		\$9.03		\$1.81
J9216	Interferon gamma 1-b inj		K	0838		\$306.66		\$61.33
J9217	Leuprolide acetate suspnsion		K	9217		\$236.06		\$47.21
J9218	Leuprolide acetate injecton		K	0861		\$7.98		\$1.60
J9219	Leuprolide acetate implant		K	7051		\$1,648.41		\$329.68
J9225	Vantas implant		K	1711		\$1,412.46		\$282.49
J9226	Supprelin LA implant	NI	K	1142		\$14,700.00		\$2,940.00
J9230	Mechlorethamine hcl inj		K	0751		\$143.08		\$28.62
J9245	Inj melphalan hydrochl 50 MG		K	0840		\$1,548.88		\$309.78
J9250	Methotrexate sodium inj		N					
J9260	Methotrexate sodium inj	CH	N					
J9261	Nelarabine injection		G	0825		\$86.84		\$17.37
J9263	Oxaliplatin		K	1738		\$9.15		\$1.83
J9264	Paclitaxel protein bound	CH	K	1712		\$8.79		\$1.76
J9265	Paclitaxel injection		K	0863		\$14.57		\$2.91
J9266	Pegaspargase/singl dose vial		K	0843		\$2,080.19		\$416.04
J9268	Pentostatin injection		K	0844		\$2,051.68		\$410.34
J9270	Plicamycin (mithramycin) inj	CH	K	1041		\$172.41		\$34.48
J9280	Mitomycin 5 MG inj		K	0862		\$14.39		\$2.88
J9290	Mitomycin 20 MG inj	CH	K	0941		\$57.56		\$11.51
J9291	Mitomycin 40 MG inj	CH	K	0942		\$115.11		\$23.02
J9293	Mitoxantrone hydrochl / 5 MG		K	0864		\$107.96		\$21.59
J9300	Gemtuzumab ozogamicin		K	9004		\$2,411.98		\$482.40
J9303	Panitumumab injection	NI	G	9235		\$83.15		\$16.63
J9305	Pemetrexed injection		K	9213		\$44.49		\$8.90
J9310	Rituximab cancer treatment		K	0849		\$504.40		\$100.88
J9320	Streptozocin injection		K	0850		\$146.93		\$29.39

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
J9340	Thiotepa injection		K	0851		\$41.12		\$8.22
J9350	Topotecan		K	0852		\$859.62		\$171.92
J9355	Trastuzumab		K	1613		\$58.51		\$11.70
J9357	Valrubicin, 200 mg		K	9167		\$77.96		\$15.59
J9360	Vinblastine sulfate inj		N					
J9370	Vincristine sulfate 1 MG inj		N					
J9375	Vincristine sulfate 2 MG inj	CH	N					
J9380	Vincristine sulfate 5 MG inj	CH	N					
J9390	Vinorelbine tartrate/10 mg		K	0855		\$21.41		\$4.28
J9395	Injection, Fulvestrant		K	9120		\$80.60		\$16.12
J9600	Porfimer sodium		K	0856		\$2,532.53		\$506.51
J9999	Chemotherapy drug		N					
K0001	Standard wheelchair		Y					
K0002	Std hemi (low seat) whlchr		Y					
K0003	Lightweight wheelchair		Y					
K0004	High strength ltwt whlchr		Y					
K0005	Ultraightweight wheelchair		Y					
K0006	Heavy duty wheelchair		Y					
K0007	Extra heavy duty wheelchair		Y					
K0009	Other manual wheelchair/base		Y					
K0010	Std wt frame power whlchr		Y					
K0011	Std wt pwr whlchr w control		Y					
K0012	Ltwt portbl power whlchr		Y					
K0014	Other power whlchr base		Y					
K0015	Detach non-adjus hght armrst		Y					
K0017	Detach adjust armrest base		Y					
K0018	Detach adjust armrst upper		Y					
K0019	Arm pad each		Y					
K0020	Fixed adjust armrest pair		Y					
K0037	High mount flip-up footrest		Y					
K0038	Leg strap each		Y					
K0039	Leg strap h style each		Y					
K0040	Adjustable angle footplate		Y					
K0041	Large size footplate each		Y					
K0042	Standard size footplate each		Y					
K0043	Ftrst lower extension tube		Y					
K0044	Ftrst upper hanger bracket		Y					
K0045	Footrest complete assembly		Y					
K0046	Elevat legrst low extension		Y					
K0047	Elevat legrst up hangr brack		Y					
K0050	Ratchet assembly		Y					
K0051	Cam relese assem frst/lgrst		Y					
K0052	Swingaway detach footrest		Y					
K0053	Elevate footrest articulate		Y					
K0056	Seat ht <17 or >=21 ltwt wc		Y					
K0065	Spoke protectors		Y					
K0069	Rear whl complete solid tire		Y					
K0070	Rear whl compl pneum tire		Y					
K0071	Front castr compl pneum tire		Y					
K0072	Frnt cstr cmpl sem-pneum tir		Y					
K0073	Caster pin lock each		Y					
K0077	Front caster assem complete		Y					
K0098	Drive belt power wheelchair		Y					
K0105	Iv hanger		Y					
K0108	W/c component-accessory NOS		Y					
K0195	Elevating whlchair leg rests		Y					
K0455	Pump uninterrupted infusion		Y					
K0462	Temporary replacement eqpmnt		Y					
K0552	Supply/ext inf pump syr type		Y					
K0553	Combination oral/nasal mask	CH	D					
K0554	Repl oral cushion combo mask	CH	D					
K0555	Repl nasal pillow comb mask	CH	D					
K0601	Repl batt silver oxide 1.5 v		Y					
K0602	Repl batt silver oxide 3 v		Y					
K0603	Repl batt alkaline 1.5 v		Y					
K0604	Repl batt lithium 3.6 v		Y					
K0605	Repl batt lithium 4.5 v		Y					
K0606	AED garment w elec analysis		Y					
K0607	Repl batt for AED		Y					
K0608	Repl garment for AED		Y					
K0609	Repl electrode for AED		Y					
K0669	Seat/back cus no sadmerc ver		Y					
K0730	Ctrl dose inh drug deliv sys		Y					
K0733	12-24hr sealed lead acid		Y					
K0734	Adj skin pro w/c cus wd<22in		Y					
K0735	Adj skin pro wc cus wd>=22in		Y					
K0736	Adj skin pro/pos wc cus<22in		Y					
K0737	Adj skin pro/pos wc cus>=22"		Y					
K0738	Portable gas oxygen system		Y					
K0800	POV group 1 std up to 300lbs		Y					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
K0801	POV group 1 hd 301–450 lbs		Y					
K0802	POV group 1 vhd 451–600 lbs		Y					
K0806	POV group 2 std up to 300lbs		Y					
K0807	POV group 2 hd 301–450 lbs		Y					
K0808	POV group 2 vhd 451–600 lbs		Y					
K0812	Power operated vehicle NOC		Y					
K0813	PWC gp 1 std port seat/back		Y					
K0814	PWC gp 1 std port cap chair		Y					
K0815	PWC gp 1 std seat/back		Y					
K0816	PWC gp 1 std cap chair		Y					
K0820	PWC gp 2 std port seat/back		Y					
K0821	PWC gp 2 std port cap chair		Y					
K0822	PWC gp 2 std seat/back		Y					
K0823	PWC gp 2 std cap chair		Y					
K0824	PWC gp 2 hd seat/back		Y					
K0825	PWC gp 2 hd cap chair		Y					
K0826	PWC gp 2 vhd seat/back		Y					
K0827	PWC gp vhd cap chair		Y					
K0828	PWC gp 2 xtra hd seat/back		Y					
K0829	PWC gp 2 xtra hd cap chair		Y					
K0830	PWC gp2 std seat elevate s/b		Y					
K0831	PWC gp2 std seat elevate cap		Y					
K0835	PWC gp2 std sing pow opt s/b		Y					
K0836	PWC gp2 std sing pow opt cap		Y					
K0837	PWC gp 2 hd sing pow opt s/b		Y					
K0838	PWC gp 2 hd sing pow opt cap		Y					
K0839	PWC gp2 vhd sing pow opt s/b		Y					
K0840	PWC gp2 xhd sing pow opt s/b		Y					
K0841	PWC gp2 std mult pow opt s/b		Y					
K0842	PWC gp2 std mult pow opt cap		Y					
K0843	PWC gp2 hd mult pow opt s/b		Y					
K0848	PWC gp 3 std seat/back		Y					
K0849	PWC gp 3 std cap chair		Y					
K0850	PWC gp 3 hd seat/back		Y					
K0851	PWC gp 3 hd cap chair		Y					
K0852	PWC gp 3 vhd seat/back		Y					
K0853	PWC gp 3 vhd cap chair		Y					
K0854	PWC gp 3 xhd seat/back		Y					
K0855	PWC gp 3 xhd cap chair		Y					
K0856	PWC gp3 std sing pow opt s/b		Y					
K0857	PWC gp3 std sing pow opt cap		Y					
K0858	PWC gp3 hd sing pow opt s/b		Y					
K0859	PWC gp3 hd sing pow opt cap		Y					
K0860	PWC gp3 vhd sing pow opt s/b		Y					
K0861	PWC gp3 std mult pow opt s/b		Y					
K0862	PWC gp3 hd mult pow opt s/b		Y					
K0863	PWC gp3 vhd mult pow opt s/b		Y					
K0864	PWC gp3 xhd mult pow opt s/b		Y					
K0868	PWC gp 4 std seat/back		Y					
K0869	PWC gp 4 std cap chair		Y					
K0870	PWC gp 4 hd seat/back		Y					
K0871	PWC gp 4 vhd seat/back		Y					
K0877	PWC gp4 std sing pow opt s/b		Y					
K0878	PWC gp4 std sing pow opt cap		Y					
K0879	PWC gp4 hd sing pow opt s/b		Y					
K0880	PWC gp4 vhd sing pow opt s/b		Y					
K0884	PWC gp4 std mult pow opt s/b		Y					
K0885	PWC gp4 std mult pow opt cap		Y					
K0886	PWC gp4 hd mult pow s/b		Y					
K0890	PWC gp5 ped sing pow opt s/b		Y					
K0891	PWC gp5 ped mult pow opt s/b		Y					
K0898	Power wheelchair NOC		Y					
K0899	Pow mobil dev no SADMERC		Y					
L0112	Cranial cervical orthosis		A					
L0120	Cerv flexible non-adjustable		A					
L0130	Flex thermoplastic collar mo		A					
L0140	Cervical semi-rigid adjustab		A					
L0150	Cerv semi-rig adj molded chn		A					
L0160	Cerv semi-rig wire occ/mand		A					
L0170	Cervical collar molded to pt		A					
L0172	Cerv col thermplas foam 2 pi		A					
L0174	Cerv col foam 2 piece w thor		A					
L0180	Cer post col occ/man sup adj		A					
L0190	Cerv collar supp adj cerv ba		A					
L0200	Cerv col supp adj bar & thor		A					
L0210	Thoracic rib belt		A					
L0220	Thor rib belt custom fabrica		A					
L0430	Dewall posture protector		A					
L0450	TLSO flex prefab thoracic		A					
L0452	tiso flex custom fab thoraci		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L0454	TLSO flex prefab sacrococ-T9		A					
L0456	TLSO flex prefab		A					
L0458	TLSO 2Mod symphis-xipho pre		A					
L0460	TLSO2Mod symphysis-stern pre		A					
L0462	TLSO 3Mod sacro-scap pre		A					
L0464	TLSO 4Mod sacro-scap pre		A					
L0466	TLSO rigid frame pre soft ap		A					
L0468	TLSO rigid frame prefab pelv		A					
L0470	TLSO rigid frame pre subclav		A					
L0472	TLSO rigid frame hyperex pre		A					
L0480	TLSO rigid plastic custom fa		A					
L0482	TLSO rigid lined custom fab		A					
L0484	TLSO rigid plastic cust fab		A					
L0486	TLSO rigidlined cust fab two		A					
L0488	TLSO rigid lined pre one pie		A					
L0490	TLSO rigid plastic pre one		A					
L0491	TLSO 2 piece rigid shell		A					
L0492	TLSO 3 piece rigid shell		A					
L0621	SIO flex pelvisacral prefab		A					
L0622	SIO flex pelvisacral custom		A					
L0623	SIO panel prefab		A					
L0624	SIO panel custom		A					
L0625	LO flexibl L1-below L5 pre		A					
L0626	LO sag stays/panels pre-fab		A					
L0627	LO sagitt rigid panel prefab		A					
L0628	LO flex w/o rigid stays pre		A					
L0629	LSO flex w/rigid stays cust		A					
L0630	LSO post rigid panel pre		A					
L0631	LSO sag-coro rigid frame pre		A					
L0632	LSO sag rigid frame cust		A					
L0633	LSO flexion control prefab		A					
L0634	LSO flexion control custom		A					
L0635	LSO sagitt rigid panel prefab		A					
L0636	LSO sagittal rigid panel cus		A					
L0637	LSO sag-coronal panel prefab		A					
L0638	LSO sag-coronal panel custom		A					
L0639	LSO s/c shell/panel prefab		A					
L0640	LSO s/c shell/panel custom		A					
L0700	Ctiso a-p-l control molded		A					
L0710	Ctiso a-p-l control w/ inter		A					
L0810	Halo cervical into jckt vest		A					
L0820	Halo cervical into body jack		A					
L0830	Halo cerv into milwaukee typ		A					
L0859	MRI compatible system		A					
L0861	Halo repl liner/interface		A					
L0960	Post surgical support pads	CH	D					
L0970	Tlso corset front		A					
L0972	Lso corset front		A					
L0974	Tlso full corset		A					
L0976	Lso full corset		A					
L0978	Axillary crutch extension		A					
L0980	Peroneal straps pair		A					
L0982	Stocking supp grips set of f		A					
L0984	Protective body sock each		A					
L0999	Add to spinal orthosis NOS		A					
L1000	Ctiso milwauke initial model		A					
L1001	CTLSO infant immobilizer		A					
L1005	Tension based scoliosis orth		A					
L1010	Ctiso axilla sling		A					
L1020	Kyphosis pad		A					
L1025	Kyphosis pad floating		A					
L1030	Lumbar bolster pad		A					
L1040	Lumbar or lumbar rib pad		A					
L1050	Sternal pad		A					
L1060	Thoracic pad		A					
L1070	Trapezius sling		A					
L1080	Outrigger		A					
L1085	Outrigger bil w/ vert extens		A					
L1090	Lumbar sling		A					
L1100	Ring flange plastic/leather		A					
L1110	Ring flange plas/leather mol		A					
L1120	Covers for upright each		A					
L1200	Furnsh initial orthosis only		A					
L1210	Lateral thoracic extension		A					
L1220	Anterior thoracic extension		A					
L1230	Milwaukee type superstructur		A					
L1240	Lumbar derotation pad		A					
L1250	Anterior asis pad		A					
L1260	Anterior thoracic derotation		A					
L1270	Abdominal pad		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L1280	Rib gusset (elastic) each		A					
L1290	Lateral trochanteric pad		A					
L1300	Body jacket mold to patient		A					
L1310	Post-operative body jacket		A					
L1499	Spinal orthosis NOS		A					
L1500	Thkao mobility frame		A					
L1510	Thkao standing frame		A					
L1520	Thkao swivel walker		A					
L1600	Abduct hip flex frejka w cvr		A					
L1610	Abduct hip flex frejka covr		A					
L1620	Abduct hip flex pavlik harne		A					
L1630	Abduct control hip semi-flex		A					
L1640	Pelv band/spread bar thigh c		A					
L1650	HO abduction hip adjustable		A					
L1652	HO bi thighcuffs w sprdr bar		A					
L1660	HO abduction static plastic		A					
L1680	Pelvic & hip control thigh c		A					
L1685	Post-op hip abduct custom fa		A					
L1686	HO post-op hip abduction		A					
L1690	Combination bilateral HO		A					
L1700	Leg perthes orth toronto typ		A					
L1710	Legg perthes orth newington		A					
L1720	Legg perthes orthosis trilat		A					
L1730	Legg perthes orth scottish r		A					
L1755	Legg perthes patten bottom t		A					
L1800	Knee orthoses elas w stays		A					
L1810	Ko elastic with joints		A					
L1815	Elastic with condylar pads		A					
L1820	Ko elas w/ condyle pads & jo		A					
L1825	Ko elastic knee cap		A					
L1830	Ko immobilizer canvas longit		A					
L1831	Knee orth pos locking joint		A					
L1832	KO adj jnt pos rigid support		A					
L1834	Ko w/o joint rigid molded to		A					
L1836	Rigid KO wo joints		A					
L1840	Ko derot ant cruciate custom		A					
L1843	KO single upright custom fit		A					
L1844	Ko w/adj jt rot cntrl molded		A					
L1845	Ko w/ adj flex/ext rotat cus		A					
L1846	Ko w adj flex/ext rotat mold		A					
L1847	KO adjustable w air chambers		A					
L1850	Ko swedish type		A					
L1855	Ko plas doub upright jnt mol	CH	D					
L1858	Ko polycentric pneumatic pad	CH	D					
L1860	Ko supracondylar socket mold		A					
L1870	Ko doub upright lacers molde	CH	D					
L1880	Ko doub upright cuffs/lacers	CH	D					
L1900	Afo sprng wir drsflx calf bd		A					
L1901	Prefab ankle orthosis		A					
L1902	Afo ankle gauntlet		A					
L1904	Afo molded ankle gauntlet		A					
L1906	Afo multiligamentus ankle su		A					
L1907	AFO supramalleolar custom		A					
L1910	Afo sing bar clasp attach sh		A					
L1920	Afo sing upright w/ adjust s		A					
L1930	Afo plastic		A					
L1932	Afo rig ant tib prefab TCF/=		A					
L1940	Afo molded to patient plasti		A					
L1945	Afo molded plas rig ant tib		A					
L1950	Afo spiral molded to pt plas		A					
L1951	AFO spiral prefabricated		A					
L1960	Afo pos solid ank plastic mo		A					
L1970	Afo plastic molded w/ankle j		A					
L1971	AFO w/ankle joint, prefab		A					
L1980	Afo sing solid stirrup calf		A					
L1990	Afo doub solid stirrup calf		A					
L2000	Kafo sing fre stirr thi/calf		A					
L2005	KAFO sng/dbl mechanical act		A					
L2010	Kafo sng solid stirrup w/o j		A					
L2020	Kafo dbl solid stirrup band/		A					
L2030	Kafo dbl solid stirrup w/o j		A					
L2034	KAFO pla sin up w/wo k/a cus		A					
L2035	KAFO plastic pediatric size		A					
L2036	Kafo plas doub free knee mol		A					
L2037	Kafo plas sing free knee mol		A					
L2038	Kafo w/o joint multi-axis an		A					
L2040	Hkafo torsion bil rot straps		A					
L2050	Hkafo torsion cable hip pelv		A					
L2060	Hkafo torsion ball bearing j		A					
L2070	Hkafo torsion unilat rot str		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L2080	Hkafo unilat torsion cable		A					
L2090	Hkafo unilat torsion ball br		A					
L2106	Afo tib fx cast plaster mold		A					
L2108	Afo tib fx cast molded to pt		A					
L2112	Afo tibial fracture soft		A					
L2114	Afo tib fx semi-rigid		A					
L2116	Afo tibial fracture rigid		A					
L2126	Kafo fem fx cast thermoplas		A					
L2128	Kafo fem fx cast molded to p		A					
L2132	Kafo femoral fx cast soft		A					
L2134	Kafo fem fx cast semi-rigid		A					
L2136	Kafo femoral fx cast rigid		A					
L2180	Plas shoe insert w ank joint		A					
L2182	Drop lock knee		A					
L2184	Limited motion knee joint		A					
L2186	Adj motion knee jnt lerman t		A					
L2188	Quadrilateral brim		A					
L2190	Waist belt		A					
L2192	Pelvic band & belt thigh fla		A					
L2200	Limited ankle motion ea jnt		A					
L2210	Dorsiflexion assist each joi		A					
L2220	Dorsi & plantar flex ass/res		A					
L2230	Split flat caliper stirr & p		A					
L2232	Rocker bottom, contact AFO		A					
L2240	Round caliper and plate atta		A					
L2250	Foot plate molded stirrup at		A					
L2260	Reinforced solid stirrup		A					
L2265	Long tongue stirrup		A					
L2270	Varus/valgus strap padded/li		A					
L2275	Plastic mod low ext pad/line		A					
L2280	Molded inner boot		A					
L2300	Abduction bar jointed adjust		A					
L2310	Abduction bar-straight		A					
L2320	Non-molded lacer		A					
L2330	Lacer molded to patient mode		A					
L2335	Anterior swing band		A					
L2340	Pre-tibial shell molded to p		A					
L2350	Prosthetic type socket molde		A					
L2360	Extended steel shank		A					
L2370	Patten bottom		A					
L2375	Torsion ank & half solid sti		A					
L2380	Torsion straight knee joint		A					
L2385	Straight knee joint heavy du		A					
L2387	Add LE poly knee custom KAFO		A					
L2390	Offset knee joint each		A					
L2395	Offset knee joint heavy duty		A					
L2397	Suspension sleeve lower ext		A					
L2405	Knee joint drop lock ea jnt		A					
L2415	Knee joint cam lock each joi		A					
L2425	Knee disc/dial lock/adj flex		A					
L2430	Knee jnt ratchet lock ea jnt		A					
L2492	Knee lift loop drop lock rin		A					
L2500	Thi/glut/ischia wgt bearing		A					
L2510	Th/wght bear quad-lat brim m		A					
L2520	Th/wght bear quad-lat brim c		A					
L2525	Th/wght bear nar m-l brim mo		A					
L2526	Th/wght bear nar m-l brim cu		A					
L2530	Thigh/wght bear lacer non-mo		A					
L2540	Thigh/wght bear lacer molded		A					
L2550	Thigh/wght bear high roll cu		A					
L2570	Hip clevis type 2 posit jnt		A					
L2580	Pelvic control pelvic sling		A					
L2600	Hip clevis/thrust bearing fr		A					
L2610	Hip clevis/thrust bearing lo		A					
L2620	Pelvic control hip heavy dut		A					
L2622	Hip joint adjustable flexion		A					
L2624	Hip adj flex ext abduct cont		A					
L2627	Plastic mold recipro hip & c		A					
L2628	Metal frame recipro hip & ca		A					
L2630	Pelvic control band & belt u		A					
L2640	Pelvic control band & belt b		A					
L2650	Pelv & thor control gluteal		A					
L2660	Thoracic control thoracic ba		A					
L2670	Thorac cont paraspinal uprig		A					
L2680	Thorac cont lat support upri		A					
L2750	Plating chrome/nickel pr bar		A					
L2755	Carbon graphite lamination		A					
L2760	Extension per extension per		A					
L2768	Ortho sidebar disconnect		A					
L2770	Low ext orthosis per bar/jnt		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L2780	Non-corrosive finish		A					
L2785	Drop lock retainer each		A					
L2795	Knee control full kneecap		A					
L2800	Knee cap medial or lateral p		A					
L2810	Knee control condylar pad		A					
L2820	Soft interface below knee se		A					
L2830	Soft interface above knee se		A					
L2840	Tibial length sock fx or equ		A					
L2850	Femoral lgth sock fx or equa		A					
L2860	Torsion mechanism knee/ankle		A					
L2999	Lower extremity orthosis NOS		A					
L3000	Ft insert ucb berkeley shell		A					
L3001	Foot insert remov molded spe		A					
L3002	Foot insert plastazote or eq		A					
L3003	Foot insert silicone gel eac		A					
L3010	Foot longitudinal arch suppo		A					
L3020	Foot longitud/metatarsal sup		A					
L3030	Foot arch support remov prem		A					
L3031	Foot lamin/prepreg composite		A					
L3040	Ft arch suprt premold longit		A					
L3050	Foot arch supp premold metat		A					
L3060	Foot arch supp longitud/meta		A					
L3070	Arch suprt att to sho longit		A					
L3080	Arch supp att to shoe metata		A					
L3090	Arch supp att to shoe long/m		A					
L3100	Hallus-valgus nght dynamic s		A					
L3140	Abduction rotation bar shoe		A					
L3150	Abduct rotation bar w/o shoe		A					
L3160	Shoe styled positioning dev		A					
L3170	Foot plastic heel stabilizer		A					
L3201	Oxford w supinat/pronator inf		A					
L3202	Oxford w/ supinat/pronator c		A					
L3203	Oxford w/ supinator/pronator		A					
L3204	Hightop w/ supp/pronator inf		A					
L3206	Hightop w/ supp/pronator chi		A					
L3207	Hightop w/ supp/pronator jun		A					
L3208	Surgical boot each infant		A					
L3209	Surgical boot each child		A					
L3211	Surgical boot each junior		A					
L3212	Benesch boot pair infant		A					
L3213	Benesch boot pair child		A					
L3214	Benesch boot pair junior		A					
L3215	Orthopedic ftwear ladies oxf		E					
L3216	Orthoped ladies shoes dpth i	CH	E					
L3217	Ladies shoes hightop depth i	CH	E					
L3219	Orthopedic mens shoes oxford		E					
L3221	Orthopedic mens shoes dpth i	CH	E					
L3222	Mens shoes hightop depth inl	CH	E					
L3224	Woman's shoe oxford brace		A					
L3225	Man's shoe oxford brace		A					
L3230	Custom shoes depth inlay		A					
L3250	Custom mold shoe remov prost		A					
L3251	Shoe molded to pt silicone s		A					
L3252	Shoe molded plastazote cust		A					
L3253	Shoe molded plastazote cust		A					
L3254	Orth foot non-stdnd size/w		A					
L3255	Orth foot non-standard size/		A					
L3257	Orth foot add charge split s		A					
L3260	Ambulatory surgical boot eac		E					
L3265	Plastazote sandal each		A					
L3300	Sho lift taper to metatarsal		A					
L3310	Shoe lift elev heel/sole neo		A					
L3320	Shoe lift elev heel/sole cor		A					
L3330	Lifts elevation metal extens		A					
L3332	Shoe lifts tapered to one-ha		A					
L3334	Shoe lifts elevation heel /i		A					
L3340	Shoe wedge sach		A					
L3350	Shoe heel wedge		A					
L3360	Shoe sole wedge outside sole		A					
L3370	Shoe sole wedge between sole		A					
L3380	Shoe clubfoot wedge		A					
L3390	Shoe outflare wedge		A					
L3400	Shoe metatarsal bar wedge ro		A					
L3410	Shoe metatarsal bar between		A					
L3420	Full sole/heel wedge btween		A					
L3430	Sho heel count plast reinfor		A					
L3440	Heel leather reinforced		A					
L3450	Shoe heel sach cushion type		A					
L3455	Shoe heel new leather standa		A					
L3460	Shoe heel new rubber standar		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L3465	Shoe heel thomas with wedge		A					
L3470	Shoe heel thomas extend to b		A					
L3480	Shoe heel pad & depress for		A					
L3485	Shoe heel pad removable for		A					
L3500	Ortho shoe add leather insol		A					
L3510	Orthopedic shoe add rub insl		A					
L3520	O shoe add felt w leath insl		A					
L3530	Ortho shoe add half sole		A					
L3540	Ortho shoe add full sole		A					
L3550	O shoe add standard toe tap		A					
L3560	O shoe add horseshoe toe tap		A					
L3570	O shoe add instep extension		A					
L3580	O shoe add instep velcro clo		A					
L3590	O shoe convert to sof counte		A					
L3595	Ortho shoe add march bar		A					
L3600	Trans shoe calip plate exist		A					
L3610	Trans shoe caliper plate new		A					
L3620	Trans shoe solid stirrup exi		A					
L3630	Trans shoe solid stirrup new		A					
L3640	Shoe dennis browne splint bo		A					
L3649	Orthopedic shoe modifica NOS		A					
L3650	Shlder fig 8 abduct restrain		A					
L3651	Prefab shoulder orthosis		A					
L3652	Prefab dbl shoulder orthosis		A					
L3660	Abduct restrainer canvas&web		A					
L3670	Acromio/clavicular canvas&we		A					
L3671	SO cap design w/o jnts CF		A					
L3672	SO airplane w/o jnts CF		A					
L3673	SO airplane w/joint CF		A					
L3675	Canvas vest SO		A					
L3677	SO hard plastic stabilizer		E					
L3700	Elbow orthoses elas w stays		A					
L3701	Prefab elbow orthosis		A					
L3702	EO w/o joints CF		A					
L3710	Elbow elastic with metal joi		A					
L3720	Forearm/arm cuffs free motio		A					
L3730	Forearm/arm cuffs ext/flex a		A					
L3740	Cuffs adj lock w/ active con		A					
L3760	EO withjoint, Prefabricated		A					
L3762	Rigid EO w/o joints		A					
L3763	EWHO rigid w/o jnts CF		A					
L3764	EWHO w/joint(s) CF		A					
L3765	EWHFO rigid w/o jnts CF		A					
L3766	EWHFO w/joint(s) CF		A					
L3800	Whfo short opponen no attach	CH	D					
L3805	Whfo long opponens no attach	CH	D					
L3806	WHFO w/joint(s) custom fab		A					
L3807	WHFO,no joint, prefabricated		A					
L3808	WHFO, rigid w/o joints		A					
L3810	Whfo thumb abduction bar	CH	D					
L3815	Whfo second m.p. abduction a	CH	D					
L3820	Whfo ip ext asst w/ mp ext s	CH	D					
L3825	Whfo m.p. extension stop	CH	D					
L3830	Whfo m.p. extension assist	CH	D					
L3835	Whfo m.p. spring extension a	CH	D					
L3840	Whfo spring swivel thumb	CH	D					
L3845	Whfo thumb ip ext ass w/ mp	CH	D					
L3850	Action wrist w/ dorsiflex as	CH	D					
L3855	Whfo adj m.p. flexion contro	CH	D					
L3860	Whfo adj m.p. flex ctrl & i	CH	D					
L3890	Torsion mechanism wrist/elbo		B					
L3900	Hinge extension/flex wrist/f		A					
L3901	Hinge ext/flex wrist finger		A					
L3904	Whfo electric custom fitted		A					
L3905	WHO w/nontorsion jnt(s) CF		A					
L3906	WHO w/o joints CF		A					
L3907	Whfo wrst gauntlt thmb spica	CH	D					
L3908	Wrist cock-up non-molded		A					
L3909	Prefab wrist orthosis		A					
L3910	Whfo swanson design	CH	D					
L3911	Prefab hand finger orthosis		A					
L3912	Flex glove w/elastic finger		A					
L3913	HFO w/o joints CF		A					
L3915	WHO w nontor jnt(s) prefab		A					
L3916	Whfo wrist extens w/ outrigg	CH	D					
L3917	Prefab metacarpal fx orthosis		A					
L3918	HFO knuckle bender	CH	D					
L3919	HO w/o joints CF		A					
L3920	Knuckle bender with outrigge	CH	D					
L3921	HFO w/joint(s) CF		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L3922	Knuckle bend 2 seg to flex j	CH	D					
L3923	HFO w/o joints PF		A					
L3924	Oppenheimer	CH	D					
L3925	FO pip/dip with joint/spring	NI	A					
L3926	Thomas suspension	CH	D					
L3927	FO pip/dip w/o joint/spring	NI	A					
L3928	Finger extension w/ clock sp	CH	D					
L3929	HFO nontorsion joint, prefab	NI	A					
L3930	Finger extension with wrist	CH	D					
L3931	WHFO nontorsion joint prefab	NI	A					
L3932	Safety pin spring wire	CH	D					
L3933	FO w/o joints CF		A					
L3934	Safety pin modified	CH	D					
L3935	FO nontorsion joint CF		A					
L3936	Palmer	CH	D					
L3938	Dorsal wrist	CH	D					
L3940	Dorsal wrist w/ outrigger at	CH	D					
L3942	Reverse knuckle bender	CH	D					
L3944	Reverse knuckle bend w/ outr	CH	D					
L3946	HFO composite elastic	CH	D					
L3948	Finger knuckle bender	CH	D					
L3950	Oppenheimer w/ knuckle bend	CH	D					
L3952	Oppenheimer w/ rev knuckle 2	CH	D					
L3954	Spreading hand	CH	D					
L3956	Add joint upper ext orthosis		A					
L3960	Sewho airplan desig abdu pos		A					
L3961	SEWHO cap design w/o jnts CF		A					
L3962	Sewho erbs palsey design abd		A					
L3964	Seo mobile arm sup att to wc		Y					
L3965	Arm supp att to wc rancho ty		Y					
L3966	Mobile arm supports reclinin		Y					
L3967	SEWHO airplane w/o jnts CF		A					
L3968	Friction dampening arm supp		Y					
L3969	Monosuspension arm/hand supp		Y					
L3970	Elevat proximal arm support		Y					
L3971	SEWHO cap design w/jnt(s) CF		A					
L3972	Offset/lat rocker arm w/ ela		Y					
L3973	SEWHO airplane w/jnt(s) CF		A					
L3974	Mobile arm support supinator		Y					
L3975	SEWHFO cap design w/o jnt CF		A					
L3976	SEWHFO airplane w/o jnts CF		A					
L3977	SEWHFO cap desgn w/jnt(s) CF		A					
L3978	SEWHFO airplane w/jnt(s) CF		A					
L3980	Upp ext fx orthosis humeral		A					
L3982	Upper ext fx orthosis rad/ul		A					
L3984	Upper ext fx orthosis wrist		A					
L3985	Forearm hand fx orth w/ wr h	CH	D					
L3986	Humeral rad/ulna wrist fx or	CH	D					
L3995	Sock fracture or equal each		A					
L3999	Upper limb orthosis NOS		A					
L4000	Repl girdle milwaukee orth		A					
L4002	Replace strap, any orthosis		A					
L4010	Replace trilateral socket br		A					
L4020	Replace quadlat socket brim		A					
L4030	Replace socket brim cust fit		A					
L4040	Replace molded thigh lacer		A					
L4045	Replace non-molded thigh lac		A					
L4050	Replace molded calf lacer		A					
L4055	Replace non-molded calf lace		A					
L4060	Replace high roll cuff		A					
L4070	Replace prox & dist upright		A					
L4080	Repl met band kafo-af0 prox		A					
L4090	Repl met band kafo-af0 calf/		A					
L4100	Repl leath cuff kafo prox th		A					
L4110	Repl leath cuff kafo-af0 cal		A					
L4130	Replace pretibial shell		A					
L4205	Ortho dvc repair per 15 min		A					
L4210	Orth dev repair/repl minor p		A					
L4350	Ankle control orthosi prefab		A					
L4360	Pneumati walking boot prefab		A					
L4370	Pneumatic full leg splint		A					
L4380	Pneumatic knee splint		A					
L4386	Non-pneum walk boot prefab		A					
L4392	Replace AFO soft interface		A					
L4394	Replace foot drop spint		A					
L4396	Static AFO		A					
L4398	Foot drop splint recumbent		A					
L5000	Sho insert w arch toe filler		A					
L5010	Mold socket ank hgt w/ toe f		A					
L5020	Tibial tubercle hgt w/ toe f		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L5050	Ank symes mold sckt sach ft		A					
L5060	Symes met fr leath socket ar		A					
L5100	Molded socket shin sach foot		A					
L5105	Plast socket jts/thgh lacer		A					
L5150	Mold sckt ext knee shin sach		A					
L5160	Mold socket bent knee shin s		A					
L5200	Kne sing axis fric shin sach		A					
L5210	No knee/ankle joints w/ ft b		A					
L5220	No knee joint with artic ali		A					
L5230	Fem focal defic constant fri		A					
L5250	Hip canad sing axi cons fric		A					
L5270	Tilt table locking hip sing		A					
L5280	Hemipelvect canad sing axis		A					
L5301	BK mold socket SACH ft endo		A					
L5311	Knee disart, SACH ft, endo		A					
L5321	AK open end SACH		A					
L5331	Hip disart canadian SACH ft		A					
L5341	Hemipelvectomy canadian SACH		A					
L5400	Postop dress & 1 cast chg bk		A					
L5410	Postop dsq bk ea add cast ch		A					
L5420	Postop dsq & 1 cast chg ak/d		A					
L5430	Postop dsq ak ea add cast ch		A					
L5450	Postop app non-wgt bear dsq		A					
L5460	Postop app non-wgt bear dsq		A					
L5500	Init bk ptb plaster direct		A					
L5505	Init ak ischal plstr direct		A					
L5510	Prep BK ptb plaster molded		A					
L5520	Perp BK ptb thermopls direct		A					
L5530	Prep BK ptb thermopls molded		A					
L5535	Prep BK ptb open end socket		A					
L5540	Prep BK ptb laminated socket		A					
L5560	Prep AK ischial plast molded		A					
L5570	Prep AK ischial direct form		A					
L5580	Prep AK ischial thermo mold		A					
L5585	Prep AK ischial open end		A					
L5590	Prep AK ischial laminated		A					
L5595	Hip disartic sach thermopls		A					
L5600	Hip disart sach laminat mold		A					
L5610	Above knee hydracadence		A					
L5611	Ak 4 bar link w/fric swing		A					
L5613	Ak 4 bar ling w/hydraul swig		A					
L5614	4-bar link above knee w/swng		A					
L5616	Ak univ multiplex sys frict		A					
L5617	AK/BK self-aligning unit ea		A					
L5618	Test socket symes		A					
L5620	Test socket below knee		A					
L5622	Test socket knee disarticula		A					
L5624	Test socket above knee		A					
L5626	Test socket hip disarticulat		A					
L5628	Test socket hemipelvectomy		A					
L5629	Below knee acrylic socket		A					
L5630	Syme typ expandabl wall sckt		A					
L5631	Ak/knee disartic acrylic soc		A					
L5632	Symes type ptb brim design s		A					
L5634	Symes type poster opening so		A					
L5636	Symes type medial opening so		A					
L5637	Below knee total contact		A					
L5638	Below knee leather socket		A					
L5639	Below knee wood socket		A					
L5640	Knee disarticulat leather so		A					
L5642	Above knee leather socket		A					
L5643	Hip flex inner socket ext fr		A					
L5644	Above knee wood socket		A					
L5645	Bk flex inner socket ext fra		A					
L5646	Below knee cushion socket		A					
L5647	Below knee suction socket		A					
L5648	Above knee cushion socket		A					
L5649	Isch containmt/narrow m-l so		A					
L5650	Tot contact ak/knee disart s		A					
L5651	Ak flex inner socket ext fra		A					
L5652	Suction susp ak/knee disart		A					
L5653	Knee disart expand wall sock		A					
L5654	Socket insert symes		A					
L5655	Socket insert below knee		A					
L5656	Socket insert knee articulac		A					
L5658	Socket insert above knee		A					
L5661	Multi-durometer symes		A					
L5665	Multi-durometer below knee		A					
L5666	Below knee cuff suspension		A					
L5668	Socket insert w/o lock lower		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L5670	Bk molded supracondylar susp		A					
L5671	BK/AK locking mechanism		A					
L5672	Bk removable medial brim sus		A					
L5673	Socket insert w lock mech		A					
L5676	Bk knee joints single axis p		A					
L5677	Bk knee joints polycentric p		A					
L5678	Bk joint covers pair		A					
L5679	Socket insert w/o lock mech		A					
L5680	Bk thigh lacer non-molded		A					
L5681	Intl custm cong/tatyp insert		A					
L5682	Bk thigh lacer glut/ischia m		A					
L5683	Initial custom socket insert		A					
L5684	Bk fork strap		A					
L5685	Below knee sus/seal sleeve		A					
L5686	Bk back check		A					
L5688	Bk waist belt webbing		A					
L5690	Bk waist belt padded and lin		A					
L5692	Ak pelvic control belt light		A					
L5694	Ak pelvic control belt pad/l		A					
L5695	Ak sleeve susp neoprene/equa		A					
L5696	Ak/knee disartic pelvic join		A					
L5697	Ak/knee disartic pelvic band		A					
L5698	Ak/knee disartic silesian ba		A					
L5699	Shoulder harness		A					
L5700	Replace socket below knee		A					
L5701	Replace socket above knee		A					
L5702	Replace socket hip		A					
L5703	Symes ankle w/o (SACH) foot		A					
L5704	Custom shape cover BK		A					
L5705	Custom shape cover AK		A					
L5706	Custom shape cvr knee disart		A					
L5707	Custom shape cvr hip disart		A					
L5710	Knee-shin exo sng axi mnl loc		A					
L5711	Knee-shin exo mnl lock ultra		A					
L5712	Knee-shin exo frict swg & st		A					
L5714	Knee-shin exo variable frict		A					
L5716	Knee-shin exo mech stance ph		A					
L5718	Knee-shin exo frct swg & sta		A					
L5722	Knee-shin pneum swg frct exo		A					
L5724	Knee-shin exo fluid swing ph		A					
L5726	Knee-shin ext jnts fld swg e		A					
L5728	Knee-shin fluid swg & stance		A					
L5780	Knee-shin pneum/hydra pneum		A					
L5781	Lower limb pros vacuum pump		A					
L5782	HD low limb pros vacuum pump		A					
L5785	Exoskeletal bk ultralt mater		A					
L5790	Exoskeletal ak ultra-light m		A					
L5795	Exoskel hip ultra-light mate		A					
L5810	Endoskel knee-shin mnl lock		A					
L5811	Endo knee-shin mnl lck ultra		A					
L5812	Endo knee-shin frct swg & st		A					
L5814	Endo knee-shin hydral swg ph		A					
L5816	Endo knee-shin polyc mch sta		A					
L5818	Endo knee-shin frct swg & st		A					
L5822	Endo knee-shin pneum swg frc		A					
L5824	Endo knee-shin fluid swing p		A					
L5826	Miniature knee joint		A					
L5828	Endo knee-shin fluid swg/sta		A					
L5830	Endo knee-shin pneum/swg pha		A					
L5840	Multi-axial knee/shin system		A					
L5845	Knee-shin sys stance flexion		A					
L5848	Knee-shin sys hydraul stance		A					
L5850	Endo ak/hip knee extens assi		A					
L5855	Mech hip extension assist		A					
L5856	Elec knee-shin swing/stance		A					
L5857	Elec knee-shin swing only		A					
L5858	Stance phase only		A					
L5910	Endo below knee alignable sy		A					
L5920	Endo ak/hip alignable system		A					
L5925	Above knee manual lock		A					
L5930	High activity knee frame		A					
L5940	Endo bk ultra-light material		A					
L5950	Endo ak ultra-light material		A					
L5960	Endo hip ultra-light materia		A					
L5962	Below knee flex cover system		A					
L5964	Above knee flex cover system		A					
L5966	Hip flexible cover system		A					
L5968	Multiaxial ankle w dorsiflex		A					
L5970	Foot external keel sach foot		A					
L5971	SACH foot, replacement		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L5972	Flexible keel foot		A					
L5974	Foot single axis ankle/foot		A					
L5975	Combo ankle/foot prosthesis		A					
L5976	Energy storing foot		A					
L5978	Ft prosth multiaxial anl/ft		A					
L5979	Multi-axial ankle/ft prosth		A					
L5980	Flex foot system		A					
L5981	Flex-walk sys low ext prosth		A					
L5982	Exoskeletal axial rotation u		A					
L5984	Endoskeletal axial rotation		A					
L5985	Lwr ext dynamic prosth pylon		A					
L5986	Multi-axial rotation unit		A					
L5987	Shank ft w vert load pylon		A					
L5988	Vertical shock reducing pylo		A					
L5990	User adjustable heel height		A					
L5993	Heavy duty feature, foot		A					
L5994	Heavy duty feature, knee		A					
L5995	Lower ext pros heavyduty fea		A					
L5999	Lowr extremity prosth NOS		A					
L6000	Par hand robin-aids thum rem		A					
L6010	Hand robin-aids little/ring		A					
L6020	Part hand robin-aids no fing		A					
L6025	Part hand disart myoelectric		A					
L6050	Wrst MLd sock flx hng tri pad		A					
L6055	Wrst mold sock w/exp interfa		A					
L6100	Elb mold sock flex hinge pad		A					
L6110	Elbow mold sock suspension t		A					
L6120	Elbow mold doub split soc ste		A					
L6130	Elbow stump activated lock h		A					
L6200	Elbow mold outsid lock hinge		A					
L6205	Elbow molded w/ expand inter		A					
L6250	Elbow inter loc elbow forarm		A					
L6300	Shlder disart int lock elbow		A					
L6310	Shoulder passive restor comp		A					
L6320	Shoulder passive restor cap		A					
L6350	Thoracic intern lock elbow		A					
L6360	Thoracic passive restor comp		A					
L6370	Thoracic passive restor cap		A					
L6380	Postop dsg cast chg wrst/elb		A					
L6382	Postop dsg cast chg elb dis/		A					
L6384	Postop dsg cast chg shlder/t		A					
L6386	Postop ea cast chg & realign		A					
L6388	Postop applicat rigid dsg on		A					
L6400	Below elbow prosth tiss shap		A					
L6450	Elb disart prosth tiss shap		A					
L6500	Above elbow prosth tiss shap		A					
L6550	Shldr disar prosth tiss shap		A					
L6570	Scap thorac prosth tiss shap		A					
L6580	Wrist/elbow bowden cable mol		A					
L6582	Wrist/elbow bowden cbl dir f		A					
L6584	Elbow fair lead cable molded		A					
L6586	Elbow fair lead cable dir fo		A					
L6588	Shdr fair lead cable molded		A					
L6590	Shdr fair lead cable direct		A					
L6600	Polycentric hinge pair		A					
L6605	Single pivot hinge pair		A					
L6610	Flexible metal hinge pair		A					
L6611	Additional switch, ext power		A					
L6615	Disconnect locking wrist uni		A					
L6616	Disconnect insert locking wr		A					
L6620	Flexion/extension wrist unit		A					
L6621	Flex/ext wrist w/wo friction		A					
L6623	Spring-ass rot wrst w/ latch		A					
L6624	Flex/ext/rotation wrist unit		A					
L6625	Rotation wrst w/ cable lock		A					
L6628	Quick disconn hook adapter o		A					
L6629	Lamination collar w/ couplin		A					
L6630	Stainless steel any wrist		A					
L6632	Latex suspension sleeve each		A					
L6635	Lift assist for elbow		A					
L6637	Nudge control elbow lock		A					
L6638	Elec lock on manual pw elbow		A					
L6639	Heavy duty elbow feature		A					
L6640	Shoulder abduction joint pai		A					
L6641	Excursion amplifier pulley t		A					
L6642	Excursion amplifier lever ty		A					
L6645	Shoulder flexion-abduction j		A					
L6646	Multipo locking shoulder jnt		A					
L6647	Shoulder lock actuator		A					
L6648	Ext pwrld shlder lock/unlock		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L6650	Shoulder universal joint	A						
L6655	Standard control cable extra	A						
L6660	Heavy duty control cable	A						
L6665	Teflon or equal cable lining	A						
L6670	Hook to hand cable adapter	A						
L6672	Harness chest/shldr saddle	A						
L6675	Harness figure of 8 sing con	A						
L6676	Harness figure of 8 dual con	A						
L6677	UE triple control harness	A						
L6680	Test sock wrist disart/bel e	A						
L6682	Test sock elbw disart/above	A						
L6684	Test socket shldr disart/tho	A						
L6686	Suction socket	A						
L6687	Frame typ socket bel elbow/w	A						
L6688	Frame typ sock above elb/dis	A						
L6689	Frame typ socket shoulder di	A						
L6690	Frame typ sock interscap-tho	A						
L6691	Removable insert each	A						
L6692	Silicone gel insert or equal	A						
L6693	Lockingelbow forearm cntrbal	A						
L6694	Elbow socket ins use w/lock	A						
L6695	Elbow socket ins use w/o lck	A						
L6696	Cus elbo skt in for con/atyp	A						
L6697	Cus elbo skt in not con/atyp	A						
L6698	Below/above elbow lock mech	A						
L6703	Term dev, passive hand mitt	A						
L6704	Term dev, sport/rec/work att	A						
L6706	Term dev mech hook vol open	A						
L6707	Term dev mech hook vol close	A						
L6708	Term dev mech hand vol open	A						
L6709	Term dev mech hand vol close	A						
L6805	Term dev modifier wrist unit	A						
L6810	Term dev precision pinch dev	A						
L6881	Term dev auto grasp feature	A						
L6882	Microprocessor control uplmb	A						
L6883	Replc sockt below e/w disa	A						
L6884	Replc sockt above elbow disa	A						
L6885	Replc sockt shldr dis/interc	A						
L6890	Prefab glove for term device	A						
L6895	Custom glove for term device	A						
L6900	Hand restorat thumb/1 finger	A						
L6905	Hand restoration multiple fi	A						
L6910	Hand restoration no fingers	A						
L6915	Hand restoration replacmnt g	A						
L6920	Wrist disarticul switch ctrl	A						
L6925	Wrist disart myoelectronic c	A						
L6930	Below elbow switch control	A						
L6935	Below elbow myoelectronic ct	A						
L6940	Elbow disarticulation switch	A						
L6945	Elbow disart myoelectronic c	A						
L6950	Above elbow switch control	A						
L6955	Above elbow myoelectronic ct	A						
L6960	Shldr disartic switch contro	A						
L6965	Shldr disartic myoelectronic	A						
L6970	Interscapular-thor switch ct	A						
L6975	Interscap-thor myoelectronic	A						
L7007	Adult electric hand	A						
L7008	Pediatric electric hand	A						
L7009	Adult electric hook	A						
L7040	Prehensile actuator	A						
L7045	Pediatric electric hook	A						
L7170	Electronic elbow hosmer swit	A						
L7180	Electronic elbow sequential	A						
L7181	Electronic elbo simultaneous	A						
L7185	Electron elbow adolescent sw	A						
L7186	Electron elbow child switch	A						
L7190	Elbow adolescent myoelectron	A						
L7191	Elbow child myoelectronic ct	A						
L7260	Electron wrist rotator otto	A						
L7261	Electron wrist rotator utah	A						
L7266	Servo control steeper or equ	A						
L7272	Analogue control unb or equa	A						
L7274	Proportional ctl 12 volt uta	A						
L7360	Six volt bat otto bock/eq ea	A						
L7362	Battery chgrg six volt otto	A						
L7364	Twelve volt battery utah/equ	A						
L7366	Battery chgrg 12 volt utah/e	A						
L7367	Replacmnt lithium ionbatter	A						
L7368	Lithium ion battery charger	A						
L7400	Add UE prost be/wd, ultlite	A						

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L7401	Add UE prost a/e utlitle mat		A					
L7402	Add UE prost s/d utlitle mat		A					
L7403	Add UE prost b/e acrylic		A					
L7404	Add UE prost a/e acrylic		A					
L7405	Add UE prost s/d acrylic		A					
L7499	Upper extremity prosthes NOS		A					
L7500	Prosthetic dvc repair hourly		A					
L7510	Prosthetic device repair rep		A					
L7520	Repair prosthesis per 15 min		A					
L7600	Prosthetic donning sleeve		E					
L7611	Ped term dev, hook, vol open	NI	A					
L7612	Ped term dev, hook, vol clos	NI	A					
L7613	Ped term dev, hand, vol open	NI	A					
L7614	Ped term dev, hand, vol clos	NI	A					
L7621	Hook/hand, hvy dty, vol open	NI	A					
L7622	Hook/hand, hvy dty, vol clos	NI	A					
L7900	Male vacuum erection system		A					
L8000	Mastectomy bra		A					
L8001	Breast prosthesis bra & form		A					
L8002	Brst prsth bra & bilat form		A					
L8010	Mastectomy sleeve		A					
L8015	Ext breastprosthesis garment		A					
L8020	Mastectomy form		A					
L8030	Breast prosthesis silicone/e		A					
L8035	Custom breast prosthesis		A					
L8039	Breast prosthesis NOS		A					
L8040	Nasal prosthesis		A					
L8041	Midfacial prosthesis		A					
L8042	Orbital prosthesis		A					
L8043	Upper facial prosthesis		A					
L8044	Hemi-facial prosthesis		A					
L8045	Auricular prosthesis		A					
L8046	Partial facial prosthesis		A					
L8047	Nasal septal prosthesis		A					
L8048	Unspec maxillofacial prosth		A					
L8049	Repair maxillofacial prosth		A					
L8300	Truss single w/ standard pad		A					
L8310	Truss double w/ standard pad		A					
L8320	Truss addition to std pad wa		A					
L8330	Truss add to std pad scrotal		A					
L8400	Sheath below knee		A					
L8410	Sheath above knee		A					
L8415	Sheath upper limb		A					
L8417	Pros sheath/sock w gel cushn		A					
L8420	Prosthetic sock multi ply BK		A					
L8430	Prosthetic sock multi ply AK		A					
L8435	Pros sock multi ply upper lm		A					
L8440	Shrinker below knee		A					
L8460	Shrinker above knee		A					
L8465	Shrinker upper limb		A					
L8470	Pros sock single ply BK		A					
L8480	Pros sock single ply AK		A					
L8485	Pros sock single ply upper l		A					
L8499	Unlisted misc prosthetic ser		A					
L8500	Artificial larynx		A					
L8501	Tracheostomy speaking valve		A					
L8505	Artificial larynx, accessory		A					
L8507	Trach-esoph voice pros pt in		A					
L8509	Trach-esoph voice pros md in		A					
L8510	Voice amplifier		A					
L8511	Indwelling trach insert		A					
L8512	Gel cap for trach voice pros		A					
L8513	Trach pros cleaning device		A					
L8514	Repl trach puncture dilator		A					
L8515	Gel cap app device for trach		A					
L8600	Implant breast silicone/eq		N					
L8603	Collagen imp urinary 2.5 ml		N					
L8606	Synthetic implnt urinary 1ml		N					
L8609	Artificial cornea		N					
L8610	Ocular implant		N					
L8612	Aqueous shunt prosthesis		N					
L8613	Ossicular implant		N					
L8614	Cochlear device		N					
L8615	Coch implant headset replace		A					
L8616	Coch implant microphone repl		A					
L8617	Coch implant trans coil repl		A					
L8618	Coch implant tran cable repl		A					
L8619	Replace cochlear processor		A					
L8621	Repl zinc air battery		A					
L8622	Repl alkaline battery		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
L8623	Lith ion batt CID,non-earlvl		A					
L8624	Lith ion batt CID, ear level		A					
L8630	Metacarpophalangeal implant		N					
L8631	MCP joint repl 2 pc or more		N					
L8641	Metatarsal joint implant		N					
L8642	Hallux implant		N					
L8658	Interphalangeal joint spacer		N					
L8659	Interphalangeal joint repl		N					
L8670	Vascular graft, synthetic		N					
L8680	Implt neurostim elctr each		B					
L8681	Pt prgrm for implt neurostim		A					
L8682	Implt neurostim radiofq rec		N					
L8683	Radiofq trsmtr for implt neu		A					
L8684	Radiof trsmtr implt scr1 neu		A					
L8685	Implt nrostm pls gen sng rec		B					
L8686	Implt nrostm pls gen sng non		B					
L8687	Implt nrostm pls gen dua rec		B					
L8688	Implt nrostm pls gen dua non		B					
L8689	External recharg sys intern		A					
L8690	Aud osseo dev, int/ext comp		H	1032				
L8691	Aud osseo dev ext snd proces		A					
L8695	External recharg sys extern		A					
L8699	Prosthetic implant NOS		N					
L9900	O&P supply/accessory/service		A					
M0064	Visit for drug monitoring	CH	Q	0606	1.3226	\$84.24		\$16.85
M0075	Cellular therapy		E					
M0076	Prolotherapy		E					
M0100	Intragastric hypothermia		E					
M0300	IV chelationtherapy		E					
M0301	Fabric wrapping of aneurysm		E					
P2028	Cephalin flocculation test		A					
P2029	Congo red blood test		A					
P2031	Hair analysis		E					
P2033	Blood thymol turbidity		A					
P2038	Blood mucoprotein		A					
P3000	Screen pap by tech w md supv		A					
P3001	Screening pap smear by phys		B					
P7001	Culture bacterial urine		E					
P9010	Whole blood for transfusion		K	0950	4.0011	\$254.85		\$50.97
P9011	Blood split unit		K	0967	2.3409	\$149.10		\$29.82
P9012	Cryoprecipitate each unit		K	0952	0.6474	\$41.24		\$8.25
P9016	RBC leukocytes reduced		K	0954	2.9069	\$185.15		\$37.03
P9017	Plasma 1 donor frz w/in 8 hr		K	9508	1.0524	\$67.03		\$13.41
P9019	Platelets, each unit		K	0957	1.0911	\$69.50		\$13.90
P9020	Plaelet rich plasma unit		K	0958	5.7070	\$363.50		\$72.70
P9021	Red blood cells unit		K	0959	2.0356	\$129.66		\$25.93
P9022	Washed red blood cells unit		K	0960	4.3494	\$277.03		\$55.41
P9023	Frozen plasma, pooled, sd		K	0949	1.1598	\$73.87		\$14.77
P9031	Platelets leukocytes reduced		K	1013	1.6879	\$107.51		\$21.50
P9032	Platelets, irradiated		K	9500	1.9110	\$121.72		\$24.34
P9033	Platelets leukoreduced irrads		K	0968	2.1971	\$139.94		\$27.99
P9034	Platelets, pheresis		K	9507	6.9242	\$441.03		\$88.21
P9035	Platelet pheres leukoreduced		K	9501	7.8426	\$499.53		\$99.91
P9036	Platelet pheresis irradiated		K	9502	6.5581	\$417.71		\$83.54
P9037	Plate pheres leukoredu irrads		K	1019	9.8923	\$630.08		\$126.02
P9038	RBC irradiated		K	9505	3.0643	\$195.18		\$39.04
P9039	RBC deglycerolized		K	9504	5.4516	\$347.23		\$69.45
P9040	RBC leukoreduced irradiated		K	0969	3.7722	\$240.27		\$48.05
P9041	Albumin (human),5%, 50ml		K	0961	0.3413	\$21.74		\$4.35
P9043	Plasma protein fract,5%,50ml		K	0956	1.4739	\$93.88		\$18.78
P9044	Cryoprecipitatereducedplasma		K	1009	1.3139	\$83.69		\$16.74
P9045	Albumin (human), 5%, 250 ml		K	0963	1.0987	\$69.98		\$14.00
P9046	Albumin (human), 25%, 20 ml		K	0964	0.4118	\$26.23		\$5.25
P9047	Albumin (human), 25%, 50ml		K	0965	1.1362	\$72.37		\$14.47
P9048	Plasmaprotein fract,5%,250ml		K	0966	3.3792	\$215.23		\$43.05
P9050	Granulocytes, pheresis unit		K	9506	21.7847	\$1,387.55		\$277.51
P9051	Blood, l/r, cmv-neg		K	1010	2.3221	\$147.90		\$29.58
P9052	Platelets, hla-m, l/r, unit		K	1011	10.1413	\$645.94		\$129.19
P9053	Plt, pher, l/r cmv-neg, irr		K	1020	10.7787	\$686.54		\$137.31
P9054	Blood, l/r, froz/degly/wash		K	1016	3.4353	\$218.81		\$43.76
P9055	Plt, aph/pher, l/r, cmv-neg		K	1017	7.6733	\$488.74		\$97.75
P9056	Blood, l/r, irradiated		K	1018	2.3099	\$147.13		\$29.43
P9057	RBC, frz/deg/wsh, l/r, irrads		K	1021	5.8716	\$373.99		\$74.80
P9058	RBC, l/r, cmv-neg, irrads		K	1022	4.1363	\$263.46		\$52.69
P9059	Plasma, frz between 8-24hour		K	0955	1.2235	\$77.93		\$15.59
P9060	Fr frz plasma donor retested		K	9503	0.8264	\$52.64		\$10.53
P9603	One-way allow prorated miles		A					
P9604	One-way allow prorated trip		A					
P9612	Catheterize for urine spec		A					
P9615	Urine specimen collect mult		N					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
Q0035	Cardiokymography		X	0100	2.5547	\$162.72	\$41.44	\$32.54
Q0081	Infusion ther other than che		B					
Q0083	Chemo by other than infusion		B					
Q0084	Chemotherapy by infusion		B					
Q0085	Chemo by both infusion and o		B					
Q0091	Obtaining screen pap smear		T	0191	0.1309	\$8.34	\$2.36	\$1.67
Q0092	Set up port xray equipment		N					
Q0111	Wet mounts/ w preparations		A					
Q0112	Potassium hydroxide preps		A					
Q0113	Pinworm examinations		A					
Q0114	Fern test		A					
Q0115	Post-coital mucous exam		A					
Q0144	Azithromycin dihydrate, oral		E					
Q0163	Diphenhydramine HCl 50mg		N					
Q0164	Prochlorperazine maleate 5mg		N					
Q0165	Prochlorperazine maleate10mg		B					
Q0166	Granisetron HCl 1 mg oral		K	0765		\$49.96		\$9.99
Q0167	Dronabinol 2.5mg oral		N					
Q0168	Dronabinol 5mg oral		B					
Q0169	Promethazine HCl 12.5mg oral		N					
Q0170	Promethazine HCl 25 mg oral		B					
Q0171	Chlorpromazine HCl 10mg oral		N					
Q0172	Chlorpromazine HCl 25mg oral		B					
Q0173	Trimethobenzamide HCl 250mg		N					
Q0174	Thiethylperazine maleate10mg		N					
Q0175	Perphenazine 4mg oral		N					
Q0176	Perphenazine 8mg oral		B					
Q0177	Hydroxyzine pamoate 25mg		N					
Q0178	Hydroxyzine pamoate 50mg		B					
Q0179	Ondansetron HCl 8mg oral		K	0769		\$18.37		\$3.67
Q0180	Dolasetron mesylate oral		K	0763		\$43.77		\$8.75
Q0181	Unspecified oral anti-emetic		E					
Q0480	Driver pneumatic vad, rep		A					
Q0481	Micropcsr cu elec vad, rep		A					
Q0482	Micropcsr cu combo vad, rep		A					
Q0483	Monitor elec vad, rep		A					
Q0484	Monitor elec or comb vad rep		A					
Q0485	Monitor cable elec vad, rep		A					
Q0486	Mon cable elec/pneum vad rep		A					
Q0487	Leads any type vad, rep only		A					
Q0488	Pwr pack base elec vad, rep		A					
Q0489	Pwr pck base combo vad, rep		A					
Q0490	Emr pwr source elec vad, rep		A					
Q0491	Emr pwr source combo vad rep		A					
Q0492	Emr pwr cbl elec vad, rep		A					
Q0493	Emr pwr cbl combo vad, rep		A					
Q0494	Emr hd pmp elec/combo, rep		A					
Q0495	Charger elec/combo vad, rep		A					
Q0496	Battery elec/combo vad, rep		A					
Q0497	Bat clips elec/comb vad, rep		A					
Q0498	Holster elec/combo vad, rep		A					
Q0499	Belt/vest elec/combo vad rep		A					
Q0500	Filters elec/combo vad, rep		A					
Q0501	Shwr cov elec/combo vad, rep		A					
Q0502	Mobility cart pneum vad, rep		A					
Q0503	Battery pneum vad replacemnt		A					
Q0504	Pwr adpt pneum vad, rep veh		A					
Q0505	Misc supply/accessory vad		A					
Q0510	Dispens fee immunosuppressive		B					
Q0511	Sup fee antiem,antica,immuno		B					
Q0512	Px sup fee anti-can sub pres		B					
Q0513	Disp fee inhal drugs/30 days		B					
Q0514	Disp fee inhal drugs/90 days		B					
Q0515	Sermorelin acetate injection		K	3050		\$1.74		\$0.35
Q1003	Ntiol category 3		N					
Q1004	Ntiol category 4		E					
Q1005	Ntiol category 5	CH	E					
Q2004	Bladder calculi irrig sol	CH	N					
Q2009	Fosphenytoin, 50 mg		K	7028		\$5.76		\$1.15
Q2017	Teniposide, 50 mg		K	7035		\$280.26		\$56.05
Q3001	Brachytherapy Radioelements		B					
Q3014	Telehealth facility fee		A					
Q3025	IM inj interferon beta 1-a		K	9022		\$118.84		\$23.77
Q3026	Subc inj interferon beta-1a		E					
Q3031	Collagen skin test		N					
Q4001	Cast sup body cast plaster		B					
Q4002	Cast sup body cast fiberglas		B					
Q4003	Cast sup shoulder cast plstr		B					
Q4004	Cast sup shoulder cast fbrgl		B					
Q4005	Cast sup long arm adult plst		B					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
Q4006	Cast sup long arm adult fbrg		B					
Q4007	Cast sup long arm ped plster		B					
Q4008	Cast sup long arm ped fbrgls		B					
Q4009	Cast sup sht arm adult plstr		B					
Q4010	Cast sup sht arm adult fbrgl		B					
Q4011	Cast sup sht arm ped plaster		B					
Q4012	Cast sup sht arm ped fbrgls		B					
Q4013	Cast sup gauntlet plaster		B					
Q4014	Cast sup gauntlet fiberglass		B					
Q4015	Cast sup gauntlet ped plster		B					
Q4016	Cast sup gauntlet ped fbrgls		B					
Q4017	Cast sup lng arm splint plst		B					
Q4018	Cast sup lng arm splint fbrg		B					
Q4019	Cast sup lng arm splnt ped p		B					
Q4020	Cast sup lng arm splnt ped f		B					
Q4021	Cast sup sht arm splint plst		B					
Q4022	Cast sup sht arm splint fbrg		B					
Q4023	Cast sup sht arm splnt ped p		B					
Q4024	Cast sup sht arm splnt ped f		B					
Q4025	Cast sup hip spica plaster		B					
Q4026	Cast sup hip spica fiberglas		B					
Q4027	Cast sup hip spica ped plstr		B					
Q4028	Cast sup hip spica ped fbrgl		B					
Q4029	Cast sup long leg plaster		B					
Q4030	Cast sup long leg fiberglass		B					
Q4031	Cast sup lng leg ped plaster		B					
Q4032	Cast sup lng leg ped fbrgls		B					
Q4033	Cast sup lng leg cylinder pl		B					
Q4034	Cast sup lng leg cylinder fb		B					
Q4035	Cast sup lngleg cylindr ped p		B					
Q4036	Cast sup lngleg cylindr ped f		B					
Q4037	Cast sup shrt leg plaster		B					
Q4038	Cast sup shrt leg fiberglass		B					
Q4039	Cast sup shrt leg ped plster		B					
Q4040	Cast sup shrt leg ped fbrgls		B					
Q4041	Cast sup lng leg splnt plstr		B					
Q4042	Cast sup lng leg splnt fbrgl		B					
Q4043	Cast sup lng leg splnt ped p		B					
Q4044	Cast sup lng leg splnt ped f		B					
Q4045	Cast sup sht leg splnt plstr		B					
Q4046	Cast sup sht leg splnt fbrgl		B					
Q4047	Cast sup sht leg splnt ped p		B					
Q4048	Cast sup sht leg splnt ped f		B					
Q4049	Finger splint, static		B					
Q4050	Cast supplies unlisted		B					
Q4051	Splint supplies misc		B					
Q4079	Natalizumab injection	CH	D					
Q4080	Iloprost non-comp unit dose		Y					
Q4081	Epoetin alfa, 100 units ESRD		A					
Q4082	Drug/bio NOC part B drug CAP		B					
Q4083	Hyalgan/supartz inj per dose	CH	D					
Q4084	Synvisc inj per dose	CH	D					
Q4085	Euflexxa inj per dose	CH	D					
Q4086	Orthovisc inj per dose	CH	D					
Q4087	Octagam injection	CH	D					
Q4088	Gammagard liquid injection	CH	D					
Q4089	Rhophylac injection	CH	D					
Q4090	HepaGam B IM injection	CH	D					
Q4091	Flebogamma injection	CH	D					
Q4092	Gamunex injection	CH	D					
Q4093	Albuterol inh non-comp con	CH	D					
Q4094	Albuterol inh non-comp u d	CH	D					
Q4095	Reclast injection	CH	D					
Q5001	Hospice in patient home		B					
Q5002	Hospice in assisted living		B					
Q5003	Hospice in LT/non-skilled NF		B					
Q5004	Hospice in SNF		B					
Q5005	Hospice, inpatient hospital		B					
Q5006	Hospice in hospice facility		B					
Q5007	Hospice in LTCH		B					
Q5008	Hospice in inpatient psych		B					
Q5009	Hospice care, NOS		B					
Q9945	LOCM <=149 mg/ml iodine, 1ml	CH	D					
Q9946	LOCM 150–199mg/ml iodine, 1ml	CH	D					
Q9947	LOCM 200–249mg/ml iodine, 1ml	CH	D					
Q9948	LOCM 250–299mg/ml iodine, 1ml	CH	D					
Q9949	LOCM 300–349mg/ml iodine, 1ml	CH	D					
Q9950	LOCM 350–399mg/ml iodine, 1ml	CH	D					
Q9951	LOCM >= 400 mg/ml iodine, 1ml	CH	N					
Q9952	Inj Gad-base MR contrast, 1ml	CH	D					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
Q9953	Inj Fe-based MR contrast,1ml	CH	N					
Q9954	Oral MR contrast, 100 ml	CH	N					
Q9955	Inj perflerane lip micros,ml	CH	N					
Q9956	Inj octafluoropropane mic,ml	CH	N					
Q9957	Inj perflutren lip micros,ml	CH	N					
Q9958	HOCM <=149 mg/ml iodine, 1ml		N					
Q9959	HOCM 150–199mg/ml iodine,1ml		N					
Q9960	HOCM 200–249mg/ml iodine,1ml		N					
Q9961	HOCM 250–299mg/ml iodine,1ml		N					
Q9962	HOCM 300–349mg/ml iodine,1ml		N					
Q9963	HOCM 350–399mg/ml iodine,1ml		N					
Q9964	HOCM>= 400mg/ml iodine, 1ml		N					
Q9965	LOCM 100–199mg/ml iodine,1ml	NI	N					
Q9966	LOCM 200–299mg/ml iodine,1ml	NI	N					
Q9967	LOCM 300–399mg/ml iodine,1ml	NI	N					
R0070	Transport portable x-ray		B					
R0075	Transport port x-ray multipl		B					
R0076	Transport portable EKG		B					
V2020	Vision svcs frames purchases		A					
V2025	Eyeglasses delux frames		E					
V2100	Lens spher single plano 4.00		A					
V2101	Single visn sphere 4.12–7.00		A					
V2102	Singl visn sphere 7.12–20.00		A					
V2103	Spherocylindr 4.00d/12–2.00d		A					
V2104	Spherocylindr 4.00d/2.12–4d		A					
V2105	Spherocylinder 4.00d/4.25–6d		A					
V2106	Spherocylinder 4.00d/>6.00d		A					
V2107	Spherocylinder 4.25d/12–2d		A					
V2108	Spherocylinder 4.25d/2.12–4d		A					
V2109	Spherocylinder 4.25d/4.25–6d		A					
V2110	Spherocylinder 4.25d/over 6d		A					
V2111	Spherocylindr 7.25d/.25–2.25		A					
V2112	Spherocylindr 7.25d/2.25–4d		A					
V2113	Spherocylindr 7.25d/4.25–6d		A					
V2114	Spherocylinder over 12.00d		A					
V2115	Lens lenticular bifocal		A					
V2118	Lens aniseikonic single		A					
V2121	Lenticular lens, single		A					
V2199	Lens single vision not oth c		A					
V2200	Lens spher bifoc plano 4.00d		A					
V2201	Lens sphere bifocal 4.12–7.0		A					
V2202	Lens sphere bifocal 7.12–20		A					
V2203	Lens sphcyl bifocal 4.00d/.1		A					
V2204	Lens sphcyl bifocal 4.00d/2.1		A					
V2205	Lens sphcyl bifocal 4.00d/4.2		A					
V2206	Lens sphcyl bifocal 4.00d/ove		A					
V2207	Lens sphcyl bifocal 4.25–7d/		A					
V2208	Lens sphcyl bifocal 4.25–7/2		A					
V2209	Lens sphcyl bifocal 4.25–7/4		A					
V2210	Lens sphcyl bifocal 4.25–7/ov		A					
V2211	Lens sphcyl bifo 7.25–12/.25		A					
V2212	Lens sphcyl bifo 7.25–12/2.2		A					
V2213	Lens sphcyl bifo 7.25–12/4.2		A					
V2214	Lens sphcyl bifocal over 12		A					
V2215	Lens lenticular bifocal		A					
V2218	Lens aniseikonic bifocal		A					
V2219	Lens bifocal seg width over		A					
V2220	Lens bifocal add over 3.25d		A					
V2221	Lenticular lens, bifocal		A					
V2299	Lens bifocal speciality		A					
V2300	Lens sphere trifocal 4.00d		A					
V2301	Lens sphere trifocal 4.12–7		A					
V2302	Lens sphere trifocal 7.12–20		A					
V2303	Lens sphcyl trifocal 4.0/.12-		A					
V2304	Lens sphcyl trifocal 4.0/2.25		A					
V2305	Lens sphcyl trifocal 4.0/4.25		A					
V2306	Lens sphcyl trifocal 4.00/>6		A					
V2307	Lens sphcyl trifocal 4.25–7/		A					
V2308	Lens sphc trifocal 4.25–7/2		A					
V2309	Lens sphc trifocal 4.25–7/4		A					
V2310	Lens sphc trifocal 4.25–7/>6		A					
V2311	Lens sphc trifo 7.25–12/.25-		A					
V2312	Lens sphc trifo 7.25–12/2.25		A					
V2313	Lens sphc trifo 7.25–12/4.25		A					
V2314	Lens sphcyl trifocal over 12		A					
V2315	Lens lenticular trifocal		A					
V2318	Lens aniseikonic trifocal		A					
V2319	Lens trifocal seg width > 28		A					
V2320	Lens trifocal add over 3.25d		A					
V2321	Lenticular lens, trifocal		A					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
V2399	Lens trifocal speciality		A					
V2410	Lens variab asphericity sing		A					
V2430	Lens variable asphericity bi		A					
V2499	Variable asphericity lens		A					
V2500	Contact lens pmma spherical		A					
V2501	Cntct lens pmma-toric/prism		A					
V2502	Contact lens pmma bifocal		A					
V2503	Cntct lens pmma color vision		A					
V2510	Cntct gas permeable sphericl		A					
V2511	Cntct toric prism ballast		A					
V2512	Cntct lens gas permbl bifocl		A					
V2513	Contact lens extended wear		A					
V2520	Contact lens hydrophilic		A					
V2521	Cntct lens hydrophilic toric		A					
V2522	Cntct lens hydrophil bifocl		A					
V2523	Cntct lens hydrophil extend		A					
V2530	Contact lens gas impermeable		A					
V2531	Contact lens gas permeable		A					
V2599	Contact lens/es other type		A					
V2600	Hand held low vision aids		A					
V2610	Single lens spectacle mount		A					
V2615	Telescop/othr compound lens		A					
V2623	Plastic eye prosth custom		A					
V2624	Polishing artificial eye		A					
V2625	Enlargemnt of eye prosthesis		A					
V2626	Reduction of eye prosthesis		A					
V2627	Scleral cover shell		A					
V2628	Fabrication & fitting		A					
V2629	Prosthetic eye other type		A					
V2630	Anter chamber intraocul lens		N					
V2631	Iris support intraoclr lens		N					
V2632	Post chmbr intraocular lens		N					
V2700	Balance lens		A					
V2702	Deluxe lens feature		E					
V2710	Glass/plastic slab off prism		A					
V2715	Prism lens/es		A					
V2718	Fresnell prism press-on lens		A					
V2730	Special base curve		A					
V2744	Tint photochromatic lens/es		A					
V2745	Tint, any color/solid/grad		A					
V2750	Anti-reflective coating		A					
V2755	UV lens/es		A					
V2756	Eye glass case		E					
V2760	Scratch resistant coating		A					
V2761	Mirror coating		B					
V2762	Polarization, any lens		A					
V2770	Occluder lens/es		A					
V2780	Oversize lens/es		A					
V2781	Progressive lens per lens		B					
V2782	Lens, 1.54–1.65 p/1.60–1.79g		A					
V2783	Lens, >= 1.66 p/>=1.80 g		A					
V2784	Lens polycarb or equal		A					
V2785	Corneal tissue processing		F					
V2786	Occupational multifocal lens		A					
V2787	Astigmatism-correct function	NI	E					
V2788	Presbyopia-correct function		E					
V2790	Amniotic membrane		N					
V2797	Vis item/svc in other code		A					
V2799	Miscellaneous vision service		A					
V5008	Hearing screening		E					
V5010	Assessment for hearing aid		E					
V5011	Hearing aid fitting/checking		E					
V5014	Hearing aid repair/modifying		E					
V5020	Conformity evaluation		E					
V5030	Body-worn hearing aid air		E					
V5040	Body-worn hearing aid bone		E					
V5050	Hearing aid monaural in ear		E					
V5060	Behind ear hearing aid		E					
V5070	Glasses air conduction		E					
V5080	Glasses bone conduction		E					
V5090	Hearing aid dispensing fee		E					
V5095	Implant mid ear hearing pros		E					
V5100	Body-worn bilat hearing aid		E					
V5110	Hearing aid dispensing fee		E					
V5120	Body-worn binaur hearing aid		E					
V5130	In ear binaural hearing aid		E					
V5140	Behind ear binaur hearing ai		E					
V5150	Glasses binaural hearing aid		E					
V5160	Dispensing fee binaural		E					
V5170	Within ear cros hearing aid		E					

ADDENDUM B.—OPPS PAYMENT BY HCPCS CODE FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	APC	Relative weight	Payment rate	National unadjusted copayment	Minimum unadjusted copayment
V5180	Behind ear cros hearing aid		E					
V5190	Glasses cros hearing aid		E					
V5200	Cros hearing aid dispens fee		E					
V5210	In ear bicros hearing aid		E					
V5220	Behind ear bicros hearing ai		E					
V5230	Glasses bicros hearing aid		E					
V5240	Dispensing fee bicros		E					
V5241	Dispensing fee, monaural		E					
V5242	Hearing aid, monaural, cic		E					
V5243	Hearing aid, monaural, itc		E					
V5244	Hearing aid, prog, mon, cic		E					
V5245	Hearing aid, prog, mon, itc		E					
V5246	Hearing aid, prog, mon, ite		E					
V5247	Hearing aid, prog, mon, bte		E					
V5248	Hearing aid, binaural, cic		E					
V5249	Hearing aid, binaural, itc		E					
V5250	Hearing aid, prog, bin, cic		E					
V5251	Hearing aid, prog, bin, itc		E					
V5252	Hearing aid, prog, bin, ite		E					
V5253	Hearing aid, prog, bin, bte		E					
V5254	Hearing id, digit, mon, cic		E					
V5255	Hearing aid, digit, mon, itc		E					
V5256	Hearing aid, digit, mon, ite		E					
V5257	Hearing aid, digit, mon, bte		E					
V5258	Hearing aid, digit, bin, cic		E					
V5259	Hearing aid, digit, bin, itc		E					
V5260	Hearing aid, digit, bin, ite		E					
V5261	Hearing aid, digit, bin, bte		E					
V5262	Hearing aid, disp, monaural		E					
V5263	Hearing aid, disp, binaural		E					
V5264	Ear mold/insert		E					
V5265	Ear mold/insert, disp		E					
V5266	Battery for hearing device		E					
V5267	Hearing aid supply/accessory		E					
V5268	ALD Telephone Amplifier		E					
V5269	Alerting device, any type		E					
V5270	ALD, TV amplifier, any type		E					
V5271	ALD, TV caption decoder		E					
V5272	Tdd		E					
V5273	ALD for cochlear implant		E					
V5274	ALD unspecified		E					
V5275	Ear impression		E					
V5298	Hearing aid noc		E					
V5299	Hearing service		B					
V5336	Repair communication device		E					
V5362	Speech screening		E					
V5363	Language screening		E					
V5364	Dysphagia screening		E					

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008
 [Including Ancillary Services for Which Payment Is Packaged]

HCPCS code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
0028T	Dexa body composition study		N1		
0042T	Ct perfusion w/contrast, cbf		N1		
0054T	Bone surgery using computer	CH	D5		
0055T	Bone surgery using computer	CH	D5		
0056T	Bone surgery using computer	CH	D5		
0067T	Ct colonography;dx		Z2	3.0109	\$124.65
0071T	U/s leiomyomata ablate <200		Z2	61.6965	\$2,554.30
0072T	U/s leiomyomata ablate >200		Z2	61.6965	\$2,554.30
0073T	Delivery, comp imrt		Z2	5.4582	\$225.97
0126T	Chd risk imt study		N1		
0144T	Ct heart wo dye; qual calc		Z2	1.5839	\$65.58
0145T	Ct heart w/wo dye funct		Z2	4.7005	\$194.61
0146T	Ccta w/wo dye		Z2	4.7005	\$194.61
0147T	Ccta w/wo, quan calcium		Z2	4.7005	\$194.61
0148T	Ccta w/wo, strxr		Z2	4.7005	\$194.61
0149T	Ccta w/wo, strxr quan calc		Z2	4.7005	\$194.61
0150T	Ccta w/wo, disease strxr		Z2	4.7005	\$194.61
0151T	Ct heart funct add-on		Z2	1.5839	\$65.58
0159T	Cad breast mri		N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
0174T	Cad cxr with interp		N1		
0175T	Cad cxr remote		N1		
0182T	Hdr elect brachytherapy	CH	Z2	27.4752	\$1,137.50
0185T	Comptr probability analysis	NI	N1		
70010	Contrast x-ray of brain	CH	N1		
70015	Contrast x-ray of brain	CH	N1		
70030	X-ray eye for foreign body		Z3	0.3949	\$16.35
70100	X-ray exam of jaw		Z3	0.4526	\$18.74
70110	X-ray exam of jaw		Z3	0.5514	\$22.83
70120	X-ray exam of mastoids		Z3	0.5183	\$21.46
70130	X-ray exam of mastoids		Z2	0.6954	\$28.79
70134	X-ray exam of middle ear		Z3	0.6253	\$25.89
70140	X-ray exam of facial bones		Z3	0.4609	\$19.08
70150	X-ray exam of facial bones		Z3	0.6336	\$26.23
70160	X-ray exam of nasal bones		Z3	0.4773	\$19.76
70170	X-ray exam of tear duct	CH	N1		
70190	X-ray exam of eye sockets		Z3	0.5183	\$21.46
70200	X-ray exam of eye sockets		Z3	0.6418	\$26.57
70210	X-ray exam of sinuses		Z3	0.4691	\$19.42
70220	X-ray exam of sinuses		Z3	0.5925	\$24.53
70240	X-ray exam, pituitary saddle		Z3	0.3949	\$16.35
70250	X-ray exam of skull		Z3	0.5101	\$21.12
70260	X-ray exam of skull		Z3	0.6831	\$28.28
70300	X-ray exam of teeth		Z3	0.1894	\$7.84
70310	X-ray exam of teeth		Z3	0.4855	\$20.10
70320	Full mouth x-ray of teeth		Z2	0.5749	\$23.80
70328	X-ray exam of jaw joint		Z3	0.4362	\$18.06
70330	X-ray exam of jaw joints	CH	Z2	0.6954	\$28.79
70332	X-ray exam of jaw joint	CH	N1		
70336	Magnetic image, jaw joint		Z2	4.883	\$202.16
70350	X-ray head for orthodontia		Z3	0.2715	\$11.24
70355	Panoramic x-ray of jaws		Z3	0.3292	\$13.63
70360	X-ray exam of neck		Z3	0.3785	\$15.67
70370	Throat x-ray & fluoroscopy		Z3	1.1768	\$48.72
70371	Speech evaluation, complex		Z2	1.3271	\$54.94
70373	Contrast x-ray of larynx	CH	N1		
70380	X-ray exam of salivary gland		Z3	0.5925	\$24.53
70390	X-ray exam of salivary duct	CH	N1		
70450	Ct head/brain w/o dye		Z2	3.0109	\$124.65
70460	Ct head/brain w/dye		Z2	4.3564	\$180.36
70470	Ct head/brain w/o & w/dye		Z2	5.1125	\$211.66
70480	Ct orbit/ear/fossa w/o dye		Z2	3.0109	\$124.65
70481	Ct orbit/ear/fossa w/dye		Z2	4.3564	\$180.36
70482	Ct orbit/ear/fossa w/o&w/dye		Z2	5.1125	\$211.66
70486	Ct maxillofacial w/o dye		Z2	3.0109	\$124.65
70487	Ct maxillofacial w/dye		Z2	4.3564	\$180.36
70488	Ct maxillofacial w/o & w/dye		Z2	5.1125	\$211.66
70490	Ct soft tissue neck w/o dye		Z2	3.0109	\$124.65
70491	Ct soft tissue neck w/dye		Z2	4.3564	\$180.36
70492	Ct sft tsue nck w/o & w/dye		Z2	5.1125	\$211.66
70496	Ct angiography, head		Z2	5.1641	\$213.80
70498	Ct angiography, neck		Z2	5.1641	\$213.80
70540	Mri orbit/face/neck w/o dye		Z2	5.3933	\$223.29
70542	Mri orbit/face/neck w/dye		Z2	6.235	\$258.14
70543	Mri orbit/fac/nck w/o & w/dye		Z2	8.2463	\$341.41
70544	Mr angiography head w/o dye		Z2	5.3933	\$223.29
70545	Mr angiography head w/dye		Z2	6.235	\$258.14
70546	Mr angiograph head w/o&w/dye		Z2	8.2463	\$341.41
70547	Mr angiography neck w/o dye		Z2	5.3933	\$223.29
70548	Mr angiography neck w/dye		Z2	6.235	\$258.14
70549	Mr angiograph neck w/o&w/dye		Z2	8.2463	\$341.41
70551	Mri brain w/o dye		Z2	5.3933	\$223.29
70552	Mri brain w/dye		Z2	6.235	\$258.14
70553	Mri brain w/o & w/dye		Z2	8.2463	\$341.41
70554	Fmri brain by tech		Z2	5.3933	\$223.29
70555	Fmri brain by phys/psych		Z2	5.3933	\$223.29
70557	Mri brain w/o dye		Z2	5.3933	\$223.29
70558	Mri brain w/dye		Z2	6.235	\$258.14

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPCS code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
70559	Mri brain w/o & w/dye		Z2	8.2463	\$341.41
71010	Chest x-ray		Z3	0.3456	\$14.31
71015	Chest x-ray		Z3	0.4196	\$17.37
71020	Chest x-ray		Z3	0.4609	\$19.08
71021	Chest x-ray		Z3	0.5514	\$22.83
71022	Chest x-ray		Z3	0.6253	\$25.89
71023	Chest x-ray and fluoroscopy		Z3	0.8968	\$37.13
71030	Chest x-ray		Z3	0.6582	\$27.25
71034	Chest x-ray and fluoroscopy		Z2	1.3271	\$54.94
71035	Chest x-ray		Z3	0.5101	\$21.12
71040	Contrast x-ray of bronchi	CH	N1		
71060	Contrast x-ray of bronchi	CH	N1		
71090	X-ray & pacemaker insertion	CH	N1		
71100	X-ray exam of ribs		Z3	0.4609	\$19.08
71101	X-ray exam of ribs/chest		Z3	0.5514	\$22.83
71110	X-ray exam of ribs		Z3	0.6007	\$24.87
71111	X-ray exam of ribs/chest		Z3	0.757	\$31.34
71120	X-ray exam of breastbone		Z3	0.4937	\$20.44
71130	X-ray exam of breastbone		Z3	0.5679	\$23.51
71250	Ct thorax w/o dye		Z2	3.0109	\$124.65
71260	Ct thorax w/dye		Z2	4.3564	\$180.36
71270	Ct thorax w/o & w/dye		Z2	5.1125	\$211.66
71275	Ct angiography, chest		Z2	5.1641	\$213.80
71550	Mri chest w/o dye		Z2	5.3933	\$223.29
71551	Mri chest w/dye		Z2	6.235	\$258.14
71552	Mri chest w/o & w/dye		Z2	8.2463	\$341.41
72010	X-ray exam of spine		Z2	0.6954	\$28.79
72020	X-ray exam of spine		Z3	0.3456	\$14.31
72040	X-ray exam of neck spine		Z3	0.5348	\$22.14
72050	X-ray exam of neck spine		Z3	0.7652	\$31.68
72052	X-ray exam of neck spine		Z3	0.9874	\$40.88
72069	X-ray exam of trunk spine		Z3	0.4773	\$19.76
72070	X-ray exam of thoracic spine		Z3	0.5019	\$20.78
72072	X-ray exam of thoracic spine		Z3	0.5843	\$24.19
72074	X-ray exam of thoracic spine	CH	Z2	0.6954	\$28.79
72080	X-ray exam of trunk spine		Z3	0.5266	\$21.80
72090	X-ray exam of trunk spine		Z3	0.6418	\$26.57
72100	X-ray exam of lower spine		Z3	0.5761	\$23.85
72110	X-ray exam of lower spine		Z3	0.7983	\$33.05
72114	X-ray exam of lower spine		Z3	1.078	\$44.63
72120	X-ray exam of lower spine		Z3	0.7734	\$32.02
72125	Ct neck spine w/o dye		Z2	3.0109	\$124.65
72126	Ct neck spine w/dye		Z2	4.3564	\$180.36
72127	Ct neck spine w/o & w/dye		Z2	5.1125	\$211.66
72128	Ct chest spine w/o dye		Z2	3.0109	\$124.65
72129	Ct chest spine w/dye		Z2	4.3564	\$180.36
72130	Ct chest spine w/o & w/dye		Z2	5.1125	\$211.66
72131	Ct lumbar spine w/o dye		Z2	3.0109	\$124.65
72132	Ct lumbar spine w/dye		Z2	4.3564	\$180.36
72133	Ct lumbar spine w/o & w/dye		Z2	5.1125	\$211.66
72141	Mri neck spine w/o dye		Z2	5.3933	\$223.29
72142	Mri neck spine w/dye		Z2	6.235	\$258.14
72146	Mri chest spine w/o dye		Z2	5.3933	\$223.29
72147	Mri chest spine w/dye		Z2	6.235	\$258.14
72148	Mri lumbar spine w/o dye		Z2	5.3933	\$223.29
72149	Mri lumbar spine w/dye		Z2	6.235	\$258.14
72156	Mri neck spine w/o & w/dye		Z2	8.2463	\$341.41
72157	Mri chest spine w/o & w/dye		Z2	8.2463	\$341.41
72158	Mri lumbar spine w/o & w/dye		Z2	8.2463	\$341.41
72170	X-ray exam of pelvis		Z3	0.3949	\$16.35
72190	X-ray exam of pelvis		Z3	0.5925	\$24.53
72191	Ct angiograph pelv w/o&w/dye		Z2	5.1641	\$213.80
72192	Ct pelvis w/o dye		Z2	3.0109	\$124.65
72193	Ct pelvis w/dye		Z2	4.3564	\$180.36
72194	Ct pelvis w/o & w/dye		Z2	5.1125	\$211.66
72195	Mri pelvis w/o dye		Z2	5.3933	\$223.29
72196	Mri pelvis w/dye		Z2	6.235	\$258.14
72197	Mri pelvis w/o & w/dye		Z2	8.2463	\$341.41

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
72200	X-ray exam sacroiliac joints		Z3	0.4362	\$18.06
72202	X-ray exam sacroiliac joints		Z3	0.5348	\$22.14
72220	X-ray exam of tailbone		Z3	0.4526	\$18.74
72240	Contrast x-ray of neck spine	CH	N1		
72255	Contrast x-ray, thorax spine	CH	N1		
72265	Contrast x-ray, lower spine	CH	N1		
72270	Contrast x-ray, spine	CH	N1		
72275	Epidurography	CH	N1		
72285	X-ray c/t spine disk	CH	N1		
72291	Perq vertebroplasty, fluor	CH	N1		
72292	Perq vertebroplasty, ct	CH	N1		
72295	X-ray of lower spine disk	CH	N1		
73000	X-ray exam of collar bone		Z3	0.4196	\$17.37
73010	X-ray exam of shoulder blade		Z3	0.428	\$17.72
73020	X-ray exam of shoulder		Z3	0.3539	\$14.65
73030	X-ray exam of shoulder		Z3	0.4444	\$18.40
73040	Contrast x-ray of shoulder	CH	N1		
73050	X-ray exam of shoulders		Z3	0.5432	\$22.49
73060	X-ray exam of humerus		Z3	0.4444	\$18.40
73070	X-ray exam of elbow		Z3	0.4196	\$17.37
73080	X-ray exam of elbow		Z3	0.5183	\$21.46
73085	Contrast x-ray of elbow	CH	N1		
73090	X-ray exam of forearm		Z3	0.4196	\$17.37
73092	X-ray exam of arm, infant		Z3	0.4196	\$17.37
73100	X-ray exam of wrist		Z3	0.428	\$17.72
73110	X-ray exam of wrist		Z3	0.5101	\$21.12
73115	Contrast x-ray of wrist	CH	N1		
73120	X-ray exam of hand		Z3	0.4113	\$17.03
73130	X-ray exam of hand		Z3	0.4609	\$19.08
73140	X-ray exam of finger(s)		Z3	0.4362	\$18.06
73200	Ct upper extremity w/o dye		Z2	3.0109	\$124.65
73201	Ct upper extremity w/dye		Z2	4.3564	\$180.36
73202	Ct uppr extremity w/o&w/dye		Z2	5.1125	\$211.66
73206	Ct angio upr extrm w/o&w/dye		Z2	5.1641	\$213.80
73218	Mri upper extremity w/o dye		Z2	5.3933	\$223.29
73219	Mri upper extremity w/dye		Z2	6.235	\$258.14
73220	Mri uppr extremity w/o&w/dye		Z2	8.2463	\$341.41
73221	Mri joint upr extrem w/o dye		Z2	5.3933	\$223.29
73222	Mri joint upr extrem w/dye		Z2	6.235	\$258.14
73223	Mri joint upr extr w/o&w/dye		Z2	8.2463	\$341.41
73500	X-ray exam of hip		Z3	0.3703	\$15.33
73510	X-ray exam of hip		Z3	0.5266	\$21.80
73520	X-ray exam of hips		Z3	0.5596	\$23.17
73525	Contrast x-ray of hip	CH	N1		
73530	X-ray exam of hip	CH	N1		
73540	X-ray exam of pelvis & hips		Z3	0.5348	\$22.14
73542	X-ray exam, sacroiliac joint	CH	N1		
73550	X-ray exam of thigh		Z3	0.4362	\$18.06
73560	X-ray exam of knee, 1 or 2		Z3	0.428	\$17.72
73562	X-ray exam of knee, 3		Z3	0.5101	\$21.12
73564	X-ray exam, knee, 4 or more		Z3	0.5761	\$23.85
73565	X-ray exam of knees		Z3	0.4444	\$18.40
73580	Contrast x-ray of knee joint	CH	N1		
73590	X-ray exam of lower leg		Z3	0.4113	\$17.03
73592	X-ray exam of leg, infant		Z3	0.4196	\$17.37
73600	X-ray exam of ankle		Z3	0.4113	\$17.03
73610	X-ray exam of ankle		Z3	0.4691	\$19.42
73615	Contrast x-ray of ankle	CH	N1		
73620	X-ray exam of foot		Z3	0.4031	\$16.69
73630	X-ray exam of foot		Z3	0.4609	\$19.08
73650	X-ray exam of heel		Z3	0.3949	\$16.35
73660	X-ray exam of toe(s)		Z3	0.4196	\$17.37
73700	Ct lower extremity w/o dye		Z2	3.0109	\$124.65
73701	Ct lower extremity w/dye		Z2	4.3564	\$180.36
73702	Ct lwr extremity w/o&w/dye		Z2	5.1125	\$211.66
73706	Ct angio lwr extr w/o&w/dye		Z2	5.1641	\$213.80
73718	Mri lower extremity w/o dye		Z2	5.3933	\$223.29
73719	Mri lower extremity w/dye		Z2	6.235	\$258.14

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
73720	Mri lwr extremity w/o&w/dye	Z2	8.2463	\$341.41
73721	Mri jnt of lwr extre w/o dye	Z2	5.3933	\$223.29
73722	Mri joint of lwr extr w/dye	Z2	6.235	\$258.14
73723	Mri joint lwr extr w/o&w/dye	Z2	8.2463	\$341.41
74000	X-ray exam of abdomen	Z3	0.3785	\$15.67
74010	X-ray exam of abdomen	Z3	0.5266	\$21.80
74020	X-ray exam of abdomen	Z3	0.5514	\$22.83
74022	X-ray exam series, abdomen	Z3	0.6582	\$27.25
74150	Ct abdomen w/o dye	Z2	3.0109	\$124.65
74160	Ct abdomen w/dye	Z2	4.3564	\$180.36
74170	Ct abdomen w/o & w/dye	Z2	5.1125	\$211.66
74175	Ct angio abdom w/o & w/dye	Z2	5.1641	\$213.80
74181	Mri abdomen w/o dye	Z2	5.3933	\$223.29
74182	Mri abdomen w/dye	Z2	6.235	\$258.14
74183	Mri abdomen w/o & w/dye	Z2	8.2463	\$341.41
74190	X-ray exam of peritoneum	CH	N1
74210	Contrst x-ray exam of throat	Z3	1.1604	\$48.04
74220	Contrast x-ray, esophagus	Z3	1.2507	\$51.78
74230	Cine/vid x-ray, throat/esoph	Z3	1.2589	\$52.12
74235	Remove esophagus obstruction	CH	N1
74240	X-ray exam, upper gi tract	CH	Z2	1.3834	\$57.27
74241	X-ray exam, upper gi tract	Z2	1.3834	\$57.27
74245	X-ray exam, upper gi tract	Z2	2.2222	\$92.00
74246	Contrst x-ray uppr gi tract	Z2	1.3834	\$57.27
74247	Contrst x-ray uppr gi tract	Z2	1.3834	\$57.27
74249	Contrst x-ray uppr gi tract	Z2	2.2222	\$92.00
74250	X-ray exam of small bowel	CH	Z2	1.3834	\$57.27
74251	X-ray exam of small bowel	Z2	2.2222	\$92.00
74260	X-ray exam of small bowel	Z2	1.3834	\$57.27
74270	Contrast x-ray exam of colon	Z2	1.3834	\$57.27
74280	Contrast x-ray exam of colon	Z2	2.2222	\$92.00
74283	Contrast x-ray exam of colon	Z2	1.3834	\$57.27
74290	Contrast x-ray, gallbladder	Z3	0.9053	\$37.48
74291	Contrast x-rays, gallbladder	Z3	0.7816	\$32.36
74300	X-ray bile ducts/pancreas	CH	N1
74301	X-rays at surgery add-on	CH	N1
74305	X-ray bile ducts/pancreas	CH	N1
74320	Contrast x-ray of bile ducts	CH	N1
74327	X-ray bile stone removal	CH	N1
74328	X-ray bile duct endoscopy	N1
74329	X-ray for pancreas endoscopy	N1
74330	X-ray bile/panc endoscopy	N1
74340	X-ray guide for gi tube	CH	N1
74350	X-ray guide, stomach tube	CH	D5
74355	X-ray guide, intestinal tube	CH	N1
74360	X-ray guide, gi dilation	CH	N1
74363	X-ray, bile duct dilation	CH	N1
74400	Contrst x-ray, urinary tract	Z3	1.6869	\$69.84
74410	Contrst x-ray, urinary tract	Z3	1.835	\$75.97
74415	Contrst x-ray, urinary tract	Z3	2.1478	\$88.92
74420	Contrst x-ray, urinary tract	Z2	2.6121	\$108.14
74425	Contrst x-ray, urinary tract	CH	N1
74430	Contrast x-ray, bladder	CH	N1
74440	X-ray, male genital tract	CH	N1
74445	X-ray exam of penis	CH	N1
74450	X-ray, urethra/bladder	CH	N1
74455	X-ray, urethra/bladder	CH	N1
74470	X-ray exam of kidney lesion	CH	N1
74475	X-ray control, cath insert	CH	N1
74480	X-ray control, cath insert	CH	N1
74485	X-ray guide, gu dilation	CH	N1
74710	X-ray measurement of pelvis	Z3	0.65	\$26.91
74740	X-ray, female genital tract	CH	N1
74742	X-ray, fallopian tube	CH	N1
74775	X-ray exam of perineum	Z2	2.6121	\$108.14
75552	Heart mri for morph w/o dye	CH	D5
75553	Heart mri for morph w/dye	CH	D5
75554	Cardiac MRI/function	CH	D5

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
75555	Cardiac MRI/limited study	CH	D5
75557	Cardiac mri for morph	NI	Z2	5.3933	\$223.29
75559	Cardiac mri w/stress img	NI	Z2	5.3933	\$223.29
75561	Cardiac mri for morph w/dye	NI	Z2	8.2463	\$341.41
75563	Card mri w/stress img & dye	NI	Z2	8.2463	\$341.41
75600	Contrast x-ray exam of aorta	CH	N1
75605	Contrast x-ray exam of aorta	CH	N1
75625	Contrast x-ray exam of aorta	CH	N1
75630	X-ray aorta, leg arteries	CH	N1
75635	Ct angio abdominal arteries	CH	N1
75650	Artery x-rays, head & neck	CH	N1
75658	Artery x-rays, arm	CH	N1
75660	Artery x-rays, head & neck	CH	N1
75662	Artery x-rays, head & neck	CH	N1
75665	Artery x-rays, head & neck	CH	N1
75671	Artery x-rays, head & neck	CH	N1
75676	Artery x-rays, neck	CH	N1
75680	Artery x-rays, neck	CH	N1
75685	Artery x-rays, spine	CH	N1
75705	Artery x-rays, spine	CH	N1
75710	Artery x-rays, arm/leg	CH	N1
75716	Artery x-rays, arms/legs	CH	N1
75722	Artery x-rays, kidney	CH	N1
75724	Artery x-rays, kidneys	CH	N1
75726	Artery x-rays, abdomen	CH	N1
75731	Artery x-rays, adrenal gland	CH	N1
75733	Artery x-rays, adrenals	CH	N1
75736	Artery x-rays, pelvis	CH	N1
75741	Artery x-rays, lung	CH	N1
75743	Artery x-rays, lungs	CH	N1
75746	Artery x-rays, lung	CH	N1
75756	Artery x-rays, chest	CH	N1
75774	Artery x-ray, each vessel	CH	N1
75790	Visualize a-v shunt	CH	N1
75801	Lymph vessel x-ray, arm/leg	CH	N1
75803	Lymph vessel x-ray, arms/legs	CH	N1
75805	Lymph vessel x-ray, trunk	CH	N1
75807	Lymph vessel x-ray, trunk	CH	N1
75809	Nonvascular shunt, x-ray	CH	N1
75810	Vein x-ray, spleen/liver	CH	N1
75820	Vein x-ray, arm/leg	CH	N1
75822	Vein x-ray, arms/legs	CH	N1
75825	Vein x-ray, trunk	CH	N1
75827	Vein x-ray, chest	CH	N1
75831	Vein x-ray, kidney	CH	N1
75833	Vein x-ray, kidneys	CH	N1
75840	Vein x-ray, adrenal gland	CH	N1
75842	Vein x-ray, adrenal glands	CH	N1
75860	Vein x-ray, neck	CH	N1
75870	Vein x-ray, skull	CH	N1
75872	Vein x-ray, skull	CH	N1
75880	Vein x-ray, eye socket	CH	N1
75885	Vein x-ray, liver	CH	N1
75887	Vein x-ray, liver	CH	N1
75889	Vein x-ray, liver	CH	N1
75891	Vein x-ray, liver	CH	N1
75893	Venous sampling by catheter	CH	N1
75894	X-rays, transcath therapy	CH	N1
75896	X-rays, transcath therapy	CH	N1
75898	Follow-up angiography	CH	N1
75901	Remove cva device obstruct	CH	N1
75902	Remove cva lumen obstruct	CH	N1
75940	X-ray placement, vein filter	CH	N1
75945	Intravascular us	CH	N1
75946	Intravascular us add-on	CH	N1
75960	Transcath iv stent rs&i	CH	N1
75961	Retrieval, broken catheter	CH	N1
75962	Repair arterial blockage	CH	N1

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPCS code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
75964	Repair artery blockage, each	CH	N1		
75966	Repair arterial blockage	CH	N1		
75968	Repair artery blockage, each	CH	N1		
75970	Vascular biopsy	CH	N1		
75978	Repair venous blockage	CH	N1		
75980	Contrast xray exam bile duct	CH	N1		
75982	Contrast xray exam bile duct	CH	N1		
75984	Xray control catheter change	CH	N1		
75989	Abscess drainage under x-ray		N1		
75992	Atherectomy, x-ray exam	CH	N1		
75993	Atherectomy, x-ray exam	CH	N1		
75994	Atherectomy, x-ray exam	CH	N1		
75995	Atherectomy, x-ray exam	CH	N1		
75996	Atherectomy, x-ray exam	CH	N1		
76000	Fluoroscope examination	CH	N1		
76001	Fluoroscope exam, extensive		N1		
76010	X-ray, nose to rectum		Z3	0.4113	\$17.03
76080	X-ray exam of fistula	CH	N1		
76098	X-ray exam, breast specimen		Z3	0.2797	\$11.58
76100	X-ray exam of body section		Z2	1.157	\$47.90
76101	Complex body section x-ray	CH	Z3	2.7485	\$113.79
76102	Complex body section x-rays		Z2	2.6838	\$111.11
76120	Cine/video x-rays		Z3	1.1437	\$47.35
76125	Cine/video x-rays add-on	CH	N1		
76150	X-ray exam, dry process		Z3	0.4526	\$18.74
76350	Special x-ray contrast study		N1		
76376	3d render w/o postprocess	CH	N1		
76377	3d rendering w/postprocess	CH	N1		
76380	Cat scan follow-up study		Z2	1.5839	\$65.58
76496	Fluoroscopic procedure		Z2	1.3271	\$54.94
76497	Ct procedure		Z2	1.5839	\$65.58
76498	Mri procedure		Z2	4.883	\$202.16
76499	Radiographic procedure		Z2	0.6954	\$28.79
76506	Echo exam of head		Z2	0.957	\$39.62
76510	Ophth us, b & quant a	CH	Z3	1.5963	\$66.09
76511	Ophth us, quant a only		Z3	1.2507	\$51.78
76512	Ophth us, b w/non-quant a		Z3	1.0862	\$44.97
76513	Echo exam of eye, water bath		Z3	1.1521	\$47.70
76514	Echo exam of eye, thickness		Z3	0.0659	\$2.73
76516	Echo exam of eye		Z3	0.8968	\$37.13
76519	Echo exam of eye		Z3	0.9874	\$40.88
76529	Echo exam of eye		Z3	0.8558	\$35.43
76536	Us exam of head and neck	CH	Z2	1.5094	\$62.49
76604	Us exam, chest		Z2	0.957	\$39.62
76645	Us exam, breast(s)		Z2	0.957	\$39.62
76700	Us exam, abdom, complete		Z2	1.5094	\$62.49
76705	Echo exam of abdomen		Z3	1.4647	\$60.64
76770	Us exam abdo back wall, comp		Z2	1.5094	\$62.49
76775	Us exam abdo back wall, lim		Z3	1.4893	\$61.66
76776	Us exam k transpl w/doppler		Z2	1.5094	\$62.49
76800	Us exam, spinal canal		Z3	1.4154	\$58.60
76801	Ob us < 14 wks, single fetus		Z2	1.5094	\$62.49
76802	Ob us < 14 wks, add'l fetus		Z3	0.7241	\$29.98
76805	Ob us >= 14 wks, snl fetus		Z2	1.5094	\$62.49
76810	Ob us >= 14 wks, addl fetus		Z3	0.9874	\$40.88
76811	Ob us, detailed, snl fetus	CH	Z2	2.3792	\$98.50
76812	Ob us, detailed, addl fetus		Z2	0.957	\$39.62
76813	Ob us nuchal meas, 1 gest		Z3	1.4893	\$61.66
76814	Ob us nuchal meas, add-on		Z3	0.7077	\$29.30
76815	Ob us, limited, fetus(s)		Z2	0.957	\$39.62
76816	Ob us, follow-up, per fetus		Z2	0.957	\$39.62
76817	Transvaginal us, obstetric		Z2	0.957	\$39.62
76818	Fetal biophys profile w/nst		Z3	1.4483	\$59.96
76819	Fetal biophys profil w/o nst		Z3	1.2343	\$51.10
76820	Umbilical artery echo		Z3	0.8311	\$34.41
76821	Middle cerebral artery echo		Z3	1.3413	\$55.53
76825	Echo exam of fetal heart		Z2	1.5094	\$62.49
76826	Echo exam of fetal heart	CH	Z2	0.957	\$39.62

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
76827	Echo exam of fetal heart	CH	Z2	0.957	\$39.62
76828	Echo exam of fetal heart		Z3	0.65	\$26.91
76830	Transvaginal us, non-ob		Z2	1.5094	\$62.49
76831	Echo exam, uterus		Z3	1.6623	\$68.82
76856	Us exam, pelvic, complete		Z2	1.5094	\$62.49
76857	Us exam, pelvic, limited		Z2	0.957	\$39.62
76870	Us exam, scrotum		Z2	1.5094	\$62.49
76872	Us, transrectal		Z2	1.5094	\$62.49
76873	Echograp trans r, pros study		Z2	1.5094	\$62.49
76880	Us exam, extremity		Z2	1.5094	\$62.49
76885	Us exam infant hips, dynamic		Z2	0.957	\$39.62
76886	Us exam infant hips, static		Z2	0.957	\$39.62
76930	Echo guide, cardiocentesis	CH	N1		
76932	Echo guide for heart biopsy	CH	N1		
76936	Echo guide for artery repair	CH	N1		
76937	Us guide, vascular access		N1		
76940	Us guide, tissue ablation	CH	N1		
76941	Echo guide for transfusion	CH	N1		
76942	Echo guide for biopsy	CH	N1		
76945	Echo guide, villus sampling	CH	N1		
76946	Echo guide for amniocentesis	CH	N1		
76948	Echo guide, ova aspiration	CH	N1		
76950	Echo guidance radiotherapy	CH	N1		
76965	Echo guidance radiotherapy	CH	N1		
76970	Ultrasound exam follow-up		Z2	0.957	\$39.62
76975	Gi endoscopic ultrasound	CH	N1		
76977	Us bone density measure		Z3	0.3785	\$15.67
76998	Us guide, intraop	CH	N1		
76999	Echo examination procedure		Z2	0.957	\$39.62
77001	Fluoroguide for vein device		N1		
77002	Needle localization by xray		N1		
77003	Fluoroguide for spine inject		N1		
77011	Ct scan for localization	CH	N1		
77012	Ct scan for needle biopsy	CH	N1		
77013	Ct guide for tissue ablation	CH	N1		
77014	Ct scan for therapy guide	CH	N1		
77021	Mr guidance for needle place	CH	N1		
77022	Mri for tissue ablation	CH	N1		
77031	Stereotact guide for brst bx	CH	N1		
77032	Guidance for needle, breast	CH	N1		
77053	X-ray of mammary duct	CH	N1		
77054	X-ray of mammary ducts	CH	N1		
77071	X-ray stress view		Z3	0.3867	\$16.01
77072	X-rays for bone age		Z3	0.2961	\$12.26
77073	X-rays, bone length studies		Z3	0.5514	\$22.83
77074	X-rays, bone survey, limited		Z3	0.9381	\$38.84
77075	X-rays, bone survey complete		Z2	1.157	\$47.90
77076	X-rays, bone survey, infant		Z2	0.6954	\$28.79
77077	Joint survey, single view	CH	Z2	0.6831	\$28.28
77078	Ct bone density, axial		Z2	1.1384	\$47.13
77079	Ct bone density, peripheral	CH	Z2	1.5224	\$63.03
77080	Dxa bone density, axial		Z2	1.1384	\$47.13
77081	Dxa bone density/peripheral		Z2	0.4773	\$19.76
77082	Dxa bone density, vert fx		Z3	0.5019	\$20.78
77083	Radiographic absorptiometry		Z3	0.4362	\$18.06
77084	Magnetic image, bone marrow		Z2	4.883	\$202.16
77280	Set radiation therapy field		Z2	1.5576	\$64.49
77285	Set radiation therapy field		Z2	3.9276	\$162.61
77290	Set radiation therapy field		Z2	3.9276	\$162.61
77295	Set radiation therapy field	CH	Z2	13.5621	\$561.48
77299	Radiation therapy planning		Z2	1.5576	\$64.49
77300	Radiation therapy dose plan		Z3	0.9546	\$39.52
77301	Radiotherapy dose plan, imrt		Z2	13.5621	\$561.48
77305	Teletx isodose plan simple		Z3	1.0451	\$43.27
77310	Teletx isodose plan intermed		Z3	1.3331	\$55.19
77315	Teletx isodose plan complex		Z3	1.7444	\$72.22
77321	Special teletx port plan		Z3	2.156	\$89.26
77326	Brachytx isodose calc simp		Z2	1.5576	\$64.49

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPCS code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
77327	Brachytx isodose calc interm		Z3	2.9212	\$120.94
77328	Brachytx isodose plan compl		Z3	3.9168	\$162.16
77331	Special radiation dosimetry		Z3	0.4196	\$17.37
77332	Radiation treatment aid(s)		Z3	1.1108	\$45.99
77333	Radiation treatment aid(s)		Z3	0.8804	\$36.45
77334	Radiation treatment aid(s)		Z3	2.2876	\$94.71
77336	Radiation physics consult		Z2	1.5576	\$64.49
77370	Radiation physics consult		Z2	1.5576	\$64.49
77371	Srs, multisource		Z3	24.7441	\$1,024.43
77399	External radiation dosimetry		Z2	1.5576	\$64.49
77401	Radiation treatment delivery		Z3	0.9217	\$38.16
77402	Radiation treatment delivery		Z2	1.4229	\$58.91
77403	Radiation treatment delivery		Z2	1.4229	\$58.91
77404	Radiation treatment delivery		Z2	1.4229	\$58.91
77406	Radiation treatment delivery		Z2	1.4229	\$58.91
77407	Radiation treatment delivery		Z2	1.4229	\$58.91
77408	Radiation treatment delivery		Z2	1.4229	\$58.91
77409	Radiation treatment delivery		Z2	1.4229	\$58.91
77411	Radiation treatment delivery		Z2	2.2167	\$91.77
77412	Radiation treatment delivery		Z2	2.2167	\$91.77
77413	Radiation treatment delivery		Z2	2.2167	\$91.77
77414	Radiation treatment delivery		Z2	2.2167	\$91.77
77416	Radiation treatment delivery		Z2	2.2167	\$91.77
77417	Radiology port film(s)	CH	N1		
77418	Radiation tx delivery, imrt		Z2	5.4582	\$225.97
77421	Stereoscopic x-ray guidance	CH	N1		
77422	Neutron beam tx, simple		Z2	2.2167	\$91.77
77423	Neutron beam tx, complex		Z2	2.2167	\$91.77
77435	Sbrt management		N1		
77470	Special radiation treatment		Z3	5.0936	\$210.88
77520	Proton trmt, simple w/o comp		Z2	12.8205	\$530.78
77522	Proton trmt, simple w/comp		Z2	12.8205	\$530.78
77523	Proton trmt, intermediate		Z2	15.3404	\$635.11
77525	Proton treatment, complex		Z2	15.3404	\$635.11
77600	Hyperthermia treatment	CH	Z3	5.2583	\$217.70
77605	Hyperthermia treatment		Z2	5.7996	\$240.11
77610	Hyperthermia treatment		Z2	5.7996	\$240.11
77615	Hyperthermia treatment		Z2	5.7996	\$240.11
77620	Hyperthermia treatment	CH	Z3	5.4064	\$223.83
77750	Infuse radioactive materials		Z3	1.7529	\$72.57
77761	Apply intrcav radiat simple		Z3	3.127	\$129.46
77762	Apply intrcav radiat interm		Z3	3.8511	\$159.44
77763	Apply intrcav radiat compl		Z3	4.9373	\$204.41
77776	Apply interstit radiat simpl		Z3	3.275	\$135.59
77777	Apply interstit radiat inter		Z3	3.991	\$165.23
77778	Apply interstit radiat compl		Z3	5.2417	\$217.01
77781	High intensity brachytherapy		Z3	9.9981	\$413.93
77782	High intensity brachytherapy		Z2	11.6779	\$483.48
77783	High intensity brachytherapy		Z2	11.6779	\$483.48
77784	High intensity brachytherapy		Z2	11.6779	\$483.48
77789	Apply surface radiation		Z3	0.8558	\$35.43
77790	Radiation handling		N1		
77799	Radium/radioisotope therapy		Z2	8.514	\$352.49
78000	Thyroid, single uptake		Z3	1.1355	\$47.01
78001	Thyroid, multiple uptakes		Z3	1.4483	\$59.96
78003	Thyroid suppress/stimul		Z3	1.1437	\$47.35
78006	Thyroid imaging with uptake	CH	Z3	3.4726	\$143.77
78007	Thyroid image, mult uptakes		Z3	2.2466	\$93.01
78010	Thyroid imaging	CH	Z2	2.0471	\$84.75
78011	Thyroid imaging with flow		Z2	2.0471	\$84.75
78015	Thyroid met imaging		Z3	3.1598	\$130.82
78016	Thyroid met imaging/studies	CH	Z3	4.8221	\$199.64
78018	Thyroid met imaging, body		Z2	5.0681	\$209.82
78020	Thyroid met uptake	CH	N1		
78070	Parathyroid nuclear imaging	CH	Z3	3.0692	\$127.07
78075	Adrenal nuclear imaging	CH	Z3	6.9039	\$285.83
78099	Endocrine nuclear procedure		Z2	2.0471	\$84.75
78102	Bone marrow imaging, ltd		Z3	2.477	\$102.55

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
78103	Bone marrow imaging, mult		Z3	3.4313	\$142.06
78104	Bone marrow imaging, body		Z2	3.9293	\$162.68
78110	Plasma volume, single		Z3	1.2343	\$51.10
78111	Plasma volume, multiple		Z3	1.9091	\$79.04
78120	Red cell mass, single		Z3	1.5471	\$64.05
78121	Red cell mass, multiple		Z3	2.0572	\$85.17
78122	Blood volume		Z3	2.7567	\$114.13
78130	Red cell survival study		Z3	2.5263	\$104.59
78135	Red cell survival kinetics	CH	Z3	5.4803	\$226.89
78140	Red cell sequestration		Z3	2.7321	\$113.11
78185	Spleen imaging		Z3	3.0528	\$126.39
78190	Platelet survival, kinetics		Z2	2.9022	\$120.15
78191	Platelet survival		Z2	2.9022	\$120.15
78195	Lymph system imaging		Z2	3.9293	\$162.68
78199	Blood/lymph nuclear exam		Z2	3.9293	\$162.68
78201	Liver imaging		Z3	2.806	\$116.17
78202	Liver imaging with flow		Z3	3.3161	\$137.29
78205	Liver imaging (3d)		Z3	4.4929	\$186.01
78206	Liver image (3d) with flow		Z2	4.4603	\$184.66
78215	Liver and spleen imaging		Z3	3.1188	\$129.12
78216	Liver & spleen image/flow		Z3	2.5263	\$104.59
78220	Liver function study		Z3	2.7238	\$112.77
78223	Hepatobiliary imaging		Z2	4.4603	\$184.66
78230	Salivary gland imaging		Z3	2.5509	\$105.61
78231	Serial salivary imaging		Z3	2.3864	\$98.80
78232	Salivary gland function exam		Z3	2.5345	\$104.93
78258	Esophageal motility study		Z3	3.341	\$138.32
78261	Gastric mucosa imaging		Z2	3.7911	\$156.96
78262	Gastroesophageal reflux exam		Z2	3.7911	\$156.96
78264	Gastric emptying study		Z2	3.7911	\$156.96
78270	Vit b-12 absorption exam		Z3	1.4072	\$58.26
78271	Vit b-12 absrp exam, int fac		Z3	1.4236	\$58.94
78272	Vit b-12 absorp, combined		Z3	1.7693	\$73.25
78278	Acute gi blood loss imaging		Z2	3.7911	\$156.96
78282	Gi protein loss exam		Z2	3.7911	\$156.96
78290	Meckels divert exam		Z2	3.7911	\$156.96
78291	Leveen/shunt patency exam		Z3	3.6617	\$151.60
78299	Gi nuclear procedure		Z2	3.7911	\$156.96
78300	Bone imaging, limited area		Z3	2.6743	\$110.72
78305	Bone imaging, multiple areas		Z3	3.6371	\$150.58
78306	Bone imaging, whole body	CH	Z2	3.8039	\$157.49
78315	Bone imaging, 3 phase		Z2	3.8039	\$157.49
78320	Bone imaging (3d)		Z2	3.8039	\$157.49
78399	Musculoskeletal nuclear exam		Z2	3.8039	\$157.49
78414	Non-imaging heart function		Z2	4.862	\$201.29
78428	Cardiac shunt imaging		Z3	2.9458	\$121.96
78445	Vascular flow imaging	CH	Z3	2.5427	\$105.27
78456	Acute venous thrombus image		Z2	3.1433	\$130.14
78457	Venous thrombosis imaging	CH	Z3	2.9048	\$120.26
78458	Ven thrombosis images, bilat		Z2	3.1433	\$130.14
78459	Heart muscle imaging (pet)		Z2	21.9955	\$910.64
78460	Heart muscle blood, single		Z3	2.7567	\$114.13
78461	Heart muscle blood, multiple		Z3	3.4231	\$141.72
78464	Heart image (3d), single	CH	Z3	5.11	\$211.56
78465	Heart image (3d), multiple	CH	Z3	9.2657	\$383.61
78466	Heart infarct image		Z3	2.8391	\$117.54
78468	Heart infarct image (ef)		Z3	3.7523	\$155.35
78469	Heart infarct image (3d)	CH	Z3	4.5506	\$188.40
78472	Gated heart, planar, single	CH	Z3	4.5753	\$189.42
78473	Gated heart, multiple		Z2	4.862	\$201.29
78478	Heart wall motion add-on	CH	N1		
78480	Heart function add-on	CH	N1		
78481	Heart first pass, single		Z3	4.032	\$166.93
78483	Heart first pass, multiple		Z2	4.862	\$201.29
78491	Heart image (pet), single		Z2	21.9955	\$910.64
78492	Heart image (pet), multiple		Z2	21.9955	\$910.64
78494	Heart image, spect		Z2	4.862	\$201.29
78496	Heart first pass add-on	CH	N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
78499	Cardiovascular nuclear exam		Z2	4.862	\$201.29
78580	Lung perfusion imaging	CH	Z3	3.4149	\$141.38
78584	Lung v/q image single breath		Z3	2.4111	\$99.82
78585	Lung v/q imaging		Z2	4.9509	\$204.97
78586	Aerosol lung image, single		Z3	2.7238	\$112.77
78587	Aerosol lung image, multiple		Z3	3.3161	\$137.29
78588	Perfusion lung image		Z3	4.7233	\$195.55
78591	Vent image, 1 breath, 1 proj		Z3	2.8306	\$117.19
78593	Vent image, 1 proj, gas		Z3	3.3328	\$137.98
78594	Vent image, mult proj, gas		Z2	3.3954	\$140.57
78596	Lung differential function		Z2	4.9509	\$204.97
78599	Respiratory nuclear exam		Z2	3.9954	\$140.57
78600	Brain image < 4 views		Z3	2.9294	\$121.28
78601	Brain image w/flow < 4 views	CH	Z2	3.2295	\$133.70
78605	Brain image 4+ views		Z3	3.3161	\$137.29
78606	Brain image w/flow 4 + views	CH	Z3	5.0115	\$207.48
78607	Brain imaging (3d)	CH	Z3	6.0728	\$251.42
78608	Brain imaging (pet)		Z2	16.6001	\$687.26
78610	Brain flow imaging only		Z3	3.3738	\$139.68
78615	Cerebral vascular flow image	CH	D5		
78630	Cerebrospinal fluid scan	CH	Z3	5.5298	\$228.94
78635	Csf ventriculography	CH	Z3	4.5753	\$189.42
78645	Csf shunt evaluation		Z2	3.2295	\$133.70
78647	Cerebrospinal fluid scan	CH	Z3	5.8177	\$240.86
78650	Csf leakage imaging	CH	Z3	5.3405	\$221.10
78660	Nuclear exam of tear flow		Z3	2.5509	\$105.61
78699	Nervous system nuclear exam		Z2	3.2295	\$133.70
78700	Kidney imaging, morphol		Z3	2.9953	\$124.01
78701	Kidney imaging with flow		Z3	3.6043	\$149.22
78707	K flow/funct image w/o drug	CH	Z3	3.9581	\$163.87
78708	K flow/funct image w/drug		Z3	3.0941	\$128.10
78709	K flow/funct image, multiple		Z2	5.0824	\$210.42
78710	Kidney imaging (3d)	CH	Z3	4.5093	\$186.69
78725	Kidney function study	CH	Z3	1.6541	\$68.48
78730	Urinary bladder retention	CH	Z3	1.3908	\$57.58
78740	Ureteral reflux study		Z3	3.1188	\$129.12
78761	Testicular imaging w/flow		Z3	3.2915	\$136.27
78799	Genitourinary nuclear exam		Z2	5.0824	\$210.42
78800	Tumor imaging, limited area		Z3	3.0941	\$128.10
78801	Tumor imaging, mult areas		Z3	4.1144	\$170.34
78802	Tumor imaging, whole body	CH	Z3	5.5052	\$227.92
78803	Tumor imaging (3d)	CH	Z3	6.0564	\$250.74
78804	Tumor imaging, whole body	CH	Z3	10.5	\$434.71
78805	Abscess imaging, ltd area		Z3	3.0364	\$125.71
78806	Abscess imaging, whole body	CH	Z3	5.9576	\$246.65
78807	Nuclear localization/abscess	CH	Z3	6.0482	\$250.40
78811	Pet image, ltd area		Z2	16.6001	\$687.26
78812	Pet image, skull-thigh		Z2	16.6001	\$687.26
78813	Pet image, full body		Z2	16.6001	\$687.26
78814	Pet image w/ct, ltd		Z2	16.6001	\$687.26
78815	Pet image w/ct, skull-thigh		Z2	16.6001	\$687.26
78816	Pet image w/ct, full body		Z2	16.6001	\$687.26
78890	Nuclear medicine data proc		N1		
78891	Nuclear med data proc		N1		
78999	Nuclear diagnostic exam		Z2	1.819	\$75.31
79005	Nuclear rx, oral admin		Z3	1.5963	\$66.09
79101	Nuclear rx, iv admin		Z3	1.6623	\$68.82
79200	Nuclear rx, intracav admin		Z3	1.728	\$71.54
79300	Nuclr rx, interstit colloid		Z2	3.302	\$136.71
79403	Hematopoietic nuclear tx		Z3	2.6497	\$109.70
79440	Nuclear rx, intra-articular		Z3	1.5553	\$64.39
79445	Nuclear rx, intra-arterial		Z2	3.302	\$136.71
79999	Nuclear medicine therapy		Z2	3.302	\$136.71
90296	Diphtheria antitoxin	CH	N1		
90371	Hep b ig, im		K2		\$122.02
90375	Rabies ig, im/sc		K2		\$68.22
90376	Rabies ig, heat treated		K2		\$71.69
90385	Rh ig, minidose, im	CH	N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
90393	Vaccina ig, im	CH	N1		
90396	Varicella-zoster ig, im		K2		\$122.74
90476	Adenovirus vaccine, type 4	CH	N1		
90477	Adenovirus vaccine, type 7	CH	N1		
90581	Anthrax vaccine, sc	CH	N1		
90585	Bcg vaccine, percut		K2		\$118.98
90632	Hep a vaccine, adult im	CH	N1		
90633	Hep a vacc, ped/adol, 2 dose	CH	N1		
90634	Hep a vacc, ped/adol, 3 dose	CH	N1		
90636	Hep a/hep b vacc, adult im	CH	N1		
90645	Hib vaccine, hboc, im	CH	N1		
90646	Hib vaccine, prp-d, im	CH	N1		
90647	Hib vaccine, prp-omp, im	CH	N1		
90648	Hib vaccine, prp-t, im	CH	N1		
90665	Lyme disease vaccine, im	CH	N1		
90675	Rabies vaccine, im		K2		\$150.80
90676	Rabies vaccine, id		K2		\$119.86
90680	Rotovirus vacc 3 dose, oral	CH	N1		
90690	Typhoid vaccine, oral	CH	N1		
90691	Typhoid vaccine, im	CH	N1		
90692	Typhoid vaccine, h-p, sc/id	CH	N1		
90698	Dtap-hib-ip vaccine, im	CH	N1		
90700	Dtap vaccine, < 7 yrs, im	CH	N1		
90701	Dtp vaccine, im	CH	N1		
90702	Dt vaccine < 7, im	CH	N1		
90703	Tetanus vaccine, im	CH	N1		
90704	Mumps vaccine, sc	CH	N1		
90705	Measles vaccine, sc	CH	N1		
90706	Rubella vaccine, sc	CH	N1		
90707	Mmr vaccine, sc	CH	N1		
90708	Measles-rubella vaccine, sc		K2		\$45.53
90710	Mmrv vaccine, sc	CH	N1		
90712	Oral poliovirus vaccine	CH	N1		
90713	Poliovirus, ipv, sc/im	CH	N1		
90714	Td vaccine no prsrv >= 7 im	CH	N1		
90715	Tdap vaccine >7 im	CH	N1		
90717	Yellow fever vaccine, sc	CH	N1		
90718	Td vaccine > 7, im	CH	N1		
90719	Diphtheria vaccine, im	CH	N1		
90720	Dtp/hib vaccine, im	CH	N1		
90721	Dtap/hib vaccine, im	CH	N1		
90725	Cholera vaccine, injectable	CH	N1		
90727	Plague vaccine, im	CH	N1		
90733	Meningococcal vaccine, sc		K2		\$85.29
90734	Meningococcal vaccine, im		K2		\$82.00
90735	Encephalitis vaccine, sc		K2		\$98.17
90749	Vaccine toxoid	CH	N1		
A4218	Sterile saline or water		N1		
A4220	Infusion pump refill kit		N1		
A4248	Chlorhexidine antisept		N1		
A4262	Temporary tear duct plug		N1		
A4263	Permanent tear duct plug		N1		
A4270	Disposable endoscope sheath		N1		
A4300	Cath impl vasc access portal		N1		
A4301	Implantable access syst perc		N1		
A4305	Drug delivery system >=50 ML		N1		
A4306	Drug delivery system <=50 ml		N1		
A4648	Implantable tissue marker	NI	N1		
A4650	Implant radiation dosimeter	NI	N1		
A9527	Iodine I-125 sodium iodide	CH	H2	0.4325	\$27.55
A9535	Injection, methylene blue	CH	N1		
A9576	Inj prohance multipack	NI	N1		
A9577	Inj multihance	NI	N1		
A9578	Inj multihance multipack	NI	N1		
A9579	Gad-base MR contrast NOS,1ml	NI	N1		
A9698	Non-rad contrast materialNOC		N1		
C1713	Anchor/screw bn/bn,tis/bn		N1		
C1714	Cath, trans atherectomy, dir		N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
C1715	Brachytherapy needle		N1		
C1716	Brachytx, non-str, Gold-198	CH	H2	0.5228	\$33.30
C1717	Brachytx, non-str,HDR Ir-192	CH	H2	2.7505	\$175.19
C1719	Brachytx, NS, Non-HDRIr-192	CH	H2	1.0226	\$65.13
C1721	AICD, dual chamber		N1		
C1722	AICD, single chamber		N1		
C1724	Cath, trans atherec,rotation		N1		
C1725	Cath, translumin non-laser		N1		
C1726	Cath, bal dil, non-vascular		N1		
C1727	Cath, bal tis dis, non-vas		N1		
C1728	Cath, brachytx seed adm		N1		
C1729	Cath, drainage		N1		
C1730	Cath, EP, 19 or few elect		N1		
C1731	Cath, EP, 20 or more elec		N1		
C1732	Cath, EP, diag/abl, 3D/vect		N1		
C1733	Cath, EP, othr than cool-tip		N1		
C1750	Cath, hemodialysis,long-term		N1		
C1751	Cath, inf, per/cent/midline		N1		
C1752	Cath,hemodialysis,short-term		N1		
C1753	Cath, intravas ultrasound		N1		
C1754	Catheter, intradiscal		N1		
C1755	Catheter, intraspinal		N1		
C1756	Cath, pacing, transesoph		N1		
C1757	Cath, thrombectomy/embolect		N1		
C1758	Catheter, ureteral		N1		
C1759	Cath, intra echocardiography		N1		
C1760	Closure dev, vasc		N1		
C1762	Conn tiss, human(inc fascia)		N1		
C1763	Conn tiss, non-human		N1		
C1764	Event recorder, cardiac		N1		
C1765	Adhesion barrier		N1		
C1766	Intro/sheath,strble,non-peel		N1		
C1767	Generator, neuro non-recharg		N1		
C1768	Graft, vascular		N1		
C1769	Guide wire		N1		
C1770	Imaging coil, MR, insertable		N1		
C1771	Rep dev, urinary, w/sling		N1		
C1772	Infusion pump, programmable		N1		
C1773	Ret dev, insertable		N1		
C1776	Joint device (implantable)		N1		
C1777	Lead, AICD, endo single coil		N1		
C1778	Lead, neurostimulator		N1		
C1779	Lead, pmkr, transvenous VDD		N1		
C1780	Lens, intraocular (new tech)		N1		
C1781	Mesh (implantable)		N1		
C1782	Morcellator		N1		
C1783	Ocular imp, aqueous drain de		N1		
C1784	Ocular dev, intraop, det ret		N1		
C1785	Pmkr, dual, rate-resp		N1		
C1786	Pmkr, single, rate-resp		N1		
C1787	Patient progr, neurostim		N1		
C1788	Port, indwelling, imp		N1		
C1789	Prosthesis, breast, imp		N1		
C1813	Prosthesis, penile, inflatab		N1		
C1814	Retinal tamp, silicone oil		N1		
C1815	Pros, urinary sph, imp		N1		
C1816	Receiver/transmitter, neuro		N1		
C1817	Septal defect imp sys		N1		
C1818	Integrated keratoprosthesis		N1		
C1819	Tissue localization-excision		N1		
C1820	Generator neuro rechg bat sy	CH	N1		
C1821	Interspinous implant		J7		
C1874	Stent, coated/cov w/del sys		N1		
C1875	Stent, coated/cov w/o del sy		N1		
C1876	Stent, non-coa/non-cov w/del		N1		
C1877	Stent, non-coat/cov w/o del		N1		
C1878	Matri for vocal cord		N1		
C1879	Tissue marker, implantable		N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
C1880	Vena cava filter		N1		
C1881	Dialysis access system		N1		
C1882	AICD, other than sing/dual		N1		
C1883	Adapt/ext, pacing/neuro lead		N1		
C1884	Embolization Protect syst		N1		
C1885	Cath, translumin angio laser		N1		
C1887	Catheter, guiding		N1		
C1888	Endovas non-cardiac abl cath		N1		
C1891	Infusion pump,non-prog, perm		N1		
C1892	Intro/sheath,fixed,peel-away		N1		
C1893	Intro/sheath, fixed,non-peel		N1		
C1894	Intro/sheath, non-laser		N1		
C1895	Lead, AICD, endo dual coil		N1		
C1896	Lead, AICD, non sing/dual		N1		
C1897	Lead, neurostim test kit		N1		
C1898	Lead, pmkr, other than trans		N1		
C1899	Lead, pmkr/AICD combination		N1		
C1900	Lead, coronary venous		N1		
C2614	Probe, perc lumb disc		N1		
C2615	Sealant, pulmonary, liquid		N1		
C2616	Brachytx, non-str,Yttrium-90	CH	H2	184.7105	\$11,764.95
C2617	Stent, non-cor, tem w/o del		N1		
C2618	Probe, cryoablation		N1		
C2619	Pmkr, dual, non rate-resp		N1		
C2620	Pmkr, single, non rate-resp		N1		
C2621	Pmkr, other than sing/dual		N1		
C2622	Prosthesis, penile, non-inf		N1		
C2625	Stent, non-cor, tem w/del sy		N1		
C2626	Infusion pump, non-prog,temp		N1		
C2627	Cath, suprapubic/cystoscopic		N1		
C2628	Catheter, occlusion		N1		
C2629	Intro/sheath, laser		N1		
C2630	Cath, EP, cool-tip		N1		
C2631	Rep dev, urinary, w/o sling		N1		
C2634	Brachytx, non-str, HA, I-125	CH	H2	0.4858	\$30.94
C2635	Brachytx, non-str, HA, P-103	CH	H2	0.7366	\$46.92
C2636	Brachy linear, non-str,P-103	CH	H2	0.66	\$42.04
C2638	Brachytx, stranded, I-125	CH	H2	0.7113	\$45.31
C2639	Brachytx, non-stranded,I-125	CH	H2	0.5039	\$32.10
C2640	Brachytx, stranded, P-103	CH	H2	1.0308	\$65.66
C2641	Brachytx, non-stranded,P-103	CH	H2	0.8077	\$51.45
C2642	Brachytx, stranded, C-131	CH	H2	1.5342	\$97.72
C2643	Brachytx, non-stranded,C-131	CH	H2	1.006	\$64.08
C2698	Brachytx, stranded, NOS	CH	H2	0.7113	\$45.31
C2699	Brachytx, non-stranded, NOS	CH	H2	0.4858	\$30.94
C8900	MRA w/cont, abd		Z2	6.235	\$258.14
C8901	MRA w/o cont, abd		Z2	5.3933	\$223.29
C8902	MRA w/o fol w/cont, abd		Z2	8.2463	\$341.41
C8903	MRI w/cont, breast, uni		Z2	6.235	\$258.14
C8904	MRI w/o cont, breast, uni		Z2	5.3933	\$223.29
C8905	MRI w/o fol w/cont, brst, un		Z2	8.2463	\$341.41
C8906	MRI w/cont, breast, bi		Z2	6.235	\$258.14
C8907	MRI w/o cont, breast, bi		Z2	5.3933	\$223.29
C8908	MRI w/o fol w/cont, breast,		Z2	8.2463	\$341.41
C8909	MRA w/cont, chest		Z2	6.235	\$258.14
C8910	MRA w/o cont, chest		Z2	5.3933	\$223.29
C8911	MRA w/o fol w/cont, chest		Z2	8.2463	\$341.41
C8912	MRA w/cont, lwr ext		Z2	6.235	\$258.14
C8913	MRA w/o cont, lwr ext		Z2	5.3933	\$223.29
C8914	MRA w/o fol w/cont, lwr ext		Z2	8.2463	\$341.41
C8918	MRA w/cont, pelvis		Z2	6.235	\$258.14
C8919	MRA w/o cont, pelvis		Z2	5.3933	\$223.29
C8920	MRA w/o fol w/cont, pelvis		Z2	8.2463	\$341.41
C9003	Palivizumab, per 50 mg		K2		\$810.67
C9113	Inj pantoprazole sodium, via		N1		
C9121	Injection, argatroban		K2		\$18.96
C9232	Injection, idursulfase	CH	D5		
C9233	Injection, ranibizumab	CH	D5		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
C9234	Inj, alglucosidase alfa	CH	D5		
C9235	Injection, panitumumab	CH	D5		
C9238	Inj, levetiracetam	NI	K2		\$6.30
C9239	Inj, temsirolimus	NI	K2		\$48.41
C9350	Porous collagen tube per cm	CH	D5		
C9351	Acellular derm tissue percm2	CH	D5		
C9352	Neuragen nerve guide, per cm	NI	K2		\$482.56
C9353	Neurawrap nerve protector,cm	NI	K2		\$482.56
C9399	Unclassified drugs or biolog		K7		
E0616	Cardiac event recorder		N1		
E0749	Elec osteogen stim implanted		N1		
E0782	Non-programable infusion pump		N1		
E0783	Programmable infusion pump		N1		
E0785	Replacement impl pump cathet		N1		
E0786	Implantable pump replacement		N1		
G0130	Single energy x-ray study		Z3	0.5266	\$21.80
G0173	Linear acc stereo radsurg com		Z2	61.6965	\$2,554.30
G0251	Linear acc based stero radio		Z2	16.5911	\$686.89
G0288	Recon, CTA for surg plan	CH	N1		
G0339	Robot lin-radsurg com, first		Z2	61.6965	\$2,554.30
G0340	Robt lin-radsurg fractx 2-5		Z2	45.0693	\$1,865.91
J0120	Tetracyclin injection		N1		
J0128	Abarelix injection		K2		\$67.97
J0129	Abatacept injection		K2		\$18.69
J0130	Abciximab injection		K2		\$420.17
J0132	Acetylcysteine injection	CH	N1		
J0133	Acyclovir injection		N1		
J0135	Adalimumab injection		K2		\$329.58
J0150	Injection adenosine 6 MG		K2		\$25.10
J0152	Adenosine injection		K2		\$67.89
J0170	Adrenalin epinephrin inject		N1		
J0180	Agalsidase beta injection		K2		\$126.00
J0190	Inj biperiden lactate/5 mg		K2		\$88.15
J0200	Alatrofloxacin mesylate		N1		
J0205	Alglucerase injection		K2		\$38.85
J0207	Amifostine		K2		\$490.93
J0210	Methyldopate hcl injection		K2		\$13.04
J0215	Alefaccept		K2		\$26.47
J0220	Aglucosidase alfa injection	NI	K2		\$126.00
J0256	Alpha 1 proteinase inhibitor		K2		\$3.28
J0278	Amikacin sulfate injection		N1		
J0280	Aminophyllin 250 MG inj		N1		
J0282	Amiodarone HCl		N1		
J0285	Amphotericin B		N1		
J0287	Amphotericin b lipid complex		K2		\$10.40
J0288	Ampho b cholesteryl sulfate		K2		\$11.89
J0289	Amphotericin b liposome inj		K2		\$16.21
J0290	Ampicillin 500 MG inj		N1		
J0295	Ampicillin sodium per 1.5 gm		N1		
J0300	Amobarbital 125 MG inj		N1		
J0330	Succinylcholine chloride inj		N1		
J0348	Anadulafungin injection		K2		\$1.91
J0350	Injection anistreplase 30 u		K2		\$2,693.80
J0360	Hydralazine hcl injection		N1		
J0364	Apomorphine hydrochloride	CH	N1		
J0365	Aprotonin, 10,000 kiu		K2		\$2.66
J0380	Inj metaraminol bitartrate	CH	N1		
J0390	Chloroquine injection		N1		
J0395	Arbutamine HCl injection	CH	N1		
J0400	Aripiprazole injection	NI	K2		\$0.28
J0456	Azithromycin		N1		
J0460	Atropine sulfate injection		N1		
J0470	Dimecaprol injection		N1		
J0475	Baclofen 10 MG injection		K2		\$193.29
J0476	Baclofen intrathecal trial		K2		\$69.73
J0480	Basiliximab		K2		\$1,541.03
J0500	Dicyclomine injection		N1		
J0515	Inj benzotropine mesylate		N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
J0520	Bethanechol chloride inject		N1		
J0530	Penicillin g benzathine inj		N1		
J0540	Penicillin g benzathine inj		N1		
J0550	Penicillin g benzathine inj		N1		
J0560	Penicillin g benzathine inj		N1		
J0570	Penicillin g benzathine inj		N1		
J0580	Penicillin g benzathine inj		N1		
J0583	Bivalirudin		K2		\$1.84
J0585	Botulinum toxin a per unit		K2		\$5.21
J0587	Botulinum toxin type B		K2		\$8.63
J0592	Buprenorphine hydrochloride		N1		
J0594	Busulfan injection		K2		\$9.17
J0595	Butorphanol tartrate 1 mg		N1		
J0600	Edetate calcium disodium inj		K2		\$49.64
J0610	Calcium gluconate injection		N1		
J0620	Calcium glycer & lact/10 ML		N1		
J0630	Calcitonin salmon injection		N1		
J0636	Inj calcitriol per 0.1 mcg		N1		
J0637	Caspofungin acetate		K2		\$24.05
J0640	Leucovorin calcium injection		N1		
J0670	Inj mepivacaine HCL/10 ml		N1		
J0690	Cefazolin sodium injection		N1		
J0692	Cefepime HCl for injection		N1		
J0694	Cefoxitin sodium injection		N1		
J0696	Ceftriaxone sodium injection		N1		
J0697	Sterile cefuroxime injection		N1		
J0698	Cefotaxime sodium injection		N1		
J0702	Betamethasone acet&sod phosp		N1		
J0704	Betamethasone sod phosp/4 MG		N1		
J0706	Caffeine citrate injection	CH	N1		
J0710	Cephapirin sodium injection		N1		
J0713	Inj ceftazidime per 500 mg		N1		
J0715	Ceftizoxime sodium / 500 MG		N1		
J0720	Chloramphenicol sodium injec		N1		
J0725	Chorionic gonadotropin/1000u		N1		
J0735	Clonidine hydrochloride		K2		\$62.78
J0740	Cidofovir injection		K2		\$754.39
J0743	Cilastatin sodium injection		N1		
J0744	Ciprofloxacin iv		N1		
J0745	Inj codeine phosphate /30 MG		N1		
J0760	Colchicine injection		N1		
J0770	Colistimethate sodium inj		N1		
J0780	Prochlorperazine injection		N1		
J0795	Corticotropin ovine triflural		K2		\$4.43
J0800	Corticotropin injection		K2		\$169.77
J0835	Inj cosyntropin per 0.25 MG		K2		\$64.01
J0850	Cytomegalovirus imm IV /vial		K2		\$870.53
J0878	Daptomycin injection		K2		\$0.35
J0881	Darbepoetin alfa, non-esrd		K2		\$2.88
J0885	Epoetin alfa, non-esrd		K2		\$8.97
J0894	Decitabine injection		K2		\$26.48
J0895	Deferoxamine mesylate inj	CH	N1		
J0900	Testosterone enanthate inj		N1		
J0945	Brompheniramine maleate inj		N1		
J0970	Estradiol valerate injection		N1		
J1000	Depo-estradiol cypionate inj		N1		
J1020	Methylprednisolone 20 MG inj		N1		
J1030	Methylprednisolone 40 MG inj		N1		
J1040	Methylprednisolone 80 MG inj		N1		
J1051	Medroxyprogesterone inj		N1		
J1060	Testosterone cypionate 1 ML		N1		
J1070	Testosterone cypionat 100 MG		N1		
J1080	Testosterone cypionat 200 MG		N1		
J1094	Inj dexamethasone acetate		N1		
J1100	Dexamethasone sodium phos		N1		
J1110	Inj dihydroergotamine mesylt		N1		
J1120	Acetazolamid sodium injectio		N1		
J1160	Digoxin injection		N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPCS code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
J1162	Digoxin immune fab (ovine)		K2		\$478.88
J1165	Phenytoin sodium injection		N1		
J1170	Hydromorphone injection		N1		
J1180	Dyphylline injection		N1		
J1190	Dexrazoxane HCl injection		K2		\$162.11
J1200	Diphenhydramine hcl injectio		N1		
J1205	Chlorothiazide sodium inj		K2		\$141.07
J1212	Dimethyl sulfoxide 50% 50 ML		N1		
J1230	Methadone injection		N1		
J1240	Dimenhydrinate injection		N1		
J1245	Dipyridamole injection		N1		
J1250	Inj dobutamine HCL/250 mg		N1		
J1260	Dolasetron mesylate		K2		\$4.66
J1265	Dopamine injection		N1		
J1270	Injection, doxercalciferol		N1		
J1300	Ecuzumab injection	NI	K2		\$176.38
J1320	Amitriptyline injection		N1		
J1324	Enfuvirtide injection		K2		\$0.40
J1325	Epoprostenol injection		N1		
J1327	Eptifibatide injection		K2		\$17.67
J1330	Ergonovine maleate injection	CH	N1		
J1335	Ertapenem injection		N1		
J1364	Erythro lactobionate /500 MG		N1		
J1380	Estradiol valerate 10 MG inj		N1		
J1390	Estradiol valerate 20 MG inj		N1		
J1410	Inj estrogen conjugate 25 MG		K2		\$66.64
J1430	Ethanolamine oleate 100 mg		K2		\$79.23
J1435	Injection estrone per 1 MG		N1		
J1436	Etidronate disodium inj		K2		\$70.73
J1438	Etanercept injection		K2		\$167.12
J1440	Filgrastim 300 mcg injection		K2		\$193.79
J1441	Filgrastim 480 mcg injection		K2		\$298.39
J1450	Fluconazole		N1		
J1451	Fomepizole, 15 mg		K2		\$12.80
J1452	Intraocular Fomivirsen na	CH	N1		
J1455	Foscarnet sodium injection	CH	N1		
J1457	Gallium nitrate injection	CH	K2		\$1.61
J1458	Galsulfase injection		K2		\$306.88
J1460	Gamma globulin 1 CC inj		K2		\$11.91
J1470	Gamma globulin 2 CC inj	CH	K2		\$23.82
J1480	Gamma globulin 3 CC inj	CH	K2		\$35.72
J1490	Gamma globulin 4 CC inj	CH	K2		\$47.64
J1500	Gamma globulin 5 CC inj	CH	K2		\$59.54
J1510	Gamma globulin 6 CC inj	CH	K2		\$71.50
J1520	Gamma globulin 7 CC inj	CH	K2		\$83.30
J1530	Gamma globulin 8 CC inj	CH	K2		\$95.27
J1540	Gamma globulin 9 CC inj	CH	K2		\$107.25
J1550	Gamma globulin 10 CC inj	CH	K2		\$119.09
J1560	Gamma globulin > 10 CC inj	CH	K2		\$119.09
J1561	Gamunex injection	NI	K2		\$32.06
J1562	Vivaglobin, inj		K2		\$7.01
J1565	RSV-ivig		K2		\$16.02
J1566	Immune globulin, powder		K2		\$26.89
J1567	Immune globulin, liquid	CH	D5		
J1568	Octagam injection	NI	K2		\$33.19
J1569	Gammagard liquid injection	NI	K2		\$31.06
J1570	Ganciclovir sodium injection		N1		
J1571	Hepagam B IM injection	NI	K2		\$63.51
J1572	Flebogamma injection	NI	K2		\$32.27
J1573	Hepagam B intravenous, inj	NI	K2		\$63.51
J1580	Garamycin gentamicin inj		N1		
J1590	Gatifloxacin injection		N1		
J1595	Injection glatiramer acetate	CH	K2		\$52.04
J1600	Gold sodium thiomaleate inj		N1		
J1610	Glucagon hydrochloride/1 MG		K2		\$68.84
J1620	Gonadorelin hydroch/ 100 mcg		K2		\$178.59
J1626	Granisetron HCl injection		K2		\$5.74
J1630	Haloperidol injection		N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPCS code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
J1631	Haloperidol decanoate inj		N1		
J1640	Hemin, 1 mg		K2		\$7.08
J1642	Inj heparin sodium per 10 u		N1		
J1644	Inj heparin sodium per 1000u		N1		
J1645	Dalteparin sodium		N1		
J1650	Inj enoxaparin sodium		N1		
J1652	Fondaparinux sodium		K2		\$5.92
J1655	Tinzaparin sodium injection	CH	N1		
J1670	Tetanus immune globulin inj	CH	K2		\$103.46
J1700	Hydrocortisone acetate inj		N1		
J1710	Hydrocortisone sodium ph inj		N1		
J1720	Hydrocortisone sodium succ i		N1		
J1730	Diazoxide injection		K2		\$113.24
J1740	Ibandronate sodium injection		K2		\$138.96
J1742	Ibutilide fumarate injection		K2		\$287.15
J1743	Idursulfase injection	NI	K2		\$455.03
J1745	Infliximab injection		K2		\$54.42
J1751	Iron dextran 165 injection		K2		\$11.82
J1752	Iron dextran 267 injection		K2		\$10.30
J1756	Iron sucrose injection		K2		\$0.36
J1785	Injection imiglucerase /unit		K2		\$3.89
J1790	Droperidol injection		N1		
J1800	Propranolol injection		N1		
J1815	Insulin injection		N1		
J1817	Insulin for insulin pump use		N1		
J1830	Interferon beta-1b / .25 MG		K2		\$106.57
J1835	Itraconazole injection		K2		\$39.68
J1840	Kanamycin sulfate 500 MG inj		N1		
J1850	Kanamycin sulfate 75 MG inj		N1		
J1885	Ketorolac tromethamine inj		N1		
J1890	Cephalothin sodium injection		N1		
J1931	Laronidase injection		K2		\$23.64
J1940	Furosemide injection		N1		
J1945	Lepirudin		K2		\$159.44
J1950	Leuproliide acetate /3.75 MG		K2		\$452.58
J1956	Levofloxacin injection		N1		
J1960	Levorphanol tartrate inj		N1		
J1980	Hyoscyamine sulfate inj		N1		
J1990	Chlordiazepoxide injection		N1		
J2001	Lidocaine injection		N1		
J2010	Lincomycin injection		N1		
J2020	Linezolid injection		K2		\$25.17
J2060	Lorazepam injection		N1		
J2150	Mannitol injection		N1		
J2170	Mecasermin injection		K2		\$15.62
J2175	Meperidine hydrochl /100 MG		N1		
J2180	Meperidine/promethazine inj		N1		
J2185	Meropenem	CH	N1		
J2210	Methylergonovin maleate inj		N1		
J2248	Micafungin sodium injection		K2		\$1.44
J2250	Inj midazolam hydrochloride		N1		
J2260	Inj milrinone lactate / 5 MG		N1		
J2270	Morphine sulfate injection		N1		
J2271	Morphine so4 injection 100mg		N1		
J2275	Morphine sulfate injection		N1		
J2278	Ziconotide injection		K2		\$6.46
J2280	Inj, moxifloxacin 100 mg		N1		
J2300	Inj nalbuphine hydrochloride		N1		
J2310	Inj naloxone hydrochloride		N1		
J2315	Naltrexone, depot form		K2		\$1.87
J2320	Nandrolone decanoate 50 MG		N1		
J2321	Nandrolone decanoate 100 MG		N1		
J2322	Nandrolone decanoate 200 MG		N1		
J2323	Natalizumab injection	NI	K2		\$7.51
J2325	Nesiritide injection		K2		\$32.95
J2353	Octreotide injection, depot		K2		\$99.04
J2354	Octreotide inj, non-depot		N1		
J2355	Oprelvekin injection		K2		\$247.02

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPCS code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
J2357	Omalizumab injection		K2		\$17.12
J2360	Orphenadrine injection		N1		
J2370	Phenylephrine hcl injection		N1		
J2400	Chloroprocaine hcl injection		N1		
J2405	Ondansetron hcl injection		K2		\$0.26
J2410	Oxymorphone hcl injection		N1		
J2425	Palifermin injection		K2		\$11.24
J2430	Pamidronate disodium /30 MG		K2		\$28.31
J2440	Papaverin hcl injection		N1		
J2460	Oxytetracycline injection		N1		
J2469	Palonosetron HCl		K2		\$16.45
J2501	Paricalcitol		N1		
J2503	Pegaptanib sodium injection		K2		\$1,035.69
J2504	Pegademase bovine, 25 iu		K2		\$197.51
J2505	Injection, pegfilgrastim 6mg		K2		\$2,145.12
J2510	Penicillin g procaine inj		N1		
J2513	Pentastarch 10% solution	CH	K2		\$21.98
J2515	Pentobarbital sodium inj		N1		
J2540	Penicillin g potassium inj		N1		
J2543	Piperacillin/tazobactam		N1		
J2550	Promethazine hcl injection		N1		
J2560	Phenobarbital sodium inj		N1		
J2590	Oxytocin injection		N1		
J2597	Inj desmopressin acetate		N1		
J2650	Prednisolone acetate inj		N1		
J2670	Totazoline hcl injection		N1		
J2675	Inj progesterone per 50 MG		N1		
J2680	Fluphenazine decanoate 25 MG		N1		
J2690	Procainamide hcl injection		N1		
J2700	Oxacillin sodium injeciton		N1		
J2710	Neostigmine methylsifte inj		N1		
J2720	Inj protamine sulfate/10 MG		N1		
J2724	Protein C concentrate	NI	K2		\$12.08
J2725	Inj protirelin per 250 mcg		N1		
J2730	Pralidoxime chloride inj	CH	K2		\$35.20
J2760	Phentolaine mesylate inj		N1		
J2765	Metoclopramide hcl injection		N1		
J2770	Quinupristin/dalfopristin		K2		\$126.44
J2778	Ranibizumab injection	NI	K2		\$2,030.23
J2780	Ranitidine hydrochloride inj		N1		
J2783	Rasburicase		K2		\$144.43
J2788	Rho d immune globulin 50 mcg		K2		\$26.41
J2790	Rho d immune globulin inj		K2		\$80.79
J2791	Rhophylac injection	NI	K2		\$5.29
J2792	Rho(D) immune globulin h, sd		K2		\$15.62
J2794	Risperidone, long acting		K2		\$4.86
J2795	Ropivacaine HCl injection		N1		
J2800	Methocarbamol injection		N1		
J2805	Sincalide injection		N1		
J2810	Inj theophylline per 40 MG		N1		
J2820	Sargramostim injection		K2		\$24.86
J2850	Inj secretin synthetic human		K2		\$20.12
J2910	Aurothioglucose injeciton		N1		
J2916	Na ferric gluconate complex		N1		
J2920	Methylprednisolone injection		N1		
J2930	Methylprednisolone injection		N1		
J2940	Somatrem injection		K2		\$168.90
J2941	Somatropin injection		K2		\$48.52
J2950	Promazine hcl injection		N1		
J2993	Retepase injection		K2		\$841.28
J2995	Inj streptokinase /250000 IU		K2		\$129.75
J2997	Alteplase recombinant		K2		\$33.39
J3000	Streptomycin injection		N1		
J3010	Fentanyl citrate injeciton		N1		
J3030	Sumatriptan succinate / 6 MG		K2		\$61.27
J3070	Pentazocine injection		N1		
J3100	Tenecteplase injection		K2		\$2,034.65
J3105	Terbutaline sulfate inj		N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
J3120	Testosterone enanthate inj		N1		
J3130	Testosterone enanthate inj		N1		
J3140	Testosterone suspension inj		N1		
J3150	Testosteron propionate inj		N1		
J3230	Chlorpromazine hcl injection		N1		
J3240	Thyrotropin injection		K2		\$834.18
J3243	Tigecycline injection		K2		\$0.96
J3246	Tirofiban HCl		K2		\$7.56
J3250	Trimethobenzamide hcl inj		N1		
J3260	Tobramycin sulfate injection		N1		
J3265	Injection torsemide 10 mg/ml		N1		
J3280	Thiethylperazine maleate inj		N1		
J3285	Treprostinil injection		K2		\$55.36
J3301	Triamcinolone acetonide inj		N1		
J3302	Triamcinolone diacetate inj		N1		
J3303	Triamcinolone hexacetonl inj		N1		
J3305	Inj trimetrexate glucuronate		K2		\$148.30
J3310	Perphenazine injecton		N1		
J3315	Triptorelin pamoate		K2		\$159.38
J3320	Spectinomycn di-hcl inj	CH	N1		
J3350	Urea injection		K2		\$74.16
J3355	Urofollitropin, 75 iu		K2		\$50.22
J3360	Diazepam injection		N1		
J3364	Urokinase 5000 IU injection		N1		
J3365	Urokinase 250,000 IU inj		K2		\$453.41
J3370	Vancomycin hcl injection		N1		
J3396	Verteporfin injection		K2		\$8.99
J3400	Triflupromazine hcl inj		N1		
J3410	Hydroxyzine hcl injection		N1		
J3411	Thiamine hcl 100 mg		N1		
J3415	Pyridoxine hcl 100 mg		N1		
J3420	Vitamin b12 injection		N1		
J3430	Vitamin k phytonadione inj		N1		
J3465	Injection, voriconazole		K2		\$4.93
J3470	Hyaluronidase injection		N1		
J3471	Ovine, up to 999 USP units		N1		
J3472	Ovine, 1000 USP units		K2		\$133.77
J3473	Hyaluronidase recombinant		K2		\$0.40
J3475	Inj magnesium sulfate		N1		
J3480	Inj potassium chloride		N1		
J3485	Zidovudine		N1		
J3486	Ziprasidone mesylate		N1		
J3487	Zoledronic acid		K2		\$205.76
J3488	Reclast injection	NI	K2		\$220.81
J3490	Drugs unclassified injection		N1		
J3530	Nasal vaccine inhalation		N1		
J3590	Unclassified biologics		N1		
J7030	Normal saline solution infus		N1		
J7040	Normal saline solution infus		N1		
J7042	5% dextrose/normal saline		N1		
J7050	Normal saline solution infus		N1		
J7060	5% dextrose/water		N1		
J7070	D5w infusion		N1		
J7100	Dextran 40 infusion		N1		
J7110	Dextran 75 infusion		N1		
J7120	Ringers lactate infusion		N1		
J7130	Hypertonic saline solution		N1		
J7187	Humate-P, inj		K2		\$0.88
J7189	Factor viia		K2		\$1.15
J7190	Factor viii		K2		\$0.75
J7191	Factor VIII (porcine)	CH	N1		
J7192	Factor viii recombinant		K2		\$1.07
J7193	Factor IX non-recombinant		K2		\$0.89
J7194	Factor ix complex		K2		\$0.80
J7195	Factor IX recombinant		K2		\$0.99
J7197	Antithrombin iii injection		K2		\$1.82
J7198	Anti-inhibitor		K2		\$1.42
J7308	Aminolevulinic acid hcl top		K2		\$109.92

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
J7310	Ganciclovir long act implant		K2		\$4,707.90
J7311	Fluocinolone acetone implt		K2		\$19,162.50
J7321	Hyalgan/supartz inj per dose	NI	K2		\$101.81
J7322	Synvisc inj per dose	NI	K2		\$178.11
J7323	Euflexxa inj per dose	NI	K2		\$110.95
J7324	Orthovisc inj per dose	NI	K2		\$174.50
J7340	Metabolic active D/E tissue		K2		\$28.45
J7341	Non-human, metabolic tissue	CH	N1		
J7342	Metabolically active tissue		K2		\$36.40
J7343	Nonmetabolic act d/e tissue		K2		\$20.22
J7344	Nonmetabolic active tissue		K2		\$94.53
J7345	Non-human, non-metab tissue	CH	D5		
J7346	Injectable human tissue		K2		\$774.46
J7347	Integra matrix tissue	NI	K2		\$33.14
J7348	Tissuemend tissue	NI	K2		\$67.96
J7349	Primatrix tissue	NI	K2		\$67.96
J7500	Azathioprine oral 50mg		N1		
J7501	Azathioprine parenteral		K2		\$47.88
J7502	Cyclosporine oral 100 mg		K2		\$3.52
J7504	Lymphocyte immune globulin		K2		\$336.10
J7505	Monoclonal antibodies		K2		\$977.75
J7506	Prednisone oral		N1		
J7507	Tacrolimus oral per 1 MG		K2		\$3.69
J7509	Methylprednisolone oral		N1		
J7510	Prednisolone oral per 5 mg		N1		
J7511	Antithymocyte globulin rabbit		K2		\$337.82
J7513	Daclizumab, parenteral		K2		\$322.28
J7515	Cyclosporine oral 25 mg		N1		
J7516	Cyclosporin parenteral 250mg		N1		
J7517	Mycophenolate mofetil oral		K2		\$2.66
J7518	Mycophenolic acid		K2		\$2.41
J7520	Sirolimus, oral		K2		\$7.50
J7525	Tacrolimus injection		K2		\$138.64
J7599	Immunosuppressive drug noc		N1		
J7674	Methacholine chloride, neb		N1		
J7799	Non-inhalation drug for DME		N1		
J8501	Oral aprepitant		K2		\$4.99
J8510	Oral busulfan		K2		\$2.26
J8520	Capecitabine, oral, 150 mg		K2		\$4.28
J8521	Capecitabine, oral, 500 mg	CH	K2		\$14.19
J8530	Cyclophosphamide oral 25 MG		N1		
J8540	Oral dexamethasone		N1		
J8560	Etoposide oral 50 MG		K2		\$29.46
J8597	Antiemetic drug oral NOS		N1		
J8600	Melphalan oral 2 MG	CH	K2		\$4.14
J8610	Methotrexate oral 2.5 MG		N1		
J8650	Nabilone oral		K2		\$16.80
J8700	Temozolomide		K2		\$7.49
J9000	Doxorubic hcl 10 MG vl chemo	CH	N1		
J9001	Doxorubicin hcl liposome inj		K2		\$396.15
J9010	Alemtuzumab injection		K2		\$549.77
J9015	Aldesleukin/single use vial		K2		\$788.84
J9017	Arsenic trioxide		K2		\$34.44
J9020	Asparaginase injection		K2		\$54.26
J9025	Azacitidine injection		K2		\$4.35
J9027	Clofarabine injection		K2		\$114.41
J9031	Bcg live intravesical vac		K2		\$113.75
J9035	Bevacizumab injection		K2		\$56.93
J9040	Bleomycin sulfate injection		K2		\$42.93
J9041	Bortezomib injection		K2		\$33.20
J9045	Carboplatin injection		K2		\$7.44
J9050	Carmus bischl nitro inj		K2		\$152.24
J9055	Cetuximab injection		K2		\$49.43
J9060	Cisplatin 10 MG injection		N1		
J9062	Cisplatin 50 MG injection	CH	N1		
J9065	Inj cladribine per 1 MG		K2		\$32.04
J9070	Cyclophosphamide 100 MG inj		N1		
J9080	Cyclophosphamide 200 MG inj	CH	N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
J9090	Cyclophosphamide 500 MG inj	CH	N1		
J9091	Cyclophosphamide 1.0 grm inj	CH	N1		
J9092	Cyclophosphamide 2.0 grm inj	CH	N1		
J9093	Cyclophosphamide lyophilized	CH	N1		
J9094	Cyclophosphamide lyophilized	CH	N1		
J9095	Cyclophosphamide lyophilized	CH	N1		
J9096	Cyclophosphamide lyophilized	CH	N1		
J9097	Cyclophosphamide lyophilized	CH	N1		
J9098	Cytarabine liposome		K2		\$412.21
J9100	Cytarabine hcl 100 MG inj		N1		
J9110	Cytarabine hcl 500 MG inj	CH	N1		
J9120	Dactinomycin actinomycin d		K2		\$488.78
J9130	Dacarbazine 100 mg inj	CH	N1		
J9140	Dacarbazine 200 MG inj	CH	N1		
J9150	Daunorubicin		K2		\$19.33
J9151	Daunorubicin citrate liposom		K2		\$55.23
J9160	Denileukin diftiox, 300 mcg		K2		\$1,386.59
J9165	Diethylstilbestrol injection		N1		
J9170	Docetaxel		K2		\$310.85
J9175	Elliotts b solution per ml		N1		
J9178	Inj, epirubicin hcl, 2 mg		K2		\$19.79
J9181	Etoposide 10 MG inj		N1		
J9182	Etoposide 100 MG inj	CH	N1		
J9185	Fludarabine phosphate inj		K2		\$226.67
J9190	Fluorouracil injection		N1		
J9200	Floxuridine injection		K2		\$54.63
J9201	Gemcitabine HCl		K2		\$127.31
J9202	Goserelin acetate implant		K2		\$192.29
J9206	Irinotecan injection		K2		\$124.61
J9208	Ifosfomide injection		K2		\$38.13
J9209	Mesna injection		K2		\$7.97
J9211	Idarubicin hcl injection		K2		\$302.42
J9212	Interferon alfacon-1		K2		\$4.62
J9213	Interferon alfa-2a inj		K2		\$41.37
J9214	Interferon alfa-2b inj		K2		\$13.92
J9215	Interferon alfa-n3 inj		K2		\$9.03
J9216	Interferon gamma 1-b inj		K2		\$306.66
J9217	Leuprolide acetate suspnsion		K2		\$236.06
J9218	Leuprolide acetate injeciton		K2		\$7.98
J9219	Leuprolide acetate implant		K2		\$1,648.41
J9225	Vantas implant		K2		\$1,412.46
J9226	Supprelin LA implant	NI	K2		\$14,700.00
J9230	Mechlorethamine hcl inj		K2		\$143.08
J9245	Inj melphalan hydrochl 50 MG		K2		\$1,548.88
J9250	Methotrexate sodium inj		N1		
J9260	Methotrexate sodium inj	CH	N1		
J9261	Nelarabine injection		K2		\$86.84
J9263	Oxaliplatin		K2		\$9.15
J9264	Paclitaxel protein bound		K2		\$8.79
J9265	Paclitaxel injection		K2		\$14.57
J9266	Pegaspargase/singl dose vial		K2		\$2,080.19
J9268	Pentostatin injection		K2		\$2,051.68
J9270	Plicamycin (mithramycin) inj		K2		\$172.41
J9280	Mitomycin 5 MG inj		K2		\$14.39
J9290	Mitomycin 20 MG inj	CH	K2		\$57.56
J9291	Mitomycin 40 MG inj	CH	K2		\$115.11
J9293	Mitoxantrone hydrochl / 5 MG		K2		\$107.96
J9300	Gemtuzumab ozogamicin		K2		\$2,411.98
J9303	Panitumumab injection	NI	K2		\$83.15
J9305	Pemetrexed injection		K2		\$44.49
J9310	Rituximab cancer treatment		K2		\$504.40
J9320	Streptozocin injection		K2		\$146.93
J9340	Thiotepa injection		K2		\$41.12
J9350	Topotecan		K2		\$859.62
J9355	Trastuzumab		K2		\$58.51
J9357	Valrubicin, 200 mg		K2		\$77.96
J9360	Vinblastine sulfate inj		N1		
J9370	Vincristine sulfate 1 MG inj		N1		

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPCS code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
J9375	Vincristine sulfate 2 MG inj	CH	N1
J9380	Vincristine sulfate 5 MG inj	CH	N1
J9390	Vinorelbine tartrate/10 mg	K2	\$21.41
J9395	Injection, Fulvestrant	K2	\$80.60
J9600	Porfimer sodium	K2	\$2,532.53
J9999	Chemotherapy drug	N1
L8600	Implant breast silicone/eq	N1
L8603	Collagen imp urinary 2.5 ml	N1
L8606	Synthetic implnt urinary 1ml	N1
L8609	Artificial cornea	N1
L8610	Ocular implant	N1
L8612	Aqueous shunt prosthesis	N1
L8613	Ossicular implant	N1
L8614	Cochlear device	N1
L8630	Metacarpophalangeal implant	N1
L8631	MCP joint repl 2 pc or more	N1
L8641	Metatarsal joint implant	N1
L8642	Hallux implant	N1
L8658	Interphalangeal joint spacer	N1
L8659	Interphalangeal joint repl	N1
L8670	Vascular graft, synthetic	N1
L8682	Implt neurostim radiofq rec	N1
L8690	Aud osseo dev, int/ext comp	J7
L8699	Prosthetic implant NOS	N1
P9041	Albumin (human),5%, 50ml	CH	K2	0.3413	\$21.74
P9045	Albumin (human), 5%, 250 ml	CH	K2	1.0987	\$69.98
P9046	Albumin (human), 25%, 20 ml	CH	K2	0.4118	\$26.23
P9047	Albumin (human), 25%, 50ml	CH	K2	1.1362	\$72.37
Q0163	Diphenhydramine HCl 50mg	N1
Q0164	Prochlorperazine maleate 5mg	N1
Q0166	Granisetron HCl 1 mg oral	K2	\$49.96
Q0167	Dronabinol 2.5mg oral	N1
Q0169	Promethazine HCl 12.5mg oral	N1
Q0171	Chlorpromazine HCl 10mg oral	N1
Q0173	Trimethobenzamide HCl 250mg	N1
Q0174	Thiethylperazine maleate10mg	N1
Q0175	Perphenazine 4mg oral	N1
Q0177	Hydroxyzine pamoate 25mg	N1
Q0179	Ondansetron HCl 8mg oral	K2	\$18.37
Q0180	Dolasetron mesylate oral	K2	\$43.77
Q0515	Sermorelin acetate injection	K2	\$1.74
Q1003	Ntiol category 3	L6	\$50.00
Q2004	Bladder calculi irrig sol	N1
Q2009	Fosphenytoin, 50 mg	K2	\$5.76
Q2017	Teniposide, 50 mg	K2	\$280.26
Q3025	IM inj interferon beta 1-a	K2	\$118.84
Q4079	Natalizumab injection	CH	D5
Q4083	Hyalgan/supartz inj per dose	CH	D5
Q4084	Synvisc inj per dose	CH	D5
Q4085	Euflexxa inj per dose	CH	D5
Q4086	Orthovisc inj per dose	CH	D5
Q4087	Octagam injection	CH	D5
Q4088	Gammagard liquid injection	CH	D5
Q4089	Rhophylac injection	CH	D5
Q4090	Hepagam B IM injection	CH	D5
Q4091	Flebogamma injection	CH	D5
Q4092	Gamunex injection	CH	D5
Q4095	Reclast injection	CH	D5
Q9945	LOCM <=149 mg/ml iodine, 1ml	CH	D5
Q9946	LOCM 150-199mg/ml iodine,1ml	CH	D5
Q9947	LOCM 200-249mg/ml iodine,1ml	CH	D5
Q9948	LOCM 250-299mg/ml iodine,1ml	CH	D5
Q9949	LOCM 300-349mg/ml iodine,1ml	CH	D5
Q9950	LOCM 350-399mg/ml iodine,1ml	CH	D5
Q9951	LOCM >= 400 mg/ml iodine,1ml	CH	N1
Q9952	Inj Gad-base MR contrast,1ml	CH	D5
Q9953	Inj Fe-based MR contrast,1ml	CH	N1
Q9954	Oral MR contrast,100 ml	CH	N1

ADDENDUM BB.—ASC COVERED ANCILLARY SERVICES INTEGRAL TO COVERED SURGICAL PROCEDURES FOR CY 2008—
Continued

[Including Ancillary Services for Which Payment Is Packaged]

HCPSC code	Short descriptor	Comment indicator	Payment indicator	CY 2008 payment weight	CY 2008 payment
Q9955	Inj perflerone lip micros,ml	CH	N1
Q9956	Inj octafluoropropane mic,ml	CH	N1
Q9957	Inj perflutren lip micros,ml	CH	N1
Q9958	HOCM <=149 mg/ml iodine,1ml	N1
Q9959	HOCM 150-199mg/ml iodine,1ml	N1
Q9960	HOCM 200-249mg/ml iodine,1ml	N1
Q9961	HOCM 250-299mg/ml iodine,1ml	N1
Q9962	HOCM 300-349mg/ml iodine,1ml	N1
Q9963	HOCM 350-399mg/ml iodine,1ml	N1
Q9964	HOCM>= 400mg/ml iodine,1ml	N1
Q9965	LOCM 100-199mg/ml iodine,1ml	NI	N1
Q9966	LOCM 200-299mg/ml iodine,1ml	NI	N1
Q9967	LOCM 300-399mg/ml iodine,1ml	NI	N1
V2630	Anter chamber intraocul lens	N1
V2631	Iris support intraoculr lens	N1
V2632	Post chmbr intraocular lens	N1
V2785	Corneal tissue processing	F4
V2790	Amniotic membrane	N1

ADDENDUM D1.—OPPS PAYMENT STATUS INDICATORS

Indicator	Item/code/service	OPPS payment status
A	Services furnished to a hospital outpatient that are paid under a fee schedule or payment system other than OPPS, for example: <ul style="list-style-type: none"> • Ambulance Services. • Clinical Diagnostic Laboratory Services • Non-Implantable Prosthetic and Orthotic Devices. • EPO for ESRD Patients. • Physical, Occupational, and Speech Therapy. • Routine Dialysis Services for ESRD Patients Provided in a Certified Dialysis Unit of a Hospital. • Diagnostic Mammography. • Screening Mammography 	Not paid under OPPS. Paid by fiscal intermediaries/MACs under a fee schedule or payment system other than OPPS. Not subject to deductible or coinsurance. Not subject to deductible.
B	Codes that are not recognized by OPPS when submitted on an outpatient hospital Part B bill type (12x and 13x).	Not paid under OPPS. <ul style="list-style-type: none"> • May be paid by fiscal intermediaries/MACs when submitted on a different bill type, for example, 75x (CORF), but not paid under OPPS. • An alternate code that is recognized by OPPS when submitted on an outpatient hospital Part B bill type (12x and 13x) may be available.
C	Inpatient Procedures	Not paid under OPPS. Admit patient. Bill as inpatient.
D	Discontinued Codes	Not paid under OPPS or any other Medicare payment system.
E	Items, Codes, and Services: <ul style="list-style-type: none"> • That are not covered by Medicare based on statutory exclusion. • That are not covered by Medicare for reasons other than statutory exclusion. • That are not recognized by Medicare but for which an alternate code for the same item or service may be available. • For which separate payment is not provided by Medicare. 	Not paid under OPPS or any other Medicare payment system.
F	Corneal Tissue Acquisition; Certain CRNA Services and Hepatitis B Vaccines.	Not paid under OPPS. Paid at reasonable cost.
G	Pass-Through Drugs and Biologicals	Paid under OPPS; separate APC payment includes pass-through amount.

ADDENDUM D1.—OPPS PAYMENT STATUS INDICATORS—Continued

Indicator	Item/code/service	OPPS payment status
H	Pass-Through Device Categories	Separate cost-based pass-through payment; not subject to copayment.
K	(1) Nonpass-Through Drugs and Biologicals (2) Therapeutic Radiopharmaceuticals (3) Brachytherapy Sources (4) Blood and Blood Products	(1) Paid under OPPS; separate APC payment. (2) Paid under OPPS; separate APC payment. (3) Paid under OPPS; separate APC payment. (4) Paid under OPPS; separate APC payment.
L	Influenza Vaccine; Pneumococcal Pneumonia Vaccine	Not paid under OPPS. Paid at reasonable cost; not subject to deductible or coinsurance.
M	Items and Services Not Billable to the Fiscal Intermediary/MAC.	Not paid under OPPS.
N	Items and Services Packaged into APC Rates	Paid under OPPS; payment is packaged into payment for other services, including outliers. Therefore, there is no separate APC payment.
P	Partial Hospitalization	Paid under OPPS; per diem APC payment.
Q	Packaged Services Subject to Separate Payment under OPPS Payment Criteria.	Paid under OPPS; Addendum B displays APC assignments when services are separately payable. (1) Separate APC payment based on OPPS payment criteria. (2) If criteria are not met, payment is packaged into payment for other services, including outliers. Therefore, there is no separate APC payment.
S	Significant Procedure, Not Discounted when Multiple	Paid under OPPS; separate APC payment.
T	Significant Procedure, Multiple Reduction Applies	Paid under OPPS; separate APC payment.
V	Clinic or Emergency Department Visit	Paid under OPPS; separate APC payment.
X	Ancillary Services	Paid under OPPS; separate APC payment.
Y	Non-Implantable Durable Medical Equipment	Not paid under OPPS. All institutional providers other than home health agencies bill to DMERC.

ADDENDUM DD1.—ASC PAYMENT INDICATORS

Indicator	Payment indicator definition
A2	Surgical procedure on ASC list in CY 2007; payment based on OPPS relative payment weight.
D5	Deleted/discontinued code; no payment made.
F4	Corneal tissue acquisition; paid at reasonable cost.
G2	Non office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight.
H2	Brachytherapy source paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate.
H8	Device-intensive procedure on ASC list in CY 2007; paid at adjusted rate.
J7	OPPS pass-through device paid separately when provided integral to a surgical procedure on ASC list; payment contractor-priced.
J8	Device-intensive procedure added to ASC list in CY 2008 or later; paid at adjusted rate.
K2	Drugs and biologicals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate.
K7	Unclassified drugs and biologicals; payment contractor-priced.
L6	New Technology Intraocular Lens (NTIOL); special payment.
N1	Packaged service/item; no separate payment made.
P2	Office-based surgical procedure added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on OPPS relative payment weight.
P3	Office-based surgical procedure added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on MPFS nonfacility PE RVUs.
R2	Office-based surgical procedure added to ASC list in CY 2008 or later without MPFS nonfacility PE RVUs; payment based on OPPS relative payment weight.
Z2	Radiology service paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS relative payment weight.
Z3	Radiology service paid separately when provided integral to a surgical procedure on ASC list; payment based on MPFS nonfacility PE RVUs.

ADDENDUM DD2.—OPPS COMMENT INDICATORS

Comment indicator	Descriptor
CH	Active HCPCS code in current year and next calendar year, status indicator and/or APC assignment has changed; or active HCPCS code that will be discontinued at the end of the current calendar year.
NI	New code, interim APC assignment; comments will be accepted on the interim APC assignment for the new code.

ADDENDUM DD2.—ASC COMMENT INDICATORS

Comment indicator	Descriptor
CH	Active HCPCS code in current year and next calendar year, payment indicator has changed; or active HCPCS code that is newly recognized as payable in an ASC; or active HCPCS code that will be discontinued at the end of the current calendar year.
NI	New code, interim payment; comments will be accepted on the interim payment indicator for the new code.

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008

HCPCS code	Short descriptor	SI	CI
00176	Anesth, pharyngeal surgery	C
00192	Anesth, facial bone surgery	C
00214	Anesth, skull drainage	C
00215	Anesth, skull repair/fract	C
00452	Anesth, surgery of shoulder	C
00474	Anesth, surgery of rib(s)	C
00524	Anesth, chest drainage	C
00540	Anesth, chest surgery	C
00542	Anesth, release of lung	C
00546	Anesth, lung,chest wall surg	C
00560	Anesth, heart surg w/o pump	C
00561	Anesth, heart surg < age 1	C
00562	Anesth, heart surg w/pump	C
00580	Anesth, heart/lung transplnt	C
00604	Anesth, sitting procedure	C
00622	Anesth, removal of nerves	C
00632	Anesth, removal of nerves	C
00670	Anesth, spine, cord surgery	C
00792	Anesth, hemorr/excise liver	C
00794	Anesth, pancreas removal	C
00796	Anesth, for liver transplant	C
00802	Anesth, fat layer removal	C
00844	Anesth, pelvis surgery	C
00846	Anesth, hysterectomy	C
00848	Anesth, pelvic organ surg	C
00864	Anesth, removal of bladder	C
00865	Anesth, removal of prostate	C
00866	Anesth, removal of adrenal	C
00868	Anesth, kidney transplant	C
00882	Anesth, major vein ligation	C
00904	Anesth, perineal surgery	C
00908	Anesth, removal of prostate	C
00932	Anesth, amputation of penis	C
00934	Anesth, penis, nodes removal	C
00936	Anesth, penis, nodes removal	C
00944	Anesth, vaginal hysterectomy	C
01140	Anesth, amputation at pelvis	C
01150	Anesth, pelvic tumor surgery	C
01212	Anesth, hip disarticulation	C
01214	Anesth, hip arthroplasty	C
01232	Anesth, amputation of femur	C
01234	Anesth, radical femur surg	C
01272	Anesth, femoral artery surg	C
01274	Anesth, femoral embolectomy	C
01402	Anesth, knee arthroplasty	C
01404	Anesth, amputation at knee	C
01442	Anesth, knee artery surg	C
01444	Anesth, knee artery repair	C
01486	Anesth, ankle replacement	C
01502	Anesth, lwr leg embolectomy	C
01632	Anesth, surgery of shoulder	C

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
01634	Anesth, shoulder joint amput	C	
01636	Anesth, forequarter amput	C	
01638	Anesth, shoulder replacement	C	
01652	Anesth, shoulder vessel surg	C	
01654	Anesth, shoulder vessel surg	C	
01656	Anesth, arm-leg vessel surg	C	
01756	Anesth, radical humerus surg	C	
01990	Support for organ donor	C	
11004	Debride genitalia & perineum	C	
11005	Debride abdom wall	C	
11006	Debride genit/per/abdom wall	C	
11008	Remove mesh from abd wall	C	
15756	Free myo/skin flap microvasc	C	
15757	Free skin flap, microvasc	C	
15758	Free fascial flap, microvasc	C	
16036	Escharotomy; add'l incision	C	
19271	Revision of chest wall	C	
19272	Extensive chest wall surgery	C	
19305	Mast, radical	C	
19306	Mast, rad, urban type	C	
19361	Breast reconstr w/lat flap	C	
19364	Breast reconstruction	C	
19367	Breast reconstruction	C	
19368	Breast reconstruction	C	
19369	Breast reconstruction	C	
20660	Apply, rem fixation device	C	
20661	Application of head brace	C	
20664	Halo brace application	C	
20802	Replantation, arm, complete	C	
20805	Replant forearm, complete	C	
20808	Replantation hand, complete	C	
20816	Replantation digit, complete	C	
20824	Replantation thumb, complete	C	
20827	Replantation thumb, complete	C	
20838	Replantation foot, complete	C	
20930	Sp bone algrft morsel add-on	C	
20931	Sp bone algrft struct add-on	C	
20936	Sp bone agrft local add-on	C	
20937	Sp bone agrft morsel add-on	C	
20938	Sp bone agrft struct add-on	C	
20955	Fibula bone graft, microvasc	C	
20956	Iliac bone graft, microvasc	C	
20957	Mt bone graft, microvasc	C	
20962	Other bone graft, microvasc	C	
20969	Bone/skin graft, microvasc	C	
20970	Bone/skin graft, iliac crest	C	
21045	Extensive jaw surgery	C	
21141	Reconstruct midface, lefort	C	
21142	Reconstruct midface, lefort	C	
21143	Reconstruct midface, lefort	C	
21145	Reconstruct midface, lefort	C	
21146	Reconstruct midface, lefort	C	
21147	Reconstruct midface, lefort	C	
21151	Reconstruct midface, lefort	C	
21154	Reconstruct midface, lefort	C	
21155	Reconstruct midface, lefort	C	
21159	Reconstruct midface, lefort	C	
21160	Reconstruct midface, lefort	C	
21172	Reconstruct orbit/forehead	C	
21179	Reconstruct entire forehead	C	
21180	Reconstruct entire forehead	C	
21182	Reconstruct cranial bone	C	
21183	Reconstruct cranial bone	C	
21184	Reconstruct cranial bone	C	
21188	Reconstruction of midface	C	
21193	Reconst lwr jaw w/o graft	C	
21194	Reconst lwr jaw w/graft	C	
21196	Reconst lwr jaw w/fixation	C	
21247	Reconstruct lower jaw bone	C	
21255	Reconstruct lower jaw bone	C	
21256	Reconstruction of orbit	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
21268	Revise eye sockets	C	
21343	Treatment of sinus fracture	C	
21344	Treatment of sinus fracture	C	
21346	Treat nose/jaw fracture	C	
21347	Treat nose/jaw fracture	C	
21348	Treat nose/jaw fracture	C	
21366	Treat cheek bone fracture	C	
21386	Treat eye socket fracture	C	
21387	Treat eye socket fracture	C	
21395	Treat eye socket fracture	C	
21422	Treat mouth roof fracture	C	
21423	Treat mouth roof fracture	C	
21431	Treat craniofacial fracture	C	
21432	Treat craniofacial fracture	C	
21433	Treat craniofacial fracture	C	
21435	Treat craniofacial fracture	C	
21436	Treat craniofacial fracture	C	
21510	Drainage of bone lesion	C	
21615	Removal of rib	C	
21616	Removal of rib and nerves	C	
21620	Partial removal of sternum	C	
21627	Sternal debridement	C	
21630	Extensive sternum surgery	C	
21632	Extensive sternum surgery	C	
21705	Revision of neck muscle/rib	C	
21740	Reconstruction of sternum	C	
21750	Repair of sternum separation	C	
21810	Treatment of rib fracture(s)	C	
21825	Treat sternum fracture	C	
22010	I&d, p-spine, c/t/cerv-thor	C	
22015	I&d, p-spine, l/s/l	C	
22110	Remove part of neck vertebra	C	
22112	Remove part, thorax vertebra	C	
22114	Remove part, lumbar vertebra	C	
22116	Remove extra spine segment	C	
22206	Cut spine 3 col, thor	C	NI
22207	Cut spine 3 col, lumb	C	NI
22208	Cut spine 3 col, addl seg	C	NI
22210	Revision of neck spine	C	
22212	Revision of thorax spine	C	
22214	Revision of lumbar spine	C	
22216	Revise, extra spine segment	C	
22220	Revision of neck spine	C	
22224	Revision of lumbar spine	C	
22226	Revise, extra spine segment	C	
22318	Treat odontoid fx w/o graft	C	
22319	Treat odontoid fx w/graft	C	
22325	Treat spine fracture	C	
22326	Treat neck spine fracture	C	
22327	Treat thorax spine fracture	C	
22328	Treat each add spine fx	C	
22532	Lat thorax spine fusion	C	
22533	Lat lumbar spine fusion	C	
22534	Lat thor/lumb, add'l seg	C	
22548	Neck spine fusion	C	
22554	Neck spine fusion	C	
22556	Thorax spine fusion	C	
22558	Lumbar spine fusion	C	
22585	Additional spinal fusion	C	
22590	Spine & skull spinal fusion	C	
22595	Neck spinal fusion	C	
22600	Neck spine fusion	C	
22610	Thorax spine fusion	C	
22630	Lumbar spine fusion	C	
22632	Spine fusion, extra segment	C	
22800	Fusion of spine	C	
22802	Fusion of spine	C	
22804	Fusion of spine	C	
22808	Fusion of spine	C	
22810	Fusion of spine	C	
22812	Fusion of spine	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
22818	Kyphectomy, 1–2 segments	C	
22819	Kyphectomy, 3 or more	C	
22830	Exploration of spinal fusion	C	
22840	Insert spine fixation device	C	
22841	Insert spine fixation device	C	
22842	Insert spine fixation device	C	
22843	Insert spine fixation device	C	
22844	Insert spine fixation device	C	
22845	Insert spine fixation device	C	
22846	Insert spine fixation device	C	
22847	Insert spine fixation device	C	
22848	Insert pelv fixation device	C	
22849	Reinsert spinal fixation	C	
22850	Remove spine fixation device	C	
22852	Remove spine fixation device	C	
22855	Remove spine fixation device	C	
22857	Lumbar artif diskectomy	C	
22862	Revise lumbar artif disc	C	
22865	Remove lumb artif disc	C	
23200	Removal of collar bone	C	
23210	Removal of shoulder blade	C	
23220	Partial removal of humerus	C	
23221	Partial removal of humerus	C	
23222	Partial removal of humerus	C	
23332	Remove shoulder foreign body	C	
23472	Reconstruct shoulder joint	C	
23900	Amputation of arm & girdle	C	
23920	Amputation at shoulder joint	C	
24900	Amputation of upper arm	C	
24920	Amputation of upper arm	C	
24930	Amputation follow-up surgery	C	
24931	Amputate upper arm & implant	C	
24940	Revision of upper arm	C	
25900	Amputation of forearm	C	
25905	Amputation of forearm	C	
25909	Amputation follow-up surgery	C	
25915	Amputation of forearm	C	
25920	Amputate hand at wrist	C	
25924	Amputation follow-up surgery	C	
25927	Amputation of hand	C	
26551	Great toe-hand transfer	C	
26553	Single transfer, toe-hand	C	
26554	Double transfer, toe-hand	C	
26556	Toe joint transfer	C	
26992	Drainage of bone lesion	C	
27005	Incision of hip tendon	C	
27025	Incision of hip/thigh fascia	C	
27030	Drainage of hip joint	C	
27036	Excision of hip joint/muscle	C	
27054	Removal of hip joint lining	C	
27070	Partial removal of hip bone	C	
27071	Partial removal of hip bone	C	
27075	Extensive hip surgery	C	
27076	Extensive hip surgery	C	
27077	Extensive hip surgery	C	
27078	Extensive hip surgery	C	
27079	Extensive hip surgery	C	
27090	Removal of hip prosthesis	C	
27091	Removal of hip prosthesis	C	
27120	Reconstruction of hip socket	C	
27122	Reconstruction of hip socket	C	
27125	Partial hip replacement	C	
27130	Total hip arthroplasty	C	
27132	Total hip arthroplasty	C	
27134	Revise hip joint replacement	C	
27137	Revise hip joint replacement	C	
27138	Revise hip joint replacement	C	
27140	Transplant femur ridge	C	
27146	Incision of hip bone	C	
27147	Revision of hip bone	C	
27151	Incision of hip bones	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
27156	Revision of hip bones	C	
27158	Revision of pelvis	C	
27161	Incision of neck of femur	C	
27165	Incision/fixation of femur	C	
27170	Repair/graft femur head/neck	C	
27175	Treat slipped epiphysis	C	
27176	Treat slipped epiphysis	C	
27177	Treat slipped epiphysis	C	
27178	Treat slipped epiphysis	C	
27179	Revise head/neck of femur	C	
27181	Treat slipped epiphysis	C	
27185	Revision of femur epiphysis	C	
27187	Reinforce hip bones	C	
27215	Treat pelvic fracture(s)	C	
27217	Treat pelvic ring fracture	C	
27218	Treat pelvic ring fracture	C	
27222	Treat hip socket fracture	C	
27226	Treat hip wall fracture	C	
27227	Treat hip fracture(s)	C	
27228	Treat hip fracture(s)	C	
27232	Treat thigh fracture	C	
27236	Treat thigh fracture	C	
27240	Treat thigh fracture	C	
27244	Treat thigh fracture	C	
27245	Treat thigh fracture	C	
27248	Treat thigh fracture	C	
27253	Treat hip dislocation	C	
27254	Treat hip dislocation	C	
27258	Treat hip dislocation	C	
27259	Treat hip dislocation	C	
27268	Cltx thigh fx w/mnpj	C	NI
27269	Optx thigh fx	C	NI
27280	Fusion of sacroiliac joint	C	
27282	Fusion of pubic bones	C	
27284	Fusion of hip joint	C	
27286	Fusion of hip joint	C	
27290	Amputation of leg at hip	C	
27295	Amputation of leg at hip	C	
27303	Drainage of bone lesion	C	
27365	Extensive leg surgery	C	
27445	Revision of knee joint	C	
27447	Total knee arthroplasty	C	
27448	Incision of thigh	C	
27450	Incision of thigh	C	
27454	Realignment of thigh bone	C	
27455	Realignment of knee	C	
27457	Realignment of knee	C	
27465	Shortening of thigh bone	C	
27466	Lengthening of thigh bone	C	
27468	Shorten/lengthen thighs	C	
27470	Repair of thigh	C	
27472	Repair/graft of thigh	C	
27477	Surgery to stop leg growth	C	
27479	Surgery to stop leg growth	C	
27485	Surgery to stop leg growth	C	
27486	Revise/replace knee joint	C	
27487	Revise/replace knee joint	C	
27488	Removal of knee prosthesis	C	
27495	Reinforce thigh	C	
27506	Treatment of thigh fracture	C	
27507	Treatment of thigh fracture	C	
27511	Treatment of thigh fracture	C	
27513	Treatment of thigh fracture	C	
27514	Treatment of thigh fracture	C	
27519	Treat thigh fx growth plate	C	
27535	Treat knee fracture	C	
27536	Treat knee fracture	C	
27540	Treat knee fracture	C	
27556	Treat knee dislocation	C	
27557	Treat knee dislocation	C	
27558	Treat knee dislocation	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
27580	Fusion of knee	C	
27590	Amputate leg at thigh	C	
27591	Amputate leg at thigh	C	
27592	Amputate leg at thigh	C	
27596	Amputation follow-up surgery	C	
27598	Amputate lower leg at knee	C	
27645	Extensive lower leg surgery	C	
27646	Extensive lower leg surgery	C	
27702	Reconstruct ankle joint	C	
27703	Reconstruction, ankle joint	C	
27712	Realignment of lower leg	C	
27715	Revision of lower leg	C	
27724	Repair/graft of tibia	C	
27725	Repair of lower leg	C	
27727	Repair of lower leg	C	
27880	Amputation of lower leg	C	
27881	Amputation of lower leg	C	
27882	Amputation of lower leg	C	
27886	Amputation follow-up surgery	C	
27888	Amputation of foot at ankle	C	
28800	Amputation of midfoot	C	
28805	Amputation thru metatarsal	C	
31225	Removal of upper jaw	C	
31230	Removal of upper jaw	C	
31290	Nasal/sinus endoscopy, surg	C	
31291	Nasal/sinus endoscopy, surg	C	
31360	Removal of larynx	C	
31365	Removal of larynx	C	
31367	Partial removal of larynx	C	
31368	Partial removal of larynx	C	
31370	Partial removal of larynx	C	
31375	Partial removal of larynx	C	
31380	Partial removal of larynx	C	
31382	Partial removal of larynx	C	
31390	Removal of larynx & pharynx	C	
31395	Reconstruct larynx & pharynx	C	
31584	Treat larynx fracture	C	
31587	Revision of larynx	C	
31725	Clearance of airways	C	
31760	Repair of windpipe	C	
31766	Reconstruction of windpipe	C	
31770	Repair/graft of bronchus	C	
31775	Reconstruct bronchus	C	
31780	Reconstruct windpipe	C	
31781	Reconstruct windpipe	C	
31786	Remove windpipe lesion	C	
31800	Repair of windpipe injury	C	
31805	Repair of windpipe injury	C	
32035	Exploration of chest	C	
32036	Exploration of chest	C	
32095	Biopsy through chest wall	C	
32100	Exploration/biopsy of chest	C	
32110	Explore/repair chest	C	
32120	Re-exploration of chest	C	
32124	Explore chest free adhesions	C	
32140	Removal of lung lesion(s)	C	
32141	Remove/treat lung lesions	C	
32150	Removal of lung lesion(s)	C	
32151	Remove lung foreign body	C	
32160	Open chest heart massage	C	
32200	Drain, open, lung lesion	C	
32215	Treat chest lining	C	
32220	Release of lung	C	
32225	Partial release of lung	C	
32310	Removal of chest lining	C	
32320	Free/remove chest lining	C	
32402	Open biopsy chest lining	C	
32440	Removal of lung	C	
32442	Sleeve pneumonectomy	C	
32445	Removal of lung	C	
32480	Partial removal of lung	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
32482	Bilobectomy	C	
32484	Segmentectomy	C	
32486	Sleeve lobectomy	C	
32488	Completion pneumonectomy	C	
32491	Lung volume reduction	C	
32500	Partial removal of lung	C	
32501	Repair bronchus add-on	C	
32503	Resect apical lung tumor	C	
32504	Resect apical lung tum/chest	C	
32540	Removal of lung lesion	C	
32650	Thoracoscopy, surgical	C	
32651	Thoracoscopy, surgical	C	
32652	Thoracoscopy, surgical	C	
32653	Thoracoscopy, surgical	C	
32654	Thoracoscopy, surgical	C	
32655	Thoracoscopy, surgical	C	
32656	Thoracoscopy, surgical	C	
32657	Thoracoscopy, surgical	C	
32658	Thoracoscopy, surgical	C	
32659	Thoracoscopy, surgical	C	
32660	Thoracoscopy, surgical	C	
32661	Thoracoscopy, surgical	C	
32662	Thoracoscopy, surgical	C	
32663	Thoracoscopy, surgical	C	
32664	Thoracoscopy, surgical	C	
32665	Thoracoscopy, surgical	C	
32800	Repair lung hernia	C	
32810	Close chest after drainage	C	
32815	Close bronchial fistula	C	
32820	Reconstruct injured chest	C	
32850	Donor pneumonectomy	C	
32851	Lung transplant, single	C	
32852	Lung transplant with bypass	C	
32853	Lung transplant, double	C	
32854	Lung transplant with bypass	C	
32855	Prepare donor lung, single	C	
32856	Prepare donor lung, double	C	
32900	Removal of rib(s)	C	
32905	Revise & repair chest wall	C	
32906	Revise & repair chest wall	C	
32940	Revision of lung	C	
32997	Total lung lavage	C	
33015	Incision of heart sac	C	
33020	Incision of heart sac	C	
33025	Incision of heart sac	C	
33030	Partial removal of heart sac	C	
33031	Partial removal of heart sac	C	
33050	Removal of heart sac lesion	C	
33120	Removal of heart lesion	C	
33130	Removal of heart lesion	C	
33140	Heart revascularize (tmr)	C	
33141	Heart tmr w/other procedure	C	
33202	Insert epicard eltrd, open	C	
33203	Insert epicard eltrd, endo	C	
33236	Remove electrode/thoracotomy	C	
33237	Remove electrode/thoracotomy	C	
33238	Remove electrode/thoracotomy	C	
33243	Remove eltrd/thoracotomy	C	
33250	Ablate heart dysrhythm focus	C	
33251	Ablate heart dysrhythm focus	C	
33254	Ablate atria, lmtd	C	
33255	Ablate atria w/o bypass, ext	C	
33256	Ablate atria w/bypass, exten	C	
33257	Ablate atria, lmtd, add-on	C	NI
33258	Ablate atria, x10sv, add-on	C	NI
33259	Ablate atria w/bypass add-on	C	NI
33261	Ablate heart dysrhythm focus	C	
33265	Ablate atria, lmtd, endo	C	
33266	Ablate atria, x10sv, endo	C	
33300	Repair of heart wound	C	
33305	Repair of heart wound	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
33310	Exploratory heart surgery	C	
33315	Exploratory heart surgery	C	
33320	Repair major blood vessel(s)	C	
33321	Repair major vessel	C	
33322	Repair major blood vessel(s)	C	
33330	Insert major vessel graft	C	
33332	Insert major vessel graft	C	
33335	Insert major vessel graft	C	
33400	Repair of aortic valve	C	
33401	Valvuloplasty, open	C	
33403	Valvuloplasty, w/cp bypass	C	
33404	Prepare heart-aorta conduit	C	
33405	Replacement of aortic valve	C	
33406	Replacement of aortic valve	C	
33410	Replacement of aortic valve	C	
33411	Replacement of aortic valve	C	
33412	Replacement of aortic valve	C	
33413	Replacement of aortic valve	C	
33414	Repair of aortic valve	C	
33415	Revision, subvalvular tissue	C	
33416	Revise ventricle muscle	C	
33417	Repair of aortic valve	C	
33420	Revision of mitral valve	C	
33422	Revision of mitral valve	C	
33425	Repair of mitral valve	C	
33426	Repair of mitral valve	C	
33427	Repair of mitral valve	C	
33430	Replacement of mitral valve	C	
33460	Revision of tricuspid valve	C	
33463	Valvuloplasty, tricuspid	C	
33464	Valvuloplasty, tricuspid	C	
33465	Replace tricuspid valve	C	
33468	Revision of tricuspid valve	C	
33470	Revision of pulmonary valve	C	
33471	Valvotomy, pulmonary valve	C	
33472	Revision of pulmonary valve	C	
33474	Revision of pulmonary valve	C	
33475	Replacement, pulmonary valve	C	
33476	Revision of heart chamber	C	
33478	Revision of heart chamber	C	
33496	Repair, prosth valve clot	C	
33500	Repair heart vessel fistula	C	
33501	Repair heart vessel fistula	C	
33502	Coronary artery correction	C	
33503	Coronary artery graft	C	
33504	Coronary artery graft	C	
33505	Repair artery w/tunnel	C	
33506	Repair artery, translocation	C	
33507	Repair art, intramural	C	
33510	CABG, vein, single	C	
33511	CABG, vein, two	C	
33512	CABG, vein, three	C	
33513	CABG, vein, four	C	
33514	CABG, vein, five	C	
33516	Cabg, vein, six or more	C	
33517	CABG, artery-vein, single	C	
33518	CABG, artery-vein, two	C	
33519	CABG, artery-vein, three	C	
33521	CABG, artery-vein, four	C	
33522	CABG, artery-vein, five	C	
33523	Cabg, art-vein, six or more	C	
33530	Coronary artery, bypass/reop	C	
33533	CABG, arterial, single	C	
33534	CABG, arterial, two	C	
33535	CABG, arterial, three	C	
33536	Cabg, arterial, four or more	C	
33542	Removal of heart lesion	C	
33545	Repair of heart damage	C	
33548	Restore/remodel, ventricle	C	
33572	Open coronary endarterectomy	C	
33600	Closure of valve	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
33602	Closure of valve	C	
33606	Anastomosis/artery-aorta	C	
33608	Repair anomaly w/conduit	C	
33610	Repair by enlargement	C	
33611	Repair double ventricle	C	
33612	Repair double ventricle	C	
33615	Repair, modified fontan	C	
33617	Repair single ventricle	C	
33619	Repair single ventricle	C	
33641	Repair heart septum defect	C	
33645	Revision of heart veins	C	
33647	Repair heart septum defects	C	
33660	Repair of heart defects	C	
33665	Repair of heart defects	C	
33670	Repair of heart chambers	C	
33675	Close mult vsd	C	
33676	Close mult vsd w/resection	C	
33677	Cl mult vsd w/rem pul band	C	
33681	Repair heart septum defect	C	
33684	Repair heart septum defect	C	
33688	Repair heart septum defect	C	
33690	Reinforce pulmonary artery	C	
33692	Repair of heart defects	C	
33694	Repair of heart defects	C	
33697	Repair of heart defects	C	
33702	Repair of heart defects	C	
33710	Repair of heart defects	C	
33720	Repair of heart defect	C	
33722	Repair of heart defect	C	
33724	Repair venous anomaly	C	
33726	Repair pul venous stenosis	C	
33730	Repair heart-vein defect(s)	C	
33732	Repair heart-vein defect	C	
33735	Revision of heart chamber	C	
33736	Revision of heart chamber	C	
33737	Revision of heart chamber	C	
33750	Major vessel shunt	C	
33755	Major vessel shunt	C	
33762	Major vessel shunt	C	
33764	Major vessel shunt & graft	C	
33766	Major vessel shunt	C	
33767	Major vessel shunt	C	
33768	Cavopulmonary shunting	C	
33770	Repair great vessels defect	C	
33771	Repair great vessels defect	C	
33774	Repair great vessels defect	C	
33775	Repair great vessels defect	C	
33776	Repair great vessels defect	C	
33777	Repair great vessels defect	C	
33778	Repair great vessels defect	C	
33779	Repair great vessels defect	C	
33780	Repair great vessels defect	C	
33781	Repair great vessels defect	C	
33786	Repair arterial trunk	C	
33788	Revision of pulmonary artery	C	
33800	Aortic suspension	C	
33802	Repair vessel defect	C	
33803	Repair vessel defect	C	
33813	Repair septal defect	C	
33814	Repair septal defect	C	
33820	Revise major vessel	C	
33822	Revise major vessel	C	
33824	Revise major vessel	C	
33840	Remove aorta constriction	C	
33845	Remove aorta constriction	C	
33851	Remove aorta constriction	C	
33852	Repair septal defect	C	
33853	Repair septal defect	C	
33860	Ascending aortic graft	C	
33861	Ascending aortic graft	C	
33863	Ascending aortic graft	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
33864	Ascending aortic graft	C	NI
33870	Transverse aortic arch graft	C
33875	Thoracic aortic graft	C
33877	Thoracoabdominal graft	C
33880	Endovasc taa repr incl subcl	C
33881	Endovasc taa repr w/o subcl	C
33883	Insert endovasc prosth, taa	C
33884	Endovasc prosth, taa, add-on	C
33886	Endovasc prosth, delayed	C
33889	Artery transpose/endovas taa	C
33891	Car-car bp grft/endovas taa	C
33910	Remove lung artery emboli	C
33915	Remove lung artery emboli	C
33916	Surgery of great vessel	C
33917	Repair pulmonary artery	C
33920	Repair pulmonary atresia	C
33922	Transect pulmonary artery	C
33924	Remove pulmonary shunt	C
33925	Rpr pul art unifocal w/o cpb	C
33926	Repr pul art, unifocal w/cpb	C
33930	Removal of donor heart/lung	C
33933	Prepare donor heart/lung	C
33935	Transplantation, heart/lung	C
33940	Removal of donor heart	C
33944	Prepare donor heart	C
33945	Transplantation of heart	C
33960	External circulation assist	C
33961	External circulation assist	C
33967	Insert ia percut device	C
33968	Remove aortic assist device	C
33970	Aortic circulation assist	C
33971	Aortic circulation assist	C
33973	Insert balloon device	C
33974	Remove intra-aortic balloon	C
33975	Implant ventricular device	C
33976	Implant ventricular device	C
33977	Remove ventricular device	C
33978	Remove ventricular device	C
33979	Insert intracorporeal device	C
33980	Remove intracorporeal device	C
34001	Removal of artery clot	C
34051	Removal of artery clot	C
34151	Removal of artery clot	C
34401	Removal of vein clot	C
34451	Removal of vein clot	C
34502	Reconstruct vena cava	C
34800	Endovas aaa repr w/sm tube	C
34802	Endovas aaa repr w/2-p part	C
34803	Endovas aaa repr w/3-p part	C
34804	Endovas aaa repr w/1-p part	C
34805	Endovas aaa repr w/long tube	C
34806	Aneurysm press sensor add-on	C	NI
34808	Endovas iliac a device addon	C
34812	Xpose for endoprosth, femorl	C
34813	Femoral endovas graft add-on	C
34820	Xpose for endoprosth, iliac	C
34825	Endovasc extend prosth, init	C
34826	Endovasc exten prosth, add'l	C
34830	Open aortic tube prosth repr	C
34831	Open aortoiliac prosth repr	C
34832	Open aortofemor prosth repr	C
34833	Xpose for endoprosth, iliac	C
34834	Xpose, endoprosth, brachial	C
34900	Endovasc iliac repr w/graft	C
35001	Repair defect of artery	C
35002	Repair artery rupture, neck	C
35005	Repair defect of artery	C
35013	Repair artery rupture, arm	C
35021	Repair defect of artery	C
35022	Repair artery rupture, chest	C
35045	Repair defect of arm artery	C

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
35081	Repair defect of artery	C	
35082	Repair artery rupture, aorta	C	
35091	Repair defect of artery	C	
35092	Repair artery rupture, aorta	C	
35102	Repair defect of artery	C	
35103	Repair artery rupture, groin	C	
35111	Repair defect of artery	C	
35112	Repair artery rupture, spleen	C	
35121	Repair defect of artery	C	
35122	Repair artery rupture, belly	C	
35131	Repair defect of artery	C	
35132	Repair artery rupture, groin	C	
35141	Repair defect of artery	C	
35142	Repair artery rupture, thigh	C	
35151	Repair defect of artery	C	
35152	Repair artery rupture, knee	C	
35182	Repair blood vessel lesion	C	
35189	Repair blood vessel lesion	C	
35211	Repair blood vessel lesion	C	
35216	Repair blood vessel lesion	C	
35221	Repair blood vessel lesion	C	
35241	Repair blood vessel lesion	C	
35246	Repair blood vessel lesion	C	
35251	Repair blood vessel lesion	C	
35271	Repair blood vessel lesion	C	
35276	Repair blood vessel lesion	C	
35281	Repair blood vessel lesion	C	
35301	Rechanneling of artery	C	
35302	Rechanneling of artery	C	
35303	Rechanneling of artery	C	
35304	Rechanneling of artery	C	
35305	Rechanneling of artery	C	
35306	Rechanneling of artery	C	
35311	Rechanneling of artery	C	
35331	Rechanneling of artery	C	
35341	Rechanneling of artery	C	
35351	Rechanneling of artery	C	
35355	Rechanneling of artery	C	
35361	Rechanneling of artery	C	
35363	Rechanneling of artery	C	
35371	Rechanneling of artery	C	
35372	Rechanneling of artery	C	
35390	Reoperation, carotid add-on	C	
35400	Angioscopy	C	
35450	Repair arterial blockage	C	
35452	Repair arterial blockage	C	
35454	Repair arterial blockage	C	
35456	Repair arterial blockage	C	
35480	Atherectomy, open	C	
35481	Atherectomy, open	C	
35482	Atherectomy, open	C	
35483	Atherectomy, open	C	
35501	Artery bypass graft	C	
35506	Artery bypass graft	C	
35508	Artery bypass graft	C	
35509	Artery bypass graft	C	
35510	Artery bypass graft	C	
35511	Artery bypass graft	C	
35512	Artery bypass graft	C	
35515	Artery bypass graft	C	
35516	Artery bypass graft	C	
35518	Artery bypass graft	C	
35521	Artery bypass graft	C	
35522	Artery bypass graft	C	
35523	Artery bypass graft	C	
35525	Artery bypass graft	C	
35526	Artery bypass graft	C	
35531	Artery bypass graft	C	
35533	Artery bypass graft	C	
35536	Artery bypass graft	C	
35537	Artery bypass graft	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
35538	Artery bypass graft	C	
35539	Artery bypass graft	C	
35540	Artery bypass graft	C	
35548	Artery bypass graft	C	
35549	Artery bypass graft	C	
35551	Artery bypass graft	C	
35556	Artery bypass graft	C	
35558	Artery bypass graft	C	
35560	Artery bypass graft	C	
35563	Artery bypass graft	C	
35565	Artery bypass graft	C	
35566	Artery bypass graft	C	
35571	Artery bypass graft	C	
35583	Vein bypass graft	C	
35585	Vein bypass graft	C	
35587	Vein bypass graft	C	
35600	Harvest art for cabg add-on	C	
35601	Artery bypass graft	C	
35606	Artery bypass graft	C	
35612	Artery bypass graft	C	
35616	Artery bypass graft	C	
35621	Artery bypass graft	C	
35623	Bypass graft, not vein	C	
35626	Artery bypass graft	C	
35631	Artery bypass graft	C	
35636	Artery bypass graft	C	
35637	Artery bypass graft	C	
35638	Artery bypass graft	C	
35642	Artery bypass graft	C	
35645	Artery bypass graft	C	
35646	Artery bypass graft	C	
35647	Artery bypass graft	C	
35650	Artery bypass graft	C	
35651	Artery bypass graft	C	
35654	Artery bypass graft	C	
35656	Artery bypass graft	C	
35661	Artery bypass graft	C	
35663	Artery bypass graft	C	
35665	Artery bypass graft	C	
35666	Artery bypass graft	C	
35671	Artery bypass graft	C	
35681	Composite bypass graft	C	
35682	Composite bypass graft	C	
35683	Composite bypass graft	C	
35691	Arterial transposition	C	
35693	Arterial transposition	C	
35694	Arterial transposition	C	
35695	Arterial transposition	C	
35697	Reimplant artery each	C	
35700	Reoperation, bypass graft	C	
35701	Exploration, carotid artery	C	
35721	Exploration, femoral artery	C	
35741	Exploration popliteal artery	C	
35800	Explore neck vessels	C	
35820	Explore chest vessels	C	
35840	Explore abdominal vessels	C	
35870	Repair vessel graft defect	C	
35901	Excision, graft, neck	C	
35905	Excision, graft, thorax	C	
35907	Excision, graft, abdomen	C	
36660	Insertion catheter, artery	C	
36822	Insertion of cannula(s)	C	
36823	Insertion of cannula(s)	C	
37140	Revision of circulation	C	
37145	Revision of circulation	C	
37160	Revision of circulation	C	
37180	Revision of circulation	C	
37181	Splice spleen/kidney veins	C	
37182	Insert hepatic shunt (tips)	C	
37215	Transcath stent, cca w/eps	C	
37616	Ligation of chest artery	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
37617	Ligation of abdomen artery	C	
37618	Ligation of extremity artery	C	
37660	Revision of major vein	C	
37788	Revascularization, penis	C	
38100	Removal of spleen, total	C	
38101	Removal of spleen, partial	C	
38102	Removal of spleen, total	C	
38115	Repair of ruptured spleen	C	
38380	Thoracic duct procedure	C	
38381	Thoracic duct procedure	C	
38382	Thoracic duct procedure	C	
38562	Removal, pelvic lymph nodes	C	
38564	Removal, abdomen lymph nodes	C	
38724	Removal of lymph nodes, neck	C	
38746	Remove thoracic lymph nodes	C	
38747	Remove abdominal lymph nodes	C	
38765	Remove groin lymph nodes	C	
38770	Remove pelvis lymph nodes	C	
38780	Remove abdomen lymph nodes	C	
39000	Exploration of chest	C	
39010	Exploration of chest	C	
39200	Removal chest lesion	C	
39220	Removal chest lesion	C	
39499	Chest procedure	C	
39501	Repair diaphragm laceration	C	
39502	Repair paraesophageal hernia	C	
39503	Repair of diaphragm hernia	C	
39520	Repair of diaphragm hernia	C	
39530	Repair of diaphragm hernia	C	
39531	Repair of diaphragm hernia	C	
39540	Repair of diaphragm hernia	C	
39541	Repair of diaphragm hernia	C	
39545	Revision of diaphragm	C	
39560	Resect diaphragm, simple	C	
39561	Resect diaphragm, complex	C	
39599	Diaphragm surgery procedure	C	
41130	Partial removal of tongue	C	
41135	Tongue and neck surgery	C	
41140	Removal of tongue	C	
41145	Tongue removal, neck surgery	C	
41150	Tongue, mouth, jaw surgery	C	
41153	Tongue, mouth, neck surgery	C	
41155	Tongue, jaw, & neck surgery	C	
42426	Excise parotid gland/lesion	C	
42845	Extensive surgery of throat	C	
42894	Revision of pharyngeal walls	C	
42953	Repair throat, esophagus	C	
42961	Control throat bleeding	C	
42971	Control nose/throat bleeding	C	
43045	Incision of esophagus	C	
43100	Excision of esophagus lesion	C	
43101	Excision of esophagus lesion	C	
43107	Removal of esophagus	C	
43108	Removal of esophagus	C	
43112	Removal of esophagus	C	
43113	Removal of esophagus	C	
43116	Partial removal of esophagus	C	
43117	Partial removal of esophagus	C	
43118	Partial removal of esophagus	C	
43121	Partial removal of esophagus	C	
43122	Partial removal of esophagus	C	
43123	Partial removal of esophagus	C	
43124	Removal of esophagus	C	
43135	Removal of esophagus pouch	C	
43300	Repair of esophagus	C	
43305	Repair esophagus and fistula	C	
43310	Repair of esophagus	C	
43312	Repair esophagus and fistula	C	
43313	Esophagoplasty congenital	C	
43314	Tracheo-esophagoplasty cong	C	
43320	Fuse esophagus & stomach	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
43324	Revise esophagus & stomach	C	
43325	Revise esophagus & stomach	C	
43326	Revise esophagus & stomach	C	
43330	Repair of esophagus	C	
43331	Repair of esophagus	C	
43340	Fuse esophagus & intestine	C	
43341	Fuse esophagus & intestine	C	
43350	Surgical opening, esophagus	C	
43351	Surgical opening, esophagus	C	
43352	Surgical opening, esophagus	C	
43360	Gastrointestinal repair	C	
43361	Gastrointestinal repair	C	
43400	Ligate esophagus veins	C	
43401	Esophagus surgery for veins	C	
43405	Ligate/staple esophagus	C	
43410	Repair esophagus wound	C	
43415	Repair esophagus wound	C	
43420	Repair esophagus opening	C	
43425	Repair esophagus opening	C	
43460	Pressure treatment esophagus	C	
43496	Free jejunum flap, microvasc	C	
43500	Surgical opening of stomach	C	
43501	Surgical repair of stomach	C	
43502	Surgical repair of stomach	C	
43520	Incision of pyloric muscle	C	
43605	Biopsy of stomach	C	
43610	Excision of stomach lesion	C	
43611	Excision of stomach lesion	C	
43620	Removal of stomach	C	
43621	Removal of stomach	C	
43622	Removal of stomach	C	
43631	Removal of stomach, partial	C	
43632	Removal of stomach, partial	C	
43633	Removal of stomach, partial	C	
43634	Removal of stomach, partial	C	
43635	Removal of stomach, partial	C	
43640	Vagotomy & pylorus repair	C	
43641	Vagotomy & pylorus repair	C	
43644	Lap gastric bypass/roux-en-y	C	
43645	Lap gastr bypass incl sml i	C	
43770	Lap place gastr adj device	C	
43771	Lap revise gastr adj device	C	
43772	Lap rml gastr adj device	C	
43773	Lap replace gastr adj device	C	
43774	Lap rml gastr adj all parts	C	
43800	Reconstruction of pylorus	C	
43810	Fusion of stomach and bowel	C	
43820	Fusion of stomach and bowel	C	
43825	Fusion of stomach and bowel	C	
43832	Place gastrostomy tube	C	
43840	Repair of stomach lesion	C	
43843	Gastroplasty w/o v-band	C	
43845	Gastroplasty duodenal switch	C	
43846	Gastric bypass for obesity	C	
43847	Gastric bypass incl small i	C	
43848	Revision gastroplasty	C	
43850	Revise stomach-bowel fusion	C	
43855	Revise stomach-bowel fusion	C	
43860	Revise stomach-bowel fusion	C	
43865	Revise stomach-bowel fusion	C	
43880	Repair stomach-bowel fistula	C	
43881	Impl/redo electrd, antrum	C	
43882	Revise/remove electrd antrum	C	
44005	Freeing of bowel adhesion	C	
44010	Incision of small bowel	C	
44015	Insert needle cath bowel	C	
44020	Explore small intestine	C	
44021	Decompress small bowel	C	
44025	Incision of large bowel	C	
44050	Reduce bowel obstruction	C	
44055	Correct malrotation of bowel	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
44110	Excise intestine lesion(s)	C	
44111	Excision of bowel lesion(s)	C	
44120	Removal of small intestine	C	
44121	Removal of small intestine	C	
44125	Removal of small intestine	C	
44126	Enterectomy w/o taper, cong	C	
44127	Enterectomy w/taper, cong	C	
44128	Enterectomy cong, add-on	C	
44130	Bowel to bowel fusion	C	
44132	Enterectomy, cadaver donor	C	
44133	Enterectomy, live donor	C	
44135	Intestine transplnt, cadavel colectomy	C	
44205	Lap colectomy part w/ileum	C	
44210	Laparo total proctocolectomy	C	
44211	Lap colectomy w/proctectomy	C	
44212	Laparo total proctocolectomy	C	
44227	Lap, close enterostomy	C	
44300	Open bowel to skin	C	
44310	Ileostomy/jejunostomy	C	
44314	Revision of ileostomy	C	
44316	Devise bowel pouch	C	
44320	Colostomy	C	
44322	Colostomy with biopsies	C	
44345	Revision of colostomy	C	
44346	Revision of colostomy	C	
44602	Suture, small intestine	C	
44603	Suture, small intestine	C	
44604	Suture, large intestine	C	
44605	Repair of bowel lesion	C	
44615	Intestinal stricturoplasty	C	
44620	Repair bowel opening	C	
44625	Repair bowel opening	C	
44626	Repair bowel opening	C	
44640	Repair bowel-skin fistula	C	
44650	Repair bowel fistula	C	
44660	Repair bowel-bladder fistula	C	
44661	Repair bowel-bladder fistula	C	
44680	Surgical revision, intestine	C	
44700	Suspend bowel w/prosthesis	C	
44715	Prepare donor intestine	C	
44720	Prep donor intestine/venous	C	
44721	Prep donor intestine/artery	C	
44800	Excision of bowel pouch	C	
44820	Excision of mesentery lesion	C	
44850	Repair of mesentery	C	
44899	Bowel surgery procedure	C	
44900	Drain app abscess, open	C	
44950	Appendectomy	C	
44955	Appendectomy add-on	C	
44960	Appendectomy	C	
45110	Removal of rectum	C	
45111	Partial removal of rectum	C	
45112	Removal of rectum	C	
45113	Partial proctectomy	C	
45114	Partial removal of rectum	C	
45116	Partial removal of rectum	C	
45119	Remove rectum w/reservoir	C	
45120	Removal of rectum	C	
45121	Removal of rectum and colon	C	
45123	Partial proctectomy	C	
45126	Pelvic exenteration	C	
45130	Excision of rectal prolapse	C	
45135	Excision of rectal prolapse	C	
45136	Excise ileoanal reservoir	C	
45395	Lap, removal of rectum	C	
45397	Lap, remove rectum w/pouch	C	
45400	Laparoscopic proc	C	
45402	Lap proctopexy w/sig resect	C	
45540	Correct rectal prolapse	C	
45550	Repair rectum/remove sigmoid	C	
45562	Exploration/repair of rectum	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
45563	Exploration/repair of rectum	C	
45800	Repair rect/bladder fistula	C	
45805	Repair fistula w/colostomy	C	
45820	Repair rectourethral fistula	C	
45825	Repair fistula w/colostomy	C	
46705	Repair of anal stricture	C	
46710	Repr per/vag pouch sngl proc	C	
46712	Repr per/vag pouch dbl proc	C	
46715	Rep perf anoper fistu	C	
46716	Rep perf anoper/vestib fistu	C	
46730	Construction of absent anus	C	
46735	Construction of absent anus	C	
46740	Construction of absent anus	C	
46742	Repair of imperforated anus	C	
46744	Repair of cloacal anomaly	C	
46746	Repair of cloacal anomaly	C	
46748	Repair of cloacal anomaly	C	
46751	Repair of anal sphincter	C	
47010	Open drainage, liver lesion	C	
47015	Inject/aspirate liver cyst	C	
47100	Wedge biopsy of liver	C	
47120	Partial removal of liver	C	
47122	Extensive removal of liver	C	
47125	Partial removal of liver	C	
47130	Partial removal of liver	C	
47133	Removal of donor liver	C	
47135	Transplantation of liver	C	
47136	Transplantation of liver	C	
47140	Partial removal, donor liver	C	
47141	Partial removal, donor liver	C	
47142	Partial removal, donor liver	C	
47143	Prep donor liver, whole	C	
47144	Prep donor liver, 3-segment	C	
47145	Prep donor liver, lobe split	C	
47146	Prep donor liver/venous	C	
47147	Prep donor liver/arterial	C	
47300	Surgery for liver lesion	C	
47350	Repair liver wound	C	
47360	Repair liver wound	C	
47361	Repair liver wound	C	
47362	Repair liver wound	C	
47380	Open ablate liver tumor rf	C	
47381	Open ablate liver tumor cryo	C	
47400	Incision of liver duct	C	
47420	Incision of bile duct	C	
47425	Incision of bile duct	C	
47460	Incise bile duct sphincter	C	
47480	Incision of gallbladder	C	
47550	Bile duct endoscopy add-on	C	
47570	Laparo cholecystoenterostomy	C	
47600	Removal of gallbladder	C	
47605	Removal of gallbladder	C	
47610	Removal of gallbladder	C	
47612	Removal of gallbladder	C	
47620	Removal of gallbladder	C	
47700	Exploration of bile ducts	C	
47701	Bile duct revision	C	
47711	Excision of bile duct tumor	C	
47712	Excision of bile duct tumor	C	
47715	Excision of bile duct cyst	C	
47720	Fuse gallbladder & bowel	C	
47721	Fuse upper gi structures	C	
47740	Fuse gallbladder & bowel	C	
47741	Fuse gallbladder & bowel	C	
47760	Fuse bile ducts and bowel	C	
47765	Fuse liver ducts & bowel	C	
47780	Fuse bile ducts and bowel	C	
47785	Fuse bile ducts and bowel	C	
47800	Reconstruction of bile ducts	C	
47801	Placement, bile duct support	C	
47802	Fuse liver duct & intestine	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
47900	Suture bile duct injury	C	
48000	Drainage of abdomen	C	
48001	Placement of drain, pancreas	C	
48020	Removal of pancreatic stone	C	
48100	Biopsy of pancreas, open	C	
48105	Resect/debride pancreas	C	
48120	Removal of pancreas lesion	C	
48140	Partial removal of pancreas	C	
48145	Partial removal of pancreas	C	
48146	Pancreatectomy	C	
48148	Removal of pancreatic duct	C	
48150	Partial removal of pancreas	C	
48152	Pancreatectomy	C	
48153	Pancreatectomy	C	
48154	Pancreatectomy	C	
48155	Removal of pancreas	C	
48400	Injection, intraop add-on	C	
48500	Surgery of pancreatic cyst	C	
48510	Drain pancreatic pseudocyst	C	
48520	Fuse pancreas cyst and bowel	C	
48540	Fuse pancreas cyst and bowel	C	
48545	Pancreatorrhaphy	C	
48547	Duodenal exclusion	C	
48548	Fuse pancreas and bowel	C	
48551	Prep donor pancreas	C	
48552	Prep donor pancreas/venous	C	
48554	Transpl allograft pancreas	C	
48556	Removal, allograft pancreas	C	
49000	Exploration of abdomen	C	
49002	Reopening of abdomen	C	
49010	Exploration behind abdomen	C	
49020	Drain abdominal abscess	C	
49040	Drain, open, abdom abscess	C	
49060	Drain, open, retro abscess	C	
49062	Drain to peritoneal cavity	C	
49203	Exc abd tum 5 cm or less	C	NI
49204	Exc abd tum over 5 cm	C	NI
49205	Exc abd tum over 10 cm	C	NI
49215	Excise sacral spine tumor	C	
49220	Multiple surgery, abdomen	C	
49255	Removal of omentum	C	
49425	Insert abdomen-venous drain	C	
49428	Ligation of shunt	C	
49605	Repair umbilical lesion	C	
49606	Repair umbilical lesion	C	
49610	Repair umbilical lesion	C	
49611	Repair umbilical lesion	C	
49900	Repair of abdominal wall	C	
49904	Omental flap, extra-abdom	C	
49905	Omental flap, intra-abdom	C	
49906	Free omental flap, microvasc	C	
50010	Exploration of kidney	C	
50040	Drainage of kidney	C	
50045	Exploration of kidney	C	
50060	Removal of kidney stone	C	
50065	Incision of kidney	C	
50070	Incision of kidney	C	
50075	Removal of kidney stone	C	
50100	Revise kidney blood vessels	C	
50120	Exploration of kidney	C	
50125	Explore and drain kidney	C	
50130	Removal of kidney stone	C	
50135	Exploration of kidney	C	
50205	Biopsy of kidney	C	
50220	Remove kidney, open	C	
50225	Removal kidney open, complex	C	
50230	Removal kidney open, radical	C	
50234	Removal of kidney & ureter	C	
50236	Removal of kidney & ureter	C	
50240	Partial removal of kidney	C	
50250	Cryoablate renal mass open	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
50280	Removal of kidney lesion	C	
50290	Removal of kidney lesion	C	
50300	Remove cadaver donor kidney	C	
50320	Remove kidney, living donor	C	
50323	Prep cadaver renal allograft	C	
50325	Prep donor renal graft	C	
50327	Prep renal graft/venous	C	
50328	Prep renal graft/arterial	C	
50329	Prep renal graft/ureteral	C	
50340	Removal of kidney	C	
50360	Transplantation of kidney	C	
50365	Transplantation of kidney	C	
50370	Remove transplanted kidney	C	
50380	Reimplantation of kidney	C	
50400	Revision of kidney/ureter	C	
50405	Revision of kidney/ureter	C	
50500	Repair of kidney wound	C	
50520	Close kidney-skin fistula	C	
50525	Repair renal-abdomen fistula	C	
50526	Repair renal-abdomen fistula	C	
50540	Revision of horseshoe kidney	C	
50545	Laparo radical nephrectomy	C	
50546	Laparoscopic nephrectomy	C	
50547	Laparo removal donor kidney	C	
50548	Laparo remove w/ureter	C	
50600	Exploration of ureter	C	
50605	Insert ureteral support	C	
50610	Removal of ureter stone	C	
50620	Removal of ureter stone	C	
50630	Removal of ureter stone	C	
50650	Removal of ureter	C	
50660	Removal of ureter	C	
50700	Revision of ureter	C	
50715	Release of ureter	C	
50722	Release of ureter	C	
50725	Release/revise ureter	C	
50727	Revise ureter	C	
50728	Revise ureter	C	
50740	Fusion of ureter & kidney	C	
50750	Fusion of ureter & kidney	C	
50760	Fusion of ureters	C	
50770	Splicing of ureters	C	
50780	Reimplant ureter in bladder	C	
50782	Reimplant ureter in bladder	C	
50783	Reimplant ureter in bladder	C	
50785	Reimplant ureter in bladder	C	
50800	Implant ureter in bowel	C	
50810	Fusion of ureter & bowel	C	
50815	Urine shunt to intestine	C	
50820	Construct bowel bladder	C	
50825	Construct bowel bladder	C	
50830	Revise urine flow	C	
50840	Replace ureter by bowel	C	
50845	Appendico-vesicostomy	C	
50860	Transplant ureter to skin	C	
50900	Repair of ureter	C	
50920	Closure ureter/skin fistula	C	
50930	Closure ureter/bowel fistula	C	
50940	Release of ureter	C	
51060	Removal of ureter stone	C	
51525	Removal of bladder lesion	C	
51530	Removal of bladder lesion	C	
51550	Partial removal of bladder	C	
51555	Partial removal of bladder	C	
51565	Revise bladder & ureter(s)	C	
51570	Removal of bladder	C	
51575	Removal of bladder & nodes	C	
51580	Remove bladder/revise tract	C	
51585	Removal of bladder & nodes	C	
51590	Remove bladder/revise tract	C	
51595	Remove bladder/revise tract	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
51596	Remove bladder/create pouch	C	
51597	Removal of pelvic structures	C	
51800	Revision of bladder/urethra	C	
51820	Revision of urinary tract	C	
51840	Attach bladder/urethra	C	
51841	Attach bladder/urethra	C	
51845	Repair bladder neck	C	
51860	Repair of bladder wound	C	
51865	Repair of bladder wound	C	
51900	Repair bladder/vagina lesion	C	
51920	Close bladder-uterus fistula	C	
51925	Hysterectomy/bladder repair	C	
51940	Correction of bladder defect	C	
51960	Revision of bladder & bowel	C	
51980	Construct bladder opening	C	
53415	Reconstruction of urethra	C	
53448	Remov/replc ur sphinctr comp	C	
54125	Removal of penis	C	
54130	Remove penis & nodes	C	
54135	Remove penis & nodes	C	
54332	Revise penis/urethra	C	
54336	Revise penis/urethra	C	
54390	Repair penis and bladder	C	
54411	Remov/replc penis pros, comp	C	
54417	Remv/replc penis pros, compl	C	
54430	Revision of penis	C	
54535	Extensive testis surgery	C	
54650	Orchiopexy (Fowler-Stephens)	C	
55605	Incise sperm duct pouch	C	
55650	Remove sperm duct pouch	C	
55801	Removal of prostate	C	
55810	Extensive prostate surgery	C	
55812	Extensive prostate surgery	C	
55815	Extensive prostate surgery	C	
55821	Removal of prostate	C	
55831	Removal of prostate	C	
55840	Extensive prostate surgery	C	
55842	Extensive prostate surgery	C	
55845	Extensive prostate surgery	C	
55862	Extensive prostate surgery	C	
55865	Extensive prostate surgery	C	
55866	Laparo radical prostatectomy	C	
56630	Extensive vulva surgery	C	
56631	Extensive vulva surgery	C	
56632	Extensive vulva surgery	C	
56633	Extensive vulva surgery	C	
56634	Extensive vulva surgery	C	
56637	Extensive vulva surgery	C	
56640	Extensive vulva surgery	C	
57110	Remove vagina wall, complete	C	
57111	Remove vagina tissue, compl	C	
57112	Vaginectomy w/nodes, compl	C	
57270	Repair of bowel pouch	C	
57280	Suspension of vagina	C	
57296	Revise vag graft, open abd	C	
57305	Repair rectum-vagina fistula	C	
57307	Fistula repair & colostomy	C	
57308	Fistula repair, transperine	C	
57311	Repair urethrovaginal lesion	C	
57531	Removal of cervix, radical	C	
57540	Removal of residual cervix	C	
57545	Remove cervix/repair pelvis	C	
58140	Myomectomy abdom method	C	
58146	Myomectomy abdom complex	C	
58150	Total hysterectomy	C	
58152	Total hysterectomy	C	
58180	Partial hysterectomy	C	
58200	Extensive hysterectomy	C	
58210	Extensive hysterectomy	C	
58240	Removal of pelvis contents	C	
58267	Vag hyst w/urinary repair	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
58275	Hysterectomy/revise vagina	C
58280	Hysterectomy/revise vagina	C
58285	Extensive hysterectomy	C
58293	Vag hyst w/uro repair, compl	C
58400	Suspension of uterus	C
58410	Suspension of uterus	C
58520	Repair of ruptured uterus	C
58540	Revision of uterus	C
58548	Lap radical hyst	C
58605	Division of fallopian tube	C
58611	Ligate oviduct(s) add-on	C
58700	Removal of fallopian tube	C
58720	Removal of ovary/tube(s)	C
58740	Revise fallopian tube(s)	C
58750	Repair oviduct	C
58752	Revise ovarian tube(s)	C
58760	Remove tubal obstruction	C
58822	Drain ovary abscess, percut	C
58825	Transposition, ovary(s)	C
58940	Removal of ovary(s)	C
58943	Removal of ovary(s)	C
58950	Resect ovarian malignancy	C
58951	Resect ovarian malignancy	C
58952	Resect ovarian malignancy	C
58953	Tah, rad dissect for debulk	C
58954	Tah rad debulk/lymph remove	C
58956	Bso, omentectomy w/tah	C
58957	Resect recurrent gyn mal	C
58958	Resect recur gyn mal w/lym	C
58960	Exploration of abdomen	C
59120	Treat ectopic pregnancy	C
59121	Treat ectopic pregnancy	C
59130	Treat ectopic pregnancy	C
59135	Treat ectopic pregnancy	C
59136	Treat ectopic pregnancy	C
59140	Treat ectopic pregnancy	C
59325	Revision of cervix	C
59350	Repair of uterus	C
59514	Cesarean delivery only	C
59525	Remove uterus after cesarean	C
59620	Attempted vbac delivery only	C
59830	Treat uterus infection	C
59850	Abortion	C
59851	Abortion	C
59852	Abortion	C
59855	Abortion	C
59856	Abortion	C
59857	Abortion	C
60254	Extensive thyroid surgery	C
60270	Removal of thyroid	C
60505	Explore parathyroid glands	C
60521	Removal of thymus gland	C
60522	Removal of thymus gland	C
60540	Explore adrenal gland	C
60545	Explore adrenal gland	C
60600	Remove carotid body lesion	C
60605	Remove carotid body lesion	C
60650	Laparoscopy adrenalectomy	C
61105	Twist drill hole	C
61107	Drill skull for implantation	C
61108	Drill skull for drainage	C
61120	Burr hole for puncture	C
61140	Pierce skull for biopsy	C
61150	Pierce skull for drainage	C
61151	Pierce skull for drainage	C
61154	Pierce skull & remove clot	C
61156	Pierce skull for drainage	C
61210	Pierce skull, implant device	C
61250	Pierce skull & explore	C
61253	Pierce skull & explore	C
61304	Open skull for exploration	C

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
61305	Open skull for exploration	C	
61312	Open skull for drainage	C	
61313	Open skull for drainage	C	
61314	Open skull for drainage	C	
61315	Open skull for drainage	C	
61316	Implt cran bone flap to abdo	C	
61320	Open skull for drainage	C	
61321	Open skull for drainage	C	
61322	Decompressive craniotomy	C	
61323	Decompressive lobectomy	C	
61332	Explore/biopsy eye socket	C	
61333	Explore orbit/remove lesion	C	
61340	Subtemporal decompression	C	
61343	Incise skull (press relief)	C	
61345	Relieve cranial pressure	C	
61440	Incise skull for surgery	C	
61450	Incise skull for surgery	C	
61458	Incise skull for brain wound	C	
61460	Incise skull for surgery	C	
61470	Incise skull for surgery	C	
61480	Incise skull for surgery	C	
61490	Incise skull for surgery	C	
61500	Removal of skull lesion	C	
61501	Remove infected skull bone	C	
61510	Removal of brain lesion	C	
61512	Remove brain lining lesion	C	
61514	Removal of brain abscess	C	
61516	Removal of brain lesion	C	
61517	Implt brain chemotx add-on	C	
61518	Removal of brain lesion	C	
61519	Remove brain lining lesion	C	
61520	Removal of brain lesion	C	
61521	Removal of brain lesion	C	
61522	Removal of brain abscess	C	
61524	Removal of brain lesion	C	
61526	Removal of brain lesion	C	
61530	Removal of brain lesion	C	
61531	Implant brain electrodes	C	
61533	Implant brain electrodes	C	
61534	Removal of brain lesion	C	
61535	Remove brain electrodes	C	
61536	Removal of brain lesion	C	
61537	Removal of brain tissue	C	
61538	Removal of brain tissue	C	
61539	Removal of brain tissue	C	
61540	Removal of brain tissue	C	
61541	Incision of brain tissue	C	
61542	Removal of brain tissue	C	
61543	Removal of brain tissue	C	
61544	Remove & treat brain lesion	C	
61545	Excision of brain tumor	C	
61546	Removal of pituitary gland	C	
61548	Removal of pituitary gland	C	
61550	Release of skull seams	C	
61552	Release of skull seams	C	
61556	Incise skull/sutures	C	
61557	Incise skull/sutures	C	
61558	Excision of skull/sutures	C	
61559	Excision of skull/sutures	C	
61563	Excision of skull tumor	C	
61564	Excision of skull tumor	C	
61566	Removal of brain tissue	C	
61567	Incision of brain tissue	C	
61570	Remove foreign body, brain	C	
61571	Incise skull for brain wound	C	
61575	Skull base/brainstem surgery	C	
61576	Skull base/brainstem surgery	C	
61580	Craniofacial approach, skull	C	
61581	Craniofacial approach, skull	C	
61582	Craniofacial approach, skull	C	
61583	Craniofacial approach, skull	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
61584	Orbitocranial approach/skull	C	
61585	Orbitocranial approach/skull	C	
61586	Resect nasopharynx, skull	C	
61590	Infratemporal approach/skull	C	
61591	Infratemporal approach/skull	C	
61592	Orbitocranial approach/skull	C	
61595	Transtemporal approach/skull	C	
61596	Transcochlear approach/skull	C	
61597	Transcondylar approach/skull	C	
61598	Transpetrosal approach/skull	C	
61600	Resect/excise cranial lesion	C	
61601	Resect/excise cranial lesion	C	
61605	Resect/excise cranial lesion	C	
61606	Resect/excise cranial lesion	C	
61607	Resect/excise cranial lesion	C	
61608	Resect/excise cranial lesion	C	
61609	Transect artery, sinus	C	
61610	Transect artery, sinus	C	
61611	Transect artery, sinus	C	
61612	Transect artery, sinus	C	
61613	Remove aneurysm, sinus	C	
61615	Resect/excise lesion, skull	C	
61616	Resect/excise lesion, skull	C	
61618	Repair dura	C	
61619	Repair dura	C	
61624	Transcath occlusion, cns	C	
61680	Intracranial vessel surgery	C	
61682	Intracranial vessel surgery	C	
61684	Intracranial vessel surgery	C	
61686	Intracranial vessel surgery	C	
61690	Intracranial vessel surgery	C	
61692	Intracranial vessel surgery	C	
61697	Brain aneurysm repr, complx	C	
61698	Brain aneurysm repr, complx	C	
61700	Brain aneurysm repr, simple	C	
61702	Inner skull vessel surgery	C	
61703	Clamp neck artery	C	
61705	Revise circulation to head	C	
61708	Revise circulation to head	C	
61710	Revise circulation to head	C	
61711	Fusion of skull arteries	C	
61735	Incise skull/brain surgery	C	
61750	Incise skull/brain biopsy	C	
61751	Brain biopsy w/ct/mr guide	C	
61760	Implant brain electrodes	C	
61850	Implant neuroelectrodes	C	
61860	Implant neuroelectrodes	C	
61863	Implant neuroelectrode	C	
61864	Implant neuroelectrde, addl	C	
61867	Implant neuroelectrode	C	
61868	Implant neuroelectrde, add'l	C	
61870	Implant neuroelectrodes	C	
61875	Implant neuroelectrodes	C	
62005	Treat skull fracture	C	
62010	Treatment of head injury	C	
62100	Repair brain fluid leakage	C	
62115	Reduction of skull defect	C	
62116	Reduction of skull defect	C	
62117	Reduction of skull defect	C	
62120	Repair skull cavity lesion	C	
62121	Incise skull repair	C	
62140	Repair of skull defect	C	
62141	Repair of skull defect	C	
62142	Remove skull plate/flap	C	
62143	Replace skull plate/flap	C	
62145	Repair of skull & brain	C	
62146	Repair of skull with graft	C	
62147	Repair of skull with graft	C	
62148	Retr bone flap to fix skull	C	
62161	Dissect brain w/scope	C	
62162	Remove colloid cyst w/scope	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
62163	Neuroendoscopy w/fb removal	C	
62164	Remove brain tumor w/scope	C	
62165	Remove pituit tumor w/scope	C	
62180	Establish brain cavity shunt	C	
62190	Establish brain cavity shunt	C	
62192	Establish brain cavity shunt	C	
62200	Establish brain cavity shunt	C	
62201	Brain cavity shunt w/scope	C	
62220	Establish brain cavity shunt	C	
62223	Establish brain cavity shunt	C	
62256	Remove brain cavity shunt	C	
62258	Replace brain cavity shunt	C	
63043	Laminotomy, add'l cervical	C	
63044	Laminotomy, add'l lumbar	C	
63050	Cervical laminoplasty	C	
63051	C-laminoplasty w/graft/plate	C	
63076	Neck spine disk surgery	C	
63077	Spine disk surgery, thorax	C	
63078	Spine disk surgery, thorax	C	
63081	Removal of vertebral body	C	
63082	Remove vertebral body add-on	C	
63085	Removal of vertebral body	C	
63086	Remove vertebral body add-on	C	
63087	Removal of vertebral body	C	
63088	Remove vertebral body add-on	C	
63090	Removal of vertebral body	C	
63091	Remove vertebral body add-on	C	
63101	Removal of vertebral body	C	
63102	Removal of vertebral body	C	
63103	Remove vertebral body add-on	C	
63170	Incise spinal cord tract(s)	C	
63172	Drainage of spinal cyst	C	
63173	Drainage of spinal cyst	C	
63180	Revise spinal cord ligaments	C	
63182	Revise spinal cord ligaments	C	
63185	Incise spinal column/nerves	C	
63190	Incise spinal column/nerves	C	
63191	Incise spinal column/nerves	C	
63194	Incise spinal column & cord	C	
63195	Incise spinal column & cord	C	
63196	Incise spinal column & cord	C	
63197	Incise spinal column & cord	C	
63198	Incise spinal column & cord	C	
63199	Incise spinal column & cord	C	
63200	Release of spinal cord	C	
63250	Revise spinal cord vessels	C	
63251	Revise spinal cord vessels	C	
63252	Revise spinal cord vessels	C	
63265	Excise intraspinal lesion	C	
63266	Excise intraspinal lesion	C	
63267	Excise intraspinal lesion	C	
63268	Excise intraspinal lesion	C	
63270	Excise intraspinal lesion	C	
63271	Excise intraspinal lesion	C	
63272	Excise intraspinal lesion	C	
63273	Excise intraspinal lesion	C	
63275	Biopsy/excise spinal tumor	C	
63276	Biopsy/excise spinal tumor	C	
63277	Biopsy/excise spinal tumor	C	
63278	Biopsy/excise spinal tumor	C	
63280	Biopsy/excise spinal tumor	C	
63281	Biopsy/excise spinal tumor	C	
63282	Biopsy/excise spinal tumor	C	
63283	Biopsy/excise spinal tumor	C	
63285	Biopsy/excise spinal tumor	C	
63286	Biopsy/excise spinal tumor	C	
63287	Biopsy/excise spinal tumor	C	
63290	Biopsy/excise spinal tumor	C	
63295	Repair of laminectomy defect	C	
63300	Removal of vertebral body	C	
63301	Removal of vertebral body	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
63302	Removal of vertebral body	C	
63303	Removal of vertebral body	C	
63304	Removal of vertebral body	C	
63305	Removal of vertebral body	C	
63306	Removal of vertebral body	C	
63307	Removal of vertebral body	C	
63308	Remove vertebral body add-on	C	
63700	Repair of spinal herniation	C	
63702	Repair of spinal herniation	C	
63704	Repair of spinal herniation	C	
63706	Repair of spinal herniation	C	
63707	Repair spinal fluid leakage	C	
63709	Repair spinal fluid leakage	C	
63710	Graft repair of spine defect	C	
63740	Install spinal shunt	C	
64752	Incision of vagus nerve	C	
64755	Incision of stomach nerves	C	
64760	Incision of vagus nerve	C	
64809	Remove sympathetic nerves	C	
64818	Remove sympathetic nerves	C	
64866	Fusion of facial/other nerve	C	
64868	Fusion of facial/other nerve	C	
65273	Repair of eye wound	C	
69155	Extensive ear/neck surgery	C	
69535	Remove part of temporal bone	C	
69554	Remove ear lesion	C	
69950	Incise inner ear nerve	C	
75900	Intravascular cath exchange	C	
75952	Endovasc repair abdom aorta	C	
75953	Abdom aneurysm endovas rpr	C	
75954	Iliac aneurysm endovas rpr	C	
75956	Xray, endovasc thor ao repr	C	
75957	Xray, endovasc thor ao repr	C	
75958	Xray, place prox ext thor ao	C	
75959	Xray, place dist ext thor ao	C	
92970	Cardioassist, internal	C	
92971	Cardioassist, external	C	
92975	Dissolve clot, heart vessel	C	
92992	Revision of heart chamber	C	
92993	Revision of heart chamber	C	
99190	Special pump services	C	
99191	Special pump services	C	
99192	Special pump services	C	
99251	Inpatient consultation	C	
99252	Inpatient consultation	C	
99253	Inpatient consultation	C	
99254	Inpatient consultation	C	
99255	Inpatient consultation	C	
99293	Ped critical care, initial	C	
99294	Ped critical care, subseq	C	
99295	Neonate crit care, initial	C	
99296	Neonate critical care subseq	C	
99298	Ic for lbw infant < 1500 gm	C	
99299	Ic, lbw infant 1500–2500 gm	C	
99356	Prolonged service, inpatient	C	
99357	Prolonged service, inpatient	C	
99433	Normal newborn care/hospital	C	
99477	Init day hosp neonate care	C	NI
0048T	Implant ventricular device	C	
0049T	External circulation assist	C	
0050T	Removal circulation assist	C	
0051T	Implant total heart system	C	
0052T	Replace component heart syst	C	
0053T	Replace component heart syst	C	
0075T	Perq stent/chest vert art	C	
0076T	S&i stent/chest vert art	C	
0077T	Cereb therm perfusion probe	C	
0078T	Endovasc aort repr w/device	C	
0079T	Endovasc visc extnsn repr	C	
0080T	Endovasc aort repr rad s&i	C	
0081T	Endovasc visc extnsn s&i	C	

ADDENDUM E.—HCPCS CODES THAT ARE PAID ONLY AS INPATIENT PROCEDURES FOR CY 2008—Continued

HCPCS code	Short descriptor	SI	CI
0090T	Cervical artific disc	C	
0092T	Artific disc addl	C	
0093T	Cervical artific disectomy	C	
0095T	Artific disectomy addl	C	
0096T	Rev cervical artific disc	C	
0098T	Rev artific disc addl	C	
0157T	Open impl gast curve electr	C	
0158T	Open remv gast curve electr	C	
0163T	Lumb artif disectomy addl	C	
0164T	Remove lumb artif disc addl	C	
0165T	Revise lumb artif disc addl	C	
0166T	Tcath vsd close w/o bypass	C	
0167T	Tcath vsd close w bypass	C	
0169T	Place stereo cath brain	C	
0184T	Exc rectal tumor endoscopic	C	NI
G0341	Percutaneous islet celltrans	C	
G0342	Laparoscopy islet cell trans	C	
G0343	Laparotomy islet cell transp	C	

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
010005	*	0.0296	MARSHALL	01470
010008		0.0174	CRENSHAW	01200
010009	*	0.0092	MORGAN	01510
010010	*	0.0296	MARSHALL	01470
010012	*	0.0186	DE KALB	01240
010015		0.0046	CLARKE	01120
010022	*	0.1128	CHEROKEE	01090
010025	*	0.0235	CHAMBERS	01080
010029	*	0.0289	LEE	01400
010032		0.0325	RANDOLPH	01550
010035	*	0.0254	CULLMAN	01210
010038		0.0047	CALHOUN	01070
010045	*	0.0222	FAYETTE	01280
010047		0.0127	BUTLER	01060
010052		0.0103	TALLAPOOSA	01610
010054	*	0.0092	MORGAN	01510
010061		0.0542	JACKSON	01350
010065	*	0.0103	TALLAPOOSA	01610
010078		0.0047	CALHOUN	01070
010083	*	0.0134	BALDWIN	01010
010085	*	0.0092	MORGAN	01510
010091		0.0046	CLARKE	01120
010100	*	0.0134	BALDWIN	01010
010101	*	0.0211	TALLADEGA	01600
010109		0.0451	PICKENS	01530
010110		0.0215	BULLOCK	01050
010125		0.0476	WINSTON	01660
010128		0.0046	CLARKE	01120
010129		0.0134	BALDWIN	01010
010138		0.0066	SUMTER	01590
010143	*	0.0254	CULLMAN	01210
010146		0.0047	CALHOUN	01070
010150	*	0.0127	BUTLER	01060
010158	*	0.0023	FRANKLIN	01290
010164	*	0.0211	TALLADEGA	01600
013027		0.0134	BALDWIN	01010
014009		0.0092	MORGAN	01510
030067		0.0298	LAPAZ	03055
040014	*	0.0199	WHITE	04720
040019	*	0.0258	ST. FRANCIS	04610
040039	*	0.0172	GREENE	04270
040047		0.0117	RANDOLPH	04600
040067		0.0007	COLUMBIA	04130
040071	*	0.0149	JEFFERSON	04340
040076	*	0.1000	HOT SPRING	04290
040081		0.0357	PIKE	04540

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
040100	*	0.0199	WHITE	04720
042007		0.0149	JEFFERSON	04340
043034		0.0036	CHICOT	04080
050002		0.0010	ALAMEDA	05000
050007		0.0146	SAN MATEO	05510
050008		0.0026	SAN FRANCISCO	05480
050009	*	0.0180	NAPA	05380
050013	*	0.0180	NAPA	05380
050014	*	0.0139	AMADOR	05020
050016		0.0103	SAN LUIS OBISPO	05500
050042	*	0.0162	TEHAMA	05620
050043		0.0010	ALAMEDA	05000
050047		0.0026	SAN FRANCISCO	05480
050055		0.0026	SAN FRANCISCO	05480
050070		0.0146	SAN MATEO	05510
050073	*	0.0171	SOLANO	05580
050075		0.0010	ALAMEDA	05000
050076	*	0.0026	SAN FRANCISCO	05480
050084		0.0132	SAN JOAQUIN	05490
050090	*	0.0058	SONOMA	05590
050101	*	0.0171	SOLANO	05580
050113		0.0146	SAN MATEO	05510
050118	*	0.0132	SAN JOAQUIN	05490
050122		0.0132	SAN JOAQUIN	05490
050133	*	0.0178	YUBA	05680
050136	*	0.0058	SONOMA	05590
050150	*	0.0342	NEVADA	05390
050152		0.0026	SAN FRANCISCO	05480
050167		0.0132	SAN JOAQUIN	05490
050174	*	0.0058	SONOMA	05590
050194		0.0052	SANTA CRUZ	05540
050195		0.0010	ALAMEDA	05000
050197	*	0.0146	SAN MATEO	05510
050211		0.0010	ALAMEDA	05000
050228		0.0026	SAN FRANCISCO	05480
050232		0.0103	SAN LUIS OBISPO	05500
050242		0.0052	SANTA CRUZ	05540
050264		0.0010	ALAMEDA	05000
050283		0.0010	ALAMEDA	05000
050289		0.0146	SAN MATEO	05510
050291	*	0.0058	SONOMA	05590
050305		0.0010	ALAMEDA	05000
050313		0.0132	SAN JOAQUIN	05490
050320		0.0010	ALAMEDA	05000
050325		0.0033	TUOLUMNE	05650
050335		0.0033	TUOLUMNE	05650
050336		0.0132	SAN JOAQUIN	05490
050366		0.0015	CALAVERAS	05040
050367	*	0.0171	SOLANO	05580
050385	*	0.0058	SONOMA	05590
050407		0.0026	SAN FRANCISCO	05480
050444		0.0233	MERCED	05340
050454		0.0026	SAN FRANCISCO	05480
050457		0.0026	SAN FRANCISCO	05480
050476	*	0.0278	LAKE	05160
050488		0.0010	ALAMEDA	05000
050494	*	0.0342	NEVADA	05390
050506		0.0103	SAN LUIS OBISPO	05500
050512		0.0010	ALAMEDA	05000
050528	*	0.0233	MERCED	05340
050541	*	0.0146	SAN MATEO	05510
050547	*	0.0058	SONOMA	05590
050633		0.0103	SAN LUIS OBISPO	05500
050667	*	0.0180	NAPA	05380
050668		0.0026	SAN FRANCISCO	05480
050680	*	0.0171	SOLANO	05580
050690	*	0.0058	SONOMA	05590
050707		0.0146	SAN MATEO	05510
050714		0.0052	SANTA CRUZ	05540
050748		0.0132	SAN JOAQUIN	05490
050754		0.0146	SAN MATEO	05510

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
052034		0.0010	ALAMEDA	05000
053301		0.0010	ALAMEDA	05000
054003		0.0146	SAN MATEO	05510
054020		0.0026	SAN FRANCISCO	05480
054074		0.0171	SOLANO	05580
054089		0.0026	SAN FRANCISCO	05480
054110		0.0010	ALAMEDA	05000
054122		0.0180	NAPA	05380
054123		0.0132	SAN JOAQUIN	05490
054141		0.0171	SOLANO	05580
054144		0.0026	SAN FRANCISCO	05480
060001	*	0.0042	WELD	06610
060003	*	0.0069	BOULDER	06060
060010		0.0153	LARIMER	06340
060027	*	0.0069	BOULDER	06060
060030		0.0153	LARIMER	06340
060103	*	0.0069	BOULDER	06060
060116	*	0.0069	BOULDER	06060
063033		0.0153	LARIMER	06340
064007		0.0069	BOULDER	06060
064016		0.0153	LARIMER	06340
070006	*	0.0045	FAIRFIELD	07000
070010	*	0.0045	FAIRFIELD	07000
070018	*	0.0045	FAIRFIELD	07000
070028	*	0.0045	FAIRFIELD	07000
070033	*	0.0045	FAIRFIELD	07000
070034	*	0.0045	FAIRFIELD	07000
074000		0.0045	FAIRFIELD	07000
074012		0.0045	FAIRFIELD	07000
074014		0.0045	FAIRFIELD	07000
080001	*	0.0063	NEW CASTLE	08010
080003	*	0.0063	NEW CASTLE	08010
082000		0.0063	NEW CASTLE	08010
083300		0.0063	NEW CASTLE	08010
084001		0.0063	NEW CASTLE	08010
084002		0.0063	NEW CASTLE	08010
084003		0.0063	NEW CASTLE	08010
100014	*	0.0047	VOLUSIA	10630
100017	*	0.0047	VOLUSIA	10630
100045	*	0.0047	VOLUSIA	10630
100047	*	0.0028	CHARLOTTE	10070
100068	*	0.0047	VOLUSIA	10630
100072	*	0.0047	VOLUSIA	10630
100077	*	0.0028	CHARLOTTE	10070
100102		0.0125	COLUMBIA	10110
100118	*	0.0177	FLAGLER	10170
100156	*	0.0125	COLUMBIA	10110
100232	*	0.0054	PUTNAM	10530
100236	*	0.0028	CHARLOTTE	10070
100252	*	0.0151	OKEECHOBEE	10460
100290		0.0582	SUMTER	10590
110023	*	0.0416	GORDON	11500
110029	*	0.0052	HALL	11550
110040	*	0.1455	JACKSON	11610
110041	*	0.0623	HABERSHAM	11540
110100		0.0790	JEFFERSON	11620
110101		0.0067	COOK	11311
110142		0.0185	EVANS	11441
110146	*	0.0805	CAMDEN	11170
110150	*	0.0227	BALDWIN	11030
110187	*	0.0643	LUMPKIN	11701
110189	*	0.0066	FANNIN	11450
110190		0.0241	MACON	11710
110205		0.0507	GILMER	11471
114018		0.0227	BALDWIN	11030
130003	*	0.0235	NEZ PERCE	13340
130024		0.0675	BONNER	13080
130049	*	0.0319	KOOTENAI	13270
130066		0.0319	KOOTENAI	13270
130067	*	0.0725	BINGHAM	13050
130068		0.0319	KOOTENAI	13270

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
132001		0.0319	KOOTENAI	13270
134010		0.0725	BINGHAM	13050
140001		0.0369	FULTON	14370
140026		0.0315	LA SALLE	14580
140043	*	0.0056	WHITESIDE	14988
140058	*	0.0126	MORGAN	14770
140110	*	0.0315	LA SALLE	14580
140160	*	0.0332	STEPHENSON	14970
140161	*	0.0168	LIVINGSTON	14610
140167	*	0.0632	IROQUOIS	14460
140234		0.0315	LA SALLE	14580
150006	*	0.0113	LA PORTE	15450
150015		0.0113	LA PORTE	15450
150022		0.0158	MONTGOMERY	15530
150030	*	0.0192	HENRY	15320
150072		0.0105	CASS	15080
150076	*	0.0215	MARSHALL	15490
150088	*	0.0111	MADISON	15470
150091	*	0.0050	HUNTINGTON	15340
150102	*	0.0108	STARKE	15740
150113	*	0.0111	MADISON	15470
150133	*	0.0193	KOSCIUSKO	15420
150146	*	0.0319	NOBLE	15560
153040		0.0215	MARSHALL	15490
154014		0.0193	KOSCIUSKO	15420
154035		0.0105	CASS	15080
154047		0.0215	MARSHALL	15490
160013		0.0179	MUSCATINE	16690
160030		0.0040	STORY	16840
160032		0.0235	JASPER	16490
160080	*	0.0066	CLINTON	16220
170137	*	0.0336	DOUGLAS	17220
170150	*	0.0166	COWLEY	17170
180012	*	0.0080	HARDIN	18460
180017	*	0.0035	BARREN	18040
180049	*	0.0488	MADISON	18750
180064		0.0314	MONTGOMERY	18860
180066	*	0.0439	LOGAN	18700
180070		0.0240	GRAYSON	18420
180079		0.0259	HARRISON	18480
183028		0.0080	HARDIN	18460
184012		0.0080	HARDIN	18460
190003	*	0.0085	IBERIA	19220
190015	*	0.0243	TANGIPAHOA	19520
190017		0.0187	ST. LANDRY	19480
190034		0.0189	VERMILION	19560
190044		0.0261	ACADIA	19000
190050		0.0044	BEAUREGARD	19050
190053		0.0101	JEFFERSON DAVIS	19260
190054		0.0085	IBERIA	19220
190078		0.0187	ST. LANDRY	19480
190086	*	0.0061	LINCOLN	19300
190088	*	0.0387	WEBSTER	19590
190099	*	0.0189	AVOYELLES	19040
190106	*	0.0102	ALLEN	19010
190116		0.0085	MOREHOUSE	19330
190133		0.0102	ALLEN	19010
190140		0.0035	FRANKLIN	19200
190144	*	0.0387	WEBSTER	19590
190145		0.0090	LA SALLE	19290
190184	*	0.0161	CALDWELL	19100
190190		0.0161	CALDWELL	19100
190191	*	0.0187	ST. LANDRY	19480
190246		0.0161	CALDWELL	19100
190257		0.0061	LINCOLN	19300
192022		0.0061	LINCOLN	19300
192026		0.0387	WEBSTER	19590
192034		0.0187	ST. LANDRY	19480
192036		0.0243	TANGIPAHOA	19520
192040		0.0243	TANGIPAHOA	19520
192050		0.0261	ACADIA	19000

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
193036		0.0187	ST. LANDRY	19480
193044		0.0243	TANGIPAOHA	19520
193047		0.0189	VERMILION	19560
193049		0.0189	VERMILION	19560
193055		0.0161	CALDWELL	19100
193058		0.0085	MOREHOUSE	19330
193063		0.0243	TANGIPAOHA	19520
193067		0.0101	JEFFERSON DAVIS	19260
193068		0.0243	TANGIPAOHA	19520
193069		0.0085	MOREHOUSE	19330
193073		0.0187	ST. LANDRY	19480
193079		0.0243	TANGIPAOHA	19520
193081		0.0261	ACADIA	19000
193088		0.0261	ACADIA	19000
193091		0.0085	IBERIA	19220
194047		0.0387	WEBSTER	19590
194065		0.0061	LINCOLN	19300
194075		0.0101	JEFFERSON DAVIS	19260
194077		0.0061	LINCOLN	19300
194081		0.0044	BEAUREGARD	19050
194082		0.0101	JEFFERSON DAVIS	19260
194083		0.0085	MOREHOUSE	19330
194085		0.0261	ACADIA	19000
194087		0.0061	LINCOLN	19300
200024	*	0.0094	ANDROSCOGGIN	20000
200032		0.0466	OXFORD	20080
200034	*	0.0094	ANDROSCOGGIN	20000
200050	*	0.0227	HANCOCK	20040
210001		0.0187	WASHINGTON	21210
210023		0.0079	ANNE ARUNDEL	21010
210028		0.0512	ST. MARYS	21180
210043		0.0079	ANNE ARUNDEL	21010
212002		0.0187	WASHINGTON	21210
214001		0.0079	ANNE ARUNDEL	21010
214003		0.0187	WASHINGTON	21210
220002		0.0271	MIDDLESEX	22090
220010	*	0.0355	ESSEX	22040
220011		0.0271	MIDDLESEX	22090
220029	*	0.0355	ESSEX	22040
220033	*	0.0355	ESSEX	22040
220035	*	0.0355	ESSEX	22040
220049		0.0271	MIDDLESEX	22090
220063		0.0271	MIDDLESEX	22090
220070		0.0271	MIDDLESEX	22090
220080	*	0.0355	ESSEX	22040
220082		0.0271	MIDDLESEX	22090
220084		0.0271	MIDDLESEX	22090
220098		0.0271	MIDDLESEX	22090
220101		0.0271	MIDDLESEX	22090
220105		0.0271	MIDDLESEX	22090
220171		0.0271	MIDDLESEX	22090
220174	*	0.0355	ESSEX	22040
222000		0.0271	MIDDLESEX	22090
222003		0.0271	MIDDLESEX	22090
222024		0.0271	MIDDLESEX	22090
222026		0.0355	ESSEX	22040
222044		0.0355	ESSEX	22040
222047		0.0355	ESSEX	22040
223026		0.0271	MIDDLESEX	22090
223028		0.0355	ESSEX	22040
224007		0.0271	MIDDLESEX	22090
224022		0.0271	MIDDLESEX	22090
224033		0.0355	ESSEX	22040
224038		0.0271	MIDDLESEX	22090
230003	*	0.0220	OTTAWA	23690
230005		0.0473	LENAWEE	23450
230013	*	0.0025	OAKLAND	23620
230015		0.0295	ST. JOSEPH	23740
230019	*	0.0025	OAKLAND	23620
230021	*	0.0101	BERRIEN	23100
230022	*	0.0212	BRANCH	23110

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
230029	*	0.0025	OAKLAND	23620
230035	*	0.0095	MONTCALM	23580
230037	*	0.0210	HILLSDALE	23290
230047	*	0.0021	MACOMB	23490
230069	*	0.0210	LIVINGSTON	23460
230071	*	0.0025	OAKLAND	23620
230072	*	0.0220	OTTAWA	23690
230075	*	0.0047	CALHOUN	23120
230078	*	0.0101	BERRIEN	23100
230092	*	0.0223	JACKSON	23370
230093	*	0.0058	MECOSTA	23530
230096	*	0.0295	ST. JOSEPH	23740
230099	*	0.0231	MONROE	23570
230121	*	0.0678	SHIAWASSEE	23770
230130	*	0.0025	OAKLAND	23620
230151	*	0.0025	OAKLAND	23620
230174	*	0.0220	OTTAWA	23690
230195	*	0.0021	MACOMB	23490
230204	*	0.0021	MACOMB	23490
230207	*	0.0025	OAKLAND	23620
230208	*	0.0095	MONTCALM	23580
230217	*	0.0047	CALHOUN	23120
230222	*	0.0035	MIDLAND	23550
230223	*	0.0025	OAKLAND	23620
230227	*	0.0021	MACOMB	23490
230254	*	0.0025	OAKLAND	23620
230257	*	0.0021	MACOMB	23490
230264	*	0.0021	MACOMB	23490
230269	*	0.0025	OAKLAND	23620
230277	*	0.0025	OAKLAND	23620
230279	*	0.0210	LIVINGSTON	23460
232023	*	0.0021	MACOMB	23490
232025	*	0.0101	BERRIEN	23100
232028	*	0.0047	CALHOUN	23120
232030	*	0.0025	OAKLAND	23620
232034	*	0.0435	ALLEGAN	23020
232036	*	0.0223	JACKSON	23370
233025	*	0.0047	CALHOUN	23120
233028	*	0.0025	OAKLAND	23620
233031	*	0.0021	MACOMB	23490
234011	*	0.0025	OAKLAND	23620
234021	*	0.0021	MACOMB	23490
234023	*	0.0025	OAKLAND	23620
234024	*	0.0021	MACOMB	23490
234025	*	0.0276	TUSCOLA	23780
234037	*	0.0047	CALHOUN	23120
234039	*	0.0021	MACOMB	23490
240018	*	0.0805	GOODHUE	24240
240044	*	0.0625	WINONA	24840
240064	*	0.0134	ITASCA	24300
240069	*	0.0267	STEELE	24730
240071	*	0.0385	RICE	24650
240117	*	0.0527	MOWER	24490
240211	*	0.0812	PINE	24570
250023	*	0.0541	PEARL RIVER	25540
250040	*	0.0021	JACKSON	25290
250117	*	0.0541	PEARL RIVER	25540
250128	*	0.0446	PANOLA	25530
250160	*	0.0446	PANOLA	25530
252011	*	0.0446	PANOLA	25530
260059	*	0.0077	LACLEDE	26520
260064	*	0.0089	AUDRAIN	26030
260097	*	0.0300	JOHNSON	26500
260116	*	0.0087	ST. FRANCOIS	26930
260163	*	0.0087	ST. FRANCOIS	26930
264005	*	0.0087	ST. FRANCOIS	26930
264027	*	0.0087	CEDAR	26190
270081	*	0.0234	MUSSELSHELL	27320
280077	*	0.0080	DODGE	28260
280123	*	0.0123	GAGE	28330
290002	*	0.0277	LYON	29090

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
300011		0.0069	HILLSBOROUGH	30050
300012		0.0069	HILLSBOROUGH	30050
300020		0.0069	HILLSBOROUGH	30050
300034		0.0069	HILLSBOROUGH	30050
310002	*	0.0268	ESSEX	31200
310009	*	0.0268	ESSEX	31200
310010		0.0092	MERCER	31260
310011		0.0115	CAPE MAY	31180
310013	*	0.0268	ESSEX	31200
310018	*	0.0268	ESSEX	31200
310021	*	0.0092	MERCER	31260
310038	*	0.0209	MIDDLESEX	31270
310039	*	0.0209	MIDDLESEX	31270
310044		0.0092	MERCER	31260
310054	*	0.0268	ESSEX	31200
310070	*	0.0209	MIDDLESEX	31270
310076	*	0.0268	ESSEX	31200
310083	*	0.0268	ESSEX	31200
310092		0.0092	MERCER	31260
310093	*	0.0268	ESSEX	31200
310096	*	0.0268	ESSEX	31200
310108	*	0.0209	MIDDLESEX	31270
310110		0.0092	MERCER	31260
310119	*	0.0268	ESSEX	31200
312018		0.0209	MIDDLESEX	31270
313025		0.0268	ESSEX	31200
313027		0.0092	MERCER	31260
314010		0.0268	ESSEX	31200
314011		0.0209	MIDDLESEX	31270
314013		0.0092	MERCER	31260
314020		0.0268	ESSEX	31200
314025		0.0092	MERCER	31260
320003	*	0.0629	SAN MIGUEL	32230
320011		0.0442	RIO ARRIBA	32190
320018		0.0024	DONA ANA	32060
320085		0.0024	DONA ANA	32060
322001		0.0629	SAN MIGUEL	32230
323025		0.0629	SAN MIGUEL	32230
323032		0.0024	DONA ANA	32060
324007		0.0024	DONA ANA	32060
324009		0.0024	DONA ANA	32060
324010		0.0024	DONA ANA	32060
324011		0.0442	RIO ARRIBA	32190
324012		0.0024	DONA ANA	32060
330004	*	0.0633	ULSTER	33740
330008	*	0.0126	WYOMING	33900
330010		0.0067	MONTGOMERY	33380
330027	*	0.0123	NASSAU	33400
330033		0.0223	CHENANGO	33080
330047		0.0067	MONTGOMERY	33380
330073	*	0.0151	GENESEE	33290
330094	*	0.0503	COLUMBIA	33200
330103	*	0.0131	CATTARAUGUS	33040
330106	*	0.0123	NASSAU	33400
330126	*	0.0642	ORANGE	33540
330132		0.0131	CATTARAUGUS	33040
330135		0.0642	ORANGE	33540
330167	*	0.0123	NASSAU	33400
330175		0.0260	CORTLAND	33210
330181	*	0.0123	NASSAU	33400
330182	*	0.0123	NASSAU	33400
330191	*	0.0017	WARREN	33750
330198	*	0.0123	NASSAU	33400
330205		0.0642	ORANGE	33540
330224	*	0.0633	ULSTER	33740
330225	*	0.0123	NASSAU	33400
330235	*	0.0306	CAYUGA	33050
330259	*	0.0123	NASSAU	33400
330264		0.0642	ORANGE	33540
330276		0.0036	FULTON	33280
330331	*	0.0123	NASSAU	33400

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
330332	*	0.0123	NASSAU	33400
330372	*	0.0123	NASSAU	33400
330386	*	0.0745	SULLIVAN	33710
334017		0.0642	ORANGE	33540
334061		0.0642	ORANGE	33540
340020		0.0156	LEE	34520
340021	*	0.0162	CLEVELAND	34220
340024		0.0177	SAMPSON	34810
340027	*	0.0128	LENOIR	34530
340037		0.0162	CLEVELAND	34220
340038		0.0253	BEAUFORT	34060
340039	*	0.0101	IREDELL	34480
340068	*	0.0087	COLUMBUS	34230
340069	*	0.0015	WAKE	34910
340070	*	0.0395	ALAMANCE	34000
340071	*	0.0226	HARNETT	34420
340073	*	0.0015	WAKE	34910
340085	*	0.0250	DAVIDSON	34280
340096	*	0.0250	DAVIDSON	34280
340104		0.0162	CLEVELAND	34220
340114	*	0.0015	WAKE	34910
340124	*	0.0226	HARNETT	34420
340126	*	0.0100	WILSON	34970
340129	*	0.0101	IREDELL	34480
340133		0.0308	MARTIN	34580
340138	*	0.0015	WAKE	34910
340144	*	0.0101	IREDELL	34480
340145	*	0.0336	LINCOLN	34540
340151		0.0052	HALIFAX	34410
340173	*	0.0015	WAKE	34910
344001		0.0015	WAKE	34910
344011		0.0015	WAKE	34910
344014		0.0015	WAKE	34910
360002		0.0141	ASHLAND	36020
360010	*	0.0074	TUSCARAWAS	36800
360013	*	0.0135	SHELBY	36760
360025	*	0.0077	ERIE	36220
360036	*	0.0126	WAYNE	36860
360040		0.0387	KNOX	36430
360044		0.0127	DARKE	36190
360065	*	0.0075	HURON	36400
360071		0.0035	VAN WERT	36820
360086	*	0.0186	CLARK	36110
360096	*	0.0071	COLUMBIANA	36140
360107	*	0.0119	SANDUSKY	36730
360125	*	0.0133	ASHTABULA	36030
360156		0.0119	SANDUSKY	36730
360175	*	0.0183	CLINTON	36130
360185	*	0.0071	COLUMBIANA	36140
360187	*	0.0186	CLARK	36110
360245	*	0.0133	ASHTABULA	36030
362007		0.0119	SANDUSKY	36730
364040		0.0186	CLARK	36110
370014	*	0.0361	BRYAN	37060
370015	*	0.0366	MAYES	37480
370023		0.0090	STEPHENS	37680
370065		0.0096	CRAIG	37170
370072		0.0258	LATIMER	37380
370083		0.0051	PUSHMATAHA	37630
370100		0.0100	CHOCTAW	37110
370149	*	0.0302	POTTAWATOMIE	37620
370156		0.0121	GARVIN	37240
370169		0.0163	MCINTOSH	37450
370172		0.0258	LATIMER	37380
370214		0.0121	GARVIN	37240
372017		0.0100	CHOCTAW	37110
372019		0.0302	POTTAWATOMIE	37620
373032		0.0100	CHOCTAW	37110
380022	*	0.0067	LINN	38210
380029		0.0075	MARION	38230
380051		0.0075	MARION	38230

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
380056		0.0075	MARION	38230
384008		0.0075	MARION	38230
384011		0.0107	UMATILLA	38290
390008		0.0060	LAWRENCE	39450
390016	*	0.0060	LAWRENCE	39450
390030	*	0.0284	SCHUYLKILL	39650
390031	*	0.0284	SCHUYLKILL	39650
390044	*	0.0191	BERKS	39110
390052		0.0047	CLEARFIELD	39230
390056		0.0036	HUNTINGDON	39380
390065	*	0.0532	ADAMS	39000
390066	*	0.0372	LEBANON	39460
390079	*	0.0003	BRADFORD	39130
390086	*	0.0047	CLEARFIELD	39230
390096	*	0.0191	BERKS	39110
390110	*	0.0003	CAMBRIA	39160
390113	*	0.0053	CRAWFORD	39260
390117		0.0002	BEDFORD	39100
390122		0.0053	CRAWFORD	39260
390125		0.0022	WAYNE	39760
390130	*	0.0003	CAMBRIA	39160
390138	*	0.0218	FRANKLIN	39350
390146		0.0022	WARREN	39740
390150		0.0031	GREENE	39370
390151	*	0.0218	FRANKLIN	39350
390162	*	0.0200	NORTHAMPTON	39590
390181		0.0284	SCHUYLKILL	39650
390183	*	0.0284	SCHUYLKILL	39650
390201		0.1170	MONROE	39550
390236		0.0003	BRADFORD	39130
390313	*	0.0284	SCHUYLKILL	39650
392030		0.0532	ADAMS	39000
392031		0.0003	CAMBRIA	39160
392034		0.0200	NORTHAMPTON	39590
393026		0.0191	BERKS	39110
393050		0.0200	NORTHAMPTON	39590
394014		0.0191	BERKS	39110
394016		0.0022	WARREN	39740
394020		0.0372	LEBANON	39460
420007	*	0.0027	SPARTANBURG	42410
420009	*	0.0113	OCONEE	42360
420019		0.0158	CHESTER	42110
420027	*	0.0108	ANDERSON	42030
420030	*	0.0069	COLLETON	42140
420036	*	0.0064	LANCASTER	42280
420039	*	0.0153	UNION	42430
420043		0.0157	CHEROKEE	42100
420053		0.0035	NEWBERRY	42350
420062	*	0.0109	CHESTERFIELD	42120
420068	*	0.0027	ORANGEBURG	42370
420069	*	0.0052	CLARENDON	42130
420083	*	0.0027	SPARTANBURG	42410
422004		0.0158	CHESTER	42110
423029		0.0108	ANDERSON	42030
424011		0.0108	ANDERSON	42030
430008		0.0535	BROOKINGS	43050
430048		0.0129	LAWRENCE	43400
430094		0.0129	LAWRENCE	43400
440007		0.0219	COFFEE	44150
440008	*	0.0449	HENDERSON	44380
440016		0.0144	CARROLL	44080
440024	*	0.0230	BRADLEY	44050
440030		0.0056	HAMBLEN	44310
440031		0.0019	ROANE	44720
440033		0.0027	CAMPBELL	44060
440035	*	0.0301	MONTGOMERY	44620
440047		0.0338	GIBSON	44260
440051		0.0082	MC NAIRY	44540
440057		0.0021	CLAIBORNE	44120
440060	*	0.0338	GIBSON	44260
440067		0.0056	HAMBLEN	44310

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
440070		0.0109	DECATUR	44190
440081		0.0052	SEVIER	44770
440084		0.0025	MONROE	44610
440109		0.0070	HARDIN	44350
440115		0.0338	GIBSON	44260
440137		0.0738	BEDFORD	44010
440144	*	0.0219	COFFEE	44150
440148	*	0.0296	DE KALB	44200
440153		0.0007	COCKE	44140
440174		0.0312	HAYWOOD	44370
440180		0.0027	CAMPBELL	44060
440181		0.0365	HARDEMAN	44340
440182		0.0144	CARROLL	44080
440185	*	0.0230	BRADLEY	44050
444008		0.0365	HARDEMAN	44340
450032	*	0.0254	HARRISON	45620
450039	*	0.0024	TARRANT	45910
450052	*	0.0276	BOSQUE	45160
450059	*	0.0075	COMAL	45320
450064	*	0.0024	TARRANT	45910
450087	*	0.0024	TARRANT	45910
450090		0.0650	COOKE	45340
450099	*	0.0145	GRAY	45563
450135	*	0.0024	TARRANT	45910
450137	*	0.0024	TARRANT	45910
450144		0.0559	ANDREWS	45010
450163		0.0054	KLEBERG	45743
450192		0.0271	HILL	45651
450194		0.0213	CHEROKEE	45281
450210		0.0151	PANOLA	45842
450224	*	0.0195	WOOD	45974
450236		0.0389	HOPKINS	45654
450270		0.0271	HILL	45651
450283	*	0.0653	VAN ZANDT	45947
450324	*	0.0132	GRAYSON	45564
450347	*	0.0370	WALKER	45949
450348	*	0.0059	FALLS	45500
450370		0.0235	COLORADO	45312
450389	*	0.0618	HENDERSON	45640
450393	*	0.0132	GRAYSON	45564
450395	*	0.0441	POLK	45850
450419	*	0.0024	TARRANT	45910
450438	*	0.0235	COLORADO	45312
450451		0.0536	SOMERVELL	45893
450460		0.0053	TYLER	45942
450469	*	0.0132	GRAYSON	45564
450497		0.0375	MONTAGUE	45800
450539		0.0067	HALE	45582
450547		0.0195	WOOD	45974
450563	*	0.0024	TARRANT	45910
450565		0.0486	PALO PINTO	45841
450573		0.0126	JASPER	45690
450596	*	0.0743	HOOD	45653
450639	*	0.0024	TARRANT	45910
450641		0.0375	MONTAGUE	45800
450672	*	0.0024	TARRANT	45910
450675	*	0.0024	TARRANT	45910
450677	*	0.0024	TARRANT	45910
450698		0.0127	LAMB	45751
450747	*	0.0126	ANDERSON	45000
450755		0.0276	HOCKLEY	45652
450770	*	0.0182	MILAM	45795
450779	*	0.0024	TARRANT	45910
450813	*	0.0126	ANDERSON	45000
450838		0.0126	JASPER	45690
450872	*	0.0024	TARRANT	45910
450880	*	0.0024	TARRANT	45910
450884		0.0049	UPSHUR	45943
450886		0.0024	TARRANT	45910
450888		0.0024	TARRANT	45910
452018		0.0024	TARRANT	45910

ADDENDUM L.—OUT-MIGRATION ADJUSTMENT—Continued

Provider No.	Reclassified for FY 2008	Out-migration adjustment	Qualifying county name	County code
452019		0.0024	TARRANT	45910
452028		0.0024	TARRANT	45910
452041		0.0132	GRAYSON	45564
452088		0.0024	TARRANT	45910
453040		0.0024	TARRANT	45910
453041		0.0024	TARRANT	45910
453042		0.0024	TARRANT	45910
453089		0.0126	ANDERSON	45000
453094		0.0024	TARRANT	45910
453300		0.0024	TARRANT	45910
453303		0.0024	TARRANT	45910
454009		0.0213	CHEROKEE	45281
454012		0.0024	TARRANT	45910
454019		0.0024	TARRANT	45910
454051		0.0024	TARRANT	45910
454052		0.0024	TARRANT	45910
454061		0.0024	TARRANT	45910
454072		0.0024	TARRANT	45910
454086		0.0024	TARRANT	45910
454101		0.0067	HALE	45582
460017		0.0383	BOX ELDER	46010
460039	*	0.0383	BOX ELDER	46010
490019	*	0.1088	CULPEPER	49230
490084		0.0187	ESSEX	49280
490110		0.0185	MONTGOMERY	49600
500003	*	0.0166	SKAGIT	50280
500007	*	0.0166	SKAGIT	50280
500019		0.0131	LEWIS	50200
500039	*	0.0094	KITSAP	50170
500041	*	0.0020	COWLITZ	50070
510012		0.0124	MASON	51260
510018	*	0.0188	JACKSON	51170
510047	*	0.0269	MARION	51240
510077	*	0.0021	MINGO	51290
520028	*	0.0286	GREEN	52220
520035		0.0076	SHEBOYGAN	52580
520044		0.0076	SHEBOYGAN	52580
520057		0.0193	SAUK	52550
520059	*	0.0195	RACINE	52500
520071	*	0.0161	JEFFERSON	52270
520076	*	0.0146	DODGE	52130
520095	*	0.0193	SAUK	52550
520096		0.0195	RACINE	52500
520102	*	0.0242	WALWORTH	52630
520116	*	0.0161	JEFFERSON	52270
522005		0.0195	RACINE	52500
523026		0.0195	RACINE	52500
524020		0.0193	SAUK	52550
524021		0.0242	WALWORTH	52630
524022		0.0146	DODGE	52130

ADDENDUM M.—HCPCS CODES FOR ASSIGNMENT TO COMPOSITE APCs FOR CY 2008

HCPCS code	Short descriptor	CI	SI	Single code APC assignment	Composite APC assignment
90801	Psy dx interview	CH	Q	0323	0034
90802	Intac psy dx interview	CH	Q	0323	0034
90804	Psytx, office, 20–30 min	CH	Q	0322	0034
90805	Psytx, off, 20–30 min w/e&m	CH	Q	0322	0034
90806	Psytx, off, 45–50 min	CH	Q	0323	0034
90807	Psytx, off, 45–50 min w/e&m	CH	Q	0323	0034
90808	Psytx, office, 75–80 min	CH	Q	0323	0034
90809	Psytx, off, 75–80, w/e&m	CH	Q	0323	0034
90810	Intac psytx, off, 20–30 min	CH	Q	0322	0034
90811	Intac psytx, 20–30, w/e&m	CH	Q	0322	0034
90812	Intac psytx, off, 45–50 min	CH	Q	0323	0034
90813	Intac psytx, 45–50 min w/e&m	CH	Q	0323	0034
90814	Intac psytx, off, 75–80 min	CH	Q	0323	0034
90815	Intac psytx, 75–80 w/e&m	CH	Q	0323	0034

ADDENDUM M.—HCPCS CODES FOR ASSIGNMENT TO COMPOSITE APCS FOR CY 2008—Continued

HCPCS code	Short descriptor	CI	SI	Single code APC assignment	Composite APC assignment
90816	Psytx, hosp, 20–30 min	CH	Q	0322	0034
90817	Psytx, hosp, 20–30 min w/e&m	CH	Q	0322	0034
90818	Psytx, hosp, 45–50 min	CH	Q	0323	0034
90819	Psytx, hosp, 45–50 min w/e&m	CH	Q	0323	0034
90821	Psytx, hosp, 75–80 min	CH	Q	0323	0034
90822	Psytx, hosp, 75–80 min w/e&m	CH	Q	0323	0034
90823	Intac psytx, hosp, 20–30 min	CH	Q	0322	0034
90824	Intac psytx, hsp 20–30 w/e&m	CH	Q	0322	0034
90826	Intac psytx, hosp, 45–50 min	CH	Q	0323	0034
90827	Intac psytx, hsp 45–50 w/e&m	CH	Q	0323	0034
90828	Intac psytx, hosp, 75–80 min	CH	Q	0323	0034
90829	Intac psytx, hsp 75–80 w/e&m	CH	Q	0323	0034
90845	Psychoanalysis	CH	Q	0323	0034
90846	Family psytx w/o patient	CH	Q	0324	0034
90847	Family psytx w/patient	CH	Q	0324	0034
90849	Multiple family group psytx	CH	Q	0325	0034
90853	Group psychotherapy	CH	Q	0325	0034
90857	Intac group psytx	CH	Q	0325	0034
90862	Medication management	CH	Q	0605	0034
90865	Narcosynthesis	CH	Q	0323	0034
90880	Hypnotherapy	CH	Q	0323	0034
90899	Psychiatric service/therapy	CH	Q	0322	0034
96101	Psycho testing by pscy/phys	CH	Q	0382	0034
96102	Psycho testing by technician	CH	Q	0373	0034
96103	Psycho testing admin by comp	CH	Q	0373	0034
96110	Developmental test, lim	CH	Q	0373	0034
96111	Developmental test, exten	CH	Q	0382	0034
96116	Neurobehavioral status exam	CH	Q	0382	0034
96118	Neuropsych test by pscy/phys	CH	Q	0382	0034
96119	Neuropsych testing by tec	CH	Q	0382	0034
96120	Neuropsych tst admin w/comp	CH	Q	0373	0034
96150	Assess hlth/behave, initi	CH	Q	0432	0034
96151	Assess hlth/behave, subseq	CH	Q	0432	0034
96152	Intervene hlth/behave, indiv	CH	Q	0432	0034
96153	Intervene hlth/bhave, group	CH	Q	0432	0034
96154	Intevne hlth/behave, fam w/pt	CH	Q	0432	0034
M0064	Visit for drug monitoring	CH	Q	0605	0034
93619	Electrophysiology evaluation	CH	Q	0085	8000
93620	Electrophysiology evaluation	CH	Q	0085	8000
93650	Ablate heart dysrhythm focus	CH	Q	0085	8000
93651	Ablate heart dysrhythm focus	CH	Q	0086	8000
93652	Ablate heart dysrhythm focus	CH	Q	0086	8000
55875	Transperi needle place, pros	CH	Q	0163	8001
77778	Apply interstit radiat compl	CH	Q	0651	8001
99205	Office/outpatient visit, new	CH	Q	0608	8002
99215	Office/outpatient visit, est	CH	Q	0607	8002
G0379	Direct admit hospital observ	CH	Q	0604	8002
99284	Emergency dept visit	CH	Q	0615	8003
99285	Emergency dept visit	CH	Q	0616	8003
99291	Critical care, first hour	CH	Q	0617	8003

[FR Doc. 07–5507 Filed 11–1–07; 4:00 pm]

BILLING CODE 4120–01–P

Reader Aids

Federal Register

Vol. 72, No. 227

Tuesday, November 27, 2007

CUSTOMER SERVICE AND INFORMATION

Federal Register/Code of Federal Regulations	
General Information, indexes and other finding aids	202-741-6000
Laws	741-6000
Presidential Documents	
Executive orders and proclamations	741-6000
The United States Government Manual	741-6000
Other Services	
Electronic and on-line services (voice)	741-6020
Privacy Act Compilation	741-6064
Public Laws Update Service (numbers, dates, etc.)	741-6043
TTY for the deaf-and-hard-of-hearing	741-6086

ELECTRONIC RESEARCH

World Wide Web

Full text of the daily Federal Register, CFR and other publications is located at: <http://www.gpoaccess.gov/nara/index.html>

Federal Register information and research tools, including Public Inspection List, indexes, and links to GPO Access are located at: http://www.archives.gov/federal_register

E-mail

FEDREGTOC-L (Federal Register Table of Contents LISTSERV) is an open e-mail service that provides subscribers with a digital form of the Federal Register Table of Contents. The digital form of the Federal Register Table of Contents includes HTML and PDF links to the full text of each document.

To join or leave, go to <http://listserv.access.gpo.gov> and select *Online mailing list archives, FEDREGTOC-L, Join or leave the list (or change settings)*; then follow the instructions.

PENS (Public Law Electronic Notification Service) is an e-mail service that notifies subscribers of recently enacted laws.

To subscribe, go to <http://listserv.gsa.gov/archives/publaws-l.html> and select *Join or leave the list (or change settings)*; then follow the instructions.

FEDREGTOC-L and **PENS** are mailing lists only. We cannot respond to specific inquiries.

Reference questions. Send questions and comments about the Federal Register system to: fedreg.info@nara.gov

The Federal Register staff cannot interpret specific documents or regulations.

FEDERAL REGISTER PAGES AND DATE, NOVEMBER

61791-62104.....	1
62105-62408.....	2
62409-62558.....	5
62559-62766.....	6
62767-63096.....	7
63097-63444.....	8
63445-63782.....	9
63783-63966.....	13
63967-64118.....	14
64119-64522.....	15
64523-64918.....	16
64919-65214.....	19
65215-65440.....	20
65441-65654.....	21
65655-65884.....	23
65885-66040.....	26
66041-67226.....	27

CFR PARTS AFFECTED DURING NOVEMBER

At the end of each month, the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title.

2 CFR	5 CFR
175.....	353.....62767
	532.....63967, 63968
	575.....64523
3 CFR	6 CFR
Proclamations:	2765215, 65217, 65219,
8195.....	65221, 65224
8196.....	Ch. X.....66041
8197.....	
8198.....	7 CFR
8199.....	1.....66041
8200.....	210.....63785
8201.....	215.....63785
8202.....	220.....63785
8203.....	235.....63785
8204.....	245.....63785
8205.....	301.....62409, 65172
8206.....	305.....65172
Executive Orders:	457.....62767
12170 (See Notice of	718.....63242
Nov. 8, 2007:	761.....63242
National Emergency	762.....63242
With Iran).....	763.....63242
63965	764.....63242
12938 (See Notice of	765.....63242
Nov. 8, 2007:	766.....63242
Emergency	767.....63242
Regarding Weapons	768.....63242
of Mass	769.....63242
Destruction).....	771.....64119
63963	772.....64119
13067 (See Notice of	773.....64119
November 1,	774.....64119
2007).....	966.....64123
62407	993.....62409
13094 (See Notice of	1170.....62105
Nov. 8, 2007:	1405.....63242
Emergency	1806.....64119
Regarding Weapons	1901.....64119
of Mass	1910.....64119
Destruction).....	1924.....64119
63963	1925.....64119
13382 (See Notice of	1927.....64119
Nov. 8, 2007:	1940.....64119
Emergency	1941.....64119
Regarding Weapons	1943.....64119
of Mass	1950.....64119
Destruction).....	1951.....64119
63963	1955.....64119
13400 (See Notice of	1956.....64119
November 1,	1962.....64119
2007).....	1965.....64119
62407	Proposed Rules:
13450.....	47.....61820
64519	51.....62417
13451.....	56.....62591
65653	70.....62591
Administrative Orders:	305.....64163
Notices:	318.....64163
Notice of November 1,	331.....64540
2007.....	786.....65889
62407	1221.....65842
Notice of November 8,	
2007 (Emergency	
Regarding Weapons	
of Mass	
Destruction).....	
63963	
Notice of November 8,	
2007 (National	
Emergency With	
Iran).....	
63965	

8 CFR	14 CFR	230.....65762	63144, 63523, 63528, 63838,
245.....61791	1.....63364	232.....63513	64174, 64545, 64708
Proposed Rules:	21.....63364, 63797, 64529	239.....65762	300.....65682
100.....62593	23.....62105	240.....65762	301.....62805
103.....61821	25.....63364	249.....65762	27 CFR
204.....61821	26.....63364	270.....63513	24.....65452
212.....62593	29.....64529	18 CFR	45.....65456
214.....61821	39.....61796, 62559, 62560,	375.....65659	Proposed Rules:
299.....61821	62562, 62564, 62566, 62568,	385.....65659	4.....65256, 65261
9 CFR	63098, 63800, 63805, 64130,	388.....63980	9.....65256, 65261, 65489
94.....63796	64132, 64135, 64139, 64143,	Proposed Rules:	70.....65261
98.....64126	64532, 65215, 65217, 65219,	141.....65246	28 CFR
381.....61793	65221, 65224, 65443, 65445,	284.....65916	0.....65457
Proposed Rules:	65446, 65665, 66043	385.....65246	29 CFR
121.....64540	45.....66045	19 CFR	1910.....64342
10 CFR	71.....62107, 62108, 62110,	123.....63805	1915.....64342
2.....64529	62111, 62412, 63100, 63101,	Proposed Rules:	1917.....64342
13.....64529	64145, 64146	4.....65487	1918.....64342
30.....63969	77.....65449	122.....64012	1926.....64342
40.....63969	91.....63364	20 CFR	2520.....64710
50.....63969	97.....64533, 64534	Proposed Rules:	4022.....64150
52.....63969	121.....63364	404.....62607	4044.....64150
55.....63969	125.....63364	405.....62607	Proposed Rules:
60.....63969	129.....63364	416.....62607	1401.....62417
61.....63969	1245.....65451	616.....62145	2702.....65494
63.....63969	Proposed Rules:	21 CFR	30 CFR
70.....63969	Ch. I.....64170	510.....63986	943.....64942
71.....63969	25.....66085	520.....63986	Proposed Rules:
72.....63969	39.....61822, 61824, 62143,	522.....62771	49.....63529, 63540
76.....63969	62802, 63503, 63506, 63508,	558.....62570, 65666, 65885,	75.....63530
430.....65136	63510, 63512, 63827, 63829,	66045	250.....63155
Proposed Rules:	63831, 63834, 63836, 64005,	1306.....64921	31 CFR
50.....65470	64008, 64009, 64010, 64171,	Proposed Rules:	2.....63104
51.....64003	64172, 64540, 64542, 64955,	2.....63141	32 CFR
54.....63141	64957, 64960, 64961, 64964,	101.....62149, 66103	199.....63987, 64536
71.....65470	65227, 65228, 65229, 65471,	606.....63416	519.....64538
430.....64432	65474, 65476, 65478, 65480,	610.....63416	701.....64538
431.....64432	65678, 65897, 65901, 65903,	630.....63416	706.....62412, 63485
11 CFR	65906, 65909, 65911, 65913,	640.....63416	33 CFR
111.....64919	66087, 66089	660.....63416	101.....63106
Proposed Rules:	91.....64966	820.....63416	105.....63106
88.....62798	234.....65230, 65233	1270.....63416	106.....63106
100.....62600	250.....65237	1305.....66118	117.....63107, 63486, 63487,
104.....62600	253.....65233	1310.....65248	63488, 64152, 66046, 66047
12 CFR	259.....65233	22 CFR	165.....62117, 63488, 65459,
41.....62910, 63718	399.....65233	51.....64930	65886
201.....63097	Ch. III.....64170	62.....61800, 62112	334.....65667, 65669
202.....63445	15 CFR	24 CFR	Proposed Rules:
205.....63452	734.....62768	200.....66034	100.....63839
213.....63456	742.....62524	401.....66034	117.....63156, 63530, 64175,
213.....63456	743.....62524	983.....65206	64177
222.....62910, 63718	744.....62524, 65394	3285.....62308	165.....62609, 62613, 65275
226.....63462	772.....62524	25 CFR	167.....64968, 66122
230.....63477	774.....62524, 62768	Proposed Rules:	34 CFR
334.....62910, 63718	Proposed Rules:	502.....64545	668.....62014
364.....63718	922.....65483	542.....64545	674.....61960, 62014
403.....66042	16 CFR	543.....64545	676.....62014
407.....66042	681.....63718	546.....64545	682.....61960, 62014
414.....66042	Proposed Rules:	547.....64545	685.....61960, 62014
551.....62768	260.....66091, 66094	26 CFR	690.....62014
571.....62910, 63718	Proposed Rules:	1.....62771, 63806, 63807,	691.....62014
627.....65665	260.....66091, 66094	63813, 64147, 65667	36 CFR
630.....64129	17 CFR	64939	1228.....64153
701.....65441	1.....63976	301.....62771, 63807	Proposed Rules:
717.....62910, 63718	3.....63102, 63976	602.....63813	7.....65278
Proposed Rules:	4.....63976	Proposed Rules:	1191.....61826
308.....62310	15.....63976	1.....62608, 62805, 63143,	
363.....62310	38.....65658		
Ch. V.....64003	166.....63976		
13 CFR	211.....63484		
400.....63975	Proposed Rules:		
	150.....65483, 66097		
	228.....65762		
	229.....65762		

1193.....61827	41162585, 64161, 66222,	15.....64013	9.....64019
1194.....61827	66580	20.....65494	12.....61854
1195.....61828	412.....62585, 66222	25.....64979	14.....61854
1250.....64558	41362585, 66222, 66580	27.....64013	15.....61854
1251.....64558	414.....66222, 66580	61.....64179	16.....61854
1256.....64558	415.....66222	68.....65494	19.....61854
	416.....66580	69.....64179	27.....61854
37 CFR	418.....66222	7363866, 63867, 63868	30.....61854
202.....61801	419.....66580	74.....62616	31.....61854, 64185
Proposed Rules:	423.....66222	90.....63869, 64013	32.....61854
383.....63532	424.....66222	101.....64013	42.....61854, 64019
	482.....66222, 66580	48 CFR	44.....61854
38 CFR	484.....66222	Ch. I.....63026, 63094, 65868,	49.....61854
1.....65461	485.....66222, 66580	65883	52.....61854, 64019
2.....65461	489.....62585	1.....63027, 63089	604.....64980
	Proposed Rules:	2.....63040, 63045, 63075,	637.....64980
39 CFR	423.....64900	65868, 65873	652.....64980
301.....64155	455.....65686	3.....63045, 65873	
3001.....63662	483.....65692	4.....63040, 63075, 63076	49 CFR
3010.....63662, 64155		5.....63075, 63084	385.....62795
3015.....63662, 64155	44 CFR	6.....63084	571.....62135
3020.....63662, 64155	64.....63110, 63112	7.....63027, 63040	585.....62135
	65.....62121	11.....63040	1507.....63706
40 CFR	67.....61806	12.....63040, 63045, 63084	1572.....63106
49.....63988	Proposed Rules:	13.....63040, 63075	Proposed Rules:
52.....61806, 62119, 62338,	423.....64900	15.....63045, 63076	571.....62198, 65509
62571, 62579, 62788, 63107,	455.....65686	17.....63076	579.....62198
63990, 64156, 64158, 64946,	483.....65692	18.....63027, 63045, 63084	594.....65532
64948, 65462	45 CFR	19.....63045	1114.....62200
60.....62414, 64860	Proposed Rules:	22.....63076, 63088, 65868	1121.....62200
63.....64860	2510.....64970	23.....63040, 65868	1150.....62200
81.....62414, 63990, 64948	2513.....64970	25.....63089	1180.....62200
82.....63490	2516.....64970	26.....63084	
97.....62788	2517.....64970	27.....63045	50 CFR
180.....62788, 63992, 63994,	2520.....64970	28.....63027	17.....62736, 63123, 64286
63997, 64538	2521.....64970	32.....63027	229.....62587, 63824, 66048
721.....64951	2522.....64970	33.....63027, 63045	600.....61815
Proposed Rules:	2523.....64970	36.....65868	622.....62415, 66080
51.....63850, 65282	2524.....64970	42.....63040	648.....62416, 64000, 64952,
52.....62175, 62420, 62422,	2540.....64970	43.....63027	65466, 66082, 66083
62615, 62616, 62807, 62809,	2550.....64970	45.....63040	660.....64952
63850, 64179, 64970, 65283,	47 CFR	50.....63027	679.....62590, 63500, 64001,
65285, 65494	11.....62123	52.....63027, 63040, 63045,	66083
55.....64563	15.....63823	63076, 63084, 63089, 65868,	Proposed Rules:
63.....63159	27.....63499	65873	17.....62992, 66122
81.....65682	64.....61813	53.....63089	21.....64981
82.....63535	73.....63823	202.....63113	223.....63537
87.....64570	76.....65670	212.....63113	600.....64186
752.....65282	Proposed Rules:	225.....63113	635.....64186
42 CFR	1.....64013	Proposed Rules:	648.....64023, 64187
409.....66222	2.....65494	1.....61854	679.....63871, 64034, 65539
410.....66222, 66580	11.....62195	3.....64019	
		4.....61854	

REMINDERS

The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

RULES GOING INTO EFFECT NOVEMBER 27, 2007**AGRICULTURE DEPARTMENT**

Administrative regulations:
Official records, authentication; published 11-27-07

COMMERCE DEPARTMENT National Oceanic and Atmospheric Administration

Fishery conservation and management:
Caribbean, Gulf, and South Atlantic fisheries—
Gulf of Mexico reef fish; published 11-27-07
Northeastern United States fisheries—
Atlantic bluefish; published 11-27-07
Summer flounder; published 11-27-07

EXPORT-IMPORT BANK

Technical amendments; published 11-27-07

HEALTH AND HUMAN SERVICES DEPARTMENT**Food and Drug Administration**

Animal drugs, feeds, and related products:
Fenbendazole; published 11-27-07

HOMELAND SECURITY DEPARTMENT**Coast Guard**

Drawbridge operations:
Texas; published 11-27-07

TRANSPORTATION DEPARTMENT**Federal Aviation Administration**

Airworthiness directives:
Eclipse Aviation Corp.; published 11-27-07

COMMENTS DUE NEXT WEEK**AGRICULTURE DEPARTMENT****Agricultural Marketing Service**

Dairy Product Mandatory Reporting Program; establishment; comments

due by 12-3-07; published 11-2-07 [FR E7-21559]
Egg, poultry, and rabbit products; inspection and grading:
Fees and charges increase; comments due by 12-6-07; published 11-6-07 [FR 07-05571]

Leafy greens; handling regulations; comments due by 12-3-07; published 10-4-07 [FR E7-19629]

AGRICULTURE DEPARTMENT**Animal and Plant Health Inspection Service**

Agricultural Bioterrorism Protection Act of 2002; implementation:
Select agent and toxin list; biennial review and republication; comments due by 12-3-07; published 11-16-07 [FR E7-22431]

AGRICULTURE DEPARTMENT**Agricultural Research Service**

Patent licenses; non-exclusive, exclusive, or partially exclusive:
ISTO Technologies, Inc.; comments due by 12-6-07; published 11-6-07 [FR 07-05505]
Peterson Seed Associates; comments due by 12-6-07; published 11-6-07 [FR 07-05504]

AGRICULTURE DEPARTMENT**Grain Inspection, Packers and Stockyards Administration**

Ethanol production, differentiating grain inputs and standardized testing of ethanol production co-products; USDA role; comments due by 12-4-07; published 10-5-07 [FR E7-19733]

COMMERCE DEPARTMENT National Oceanic and Atmospheric Administration

Fishery conservation and management:
Caribbean, Gulf, and South Atlantic fisheries—
Gulf of Mexico reef fish and shrimp; comments due by 12-7-07; published 10-23-07 [FR 07-05245]

Northeastern United States fisheries—

Summer flounder, scup, and black sea bass; comments due by 12-3-07; published 11-14-07 [FR 07-05647]

DEFENSE DEPARTMENT

Non-Federal entities authorized to operate installations; procedures and support; comments due by 12-3-07; published 10-2-07 [FR E7-19446]

DEFENSE DEPARTMENT Navy Department

Admiralty claims; comments due by 12-3-07; published 10-3-07 [FR E7-19407]

ENVIRONMENTAL PROTECTION AGENCY

Acquisition regulations:
Award term incentives use, guidance; administrative amendments; comments due by 12-3-07; published 10-4-07 [FR E7-19632]

Air quality implementation plans; approval and promulgation; various States:
Colorado; comments due by 12-6-07; published 11-6-07 [FR E7-21611]

Connecticut; comments due by 12-5-07; published 11-5-07 [FR E7-21690]

Delaware; comments due by 12-7-07; published 11-7-07 [FR E7-21853]

Louisiana; comments due by 12-6-07; published 11-6-07 [FR E7-21687]

Massachusetts; comments due by 12-5-07; published 11-5-07 [FR E7-21691]

West Virginia; comments due by 12-7-07; published 11-7-07 [FR E7-21866]

Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:
Thiabendazole; comments due by 12-3-07; published 10-3-07 [FR E7-19542]

FEDERAL COMMUNICATIONS COMMISSION

Emergency Alert System; regulatory review; comments due by 12-3-07; published 11-2-07 [FR 07-05331]

Radio services, special:
Private land mobile services—
800 MHz band; improving public safety communications; comments due by 12-3-07; published 11-13-07 [FR E7-22128]

FEDERAL MEDIATION AND CONCILIATION SERVICE

Freedom of Information Act; implementation; comments due by 12-5-07; published 11-5-07 [FR E7-21629]

HEALTH AND HUMAN SERVICES DEPARTMENT**Food and Drug Administration**

Food for human consumption:

Food labeling—

Dietary noncarcinogenic carbohydrate sweeteners and dental caries; health claims; comments due by 12-3-07; published 9-17-07 [FR E7-18196]

HOMELAND SECURITY DEPARTMENT**U.S. Customs and Border Protection**

Air commerce:

Private aircraft arriving and departing U.S.; advance information requirement; comments due by 12-4-07; published 11-14-07 [FR E7-22309]

Immigration regulations:

Nonimmigrant aliens infected with HIV; visa and authorization for temporary admission into U.S.; comments due by 12-6-07; published 11-6-07 [FR E7-21841]

HOMELAND SECURITY DEPARTMENT**Coast Guard**

Drawbridge operations:

Louisiana; comments due by 12-3-07; published 10-2-07 [FR E7-19422]

Ports and waterways safety; regulated navigation areas, safety zones, security zones, etc.:

Manbirtee Key, Manatee, FL; comments due by 12-6-07; published 11-6-07 [FR E7-21761]

St. Petersburg Captain of Port Zone, FL; comments due by 12-6-07; published 11-6-07 [FR E7-21760]

HOMELAND SECURITY DEPARTMENT**U.S. Citizenship and Immigration Services**

Immigration:

Intercountry adoptions by U.S. citizens; citizenship classification of alien children under Hague Convention; comments due by 12-3-07; published 10-4-07 [FR E7-18992]

INTERIOR DEPARTMENT National Indian Gaming Commission

Indian Gaming Regulatory Act:

Facility license standards; comments due by 12-3-07; published 10-18-07 [FR E7-20541]

PERSONNEL MANAGEMENT OFFICE

Reemployment rights:

Federal employees detailed and transferred to

international organizations; comments due by 12-3-07; published 10-2-07 [FR E7-19447]

**TRANSPORTATION DEPARTMENT
Federal Aviation Administration**

Airport noise compatibility program:

Noise exposure maps—
Cincinnati/Northern Kentucky International Airport, KY; comments due by 12-8-07; published 10-17-07 [FR 07-05102]

Airworthiness directives:

Airbus; comments due by 12-3-07; published 11-1-07 [FR E7-21394]

Boeing; comments due by 12-3-07; published 10-17-07 [FR E7-20466]

Cessna; comments due by 12-3-07; published 11-2-07 [FR E7-21571]

Empresa Brasileira de Aeronautica S.A. (EMBRAER); comments due by 12-3-07; published 11-1-07 [FR E7-21490]

Honeywell; comments due by 12-4-07; published 10-5-07 [FR E7-19684]

McDonnell Douglas; comments due by 12-3-07; published 11-14-07 [FR 07-05654]

Airworthiness standards:

Aircraft engine standards for pressurized engine static

parts; comments due by 12-5-07; published 9-6-07 [FR E7-17626]

Special conditions—

Cessna Model 208B airplane; comments due by 12-3-07; published 11-2-07 [FR E7-21599]

Class E airspace; comments due by 12-5-07; published 11-2-07 [FR 07-05421]

Restricted areas; comments due by 12-7-07; published 10-23-07 [FR E7-20795]

TRANSPORTATION DEPARTMENT

National Highway Traffic Safety Administration

Motor vehicle safety standards:

Controls, telltales, and indicators; comments due by 12-3-07; published 10-4-07 [FR E7-19365]

TREASURY DEPARTMENT

International Investment Office

Foreign Investment and National Security Act (2007); implementation:

Mergers, acquisitions and takeovers; comments due by 12-7-07; published 10-11-07 [FR E7-20042]

VETERANS AFFAIRS DEPARTMENT

Compensation, pension, burial, and related benefits:

Payments to beneficiaries who are eligible for more

than one benefit; comments due by 12-3-07; published 10-2-07 [FR E7-19280]

LIST OF PUBLIC LAWS

This is a continuing list of public bills from the current session of Congress which have become Federal laws. It may be used in conjunction with "PLUS" (Public Laws Update Service) on 202-741-6043. This list is also available online at <http://www.archives.gov/federal-register/laws.html>.

The text of laws is not published in the **Federal Register** but may be ordered in "slip law" (individual pamphlet) form from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 (phone, 202-512-1808). The text will also be made available on the Internet from GPO Access at <http://www.gpoaccess.gov/plaws/index.html>. Some laws may not yet be available.

H.R. 2602/P.L. 110-118

To name the Department of Veterans Affairs medical facility in Iron Mountain, Michigan, as the "Oscar G. Johnson Department of Veterans Affairs Medical Facility". (Nov. 16, 2007; 121 Stat. 1346)

S.J. Res. 7/P.L. 110-119

Providing for the reappointment of Roger W. Sant as a citizen regent of the Board of Regents of the Smithsonian Institution. (Nov. 16, 2007; 121 Stat. 1347)

S. 2206/P.L. 110-120

To provide technical corrections to Public Law 109-116 (2 U.S.C. 2131a note) to extend the time period for the Joint Committee on the Library to enter into an agreement to obtain a statue of Rosa Parks, and for other purposes. (Nov. 19, 2007; 121 Stat. 1348)

Last List November 19, 2007

Public Laws Electronic Notification Service (PENS)

PENS is a free electronic mail notification service of newly enacted public laws. To subscribe, go to <http://listserv.gsa.gov/archives/publaws-l.html>

Note: This service is strictly for E-mail notification of new laws. The text of laws is not available through this service. **PENS** cannot respond to specific inquiries sent to this address.